https://maestrodatabase.com/ 2021-11-21T23:36:34 https://maestrodatabase.com/blog/ 2026-04-03T20:22:32 always https://maestrodatabase.com/contact/ 2021-11-21T23:36:34 https://maestrodatabase.com/about/ 2021-11-21T23:36:34 https://maestrodatabase.com/blog/problems-in-study-implementation-it-often-affects-patient-reported-outcomes 2026-03-04T23:06:15 https://maestrodatabase.com/blog/chmp-recommends-european-commission-approval-of-upadacitinib-rinvoq-for-the-treatment-of-adults-with-moderate-to-severe-ulcerative-colitis 2022-05-23T06:36:21 https://maestrodatabase.com/blog/vaxzevria-approved-in-the-eu-as-third-dose-booster-against-covid-19 2022-05-23T06:30:14 https://maestrodatabase.com/blog/covid-19-developers-of-medicines-or-vaccines-to-benefit-from-free-scientific-advice 2020-03-14T00:08:08 https://maestrodatabase.com/blog/fda-approves-abemaciclib-with-endocrine-therapy-for-early-breast-cancer 2021-10-13T19:45:27 https://maestrodatabase.com/blog/eu-may-consider-deal-on-mercks-covid-pill-after-approval-procedure-begins 2021-10-13T19:53:50 https://maestrodatabase.com/blog/expediency-versus-efficacy-re-examining-the-fdas-accelerated-drug-approval-process 2022-06-23T21:44:34 https://maestrodatabase.com/blog/interim-report-a-step-backwards 2017-06-27T12:34:48 https://maestrodatabase.com/blog/estimating-a-cost-effectiveness-threshold-for-the-spanish-nhs 2017-12-29T05:53:35 https://maestrodatabase.com/blog/calls-to-expand-access-to-oral-covid-19-drugs-as-expiry-dates-loom 2022-06-23T21:28:06 https://maestrodatabase.com/blog/the-medicines-and-health-products-that-failed-therapeutic-goods-association-testing 2017-06-27T12:28:41 https://maestrodatabase.com/blog/gw-pharmaceuticals-announces-acceptance-of-nda-filing-for-epidiolex-cannabidiol-in-the-treatment-of-lennox-gastaut-syndrome-and-dravet-syndrome 2017-12-29T06:00:50 https://maestrodatabase.com/blog/fda-explains-when-it-will-rescind-breakthrough-designations 2022-06-23T21:39:02 https://maestrodatabase.com/blog/nice-launches-a-competition-for-developers-of-health-care-technologies 2017-06-27T12:46:30 https://maestrodatabase.com/blog/fda-approves-pembrolizumab-combination-for-the-first-line-treatment-of-cervical-cancer 2021-10-13T20:20:25 https://maestrodatabase.com/blog/guild-caned-on-pharmacy-review-ban 2017-06-27T12:42:17 https://maestrodatabase.com/blog/jazz-pharmaceuticals-receives-health-canada-approval-for-epidiolex-cannabidiol-oral-solution-for-the-treatment-of-seizures-associated-with-three-rare-forms-of-epilepsy 2023-11-25T01:23:24 https://maestrodatabase.com/blog/astrazeneca-covid-19-vaccine-will-no-longer-be-made-in-australia 2021-10-13T20:26:11 https://maestrodatabase.com/blog/sanofi-and-regeneron-announce-approval-of-kevzara-sarilumab-to-treat-adult-patients-with-moderately-to-severely-active-rheumatoid-arthritis-in-the-european-unio 2017-06-27T12:51:01 https://maestrodatabase.com/blog/release-of-the-australian-governments-response-to-the-review-of-covid-19-vaccine-and-treatment-purchasing-and-procurement 2023-03-01T03:50:11 https://maestrodatabase.com/blog/scotland-is-first-country-to-offer-free-digital-therapies-to-every-adult 2021-10-13T19:57:38 https://maestrodatabase.com/blog/smc-accepts-cabometyx-slash-opdivo-combo-for-advanced-kidney-cancer-patients 2021-10-13T20:04:12 https://maestrodatabase.com/blog/eptinezumab-for-the-prevention-of-migraine 2023-03-01T05:55:31 https://maestrodatabase.com/blog/dupixent-dupilumab-injection-now-approved-by-health-canada-for-severe-chronic-rhinosinusitis-with-nasal-polyposis 2020-08-19T02:14:54 https://maestrodatabase.com/blog/why-we-can-have-both-innovative-drugs-and-lower-drug-prices 2021-10-13T20:50:15 https://maestrodatabase.com/blog/janssen-submits-application-to-the-ema-for-rybrevant-amivantamab-in-combination-with-chemotherapy-for-the-treatment-of-adult-patients-with-advanced-egfr-mutated-non-small-cell-lung-cancer-after-failure-of-prior-therapy 2023-11-25T01:59:21 https://maestrodatabase.com/blog/abata-therapeutics-receives-fda-fast-track-designation-for-aba-101-for-the-treatment-of-progressive-multiple-sclerosis 2024-08-25T22:11:28 https://maestrodatabase.com/blog/august-2018-pbac-special-meeting---public-submissions-now-available 2018-08-10T02:29:02 https://maestrodatabase.com/blog/us-fda-approves-arakoda-tafenoquine-tablets-for-oral-use-first-preventative-antimalarial-approved-in-almost-two-decades 2018-08-10T03:12:48 https://maestrodatabase.com/blog/feeling-the-pain-of-rising-drug-prices-blame-the-middle-man 2017-06-27T13:22:52 https://maestrodatabase.com/blog/senate-gop-health-care-bill-appears-in-deeper-trouble-following-new-cbo-report 2017-06-27T13:20:24 https://maestrodatabase.com/blog/thousands-set-to-benefit-from-pharmac-funded-chickenpox-vaccine 2017-06-27T21:08:07 https://maestrodatabase.com/blog/fda-tackles-drug-competition-to-improve-patient-access 2017-06-27T21:04:22 https://maestrodatabase.com/blog/the-institute-for-clinical-and-economic-review-to-collaborate-with-the-department-of-veterans-affairs-pharmacy-benefits-management-services-office 2017-06-27T21:17:00 https://maestrodatabase.com/blog/facing-revolt-on-health-care-bill-senate-republicans-delay-vote 2017-06-27T21:23:20 https://maestrodatabase.com/blog/brexit-could-have-catastrophic-effect-on-access-to-new-life-saving-drugs-for-decades-warns-expert 2017-06-27T21:38:20 https://maestrodatabase.com/blog/eight-digitally-enabled-therapies-to-treat-depression-and-anxiety-in-adults-conditionally-recommended-by-nice 2023-03-01T08:37:48 https://maestrodatabase.com/blog/icer-publishes-evidence-report-on-lecanemab-for-alzheimers-disease 2023-03-01T20:01:34 https://maestrodatabase.com/blog/nexus-pharmaceuticals-receives-fda-approval-for-emerphed-ephedrine-sulphate-injection-pre-filled-syringe 2023-03-01T19:57:17 https://maestrodatabase.com/blog/the-drug-prices-review-board-was-once-a-solution-its-now-a-problem 2023-03-01T19:54:53 https://maestrodatabase.com/blog/janssen-submits-new-drug-application-to-the-us-fda-seeking-approval-of-niraparib-and-abiraterone-acetate-dual-action-tablet-plus-prednisone-as-a-first-line-targeted-treatment-for-patients-with-metastatic-castration-resistant-prostate-cancer-with-brca-gene-mutations 2023-03-01T19:35:17 https://maestrodatabase.com/blog/lilly-cuts-insulin-prices-by-70-percent-and-caps-patient-insulin-out-of-pocket-costs-at-35-dollars-per-month 2023-03-01T19:43:43 https://maestrodatabase.com/blog/abpi-sets-out-new-proposals-to-support-the-nhs-and-economic-growth 2023-03-01T20:15:54 https://maestrodatabase.com/blog/a-review-of-patient-reported-outcome-considerations-in-oncologic-drugs-advisory-committee-meetings-2016-2021 2023-03-01T20:19:24 https://maestrodatabase.com/blog/obesity-drugs-often-arent-covered-by-insurance-experts-say-this-limits-access-increases-disparities 2023-03-01T20:09:53 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-to-aveta-biomics-drug-apg-157-for-neo-adjuvant-treatment-of-head-and-neck-cancer 2024-08-25T23:50:44 https://maestrodatabase.com/blog/european-commission-approves-balversa-erdafitinib-for-adult-patients-with-unresectable-or-metastatic-urothelial-carcinoma 2024-08-26T05:14:10 https://maestrodatabase.com/blog/vertex-announces-ema-validation-for-marketing-authorisation-application-extension-for-kaftrio-in-combination-with-ivacaftor-to-include-people-with-cystic-fibrosis-and-responsive-rare-mutations 2023-11-25T03:28:57 https://maestrodatabase.com/blog/european-commission-approves-celltrions-steqeyma-ct-p43-a-biosimilar-to-stelara-ustekinumab-for-the-treatment-of-multiple-chronic-inflammatory-diseases 2024-08-26T01:42:08 https://maestrodatabase.com/blog/astellas-submits-fezolinetant-new-drug-application-to-u-dot-s-fda 2022-06-24T03:21:14 https://maestrodatabase.com/blog/keeping-pace-with-pharmaceutical-innovation-the-importance-of-the-nice-methods-review 2020-08-19T08:09:21 https://maestrodatabase.com/blog/biosimilars-for-insulin-a-cost-saving-alternative 2018-08-10T10:42:13 https://maestrodatabase.com/blog/ironshore-pharmaceuticals-announces-fda-approval-of-jornay-pm-methylphenidate-extended-release-capsules-cii-for-the-treatment-of-adhd 2018-08-10T06:19:48 https://maestrodatabase.com/blog/my-health-record-opt-out-period-extended 2018-08-10T08:11:26 https://maestrodatabase.com/blog/the-antibiotic-paradox-why-companies-cant-afford-to-create-life-saving-drugs 2020-08-19T12:03:18 https://maestrodatabase.com/blog/the-need-for-transparency-of-clinical-evidence-for-medical-devices-in-europe 2018-08-10T10:48:51 https://maestrodatabase.com/blog/fda-approves-new-treatment-for-a-rare-genetic-disorder-fabry-disease 2018-08-10T23:58:23 https://maestrodatabase.com/blog/emmaus-life-sciences-announces-withdrawal-of-marketing-authorisation-application-to-european-medicines-agency 2019-09-20T04:46:40 https://maestrodatabase.com/blog/galapagos-announces-that-gilead-received-a-complete-response-letter-for-filgotinib-for-the-treatment-of-moderately-to-severely-active-rheumatoid-arthritis 2020-08-19T09:51:37 https://maestrodatabase.com/blog/how-an-international-price-index-might-help-reduce-drug-prices 2019-09-20T04:44:00 https://maestrodatabase.com/blog/fda-approves-first-of-its-kind-targeted-rna-based-therapy-to-treat-a-rare-disease 2018-08-11T00:04:40 https://maestrodatabase.com/blog/mylan-brings-critical-access-to-the-multiple-sclerosis-community-by-launching-a-more-affordable-treatment-option-through-a-first-generic-to-tecfidera 2020-08-19T11:44:16 https://maestrodatabase.com/blog/sanbio-granted-regenerative-medicine-advanced-therapy-designation-from-the-u-dot-s-fda-for-sb623-for-the-treatment-of-chronic-neurological-motor-deficits-secondary-to-traumatic-brain-injury 2019-09-20T04:57:26 https://maestrodatabase.com/blog/castle-creek-pharmaceuticals-receives-fda-fast-track-designation-for-diacerein-1-percent-ointment-for-treatment-of-epidermolysis-bullosa-simplex 2018-08-11T00:11:48 https://maestrodatabase.com/blog/coronavirus-csl-reveals-delivery-date-for-covid-19-vaccine-as-it-progresses-with-clinical-trials 2020-08-19T12:10:49 https://maestrodatabase.com/blog/financing-drug-innovation-in-the-us-current-framework-and-emerging-challenges 2020-08-19T12:18:49 https://maestrodatabase.com/blog/mhra-approves-aumolertinib-to-treat-non-small-cell-lung-cancer 2025-06-04T10:34:45 https://maestrodatabase.com/blog/cf-patients-furious-as-vertex-turns-back-on-nice 2018-08-11T00:22:06 https://maestrodatabase.com/blog/scott-morrison-announces-free-covid-19-vaccines-for-australians-backtracks-on-mandatory-comments 2020-08-19T12:24:59 https://maestrodatabase.com/blog/biomarin-receives-complete-response-letter-from-fda-for-valoctocogene-roxaparvovec-gene-therapy-for-severe-haemophilia-a 2020-08-19T20:51:51 https://maestrodatabase.com/blog/addition-of-kisqali-to-drug-plan-in-quebec-expands-access-to-treatment-for-metastatic-breast-cancer 2019-09-20T05:38:17 https://maestrodatabase.com/blog/pfizer-and-biontech-submit-for-us-emergency-use-authorisation-of-omicron-ba-dot-4-slash-ba-dot-5-adapted-bivalent-covid-19-booster-in-children-under-5-years 2023-03-01T21:50:08 https://maestrodatabase.com/blog/why-are-australians-ditching-private-health-insurance-during-the-coronavirus-pandemic 2020-08-19T21:30:17 https://maestrodatabase.com/blog/pharmacies-to-be-first-port-of-call-for-eventual-covid-19-vaccine 2020-08-19T21:34:36 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-14-october-2021 2021-10-14T04:05:55 https://maestrodatabase.com/blog/merck-receives-european-commission-approval-for-winrevair-sotatercept-in-combination-with-other-pulmonary-arterial-hypertension-therapies-for-the-treatment-of-pulmonary-arterial-hypertension-in-adult-patients-with-functional-class-ii-iii 2024-08-26T21:50:39 https://maestrodatabase.com/blog/ontario-woman-with-rare-disease-forced-to-pay-hundreds-of-thousands-to-cover-miracle-drug 2019-04-04T02:41:14 https://maestrodatabase.com/blog/be-prepared-for-anything-csl-boss-warns-of-key-unknowns-on-vaccine 2020-08-19T21:43:00 https://maestrodatabase.com/blog/insurance-coverage-after-job-loss----the-importance-of-the-aca-during-the-covid-associated-recession 2020-08-19T21:46:28 https://maestrodatabase.com/blog/doh-publishes-revised-agenda-for-may-2025-pbac-meeting-in-june 2025-06-04T06:29:23 https://maestrodatabase.com/blog/us-may-need-to-look-to-germany-to-reform-drug-pricing 2020-08-19T21:05:14 https://maestrodatabase.com/blog/inquiry-into-approval-processes-for-new-drugs-and-novel-medical-technologies-in-australia 2020-08-19T21:08:05 https://maestrodatabase.com/blog/ordspono-odronextamab-approved-in-the-european-union-for-the-treatment-of-relapsed-slash-refractory-follicular-lymphoma-and-diffuse-large-b-cell-lymphoma 2024-08-26T21:38:48 https://maestrodatabase.com/blog/launch-of-two-biosimilars 2020-08-19T21:12:47 https://maestrodatabase.com/blog/pharmac-confirms-widened-access-for-the-funded-flu-vaccine 2023-03-02T00:35:47 https://maestrodatabase.com/blog/beigenes-bgb-16673-receives-us-fda-fast-track-designation-for-cll-slash-sll 2024-08-26T23:33:30 https://maestrodatabase.com/blog/fda-clears-first-device-to-enable-automated-insulin-dosing-for-individuals-with-type-2-diabetes 2024-08-26T23:14:21 https://maestrodatabase.com/blog/sifi-receives-european-commission-approval-for-akantior 2024-08-27T01:20:05 https://maestrodatabase.com/blog/agilent-receives-fda-companion-diagnostic-approval-for-ki-67-ihc-mib-1-pharmdx-in-high-risk-early-breast-cancer 2021-10-14T05:18:06 https://maestrodatabase.com/blog/pharmacists-opt-out-of-third-shot-as-doses-of-vaccine-set-to-expire 2021-10-14T05:12:41 https://maestrodatabase.com/blog/vizimpro-dacomitinib-receives-marketing-authorisation-in-european-union-for-the-first-line-treatment-of-adult-patients-with-egfr-mutated-non-small-cell-lung-cancer 2019-04-04T10:10:07 https://maestrodatabase.com/blog/a-new-safe-harbour----turning-drug-rebates-into-discounts-in-medicare-part-d 2019-04-04T09:53:20 https://maestrodatabase.com/blog/european-commission-approves-filsuvez-for-the-treatment-of-dystrophic-and-junctional-epidermolysis-bullosa 2022-06-24T09:18:27 https://maestrodatabase.com/blog/biontech-receives-priority-medicines-prime-designation-from-ema-for-enhanced-regulatory-support-of-car-t-candidate-bnt211-in-testicular-cancer 2022-06-24T09:07:06 https://maestrodatabase.com/blog/health-canada-expands-approval-of-enhertu-for-adults-with-her2-positive-metastatic-breast-cancer 2022-06-24T09:13:45 https://maestrodatabase.com/blog/fda-accepts-regen-cov-casirivimab-and-imdevimab-for-priority-review-for-treatment-and-prophylaxis-of-covid-19 2021-10-14T19:51:43 https://maestrodatabase.com/blog/ema-validates-daiichi-sankyos-marketing-authorisation-application-for-pexidartinib-for-treatment-of-patients-with-tgct-a-rare-debilitating-non-malignant-tumour 2019-04-04T10:23:39 https://maestrodatabase.com/blog/coverage-for-emerging-technologies---bridging-regulatory-approval-and-patient-access 2023-11-25T23:32:24 https://maestrodatabase.com/blog/ema-starts-rolling-review-of-evusheld-tixagevimab-and-cilgavimab 2021-10-14T19:46:17 https://maestrodatabase.com/blog/fresenius-kabi-receives-european-commission-approval-for-adalimumab-biosimilar-idacio 2019-04-04T10:19:53 https://maestrodatabase.com/blog/highlights-from-the-chmp-16-19-september-2019-meeting 2019-09-20T10:09:17 https://maestrodatabase.com/blog/new-sarclisa-isatuximab-combination-now-approved-by-health-canada-for-adults-with-relapsed-and-slash-or-refractory-multiple-myeloma 2021-10-14T10:13:14 https://maestrodatabase.com/blog/ocular-therapeutix-announces-notification-of-fda-acceptance-of-supplemental-new-drug-submission-for-dextenza-dexamethasone-ophthalmic-insert-for-the-treatment-of-ocular-inflammation-following-ophthalmic-surgery 2019-04-04T10:31:56 https://maestrodatabase.com/blog/novartis-and-the-pan-canadian-pharmaceutical-alliance-complete-negotiations-for-zolgensma-for-the-treatment-of-paediatric-patients-with-spinal-muscular-atrophy 2021-10-14T10:17:48 https://maestrodatabase.com/blog/roches-evrysdi-tablet-approved-by-european-commission-as-first-and-only-for-spinal-muscular-atrophy 2025-06-05T01:15:40 https://maestrodatabase.com/blog/immunocores-lead-asset-tebentafusp-gains-fast-track-designation-for-metastatic-uveal-melanoma 2019-04-04T11:05:21 https://maestrodatabase.com/blog/cellectar-granted-us-fda-breakthrough-therapy-designation-for-iopofosine-i-131-in-waldenstrom-macroglobulinemia 2025-06-04T23:17:30 https://maestrodatabase.com/blog/rhythm-pharmaceuticals-completes-submission-of-type-ii-variation-application-to-the-european-medicines-agency-for-imcivree-setmelanotide-for-bardet-biedl-and-alstroem-syndromes 2021-10-14T20:30:48 https://maestrodatabase.com/blog/chimeric-therapeutics-cdh17-receives-fda-fast-track 2025-06-04T23:29:12 https://maestrodatabase.com/blog/fda-approves-the-reintroduction-of-zelnorm-tegaserod-for-irritable-bowel-syndrome-with-constipation-in-women-under-65 2019-04-04T11:02:06 https://maestrodatabase.com/blog/covid-19-rapid-antigen-self-tests-approved-in-australia 2021-10-14T20:44:20 https://maestrodatabase.com/blog/fda-expands-approved-use-of-metastatic-breast-cancer-treatment-to-include-male-patients 2019-04-04T19:54:31 https://maestrodatabase.com/blog/drug-pricing-tug-of-war-expected-over-car-t-therapy-kymriah 2021-10-14T20:04:29 https://maestrodatabase.com/blog/ondine-biomedical-receives-fast-track-designation-from-the-u-dot-s-fda-for-nasal-photodisinfection-system 2019-04-04T11:14:34 https://maestrodatabase.com/blog/biden-eyeing-fda-veteran-robert-califf-to-lead-the-agency 2021-10-14T20:01:30 https://maestrodatabase.com/blog/celltrion-applies-for-product-approval-for-avastin-biosimilar-in-eu 2021-10-14T20:27:03 https://maestrodatabase.com/blog/ema-grants-prime-designation-to-janssens-investigational-car-t-therapy 2019-04-04T20:02:49 https://maestrodatabase.com/blog/alps-health-commitment-is-an-investment-in-every-australian 2019-04-04T19:58:31 https://maestrodatabase.com/blog/cancer-drugs-fund-driving-early-access-to-promising-new-treatments 2017-06-28T12:39:11 https://maestrodatabase.com/blog/daiichi-sankyo-provides-update-on-ongoing-fda-review-for-quizartinib-for-treatment-of-patients-with-relapsed-slash-refractory-flt3-itd-aml 2019-04-04T20:07:52 https://maestrodatabase.com/blog/quebec-expects-to-save-millions-with-overhaul-of-generic-drug-purchasing-process 2017-06-28T12:32:34 https://maestrodatabase.com/blog/the-importance-of-predefined-rules-and-pre-specified-statistical-analyses-do-not-abandon-significance 2019-04-04T20:26:11 https://maestrodatabase.com/blog/wagga-teen-hoping-for-access-to-life-changing-cystic-fibrosis-medication 2017-06-28T12:44:22 https://maestrodatabase.com/blog/the-implications-of-medicare-for-all-for-us-hospitals 2019-04-04T20:22:11 https://maestrodatabase.com/blog/j-and-j-medtronic-push-back-against-tga-priority-review-proposal 2017-06-28T12:49:48 https://maestrodatabase.com/blog/fda-affirms-its-commitment-to-efficient-adoption-of-risk-evaluation-and-mitigation-strategy-plans-and-to-making-sure-they-do-not-impede-generic-drug-development 2019-04-04T20:18:40 https://maestrodatabase.com/blog/tga-approves-weight-loss-drug-to-treat-sleep-disorder 2025-06-05T02:14:45 https://maestrodatabase.com/blog/nice-backs-afinitor-sutent-for-neuroendocrine-tumours 2017-06-28T12:56:31 https://maestrodatabase.com/blog/rhythm-pharmaceuticals-announces-fda-acceptance-for-priority-review-of-supplemental-new-drug-application-for-imcivree-setmelanotide-in-patients-as-young-as-2-years-old 2024-08-27T03:24:28 https://maestrodatabase.com/blog/decision-on-ema-relocation-set-for-november-council-agrees-on-bidding-procedure 2017-06-28T20:57:21 https://maestrodatabase.com/blog/new-strategy-from-pharmac-to-help-pacific-communities-in-new-zealand 2017-06-28T20:53:13 https://maestrodatabase.com/blog/with-u-dot-s-health-care-bill-in-disarray-republicans-demand-revamp 2017-06-28T21:15:10 https://maestrodatabase.com/blog/icer-evidence-report-on-abuse-deterrent-opioids-finds-limited-evidence-to-demonstrate-real-world-impact-on-opioid-abuse 2017-06-28T21:10:45 https://maestrodatabase.com/blog/fda-commissioner-takes-on-martin-shkreli-wannabes-over-huge-drug-price-hikes 2017-06-28T21:18:32 https://maestrodatabase.com/blog/affordable-treatment-for-recurrent-melanoma 2023-03-02T04:54:41 https://maestrodatabase.com/blog/novartis-receives-positive-chmp-opinion-for-scemblix-a-novel-treatment-for-adult-patients-with-chronic-myeloid-leukaemia 2022-06-25T04:17:06 https://maestrodatabase.com/blog/roches-piasky-approved-in-the-eu-as-the-first-monthly-subcutaneous-treatment-for-people-with-paroxysmal-nocturnal-haemoglobinuria 2024-08-27T22:10:08 https://maestrodatabase.com/blog/boomerang-medical-earns-fda-breakthrough-device-designation 2023-03-02T19:45:52 https://maestrodatabase.com/blog/checkpoint-therapeutics-announces-fda-filing-acceptance-of-biologics-license-application-for-cosibelimab-in-metastatic-or-locally-advanced-cutaneous-squamous-cell-carcinoma 2023-03-02T20:04:10 https://maestrodatabase.com/blog/fda-accepts-for-priority-review-adx-2191-new-drug-application-for-the-treatment-of-primary-vitreoretinal-lymphoma 2023-03-02T19:53:52 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-for-bexmarilimab 2024-08-27T22:15:39 https://maestrodatabase.com/blog/santhera-submits-marketing-authorisation-application-to-the-uk-mhra-for-vamorolone-in-duchenne-muscular-dystrophy 2023-03-02T19:49:51 https://maestrodatabase.com/blog/soleno-therapeutics-announces-us-fda-acceptance-for-filing-and-priority-review-of-nda-for-dccr-diazoxide-choline-extended-release-tablets-in-prader-willi-syndrome 2024-08-27T23:25:25 https://maestrodatabase.com/blog/verrica-pharmaceuticals-announces-fda-acceptance-of-filing-of-resubmitted-nda-for-vp-102-for-the-treatment-of-molluscum-contagiosum 2023-03-02T20:35:23 https://maestrodatabase.com/blog/kye-pharmaceuticals-announces-approval-in-canada-for-accrufer-ferric-maltol-for-the-treatment-of-iron-deficiency-anaemia-in-adult-patients 2024-08-28T01:30:11 https://maestrodatabase.com/blog/efficient-rcts-with-real-world-data-for-benefit-assessments-accelerating-evidence-based-care 2023-03-02T20:27:30 https://maestrodatabase.com/blog/fda-and-ftc-collaborate-to-advance-competition-in-the-biologic-marketplace 2023-03-02T20:31:26 https://maestrodatabase.com/blog/verzenio-a-ray-of-hope-for-breast-cancer-patients-should-get-insurance-benefits 2023-11-26T20:22:46 https://maestrodatabase.com/blog/european-commission-approves-astellas-padcev-enfortumab-vedotin-in-combination-with-keytruda-pembrolizumab-for-first-line-treatment-of-advanced-urothelial-cancer 2024-08-28T00:09:52 https://maestrodatabase.com/blog/novartis-receives-eu-approval-for-first-line-use-of-zykadia-in-alk-positive-advanced-non-small-cell-lung-cancer 2017-06-29T05:28:17 https://maestrodatabase.com/blog/u-dot-s-fda-grants-priority-review-of-xarelto-rivaroxaban-snda-for-a-10-mg-dose-to-reduce-the-risk-of-recurrent-venous-thromboembolism 2017-06-29T07:02:20 https://maestrodatabase.com/blog/mark-butler-secures-22-million-iv-fluid-bags-amid-major-shortage 2024-08-28T03:00:08 https://maestrodatabase.com/blog/ultra-fast-insulin-drug-fiasp-to-be-removed-from-pbs-making-it-unaffordable-for-many-diabetes-sufferers 2023-03-02T20:57:43 https://maestrodatabase.com/blog/xtandi-to-get-expanded-coverage-for-metastatic-hormone-sensitive-prostate-cancer-next-month 2023-11-26T21:56:41 https://maestrodatabase.com/blog/life-prolonging-breast-cancer-drug-receives-expanded-access-on-the-pbs 2024-08-28T02:11:53 https://maestrodatabase.com/blog/avadel-pharmaceuticals-requests-final-fda-approval-for-lumryz-sodium-oxybate-extended-release-oral-suspension 2023-03-02T20:43:53 https://maestrodatabase.com/blog/lilly-releases-zepbound-tirzepatide-single-dose-vials-expanding-supply-and-access-for-adults-living-with-obesity 2024-08-28T01:50:07 https://maestrodatabase.com/blog/linerixibat-new-drug-application-accepted-for-review-by-the-us-fda-for-cholestatic-pruritus-in-patients-with-primary-biliary-cholangitis 2025-06-05T23:05:58 https://maestrodatabase.com/blog/rybelsus-oral-semaglutide-approved-for-the-treatment-of-adults-with-type-2-diabetes-in-the-eu 2020-04-06T07:37:07 https://maestrodatabase.com/blog/sydnexis-announces-european-commission-approval-of-syd-101-the-first-and-only-pharmaceutical-treatment-for-slowing-the-progression-of-paediatric-myopia 2025-06-06T01:10:58 https://maestrodatabase.com/blog/us-fda-awards-fast-track-designation-to-paxalisib-for-glioblastoma 2020-08-20T08:15:18 https://maestrodatabase.com/blog/medicines-australia-and-the-generic-and-biosimilar-medicines-association-granted-interim-authorisation-by-the-accc 2020-04-06T09:06:57 https://maestrodatabase.com/blog/cigna-to-remove-abbvies-humira-from-some-drug-reimbursement-lists-next-year 2024-08-28T21:10:06 https://maestrodatabase.com/blog/trump-pushed-health-officials-to-make-anti-malaria-drugs-available-as-coronavirus-treatment-report 2020-04-06T07:41:27 https://maestrodatabase.com/blog/health-canada-grants-market-authorization-for-tecentriq-in-combination-with-bevacizumab-the-first-immunotherapy-combination-treatment-for-the-most-common-form-of-liver-cancer 2020-08-20T08:06:16 https://maestrodatabase.com/blog/ibm-bet-billions-that-watson-could-improve-cancer-treatment-it-hasnt-worked 2018-08-11T07:40:02 https://maestrodatabase.com/blog/amendments-to-the-new-restrictions-on-prescribing-hydroxychloroquine-for-covid-19 2020-04-06T11:44:43 https://maestrodatabase.com/blog/cheaper-medicines-and-more-bulk-billing 2023-11-27T04:41:31 https://maestrodatabase.com/blog/msd-korea-wins-coverage-boost-for-transplant-infection-drug-prevymis 2025-06-06T02:23:51 https://maestrodatabase.com/blog/india-has-cut-off-half-the-supply-of-a-potential-coronavirus-treatment-touted-by-trump 2020-04-06T11:55:37 https://maestrodatabase.com/blog/telix-submits-nda-for-tlx101-cdx-pixclara-brain-cancer-imaging-agent 2024-08-28T22:03:48 https://maestrodatabase.com/blog/precision-biosciences-receives-fast-track-disease-designation-from-u-dot-s-fda-for-pbcar0191-investigational-allogeneic-car-t-cell-therapy 2020-08-20T09:45:01 https://maestrodatabase.com/blog/eu-authorities-agree-new-measures-to-support-availability-of-medicines-used-in-the-covid-19-pandemic 2020-04-06T20:48:50 https://maestrodatabase.com/blog/an-update-on-covid-19-from-gilead-chairman-and-ceo 2020-04-06T20:52:02 https://maestrodatabase.com/blog/democrats-split-on-joining-gop-for-health-care-fix 2017-06-29T13:10:14 https://maestrodatabase.com/blog/autolus-therapeutics-receives-prime-designation-for-auto1-for-the-treatment-of-adult-all 2021-04-03T22:49:04 https://maestrodatabase.com/blog/covid-19-suggestions-for-funding-changes 2020-04-06T20:57:21 https://maestrodatabase.com/blog/shrouded-in-secrecy-the-pharmacy-guild-resists-deeper-scrutiny 2017-06-29T12:59:37 https://maestrodatabase.com/blog/a-coronavirus-casualty-delay-in-comprehensive-drug-pricing-legislation 2020-04-06T21:02:47 https://maestrodatabase.com/blog/bill-gates-to-spend-billions-on-coronavirus-vaccine-development 2020-04-06T12:19:26 https://maestrodatabase.com/blog/final-nice-nod-for-sanofis-gaucher-therapy 2017-06-29T20:57:14 https://maestrodatabase.com/blog/covid-19-csl-joins-global-hunt-for-vaccine 2020-04-06T20:44:15 https://maestrodatabase.com/blog/fda-unveils-plan-to-eliminate-orphan-designation-backlog 2017-06-29T21:11:39 https://maestrodatabase.com/blog/ono-receives-supplemental-approval-of-opdivo-in-japan-for-expanded-use-for-treatment-of-malignant-mesothelioma-excluding-malignant-pleural-mesothelioma 2023-11-27T07:03:33 https://maestrodatabase.com/blog/biogen-disappointed-by-inesss-recommendation-on-skyclarys-and-its-impact-on-quebec-patients-with-friedreich-ataxia 2025-06-06T01:59:11 https://maestrodatabase.com/blog/cash-back-for-health-fund-members-from-covid-19 2020-04-06T20:46:37 https://maestrodatabase.com/blog/nice-issues-draft-guidance-on-the-use-of-olumiant 2017-06-29T21:04:29 https://maestrodatabase.com/blog/fda-is-reviewing-generic-applications-faster-but-what-about-those-carryover-fees 2017-06-29T21:18:07 https://maestrodatabase.com/blog/could-the-coronavirus-vaccine-be-mandatory-in-australia-experts-say-its-possible 2020-08-20T10:39:15 https://maestrodatabase.com/blog/formycon-announces-ema-submission-for-fyb203-a-biosimilar-candidate-to-eylea-aflibercept 2023-11-27T20:21:05 https://maestrodatabase.com/blog/fda-allows-marketing-of-test-to-aid-in-the-detection-of-certain-leukemias-and-lymphomas 2017-06-29T21:14:09 https://maestrodatabase.com/blog/new-agreement-means-nice-recommends-combination-treatment-for-some-lymphoma-patients 2020-08-20T20:35:17 https://maestrodatabase.com/blog/in-an-overlooked-corner-of-pharma-drastic-price-hikes-hit-medicines-for-radiology-scans 2017-06-29T21:26:02 https://maestrodatabase.com/blog/krystal-biotech-announces-ema-validation-of-marketing-authorisation-application-for-vyjuvek-for-the-treatment-of-dystrophic-epidermolysis-bullosa 2023-11-27T20:15:28 https://maestrodatabase.com/blog/martin-shkrelis-trial-shows-just-how-angry-people-are-about-drug-prices 2017-06-29T21:23:46 https://maestrodatabase.com/blog/progenics-pharmaceuticals-announces-fda-acceptance-of-new-drug-application-for-azedra-iobenguane-i-131-in-pheochromocytoma-and-paraganglioma 2017-12-29T23:06:21 https://maestrodatabase.com/blog/fda-grants-priority-review-to-springworks-therapeutics-new-drug-application-for-mirdametinib-for-the-treatment-of-adults-and-children-with-neurofibromatosis-type-1-associated-plexiform-neurofibromas 2024-08-29T01:02:47 https://maestrodatabase.com/blog/election-2020-maori-partys-john-tamihere-says-diabetes-drugs-would-be-funded-if-pakeha-were-suffering 2020-08-20T20:40:43 https://maestrodatabase.com/blog/ema-accepts-valnevas-chikungunya-vaccine-marketing-authorisation-application-for-accelerated-assessment 2023-11-27T20:11:05 https://maestrodatabase.com/blog/rare-cancer-sufferers-given-reprieve-with-new-drug-subsidy 2017-06-29T21:31:29 https://maestrodatabase.com/blog/the-crazy-math-behind-drug-prices 2017-06-29T21:28:27 https://maestrodatabase.com/blog/covid-19-update-daily-roundup-6-april-2020 2020-04-06T21:13:58 https://maestrodatabase.com/blog/merz-aesthetics-receives-approval-from-health-canada-for-radiesse-as-an-aesthetic-injectable-for-the-treatment-of-moderate-wrinkles-in-the-decollete-area 2025-06-06T04:20:54 https://maestrodatabase.com/blog/abbvie-announces-us-fda-and-ema-updates-for-epcoritamab-epkinly-slash-tepkinly-for-the-treatment-of-relapsed-slash-refractory-follicular-lymphoma 2023-11-27T20:06:05 https://maestrodatabase.com/blog/life-molecular-imaging-receives-fda-fast-track-designation-for-18f-pi-2620-in-tau-pet-imaging-across-three-neurodegenerative-conditions 2024-08-29T00:51:02 https://maestrodatabase.com/blog/read-about-a-new-covid-19-treatment-study-it-probably-wont-work 2020-04-06T21:21:30 https://maestrodatabase.com/blog/polaryx-therapeutics-receives-fda-fast-track-designation-to-plx-200-for-the-treatment-of-patients-with-juvenile-neuronal-ceroid-lipofuscinosis 2020-08-20T10:32:41 https://maestrodatabase.com/blog/states-try-reducing-malaria-drug-hoarding-amid-unproven-coronavirus-benefit 2020-04-06T21:27:52 https://maestrodatabase.com/blog/new-drug-approvals-for-fda-2017-hits-21-year-high 2017-12-29T23:16:09 https://maestrodatabase.com/blog/genmab-announces-janssen-granted-u-dot-s-fda-approval-for-darzalex-daratumumab-in-combination-with-carfilzomib-and-dexamethasone-in-relapsed-or-refractory-multiple-myeloma 2020-08-20T20:56:08 https://maestrodatabase.com/blog/gw-pharmaceuticals-submits-marketing-authorisation-application-in-europe-for-epidiolex-cannabidiol-in-the-treatment-of-lennox-gastaut-syndrome-and-dravet-syndrome 2017-12-30T02:46:06 https://maestrodatabase.com/blog/lifeline-for-wolman-disease-kids-as-nice-backs-alexion-drug 2023-11-27T20:51:38 https://maestrodatabase.com/blog/european-commission-approves-rybrevant-amivantamab-in-combination-with-chemotherapy-for-the-treatment-of-adult-patients-with-advanced-egfr-mutated-non-small-cell-lung-cancer-after-failure-of-prior-therapy 2024-08-29T01:19:25 https://maestrodatabase.com/blog/u-dot-s-fda-grants-rare-paediatric-disease-designation-to-amidebios-glucagon-analog-for-the-treatment-of-congenital-hyperinsulinism 2020-08-20T21:03:30 https://maestrodatabase.com/blog/novartis-urges-court-to-hand-it-quick-win-in-drug-price-battle 2023-11-27T20:32:25 https://maestrodatabase.com/blog/three-quarters-of-new-zealanders-intend-to-get-covid-19-vaccine 2020-08-20T20:44:52 https://maestrodatabase.com/blog/investigational-lenacapavir-receives-positive-chmp-opinion-for-people-with-multi-drug-resistant-hiv 2022-06-26T02:38:01 https://maestrodatabase.com/blog/fda-approves-illumina-cancer-biomarker-test-with-two-companion-diagnostics-to-rapidly-match-patients-to-targeted-therapies 2024-08-29T01:15:04 https://maestrodatabase.com/blog/cost-of-exempting-sole-orphan-drugs-from-medicare-negotiation 2023-11-27T20:27:07 https://maestrodatabase.com/blog/fda-approves-novartis-kesimpta-ofatumumab-the-first-and-only-self-administered-targeted-b-cell-therapy-for-patients-with-relapsing-multiple-sclerosis 2020-08-20T20:48:24 https://maestrodatabase.com/blog/drug-makers-slash-prices-to-win-chinas-bulk-buy-contracts 2020-08-20T21:24:15 https://maestrodatabase.com/blog/life-saving-cystic-fibrosis-drug-still-unavailable-in-canada 2020-08-20T21:30:23 https://maestrodatabase.com/blog/spinal-muscular-atrophy-push-to-get-3-dollars-5-cents-million-drug-approved-to-save-babies-lives 2021-04-03T23:29:44 https://maestrodatabase.com/blog/pembrolizumab-in-combination-with-platinum--and-fluoropyrimidine-based-chemotherapy-for-the-treatment-of-patients-with-advanced-her2-negative-gastric-or-gastro-oesophageal-junction-adenocarcinoma 2024-08-29T01:33:39 https://maestrodatabase.com/blog/multiple-myeloma-drug-carfilzomib-added-to-pbs 2017-12-30T03:22:39 https://maestrodatabase.com/blog/fda-approves-first-paediatric-indication-for-xeomin-incobotulinumtoxina-for-the-treatment-of-upper-limb-spasticity-excluding-spasticity-caused-by-cerebral-palsy 2020-08-20T21:10:16 https://maestrodatabase.com/blog/swiss-data-protection-chief-pushes-back-on-drug-pricing-secrecy 2020-08-20T21:17:19 https://maestrodatabase.com/blog/ema-agrees-to-review-ucbs-bimekizumab 2020-08-20T21:47:37 https://maestrodatabase.com/blog/highlights-from-the-20-23-june-2022-chmp-meeting 2022-06-26T03:50:03 https://maestrodatabase.com/blog/two-cancer-fighting-medicines-listed-on-the-pbs-and-now-accessible-to-australians 2017-12-30T11:28:24 https://maestrodatabase.com/blog/first-gene-therapy-to-treat-severe-haemophilia-a 2022-06-26T04:30:04 https://maestrodatabase.com/blog/cystic-fibrosis-medicine-applications-to-be-considered-by-pharmac-and-medsafe-in-parallel 2021-04-04T23:53:38 https://maestrodatabase.com/blog/arvinas-announces-submission-of-new-drug-application-to-us-fda-for-vepdegestrant-for-patients-with-esr1-mutated-er-plus-slash-her2--advanced-or-metastatic-breast-cancer 2025-06-06T22:25:06 https://maestrodatabase.com/blog/u-dot-s-fda-approves-bristol-myers-squibbs-car-t-cell-therapy-breyanzi-for-relapsed-or-refractory-large-b-cell-lymphoma-after-one-prior-therapy 2022-06-26T07:08:33 https://maestrodatabase.com/blog/fda-approves-nirogacestat-for-desmoid-tumours 2023-11-27T22:38:55 https://maestrodatabase.com/blog/updates-to-the-procedure-guidance-for-listing-medicines-on-the-pbs 2021-10-15T07:48:44 https://maestrodatabase.com/blog/fixed-duration-calquence-based-regimens-approved-in-eu-for-patients-with-chronic-lymphocytic-leukaemia-in-the-first-line-setting 2025-06-06T06:18:56 https://maestrodatabase.com/blog/european-commission-approves-expanded-age-indication-for-gsks-arexvy-the-first-respiratory-syncytial-virus-vaccine-for-adults-aged-50-59-at-increased-risk 2024-08-29T21:11:53 https://maestrodatabase.com/blog/pharmac-releases-final-response-to-review 2023-03-03T00:17:24 https://maestrodatabase.com/blog/johnson-and-johnson-seeks-first-approval-of-nipocalimab-to-treat-broadest-population-living-with-antibody-positive-generalised-myasthenia-gravis 2024-08-29T21:04:51 https://maestrodatabase.com/blog/argenx-receives-positive-chmp-opinion-for-efgartigimod-for-the-treatment-of-adult-patients-with-generalised-myasthenia-gravis-in-europe 2022-06-26T08:18:57 https://maestrodatabase.com/blog/copikta-duvelisib-receives-positive-chmp-opinion-for-the-treatment-of-relapsed-and-refractory-cll-and-refractory-fl 2021-04-05T00:03:32 https://maestrodatabase.com/blog/european-commission-approves-takedas-alunbrig-brigatinib-as-a-first-line-treatment-for-alk-plus-nsclc 2020-04-07T01:18:18 https://maestrodatabase.com/blog/global-plasma-leaders-collaborate-to-accelerate-development-of-potential-covid-19-hyperimmune-therapy 2020-04-07T01:24:48 https://maestrodatabase.com/blog/amryt-to-pursue-formal-dispute-resolution-for-oleogel-s10-filsuvez-nda 2022-06-26T08:50:52 https://maestrodatabase.com/blog/doh-tweaks-the-agenda-for-next-weeks-pbac-meeting-2023-slash-1 2023-03-03T00:32:31 https://maestrodatabase.com/blog/emergent-biosolutions-announces-fda-acceptance-of-biologics-license-application-for-av7909-anthrax-vaccine-candidate 2022-06-26T08:30:02 https://maestrodatabase.com/blog/jw-therapeutics-announces-nmpa-approval-of-the-supplemental-biological-license-application-for-carteyva-in-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma 2024-08-29T21:17:52 https://maestrodatabase.com/blog/us-seeks-pharmaceutical-deal-with-switzerland-to-fast-track-fda-approvals 2022-06-26T21:54:52 https://maestrodatabase.com/blog/european-commission-approves-duvyzat-for-the-treatment-of-duchenne-muscular-dystrophy 2025-06-07T01:29:01 https://maestrodatabase.com/blog/abeona-therapeutics-announces-fda-accepts-and-grants-priority-review-for-pz-cel-biologics-license-application 2023-11-28T05:41:40 https://maestrodatabase.com/blog/pharmac-widens-flu-vaccine-access-to-increase-uptake 2022-06-26T21:40:18 https://maestrodatabase.com/blog/price-disclosure-2022-october-cycle-outcomes-summary 2022-06-26T21:49:13 https://maestrodatabase.com/blog/chmp-issues-a-positive-opinion-recommending-full-approval-of-oncopeptides-pepaxti-in-eu-for-patients-with-triple-class-refractory-multiple-myeloma 2022-06-26T10:36:55 https://maestrodatabase.com/blog/fda-approves-vectibix-panitumumab-for-use-in-wild-type-ras-metastatic-colorectal-cancer 2017-06-30T05:18:06 https://maestrodatabase.com/blog/aldeyra-therapeutics-receives-complete-response-letter-from-the-us-fda-for-the-reproxalap-new-drug-application-for-the-treatment-of-dry-eye-disease 2023-11-28T06:28:46 https://maestrodatabase.com/blog/autolus-therapeutics-submits-biologics-license-application-to-us-fda-for-obecabtagene-autoleucel-obe-cel-for-patients-with-relapsed-slash-refractory-adult-b-cell-acute-lymphoblastic-leukaemia 2023-11-28T05:56:01 https://maestrodatabase.com/blog/biocryst-achieves-reimbursement-for-orladeyo-across-all-major-european-countries 2025-06-07T00:57:38 https://maestrodatabase.com/blog/genelux-corporation-receives-fda-fast-track-designation-for-olvi-vec-in-platinum-resistant-slash-refractory-ovarian-cancer 2023-11-28T05:47:13 https://maestrodatabase.com/blog/fluoxetine-supply-issue 2020-04-07T05:48:28 https://maestrodatabase.com/blog/nubeqa-darolutamide-receives-eu-approval-for-additional-indication-in-prostate-cancer 2023-03-03T05:31:11 https://maestrodatabase.com/blog/public-summary-documents---november-2022-pbac-meeting-round-1 2023-03-03T05:15:27 https://maestrodatabase.com/blog/death-sentence-for-mum-with-skin-cancer-without-$100k-for-the-drugs-she-needs 2023-03-03T05:26:44 https://maestrodatabase.com/blog/recommendations-made-between-march-2021-and-november-2021-pbac-meetings 2021-10-15T21:24:02 https://maestrodatabase.com/blog/highlights-from-chmp-11-14-october-2021-meeting 2021-10-15T21:21:51 https://maestrodatabase.com/blog/fda-approvals-strengthen-octapharma-usa-paediatric-critical-care-product-portfolio 2021-04-05T00:19:15 https://maestrodatabase.com/blog/fda-approves-atezolizumab-as-adjuvant-treatment-for-non-small-cell-lung-cancer 2021-10-15T21:39:40 https://maestrodatabase.com/blog/nice-clears-opdivo-for-resected-oesophageal-or-gastro-oesophageal-junction-cancer 2021-10-15T22:01:53 https://maestrodatabase.com/blog/abpi-response-to-government-statutory-scheme-rise 2023-03-03T20:21:04 https://maestrodatabase.com/blog/bayer-submits-aflibercept-8-mg-for-marketing-authorisation-in-japan 2023-03-03T05:52:59 https://maestrodatabase.com/blog/us-fda-broadens-indication-for-verzenio-abemaciclib-in-hormone-receptor-positive-her2-negative-node-positive-high-risk-early-breast-cancer 2023-03-03T21:02:19 https://maestrodatabase.com/blog/health-minister-disputes-claim-he-sided-with-big-pharma-interfered-with-drug-price-consultations 2023-03-03T20:47:26 https://maestrodatabase.com/blog/chmp-adopts-positive-opinion-for-bavencio-avelumab-plus-axitinib-for-first-line-treatment-of-patients-with-advanced-renal-cell-carcinoma 2019-09-21T05:04:39 https://maestrodatabase.com/blog/bipartisan-senators-introduce-bill-to-close-pharma-competition-loophole 2023-03-03T21:16:39 https://maestrodatabase.com/blog/biden-says-other-companies-will-slash-insulin-prices-after-eli-lilly-move 2023-03-03T21:30:16 https://maestrodatabase.com/blog/simplified-prescribing-arrangements-for-chemotherapy-patients-during-the-covid-19-pandemic 2020-08-21T07:50:24 https://maestrodatabase.com/blog/decision-on-schedule-changes-made-in-response-to-covid-19 2020-08-21T07:53:20 https://maestrodatabase.com/blog/tlvs-web-application-for-tnf-inhibitors-shows-room-for-savings 2021-10-15T22:43:58 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-treatment-for-schizophrenia 2023-11-28T20:08:21 https://maestrodatabase.com/blog/astellas-receives-positive-chmp-opinion-for-xospata-gilteritinib-as-a-monotherapy-for-patients-with-relapsed-or-refractory-acute-myeloid-leukaemia-with-a-flt3-mutation 2019-09-21T05:19:18 https://maestrodatabase.com/blog/supernus-announces-fda-approval-of-qelbree-spn-812-for-the-treatment-of-adhd 2021-04-05T03:40:18 https://maestrodatabase.com/blog/orexo-announces-fda-acceptance-of-new-drug-application-filing-for-ox124-a-high-dose-rescue-medication-for-opioid-overdose 2023-11-28T19:59:48 https://maestrodatabase.com/blog/chmp-recommends-approval-of-dupixent-dupilumab-for-severe-chronic-rhinosinusitis-with-nasal-polyposis 2019-09-21T06:31:43 https://maestrodatabase.com/blog/daichirona-for-intramuscular-injection-for-booster-vaccination-approved-in-japan-as-omicron-xbb-dot-1-5-adapted-monovalent-mrna-vaccine-against-covid-19 2023-11-28T10:55:53 https://maestrodatabase.com/blog/humana-ceo-competition-and-innovation-lower-drug-prices-better-than-just-putting-a-cap-on-them 2019-09-21T06:26:30 https://maestrodatabase.com/blog/sernova-receives-orphan-drug-and-rare-paediatric-disease-designations-for-its-haemophilia-a-program-from-fda 2023-11-28T07:25:24 https://maestrodatabase.com/blog/fda-approves-first-oral-glp-1-treatment-for-type-2-diabetes 2019-09-21T06:19:16 https://maestrodatabase.com/blog/fda-fast-track-designation-granted-for-vaxinia-trial-program 2023-11-28T20:14:17 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac---july-2020 2020-08-21T08:19:02 https://maestrodatabase.com/blog/novartis-responds-to-social-media-criticism-of-trump-administration-promoting-hydroxychloroquine 2020-04-07T07:24:38 https://maestrodatabase.com/blog/celltrion-and-teva-announce-u-dot-s-fda-acceptance-of-biologics-license-application-for-proposed-biosimilar-to-rituxan-rituximab 2017-06-30T07:34:03 https://maestrodatabase.com/blog/esperion-announces-european-commission-approval-of-the-nilemdo-bempedoic-acid-tablet-for-the-treatment-of-hypercholesterolaemia-and-mixed-dyslipidaemia 2020-04-07T07:28:39 https://maestrodatabase.com/blog/abbvie-receives-chmp-positive-opinion-for-risankizumab-skyrizi-for-the-treatment-of-adults-with-active-psoriatic-arthritis-in-the-european-union 2021-10-16T00:03:41 https://maestrodatabase.com/blog/samsung-bioepis-receives-european-commission-approval-for-aynbintio-bevacizumab 2020-08-21T11:47:04 https://maestrodatabase.com/blog/tafasitamab-with-lenalidomide-for-treating-relapsed-or-refractory-diffuse-large-b-cell-lymphoma 2023-05-03T02:20:01 https://maestrodatabase.com/blog/agenda-for-the-september-2024-pbac-intracycle-meeting 2024-08-30T06:38:22 https://maestrodatabase.com/blog/celltrion-healthcare-receives-chmp-positive-opinion-for-biosimilar-bevacizumab-vegzelma-ct-p16 2022-06-27T04:56:53 https://maestrodatabase.com/blog/biomarin-submits-new-drug-application-to-u-dot-s-fda-for-vosoritide-to-treat-children-with-achondroplasia 2020-08-21T08:47:16 https://maestrodatabase.com/blog/novartis-announces-first-european-donation-of-hydroxychloroquine-to-switzerland 2020-04-07T11:02:55 https://maestrodatabase.com/blog/effector-receives-us-fda-fast-track-designation-for-zotatifin-in-combination-with-fulvestrant-and-abemaciclib-for-treatment-of-er-positive-slash-her2-negative-advanced-metastatic-breast-cancer 2023-11-29T07:01:56 https://maestrodatabase.com/blog/emergent-biosolutions-acam2000-smallpox-and-mpox-vaccinia-vaccine-live-receives-us-fda-approval-for-mpox-indication 2024-08-30T21:45:55 https://maestrodatabase.com/blog/public-summary-documents---may-2024-pbac-meeting 2024-08-30T06:51:00 https://maestrodatabase.com/blog/trumps-aggressive-advocacy-of-malaria-drug-for-treating-coronavirus-divides-medical-community 2020-04-07T10:39:49 https://maestrodatabase.com/blog/new-35-dollars-co-pay-now-available-through-lilly-insulin-value-program-in-response-to-covid-19-crisis-in-u-dot-s 2020-04-07T10:45:39 https://maestrodatabase.com/blog/essential-work-to-combat-the-covid-19-pandemic-to-continue-during-emas-easter-break-from-9-to-13-april-2020 2020-04-07T10:52:22 https://maestrodatabase.com/blog/chmp-recommends-approval-of-upadacitinib-rinvoq-for-the-treatment-of-adults-with-active-non-radiographic-axial-spondyloarthritis 2022-06-27T06:38:55 https://maestrodatabase.com/blog/trastuzumab-deruxtecan-recommended-for-approval-in-the-eu-by-chmp-for-patients-with-her2-positive-metastatic-breast-cancer-treated-with-a-prior-anti-her2-based-regimen 2022-06-27T06:32:03 https://maestrodatabase.com/blog/janssen-receives-positive-chmp-opinion-for-rybrevant-amivantamab-for-the-treatment-of-patients-with-advanced-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations-after-failure-of-platinum-based-therapy 2021-10-16T02:06:49 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-january-2018 2018-01-02T03:00:13 https://maestrodatabase.com/blog/foslevodopa-with-foscarbidopa-for-the-treatment-of-patients-with-advanced-parkinsons-with-motor-symptoms 2023-11-29T09:13:55 https://maestrodatabase.com/blog/scientists-rush-to-find-coronavirus-cure--but-it-still-isnt-fast-enough 2020-04-07T11:51:09 https://maestrodatabase.com/blog/india-again-allows-export-of-anti-malarial-drug-touted-for-coronavirus 2020-04-07T12:00:04 https://maestrodatabase.com/blog/trastuzumab-deruxtecan-supplemental-new-drug-application-submitted-in-japan-for-patients-with-her2-low-metastatic-breast-cancer 2022-06-27T06:57:43 https://maestrodatabase.com/blog/bristol-myers-squibb-expands-patient-support-programs-to-help-newly-uninsured-patients-in-the-u-dot-s 2020-04-07T11:29:09 https://maestrodatabase.com/blog/lynparza-recommended-for-approval-in-the-eu-by-chmp-as-adjuvant-treatment-for-patients-with-germline-brca-mutated-her2-negative-high-risk-early-breast-cancer 2022-06-27T06:50:01 https://maestrodatabase.com/blog/mallinckrodt-initiates-rolling-submission-of-biologics-license-application-for-stratagraft-regenerative-skin-tissue-to-u-dot-s-fda 2020-04-07T11:33:34 https://maestrodatabase.com/blog/alnylam-prices-first-gene-silencing-drug-at-450-000-dollars-per-patient-but-offers-money-back-guarantee 2018-08-12T01:53:01 https://maestrodatabase.com/blog/karuna-therapeutics-announces-us-fda-accepts-new-drug-application-for-karxt-for-the-treatment-of-schizophrenia 2023-11-29T19:59:03 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-september-2024 2024-08-31T21:17:19 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-september-2024 2024-08-31T21:13:19 https://maestrodatabase.com/blog/global-regulators-discuss-observational-studies-of-real-world-data-for-covid-19-medicines 2020-04-07T20:37:55 https://maestrodatabase.com/blog/japans-ministry-of-health-labour-and-welfare-approves-csl-and-arcturus-therapeutics-arct-154-the-first-self-amplifying-mrna-vaccine-approved-for-covid-in-adults 2023-11-29T19:50:08 https://maestrodatabase.com/blog/european-commission-approves-keytruda-pembrolizumab-as-adjuvant-treatment-for-adult-and-adolescent-patients-12-years-of-age-with-stage-iib-or-iic-melanoma-following-complete-resection 2022-06-27T07:32:53 https://maestrodatabase.com/blog/merck-receives-priority-review-from-fda-for-second-application-for-keytruda-pembrolizumab-based-on-biomarker-regardless-of-tumour-type 2020-04-07T20:42:04 https://maestrodatabase.com/blog/fyb201-formycons-biosimilar-for-lucentis-ranibizumab-receives-chmp-recommendation-from-ema 2022-06-27T07:23:35 https://maestrodatabase.com/blog/patients-on-edge-as-drug-price-bargaining-for-braftovi-prolongs 2023-11-29T19:45:54 https://maestrodatabase.com/blog/tisagenlecleucel-for-the-treatment-of-adults-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-after-2-or-more-systemic-therapies 2023-11-29T10:33:34 https://maestrodatabase.com/blog/fda-introduces-innovative-proposal-to-advance-consumer-access-to-non-prescription-drugs 2022-06-27T21:26:34 https://maestrodatabase.com/blog/cabometyx-cabozantinib-now-available-for-eligible-patients-with-non-clear-cell-renal-cell-carcinoma-via-the-pbs 2024-09-01T21:27:32 https://maestrodatabase.com/blog/blaze-bioscience-announces-fda-has-granted-fast-track-designation-to-blz-100-tozuleristide-for-paediatric-central-nervous-system-tumours 2020-04-07T21:07:06 https://maestrodatabase.com/blog/ipsen-announces-sale-of-priority-review-voucher-for-158-dollars-million 2024-09-01T21:19:21 https://maestrodatabase.com/blog/positive-mhra-decision-for-briviact 2022-06-27T11:06:20 https://maestrodatabase.com/blog/fda-authorises-updated-novavax-covid-19-vaccine-to-better-protect-against-currently-circulating-variants 2024-09-01T21:12:22 https://maestrodatabase.com/blog/oral-azacitidine-for-maintenance-treatment-of-acute-myeloid-leukaemia-after-induction-therapy 2022-10-05T11:04:43 https://maestrodatabase.com/blog/tlv-receives-assignments-for-medicines-for-rare-diseases 2022-06-27T21:52:24 https://maestrodatabase.com/blog/fda-investigating-serious-risk-of-t-cell-malignancy-following-bcma-directed-or-cd19-directed-autologous-chimeric-antigen-receptor-car-t-cell-immunotherapies 2023-11-29T20:42:23 https://maestrodatabase.com/blog/tlv-receives-a-new-assignment-on-precision-medicine-and-atmp 2022-06-27T21:44:35 https://maestrodatabase.com/blog/why-wont-congress-do-what-mark-cuban-is-doing-for-affordable-drug-prices 2022-06-27T21:47:57 https://maestrodatabase.com/blog/u-dot-s-fda-declines-to-approve-speros-urinary-tract-infection-drug 2022-06-27T21:37:37 https://maestrodatabase.com/blog/belzutifan-for-the-treatment-of-patients-with-a-tumour-associated-with-von-hippel-lindau-disease 2023-11-29T20:20:28 https://maestrodatabase.com/blog/fda-approves-treatment-for-chronic-weight-management-in-certain-paediatric-patients-aged-12-years-and-older 2022-06-27T21:40:26 https://maestrodatabase.com/blog/rare-disorders-nz-wants-new-minister-for-pharmac-to-act-swiftly-to-remove-pharmac-chair 2023-11-29T20:16:20 https://maestrodatabase.com/blog/biomarin-gilead-drug-rejections-dont-signal-a-change-in-attitude-at-the-fda 2020-08-21T21:22:56 https://maestrodatabase.com/blog/maestro-database-on-exhibit-at-ispor-asia-pacific-conference 2018-08-12T05:03:41 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-positive-chmp-opinion-for-zeposia-ozanimod-as-a-treatment-for-adult-patients-with-moderately-to-severely-active-ulcerative-colitis 2021-10-16T21:16:56 https://maestrodatabase.com/blog/phrma-scrambles-to-respond-to-trumps-drug-pricing-ultimatum-as-monday-deadline-looms 2020-08-21T22:54:09 https://maestrodatabase.com/blog/covid-19-vaccine-rollout-delay-hits-chemists 2021-04-05T20:55:37 https://maestrodatabase.com/blog/merck-receives-positive-chmp-opinion-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-in-individuals-18-years-of-age-and-older 2021-10-16T23:41:47 https://maestrodatabase.com/blog/icer-publishes-evidence-report-on-therapies-for-multiple-myeloma 2021-04-05T20:58:56 https://maestrodatabase.com/blog/smc---june-2025-decisions 2025-06-09T23:07:00 https://maestrodatabase.com/blog/pfizers-abrocitinib-receives-positive-chmp-opinion-for-the-treatment-of-adults-with-moderate-to-severe-atopic-dermatitis 2021-10-17T01:54:50 https://maestrodatabase.com/blog/curium-announces-the-submission-of-its-marketing-authorisation-application-for-18f--dcfpyl-to-the-ema 2022-06-28T03:41:50 https://maestrodatabase.com/blog/adverum-biotechnologies-granted-priority-medicines-prime-designation-by-ema-for-advm-022-in-wet-amd 2022-06-28T04:02:59 https://maestrodatabase.com/blog/merck-and-eisai-receive-positive-eu-chmp-opinions-for-keytruda-pembrolizumab-plus-lenvima-lenvatinib-in-two-different-types-of-cancer 2021-10-17T01:40:55 https://maestrodatabase.com/blog/george-medicines-announces-fda-approval-of-widaplik-telmisartan-amlodipine-and-indapamide-a-new-single-pill-combination-treatment-for-hypertension-in-adults-including-initial-treatment 2025-06-09T23:14:52 https://maestrodatabase.com/blog/lipocine-announces-filing-of-new-drug-submission-for-tlando-in-canada 2025-06-10T02:06:24 https://maestrodatabase.com/blog/camp4-therapeutics-secures-rare-paediatric-disease-designation-for-cmp-cps-001-for-the-treatment-of-urea-cycle-disorders 2024-09-02T01:27:58 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-to-sacituzumab-govitecan-for-urothelial-cancer 2020-04-08T03:49:00 https://maestrodatabase.com/blog/us-fda-approves-mercks-enflonsia-clesrovimab-cfor-for-prevention-of-respiratory-syncytial-virus-lower-respiratory-tract-disease-in-infants-born-during-or-entering-their-first-rsv-season 2025-06-10T02:17:32 https://maestrodatabase.com/blog/agenus-receives-fast-track-designation-for-balstilimab-in-advanced-cervical-cancer 2020-04-08T04:40:37 https://maestrodatabase.com/blog/medicine-and-medical-device-pricing-and-reimbursement-in-netherlands 2023-03-05T06:39:03 https://maestrodatabase.com/blog/3-dot-2-million-cheaper-medicine-in-2023 2023-03-05T09:55:35 https://maestrodatabase.com/blog/replacing-rcts-with-real-world-data-for-regulatory-decision-making-a-self-fulfilling-prophecy 2023-03-05T05:37:21 https://maestrodatabase.com/blog/australians-save-over-half-a-billion-dollars-on-cheaper-medicines 2024-09-02T02:32:00 https://maestrodatabase.com/blog/fees-and-charges-summary-from-1-july-2022 2022-06-28T05:14:00 https://maestrodatabase.com/blog/duncan-garner-dr-clark-this-is-life-or-death-please-help 2018-08-12T21:14:50 https://maestrodatabase.com/blog/fda-approves-new-vaginal-ring-for-one-year-of-birth-control 2018-08-12T21:19:46 https://maestrodatabase.com/blog/trump-administration-ends-medicaid-loophole-in-drug-rebates 2018-08-12T21:44:08 https://maestrodatabase.com/blog/swissmedic-approval-times-slow-down 2020-08-22T01:24:36 https://maestrodatabase.com/blog/alnylam-completes-rolling-submission-of-new-drug-application-to-the-u-dot-s-fda-and-submits-marketing-authorisation-application-to-the-ema-for-lumasiran-for-the-treatment-of-primary-hyperoxaluria-type-1 2020-04-08T05:21:16 https://maestrodatabase.com/blog/beyondspring-announces-submission-of-new-drug-application-to-u-dot-s-fda-and-china-nmpa-for-plinabulin-and-g-csf-combination-for-the-prevention-of-chemotherapy-induced-neutropenia 2021-04-05T23:51:10 https://maestrodatabase.com/blog/alnylam-receives-european-commission-approval-for-amvuttra-vutrisiran-for-the-treatment-of-attr-amyloidosis-with-cardiomyopathy 2025-06-10T02:42:05 https://maestrodatabase.com/blog/a-new-deal-protects-australians-chemists-at-the-expense-of-patients 2019-09-22T03:11:58 https://maestrodatabase.com/blog/kite-submits-supplemental-biologics-license-application-to-u-dot-s-fda-for-tecartus-in-adult-patients-with-relapsed-or-refractory-acute-lymphoblastic-leukaemia 2021-04-06T00:55:19 https://maestrodatabase.com/blog/our-progress-in-the-funding-of-medicines-for-rare-disorders 2023-03-05T19:56:43 https://maestrodatabase.com/blog/innovent-and-lilly-jointly-announce-the-approval-of-tyvyt-sintilimab-by-china-nmpa-in-combination-with-chemotherapy-as-first-line-treatment-of-advanced-or-metastatic-gastric-or-gastro-oesophageal-junction-adenocarcinoma 2022-06-28T08:03:30 https://maestrodatabase.com/blog/catherine-has-stage-four-breast-cancer-but-she-cant-access-a-new-treatment-in-australia 2023-03-05T19:50:49 https://maestrodatabase.com/blog/nexviadyme-avalglucosidase-alfa-approved-by-european-commission-as-a-potential-new-standard-of-care-for-the-treatment-of-pompe-disease 2022-06-28T07:55:42 https://maestrodatabase.com/blog/mercks-pifelto-doravirine-and-delstigo-doravirine-slash-lamivudine-slash-tenofovir-disoproxil-fumarate-receive-us-fda-approval-for-use-in-appropriate-adults-living-with-hiv-1-who-are-virologically-suppressed 2019-09-22T03:05:44 https://maestrodatabase.com/blog/cosentyx-secukinumab-receives-expanded-approvals-in-eu-for-use-in-childhood-arthritic-conditions 2022-06-28T07:51:01 https://maestrodatabase.com/blog/united-therapeutics-announces-fda-approval-and-launch-of-tyvaso-for-the-treatment-of-pulmonary-hypertension-associated-with-interstitial-lung-disease 2021-04-06T00:05:40 https://maestrodatabase.com/blog/accelerating-the-shift-toward-person-generated-real-world-evidence 2019-09-22T03:17:27 https://maestrodatabase.com/blog/xenpozyme-olipudase-alfa-approved-by-european-commission-as-first-and-only-treatment-for-asmd 2022-06-28T07:41:38 https://maestrodatabase.com/blog/axsome-therapeutics-provides-update-on-the-new-drug-application-for-axs-14-for-the-management-of-fibromyalgia 2025-06-10T03:35:01 https://maestrodatabase.com/blog/fda-needs-a-competitiveness-czar 2021-10-17T20:29:34 https://maestrodatabase.com/blog/acadia-pharmaceuticals-receives-complete-response-letter-from-u-dot-s-fda-for-supplemental-new-drug-application-for-pimavanserin-for-the-treatment-of-hallucinations-and-delusions-associated-with-dementia-related-psychosis 2021-04-06T01:17:28 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac---september-2021-intracycle-meeting 2021-10-17T19:59:13 https://maestrodatabase.com/blog/recent-trends-in-medicaid-spending-and-use-of-drugs-with-us-food-and-drug-administration-accelerated-approval 2021-10-17T20:25:14 https://maestrodatabase.com/blog/how-much-does-it-cost-to-research-and-develop-a-new-drug-a-systematic-review-and-assessment 2021-10-17T20:21:21 https://maestrodatabase.com/blog/gilead-resubmits-new-drug-application-to-u-dot-s-fda-for-lenacapavir-an-investigational-long-acting-hiv-1-capsid-inhibitor 2022-06-28T08:11:45 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-january-2018-update 2018-01-02T07:15:56 https://maestrodatabase.com/blog/janssen-receives-positive-chmp-opinion-for-imbruvica-ibrutinib-in-a-fixed-duration-combination-regimen-for-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia 2022-06-28T11:20:19 https://maestrodatabase.com/blog/research-funding-and-more-treatment-options-to-support-the-fight-against-mnd 2025-06-10T07:33:06 https://maestrodatabase.com/blog/nhs-cannabis-guidelines-challenged-in-court 2020-08-22T02:27:30 https://maestrodatabase.com/blog/why-the-u-dot-s-spends-so-much-more-than-other-nations-on-health-care 2018-01-02T11:25:46 https://maestrodatabase.com/blog/kyowa-kirin-receives-positive-chmp-opinion-for-use-of-crysvita-burosumab-for-the-treatment-of-tumour-induced-osteomalacia 2022-06-28T11:11:52 https://maestrodatabase.com/blog/the-innovative-medicines-fund---good-news-for-patients-but-has-an-opportunity-been-missed-to-be-more-ambitious 2022-06-28T21:46:01 https://maestrodatabase.com/blog/idecabtagene-vicleucel-for-the-treatment-of-patients-with-relapsed-and-refractory-multiple-myeloma-after-3-or-more-treatments 2023-11-30T04:04:44 https://maestrodatabase.com/blog/monkeypox-ema-starts-review-for-imvanex 2022-06-28T12:16:31 https://maestrodatabase.com/blog/doh-publishes-revised-agenda-for-july-2025-pbac-meeting-version-4 2025-06-10T05:15:50 https://maestrodatabase.com/blog/apnimed-granted-fda-fast-track-designation-for-ad109-a-novel-first-in-class-oral-pharmacologic-combination-for-the-treatment-of-obstructive-sleep-apnoea 2022-06-28T12:08:03 https://maestrodatabase.com/blog/cystic-fibrosis-survivor-calls-for-trikafta-to-be-listed-on-pbs 2021-04-06T02:28:09 https://maestrodatabase.com/blog/genentech-provides-regulatory-update-on-risdiplam-for-the-treatment-of-spinal-muscular-atrophy 2020-04-08T06:47:38 https://maestrodatabase.com/blog/pear-therapeutics-and-prescryptive-health-announce-formulary-coverage-for-prescription-digital-therapeutics-reset-and-reset-o-for-the-treatment-of-substance-and-opioid-use-disorders 2021-04-06T02:01:50 https://maestrodatabase.com/blog/health-canada-approves-opdivo-nivolumab-as-monotherapy-for-the-adjuvant-treatment-of-adults-with-urothelial-carcinoma-at-high-risk-of-recurrence-after-undergoing-radical-resection-of-urothelial-carcinoma 2022-06-28T21:59:35 https://maestrodatabase.com/blog/submissions-on-whether-the-tga-should-publish-that-a-prescription-medicine-is-under-evaluation 2020-04-08T07:40:30 https://maestrodatabase.com/blog/development-of-an-international-template-to-support-patient-submissions-in-health-technology-assessments 2021-04-06T03:34:30 https://maestrodatabase.com/blog/zepzelca-lurbinectedin-and-atezolizumab-tecentriq-combination-granted-us-fda-priority-review-for-first-line-maintenance-treatment-of-extensive-stage-small-cell-lung-cancer 2025-06-10T23:37:18 https://maestrodatabase.com/blog/statement-by-acting-australian-government-chief-medical-officer-professor-michael-kidd-and-head-of-the-therapeutic-goods-administration-adjunct-professor-john-skerritt 2021-04-06T04:39:56 https://maestrodatabase.com/blog/snt-5505-awarded-us-fda-fast-track-designation 2025-06-10T23:44:36 https://maestrodatabase.com/blog/fda-makes-two-revisions-to-moderna-covid-19-vaccine-emergency-use-authorization-to-help-increase-the-number-of-vaccine-doses-available 2021-04-06T05:06:17 https://maestrodatabase.com/blog/biofrontera-submits-application-for-fda-approval-of-new-bf-rhodoled-xl-lamp 2021-04-06T04:21:40 https://maestrodatabase.com/blog/decision-to-widen-access-to-secukinumab-for-psoriatic-arthritis-and-ankylosing-spondylitis 2021-04-06T04:29:34 https://maestrodatabase.com/blog/advanced-accelerator-applications-announces-health-canada-approval-of-netspot-diagnostic-imaging-agent-kit-to-detect-neuroendocrine-tumours 2020-04-08T10:39:55 https://maestrodatabase.com/blog/x4-pharmaceuticals-granted-fast-track-designation-for-mavorixafor-for-the-treatment-of-chronic-neutropenia-by-us-fda 2025-06-10T23:31:39 https://maestrodatabase.com/blog/new-treatment-game-changer-for-cancer-patient 2020-04-08T10:52:29 https://maestrodatabase.com/blog/cabozantinib-maleate-with-nivolumab-for-patients-with-untreated-advanced-renal-cell-carcinoma 2023-11-30T06:01:49 https://maestrodatabase.com/blog/chinas-drugs-problem-spells-opportunity-for-pharma-giants 2018-08-13T05:47:21 https://maestrodatabase.com/blog/unitedhealth-will-speed-payments-to-doctors-hospitals 2020-04-08T11:00:46 https://maestrodatabase.com/blog/oxford-biotherapeutics-announces-partner-boehringer-ingelheim-received-us-fda-fast-track-designation-for-bi-764532-for-the-potential-treatment-of-advanced-or-metastatic-large-cell-neuroendocrine-carcinoma-of-the-lung 2023-11-30T05:54:14 https://maestrodatabase.com/blog/esperion-announces-european-commission-approval-of-the-nustendi-bempedoic-acid-and-ezetimibe-tablet-for-the-treatment-of-hypercholesterolaemia-and-mixed-dyslipidaemia 2020-04-08T11:04:42 https://maestrodatabase.com/blog/fewer-australians-are-dying-from-hepatitis-c-but-thousands-are-still-missing-out-on-treatment 2018-08-13T03:07:16 https://maestrodatabase.com/blog/tga-provisional-approval-of-roche-covid-19-treatment-casirivimab-with-imdevimab-ronapreve 2021-10-18T00:08:14 https://maestrodatabase.com/blog/ipsen-announces-u-dot-s-fda-priority-review-for-palovarotene-new-drug-application-in-patients-with-fibrodysplasia-ossificans-progressiva-following-resubmission 2022-06-29T11:50:41 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-european-commission-approval-of-reblozyl-luspatercept-for-anaemia-in-adult-patients-with-non-transfusion-dependent-beta-thalassaemia 2023-03-06T08:47:23 https://maestrodatabase.com/blog/bristol-myers-squibb-announces-acceptance-of-u-dot-s-and-eu-regulatory-filings-for-opdivo-nivolumab-plus-yervoy-ipilimumab-combined-with-limited-chemotherapy-in-first-line-lung-cancer 2020-04-08T11:22:58 https://maestrodatabase.com/blog/fda-accepts-supplemental-biologics-license-application-and-grants-priority-review-for-adcetris-brentuximab-vedotin-in-front-line-advanced-hodgkins-lymphoma 2018-01-02T23:16:59 https://maestrodatabase.com/blog/fda-accepts-eisais-filing-of-a-supplemental-biologics-license-application-and-grants-priority-review-for-traditional-approval-of-leqembi-lecanemab-irmb-for-the-treatment-of-alzheimers-disease 2023-03-06T02:11:03 https://maestrodatabase.com/blog/achaogen-announces-fda-acceptance-of-new-drug-application-with-priority-review-for-plazomicin-for-treatment-of-complicated-urinary-tract-infections-and-bloodstream-infections 2018-01-02T23:36:41 https://maestrodatabase.com/blog/bavarian-nordic-announces-grant-of-prime-eligibility-from-the-ema-for-its-rsv-vaccine-candidate-for-the-prevention-of-respiratory-syncytial-virus-in-older-adults 2022-06-29T12:35:59 https://maestrodatabase.com/blog/priorities-for-a-new-fda 2025-06-11T02:57:06 https://maestrodatabase.com/blog/breast-cancer-sufferer-calls-for-life-saving-kadcyla-drug-to-be-publicly-funded 2018-08-13T08:53:19 https://maestrodatabase.com/blog/ozempic-like-weight-loss-drug-wegovy-coming-to-the-uk-market-and-it-will-cost-a-fraction-of-what-americans-pay 2023-03-06T19:43:15 https://maestrodatabase.com/blog/obseva-announces-uk-mhra-marketing-authorisation-for-yselty-linzagolix-an-oral-gnrh-antagonist-for-the-treatment-of-uterine-fibroids 2022-06-29T12:24:28 https://maestrodatabase.com/blog/roche-receives-fda-approval-of-label-expansion-for-ventana-pd-l1-sp263-assay-to-identify-patients-with-locally-advanced-and-metastatic-non-small-cell-lung-cancer-eligible-for-libtayo 2023-03-06T09:30:42 https://maestrodatabase.com/blog/us-fda-approves-intramuscular-administration-for-mercks-mmrv-family-of-vaccines-m-m-rii-measles-mumps-and-rubella-virus-vaccine-live-varivax-varicella-virus-vaccine-live-and-proquad-measles-mumps-rubella-and-varicella-virus-vaccine-live 2023-03-06T19:38:30 https://maestrodatabase.com/blog/declining-hiv-numbers-bolstered-by-new-prevention-drug-but-more-data-needed 2018-08-13T20:35:51 https://maestrodatabase.com/blog/nice-publishes-its-800th-technology-assessment 2022-06-29T12:06:41 https://maestrodatabase.com/blog/sooma-medical-receives-fda-breakthrough-device-designation-for-its-innovative-at-home-depression-treatment-device 2023-03-06T09:26:25 https://maestrodatabase.com/blog/melbourne-man-spends-80-000-dollars-on-the-miracle-cancer-drug-that-saved-his-life 2018-08-13T20:41:52 https://maestrodatabase.com/blog/ms-patient-tells-of-stress-of-meeting-pharmac-criteria 2018-08-13T20:32:52 https://maestrodatabase.com/blog/eylea-aflibercept-injection-sbla-for-every-16-week-dosing-regimen-in-patients-with-diabetic-retinopathy-accepted-for-fda-review 2022-06-29T11:57:46 https://maestrodatabase.com/blog/real-world-evidence-and-real-world-data-for-evaluating-drug-safety-and-effectiveness 2018-08-13T20:58:05 https://maestrodatabase.com/blog/breaking-the-rule-of-drug-pricing-in-america 2022-06-29T21:32:21 https://maestrodatabase.com/blog/promoting-patient-interests-in-implementing-the-federal-right-to-try-act 2018-08-13T21:01:43 https://maestrodatabase.com/blog/smc---august-2018-decisions 2018-08-13T20:52:45 https://maestrodatabase.com/blog/acceleron-receives-fda-breakthrough-therapy-designation-for-sotatercept-in-pulmonary-arterial-hypertension 2020-04-08T11:53:33 https://maestrodatabase.com/blog/reimbursement-price-of-gerd-drug-fexclu-finalised-at-0-dollars-73-cents 2022-06-29T21:26:15 https://maestrodatabase.com/blog/trevena-announces-fda-acceptance-for-review-of-new-drug-application-for-olinvo-oliceridine-injection 2018-01-03T01:27:15 https://maestrodatabase.com/blog/azurity-pharmaceuticals-announces-the-fda-approval-of-xifyrm-meloxicam-injection-for-the-management-of-moderate-to-severe-pain-in-adults 2025-06-11T01:30:17 https://maestrodatabase.com/blog/gsk-receives-positive-chmp-opinion-for-intravenous-benlysta-in-children-with-lupus-aged-five-years-and-above 2019-09-22T20:34:45 https://maestrodatabase.com/blog/ikena-oncology-receives-fda-fast-track-designation-for-novel-ahr-antagonist-ik-175-in-combination-with-nivolumab-to-treat-urothelial-carcinoma 2023-03-06T20:03:40 https://maestrodatabase.com/blog/accuretic-supply-issue-almost-36-000-new-zealanders-taking-the-blood-pressure-medicine-will-need-to-change-treatments 2022-06-29T21:15:28 https://maestrodatabase.com/blog/interacting-with-the-fda-on-complex-innovative-trial-designs-for-drugs-and-biological-products 2019-09-22T20:28:58 https://maestrodatabase.com/blog/fearing-blue-wave-drug-insurance-companies-build-single-payer-defence 2018-08-13T21:16:27 https://maestrodatabase.com/blog/cvs-move-to-lean-on-icer-data-could-mean-dramatic-shift-in-drug-pricing-leverage 2018-08-13T21:06:10 https://maestrodatabase.com/blog/calls-for-weight-loss-drugs-like-ozempic-to-be-subsidised-for-people-with-schizophrenia 2025-06-11T01:46:58 https://maestrodatabase.com/blog/regeneron-provides-regulatory-update-on-eylea-aflibercept-injection-sbla-in-wet-age-related-macular-degeneration 2018-08-13T21:08:59 https://maestrodatabase.com/blog/janssen-announces-u-dot-s-fda-breakthrough-therapy-designation-granted-for-talquetamab-for-the-treatment-of-relapsed-or-refractory-multiple-myeloma 2022-06-29T21:08:19 https://maestrodatabase.com/blog/will-reimbursement-criteria-of-sma-treatment-spinraza-change 2023-03-06T19:52:38 https://maestrodatabase.com/blog/amicus-sets-315-000-dollars-price-for-new-fabry-disease-treatment 2018-08-13T21:29:54 https://maestrodatabase.com/blog/patient-focused-drug-development-selecting-developing-or-modifying-fit-for-purpose-clinical-outcome-assessments 2022-06-29T21:57:11 https://maestrodatabase.com/blog/gottlieb-fda-will-streamline-drug-safety-evaluations 2018-08-13T21:18:33 https://maestrodatabase.com/blog/stemline-therapeutics-announces-that-fda-accepts-elzonris-biologics-license-application-and-grants-priority-review 2018-08-13T21:22:05 https://maestrodatabase.com/blog/clinical-benefit-and-expedited-approval-of-cancer-drugs-in-the-united-states-european-union-switzerland-japan-canada-and-australia 2022-06-29T21:46:49 https://maestrodatabase.com/blog/new-class-of-drugs-fulfils-promise-of-rna-based-medicine 2018-08-13T23:26:02 https://maestrodatabase.com/blog/cantargias-nadunolimab-antibody-awarded-us-fda-fast-track-designation 2025-06-11T23:06:31 https://maestrodatabase.com/blog/sanofi-caps-out-of-pocket-insulin-cost-at-35-dollars-for-uninsured-u-dot-s-patients 2022-06-29T21:41:17 https://maestrodatabase.com/blog/nice-backs-restricted-use-of-ondexxya 2021-04-06T11:40:14 https://maestrodatabase.com/blog/calls-to-make-cancer-drugs-more-affordable 2018-08-13T21:34:00 https://maestrodatabase.com/blog/cows-come-home-for-csl-in-covid-19-vaccine-battle 2020-04-08T20:57:35 https://maestrodatabase.com/blog/us-fda-approves-expanded-indication-for-abbvies-mavyret-glecaprevir-slash-pibrentasvir-as-first-and-only-treatment-for-people-with-acute-hepatitis-c-virus 2025-06-11T21:24:39 https://maestrodatabase.com/blog/csl-boosting-flu-vaccine-supply-in-coronavirus-crisis 2020-04-08T21:01:29 https://maestrodatabase.com/blog/its-huge-life-changing-cystic-fibrosis-drug-a-step-closer-to-being-funded-by-pharmac 2021-04-06T20:51:57 https://maestrodatabase.com/blog/fda-approves-taletrectinib-for-ros1-positive-non-small-cell-lung-cancer 2025-06-11T21:32:04 https://maestrodatabase.com/blog/fda-accepts-new-drug-application-to-review-midazolam-nasal-spray-an-investigational-product-for-the-acute-treatment-of-seizure-clusters 2018-08-13T23:31:38 https://maestrodatabase.com/blog/pharmaceutical-profits-and-public-health-are-not-incompatible 2020-04-08T21:07:44 https://maestrodatabase.com/blog/lilly-and-incyte-communicate-review-extension-of-supplemental-new-drug-application-for-baricitinib-for-the-treatment-of-moderate-to-severe-atopic-dermatitis 2021-04-06T20:56:26 https://maestrodatabase.com/blog/cadth-and-covid-19 2020-04-08T20:48:55 https://maestrodatabase.com/blog/novartis-kisqali-received-fda-breakthrough-therapy-designation-for-initial-endocrine-based-treatment-in-pre-menopausal-women-with-hr-plus-slash-her2--advanced-breast-cancer 2018-01-03T07:29:32 https://maestrodatabase.com/blog/fda-approves-first-generic-of-a-commonly-used-albuterol-slash-salbutamol-inhaler-to-treat-and-prevent-bronchospasm 2020-04-08T20:52:12 https://maestrodatabase.com/blog/nhs-prescription-charges-to-rise-in-price-today 2021-04-06T20:49:16 https://maestrodatabase.com/blog/gene-therapy-for-inherited-blindness-sets-precedent-850-000-dollar-price-tag 2018-01-03T21:35:35 https://maestrodatabase.com/blog/fda-grants-breakthrough-therapy-designation-for-xolair-omalizumab-for-food-allergies 2018-08-14T02:21:30 https://maestrodatabase.com/blog/statement-from-fda-commissioner-on-new-steps-to-facilitate-efficient-generic-drug-review-to-enhance-competition-promote-access-and-lower-drug-prices 2018-01-03T21:31:47 https://maestrodatabase.com/blog/burosumab-for-the-treatment-of-adults-with-x-linked-hypophosphataemia 2024-08-07T03:10:26 https://maestrodatabase.com/blog/prevalence-and-nature-of-manufacturer-sponsored-patient-support-programs-for-prescription-drugs-in-canada-a-cross-sectional-study 2023-11-30T09:34:20 https://maestrodatabase.com/blog/update-on-u-dot-s-fda-review-of-biologics-license-application-for-bimekizumab 2022-05-13T21:33:09 https://maestrodatabase.com/blog/ema-starts-evaluating-use-of-covid-19-vaccine-comirnaty-in-children-aged-5-to-11 2021-10-18T19:37:24 https://maestrodatabase.com/blog/cellectars-clr-131-receives-fda-rare-paediatric-disease-designation-for-the-treatment-of-ewings-sarcoma 2018-08-14T03:07:57 https://maestrodatabase.com/blog/novartis-applauds-quebec-the-first-province-to-list-zolgensma-for-the-treatment-of-paediatric-patients-with-spinal-muscular-atrophy 2021-10-18T06:39:07 https://maestrodatabase.com/blog/radiopharm-theranostics-granted-us-fda-fast-track-designation-for-rad101-imaging-in-brain-metastases 2025-06-12T00:19:57 https://maestrodatabase.com/blog/fda-approves-cyltezo-the-first-interchangeable-biosimilar-to-humira 2021-10-18T19:48:38 https://maestrodatabase.com/blog/australia-secures-additional-covid-19-treatments 2021-10-18T20:02:05 https://maestrodatabase.com/blog/fda-approves-naloxone-injection-to-counteract-opioid-overdoses 2021-10-18T19:56:57 https://maestrodatabase.com/blog/new-asthma-drug-approved-on-nhs-branded-a-wonder-drug 2021-10-18T19:41:38 https://maestrodatabase.com/blog/oxford-vaccine-against-deadly-nipah-virus-granted-ema-prime-designation 2025-06-12T01:32:17 https://maestrodatabase.com/blog/health-canada-authorises-piasky-crovalimab-for-injection-as-the-first-monthly-every-four-weeks-subcutaneous-treatment-for-people-with-paroxysmal-nocturnal-haemoglobinuria 2025-06-12T01:36:49 https://maestrodatabase.com/blog/nice-approves-ofev-for-pf-ild 2021-10-18T19:44:48 https://maestrodatabase.com/blog/pharmac-announces-decision-to-fund-trikafta 2023-03-07T00:44:41 https://maestrodatabase.com/blog/omeros-receives-complete-response-letter-from-fda-for-biologics-license-application-for-narsoplimab-in-the-treatment-of-hsct-tma 2021-10-18T20:22:08 https://maestrodatabase.com/blog/ema-grants-prime-designation-for-jr-141-for-the-treatment-of-mucopolysaccharidosis-type-ii-hunter-syndrome 2021-10-18T20:06:00 https://maestrodatabase.com/blog/revance-provides-regulatory-update-on-daxibotulinumtoxina-for-injection-for-the-treatment-of-moderate-to-severe-glabellar-frown-lines 2021-10-18T20:17:11 https://maestrodatabase.com/blog/oyster-point-pharma-announces-fda-approval-of-tyrvaya-varenicline-solution-nasal-spray-for-the-treatment-of-the-signs-and-symptoms-of-dry-eye-disease 2021-10-18T20:11:40 https://maestrodatabase.com/blog/alnylam-receives-positive-reimbursement-recommendation-from-the-cadth-for-use-of-givlaari-for-the-treatment-of-acute-hepatic-porphyria-in-adults 2021-10-18T20:42:39 https://maestrodatabase.com/blog/gileads-trodelvy-wins-korean-coverage-for-breast-cancer----too-late-for-some-and-still-off-limits-up-front 2025-06-12T03:26:26 https://maestrodatabase.com/blog/u-dot-s-fda-approves-braftovi-encorafenib-in-combination-with-cetuximab-for-the-treatment-of-braf-v600e-mutant-metastatic-colorectal-cancer-after-prior-therapy 2020-04-08T23:39:19 https://maestrodatabase.com/blog/vadadustat-for-symptomatic-anaemia-due-to-chronic-kidney-disease-missed-opportunity 2024-09-03T03:56:14 https://maestrodatabase.com/blog/us-fda-approves-tablet-formulation-of-beones-brukinsa-for-all-approved-indications 2025-06-12T03:38:03 https://maestrodatabase.com/blog/united-therapeutics-provides-an-update-on-the-progress-of-the-tyvaso-dpi-new-drug-application 2021-10-18T20:29:44 https://maestrodatabase.com/blog/dupixent-dupilumab-application-for-treatment-of-chronic-spontaneous-urticaria-in-adults-and-adolescents-accepted-for-fda-review 2023-03-07T06:16:10 https://maestrodatabase.com/blog/us-fda-approves-expanded-indication-of-gileads-biktarvy-for-treatment-of-hiv-1-in-paediatric-populations 2021-10-18T20:37:52 https://maestrodatabase.com/blog/doh-makes-further-tweaks-to-the-agenda-for-this-weeks-pbac-meeting 2023-03-07T00:56:47 https://maestrodatabase.com/blog/pharmac-funds-two-new-treatments-for-lung-cancer 2023-03-07T01:51:55 https://maestrodatabase.com/blog/tech-giants-pledge-to-ease-patient-provider-access-to-health-data 2018-08-14T04:34:38 https://maestrodatabase.com/blog/ema-2024-annual-report-is-published 2025-06-12T04:02:16 https://maestrodatabase.com/blog/on-covid-19-booster-shots-the-fda-has-overstepped-its-role 2021-10-18T21:21:43 https://maestrodatabase.com/blog/fda-approves-mitomycin-intravesical-solution-for-recurrent-low-grade-intermediate-risk-non-muscle-invasive-bladder-cancer 2025-06-12T22:13:53 https://maestrodatabase.com/blog/fda-approves-neo-adjuvant-and-adjuvant-pembrolizumab-for-resectable-locally-advanced-head-and-neck-squamous-cell-carcinoma 2025-06-12T22:20:23 https://maestrodatabase.com/blog/ionis-announces-fda-acceptance-of-new-drug-application-for-eplontersen-for-the-treatment-of-hereditary-transthyretin-mediated-amyloid-polyneuropathy 2023-03-07T19:18:40 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-december-2023 2023-11-30T19:49:09 https://maestrodatabase.com/blog/cigna-humana-in-talks-for-blockbuster-merger 2023-11-30T19:43:16 https://maestrodatabase.com/blog/avadel-pharmaceuticals-announces-ongoing-fda-review-of-nda-for-ft218-for-patients-with-narcolepsy 2021-10-18T21:44:57 https://maestrodatabase.com/blog/biomarin-provides-update-on-fda-review-of-roctavian-valoctocogene-roxaparvovec-gene-therapy-for-adults-with-severe-haemophilia-a 2023-03-07T06:51:12 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-december-2023 2023-11-30T20:00:39 https://maestrodatabase.com/blog/fda-grants-lenire-tinnitus-treatment-device-de-novo-approval 2023-03-07T19:40:47 https://maestrodatabase.com/blog/sumitomo-pharma-america-announces-that-nuvisertib-tp-3654-has-received-fda-fast-track-designation-for-the-treatment-of-myelofibrosis 2025-06-12T23:13:52 https://maestrodatabase.com/blog/shorla-oncology-announces-us-fda-approval-of-nelarabine-injection-for-the-treatment-of-t-cell-leukaemia 2023-03-07T19:23:46 https://maestrodatabase.com/blog/adding-more-medicines-to-the-pbs-to-help-more-patients 2017-07-01T07:12:04 https://maestrodatabase.com/blog/fda-grants-priority-review-to-hiv-monoclonal-antibody-and-long-acting-investigational-anti-retroviral-ibalizumab 2017-07-01T07:24:52 https://maestrodatabase.com/blog/thousands-to-benefit-from-five-minute-breast-cancer-treatment 2021-04-07T01:44:28 https://maestrodatabase.com/blog/fda-accepts-arcutis-supplemental-new-drug-application-for-roflumilast-0-dot-15-percent-cream-for-the-treatment-of-atopic-dermatitis-in-adults-and-children-down-to-age-6 2023-11-30T20:29:12 https://maestrodatabase.com/blog/revised-dispensing-of-pbs-items-for-nursing-home-residents 2017-07-01T08:47:31 https://maestrodatabase.com/blog/caribou-biosciences-announces-the-fda-has-granted-fast-track-designations-to-cb-010-in-refractory-sle-and-to-cb-012-in-relapsed-or-refractory-aml 2024-09-03T23:51:58 https://maestrodatabase.com/blog/nice-would-welcome-further-discussions-about-access-to-spinal-muscular-atrophy-drug-nusinersen 2018-08-14T11:28:32 https://maestrodatabase.com/blog/public-summary-documents---march-2017-pbac-meeting 2017-07-01T08:05:43 https://maestrodatabase.com/blog/trump-warms-to-old-idea-kill-health-law-now-and-replace-it-later 2017-07-01T09:01:12 https://maestrodatabase.com/blog/saving-lives-efficiently-across-sectors-the-need-for-a-congressional-cost-effectiveness-committee 2017-07-01T08:54:34 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-july-2017 2017-07-01T09:03:59 https://maestrodatabase.com/blog/the-large-hidden-costs-of-medicares-prescription-drug-program 2018-08-14T12:12:24 https://maestrodatabase.com/blog/motif-bio-announces-fda-acceptance-of-new-drug-application-with-priority-review-for-iclaprim-for-treatment-of-acute-bacterial-skin-and-skin-structure-infections 2018-08-14T11:32:27 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-july-2017-update 2017-07-01T09:14:05 https://maestrodatabase.com/blog/new-drugs-so-pricey-they-need-new-payment-plans 2018-08-14T13:18:28 https://maestrodatabase.com/blog/there-will-be-a-breach-labor-vows-to-fix-my-health-record 2018-08-14T13:32:28 https://maestrodatabase.com/blog/pharmac-funding-of-ms-drugs-restrictive-and-cruel 2018-08-14T12:25:25 https://maestrodatabase.com/blog/call-for-pharmaceutical-benefits-scheme-to-include-subsidies-for-more-rare-cancer-treatments 2018-08-14T13:04:21 https://maestrodatabase.com/blog/nice-appraisal-for-bms-kidney-cancer-immunotherapy-combination 2019-04-07T07:32:55 https://maestrodatabase.com/blog/obsidian-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-designation-for-obx-115-for-the-treatment-of-advanced-melanoma 2024-09-03T23:56:45 https://maestrodatabase.com/blog/drug-pricing-policy-hhs-introduces-step-therapy-in-medicare-advantage 2018-08-14T21:08:38 https://maestrodatabase.com/blog/grandmothers-lobby-government-for-rare-genetic-disease-medication 2019-04-07T07:28:23 https://maestrodatabase.com/blog/five-predictions-for-ai-and-real-world-data-in-oncology 2018-08-14T21:12:29 https://maestrodatabase.com/blog/formycon-and-fresenius-kabi-announce-file-acceptance-for-fyb202-a-biosimilar-candidate-to-stelara-ustekinumab-by-the-us-fda 2023-11-30T21:58:46 https://maestrodatabase.com/blog/fdas-gottlieb-heads-back-to-aei-to-tackle-drug-prices 2019-04-07T07:45:50 https://maestrodatabase.com/blog/house-committee-passes-bills-to-strengthen-obamacare-and-lower-drug-prices 2019-04-07T07:42:25 https://maestrodatabase.com/blog/eu-approves-new-dosing-schedule-for-msds-keytruda 2019-04-07T07:38:23 https://maestrodatabase.com/blog/kyowa-kirin-announces-fda-acceptance-of-istradefylline-kw-6002-new-drug-application-resubmission-in-the-us 2019-04-07T07:59:11 https://maestrodatabase.com/blog/fda-grants-priority-review-for-supplemental-biologics-license-application-of-padcev-enfortumab-vedotin-ejfv-with-keytruda-pembrolizumab-for-first-line-treatment-of-advanced-bladder-cancer 2023-11-30T22:43:35 https://maestrodatabase.com/blog/lilly-canada-and-the-pan-canadian-pharmaceutical-alliance-successfully-complete-negotiations-for-omvoh-mirikizumab-for-adults-with-moderately-to-severely-active-ulcerative-colitis 2024-09-04T02:03:57 https://maestrodatabase.com/blog/abeona-therapeutics-receives-fda-fast-track-designation-for-abo-101-for-treatment-of-sanfilippo-syndrome-type-b 2019-04-07T07:54:20 https://maestrodatabase.com/blog/trump-is-being-vague-about-what-he-wants-to-replace-obamacare-but-there-are-clues 2019-04-07T10:40:58 https://maestrodatabase.com/blog/celgene-corporation-and-acceleron-pharma-announce-submission-of-luspatercept-biologics-license-application-to-u-dot-s-fda 2019-04-07T11:05:22 https://maestrodatabase.com/blog/gilead-submits-supplemental-new-drug-application-to-u-dot-s-fda-for-once-daily-descovy-for-hiv-pre-exposure-prophylaxis 2019-04-07T10:50:37 https://maestrodatabase.com/blog/fda-accepts-biomarins-supplemental-new-drug-application-to-expand-use-of-voxzogo-vosoritide-for-injection-to-treat-children-with-achondroplasia-under-the-age-of-5 2023-03-08T01:51:58 https://maestrodatabase.com/blog/tga-to-review-advertising-of-stem-cell-therapies-to-the-australian-public 2021-04-07T07:26:34 https://maestrodatabase.com/blog/the-unique-device-identifier-a-unique-opportunity 2023-03-08T02:09:56 https://maestrodatabase.com/blog/prostate-cancer-treatment-nubeqa-made-available-for-free-in-australia-by-bayer 2020-08-23T08:21:45 https://maestrodatabase.com/blog/genethon-given-prime-status-by-ema-for-gene-therapy-to-treat-crigler-najjar-syndrome-a-rare-liver-disease 2023-03-08T02:04:52 https://maestrodatabase.com/blog/unicycive-therapeutics-announces-submission-of-the-new-drug-application-to-the-us-fda-for-oxylanthanum-carbonate-for-the-treatment-of-hyperphosphataemia-in-patients-with-chronic-kidney-disease-on-dialysis 2024-09-04T05:24:20 https://maestrodatabase.com/blog/in-amsterdam-eu-drugs-regulator-doesnt-want-brothel-moving-in-next-door 2023-03-08T01:56:07 https://maestrodatabase.com/blog/alp-makes-election-pledge-to-list-every-medicine-recommended-by-the-pbac-on-the-pbs 2019-04-07T12:15:41 https://maestrodatabase.com/blog/health-canada-receives-submission-from-pfizer-biontech-to-authorise-the-use-of-comirnaty-covid-19-vaccine-in-children-5-to-11-years-of-age 2021-10-19T19:44:04 https://maestrodatabase.com/blog/can-cheaper-drugs-help-home-grown-labs-turn-the-table-on-foreign-big-pharma-in-chinas-cancer-treatment-market 2019-04-07T12:13:00 https://maestrodatabase.com/blog/zanubrutinib-for-the-treatment-of-patients-with-marginal-zone-lymphoma-after-anti-cd20-based-treatment 2024-09-04T08:02:15 https://maestrodatabase.com/blog/democrats-drug-pricing-reforms-arent-what-they-seem 2021-10-19T19:55:40 https://maestrodatabase.com/blog/supporting-greater-availability-of-lower-cost-generic-drugs-for-canadians 2019-04-07T12:07:56 https://maestrodatabase.com/blog/fda-to-allow-mix-and-match-approach-for-covid-booster-shots 2021-10-19T19:47:56 https://maestrodatabase.com/blog/iptacopan-hydrochloride-for-the-treatment-of-patients-with-paroxysmal-nocturnal-haemoglobinuria 2024-09-04T07:52:03 https://maestrodatabase.com/blog/fda-issues-emergency-use-authorisation-for-convalescent-plasma-as-potential-promising-covid-19-treatment-another-achievement-in-administrations-fight-against-pandemic 2020-08-23T21:40:22 https://maestrodatabase.com/blog/we-shouldnt-pin-all-our-hopes-on-a-vaccine 2020-08-23T21:52:12 https://maestrodatabase.com/blog/dont-attack-nice-for-relying-on-facts-instead-of-emotion 2019-04-07T21:08:22 https://maestrodatabase.com/blog/vibegron-for-the-treatment-of-patients-with-symptoms-of-overactive-bladder-syndrome 2024-09-04T07:35:47 https://maestrodatabase.com/blog/gene-therapy-was-hailed-as-a-revolution-then-came-the-bill 2019-04-07T20:59:57 https://maestrodatabase.com/blog/health-insurers-welcome-coalition-review-on-natural-therapies 2019-04-07T20:54:53 https://maestrodatabase.com/blog/who-led-programme-aims-to-buy-antiviral-covid-19-pills-for-10-dollars 2021-10-19T20:31:57 https://maestrodatabase.com/blog/new-medicine-for-breast-cancer-approved-by-the-tga 2021-10-19T19:58:16 https://maestrodatabase.com/blog/strategies-for-generic-slash-biosimilar-market-entry-in-australia 2021-10-19T20:24:15 https://maestrodatabase.com/blog/dr-reddys-laboratories-announces-approval-for-lenalidomide-capsules-from-the-u-dot-s-fda 2021-10-19T20:03:51 https://maestrodatabase.com/blog/mhra-approves-spikevax-jn-dot-1-covid-19-vaccines-for-adults-and-children-from-infancy 2024-09-04T08:10:56 https://maestrodatabase.com/blog/several-drug-makers-just-raised-their-prices-by-nearly-10-percent-and-buyers-expect-more-price-hikes 2018-01-04T05:47:47 https://maestrodatabase.com/blog/fda-accepts-novans-nda-for-berdazimer-10-dot-3-percent-topical-gel-for-the-treatment-of-molluscum-contagiosum 2023-03-08T04:54:30 https://maestrodatabase.com/blog/liquidia-announces-fda-acceptance-of-new-drug-application-for-liq861-treprostinil-inhalation-powder-for-the-treatment-of-pulmonary-arterial-hypertension 2020-04-09T04:54:20 https://maestrodatabase.com/blog/fda-grants-priority-review-for-zoliflodacin-new-drug-application-for-the-treatment-of-uncomplicated-gonorrhoea 2025-06-13T03:41:47 https://maestrodatabase.com/blog/vistagen-therapeutics-receives-fda-fast-track-designation-for-av-101-for-the-treatment-of-major-depressive-disorder 2018-01-04T05:53:07 https://maestrodatabase.com/blog/astellas-submits-supplemental-new-drug-application-for-mirabegron-for-use-in-combination-with-solifenacin-succinate-5-mg-for-the-treatment-of-overactive-bladder 2017-07-02T11:53:10 https://maestrodatabase.com/blog/rare-disease-therapeutics-announces-new-expanded-fda-approved-indication-for-antivenom-anavip-for-treatment-of-north-american-pit-viper-envenomation 2021-04-07T09:34:24 https://maestrodatabase.com/blog/bupa-slams-comparator-websites-for-diverting-funds-from-healthcare-and-demands-transparency 2018-01-04T06:57:05 https://maestrodatabase.com/blog/janssens-prostate-cancer-drug-gets-reimbursement-for-mhspc 2021-04-07T09:17:50 https://maestrodatabase.com/blog/uk-rolls-out-modernas-covid-vaccine 2021-04-07T09:14:16 https://maestrodatabase.com/blog/insights-from-the-agenda-for-the-july-2021-pbac-meeting 2021-04-07T10:05:14 https://maestrodatabase.com/blog/icecure-medical-granted-fda-breakthrough-device-designation-for-prosense-cryoablation-system 2021-04-07T09:56:39 https://maestrodatabase.com/blog/bayer-launches-pre-filled-syringe-to-administer-eye-medication-eylea-in-europe 2020-04-09T06:07:46 https://maestrodatabase.com/blog/i-d-rather-be-a-lab-rat-than-a-dead-rat-how-julie-beat-cancer-death-sentence 2017-07-02T12:20:56 https://maestrodatabase.com/blog/novartis-receives-fda-breakthrough-therapy-designation-for-first-line-use-in-severe-aplastic-anaemia 2018-01-04T06:59:36 https://maestrodatabase.com/blog/high-drug-prices-are-bad-cutting-them-could-be-worse 2017-07-02T12:13:53 https://maestrodatabase.com/blog/pfizer-announces-extension-of-review-of-new-drug-application-of-abrocitinib-for-the-treatment-of-moderate-to-severe-atopic-dermatitis 2021-04-07T12:26:57 https://maestrodatabase.com/blog/fears-over-a-medical-gold-rush-in-cancer-drug-race 2017-07-02T21:50:30 https://maestrodatabase.com/blog/fda-approves-altheras-roszet-rosuvastatin-and-ezetimibe-tablets-a-new-oral-therapy-for-powerful-cholesterol-reduction 2021-04-07T09:42:12 https://maestrodatabase.com/blog/over-16-000-australian-children-prescribed-antipsychotics-pbs-data-shows 2017-07-02T21:45:30 https://maestrodatabase.com/blog/ucbs-new-psoriasis-biologic-bimzelx-debuts-in-korea-with-reimbursement 2025-06-13T06:42:09 https://maestrodatabase.com/blog/abbvies-epkinly-eisais-lenvima-pass-reimbursement-review-janssens-tecvayli-fails 2025-06-13T06:47:06 https://maestrodatabase.com/blog/fda-grants-regular-approval-to-sacituzumab-govitecan-for-triple-negative-breast-cancer 2021-04-07T20:54:54 https://maestrodatabase.com/blog/more-than-700-000-astrazeneca-doses-secretly-flown-to-australia-from-britain 2021-04-07T21:00:12 https://maestrodatabase.com/blog/nice-recommended-weight-loss-drug-to-be-made-available-in-specialist-nhs-services 2023-03-08T06:18:24 https://maestrodatabase.com/blog/xiidra-lifitegrast-ophthalmic-solution-5-percent-approved-by-health-canada-to-treat-the-signs-and-symptoms-of-dry-eye-disease 2018-01-04T07:19:38 https://maestrodatabase.com/blog/brendan-murphy-says-csl-will-reach-a-million-covid-vaccines-a-week-soon 2021-04-07T12:32:14 https://maestrodatabase.com/blog/abbvie-submits-regulatory-applications-for-skyrizi-risankizumab-in-psoriatic-arthritis-to-fda-and-ema 2021-04-07T20:50:22 https://maestrodatabase.com/blog/fda-accepts-mesoblasts-resubmission-of-the-biologic-license-application-for-remestemcel-l-in-children-with-steroid-refractory-acute-graft-versus-host-disease-as-a-complete-response 2023-03-08T05:51:47 https://maestrodatabase.com/blog/landmark-schizophrenia-data-that-bring-hope-in-breaking-the-cycle-of-hospitalisation-and-incarceration-receive-fda-approval-for-inclusion-in-invega-sustenna-paliperidone-palmitate-label 2018-01-04T07:15:30 https://maestrodatabase.com/blog/astrazenecas-covid-19-vaccine-ema-finds-possible-link-to-very-rare-cases-of-unusual-blood-clots-with-low-blood-platelets 2021-04-07T20:46:47 https://maestrodatabase.com/blog/nice-leads-the-way-in-approving-breakthrough-treatment-for-multiple-myeloma 2025-06-14T00:13:48 https://maestrodatabase.com/blog/akero-therapeutics-receives-fda-fast-track-designation-for-efruxifermin-for-the-treatment-of-nash 2021-10-19T23:36:57 https://maestrodatabase.com/blog/paratek-provides-update-on-pipeline-progress 2018-01-04T08:34:29 https://maestrodatabase.com/blog/mhra-issues-new-advice-concluding-a-possible-link-between-covid-19-vaccine-astrazeneca-and-extremely-rare-unlikely-to-occur-blood-clots 2021-04-07T21:07:48 https://maestrodatabase.com/blog/hanmis-short-bowel-syndrome-drug-gets-fda-fast-track-status 2021-04-07T21:04:32 https://maestrodatabase.com/blog/venatorx-pharmaceuticals-receives-fdas-qidp-and-fast-track-designations-for-development-of-its-lead-antibiotic-program 2018-01-04T09:28:06 https://maestrodatabase.com/blog/amphastar-pharmaceuticals-receives-fda-approval-for-naloxone-hydrochloride-nasal-spray-4-mg 2023-03-08T19:31:43 https://maestrodatabase.com/blog/us-fda-accepts-supplemental-new-drug-application-for-jardiance-for-children-10-years-and-older-with-type-2-diabetes 2023-03-08T19:23:41 https://maestrodatabase.com/blog/innovent-receives-fast-track-designation-from-the-us-fda-for-ibi363-pd-1-slash-il-2a-bispecific-antibody-fusion-protein-as-monotherapy-for-advanced-melanoma 2024-09-05T00:45:49 https://maestrodatabase.com/blog/akesos-cadonilimab-pd-1-slash-ctla-4-the-first-dual-immune-checkpoint-inhibitor-to-treat-cancer-approved-for-marketing-in-china 2022-06-30T07:21:08 https://maestrodatabase.com/blog/moderna-receives-us-fda-approval-for-rsv-vaccine-mresvia-in-adults-aged-18-59-at-increased-risk-for-rsv-disease 2025-06-14T00:21:49 https://maestrodatabase.com/blog/provisional-determination-granted-to-pfizer-in-relation-to-covid-19-vaccine-comirnaty---for-use-in-individuals-6-months-up-to-5-years 2022-06-30T07:09:16 https://maestrodatabase.com/blog/biden-calls-for-tax-on-the-wealthy-to-extend-medicare-funding 2023-03-08T19:55:39 https://maestrodatabase.com/blog/cms-grants-transitional-pass-through-payment-for-carlsmeds-aprevo-personalized-interbody-device 2021-10-20T00:11:46 https://maestrodatabase.com/blog/jazz-pharmaceuticals-secures-eight-additional-provincial-reimbursements-for-vyxeos-for-treatment-of-adults-with-newly-diagnosed-therapy-related-acute-myeloid-leukaemia-or-acute-myeloid-leukaemia-with-myelodysplasia-related-changes 2023-03-08T19:58:45 https://maestrodatabase.com/blog/new-frontier-will-lead-to-better-health-outcomes 2023-12-01T01:38:04 https://maestrodatabase.com/blog/preterm-birth-drug-withdrawn-after-12-years 2023-03-08T19:51:26 https://maestrodatabase.com/blog/winrevair-sotatercept-is-now-authorised-for-use-in-canada-for-adults-with-pulmonary-arterial-hypertension 2024-09-05T01:30:36 https://maestrodatabase.com/blog/bringing-a-consumer-perspective-to-clinical-advice 2021-10-20T01:06:53 https://maestrodatabase.com/blog/gsks-rsv-vaccine-arexvy-accepted-for-regulatory-review-by-the-ema-to-expand-use-in-adults-18-years-and-older 2025-06-14T01:20:09 https://maestrodatabase.com/blog/pfizer-announces-submission-of-new-drug-application-to-the-u-dot-s-fda-for-paxlovid 2022-06-30T11:19:45 https://maestrodatabase.com/blog/galderma-canada-announces-new-indication-for-dysport-aesthetic 2018-08-15T05:39:53 https://maestrodatabase.com/blog/update-to-continued-dispensing-arrangements 2022-06-30T11:15:47 https://maestrodatabase.com/blog/eli-lilly-is-defying-california-law-with-its-insulin-price-hikes-a-law-maker-calls-its-actions-offensive 2018-08-15T05:36:38 https://maestrodatabase.com/blog/more-results-needed-before-company-renews-push-to-list-meningococcal-b-vaccine-on-pbs 2018-08-15T20:35:54 https://maestrodatabase.com/blog/synthekine-granted-us-fda-fast-track-designation-for-cd19-car-t-and-orthogonal-il-2-investigational-therapy-syncar-001-plus-stk-009-for-the-treatment-of-lupus-without-lymphodepletion 2024-09-05T01:45:25 https://maestrodatabase.com/blog/from-fda-to-mhra-are-drug-regulators-for-hire 2022-06-30T10:54:46 https://maestrodatabase.com/blog/review-into-covid-19-vaccine-and-treatment-purchases 2022-06-30T11:11:44 https://maestrodatabase.com/blog/zanubrutinib-for-the-treatment-of-adults-with-waldenstroems-macroglobulinaemia 2022-06-30T09:04:26 https://maestrodatabase.com/blog/fda-pre-submission-for-saliva-based-glucose-test-to-replace-invasive-finger-prick 2021-10-20T04:52:29 https://maestrodatabase.com/blog/new-strategic-agreements-with-the-medicines-industry---pbs-website-updates 2022-06-30T21:46:16 https://maestrodatabase.com/blog/ema-scales-back-transparency-initiatives-because-of-workload 2018-08-15T20:48:52 https://maestrodatabase.com/blog/fda-recalls-are-a-reminder-that-china-controls-much-of-worlds-drug-supply 2018-08-15T20:53:47 https://maestrodatabase.com/blog/the-30-dollars-billion-in-health-costs-eating-a-hole-in-your-pocket 2018-08-15T20:39:12 https://maestrodatabase.com/blog/chiesi-global-rare-diseases-announces-approval-of-ferriprox-deferiprone-in-canada-for-the-treatment-of-iron-overload-in-sickle-cell-disease 2021-10-20T05:26:24 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-july-2022 2022-06-30T21:38:43 https://maestrodatabase.com/blog/fda-advances-efficient-approaches-to-designing-and-conducting-cancer-clinical-trials 2018-08-15T20:45:18 https://maestrodatabase.com/blog/you-have-the-medicine-that-can-make-me-feel-much-better-boy-8-pens-letter-asking-drug-company-to-lower-prices 2018-08-15T21:06:50 https://maestrodatabase.com/blog/aura-biosciences-receives-fda-fast-track-designation-for-belzupacap-sarotalocan-au-011-for-the-treatment-of-non-muscle-invasive-bladder-cancer 2022-06-30T21:32:08 https://maestrodatabase.com/blog/feds-urge-states-to-encourage-cheaper-plans-off-the-exchanges 2018-08-15T20:59:17 https://maestrodatabase.com/blog/revlimid-maintenance-therapy-passes-reimbursement-review 2022-06-30T11:27:42 https://maestrodatabase.com/blog/i-wish-they-approved-this-new-leukaemia-drug-two-years-ago-then-i-wouldnt-have-had-to-go-through-hell 2018-08-15T21:21:01 https://maestrodatabase.com/blog/public-summary-documents---december-2019-pbac-meeting 2020-04-09T07:46:08 https://maestrodatabase.com/blog/when-insurance-wouldnt-pay-parents-funded-cancer-patients-95-000-dollars-life-saving-treatment 2018-08-15T21:16:28 https://maestrodatabase.com/blog/pear-therapeutics-launches-pear-prescription-digital-therapeutics-digest-provides-roadmap-for-payer-coverage-considerations 2021-10-20T07:26:28 https://maestrodatabase.com/blog/australian-medical-association-prescribes-new-regulator-to-save-private-health-system 2022-06-30T21:58:02 https://maestrodatabase.com/blog/national-coverage-analysis-of-car-t-therapies----policy-evidence-and-payment 2018-08-15T21:53:38 https://maestrodatabase.com/blog/xediton-pharmaceuticals-announced-today-the-canadian-approval-and-availability-of-vabomere-meropenem-vaborbactam-in-canada 2025-06-14T23:34:09 https://maestrodatabase.com/blog/pbs-listing-for-australian-success-story-blood-cancer-drug 2022-06-30T21:55:20 https://maestrodatabase.com/blog/no-drug-price-pledges-by-pfizer-others-in-talks-with-us-government-pfizer-ceo-says 2025-06-14T23:53:17 https://maestrodatabase.com/blog/fda-approves-new-dosing-regimen-for-cetuximab 2021-04-07T23:27:36 https://maestrodatabase.com/blog/luminopia-announces-fda-approval-of-digital-therapeutic-that-uses-tv-shows-to-improve-vision-in-children-with-lazy-eye 2021-10-20T20:06:15 https://maestrodatabase.com/blog/sales-of-biogens-costly-new-alzheimers-drug-fall-far-short-of-expectations 2021-10-20T20:11:17 https://maestrodatabase.com/blog/tga-approves-brukinsa-for-another-use 2021-10-20T07:35:50 https://maestrodatabase.com/blog/breakthrough-therapies-approved-based-on-surrogate-endpoints-often-lack-post-marketing-requirements 2024-09-05T02:44:39 https://maestrodatabase.com/blog/pharmac-says-all-patients-who-meet-criteria-will-get-next-generation-diabetes-drugs-despite-concerns 2021-10-20T08:20:55 https://maestrodatabase.com/blog/coverage-with-evidence-development-schemes-for-medical-devices-in-europe-characteristics-and-challenges 2021-10-20T20:38:36 https://maestrodatabase.com/blog/wider-storage-and-transportation-conditions-for-the-pfizer-covid-19-vaccine-now-approved 2021-04-08T01:52:47 https://maestrodatabase.com/blog/axsome-therapeutics-announces-fda-acceptance-of-nda-resubmission-for-axs-07-for-the-acute-treatment-of-migraine 2024-09-05T04:14:53 https://maestrodatabase.com/blog/icer-publishes-final-evidence-report-and-policy-recommendations-on-therapies-for-myasthenia-gravis 2021-10-20T20:21:37 https://maestrodatabase.com/blog/ema-establishes-task-force-to-take-quick-and-coordinated-regulatory-action-related-to-covid-19-medicines 2020-04-09T12:34:00 https://maestrodatabase.com/blog/prilenias-pridopidine-for-huntingtons-disease-accepted-for-european-marketing-authorisation-review 2024-09-05T04:25:51 https://maestrodatabase.com/blog/merck-and-pfizer-receive-us-fda-breakthrough-therapy-designation-and-submit-application-for-bavencio-for-first-line-maintenance-treatment-of-locally-advanced-or-metastatic-urothelial-carcinoma 2020-04-09T12:45:54 https://maestrodatabase.com/blog/global-regulators-stress-need-for-robust-evidence-on-covid-19-treatments 2020-04-09T12:31:35 https://maestrodatabase.com/blog/celltrion-healthcare-receives-chmp-positive-opinion-for-novel-subcutaneous-formulation-of-ct-p13-biosimilar-infliximab-for-the-treatment-of-people-with-rheumatoid-arthritis 2019-09-23T07:24:27 https://maestrodatabase.com/blog/nice-publishes-new-covid-19-guidelines-on-cystic-fibrosis-chronic-obstructive-pulmonary-disease-and-dermatological-conditions-treated-with-drugs-affecting-the-immune-response 2020-04-09T22:27:19 https://maestrodatabase.com/blog/pembrolizumab-in-metastatic-nsclc-now-added-benefit-for-subpopulations 2019-09-23T07:19:41 https://maestrodatabase.com/blog/mallinckrodt-announces-reimbursement-approval-in-japan-for-the-celllex-extracorporeal-photopheresis-system-for-the-treatment-of-chronic-graft-versus-host-disease 2023-03-09T19:39:39 https://maestrodatabase.com/blog/with-millions-vaccinated-rare-side-effects-of-jabs-are-emerging 2021-04-08T02:41:23 https://maestrodatabase.com/blog/use-warranties-not-outcomes-based-agreements-to-make-payers-whole-when-a-gene-therapy-fails 2023-03-09T19:30:19 https://maestrodatabase.com/blog/cadth-recommends-reimbursement-for-biocrysts-orladeyo-berotralstat-for-the-routine-prevention-of-attacks-in-hereditary-angioedema-patients-in-canada 2023-03-09T19:34:20 https://maestrodatabase.com/blog/vitrakvi-larotrectinib-receives-first-tumour-agnostic-approval-in-eu 2019-09-23T12:16:13 https://maestrodatabase.com/blog/updates-from-the-health-technology-assessment-policy-and-methods-review-reference-committee-march-2023 2023-03-09T09:13:04 https://maestrodatabase.com/blog/authorised-prescribers 2017-07-03T07:34:08 https://maestrodatabase.com/blog/fda-expands-approval-of-dupixent-dupilumab-to-include-children-aged-6-to-11-years-with-moderate-to-severe-asthma 2021-10-20T22:58:09 https://maestrodatabase.com/blog/special-access-scheme 2017-07-03T07:30:59 https://maestrodatabase.com/blog/pembrolizumab-with-trastuzumab-and-chemotherapy-for-the-first-line-treatment-of-patients-with-advanced-her2-positive-gastric-or-gastro-oesophageal-junction-cancer 2023-12-01T20:40:37 https://maestrodatabase.com/blog/xynomic-pharma-receives-fast-track-designation-from-the-us-fda-for-abexinostat-as-fourth-line-therapy-treating-follicular-lymphoma 2019-09-23T12:36:49 https://maestrodatabase.com/blog/stealth-biotherapeutics-receives-refusal-to-file-letter-from-the-fda 2021-10-20T23:09:01 https://maestrodatabase.com/blog/besponsa-approved-in-the-eu-for-adult-patients-with-relapsed-or-refractory-b-cell-precursor-acute-lymphoblastic-leukaemia 2017-07-03T07:42:57 https://maestrodatabase.com/blog/samsung-bioepis-launches-lucentis-biosimilar-in-canada-germany 2023-03-09T20:05:20 https://maestrodatabase.com/blog/ama-urges-immediate-action-to-save-patients-on-pbs-medicines 2023-03-09T19:53:49 https://maestrodatabase.com/blog/popular-cancer-pill-goes-generic-yet-patients-costs-stay-high 2017-07-03T08:17:16 https://maestrodatabase.com/blog/u-dot-s-voters-support-expanding-medicare-but-not-eliminating-private-health-insurance 2019-09-23T21:03:28 https://maestrodatabase.com/blog/swissmedic-issues-unlimited-authorisation-for-booster-dose-of-modernas-bivalent-covid-19-original-slash-omicron-ba-dot-4-5-vaccine 2023-03-09T19:55:50 https://maestrodatabase.com/blog/is-private-health-care-worth-the-premium-price-tag 2019-09-23T21:01:24 https://maestrodatabase.com/blog/nice-seeks-feedback-from-users-of-the-evidence-standards-framework-for-digital-health-technologies 2019-09-23T20:53:27 https://maestrodatabase.com/blog/new-drugs-are-coming-to-market-at-sky-high-prices 2023-03-09T19:45:12 https://maestrodatabase.com/blog/xiapex-gets-recommendation-to-be-made-available-on-national-health-service-in-england 2017-07-03T08:21:31 https://maestrodatabase.com/blog/patent-system-key-to-lower-drug-prices-experts-say 2023-03-09T19:49:17 https://maestrodatabase.com/blog/statement-on-fda-efforts-to-encourage-patient-engagement-in-medical-device-clinical-investigations 2019-09-23T20:48:56 https://maestrodatabase.com/blog/uk-families-in-buyers-club-fly-to-argentina-for-cystic-fibrosis-drugs 2019-09-23T21:09:03 https://maestrodatabase.com/blog/supreme-court-hands-patent-win-to-pharmaceutical-companies 2017-07-03T08:30:28 https://maestrodatabase.com/blog/european-commission-approves-kaftrio-ivacaftor-slash-tezacaftor-slash-elexacaftor-in-combination-with-ivacaftor-to-treat-cystic-fibrosis-in-people-ages-12-years-and-older 2020-08-24T08:35:06 https://maestrodatabase.com/blog/labour-will-abolish-prescription-fees-for-everyone-in-england-party-to-announce 2019-09-23T21:07:15 https://maestrodatabase.com/blog/annexon-biosciences-announces-fda-fast-track-designation-for-novel-c1q-inhibitor-anx005-for-the-treatment-of-guillain-barre-syndrome 2019-09-23T21:15:49 https://maestrodatabase.com/blog/novo-prices-oral-rybelsus-on-par-with-injectable-rivals-ending-discount-fears 2019-09-23T21:13:00 https://maestrodatabase.com/blog/drug-prices-for-seniors-once-again-rose-faster-than-inflation-report-says 2019-09-23T21:31:50 https://maestrodatabase.com/blog/nice-numbers-at-20---a-closer-look-at-cancer 2019-09-23T21:28:49 https://maestrodatabase.com/blog/insights-from-the-july-2020-pbac-meeting---insight-number-1-agenda 2020-08-24T20:43:01 https://maestrodatabase.com/blog/health-related-quality-of-life-in-oncology-drug-reimbursement-submissions-in-canada-a-review-of-submissions-to-the-pan-canadian-oncology-drug-review 2019-09-23T21:23:51 https://maestrodatabase.com/blog/tricida-receives-complete-response-letter-from-the-fda-for-its-new-drug-application-for-veverimer-for-the-treatment-of-metabolic-acidosis-and-slowing-of-kidney-disease-progression-in-patients-with-metabolic-acidosis-associated-with-ckd 2020-08-24T20:54:38 https://maestrodatabase.com/blog/shire-receives-fda-breakthrough-therapy-designation-for-maribavir-an-investigational-treatment-for-cytomegalovirus-infection-in-transplant-patients 2018-01-04T23:43:32 https://maestrodatabase.com/blog/ema-goes-all-virtual-for-remainder-of-2020 2020-08-24T08:45:00 https://maestrodatabase.com/blog/insulin-users-beware-your-medicare-drug-plan-may-drop-your-insulin-what-it-means-for-you 2023-12-01T21:05:43 https://maestrodatabase.com/blog/ema-and-fda-encourage-use-of-innovative-approaches-in-the-development-of-medicines-for-gaucher-disease 2017-07-03T10:30:00 https://maestrodatabase.com/blog/two-more-bills-aiming-to-boost-biosimilars-introduced-in-congress 2019-09-23T21:36:37 https://maestrodatabase.com/blog/grant-robertson-says-government-focused-on-pharmac-solution-to-cancer-treatment 2021-04-08T04:17:20 https://maestrodatabase.com/blog/fdas-convalescent-plasma-eua-requires-all-donor-blood-units-be-tested-only-with-orthos-covid-19-igg-antibody-test 2020-08-24T21:13:39 https://maestrodatabase.com/blog/fda-clears-expanded-use-of-cooling-cap-to-reduce-hair-loss-during-chemotherapy 2017-07-03T21:04:23 https://maestrodatabase.com/blog/why-an-amazon-and-airbnb-vet-joined-a-digital-health-company-that-wants-to-slash-drug-prices 2020-08-24T21:19:23 https://maestrodatabase.com/blog/iqwig-finds-no-additional-benefit-for-tenofovir-alafenamide-fumarate-in-chronic-hepatitis-b 2017-07-03T21:17:59 https://maestrodatabase.com/blog/insights-from-the-july-2020-pbac-meeting---insight-number-2-agenda 2020-08-24T21:21:10 https://maestrodatabase.com/blog/adults-with-von-hippel-lindau-disease-to-benefit-from-new-treatment 2024-09-05T11:00:56 https://maestrodatabase.com/blog/two-cancer-drug-prices-have-already-been-hiked-by-8-percent-this-year 2017-07-03T21:08:41 https://maestrodatabase.com/blog/exelixis-announces-submission-of-supplemental-new-drug-application-to-u-dot-s-fda-for-cabometyx-cabozantinib-in-combination-with-opdivo-nivolumab-for-advanced-renal-cell-carcinoma 2020-08-24T21:04:23 https://maestrodatabase.com/blog/the-european-commission-grants-marketing-authorisation-for-the-new-subcutaneous-administration-of-tysabri-natalizumab-to-treat-relapsing-remitting-multiple-sclerosis 2021-04-08T05:03:01 https://maestrodatabase.com/blog/fda-grants-breakthrough-device-designation-for-biological-dynamics-early-stage-pancreatic-cancer-detection-test 2021-10-21T00:59:24 https://maestrodatabase.com/blog/fda-approves-new-kyprolis-carfilzomib-combination-regimen-with-darzalex-daratumumab-and-dexamethasone-in-both-once--and-twice-weekly-dosing-regimens 2020-08-24T21:09:00 https://maestrodatabase.com/blog/nice-final-draft-guidance-recommends-gene-therapy-for-rare-bubble-baby-syndrome 2018-01-05T01:05:59 https://maestrodatabase.com/blog/insights-from-the-july-2020-pbac-meeting---insight-number-3-outcomes 2020-08-24T21:46:24 https://maestrodatabase.com/blog/covid-19-vaccine-safety-report-30-june-2022 2022-07-01T03:55:08 https://maestrodatabase.com/blog/this-week-five-pharmacy-middlemen-head-to-capitol-hills-hot-seat-some-of-them-have-an-easier-defence-than-others 2019-04-08T09:07:08 https://maestrodatabase.com/blog/cadth-publishes-final-recommendation-on-new-indication-for-soliris 2020-08-24T21:28:50 https://maestrodatabase.com/blog/made-in-china-new-and-potentially-lifesaving-drugs 2018-01-05T01:15:59 https://maestrodatabase.com/blog/trump-considers-fast-tracking-uk-covid-19-vaccine-before-us-election 2020-08-24T21:38:38 https://maestrodatabase.com/blog/greater-flexibility-needed-by-pharmac-to-fund-new-medicines-including-cancer-drug---expert 2019-04-08T09:02:38 https://maestrodatabase.com/blog/avacopan-conditional-marketing-authorisation-application-accepted-for-regulatory-review-by-ema 2018-01-05T01:39:22 https://maestrodatabase.com/blog/fda-may-fine-clinical-trial-sponsors-that-dont-report-data 2020-08-24T21:43:41 https://maestrodatabase.com/blog/dying-patients-wait-in-vain-after-trump-era-easing-of-drug-law 2021-04-08T07:21:12 https://maestrodatabase.com/blog/pharmac-funding-to-support-access-equity-research 2021-04-08T20:48:43 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-pirtobrutinib-for-chronic-lymphocytic-leukaemia-and-small-lymphocytic-lymphoma 2023-12-01T23:05:15 https://maestrodatabase.com/blog/us-fda-approves-foundationone-cdx-and-foundationone-liquid-cdx-as-companion-diagnostics-for-lynparza-olaparib-in-combination-with-abiraterone-for-patients-with-brca-mutated-metastatic-castration-resistant-prostate-cancer 2024-09-05T21:51:08 https://maestrodatabase.com/blog/the-best-way-to-tackle-drug-prices 2021-04-08T20:51:35 https://maestrodatabase.com/blog/icer-to-assess-treatment-for-hypertrophic-cardiomyopathy 2021-04-08T12:36:41 https://maestrodatabase.com/blog/celltrion-announces-us-fda-approval-of-additional-presentation-of-steqeyma-ustekinumab-stba-expanding-dosing-options-for-pediatric-patients 2025-06-16T01:13:46 https://maestrodatabase.com/blog/immutep-achieves-fast-track-designation-from-us-fda-for-efti-a-soluble-lag-3-protein-in-first-line-recurrent-slash-metastatic-head-and-neck-cancer 2021-04-08T12:41:33 https://maestrodatabase.com/blog/teva-canada-announces-new-auto-injector-for-ajovy-for-the-preventive-treatment-of-migraine-in-adults 2021-04-08T21:14:38 https://maestrodatabase.com/blog/october-vaccine-target-all-but-over-after-astrazeneca-blood-clot-concerns-prompt-rollout-shakeup 2021-04-08T21:31:42 https://maestrodatabase.com/blog/atagi-statement-on-astrazeneca-vaccine-in-response-to-new-vaccine-safety-concerns 2021-04-08T21:22:04 https://maestrodatabase.com/blog/astrazeneca-worldwide-whos-using-the-jab-and-whos-not 2021-04-08T21:04:12 https://maestrodatabase.com/blog/nice-publishes-guidance-on-nivolumab---ipilumumab-combo 2021-04-08T20:56:11 https://maestrodatabase.com/blog/before-end-of-this-year-novavax-covid-vaccine-could-be-months-away 2021-04-08T21:11:25 https://maestrodatabase.com/blog/tevimbra-and-pemazyre-pass-cancer-panel-after-rechallenge 2024-09-05T23:19:59 https://maestrodatabase.com/blog/perspective-therapeutics-granted-fast-track-designation-for-vmt01-for-the-diagnosis-and-treatment-of-mc1r-positive-melanoma 2024-09-05T23:06:19 https://maestrodatabase.com/blog/fda-approves-kalydeco-ivacaftor-as-first-and-only-medicine-to-treat-the-underlying-cause-of-cf-in-children-ages-12-to-<24-months-with-certain-mutations-in-the-cftr-gene 2018-08-16T02:41:30 https://maestrodatabase.com/blog/new-pbs-listings-from-1-july-2022 2022-07-01T04:59:07 https://maestrodatabase.com/blog/todays-the-day-we-are-officially-canadas-drug-agency 2024-09-05T23:44:41 https://maestrodatabase.com/blog/breakthrough-therapy-designation-for-sanbexin-sublingual-tablets-granted-by-the-us-fda 2024-09-05T23:31:21 https://maestrodatabase.com/blog/fda-approves-xgeva-denosumab-for-the-prevention-of-skeletal-related-events-in-patients-with-multiple-myeloma 2018-01-06T01:29:26 https://maestrodatabase.com/blog/ensuring-access-to-medications-in-the-us-during-the-covid-19-pandemic 2020-04-10T04:45:17 https://maestrodatabase.com/blog/orchard-therapeutics-receives-us-fda-fast-track-designation-for-otl-203-in-mps-ih 2023-12-02T00:29:28 https://maestrodatabase.com/blog/fda-grants-paediatric-disease-designation-for-mateons-ot101 2019-09-24T04:14:19 https://maestrodatabase.com/blog/will-nz-neurological-drug-trofinetide-for-rett-syndrome-get-us-fda-approval-and-make-history 2023-03-10T02:09:41 https://maestrodatabase.com/blog/this-is-what-medicare-part-d-has-done-to-prescription-costs 2019-09-24T03:40:01 https://maestrodatabase.com/blog/patients-will-be-the-losers-as-pelosis-plan-to-control-drug-prices-nearly-strikes-out 2019-09-24T03:30:16 https://maestrodatabase.com/blog/astellas-and-seagen-announce-chinas-national-medical-products-administration-accepts-biologics-license-application-for-enfortumab-vedotin-in-certain-patients-with-locally-advanced-or-metastatic-urothelial-cancer 2023-03-10T02:02:53 https://maestrodatabase.com/blog/institutional-investors-urging-congress-to-vote-down-cusma-citing-effect-on-drug-prices 2019-09-24T03:27:34 https://maestrodatabase.com/blog/fda-grants-priority-review-to-mercks-application-for-keytruda-pembrolizumab-plus-padcev-enfortumab-vedotin-ejfv-for-the-first-line-treatment-of-patients-with-locally-advanced-or-metastatic-urothelial-cancer 2023-12-02T06:23:41 https://maestrodatabase.com/blog/keytruda-is-a-step-closer-to-being-available-for-more-cancers-listed-on-the-pbs 2023-12-02T01:06:06 https://maestrodatabase.com/blog/icer-publishes-evidence-report-on-treatments-for-transthyretin-amyloid-cardiomyopathy 2024-09-06T00:03:00 https://maestrodatabase.com/blog/steve-maharey-quits-as-chair-of-pharmac-acc 2023-12-02T01:03:56 https://maestrodatabase.com/blog/pharmac-making-progress-on-action-plan-to-enhance-organisational-culture 2023-12-02T01:01:32 https://maestrodatabase.com/blog/updates-to-the-hta-policy-and-methods-review-reference-committee-1-december-2023 2023-12-02T00:58:00 https://maestrodatabase.com/blog/plan-to-end-drug-rebates-adds-protections-for-insurers 2019-04-08T11:30:21 https://maestrodatabase.com/blog/tasmanias-pharmacy-guild-wants-antiviral-covid-19-pills-available-in-all-pharmacies 2021-10-21T04:00:37 https://maestrodatabase.com/blog/turning-point-therapeutics-granted-fast-track-designation-for-repotrectinib-in-ntrk-positive-tki-pre-treated-advanced-solid-tumours 2020-08-25T01:50:03 https://maestrodatabase.com/blog/italfarmaco-group-announces-new-pdufa-date-for-givinostat-dmd-nda 2023-12-02T07:37:44 https://maestrodatabase.com/blog/agenda-for-the-november-2024-pbac-meeting-version-4 2024-09-06T06:27:54 https://maestrodatabase.com/blog/chinas-new-cancer-drug-toripalimab-is-approved-in-the-us-but-will-cost-30-times-more 2023-12-02T07:26:35 https://maestrodatabase.com/blog/us-fda-seeks-more-information-on-maxigesic-iv-application 2022-07-01T10:38:26 https://maestrodatabase.com/blog/public-summary-documents---march-2022-pbac-meeting 2022-07-01T10:49:09 https://maestrodatabase.com/blog/fda-takes-additional-actions-on-the-use-of-a-booster-dose-for-covid-19-vaccines 2021-10-21T20:14:55 https://maestrodatabase.com/blog/icer-to-assess-gene-therapy-for-metachromatic-leukodystrophy 2023-03-10T04:15:21 https://maestrodatabase.com/blog/fda-issues-draft-guidance-for-industry-on-data-standards-for-drug-and-biological-product-submissions-containing-real-world-data 2021-10-21T20:24:48 https://maestrodatabase.com/blog/nice-recommends-gene-silencing-therapy-for-porphyria-patients-on-nhs 2021-10-21T19:41:44 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-21-october-2021 2021-10-21T10:55:41 https://maestrodatabase.com/blog/delivery-of-novavax-vaccine-may-be-delayed-in-australia-due-to-reported-manufacturing-issues 2021-10-21T20:12:08 https://maestrodatabase.com/blog/gw-pharmaceuticals-receives-european-commission-approval-for-epidyolex-cannabidiol-for-the-treatment-of-seizures-in-patients-with-two-rare-severe-forms-of-childhood-onset-epilepsy 2019-09-24T05:13:31 https://maestrodatabase.com/blog/canadas-trudeau-promises-national-prescription-drug-plan-if-re-elected 2019-09-24T05:09:54 https://maestrodatabase.com/blog/prostate-cancer-hormone-therapy-rejected-on-nhs-in-england 2019-04-08T20:45:22 https://maestrodatabase.com/blog/fda-approves-first-two-drug-complete-regimen-for-hiv-infected-patients-who-have-never-received-antiretroviral-treatment 2019-04-08T20:41:09 https://maestrodatabase.com/blog/drug-firms-admit-to-colluding-in-order-to-keep-prices-up 2019-09-24T05:20:32 https://maestrodatabase.com/blog/over-200-medical-professionals-launch-petition-calling-for-better-medication-for-bowel-disease 2020-08-25T07:22:36 https://maestrodatabase.com/blog/pazdur-on-pandemonium-calls-for-collaboration-competition-on-pd-1-drugs 2019-04-08T21:06:32 https://maestrodatabase.com/blog/zogenix-receives-refusal-to-file-letter-from-u-dot-s-fda-for-fintepla-new-drug-application 2019-04-08T21:02:48 https://maestrodatabase.com/blog/health-canada-grants-market-authorisation-for-kalydeco-ivacaftor-for-eligible-children-with-cystic-fibrosis-ages-2-months-and-older 2023-12-02T08:51:13 https://maestrodatabase.com/blog/life-changing-drug-for-chronic-migraine-approved-in-scotland 2019-04-08T20:58:24 https://maestrodatabase.com/blog/smc---april-2019-decisions 2019-04-08T20:49:55 https://maestrodatabase.com/blog/express-scripts-staking-out-million-dollar-gene-therapies 2018-08-16T13:01:43 https://maestrodatabase.com/blog/value-based-agreements-could-disrupt-how-we-pay-for-new-therapies 2019-04-08T21:43:01 https://maestrodatabase.com/blog/nice-encourages-use-of-greener-asthma-inhalers 2019-04-08T21:40:45 https://maestrodatabase.com/blog/ortho-dermatologics-resubmits-u-dot-s-new-drug-application-for-duobrii-halobetasol-propionate-and-tazarotene-lotion 2018-08-16T10:58:23 https://maestrodatabase.com/blog/why-big-pharma-is-winning-the-drug-price-wars 2019-04-08T21:36:36 https://maestrodatabase.com/blog/fda-approves-first-generic-version-of-epipen 2018-08-16T20:49:04 https://maestrodatabase.com/blog/statement-from-fda-commissioner-on-advancing-the-science-and-regulation-of-live-microbiome-based-products-used-to-prevent-treat-or-cure-diseases-in-humans 2018-08-16T20:52:25 https://maestrodatabase.com/blog/pegzilarginase-for-the-treatment-of-patients-with-arginase-1-deficiency 2024-09-06T21:23:11 https://maestrodatabase.com/blog/promising-more-appraisal-capacity-nice-revives-industry-fee-idea 2018-08-16T13:12:04 https://maestrodatabase.com/blog/us-will-still-pay-at-least-twice-as-much-after-negotiating-drug-prices 2024-09-06T21:14:44 https://maestrodatabase.com/blog/drug-middlemen-push-back-that-rebates-are-to-blame-for-high-drug-prices 2018-08-16T13:16:34 https://maestrodatabase.com/blog/advanz-pharma-secures-temporary-suspension-of-the-european-commission-decision-on-the-ocaliva-conditional-marketing-authorisation-in-europe 2024-09-06T21:09:29 https://maestrodatabase.com/blog/european-drug-agency-loses-30-percent-of-staff-in-planned-move-to-amsterdam 2018-08-16T21:03:33 https://maestrodatabase.com/blog/sma-groups-outraged-over-uk-rejection-of-spinraza-coverage-as-too-expensive 2018-08-16T21:10:14 https://maestrodatabase.com/blog/cancer-patients-wait-18-months-for-treatment 2018-08-16T20:58:09 https://maestrodatabase.com/blog/travere-therapeutics-announces-full-fda-approval-of-filspari-sparsentan-the-only-non-immunosuppressive-treatment-that-significantly-slows-kidney-function-decline-in-iga-nephropathy 2024-09-06T20:55:45 https://maestrodatabase.com/blog/why-are-trump-and-the-republicans-so-afraid-of-competition-when-it-comes-to-drug-prices 2020-08-25T09:06:33 https://maestrodatabase.com/blog/eliminate-pharmaceutical-rebates-to-improve-patient-welfare 2018-08-16T21:20:27 https://maestrodatabase.com/blog/how-disruptive-innovation-by-business-and-technology-firms-could-improve-population-health 2018-08-16T21:28:04 https://maestrodatabase.com/blog/ema-publishes-agenda-for-16-19-june-2025-chmp-meeting 2025-06-16T21:44:07 https://maestrodatabase.com/blog/never-mind-the-rebates-maybe-behind-the-scenes-fees-are-boosting-drug-prices 2018-08-16T21:17:54 https://maestrodatabase.com/blog/association-of-immunotherapy-with-durable-survival-as-defined-by-value-frameworks-for-cancer-care 2018-01-06T03:57:40 https://maestrodatabase.com/blog/ema-committee-for-medicinal-products-for-human-use-adopts-positive-opinion-recommending-authorisation-of-modernas-covid-19-mrna-vaccine-targeting-the-sars-cov-2-variant-jn-dot-1 2024-09-06T21:52:10 https://maestrodatabase.com/blog/nice-publishes-draft-guidance-on-new-cellular-therapy-for-crohns-disease 2018-08-16T21:44:02 https://maestrodatabase.com/blog/us-insurers-can-peg-access-to-icer-value-reviews 2018-08-16T21:37:05 https://maestrodatabase.com/blog/high-and-random-medical-gap-costs-revealed 2018-08-16T21:41:53 https://maestrodatabase.com/blog/fedratinib-dihydrochloride-monohydrate-for-the-treatment-of-patients-with-disease-related-splenomegaly-or-symptoms-in-myelofibrosis 2024-09-06T21:33:19 https://maestrodatabase.com/blog/characteristics-of-managed-entry-agreements-in-australia 2018-01-06T06:47:02 https://maestrodatabase.com/blog/patient-centered-decision-making-lessons-from-multi-criteria-decision-analysis-for-quantifying-patient-preferences 2018-01-06T06:57:01 https://maestrodatabase.com/blog/sun-pharma-announces-u-dot-s-fda-approval-of-cequa-to-treat-dry-eye-disease 2018-08-17T02:23:01 https://maestrodatabase.com/blog/insights-from-the-july-2020-pbac-meeting---insights-number-4-outcomes 2020-08-25T09:29:01 https://maestrodatabase.com/blog/pfizers-zavzpret-zavegepant-migraine-nasal-spray-receives-fda-approval 2023-03-10T20:22:03 https://maestrodatabase.com/blog/anxious-wait-for-cystic-fibrosis-pbs-announcement 2018-08-16T21:50:03 https://maestrodatabase.com/blog/kala-pharmaceuticals-announces-new-drug-application-for-inveltys-kpi-121-1-percent-has-been-accepted-for-review-by-the-u-dot-s-fda 2018-01-06T04:05:44 https://maestrodatabase.com/blog/kalvista-pharmaceuticals-announces-fda-will-not-meet-pdufa-goal-date-for-sebetralstat-nda-for-hereditary-angioedema-due-to-fda-resource-constraints 2025-06-16T23:03:17 https://maestrodatabase.com/blog/two-proposed-bills-aim-to-cut-drug-costs-for-retired-americans 2019-09-24T20:46:20 https://maestrodatabase.com/blog/novartis-unit-says-fda-wasnt-told-of-data-manipulation-sooner-because-it-was-highly-complex 2019-09-24T20:43:02 https://maestrodatabase.com/blog/aquestive-therapeutics-announces-fda-acceptance-of-new-drug-application-and-pdufa-date-for-anaphylm-for-the-treatment-of-severe-allergic-reactions 2025-06-16T23:10:53 https://maestrodatabase.com/blog/albertas-import-of-childrens-medication-to-cost-taxpayers-80-dollars-million 2023-03-10T07:59:01 https://maestrodatabase.com/blog/government-announces-no-deal-protection-for-uk-nationals-in-eu 2019-09-24T10:14:30 https://maestrodatabase.com/blog/azurity-pharmaceuticals-announces-fda-approval-of-nymalize-nimodipine-oral-solution-30-mg-slash-5-ml-pre-filled-enfit-syringe 2024-09-06T22:28:26 https://maestrodatabase.com/blog/9-in-10-canadians-want-national-pharmacare-heart-and-stroke-poll 2019-09-24T21:01:00 https://maestrodatabase.com/blog/medicare-will-take-r-and-d-costs-effectiveness-into-account-when-it-negotiates-drug-prices-but-studies-show-that-doesnt-affect-prices 2023-03-10T21:17:06 https://maestrodatabase.com/blog/trudeau-pledges-6-dollars-billion-to-kickstart-talks-on-health-care-national-pharmacare-with-provinces 2019-09-24T20:58:08 https://maestrodatabase.com/blog/ultimovacs-receives-dual-fda-fast-track-designation-for-uv1-in-advanced-malignant-melanoma 2021-10-21T23:20:10 https://maestrodatabase.com/blog/canadian-health-policy-institute-reports-national-pharmacare-is-unnecessary-bad-for-privately-insured-canadians-and-costly-for-taxpayers-evidence-counters-hoskins-report 2019-09-24T20:54:29 https://maestrodatabase.com/blog/the-democrats-shepherding-pelosis-drug-pricing-bill-have-taken-plenty-of-campaign-cash-from-pharma 2019-09-24T20:47:56 https://maestrodatabase.com/blog/health-canada-proposes-pause-the-clock-mechanism-for-pre-market-submissions 2018-08-17T04:42:19 https://maestrodatabase.com/blog/eisai-and-merck-announce-fda-approval-of-lenvima-lenvatinib-capsules-for-first-line-treatment-of-unresectable-hepatocellular-carcinoma 2018-08-17T05:16:30 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-positive-chmp-opinion-recommending-approval-of-opdivo-nivolumab-four-week-dosing-schedule-for-the-adjuvant-treatment-of-adult-patients-with-melanoma-with-involvement-of-lymph-nodes-or-metastatic-disease-who-have-undergone-complete-resection 2019-09-24T21:09:00 https://maestrodatabase.com/blog/eicosis-ec5026-granted-fast-track-designation-by-fda-for-neuropathic-pain 2020-04-10T12:19:42 https://maestrodatabase.com/blog/aussies-struggle-as-health-care-costs-skyrocket 2019-09-24T21:04:29 https://maestrodatabase.com/blog/sun-pharma-and-moebius-medical-announce-fast-track-designation-granted-for-mm-ii-for-the-treatment-of-osteoarthritis-knee-pain 2024-09-06T23:25:17 https://maestrodatabase.com/blog/solascure-receives-fda-fast-track-designation-for-aurase-wound-gel-to-treat-calciphylaxis-ulcers 2025-06-16T23:31:51 https://maestrodatabase.com/blog/kalvista-announces-fda-acceptance-of-new-drug-application-for-sebetralstat-for-oral-on-demand-treatment-of-hereditary-angioedema 2024-09-07T03:05:13 https://maestrodatabase.com/blog/new-chief-executive-for-pharmac 2025-06-16T23:48:25 https://maestrodatabase.com/blog/update-on-eu-actions-to-support-availability-of-medicines-during-covid-19-pandemic 2020-04-10T13:58:01 https://maestrodatabase.com/blog/this-tiny-federal-agency-was-built-to-respond-to-a-crisis-like-coronavirus-now-that-its-here-is-barda-ready 2020-04-10T14:01:29 https://maestrodatabase.com/blog/cancer-doctors-labor-plan-wont-cure-system 2019-04-09T01:09:34 https://maestrodatabase.com/blog/government-pharmacy-shake-up-set-to-hit-australians-hip-pockets 2017-07-04T06:59:55 https://maestrodatabase.com/blog/hhs-secretary-azar-meets-with-specialty-and-patient-groups-regarding-drug-pricing 2018-08-17T05:33:26 https://maestrodatabase.com/blog/drug-for-painful-skin-disease-on-the-pbs 2017-07-04T07:05:35 https://maestrodatabase.com/blog/phasebio-receives-fda-breakthrough-therapy-designation-for-pb2452-for-the-reversal-of-the-anti-platelet-activity-of-ticagrelor 2019-04-09T01:27:19 https://maestrodatabase.com/blog/post-brexit-eu-drug-regulation-deal-urged-by-ministers 2017-07-04T07:40:13 https://maestrodatabase.com/blog/uniqure-receives-fda-fast-track-designation-for-amt-130-gene-therapy-for-the-treatment-of-huntingtons-disease 2019-04-09T01:15:29 https://maestrodatabase.com/blog/minimal-residual-disease-as-a-surrogate-outcome-for-product-development-for-multiple-myeloma-comparing-fda-and-ema-guidances 2019-04-09T01:37:43 https://maestrodatabase.com/blog/biosimilars-are-a-distraction 2019-04-09T01:34:53 https://maestrodatabase.com/blog/axogen-completes-submission-of-biologics-license-application-to-us-fda-for-avance-nerve-graft 2024-09-07T22:12:24 https://maestrodatabase.com/blog/acadia-pharmaceuticals-announces-us-fda-approval-of-daybue-trofinetide-for-the-treatment-of-rett-syndrome-in-adult-and-paediatric-patients-two-years-of-age-and-older 2023-03-11T06:09:23 https://maestrodatabase.com/blog/daiichi-sankyos-ezh1-slash-2-dual-inhibitor-valemetostat-ds-3201-receives-sakigake-designation-for-treatment-of-patients-with-relapsed-slash-refractory-peripheral-t-cell-lymphoma-from-japan-mhlw 2019-04-09T01:55:27 https://maestrodatabase.com/blog/covid-19-vaccine-safety-report-9-march-2023 2023-03-11T07:17:20 https://maestrodatabase.com/blog/as-covid-19-pressures-mount-political-newcomer-stephen-hahn-struggles-to-protect-an-fda-under-siege 2020-08-25T10:59:39 https://maestrodatabase.com/blog/nice-sticks-with-no-for-use-of-perjeta-after-breast-cancer-surgery 2018-08-17T10:33:44 https://maestrodatabase.com/blog/u-dot-s-fda-approves-opdivo-nivolumab-as-the-first-new-medication-in-nearly-20-years-for-certain-patients-with-previously-treated-small-cell-lung-cancer 2018-08-17T11:11:29 https://maestrodatabase.com/blog/recruitment-begins-to-fill-up-to-seven-non-executive-roles-on-the-nice-board 2020-08-25T20:46:20 https://maestrodatabase.com/blog/fda-approves-generic-epipen-that-may-be-cheaper 2018-08-17T10:52:04 https://maestrodatabase.com/blog/abbvie-aubmits-regulatory-application-to-fda-for-rinvoq-upadacitinib-for-the-treatment-of-adults-with-active-ankylosing-spondylitis 2020-08-25T20:48:40 https://maestrodatabase.com/blog/fda-approves-eylea-aflibercept-injection-sbla-in-wet-age-related-macular-degeneration 2018-08-17T21:50:04 https://maestrodatabase.com/blog/hundreds-of-cancer-patients-received-partial-doses-of-medication 2018-08-17T22:04:15 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac---july-2018 2018-08-17T11:58:24 https://maestrodatabase.com/blog/fda-accepts-filing-of-new-drug-application-for-tepotinib-for-the-treatment-of-patients-with-metastatic-nsclc-with-metex14-skipping-alterations 2020-08-25T21:16:22 https://maestrodatabase.com/blog/imfinzi-approved-in-japan-for-the-treatment-of-extensive-stage-small-cell-lung-cancer 2020-08-25T21:33:21 https://maestrodatabase.com/blog/amphora-l-lactic-acid-citric-acid-and-potassium-bitartrate-receives-qidp-designation-from-the-fda 2017-07-04T08:25:50 https://maestrodatabase.com/blog/trump-deadline-for-drug-pricing-order-passes-with-no-action 2020-08-25T20:58:31 https://maestrodatabase.com/blog/australia-secures-20-million-more-doses-of-pfizer-vaccine 2021-04-09T05:11:51 https://maestrodatabase.com/blog/f-dot-d-a-grossly-misrepresented-blood-plasma-data-scientists-say 2020-08-25T21:13:46 https://maestrodatabase.com/blog/mercks-keytruda-pembrolizumab-receives-two-new-approvals-in-japan 2021-08-28T05:06:01 https://maestrodatabase.com/blog/fda-approves-first-therapy-for-children-with-debilitating-and-disfiguring-rare-disease 2020-04-10T22:14:22 https://maestrodatabase.com/blog/maxigesic-rapid-tablets-gain-us-fda-approval 2023-03-11T21:53:56 https://maestrodatabase.com/blog/aldeyra-therapeutics-receives-fast-track-designation-for-adx-2191-for-the-prevention-of-proliferative-vitreoretinopathy 2019-09-24T23:41:00 https://maestrodatabase.com/blog/averoa-receives-european-marketing-authorisation-for-xoanacyl-an-oral-therapy-for-chronic-kidney-disease 2025-06-17T01:27:19 https://maestrodatabase.com/blog/pbac-public-summary-documents---december-2020-intracycle-meeting 2021-04-09T07:36:58 https://maestrodatabase.com/blog/provention-bio-provides-regulatory-update-on-biologics-license-application-for-teplizumab-for-the-delay-or-prevention-of-clinical-type-1-diabetes-in-at-risk-individuals 2021-04-09T08:13:06 https://maestrodatabase.com/blog/yoltech-therapeutics-receives-us-fda-rare-paediatric-disease-designation-for-yolt-203-in-treating-primary-hyperoxaluria-type-1 2024-09-08T03:33:37 https://maestrodatabase.com/blog/veltassa-approved-for-marketing-in-switzerland-for-the-treatment-of-hyperkalaemia 2018-01-06T22:35:40 https://maestrodatabase.com/blog/conditional-financing-of-drugs-in-the-netherlands-past-present-and-future--results-from-stakeholder-interviews 2019-04-09T05:32:51 https://maestrodatabase.com/blog/vanflyta-is-now-approved-in-canada-specifically-for-adult-patients-with-newly-diagnosed-flt3-itd-positive-aml 2025-06-17T02:08:50 https://maestrodatabase.com/blog/medicare-part-d-coverage-of-anti-obesity-medications----challenges-and-uncertainty-ahead 2023-03-12T00:42:24 https://maestrodatabase.com/blog/genmab-and-seagen-announce-u-dot-s-fda-filing-acceptance-for-priority-review-of-tisotumab-vedotin-biologics-license-application-for-patients-with-recurrent-or-metastatic-cervical-cancer 2021-04-09T21:23:57 https://maestrodatabase.com/blog/ema-and-eunethta-step-up-interaction-to-align-data-requirements 2017-07-04T09:23:52 https://maestrodatabase.com/blog/international-work-sharing-initiative---abemaciclib-verzenio 2019-04-09T09:31:19 https://maestrodatabase.com/blog/mavenclad-cladribine-tablets-now-covered-by-express-scripts 2019-04-09T09:09:58 https://maestrodatabase.com/blog/fda-authorises-marketing-of-first-device-that-uses-artificial-intelligence-to-help-detect-potential-signs-of-colon-cancer 2021-04-09T23:01:20 https://maestrodatabase.com/blog/drug-pricing-throughout-the-product-lifecycle-a-work-in-progress 2023-03-11T22:55:52 https://maestrodatabase.com/blog/are-drug-regulators-really-too-slow 2017-07-04T10:23:41 https://maestrodatabase.com/blog/us-fda-approves-csls-andembry-garadacimab-gxii-the-only-prophylactic-hereditary-angioedema-treatment-targeting-factor-xiia-with-once-monthly-dosing-for-all-patients-from-the-start 2025-06-17T08:11:00 https://maestrodatabase.com/blog/pfizer-requests-fda-clearance-for-vaccine-in-kids-ages-12-to-15 2021-04-09T23:11:42 https://maestrodatabase.com/blog/mallinckrodt-completes-stannsoporfin-new-drug-application-filing 2018-01-06T23:02:33 https://maestrodatabase.com/blog/milestone-pharmaceuticals-submits-response-to-the-fdas-crl-for-cardamyst-etripamil-nasal-spray-for-psvt-following-type-a-meeting 2025-06-17T21:38:37 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-releases-draft-evidence-report-on-treatments-for-peanut-allergy 2019-04-09T20:33:15 https://maestrodatabase.com/blog/medicare-doesnt-pay-for-obesity-drugs-lifting-this-coverage-prohibition-faces-considerable-hurdles 2023-03-12T20:16:38 https://maestrodatabase.com/blog/fda-acceptance-of-nda-filing-for-baremsis-for-the-management-of-post-operative-nausea-and-vomiting 2018-01-06T23:18:55 https://maestrodatabase.com/blog/the-value-of-medical-innovation-versus-industry-rewards 2023-03-12T20:10:29 https://maestrodatabase.com/blog/official-inquiry-into-pharmac-necessary 2019-04-09T20:44:07 https://maestrodatabase.com/blog/whens-our-turn-pharmacs-new-funding-wont-cover-breast-cancer-fighters-$100k-bill 2023-03-12T19:59:54 https://maestrodatabase.com/blog/by-cutting-insulin-prices-eli-lilly-avoids-paying-big-medicaid-rebates 2023-03-12T20:04:50 https://maestrodatabase.com/blog/fda-approves-new-treatment-for-osteoporosis-in-post-menopausal-women-at-high-risk-of-fracture 2019-04-09T20:39:00 https://maestrodatabase.com/blog/tackle-biggest-killer-cardiologists-tell-labor 2019-04-09T21:01:19 https://maestrodatabase.com/blog/both-sides-bank-on-patient-power 2019-04-09T20:53:27 https://maestrodatabase.com/blog/ferrer-receives-fda-fast-track-designation-for-fnp-223-in-progressive-supranuclear-palsy 2025-06-17T23:47:42 https://maestrodatabase.com/blog/more-funding-sought-for-lung-cancer-treatments 2019-04-09T20:48:56 https://maestrodatabase.com/blog/tisento-therapeutics-receives-us-fda-fast-track-designation-for-zagociguat-for-the-treatment-of-mela 2025-06-17T23:51:21 https://maestrodatabase.com/blog/johnson-and-johnson-seeks-us-fda-approval-of-stelara-ustekinumab-for-the-treatment-of-paediatric-crohns-disease 2025-06-18T06:31:40 https://maestrodatabase.com/blog/health-canada-approves-new-drug-to-treat-metastatic-breast-cancer-through-international-and-domestic-joint-reviews 2019-04-09T21:04:05 https://maestrodatabase.com/blog/hi-tech-hospital-costs-soar-as-almost-half-of-stays-top-10-000-dollars 2017-07-04T20:56:19 https://maestrodatabase.com/blog/cost-recovery-implementation-statement-2017-18 2017-07-04T21:13:27 https://maestrodatabase.com/blog/ps4-drug-which-triples-a-womans-chances-of-getting-pregnant-is-being-blocked-by-the-nhs 2017-07-04T21:01:29 https://maestrodatabase.com/blog/generic-drug-prices-rise-when-market-competition-drops 2017-07-04T21:24:04 https://maestrodatabase.com/blog/pharmac-declines-inactive-medicine-applications 2025-06-18T07:04:22 https://maestrodatabase.com/blog/bioaegis-therapeutics-receives-fda-fast-track-designation-for-lead-product-recombinant-human-gelsolin-for-the-treatment-of-acute-respiratory-distress-syndrome 2025-06-18T06:47:19 https://maestrodatabase.com/blog/dyne-therapeutics-announces-fda-breakthrough-therapy-designation-for-dyne-101 2025-06-18T06:57:18 https://maestrodatabase.com/blog/metacrine-announces-met409-receives-fda-fast-track-designation-for-the-treatment-of-nash 2020-08-26T01:08:45 https://maestrodatabase.com/blog/new-and-expanded-pbs-listings-for-fabry-disease-and-kidney-cancer 2024-09-09T02:27:43 https://maestrodatabase.com/blog/sarepta-therapeutics-announces-fda-acceptance-of-casimersen-srp-4045-new-drug-application-for-patients-with-duchenne-muscular-dystrophy-amenable-to-skipping-exon-45 2020-08-26T01:15:43 https://maestrodatabase.com/blog/duke-street-bio-receives-fda-fast-track-designation-for-dsb2455 2025-06-18T07:22:31 https://maestrodatabase.com/blog/scilex-has-received-from-fda-a-snda-approval-for-ztlido-label-expansion 2021-04-10T06:58:03 https://maestrodatabase.com/blog/obecabtagene-autoleucel-for-the-treatment-of-patients-with-relapsed-or-refractory-b-cell-acute-lymphoblastic-leukaemia 2025-06-18T07:34:58 https://maestrodatabase.com/blog/knight-and-therapeuticsmd-announce-health-canada-approval-of-imvexxy 2020-08-26T01:24:43 https://maestrodatabase.com/blog/fda-approves-tafasitamab-cxix-for-relapsed-or-refractory-follicular-lymphoma 2025-06-18T21:54:30 https://maestrodatabase.com/blog/agenus-provides-update-on-balstilimab-development 2021-10-22T22:20:13 https://maestrodatabase.com/blog/cancer-inhibitors-scrapped-from-basic-insurance-for-some-users 2025-06-18T22:02:09 https://maestrodatabase.com/blog/agenda-for-the-december-2023-pbac-intracycle-meeting 2023-12-03T20:02:13 https://maestrodatabase.com/blog/fda-to-issue-new-commissioners-national-priority-vouchers-to-companies-supporting-us-national-interests 2025-06-18T22:18:24 https://maestrodatabase.com/blog/fda-approves-roches-susvimo-a-first-of-its-kind-therapeutic-approach-for-neovascular-or-wet-age-related-macular-degeneration 2021-10-22T22:01:14 https://maestrodatabase.com/blog/oncopeptides-withdraws-pepaxto-in-us-scale-down-organisation-and-focus-on-r-and-d 2021-10-22T23:00:39 https://maestrodatabase.com/blog/bavarian-nordic-announces-sale-of-priority-review-voucher-for-usd-160-million 2025-06-18T21:28:52 https://maestrodatabase.com/blog/drug-makers-worried-about-losing-pricing-power-are-lobbying-hard 2019-09-25T05:19:27 https://maestrodatabase.com/blog/cystic-fibrosis-drug-could-reduce-severe-disease-deaths-if-made-available-to-canadians 2020-08-26T02:04:58 https://maestrodatabase.com/blog/fda-approves-first-live-non-replicating-vaccine-to-prevent-smallpox-and-monkeypox 2019-09-25T05:15:50 https://maestrodatabase.com/blog/tga-to-consider-booster-doses-as-health-authorities-assure-the-fully-vaccinated-that-they-are-protected 2021-10-23T08:37:46 https://maestrodatabase.com/blog/yeztugo-lenacapavir-is-now-the-first-and-only-fda-approved-hiv-prevention-option-offering-6-months-of-protection 2025-06-18T21:39:52 https://maestrodatabase.com/blog/chinas-drug-price-cuts-pressure-lipitor-and-other-foreign-pills 2019-09-25T05:12:28 https://maestrodatabase.com/blog/humiras-best-selling-drug-formula-start-at-a-high-price-go-higher 2018-01-07T11:35:31 https://maestrodatabase.com/blog/junshi-biosciences-announces-new-chemical-entity-application-for-toripalimab-accepted-by-australias-tga 2023-12-03T22:10:43 https://maestrodatabase.com/blog/first-cancer-medicine-decision-following-pharmac-funding-boost 2024-09-09T05:16:47 https://maestrodatabase.com/blog/pre-implantation-genetic-testing-for-ivf-to-be-covered-by-medicare 2021-10-23T20:34:16 https://maestrodatabase.com/blog/amneal-and-shilpa-announce-us-fda-approval-of-boruzu-the-first-ready-to-use-version-of-bortezomib-for-subcutaneous-administration 2024-09-09T21:09:38 https://maestrodatabase.com/blog/doctors-stop-offering-astrazeneca-jabs-over-legal-risk 2021-04-10T21:12:24 https://maestrodatabase.com/blog/pharmac-to-fund-two-brands-of-oestradiol-patches-from-1-december-2025 2025-06-18T22:23:30 https://maestrodatabase.com/blog/drug-pricing-talks-heat-up-as-democrats-work-to-win-over-skeptics 2021-10-23T21:57:19 https://maestrodatabase.com/blog/pharmac-funding-u-turn-for-patients 2025-06-18T22:27:02 https://maestrodatabase.com/blog/celltrions-stelara-biosimilar-secures-uk-approval 2024-09-09T21:24:08 https://maestrodatabase.com/blog/cost-effectiveness-analysis-of-germ-line-brca-testing-in-women-with-breast-cancer-and-cascade-testing-in-family-members-of-mutation-carriers 2018-01-07T21:26:45 https://maestrodatabase.com/blog/medical-research-congress-cheers-medical-care-congress-brawls 2018-01-07T21:18:53 https://maestrodatabase.com/blog/smc---september-2024-decisions 2024-09-09T22:19:25 https://maestrodatabase.com/blog/johnson-and-johnson-covid-19-vaccine-under-review-by-ema-over-blood-clots 2021-04-10T21:34:04 https://maestrodatabase.com/blog/duchesnay-is-seeking-health-canada-approval-for-a-segesterone-acetate-slash-ethinyl-estradiol-contraceptive-vaginal-system-a-new-option-for-women 2023-12-03T23:45:40 https://maestrodatabase.com/blog/agenda-for-the-november-2020-pbac-meeting 2020-08-26T05:38:19 https://maestrodatabase.com/blog/uk-in-push-to-remain-part-of-eu-medicines-agency 2018-01-08T02:07:50 https://maestrodatabase.com/blog/zolbetuximab-in-combination-with-chemotherapy-for-the-first-line-treatment-of-adults-with-unresectable-advanced-claudin-18-dot-2-positive-her2-negative-gastric-or-gastro-oesophageal-junction-adenocarcinoma 2024-09-09T22:40:43 https://maestrodatabase.com/blog/xtandi-emerges-as-convenient-treatment-option-for-prostate-cancer-patients 2019-09-25T12:00:43 https://maestrodatabase.com/blog/drug-pricing-executive-order-will-consumers-get-the-reforms-they-need 2020-08-26T20:34:12 https://maestrodatabase.com/blog/children-with-cancer-are-missing-out-on-precision-medicine-study-finds 2019-09-25T11:56:13 https://maestrodatabase.com/blog/fda-chief-apologises-for-overstating-plasma-effect-on-virus 2020-08-26T20:37:17 https://maestrodatabase.com/blog/catalyst-takes-its-fight-over-a-rare-disease-drug-to-canada-suing-the-countrys-regulator 2020-08-26T20:43:24 https://maestrodatabase.com/blog/proposal-for-value-based-tiered-reimbursement-for-tumour-biomarker-tests-to-promote-innovation-and-evidence-generation 2019-09-25T11:47:07 https://maestrodatabase.com/blog/sio-gene-therapies-announces-granting-of-fda-fast-track-designation-for-investigational-axo-aav-gm1-aav9-glb1-gene-therapy-in-patients-with-gm1-gangliosidosis 2021-10-23T22:40:19 https://maestrodatabase.com/blog/how-chinas-new-drug-buying-program-is-causing-pain 2019-12-05T20:50:16 https://maestrodatabase.com/blog/is-the-pbac-becoming-more-risk-averse 2020-08-26T10:59:06 https://maestrodatabase.com/blog/theres-a-lot-of-us-out-there-that-just-cant-even-get-out-of-bed-living-with-crippling-migraines 2021-04-11T05:14:14 https://maestrodatabase.com/blog/drug-industry-lobbyists-circulate-two-drug-pricing-proposals-in-hopes-of-warding-off-a-trump-executive-order 2020-08-26T12:01:41 https://maestrodatabase.com/blog/paper-by-european-regulators-foresees-continuing-reduction-in-clinical-data-requirements-for-biosimilars 2019-09-25T12:27:18 https://maestrodatabase.com/blog/trump-administration-drives-down-medicare-advantage-and-part-d-premiums-for-seniors 2019-09-25T12:12:36 https://maestrodatabase.com/blog/insights-from-the-agenda-for-the-november-2020-pbac-meeting 2020-08-26T12:03:53 https://maestrodatabase.com/blog/can-australia-produce-mrna-covid-19-vaccines-such-as-pfizer 2021-04-11T08:21:01 https://maestrodatabase.com/blog/impeachment-wont-scare-off-drug-pricing-boogeyman-for-health-sector 2019-09-25T21:03:18 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-therapies-for-haemophilia-a 2020-08-26T21:54:29 https://maestrodatabase.com/blog/an-unprecedented-opportunity-for-washington-to-lower-drug-prices 2019-09-25T21:01:23 https://maestrodatabase.com/blog/tga-approves-drug-to-fight-ovarian-cancer 2019-09-25T20:53:44 https://maestrodatabase.com/blog/labour-party-takes-aim-at-pharma-calls-attention-to-orkambi-row 2019-09-25T21:24:15 https://maestrodatabase.com/blog/achillion-receives-breakthrough-therapy-designation-from-fda-for-danicopan-for-treatment-of-paroxysmal-nocturnal-hemoglobinuria 2019-09-25T21:10:21 https://maestrodatabase.com/blog/developing-safe-and-effective-covid-vaccines----operation-warp-speeds-strategy-and-approach 2020-08-26T21:41:45 https://maestrodatabase.com/blog/breast-cancer-drug-advocate-lashes-out-at-labour-after-pharmac-inquiry-blocked 2019-04-10T03:41:05 https://maestrodatabase.com/blog/celltrion-submits-application-for-fda-approval-of-prolia-biosimilar-ct-p41 2023-12-04T19:44:41 https://maestrodatabase.com/blog/significant-step-forward-for-treating-people-with-head-and-neck-cancer 2018-01-08T05:41:00 https://maestrodatabase.com/blog/a-key-precedent-may-sustain-negotiation-to-keep-down-medicare-drug-prices 2022-07-03T12:08:22 https://maestrodatabase.com/blog/rare-blood-cancer-drug-brukinsa-to-be-listed-for-the-first-time-on-pharmaceutical-benefits-scheme 2022-07-03T11:55:43 https://maestrodatabase.com/blog/nice-terminates-another-three-assessments 2019-09-25T21:27:07 https://maestrodatabase.com/blog/drug-prices-make-headlines-again-as-senate-democrats-push-forward-pricing-reforms 2022-07-03T11:59:56 https://maestrodatabase.com/blog/nhs-saves-1-dot-2-billion-pounds-on-medicines-over-three-years 2022-07-03T11:47:53 https://maestrodatabase.com/blog/ucb-announces-european-commission-approval-of-zilbrysq-zilucoplan-for-the-treatment-of-adults-with-generalised-myasthenia-gravis 2023-12-04T06:46:20 https://maestrodatabase.com/blog/nice-to-look-again-at-pfizers-besponsa-after-appeal 2018-01-08T05:50:39 https://maestrodatabase.com/blog/pharmac-publishes-minutes-from-august-2023-ptac-meeting 2023-12-04T05:43:02 https://maestrodatabase.com/blog/smc---march-2023-decisions 2023-03-13T20:15:30 https://maestrodatabase.com/blog/new-name-for-department 2022-07-03T21:25:50 https://maestrodatabase.com/blog/albanese-government-delivering-life-changing-devices-for-australians-with-type-1-diabetes 2022-07-03T21:29:25 https://maestrodatabase.com/blog/haihe-biopharma-announces-gumarontinib-receives-approval-from-the-nmpa-of-china-for-the-treatment-of-locally-advanced-or-metastatic-nsclc-with-met-exon-14-skipping-mutation 2023-03-13T20:10:22 https://maestrodatabase.com/blog/abbvies-upadacitinib-granted-breakthrough-therapy-designation-from-the-u-dot-s-fda-for-atopic-dermatitis 2018-01-08T19:54:25 https://maestrodatabase.com/blog/vosoritide-in-achondroplasia-indication-of-an-additional-clinical-benefit-for-children-aged-two-and-over 2023-12-04T19:57:22 https://maestrodatabase.com/blog/health-canada-approves-novartis-kisqali-for-hr-positive-her2-negative-early-breast-cancer-patients-at-high-risk-of-recurrence 2025-06-19T01:27:26 https://maestrodatabase.com/blog/pixuvri-pixantrone-receives-positive-chmp-opinion-to-convert-conditional-approval-into-standard-marketing-authorisation-in-patients-with-aggressive-non-hodgkin-b-cell-lymphoma 2019-04-10T04:48:28 https://maestrodatabase.com/blog/prescriptive-changes-for-price-reduction-of-older-medicines 2023-12-04T19:54:53 https://maestrodatabase.com/blog/how-the-eu-fails-patients-trying-to-access-critical-medicines 2019-04-10T04:45:57 https://maestrodatabase.com/blog/ftc-goes-after-pbms-warns-of-legal-action 2022-07-03T12:13:47 https://maestrodatabase.com/blog/harrow-announces-transitional-pass-through-reimbursement-status-for-iheezo-chloroprocaine-hydrochloride-3-percent-ophthalmic-gel 2023-03-13T19:52:08 https://maestrodatabase.com/blog/heron-therapeutics-announces-centers-for-medicare-and-medicaid-services-granted-pass-through-payment-status-for-aponvie 2023-03-13T20:03:52 https://maestrodatabase.com/blog/the-evolving-uses-of-real-world-data 2019-04-10T05:03:47 https://maestrodatabase.com/blog/masterton-woman-feels-abandoned-after-medical-funding-rejected 2021-04-11T21:07:35 https://maestrodatabase.com/blog/sanders-to-roll-out-updated-medicare-for-all-proposal-wednesday 2019-04-10T04:58:56 https://maestrodatabase.com/blog/ionis-inotersen-nda-accepted-for-priority-review-by-the-fda 2018-01-08T20:05:57 https://maestrodatabase.com/blog/brexit-fears-are-diverting-millions-of-pounds-from-vital-cancer-battle-say-drug-firms 2018-01-08T20:23:53 https://maestrodatabase.com/blog/drug-manufacturers-are-root-cause-of-high-drug-costs-pbms-drive-costs-down 2022-07-03T21:43:42 https://maestrodatabase.com/blog/hhs-nominee-azar-needs-to-come-clean-on-obamacare-medicare-in-senate-hearings 2018-01-08T20:29:19 https://maestrodatabase.com/blog/scott-morrison-abandons-target-to-have-all-australians-vaccinated-against-covid-19-by-the-end-of-the-year 2021-04-11T20:58:47 https://maestrodatabase.com/blog/australian-medical-association-says-gps-are-protected-when-administering-astrazeneca-vaccines 2021-04-11T20:55:20 https://maestrodatabase.com/blog/health-ministers-and-health-chief-executives-met-today-in-canberra-to-discuss-priorities-for-the-australian-health-system 2022-07-03T21:35:35 https://maestrodatabase.com/blog/atezolizumab-for-the-adjuvant-treatment-of-patients-with-resected-non-small-cell-lung-cancer 2025-06-19T04:31:55 https://maestrodatabase.com/blog/plans-to-slash-medical-costs-in-america-run-into-generic-drug-concerns 2018-01-08T20:42:23 https://maestrodatabase.com/blog/kye-pharmaceuticals-receives-health-canada-approval-for-new-dosing-guidance-for-firdapse-and-an-additional-paediatric-indication 2025-06-19T02:03:02 https://maestrodatabase.com/blog/european-medicines-agency-accepts-filing-for-evenity-romosozumab 2018-01-08T20:32:44 https://maestrodatabase.com/blog/pembrolizumab-for-adjuvant-treatment-of-patients-with-resected-non-small-cell-lung-cancer 2024-09-10T03:23:18 https://maestrodatabase.com/blog/lilly-to-offer-all-approved-doses-of-zepbound-tirzepatide-single-dose-vials-through-lillydirect-self-pay-pharmacy-solutions 2025-06-19T03:21:55 https://maestrodatabase.com/blog/cartesian-therapeutics-receives-fda-rare-paediatric-disease-designation-for-descartes-08-for-the-treatment-of-juvenile-dermatomyositis 2024-09-10T07:18:47 https://maestrodatabase.com/blog/breast-cancer-treatment-expanded-on-the-pharmaceutical-benefits-scheme 2021-10-24T00:17:16 https://maestrodatabase.com/blog/taking-the-pressure-off-high-blood-pressure 2021-10-24T00:27:43 https://maestrodatabase.com/blog/medicare-rebates-for-bowel-inflammation-testing 2021-10-24T00:21:37 https://maestrodatabase.com/blog/eu-decision-on-russias-sputnik-v-shot-impossible-this-year 2021-10-24T00:13:52 https://maestrodatabase.com/blog/bridgebio-receives-fdas-regenerative-medicine-advanced-therapy-designation-for-bbp-812-canavan-disease-gene-therapy-program 2024-09-10T23:12:28 https://maestrodatabase.com/blog/patient-and-payer-incentives-to-use-patented-brand-name-drugs-vs-authorised-generic-drugs-in-medicare-part-d 2021-10-24T20:29:54 https://maestrodatabase.com/blog/tislelizumab-for-the-treatment-of-adults-with-advanced-non-small-cell-lung-cancer-after-platinum-based-chemotherapy 2025-06-19T11:08:45 https://maestrodatabase.com/blog/litfulo-receives-health-canada-approval-becoming-the-first-approved-treatment-for-severe-alopecia-areata-in-canada 2023-12-05T01:18:50 https://maestrodatabase.com/blog/final-draft-guidance-finds-benefits-of-two-treatments-for-patients-with-alzheimers-disease-remain-too-small-to-justify-the-additional-cost-to-the-nhs 2025-06-19T11:44:01 https://maestrodatabase.com/blog/new-help-for-australians-on-the-ivf-journey 2021-10-24T20:39:18 https://maestrodatabase.com/blog/small-pharma-granted-fast-track-designation-from-uk-regulator-for-dmt-assisted-therapy-for-major-depressive-disorder 2021-10-24T02:44:59 https://maestrodatabase.com/blog/real-world-use-of-and-spending-on-new-oral-targeted-cancer-drugs-in-the-us-2011-2018 2021-10-24T20:26:17 https://maestrodatabase.com/blog/cvs-cigna-humana-blame-big-pharma-at-senate-hearing-for-skyrocketing-us-drug-prices 2019-04-10T10:12:02 https://maestrodatabase.com/blog/arrowhead-pharmaceuticals-receives-fda-breakthrough-therapy-designation-for-plozasiran 2024-09-10T23:55:54 https://maestrodatabase.com/blog/novartis-kisqali-hit-with-nice-rejection 2019-04-10T20:23:44 https://maestrodatabase.com/blog/he-calls-me-i-call-him-alex-azar-on-his-relationship-with-president-trump-drug-pricing-and-winning-over-skeptical-conservatives 2019-04-10T12:01:18 https://maestrodatabase.com/blog/the-biopharmaceutical-cartel-and-high-drug-prices 2019-04-10T11:54:11 https://maestrodatabase.com/blog/number-orkambinow 2019-04-10T11:38:02 https://maestrodatabase.com/blog/johnson-and-johnsons-investigational-tar-200-granted-us-fda-breakthrough-therapy-designation-for-the-treatment-of-high-risk-non-muscle-invasive-bladder-cancer 2023-12-05T02:01:45 https://maestrodatabase.com/blog/sanofi-sets-a-fixed-price-of-insulin-at-99-dollars-per-month-for-some-patients 2019-04-10T20:44:39 https://maestrodatabase.com/blog/alp-cancer-plan-divisive-inequitable 2019-04-10T20:35:40 https://maestrodatabase.com/blog/canada-needs-to-read-the-fine-print-on-pharma-costs 2019-04-10T20:30:00 https://maestrodatabase.com/blog/bayer-files-for-approval-of-gadoquatrane-in-the-us 2025-06-19T23:10:01 https://maestrodatabase.com/blog/pharmacs-consideration-of-ibrance-and-kadcyla---what-we-know-and-what-we-dont 2019-04-10T20:59:33 https://maestrodatabase.com/blog/doh-publishes-yet-another-revised-version-of-the-agenda-for-the-november-2021-pbac-meeting 2021-10-24T23:37:55 https://maestrodatabase.com/blog/biogens-orphan-drug-spinraza-to-get-reimbursement 2019-04-10T20:54:38 https://maestrodatabase.com/blog/health-canada-approves-abbvies-constella-linaclotide-for-the-treatment-of-functional-constipation-in-paediatric-patients-6-to-17-years-of-age 2024-09-11T01:27:05 https://maestrodatabase.com/blog/fda-brigham-and-womens-to-test-if-rwe-is-ripe-now-for-replacing-clinical-drug-trials 2019-04-10T20:50:31 https://maestrodatabase.com/blog/health-benefits-in-2019-premiums-inch-higher-employers-respond-to-federal-policy 2019-09-26T01:29:04 https://maestrodatabase.com/blog/unaids-urges-gilead-to-drop-price-of-new-hiv-prevention-shot 2025-06-20T01:43:28 https://maestrodatabase.com/blog/zemcelpro-um171-cell-therapy-receives-positive-chmp-opinion-for-treatment-of-blood-cancer-patients-without-access-to-suitable-donor-cells 2025-06-20T02:02:55 https://maestrodatabase.com/blog/doh-publishes-revised-agenda-for-next-weeks-pbac-meeting 2022-07-04T05:51:53 https://maestrodatabase.com/blog/vanda-pharmaceuticals-announces-that-us-fda-accepts-new-drug-application-for-tradipitant-for-the-treatment-of-gastroparesis 2023-12-05T03:37:53 https://maestrodatabase.com/blog/veterans-affairs-to-be-first-major-insurer-to-cover-alzheimers-drug-leqembi 2023-03-14T05:23:42 https://maestrodatabase.com/blog/teva-canada-announces-the-approval-of-truxima-the-first-biosimilar-to-rituxan-in-canada-for-the-treatment-of-non-hodgkins-lymphoma-chronic-lymphocytic-leukaemia-and-rheumatoid-arthritis 2019-04-11T01:12:23 https://maestrodatabase.com/blog/dupixent-dupilumab-approved-in-the-us-as-the-only-targeted-medicine-to-treat-patients-with-bullous-pemphigoid 2025-06-20T05:05:49 https://maestrodatabase.com/blog/pharmacists-want-women-to-save-a-trip-to-the-doctor 2019-09-26T02:22:07 https://maestrodatabase.com/blog/evinacumab-for-the-treatment-of-patients-12-years-of-age-and-older-with-homozygous-familial-hypercholesterolaemia 2024-09-11T01:52:04 https://maestrodatabase.com/blog/cycle-pharmaceuticals-harliku-nitisinone-tablets-receive-first-fda-approval-as-treatment-for-alkaptonuria 2025-06-20T05:18:48 https://maestrodatabase.com/blog/final-reports-of-the-hta-policy-and-methods-review-and-enhanced-consumer-engagement-process 2024-09-11T01:45:53 https://maestrodatabase.com/blog/new-and-amended-pbs-listing-to-counter-short-bowel-syndrome-upper-limb-spasticity 2019-09-26T02:16:43 https://maestrodatabase.com/blog/eu-medicines-agencies-reflect-on-lessons-learned-from-covid-19 2023-12-05T06:58:22 https://maestrodatabase.com/blog/2022-october-price-disclosure-cycle---indicative-prices 2022-07-04T11:01:47 https://maestrodatabase.com/blog/cvs-plans-to-overhaul-how-much-drugs-cost 2023-12-05T06:27:27 https://maestrodatabase.com/blog/pharmaceutical-benefits-advisory-committee-recommends-orkambi-for-pbs 2018-08-18T08:43:28 https://maestrodatabase.com/blog/global-regulators-agree-on-key-principles-on-adapting-vaccines-to-tackle-virus-variants 2022-07-04T07:36:28 https://maestrodatabase.com/blog/hta-review-outlines-first-nations-pediatric-reform-and-quick-cheap-medicine 2024-09-11T02:24:48 https://maestrodatabase.com/blog/report-on-cell-gene-and-tissue-regulatory-framework-in-australia-stakeholder-perspectives---tga-response 2022-07-04T21:37:50 https://maestrodatabase.com/blog/tlv-reconsiders-orkambis-subsidy 2022-07-04T21:39:50 https://maestrodatabase.com/blog/ceos-appointment-to-hta-review-reference-committee 2023-03-14T19:41:44 https://maestrodatabase.com/blog/us-fda-accepts-for-priority-review-bristol-myers-squibbs-application-for-opdivo-nivolumab-in-combination-with-cisplatin-based-chemotherapy-for-the-first-line-treatment-of-adult-patients-with-unresectable-or-metastatic-urothelial-carcinoma 2023-12-05T19:36:21 https://maestrodatabase.com/blog/cvss-drug-price-plan-lets-pharma-off-too-easy 2018-08-18T13:50:13 https://maestrodatabase.com/blog/states-rush-to-rein-in-prescription-costs-and-drug-companies-fight-back 2018-08-19T23:59:17 https://maestrodatabase.com/blog/health-products-portal---webinars 2019-09-26T04:08:49 https://maestrodatabase.com/blog/accuretic-users-annoyed-over-contaminated-blood-pressure-medication-muddle 2022-07-04T11:07:58 https://maestrodatabase.com/blog/fda-declines-emergency-use-authorisation-for-zyseami-aviptadil-for-sub-group-of-patients-with-critical-covid-19-at-immediate-risk-of-death-from-respiratory-failure-despite-treatment-with-approved-therapy-including-remdesivir 2022-07-04T12:04:06 https://maestrodatabase.com/blog/family-faces-deportation-from-australia-after-son-diagnosed-with-cystic-fibrosis 2019-04-11T02:04:16 https://maestrodatabase.com/blog/relaunched-ema-website-now-live 2023-12-05T20:13:41 https://maestrodatabase.com/blog/the-eu-commission-grants-conditional-approval-for-idefirix-imlifidase-in-highly-sensitised-kidney-transplant-patients-in-the-european-union 2020-08-27T02:11:25 https://maestrodatabase.com/blog/life-saving-cancer-drug-keytruda-worth-150-000-dollars-goes-on-the-pbs 2018-08-18T22:34:37 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-treatment-for-paroxysmal-nocturnal-haemoglobinuria 2023-12-05T19:58:56 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac---may-2025 2025-06-20T07:40:04 https://maestrodatabase.com/blog/bms-pfizer-abbvie-drugs-likely-to-face-us-price-negotiation 2023-03-14T20:00:48 https://maestrodatabase.com/blog/government-sends-mixed-message-to-global-life-science-investors 2023-12-05T19:52:51 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-july-2022 2022-07-04T21:43:46 https://maestrodatabase.com/blog/novo-nordisk-to-lower-us-prices-of-several-pre-filled-insulin-pens-and-vials-up-to-75-percent-for-people-living-with-diabetes-in-january-2024 2023-03-14T19:49:41 https://maestrodatabase.com/blog/zepbound-tirzepatide-is-now-available-in-us-pharmacies-for-adults-living-with-obesity 2023-12-05T19:45:22 https://maestrodatabase.com/blog/fda-approves-foundation-medicines-foundationone-liquid-cdx-a-comprehensive-pan-tumour-liquid-biopsy-test-with-multiple-companion-diagnostic-indications-for-patients-with-advanced-cancer 2020-08-27T02:27:47 https://maestrodatabase.com/blog/mylan-lupin-launch-etanercept-biosimilar-in-germany 2020-08-27T02:18:08 https://maestrodatabase.com/blog/insights-from-the-july-2018-pbac-meeting 2018-08-19T21:20:49 https://maestrodatabase.com/blog/european-commission-approves-blenrep-belantamab-mafodotin-for-the-treatment-of-patients-with-relapsed-and-refractory-multiple-myeloma 2020-08-27T02:22:45 https://maestrodatabase.com/blog/biogens-spinraza-nusinersen-receives-notice-of-compliance-from-health-canada-for-the-treatment-of-5q-spinal-muscular-atrophy 2017-07-05T05:50:34 https://maestrodatabase.com/blog/european-commission-approves-mercks-keytruda-pembrolizumab-plus-chemotherapy-as-treatment-for-certain-patients-with-locally-recurrent-unresectable-or-metastatic-triple-negative-breast-cancer 2021-10-25T07:16:16 https://maestrodatabase.com/blog/cardiome-partner-steadymed-submits-u-dot-s-new-drug-application-for-trevyent-for-the-treatment-of-pulmonary-arterial-hypertension 2017-07-05T05:57:40 https://maestrodatabase.com/blog/editas-medicine-receives-rare-paediatric-disease-designation-for-edit-301-for-the-treatment-of-sickle-cell-disease 2020-08-27T02:36:32 https://maestrodatabase.com/blog/serious-concerns-over-true-intentions-of-review 2017-07-05T06:32:40 https://maestrodatabase.com/blog/kye-pharmaceuticals-and-catalyst-pharmaceuticals-challenge-health-canadas-decision-to-overlook-firdapse-data-exclusivity 2020-08-27T02:40:51 https://maestrodatabase.com/blog/nice-terminates-another-three-cancer-medicine-assessments 2017-07-05T08:04:27 https://maestrodatabase.com/blog/fda-works-to-evaluate-cancer-therapies-in-patients-with-brain-metastases 2020-08-27T21:14:55 https://maestrodatabase.com/blog/strensiq-new-deal-paves-way-for-nice-approval-of-life-saving-drug 2017-07-05T10:21:56 https://maestrodatabase.com/blog/drug-makers-to-sue-government-for-limiting-choline-alfoscerate-benefit 2020-08-27T21:21:27 https://maestrodatabase.com/blog/this-is-a-heart-drug-that-the-world-doesnt-need 2020-08-27T21:23:51 https://maestrodatabase.com/blog/mercks-keytruda-lillys-lartruvo-available-via-cdf 2017-07-05T10:17:18 https://maestrodatabase.com/blog/call-for-inquiry-into-medical-devices 2017-07-05T13:02:49 https://maestrodatabase.com/blog/cancers-and-other-illnesses-are-going-undetected-because-patients-cant-afford-100-dollars-bill-for-scans 2017-07-05T21:08:06 https://maestrodatabase.com/blog/private-health-insurers-must-do-more-to-arrest-rise-in-complaints-senate-told 2017-07-05T21:04:00 https://maestrodatabase.com/blog/cassiopea-receives-fda-approval-for-winlevi-1-percent-clascoterone-cream-first-in-class-topical-acne-treatment-targeting-the-androgen-receptor 2020-08-27T14:29:40 https://maestrodatabase.com/blog/cost-of-employer-provided-health-coverage-passes-20-000-dollars-a-year 2019-09-26T06:56:14 https://maestrodatabase.com/blog/alkermes-receives-fda-fast-track-designation-for-nemvaleukin-alfa-in-combination-with-pembrolizumab-for-the-treatment-of-platinum-resistant-ovarian-cancer 2021-10-25T19:45:35 https://maestrodatabase.com/blog/exagamglogene-autotemcel-for-the-treatment-of-patients-12-years-of-age-and-older-with-transfusion-dependent-beta-thalassaemia 2024-09-11T05:20:42 https://maestrodatabase.com/blog/pfizer-facing-nice-showdown-over-leukaemia-drug 2017-07-05T21:11:45 https://maestrodatabase.com/blog/covid-19-ema-starts-rolling-review-of-molnupiravir 2021-10-25T19:37:37 https://maestrodatabase.com/blog/roches-ventana-pd-l1-sp263-assay-receives-fda-approval-as-a-companion-diagnostic-to-identify-certain-non-small-cell-lung-cancer-patients-eligible-for-tecentriq-atezolizumab 2021-10-25T19:50:17 https://maestrodatabase.com/blog/ars-pharmaceuticals-submits-snda-to-fda-for-neffy-1-mg-dose-for-paediatric-patients-with-type-i-allergic-reactions-who-weigh-15-to-30-kg-33-66-lbs 2024-09-11T03:48:17 https://maestrodatabase.com/blog/trump-has-launched-an-all-out-attack-on-the-fda-will-its-scientific-integrity-survive 2020-08-27T21:28:21 https://maestrodatabase.com/blog/psivida-submits-new-drug-application-for-durasert-three-year-treatment-for-posterior-segment-uveitis-to-the-u-dot-s-fda 2018-01-09T05:15:38 https://maestrodatabase.com/blog/covid-19-vaccines-are-getting-closer-should-we-be-worried-theyve-come-so-quickly 2020-08-27T21:51:01 https://maestrodatabase.com/blog/biden-speaks-with-potential-fda-commissioner 2021-10-25T19:35:17 https://maestrodatabase.com/blog/pfizers-leukaemia-therapy-besponsa-to-get-insurance-benefit 2019-09-26T09:14:17 https://maestrodatabase.com/blog/merck-and-ridgeback-announce-initiation-of-a-rolling-review-by-the-european-medicines-agency-for-molnupiravir-an-investigational-oral-anti-viral-medicine-for-the-treatment-of-covid-19-in-adults 2021-10-25T20:16:09 https://maestrodatabase.com/blog/pierre-fabre-laboratories-receives-european-commission-approval-for-braftovi-encorafenib-in-combination-with-mektovi-binimetinib-for-the-treatment-of-adult-patients-with-advanced-non-small-cell-lung-cancer-with-a-braf-v600e-mutation 2024-09-11T21:05:00 https://maestrodatabase.com/blog/spikevax-ema-recommendation-on-booster 2021-10-25T20:36:59 https://maestrodatabase.com/blog/ema-fda-parallel-scientific-advice-program-has-limited-uptake 2023-03-15T03:18:55 https://maestrodatabase.com/blog/wave-life-sciences-receives-us-orphan-drug-and-rare-paediatric-disease-designations-for-wve-210201 2018-08-20T00:10:24 https://maestrodatabase.com/blog/drug-pricing-reform-opponents-win-most-pharma-lobbying-money 2021-10-25T20:02:19 https://maestrodatabase.com/blog/eylea-8-mg-pre-filled-syringe-approved-in-the-eu 2024-09-11T20:56:12 https://maestrodatabase.com/blog/network-meta-analysis-in-health-care-decision-making 2018-08-20T00:01:43 https://maestrodatabase.com/blog/the-risks-of-government-negotiation-of-drug-prices 2021-10-25T20:05:00 https://maestrodatabase.com/blog/home-to-home-time----measuring-what-matters-to-patients-and-payers 2017-07-05T22:07:25 https://maestrodatabase.com/blog/superannuation-plundered-to-pay-medical-bills 2018-01-09T07:23:06 https://maestrodatabase.com/blog/patient-reported-outcomes----are-they-living-up-to-their-potential 2017-07-05T21:42:20 https://maestrodatabase.com/blog/argenx-announces-uk-mhra-approval-of-vyvgart-for-the-treatment-of-generalised-myasthenia-gravis 2023-03-15T19:53:27 https://maestrodatabase.com/blog/evolus-granted-approval-of-dwp-450-by-health-canada 2018-08-20T00:16:47 https://maestrodatabase.com/blog/mhra-to-receive-ps10-million-from-hm-treasury-to-fast-track-patient-access-to-cutting-edge-medical-products 2023-03-15T19:50:40 https://maestrodatabase.com/blog/trump-health-pick-wary-of-government-drug-price-negotiations 2018-01-09T19:57:27 https://maestrodatabase.com/blog/how-allergan-continues-to-make-drug-prices-insane 2018-01-09T19:59:51 https://maestrodatabase.com/blog/fy-2017-report-from-the-director 2018-01-09T07:26:39 https://maestrodatabase.com/blog/reflections-on-a-landmark-year-for-medical-product-innovation-and-public-health-advances-and-looking-ahead-to-policy-in-2018 2018-01-09T19:40:41 https://maestrodatabase.com/blog/inflation-reduction-act-tamps-down-on-prescription-drug-price-increases-above-inflation 2023-03-15T20:27:22 https://maestrodatabase.com/blog/hhs-releases-initial-guidance-for-historic-medicare-drug-price-negotiation-program-for-price-applicability-year-2026 2023-03-15T20:34:33 https://maestrodatabase.com/blog/icer-publishes-white-paper-recommending-health-technology-assessment-methods-that-support-health-equity 2023-03-15T20:17:57 https://maestrodatabase.com/blog/ipsen-announces-fda-approval-of-dysport-abobotulinumtoxina-for-the-treatment-of-upper-limb-spasticity-in-children-excluding-cerebral-palsy 2019-09-26T12:19:32 https://maestrodatabase.com/blog/fda-authorises-bivalent-pfizer-biontech-covid-19-vaccine-as-booster-dose-for-certain-children-6-months-through-4-years-of-age 2023-03-15T20:10:28 https://maestrodatabase.com/blog/acacia-pharma-announces-new-barhemsys-pdufa-target-date-of-26-february-2020 2019-09-26T11:12:05 https://maestrodatabase.com/blog/china-national-medical-products-administration-accepts-regulatory-submission-for-nucala-mepolizumab-in-severe-eosinophilic-asthma 2023-03-15T19:59:30 https://maestrodatabase.com/blog/fda-approves-treatment-for-adults-and-children-with-all-genotypes-of-hepatitis-c-and-compensated-cirrhosis-that-shortens-duration-of-treatment-to-eight-weeks 2019-09-26T20:16:23 https://maestrodatabase.com/blog/health-canada-approves-the-use-of-cibinqo-abrocitinib-for-the-treatment-of-patients-12-years-of-age-and-older-with-moderate-to-severe-atopic-dermatitis 2022-07-05T01:38:54 https://maestrodatabase.com/blog/migraine-drug-not-cost-effective-nice-says-in-final-draft-guidance 2019-09-26T20:13:33 https://maestrodatabase.com/blog/fda-begins-reorganisation-phase-of-modernisation-efforts-to-increase-efficiency-and-further-support-new-drug-development 2019-09-26T20:25:00 https://maestrodatabase.com/blog/cg-oncology-receives-both-fda-fast-track-and-breakthrough-therapy-designation-for-cretostimogene-grenadenorepvec-in-high-risk-bcg-unresponsive-non-muscle-invasive-bladder-cancer 2023-12-05T23:28:25 https://maestrodatabase.com/blog/fda-approves-daratumumab-for-transplant-eligible-multiple-myeloma 2019-09-26T20:20:20 https://maestrodatabase.com/blog/zanubrutinib-in-chronic-lymphocytic-leukaemia-additional-benefit-for-certain-patients 2023-03-15T20:37:40 https://maestrodatabase.com/blog/change-of-name-of-liposomal-medicines-at-high-risk-of-medication-errors 2019-09-26T20:42:07 https://maestrodatabase.com/blog/neurocrine-biosciences-receives-breakthrough-therapy-designation-from-us-fda-for-crinecerfont-in-congenital-adrenal-hyperplasia 2023-12-06T01:18:18 https://maestrodatabase.com/blog/why-elizabeth-warren-is-vague-about-health-care 2019-09-26T20:39:07 https://maestrodatabase.com/blog/osteal-therapeutics-vt-x7-receives-fdas-breakthrough-therapy-designation-for-the-treatment-of-periprosthetic-joint-infection-of-the-hip-and-knee 2023-12-05T23:46:10 https://maestrodatabase.com/blog/pharmac-poised-to-fund-long-acting-contraceptive-mirena 2019-09-26T20:33:42 https://maestrodatabase.com/blog/finding-rcts-of-new-drugs-searches-in-trial-registries-require-specific-adaptations 2018-01-09T20:44:16 https://maestrodatabase.com/blog/new-medicine-and-an-easier-renewal-process-proposed-for-people-with-adhd 2024-09-11T22:43:21 https://maestrodatabase.com/blog/proposal-to-list-nintedanib-ofev-and-remove-restrictions-from-tiotropium-bromide-spiriva 2018-08-20T06:12:38 https://maestrodatabase.com/blog/lilly-modified-covid-19-purchase-agreement-for-bamlanivimab-alone-with-the-u-dot-s-government-and-is-focusing-on-supply-of-bamlanivimab-and-etesevimab-together 2021-04-12T10:55:38 https://maestrodatabase.com/blog/johnson-and-johnsons-one-dose-covid-19-vaccine-wont-be-coming-to-australia 2021-04-12T20:18:22 https://maestrodatabase.com/blog/neuraptive-therapeutics-receives-fda-breakthrough-therapy-designation-for-ntx-001 2024-09-11T23:46:58 https://maestrodatabase.com/blog/novartis-receives-fda-approval-for-fabhalta-iptacopan-offering-superior-haemoglobin-improvement-in-the-absence-of-transfusions-as-the-first-oral-monotherapy-for-adults-with-pnh 2023-12-06T01:24:45 https://maestrodatabase.com/blog/jazz-pharmaceuticals-announces-fda-acceptance-and-priority-review-of-supplemental-new-drug-application-for-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-in-idiopathic-hypersomnia 2021-04-12T20:38:38 https://maestrodatabase.com/blog/icer-to-use-aetion-observational-rwe-to-update-value-assessment-of-treatments-for-hereditary-angioedema 2021-04-12T20:34:31 https://maestrodatabase.com/blog/cbo-report-shows-enacting-drug-pricing-legislation-will-result-in-fewer-new-drugs 2021-04-12T20:43:52 https://maestrodatabase.com/blog/fibrogen-receives-fast-track-designation-from-the-u-dot-s-fda-for-pamrevlumab-for-the-treatment-of-duchenne-muscular-dystrophy 2021-04-12T20:22:09 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-rheumatoid-arthritis-therapies 2019-09-26T21:31:26 https://maestrodatabase.com/blog/fda-approves-xolair-omalizumab-pre-filled-syringe-for-self-injection-across-all-indications 2021-04-12T20:30:13 https://maestrodatabase.com/blog/prevalence-of-immature-survival-data-for-anti-cancer-drugs-presented-to-the-national-institute-for-health-and-care-excellence-and-impact-on-decision-making 2021-04-12T21:16:13 https://maestrodatabase.com/blog/international-reference-pricing-for-prescription-drugs-in-the-united-states-administrative-limitations-and-collateral-effects 2021-04-12T21:12:36 https://maestrodatabase.com/blog/the-regulation-of-medical-devices-is-flawed-and-another-scandal-is-inevitable-health-advocates 2018-08-20T20:54:41 https://maestrodatabase.com/blog/merck-canada-and-the-pan-canadian-pharmaceutical-alliance-successfully-complete-negotiations-for-welireg-belzutifan 2024-09-12T01:43:00 https://maestrodatabase.com/blog/fda-grants-priority-review-of-immunogens-supplemental-biologics-license-application-for-elahere-mirvetuximab-soravtansine-gynx-in-platinum-resistant-ovarian-cancer 2023-12-06T03:15:44 https://maestrodatabase.com/blog/pbac-recommendation-moves-approximately-1-300-patients-in-australia-closer-to-access-to-lumacaftor-slash-ivacaftor-and-vertex-is-now-working-with-the-australian-government-to-finalize-a-reimbursement-agreement-as-soon-as-possible 2018-08-20T20:48:38 https://maestrodatabase.com/blog/faricimab-for-the-treatment-of-patients-with-visual-impairment-caused-by-macular-oedema-after-retinal-vein-occlusion 2024-09-12T01:36:25 https://maestrodatabase.com/blog/u-dot-s-fda-grants-fast-track-designation-to-aravive-biologics-avb-s6-500 2018-08-20T21:09:51 https://maestrodatabase.com/blog/u-dot-s-health-secretary-says-agency-can-eliminate-drug-rebates 2018-08-20T21:14:15 https://maestrodatabase.com/blog/icer-publishes-research-protocol-for-assessing-the-unsupported-price-increases-on-prescription-drugs-that-occurred-in-2020 2021-04-12T20:47:46 https://maestrodatabase.com/blog/cavazzoni-to-take-over-influential-spot-atop-fda-drug-center 2021-04-12T21:02:29 https://maestrodatabase.com/blog/health-canada-approves-cabtreo-clindamycin-phosphate-adapalene-and-benzoyl-peroxide-triple-combination-topical-treatment-for-acne-vulgaris-in-patients-12-years-of-age-and-older 2024-09-12T01:29:11 https://maestrodatabase.com/blog/companies-report-no-signs-of-drug-makers-cutting-prices-despite-trump-pledge 2018-08-20T21:00:59 https://maestrodatabase.com/blog/smc---april-2021-decisions 2021-04-12T20:55:05 https://maestrodatabase.com/blog/proposal-to-change-the-funded-brand-of-epoetin-alfa 2018-08-21T00:11:00 https://maestrodatabase.com/blog/china-expedites-price-reduction-of-anti-cancer-drugs 2018-08-20T21:25:46 https://maestrodatabase.com/blog/treatment-funded-in-australia-but-new-zealand-brother-misses-out 2018-08-20T21:28:51 https://maestrodatabase.com/blog/meiragtx-announces-aav-cngb3-granted-fast-track-designation-by-u-dot-s-fda-for-treatment-of-achromatopsia 2018-08-21T00:21:41 https://maestrodatabase.com/blog/fda-approves-expanded-indication-for-telixs-illuccix-to-include-patient-selection-for-psma-directed-radioligand-therapy 2023-03-16T19:04:45 https://maestrodatabase.com/blog/secukinumab-for-the-treatment-of-patients-with-moderate-to-severe-hidradenitis-suppurativa-final-guidance 2023-12-06T06:30:44 https://maestrodatabase.com/blog/atagi-update-following-weekly-covid-19-meeting-29-june-2022 2022-07-05T10:00:55 https://maestrodatabase.com/blog/icer-publishes-white-paper-on-using-comparative-effectiveness-research-to-address-prescription-drug-spending-in-california 2023-03-16T20:51:29 https://maestrodatabase.com/blog/being-more-strategic-and-coordinated-when-we-collaborate 2023-12-06T04:22:20 https://maestrodatabase.com/blog/nice-recommends-three-more-treatments-for-atopic-dermatitis 2022-07-05T09:55:08 https://maestrodatabase.com/blog/ipsen-receives-new-fda-pdufa-date-for-investigational-palovarotene-for-the-treatment-of-people-with-fop 2023-03-16T18:54:03 https://maestrodatabase.com/blog/pfizer-will-have-to-pay-rebates-to-medicare-for-five-drugs-under-biden-plan-to-lower-rx-costs 2023-03-16T19:00:33 https://maestrodatabase.com/blog/bridgebio-pharma-announces-submission-of-new-drug-application-to-us-fda-for-acoramidis-for-the-treatment-of-patients-with-transthyretin-amyloid-cardiomyopathy 2023-12-06T03:43:43 https://maestrodatabase.com/blog/gbt-receives-fda-breakthrough-therapy-designation-for-voxelotor-for-treatment-of-sickle-cell-disease 2018-01-09T23:05:20 https://maestrodatabase.com/blog/diabetes-drug-mounjaro-approved-for-obesity-treatment-by-tga 2024-09-12T02:09:19 https://maestrodatabase.com/blog/government-drug-price-negotiations-offer-a-false-promise 2022-07-05T21:51:06 https://maestrodatabase.com/blog/eisai-and-merck-receive-breakthrough-therapy-designation-from-u-dot-s-fda-for-lenvima-lenvatinib-mesylate-and-keytruda-pembrolizumab-as-combination-therapy-for-advanced-and-slash-or-metastatic-renal-cell-carcinoma 2018-01-09T23:13:52 https://maestrodatabase.com/blog/reimbursement-to-pharmacies-for-generic-drugs-by-medicare-part-d-sponsors 2023-12-06T20:51:46 https://maestrodatabase.com/blog/pharmacs-new-equity-policy 2023-12-06T20:25:31 https://maestrodatabase.com/blog/sandoz-canada-expands-its-generics-portfolio-with-three-new-products 2022-07-05T21:48:02 https://maestrodatabase.com/blog/first-drugs-facing-medicare-price-penalty-are-named 2023-03-16T20:58:03 https://maestrodatabase.com/blog/new-medicines-could-be-pbs-listed-in-just-four-weeks-under-a-proposal-the-health-minister-calls-visionary 2024-09-12T02:18:56 https://maestrodatabase.com/blog/sanofi-cuts-us-list-price-of-lantus-its-most-prescribed-insulin-by-78-percent-and-caps-out-of-pocket-lantus-costs-at-35-dollars-for-all-patients-with-commercial-insurance 2023-03-16T20:54:19 https://maestrodatabase.com/blog/fda-approves-dabrafenib-with-trametinib-for-paediatric-patients-with-low-grade-glioma-with-a-braf-v600e-mutation 2023-03-17T00:08:13 https://maestrodatabase.com/blog/government-maintains-access-to-fast-acting-insulin 2023-03-17T00:40:20 https://maestrodatabase.com/blog/european-medicines-agency-chmp-recommends-eu-approval-of-partner-therapeutics-imreplys-sargramostim-rhu-gm-csf-to-treat-exposure-to-myelosuppressive-doses-of-radiation-haematopoietic-sub-syndrome-of-acute-radiation-syndrome 2025-06-21T01:09:49 https://maestrodatabase.com/blog/ilya-pharma-receives-rare-paediatric-disease-designation-from-the-us-fda-for-emilimogene-sigulactibac-for-the-treatment-of-skin-wounds-in-savi-patients 2024-09-12T02:56:30 https://maestrodatabase.com/blog/rocket-pharmaceuticals-receives-fda-fast-track-designation-for-rp-l401-gene-therapy-for-infantile-malignant-osteopetrosis 2020-08-28T02:29:42 https://maestrodatabase.com/blog/taysha-gene-therapies-receives-orphan-drug-designation-and-rare-paediatric-disease-designation-for-tsha-101-for-gm2-gangliosidosis 2020-08-28T03:08:56 https://maestrodatabase.com/blog/cimzia-certolizumab-pegol-label-change-marks-important-advance-for-european-women-of-childbearing-age-with-chronic-rheumatic-disease 2018-01-10T04:16:44 https://maestrodatabase.com/blog/cosmo-pharmaceuticals-announces-submission-of-remimazolam-nda-to-fda 2019-04-11T08:02:42 https://maestrodatabase.com/blog/agenda-for-july-2022-pbac-meeting-version-3 2022-07-06T01:06:50 https://maestrodatabase.com/blog/the-health-202-this-years-top-10-new-drugs 2018-01-10T19:50:19 https://maestrodatabase.com/blog/would-medicare-for-all-save-billions-or-cost-billions 2019-04-11T08:14:39 https://maestrodatabase.com/blog/empagliflozin-for-the-treatment-of-adolescents-with-type-2-diabetes-mellitus 2024-09-12T03:34:28 https://maestrodatabase.com/blog/nice-backs-wider-use-of-msds-simponi 2018-01-10T20:01:04 https://maestrodatabase.com/blog/pharmac-considering-funding-new-medicines-for-lung-cancer 2022-07-06T00:55:15 https://maestrodatabase.com/blog/ipsen-biopharmaceuticals-canada-announces-health-canada-approval-of-dysport-therapeutic-abobotulinumtoxina-for-the-treatment-of-lower-limb-spasticity-in-children-aged-two-and-older 2018-01-10T04:29:56 https://maestrodatabase.com/blog/lynparza-approved-in-eu-for-the-treatment-of-germline-brca-mutated-her2-negative-advanced-breast-cancer 2019-04-11T08:07:28 https://maestrodatabase.com/blog/futibatinib-for-previously-treated-patients-with-advanced-cholangiocarcinoma-with-fgfr2-fusion-or-rearrangement 2024-09-12T03:05:31 https://maestrodatabase.com/blog/ozempic-approved-in-canada-for-the-treatment-of-adults-with-type-2-diabetes 2018-01-10T20:17:03 https://maestrodatabase.com/blog/labour-mp-rejects-claims-she-said-health-minister-nixed-pharmac-inquiry 2019-04-11T08:22:18 https://maestrodatabase.com/blog/ontario-has-added-erelzi-etanercept-to-public-drug-plan-for-the-treatment-of-multiple-inflammatory-diseases 2018-01-10T20:23:23 https://maestrodatabase.com/blog/covid-19-sanofi-to-donate-100-million-doses-of-hydroxychloroquine-across-50-countries 2020-04-13T11:25:17 https://maestrodatabase.com/blog/vertex-receives-expanded-eu-approval-for-orkambi-lumacaftor-slash-ivacaftor-in-children-ages-6-11-years 2018-01-10T20:05:01 https://maestrodatabase.com/blog/how-a-premier-u-dot-s-drug-company-became-a-virus-super-spreader 2020-04-13T11:32:45 https://maestrodatabase.com/blog/shooting-the-pharmac-messenger 2019-04-11T08:18:49 https://maestrodatabase.com/blog/fda-accepts-priority-review-of-alxn1210-as-a-treatment-for-patients-with-paroxysmal-nocturnal-haemoglobinuria-in-the-us 2018-08-21T04:32:18 https://maestrodatabase.com/blog/trump-likes-drug-price-negotiations-his-nominee-for-health-secretary-doesnt 2018-01-10T20:37:25 https://maestrodatabase.com/blog/fda-grants-priority-review-to-genentechs-mosunetuzumab-for-people-with-relapsed-or-refractory-follicular-lymphoma 2022-07-06T08:08:55 https://maestrodatabase.com/blog/the-u-dot-s-fda-accepts-and-grants-priority-review-for-eisais-biologics-license-application-of-lecanemab-for-early-alzheimers-disease-under-the-accelerated-approval-pathway 2022-07-06T02:08:59 https://maestrodatabase.com/blog/setmelanotide-for-the-treatment-of-patients-with-obesity-caused-by-lepr-or-pomc-deficiency 2022-07-06T08:26:51 https://maestrodatabase.com/blog/inventiva-receives-fda-fast-track-designation-for-lead-asset-lanifibranor-in-nash 2019-09-27T00:12:15 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-treatment-for-epstein-barr-virus-positive-post-transplant-lymphoproliferative-disease 2024-09-12T21:21:53 https://maestrodatabase.com/blog/pharmac-opens-door-to-funding-keytruda-in-biggest-step-forward-in-treatment-of-lung-cancer 2022-07-06T08:17:04 https://maestrodatabase.com/blog/tremfya-guselkumab-receives-us-fda-approval-for-adults-with-moderately-to-severely-active-ulcerative-colitis-strengthening-johnson-and-johnsons-leadership-in-inflammatory-bowel-disease 2024-09-12T21:13:44 https://maestrodatabase.com/blog/fda-approves-expanded-label-for-mercks-keytruda-pembrolizumab-in-combination-with-pemetrexed-alimta-and-platinum-chemotherapy-for-first-line-treatment-of-patients-with-metastatic-non-squamous-nsclc-with-no-egfr-or-alk-genomic-tumour-aberrations 2018-08-21T05:44:47 https://maestrodatabase.com/blog/raising-funds-for-a-life-saving-drug-in-the-middle-of-lockdown 2020-04-13T21:13:27 https://maestrodatabase.com/blog/fda-authorises-first-over-the-counter-hearing-aid-software 2024-09-12T22:38:49 https://maestrodatabase.com/blog/fda-approves-atezolizumab-and-hyaluronidase-tqjs-for-subcutaneous-injection 2024-09-12T22:14:00 https://maestrodatabase.com/blog/tga-grants-provisional-determinations-to-pfizer-for-covid-19-vaccines-to-target-omicron-variant 2022-07-06T11:25:11 https://maestrodatabase.com/blog/public-summary-documents---may-2020-pbac-meeting 2020-08-28T05:16:02 https://maestrodatabase.com/blog/junshi-biosciences-and-coherus-announce-fda-acceptance-of-resubmission-of-bla-for-toripalimab-for-the-treatment-of-nasopharyngeal-carcinoma 2022-07-06T12:24:40 https://maestrodatabase.com/blog/johnson-and-johnson-seeks-first-eu-approval-of-nipocalimab-to-treat-a-broad-population-of-patients-living-with-antibody-positive-generalised-myasthenia-gravis 2024-09-13T02:39:31 https://maestrodatabase.com/blog/the-challenges-of-inadequate-financial-support-for-australians-with-cancer 2021-10-26T02:26:02 https://maestrodatabase.com/blog/australian-technical-advisory-group-on-immunisation-makes-call-on-fourth-covid-vaccine-dose 2022-07-06T11:48:59 https://maestrodatabase.com/blog/dupixent-dupilumab-injection-approved-in-canada-for-the-treatment-of-children-aged-1-year-and-older-with-eosinophilic-oesophagitis 2024-09-13T02:08:42 https://maestrodatabase.com/blog/health-canada-approves-keytruda-as-monotherapy-for-the-treatment-of-adult-and-paediatric-patients-with-unresectable-or-metastatic-microsatellite-instability-high-or-mismatch-repair-deficient-solid-tumours-that-have-progressed-following-prior-treatment-and-who-have-no-satisfactory-alternative-treatment-options 2024-09-13T02:04:19 https://maestrodatabase.com/blog/new-guidance-when-can-the-fda-refuse-to-file-ndas-and-blas 2018-01-11T05:30:06 https://maestrodatabase.com/blog/rejuvenating-regenerative-medicine-regulation 2018-02-08T00:47:02 https://maestrodatabase.com/blog/proposal-to-fund-medicines-for-lung-cancer-breast-cancer-and-respiratory-conditions 2024-09-13T03:05:45 https://maestrodatabase.com/blog/health-canada-approves-hyqvia-a-new-treatment-for-canadians-with-immune-deficiencies 2022-07-06T21:06:19 https://maestrodatabase.com/blog/prestige-biopharmas-pancreatic-cancer-drug-candidate-put-on-fda-fast-track 2023-03-19T07:53:38 https://maestrodatabase.com/blog/lower-drug-prices-are-a-good-thing-canadas-approach-to-achieving-them-was-not 2023-03-19T07:46:45 https://maestrodatabase.com/blog/inflarx-receives-fda-fast-track-designation-for-treatment-of-ulcerative-pyoderma-gangrenosum 2022-07-06T20:57:14 https://maestrodatabase.com/blog/black-triangle-scheme---information-for-sponsors 2018-01-11T05:52:18 https://maestrodatabase.com/blog/public-summary-documents-first-time-decisions-not-to-recommend-and-deferrals---november-2022-pbac-meeting 2023-03-19T07:39:34 https://maestrodatabase.com/blog/federal-right-to-try-legislation----threatening-the-fdas-public-health-mission 2018-02-22T20:36:32 https://maestrodatabase.com/blog/bristol-myers-squibbs-abecma-becomes-first-car-t-approved-for-use-in-earlier-lines-of-therapy-for-patients-with-relapsed-or-refractory-multiple-myeloma-in-japan 2023-12-07T00:03:42 https://maestrodatabase.com/blog/nice-recommends-janssens-treatment-for-active-psoriatic-arthritis 2022-07-06T21:27:50 https://maestrodatabase.com/blog/astrazeneca-receives-eu-approval-of-fasenra-for-severe-eosinophilic-asthma 2018-01-11T19:44:48 https://maestrodatabase.com/blog/deciphera-pharmaceuticals-announces-fda-grants-breakthrough-therapy-designation-for-qinlock-in-second-line-gist-patients-with-mutations-in-kit-exon-11-and-17-slash-18 2023-03-19T08:25:07 https://maestrodatabase.com/blog/canada-approves-daewoong-pharmaceuticals-btx-nabota 2018-08-21T07:09:56 https://maestrodatabase.com/blog/peters-accuses-bennett-of-using-peoples-illnesses-to-gain-political-points-in-exchange-about-pharmac-funding 2019-04-11T09:09:47 https://maestrodatabase.com/blog/u-dot-s-senate-democrats-advance-deal-to-lower-drug-prices 2022-07-06T21:20:20 https://maestrodatabase.com/blog/many-firsts-for-cders-2017-drug-approvals-reflect-innovation-and-enhanced-patient-care 2018-01-11T20:05:58 https://maestrodatabase.com/blog/democratic-drug-pricing-bill-removes-insulin-cost-cap-amid-bipartisan-push 2022-07-06T21:22:40 https://maestrodatabase.com/blog/regulatory-submission-for-gsks-daprodustat-accepted-into-health-canada-review 2022-07-06T21:13:11 https://maestrodatabase.com/blog/obamacare-repeal-fades-from-gop-priorities-list-in-new-year 2018-01-11T19:55:15 https://maestrodatabase.com/blog/middlemen-are-driving-up-the-cost-of-life-saving-drugs 2018-01-11T19:59:51 https://maestrodatabase.com/blog/nhs-managers-warn-no-deal-brexit-risks-drug-shortages 2018-08-21T09:09:46 https://maestrodatabase.com/blog/nmpa-approves-toripalimab-in-patients-with-locally-advanced-or-metastatic-urothelial-carcinoma-who-failed-platinum-containing-chemotherapy-or-progressed-within-12-months-of-neo-adjuvant-or-adjuvant-platinum-containing-chemotherapy 2021-04-13T06:04:13 https://maestrodatabase.com/blog/fennec-pharmaceuticals-announces-fda-filing-acceptance-and-priority-review-of-new-drug-application-for-pedmark 2020-04-13T23:13:09 https://maestrodatabase.com/blog/fda-authorises-pharmacists-to-prescribe-paxlovid-with-certain-limitations 2022-07-06T21:35:21 https://maestrodatabase.com/blog/go-off-in-a-corner-and-quietly-die---cancer-patients-feelings-of-betrayal-after-vote-against-pharmac 2019-04-11T09:20:39 https://maestrodatabase.com/blog/gilead-canada-submits-supplemental-new-drug-submission-to-health-canada-for-descovy-for-hiv-pre-exposure-prophylaxis 2020-04-13T23:22:30 https://maestrodatabase.com/blog/novartis-receives-approval-in-the-eu-for-cosentyx-label-update-includes-long-term-superiority-data-versus-stelara-in-psoriasis 2017-07-06T06:52:52 https://maestrodatabase.com/blog/no-deal-brexit-could-see-hospitals-run-out-of-medicine-reveals-leaked-letter-from-health-chief 2018-08-21T20:53:03 https://maestrodatabase.com/blog/bausch-plus-lomb-and-clearside-biomedical-announce-fda-approval-of-xipere-triamcinolone-acetonide-injectable-suspension-for-suprachoroidal-use-for-the-treatment-of-macular-oedema-associated-with-uveitis 2021-10-26T10:35:41 https://maestrodatabase.com/blog/duncan-garner-complains-to-chief-ombudsman-peter-boshier-on-air-about-breast-cancer-drug-funding 2019-04-11T09:55:33 https://maestrodatabase.com/blog/eyenovia-announces-reclassification-of-mydcombi-as-drug-device-combination-product-by-fda 2021-10-26T10:43:12 https://maestrodatabase.com/blog/dupilumab-for-the-treatment-of-patients-with-eosinophilic-oesophagitis 2023-12-07T02:57:07 https://maestrodatabase.com/blog/fda-kicks-off-effort-to-examine-importing-drugs 2018-08-21T12:14:02 https://maestrodatabase.com/blog/generating-high-quality-evidence-from-registry-based-studies 2021-10-26T10:23:36 https://maestrodatabase.com/blog/canadians-living-with-multiple-myeloma-need-access-to-therapies-now 2017-07-06T07:10:35 https://maestrodatabase.com/blog/resignations-at-canadas-drug-pricing-panel-raise-independence-questions 2023-03-20T09:36:38 https://maestrodatabase.com/blog/brand-name-combo-pills-may-cost-more-than-getting-drugs-separately 2018-08-21T21:08:39 https://maestrodatabase.com/blog/nhs-scotland-works-up-detailed-no-deal-brexit-plan 2018-08-21T20:55:51 https://maestrodatabase.com/blog/fda-analysis-shows-similar-success-rates-for-paediatric-trials-using-clinical-and-surrogate-outcomes 2018-08-21T21:05:22 https://maestrodatabase.com/blog/nice-draft-guidance-does-not-recommend-tucatinib-for-advanced-breast-cancer 2021-10-26T10:26:12 https://maestrodatabase.com/blog/indira-stewart-on-being-called-likely-prejudiced-by-pharmac 2023-03-20T09:30:36 https://maestrodatabase.com/blog/mhra-licenses-ryeqo-for-symptoms-of-uterine-fibroids 2021-10-26T19:49:28 https://maestrodatabase.com/blog/paving-the-way-for-biosimilars 2018-08-21T21:25:41 https://maestrodatabase.com/blog/fda-takes-additional-action-to-mitigate-shortages-of-epipen-by-extending-expiration-date-for-specific-lots-of-medication 2018-08-21T21:16:45 https://maestrodatabase.com/blog/united-states-fda-approves-tevas-generic-epinephrine-injection-auto-injector 2018-08-21T21:19:53 https://maestrodatabase.com/blog/lilly-pipeline-success-strengthens-future-growth-potential 2021-10-26T19:56:14 https://maestrodatabase.com/blog/bristols-opdivo-reportedly-priced-in-china-at-half-the-u-dot-s-cost 2018-08-21T21:36:39 https://maestrodatabase.com/blog/theratechnologies-announces-reimbursement-agreement-in-italy-for-trogarzo-for-eligible-patients-with-multi-drug-resistant-hiv-1 2021-10-26T11:02:05 https://maestrodatabase.com/blog/trump-administration-says-its-drug-blueprint-has-already-lowered-prices 2018-08-21T21:29:20 https://maestrodatabase.com/blog/astellas-announces-acceptance-of-xospata-gilteritinib-for-regulatory-review-in-china-by-the-national-medical-products-administration 2020-04-13T23:29:55 https://maestrodatabase.com/blog/geron-enters-new-innovative-licensing-and-access-pathway-in-the-united-kingdom-for-imetelstat 2021-10-26T11:16:41 https://maestrodatabase.com/blog/large-employer-group-launches-pharmacy-benefit-management-business 2021-10-26T20:30:39 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-to-assess-treatments-for-type-2-diabetes-mellitus 2019-04-11T20:51:17 https://maestrodatabase.com/blog/on-rising-insulin-prices-law-maker-tells-pharma-execs-your-days-are-numbered 2019-04-11T12:55:32 https://maestrodatabase.com/blog/covid-19-world-needs-a-global-approach-to-fight-bill-gates 2020-04-14T00:27:11 https://maestrodatabase.com/blog/the-role-of-regulators-in-establishing-added-benefit-of-novel-therapies 2019-04-11T12:46:30 https://maestrodatabase.com/blog/strengthening-the-reporting-of-observational-studies-in-epidemiology-using-mendelian-randomisation-the-strobe-mr-statement 2021-10-26T20:33:41 https://maestrodatabase.com/blog/the-perils-of-value-based-pricing-for-prescription-drugs 2019-04-11T21:21:11 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-posts-draft-scoping-document-for-the-assessment-of-treatments-for-rheumatoid-arthritis 2019-04-11T21:10:39 https://maestrodatabase.com/blog/cystic-fibrosis-medicine-added-to-pharmacs-options-for-investment-list 2021-10-26T20:16:27 https://maestrodatabase.com/blog/select-committee-inquiry-into-pharmac-would-be-too-slow---labour 2019-04-11T21:00:38 https://maestrodatabase.com/blog/uk-to-give-near-automatic-sign-off-for-treatments-approved-by-trusted-regulators 2023-03-20T10:02:02 https://maestrodatabase.com/blog/diabetes-treatment-can-be-incredibly-costly-but-the-biggest-cost-is-surprisingly-not-insulin 2023-03-20T12:05:46 https://maestrodatabase.com/blog/unitedhealth-to-remove-abbvies-humira-from-some-us-drug-reimbursement-lists-next-year 2024-09-13T21:34:24 https://maestrodatabase.com/blog/solid-biosciences-receives-fda-fast-track-designation-for-duchenne-muscular-dystrophy-gene-therapy-sgt-003 2023-12-07T19:27:51 https://maestrodatabase.com/blog/expanded-eligibility-for-fourth-covid-19-vaccine-dose 2022-07-07T07:52:44 https://maestrodatabase.com/blog/arrowhead-receives-fda-fast-track-designation-for-aro-apoc3 2023-03-20T11:53:38 https://maestrodatabase.com/blog/sanofi-slash-regenerons-dupixent-approved-by-mhra-to-treat-uncontrolled-copd 2024-09-13T21:25:52 https://maestrodatabase.com/blog/opioid-settlement-hinders-patients-access-to-a-wide-array-of-drugs 2023-03-20T12:02:18 https://maestrodatabase.com/blog/evolving-our-approach-to-covid-19-vaccines-and-treatments 2023-12-07T05:52:32 https://maestrodatabase.com/blog/audentes-announces-regenerative-medicine-advanced-therapy-designation-granted-by-the-fda-to-at132-for-the-treatment-of-x-linked-myotubular-myopathy 2018-08-21T23:39:24 https://maestrodatabase.com/blog/vertex-raises-price-of-top-selling-cystic-fibrosis-drug-for-first-time 2017-07-06T10:04:40 https://maestrodatabase.com/blog/adamis-pharmaceuticals-provides-an-update-on-zimhi 2021-04-13T09:37:58 https://maestrodatabase.com/blog/the-evolution-of-the-italian-national-health-service 2021-10-26T20:39:35 https://maestrodatabase.com/blog/atagi-updated-recommendations-for-a-winter-dose-of-covid-19-vaccine 2022-07-07T07:33:58 https://maestrodatabase.com/blog/bristol-myers-squibbs-orencia-abatacept-receives-fda-approval-for-treatment-of-active-psoriatic-arthritis-in-adults 2017-07-06T11:38:56 https://maestrodatabase.com/blog/evrysdi-is-not-included-in-the-high-cost-protection 2021-10-26T20:46:17 https://maestrodatabase.com/blog/one-in-three-ra-patients-rejecting-meds-because-of-cost 2017-07-06T20:54:54 https://maestrodatabase.com/blog/how-the-gop-and-democrats-might-begin-to-compromise-on-health-care 2017-07-06T20:59:05 https://maestrodatabase.com/blog/employers-are-planning-how-to-blunt-the-cost-of-gene-therapies-pricey-new-specialty-drugs 2020-08-28T12:06:13 https://maestrodatabase.com/blog/kidney-cancer-charity-slams-nice-rejection-of-keytruda-slash-inlyta 2020-08-28T12:09:53 https://maestrodatabase.com/blog/evaluating-the-evidence-behind-the-surrogate-measures-included-in-the-fdas-table-of-surrogate-endpoints-as-supporting-approval-of-cancer-drugs 2020-04-14T01:16:46 https://maestrodatabase.com/blog/pacific-communities-in-new-zealand-respond-to-pharmacs-new-strategy 2017-07-06T21:07:37 https://maestrodatabase.com/blog/tga-approves-booster-doses-of-the-pfizer-covid-19-vaccine-comirnaty 2021-10-27T05:26:32 https://maestrodatabase.com/blog/ipsen-confirms-us-fda-grants-priority-review-for-new-drug-application-for-elafibranor-for-the-treatment-of-rare-cholestatic-liver-disease-pbc 2023-12-07T19:48:50 https://maestrodatabase.com/blog/learning-each-others-language-fda-patent-office-seek-to-work-together-to-lower-drug-prices 2023-12-07T19:44:33 https://maestrodatabase.com/blog/biden-administration-could-seize-patents-for-high-priced-drugs 2023-12-07T19:34:30 https://maestrodatabase.com/blog/changes-could-reduce-access-to-medications 2017-07-06T21:14:29 https://maestrodatabase.com/blog/allergan-receives-complete-response-letter-from-the-u-dot-s-fda-for-ulipristal-acetate-new-drug-application 2018-08-22T02:39:37 https://maestrodatabase.com/blog/brexit-must-not-disrupt-drug-r-and-d-say-pharma-chiefs 2017-07-06T21:27:59 https://maestrodatabase.com/blog/fda-approves-ocrevus-zunovo-as-the-first-and-only-twice-a-year-10-minute-subcutaneous-injection-for-people-with-relapsing-and-progressive-multiple-sclerosis 2024-09-13T22:15:51 https://maestrodatabase.com/blog/additional-listings-on-the-pharmaceutical-schedule-of-a-range-of-orthopaedic-implants-and-associated-products-with-johnson-and-johnson 2017-07-06T21:21:15 https://maestrodatabase.com/blog/pbac-drug-utilisation-sub-committee-utilisation-analysis---public-release-documents 2018-08-22T02:08:54 https://maestrodatabase.com/blog/has-publishes-tc-opinion-on-olumiant 2017-07-06T21:44:39 https://maestrodatabase.com/blog/dupixent-dupilumab-approved-in-the-us-as-first-and-only-treatment-for-adolescents-with-chronic-rhinosinusitis-with-nasal-polyps 2024-09-13T22:06:42 https://maestrodatabase.com/blog/white-house-backs-conservative-health-plan-but-g-dot-o-p-leaders-are-leery 2017-07-06T21:32:48 https://maestrodatabase.com/blog/what-does-knee-surgery-cost-few-know-and-thats-a-problem 2018-08-22T04:31:58 https://maestrodatabase.com/blog/lobbying-firms-earning-hundreds-of-thousands-from-contracts-with-government-agencies 2023-03-21T04:36:26 https://maestrodatabase.com/blog/prestige-biopharma-receives-fda-fast-track-designation-for-pbp1510-in-the-treatment-of-pancreatic-cancer 2023-03-21T04:42:33 https://maestrodatabase.com/blog/avenue-therapeutics-announces-that-the-fda-is-still-reviewing-its-nda-resubmission-for-iv-tramadol 2021-04-13T11:04:05 https://maestrodatabase.com/blog/fda-approves-lillys-ebglyss-lebrikizumab-lbkz-for-adults-and-children-12-years-and-older-with-moderate-to-severe-atopic-dermatitis 2024-09-13T22:20:56 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-posts-draft-scoping-document-on-elagolix-for-endometriosis 2018-01-11T23:16:41 https://maestrodatabase.com/blog/accelerated-approval---taking-the-fdas-concerns-seriously 2022-07-07T09:11:22 https://maestrodatabase.com/blog/top-fda-official-agency-needs-to-start-using-accelerated-approval-for-gene-therapies 2023-03-21T04:46:36 https://maestrodatabase.com/blog/joint-cdc-and-fda-statement-on-johnson-and-johnson-covid-19-vaccine 2021-04-13T20:32:03 https://maestrodatabase.com/blog/europe-tries-to-lower-drug-prices-with-small-doses-of-transparency 2021-04-13T20:48:12 https://maestrodatabase.com/blog/terms-of-reference-for-the-health-technology-assessment-policy-and-methods-review 2023-03-22T05:31:40 https://maestrodatabase.com/blog/hta-reform-gets-underway---terms-of-reference-released-today 2023-03-22T05:48:37 https://maestrodatabase.com/blog/qilian-international-announces-inclusion-of-16-products-into-chinas-national-reimbursement-drugs-list 2021-04-13T20:51:21 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-sacituzumab-govitecan-for-advanced-urothelial-cancer 2021-04-13T20:40:39 https://maestrodatabase.com/blog/vtv-therapeutics-receives-fda-breakthrough-therapy-designation-for-ttp399-for-the-treatment-of-type-1-diabetes 2021-04-13T20:36:18 https://maestrodatabase.com/blog/four-medicines-accepted-for-use-by-nhs-scotland 2021-04-13T20:44:59 https://maestrodatabase.com/blog/new-recommendations-on-the-critical-appraisal-of-systematic-reviews-with-cost-and-cost-effectiveness-outcomes 2021-04-13T21:15:58 https://maestrodatabase.com/blog/dupixent-dupilumab-approved-by-european-commission-as-first-and-only-targeted-medicine-for-children-as-young-as-six-months-old-with-severe-atopic-dermatitis 2023-03-22T06:54:31 https://maestrodatabase.com/blog/u-dot-s-fda-to-scrutinise-vaccine-design-behind-covid-19-shots-linked-to-blood-clots 2021-04-13T21:38:44 https://maestrodatabase.com/blog/atossa-therapeutics-announces-ovarian-cancer-patient-has-begun-treatment-with-oral-endoxifen-under-fdas-expanded-access-pathway 2021-04-13T21:20:47 https://maestrodatabase.com/blog/sandoz-receives-us-fda-approval-for-biosimilar-hyrimoz-adalimumab-adaz-high-concentration-formulation 2023-03-22T06:40:36 https://maestrodatabase.com/blog/scotland-opens-door-to-translarna-for-duchenne-muscular-dystrophy 2021-04-13T20:58:31 https://maestrodatabase.com/blog/techdow-usa-announces-fda-approval-of-generic-lovenox-enoxaparin-sodium---preservative-free-in-pre-filled-syringes 2023-03-22T06:31:08 https://maestrodatabase.com/blog/did-australia-get-it-right-on-astrazeneca 2021-04-13T21:12:06 https://maestrodatabase.com/blog/moderna-expects-to-price-its-covid-vaccine-at-about-130-dollars-in-the-us 2023-03-22T06:25:59 https://maestrodatabase.com/blog/national-cabinet-to-return-to-war-footing-in-effort-to-fix-problem-plagued-covid-vaccine-rollout 2021-04-13T21:09:22 https://maestrodatabase.com/blog/ema-finalises-companion-diagnostic-guidance 2022-07-07T20:55:58 https://maestrodatabase.com/blog/us-fda-grants-rpd-designation-to-senhwa-biosciences-silmitasertib-for-paediatric-neuroblastoma 2024-09-14T03:35:18 https://maestrodatabase.com/blog/vertex-announces-letter-of-intent-with-the-pan-canadian-pharmaceutical-alliance-for-public-reimbursement-of-trikafta-elexacaftor-slash-tezacaftor-slash-ivacaftor-and-ivacaftor-in-children-with-cystic-fibrosis-ages-6-and-older 2022-07-07T21:03:10 https://maestrodatabase.com/blog/pharmac-keeps-medical-devices-role-despite-failing-to-curb-costs 2022-07-07T20:50:20 https://maestrodatabase.com/blog/u-dot-s-fda-approves-cystadrops-0-dot-37-percent-cysteamine-ophthalmic-solution-a-new-practical-treatment-option-for-the-ocular-manifestations-of-cystinosis 2020-08-28T23:30:25 https://maestrodatabase.com/blog/drug-repurposing-during-the-covid-19-pandemic-lessons-for-expediting-drug-development-and-access 2023-03-22T08:19:32 https://maestrodatabase.com/blog/democratic-senators-raise-concerns-with-potential-fda-pick 2021-10-27T08:15:11 https://maestrodatabase.com/blog/advancing-regulatory-science-in-the-eu---mid-point-report-published 2023-03-22T12:06:43 https://maestrodatabase.com/blog/updates-to-the-hta-policy-and-methods-review-reference-committee-8-december-2023 2023-12-07T22:58:16 https://maestrodatabase.com/blog/with-brexit-looming-what-does-the-future-hold-for-uk-biosimilars 2019-09-27T05:39:29 https://maestrodatabase.com/blog/nivolumab-in-combination-with-chemotherapy-for-the-neo-adjuvant-treatment-of-patients-with-resectable-non-small-cell-lung-cancer 2023-03-22T11:59:55 https://maestrodatabase.com/blog/insurers-drug-makers-and-patient-advocates-blast-two-trump-proposals-to-drive-down-drug-prices 2020-04-14T04:42:38 https://maestrodatabase.com/blog/us-fda-awards-rare-paediatric-disease-designation-to-paxalisib-for-at-slash-rt-a-rare-form-of-childhood-brain-cancer 2022-07-07T21:46:18 https://maestrodatabase.com/blog/tga-approval-for-pfizer-covid-19-vaccine-booster-dose 2021-10-27T08:19:58 https://maestrodatabase.com/blog/testing-for-differences-in-survival-when-treatment-effects-are-persistent-decaying-or-delayed 2022-07-07T21:12:14 https://maestrodatabase.com/blog/fda-approves-first-in-class-evkeeza-evinacumab-dgnb-for-young-children-with-ultra-rare-form-of-high-cholesterol 2023-03-22T11:52:57 https://maestrodatabase.com/blog/health-canada-issues-notice-of-compliance-with-conditions-for-libtayo-cemiplimab-the-first-and-only-biologic-for-the-treatment-of-advanced-cutaneous-squamous-cell-carcinom 2019-04-12T01:25:11 https://maestrodatabase.com/blog/msac-updates-agenda-for-july-2022-meeting 2022-07-07T21:24:14 https://maestrodatabase.com/blog/swissmedic-updates-biosimilar-guidance-to-allow-comparators-of-us-origin 2018-01-12T02:19:02 https://maestrodatabase.com/blog/fda-approves-expanded-monotherapy-label-for-mercks-keytruda-pembrolizumab 2019-04-12T01:18:46 https://maestrodatabase.com/blog/fda-collaborates-with-health-canada-and-uks-mhra-to-foster-good-machine-learning-practice 2021-10-27T20:19:24 https://maestrodatabase.com/blog/fda-nih-and-15-private-organisations-join-forces-to-increase-effective-gene-therapies-for-rare-diseases 2021-10-27T20:16:47 https://maestrodatabase.com/blog/pharma-collaborates-to-improve-chances-of-nice-backing-duchenne-drugs 2018-01-12T03:04:46 https://maestrodatabase.com/blog/moderna-announces-swissmedic-authorises-booster-dose-of-modernas-covid-19-vaccine 2021-10-27T20:23:44 https://maestrodatabase.com/blog/decision-to-widen-access-to-pulmonary-arterial-hypertension-treatments 2018-01-12T03:10:08 https://maestrodatabase.com/blog/novartis-receives-priority-review-by-us-fda-and-filing-acceptance-by-ema-for-kymriah-to-treat-patients-with-relapsed-or-refractory-follicular-lymphoma 2021-10-27T19:42:34 https://maestrodatabase.com/blog/vertexs-supplement-to-a-new-drug-aubmission-for-trikafta-elexacaftor-slash-tezacaftor-slash-ivacaftor-and-ivacaftor-in-patients-ages-6-11-accepted-for-priority-review-by-health-canada 2021-10-27T20:03:51 https://maestrodatabase.com/blog/abbvie-provides-regulatory-update-on-abbv-951-foscarbidopa-slash-foslevodopa-new-drug-application 2023-03-23T05:02:51 https://maestrodatabase.com/blog/audrey-ashmans-bone-treatment-for-rare-genetic-disease-known-as-xlh-denied-government-subsidy 2021-10-27T20:42:09 https://maestrodatabase.com/blog/novavax-files-for-authorisation-of-its-covid-19-vaccine-in-the-united-kingdom 2021-10-27T20:30:17 https://maestrodatabase.com/blog/investments-to-support-access-to-drugs-for-rare-diseases 2023-03-23T06:04:00 https://maestrodatabase.com/blog/cidara-therapeutics-and-melinta-therapeutics-announce-fda-approval-of-rezzayo-rezafungin-for-injection-for-the-treatment-of-candidemia-and-invasive-candidiasis 2023-03-23T06:06:45 https://maestrodatabase.com/blog/pharmac-considers-funding-rituximab-for-igg4-related-disease 2023-03-23T05:49:34 https://maestrodatabase.com/blog/government-of-canada-improves-access-to-affordable-and-effective-drugs-for-rare-diseases 2023-03-23T06:00:07 https://maestrodatabase.com/blog/potential-coronavirus-drugs-may-cost-as-little-as-1-dollars-study-says 2020-04-14T05:01:29 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-retifanlimab-dlwr-for-metastatic-or-recurrent-locally-advanced-merkel-cell-carcinoma 2023-03-23T05:12:08 https://maestrodatabase.com/blog/be-careful-who-you-sue-cytodyn-knowingly-submitted-an-incomplete-drug-application-to-fda-new-documents-show 2021-10-28T10:43:52 https://maestrodatabase.com/blog/lilly-announces-health-canadas-authorisation-of-verzenio-abemaciclib-label-expansion 2023-12-08T01:38:38 https://maestrodatabase.com/blog/my01-continuous-compartmental-pressure-monitor-granted-breakthrough-device-designation-from-the-fda 2021-10-28T10:52:19 https://maestrodatabase.com/blog/drug-makers-push-back-on-a-clever-tactic-employers-use-to-avoid-paying-for-specialty-medicines 2023-03-23T07:45:51 https://maestrodatabase.com/blog/calquence-granted-first-regulatory-approval-in-china-for-adults-with-previously-treated-mantle-cell-lymphoma 2023-03-23T07:50:58 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-28-october-2021 2021-10-28T10:26:34 https://maestrodatabase.com/blog/a-roadmap-for-improving-medicares-application-of-coverage-with-evidence-development 2024-09-14T12:49:50 https://maestrodatabase.com/blog/vulnerable-house-democrats-warn-not-to-drop-drug-pricing-from-package 2021-10-28T11:09:26 https://maestrodatabase.com/blog/ema-nod-for-excessive-daytime-sleepiness-med-ozawade 2021-10-28T20:01:39 https://maestrodatabase.com/blog/repurposing-of-authorised-medicines-pilot-to-support-not-for-profit-organisations-and-academia 2021-10-28T19:58:15 https://maestrodatabase.com/blog/booster-doses-of-covid-19-vaccines-recommended-for-people-aged-18-and-over 2021-10-28T11:02:36 https://maestrodatabase.com/blog/breakthrough-ortek-ecd-technology-enables-dentists-to-detect-cavities-often-not-seen-by-x-rays 2021-10-28T10:57:22 https://maestrodatabase.com/blog/covid-19-ebola-drug-leads-treatment-race 2020-04-14T05:50:52 https://maestrodatabase.com/blog/intelgenx-announces-resubmission-of-rizaport-new-drug-application 2019-09-27T12:12:18 https://maestrodatabase.com/blog/doctors-pharmacists-call-for-better-support-to-prescribe-anti-virals 2022-07-08T04:58:35 https://maestrodatabase.com/blog/health-canada-approves-fyb201-slash-ranopto-ranibizumab-a-biosimilar-to-lucentis 2023-12-08T02:33:41 https://maestrodatabase.com/blog/industry-shoots-down-labours-plans-to-tackle-extortionate-drug-prices 2019-09-27T07:21:31 https://maestrodatabase.com/blog/fda-acknowledges-hurdles-in-utilising-real-world-data 2021-10-28T20:39:07 https://maestrodatabase.com/blog/biden-abandons-his-push-to-lower-drug-prices 2021-10-28T20:31:10 https://maestrodatabase.com/blog/spero-therapeutics-submits-new-drug-application-to-u-dot-s-fda-for-tebipenem-hydrobromide-for-the-treatment-of-complicated-urinary-tract-infections-including-pyelonephritis 2021-10-28T20:15:52 https://maestrodatabase.com/blog/china-national-medical-products-administration-approves-beigenes-tislelizumab-for-patients-with-previously-treated-locally-advanced-or-metastatic-urothelial-carcinoma 2020-04-14T05:45:11 https://maestrodatabase.com/blog/rybelsus-is-included-in-the-high-cost-protection-with-restriction 2020-08-29T02:05:07 https://maestrodatabase.com/blog/mallinckrodt-and-terumo-blood-and-cell-technologies-announce-positive-recommendations-in-australia-for-public-funding-of-uvadex-methoxsalen-for-ecp-administration-with-the-therakos-cellex-photopheresis-system-for-chronic-graft-versus-host-disease-in-adults 2021-10-28T20:24:15 https://maestrodatabase.com/blog/fda-clarifies-how-it-will-regulate-digital-health-and-artificial-intelligence 2019-09-27T12:19:37 https://maestrodatabase.com/blog/smc---april-2020-decisions 2020-04-14T11:25:09 https://maestrodatabase.com/blog/adaptimmune-completes-submission-of-rolling-biologics-license-application-to-us-fda-for-afami-cel-for-the-treatment-of-advanced-synovial-sarcoma 2023-12-08T05:44:41 https://maestrodatabase.com/blog/erbitux-in-combination-with-folfox-or-folfiri-approved-as-first-line-therapy-for-patients-in-china-with-ras-wild-type-metastatic-colorectal-cancer 2019-09-27T12:51:37 https://maestrodatabase.com/blog/public-statement-for-collaboration-on-covid-19-vaccine-development 2020-04-14T11:29:17 https://maestrodatabase.com/blog/regulators-split-on-anti-malarials-for-covid-19 2020-04-14T11:35:08 https://maestrodatabase.com/blog/nice-publishes-final-guidance-for-janssens-apalutamide 2021-10-28T20:41:45 https://maestrodatabase.com/blog/alpha-cognition-announces-fda-acceptance-of-new-drug-application-for-alpha-1062-for-mild-to-moderate-alzheimers-disease 2023-12-08T03:14:24 https://maestrodatabase.com/blog/alnylam-receives-fast-track-designation-for-vutrisiran-for-the-treatment-of-the-polyneuropathy-of-hattr-amyloidosis 2020-04-14T21:05:25 https://maestrodatabase.com/blog/why-a-decades-old-tb-vaccine-is-getting-attention-in-the-fight-against-covid-19 2020-04-14T11:41:55 https://maestrodatabase.com/blog/pharmacologic-treatments-for-coronavirus-disease-2019-covid-19-a-review 2020-04-14T20:56:23 https://maestrodatabase.com/blog/vaccine-development-is-a-case-of-market-failure 2020-04-14T21:01:21 https://maestrodatabase.com/blog/lapse-of-provisional-registration-for-tecentriq-atezolizumab-for-the-treatment-of-locally-advanced-or-metastatic-triple-negative-breast-cancer 2023-03-25T03:31:07 https://maestrodatabase.com/blog/fda-approves-bio-thera-solutions-avzivi-bevacizumab-tnjn-a-biosimilar-referencing-avastin 2023-12-08T07:16:57 https://maestrodatabase.com/blog/fda-approves-first-treatment-for-children-with-rare-diseases-that-cause-inflammation-of-small-blood-vessels 2019-09-27T22:27:39 https://maestrodatabase.com/blog/pbs-arrangements-for-tocilizumab-shortage---1-november-2021 2021-10-29T00:04:48 https://maestrodatabase.com/blog/tlv-is-preparing-for-an-increase-in-ceiling-prices 2023-03-25T03:55:12 https://maestrodatabase.com/blog/mhra-to-streamline-clinical-trial-approvals-in-biggest-overhaul-of-trial-regulation-in-20-years 2023-03-25T03:50:55 https://maestrodatabase.com/blog/fda-approves-first-gene-therapies-to-treat-patients-with-sickle-cell-disease 2023-12-08T20:25:46 https://maestrodatabase.com/blog/fda-approves-first-treatment-for-breast-cancer-with-a-certain-inherited-genetic-mutation 2018-01-13T00:17:24 https://maestrodatabase.com/blog/incyte-provides-regulatory-update-on-ruxolitinib-extended-release-tablets 2023-03-25T03:44:44 https://maestrodatabase.com/blog/nice-recommends-life-changing-gene-therapy-for-children-with-ultra-rare-genetic-disorder-in-final-draft-guidance 2023-03-25T03:37:12 https://maestrodatabase.com/blog/fda-approves-first-treatment-for-activated-phosphoinositide-3-kinase-delta-syndrome 2023-03-25T03:40:40 https://maestrodatabase.com/blog/addressing-health-system-values-in-health-technology-assessment-the-use-of-evidence-informed-deliberative-processes 2019-04-12T06:21:47 https://maestrodatabase.com/blog/columvi-glofitamab-for-injection-receives-health-canada-authorisation-with-conditions-for-adult-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma 2023-03-27T04:23:02 https://maestrodatabase.com/blog/cvss-new-drug-payment-plan-wont-lower-patients-prices-experts-warn 2023-12-08T21:13:30 https://maestrodatabase.com/blog/statement-from-fda-commissioner-on-fda-decision-to-seek-additional-time-to-reassess-rule-that-would-have-changed-longstanding-practices-for-how-the-agency-determined-the-intended-use-of-medical-products 2018-01-13T00:29:22 https://maestrodatabase.com/blog/health-canada-approves-first-treatment-option-for-generalised-pustular-psoriasis-flares-in-adults 2023-03-27T04:18:08 https://maestrodatabase.com/blog/fda-approves-expanded-use-of-cresemba-isavuconazonium-sulphate-in-children-with-invasive-aspergillosis-and-invasive-mucormycosis 2023-12-08T20:58:03 https://maestrodatabase.com/blog/drug-evaluation-during-the-covid-19-pandemic 2020-04-14T23:13:04 https://maestrodatabase.com/blog/worlds-first-chemo-drone-delivery-announced-on-nhs-birthday 2022-07-08T06:47:48 https://maestrodatabase.com/blog/lifemax-receives-fast-track-designation-for-lm-030-for-the-treatment-of-netherton-syndrome 2020-04-14T23:16:40 https://maestrodatabase.com/blog/fda-broadens-emergency-use-authorisation-for-veklury-remdesivir-to-include-all-hospitalised-patients-for-treatment-of-covid-19 2020-08-29T02:31:16 https://maestrodatabase.com/blog/phathom-pharmaceuticals-announces-fda-acceptance-for-filing-of-voquenza-vonoprazan-tablets-new-drug-application-for-the-treatment-of-heartburn-associated-with-non-erosive-gerd 2023-12-08T20:49:30 https://maestrodatabase.com/blog/cytodyn-announces-fda-accepts-revised-rolling-review-timeline-for-resubmission-of-its-bla 2021-10-29T00:34:44 https://maestrodatabase.com/blog/european-commission-approves-pfizers-elrexfio-for-relapsed-and-refractory-multiple-myeloma 2023-12-08T20:43:18 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-report-on-voretigene-neparvovec-suggests-substantial-price-discount-needed-to-meet-traditional-cost-effectiveness-standards 2018-01-13T00:34:40 https://maestrodatabase.com/blog/gsk-receives-fda-approval-for-expanded-indication-for-fluarix-quadrivalent-influenza-vaccine-for-persons-6-months-and-older 2018-01-13T03:03:24 https://maestrodatabase.com/blog/biden-says-he-wants-to-bring-down-drug-prices-his-actions-tell-a-different-story 2023-03-27T04:45:42 https://maestrodatabase.com/blog/fda-outlines-plan-for-digital-health-technologies-for-clinical-trials 2023-03-27T04:48:35 https://maestrodatabase.com/blog/covid-19-vaccine-safety-report-23-march-2023 2023-03-27T04:38:49 https://maestrodatabase.com/blog/roches-ocrevus-ocrelizumab-approved-in-the-european-union-for-relapsing-forms-of-multiple-sclerosis-and-primary-progressive-multiple-sclerosis 2018-01-13T02:57:39 https://maestrodatabase.com/blog/tgas-new-powers-will-help-reduce-the-impact-of-medicine-shortages-on-patients 2023-03-27T04:41:30 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-to-concert-pharmaceuticals-ctp-543-for-the-treatment-of-alopecia-areata 2018-01-13T05:09:33 https://maestrodatabase.com/blog/health-canada-authorises-imbruvica-ibrutinib-in-a-fixed-duration-combination-with-venetoclax-for-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia 2023-03-27T04:30:42 https://maestrodatabase.com/blog/us-sets-policy-to-seize-patents-of-government-funded-drugs-if-price-deemed-too-high 2023-12-08T21:18:19 https://maestrodatabase.com/blog/iovance-biotherapeutics-completes-biologics-license-application-submission-for-lifileucel-in-advanced-melanoma 2023-03-27T11:32:05 https://maestrodatabase.com/blog/price-disclosure-2018-april-cycle-outcomes-summary 2018-01-13T05:31:34 https://maestrodatabase.com/blog/kites-yescarta-axicabtagene-ciloleucel-first-car-t-cell-therapy-to-receive-health-canada-authorisation-for-use-in-second-line-large-b-cell-lymphoma 2023-03-27T05:21:51 https://maestrodatabase.com/blog/batch-release-assessment-of-covid-19-vaccines 2021-04-14T01:00:05 https://maestrodatabase.com/blog/ema-validates-marketing-authorisation-application-for-henlius-hansizhuang-serplulimab 2023-03-27T04:52:45 https://maestrodatabase.com/blog/estimating-the-reference-incremental-cost-effectiveness-ratio-for-the-australian-health-system 2018-01-13T06:47:58 https://maestrodatabase.com/blog/agenda-for-the-november-2018-pbac-meeting 2018-08-22T12:08:51 https://maestrodatabase.com/blog/cystic-fibrosis-drug-to-be-listed-on-pbs 2018-08-22T12:15:33 https://maestrodatabase.com/blog/medicines-lobby-says-the-pbs-has-not-kept-up-with-advances----or-approvals----in-medicines 2023-12-09T02:20:00 https://maestrodatabase.com/blog/alberta-may-circumvent-health-canada-to-gain-access-to-covid-19-tests-and-drugs-premier-says 2020-04-15T01:11:22 https://maestrodatabase.com/blog/engeneic-granted-fda-fast-track-designation-for-novel-armed-nanocell-drug-conjugate-pancreatic-cancer-therapeutic 2023-12-08T23:42:57 https://maestrodatabase.com/blog/delcath-systems-announces-fda-acceptance-of-new-drug-application-resubmission-of-hepzato-kit-with-a-pdufa-date-of-14-august-2023 2023-03-27T19:55:45 https://maestrodatabase.com/blog/statement-from-president-joe-biden-on-fda-approval-of-gene-therapies-to-treat-sickle-cell-disease 2023-12-08T23:23:44 https://maestrodatabase.com/blog/enhertu-approved-in-japan-as-the-first-her2-directed-therapy-for-patients-with-her2-low-metastatic-breast-cancer 2023-03-27T11:36:43 https://maestrodatabase.com/blog/icer-posts-draft-scoping-document-on-avxs-101-and-nusinersen-for-spinal-muscular-atrophy 2018-08-22T20:43:19 https://maestrodatabase.com/blog/finerenone-for-the-treatment-of-chronic-kidney-disease-in-patients-with-type-2-diabetes 2023-03-27T20:36:13 https://maestrodatabase.com/blog/easier-access-to-rare-metabolic-disorder-treatments 2021-04-14T02:32:44 https://maestrodatabase.com/blog/clinical-trial-considerations-to-support-accelerated-approval-of-oncology-therapeutics 2023-03-27T20:16:17 https://maestrodatabase.com/blog/statement-by-fda-commissioner-on-new-steps-to-advance-the-development-of-evidence-based-indication-specific-guidelines-to-help-guide-appropriate-prescribing-of-opioid-analgesics 2018-08-22T20:51:21 https://maestrodatabase.com/blog/final-reconciliation-of-savings-from-side-agreements-for-the-full-year-2022 2023-03-27T20:04:19 https://maestrodatabase.com/blog/mallinckrodt-confirms-receipt-of-stannsoporfin-complete-response-letter 2018-08-22T21:01:55 https://maestrodatabase.com/blog/fda-approves-first-drug-for-neurotrophic-keratitis-a-rare-eye-disease 2018-08-22T21:15:23 https://maestrodatabase.com/blog/product-specific-guidances-for-chloroquine-phosphate-and-hydroxychloroquine-sulphate 2020-04-15T03:16:15 https://maestrodatabase.com/blog/moleculin-awarded-new-rare-paediatric-disease-designation-from-u-dot-s-fda-for-wp1066-for-the-treatment-of-ependymoma 2021-04-14T11:38:36 https://maestrodatabase.com/blog/fda-ousts-spokeswoman-after-covid-therapy-misstatements 2020-08-29T04:53:29 https://maestrodatabase.com/blog/new-drug-able-to-overcome-migraines-available-in-australia-for-millions-suffering-in-silence 2018-08-22T21:10:36 https://maestrodatabase.com/blog/tagrisso-approved-in-china-in-early-lung-cancer 2021-04-14T06:43:33 https://maestrodatabase.com/blog/fda-announces-advisory-committee-meeting-to-discuss-covid-19-vaccines 2020-08-29T04:47:59 https://maestrodatabase.com/blog/cms-releases-formal-approach-to-ensure-medicaid-demonstrations-remain-budget-neutral 2018-08-22T21:20:20 https://maestrodatabase.com/blog/tga-grants-provisional-determination-to-gsk-for-covid-19-monoclonal-antibody-treatment---sotrovimab 2021-04-14T09:31:44 https://maestrodatabase.com/blog/astrazenecas-covid-19-vaccine-ema-to-provide-further-context-on-risk-of-very-rare-blood-clots-with-low-blood-platelets 2021-04-14T20:58:59 https://maestrodatabase.com/blog/covid-19-vaccine-janssen-assessment-of-very-rare-cases-of-unusual-blood-clots-with-low-platelets-continues 2021-04-14T20:56:34 https://maestrodatabase.com/blog/incyte-announces-japanese-approval-of-pemazyre-pemigatinib-for-the-treatment-of-patients-with-myeloid-slash-lymphoid-neoplasms 2023-03-27T21:53:37 https://maestrodatabase.com/blog/tga-accepts-telixs-prostate-cancer-imaging-product-submission-and-commences-priority-evaluation-process 2021-04-14T21:06:14 https://maestrodatabase.com/blog/reata-pharmaceuticals-submits-marketing-authorisation-application-to-the-ema-for-bardoxolone-methyl-in-chronic-kidney-disease-caused-by-alport-syndrome 2021-10-29T04:01:33 https://maestrodatabase.com/blog/nice-recommends-opdivo-as-post-surgery-treatment 2022-07-08T23:10:00 https://maestrodatabase.com/blog/rare-disease-drug-makers-join-in-worries-over-gop-health-overhaul 2017-07-07T09:20:16 https://maestrodatabase.com/blog/new-blow-to-rollout-as-novavax-covid-19-vaccine-hits-supply-hiccup 2021-04-14T21:29:14 https://maestrodatabase.com/blog/public-summary-documents---july-2021-pbac-meeting 2021-10-29T05:06:29 https://maestrodatabase.com/blog/how-to-harness-the-private-sector-for-universal-health-coverage 2017-07-07T11:40:18 https://maestrodatabase.com/blog/fda-approves-krystexxa-pegloticase-injection-co-administered-with-methotrexate-expanding-the-labelling-to-help-more-people-with-uncontrolled-gout-achieve-a-complete-response-to-therapy 2022-07-09T03:03:28 https://maestrodatabase.com/blog/phrmas-three-part-approach-to-build-a-better-health-care-system 2021-04-14T21:36:02 https://maestrodatabase.com/blog/kites-tecartus-brexucabtagene-autoleucel-authorised-by-health-canada-for-the-treatment-of-relapsed-or-refractory-mantle-cell-lymphoma 2021-10-29T05:11:50 https://maestrodatabase.com/blog/pfizer-and-biontech-announce-u-dot-s-fda-approval-of-their-covid-19-vaccine-comirnaty-for-adolescents-12-through-15-years-of-age 2022-07-09T02:20:04 https://maestrodatabase.com/blog/petition-filed-for-better-access-to-haemophilia-a-drug 2021-04-14T21:11:47 https://maestrodatabase.com/blog/europe-bets-heavily-on-pfizer-in-vaccine-strategy-overhaul 2021-04-14T21:25:22 https://maestrodatabase.com/blog/novavax-covid-19-vaccine-in-australia-when-will-we-get-it-and-is-it-better-than-pfizer 2021-04-14T21:17:10 https://maestrodatabase.com/blog/incyte-announces-the-validation-of-the-european-marketing-authorisation-application-for-ruxolitinib-cream-in-vitiligo 2021-10-29T04:57:53 https://maestrodatabase.com/blog/the-skys-the-limit-how-australian-scientists-rewrote-the-cancer-script 2025-06-22T22:59:18 https://maestrodatabase.com/blog/fda-approves-first-targeted-therapy-for-metastatic-bladder-cancer 2019-04-13T02:36:55 https://maestrodatabase.com/blog/patient-and-public-involvement-in-health-technology-assessment-a-new-dawn 2021-04-14T21:44:37 https://maestrodatabase.com/blog/update-on-fda-review-of-ruxolitinib-cream-opzelura-for-children-ages-2-11-with-atopic-dermatitis 2025-06-22T22:44:43 https://maestrodatabase.com/blog/pfizer-and-biontech-submit-a-variation-to-ema-for-the-vaccination-of-children-6-months-to-less-than-5-years-with-comirnaty 2022-07-10T07:01:04 https://maestrodatabase.com/blog/covid-19-nz-should-develop-vaccine-programme-say-scientists 2020-04-15T05:43:13 https://maestrodatabase.com/blog/sanofi-and-gsk-to-join-forces-in-unprecedented-vaccine-collaboration-to-fight-covid-19 2020-04-15T05:47:41 https://maestrodatabase.com/blog/health-canada-approves-tecentriq-in-combination-with-chemotherapy-nab-paclitaxel-as-first-immunotherapy-treatment-for-aggressive-form-of-breast-cancer 2019-09-28T03:28:40 https://maestrodatabase.com/blog/covid-19-oral-treatment-eligibility-expanded-from-11-july-2022 2022-07-10T09:33:59 https://maestrodatabase.com/blog/intercept-submits-new-drug-application-to-the-u-dot-s-fda-for-obeticholic-acid-in-patients-with-fibrosis-due-to-nash 2019-09-28T03:23:34 https://maestrodatabase.com/blog/missing-from-the-pbm-hearings-value-based-drug-reimbursement 2019-04-13T10:32:41 https://maestrodatabase.com/blog/celltrion-pharms-liver-disease-drug-may-lose-insurance-benefits 2022-07-10T07:42:08 https://maestrodatabase.com/blog/monkeypox-a-preventive-vaccination-offered-to-those-most-at-risk-of-exposure 2022-07-10T07:29:16 https://maestrodatabase.com/blog/avexis-rules-out-eu-compassionate-use-of-sma-gene-therapy-says-biogen-option-is-available 2019-09-28T03:33:01 https://maestrodatabase.com/blog/pbac-recommendation-for-amendments-to-covid-19-oral-treatment-restrictions 2022-07-10T07:32:17 https://maestrodatabase.com/blog/how-are-gene-therapies-going-to-get-paid-for 2019-04-13T10:42:13 https://maestrodatabase.com/blog/cour-pharmaceuticals-receives-fda-fast-track-designation-for-timp-glia 2018-01-13T23:26:17 https://maestrodatabase.com/blog/polyphors-antibiotic-murepavadin-receives-us-fda-qualified-infectious-disease-product-designation-in-four-new-indications 2019-04-13T10:37:38 https://maestrodatabase.com/blog/millions-of-australians-to-gain-access-to-covid-treatments 2022-07-10T10:12:14 https://maestrodatabase.com/blog/astellas-veoza-fezolinetant-approved-by-european-commission-for-treatment-of-vasomotor-symptoms-associated-with-menopause 2023-12-10T23:57:28 https://maestrodatabase.com/blog/novavax-nuvaxovid-covid-19-vaccine-conditionally-authorised-in-the-european-union-for-adolescents-aged-12-through-17 2022-07-10T21:09:32 https://maestrodatabase.com/blog/human-genetics-evidence-supports-two-thirds-of-the-2021-fda-approved-drugs 2022-07-10T21:00:37 https://maestrodatabase.com/blog/prices-and-clinical-benefit-of-national-price-negotiated-anti-cancer-medicines-in-china 2022-07-10T21:03:47 https://maestrodatabase.com/blog/review-of-cancer-drug-benefits-delayed-amid-social-distancing 2020-04-15T06:41:20 https://maestrodatabase.com/blog/novavax-files-in-switzerland-for-expanded-conditional-marketing-authorisation-of-nuvaxovid-covid-19-vaccine-for-adolescents-aged-12-through-17-and-as-a-booster-in-individuals-aged-18-and-over 2022-07-10T21:22:13 https://maestrodatabase.com/blog/ono-receives-supplemental-approval-of-opdivo-in-combination-with-chemotherapy-for-neo-adjuvant-treatment-of-non-small-cell-lung-cancer-in-japan 2023-03-28T06:26:04 https://maestrodatabase.com/blog/amicus-therapeutics-announces-european-commission-approval-for-pombiliti-in-patients-with-late-onset-pompe-disease 2023-03-28T06:16:03 https://maestrodatabase.com/blog/siga-technologies-receives-approval-from-uk-for-tecovirimat 2022-07-10T21:16:02 https://maestrodatabase.com/blog/mhra-approves-uks-first-anti-pd-1-monoclonal-antibody-for-treatment-of-aggressive-form-of-lung-cancer 2025-06-23T05:18:08 https://maestrodatabase.com/blog/drug-makers-see-a-pricing-blueprint-in-an-850-000-dollar-gene-therapy 2018-01-14T06:11:32 https://maestrodatabase.com/blog/agenda-for-10-january-tc-meeting 2018-01-14T06:20:06 https://maestrodatabase.com/blog/a-managed-access-approach-to-appraising-new-cancer-drugs-in-england 2018-01-14T06:13:41 https://maestrodatabase.com/blog/ionctura-awarded-uks-mhra-innovation-passport-for-entry-into-innovative-licensing-and-access-pathway 2023-03-28T09:46:08 https://maestrodatabase.com/blog/darwin-eu-has-completed-its-first-studies-and-is-calling-for-new-data-partners 2023-03-28T20:05:02 https://maestrodatabase.com/blog/fda-approves-first-therapy-for-treatment-of-low-grade-upper-tract-urothelial-cancer 2020-04-15T20:40:26 https://maestrodatabase.com/blog/fema-ships-out-nearly-20-million-hydroxychloroquine-tablets 2020-04-15T21:07:52 https://maestrodatabase.com/blog/cheaper-medicines-for-breast-cancer-small-cell-lung-cancer-biliary-tract-cancer-juvenile-idiopathic-arthritis-and-crohns-disease 2023-12-11T02:10:29 https://maestrodatabase.com/blog/novo-nordisk-offers-free-90-day-insulin-supply-to-people-experiencing-financial-hardship-due-to-covid-19 2020-04-15T21:12:09 https://maestrodatabase.com/blog/clarification-on-the-subsidy-limitation-for-drugs-for-diabetes 2023-03-28T20:34:08 https://maestrodatabase.com/blog/from-the-european-medicines-agency-to-project-orbis-new-activities-and-challenges-to-facilitate-uk-oncology-drug-approval-following-brexit 2023-03-28T20:26:05 https://maestrodatabase.com/blog/can-your-hip-replacement-kill-you 2018-01-14T21:23:58 https://maestrodatabase.com/blog/pharmacy-reimbursement-often-lags-for-generics-undergoing-price-hikes-jeopardising-patient-access 2020-04-15T21:02:07 https://maestrodatabase.com/blog/to-develop-digital-health-separate-insurance-coverage-system-needed 2023-03-28T20:13:08 https://maestrodatabase.com/blog/concerns-grow-about-supply-of-drugs-for-covid-19-patients-on-ventilators 2020-04-15T21:04:30 https://maestrodatabase.com/blog/vaccine-development-becomes-reality-tv-can-it-make-viewers-rethink-pharma 2020-04-15T21:29:44 https://maestrodatabase.com/blog/distributions-and-what-to-do-when-they-are-non-normal 2018-01-14T21:36:50 https://maestrodatabase.com/blog/merck-announces-us-launch-of-ontruzant-trastuzumab-dttb-a-biosimilar-of-herceptin-trastuzumab 2020-04-15T21:39:28 https://maestrodatabase.com/blog/fujifilm-accelerates-production-of-its-influenza-anti-viral-drug-avigan-for-covid-19 2020-04-15T21:17:04 https://maestrodatabase.com/blog/science-says-trump-was-right-malaria-drugs-need-to-be-pursued-as-a-coronavirus-therapy 2020-04-15T21:21:52 https://maestrodatabase.com/blog/the-sense-and-sensibility-of-sensitivity-analyses 2024-09-16T06:10:56 https://maestrodatabase.com/blog/understanding-modelled-economic-evaluations-a-readers-guide-for-clinicians 2024-09-16T06:07:14 https://maestrodatabase.com/blog/petition-urges-pharmac-to-fund-crohns-and-colitis-medication 2020-08-30T02:41:05 https://maestrodatabase.com/blog/new-poll-shows-wide-support-for-several-trump-drug-pricing-reforms-but-not-rebate-changes 2020-08-30T02:46:42 https://maestrodatabase.com/blog/barriers-lifted-cystic-fibrosis-treatment-reaches-final-waiting-patients 2025-06-23T22:03:26 https://maestrodatabase.com/blog/fda-grants-priority-review-of-melflufen-for-patients-with-triple-class-refractory-multiple-myeloma 2020-08-30T02:34:49 https://maestrodatabase.com/blog/saving-charlotte-bennett-to-present-parliament-with-petition-calling-for-funding-of-sma-drug 2019-04-14T11:02:57 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-datopotamab-deruxtecan-dlnk-for-egfr-mutated-non-small-cell-lung-cancer 2025-06-23T21:51:51 https://maestrodatabase.com/blog/lung-foundation-launches-petition-for-more-pharmac-funding 2019-04-14T10:59:38 https://maestrodatabase.com/blog/meningococcal-vaccine-rollout-announced-as-government-rejects-claims-it-isnt-listening-to-concerns 2018-07-26T06:09:31 https://maestrodatabase.com/blog/when-are-rcts-required-for-breakthrough-drugs-hdes-jama-study-investigates 2019-09-12T02:28:39 https://maestrodatabase.com/blog/mhra-approves-guselkumab-for-crohns-disease-and-ulcerative-colitis 2025-05-18T00:05:22 https://maestrodatabase.com/blog/nice-backing-for-keytruda-in-classical-hodgkins-lymphoma 2018-07-26T08:48:29 https://maestrodatabase.com/blog/announcing-the-launch-of-maestro-snapshot 2018-07-26T07:18:13 https://maestrodatabase.com/blog/health-minister-hunt-to-discuss-bolstering-my-health-privacy-with-medicos 2018-07-26T10:51:27 https://maestrodatabase.com/blog/60deg-pharmaceuticals-submits-new-drug-application-to-us-fda-for-anti-malarial-drug-tafenoquine 2017-12-19T02:17:44 https://maestrodatabase.com/blog/aerie-pharmaceuticals-announces-u-dot-s-fda-approval-of-rhopressa-netarsudil-ophthalmic-solution-0-dot-02-percent-for-the-lowering-of-elevated-intra-ocular-pressure-in-patients-with-open-angle-glaucoma-or-ocular-hypertension 2017-12-19T02:25:15 https://maestrodatabase.com/blog/astrazeneca-joins-u-dot-s-drug-price-freeze-for-rest-of-2018 2018-07-26T21:14:47 https://maestrodatabase.com/blog/regenerons-billionaire-founder-battles-the-drug-pricing-system 2018-07-26T21:17:14 https://maestrodatabase.com/blog/fda-expands-lillys-erbitux-cetuximab-label-with-combination-of-braftovi-encorafenib-for-the-treatment-of-braf-v600e-mutation-positive-metastatic-colorectal-cancer-after-prior-therapy 2021-09-29T03:20:21 https://maestrodatabase.com/blog/endometriosis-sufferer-calls-for-essential-medications-to-be-added-to-pbs 2018-07-26T21:01:18 https://maestrodatabase.com/blog/drug-companies-cant-game-paediatric-drug-laws-anymore 2018-07-26T21:12:27 https://maestrodatabase.com/blog/pharmather-announces-fda-extends-review-period-for-ketamine-new-approval-goal-date-9-august-2025 2025-05-17T23:46:34 https://maestrodatabase.com/blog/pfizer-and-lilly-receive-fda-fast-track-designation-for-tanezumab 2017-06-14T01:10:18 https://maestrodatabase.com/blog/celgene-bows-to-white-house-pressure-after-raising-prices-for-cancer-drug 2018-07-26T21:24:25 https://maestrodatabase.com/blog/outcome-statement---april-2025-dusc-meeting 2025-05-17T23:59:29 https://maestrodatabase.com/blog/ionis-announces-zilganersen-new-drug-application-for-alexander-disease-accepted-by-fda-for-priority-review 2026-03-23T23:11:23 https://maestrodatabase.com/blog/high-hopes-for-president-trumps-drug-pricing-plan 2018-07-26T21:20:36 https://maestrodatabase.com/blog/meningococcal-vaccine-rejected-as-not-being-cost-effective 2018-07-26T21:42:06 https://maestrodatabase.com/blog/canada-to-create-national-drug-agency-to-help-cut-cost-of-medicines 2019-03-20T11:49:05 https://maestrodatabase.com/blog/why-chinas-premier-used-hit-movie-dying-to-survive-to-push-for-cheaper-cancer-drugs 2018-07-26T21:27:35 https://maestrodatabase.com/blog/fda-announces-two-initiatives-to-modernise-drug-quality-programs 2018-07-26T21:34:13 https://maestrodatabase.com/blog/dupixent-dupilumab-approved-in-japan-as-the-first-targeted-medicine-to-treat-adults-with-bullous-pemphigoid 2026-03-24T10:33:52 https://maestrodatabase.com/blog/partisan-squabbles-shadow-congress-efforts-to-lower-drug-prices 2019-03-20T12:00:59 https://maestrodatabase.com/blog/iaso-bio-announces-ct103a-granted-regenerative-medicine-advanced-therapy-and-fast-track-designations-by-the-fda 2023-02-13T04:10:00 https://maestrodatabase.com/blog/cancer-society-slams-pharmacs-treatment-of-patients 2019-03-20T11:57:28 https://maestrodatabase.com/blog/ptac-recommends-immune-checkpoint-inhibitors-for-certain-patients-with-advanced-urothelial-carcinoma 2018-07-26T21:47:41 https://maestrodatabase.com/blog/roche-and-the-pan-canadian-pharmaceutical-alliance-complete-negotiations-for-multiple-sclerosis-treatment-ocrevus-ocrelizumab-for-both-rrms-and-ppms 2019-03-20T11:52:02 https://maestrodatabase.com/blog/fda-approves-qulipta-atogepant-the-first-and-only-oral-cgrp-receptor-antagonist-specifically-developed-for-the-preventive-treatment-of-migraine 2021-09-29T04:09:00 https://maestrodatabase.com/blog/novo-nordisk-files-oral-semaglutide-for-us-regulatory-approval-of-glycaemic-control-as-well-as-for-cv-risk-reduction-for-oral-semaglutide-and-ozempic 2019-03-20T19:52:06 https://maestrodatabase.com/blog/fda-reform-its-time-to-act-but-not-as-an-independent-agency 2019-03-20T19:48:09 https://maestrodatabase.com/blog/new-medsearch-app-is-now-available-for-download 2017-06-14T01:38:02 https://maestrodatabase.com/blog/the-shadow-of-brexit-on-speed-of-access 2019-03-20T19:42:12 https://maestrodatabase.com/blog/amgen-pricing-for-its-humira-biosimilar-may-benefit-pbms-and-insurers-more-than-patients 2023-02-13T04:41:37 https://maestrodatabase.com/blog/iterum-therapeutics-receives-qidp-for-oral-and-iv-sulopenem-in-four-additional-indications-as-well-as-fast-track-designation 2019-03-20T20:03:20 https://maestrodatabase.com/blog/biosimilar-approval-and-adoption-in-the-u-dot-s-needs-to-be-expedited 2019-03-20T20:28:05 https://maestrodatabase.com/blog/where-is-the-champion-for-pharmacare 2019-03-20T20:23:08 https://maestrodatabase.com/blog/national-drug-agency-touted-as-building-block-of-pharmacare-plan 2019-03-20T20:21:31 https://maestrodatabase.com/blog/senate-bill-endorses-azars-call-to-allow-drug-imports 2019-03-20T20:14:29 https://maestrodatabase.com/blog/selux-diagnostics-earns-fda-breakthrough-device-designation-for-next-generation-phenotyping-platform-for-positive-blood-culture-and-sterile-body-fluid-samples 2021-09-29T05:22:27 https://maestrodatabase.com/blog/york-man-paul-thomas-peter-says-he-could-die-because-nhs-wont-fund-drug 2019-03-20T20:42:33 https://maestrodatabase.com/blog/novian-health-gains-fda-breakthrough-designation-for-novilase-breast-therapy 2021-09-29T04:30:43 https://maestrodatabase.com/blog/why-do-health-technology-assessment-coverage-recommendations-for-the-same-drugs-differ-across-settings-applying-a-mixed-methods-framework-to-systematically-compare-orphan-drug-decisions-in-four-european-countries 2017-06-14T02:09:57 https://maestrodatabase.com/blog/assembly-biosciences-announces-fda-fast-track-designation-granted-to-abi-h0731-for-the-treatment-of-hepatitis-b-virus-infection 2018-07-26T23:12:56 https://maestrodatabase.com/blog/unprecedented-drug-shortage-linked-to-brexit-nhs-bosses-say 2019-03-20T20:38:08 https://maestrodatabase.com/blog/biosimilar-groups-offer-proposals-to-help-us-better-mirror-eu-successes 2019-03-20T20:30:15 https://maestrodatabase.com/blog/smc---february-2023-decisions 2023-02-13T19:38:42 https://maestrodatabase.com/blog/ocuphire-announces-fda-acceptance-of-new-drug-application-and-pdufa-date-of-28-september-2023-for-nyxol-eye-drops-for-reversal-of-mydriasis 2023-02-13T19:31:54 https://maestrodatabase.com/blog/ironwood-pharmaceuticals-announces-fda-filing-acceptance-and-priority-review-of-supplemental-new-drug-application-for-linzess-linaclotide-for-functional-constipation-in-children-and-adolescents-ages-6-17-years-old 2023-02-13T19:19:31 https://maestrodatabase.com/blog/us-fda-issues-a-crl-for-the-biologics-license-application-for-bevacizumab 2023-02-13T19:24:16 https://maestrodatabase.com/blog/mitsubishi-tanabe-pharma-canada-announces-radicava-edaravone-oral-suspension-is-now-available-in-canada-for-the-treatment-of-patients-with-als 2023-02-13T08:14:44 https://maestrodatabase.com/blog/assessment-of-fda-approved-drugs-not-recommended-for-use-or-reimbursement-in-other-countries-2017-2020 2023-02-13T20:10:08 https://maestrodatabase.com/blog/us-fda-approval-of-drugs-not-meeting-pivotal-trial-primary-outcomes-2018-2021 2023-02-13T20:06:57 https://maestrodatabase.com/blog/like-medicare-the-pbs-urgently-needs-overhauling---for-all-our-sakes 2023-02-13T19:54:37 https://maestrodatabase.com/blog/new-public-listings-for-canadians-living-with-pulmonary-arterial-hypertension 2026-03-25T01:59:29 https://maestrodatabase.com/blog/gsk-announces-us-fda-approval-of-priorix-for-the-prevention-of-measles-mumps-and-rubella-in-individuals-12-months-of-age-and-older 2022-06-06T10:31:19 https://maestrodatabase.com/blog/gbts-inclacumab-and-gbt601-receive-u-dot-s-fda-orphan-drug-and-rare-paediatric-disease-designations-for-the-treatment-of-sickle-cell-disease 2022-06-06T20:39:36 https://maestrodatabase.com/blog/fda-approves-riabni-rituximab-arrx-a-biosimilar-to-rituxan-rituximab-for-adults-with-moderate-to-severe-rheumatoid-arthritis 2022-06-06T20:32:35 https://maestrodatabase.com/blog/nonagen-bioscience-granted-fda-breakthrough-device-designation 2021-09-29T06:18:13 https://maestrodatabase.com/blog/medigen-applies-for-australian-vaccine-approval 2022-06-06T21:15:34 https://maestrodatabase.com/blog/novavax-faces-high-stakes-fda-review-this-week-that-will-decide-the-fate-of-its-covid-vaccine-in-the-u-dot-s 2022-06-06T21:09:35 https://maestrodatabase.com/blog/chf-supports-stronger-protection-for-patient-records 2018-07-27T01:39:05 https://maestrodatabase.com/blog/bristol-myers-squibb-withdraws-supplemental-biologics-license-application-for-reblozyl-luspatercept-aamt-for-non-transfusion-dependent-beta-thalassaemia 2022-06-06T20:57:21 https://maestrodatabase.com/blog/fda-clears-first-blood-test-used-in-diagnosing-alzheimers-disease 2025-05-18T23:16:19 https://maestrodatabase.com/blog/covid-mrna-vaccines-can-be-quickly-updated-for-new-variants-so-wheres-my-omicron-booster 2022-06-06T21:48:29 https://maestrodatabase.com/blog/biocryst-announces-health-canada-has-authorised-orladeyo-berotralstat-the-only-oral-treatment-for-the-prevention-of-hereditary-angioedema-attacks 2022-06-06T21:41:30 https://maestrodatabase.com/blog/rznomics-secures-fast-track-designation-from-the-us-fda-for-rz-001 2023-11-11T01:26:19 https://maestrodatabase.com/blog/be-grateful-for-your-health-insurance-company 2019-09-12T09:03:57 https://maestrodatabase.com/blog/fda-authorises-first-machine-learning-based-screening-device-to-identify-certain-biomarkers-that-may-indicate-covid-19-infection 2021-03-20T23:36:39 https://maestrodatabase.com/blog/u-dot-s-fda-approves-livmarli-maralixibat-as-the-first-and-only-approved-medication-for-the-treatment-of-cholestatic-pruritus-in-patients-with-alagille-syndrome-one-year-of-age-and-older 2021-09-29T20:51:34 https://maestrodatabase.com/blog/kiwi-cancer-survival-rates-improving-at-slower-rate-than-comparable-countries-study-shows 2019-09-12T08:12:53 https://maestrodatabase.com/blog/pbac-public-summary-documents-first-time-rejections-and-deferrals---november-2020-meeting 2021-03-20T23:42:41 https://maestrodatabase.com/blog/highlights-from-the-6-9-november-2023-chmp-meeting 2023-11-11T01:22:51 https://maestrodatabase.com/blog/agenda-for-the-july-2026-pbac-meeting-25-march-2026 2026-03-25T07:11:32 https://maestrodatabase.com/blog/icer-publishes-evidence-report-on-additive-cardiovascular-disease-therapies 2019-09-12T11:49:34 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-filings-for-amicus-at-gaa-for-the-treatment-of-pompe-disease 2021-09-29T20:44:12 https://maestrodatabase.com/blog/fda-approves-relacorilant-with-nab-paclitaxel-for-platinum-resistant-epithelial-ovarian-fallopian-tube-or-primary-peritoneal-cancer 2026-03-25T19:49:20 https://maestrodatabase.com/blog/smc-u-turn-for-vertexs-cf-drugs 2019-09-12T11:41:36 https://maestrodatabase.com/blog/ema-implements-new-measures-to-minimise-animal-testing-during-medicines-development 2021-09-29T20:39:21 https://maestrodatabase.com/blog/aspens-drug-to-prevent-preterm-birth-approved-by-fda 2019-09-12T20:50:24 https://maestrodatabase.com/blog/helsinn-group-and-bridgebio-pharmas-affiliate-qed-therapeutics-announce-health-canada-conditional-approval-of-truseltiq-infigratinib-for-patients-with-cholangiocarcinoma 2021-09-29T21:14:28 https://maestrodatabase.com/blog/benefit-risk-assessment-for-new-drug-and-biological-products 2021-09-29T21:24:22 https://maestrodatabase.com/blog/ardelyx-receives-fda-approval-for-ibsrela-tenapanor-an-nhe3-sodium-transport-inhibitor-for-the-treatment-of-irritable-bowel-syndrome-with-constipation 2019-09-12T20:58:21 https://maestrodatabase.com/blog/bayers-aflibercept-8-mg-recommended-for-approval-in-eu 2023-11-11T05:10:05 https://maestrodatabase.com/blog/nucala-is-the-first-biologic-approved-in-the-us-for-six-to-11-year-old-children-with-severe-eosinophilic-asthma 2019-09-12T20:53:24 https://maestrodatabase.com/blog/nucana-receives-fast-track-designation-from-the-u-dot-s-food-and-drug-administration-for-acelarin-nuc-1031-for-the-treatment-of-biliary-tract-cancer 2021-09-29T21:06:07 https://maestrodatabase.com/blog/data-protection-scheme-for-assessed-listed-medicines 2021-09-29T21:49:02 https://maestrodatabase.com/blog/big-pharma-is-abusing-patents-and-its-hurting-americans 2019-09-12T21:11:07 https://maestrodatabase.com/blog/top-fda-official-interested-in-project-orbis-for-cell-and-gene-therapies 2023-02-14T05:51:48 https://maestrodatabase.com/blog/in-u-dot-s-biosimilars-run-into-more-roadblocks 2019-09-12T21:27:37 https://maestrodatabase.com/blog/camurus-withdraws-variation-application-for-cam2038-to-include-chronic-pain 2023-02-14T05:32:07 https://maestrodatabase.com/blog/fresenius-submits-first-biosimilar-marketing-authorisation-application 2017-12-19T06:04:24 https://maestrodatabase.com/blog/public-plans-covered-only-26-percent-of-the-491-new-drugs-approved-by-health-canada-from-2009-to-2018-national-pharmacare-is-an-empty-promise-for-23-dot-2-million-canadians-now-covered-by-private-plans 2019-09-12T21:21:52 https://maestrodatabase.com/blog/transmedics-receives-fda-approval-for-its-ocs-liver-system-for-preservation-and-assessment-of-donor-livers-for-transplantation 2021-09-29T21:28:08 https://maestrodatabase.com/blog/why-canada-cant-be-americas-pharmacy 2019-09-12T21:18:45 https://maestrodatabase.com/blog/global-disparity-in-access-to-novel-therapeutics-for-metastatic-prostate-cancer 2021-09-29T21:37:21 https://maestrodatabase.com/blog/new-rules-will-keep-the-best-medications-from-desperate-canadians 2019-09-12T21:15:18 https://maestrodatabase.com/blog/chinas-grip-on-pharmaceutical-drugs-is-a-national-security-issue 2019-09-12T21:45:12 https://maestrodatabase.com/blog/fda-approves-novel-gene-therapy-to-treat-patients-with-a-rare-form-of-inherited-vision-loss 2017-12-19T20:00:12 https://maestrodatabase.com/blog/batten-disease-treatment-parents-win-battle-ahead-of-court-date 2019-09-12T21:34:07 https://maestrodatabase.com/blog/republican-bill-to-reduce-tax-credits-for-rare-disease-drugs 2017-12-19T10:39:12 https://maestrodatabase.com/blog/draft-pelosi-plan-targets-drugs-lacking-biosimilar-or-generic-option 2019-09-12T21:31:24 https://maestrodatabase.com/blog/report-urges-transparency-in-health-system 2017-12-19T19:53:15 https://maestrodatabase.com/blog/mirum-pharmaceuticals-submits-supplemental-new-drug-application-to-fda-for-livmarli-in-patients-with-cholestatic-pruritus-in-progressive-familial-intrahepatic-cholestasis 2023-02-14T19:17:15 https://maestrodatabase.com/blog/trump-in-zigzag-calls-house-republicans-health-bill-mean 2017-06-14T08:27:12 https://maestrodatabase.com/blog/soligenix-receives-refusal-to-file-letter-from-us-fda-for-hybryte-new-drug-application-in-the-treatment-of-cutaneous-t-cell-lymphoma 2023-02-14T19:07:43 https://maestrodatabase.com/blog/scotland-becomes-first-part-of-uk-to-approve-new-cervical-cancer-drug 2023-02-14T07:07:46 https://maestrodatabase.com/blog/who-helps-keep-drug-costs-affordable-pharmacy-benefit-managers 2023-02-14T19:32:27 https://maestrodatabase.com/blog/turnbull-governments-44-dollars-million-plan-to-give-sick-kiddies-free-meds 2017-06-14T20:56:15 https://maestrodatabase.com/blog/astrazeneca-vaccine-allowed-by-government-regulators-to-be-produced-in-australia 2021-03-21T09:24:16 https://maestrodatabase.com/blog/nice-publishes-multiple-outcomes-for-adcetris 2017-06-14T21:08:32 https://maestrodatabase.com/blog/fda-grants-15-june-2023-pdufa-date-to-albireo-for-bylvay-in-alagille-syndrome 2023-02-14T19:23:22 https://maestrodatabase.com/blog/tga-approves-csl---seqirus-to-manufacture-astrazeneca-covid-19-vaccine-in-australia 2021-03-21T20:41:25 https://maestrodatabase.com/blog/anavex-life-sciences-provides-update-on-regulatory-review-in-the-eu-for-blarcamesine-to-treat-early-alzheimers-disease 2026-03-25T20:52:21 https://maestrodatabase.com/blog/how-creative-fda-regulation-led-to-first-in-the-world-approval-of-a-cutting-edge-heart-valve 2017-06-14T21:01:37 https://maestrodatabase.com/blog/washington-may-become-the-second-state-to-distribute-its-own-generic-drugs 2021-03-21T09:33:02 https://maestrodatabase.com/blog/fda-approves-drug-to-treat-neurologic-manifestations-of-hunter-syndrome 2026-03-25T20:56:52 https://maestrodatabase.com/blog/senate-white-house-working-on-drug-pricing 2017-06-14T21:21:28 https://maestrodatabase.com/blog/controlling-the-cost-of-medicaid 2017-07-20T11:02:13 https://maestrodatabase.com/blog/the-remarkable-steps-republicans-are-taking-to-obscure-whats-in-their-health-care-bill 2017-06-14T21:25:39 https://maestrodatabase.com/blog/is-orkambi-deal-close-vertex-meets-again-today-with-nhs-england 2019-03-21T11:18:11 https://maestrodatabase.com/blog/the-future-of-voice-technologies-in-health-care 2023-02-14T19:55:38 https://maestrodatabase.com/blog/natco-files-generic-olaparib-tablets-in-us 2023-02-14T20:07:07 https://maestrodatabase.com/blog/adma-biologics-receives-pdufa-date-for-bivigam-regulatory-submission 2018-07-27T04:02:27 https://maestrodatabase.com/blog/jazz-pharmaceuticals-announces-u-dot-s-fda-approval-of-sunosi-solriamfetol-for-excessive-daytime-sleepiness-associated-with-narcolepsy-or-obstructive-sleep-apnea 2019-03-21T11:12:27 https://maestrodatabase.com/blog/verve-therapeutics-announces-verve-101-awarded-innovation-passport-by-the-uk-mhra-for-the-treatment-of-heterozygous-familial-hypercholesterolaemia 2023-02-14T19:44:21 https://maestrodatabase.com/blog/the-online-pharmaceutical-schedule-gets-a-refresh 2022-06-07T03:43:47 https://maestrodatabase.com/blog/struggling-to-stay-alive-rising-insulin-prices-cause-diabetics-to-go-to-extremes 2019-03-21T19:59:57 https://maestrodatabase.com/blog/abbvie-is-sued-for-using-humira-patent-deals-to-block-competition-in-the-u-dot-s 2019-03-21T11:28:11 https://maestrodatabase.com/blog/amgens-new-migraine-drug-hits-insurance-hurdles 2018-07-27T05:09:22 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-releases-draft-evidence-report-on-esketamine-for-treatment-resistant-depression 2019-03-21T20:24:28 https://maestrodatabase.com/blog/mystery-solved-the-pharma-backed-group-with-a-lot-to-say-on-trumps-pitch-to-end-drug-rebates 2019-03-21T20:22:10 https://maestrodatabase.com/blog/fda-approves-new-device-for-treating-moderate-to-severe-chronic-heart-failure-in-patients 2019-03-21T20:18:17 https://maestrodatabase.com/blog/why-ontario-parents-could-soon-be-paying-more-for-prescription-drugs 2019-03-21T20:08:53 https://maestrodatabase.com/blog/kentucky-launches-probe-into-drug-overcharges-by-pharmacy-benefit-managers 2019-03-21T20:30:29 https://maestrodatabase.com/blog/medchem-a-game-changer-in-identifying-lifesaving-new-drugs 2023-11-12T02:09:39 https://maestrodatabase.com/blog/cheaper-medicines-for-rare-genetic-disorders-and-cancer 2024-08-12T04:05:06 https://maestrodatabase.com/blog/fda-grants-breakthrough-therapy-designation-to-omeros-masp-2-inhibitor-oms721-for-the-treatment-of-iga-nephropathy 2017-06-14T23:25:37 https://maestrodatabase.com/blog/nice-terminates-yet-another-assessment-of-a-cancer-medicine 2019-03-21T20:47:12 https://maestrodatabase.com/blog/promoting-biosimilars-up-to-health-plans-manufacturers-doctors-gottlieb-says 2019-03-21T20:33:52 https://maestrodatabase.com/blog/sandoz-receives-fda-approval-for-enzeevu-aflibercept-abzv-further-strengthening-us-biosimilar-position 2024-08-12T05:43:36 https://maestrodatabase.com/blog/changes-in-revenues-associated-with-antimicrobial-reimbursement-reforms-in-germany 2024-08-12T07:33:25 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-positive-chmp-opinion-recommending-approval-of-zeposia-ozanimod-for-the-treatment-of-adult-patients-with-relapsing-remitting-multiple-sclerosis-with-active-disease 2020-03-28T01:02:14 https://maestrodatabase.com/blog/hhs-secretary-responds-to-the-presidents-executive-order-on-drug-prices 2023-02-14T21:29:31 https://maestrodatabase.com/blog/avexis-receives-positive-chmp-opinion-for-zolgensma-the-only-gene-therapy-for-spinal-muscular-atrophy 2020-03-28T01:14:21 https://maestrodatabase.com/blog/prime-therapeutics-and-pear-therapeutics-announce-first-comprehensive-value-based-agreement-for-prescription-digital-therapeutics-reset-and-reset-o-for-the-treatment-of-substance-and-opioid-use-disorders 2021-09-30T01:11:05 https://maestrodatabase.com/blog/bluebird-bios-lentiglobin-gene-therapy-granted-accelerated-assessment-by-ema-for-the-treatment-of-transfusion-dependent-b-thalassemia 2018-07-27T08:56:59 https://maestrodatabase.com/blog/novartis-cosentyx-gains-positive-chmp-opinion-for-new-indication-in-the-axial-spondyloarthritis-spectrum 2020-03-28T01:07:26 https://maestrodatabase.com/blog/zogenix-submits-supplemental-new-drug-application-for-fintempla-fenfluramine-for-the-treatment-of-seizures-associated-with-lennox-gastaut-syndrome 2021-09-30T01:04:50 https://maestrodatabase.com/blog/triana-biomedicines-tri-611-granted-us-fda-fast-track-designation-for-treatment-of-alk-positive-non-small-cell-lung-cancer 2026-03-25T23:11:57 https://maestrodatabase.com/blog/fears-health-premium-cap-may-threaten-insurers-viability 2018-07-27T09:29:34 https://maestrodatabase.com/blog/icer-launches-program-to-accelerate-the-consideration-of-value-into-drug-development-programs 2026-03-25T23:19:26 https://maestrodatabase.com/blog/enzyvants-investigational-farber-disease-enzyme-replacement-therapy-rvt-801-receives-fda-fast-track-and-rare-paediatric-disease-designations 2019-03-21T23:04:36 https://maestrodatabase.com/blog/kesimpta-game-changing-multiple-sclerosis-drug-now-on-pbs 2021-09-30T02:25:01 https://maestrodatabase.com/blog/ovid-therapeutics-announces-ov101-granted-fast-track-designation-by-u-dot-s-fda-for-treatment-of-angelman-syndrome 2017-12-19T23:09:21 https://maestrodatabase.com/blog/landmark-pbs-listings-to-reduce-the-cost-of-medicines-for-australians 2021-09-30T02:06:24 https://maestrodatabase.com/blog/actio-biosciences-receives-orphan-drug-and-rare-paediatric-disease-designations-for-the-treatment-of-charcot-marie-tooth-disease-2c 2024-08-12T21:37:17 https://maestrodatabase.com/blog/covid-19-australia-post-announces-launch-of-pharmacy-home-delivery-service-amid-coronavirus-crisis 2020-03-28T01:31:05 https://maestrodatabase.com/blog/amazon-hasnt-figured-out-drug-stores-yet-but-it-will-have-to 2017-12-19T23:17:11 https://maestrodatabase.com/blog/ema-advises-continued-use-of-medicines-for-hypertension-heart-or-kidney-disease-during-covid-19-pandemic 2020-03-28T01:20:00 https://maestrodatabase.com/blog/acacia-pharma-announces-submission-and-validation-of-marketing-authorisation-application-for-barhemsys-amisulpride-injection-in-major-european-markets 2021-09-30T03:13:41 https://maestrodatabase.com/blog/highlights-from-the-23-26-march-2020-chmp-meeting 2020-03-28T01:22:26 https://maestrodatabase.com/blog/medicines-industry-continues-to-protect-australians-from-medicine-shortages 2021-09-30T03:24:40 https://maestrodatabase.com/blog/guidelines-for-statistical-analysis-plans 2017-12-19T23:29:08 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-30-september-2021 2021-09-30T05:33:04 https://maestrodatabase.com/blog/fda-approves-yorvipath-palopegteriparatide-as-the-first-and-only-treatment-for-hypoparathyroidism-in-adults 2024-08-12T22:46:22 https://maestrodatabase.com/blog/icer-publishes-protocol-for-first-annual-launch-price-and-access-report 2025-05-19T22:49:35 https://maestrodatabase.com/blog/zai-lab-receives-us-fda-fast-track-designation-for-zl-1310-a-dll3-targeted-antibody-drug-conjugate-for-treatment-of-extensive-stage-small-cell-lung-cancer 2025-05-19T23:07:46 https://maestrodatabase.com/blog/eu-has-absolutely-no-need-of-russias-sputnik-v-vaccine-commissioner-says 2021-03-22T05:59:25 https://maestrodatabase.com/blog/novo-nordisk-to-discontinue-levemir-insulin-in-us-market 2023-11-13T03:24:58 https://maestrodatabase.com/blog/outcome-statement---september-2023-dusc-meeting 2023-11-13T04:33:33 https://maestrodatabase.com/blog/trump-wants-to-equalize-and-lower-drug-prices-could-canada-be-impacted 2025-05-19T23:28:55 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-releases-draft-evidence-report-on-car-t-therapy-for-b-cell-cancers 2017-12-20T01:26:54 https://maestrodatabase.com/blog/vutrisiran-for-the-treatment-of-patients-with-hereditary-transthyretin-related-amyloidosis 2023-02-15T04:01:05 https://maestrodatabase.com/blog/us-fda-approves-bla-for-novavaxs-covid-19-vaccine 2025-05-20T07:53:14 https://maestrodatabase.com/blog/people-with-advanced-or-metastatic-urothelial-cancer-to-get-life-extending-treatment 2021-09-30T09:02:41 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-october-2021 2021-09-30T07:01:21 https://maestrodatabase.com/blog/apotex-expands-canadian-ophthalmology-portfolio-with-health-canadas-approval-of-clobivis-clobetasol-propionate-ophthalmic-suspension-0-dot-05-percent 2026-03-26T01:39:54 https://maestrodatabase.com/blog/redefining-value-assessment-and-healthcare-funding-priorities-for-medicines-the-journey-to-patient-centric-decision-making-in-apac---a-systematic-literature-review 2025-05-20T22:31:24 https://maestrodatabase.com/blog/gsk-receives-positive-chmp-opinion-recommending-momelotinib-for-myelofibrosis-patients-with-anaemia 2023-11-13T09:39:11 https://maestrodatabase.com/blog/in-shocking-reversal-cms-wants-to-allow-medicare-part-d-plan-sponsors-to-substitute-non-interchangeable-biosimilars 2023-11-13T09:33:37 https://maestrodatabase.com/blog/fda-clears-first-major-imaging-device-advancement-for-computed-tomography-in-nearly-a-decade 2021-09-30T20:47:55 https://maestrodatabase.com/blog/tlv-gets-a-leading-role-in-european-hta-project 2021-09-30T11:32:40 https://maestrodatabase.com/blog/kinnate-biopharma-receives-fast-track-designation-from-the-us-fda-for-kin-3248-an-investigational-pan-fgfr-inhibitor 2023-02-15T06:56:52 https://maestrodatabase.com/blog/fda-grants-priority-review-for-investigational-targeted-radioligand-therapy-177lu-psma-617-for-patients-with-metastatic-castration-resistant-prostate-cancer 2021-09-30T20:56:17 https://maestrodatabase.com/blog/pbac-report---options-for-listing-pd--l-1-checkpoint-inhibitors-for-multiple-cancer-indications-on-the-pbs 2019-03-22T06:57:53 https://maestrodatabase.com/blog/atagi-statement-and-clinical-guidance-on-astrazeneca-covid-19-vaccine-following-ema-safety-review 2021-03-22T07:35:12 https://maestrodatabase.com/blog/diamedica-therapeutics-announces-fast-track-designation-granted-to-dm199-for-the-treatment-of-acute-ischaemic-stroke 2021-09-30T21:16:16 https://maestrodatabase.com/blog/oakrum-pharma-and-aucta-pharma-announce-u-dot-s-fda-approval-of-generic-version-of-jadenu-sprinkle-deferasirox-granules 2021-03-22T20:15:24 https://maestrodatabase.com/blog/phase-1b-covid-19-vaccination-rollout-begins 2021-03-22T20:25:12 https://maestrodatabase.com/blog/galera-announces-fda-acceptance-and-priority-review-of-avasopasem-nda-for-radiotherapy-induced-severe-oral-mucositis 2023-02-15T19:19:23 https://maestrodatabase.com/blog/early-benefit-assessment---the-whole-spectrum 2021-03-22T20:22:40 https://maestrodatabase.com/blog/u-dot-s-house-panel-approves-fourth-bill-aimed-at-drug-prices 2021-09-30T21:23:47 https://maestrodatabase.com/blog/rich-countries-signed-away-a-chance-to-vaccinate-the-world 2021-03-22T09:41:10 https://maestrodatabase.com/blog/triple-therapy-recommended-by-nice-for-patients-with-multiple-myeloma 2021-03-22T09:31:01 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-october-2021 2021-09-30T21:08:43 https://maestrodatabase.com/blog/us-fda-grants-approval-for-jivi-anti-hemophilic-factor-recombinant-pegylated-aucl-in-paediatric-patients-7-to-under-12-years-of-age-with-haemophilia-a 2025-05-21T02:02:32 https://maestrodatabase.com/blog/democrats-set-sights-on-reducing-drug-prices-a-topic-long-championed-by-trump 2021-03-22T20:01:02 https://maestrodatabase.com/blog/henlius-announces-us-fda-acceptance-of-biologics-license-application-for-proposed-biosimilar-trastuzumab-hlx02 2023-02-15T10:21:12 https://maestrodatabase.com/blog/germany-proposes-to-fix-shortages-in-certain-medicines 2023-02-15T19:50:32 https://maestrodatabase.com/blog/icer-to-assess-treatment-for-smoking-cessation 2025-05-21T00:02:43 https://maestrodatabase.com/blog/us-government-payer-funded-trials-to-address-oncologys-drug-dosing-conundrum-a-congressional-call-to-action 2023-02-15T19:54:03 https://maestrodatabase.com/blog/transferable-exclusivity-voucher-a-flawed-incentive-to-stimulate-antibiotic-innovation 2023-02-15T19:46:21 https://maestrodatabase.com/blog/pbac-publishes-sham-public-summary-document-for-upadacitinib 2021-03-22T20:29:31 https://maestrodatabase.com/blog/the-pbm-transparency-act-will-not-lower-drug-prices 2023-02-15T19:44:07 https://maestrodatabase.com/blog/nice-terminates-another-two-appraisals 2021-09-30T21:26:46 https://maestrodatabase.com/blog/ontario-may-lift-ban-preventing-major-pharmacies-from-selling-private-label-generic-drugs 2019-03-22T07:24:38 https://maestrodatabase.com/blog/fda-gene-therapy-head-raises-concern-on-accelerated-approval-use 2023-02-15T19:30:57 https://maestrodatabase.com/blog/highlights-from-the-chmp-23-26-july-2018-meeting 2018-07-28T00:15:44 https://maestrodatabase.com/blog/price-elasticities-of-pharmaceuticals-in-a-value-based-formulary-setting 2018-07-28T00:23:44 https://maestrodatabase.com/blog/estimating-drug-costs-how-do-manufacturer-net-prices-compare-with-other-common-us-price-references 2018-07-28T00:26:33 https://maestrodatabase.com/blog/u-dot-s-fda-approves-pfizers-bosulif-bosutinib-for-the-treatment-of-patients-with-newly-diagnosed-ph-plus-chronic-myelogenous-leukaemia-cml 2017-12-20T02:43:28 https://maestrodatabase.com/blog/tackling-inequalities-to-improve-wellbeing-in-new-zealand 2018-07-28T00:21:22 https://maestrodatabase.com/blog/bendamustine-funding-approved 2017-06-15T12:40:38 https://maestrodatabase.com/blog/ucb-receives-positive-chmp-opinion-for-new-zilbrysq-zilucoplan-pre-filled-pen-in-eu-for-adults-living-with-generalised-myasthenia-gravis 2026-03-26T06:06:31 https://maestrodatabase.com/blog/kadcyla-new-deal-for-breast-cancer-patients-given-green-light-in-final-draft-guidance 2017-06-15T12:48:01 https://maestrodatabase.com/blog/providing-400-000-dollars-life-saving-drug-to-australian-kids-with-rare-disease 2017-06-15T12:53:18 https://maestrodatabase.com/blog/this-little-boy-can-finally-be-a-typical-boy-thanks-to-this-drug 2017-06-15T12:58:47 https://maestrodatabase.com/blog/nib-ceo-mark-fitzgibbon-says-reforms-needed-to-halt-health-insurance-premium-hikes 2017-06-15T13:03:36 https://maestrodatabase.com/blog/government-lilly-korea-turn-a-blind-eye-to-retevmos-prohibitive-cost 2024-08-13T01:14:01 https://maestrodatabase.com/blog/cancer-has-biggest-impact-on-our-health-research 2017-06-15T21:04:50 https://maestrodatabase.com/blog/cancer-patients-children-and-people-with-hiv-amongst-those-to-benefit-from-pharmac-decisions 2017-06-15T20:55:23 https://maestrodatabase.com/blog/fostering-medical-innovation-a-plan-for-digital-health-devices 2017-06-15T21:12:59 https://maestrodatabase.com/blog/patients-to-have-earlier-access-to-cutting-edge-treatments-on-nhs 2022-06-07T20:28:41 https://maestrodatabase.com/blog/smc---august-2024-decisions 2024-08-13T03:20:33 https://maestrodatabase.com/blog/response-to-engagement-on-proposals-for-the-innovative-medicines-fund 2022-06-07T20:31:39 https://maestrodatabase.com/blog/tixagevimab-and-cilgavimab-for-the-the-prevention-of-covid-19-disease 2023-02-16T00:49:55 https://maestrodatabase.com/blog/sifi-announces-ema-validation-of-its-marketing-authorisation-application-for-akantior-for-the-treatment-of-acanthamoeba-keratitis 2022-06-07T20:23:08 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-to-evaluate-voretigene-neparvovec-in-upcoming-review 2017-06-15T21:19:35 https://maestrodatabase.com/blog/g-dot-o-p-senators-might-not-realize-it-but-not-one-state-supports-the-republican-health-bill 2017-06-15T21:36:22 https://maestrodatabase.com/blog/monumental-u-turn-on-cancer-drug 2017-06-15T21:24:05 https://maestrodatabase.com/blog/novo-nordisk-submits-application-in-the-eu-for-including-data-from-the-devote-trial-in-the-tresiba-label 2017-06-15T21:40:31 https://maestrodatabase.com/blog/trump-administration-prepares-a-drug-pricing-executive-order-sources-say 2017-06-15T21:52:11 https://maestrodatabase.com/blog/fda-approves-drug-for-prevention-of-organ-rejection-in-paediatric-recipients-of-heart-and-liver-transplants 2022-06-07T21:05:35 https://maestrodatabase.com/blog/mediwound-receives-positive-chmp-opinion-recommending-approval-for-nexobrid-to-treat-paediatric-patients 2023-11-13T19:42:46 https://maestrodatabase.com/blog/a-patients-journey-with-melanoma-and-drug-coverage-concerns 2019-03-23T04:24:08 https://maestrodatabase.com/blog/smc---november-2023-decisions 2023-11-13T19:39:35 https://maestrodatabase.com/blog/fda-accepts-sandoz-regulatory-submission-for-a-generic-version-of-advair-diskus 2017-06-15T21:44:40 https://maestrodatabase.com/blog/fda-approves-dupixent-dupilumab-as-first-biologic-medicine-for-children-aged-6-months-to-5-years-with-moderate-to-severe-atopic-dermatitis 2022-06-07T21:09:36 https://maestrodatabase.com/blog/global-expert-panel-publishes-guidance-on-deliberative-processes-for-health-technology-assessment 2022-06-07T20:52:50 https://maestrodatabase.com/blog/u-dot-s-probes-how-pharmacies-set-drug-prices-as-costs-rise 2022-06-07T20:40:47 https://maestrodatabase.com/blog/wave-life-sciences-receives-fda-rare-paediatric-disease-designation-for-wve-n531-for-the-treatment-of-duchenne-muscular-dystrophy 2024-08-13T03:38:24 https://maestrodatabase.com/blog/japan-drug-maker-tests-medicine-vending-machine-in-train-station 2022-06-07T20:47:18 https://maestrodatabase.com/blog/genmab-announces-european-regulatory-submission-for-daratumumab-in-combination-with-lenalidomide-and-dexamethasone-in-frontline-multiple-myeloma 2019-03-23T04:27:29 https://maestrodatabase.com/blog/aarp-continues-fight-for-lower-prescription-drug-prices 2022-06-07T20:35:06 https://maestrodatabase.com/blog/pbs-listing-puts-opdivo-within-financial-reach-of-cancer-patients 2018-07-28T02:05:22 https://maestrodatabase.com/blog/informing-real-time-decisions-with-post-market-drug-evidence 2023-11-13T19:54:38 https://maestrodatabase.com/blog/exelixis-announces-u-dot-s-fda-approval-of-cabometyx-cabozantinib-tablets-for-previously-untreated-advanced-renal-cell-carcinoma 2017-12-20T04:10:20 https://maestrodatabase.com/blog/lenz-therapeutics-announces-submission-of-new-drug-application-to-us-fda-for-lnz100-for-the-treatment-of-presbyopia 2024-08-13T04:00:43 https://maestrodatabase.com/blog/recro-pharma-receives-complete-response-letter-from-the-fda-for-intravenous-meloxicam 2019-03-23T04:56:05 https://maestrodatabase.com/blog/fda-approves-pembrolizumab-for-oesophageal-or-gej-carcinoma 2021-03-23T02:35:51 https://maestrodatabase.com/blog/trends-in-prescription-drug-launch-prices-2008-2021 2022-06-07T21:23:17 https://maestrodatabase.com/blog/taranaki-man-fearful-drug-funding-change-will-bring-back-a-life-of-seizures 2019-09-13T07:09:54 https://maestrodatabase.com/blog/fda-issues-complete-response-letter-for-zynquista-sotagliflozin 2019-03-23T05:07:45 https://maestrodatabase.com/blog/introducing-jubbonti-and-wyost-the-first-denosumab-biosimilars-on-the-canadian-market 2024-08-13T05:55:37 https://maestrodatabase.com/blog/fda-takes-new-steps-to-advance-natural-history-studies-for-accelerating-novel-treatments-for-rare-diseases 2019-03-23T05:04:55 https://maestrodatabase.com/blog/covid-19-health-funds-delay-premium-increase-to-assist-members 2020-03-29T20:08:11 https://maestrodatabase.com/blog/medexus-reports-health-quality-ontario-recommends-gliolan-for-public-reimbursement 2019-09-13T07:31:27 https://maestrodatabase.com/blog/senate-panel-to-hear-from-pharmacy-middlemen-on-drug-prices 2019-03-23T05:21:06 https://maestrodatabase.com/blog/coronavirus-a-wake-up-call-for-canadas-prescription-drug-supply 2020-03-29T20:19:21 https://maestrodatabase.com/blog/a-tiered-health-care-delivery-system-for-china 2019-03-23T05:14:17 https://maestrodatabase.com/blog/pharmas-future-blockbusters-laid-up-with-coronavirus 2020-03-29T10:14:46 https://maestrodatabase.com/blog/nice-nod-for-takedas-adcetris-in-advanced-stage-ctcl 2019-03-23T06:36:14 https://maestrodatabase.com/blog/vertex-announces-new-access-agreement-with-scottish-government-for-orkambi-lumacaftor-slash-ivacaftor-and-symkevi-tezacaftor-slash-ivacaftor 2019-09-13T11:56:14 https://maestrodatabase.com/blog/drug-company-protections-are-latest-stumbling-block-for-nafta-rewrite 2019-03-23T06:06:31 https://maestrodatabase.com/blog/infinity-receives-fast-track-designation-for-ipi-549-in-combination-with-the-checkpoint-inhibitor-opdivo-for-the-treatment-of-advanced-urothelial-cancer 2020-03-29T10:19:09 https://maestrodatabase.com/blog/agenda-for-the-march-2018-pbac-meeting 2017-12-20T07:54:08 https://maestrodatabase.com/blog/delcath-systems-announces-new-drug-application-resubmission-for-hepzato-kit 2023-02-16T09:33:50 https://maestrodatabase.com/blog/post-market-review-of-ezetimibe---final-report 2017-12-20T08:03:42 https://maestrodatabase.com/blog/biocryst-announces-approval-of-orladeyo-berotralstat-by-swissmedic 2022-06-08T08:59:39 https://maestrodatabase.com/blog/moderna-says-its-covid-vaccine-will-remain-free-for-all-consumers-even-those-uninsured 2023-02-16T20:03:00 https://maestrodatabase.com/blog/merit-medical-receives-fda-breakthrough-device-designation-for-the-new-scout-md-surgical-guidance-system 2023-02-16T19:52:45 https://maestrodatabase.com/blog/testing-a-hypothesis-can-we-promote-both-innovation-and-affordability-of-drugs 2023-02-16T19:58:38 https://maestrodatabase.com/blog/health-economic-assessment-of-kimmtrak-in-disseminated-ocular-melanoma 2023-02-16T19:41:20 https://maestrodatabase.com/blog/lillys-kisunla-donanemab-receives-marketing-authorisation-in-australia-for-the-treatment-of-early-symptomatic-alzheimers-disease 2025-05-21T21:39:56 https://maestrodatabase.com/blog/thomas-kaiser-becomes-the-new-head-of-iqwig 2023-02-16T19:46:12 https://maestrodatabase.com/blog/forus-therapeutics-announces-xpovio-selinexor-is-authorised-for-sale-by-health-canada 2022-06-08T08:54:50 https://maestrodatabase.com/blog/human-medicines-highlights-of-2022 2023-02-16T19:34:20 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-treatments-for-non-alcoholic-steatohepatitis 2023-02-16T19:36:21 https://maestrodatabase.com/blog/soaring-cost-of-cancer-treatment-moving-beyond-sticker-shock 2017-12-20T09:22:21 https://maestrodatabase.com/blog/updated-price-disclosure-guidelines-price-disclosure-webpages-and-price-disclosure-dispute-resolution-process 2022-06-08T09:22:49 https://maestrodatabase.com/blog/enhertu-approved-in-china-for-patients-with-previously-treated-her2-positive-advanced-or-metastatic-gastric-cancer 2024-08-13T11:57:27 https://maestrodatabase.com/blog/decision-to-fund-cetuximab-for-head-and-neck-cancer 2017-12-20T19:45:04 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-for-biocrysts-alk-2-inhibitor-bcx9250 2022-06-08T11:56:10 https://maestrodatabase.com/blog/fda-to-require-diversity-plan-for-clinical-trials 2023-02-16T20:43:42 https://maestrodatabase.com/blog/cstone-and-pfizer-announce-nmpa-approval-of-sugemalimab-in-patients-with-unresectable-stage-iii-non-small-cell-lung-cancer 2022-06-08T09:19:21 https://maestrodatabase.com/blog/u-dot-s-food-and-drug-administration-approves-prior-approval-supplement-for-commercial-launch-of-portola-pharmaceuticals-novel-oral-anti-coagulant-bevyxxa-betrixaban 2017-12-20T09:02:02 https://maestrodatabase.com/blog/nice-says-evidence-that-covid-19-treatment-evusheld-is-effective-in-protecting-vulnerable-adults-against-current-variants-is-lacking-as-it-announces-new-rapid-update-process-for-covid-19-medicines 2023-02-16T20:20:18 https://maestrodatabase.com/blog/living-health-technology-assessments-how-close-to-living-reality 2023-02-16T20:15:41 https://maestrodatabase.com/blog/takedas-ninlaro-approved-for-nhs-use-via-cancer-drugs-fund 2017-12-20T19:58:03 https://maestrodatabase.com/blog/pharmac-says-funding-trikafta-would-take-almost-all-new-money 2022-06-08T09:10:48 https://maestrodatabase.com/blog/johnson-and-johnson-covid-vaccine-approved-for-use-in-switzerland 2021-03-23T03:47:57 https://maestrodatabase.com/blog/novartis-combination-tafinlar-plus-mekinist-receives-positive-chmp-opinion-for-adjuvant-treatment-of-braf-v600-mutation-positive-melanoma 2018-07-28T03:34:03 https://maestrodatabase.com/blog/another-new-month-another-terminated-nice-appraisal 2022-06-08T09:05:07 https://maestrodatabase.com/blog/nusinersen-amazing-spinal-muscular-atrophy-drug-rejected-for-pharmaceutical-benefits-scheme 2017-12-20T19:51:03 https://maestrodatabase.com/blog/stimufend-pegfilgrastim-fpgk-now-available-in-the-united-states 2023-02-16T20:08:47 https://maestrodatabase.com/blog/drugs-are-too-expensive-for-the-nhs---and-people-are-paying-with-their-lives 2017-12-20T20:10:52 https://maestrodatabase.com/blog/allogene-therapeutics-announces-the-fda-granted-regenerative-medicine-advanced-therapy-designation-to-allo-501a-for-large-b-cell-lymphoma 2022-06-08T21:15:52 https://maestrodatabase.com/blog/nice-turns-down-rare-skin-disease-implant 2017-12-20T20:02:46 https://maestrodatabase.com/blog/mhra-gives-alnylam-innovation-passport-for-hypertension-drug-zilebesiran 2022-06-08T12:15:02 https://maestrodatabase.com/blog/increasingly-europeans-do-not-trust-astrazenecas-vaccine 2021-03-23T04:21:11 https://maestrodatabase.com/blog/vertex-announces-inaxaplin-vx-147-granted-breakthrough-therapy-designation-by-u-dot-s-fda-and-prime-designation-by-the-ema 2022-06-08T12:09:29 https://maestrodatabase.com/blog/the-uk-mhra-australian-tga-and-health-canada-approve-kimmtrak-tebentafusp-for-the-treatment-of-unresectable-or-metastatic-uveal-melanoma 2022-06-08T12:03:44 https://maestrodatabase.com/blog/zephyrus-innovations-announces-us-fda-approval-for-its-aeroject-3-ml-safety-syringe 2023-02-16T20:47:24 https://maestrodatabase.com/blog/health-canada-approves-tabrecta-targeted-cancer-therapy-for-locally-advanced-unresectable-or-metastatic-non-small-cell-lung-cancer-nsclc-harbouring-mesenchymal-epithelial-transition-met-exon-14-skipping-alterations 2022-06-08T21:35:51 https://maestrodatabase.com/blog/new-weekly-treatment-option-approved-for-patients-with-haemophilia-b 2025-05-21T21:53:55 https://maestrodatabase.com/blog/tlv-reconsiders-subsidy-of-cyclin-dependent-kinase-4-slash-6-inhibitor-verzenios 2022-06-08T21:25:31 https://maestrodatabase.com/blog/combination-treatment-tafinlar-dabrafenib-plus-mekinist-trametinib-approved-by-health-canada-to-treat-braf-v600-positive-metastatic-non-small-cell-lung-cancer-after-prior-systemic-therapy 2017-06-16T03:07:53 https://maestrodatabase.com/blog/xbrane-biopharma-announces-that-partner-stadas-marketing-authorisation-application-for-ranibizumab-is-submitted-and-validated-by-european-medicines-agency 2021-10-01T04:22:11 https://maestrodatabase.com/blog/ema-adopts-first-list-of-critical-medicines-for-covid-19 2022-06-08T21:29:20 https://maestrodatabase.com/blog/irish-parents-breaking-down-and-crying-as-children-denied-life-changing-cystic-fibrosis-medication 2022-06-08T21:21:21 https://maestrodatabase.com/blog/belite-bio-announces-fda-granting-of-breakthrough-therapy-designation-for-tinlarebant-for-the-treatment-of-stargardt-disease 2025-05-21T23:11:50 https://maestrodatabase.com/blog/exploring-the-application-of-cost-effectiveness-evaluation-in-the-japanese-national-health-insurance-system 2020-02-05T20:03:12 https://maestrodatabase.com/blog/lyrica-pfizer-and-how-big-pharma-gets-what-it-wants 2019-03-23T22:56:51 https://maestrodatabase.com/blog/european-commission-approves-roches-first-in-class-bispecific-antibody-lunsumio-for-people-with-relapsed-or-refractory-follicular-lymphoma 2022-06-08T21:44:34 https://maestrodatabase.com/blog/moderna-provides-update-on-bla-submission-for-combination-vaccine-against-influenza-and-covid-19 2025-05-21T22:23:41 https://maestrodatabase.com/blog/fda-takes-steps-to-enhance-state-importation-programs-to-help-lower-prescription-drug-prices 2025-05-21T22:48:40 https://maestrodatabase.com/blog/tg-therapeutics-submits-biologics-license-application-to-the-u-dot-s-fda-for-ublituximab-as-a-treatment-for-patients-with-relapsing-forms-of-multiple-sclerosis 2021-10-01T04:41:08 https://maestrodatabase.com/blog/drug-prices-on-tv-they-may-be-coming 2019-03-24T01:24:58 https://maestrodatabase.com/blog/iveric-bio-announces-fda-accepts-new-drug-application-and-grants-priority-review-for-avacincaptad-pegol-for-the-treatment-of-geographic-atrophy 2023-02-17T01:01:53 https://maestrodatabase.com/blog/pharmamar-has-submitted-eu-marketing-authorization-application-for-lurbinectedin-in-combination-with-atezolizumab-in-first-line-maintenance-therapy-for-extensive-stage-small-cell-lung-cancer 2025-05-22T01:32:03 https://maestrodatabase.com/blog/as-political-scrutiny-mounts-eli-lilly-divulges-new-insulin-pricing-data 2019-03-24T20:15:55 https://maestrodatabase.com/blog/alternative-option-for-common-disease-listed-on-pbs-for-the-first-time 2021-10-01T05:20:43 https://maestrodatabase.com/blog/pharming-provides-update-on-ema-regulatory-review-of-leniolisib-for-apds-in-europe 2023-02-17T01:27:22 https://maestrodatabase.com/blog/tagrisso-approved-with-conditions-in-canada-for-patients-with-unresectable-stage-iii-egfr-mutated-non-small-cell-lung-cancer 2025-05-22T01:26:48 https://maestrodatabase.com/blog/dostarlimab-with-platinum-based-chemotherapy-for-treating-primary-advanced-or-recurrent-endometrial-cancer-with-high-microsatellite-instability-or-mismatch-repair-deficiency 2025-05-22T03:54:58 https://maestrodatabase.com/blog/zealand-pharma-announces-fda-approval-of-zegalogue-dasiglucagon-injection-for-the-treatment-of-severe-hypoglycaemia-in-people-with-diabetes 2021-03-23T05:28:51 https://maestrodatabase.com/blog/ipsen-and-medison-pharma-announce-health-canada-approval-of-bylvay-odevixibat-for-the-treatment-of-pruritus-due-to-progressive-familial-intrahepatic-cholestasis 2023-11-14T01:51:31 https://maestrodatabase.com/blog/chiesi-global-rare-diseases-announces-fda-approval-of-lamzede-velmanase-alfa-tycv-for-alfa-mannosidosis 2023-02-17T03:29:39 https://maestrodatabase.com/blog/mitapivat-sulphate-for-the-treatment-of-patients-with-pyruvate-kinase-deficiency 2023-02-17T02:56:26 https://maestrodatabase.com/blog/eisai-and-nuvation-bio-announce-marketing-authorisation-application-for-taletrectinib-for-the-treatment-of-advanced-ros1-positive-non-small-cell-lung-cancer-validated-by-the-ema 2026-03-27T01:15:51 https://maestrodatabase.com/blog/kite-submits-supplemental-biologics-license-application-to-u-dot-s-fda-for-earlier-use-of-yescarta-in-large-b-cell-lymphoma 2021-10-01T06:26:10 https://maestrodatabase.com/blog/fda-approves-first-gene-therapy-for-severe-leukocyte-adhesion-deficiency-type-i 2026-03-27T01:04:45 https://maestrodatabase.com/blog/pharmamar-announces-the-approval-of-zepzelca-lurbinectedin-for-the-treatment-of-relapsed-stage-iii-or-metastatic-small-cell-lung-cancer-in-canada 2021-10-01T06:12:42 https://maestrodatabase.com/blog/bydureon-bcise-exenatide-prolonged-release-approved-in-the-eu-for-paediatric-patients-with-type-2-diabetes 2022-06-09T01:51:41 https://maestrodatabase.com/blog/new-alzheimers-drug-available-today-for-australian-patients 2025-05-22T03:51:07 https://maestrodatabase.com/blog/nice-publishes-single-guideline-for-managing-covid-19 2021-03-23T19:54:18 https://maestrodatabase.com/blog/optellum-receives-fda-clearance-for-the-worlds-first-ai-powered-clinical-decision-support-software-for-early-lung-cancer-diagnosis 2021-03-23T19:57:47 https://maestrodatabase.com/blog/pacira-announces-fda-approval-of-supplemental-new-drug-application-for-exparel-bupivacaine-liposome-injectable-suspension-in-paediatric-patients 2021-03-23T08:21:55 https://maestrodatabase.com/blog/scynexis-announces-submission-of-supplemental-new-drug-application-of-brexafemme-ibrexafungerp-tablets-to-the-u-dot-s-fda-for-an-expanded-indication-for-the-prevention-of-recurrent-vaginal-yeast-infection 2022-06-09T07:42:22 https://maestrodatabase.com/blog/melbourne-made-covid-19-vaccine-now-available 2021-03-23T08:43:45 https://maestrodatabase.com/blog/japans-mhlw-approves-pfizers-cibinqo-abrocitinib-for-adults-and-adolescents-with-moderate-to-severe-atopic-dermatitis 2021-10-01T23:32:50 https://maestrodatabase.com/blog/democrats-see-a-pathway-for-their-ambitious-drug-pricing-bill 2021-03-23T20:11:16 https://maestrodatabase.com/blog/health-canada-approves-kesimpta-the-first-and-only-self-administered-targeted-b-cell-therapy-for-relapsing-remitting-multiple-sclerosis 2021-03-23T20:17:29 https://maestrodatabase.com/blog/the-days-of-the-independent-republic-of-pharmac-are-far-from-over 2022-06-09T07:58:13 https://maestrodatabase.com/blog/bernie-sanders-making-plans-to-push-prescription-drug-reforms-through-reconciliation 2021-03-23T20:13:55 https://maestrodatabase.com/blog/novo-nordisk-receives-refusal-to-file-letter-for-once-weekly-semaglutide-2-mg-for-the-treatment-of-type-2-diabetes 2021-03-23T20:02:03 https://maestrodatabase.com/blog/indian-cancer-drug-manufacturer-to-pay-50-dollars-million-for-concealing-and-destroying-records-in-advance-of-fda-inspection 2021-03-23T20:06:33 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-fda-approval-for-opdivo-nivolumab-as-adjuvant-therapy-in-patients-with-completely-resected-melanoma-with-lymph-node-involvement-or-metastatic-disease 2017-12-21T02:03:01 https://maestrodatabase.com/blog/new-type-of-treatment-for-crohns-disease-is-approved-by-nice 2017-06-16T09:19:21 https://maestrodatabase.com/blog/price-disclosure-2017-october-cycle-outcomes-summary 2017-06-16T09:13:01 https://maestrodatabase.com/blog/therapeuticsmd-announces-fda-acceptance-of-new-drug-application-and-prescription-drug-user-fee-act-date-for-tx-004hr 2017-12-21T02:10:33 https://maestrodatabase.com/blog/pbac-publishes-confusing-public-summary-document-for-tofacitinib-citrate-xeljanz 2021-03-23T20:31:00 https://maestrodatabase.com/blog/astrazeneca-vaccine-trial-data-questions-raised-by-us-drug-agency 2021-03-23T20:26:42 https://maestrodatabase.com/blog/everest-medicines-announces-acceptance-of-new-drug-application-by-china-nmpa-for-xerava-for-the-treatment-of-complicated-intra-abdominal-infections 2021-03-23T20:46:23 https://maestrodatabase.com/blog/meiragtx-announces-fda-breakthrough-therapy-designation-for-aav2-haqp1-for-the-treatment-of-grade-2-and-grade-3-radiation-induced-xerostomia 2026-03-27T02:12:26 https://maestrodatabase.com/blog/pharmac-joins-acts-call-for-a-medicines-strategy 2022-06-09T20:59:40 https://maestrodatabase.com/blog/bavarian-nordic-announces-fda-acceptance-and-priority-review-of-the-bla-for-its-chikungunya-vaccine 2024-08-13T23:59:18 https://maestrodatabase.com/blog/u-dot-s-fda-approves-foundation-medicines-foundationone-cdx-as-a-companion-diagnostic-for-roches-rozlytrek-entrectinib 2022-06-09T13:28:03 https://maestrodatabase.com/blog/teclistamab-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma-after-three-or-more-therapies 2023-02-17T06:58:41 https://maestrodatabase.com/blog/insignis-therapeutics-receives-fda-fast-track-designation-for-in-001-for-anaphylaxis-treatment 2024-08-13T23:51:45 https://maestrodatabase.com/blog/lupin-receives-tentative-approval-from-u-dot-s-fda-for-ivacaftor-tablets 2022-06-09T20:55:05 https://maestrodatabase.com/blog/algotxs-atx01-granted-fast-track-designation-by-fda-for-chemotherapy-induced-neuropathic-pain 2022-06-09T13:23:21 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-9-june-2022 2022-06-09T08:49:51 https://maestrodatabase.com/blog/u-dot-s-senators-ask-regulators-to-clear-drug-patent-thickets 2022-06-09T21:47:13 https://maestrodatabase.com/blog/norgine-announces-swissmedic-approval-of-pedmarqsi-for-the-prevention-of-cisplatin-induced-hearing-loss-in-children 2026-03-27T03:39:10 https://maestrodatabase.com/blog/roxadustat-for-treating-anaemia-in-people-with-chronic-kidney-disease 2022-06-09T21:18:11 https://maestrodatabase.com/blog/the-regulatory-accountability-act-of-2017----implications-for-fda-regulation-and-public-health 2017-12-21T03:26:43 https://maestrodatabase.com/blog/drug-importation-is-dangerous-and-wont-lower-prices 2022-06-09T21:04:27 https://maestrodatabase.com/blog/tetraphase-pharmaceuticals-receives-positive-chmp-opinion-for-xerava-eravacycline-as-a-treatment-for-complicated-intra-abdominal-infections 2018-07-28T08:57:17 https://maestrodatabase.com/blog/maker-of-promising-alzheimers-drug-leqembi-expects-full-fda-approval-this-summer-expanded-medicare-coverage 2023-02-17T19:17:30 https://maestrodatabase.com/blog/everest-medicines-announces-approval-of-trodelvy-in-china-for-second-line-metastatic-triple-negative-breast-cancer 2022-06-10T08:17:54 https://maestrodatabase.com/blog/high-drug-prices-are-not-justified-by-industrys-spending-on-research-and-development 2023-02-17T19:09:07 https://maestrodatabase.com/blog/hundreds-of-thousands-set-to-benefit-as-nice-final-draft-guidance-recommends-new-treatment-to-prevent-heart-attacks-and-strokes-in-people-with-raised-blood-fats 2022-06-10T08:09:41 https://maestrodatabase.com/blog/galderma-receives-us-fda-approval-for-nemluvio-nemolizumab-for-adult-patients-living-with-prurigo-nodularis 2024-08-14T00:34:37 https://maestrodatabase.com/blog/us-fda-accepts-for-priority-review-the-supplemental-new-drug-application-for-mercks-prevymis-for-prophylaxis-of-cytomegalovirus-disease-in-kidney-transplant-recipients-at-high-risk 2023-02-17T19:04:51 https://maestrodatabase.com/blog/awiqli-approved-in-the-us-the-first-and-only-once-weekly-basal-insulin-treatment-for-adults-with-type-2-diabetes 2026-03-27T12:17:43 https://maestrodatabase.com/blog/melbournes-peter-maccallum-cancer-centre-to-be-home-of-the-next-great-wave-in-treatment 2019-03-25T02:08:43 https://maestrodatabase.com/blog/super-flu-vaccine-gets-the-go-ahead 2021-03-24T00:38:09 https://maestrodatabase.com/blog/medicare-advisers-suggest-tweaks-to-coverage-process-for-alzheimers-drugs 2023-02-17T19:46:06 https://maestrodatabase.com/blog/post-market-review-of-medicines-available-on-the-pbs-opiate-dependence-treatment-program 2021-03-24T00:34:36 https://maestrodatabase.com/blog/uks-most-expensive-drug-libmeldy-saved-teddi-shaw-but-is-too-late-for-her-sister 2023-02-17T19:31:23 https://maestrodatabase.com/blog/other-countries-are-getting-a-free-ride-on-prescription-drug-prices-says-former-pharma-executive 2018-07-28T21:56:53 https://maestrodatabase.com/blog/the-fda-should-withdraw-approval-of-more-than-400-tainted-medicines 2024-08-14T03:16:14 https://maestrodatabase.com/blog/dusc-utilisation-analysis-public-release-documents-june-2023 2023-11-14T08:06:59 https://maestrodatabase.com/blog/ancillary-product-patents-to-extend-biologic-patent-life 2023-11-14T07:44:05 https://maestrodatabase.com/blog/formycon-and-bioeq-announce-file-acceptance-for-fyb201-a-biosimilar-candidate-to-lucentis-ranibizumab-by-the-u-dot-s-fda 2021-10-02T05:48:37 https://maestrodatabase.com/blog/imfinzi-plus-chemotherapy-approved-in-china-as-first-immunotherapy-regimen-for-patients-with-locally-advanced-or-metastatic-biliary-tract-cancer 2023-11-14T07:38:02 https://maestrodatabase.com/blog/fda-approves-brexucabtagene-autoleucel-for-relapsed-or-refractory-b-cell-precursor-acute-lymphoblastic-leukemia 2021-10-02T05:07:45 https://maestrodatabase.com/blog/medical-device-reforms-to-lower-health-fund-premiums 2021-10-02T05:02:22 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-to-sonalasenses-sonala-001-in-combination-with-the-insightec-transcranial-ultrasound-device-for-sonodynamic-therapy-of-dipg-a-rare-paediatric-brain-cancer 2023-11-14T19:40:34 https://maestrodatabase.com/blog/doordash-launches-on-demand-delivery-of-covid-19-pcr-test-collection-kits-through-partnerships-with-vault-health-and-everlywell 2021-03-24T03:16:19 https://maestrodatabase.com/blog/travere-therapeutics-announces-fda-accelerated-approval-of-filspari-sparsentan-the-first-and-only-non-immunosuppressive-therapy-for-the-reduction-of-proteinuria-in-iga-nephropathy 2023-02-18T01:09:03 https://maestrodatabase.com/blog/atsena-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-designation-for-atsn-101-gene-therapy-for-gucy2d-associated-leber-congenital-amaurosis 2023-11-14T19:30:55 https://maestrodatabase.com/blog/the-u-dot-s-can-lower-drug-prices-without-sacrificing-innovation 2021-10-02T05:56:38 https://maestrodatabase.com/blog/biocon-biologics-receives-uk-mhra-approval-for-yesafili-biosimilar-aflibercept 2023-11-14T10:23:50 https://maestrodatabase.com/blog/fda-approves-syfovre-pegcetacoplan-injection-as-the-first-and-only-treatment-for-geographic-atrophy-a-leading-cause-of-blindness 2023-02-18T00:51:57 https://maestrodatabase.com/blog/inequitable-conduct-and-invalidation-of-patents-related-to-fda-regulated-products 2023-11-14T08:10:20 https://maestrodatabase.com/blog/fda-approves-genentechs-perjeta-pertuzumab-for-adjuvant-treatment-of-specific-type-of-early-breast-cancer 2017-12-21T10:19:59 https://maestrodatabase.com/blog/fda-approves-new-oncology-drugs-quicker-than-ema 2022-06-11T09:48:59 https://maestrodatabase.com/blog/pbs-expenditure-and-prescriptions-report---2016-17 2017-12-21T10:03:58 https://maestrodatabase.com/blog/aeterna-zentaris-announces-fda-approval-of-macrilen-macimorelin-for-diagnosis-of-adult-growth-hormone-deficiency 2017-12-21T10:12:01 https://maestrodatabase.com/blog/fda-approves-new-drug-for-hypoparathyroidism-a-rare-disorder 2024-08-14T06:36:45 https://maestrodatabase.com/blog/fda-accepts-new-drug-application-for-seysara-sarecycline-for-the-treatment-of-moderate-to-severe-acne 2017-12-21T10:30:45 https://maestrodatabase.com/blog/samsung-bioepis-sb3-trastuzumab-biosimilar-candidate-accepted-for-review-by-the-us-fda 2017-12-21T10:35:39 https://maestrodatabase.com/blog/icer-publishes-evidence-report-on-treatment-for-pulmonary-arterial-hypertension 2023-11-14T19:52:10 https://maestrodatabase.com/blog/relugolix-for-the-treatment-of-patients-with-hormone-sensitive-prostate-cancer 2024-08-14T06:28:27 https://maestrodatabase.com/blog/bayer-announces-initiation-of-rolling-submission-of-new-drug-application-in-the-u-dot-s-for-larotrectinib-for-the-treatment-of-trk-fusion-cancers 2017-12-21T10:25:45 https://maestrodatabase.com/blog/bayer-provides-update-on-aliqopa-copanlisib 2023-11-14T19:46:32 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-report-finds-inadequate-evidence-to-distinguish-between-anabolic-therapies-for-osteoporosis 2017-06-17T00:59:31 https://maestrodatabase.com/blog/multiple-sclerosis-patients-to-have-routine-access-to-beta-interferon-drug-says-nice-in-new-draft-guidance 2017-12-21T10:53:10 https://maestrodatabase.com/blog/evidence-based-health-policy 2017-12-21T10:40:46 https://maestrodatabase.com/blog/gop-senate-leaders-aim-to-bring-health-care-legislation-to-the-floor-by-end-of-june 2017-06-17T01:06:04 https://maestrodatabase.com/blog/nice-proposes-restricting-multiple-sclerosis-therapies 2017-12-21T10:45:18 https://maestrodatabase.com/blog/genmab-announces-u-dot-s-fda-approval-of-darzalex-daratumumab-in-combination-with-pomalidomide-and-dexamethasone-for-relapsed-or-refractory-multiple-myeloma 2017-06-17T01:11:44 https://maestrodatabase.com/blog/adamis-wins-u-dot-s-approval-to-sell-epipen-rival-shares-soar 2017-06-17T01:08:12 https://maestrodatabase.com/blog/european-commission-approves-roches-alecensa-alectinib-as-first-line-treatment-in-alk-positive-lung-cancer 2017-12-21T20:39:18 https://maestrodatabase.com/blog/lynparza-and-imfinzi-combination-approved-in-the-eu-for-patients-with-mismatch-repair-proficient-advanced-or-recurrent-endometrial-cancer 2024-08-14T06:46:58 https://maestrodatabase.com/blog/fda-grants-breakthrough-therapy-designation-for-alevumab-in-combination-with-inlyta-in-advanced-renal-cell-carcinoma 2017-12-21T20:20:25 https://maestrodatabase.com/blog/nrx-pharmaceuticals-provides-update-on-breakthrough-therapy-designation-request-for-zyesami-aviptadil 2022-06-12T00:06:33 https://maestrodatabase.com/blog/diabetes-is-officially-the-messiest-drug-market 2017-12-21T20:32:15 https://maestrodatabase.com/blog/updated-financial-estimates-workbook-and-manual 2020-03-30T06:32:25 https://maestrodatabase.com/blog/mylan-and-lupin-announce-positive-chmp-opinion-for-nepexto-biosimilar-etanercept 2020-03-30T06:36:56 https://maestrodatabase.com/blog/drug-makers-dodged-1-dot-3-billion-dollars-in-payments-to-medicaid-report-finds 2017-12-21T20:48:23 https://maestrodatabase.com/blog/pfizer-announces-positive-talzenna-and-xtandi-combination-data-from-phase-3-talapro-2-trial 2023-02-18T21:07:06 https://maestrodatabase.com/blog/reatas-toss-up-drug-approval-decision-is-in-the-unpredictable-hands-of-fdas-billy-dunn 2023-02-18T20:49:41 https://maestrodatabase.com/blog/nucala-mepolizumab-approved-by-us-fda-for-use-in-adults-with-chronic-obstructive-pulmonary-disease 2025-05-22T22:00:27 https://maestrodatabase.com/blog/seqirus-ready-to-reinforce-canadas-influenza-pandemic-preparedness-plans 2021-03-24T05:27:08 https://maestrodatabase.com/blog/defining-capacity-building-in-the-context-of-hta-a-proposal-by-the-htai-scientific-development-and-capacity-building-committee 2019-09-14T05:00:21 https://maestrodatabase.com/blog/european-medicines-agency-validates-bristol-myers-squibbs-application-for-lag-3-blocking-antibody-relatlimab-and-nivolumab-fixed-dose-combination-as-first-line-treatment-for-patients-with-unresectable-or-metastatic-melanoma 2021-10-02T09:13:01 https://maestrodatabase.com/blog/locally-produced-astrazeneca-single-best-thing-as-government-gives-up-on-international-supply 2021-03-24T05:34:58 https://maestrodatabase.com/blog/ipsen-announces-fda-approval-of-dysport-abobotulinumtoxin-a-for-the-treatment-of-lower-limb-spasticity-in-adults 2017-06-17T01:31:17 https://maestrodatabase.com/blog/the-u-dot-s-health-care-system-found-a-way-to-make-peanuts-cost-4-200-dollars 2019-09-14T04:53:03 https://maestrodatabase.com/blog/european-medicines-agency-validates-bristol-myers-squibbs-application-for-mavacamten-for-the-treatment-of-obstructive-hypertrophic-cardiomyopathy 2021-10-02T09:05:11 https://maestrodatabase.com/blog/health-canada-says-astrazeneca-shot-is-safe-as-u-dot-s-questions-vaccines-clinical-trial-data 2021-03-24T04:33:55 https://maestrodatabase.com/blog/tga-advice-on-recognition-of-covid-19-vaccines-not-registered-in-australia-but-used-internationally 2021-10-02T09:10:38 https://maestrodatabase.com/blog/right-to-try-remains-a-bust-as-many-drug-makers-prefer-fda-reviews 2019-09-14T05:27:46 https://maestrodatabase.com/blog/harvard-professors-continue-to-push-misconceptions-to-justify-drug-price-controls 2022-06-12T07:18:43 https://maestrodatabase.com/blog/merck-boss-hits-back-at-drug-pricing-criticism 2017-06-17T02:03:51 https://maestrodatabase.com/blog/daiichi-sankyo-submits-application-for-car-t-therapy-axicabtagene-ciloleucel-for-treatment-of-patients-with-certain-relapsed-slash-refractory-b-cell-lymphomas-in-japan 2020-03-30T10:52:23 https://maestrodatabase.com/blog/fda-science-working-at-the-speed-of-emerging-technologies 2017-06-17T01:57:39 https://maestrodatabase.com/blog/lillys-taltz-ixekizumab-receives-u-dot-s-fda-approval-for-the-treatment-of-paediatric-patients-with-moderate-to-severe-plaque-psoriasis 2020-03-30T10:56:42 https://maestrodatabase.com/blog/chugai-obtains-approval-for-polivy-for-the-treatment-of-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma 2021-03-24T06:27:31 https://maestrodatabase.com/blog/fda-approves-genentechs-susvimo-for-diabetic-retinopathy 2025-05-22T23:14:26 https://maestrodatabase.com/blog/bayer-receives-approval-for-vitrakvi-in-japan 2021-03-24T05:38:52 https://maestrodatabase.com/blog/u-dot-s-officials-worried-about-chinese-control-of-american-drug-supply 2019-09-14T06:48:07 https://maestrodatabase.com/blog/ema-to-issue-electronic-certificates-for-medicines 2020-03-30T20:04:40 https://maestrodatabase.com/blog/fda-on-signing-of-the-covid-19-emergency-relief-bill-including-landmark-over-the-counter-drug-reform-and-user-fee-legislation 2020-03-30T20:07:08 https://maestrodatabase.com/blog/fda-grants-breakthrough-device-designation-to-tempus-atrial-fibrillation-ecg-analysis-platform-developed-in-collaboration-with-geisinger 2021-03-24T19:52:44 https://maestrodatabase.com/blog/ren001-granted-fast-track-designation-by-fda-for-patients-with-primary-mitochondrial-myopathies 2021-03-24T19:58:25 https://maestrodatabase.com/blog/fda-guidance-on-conduct-of-clinical-trials-of-medical-products-during-the-covid-19-pandemic 2020-03-30T20:10:59 https://maestrodatabase.com/blog/zai-lab-announces-breakthrough-therapy-designations-granted-for-repotrectinib-in-china 2022-06-12T08:00:31 https://maestrodatabase.com/blog/johnson-landmark-new-partnership-with-u-dot-s-department-of-health-and-commitment-to-supply-one-billion-vaccines-worldwide-for-emergency-pandemic-use 2020-03-30T20:19:58 https://maestrodatabase.com/blog/fda-authorises-letsgetcheckeds-home-collection-coronavirus-covid-19-test-for-direct-to-consumer-purchase 2021-03-24T10:39:57 https://maestrodatabase.com/blog/fda-approves-durvalumab-for-extensive-stage-small-cell-lung-cancer 2020-03-30T20:00:59 https://maestrodatabase.com/blog/bidens-choice-and-fdas-loosening-standards-of-evidence 2021-03-24T19:50:24 https://maestrodatabase.com/blog/trump-administration-in-talks-with-india-to-avoid-u-dot-s-drug-supply-shortage 2020-03-30T20:50:59 https://maestrodatabase.com/blog/the-contribution-of-french-patient-and-consumer-groups-to-health-technology-assessments-over-a-2-year-period-an-observational-retrospective-study 2021-03-24T20:27:54 https://maestrodatabase.com/blog/is-it-worthwhile-having-private-health-insurance-during-the-coronavirus-epidemic 2020-03-30T20:54:47 https://maestrodatabase.com/blog/nice-publishes-draft-guidance-for-secukinumab-cosentyx 2021-03-24T20:46:38 https://maestrodatabase.com/blog/pharmac-eases-restrictions-on-cancer-drugs-during-covid-19-pandemic 2020-03-30T20:28:23 https://maestrodatabase.com/blog/new-who-guide-to-help-countries-expand-access-to-essential-medicines 2020-03-30T20:39:34 https://maestrodatabase.com/blog/nice-publishes-draft-guidance-for-ixekizumab-taltz 2021-03-24T20:09:18 https://maestrodatabase.com/blog/fda-grants-two-new-breakthrough-device-designations-for-nateras-signatera-mrd-test 2021-03-24T20:04:11 https://maestrodatabase.com/blog/u-dot-s-regulator-approves-limited-use-of-malaria-drugs-for-covid-19 2020-03-30T20:46:45 https://maestrodatabase.com/blog/pembrolizumab-for-adjuvant-treatment-of-adults-with-renal-cell-carcinoma 2022-10-19T05:37:26 https://maestrodatabase.com/blog/fda-sponsors-advance-reliance-on-real-world-data-and-evidence 2021-10-02T22:39:42 https://maestrodatabase.com/blog/soleno-therapeutics-announces-submission-and-ema-validation-of-marketing-authorisation-application-for-diazoxide-choline-prolonged-release-tablets-for-the-treatment-of-hyperphagia-in-patients-with-prader-willi-syndrome 2025-05-23T01:49:24 https://maestrodatabase.com/blog/health-funding-facts-website-launched 2019-03-25T07:05:41 https://maestrodatabase.com/blog/ptac-defers-submission-for-new-indication-for-pd-l1-antagonist 2018-07-29T21:25:16 https://maestrodatabase.com/blog/new-drug-for-aussies-with-hepatitis-c-on-pbs 2018-07-29T21:16:02 https://maestrodatabase.com/blog/china-pledges-stronger-reform-on-approving-monitoring-new-drugs 2019-03-25T07:19:35 https://maestrodatabase.com/blog/roches-subcutaneous-injection-of-tecentriq-recommended-by-the-eus-chmp-for-multiple-cancer-types 2023-11-15T04:14:01 https://maestrodatabase.com/blog/medicare-for-all-would-abolish-private-insurance-theres-no-precedent-in-american-history-dot 2019-03-25T07:13:51 https://maestrodatabase.com/blog/19-000-australians-now-using-pbs-subsidised-anti-hiv-drugs 2019-03-25T07:08:49 https://maestrodatabase.com/blog/palmerston-north-mum-appeals-to-pharmac-for-desperately-needed-drug 2019-03-25T19:53:16 https://maestrodatabase.com/blog/mavenclad-cladribine-tablets-approved-as-the-first-short-course-oral-treatment-for-relapsing-remitting-multiple-sclerosis-in-switzerland 2019-03-25T11:39:05 https://maestrodatabase.com/blog/omeros-provides-regulatory-update-on-biologics-license-application-for-narsoplimab-in-the-treatment-of-hematopoietic-stem-cell-transplant-associated-thrombotic-microangiopathy 2021-10-02T23:23:38 https://maestrodatabase.com/blog/vat-cut-on-orphan-drugs-will-lift-healthcare-burden-but-many-still-struggle-to-afford-medication 2019-03-25T10:01:59 https://maestrodatabase.com/blog/ema-publishes-agenda-for-25-28-march-chmp-meeting 2019-03-25T20:07:39 https://maestrodatabase.com/blog/rotorua-teacher-needs-$100k-for-cancer-drug-to-live-longer-for-his-young-sons 2019-03-25T20:03:01 https://maestrodatabase.com/blog/cancer-patients-wait-up-to-12-weeks-for-urgent-treatment 2019-03-25T19:57:28 https://maestrodatabase.com/blog/eli-lilly-sheds-light-on-confidential-drug-pricing-discloses-charges-for-popular-diabetes-medicine-humalog 2019-03-25T20:20:14 https://maestrodatabase.com/blog/pharma-fears-lack-of-focus-on-no-deal-brexit-preparations 2019-03-25T20:13:56 https://maestrodatabase.com/blog/coherus-biosciences-receives-positive-chmp-opinion-for-udencya-pegfilgrastim-biosimilar-candidate 2018-07-29T22:23:47 https://maestrodatabase.com/blog/hira-puts-brakes-on-gileads-aids-treatment-receiving-reimbursement 2019-03-25T20:33:26 https://maestrodatabase.com/blog/fda-approves-axatilimab-csfr-for-chronic-graft-versus-host-disease 2024-08-14T20:55:47 https://maestrodatabase.com/blog/lutetium-lu-177-vipivotide-tetraxetan-for-the-treatment-of-patients-with-metastatic-psma-positive-hormone-relapsed-prostate-cancer-after-two-or-more-treatments 2023-11-15T05:27:54 https://maestrodatabase.com/blog/relief-therapeutics-receives-fda-rare-paediatric-disease-designation-for-rlf-td011 2025-05-23T03:15:31 https://maestrodatabase.com/blog/canadian-public-places-high-priority-on-drugs-safety-effectiveness-and-certainty-of-evidence 2019-03-25T20:29:03 https://maestrodatabase.com/blog/one-canadian-payers-experience-with-biosimilars 2019-03-25T20:24:11 https://maestrodatabase.com/blog/fda-approves-perseris-risperidone-for-extended-release-injectable-suspension-for-the-treatment-of-schizophrenia-in-adults 2018-07-29T22:37:59 https://maestrodatabase.com/blog/braftovi-encorafenib-plus-mektovi-binimetinib-receives-positive-chmp-opinion-for-advanced-braf-mutant-melanoma 2018-07-29T22:30:30 https://maestrodatabase.com/blog/vertex-receives-australian-tga-approval-for-trikafta-elexacaftor-slash-tezacaftor-slash-ivacaftor-and-ivacaftor-to-treat-people-with-cystic-fibrosis-ages-12-years-and-older-who-have-at-least-one-f508del-mutation 2021-03-24T23:38:45 https://maestrodatabase.com/blog/fda-approves-first-systemic-treatment-for-alopecia-areata 2022-06-13T20:56:25 https://maestrodatabase.com/blog/gileads-livdelzi-seladelpar-granted-accelerated-approval-for-primary-biliary-cholangitis-by-us-fda 2024-08-14T21:07:14 https://maestrodatabase.com/blog/fda-accepts-application-for-mercks-keytruda-pembrolizumab-as-adjuvant-therapy-for-stage-ib-4-cm--iiia-non-small-cell-lung-cancer-following-complete-surgical-resection 2022-06-13T21:28:26 https://maestrodatabase.com/blog/insys-therapeutics-receives-complete-response-letter-from-fda-for-buprenorphine-nda 2018-07-29T22:53:03 https://maestrodatabase.com/blog/smc---june-2022-decisions 2022-06-13T21:33:38 https://maestrodatabase.com/blog/amylyx-pharmaceuticals-announces-health-canada-approval-of-albrioza-for-the-treatment-of-als 2022-06-13T21:22:29 https://maestrodatabase.com/blog/beigene-announces-pdufa-goal-date-extension-for-u-dot-s-snda-for-brukinsa-for-the-treatment-of-cll-slash-sll 2022-06-13T21:15:27 https://maestrodatabase.com/blog/sandoz-receives-european-commission-approval-for-biosimilar-hyrimoz-adalimumab 2018-07-29T23:05:02 https://maestrodatabase.com/blog/the-startup-that-manipulated-data-to-get-a-miracle-drug-to-market 2019-09-15T04:45:34 https://maestrodatabase.com/blog/u-dot-s-fda-approves-humalog-junior-kwikpen-for-the-treatment-of-diabetes 2017-06-17T05:38:47 https://maestrodatabase.com/blog/mallinckrodt-announces-resubmission-of-terlipressin-to-the-fda-for-the-treatment-of-hepatorenal-syndrome 2022-06-13T21:07:35 https://maestrodatabase.com/blog/amivas-receives-authorisation-from-the-mhra-to-market-artesunate-amivas-artesunate-in-u-dot-k-for-initial-treatment-of-severe-malaria 2022-06-13T21:52:12 https://maestrodatabase.com/blog/secrecy-surrounding-senate-health-bill-raises-alarms-in-both-parties 2017-06-17T06:08:47 https://maestrodatabase.com/blog/medicines-australia-moves-quickly-to-put-hta-system-reform-high-on-new-governments-agenda 2022-06-13T21:44:30 https://maestrodatabase.com/blog/ip-waiver-for-covid-vaccines-misses-the-mark-in-vaccinating-the-world 2022-06-13T21:46:10 https://maestrodatabase.com/blog/early-benefit-assessment-meaningful-rcts-are-also-feasible-in-late-oncological-treatment-lines 2023-11-15T19:33:54 https://maestrodatabase.com/blog/fda-approves-new-drug-under-special-pathway-for-patients-receiving-haemodialysis 2023-11-15T19:27:27 https://maestrodatabase.com/blog/ultragenyx-announces-first-patient-dosed-in-phase-1-slash-2-study-of-dtx401-a-gene-therapy-for-the-treatment-of-glycogen-storage-disease-type-ia-fda-grants-fast-track-designation-to-gene-therapy-program 2018-07-29T23:41:09 https://maestrodatabase.com/blog/teva-announces-fda-approval-of-austedo-xr-deutetrabenazine-extended-release-tablets-a-new-once-daily-formulation-of-austedo-deutetrabenazine-tablets 2023-02-19T02:16:55 https://maestrodatabase.com/blog/ama-urges-coverage-of-obesity-treatments-as-payers-balk-at-costs 2023-11-15T19:53:50 https://maestrodatabase.com/blog/numerous-g-ba-decisions-on-new-medicines---five-active-substances-with-considerable-added-value 2019-03-26T03:48:52 https://maestrodatabase.com/blog/cost-plus-drugs-an-altruistic-capitalist-venture 2023-11-15T19:48:28 https://maestrodatabase.com/blog/chemomab-therapeutics-receives-fda-fast-track-designation-for-cm-101-for-the-treatment-of-primary-sclerosing-cholangitis 2023-11-15T19:41:55 https://maestrodatabase.com/blog/more-than-800-us-counties-are-insulin-deserts-dot-how-these-senators-want-to-help-americans-with-diabetes 2023-11-15T19:37:57 https://maestrodatabase.com/blog/65-dollars-million-to-unlock-the-potential-of-personalised-medicine-through-genomics 2019-03-26T04:08:15 https://maestrodatabase.com/blog/alnylam-announces-fda-approval-of-amvuttra-vutrisiran-an-rnai-therapeutic-for-the-treatment-of-the-polyneuropathy-of-hereditary-transthyretin-mediated-amyloidosis-in-adults 2022-06-14T02:10:28 https://maestrodatabase.com/blog/health-canada-authorises-modernas-omicron-targeting-bivalent-covid-19-vaccine-in-children-and-adolescents-6-17-years 2023-02-19T02:37:55 https://maestrodatabase.com/blog/european-commission-approves-elmiron-for-bladder-pain-syndrome 2017-06-17T08:52:52 https://maestrodatabase.com/blog/to-get-things-done-fast-at-fda-dont-tell-anybody-cancer-chief-says 2023-11-15T19:55:56 https://maestrodatabase.com/blog/celgene-submits-application-to-fda-for-ozanimod-for-the-treatment-of-relapsing-forms-of-multiple-sclerosis 2019-03-26T04:18:41 https://maestrodatabase.com/blog/taxpayers-fund-research-and-drug-companies-make-a-fortune 2021-03-25T05:49:13 https://maestrodatabase.com/blog/special-access-scheme-online-system 2018-07-30T00:45:16 https://maestrodatabase.com/blog/over-4-200-people-set-to-benefit-after-we-recommend-daily-pill-to-treat-rare-chronic-kidney-disease 2025-05-23T22:00:24 https://maestrodatabase.com/blog/health-canada-approves-cimzia-certolizumab-pegol-for-moderate-to-severe-psoriasis 2019-03-26T04:32:15 https://maestrodatabase.com/blog/health-system-neglects-vulnerable-australians-grattan-institute-report 2018-07-30T00:51:28 https://maestrodatabase.com/blog/bluebird-bio-statement-on-european-regulatory-status-of-lentiglobin 2019-03-26T04:24:15 https://maestrodatabase.com/blog/bepirovirsen-accepted-for-review-by-the-ema-as-a-potential-first-in-class-treatment-for-chronic-hepatitis-b 2026-03-28T05:43:26 https://maestrodatabase.com/blog/covid-19-vaccine-astrazeneca---update-on-ongoing-evaluation-of-blood-clot-cases 2021-03-25T19:52:59 https://maestrodatabase.com/blog/wegovy-discount-price-for-weight-loss-drug-gets-cut-to-199-dollars-but-theres-a-catch 2025-05-23T06:51:43 https://maestrodatabase.com/blog/biden-praises-pharma-to-donors-even-as-he-pushes-to-cut-prices 2019-09-15T08:49:25 https://maestrodatabase.com/blog/high-cost-patented-drugs-now-account-for-50-percent-of-sales 2021-03-25T20:10:34 https://maestrodatabase.com/blog/uplinza-inebilizumab-cdon-approved-by-japanese-ministry-of-health-labour-and-welfare-for-the-prevention-of-relapses-of-neuromyelitis-optica-spectrum-disorder 2021-03-25T20:24:09 https://maestrodatabase.com/blog/europes-plans-to-restrict-vaccine-exports-are-dangerous 2021-03-25T20:20:57 https://maestrodatabase.com/blog/bavarian-nordic-submits-data-to-ema-to-extend-mpox-and-smallpox-vaccine-approval-to-children-aged-2-11-years 2026-03-28T06:08:06 https://maestrodatabase.com/blog/cstone-announces-new-drug-approval-of-gavreto-pralsetinib-as-first-selective-ret-inhibitor-in-china-providing-a-new-therapy-for-a-subset-of-non-small-cell-lung-cancer-patients 2021-03-25T19:56:23 https://maestrodatabase.com/blog/the-potential-loophole-in-trumps-plan-to-get-other-countries-to-pay-more-for-drugs 2026-03-28T06:13:30 https://maestrodatabase.com/blog/statement-on-covid-19-vaccine-supply-at-anagni-plant-in-italy 2021-03-25T20:07:17 https://maestrodatabase.com/blog/too-high-price-for-drugs-for-cystic-fibrosis 2021-03-25T20:33:06 https://maestrodatabase.com/blog/new-diabetes-and-hepatitis-c-medications-available-to-patients-this-week 2018-07-30T02:50:22 https://maestrodatabase.com/blog/akebia-therapeutics-announces-approval-for-additional-indication-of-riona-ferric-citrate-hydrate-for-the-treatment-of-iron-deficiency-anaemia-in-adult-patients-in-japan 2021-03-25T20:45:09 https://maestrodatabase.com/blog/lamira-an-eflow-rechnology-nebulizer-expected-to-launch-in-japan-as-a-medical-device-for-exclusive-administration-of-arikayce-amikacin-liposome-inhalation-suspension 2021-03-25T20:28:52 https://maestrodatabase.com/blog/novavax-covid-19-vaccine-nuvaxovid-provisionally-registered-in-australia-as-a-booster-in-individuals-aged-18-and-over 2022-06-14T07:06:01 https://maestrodatabase.com/blog/richter-receives-european-commission-approval-for-fylrevy-estetrol-tablet-as-hormonal-replacement-therapy 2026-03-28T06:35:53 https://maestrodatabase.com/blog/pharmac-seeks-views-on-access-criteria-for-covid-19-treatments 2022-06-14T06:45:59 https://maestrodatabase.com/blog/kiromic-biopharmas-deltacel-receives-fda-fast-track-designation 2024-08-15T07:01:57 https://maestrodatabase.com/blog/bright-side-of-the-moonshots 2021-03-25T20:52:35 https://maestrodatabase.com/blog/us-fda-approves-augtyro-repotrectinib-a-next-generation-tyrosine-kinase-inhibitor-for-the-treatment-of-locally-advanced-or-metastatic-ros1-positive-non-small-cell-lung-cancer 2023-11-16T00:24:57 https://maestrodatabase.com/blog/urogen-submits-completed-ugn-102-nda-seeking-approval-as-the-first-fda-approved-treatment-for-low-grade-intermediate-risk-non-muscle-invasive-bladder-cancer 2024-08-15T06:56:51 https://maestrodatabase.com/blog/data-sharing-a-a-new-era-for-research-funded-by-the-us-government 2023-11-16T00:00:11 https://maestrodatabase.com/blog/accutar-biotechnology-receives-fda-fast-track-designation-for-ac699-in-er-positive-her2-negative-breast-cancer 2024-08-15T08:47:25 https://maestrodatabase.com/blog/new-treatment-for-advanced-prostate-cancer-added-to-the-pbs 2023-11-16T02:47:16 https://maestrodatabase.com/blog/imfinzi-granted-priority-review-and-breakthrough-therapy-designation-for-patients-with-limited-stage-small-cell-lung-cancer-in-the-us 2024-08-15T07:38:09 https://maestrodatabase.com/blog/egetis-announces-fda-acceptance-and-priority-review-of-nda-for-emcitate-tiratricol-for-mct8-feficiency 2026-03-28T06:27:07 https://maestrodatabase.com/blog/zolbetuximab-approved-to-treat-adults-with-stomach-or-gastro-oesophageal-junction-cancer 2024-08-15T08:54:03 https://maestrodatabase.com/blog/sanofis-sarclisa-subcutaneous-formulation-administered-via-on-body-injector-recommended-for-eu-approval-by-the-chmp-to-treat-multiple-myeloma 2026-03-28T07:00:49 https://maestrodatabase.com/blog/1-dot-6-million-cheaper-medicines-in-january 2023-02-20T00:45:21 https://maestrodatabase.com/blog/enhertu-granted-breakthrough-therapy-designation-in-u-dot-s-for-patients-with-her2-positive-metastatic-breast-cancer-treated-with-one-or-more-prior-anti-her2-based-regimens 2021-10-04T19:58:21 https://maestrodatabase.com/blog/empagliflozin-jardiance-approved-by-mhra-as-uks-first-effective-treatment-for-symptomatic-chronic-heart-failure-regardless-of-ejection-fraction 2022-06-14T21:28:01 https://maestrodatabase.com/blog/azar-says-hhs-will-create-more-open-market-for-prescription-drugs 2018-07-30T07:23:05 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-treatments-for-amyotrophic-lateral-sclerosis 2022-06-14T21:20:04 https://maestrodatabase.com/blog/bayer-receives-positive-chmp-opinion-for-rivaroxaban-for-patients-with-coronary-or-peripheral-artery-disease 2018-07-30T07:29:37 https://maestrodatabase.com/blog/fdas-treatment-of-china-developed-drugs-spurs-demands-for-multiregional-clinical-trials 2022-06-14T21:22:54 https://maestrodatabase.com/blog/mylan-and-fujifilm-kyowa-kirin-biologics-announce-positive-chmp-opinion-for-hulio-biosimilar-adalimumab 2018-07-30T06:41:00 https://maestrodatabase.com/blog/fda-should-step-in-to-help-spur-ai-slash-ml-standards 2022-06-14T08:19:05 https://maestrodatabase.com/blog/abbvie-announces-first-regulatory-approval-of-skyrizi-risankizumab-for-the-treatment-of-plaque-psoriasis-generalised-pustular-psoriasis-and-erythrodermic-psoriasis-and-psoriatic-arthritis-in-japan 2019-03-26T06:09:31 https://maestrodatabase.com/blog/fda-approves-new-indication-for-drug-to-treat-neurogenic-detrusor-overactivity-in-paediatric-patients 2021-03-25T22:17:20 https://maestrodatabase.com/blog/ema-validates-marketing-authorisation-application-for-oral-once-daily-berotralstat-bcx7353-to-prevent-hae-attacks 2020-03-31T04:59:49 https://maestrodatabase.com/blog/developing-covid-19-vaccines-at-pandemic-speed 2020-03-31T05:15:32 https://maestrodatabase.com/blog/astellas-provides-update-on-fezolinetant-new-drug-application-in-us 2023-02-20T01:34:17 https://maestrodatabase.com/blog/fda-approves-drug-to-treat-dangerously-low-blood-pressure 2017-12-22T02:44:13 https://maestrodatabase.com/blog/clinical-trial-processes 2020-03-31T05:10:15 https://maestrodatabase.com/blog/vertex-and-crispr-therapeutics-announce-authorisation-of-the-first-crispr-slash-cas9-gene-edited-therapy-casgevy-exagamglogene-autotemcel-by-the-united-kingdom-mhra-for-the-treatment-of-sickle-cell-disease-and-transfusion-dependent-beta-thalassaemia 2023-11-16T08:12:54 https://maestrodatabase.com/blog/johnson-and-johnsons-darzalex-daratumumab-becomes-the-first-oncology-injectable-approved-for-administration-by-patients-or-caregivers 2026-03-28T07:35:08 https://maestrodatabase.com/blog/meet-the-rebate-the-new-villain-of-high-drug-prices 2018-07-30T08:15:28 https://maestrodatabase.com/blog/updates-to-the-hta-policy-and-methods-review-reference-committee-16-november-2023 2023-11-16T06:34:04 https://maestrodatabase.com/blog/tga-publishes-another-auspar-for-opdivo-nivolumab 2020-03-31T06:13:05 https://maestrodatabase.com/blog/ensuring-continued-access-to-medicines-during-the-covid-19-pandemic 2020-03-31T06:25:48 https://maestrodatabase.com/blog/alimera-sciences-announces-approval-received-in-the-mutual-recognition-procedure-for-new-indication-for-iluvien-in-europe 2019-03-26T08:06:27 https://maestrodatabase.com/blog/forxiga-approved-in-europe-for-type-1-diabetes-mellitus 2019-03-26T07:58:56 https://maestrodatabase.com/blog/nubeqa-darolutamide-receives-eu-approval-as-a-new-treatment-for-men-with-non-metastatic-castration-resistant-prostate-cancer 2020-03-31T06:05:15 https://maestrodatabase.com/blog/expedited-covid-19-medical-device-application-process 2020-03-31T06:09:17 https://maestrodatabase.com/blog/u-dot-s-fda-grants-priority-review-to-janssen-for-apalutamide-as-a-treatment-for-non-metastatic-castration-resistant-prostate-cancer 2017-12-22T02:54:20 https://maestrodatabase.com/blog/tga-grants-provisional-approval-to-modernas-covid-19-bivalent-spikevax-bivalent-original-slash-omicron-ba-dot-4-5-booster-dose-vaccine 2023-02-20T02:35:15 https://maestrodatabase.com/blog/us-fda-approves-liquidias-yutrepia-treprostinil-inhalation-powder-for-patients-with-pulmonary-arterial-hypertension-and-pulmonary-hypertension-associated-with-interstitial-lung-disease 2025-05-24T01:09:55 https://maestrodatabase.com/blog/expanded-access-as-a-source-of-real-world-data-an-overview-of-fda-and-ema-approvals 2020-03-31T09:04:46 https://maestrodatabase.com/blog/mesoblast-receives-fda-regenerative-medicine-advanced-therapy-designation-for-its-cell-therapy-in-heart-failure-patients-with-left-ventricular-assist-devices 2017-12-22T03:14:42 https://maestrodatabase.com/blog/bristol-myers-squibb-and-bluebird-bio-announce-submission-of-biologics-license-application-for-anti-bcma-car-t-cell-therapy-idecabtagene-vicleucel-ide-cel-bb2121-to-fda 2020-03-31T12:09:06 https://maestrodatabase.com/blog/basilea-reports-that-ceftobiprole-received-qidp-designation-from-u-dot-s-fda-for-the-treatment-of-staphylococcus-aureus-bacteremia 2017-12-22T03:03:30 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-april-2020-update 2020-03-31T12:15:43 https://maestrodatabase.com/blog/expansion-of-pharmaceutical-benefits-scheme-continued-dispensing-arrangements-covid-19 2020-03-31T06:29:46 https://maestrodatabase.com/blog/expanded-immunotherapy-pbs-listing-to-treat-more-cancers 2026-03-29T03:04:31 https://maestrodatabase.com/blog/fda-approves-pembrolizumab-with-chemotherapy-for-her2-negative-gastric-or-gastro-oesophageal-junction-adenocarcinoma 2023-11-16T19:54:30 https://maestrodatabase.com/blog/1-april-2020-price-disclosure-confirmed-prices 2020-03-31T06:33:16 https://maestrodatabase.com/blog/fda-accepts-valnevas-chikungunya-vaccine-license-application-for-priority-review 2023-02-20T06:48:11 https://maestrodatabase.com/blog/ascendis-pharma-resubmits-nda-for-transcon-pth-to-the-us-fda 2023-11-16T19:39:33 https://maestrodatabase.com/blog/us-to-select-10-costliest-drugs-for-medicare-pricing-negotiation 2023-02-20T03:56:11 https://maestrodatabase.com/blog/senators-call-on-medicare-to-offer-broad-coverage-of-alzheimers-treatments-as-public-pressure-grows 2023-02-20T04:10:08 https://maestrodatabase.com/blog/fibrocell-receives-rare-paediatric-disease-designation-from-fda-for-fcx-013-for-treatment-of-localised-scleroderma 2017-06-18T01:49:08 https://maestrodatabase.com/blog/novartis-combination-therapy-tafinlar-and-mekinist-granted-fda-priority-review-for-the-adjuvant-treatment-of-stage-iii-braf-v600-mutation-positive-melanoma 2017-12-22T07:16:02 https://maestrodatabase.com/blog/agenda-for-21-june-tc-meeting 2017-06-18T02:00:51 https://maestrodatabase.com/blog/ema-tells-pharma-companies-to-continue-to-prepare-for-uks-withdrawal 2019-03-26T10:38:41 https://maestrodatabase.com/blog/cancer-society-critical-of-pharmac-saying-they-lack-accountability-lack-transparency-are-slow 2019-03-26T10:34:23 https://maestrodatabase.com/blog/viiv-healthcare-submits-fda-application-for-first-dispersible-single-tablet-regimen-containing-dolutegravir-for-children-living-with-hiv 2021-10-04T23:10:27 https://maestrodatabase.com/blog/ema-validates-marketing-authorisation-application-for-sacituzumab-govitecan-hziy-for-the-treatment-of-metastatic-triple-negative-breast-cancer 2021-03-26T02:36:38 https://maestrodatabase.com/blog/trump-administration-asks-court-to-completely-invalidate-obamas-affordable-care-act 2019-03-26T19:51:16 https://maestrodatabase.com/blog/medicare-annual-statistics---rolling-12-months-july-2009-to-december-2022 2023-02-20T19:56:52 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-april-2020-update 2020-03-31T20:19:51 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-to-assess-upadacitinib-and-other-treatments-for-rheumatoid-arthritis 2019-03-26T19:45:32 https://maestrodatabase.com/blog/ema-publishes-agenda-for-20-23-february-2023-chmp-meeting 2023-02-20T19:50:42 https://maestrodatabase.com/blog/people-over-65-to-be-given-new-flu-shot-for-free 2020-03-31T20:38:19 https://maestrodatabase.com/blog/attacks-on-astrazeneca-cast-doubt-over-its-vaccine-pricing-says-top-scientist 2021-03-26T03:13:22 https://maestrodatabase.com/blog/abpi-response-to-lord-oshaughnessy-review 2023-02-20T19:42:19 https://maestrodatabase.com/blog/nice-at-20 2019-03-26T20:13:21 https://maestrodatabase.com/blog/caught-in-the-middle-a-battle-between-vertex-and-insurers-is-leaving-cystic-fibrosis-patients-with-crushing-drug-costs 2023-02-20T19:44:59 https://maestrodatabase.com/blog/white-house-and-pelosis-staff-in-early-talks-about-legislation-to-cut-high-drug-costs 2019-03-26T20:06:32 https://maestrodatabase.com/blog/pharmac-defends-not-funding-expensive-breast-cancer-drugs 2019-03-26T20:02:30 https://maestrodatabase.com/blog/house-democratic-leaders-to-unveil-health-bill-minus-medicare-for-all 2019-03-26T19:53:20 https://maestrodatabase.com/blog/azafaros-receives-additional-regulatory-designations-for-az-3102-from-fda-ema-and-mhra 2023-02-20T19:35:26 https://maestrodatabase.com/blog/european-medicines-agency-accepts-marketing-authorisation-application-for-enfortumab-vedotin 2021-03-26T06:14:40 https://maestrodatabase.com/blog/improve-ventilation-and-make-antiviral-drug-widely-available-long-covid-inquiry-hears 2023-02-20T20:18:42 https://maestrodatabase.com/blog/covid-19-cancer-and-rare-disorder-patients-will-die-if-pharmac-doesnt-spend-money-on-medicines 2020-03-31T20:42:49 https://maestrodatabase.com/blog/takeda-begins-regulatory-submissions-for-dengue-vaccine-candidate-in-eu-and-dengue-endemic-countries 2021-03-26T03:28:40 https://maestrodatabase.com/blog/advancing-regulatory-science-in-the-eu---new-strategy-adopted 2020-03-31T20:46:45 https://maestrodatabase.com/blog/europe-slams-the-brakes-on-vaccine-exports-until-its-needs-are-met 2021-03-26T03:33:20 https://maestrodatabase.com/blog/promedior-received-breakthrough-therapy-designation-from-fda-for-prm-151-in-idiopathic-pulmonary-fibrosis 2019-03-26T23:17:13 https://maestrodatabase.com/blog/fda-approves-first-in-the-world-device-to-treat-patients-with-congenital-heart-disease 2021-03-26T20:29:59 https://maestrodatabase.com/blog/fda-updates-the-label-of-tasigna-to-reflect-that-certain-patients-with-a-type-of-leukaemia-may-be-eligible-to-stop-treatment-after-sustained-response 2017-12-22T21:40:59 https://maestrodatabase.com/blog/increase-in-vaccine-manufacturing-capacity-and-supply-for-covid-19-vaccines-from-astrazeneca-biontech-slash-pfizer-and-moderna 2021-03-26T20:37:03 https://maestrodatabase.com/blog/fda-authorises-marketing-of-device-to-improve-gait-in-multiple-sclerosis-patients 2021-03-26T20:33:34 https://maestrodatabase.com/blog/agios-receives-fda-breakthrough-therapy-designation-for-tibsovo-ivosidenib-in-combination-with-azacitidine-for-the-treatment-of-newly-diagnosed-acute-myeloid-leukaemia-with-an-idh1-mutation-in-adult-patients-ineligible-for-intensive-chemotherapy 2019-03-26T23:55:35 https://maestrodatabase.com/blog/enhertu-followed-by-thp-approved-in-china-as-the-first-and-only-her2-directed-adc-for-the-neo-adjuvant-treatment-of-her2-positive-breast-cancer 2026-03-29T06:18:39 https://maestrodatabase.com/blog/novartis-receives-fda-approval-for-mayzent-siponimod-the-first-oral-drug-to-treat-secondary-progressive-ms-with-active-disease 2019-03-26T23:47:15 https://maestrodatabase.com/blog/highlights-from-the-chmp-22-25-march-2022-meeting 2021-03-26T20:42:08 https://maestrodatabase.com/blog/pharmaceutical-industry-backs-workplace-vaccinations 2021-10-05T00:59:41 https://maestrodatabase.com/blog/calls-for-blockbuster-osteoporosis-drug-to-be-made-widely-available 2022-06-15T04:32:22 https://maestrodatabase.com/blog/ema-receives-application-for-marketing-authorisation-for-regkirona-regdanvimab-for-treating-patients-with-covid-19 2021-10-05T01:38:30 https://maestrodatabase.com/blog/pharmac-announces-first-round-of-medicine-funding-decisions-following-191-dollars-million-pharmaceutical-budget-increase 2022-06-15T04:28:54 https://maestrodatabase.com/blog/heron-therapeutics-announces-filing-of-a-supplemental-new-drug-application-for-significant-expansion-of-zynrelef-indication-statement-based-on-successful-outcome-of-fda-type-c-meeting 2021-10-05T02:53:45 https://maestrodatabase.com/blog/fda-approves-capivasertib-with-fulvestrant-for-breast-cancer 2023-11-17T01:09:00 https://maestrodatabase.com/blog/comirnaty-and-spikevax-ema-recommendations-on-extra-doses-and-boosters 2021-10-05T02:04:12 https://maestrodatabase.com/blog/turning-point-therapeutics-granted-breakthrough-therapy-designation-for-repotrectinib-treatment-in-patients-with-ntrk-positive-tki-pretreated-advanced-solid-tumours 2021-10-05T01:52:38 https://maestrodatabase.com/blog/fdas-naming-rule-for-biosimilars-has-undermined-congress-and-health-care 2021-10-05T01:59:32 https://maestrodatabase.com/blog/nice-recommends-first-treatment-in-two-decades-for-sickle-cell-disease 2021-10-05T09:47:33 https://maestrodatabase.com/blog/adjuvant-treatment-for-nsclc-osimertinib-mesylate-may-benefit-certain-people 2021-10-05T09:54:30 https://maestrodatabase.com/blog/who-prioritises-access-to-diabetes-and-cancer-treatments-in-new-essential-medicines-lists 2021-10-05T02:58:59 https://maestrodatabase.com/blog/genmab-announces-submission-of-supplemental-biologics-license-application-to-fda-for-daratumumab-in-combination-with-bortezomib-thalidomide-and-dexamethasone-in-frontline-multiple-myeloma 2019-03-27T03:04:44 https://maestrodatabase.com/blog/medicare-reverses-course-on-decision-to-universally-cover-breakthrough-medical-devices-for-4-years 2021-10-05T04:27:59 https://maestrodatabase.com/blog/health-economic-assessment-of-keytruda-in-combination-with-inlyta-in-kidney-cell-cancer 2020-03-31T23:32:15 https://maestrodatabase.com/blog/ema-adopts-positive-opinion-for-keytruda-pembrolizumab-combination-with-pemetrexed-and-platinum-chemotherapy-for-the-first-line-treatment-of-metastatic-non-squamous-non-small-cell-lung-cancer 2018-07-30T12:48:58 https://maestrodatabase.com/blog/jemperli-dostarlimab-for-injection-plus-carboplatin-and-paclitaxel-approved-in-canada-as-a-treatment-option-for-primary-advanced-or-recurrent-dmmr-slash-msi-h-endometrial-cancer 2023-11-17T02:48:51 https://maestrodatabase.com/blog/julia-mcnicol-doesnt-have-enough-cancer-to-get-the-drugs-she-needs-to-fight-it 2018-07-30T20:53:55 https://maestrodatabase.com/blog/australians-are-rightly-concerned-about-trusting-my-health-record-says-privacy-commissioner 2018-07-30T21:02:01 https://maestrodatabase.com/blog/chmp-recommends-eu-approval-of-roches-itovebi-for-pik3ca-mutated-er-positive-her2-negative-advanced-breast-cancer 2025-05-25T01:38:03 https://maestrodatabase.com/blog/tga-approval-of-kimmtrak 2022-06-15T06:11:50 https://maestrodatabase.com/blog/the-product-monograph-for-protopic-has-been-updated 2021-10-05T20:18:00 https://maestrodatabase.com/blog/pharmacs-communications-approach-for-the-trikafta-consultation 2023-02-21T00:03:24 https://maestrodatabase.com/blog/mhra-approves-polihexanide-to-treat-acanthamoeba-keratitis 2025-05-25T00:12:13 https://maestrodatabase.com/blog/azd7442-request-for-emergency-use-authorisation-for-covid-19-prophylaxis-filed-in-us 2021-10-05T20:25:04 https://maestrodatabase.com/blog/palvella-therapeutics-announces-us-fda-breakthrough-therapy-designation-granted-to-qtorin-3-dot-9-percent-rapamycin-anhydrous-gel-qtorin-rapamycin-for-the-treatment-of-microcystic-lymphatic-malformations 2023-11-17T03:19:12 https://maestrodatabase.com/blog/tga-grants-provisional-determination-to-pfizers-covid-19-treatment-pf-07321332-and-ritonavir 2021-10-05T20:00:33 https://maestrodatabase.com/blog/venetoclax-comes-close-to-gaining-support-from-nice 2021-10-05T19:55:55 https://maestrodatabase.com/blog/fda-approves-neo-adjuvant-slash-adjuvant-durvalumab-for-resectable-non-small-cell-lung-cancer 2024-08-15T23:34:11 https://maestrodatabase.com/blog/nivolumab-and-ipilimumab-added-benefit-in-pleural-mesothelioma-with-non-epithelioid-tumour-histology 2021-10-05T20:12:56 https://maestrodatabase.com/blog/pfizer-and-astellas-xtandi-approved-by-us-fda-in-earlier-prostate-cancer-treatment-setting 2023-11-17T03:38:12 https://maestrodatabase.com/blog/blenrep-belantamab-mafodotin-combinations-receive-positive-chmp-opinion-in-relapsed-slash-refractory-multiple-myeloma 2025-05-25T07:23:11 https://maestrodatabase.com/blog/pharmac-signals-first-step-towards-funding-continuous-glucose-monitors 2023-02-21T01:07:10 https://maestrodatabase.com/blog/xbrane-biopharma-updates-on-us-fda-biologics-license-application-for-its-investigational-biosimilar-candidate-to-lucentis-ranibizumab 2025-05-25T04:40:38 https://maestrodatabase.com/blog/moderna-files-fda-application-for-the-lp-dot-8-1-targeting-covid-19-vaccine 2025-05-25T04:48:25 https://maestrodatabase.com/blog/springworks-therapeutics-receives-positive-chmp-opinion-for-mirdametinib-for-the-treatment-of-adult-and-paediatric-patients-with-nf1-pn 2025-05-25T04:52:29 https://maestrodatabase.com/blog/effectiveness-in-the-absence-of-efficacy-cautionary-tales-from-real-world-evidence 2019-03-27T09:49:08 https://maestrodatabase.com/blog/fda-approves-first-treatment-for-rare-adrenal-tumours 2018-07-31T01:18:27 https://maestrodatabase.com/blog/rimegepant-sulphate-for-the-treatment-or-prevention-of-migraine 2023-02-21T02:40:05 https://maestrodatabase.com/blog/novartis-marks-a-new-era-for-migraine-patients-with-the-eu-approval-of-aimovig-a-first-of-its-kind-treatment-specifically-designed-for-migraine-prevention 2018-07-31T01:52:58 https://maestrodatabase.com/blog/millions-of-australians-plan-to-switch-or-downgrade-health-insurance-ahead-of-april-price-hike 2019-03-27T10:26:30 https://maestrodatabase.com/blog/fda-accepts-file-for-cladribine-tablets-as-potential-treatment-for-relapsing-forms-of-multiple-sclerosis 2018-07-31T01:48:27 https://maestrodatabase.com/blog/leading-cancer-drug-subsidised-for-thousands-of-patients 2026-03-30T02:25:58 https://maestrodatabase.com/blog/pbs-process-improvements-webinar-information-forum 2019-03-27T10:14:13 https://maestrodatabase.com/blog/new-epilepsy-medicine-to-provide-much-needed-support-to-thousands-of-australians 2018-07-31T02:02:15 https://maestrodatabase.com/blog/lutetium-lu-177-vipivotide-tetraxetan-for-the-treatment-of-adults-with-psma-positive-hormone-relapsed-metastatic-prostate-cancer-after-two-or-more-therapies 2023-02-21T03:28:21 https://maestrodatabase.com/blog/new-treatment-option-for-canadians-with-metastatic-lung-cancer 2018-07-31T01:58:05 https://maestrodatabase.com/blog/nektar-therapeutics-announces-new-drug-application-for-nktr-181-accepted-for-review-by-fda 2018-07-31T02:09:55 https://maestrodatabase.com/blog/another-week-another-terminated-nice-appraisal 2022-06-15T09:44:28 https://maestrodatabase.com/blog/nice-recommends-3-treatments-for-covid-19-in-final-draft-guidance 2023-02-21T09:28:13 https://maestrodatabase.com/blog/nice-recommendation-for-steglatro-in-type-2-diabetes-mellitus 2019-03-27T20:02:45 https://maestrodatabase.com/blog/covid-19-update-fda-continues-to-accelerate-development-of-novel-therapies-for-covid-19 2020-04-01T01:32:54 https://maestrodatabase.com/blog/kalvista-announces-validation-of-marketing-authorisation-application-by-the-ema-for-sebetralstat-for-hereditary-angioedema 2024-08-16T01:53:26 https://maestrodatabase.com/blog/pharmac-widens-access-to-safe-sex-drug-after-overwhelming-support 2022-06-15T10:25:04 https://maestrodatabase.com/blog/fda-accepts-orasis-pharmaceuticals-new-drug-application-for-csf-1-for-the-treatment-of-presbyopia 2023-02-21T19:27:58 https://maestrodatabase.com/blog/new-eudravigilance-system-improves-reporting-of-side-effects-and-detection-of-safety-signals 2019-03-27T20:00:27 https://maestrodatabase.com/blog/the-fda-returns-to-its-bad-habits 2023-02-21T06:55:22 https://maestrodatabase.com/blog/authorised-nurse-practitioners-now-eligible-to-prescribe-certain-highly-specialised-drugs 2020-04-01T01:39:55 https://maestrodatabase.com/blog/fda-approves-new-oral-testosterone-capsule-for-treatment-of-men-with-certain-forms-of-hypogonadism 2019-03-27T19:57:32 https://maestrodatabase.com/blog/600-years-supply-of-cystic-fibrosis-drug-destroyed-in-price-row 2019-03-27T20:31:06 https://maestrodatabase.com/blog/first-gene-therapy-for-haemophilia-b-csls-hemgenix-approved-by-the-european-commission 2023-02-21T06:40:02 https://maestrodatabase.com/blog/charging-for-technology-appraisals-and-highly-specialised-technologies 2019-03-27T20:25:58 https://maestrodatabase.com/blog/whanganui-district-health-board-says-small-number-of-patients-affects-cancer-treatment-wait-time-results 2019-03-27T20:22:24 https://maestrodatabase.com/blog/mei-pharma-announces-fast-track-designation-granted-by-u-dot-s-fda-for-me-401-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-follicular-lymphoma 2020-04-01T01:26:42 https://maestrodatabase.com/blog/cancer-advocate-pharmac-is-compromised-by-limited-spending 2019-03-27T20:18:35 https://maestrodatabase.com/blog/fda-accepts-mesoblasts-biologics-licence-application-for-ryoncil-and-agrees-to-priority-review 2020-04-01T02:12:34 https://maestrodatabase.com/blog/englands-innovative-medicines-fund-hits-another-milestone 2022-06-15T10:48:54 https://maestrodatabase.com/blog/novartis-makes-new-ms-drug-cheaper-than-its-older-option 2019-03-27T20:37:14 https://maestrodatabase.com/blog/gw-pharmaceuticals-and-greenwich-biosciences-announce-fda-acceptance-of-snda-filing-with-priority-review-for-epidiolex-cannabidiol-in-the-treatment-of-seizures-associated-with-tuberous-sclerosis-complex 2020-04-01T02:21:13 https://maestrodatabase.com/blog/biohavens-taldefgrobep-alfa-receives-fda-fast-track-designation-for-spinal-muscular-atrophy 2023-02-21T19:33:47 https://maestrodatabase.com/blog/pozelimab-c5-antibody-bla-for-treatment-of-children-and-adults-with-ultra-rare-chaple-disease-accepted-for-fda-priority-review 2023-02-21T19:38:38 https://maestrodatabase.com/blog/outcomes-based-pricing-not-a-panacea-for-high-priced-drugs 2019-03-27T20:34:45 https://maestrodatabase.com/blog/nices-early-value-assessment-for-medtech-panning-for-nuggets-of-innovation-gold 2022-06-15T10:45:16 https://maestrodatabase.com/blog/tga-approves-vyxeos 2022-06-15T10:29:16 https://maestrodatabase.com/blog/efpia-eurordis-joint-statement-on-patient-access-to-medicines-for-rare-diseases 2022-06-15T21:34:46 https://maestrodatabase.com/blog/a-first-step-towards-best-practice-recommendations-for-the-design-and-statistical-analyses-of-pragmatic-clinical-trials-a-modified-delphi-approach 2022-06-15T21:23:08 https://maestrodatabase.com/blog/a-safe-space-for-addressing-complex-health-technology-assessment-challenges 2022-06-15T21:29:04 https://maestrodatabase.com/blog/vertex-receives-european-chmp-positive-opinion-for-symkevi-tezacaftor-slash-ivacaftor-for-people-with-cystic-fibrosis-aged-12-and-older-with-certain-mutations-in-the-cftr-gene 2018-07-31T06:25:19 https://maestrodatabase.com/blog/first-public-drug-plans-provide-reimbursement-for-camzyos-for-adults-with-symptomatic-obstructive-hypertrophic-cardiomyopathy 2024-08-16T02:35:21 https://maestrodatabase.com/blog/effective-biomedical-public-private-partnerships-are-about-innovation-not-lower-drug-prices 2022-06-15T21:12:14 https://maestrodatabase.com/blog/start-of-rolling-review-for-adapted-comirnaty-covid-19-vaccine 2022-06-15T20:56:03 https://maestrodatabase.com/blog/shionogi-signs-agreement-with-nhs-england-to-begin-an-innovative-subscription-payment-model-for-reimbursement-of-its-antibiotic-fetcroja-cefiderocol 2022-06-15T21:00:48 https://maestrodatabase.com/blog/130-000-dollars-a-year-for-medicine-is-outrageous-but-i-blame-the-government-not-drug-makers 2023-02-21T20:04:50 https://maestrodatabase.com/blog/karyopharm-and-menarini-receive-full-marketing-authorisation-from-the-uk-medicines-and-healthcare-products-regulatory-agency-for-nexpovio-selinexor-in-combination-with-bortezomib-and-dexamethasone-for-the-treatment-of-adult-patients-with-multiple-myeloma-who-have-received-at-least-one-prior-therapy 2023-02-21T20:10:29 https://maestrodatabase.com/blog/icer-publishes-final-evidence-report-on-treatments-for-multiple-sclerosis 2023-02-21T19:59:27 https://maestrodatabase.com/blog/alnylam-announces-us-fda-acceptance-of-supplemental-new-drug-application-for-onpattro-patisiran-for-the-treatment-of-the-cardiomyopathy-of-attr-amyloidosis 2023-02-21T19:52:37 https://maestrodatabase.com/blog/ema-confirms-acceptance-of-marketing-application-for-avt06-a-proposed-biosimilar-to-eylea-aflibercept 2024-08-16T03:30:05 https://maestrodatabase.com/blog/santen-receives-complete-response-letter-from-u-dot-s-fda-for-intravitreal-sirolimus-de-109 2017-12-23T01:23:04 https://maestrodatabase.com/blog/icosavax-granted-fda-fast-track-designation-for-ivx-a12 2023-02-21T20:34:46 https://maestrodatabase.com/blog/us-fda-accepts-biologics-license-application-for-pfizers-respiratory-syncytial-virus-maternal-vaccine-candidate-for-priority-review 2023-02-21T20:20:53 https://maestrodatabase.com/blog/kintara-therapeutics-granted-fast-track-designation-from-the-fda-for-val-083-for-newly-diagnosed-glioblastoma 2022-06-16T00:43:29 https://maestrodatabase.com/blog/fda-approves-first-cell-based-gene-therapy-for-adult-patients-with-multiple-myeloma 2021-03-27T21:19:13 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-reviews-final-report-on-vmat2-inhibitors-for-tardive-dyskinesia-calls-for-manufacturer-and-payer-action-to-lower-prices-and-assure-adequate-access 2017-12-23T03:21:03 https://maestrodatabase.com/blog/biomarin-receives-anticipated-notification-of-pdufa-extension-for-pegvaliase-biologics-license-application-to-28-may-2018 2017-12-23T02:14:16 https://maestrodatabase.com/blog/agile-therapeutics-receives-a-complete-response-letter-from-the-fda-for-twirla-ag200-15-for-the-prevention-of-pregnancy 2017-12-23T03:29:42 https://maestrodatabase.com/blog/us-fda-grants-fast-track-designation-for-jr-171-for-the-treatment-of-mucopolysaccaridosis-type-i 2021-10-06T00:35:40 https://maestrodatabase.com/blog/aveo-oncology-announces-submission-of-new-drug-application-to-u-dot-s-fda-for-tivozanib-in-patients-with-relapsed-or-refractory-renal-cell-carcinoma 2020-04-01T04:00:58 https://maestrodatabase.com/blog/us-fda-accepts-for-priority-review-decipheras-new-drug-application-for-vimseltinib-for-the-treatment-of-patients-with-tenosynovial-giant-cell-tumour 2024-08-16T03:59:59 https://maestrodatabase.com/blog/new-pharmac-funded-cancer-drugs-already-old-and-cheap-patient-advocate-malcolm-mulholland-says 2022-06-16T01:23:54 https://maestrodatabase.com/blog/many-fda-approved-cancer-drugs-might-lack-clinical-benefit 2017-12-23T05:47:34 https://maestrodatabase.com/blog/amazing-coincidence-moderna-offered-free-vaccines-when-asked-to-testify-bernie-sanders-says 2023-02-21T21:54:20 https://maestrodatabase.com/blog/amber-implants-vcfix-spinal-system-receives-us-fda-breakthrough-designation 2021-10-06T01:00:32 https://maestrodatabase.com/blog/australia-secures-additional-supplies-of-sotrovimab 2021-10-06T01:53:48 https://maestrodatabase.com/blog/alnylam-receives-positive-chmp-opinion-for-onpattro-patisiran-for-the-treatment-of-hereditary-transthyretin-mediated-amyloidosis-in-adults-with-stage-1-or-stage-2-polyneuropathy 2018-07-31T08:10:45 https://maestrodatabase.com/blog/soleno-therapeutics-receives-fast-track-designation-from-fda-for-dccr-for-treatment-of-prader-willi-syndrome 2018-07-31T08:04:53 https://maestrodatabase.com/blog/rhythm-pharmaceuticals-completes-rolling-submission-of-new-drug-application-to-u-dot-s-fda-for-setmelanotide-in-pomc-and-lepr-deficiency-obesities 2020-04-01T05:09:13 https://maestrodatabase.com/blog/influenza-vaccines-released-for-2020-season 2020-05-08T05:53:26 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-for-farxiga-in-heart-failure 2019-09-16T12:46:51 https://maestrodatabase.com/blog/australian-government-buys-300-000-doses-of-merck-covid-19-treatment-drug-molnupiravir-that-has-not-yet-been-approved 2021-10-06T03:00:58 https://maestrodatabase.com/blog/janssen-submits-application-to-u-dot-s-fda-seeking-first-in-class-approval-of-tremfya-guselkumab-for-treatment-of-adults-with-active-psoriatic-arthritis 2019-09-16T12:40:47 https://maestrodatabase.com/blog/ema-publishes-agenda-for-16-19-september-chmp-meeting 2019-09-16T20:28:27 https://maestrodatabase.com/blog/wave-life-sciences-announces-fast-track-designation-from-u-dot-s-fda-for-suvodirsen 2019-09-16T12:58:08 https://maestrodatabase.com/blog/landmark-pbs-medicines-listings-to-provide-hope-for-thousands-of-australians 2021-03-28T00:11:08 https://maestrodatabase.com/blog/seattle-genetics-and-astellas-announce-u-dot-s-fda-grants-priority-review-for-enfortumab-vedotin-biologics-license-application-in-locally-advanced-or-metastatic-urothelial-cancer 2019-09-16T12:50:47 https://maestrodatabase.com/blog/accelerated-assessment-of-medical-devices---priority-review-pathway 2017-06-19T06:44:40 https://maestrodatabase.com/blog/ixazomib-citrate-and-lenalidomide-and-dexamethasone-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma 2023-02-22T02:50:43 https://maestrodatabase.com/blog/verrica-pharmaceuticals-submits-new-drug-application-to-u-dot-s-fda-for-vp-102-for-the-treatment-of-molluscum-contagiosum 2019-09-16T20:40:40 https://maestrodatabase.com/blog/sandoz-receives-approval-in-europe-for-rixathon-biosimilar-rituximab-to-treat-blood-cancers-and-immunological-diseases 2017-06-19T06:53:42 https://maestrodatabase.com/blog/canada-decides-leading-parties-plan-to-tackle-ways-to-make-medicine-affordable 2019-09-16T21:02:37 https://maestrodatabase.com/blog/elevar-therapeutics-announces-fda-acceptance-for-review-of-new-drug-application-for-lirafugratinib-as-second-line-cholangiocarcinoma-treatment 2026-03-30T22:29:53 https://maestrodatabase.com/blog/lenvima-to-get-benefit-as-first-line-treatment-of-hepatocellular-carcinoma 2019-09-16T20:55:23 https://maestrodatabase.com/blog/prescription-drug-price-gouging-must-stop 2019-09-16T20:50:00 https://maestrodatabase.com/blog/pharmaceutical-benefits-scheme-safety-net-threshold-reduction-from-1-july-2022 2022-06-16T06:46:37 https://maestrodatabase.com/blog/european-commission-approves-bristol-myers-squibbs-opdivo-nivolumab-for-the-adjuvant-treatment-of-adult-patients-with-melanoma-with-involvement-of-lymph-nodes-or-metastatic-disease-who-have-undergone-complete-resection 2018-07-31T12:19:24 https://maestrodatabase.com/blog/wholesale-drug-prices-have-been-falling-and-so-have-net-prices 2019-09-16T20:46:45 https://maestrodatabase.com/blog/johnson-and-johnson-announces-submission-of-emergency-use-authorisation-amendment-to-the-u-dot-s-fda-to-support-booster-of-its-single-shot-covid-19-vaccine 2021-10-06T03:19:59 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-august-2018-update 2018-07-31T12:51:37 https://maestrodatabase.com/blog/fda-seeks-input-on-product-specific-guidances-to-facilitate-generic-drug-development 2019-09-16T21:34:45 https://maestrodatabase.com/blog/icer-to-assess-treatments-for-hypertension 2026-03-30T22:04:44 https://maestrodatabase.com/blog/health-minister-backs-down-on-my-health-record 2018-07-31T12:33:06 https://maestrodatabase.com/blog/hta-in-the-european-union-osteoporosis-screening-without-proof-of-benefit 2019-09-16T21:14:57 https://maestrodatabase.com/blog/otsuka-announces-fda-acceptance-and-priority-review-of-biologics-license-application-for-sibeprenlimab-in-the-treatment-of-immunoglobulin-a-nephropathy 2025-05-26T02:42:27 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-august-2018-update 2018-07-31T13:29:29 https://maestrodatabase.com/blog/over-500-000-australians-vaccinated-against-covid-19 2021-03-28T01:10:24 https://maestrodatabase.com/blog/maestro-snapshot---august-2018 2018-07-31T21:08:25 https://maestrodatabase.com/blog/special-or-standard-pricing-arrangements-apply 2018-07-31T21:30:07 https://maestrodatabase.com/blog/mhra-pilot-seeks-evidence-of-patient-involvement-in-r-and-d 2021-03-28T02:17:42 https://maestrodatabase.com/blog/secret-drug-price-rebates-will-go-away-pfizer-ceo-predicts 2018-07-31T21:46:05 https://maestrodatabase.com/blog/astellas-receives-positive-chmp-opinion-for-xtandi-enzalutamide-for-patients-with-metastatic-hormone-sensitive-prostate-cancer 2021-03-28T06:34:40 https://maestrodatabase.com/blog/msac-publishes-agenda-for-june-2023-esc-meeting 2023-02-22T03:47:48 https://maestrodatabase.com/blog/how-did-health-care-get-to-be-such-a-mess 2017-06-19T08:11:48 https://maestrodatabase.com/blog/ema-to-consider-rolling-review-for-mercks-molnupiravir-in-coming-days 2021-10-06T04:53:34 https://maestrodatabase.com/blog/australian-first-whole-genome-sequencing-and-health-testing-open-to-public 2017-06-19T21:07:31 https://maestrodatabase.com/blog/new-treatment-to-increase-the-chances-of-a-successful-kidney-transplant-recommended-by-nice 2022-06-16T10:46:46 https://maestrodatabase.com/blog/new-programme-will-assess-how-digital-therapies-can-help-treat-anxiety-and-depression 2017-06-19T11:01:15 https://maestrodatabase.com/blog/fda-accepts-amgens-supplemental-biologics-license-application-to-expand-indication-for-xgeva-denosumab-to-include-multiple-myeloma-patients 2017-06-19T21:26:11 https://maestrodatabase.com/blog/eli-lilly-pushes-for-nhs-drug-price-increases-in-return-for-its-uk-investment 2026-03-30T23:20:14 https://maestrodatabase.com/blog/kids-under-11-offered-free-chickenpox-vaccine-but-older-kiwis-miss-out 2017-06-19T21:13:06 https://maestrodatabase.com/blog/gilead-receives-approval-in-canada-for-vemlidy-tenofovir-alafenamide-for-the-treatment-of-chronic-hepatitis-b-virus-infection 2017-06-19T21:32:29 https://maestrodatabase.com/blog/pbs-listing-slashes-breast-cancer-treatment-from-$50k-to-hundreds-of-dollars 2021-03-28T20:28:21 https://maestrodatabase.com/blog/fast-tracking-of-new-drugs-getting-the-balance-right 2018-08-01T00:08:38 https://maestrodatabase.com/blog/despite-pressure-over-prices-the-drug-industry-is-coasting-on-capitol-hill 2017-06-19T21:38:14 https://maestrodatabase.com/blog/eisai-and-merck-announce-fda-grants-breakthrough-therapy-designation-for-lenvima-lenvatinib-in-combination-with-keytruda-pembrolizumab-as-therapy-for-previously-treated-patients-with-advanced-and-slash-or-metastatic-non-msi-h-slash-pmmr-endometrial-carcinoma 2018-08-01T00:12:36 https://maestrodatabase.com/blog/novartis-receives-gb-licence-for-scemblix-asciminib-the-first-stamp-inhibitor-for-patients-with-chronic-myeloid-leukaemia 2022-06-16T20:50:19 https://maestrodatabase.com/blog/the-amount-you-pay-for-cancer-drugs-may-double----heres-why 2017-06-19T21:43:30 https://maestrodatabase.com/blog/ema-confirms-accelerated-assessment-procedure-for-trogarzo 2018-08-01T05:56:31 https://maestrodatabase.com/blog/how-trump-can-curb-runaway-drug-prices 2017-06-19T21:40:25 https://maestrodatabase.com/blog/complete-response-letter-received-from-fda 2021-10-06T19:53:21 https://maestrodatabase.com/blog/acer-therapeutics-and-relief-therapeutics-announce-fda-acceptance-for-filing-of-new-drug-application-for-acer-001-to-treat-urea-cycle-disorders 2021-10-06T20:01:23 https://maestrodatabase.com/blog/ema-publishes-agenda-for-june-19-22-chmp-meeting 2017-06-19T21:56:02 https://maestrodatabase.com/blog/emerging-use-of-early-health-technology-assessment-in-medical-product-development-a-scoping-review-of-the-literature 2017-06-19T21:51:32 https://maestrodatabase.com/blog/moderna-announces-european-medicines-agency-authorises-third-dose-of-covid-19-vaccine-for-immunocompromised-individuals-aged-12-years-and-older 2021-10-06T08:18:08 https://maestrodatabase.com/blog/where-has-pharmac-gone 2021-10-06T19:50:03 https://maestrodatabase.com/blog/axsome-therapeutics-receives-fda-breakthrough-therapy-designation-for-axs-05-for-the-treatment-of-major-depressive-disorder 2019-03-28T03:59:46 https://maestrodatabase.com/blog/savara-awarded-innovation-passport-in-united-kingdom-for-molgramostim-nebuliser-solution-a-novel-investigational-inhaled-biologic 2022-06-16T21:12:28 https://maestrodatabase.com/blog/subsidy-for-medicine-for-duchenne-muscular-dystrophy-expires 2022-06-16T21:06:37 https://maestrodatabase.com/blog/breakthrough-medicines-now-available-for-blood-cancer-breast-cancer-hiv-and-epilepsy-saving-patients-up-to-194-000-dollars 2020-04-01T20:09:19 https://maestrodatabase.com/blog/aetion-and-nice-announce-collaboration-to-explore-use-of-real-world-evidence-for-comparative-effectiveness-studies-to-inform-clinical-guidance 2021-10-06T20:15:52 https://maestrodatabase.com/blog/former-fda-officials-call-for-more-transparency-for-drug-approvals 2022-06-16T20:58:04 https://maestrodatabase.com/blog/rhythm-pharmaceuticals-announces-fda-approval-of-imcivree-setmelanotide-for-use-in-patients-with-bardet-biedl-syndrome 2022-06-16T21:00:37 https://maestrodatabase.com/blog/coronavirus-treatment-acceleration-program 2020-04-01T20:29:26 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-16-june-2022 2022-06-16T21:53:27 https://maestrodatabase.com/blog/pharmac-widens-funding-for-lenalidomide-for-those-with-blood-cancer 2020-04-01T20:38:13 https://maestrodatabase.com/blog/core-network-partners-announced-for-cadths-post-market-drug-evaluation-network 2022-06-16T21:49:34 https://maestrodatabase.com/blog/flu-vaccination-more-important-than-ever-during-the-month-of-april 2020-04-01T20:14:41 https://maestrodatabase.com/blog/mhra-joins-international-partnerships-to-set-global-standards-for-medicines-and-medical-devices-regulation 2022-06-16T21:20:14 https://maestrodatabase.com/blog/regulatory-information---1-dot-6-percent-increase-in-fees-from-1-april-2020 2020-04-01T20:17:54 https://maestrodatabase.com/blog/nhs-lands-breakthrough-in-global-battle-against-superbugs 2022-06-16T21:40:45 https://maestrodatabase.com/blog/covid-19-chloroquine-and-hydroxychloroquine-only-to-be-used-in-clinical-trials-or-emergency-use-programmes 2020-04-01T20:19:46 https://maestrodatabase.com/blog/fda-approves-additional-treatment-for-adults-and-adolescents-with-haemophilia-a-or-b-and-inhibitors 2020-04-01T20:24:35 https://maestrodatabase.com/blog/fda-grants-breakthrough-therapy-designation-to-daiichi-sankyos-flt3-inhibitor-quizartinib-for-relapsed-slash-refractory-flt3-itd-aml 2018-08-01T07:45:10 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-to-evaluate-comparative-clinical-effectiveness-and-value-of-avxs-101-and-nusinersen-for-spinal-muscular-atrophy 2018-08-01T07:52:19 https://maestrodatabase.com/blog/promising-lung-cancer-treatment-approved-for-cancer-drugs-fund 2019-03-28T11:17:25 https://maestrodatabase.com/blog/take-over-pharma-to-create-new-medicines-says-top-adviser 2019-03-28T06:45:55 https://maestrodatabase.com/blog/louisiana-picks-drug-company-for-hepatitis-c-treatment-plan 2019-03-28T06:37:39 https://maestrodatabase.com/blog/medicare-for-all-means-hope-for-none 2019-03-28T19:54:01 https://maestrodatabase.com/blog/greg-hunt-shelves-plan-for-two-month-scripts-after-pharmacist-backlash 2019-03-28T11:33:59 https://maestrodatabase.com/blog/xeljanz-tofacitinib-citrate-receives-marketing-authorisation-in-the-european-union-for-moderately-to-severely-active-ulcerative-colitis 2018-08-01T08:31:32 https://maestrodatabase.com/blog/im-not-in-dot-dot-dot-some-third-world-place-bladder-cancer-patients-face-ongoing-scarcity-of-life-saving-drug 2019-09-17T04:14:28 https://maestrodatabase.com/blog/fda-approves-treatment-for-patients-with-a-type-of-inflammatory-arthritis 2019-03-28T20:13:31 https://maestrodatabase.com/blog/almirall-receives-european-commission-approval-of-ebglyss-lebrikizumab-for-moderate-to-severe-atopic-dermatitis 2023-11-18T00:11:27 https://maestrodatabase.com/blog/pfizer-receives-european-approval-for-oncology-biosimilar-trazimera-trastuzumab 2018-08-01T08:37:44 https://maestrodatabase.com/blog/20-years-of-sampling-and-testing-programme-for-medicines-authorised-for-the-eu 2019-03-28T20:10:16 https://maestrodatabase.com/blog/fda-approves-blood-disorder-drug-made-by-japans-shionogi 2018-08-01T08:51:42 https://maestrodatabase.com/blog/declare-lung-cancer-national-priority---lung-foundation-nz 2019-03-28T20:05:19 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-to-axovants-nelotanserin-for-visual-hallucinations-in-dementia-with-lewy-bodies 2017-06-20T01:01:29 https://maestrodatabase.com/blog/horizon-pharma-announces-health-canada-approval-of-procysbi-cysteamine-delayed-release-capsules-for-the-treatment-of-nephropathic-cystinosis 2017-06-20T01:12:40 https://maestrodatabase.com/blog/when-cholesterol-drugs-cost-14-000-dollars-an-insurance-tug-of-war 2017-06-20T01:19:15 https://maestrodatabase.com/blog/why-j-and-j-raced-to-put-drug-prices-in-some-tv-ads 2019-03-28T20:26:18 https://maestrodatabase.com/blog/beigene-receives-european-commission-approval-for-brukinsa-zanubrutinib-for-the-treatment-of-relapsed-or-refractory-follicular-lymphoma 2023-11-18T00:38:39 https://maestrodatabase.com/blog/drug-makers-continue-to-clamour-for-fda-approval-of-orphan-drugs 2019-03-28T20:22:23 https://maestrodatabase.com/blog/hospital-pharmacists-face-dozens-of-drug-shortages-yearly 2019-03-28T20:41:09 https://maestrodatabase.com/blog/six-health-stories-to-watch-in-2018 2017-12-26T21:59:45 https://maestrodatabase.com/blog/national-pharmacare-to-make-prescription-drugs-more-accessible-and-affordable 2019-03-28T20:31:23 https://maestrodatabase.com/blog/cancer-drug-price-rises-1-400-percent-with-no-generic-to-challenge-it 2017-12-26T22:02:28 https://maestrodatabase.com/blog/coalition-attacks-trump-plan-to-end-drug-rebates-calling-it-a-big-pharma-bailout 2019-03-28T20:28:56 https://maestrodatabase.com/blog/melinta-therapeutics-announces-u-dot-s-fda-approval-of-baxdela-delafloxacin-for-acute-bacterial-skin-and-skin-structure-infections-absssi 2017-06-20T02:15:17 https://maestrodatabase.com/blog/novelion-therapeutics-announces-marketing-authorisation-for-myalepta-metreleptin-in-the-european-union-to-treat-generalised-and-partial-lipodystrophy 2018-08-01T10:31:45 https://maestrodatabase.com/blog/priority-generic-drug-reviews-new-fda-draft-guidance 2017-06-20T02:05:33 https://maestrodatabase.com/blog/keeping-up-the-pace-at-the-scottish-medicines-consortium 2019-03-28T20:52:36 https://maestrodatabase.com/blog/single-payer-drug-pricing-in-a-multi-payer-health-system-does-germany-offer-a-model-for-the-us 2019-03-28T20:45:50 https://maestrodatabase.com/blog/halozyme-announces-argenx-receives-european-commission-approval-of-vvyvart-sc-with-enhanze-for-generalised-myasthenia-gravis 2023-11-18T01:09:55 https://maestrodatabase.com/blog/steve-maharey-appointed-as-pharmac-chairman 2018-08-01T10:45:26 https://maestrodatabase.com/blog/free-access-plan-for-revolutionary-drug-that-could-eliminate-hepatitis-c-by-2030 2018-08-01T10:50:33 https://maestrodatabase.com/blog/lundbeck-and-otsukas-rxulti-brexpiprazole-approved-by-the-european-commission 2018-08-01T10:39:11 https://maestrodatabase.com/blog/canadas-drug-agency-advised-against-reimbursing-a-costly-eczema-drug----heres-why-people-are-worried 2018-08-01T10:54:02 https://maestrodatabase.com/blog/zymeworks-receives-us-fda-fast-track-designation-for-zw191-a-folate-receptor-alfa-targeting-antibody-drug-conjugate 2026-03-31T01:42:49 https://maestrodatabase.com/blog/building-a-more-robust-medicine-supply---proposals-to-help-prevent-mitigate-and-manage-medicine-shortages 2021-03-29T00:22:05 https://maestrodatabase.com/blog/brexit-preparedness-ema-to-further-temporarily-scale-back-and-suspend-activities 2018-08-01T21:15:08 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-posts-draft-scoping-document-on-canakinumab-for-atherosclerosis 2018-08-01T21:10:25 https://maestrodatabase.com/blog/trump-is-losing-the-war-on-drug-prices 2018-08-01T21:19:30 https://maestrodatabase.com/blog/roche-korea-to-launch-reimbursed-vabysmo-pre-filled-syringe-in-april-expanding-retinal-treatment-options 2026-03-31T02:12:39 https://maestrodatabase.com/blog/indigenous-australians-are-skeptical-about-covid-19-vaccines-and-theyre-hard-to-reach 2021-03-29T01:56:13 https://maestrodatabase.com/blog/polaris-group-initiates-rolling-submission-of-biologic-license-application-for-adi-peg-20-with-us-fda-to-treat-malignant-pleural-mesothelioma 2023-11-18T03:02:48 https://maestrodatabase.com/blog/savara-announces-ema-validation-of-marketing-authorisation-application-for-molbreevi-in-auto-immune-pulmonary-alveolar-proteinosis 2026-03-31T04:47:24 https://maestrodatabase.com/blog/european-commission-approves-kygevi-doxecitine-and-doxribtimine-as-first-and-only-treatment-for-thymidine-kinase-2-deficiency 2026-03-31T06:40:58 https://maestrodatabase.com/blog/ataluren-for-the-treatment-of-patients-with-duchenne-muscular-dystrophy-with-a-nonsense-mutation-in-the-dystrophin-gene 2023-02-22T05:05:54 https://maestrodatabase.com/blog/mezzion-announces-resubmission-of-new-drug-application-for-its-orphan-drug-udenafil-to-treat-patients-who-have-undergone-the-fontan-operation-for-single-ventricle-heart-disease 2021-03-29T02:09:01 https://maestrodatabase.com/blog/optinose-submits-supplemental-new-drug-application-for-xhance-label-expansion 2023-02-22T05:00:28 https://maestrodatabase.com/blog/fda-supports-critical-research-to-spur-innovation-for-continuous-manufacturing-technology-to-support-and-advance-drug-and-biologics-development 2018-08-01T22:12:37 https://maestrodatabase.com/blog/amazon-gets-emergency-fda-approval-for-at-home-covid-19-test-kit 2021-03-29T02:18:23 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-7-october-2021 2021-10-07T04:37:10 https://maestrodatabase.com/blog/schedule-rule-changes-will-improve-continuity-of-cancer-care 2025-05-27T00:15:16 https://maestrodatabase.com/blog/fda-approves-new-high-dose-regimen-of-spinraza-nusinersen-for-spinal-muscular-atrophy 2026-03-31T03:00:14 https://maestrodatabase.com/blog/mayne-pharma-provides-fda-update-on-generic-nuvaring 2021-10-07T09:29:19 https://maestrodatabase.com/blog/teva-gains-biosimilar-momentum-with-us-fda-approval-of-ponlimsi-denosumab-adet-and-dual-filing-acceptance-for-biosimilar-candidate-to-xolair-omalizumab 2026-03-31T03:07:21 https://maestrodatabase.com/blog/praxis-precision-medicines-announces-fda-acceptance-and-priority-review-of-new-drug-application-for-relutrigine-in-patients-with-scn2a-and-scn8a-dees 2026-03-31T03:12:57 https://maestrodatabase.com/blog/tlv-subsidises-melatonin-for-children-and-adolescents-with-adhd 2021-03-29T02:36:43 https://maestrodatabase.com/blog/moderna-asks-health-canada-to-approve-covid-19-vaccine-booster-shot 2021-10-07T02:08:08 https://maestrodatabase.com/blog/ema-validates-indication-extension-application-for-tryngolza-olezarsen-for-the-treatment-of-severe-hypertriglyceridaemia 2026-03-31T03:55:12 https://maestrodatabase.com/blog/bridgebio-submits-nda-to-fda-for-bbp-418-for-individuals-living-with-lgmd2i-slash-r9 2026-03-31T04:40:06 https://maestrodatabase.com/blog/imfinzi-plus-imjudo-approved-in-the-eu-for-patients-with-advanced-liver-and-non-small-cell-lung-cancers 2023-02-22T07:12:20 https://maestrodatabase.com/blog/fda-issues-final-order-and-guidance-on-surgical-staplers-and-staples-for-internal-use 2021-10-07T20:26:13 https://maestrodatabase.com/blog/ban-on-negotiating-medicare-drug-prices-under-pressure 2021-10-07T19:55:05 https://maestrodatabase.com/blog/calls-to-nix-august-recess-gain-steam-as-gop-agenda-hits-roadblocks 2017-06-20T20:46:00 https://maestrodatabase.com/blog/icer-publishes-evidence-report-on-mavacamten-for-hypertrophic-cardiomyopathy 2021-10-07T20:12:51 https://maestrodatabase.com/blog/fda-recognises-memorial-sloan-kettering-database-of-molecular-tumour-marker-information 2021-10-07T20:10:09 https://maestrodatabase.com/blog/so-much-for-trump-going-after-big-pharma 2017-06-20T21:01:00 https://maestrodatabase.com/blog/outcomes-of-the-may-2022-pbac-intracycle-meeting 2022-06-17T09:57:26 https://maestrodatabase.com/blog/trump-drug-pricing-order-may-be-weeks-away 2017-06-20T20:57:20 https://maestrodatabase.com/blog/beigene-announces-first-regulatory-approval-in-australia-for-brukinsa-zanubrutinib-for-treatment-of-patients-with-waldenstroems-macroglobulinaemia 2021-10-07T20:43:41 https://maestrodatabase.com/blog/democrats-protest-senate-republican-healthcare-secrecy 2017-06-20T21:12:13 https://maestrodatabase.com/blog/public-consultation-draft-2022-23-cost-recovery-implementation-statement-for-listing-medicines-on-the-pbs-and-designated-vaccines-on-the-nip 2022-06-17T09:36:22 https://maestrodatabase.com/blog/fda-to-clear-path-for-drugs-aimed-at-cancer-causing-genes 2017-06-20T21:04:53 https://maestrodatabase.com/blog/gsks-depemokimab-accepted-for-review-by-health-canada-for-the-treatment-of-asthma-with-type-2-inflammation-and-for-chronic-rhinosinusitis-with-nasal-polyps 2025-05-27T01:56:28 https://maestrodatabase.com/blog/sandoz-application-for-proposed-biosimilar-adalimumabs-high-concentration-formulation-accepted-by-ema 2022-06-17T07:03:25 https://maestrodatabase.com/blog/pfizer-seeks-us-authorisation-of-covid-19-vaccine-for-ages-5-11 2021-10-07T20:33:54 https://maestrodatabase.com/blog/the-fda-should-better-regulate-medical-algorithms 2021-10-07T20:39:13 https://maestrodatabase.com/blog/calquence-tablet-formulation-approved-in-the-eu-for-patients-with-chronic-lymphocytic-leukaemia 2023-02-22T07:17:39 https://maestrodatabase.com/blog/fda-still-without-a-permanent-leader-as-clock-ticks-down-on-acting-head 2021-10-07T20:37:24 https://maestrodatabase.com/blog/negotiating-for-lower-drug-prices-works-saves-billions 2024-08-17T07:27:53 https://maestrodatabase.com/blog/pharmacies-may-only-dispense-drugs-for-90-days 2020-04-02T00:21:07 https://maestrodatabase.com/blog/vertex-receives-chmp-positive-opinion-for-kaftrio-ivacaftor-slash-tezacaftor-slash-elexacaftor-in-combination-with-ivacaftor-to-treat-people-with-cystic-fibrosis-with-at-least-one-f508del-mutation 2021-03-29T05:07:44 https://maestrodatabase.com/blog/pfizers-elranatamab-receives-fda-and-ema-filing-acceptance 2023-02-22T19:16:19 https://maestrodatabase.com/blog/eylea-8-mg-with-extended-6-month-treatment-interval-recommended-for-approval-in-eu 2025-05-27T03:19:32 https://maestrodatabase.com/blog/gsk-receives-chmp-positive-opinion-recommending-approval-of-benlysta-for-adult-patients-with-active-lupus-nephritis 2021-03-29T05:17:48 https://maestrodatabase.com/blog/medicares-drug-price-talks-are-about-to-get-more-heated 2024-08-17T07:47:37 https://maestrodatabase.com/blog/commemorating-the-second-anniversary-of-the-biden-harris-lower-cost-prescription-drug-law 2024-08-17T07:37:18 https://maestrodatabase.com/blog/intravenous-scandal-escalates-the-excuses-are-fluid 2024-08-17T07:33:25 https://maestrodatabase.com/blog/dynavax-announces-european-medicines-agency-accepts-marketing-authorisation-application-for-heplisav-b-for-prevention-of-hepatitis-b-in-adults 2019-03-29T04:00:58 https://maestrodatabase.com/blog/saxenda-recommended-for-approval-by-european-medicines-agency-committee-for-the-treatment-of-obesity-in-adolescents-aged-12-17-years 2021-03-29T07:04:59 https://maestrodatabase.com/blog/janssen-submits-supplemental-new-drug-application-to-u-dot-s-fda-for-invokana-canagliflozin-for-the-treatment-of-chronic-kidney-disease-in-patients-with-type-2-diabetes-mellitus 2019-03-29T04:16:42 https://maestrodatabase.com/blog/amarin-submits-supplemental-new-drug-application-to-u-dot-s-fda-seeking-new-indication-for-vascepa-icosapent-ethyl-to-reduce-the-risk-of-major-adverse-cardiovascular-events-based-on-landmark-reduce-it-cardiovascular-outcomes-study 2019-03-29T04:10:43 https://maestrodatabase.com/blog/rocket-pharmaceuticals-receives-ema-priority-medicines-prime-designation-for-rp-l201-gene-therapy-for-treatment-of-leukocyte-adhesion-deficiency-i 2021-03-29T19:58:25 https://maestrodatabase.com/blog/mirum-pharmaceuticals-announces-fda-acceptance-of-new-drug-application-and-priority-review-for-maralixibat-in-alagille-syndrome 2021-03-29T19:51:39 https://maestrodatabase.com/blog/savara-receives-refusal-to-file-letter-from-the-us-fda-for-the-biologics-license-application-for-molbreevi-to-treat-patients-with-auto-immune-pulmonary-alveolar-proteinosis 2025-05-27T21:48:40 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-treatments-for-spinal-muscular-atrophy 2025-05-27T21:54:24 https://maestrodatabase.com/blog/cystic-fibrosis-scandal-drugs-deal-moves-a-step-closer-to-saving-children 2019-03-29T06:46:34 https://maestrodatabase.com/blog/alberta-family-waiting-on-approval-for-expensive-life-saving-drug-for-young-boy 2021-03-29T20:17:51 https://maestrodatabase.com/blog/32-dollars-6-cents-million-for-breast-cancer-scans-under-medicare 2019-03-29T05:05:52 https://maestrodatabase.com/blog/amryt-announces-validation-of-its-maa-by-the-ema-for-oleogel-s10-filsuvez 2021-03-29T20:10:29 https://maestrodatabase.com/blog/arcutis-zoryve-roflumilast-0-dot-3-percent-topical-foam-approved-by-us-fda-for-the-treatment-of-plaque-psoriasis-in-adults-and-adolescents-ages-12-and-older 2025-05-27T06:04:30 https://maestrodatabase.com/blog/b-dot-c-woman-petitions-province-to-cover-cost-of-life-changing-migraine-medication 2021-03-29T20:21:08 https://maestrodatabase.com/blog/european-medicines-agency-validates-bristol-myers-squibbs-application-for-opdivo-nivolumab-as-adjuvant-treatment-for-patients-with-muscle-invasive-urothelial-carcinoma 2021-03-29T20:04:54 https://maestrodatabase.com/blog/imfinzi-recommended-for-approval-in-the-eu-by-chmp-as-first-and-only-peri-operative-immunotherapy-for-muscle-invasive-bladder-cancer 2025-05-27T06:08:59 https://maestrodatabase.com/blog/neos-therapeutics-announces-fda-approval-of-cotempla-xr-odt-methylphenidate-extended-release-orally-disintegrating-tablets-for-the-treatment-of-adhd-in-patients-6-to-17-years-old 2017-06-21T02:56:03 https://maestrodatabase.com/blog/democrats-gear-up-for-major-push-to-lower-drug-prices 2021-03-29T20:08:10 https://maestrodatabase.com/blog/my-health-record-changes-positive-step-for-consumers 2018-08-02T01:47:19 https://maestrodatabase.com/blog/teva-celiac-disease-candidate-granted-fast-track-designation-by-us-fda 2025-05-27T23:13:00 https://maestrodatabase.com/blog/u-dot-s-fda-approves-mydayis-mixed-salts-of-a-single-entity-amphetamine-product---a-new-once-daily-option-for-adhd-symptom-control-in-patients-13-years-and-older 2017-06-21T03:04:40 https://maestrodatabase.com/blog/proposal-to-fund-modified-release-pancreatic-enzyme-granules-creon-micro 2020-04-02T01:39:38 https://maestrodatabase.com/blog/fda-and-ema-to-hold-workshop-on-breakthrough-therapy-and-prime-designations 2018-08-02T01:41:27 https://maestrodatabase.com/blog/merck-receives-complete-response-letter-from-us-fda-for-supplemental-biologics-license-application-for-keytruda-pembrolizumab-in-high-risk-early-stage-triple-negative-breast-cancer 2021-03-29T20:34:54 https://maestrodatabase.com/blog/batten-disease-medication-brineura-available-to-australian-children-via-life-saving-drugs-program 2019-03-29T08:31:46 https://maestrodatabase.com/blog/icer-publishes-final-evidence-report-on-therapies-for-iga-nephropathy 2026-03-31T21:12:46 https://maestrodatabase.com/blog/pharmac-may-have-to-compete-for-measles-vaccine 2019-09-17T08:15:51 https://maestrodatabase.com/blog/beigene-receives-positive-chmp-opinion-for-tevimbra-as-a-first-line-treatment-for-nasopharyngeal-cancer 2025-05-27T22:00:17 https://maestrodatabase.com/blog/skyrizi-risankizumab-rzaa-receives-fda-approval-as-the-first-and-only-specific-interleukin-23-to-treat-moderately-to-severely-active-crohns-disease-in-adults 2022-06-17T12:17:01 https://maestrodatabase.com/blog/fda-accepts-mercks-biologics-license-application-and-grants-priority-review-for-v920-the-companys-investigational-vaccine-for-ebola-zaire-virus 2019-09-17T11:11:27 https://maestrodatabase.com/blog/with-ominous-tv-spots-and-a-senior-strike-force-aarp-launches-an-all-out-attack-on-pharma 2019-09-17T10:17:37 https://maestrodatabase.com/blog/takeda-and-tigenix-announce-that-swissmedic-has-accepted-for-review-the-file-on-cx601-for-the-treatment-of-complex-perianal-fistulas-in-crohns-disease-patients 2017-06-21T04:18:56 https://maestrodatabase.com/blog/does-anyone-really-love-private-health-insurance 2019-09-17T20:44:40 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-april-2026 2026-03-31T23:02:10 https://maestrodatabase.com/blog/surgery-for-women-with-birth-injuries-set-to-be-subsidised-again 2021-10-08T02:00:02 https://maestrodatabase.com/blog/nice-recommends-new-targeted-treatment-for-early-breast-cancer 2022-06-17T21:38:35 https://maestrodatabase.com/blog/price-controls-for-medicare-dont-put-america-first 2019-09-17T21:04:10 https://maestrodatabase.com/blog/news-nhs-england-explores-funding-options-for-cystic-fibrosis-drug 2019-09-17T20:54:38 https://maestrodatabase.com/blog/fda-takes-first-action-under-new-international-collaboration-with-australia-and-canada-designed-to-provide-a-framework-for-concurrent-review-of-cancer-therapies-approving-treatment-for-patients-with-endometrial-carcinoma 2019-09-17T20:50:21 https://maestrodatabase.com/blog/medicare-part-d-premiums-continue-to-decline-in-2019 2018-08-02T05:23:01 https://maestrodatabase.com/blog/amid-epipen-shortage-a-canadian-based-company-has-approval-for-an-alternative 2018-08-02T11:24:14 https://maestrodatabase.com/blog/sierra-oncology-announces-submission-of-new-drug-application-for-momelotinib-to-us-food-and-drug-administration 2022-06-17T22:02:33 https://maestrodatabase.com/blog/ocugen-announces-rare-paediatric-disease-designation-granted-for-ocu410st--modifier-gene-therapy-for-the-treatment-of-stargardt-disease 2025-05-28T02:54:07 https://maestrodatabase.com/blog/provisional-approval-of-lenvatinib-in-combination-with-pembrolizumab-for-the-treatment-of-advanced-endometrial-carcinoma 2019-09-17T21:09:21 https://maestrodatabase.com/blog/novartis-achieves-important-regulatory-milestone-for-amg-334-erenumab-in-migraine-prevention-with-ema-filing-acceptance 2017-06-21T05:24:33 https://maestrodatabase.com/blog/sanofi-novartis-latest-to-stockpile-drugs-in-case-of-no-deal-brexit 2018-08-02T05:17:02 https://maestrodatabase.com/blog/new-subcutaneous-formulation-of-opdivo-approved-in-canada-for-use-across-all-authorised-solid-tumour-indications 2025-05-28T03:01:23 https://maestrodatabase.com/blog/nice-publishes-final-appraisal-determination-for-sanofis-dupixent 2018-08-02T11:56:24 https://maestrodatabase.com/blog/acrux-submits-first-to-file-application-for-generic-version-of-jublia-making-it-eligible-for-180-days-of-generic-exclusivity 2018-08-02T20:33:08 https://maestrodatabase.com/blog/evolus-announces-early-resubmission-to-the-fda-of-its-biologics-licence-application-for-dwp-450 2018-08-02T20:37:05 https://maestrodatabase.com/blog/aimovig-erenumab-a-novel-treatment-developed-specifically-for-migraine-prevention-receives-health-canada-approval 2018-08-02T20:48:18 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-lists-potential-options-for-assessments-in-2019 2018-08-02T20:51:20 https://maestrodatabase.com/blog/scholar-rock-resubmits-biologics-license-application-to-fda-for-apitegromab-for-treatment-of-children-and-adults-with-spinal-muscular-atrophy 2026-04-01T03:09:47 https://maestrodatabase.com/blog/nhs-saved-ps324-million-by-switching-to-biosimilars-and-generics 2018-08-02T20:44:57 https://maestrodatabase.com/blog/fresenius-kabi-to-announce-the-commercial-launch-of-otulfi-an-approved-ustekinumab-biosimilar-in-canada 2025-05-28T06:13:08 https://maestrodatabase.com/blog/arcutis-submits-topical-roflumilast-cream-new-drug-application-to-fda-for-the-treatment-of-adults-and-adolescents-with-plaque-psoriasis 2021-10-08T03:48:20 https://maestrodatabase.com/blog/short-term-health-insurance-up-to-3-years-under-new-trump-policy 2018-08-02T21:35:08 https://maestrodatabase.com/blog/health-canada-approves-the-use-of-rinvoq-upadacitinib-for-the-treatment-of-adults-and-adolescents-with-moderate-to-severe-atopic-dermatitis 2021-10-08T04:04:12 https://maestrodatabase.com/blog/highlights-from-chmp-25-28-march-2019-meeting 2019-03-29T21:13:23 https://maestrodatabase.com/blog/cheaper-medicines-for-people-fighting-cancer-and-rare-diseases 2026-04-01T02:31:28 https://maestrodatabase.com/blog/henlius-receives-two-positive-chmp-opinions-for-serplulimab-advancing-global-regulatory-progress 2026-04-01T02:40:33 https://maestrodatabase.com/blog/tg-therapeutics-completes-rolling-submission-of-biologics-license-application-to-the-u-dot-s-fda-for-ublituximab-in-combination-with-ukoniq-umbralisib-as-a-treatment-for-patients-with-chronic-lymphocytic-leukaemia 2021-03-29T23:30:53 https://maestrodatabase.com/blog/recursion-is-granted-fda-fast-track-designation-for-rec-2282-for-the-potential-treatment-of-nf2-mutated-meningiomas 2021-10-08T04:09:33 https://maestrodatabase.com/blog/fda-approves-new-oral-treatment-for-multiple-sclerosis 2019-03-29T21:57:03 https://maestrodatabase.com/blog/docs-use-rubber-stamp-for-drugs 2021-10-08T21:11:08 https://maestrodatabase.com/blog/canadas-amendment-to-patented-drug-price-regulation-a-prescription-for-global-drug-cost-control 2019-03-29T22:02:49 https://maestrodatabase.com/blog/chemocentryx-announces-fda-approval-of-tavneos-avacopan-in-anca-associated-vasculitis 2021-10-08T21:19:24 https://maestrodatabase.com/blog/bluebird-bio-receives-positive-opinion-from-chmp-for-zynteglo-autologous-cd34-plus-cells-encoding-ba-t87q-globin-gene-gene-therapy-for-patients-12-years-and-older-with-transfusion-dependent-b-thalassemia-who-do-not-have-b0-slash-b0-genotype 2019-03-30T01:33:00 https://maestrodatabase.com/blog/booster-shot-for-severely-immunocompromised-australians 2021-10-08T04:20:24 https://maestrodatabase.com/blog/y-mabs-announces-submission-of-naxitamab-biologics-license-application-to-u-dot-s-fda 2020-04-02T03:57:07 https://maestrodatabase.com/blog/spero-therapeutics-receives-fda-fast-track-designation-for-spr994-for-the-treatment-of-complicated-urinary-tract-infections-and-acute-pyelonephritis 2019-03-30T01:39:58 https://maestrodatabase.com/blog/european-commission-approves-extension-of-indication-for-otsukas-jinarc-tolvaptan-to-include-treatment-of-adpkd-patients-with-advanced-chronic-kidney-disease-ckd-stage-4 2018-08-03T07:52:53 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-european-commission-approval-for-the-subcutaneous-formulation-of-opdivo-nivolumab-across-multiple-solid-tumour-indications 2025-05-28T21:37:20 https://maestrodatabase.com/blog/statement-by-fda-commissioner-director-of-fdas-center-for-drug-evaluation-and-research-and-director-of-fdas-center-for-biologics-evaluation-and-research-on-expanded-access-looking-forward 2019-03-30T02:52:19 https://maestrodatabase.com/blog/myovant-sciences-announces-european-medicines-agency-validation-of-marketing-authorisation-application-for-relugolix-for-the-treatment-of-advanced-prostate-cancer 2021-03-30T02:33:16 https://maestrodatabase.com/blog/celltrions-biosimilar-herzuma-approved-in-australia 2018-08-03T08:01:46 https://maestrodatabase.com/blog/fda-working-to-lift-barriers-to-generic-drug-competition 2017-06-21T20:42:06 https://maestrodatabase.com/blog/diurnals-european-marketing-authorisation-application-for-chronocort-passes-validation-stage-with-ema 2020-04-02T04:03:27 https://maestrodatabase.com/blog/draft-order-on-drug-prices-proposes-easing-regulations 2017-06-21T20:48:40 https://maestrodatabase.com/blog/senate-gop-leaders-will-present-health-bill-this-week-even-as-divisions-flare 2017-06-21T20:45:05 https://maestrodatabase.com/blog/patient-need-must-be-first-priority-in-public-hospitals 2017-06-21T21:04:39 https://maestrodatabase.com/blog/agreement-with-arjohuntleigh-limited-for-the-supply-of-medical-devices-used-in-the-prevention-of-venous-thromboembolism 2017-06-21T21:00:50 https://maestrodatabase.com/blog/visiting-patient-advocates-say-new-zealand-isnt-treating-its-cancer-patients-fairly 2018-08-03T08:43:43 https://maestrodatabase.com/blog/transparency-commission-publishes-opinion-for-keytruda 2017-06-21T21:10:34 https://maestrodatabase.com/blog/samsung-bioepis-continues-global-market-expansion-with-launch-of-hadlima-in-australia-and-canada-in-partnership-with-merck 2021-03-30T02:38:28 https://maestrodatabase.com/blog/daratumumab-in-combination-with-lenalidomide-and-dexamethasone-for-the-first-line-treatment-of-patients-with-multiple-myeloma-when-stem-cell-transplantation-is-unsuitable 2023-02-23T04:05:13 https://maestrodatabase.com/blog/pfizer-biontech-covid-19-vaccine-receives-fda-emergency-use-authorisation-for-children-6-months-through-4-years-of-age 2022-06-18T05:12:25 https://maestrodatabase.com/blog/seqirus-announces-positive-chmp-opinion-for-its-adjuvanted-quadrivalent-influenza-vaccine 2020-04-02T06:40:08 https://maestrodatabase.com/blog/covid-19-has-changed-how-the-world-does-science-together 2020-04-02T11:29:18 https://maestrodatabase.com/blog/ema-grants-prime-status-for-roche-huntingtons-drug 2018-08-04T00:03:25 https://maestrodatabase.com/blog/us-fda-accepts-new-drug-application-under-priority-review-for-sevabertinib-bay-2927088-in-her2-mutant-non-small-cell-lung-cancer 2025-05-28T23:11:54 https://maestrodatabase.com/blog/more-ill-as-state-waits-for-vaccine 2018-08-04T00:35:03 https://maestrodatabase.com/blog/canada-urges-halt-in-use-of-astrazeneca-covid-19-vaccine-in-people-under-55 2021-03-30T04:55:31 https://maestrodatabase.com/blog/candel-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-designation-for-can-2409-for-the-treatment-of-prostate-cancer 2025-05-28T23:18:31 https://maestrodatabase.com/blog/karyopharm-receives-conditional-marketing-authorisation-from-the-european-commission-for-nexpovio-selinexor-in-combination-with-dexamethasone-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-multiple-myeloma 2021-03-30T05:08:51 https://maestrodatabase.com/blog/statement-from-fda-commissioner-scott-gottlieb-on-new-steps-the-agency-is-taking-to-support-the-development-of-novel-nicotine-replacement-drug-therapies-to-help-smokers-quit-cigarettes 2018-08-04T00:48:48 https://maestrodatabase.com/blog/most-expensive-treatments-remain-out-of-reach-without-health-reform 2024-08-19T04:52:20 https://maestrodatabase.com/blog/icer-updated-report-on-targeted-treatments-for-plaque-psoriasis-finds-guselkumab-and-risankizumab-offer-superior-health-benefit-compared-with-tnfa-inhibitors 2018-08-04T00:56:38 https://maestrodatabase.com/blog/experimental-drug-development-centre-granted-us-fda-fast-track-designation-for-antibody-drug-conjugate-ebc-129-to-treat-pancreatic-ductal-adenocarcinoma 2025-05-28T23:34:05 https://maestrodatabase.com/blog/moderna-receives-fda-authorisation-for-emergency-use-of-its-covid-19-vaccine-for-children-6-months-of-age-and-older 2022-06-18T05:56:13 https://maestrodatabase.com/blog/major-incorrect-fact-in-the-annual-review-of-pharmac 2019-03-30T23:21:05 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-april-2026 2026-04-01T06:22:02 https://maestrodatabase.com/blog/how-drug-companies-are-beating-trump-at-his-own-game 2018-08-04T00:41:31 https://maestrodatabase.com/blog/icer-final-report-highlights-limitations-in-evidence-on-long-term-safety-and-effectiveness-of-elagolix-for-endometriosis-discusses-options-for-insurance-coverage-criteria 2018-08-04T01:03:10 https://maestrodatabase.com/blog/enhertu-granted-breakthrough-therapy-designation-in-us-for-certain-patients-with-her2-low-or-her2-ultralow-metastatic-breast-cancer 2024-08-19T06:43:38 https://maestrodatabase.com/blog/health-canada-taking-further-action-to-confirm-the-benefit-risk-profile-of-the-astrazeneca-vaccine 2021-03-30T05:56:30 https://maestrodatabase.com/blog/covid-19-australia-to-get-virus-miracle-drug-soon 2020-04-02T20:13:22 https://maestrodatabase.com/blog/vir-biotechnology-announces-positive-final-draft-guidance-on-sotrovimab-from-the-uks-nice 2023-02-23T05:50:33 https://maestrodatabase.com/blog/pfizer-receives-expanded-health-canada-approval-for-ibrance 2017-06-22T10:25:05 https://maestrodatabase.com/blog/injection-for-more-than-a-million-people-to-help-prevent-heart-attacks-and-strokes-recommended 2026-04-01T07:53:39 https://maestrodatabase.com/blog/csiro-scientists-in-australia-start-testing-potential-coronavirus-vaccine-on-ferrets 2020-04-02T20:17:01 https://maestrodatabase.com/blog/incyte-announces-the-european-commission-approval-of-pemazyre-pemigatinib-as-a-treatment-for-adults-with-locally-advanced-or-metastatic-cholangiocarcinoma-with-a-fibroblast-growth-factor-receptor-2-fusion-or-rearrangement 2021-03-30T05:44:47 https://maestrodatabase.com/blog/seattle-genetics-submits-supplemental-biologics-license-application-to-fda-for-adcetris-brentuximab-vedotin-in-cutaneous-t-cell-lymphoma 2017-06-22T10:35:28 https://maestrodatabase.com/blog/genentechs-anti-amyloid-beta-antibody-gantenerumab-granted-fda-breakthrough-therapy-designation-in-alzheimers-disease 2021-10-08T22:42:35 https://maestrodatabase.com/blog/patents-and-negotiations-three-new-reports-dig-in-on-drug-prices 2018-08-04T01:17:30 https://maestrodatabase.com/blog/release-of-the-reviews-interim-report 2017-06-22T11:05:07 https://maestrodatabase.com/blog/pfizer-receives-european-approval-for-oncology-biosimilar-ruxience-rituximab 2020-04-02T20:38:40 https://maestrodatabase.com/blog/more-help-with-medications-through-community-pharmacies 2017-06-22T10:56:41 https://maestrodatabase.com/blog/enhertu-type-ii-variation-application-validated-by-ema-for-patients-with-her2-low-or-her2-ultralow-metastatic-breast-cancer-following-at-least-one-endocrine-therapy 2024-08-19T07:10:12 https://maestrodatabase.com/blog/biosimilars-could-disappear-if-the-supreme-court-overturns-the-aca 2020-04-02T20:43:04 https://maestrodatabase.com/blog/update-from-the-pbac-august-2024 2024-08-19T07:03:15 https://maestrodatabase.com/blog/clinical-trial-of-gileads-coronavirus-hopeful-remdesivir-begins-in-uk 2020-04-02T20:49:31 https://maestrodatabase.com/blog/ema-urges-caution-on-malaria-drugs-use-for-covid-19-in-absence-of-evidence 2020-04-02T20:22:41 https://maestrodatabase.com/blog/new-pbs-listing-for-migalastat-galafold-for-the-treatment-of-fabry-disease 2024-08-19T06:57:54 https://maestrodatabase.com/blog/a-nice-transformation 2020-04-02T20:27:35 https://maestrodatabase.com/blog/canadian-lupus-patients-missing-critical-drug-after-claims-it-treats-coronavirus 2020-04-02T20:33:27 https://maestrodatabase.com/blog/nice-approves-copd-treatment-roflumilast-for-routine-nhs-use 2017-06-22T11:59:21 https://maestrodatabase.com/blog/blood-cancer-treatment-added-to-pbs 2020-04-02T20:53:42 https://maestrodatabase.com/blog/covid-19-vaccine-safety-report-23-february-2023 2023-02-23T06:03:25 https://maestrodatabase.com/blog/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program 2026-04-01T19:57:33 https://maestrodatabase.com/blog/truvada-removed-from-pbs-in-australia-but-affordable-generic-prep-alternatives-available 2020-04-02T20:56:24 https://maestrodatabase.com/blog/turmoil-in-the-individual-insurance-market----where-it-came-from-and-how-to-fix-it 2017-06-22T12:04:30 https://maestrodatabase.com/blog/consumer-voice-for-community-pharmacy 2017-06-22T20:51:25 https://maestrodatabase.com/blog/onward-receives-new-fda-breakthrough-device-designations-for-bladder-control-alleviation-of-spasticity-and-blood-pressure-regulation-after-spinal-cord-injury 2023-02-23T09:55:47 https://maestrodatabase.com/blog/health-funds-say-lifetime-health-cover-loading-has-lost-desired-effect-over-17-years 2017-06-22T20:48:10 https://maestrodatabase.com/blog/centers-for-medicare-and-medicaid-services-administrator-seema-verma-commends-senates-progress-on-healthcare-reform-bill 2017-06-22T20:57:25 https://maestrodatabase.com/blog/clinical-trials-provide-$1-dot-1b-to-australian-economy-mtpconnect-releases-report-on-clinical-trials-ecosystem-in-australia 2017-06-22T20:54:31 https://maestrodatabase.com/blog/senate-health-care-draft-repeals-obamacare-taxes-provides-bigger-subsidies-for-low-income-americans-than-house-bill 2017-06-22T21:07:03 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-releases-final-value-assessment-framework-for-2017-2019 2017-06-22T21:01:33 https://maestrodatabase.com/blog/ema-validates-bristol-myers-squibbs-application-for-car-t-cell-therapy-breyanzi-for-relapsed-or-refractory-follicular-lymphoma 2024-08-19T11:24:12 https://maestrodatabase.com/blog/fda-approves-rituxan-hycela-rituximab-and-hyaluronidase-human-for-subcutaneous-injection-in-certain-blood-cancers 2017-06-22T21:25:33 https://maestrodatabase.com/blog/trump-plan-aims-to-be-pro-pharma-and-cut-drug-prices 2017-06-22T21:20:22 https://maestrodatabase.com/blog/janssen-submits-application-seeking-u-dot-s-fda-approval-of-stelara-ustekinumab-for-the-treatment-of-paediatric-patients-with-juvenile-psoriatic-arthritis 2021-10-08T23:01:15 https://maestrodatabase.com/blog/will-trumps-fda-relax-standards-for-drug-approval-well-get-a-clue-soon-with-decision-on-portolas-anticoagulant 2017-06-22T21:34:46 https://maestrodatabase.com/blog/ema-accepts-the-marketing-authorisation-applications-for-two-additional-indications-of-anti-cancer-agent-lenvatinib-in-combination-with-pembrolizumab-as-a-treatment-for-advanced-renal-cell-carcinoma-and-advanced-endometrial-carcinoma 2021-03-30T20:08:29 https://maestrodatabase.com/blog/moleculin-receives-fda-approval-of-fast-track-designation-for-annamycin-in-the-treatment-of-sarcoma-lung-metastases 2021-03-30T20:00:19 https://maestrodatabase.com/blog/fda-continues-important-work-to-advance-medical-products-for-patients-with-rare-diseases 2023-02-23T20:27:30 https://maestrodatabase.com/blog/novartis-combination-targeted-therapy-tafinlar-and-mekinist-receives-fda-approval-for-braf-v600e-mutant-metastatic-non-small-cell-lung-cancer 2017-06-22T21:47:08 https://maestrodatabase.com/blog/terminal-cancer-patients-denied-new-treatments-due-to-slow-tga-approval 2021-03-30T20:15:13 https://maestrodatabase.com/blog/us-medicare-says-no-change-to-alzheimers-drug-restrictions 2023-02-23T20:13:32 https://maestrodatabase.com/blog/germany-to-restrict-astrazeneca-use-in-under-60s-over-clots 2021-03-30T19:49:53 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-abbvies-new-drug-application-for-atogepant-for-the-preventive-treatment-of-migraine 2021-03-30T19:46:28 https://maestrodatabase.com/blog/aflibercept-8-mg-bla-for-treatment-of-wet-age-related-macular-degeneration-and-diabetic-macular-oedema-accepted-for-fda-priority-review 2023-02-23T20:08:08 https://maestrodatabase.com/blog/oculis-announces-ema-prime-designation-for-privosegtor-advancing-a-potential-first-in-class-neuroprotective-candidate-for-optic-neuritis 2026-04-01T22:23:26 https://maestrodatabase.com/blog/moderna-and-merck-announce-mrna-4157-slash-v940-an-investigational-personalised-mrna-cancer-vaccine-in-combination-with-pembrolizumab-was-granted-breakthrough-therapy-designation-by-the-fda-for-adjuvant-treatment-of-patients-with-high-risk-melanoma-following-complete-resection 2023-02-23T19:50:00 https://maestrodatabase.com/blog/octapharma-usa-requests-fda-approval-for-wilate-vwd-prophylaxis-supplement 2023-02-23T20:00:11 https://maestrodatabase.com/blog/akebia-submits-new-drug-application-to-the-fda-for-vadadustat-for-the-treatment-of-anaemia-due-to-chronic-kidney-disease-in-adult-patients-on-dialysis-and-not-on-dialysis 2021-03-30T19:55:23 https://maestrodatabase.com/blog/alcon-announces-fda-approval-of-tryptyr-acoltremon-ophthalmic-solution-0-dot-003-percent-for-the-treatment-of-the-signs-and-symptoms-of-dry-eye-disease 2025-05-29T01:07:47 https://maestrodatabase.com/blog/pfizer-and-biontech-submit-ema-application-for-covid-19-vaccine-targeting-lp-dot-8-1-for-2025-2026-season 2025-05-29T01:15:47 https://maestrodatabase.com/blog/orca-bio-announces-fda-review-extension-of-bla-for-orca-t-for-the-treatment-of-haematologic-malignancies 2026-04-01T20:13:24 https://maestrodatabase.com/blog/bavarian-nordic-submits-data-to-ema-to-extend-mpox-slash-smallpox-vaccine-approval-to-adolescents 2024-08-19T21:27:53 https://maestrodatabase.com/blog/phenylketonuria-sufferer-has-new-hope-for-wonder-drug-after-government-responds-to-plea 2021-03-30T20:34:25 https://maestrodatabase.com/blog/us-fda-approves-sanofis-bleeding-disorder-therapy 2023-02-23T20:44:58 https://maestrodatabase.com/blog/vertex-announces-us-fda-approval-for-label-extensions-of-alyftrek-and-trikafta-expanding-availability-of-these-medicines-to-~95-percent-of-all-people-with-cf-in-the-united-states 2026-04-01T22:05:40 https://maestrodatabase.com/blog/nice-methods-and-process-review-aims-to-create-fertile-ground-for-innovation 2021-03-30T20:25:43 https://maestrodatabase.com/blog/arcutis-submits-roflumilast-0-dot-3-percent-topical-foam-new-drug-application-to-the-fda-for-the-treatment-of-seborrheic-dermatitis-in-adults-and-adolescents 2023-02-23T20:32:32 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-april-2019-update 2019-03-31T09:19:50 https://maestrodatabase.com/blog/fda-approves-innovative-treatment-for-paediatric-patients-with-congenital-athymia 2021-10-09T00:08:18 https://maestrodatabase.com/blog/bernie-sanders-vows-to-cut-prescription-drug-prices-by-half-if-hes-elected 2019-03-31T20:21:26 https://maestrodatabase.com/blog/u-dot-s-fda-approves-supplemental-new-drug-application-for-erleada-apalutamide-for-the-treatment-of-patients-with-metastatic-castration-sensitive-prostate-cancer 2019-09-18T02:13:02 https://maestrodatabase.com/blog/current-issues-in-health-technology-assessment-of-cancer-therapies-a-survey-of-stakeholders-and-opinion-leaders-in-australia 2022-06-19T21:27:00 https://maestrodatabase.com/blog/klobuchar-porter-call-for-ftc-to-investigate-price-hikes-by-janssen-bristol-myers-squibb 2022-06-19T21:22:29 https://maestrodatabase.com/blog/fda-approves-lillys-foundayo-orforglipron-the-only-glp-1-pill-for-weight-loss-that-can-be-taken-any-time-of-day-without-food-or-water-restrictions 2026-04-01T22:39:12 https://maestrodatabase.com/blog/canadian-drug-prices-new-regulations-could-save-billions-of-dollars 2022-06-19T21:13:06 https://maestrodatabase.com/blog/egetis-therapeutics-receives-fda-fast-track-designation-for-emcitate-for-mct8-deficiency 2021-10-09T00:51:46 https://maestrodatabase.com/blog/canadian-regulator-oks-hugels-botulinum-toxin-product 2022-06-19T21:17:58 https://maestrodatabase.com/blog/fda-grants-insys-therapeutics-fast-track-designation-for-cannabidiol-oral-solution-as-investigational-treatment-for-prader-willi-syndrome 2017-12-27T04:29:41 https://maestrodatabase.com/blog/alpha-tau-receives-fdas-breakthrough-device-designation-for-the-treatment-of-recurrent-glioblastoma-multiforme 2021-10-09T06:19:57 https://maestrodatabase.com/blog/start-of-rolling-review-for-adapted-spikevax-covid-19-vaccine 2022-06-19T21:00:19 https://maestrodatabase.com/blog/ip-waiver-for-covid-vaccines-is-a-threat-to-future-innovation 2022-06-19T21:40:42 https://maestrodatabase.com/blog/delmar-pharmaceuticals-announces-fast-track-designation-for-val-083-in-recurrent-glioblastoma 2017-12-27T04:40:22 https://maestrodatabase.com/blog/drug-pricing-debate-in-washington-is-a-headache-for-pharma 2022-06-19T21:33:20 https://maestrodatabase.com/blog/eu-hta-regulation-international-preparatory-meeting-in-cologne 2022-06-19T21:37:44 https://maestrodatabase.com/blog/agios-submits-new-drug-application-to-the-fda-for-ivosidenib-for-the-treatment-of-patients-with-relapsed-slash-refractory-acute-myeloid-leukaemia-and-an-idh1-mutation 2017-12-27T05:05:14 https://maestrodatabase.com/blog/amarin-receives-european-commission-approval-for-vazkepa-to-reduce-cardiovascular-risk 2021-03-31T04:53:47 https://maestrodatabase.com/blog/roches-evrysdi-approved-by-european-commission-as-first-and-only-at-home-treatment-for-spinal-muscular-atrophy 2021-03-31T05:02:31 https://maestrodatabase.com/blog/vfmcrp-and-cara-therapeutics-announce-european-medicines-agency-has-accepted-to-review-the-marketing-authorisation-application-for-difelikefalin 2021-03-31T04:48:52 https://maestrodatabase.com/blog/my-health-record-can-store-genomic-data-but-critics-say-its-not-ready 2018-08-05T21:12:01 https://maestrodatabase.com/blog/jazz-pharmaceuticals-announces-fda-approval-of-additional-indication-for-vyxeos-daunorubicin-and-cytarabine-for-the-treatment-of-secondary-acute-myeloid-leukaemia-in-paediatric-patients 2021-03-31T06:06:20 https://maestrodatabase.com/blog/ontozry-cenobamate-receives-european-commission-approval-for-the-treatment-of-drug-resistant-focal-onset-seizures-in-adults 2021-03-31T06:11:33 https://maestrodatabase.com/blog/evive-biotech-submits-biologics-license-application-to-us-fda-for-ryzneuta 2021-03-31T05:09:23 https://maestrodatabase.com/blog/agenda-for-the-july-2021-pbac-meeting 2021-04-06T04:42:58 https://maestrodatabase.com/blog/novartis-receives-eu-approval-for-kesimpta-ofatumumab-the-first-and-only-self-administered-targeted-b-cell-therapy-for-adult-patients-with-relapsing-multiple-sclerosis 2021-03-31T05:15:01 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-april-2021 2021-03-31T19:57:30 https://maestrodatabase.com/blog/biden-in-no-rush-to-pick-new-fda-chief 2021-03-31T20:03:56 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-april-2021 2021-03-31T09:47:54 https://maestrodatabase.com/blog/nice-recommends-sobis-kineret-for-first-line-use-in-stills-disease 2021-03-31T09:41:22 https://maestrodatabase.com/blog/nice-publishes-guidance-on-new-use-for-kisqali 2021-03-31T20:23:56 https://maestrodatabase.com/blog/trump-gave-drug-companies-a-last-minute-win-on-prescription-prices-democrats-want-biden-to-roll-it-back 2021-03-31T20:28:45 https://maestrodatabase.com/blog/bluestar-genomics-receives-fda-breakthrough-device-designation-for-first-of-its-kind-pancreatic-cancer-screening-test 2021-03-31T20:15:41 https://maestrodatabase.com/blog/realta-life-sciences-granted-fda-orphan-drug-designation-and-fast-track-designation-for-rls-0071-for-the-treatment-of-steroid-refractory-acute-graft-versus-host-disease 2024-08-20T01:20:46 https://maestrodatabase.com/blog/vertical-pharmaceuticals-announces-submission-of-new-drug-application-for-rvl-1201 2019-09-18T03:06:35 https://maestrodatabase.com/blog/premia-spine-announces-fda-breakthrough-device-designation-for-its-tops-spinal-arthroplasty-system 2021-03-31T20:20:01 https://maestrodatabase.com/blog/arthrosi-therapeutics-receives-fda-fast-track-designation-for-ar882-in-tophaceous-gout 2024-08-20T01:16:30 https://maestrodatabase.com/blog/fda-approves-sarclisa-isatuximab-in-combination-with-carfilzomib-and-dexamethasone-for-patients-with-relapsed-or-refractory-multiple-myeloma 2021-03-31T22:20:48 https://maestrodatabase.com/blog/eton-pharmaceuticals-announces-us-fda-approval-for-khindivi-hydrocortisone-oral-solution 2025-05-29T22:12:45 https://maestrodatabase.com/blog/patritumab-deruxtecan-biologics-license-application-for-patients-with-previously-treated-locally-advanced-or-metastatic-egfr-mutated-non-small-cell-lung-cancer-voluntarily-withdrawn 2025-05-29T22:22:07 https://maestrodatabase.com/blog/astrazeneca-covid-19-vaccine-review-of-very-rare-cases-of-unusual-blood-clots-continues 2021-03-31T22:45:31 https://maestrodatabase.com/blog/biofrontera-files-label-extension-for-ameluz-in-eu-to-include-treatment-of-actinic-keratosis-on-extremities-and-trunk-slash-neck 2019-09-18T03:28:32 https://maestrodatabase.com/blog/fda-approves-first-subcutaneous-c1-esterase-inhibitor-to-treat-rare-genetic-disease 2017-06-23T04:47:56 https://maestrodatabase.com/blog/brii-bio-initiates-submission-of-emergency-use-authorisation-filing-to-u-dot-s-fda-for-brii-196-slash-brii-198-its-monoclonal-antibody-combination-therapy-for-non-hospitalised-covid-19-patients-at-high-risk-of-clinical-progression-to-severe-disease 2021-10-10T05:02:04 https://maestrodatabase.com/blog/fasenra-approved-in-china-for-the-treatment-of-severe-eosinophilic-asthma 2024-08-20T10:50:29 https://maestrodatabase.com/blog/patients-to-save-tens-of-thousands-on-two-key-cancer-drugs 2019-04-01T02:07:26 https://maestrodatabase.com/blog/zealand-pharma-submits-new-drug-application-to-the-u-dot-s-fda-for-the-dasiglucagon-hypopal-rescue-pen-for-treatment-of-severe-hypoglycemia 2020-04-03T03:06:17 https://maestrodatabase.com/blog/merck-receives-positive-eu-chmp-opinion-for-updated-label-of-keytruda-pembrolizumab-to-include-results-of-phase-3-keynote-361-trial-in-certain-adult-patients-with-locally-advanced-or-metastatic-urothelial-cancer 2021-03-31T22:58:21 https://maestrodatabase.com/blog/chinas-nmpa-approves-padcev-enfortumab-vedotin-for-treatment-of-locally-advanced-or-metastatic-urothelial-cancer 2024-08-20T05:42:07 https://maestrodatabase.com/blog/new-covid-19-vaccines-available-to-target-current-variants 2023-11-20T07:06:53 https://maestrodatabase.com/blog/new-fda-chief-cant-come-soon-enough-for-beleaguered-agency 2021-10-10T04:59:31 https://maestrodatabase.com/blog/haegarda-c1-esterase-inhibitor-subcutaneous-human-fda-approval 2017-06-23T04:57:57 https://maestrodatabase.com/blog/european-commission-grants-second-indication-approval-for-tepkinly-epcoritamab-for-the-treatment-of-adults-with-relapsed-slash-refractory-follicular-lymphoma 2024-08-20T05:28:08 https://maestrodatabase.com/blog/icer-publishes-evidence-report-on-treatment-for-secondary-progressive-multiple-sclerosis 2025-05-29T22:59:08 https://maestrodatabase.com/blog/u-dot-s-fda-acknowledges-receipt-of-intellipharmaceutics-resubmission-of-oxycodone-er-new-drug-application-deems-it-a-complete-response-and-designates-28-august-2019-as-goal-date-for-review 2019-04-01T03:09:59 https://maestrodatabase.com/blog/capsida-receives-fda-fast-track-designation-for-its-potential-first-in-class-iv-administered-gene-therapy-for-stxbp1-developmental-and-epileptic-encephalopathy 2025-05-29T23:11:41 https://maestrodatabase.com/blog/psivida-submits-marketing-authorisation-application-for-approval-of-durasert-three-year-treatment-for-posterior-segment-uveitis-in-the-european-union 2017-06-23T06:51:36 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-april-2019-update 2019-04-01T03:44:50 https://maestrodatabase.com/blog/zydus-receives-us-fda-fast-track-designation-for-usnoflast-a-novel-oral-nlrp3-inhibitor-for-the-treatment-of-amyotrophic-lateral-sclerosis 2025-05-29T23:17:07 https://maestrodatabase.com/blog/the-fda-is-at-a-crossroads-on-cell-and-gene-therapies 2023-11-20T09:42:07 https://maestrodatabase.com/blog/1-april-2019-price-disclosure-confirmed-prices 2019-04-01T03:55:47 https://maestrodatabase.com/blog/viiv-healthcare-receives-eu-marketing-authorisation-for-triumeq-pd-the-first-dispersible-single-tablet-regimen-containing-dolutegravir-a-once-daily-treatment-for-children-living-with-hiv-in-europe 2023-02-24T03:49:37 https://maestrodatabase.com/blog/assessing-data-sources-for-medicine-price-studies 2019-04-01T03:52:02 https://maestrodatabase.com/blog/the-stepped-wedge-cluster-randomised-trial-what-it-is-and-when-it-should-be-used 2019-04-01T03:48:58 https://maestrodatabase.com/blog/a2-biotherapeutics-receives-us-fda-fast-track-designation-for-a2b543-a-logic-gated-car-t-cell-therapy-enhanced-with-a-membrane-tethered-il-12-booster 2026-04-02T01:28:02 https://maestrodatabase.com/blog/breast-cancer-and-rare-skin-cancer-medicines-on-the-pbs 2019-04-01T04:10:00 https://maestrodatabase.com/blog/foresee-pharmaceuticals-announces-submission-of-nda-for-fda-approval-of-lmis-50-mg 2020-07-28T10:37:22 https://maestrodatabase.com/blog/pharmac-negotiates-deal-for-molnupiravir-to-treat-covid-19 2021-10-10T19:54:31 https://maestrodatabase.com/blog/70-percent-of-kiwis-want-government-to-give-pharmac-more-money---survey 2021-10-10T19:51:29 https://maestrodatabase.com/blog/circassia-announces-fda-approval-of-tudorza-supplemental-new-drug-application 2019-04-01T06:17:11 https://maestrodatabase.com/blog/novartis-kisqali-ribociclib-receives-positive-chmp-opinion-as-first-line-treatment-for-hr-plus-slash-her2--locally-advanced-or-metastatic-breast-cancer-in-combination-with-any-aromatase-inhibitor 2017-06-23T11:15:53 https://maestrodatabase.com/blog/recommendations-made-out-of-session-by-the-pbac-november-2022-and-march-2023-meetings 2023-02-24T05:35:26 https://maestrodatabase.com/blog/provinces-lead-the-way-towards-pharmacare-in-canada 2017-06-23T11:24:20 https://maestrodatabase.com/blog/fda-approves-once-weekly-altuviiio-a-new-class-of-factor-viii-therapy-for-haemophilia-a-that-offers-significant-bleed-protection 2023-02-24T05:25:47 https://maestrodatabase.com/blog/fda-approves-lazertinib-with-amivantamab-vmjw-for-non-small-lung-cancer 2024-08-20T12:21:22 https://maestrodatabase.com/blog/pasithea-therapeutics-announces-grant-of-fast-track-designation-by-fda-to-pas-004-for-treatment-of-neurofibromatosis-type-1-associated-plexiform-neurofibromas-causing-significant-morbidity 2026-04-02T02:00:09 https://maestrodatabase.com/blog/covid-19-and-the-supply-and-distribution-of-generic-and-biosimilar-prescription-medicines-in-canada 2020-04-03T05:15:12 https://maestrodatabase.com/blog/janssen-submits-supplemental-biologics-license-application-to-us-fda-seeking-approval-of-rybrevant-amivantamab-vmjw-plus-chemotherapy-for-the-treatment-of-patients-with-egfr-mutated-non-small-cell-lung-cancer-who-progressed-on-or-after-osimertinib 2023-11-20T19:54:11 https://maestrodatabase.com/blog/fda-grants-breakthrough-therapy-designation-for-roches-gazyva-obinutuzumab-in-lupus-nephritis 2019-09-18T10:41:21 https://maestrodatabase.com/blog/bristol-myers-squibb-and-2seventy-bio-provide-update-on-us-fda-review-of-sbla-for-abecma-idecabtagene-vicleucel-in-earlier-lines-of-therapy-for-triple-class-exposed-relapsed-or-refractory-multiple-myeloma 2023-11-20T19:45:11 https://maestrodatabase.com/blog/a-childs-health-should-not-be-a-postcode-lottery-anger-of-cystic-fibrosis-sufferers-forced-to-pay-ps20-000-for-drug-abroad 2019-09-18T11:17:17 https://maestrodatabase.com/blog/selumetinib-granted-us-breakthrough-therapy-designation-in-neurofibromatosis-type-1 2019-04-01T10:14:16 https://maestrodatabase.com/blog/regulatory-information---1-dot-7-percent-increase-of-fees-from-1-april-2019 2019-04-01T08:20:25 https://maestrodatabase.com/blog/susan-g-komen-big-data-for-breast-cancer-initiative-how-patient-advocacy-organisations-can-facilitate-using-big-data-to-improve-patient-outcomes 2019-09-18T11:07:21 https://maestrodatabase.com/blog/fda-continues-steps-to-promote-innovation-in-medical-devices-that-help-advance-patient-safety-through-the-safer-technologies-program 2019-09-18T20:47:27 https://maestrodatabase.com/blog/international-regulators-discuss-available-knowledge-supporting-covid-19-medicine-development 2020-04-03T11:08:29 https://maestrodatabase.com/blog/teva-announces-approval-of-a-generic-version-of-forteo-teriparatide-injection-in-the-us 2023-11-20T20:17:53 https://maestrodatabase.com/blog/apollomics-announces-the-first-approval-of-vebreltinib-for-met-exon-14-skip-non-small-cell-lung-cancer 2023-11-20T20:08:23 https://maestrodatabase.com/blog/three-year-old-matildas-ability-to-walk-is-giving-hope-to-those-with-spinal-muscular-atrophy 2019-09-18T11:53:07 https://maestrodatabase.com/blog/landmark-medicines-deal-to-boost-nations-health-save-nhs-ps14-billion-and-support-research-investment 2023-11-20T20:04:22 https://maestrodatabase.com/blog/nice-recommends-takhzyro 2019-09-18T11:43:03 https://maestrodatabase.com/blog/u-dot-s-fda-grants-fast-track-designation-for-biocrysts-bcx7353 2018-08-06T12:20:04 https://maestrodatabase.com/blog/health-technology-agency-insights-informing-modification-of-a-qualitative-benefit-risk-framework-for-health-technology-reassessment-of-prescription-medications 2019-09-18T21:00:12 https://maestrodatabase.com/blog/nice-gets-ready-to-assess-new-dementia-treatments 2023-11-20T20:00:41 https://maestrodatabase.com/blog/health-insurance-that-doesnt-cover-the-bills-has-flooded-the-market-under-trump 2019-09-18T20:56:26 https://maestrodatabase.com/blog/janssen-receives-positive-chmp-opinion-to-expand-invokana-and-vokanamet-labelling-to-include-positive-data-on-cardiovascular-morbidity-and-mortality 2018-08-06T12:13:48 https://maestrodatabase.com/blog/fda-issues-final-guidance-to-address-gaming-by-the-use-of-citizen-petitions 2019-09-18T20:50:08 https://maestrodatabase.com/blog/xanax-still-being-overprescribed-despite-policy-changes 2019-09-18T21:21:19 https://maestrodatabase.com/blog/shionogi-announces-submission-of-cefiderocol-marketing-authorisation-application 2019-04-01T20:20:27 https://maestrodatabase.com/blog/medicare-part-d-rebates-substantially-reduced-drug-spending-but-not-enough-to-offset-price-hikes 2019-09-18T21:12:20 https://maestrodatabase.com/blog/abbvies-epkinly-gets-health-insurance-coverage-for-dlbcl-in-korea 2026-04-02T03:39:00 https://maestrodatabase.com/blog/complete-response-letter-issued-for-remoxy 2018-08-06T12:24:54 https://maestrodatabase.com/blog/pharmac-called-out-over-failure-to-fund-breast-cancer-drug-ibrance 2019-04-01T20:10:03 https://maestrodatabase.com/blog/baby-pia-almost-1-million-belgians-pay-for-life-saving-drug 2019-09-18T21:07:14 https://maestrodatabase.com/blog/nice-20-years-of-evidence-based-decision-making 2019-04-01T20:07:06 https://maestrodatabase.com/blog/fda-takes-new-steps-to-encourage-the-development-of-novel-medicines-for-the-treatment-of-opioid-use-disorder 2018-08-06T13:50:11 https://maestrodatabase.com/blog/listing-of-new-medicines-on-the-pbs---are-we-soon-to-change-to-an-el-nino-pattern 2019-04-01T20:30:13 https://maestrodatabase.com/blog/no-deal-brexit-could-mean-temporary-medicines-export-ban 2019-04-01T20:27:11 https://maestrodatabase.com/blog/kamada-announces-withdrawal-of-european-marketing-authorisation-application-for-inhaled-alfa-1-anti-trypsin-for-treatment-of-alfa-1-anti-trypsin-deficiency-disease 2017-06-23T13:00:11 https://maestrodatabase.com/blog/epipen-shortage-is-critical---and-not-easy-to-fix 2018-08-06T12:35:26 https://maestrodatabase.com/blog/duncan-garners-desperate-plea-to-jacinda-ardern-over-cancer-funding 2018-08-06T21:24:02 https://maestrodatabase.com/blog/us-fda-approves-foundationone-cdx-as-a-companion-diagnostic-for-astrazenecas-truqap-capivasertib-in-combination-with-faslodex-fulvestrant-to-identify-patients-with-hr-positive-her2-negative-advanced-breast-cancer 2023-11-20T22:25:43 https://maestrodatabase.com/blog/trump-puts-australias-drugs-scheme-digital-rules-in-firing-line 2026-04-02T03:12:15 https://maestrodatabase.com/blog/supply-of-anti-retroviral-treatments 2018-08-06T21:15:49 https://maestrodatabase.com/blog/mhra-clarifies-post-brexit-clinical-trials-rules 2018-08-06T21:20:42 https://maestrodatabase.com/blog/fore-biotherapeutics-receives-breakthrough-therapy-designation-for-plixorafenib 2026-04-02T03:15:30 https://maestrodatabase.com/blog/luye-pharmas-rykindo-expected-to-be-the-first-chinese-innovative-drug-to-receive-u-dot-s-fda-approval 2019-04-01T21:03:59 https://maestrodatabase.com/blog/glatect-alternative-to-copaxone-added-to-public-health-plans-of-5-canadian-provinces 2018-08-06T21:40:43 https://maestrodatabase.com/blog/karyopharm-completes-rolling-submission-of-new-drug-application-to-u-dot-s-fda-for-selinexor-as-a-treatment-for-patients-with-penta-refractory-multiple-myeloma 2018-08-06T21:44:53 https://maestrodatabase.com/blog/private-health-insurance-excluding-benefits-under-the-radar 2018-08-06T21:35:21 https://maestrodatabase.com/blog/pfizer-provides-update-on-proposed-epoetin-alfa-biosimilar 2017-06-23T20:58:57 https://maestrodatabase.com/blog/government-urged-to-dump-flawed-health-insurance-discount-plan-for-young-people 2018-08-06T21:37:27 https://maestrodatabase.com/blog/the-review-shows-that-it-is-possible-to-lower-the-cost-of-medicines 2020-04-03T21:28:45 https://maestrodatabase.com/blog/division-on-european-hta 2018-08-06T21:51:42 https://maestrodatabase.com/blog/ema-provides-recommendations-on-compassionate-use-of-remdesivir-for-covid-19 2020-04-03T21:36:17 https://maestrodatabase.com/blog/u-dot-s-fda-approves-reblozyl-luspatercept-aamt-the-first-and-only-erythroid-maturation-agent-to-treat-anaemia-in-adults-with-lower-risk-myelodysplastic-syndromes 2020-04-03T21:38:58 https://maestrodatabase.com/blog/oncosec-announces-advanced-therapy-medicinal-product-classification-from-the-ema-for-tavo-in-refractory-metastatic-melanoma 2019-04-01T23:21:17 https://maestrodatabase.com/blog/ziopharm-oncology-announces-fda-fast-track-designation-for-ad-rts-hil-12-plus-veledimex-for-the-treatment-of-recurrent-glioblastoma 2019-04-01T23:12:29 https://maestrodatabase.com/blog/abbvie-receives-chmp-positive-opinion-for-maviret-glecaprevir-slash-pibrentasvir-for-the-treatment-of-chronic-hepatitis-c-in-all-major-genotypes 2017-06-23T21:57:39 https://maestrodatabase.com/blog/deep-cuts-to-medicaid-remain-the-centerpiece-of-the-republicans-proposals 2017-06-23T22:11:20 https://maestrodatabase.com/blog/senate-health-care-bill-includes-deep-cuts-to-medicaid 2017-06-23T22:07:35 https://maestrodatabase.com/blog/advanced-therapy-medicinal-products-and-health-technology-assessment-principles-and-practices-for-value-based-and-sustainable-healthcarehe 2019-04-02T00:34:12 https://maestrodatabase.com/blog/akebia-receives-positive-chmp-opinion-in-europe-for-vafseo-vadadustat-for-the-treatment-of-symptomatic-anaemia-associated-with-chronic-kidney-disease-in-adults-on-chronic-maintenance-dialysis 2023-02-24T09:03:52 https://maestrodatabase.com/blog/slow-rollout-more-fine-print-with-trump-health-care-options 2018-08-07T00:08:02 https://maestrodatabase.com/blog/when-is-the-price-of-a-drug-unjust-the-average-lifetime-earnings-standard 2019-04-02T00:38:41 https://maestrodatabase.com/blog/gsk-receives-us-fda-breakthrough-therapy-designation-for-its-b7-h3-targeted-antibody-drug-conjugate-in-relapsed-or-refractory-extensive-stage-small-cell-lung-cancer 2024-08-20T23:51:39 https://maestrodatabase.com/blog/regeneron-provides-update-on-biologics-license-application-for-linvoseltamab 2024-08-21T00:06:15 https://maestrodatabase.com/blog/prices-for-common-cardiovascular-drugs-in-the-us-are-not-consistently-aligned-with-value 2018-08-07T01:05:03 https://maestrodatabase.com/blog/janssen-receives-positive-chmp-opinion-for-akeega-niraparib-and-abiraterone-acetate-dual-action-tablet-plus-prednisone-or-prednisolone-for-the-treatment-of-adult-patients-with-brca1-slash-2-gene-mutated-metastatic-castration-resistant-prostate-cancer 2023-02-24T19:28:16 https://maestrodatabase.com/blog/health-insurance-needs-in-depth-scrutiny-in-the-public-interest 2018-08-07T05:08:38 https://maestrodatabase.com/blog/pharmac-takes-three-years-to-review-brand-new-cancer-drugs-and-kiwis-are-missing-out 2018-08-07T20:58:07 https://maestrodatabase.com/blog/health-insurance-discounts-will-benefit-only-the-young-rich-consumer-groups 2018-08-07T21:06:13 https://maestrodatabase.com/blog/chiesi-global-rare-diseases-and-protalix-biotherapeutics-receive-positive-chmp-opinion-for-pegunigalsidase-alfa-for-treatment-of-fabry-disease 2023-02-24T19:44:35 https://maestrodatabase.com/blog/government-looks-to-include-biosimilars-in-price-controls 2018-08-07T12:28:17 https://maestrodatabase.com/blog/express-scripts-to-drop-big-sellers-from-abbvie-gilead-in-2019 2018-08-07T21:19:05 https://maestrodatabase.com/blog/survival-of-the-richest-rich-access-drugs-pharmac-wont-fund 2018-08-07T21:10:46 https://maestrodatabase.com/blog/nzs-cancer-death-rates-worse-than-australias-due-to-medicine-inaccessibility---oncologist 2018-08-07T21:13:25 https://maestrodatabase.com/blog/array-biopharma-receives-fda-breakthrough-therapy-designation-for-braftovi-in-combination-with-mektovi-and-cetuximab-for-braf-v600e-mutant-metastatic-colorectal-cancer 2018-08-07T21:32:11 https://maestrodatabase.com/blog/cms-empowers-patients-with-more-choices-and-takes-action-to-lower-drug-prices 2018-08-07T21:22:20 https://maestrodatabase.com/blog/the-european-medicines-agency-primed-for-access 2018-08-07T21:26:58 https://maestrodatabase.com/blog/changes-to-drug-prices-gestures-and-real-policy-shifts 2018-08-07T21:51:33 https://maestrodatabase.com/blog/trump-forces-pharma-to-face-more-medicare-drug-price-negotiation 2018-08-07T21:38:05 https://maestrodatabase.com/blog/express-scripts-announces-new-recommendations-tackling-high-drug-prices 2018-08-07T21:47:14 https://maestrodatabase.com/blog/anavex-initiates-regulatory-submission-of-oral-blarcamesine-for-alzheimers-disease-to-ema 2023-11-21T03:40:47 https://maestrodatabase.com/blog/fda-approves-orkambi-lumacaftor-slash-ivacaftor-as-first-medicine-to-treat-the-underlying-cause-of-cystic-fibrosis-for-children-ages-2-5-years-with-most-common-form-of-the-disease 2018-08-07T21:58:24 https://maestrodatabase.com/blog/ascendis-pharma-announces-european-commission-approval-of-yorvipath-palopegteriparatide-for-the-treatment-of-adults-with-chronic-hypoparathyroidism 2023-11-21T03:33:10 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-for-spi-1005-in-the-treatment-of-menieres-disease 2019-09-19T00:16:51 https://maestrodatabase.com/blog/us-fda-grants-tentative-approval-of-yutrepia-treprostinil-inhalation-powder-for-patients-with-pulmonary-arterial-hypertension-and-pulmonary-hypertension-associated-with-interstitial-lung-disease 2024-08-21T02:53:27 https://maestrodatabase.com/blog/cara-receives-breakthrough-therapy-designation-from-fda-for-i-dot-v-cr845-for-the-treatment-of-chronic-kidney-disease-associated-pruritus-in-hemodialysis-patients 2017-06-23T23:34:37 https://maestrodatabase.com/blog/european-commission-approves-cabometyx-in-combination-with-opdivo-as-a-first-line-treatment-for-patients-living-with-advanced-renal-cell-carcinoma 2021-04-01T07:12:24 https://maestrodatabase.com/blog/heron-announces-european-medicines-agency-validation-of-marketing-authorisation-application-for-htx-011-for-post-operative-pain-management 2019-04-02T04:32:37 https://maestrodatabase.com/blog/member-of-canadas-drug-pricing-regulator-quits-over-lack-of-support-for-medicine-cost-reforms 2023-02-24T20:54:48 https://maestrodatabase.com/blog/review-of-the-national-medicines-policy 2021-10-11T04:27:37 https://maestrodatabase.com/blog/enhertu-approved-in-china-for-patients-with-her2-positive-metastatic-breast-cancer-treated-with-one-or-more-prior-anti-her2-based-regimens 2023-02-24T20:57:57 https://maestrodatabase.com/blog/libtayo-cemiplimab-in-combination-with-chemotherapy-receives-positive-chmp-opinion-for-the-treatment-of-advanced-pd-l1-positive-non-small-cell-lung-cancer 2023-02-24T20:50:24 https://maestrodatabase.com/blog/price-controls-are-never-the-answer 2019-04-02T04:46:40 https://maestrodatabase.com/blog/european-medicines-agency-accepts-takedas-marketing-authorisation-application-for-a-subcutaneous-formulation-of-vedolizumab-for-maintenance-therapy-in-moderately-to-severely-active-ulcerative-colitis-and-crohns-disease 2019-04-02T04:37:57 https://maestrodatabase.com/blog/controversial-malaria-drug-for-covid-19-cases-on-way-to-australia 2020-04-04T01:17:58 https://maestrodatabase.com/blog/belgium-may-remove-step-between-paying-doctors-and-reimbursement 2021-10-11T07:40:27 https://maestrodatabase.com/blog/alternative-drug-purchasing-arrangements-do-not-justify-raising-the-prices-medicaid-pays-for-brand-drugs 2020-04-04T01:22:01 https://maestrodatabase.com/blog/ema-receives-application-for-marketing-authorisation-for-ronapreve-casirivimab-with-imdevimab-for-treatment-and-prevention-of-covid-19 2021-10-11T19:50:15 https://maestrodatabase.com/blog/nice-backs-rinvoq-for-moderate-active-ra 2021-10-11T10:54:16 https://maestrodatabase.com/blog/u-dot-s-fda-approves-bevyxxa-betrixaban-first-and-only-anticoagulant-for-hospital-and-extended-duration-prevention-of-venous-thromboembolism-in-acutely-ill-medical-patients 2017-06-24T00:59:21 https://maestrodatabase.com/blog/ema-grants-prime-eligibility-for-kb103-to-treat-dystrophic-epidermolysis-bullosa 2019-04-02T05:29:41 https://maestrodatabase.com/blog/oia-documents-prove-pharmacs-independent-inquiry-is-a-toothless-whitewash 2021-10-11T05:44:57 https://maestrodatabase.com/blog/minister-for-health-announces-hse-approval-to-reimburse-zolgensma-onasemnogene-abeparvovec-as-part-of-a-joint-beneluxa-collaboration 2021-10-11T07:02:24 https://maestrodatabase.com/blog/novartis-first-in-class-cosentyx-approved-in-china-for-psoriasis-patients 2019-04-02T05:23:44 https://maestrodatabase.com/blog/dying-patients-up-for-4-000-dollars-painkillers-in-drug-supply-crisis 2024-08-21T04:44:27 https://maestrodatabase.com/blog/eylea-hd-aflibercept-approved-by-fda-as-first-and-only-injectable-anti-vegf-with-dosing-intervals-up-to-5-months-for-wet-age-related-macular-degeneration-and-diabetic-macular-oedema 2026-04-02T22:38:57 https://maestrodatabase.com/blog/health-economic-assessment-of-enhertu-in-breast-cancer 2023-10-16T20:08:11 https://maestrodatabase.com/blog/tegsedi-receives-innovative-drug-category-pricing-in-brazil 2021-10-11T20:10:48 https://maestrodatabase.com/blog/ocular-therapeutix-announces-fda-approval-of-supplemental-new-drug-application-for-dextenza-dexamethasone-ophthalmic-insert-0-dot-4-mg-for-intracanalicular-use-for-the-treatment-of-ocular-itching-associated-with-allergic-conjunctivitis 2021-10-11T19:55:45 https://maestrodatabase.com/blog/medicare-drug-pricing-debate-pits-savings-against-innovation 2021-10-11T20:03:46 https://maestrodatabase.com/blog/nohla-therapeutics-receives-fda-fast-track-designation-for-dilanubicel-for-allogeneic-cord-blood-transplant-patients 2018-08-07T23:56:39 https://maestrodatabase.com/blog/merck-and-ridgeback-announce-submission-of-emergency-use-authorisation-application-to-the-u-dot-s-fda-for-molnupiravir-an-investigational-oral-anti-viral-medicine-for-the-treatment-of-mild-to-moderate-covid-19-in-at-risk-adults 2021-10-11T20:30:20 https://maestrodatabase.com/blog/consternation-as-nice-rejects-janssen-ms-drug-ponvory 2021-10-11T20:27:09 https://maestrodatabase.com/blog/takedas-ovarian-cancer-drug-zejula-gets-expanded-insurance-benefit 2021-10-11T20:14:39 https://maestrodatabase.com/blog/highlights-from-the-chmp-19-22-june-2017-meeting 2017-06-24T04:43:56 https://maestrodatabase.com/blog/paying-for-cancer-drugs-that-prove-their-benefit 2021-10-11T20:40:13 https://maestrodatabase.com/blog/ultragenyx-announces-us-fda-acceptance-of-bla-resubmission-for-ux111-aav-gene-therapy-to-treat-sanfilippo-syndrome-type-a 2026-04-02T23:16:09 https://maestrodatabase.com/blog/health-economic-assessment-of-poteligeo-in-the-treatment-of-mycosis-fungoides-or-sezary-syndrome 2021-10-11T20:36:53 https://maestrodatabase.com/blog/pharmacs-latest-breast-cancer-drug-funding-way-short---advocate 2022-06-20T20:54:21 https://maestrodatabase.com/blog/efpia-and-vaccines-europe-are-deeply-disappointed-about-the-decision-taken-by-world-trade-organization-at-the-ministerial-conference-to-endorse-a-trips-waiver-for-covid-19-vaccines 2022-06-20T21:01:43 https://maestrodatabase.com/blog/covid-19-shipment-of-anti-depressant-drug-fluoxetine-held-up-by-pandemic 2020-04-04T02:45:29 https://maestrodatabase.com/blog/cocrystal-pharma-receives-fda-fast-track-designation-for-cdi-988-for-norovirus-infection-treatment-and-preventive 2026-04-02T23:41:40 https://maestrodatabase.com/blog/swiss-government-expands-powers-to-force-firms-to-make-supplies-to-fight-covid-19 2020-04-04T02:43:10 https://maestrodatabase.com/blog/ema-publishes-agenda-for-20-23-june-2022-chmp-meeting 2022-06-20T21:30:12 https://maestrodatabase.com/blog/fda-caught-up-on-domestic-pre-approval-inspections-foreign-inspections-still-a-challenge 2022-06-20T21:46:42 https://maestrodatabase.com/blog/icer-to-assess-treatment-for-chronic-obstructive-pulmonary-disease 2023-11-21T19:35:56 https://maestrodatabase.com/blog/fda-faces-reckoning-over-short-cut-drug-approvals 2023-11-21T19:33:16 https://maestrodatabase.com/blog/hira-reviews-reimbursing-antidiabetic-combo-therapies 2022-06-20T21:21:57 https://maestrodatabase.com/blog/funding-verdict-looms-on-future-of-cancer-therapy 2023-11-21T19:28:33 https://maestrodatabase.com/blog/global-regulators-work-towards-strengthening-collaboration-on-observational-research-beyond-covid-19-pandemic 2022-06-20T21:10:45 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-us-food-and-drug-administration-sbla-acceptance-for-first-line-treatment-of-unresectable-hepatocellular-carcinoma 2024-08-21T11:24:48 https://maestrodatabase.com/blog/zeposia-is-included-in-the-high-cost-protection-with-limitation 2022-06-20T21:14:57 https://maestrodatabase.com/blog/mhra-extends-licence-of-vertexs-cystic-fibrosis-drugs-for-young-children 2023-11-21T11:18:02 https://maestrodatabase.com/blog/context-therapeutics-announces-ctim-76-receives-fda-fast-track-designation-for-the-treatment-of-platinum-resistant-ovarian-cancer 2026-04-03T00:44:07 https://maestrodatabase.com/blog/pharmac-proposes-to-widen-access-to-medicine-used-in-the-treatment-of-heart-failure 2024-08-21T10:23:18 https://maestrodatabase.com/blog/givlaari-is-included-in-the-high-cost-protection-with-limitation 2022-06-20T21:07:19 https://maestrodatabase.com/blog/portola-pharmaceuticals-provides-update-on-biologics-license-application-for-andexxa-andexanet-alfa 2017-12-28T00:29:46 https://maestrodatabase.com/blog/iveric-bio-announces-fast-track-designation-from-u-dot-s-fda-for-zimura-for-the-treatment-of-geographic-atrophy-secondary-to-dry-age-related-macular-degeneration 2020-04-04T03:01:09 https://maestrodatabase.com/blog/sandoz-launches-hyrimoz-adalimumab-high-concentration-formulation-in-europe-aiming-to-improve-patient-care 2023-11-21T19:59:40 https://maestrodatabase.com/blog/moderna-receives-us-fda-approval-for-covid-19-vaccine-mnexspike 2025-06-01T02:47:35 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-june-2025 2025-06-01T03:11:39 https://maestrodatabase.com/blog/sun-pharma-announces-us-fda-acceptance-of-nda-for-otx-101 2017-12-28T00:37:23 https://maestrodatabase.com/blog/essential-drug-supplies-for-virus-patients-are-running-low 2020-04-04T03:07:53 https://maestrodatabase.com/blog/savings-from-side-deals-higher-than-previously-forecast 2023-11-21T20:17:19 https://maestrodatabase.com/blog/merck-and-ridgeback-provide-update-on-eu-marketing-authorisation-application-for-lagevrio-molnupiravir 2023-02-24T23:29:52 https://maestrodatabase.com/blog/cstone-announces-china-nmpa-new-drug-approval-of-precision-therapy-ayvakit-avapritinib-for-the-treatment-of-adults-with-unresectable-or-metastatic-pdgfra-exon-18-mutant-gastro-intestinal-stromal-tumour 2021-04-01T22:14:24 https://maestrodatabase.com/blog/smc---october-2021-decisions 2021-10-12T01:58:00 https://maestrodatabase.com/blog/health-canada-approves-hemlibra-for-haemophilia-a-patients-with-inhibitors 2018-08-08T02:10:27 https://maestrodatabase.com/blog/atagi-recommendations-on-use-of-the-moderna-and-pfizer-monovalent-omicron-xbb-dot-1-5-covid-19-vaccines 2023-11-22T02:15:25 https://maestrodatabase.com/blog/prices-of-generic-drugs-associated-with-numbers-of-manufacturers 2017-12-28T01:59:15 https://maestrodatabase.com/blog/ai-developers-battle-with-fda-whats-next-with-amazon-and-one-medical-and-protecting-wearables-data 2023-02-25T05:03:17 https://maestrodatabase.com/blog/updates-to-the-hta-review-research-and-analysis-papers-collection-draft-hta-expert-paper-published 2023-11-22T01:27:49 https://maestrodatabase.com/blog/horizon-pharma-announces-fda-approval-to-expand-the-indication-for-procysbi-cysteamine-bitartrate-delayed-release-capsules-to-include-children-one-year-of-age-and-older-living-with-nephropathic-cystinosis 2017-12-28T01:33:17 https://maestrodatabase.com/blog/highlights-from-the-20-23-february-2023-chmp-meeting 2023-02-24T23:48:02 https://maestrodatabase.com/blog/ema-publishes-agenda-for-19-22-august-2024-chmp-meeting 2024-08-21T23:15:33 https://maestrodatabase.com/blog/european-medicines-agency-validates-bristol-myers-squibbs-application-for-car-t-cell-therapy-breyanzi-in-relapsed-or-refractory-large-b-cell-lymphoma-after-first-line-therapy 2022-06-21T07:25:18 https://maestrodatabase.com/blog/gensight-biologics-announces-fda-grant-of-fast-track-designation-for-optogenetic-therapy-gs030-as-treatment-for-retinitis-pigmentosa 2021-10-12T09:08:43 https://maestrodatabase.com/blog/agenda-for-the-march-2024-pbac-meeting 2023-11-22T03:30:57 https://maestrodatabase.com/blog/zanubrutinib-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia-final-guidance 2023-11-22T02:58:55 https://maestrodatabase.com/blog/quanterix-granted-breakthrough-device-designation-from-u-dot-s-fda-for-blood-based-ptau-181-assay-for-alzheimers-disease 2021-10-12T09:04:58 https://maestrodatabase.com/blog/msac-publishes-agenda-for-april-msac-meeting 2023-11-22T10:33:25 https://maestrodatabase.com/blog/tevas-ajovy-receives-eu-approval-offering-patients-the-first-and-only-anti-cgrp-treatment-with-both-quarterly-and-monthly-dosing-for-the-prophylaxis-of-migraine-in-adults 2019-04-02T10:17:36 https://maestrodatabase.com/blog/nice-nod-for-breast-cancer-delay-drug 2019-04-02T10:12:53 https://maestrodatabase.com/blog/ec-approves-pharmaands-rubraca-as-advanced-ovarian-cancer-maintenance-treatment 2023-11-22T11:55:03 https://maestrodatabase.com/blog/fda-grants-breakthrough-therapy-designation-for-taiho-oncologys-futibatinib-for-treatment-of-advanced-cholangiocarcinoma 2021-04-01T23:42:58 https://maestrodatabase.com/blog/tebentafusp-for-treating-advanced-unresectable-or-metastatic-uveal-melanoma 2022-06-21T11:34:20 https://maestrodatabase.com/blog/record-investment-advances-long-term-national-health-plan 2019-04-02T10:30:10 https://maestrodatabase.com/blog/trump-administration-opens-up-more-drugs-covered-by-medicare-to-price-negotiations 2018-08-08T09:36:22 https://maestrodatabase.com/blog/mhra-nice-pathway-opens-for-business---everything-you-need-to-know-to-get-started 2026-04-03T02:33:03 https://maestrodatabase.com/blog/uk-unveils-plans-for-bigger-medicines-price-squeeze 2018-08-08T09:42:25 https://maestrodatabase.com/blog/abbvie-submits-supplemental-new-drug-application-to-u-dot-s-fda-for-atogepant-qulipta-to-support-label-expansion-for-the-preventive-treatment-of-migraine 2022-06-21T20:50:19 https://maestrodatabase.com/blog/changes-to-nices-cost-effectiveness-thresholds-take-effect 2026-04-03T02:36:15 https://maestrodatabase.com/blog/comparing-the-icers-in-medicine-reimbursement-submissions-to-nice-and-pbac--does-the-presence-of-an-explicit-threshold-affect-the-icer-proposed 2018-08-08T09:29:46 https://maestrodatabase.com/blog/trump-slaps-100pc-tariffs-on-australian-drugs---with-exceptions 2026-04-03T02:39:01 https://maestrodatabase.com/blog/the-fda-is-poised-to-approve-the-first-ever-drug-that-mutes-disease-causing-genes 2018-08-08T11:28:05 https://maestrodatabase.com/blog/acer-therapeutics-and-relief-therapeutics-announce-update-on-u-dot-s-fda-review-of-new-drug-application-for-acer-001 2022-06-21T20:41:05 https://maestrodatabase.com/blog/patient-reported-outcome-measures-in-the-fda-pilot-compendium-meeting-todays-standards-for-patient-engagement-in-development 2018-08-08T09:49:01 https://maestrodatabase.com/blog/abpi-response-mhra-guidance-on-brexit-implementation 2018-08-08T11:20:03 https://maestrodatabase.com/blog/paratek-pharmaceuticals-nuzyra-receives-fda-fast-track-designation-for-the-treatment-of-pulmonary-non-tuberculous-mycobacterial-disease-caused-by-mycobacterium-avium-complex-and-mycobacterium-abscessus 2022-06-21T21:14:15 https://maestrodatabase.com/blog/fda-approves-first-generic-drug-under-new-pathway-aimed-at-enhancing-market-competition-for-sole-source-drugs 2018-08-08T20:57:53 https://maestrodatabase.com/blog/fda-approves-treatment-for-two-rare-types-of-non-hodgkin-lymphoma 2018-08-08T21:00:42 https://maestrodatabase.com/blog/kura-oncology-and-kyowa-kirin-announce-fda-acceptance-and-priority-review-of-new-drug-application-for-ziftomenib-in-adults-with-relapsed-or-refractory-npm1-mutant-aml 2025-06-02T01:54:25 https://maestrodatabase.com/blog/nice-publishes-final-appraisal-determination-for-alecensa 2018-08-08T21:20:43 https://maestrodatabase.com/blog/nice-publishes-draft-guidance-on-new-use-for-lenvatinib-mesylate 2018-08-08T21:26:13 https://maestrodatabase.com/blog/eqrx-announces-acceptance-of-marketing-authorisation-application-by-the-uks-medicines-and-healthcare-products-regulatory-agency-for-aumolertinib-in-egfr-mutated-non-small-cell-lung-cancer 2022-06-21T21:05:13 https://maestrodatabase.com/blog/trump-says-drug-prices-will-drop-`really-really-substantially 2018-08-08T21:07:35 https://maestrodatabase.com/blog/medicare-couldve-saved-3-dollars-6-cents-billion-by-buying-drugs-at-same-prices-as-mark-cubans-online-pharmacy-according-to-a-new-study 2022-06-21T21:00:50 https://maestrodatabase.com/blog/amid-drug-price-scrutiny-cvs-says-its-pbm-retains-just-2-percent-of-rebates 2018-08-08T21:10:44 https://maestrodatabase.com/blog/benefits-of-new-alzheimers-treatment-lecanemab-are-too-small-to-justify-the-cost-to-the-nhs 2024-08-22T22:34:21 https://maestrodatabase.com/blog/lenvatinib-mesylate-and-sorafenib-tosylate-for-the-treatment-of-patients-with-differentiated-thyroid-cancer-after-the-use-of-radioactive-iodine 2018-08-08T21:54:35 https://maestrodatabase.com/blog/ixekizumab-for-treatment-of-adults-with-active-psoriatic-arthritis 2018-08-08T21:45:11 https://maestrodatabase.com/blog/review-of-national-hospital-funding-agreement 2023-02-25T23:23:04 https://maestrodatabase.com/blog/servier-receives-a-positive-chmp-opinion-for-tibsovo-in-idh1-mutated-acute-myeloid-leukaemia-and-cholangiocarcinoma-patients 2023-02-26T20:36:57 https://maestrodatabase.com/blog/health-technology-assessment-2025-and-beyond-lifecycle-approaches-to-promote-engagement-and-efficiency-in-health-technology-assessment 2023-02-25T23:55:17 https://maestrodatabase.com/blog/minister-for-health-publishes-review-of-governance-arrangements-to-support-hse-drug-reimbursement-process 2023-02-26T20:32:20 https://maestrodatabase.com/blog/butler-confident-of-csl-exemption-as-australian-drugs-incur-100pc-tariff 2026-04-03T20:14:44 https://maestrodatabase.com/blog/trump-announces-100-percent-tariffs-on-brand-name-drugs-with-plenty-of-carveouts 2026-04-03T20:22:32 https://maestrodatabase.com/blog/doctors-group-cannot-sue-over-cuts-to-medicare-drug-reimbursements 2019-04-02T20:01:38 https://maestrodatabase.com/blog/fda-approves-and-authorises-updated-mrna-covid-19-vaccines-to-better-protect-against-currently-circulating-variants 2024-08-22T23:28:26 https://maestrodatabase.com/blog/alladapt-immunotherapeutics-receives-fda-fast-track-designation-for-adp101-for-the-treatment-of-mono--and-multi-food-allergies 2023-11-23T02:42:51 https://maestrodatabase.com/blog/clarity-receives-fda-fast-track-designation-for-64cu-sar-bispsma 2024-08-22T23:15:32 https://maestrodatabase.com/blog/statement-from-fda-commissioner-on-the-agencys-continued-efforts-to-bring-competition-to-the-insulin-market-to-lower-prices-and-expand-access 2019-04-02T19:58:49 https://maestrodatabase.com/blog/icer-publishes-final-evidence-report-on-treatment-for-anaemia-in-myelodysplastic-syndrome 2024-08-22T23:08:47 https://maestrodatabase.com/blog/pbac-recommended-new-medicines-yet-to-be-listed-on-the-pbs---the-ones-that-missed-the-cut 2019-04-02T20:04:20 https://maestrodatabase.com/blog/opus-genetics-receives-rare-paediatric-disease-designation-from-the-us-fda-for-ocular-gene-therapy-opgx-lca5-to-treat-rare-inherited-retinal-disease-lca5 2024-08-22T23:52:10 https://maestrodatabase.com/blog/nhs-patients-and-british-businesses-to-benefit-from-historic-changes-to-medicines-access-following-pharmaceutical-partnership-with-us 2026-04-03T10:09:53 https://maestrodatabase.com/blog/sevabertinib-approved-to-treat-adults-with-her2-positive-lung-cancer-that-has-spread-or-cannot-be-removed-by-surgery 2026-04-03T10:15:35 https://maestrodatabase.com/blog/uk-faces-ps50-billion-economic-hit-due-to-spiralling-medicines-levy 2023-10-16T19:58:42 https://maestrodatabase.com/blog/abbvie-receives-positive-chmp-opinion-for-upadacitinib-rinvoq-for-the-treatment-of-adults-with-moderate-to-severe-crohns-disease 2023-02-27T07:41:27 https://maestrodatabase.com/blog/pharmac-shares-the-agenda-items-for-the-upcoming-rare-disorders-committee-meeting-may-2024 2024-05-13T09:48:42 https://maestrodatabase.com/blog/electronic-prescribing 2019-09-19T05:21:01 https://maestrodatabase.com/blog/trastuzumab-deruxtecan-type-ii-variation-application-validated-by-ema-for-patients-with-her2-low-metastatic-breast-cancer-with-hr-positive-and-hr-negative-disease 2022-06-22T07:09:17 https://maestrodatabase.com/blog/celltrion-has-come-forward-to-explain-reasons-for-the-delayed-approval-of-its-humira-biosimilar-yuflyma-ct-p17-in-the-us-saying-there-were-some-problems-but-they-have-been-solved-now 2023-02-27T07:47:44 https://maestrodatabase.com/blog/will-courts-allow-states-to-regulate-drug-prices 2018-08-09T00:18:01 https://maestrodatabase.com/blog/y-mabs-177lu-omburtamab-dtpa-for-the-treatment-of-patients-with-medulloblastoma-granted-rare-paediatric-disease-designation-by-fda 2021-10-12T19:56:37 https://maestrodatabase.com/blog/biomarin-announces-the-ministry-of-health-labor-and-welfare-in-japan-granted-approval-for-voxzogo-vosoritide-for-injection-for-the-treatment-of-children-with-achondroplasia-whose-growth-plates-are-not-closed 2022-06-22T10:15:44 https://maestrodatabase.com/blog/garadacimab-in-hereditary-angioedema-evidence-of-considerable-additional-benefit 2025-06-02T23:25:42 https://maestrodatabase.com/blog/ema-ends-rolling-review-of-cvncov-covid-19-vaccine-following-withdrawal-by-curevac 2021-10-12T19:52:21 https://maestrodatabase.com/blog/pfizer-and-biontech-submit-supplemental-biologics-license-application-for-us-fda-approval-of-omicron-ba-dot-4-slash-ba-dot-5-adapted-bivalent-covid-19-vaccine-for-ages-12-years-and-older-as-primary-series-or-booster 2023-02-27T08:12:00 https://maestrodatabase.com/blog/ema-publishes-agenda-for-11-14-october-chmp-meeting 2021-10-12T20:11:03 https://maestrodatabase.com/blog/rsv-prophylaxis-with-nirsevimab-benefits-for-healthy-children-in-the-first-rsv-season 2025-06-02T23:28:59 https://maestrodatabase.com/blog/incyte-announces-positive-chmp-opinion-for-ruxolitinib-cream-opzelura-for-the-treatment-of-non-segmental-vitiligo-in-adults-and-adolescents 2023-02-27T08:05:32 https://maestrodatabase.com/blog/australian-scientists-discover-head-lice-drug-kills-coronavirus-in-lab 2020-04-04T21:23:59 https://maestrodatabase.com/blog/fda-grants-breakthrough-device-designation-to-vr-mental-illness-treatment 2022-06-22T10:10:20 https://maestrodatabase.com/blog/nice-publishes-new-covid-19-guidelines-on-severe-asthma-pneumonia-rheumatological-disorders-and-symptom-management 2020-04-04T21:27:15 https://maestrodatabase.com/blog/springworks-therapeutics-announces-fda-acceptance-and-priority-review-of-new-drug-application-for-nirogacestat-for-the-treatment-of-adults-with-desmoid-tumours 2023-02-27T20:13:30 https://maestrodatabase.com/blog/deciphera-announces-approval-of-qinlock-in-switzerland-for-the-treatment-of-fourth-line-gastro-intestinal-stromal-tumour 2021-10-12T20:34:55 https://maestrodatabase.com/blog/nice-guidance-on-inclisiran-should-be-reconsidered 2021-10-12T20:39:31 https://maestrodatabase.com/blog/glaukos-submits-new-drug-application-to-us-fda-for-idose-tr 2023-02-27T20:09:04 https://maestrodatabase.com/blog/vaccinations-can-end-political-blame-game-csl 2021-10-12T20:24:54 https://maestrodatabase.com/blog/ema-pilots-scientific-advice-for-certain-high-risk-medical-devices 2023-02-27T19:58:07 https://maestrodatabase.com/blog/doh-revises-agenda-ahead-of-new-months-pbac-meeting 2021-10-12T20:17:56 https://maestrodatabase.com/blog/for-cytokinetics-an-fda-rejection-of-its-heart-drug-would-help-not-hinder 2023-02-27T20:01:11 https://maestrodatabase.com/blog/evive-biotech-and-acrotech-biopharma-announce-fda-approval-of-ryzneuta-efbemalenograstim-alfa-injection-for-chemotherapy-induced-neutropenia 2023-11-23T06:13:04 https://maestrodatabase.com/blog/outdated-criteria-for-drug-plan-reimbursement-obstruct-evidence-based-care 2021-10-12T20:31:45 https://maestrodatabase.com/blog/fda-accepts-transcon-cnp-nda-for-priority-review 2025-06-02T23:11:45 https://maestrodatabase.com/blog/where-is-the-pharmac-review-panels-interim-report 2021-10-12T20:27:35 https://maestrodatabase.com/blog/enhertu-trastuzumab-deruxtecan-receives-time-limited-reimbursement-recommendation-from-canadas-drug-agency-for-gastric-cancer 2025-06-02T23:19:14 https://maestrodatabase.com/blog/krystal-biotech-submits-biologics-license-application-to-u-dot-s-fda-seeking-approval-of-b-vec-for-the-treatment-of-patients-with-dystrophic-epidermolysis-bullosa 2022-06-22T20:56:54 https://maestrodatabase.com/blog/genmab-announces-submission-of-u-dot-s-and-eu-regulatory-applications-seeking-approval-of-darzalex-daratumumab-split-dosing-regimen 2018-08-09T02:44:11 https://maestrodatabase.com/blog/ikena-oncology-receives-fda-fast-track-designation-for-novel-tead-inhibitor-ik-930-to-treat-unresectable-nf2-deficient-mesothelioma 2022-06-22T11:44:43 https://maestrodatabase.com/blog/fdas-accelerated-approval-program-is-change-on-the-way 2021-10-12T20:49:06 https://maestrodatabase.com/blog/doctor-with-stage-4-cancer-is-refused-access-to-lifesaving-treatment-on-the-nhs 2023-02-27T20:37:17 https://maestrodatabase.com/blog/when-is-the-novavax-vaccine-coming-to-australia-will-it-be-used-for-booster-shots 2021-10-12T20:44:04 https://maestrodatabase.com/blog/european-authorities-launch-hta-network 2021-10-12T20:52:53 https://maestrodatabase.com/blog/areteia-therapeutics-granted-ilap-designation-from-uk-mhra-for-oral-dexpramipexole-for-eosinophilic-asthma 2023-02-27T20:21:22 https://maestrodatabase.com/blog/msac-publishes-agenda-for-october-2022-esc-meeting 2022-06-22T21:45:20 https://maestrodatabase.com/blog/slow-release-potassium-bicarbonate-potassium-citrate-for-treating-distal-renal-tubular-acidosis 2022-11-02T15:04:51 https://maestrodatabase.com/blog/new-11-dollars-million-winter-vaccine-communication-campaign-and-availability-of-antivirals 2022-06-22T21:30:23 https://maestrodatabase.com/blog/u-dot-s-fda-approves-mercks-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-the-prevention-of-invasive-pneumococcal-disease-in-infants-and-children 2022-06-22T21:01:21 https://maestrodatabase.com/blog/killing-time-one-year-on-still-no-final-response-from-pharmac-to-the-independent-review 2023-02-28T11:11:58 https://maestrodatabase.com/blog/supplies-secured-of-latest-moderna-covid-19-vaccine-as-recommended-by-halton-review 2023-02-28T11:01:35 https://maestrodatabase.com/blog/balancing-act-needed-on-unproven-cancer-drugs---health-minister-david-clark 2018-08-09T03:22:04 https://maestrodatabase.com/blog/axicabtagene-ciloleucel-for-the-treatment-of-adults-with-diffuse-large-b-cell-lymphoma-and-primary-mediastinal-large-b-cell-lymphoma-after-two-or-more-systemic-therapies 2023-02-28T11:05:27 https://maestrodatabase.com/blog/zealand-pharma-submits-marketing-authorisation-application-to-the-ema-for-glepaglutide-in-short-bowel-syndrome 2025-06-03T01:12:45 https://maestrodatabase.com/blog/darolutamide-receives-approval-for-additional-prostate-cancer-indication-in-japan 2023-02-28T11:30:53 https://maestrodatabase.com/blog/biologics-license-application-for-lecanemab-designated-for-priority-review-by-china-nmpa 2023-02-28T11:22:15 https://maestrodatabase.com/blog/maat-pharma-submits-marketing-authorisation-application-to-the-ema-for-xervyteg-maat013-in-acute-graft-versus-host-disease 2025-06-03T01:25:29 https://maestrodatabase.com/blog/cvs-chief-dont-blame-us-for-higher-drug-prices 2018-08-09T07:47:14 https://maestrodatabase.com/blog/pharmac-will-fund-meningococcal-b-vaccine-for-babies-teens-and-young-people 2023-02-28T11:15:59 https://maestrodatabase.com/blog/design-characteristics-risk-of-bias-and-reporting-of-randomised-controlled-trials-supporting-approvals-of-cancer-drugs-by-european-medicines-agency-2014-16-cross-sectional-analysis 2019-09-19T08:05:26 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-march-2023 2023-02-28T20:05:45 https://maestrodatabase.com/blog/my-sons-time-is-running-out-due-to-a-rare-disease-the-fda-needs-to-add-more-clinical-trial-flexibility 2023-02-28T20:02:17 https://maestrodatabase.com/blog/novartis-has-submitted-application-to-ema-for-approval-of-cosentyx-in-nr-axspa-which-would-be-the-fourth-indication 2019-09-19T20:59:43 https://maestrodatabase.com/blog/pelosis-drug-plan-would-let-u-dot-s-negotiate-prices-of-250-medications 2019-09-19T20:54:14 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-march-2023 2023-02-28T19:51:53 https://maestrodatabase.com/blog/flawed-evidence-underpins-approval-of-new-cancer-drugs 2019-09-19T20:43:16 https://maestrodatabase.com/blog/cstone-announces-chinas-nmpa-has-accepted-the-supplementary-new-drug-application-of-sugemalimab-as-first-line-treatment-for-patients-with-locally-advanced-or-metastatic-gastric-slash-gastro-oesophageal-junction-adenocarcinoma 2023-02-28T19:47:19 https://maestrodatabase.com/blog/why-prescription-drugs-cost-so-much-more-in-america 2019-09-19T08:13:41 https://maestrodatabase.com/blog/5-people-setting-eu-drug-prices 2019-09-19T21:13:21 https://maestrodatabase.com/blog/fda-continues-to-take-steps-to-fulfil-its-commitment-to-strengthen-and-modernise-the-510-k-medical-device-program 2019-09-19T21:08:18 https://maestrodatabase.com/blog/mcconnell-warns-pelosis-drug-pricing-plan-is-doa 2019-09-19T21:04:49 https://maestrodatabase.com/blog/baricitinib-for-the-treatment-of-patients-with-severe-alopecia-areata 2023-02-28T20:31:26 https://maestrodatabase.com/blog/national-pharmacare-cheaper-than-healing-people-who-cant-afford-their-drugs 2019-09-19T21:34:45 https://maestrodatabase.com/blog/first-biosimilar-of-dornase-alfa-inhalation-solution-for-cf-approved-in-russia-companies-announce 2019-09-19T21:18:28 https://maestrodatabase.com/blog/drugs-likely-subject-to-medicare-negotiation-2026-2028 2023-02-28T20:18:01 https://maestrodatabase.com/blog/anheart-therapeutics-and-innovent-announce-chinas-nmpa-has-accepted-a-new-drug-application-for-taletrectinib-ros1-inhibitor 2023-11-23T11:01:49 https://maestrodatabase.com/blog/nice-changes-its-mind-on-pfizers-besponsa 2018-08-09T10:28:59 https://maestrodatabase.com/blog/cedazuridine-with-decitabine-for-patients-with-untreated-acute-myeloid-leukaemia-when-intensive-chemotherapy-is-unsuitable 2023-11-23T10:46:57 https://maestrodatabase.com/blog/desperate-plea-for-increased-medicines-funding-for-cancer-sufferers 2018-08-09T11:03:37 https://maestrodatabase.com/blog/david-agnew-appointed-chair-of-the-cadth-board-of-directors 2018-08-09T10:33:02 https://maestrodatabase.com/blog/too-keen-medicos-cost-patients-millions 2018-08-09T13:26:14 https://maestrodatabase.com/blog/breast-cancer-sufferer-brandi-allsop-needs-costly-treatment-for-a-chance-to-stay-alive 2024-08-24T07:12:25 https://maestrodatabase.com/blog/trump-plan-to-give-private-medicare-leverage-over-drug-costs-would-boost-pbms-and-biosimilars 2018-08-09T13:01:49 https://maestrodatabase.com/blog/glenmark-pharmaceuticals-announces-fda-acceptance-of-the-companys-first-new-drug-application-for-ryaltris-for-patients-with-seasonal-allergic-rhinitis 2018-08-09T13:07:20 https://maestrodatabase.com/blog/sesen-bio-announces-vicinium-granted-fast-track-designation-by-fda-for-treatment-of-non-muscle-invasive-bladder-cancer 2018-08-09T21:08:22 https://maestrodatabase.com/blog/unions-urge-members-to-opt-out-of-myhealth-record 2018-08-09T21:01:32 https://maestrodatabase.com/blog/praxis-precision-medicines-receives-prime-designation-from-the-ema-for-elsunersen-prax-222-for-treatment-of-scn2a-gain-of-function-developmental-epilepsies 2023-11-23T20:06:46 https://maestrodatabase.com/blog/european-commission-approves-kaftrio-in-combination-with-ivacaftor-for-the-treatment-of-children-with-cystic-fibrosis-ages-2-through-5 2023-11-23T19:39:08 https://maestrodatabase.com/blog/henlius-trastuzumab-receives-approval-in-canada 2024-08-25T00:39:50 https://maestrodatabase.com/blog/better-u-dot-s-patient-access-to-cancer-drugs-comes-at-a-price 2018-08-09T21:24:41 https://maestrodatabase.com/blog/gw-pharmaceuticals-slaps-price-tag-on-cannabis-based-epilepsy-drug 2018-08-09T21:31:44 https://maestrodatabase.com/blog/moderna-receives-european-commission-approval-for-rsv-vaccine-mresvia 2024-08-25T00:33:30 https://maestrodatabase.com/blog/new-from-cadth-pharmaceutical-reviews-update 2018-08-09T21:14:12 https://maestrodatabase.com/blog/health-canada-approves-keytruda-for-the-treatment-of-adult-patients-with-unresectable-locally-advanced-or-metastatic-urothelial-cancer-with-no-prior-systemic-therapy-for-metastatic-urothelial-cancer-in-combination-with-enfortumab-vedotin 2024-08-25T00:29:19 https://maestrodatabase.com/blog/americans-fund-most-of-the-worlds-drug-research-heres-how-trump-can-end-that 2018-08-09T21:21:36 https://maestrodatabase.com/blog/chemists-have-been-overcharging-customers-for-medicines-a-government-review-finds 2017-06-25T11:57:58 https://maestrodatabase.com/blog/lupin-receives-health-canada-approval-for-biosimilar-pegfilgrastim 2024-08-25T00:21:46 https://maestrodatabase.com/blog/lecanemab-licensed-for-adult-patients-in-the-early-stages-of-alzheimers-disease 2024-08-25T02:02:47 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac---july-2024 2024-08-25T02:13:26 https://maestrodatabase.com/blog/abbvie-announces-extension-of-review-for-supplemental-new-drug-application-of-upadacitinib-for-the-treatment-of-moderate-to-severe-atopic-dermatitis 2021-04-02T22:31:58 https://maestrodatabase.com/blog/what-the-newly-released-medicare-prices-for-10-drugs-do-and-dont-tell-us 2024-08-25T02:06:44 https://maestrodatabase.com/blog/taltz-ixekizumab-approved-by-health-canada-for-the-treatment-of-paediatric-patients-six-to-less-than-18-years-of-age-with-moderate-to-severe-plaque-psoriasis 2021-04-03T03:44:28 https://maestrodatabase.com/blog/vulnerable-aussies-may-remain-unprotected-against-severe-rsv 2024-08-25T02:17:02 https://maestrodatabase.com/blog/priority-review-pathway-prescription-medicines 2017-06-26T08:17:01 https://maestrodatabase.com/blog/overcharging-claims-give-false-impression 2017-06-26T08:24:11 https://maestrodatabase.com/blog/has-the-interim-report-considered-long-term-supply-chain-impacts 2017-06-26T08:20:17 https://maestrodatabase.com/blog/biodelivery-sciences-announces-health-canada-approval-of-belbuca 2017-06-26T11:04:56 https://maestrodatabase.com/blog/novartis-tafinlar-and-mekinist-receives-fda-approval-for-first-tumour-agnostic-indication-for-braf-v600e-solid-tumours 2022-06-23T00:54:39 https://maestrodatabase.com/blog/us-fda-accepts-bristol-myers-squibbs-supplemental-biologics-license-application-and-ema-validates-application-for-opdivo-nivolumab-as-an-adjuvant-treatment-for-patients-with-completely-resected-stage-iib-or-iic-melanoma 2023-02-28T22:53:27 https://maestrodatabase.com/blog/padcev-enfortumab-vedotin-in-combination-with-pembrolizumab-approved-by-health-canada-to-treat-advanced-bladder-cancer 2024-08-25T02:33:27 https://maestrodatabase.com/blog/the-fda-has-never-approved-a-drug-like-this-in-its-111-year-history 2017-06-26T11:16:38 https://maestrodatabase.com/blog/risankizumab-for-the-treatment-of-patients-with-moderately-to-severely-active-ulcerative-colitis 2024-08-25T02:22:20 https://maestrodatabase.com/blog/poor-bone-health-costing-australia-billions 2017-06-26T20:32:59 https://maestrodatabase.com/blog/ipsens-cabometyx-kidney-cancer-reimbursement-bid-collapses-in-korea-after-price-talks-fail 2025-06-03T07:46:39 https://maestrodatabase.com/blog/orphan-drug-program-reforms 2017-06-26T20:24:22 https://maestrodatabase.com/blog/more-people-who-can-get-the-flu-jab-for-free-should-be-vaccinated-says-nice 2017-06-26T20:39:47 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-appoints-dr-pamela-bradt-as-chief-scientific-officer 2019-04-03T07:44:41 https://maestrodatabase.com/blog/shire-announces-ema-validation-of-veyvondi-von-willebrand-factor-recombinant-marketing-authorisation-application-for-treatment-of-von-willebrand-disease 2017-06-26T20:43:38 https://maestrodatabase.com/blog/sandoz-resubmits-biosimilar-pegfilgrastim-application-to-us-fda 2019-04-03T07:40:09 https://maestrodatabase.com/blog/why-fdas-issuance-of-euas-are-not-approvals-and-why-that-matters 2020-04-05T01:26:21 https://maestrodatabase.com/blog/cladribine-tablets-receives-positive-chmp-opinion-for-treatment-of-relapsing-forms-of-multiple-sclerosis 2017-06-26T20:50:50 https://maestrodatabase.com/blog/samsung-bioepis-imraldi-adalimumab-recommended-for-approval-by-european-medicines-agency 2017-06-26T20:59:50 https://maestrodatabase.com/blog/european-commission-approves-adcetris-brentuximab-vedotin-for-the-treatment-of-adult-patients-with-newly-diagnosed-stage-iib-slash-iii-slash-iv-hodgkin-lymphoma-in-combination-with-ecadd 2025-06-03T21:54:04 https://maestrodatabase.com/blog/handoks-vyxeos-gileads-trodelvy-pass-cancer-drug-review-for-insurance-coverage 2023-11-24T04:22:27 https://maestrodatabase.com/blog/win-win-as-pharmac-drops-restrictions-on-hiv-medication 2017-06-26T21:06:35 https://maestrodatabase.com/blog/senate-republican-healthcare-bill-would-cause-22-million-to-lose-insurance 2017-06-26T21:21:27 https://maestrodatabase.com/blog/aveo-oncology-announces-positive-chmp-opinion-for-tivozanib-as-a-treatment-of-advanced-renal-cell-carcinoma 2017-06-26T21:13:43 https://maestrodatabase.com/blog/eu-tests-limits-of-drug-pricing-freedom-in-landmark-probe 2017-06-26T21:23:56 https://maestrodatabase.com/blog/fda-finalises-penalties-for-clinical-trial-sponsors-that-dont-share-data-but-critics-say-they-fall-short 2020-08-18T20:49:03 https://maestrodatabase.com/blog/adding-sickle-cell-disease-to-fdas-priority-review-voucher-list-of-neglected-tropical-diseases 2020-08-18T20:53:37 https://maestrodatabase.com/blog/ema-publishes-agenda-for-17-20-august-chmp-meeting 2020-08-18T21:01:44 https://maestrodatabase.com/blog/atopic-dermatitis-drug-adtralza-passes-insurance-panel-at-ultrafast-speed 2023-11-24T05:10:07 https://maestrodatabase.com/blog/sandoz-receives-approval-in-europe-for-erelzi-biosimilar-etanercept-to-treat-multiple-inflammatory-diseases 2017-06-27T05:46:50 https://maestrodatabase.com/blog/fda-approves-darolutamide-for-metastatic-castration-sensitive-prostate-cancer 2025-06-03T21:28:20 https://maestrodatabase.com/blog/fda-initiatives-to-accelerate-the-development-of-covid-19-therapeutics 2020-08-18T11:49:22 https://maestrodatabase.com/blog/the-fda-response-to-covid-19-at-six-months-regulatory-innovation-in-the-face-of-a-pandemic 2020-08-18T11:59:52 https://maestrodatabase.com/blog/free-for-everyone-coronavirus-vaccine-deal-locked-in 2020-08-18T20:46:04 https://maestrodatabase.com/blog/canada-takes-cautious-approach-to-unapproved-covid-19-drugs-as-others-prescribe-wide-use 2020-04-05T21:14:38 https://maestrodatabase.com/blog/atagi-recommendations-on-use-of-the-moderna-bivalent-original-slash-omicron-ba-dot-4-slash-5-covid-19-vaccine 2023-03-01T01:12:56 https://maestrodatabase.com/blog/novartis-receives-european-commission-approval-for-tabrecta-for-the-treatment-of-metex14-skipping-advanced-non-small-cell-lung-cancer 2022-06-23T06:20:40 https://maestrodatabase.com/blog/medicines-matter---government-confirms-commitment-to-uncapped-pbs 2019-04-03T08:16:32 https://maestrodatabase.com/blog/reata-pharmaceuticals-announces-fda-approval-of-skyclarys-omavaloxolone-the-first-and-only-drug-indicated-for-patients-with-friedreichs-ataxia 2023-03-01T01:05:01 https://maestrodatabase.com/blog/maviret-glecaprevir-slash-pibrentasvir-approved-by-health-canada-for-paediatric-patients-with-chronic-hepatitis-c 2022-06-23T02:00:01 https://maestrodatabase.com/blog/drug-companies-call-out-pharmac-for-lack-of-transparency-and-timeliness 2019-04-03T08:22:48 https://maestrodatabase.com/blog/nice-appoints-two-directors-to-key-new-positions 2020-08-18T21:07:11 https://maestrodatabase.com/blog/coronavirus-updates-who-calls-for-global-co-operation-and-an-end-to-vaccine-nationalism 2020-08-18T21:16:46 https://maestrodatabase.com/blog/provisional-determination-granted-to-pfizers-covid-19-vaccine-comirnaty---proposed-for-use-in-children-5-11-years-of-age 2021-10-13T10:03:56 https://maestrodatabase.com/blog/evoke-pharma-receives-complete-response-letter-and-recommendations-to-address-deficiencies-from-fda-for-gimoti-nda 2019-04-03T10:56:51 https://maestrodatabase.com/blog/kevzara-sarilumab-approved-by-fda-as-first-and-only-biologic-indicated-for-patients-with-polymyalgia-rheumatica 2023-03-01T01:32:29 https://maestrodatabase.com/blog/cignas-express-scripts-pbm-to-cap-insulin-costs-amid-drug-price-scrutiny 2019-04-03T11:17:08 https://maestrodatabase.com/blog/gottlieb-signs-off-with-flair---and-pledge-of-further-drug-price-commentary 2019-04-03T11:15:11 https://maestrodatabase.com/blog/menarini-group-and-radius-health-submit-new-drug-application-to-the-u-dot-s-fda-for-elacestrant 2022-06-23T06:31:32 https://maestrodatabase.com/blog/fda-approves-asceniv-a-novel-intravenous-immune-globulin 2019-04-03T11:04:04 https://maestrodatabase.com/blog/intelgenx-receives-complete-response-letter-from-fda-for-rizaport-nda 2020-03-29T09:59:21 https://maestrodatabase.com/blog/ritlecitinib-tosylate-for-the-treatment-of-people-with-alopecia-areata 2023-11-24T12:41:32 https://maestrodatabase.com/blog/mhra-backs-mercks-met-inhibitor-tepmetko 2021-10-13T10:08:04 https://maestrodatabase.com/blog/amylyx-pharmaceuticals-receives-us-fda-fast-track-designation-for-amx0114-for-the-treatment-of-amyotrophic-lateral-sclerosis 2025-06-03T23:35:08 https://maestrodatabase.com/blog/trump-retreats-on-health-care-after-mcconnell-warns-it-wont-happen 2019-04-03T11:45:50 https://maestrodatabase.com/blog/price-hikes-on-these-top-selling-drugs-were-a-lot-smaller-this-year-stat-analysis-finds 2017-12-29T05:08:11 https://maestrodatabase.com/blog/icer-issues-final-report-on-spinraza-and-zolgensma-provides-policy-recommendations-related-to-pricing-and-coverage-of-treatments-for-spinal-muscular-atrophy 2019-04-03T20:09:50 https://maestrodatabase.com/blog/montreal-woman-with-als-fights-for-canadian-access-to-new-drugs 2017-12-29T05:03:59 https://maestrodatabase.com/blog/abbvies-massive-humira-discounts-are-stifling-netherlands-biosimilars 2019-04-03T20:34:03 https://maestrodatabase.com/blog/icers-guideline-on-the-acceptance-and-use-of-in-confidence-data-from-manufacturers-of-pharmaceuticals-devices-and-other-health-care-interventions 2017-12-29T05:11:17 https://maestrodatabase.com/blog/overprescribed-high-cost-isnt-americas-only-drug-problem 2019-04-03T20:26:19 https://maestrodatabase.com/blog/synlogic-receives-fast-track-designation-in-u-dot-s-for-lead-candidate-synb1020 2017-06-27T07:39:58 https://maestrodatabase.com/blog/nice-opts-to-reject-acordas-ms-drug-fampyra 2022-06-23T11:12:10 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-23-june-2022 2022-06-23T07:55:46 https://maestrodatabase.com/blog/cytokinetics-receives-complete-response-letter-from-fda-for-new-drug-application-for-omecamtiv-mecarbil 2023-03-01T03:07:52 https://maestrodatabase.com/blog/ema-recommends-valnevas-covid-19-vaccine-for-authorisation-in-the-eu 2022-06-23T21:16:21 https://maestrodatabase.com/blog/pheast-therapeutics-receives-fda-fast-track-designation-for-phst001-for-the-treatment-of-ovarian-cancer 2025-06-03T23:40:39 https://maestrodatabase.com/blog/industry-sponsorship-bias-in-cost-effectiveness-analysis-registry-based-analysis 2022-06-23T21:13:59 https://maestrodatabase.com/blog/ema-recommends-authorisation-of-nuvaxovid-for-adolescents-aged-12-to-17 2022-06-23T21:05:54 https://maestrodatabase.com/blog/innovent-and-lilly-jointly-announce-the-approval-of-tyvyt-sintilimab-injection-by-china-nmpa-in-combination-with-chemotherapy-as-first-line-treatment-for-oesophageal-squamous-cell-carcinoma 2022-06-23T12:21:20 https://maestrodatabase.com/blog/medicare-premiums-to-jump-in-part-due-to-pricey-alzheimers-drug 2021-11-15T02:55:25 https://maestrodatabase.com/blog/new-drugs-but-slow-access----heres-how-to-speed-breakthroughs-to-patients 2018-01-31T00:04:32 https://maestrodatabase.com/blog/ozempic-2-mg-recommended-for-approval-for-the-treatment-of-type-2-diabetes-by-the-european-medicines-agency 2021-11-15T03:45:50 https://maestrodatabase.com/blog/health-policy-reform-not-helped-by-bill-shorten 2018-01-31T20:00:14 https://maestrodatabase.com/blog/industry-needs-clarity-to-invest-in-australia 2018-01-31T20:03:00 https://maestrodatabase.com/blog/cdf-to-save-nhs-ps140m-over-five-years 2018-01-31T19:50:51 https://maestrodatabase.com/blog/terns-pharmaceuticals-receives-fast-track-designation-for-tern-201-as-a-treatment-for-nash 2020-09-10T23:24:01 https://maestrodatabase.com/blog/a-better-way-to-disrupt-health-care 2018-01-31T19:56:47 https://maestrodatabase.com/blog/selumetinib-recommended-for-approval-in-the-eu-by-chmp-as-the-first-medicine-for-paediatric-patients-with-neurofibromatosis-type-1-and-plexiform-neurofibromas 2021-04-26T06:21:17 https://maestrodatabase.com/blog/how-to-better-apply-the-paediatric-legislation-to-boost-development-of-medicines-for-children 2018-01-31T20:08:02 https://maestrodatabase.com/blog/waste-in-the-us-health-care-system-estimated-costs-and-potential-for-savings 2019-10-08T04:32:22 https://maestrodatabase.com/blog/alkermes-submits-new-drug-application-to-u-dot-s-fda-for-alks-5461-for-the-adjunctive-treatment-of-major-depressive-disorder 2018-01-31T20:16:24 https://maestrodatabase.com/blog/kites-yescarta-axicabtagene-ciloleucel-reimbursed-in-alberta-for-the-treatment-of-certain-types-of-aggressive-non-hodgkin-lymphoma 2021-04-26T06:28:37 https://maestrodatabase.com/blog/more-government-tax-incentives-for-health-insurance 2018-01-31T20:05:35 https://maestrodatabase.com/blog/`life-changing-breast-cancer-drug-can-be-routinely-used-in-nhs-says-nice 2018-01-31T20:25:11 https://maestrodatabase.com/blog/european-commission-approves-gsks-jemperli-dostarlimab-the-first-anti-pd-1-therapy-approved-for-recurrent-or-advanced-endometrial-cancer 2021-04-26T06:02:37 https://maestrodatabase.com/blog/teva-announces-u-dot-s-approval-of-ajovy-fremanezumab-vfrm-injection-the-first-and-only-anti-cgrp-treatment-with-both-quarterly-and-monthly-dosing-for-the-preventive-treatment-of-migraine-in-adults 2018-09-16T08:54:55 https://maestrodatabase.com/blog/novartis-receives-fda-approval-for-beovu-offering-wet-amd-patients-vision-gains-and-greater-fluid-reductions-vs-aflibercept 2019-10-08T05:24:39 https://maestrodatabase.com/blog/trump-urges-u-dot-s-congress-to-back-right-to-try-for-terminally-ill 2018-01-31T20:35:22 https://maestrodatabase.com/blog/tagrisso-recommended-for-approval-in-the-eu-by-chmp-for-the-adjuvant-treatment-of-patients-with-early-stage-egfr-mutated-lung-cancer 2021-04-26T06:08:29 https://maestrodatabase.com/blog/abbvies-skyrizi-risankizumab-accepted-for-use-within-nhs-scotland 2019-10-08T05:08:41 https://maestrodatabase.com/blog/proposal-to-increase-the-subsidy-for-hexamine-hippurate-tablets-and-for-flecainide-acetate-injection 2019-10-08T04:35:27 https://maestrodatabase.com/blog/janssen-announces-submission-of-two-applications-to-u-dot-s-fda-seeking-approval-of-simponi-aria-golimumab-for-the-treatment-of-polyarticular-juvenile-idiopathic-arthritis-and-juvenile-psoriatic-arthritis 2020-04-26T03:45:16 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-february-2018-update 2018-01-31T20:53:15 https://maestrodatabase.com/blog/fda-embraces-radical-transparency-by-publishing-complete-response-letters 2025-07-16T04:23:58 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-february-2018 2018-01-31T20:48:18 https://maestrodatabase.com/blog/vertex-announces-health-canada-market-authorisation-for-orkambi-lumacaftor-slash-ivacaftor-in-children-with-cystic-fibrosis-ages-1-to-<2-years 2023-04-13T01:19:48 https://maestrodatabase.com/blog/policy-updates-on-access-to-and-affordability-of-innovative-medicines-in-china 2022-07-25T07:54:22 https://maestrodatabase.com/blog/health-canada-approves-lillys-omvoh-mirikizumab-for-crohns-disease-new-citrate-free-formulation 2025-07-16T02:32:46 https://maestrodatabase.com/blog/cancer-patients-to-benefit-from-new-pharmac-funded-drugs 2019-10-08T06:46:04 https://maestrodatabase.com/blog/corcept-submits-new-drug-application-for-relacorilant-as-a-treatment-for-patients-with-platinum-resistant-ovarian-cancer 2025-07-16T03:11:45 https://maestrodatabase.com/blog/junshi-biosciences-receives-fda-breakthrough-therapy-designation-for-toripalimab-for-the-treatment-of-nasopharyngeal-carcinoma 2020-09-11T02:45:28 https://maestrodatabase.com/blog/biden-administrations-medicare-drug-price-negotiations-will-face-major-tests-in-2024 2023-12-29T23:23:13 https://maestrodatabase.com/blog/nanoscope-therapeutics-initiates-rolling-submission-of-biologics-license-application-to-fda-for-mco-010-the-first-gene-agnostic-therapy-to-treat-retinitis-pigmentosa 2025-07-16T03:19:12 https://maestrodatabase.com/blog/father-of-two-has-to-get-cancer-treatment-in-germany-after-pharmac-complications 2023-12-29T23:05:35 https://maestrodatabase.com/blog/nsw-boy-with-severe-eczema-says-hes-tired-of-living-with-illness-as-family-ask-for-drug-to-be-subsidised 2020-09-11T02:50:27 https://maestrodatabase.com/blog/beone-bets-tevimbra-will-beat-rivals-to-pd-1-reimbursement-in-korea 2025-07-16T03:56:53 https://maestrodatabase.com/blog/nice-recommends-cenobamate-for-treatment-of-adult-epilepsy-patients-in-uk 2021-11-15T19:56:37 https://maestrodatabase.com/blog/mhra-approves-sebetralstat-ekterly-to-treat-hereditary-angioedema-attacks-in-patients-aged-12-and-over 2025-07-16T08:57:02 https://maestrodatabase.com/blog/tga-provisionally-approves-the-biocelect-novavax-covid-19-vaccine-nuvaxovid-for-use-in-individuals-aged-12-17-years 2022-07-25T08:18:42 https://maestrodatabase.com/blog/rhythm-pharmaceuticals-announces-fda-acceptance-for-filing-and-priority-review-of-supplemental-new-drug-application-for-imcivree-setmelanotide-for-patients-with-bardet-biedl-syndrome-and-alstroem-syndrome 2021-11-15T20:02:27 https://maestrodatabase.com/blog/smc---july-2025-decisions 2025-07-16T10:32:02 https://maestrodatabase.com/blog/horizon-therapeutics-receives-chmp-positive-opinion-for-uplinza-inebilizumab-as-a-monotherapy-for-the-treatment-of-adult-patients-with-neuromyelitis-optica-spectrum-disorder 2021-11-15T10:54:25 https://maestrodatabase.com/blog/medexus-reports-health-canada-approval-of-gleolan-for-use-in-guided-surgical-resection-of-high-grade-gliomas 2020-09-11T03:29:48 https://maestrodatabase.com/blog/no-outcomes-on-breast-cancer-drugs-kadcyla-and-ibrance-yet-says-pharmac 2019-04-25T10:23:59 https://maestrodatabase.com/blog/new-fda-chief-will-face-covid-woes-and-calls-for-drug-approval-reform 2021-11-15T20:26:30 https://maestrodatabase.com/blog/aytu-bioscience-announces-submission-of-zolpimist-for-approval-to-australian-tga 2019-04-25T10:17:54 https://maestrodatabase.com/blog/celltrions-monoclonal-antibody-treatment-regdanvimab-approved-by-the-european-commission-for-the-treatment-of-covid-19 2021-11-15T20:29:15 https://maestrodatabase.com/blog/is-arbitration-an-answer-for-high-drug-prices 2019-04-25T10:38:54 https://maestrodatabase.com/blog/pharmas-charity-allies-help-its-fight-to-keep-drug-prices-high 2019-04-25T10:36:03 https://maestrodatabase.com/blog/pharmac-says-it-will-need-more-funding-amid-global-covid-19-crisis 2020-04-26T20:43:10 https://maestrodatabase.com/blog/at-a-lively-drug-pricing-debate-experts-suggest-killing-off-copays 2019-04-25T10:32:41 https://maestrodatabase.com/blog/medicines-australia-reinforces-need-for-continued-collaborative-commitment-to-australias-medicine-supplies 2020-04-26T20:47:46 https://maestrodatabase.com/blog/its-time-for-congress-to-get-medicare-drug-pricing-reform-right 2021-11-15T20:15:39 https://maestrodatabase.com/blog/califf-has-lots-of-unfinished-fda-business 2021-11-15T20:07:05 https://maestrodatabase.com/blog/fda-hires-pew-director-to-lead-regulatory-policy 2019-04-25T10:41:44 https://maestrodatabase.com/blog/competing-with-and-learning-from-china-in-the-global-pharmaceutical-innovation-race 2021-11-15T20:44:19 https://maestrodatabase.com/blog/when-insurers-choose-patients-lose---campaign-launched-to-protect-patient-choice 2021-11-15T20:34:30 https://maestrodatabase.com/blog/health-canada-approves-tremfya-guselkumab-injection-a-first-in-class-selective-interleukin-23-inhibitor-for-active-psoriatic-arthritis 2020-09-11T04:54:07 https://maestrodatabase.com/blog/new-who-report-maps-barriers-to-insulin-availability-and-suggests-actions-to-promote-universal-access 2021-11-15T20:49:55 https://maestrodatabase.com/blog/medicare-proposes-boosting-payments-for-car-t-cancer-therapy 2019-04-25T11:11:16 https://maestrodatabase.com/blog/icer-publishes-evidence-report-on-treatments-for-non-alcoholic-steatohepatitis 2023-04-13T20:34:42 https://maestrodatabase.com/blog/fda-accepts-application-for-mercks-keytruda-pembrolizumab-plus-chemotherapy-as-first-line-treatment-for-locally-advanced-unresectable-or-metastatic-gastric-or-gastro-esophageal-junction-adenocarcinoma 2023-04-13T20:28:44 https://maestrodatabase.com/blog/blocking-fda-approval-of-abortion-pill-could-stifle-innovation-in-the-biopharma-industry-experts-say 2023-04-13T20:25:34 https://maestrodatabase.com/blog/la-jolla-pharmaceutical-announces-u-dot-s-fdas-grant-of-breakthrough-therapy-designation-for-ljpc-0118-for-the-treatment-of-severe-malaria 2019-04-25T11:13:37 https://maestrodatabase.com/blog/regulatory-health-technology-assessment-and-company-interactions-the-current-landscape-and-future-ecosystem-for-drug-development-review-and-reimbursement 2023-04-13T20:53:34 https://maestrodatabase.com/blog/cancer-deaths-could-be-reduced-with-genomic-testing-investment-says-national-oncology-alliance 2021-04-26T09:57:04 https://maestrodatabase.com/blog/lilly-to-establish-an-access-program-for-patients-as-it-prepares-to-withdraw-lartruvo-from-the-global-market 2019-04-25T11:50:26 https://maestrodatabase.com/blog/u-dot-s-fda-issues-complete-response-letter-for-mirikizumab 2023-04-13T20:42:10 https://maestrodatabase.com/blog/how-lowering-the-price-of-a-common-asthma-drug-made-it-harder-to-get 2024-01-01T05:10:20 https://maestrodatabase.com/blog/pbs-medicines-to-cost-aussies-more-from-today-safety-net-thresholds-also-increase 2024-01-01T05:06:40 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-january-2024 2024-01-01T01:52:48 https://maestrodatabase.com/blog/sun-pharma-and-sparc-announce-us-fda-approval-of-xelpros-to-treat-open-angle-glaucoma-or-ocular-hypertension 2018-09-17T00:07:03 https://maestrodatabase.com/blog/prescriptions-surged-as-trump-praised-drugs-in-coronavirus-fight 2020-04-27T00:53:16 https://maestrodatabase.com/blog/carsgen-announces-car-t-cell-product-candidate-ct041-granted-prime-eligibility-by-the-ema 2021-11-16T01:12:39 https://maestrodatabase.com/blog/how-surrogate-outcomes-influence-long-term-health-outcomes 2023-04-13T20:56:47 https://maestrodatabase.com/blog/ema-validates-marketing-authorisation-application-for-trogarzo 2018-09-17T00:01:19 https://maestrodatabase.com/blog/nexviazyme-avalglucosidase-alfa-for-injection-is-now-approved-in-canada-for-patients-with-late-onset-pompe-disease-acid-a-glucosidase-deficiency 2021-11-16T01:28:59 https://maestrodatabase.com/blog/a-global-outlier-how-drug-firms-are-fighting-back-against-uk-tax-increases 2023-04-13T20:59:29 https://maestrodatabase.com/blog/patients-with-high-risk-skin-cancer-have-new-treatment-option 2018-09-17T11:08:17 https://maestrodatabase.com/blog/when-prescribing-cures-for-overpriced-drugs-governments-first-duty-is-do-no-harm 2019-04-25T23:38:57 https://maestrodatabase.com/blog/european-medicines-agency-to-appeal-brexit-lease-case 2019-04-25T23:35:52 https://maestrodatabase.com/blog/drug-rebates-arent-kickbacks 2018-09-17T01:51:49 https://maestrodatabase.com/blog/nzord-supports-rare-medicine-petitions-to-government 2019-04-25T23:34:06 https://maestrodatabase.com/blog/axsome-therapeutics-announces-fda-acceptance-and-priority-review-of-new-drug-application-for-axs-05-for-treatment-of-major-depressive-disorder 2021-04-26T11:26:14 https://maestrodatabase.com/blog/dutch-swiss-regulators-forge-agreement-on-data-exchange 2018-09-17T02:10:05 https://maestrodatabase.com/blog/bridgebio-pharma-and-sentynl-therapeutics-receive-positive-chmp-opinion-for-nulibry-fosdenopterin-for-the-treatment-of-mocd-type-a 2022-07-25T21:42:04 https://maestrodatabase.com/blog/fda-approves-bausch-healths-duobrii-halobetasol-propionate-and-tazarotene-lotion-0-dot-01-percent-slash-0-dot-045-percent-for-plaque-psoriasis-in-adults 2019-04-25T23:44:36 https://maestrodatabase.com/blog/hls-announces-that-vascepa-is-now-reimbursed-by-ontarios-provincial-drug-plan 2022-07-25T13:09:37 https://maestrodatabase.com/blog/targeted-treatment-for-melanoma-to-be-free-on-nhs 2018-09-17T11:17:17 https://maestrodatabase.com/blog/treosulphan-nda-resubmitted-to-fda 2022-07-25T12:55:34 https://maestrodatabase.com/blog/a-commerce-department-report-causes-a-stir-over-whether-to-use-federal-law-to-lower-drug-prices 2019-04-25T23:41:10 https://maestrodatabase.com/blog/vertex-and-crispr-therapeutics-announce-priority-medicines-prime-designation-granted-by-the-european-medicines-agency-to-ctx001-for-transfusion-dependent-beta-thalassaemia 2021-04-26T12:46:10 https://maestrodatabase.com/blog/u-dot-s-to-share-60-million-doses-of-astrazeneca-covid-19-vaccine-with-other-countries 2021-04-26T21:06:14 https://maestrodatabase.com/blog/more-affordable-drugs-offered-with-health-care-reform 2019-04-25T23:49:52 https://maestrodatabase.com/blog/ema-and-ecdc-join-forces-for-enhanced-post-marketing-monitoring-of-covid-19-vaccines-in-europe 2021-04-26T20:57:02 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-january-2024 2024-01-01T05:52:52 https://maestrodatabase.com/blog/icer-publishes-white-paper-evaluating-policy-options-to-strengthen-fdas-accelerated-approval-pathway-for-prescription-drugs 2021-04-26T12:00:52 https://maestrodatabase.com/blog/sab-biotherapeutics-granted-fast-track-designation-from-fda-for-sab-176-influenza-immunotherapy-with-high-cross-reactivity-to-multiple-strains-of-influenza 2023-04-13T23:24:08 https://maestrodatabase.com/blog/hospital-costs-not-drug-prices-are-out-of-control 2021-04-26T12:10:51 https://maestrodatabase.com/blog/anti-pd-1-monoclonal-antibody-puyouheng-hx-008-pucotenlimab-co-developed-by-lepu-biopharma-and-hanx-biopharmaceuticals-was-approved-for-marketing-in-china-by-nmpa 2022-07-25T21:47:31 https://maestrodatabase.com/blog/antimicrobial-resistance-fda-discusses-reimbursement-reforms 2018-09-17T13:48:35 https://maestrodatabase.com/blog/icer-publishes-evidence-report-on-targeted-immune-modulator-therapies-for-ulcerative-colitis 2020-09-11T12:28:40 https://maestrodatabase.com/blog/fda-grants-rare-paediatric-disease-designation-to-cellectar-biosciences-clr-131-for-the-treatment-of-osteosarcoma 2018-09-17T13:51:27 https://maestrodatabase.com/blog/surrogate-outcomes-in-health-technology-assessment-an-international-review-of-methodological-guidelines 2020-09-11T12:37:38 https://maestrodatabase.com/blog/pfizer-seeks-emergency-use-authorisation-for-novel-covid-19-oral-antiviral-candidate 2021-11-16T19:57:51 https://maestrodatabase.com/blog/viatris-and-biocon-biologics-announce-launch-of-interchangeable-semglee-insulin-glargine-yfgn-injection-and-insulin-glargine-insulin-glargine-yfgn-injection 2021-11-16T20:19:02 https://maestrodatabase.com/blog/health-groups-sue-to-block-trump-expansion-of-non-obamacare-plans 2018-09-17T13:38:44 https://maestrodatabase.com/blog/are-we-measuring-what-matters-most-on-uptake-to-medicines-in-england 2021-11-16T20:09:39 https://maestrodatabase.com/blog/insights-from-the-march-2020-pbac-meeting---semaglutide-ozempic 2020-04-27T04:01:55 https://maestrodatabase.com/blog/icer-identifies-costliest-us-drug-price-hikes-that-are-not-supported-by-new-clinical-evidence 2019-10-08T19:15:52 https://maestrodatabase.com/blog/fda-authorises-marketing-of-virtual-reality-system-for-chronic-pain-reduction 2021-11-16T19:43:37 https://maestrodatabase.com/blog/fda-approves-first-treatment-to-increase-pain-free-light-exposure-in-patients-with-a-rare-disorder 2019-10-08T19:13:04 https://maestrodatabase.com/blog/medicines-australia-welcomes-covid-19-tracking-app 2020-04-27T03:32:20 https://maestrodatabase.com/blog/nice-backs-portolas-ondexxya 2020-09-11T12:03:35 https://maestrodatabase.com/blog/icer-identifies-most-significant-2020-us-drug-price-hikes-not-supported-by-new-clinical-evidence 2021-11-16T19:54:14 https://maestrodatabase.com/blog/sanofis-sar446597-earns-fast-track-designation-in-the-us-for-geographic-atrophy-due-to-age-related-macular-degeneration 2025-07-16T23:05:31 https://maestrodatabase.com/blog/fda-approves-device-for-treatment-of-acute-coronary-artery-perforations 2018-09-17T21:40:42 https://maestrodatabase.com/blog/icer-to-assess-treatments-for-non-alcoholic-steatohepatitis 2022-10-05T19:51:35 https://maestrodatabase.com/blog/pre-approval-and-post-approval-availability-of-evidence-and-clinical-benefit-of-conditionally-approved-cancer-drugs-in-europe-a-comparison-with-standard-approved-cancer-drugs 2021-11-16T20:41:34 https://maestrodatabase.com/blog/call-for-government-to-help-pay-sick-australians-health-insurance-premiums 2019-10-08T19:50:56 https://maestrodatabase.com/blog/humira-rituxan-top-list-of-u-dot-s-costliest-drug-price-increases 2019-10-08T19:19:59 https://maestrodatabase.com/blog/pharmac-widens-access-to-adalimumab-through-transition-to-biosimilar 2021-11-16T20:45:01 https://maestrodatabase.com/blog/new-medical-treatments-will-use-genetic-scissors-and-other-clever-tricks 2024-01-01T07:06:15 https://maestrodatabase.com/blog/fda-accepts-resubmitted-new-drug-application-for-itca-650 2019-10-08T20:54:00 https://maestrodatabase.com/blog/changes-in-drug-pricing-after-drug-shortages-in-the-united-states 2018-09-17T21:49:59 https://maestrodatabase.com/blog/hiv-prevention-drugs-will-be-available-without-a-prescription-in-california 2019-10-08T20:51:16 https://maestrodatabase.com/blog/genetesis-receives-second-fda-breakthrough-device-designation-for-non-invasive-diagnosis-of-myocardial-ischaemia-using-cardioflux-mcg 2023-04-14T01:49:00 https://maestrodatabase.com/blog/pharma-companies-avoid-estimated-$215m-a-year-in-local-tax-oxfam 2018-09-17T21:57:35 https://maestrodatabase.com/blog/pfizer-and-the-medicines-patent-pool-sign-licensing-agreement-for-covid-19-oral-antiviral-treatment-candidate-to-expand-access-in-low-and-middle-income-countries 2021-11-16T20:33:38 https://maestrodatabase.com/blog/the-fourth-edition-of-the-european-network-for-health-technology-assessment-forum-highlights-and-outcomes 2020-04-27T05:05:02 https://maestrodatabase.com/blog/abbvie-expands-immunology-portfolio-in-the-european-union-with-the-european-commission-approval-of-skyrizi-risankizumab-for-the-treatment-of-adults-with-active-psoriatic-arthritis 2021-11-17T20:31:50 https://maestrodatabase.com/blog/european-commission-approves-nucala-mepolizumab-in-three-additional-eosinophil-driven-diseases 2021-11-17T20:24:00 https://maestrodatabase.com/blog/pfizer-loses-u-dot-s-appeal-over-co-pays-for-heart-failure-patients 2022-07-26T01:02:35 https://maestrodatabase.com/blog/fda-grants-lin-bioscience-rare-paediatric-disease-status-for-lbs-008-to-treat-stargardt-disease 2018-09-18T03:02:08 https://maestrodatabase.com/blog/lokelma-granted-fast-track-designation-in-the-us-to-reduce-cardiovascular-outcomes-in-patients-on-chronic-haemodialysis-with-hyperkalaemia 2021-11-17T20:42:17 https://maestrodatabase.com/blog/nice-the-nhs-and-cancer-drugs 2018-02-01T06:14:30 https://maestrodatabase.com/blog/icer-publishes-final-evidence-report-and-policy-recommendations-on-mavacamten-for-hypertrophic-cardiomyopathy 2021-11-17T20:16:15 https://maestrodatabase.com/blog/ema-receives-application-for-conditional-marketing-authorisation-of-novavaxs-covid-19-vaccine-nuvaxovid 2021-11-17T20:21:00 https://maestrodatabase.com/blog/changes-to-tga-slash-pbac-parallel-processing-arrangements-for-biosimilar-medicines 2018-09-18T03:25:21 https://maestrodatabase.com/blog/alvotech-provides-regulatory-update-on-avt02-biologics-license-application 2023-04-14T21:32:13 https://maestrodatabase.com/blog/tga-international-engagement-strategy-operations-plan-2018-19 2018-09-18T03:22:12 https://maestrodatabase.com/blog/fda-approves-octapharmas-wilate-for-haemophilia-a-in-adult-and-adolescent-patients 2019-10-08T21:10:25 https://maestrodatabase.com/blog/zentalis-pharmaceuticals-announces-fast-track-designation-granted-by-the-u-dot-s-fda-to-zn-c3-for-the-treatment-of-uterine-serous-carcinoma 2021-11-17T20:49:32 https://maestrodatabase.com/blog/america-needs-to-win-the-coronavirus-vaccine-race 2020-04-27T06:10:44 https://maestrodatabase.com/blog/improved-agreement-means-nice-now-recommends-lung-cancer-treatment 2020-09-11T22:58:33 https://maestrodatabase.com/blog/nice-chief-executive-and-chairman-thank-non-executive-director-for-his-service-as-he-announces-resignation 2020-09-11T23:01:41 https://maestrodatabase.com/blog/throwing-the-baby-out-with-the-bath-water-congress-considers-banning-the-qaly 2023-04-14T21:47:19 https://maestrodatabase.com/blog/call-for-rsv-vaccine-subsidies-for-elderly-as-severe-hospitalisations-on-rise 2025-07-16T23:54:40 https://maestrodatabase.com/blog/health-canada-issues-warning-against-use-of-hydroxychloroquine-for-covid-19 2020-04-27T11:06:08 https://maestrodatabase.com/blog/insights-from-the-march-2020-pbac-meeting---pembrolizumab-keytruda 2020-04-27T11:21:24 https://maestrodatabase.com/blog/insights-from-the-march-2020-pbac-meeting---dupilumab-dupixent 2020-04-27T06:38:27 https://maestrodatabase.com/blog/ousting-vaccine-chief-is-going-to-set-us-back-former-fda-head-says 2020-04-27T11:00:33 https://maestrodatabase.com/blog/cytodyn-submits-completed-biologics-license-application-to-the-fda-for-leronlimab-as-a-combination-therapy-for-highly-treatment-experienced-hiv-patients 2020-04-27T20:45:48 https://maestrodatabase.com/blog/mhra-grants-marketing-authorisation-for-gbts-oxbryta-voxelotor-for-use-in-great-britain-for-the-treatment-of-haemolytic-anaemia-in-patients-with-sickle-cell-disease-age-12-years-and-older 2022-07-26T12:30:55 https://maestrodatabase.com/blog/erc-granted-fda-fast-track-designation-for-sitoiganap-in-patients-with-recurrent-glioblastoma 2022-07-26T12:23:19 https://maestrodatabase.com/blog/takeda-announces-u-dot-s-fda-breakthrough-therapy-designation-for-mobocertinib-tak-788-for-the-treatment-of-nsclc-patients-with-egfr-exon-20-insertion-mutations 2020-04-27T20:52:00 https://maestrodatabase.com/blog/australia-unveils-strategy-for-engaging-with-foreign-regulators 2018-09-18T11:16:24 https://maestrodatabase.com/blog/european-commission-approves-rinvoq-upadacitinib-for-the-treatment-of-adults-with-moderate-to-severe-ulcerative-colitis 2022-07-26T12:17:33 https://maestrodatabase.com/blog/ema-validates-bristol-myers-squibbs-application-for-empliciti-elotuzumab-plus-pomalidomide-and-low-dose-dexamethasone-in-patients-with-multiple-myeloma 2018-09-18T11:18:29 https://maestrodatabase.com/blog/information-forums---streamlining-pbs-medicines-listing-processes 2018-09-18T11:09:40 https://maestrodatabase.com/blog/tga-gives-a-tick-to-scemblix 2022-07-26T12:09:50 https://maestrodatabase.com/blog/ema-publishes-agenda-for-chmp-17-20-september-meeting 2018-09-18T11:35:36 https://maestrodatabase.com/blog/new-zealands-vaccination-program-is-built-on-pfizer-and-a-plan-to-take-it-slow 2021-04-26T23:48:48 https://maestrodatabase.com/blog/novavax-announces-expanded-approval-of-nuvaxovid-covid-19-vaccine-for-adolescents-aged-12-through-17-in-japan 2022-07-26T13:52:07 https://maestrodatabase.com/blog/icer-releases-evidence-report-on-treatments-for-cystic-fibrosis 2020-04-27T21:02:39 https://maestrodatabase.com/blog/ionis-announces-that-fda-accepts-new-drug-application-and-grants-priority-review-of-tofersen-for-a-rare-genetic-form-of-als 2022-07-26T13:05:59 https://maestrodatabase.com/blog/the-european-union-sues-astrazeneca-over-missing-vaccine-doses 2021-04-27T01:50:15 https://maestrodatabase.com/blog/change-of-access-to-funded-nicotine-replacement-therapy-and-the-emergency-contraceptive-pill 2017-07-20T03:04:22 https://maestrodatabase.com/blog/merger-of-cigna-and-express-scripts-gets-approval-from-justice-department 2018-09-18T11:27:21 https://maestrodatabase.com/blog/despite-their-anger-over-high-drug-prices-americans-are-giving-pharma-credit-for-helping-contain-covid-19 2022-07-26T13:02:14 https://maestrodatabase.com/blog/harvard-professors-attack-on-pharmas-clinical-trials-is-absurd 2018-09-18T11:44:46 https://maestrodatabase.com/blog/lokelma-us-label-updated-to-include-dosing-guidance-for-the-treatment-of-hyperkalaemia-in-patients-with-end-stage-renal-disease-on-haemodialysis 2020-04-27T20:58:21 https://maestrodatabase.com/blog/the-fda-needs-to-get-ready-to-evaluate-synthetic-cells-the-next-generation-of-therapeutics 2022-07-26T12:36:26 https://maestrodatabase.com/blog/lfb-announces-the-approval-of-cevenfacta-eptacog-beta-in-the-european-union 2022-07-26T12:41:32 https://maestrodatabase.com/blog/global-leaders-unite-to-ensure-everyone-everywhere-can-access-new-vaccines-tests-and-treatments-for-covid-19 2020-04-27T21:36:04 https://maestrodatabase.com/blog/no-magic-bullet-for-drug-makers-and-the-fda-clinical-trials-on-ultra-rare-diseases-pose-thorny-challenges 2022-07-26T21:42:27 https://maestrodatabase.com/blog/vaccine-could-potentially-be-available-later-this-year-coalition-says 2020-04-27T21:40:06 https://maestrodatabase.com/blog/vast-therapeutics-receives-qualified-infectious-disease-product-status-for-bioc11 2019-10-09T01:18:50 https://maestrodatabase.com/blog/eiger-biopharmaceuticals-announces-ema-validation-of-lonafarnib-maa-for-treatment-of-progeria-and-progeroid-laminopathies 2020-04-27T21:15:25 https://maestrodatabase.com/blog/health-canada-approves-label-expansion-for-telixs-illuccix-to-include-patient-selection-for-psma-targeted-therapy 2024-10-07T01:03:54 https://maestrodatabase.com/blog/karyopharm-announces-european-medicines-agencys-validation-of-its-type-ii-variation-marketing-authorisation-application-for-nexpovio-selinexor-in-combination-with-velcade-bortezomib-and-dexamethasone-for-the-treatment-of-adult-patients-with-multiple-myeloma 2021-04-27T01:54:58 https://maestrodatabase.com/blog/advance-notice-of-consultation-about-changes-to-the-pharmaceutical-schedule-rules 2018-02-01T11:24:40 https://maestrodatabase.com/blog/henlius-hanquyou-received-tga-approval-in-australia 2022-07-26T21:34:35 https://maestrodatabase.com/blog/neurocrine-biosciences-announces-fda-approval-of-once-daily-ongentys-opicapone-as-an-add-on-treatment-for-patients-with-parkinsons-disease-experiencing-off-episodes 2020-04-27T21:22:22 https://maestrodatabase.com/blog/nice-widens-its-zolgensma-appraisal-due-to-european-marketing-authorisation 2020-09-12T02:46:51 https://maestrodatabase.com/blog/45-medicines-affected-by-supply-issues-as-covid-causes-unprecedented-challenge 2022-07-26T21:19:52 https://maestrodatabase.com/blog/health-canada-approves-calquence-acalabrutinib-for-adult-patients-with-previously-treated-mantle-cell-lymphoma 2019-10-09T01:12:28 https://maestrodatabase.com/blog/lowest-drug-plan-premium-does-not-always-mean-lowest-cost-for-you 2022-07-26T21:24:57 https://maestrodatabase.com/blog/sanofi-dndi-seek-european-medicines-agency-review-for-sleeping-sickness-treatment 2018-02-01T11:39:50 https://maestrodatabase.com/blog/kiwi-mum-pleads-with-pharmac-to-fund-life-changing-drug-spinraza-for-her-two-children 2020-09-12T22:46:06 https://maestrodatabase.com/blog/fda-explains-the-ins-and-outs-of-real-time-oncology-review-program-in-new-guidance 2022-07-27T11:22:33 https://maestrodatabase.com/blog/evaluation-of-advanced-therapy-medicines 2018-02-01T11:32:16 https://maestrodatabase.com/blog/duvelisib-for-patients-with-chronic-lymphocytic-leukaemia 2022-07-27T11:11:54 https://maestrodatabase.com/blog/final-nhs-nod-for-janssens-imbruvica 2018-02-01T11:35:32 https://maestrodatabase.com/blog/agenda-for-the-november-2022-pbac-meeting 2022-07-27T11:16:40 https://maestrodatabase.com/blog/nhs-england-takes-charge-on-market-access 2018-02-01T20:23:39 https://maestrodatabase.com/blog/ema-response-to-the-monkeypox-public-health-emergency 2022-07-27T11:08:01 https://maestrodatabase.com/blog/labor-and-coalition-in-lockstep-as-trump-threatens-to-pull-pharma-tariffs-forward 2025-07-17T02:48:03 https://maestrodatabase.com/blog/a-revolution-in-health-care-is-coming 2018-02-01T20:29:59 https://maestrodatabase.com/blog/tga-approves-first-humira-biosimilar 2018-02-01T11:47:11 https://maestrodatabase.com/blog/pfizer-broadside-on-pbs-productivity-amid-pharma-tariff-fears 2025-07-17T02:50:48 https://maestrodatabase.com/blog/demand-is-outstripping-the-supply-is-canada-running-out-of-astrazeneca-covid-19-vaccines 2021-04-27T03:08:45 https://maestrodatabase.com/blog/post-brexit-destination-of-eu-medicines-regulator-thrown-into-doubt-as-italy-launches-appeal 2018-02-01T20:19:30 https://maestrodatabase.com/blog/eli-lilly-calls-out-korea-as-verzenios-$36k-cost-threatens-cure-window 2025-07-17T05:07:52 https://maestrodatabase.com/blog/fda-approves-avycaz-ceftazidime-and-avibactam-for-the-treatment-of-patients-with-hospital-acquired-bacterial-pneumonia-and-ventilator-associated-bacterial-pneumonia 2018-02-02T01:18:27 https://maestrodatabase.com/blog/reata-announces-fda-accepted-for-filing-the-nda-for-bardoxolone-for-the-treatment-of-patients-with-chronic-kidney-disease-caused-by-alport-syndrome 2021-04-27T03:33:49 https://maestrodatabase.com/blog/eu-proposes-joint-studies-to-speed-acceptance-of-new-medicine 2018-02-01T20:45:07 https://maestrodatabase.com/blog/protalix-biotherapeutics-pegunigalsidase-alfa-receives-fast-track-designation-from-the-u-dot-s-fda 2018-02-02T01:31:41 https://maestrodatabase.com/blog/msac-publishes-agenda-for-november-2022-meeting 2022-07-27T11:30:29 https://maestrodatabase.com/blog/new-treatment-option-for-adults-with-adhd-foquest-methylphenidate-controlled-release-capsules-now-available-in-canada 2018-02-02T01:25:55 https://maestrodatabase.com/blog/new-flexible-service-through-our-scientific-advice-program 2024-10-07T04:28:12 https://maestrodatabase.com/blog/free-meningococcal-vaccine-backed-at-national-level 2018-02-03T05:37:56 https://maestrodatabase.com/blog/thousands-more-breast-cancer-patients-to-benefit-from-new-nhs-treatment 2025-07-17T11:53:07 https://maestrodatabase.com/blog/agenda-for-november-2020-pbac-meeting 2020-09-13T02:07:17 https://maestrodatabase.com/blog/strengthened-guidance-on-follow-up-and-risk-management-for-atmp-developers 2018-02-03T05:45:52 https://maestrodatabase.com/blog/glenmarks-ryaltris-nasal-spray-now-approved-in-europe-for-the-first-line-treatment-of-allergic-rhinitis-in-patients-over-12-years-of-age 2021-04-27T06:37:53 https://maestrodatabase.com/blog/fda-guidance-says-sponsors-should-provide-convincing-proof-of-concept-data-to-support-inds-for-individualised-medicine 2021-04-27T11:15:11 https://maestrodatabase.com/blog/confirmatory-trials-of-accelerated-approval-drugs----will-imposing-fines-reduce-delays 2024-10-07T04:16:20 https://maestrodatabase.com/blog/world-first-cancer-treatment-now-accessible-for-hundreds-more-aussies-as-prices-slashed-with-addition-to-the-pbs 2024-10-07T04:09:42 https://maestrodatabase.com/blog/health-canada-initiates-the-review-of-the-rolling-submission-for-the-first-canadian-based-covid-19-vaccine-candidate 2021-04-27T05:12:34 https://maestrodatabase.com/blog/european-medicines-agency-accepts-fremanezumab-marketing-authorisation-application 2018-02-03T05:48:42 https://maestrodatabase.com/blog/ms-health-push-for-nurses-to-hand-out-abortion-pills 2022-07-27T12:01:17 https://maestrodatabase.com/blog/eu-watchdog-concerned-drug-agency-ema-may-be-too-close-to-companies 2017-07-20T06:49:13 https://maestrodatabase.com/blog/lexicon-announces-fda-acceptance-of-new-drug-application-for-sotagliflozin-to-treat-heart-failure 2022-07-27T12:28:17 https://maestrodatabase.com/blog/flu-vaccine-war-chemists-accused-of-delivering-weaker-jab 2021-04-27T11:48:42 https://maestrodatabase.com/blog/enzyvant-resubmits-biologics-licence-application-to-fda-for-rvt-802-for-paediatric-congenital-athymia 2021-04-27T20:55:14 https://maestrodatabase.com/blog/trump-demands-that-senators-find-a-way-to-replace-obamacare 2017-07-20T11:06:52 https://maestrodatabase.com/blog/merck-announces-u-dot-s-fda-grants-tentative-approval-for-lusduna-nexvue-insulin-glargine-injection-a-follow-on-biologic-basal-insulin 2017-07-20T20:55:44 https://maestrodatabase.com/blog/ema-grants-accelerated-assessment-procedure-for-nefecon-for-the-treatment-of-iga-nephropathy 2021-04-27T11:22:07 https://maestrodatabase.com/blog/crossing-the-equity-chasm-addressing-a-second-valley-of-death-in-biomedical-innovation 2024-10-07T05:15:53 https://maestrodatabase.com/blog/leo-pharma-receives-marketing-authorisation-for-kyntheum-brodalumab-a-new-biologic-for-the-treatment-of-moderate-to-severe-plaque-psoriasis-in-the-european-union 2017-07-20T12:16:35 https://maestrodatabase.com/blog/fractyl-announces-fda-breakthrough-device-designation-for-revita-dmr-in-insulin-treated-type-2-diabetes 2021-04-27T11:30:59 https://maestrodatabase.com/blog/us-fda-approves-gsks-shingrix-in-a-pre-filled-syringe-presentation 2025-07-17T22:52:37 https://maestrodatabase.com/blog/ultragenyx-receives-breakthrough-therapy-designation-for-setrusumab-ux143-in-osteogenesis-imperfecta 2024-10-07T23:10:11 https://maestrodatabase.com/blog/expanded-pbs-listings-make-vital-treatments-more-affordable 2024-01-02T02:29:09 https://maestrodatabase.com/blog/abbvie-submits-regulatory-applications-to-fda-and-ema-for-upadacitinib-rinvoq-in-crohns-disease 2022-07-27T12:59:54 https://maestrodatabase.com/blog/prescription-drug-price-cuts-set-to-be-left-out-of-white-house-proposal 2021-04-27T21:07:06 https://maestrodatabase.com/blog/tevas-cinqaero-to-challenge-nucala-after-clearing-nice 2017-07-20T21:09:38 https://maestrodatabase.com/blog/sol-gel-technologies-provides-update-on-fda-review-of-epsolay 2021-04-27T21:00:28 https://maestrodatabase.com/blog/fda-clears-first-neonatal-magnetic-resonance-imaging-device 2017-07-20T21:17:36 https://maestrodatabase.com/blog/to-address-drug-affordability-grab-the-low-hanging-fruit 2021-04-27T21:24:13 https://maestrodatabase.com/blog/patients-face-return-trips-to-doctor-under-proposed-ban-on-antibiotic-repeat-prescriptions 2019-10-09T02:04:03 https://maestrodatabase.com/blog/three-steps-to-fix-obamacare 2017-07-20T21:15:27 https://maestrodatabase.com/blog/medtronic-receives-fda-breakthrough-designation-for-the-emprint-ablation-catheter-kit 2021-04-27T21:17:02 https://maestrodatabase.com/blog/gops-obamacare-repeal-cuts-insured-by-32-million-cbo-says 2017-07-20T21:25:38 https://maestrodatabase.com/blog/fda-may-publicly-shame-drug-makers-for-thwarting-generic-rivals 2017-07-20T21:22:54 https://maestrodatabase.com/blog/keeping-the-u-dot-s-prescription-drug-supply-chain-among-the-safest-in-the-world 2017-07-20T21:37:48 https://maestrodatabase.com/blog/nice-recommends-cinqaero-reslizumab-for-the-treatment-of-severe-eosinophilic-asthma 2017-07-20T21:29:46 https://maestrodatabase.com/blog/prescription-opioid-dispensing-in-australian-children-and-adolescents-a-national-population-based-study 2019-10-09T02:30:04 https://maestrodatabase.com/blog/proposal-to-change-aripiprazole-access-and-brand 2017-07-20T21:45:58 https://maestrodatabase.com/blog/enhertu-plus-pertuzumab-granted-breakthrough-therapy-designation-in-the-us-as-first-line-therapy-for-patients-with-her2-positive-metastatic-breast-cancer 2025-07-17T22:59:13 https://maestrodatabase.com/blog/trump-says-he-has-signed-new-executive-order-to-lower-drug-prices 2020-09-13T20:27:56 https://maestrodatabase.com/blog/fda-grants-import-discretion-of-braccos-iodinated-contrast-medium-iomeron-iomeprol-to-address-supply-shortages 2022-07-27T21:12:01 https://maestrodatabase.com/blog/gsk-announces-us-fda-approval-of-benlysta-belimumab-for-paediatric-patients-with-active-lupus-nephritis 2022-07-27T21:07:05 https://maestrodatabase.com/blog/cost-recovery---consultation-feedback 2020-04-28T01:49:11 https://maestrodatabase.com/blog/icer-publishes-evidence-report-on-treatments-for-spinal-muscular-atrophy 2025-07-18T00:42:05 https://maestrodatabase.com/blog/pierre-fabre-announces-transfer-of-investigational-new-drug-application-for-tabelecleucel-from-atara-biotherapeutics 2025-07-18T00:50:10 https://maestrodatabase.com/blog/janssen-submits-new-drug-application-to-u-dot-s-fda-seeking-approval-of-erdafitinib-for-the-treatment-of-metastatic-urothelial-cancer 2018-09-19T04:13:06 https://maestrodatabase.com/blog/praxis-precision-medicines-receives-fda-breakthrough-therapy-designation-for-relutrigine-for-the-treatment-of-seizures-associated-with-scn2a-and-scn8a-developmental-and-epileptic-encephalopathies 2025-07-18T01:36:22 https://maestrodatabase.com/blog/beyfortus-approved-in-china-for-the-prevention-of-rsv-disease-in-infants 2024-01-02T23:05:51 https://maestrodatabase.com/blog/indiviors-sublocade-rapid-induction-slash-alternative-injection-site-prior-approval-supplement-receives-fda-priority-review 2024-10-08T04:33:35 https://maestrodatabase.com/blog/new-cheaper-medicines-for-auto-immune-conditions-cancer-and-heart-disease 2024-10-08T04:26:16 https://maestrodatabase.com/blog/neuvivo-seeks-fda-approval-for-its-breakthrough-als-treatment-np001 2024-10-08T04:17:22 https://maestrodatabase.com/blog/alnylam-announces-fda-acceptance-of-new-drug-application-and-priority-review-status-for-patisiran-an-investigational-rnai-therapeutic-for-the-treatment-of-hereditary-attr-amyloidosis 2018-02-04T07:31:59 https://maestrodatabase.com/blog/european-medicines-agency-validates-bristol-myers-squibbs-application-for-repotrectinib-for-the-treatment-of-locally-advanced-or-metastatic-ros1-positive-non-small-cell-lung-cancer-and-ntrk-positive-solid-tumours 2024-01-02T23:09:34 https://maestrodatabase.com/blog/the-fda-approved-a-self-administered-nasal-spray-for-the-flu-heres-how-it-compares-to-the-traditional-flu-shot 2024-10-08T06:24:17 https://maestrodatabase.com/blog/johnson-and-johnson-receives-us-fda-priority-review-for-tar-200-nda-in-high-risk-non-muscle-invasive-bladder-cancer 2025-07-18T02:59:53 https://maestrodatabase.com/blog/drug-makers-set-to-raise-us-prices-on-at-least-500-drugs-in-january 2024-01-03T06:35:20 https://maestrodatabase.com/blog/more-americans-can-now-get-insulin-for-35-dollars 2024-01-03T06:19:25 https://maestrodatabase.com/blog/sun-pharma-announces-receipt-of-european-commission-approval-for-ilumetri-tildrakizumab-by-almirall-for-treatment-of-moderate-to-severe-chronic-plaque-psoriasis 2018-09-19T05:16:31 https://maestrodatabase.com/blog/is-europe-ready-for-a-single-health-technology-assessment 2018-02-04T20:11:04 https://maestrodatabase.com/blog/tagrisso-osimertinib-receives-full-health-canada-approval-for-targeted-treatment-of-non-small-cell-lung-cancer 2018-02-04T20:22:09 https://maestrodatabase.com/blog/clive-palmers-coronavirus-newspaper-ad-slammed-as-dangerous-and-misleading 2020-04-28T04:32:21 https://maestrodatabase.com/blog/theratechnologies-submits-sbla-for-trogarzo-intramuscular-method-of-administration-to-fda 2024-01-03T20:45:21 https://maestrodatabase.com/blog/generic-drugs-are-they-the-future-for-affordable-medicine 2018-02-04T20:44:40 https://maestrodatabase.com/blog/the-health-202-how-right-to-try-caught-washingtons-eye 2018-02-04T20:52:48 https://maestrodatabase.com/blog/the-real-story-behind-the-sudden-drop-in-canadas-drug-prices 2018-02-04T20:30:24 https://maestrodatabase.com/blog/health-canada-approves-evenity-for-the-treatment-of-osteoporosis-in-post-menopausal-women-at-high-risk-for-fracture 2019-10-09T05:03:14 https://maestrodatabase.com/blog/california-is-first-us-state-to-ban-pay-for-delay-deals 2019-10-09T09:53:28 https://maestrodatabase.com/blog/bimekizumab-for-the-treatment-of-patients-with-moderate-to-severe-hidradenitis-suppurativa 2024-10-08T07:24:31 https://maestrodatabase.com/blog/a-small-biotech-raises-the-price-on-its-cancer-drug-by-20-percent-this-year-but-will-anyone-notice 2019-10-09T09:48:37 https://maestrodatabase.com/blog/october-2024-decisions 2024-10-08T07:19:26 https://maestrodatabase.com/blog/mhras-new-international-recognition-procedure-goes-live-from-1-january-2024 2024-01-03T21:40:09 https://maestrodatabase.com/blog/fruquintinib-for-patients-with-previously-treated-metastatic-colorectal-cancer 2024-10-08T10:49:05 https://maestrodatabase.com/blog/public-summary-documents-first-time-decisions-not-to-recommend-and-deferrals---march-2025-pbac-meeting 2025-07-18T06:57:23 https://maestrodatabase.com/blog/australian-drug-maker-jumps-51-percent-after-winning-fda-approval 2019-10-09T20:01:25 https://maestrodatabase.com/blog/california-fines-more-than-a-dozen-drug-makers-for-not-providing-drug-pricing-data 2020-04-28T10:48:42 https://maestrodatabase.com/blog/shionogi-receives-european-commission-marketing-authorisation-for-fetcroja-cefiderocol-for-the-treatment-of-infections-due-to-aerobic-gram-negative-bacteria-in-adults-with-limited-treatment-options 2020-04-28T10:53:14 https://maestrodatabase.com/blog/low-income-canadians-struggling-to-pay-for-medications-plead-for-pharmacare 2019-10-09T19:56:58 https://maestrodatabase.com/blog/2020-democrats-embrace-aggressive-step-on-drug-prices 2019-10-09T19:48:38 https://maestrodatabase.com/blog/outcome-statement---june-2025-dusc-meeting 2025-07-18T06:36:11 https://maestrodatabase.com/blog/high-health-care-costs-suggest-review-is-needed-report 2019-10-09T19:45:42 https://maestrodatabase.com/blog/international-regulators-pledge-collective-support-to-combat-covid-19-pandemic 2020-04-28T10:59:19 https://maestrodatabase.com/blog/nice-u-turn-backs-stelara-for-ulcerative-colitis 2020-04-28T10:27:11 https://maestrodatabase.com/blog/merck-slashes-key-cancer-drug-price-for-china 2018-09-19T06:50:55 https://maestrodatabase.com/blog/scottish-government-readies-ports-to-mitigate-brexit-supply-disruptions 2019-10-09T20:26:22 https://maestrodatabase.com/blog/in-race-for-a-coronavirus-vaccine-an-oxford-group-leaps-ahead 2020-04-28T10:31:25 https://maestrodatabase.com/blog/most-americans-believe-trump-has-failed-to-make-progress-lowering-drug-prices 2020-04-28T10:45:57 https://maestrodatabase.com/blog/a-new-fda-fast-track-designation-for-zambon 2020-04-28T20:57:38 https://maestrodatabase.com/blog/pfizer-canada-initiates-submission-to-health-canada-for-its-bivalent-respiratory-syncytial-virus-vaccine 2023-04-15T05:17:49 https://maestrodatabase.com/blog/remdesivir-drug-to-be-approved-for-coronavirus-patients-in-may 2020-04-28T21:02:28 https://maestrodatabase.com/blog/fda-approves-mercks-keytruda-pembrolizumab-for-use-at-an-additional-recommended-dose-of-400-mg-every-six-weeks-for-all-approved-adult-indications 2020-04-28T21:18:32 https://maestrodatabase.com/blog/spinraza-could-give-teen-a-longer-life-but-government-says-its-too-expensive 2020-04-28T20:45:43 https://maestrodatabase.com/blog/how-medicine-supplies-are-managed-during-covid-19-crisis 2020-04-28T20:49:03 https://maestrodatabase.com/blog/covid-19-queensland-vaccine-researchers-make-crucial-breakthrough 2020-04-28T20:51:54 https://maestrodatabase.com/blog/pharmac-failure-to-fund-effective-contraceptive-embarrassing 2019-04-26T22:38:12 https://maestrodatabase.com/blog/the-race-for-coronavirus-vaccines-a-graphical-guide 2020-04-28T21:24:54 https://maestrodatabase.com/blog/y-mabs-submits-omburtamab-marketing-authorisation-application-to-the-ema 2021-04-28T02:25:59 https://maestrodatabase.com/blog/rockwell-medical-announces-marketing-approval-of-triferic-avnu-in-canada 2021-04-28T02:35:34 https://maestrodatabase.com/blog/applied-therapeutics-announces-maa-validation-and-nda-submission-of-govorestat-at-007-for-treatment-of-classic-galactosaemia 2024-01-04T01:12:00 https://maestrodatabase.com/blog/2023-fda-approvals 2024-01-04T02:35:23 https://maestrodatabase.com/blog/health-canada-approves-pfizer-canadas-gene-therapy-in-haemophilia-b 2024-01-04T02:24:23 https://maestrodatabase.com/blog/takeda-announces-u-dot-s-fda-grants-priority-review-for-new-drug-application-for-mobocertinib-tak-788-as-a-treatment-for-egfr-exon-20-insertion-positive-metastatic-non-small-cell-lung-cancer 2021-04-28T02:39:43 https://maestrodatabase.com/blog/cidara-therapeutics-submits-nda-for-rezafungin-and-announces-license-agreement-with-melinta-therapeutics-for-commercialisation-of-rezafungin-in-the-u-dot-s 2022-07-28T04:10:22 https://maestrodatabase.com/blog/financial-stress-impacting-cancer-survivors 2017-07-21T02:41:39 https://maestrodatabase.com/blog/fda-begins-review-of-gc-pharmas-blood-product-for-marketing-authorisation 2021-04-28T03:04:03 https://maestrodatabase.com/blog/pfizer-ceo-preparing-for-likelihood-of-vaccine-approval-before-end-of-year 2020-09-14T01:14:39 https://maestrodatabase.com/blog/big-data-use-for-public-health-publication-of-big-data-steering-group-workplan-2022-25 2022-07-28T12:16:19 https://maestrodatabase.com/blog/covid-19-vaccine-safety-report-28-july-2022 2022-07-28T12:28:37 https://maestrodatabase.com/blog/ema-reviewing-data-on-sabizabulin-for-covid-19 2022-07-28T08:15:11 https://maestrodatabase.com/blog/quality-of-health-economic-evaluations-submitted-to-the-italian-medicines-agency-current-state-and-future-actions 2020-09-14T00:23:27 https://maestrodatabase.com/blog/boehringer-receives-us-fda-breakthrough-therapy-designation-and-initiates-two-phase-3-trials-in-mash-for-survodutide 2024-10-08T23:34:15 https://maestrodatabase.com/blog/aldeyra-therapeutics-announces-fda-acceptance-for-review-of-reproxalap-new-drug-application-for-the-treatment-of-dry-eye-disease 2025-07-18T11:50:28 https://maestrodatabase.com/blog/icer-to-assess-treatment-for-myelodysplastic-syndrome 2024-01-04T02:58:23 https://maestrodatabase.com/blog/trump-pressed-for-plasma-therapy-officials-worry-is-an-unvetted-vaccine-next 2020-09-14T00:36:43 https://maestrodatabase.com/blog/revolutionary-cancer-medicine-vitrakvi-shrinks-tumours-in-days 2020-09-14T01:05:35 https://maestrodatabase.com/blog/immunitybio-announces-fda-acceptance-of-biologics-license-application-for-n-803-in-bcg-unresponsive-non-muscle-invasive-bladder-cancer-carcinoma-in-situ 2022-07-28T21:21:45 https://maestrodatabase.com/blog/is-private-health-insurance-worth-it-more-people-say-yes 2022-07-28T21:18:29 https://maestrodatabase.com/blog/european-commission-grants-conditional-approval-of-ezmekly 2025-07-18T21:26:04 https://maestrodatabase.com/blog/to-promote-innovation-congress-and-companies-should-support-drug-development-cost-disclosure 2022-07-28T21:15:08 https://maestrodatabase.com/blog/evaluation-of-patient-involvement-strategies-in-health-technology-assessment-in-spain-the-viewpoint-of-hta-researchers 2020-09-14T01:42:05 https://maestrodatabase.com/blog/acer-therapeutics-and-relief-therapeutics-announce-fda-acceptance-for-review-of-nda-resubmission-for-acer-001-for-treatment-of-ucds 2022-07-28T13:33:08 https://maestrodatabase.com/blog/novartis-beovu-recommended-by-nice 2022-07-28T21:10:31 https://maestrodatabase.com/blog/fda-approves-first-drug-to-improve-growth-in-children-with-most-common-form-of-dwarfism 2021-11-20T02:02:58 https://maestrodatabase.com/blog/genentech-provides-update-on-supplemental-biologics-license-application-for-columvi-combination-for-people-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma 2025-07-18T21:13:01 https://maestrodatabase.com/blog/drug-industry-poised-for-rare-political-loss-on-prices 2022-07-28T21:33:09 https://maestrodatabase.com/blog/fda-advisory-committee-votes-in-favour-of-maintaining-accelerated-approval-of-genentechs-tecentriq-for-pd-l1-positive-metastatic-triple-negative-breast-cancer 2021-04-28T03:38:59 https://maestrodatabase.com/blog/health-canada-approves-rozlytrek-entrectinib-for-ntrk-gene-fusion-positive-solid-tumours-in-locally-advanced-or-metastatic-patients 2020-04-29T01:47:43 https://maestrodatabase.com/blog/reata-pharmaceuticals-receives-fast-track-designation-from-the-fda-for-omaveloxolone-for-the-treatment-of-friedreichs-ataxia 2021-11-20T02:59:25 https://maestrodatabase.com/blog/fda-approves-mercks-keytruda-pembrolizumab-as-adjuvant-therapy-for-certain-patients-with-renal-cell-carcinoma-following-surgery 2021-11-20T02:24:46 https://maestrodatabase.com/blog/fda-approves-use-of-up-to-three-tubes-of-biofronteras-ameluz-aminolevulinic-acid-hydrochloride-10-percent-topical-gel-in-one-treatment 2024-10-09T01:29:09 https://maestrodatabase.com/blog/fda-grants-dupixent-dupilumab-breakthrough-therapy-designation-for-eosinophilic-oesophagitis 2020-09-14T05:19:50 https://maestrodatabase.com/blog/ema-starts-review-of-paxlovid-for-treating-patients-with-covid-19 2021-11-20T03:39:03 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-18-november-2021 2021-11-20T03:29:00 https://maestrodatabase.com/blog/erytech-pharma-granted-u-dot-s-fda-fast-track-designation-for-eryaspase-in-second-line-pancreatic-cancer 2020-04-29T01:51:15 https://maestrodatabase.com/blog/teva-prolia-denosumab-biosimilar-candidate-is-accepted-for-review-by-us-fda-and-eu-ema 2024-10-09T02:05:15 https://maestrodatabase.com/blog/two-new-options-for-self-administration-of-nucala-now-approved-in-canada-making-it-the-first-anti-il5-biologic-to-offer-patients-with-severe-eosinophilic-asthma-a-choice-of-how-and-where-to-receive-treatment 2019-10-10T02:10:56 https://maestrodatabase.com/blog/fda-grants-carmell-therapeutics-expedited-review-for-ct-101-bone-healing-accelerant 2020-04-29T02:36:41 https://maestrodatabase.com/blog/the-road-ahead-what-two-more-years-of-life-could-mean 2020-09-16T20:19:35 https://maestrodatabase.com/blog/nice-recommends-inrebic-for-rare-blood-cancer 2021-11-20T04:12:02 https://maestrodatabase.com/blog/swissmedic-reviewing-licence-extension-for-the-sglt2-inhibitor-invokana-canagliflozin-in-fast-track-procedure 2019-10-10T02:07:32 https://maestrodatabase.com/blog/cancer-patients-call-on-government-to-fund-life-extending-medicines 2020-09-14T20:43:06 https://maestrodatabase.com/blog/stranded-mum-with-dying-daughter-makes-desperate-plea-to-jacinda-ardern 2020-09-14T20:46:39 https://maestrodatabase.com/blog/cpo301-receives-fast-track-designation-from-the-us-fda 2024-10-09T02:52:58 https://maestrodatabase.com/blog/mhra-authorises-vumerity-for-multiple-sclerosis-patients 2021-11-20T04:21:42 https://maestrodatabase.com/blog/novartis-completes-certification-of-initial-sites-in-quebec-for-first-approved-canadian-car-t-therapy-kymriah-tisagenlecleucel 2019-10-10T02:01:37 https://maestrodatabase.com/blog/making-best-use-of-big-data-for-public-health-publication-of-the-big-data-steering-group-workplan-for-2020-21 2020-09-14T09:43:13 https://maestrodatabase.com/blog/nice-approves-first-long-acting-injectable-hiv-1-treatment 2021-11-20T03:49:37 https://maestrodatabase.com/blog/rinvoq-upadacitinib-approved-by-european-commission-as-an-oral-treatment-for-adults-with-active-non-radiographic-axial-spondyloarthritis 2022-07-29T08:43:03 https://maestrodatabase.com/blog/zealand-pharma-provides-us-regulatory-update-on-dasiglucagon-in-congenital-hyperinsulinism 2024-10-09T02:44:14 https://maestrodatabase.com/blog/nice-draft-guidance-recommends-new-treatment-for-spinal-muscular-atrophy-as-part-of-a-managed-access-agreement 2021-11-20T04:06:38 https://maestrodatabase.com/blog/mallinckrodt-receives-a-complete-response-letter-from-the-u-dot-s-fda-for-terlipressin-for-the-treatment-of-hepatorenal-syndrome-type-1 2020-09-14T12:07:33 https://maestrodatabase.com/blog/atagi-update-following-weekly-covid-19-meeting-27-july-2022 2022-07-29T08:37:07 https://maestrodatabase.com/blog/essa-pharma-announces-fast-track-designation-granted-by-the-fda-to-epi-7386-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer 2020-09-14T20:57:02 https://maestrodatabase.com/blog/roche-drugs-chief-criticises-trump-drug-price-order-says-exceeds-authority 2020-09-14T21:07:46 https://maestrodatabase.com/blog/vaccine-makers-keep-safety-details-quiet-alarming-scientists 2020-09-14T21:09:48 https://maestrodatabase.com/blog/sol-gel-technologies-announces-fda-acceptance-for-filing-of-new-drug-application-for-epsolay-for-the-treatment-of-inflammatory-lesions-of-rosacea 2020-09-14T20:52:28 https://maestrodatabase.com/blog/ema-issues-advice-on-use-of-lagevrio-molnupiravir-for-the-treatment-of-covid-19 2021-11-20T04:27:00 https://maestrodatabase.com/blog/ema-recommends-withdrawal-of-marketing-authorisation-for-cancer-medicine-lartruvo 2019-04-27T01:05:25 https://maestrodatabase.com/blog/mhra-launches-2024-slash-25-business-plan-with-focus-on-enabling-access-to-groundbreaking-new-technology-while-optimising-delivery-for-all-who-need-our-services 2024-10-09T07:31:28 https://maestrodatabase.com/blog/will-tagrisso-win-insurance-benefits-in-korea-too 2020-09-14T21:13:06 https://maestrodatabase.com/blog/knight-therapeutics-announces-filing-of-new-drug-submission-for-crexont-carbidopa-and-levodopa-extended-release-capsules-in-canada 2025-07-19T03:33:38 https://maestrodatabase.com/blog/nice-encourages-further-discussions-on-kymriah-for-adult-lymphoma 2018-09-19T13:23:54 https://maestrodatabase.com/blog/heart-attack-survivors-find-new-treatment-for-recurrence-risk 2024-10-09T20:17:32 https://maestrodatabase.com/blog/standard-deviation-and-standard-error-interpretation-usage-and-reporting 2018-02-05T06:40:24 https://maestrodatabase.com/blog/calls-for-life-saving-drug-to-be-free 2018-09-19T13:34:19 https://maestrodatabase.com/blog/elafibranor-approved-as-first-medicine-to-treat-adults-with-a-rare-liver-disease-known-as-primary-biliary-cholangitis 2024-10-09T19:58:31 https://maestrodatabase.com/blog/nice-rejects-novartis-car-t-kymriah-for-adult-lymphoma 2018-09-19T13:26:37 https://maestrodatabase.com/blog/can-patient-advocates-help-make-akcea-the-next-sarepta-and-overcome-the-fdas-rejection 2018-09-19T13:29:24 https://maestrodatabase.com/blog/pharming-receives-complete-response-letter-from-fda 2018-09-19T13:43:29 https://maestrodatabase.com/blog/amag-pharmaceuticals-announces-fda-approval-of-supplemental-new-drug-application-for-feraheme-ferumoxytol-injection 2018-02-05T20:03:44 https://maestrodatabase.com/blog/new-independent-chair-wants-improved-equitable-access-to-breakthrough-medicines 2018-02-05T06:43:13 https://maestrodatabase.com/blog/biontech-receives-fda-fast-track-designation-for-its-fixvac-candidate-bnt111-in-advanced-melanoma 2021-11-20T23:42:40 https://maestrodatabase.com/blog/thank-mediscare-for-high-private-health-insurance-premiums 2018-02-05T19:56:00 https://maestrodatabase.com/blog/capricor-receives-fda-regenerative-medicine-advanced-therapy-designation-for-duchenne-muscular-dystrophy-therapy 2018-02-05T20:19:44 https://maestrodatabase.com/blog/moderna-announces-fda-authorisation-of-booster-dose-of-covid-19-vaccine-in-the-u-dot-s-for-adults-18-years-and-older 2021-11-20T08:12:48 https://maestrodatabase.com/blog/emergent-biosolutions-receives-ema-prime-designation-for-its-chikungunya-virus-vaccine-candidate 2019-10-10T12:02:53 https://maestrodatabase.com/blog/doctors-welcome-ban-on-repeat-antibiotics 2019-10-10T11:58:56 https://maestrodatabase.com/blog/pfizers-xeljanz-tofacitinib-receives-marketing-authorisation-in-the-european-union-for-the-treatment-of-active-ankylosing-spondylitis 2021-11-20T08:26:26 https://maestrodatabase.com/blog/elmiron-bags-draft-nice-approval 2019-10-10T11:48:50 https://maestrodatabase.com/blog/announcing-the-passing-of-professor-alan-maynard 2018-02-05T20:15:28 https://maestrodatabase.com/blog/phrma-ceo-warns-pelosi-bill-to-lower-drug-prices-would-be-devastating-for-industry 2019-10-10T19:57:25 https://maestrodatabase.com/blog/biogen-to-expand-access-to-its-als-drug-but-move-may-come-too-late-for-some-patient 2021-04-28T08:09:56 https://maestrodatabase.com/blog/n-of-1-trials-fda-plots-path-to-regulation 2019-10-10T19:52:05 https://maestrodatabase.com/blog/cancer-research-funding-has-an-inherent-bias-that-often-excludes-rare-cancers-expert-says 2018-02-05T20:46:14 https://maestrodatabase.com/blog/huge-price-hikes-by-drug-companies-are-immoral 2018-09-19T21:21:17 https://maestrodatabase.com/blog/ema-publishes-agenda-for-14-17-september-chmp-meeting 2020-09-14T22:56:30 https://maestrodatabase.com/blog/acerus-pharmas-natesto-to-be-listed-for-public-reimbursement-in-quebec 2018-02-05T20:30:11 https://maestrodatabase.com/blog/emas-committee-for-medicinal-products-for-human-use-elects-new-chair 2018-09-19T21:10:46 https://maestrodatabase.com/blog/i-m-not-ready-to-bring-her-back---nz-not-safe-for-three-year-old-with-motor-neuron-disease-mum-says 2019-10-10T19:46:00 https://maestrodatabase.com/blog/fda-smashes-record-for-most-anda-complete-responses-in-one-year 2018-09-19T21:15:24 https://maestrodatabase.com/blog/my-health-record-big-pharma-can-apply-to-access-data 2018-09-19T21:36:46 https://maestrodatabase.com/blog/pay-pharmacists-to-improve-our-health-not-just-supply-medicines 2019-10-10T20:14:58 https://maestrodatabase.com/blog/sunovion-announces-health-canada-approval-of-aptiom-eslicarbazepine-acetate-as-adjunctive-therapy-for-the-treatment-of-partial-onset-seizures-in-adolescents-and-children-above-six-years-of-age 2018-09-19T21:42:06 https://maestrodatabase.com/blog/ferrings-zomacton-somatropin-for-injection-receives-fda-approval-to-treat-growth-hormone-deficiency-in-adults 2018-02-05T20:50:58 https://maestrodatabase.com/blog/h-dot-i-v-drugs-cost-75-dollars-in-africa-39-000-dollars-in-the-u-dot-s-does-it-matter 2018-09-19T21:29:01 https://maestrodatabase.com/blog/phrma-foundation-partners-with-national-health-council-to-host-first-of-its-kind-conference-on-new-approaches-to-value-assessment 2019-10-10T20:09:33 https://maestrodatabase.com/blog/eyemate-system-for-remote-glaucoma-management-obtains-fda-breakthrough-device-designation 2021-04-28T08:00:27 https://maestrodatabase.com/blog/fda-cuts-red-tape-in-diagnosis-applications-for-cancer-trials 2019-10-10T20:04:22 https://maestrodatabase.com/blog/payment-and-delivery-system-reform----the-next-phase 2018-09-19T21:56:49 https://maestrodatabase.com/blog/fda-grants-fx-322-fast-track-designation 2019-10-10T20:36:09 https://maestrodatabase.com/blog/thousands-with-high-cholesterol-set-to-benefit-from-new-treatment-on-the-nhs 2021-04-28T10:49:41 https://maestrodatabase.com/blog/meeting-highlights-from-the-chmp-23-26-april-2019 2019-04-27T01:37:00 https://maestrodatabase.com/blog/truvada-ruling-could-allow-cheap-hiv-prevention-in-the-uk 2018-09-19T21:52:40 https://maestrodatabase.com/blog/who-welcomes-vital-new-funding-for-the-global-fund 2019-10-10T20:17:11 https://maestrodatabase.com/blog/novo-nordisk-files-for-eu-regulatory-approval-of-oral-semaglutide-for-the-treatment-of-type-2-diabetes 2019-04-27T03:28:43 https://maestrodatabase.com/blog/protalix-biotherapeutics-and-chiesi-global-rare-diseases-receive-complete-response-letter-for-pegunigalsidase-alfa-from-fda 2021-04-28T09:22:12 https://maestrodatabase.com/blog/u-dot-s-hospitals-turn-down-remdesivir-limit-use-to-sickest-covid-19-patients 2020-09-14T23:32:54 https://maestrodatabase.com/blog/bio-thera-solutions-announces-fda-accepts-biologics-license-application-for-bat2506-a-proposed-biosimilar-to-simponi 2025-07-19T05:43:51 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac---march-2019 2019-06-01T02:59:01 https://maestrodatabase.com/blog/fda-grants-theradaptive-breakthrough-medical-device-designation 2021-11-20T23:58:00 https://maestrodatabase.com/blog/fda-approves-first-treatment-for-paediatric-patients-with-lupus 2019-04-27T03:23:03 https://maestrodatabase.com/blog/biosimilars-in-the-uk-where-are-we-now-and-where-does-the-nhs-want-to-go 2019-10-10T20:43:38 https://maestrodatabase.com/blog/fda-grants-priority-review-for-nefecon-for-patients-with-iga-nephropathy 2021-04-28T11:58:45 https://maestrodatabase.com/blog/novartis-receives-positive-chmp-opinion-for-rydapt-midostaurin-for-newly-diagnosed-flt3-mutated-acute-myeloid-leukaemia-and-three-types-of-advanced-systemic-mastocytosis 2017-07-21T11:34:33 https://maestrodatabase.com/blog/vertex-announces-european-commission-approval-for-kaftrio-ivacaftor-slash-tezacaftor-slash-elexacaftor-in-combination-with-ivacaftor-to-treat-cystic-fibrosis-patients-12-years-and-older-with-at-least-one-f508del-mutation-in-the-cftr-gene 2021-04-28T11:44:20 https://maestrodatabase.com/blog/do-existing-real-world-data-sources-generate-suitable-evidence-for-the-hta-of-medical-devices-in-europe-mapping-and-critical-appraisal 2021-04-28T21:01:28 https://maestrodatabase.com/blog/seizing-opportunities-in-a-changing-medicines-landscape 2024-10-09T21:50:34 https://maestrodatabase.com/blog/ema-publishes-agenda-for-28-30-april-chmp-meeting 2020-04-29T10:46:22 https://maestrodatabase.com/blog/nice-signs-up-to-join-the-getreal-institute 2021-04-28T20:54:24 https://maestrodatabase.com/blog/university-of-queensland-says-covid-19-vaccine-ready-by-september 2020-04-29T10:55:12 https://maestrodatabase.com/blog/h-dot-r-3s-international-reference-pricing-misses-the-mark 2021-04-28T21:07:53 https://maestrodatabase.com/blog/japan-to-offer-anti-flu-drug-avigan-to-38-countries-as-early-as-this-week 2020-04-29T11:15:17 https://maestrodatabase.com/blog/medicines-australia-encourages-22-000-plus-employees-of-the-medicines-industry-to-download-the-covidsafe-app 2020-04-29T05:12:40 https://maestrodatabase.com/blog/agenda-for-the-july-2020-pbac-meeting-revised 2020-05-03T11:18:50 https://maestrodatabase.com/blog/fda-takes-action-for-failure-to-submit-required-clinical-trial-results-information-to-clinicaltrials-dot-gov 2021-04-28T20:49:44 https://maestrodatabase.com/blog/novartis-cosentyx-gains-fourth-indication-in-eu-with-first-in-class-approval-in-axial-spondyloarthritis-spectrum 2020-04-29T05:17:38 https://maestrodatabase.com/blog/akari-therapeutics-receives-fda-fast-track-designation-for-nomacopan-for-the-treatment-of-bullous-pemphigoid 2021-04-28T20:42:55 https://maestrodatabase.com/blog/what-do-high-drug-prices-buy-us 2020-04-29T12:22:55 https://maestrodatabase.com/blog/fda-approves-zejula-niraparib-as-the-only-once-daily-parp-inhibitor-in-first-line-monotherapy-maintenance-treatment-for-women-with-platinum-responsive-advanced-ovarian-cancer-regardless-of-biomarker-status 2020-04-29T20:40:44 https://maestrodatabase.com/blog/fda-in-ongoing-talks-with-gilead-to-make-remdesivir-available-to-coronavirus-patients-as-quickly-as-possible 2020-04-29T20:45:39 https://maestrodatabase.com/blog/fda-approves-ortho-dermatologics-labeling-for-jublia-efinaconazole-10-percent-topical-solution-in-patients-as-young-as-six-years-old 2020-04-29T11:43:33 https://maestrodatabase.com/blog/biogen-receives-us-fda-breakthrough-therapy-designation-for-felzartamab-for-the-treatment-of-antibody-mediated-rejection-in-kidney-transplant-recipients 2024-10-09T23:03:19 https://maestrodatabase.com/blog/updated-fees-for-cadth-pharmaceutical-reviews 2020-04-29T20:57:28 https://maestrodatabase.com/blog/influenza-vaccinations-for-2020 2020-04-29T21:07:30 https://maestrodatabase.com/blog/covid-19-ptac-meeting-arrangements 2020-04-29T21:09:42 https://maestrodatabase.com/blog/cvs-will-remove-abbvies-humira-from-some-drug-reimbursement-lists-in-april 2024-01-05T00:03:43 https://maestrodatabase.com/blog/vertex-announces-european-medicines-agency-type-ii-variation-marketing-authorisation-application-validation-for-kaftrio-ivacaftor-slash-tezacaftor-slash-elexacaftor-in-combination-with-ivacaftor-in-people-with-one-copy-of-the-f508del-mutation 2020-09-15T05:24:09 https://maestrodatabase.com/blog/fda-approves-arcutis-zoryve-roflumilast-0-dot-3-percent-cream-for-the-treatment-of-plaque-psoriasis-in-individuals-age-12-and-older 2022-07-30T07:28:14 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-for-biomarker-guided-db104-liafensine-in-patients-with-treatment-resistant-depression 2024-10-10T00:07:51 https://maestrodatabase.com/blog/vaccine-maker-got-1-dollars-billion-from-taxpayers-now-its-boosting-drug-prices 2020-09-15T05:20:44 https://maestrodatabase.com/blog/european-medicines-agency-approves-safety-label-update-for-novartis-beovu 2020-09-15T08:14:44 https://maestrodatabase.com/blog/accc-approves-local-merger-of-pharma-firms-arrow-and-apotex 2018-09-20T04:03:48 https://maestrodatabase.com/blog/exelixis-partner-ipsen-announces-health-canadas-approval-of-cabometyx-cabozantinib-tablets-for-the-treatment-of-adults-with-previously-treated-advanced-renal-cell-carcinoma 2018-09-20T03:06:56 https://maestrodatabase.com/blog/trumps-last-ditch-drug-pricing-moves-could-help-him-in-november-but-they-likely-wont-save-americans-money 2020-09-15T10:54:42 https://maestrodatabase.com/blog/rare-condition-medication-going-on-pbs 2021-11-21T20:50:18 https://maestrodatabase.com/blog/us-fda-grants-fast-track-designation-to-jardiance-empagliflozin-to-improve-outcomes-following-a-heart-attack 2020-09-15T20:43:19 https://maestrodatabase.com/blog/mhra-approves-adrenaline-nasal-spray---the-first-needle-free-emergency-treatment-for-anaphylaxis-in-the-uk 2025-07-19T22:19:50 https://maestrodatabase.com/blog/moderna-files-for-authorisation-of-its-covid-19-vaccine-with-health-canada-to-include-children-ages-6-11-years 2021-11-21T20:54:12 https://maestrodatabase.com/blog/nice-joins-global-alliance-to-shine-spotlight-on-evidence-based-health-care 2020-09-15T20:47:14 https://maestrodatabase.com/blog/pharmac-improves-access-to-three-cancer-medicines 2024-10-10T01:02:03 https://maestrodatabase.com/blog/valneva-and-dynavax-announce-commercial-supply-agreement-for-inactivated-adjuvanted-covid-19-vaccine 2020-09-15T08:35:40 https://maestrodatabase.com/blog/ziopharm-oncology-granted-rare-paediatric-disease-designation-for-controlled-il-12-for-the-treatment-of-dipg 2020-09-15T09:15:47 https://maestrodatabase.com/blog/trump-advisor-kushner-defends-plan-to-cut-drug-prices-says-americans-should-pay-the-same-as-europeans 2020-09-15T21:01:55 https://maestrodatabase.com/blog/phrma-statement-on-most-favoured-nation-executive-order 2020-09-15T21:07:41 https://maestrodatabase.com/blog/plus-therapeutics-receives-fast-track-designation-from-fda-for-its-novel-glioblastoma-treatment 2020-09-15T20:50:55 https://maestrodatabase.com/blog/quebec-adds-erelzi-etanercept-to-provincial-drug-plans-for-the-treatment-of-multiple-inflammatory-diseases 2018-02-06T05:09:53 https://maestrodatabase.com/blog/apellis-announces-submission-of-pegcetacoplan-marketing-applications-to-fda-and-ema-for-patients-with-pnh 2020-09-15T20:57:04 https://maestrodatabase.com/blog/paratek-completes-submission-of-new-drug-applications-to-u-dot-s-fda-for-oral-and-intravenous-omadacycline-for-pneumonia-and-skin-infections 2018-02-06T05:00:58 https://maestrodatabase.com/blog/ausbiotech-says-plan-to-disadvantage-life-sciences-innovation 2018-02-06T07:37:42 https://maestrodatabase.com/blog/amylyx-pharmaceuticals-announces-albrioza-is-now-available-in-canada-for-the-treatment-of-amyotrophic-lateral-sclerosis 2022-07-30T08:33:00 https://maestrodatabase.com/blog/amivantamab-in-combination-with-lazertinib-for-the-first-line-treatment-of-patients-with-advanced-egfr-mutation-positive-non-small-cell-lung-cancer 2025-07-20T00:00:05 https://maestrodatabase.com/blog/gw-pharmaceuticals-announces-the-ema-accepts-epidiolex-cannabidiol-marketing-authorisation-application-for-review 2018-02-06T05:19:02 https://maestrodatabase.com/blog/nih-very-concerned-about-serious-side-effect-in-astrazeneca-coronavirus-vaccine-trial 2020-09-15T21:11:48 https://maestrodatabase.com/blog/rep-grothman-introduces-bill-for-automatic-insulin-biosimilar-interchangeablity 2020-09-15T21:16:58 https://maestrodatabase.com/blog/estimating-risk-ratios-and-risk-differences-alternatives-to-odds-ratios 2020-09-15T22:13:25 https://maestrodatabase.com/blog/health-economic-assessment-of-keytruda-in-head-and-neck-cancer 2020-04-30T00:46:19 https://maestrodatabase.com/blog/fda-publishes-comparative-performance-data-for-covid-19-molecular-diagnostic-tests 2020-09-15T22:19:01 https://maestrodatabase.com/blog/capricor-therapeutics-announces-initiation-of-rolling-submission-of-biologics-license-application-with-us-fda-for-deramiocel-for-the-treatment-of-duchenne-muscular-dystrophy 2024-10-10T02:48:14 https://maestrodatabase.com/blog/janssen-receives-positive-chmp-opinion-for-symtuza-the-first-darunavir-based-single-tablet-regimen-for-the-treatment-of-hiv 2017-07-21T22:37:52 https://maestrodatabase.com/blog/australian-cancer-patients-spend-200-dollars-million-a-year-on-treatments-not-on-the-pbs-and-its-got-to-change 2023-04-16T04:03:44 https://maestrodatabase.com/blog/genascence-announces-us-fda-grants-regenerative-medicine-advanced-therapy-designation-to-gnsc-001-for-knee-osteoarthritis 2025-07-20T01:12:02 https://maestrodatabase.com/blog/alnylam-submits-supplemental-new-drug-application-to-the-us-fda-for-vutrisiran-for-the-treatment-of-transthyretin-amyloidosis-with-cardiomyopathy 2024-10-10T03:10:36 https://maestrodatabase.com/blog/rocket-pharmaceuticals-receives-fda-regenerative-medicine-advanced-therapy-designation-for-rp-a601-gene-therapy-for-pkp2-arhythmogenic-cardiomyopathy 2025-07-20T01:20:25 https://maestrodatabase.com/blog/chmp-recommends-eu-approval-for-roches-tecentriq-atezolizumab-in-a-specific-type-of-metastatic-lung-and-two-types-of-metastatic-bladder-cancer 2017-07-21T23:23:53 https://maestrodatabase.com/blog/price-of-a-life-australians-wait-two-years-longer-for-breakthrough-medicines-than-us-citizens 2023-04-16T09:22:00 https://maestrodatabase.com/blog/nice-restricts-nhs-use-of-roches-ipf-drug-esbriet 2018-02-06T18:40:47 https://maestrodatabase.com/blog/commonwealth-fails-in-its-claim-for-compensation-for-delayed-pbs-listing-of-generic-clopidogrel 2020-04-30T02:05:09 https://maestrodatabase.com/blog/horizon-therapeutics-announces-fda-approval-of-an-update-to-the-indication-language-for-tepezza-teprotumumab-trbw-to-specify-its-use-in-thyroid-eye-disease-patients-regardless-of-disease-activity-or-duration 2023-04-16T09:06:10 https://maestrodatabase.com/blog/general-court-confirms-ema-approach-to-transparency 2018-02-06T18:37:19 https://maestrodatabase.com/blog/fda-approves-inavolisib-with-palbociclib-and-fulvestrant-for-endocrine-resistant-pik3ca-mutated-hr-positive-her2-negative-advanced-breast-cancer 2024-10-10T19:48:18 https://maestrodatabase.com/blog/zogenix-announces-receipt-of-fda-breakthrough-therapy-designation-for-zx008-in-dravet-syndrome 2018-02-06T20:23:34 https://maestrodatabase.com/blog/biden-harris-administration-takes-next-step-on-proposed-model-to-lower-prescription-drug-costs-for-people-with-medicare 2024-10-10T11:15:32 https://maestrodatabase.com/blog/priority-review-pathway---first-registration-decision 2018-02-07T10:02:12 https://maestrodatabase.com/blog/gene-therapy-international-regulatory-and-health-technology-assessment-activities-and-reimbursement-status 2018-03-27T20:42:38 https://maestrodatabase.com/blog/pharmac-widening-access-to-truvada-for-the-prevention-of-hiv-infection 2018-02-07T09:56:25 https://maestrodatabase.com/blog/no-political-pressure-in-hiv-drug-funding-call---pharmac 2018-02-07T10:12:29 https://maestrodatabase.com/blog/new-and-expanded-cheaper-medicines-for-severe-and-life-threatening-conditions 2025-07-20T02:55:21 https://maestrodatabase.com/blog/patients-to-benefit-from-myeloma-treatment-through-cdf-deal 2018-02-07T10:05:51 https://maestrodatabase.com/blog/pulmonary-fibrosis-drug-ofev-nears-key-reimbursement-decision-in-korea 2024-10-10T20:08:59 https://maestrodatabase.com/blog/tga-publishes-more-information-about-medicine-formulations 2020-04-30T03:21:46 https://maestrodatabase.com/blog/procedure-guidance-for-standardised-redactions-to-pbac-public-summary-documents 2020-04-30T03:23:29 https://maestrodatabase.com/blog/ipsen-receives-positive-chmp-opinion-for-approval-of-xermelo-telotristat-ethyl-for-the-treatment-of-carcinoid-syndrome-diarrhoea-in-patients-inadequately-controlled-by-somatostatin-analogue-therapy 2017-07-21T23:57:26 https://maestrodatabase.com/blog/drug-treatment-for-rare-blood-cancer-will-save-more-lives 2018-09-20T11:19:24 https://maestrodatabase.com/blog/eu-green-light-for-new-humira-biosimilar 2018-09-20T10:48:09 https://maestrodatabase.com/blog/integration-of-ethical-considerations-into-hta-reports-an-analysis-of-integration-levels-using-a-systematic-review 2021-04-29T02:40:18 https://maestrodatabase.com/blog/australia-has-surpassed-2-million-vaccines-but-lacks-data-on-second-doses 2021-04-29T02:36:31 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report---28-04-2021 2021-04-29T02:04:39 https://maestrodatabase.com/blog/pfizer-granted-fda-breakthrough-therapy-designation-for-20-valent-pneumococcal-conjugate-vaccine-for-the-prevention-of-invasive-disease-and-pneumonia-in-adults-aged-18-years-ands-older 2018-09-20T12:40:26 https://maestrodatabase.com/blog/gileads-magrolimab-an-investigational-anti-cd47-monoclonal-antibody-receives-fda-breakthrough-therapy-designation-for-treatment-of-myelodysplastic-syndrome 2020-09-15T23:25:19 https://maestrodatabase.com/blog/mediscare-merchants-bid-up-private-health-insurance-premiums 2018-02-07T20:00:36 https://maestrodatabase.com/blog/hiv-has-nowhere-to-go-now-breakthrough-drug-prep-to-be-approved-for-public-subsidy 2018-02-07T19:56:14 https://maestrodatabase.com/blog/generics-would-hit-the-market-faster-under-senate-bill-saving-more-than-3-billion-dollars-says-cbo 2018-09-20T21:22:07 https://maestrodatabase.com/blog/canadian-generic-drug-prices-higher-than-international-levels-in-recent-years 2018-02-07T20:13:47 https://maestrodatabase.com/blog/non-profit-takes-on-drug-makers-lobbying-on-medicare-drug-discount 2018-09-20T21:24:39 https://maestrodatabase.com/blog/biden-called-for-drug-pricing-reform-this-year-but-its-an-empty-call 2021-04-29T05:30:58 https://maestrodatabase.com/blog/management-board-started-building-approval-process-of-ema-premises-in-amsterdam 2018-02-07T20:03:16 https://maestrodatabase.com/blog/abbvie-receives-a-positive-recommendation-from-the-cadth-canadian-drug-expert-committee-for-maviret---an-oral-therapy-for-the-treatment-of-patients-with-hepatitis-c 2018-02-07T20:09:03 https://maestrodatabase.com/blog/portugal-to-also-benefit-from-eu-us-mutual-recognition-agreement-for-inspections 2018-09-20T21:09:23 https://maestrodatabase.com/blog/siga-technologies-announces-fda-accepts-nda-and-grants-priority-review-for-oral-tpoxx-to-treat-smallpox 2018-02-07T20:30:30 https://maestrodatabase.com/blog/health-insurer-takes-pharma-giant-to-court-for-evergreening 2018-09-20T21:42:24 https://maestrodatabase.com/blog/pharma-lobby-mounts-last-ditch-effort-to-fix-prescription-doughnut-hole 2018-09-20T21:45:13 https://maestrodatabase.com/blog/emas-chmp-issues-positive-opinion-for-avelumab-for-the-treatment-of-metastatic-merkel-cell-carcinoma 2017-07-22T00:49:34 https://maestrodatabase.com/blog/using-evidence-from-randomised-controlled-trials-in-economic-models-what-information-is-relevant-and-is-there-a-minimum-amount-of-sample-data-required-to-make-decisions 2018-09-20T21:28:27 https://maestrodatabase.com/blog/will-cvs-caremark-make-icer-the-american-nice 2018-09-20T21:36:09 https://maestrodatabase.com/blog/valeo-pharmas-redesca-and-redesca-hp-to-be-covered-under-the-ontario-public-drug-benefit-program 2021-04-29T05:07:39 https://maestrodatabase.com/blog/biden-vows-to-target-high-prescription-drug-prices-strengthen-aca 2021-04-29T20:58:12 https://maestrodatabase.com/blog/accord-biopharma-announces-us-fda-acceptance-of-biologics-license-application-for-proposed-stelara-biosimilar-dmb-3115 2024-01-05T05:35:38 https://maestrodatabase.com/blog/cms-should-offer-immediate-reimbursement-coverage-to-fda-approved-breakthrough-devices 2021-04-29T20:47:56 https://maestrodatabase.com/blog/australia-accused-of-delaying-campaign-to-allow-generic-covid-vaccines 2021-04-29T21:05:07 https://maestrodatabase.com/blog/sanofi-and-regeneron-receive-positive-chmp-opinion-for-dupixent-dupilumab-to-treat-adult-patients-with-moderate-to-severe-atopic-dermatitis 2017-07-22T01:05:07 https://maestrodatabase.com/blog/biogen-provides-regulatory-update-on-the-supplemental-biologic-license-application-for-subcutaneous-administration-of-tysabri-natalizumab 2021-04-29T20:37:52 https://maestrodatabase.com/blog/volixibat-granted-breakthrough-therapy-designation-for-cholestatic-pruritus-in-primary-biliary-cholangitis 2024-10-10T23:13:51 https://maestrodatabase.com/blog/ema-starts-evaluating-use-of-olumiant-in-hospitalised-covid-19-patients-requiring-supplemental-oxygen 2021-04-29T20:42:28 https://maestrodatabase.com/blog/developing-a-quality-management-system-for-the-european-network-for-health-technology-assessment-eunethta-toward-european-hta-collaboration 2021-04-29T21:24:04 https://maestrodatabase.com/blog/fda-advisory-committee-votes-in-favour-of-maintaining-accelerated-approval-of-genentechs-tecentriq-for-previously-untreated-metastatic-bladder-cancer 2021-04-29T21:41:55 https://maestrodatabase.com/blog/toothful-or-toothless-bidens-biosimilar-bills-under-the-microscope 2021-04-29T21:32:02 https://maestrodatabase.com/blog/bavencio-receives-reimbursement-recommendation-from-pcodr-and-inesss-for-the-maintenance-treatment-of-patients-with-advanced-bladder-cancer 2021-04-29T21:08:49 https://maestrodatabase.com/blog/ispor-launches-heor-solutions-centre 2021-04-29T21:18:22 https://maestrodatabase.com/blog/ccrm-and-amgen-partner-to-advance-emerging-medical-innovations 2021-04-29T21:14:02 https://maestrodatabase.com/blog/roche-canada-announces-columvi-glofitamab-for-injection-is-publicly-reimbursed-in-7-provinces-including-quebec-ontario-manitoba-saskatchewan-nova-scotia-and-newfoundland 2024-10-11T01:28:14 https://maestrodatabase.com/blog/ema-confirms-acceptance-of-marketing-application-for-avt03-a-proposed-biosimilar-to-prolia-and-xgeva 2024-10-11T01:59:25 https://maestrodatabase.com/blog/chmp-recommends-eu-approval-of-roches-gazyvaro-for-people-with-previously-untreated-advanced-follicular-lymphoma 2017-07-22T01:53:03 https://maestrodatabase.com/blog/gensight-biologics-submits-eu-marketing-authorisation-application-for-lumevoq-gene-therapy-to-treat-vision-loss-due-to-leber-hereditary-optic-neuropathy 2020-09-16T01:25:11 https://maestrodatabase.com/blog/brenzys-etanercept-injection-now-indicated-for-the-treatment-of-plaque-psoriasis-psoriatic-arthritis-and-juvenile-idiopathic-arthritis 2020-09-16T01:13:14 https://maestrodatabase.com/blog/new-pbs-listing-helps-australians-with-rare-genetic-condition 2021-11-22T05:52:17 https://maestrodatabase.com/blog/johnson-and-johnson-submits-application-to-the-ema-for-darzalex-daratumumab-sc-based-quadruplet-regimen-for-newly-diagnosed-multiple-myeloma-patients 2024-10-11T02:12:50 https://maestrodatabase.com/blog/abbvie-receives-chmp-positive-opinion-for-humira-adalimumab-for-the-treatment-of-paediatric-patients-with-chronic-non-infectious-anterior-uveitis 2017-07-22T02:37:34 https://maestrodatabase.com/blog/ema-approves-label-update-for-hyqvia-human-normal-immunoglobulin-10-percent-and-recombinant-human-hyaluronidase-expanding-its-use-to-a-broader-group-of-patients-with-secondary-immunodeficiencies 2020-09-16T01:19:24 https://maestrodatabase.com/blog/ema-validates-bristol-myers-squibbs-type-ii-variation-application-for-opdivo-nivolumab-plus-yervoy-ipilimumab-for-first-line-treatment-of-malignant-pleural-mesothelioma 2020-09-16T01:31:12 https://maestrodatabase.com/blog/simplified-chemotherapy-prescribing-arrangements 2020-09-16T05:48:37 https://maestrodatabase.com/blog/gsks-meningitis-b-vaccine-bexsero-receives-breakthrough-therapy-designation-from-us-fda-for-prevention-of-invasive-meningococcal-disease-in-children-2-10-years-of-age 2018-02-08T00:50:19 https://maestrodatabase.com/blog/european-medicines-agencys-chmp-recommends-approval-for-mercks-keytruda-pembrolizumab-for-the-treatment-of-certain-patients-with-locally-advanced-or-metastatic-urothelial-carcinoma-a-type-of-bladder-cancer 2017-07-22T02:59:08 https://maestrodatabase.com/blog/health-canada-has-authorised-takhyzro-lanadelumab-injection-a-first-of-its-kind-monoclonal-antibody-treatment-for-the-prevention-of-hereditary-angioedema-attacks 2018-09-21T01:52:41 https://maestrodatabase.com/blog/cerapedics-announces-fda-breakthrough-device-designation-granted-for-p-15l-bone-graft-for-the-treatment-of-degenerative-disc-disease 2021-04-30T00:20:09 https://maestrodatabase.com/blog/historic-pbs-listing-for-australians-with-a-rare-epilepsy-condition 2021-04-30T00:35:39 https://maestrodatabase.com/blog/daratumumab-in-combination-with-bortezomib-and-dexamethasone-for-the-treatment-of-patients-with-previously-treated-multiple-myeloma 2023-04-17T07:31:25 https://maestrodatabase.com/blog/profoundbio-announces-rinatabart-sesutecan-fda-fast-track-designation-for-patients-with-advanced-ovarian-cancer 2024-01-05T23:07:16 https://maestrodatabase.com/blog/mhra-approves-comirnaty-kp-dot-2-covid-19-vaccine-for-adults 2024-10-11T21:40:35 https://maestrodatabase.com/blog/bristol-myers-squibbs-supplemental-new-drug-application-for-sotyktu-deucravacitinib-for-the-treatment-of-adults-with-active-psoriatic-arthritis-accepted-for-review-across-four-regions-globally 2025-07-21T12:16:26 https://maestrodatabase.com/blog/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of-moderately-to-severely-active-crohns-disease 2023-04-17T07:27:37 https://maestrodatabase.com/blog/roche-gains-positive-chmp-opinion-for-actemra-slash-roactemra-in-giant-cell-arteritis 2017-07-22T03:37:27 https://maestrodatabase.com/blog/mediwound-announces-fda-acceptance-of-biologics-license-application-for-nexobrid-for-the-treatment-of-severe-thermal-burns 2020-09-16T12:11:00 https://maestrodatabase.com/blog/pierre-fabre-receives-eu-approval-for-braftovi-encorafenib-plus-mektovi-binimetinib-in-adult-patients-with-advanced-braf-mutant-melanoma 2018-09-21T03:06:01 https://maestrodatabase.com/blog/new-indication-for-opdivo-nivolumab-after-tga-approval-for-hepatocellular-carcinoma 2018-09-21T02:59:40 https://maestrodatabase.com/blog/icer-publishes-final-evidence-report-on-lecanemab-for-alzheimers-disease 2023-04-17T20:17:32 https://maestrodatabase.com/blog/gilead-sciences-statement-on-fda-acceptance-of-new-drug-application-for-investigational-lenacapavir 2022-07-31T11:26:45 https://maestrodatabase.com/blog/orphazyme-announces-u-dot-s-fda-acceptance-and-priority-review-of-new-drug-application-for-arimoclomol-for-niemann-pick-disease-type-c 2020-09-16T20:13:21 https://maestrodatabase.com/blog/xeris-pharmaceuticals-receives-u-dot-k-mhra-approval-of-ogluo-glucagon-injection-for-the-treatment-of-severe-hypoglycaemia-in-adults-adolescents-and-children-aged-2-years-and-over-with-diabetes-mellitus 2021-04-30T01:28:20 https://maestrodatabase.com/blog/fda-approves-new-treatment-for-haemophilia-a-or-b 2024-10-11T21:59:59 https://maestrodatabase.com/blog/msf-demands-johnson-and-johnson-reduce-price-of-life-saving-tb-drug 2019-10-11T06:15:19 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-august-2022 2022-07-31T11:20:15 https://maestrodatabase.com/blog/tetraphase-pharmaceuticals-announces-adoption-of-commission-decision-granting-marketing-authorisation-approval-in-the-european-union-for-xerava-eravacycline-for-the-treatment-of-complicated-intra-abdominal-infections 2018-09-21T03:15:24 https://maestrodatabase.com/blog/pharma-industry-is-right-in-the-crosshairs-merck-ceo-kenneth-frazier-says 2019-10-11T06:10:28 https://maestrodatabase.com/blog/human-rights-commission-grants-case-against-pharmac-for-failing-to-fund-rare-muscular-disorder-drug 2020-09-16T09:03:16 https://maestrodatabase.com/blog/prioritising-patients-in-negotiations-over-drug-pricing 2023-04-29T01:17:02 https://maestrodatabase.com/blog/nationals-health-policy---more-money-for-pharmac-elective-surgery-guarantees 2020-09-16T10:13:25 https://maestrodatabase.com/blog/otc-naloxone-is-a-baby-step-toward-making-the-life-saving-medication-accessible 2023-04-17T10:41:42 https://maestrodatabase.com/blog/olaparib-in-metastatic-prostate-cancer-added-benefit-for-certain-patients 2023-04-17T20:33:19 https://maestrodatabase.com/blog/pfizer-to-provide-u-dot-s-government-with-10-million-treatments-courses-of-investigational-oral-antiviral-candidate-to-help-combat-covid-19 2021-11-22T09:26:47 https://maestrodatabase.com/blog/u-dot-s-would-gain-power-to-negotiate-drug-prices-under-manchin-schumer-bill 2022-07-31T11:54:23 https://maestrodatabase.com/blog/icer-releases-updated-draft-evidence-report-on-rheumatoid-arthritis-therapies 2019-10-11T11:57:52 https://maestrodatabase.com/blog/fda-provides-update-on-agency-response-to-monkeypox-outbreak 2022-07-31T12:05:03 https://maestrodatabase.com/blog/obseva-announces-u-dot-s-fda-acceptance-of-new-drug-application-for-linzagolix 2021-11-22T09:38:49 https://maestrodatabase.com/blog/ilaris-receives-health-canada-approval-as-first-of-its-kind-treatment-for-rare-inflammatory-disorder-adult-onset-stills-disease 2021-04-30T02:08:08 https://maestrodatabase.com/blog/2022-october-price-disclosure-cycle---patient-savings 2022-07-31T11:38:21 https://maestrodatabase.com/blog/novavaxs-updated-2024-2025-nuvaxovid-covid-19-vaccine-receives-authorisation-in-the-eu 2024-10-11T22:18:19 https://maestrodatabase.com/blog/fda-granted-paediatric-disease-designation-for-oxi-4503 2020-09-16T20:24:04 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-august-2022 2022-07-31T11:45:50 https://maestrodatabase.com/blog/phrmas-talking-points-shouldnt-derail-the-pelosi-drug-pricing-bill 2019-10-11T12:15:24 https://maestrodatabase.com/blog/tga-grants-provisional-determination-to-grand-pacific-for-its-covid-19-protein-based-subunit-vaccine 2021-11-22T09:23:27 https://maestrodatabase.com/blog/another-treatment-option-for-ovarian-cancer-approved-for-the-cancer-drugs-fund 2019-10-11T12:04:55 https://maestrodatabase.com/blog/if-money-is-no-longer-an-issue-i-have-one-request---double-the-pharmac-budget 2020-09-16T20:30:52 https://maestrodatabase.com/blog/astrazeneca-struggles-with-data-needed-for-covid-19-vaccines-approval 2021-04-30T02:20:01 https://maestrodatabase.com/blog/intelgenx-announces-fda-approval-of-rizafilm-for-the-treatment-of-acute-migraine 2023-04-17T20:51:56 https://maestrodatabase.com/blog/thousands-could-benefit-from-first-immunotherapy-for-severe-birch-tree-pollen-allergy 2025-07-21T21:31:40 https://maestrodatabase.com/blog/regulatory-applications-accepted-across-three-regions-globally-for-abecma-for-earlier-use-in-adults-with-triple-class-exposed-relapsed-and-slash-or-refractory-multiple-myeloma 2023-04-17T20:46:52 https://maestrodatabase.com/blog/health-canada-approves-pfizers-bivalent-respiratory-syncytial-virus-vaccine-for-older-adults-and-infants-through-maternal-immunisation 2024-01-06T01:03:49 https://maestrodatabase.com/blog/fda-grants-breakthrough-designation-for-early-stage-breast-cancer-detection-blood-test-developed-by-datar-cancer-genetics 2021-11-22T09:46:49 https://maestrodatabase.com/blog/bristol-myers-squibb-statement-on-fda-advisory-committee-meeting-on-opdivo-post-sorafenib-hepatocellular-carcinoma-u-dot-s-indication 2021-04-30T02:43:54 https://maestrodatabase.com/blog/fda-approves-cell-therapy-for-patients-with-blood-cancers-to-reduce-risk-of-infection-following-stem-cell-transplantation 2023-04-17T20:38:43 https://maestrodatabase.com/blog/uk-recognises-covaxin-as-valid-covid-19-vaccine-for-travel 2021-11-22T19:43:43 https://maestrodatabase.com/blog/ensysce-biosciences-receives-fast-track-designation-for-pf614-bio-md-abuse-deterrent-extended-release-oxycodone-prodrug 2018-02-08T02:55:26 https://maestrodatabase.com/blog/bluebird-bio-announces-fda-priority-review-of-biologics-license-application-for-beti-cel-gene-therapy-for-patients-with-b-thalassemia-who-require-regular-red-blood-cell-transfusions 2021-11-22T19:49:09 https://maestrodatabase.com/blog/fda-approves-praluent-alirocumab-to-prevent-heart-attack-stroke-and-unstable-angina-requiring-hospitalisation 2019-04-28T11:07:10 https://maestrodatabase.com/blog/agenus-receives-fast-track-designation-for-botensilimab-and-balstilimab-in-colorectal-cancer 2023-04-17T21:00:11 https://maestrodatabase.com/blog/chmp-issues-positive-opinion-for-libtayo-cemiplimab-in-advanced-cutaneous-squamous-cell-carcinoma 2019-04-28T11:26:14 https://maestrodatabase.com/blog/fda-approves-samsung-bioepis-etanercept-biosimilar-eticovo 2019-04-28T11:21:43 https://maestrodatabase.com/blog/ema-evaluating-data-on-booster-dose-of-covid-19-vaccine-janssen 2021-11-22T19:39:56 https://maestrodatabase.com/blog/pharmas-secret-to-lobbying-for-higher-drug-prices 2019-04-28T11:14:58 https://maestrodatabase.com/blog/candel-therapeutics-receives-fda-fast-track-designation-for-can-2409-in-non-small-cell-lung-cancer 2023-04-17T20:56:00 https://maestrodatabase.com/blog/up-is-down----pharmaceutical-industry-caution-versus-federal-acceleration-of-covid-19-vaccine-approval 2020-09-16T21:45:02 https://maestrodatabase.com/blog/crispr-therapeutics-announces-fda-regenerative-medicine-advanced-therapy-designation-granted-to-ctx110-for-the-treatment-of-relapsed-or-refractory-cd19-plus-b-cell-malignancies 2021-11-22T20:01:37 https://maestrodatabase.com/blog/celgene-corporation-and-acceleron-pharma-announce-submission-of-luspatercept-marketing-authorisation-application-to-the-ema-for-mds-and-beta-thalassemia 2019-04-28T11:35:17 https://maestrodatabase.com/blog/viiv-healthcare-announces-chmp-positive-opinion-for-dovato-dolutegravir-slash-lamivudine-as-a-once-daily-single-pill-two-drug-regimen-for-the-treatment-of-hiv-infection 2019-04-28T11:30:07 https://maestrodatabase.com/blog/bristol-myers-squibb-announces-new-pdufa-date-for-mavacamten 2021-11-22T20:06:06 https://maestrodatabase.com/blog/evolus-receives-positive-chmp-opinion-for-nuceiva-in-the-european-union 2019-04-28T20:58:28 https://maestrodatabase.com/blog/if-the-states-dont-treat-pharma-as-a-utility-it-may-be-lights-out-for-too-many-patients 2019-04-28T20:53:25 https://maestrodatabase.com/blog/pear-therapeutics-receives-fda-breakthrough-device-designation-for-prescription-digital-therapeutic-candidate-to-treat-alcohol-use-disorder 2021-11-22T19:56:26 https://maestrodatabase.com/blog/us-fda-approves-gileads-biktarvy-bictegravir-emtricitabine-tenofovir-alafenamide-for-treatment-of-hiv-1-infection 2018-02-08T04:03:15 https://maestrodatabase.com/blog/pfizer-receives-positive-chmp-opinion-for-talzenna-talazoparib-for-patents-with-inherited-germline-brca-mutated-locally-advanced-or-metastatic-breast-cancer 2019-04-28T20:42:02 https://maestrodatabase.com/blog/updates-to-antibiotic-repeats-on-the-pharmaceutical-benefits-scheme-item-august-2019 2020-04-30T05:30:36 https://maestrodatabase.com/blog/intarcia-therapeutics-takes-one-last-shot-at-fda-approval 2021-11-22T20:15:38 https://maestrodatabase.com/blog/verastem-submits-new-drug-application-to-u-dot-s-fda-for-duvelisib-for-the-treatment-of-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukaemia-leukaemia-slash-small-lymphocytic-lymphoma-and-follicular-lymphoma 2018-02-08T06:07:42 https://maestrodatabase.com/blog/gilead-submits-biologics-license-application-to-u-dot-s-food-and-drug-administration-for-bulevirtide-an-investigational-treatment-for-people-living-with-chronic-hepatitis-delta 2021-11-22T20:27:02 https://maestrodatabase.com/blog/adverum-biotechnologies-receives-fast-track-designation-for-advm-022-gene-therapy-for-the-treatment-of-wamd 2018-09-21T06:55:04 https://maestrodatabase.com/blog/vertex-announces-reimbursement-agreement-in-spain-for-kaftrio-ivacaftor-slash-tezacaftor-slash-elexacaftor-in-combination-with-ivacaftor-to-treat-people-with-cystic-fibrosis-12-years-and-older-with-at-least-one-f508del-mutation-in-the-cftr-gene 2021-11-22T20:12:40 https://maestrodatabase.com/blog/european-commission-approves-roches-gavreto-pralsetinib-for-the-treatment-of-adults-with-ret-fusion-positive-advanced-non-small-cell-lung-cancer 2021-11-22T20:39:02 https://maestrodatabase.com/blog/cancer-expert-to-head-review-into-efficient-and-equitable-access-to-chemotherapy-medicines 2021-04-30T11:14:31 https://maestrodatabase.com/blog/deciphera-receives-european-commission-approval-of-qinlock-for-the-treatment-of-fourth-line-gastro-intestinal-stromal-tumour 2021-11-22T20:45:55 https://maestrodatabase.com/blog/update-on-u-dot-s-fda-review-of-leo-pharmas-biologics-license-application-for-tralokinumab-for-the-treatment-of-adults-with-moderate-to-severe-atopic-dermatitis 2021-04-30T09:12:08 https://maestrodatabase.com/blog/ema-publishes-agenda-for-21-24-july-2025-chmp-meeting 2025-07-21T22:47:34 https://maestrodatabase.com/blog/promis-neurosciences-granted-fast-track-designation-by-us-fda-for-pmn310-in-the-treatment-of-alzheimers-disease 2025-07-22T01:10:56 https://maestrodatabase.com/blog/u-dot-s-food-and-drug-administration-accepts-for-priority-review-bristol-myers-squibbs-application-for-opdivo-nivolumab-as-adjuvant-treatment-for-patients-with-muscle-invasive-urothelial-carcinoma 2021-04-30T21:03:52 https://maestrodatabase.com/blog/americans-paid-two-to-four-times-as-much-for-some-drugs-as-in-three-other-countries 2021-04-30T12:30:50 https://maestrodatabase.com/blog/bayers-nubeqa-darolutamide-receives-eu-approval-in-third-indication-for-patients-with-advanced-prostate-cancer 2025-07-22T01:15:40 https://maestrodatabase.com/blog/fda-approves-treatment-for-chronic-kidney-disease 2021-04-30T21:32:25 https://maestrodatabase.com/blog/health-canada-approves-keytruda-for-the-treatment-of-adult-patients-with-figo-2014-stage-iii-iva-cervical-cancer-in-combination-with-chemoradiotherapy 2025-07-22T01:37:06 https://maestrodatabase.com/blog/johnson-and-johnson-seeks-first-icotrokinra-us-fda-approval-aiming-to-revolutionise-treatment-paradigm-for-adults-and-adolescents-with-plaque-psoriasis 2025-07-22T01:44:56 https://maestrodatabase.com/blog/google-searches-for-unproven-covid-19-cures-spike-by-1000-per-cent-after-trump-musk-endorsements 2020-04-30T08:50:40 https://maestrodatabase.com/blog/fda-approves-higher-dosage-of-naloxone-nasal-spray-to-treat-opioid-overdose 2021-04-30T22:05:12 https://maestrodatabase.com/blog/fda-approves-new-treatment-for-patients-with-migraine 2019-10-12T01:54:14 https://maestrodatabase.com/blog/government-throwing-billions-at-covid-19-but-not-doubling-pharmac-budget-makes-no-sense---malcolm-mullholland 2020-09-17T02:42:51 https://maestrodatabase.com/blog/canadas-decision-to-make-public-more-clinical-trial-data-puts-pressure-on-fda 2019-10-12T02:01:30 https://maestrodatabase.com/blog/us-fda-approves-qulipta-atogepant-for-adults-with-chronic-migraine 2023-04-18T02:56:58 https://maestrodatabase.com/blog/subsidy-for-hiv-prevention-drug-prep-to-slash-cost-from-10-000-dollars-a-year-to-just-474-dollars 2018-02-08T19:58:50 https://maestrodatabase.com/blog/once-a-day-pill-for-ovarian-cancer-could-be-made-available-on-the-cdf 2018-02-08T20:05:34 https://maestrodatabase.com/blog/glaxos-key-drug-gains-time-as-fda-denies-novartis-generic 2018-02-08T20:24:36 https://maestrodatabase.com/blog/patient-advocate-says-novartis-475-000-dollar-breakthrough-should-cost-just-160-000-dollars 2018-02-08T20:31:53 https://maestrodatabase.com/blog/nice-launches-online-resource-to-help-development-and-adoption-of-new-health-technologies 2019-04-29T11:47:03 https://maestrodatabase.com/blog/sage-therapeutics-receives-fda-breakthrough-therapy-designation-for-sage-217-for-the-treatment-of-major-depressive-disorder 2018-02-08T20:36:23 https://maestrodatabase.com/blog/novartis-receives-fda-approval-for-cosentyx-label-update-to-include-moderate-to-severe-scalp-psoriasis 2018-02-08T20:49:45 https://maestrodatabase.com/blog/rare-disorders-new-zealand-supports-human-rights-commission-case-against-pharmac 2020-09-17T03:55:07 https://maestrodatabase.com/blog/express-scripts-excludes-lillys-new-low-cost-insulin-generic 2019-04-29T22:26:51 https://maestrodatabase.com/blog/zynquista-now-approved-in-the-european-union-for-treatment-of-adults-with-type-1-diabetes 2019-04-29T11:51:56 https://maestrodatabase.com/blog/health-groups-to-present-multiple-petitions 2019-04-29T22:39:06 https://maestrodatabase.com/blog/beefed-up-pharmac-funding-would-be-welcome-budget-boost 2019-04-29T22:36:48 https://maestrodatabase.com/blog/proposal-to-decline-inactive-applications 2019-04-29T22:31:48 https://maestrodatabase.com/blog/aadi-bioscience-announces-fda-approval-of-its-first-product-fyarro-for-patients-with-locally-advanced-unresectable-or-metastatic-malignant-perivascular-epithelioid-cell-tumour 2021-11-23T19:38:08 https://maestrodatabase.com/blog/pharmac-proposes-to-give-more-clarity-about-funding-decisions 2019-04-29T22:30:05 https://maestrodatabase.com/blog/burning-liquid-fire-sick-aussies-endure-agonising-injections-while-painless-drug-is-available-overseas 2020-09-17T04:25:51 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-new-drug-application-and-grants-priority-review-for-darolutamide 2019-04-29T22:47:07 https://maestrodatabase.com/blog/fda-approves-device-to-help-increase-access-to-more-lungs-for-transplant 2019-04-29T22:44:01 https://maestrodatabase.com/blog/progressive-democrats-have-a-plan-to-drastically-lower-drug-prices-for-medicare-beneficiaries 2019-04-29T22:56:50 https://maestrodatabase.com/blog/prilenia-receives-fast-track-designation-for-pridopidine-for-the-treatment-of-huntingtons-disease 2021-11-23T19:47:45 https://maestrodatabase.com/blog/seqirus-announces-u-dot-s-fda-approval-for-multi-dose-vial-presentation-of-first-ever-adjuvanted-cell-based-pandemic-influenza-vaccine 2021-11-23T19:56:06 https://maestrodatabase.com/blog/the-obscure-advisory-committees-at-the-heart-of-the-u-dot-s-drug-pricing-debate 2019-04-29T22:51:14 https://maestrodatabase.com/blog/isofol-medical-receives-fda-fast-track-designation-for-arfolitixorin-in-advanced-colorectal-cancer 2021-11-23T19:51:50 https://maestrodatabase.com/blog/update-on-regulatory-review-of-aducanumab-in-the-european-union 2021-11-23T19:42:31 https://maestrodatabase.com/blog/us-fda-approves-dong-a-sts-imuldosa-ustekinumab-srlf-a-biosimilar-to-stelara 2024-10-13T21:52:18 https://maestrodatabase.com/blog/ema-receives-application-for-marketing-authorisation-for-lagevrio-molnupiravir-for-treating-patients-with-covid-19 2021-11-23T20:12:53 https://maestrodatabase.com/blog/tga-approves-new-medicine-for-nsclc-patients-with-an-egfr-exon-20-mutation 2022-08-01T10:48:01 https://maestrodatabase.com/blog/the-bbbs-threat-to-biosimilar-drug-development 2021-11-23T20:46:53 https://maestrodatabase.com/blog/use-of-confidence-intervals-in-interpreting-non-statistically-significant-results 2021-11-23T20:23:56 https://maestrodatabase.com/blog/amryt-provides-update-on-regulatory-review-process-for-oleogel-s10 2021-11-23T20:00:57 https://maestrodatabase.com/blog/changes-to-pbs-listing-of-hydromorphone-oral-solution 2022-08-01T11:11:35 https://maestrodatabase.com/blog/mum-fears-dance-loving-toddler-will-lose-ability-to-walk-without-unfunded-drug 2022-08-01T11:07:05 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-may-2021-update 2021-05-01T00:42:09 https://maestrodatabase.com/blog/abbvie-announces-provincial-reimbursement-for-vraylar-cariprazine-for-the-treatment-of-schizophrenia-in-quebec 2023-04-18T05:55:32 https://maestrodatabase.com/blog/coronavirus-vaccine-donald-trump-contradicts-cdc-director-robert-redfield 2020-09-17T06:10:43 https://maestrodatabase.com/blog/pbs-listings-will-help-people-with-spinal-muscular-atrophy-schizophrenia-and-multiple-sclerosis 2022-08-01T10:57:42 https://maestrodatabase.com/blog/health-canada-approves-alhemo-the-first-subcutaneous-prophylactic-treatment-for-people-living-with-haemophilia-b-with-inhibitors 2023-04-18T05:51:54 https://maestrodatabase.com/blog/medicare-coverage-of-aducanumab----implications-for-state-budgets 2021-11-23T20:49:42 https://maestrodatabase.com/blog/why-is-aducanumab-priced-at-56-000-dollars-per-patient-lessons-for-drug-pricing-reform 2021-11-23T20:54:02 https://maestrodatabase.com/blog/zytiga-abiraterone-acetate-plus-prednisone-approved-for-treatment-of-earlier-form-of-metastatic-prostate-cancer 2018-02-09T09:46:21 https://maestrodatabase.com/blog/arcutis-submits-roflumilast-cream-0-dot-15-percent-supplemental-new-drug-application-to-the-fda-for-the-treatment-of-atopic-dermatitis-in-adults-and-children-ages-6-years-and-older 2023-09-14T10:05:29 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac---december-2017 2018-02-09T09:31:49 https://maestrodatabase.com/blog/csl-behring-receives-fda-approval-for-hizentra-immune-globulin-subcutaneous-human-20-percent-liquid-50-ml-pre-filled-syringe 2023-04-18T20:41:54 https://maestrodatabase.com/blog/anti-hiv-pill-set-for-federal-drug-scheme 2018-02-09T09:41:19 https://maestrodatabase.com/blog/legend-biotech-announces-submission-of-european-marketing-authorisation-application-for-bcma-car-t-therapy-ciltacabtagene-autoleucel-cilta-cel-for-the-treatment-of-relapsed-and-slash-or-refractory-multiple-myeloma 2021-05-01T01:12:06 https://maestrodatabase.com/blog/why-are-there-drug-shortages 2023-04-18T20:38:36 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-may-2021 2021-05-01T01:24:04 https://maestrodatabase.com/blog/gamida-cell-announces-fda-acceptance-of-biologics-license-application-for-omidubicel-with-priority-review 2022-08-01T11:19:09 https://maestrodatabase.com/blog/replimune-receives-complete-response-letter-from-fda-for-rp1-biologics-license-application-for-the-treatment-of-advanced-melanoma 2025-07-22T21:18:55 https://maestrodatabase.com/blog/hugel-hit-with-another-complete-response-letter-from-the-fda 2023-04-18T10:34:06 https://maestrodatabase.com/blog/hutchmed-announces-nda-acceptance-in-china-for-fruquintinib-in-second-line-gastric-cancer 2023-04-18T20:33:27 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-may-2019-update 2019-04-30T11:58:45 https://maestrodatabase.com/blog/alx-oncologys-evorpacept-receives-fast-track-designation-from-fda-as-first-line-treatment-for-head-and-neck-squamous-cell-carcinoma 2022-08-01T11:58:10 https://maestrodatabase.com/blog/added-therapeutic-benefit-of-top-selling-brand-name-drugs-in-medicare 2023-04-18T21:27:43 https://maestrodatabase.com/blog/ucb-receives-us-fda-approval-for-320-mg-single-injection-device-presentations-of-bimzelx-bimekizumab-bkzx 2024-10-14T05:01:46 https://maestrodatabase.com/blog/european-commission-approves-skyrizi-risankizumab-for-the-treatment-of-moderate-to-severe-plaque-psoriasis 2019-04-30T11:48:35 https://maestrodatabase.com/blog/60-degrees-pharmaceuticals-receives-priority-review-designation-for-malaria-drug 2018-02-09T10:03:55 https://maestrodatabase.com/blog/changes-to-proton-pump-inhibitor-restriction-level 2019-04-30T11:43:00 https://maestrodatabase.com/blog/cost-effectiveness-thresholds-used-by-study-authors-1990-2021 2023-04-18T21:24:56 https://maestrodatabase.com/blog/changes-to-cost-recovery-arrangements-from-1-august-2022 2022-08-01T11:54:21 https://maestrodatabase.com/blog/hse-weighs-up-impact-of-obesity-drug-that-costs-250-euros-a-month 2022-08-01T11:47:26 https://maestrodatabase.com/blog/scynexis-announces-u-dot-s-fda-acceptance-and-priority-review-of-the-supplemental-new-drug-application-for-brexafemme-ibrexafungerp-for-prevention-of-recurrent-vaginal-yeast-infections 2022-08-01T20:53:53 https://maestrodatabase.com/blog/nice-announces-autumn-series-of-virtual-events 2020-09-17T20:35:37 https://maestrodatabase.com/blog/stelara-ustekinumab-approved-by-the-u-dot-s-fda-to-treat-paediatric-patients-with-active-psoriatic-arthritis 2022-08-01T20:47:43 https://maestrodatabase.com/blog/pbs-restriction-requirement-exemptions-for-some-medicines-during-the-covid-19-pandemic 2020-04-30T12:06:20 https://maestrodatabase.com/blog/pharming-receives-accelerated-assessment-in-europe-for-leniolisib-for-the-treatment-of-rare-immunodeficiency-apds 2022-08-01T21:16:08 https://maestrodatabase.com/blog/roche-receives-fda-approval-for-expanded-use-of-the-cintec-plus-cytology-test-to-aid-clinicians-in-preventing-cervical-cancer 2020-09-17T21:05:22 https://maestrodatabase.com/blog/tell-your-senator-to-lower-rx-drug-prices-now 2022-08-01T21:10:11 https://maestrodatabase.com/blog/the-best-possible-security-of-supply-for-cancer-therapy-with-car-t-cells 2020-09-17T21:12:03 https://maestrodatabase.com/blog/trumps-most-favored-nation-executive-order-on-drug-prices-is-a-scam-for-seniors 2020-09-17T20:39:58 https://maestrodatabase.com/blog/ema-close-to-finalising-guidance-for-advanced-therapies 2020-09-17T20:42:27 https://maestrodatabase.com/blog/revised-pbs-restrictions-for-medicine-for-pulmonary-arterial-hypertension 2020-04-30T12:01:46 https://maestrodatabase.com/blog/real-world-data-for-health-technology-assessment-for-reimbursement-decisions-in-asia-current-landscape-and-a-way-forward 2020-09-17T20:51:51 https://maestrodatabase.com/blog/chemocentryx-announces-fda-acceptance-of-the-avacopan-new-drug-application-for-the-treatment-of-anca-associated-vasculitis 2020-09-17T20:57:11 https://maestrodatabase.com/blog/enhertu-approved-in-china-as-first-her2-directed-therapy-for-patients-with-her2-mutant-metastatic-non-small-cell-lung-cancer 2024-10-14T09:56:39 https://maestrodatabase.com/blog/advancing-innovative-clinical-trials-to-efficiently-deliver-medicines-to-patients 2022-08-01T21:41:15 https://maestrodatabase.com/blog/fda-approves-first-treatment-for-common-type-of-post-transplant-infection-that-is-resistant-to-other-drugs 2021-11-24T00:08:52 https://maestrodatabase.com/blog/federal-officials-unveil-plan-to-provide-free-coronavirus-vaccine 2020-09-17T21:17:15 https://maestrodatabase.com/blog/fda-may-approve-first-otc-birth-control-pill-in-u-dot-s-more-novel-prescription-to-otc-switches-could-be-on-tap 2022-08-01T21:30:36 https://maestrodatabase.com/blog/icer-releases-draft-evidence-reports-on-bladder-cancer-and-digital-therapeutics-for-opioid-use-disorder 2020-09-17T21:27:36 https://maestrodatabase.com/blog/transparency-commission-publishes-its-opinion-on-veklury 2020-09-17T21:33:21 https://maestrodatabase.com/blog/marinus-pharmaceuticals-announces-u-dot-s-commercial-launch-of-ztalmy-ganaxolone-for-seizures-associated-with-cdkl5-deficiency-disorder 2022-08-01T21:20:58 https://maestrodatabase.com/blog/11-state-treasurers-call-on-gilead-to-reduce-remdesivir-pricing 2020-09-17T21:48:58 https://maestrodatabase.com/blog/listing-breakthrough-brings-hope-for-people-with-spinal-condition 2022-08-01T21:27:03 https://maestrodatabase.com/blog/madrigal-receives-breakthrough-therapy-designation-from-fda-for-resmetirom 2023-04-19T01:59:58 https://maestrodatabase.com/blog/pharmacs-budget-hole-hundreds-of-millions-of-dollars-deep 2021-05-02T20:57:24 https://maestrodatabase.com/blog/nice-joins-international-collaboratives-to-respond-to-the-covid-19-pandemic 2020-04-30T12:46:16 https://maestrodatabase.com/blog/us-fda-accepts-for-priority-review-taiho-oncologys-supplemental-new-drug-application-for-the-use-of-trifluridine-slash-tipiracil-lonsurf-in-combination-with-bevacizumab-for-refractory-metastatic-colorectal-cancer 2023-04-19T02:30:33 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-update---1-may-2020 2020-04-30T20:44:16 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-may-2020-update 2020-04-30T20:48:39 https://maestrodatabase.com/blog/sk-bioscience-submits-application-for-conditional-marketing-authorisation-of-covid-19-vaccine-skycovion-to-european-medicines-agency 2022-08-02T01:22:32 https://maestrodatabase.com/blog/using-qalys-versus-dalys-to-measure-cost-effectiveness-how-much-does-it-matter 2020-04-30T12:53:18 https://maestrodatabase.com/blog/teva-canada-announces-the-launch-of-ajovy-for-the-preventive-treatment-of-migraine-in-adults-who-have-at-least-four-migraine-days-per-month 2020-04-30T13:01:05 https://maestrodatabase.com/blog/ema-starts-rolling-review-of-remdesivir-for-covid-19 2020-04-30T20:39:41 https://maestrodatabase.com/blog/trump-proposes-reduction-of-drug-costs-under-medicare 2018-02-09T23:29:56 https://maestrodatabase.com/blog/highlights-from-the-28-30-april-chmp-meeting 2020-04-30T21:01:52 https://maestrodatabase.com/blog/fda-moving-at-lightning-speed-on-gilead-drug-commissioner-says 2020-04-30T21:06:34 https://maestrodatabase.com/blog/hagar-gwave-awarded-fda-breakthrough-device-designation 2021-11-24T01:37:12 https://maestrodatabase.com/blog/eladocagene-exuparvovec-for-the-treatment-of-patients-with-aromatic-l-amino-acid-decarboxylase-deficiency 2023-04-19T05:23:18 https://maestrodatabase.com/blog/health-canada-approves-keytruda-pembrolizumab-in-combination-with-chemotherapy-for-the-treatment-of-locally-recurrent-unresectable-or-metastatic-triple-negative-breast-cancer-whose-tumours-express-pd-l1-cps-10 2021-11-24T02:12:30 https://maestrodatabase.com/blog/biocryst-receives-european-commission-approval-of-orladeyo-berotralstat-first-oral-once-daily-therapy-to-prevent-attacks-in-hereditary-angioedema-patients 2021-05-03T00:29:59 https://maestrodatabase.com/blog/swiss-regulator-approves-pfizer-slash-biontech-booster-for-16-and-up 2021-11-24T03:07:47 https://maestrodatabase.com/blog/have-fdas-generic-approvals-helped-with-competition-researchers-say-too-early-to-tell 2019-10-12T07:16:57 https://maestrodatabase.com/blog/landscape-analysis-of-health-technology-assessment-systems-and-practices-in-asia 2019-10-12T07:13:15 https://maestrodatabase.com/blog/ozempic-semaglutide-approved-in-the-eu-for-the-treatment-of-type-2-diabetes 2018-02-10T01:09:42 https://maestrodatabase.com/blog/characteristics-of-key-patents-covering-recent-fda-approved-drugs 2022-08-02T03:39:42 https://maestrodatabase.com/blog/californias-new-transparency-law-shows-staggering-rise-in-wholesale-drug-prices 2019-10-12T07:20:58 https://maestrodatabase.com/blog/semaglutide-wegovy-stakeholder-meeting-outcome-statement 2021-11-24T03:48:17 https://maestrodatabase.com/blog/proposal-to-fund-emicizumab-for-people-with-haemophilia-a 2020-09-18T00:43:45 https://maestrodatabase.com/blog/fda-nomination-slips-after-biden-admin-fails-to-send-papers-to-congress 2021-11-24T03:43:07 https://maestrodatabase.com/blog/janssen-submits-marketing-authorisation-application-for-apalutamide-to-treat-patients-with-high-risk-non-metastatic-castration-resistant-prostate-cancer 2018-02-10T01:15:50 https://maestrodatabase.com/blog/gsks-immunotherapy-jemperli-paves-way-for-second-line-endometrial-cancer-treatment 2024-01-08T02:32:47 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-treatment-for-non-cystic-fibrosis-bronchiectasis 2025-07-23T21:09:38 https://maestrodatabase.com/blog/review-of-real-world-evidence-and-patient-reported-outcomes 2021-11-24T05:54:24 https://maestrodatabase.com/blog/florida-is-first-state-allowed-to-import-drugs-from-canada-in-bid-to-reduce-costs 2024-01-08T02:49:24 https://maestrodatabase.com/blog/califf-bidens-pick-to-lead-fda-has-millions-invested-in-pharma-and-tech-companies 2021-11-24T04:23:34 https://maestrodatabase.com/blog/journey-medical-corporation-submits-new-drug-application-to-fda-for-dfd-29-to-treat-rosacea 2024-01-08T02:43:51 https://maestrodatabase.com/blog/sab-biotherapeutics-announces-us-fda-grants-breakthrough-therapy-designation-to-sab-176-influenza-immunotherapy 2023-04-19T08:10:08 https://maestrodatabase.com/blog/covid-19-vaccine-indemnity 2021-11-24T20:15:17 https://maestrodatabase.com/blog/agenda-for-the-march-2022-pbac-meeting 2021-11-24T08:55:53 https://maestrodatabase.com/blog/pharmac-likely-to-end-blanket-funding-for-kids-cancer-drugs 2021-05-03T01:24:26 https://maestrodatabase.com/blog/a-vision-for-use-of-real-world-evidence-in-eu-medicines-regulation 2021-11-24T20:20:23 https://maestrodatabase.com/blog/the-fdas-dysfunction-is-a-public-health-crisis-of-its-own 2021-11-24T20:17:58 https://maestrodatabase.com/blog/bavarian-nordic-receives-acceptance-from-health-canada-for-review-of-the-new-drug-submission-for-its-chikungunya-vaccine 2025-07-23T06:58:45 https://maestrodatabase.com/blog/agenda-for-the-november-2024-pbac-meeting-version-5 2024-10-15T00:38:23 https://maestrodatabase.com/blog/dualitybios-next-generation-her3-adc-db-1310-granted-fda-fast-track-designation 2025-07-23T07:06:30 https://maestrodatabase.com/blog/grifols-hyperrab-rabies-immune-globulin-human-300-iu-slash-ml-receives-fda-approval-to-treat-patients-exposed-to-rabies-virus-infection 2018-02-10T02:18:27 https://maestrodatabase.com/blog/the-us-fda-grants-fast-track-designation-to-coherent-biopharmas-cbp-1008 2024-10-15T00:05:40 https://maestrodatabase.com/blog/lilly-receives-positive-chmp-opinion-for-emgality-galcanezumab-for-the-prophylaxis-of-migraine-in-adults 2018-09-22T02:46:27 https://maestrodatabase.com/blog/abortion-pill-maker-sues-fda-to-preserve-access 2023-04-19T20:36:16 https://maestrodatabase.com/blog/fda-approves-genentechs-polivy-in-combination-with-r-chp-for-people-with-certain-types-of-previously-untreated-diffuse-large-b-cell-lymphoma 2023-04-19T20:39:11 https://maestrodatabase.com/blog/onasemnogene-abeparvovec-for-the-treatment-of-patients-with-presymptomatic-spinal-muscular-atrophy 2023-04-19T20:31:17 https://maestrodatabase.com/blog/ontario-becomes-first-province-to-provide-public-funding-of-tresiba-for-adults-with-diabetes-mellitus 2018-09-22T02:39:42 https://maestrodatabase.com/blog/european-commission-approves-roches-itovebi-for-people-with-er-positive-her2-negative-advanced-breast-cancer-with-a-pik3ca-mutation 2025-07-23T22:11:48 https://maestrodatabase.com/blog/european-commission-approves-imbruvica-ibrutinib-as-the-first-targeted-therapy-for-patients-with-previously-untreated-mantle-cell-lymphoma-who-would-be-eligible-for-autologous-stem-cell-transplant 2025-07-23T22:19:32 https://maestrodatabase.com/blog/trodelvy-sacituzumab-govitecan-granted-european-commission-marketing-authorisation-for-treatment-of-metastatic-triple-negative-breast-cancer-in-second-line 2021-11-24T20:25:37 https://maestrodatabase.com/blog/delay-of-evrysdi-reimbursement-review-denies-sma-patients-right-to-drug-choice 2022-08-02T08:33:18 https://maestrodatabase.com/blog/bayer-submits-application-for-third-indication-of-darolutamide-in-the-eu 2024-10-15T01:20:05 https://maestrodatabase.com/blog/covid-windfall-continues-for-corporate-insurers 2021-11-24T20:37:48 https://maestrodatabase.com/blog/germanys-government-to-be-eyes-backdated-drug-price-cuts 2021-11-24T20:33:17 https://maestrodatabase.com/blog/koreas-first-gene-treatment-for-sma-zolgensma-gets-insurance-benefits 2022-08-02T07:30:29 https://maestrodatabase.com/blog/icer-publishes-white-paper-evaluating-best-practices-and-potential-reforms-for-white-bagging-brown-bagging-and-site-of-service-policies-that-seek-to-address-high-markup-in-drug-prices 2023-04-19T21:21:36 https://maestrodatabase.com/blog/abbvie-receives-positive-chmp-opinion-for-a-novel-chemotherapy-free-combination-of-venclyxto-venetoclax-with-rituximab-as-a-treatment-with-a-fixed-duration-for-patients-with-chronic-lymphocytic-leukaemia-who-have-received-at-least-one-prior-therapy 2018-09-22T02:57:24 https://maestrodatabase.com/blog/gsk-announces-extension-of-us-fda-an-review-period-for-blenrep-belantamab-mafodotin-blmf-in-relapsed-slash-refractory-multiple-myeloma 2025-07-23T23:04:09 https://maestrodatabase.com/blog/new-drug-submission-filed-for-vascepa-with-health-canada 2019-04-30T16:03:59 https://maestrodatabase.com/blog/janssen-announces-submission-of-new-drug-application-to-u-dot-s-fda-for-the-first-monthly-injectable-two-drug-regimen-of-rilpivirine-and-cabotegravir-for-treatment-of-hiv 2019-04-30T16:00:24 https://maestrodatabase.com/blog/fda-scraps-another-last-minute-trump-era-policy 2021-05-03T01:50:07 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-may-2019-update 2019-04-30T16:20:23 https://maestrodatabase.com/blog/finch-therapeutics-receives-fast-track-designation-for-the-investigation-of-full-spectrum-microbiota-as-a-treatment-for-children-with-autism-spectrum-disorder 2019-04-30T16:10:12 https://maestrodatabase.com/blog/pharmac-scrutiny-a-win-for-transparency 2022-08-02T09:52:23 https://maestrodatabase.com/blog/company-at-heart-of-97-000-percent-drug-price-hike-bribed-doctors-to-boost-sales 2019-04-30T16:26:04 https://maestrodatabase.com/blog/novo-nordisk-receives-fda-approval-for-rebinyn-for-routine-prophylaxis-to-prevent-bleeding-in-people-living-with-haemophilia-b 2022-08-02T11:30:00 https://maestrodatabase.com/blog/fda-official-patients-play-an-increasing-role-in-rare-disease-drug-development 2022-08-02T12:07:27 https://maestrodatabase.com/blog/chi-med-announces-second-nda-acceptance-in-china-for-surufatinib-in-pancreatic-neuroendocrine-tumours 2020-09-18T04:03:21 https://maestrodatabase.com/blog/decision-to-fund-an-additional-brand-of-budesonide-with-eformoterol 2020-09-18T04:09:17 https://maestrodatabase.com/blog/chiesi-global-rare-diseases-announces-fda-approval-of-ferriprox-deferiprone-for-treatment-of-transfusional-iron-overload-due-to-sickle-cell-disease 2021-05-03T03:18:18 https://maestrodatabase.com/blog/cancer-patients-waiting-a-year-for-keytruda-funding-decision-from-pharmac 2018-02-11T20:00:13 https://maestrodatabase.com/blog/roche-wins-uk-watchdogs-nod-for-lymphoma-drug-after-initial-snub 2018-02-11T10:36:04 https://maestrodatabase.com/blog/salix-provides-update-on-fda-submission-for-plenvu 2018-02-11T20:11:56 https://maestrodatabase.com/blog/falling-insulin-prices----what-just-happened 2023-04-20T02:16:42 https://maestrodatabase.com/blog/pharmac-announces-new-deputy-medical-director-maori 2023-04-20T02:22:21 https://maestrodatabase.com/blog/marius-pharmaceuticals-receives-fda-approval-of-kyzatrex-an-oral-testosterone-replacement-therapy 2022-08-02T20:09:40 https://maestrodatabase.com/blog/f-dot-d-a-chief-goes-against-the-administration-stereotype 2018-02-11T20:06:20 https://maestrodatabase.com/blog/critics-decry-drug-pricing-provisions-in-inflation-reduction-act-say-they-will-stifle-innovation 2022-08-02T20:20:40 https://maestrodatabase.com/blog/pharmac-fully-funding-innovative-improvements-in-haemophilia-treatment 2019-05-01T10:46:09 https://maestrodatabase.com/blog/patient-reported-outcome-measures-in-clinical-research 2022-08-02T21:47:33 https://maestrodatabase.com/blog/agenda-for-the-july-2019-pbac-meeting 2019-05-01T10:41:36 https://maestrodatabase.com/blog/newly-approved-ms-drug-to-offer-relief-to-children 2019-05-01T10:56:45 https://maestrodatabase.com/blog/pharmac-sheds-a-little-more-light-on-procedures-in-savvy-political-move 2019-05-01T10:52:18 https://maestrodatabase.com/blog/updates-from-the-health-technology-assessment-policy-and-methods-review-reference-committee---march-and-april-2023 2023-04-20T02:54:13 https://maestrodatabase.com/blog/why-pharmac-wont-fund-lifesaving-epipens 2019-05-01T10:49:38 https://maestrodatabase.com/blog/us-food-and-drug-administration-approves-zelsumvi-as-a-first-in-class-medication-for-the-treatment-of-molluscum-contagiosum 2024-01-08T06:00:46 https://maestrodatabase.com/blog/ardelyx-resubmits-new-drug-application-to-us-fda-for-xphozah-tenapanor 2023-04-20T03:07:54 https://maestrodatabase.com/blog/fda-approves-first-treatment-for-all-genotypes-of-hepatitis-c-in-paediatric-patients 2019-05-01T11:08:51 https://maestrodatabase.com/blog/leriglitazone-marketing-authorisation-application-submitted-for-treatment-of-cerebral-adrenoleukodystrophy-has-been-validated-by-ema 2025-07-24T03:47:19 https://maestrodatabase.com/blog/nabriva-therapeutics-receives-complete-response-letter-from-fda-on-nda-for-intravenous-contepo-fosfomycin-for-injection 2019-05-01T14:51:24 https://maestrodatabase.com/blog/statement-from-health-canada-on-janssen-covid-19-vaccines-and-emergent-biosolutions 2021-05-03T09:28:34 https://maestrodatabase.com/blog/janssen-submits-application-to-u-dot-s-fda-seeking-approval-of-erleada-apalutamide-for-patients-with-metastatic-castration-sensitive-prostate-cancer 2019-05-01T14:59:32 https://maestrodatabase.com/blog/hutchmed-completes-rolling-submission-of-nda-to-u-dot-s-fda-for-surufatinib-for-the-treatment-of-advanced-neuroendocrine-tumours 2021-05-03T12:02:04 https://maestrodatabase.com/blog/the-fda-announces-patient-engagement-advisory-committee-meeting-on-utilising-real-world-data-from-patient-driven-platforms-that-connect-and-empower-patients 2018-09-22T23:48:48 https://maestrodatabase.com/blog/ucb-announces-european-commission-approval-of-rystiggo-rozanolixizumab-for-the-treatment-of-adults-with-generalised-myasthenia-gravis-in-europe 2024-01-08T06:15:45 https://maestrodatabase.com/blog/solid-biosciences-receives-fda-fast-track-designation-for-sgt-501-first-in-class-gene-therapy-for-catecholaminergic-polymorphic-ventricular-tachycardia 2025-07-24T02:27:49 https://maestrodatabase.com/blog/novartis-announces-positive-chmp-opinion-for-one-time-gene-therapy-luxturna-to-treat-children-and-adults-with-rare-inherited-retinal-disease 2018-09-22T23:55:10 https://maestrodatabase.com/blog/als-groups-to-the-fda-and-drug-sponsors-we-wont-be-played-again 2021-05-03T09:22:39 https://maestrodatabase.com/blog/intra-cellular-therapies-announces-fda-acceptance-of-caplyta-lumateperone-sndas-for-the-treatment-of-bipolar-depression 2021-05-03T21:04:10 https://maestrodatabase.com/blog/how-the-fdas-master-plan-will-affect-nih-funding-for-digital-medicine-projects 2021-05-03T21:01:05 https://maestrodatabase.com/blog/immunomet-therapeutics-granted-fast-track-designation-by-u-dot-s-fda-for-im156-in-idiopathic-pulmonary-fibrosis 2021-05-03T21:08:50 https://maestrodatabase.com/blog/novartis-receives-positive-chmp-opinion-for-gilenya-for-the-treatment-of-children-and-adolescents-with-ms-marking-a-major-medical-advance-for-young-ms-patients-in-europe 2018-09-23T02:28:49 https://maestrodatabase.com/blog/ema-starts-evaluating-use-of-covid-19-vaccine-comirnaty-in-young-people-aged-12-to-15 2021-05-03T12:06:55 https://maestrodatabase.com/blog/tga-approves-key-label-updates-to-buvidal-for-treatment-of-opioid-dependence 2021-05-03T20:51:15 https://maestrodatabase.com/blog/fda-proposes-stiff-fines-for-failing-to-report-clinical-trials 2018-09-23T02:21:28 https://maestrodatabase.com/blog/childrens-commissioner-worried-pharmac-will-cut-childrens-access-to-cancer-drugs 2021-05-03T20:47:34 https://maestrodatabase.com/blog/lilly-to-launch-mounjaro-in-korea-in-august-without-reimbursement 2025-07-24T05:26:48 https://maestrodatabase.com/blog/phoenix-tissue-repair-receives-fda-fast-track-designation-for-ptr-01-for-the-treatment-of-dystrophic-epidermolysis-bullosa 2019-05-01T15:17:36 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-25-november-2021 2021-11-25T08:00:11 https://maestrodatabase.com/blog/a-divisive-ruling-on-devices----genus-medical-technologies-v-fda 2021-11-25T07:49:37 https://maestrodatabase.com/blog/amphastar-pharmaceuticals-receives-fda-approval-for-morphine-sulphate-injection 2021-05-03T21:25:51 https://maestrodatabase.com/blog/fda-approves-kalydeco-ivacaftor-as-first-and-only-cftr-modulator-to-treat-eligible-infants-with-cf-as-early-as-six-months-of-age 2019-05-01T15:34:07 https://maestrodatabase.com/blog/tlv-reconsiders-subsidy-for-eleven-tnf-alfa-inhibitors-included-in-the-high-cost-protection 2021-05-03T21:15:44 https://maestrodatabase.com/blog/medicines-australia-welcomes-tabling-of-parliamentary-report-about-approval-processes-for-new-drugs-and-novel-medical-technologies 2021-11-25T04:07:02 https://maestrodatabase.com/blog/lantern-pharmas-investigational-drug-candidate-lp-184-receives-fast-track-designation-in-glioblastoma-from-the-fda 2024-10-15T23:08:51 https://maestrodatabase.com/blog/taiwan-national-health-insurance-administration-of-the-ministry-of-health-and-welfare-approves-vemlidy-tenofovir-alafenamide-for-reimbursement 2019-05-01T15:29:34 https://maestrodatabase.com/blog/doubt-over-local-mrna-plans-as-major-companies-pull-out-of-australia 2021-05-03T21:39:23 https://maestrodatabase.com/blog/sarepta-receives-negative-chmp-re-examination-opinion-for-eteplirsen 2018-09-23T02:49:13 https://maestrodatabase.com/blog/heron-therapeutics-receives-complete-response-letter-for-htx-011-for-the-management-of-post-operative-pain 2020-06-30T00:50:13 https://maestrodatabase.com/blog/the-french-solution-to-us-drug-prices 2019-05-01T15:49:37 https://maestrodatabase.com/blog/comirnaty-covid-19-vaccine-ema-recommends-approval-for-children-aged-5-to-11 2021-11-25T19:45:24 https://maestrodatabase.com/blog/highlights-from-the-17-20-september-chmp-meeting 2018-09-23T02:44:59 https://maestrodatabase.com/blog/drug-maker-takeda-to-introduce-value-based-pricing-in-europe 2019-05-01T15:46:05 https://maestrodatabase.com/blog/tagrisso-opdivo-fail-to-get-broader-reimbursement 2021-11-25T19:58:32 https://maestrodatabase.com/blog/ama-urges-pharmacy-reform-to-deliver-lower-medicine-prices 2023-04-20T21:01:32 https://maestrodatabase.com/blog/nhs-england-finalises-procurement-to-eliminate-hepatitis-c 2019-05-01T15:38:57 https://maestrodatabase.com/blog/health-funds-not-meeting-expectations 2021-11-25T19:54:07 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-european-commission-approval-of-zeposia-ozanimod-for-use-in-adults-with-moderately-to-severely-active-ulcerative-colitis 2021-11-25T11:02:46 https://maestrodatabase.com/blog/breakthrough-new-medicine-listings-on-the-pbs-for-cardiovascular-disease-rheumatoid-arthritis-and-asthma 2020-05-01T03:14:52 https://maestrodatabase.com/blog/fda-approval-processes-for-therapeutic-drugs-must-be-improved 2023-04-20T20:54:24 https://maestrodatabase.com/blog/drugmakers-gear-up-for-price-restrictions-in-bidens-legislative-agenda 2021-11-25T19:41:48 https://maestrodatabase.com/blog/why-cancer-treatment-will-always-have-out-of-pocket-costs 2019-05-01T21:39:51 https://maestrodatabase.com/blog/mtaa-welcomes-new-frontiers-report 2021-11-25T11:10:53 https://maestrodatabase.com/blog/anzupgo-delgocitinib-cream-is-now-the-first-and-only-fda-approved-treatment-for-moderate-to-severe-chronic-hand-eczema-in-adults 2025-07-24T08:19:26 https://maestrodatabase.com/blog/insights-from-the-agenda-version-1-dot-0-for-the-march-2022-pbac-meeting 2021-11-25T20:28:18 https://maestrodatabase.com/blog/tga-commences-evaluation-of-pfizers-covid-19-vaccine-comirnaty-for-children-aged-6-months-to-less-than-5-years 2022-08-03T04:26:05 https://maestrodatabase.com/blog/preparing-for-health-cares-new-frontier-committee-releases-major-report-on-reforming-the-process-for-new-medicines-and-health-technology 2021-11-25T20:09:39 https://maestrodatabase.com/blog/revolution-medicines-announces-fda-breakthrough-therapy-designation-for-elironrasib 2025-07-24T07:34:52 https://maestrodatabase.com/blog/icer-publishes-final-evidence-report-on-treatment-for-pulmonary-arterial-hypertension 2024-01-08T20:59:11 https://maestrodatabase.com/blog/pharmac-publishes-minutes-of-august-2021-ptac-meeting 2021-11-25T20:16:14 https://maestrodatabase.com/blog/novel-drug-approvals-for-2023 2024-01-08T20:54:43 https://maestrodatabase.com/blog/nice-u-turn-sees-akceas-waylivra-win-nhs-funding 2020-09-18T11:10:04 https://maestrodatabase.com/blog/rybrevant-amivantamab-receives-positive-cadth-reimbursement-recommendation-for-the-treatment-of-adult-patients-with-non-small-cell-lung-cancer-with-activating-egfr-exon-20-insertion-mutations 2023-04-20T21:30:37 https://maestrodatabase.com/blog/bms-opdivo-wins-new-nice-lung-cancer-backing 2020-09-18T11:34:10 https://maestrodatabase.com/blog/highlights-from-14-17-september-chmp-meeting 2020-09-18T11:36:50 https://maestrodatabase.com/blog/pralsetinib-for-treating-advanced-ret-fusion-positive-non-small-cell-lung-cancer 2022-08-03T04:31:52 https://maestrodatabase.com/blog/ema-endorses-use-of-dexamethasone-in-covid-19-patients-on-oxygen-or-mechanical-ventilation 2020-09-18T11:03:45 https://maestrodatabase.com/blog/bupa-ramsay-fight-puts-pressure-on-customers-and-health-minister-mark-butler 2022-08-03T05:22:58 https://maestrodatabase.com/blog/influenza-vaccine-for-2018-season 2018-02-12T03:13:09 https://maestrodatabase.com/blog/avidity-biosciences-receives-fda-breakthrough-therapy-designation-for-delpacibart-zotadirsen-for-the-treatment-of-dmd-in-people-with-mutations-amenable-to-exon-44-skipping 2025-07-24T08:40:48 https://maestrodatabase.com/blog/commissioners-national-priority-voucher-pilot-program 2025-07-24T10:44:45 https://maestrodatabase.com/blog/novartis-receives-chmp-positive-opinion-for-enerzair-breezhaler-qvm149-a-potential-first-in-class-inhaled-laba-slash-lama-slash-ics-combination-for-uncontrolled-asthma 2020-05-01T05:48:05 https://maestrodatabase.com/blog/andrew-little-not-pleased-with-childrens-commissioner-comments-on-potential-pharmac-move 2021-05-04T03:25:29 https://maestrodatabase.com/blog/chmp-recommends-approval-of-lillys-baricitinib-for-the-treatment-of-adults-with-moderate-to-severe-atopic-dermatitis 2020-09-18T22:38:53 https://maestrodatabase.com/blog/clearside-biomedical-announces-approval-of-xipere-suprachoroidal-treatment-for-uveitic-macular-oedema-in-canada 2025-07-24T11:30:22 https://maestrodatabase.com/blog/fda-grants-soligenix-fast-track-designation-for-dusquetide-in-the-treatment-of-oral-lesions-of-behcets-disease 2024-01-08T23:25:27 https://maestrodatabase.com/blog/blenrep-belantamab-mafodotin-combinations-approved-in-canada-for-the-treatment-of-relapsed-slash-refractory-multiple-myeloma 2025-07-24T11:37:10 https://maestrodatabase.com/blog/sellas-announces-us-fda-rare-paediatric-disease-designation-granted-to-galinpepimut-s-for-the-treatment-of-paediatric-acute-myeloid-leukaemia 2024-10-16T02:53:27 https://maestrodatabase.com/blog/cabaletta-bio-receives-additional-fda-fast-track-designations-for-caba-201-in-dermatomyositis-and-systemic-sclerosis 2024-01-08T23:58:38 https://maestrodatabase.com/blog/todays-health-debate-should-focus-on-ensuring-the-pbs-is-well-funded-and-fit-for-the-future 2019-05-02T10:20:08 https://maestrodatabase.com/blog/diabetes-drugs-list-price-increases-were-not-always-reflected-in-net-price-impact-of-brand-competition-unclear 2021-05-04T05:04:34 https://maestrodatabase.com/blog/liver-cancer-patients-barred-from-nhs-access-to-bayers-stivarga 2018-02-12T10:22:08 https://maestrodatabase.com/blog/labor-will-not-rule-out-scrapping-6-dollars-billion-health-insurance-rebate 2019-05-02T10:34:49 https://maestrodatabase.com/blog/fda-approves-coherus-cimerli-ranibizumab-eqrn-as-the-first-and-only-interchangeable-biosimilar-to-lucentis-for-all-five-indications-with-12-months-of-interchangeability-exclusivity 2022-08-03T06:25:10 https://maestrodatabase.com/blog/coalition-promises-cheaper-medicines 2019-05-02T10:30:30 https://maestrodatabase.com/blog/pharmac-tells-mps-medicine-buying-agency-undergoing-substantial-change 2022-08-03T06:10:24 https://maestrodatabase.com/blog/sma-petition-family-forced-to-move-to-australia-to-get-daughters-treated 2019-05-02T10:26:10 https://maestrodatabase.com/blog/the-health-202-trump-needs-help-from-pelosi-to-notch-a-big-drug-pricing-win 2019-05-02T10:52:23 https://maestrodatabase.com/blog/drug-company-says-it-will-negotiate-terms-to-allow-children-to-access-new-treatment-for-rare-genetic-disorder 2018-02-12T19:59:21 https://maestrodatabase.com/blog/fdas-efforts-to-advance-the-development-of-gene-therapy 2019-05-02T10:48:28 https://maestrodatabase.com/blog/astellas-provides-update-on-zolbetuximab-biologics-license-application-in-us 2024-01-09T01:12:26 https://maestrodatabase.com/blog/nice-asks-tesaro-to-submit-cdf-application-for-zejula 2018-02-12T10:25:23 https://maestrodatabase.com/blog/health-canada-approves-wegovy-for-the-treatment-of-adults-with-obesity 2021-11-26T05:54:34 https://maestrodatabase.com/blog/nice-backs-eusas-kidney-cancer-drug-fotivda 2018-02-12T19:54:41 https://maestrodatabase.com/blog/first-fda-approved-vaccine-for-the-prevention-of-dengue-disease-in-endemic-regions 2019-05-02T10:43:09 https://maestrodatabase.com/blog/u-dot-s-fda-files-new-drug-application-under-priority-review-for-migalastat-for-treatment-of-fabry-disease 2018-02-12T20:20:28 https://maestrodatabase.com/blog/white-house-releases-white-paper-on-lowering-drug-prices 2018-02-12T20:10:50 https://maestrodatabase.com/blog/zevra-therapeutics-receives-fda-acceptance-of-resubmission-of-nda-for-arimoclomol-as-a-treatment-for-niemann-pick-disease-type-c 2024-01-09T01:04:33 https://maestrodatabase.com/blog/sma-patients-in-saskatchewan-canada-gain-wider-access-to-spinraza 2019-05-02T10:59:11 https://maestrodatabase.com/blog/mccain-and-baldwin-to-trump-hold-pharmas-feet-to-the-fire-on-drug-prices 2018-02-12T20:13:51 https://maestrodatabase.com/blog/verastem-oncology-granted-fast-track-designation-for-vs-7375-for-the-treatment-of-kras-g12d-mutated-locally-advanced-or-metastatic-pancreatic-cancer 2025-07-24T23:30:54 https://maestrodatabase.com/blog/mediwound-announces-us-fda-acceptance-of-biologics-license-application-for-nexobrid-for-the-treatment-of-severe-thermal-burns 2022-08-03T11:41:48 https://maestrodatabase.com/blog/adamis-pharmaceuticals-announces-fda-acceptance-for-review-for-the-supplemental-new-drug-application-of-its-low-dose-symjepi-product-candidate 2018-02-12T20:29:07 https://maestrodatabase.com/blog/johnson-and-johnson-covid-19-vaccine-fully-approved-by-health-canada-to-prevent-covid-19-in-individuals-18-years-and-older 2021-11-26T06:03:42 https://maestrodatabase.com/blog/astellas-xtandi-enzalutamide-approved-by-european-commission-for-men-with-metastatic-hormone-sensitive-prostate-cancer 2021-05-04T06:04:39 https://maestrodatabase.com/blog/lower-drug-prices-new-proposals-carry-lots-of-promises 2018-02-12T20:36:49 https://maestrodatabase.com/blog/drug-shortages-may-add-230-dollars-million-to-annual-u-dot-s-drug-costs 2018-09-23T21:05:37 https://maestrodatabase.com/blog/health-canada-issues-notice-of-compliance-for-trodelvy-a-new-treatment-option-for-an-aggressive-type-of-metastatic-breast-cancer 2021-11-26T05:58:14 https://maestrodatabase.com/blog/smc---february-2018-decisions 2018-02-12T20:39:27 https://maestrodatabase.com/blog/nhs-wins-legal-battle-against-drugs-giants-over-saving-millions-with-cheaper-medicine 2018-09-23T21:10:10 https://maestrodatabase.com/blog/european-commission-approves-byannli-6-monthly-paliperidone-palmitate-for-the-maintenance-treatment-of-schizophrenia-in-adults 2021-11-26T06:21:47 https://maestrodatabase.com/blog/scots-patients-with-advanced-bladder-cancer-get-first-new-drug-for-25-years-after-smc-approves-pembrolizumab 2018-02-12T20:43:02 https://maestrodatabase.com/blog/blackrock-neurotechs-moveagain-brain-computer-interface-system-receives-breakthrough-device-designation-from-the-fda 2021-11-26T06:15:26 https://maestrodatabase.com/blog/anheart-therapeutics-receives-fda-breakthrough-therapy-designation-for-taletrectinib-in-ros1-positive-non-small-cell-lung-cancer 2022-08-03T21:04:00 https://maestrodatabase.com/blog/urogen-announces-fda-acceptance-of-its-new-drug-application-for-ugn-102 2024-10-16T22:52:40 https://maestrodatabase.com/blog/quizartinib-nda-review-for-patients-with-newly-diagnosed-flt3-itd-positive-aml-extended-by-fda 2023-04-21T01:18:58 https://maestrodatabase.com/blog/covid-19-vaccination-for-children-aged-6-months-to-under-5-years 2022-08-03T12:06:14 https://maestrodatabase.com/blog/bupa-patients-worried-ramsay-health-care-hospital-dispute-will-leave-them-out-of-pocket 2022-08-03T21:36:12 https://maestrodatabase.com/blog/orphan-drug-label-expansions-analysis-of-subsequent-rare-and-common-indication-approvals 2024-01-09T05:55:13 https://maestrodatabase.com/blog/u-dot-s-prescription-drug-market-lacks-certain-competitive-features-case-of-biosimilars 2022-08-03T21:27:27 https://maestrodatabase.com/blog/gensight-biologics-withdraws-its-ema-application-for-lumevoq 2023-04-21T01:28:28 https://maestrodatabase.com/blog/fresenius-kabis-biologics-license-application-for-biosimilar-candidate-tocilizumab-accepted-for-review-by-the-fda 2022-08-03T21:20:21 https://maestrodatabase.com/blog/supply-a-factor-in-restricting-covid-vaccines-for-babies-and-toddlers 2022-08-03T21:10:19 https://maestrodatabase.com/blog/amylyx-pharmaceuticals-announces-fda-advisory-committee-will-reconvene-to-review-new-drug-application-for-amx0035-for-the-treatment-of-als 2022-08-03T21:13:09 https://maestrodatabase.com/blog/additional-insights-from-the-agenda-for-the-march-2022-pbac-meeting 2021-11-26T06:32:49 https://maestrodatabase.com/blog/the-global-imperative-to-make-cancer-medications-affordable 2020-05-01T10:16:36 https://maestrodatabase.com/blog/reblozyl-luspatercept-receives-positive-chmp-opinion-for-the-treatment-of-adults-with-anaemia-in-beta-thalassemia-and-myelodysplastic-syndromes 2020-05-01T10:33:52 https://maestrodatabase.com/blog/seven-years-ago-i-ditched-my-private-hospital-cover-this-is-why-im-now-getting-it-back 2022-08-03T21:49:10 https://maestrodatabase.com/blog/incyte-announces-european-commission-approval-of-opzelura-ruxolitinib-cream-for-the-treatment-of-non-segmental-vitiligo-with-facial-involvement-in-adults-and-adolescents 2023-04-21T01:46:13 https://maestrodatabase.com/blog/connecting-electronic-health-records-to-clinical-trials-how-to-embrace-the-promise-of-real-world-data 2022-08-03T21:43:56 https://maestrodatabase.com/blog/abbvie-wins-appeal-in-antitrust-case-over-humira-patent-thicket 2022-08-03T22:45:07 https://maestrodatabase.com/blog/clearside-biomedical-announces-resubmission-of-new-drug-application-for-xipere-for-treatment-of-macular-oedema-associated-with-uveitis 2021-05-04T09:28:15 https://maestrodatabase.com/blog/ema-publishes-agenda-for-14-17-october-2024-chmp-meeting 2024-10-17T00:29:41 https://maestrodatabase.com/blog/valneva-and-limmatech-awarded-fda-fast-track-designation-for-tetravalent-shigella-vaccine-candidate-s4v 2024-10-17T00:24:45 https://maestrodatabase.com/blog/swiss-study-sees-no-link-between-cancer-drug-prices-and-patient-benefits 2020-05-01T10:45:10 https://maestrodatabase.com/blog/nice-announces-more-people-eligible-for-nusinersen-sodium-following-review-of-managed-access-agreement 2021-05-04T10:46:43 https://maestrodatabase.com/blog/ema-starts-rolling-review-of-covid-19-vaccine-vero-cell-inactivated 2021-05-04T10:44:03 https://maestrodatabase.com/blog/experts-label-tgas-decision-to-not-register-alzheimers-drug-extremely-disappointing 2024-10-17T00:48:35 https://maestrodatabase.com/blog/lisocabtagene-maraleucel-in-follicular-lymphoma-mysterious-study-discontinuation 2025-07-25T00:33:17 https://maestrodatabase.com/blog/micurx-announces-receipt-of-fdas-qidp-and-fast-track-designations-for-contezolid-and-contezolid-acefosamil 2018-09-24T00:19:37 https://maestrodatabase.com/blog/economic-evaluation-of-genomic-slash-genetic-tests-a-review-and-future-directions 2022-08-04T00:28:03 https://maestrodatabase.com/blog/siga-announces-new-drug-application-filing-with-fda-for-intravenous-formulation-of-tpoxx 2021-05-04T11:38:54 https://maestrodatabase.com/blog/cinfa-biotech-receives-positive-chmp-opinion-for-pelmeg-pegfilgrastim-a-proposed-biosimilar-to-neulasta 2018-09-24T00:36:28 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-for-priority-review-bristol-myers-squibbs-application-for-cc-486-for-maintenance-treatment-of-adult-patients-in-remission-with-acute-myeloid-leukaemia 2020-05-01T11:09:45 https://maestrodatabase.com/blog/alnylam-submits-regulatory-application-to-the-ema-for-vutrisiran-for-the-treatment-of-attr-amyloidosis-with-cardiomyopathy 2024-10-17T01:26:33 https://maestrodatabase.com/blog/bayer-submits-eu-marketing-authorization-application-for-elinzanetant-to-treat-moderate-to-severe-vasomotor-symptoms 2024-10-17T01:21:54 https://maestrodatabase.com/blog/sandoz-receives-positive-chmp-opinion-for-proposed-biosimilar-pegfilgrastim 2018-09-24T00:29:35 https://maestrodatabase.com/blog/cabometyx-approved-in-the-eu-for-previously-treated-advanced-neuroendocrine-tumours 2025-07-25T02:01:52 https://maestrodatabase.com/blog/merck-receives-positive-chmp-opinion-for-delstrigo-doravirine-slash-lamivudine-slash-tenofovir-disoproxil-fumarate-and-pifeltro-doravirine-in-the-european-union-for-the-treatment-of-hiv-1-infection 2018-09-24T00:50:39 https://maestrodatabase.com/blog/mylan-and-biocon-announce-positive-chmp-opinion-for-fulphila-biosimilar-pegfilgrastim 2018-09-24T00:43:09 https://maestrodatabase.com/blog/uncertain-effect-and-high-prices-of-precision-medicine-are-challenging 2021-05-04T11:56:08 https://maestrodatabase.com/blog/fda-grants-priority-review-for-addyi-flibanserin-paving-the-way-for-expanded-access-to-treat-low-sexual-desire-in-post-menopausal-women 2025-07-25T02:44:04 https://maestrodatabase.com/blog/melinta-therapeutics-receives-positive-chmp-opinion-for-vabomere-meropenem-and-vaborbactam 2018-09-24T01:13:23 https://maestrodatabase.com/blog/trump-administration-files-formal-request-to-strike-down-all-of-obamacare 2019-05-02T16:40:51 https://maestrodatabase.com/blog/icer-posts-draft-scoping-document-for-the-assessment-of-treatments-for-type-2-diabetes-mellitus 2019-05-02T16:36:10 https://maestrodatabase.com/blog/drug-insulin-price-caps-head-for-showdown-over-senate-rules 2021-11-26T20:51:24 https://maestrodatabase.com/blog/incyte-announces-health-canada-approval-of-opzelura-ruxolitinib-cream-for-the-treatment-of-atopic-dermatitis-and-non-segmental-vitiligo 2024-10-17T02:35:51 https://maestrodatabase.com/blog/ipsen-receives-positive-chmp-opinion-for-cabometyx-cabozantinib-for-the-second-line-treatment-of-patients-with-hepatocellular-carcinoma 2018-09-24T01:06:40 https://maestrodatabase.com/blog/the-antibiotic-industry-is-broken 2019-05-02T16:31:38 https://maestrodatabase.com/blog/fda-advances-the-science-of-patient-input-by-seeking-specific-feedback-on-patient-preferences-that-may-impact-regulatory-decisions-on-medical-devices 2019-05-02T16:27:34 https://maestrodatabase.com/blog/acadia-pharmaceuticals-announces-health-canada-approval-of-daybue-trofinetide-for-the-treatment-of-rett-syndrome 2024-10-17T02:29:04 https://maestrodatabase.com/blog/there-is-an-effective-treatment-for-monkeypox-but-its-hard-to-get 2022-08-04T02:32:15 https://maestrodatabase.com/blog/blenrep-belantamab-mafodotin-combinations-approved-in-eu-for-treatment-of-relapsed-slash-refractory-multiple-myeloma 2025-07-25T01:39:00 https://maestrodatabase.com/blog/icer-seeks-public-input-for-2020-value-assessment-framework 2019-05-02T16:45:26 https://maestrodatabase.com/blog/australias-tga-grants-approval-to-first-objective-concussion-diagnostic 2021-05-04T20:51:30 https://maestrodatabase.com/blog/tga-approves-new-treatment-for-aggressive-form-of-prostate-cancer 2021-05-04T21:00:24 https://maestrodatabase.com/blog/viiv-healthcare-initiates-rolling-submission-of-new-drug-application-with-us-fda-for-long-acting-cabotegravir-for-prevention-of-hiv 2021-05-04T20:57:18 https://maestrodatabase.com/blog/seres-therapeutics-announces-us-fda-fast-track-designation-for-ser-155 2024-01-09T23:53:46 https://maestrodatabase.com/blog/micro-medical-solutions-receives-fda-breakthrough-device-designation-for-microstent-vascular-stent 2021-05-04T20:45:40 https://maestrodatabase.com/blog/gepotidacin-accepted-for-priority-review-by-us-fda-for-treatment-of-uncomplicated-urinary-tract-infections-in-female-adults-and-adolescents 2024-10-17T02:50:36 https://maestrodatabase.com/blog/sellas-life-sciences-receives-fda-fast-track-designation-for-sls009-for-treatment-of-relapsed-slash-refractory-acute-myeloid-leukaemia 2024-01-09T23:34:35 https://maestrodatabase.com/blog/medicares-first-round-of-drug-price-negotiation---measuring-success 2024-10-17T02:46:52 https://maestrodatabase.com/blog/new-zealand-falling-behind-in-lung-cancer-treatment 2021-05-04T21:18:44 https://maestrodatabase.com/blog/gsks-zejula-is-recommended-for-reimbursement-by-cadth-and-inesss-for-advanced-ovarian-cancer-following-response-to-first-line-platinum-based-chemotherapy 2021-05-04T21:13:08 https://maestrodatabase.com/blog/pfizer-will-file-for-full-fda-approval-by-end-of-may 2021-05-04T21:03:42 https://maestrodatabase.com/blog/tga-says-go-to-biomarin-for-voxzogo 2022-08-04T03:46:35 https://maestrodatabase.com/blog/agenus-initiates-rolling-bla-submission-of-balstilimab-for-recurrent-slash-metastatic-cervical-cancer 2020-09-19T03:55:10 https://maestrodatabase.com/blog/pear-therapeutics-and-cove-behavioral-health-to-provide-patients-access-to-prescription-digital-therapeutic-for-the-treatment-of-opioid-use-disorder 2022-08-04T03:41:16 https://maestrodatabase.com/blog/chmp-grants-positive-opinion-for-darzalex-daratumumab-subcutaneous-formulation-for-the-treatment-of-patients-with-multiple-myeloma 2020-05-01T12:24:41 https://maestrodatabase.com/blog/rising-wholesale-drug-prices-really-do-matter-to-half-of-all-commercially-insured-americans 2021-05-04T21:09:35 https://maestrodatabase.com/blog/the-science-of-biosimilars---updating-interchangeability 2024-10-17T04:14:06 https://maestrodatabase.com/blog/tonix-pharmaceuticals-announces-submission-of-the-tnx-102-sl-new-drug-application-for-fibromyalgia-to-the-us-fda 2024-10-17T03:33:50 https://maestrodatabase.com/blog/donanemab-receives-positive-opinion-from-the-chmp-in-early-symptomatic-alzheimers-disease 2025-07-25T11:01:40 https://maestrodatabase.com/blog/fda-approves-symdeko-tezacaftor-slash-ivacaftor-and-ivacaftor-to-treat-the-underlying-cause-of-cystic-fibrosis-in-people-ages-12-and-older-with-certain-mutations-in-the-cftr-gene 2018-02-13T01:10:36 https://maestrodatabase.com/blog/bayer-receives-positive-chmp-opinion-for-its-haemophilia-a-treatment-bay94-9027 2018-09-24T03:38:24 https://maestrodatabase.com/blog/trixeo-aerosphere-receives-positive-eu-chmp-opinion-as-first-inhaled-medicine-using-next-generation-propellant-with-near-zero-global-warming-potential 2025-07-25T11:08:57 https://maestrodatabase.com/blog/mirvetuximab-soravtansine-approved-to-treat-adult-patients-who-have-ovarian-fallopian-tube-or-primary-peritoneal-cancer 2025-07-25T11:15:56 https://maestrodatabase.com/blog/first-targeted-treatment-to-reduce-the-risk-of-alk-positive-lung-cancer-returning-after-complete-tumour-removal-recommended-by-nice 2024-10-17T10:45:28 https://maestrodatabase.com/blog/takeda-receives-positive-chmp-opinion-recommending-alunbrig-brigatinib-for-the-treatment-of-alk-plus-non-small-cell-lung-cancer-in-patients-previously-treated-with-crizotinib 2018-09-24T03:50:46 https://maestrodatabase.com/blog/travere-therapeutics-provides-regulatory-updates-on-its-development-programs 2022-08-04T07:11:20 https://maestrodatabase.com/blog/eplontersen-approved-to-treat-adults-with-rare-inherited-nerve-disease-or-polyneuropathy 2024-10-17T10:17:10 https://maestrodatabase.com/blog/trelegy-ellipta-receives-positive-chmp-opinion-supporting-expanded-copd-indication-in-europe 2018-09-24T04:11:10 https://maestrodatabase.com/blog/u-dot-s-eu-and-japan-health-authorities-accept-regulatory-submissions-for-review-of-pfizers-third-generation-alk-inhibitor-lorlatinib 2018-02-13T01:19:43 https://maestrodatabase.com/blog/avita-medical-announces-fda-approval-of-the-recell-system-for-the-treatment-of-severe-burns-in-the-u-dot-s 2018-09-24T04:21:42 https://maestrodatabase.com/blog/european-regulatory-authority-adopts-positive-opinion-for-novo-nordisks-alhemo-concizumab-recommending-label-expansion-to-treat-haemophilia-a-and-b-without-inhibitors 2025-07-25T11:30:10 https://maestrodatabase.com/blog/european-commission-approves-pfizers-talzenna-in-combination-with-xtandi-for-adult-patients-with-metastatic-castration-resistant-prostate-cancer 2024-01-10T20:00:55 https://maestrodatabase.com/blog/publication-of-stage-1-and-stage-2-pbs-process-improvements-metrics-report-2021-22 2023-04-21T04:26:48 https://maestrodatabase.com/blog/lynparza-approved-in-the-eu-as-adjuvant-treatment-for-patients-with-germline-brca-mutated-her2-negative-high-risk-early-breast-cancer 2022-08-04T07:43:32 https://maestrodatabase.com/blog/braeburn-and-camurus-announce-submission-for-cam2038-for-opioid-use-disorder 2017-07-23T04:35:43 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac-march-2023 2023-04-21T06:51:02 https://maestrodatabase.com/blog/covid-19-update-fda-issues-emergency-use-authorisation-for-potential-covid-19-treatment 2020-05-01T22:07:47 https://maestrodatabase.com/blog/tivdak-supplemental-biologics-license-application-accepted-for-priority-review-by-fda-for-patients-with-recurrent-or-metastatic-cervical-cancer 2024-01-10T20:08:00 https://maestrodatabase.com/blog/panicked-patients-as-popular-medications-get-wiped-from-pharmacy-shelves 2022-08-04T08:45:19 https://maestrodatabase.com/blog/gsk-receives-fda-approval-for-a-new-self-injectable-formulation-of-benlysta-belimumab-for-systemic-lupus-erythematosus 2017-07-23T04:49:36 https://maestrodatabase.com/blog/gilead-readies-to-sell-anticancer-drug-trodelvy-in-korea 2021-05-05T01:02:57 https://maestrodatabase.com/blog/radical-or-not-nice-makes-evidence-based-recommendations 2021-11-27T03:02:29 https://maestrodatabase.com/blog/curtailing-medicaid-coverage-of-accelerated-approval-therapies-threatens-patients-access 2021-05-05T01:47:20 https://maestrodatabase.com/blog/icer-publishes-evidence-report-on-treatments-for-amyotrophic-lateral-sclerosis 2022-08-04T12:35:47 https://maestrodatabase.com/blog/tgas-decision-to-not-register-lecanemab-leqembi 2024-10-17T21:55:09 https://maestrodatabase.com/blog/u-dot-s-prescription-drug-pricing-doesnt-favour-the-patient-case-of-sub-optimal-market-for-cancer-pharmaceuticals 2022-08-04T12:31:58 https://maestrodatabase.com/blog/tackling-submission-and-publication-bias 2017-07-23T06:11:48 https://maestrodatabase.com/blog/shingrix-approved-in-canada-for-adults-at-increased-risk-of-shingles-due-to-immunodeficiency-or-immunosuppression 2021-11-27T02:04:44 https://maestrodatabase.com/blog/sunovions-latuda-lurasidone-hydrochloride-receives-health-canada-approval-to-treat-adolescents-with-schizophrenia 2017-07-23T06:15:04 https://maestrodatabase.com/blog/its-time-to-better-support-the-three-million-canadians-with-a-rare-disease 2021-11-27T03:31:42 https://maestrodatabase.com/blog/leqembi-approved-for-the-treatment-of-alzheimers-disease-in-china 2024-01-10T20:51:51 https://maestrodatabase.com/blog/with-john-mccain-out-mcconnell-still-plans-a-senate-health-care-vote-next-week 2017-07-23T06:24:31 https://maestrodatabase.com/blog/aarp-statement-on-fdas-prescription-drugs-importation-approval-for-florida 2024-01-10T20:39:39 https://maestrodatabase.com/blog/shift-to-political-left-seen-on-health-care 2017-07-23T06:26:58 https://maestrodatabase.com/blog/highlights-from-the-chmp-17-20-july-2017-meeting 2017-07-23T07:08:15 https://maestrodatabase.com/blog/ema-panel-recommends-against-nektar-daiichi-sankyos-breast-cancer-drug 2017-07-23T07:02:37 https://maestrodatabase.com/blog/pharmaceutical-protections-in-u-dot-s-trade-deals----what-do-americans-get-in-return 2019-05-02T20:46:47 https://maestrodatabase.com/blog/vaxcyte-provides-positive-regulatory-updates-for-vax-24-adult-and-paediatric-programs 2022-08-04T20:52:52 https://maestrodatabase.com/blog/substandard-control-arms-question-the-utility-of-some-new-cancer-drugs 2019-05-02T19:15:28 https://maestrodatabase.com/blog/apalutamide-in-prostate-cancer-indication-of-significant-added-benefit 2019-05-02T19:10:44 https://maestrodatabase.com/blog/bulk-billing-on-verge-of-collapse 2022-08-04T20:48:17 https://maestrodatabase.com/blog/sun-pharma-announces-australian-tga-approval-of-ilumya-tildrakizumab-for-treatment-of-moderate-to-severe-plaque-psoriasis 2018-09-24T05:02:43 https://maestrodatabase.com/blog/icer-presents-alternative-pricing-models-for-remdesivir-as-a-treatment-for-covid-19 2020-05-01T23:01:39 https://maestrodatabase.com/blog/u-dot-s-regulators-defend-requiring-more-data-on-monkeypox-drug 2022-08-04T21:49:23 https://maestrodatabase.com/blog/advanced-oesophageal-carcinoma-nivolumab-in-combination-with-chemotherapy-or-ipilimumab-prolongs-life-compared-to-chemotherapy-alone 2022-08-04T21:33:27 https://maestrodatabase.com/blog/tens-of-millions-in-secret-cuts-to-subsidised-medicines 2019-05-03T05:26:33 https://maestrodatabase.com/blog/the-patient-voice---the-value-of-patient-reported-outcomes-in-hta 2022-08-04T21:44:46 https://maestrodatabase.com/blog/what-happened-to-the-promise-of-universal-pharmacare 2021-11-27T03:41:40 https://maestrodatabase.com/blog/regression-models-for-ordinal-outcomes 2022-08-04T21:01:03 https://maestrodatabase.com/blog/icer-publishes-evidence-report-on-the-use-of-siponimod-to-treat-secondary-progressive-multiple-sclerosis 2019-05-03T05:53:58 https://maestrodatabase.com/blog/private-cover-is-the-canary-in-the-coal-mine-for-whole-health-system 2019-05-03T05:39:40 https://maestrodatabase.com/blog/cresemba-now-available-in-canada-for-the-treatment-of-invasive-aspergillosis-and-invasive-mucormycosis 2019-05-03T05:29:21 https://maestrodatabase.com/blog/using-instrumental-variables-to-address-bias-from-unobserved-confounders 2019-05-03T06:03:25 https://maestrodatabase.com/blog/agios-announces-fda-approval-of-supplemental-new-drug-application-for-tibsovo-as-monotherapy-for-newly-diagnosed-adult-patients-with-idh1-mutant-acute-myeloid-leukaemia-not-eligible-for-intensive-chemotherapy 2019-05-03T06:07:49 https://maestrodatabase.com/blog/all-tga-approvals-for-prescription-medicines-in-2017-met-the-statutory-timeframe-of-255-working-days 2018-02-13T04:36:56 https://maestrodatabase.com/blog/ono-receives-approval-of-opdivo-nivolumab-for-expanded-use-for-two-indications-in-japan 2021-11-27T04:00:16 https://maestrodatabase.com/blog/here-we-go-again---version-2-dot-0 2021-11-27T04:18:39 https://maestrodatabase.com/blog/sandoz-announces-us-fda-approval-and-launch-of-glatopa-40-mg-slash-ml-three-times-a-week-generic-option-for-relapsing-forms-of-multiple-sclerosis 2018-02-13T06:27:37 https://maestrodatabase.com/blog/icon-bioscience-receives-fda-approval-for-dexycu-a-potentially-transformational-drug-therapy-for-treating-inflammation-associated-with-cataract-surgery 2018-02-13T07:50:22 https://maestrodatabase.com/blog/21-000-to-benefit-from-mirena-and-jaydess 2019-10-14T05:04:06 https://maestrodatabase.com/blog/servier-announces-fda-filing-acceptance-and-priority-review-for-tibsovo-ivosidenib-in-idh1-mutated-cholangiocarcinoma 2021-05-05T12:05:26 https://maestrodatabase.com/blog/european-commission-approves-marketing-authorisation-for-veltassa 2017-07-23T21:11:51 https://maestrodatabase.com/blog/fda-accepts-amgens-supplemental-new-drug-application-for-otezla-apremilast-for-adults-with-mild-to-moderate-plaque-psoriasis 2021-05-05T20:46:40 https://maestrodatabase.com/blog/us-fda-accepts-gc-pharmas-biologics-license-application-for-immunoglobulin-gc5107 2021-05-05T12:12:02 https://maestrodatabase.com/blog/plaque-psoriasis-patients-to-get-nhs-access-to-leos-kyntheum 2018-02-13T20:06:23 https://maestrodatabase.com/blog/can-we-trust-strong-recommendations-based-on-low-quality-evidence 2021-11-27T04:36:35 https://maestrodatabase.com/blog/almost-1-million-canadians-give-up-food-heat-to-afford-prescriptions-study 2018-02-13T20:13:34 https://maestrodatabase.com/blog/roches-tecentriq-approved-by-european-commission-as-a-first-line-monotherapy-treatment-for-people-with-a-type-of-metastatic-non-small-cell-lung-cancer 2021-05-05T11:51:04 https://maestrodatabase.com/blog/ma-welcomes-passing-of-pbs-amendment-bill 2018-02-13T19:59:01 https://maestrodatabase.com/blog/pharmac-asked-to-fund-drug-for-children-with-spinal-muscular-atrophy-after-it-changes-four-year-olds-life 2021-05-05T11:58:00 https://maestrodatabase.com/blog/more-australians-dispose-of-health-insurance-because-of-rising-premiums 2018-02-13T20:01:34 https://maestrodatabase.com/blog/pbs-process-improvements-webinar 2019-10-14T05:06:46 https://maestrodatabase.com/blog/how-hard-could-it-be-to-vaccinate-the-whole-world-this-hard 2021-05-05T21:14:59 https://maestrodatabase.com/blog/legal-challenges-to-state-drug-pricing-laws 2018-02-13T20:33:57 https://maestrodatabase.com/blog/states-look-to-lower-drug-costs-consider-canadian-imports 2018-02-13T20:16:43 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-aducanumab-for-alzheimers-disease 2021-05-05T21:23:34 https://maestrodatabase.com/blog/pharma-gets-the-worst-of-both-drug-pricing-worlds 2018-02-13T20:20:16 https://maestrodatabase.com/blog/intimidating-pharmac-move-may-lead-to-child-cancer-drug-delays 2021-05-05T21:18:56 https://maestrodatabase.com/blog/medicaid-and-the-health-care-policy-debate-ahead-of-2020-elections 2019-10-14T05:40:28 https://maestrodatabase.com/blog/statement-from-fda-commissioner-scott-gottlieb-on-administrations-request-for-new-fda-funding-to-promote-innovation-and-broaden-patient-access-through-competition 2018-02-13T20:57:20 https://maestrodatabase.com/blog/acacia-pharma-receives-complete-response-letter-from-fda-for-barhemsys 2019-05-03T09:10:24 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-pembrolizumab-for-her2-positive-gastric-cancer 2021-05-05T21:00:31 https://maestrodatabase.com/blog/canadian-agency-recommends-ruzurgi-be-reimbursed-with-conditions 2021-05-05T20:53:08 https://maestrodatabase.com/blog/cbo-says-house-speaker-nancy-pelosis-drug-pricing-plan-saves-medicare-345-dollars-billion-over-decade 2019-10-14T19:58:29 https://maestrodatabase.com/blog/stada-and-alvotech-secure-approval-for-uzpruvo-europes-first-ustekinumab-biosimilar-to-stelara 2024-01-11T02:13:23 https://maestrodatabase.com/blog/nice-recommends-roches-tecentriq-for-metastatic-nsclc 2019-05-03T09:27:37 https://maestrodatabase.com/blog/biontech-nearing-request-for-approval-of-longer-lasting-version-of-covid-vaccine 2021-05-05T21:37:41 https://maestrodatabase.com/blog/u-dot-s-fda-approves-xarelto-rivaroxaban-to-help-prevent-blood-clots-in-acutely-ill-medical-patients 2019-10-14T19:52:41 https://maestrodatabase.com/blog/gps-to-get-increased-supplies-of-covid-19-vaccines 2021-05-05T21:41:15 https://maestrodatabase.com/blog/democrats-push-elizabeth-warren-for-plan-to-pay-for-medicare-for-all 2019-10-14T05:42:51 https://maestrodatabase.com/blog/fda-bid-to-bolster-generic-competition-and-combat-shortages-isnt-working----yet 2019-10-14T20:09:33 https://maestrodatabase.com/blog/health-canada-authorises-use-of-the-pfizer-biontech-covid-19-vaccine-in-children-12-to-15-years-of-age 2021-05-05T21:28:42 https://maestrodatabase.com/blog/fda-is-smashing-the-status-quo-for-regulatory-science 2019-10-14T20:07:17 https://maestrodatabase.com/blog/pfizer-says-it-will-seek-clearance-in-september-for-its-vaccine-to-be-used-in-children-aged-2-to-11 2021-05-05T21:34:10 https://maestrodatabase.com/blog/why-high-drug-prices-persist-despite-the-fact-good-medicines-are-lowering-health-care-spending 2019-10-14T20:02:30 https://maestrodatabase.com/blog/pbs-drug-listings-being-delayed-by-bureaucracy-medicines-lobby-says 2019-10-14T20:19:22 https://maestrodatabase.com/blog/flexion-therapeutics-announces-extended-fda-review-of-supplemental-new-drug-application-for-zilretta 2019-10-14T20:12:30 https://maestrodatabase.com/blog/nucala-mepolizumab-approved-in-china-for-use-in-severe-asthma-with-an-eosinophilic-phenotype 2024-01-11T05:07:16 https://maestrodatabase.com/blog/sta-to-market-sarcoma-drug-in-australia-new-zealand-and-se-asia-following-license-deal 2019-10-14T20:33:00 https://maestrodatabase.com/blog/arcutis-canada-announces-health-canada-acceptance-of-the-supplement-to-a-new-drug-submission-for-roflumilast-0-dot-3-percent-foam-for-the-treatment-of-seborrheic-dermatitis-in-individuals-9-years-of-age-and-older 2024-01-11T04:54:32 https://maestrodatabase.com/blog/sanofi-to-cover-part-of-dupixent-cost-for-atopic-dermatitis-patients 2019-10-14T20:27:29 https://maestrodatabase.com/blog/veiled-in-secrecy-call-for-surgeons-to-disclose-complications-rates 2019-10-14T20:54:14 https://maestrodatabase.com/blog/us-fda-grants-once-daily-dosing-option-for-nityr-nitisinone-tablets-for-ht-1-patients 2020-09-19T22:24:51 https://maestrodatabase.com/blog/ema-publishes-agenda-for-14-17-october-chmp-meeting 2019-10-14T20:41:26 https://maestrodatabase.com/blog/free-vaccine-for-teenagers-amidst-rise-of-deadly-meningococcal-disease 2018-09-24T21:00:39 https://maestrodatabase.com/blog/genmab-announces-u-dot-s-fda-approval-of-subcutaneous-formulation-of-daratumumab-darzalex-faspro-daratumumab-and-hyaluronidase-fihj-for-the-treatment-of-patients-with-multiple-myeloma 2020-05-02T00:27:20 https://maestrodatabase.com/blog/thousands-affected-by-prescription-medicine-shortages 2018-09-24T21:03:19 https://maestrodatabase.com/blog/ema-to-launch-new-corporate-website-on-27-september-2018 2018-09-24T11:45:31 https://maestrodatabase.com/blog/fda-awards-12-grants-to-fund-new-clinical-trials-to-advance-the-development-of-medical-products-for-the-treatment-of-rare-diseases 2019-10-08T20:49:06 https://maestrodatabase.com/blog/new-treatment-for-australians-with-leukaemia 2021-11-28T04:00:16 https://maestrodatabase.com/blog/gilead-subsidiary-to-launch-authorised-generics-of-epclusa-sofosbuvir-slash-velpatasvir-and-harvoni-ledipasvir-slash-sofosbuvir-for-the-treatment-of-chronic-hepatitis-c 2018-09-24T23:07:58 https://maestrodatabase.com/blog/cms-outlines-comprehensive-strategy-to-foster-innovation-for-transformative-medical-technologies 2019-05-03T18:58:04 https://maestrodatabase.com/blog/csl-vifor-and-travere-therapeutics-announce-swissmedic-approval-of-filspari-sparsentan-for-the-treatment-of-iga-nephropathy 2024-10-18T04:24:49 https://maestrodatabase.com/blog/sanofis-sarclisa-approved-in-the-eu-for-the-treatment-of-transplant-eligible-newly-diagnosed-multiple-myeloma 2025-07-26T01:05:43 https://maestrodatabase.com/blog/in-power-grab-health-secretary-azar-asserts-authority-over-fda 2020-09-20T03:14:54 https://maestrodatabase.com/blog/ardelyx-announces-fda-acceptance-for-filing-of-its-new-drug-application-of-tenapanor-for-the-control-of-serum-phosphorus-in-adult-patients-with-ckd-on-dialysis 2020-09-20T03:28:00 https://maestrodatabase.com/blog/update-on-regulatory-review-of-lecanemab-for-early-alzheimers-disease-in-australia 2024-10-18T04:03:42 https://maestrodatabase.com/blog/almost-6-dollars-million-poured-into-three-australian-made-covid-19-vaccines 2020-09-20T09:12:12 https://maestrodatabase.com/blog/how-many-examples-does-it-take-for-the-pbac-to-set-a-precedent 2020-09-20T20:37:29 https://maestrodatabase.com/blog/crohns-sufferers-running-out-of-treatment-options-lobby-pharmac-for-new-drugs 2020-09-20T20:40:35 https://maestrodatabase.com/blog/fresenius-kabi-launches-tyenne-the-first-and-only-approved-tocilizumab-biosimilar-in-canada 2024-10-18T05:10:20 https://maestrodatabase.com/blog/companies-stepping-up-efforts-to-ensure-medicine-supply-post-brexit 2018-09-25T00:24:03 https://maestrodatabase.com/blog/verastem-oncology-receives-fda-approval-of-copiktra-duvelisib-capsules 2018-09-25T00:27:49 https://maestrodatabase.com/blog/outcomes-of-the-september-2024-pbac-intracycle-meeting 2024-10-18T06:59:26 https://maestrodatabase.com/blog/us-fda-approves-vyalev-foscarbidopa-and-foslevodopa-for-adults-living-with-advanced-parkinsons-disease 2024-10-18T06:55:41 https://maestrodatabase.com/blog/bayer-provides-regulatory-update-on-elinzanetant-in-the-us 2025-07-26T01:20:43 https://maestrodatabase.com/blog/for-insulin-and-other-medications-rising-costs-arent-slowing-down 2020-09-20T20:44:02 https://maestrodatabase.com/blog/health-canada-grants-marketing-authorisation-for-bayers-lynkuet-elinzanetant 2025-07-26T01:27:36 https://maestrodatabase.com/blog/decision-to-change-the-funded-brand-of-epoetin-alfa 2018-09-25T00:39:42 https://maestrodatabase.com/blog/health-canada-approves-ipsens-somatuline-autogel-for-the-treatment-of-carcinoid-syndrome-in-adult-patients-with-neuroendocrine-tumours 2018-02-14T11:47:50 https://maestrodatabase.com/blog/australia-secures-new-third-generation-monkeypox-virus-vaccine 2022-08-05T07:52:39 https://maestrodatabase.com/blog/qternmet-xr-approved-in-the-us-for-the-treatment-of-type-2-diabetes 2019-05-04T06:15:09 https://maestrodatabase.com/blog/health-canada-issues-notice-of-compliance-for-bausch-healths-bryhali 2021-05-06T04:33:54 https://maestrodatabase.com/blog/fda-approves-new-treatment-for-a-certain-type-of-prostate-cancer-using-novel-clinical-trial-endpoint 2018-02-14T19:59:51 https://maestrodatabase.com/blog/novartis-receives-positive-chmp-opinion-for-kisqali-to-help-reduce-risk-of-recurrence-in-people-with-hr-plus-slash-her2--early-breast-cancer 2024-10-18T11:05:52 https://maestrodatabase.com/blog/astellas-receives-positive-chmp-opinion-for-xtandi-enzalutamide-for-adult-men-with-high-risk-non-metastatic-castration-resistant-prostate-cancer 2018-09-25T01:14:13 https://maestrodatabase.com/blog/pharmaceutical-industry-donates-millions-to-both-australian-political-parties 2018-09-25T00:46:21 https://maestrodatabase.com/blog/advaxis-submits-conditional-marketing-authorisation-application-for-axalimogene-filolisbac-for-the-second-line-treatment-of-metastatic-cervical-cancer-in-european-union 2018-02-14T11:51:41 https://maestrodatabase.com/blog/covid-19-vaccine-donations-have-yet-to-take-off 2021-05-06T05:46:53 https://maestrodatabase.com/blog/cost-of-clinical-trials-for-new-drug-fda-approval-are-fraction-of-total-tab 2018-09-25T01:19:40 https://maestrodatabase.com/blog/the-stepped-wedge-clinical-trial 2018-02-14T20:26:16 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-biologic-treatments-for-asthma 2018-09-25T01:25:25 https://maestrodatabase.com/blog/designing-an-independent-public-health-agency 2021-05-06T05:43:21 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report 2021-05-20T08:39:08 https://maestrodatabase.com/blog/calquence-tablet-formulation-approved-in-the-us-across-current-indications 2022-08-05T11:12:58 https://maestrodatabase.com/blog/medicines-australia-updated-position-on-intellectual-property-in-light-of-trips-waiver 2021-05-06T05:52:21 https://maestrodatabase.com/blog/drug-prices-seen-surging-despite-key-trump-pledge-to-curb-increases 2018-09-25T02:20:29 https://maestrodatabase.com/blog/european-commission-approves-benlysta-for-adult-patients-with-active-lupus-nephritis 2021-05-06T05:02:14 https://maestrodatabase.com/blog/alnylam-pharmaceuticals-receives-priority-review-in-canada-for-patisiran-an-investigational-rnai-therapeutic-for-the-treatment-of-hereditary-transthyretin-mediated-amyloidosis-with-polyneuropathy 2018-09-25T02:31:11 https://maestrodatabase.com/blog/australia-has-backed-a-global-push-to-fast-track-generic-covid-19-jabs 2021-05-06T05:22:17 https://maestrodatabase.com/blog/icer-final-report-broader-benefits-of-voretigene-neparvovec-to-affected-individuals-and-society-provide-reasonable-long-term-value-despite-high-price 2018-02-14T20:37:25 https://maestrodatabase.com/blog/acadia-pharmaceuticals-receives-complete-response-letter-from-u-dot-s-fda-for-supplemental-new-drug-application-for-pimavanserin-for-the-treatment-of-hallucinations-and-delusions-associated-with-alzheimers-disease-psychosis 2022-08-05T08:05:14 https://maestrodatabase.com/blog/sanofi-and-gsk-will-provide-up-to-300-million-doses-of-covid-19-vaccine-to-the-european-union 2020-09-20T23:03:43 https://maestrodatabase.com/blog/shanton-receives-fast-track-designation-from-us-fda-for-refractory-gout-program 2025-07-26T01:44:26 https://maestrodatabase.com/blog/fda-approves-first-targeted-therapy-for-her2-low-breast-cancer 2022-08-05T21:26:51 https://maestrodatabase.com/blog/preliminary-nice-no-for-mercks-bavencio 2021-05-06T20:46:28 https://maestrodatabase.com/blog/merck-and-eisai-receive-priority-review-from-fda-for-keytruda-pembrolizumab-plus-lenvima-lenvatinib-applications-for-advanced-renal-cell-carcinoma-and-for-advanced-endometrial-carcinoma 2021-05-06T11:25:23 https://maestrodatabase.com/blog/injectafer-ferric-carboxymaltose-injection-receives-fda-approval-for-single-dose-option-for-the-treatment-of-adult-patients-with-iron-deficiency-anaemia 2021-05-06T12:42:29 https://maestrodatabase.com/blog/roche-receives-positive-chmp-opinion-for-tecentriq-in-combination-with-avastin-for-the-treatment-of-people-with-the-most-common-form-of-liver-cancer 2020-09-20T22:56:07 https://maestrodatabase.com/blog/icer-to-assess-treatment-for-severe-asthma 2021-05-06T21:27:03 https://maestrodatabase.com/blog/alberta-canada-begins-mandating-switches-from-originator-to-biosimilar-humira 2021-05-06T21:12:06 https://maestrodatabase.com/blog/fda-approves-genentechs-kadcyla-for-adjuvant-treatment-of-people-with-her2-positive-early-breast-cancer-with-residual-invasive-disease-after-neo-adjuvant-treatment 2019-05-04T06:43:51 https://maestrodatabase.com/blog/fda-considering-dividing-jynneos-doses-into-fifths-to-increase-vaccine-supply 2022-08-05T22:03:42 https://maestrodatabase.com/blog/coverage-of-oncology-medicines-well-aligned-across-canadian-provinces-but-sources-of-funding-differ 2021-05-06T21:01:01 https://maestrodatabase.com/blog/gilead-receives-positive-chmp-opinions-under-accelerated-review-from-ema-for-twice-yearly-lenacapavir-for-hiv-prevention 2025-07-26T03:34:42 https://maestrodatabase.com/blog/viome-receives-fda-approval-for-its-unique-mrna-technology-and-ai-platform-to-detect-cancers 2021-05-06T20:49:53 https://maestrodatabase.com/blog/seattle-genetics-announces-progress-in-expanding-adcentis-brentuximab-vedotin-indications-in-canada 2019-05-04T07:06:18 https://maestrodatabase.com/blog/the-difference-between-an-interchangeable-biosimilar-and-one-that-isnt 2021-05-06T21:09:28 https://maestrodatabase.com/blog/pfizer-and-biontech-receive-positive-chmp-opinion-for-lp-dot-8-1-adapted-covid-19-vaccine-in-the-european-union 2025-07-26T04:09:04 https://maestrodatabase.com/blog/cms-increases-medicare-payment-for-covid-19-monoclonal-antibody-infusions 2021-05-06T21:04:30 https://maestrodatabase.com/blog/australias-pbs-must-absolutely-be-protected-in-trade-talks-says-make-america-healthy-again-medical-adviser-aseem-malhotra 2025-07-26T03:04:02 https://maestrodatabase.com/blog/roche-provides-regulatory-update-on-elevidys-gene-therapy-for-duchenne-muscular-dystrophy-in-the-eu 2025-07-26T03:08:07 https://maestrodatabase.com/blog/i-took-it-for-my-family-accepting-risks-of-multiple-sclerosis-drug-a-part-of-sask-couples-love-story 2019-05-04T07:14:15 https://maestrodatabase.com/blog/sobi-announces-us-fda-approves-doptelet-avatrombopag-for-the-treatment-of-thrombocytopenia-in-paediatric-patients-one-year-and-older-with-persistent-or-chronic-immune-thrombocytopenia 2025-07-26T07:50:20 https://maestrodatabase.com/blog/democratic-chairman-says-white-house-blocked-fda-commissioner-from-testifying 2020-09-21T01:30:07 https://maestrodatabase.com/blog/european-commission-approves-imfinzi-for-locally-advanced-unresectable-nsclc 2018-09-25T05:08:06 https://maestrodatabase.com/blog/health-canada-grants-priority-review-status-of-viiv-healthcares-new-drug-submission-for-cabotegravir-long-acting-injectable-and-tablets-for-prevention-of-hiv 2024-01-12T01:50:57 https://maestrodatabase.com/blog/pbs-process-improvements---stage-2-fact-sheet 2020-09-21T04:50:40 https://maestrodatabase.com/blog/lynparza-recommended-for-approval-in-eu-by-chmp-as-first-line-maintenance-treatment-with-bevacizumab-for-hrd-positive-advanced-ovarian-cancer 2020-09-21T06:11:40 https://maestrodatabase.com/blog/nicotine-replacement-therapy 2017-07-24T05:08:33 https://maestrodatabase.com/blog/alhemo-recommended-for-european-approval-as-first-once-daily-subcutaneous-prophylactic-treatment-for-people-living-with-haemophilia-a-or-b-with-inhibitors 2024-10-18T21:46:37 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-positive-chmp-opinion-recommending-approval-of-opdivo-nivolumab-plus-yervoy-ipilimumab-combined-with-two-cycles-of-chemotherapy-as-first-line-treatment-of-metastatic-non-small-cell-lung-cancer 2020-09-21T04:43:22 https://maestrodatabase.com/blog/european-commission-approves-krazati-adagrasib-as-a-targeted-treatment-option-for-patients-with-advanced-non-small-cell-lung-cancer-with-a-kras-g12c-mutation 2024-01-12T02:07:46 https://maestrodatabase.com/blog/gsk-submits-eu-filing-for-extended-use-of-relvar-ellipta-in-patients-with-controlled-asthma-on-an-ics-slash-laba-combination 2017-07-24T11:29:22 https://maestrodatabase.com/blog/akorn-receives-fda-approval-for-betamethasone-dipropionate-0-dot-05-percent-lotion-usp-augmented 2019-10-15T01:36:24 https://maestrodatabase.com/blog/managing-conflicts-of-interest---making-good-decisions 2017-07-24T11:24:10 https://maestrodatabase.com/blog/lynparza-recommended-for-approval-in-the-eu-by-chmp-for-brca-mutated-metastatic-castration-resistant-prostate-cancer 2020-09-21T06:26:35 https://maestrodatabase.com/blog/nhs-england-consults-on-blocking-wasteful-prescriptions 2017-07-24T11:35:09 https://maestrodatabase.com/blog/anti-cancer-agent-herceptin-approved-for-additional-indication-of-salivary-gland-cancer 2021-11-28T20:09:21 https://maestrodatabase.com/blog/companies-rush-to-develop-utterly-transformative-gene-therapies 2017-07-24T11:57:22 https://maestrodatabase.com/blog/fda-approves-darolutamide-tablets-for-metastatic-hormone-sensitive-prostate-cancer 2022-08-05T23:15:21 https://maestrodatabase.com/blog/u-dot-s-fda-expands-approval-of-yervoy-ipilimumab-to-include-paediatric-patients-12-years-and-older-with-unresectable-or-metastatic-melanoma 2017-07-24T11:52:29 https://maestrodatabase.com/blog/xenikos-receives-fda-fast-track-designation-for-t-guard-r-for-treating-steroid-refractory-acute-graft-versus-host-disease 2019-10-15T01:44:30 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-bristol-myers-squibbs-applications-for-opdivo-nivolumab-four-week-dosing-schedule-across-all-approved-indications 2017-07-24T20:38:14 https://maestrodatabase.com/blog/merck-announces-u-dot-s-launch-of-renflexis-infliximab-abda-a-biosimilar-of-remicade-for-all-eligible-indications 2017-07-24T20:46:31 https://maestrodatabase.com/blog/health-minister-mark-butler-terrified-of-low-gp-numbers-as-bulk-billing-declines 2022-08-05T23:44:14 https://maestrodatabase.com/blog/democrats-take-aim-at-big-business-and-drug-prices-in-new-economic-campaign 2017-07-24T20:43:44 https://maestrodatabase.com/blog/government-moves-to-legislate-to-increase-generic-and-biosimilar-medicine-uptake-and-cut-medicine-prices 2017-07-24T20:54:24 https://maestrodatabase.com/blog/revised-opioids-pbs-listings-from-1-october-2020 2020-09-21T07:53:35 https://maestrodatabase.com/blog/crinetics-pharmaceuticals-receives-rare-paediatric-disease-designation-from-fda-for-crn04777-for-the-treatment-of-congenital-hyperinsulinism 2020-09-21T21:00:02 https://maestrodatabase.com/blog/you-can-trust-the-fdas-vaccine-process 2020-09-21T21:05:36 https://maestrodatabase.com/blog/a-deal-on-drug-prices-undone-by-white-house-insistence-on-trump-cards 2020-09-21T21:08:14 https://maestrodatabase.com/blog/the-next-step-in-tlvs-review-of-pricing-of-stock-preparations 2020-09-21T20:53:41 https://maestrodatabase.com/blog/familys-50-000-dollars-cost-for-dads-life-extending-bowel-cancer-medicine 2020-09-21T20:56:52 https://maestrodatabase.com/blog/updated-agenda-for-the-july-2021-pbac-meeting 2021-05-07T07:28:34 https://maestrodatabase.com/blog/avelumab-not-recommended-as-a-maintenance-treatment-of-urothelial-cancer-after-platinum-based-chemotherapy 2021-05-07T10:03:56 https://maestrodatabase.com/blog/ema-starts-rolling-review-of-sotrovimab-vir-7831-for-covid-19 2021-05-07T09:59:47 https://maestrodatabase.com/blog/pear-therapeutics-and-preferredone-announce-broad-based-patient-access-and-reimbursement-for-reset-and-reset-o-for-people-with-substance-use-disorder-and-opioid-use-disorder 2020-09-21T21:15:04 https://maestrodatabase.com/blog/uk-regulators-contend-biosimilar-efficacy-trials-are-redundant 2020-09-21T21:23:16 https://maestrodatabase.com/blog/second-joint-meeting-on-innovations-in-healthcare 2020-09-21T21:32:07 https://maestrodatabase.com/blog/australian-cancer-atlas-shows-cancer-burden-across-the-country 2018-09-25T10:45:05 https://maestrodatabase.com/blog/pharmac-seeking-bids-from-suppliers-for-covid-19-vaccines 2024-10-18T23:03:06 https://maestrodatabase.com/blog/international-regulators-and-who-call-for-wider-public-access-to-clinical-data 2021-05-07T10:10:24 https://maestrodatabase.com/blog/to-include-or-not-include-drug-prices-in-dtc-advertisements 2018-09-25T21:09:23 https://maestrodatabase.com/blog/patients-call-for-end-to-cf-drug-price-row-at-key-meeting 2018-09-25T21:14:17 https://maestrodatabase.com/blog/pbac-to-conduct-stakeholder-forum-on-the-post-market-review-of-the-use-of-biologics-in-the-treatment-of-severe-chronic-plaque-psoriasis 2017-07-25T00:33:41 https://maestrodatabase.com/blog/synergy-pharmaceuticals-strengthens-coverage-for-trulance-plecanatide-with-key-new-market-access-wins 2018-09-25T21:03:59 https://maestrodatabase.com/blog/daughters-fight-to-save-fathers-life 2017-07-25T00:52:07 https://maestrodatabase.com/blog/bydureon-receives-positive-eu-chmp-opinion-for-exscel-cardiovascular-outcomes-data 2018-09-25T21:27:46 https://maestrodatabase.com/blog/canada-says-it-could-offer-access-to-mifepristone-if-the-abortion-drug-is-banned-in-the-us 2023-04-22T23:51:34 https://maestrodatabase.com/blog/mifepristone-us-supreme-court-preserves-abortion-drug-access 2023-04-22T23:10:22 https://maestrodatabase.com/blog/celltrion-receives-eu-approval-for-trastuzumab-biosimilar 2018-02-15T10:12:23 https://maestrodatabase.com/blog/patients-seeking-novel-weight-loss-drugs-find-a-wild-west-of-online-prescribers 2022-08-06T03:10:41 https://maestrodatabase.com/blog/1-dot-4-million-more-people-at-risk-of-severe-covid-19-to-have-access-to-antiviral-paxlovid 2024-01-14T20:25:52 https://maestrodatabase.com/blog/alternative-treatments-for-people-with-thyroid-cancer-to-be-offered-routinely-on-the-nhs-says-nice 2018-02-15T10:08:41 https://maestrodatabase.com/blog/fda-approves-pembrolizumab-with-chemoradiotherapy-for-figo-2014-stage-iii-iva-cervical-cancer 2024-01-14T20:20:08 https://maestrodatabase.com/blog/amag-pharmaceuticals-announces-fda-approval-of-makena-hydroxyprogesterone-caproate-injection-subcutaneous-auto-injector-to-reduce-the-risk-of-preterm-birth-in-certain-at-risk-women 2018-02-15T10:24:54 https://maestrodatabase.com/blog/public-summary-documents-first-time-decisions-not-to-recommend-and-deferrals---september-2023-pbac-meeting 2024-01-14T20:10:41 https://maestrodatabase.com/blog/gsk-submits-landmark-impact-data-to-european-medicines-agency-to-support-expanded-label-for-trelegy-ellipta 2018-02-15T10:20:28 https://maestrodatabase.com/blog/doh-publishes-revised-agenda-for-march-2024-pbac-meeting-version-3 2024-01-14T21:49:35 https://maestrodatabase.com/blog/fda-accepts-new-drug-application-and-grants-priority-review-for-ivosidenib-in-relapsed-or-refractory-aml-with-an-idh1-mutation 2018-02-15T20:04:27 https://maestrodatabase.com/blog/statement-from-fda-commissioner-on-advancing-the-development-of-novel-treatments-for-neurological-conditions-part-of-broader-effort-on-modernizing-fdas-new-drug-review-programs 2018-02-15T19:49:14 https://maestrodatabase.com/blog/new-zealand-allowed-pharmacists-to-dispense-covid-19-antivirals-and-everyone-realised-it-was-a-win 2022-08-06T03:44:15 https://maestrodatabase.com/blog/pharmacists-warn-pbs-changes-risk-medicines-shortage 2023-04-23T03:05:38 https://maestrodatabase.com/blog/drug-industry-scrambles-after-rare-loss-in-budget-deal 2018-02-15T20:01:04 https://maestrodatabase.com/blog/ema-addresses-considerations-for-single-arm-trials 2023-04-23T03:02:39 https://maestrodatabase.com/blog/us-government-about-to-get-long-awaited-powers-on-drug-pricing 2022-08-06T03:38:22 https://maestrodatabase.com/blog/patient-experience-data-researchers-call-for-more-consistency-from-fda 2019-10-15T03:52:42 https://maestrodatabase.com/blog/obesity-drug-supply-delay-not-unusual-says-novo-nordisk-ceo 2022-08-06T03:19:08 https://maestrodatabase.com/blog/canadians-are-being-fooled-into-thinking-well-like-pharmacare-we-really-really-wont 2018-02-15T20:28:27 https://maestrodatabase.com/blog/canadian-patient-groups-call-on-federal-health-minister-to-halt-the-process-examining-proposed-amendments-to-the-patented-medicine-regulations-pending-constructive-consultations 2018-02-15T20:32:03 https://maestrodatabase.com/blog/horizon-pharma-jacks-painkiller-drug-price-from-138-dollars-to-2-979-dollars 2018-02-15T20:19:10 https://maestrodatabase.com/blog/congress-should-set-fair-rules-that-force-drug-corporations-to-negotiate-prices 2019-10-15T04:04:32 https://maestrodatabase.com/blog/vertex-announces-marketing-authorisation-in-canada-for-alyftrek-a-once-daily-next-generation-cftr-modulator-for-the-treatment-of-cystic-fibrosis 2025-07-27T22:13:47 https://maestrodatabase.com/blog/remegens-rc88-obtained-fda-fast-track-designation-heralds-new-hope-for-ovarian-cancer-patients 2024-01-14T23:19:01 https://maestrodatabase.com/blog/dupilumab-for-the-treatment-of-adults-with-severe-chronic-rhinosinusitis-with-nasal-polyps-review-of-ta648 2025-07-28T00:18:34 https://maestrodatabase.com/blog/shorla-oncology-announces-fda-filing-acceptance-of-new-drug-application-for-novel-formulation-to-treat-breast-and-ovarian-cancer 2024-01-14T22:34:30 https://maestrodatabase.com/blog/drug-farm-receives-rare-paediatric-disease-designation-from-the-us-fda-for-df-003-to-treat-rosah-syndrome 2024-01-14T23:31:44 https://maestrodatabase.com/blog/u-dot-s-food-and-drug-administration-approves-longeverons-lomecel-b-for-rare-paediatric-disease-designation-to-treat-life-threatening-infant-heart-condition 2021-11-29T11:34:47 https://maestrodatabase.com/blog/tga-approves-new-medicines-for-patients-with-graft-versus-host-disease 2021-11-29T19:51:12 https://maestrodatabase.com/blog/nice-publishes-draft-guidance-on-new-medicine-for-osteoporosis 2021-11-29T19:44:02 https://maestrodatabase.com/blog/cbs-news-poll-most-americans-favour-a-national-health-plan 2019-10-15T20:03:00 https://maestrodatabase.com/blog/pharmaceutical-benefits-advisory-committee-responds-to-criticism 2019-10-15T19:56:06 https://maestrodatabase.com/blog/fennec-pharmaceuticals-expects-to-receive-complete-response-letter-from-the-fda-for-its-new-drug-application-for-pedmark-to-prevent-ototoxicity-associated-with-cisplatin-in-paediatric-patients-with-localised-non-metastatic-solid-tumours 2021-11-29T11:20:09 https://maestrodatabase.com/blog/new-early-scientific-advice-service-to-support-medicine-registrations 2020-09-22T01:01:31 https://maestrodatabase.com/blog/mayne-pharma-and-mithra-announce-tga-approval-of-nextstellis-oral-contraceptive 2021-11-29T11:28:16 https://maestrodatabase.com/blog/durvalumab-with-cisplatin-and-gemcitabine-hydrochloride-for-the-treatment-of-patients-with-unresectable-or-advanced-biliary-tract-cancer 2024-01-15T00:20:06 https://maestrodatabase.com/blog/fda-issues-draft-guidance-assessing-registries-to-support-regulatory-decision-making-for-drug-and-biological-products 2021-11-29T20:08:57 https://maestrodatabase.com/blog/u-dot-s-fda-approves-secuado-asenapine-transdermal-system-the-first-and-only-transdermal-patch-for-the-treatment-of-adults-with-schizophrenia 2019-10-15T20:10:01 https://maestrodatabase.com/blog/tga-approves-bayers-verquvo 2021-11-29T20:14:08 https://maestrodatabase.com/blog/santhera-receives-approval-for-agamree-vamorolone-as-a-treatment-for-duchenne-muscular-dystrophy-in-the-united-kingdom 2024-01-15T00:01:56 https://maestrodatabase.com/blog/most-americans-back-various-ideas-to-lower-drug-costs-but-some-fear-impeachment-will-get-in-the-way 2019-10-15T20:20:34 https://maestrodatabase.com/blog/fda-approves-new-imaging-drug-to-help-identify-ovarian-cancer-lesions 2021-11-29T19:56:37 https://maestrodatabase.com/blog/in-contrast-to-australias-success-with-hepatitis-c-our-response-to-hepatitis-b-is-lagging 2019-10-15T20:17:34 https://maestrodatabase.com/blog/diy-drugs-should-hospitals-make-their-own-medicine 2019-10-15T20:15:20 https://maestrodatabase.com/blog/flemish-alzheimerliga-wants-to-maintain-reimbursement-of-alzheimers-disease-medication 2019-10-15T20:30:25 https://maestrodatabase.com/blog/chmp-grants-positive-opinion-for-expanded-use-of-otsukas-deltyba-delamanid-in-children-and-adolescents-weighing-at-least-30-kg-treated-for-pulmonary-multi-drug-resistant-tuberculosis 2020-09-22T02:19:56 https://maestrodatabase.com/blog/high-council-for-health-calls-for-reimbursement-for-adhd-medication 2021-05-07T22:47:33 https://maestrodatabase.com/blog/medicare-beneficiaries-cant-wait-for-lower-drug-prices 2021-05-07T22:51:49 https://maestrodatabase.com/blog/faced-with-a-drug-shortfall-doctors-scramble-to-treat-children-with-cancer 2019-10-15T20:25:52 https://maestrodatabase.com/blog/the-national-audit-offices-review-can-contribute-to-strengthening-tlvs-work 2021-05-07T22:37:37 https://maestrodatabase.com/blog/bristol-myers-squibbs-applications-for-deucravacitinib-for-the-treatment-of-moderate-to-severe-plaque-psoriasis-accepted-by-u-dot-s-food-and-drug-administration-and-validated-by-european-medicines-agency 2021-11-29T20:28:58 https://maestrodatabase.com/blog/health-minister-greg-hunt-promises-to-speed-up-drug-subsidy-approvals 2019-10-15T20:44:08 https://maestrodatabase.com/blog/knight-and-therapeuticsmd-announce-health-canada-approval-of-bijuva 2020-09-22T02:06:31 https://maestrodatabase.com/blog/biosimilar-industry-vets-critique-bidens-drug-pricing-reforms 2021-11-29T20:24:46 https://maestrodatabase.com/blog/accounting-for-hope-using-mean-survival-gain-to-price-new-cancer-drugs 2019-10-15T20:40:29 https://maestrodatabase.com/blog/health-canada-approves-inrebic-fedratinib-first-new-treatment-in-nearly-a-decade-for-patients-living-with-myelofibrosis 2020-09-22T02:12:23 https://maestrodatabase.com/blog/pfizer-and-biontech-initiate-rolling-submission-of-biologics-license-application-for-u-dot-s-fda-approval-of-their-covid-19-vaccine 2021-05-07T22:41:41 https://maestrodatabase.com/blog/wanted-better-policies-and-incentives-to-revitalise-r-and-d-for-new-antimicrobial-drugs 2019-10-15T20:33:09 https://maestrodatabase.com/blog/rather-than-turning-its-back-on-the-qaly-pharma-should-collaborate-on-efforts-to-improve-it 2021-05-07T22:39:15 https://maestrodatabase.com/blog/worlds-most-expensive-drug-may-not-be-covered-by-dutch-insurance 2021-05-07T22:59:24 https://maestrodatabase.com/blog/prescription-drug-and-health-care-costs-are-rising 2020-09-22T03:23:55 https://maestrodatabase.com/blog/adc-therapeutics-submits-biologics-license-application-to-the-u-dot-s-fda-for-loncastuximab-tesirine-for-treatment-of-relapsed-or-refractory-diffuse-large-b-cell-lymphoma 2020-09-22T03:09:07 https://maestrodatabase.com/blog/government-continues-to-make-medicines-cheaper 2025-07-28T02:32:30 https://maestrodatabase.com/blog/abbvie-receives-approval-from-health-canada-for-the-combination-of-venclexta-with-rituximab-as-a-treatment-for-patients-with-chronic-lymphocytic-leukaemia 2018-09-26T11:53:14 https://maestrodatabase.com/blog/pharmac-urged-to-subsidise-cost-prohibitive-but-highly-effective-contraceptive-option 2018-09-26T11:44:36 https://maestrodatabase.com/blog/price-reductions-for-pbs-listed-medicines 2018-09-26T21:02:03 https://maestrodatabase.com/blog/gyroscope-therapeutics-granted-fda-fast-track-designation-for-gt005-an-investigational-gene-therapy-for-dry-age-related-macular-degeneration 2020-09-22T06:43:57 https://maestrodatabase.com/blog/cheaper-drugs-on-way-as-medicine-costs-slashed 2018-09-26T21:04:36 https://maestrodatabase.com/blog/pharmacists-may-soon-be-able-to-tell-you-the-cheapest-way-to-get-prescriptions 2018-09-26T11:57:41 https://maestrodatabase.com/blog/ema-launches-new-corporate-website 2018-09-26T20:58:52 https://maestrodatabase.com/blog/big-pharma-boosts-drug-prices-as-supplies-run-low-study-reveals 2018-09-26T21:14:23 https://maestrodatabase.com/blog/early-dialogue-in-europe-perspectives-on-value-challenges-and-continuing-evolution 2018-09-26T21:19:46 https://maestrodatabase.com/blog/ema-takes-issue-with-bmj-article-on-pandemrix-vaccine 2018-09-26T21:07:36 https://maestrodatabase.com/blog/neurelis-files-new-drug-application-with-the-fda-for-valtoco-nasal-spray-an-investigational-treatment-for-paediatric-adolescent-and-adult-epilepsy-patients 2018-09-26T21:28:56 https://maestrodatabase.com/blog/fda-grants-qidp-and-fast-track-designations-to-cidara-therapeutics-rezafungin-prophylaxis-development-program 2018-09-26T21:24:03 https://maestrodatabase.com/blog/astrazeneca-weighs-seeking-full-u-dot-s-approval-for-covid-19-shot-skipping-emergency-use-application 2021-05-08T03:19:08 https://maestrodatabase.com/blog/quality-assurance-of-registries-for-health-technology-assessment 2018-09-26T21:39:44 https://maestrodatabase.com/blog/the-health-industry-as-an-economic-priority-for-victoria-joint-statement 2018-09-26T21:46:54 https://maestrodatabase.com/blog/smc---january-2024-decisions 2024-01-15T20:49:27 https://maestrodatabase.com/blog/highlights-from-the-21-24-july-2025-chmp-meeting 2025-07-28T03:51:40 https://maestrodatabase.com/blog/insulin-prices-could-be-much-lower-and-drug-makers-would-still-make-healthy-profits 2018-09-26T21:34:41 https://maestrodatabase.com/blog/mylan-and-novartis-to-fda-where-are-the-suffixes 2018-09-26T21:56:30 https://maestrodatabase.com/blog/chinese-drug-maker-clarifies-development-strategy-for-bringing-cancer-drug-to-the-u-dot-s-market 2018-09-26T21:49:51 https://maestrodatabase.com/blog/fda-launches-the-digital-health-center-of-excellence 2020-09-22T20:23:46 https://maestrodatabase.com/blog/drug-giants-targeting-australias-pbs-are-paying-tiny-amounts-of-tax 2025-07-28T03:24:27 https://maestrodatabase.com/blog/agenda-for-21-february-tc-meeting 2018-02-16T01:00:40 https://maestrodatabase.com/blog/medeor-therapeutics-transplant-immune-tolerance-therapy-receives-regenerative-medicine-advanced-therapy-designation-from-fda 2020-09-22T20:38:13 https://maestrodatabase.com/blog/nice-publishes-draft-guidance-on-new-use-for-kyprolis 2020-09-22T20:45:59 https://maestrodatabase.com/blog/sanofi-and-gsk-sign-agreements-with-the-government-of-canada-to-supply-up-to-72-million-doses-of-adjuvanted-covid-19-vaccine 2020-09-22T20:26:45 https://maestrodatabase.com/blog/health-funds-want-to-raise-a-tax-penalty-to-force-you-to-buy-their-products 2019-05-04T20:55:24 https://maestrodatabase.com/blog/tga-annual-performance-statistics-report-july-2017-to-june-2018 2018-09-27T00:04:13 https://maestrodatabase.com/blog/trump-drug-rebate-plan-wont-see-lower-list-prices-cbo-says 2019-05-04T20:48:28 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-for-priority-review-bristol-myers-squibb-and-bluebird-bio-application-for-anti-bcma-car-t-cell-therapy-idecabtagene-vicleucel-ide-cel-bb2121 2020-09-22T20:32:14 https://maestrodatabase.com/blog/imfinzi-granted-priority-review-and-breakthrough-therapy-designation-in-the-us-for-patients-with-resectable-early-stage-gastric-and-gastro-oesophageal-junction-cancers 2025-07-28T06:29:41 https://maestrodatabase.com/blog/australia-commits-123-dollars-million-to-a-worldwide-vaccine-distribution-alliance 2020-09-22T21:34:16 https://maestrodatabase.com/blog/hikma-updates-on-anda-for-generic-advair-diskus 2020-09-22T20:51:18 https://maestrodatabase.com/blog/icer-posts-draft-scoping-document-on-therapies-for-multiple-myeloma 2020-09-22T21:00:46 https://maestrodatabase.com/blog/taking-steps-toward-transparency-in-real-world-evidence-studies 2020-09-22T21:12:09 https://maestrodatabase.com/blog/botox-cosmetic-onabotulinumtoxina-receives-fda-approval-for-moderate-to-severe-vertical-bands-connecting-the-jaw-and-neck-platysma-bands 2024-10-19T01:25:00 https://maestrodatabase.com/blog/cheaper-medicines-for-australian-patients 2018-09-27T01:10:06 https://maestrodatabase.com/blog/health-insurance-premiums-are-heading-higher-but-by-how-much 2022-08-07T01:04:32 https://maestrodatabase.com/blog/australians-forced-to-pay-for-methadone-and-other-drugs-to-get-off-addictive-pbs-medication 2022-08-07T01:08:49 https://maestrodatabase.com/blog/a-perspective-from-our-ceo-gilead-subsidiary-to-launch-authorised-generics-to-treat-hcv 2018-09-27T01:15:56 https://maestrodatabase.com/blog/myovant-sciences-and-pfizer-receive-u-dot-s-fda-approval-of-myfembree-a-once-daily-treatment-for-the-management-of-moderate-to-severe-pain-associated-with-endometriosis 2022-08-07T02:29:41 https://maestrodatabase.com/blog/updated-2021---22-cost-recovery-implementation-statement 2021-11-30T03:48:05 https://maestrodatabase.com/blog/arcutis-announces-health-canada-approval-of-zoryve-roflumilast-foam-0-dot-3-percent-to-treat-seborrheic-dermatitis-in-individuals-9-years-of-age-and-older 2024-10-19T01:51:17 https://maestrodatabase.com/blog/new-zealand-doesnt-have-help-juice---pharmacs-decision-leaves-family-stuck-abroad 2020-05-03T07:43:29 https://maestrodatabase.com/blog/gsk-submits-us-regulatory-filing-of-arnuity-ellipta-in-children-with-asthma 2017-07-25T04:20:22 https://maestrodatabase.com/blog/fda-approves-zolbetuximab-clzb-with-chemotherapy-for-gastric-or-gastro-oesophageal-junction-adenocarcinoma 2024-10-19T01:43:58 https://maestrodatabase.com/blog/chmp-recommends-approval-of-menquadfi-for-active-immunisation-of-individuals-from-the-age-of-12-months-and-older-against-invasive-meningococcal-acwy-disease 2020-09-22T23:23:58 https://maestrodatabase.com/blog/changes-to-treatment-phases-and-authority-levels-in-medicines-for-the-treatment-of-alzheimers-disease 2023-04-24T02:54:58 https://maestrodatabase.com/blog/drug-price-bill-pruned-in-senate-in-partial-industry-win 2022-08-07T02:39:03 https://maestrodatabase.com/blog/chmp-recommends-approval-of-supemtek-quadrivalent-recombinant-influenza-vaccine-for-the-prevention-of-influenza-in-adults-aged-18-years-and-older 2020-09-22T23:15:33 https://maestrodatabase.com/blog/ema-publishes-agenda-for-24-26-april-2023-chmp-meeting 2023-04-24T10:42:00 https://maestrodatabase.com/blog/valneva-receives-fda-fast-track-designation-for-its-lyme-disease-vaccine-candidate-vla15 2017-07-25T04:45:13 https://maestrodatabase.com/blog/health-canada-approves-new-antibody-drug-to-help-prevent-serious-rsv-in-babies 2023-04-24T09:11:45 https://maestrodatabase.com/blog/janssen-marks-first-approval-worldwide-for-akeega-niraparib-and-abiraterone-acetate-dual-action-tablet-with-ec-authorisation-for-the-treatment-of-patients-with-metastatic-castration-resistant-prostate-cancer-with-brca1-slash-2-mutations 2023-04-24T08:52:59 https://maestrodatabase.com/blog/trade-deals-arent-just-for-manufacturing-they-can-lower-drug-prices-too 2018-09-27T02:12:31 https://maestrodatabase.com/blog/pierre-fabre-receives-positive-chmp-opinion-for-braftovi-encorafenib-in-combination-with-cetuximab-for-the-treatment-of-adult-patients-with-braf-v600e-mutant-metastatic-colorectal-cancer 2020-05-03T08:33:03 https://maestrodatabase.com/blog/liminal-biosciences-provides-update-on-progress-on-bla-for-ryplazim-plasminogen 2020-09-23T01:54:05 https://maestrodatabase.com/blog/democrats-will-have-to-limit-their-drug-pricing-reforms-to-medicare-to-comply-with-senate-rules 2022-08-07T03:17:41 https://maestrodatabase.com/blog/aronoras-new-blood-clot-treatment-receives-fda-fast-track-designation 2018-09-27T02:45:02 https://maestrodatabase.com/blog/1-october-2018-price-disclosure-confirmed-prices 2018-09-27T02:51:01 https://maestrodatabase.com/blog/instrumentation-laboratory-receives-us-fda-marketing-authorisation-for-the-first-apixaban-diagnostic-test 2020-09-23T02:19:18 https://maestrodatabase.com/blog/health-canada-approves-ocrevus-ocrelizumab-for-canadians-living-with-primary-progressive-multiple-sclerosis 2018-02-16T04:14:12 https://maestrodatabase.com/blog/quebec-and-new-brunswick-become-first-provinces-to-provide-public-funding-of-ibrance-for-the-first-line-treatment-of-metastatic-breast-cancer 2018-02-16T04:32:38 https://maestrodatabase.com/blog/health-canada-approves-new-indication-for-zytiga-abiraterone-acetate-broadening-its-use-for-treatment-of-newly-diagnosed-metastatic-prostate-cancer 2018-02-16T04:25:18 https://maestrodatabase.com/blog/ucb-achieves-important-regulatory-milestone-for-bimekizumab 2020-09-23T02:52:37 https://maestrodatabase.com/blog/lynparza-granted-priority-review-in-the-us-for-brca-mutated-her2-negative-high-risk-early-breast-cancer 2021-11-30T07:02:41 https://maestrodatabase.com/blog/draft-nice-decision-rejects-respreeza-for-incurable-genetic-disorder 2018-09-27T20:58:44 https://maestrodatabase.com/blog/australia-now-eligible-to-purchase-covid-19-vaccine-doses-through-covax 2020-09-23T04:20:24 https://maestrodatabase.com/blog/allergan-announces-fda-acceptance-of-supplemental-new-drug-application-for-vraylar-cariprazine 2018-09-27T21:02:27 https://maestrodatabase.com/blog/differentiation-of-health-related-quality-of-life-outcomes-between-five-disease-areas-results-from-an-international-survey-of-patients 2018-09-27T21:19:12 https://maestrodatabase.com/blog/nice-collaborates-with-international-partner-agencies-to-streamline-the-confidential-marking-process 2023-04-24T22:35:32 https://maestrodatabase.com/blog/avadel-pharmaceuticals-announces-fda-approval-of-lumryz-sodium-oxybate-extended-release-oral-suspension-for-the-treatment-of-cataplexy-or-excessive-daytime-sleepiness-in-patients-7-years-of-age-and-older-with-narcolepsy 2024-10-20T20:10:16 https://maestrodatabase.com/blog/protagonist-therapeutics-announces-fast-track-designation-granted-by-u-dot-s-fda-to-hepcidin-mimetic-ptg-300 2018-09-27T21:12:46 https://maestrodatabase.com/blog/maia-biotechnology-receives-fdas-fast-track-designation-for-ateganosine-as-a-treatment-for-non-small-cell-lung-cancer 2025-07-28T23:22:27 https://maestrodatabase.com/blog/caldolor-now-fda-approved-for-pre-operative-administration 2021-11-30T06:55:36 https://maestrodatabase.com/blog/medicare-wouldnt-cover-costs-of-administering-coronavirus-vaccine-approved-under-emergency-use-authorisation 2020-09-23T03:53:56 https://maestrodatabase.com/blog/statement-by-fda-commissioner-on-preparations-for-the-upcoming-flu-season-and-vaccinations 2018-09-27T21:34:53 https://maestrodatabase.com/blog/samsung-bioepis-biologics-license-application-for-sb5-adalimumab-biosimilar-candidate-accepted-for-review-by-the-u-dot-s-fda 2018-09-27T21:41:20 https://maestrodatabase.com/blog/tracon-pharmaceuticals-reports-regulatory-approval-of-envafolimab-in-china 2021-11-30T07:22:19 https://maestrodatabase.com/blog/blockchain-hype-may-finally-turn-into-reality-in-pharmaceuticals 2018-09-27T21:26:34 https://maestrodatabase.com/blog/fda-budget-matters-advancing-innovation-in-digital-health 2018-09-27T21:32:03 https://maestrodatabase.com/blog/intercept-provides-regulatory-update-regarding-snda-for-ocaliva 2024-10-20T20:50:33 https://maestrodatabase.com/blog/paying-for-value-us-state-of-play 2018-09-27T21:46:44 https://maestrodatabase.com/blog/lantheus-and-point-biopharma-announce-fda-grants-fast-track-designation-for-177lu-pnt2002-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer 2023-04-24T23:35:05 https://maestrodatabase.com/blog/with-payers-under-pressure-biosimilars-must-demonstrate-their-value 2018-09-27T21:49:52 https://maestrodatabase.com/blog/decision-to-amend-the-distribution-and-access-criteria-for-dasatinib-sprycel 2019-05-06T06:55:56 https://maestrodatabase.com/blog/pharmac-funding-how-it-works---and-the-changes-its-critics-want 2019-05-06T06:52:40 https://maestrodatabase.com/blog/esperion-announces-u-dot-s-fda-acceptance-of-new-drug-applications-for-both-bempedoic-acid-and-the-bempedoic-acid-with-ezetimibe-combination-tablet-for-filing-and-regulatory-review 2019-05-06T10:32:56 https://maestrodatabase.com/blog/proposal-to-widen-access-to-etanercept-and-award-sole-supply 2019-05-06T07:07:42 https://maestrodatabase.com/blog/eisai-receives-positive-opinion-from-emas-chmp-on-use-of-anti-epileptic-agent-fycompa-in-paediatric-patients 2020-09-23T10:35:24 https://maestrodatabase.com/blog/avidity-biosciences-granted-fda-fast-track-designation-for-aoc-1044-for-treatment-of-duchenne-muscular-dystrophy-mutations-amenable-to-exon-44-skipping 2023-04-24T23:50:19 https://maestrodatabase.com/blog/fda-expands-approval-of-imfinzi-to-reduce-the-risk-of-non-small-cell-lung-cancer-progressing 2018-02-16T22:15:42 https://maestrodatabase.com/blog/icer-to-assess-treatments-for-amyloidosis-prostate-cancer-in-upcoming-reports 2018-02-16T22:23:05 https://maestrodatabase.com/blog/ptc-therapeutics-announces-fda-approval-of-sephience-sepiapterin-for-the-treatment-of-children-and-adults-living-with-phenylketonuria 2025-07-29T01:22:24 https://maestrodatabase.com/blog/fda-opens-new-path-for-alzheimers-treatments 2018-02-16T22:30:19 https://maestrodatabase.com/blog/fda-approves-apellis-empaveli-pegcetacoplan-as-the-first-c3g-and-primary-ic-mpgn-treatment-for-patients-12-and-older 2025-07-29T01:28:40 https://maestrodatabase.com/blog/bluebird-bio-submits-biologics-license-application-to-fda-for-lovotibeglogene-autotemcel-lovo-cel-for-patients-with-sickle-cell-disease-12-years-and-older-with-a-history-of-vaso-occlusive-events 2023-04-25T04:16:01 https://maestrodatabase.com/blog/shire-announces-fda-acceptance-of-application-for-cinryze-c1-esterase-inhibitor-human-for-paediatric-hereditary-angioedema-use 2018-02-16T22:50:11 https://maestrodatabase.com/blog/canadian-prescription-drug-prices-come-under-scrutiny-of-u-dot-s-trade-representative 2020-05-03T09:53:22 https://maestrodatabase.com/blog/senate-legislation-would-cap-insulin-at-35-dollars-per-month-for-people-with-private-insurance 2023-04-25T00:41:31 https://maestrodatabase.com/blog/zevra-therapeutics-submits-marketing-authorisation-application-to-ema-to-review-arimoclomol-for-the-treatment-of-niemann-pick-disease-type-c 2025-07-29T01:36:17 https://maestrodatabase.com/blog/azar-defends-trump-drug-pricing-proposals-pushing-back-against-criticism 2018-02-16T22:33:13 https://maestrodatabase.com/blog/lilly-expects-us-medicare-to-reverse-course-fully-cover-alzheimers-drugs 2023-04-25T00:23:44 https://maestrodatabase.com/blog/weight-loss-drugmakers-lobby-for-medicare-coverage 2023-04-25T00:35:37 https://maestrodatabase.com/blog/fda-head-vows-to-tackle-high-drug-prices-and-drug-makers-gaming-the-system 2018-02-16T22:35:46 https://maestrodatabase.com/blog/fda-accepts-supplemental-new-drug-application-for-pfizers-xalkori-crizotinib-for-the-treatment-of-paediatric-alk-positive-anaplastic-large-cell-lymphoma 2020-09-23T11:26:40 https://maestrodatabase.com/blog/how-incidents-with-medicines-are-managed-in-the-eu---a-ten-year-analysis 2020-09-23T20:40:53 https://maestrodatabase.com/blog/pfizer-receives-breakthrough-therapy-designation-from-fda-for-pf-04965842-an-oral-jak1-inhibitor-for-the-treatment-of-patients-with-moderate-to-severe-atopic-dermatitis 2018-02-16T23:08:17 https://maestrodatabase.com/blog/fda-approves-skytrofa-lonapegsomatropin-tcgd-for-the-once-weekly-treatment-of-adults-with-growth-hormone-deficiency 2025-07-29T01:09:24 https://maestrodatabase.com/blog/fda-grants-rmat-designation-to-multistem-cell-therapy-for-the-treatment-of-acute-respiratory-distress-syndrome 2020-09-23T10:54:17 https://maestrodatabase.com/blog/junshi-biosciences-announces-approval-of-supplemental-new-drug-application-by-nmpa-for-toripalimab-in-combination-with-cisplatin-and-gemcitabine-as-first-line-treatment-for-patients-with-locally-recurrent-or-metastatic-nasopharyngeal-carcinoma 2021-11-30T08:22:20 https://maestrodatabase.com/blog/fda-poised-to-announce-tougher-standards-for-a-covid-19-vaccine-that-make-it-unlikely-one-will-be-cleared-by-election-day 2020-09-23T20:43:34 https://maestrodatabase.com/blog/proqr-receives-rare-paediatric-disease-designation-from-fda-for-sepofarsen-for-the-treatment-of-lca10 2019-10-16T06:40:06 https://maestrodatabase.com/blog/fda-grants-priority-review-for-genentechs-rituxan-rituximab-for-pemphigus-vulgaris 2018-02-16T23:20:26 https://maestrodatabase.com/blog/icer-issues-final-report-and-policy-recommendations-on-treatments-for-cystic-fibrosis 2020-09-23T20:46:40 https://maestrodatabase.com/blog/prostate-cancer-significant-additional-benefit-for-psma-diagnostics-with-gozetotide 2024-10-20T23:16:14 https://maestrodatabase.com/blog/health-canada-approves-ipsens-cabometyx-cabozantinib-for-the-first-line-treatment-of-adults-with-advanced-renal-cell-carcinoma 2019-10-16T06:46:25 https://maestrodatabase.com/blog/lilly-and-incyte-provide-update-on-baricitinib 2017-07-25T10:28:43 https://maestrodatabase.com/blog/more-patients-will-have-access-to-medicines-within-the-high-cost-protection 2020-09-23T21:01:18 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-december-2021 2021-11-30T20:02:55 https://maestrodatabase.com/blog/first-algenex-crisbio-based-vaccine-submitted-to-european-medicines-agency 2019-10-16T06:43:22 https://maestrodatabase.com/blog/nice-publishes-final-guidance-for-another-roche-cancer-medicine 2020-09-23T21:06:28 https://maestrodatabase.com/blog/chmp-recommends-eu-approval-of-henlius-denosumab-biosimilar-hlx14 2025-07-29T01:51:33 https://maestrodatabase.com/blog/the-tasmanian-hepatitis-c-buyers-club 2017-07-25T11:10:31 https://maestrodatabase.com/blog/why-one-nova-scotia-boy-is-being-treated-with-drugs-that-cost-6-dollars-million-a-year-despite-a-better-cheaper-alternative 2019-05-06T11:03:41 https://maestrodatabase.com/blog/nice-board-agrees-to-stimulate-action-following-publication-of-independent-medicines-and-medical-devices-safety-review-report 2020-09-23T21:16:38 https://maestrodatabase.com/blog/uk-medicines-regulator-issues-its-first-authorisation-under-project-orbis 2021-05-08T23:13:32 https://maestrodatabase.com/blog/european-commission-approves-keytruda-pembrolizumab-plus-lenvima-lenvatinib-as-first-line-treatment-for-adult-patients-with-advanced-renal-cell-carcinoma 2021-11-30T20:19:59 https://maestrodatabase.com/blog/alteogen-receives-positive-chmp-opinion-for-aflibercept-biosimilar-eyluxvi-alt-l9 2025-07-29T01:57:19 https://maestrodatabase.com/blog/over-600-people-set-to-benefit-from-innovative-lung-cancer-treatment-within-the-cancer-drugs-fund 2021-11-30T10:40:45 https://maestrodatabase.com/blog/abbvie-submits-application-for-risankizumab-skyrizi-in-moderate-to-severe-crohns-disease-to-european-medicines-agency 2021-11-30T19:57:54 https://maestrodatabase.com/blog/the-european-medicines-agency-accepts-application-to-extend-the-buvidal-indication-to-include-treatment-of-chronic-pain 2021-11-30T11:00:03 https://maestrodatabase.com/blog/vismodegib-for-treatment-of-patients-with-basal-cell-carcinoma 2017-07-25T20:55:51 https://maestrodatabase.com/blog/revised-guideline-on-first-in-human-clinical-trials 2017-07-25T20:49:37 https://maestrodatabase.com/blog/icer-seeks-public-comment-on-proposed-value-assessment-framework-for-treatments-that-represent-a-potential-major-advance-for-serious-ultra-rare-conditions 2017-07-25T21:02:37 https://maestrodatabase.com/blog/brothers-have-the-same-deadly-disease-but-only-one-gets-what-their-parents-hope-is-life-saving-treatment 2019-05-06T11:08:18 https://maestrodatabase.com/blog/amf-medical-receives-fda-breakthrough-device-designation-for-its-sigi-insulin-management-system 2021-11-30T20:46:41 https://maestrodatabase.com/blog/yes-we-can-lower-sky-high-drug-prices----other-countries-have-done-it 2017-07-25T21:13:45 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-for-qalsody-tofersen-for-sod1-als-a-major-scientific-advancement-as-the-first-treatment-to-target-a-genetic-cause-of-als 2023-04-25T20:50:24 https://maestrodatabase.com/blog/mccain-returns-for-obamacare-vote 2017-07-25T21:10:20 https://maestrodatabase.com/blog/european-commission-approves-keytruda-pembrolizumab-plus-lenvima-lenvatinib-for-patients-with-certain-types-of-endometrial-carcinoma 2021-11-30T20:24:00 https://maestrodatabase.com/blog/democrats-recycling-old-ideas-call-for-a-federal-enforcer-to-tackle-drug-price-gouging 2017-07-25T21:27:08 https://maestrodatabase.com/blog/mercks-keytruda-pembrolizumab-approved-in-japan-in-combination-with-chemotherapy-for-first-line-treatment-of-patients-with-radically-unresectable-advanced-or-recurrent-oesophageal-carcinoma 2021-11-30T20:38:08 https://maestrodatabase.com/blog/mccain-case-reopens-debate-for-brain-cancer-drug-subsidy 2017-07-25T21:16:47 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-december-2021 2021-11-30T20:29:58 https://maestrodatabase.com/blog/dr-steve-pearson-on-using-health-technology-assessment-to-guide-decision-making 2017-07-25T21:52:33 https://maestrodatabase.com/blog/lillys-emgality-galcanezumab-gnlm-receives-u-dot-s-fda-approval-for-the-preventive-treatment-of-migraine-in-adults 2018-09-28T01:09:59 https://maestrodatabase.com/blog/practical-improvements-for-medical-device-evaluation 2017-07-25T21:33:08 https://maestrodatabase.com/blog/hepion-pharmaceuticals-receives-fda-fast-track-designation-for-crv431-for-the-treatment-of-nash 2021-11-30T20:49:49 https://maestrodatabase.com/blog/u-dot-s-fda-approves-vizimpro-dacomitinib-for-the-first-line-treatment-of-patients-with-egfr-mutated-metastatic-non-small-cell-lung-cancer 2018-09-28T01:20:53 https://maestrodatabase.com/blog/major-pbs-shake-up-will-allow-australians-to-purchase-more-medicine-for-less-saving-buyers-1-dollars-6-cents-billion 2023-04-25T21:26:46 https://maestrodatabase.com/blog/pharmaceutical-giants-plan-to-end-australias-reliance-on-indian-and-chinese-medicines-after-covid-19 2020-05-03T21:42:44 https://maestrodatabase.com/blog/abbvie-submits-for-us-fda-approval-of-combination-treatment-of-venclexta-venetoclax-and-acalabrutinib-for-previously-untreated-patients-with-chronic-lymphocytic-leukaemia 2025-07-29T20:52:19 https://maestrodatabase.com/blog/pharming-receives-european-commission-approval-for-treatment-of-acute-hereditary-angioedema-attacks-in-children-with-ruconest 2020-05-03T21:49:52 https://maestrodatabase.com/blog/atea-pharmaceuticals-announces-us-fda-fast-track-designation-granted-to-bemnifosbuvir-an-investigational-oral-anti-viral-for-the-treatment-of-covid-19 2023-04-26T00:09:41 https://maestrodatabase.com/blog/decision-to-fund-sapropterin 2018-09-28T01:27:13 https://maestrodatabase.com/blog/beone-medicines-receives-positive-chmp-opinion-for-tevimbra-in-neo-adjuvant-slash-adjuvant-nsclc-treatment 2025-07-29T08:20:25 https://maestrodatabase.com/blog/smc-plays-key-role-in-helping-to-secure-access-to-covid-19-treatments 2020-09-23T23:43:19 https://maestrodatabase.com/blog/tofersen-approved-by-the-mhra-to-treat-rare-inherited-form-of-motor-neurone-disease 2025-07-29T08:27:11 https://maestrodatabase.com/blog/gw-pharmaceuticals-receives-australian-therapeutic-goods-administration-approval-for-epidyolex-cannabidiol-for-the-treatment-of-seizures-in-patients-with-two-rare-severe-forms-of-childhood-onset-epilepsy 2020-09-24T01:58:19 https://maestrodatabase.com/blog/nektar-therapeutics-receives-fast-track-designation-for-rezpegaldesleukin-for-the-treatment-of-severe-to-very-severe-alopecia-areata 2025-07-30T04:30:39 https://maestrodatabase.com/blog/families-plead-for-pbs-listing-for-life-saving-cystic-fibrosis-drug 2021-05-09T02:27:49 https://maestrodatabase.com/blog/funding-for-lifesaving-drug-denied-by-b-dot-c-health-authority-as-couple-struggles-to-fund-their-portion 2022-08-08T02:22:45 https://maestrodatabase.com/blog/calidi-biotherapeutics-receives-fda-fast-track-designation-for-cld-201-supernova-a-first-in-class-stem-cell-loaded-viral-therapy-for-the-treatment-of-patients-with-soft-tissue-sarcoma 2025-07-30T04:35:14 https://maestrodatabase.com/blog/european-medicines-agency-validates-marketing-authorisation-application-for-jemperli-dostarlimab-plus-chemotherapy-for-the-treatment-of-dmmr-slash-msi-h-primary-advanced-or-recurrent-endometrial-cancer 2023-04-26T01:12:48 https://maestrodatabase.com/blog/johnson-and-johnson-files-with-us-fda-to-include-new-evidence-in-tremfya-guselkumab-label-as-the-only-il-23-inhibitor-to-demonstrate-significant-inhibition-of-joint-structural-damage-in-active-psoriatic-arthritis 2025-07-30T04:40:32 https://maestrodatabase.com/blog/cder-conversation-complex-innovative-trial-designs 2018-09-28T04:19:49 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac---august-2018 2018-09-28T08:37:20 https://maestrodatabase.com/blog/cheaper-medicines-to-ease-cost-of-living 2023-04-26T02:12:18 https://maestrodatabase.com/blog/novartis-and-the-pan-canadian-pharmaceutical-alliance-achieve-milestone-agreement-on-cosentyx-for-hidradenitis-suppurativa 2025-07-30T05:46:24 https://maestrodatabase.com/blog/rwe-to-supplement-rcts-fda-projects-continue 2019-10-16T11:14:54 https://maestrodatabase.com/blog/revised-pbs-restrictions-for-ezetimibe-and-ezetimibe-statin-effective-1-october-2018 2018-09-28T08:40:49 https://maestrodatabase.com/blog/labors-pbs-reforms-could-lead-to-drug-hunger-games-pharmacists-warn 2023-04-26T03:03:14 https://maestrodatabase.com/blog/stage-2-pbs-process-improvement-information-forum---webinar-recording-and-resources-available 2020-09-24T07:45:47 https://maestrodatabase.com/blog/cda-issues-positive-reimbursement-recommendation-for-skyclarys-omaveloxolone-the-only-health-canada-approved-treatment-for-managing-friedreich-ataxia 2025-07-30T05:52:38 https://maestrodatabase.com/blog/publication-of-outcome-from-august-2018-pbac-special-meeting 2018-09-28T07:13:16 https://maestrodatabase.com/blog/there-are-solutions-to-the-global-drug-price-problem 2019-10-16T19:47:55 https://maestrodatabase.com/blog/iud-appointments-booked-out-until-2020-after-pharmac-announces-funding 2019-10-16T19:41:16 https://maestrodatabase.com/blog/harnessing-the-potential-of-real-world-data-through-a-learning-health-care-system 2018-09-28T11:28:07 https://maestrodatabase.com/blog/viiv-healthcare-submits-supplemental-new-drug-application-to-us-fda-for-use-of-dovato-in-virologically-suppressed-adults-with-hiv-1 2019-10-16T11:20:19 https://maestrodatabase.com/blog/statement-on-continued-progress-enhancing-patient-access-to-high-quality-low-cost-generic-drugs 2019-10-16T20:03:48 https://maestrodatabase.com/blog/guideline-on-registry-based-studies---launch-of-public-consultation 2020-09-24T11:20:09 https://maestrodatabase.com/blog/election-2019-unprecedented-hope-for-universal-pharmacare 2019-10-16T19:59:30 https://maestrodatabase.com/blog/ovarian-cancer-treatment-to-be-made-available-to-more-women 2018-09-28T12:35:50 https://maestrodatabase.com/blog/eli-lilly-migraine-drug-approved-and-will-be-free-to-patients 2018-09-28T12:19:40 https://maestrodatabase.com/blog/house-democrats-change-drug-pricing-bill-in-bid-to-address-progressive-concerns 2019-10-16T19:54:18 https://maestrodatabase.com/blog/telix-pharmaceuticals-submits-new-drug-application-to-us-fda-for-prostate-cancer-imaging-product 2020-09-24T11:30:18 https://maestrodatabase.com/blog/wainzua-eplontersen-recommended-for-approval-in-the-eu-by-chmp-for-the-treatment-of-adult-patients-with-polyneuropathy-associated-with-hereditary-transthyretin-mediated-amyloidosis 2024-10-21T06:59:52 https://maestrodatabase.com/blog/drug-price-controls-gaining-traction-at-federal-and-state-levels 2019-10-16T19:50:40 https://maestrodatabase.com/blog/trump-claims-white-house-can-overrule-fdas-attempt-to-toughen-guidelines-for-coronavirus-vaccine 2020-09-24T11:43:08 https://maestrodatabase.com/blog/bill-to-create-cms-star-ratings-program-for-biosimilars-introduced-in-house 2019-10-16T20:17:13 https://maestrodatabase.com/blog/fda-approves-a-new-antibacterial-drug-to-treat-a-serious-lung-disease-using-a-novel-pathway-to-spur-innovation 2018-09-28T21:22:15 https://maestrodatabase.com/blog/celltrion-seeks-approval-for-xolair-biosimilar-in-eu 2023-04-26T03:06:36 https://maestrodatabase.com/blog/study-medicare-for-all-not-only-way-to-universal-coverage 2019-10-16T20:10:37 https://maestrodatabase.com/blog/fda-authorises-first-point-of-care-antibody-test-for-covid-19 2020-09-24T20:47:42 https://maestrodatabase.com/blog/gilead-provides-update-on-us-indication-for-trodelvy-in-metastatic-urothelial-cancer 2024-10-21T20:29:01 https://maestrodatabase.com/blog/msac-publishes-agenda-for-november-2025-msac-meeting 2025-07-30T06:25:38 https://maestrodatabase.com/blog/fda-authorizes-first-next-generation-sequencing-based-test-to-detect-very-low-levels-of-remaining-cancer-cells-in-patients-with-acute-lymphoblastic-leukaemia-or-multiple-myeloma 2018-09-28T21:28:27 https://maestrodatabase.com/blog/fda-grants-spirovant-sciences-orphan-drug-and-rare-paediatric-disease-designations-for-spiro-2101-for-treatment-of-cystic-fibrosis 2020-09-24T20:50:54 https://maestrodatabase.com/blog/fda-approves-first-treatment-for-advanced-form-of-the-second-most-common-skin-cancer 2018-09-28T21:31:48 https://maestrodatabase.com/blog/leap-therapeutics-announces-fda-fast-track-designation-granted-to-dkn-01-for-the-treatment-of-gastric-and-gastro-esophageal-junction-cancer 2020-09-24T12:03:35 https://maestrodatabase.com/blog/prescription-medicines-changes-place-savings-for-patients-ahead-of-profits-for-pharmacies 2023-04-26T06:15:51 https://maestrodatabase.com/blog/apricus-biosciences-receives-complete-response-letter-from-fda-for-vitaros 2018-02-17T21:34:48 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-supervised-injection-facilities 2020-09-24T20:44:44 https://maestrodatabase.com/blog/wellcare-to-buy-aetnas-medicare-drug-plans-easing-a-cvs-antitrust-issue 2018-09-28T21:47:53 https://maestrodatabase.com/blog/pharma-resistance-to-battle-superbugs 2020-09-24T21:15:31 https://maestrodatabase.com/blog/bausch-health-announces-vyzulta-latanoprostene-bunod-0-dot-024-percent-ophthalmic-solution-is-now-approved-in-seven-countries 2020-09-24T21:18:41 https://maestrodatabase.com/blog/protest-calls-for-more-drug-spending 2021-05-09T07:28:15 https://maestrodatabase.com/blog/astrazeneca-boss-says-transparency-key-for-vaccine 2020-09-24T21:36:26 https://maestrodatabase.com/blog/fda-grants-at-007-paediatric-rare-disease-designation-and-orphan-designation-for-treatment-of-pmm2-cdg 2020-09-24T20:57:18 https://maestrodatabase.com/blog/bluebird-bios-lentiglobin-for-sickle-cell-disease-gene-therapy-bb1111-granted-priority-medicines-prime-designation-by-european-medicines-agency 2020-09-24T21:03:19 https://maestrodatabase.com/blog/mayne-pharma-and-mithra-announce-fda-approval-of-haloette-a-generic-version-of-nuvaring 2022-08-08T06:27:19 https://maestrodatabase.com/blog/boris-johnsons-global-vaccine-push-as-he-revealed-the-birth-of-his-son-helped-him-fight-covid-19 2020-05-04T03:19:57 https://maestrodatabase.com/blog/astrazeneca-to-make-oxford-vaccine-as-covid-19-race-heats-up 2020-05-04T03:24:52 https://maestrodatabase.com/blog/if-a-covid-19-vaccine-is-found-heres-how-long-it-will-take-to-get-to-your-gp 2020-09-24T21:13:04 https://maestrodatabase.com/blog/human-medicines-highlights-of-2023 2024-01-16T19:50:19 https://maestrodatabase.com/blog/elevar-therapeutics-announces-fda-acceptance-of-new-drug-application-resubmission-for-rivoceranib-in-combination-with-camrelizumab-as-a-first-line-systemic-treatment-for-unresectable-hepatocellular-carcinoma 2026-01-30T22:20:39 https://maestrodatabase.com/blog/allecra-therapeutics-announces-fast-track-designation-for-lead-antibiotic-in-resistant-infections 2018-02-17T22:01:29 https://maestrodatabase.com/blog/ono-pharms-braftovi-for-braf-v600e-mutated-colorectal-cancer-gets-reimbursement 2024-01-16T20:27:57 https://maestrodatabase.com/blog/nrx-pharmaceuticals-announces-fda-qualified-infectious-disease-product-and-fast-track-designation-of-nrx-101-in-complicated-urinary-tract-infection-and-pyelonephritis 2024-01-16T20:19:31 https://maestrodatabase.com/blog/us-fda-approves-takedas-hyqvia-as-maintenance-therapy-in-adults-with-chronic-inflammatory-demyelinating-polyneuropathy 2024-01-16T20:01:36 https://maestrodatabase.com/blog/vertex-announces-us-fda-approval-of-casgevy-exagamglogene-autotemcel-for-the-treatment-of-transfusion-dependent-beta-thalassaemia 2024-01-16T19:52:39 https://maestrodatabase.com/blog/fda-approves-new-treatments-for-heart-disease-caused-by-a-serious-rare-disease-transthyretin-mediated-amyloidosis 2019-05-06T15:15:30 https://maestrodatabase.com/blog/drug-price-negotiations-for-obstructive-hypertrophic-cardiomyopathy-drug-camzyos-stall-delaying-reimbursement 2024-10-21T22:07:40 https://maestrodatabase.com/blog/new-listings-welcomed-amongst-covid-backdrop 2020-05-04T04:46:54 https://maestrodatabase.com/blog/pharmac---2023-in-review 2024-01-16T20:31:41 https://maestrodatabase.com/blog/vertex-receives-european-chmp-positive-opinion-for-kalydeco-ivacaftor-for-children-and-adolescents-with-cystic-fibrosis-between-the-ages-6-months-and-18-years-with-the-r117h-mutation-in-the-cftr-gene 2020-05-04T05:11:56 https://maestrodatabase.com/blog/agenda-for-the-november-2025-pbac-meeting 2025-07-30T08:47:35 https://maestrodatabase.com/blog/akebia-receives-european-commission-approval-for-vafseo-vadadustat-for-the-treatment-of-symptomatic-anaemia-associated-with-chronic-kidney-disease-in-adults-on-chronic-maintenance-dialysis 2023-04-26T08:43:52 https://maestrodatabase.com/blog/banner-life-sciences-announces-final-fda-approval-of-bafiertam-for-multiple-sclerosis 2020-05-04T05:18:09 https://maestrodatabase.com/blog/health-canada-expands-approval-of-scemblix-making-it-an-option-for-newly-diagnosed-and-previously-treated-chronic-myeloid-leukaemia-patients 2025-07-30T21:05:14 https://maestrodatabase.com/blog/gileads-investigational-anti-viral-remdesivir-receives-u-dot-s-fda-emergency-use-authorisation-for-the-treatment-of-covid-19 2020-05-04T11:32:18 https://maestrodatabase.com/blog/phrmas-ubl-calls-senate-passage-of-partisan-drug-pricing-plan-a-tragic-loss-for-patients 2022-08-08T21:08:03 https://maestrodatabase.com/blog/sales-agent-change-gives-red-light-to-gavretos-reimbursement-review 2023-04-26T08:58:50 https://maestrodatabase.com/blog/democrats-vote-to-raise-drug-prices 2022-08-08T20:52:32 https://maestrodatabase.com/blog/lurbinectedin-receives-the-innovative-medicine-designation-by-the-uks-mhra 2022-08-08T20:57:39 https://maestrodatabase.com/blog/smc---august-2022-decisions 2022-08-08T20:47:53 https://maestrodatabase.com/blog/china-national-medical-products-administration-approves-doptelet-avatrombopag-for-the-treatment-of-thrombocytopenia-in-adult-patients-with-chronic-liver-disease-who-are-scheduled-to-undergo-a-procedure 2020-05-04T05:26:39 https://maestrodatabase.com/blog/time-taken-for-pharmac-funding-decisions-too-long-says-medicines-nz 2023-04-26T08:53:02 https://maestrodatabase.com/blog/lillys-taltz-ixekizumab-now-available-in-new-citrate-free-formulation-to-reduce-injection-site-pain-for-improved-patient-experience 2022-08-08T11:32:22 https://maestrodatabase.com/blog/ensuring-global-access-to-covid-19-vaccines 2020-05-04T06:32:46 https://maestrodatabase.com/blog/nda-filing-for-potential-new-adhd-treatment-kp415-accepted-by-fda 2020-05-04T21:09:59 https://maestrodatabase.com/blog/the-gop-blocked-an-insulin-price-cap-what-it-means-for-diabetics 2022-08-08T21:24:13 https://maestrodatabase.com/blog/fda-approves-fensolvi-leuprolide-acetate-for-injectable-suspension-for-paediatric-patients-with-central-precocious-puberty 2020-05-04T21:16:45 https://maestrodatabase.com/blog/bot-image-receives-fda-clearance-for-artificial-intelligence-software-used-in-detection-and-diagnosis-of-prostate-cancer 2022-08-08T21:19:41 https://maestrodatabase.com/blog/protara-therapeutics-granted-fda-fast-track-designation-for-intravenous-choline-chloride-for-patients-receiving-parenteral-support 2024-10-21T23:07:29 https://maestrodatabase.com/blog/without-keytruda-30-deaths-a-week-in-new-zealand-from-cancer---lung-foundation 2020-05-04T11:55:37 https://maestrodatabase.com/blog/covid-19-how-ema-fast-tracks-development-support-and-approval-of-medicines-and-vaccines 2020-05-04T20:48:30 https://maestrodatabase.com/blog/eu-approves-label-update-for-astrazenecas-lokelma 2020-05-04T20:57:43 https://maestrodatabase.com/blog/pear-therapeutics-and-selecthealth-announce-coverage-to-provide-access-to-fda-authorised-prescription-digital-therapeutic-for-the-treatment-of-opioid-use-disorder 2022-08-08T21:12:33 https://maestrodatabase.com/blog/us-wary-of-boosting-china-biotech-with-covid-vaccine-patent-waiver 2021-05-09T20:53:26 https://maestrodatabase.com/blog/u-dot-s-law-makers-question-jaguar-health-on-price-hike-of-drug-that-may-help-treat-covid-19-patients 2020-05-04T21:39:25 https://maestrodatabase.com/blog/cost-effectiveness-and-financial-risks-associated-with-immune-checkpoint-inhibitor-therapy 2020-05-04T22:21:07 https://maestrodatabase.com/blog/in-their-own-bubble-how-a-cancer-center-promoted-an-exclusive-experimental-drug-to-attract-patients 2021-05-09T21:00:04 https://maestrodatabase.com/blog/randomised-clinical-trials-and-covid-19-managing-expectations 2020-05-04T22:36:28 https://maestrodatabase.com/blog/monkeypox-vaccines-heres-how-many-have-been-shipped-and-where-as-white-house-declares-public-health-emergency 2022-08-08T21:32:23 https://maestrodatabase.com/blog/two-potential-therapies-for-covid-19-have-some-effect 2020-05-04T21:22:44 https://maestrodatabase.com/blog/how-remdesivir-new-hope-for-covid-19-patients-was-resurrected 2020-05-04T21:35:36 https://maestrodatabase.com/blog/monkeypox-vaccines-have-arrived-in-victoria-heres-how-the-rollout-will-work 2022-08-08T21:29:11 https://maestrodatabase.com/blog/vertex-announces-us-fda-approval-for-trikafta-elexacaftor-slash-tezacaftor-slash-ivacaftor-and-ivacaftor-in-children-with-cystic-fibrosis-ages-2-through-5-with-certain-mutations 2023-04-26T20:45:28 https://maestrodatabase.com/blog/a-future-for-regulatory-science-in-the-european-union-the-european-medicines-agencys-strategy 2020-05-04T22:40:59 https://maestrodatabase.com/blog/glofitamab-in-combination-with-gemcitabine-hydrochloride-and-oxaliplatin-for-the-treatment-of-patients-with-relapsed-or-refractory-diffuse-large-bcell-lymphoma 2025-07-31T02:21:53 https://maestrodatabase.com/blog/highlights-from-the-24-26-april-2023-chmp-meeting 2023-04-26T22:37:27 https://maestrodatabase.com/blog/nice-terminates-appraisal-of-new-treatment-for-adolescents-with-obesity 2021-12-01T04:12:59 https://maestrodatabase.com/blog/nurix-therapeutics-receives-us-fda-fast-track-designation-for-nx-5948-for-the-treatment-of-relapsed-or-refractory-cll-and-sll 2024-01-16T23:21:54 https://maestrodatabase.com/blog/patients-drug-costs-surge-for-some-neurologic-conditions 2019-05-06T16:27:19 https://maestrodatabase.com/blog/orchard-therapeutics-announces-that-otl-101-has-received-a-rare-paediatric-disease-designation 2017-07-26T01:28:01 https://maestrodatabase.com/blog/icer-report-finds-costs-of-approved-car-t-therapies-align-with-clinical-benefit 2018-02-18T00:36:29 https://maestrodatabase.com/blog/tga-approves-nexviazyme 2021-12-01T05:08:02 https://maestrodatabase.com/blog/mereo-biopharma-receives-fda-rare-paediatric-disease-designation-for-setrusumab-for-the-treatment-of-osteogenesis-imperfecta 2020-09-25T04:50:31 https://maestrodatabase.com/blog/nine-provinces-approve-accelerated-public-reimbursement-of-diffuse-large-b-cell-lymphoma-treatment-under-new-early-access-process 2024-10-22T01:54:28 https://maestrodatabase.com/blog/innova-therapeutics-receives-rare-paediatric-disease-designation-from-the-fda-for-ivt-8086-for-the-treatment-of-osteosarcoma 2020-09-25T04:54:19 https://maestrodatabase.com/blog/pfizer-gets-u-dot-s-approval-for-$225-000-slash-year-heart-drug 2019-05-06T18:14:42 https://maestrodatabase.com/blog/deputy-prime-minister-admits-pharmac-needs-more-money 2019-10-17T03:49:16 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-to-flex-pharmas-flx-787-for-the-treatment-of-severe-muscle-cramps-associated-with-al 2017-07-26T01:51:45 https://maestrodatabase.com/blog/well-being-budget-should-fund-cancer-treatment 2019-05-06T20:50:51 https://maestrodatabase.com/blog/parliament-rally-to-present-eight-petitions-for-more-pharmac-funding-for-medicines 2019-05-06T20:46:29 https://maestrodatabase.com/blog/pharmac-chairman-backs-early-access-scheme-for-new-drugs 2019-05-06T20:34:48 https://maestrodatabase.com/blog/pharmaceutical-benefits-scheme-continued-dispensing-arrangements 2021-11-06T03:52:04 https://maestrodatabase.com/blog/savara-announces-molgradex-received-fast-track-designation-by-fda-for-treatment-of-auto-immune-pulmonary-alveolar-proteinosis 2019-05-07T05:46:00 https://maestrodatabase.com/blog/fda-approves-first-treatment-for-children-with-lambert-eaton-myasthenic-syndrome-a-rare-auto-immune-disorder 2019-05-07T05:39:38 https://maestrodatabase.com/blog/european-commission-approves-palynziq-pegvaliase-injection-for-treatment-of-phenylketonuria-in-patients-aged-16-years-or-older 2019-05-07T05:57:16 https://maestrodatabase.com/blog/fda-takes-actions-to-help-lower-u-dot-s-prescription-drug-prices 2020-09-25T05:29:17 https://maestrodatabase.com/blog/post-market-review-of-pulmonary-arterial-hypertension-medicines---public-consultation-process 2017-07-26T02:25:12 https://maestrodatabase.com/blog/crispr-therapeutics-and-vertex-pharmaceuticals-announce-priority-medicines-prime-designation-granted-by-the-ema-to-ctx001-for-the-treatment-of-sickle-cell-disease 2020-09-25T05:32:59 https://maestrodatabase.com/blog/fda-approves-first-drug-to-treat-group-of-rare-blood-disorders-in-nearly-14-years 2020-09-25T23:01:30 https://maestrodatabase.com/blog/zynerba-pharmaceuticals-receives-fast-track-designation-for-zygel-for-the-treatment-of-behavioural-symptoms-associated-with-fragile-x-syndrome 2019-05-07T05:50:15 https://maestrodatabase.com/blog/aquestive-therapeutics-receives-complete-response-letter-from-fda-for-libervant-diazepam-buccal-film-for-management-of-seizure-clusters 2020-09-26T02:40:08 https://maestrodatabase.com/blog/highlights-from-the-14-17-october-2024-chmp-meeting 2024-10-22T03:08:41 https://maestrodatabase.com/blog/papillon-therapeutics-receives-rare-paediatric-disease-designation-from-the-us-fda-for-ppl-002-for-the-treatment-of-danon-disease 2024-10-22T02:46:34 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-october-2018-update 2018-09-29T21:38:43 https://maestrodatabase.com/blog/trastuzumab-deruxtecan-ds-8201-granted-fda-priority-review-for-treatment-of-patients-with-her2-positive-metastatic-breast-cancer 2019-10-17T07:36:15 https://maestrodatabase.com/blog/remegen-announces-us-fda-has-granted-breakthrough-therapy-designation-for-disitamab-vedotin-rc48-in-urothelial-cancer 2020-09-26T02:30:46 https://maestrodatabase.com/blog/acceleron-receives-prime-designation-from-ema-for-sotatercept-in-pulmonary-arterial-hypertension 2020-05-05T02:11:57 https://maestrodatabase.com/blog/in-a-crafty-move-fda-may-have-found-a-way-to-dampen-controversy-over-a-375-000-dollars-rare-disease-drug 2019-05-07T06:41:08 https://maestrodatabase.com/blog/pelosis-drug-pricing-plan-puts-medical-innovation-at-risk 2019-10-17T10:49:07 https://maestrodatabase.com/blog/hundreds-rally-at-parliament-to-present-petitions-for-better-pharmac-funding 2019-05-07T06:38:06 https://maestrodatabase.com/blog/some-say-a-non-profit-research-group-unfairly-influences-drug-prices 2019-10-17T10:44:23 https://maestrodatabase.com/blog/health-minister-greg-hunt-considering-supervised-prescribing-by-pharmacists 2019-10-17T09:50:23 https://maestrodatabase.com/blog/european-commission-grants-marketing-authorisation-for-jyseleca-filgotinib-for-the-treatment-of-adults-with-moderate-to-severe-active-rheumatoid-arthritis 2020-09-26T03:03:37 https://maestrodatabase.com/blog/australia-canada-singapore-switzerland-consortium-regulators-pledge-support-to-tackle-covid-19 2020-05-05T02:07:28 https://maestrodatabase.com/blog/atsena-therapeutics-receives-rare-paediatric-disease-designation-from-fda-for-atsn-101-gene-therapy-for-gucy2d-associated-leber-congenital-amaurosis 2024-01-17T02:39:20 https://maestrodatabase.com/blog/pelosi-democrats-will-name-marquee-drug-pricing-bill-for-late-rep-cummings 2019-10-17T19:59:43 https://maestrodatabase.com/blog/congress-can-act-now-to-lower-drug-prices 2019-10-17T19:56:52 https://maestrodatabase.com/blog/chmp-recommends-the-approval-of-dong-a-sts-imuldosa-a-biosimilar-to-stelara 2024-10-22T05:07:29 https://maestrodatabase.com/blog/icer-issues-final-report-and-policy-recommendations-regarding-additive-treatments-for-cardiovascular-disease 2019-10-17T19:50:37 https://maestrodatabase.com/blog/tocagen-receives-european-medicines-agency-priority-medicines-prime-designation-for-toca-511-in-high-grade-glioma 2017-07-26T03:18:56 https://maestrodatabase.com/blog/genentech-announces-fda-approval-of-xofluza-baloxavir-marboxil-for-people-at-high-risk-of-developing-influenza-related-complications 2019-10-17T20:05:55 https://maestrodatabase.com/blog/the-government-and-medicines-australia-jointly-agree-to-finalise-patient-centric-strategic-agreement-after-the-budget 2021-05-10T00:35:13 https://maestrodatabase.com/blog/pelosi-moves-on-drug-prices-despite-falling-out-with-trump 2019-10-17T20:02:14 https://maestrodatabase.com/blog/canadian-breakthrough-that-became-the-worlds-most-expensive-drug-then-vanished-gets-second-chance 2019-10-17T20:20:32 https://maestrodatabase.com/blog/icer-publishes-final-evidence-report-on-treatments-for-transthyretin-amyloid-cardiomyopathy 2024-10-22T07:11:20 https://maestrodatabase.com/blog/ema-validates-atara-biotherapeutics-marketing-authorisation-application-for-tabelecleucel-for-the-treatment-of-epstein-barr-virus-positive-post-transplant-lymphoproliferative-disease 2021-12-01T06:24:19 https://maestrodatabase.com/blog/camurus-provides-regulatory-update-on-the-us-nda-for-cam2029-in-acromegaly 2024-10-22T07:04:33 https://maestrodatabase.com/blog/ucb-and-dermira-announce-u-dot-s-and-eu-regulatory-submissions-for-cimzia-certolizumab-pegol-for-the-treatment-of-moderate-to-severe-chronic-plaque-psoriasis 2017-07-26T03:56:11 https://maestrodatabase.com/blog/foamix-announces-fda-acceptance-of-its-new-drug-application-for-fmx103-minocycline-foam-for-the-treatment-of-moderate-to-severe-papulopustular-rosacea 2019-10-17T20:15:50 https://maestrodatabase.com/blog/fda-must-fast-track-insulin-for-the-millions-of-americans-living-with-diabetes 2019-10-17T20:11:08 https://maestrodatabase.com/blog/covid-19-australias-pledge-to-12-dollars-billion-virus-fight-who-issues-vaccine-warning 2020-05-05T03:03:14 https://maestrodatabase.com/blog/most-state-medicaid-programs-continue-to-restrict-access-to-hepatitis-c-medicines 2019-10-17T20:45:32 https://maestrodatabase.com/blog/complexity-in-assessing-the-benefit-versus-risk-of-vaccines-experience-with-rotavirus-and-dengue-virus-vaccines 2019-10-17T20:37:40 https://maestrodatabase.com/blog/have-fda-actions-to-ease-generic-drug-shortages-taken-effect-yet 2019-10-17T20:32:50 https://maestrodatabase.com/blog/win-for-cancer-patients-may-be-end-to-chemotherapy-as-immunotherapies-fast-tracked 2018-02-18T20:11:05 https://maestrodatabase.com/blog/european-commission-approves-roches-tecentriq-sc-the-eus-first-pd--l-1-cancer-immunotherapy-subcutaneous-injection-for-multiple-cancer-types 2024-01-17T06:07:05 https://maestrodatabase.com/blog/cti-biopharma-announces-extension-of-fda-review-period-for-pacritinib-in-myelofibrosis-with-severe-thrombocytopenia 2021-12-01T06:33:04 https://maestrodatabase.com/blog/prescription-drug-affordability-act-aims-to-set-limits-on-high-medication-prices 2024-01-17T20:23:12 https://maestrodatabase.com/blog/dupixent-dupilumab-us-label-updated-with-data-further-supporting-use-in-atopic-dermatitis-with-moderate-to-severe-hand-and-foot-involvement 2024-01-17T20:13:45 https://maestrodatabase.com/blog/pbac---2023-in-review 2024-01-17T20:06:01 https://maestrodatabase.com/blog/olaparib-in-combination-with-bevacizumab-for-the-maintenance-treatment-of-adults-with-advanced-high-grade-epithelial-ovarian-fallopian-tube-or-primary-peritoneal-cancer 2024-01-17T20:00:09 https://maestrodatabase.com/blog/senate-gop-measure-to-repeal-and-replace-obamacare-fails 2017-07-26T06:46:14 https://maestrodatabase.com/blog/fda-grants-rare-paediatric-disease-designation-to-volasertib-for-rhabdomyosarcoma 2020-09-26T03:54:04 https://maestrodatabase.com/blog/health-canada-approves-adcetris-brentuximab-vedotin-for-the-post-asct-consolidation-treatment-of-patients-with-hodgkin-lymphoma-at-increased-risk-of-relapse-or-progression 2017-07-26T06:55:13 https://maestrodatabase.com/blog/should-the-u-dot-s-save-medicare-money-by-pegging-drug-prices-to-what-other-countries-pay 2019-05-07T12:18:12 https://maestrodatabase.com/blog/working-together-for-safe-medicines-in-the-eu 2019-05-07T12:13:41 https://maestrodatabase.com/blog/silverlon-receives-fda-breakthrough-device-designation-for-radiation-dermatitis-and-cutaneous-radiation-injury 2021-12-01T06:51:17 https://maestrodatabase.com/blog/fda-approves-kalydeco-ivacaftor-as-first-and-only-cftr-modulator-to-treat-eligible-infants-with-cf-as-early-as-four-months-of-age 2020-09-26T03:44:30 https://maestrodatabase.com/blog/launch-and-post-launch-prices-of-injectable-cancer-drugs-in-the-us-clinical-benefit-innovation-epidemiology-and-competition 2024-01-17T20:26:17 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-october-2018-update 2018-09-30T12:46:41 https://maestrodatabase.com/blog/gileads-drug-pricing-in-the-crosshairs-again-in-wake-of-ok-to-use-remdesivir-against-covid-19 2020-05-05T04:23:32 https://maestrodatabase.com/blog/rfp---supply-of-the-levonorgestrel-intrauterine-system 2019-05-07T12:31:54 https://maestrodatabase.com/blog/secura-bio-announces-u-dot-s-withdrawal-of-farydak-panobinostat 2021-12-01T09:24:45 https://maestrodatabase.com/blog/cancer-sufferers-deliver-eight-pharmac-funding-petitions-to-parliament 2019-05-07T12:20:23 https://maestrodatabase.com/blog/huyabio-international-receives-regulatory-approval-for-hiyasta-monotherapy-of-peripheral-t-cell-lymphoma-in-japan 2021-12-01T10:16:27 https://maestrodatabase.com/blog/vbi-vaccines-announces-fda-approval-of-prehevbrio-for-the-prevention-of-hepatitis-b-in-adults 2021-12-01T19:25:47 https://maestrodatabase.com/blog/fennec-pharmaceuticals-receives-complete-response-letter-from-the-us-fda-for-its-new-drug-application-for-pedmark-to-prevent-ototoxicity-associated-with-cisplatin-in-paediatric-patients-with-localised-non-metastatic-solid-tumours 2021-12-01T09:59:51 https://maestrodatabase.com/blog/zogenix-announces-u-dot-s-fda-acceptance-for-priority-review-of-supplemental-new-drug-application-for-fintepla-fenfluramine-for-the-treatment-of-seizures-associated-with-lennox-gastaut-syndrome 2021-12-01T19:36:27 https://maestrodatabase.com/blog/ema-chmp-adopts-positive-opinion-recommending-authorisation-of-modernas-covid-19-mrna-vaccine-targeting-the-sars-cov-2-variant-lp-dot-8-1 2025-07-31T21:53:44 https://maestrodatabase.com/blog/medicines-industry-says-measures-are-in-place-to-mitigate-supply-risk 2023-04-27T02:27:29 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-for-priority-review-the-supplemental-biologics-license-application-for-mercks-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-use-in-infants-and-children 2021-12-01T19:31:10 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-august-2025 2025-07-31T23:28:11 https://maestrodatabase.com/blog/bioxcel-therapeutics-announces-extension-of-fda-review-period-of-its-nda-for-bxcl501-for-the-acute-treatment-of-agitation-associated-with-schizophrenia-and-bipolar-disorders 2021-12-01T19:52:52 https://maestrodatabase.com/blog/revalesio-receives-fda-fast-track-designation-for-rns60-for-the-treatment-of-acute-ischaemic-stroke 2025-07-31T23:41:57 https://maestrodatabase.com/blog/chmp-recommends-eu-approval-of-roches-fixed-duration-columvi-glofitamab-for-people-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma 2023-04-27T02:56:23 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-positive-chmp-opinion-recommending-approval-for-camzyos-mavacamten-for-the-treatment-of-symptomatic-obstructive-hypertrophic-cardiomyopathy 2023-04-27T02:50:58 https://maestrodatabase.com/blog/fda-approves-darzalex-faspro-kyprolis-and-dexamethasone-for-multiple-myeloma 2021-12-01T19:47:40 https://maestrodatabase.com/blog/first-vaccine-to-protect-older-adults-from-respiratory-syncytial-virus-rsv-infection 2023-04-27T02:44:19 https://maestrodatabase.com/blog/fda-approves-genentechs-xolair-omalizumab-pre-filled-syringe-formulation 2018-10-01T01:44:32 https://maestrodatabase.com/blog/nice-approval-for-nivolumab-provides-new-treatment-for-advanced-blood-cancer 2017-07-26T09:52:50 https://maestrodatabase.com/blog/lilly-canada-concludes-successful-negotiation-with-the-pan-canadian-pharmaceutical-alliance-for-baqsimi-glucagon-nasal-powder 2021-12-01T20:09:10 https://maestrodatabase.com/blog/novartis-cosentyx-gains-positive-chmp-opinion-for-hidradenitis-suppurativa 2023-04-27T04:02:44 https://maestrodatabase.com/blog/bristol-myers-squibbs-orencia-abatacept-receives-second-european-commission-approval-in-less-than-a-year---new-approval-for-treatment-of-active-psoriatic-arthritis 2017-07-26T11:16:39 https://maestrodatabase.com/blog/fycompa-newly-approved-by-u-dot-s-fda-as-treatment-for-partial-onset-seizures-in-paediatric-patients-with-epilepsy 2018-10-01T01:38:15 https://maestrodatabase.com/blog/pharmac-in-review-2021 2021-12-01T20:12:51 https://maestrodatabase.com/blog/hightide-therapeutics-receives-fast-track-designation-from-the-u-dot-s-fda-for-htd1801-treating-primary-sclerosing-cholangitis 2018-10-01T01:54:26 https://maestrodatabase.com/blog/new-treatment-available-free-for-haemophilia-a-patients 2020-09-26T06:56:56 https://maestrodatabase.com/blog/modernas-covid-19-vaccine-spikevax-receives-approval-for-full-registration 2023-04-27T03:10:45 https://maestrodatabase.com/blog/medicines-for-haemophilia-remain-in-the-high-cost-protection-after-tlvs-reconsideration 2020-09-26T07:02:34 https://maestrodatabase.com/blog/icer-publishes-first-annual-assessment-of-barriers-to-fair-access-within-us-commercial-insurance-prescription-drug-coverage 2021-12-01T20:00:46 https://maestrodatabase.com/blog/two-new-personalised-immunotherapy-treatments-for-aggressive-forms-of-blood-cancer-recommended-for-the-cancer-drugs-fund 2023-04-27T03:06:12 https://maestrodatabase.com/blog/intra-cellular-therapies-completes-submission-of-new-drug-application-for-lumateperone-for-treatment-of-schizophrenia 2018-10-01T01:49:49 https://maestrodatabase.com/blog/age-related-macular-degeneration-treatment-at-what-cost 2018-10-01T02:03:06 https://maestrodatabase.com/blog/america-wants-to-waive-patent-protection-for-vaccines 2021-05-10T06:54:52 https://maestrodatabase.com/blog/adamis-pharmaceuticals-receives-fda-approval-for-its-lower-dose-symjepi-product 2018-10-01T01:59:13 https://maestrodatabase.com/blog/roche-hails-4-year-nice-access-deal-for-gazyvaro 2017-07-26T20:58:43 https://maestrodatabase.com/blog/a-bid-for-hhs-to-override-patents-on-pricey-drugs-is-shot-down 2017-07-26T21:11:43 https://maestrodatabase.com/blog/how-should-the-world-pay-for-a-coronavirus-disease-covid-19-vaccine 2021-05-10T05:01:39 https://maestrodatabase.com/blog/trumps-fda-commissioner-on-drug-prices-regulations-science 2017-07-26T21:18:32 https://maestrodatabase.com/blog/congratulations-your-study-went-nowhere 2018-10-01T02:12:28 https://maestrodatabase.com/blog/china-nmpa-approves-parp-inhibitor-pamiparib-for-patients-with-previously-treated-advanced-ovarian-cancer 2021-05-10T06:34:41 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-announces-potential-topics-for-review-in-2018 2017-07-26T21:14:11 https://maestrodatabase.com/blog/pbs-listing-timelines-for-new-checkpoint-inhibitors 2018-10-01T02:17:02 https://maestrodatabase.com/blog/positive-chmp-opinion-for-self-administered-crysvita 2021-05-10T11:35:59 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-august-2015 2025-07-31T23:50:23 https://maestrodatabase.com/blog/gsk-receives-european-approval-for-expanded-indication-for-fluarix-tetra-influenza-vaccine-for-ages-six-months-and-older 2018-02-18T23:29:56 https://maestrodatabase.com/blog/even-drugs-winning-fast-track-nods-frustrate-before-reimbursement-wall 2023-04-27T10:35:54 https://maestrodatabase.com/blog/price-transparency-in-medicine-faces-stiff-opposition----from-hospitals-and-doctors 2017-07-26T21:22:05 https://maestrodatabase.com/blog/cadth-formalises-offering-on-real-world-evidence-through-its-scientific-advice-program 2023-04-27T20:43:54 https://maestrodatabase.com/blog/ucb-receives-positive-chmp-opinions-for-bimekizumab-for-the-treatment-of-adults-with-psoriatic-arthritis-and-axial-spondyloarthritis-in-the-european-union 2023-04-27T05:08:20 https://maestrodatabase.com/blog/dutch-advisory-group-says-zolgensma-shouldnt-be-covered-unless-novartis-halves-price 2021-05-10T21:02:09 https://maestrodatabase.com/blog/budget-2021-alison-day-meets-with-greg-hunt-to-help-other-cancer-sufferers 2021-05-10T21:08:10 https://maestrodatabase.com/blog/smc---may-2021-decisions 2021-05-10T21:05:45 https://maestrodatabase.com/blog/cadth-icer-and-nice-release-joint-position-statement-on-redacting-clinical-data-awaiting-publication 2023-04-27T21:04:19 https://maestrodatabase.com/blog/amgen-announces-tezepelumab-biologics-license-application-submitted-to-u-dot-s-fda 2021-05-10T20:47:38 https://maestrodatabase.com/blog/us-fda-approves-new-biktarvy-indication-for-people-with-hiv-who-are-treatment-experienced-and-restarting-antiretroviral-treatment 2025-08-01T01:07:42 https://maestrodatabase.com/blog/smart-immune-announces-fda-orphan-drug-status-ind-acceptance-and-fast-track-designation-to-commence-phase-1-slash-2-clinical-trial-of-proprietary-allogeneic-t-cell-progenitor-product-smart-101-protcell-for-aml-and-all 2021-05-10T20:56:02 https://maestrodatabase.com/blog/seres-therapeutics-and-nestle-health-science-announce-fda-approval-of-vowst-fecal-microbiota-spores-live-brpk-for-prevention-of-recurrence-of-c-difficile-infection-in-adults-following-antibacterial-treatment-for-recurrent-cdi 2023-04-27T20:47:22 https://maestrodatabase.com/blog/the-price-of-crossing-the-border-for-medications 2017-07-26T21:54:32 https://maestrodatabase.com/blog/ispor-announces-2021-2022-board-of-directors 2021-05-10T21:38:14 https://maestrodatabase.com/blog/nsw-residents-aged-in-40-49-age-group-could-get-covid-19-vaccine-in-coming-weeks 2021-05-10T21:49:20 https://maestrodatabase.com/blog/roche-agreed-msd-and-bms-should-too 2019-05-07T16:19:58 https://maestrodatabase.com/blog/a-refreshed-evidence-standards-framework-for-digital-health-technologies-and-an-increased-focus-on-digital-health-for-nice 2021-05-10T21:26:15 https://maestrodatabase.com/blog/medicines-for-colorectal-skin-and-ovarian-cancers-approved-for-nhs-scotland-use 2021-05-10T21:20:23 https://maestrodatabase.com/blog/fda-authorizes-pfizer-biontech-covid-19-vaccine-for-emergency-use-in-adolescents-in-another-important-action-in-fight-against-pandemic 2021-05-10T21:31:42 https://maestrodatabase.com/blog/dostarlimab-in-combination-with-platinum-based-chemotherapy-for-the-treatment-of-patients-with-advanced-or-recurrent-endometrial-cancer-with-microsatellite-stability-or-mismatch-repair-proficiency 2025-08-01T00:33:16 https://maestrodatabase.com/blog/using-external-reference-pricing-in-medicare-part-d-to-reduce-drug-price-differentials-with-other-countries 2019-05-07T16:15:02 https://maestrodatabase.com/blog/trump-directs-azar-to-work-on-florida-drug-import-plan 2019-05-07T16:07:43 https://maestrodatabase.com/blog/paratek-withdraws-european-marketing-authorisation-application-for-oral-and-intravenous-nuzyra-in-skin-infections-and-pneumonia 2019-10-18T01:26:39 https://maestrodatabase.com/blog/celgenes-myelodysplastic-syndrome-treatment-gets-more-insurance-benefits 2019-05-07T16:22:07 https://maestrodatabase.com/blog/health-canada-approves-uplinza-inebilizumab-for-the-treatment-of-neuromyelitis-optica-spectrum-disorders 2024-01-18T01:07:13 https://maestrodatabase.com/blog/u-dot-s-fda-grants-bionomics-fast-track-designation-to-bnc210-for-the-acute-treatment-of-social-anxiety-disorder-and-other-anxiety-related-disorders 2021-12-01T23:27:06 https://maestrodatabase.com/blog/teva-and-celltrion-healthcare-announce-the-launch-of-truxima-rituximab-abbs-injection-for-rheumatoid-arthritis-the-only-biosimilar-to-rituxan-rituximab-available-in-the-united-states-for-this-indication 2020-05-05T06:47:55 https://maestrodatabase.com/blog/icer-to-assess-therapies-for-iga-nephropathy 2025-08-01T01:52:58 https://maestrodatabase.com/blog/abolishing-drug-rebates-may-push-consumer-drug-costs-higher 2018-10-01T08:48:22 https://maestrodatabase.com/blog/sa-governments-free-meningococcal-b-vaccination-program-starts 2018-10-01T08:39:23 https://maestrodatabase.com/blog/pharmac-must-fund-breakthrough-treatment 2018-10-01T08:42:16 https://maestrodatabase.com/blog/pharmac-publishes-draft-agenda-for-november-2019-ptac-meeting 2019-10-18T03:32:11 https://maestrodatabase.com/blog/how-much-does-it-cost-to-have-cancer 2019-04-14T11:10:52 https://maestrodatabase.com/blog/cystic-fibrosis-scandal-mp-demands-answers-on-delay-of-vital-nhs-drugs-deal 2019-04-14T21:02:50 https://maestrodatabase.com/blog/why-pharmac-should-fund-sma-drug 2019-04-14T20:54:07 https://maestrodatabase.com/blog/biopharma-ceos-explain-problems-with-biosimilars-to-congress 2019-04-14T11:17:48 https://maestrodatabase.com/blog/public-consultation---draft-2021-22-cost-recovery-implementation-statement-for-listing-medicines-on-the-pbs-and-designated-vaccines-on-the-nip 2021-04-15T04:19:20 https://maestrodatabase.com/blog/new-drug-application-for-treatment-of-dry-eyes-disease-submitted-to-fda 2022-07-10T23:52:25 https://maestrodatabase.com/blog/medicare-aims-to-expand-coverage-of-cancer-care-but-is-it-enough 2019-04-14T21:28:00 https://maestrodatabase.com/blog/use-of-multiple-sclerosis-medicine-lemtrada-restricted-while-ema-review-is-ongoing 2019-04-14T21:20:25 https://maestrodatabase.com/blog/pd-l-1-checkpoint-inhibitor-stakeholder-meeting-outcome-statement 2019-04-14T21:06:35 https://maestrodatabase.com/blog/cigna-calls-off-humana-pursuit-plans-big-stock-buyback 2023-12-11T06:21:17 https://maestrodatabase.com/blog/novartis-uk-awarded-innovation-passport-for-investigational-therapy 2021-10-31T00:07:42 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-european-commission-approval-for-opdivo-nivolumab-in-combination-with-cabometyx-cabozantinib-as-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma 2021-04-15T05:00:44 https://maestrodatabase.com/blog/fda-approves-novartis-scemblix-asciminib-with-novel-mechanism-of-action-for-the-treatment-of-chronic-myeloid-leukemia 2021-10-30T23:53:54 https://maestrodatabase.com/blog/fda-authorises-pfizer-biontech-covid-19-vaccine-for-emergency-use-in-children-5-through-11-years-of-age 2021-10-31T00:44:36 https://maestrodatabase.com/blog/fda-approves-new-treatment-for-sickle-cell-disease 2017-07-08T01:28:01 https://maestrodatabase.com/blog/advocates-frustrated-after-pharmac-stops-funding-two-epilepsy-drugs 2019-09-29T00:17:33 https://maestrodatabase.com/blog/u-dot-s-food-and-drug-administration-approves-vuity-pilocarpine-hydrochloride-1-dot-25-percent-ophthalmic-solution-the-first-and-only-eye-drop-to-treat-presbyopia-age-related-blurry-near-vision 2021-10-31T00:24:54 https://maestrodatabase.com/blog/central-coast-womans-death-after-covid-19-vaccine-being-investigated 2021-04-15T11:01:55 https://maestrodatabase.com/blog/endo-gives-in-to-fda-demand-and-agrees-to-yank-its-opioid-painkiller 2017-07-08T01:45:33 https://maestrodatabase.com/blog/new-glucose-test-should-be-government-funded---diabetes-new-zealand 2017-07-08T02:18:23 https://maestrodatabase.com/blog/drug-trade-group-sues-maryland-over-first-in-the-nation-price-gouging-law 2017-07-08T02:07:18 https://maestrodatabase.com/blog/health-cover-at-tipping-point 2017-07-08T02:23:09 https://maestrodatabase.com/blog/fda-wants-more-data-on-promising-als-drug-frustrating-patients-seeking-faster-access 2021-04-15T12:02:25 https://maestrodatabase.com/blog/health-canada-stands-by-approval-of-astrazeneca-johnson-and-johnson-covid-19-vaccines 2021-04-15T11:56:54 https://maestrodatabase.com/blog/fibrogen-receives-rare-paediatric-disease-designation-from-the-u-dot-s-fda-for-pamrevlumab-for-the-treatment-of-duchenne-muscular-dystrophy 2021-04-15T20:43:10 https://maestrodatabase.com/blog/poseida-therapeutics-receives-regenerative-medicine-advanced-therapy-designation-from-fda-for-p-bcma-allo1-to-treat-relapsed-slash-refractory-multiple-myeloma 2024-09-17T01:44:28 https://maestrodatabase.com/blog/australians-with-cystic-fibrosis-benefit-from-life-changing-expanded-listing 2025-06-24T02:28:59 https://maestrodatabase.com/blog/white-house-expands-list-of-potential-fda-commissioners 2021-04-15T21:00:10 https://maestrodatabase.com/blog/perimeter-medical-imaging-ai-receives-u-dot-s-fda-breakthrough-device-designation-for-its-optical-coherence-tomography-imaging-system-with-imgassist-ai 2021-04-15T20:53:30 https://maestrodatabase.com/blog/drug-pricing-policy-in-south-korea-revised-to-tiered-pricing-system 2021-04-15T21:06:11 https://maestrodatabase.com/blog/ema-starts-review-of-vir-7831-for-treating-patients-with-covid-19 2021-04-15T20:48:45 https://maestrodatabase.com/blog/agenda-for-the-july-2023-pbac-meeting 2023-03-29T10:33:53 https://maestrodatabase.com/blog/hundreds-of-people-are-set-to-receive-the-first-immunotherapy-drug-for-advanced-cervical-cancer-through-the-cancer-drugs-fund 2023-03-29T10:36:36 https://maestrodatabase.com/blog/fda-head-says-he-is-willing-to-fast-track-covid-19-vaccine 2020-08-30T20:49:21 https://maestrodatabase.com/blog/trump-program-to-cover-uninsured-covid-19-patients-falls-short-of-promise 2020-08-30T21:07:43 https://maestrodatabase.com/blog/eu-drug-regulator-to-issue-view-on-j-and-j-vaccine-next-week 2021-04-15T21:13:13 https://maestrodatabase.com/blog/fda-announces-a-new-sentinel-system-contract-affirming-its-commitment-to-harnessing-real-world-data-to-improve-the-safety-and-effectiveness-of-drugs 2019-09-29T01:36:54 https://maestrodatabase.com/blog/nice-publishes-draft-guidance-on-new-use-for-fenfluramine-hydrochloride 2021-04-15T21:26:26 https://maestrodatabase.com/blog/alexions-pricey-ultomiris-wins-backing-from-englands-cost-watchdogs-thanks-to-confidential-discount 2021-04-15T21:23:20 https://maestrodatabase.com/blog/sarclisa-recommended-for-eu-approval-by-the-chmp-to-treat-transplant-eligible-newly-diagnosed-multiple-myeloma 2025-06-24T02:46:28 https://maestrodatabase.com/blog/orladeyo-now-reimbursable-in-japan-via-national-health-insurance 2021-04-15T21:40:29 https://maestrodatabase.com/blog/australian-population-unlikely-to-be-vaccinated-until-end-of-next-year 2021-04-15T21:51:21 https://maestrodatabase.com/blog/medicare-benefits-schedule-electrocardiogram-review-committee---appointment-of-committee-members 2021-04-15T21:48:22 https://maestrodatabase.com/blog/pharmac-approves-funding-for-treatment-for-mighty-mon 2018-01-15T19:32:19 https://maestrodatabase.com/blog/italy-fights-back-against-eu-milans-bid-to-scupper-ema-move-to-amsterdam 2018-01-15T19:41:00 https://maestrodatabase.com/blog/medical-device-companies-now-need-to-prove-to-fda-theyre-protected-against-cyber-attacks 2023-03-29T10:47:37 https://maestrodatabase.com/blog/fda-accepts-for-review-resubmitted-nda-for-transcon-pth-palopegteriparatide-in-adult-patients-with-hypoparathyroidism 2023-12-11T20:05:07 https://maestrodatabase.com/blog/ema-publishes-agenda-for-11-14-december-2023-chmp-agenda 2023-12-11T19:52:55 https://maestrodatabase.com/blog/scottish-medicines-consortium-rejects-cancer-drugs-for-routine-use-on-nhs 2018-01-15T19:53:03 https://maestrodatabase.com/blog/msac-secretariat-publishes-agenda-for-july-2023-msac-meeting 2023-03-29T10:41:55 https://maestrodatabase.com/blog/german-watchdog-calls-for-direct-comparison-of-cancer-immunotherapies 2018-01-15T20:03:22 https://maestrodatabase.com/blog/smc---december-2023-decisions 2023-12-11T19:46:04 https://maestrodatabase.com/blog/smc---january-2018-decisions 2018-01-15T19:49:15 https://maestrodatabase.com/blog/revolution-medicines-announces-fda-breakthrough-therapy-designation-for-daraxonrasib-in-previously-treated-metastatic-pancreatic-cancer-with-kras-g12-mutations 2025-06-24T03:11:46 https://maestrodatabase.com/blog/icer-posts-draft-scoping-document-for-the-assessment-of-treatments-for-ulcerative-colitis 2019-09-29T07:13:01 https://maestrodatabase.com/blog/libtayo-cemiplimab-in-combination-with-chemotherapy-approved-by-european-commission-for-the-first-line-treatment-of-advanced-pd-l1-positive-non-small-cell-lung-cancer 2023-03-29T11:07:08 https://maestrodatabase.com/blog/gsks-jemperli-dostarlimab-plus-chemotherapy-approved-as-the-first-and-only-frontline-immuno-oncology-treatment-in-the-european-union-for-dmmr-slash-msi-h-primary-advanced-or-recurrent-endometrial-cancer 2023-12-11T20:30:22 https://maestrodatabase.com/blog/parents-of-kids-with-rare-neuromuscular-disorder-want-funding-for-expensive-drug 2018-01-15T20:09:37 https://maestrodatabase.com/blog/icer-identifies-most-significant-2022-us-drug-price-hikes-unsupported-by-new-clinical-evidence 2023-12-11T20:21:45 https://maestrodatabase.com/blog/cstone-announces-nmpa-approval-of-sugemalimab-as-first-line-treatment-for-oesophageal-squamous-cell-carcinoma 2023-12-11T20:16:03 https://maestrodatabase.com/blog/trump-is-finalising-an-executive-order-allowing-imports-of-some-prescription-drugs 2019-09-29T07:24:49 https://maestrodatabase.com/blog/ema-recommends-market-approval-of-avt06-alvotechs-proposed-biosimilar-to-eylea-aflibercept 2025-06-24T04:36:08 https://maestrodatabase.com/blog/seizures-driving-stand-downs-as-pharmac-pulls-epilepsy-drug-funding 2019-09-29T20:43:01 https://maestrodatabase.com/blog/fda-approves-first-over-the-counter-naloxone-nasal-spray 2023-03-29T19:57:12 https://maestrodatabase.com/blog/ozempic-receives-eu-recommendation-in-peripheral-arterial-disease-cementing-the-broad-benefits-of-semaglutide-for-people-with-type-2-diabetes-and-co-morbidities 2025-06-24T05:13:21 https://maestrodatabase.com/blog/teva-announces-u-dot-s-fda-approval-of-trisenox-arsenic-trioxide-injection-for-first-line-treatment-of-acute-promyelocytic-leukaemia 2018-01-16T03:14:13 https://maestrodatabase.com/blog/half-a-million-aussies-to-get-cheaper-drugs-thanks-to-new-pbs-inclusions 2019-09-29T21:36:49 https://maestrodatabase.com/blog/does-insulin-price-reduction-suggest-a-path-forward-for-lowering-drug-costs 2023-03-29T20:13:54 https://maestrodatabase.com/blog/hansa-biopharma-announces-positive-reimbursement-decision-in-spain-for-idefirix-imlifidase-as-desensitisation-treatment-for-highly-sensitised-patients-in-kidney-transplantation 2023-03-29T20:19:17 https://maestrodatabase.com/blog/fda-grants-breakthrough-device-designation-to-aural-analytics-for-speech-analytics-software-to-be-used-in-treatment-of-als 2023-03-29T20:07:24 https://maestrodatabase.com/blog/epicentrx-receives-fast-track-designation-from-the-us-fda-for-lead-asset-rrx-001-to-prevent-slash-attenuate-chemotherapy-and-radiation-treatment-induced-severe-oral-mucositis 2023-03-29T20:01:38 https://maestrodatabase.com/blog/fda-approves-benlysta-belimumab-auto-injector-for-children-with-active-lupus-nephritis 2025-06-25T00:17:13 https://maestrodatabase.com/blog/y-mabs-receives-breakthrough-therapy-designation-for-naxitamab-for-the-treatment-of-high-risk-neuroblastoma 2018-08-23T06:37:36 https://maestrodatabase.com/blog/big-pharma-might-cut-research-delay-new-drugs-if-pharmacare-means-more-generics 2019-04-15T10:52:48 https://maestrodatabase.com/blog/pharmac-negotiates-deal-for-a-further-covid-19-treatment 2021-10-31T06:50:08 https://maestrodatabase.com/blog/erasca-granted-fda-fast-track-designation-for-pan-raf-inhibitor-naporafenib-in-patients-with-advanced-nras-mutated-melanoma 2023-12-11T23:33:02 https://maestrodatabase.com/blog/no-deal-risk-recedes-but-new-brexit-delay-adds-to-uncertainty 2019-04-15T10:56:53 https://maestrodatabase.com/blog/takeda-receives-approval-to-manufacture-and-market-entyvio-subcutaneous-injection-in-japan-for-the-maintenance-treatment-of-moderate-to-severe-ulcerative-colitis 2023-03-29T20:22:32 https://maestrodatabase.com/blog/the-european-commission-granted-marketing-authorisation-for-vueway-gadopiclenol-in-the-european-union 2023-12-12T02:01:10 https://maestrodatabase.com/blog/sobi-secures-nhs-reimbursement-for-ravicti 2018-08-23T08:07:44 https://maestrodatabase.com/blog/new-and-amended-pbs-listings-to-help-thousands-of-australians 2021-10-31T06:56:44 https://maestrodatabase.com/blog/decision-to-list-terbutaline-sulphate-powder-for-inhalation-bricanyl-turbuhaler-in-a-new-model-of-the-turbuhaler-device 2020-04-16T04:58:35 https://maestrodatabase.com/blog/novimmune-submits-marketing-authorisation-application-in-europe-for-its-lead-drug-emapalumab 2018-08-23T09:47:12 https://maestrodatabase.com/blog/future-in-cancer-treatment-arrives-for-australian-children-and-young-adults-battling-leukaemia 2019-04-15T12:30:44 https://maestrodatabase.com/blog/novartis-announces-fda-filing-acceptance-and-priority-review-of-brolucizumab-rth258-for-patients-with-wet-amd 2019-04-15T20:31:31 https://maestrodatabase.com/blog/mayne-pharma-and-mithra-announce-fda-approval-of-new-oral-contraceptive-estelle 2021-04-16T02:53:29 https://maestrodatabase.com/blog/at-who-forum-on-medicines-countries-and-civil-society-push-for-greater-transparency-and-fairer-prices 2019-04-15T12:48:24 https://maestrodatabase.com/blog/biopharmaceutical-sector-waging-war-on-covid-19-with-over-60-vaccines-and-medicines 2020-04-16T05:01:38 https://maestrodatabase.com/blog/quoin-pharmaceuticals-announces-fda-grants-rare-paediatric-disease-designation-for-qrx003-in-netherton-syndrome 2025-06-25T04:56:35 https://maestrodatabase.com/blog/free-blood-tests-labor-raises-health-pressure 2019-04-15T20:44:19 https://maestrodatabase.com/blog/kiwi-fathers-emotional-plea-to-jacinda-ardern-to-fund-life-saving-drug-for-rare-disease 2019-04-15T20:40:38 https://maestrodatabase.com/blog/fda-and-ema-accept-marstacimab-regulatory-submissions-for-the-treatment-of-haemophilia-a-and-b 2023-12-12T02:36:24 https://maestrodatabase.com/blog/new-hope-for-australian-leukaemia-and-lymphoma-patients-with-key-treatment-option-listed-on-pbs 2020-08-31T01:11:23 https://maestrodatabase.com/blog/pharmacs-early-access-scheme-needs-work---prime-minister-jacinda-ardern 2019-04-15T20:37:00 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---november-2021-update 2021-10-31T20:16:26 https://maestrodatabase.com/blog/syndax-announces-fda-priority-review-of-snda-for-revuforj-revumenib-in-relapsed-or-refractory-mnpm1-acute-myeloid-leukaemia 2025-06-25T02:50:18 https://maestrodatabase.com/blog/section-19a-medicines-subsidised-by-the-pharmaceutical-benefits-scheme 2021-10-31T20:22:42 https://maestrodatabase.com/blog/pharmac-proposes-to-fund-treatments-for-breast-and-blood-cancer 2023-12-12T03:27:11 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-for-priority-review-bms-application-for-empliciti-elotuzumab-plus-pomalidomide-and-low-dose-dexamethasone-in-patients-with-relapsed-or-refractory-multiple-myeloma 2018-08-23T11:37:46 https://maestrodatabase.com/blog/missing-out-on-basic-health-care-australians-spend-34-dollars-billion-a-year-on-out-of-pocket-health-costs 2019-04-15T21:08:49 https://maestrodatabase.com/blog/linerixibat-accepted-for-review-by-the-ema-for-cholestatic-pruritus-in-patients-with-primary-biliary-cholangitis 2025-06-25T03:24:01 https://maestrodatabase.com/blog/fda-approves-puretechs-obesity-device-plenity 2019-04-15T20:59:30 https://maestrodatabase.com/blog/nice-publishes-final-guidance-for-dinutuximab 2018-08-23T20:52:08 https://maestrodatabase.com/blog/consultation-on-the-medical-services-advisory-committee-revised-draft-guidelines 2020-08-31T03:16:46 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-long-term-treatments-for-prevention-of-hereditary-angioedema-attacks 2018-08-23T21:04:25 https://maestrodatabase.com/blog/prostate-cancer-treatment-to-be-put-on-pbs 2021-10-31T20:42:52 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-november-2021-update 2021-10-31T20:25:54 https://maestrodatabase.com/blog/5-700-people-to-benefit-from-widened-access-to-funded-medicines 2024-09-17T06:48:05 https://maestrodatabase.com/blog/nice-publishes-preliminary-guidance-on-new-combo-product-for-aml 2018-08-23T20:57:35 https://maestrodatabase.com/blog/a-strategy-for-improving-u-dot-s-health-care-delivery----conducting-more-randomised-controlled-trials 2020-04-16T05:31:09 https://maestrodatabase.com/blog/fda-approves-ribociclib-with-an-aromatase-inhibitor-and-ribociclib-and-letrozole-co-pack-for-early-high-risk-breast-cancer 2024-09-17T20:31:25 https://maestrodatabase.com/blog/fdas-new-generic-epipen-approval-exemplifies-progress-on-drug-price-reform 2018-08-23T21:12:18 https://maestrodatabase.com/blog/trumps-plan-on-drug-pricing-transparency-takes-step-forward 2018-08-23T21:15:07 https://maestrodatabase.com/blog/rozanolixizumab-for-the-treatment-of-patients-with-generalised-antibody-positive-myasthenia-gravis 2024-09-17T10:52:39 https://maestrodatabase.com/blog/fda-adds-four-tropical-diseases-to-priority-review-voucher-program-to-encourage-drug-development-in-areas-of-unmet-need 2018-08-23T21:09:47 https://maestrodatabase.com/blog/rucaparib-camsylate-for-the-maintenance-treatment-of-patients-with-relapsed-platinum-sensitive-ovarian-fallopian-tube-or-peritoneal-cancer-final-guidance 2024-09-17T10:42:21 https://maestrodatabase.com/blog/novadip-receives-rmat-designation-for-nvd003-its-regenerative-treatment-for-congenital-pseudarthosis-of-the-tibia 2025-06-25T05:15:24 https://maestrodatabase.com/blog/insights-from-the-agenda-for-the-november-2018-pbac-meeting 2018-08-23T21:31:10 https://maestrodatabase.com/blog/case-control-studies-using-real-world-evidence-to-assess-association 2018-08-23T21:18:26 https://maestrodatabase.com/blog/icer-to-assess-treatment-for-retinitis-pigmentosa 2024-09-17T20:58:42 https://maestrodatabase.com/blog/after-9-year-wait-boehringers-ipf-drug-ofev-faces-generic-threat-weeks-into-korea-launch 2025-06-25T22:13:22 https://maestrodatabase.com/blog/ema-restricts-use-of-multiple-sclerosis-medicine-zinbryta 2017-07-09T08:29:17 https://maestrodatabase.com/blog/the-private-equity-firm-that-quietly-profits-on-top-selling-drugs 2017-07-09T08:39:49 https://maestrodatabase.com/blog/pressure-on-nhs-finances-drives-new-wave-of-postcode-rationing 2017-07-09T08:46:22 https://maestrodatabase.com/blog/why-obamacares-loudest-critics-arent-as-loud-anymore 2017-07-09T08:42:44 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-to-remegens-telitacicept-as-a-treatment-for-systemic-lupus-erythematosus 2020-04-16T06:10:00 https://maestrodatabase.com/blog/lilly-requests-revocation-of-emergency-use-authorization-for-bamlanivimab-alone-to-complete-transition-to-bamlanivimab-and-etesevimab-together-for-treatment-of-covid-19-in-the-u-dot-s 2021-04-16T12:24:47 https://maestrodatabase.com/blog/the-harsh-reality-of-real-world-data-external-comparators-for-health-technology-assessment 2022-07-11T08:22:53 https://maestrodatabase.com/blog/fda-approves-updated-label-for-lillys-amyvid-florbetapir-f-18-injection-to-support-diagnosis-of-alzheimers-disease-in-patients 2025-06-26T01:28:31 https://maestrodatabase.com/blog/extreme-australian-gps-prescribing-antibiotics-at-up-to-nine-times-recommended-rates-study-funds 2017-07-09T21:11:07 https://maestrodatabase.com/blog/icer-publishes-final-evidence-report-and-policy-recommendations-on-therapies-for-lupus-nephritis 2021-04-16T12:27:57 https://maestrodatabase.com/blog/sandoz-regulatory-submission-for-proposed-biosimilar-adalimumab-accepted-by-fda 2018-01-16T09:53:40 https://maestrodatabase.com/blog/medicares-45-000-daily-hits-under-scrutiny 2017-07-09T21:22:38 https://maestrodatabase.com/blog/fda-approves-pembrolizumab-with-chemotherapy-for-unresectable-advanced-or-metastatic-malignant-pleural-mesothelioma 2024-09-17T22:20:49 https://maestrodatabase.com/blog/private-health-insurers-should-improve-useless-products-not-punish-people-who-avoid-them-ama 2018-01-16T19:46:17 https://maestrodatabase.com/blog/atezolizumab-pembrolizumab-nivolumab-in-urothelial-carcinoma-studies-of-direct-comparison-are-useful 2018-01-16T19:55:09 https://maestrodatabase.com/blog/shire-granted-eu-marketing-authorisation-for-adynovi-anti-haemophilic-factor-recombinant-pegylated-for-adults-and-adolescents-with-haemophilia-a 2018-01-16T10:06:57 https://maestrodatabase.com/blog/bridgebio-announces-infigratinib-is-the-first-ever-investigational-therapeutic-option-for-achondroplasia-to-be-awarded-breakthrough-therapy-designation-by-the-fda 2024-09-17T23:25:07 https://maestrodatabase.com/blog/anthos-therapeutics-announces-that-abelacimab-has-received-fda-fast-track-designation-for-the-treatment-of-thrombosis-associated-with-cancer 2022-07-11T08:29:32 https://maestrodatabase.com/blog/how-ottawas-using-a-fake-drug-crisis-to-force-through-damaging-pharmaceutical-policy 2018-01-16T20:15:14 https://maestrodatabase.com/blog/in-a-nutshell-2017-new-issue-with-facts-and-graphics-from-the-iqwig 2018-01-16T20:00:14 https://maestrodatabase.com/blog/fda-grants-rmat-designation-for-engenes-detalimogene-enabling-potential-for-expedited-review-in-high-risk-non-muscle-invasive-bladder-cancer 2025-06-26T01:22:03 https://maestrodatabase.com/blog/fda-commissioner-on-new-steps-fda-is-taking-to-enhance-transparency-of-clinical-trial-information-to-support-innovation-and-scientific-inquiry-related-to-new-drugs 2018-01-16T20:09:26 https://maestrodatabase.com/blog/governor-ron-de-santis-takes-additional-actions-to-lower-prescription-drug-prices-for-floridians 2022-07-11T09:17:04 https://maestrodatabase.com/blog/statement-from-fda-commissioner-responding-to-report-from-gao-and-updating-on-fdas-ongoing-efforts-to-increase-access-to-complex-generic-drugs 2018-01-16T20:26:58 https://maestrodatabase.com/blog/mallinckrodt-and-npxe-announce-fda-fast-track-designation-for-phase-3-trial-of-inhaled-xenon-gas-therapy 2018-08-24T00:16:04 https://maestrodatabase.com/blog/statement-from-fda-commissioner-in-response-to-gao-report-regarding-fdas-ongoing-commitment-to-employing-a-least-burdensome-approach-to-device-review 2018-01-16T20:34:25 https://maestrodatabase.com/blog/u-dot-s-california-will-start-making-its-own-insulin-to-combat-high-drug-prices-governor-says 2022-07-11T09:28:27 https://maestrodatabase.com/blog/centrexion-therapeutics-announces-fast-track-designation-granted-by-fda-to-cntx-4975-for-treatment-of-knee-osteoarthritis-pain 2018-01-16T20:19:04 https://maestrodatabase.com/blog/oncology-accelerated-approvals-are-often-based-on-non-comparative-trials-evaluating-response-rate 2024-09-18T00:10:54 https://maestrodatabase.com/blog/beone-medicines-receives-positive-chmp-opinion-for-tablet-formulation-of-brukinsa 2025-06-26T03:08:10 https://maestrodatabase.com/blog/precision-biosciences-receives-fda-rare-paediatric-disease-designation-for-pbgene-dmd-for-the-treatment-of-duchenne-muscular-dystrophy 2025-06-26T03:15:18 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-september-2020 2020-08-31T07:30:04 https://maestrodatabase.com/blog/icer-appoints-yvette-venable-as-vice-president-of-patient-engagement 2020-04-16T12:14:22 https://maestrodatabase.com/blog/us-fda-grants-spectral-medical-breakthrough-device-designation-for-toraymyxin-for-the-treatment-of-endotoxemic-septic-shock 2022-07-11T21:01:34 https://maestrodatabase.com/blog/mayne-pharma-submits-new-drug-application-for-e4-slash-drsp-to-the-fda 2020-04-16T12:17:25 https://maestrodatabase.com/blog/smc---july-2022-decisions 2022-07-11T20:59:16 https://maestrodatabase.com/blog/meeting-highlights-from-icmra-global-regulatory-workshop-on-covid-19-observational-studies-and-real-world-data 2020-04-16T20:49:02 https://maestrodatabase.com/blog/ecdc-and-ema-update-recommendations-on-additional-booster-doses-of-mrna-covid-19-vaccines 2022-07-11T11:31:19 https://maestrodatabase.com/blog/orchard-therapeutics-receives-swissmedic-approval-for-libmeldy-in-early-onset-mld 2023-12-12T06:07:40 https://maestrodatabase.com/blog/icer-launches-initiative-to-evaluate-and-advance-health-technology-assessment-methods-that-support-health-equity 2022-07-11T11:56:30 https://maestrodatabase.com/blog/aid-groups-ask-uk-gov-to-stop-pharma-profiteering-from-covid-19 2020-04-16T11:37:48 https://maestrodatabase.com/blog/lower-priced-versions-of-humalog-mix75-slash-25-kwikpen-and-humalog-junior-kwikpen-now-available 2020-04-16T11:55:45 https://maestrodatabase.com/blog/bayers-chloroquine-donation-to-u-dot-s-raises-concern-about-fda-standards-in-pandemic 2020-04-16T21:07:31 https://maestrodatabase.com/blog/cadth-advisory-panel-report-recommends-framework-for-potential-pan-canadian-formulary 2022-07-11T21:31:38 https://maestrodatabase.com/blog/can-the-world-find-a-good-covid-19-vaccine-quickly-enough 2020-04-16T21:17:08 https://maestrodatabase.com/blog/pharmac-procrastinating-over-funding-glucose-monitors-diabetes-nz-says 2022-07-11T21:27:00 https://maestrodatabase.com/blog/japan-china-vie-to-be-global-supplier-of-unproven-coronavirus-drug 2020-04-16T21:25:07 https://maestrodatabase.com/blog/fasenra-approved-in-the-us-for-eosinophilic-granulomatosis-with-polyangiitis 2024-09-18T06:11:30 https://maestrodatabase.com/blog/t2-biosystems-receives-fda-breakthrough-device-designation-for-the-t2lyme-panel 2022-07-11T21:16:35 https://maestrodatabase.com/blog/pharmacies-run-off-their-feet-people-waiting-days-for-prescriptions 2020-04-16T20:53:33 https://maestrodatabase.com/blog/covid-19-update-fda-continues-user-fee-related-reviews 2020-04-16T20:55:46 https://maestrodatabase.com/blog/arcutis-biotherapeutics-announces-health-canada-accepts-for-review-the-new-drug-submission-for-roflumilast-cream-for-adults-and-adolescents-with-plaque-psoriasis 2022-07-11T21:12:00 https://maestrodatabase.com/blog/ema-shares-advice-on-validated-computer-systems-used-in-clinical-trials 2020-04-16T21:02:59 https://maestrodatabase.com/blog/european-commission-grants-marketing-authorisation-for-lenvima-lenvatinib-as-first-line-treatment-in-adults-with-advanced-or-unresectable-hepatocellular-carcinoma 2018-08-24T01:52:57 https://maestrodatabase.com/blog/clarity-around-pharmacs-priority-lists 2023-03-30T04:11:08 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-september-2020-update 2020-08-31T11:33:09 https://maestrodatabase.com/blog/australia-to-subsidise-multiple-myeloma-drug-darzalex-under-pbs 2021-11-01T03:56:46 https://maestrodatabase.com/blog/grace-therapeutics-announces-submission-of-new-drug-application-to-us-fda-for-gtx-104 2025-06-26T04:44:20 https://maestrodatabase.com/blog/kala-pharmaceuticals-announces-fda-approval-of-inveltys-for-the-treatment-of-post-operative-inflammation-and-pain-following-ocular-surgery 2018-08-24T02:04:09 https://maestrodatabase.com/blog/making-more-new-cancer-treatments-available-for-new-zealanders 2024-09-18T06:35:14 https://maestrodatabase.com/blog/it-treats-pharmacists-with-contempt 2020-04-16T21:31:24 https://maestrodatabase.com/blog/korea-should-introduce-indication-specific-drug-pricing 2020-08-31T11:26:19 https://maestrodatabase.com/blog/perrigos-hra-pharma-submits-application-to-fda-for-first-ever-otc-birth-control-pill 2022-07-11T21:41:29 https://maestrodatabase.com/blog/a-quick-virus-test-sure-if-you-can-afford-it 2020-08-31T11:29:29 https://maestrodatabase.com/blog/shire-announces-fda-approval-of-takhyzro-lanadelumab-flyo-a-first-of-its-kind-mab-preventive-treatment-for-hereditary-angioedema 2018-08-24T02:12:42 https://maestrodatabase.com/blog/velosbio-announces-fda-fast-track-and-orphan-drug-designations-for-vls-101-in-patients-with-mantle-cell-lymphoma 2020-08-31T12:08:55 https://maestrodatabase.com/blog/cms-acts-to-spur-innovation-for-americas-seniors 2020-08-31T20:25:53 https://maestrodatabase.com/blog/cormedix-announces-fda-acceptance-for-filing-and-priority-review-of-new-drug-application-for-defencath 2020-08-31T12:04:55 https://maestrodatabase.com/blog/icer-to-assess-car-t-cell-therapies-for-multiple-myeloma 2020-08-31T20:53:17 https://maestrodatabase.com/blog/a-new-biosimilar-to-novorapid-is-included-in-the-high-cost-protection 2020-08-31T21:01:55 https://maestrodatabase.com/blog/fda-releases-draft-guidance-on-pros-for-device-manufacturers 2020-08-31T20:33:59 https://maestrodatabase.com/blog/fda-approves-xaracoll-bupivacaine-hydrochloride-implant-a-non-opioid-drug-device-treatment-option-for-acute-post-surgical-pain-relief-for-up-to-24-hours-following-open-inguinal-hernia-repair-in-adults 2020-08-31T20:37:03 https://maestrodatabase.com/blog/with-canada-and-mexico-borders-closed-americans-are-trapped-in-their-own-health-care-system 2020-08-31T21:18:22 https://maestrodatabase.com/blog/hansa-biopharma-announces-first-patient-treated-in-the-post-authorisation-efficacy-study-of-idefirix-imlifidase-in-highly-sensitised-kidney-transplant-patients 2022-07-12T02:48:30 https://maestrodatabase.com/blog/mezzion-shares-tumble-on-fdas-return-of-heart-disease-med-nda 2020-08-31T21:05:03 https://maestrodatabase.com/blog/icer-posts-draft-scoping-document-on-lupus-nephritis 2020-08-31T21:14:19 https://maestrodatabase.com/blog/tga-recognises-two-more-covid-19-vaccines-not-registered-in-australia-but-used-widely-internationally 2021-11-01T10:31:56 https://maestrodatabase.com/blog/federal-government-takes-first-major-step-in-adopting-new-wave-of-personalised-medicine-for-australian-patients 2019-04-16T03:05:00 https://maestrodatabase.com/blog/ema-publishes-agenda-for-16-19-september-2024-chmp-meeting 2024-09-18T10:10:59 https://maestrodatabase.com/blog/fda-approves-nivolumab-in-combination-with-chemotherapy-for-metastatic-gastric-cancer-and-oesophageal-adenocarcinoma 2021-04-16T22:19:32 https://maestrodatabase.com/blog/biogens-new-drug-submission-for-omaveloxolone-accepted-for-priority-review-by-health-canada-for-the-treatment-of-friedreichs-ataxia 2024-09-18T08:57:24 https://maestrodatabase.com/blog/drug-company-boss-calls-for-inquiry-over-breast-cancer-drug-prices 2019-04-16T03:13:16 https://maestrodatabase.com/blog/iterum-therapeutics-announces-special-protocol-assessment-agreement-with-the-fda 2022-07-12T11:26:37 https://maestrodatabase.com/blog/fda-rule-would-facilitate-prescription-to-otc-switches-but-nix-a-third-class-of-drugs 2022-07-12T10:58:36 https://maestrodatabase.com/blog/provention-bio-initiates-rolling-submission-of-biologic-license-application-for-teplizumab-for-the-delay-or-prevention-of-clinical-type-1-diabetes-in-at-risk-individuals 2020-04-16T23:39:15 https://maestrodatabase.com/blog/ema-launches-pilot-project-on-analysis-of-raw-data-from-clinical-trials 2022-07-12T10:53:16 https://maestrodatabase.com/blog/fda-accepts-byondis-biologics-license-application-for-vic--trastuzumab-duocarmazine-syd985-in-her2-positive-metastatic-breast-cancer 2022-07-12T12:15:29 https://maestrodatabase.com/blog/fda-revokes-emergency-use-authorisation-for-monoclonal-antibody-bamlanivimab 2021-04-16T23:18:14 https://maestrodatabase.com/blog/humacyte-submits-biologics-license-application-to-us-fda-seeking-approval-of-human-acellular-vessel-for-the-treatment-of-vascular-trauma 2023-12-12T20:14:59 https://maestrodatabase.com/blog/candel-therapeutics-receives-fda-fast-track-designation-for-can-2409-in-pancreatic-cancer 2023-12-12T20:05:48 https://maestrodatabase.com/blog/fda-accepts-for-priority-review-biologics-license-application-for-regn-eb3-to-treat-ebola 2020-04-17T00:52:07 https://maestrodatabase.com/blog/fda-creates-new-advisory-committee-for-evaluation-of-genetic-metabolic-disease-treatments 2023-12-12T20:01:34 https://maestrodatabase.com/blog/efgartigimod-for-the-treatment-of-patients-with-generalised-myasthenia-gravis-draft-guidance-2 2023-12-12T19:56:13 https://maestrodatabase.com/blog/multiple-myeloma-meeting-outcome-statement 2018-08-25T07:35:37 https://maestrodatabase.com/blog/ortho-dermatologics-receives-fda-approval-for-altreno-tretinoin-0-dot-05-percent-lotion-for-acne 2018-08-25T07:44:25 https://maestrodatabase.com/blog/healthy-dot-io-receives-landmark-fda-clearance-for-first-and-only-smartphone-powered-home-kidney-test 2022-07-12T21:14:19 https://maestrodatabase.com/blog/icer-report-finds-evidence-inadequate-to-distinguish-the-clinical-benefits-of-different-anti-androgen-therapies-for-men-with-non-metastatic-castration-resistant-prostate-cancer 2018-08-25T08:08:49 https://maestrodatabase.com/blog/philogen-provides-update-on-marketing-authorisation-application-for-nidlegy-in-the-european-union 2025-06-27T01:20:59 https://maestrodatabase.com/blog/teaching-the-basics-of-health-technology-assessment 2022-07-12T21:19:09 https://maestrodatabase.com/blog/xtandi-enzalutamide-now-funded-in-ontario-for-all-approved-prostate-cancer-indications 2025-06-27T01:29:11 https://maestrodatabase.com/blog/fda-says-sponsors-should-limit-placebo-controlled-trials-in-cancer 2018-08-25T07:56:50 https://maestrodatabase.com/blog/uk-drugs-regulator-plays-down-brexit-disruption-threat 2018-01-17T01:06:21 https://maestrodatabase.com/blog/ensuring-patient-voices-are-heard-how-patients-can-contribute-to-the-cadth-symposium 2018-08-25T08:02:06 https://maestrodatabase.com/blog/provepharm-announces-that-it-has-received-fda-approval-for-bludigo-indigotindisulfonate-sodium-usp-injection 2022-07-12T20:59:46 https://maestrodatabase.com/blog/this-drug-is-safe-and-effective-wait-compared-with-what 2018-08-25T08:18:10 https://maestrodatabase.com/blog/health-canada-approves-an-extended-indication-for-kisqali-ribociclib-in-combination-treatment 2020-04-17T01:57:36 https://maestrodatabase.com/blog/ancora-heart-receives-breakthrough-device-designation-from-fda-for-the-accucinch-ventricular-restoration-system 2022-07-13T06:55:00 https://maestrodatabase.com/blog/krystal-biotechs-kb105-receives-rare-paediatric-disease-designation-from-the-fda-to-treat-patients-with-tgm-1-deficient-autosomal-recessive-congenital-ichthyosis 2018-08-26T21:11:40 https://maestrodatabase.com/blog/health-canada-authorises-evrysdi-risdiplam-for-the-treatment-of-spinal-muscular-atrophy-in-adults-and-children 2021-04-17T05:34:21 https://maestrodatabase.com/blog/oncopeptides-submits-application-for-conditional-marketing-authorisation-of-melflufen-in-the-eu 2021-04-17T05:10:29 https://maestrodatabase.com/blog/abbott-receives-fda-breakthrough-device-designation-to-explore-use-of-deep-brain-stimulation-to-manage-severe-depression 2022-07-13T06:44:12 https://maestrodatabase.com/blog/alberta-expands-access-to-cystic-fibrosis-drug-trikafta-for-children-6-to-11 2022-07-12T21:33:13 https://maestrodatabase.com/blog/drug-prices-in-ads-senate-passes-amendment 2018-08-26T12:37:55 https://maestrodatabase.com/blog/janssen-announces-extension-of-u-dot-s-fda-bla-pdufa-date-for-bcma-car-t-ciltacabtagene-autoleucel 2021-11-02T02:54:15 https://maestrodatabase.com/blog/fda-approves-diacomit-stiripentol-for-the-treatment-of-seizures-associated-with-dravet-syndrome-in-patients-2-years-of-age-and-older-taking-clobazam 2018-08-26T21:37:03 https://maestrodatabase.com/blog/evidence-required-by-heath-technology-assessment-and-reimbursement-bodies-evaluating-diagnostic-or-prognostic-algorithms-that-include-omics-data 2018-08-26T21:26:02 https://maestrodatabase.com/blog/fda-approves-first-of-its-kind-automated-insulin-delivery-and-monitoring-system-for-use-in-young-paediatric-patients 2020-09-01T00:10:28 https://maestrodatabase.com/blog/fda-converts-to-full-approval-indication-for-keytruda-pembrolizumab-for-certain-adult-and-paediatric-patients-with-advanced-microsatellite-instability-high-or-mismatch-repair-deficient-solid-tumours 2023-03-30T11:16:34 https://maestrodatabase.com/blog/incyte-announces-acceptance-of-nda-for-parsaclisib-for-three-types-of-relapsed-or-refractory-non-hodgkin-lymphomas 2021-11-02T02:49:10 https://maestrodatabase.com/blog/medicare-to-fund-allied-health-case-conferencing 2021-11-02T02:29:29 https://maestrodatabase.com/blog/to-deal-with-the-next-pandemic-the-fda-needs-an-office-of-preparedness-and-response 2023-03-30T11:26:33 https://maestrodatabase.com/blog/tga-to-improve-the-handling-of-advertising-complaints 2017-07-10T04:29:34 https://maestrodatabase.com/blog/novartis-granted-us-fda-priority-review-for-kymriah-tisagenlecleucel-formerly-ctl019-for-adults-with-r-slash-r-dlbcl 2018-01-17T07:39:46 https://maestrodatabase.com/blog/nice-approves-cdf-funding-for-janssens-darzalex 2018-01-17T19:58:21 https://maestrodatabase.com/blog/consumers-to-be-slugged-with-200-dollars-private-health-insurance-price-rises 2018-01-17T19:50:55 https://maestrodatabase.com/blog/is-an-orphan-medicine-still-an-orphan-once-it-gets-on-the-market 2018-01-17T19:55:10 https://maestrodatabase.com/blog/3-dot-2-million-more-people-were-uninsured-at-the-end-of-2017-than-at-the-end-of-2016 2018-01-17T20:15:19 https://maestrodatabase.com/blog/nice-issues-final-guidance-for-reimbursement-making-vazkepa-icosapent-ethyl-available-across-the-nhs-in-england-and-wales 2022-07-13T20:56:13 https://maestrodatabase.com/blog/pfizer-asked-to-submit-cdf-proposal-for-xalkori 2018-01-17T20:01:48 https://maestrodatabase.com/blog/junshi-biosciences-and-coherus-announce-fda-acceptance-of-bla-filing-for-toripalimab-for-treatment-of-nasopharyngeal-carcinoma 2021-11-02T07:31:25 https://maestrodatabase.com/blog/gottlieb-changes-course-on-fda-publication-of-rejection-letters 2018-01-17T20:11:04 https://maestrodatabase.com/blog/fda-authorises-emergency-use-of-novavax-covid-19-vaccine-adjuvanted 2022-07-13T20:51:34 https://maestrodatabase.com/blog/accelerating-pooled-licensing-of-medicines-to-enhance-global-production-and-equitable-access 2022-07-13T08:34:39 https://maestrodatabase.com/blog/an-open-letter-to-dr-scott-gottlieb-on-fda-transparency 2018-01-17T20:25:45 https://maestrodatabase.com/blog/ani-pharmaceuticals-announces-fda-approval-of-purified-cortrophin-gel-for-multiple-indications-including-multiple-sclerosis-rheumatoid-arthritis-and-nephrotic-syndrome 2021-11-02T07:22:30 https://maestrodatabase.com/blog/maps-pbc-announces-submission-of-new-drug-application-to-the-fda-for-mdma-assisted-therapy-for-ptsd 2023-12-13T03:36:46 https://maestrodatabase.com/blog/ema-ends-rolling-review-of-the-antibodies-bamlanivimab-and-etesevimab-for-covid-19-following-withdrawal-by-lilly 2021-11-02T19:48:39 https://maestrodatabase.com/blog/ribociclib-in-advanced-breast-cancer-survival-benefits-but-also-severe-side-effects 2019-04-16T05:34:50 https://maestrodatabase.com/blog/biosimilar-uptake-accelerates-in-us--and-so-do-the-savings 2022-07-13T21:39:29 https://maestrodatabase.com/blog/otsuka-submits-initial-marketing-authorization-application-to-the-european-medicines-agency-for-vadadustat-for-the-treatment-of-adults-with-anemia-associated-with-chronic-kidney-disease 2021-11-02T10:22:20 https://maestrodatabase.com/blog/who-advisers-to-consider-whether-obesity-medication-should-be-added-to-essential-medicines-list 2023-03-30T20:14:50 https://maestrodatabase.com/blog/achieve-life-sciences-announces-submission-of-nda-to-fda-for-cytisinicline-as-a-treatment-of-nicotine-dependence-for-smoking-cessation 2025-06-27T04:00:17 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-treatments-for-obesity-management 2022-07-13T21:17:11 https://maestrodatabase.com/blog/expanded-access-to-subsidised-oral-antiviral-paxlovid-and-other-covid-19-supports 2023-03-30T20:03:35 https://maestrodatabase.com/blog/ema-recommends-approval-of-bimervax-as-a-covid-19-booster-vaccine 2023-03-30T20:08:16 https://maestrodatabase.com/blog/nice-terminates-appraisal-of-belimumab-for-new-indication 2022-07-13T21:20:18 https://maestrodatabase.com/blog/renovion-receives-fda-fast-track-designation-for-arina-1-for-the-prevention-of-bos-progression-in-lung-transplant-patients 2023-03-30T19:57:47 https://maestrodatabase.com/blog/new-pbs-listings-will-give-more-than-500-000-australians-cheaper-medicines 2019-09-30T05:40:03 https://maestrodatabase.com/blog/canada-making-progress-in-prescription-drug-coverage 2022-07-13T21:08:52 https://maestrodatabase.com/blog/moderna-provides-update-on-timing-of-u-dot-s-emergency-use-authorisation-of-its-covid-19-vaccine-for-adolescents 2021-11-02T09:57:41 https://maestrodatabase.com/blog/how-health-reimbursement-agreements-help-employers-expand-coverage-options-for-their-employees 2019-09-30T05:35:21 https://maestrodatabase.com/blog/nice-issues-final-guidance-on-the-use-of-risankizumab-for-psoriatic-arthritis 2022-07-13T21:12:32 https://maestrodatabase.com/blog/a-new-treatment-option-for-people-with-kidney-cancer 2017-07-10T07:59:07 https://maestrodatabase.com/blog/evenity-romosozumab-aqqg-now-available-in-the-united-states-for-the-treatment-of-osteoporosis-in-post-menopausal-women-at-high-risk-for-fracture 2019-04-16T05:46:29 https://maestrodatabase.com/blog/novavax-files-for-covid-19-vaccine-authorisation-with-health-canada-and-completes-submission-for-rolling-review-to-european-medicines-agency 2021-11-02T10:18:56 https://maestrodatabase.com/blog/fda-grants-priority-review-for-lillys-abemaciclib-for-the-treatment-of-advanced-breast-cancer 2017-07-10T11:54:06 https://maestrodatabase.com/blog/pharmacs-reduced-funding-for-epilepsy-drug-raises-concerns-over-driving-seizures 2019-09-30T11:02:46 https://maestrodatabase.com/blog/bayer-secures-approval-in-the-eu-for-xarelto-rivaroxaban-for-patients-with-coronary-or-peripheral-artery-disease 2018-08-27T05:05:03 https://maestrodatabase.com/blog/the-icer-developing-special-report-for-submission-to-cms-as-part-of-public-comment-process-on-medicare-drug-price-negotiations 2024-09-18T23:53:56 https://maestrodatabase.com/blog/interview-with-david-koch-on-channel-7s-sunrise 2019-09-30T09:28:45 https://maestrodatabase.com/blog/pricing-vaccines-and-drugs-in-europe-worth-differentiating 2021-11-02T20:20:07 https://maestrodatabase.com/blog/schroedinger-receives-fast-track-designation-for-sgr-1505-for-the-treatment-of-relapsed-slash-refractory-waldenstroems-macroglobulinemia 2025-06-27T23:03:09 https://maestrodatabase.com/blog/cheaper-medicine-for-over-500-000-patients 2019-09-30T09:23:21 https://maestrodatabase.com/blog/update-on-proposal-to-fund-a-pangenotypic-hepatitis-c-treatment---glecaprevir-and-pibrentasvir-maviret 2018-08-27T04:59:42 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-for-priority-review-bristol-myers-squibbs-application-for-sprycel-dasatinib-in-children-with-philadelphia-chromosome-positive-chronic-phase-chronic-myeloid-leukaemia 2017-07-10T11:57:39 https://maestrodatabase.com/blog/fda-grants-breakthrough-status-for-alzheimers-treatment 2021-11-02T20:25:05 https://maestrodatabase.com/blog/health-canada-approves-dupixent-as-the-first-biologic-for-the-treatment-of-adolescents-with-moderate-to-severe-atopic-dermatitis 2019-09-30T05:41:45 https://maestrodatabase.com/blog/smc---july-2017-decisions 2017-07-10T20:51:27 https://maestrodatabase.com/blog/gop-senators-suggest-bill-to-repeal-health-care-law-dead 2017-07-10T20:45:27 https://maestrodatabase.com/blog/delaware-to-regulate-multi-billion-dollar-pharmacy-benefit-manager-industry-protecting-consumers-and-local-businesses 2021-11-02T19:56:17 https://maestrodatabase.com/blog/novartis-receives-european-commission-approval-of-its-car-t-cell-therapy-kymriah-tisagenlecleucel 2018-08-27T05:20:06 https://maestrodatabase.com/blog/health-canada-authorises-enspryng-for-canadians-living-with-neuromyelitis-optica-spectrum-disorder 2020-09-01T02:24:58 https://maestrodatabase.com/blog/ive-worked-with-robert-califf-he-is-the-leader-the-fda-needs 2021-11-02T20:12:58 https://maestrodatabase.com/blog/fewer-issuers-apply-to-participate-in-health-insurance-exchanges-for-2018 2017-07-10T20:54:31 https://maestrodatabase.com/blog/can-washington-deliver-on-drug-costs-amid-impeachment-probe 2019-09-30T11:07:12 https://maestrodatabase.com/blog/democrats-reach-a-breakthrough-deal-on-drug-prices-as-spending-bill-nears-the-finish-line 2021-11-02T20:00:54 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-october-2019 2019-09-30T11:33:48 https://maestrodatabase.com/blog/sephience-sepiapterin-granted-marketing-authorisation-by-the-european-commission-for-the-treatment-of-children-and-adults-living-with-phenylketonuria 2025-06-27T12:04:03 https://maestrodatabase.com/blog/coronavirus-vaccine-before-election-unlikely----dr-gottlieb-on-fda-chiefs-possible-fast-track 2020-09-01T05:41:48 https://maestrodatabase.com/blog/abpi-applies-for-judicial-review-over-new-procedures-that-restrict-access-to-cost-effective-medicines 2017-07-10T20:59:18 https://maestrodatabase.com/blog/abbvie-announces-imbruvica-ibrutinib-plus-rituximab-approval-by-u-dot-s-fda-as-first-chemotherapy-free-combination-treatment-in-adults-with-waldenstroems-macroglobulinemia-a-rare-type-of-blood-cancer 2018-08-27T12:30:39 https://maestrodatabase.com/blog/1-october-2019-price-disclosure-confirmed-prices 2019-09-30T11:21:25 https://maestrodatabase.com/blog/astrazeneca-gets-approval-to-sell-chinas-first-ovarian-cancer-focused-drug 2018-08-27T06:12:09 https://maestrodatabase.com/blog/new-lung-cancer-drug-approved-for-routine-use-in-scotland 2017-07-10T21:13:44 https://maestrodatabase.com/blog/value-based-pricing-and-state-reform-of-prescription-drug-costs 2017-07-10T21:04:45 https://maestrodatabase.com/blog/new-treatment-for-pulmonary-arterial-hypertension-rejected-for-use-on-nhs 2017-07-10T21:16:20 https://maestrodatabase.com/blog/bupa-blunder-health-insurer-pays-price-for-restricting-hospital-options 2018-08-27T20:52:59 https://maestrodatabase.com/blog/imcheck-receives-fda-fast-track-designation-for-ict01-in-combination-with-azacitidine-and-venetoclax-in-first-line-acute-myeloid-leukaemia-for-patients-unfit-for-induction-chemotherapy-treatment 2024-09-19T00:00:07 https://maestrodatabase.com/blog/u-dot-s-fda-approves-invokana-canagliflozin-to-treat-diabetic-kidney-disease-and-reduce-the-risk-of-hospitalisation-for-heart-failure-in-patients-with-type-2-diabetes-and-diabetic-kidney-disease 2019-09-30T20:54:55 https://maestrodatabase.com/blog/amgen-submits-supplemental-new-drug-application-for-kyprolis-carfilzomib-once-weekly-70-mg-slash-m2-in-combination-with-dexamethasone 2018-08-27T20:57:08 https://maestrodatabase.com/blog/blood-cancer-treatment-approved-for-use-by-nhs-scotland 2017-07-10T21:27:26 https://maestrodatabase.com/blog/battling-cancer-and-fighting-for-funding 2018-08-27T20:47:50 https://maestrodatabase.com/blog/fda-issues-draft-guidance-on-patient-focused-drug-development-methods-to-identify-what-is-important-to-patients 2019-09-30T20:43:48 https://maestrodatabase.com/blog/harnessing-the-patient-voice-in-real-world-evidence-the-essential-role-of-patient-reported-outcomes 2019-09-30T20:41:24 https://maestrodatabase.com/blog/canada-secures-deals-for-up-to-114-million-doses-of-potential-covid-19-vaccines-from-u-dot-s-drug-companies 2020-09-01T03:13:17 https://maestrodatabase.com/blog/drug-industry-to-challenge-nice-over-new-cost-limits 2017-07-10T21:33:27 https://maestrodatabase.com/blog/imfinzi-approved-in-the-eu-for-the-treatment-of-extensive-stage-small-cell-lung-cancer 2020-09-01T06:27:39 https://maestrodatabase.com/blog/gilead-wins-6-dollars-million-deal-to-distribute-hiv-drug-it-donated 2019-09-30T21:07:37 https://maestrodatabase.com/blog/ai-needs-patients-voices-in-order-to-revolutionise-health-care 2019-09-30T21:04:22 https://maestrodatabase.com/blog/csl-to-fight-patent-infringement-claim-from-us-based-bioverativ 2017-07-10T21:36:17 https://maestrodatabase.com/blog/fda-approves-gamifant-emapalumab-lzsg-as-first-ever-treatment-for-adults-and-children-with-macrophage-activation-syndrome-in-stills-disease 2025-06-28T01:07:39 https://maestrodatabase.com/blog/tetraphase-pharmaceuticals-announces-fda-approval-of-xerava-eravacycline-for-complicated-intra-abdominal-infection 2018-08-27T21:13:20 https://maestrodatabase.com/blog/eli-lilly-ceo-why-consumers-are-key-to-bringing-down-health-care-costs 2018-08-27T21:40:01 https://maestrodatabase.com/blog/considering-the-side-effects-of-drug-makers-money-back-guarantees 2017-07-10T21:45:02 https://maestrodatabase.com/blog/when-medical-innovation-meets-politics 2018-08-27T21:44:58 https://maestrodatabase.com/blog/omeros-submits-narsoplimab-marketing-authorization-application-to-the-ema-for-the-treatment-of-ta-tma 2025-06-28T01:12:35 https://maestrodatabase.com/blog/fda-mandated-listing-of-drug-prices-in-ads-would-flunk-legal-and-constitutional-tests 2018-08-27T21:28:17 https://maestrodatabase.com/blog/vyxeos-receives-marketing-authorisation-in-the-european-union-for-treatment-of-certain-types-of-high-risk-acute-myeloid-leukaemia 2018-08-27T21:53:10 https://maestrodatabase.com/blog/concerns-over-single-brand-move-for-epilepsy-sufferers 2019-04-16T08:32:41 https://maestrodatabase.com/blog/ultragenyx-receives-breakthrough-therapy-designation-for-gtx-102-in-angelman-syndrome 2025-06-27T23:26:58 https://maestrodatabase.com/blog/roche-receives-fda-approval-for-first-hiv-1-slash-hiv-2-qualitative-test-on-the-cobas-6800-slash-8800-systems-in-the-fight-against-hiv-slash-aids 2020-09-01T12:38:34 https://maestrodatabase.com/blog/pembrolizumab-and-chemotherapy-with-or-without-bevacizumab-for-patients-with-persistent-recurrent-or-metastatic-cervical-cancer 2023-12-13T19:42:42 https://maestrodatabase.com/blog/new-formulation-of-entyvio-is-included-in-the-high-cost-protection-with-limitation 2020-09-01T12:41:35 https://maestrodatabase.com/blog/fda-accepts-vertexs-supplemental-new-drug-applications-for-trikafta-elexacaftor-slash-tezacaftor-slash-ivacaftor-and-ivacaftor-symdeko-tezacaftor-slash-ivacaftor-and-ivacaftor-and-kalydeco-ivacaftor-for-additional-cftr-mutations 2020-09-01T20:43:17 https://maestrodatabase.com/blog/biocon-biologics-receives-health-canada-approval-for-yesafili-aflibercept-first-global-launch-scheduled-for-july-2025 2025-06-28T02:21:28 https://maestrodatabase.com/blog/athenex-announces-fda-acceptance-for-filing-of-u-dot-s-nda-for-oral-paclitaxel-and-encequidar-in-metastatic-breast-cancer-with-priority-review 2020-09-01T12:33:37 https://maestrodatabase.com/blog/velmanase-alfa-for-the-treatment-of-patients-with-alfa-mannosidosis 2023-12-13T20:16:06 https://maestrodatabase.com/blog/alphabet-taps-former-fda-commissioner-to-oversee-health-strategy-and-policy 2019-09-30T21:45:30 https://maestrodatabase.com/blog/us-diabetes-patients-face-delays-as-insurers-tighten-ozempic-coverage 2023-12-13T20:11:00 https://maestrodatabase.com/blog/update-on-the-agenda-for-the-november-2020-pbac-meeting 2020-09-01T21:11:34 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-october-2019-update 2019-09-30T21:12:06 https://maestrodatabase.com/blog/fda-grants-alpheus-medical-orphan-drug-and-fast-track-designations-for-novel-sonodynamic-therapy-for-brain-cancer 2022-07-14T00:29:07 https://maestrodatabase.com/blog/akcea-steals-march-on-alnylam-with-nice-approval 2019-04-16T12:39:24 https://maestrodatabase.com/blog/hutchmed-announces-continued-inclusion-of-elunate-fruquintinib-and-sulanda-surufatinib-in-the-national-reimbursement-drug-list-in-china-at-current-terms 2023-12-13T20:02:22 https://maestrodatabase.com/blog/fda-approves-onureg-azacitidine-tablets-for-acute-myeloid-leukaemia 2020-09-01T20:55:21 https://maestrodatabase.com/blog/first-version-of-the-union-list-of-critical-medicines-agreed-to-help-avoid-potential-shortages-in-the-eu 2023-12-13T19:56:08 https://maestrodatabase.com/blog/japans-ministry-of-health-labour-and-welfare-accepts-arexvy-rsv-vaccine-regulatory-application-to-prevent-rsv-disease-in-adults-aged-50-59-at-increased-risk 2023-12-13T19:52:25 https://maestrodatabase.com/blog/emgality-is-included-in-the-high-cost-protection-with-limitation 2020-09-01T21:26:35 https://maestrodatabase.com/blog/glycomine-receives-fda-fast-track-designation-for-glm101-for-the-treatment-of-pmm2-cdg 2024-09-19T01:53:46 https://maestrodatabase.com/blog/trump-says-he-will-meet-with-drug-makers-this-week-over-pricing 2020-09-01T21:29:51 https://maestrodatabase.com/blog/draft-report-for-the-post-market-review-of-the-use-of-biologics-in-the-treatment-of-severe-chronic-plaque-psoriasis 2018-01-18T05:39:46 https://maestrodatabase.com/blog/cadth-publishes-final-outcome-for-new-medicine-for-patients-with-acquired-thrombotic-thrombocytopenic-purpura 2020-09-01T21:16:48 https://maestrodatabase.com/blog/pharmac-widens-access-for-covid-19-anti-viral-treatments 2022-07-14T03:05:05 https://maestrodatabase.com/blog/fda-to-launch-new-website-next-week 2019-04-16T20:40:14 https://maestrodatabase.com/blog/thousands-drop-private-health-insurance-after-questioning-its-value 2020-09-01T21:33:58 https://maestrodatabase.com/blog/yescarta-axicabtagene-ciloleucel-receives-european-marketing-authorisation-for-the-treatment-of-relapsed-or-refractory-dlbcl-and-pmbcl-after-two-or-more-lines-of-systemic-therapy 2018-08-28T01:59:56 https://maestrodatabase.com/blog/women-die-waiting-for-decision-on-pharmac-funding-for-breast-cancer-drugs 2019-04-16T20:32:46 https://maestrodatabase.com/blog/fda-approves-weekly-therapy-for-adult-growth-hormone-deficiency 2020-09-01T21:36:17 https://maestrodatabase.com/blog/cantex-pharmaceuticals-receives-fda-fast-track-designation-for-cx-01-for-the-treatment-of-patients-over-age-60-with-newly-diagnosed-acute-myeloid-leukaemia 2018-08-28T01:39:46 https://maestrodatabase.com/blog/department-of-health-and-social-care-seeks-new-chair-to-lead-nice-board 2019-06-19T09:42:03 https://maestrodatabase.com/blog/azitra-receives-fast-track-designation-for-atr-04-for-skin-rash-from-egfr-inhibitors 2024-09-19T02:10:20 https://maestrodatabase.com/blog/recordati-to-seek-canadian-approval-for-kidney-disease-drug 2019-04-16T21:00:10 https://maestrodatabase.com/blog/valneva-submits-label-extension-applications-for-its-chikungunya-vaccine-ixchiq-to-ema-and-health-canada 2024-09-19T02:47:57 https://maestrodatabase.com/blog/fda-agrees-to-rolling-review-of-mesoblasts-biologic-licence-application-for-its-cell-therapy-in-children-with-steroid-refractory-acute-graft-versus-host-disease 2019-04-16T20:44:00 https://maestrodatabase.com/blog/bach-co-authors-call-for-regulated-pricing-for-biologics-as-an-alternative-to-biosimilars 2019-04-16T21:15:03 https://maestrodatabase.com/blog/new-genetic-therapies-in-cancer-treatment-could-impact-benefits-plans 2019-04-16T21:07:36 https://maestrodatabase.com/blog/aspyrian-therapeutics-announces-successful-advances-in-rm-1929-clinical-development-in-recurrent-head-and-neck-cancer-including-fast-track-designation-granted-by-the-fda 2018-01-18T06:45:48 https://maestrodatabase.com/blog/democrats-feud-over-drug-pricing-policy-as-progressives-push-pragmatists-to-be-bolder 2019-04-16T21:04:25 https://maestrodatabase.com/blog/fda-approves-addition-of-overall-survival-data-to-kyprolis-carfilzomib-label 2018-01-18T06:59:05 https://maestrodatabase.com/blog/ultragenyx-announces-approval-of-mepsevii-vestronidase-alfa-in-europe-for-the-treatment-of-mucopolysaccharidosis-vii 2018-08-28T02:48:53 https://maestrodatabase.com/blog/department-of-health-tweaks-agenda-for-this-weeks-pbac-meeting 2021-11-03T01:13:00 https://maestrodatabase.com/blog/aprea-therapeutics-receives-fda-fast-track-designation-and-orphan-drug-designation-for-apr-246-for-the-treatment-of-myelodysplastic-syndromes 2019-04-16T21:25:40 https://maestrodatabase.com/blog/labor-to-fast-track-leukaemia-drug-trials 2019-04-16T21:20:24 https://maestrodatabase.com/blog/program-to-protect-sa-newborns-from-rsv 2024-09-19T03:15:11 https://maestrodatabase.com/blog/health-canada-issues-notice-of-compliance-for-jardiance-empagliflozin-for-the-treatment-of-heart-failure-with-reduced-ejection-fraction 2021-11-03T01:40:22 https://maestrodatabase.com/blog/out-of-pocket-pain---share-your-experience 2018-01-18T19:51:48 https://maestrodatabase.com/blog/amylyx-pharmaceuticals-submits-new-drug-application-for-amx0035-for-the-treatment-of-als 2021-11-03T01:23:21 https://maestrodatabase.com/blog/lyric-pharma-granted-fda-fast-track-designation-for-lead-product-ulimorelen-for-enteral-feeding-intolerance 2018-01-18T07:40:51 https://maestrodatabase.com/blog/law-makers-weigh-measure-to-fight-high-drug-prices 2018-01-18T20:16:00 https://maestrodatabase.com/blog/opdivo-receives-two-new-health-canada-approvals 2021-11-03T02:03:21 https://maestrodatabase.com/blog/cancer-researcher-david-thomas-says-more-should-be-done-attract-big-pharma 2021-04-18T20:54:22 https://maestrodatabase.com/blog/early-benefit-assessments-the-220th-dossier-evaluation-completed-at-the-turn-of-the-year 2018-01-18T20:03:07 https://maestrodatabase.com/blog/fed-up-with-drug-companies-hospitals-decide-to-start-their-own 2018-01-18T20:07:35 https://maestrodatabase.com/blog/democrats-revive-drug-pricing-reform-with-a-narrow-set-of-proposed-measures 2021-11-03T02:09:28 https://maestrodatabase.com/blog/loxo-oncology-announces-submission-of-european-marketing-authorisation-application-for-larotrectinib 2018-08-28T04:17:24 https://maestrodatabase.com/blog/vaccines-for-over-50s-to-be-brought-forward-as-national-cabinet-reconfigures-rollout 2021-04-18T20:50:33 https://maestrodatabase.com/blog/president-biden-announces-prescription-drug-pricing-plan-in-build-back-better-framework 2021-11-03T09:32:50 https://maestrodatabase.com/blog/fda-approves-eflornithine-for-adult-and-paediatric-patients-with-high-risk-neuroblastoma 2023-12-14T02:36:16 https://maestrodatabase.com/blog/major-pharmac-review-delayed-nearly-3-months 2021-11-03T06:02:22 https://maestrodatabase.com/blog/akcea-and-ionis-receive-complete-response-letter-for-waylivra-from-fda 2018-08-28T05:04:36 https://maestrodatabase.com/blog/greg-hunt-confirms-high-interest-in-producing-mrna-vaccines-onshore 2021-04-18T21:12:30 https://maestrodatabase.com/blog/kyverna-therapeutics-granted-fda-fast-track-designation-for-kyv-101-in-the-treatment-of-patients-with-refractory-myasthenia-gravis 2023-12-14T00:18:49 https://maestrodatabase.com/blog/avrobio-receives-rare-paediatric-disease-designation-from-the-u-dot-s-fda-for-avr-rd-05-a-gene-therapy-for-mucopolysaccharidosis-type-ii-or-hunter-syndrome 2021-11-03T19:54:23 https://maestrodatabase.com/blog/government-makes-a-mockery-of-pharmac-review 2021-11-03T09:55:49 https://maestrodatabase.com/blog/allena-pharmaceuticals-receives-fast-track-designation-from-fda-for-the-development-of-alln-346-for-chronic-treatment-of-hyperuricemia-in-patients-with-gout-and-advanced-chronic-kidney-disease 2021-11-03T19:50:07 https://maestrodatabase.com/blog/fda-grants-priority-review-to-amgens-tarlatamab-application-for-advanced-small-cell-lung-cancer 2023-12-14T02:43:49 https://maestrodatabase.com/blog/valeo-pharma-obtains-public-reimbursement-for-enerzair-breezhaler-and-atectura-breezhaler-in-alberta 2021-11-03T20:15:02 https://maestrodatabase.com/blog/bayer-donates-8-million-chloroquine-tablets-to-the-german-federal-government 2020-04-17T08:56:13 https://maestrodatabase.com/blog/america-can-afford-a-world-class-health-care-system-why-dont-we-have-one 2020-04-17T11:49:18 https://maestrodatabase.com/blog/phrma-statement-on-democrats-drug-pricing-deal-in-reconciliation-package 2021-11-03T20:22:12 https://maestrodatabase.com/blog/chi-med-announces-surufatinib-granted-u-dot-s-fda-fast-track-designations-for-the-treatment-of-both-pancreatic-and-non-pancreatic-neuroendocrine-tumours 2020-04-17T12:04:34 https://maestrodatabase.com/blog/zai-lab-announces-acceptance-by-chinas-nmpa-of-the-bla-for-efgartigimod-for-patients-with-generalised-myasthenia-gravis 2022-07-14T07:08:45 https://maestrodatabase.com/blog/transthera-receives-fast-track-designation-from-fda-for-its-core-product-tt-00420-to-treat-cholangiocarcinoma 2021-11-03T20:02:50 https://maestrodatabase.com/blog/nice-says-no-to-gileads-yescarta-in-draft-guidelines 2018-08-28T08:43:32 https://maestrodatabase.com/blog/coverage-is-available-for-covid-19-vaccinations-for-eligible-children-ages-5-through-11 2021-11-03T20:09:40 https://maestrodatabase.com/blog/the-coronavirus-is-mutating-what-does-that-mean-for-a-vaccine 2020-04-17T08:51:06 https://maestrodatabase.com/blog/feedback-encouraged-to-allow-use-of-life-extending-treatment-on-nhs-for-those-with-blood-cancer 2018-08-28T12:31:43 https://maestrodatabase.com/blog/mhra-supports-launch-of-innovate-uks-first-of-its-kind-initiative-to-fund-new-regulatory-science-and-innovation-networks 2023-12-14T20:04:44 https://maestrodatabase.com/blog/co-ordinated-clinical-trials-could-help-more-australians 2018-08-28T21:04:44 https://maestrodatabase.com/blog/us-fda-updates-ldl-c-lowering-indication-for-esperions-nexletol-bempedoic-acid-tablet-and-nexlizet-bempedoic-acid-and-ezetimibe-tablet 2023-12-14T19:56:17 https://maestrodatabase.com/blog/ottawas-drug-pricing-changes-threaten-canadians-who-suffer-from-rare-diseases 2018-08-28T21:14:44 https://maestrodatabase.com/blog/trastuzumab-deruxtecan-type-ii-variation-application-validated-by-ema-for-the-treatment-of-her2-positive-advanced-gastric-cancer 2021-11-03T20:31:11 https://maestrodatabase.com/blog/she-paid-3-dollars-47-cents-for-a-prescription-drug-the-retail-price-was-10-000-percent-higher 2018-08-28T21:19:31 https://maestrodatabase.com/blog/glaukos-announces-fda-approval-of-idose-tr-travoprost-intracameral-implant 2023-12-14T19:51:19 https://maestrodatabase.com/blog/cabometyx-gets-nice-recommendation-in-renal-cell-carcinoma 2018-08-28T21:07:56 https://maestrodatabase.com/blog/cms-releases-revised-guidance-for-medicare-prescription-drug-inflation-rebate-program 2023-12-14T19:44:53 https://maestrodatabase.com/blog/nice-releases-guidance-on-medicine-for-patients-with-thyroid-cancer 2021-11-03T20:36:57 https://maestrodatabase.com/blog/pfizer-calls-for-fda-guidance-to-address-false-and-misleading-biosimilar-advertisements 2018-08-28T21:30:10 https://maestrodatabase.com/blog/nice-recommends-piqray-and-trodelvy-maintaining-100-percent-approvals-of-breast-cancer-drugs-since-2018 2022-07-14T10:49:52 https://maestrodatabase.com/blog/pbms-are-hogging-our-drug-discounts 2018-08-28T21:21:30 https://maestrodatabase.com/blog/you-may-start-seeing-drug-prices-in-ads-but-will-you-understand-the-point 2018-08-28T21:24:34 https://maestrodatabase.com/blog/mirum-pharmaceuticals-initiates-rolling-submission-of-a-new-drug-application-for-maralixibat-for-the-treatment-of-cholestatic-pruritus-in-patients-with-alagille-syndrome-and-launches-expanded-access-program 2020-09-02T02:10:14 https://maestrodatabase.com/blog/antengene-announces-inclusion-of-xpovio-selinexor-in-2023-chinas-national-reimbursement-drug-list 2023-12-14T20:09:07 https://maestrodatabase.com/blog/data-enclaves-for-sharing-information-derived-from-clinical-and-administrative-data 2018-08-28T21:36:14 https://maestrodatabase.com/blog/comparison-of-two-treatment-models-precision-medicine-and-preventive-medicine 2018-08-28T21:39:42 https://maestrodatabase.com/blog/covid-19-vaccine-safety-report-14-july-2022 2022-07-14T21:01:03 https://maestrodatabase.com/blog/fda-approves-crizotinib-for-alk-positive-inflammatory-myofibroblastic-tumour 2022-07-14T21:04:26 https://maestrodatabase.com/blog/roxadustat-for-treating-symptomatic-anaemia-in-chronic-kidney-disease 2022-07-14T20:55:24 https://maestrodatabase.com/blog/revolo-biotherapeutics-awarded-innovation-passport-for-1805-in-the-united-kingdom-for-the-treatment-of-moderate-to-severe-rheumatoid-arthritis 2022-07-14T20:50:23 https://maestrodatabase.com/blog/beigene-provides-regulatory-update-on-the-u-dot-s-biologics-license-application-for-pd-1-inhibitor-tislelizumab-in-second-line-oesophageal-squamous-cell-carcinoma 2022-07-14T10:54:03 https://maestrodatabase.com/blog/breakthrough-treatment-to-boost-life-chances-for-hundreds-of-people-with-respiratory-cancer 2022-07-14T21:24:00 https://maestrodatabase.com/blog/fda-clears-dyansys-neurostimulation-device-first-relief-to-treat-diabetic-neuropathic-pain 2022-07-14T21:20:42 https://maestrodatabase.com/blog/apellis-provides-update-on-on-going-regulatory-review-of-pegcetacoplan-for-ga-in-the-european-union 2023-12-14T21:42:41 https://maestrodatabase.com/blog/increasing-access-to-new-treatments-for-special-patient-populations 2019-04-17T01:16:32 https://maestrodatabase.com/blog/thousands-of-patients-to-benefit-as-nhs-marks-100th-fast-tracked-cancer-drug 2022-07-14T21:12:43 https://maestrodatabase.com/blog/eylea-8-mg-with-extended-6-month-treatment-interval-approved-in-the-eu 2025-06-28T23:47:34 https://maestrodatabase.com/blog/marinus-pharmaceuticals-sells-rare-paediatric-disease-priority-review-voucher-for-110-dollars-million 2022-07-14T21:30:07 https://maestrodatabase.com/blog/ultragenyx-announces-ux007-granted-fast-track-designation-and-rare-pediatric-disease-designation-by-u-dot-s-fda-for-treatment-of-long-chain-fatty-acid-oxidation-disorders 2019-04-17T06:39:28 https://maestrodatabase.com/blog/crispr-therapeutics-and-vertex-announce-fda-fast-track-designation-for-ctx001-for-the-treatment-of-beta-thalassemia 2019-04-17T06:34:54 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-4-november-2021 2021-11-04T04:52:06 https://maestrodatabase.com/blog/a-breakthrough-treatment-for-cystic-fibrosis-needs-funding-now 2021-11-04T05:03:04 https://maestrodatabase.com/blog/icer-posts-draft-scoping-document-for-the-assessment-of-treatments-for-cystic-fibrosis 2019-10-01T02:20:47 https://maestrodatabase.com/blog/fda-declines-to-approve-vandas-marketing-application-for-tradipitant-in-gastroparesis 2024-09-19T21:02:27 https://maestrodatabase.com/blog/drug-maker-raises-u-dot-s-price-of-muscular-dystrophy-treatment 2018-01-19T05:44:56 https://maestrodatabase.com/blog/avion-pharmaceuticals-announces-approval-of-first-nda-in-the-oral-contraceptive-category 2018-01-19T04:02:01 https://maestrodatabase.com/blog/european-commission-approves-amgen-and-allergans-mvasi-biosimilar-bevacizumab-for-the-treatment-of-certain-types-of-cancer 2018-01-19T06:25:20 https://maestrodatabase.com/blog/aquestive-therapeutics-announces-u-dot-s-fda-filing-acceptance-of-new-drug-application-for-clobazam-oral-soluble-film-to-treat-lennox-gastaut-syndrome 2018-01-19T06:57:40 https://maestrodatabase.com/blog/geron-announces-fast-track-designation-granted-to-imetelstat-for-relapsed-slash-refractory-myelofibrosis 2019-10-01T03:12:50 https://maestrodatabase.com/blog/daiichi-sankyos-vanflyta-recommended-by-nice-for-acute-myeloid-leukaemia 2024-09-19T21:22:04 https://maestrodatabase.com/blog/symbicort-turbuhaler-now-approved-by-health-canada-for-use-in-mild-persistent-moderate-or-severe-asthma 2019-10-01T03:48:52 https://maestrodatabase.com/blog/fda-approves-first-new-drug-under-international-collaboration-a-treatment-option-for-patients-with-her2-positive-metastatic-breast-cancer 2020-04-17T23:24:19 https://maestrodatabase.com/blog/abbisko-therapeutics-announces-that-us-fda-has-granted-fast-track-designation-for-its-csf-1r-inhibitor-pimicotinib-absk021 2023-12-15T00:04:56 https://maestrodatabase.com/blog/ultragenyx-and-kyowa-kirin-announce-u-dot-s-fda-approves-label-update-for-crysvita-burosumab-for-the-treatment-of-x-linked-hypophosphataemia 2019-10-01T05:08:13 https://maestrodatabase.com/blog/radio-personality-michael-kooge-says-hes-being-left-to-die-as-he-cant-afford-cancer-treatment 2019-10-01T03:53:30 https://maestrodatabase.com/blog/fda-approves-first-targeted-treatment-for-patients-with-cholangiocarcinoma-a-cancer-of-bile-ducts 2020-04-17T23:42:43 https://maestrodatabase.com/blog/fees-for-redeeming-priority-review-vouchers-fall-to-all-time-low-in-fy2020 2019-10-01T05:13:53 https://maestrodatabase.com/blog/csls-garadacimab-a-first-in-class-factor-xiia-inhibitor-receives-fda-and-ema-filing-acceptance 2023-12-15T01:11:08 https://maestrodatabase.com/blog/funding-hole-makes-cracking-covid-19-vaccine-code-a-tougher-ask 2021-11-04T10:32:54 https://maestrodatabase.com/blog/fda-approves-amivantamab-vmjw-with-carboplatin-and-pemetrexed-for-non-small-cell-lung-cancer-with-egfr-exon-19-deletions-or-l858r-mutations 2024-09-19T22:21:41 https://maestrodatabase.com/blog/duzallo-a-fixed-dose-combination-therapy-for-gout-approved-in-europe 2018-08-29T05:38:38 https://maestrodatabase.com/blog/familys-appeal-to-fund-lifesaving-us-cancer-treatment-for-6-year-old-nora 2019-10-01T06:17:09 https://maestrodatabase.com/blog/union-therapeutics-receives-fda-fast-track-designation-for-oral-orismilast-for-the-treatment-of-moderate-to-severe-atopic-dermatitis 2021-11-04T10:59:33 https://maestrodatabase.com/blog/icer-publishes-evidence-report-on-tezepelumab-for-severe-asthma 2021-11-04T19:51:48 https://maestrodatabase.com/blog/nice-recommends-namuscla-for-nhs-to-treat-genetic-disorder 2021-11-04T19:48:15 https://maestrodatabase.com/blog/epizyme-receives-fast-track-designation-from-u-dot-s-fda-and-announces-initiation-of-phase-1-slash-1b-study-of-its-novel-setd2-inhibitor-ezm0414 2021-11-04T10:56:11 https://maestrodatabase.com/blog/tectraums-pro2cool-receives-fda-designation-as-a-breakthrough-device-for-the-treatment-of-concussions 2021-11-04T10:52:37 https://maestrodatabase.com/blog/covid-19-government-funds-$276m-for-ppe-pharmac-and-residential-aged-care 2020-04-17T23:53:57 https://maestrodatabase.com/blog/finding-effective-treatments-for-covid-19-scientific-integrity-and-public-confidence-in-a-time-of-crisis 2020-04-18T01:21:18 https://maestrodatabase.com/blog/impact-of-medicare-only-limits-on-drug-prices 2021-11-04T20:04:00 https://maestrodatabase.com/blog/nih-to-launch-public-private-partnership-to-speed-covid-19-vaccine-and-treatment-options 2020-04-18T01:27:50 https://maestrodatabase.com/blog/os-therapies-receives-rare-paediatric-disease-designation-in-osteosarcoma-for-ost-her2-listeria-monocytogenes 2021-11-04T20:09:57 https://maestrodatabase.com/blog/lipocine-announces-fda-grants-fast-track-designation-to-lpcn-1144-for-treatment-of-non-cirrhotic-nash 2021-11-04T19:59:38 https://maestrodatabase.com/blog/libtayo-cemiplimab-approved-in-canada-for-the-first-line-treatment-of-adult-patients-with-non-small-cell-lung-cancer-expressing-pd-l1-in-50-percent-of-tumour-cells-with-no-egfr-alk-or-ros1-aberrations 2021-11-04T20:43:15 https://maestrodatabase.com/blog/abrysvo-pfizer-canadas-newly-publicly-funded-vaccine-a-step-towards-national-rsv-prevention-in-older-adults 2024-09-20T01:37:21 https://maestrodatabase.com/blog/proposal-to-move-to-one-funded-brand-of-lamotrigine-logem 2018-08-29T06:24:05 https://maestrodatabase.com/blog/greg-hunt-australia-now-leading-the-race-for-a-vaccine 2020-04-18T02:45:56 https://maestrodatabase.com/blog/libtayo-cemiplimab-approved-in-canada-for-locally-advanced-basal-cell-carcinoma-patients 2021-11-04T20:16:11 https://maestrodatabase.com/blog/tga-approves-illuccix-for-prostate-cancer-imaging 2021-11-04T20:31:29 https://maestrodatabase.com/blog/pegzilarginase-for-the-treatment-of-patients-2-years-of-age-and-older-with-arginase-1-deficiency 2025-06-29T04:28:55 https://maestrodatabase.com/blog/what-to-watch-for-as-novartis-heads-to-the-fda-with-a-novel-cancer-therapy 2017-07-11T08:15:41 https://maestrodatabase.com/blog/fda-speeding-generic-drug-approvals-not-just-lip-service 2017-07-11T08:11:19 https://maestrodatabase.com/blog/uk-approval-for-msd-slash-ridgebacks-covid-19-anti-viral-medicine 2021-11-04T20:19:11 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-posts-draft-scoping-document-on-voretigene-neparvovec-first-gene-therapy-submitted-for-fda-approval 2017-07-11T08:20:41 https://maestrodatabase.com/blog/ema-seeks-views-of-public-during-its-safety-review-of-valproate 2017-07-11T13:17:19 https://maestrodatabase.com/blog/tga-to-be-one-stop-shop-for-complaints 2017-07-11T08:26:31 https://maestrodatabase.com/blog/nice-green-light-for-immunotherapy-bavencio 2020-09-02T09:24:27 https://maestrodatabase.com/blog/health-reform-both-real-and-conservative 2017-07-11T21:19:56 https://maestrodatabase.com/blog/gop-struggles-to-revamp-ailing-obamacare-repeal-bill 2017-07-11T21:11:00 https://maestrodatabase.com/blog/opiant-receives-fda-fast-track-designation-for-opnt003-nasal-nalmefene-for-treatment-of-opioid-overdose 2021-11-04T20:51:18 https://maestrodatabase.com/blog/bavarian-nordic-receives-ema-approval-of-mpox-vaccine-for-adolescents 2024-09-20T01:56:46 https://maestrodatabase.com/blog/first-gene-therapy----a-true-living-drug----on-the-cusp-of-fda-approval 2017-07-11T21:24:32 https://maestrodatabase.com/blog/the-donald-piles-on-the-pressure-for-health-reform-bill 2017-07-11T21:38:11 https://maestrodatabase.com/blog/namuscla-is-granted-a-temporary-subsidy 2020-09-02T12:34:46 https://maestrodatabase.com/blog/two-recent-scientific-advances-underscore-an-encouraging-future-for-precision-medicine-at-fda 2017-07-11T21:30:37 https://maestrodatabase.com/blog/talazoparib-in-breast-cancer-hint-of-considerable-added-benefit 2020-09-02T12:45:17 https://maestrodatabase.com/blog/novo-launches-type-2-diabetes-pill-in-uk-after-nice-waives-review 2020-09-02T09:42:48 https://maestrodatabase.com/blog/the-fda-should-shine-more-light-on-drug-rejections 2018-01-20T02:03:57 https://maestrodatabase.com/blog/house-oversight-democrats-to-subpoena-abbvie-in-drug-pricing-probe 2020-09-02T12:29:07 https://maestrodatabase.com/blog/u-dot-s-fda-grants-priority-review-for-daratumumab-in-front-line-multiple-myeloma 2018-01-20T07:32:14 https://maestrodatabase.com/blog/nice-terminates-yet-another-assessment-of-a-new-cancer-medicine 2020-09-02T21:14:48 https://maestrodatabase.com/blog/who-touts-steroids-as-effective-treatment-to-combat-covid-19 2020-09-02T21:31:23 https://maestrodatabase.com/blog/23-attorneys-general-urge-fda-to-ensure-affordable-access-to-insulin 2020-09-02T21:43:08 https://maestrodatabase.com/blog/european-commission-approves-second-indication-of-sarclisa-isatuximab-for-relapsed-multiple-myeloma 2021-04-19T05:06:42 https://maestrodatabase.com/blog/chief-medical-officers-statement-on-standard-of-care-on-covid-19-oral-antiviral-treatments-in-residential-aged-care-facilities 2022-07-15T03:21:23 https://maestrodatabase.com/blog/tga-announces-it-has-approved-yescarta 2020-09-02T20:56:31 https://maestrodatabase.com/blog/ema-receives-application-for-marketing-authorisation-of-dexamethasone-taw-for-covid-19 2020-09-02T21:01:53 https://maestrodatabase.com/blog/astrazeneca-provides-an-update-on-us-regulatory-review-of-pt010-in-copd 2019-10-01T10:48:19 https://maestrodatabase.com/blog/variation-in-prescription-drug-prices-by-retail-pharmacy-type-a-national-cross-sectional-study 2019-10-01T10:42:21 https://maestrodatabase.com/blog/nice-unable-to-assess-new-indication-for-soliris 2020-09-02T21:06:56 https://maestrodatabase.com/blog/tga-approves-grifols-xembify 2022-07-15T04:42:41 https://maestrodatabase.com/blog/biocryst-and-the-pan-canadian-pharmaceutical-alliance-successfully-complete-negotiations-for-orladeyo-berotralstat-an-oral-once-daily-therapy-for-the-prevention-of-hereditary-angioedema-attacks 2024-09-20T03:05:29 https://maestrodatabase.com/blog/health-canada-authorises-use-of-moderna-covid-19-vaccine-in-children-6-months-to-5-years-of-age 2022-07-15T05:21:50 https://maestrodatabase.com/blog/fda-grants-full-approval-for-blincyto-blinatumomab-to-treat-relapsed-or-refractory-b-cell-precursor-acute-lymphoblastic-leukaemia-in-adults-and-children 2017-07-12T01:34:33 https://maestrodatabase.com/blog/cancer-medicines-need-to-be-part-of-the-plan 2019-10-01T20:32:29 https://maestrodatabase.com/blog/fda-informs-patients-providers-and-manufacturers-about-potential-cybersecurity-vulnerabilities-for-connected-medical-devices-and-health-care-networks-that-use-certain-communication-software 2019-10-01T20:24:30 https://maestrodatabase.com/blog/us-food-and-drug-administration-review-of-statistical-analysis-of-patient-reported-outcomes-in-lung-cancer-clinical-trials-approved-between-january-2008-and-december-2017 2019-10-01T20:21:36 https://maestrodatabase.com/blog/why-transparency-in-drug-pricing-is-more-complicated-than-it-seems 2019-10-01T20:53:17 https://maestrodatabase.com/blog/european-commission-approves-novartis-combination-therapy-tafinlar-and-mekinist-for-adjuvant-treatment-of-braf-v600-mutation-positive-melanoma 2018-08-29T07:41:15 https://maestrodatabase.com/blog/heron-therapeutics-resubmits-new-drug-application-to-fda-for-htx-011-for-the-management-of-post-operative-pain 2019-10-01T20:37:57 https://maestrodatabase.com/blog/novartis-and-microsoft-announce-collaboration-to-transform-medicine-with-artificial-intelligence 2019-10-01T21:02:51 https://maestrodatabase.com/blog/pelosis-drug-pricing-plan-could-wipe-out-some-key-funding-for-low-income-hospitals 2019-10-01T20:57:46 https://maestrodatabase.com/blog/seagen-and-astellas-announce-u-dot-s-fda-acceptance-of-two-supplemental-biologics-license-applications-for-padcev-enfortumab-vedotin-ejfv-in-locally-advanced-or-metastatic-urothelial-cancer 2021-04-19T12:56:28 https://maestrodatabase.com/blog/nice-launches-ambitious-strategy-to-provide-quicker-access-to-new-treatments-and-innovations 2021-04-19T12:51:14 https://maestrodatabase.com/blog/alk-gains-paediatric-approval-for-its-ragweed-slit-tablet-in-the-usa 2021-04-19T20:39:27 https://maestrodatabase.com/blog/fosdenopterin-hydrobromide-for-the-treatment-of-patients-molybdenum-cofactor-deficiency-type-a 2024-09-20T05:37:14 https://maestrodatabase.com/blog/prescription-drug-costs-are-spiralling-but-price-controls-are-the-wrong-solution 2020-04-18T22:41:30 https://maestrodatabase.com/blog/ema-publishes-agenda-for-19-22-april-2022-chmp-meeting 2022-04-19T10:00:29 https://maestrodatabase.com/blog/a-12-week-sprint-pm-flags-plan-to-vaccinate-under-50s-in-lead-up-to-christmas 2021-04-19T08:43:41 https://maestrodatabase.com/blog/canada-confirms-second-blood-clot-case-linked-to-astrazeneca-coronavirus-vaccine-but-it-will-be-used-to-battle-third-wave 2021-04-19T21:01:38 https://maestrodatabase.com/blog/darzalex-sc-becomes-the-first-and-only-health-canada-approved-treatment-for-patients-with-newly-diagnosed-light-chain-amyloidosis-a-rare-disease 2021-04-19T21:06:55 https://maestrodatabase.com/blog/agenus-submits-balstilimab-biologics-license-application-to-the-u-dot-s-fda-for-patients-with-recurrent-or-metastatic-cervical-cancer 2021-04-19T20:42:38 https://maestrodatabase.com/blog/outcome-statement---february-2023-dusc-meeting 2023-04-01T01:30:29 https://maestrodatabase.com/blog/cheap-chinese-immune-checkpoint-inhibitors-may-shake-global-oncology-market 2021-04-19T20:55:10 https://maestrodatabase.com/blog/united-therapeutics-announces-submission-of-tvyaso-dpi-new-drug-application-to-fda 2021-04-19T20:50:12 https://maestrodatabase.com/blog/fauci-says-he-expects-a-decision-friday-on-whether-the-u-dot-s-can-resume-using-johnson-and-johnsons-vaccine 2021-04-19T21:24:04 https://maestrodatabase.com/blog/abbvie-receives-positive-chmp-opinion-for-mirvetuximab-soravtansine-elahere-for-the-treatment-of-certain-adult-ovarian-cancer 2024-09-20T21:21:26 https://maestrodatabase.com/blog/the-mother-of-three-on-her-last-chance-to-beat-blood-cancer 2020-09-03T02:11:27 https://maestrodatabase.com/blog/mystery-of-2-dot-7-million-missing-vaccine-doses 2021-04-19T21:20:08 https://maestrodatabase.com/blog/biologic-patent-thickets-and-terminal-disclaimers 2023-12-15T06:58:08 https://maestrodatabase.com/blog/fda-issues-final-rule-removing-certain-software-from-medical-device-regulations 2021-04-19T21:39:27 https://maestrodatabase.com/blog/pbac-public-summary-documents-first-time-rejections-and-deferrals---march-2022-meeting 2022-07-15T06:26:03 https://maestrodatabase.com/blog/citrine-medicine-and-sinopharm-group-announce-strategic-partnership-to-broaden-and-accelerate-access-to-rare-disease-drugs-in-china 2021-04-19T21:11:34 https://maestrodatabase.com/blog/changes-to-vaccine-rollout-redirect-doses-unused-by-younger-people-to-over-50s 2021-04-19T21:17:34 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-april-2023 2023-04-01T02:13:17 https://maestrodatabase.com/blog/csl-behrings-hemgenix-granted-first-ever-direct-access-in-france-for-haemophilia-b-gene-therapy 2023-12-15T07:26:12 https://maestrodatabase.com/blog/monkeypox-patients-should-not-be-left-to-suffer-when-an-fda-approved-drug-could-help 2022-07-16T00:22:19 https://maestrodatabase.com/blog/developing-tools-to-support-digital-health-and-medtech-innovation 2018-08-29T11:13:00 https://maestrodatabase.com/blog/fda-approves-first-treatment-for-niemann-pick-disease-type-c 2024-09-20T21:50:02 https://maestrodatabase.com/blog/towards-improving-the-availability-of-medicines-in-the-eu 2018-08-29T12:23:28 https://maestrodatabase.com/blog/uk-lags-behind-eu-in-authorising-new-medicines-after-brexit 2022-07-15T08:04:36 https://maestrodatabase.com/blog/highlights-from-the-27---30-march-2023-chmp-meeting 2023-04-01T03:49:05 https://maestrodatabase.com/blog/life-changing-drug-spinraza-for-spinal-muscular-atrophy-patients-costing-adults-at-least-500-000-dollars 2018-08-29T20:55:25 https://maestrodatabase.com/blog/b-dot-c-to-sue-opioid-makers-for-health-care-expenses-of-overdose-crisis 2018-08-29T11:21:30 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-april-2023 2023-04-01T03:20:21 https://maestrodatabase.com/blog/fda-launches-new-pilot-to-advance-innovative-clinical-trial-designs-as-part-of-agencys-broader-program-to-modernise-drug-development-and-promote-innovation-in-drugs-targeted-to-unmet-needs 2018-08-29T21:09:31 https://maestrodatabase.com/blog/patients-being-bled-by-specialists-as-out-of-pocket-costs-surge 2018-08-29T21:02:43 https://maestrodatabase.com/blog/surprise-trump-might-actually-lower-drug-prices 2018-08-29T21:19:54 https://maestrodatabase.com/blog/fda-approves-belzutifan-for-advanced-renal-cell-carcinoma 2023-12-15T08:00:07 https://maestrodatabase.com/blog/evolus-receives-acceptance-of-fda-bla-resubmission-for-dwp-450 2018-08-29T21:13:19 https://maestrodatabase.com/blog/fda-pushes-for-development-of-non-opioid-pain-medications 2018-08-29T21:17:29 https://maestrodatabase.com/blog/polpharma-biologics-announces-ema-acceptance-of-marketing-authorisation-application-for-proposed-biosimilar-natalizumab 2022-07-16T02:00:11 https://maestrodatabase.com/blog/cms-provides-new-flexibility-to-increase-prescription-drug-choices-and-strengthen-negotiation-for-medicare-enrollees 2018-08-29T21:26:51 https://maestrodatabase.com/blog/cancer-charities-dismayed-after-new-generation-therapy-rejected-as-too-expensive 2018-08-29T21:33:28 https://maestrodatabase.com/blog/amgens-investigational-targeted-treatment-bemarituzumab-granted-breakthrough-therapy-designation 2021-04-20T00:17:57 https://maestrodatabase.com/blog/u-dot-k-mhra-grants-meeting-to-cytodyn-to-discuss-fast-track-approval-of-leronlimab-for-covid-19-patients 2020-09-03T04:37:45 https://maestrodatabase.com/blog/astrazeneca-canada-files-for-health-canada-authorisation-of-azd7442-for-prevention-of-covid-19 2021-11-05T05:12:11 https://maestrodatabase.com/blog/fda-approves-isatuximab-irfc-with-bortezomib-lenalidomide-and-dexamethasone-for-newly-diagnosed-multiple-myeloma 2024-09-20T22:47:45 https://maestrodatabase.com/blog/icer-finds-current-list-price-of-patisiran-for-amyloidosis-far-exceeds-standard-cost-effectiveness-levels 2018-08-30T01:25:14 https://maestrodatabase.com/blog/theratechnologies-files-marketing-authorisation-application-for-trogarzo-in-europe 2018-08-30T01:18:51 https://maestrodatabase.com/blog/knight-therapeutics-announces-approval-of-ibrelsa-in-canada 2020-04-19T01:16:25 https://maestrodatabase.com/blog/health-minister-set-to-make-u-dot-s-made-epipen-alternative-available-in-canada 2018-08-30T01:42:05 https://maestrodatabase.com/blog/dupixent-dupilumab-recommended-for-eu-approval-by-the-chmp-to-treat-eosinophilic-oesophagitis-in-children-as-young-as-1-year-old 2024-09-20T23:16:55 https://maestrodatabase.com/blog/pharmacy-review---an-update-from-the-chair 2017-07-12T10:18:36 https://maestrodatabase.com/blog/fda-approves-nasal-spray-influenza-vaccine-for-self-or-caregiver-administration 2024-09-20T23:44:53 https://maestrodatabase.com/blog/proposal-to-list-sapropterin-for-use-in-pregnancy-by-women-with-phenylketonuria 2018-08-30T05:34:20 https://maestrodatabase.com/blog/fda-fast-track-designation-for-narmafotinib-in-advanced-pancreatic-cancer 2024-09-21T00:09:49 https://maestrodatabase.com/blog/astellas-receives-approval-from-the-european-commission-for-vyloy-zolbetuximab-in-combination-with-chemotherapy-for-advanced-gastric-and-gastro-oesophageal-junction-cancer 2024-09-21T00:04:48 https://maestrodatabase.com/blog/european-commission-approves-blincyto-blinatumomab-for-use-in-paediatric-patients-with-philadelphia-chromosome-negative-relapsed-or-refractory-b-cell-precursor-acute-lymphoblastic-leukaemia 2018-08-30T06:10:40 https://maestrodatabase.com/blog/novartis-entresto-receives-positive-chmp-opinion-for-a-heart-failure 2023-04-02T00:09:36 https://maestrodatabase.com/blog/fda-accepts-resubmission-of-new-drug-application-for-duobrii-halobetasol-propionate-and-tazarotene-lotion 2018-08-30T06:05:52 https://maestrodatabase.com/blog/new-covid-19-vaccine-by-moderna-approved-by-health-canada 2024-09-21T00:29:35 https://maestrodatabase.com/blog/california-may-be-the-first-state-to-develop-its-own-generic-drugs 2020-09-03T07:59:08 https://maestrodatabase.com/blog/minovia-therapeutics-announces-fda-fast-track-and-rare-paediatric-disease-designations-for-mnv-201-in-pearson-syndrome 2025-06-30T23:57:34 https://maestrodatabase.com/blog/takeda-announces-us-fda-approval-of-gammagard-liquid-erc-the-only-ready-to-use-liquid-immunoglobulin-therapy-with-low-immunoglobulin-a-content 2025-07-01T00:37:12 https://maestrodatabase.com/blog/record-16-dot-5-million-flu-vaccines-to-protect-australians 2020-04-19T20:56:41 https://maestrodatabase.com/blog/janssen-disappointed-with-second-nice-no-for-spravato 2020-09-03T09:00:13 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-positive-chmp-opinion-for-car-t-cell-therapy-breyanzi-lisocabtagene-maraleucel-for-relapsed-or-refractory-large-b-cell-lymphoma-after-one-prior-therapy 2023-04-02T04:45:05 https://maestrodatabase.com/blog/at-262-dollars-40-cents-per-pill-the-cancer-drug-that-could-save-her-life-isnt-covered-in-b-dot-c 2018-01-21T19:58:37 https://maestrodatabase.com/blog/how-trump-could-use-a-rare-regulatory-manoeuvre-to-lower-drug-prices-before-election-day-and-how-it-could-backfire 2020-09-03T20:23:06 https://maestrodatabase.com/blog/cms-grants-additional-reimbursement-for-the-eluvia-drug-eluting-vascular-stent-system 2020-09-03T20:31:17 https://maestrodatabase.com/blog/uk-bladder-cancer-patients-get-early-access-to-bavencio 2020-09-03T09:18:51 https://maestrodatabase.com/blog/pfizer-and-biontech-to-supply-the-european-union-with-100-million-additional-doses-of-comirnaty 2021-04-20T04:47:47 https://maestrodatabase.com/blog/a-tale-of-2-friends-with-breast-cancer-1-has-coverage-for-costly-drug-the-other-forced-to-pay 2018-01-21T20:02:27 https://maestrodatabase.com/blog/second-trump-appointee-out-at-fda-amid-credibility-concerns 2020-09-03T12:19:14 https://maestrodatabase.com/blog/debate-rages-over-whether-fda-should-use-emergency-powers-to-clear-a-coronavirus-vaccine-early 2020-09-03T20:19:55 https://maestrodatabase.com/blog/alnylam-submits-new-drug-application-with-u-dot-s-fda-for-vutrisiran-for-the-treatment-of-the-polyneuropathy-of-hereditary-attr-amyloidosis-in-adults 2021-04-20T06:22:06 https://maestrodatabase.com/blog/new-us-health-care-plan-to-be-unveiled 2017-07-12T21:03:26 https://maestrodatabase.com/blog/aerie-pharmaceuticals-receives-marketing-authorisation-of-roclanda-50-mcg-slash-ml-plus-200-mcg-slash-ml-solution-eye-drops-latanoprost-plus-netarsudil-in-great-britain 2021-04-20T06:14:14 https://maestrodatabase.com/blog/unitedhealthcare-to-offer-0-dollars-insulin-epi-pens-but-only-for-some-members 2022-07-16T06:38:37 https://maestrodatabase.com/blog/tg-therapeutics-announces-positive-chmp-opinion-for-briumvi-ublituximab-xiiy-for-the-treatment-of-relapsing-forms-of-multiple-sclerosis-in-adults 2023-04-02T05:00:58 https://maestrodatabase.com/blog/curevac-swiss-initiates-rolling-submission-process-for-mrna-based-covid-19-vaccine-candidate-cvncov-with-swissmedic 2021-04-20T06:05:13 https://maestrodatabase.com/blog/multiple-factors-will-influence-pricing-for-covid-19-vaccine-in-canada-says-health-economist 2020-09-03T20:37:07 https://maestrodatabase.com/blog/unicycive-therapeutics-announces-receipt-of-complete-response-letter-for-oxylanthanum-carbonate-for-the-treatment-of-hyperphosphataemia-in-patients-with-chronic-kidney-disease-on-dialysis 2025-07-01T02:12:23 https://maestrodatabase.com/blog/ocular-therapeutix-receives-complete-response-letter-from-fda-for-dextenza-nda 2017-07-12T21:20:28 https://maestrodatabase.com/blog/tolak-is-included-in-the-high-cost-protection 2020-09-03T20:42:55 https://maestrodatabase.com/blog/fda-collaborates-to-promote-safety-quality-in-clinical-trials-done-in-india 2017-07-12T21:14:19 https://maestrodatabase.com/blog/the-price-war-in-weight-loss-drugs-is-here 2024-09-21T04:21:21 https://maestrodatabase.com/blog/voucher-program-notches-win-as-clock-ticks 2024-09-21T04:10:42 https://maestrodatabase.com/blog/novartis-car-t-cell-therapy-ctl019-unanimously-10-0-recommended-for-approval-by-fda-advisory-committee-to-treat-paediatric-young-adult-r-slash-r-b-cell-all 2017-07-12T21:30:51 https://maestrodatabase.com/blog/fda-awards-breakthrough-device-designation-to-the-rewalk-reboot-soft-exo-suit 2021-11-05T07:18:39 https://maestrodatabase.com/blog/novartis-price-dilemma-over-21-000-dollars-drug 2017-07-12T21:37:17 https://maestrodatabase.com/blog/cms-care-compare-empowers-patients-when-making-important-health-care-decisions 2020-09-03T21:14:24 https://maestrodatabase.com/blog/the-economics-of-indication-based-drug-pricing 2017-07-12T21:46:50 https://maestrodatabase.com/blog/fda-approves-additional-doses-of-trulicity-dulaglutide-for-the-treatment-of-type-2-diabetes-mellitus 2020-09-03T21:17:26 https://maestrodatabase.com/blog/tga-says-it-is-already-in-discussions-with-pharmaceutical-companies-developing-covid-vaccines 2020-09-03T21:22:44 https://maestrodatabase.com/blog/cymabay-submits-new-drug-application-to-fda-for-seladelpar-for-the-treatment-of-primary-biliary-cholangitis 2023-12-15T23:24:38 https://maestrodatabase.com/blog/fda-approves-enfortumab-vedotin-ejfv-with-pembrolizumab-for-locally-advanced-or-metastatic-urothelial-cancer 2023-12-15T23:19:32 https://maestrodatabase.com/blog/c-dot-d-c-tells-states-how-to-prepare-for-covid-19-vaccine-by-early-november 2020-09-03T21:05:43 https://maestrodatabase.com/blog/ftc-accuses-drug-middlemen-of-inflating-insulin-prices 2024-09-21T04:32:22 https://maestrodatabase.com/blog/lexeo-therapeutics-announces-fda-fast-track-designation-granted-to-lx1001-for-the-treatment-of-apoe4-associated-alzheimers-disease 2021-04-20T14:09:36 https://maestrodatabase.com/blog/nices-five-year-strategy-sets-a-positive-vision-for-the-future 2021-04-20T20:46:11 https://maestrodatabase.com/blog/covid-19-vaccine-janssen-ema-finds-possible-link-to-very-rare-cases-of-unusual-blood-clots-with-low-blood-platelets 2021-04-20T20:42:18 https://maestrodatabase.com/blog/health-department-moving-tga-to-new-60-dollars-million-canberra-airport-campus 2020-09-03T21:24:59 https://maestrodatabase.com/blog/nice-draft-guidance-provides-cancer-drugs-fund-first-in-europe-access-to-new-treatment-option-for-advanced-breast-cancer 2021-04-20T11:14:20 https://maestrodatabase.com/blog/how-to-ensure-that-novel-analytic-methods-are-fit-for-decision-making 2019-10-02T07:58:38 https://maestrodatabase.com/blog/survey-on-patients-access-to-medicines-for-the-treatment-of-rare-health-conditions 2023-04-02T20:48:22 https://maestrodatabase.com/blog/lamotrigine-brand-change-from-today 2019-10-02T07:52:31 https://maestrodatabase.com/blog/health-officials-meet-with-pfizer-to-discuss-vaccine-booster-doses 2021-04-20T21:07:11 https://maestrodatabase.com/blog/ensuring-public-trust-in-an-empowered-fda 2023-04-02T20:51:41 https://maestrodatabase.com/blog/amgen-launches-biomarker-assist-a-program-to-help-more-patients-with-non-small-cell-lung-cancer-gain-access-to-biomarker-testing 2021-04-20T21:14:21 https://maestrodatabase.com/blog/braeburn-receives-complete-response-letter-for-cam2038-injectable-buprenorphine-depot-for-the-treatment-of-opioid-use-disorder 2018-01-22T00:05:31 https://maestrodatabase.com/blog/european-commission-approves-nucala-mepolizumab-for-the-treatment-of-children-with-severe-asthma 2018-08-30T10:00:59 https://maestrodatabase.com/blog/trade-agreement-drug-monopoly-is-obsolete-given-faster-better-drug-discovery 2019-10-02T11:54:04 https://maestrodatabase.com/blog/biocartis-announces-us-fda-510-k-submission-of-its-idylla-msi-test 2021-04-20T20:50:35 https://maestrodatabase.com/blog/health-economic-assessment-of-darzalex-in-multiple-myeloma 2021-04-20T20:59:00 https://maestrodatabase.com/blog/evolus-receives-approval-for-nuceiva-in-the-european-union 2019-10-02T11:24:41 https://maestrodatabase.com/blog/progressing-the-long-term-plan-for-stem-cell-research 2019-10-02T08:03:58 https://maestrodatabase.com/blog/advancing-patient-engagement 2019-10-02T12:07:27 https://maestrodatabase.com/blog/fda-accepts-two-applications-for-mercks-dificid-fidaxomicin-to-treat-children-aged-six-months-up-to-18-years-with-clostridium-difficile-infections 2019-10-02T11:57:32 https://maestrodatabase.com/blog/negative-news-on-astrazeneca-to-impact-the-hesitant-australians 2021-04-20T21:30:32 https://maestrodatabase.com/blog/u-dot-s-fda-submission-of-new-drug-application-for-ns-065-slash-ncnp-01-viltolarsen 2019-10-02T21:14:38 https://maestrodatabase.com/blog/major-health-sector-shake-up-government-scraps-all-district-health-boards-in-favour-of-one-national-authority 2021-04-20T21:27:11 https://maestrodatabase.com/blog/samsung-bioepis-receives-positive-chmp-opinion-for-eculizumab-biosimilar-epysqli 2023-04-02T20:55:22 https://maestrodatabase.com/blog/gsk-submits-filing-to-fda-for-trelegy-ellipta-use-in-patients-with-asthma 2019-10-02T21:03:20 https://maestrodatabase.com/blog/mitsubishi-tanabe-pharma-canada-receives-engagement-letter-from-pan-canadian-pharmaceutical-alliance-for-radicava-oral-suspension 2023-04-02T21:01:08 https://maestrodatabase.com/blog/nice-numbers-at-20-trends-in-deals 2019-10-02T21:26:10 https://maestrodatabase.com/blog/trump-says-pelosis-promise-to-work-with-him-on-drug-price-plan-is-camouflage-for-impeachment 2019-10-02T21:22:19 https://maestrodatabase.com/blog/the-real-impact-of-drug-price-legislation-on-biopharmaceutical-r-and-d 2019-10-02T21:20:03 https://maestrodatabase.com/blog/trump-administration-invitation-for-states-to-design-wellness-programs-draws-swift-backlash 2019-10-02T21:34:50 https://maestrodatabase.com/blog/trump-and-pelosi-aides-talk-drug-costs-despite-impeachment 2019-10-02T21:32:54 https://maestrodatabase.com/blog/cdk4-slash-6-inhibitor-plus-fulvestrant-combo-nears-getting-benefit 2019-10-02T21:29:09 https://maestrodatabase.com/blog/european-commission-approves-new-easy-to-use-once-weekly-bydureon-bcise-device-for-patients-with-type-2-diabetes-mellitus 2018-08-30T11:23:11 https://maestrodatabase.com/blog/u-dot-s-food-and-drug-administration-accepts-bristol-myers-squibbs-application-for-sprycel-dasatinib-in-paediatric-patients-with-newly-diagnosed-philadelphia-chromosome-positive-acute-lymphoblastic-leukaemia 2018-08-30T11:16:28 https://maestrodatabase.com/blog/trump-set-to-nominate-stephen-hahn-as-fda-commissioner-pending-vetting-process 2019-10-02T21:42:57 https://maestrodatabase.com/blog/so-the-government-has-agreed-to-reduce-the-time-from-pbac-recommendation-to-pbs-listing-by-two-months 2018-08-30T11:52:59 https://maestrodatabase.com/blog/bayer-receives-us-approval-for-modern-haemophilia-a-treatment-jivi-with-a-step-wise-prophylaxis-dosing-regimen 2018-08-30T20:24:14 https://maestrodatabase.com/blog/fda-approves-mercks-delstrigo-doravirine-with-lamivudine-and-tenofovir-disoproxil-fumarate-a-once-daily-fixed-dose-combination-tablet-as-a-complete-regimen-and-pifeltro-doravirine-an-nnrti-both-for-the-treatment-of-hiv-1-in-appropriate-patients 2018-08-30T21:30:14 https://maestrodatabase.com/blog/renflexis-infliximab-for-injection-added-to-british-columbias-provincial-drug-plan-for-all-approved-indications 2018-08-30T20:32:13 https://maestrodatabase.com/blog/fdas-comprehensive-effort-to-advance-new-innovations-initiatives-to-modernise-for-innovation 2018-08-30T20:38:56 https://maestrodatabase.com/blog/womans-desperate-plea-to-pharmac-to-fund-$6-000-slash-month-cancer-drug 2018-08-30T21:42:08 https://maestrodatabase.com/blog/pixium-vision-announces-fda-breakthrough-device-designation-for-the-prima-system-in-dry-amd 2023-04-02T23:25:25 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-july-2025 2025-07-01T23:00:01 https://maestrodatabase.com/blog/tris-pharma-announces-fda-approval-of-dyanavel-xr-amphetamine-once-daily-extended-release-oral-tablets-cii-for-adhd 2021-11-06T01:48:11 https://maestrodatabase.com/blog/adagrasib-for-adults-with-previously-treated-advanced-kras-g12c-mutation-positive-non-small-cell-lung-cancer 2025-07-02T00:14:19 https://maestrodatabase.com/blog/expensive-life-prolonging-drug-not-an-option-for-many-women 2018-08-30T21:46:14 https://maestrodatabase.com/blog/pharmac-to-fund-baricitinib-to-treat-moderate-to-severe-cases-of-covid-19 2021-11-06T02:02:11 https://maestrodatabase.com/blog/nice-recommend-dapagliflozin-for-people-with-chronic-kidney-disease 2021-11-06T01:39:42 https://maestrodatabase.com/blog/fruquintinib-approved-to-treat-adult-patients-with-metastatic-colorectal-cancer 2024-09-22T01:36:18 https://maestrodatabase.com/blog/nice-welcomes-the-inclusion-of-measures-for-equal-treatment-of-medicines-and-health-technologies 2025-07-01T23:19:30 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-july-2025 2025-07-01T23:55:24 https://maestrodatabase.com/blog/actelion-submits-application-to-ema-seeking-approval-of-opsumit-macitentan-for-the-treatment-of-chronic-thromboembolic-pulmonary-hypertension 2018-08-31T10:53:10 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-september-2018-update 2018-08-31T11:11:01 https://maestrodatabase.com/blog/medicines-australia-welcomes-announcement-lsdp-expert-panel 2018-08-31T11:23:58 https://maestrodatabase.com/blog/pharma-interactions-educate-and-improve-health-outcomes 2018-08-31T11:28:58 https://maestrodatabase.com/blog/alnylam-receives-approval-of-onpattro-patisiran-in-europe 2018-08-31T11:17:42 https://maestrodatabase.com/blog/how-to-prevent-drug-price-shenanigans 2018-01-22T02:13:30 https://maestrodatabase.com/blog/choice-of-control-group-in-randomised-trials-of-cancer-medicine-are-we-testing-trivialities 2018-08-31T22:52:30 https://maestrodatabase.com/blog/crossing-the-global-health-care-quality-chasm-a-key-component-of-universal-health-coverage 2018-08-31T23:11:33 https://maestrodatabase.com/blog/novavax-files-covid-19-vaccine-for-provisional-approval-in-new-zealand 2021-11-06T03:48:55 https://maestrodatabase.com/blog/to-lower-drug-costs-cms-wants-medicare-part-d-plans-to-loosen-formularies 2018-09-01T00:39:41 https://maestrodatabase.com/blog/statistical-analysis-of-patient-reported-outcome-data-in-randomised-controlled-trials-of-locally-advanced-and-metastatic-breast-cancer-a-systematic-review 2018-08-31T22:57:07 https://maestrodatabase.com/blog/prospects-for-us-single-payer-national-health-care 2018-09-01T00:46:44 https://maestrodatabase.com/blog/novavax-files-covid-19-vaccine-for-emergency-use-listing-with-world-health-organization 2021-11-06T06:51:13 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-september-2018-update 2018-09-01T02:10:01 https://maestrodatabase.com/blog/life-saving-breast-cancer-drug-now-cheaper-thanks-to-expansion-of-the-pbs 2025-07-02T11:05:46 https://maestrodatabase.com/blog/calls-for-missing-piece-menopause-drug-to-be-added-to-the-pbs 2025-07-02T11:10:08 https://maestrodatabase.com/blog/rheumatoid-arthritis-adhd-drugs-added-to-pbs-prices-plunge 2018-09-01T02:15:51 https://maestrodatabase.com/blog/biden-administration-to-impose-inflation-penalties-on-dozens-of-drugs 2023-12-16T05:06:36 https://maestrodatabase.com/blog/vertex-receives-chmp-positive-opinion-for-the-first-crispr-slash-cas9-gene-edited-therapy-casgevy-exagamglogene-autotemcel-for-the-treatment-of-sickle-cell-disease-and-transfusion-dependent-beta-thalassaemia 2023-12-16T02:18:27 https://maestrodatabase.com/blog/fda-issues-a-complete-response-letter-for-new-drug-application-for-dasatroline-for-the-treatment-of-adhd 2018-09-01T10:04:13 https://maestrodatabase.com/blog/fda-approves-labeling-supplement-for-puma-biotechnologys-nerlynx-neratinib-for-the-extended-adjuvant-treatment-of-her2-positive-early-stage-breast-cancer 2019-10-03T01:22:11 https://maestrodatabase.com/blog/covid-antivirals-available-by-telehealth-phone-consultation 2022-07-17T03:01:24 https://maestrodatabase.com/blog/has-the-centers-for-medicare-medicaid-services-implicitly-adopted-a-value-framework-for-medicare-drug-price-negotiations 2023-12-16T05:22:04 https://maestrodatabase.com/blog/modifying-funded-access-to-mifepristone-and-misoprostol 2020-07-02T11:14:00 https://maestrodatabase.com/blog/report-on-the-collection-of-under-co-payment-data-2022-23 2023-12-16T05:16:01 https://maestrodatabase.com/blog/novartis-to-sponsor-large-clinical-trial-of-hydroxychloroquine-in-hospitalised-covid-19-patients 2020-04-20T06:21:50 https://maestrodatabase.com/blog/trump-hasnt-attacked-drug-prices-as-he-promised-he-would-during-his-first-year-in-office 2018-01-22T06:05:07 https://maestrodatabase.com/blog/new-appointment-to-the-pbac 2017-07-13T01:49:29 https://maestrodatabase.com/blog/janssen-submits-supplemental-new-drug-application-to-u-dot-s-fda-for-spravato-esketamine-ciii-nasal-spray-for-the-rapid-reduction-of-depressive-symptoms-in-adults-with-major-depressive-disorder-who-have-active-suicidal-ideation-with-intent 2019-10-03T01:26:22 https://maestrodatabase.com/blog/fda-draft-guidance-allows-ai-slash-ml-devices-to-evolve-without-requiring-new-submissions 2023-04-03T04:36:05 https://maestrodatabase.com/blog/ultomiris-recommended-for-approval-in-the-eu-by-chmp-for-the-treatment-of-adults-with-neuromyelitis-optica-spectrum-disorder 2023-04-03T06:33:57 https://maestrodatabase.com/blog/china-cde-grants-breakthrough-therapy-designation-to-neurophths-nr082-in-lebers-hereditary-optic-neuropathy 2022-07-17T03:52:47 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-reviewing-olaparib-rucaparib-and-niraparib-for-ovarian-cancer 2017-07-13T01:52:44 https://maestrodatabase.com/blog/prescription-medication-prices-to-rise 2022-07-17T03:49:10 https://maestrodatabase.com/blog/fda-and-ema-accept-applications-for-genentechs-ocrevus-ocrelizumab-shorter-two-hour-infusion-time 2020-04-20T11:51:04 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-linvoseltamab-gcpt-for-relapsed-or-refractory-multiple-myeloma 2025-07-03T01:36:22 https://maestrodatabase.com/blog/novartis-entresto-receives-fda-approval-for-paediatric-heart-failure-helping-to-address-critical-unmet-need-for-treatment-options 2019-10-03T01:34:41 https://maestrodatabase.com/blog/ethical-challenges-associated-with-pragmatic-and-cluster-rcts 2024-09-22T03:44:06 https://maestrodatabase.com/blog/improved-consumer-medicine-information-template 2020-04-20T06:25:35 https://maestrodatabase.com/blog/avigan-ingredient-shortage-hits-japan-stockpile-plan 2020-04-20T06:27:35 https://maestrodatabase.com/blog/men-get-breast-cancer-too-but-they-cant-always-access-new-drugs 2024-09-22T03:36:35 https://maestrodatabase.com/blog/five-factors-driving-up-the-cost-of-oncology-drugs 2018-01-22T20:04:04 https://maestrodatabase.com/blog/fast-tracking-a-vaccine-how-comfortable-are-americans 2020-09-04T06:19:57 https://maestrodatabase.com/blog/european-commission-approves-bristol-myers-squibbs-yervoy-ipilimumab-for-treatment-of-paediatric-patients-12-years-and-older-with-unresectable-or-metastatic-melanoma 2018-01-22T20:09:23 https://maestrodatabase.com/blog/gw-pharmaceuticals-receives-european-commission-approval-for-epidyolex-cannabidiol-for-the-treatment-of-seizures-associated-with-tuberous-sclerosis-complex 2021-04-21T03:46:23 https://maestrodatabase.com/blog/eu-actions-to-support-availability-of-medicines-during-covid-19-pandemic---update-number-2 2020-04-20T20:50:49 https://maestrodatabase.com/blog/hhs-secretary-azar-says-1-november-coronavirus-vaccine-deadline-has-nothing-to-do-with-elections 2020-09-04T06:26:54 https://maestrodatabase.com/blog/biogen-optimistic-for-nhs-access-to-spinraza 2018-01-22T19:53:49 https://maestrodatabase.com/blog/update-to-guidance-on-regulatory-expectations-in-the-context-of-covid-19-pandemic 2020-04-20T20:52:58 https://maestrodatabase.com/blog/epidyolex-is-granted-temporary-subsidy 2020-04-20T21:10:37 https://maestrodatabase.com/blog/innovent-announces-nmpa-granted-marketing-approval-for-sulinno-adalimumab-injection-in-china 2020-09-04T06:30:36 https://maestrodatabase.com/blog/ema-publishes-agenda-for-22-25-january-chmp-meeting 2018-01-22T20:26:34 https://maestrodatabase.com/blog/big-pharma-has-the-chance-to-come-to-the-worlds-rescue 2020-04-20T12:01:08 https://maestrodatabase.com/blog/additional-analysis-of-kymriah-in-the-treatment-of-patients-with-diffuse-large-cell-b-cell-lymphoma 2020-04-20T12:06:30 https://maestrodatabase.com/blog/generic-drug-firms-fall-as-u-dot-s-threatens-to-sue-for-damages 2018-01-22T20:14:53 https://maestrodatabase.com/blog/covid-19-treatment-remedsivir-is-not-available-for-australian-trial 2020-04-20T12:19:31 https://maestrodatabase.com/blog/the-prescription-drug-price-negotiation-plan-in-the-biden-bbb-bill-is-not-what-its-claimed-to-be 2021-11-07T03:51:57 https://maestrodatabase.com/blog/pbac-announces-appointment-of-industry-expert-to-committee 2017-07-13T02:22:54 https://maestrodatabase.com/blog/registration-of-new-chemical-entities-in-australia 2018-01-22T20:38:54 https://maestrodatabase.com/blog/apotex-receives-health-canada-approval-for-aflivu-a-biosimilar-to-eylea-available-in-pre-filled-syringe-and-vial-formats 2025-07-03T03:19:10 https://maestrodatabase.com/blog/astrazeneca-pulls-request-for-swiss-approval-of-covid-shot 2021-11-07T03:47:46 https://maestrodatabase.com/blog/hydroxychloroquine-and-other-auto-immune-drugs-dont-fully-protect-against-coronavirus-early-data-suggest 2020-04-20T21:21:05 https://maestrodatabase.com/blog/crisis-or-not-alberta-must-not-do-an-end-run-around-health-canada 2020-04-20T21:24:29 https://maestrodatabase.com/blog/ocugen-announces-submission-of-emergency-use-authorisation-request-to-the-us-fda-for-investigational-covid-19-vaccine-covaxin-bbv152-for-children-ages-2-18-years 2021-11-07T04:19:37 https://maestrodatabase.com/blog/fda-grants-priority-review-for-winrevair-sotatercept-csrk-to-update-label-based-on-results-from-zenith-trial 2025-07-03T02:28:20 https://maestrodatabase.com/blog/big-pharma-calls-out-australias-freeloading-on-us-medicine 2025-07-03T02:47:48 https://maestrodatabase.com/blog/top-level-push-for-taxpayer-funding-of-weight-loss-drugs-gathers-pace 2025-07-03T02:50:10 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-sunvozertinib-for-metastatic-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations 2025-07-03T02:55:55 https://maestrodatabase.com/blog/covid-19-pharmac-confident-with-growing-stock-of-drugs-to-treat-virus 2021-11-07T10:48:43 https://maestrodatabase.com/blog/sandoz-receives-approval-by-european-commission-for-hyrimoz-adalimumab-high-concentration-formulation 2023-04-03T20:46:03 https://maestrodatabase.com/blog/release-of-provisional-recommendations-for-expert-advisory-committees 2025-07-03T05:34:31 https://maestrodatabase.com/blog/cashed-up-insurers-should-hand-back-profits 2021-11-07T06:57:11 https://maestrodatabase.com/blog/pfizer-moderna-style-vaccines-could-soon-be-made-in-melbourne 2021-04-21T04:52:08 https://maestrodatabase.com/blog/switzerland-unfortunately-still-awaiting-astrazeneca-covid-19-vaccine-data 2021-04-21T05:06:04 https://maestrodatabase.com/blog/effrx-obtains-swiss-marketing-authorization-for-bronchitol-in-cystic-fibrosis 2021-11-07T20:31:25 https://maestrodatabase.com/blog/bayers-adempas-gets-insurance-coverage-in-korea-11-years-after-approval 2025-07-03T04:51:19 https://maestrodatabase.com/blog/vertex-and-crispr-therapeutics-complete-submission-of-rolling-biologics-license-applications-to-the-us-fda-for-exa-cel-for-the-treatment-of-sickle-cell-disease-and-transfusion-dependent-beta-thalassaemia 2023-04-03T20:51:22 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-enfortumab-vedotin-ejfv-with-pembrolizumab-for-locally-advanced-or-metastatic-urothelial-carcinoma 2023-04-03T21:10:30 https://maestrodatabase.com/blog/government-excessively-controls-drug-prices-not-recognising-novel-drugs-value 2022-07-17T21:10:37 https://maestrodatabase.com/blog/biocom-california-opposes-new-drug-pricing-proposal-as-written 2021-11-07T20:38:11 https://maestrodatabase.com/blog/medicare-system-is-not-fit-for-purpose-review-finds 2023-04-03T21:07:18 https://maestrodatabase.com/blog/medicine-affordability-hardships-bite-for-australians-as-cost-of-living-pressures-build 2022-07-17T21:07:26 https://maestrodatabase.com/blog/nucala-mepolizumab-is-now-listed-on-the-pbs-for-australians-with-chronic-rhinosinusitis-with-nasal-polyps 2023-04-03T21:01:28 https://maestrodatabase.com/blog/brisbane-man-treated-for-blood-clots-after-receiving-vaccine 2021-04-21T07:38:04 https://maestrodatabase.com/blog/china-to-list-more-cancer-drugs-for-medical-insurance-coverage 2019-04-19T06:56:00 https://maestrodatabase.com/blog/wegovy-recommended-by-the-european-regulatory-authorities-for-label-update-to-reflect-reduced-heart-failure-symptoms-and-improved-physical-function 2024-09-22T09:23:22 https://maestrodatabase.com/blog/inside-the-quiet-strategy-pharma-giants-are-using-to-fend-off-generics-and-drive-up-the-cost-of-medicines 2024-09-22T04:53:21 https://maestrodatabase.com/blog/the-impact-of-generic-entry-of-pharmaceuticals-in-australia 2024-09-22T04:49:49 https://maestrodatabase.com/blog/start-of-covid-19-booster-vaccination-program 2021-11-07T22:47:28 https://maestrodatabase.com/blog/fda-make-medical-apps-reliable-not-risky 2021-04-21T10:55:47 https://maestrodatabase.com/blog/additional-analysis-of-luxturna-in-the-treatment-of-visual-impairment-caused-by-hereditary-eye-disease 2021-04-21T21:21:16 https://maestrodatabase.com/blog/medtronic-receives-u-dot-s-fda-approval-for-pipeline-flex-embolisation-device-with-shield-technology 2021-04-21T21:17:31 https://maestrodatabase.com/blog/novartis-ms-therapy-kesimpta-wins-nice-backing 2021-04-21T12:16:56 https://maestrodatabase.com/blog/health-economic-assessment-of-qarziba-in-patients-with-high-risk-neuroblastoma 2021-04-21T21:07:43 https://maestrodatabase.com/blog/clinical-trials-information-system-reaches-major-milestone-towards-go-live-and-application-of-the-clinical-trial-regulation 2021-04-21T21:04:20 https://maestrodatabase.com/blog/fda-continues-important-steps-to-ensure-quality-safety-and-effectiveness-of-authorised-covid-19-vaccines 2021-04-21T21:51:27 https://maestrodatabase.com/blog/j-and-j-resumes-roll-out-of-covid-19-vaccine-in-eu 2021-04-21T21:47:02 https://maestrodatabase.com/blog/reducing-the-time-from-pbac-recommendation-to-pbs-listing 2018-09-03T21:30:43 https://maestrodatabase.com/blog/major-missed-opportunity-on-pharmac-reform 2021-04-21T21:25:07 https://maestrodatabase.com/blog/eligible-cystic-fibrosis-patients-get-free-access-to-life-changing-drug 2018-09-02T21:46:14 https://maestrodatabase.com/blog/pbs-website-medicine-data-update 2021-04-21T21:44:01 https://maestrodatabase.com/blog/national-cabinet-to-meet-for-second-time-this-week-with-vaccine-rollout-expansion-on-the-agenda 2021-04-21T21:29:47 https://maestrodatabase.com/blog/hutchmed-completes-rolling-submission-of-nda-to-us-fda-for-fruquintinib-for-the-treatment-of-refractory-metastatic-colorectal-cancer 2023-04-04T02:04:21 https://maestrodatabase.com/blog/johnson-and-johnson-submits-application-to-the-ema-seeking-indication-extension-of-akeega-niraparib-and-abiraterone-acetate-dual-action-tablet-for-the-treatment-of-adult-patients-with-metastatic-hormone-sensitive-prostate-cancer-and-hrr-gene-alterations 2025-07-04T02:55:27 https://maestrodatabase.com/blog/the-federal-right-to-try-act-of-2017--a-wrong-turn-for-access-to-investigational-drugs-and-the-path-forward 2018-03-06T11:13:03 https://maestrodatabase.com/blog/out-of-pocket-spending-and-premium-contributions-after-implementation-of-the-affordable-care-act 2018-01-23T02:27:09 https://maestrodatabase.com/blog/chiesi-global-rare-diseases-announces-approval-of-ferriprox-mr-deferiprone-extended-release-tablets-in-canada 2023-04-04T01:57:40 https://maestrodatabase.com/blog/jazz-pharmaceuticals-receives-european-commission-marketing-authorisation-for-ziihera-zanidatamab-for-the-treatment-of-advanced-her2-positive-biliary-tract-cancer 2025-07-04T03:41:54 https://maestrodatabase.com/blog/dangling-accelerated-approvals-in-oncology 2021-04-21T22:48:42 https://maestrodatabase.com/blog/fda-grants-tentative-approval-for-liquidias-yutrepia-treprostinil-inhalation-powder 2021-11-08T11:20:52 https://maestrodatabase.com/blog/seattle-genetics-announces-adcetris-brentuximab-vedotin-receives-european-commission-approval-for-cd30-positive-cutaneous-t-cell-lymphoma-after-at-least-one-prior-systemic-therapy 2018-01-23T02:32:26 https://maestrodatabase.com/blog/eu-approval-of-the-articular-cartilage-product-by-the-european-commission 2017-07-13T05:13:23 https://maestrodatabase.com/blog/covid-19-ema-and-heads-of-medicines-agencies-update-on-molnupiravir 2021-11-08T19:40:49 https://maestrodatabase.com/blog/ausbiotech-welcomes-industry-nominee-to-pbac 2017-07-13T05:20:38 https://maestrodatabase.com/blog/baxter-announces-u-dot-s-fda-approval-of-ready-to-use-cardiovascular-medication-bivalirudin 2018-01-23T02:42:39 https://maestrodatabase.com/blog/indicative-1-october-2017-prices---2017-october-cycle 2017-07-13T05:27:26 https://maestrodatabase.com/blog/azurity-pharmaceuticals-announces-fda-approval-of-eprontia-topiramate-oral-solution 2021-11-08T11:14:49 https://maestrodatabase.com/blog/update-on-proposal-to-fund-ferric-carboxymaltose-infusions-in-the-community 2017-07-13T05:23:14 https://maestrodatabase.com/blog/koselugo-approved-in-canada-for-paediatric-patients-with-neurofibromatosis-type-1-plexiform-neurofibromas 2023-04-04T03:26:23 https://maestrodatabase.com/blog/man-and-science-announces-u-dot-s-fda-breakthrough-device-designation-granted-for-the-treatment-of-chronic-cluster-headache 2021-11-08T20:16:27 https://maestrodatabase.com/blog/fda-approves-arcutis-zoryve-roflumilast-topical-foam-0-dot-3-percent-for-the-treatment-of-seborrheic-dermatitis-in-individuals-aged-9-years-and-older 2023-12-17T20:41:46 https://maestrodatabase.com/blog/az-announces-us-fast-track-designation-for-il-5-inhibitor-fasenra 2021-11-08T20:02:18 https://maestrodatabase.com/blog/new-improved-bnf-and-bnfc-app-launched 2017-07-13T09:42:35 https://maestrodatabase.com/blog/seelos-therapeutics-announces-fda-grant-of-fast-track-designation-for-sls-005-iv-trehalose-for-the-treatment-of-spinocerebellar-ataxia 2021-11-08T20:10:33 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac-november-2023 2023-12-17T19:55:43 https://maestrodatabase.com/blog/why-does-the-fda-want-to-stop-improving-medicines-via-patent-areas-of-concern 2021-11-08T20:08:00 https://maestrodatabase.com/blog/prac-recommends-revoking-marketing-authorisation-of-ulipristal-acetate-for-uterine-fibroids 2020-09-04T23:41:20 https://maestrodatabase.com/blog/genmab-announces-european-marketing-authorisation-for-darzalex-daratumumab-for-front-line-multiple-myeloma 2018-09-03T02:55:11 https://maestrodatabase.com/blog/ema-publishes-agenda-for-8-11-november-chmp-meeting 2021-11-08T20:30:07 https://maestrodatabase.com/blog/smc---november-2021-decisions 2021-11-08T20:25:38 https://maestrodatabase.com/blog/drugs-against-rare-diseases-libmeldy-gene-therapy-shows-additional-benefits---zolgensma-cell-therapy-on-the-other-hand-does-not 2021-11-08T20:50:12 https://maestrodatabase.com/blog/emergency-epipen-alternative-priced-for-canadian-market-at-170-dollars-each 2018-09-03T02:51:37 https://maestrodatabase.com/blog/the-hurried-push-by-congress-to-address-drug-costs-shouldnt-undermine-the-vast-savings-from-generics-and-biosimilars 2021-11-08T20:41:39 https://maestrodatabase.com/blog/imfinzi-approved-in-the-eu-as-first-and-only-peri-operative-immunotherapy-for-muscle-invasive-bladder-cancer 2025-07-04T08:36:08 https://maestrodatabase.com/blog/pharmacists-welcome-medicine-review-update 2020-04-21T03:44:48 https://maestrodatabase.com/blog/tga-facebook-has-officially-launched 2018-09-03T03:06:00 https://maestrodatabase.com/blog/why-countries-cant-meet-the-demand-for-gear-against-covid-19 2020-04-21T04:08:01 https://maestrodatabase.com/blog/fasenra-recommended-for-approval-in-the-eu-by-chmp-for-the-treatment-of-eosinophilic-granulomatosis-with-polyangiitis 2024-09-23T06:15:24 https://maestrodatabase.com/blog/britain-loses-medicines-contracts-as-eu-body-anticipates-brexit 2018-09-03T03:02:58 https://maestrodatabase.com/blog/the-controversial-malaria-drug-has-been-approved-for-an-official-trial 2020-04-21T04:12:07 https://maestrodatabase.com/blog/pharmac-seeking-feedback-on-the-covid-19-anti-viral-molnupiravir 2023-04-04T07:12:26 https://maestrodatabase.com/blog/henlius-and-intas-receive-positive-chmp-opinion-for-hetronifly-in-european-markets-as-first-line-treatment-for-adult-patients-with-extensive-stage-small-cell-lung-cancer 2024-09-23T06:07:41 https://maestrodatabase.com/blog/nice-backs-humira-enbrel-and-stelara-for-plaque-psoriasis-in-children 2017-07-13T20:58:11 https://maestrodatabase.com/blog/more-australians-now-eligible-for-free-shingles-vaccination 2024-09-23T05:58:34 https://maestrodatabase.com/blog/choice-says-health-insurance-is-too-complex-and-stopping-people-from-switching 2017-07-13T20:53:28 https://maestrodatabase.com/blog/multidimensional-evidence-generation-and-fda-regulatory-decision-making-defining-and-using-real-world-data 2017-07-13T21:09:59 https://maestrodatabase.com/blog/agenda-for-september-5-tc-meeting 2018-09-03T03:17:54 https://maestrodatabase.com/blog/fda-grants-insys-therapeutics-fast-track-designation-for-epinephrine-nasal-spray-as-investigational-treatment-for-anaphylaxis 2018-09-03T03:24:57 https://maestrodatabase.com/blog/senators-explore-bipartisan-plan-b-to-troubled-gop-health-bill 2017-07-13T21:19:38 https://maestrodatabase.com/blog/vaccine-makers-plan-public-stance-to-counter-pressure-on-fda 2020-09-04T23:50:54 https://maestrodatabase.com/blog/proposed-revision-to-the-procedure-for-the-cadth-common-drug-review-and-the-cadth-therapeutic-review-framework 2017-07-13T21:14:04 https://maestrodatabase.com/blog/car-ts-clear-one-roadblock-but-face-many-more 2017-07-13T21:44:25 https://maestrodatabase.com/blog/vertex-announces-european-commission-approval-of-alyftek-a-new-once-daily-cftr-modulator-for-the-treatment-of-cystic-fibrosis 2025-07-04T22:41:35 https://maestrodatabase.com/blog/house-poised-to-pass-bill-critical-for-drug-industry-the-senate-may-be-a-slog 2017-07-13T21:22:42 https://maestrodatabase.com/blog/out-of-pocket-gp-costs-soar-45-per-cent-for-non-bulk-billed-patients 2024-09-23T07:12:34 https://maestrodatabase.com/blog/ucb-announces-us-fda-approvals-for-bimzelx-bimekizumab-bkzx-for-the-treatment-of-psoriatic-arthritis-non-radiographic-axial-spondyloarthritis-and-ankylosing-spondylitis 2024-09-23T07:07:31 https://maestrodatabase.com/blog/public-summary-documents---march-2025-pbac-meeting 2025-07-04T08:42:34 https://maestrodatabase.com/blog/alk-announces-health-canada-approval-of-itulatek-slit-tablets-for-the-treatment-of-tree-pollen-allergy 2020-04-21T11:06:04 https://maestrodatabase.com/blog/launch-of-enhanced-monitoring-system-for-availability-of-medicines-used-for-treating-covid-19 2020-04-21T20:37:14 https://maestrodatabase.com/blog/human-trials-to-begin-on-covid-19-vaccine-by-thursday 2020-04-21T20:43:46 https://maestrodatabase.com/blog/heres-why-a-covid-19-vaccine-could-end-up-costing-you-a-small-fortune 2020-04-21T20:46:44 https://maestrodatabase.com/blog/if-pharma-helps-quench-the-covid-19-pandemic-what-will-it-want-in-return 2020-04-21T11:10:46 https://maestrodatabase.com/blog/coronavirus-puts-big-pharmas-ip-regime-to-the-test 2020-04-21T11:13:56 https://maestrodatabase.com/blog/fda-accepts-leo-pharmas-filing-of-delgocitinib-cream-new-drug-application-for-the-treatment-of-chronic-hand-eczema 2024-09-24T03:57:47 https://maestrodatabase.com/blog/imbruvica-ibrutinib-receives-11th-fda-approval 2020-04-21T20:29:20 https://maestrodatabase.com/blog/allogene-therapeutics-announces-fda-regenerative-medicine-advanced-therapy-designation-granted-to-allo-715-an-allocar-t-cell-therapy-in-development-for-relapsed-slash-refractory-multiple-myeloma 2021-04-22T00:35:58 https://maestrodatabase.com/blog/takeda-receives-positive-chmp-opinion-for-hyqvia-as-maintenance-therapy-in-patients-with-chronic-inflammatory-demyelinating-polyneuropathy 2023-12-17T22:19:26 https://maestrodatabase.com/blog/patients-wanting-special-funding-for-anti-depressants-turned-down-by-pharmac 2018-09-03T05:41:40 https://maestrodatabase.com/blog/myovant-sciences-submits-new-drug-application-to-the-fda-for-once-daily-oral-relugolix-for-the-treatment-of-men-with-advanced-prostate-cancer 2020-04-21T21:18:25 https://maestrodatabase.com/blog/ipsens-kayfanda-odevixibat-approved-in-european-union-for-cholestatic-pruritus-in-alagille-syndrome-a-rare-liver-disease 2024-09-24T05:37:23 https://maestrodatabase.com/blog/clark-accused-of-cronyism-over-pharmac-appointment 2018-09-03T05:45:03 https://maestrodatabase.com/blog/andexanet-alfa-for-reversing-anticoagulation 2020-04-21T21:30:22 https://maestrodatabase.com/blog/swiss-deal-on-cystic-fibrosis-drugs-could-change-price-negotiations 2020-04-21T20:50:54 https://maestrodatabase.com/blog/merck-receives-positive-eu-chmp-opinions-for-keytruda-pembrolizumab-regimens-as-treatment-for-patients-with-two-types-of-gynaecologic-cancers 2024-09-24T05:16:50 https://maestrodatabase.com/blog/nice-recommends-vitrakvi-larotrectinib-for-use-on-cancer-drugs-fund 2020-04-21T21:01:10 https://maestrodatabase.com/blog/doj-clears-u-dot-s-drug-companies-to-distribute-hydroxychloroquine-to-coronavirus-patients 2020-04-21T21:07:57 https://maestrodatabase.com/blog/director-of-u-dot-s-agency-key-to-vaccine-development-leaves-role-suddenly-amid-coronavirus-pandemic 2020-04-21T21:40:10 https://maestrodatabase.com/blog/priovant-therapeutics-announces-receipt-of-fast-track-designation-from-fda-for-brepocitinib-in-non-anterior-non-infectious-uveitis 2024-09-24T06:14:29 https://maestrodatabase.com/blog/new-brunswick-becomes-third-province-in-canada-to-implement-biosimilar-switching-policy 2021-04-22T01:19:30 https://maestrodatabase.com/blog/european-commission-approves-leo-pharmas-anzupgo-delgocitinib-cream-for-adults-with-moderate-to-severe-chronic-hand-eczema 2024-09-24T05:47:49 https://maestrodatabase.com/blog/abpi-details-brexit-plans-at-pipa-conference 2019-10-03T12:36:27 https://maestrodatabase.com/blog/principles-of-ethical-prescribing-for-self-and-others-hydroxychloroquine-in-the-covid-19-pandemic 2020-04-21T22:10:16 https://maestrodatabase.com/blog/chmp-issues-positive-opinion-for-biogens-skyclarys-omaveloxolone-the-first-therapy-to-treat-friedreichs-ataxia-a-rare-neurodegenerative-disease 2023-12-18T01:28:36 https://maestrodatabase.com/blog/nice-looks-to-company-to-ensure-a-new-treatment-for-advanced-breast-cancer-with-significant-unmet-need-is-cost-effective 2019-10-03T12:32:48 https://maestrodatabase.com/blog/ema-recommends-arpraziquantel-for-treatment-of-schistosomiasis-in-pre-school-aged-children 2023-12-18T00:53:18 https://maestrodatabase.com/blog/update-of-pbs-forms-and-procedure-guidance-for-listing-medicines-on-the-pbs 2019-10-03T10:50:11 https://maestrodatabase.com/blog/amgen-and-allergan-to-discuss-data-supporting-biologics-license-application-for-abp-215-a-biosimilar-candidate-to-avastin-bevacizumab 2017-07-13T23:26:52 https://maestrodatabase.com/blog/mercks-keytruda-pembrolizumab-now-approved-as-monotherapy-in-china-for-first-line-treatment-of-certain-patients-with-advanced-non-small-cell-lung-cancer-nsclc-whose-tumours-express-pd-l1 2019-10-03T12:54:16 https://maestrodatabase.com/blog/medicare-funded-cancer-genetic-tests-a-note-of-caution 2018-09-03T07:48:53 https://maestrodatabase.com/blog/pelosis-plan-to-slash-drug-prices-will-backfire 2019-10-03T12:48:42 https://maestrodatabase.com/blog/cablivi-caplacizumab-approved-in-europe-for-adults-with-acquired-thrombotic-thrombocytopenic-purpura 2018-09-03T09:53:23 https://maestrodatabase.com/blog/drug-firms-colluded-to-overcharge-nhs-by-up-to-1-800-percent 2019-10-03T20:59:36 https://maestrodatabase.com/blog/dr-brian-orourke-to-retire-as-cadths-president-and-ceo 2019-10-03T20:50:02 https://maestrodatabase.com/blog/youll-never-guess-which-company-is-reinventing-health-benefits 2018-09-03T10:57:02 https://maestrodatabase.com/blog/fda-approves-second-drug-to-prevent-hiv-infection-as-part-of-ongoing-efforts-to-end-the-hiv-epidemic 2019-10-03T20:47:24 https://maestrodatabase.com/blog/leo-pharma-announces-us-fda-approval-of-adbry-tralokinumab-ldrm-for-the-treatment-of-moderate-to-severe-atopic-dermatitis-in-paediatric-patients-aged-12-17-years 2023-12-18T05:45:15 https://maestrodatabase.com/blog/trump-to-unveil-order-aiming-to-boost-medicare-health-program-woo-seniors 2019-10-03T13:05:58 https://maestrodatabase.com/blog/nice-backs-bayers-eylea-novartis-lucentis-for-sight-condition 2018-01-23T20:00:36 https://maestrodatabase.com/blog/private-health-struggles-as-young-drop-out 2019-10-03T21:15:00 https://maestrodatabase.com/blog/what-you-need-to-know-about-pharmacare-this-election 2019-10-03T21:12:37 https://maestrodatabase.com/blog/ema-gives-positive-opinion-to-fexinidazole-winthrop-as-first-oral-treatment-of-acute-form-of-sleeping-sickness-rhodesiense-found-in-east-and-southern-africa 2023-12-18T05:05:03 https://maestrodatabase.com/blog/ema-surveys-pharma-companies-on-their-preparedness-for-brexit 2018-01-23T19:36:49 https://maestrodatabase.com/blog/white-house-insists-drug-prices-are-falling-but-critics-say-its-report-is-flawed 2019-10-03T21:07:45 https://maestrodatabase.com/blog/human-medicines-highlights-of-2017 2018-01-23T19:56:47 https://maestrodatabase.com/blog/an-unconventional-health-care-speech-trump-wishes-pharma-stocks-would-drop-and-implies-drug-industry-is-behind-impeachment 2019-10-03T21:05:28 https://maestrodatabase.com/blog/elevation-oncology-receives-fast-track-designation-from-the-fda-for-eo-3021-for-the-treatment-of-adult-patients-with-advanced-or-metastatic-gastric-or-gastro-oesophageal-junction-cancer-expressing-claudin-18-dot-2 2024-09-24T06:36:43 https://maestrodatabase.com/blog/jeremy-hunt-admits-supply-of-eu-cancer-drugs-to-britain-could-be-disrupted-if-brexit-talks-break-down 2018-01-23T20:13:22 https://maestrodatabase.com/blog/competition-in-pharmaceuticals-more-product--than-price-oriented 2018-01-23T20:16:45 https://maestrodatabase.com/blog/the-one-year-anniversary-of-the-oncology-center-of-excellence 2018-01-23T20:05:19 https://maestrodatabase.com/blog/fda-accepts-investigational-new-drug-application-and-grants-fast-track-status-for-sobi003-for-the-treatment-of-mps-iiia 2018-01-23T20:09:50 https://maestrodatabase.com/blog/registration-of-new-chemical-entities-in-australia-update 2018-01-23T20:23:17 https://maestrodatabase.com/blog/european-commission-approves-biocon-biologics-denosumab-biosimilars 2025-07-05T00:33:58 https://maestrodatabase.com/blog/us-fda-issues-complete-response-letter-for-cosibelimab-solely-due-to-inspection-findings-at-third-party-manufacturer 2023-12-18T20:52:47 https://maestrodatabase.com/blog/tlv-reconsiders-the-subsidy-of-lumykras-sotorasib 2023-04-04T20:48:48 https://maestrodatabase.com/blog/health-canada-approves-skyrizi-risankizumab-for-the-treatment-of-moderate-to-severe-plaque-psoriasis 2019-04-20T04:20:10 https://maestrodatabase.com/blog/plus-therapeutics-receives-fda-fast-track-designation-for-186rnl-targeted-radiotherapeutic-for-leptomeningeal-metastases 2021-11-09T19:47:32 https://maestrodatabase.com/blog/fda-authorises-gohibic-vilobelimab-injection-for-the-treatment-of-covid-19 2023-04-04T20:52:40 https://maestrodatabase.com/blog/lantern-pharma-announces-three-us-fda-rare-paediatric-disease-designations-granted-to-lp-184-in-multiple-ultra-rare-childrens-cancers 2024-09-24T08:20:35 https://maestrodatabase.com/blog/long-waited-drugs-were-approved-but-patients-must-wait-for-insurance-benefits 2023-04-04T20:44:52 https://maestrodatabase.com/blog/bergenbio-receives-fda-fast-track-designation-for-bemcentinib-in-stk11-mutated-advanced-slash-metastatic-non-small-cell-lung-cancer 2021-11-09T19:52:37 https://maestrodatabase.com/blog/zai-lab-announces-the-first-listing-of-vyvgart-efgartigimod-alfa-and-other-updates-in-chinas-national-reimbursement-drug-list 2023-12-18T21:16:43 https://maestrodatabase.com/blog/drug-makers-reveal-list-prices-online-after-pressure-from-trump 2019-04-20T04:38:39 https://maestrodatabase.com/blog/tga-grants-provisional-determination-to-astrazeneca-for-covid-19-preventative-treatment-tixagevimab-and-cilgavimab-evusheld 2021-11-09T10:41:52 https://maestrodatabase.com/blog/new-features-further-strengthen-priority-medicines-scheme-prime 2023-04-04T20:38:26 https://maestrodatabase.com/blog/daridorexant-for-the-treatment-of-patients-with-insomnia-disorder 2023-04-04T20:40:48 https://maestrodatabase.com/blog/nice-final-guidance-published-for-cimzia 2019-04-20T04:32:53 https://maestrodatabase.com/blog/a-toxic-drug-price-deal 2021-11-09T10:52:47 https://maestrodatabase.com/blog/fda-approves-first-generic-naloxone-nasal-spray-to-treat-opioid-overdose 2019-04-20T04:25:06 https://maestrodatabase.com/blog/medicare-non-compliance-and-fraud-costing-australians 2023-04-04T20:35:57 https://maestrodatabase.com/blog/dutch-doctors-fight-pharma-companys-500-fold-drug-price-rise 2018-09-03T21:12:21 https://maestrodatabase.com/blog/merck-and-ridgeback-announce-u-dot-s-government-to-purchase-1-dot-4-million-additional-courses-of-molnupiravir-an-investigational-oral-anti-viral-medicine-for-the-treatment-of-mild-to-moderate-covid-19-in-at-risk-adults 2021-11-09T20:19:36 https://maestrodatabase.com/blog/expanding-the-scope-of-costs-and-benefits-for-economic-evaluations-in-health-some-words-of-caution 2019-04-20T04:55:59 https://maestrodatabase.com/blog/fda-accepts-pfizers-supplemental-new-drug-applications-for-braftovi-plus-mektovi 2023-04-04T21:05:03 https://maestrodatabase.com/blog/who-warns-of-massive-syringe-shortfall-in-2022 2021-11-09T20:25:45 https://maestrodatabase.com/blog/fdas-efforts-to-advance-the-development-of-biologics 2019-04-20T04:52:27 https://maestrodatabase.com/blog/how-robots-and-smart-bomb-drugs-saved-dying-baby-ellie 2018-09-03T21:06:24 https://maestrodatabase.com/blog/fdas-woodcock-says-agency-has-resumed-normal-review-pace-for-biosimilars-generics 2021-11-09T20:06:33 https://maestrodatabase.com/blog/shionogi-receives-us-fda-fast-track-designation-for-ensitrelvir-fumaric-acid-an-investigational-oral-anti-viral-for-covid-19 2023-04-04T20:59:49 https://maestrodatabase.com/blog/elevar-therapeutics-resubmits-new-drug-application-to-fda-for-combination-of-camrelizumab-plus-rivoceranib-as-first-line-treatment-option-for-unresectable-hepatocellular-carcinoma-boosted-by-cares-310-leading-overall-survival-analysis 2024-09-24T20:44:53 https://maestrodatabase.com/blog/moderna-files-to-expand-the-conditional-marketing-authorisation-for-its-covid-19-vaccine-in-the-european-union-to-include-children-ages-6-11-years 2021-11-09T20:03:49 https://maestrodatabase.com/blog/improved-access-to-medicines-for-urinary-tract-infections-and-parkinsons-disease 2024-09-24T09:08:35 https://maestrodatabase.com/blog/abbvie-submits-marketing-authorisation-application-to-ema-for-atogepant-for-the-preventive-treatment-of-migraine 2022-07-18T07:31:18 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-tirzepatide-for-type-2-diabetes-mellitus 2021-11-09T20:10:24 https://maestrodatabase.com/blog/japans-ministry-of-health-labour-and-welfare-approves-padcev-enfortumab-vedotin-with-keytruda-pembrolizumab-for-first-line-treatment-of-radically-unresectable-urothelial-carcinoma 2024-09-24T08:56:36 https://maestrodatabase.com/blog/gc-biopharma-announces-us-fda-approval-for-alyglo-immune-globulin-intravenous-human-stwk-10-percent-liquid-for-adults-with-primary-humoral-immunodeficiency 2023-12-18T22:45:25 https://maestrodatabase.com/blog/endeavorrx-worlds-first-and-only-prescription-video-game-treatment-secures-fda-label-expansion-for-paediatric-adhd-patients-aged-13-17 2023-12-18T22:34:00 https://maestrodatabase.com/blog/tga-publishes-auspar-for-zolgensma 2021-04-22T06:28:40 https://maestrodatabase.com/blog/australia-to-wait-for-data-from-us-children-before-clearing-vaccine-here 2021-11-09T20:55:37 https://maestrodatabase.com/blog/teprotumumab-for-the-treatment-of-patients-with-thyroid-eye-disease 2025-07-05T04:02:25 https://maestrodatabase.com/blog/relief-therapeutics-announces-that-its-collaboration-partner-has-resubmitted-the-acer-001-sodium-phenylbutyrate-new-drug-application-to-the-fda-for-the-treatment-of-urea-cycle-disorders 2022-07-18T07:45:54 https://maestrodatabase.com/blog/delcath-systems-announces-revised-nice-guidance-for-chemosat-in-the-united-kingdom 2021-04-22T06:41:28 https://maestrodatabase.com/blog/ema-validates-marketing-authorisation-application-for-trastuzumab-duocarmazine-syd985-in-her2-positive-metastatic-breast-cancer 2022-07-18T09:56:44 https://maestrodatabase.com/blog/telix-submits-biologics-license-application-for-tlx250-cdx-zircaix-for-imaging-of-kidney-cancer 2023-12-18T23:40:34 https://maestrodatabase.com/blog/everest-medicines-announces-european-commission-grants-approval-of-kinpeygo-for-adults-with-primary-iga-nephropathy-to-our-partner-calliditas-therapeutics 2022-07-18T08:16:43 https://maestrodatabase.com/blog/lexeo-therapeutics-granted-fda-fast-track-designation-and-orphan-drug-designation-for-lx2020-an-aav-based-gene-therapy-candidate-for-pkp2-arrhythmogenic-cardiomyopathy 2023-12-18T23:17:40 https://maestrodatabase.com/blog/anheart-therapeutics-and-innovent-announce-chinas-nmpa-has-granted-taletrectinib-ros1-inhibitor-priority-review-designation 2023-12-18T23:02:46 https://maestrodatabase.com/blog/kite-submits-supplemental-biologics-license-application-to-u-dot-s-fda-for-yescarta-in-relapsed-or-refractory-indolent-non-hodgkins-lymphomas 2020-09-05T02:09:23 https://maestrodatabase.com/blog/azurity-pharmaceuticals-announces-fda-approval-of-zonisade-zonisamide-oral-suspension 2022-07-18T11:06:01 https://maestrodatabase.com/blog/the-tga-claims-tenofovir-emtricitabine-sandoz-is-a-first-generic-but-is-it 2021-04-22T08:17:13 https://maestrodatabase.com/blog/renuvion-cleared-by-fda-for-neck-laxity-procedures-offering-patients-a-minimally-invasive-option-to-eliminate-sagging-neck 2022-07-18T20:55:58 https://maestrodatabase.com/blog/vitalgens-gene-therapy-drug-vgn-r09b-for-primary-parkinsons-disease-receives-fda-fast-track-designation 2025-07-05T04:20:02 https://maestrodatabase.com/blog/janssen-announces-u-dot-s-fda-approval-of-tremfya-guselkumab-for-the-treatment-of-moderate-to-severe-plaque-psoriasis 2017-07-14T01:29:11 https://maestrodatabase.com/blog/ascendis-pharma-announces-u-dot-s-fda-accepts-biologics-license-application-for-transcon-hgh-for-paediatric-growth-hormone-deficiency 2020-09-05T02:16:10 https://maestrodatabase.com/blog/novartis-to-discontinue-sales-of-piqray-in-germany 2021-04-22T08:47:33 https://maestrodatabase.com/blog/genentech-announces-fda-approval-of-gavreto-pralsetinib-for-the-treatment-of-adults-with-metastatic-ret-fusion-positive-non-small-cell-lung-cancer 2020-09-05T02:22:37 https://maestrodatabase.com/blog/a-price-that-isnt-soaring-prescription-drugs 2022-07-18T21:23:36 https://maestrodatabase.com/blog/global-blockbusters-failure-to-win-insurance-coverage-raises-questions-about-fairness 2023-04-05T08:38:49 https://maestrodatabase.com/blog/fda-accepts-arcutis-supplemental-new-drug-application-for-zoryve-roflumilast-foam-for-the-treatment-of-scalp-and-body-psoriasis-in-adults-and-adolescents-ages-12-and-over 2024-09-25T00:06:50 https://maestrodatabase.com/blog/dirx-launches-groundbreaking-annual-savings-plan-unlimited-prescriptions-and-refills-for-more-than-1-000-generic-medications-for-one-annual-fee 2022-07-18T21:16:48 https://maestrodatabase.com/blog/texas-makes-a-stand-against-big-pharmas-covid-vaccines 2023-12-19T00:04:04 https://maestrodatabase.com/blog/biosimilar-medicines-are-the-key-to-success 2018-09-04T01:35:52 https://maestrodatabase.com/blog/velmanase-alfa-for-the-treatment-of-alfa-mannosidosis 2022-07-18T21:02:49 https://maestrodatabase.com/blog/seniors-suffer-the-most-from-antiquated-fda-approval-process 2020-09-05T02:39:02 https://maestrodatabase.com/blog/acadia-pharmaceuticals-submits-new-drug-application-to-the-u-dot-s-fda-for-trofinetide-for-the-treatment-of-rett-syndrome 2022-07-18T21:07:26 https://maestrodatabase.com/blog/mhra-grants-advantage-therapeutics-innovative-licensing-and-access-pathway-designation-for-novel-lead-product-ad04-for-phase-2b-trial-in-alzheimers-sisease 2023-04-05T20:54:19 https://maestrodatabase.com/blog/the-government-of-canada-announces-the-creation-of-the-canadian-drug-agency 2023-12-19T02:05:47 https://maestrodatabase.com/blog/celcuity-announces-fda-breakthrough-therapy-designation-for-gedatolisib-for-treatment-of-hr-positive-her2-negative-metastatic-breast-cancer 2022-07-18T21:45:50 https://maestrodatabase.com/blog/artificial-intelligence-workplan-to-guide-use-of-ai-in-medicines-regulation 2023-12-19T00:58:35 https://maestrodatabase.com/blog/international-reference-pricing-discounts-down-under-far-surpass-u-dot-s-drug-price-concessions 2020-09-05T02:59:28 https://maestrodatabase.com/blog/patient-charges-for-pbs-prescriptions-example-calculations 2018-09-04T04:43:42 https://maestrodatabase.com/blog/mycovia-pharmaceuticals-announces-u-dot-s-availability-of-vivjoa-oteseconazole-capsules-the-first-and-only-fda-approved-medication-for-recurrent-vulvovaginal-candidiasis-chronic-yeast-infection 2022-07-18T21:38:55 https://maestrodatabase.com/blog/ipsen-reacts-to-nices-cabometyx-verdict 2023-04-05T20:49:59 https://maestrodatabase.com/blog/vertex-announces-reimbursement-agreement-in-australia-for-orkambi-lumacaftor-slash-ivacaftor-for-people-with-cystic-fibrosis-ages-six-years-and-older-with-two-copies-of-the-f508del-mutation 2018-09-04T04:56:56 https://maestrodatabase.com/blog/takeda-receives-approval-for-fruzaqla-fruquintinib-in-japan-for-the-treatment-of-unresectable-advanced-or-recurrent-colorectal-cancer 2024-09-25T00:24:10 https://maestrodatabase.com/blog/sangamo-receives-fast-track-designation-from-the-fda-for-sb-318-and-sb-913-in-vivo-genome-editing-product-candidates-for-the-treatment-of-mps-i-and-mps-ii 2017-07-14T01:52:32 https://maestrodatabase.com/blog/faster-uk-drug-approvals-by-relying-on-other-countries 2023-04-05T20:46:50 https://maestrodatabase.com/blog/aussies-could-get-omicron-targeted-jab-earlier-than-most 2022-07-18T21:35:38 https://maestrodatabase.com/blog/quebec-implements-public-reimbursement-of-pluvicto---a-defining-milestone-for-radioligand-therapy-in-canada 2025-07-05T07:23:46 https://maestrodatabase.com/blog/more-children-now-eligible-for-cystic-fibrosis-drug 2022-07-18T21:29:52 https://maestrodatabase.com/blog/are-german-drug-pricing-regulations-chasing-some-drug-makers-away-causing-them-to-withdraw-products-from-the-market 2023-04-05T20:42:56 https://maestrodatabase.com/blog/caribou-biosciences-announces-fda-granted-fast-track-designation-to-cb-011-an-allogeneic-car-t-cell-therapy-for-relapsed-or-refractory-multiple-myeloma 2023-04-05T21:19:10 https://maestrodatabase.com/blog/pharmac-shares-next-steps-in-reviewing-rule-8-dot-1b 2023-04-05T21:23:33 https://maestrodatabase.com/blog/japan-drug-price-reforms-risk-hurting-investment-bristol-myers-ceo 2019-10-04T06:50:12 https://maestrodatabase.com/blog/verismo-therapeutics-secures-fast-track-designation-from-the-us-fda-for-synkir-110 2023-04-05T21:14:59 https://maestrodatabase.com/blog/proposal-to-list-eplerenone-for-the-treatment-of-heart-failure-in-patients-intolerant-to-spironolactone 2018-01-24T04:56:59 https://maestrodatabase.com/blog/hhs-finalises-rule-to-strengthen-medicare-improve-access-to-affordable-prescription-drug-coverage-and-hold-private-insurance-companies-accountable-to-delivering-quality-health-care-for-americas-seniors-and-people-with-disabilities 2023-04-05T21:11:05 https://maestrodatabase.com/blog/pm-says-government-will-listen-to-all-suggestions-to-arrest-slide-in-private-health-insurance 2019-10-04T07:51:36 https://maestrodatabase.com/blog/catalyst-pharmaceuticals-announces-firdapse-new-drug-application-submitted-in-japan-by-partner-dydo-pharma 2023-12-19T02:35:24 https://maestrodatabase.com/blog/merck-gets-partial-thumbs-down-on-keytruda-in-lymphoma-from-nice-cost-effectiveness-watchdogs 2018-09-04T20:51:20 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac---august-2019-intracycle-meeting 2019-10-04T07:46:33 https://maestrodatabase.com/blog/an-absolute-game-changer-children-under-12-to-receive-life-saving-drug 2023-04-05T21:00:01 https://maestrodatabase.com/blog/how-excluding-some-benefits-from-value-assessment-of-new-drugs-impacts-innovation 2018-01-24T04:48:29 https://maestrodatabase.com/blog/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-for-keytruda-pembrolizumab-for-the-treatment-of-merkel-cell-carcinoma-a-rare-form-of-skin-cancer 2018-09-04T20:44:40 https://maestrodatabase.com/blog/characteristics-of-interim-publications-of-randomised-clinical-trials-and-comparison-with-final-publications 2018-01-24T04:52:11 https://maestrodatabase.com/blog/lartruvo-olaratumab-approved-in-canada-for-the-treatment-of-advanced-soft-tissue-sarcoma-in-adults 2018-01-24T20:09:01 https://maestrodatabase.com/blog/australian-millennials-are-sick-of-paying-for-baby-boomers-health-care 2018-09-04T21:09:55 https://maestrodatabase.com/blog/janssen-submits-esketamine-nasal-spray-new-drug-application-to-u-dot-s-fda-for-treatment-resistant-depression 2018-09-04T21:13:48 https://maestrodatabase.com/blog/lillys-taltz-wins-eu-approval-for-psoriatic-arthritis 2018-01-24T10:10:32 https://maestrodatabase.com/blog/china-is-sprucing-up-its-pharma-sector 2018-09-04T20:58:23 https://maestrodatabase.com/blog/lillys-kisunla-donanemab-azbt-approved-in-japan-for-the-treatment-of-early-symptomatic-alzheimers-disease 2024-09-25T00:58:33 https://maestrodatabase.com/blog/director-at-nice-leaves-after-17-years 2018-01-24T20:03:38 https://maestrodatabase.com/blog/insurance-tactic-drags-down-u-dot-s-drug-prices-in-second-quarter 2018-09-04T21:26:29 https://maestrodatabase.com/blog/why-arent-final-base-case-icers-published-in-the-pbac-public-summary-documents 2018-09-04T21:33:07 https://maestrodatabase.com/blog/phrma-launches-new-consumer-facing-lets-talk-about-cost-website 2018-01-24T20:29:30 https://maestrodatabase.com/blog/fda-on-pace-for-record-generic-approvals-in-2018 2018-09-04T21:17:52 https://maestrodatabase.com/blog/medicaid-to-introduce-value-based-drug-pricing 2018-09-04T21:22:57 https://maestrodatabase.com/blog/european-commission-approves-mercks-keytruda-pembrolizumab-plus-chemotherapy-for-new-first-line-indications-in-advanced-her2-negative-gastric-or-gej-adenocarcinoma-in-tumours-expressing-pd-l1-cps-1-and-advanced-biliary-tract-cancer 2023-12-20T05:41:38 https://maestrodatabase.com/blog/santhera-announces-acceptance-by-swissmedic-of-marketing-authorisation-application-for-agamree-vamorolone-in-duchenne-muscular-dystrophy 2024-09-25T02:25:54 https://maestrodatabase.com/blog/wockhardt-receives-us-fda-qualified-infectious-disease-product-designation-for-wck-6777-a-first-ever-once-a-day-b-lactam-enhancer-class-antibiotic 2020-04-22T01:37:51 https://maestrodatabase.com/blog/gsks-menveo-meningococcal-vaccine-in-new-single-vial-fully-liquid-presentation-receives-positive-european-chmp-opinion 2024-09-25T03:05:00 https://maestrodatabase.com/blog/medicines-that-cannot-be-parallel-exported-from-the-uk 2019-10-04T08:33:06 https://maestrodatabase.com/blog/fda-grants-priority-review-to-xolair-omalizumab-for-children-and-adults-with-food-allergies-based-on-positive-national-institutes-of-health-phase-3-study-results 2023-12-20T05:50:36 https://maestrodatabase.com/blog/janssen-announces-u-dot-s-fda-breakthrough-therapy-designation-granted-for-niraparib-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer 2019-10-04T08:26:09 https://maestrodatabase.com/blog/fda-grants-priority-review-to-mercks-new-biologics-license-application-for-v116-an-investigational-21-valent-pneumococcal-conjugate-vaccine-specifically-designed-to-protect-adults 2023-12-20T05:46:32 https://maestrodatabase.com/blog/ocugen-announces-ocu400-receives-regenerative-medicine-advanced-therapy-designation-for-treatment-of-retinitis-pigmentosa-associated-with-rho-mutations 2023-12-20T07:42:17 https://maestrodatabase.com/blog/nice-recommends-new-treatment-for-rare-blood-disorder 2021-04-22T12:52:43 https://maestrodatabase.com/blog/eu-regulator-reviews-pfizer-biontech-covid-shot-in-children-as-young-as-6-months 2022-07-19T01:54:49 https://maestrodatabase.com/blog/who-and-ema-to-inspect-sputnik-v-manufacturing-in-may 2021-04-22T10:56:36 https://maestrodatabase.com/blog/tga-provisionally-approves-moderna-covid-19-vaccine-spikevax-for-use-in-children-from-6-months 2022-07-19T01:36:25 https://maestrodatabase.com/blog/phrma-scores-a-small-win-in-legal-challenge-to-medicares-drug-price-negotiation 2024-09-25T03:38:28 https://maestrodatabase.com/blog/house-democrats-to-unveil-drug-pricing-measure-ahead-of-biden-package 2021-04-22T10:58:59 https://maestrodatabase.com/blog/bluebirds-withdrawal-of-therapy-from-germany-could-chill-talks-over-gene-therapy-prices-across-europe 2021-04-22T21:14:08 https://maestrodatabase.com/blog/over-50s-to-receive-astrazeneca 2021-04-22T21:10:05 https://maestrodatabase.com/blog/fda-approves-immunotherapy-for-endometrial-cancer-with-specific-biomarker 2021-04-22T21:00:15 https://maestrodatabase.com/blog/outcomes-from-the-march-2021-pbac-set-for-public-release 2021-04-22T20:56:45 https://maestrodatabase.com/blog/mhra-approves-nogapendekin-alfa-inbakicept-to-treat-adult-patients-with-non-muscle-invasive-bladder-cancer 2025-07-06T03:45:53 https://maestrodatabase.com/blog/the-thorny-issue-of-value-alignment-how-development-focused-health-technology-assessment-can-help-find-win-win-situations-for-patients-and-health-care-systems-and-commercial-investors 2021-04-22T21:37:15 https://maestrodatabase.com/blog/european-commission-grants-marketing-authorisation-for-puma-biotechnologys-nerlynx-neratinib-for-extended-adjuvant-treatment-of-hormone-receptor-positive-her2-positive-early-stage-breast-cancer 2018-09-05T01:20:34 https://maestrodatabase.com/blog/new-analysis-shows-international-reference-drug-pricing-would-have-a-catastrophic-impact-on-alzheimers-disease-research 2021-04-22T21:22:47 https://maestrodatabase.com/blog/baxter-announces-health-canada-approval-of-olimel-7-dot-6-percent-high-protein-parenteral-nutrition-formulations 2018-09-05T02:02:17 https://maestrodatabase.com/blog/health-canada-approves-perjeta-pertuzumab-for-the-treatment-of-her2-positive-early-breast-cancer-after-surgery 2018-09-05T01:56:49 https://maestrodatabase.com/blog/ema-publishes-agenda-for-18-21-july-2022-chmp-meeting 2022-07-19T02:51:04 https://maestrodatabase.com/blog/trifluridine-with-tipiracil-hydrochloride-in-combination-with-bevacizumab-for-the-treatment-of-patients-with-metastatic-colorectal-cancer-after-two-systemic-treatments-final-guidance 2024-09-25T06:03:41 https://maestrodatabase.com/blog/mirum-submits-for-european-approval-of-livmarli-in-progressive-familial-intrahepatic-cholestasis 2023-04-06T01:18:10 https://maestrodatabase.com/blog/garadacimab-for-the-prevention-of-recurrent-attacks-of-hereditary-angioedema-in-patients-12-years-of-age-and-older 2025-07-06T06:06:06 https://maestrodatabase.com/blog/mmr-vaccine-commonly-used-to-protect-against-mumps-measles-and-rubella-could-be-effective-against-coronavirus 2020-04-22T03:24:26 https://maestrodatabase.com/blog/fda-approves-new-drug-to-treat-niemann-pick-disease-type-c 2024-09-25T21:04:05 https://maestrodatabase.com/blog/fda-approves-osimertinib-for-locally-advanced-unresectable-stage-iii-non-small-cell-lung-cancer-following-chemoradiation-therapy 2024-09-25T20:56:52 https://maestrodatabase.com/blog/modernas-covid-19-vaccine-spikevax---provisional-determination-granted-for-proposed-use-in-children-and-booster-shot-for-adults-under-evaluation 2021-11-10T04:55:00 https://maestrodatabase.com/blog/fda-approves-new-therapy-for-triple-negative-breast-cancer-that-has-spread-not-responded-to-other-treatments 2020-04-22T20:35:22 https://maestrodatabase.com/blog/novartis-kymriah-receives-fda-regenerative-medicine-advanced-therapy-designation-in-follicular-lymphoma 2020-04-22T07:15:35 https://maestrodatabase.com/blog/pharmac-back-tracks-on-plan-to-fund-lung-cancer-drug-keytruda 2020-04-22T20:45:50 https://maestrodatabase.com/blog/mallinckrodt-announces-u-dot-s-fda-filing-acceptance-of-new-drug-application-for-terlipressin-for-treatment-of-hepatorenal-syndrome-type-1 2020-04-22T20:54:42 https://maestrodatabase.com/blog/managed-entry-agreements-policy-analysis-from-the-european-perspective 2020-04-22T21:24:25 https://maestrodatabase.com/blog/deal-for-nhs-to-offer-exciting-new-child-cancer-therapy 2018-09-05T06:04:10 https://maestrodatabase.com/blog/health-canada-authorises-the-use-of-the-pfizer-biontech-comirnaty-covid-19-vaccine-as-a-booster-shot 2021-11-10T05:51:47 https://maestrodatabase.com/blog/uk-underinvested-in-health-care-says-pharma-boss 2020-04-22T21:29:11 https://maestrodatabase.com/blog/budesonide-for-the-treating-primary-iga-nephropathy 2023-12-20T20:01:36 https://maestrodatabase.com/blog/ravulizumab-for-the-treatment-of-patients-with-generalised-myasthenia-gravis 2023-12-20T19:55:51 https://maestrodatabase.com/blog/prediction-models---development-evaluation-and-clinical-application 2020-04-22T21:39:56 https://maestrodatabase.com/blog/universal-health-care-is-a-fundamental-right----being-delusional-is-not 2021-11-10T06:09:33 https://maestrodatabase.com/blog/new-u-dot-s-treatment-guidelines-for-covid-19-dont-see-much-progress 2020-04-22T21:08:03 https://maestrodatabase.com/blog/atagi-update-following-weekly-covid-19-meeting-13-july-2022 2022-07-19T04:37:05 https://maestrodatabase.com/blog/dova-pharmaceuticals-submits-supplemental-new-drug-application-for-doptelet-avatrombopag-for-the-treatment-of-chronic-itp 2018-09-05T06:17:58 https://maestrodatabase.com/blog/doctor-says-he-was-removed-from-federal-post-after-opposing-funding-for-unproven-drugs 2020-04-22T21:15:21 https://maestrodatabase.com/blog/pfizer-canada-and-biontech-receive-health-canada-approval-of-omicron-kp-dot-2-variant-adapted-covid-19-vaccine 2024-09-26T09:28:49 https://maestrodatabase.com/blog/moderna-receives-health-canada-approval-for-updated-covid-19-vaccine-targeting-kp-dot-2-variant-of-sars-cov-2-for-ages-six-months-and-older 2024-09-25T23:59:02 https://maestrodatabase.com/blog/biocon-mylan-launch-semglee-and-seek-biosimilar-interchangeable-status 2020-09-05T07:49:00 https://maestrodatabase.com/blog/empagliflozin-for-the-treatment-of-patients-with-chronic-kidney-disease 2023-12-20T20:26:03 https://maestrodatabase.com/blog/abbvie-receives-health-canada-approval-of-humira-adalimumab-for-the-treatment-of-paediatric-patients-with-moderately-to-severely-active-ulcerative-colitis 2021-04-23T03:46:46 https://maestrodatabase.com/blog/chiesi-global-rare-diseases-receives-fda-approval-for-filzuvez-birch-triterpenes-topical-gel-for-the-treatment-of-epidermolysis-bullosa 2023-12-20T20:12:16 https://maestrodatabase.com/blog/real-world-evidence-to-support-payer-slash-hta-decisions-about-highly-innovative-technologies-in-the-eu--actions-for-stakeholders 2020-09-05T21:30:39 https://maestrodatabase.com/blog/ravulizumab-for-the-treatment-of-patients-with-aqp4-antibody-positive-neuromyelitis-optica-spectrum-disorder 2023-12-21T09:47:41 https://maestrodatabase.com/blog/future-supply-of-new-covid-19-vaccines-confirmed 2023-12-21T09:44:44 https://maestrodatabase.com/blog/hamilton-22-year-old-given-compassionate-access-to-$80k-cancer-treatment-unfunded-by-pharmac 2020-09-05T08:24:46 https://maestrodatabase.com/blog/tepezza-teprotumumab-receives-approval-in-japan-for-the-treatment-of-active-thyroid-eye-disease 2024-09-26T11:03:40 https://maestrodatabase.com/blog/calliditas-therapeutics-announces-full-fda-approval-of-tarpeyo-the-only-fda-approved-treatment-for-iga-nephropathy-to-significantly-reduce-the-loss-of-kidney-function 2023-12-21T19:44:22 https://maestrodatabase.com/blog/health-canada-grants-marketing-authorisation-of-first-crispr-slash-cas9-gene-edited-therapy-casgevy-exagamglogene-autotemcel-for-the-treatment-of-sickle-cell-disease-and-transfusion-dependent-beta-thalassaemia 2024-09-26T10:43:46 https://maestrodatabase.com/blog/nice-u-turn-approves-funding-for-rare-disease-therapy-crysvita 2018-09-05T09:29:45 https://maestrodatabase.com/blog/pricey-drug-could-help-digby-dad-fighting-rare-cancer 2018-01-25T04:05:58 https://maestrodatabase.com/blog/life-changing-cystic-fibrosis-treatment-now-available-to-children-6-years-and-above 2023-04-06T03:54:22 https://maestrodatabase.com/blog/merck-provides-us-regulatory-update-on-gefapixant 2023-12-21T19:29:55 https://maestrodatabase.com/blog/value-based-pricing-lenfant-terrible 2018-01-25T04:50:52 https://maestrodatabase.com/blog/enhertu-approved-in-the-eu-for-patients-with-her2-positive-metastatic-breast-cancer-treated-with-one-or-more-prior-anti-her2-based-regimens 2022-07-19T07:35:26 https://maestrodatabase.com/blog/discounted-drugs-for-needy-patients-and-hospitals---understanding-the-340b-debate 2018-01-25T06:33:47 https://maestrodatabase.com/blog/remegen-announces-continued-inclusion-of-telitacicept-and-disitamab-vedotin-in-china-national-reimbursement-drug-list-ensuring-continuous-accessibility-of-innovative-drugs-for-more-patients 2023-12-21T20:21:40 https://maestrodatabase.com/blog/health-premium-4-per-cent-price-hike-to-cost-families 2018-01-25T04:10:20 https://maestrodatabase.com/blog/janssen-submits-marketing-authorisation-application-to-the-ema-seeking-approval-of-lazertinib-in-combination-with-rybrevant-amivantamab-for-the-first-line-treatment-of-patients-with-egfr-mutated-non-small-cell-lung-cancer 2023-12-21T20:17:21 https://maestrodatabase.com/blog/johnson-and-johnson-submits-supplemental-biologics-license-application-and-new-drug-application-to-us-fda-seeking-approval-of-rybrevant-amivantamab-vmjw-plus-lazertinib-for-the-treatment-of-patients-with-egfr-mutated-non-small-cell-lung-cancer 2023-12-21T20:02:58 https://maestrodatabase.com/blog/brad-hazzards-call-to-stop-free-health-care-for-tourists-and-visitors 2018-09-05T20:48:03 https://maestrodatabase.com/blog/outcomes-from-the-march-2021-pbac-meeting 2021-04-23T08:03:48 https://maestrodatabase.com/blog/4dmt-receives-fda-regenerative-medicine-advanced-therapy-designation-for-4d-150-genetic-medicine-for-intravitreal-treatment-of-wet-amd-the-first-rmat-designation-in-wet-amd 2023-12-21T19:54:22 https://maestrodatabase.com/blog/eisai-and-merck-announce-china-national-medical-products-administration-approval-of-lenvima-lenvatinib-for-treatment-of-unresectable-hepatocellular-carcinoma 2018-09-05T11:48:43 https://maestrodatabase.com/blog/incyte-announces-u-dot-s-fda-approval-of-opzelura-ruxolitinib-cream-for-the-treatment-of-vitiligo 2022-07-19T09:57:13 https://maestrodatabase.com/blog/wainua-eplontersen-granted-first-ever-regulatory-approval-in-the-us-for-the-treatment-of-adults-with-polyneuropathy-of-hereditary-transthyretin-mediated-amyloidosis 2023-12-22T04:14:10 https://maestrodatabase.com/blog/pbs-expenditure-and-prescriptions-report-2022-23 2023-12-22T03:37:12 https://maestrodatabase.com/blog/daewoongs-idiopathic-pulmonary-fibrosis-drug-gets-fdas-fast-track-status 2022-07-19T10:04:48 https://maestrodatabase.com/blog/hand-surgeons-career-saved-by-gene-silencing-drug 2018-09-05T20:51:07 https://maestrodatabase.com/blog/new-study-finds-some-hospitals-mark-up-medicine-prices-at-least-700-percent 2018-09-05T20:57:40 https://maestrodatabase.com/blog/takeda-announces-china-nmpa-approval-of-livtencity-maribavir-for-the-treatment-of-adults-with-post-transplant-cytomegalovirus-refractory-to-prior-therapies 2023-12-22T03:14:16 https://maestrodatabase.com/blog/statement-from-fda-commissioner-on-the-agencys-global-efforts-to-help-assure-product-quality-and-transparency-at-foreign-drug-manufacturing-facilities 2018-09-05T21:25:12 https://maestrodatabase.com/blog/genmab-announces-that-abbvie-will-submit-marketing-authorisation-application-to-ema-for-epcoritamab-for-the-treatment-of-relapsed-slash-refractory-diffuse-large-b-cell-lymphoma 2022-07-19T09:44:42 https://maestrodatabase.com/blog/keytruda-pembrolizumab-plus-lenvima-lenvatinib-receive-public-listing-for-patients-with-advanced-endometrial-carcinoma-that-is-not-msi-h-or-dmmr 2023-12-22T03:04:20 https://maestrodatabase.com/blog/pfizer-voluntarily-withdraws-all-lots-of-sickle-cell-disease-treatment-oxbryta-voxelotor-from-worldwide-markets 2024-09-26T21:08:19 https://maestrodatabase.com/blog/chi-med-announces-the-approval-of-fruquintinib-capsules-for-previously-treated-colorectal-cancer-in-china 2018-09-05T21:06:59 https://maestrodatabase.com/blog/loxo-oncology-announces-receipt-of-breakthrough-therapy-designation-from-u-dot-s-fda-for-loxo-292 2018-09-05T21:18:15 https://maestrodatabase.com/blog/new-program-with-payers-aims-to-accelerate-patient-access-to-medical-devices 2018-09-05T21:27:40 https://maestrodatabase.com/blog/roches-elecsys-amyloid-plasma-panel-granted-fda-breakthrough-device-designation-to-enable-a-timely-diagnosis-of-alzheimers-disease 2022-07-19T10:25:35 https://maestrodatabase.com/blog/publication-of-final-base-case-icers-icurs-by-health-technology-assessment-agencies 2018-09-05T21:33:16 https://maestrodatabase.com/blog/kalvista-pharmaceuticals-announces-fda-approval-of-ekterly-sebetralstat-first-and-only-oral-on-demand-treatment-for-hereditary-angioedema 2025-07-07T22:24:11 https://maestrodatabase.com/blog/biontech-and-dualitybio-receive-fda-breakthrough-therapy-designation-for-antibody-drug-conjugate-candidate-bnt323-slash-db-1303-in-endometrial-cancer 2023-12-22T04:22:49 https://maestrodatabase.com/blog/ema-recommends-suspension-of-sickle-cell-disease-medicine-oxbryta 2024-09-26T21:55:56 https://maestrodatabase.com/blog/the-path-to-the-first-fda-approved-cannabis-derived-treatment-and-what-comes-next 2018-09-05T22:57:53 https://maestrodatabase.com/blog/apellis-announces-fda-acceptance-and-priority-review-of-the-new-drug-application-for-pegcetacoplan-for-the-treatment-of-geographic-atrophy 2022-07-19T11:03:29 https://maestrodatabase.com/blog/will-miracle-hiv-drug-go-on-the-pbs 2025-07-07T11:26:08 https://maestrodatabase.com/blog/dbv-technologies-announces-fda-acceptance-of-bla-filing-for-viaskin-peanut-for-the-treatment-of-peanut-allergy 2019-10-05T01:58:27 https://maestrodatabase.com/blog/german-government-announces-bill-to-drastically-slash-drug-reimbursement 2022-07-19T20:59:02 https://maestrodatabase.com/blog/fda-approves-drug-with-new-mechanism-of-action-for-treatment-of-schizophrenia 2024-09-27T06:19:47 https://maestrodatabase.com/blog/galderma-receives-fda-approval-for-aklief-trifarotene-0-dot-005-percent-cream-the-first-new-retinoid-molecule-for-the-treatment-of-acne-in-over-20-years 2019-10-05T02:05:12 https://maestrodatabase.com/blog/peptilogics-receives-fda-fast-track-designation-for-plg0206-an-investigational-peptide-therapeutic-in-development-for-the-treatment-of-peri-prosthetic-joint-infection 2022-07-19T20:51:34 https://maestrodatabase.com/blog/thousands-benefit-from-pharmac-decision-to-fund-oestradiol-gel 2024-09-27T05:30:32 https://maestrodatabase.com/blog/is-congress-too-afraid-to-fight-big-pharma 2019-10-05T02:02:30 https://maestrodatabase.com/blog/neurostar-advanced-therapy-for-mental-health-receives-fda-clearance-for-treatment-of-anxious-depression 2022-07-19T11:32:50 https://maestrodatabase.com/blog/fda-grants-breakthrough-therapy-designation-to-cobimetinib-for-mek-inhibition-in-histiocytic-neoplasms-research-led-by-msk 2019-10-05T02:15:31 https://maestrodatabase.com/blog/wugen-receives-us-fda-fast-track-and-rare-paediatric-disease-designations-for-wu-cart-007-for-the-treatment-of-r-slash-r-t-all-slash-lbl 2022-07-19T21:24:58 https://maestrodatabase.com/blog/ascentage-pharma-and-innovent-announce-the-china-nmpa-accepted-and-granted-priority-review-designation-to-a-new-drug-application-for-olverembatinib-for-the-treatment-of-drug-resistant-cml 2022-07-19T21:15:55 https://maestrodatabase.com/blog/fasenra-approved-in-the-us-for-self-administration-in-a-new-pre-filled-auto-injector-the-fasenra-pen 2019-10-05T02:10:09 https://maestrodatabase.com/blog/why-prescription-drug-prices-in-the-us-are-so-high 2023-06-07T04:50:47 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-to-ptc518-huntingtons-disease-program 2024-09-27T06:26:56 https://maestrodatabase.com/blog/icer-publishes-final-evidence-report-and-policy-recommendations-on-beti-cel-gene-therapy-for-beta-thalassaemia 2022-07-19T21:06:58 https://maestrodatabase.com/blog/increase-in-vaccine-manufacturing-capacity-and-supply-for-covid-19-vaccines-from-biontech-slash-pfizer-and-moderns 2021-04-23T12:53:31 https://maestrodatabase.com/blog/heres-how-trump-could-bigfoot-the-fda-and-get-a-vaccine-out-ahead-of-the-science 2020-09-06T09:07:28 https://maestrodatabase.com/blog/coronavirus-vaccine-australia-reaches-deal-to-secure-priority-access 2020-09-06T20:46:42 https://maestrodatabase.com/blog/nice-not-supportive-of-encorafenib-for-metastatic-colorectal-cancer 2020-09-06T20:49:56 https://maestrodatabase.com/blog/lexeo-therapeutics-announces-fda-breakthrough-therapy-designation-for-lx2006-in-friedreich-ataxia 2025-07-08T00:32:39 https://maestrodatabase.com/blog/new-agreement-makes-more-medicines-available-to-treat-range-of-health-conditions 2018-09-06T02:23:51 https://maestrodatabase.com/blog/moleculin-receives-fda-approval-of-fast-track-designation-for-annamycin 2019-04-21T11:11:36 https://maestrodatabase.com/blog/astrazeneca-vaccine-discontinued-by-federal-government 2023-04-06T08:14:09 https://maestrodatabase.com/blog/bayer-submits-supplemental-new-drug-application-to-us-fda-seeking-expanded-indication-for-nubeqa-darolutamide-in-metastatic-hormone-sensitive-prostate-cancer 2024-09-28T23:39:45 https://maestrodatabase.com/blog/denali-therapeutics-announces-fda-acceptance-and-priority-review-of-biologics-license-application-for-tividenofusp-alfa-for-hunter-syndrome 2025-07-08T00:23:13 https://maestrodatabase.com/blog/public-summary-documents---december-2022-pbac-meeting 2023-04-06T08:06:23 https://maestrodatabase.com/blog/roche-receives-fda-approval-for-first-companion-diagnostic-to-identify-endometrial-cancer-patients-eligible-for-immunotherapy 2021-04-23T13:04:49 https://maestrodatabase.com/blog/mhra-approves-first-medicine-for-rare-immune-disease-apds 2024-09-28T23:33:12 https://maestrodatabase.com/blog/dupixent-dupilumab-approved-in-china-as-the-first-ever-biologic-medicine-for-patients-with-chronic-obstructive-pulmonary-disease 2024-09-28T23:20:24 https://maestrodatabase.com/blog/mhra-authorises-amarins-heart-drug-vazkepa 2021-04-23T12:58:09 https://maestrodatabase.com/blog/revised-pbs-listings-for-hydroxychloroquine-for-the-treatment-of-auto-immune-disorders-and-malaria-from-1-may-2020 2020-04-23T01:57:54 https://maestrodatabase.com/blog/proposal-on-the-funding-of-infliximab-rituximab-and-tocilizumab 2018-09-06T06:20:25 https://maestrodatabase.com/blog/additional-public-summary-documents---pbac-march-2017-meeting 2017-07-14T08:25:12 https://maestrodatabase.com/blog/trastuzumab-deruxtecan-for-the-treatment-of-patients-with-her2-positive-unresectable-or-metastatic-gastric-or-gastro-oesophageal-junction-cancer-after-anti-her2-treatment 2023-04-06T08:21:03 https://maestrodatabase.com/blog/approval-of-multi-product-funding-agreement-with-novartis 2018-09-06T06:18:02 https://maestrodatabase.com/blog/genfit-announces-fda-grant-of-breakthrough-therapy-designation-to-elafibranor-for-the-treatment-of-pbc 2019-04-21T11:29:21 https://maestrodatabase.com/blog/justice-department-nearing-antitrust-approval-of-health-mergers-combining-cvs-aetna-cigna-express-scripts 2018-09-06T06:30:38 https://maestrodatabase.com/blog/roche-executive-says-alzheimers-drug-price-will-be-competitive 2021-11-10T19:50:52 https://maestrodatabase.com/blog/vertex-announces-health-canada-acceptance-of-new-drug-submission-for-vanzacaftor-slash-tezacaftor-slash-deutivacaftor-a-next-in-class-triple-combination-treatment-for-cystic-fibrosis 2024-09-29T00:25:35 https://maestrodatabase.com/blog/krpia-raises-concern-over-hiras-cost-effectiveness-evaluation-plan 2021-11-10T19:57:54 https://maestrodatabase.com/blog/revised-pbs-listings-for-certain-antibiotics-from-1-may-2020 2020-04-23T02:01:26 https://maestrodatabase.com/blog/ema-starts-evaluating-use-of-covid-19-vaccine-spikevax-in-children-aged-6-to-11 2021-11-10T19:38:09 https://maestrodatabase.com/blog/viela-bio-receives-u-dot-s-fda-breakthrough-therapy-designation-for-inebilizumab-for-treatment-of-neuromyelitis-optica-spectrum-disorder 2019-04-21T11:49:15 https://maestrodatabase.com/blog/uk-lags-behind-most-of-europe-in-access-to-biologics-for-patients-with-rheumatoid-arthritis 2018-09-06T06:35:01 https://maestrodatabase.com/blog/nice-publishes-final-recommendation-for-almiralls-ilumetri-tildrakizumab-as-a-cost-effective-option-for-adults-with-moderate-to-severe-plaque-psoriasis 2019-04-21T11:45:17 https://maestrodatabase.com/blog/smc-accepts-oral-therapy-for-relapsing-multiple-sclerosis 2021-11-10T19:42:30 https://maestrodatabase.com/blog/abbvie-submits-biologics-license-application-to-the-fda-for-telisotuzumab-vedotin-in-previously-treated-non-small-cell-lung-cancer 2024-09-29T00:02:30 https://maestrodatabase.com/blog/centralised-marketing-authorisations-of-generic-versions-of-tecfidera-are-revoked-by-the-european-commission 2023-12-22T22:50:21 https://maestrodatabase.com/blog/fda-extends-review-time-for-roches-tecentriq-slash-avastin-combination 2018-09-06T10:35:46 https://maestrodatabase.com/blog/ellumes-covid-19-home-test-recall-most-serious-fda-says 2021-11-10T20:21:29 https://maestrodatabase.com/blog/fda-authorises-marketing-of-device-to-facilitate-muscle-rehabilitation-in-stroke-patients 2021-04-23T23:13:02 https://maestrodatabase.com/blog/nice-terminates-appraisal-of-new-first-in-class-radioenhancer-hafnium-oxide-nanoparticle 2021-11-10T20:27:34 https://maestrodatabase.com/blog/pfizer-and-biontech-complete-submission-to-european-medicines-agency-for-omicron-ba-dot-1-adapted-bivalent-vaccine-candidate 2022-07-20T08:16:53 https://maestrodatabase.com/blog/fda-approves-selpercatinib-for-ret-fusion-positive-medullary-thyroid-cancer 2024-09-29T00:34:26 https://maestrodatabase.com/blog/the-last-drugstore-rural-america-is-losing-its-pharmacies 2021-11-10T20:04:26 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-loncastuximab-tesirine-lpyl-for-large-b-cell-lymphoma 2021-04-23T21:59:04 https://maestrodatabase.com/blog/merck-and-ridgeback-announce-japanese-government-to-purchase-1-dot-6-million-courses-of-molnupiravir-an-investigational-oral-covid-19-anti-viral-medicine-upon-authorisation-or-approval 2021-11-10T20:16:42 https://maestrodatabase.com/blog/why-tga-head-john-skerritt-must-go-over-vaccine-claim 2021-11-10T20:07:31 https://maestrodatabase.com/blog/alnylam-announces-ema-acceptance-of-marketing-authorisation-application-for-patisiran-for-the-treatment-of-hereditary-attr-amyloidosis 2018-01-26T03:28:01 https://maestrodatabase.com/blog/senate-confirms-trump-nominee-alex-azar-as-health-secretary 2018-01-26T04:24:39 https://maestrodatabase.com/blog/lowest-private-health-insurance-premium-change-in-17-years 2018-01-26T04:27:54 https://maestrodatabase.com/blog/synergy-pharmaceuticals-announces-fda-approval-of-trulance-plecanatide-for-the-treatment-of-irritable-bowel-syndrome-with-constipation-in-adults 2018-01-26T03:33:24 https://maestrodatabase.com/blog/drug-reimbursement-panel-approves-iptacopan-for-pnh-reimbursement-rejects-danicopan-over-cost-concerns 2025-07-08T07:49:34 https://maestrodatabase.com/blog/statement-by-president-joe-biden-on-fda-and-cdc-authorising-novavaxs-covid--19-vaccine-for-adults 2022-07-20T09:01:04 https://maestrodatabase.com/blog/recent-pharmac-funding-decisions 2020-04-23T05:24:36 https://maestrodatabase.com/blog/health-insurance-funds-to-help-government-sell-premium-hikes 2018-09-06T20:58:56 https://maestrodatabase.com/blog/cvs-drug-coverage-plan-based-on-outside-pricing-review-is-off-to-a-slow-start 2019-10-05T05:45:09 https://maestrodatabase.com/blog/we-can-make-medicine-affordable-without-the-damage-pharmacare-will-cause-canadians 2018-09-06T21:01:46 https://maestrodatabase.com/blog/venclyxto-in-combination-with-obinutuzumab-is-included-in-the-high-cost-protection-with-limitation 2020-09-06T23:02:14 https://maestrodatabase.com/blog/pelosis-expensive-drug-bill 2019-10-05T05:40:58 https://maestrodatabase.com/blog/karyopharm-granted-regulatory-designations-for-eltanexor-for-the-treatment-of-myelodysplastic-syndromes 2022-07-20T11:20:42 https://maestrodatabase.com/blog/easier-access-to-locally-applied-hrt-to-treat-post-menopausal-vaginal-symptoms-in-landmark-mhra-reclassification 2022-07-20T11:10:50 https://maestrodatabase.com/blog/half-of-all-health-fund-members-to-lose-cover-for-hip-and-knee-replacements 2018-09-06T20:56:34 https://maestrodatabase.com/blog/enanta-pharmaceuticals-receives-fda-fast-track-designation-for-edp-323-its-oral-l-protein-inhibitor-in-development-for-the-treatment-of-respiratory-syncytial-virus 2023-04-06T23:08:50 https://maestrodatabase.com/blog/will-trumps-pharma-shaming-bring-down-drug-prices-not-likely-poll-says 2018-09-06T21:13:57 https://maestrodatabase.com/blog/dupixent-dupilumab-approved-in-the-us-as-the-first-ever-biologic-medicine-for-patients-with-copd 2024-09-29T03:10:54 https://maestrodatabase.com/blog/itf-pharma-announces-fda-approval-of-tiglutik-riluzole-oral-suspension-for-the-treatment-of-amyotrophic-lateral-sclerosis 2018-09-06T21:06:24 https://maestrodatabase.com/blog/drug-pricing-could-labours-radical-plan-work 2019-10-05T05:47:59 https://maestrodatabase.com/blog/blame-emergency-rooms-for-the-out-of-control-cost-of-health-care 2018-09-06T21:32:07 https://maestrodatabase.com/blog/zealand-pharma-submits-new-drug-application-to-the-us-fda-for-glepaglutide-in-short-bowel-syndrome 2023-12-23T03:53:48 https://maestrodatabase.com/blog/is-it-time-for-a-review-of-the-content-in-pbac-public-summary-documents 2018-09-06T21:34:02 https://maestrodatabase.com/blog/senate-unanimously-passes-bill-banning-pharmacy-gag-clauses-in-medicare 2018-09-06T21:21:02 https://maestrodatabase.com/blog/hospitals-are-fed-up-with-drug-companies-so-theyre-starting-their-own 2018-09-06T21:23:10 https://maestrodatabase.com/blog/fda-approves-new-treatment-for-certain-digestive-tract-cancers 2018-01-26T20:44:24 https://maestrodatabase.com/blog/enterprise-therapeutics-granted-rare-paediatric-disease-designation-in-the-us-for-novel-cystic-fibrosis-investigational-therapy-etd001 2024-09-29T07:25:37 https://maestrodatabase.com/blog/fda-commissioner-and-chief-scientist-announce-decision-to-withdraw-approval-of-makena 2023-04-07T21:50:26 https://maestrodatabase.com/blog/fda-approves-qsymia-for-the-treatment-of-obesity-in-adolescents-ages-12-17 2022-07-20T21:02:38 https://maestrodatabase.com/blog/sarepta-therapeutics-submits-efficacy-supplement-to-expand-the-elevidys-label-to-include-duchenne-muscular-dystrophy-patients-without-restriction-to-age-or-ambulatory-status 2023-12-23T04:16:33 https://maestrodatabase.com/blog/cabotegravir-for-the-prevention-of-hiv-1-infection-in-adults-and-adolescents 2024-09-29T12:11:59 https://maestrodatabase.com/blog/simulating-colorectal-cancer-trials-using-real-world-data 2022-07-20T21:43:49 https://maestrodatabase.com/blog/update-on-imbruvica-ibrutinib-us-accelerated-approvals-for-mantle-cell-lymphoma-and-marginal-zone-lymphoma-indications 2023-04-07T22:33:17 https://maestrodatabase.com/blog/for-medicaid-insured-patients-with-cancer-health-insurance-does-not-always-mean-health-access 2022-07-20T21:19:34 https://maestrodatabase.com/blog/fda-announces-an-oncologic-drugs-advisory-committee-meeting-to-discuss-benefit-slash-risk-profile-of-oncopeptides-pepaxto 2022-07-20T21:07:41 https://maestrodatabase.com/blog/chmp-recommends-eu-approval-of-roches-enspryng-satralizumab-for-adults-and-adolescents-with-neuromyelitis-optica-spectrum-disorder 2021-04-24T00:16:36 https://maestrodatabase.com/blog/the-big-squeeze 2022-07-20T21:17:02 https://maestrodatabase.com/blog/csl-in-deal-with-commonwealth-to-produce-oxford-university-and-university-of-queensland-covid-19-vaccines 2020-09-07T01:24:18 https://maestrodatabase.com/blog/tga-approves-padcev 2022-07-21T07:54:29 https://maestrodatabase.com/blog/increasing-problem-australia-facing-shortages-of-more-than-320-medicines 2022-07-21T08:52:07 https://maestrodatabase.com/blog/fda-and-cdc-lift-recommended-pause-on-johnson-and-johnson-janssen-covid-19-vaccine-use-following-thorough-safety-review 2021-04-24T00:54:09 https://maestrodatabase.com/blog/sandoz-supplemental-biologics-license-application-accepted-by-us-fda-for-biosimilar-hyrimoz-adalimumab-adaz-high-concentration-formulation 2022-07-21T08:19:50 https://maestrodatabase.com/blog/atagi-update-following-weekly-covid-19-meeting-20-july-2022 2022-07-21T08:11:48 https://maestrodatabase.com/blog/nice-final-draft-guidance-recommends-olaparib-for-early-breast-cancer-and-metastatic-prostate-cancer-following-new-commercial-deals 2023-04-08T00:00:48 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-releases-draft-evidence-report-on-emicizumab-for-haemophilia-a 2018-01-26T23:36:23 https://maestrodatabase.com/blog/icer-appoints-jon-campbell-as-senior-vice-president-for-health-economics 2020-04-23T12:29:45 https://maestrodatabase.com/blog/the-race-to-find-a-covid-19-vaccine 2020-04-23T12:34:49 https://maestrodatabase.com/blog/canadas-apotex-donates-two-million-dosages-of-hydroxychloroquine-to-the-public-health-agency-of-canada 2020-04-23T12:40:20 https://maestrodatabase.com/blog/ultra-expensive-sma-drug-zolgensma-to-get-insurance-benefits-from-august 2022-07-21T09:47:20 https://maestrodatabase.com/blog/highlights-from-january-2018-chmp-meeting 2018-01-26T23:40:48 https://maestrodatabase.com/blog/covid-19-reminder-of-risk-of-serious-side-effects-with-chloroquine-and-hydroxychloroquine 2020-04-23T09:19:14 https://maestrodatabase.com/blog/pbs-not-on-the-table-in-battle-for-pharmaceutical-tariff-exemption-despite-lobbying 2025-07-09T05:52:49 https://maestrodatabase.com/blog/essential-work-to-combat-the-covid-19-pandemic-to-continue-during-emas-closure-on-27-april-and-on-1-may-2020 2020-04-23T20:56:21 https://maestrodatabase.com/blog/olema-oncology-receives-fda-fast-track-designation-for-op-1250-for-the-treatment-of-er-positive-her2-negative-metastatic-breast-cancer 2022-07-21T21:16:45 https://maestrodatabase.com/blog/supplemental-new-drug-application-submitted-to-us-fda-for-caplyta-lumateperone-with-data-demonstrating-significant-schizophrenia-relapse-prevention-compared-to-placebo 2025-07-09T06:04:01 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-to-vt-1598-for-treatment-of-valley-fever 2017-07-14T11:56:00 https://maestrodatabase.com/blog/nice-publishes-two-new-covid-19-guidelines 2020-04-23T20:59:21 https://maestrodatabase.com/blog/pliant-therapeutics-receives-fda-fast-track-designation-for-pln-74809-for-the-treatment-of-primary-sclerosing-cholangitis 2022-07-21T21:12:38 https://maestrodatabase.com/blog/cidara-therapeutics-announces-european-approval-of-rezzayo-rezafungin-for-the-treatment-of-invasive-candidiasis-in-adults 2023-12-23T21:53:00 https://maestrodatabase.com/blog/drug-maker-tripled-the-price-of-a-pill-as-it-pursued-coronavirus-use 2020-04-23T21:05:12 https://maestrodatabase.com/blog/fda-offers-new-guidance-on-therapeutic-equivalence-evaluations 2022-07-21T12:37:04 https://maestrodatabase.com/blog/swift-covid-19-vaccine-within-reach-say-swiss-scientists 2020-04-23T12:45:26 https://maestrodatabase.com/blog/health-canada-approves-abbvies-rinvoq-upadacitinib-for-the-treatment-of-adults-with-active-ankylosing-spondylitis 2022-07-21T11:09:09 https://maestrodatabase.com/blog/bill-gates-on-how-to-fight-future-pandemics 2020-04-23T20:49:54 https://maestrodatabase.com/blog/fda-approves-imaging-drug-for-evaluation-of-myocardial-ischaemia-and-infarction 2024-09-30T03:24:15 https://maestrodatabase.com/blog/australia-secures-onshore-manufacturing-agreements-for-two-covid-19-vaccines 2020-09-07T06:53:50 https://maestrodatabase.com/blog/covid-19-critical-care-advisory-group 2020-04-23T20:52:44 https://maestrodatabase.com/blog/cost-barriers-to-medication-access-in-australia-an-analysis-of-the-patient-experience-survey-in-context 2024-09-30T03:07:37 https://maestrodatabase.com/blog/barriers-to-accessing-life-saving-overdose-reversal-medicine-are-putting-kiwis-at-risk---nz-drug-foundation 2022-07-21T21:50:02 https://maestrodatabase.com/blog/vertex-offers-free-cystic-fibrosis-medicines-if-canada-will-negotiate 2020-04-23T21:28:57 https://maestrodatabase.com/blog/fda-approves-updated-label-for-lillys-kisunla-donanemab-azbt-with-new-dosing-in-early-symptomatic-alzheimers-disease 2025-07-09T11:22:41 https://maestrodatabase.com/blog/pfizer-announces-prevnar-20-pneumococcal-20-valent-conjugate-vaccine-is-now-available-in-canada-for-the-prevention-of-pneumonia-and-invasive-pneumococcal-disease-in-adults-18-years-of-age-and-older 2022-07-21T21:38:53 https://maestrodatabase.com/blog/karyopharm-and-menarini-receive-full-marketing-authorisation-from-the-european-commission-for-nexpovio-selinexor-for-the-treatment-of-patients-with-multiple-myeloma-after-at-least-one-prior-therapy 2022-07-21T21:28:19 https://maestrodatabase.com/blog/increasing-access-to-fda-inspection-reports-on-irregularities-and-misconduct-in-clinical-trials 2020-04-23T21:18:13 https://maestrodatabase.com/blog/federal-judge-stays-fda-abortion-pill-approval-gives-biden-administration-time-to-appeal 2023-04-08T00:22:15 https://maestrodatabase.com/blog/hospitals-stand-to-lose-billions-under-medicare-for-all 2019-04-22T08:43:51 https://maestrodatabase.com/blog/european-commission-approves-nintedanib-for-the-treatment-of-systemic-sclerosis-associated-interstitial-lung-disease 2020-04-23T21:22:03 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-11-november-2021 2021-11-11T05:13:21 https://maestrodatabase.com/blog/medicare-advantage-and-medicare-prescription-drug-programs-to-remain-stable-as-cms-implements-improvements-to-the-programs-in-2025 2024-09-30T05:38:15 https://maestrodatabase.com/blog/aotearoa-less-affected-by-medicine-supply-issues-than-other-countries 2022-07-21T21:22:27 https://maestrodatabase.com/blog/new-wegovy-dose-submitted-to-ema-for-approval-with-1-in-3-trial-participants-achieving-25-percent-or-more-weight-loss 2025-07-09T10:50:23 https://maestrodatabase.com/blog/patritumab-deruxtecan-granted-priority-review-in-the-us-for-certain-patients-with-previously-treated-locally-advanced-or-metastatic-egfr-mutated-non-small-cell-lung-cancer 2023-12-23T22:32:34 https://maestrodatabase.com/blog/accord-biopharma-announces-us-fda-acceptance-of-biologics-license-application-for-proposed-biosimilar-trastuzumab-hlx02 2023-04-08T01:01:30 https://maestrodatabase.com/blog/leader-of-u-dot-s-vaccine-push-says-hell-quit-if-politics-trumps-science 2020-09-07T20:34:06 https://maestrodatabase.com/blog/tremfya-guselkumab-approved-for-reimbursement-in-ireland-for-active-psoriatic-arthritis 2021-11-11T10:26:23 https://maestrodatabase.com/blog/astrazenecas-covid-19-vaccine-benefits-and-risks-in-context 2021-04-24T02:01:31 https://maestrodatabase.com/blog/smc-recommends-mercks-keytruda-for-another-two-indications 2020-09-07T21:05:55 https://maestrodatabase.com/blog/valneva-receives-eu-deal-for-covid-jab-and-seeks-apology-from-uk 2021-11-11T19:44:21 https://maestrodatabase.com/blog/astrazeneca-vaccine-most-likely-to-roll-out-in-the-u-dot-k-early-next-year 2020-09-07T21:37:19 https://maestrodatabase.com/blog/us-fda-accepts-supplemental-new-drug-application-and-grants-priority-review-for-jardiance-for-adults-with-heart-failure-independent-of-left-ventricular-ejection-fraction 2021-11-11T19:58:31 https://maestrodatabase.com/blog/vaccine-experts-surprised-over-governments-optimistic-covid-19-vaccine-rollout-timeline 2020-09-07T20:39:19 https://maestrodatabase.com/blog/moderna-booster-progress-well-advanced-as-regulator-considers-child-vaccines 2021-11-11T10:47:35 https://maestrodatabase.com/blog/smc---september-2020-decisions 2020-09-07T20:42:56 https://maestrodatabase.com/blog/hse-approves-reimbursement-of-ajovy-fremanezumab-in-migraine 2021-11-11T10:32:35 https://maestrodatabase.com/blog/smc-accepts-spravato-esketamine-nasal-spray-for-use-in-adults-with-treatment-resistant-major-depressive-disorder-in-scotland 2020-09-07T20:47:29 https://maestrodatabase.com/blog/covid-19-ema-recommends-authorisation-of-two-monoclonal-antibody-medicines 2021-11-11T19:41:41 https://maestrodatabase.com/blog/average-family-premiums-for-employer-based-health-insurance-have-jumped-47-percent-in-the-last-decade-outpacing-wage-growth-and-inflation 2021-11-11T20:27:30 https://maestrodatabase.com/blog/inclusion-in-health-technology-assessments-the-first-step-toward-equity 2021-11-11T20:32:17 https://maestrodatabase.com/blog/european-council-green-lights-new-rules-on-health-technology-assessment-improving-access-to-medicines-and-simplifying-procedures 2021-11-11T20:30:00 https://maestrodatabase.com/blog/four-new-medicines-accepted-by-smc-through-an-expedited-approach 2020-09-07T21:39:51 https://maestrodatabase.com/blog/fresenius-kabi-and-formycon-receive-us-fda-approval-for-biosimilar-otulfi-ustekinumab-aauz 2024-09-30T22:06:32 https://maestrodatabase.com/blog/patient-access-to-affordable-cancer-treatment-increases-with-the-launch-of-new-biosimilar-in-canada 2021-11-11T20:20:57 https://maestrodatabase.com/blog/pfizer-receives-breakthrough-therapy-designation-from-fda-for-pf-06651600-an-oral-jak3-inhibitor-for-the-treatment-of-patients-with-alopecia-areata 2018-09-07T07:36:38 https://maestrodatabase.com/blog/novartis-receives-health-canada-approval-of-its-car-t-cell-therapy-kymriah-tisagenlecleucel 2018-09-07T07:29:08 https://maestrodatabase.com/blog/highlights-from-the-april-19-22-chmp-meeting 2021-04-24T03:13:03 https://maestrodatabase.com/blog/health-tech-questions-await-next-fda-chief 2021-11-11T20:37:46 https://maestrodatabase.com/blog/chmp-recommends-eu-approval-of-roches-hemlibra-for-people-with-haemophilia-a-with-inhibitors 2018-01-27T01:57:36 https://maestrodatabase.com/blog/bolstering-our-ability-to-value-health-technology-a-few-less-considered-issues 2021-11-11T20:35:21 https://maestrodatabase.com/blog/three-cancer-drugs-approved-for-nhs-use-in-scotland 2021-11-11T20:47:54 https://maestrodatabase.com/blog/fda-touts-success-and-challenges-in-biosimilar-development 2021-11-11T20:40:13 https://maestrodatabase.com/blog/progress-update-post-market-review-of-medicines-for-smoking-cessation 2021-11-12T05:32:28 https://maestrodatabase.com/blog/gsks-shingrix-receives-positive-opinion-from-the-chmp-in-europe-for-the-prevention-of-shingles-in-adults-aged-50-and-over 2018-01-27T02:02:13 https://maestrodatabase.com/blog/fibrocell-announces-fda-fast-track-designation-of-fcx-013-for-treatment-of-moderate-to-severe-localised-scleroderma 2018-09-07T11:37:01 https://maestrodatabase.com/blog/fda-approves-grifols-new-gamastan-immunoglobulin-human-to-treat-patients-exposed-to-hepatitis-a-and-measles 2018-09-07T11:53:35 https://maestrodatabase.com/blog/medicines-industry-working-to-minimise-medicine-supply-shortages 2022-07-22T08:19:40 https://maestrodatabase.com/blog/repros-announces-negative-opinion-from-the-ema-for-enclomiphene 2018-01-27T03:37:18 https://maestrodatabase.com/blog/global-regulators-call-for-international-collaboration-to-integrate-real-world-evidence-into-regulatory-decision-making 2022-07-22T08:59:51 https://maestrodatabase.com/blog/monoferric-iron-isomaltoside-1000-for-injection-receives-marketing-approval-from-health-canada 2018-09-07T12:05:06 https://maestrodatabase.com/blog/upstaza-granted-marketing-authorisation-by-european-commission-as-first-disease-modifying-treatment-for-aadc-deficiency 2022-07-22T09:08:00 https://maestrodatabase.com/blog/rollout-of-new-medicines-across-new-zealand-begins 2024-10-01T00:49:20 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-october-2024 2024-10-01T00:22:37 https://maestrodatabase.com/blog/daewoong-pharmaceutical-gets-first-korean-us-fda-fast-track-for-new-idiopathic-pulmonary-fibrosis-drug 2022-07-22T10:54:29 https://maestrodatabase.com/blog/enhertu-granted-priority-review-in-the-us-for-patients-with-her2-low-or-her2-ultra-low-metastatic-breast-cancer-who-have-received-at-least-one-line-of-endocrine-therapy 2024-10-01T06:44:06 https://maestrodatabase.com/blog/ema-recommends-restricting-use-of-cancer-medicine-rubraca 2022-07-22T11:08:27 https://maestrodatabase.com/blog/astrazeneca-cancer-drug-calquence-cost-tumbles-with-pbs-listing 2023-12-24T21:47:31 https://maestrodatabase.com/blog/fda-approves-new-dosage-strength-of-buprenorphine-and-naloxone-sublingual-film-as-maintenance-treatment-for-opioid-dependence 2018-09-07T20:45:46 https://maestrodatabase.com/blog/europes-drug-agency-warns-on-work-crunch-after-brexit-move 2019-10-06T01:47:06 https://maestrodatabase.com/blog/mum-hopeful-after-baby-kaan-hunter-starts-$250k-a-year-medication-for-rare-bone-disease 2019-10-06T01:42:09 https://maestrodatabase.com/blog/janssen-announces-european-commission-decision-for-expanded-use-of-imbruvica-ibrutinib-in-combination-with-rituximab-for-previously-untreated-patients-with-chronic-lymphocytic-leukaemia 2020-09-08T01:09:32 https://maestrodatabase.com/blog/tezepelumab-granted-breakthrough-therapy-designation-by-us-fda 2018-09-07T20:50:18 https://maestrodatabase.com/blog/concern-proposed-bill-may-make-cancer-medication-unaffordable-for-kiwis 2019-10-06T20:37:58 https://maestrodatabase.com/blog/icr-welcomes-approval-of-immunotherapy-for-head-and-neck-cancer-in-scotland-but-warns-of-home-nations-lottery 2020-09-08T01:15:55 https://maestrodatabase.com/blog/pharmaceutical-benefits-advisory-committee-recommendations-in-australia 2017-12-17T20:48:02 https://maestrodatabase.com/blog/public-summary-documents-first-time-decisions-not-to-recommend-and-deferrals---may-2024-pbac-meeting 2024-10-01T07:25:28 https://maestrodatabase.com/blog/mhra-approves-elinzanetant-to-treat-moderate-to-severe-vasomotor-symptoms-hot-flushes-caused-by-menopause 2025-07-10T10:08:01 https://maestrodatabase.com/blog/returns-to-scientific-publications-for-pharmaceutical-products-in-the-united-states 2017-07-15T02:25:28 https://maestrodatabase.com/blog/disappointment-as-government-delays-pharma-friendly-policies 2017-07-15T02:40:31 https://maestrodatabase.com/blog/trumpcare-version-three 2017-07-15T02:29:19 https://maestrodatabase.com/blog/us-food-and-drug-administration-issues-complete-response-letter-for-dasiglucagon-in-congenital-hyperinsulinism-for-up-to-three-weeks-of-dosing-due-to-inspection-findings-at-third-party-manufacturing-facility 2023-12-26T06:35:07 https://maestrodatabase.com/blog/albanese-should-consider-tweaks-to-pbs-to-avoid-trump-tariff-csl-chair 2025-07-10T07:48:37 https://maestrodatabase.com/blog/u-dot-s-health-care-system-has-widest-gap-between-people-with-higher-and-lower-incomes 2017-07-15T02:48:19 https://maestrodatabase.com/blog/nurse-specialists-say-plight-of-severely-ill-bowel-disease-patients-in-nz-is-bitterly-unfair 2020-09-08T05:09:22 https://maestrodatabase.com/blog/agenda-for-19-july-tc-meeting 2017-07-15T05:04:03 https://maestrodatabase.com/blog/smc-accepts-three-new-health-technologies-for-interim-use 2020-09-08T06:39:56 https://maestrodatabase.com/blog/is-us-medical-care-inefficient 2018-09-07T21:12:27 https://maestrodatabase.com/blog/fda-grants-rare-paediatric-disease-designation-to-mdl-101-for-the-treatment-of-congenital-muscular-dystrophy-type-1a 2024-10-01T11:28:28 https://maestrodatabase.com/blog/trump-health-chief-meets-with-gop-law-makers-on-lowering-drug-prices 2018-09-07T21:16:21 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-medications-for-treatment-of-opioid-use-disorder 2018-09-07T21:07:58 https://maestrodatabase.com/blog/singapores-agency-for-care-effectiveness-publishes-another-tranche-of-drug-guidances 2020-09-08T08:02:38 https://maestrodatabase.com/blog/south-korea-to-shorten-licensing-review-period-new-drugs-on-rare-diseases-by-25-days 2020-09-08T08:11:39 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-biologics-license-application-for-eptinezumab 2019-04-23T04:26:54 https://maestrodatabase.com/blog/us-fda-approves-duaklir-pressair-aclidinium-slash-formoterol-for-patients-with-chronic-obstructive-pulmonary-disease 2019-04-23T06:29:37 https://maestrodatabase.com/blog/more-than-1-million-americans-have-lost-health-insurance-since-2016 2019-04-23T05:39:13 https://maestrodatabase.com/blog/radiomedix-and-curium-announce-fda-approval-of-detectnet-copper-cu-64-dotatate-injection-in-the-u-dot-s 2020-09-08T10:01:06 https://maestrodatabase.com/blog/priority-review-vouchers-have-helped-to-improve-access-to-drugs-targeting-neglected-diseases 2019-04-23T04:33:15 https://maestrodatabase.com/blog/nice-releases-initial-guidance-for-another-indication-for-lenalidomide 2020-09-08T10:10:54 https://maestrodatabase.com/blog/governors-from-both-parties-denounce-senate-obamacare-repeal-bill 2017-07-15T23:33:38 https://maestrodatabase.com/blog/fda-approves-mercks-keytruda-pembrolizumab-in-combination-with-inlyta-axitinib-as-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma 2019-04-23T06:34:54 https://maestrodatabase.com/blog/first-in-class-medicine-recommended-for-treatment-of-rare-blood-vessel-inflammation 2021-11-12T23:13:47 https://maestrodatabase.com/blog/second-best-in-the-world-no-guarantee-of-an-equitable-health-care-system 2017-07-16T21:04:30 https://maestrodatabase.com/blog/zilganersen-granted-us-fda-fast-track-designation-for-people-living-with-alexander-disease 2024-10-02T00:27:30 https://maestrodatabase.com/blog/cti-biopharma-announces-european-medicines-agency-validation-of-pacritinib-marketing-authorisation-application-for-patients-with-myelofibrosis-who-have-thrombocytopenia 2017-07-16T21:10:21 https://maestrodatabase.com/blog/sagimet-receives-fda-breakthrough-therapy-designation-for-denifanstat-in-mash 2024-10-02T01:12:06 https://maestrodatabase.com/blog/beneluxa-what-are-the-prospects-for-collective-bargaining-on-pharmaceutical-prices-given-diverse-health-technology-assessment-processes 2019-04-23T08:26:36 https://maestrodatabase.com/blog/intensity-therapeutics-receives-fast-track-designation-from-u-dot-s-fda-for-development-of-int230-6-as-treatment-for-relapsed-or-metastatic-triple-negative-breast-cancer 2019-04-23T08:21:05 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-october-2024 2024-10-02T00:52:18 https://maestrodatabase.com/blog/johnson-and-johnson-files-for-us-fda-approval-of-darzalex-faspro-based-quadruplet-regimen-for-newly-diagnosed-multiple-myeloma-patients-for-whom-transplant-is-not-planned 2024-10-02T01:44:23 https://maestrodatabase.com/blog/labour-pledges-to-fund-anti-hiv-meds 2017-07-16T21:37:10 https://maestrodatabase.com/blog/daliresp-receives-us-fda-approval-for-250-mcg-starting-dose-for-patients-with-severe-copd 2018-01-27T23:35:47 https://maestrodatabase.com/blog/clinuvel-files-canadian-new-drug-submission-for-scenesse-in-epp 2024-10-02T01:18:58 https://maestrodatabase.com/blog/nice-ready-to-work-with-company-to-address-uncertainty-in-evidence-for-elacestrant-for-advanced-breast-cancer 2024-10-02T02:42:15 https://maestrodatabase.com/blog/biopharma-leaders-unite-to-stand-with-science 2020-09-08T11:26:04 https://maestrodatabase.com/blog/pharmac-wont-fund-drug-spinraza-to-help-children-with-spinal-muscular-atrophy 2020-04-24T02:11:22 https://maestrodatabase.com/blog/is-end-of-life-a-special-case-connecting-q-with-survey-methods-to-measure-societal-support-for-views-on-the-value-of-life-extending-treatments 2018-01-28T00:13:34 https://maestrodatabase.com/blog/medical-miracles-from-fda-inefficiency 2018-01-28T00:10:23 https://maestrodatabase.com/blog/its-not-just-the-epipen-canada-had-25-new-drug-shortages-this-week-alone 2018-09-09T21:30:10 https://maestrodatabase.com/blog/transparency-and-dermatologic-device-approval-by-the-us-food-and-drug-administration 2018-01-28T00:16:54 https://maestrodatabase.com/blog/gsk-receives-complete-response-letter-from-us-fda-for-use-of-mepolizumab-in-copd-patients 2018-09-09T21:22:37 https://maestrodatabase.com/blog/fda-sets-up-vaccine-safeguards-to-counter-pressure-from-trump 2020-09-08T11:55:08 https://maestrodatabase.com/blog/nice-does-not-recommend-elosulfase-alfa-for-nhs-use-following-evaluation-of-new-evidence 2021-11-13T00:18:22 https://maestrodatabase.com/blog/european-commission-expands-labelling-for-janssens-invokana-and-vokanamet-to-include-positive-data-on-cardiovascular-outcomes 2018-09-10T13:36:04 https://maestrodatabase.com/blog/scilex-announces-filing-of-a-new-drug-submission-to-health-canadas-pharmaceutical-drugs-directorate-bureau-of-cardiology-allergy-and-neurological-sciences-for-the-approval-of-elyxyb-for-acute-treatment-of-migraine-with-or-without-aura-in-canada 2023-12-27T07:32:38 https://maestrodatabase.com/blog/ms-society-launches-petition-against-nices-rejection-of-ocrevus 2018-09-10T13:22:55 https://maestrodatabase.com/blog/roche-faces-uk-pricing-row-over-multiple-sclerosis-drug-ocrevus 2018-09-10T13:29:13 https://maestrodatabase.com/blog/synthons-vic--trastuzumab-duocarmazine-syd985-granted-fda-fast-track-designation-for-pre-treated-her2-positive-metastatic-breast-cancer 2018-01-28T00:35:12 https://maestrodatabase.com/blog/fda-permits-marketing-of-first-medical-device-for-treatment-of-adhd 2019-04-23T11:42:29 https://maestrodatabase.com/blog/endocyte-announces-fda-acceptance-of-radiographic-progression-free-survival-as-an-alternative-primary-endpoint-of-the-vision-trial-in-addition-to-overall-survival 2018-09-10T21:24:57 https://maestrodatabase.com/blog/drug-firms-try-to-rip-off-taxpayers-says-matt-hancock 2018-09-10T21:12:59 https://maestrodatabase.com/blog/smc---september-2018-decisions 2018-09-10T21:18:58 https://maestrodatabase.com/blog/canadian-dermatology-association-and-canadian-society-of-allergy-and-clinical-immunology-issue-joint-statement-against-the-canadian-agency-for-drugs-and-technologies-in-health-recommendation 2018-09-10T21:31:29 https://maestrodatabase.com/blog/capricor-therapeutics-provides-regulatory-update-on-deramiocel-bla-for-duchenne-muscular-systrophy 2025-07-11T22:14:59 https://maestrodatabase.com/blog/pharmac-reportedly-has-rejected-funding-for-breast-cancer-drug 2019-04-23T12:13:05 https://maestrodatabase.com/blog/additional-embargo-period-following-revised-cdec-recommendations 2019-04-23T11:49:18 https://maestrodatabase.com/blog/nice-turns-down-opdivo-for-adjuvant-melanoma-therapy 2018-09-10T21:52:04 https://maestrodatabase.com/blog/public-summary-documents-first-time-rejections-and-deferrals---july-2021-pbac-meeting 2021-11-13T00:41:27 https://maestrodatabase.com/blog/bimzelx-bimekizumab-receives-approval-in-japan-for-the-treatment-of-psoriatic-arthritis-non-radiographic-axial-spondyloarthritis-and-ankylosing-spondylitis 2023-12-27T07:54:01 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-for-tre-515-in-combination-with-radiation-therapy-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer 2025-07-11T22:34:19 https://maestrodatabase.com/blog/mesoblast-claims-coronavirus-treatment-breakthrough 2020-04-24T03:21:01 https://maestrodatabase.com/blog/swissmedic-approves-ifinwil-eflornithine-for-children-diagnosed-with-high-risk-neuroblastoma 2025-07-11T22:44:02 https://maestrodatabase.com/blog/pharma-lobby-nears-spending-records-with-drug-prices-under-fire 2019-04-23T12:19:27 https://maestrodatabase.com/blog/if-you-dont-believe-single-payer-can-work-see-how-they-do-it-in-taiwan 2018-09-10T21:48:30 https://maestrodatabase.com/blog/amgen-provides-regulatory-update-on-the-status-of-lumakras-sotorasib 2023-12-27T07:43:23 https://maestrodatabase.com/blog/amgen-and-ucb-provide-update-on-regulatory-status-of-evenity-romosozumab-in-the-us 2017-07-17T06:14:14 https://maestrodatabase.com/blog/european-commission-approves-mercks-keytruda-pembrolizumab-in-combination-with-pemetrexed-and-platinum-chemotherapy-for-the-first-line-treatment-of-patients-with-metastatic-non-squamous-nsclc-with-no-egfr-or-alk-genomic-tumour-aberrations 2018-09-10T21:55:15 https://maestrodatabase.com/blog/amgen-submits-regulatory-applications-in-us-and-europe-to-include-overall-survival-data-in-kyprolis-carfilzomib-label 2017-07-17T06:08:01 https://maestrodatabase.com/blog/us-fda-issues-complete-response-letter-for-dasiglucagon-in-congenital-hyperinsulinism-for-up-to-three-weeks-of-dosing-due-to-inspection-findings-at-third-party-manufacturing-facility 2023-12-27T21:33:54 https://maestrodatabase.com/blog/elacestrant-dihydrochloride-for-the-treatment-of-patients-with-advanced-oestrogen-receptor-positive-esr1-mutation-positive-her2-negative-breast-cancer-after-at-least-one-endocrine-treatment 2024-10-02T11:37:17 https://maestrodatabase.com/blog/new-law-to-protect-patients-against-medicine-shortages 2018-09-11T02:10:39 https://maestrodatabase.com/blog/quebec-expects-1-dollars-2-cents-billion-in-savings-with-new-drug-price-deal 2017-07-17T06:29:08 https://maestrodatabase.com/blog/trump-health-care-bill-vote-delayed-for-john-mccain-health-reasons 2017-07-17T06:45:47 https://maestrodatabase.com/blog/amicus-therapeutics-announces-regulatory-and-clinical-updates-for-at-gaa-in-pompe-disease 2018-09-11T04:40:13 https://maestrodatabase.com/blog/cipher-pharmaceuticals-receives-health-canada-approval-of-xydalba-dalbavancin-hydrochloride 2018-09-11T03:12:47 https://maestrodatabase.com/blog/ema-recommends-approval-of-imvanex-for-the-prevention-of-monkeypox-disease 2022-07-23T02:40:06 https://maestrodatabase.com/blog/zepbound-kwikpen-tirzepatide-the-first-and-only-dual-receptor-agonist-for-the-treatment-of-obesity-now-approved-and-available-in-canada 2025-07-11T22:49:06 https://maestrodatabase.com/blog/pharmac-rejects-own-experts-view-on-breast-cancer-drug 2019-04-23T20:52:54 https://maestrodatabase.com/blog/transcend-therapeutics-receives-breakthrough-therapy-designation-for-tsnd--201-methylone-for-the-treatment-of-ptsd 2025-07-11T22:55:13 https://maestrodatabase.com/blog/unhealthy-diagnosis-for-medibank-as-young-baulk-at-insurance 2017-07-17T20:51:07 https://maestrodatabase.com/blog/icers-growing-impact-on-drug-pricing-and-reimbursement 2019-04-23T21:13:53 https://maestrodatabase.com/blog/top-down-government-efforts-to-corral-drug-prices-will-fail 2019-04-23T21:11:14 https://maestrodatabase.com/blog/ending-drug-rebates-will-not-reduce-drug-prices 2019-04-23T21:05:13 https://maestrodatabase.com/blog/new-medicine-for-multiple-myeloma-patients-with-limited-treatment-options 2022-07-23T02:53:10 https://maestrodatabase.com/blog/ema-publishes-agenda-for-17-20-chmp-meeting 2017-07-17T20:55:34 https://maestrodatabase.com/blog/canadians-will-wait-longer-for-new-medicines-if-health-canada-gets-its-way 2019-04-23T21:02:33 https://maestrodatabase.com/blog/fda-approves-new-treatment-to-reduce-the-risk-of-breast-cancer-returning 2017-07-17T21:06:53 https://maestrodatabase.com/blog/building-a-strong-fda-workforce-to-bring-scientific-advances-to-patients 2017-07-17T21:14:02 https://maestrodatabase.com/blog/new-lets-talk-about-cost-campaign-convenes-national-dialogue-on-medicine-costs 2017-07-17T21:21:58 https://maestrodatabase.com/blog/the-art-of-the-deal-why-a-money-back-guarantee-for-drugs-is-a-bad-idea 2017-07-17T21:18:35 https://maestrodatabase.com/blog/how-the-republican-health-care-bill-could-raise-premiums-for-177-million-americans 2017-07-17T21:41:18 https://maestrodatabase.com/blog/alnylam-receives-positive-chmp-opinion-for-vutrisiran-for-the-treatment-of-hereditary-transthyretin-mediated-amyloidosis-in-adult-patients-with-stage-1-or-stage-2-polyneuropathy 2022-07-23T09:03:09 https://maestrodatabase.com/blog/a-top-republican-vows-a-vote-on-health-care-but-uncertainty-reigns 2017-07-17T21:32:42 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-to-henlius-egfr-targeting-adc-hlx42-for-nsclc-patients-with-disease-progression-on-egfr-targeted-therapies 2023-12-27T23:07:18 https://maestrodatabase.com/blog/how-the-nhs-became-embroiled-in-a-global-drugs-price-clash 2017-07-17T21:56:14 https://maestrodatabase.com/blog/coherus-announces-fda-approval-of-udenyca-onbody-a-novel-and-proprietary-state-of-the-art-delivery-system-for-pegfilgrastim-cbqv 2023-12-27T22:59:48 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-reviews-final-evidence-report-finds-prices-of-anabolic-agents-for-osteoporosis-too-high-not-aligned-with-potential-benefits-over-other-treatments 2017-07-17T22:58:39 https://maestrodatabase.com/blog/spark-therapeutics-biologics-license-application-for-investigational-voretigene-neparvovec-accepted-for-filing-by-fda 2017-07-18T07:50:44 https://maestrodatabase.com/blog/trump-health-bill-all-but-dead 2017-07-18T07:45:24 https://maestrodatabase.com/blog/review-of-the-life-saving-drugs-program---final-report-and-government-response 2018-01-28T20:11:39 https://maestrodatabase.com/blog/ultragenyx-receives-complete-response-letter-from-fda-for-ux111-aav-gene-therapy-to-treat-sanfilippo-syndrome-type-a 2025-07-13T02:49:59 https://maestrodatabase.com/blog/drug-makers-prepare-to-make-coronavirus-treatments 2020-04-24T04:51:32 https://maestrodatabase.com/blog/vertex-advances-vx-548-in-acute-and-neuropathic-pain 2022-07-23T12:36:47 https://maestrodatabase.com/blog/roches-ocrevus-ocrelizumab-approved-for-relapsing-and-primary-progressive-multiple-sclerosis-in-australia 2017-07-18T08:44:26 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-positive-chmp-opinion-recommending-approval-for-lag-3-blocking-antibody-combination-opdualag-nivolumab-and-relatlimab-for-treatment-of-patients-with-unresectable-or-metastatic-melanoma 2022-07-23T09:08:32 https://maestrodatabase.com/blog/health-fund-reforms-parliament-passes-drastic-changes-here-is-what-they-mean 2018-09-11T21:15:45 https://maestrodatabase.com/blog/scotland-could-be-world-leader-in-precision-medicine-says-first-minister 2018-09-11T21:19:13 https://maestrodatabase.com/blog/kites-car-t-cell-therapy-tecartus-receives-positive-chmp-opinion-in-relapsed-or-refractory-acute-lymphoblastic-leukaemia 2022-07-23T12:59:01 https://maestrodatabase.com/blog/imaging-biometrics-granted-fda-fast-track 2023-12-27T23:53:59 https://maestrodatabase.com/blog/fda-approves-first-ngs-based-companion-diagnostic-for-ret-fusion-positive-non-small-cell-lung-cancer 2020-09-08T20:54:41 https://maestrodatabase.com/blog/health-care-regulators-outdated-thinking-will-cost-american-ives 2023-04-10T20:52:32 https://maestrodatabase.com/blog/pharma-executive-says-he-had-moral-requirement-to-raise-drug-price-400-percent 2018-09-11T21:32:05 https://maestrodatabase.com/blog/cheaper-medicines-for-graft-versus-host-disease-chronic-rhinosinusitis-and-oesophageal-cancer 2023-04-10T20:40:13 https://maestrodatabase.com/blog/securing-supply-of-prep 2024-10-02T23:24:43 https://maestrodatabase.com/blog/health-secretarys-rip-off-remarks-anger-uk-pharma 2018-09-11T21:44:05 https://maestrodatabase.com/blog/covid-19-vaccine-safety-report-6-april-2023 2023-04-10T20:45:07 https://maestrodatabase.com/blog/minimal-residual-disease-negativity-data-a-measure-of-undetectable-disease-added-to-venclexta-venetoclax-tablets-label 2018-09-11T21:23:27 https://maestrodatabase.com/blog/the-secret-drug-pricing-system-middlemen-use-to-rake-in-millions 2018-09-11T21:29:45 https://maestrodatabase.com/blog/formycon-announces-ema-acceptance-of-the-maa-for-fyb203-a-biosimilar-candidate-to-eylea-aflibercept 2023-12-28T01:15:58 https://maestrodatabase.com/blog/liminal-biosciences-announces-resubmission-of-biologics-license-application-to-u-dot-s-fda-for-ryplazim-plasminogen 2020-09-08T21:07:49 https://maestrodatabase.com/blog/roche-canada-announces-foundationone-liquid-cdx-now-available-in-canada 2020-09-08T21:14:54 https://maestrodatabase.com/blog/european-commission-approves-tevimbra-in-combination-with-chemotherapy-as-a-first-line-treatment-for-nasopharyngeal-carcinoma 2025-07-13T03:50:02 https://maestrodatabase.com/blog/roche-receives-fda-clearance-for-bk-virus-quantitative-test-on-cobas-6800-slash-8800-systems-to-support-better-care-for-transplant-patients 2020-09-08T21:22:39 https://maestrodatabase.com/blog/abpi-hits-out-at-punitive-uk-medicines-cost-controls 2018-09-11T21:46:49 https://maestrodatabase.com/blog/bayer-files-for-eu-approval-of-gadoquatrane 2025-07-13T04:04:24 https://maestrodatabase.com/blog/fda-approves-vosevi-for-hepatitis-c 2017-07-18T20:54:11 https://maestrodatabase.com/blog/u-dot-s-fda-approves-athena-biosciences-new-drug-application-for-qdolo-tramadol-hydrochloride-oral-solution 2020-09-08T21:03:37 https://maestrodatabase.com/blog/dutch-health-insurance-what-changes-in-2022 2021-11-13T04:51:09 https://maestrodatabase.com/blog/calquence-granted-priority-review-in-the-us-for-patients-with-untreated-mantle-cell-lymphoma 2024-10-03T06:09:53 https://maestrodatabase.com/blog/milestone-pharmaceuticals-announces-fda-acceptance-of-the-companys-response-to-the-crl-for-cardamyst-etripamil-nasal-spray 2025-07-13T03:20:07 https://maestrodatabase.com/blog/eu-regulators-charge-teva-over-pay-for-delay-drug-deal 2017-07-18T21:07:10 https://maestrodatabase.com/blog/senate-to-take-up-bill-to-repeal-obamacare-without-replacement-plan 2017-07-18T21:04:27 https://maestrodatabase.com/blog/strengthening-the-fdas-enforcement-of-clinicaltrials-dot-gov-reporting-requirements 2021-11-13T04:54:05 https://maestrodatabase.com/blog/kalvista-announces-the-submission-of-additional-marketing-authorisation-applications-for-sebetralstat-for-the-oral-on-demand-treatment-of-hereditary-angioedema 2024-10-03T05:29:37 https://maestrodatabase.com/blog/celltrion-seeks-approval-for-xolair-biosimilar-in-canada 2023-12-28T01:30:10 https://maestrodatabase.com/blog/cardiome-announces-health-canada-approval-of-aggrastat-high-dose-bolus-regimen 2017-07-18T21:23:49 https://maestrodatabase.com/blog/volastra-therapeutics-granted-fda-fast-track-designation-for-novel-kif18a-inhibitor-in-ovarian-cancer 2024-10-03T01:14:28 https://maestrodatabase.com/blog/beyondspring-receives-breakthrough-therapy-designations-from-both-u-dot-s-fda-and-china-nmpa-for-plinabulin-in-chemotherapy-induced-neutropenia-indication 2020-09-08T21:29:44 https://maestrodatabase.com/blog/zanubrutinib-for-the-treatment-of-patients-with-relapsed-or-refractory-mantle-cell-lymphoma 2025-07-13T04:33:48 https://maestrodatabase.com/blog/highlights-from-chmp-8-11-november-2021-meeting 2021-11-13T05:15:08 https://maestrodatabase.com/blog/bertilimumab-granted-fast-track-designation-for-the-treatment-of-bullous-pemphigoid 2018-09-11T23:06:40 https://maestrodatabase.com/blog/european-union-regulation-of-health-technology-assessment-what-is-required-for-it-to-succeed 2022-07-23T13:23:19 https://maestrodatabase.com/blog/jacinda-ardern-hails-exciting-phase-of-cancer-research-as-pharmac-funds-three-new-drugs 2019-10-07T07:23:25 https://maestrodatabase.com/blog/ema-chmp-recommends-use-of-the-moderna-covid-19-booster-in-adolescents-12-17-years-in-the-european-union 2022-07-23T22:25:30 https://maestrodatabase.com/blog/pharmac-signs-bundle-deal-for-more-cancer-medicines 2019-10-07T07:18:40 https://maestrodatabase.com/blog/vertex-receives-chmp-positive-opinion-for-kaftrio-ivacaftor-slash-tezacaftor-slash-elexacaftor-in-combination-with-ivacaftor-in-children-with-cystic-fibrosis-ages-6-through-11 2021-11-13T05:28:21 https://maestrodatabase.com/blog/improving-efficiency-of-approval-process-for-new-medicines-in-the-eu 2024-10-03T21:27:23 https://maestrodatabase.com/blog/fda-grants-breakthrough-therapy-designation-for-concentric-analgesics-ca-008-in-post-surgical-pain 2018-09-11T23:27:31 https://maestrodatabase.com/blog/cms-repeals-mcit-slash-r-will-consider-other-coverage-pathways-to-enhance-access-to-innovative-medical-devices 2021-11-13T05:38:20 https://maestrodatabase.com/blog/decision-to-list-nintedanib-ofev-and-remove-restrictions-from-tiotropium-bromide-spiriva 2018-09-12T14:06:39 https://maestrodatabase.com/blog/shire-granted-eu-marketing-authorization-for-veyvondi-vonicog-alfa-recombinant-von-willebrand-factor-for-adults-with-von-willebrand-disease 2018-09-12T14:12:52 https://maestrodatabase.com/blog/pfenex-receives-u-dot-s-fda-approval-for-pf708-to-treat-osteoporosis 2019-10-07T09:13:25 https://maestrodatabase.com/blog/left-on-the-scrapheap-pharmac-decision-bittersweet-for-ms-patients 2019-10-07T07:25:48 https://maestrodatabase.com/blog/in-australia-novatears-eye-drops-are-available-on-the-pharmaceutical-benefits-scheme 2018-09-12T14:20:39 https://maestrodatabase.com/blog/is-fda-too-lax-with-its-drug-approval-standards-senior-fda-officials-discuss 2019-10-07T20:11:02 https://maestrodatabase.com/blog/fibrogen-receives-fast-track-designation-from-the-u-dot-s-fda-for-pamrevlumab-for-the-treatment-of-idiopathic-pulmonary-fibrosis 2018-09-12T14:28:56 https://maestrodatabase.com/blog/conservatives-launch-ad-campaign-against-pelosi-drug-pricing-plan-socialised-medicine 2019-10-07T20:08:14 https://maestrodatabase.com/blog/chmp-recommends-eu-approval-of-roches-vabysmo-the-first-bispecific-antibody-for-the-eye-for-two-leading-causes-of-vision-loss 2022-07-24T06:03:55 https://maestrodatabase.com/blog/buttigiegs-balancing-act-he-wants-far-lower-drug-prices-even-as-he-hopes-the-drug-industry-will-thrive 2019-10-07T20:06:36 https://maestrodatabase.com/blog/buttigieg-unveils-an-aggressive-plan-for-lowering-drug-prices 2019-10-07T20:04:53 https://maestrodatabase.com/blog/fda-approves-treatment-for-rare-blood-disease 2021-11-13T05:52:31 https://maestrodatabase.com/blog/janssen-submits-application-to-u-dot-s-fda-seeking-approval-of-stelera-ustekinumab-for-the-treatment-of-paediatric-patients-with-moderate-to-severe-plaque-psoriasis 2019-10-07T20:19:59 https://maestrodatabase.com/blog/fda-awards-five-grants-to-advance-the-development-of-paediatric-medical-devices 2018-09-12T21:11:03 https://maestrodatabase.com/blog/biden-nominates-califf-as-fda-chief 2021-11-13T05:48:11 https://maestrodatabase.com/blog/mereo-biopharma-receives-fda-fast-track-designation-for-navicixizumab-for-the-treatment-of-heavily-pre-treated-ovarian-cancer 2019-10-07T20:14:49 https://maestrodatabase.com/blog/chmp-adopts-positive-opinion-recommending-veklury-remdesivir-receive-full-marketing-authorisation-for-the-treatment-of-patients-with-covid-19 2022-07-23T22:32:27 https://maestrodatabase.com/blog/health-canada-approves-mercks-stromectol-ivermectin-for-the-treatment-of-intestinal-strongyloidiasis-and-onchocerciasis 2018-09-12T14:36:36 https://maestrodatabase.com/blog/digital-medicine-movement-is-growing-up-and-thats-a-good-thing 2019-10-07T20:38:48 https://maestrodatabase.com/blog/gottlieb-on-price-gouging 2018-09-12T21:23:52 https://maestrodatabase.com/blog/health-canada-authorises-the-use-of-the-moderna-spikevax-covid-19-vaccine-as-a-booster-shot 2021-11-13T06:06:31 https://maestrodatabase.com/blog/new-pharmac-drug-funding-approved-but-some-new-zealanders-still-missing-out 2019-10-07T20:35:35 https://maestrodatabase.com/blog/milestone-pharmaceuticals-receives-refusal-to-file-letter-from-us-fda-for-new-drug-application-for-etripamil-in-the-treatment-of-psvt 2023-12-28T03:33:27 https://maestrodatabase.com/blog/trumps-early-efforts-to-trim-drug-costs-face-patient-backlash 2018-09-12T21:25:53 https://maestrodatabase.com/blog/it-shows-how-much-pharma-has-on-their-plate-congress-just-quietly-passed-a-bill-that-will-cost-drug-makers-3-dollars-billion 2019-10-07T20:30:02 https://maestrodatabase.com/blog/statement-from-fda-commissioner-and-center-for-devices-and-radiological-health-director-on-agency-efforts-to-work-with-tech-industry-to-spur-innovation-in-digital-health 2018-09-12T21:13:11 https://maestrodatabase.com/blog/smc---october-2019-decisions 2019-10-07T20:27:03 https://maestrodatabase.com/blog/are-we-being-misled-about-precision-medicine 2018-09-12T21:20:53 https://maestrodatabase.com/blog/sunovion-announces-health-canada-acceptance-of-new-drug-submission-for-apomorphine-sublingual-film-apl-130277 2018-09-12T21:46:43 https://maestrodatabase.com/blog/elizabeth-warren-has-many-plans-but-on-health-care-shes-with-bernie 2019-10-07T20:56:01 https://maestrodatabase.com/blog/fda-to-review-supplemental-biologics-license-application-for-praluent-alirocumab-injection-as-potential-treatment-to-reduce-major-adverse-cardiovascular-events 2018-09-12T21:32:39 https://maestrodatabase.com/blog/battle-for-wonder-drug-pays-off 2018-09-12T21:42:26 https://maestrodatabase.com/blog/war-on-superbugs-to-end-repeat-scripts 2019-10-07T20:42:27 https://maestrodatabase.com/blog/a-breakthrough-cancer-drug-has-been-approved-now-comes-the-battle-over-the-price 2018-09-12T21:54:44 https://maestrodatabase.com/blog/resubmission-of-arimoclomol-new-drug-application-to-the-us-fda 2023-12-28T03:48:14 https://maestrodatabase.com/blog/doh-moves-to-ensure-equal-access-to-cancer-drugs-in-northern-ireland 2018-09-13T10:11:17 https://maestrodatabase.com/blog/limiting-state-flexibility-in-drug-pricing 2018-09-13T01:37:51 https://maestrodatabase.com/blog/the-ghost-of-martin-shkreli-still-haunts-drug-prices 2018-09-13T01:43:21 https://maestrodatabase.com/blog/trump-eyeing-disruptive-changes-to-drug-pricing-health-secretary-says 2018-09-13T10:27:09 https://maestrodatabase.com/blog/fda-grants-priority-review-to-mercks-application-for-keytruda-pembrolizumab-monotherapy-for-first-line-treatment-of-locally-advanced-or-metastatic-non-small-cell-lung-cancer-in-patients-whose-tumours-express-pd-l1-tps-1-percent 2018-09-13T10:37:58 https://maestrodatabase.com/blog/improving-understanding-of-biosimilars-in-the-eu 2018-09-13T13:22:47 https://maestrodatabase.com/blog/pharmac-seeking-views-on-new-type-2-diabetes-medicines 2020-09-09T00:52:48 https://maestrodatabase.com/blog/ascendis-pharma-submits-marketing-authorisation-application-to-the-ema-for-transcon-hgh-for-the-treatment-of-paediatric-growth-hormone-deficiency 2020-09-09T01:14:19 https://maestrodatabase.com/blog/agenda-for-31-january-tc-meeting 2018-01-29T01:44:37 https://maestrodatabase.com/blog/fda-issues-54-product-specific-guidances-to-promote-generic-drug-access-and-drug-price-competition 2018-09-13T13:28:57 https://maestrodatabase.com/blog/capricor-receives-rare-paediatric-disease-designation-from-fda-for-cap-1002-for-patients-with-duchenne-muscular-dystrophy 2017-07-19T02:07:29 https://maestrodatabase.com/blog/gilead-sciences-submits-new-drug-application-in-japan-for-filgotinib-for-the-treatment-of-ulcerative-colitis-with-an-inadequate-response-to-conventional-therapies 2021-04-25T06:39:11 https://maestrodatabase.com/blog/the-price-of-a-vertex-cystic-fibrosis-treatment-stirs-anger-in-australia 2021-04-25T06:30:51 https://maestrodatabase.com/blog/public-summary-documents---september-2023-pbac-meeting 2023-12-28T04:58:53 https://maestrodatabase.com/blog/abbvie-receives-positive-chmp-opinion-for-venclyxto-venetoclax-as-a-combination-regimen-for-adult-patients-with-newly-diagnosed-acute-myeloid-leukaemia-who-are-ineligible-for-intensive-chemotherapy 2021-04-25T06:20:14 https://maestrodatabase.com/blog/roche-wins-fdas-breakthrough-therapy-designation-for-autism-drug 2018-01-29T06:51:43 https://maestrodatabase.com/blog/atagi-reinforce-recommendations-on-use-of-covid-19-vaccines-following-review-of-vaccine-safety-data-and-benefits 2021-04-25T20:53:34 https://maestrodatabase.com/blog/swissmedic-accepts-our-filing-for-edaravone-to-treat-als 2018-01-29T06:32:12 https://maestrodatabase.com/blog/new-life-saving-medicines 2023-04-11T02:51:48 https://maestrodatabase.com/blog/public-summary-documents-rejections-slash-deferrals-slash-other-matters---december-2020-pbac-intracycle-meeting 2021-04-25T21:00:42 https://maestrodatabase.com/blog/roche-haemophilia-drug-lowers-costs-despite-high-price-icer 2018-01-29T11:02:47 https://maestrodatabase.com/blog/medicines-australia-welcomes-lsdp-review-outcomes 2018-01-29T10:47:46 https://maestrodatabase.com/blog/rare-disease-medicine-changes-offer-clarity 2018-01-29T10:50:13 https://maestrodatabase.com/blog/brexit-alliance-calls-for-brexit-deal-on-medicines-regulation 2018-01-29T20:11:56 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac---march-2020 2020-04-24T09:01:50 https://maestrodatabase.com/blog/fda-approves-neo-adjuvant-slash-adjuvant-nivolumab-for-resectable-non-small-cell-lung-cancer 2024-10-04T02:06:41 https://maestrodatabase.com/blog/statement-by-ema-executive-director-guido-rasi-in-the-hague 2018-01-29T20:08:38 https://maestrodatabase.com/blog/a-joint-statement-from-the-pan-canadian-pharmaceutical-alliance-and-the-canadian-generic-pharmaceutical-association 2018-01-29T20:34:42 https://maestrodatabase.com/blog/doctors-are-cleared-to-prescribe-cheaper-drug-for-wet-amd 2018-01-29T20:16:18 https://maestrodatabase.com/blog/fda-approved-record-number-of-generic-drugs-last-year 2018-01-29T20:19:53 https://maestrodatabase.com/blog/delgocitinib-for-the-treatment-of-patients-with-moderate-to-severe-chronic-hand-eczema 2025-07-13T22:25:08 https://maestrodatabase.com/blog/pharmac-funds-second-treatment-for-spinal-muscular-atrophy 2023-04-11T20:27:49 https://maestrodatabase.com/blog/pharmac-opens-consultation-to-address-new-zealands-biggest-health-issue 2020-09-09T05:02:03 https://maestrodatabase.com/blog/how-big-pharma-games-the-system----and-keeps-drugs-prices-high 2023-04-11T20:36:43 https://maestrodatabase.com/blog/fda-approves-new-kind-of-treatment-for-hairy-cell-leukaemia 2018-09-13T21:11:53 https://maestrodatabase.com/blog/regenxbio-receives-fda-fast-track-designation-for-rgx-202-a-novel-gene-therapy-candidate-for-the-treatment-of-duchenne-muscular-dystrophy 2023-04-11T20:22:49 https://maestrodatabase.com/blog/covid-19-vaccine-development 2020-09-09T05:06:19 https://maestrodatabase.com/blog/pharmac-defends-position-not-to-fund-bowel-cancer-drug 2018-09-13T21:23:41 https://maestrodatabase.com/blog/health-technology-assessment-policy-and-methods-review-consultation 2023-04-11T11:16:10 https://maestrodatabase.com/blog/dying-cancer-patients-refused-pharmac-funding 2018-09-13T21:20:17 https://maestrodatabase.com/blog/fda-to-review-eylea-aflibercept-injection-for-the-treatment-of-diabetic-retinopathy 2018-09-13T21:41:26 https://maestrodatabase.com/blog/alimera-sciences-obtains-reimbursement-approval-for-iluvien-use-in-non-infectious-posterior-uveitis-in-scotland 2020-09-09T06:48:12 https://maestrodatabase.com/blog/beleaguered-price-hiking-drug-ceo-says-he-wasnt-defending-shkreli-he-was-condemning-fda 2018-09-13T21:32:36 https://maestrodatabase.com/blog/bio-allergan-and-roche-call-for-fda-flexibility-with-patient-experience-data 2018-09-13T21:35:48 https://maestrodatabase.com/blog/tga-approves-yet-another-flu-vaccine 2020-09-09T05:27:24 https://maestrodatabase.com/blog/cancer-drug-shortages-are-creating-dire-circumstances-for-some-patients 2023-04-11T20:45:54 https://maestrodatabase.com/blog/icer-publishes-2023-research-protocol-for-assessing-unsupported-price-increases-on-prescription-drugs 2023-04-11T20:48:03 https://maestrodatabase.com/blog/for-first-time-since-2010-americas-progress-on-health-insurance-stalls 2018-09-13T21:49:28 https://maestrodatabase.com/blog/can-a-cancer-drug-originated-in-china-be-a-success-in-the-u-dot-s 2018-09-13T21:52:36 https://maestrodatabase.com/blog/abortion-ruling-could-undermine-the-fdas-drug-approval-authority 2023-04-11T20:42:15 https://maestrodatabase.com/blog/another-appraisal-terminated-by-nice 2020-09-09T20:23:56 https://maestrodatabase.com/blog/acorda-announces-fda-extends-inbrija-nda-review-period 2018-09-14T00:05:28 https://maestrodatabase.com/blog/evaluation-of-precision-medicine-assessment-reports-of-the-belgian-health-care-payer-to-inform-reimbursement-decisions 2020-09-09T20:43:30 https://maestrodatabase.com/blog/what-does-it-take-for-a-hta-agency-to-accept-a-claim-of-clinical-superiority 2020-09-09T20:47:28 https://maestrodatabase.com/blog/ironwood-pharmaceuticals-announces-fda-fast-track-designation-for-praliciguat-for-the-treatment-of-heart-failure-with-preserved-ejection-fraction 2018-09-14T00:16:06 https://maestrodatabase.com/blog/statement-on-astrazeneca-oxford-sars-cov-2-vaccine-azd1222-covid-19-vaccine-trials-temporary-pause 2020-09-09T20:21:01 https://maestrodatabase.com/blog/reporting-suspected-side-effects-of-medicines-in-patients-with-covid-19 2020-04-24T11:30:23 https://maestrodatabase.com/blog/fda-approves-menquadfi-the-latest-innovation-in-meningococcal-menacwy-vaccination 2020-04-24T11:33:07 https://maestrodatabase.com/blog/miransertib-arq-092-granted-fast-track-designation-for-the-treatment-of-pik3ca-related-overgrowth-spectrum 2018-09-14T00:21:04 https://maestrodatabase.com/blog/rfp---supply-of-entecavir-and-tenofovir-disoproxil-tablets-or-capsules 2017-07-19T04:21:04 https://maestrodatabase.com/blog/canbridge-pharmaceuticals-receives-chinese-marketing-approval-for-hunterase-first-enzyme-replacement-therapy-for-hunter-syndrome-in-china 2020-09-09T21:15:26 https://maestrodatabase.com/blog/clarity-pharmaceuticals-announces-the-us-fda-grants-rare-paediatric-disease-designation-to-64-cu-sartate-a-diagnostic-for-the-clinical-management-of-neuroblastoma 2020-09-09T20:55:32 https://maestrodatabase.com/blog/new-diabetes-drug-funding-format-is-unethical 2020-09-09T21:05:12 https://maestrodatabase.com/blog/aldeyra-therapeutics-resubmits-reproxalap-new-drug-application-for-the-treatment-of-dry-eye-disease 2025-06-18T22:05:31 https://maestrodatabase.com/blog/swissmedic-approves-beyfortus-for-rsv-prophylaxis-in-newborns-infants-and-young-children 2023-12-28T22:17:34 https://maestrodatabase.com/blog/application-for-covid-19-vaccine-nuvaxovid-against-omicron-variant-xbb-dot-1-5-withdrawn 2023-12-28T22:13:41 https://maestrodatabase.com/blog/scottish-medicines-consortium-accepts-nasal-spray-for-depression-previously-rejected-by-nice 2020-09-09T21:20:58 https://maestrodatabase.com/blog/you-cant-rush-science----merck-ceo-stresses-need-for-careful-approach-to-coronavirus-vaccine 2020-09-09T21:32:20 https://maestrodatabase.com/blog/private-health-insurance-hikes-set-to-hit-australians-soon 2020-09-09T21:53:52 https://maestrodatabase.com/blog/abbvie-expands-immunology-portfolio-in-the-u-dot-s-with-fda-approval-of-skyrizi-risankizumab-rzaa-for-moderate-to-severe-plaque-psoriasis 2019-04-24T08:30:00 https://maestrodatabase.com/blog/new-campaign-to-promote-covid-19-oral-antiviral-treatments 2022-07-24T12:08:18 https://maestrodatabase.com/blog/u-dot-s-fda-designates-mallinckrodts-stratagraft-as-regenerative-medicine-advanced-therapy 2017-07-19T05:19:36 https://maestrodatabase.com/blog/calls-for-pharmac-to-fund-more-effective-shingles-vaccine-with-cases-expected-to-rise-due-to-covid-19 2022-07-24T22:20:54 https://maestrodatabase.com/blog/astellas-korea-renews-bid-to-reimburse-targeted-gastric-cancer-drug-vyloy 2025-07-14T05:43:55 https://maestrodatabase.com/blog/fda-grants-zeniths-zen-3694-fast-track-status 2025-07-15T02:56:11 https://maestrodatabase.com/blog/us-fda-approves-finerenone-for-new-indication-in-patients-with-heart-failure-with-left-ventricular-ejection-fraction-of-40-percent 2025-07-15T03:01:25 https://maestrodatabase.com/blog/atara-biotherapeutics-provides-regulatory-and-business-updates-on-tabelecleucel 2025-07-15T03:11:16 https://maestrodatabase.com/blog/drug-pricing-debate-redux----should-cost-effectiveness-analysis-be-used-now-to-price-pharmaceuticals 2021-11-14T07:40:43 https://maestrodatabase.com/blog/rhythm-pharmaceuticals-receives-positive-chmp-opinion-for-imcivree-setmelanotide-for-the-treatment-of-obesity-and-control-of-hunger-in-patients-with-bardet-biedl-syndrome 2022-07-24T23:22:20 https://maestrodatabase.com/blog/moderna-receives-full-us-fda-approval-for-covid-19-vaccine-spikevax-in-children-aged-6-months-through-11-years-at-increased-risk-for-covid-19-disease 2025-07-15T01:31:17 https://maestrodatabase.com/blog/fda-approves-subcutaneous-formulation-of-actemra-for-use-in-active-systemic-juvenile-idiopathic-arthritis-a-rare-form-of-juvenile-arthritis 2018-09-14T13:19:27 https://maestrodatabase.com/blog/regulating-drug-prices-while-increasing-innovation 2021-11-14T07:32:09 https://maestrodatabase.com/blog/netarsudil-mesylate-with-latanoprost-for-the-treatment-of-patients-with-primary-open-angle-glaucoma-or-ocular-hypertension 2024-10-04T05:17:14 https://maestrodatabase.com/blog/ema-priority-medicines-scheme-prime-will-more-paying-for-performance-agreements-be-needed-due-to-immature-data 2018-09-14T13:05:40 https://maestrodatabase.com/blog/house-gop-blocks-trump-supported-drug-pricing-provision-from-spending-bill 2018-09-14T13:15:30 https://maestrodatabase.com/blog/blood-cancer-drugs-added-to-pbs 2018-09-14T13:35:32 https://maestrodatabase.com/blog/opdualag-licensed-for-patients-with-advanced-melanoma 2023-12-29T02:26:53 https://maestrodatabase.com/blog/consultation-on-nhs-england-proposals-for-a-phased-launch-of-obesity-injection 2024-10-04T11:18:29 https://maestrodatabase.com/blog/active-ingredient-prescribing 2020-09-10T03:31:25 https://maestrodatabase.com/blog/medicines-regulators-weigh-hope-and-hype-with-new-alzheimers-drugs 2024-10-04T07:52:29 https://maestrodatabase.com/blog/viiv-healthcare-submits-regulatory-application-to-ema-for-single-tablet-two-drug-regimen-of-dolutegravir-and-lamivudine-for-treatment-of-hiv 2018-09-14T13:29:39 https://maestrodatabase.com/blog/enhertu-supplemental-new-drug-application-submitted-in-japan-for-patients-with-her2-low-or-her2-ultra-low-metastatic-breast-cancer 2024-10-04T06:35:29 https://maestrodatabase.com/blog/hhs-releases-final-guidance-for-second-cycle-of-historic-medicare-drug-price-negotiation-program 2024-10-04T06:22:36 https://maestrodatabase.com/blog/uk-less-interesting-to-pharma-because-of-brexit---roche-ceo 2018-09-14T13:45:20 https://maestrodatabase.com/blog/blue-shield-of-california-slashes-cost-of-worlds-best-selling-drug 2024-10-04T06:02:33 https://maestrodatabase.com/blog/reach-neuro-receives-fda-breakthrough-device-designation-for-device-to-restore-arm-and-hand-movement-to-chronic-stroke-patients 2023-04-12T01:19:28 https://maestrodatabase.com/blog/beigene-announces-acceptance-and-priority-review-by-health-canada-of-new-drug-submission-for-brukinsa-zanubrutinib-in-waldenstroems-macroglobulinaemia 2020-09-10T03:36:12 https://maestrodatabase.com/blog/abeona-receives-fda-regenerative-medicine-advanced-therapy-designation-for-eb-101-gene-therapy-in-epidermolysis-bullosa 2018-01-30T07:08:32 https://maestrodatabase.com/blog/aradigm-receives-complete-response-letter-from-the-fda-for-linhaliq-nda 2018-01-30T07:35:35 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-positive-chmp-opinion-for-onureg-azacitidine-tablets-cc-486-as-frontline-oral-maintenance-therapy-for-adults-with-acute-myeloid-leukaemia-in-first-remission 2021-04-26T02:03:26 https://maestrodatabase.com/blog/health-canada-extends-the-approval-of-evkeeza-evinacumab-to-children-as-young-as-6-months-old-with-homozygous-familial-hypercholesterolaemia 2025-07-15T05:04:40 https://maestrodatabase.com/blog/the-impact-of-parallel-regulatory-hta-scientific-advice-on-clinical-development-assessing-the-uptake-of-regulatory-and-hta-recommendations 2018-01-30T11:24:45 https://maestrodatabase.com/blog/aurinia-announces-positive-chmp-opinion-for-lupkynis-voclosporin-for-the-treatment-of-adults-with-active-lupus-nephritis-in-europe 2022-07-25T00:01:18 https://maestrodatabase.com/blog/nice-approves-more-tolerable-treatment-for-blood-cancer 2017-07-19T10:10:09 https://maestrodatabase.com/blog/transforming-health-care-through-precision-medicine 2018-01-30T20:27:49 https://maestrodatabase.com/blog/involving-young-people-in-ema-activities 2017-07-19T10:07:45 https://maestrodatabase.com/blog/greens-ban-cancer-medicine-gender-in-new-sweeping-policy-platform 2017-07-19T20:49:49 https://maestrodatabase.com/blog/post-market-review-of-chronic-obstructive-pulmonary-disease-medicines---final-report-released 2018-01-30T11:29:59 https://maestrodatabase.com/blog/private-health-insurance-fix-hurdle 2017-07-19T10:17:45 https://maestrodatabase.com/blog/prescription-medicines-and-biologicals-tga-annual-summary-2017 2018-01-30T20:18:55 https://maestrodatabase.com/blog/trump-wants-new-u-dot-s-health-secretary-to-get-tough-on-drug-prices-opioids 2018-01-30T20:41:38 https://maestrodatabase.com/blog/vivus-announces-acceptance-of-qsymia-decentralised-marketing-authorisation-application-in-europe 2019-10-08T01:14:03 https://maestrodatabase.com/blog/vertex-announces-broad-reimbursement-agreement-with-nhs-england-for-alyftrek-deutivacaftor-slash-tezacaftor-slash-vanzacaftor-an-innovative-once-daily-cftr-modulator-for-the-treatment-of-cystic-fibrosis 2025-07-15T07:54:59 https://maestrodatabase.com/blog/donald-trump-holds-republican-war-party-to-revive-health-care-plans 2017-07-19T20:56:59 https://maestrodatabase.com/blog/medytox-submits-bla-for-non-animal-derived-liquid-btx-formulation-in-us 2023-12-29T04:08:06 https://maestrodatabase.com/blog/fda-has-to-explain-why-amgen-was-denied-a-key-marketing-incentive 2018-01-30T20:34:05 https://maestrodatabase.com/blog/sun-pharma-announces-launch-of-leqselvi-deuruxolitinib-in-the-us-for-the-treatment-of-severe-alopecia-areata 2025-07-15T08:54:58 https://maestrodatabase.com/blog/european-chmp-issues-positive-opinion-for-cariprazine-for-the-treatment-of-schizophrenia 2017-07-19T21:03:20 https://maestrodatabase.com/blog/to-avoid-open-bidding-generic-drug-makers-cut-prices-outside-quebec 2018-01-30T20:37:22 https://maestrodatabase.com/blog/asco-addresses-high-cost-of-cancer-drugs 2017-07-19T21:23:08 https://maestrodatabase.com/blog/rare-cancer-drug-to-be-subsidised 2021-11-14T20:38:06 https://maestrodatabase.com/blog/how-do-you-measure-value-in-a-drug----or-anything-else-in-medicine 2017-07-19T21:19:38 https://maestrodatabase.com/blog/eu-review-extended-for-biomarins-gene-therapy-valrox 2020-09-10T10:23:21 https://maestrodatabase.com/blog/additional-support-for-australians-with-rare-skin-conditions 2021-11-14T20:34:12 https://maestrodatabase.com/blog/from-last-to-first---could-the-u-dot-s-health-care-system-become-the-best-in-the-world 2017-09-07T12:16:56 https://maestrodatabase.com/blog/takedas-zika-vaccine-gets-u-dot-s-fdas-fast-track-status 2018-01-30T20:44:50 https://maestrodatabase.com/blog/aussies-to-be-denied-repeat-prescriptions-for-common-antibiotics 2019-10-08T01:21:27 https://maestrodatabase.com/blog/trump-says-he-wants-to-let-obamacare-fail-dot-heres-how-he-could-make-it-fail 2017-07-19T21:28:52 https://maestrodatabase.com/blog/theravance-biopharma-and-mylan-announce-fda-acceptance-of-new-drug-application-for-revefenacin-td-4208-in-adults-with-chronic-obstructive-pulmonary-disease 2018-01-30T20:49:08 https://maestrodatabase.com/blog/importing-medicines-from-overseas-guidance-needed 2022-07-25T02:11:29 https://maestrodatabase.com/blog/indicative-1-april-2018-prices---2018-april-cycle 2018-01-30T20:57:31 https://maestrodatabase.com/blog/some-good-news-on-covid-19 2020-09-10T07:07:14 https://maestrodatabase.com/blog/fda-approves-trelegy-ellipta-as-the-first-once-daily-single-inhaler-triple-therapy-for-the-treatment-of-both-asthma-and-copd-in-the-us 2020-09-10T08:09:24 https://maestrodatabase.com/blog/regulatory-and-clinical-outcomes-of-non-oncology-accelerated-approvals 2025-07-15T10:02:59 https://maestrodatabase.com/blog/new-cystic-fibrosis-drug-fast-tracked-for-nhs-use 2025-07-15T10:06:25 https://maestrodatabase.com/blog/the-who-launches-a-global-initiative-on-treatments-for-covid-19 2020-04-25T08:40:20 https://maestrodatabase.com/blog/fda-to-scrutinise-unproven-cancer-drugs-after-10-year-gap 2021-04-26T03:24:00 https://maestrodatabase.com/blog/maker-of-drug-touted-as-coronavirus-cure-accuses-china-of-gouging 2020-04-25T08:45:38 https://maestrodatabase.com/blog/hell-has-frozen-over-the-pharmaceutical-industry-stands-in-for-a-politically-impaired-fda 2020-09-10T20:41:45 https://maestrodatabase.com/blog/majority-of-americans-believe-political-pressure-will-cause-fda-to-rush-a-coronavirus-vaccine-new-poll-finds 2020-09-10T20:43:49 https://maestrodatabase.com/blog/fdas-woodcock-on-authorising-the-emergency-use-for-hydroxychloroquine-we-did-the-best-we-could 2020-04-25T08:49:53 https://maestrodatabase.com/blog/us-fda-accepts-application-to-review-expanded-use-of-gsks-rsv-vaccine-arexvy-for-adults-18-49-at-increased-risk 2025-07-15T09:48:32 https://maestrodatabase.com/blog/fda-chief-says-he-has-no-intention-of-overruling-career-staff-on-coronavirus-vaccine-decision 2020-09-10T20:46:20 https://maestrodatabase.com/blog/vaccine-developers-hustle-to-meet-fda-data-requirements-to-submit-for-approval 2020-09-10T20:24:44 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-positive-chmp-opinion-recommending-approval-for-opdivo-nivolumab-plus-yervoy-ipilimumab-as-first-line-treatment-for-unresectable-malignant-pleural-mesothelioma 2021-04-26T03:16:39 https://maestrodatabase.com/blog/herceptin-trastuzumab-subcutaneous-formulation-approved-in-canada-for-the-treatment-of-her2-positive-breast-cancer 2018-09-15T00:07:35 https://maestrodatabase.com/blog/lilly-commits-insulin-value-program-featuring-35-dollars-copay-card-to-suite-of-affordability-solutions-for-people-with-diabetes 2020-09-10T20:27:26 https://maestrodatabase.com/blog/hta-reform-starts-today---consultations-open 2023-04-12T06:14:32 https://maestrodatabase.com/blog/fda-approves-device-for-treatment-of-acute-coronary-artery-perforation 2018-09-14T23:59:55 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-to-evaluate-car-t-therapies-in-upcoming-report 2017-07-19T23:09:51 https://maestrodatabase.com/blog/halozyme-announces-janssen-submission-for-fda-approval-of-darzalex-faspro-daratumumab-and-hyaluronidase-fihj-for-the-treatment-of-patients-with-light-chain-amyloidosis 2020-09-10T20:34:58 https://maestrodatabase.com/blog/csls-blood-payments-in-us-under-the-microscope 2020-04-25T21:19:40 https://maestrodatabase.com/blog/enhertu-granted-priority-review-in-the-u-dot-s-for-patients-with-her2-low-metastatic-breast-cancer 2022-07-25T06:36:57 https://maestrodatabase.com/blog/fda-cautions-against-use-of-hydroxychloroquine-or-chloroquine-for-covid-19-outside-of-the-hospital-setting-or-a-clinical-trial-due-to-risk-of-heart-rhythm-problems 2020-04-25T21:24:07 https://maestrodatabase.com/blog/china-debates-cutting-us-access-to-drugs-as-hostilities-spike 2020-09-10T21:14:35 https://maestrodatabase.com/blog/icer-publishes-final-evidence-report-on-treatment-for-secondary-progressive-multiple-sclerosis 2025-07-15T21:40:40 https://maestrodatabase.com/blog/applications-for-proposed-first-of-a-kind-multiple-sclerosis-biosimilar-natalizumab-accepted-by-us-fda-and-ema 2022-07-25T06:31:18 https://maestrodatabase.com/blog/single-fda-centre-fo-rare-diseases-could-be-negative-to-rare-disease-cause 2018-09-15T00:14:05 https://maestrodatabase.com/blog/eu-actions-to-support-availability-of-medicines-during-covid-19-pandemic---update-number-3 2020-04-25T08:54:12 https://maestrodatabase.com/blog/sigma-aims-to-distribute-covid-19-vaccine 2020-09-10T20:51:16 https://maestrodatabase.com/blog/merck-resubmits-supplemental-biologics-license-applications-for-keytruda-pembrolizumab-six-week-dosing-schedule 2020-04-25T09:30:01 https://maestrodatabase.com/blog/pfizer-may-win-the-covid-vaccine-race-but-distributing-it-could-be-another-matter 2020-09-10T20:53:57 https://maestrodatabase.com/blog/fda-describes-plans-to-expand-remote-regulatory-assessments 2022-07-25T04:25:21 https://maestrodatabase.com/blog/covid-19-drug-rationed-in-the-us-is-plentiful-in-developing-countries 2020-09-10T20:59:23 https://maestrodatabase.com/blog/pharmac-seeking-views-on-widened-access-to-juvenile-idiopathic-arthritis-medicines 2020-09-10T21:04:02 https://maestrodatabase.com/blog/tlv-has-decided-on-an-increase-in-ceiling-prices 2023-04-12T20:33:33 https://maestrodatabase.com/blog/tezspire-recommended-for-approval-in-the-eu-by-chmp-for-the-treatment-of-severe-asthma 2022-07-25T07:02:04 https://maestrodatabase.com/blog/takeda-receives-fda-approval-to-expand-the-use-of-hyqvia-to-treat-primary-immunodeficiency-in-children 2023-04-12T20:42:15 https://maestrodatabase.com/blog/ultomiris-recommended-for-approval-in-the-eu-by-chmp-for-the-treatment-of-adults-with-generalised-myasthenia-gravis 2022-07-25T06:48:16 https://maestrodatabase.com/blog/biocon-biologics-expands-diabetes-portfolio-with-fda-approval-of-kirsty-the-first-and-only-interchangeable-rapid-acting-insulin-aspart-in-the-us 2025-07-15T21:33:13 https://maestrodatabase.com/blog/hta-barriers-for-conditional-approval-drugs 2023-04-12T21:09:22 https://maestrodatabase.com/blog/asco-policy-statement-on-biosimilar-and-interchangeable-products-in-oncology 2023-04-12T21:17:00 https://maestrodatabase.com/blog/kala-pharmaceuticals-receives-fda-fast-track-designation-for-kpi-012-a-human-msc-s-therapy-for-persistent-corneal-epithelial-defect 2023-04-12T20:59:48 https://maestrodatabase.com/blog/taxis-pharmaceuticals-earns-fda-qidp-designation-for-txa14007-an-investigational-efflux-pump-inhibitor-to-combat-antibiotic-resistant-pneumonia 2025-07-15T23:09:48 https://maestrodatabase.com/blog/supporting-australians-with-rare-stomach-and-bowel-cancer 2021-11-15T01:14:21 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-gene-therapies-for-sickle-cell-disease 2023-04-12T20:52:15 https://maestrodatabase.com/blog/leo-pharma-receives-positive-chmp-opinion-of-adtralza-tralokinumab-for-the-treatment-of-adults-with-moderate-to-severe-atopic-dermatitis 2021-04-26T04:13:25 https://maestrodatabase.com/blog/egetis-receives-fda-breakthrough-therapy-designation-for-tiratricol-for-mct8-deficiency 2025-07-15T23:15:26 https://maestrodatabase.com/blog/patient-groups-attack-cvs-use-of-icer-metrics-urge-rethink 2018-09-15T23:47:10 https://maestrodatabase.com/blog/compliance-with-requirement-to-report-results-on-the-eu-clinical-trials-register-cohort-study-and-web-resource 2018-09-15T23:50:15 https://maestrodatabase.com/blog/u-dot-s-drug-prices-sky-high-in-international-comparison 2022-07-25T07:14:46 https://maestrodatabase.com/blog/wegovy-recommended-for-approval-for-the-treatment-of-obesity-by-the-european-regulatory-authorities 2021-11-15T02:07:35 https://maestrodatabase.com/blog/children-with-chronic-graft-versus-host-disease-may-now-be-prescribed-imbruvica-ibrutinib 2022-08-25T03:12:24 https://maestrodatabase.com/blog/government-to-re-evaluate-dementia-drug-choline-alfoscerate 2020-05-18T11:34:49 https://maestrodatabase.com/blog/global-sarcoma-therapy-now-approved-for-australian-patients 2021-04-26T05:06:02 https://maestrodatabase.com/blog/australia-must-work-to-avoid-vaccine-nationalism-former-top-bureaucrat-warns 2020-05-18T20:44:01 https://maestrodatabase.com/blog/galderma-receives-fda-approval-for-new-sculptra-label-offering-more-options-to-aesthetic-partners 2021-12-14T03:19:56 https://maestrodatabase.com/blog/adamis-pharmaceuticals-resubmits-zimhi-new-drug-application-to-fda 2020-05-18T20:48:19 https://maestrodatabase.com/blog/beware-of-underpriced-drugs-for-covid-19-treatments 2020-05-18T20:54:41 https://maestrodatabase.com/blog/mobocertinib-succinate-for-patients-with-advanced-egfr-exon-20-insertion-mutation-positive-non-small-cell-lung-cancer-after-platinum-based-chemotherapy 2023-01-04T09:27:27 https://maestrodatabase.com/blog/agency-for-7-march-tc-meeting 2018-03-06T03:34:52 https://maestrodatabase.com/blog/blueprint-pays-the-price-of-ayvakit-phase-3-miss-as-fda-rejects-drug 2020-05-18T11:38:16 https://maestrodatabase.com/blog/amivantamab-for-the-treatment-of-patients-with-egfr-exon-20-insertion-mutation-positive-advanced-non-small-cell-lung-cancer-after-platinum-based-chemotherapy 2022-12-15T09:55:06 https://maestrodatabase.com/blog/health-economic-assessment-of-bavencio-and-inlyta 2020-05-18T11:46:07 https://maestrodatabase.com/blog/ab-science-announces-that-it-has-filed-an-application-for-conditional-marketing-authorisation-to-ema-for-masitinib-in-the-treatment-of-als 2022-08-25T03:49:24 https://maestrodatabase.com/blog/the-coronavirus-exposed-the-us-reliance-on-india-for-generic-drugs-but-that-supply-chain-is-ultimately-controlled-by-china 2020-05-18T21:30:07 https://maestrodatabase.com/blog/montreal-mother-launches-desperate-plea-for-help-to-access-experimental-cancer-treatment 2020-05-18T21:42:59 https://maestrodatabase.com/blog/janssen-marks-first-approval-worldwide-for-tecvayli-teclistamab-with-ec-authorisation-of-first-in-class-bispecific-antibody-for-the-treatment-of-patients-with-multiple-myeloma 2022-08-25T08:22:38 https://maestrodatabase.com/blog/takeda-and-hutchmed-announce-new-drug-application-for-fruquintinib-for-treatment-of-previously-treated-metastatic-colorectal-cancer-granted-priority-review 2023-05-26T02:12:01 https://maestrodatabase.com/blog/international-reference-pricing-gets-thumbs-down-from-ispor-panel 2020-05-18T20:57:22 https://maestrodatabase.com/blog/lynparza-approved-in-japan-as-adjuvant-treatment-for-patients-with-brca-mutated-her2-negative-high-risk-early-breast-cancer 2022-08-25T08:14:53 https://maestrodatabase.com/blog/ema-may-conditionally-authorise-remdesivir-in-the-coming-days 2020-05-18T21:01:56 https://maestrodatabase.com/blog/janssen-seeks-european-commission-approval-of-a-new-indication-for-carvykti-ciltacabtagene-autoleucel-cilta-cel-for-the-earlier-treatment-of-patients-with-relapsed-and-refractory-multiple-myeloma 2023-05-26T01:10:34 https://maestrodatabase.com/blog/the-threat-of-fungal-infections-is-growing-why-is-it-so-hard-to-make-new-drugs 2024-02-13T04:23:35 https://maestrodatabase.com/blog/first-gene-therapy-for-adults-with-severe-haemophilia-a-biomarins-roctavian-valoctocogene-roxaparvovec-approved-by-european-commission 2022-08-25T08:07:37 https://maestrodatabase.com/blog/fda-approves-genentechs-tecentriq-as-a-first-line-monotherapy-for-certain-people-with-metastatic-non-small-cell-lung-cancer 2020-05-18T21:07:53 https://maestrodatabase.com/blog/ultomiris-approved-in-japan-for-the-treatment-of-adults-with-generalised-myasthenia-gravis 2022-08-25T09:00:51 https://maestrodatabase.com/blog/covid-19-vaccine-safety-report-25-august-2022 2022-08-25T08:55:51 https://maestrodatabase.com/blog/breast-cancer-sufferers-march-on-parliament-calling-on-pharmac-to-fund-two-game-changer-drugs 2018-10-16T06:12:52 https://maestrodatabase.com/blog/chugai-obtains-regulatory-approval-for-polivy-for-additional-indication-of-previously-untreated-diffuse-large-b-cell-lymphoma 2022-08-25T08:46:28 https://maestrodatabase.com/blog/tagrisso-approved-in-japan-for-the-adjuvant-treatment-of-patients-with-early-stage-egfr-mutated-lung-cancer 2022-08-25T08:40:31 https://maestrodatabase.com/blog/proposal-to-award-sole-supply-and-change-some-anti-retroviral-brands 2018-10-16T04:11:44 https://maestrodatabase.com/blog/cms-proposes-to-require-manufacturers-to-disclose-drug-prices-in-television-ads 2018-10-16T05:24:57 https://maestrodatabase.com/blog/talking-with-tama-a-sick-toddler-who-cant-access-the-drug-he-needs 2019-11-05T06:06:44 https://maestrodatabase.com/blog/new-leukaemia-medicine-means-three-new-cancer-drugs-funded-this-year 2019-11-05T06:05:05 https://maestrodatabase.com/blog/the-failed-promise-of-the-uss-inflation-reduction-act-for-patients-with-diabetes 2022-08-25T20:38:27 https://maestrodatabase.com/blog/pharmac-funding-new-leukaemia-medicine 2019-11-05T05:58:03 https://maestrodatabase.com/blog/drug-companies-need-to-make-costs-more-reasonable 2018-10-16T06:16:12 https://maestrodatabase.com/blog/myriad-genetics-receives-expanded-coverage-in-japan-for-use-of-bracanalysis-diagnostic-system-as-a-companion-diagnostic-for-lynparza-in-early-stage-breast-cancer 2022-08-25T20:43:34 https://maestrodatabase.com/blog/redhill-biopharma-announces-fda-approval-of-talicia-for-treatment-of-h-pylori-in-adults 2019-11-05T06:19:12 https://maestrodatabase.com/blog/new-checks-to-crack-down-on-free-prescription-fraud 2018-10-16T20:01:56 https://maestrodatabase.com/blog/iovance-biotherapeutics-initiates-biologics-license-application-submission-for-lifileucel-in-advanced-melanoma 2022-08-25T20:30:45 https://maestrodatabase.com/blog/fda-verdict-on-biogens-alzheimers-drug-likely-to-be-a-political-decision-analyst-says 2019-11-05T06:17:22 https://maestrodatabase.com/blog/cystic-fibrosis-patients-worry-about-future-of-life-changing-drug 2018-10-16T20:05:01 https://maestrodatabase.com/blog/obscure-model-puts-a-price-on-good-health--and-drives-down-drug-costs 2019-11-05T06:13:49 https://maestrodatabase.com/blog/model-structuring-for-economic-evaluations-of-new-health-technologies 2018-10-16T19:43:31 https://maestrodatabase.com/blog/fda-plans-to-authorise-bivalent-boosters-by-labor-day-sources-say 2022-08-25T09:06:21 https://maestrodatabase.com/blog/a-cash-grab-states-declare-war-with-health-funds-over-patients-in-public-hospitals 2019-11-05T06:11:19 https://maestrodatabase.com/blog/fda-guides-on-minimal-residual-disease-endpoint-in-haematologic-cancer-trials 2018-10-16T19:48:32 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-positive-chmp-opinion-recommending-opdivo-nivolumab-plus-yervoy-ipilimumab-for-treatment-of-mismatch-repair-deficient-or-microsatellite-instability-high-metastatic-colorectal-cancer-after-prior-chemotherapy 2021-05-24T02:50:05 https://maestrodatabase.com/blog/agenda-for-the-september-2022-pbac-intracycle-meeting 2022-08-26T08:09:38 https://maestrodatabase.com/blog/drug-price-transparency-wont-end-the-patent-games 2018-10-16T20:24:41 https://maestrodatabase.com/blog/fda-approves-pfizers-drug-for-advanced-breast-cancer 2018-10-16T20:16:31 https://maestrodatabase.com/blog/sandoz-receives-us-fda-approval-for-long-acting-oncology-supportive-care-biosimilar-ziextenzo-pegfilgrastim-bmez 2019-11-05T06:24:41 https://maestrodatabase.com/blog/jazz-pharmaceuticals-announces-fda-acceptance-of-nda-for-solriamfetol-jzp-110-for-excessive-sleepiness-associated-with-narcolepsy-or-obstructive-sleep-apnea 2018-03-06T06:37:40 https://maestrodatabase.com/blog/pbac-public-summary-documents---may-2022-meeting 2022-08-26T07:45:21 https://maestrodatabase.com/blog/government-secures-monkeypox-medicine-pharmac-working-on-getting-vaccines 2022-08-26T07:51:20 https://maestrodatabase.com/blog/atagi-slash-thanz-statement-provides-further-guidance-for-the-astrazeneca-vaccine-and-narrows-contra-indication 2021-05-24T02:35:39 https://maestrodatabase.com/blog/new-hope-offered-to-rare-disease-patients 2021-12-14T04:02:57 https://maestrodatabase.com/blog/novavax-vaccine-for-adolescents-aged-12-17-years 2022-08-25T20:51:27 https://maestrodatabase.com/blog/bristol-myers-squibbs-opdivo-nivolumab-now-the-first-and-only-fda-approved-pd-1-inhibitor-to-offer-every-four-week-dosing 2018-03-06T20:00:59 https://maestrodatabase.com/blog/ge-healthcare-announces-u-dot-s-fda-approval-of-macrocyclic-mri-contrast-agent-clariscan-gadoterate-meglumine-injection-for-intravenous-use 2019-11-05T08:56:47 https://maestrodatabase.com/blog/atagi-update-following-weekly-covid-19-meeting-24-august-2022 2022-08-26T21:39:27 https://maestrodatabase.com/blog/vabysmo-faricimab-injection-now-publicly-funded-for-macular-oedema-secondary-to-retinal-vein-occlusion-in-ontario 2025-08-31T00:47:40 https://maestrodatabase.com/blog/fda-approves-new-hiv-treatment-for-patients-who-have-limited-treatment-options 2018-03-06T20:07:42 https://maestrodatabase.com/blog/health-minister-orders-investigation-into-health-insurer-bupa-after-alarming-announcements 2018-03-06T19:53:31 https://maestrodatabase.com/blog/biogen-received-european-commission-approval-for-skyclarys-omaveloxolone-the-first-therapy-to-treat-friedreichs-ataxia 2024-02-13T05:11:22 https://maestrodatabase.com/blog/patient-registries-ema-officials-highlight-opportunities-in-orphan-drug-development 2022-08-26T21:33:42 https://maestrodatabase.com/blog/fda-authorises-with-special-controls-direct-to-consumer-test-that-reports-three-mutations-in-the-brca-breast-cancer-genes 2018-03-06T19:56:20 https://maestrodatabase.com/blog/sanofis-wayrilz-approved-in-us-as-first-btk-inhibitor-for-immune-thrombocytopenia 2025-08-31T00:52:05 https://maestrodatabase.com/blog/fda-approves-fluzone-high-dose-quadrivalent-influenza-vaccine-for-adults-65-years-of-age-and-older 2019-11-05T08:37:41 https://maestrodatabase.com/blog/stakeholders-ask-fda-to-be-more-flexible-on-rescinding-breakthrough-drug-designations 2022-08-26T21:30:02 https://maestrodatabase.com/blog/game-changing-asthma-treatment-for-kids-listed-on-pbs 2025-08-31T01:03:51 https://maestrodatabase.com/blog/incyte-announces-fda-approval-of-pemazyre-pemigatinib-as-the-first-and-only-targeted-treatment-for-myeloid-slash-lymphoid-neoplasms-with-fgfr1-rearrangement 2022-08-26T21:25:30 https://maestrodatabase.com/blog/unitedhealth-will-pass-drug-rebates-directly-to-some-consumers 2018-03-06T20:29:43 https://maestrodatabase.com/blog/iovance-biotherapeutics-announces-us-fda-acceptance-of-the-biologics-license-application-of-lifileucel-for-the-treatment-of-advanced-melanoma 2023-05-27T05:56:20 https://maestrodatabase.com/blog/unitedhealth-group-hits-64-dollars-billion-in-value-based-care-spending 2018-03-06T20:34:46 https://maestrodatabase.com/blog/european-commission-approves-first-crispr-slash-cas9-gene-edited-therapy-casgevy-exagamglogene-autotemcel-for-the-treatment-of-sickle-cell-disease-and-transfusion-dependent-beta-thalassaemia 2024-02-13T07:12:03 https://maestrodatabase.com/blog/access-to-new-drugs-for-rare-disorders-in-canada 2018-03-06T20:22:03 https://maestrodatabase.com/blog/government-to-cut-price-of-opdivo-by-over-20-percent 2018-03-06T20:40:14 https://maestrodatabase.com/blog/heres-a-real-trade-abuse-trump-should-address 2018-03-06T20:50:50 https://maestrodatabase.com/blog/positive-chmp-opinion-for-ryeqo-relugolix-combination-tablet 2021-05-24T04:15:12 https://maestrodatabase.com/blog/stage-2-pbs-process-improvements---consultation-closed 2020-10-13T02:57:43 https://maestrodatabase.com/blog/a-severe-shortage-hits-a-drug-used-for-cancer-immune-disorders-epilepsy-causing-canceled-treatments-and-rationing 2019-11-05T18:04:39 https://maestrodatabase.com/blog/private-health-pushes-back-on-rates-rise-queries-from-greg-hunt 2021-12-14T18:50:20 https://maestrodatabase.com/blog/highlights-from-the-chmp-22-25-may-2023-meeting 2023-05-27T06:57:36 https://maestrodatabase.com/blog/prescription-drug-prices-are-falling-at-historic-levels-thanks-to-trump-administration-policies 2019-11-05T16:35:26 https://maestrodatabase.com/blog/fda-publishes-discussion-paper-and-seeks-public-input-on-3d-printing-of-medical-devices-at-the-point-of-care 2021-12-14T11:04:02 https://maestrodatabase.com/blog/nice-international-returns-to-deal-with-growing-overseas-enquiries 2019-11-05T16:24:38 https://maestrodatabase.com/blog/fda-approves-irinotecan-liposome-for-first-line-treatment-of-metastatic-pancreatic-adenocarcinoma 2024-02-13T20:13:59 https://maestrodatabase.com/blog/newly-funded-medicine-to-benefit-110-more-people-with-thyroid-liver-and-kidney-cancer 2024-11-08T00:05:46 https://maestrodatabase.com/blog/ema-reviewing-new-data-on-effectiveness-of-lagevrio-molnupiravir-for-the-treatment-of-covid-19 2021-12-14T18:53:03 https://maestrodatabase.com/blog/access-consortium-statement-on-covid-19-medicines 2021-12-14T07:52:16 https://maestrodatabase.com/blog/fda-authorises-marketing-of-first-next-generation-sequencing-test-for-detecting-hiv-1-drug-resistance-mutations 2019-11-06T06:12:50 https://maestrodatabase.com/blog/federal-judge-tosses-phrma-lawsuit-challenging-medicare-drug-negotiations 2024-02-13T20:10:44 https://maestrodatabase.com/blog/australia-launches-national-preventive-health-strategy 2021-12-14T07:02:52 https://maestrodatabase.com/blog/adjusting-for-covariates-in-randomized-clinical-trials-for-drugs-and-biological-products 2023-05-27T06:52:50 https://maestrodatabase.com/blog/edgewise-receives-us-fda-fast-track-designation-for-edg-5506-for-the-treatment-of-duchenne-muscular-dystrophy 2024-02-13T20:06:46 https://maestrodatabase.com/blog/medibank-ceo-warns-private-health-sustainability-in-jeopardy 2019-11-06T06:02:28 https://maestrodatabase.com/blog/gilead-withdraws-submission-for-jyseleca 2021-05-24T04:34:08 https://maestrodatabase.com/blog/fda-approval-of-leqembi-subcutaneous-formulation-charts-path-to-combination-therapies-for-alzheimers-disease 2025-08-31T02:10:59 https://maestrodatabase.com/blog/is-the-fda-doing-enough-to-bring-biosimilars-to-market 2019-11-06T05:54:33 https://maestrodatabase.com/blog/permanent-telehealth-to-strengthen-universal-medicare 2021-12-14T07:58:35 https://maestrodatabase.com/blog/smc---february-2024-decisions 2024-02-13T08:02:09 https://maestrodatabase.com/blog/tg-therapeutics-announces-fda-acceptance-of-biologics-license-application-for-ublituximab-as-a-treatment-for-patients-with-relapsing-forms-of-multiple-sclerosis 2021-12-14T19:14:30 https://maestrodatabase.com/blog/ftc-takes-pharma-bro-martin-shkreli-to-trial-over-drug-price-hike 2021-12-14T19:20:49 https://maestrodatabase.com/blog/white-house-and-pelosi-part-ways-on-relief-for-drug-prices 2019-11-06T15:45:11 https://maestrodatabase.com/blog/trastuzumab-deruxtecan-supplemental-new-drug-application-submitted-in-japan-for-treatment-of-patients-with-her2-positive-metastatic-breast-cancer 2021-12-14T19:02:33 https://maestrodatabase.com/blog/smc-approves-first-immunotherapy-combination-for-advanced-bowel-cancer-patients-with-rare-mutation 2021-12-14T18:59:44 https://maestrodatabase.com/blog/medibank-chief-craig-drummond-lashes-suppliers 2019-11-06T15:40:39 https://maestrodatabase.com/blog/accelerating-covid-19-therapeutic-interventions-and-vaccines-activ-an-unprecedented-partnership-for-unprecedented-times 2020-05-19T01:36:02 https://maestrodatabase.com/blog/eu-regulation-passed-g-ba-works-on-european-hta-assessment 2021-12-14T19:07:58 https://maestrodatabase.com/blog/can-3110-receives-fda-fast-track-designation-for-treatment-of-recurrent-high-grade-glioma 2024-02-13T20:23:31 https://maestrodatabase.com/blog/aicuris-granted-fast-track-designation-by-u-dot-s-fda-for-oral-pritelivir-for-treatment-of-hsv-infections-in-immunocompromised-adults 2017-08-02T09:49:31 https://maestrodatabase.com/blog/extending-the-user-fee-approach-to-pharmaceuticals 2018-10-17T03:02:24 https://maestrodatabase.com/blog/covid-19-new-zealand-to-buy-1-dot-5-million-doses-of-potential-vaccine 2020-10-13T04:19:55 https://maestrodatabase.com/blog/health-canada-approves-xermelo-telotristat-ethyl-for-the-treatment-of-adult-patients-suffering-from-refractory-carcinoid-syndrome-diarrhea 2018-10-17T03:05:34 https://maestrodatabase.com/blog/octapharmas-fibryga-receives-european-label-extension-to-treat-acquired-fibrinogen-deficiency-afd 2019-11-06T06:51:01 https://maestrodatabase.com/blog/corbyn-accuses-tories-of-planning-deal-to-hike-drug-prices-with-trump-as-election-looms 2019-11-06T15:57:50 https://maestrodatabase.com/blog/oxular-receives-rare-paediatric-disease-and-orphan-drug-designations-for-retinoblastoma-treatment 2020-10-13T05:02:13 https://maestrodatabase.com/blog/one-shot-drug-to-end-sicilian-curse-comes-at-1-dollars-8-cents-million-cost 2019-11-06T15:48:36 https://maestrodatabase.com/blog/fda-office-of-hematology-oncology-products-reorganises-renamed-office-of-oncologic-diseases 2019-11-06T16:29:03 https://maestrodatabase.com/blog/pfizer-and-biontech-complete-submission-to-ema-for-omicron-ba-dot-4-slash-ba-dot-5-adapted-bivalent-vaccine 2022-08-27T03:21:08 https://maestrodatabase.com/blog/pharmac-still-stalled-on-lung-cancer-drug 2021-12-14T19:25:04 https://maestrodatabase.com/blog/bionomics-announces-fast-track-designation-granted-by-u-dot-s-fda-to-bnc210-development-program-for-the-treatment-of-ptsd 2019-11-06T16:21:20 https://maestrodatabase.com/blog/health-technology-assessment-european-commission-welcomes-the-adoption-of-new-rules-to-improve-access-to-innovative-technologies 2021-12-14T19:29:49 https://maestrodatabase.com/blog/innovation-and-access-at-the-mercy-of-payment-policy-the-future-of-chimeric-antigen-receptor-therapies 2019-11-06T16:44:19 https://maestrodatabase.com/blog/novartis-says-delayed-telling-fda-of-zolgensma-concern-due-to-mistake 2019-11-06T16:38:11 https://maestrodatabase.com/blog/canadian-ambassador-says-drug-imports-would-not-lower-u-dot-s-prices 2019-11-06T16:34:45 https://maestrodatabase.com/blog/statement-on-the-agencys-efforts-to-protect-patients-through-post-market-drug-safety-surveillance-practices 2019-11-07T08:54:10 https://maestrodatabase.com/blog/pbs-process-improvements-information-forum 2019-11-07T08:43:24 https://maestrodatabase.com/blog/roche-invited-to-submit-a-cdf-proposal-for-urothelial-cancer-drug 2017-08-02T11:20:19 https://maestrodatabase.com/blog/dr-stephen-hahn-nominated-to-be-next-fda-commissioner 2019-11-06T16:54:56 https://maestrodatabase.com/blog/u-dot-s-fda-approves-enhanced-formulation-of-pliaglis 2019-11-07T09:03:14 https://maestrodatabase.com/blog/pharmac-to-fund-new-treatments-for-breast-and-blood-cancer 2024-02-13T23:48:50 https://maestrodatabase.com/blog/fda-approves-kalydeco-ivacaftor-for-more-than-600-people-ages-2-and-older-with-cystic-fibrosis-who-have-certain-residual-function-mutations 2017-08-02T11:39:10 https://maestrodatabase.com/blog/endoceutics-receives-health-canada-approval-for-intrarosa 2019-11-07T09:00:00 https://maestrodatabase.com/blog/republicans-in-congress-bypass-trump-to-shore-up-health-law 2017-08-02T11:47:37 https://maestrodatabase.com/blog/avexis-receives-ec-approval-and-activates-day-one-access-program-for-zolgensma-the-only-gene-therapy-for-spinal-muscular-atrophy 2020-05-19T06:39:19 https://maestrodatabase.com/blog/fda-and-dhs-increase-coordination-of-responses-to-medical-device-cybersecurity-threats-under-new-partnership-a-part-of-the-two-agencies-broader-effort-to-protect-patient-safety 2018-10-17T03:57:04 https://maestrodatabase.com/blog/fda-approves-treatment-for-chronic-graft-versus-host-disease 2017-08-02T20:53:05 https://maestrodatabase.com/blog/nibs-mark-fitzgibbon-calls-for-single-payer-in-healthcare 2017-08-02T20:49:29 https://maestrodatabase.com/blog/medicare-issues-projected-drug-premiums-for-2018 2017-08-02T20:56:35 https://maestrodatabase.com/blog/pfizer-and-biontechs-comirnaty-receives-us-fda-approval-for-adults-65-and-older-and-individuals-ages-5-through-64-at-increased-risk-for-severe-covid-19 2025-08-31T03:44:40 https://maestrodatabase.com/blog/novavax-covid-19-vaccine-approved-for-12-to-17s-by-mhra 2022-08-27T23:03:37 https://maestrodatabase.com/blog/the-generic-drug-industry-has-brought-huge-cost-savings-that-may-be-changing 2017-08-02T21:01:00 https://maestrodatabase.com/blog/senate-plans-to-vote-on-fda-user-fees-legislation-this-week-senators-say 2017-08-02T21:05:58 https://maestrodatabase.com/blog/health-canada-approves-keytruda-in-combination-with-trastuzumab-and-chemotherapy-as-a-first-line-treatment-for-patients-with-locally-advanced-unresectable-or-metastatic-her2-positive-gastric-or-gastro-oesophageal-junction-adenocarcinoma-whose-tumours-express-pd-l1 2024-02-14T02:41:40 https://maestrodatabase.com/blog/evidence-for-health-decision-making----beyond-randomised-controlled-trials 2017-08-02T21:56:56 https://maestrodatabase.com/blog/libtayo-cemiplimab-receives-positive-chmp-opinion-for-the-treatment-in-europe-of-two-advanced-cancers 2021-05-24T06:41:12 https://maestrodatabase.com/blog/top-pharma-official-rejects-idea-of-free-covid-19-vaccine-for-all 2020-05-19T11:29:34 https://maestrodatabase.com/blog/cadth-board-of-directors-names-suzanne-mcgurn-as-next-president-and-ceo 2020-05-19T11:35:10 https://maestrodatabase.com/blog/heterogeneity-of-treatment-effect-estimating-how-the-effects-of-interventions-vary-across-individuals 2021-12-14T23:23:52 https://maestrodatabase.com/blog/almost-10-000-australians-drop-private-health-insurance-during-pandemic 2020-05-19T11:45:01 https://maestrodatabase.com/blog/fda-appears-to-soften-stance-on-hydroxychloroquine-after-trump-says-he-takes-malaria-drug 2020-05-19T20:43:19 https://maestrodatabase.com/blog/almirall-receives-positive-chmp-opinion-for-klisyri-tirbanibulin-an-innovative-topical-treatment-for-actinic-keratosis 2021-05-24T06:57:21 https://maestrodatabase.com/blog/celltrion-seeks-european-approval-for-actemra-biosimilar 2024-02-14T02:59:15 https://maestrodatabase.com/blog/bevespi-aerosphere-approved-in-china-for-patients-with-copd 2020-05-19T11:21:09 https://maestrodatabase.com/blog/china-approves-austedo-for-treating-chorea-associated-with-huntingtons-disease-and-tardive-dyskinesia-in-adults 2020-05-19T11:24:29 https://maestrodatabase.com/blog/teva-canada-secures-salbutamol-inhalers-from-its-global-supply-chain-to-mitigate-shortage-in-canadian-market 2020-05-19T21:00:19 https://maestrodatabase.com/blog/moderna-receives-us-fda-approval-for-updated-covid-19-vaccines-targeting-lp-dot-8-1-variant-of-sars-cov-2 2025-08-31T03:50:33 https://maestrodatabase.com/blog/uk-bulk-buys-hydroxychloroquine-as-potential-covid-19-treatment 2020-05-19T21:19:56 https://maestrodatabase.com/blog/trump-admin-taps-startup-to-build-nations-first-stockpile-of-key-drug-ingredients 2020-05-19T20:48:18 https://maestrodatabase.com/blog/covid-19-update-fda-collaborations-promote-rigorous-analyses-of-real-world-data-to-inform-pandemic-response 2020-05-19T20:50:40 https://maestrodatabase.com/blog/gilead-ups-its-donation-of-the-covid-19-drug-remdesivir-for-u-dot-s-hospitals 2020-05-19T20:55:52 https://maestrodatabase.com/blog/rocket-pharmaceuticals-announces-update-on-fda-review-timeline-of-kresladi-marnetegragene-autotemcel-for-the-treatment-of-severe-leukocyte-adhesion-deficiency-i 2024-02-14T20:12:42 https://maestrodatabase.com/blog/galderma-announces-regulatory-filing-acceptance-for-nemolizumab-in-prurigo-nodularis-and-atopic-dermatitis-in-the-us-and-eu 2024-02-14T20:07:18 https://maestrodatabase.com/blog/sunovion-receives-fda-approval-of-supplemental-new-drug-application-for-use-of-latuda-lurasidone-hydrochloride-in-the-treatment-of-bipolar-depression-in-paediatric-patients-10-to-17-years-of-age 2018-03-07T01:23:03 https://maestrodatabase.com/blog/fda-approves-first-medication-to-treat-severe-frostbite 2024-02-14T20:01:16 https://maestrodatabase.com/blog/eiger-biopharmaceuticals-announces-fda-acceptance-of-nda-for-filing-with-priority-review-of-zokinvy-lonafarnib-for-treatment-of-progeria-and-progeroid-laminopathies 2020-05-19T21:26:24 https://maestrodatabase.com/blog/us-fda-accepts-for-priority-review-bristol-myers-squibbs-application-for-augtyro-repotrectinib-for-the-treatment-of-patients-with-ntrk-positive-locally-advanced-or-metastatic-solid-tumours 2024-02-14T19:48:59 https://maestrodatabase.com/blog/health-canada-approves-lonsurf-trifluridine-slash-tipiracil-for-metastatic-colorectal-cancer 2018-03-07T01:32:38 https://maestrodatabase.com/blog/rinvoq-upadacitinib-receives-u-dot-s-fda-approval-for-active-psoriatic-arthritis 2021-12-15T00:06:26 https://maestrodatabase.com/blog/askbio-receives-fda-rare-paediatric-disease-and-orphan-drug-designations-for-ab-1003-for-the-treatment-of-limb-girdle-muscular-dystrophy-type-2i-slash-r9 2024-11-08T02:42:19 https://maestrodatabase.com/blog/ceo-tapped-by-trump-to-make-generic-drugs-during-pandemic-has-a-dicey-track-record 2020-05-19T21:43:32 https://maestrodatabase.com/blog/fda-approves-medicines360s-snda-for-liletta-levonorgestrel-releasing-intrauterine-system-52-mg-to-prevent-pregnancy-for-up-to-five-years 2018-10-17T06:50:56 https://maestrodatabase.com/blog/nine-ways-covid-19-may-forever-upend-the-u-dot-s-health-care-industry 2020-05-19T21:45:25 https://maestrodatabase.com/blog/trumenba-meningococcal-group-b-vaccine-now-available-in-canada 2018-03-07T01:44:37 https://maestrodatabase.com/blog/japan-issues-final-approval-for-moderna-and-astrazeneca-vaccines 2021-05-24T11:20:31 https://maestrodatabase.com/blog/j-and-j-applauds-u-dot-s-proposal-on-drug-prices-in-tv-ads 2018-10-17T09:39:13 https://maestrodatabase.com/blog/liberals-want-to-build-their-campaign-around-pharmacare-but-ignore-where-drugs-would-end-up 2019-05-24T06:05:27 https://maestrodatabase.com/blog/decision-to-change-the-funded-brand-of-aripiprazole-and-remove-listing-restrictions 2018-03-07T02:22:31 https://maestrodatabase.com/blog/express-scripts-covers-amgen-lilly-migraine-drugs-excludes-teva 2018-10-17T19:42:49 https://maestrodatabase.com/blog/akesos-penpulimab-monoclonal-antibody-submitted-bla-in-the-united-states 2021-05-24T20:53:19 https://maestrodatabase.com/blog/the-u-dot-s-insulin-crisis----rationing-a-lifesaving-medication-discovered-in-the-1920s 2019-11-07T11:32:55 https://maestrodatabase.com/blog/if-warren-scraps-private-health-care-beware-the-unintended-consequences 2019-11-07T11:25:48 https://maestrodatabase.com/blog/abbvie-announces-supplemental-new-drug-application-accepted-for-priority-review-by-u-dot-s-fda-for-imbruvica-ibrutinib-in-combination-with-obinutuzumab-gazyva-for-previously-untreated-chronic-lymphocytic-leukaemia 2018-10-17T19:32:56 https://maestrodatabase.com/blog/swiss-pharma-industry-fights-lower-drug-prices-in-the-us 2021-05-24T21:01:24 https://maestrodatabase.com/blog/pharmac-publishes-record-from-feb-2021-ptac-meeting 2021-05-24T20:58:05 https://maestrodatabase.com/blog/shaping-regulatory-science-to-2025 2018-10-17T19:57:24 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-positive-chmp-opinion-recommending-approval-for-opdivo-nivolumab-with-chemotherapy-as-neo-adjuvant-treatment-of-resectable-non-small-cell-lung-cancer-at-high-risk-of-recurrence-in-patients-with-tumour-cell-pd-l1-expression-1-percent 2023-05-28T22:48:06 https://maestrodatabase.com/blog/final-nice-guidance-issued-for-akceas-tegsedi 2019-05-24T22:51:39 https://maestrodatabase.com/blog/adjusting-for-covariates-in-randomised-clinical-trials-for-drugs-and-biological-products 2021-05-24T11:34:05 https://maestrodatabase.com/blog/ema-facilitates-early-engagement-with-medicine-developers-to-combat-antimicrobial-resistance 2019-05-24T22:49:23 https://maestrodatabase.com/blog/further-hepatitis-c-drug-delay-cruel 2018-10-17T19:49:21 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-acute-migraine-therapies 2019-11-07T11:36:43 https://maestrodatabase.com/blog/boehringer-ingelheims-investigational-treatment-for-cognitive-impairment-associated-with-schizophrenia-receives-fda-breakthrough-therapy-designation 2021-05-24T20:45:12 https://maestrodatabase.com/blog/lojuxta-to-be-reimbursed-in-france 2018-10-17T20:05:17 https://maestrodatabase.com/blog/rising-drug-prices-widen-gap-between-have-have-not-patients 2018-10-17T20:00:30 https://maestrodatabase.com/blog/fda-approves-innovative-gene-therapy-to-treat-paediatric-patients-with-spinal-muscular-atrophy-a-rare-disease-and-leading-genetic-cause-of-infant-mortality 2019-05-24T22:55:03 https://maestrodatabase.com/blog/why-is-tagrisso-not-reimbursable-as-first-line-treatment-in-korea 2021-05-24T21:04:51 https://maestrodatabase.com/blog/avexis-announces-innovative-zolgensma-gene-therapy-access-programs-for-us-payers-and-families 2019-05-24T23:02:03 https://maestrodatabase.com/blog/coverage-for-biosimilars-vs-reference-products-among-us-commercial-health-plans 2020-05-20T02:13:47 https://maestrodatabase.com/blog/fda-approves-first-pi3k-inhibitor-for-breast-cancer 2019-05-24T23:15:57 https://maestrodatabase.com/blog/b-dot-c-teen-with-rare-disease-wins-fight-to-receive-costly-drug-from-province 2020-05-20T01:58:31 https://maestrodatabase.com/blog/fda-approves-jakafi-ruxolitinib-for-the-treatment-of-patients-with-acute-graft-versus-host-disease 2019-05-24T23:52:54 https://maestrodatabase.com/blog/doctors-warn-australias-private-health-sector-is-heading-towards-a-us-style-system 2019-05-24T23:48:53 https://maestrodatabase.com/blog/icer-posts-draft-scoping-document-for-the-assessment-of-supervised-injection-facilities 2020-05-20T02:34:43 https://maestrodatabase.com/blog/trump-administration-preparing-executive-order-on-health-cost-disclosure 2019-05-25T01:37:30 https://maestrodatabase.com/blog/health-officials-warn-of-practical-limitations-to-medicine-subsidies-despite-triage 2024-11-08T11:07:37 https://maestrodatabase.com/blog/top-democrats-call-for-watchdog-to-review-trump-medicare-drug-cards 2020-10-13T19:37:22 https://maestrodatabase.com/blog/icer-comments-on-the-fda-approval-of-zolgensma-for-the-treatment-of-spinal-muscular-atrophy 2019-05-25T00:10:58 https://maestrodatabase.com/blog/additional-pbac-meeting 2024-11-08T07:33:23 https://maestrodatabase.com/blog/cumberland-pharmaceuticals-receives-fda-orphan-drug-and-rare-paediatric-disease-designations-for-new-treatment-of-duchenne-muscular-dystrophy 2024-11-08T07:25:07 https://maestrodatabase.com/blog/health-canada-has-approved-invokana-canagliflozin-for-reduction-of-major-adverse-cardiovascular-events-the-first-sglt2-inhibitor-in-canada-to-receive-this-indication 2018-10-18T02:27:21 https://maestrodatabase.com/blog/blink-health-taking-on-middle-men-to-democratise-drug-prices 2019-05-25T01:55:07 https://maestrodatabase.com/blog/bupa-tweaks-controversial-gap-cover-plan-following-public-outcry 2018-03-07T10:40:26 https://maestrodatabase.com/blog/daewoongs-antipyretic-unable-to-get-insurance-benefits 2020-10-13T19:55:37 https://maestrodatabase.com/blog/fda-grants-breakthrough-therapy-designation-to-kadmons-kd025-for-chronic-graft-versus-host-disease 2018-10-18T02:31:47 https://maestrodatabase.com/blog/roche-to-launch-laboratory-sars-cov-2-antigen-test-to-support-high-volume-testing-of-suspected-covid-19-patients 2020-10-13T20:04:36 https://maestrodatabase.com/blog/albireo-receives-fda-fast-track-designation-for-a4250 2018-10-18T02:37:54 https://maestrodatabase.com/blog/regenxbio-announces-first-fda-approval-of-a-gene-therapy-based-on-its-proprietary-nav-technology-platform 2019-05-25T01:49:06 https://maestrodatabase.com/blog/moderna-announces-initiation-of-rolling-submission-to-health-canada-for-mrna-vaccine-against-covid-19-mrna-1273 2020-10-13T20:12:48 https://maestrodatabase.com/blog/pbs-price-disclosure---42-month-clock-list-for-a-30-percent-unadjusted-price-reduction-for-the-2018-april-cycle 2018-03-07T06:35:41 https://maestrodatabase.com/blog/dermavant-submits-supplemental-new-drug-application-to-fda-for-vtama-tapinarof-1-percent-cream-for-the-treatment-of-atopic-dermatitis-in-adults-and-children-2-years-of-age-and-older 2024-02-15T04:33:22 https://maestrodatabase.com/blog/rigged-system-blocks-use-of-lower-cost-drugs-fda-chief-says 2018-03-07T20:08:59 https://maestrodatabase.com/blog/covid-19-vaccines-are-chance-at-salvation-financial-and-beyond-for-drug-makers 2020-10-13T19:42:00 https://maestrodatabase.com/blog/unitedhealthcare-will-pass-some-rebates-to-consumers-but-will-this-really-lower-drug-prices 2018-03-07T20:12:50 https://maestrodatabase.com/blog/pmv-pharma-granted-fda-fast-track-designation-of-pc14586-for-the-treatment-of-advanced-cancer-patients-that-have-tumours-with-a-p53-y220c-mutation 2020-10-13T19:46:37 https://maestrodatabase.com/blog/ema-recommends-immediate-suspension-and-recall-of-multiple-sclerosis-medicine-zinbryta 2018-03-07T19:56:41 https://maestrodatabase.com/blog/consultation-for-various-vaccine-supply-agreements 2023-05-29T00:01:01 https://maestrodatabase.com/blog/u-dot-s-fda-approves-pfizers-xeljanz-tofacitinib-for-the-treatment-of-active-ankylosing-spondylitis 2021-12-15T02:48:35 https://maestrodatabase.com/blog/elrexfio-is-authorised-by-health-canada-for-adults-with-relapsed-or-refractory-multiple-myeloma-in-canada 2024-02-15T08:01:17 https://maestrodatabase.com/blog/cancer-sufferers-want-oz-treatments-i-want-to-live 2018-03-07T20:27:04 https://maestrodatabase.com/blog/citius-pharmaceuticals-resubmits-the-biologics-license-application-of-lymphir-denileukin-diftitox-for-the-treatment-of-adults-with-relapsed-or-refractory-cutaneous-t-cell-lymphoma 2024-02-15T06:27:05 https://maestrodatabase.com/blog/achaogen-submits-marketing-authorisation-application-to-the-ema-for-plazomicin 2018-10-18T02:47:36 https://maestrodatabase.com/blog/alnylam-submits-regulatory-applications-to-the-u-dot-s-fda-and-ema-to-support-label-expansion-for-oxlumo-for-the-treatment-of-advanced-primary-hyperoxaluria-type-1 2021-12-15T03:25:25 https://maestrodatabase.com/blog/updates-to-the-hta-review-research-and-analysis-papers-collection-emerging-health-technologies 2024-02-15T20:31:03 https://maestrodatabase.com/blog/diamyd-medical-receives-us-fda-fast-track-designation-for-diamyd 2024-02-15T20:26:20 https://maestrodatabase.com/blog/japans-fy-2024-pricing-reform-expected-to-favour-new-listed-innovative-drugs 2024-02-15T20:20:38 https://maestrodatabase.com/blog/launch-of-new-hma-ema-catalogues-of-real-world-data-sources-and-studies 2024-02-15T20:13:08 https://maestrodatabase.com/blog/more-than-30-000-people-to-benefit-under-pharmac-proposal 2024-02-15T20:08:45 https://maestrodatabase.com/blog/incyte-announces-acceptance-and-priority-review-of-snda-for-ruxolitinib-cream-opzelura-as-a-treatment-for-patients-with-vitiligo 2021-12-15T03:11:28 https://maestrodatabase.com/blog/how-china-could-choke-eu-supply-of-medicines 2023-05-29T00:39:21 https://maestrodatabase.com/blog/ultomiris-approved-in-japan-for-the-prevention-of-relapses-in-patients-with-neuromyelitis-optica-spectrum-disorder 2023-05-29T00:42:15 https://maestrodatabase.com/blog/marinus-pharmaceuticals-receives-positive-chmp-opinion-for-ztalmy-ganaxolone-for-the-adjunctive-treatment-of-seizures-associated-with-cdkl5-deficiency-disorder 2023-05-29T02:11:46 https://maestrodatabase.com/blog/nice-welcomes-life-sciences-review-recommendations 2023-05-29T02:09:35 https://maestrodatabase.com/blog/immusoft-receives-rare-paediatric-disease-designation-for-treatment-of-mps-i 2018-10-18T05:07:27 https://maestrodatabase.com/blog/nhs-green-light-for-novartis-skin-cancer-combo 2018-10-18T09:57:32 https://maestrodatabase.com/blog/ema-validates-bratovi-mektovi-application-for-some-mcrc 2019-11-07T17:36:52 https://maestrodatabase.com/blog/paying-ps500-million-more-a-week-for-drugs-post-brexit-is-based-on-a-fairly-extreme-scenario 2019-11-07T17:45:36 https://maestrodatabase.com/blog/msac-publishes-agenda-for-august-pasc-meeting 2023-05-29T02:24:23 https://maestrodatabase.com/blog/tga-approves-new-medicine-for-paediatric-cancer 2021-12-15T04:04:13 https://maestrodatabase.com/blog/a-review-of-hta-guidelines-on-societal-and-novel-value-elements 2023-05-29T02:36:16 https://maestrodatabase.com/blog/brexit-what-it-could-mean-for-drug-prices 2019-11-07T17:42:33 https://maestrodatabase.com/blog/northland-mum-alethea-nathan-with-lung-cancer-pleads-for-publicly-funded-medicine 2018-10-18T19:44:20 https://maestrodatabase.com/blog/califf-sails-through-confirmation-hearing-for-fda-job-despite-tensions-over-opioids 2021-12-15T04:14:37 https://maestrodatabase.com/blog/the-fda-needs-to-set-standards-for-using-artificial-intelligence-in-drug-development 2019-11-07T17:57:14 https://maestrodatabase.com/blog/little-consistency-in-evidence-cited-by-commercial-plans-for-specialty-drug-coverage 2019-11-07T17:53:41 https://maestrodatabase.com/blog/advancing-toward-the-goal-of-global-approval-for-generic-drugs-fda-proposes-critical-first-steps-to-harmonise-the-global-scientific-and-technical-standards-for-generic-drugs 2018-10-18T19:50:47 https://maestrodatabase.com/blog/what-to-do-about-prescription-drug-prices 2019-11-07T17:48:32 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-september-2025 2025-09-01T00:03:06 https://maestrodatabase.com/blog/lexicon-announces-fda-approval-of-inpefa-sotagliflozin-for-treatment-of-heart-failure 2023-05-29T07:06:35 https://maestrodatabase.com/blog/how-would-elizabeth-warren-pay-for-her-health-policy 2019-11-07T20:34:34 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-september-2025 2025-09-01T00:32:22 https://maestrodatabase.com/blog/fda-approves-obecabtagene-autoleucel-for-adults-with-relapsed-or-refractory-b-cell-precursor-acute-lymphoblastic-leukaemia 2024-11-08T21:24:00 https://maestrodatabase.com/blog/ema-recommends-revocation-of-authorisation-for-sickle-cell-disease-medicine-adakveo 2023-05-29T07:35:25 https://maestrodatabase.com/blog/more-cheaper-medicines-now-available-for-australians 2025-09-01T02:09:04 https://maestrodatabase.com/blog/fda-approves-tepotinib-for-metastatic-non-small-cell-lung-cancer 2024-02-15T23:03:27 https://maestrodatabase.com/blog/nice-u-turn-on-treatment-for-giant-cell-arteritis 2018-03-08T19:52:42 https://maestrodatabase.com/blog/once-weekly-sogroya-somapacitan-receives-chmp-positive-opinion-for-expanded-use-in-children-and-adolescents-with-growth-hormone-deficiency 2023-05-29T22:44:39 https://maestrodatabase.com/blog/patient-and-public-involvement-in-early-awareness-and-alert-activities-an-example-from-the-united-kingdom 2018-03-08T20:31:46 https://maestrodatabase.com/blog/balancing-safety-and-innovation-for-cell-based-regenerative-medicine 2018-03-08T20:39:53 https://maestrodatabase.com/blog/ovarian-cancer-drug-that-costs-up-to-$130k-will-soon-be-affordable-for-hundreds-of-patients 2022-08-28T21:01:17 https://maestrodatabase.com/blog/cigna-to-buy-express-scripts-as-health-shakeout-speeds-up 2018-03-08T20:01:19 https://maestrodatabase.com/blog/cignas-54-dollars-billion-purchase-of-express-scripts-could-upend-the-prescription-drug-market 2018-03-08T20:15:20 https://maestrodatabase.com/blog/push-to-get-nuclear-warhead-prostate-cancer-drug-funded 2022-08-28T21:05:05 https://maestrodatabase.com/blog/care-for-people-with-rare-and-less-common-cancers-delayed-and-fragmented-new-report-reveals 2025-09-01T02:45:41 https://maestrodatabase.com/blog/23andme-granted-first-fda-authorisation-for-direct-to-consumer-genetic-test-on-cancer-risk 2018-03-08T20:50:21 https://maestrodatabase.com/blog/pharmac-confirms-continued-access-to-comirnaty-covid-19-vaccine 2025-09-01T02:48:28 https://maestrodatabase.com/blog/us-cancer-network-recommending-expensive-drugs-based-on-weak-evidence-study-finds 2018-03-08T20:45:50 https://maestrodatabase.com/blog/cadth-common-drug-review-will-accept-submissions-up-to-six-months-pre-notice-of-compliance 2018-03-08T20:56:52 https://maestrodatabase.com/blog/cti-biopharma-initiates-rolling-submission-of-new-drug-application-for-pacritinib-in-myelofibrosis-patients-with-severe-thrombocytopenia 2020-10-14T05:04:46 https://maestrodatabase.com/blog/covid-19-vaccine-janssen-ema-recommendation-on-booster-dose 2021-12-15T11:09:59 https://maestrodatabase.com/blog/europe-falls-behind-u-dot-s-in-funding-coronavirus-vaccine-and-securing-access 2020-05-20T11:18:05 https://maestrodatabase.com/blog/lynparza-approved-in-the-us-for-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer 2020-05-20T11:35:04 https://maestrodatabase.com/blog/fda-approves-first-drug-to-prevent-graft-versus-host-disease 2021-12-15T19:09:37 https://maestrodatabase.com/blog/chmp-adopts-positive-opinion-to-extend-the-use-of-veklury-remdesivir-to-treat-covid-19-in-people-with-severe-renal-impairment-including-those-on-dialysis 2023-05-29T23:13:11 https://maestrodatabase.com/blog/ipsen-receives-chmp-negative-opinion-following-re-examination-of-potential-first-fop-treatment-in-the-eu 2023-05-29T23:06:53 https://maestrodatabase.com/blog/public-consultation---draft-2020-21-cost-recovery-implementation-statement-for-listing-medicines-on-the-pbs-and-designated-vaccines-on-the-nip 2020-05-20T11:09:12 https://maestrodatabase.com/blog/is-your-health-data-safe-as-my-health-record-hacking-revealed 2020-05-20T11:14:59 https://maestrodatabase.com/blog/evoke-receives-fda-conditional-acceptance-of-gimoti-brand-name-following-nda-resubmission 2020-05-20T20:50:40 https://maestrodatabase.com/blog/nuvation-bio-receives-fda-fast-track-designation-for-nuv-422-for-the-treatment-of-high-grade-gliomas-including-glioblastoma-multiforme 2021-12-15T19:28:36 https://maestrodatabase.com/blog/a-new-entry-in-the-race-for-a-coronavirus-vaccine-hope 2020-05-20T20:55:20 https://maestrodatabase.com/blog/global-regulators-commit-to-cooperate-on-observational-research-in-the-context-of-covid-19 2020-05-20T20:39:06 https://maestrodatabase.com/blog/valuing-and-pricing-remdesivir-should-drug-makers-get-paid-for-helping-us-get-back-to-work 2020-05-20T20:41:05 https://maestrodatabase.com/blog/us-fda-accepts-regulatory-submission-for-acalabrutinib-and-grants-priority-review 2017-08-03T03:39:22 https://maestrodatabase.com/blog/karyopharm-submits-supplemental-new-drug-application-to-fda-for-xpovio-selinexor-as-a-treatment-for-patients-with-multiple-myeloma-after-at-least-one-prior-line-of-therapy 2020-05-20T20:45:09 https://maestrodatabase.com/blog/u-dot-s-fda-grants-priority-review-for-spesolimab-for-the-treatment-of-flares-in-patients-with-generalised-pustular-psoriasis-a-rare-life-threatening-skin-disease 2021-12-15T19:21:53 https://maestrodatabase.com/blog/ema-launches-the-regulatory-science-research-needs-initiative 2021-12-15T19:17:45 https://maestrodatabase.com/blog/sapience-therapeutics-receives-fda-fast-track-designation-for-st101-for-advanced-cutaneous-melanoma 2021-12-15T19:50:34 https://maestrodatabase.com/blog/atagi-advice-on-the-preferential-use-of-bivalent-covid-19-vaccines-for-primary-vaccination-of-people-aged-12-years-or-older 2023-05-30T00:21:50 https://maestrodatabase.com/blog/health-minister-david-clark-postcode-cancer-care-embarrassing 2019-11-08T22:27:36 https://maestrodatabase.com/blog/valeo-pharma-obtains-public-reimbursement-for-enerzair-breezhaler-and-atectura-breezhaler-in-quebec-and-nova-scotia 2021-12-15T20:00:00 https://maestrodatabase.com/blog/insurers-back-plan-for-private-health-plans-to-cover-kids-up-to-age-30 2020-05-20T20:59:58 https://maestrodatabase.com/blog/wales-is-first-uk-country-to-fund-gws-epidyolex-for-tuberous-sclerosis 2021-12-15T19:34:54 https://maestrodatabase.com/blog/novavaxs-nuvaxovid-receives-positive-chmp-opinion-for-full-marketing-authorisation-for-the-prevention-of-covid-in-the-eu 2023-05-30T00:16:24 https://maestrodatabase.com/blog/cost-effectiveness-evaluation-for-pricing-medicines-and-devices-a-new-value-based-price-adjustment-system-in-japan 2020-05-20T21:12:59 https://maestrodatabase.com/blog/fda-approves-first-therapy-to-treat-patients-with-rare-blood-disorder 2019-11-09T07:59:05 https://maestrodatabase.com/blog/nice-finally-accepts-use-of-rare-cancer-therapy-poteligeo 2021-12-15T19:42:20 https://maestrodatabase.com/blog/trump-pushing-for-drug-pricing-action-after-senate-lunch 2020-05-20T21:48:56 https://maestrodatabase.com/blog/employers-call-on-congress-to-take-action-on-drug-prices-as-the-cost-of-providing-coverage-grows 2019-11-09T07:55:33 https://maestrodatabase.com/blog/caliway-received-us-fda-fast-track-designation-for-cbl-514-for-the-treatment-of-dercums-disease 2024-02-16T03:20:45 https://maestrodatabase.com/blog/teva-and-celltrion-announce-the-availability-of-truxima-rituximab-abbs-injection-the-first-biosimilar-to-rituxan-rituximab-in-the-united-states 2019-11-09T08:06:06 https://maestrodatabase.com/blog/dizal-submits-new-drug-application-to-the-us-fda-for-sunvozertinib-in-treating-relapsed-or-refractory-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations 2024-11-08T23:19:25 https://maestrodatabase.com/blog/janssen-announces-submission-of-supplemental-new-drug-application-to-u-dot-s-fda-seeking-approval-of-imbruvica-ibrutinib-in-combination-with-rituximab-for-previously-untreated-patients-with-chronic-lymphocytic-leukaemia 2019-11-09T08:17:17 https://maestrodatabase.com/blog/johnson-and-johnson-submits-applications-in-the-us-and-eu-seeking-approval-of-darzalex-faspro-slash-darzalex-as-subcutaneous-monotherapy-for-high-risk-smoldering-multiple-myeloma 2024-11-08T23:10:50 https://maestrodatabase.com/blog/japan-first-in-the-world-to-approve-dupixent-for-chronic-spontaneous-urticaria 2024-02-16T20:38:04 https://maestrodatabase.com/blog/johnson-and-johnson-announces-submission-of-european-marketing-authorisation-applications-for-janssens-investigational-ebola-vaccine-regimen 2019-11-09T08:35:52 https://maestrodatabase.com/blog/janssen-announces-health-canada-approval-of-imbruvica-ibrutinib-in-combination-with-obinutuzumab-for-treatment-naive-patients-with-chronic-lymphocytic-leukaemia 2019-11-09T08:28:56 https://maestrodatabase.com/blog/tga-approves-more-flexible-storage-conditions-for-pfizer-biontech-covid-19-vaccine 2021-05-25T05:05:08 https://maestrodatabase.com/blog/the-fda-is-ignoring-patients-in-clinical-trials 2023-05-30T02:03:21 https://maestrodatabase.com/blog/european-medicines-agency-grants-biomarins-request-for-accelerated-assessment-of-valoctocogene-roxaparvovec-for-treatment-of-severe-haemophilia-a 2021-05-25T07:19:27 https://maestrodatabase.com/blog/medibank-ceos-plan-to-fix-health-insurance 2019-11-09T10:01:30 https://maestrodatabase.com/blog/sosei-heptares-notes-that-a-valid-marketing-authorisation-application-for-qvm149-a-potential-new-inhaled-combination-therapy-for-asthma-has-been-filed-with-the-european-medicines-agency 2019-05-25T08:52:00 https://maestrodatabase.com/blog/lack-of-dhb-testing-means-lung-cancer-patients-could-be-missing-out-on-life-prolonging-drugs 2019-11-09T09:58:36 https://maestrodatabase.com/blog/sibeprenlimab-received-us-fda-breakthrough-therapy-designation-for-the-treatment-of-immunoglobulin-a-nephropathy 2024-02-16T21:02:31 https://maestrodatabase.com/blog/european-commission-approves-ponvory-ponesimod-for-the-treatment-of-adults-with-relapsing-forms-of-multiple-sclerosis-with-active-disease-defined-by-clinical-or-imaging-features 2021-05-25T05:26:50 https://maestrodatabase.com/blog/scholar-rock-receives-fast-track-designation-from-the-u-dot-s-fda-for-apitegromab-for-the-treatment-of-patients-with-spinal-muscular-atrophy 2021-05-25T07:52:48 https://maestrodatabase.com/blog/amazon-versus-apple-only-one-will-rewrite-the-rules-of-health-care 2022-08-29T09:32:25 https://maestrodatabase.com/blog/european-commission-approves-ranivisio-ranibizumab-a-biosimilar-to-lucentis 2022-08-29T07:57:16 https://maestrodatabase.com/blog/with-medical-bills-skyrocketing-more-hospitals-are-suing-for-payment 2019-11-09T10:05:14 https://maestrodatabase.com/blog/abbvie-announces-global-resolution-of-humira-adalimumab-patent-disputes-with-fresenius-kabi 2018-10-19T01:46:11 https://maestrodatabase.com/blog/verastem-oncology-receives-breakthrough-therapy-designation-for-vs-6766-with-defactinib-in-recurrent-low-grade-serous-ovarian-cancer 2021-05-25T07:28:30 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-lifileucel-for-unresectable-or-metastatic-melanoma 2024-02-16T22:55:01 https://maestrodatabase.com/blog/patient-reported-endpoints-underrepresented-in-product-information-on-new-drugs 2021-12-16T03:00:25 https://maestrodatabase.com/blog/bayer-submits-supplemental-new-drug-application-to-the-fda-for-intrauterine-device-mirena-levonorgestrel-releasing-intrauterine-system-52-mg 2020-10-14T19:28:48 https://maestrodatabase.com/blog/merck-receives-positive-eu-chmp-opinion-for-keytruda-pembrolizumab-in-combination-with-chemotherapy-as-first-line-treatment-for-certain-patients-with-oesophageal-cancer-or-her2-negative-gastro-oesophageal-junction-adenocarcinoma 2021-05-25T11:12:07 https://maestrodatabase.com/blog/fda-approves-first-medication-to-help-reduce-allergic-reactions-to-multiple-foods-after-accidental-exposure 2024-02-18T03:51:42 https://maestrodatabase.com/blog/harmony-biosciences-receives-fda-approval-for-expanded-use-of-wakix-pitolisant-for-the-treatment-of-cataplexy-in-adult-patients-with-narcolepsy 2020-10-14T19:33:59 https://maestrodatabase.com/blog/the-wild-west-of-checkpoint-inhibitor-development 2021-12-16T03:07:12 https://maestrodatabase.com/blog/csl-behring-receives-accelerated-chmp-assessment-for-etranacogene-dezaparvovec-for-european-patients-living-with-haemophilia-b 2021-12-16T02:22:57 https://maestrodatabase.com/blog/sarepta-therapeutics-announces-us-fda-acceptance-of-an-efficacy-supplement-to-expand-the-elevidys-indication 2024-02-18T03:42:13 https://maestrodatabase.com/blog/nice-rejects-lillys-breast-cancer-drug-verzenios 2018-10-19T11:48:34 https://maestrodatabase.com/blog/fda-approves-osimertinib-with-chemotherapy-for-egfr-mutated-non-small-cell-lung-cancer 2024-02-16T23:57:04 https://maestrodatabase.com/blog/viiv-healthcare-submits-new-drug-application-to-us-fda-for-single-tablet-two-drug-regimen-of-dolutegravir-and-lamivudine-for-treatment-of-hiv 2018-10-19T12:00:27 https://maestrodatabase.com/blog/scotland-backs-two-myeloma-drugs-turned-down-by-nice-in-england 2020-10-14T19:57:38 https://maestrodatabase.com/blog/pharmac-looking-to-fund-medicines-for-lung-and-ovarian-cancer 2021-12-16T03:24:12 https://maestrodatabase.com/blog/competition-watchdogs-appeal-over-pfizer-ruling-dismissed 2018-10-19T12:05:52 https://maestrodatabase.com/blog/tg-therapeutics-announces-fda-acceptance-of-biologics-license-application-for-ublituximab-in-combination-with-ukoniq-umbralisib-as-a-treatment-for-patients-with-chronic-lymphocytic-leukaemia-and-small-lymphocytic-lymphoma 2021-05-25T11:39:33 https://maestrodatabase.com/blog/fda-boldly-bows-to-big-pharma-at-americans-expense 2022-08-29T20:43:18 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-biohavens-supplemental-new-drug-application-of-nurtec-odt-for-the-preventive-treatment-of-migraine 2020-10-14T19:41:28 https://maestrodatabase.com/blog/dupixent-dupilumab-now-publicly-reimbursed-in-ontario-and-new-brunswick-for-the-treatment-of-moderate-to-severe-atopic-dermatitis 2021-05-25T11:33:31 https://maestrodatabase.com/blog/health-insurance-changes-leave-many-surprised-with-lack-of-cover 2020-10-14T19:50:31 https://maestrodatabase.com/blog/abbvie-receives-european-commission-approval-of-venclyxto-venetoclax-in-combination-with-a-hypomethylating-agent-for-patients-with-newly-diagnosed-acute-myeloid-leukaemia-who-are-ineligible-for-intensive-chemotherapy 2021-05-25T12:17:04 https://maestrodatabase.com/blog/evidence-for-hta-innovative-methods-for-challenging-times 2020-10-14T20:24:53 https://maestrodatabase.com/blog/gsk-announces-positive-eu-approval-for-labelling-update-to-relvar-ellipta-in-patients-with-asthma 2018-03-09T04:35:15 https://maestrodatabase.com/blog/eip-pharma-announces-u-dot-s-fda-grants-fast-track-designation-to-neflamapimod-as-a-treatment-for-dementia-with-lewy-bodies 2019-11-09T18:46:19 https://maestrodatabase.com/blog/fda-expected-to-authorise-moderna-pfizer-biontech-omicron-boosters 2022-08-29T21:44:45 https://maestrodatabase.com/blog/canadas-drug-agency-recommends-winrevair-sotatercept-for-reimbursement 2024-11-09T06:54:07 https://maestrodatabase.com/blog/jacinda-ardern-listening-to-calls-for-pharmac-to-fund-13-year-olds-life-changing-drugs-but-nothing-she-can-do 2021-05-25T20:58:24 https://maestrodatabase.com/blog/spinal-stabilization-technologies-earns-fda-breakthrough-designation-for-perqdisc-nucleus-replacement-system-for-degenerative-disc-disease 2021-05-25T21:05:42 https://maestrodatabase.com/blog/apellis-and-sobi-announce-eu-approval-of-aspaveli-pegcetacoplan-for-treatment-of-pnh 2021-12-16T04:43:55 https://maestrodatabase.com/blog/melinta-therapeutics-partner-menarini-group-submits-marketing-authorisation-application-for-delafloxacin-in-europe 2018-03-09T04:44:58 https://maestrodatabase.com/blog/cassiopea-announces-fda-acceptance-of-its-new-drug-application-for-clascoterone-1-percent-cream-the-first-new-mechanism-of-action-for-acne-in-nearly-40-years 2019-11-09T18:52:32 https://maestrodatabase.com/blog/triumvira-immunologics-announces-fast-track-designation-for-its-first-tac-t-cell-therapeutic-product-candidate-tac01-cd19 2019-11-09T19:05:43 https://maestrodatabase.com/blog/therapeuticsmd-announces-submission-of-low-dose-bijuva-0-dot-5-mg-slash-100-mg-supplemental-new-drug-application-to-fda 2021-05-25T20:45:35 https://maestrodatabase.com/blog/icer-publishes-protocol-for-first-annual-assessment-of-drug-coverage-policies-that-present-barriers-to-fair-access 2021-05-25T12:22:55 https://maestrodatabase.com/blog/nz-man-levi-holley-selling-his-belongings-to-pay-for-brain-cancer-treatment 2019-11-09T19:02:11 https://maestrodatabase.com/blog/president-biden-still-hasnt-appointed-a-permanent-fda-commissioner-that-has-big-implications-for-upcoming-drug-approvals 2021-05-25T20:50:57 https://maestrodatabase.com/blog/veloxis-files-with-fda-for-the-de-novo-indication-for-envarsus-xr 2018-03-09T05:03:24 https://maestrodatabase.com/blog/adjusting-for-non-adherence-or-stopping-treatments-in-randomised-clinical-trials 2021-05-25T21:18:26 https://maestrodatabase.com/blog/tga-decision-will-open-up-general-practice-to-pfizer 2021-05-25T21:24:33 https://maestrodatabase.com/blog/therapeuticsmd-announces-fda-acceptance-of-new-drug-application-and-prescription-drug-user-fee-act-date-for-tx-001hr 2018-03-09T05:19:02 https://maestrodatabase.com/blog/xeomin-cosmetic-licensed-for-additional-indications-in-canada 2019-11-09T21:07:40 https://maestrodatabase.com/blog/moderna-receives-health-canada-approval-for-rsv-vaccine-for-adults-aged-60-years-and-older 2024-11-09T07:11:12 https://maestrodatabase.com/blog/patient-perspective-is-vital-to-fdas-work 2019-11-10T17:38:53 https://maestrodatabase.com/blog/better-support-for-patients-with-low-survival-cancers-and-diseases 2018-03-09T05:28:33 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-16-december-2021 2021-12-16T06:39:59 https://maestrodatabase.com/blog/oncologist-urges-kiwi-lung-cancer-patients-to-be-screened-for-access-to-free-medication 2019-11-11T15:54:03 https://maestrodatabase.com/blog/charity-to-provide-free-epipens-as-pharmac-still-hasnt-funded-them 2019-11-11T15:50:34 https://maestrodatabase.com/blog/tga-approved-terminology-for-therapeutic-goods 2019-11-11T15:45:06 https://maestrodatabase.com/blog/roche-canada-and-the-pan-canadian-pharmaceutical-alliance-successfully-complete-negotiations-for-vabysmo-faricimab-injection-for-the-treatment-of-neovascular-wet-age-related-macular-degeneration-and-diabetic-macular-oedema 2023-05-30T06:31:37 https://maestrodatabase.com/blog/nice-u-turn-for-epidyolex-in-epilepsy 2019-11-11T16:03:15 https://maestrodatabase.com/blog/regulatory-science-to-2025-live-broadcast-of-post-consultation-workshop 2019-11-11T16:00:24 https://maestrodatabase.com/blog/doctors-hospitals-take-up-arms-against-democrats-health-care-changes 2019-11-11T15:57:46 https://maestrodatabase.com/blog/a-victim-of-its-own-success-inside-the-great-ozempic-shortage 2023-05-30T06:13:00 https://maestrodatabase.com/blog/medical-cannabis-ruled-out-for-chronic-pain-by-nhs-drug-watchdog-in-decision-branded-devastating 2019-11-11T16:38:09 https://maestrodatabase.com/blog/u-dot-s-fda-approves-expanded-labeling-for-epclusa-sofosbuvir-slash-velpatasvir-for-the-treatment-of-chronic-hepatitis-c-in-patients-co-infected-with-hiv 2017-08-03T07:28:27 https://maestrodatabase.com/blog/more-than-ever-democratic-presidential-hopefuls-want-to-take-on-pharma-heres-how-theyd-do-it 2019-11-11T16:33:42 https://maestrodatabase.com/blog/chinas-drug-market-is-opening-up 2019-11-11T16:29:46 https://maestrodatabase.com/blog/smc---november-2019-decisions 2019-11-11T16:21:14 https://maestrodatabase.com/blog/fda-approves-first-treatment-for-ebola-virus 2020-10-14T22:27:02 https://maestrodatabase.com/blog/f2g-receives-us-fda-breakthrough-therapy-designation-for-olorofim 2019-11-11T16:52:03 https://maestrodatabase.com/blog/breast-and-kidney-cancer-drugs-get-approval-for-use-across-scotlands-nhs 2019-11-11T17:10:26 https://maestrodatabase.com/blog/fda-admits-it-goofed-when-granting-orphan-status-to-an-opioid-addiction-treatment 2019-11-11T17:01:17 https://maestrodatabase.com/blog/health-officials-assail-pricing-schemes-that-gouge-patients 2018-03-11T02:14:24 https://maestrodatabase.com/blog/proposal-to-award-sole-supply-of-infliximab-in-dhb-hospitals 2020-05-21T04:03:34 https://maestrodatabase.com/blog/is-it-lawful-and-ethical-to-prioritise-racial-minorities-for-covid-19-vaccines 2020-10-14T22:34:03 https://maestrodatabase.com/blog/aradigm-submits-marketing-authorisation-application-to-ema-for-eu-marketing-approval-of-linhaliq-in-non-cystic-fibrosis-bronchiectasis 2018-03-11T02:22:51 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-for-priority-review-bristol-myers-squibbs-application-for-opdivo-nivolumab-plus-yervoy-ipilimumab-combination-for-patients-with-previously-treated-advanced-hepatocellular-carcinoma 2019-11-11T16:57:18 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-updates-value-based-price-benchmark-for-alirocumab-a-pcsk9-inhibitor-for-treatment-of-high-cholesterol 2018-03-11T07:31:53 https://maestrodatabase.com/blog/tga-grants-second-provisional-determination-for-a-covid-19-vaccine 2020-10-14T23:27:31 https://maestrodatabase.com/blog/is-icer-nicer 2018-03-11T02:36:17 https://maestrodatabase.com/blog/yukon-woman-paid-7-000-dollars-for-private-ketamine-treatment-only-to-learn-that-the-yukon-government-covers-it 2022-08-30T03:51:51 https://maestrodatabase.com/blog/the-relative-importance-of-clinical-economic-patient-values-and-feasibility-criteria-in-cancer-drug-reimbursement-in-canada-a-revealed-preferences-analysis-of-recommendations-of-the-pan-canadian-oncology-drug-review-2011-2017 2018-03-11T07:27:00 https://maestrodatabase.com/blog/amniofix-injectable-granted-regenerative-medicine-advanced-therapy-designation-by-the-fda-for-the-treatment-of-osteoarthritis-of-the-knee 2018-03-13T02:29:32 https://maestrodatabase.com/blog/biosimilar-renflexis-infliximab-available-on-pbs-from-1st-august 2017-08-03T08:10:07 https://maestrodatabase.com/blog/swissmedic-authorises-modernas-omicron-targeting-bivalent-booster-candidate-mrna-1273-dot-214 2022-08-30T03:45:12 https://maestrodatabase.com/blog/sandoz-erelzi-etanercept-receives-positive-reimbursement-recommendation-from-common-drug-review-for-treatment-of-multiple-inflammatory-diseases 2017-08-03T08:17:50 https://maestrodatabase.com/blog/fda-snubs-novartis-bid-to-repurpose-inflammation-drug-for-heart-attacks 2018-10-20T00:49:03 https://maestrodatabase.com/blog/us-fda-accepts-for-priority-review-bristol-myers-squibbs-application-for-repotrectinib-for-the-treatment-of-patients-with-locally-advanced-or-metastatic-ros1-positive-non-small-cell-lung-cancer 2023-05-30T22:07:42 https://maestrodatabase.com/blog/martin-shkrelis-going-away-americas-drug-price-problem-isnt 2018-03-11T08:00:42 https://maestrodatabase.com/blog/proposal-to-widen-access-and-change-the-funded-brand-of-tenofovir-disoproxil-and-entecavir 2018-03-11T20:22:49 https://maestrodatabase.com/blog/canada-grapples-with-drug-price-escalation 2020-05-21T07:45:19 https://maestrodatabase.com/blog/braeburn-receives-new-complete-response-letter-for-brixadi-in-the-us 2021-12-16T09:17:12 https://maestrodatabase.com/blog/key-design-considerations-for-adaptive-clinical-trials-a-primer-for-clinicians 2018-03-11T08:18:16 https://maestrodatabase.com/blog/fda-grants-priority-review-to-efanesoctocog-alfa-for-people-with-haemophilia-a 2022-08-30T06:20:32 https://maestrodatabase.com/blog/new-free-vaccine-to-protect-kids-against-pneumococcal 2025-09-02T04:36:26 https://maestrodatabase.com/blog/janssen-submits-new-drug-application-to-us-fda-seeking-approval-of-investigational-single-tablet-combination-therapy-of-macitentan-and-tadalafil-for-treatment-of-patients-with-pulmonary-arterial-hypertension 2023-05-30T22:32:22 https://maestrodatabase.com/blog/family-seek-to-raise-money-for-lung-cancer-drug 2023-05-30T22:27:35 https://maestrodatabase.com/blog/health-canada-grants-market-authorisation-to-rozlytrek-entrectinib-for-ros1-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer-patients-not-previously-treated-with-crizotinib 2020-05-21T11:32:57 https://maestrodatabase.com/blog/fda-approves-asthma-indication-for-dupixent-dupilumab 2018-10-20T01:40:14 https://maestrodatabase.com/blog/some-european-countries-decide-to-cover-cancer-drugs-much-faster-than-others 2018-10-20T01:44:11 https://maestrodatabase.com/blog/covid-19-vaccines-undergoing-evaluation-30-august-2022 2022-08-30T06:41:51 https://maestrodatabase.com/blog/fda-approves-first-treatment-for-certain-types-of-poor-prognosis-acute-myeloid-leukaemia 2017-08-03T20:52:35 https://maestrodatabase.com/blog/call-to-strip-government-subsidies-from-junk-health-insurance 2017-08-03T20:46:50 https://maestrodatabase.com/blog/fda-grants-calliditas-therapeutics-accelerated-approval-of-tarpeyo-budesonide-to-reduce-proteinuria-in-iga-nephropathy 2021-12-16T10:15:58 https://maestrodatabase.com/blog/fda-approves-mavyret-for-hepatitis-c 2017-08-03T21:02:17 https://maestrodatabase.com/blog/quizartinib-supplemental-new-drug-application-submitted-in-japan-for-patients-with-newly-diagnosed-flt3-itd-positive-acute-myeloid-leukaemia 2022-08-30T07:07:17 https://maestrodatabase.com/blog/fda-approves-label-update-for-genentechs-rituxan-rituximab-in-two-rare-forms-of-vasculitis 2018-10-20T01:49:33 https://maestrodatabase.com/blog/addressing-antimicrobial-resistance-and-stewardship-the-priority-antimicrobial-value-and-entry-pave-award 2017-08-03T21:19:06 https://maestrodatabase.com/blog/astrazeneca-secures-orders-for-virus-vaccine-under-testing 2020-05-21T11:45:04 https://maestrodatabase.com/blog/multiple-myeloma-drug-darzalex-to-get-expanded-coverage-from-september 2025-09-02T06:52:28 https://maestrodatabase.com/blog/negative-nice-draft-guidance-for-lutathera 2017-08-03T21:28:26 https://maestrodatabase.com/blog/doh-publishes-revised-agenda-for-september-2025-pbac-meeting-version-2 2025-09-02T07:03:25 https://maestrodatabase.com/blog/mithra-and-searchlight-pharma-announce-filing-of-new-drug-submission-for-estelle-in-canada 2020-05-21T12:09:48 https://maestrodatabase.com/blog/us-fda-approves-blue-earth-diagnostics-posluma-flotufolastat-f-18-injection-first-radiohybrid-psma-targeted-pet-imaging-agent-for-prostate-cancer 2023-05-30T22:58:16 https://maestrodatabase.com/blog/cadth-publishes-initial-recommendation-for-keytruda 2017-08-03T21:33:25 https://maestrodatabase.com/blog/ispor-holds-its-first-completely-virtual-conference 2020-05-21T12:16:21 https://maestrodatabase.com/blog/cost-of-pbs-scripts-to-be-dropped-to-25-dollars-from-january-1-2026 2025-09-02T05:33:53 https://maestrodatabase.com/blog/cipla-receives-final-approval-for-generic-version-of-migranal-dihydroergotamine-mesylate-4-mg-slash-ml-nasal-spray-with-a-competitive-generic-therapy-designation 2020-05-21T12:29:23 https://maestrodatabase.com/blog/cadth-publishes-initial-recommendation-for-daratumumab 2017-08-03T21:40:55 https://maestrodatabase.com/blog/global-regulators-agree-on-way-forward-to-adapt-covid-19-vaccines-to-emerging-variants 2023-05-30T22:54:57 https://maestrodatabase.com/blog/a-rush-for-immunotherapy-cancer-drugs-means-new-bedfellows 2017-08-03T21:52:10 https://maestrodatabase.com/blog/pharmas-quieter-price-war-continues 2017-08-03T21:48:49 https://maestrodatabase.com/blog/verrica-pharmaceuticals-announces-acceptance-by-fda-of-nda-resubmission-for-vp-102-for-the-treatment-of-molluscum-contagiosum 2021-12-16T19:01:24 https://maestrodatabase.com/blog/uk-finds-roche-bladder-cancer-drug-too-costly-for-routine-use 2017-08-03T21:55:58 https://maestrodatabase.com/blog/novartis-scemblix-with-novel-mechanism-of-action-approved-by-the-european-commission-for-adult-patients-with-chronic-myeloid-leukaemia 2022-08-30T07:27:18 https://maestrodatabase.com/blog/ema-recommends-approval-for-use-of-kineret-in-adults-with-covid-19 2021-12-16T18:58:36 https://maestrodatabase.com/blog/drug-innovation-is-back-in-fashion 2020-05-21T21:01:12 https://maestrodatabase.com/blog/nice-recommends-offering-prep-to-people-at-high-risk-of-hiv-for-first-time 2021-12-16T19:21:11 https://maestrodatabase.com/blog/tga-provisionally-approves-moderna-bivalent-covid-19-vaccine-for-use-as-a-booster-dose-in-adults 2022-08-30T08:38:05 https://maestrodatabase.com/blog/new-rule-makes-it-harder-for-patients-to-lower-their-out-of-pocket-costs 2020-05-21T21:07:53 https://maestrodatabase.com/blog/voters-are-angry-about-prescription-drug-costs 2019-05-26T06:23:49 https://maestrodatabase.com/blog/medicines-with-one-seller-and-many-buyers-strategies-to-increase-the-power-of-the-payer 2020-05-21T21:11:54 https://maestrodatabase.com/blog/cadth-posts-final-recommendation-for-entyvio 2020-05-21T21:39:58 https://maestrodatabase.com/blog/ema-issues-advice-on-use-of-paxlovid-pf-07321332-and-ritonavir-for-the-treatment-of-covid-19 2021-12-16T19:25:17 https://maestrodatabase.com/blog/a-short-supply-of-cancer-drugs-has-doctors-and-patients-worried-were-at-a-critical-juncture 2023-05-30T23:22:08 https://maestrodatabase.com/blog/chiesi-group-receives-fda-approval-for-ferriprox-deferiprone-twice-a-day-tablets 2020-05-21T20:49:20 https://maestrodatabase.com/blog/covid-19-ema-recommends-authorisation-of-antibody-medicine-xevudy 2021-12-16T19:12:24 https://maestrodatabase.com/blog/inhibrx-granted-fast-track-designation-for-inbrx-101-for-the-treatment-of-alfa-1-antitrypsin-deficiency 2023-05-30T23:14:59 https://maestrodatabase.com/blog/ema-announces-withdrawal-of-two-submissions-for-cancer-medicines 2022-08-30T08:24:56 https://maestrodatabase.com/blog/bristol-myers-squibb-provides-update-on-the-ongoing-regulatory-review-of-opdivo-plus-low-dose-yervoy-in-first-line-lung-cancer-patients-with-tumour-mutational-burden-10-mut-slash-mb 2018-10-20T04:19:18 https://maestrodatabase.com/blog/coronavirus-revives-debate-over-drug-pricing 2020-05-21T20:53:31 https://maestrodatabase.com/blog/avt02-alvotechs-biosimilar-to-high-concentration-formulation-of-adalimumab-humira-approved-for-use-in-european-union 2021-12-16T19:14:54 https://maestrodatabase.com/blog/what-to-expect-when-a-coronavirus-vaccine-finally-arrives 2020-05-21T20:56:44 https://maestrodatabase.com/blog/valneva-files-for-chikungunya-vaccine-authorisation-with-health-canada 2023-05-30T23:09:49 https://maestrodatabase.com/blog/three-deaths-following-epilepsy-drug-brand-switch 2019-11-12T11:38:22 https://maestrodatabase.com/blog/datopotamab-deruxtecan-biologics-license-application-accepted-in-the-us-for-patients-with-previously-treated-advanced-non-squamous-non-small-cell-lung-cancer 2024-02-19T10:19:01 https://maestrodatabase.com/blog/tga-launches-new-look-website 2022-08-30T11:06:25 https://maestrodatabase.com/blog/padcev-enfortumab-vedotin-with-keytruda-pembrolizumab-granted-priority-review-by-japans-ministry-of-health-labour-and-welfare-for-first-line-treatment-of-advanced-bladder-cancer 2024-02-19T02:32:02 https://maestrodatabase.com/blog/nice-recommend-venetoclax-and-azacitidine-for-patients-with-aggressive-blood-cancer 2021-12-16T19:35:27 https://maestrodatabase.com/blog/pancreatic-cancer-patients-to-have-routine-access-to-life-extending-drug-after-new-deal-says-nice 2017-08-04T21:21:58 https://maestrodatabase.com/blog/ema-extends-virtual-only-meeting-policy-through-august 2020-05-21T21:47:29 https://maestrodatabase.com/blog/incyte-and-morphosys-announce-the-validation-of-the-european-marketing-authorisation-application-for-tafasitamab 2020-05-21T21:50:39 https://maestrodatabase.com/blog/nice-leans-towards-a-no-for-keytruda-in-urothelial-cancer 2017-08-04T21:38:53 https://maestrodatabase.com/blog/cost-context-and-decisions-in-health-economics-and-health-technology-assessment 2018-10-20T05:06:40 https://maestrodatabase.com/blog/highlights-from-chmp-15-18-october-2018-meeting 2018-10-20T08:04:19 https://maestrodatabase.com/blog/senate-passes-f-dot-d-a-funding-and-right-to-try-drug-bills 2017-08-04T21:29:46 https://maestrodatabase.com/blog/lung-cancer-alk-plus-nsclc-genetic-mutation-screening-could-save-lives---doctors 2019-11-12T11:41:44 https://maestrodatabase.com/blog/fda-grants-genentechs-alecensa-priority-review-for-initial-treatment-of-people-with-alk-positive-lung-cancer 2017-08-04T21:43:03 https://maestrodatabase.com/blog/accelerating-clinical-trials-in-the-eu-publication-of-2022-2026-workplan 2022-08-30T11:36:40 https://maestrodatabase.com/blog/portola-pharmaceuticals-announces-resubmission-of-biologics-license-application-for-andexxa-andexanet-alfa 2017-08-04T21:50:59 https://maestrodatabase.com/blog/prime-minister-committed-to-pharmac-investigation-but-health-minister-at-odds 2020-10-15T01:04:33 https://maestrodatabase.com/blog/its-tiny-biotechs----not-big-drug-makers----that-fear-nuclear-winter-from-pelosis-drug-pricing-bill 2019-11-12T12:15:44 https://maestrodatabase.com/blog/nice-minded-to-reject-keytruda-for-classical-hodgkin-lymphoma 2018-03-12T20:26:22 https://maestrodatabase.com/blog/googles-project-nightingale-gathers-personal-health-data-on-millions-of-americans 2019-11-12T12:09:27 https://maestrodatabase.com/blog/illuminare-1-a-novel-nerve-visualisation-investigational-fluorophore-granted-fast-track-designation-by-u-dot-s-fda 2021-05-26T03:59:02 https://maestrodatabase.com/blog/why-the-big-questions-about-drug-prices-are-rarely-asked-its-hard-to-do 2021-12-16T19:43:17 https://maestrodatabase.com/blog/health-canada-approves-remsima-sc-for-the-treatment-of-inflammatory-bowel-disease 2024-02-19T10:24:59 https://maestrodatabase.com/blog/mercks-ervebo-ebola-zaire-vaccine-rvsvdg-zebov-gp-live-granted-conditional-approval-in-the-european-union 2019-11-12T11:58:49 https://maestrodatabase.com/blog/is-the-eunethta-hta-core-model-fit-for-purpose-evaluation-from-an-industry-perspective 2018-10-20T22:58:28 https://maestrodatabase.com/blog/regeneron-and-sanofi-announce-plans-to-make-praluent-alirocumab-more-accessible-and-affordable-for-patients-with-the-greatest-health-risk-and-unmet-need 2018-03-12T09:47:05 https://maestrodatabase.com/blog/rafa-receives-fda-approval-for-life-saving-midazolam-auto-injector 2022-08-30T11:27:24 https://maestrodatabase.com/blog/dynavax-provides-u-dot-s-regulatory-update-on-heplisav-following-fda-advisory-committee-meeting 2017-08-04T23:16:12 https://maestrodatabase.com/blog/how-much-should-we-spend-on-health-care 2017-08-04T23:23:55 https://maestrodatabase.com/blog/rare-disease-fund-now-covers-pompe-disease-a-rare-inherited-neuromuscular-disorder 2019-11-12T12:25:27 https://maestrodatabase.com/blog/hikma-provides-an-update-on-the-status-of-its-anda-for-generic-advair-diskus 2018-03-12T20:30:41 https://maestrodatabase.com/blog/unity-ha-awarded-breakthrough-device-designation-for-implantable-neurostimulation-technology-to-treat-cluster-headache-pain 2021-05-26T04:19:52 https://maestrodatabase.com/blog/ema-publishes-agenda-for-19-22-february-2024-chmp-meeting 2024-02-19T20:21:24 https://maestrodatabase.com/blog/vivagel-bv-us-fda-appeal-outcome 2024-02-19T20:03:33 https://maestrodatabase.com/blog/outlook-therapeutics-re-submits-biologics-license-application-for-ons-5010-as-a-treatment-for-wet-amd-to-the-us-fda 2022-08-30T20:36:55 https://maestrodatabase.com/blog/certa-therapeutics-ft011-granted-us-fda-fast-track-for-the-treatment-of-systemic-sclerosis 2024-02-19T10:48:57 https://maestrodatabase.com/blog/ema-publishes-agenda-for-11-14-november-chmp-meeting 2019-11-12T13:04:39 https://maestrodatabase.com/blog/serious-implications-if-menopause-treatments-removed-from-pbs 2021-05-26T04:34:05 https://maestrodatabase.com/blog/evusheld-long-acting-antibody-combination-approved-for-prevention-and-treatment-of-covid-19-in-japan 2022-08-30T12:18:49 https://maestrodatabase.com/blog/spinal-muscular-atrophy-community-rejoices-as-life-changing-drug-spinraza-approved-for-adults 2022-08-30T21:12:55 https://maestrodatabase.com/blog/incredibly-upsetting-breast-cancer-patients-dealing-with-shortage-of-common-drug-treatment 2019-11-12T13:26:59 https://maestrodatabase.com/blog/labour-peer-says-he-opposes-corbyn-style-state-funded-drugs-firm 2019-11-12T13:22:36 https://maestrodatabase.com/blog/can-the-inflation-reduction-act-bring-down-drug-prices 2022-08-30T21:07:21 https://maestrodatabase.com/blog/hospital-sticker-prices-can-rise-faster-than-inflation 2019-11-12T14:07:05 https://maestrodatabase.com/blog/caris-life-sciences-receives-fda-approval-for-mi-cancer-seek-as-a-companion-diagnostic-test 2024-11-09T21:29:03 https://maestrodatabase.com/blog/first-new-kidney-treatment-in-20-years-delays-dialysis-and-transplant 2022-08-30T20:48:21 https://maestrodatabase.com/blog/calls-for-life-changing-drug-aimovig-on-nhs-in-england 2019-05-26T11:04:29 https://maestrodatabase.com/blog/health-economic-assessment-of-tecentriq-for-triple-negative-breast-cancer 2019-11-12T14:27:02 https://maestrodatabase.com/blog/x4-pharmaceuticals-receives-breakthrough-therapy-designation-from-the-fda-for-mavorixafor-for-the-treatment-of-whim-syndrome 2019-11-12T15:20:21 https://maestrodatabase.com/blog/pharmac-switches-epilepsy-drug-against-medsafe-advice 2019-05-26T20:06:37 https://maestrodatabase.com/blog/epilepsy-nz-calls-for-halt-to-drug-switch-following-deaths-of-three-people 2019-11-13T05:30:35 https://maestrodatabase.com/blog/policy-recommendations-for-pharmacy-benefit-managers-to-stem-the-escalating-costs-of-prescription-drugs-a-position-paper-from-the-american-college-of-physicians 2019-11-12T15:27:40 https://maestrodatabase.com/blog/pharmacists-crash-question-time-as-albanese-government-is-slammed-over-60-day-pbs-dispensing-change 2023-05-31T07:53:28 https://maestrodatabase.com/blog/what-big-pharma-fears-most-a-trump-alliance-with-democrats-to-cut-drug-prices 2018-10-21T08:39:00 https://maestrodatabase.com/blog/icer-publishes-final-evidence-report-and-policy-recommendations-on-tezepelumab-for-severe-asthma 2021-12-16T23:43:46 https://maestrodatabase.com/blog/taysha-gene-therapies-receives-rare-paediatric-disease-designation-and-orphan-drug-designation-for-tsha-102-as-a-treatment-for-rett-syndrome 2020-10-15T04:57:50 https://maestrodatabase.com/blog/130-000-additional-vaccines-for-victoria 2021-05-26T12:18:39 https://maestrodatabase.com/blog/tga-approves-pathway-for-more-plasma-donors 2023-05-31T22:15:18 https://maestrodatabase.com/blog/colchester-babys-parents-feel-abandoned-over-ps1-dot-7-million-drug 2021-05-26T07:00:43 https://maestrodatabase.com/blog/nice-recommends-novartis-mayzent-on-the-heels-of-smc-approval 2020-10-15T09:48:13 https://maestrodatabase.com/blog/myovant-sciences-and-pfizer-receive-fda-approval-for-myfembree-the-first-once-daily-treatment-for-heavy-menstrual-bleeding-associated-with-uterine-fibroids 2021-05-26T20:53:28 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-june-2023 2023-05-31T21:40:11 https://maestrodatabase.com/blog/icer-requests-public-comment-on-two-draft-scoping-documents-treatments-for-high-risk-prostate-cancer-and-amyloidosis 2018-03-13T02:49:27 https://maestrodatabase.com/blog/insurers-call-for-reform-to-allow-hospital-in-the-home-for-patients 2023-05-31T08:33:15 https://maestrodatabase.com/blog/nice-terminates-yet-another-two-appraisals 2021-05-26T05:54:01 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-june-2023 2023-05-31T21:34:44 https://maestrodatabase.com/blog/emmaus-life-sciences-receives-validation-from-ema-on-marketing-authorisation-application-for-sickle-cell-disease-treatment-xyndari-oral-glutamine 2018-03-13T04:30:01 https://maestrodatabase.com/blog/woebot-health-receives-fda-breakthrough-device-designation-for-post-partum-depression-treatment 2021-05-26T21:04:08 https://maestrodatabase.com/blog/racgp-opposes-glp-1-ra-prescribing-restrictions 2023-05-31T22:39:58 https://maestrodatabase.com/blog/ema-confirms-eligibility-for-submission-of-modernas-covid-19-vaccine 2020-10-15T10:46:02 https://maestrodatabase.com/blog/health-canada-approves-elahere-for-certain-types-of-platinum-resistant-ovarian-cancers 2025-09-03T01:28:26 https://maestrodatabase.com/blog/fda-approves-expanded-indication-for-mercks-keytruda-pembrolizumab-in-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma 2020-10-15T10:49:48 https://maestrodatabase.com/blog/brukinsa-approved-in-canada-for-the-treatment-of-chronic-lymphocytic-leukaemia 2023-05-31T22:35:16 https://maestrodatabase.com/blog/fda-announces-draft-guidances-to-help-increase-transparency-assist-reporting-and-timely-completion-for-certain-medical-device-studies-after-fda-approval-or-clearance 2021-05-26T21:22:16 https://maestrodatabase.com/blog/nice-draft-guidance-recommends-siponimod-for-treating-secondary-progressive-multiple-sclerosis 2020-10-15T19:24:55 https://maestrodatabase.com/blog/medical-device-regulation-comes-into-application 2021-05-26T21:14:56 https://maestrodatabase.com/blog/streamlining-smc-processes-for-medicines-that-clearly-offer-good-value-to-nhsscotland 2023-05-31T22:30:39 https://maestrodatabase.com/blog/varian-receives-fda-breakthrough-device-designation-for-its-cardiac-radioablation-system-for-treatment-of-refractory-ventricular-tachycardia 2021-05-26T20:58:48 https://maestrodatabase.com/blog/exelixis-partner-ipsen-announces-health-canadas-approval-of-cabometyx-cabozantinib-tablets-for-the-treatment-of-patients-with-previously-treated-advanced-hepatocellular-carcinoma 2019-11-13T06:46:56 https://maestrodatabase.com/blog/eu-seeks-large-astrazeneca-fine 2021-05-26T21:48:27 https://maestrodatabase.com/blog/ibrutinib-and-venetoclax-for-untreated-chronic-lymphocytic-leukaemia 2023-05-31T23:10:52 https://maestrodatabase.com/blog/influencers-say-they-were-urged-to-criticise-pfizer-vaccine 2021-05-26T21:44:44 https://maestrodatabase.com/blog/icer-finalises-method-adaptations-for-assessing-potential-cures-and-other-high-impact-single-or-short-term-therapies 2019-11-13T06:43:30 https://maestrodatabase.com/blog/145-000-people-in-england-to-have-further-treatment-choice-for-preventing-migraine-attacks 2023-05-31T22:58:07 https://maestrodatabase.com/blog/testing-requirements-are-likely-slowing-biosimilar-entries-in-the-us 2020-10-15T19:54:21 https://maestrodatabase.com/blog/health-canada-approves-first-ever-gene-replacement-therapy-luxturna 2020-10-15T20:03:19 https://maestrodatabase.com/blog/lumasiran-granted-breakthrough-therapy-designation-by-the-united-states-fda 2018-03-13T04:54:04 https://maestrodatabase.com/blog/smc---march-2018-decisions 2018-03-13T05:01:32 https://maestrodatabase.com/blog/allergan-receives-fda-qualified-infectious-disease-product-designation-and-fast-track-designation-for-atm-avi-aztreonam-and-avibactam-for-antibiotic-resistant-gram-negative-infections 2019-11-13T10:34:18 https://maestrodatabase.com/blog/ema-cancer-symposium-new-approaches-in-patient-focused-cancer-medicine-development 2020-10-15T19:29:42 https://maestrodatabase.com/blog/proteostasis-therapeutics-announces-fda-grants-breakthrough-therapy-designation-for-pti-428-in-cystic-fibrosis 2018-03-13T04:44:11 https://maestrodatabase.com/blog/scynexis-announces-submission-of-new-drug-application-to-the-u-dot-s-fda-for-oral-ibrexafungerp-for-the-treatment-of-vaginal-yeast-infection 2020-10-15T19:33:00 https://maestrodatabase.com/blog/fda-approves-olaparib-with-abiraterone-and-prednisone-or-prednisolone-for-brca-mutated-metastatic-castration-resistant-prostate-cancer 2023-05-31T22:48:06 https://maestrodatabase.com/blog/prime-therapeutics-launches-meddrive-a-first-of-its-kind-medical-drug-management-program-uniquely-aligned-with-its-blue-plan-clients 2021-05-26T21:27:01 https://maestrodatabase.com/blog/actelion-withdraws-regulatory-filings-to-extend-the-indication-of-opsumit-macitentan-10mg-in-cteph 2019-11-13T11:30:30 https://maestrodatabase.com/blog/analysis-new-drug-decisions-and-nhs-spending-conundrums 2018-03-13T05:09:12 https://maestrodatabase.com/blog/biden-and-bloomberg-are-bigger-threats-to-big-pharma-than-warren-analyst-says 2019-11-13T10:47:56 https://maestrodatabase.com/blog/a-billionaire-pledges-to-fight-high-drug-prices-and-the-industry-is-rattled 2018-10-22T02:07:12 https://maestrodatabase.com/blog/pharmac-playing-money-game-by-not-funding-drug-49-other-countries-back---campaigner 2019-05-27T02:10:09 https://maestrodatabase.com/blog/icer-seeks-public-input-to-guide-selection-of-non-drug-assessment-topics-for-2020 2019-11-13T18:36:07 https://maestrodatabase.com/blog/pharmaceutical-pricing-conundrum-time-to-get-rid-of-it 2018-10-22T03:59:40 https://maestrodatabase.com/blog/medicines-australia-welcomes-morrison-government-ministry 2019-05-27T02:07:29 https://maestrodatabase.com/blog/nice-recommends-elmiron-for-bladder-pain-syndrome 2019-11-13T18:30:59 https://maestrodatabase.com/blog/application-of-the-new-process-for-unapproved-drug-use-dilemma-of-universal-health-care-coverage-in-japan 2019-11-13T11:42:58 https://maestrodatabase.com/blog/chmp-recommends-eu-marketing-authorisation-of-lanadelumab-for-the-prevention-of-hae-attacks 2018-10-22T02:00:45 https://maestrodatabase.com/blog/mylan-and-biocon-announce-positive-chmp-opinion-for-ogivri-biosimilar-trastuzumab 2018-10-22T05:37:39 https://maestrodatabase.com/blog/fdas-project-orbis-may-expand-to-singapore-and-switzerland 2019-11-13T18:44:03 https://maestrodatabase.com/blog/nhs-england-wants-money-back-guarantee-on-orkambi 2019-05-27T02:42:15 https://maestrodatabase.com/blog/fda-grants-priority-review-to-mercks-application-for-keytruda-pembrolizumab-plus-chemotherapy-as-treatment-for-primary-advanced-or-recurrent-endometrial-carcinoma 2024-02-20T20:00:41 https://maestrodatabase.com/blog/viracta-receives-fast-track-designation-for-nanatinostat-combination-for-the-treatment-of-ebv-associated-lymphomas 2019-11-13T18:40:16 https://maestrodatabase.com/blog/what-pharma-giant-johnson-and-johnsons-ceo-has-to-say-about-the-drug-price-debate 2018-10-22T04:04:45 https://maestrodatabase.com/blog/us-fda-accepts-supplemental-new-drug-application-for-krazati-adagrasib-in-combination-with-cetuximab-as-a-targeted-treatment-option-for-patients-with-previously-treated-kras-g12c-mutated-locally-advanced-or-metastatic-colorectal-cancer-for-priority-review 2024-02-20T19:51:38 https://maestrodatabase.com/blog/improving-access-to-high-cost-technologies-in-the-asia-region 2019-05-27T02:16:03 https://maestrodatabase.com/blog/vertex-receives-european-chmp-positive-opinion-for-kalydeco-ivacaftor-to-treat-patients-with-cystic-fibrosis-aged-12-to-<24-months-with-certain-mutations-in-the-cftr-gene 2018-10-22T06:12:16 https://maestrodatabase.com/blog/13-percent-of-americans-say-they-know-someone-who-died-after-they-couldnt-afford-health-care-survey-says 2019-11-13T18:52:56 https://maestrodatabase.com/blog/european-commission-approves-pfizers-velsipity-for-patients-with-moderately-to-severely-active-ulcerative-colitis 2024-02-20T01:21:13 https://maestrodatabase.com/blog/lung-cancer-survivor-wants-pharmac-to-fund-drugs-she-received-in-trial 2018-10-22T05:53:13 https://maestrodatabase.com/blog/clovis-oncology-announces-reimbursement-for-rubraca-rucaparib-tablets-for-women-with-relapsed-ovarian-cancer-in-italy 2019-11-13T18:47:22 https://maestrodatabase.com/blog/how-sempre-health-mark-cuban-and-more-are-leading-the-charge-to-disrupt-drug-pricing 2024-02-20T20:27:14 https://maestrodatabase.com/blog/pharmac-considering-multiple-new-treatments-from-takeda 2022-09-19T04:33:51 https://maestrodatabase.com/blog/rolling-sbla-initiated-to-the-us-fda-for-leqembi-iqlik-lecanemab-irmb-as-a-subcutaneous-starting-dose-for-the-treatment-of-early-alzheimers-disease-under-fast-track-status 2025-09-03T03:39:10 https://maestrodatabase.com/blog/sandoz-receives-health-canada-approval-for-jubbonti-first-and-only-denosumab-biosimilar-for-treatment-of-osteoporosis 2024-02-20T20:22:34 https://maestrodatabase.com/blog/regulators-advice-can-make-a-difference-for-faster-patient-access-to-highly-innovative-therapies 2019-11-13T18:57:02 https://maestrodatabase.com/blog/pepgen-receives-us-fda-fast-track-designation-for-pgn-edodm1-for-the-treatment-of-myotonic-dystrophy-type-1 2024-02-20T20:17:40 https://maestrodatabase.com/blog/10-year-update-on-study-results-submitted-to-clinicaltrials-dot-gov 2019-11-14T00:41:12 https://maestrodatabase.com/blog/fda-accepts-shionogis-ensitrelvir-nda-as-the-first-oral-therapy-for-the-prevention-of-covid-19-following-exposure 2025-09-03T03:51:32 https://maestrodatabase.com/blog/disc-medicine-receives-fda-fast-track-designation-for-disc-0974-for-the-treatment-of-anaemia-in-non-dialysis-dependent-chronic-kidney-disease 2024-02-20T20:13:40 https://maestrodatabase.com/blog/argenx-announces-fda-acceptance-of-supplemental-biologics-license-application-with-priority-review-for-vyvgart-hytrulo-in-chronic-inflammatory-demyelinating-polyneuropathy 2024-02-20T20:05:13 https://maestrodatabase.com/blog/drug-companies-exaggerate----controlling-drug-prices-wont-threaten-innovation 2019-11-14T02:56:43 https://maestrodatabase.com/blog/health-products-portal---intent-to-apply 2019-11-14T00:57:09 https://maestrodatabase.com/blog/more-than-my-rent-nsw-womans-1000-dollars-a-month-fight-for-relief 2025-09-03T02:28:11 https://maestrodatabase.com/blog/pharmac-widening-access-to-the-meningococcal-acwy-vaccine 2019-11-14T00:47:57 https://maestrodatabase.com/blog/icer-publishes-final-evidence-report-on-treatments-for-spinal-muscular-atrophy 2025-09-03T02:33:46 https://maestrodatabase.com/blog/watched-by-apple 2019-11-14T00:45:03 https://maestrodatabase.com/blog/biosimilar-rituximab-and-insulin-glargine-on-the-pbs-and-other-pbs-listing-changes---information-for-health-professionals-and-patients 2019-11-14T03:37:05 https://maestrodatabase.com/blog/immuneering-receives-fda-fast-track-designation-for-imm-1-104-in-pancreatic-cancer 2024-02-20T20:31:58 https://maestrodatabase.com/blog/european-medicines-agency-accepts-astellas-marketing-authorisation-application-for-roxadustat 2020-05-22T03:38:49 https://maestrodatabase.com/blog/sk-bioscience-receives-marketing-authorisation-of-covid-19-vaccine-from-uk-mhra 2023-06-01T01:41:48 https://maestrodatabase.com/blog/hatred-of-big-pharma-wont-get-us-better-drug-prices 2018-10-22T19:53:04 https://maestrodatabase.com/blog/how-pharma-companies-try-to-use-funding-to-sway-patient-advocate-groups 2018-10-22T11:29:23 https://maestrodatabase.com/blog/charity-calls-on-nice-to-reverse-opdivo-rejection 2016-07-06T21:26:49 https://maestrodatabase.com/blog/mederas-sardocor-announces-fast-track-designation-and-dosing-of-3-patients-in-first-in-human-hfpef-gene-therapy-trial 2024-02-20T21:24:56 https://maestrodatabase.com/blog/trump-and-his-team-fight-for-health-consumers-starting-with-drug-price-transparency 2018-10-22T20:04:56 https://maestrodatabase.com/blog/eiger-biopharmaceuticals-receives-fda-rare-paediatric-disease-designation-for-lonafarnib-for-the-treatment-of-progeria-and-progeroid-laminopathies-and-plans-nda-filing-in-2019 2018-10-22T19:57:15 https://maestrodatabase.com/blog/novartis-leukaemia-drug-approved-in-switzerland 2018-10-22T20:15:23 https://maestrodatabase.com/blog/chmp-grants-positive-opinion-for-shorter-treatment-duration-with-abbvies-viekirax-ombitasvirparitaprevirritonavir-tablets-for-patients-with-genotype-4-chronic-hepatitis-c-with-compensated-cirrhosis-child-pugh-a 2016-07-25T08:30:16 https://maestrodatabase.com/blog/pharmaceutical-benefits-scheme-supplied-medications 2022-08-31T07:10:45 https://maestrodatabase.com/blog/coil-is-more-effective-than-pill-as-emergency-contraception-says-nice 2016-09-08T12:46:37 https://maestrodatabase.com/blog/americas-nice 2018-03-13T20:09:10 https://maestrodatabase.com/blog/truvada-gets-tga-nod-but-pbs-listing-vital 2016-05-26T18:20:14 https://maestrodatabase.com/blog/brolucizumab-for-treating-diabetic-macular-oedema 2022-08-31T06:58:42 https://maestrodatabase.com/blog/us-fda-approves-labeling-update-of-rexulti-brexpiprazole-for-maintenance-treatment-of-schizophrenia 2016-09-26T05:26:17 https://maestrodatabase.com/blog/edge-in-u-dot-s-cancer-drug-development-spurred-by-regulatory-and-reimbursement-policies 2018-10-22T20:10:29 https://maestrodatabase.com/blog/canadian-families-stunned-by-3-000-percent-increase-in-price-of-life-saving-drug 2018-03-13T20:21:32 https://maestrodatabase.com/blog/health-funds-pressure-canberra-over-700-dollars-million-medical-devices-failure 2019-11-14T06:57:27 https://maestrodatabase.com/blog/proposal-to-list-bedaquiline-sirturo-and-siltuximab-sylvant-for-rare-disorders 2016-04-12T08:31:06 https://maestrodatabase.com/blog/statement-from-fda-commissioner-robert-califf-md-on-the-release-of-the-final-individual-patient-expanded-access-form 2016-06-02T21:52:28 https://maestrodatabase.com/blog/private-health-too-costly-sector-too-complex 2019-11-14T06:50:55 https://maestrodatabase.com/blog/european-parliament-approves-ema-move-to-amsterdam 2018-03-13T20:14:48 https://maestrodatabase.com/blog/cutting-edge-nhs-drugs-do-more-harm-than-good 2018-03-13T20:17:50 https://maestrodatabase.com/blog/us-fda-approves-abrysvo-pfizers-vaccine-for-the-prevention-of-respiratory-syncytial-virus-in-older-adults 2023-06-01T02:38:14 https://maestrodatabase.com/blog/novartis-tries-to-get-us-ban-lifted-on-sale-of-neupogen-copycat 2015-08-05T11:37:06 https://maestrodatabase.com/blog/cancer-panel-calls-for-measures-to-lower-drug-costs 2018-03-13T20:30:44 https://maestrodatabase.com/blog/in-the-war-against-high-drug-prices-some-patients-are-collateral-damage 2018-03-13T20:34:05 https://maestrodatabase.com/blog/price-and-clinical-factors-impact-canadian-orphan-drug-recommendation-rates 2018-03-13T20:25:35 https://maestrodatabase.com/blog/long-term-benefits-of-breast-cancer-drug-pertuzumab-too-uncertain-says-nice-in-draft-guidance 2016-05-20T09:18:08 https://maestrodatabase.com/blog/eu-approves-roches-avastin-plus-chemotherapy-for-women-with-advanced-cervical-cancer 2015-08-05T11:37:22 https://maestrodatabase.com/blog/prime-minister-malcolm-turnbulls-lifeline-for-sufferers-of-rare-diseases-early-access-to-life-saving-drugs 2016-09-04T01:05:59 https://maestrodatabase.com/blog/cvs-health-announces-formulary-and-therapy-strategy-for-pcsk9-inhibitors 2015-11-23T20:33:57 https://maestrodatabase.com/blog/unitedhealth-group-announces-leadership-actions 2018-03-13T20:38:47 https://maestrodatabase.com/blog/head-of-cancer-drugs-fund-regrets-its-establishment-conference-hears 2015-08-05T11:37:05 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac---september-2020-intracycle-meeting-and-out-of-session-between-july-2020-and-september-2020-meetings 2020-10-16T12:17:57 https://maestrodatabase.com/blog/evaluating-biosimilar-medicines 2015-08-05T11:37:24 https://maestrodatabase.com/blog/pharmac_s_review_of_the_named_patient_pharmaceutical_assessment_policy__nppa____seeking_views 2015-08-05T11:37:18 https://maestrodatabase.com/blog/improving-the-us-health-insurance-marketplace-through-innovation 2016-05-10T08:38:43 https://maestrodatabase.com/blog/most-hated-man-on-internet-maintains-5000-inflation-on-lifesaving-drug 2015-11-28T23:52:44 https://maestrodatabase.com/blog/aimmune-therapeutics-receives-fda-breakthrough-therapy-designation-for-ar101 2015-08-05T11:37:18 https://maestrodatabase.com/blog/the-price-for-lowering-cholesterol 2015-09-08T20:42:52 https://maestrodatabase.com/blog/five-new-drugs-for-nhs-scotland 2015-08-05T11:37:08 https://maestrodatabase.com/blog/nice-gears-up-to-support-world-evidence-based-health-care-day 2020-10-16T12:21:07 https://maestrodatabase.com/blog/survey-highlights-oncologists-dismay-over-cdf-cuts 2015-08-05T11:37:22 https://maestrodatabase.com/blog/nice-ok-for-sativex-in-ms 2019-11-14T18:47:12 https://maestrodatabase.com/blog/2016-cadth-symposium-call-for-abstracts 2015-09-24T21:20:31 https://maestrodatabase.com/blog/epilepsy-patients-terrified-after-pharmac-switches-funding 2019-11-14T10:19:59 https://maestrodatabase.com/blog/national-immunisation-program-new-and-amended-listings 2016-05-04T03:54:42 https://maestrodatabase.com/blog/us-fda-accepts-regulatory-submission-for-selumetinib-in-neurofibromatosis-type-1-and-grants-priority-review 2019-11-14T19:51:32 https://maestrodatabase.com/blog/utility-of-cancer-value-frameworks-for-patients-payers-and-physicians 2016-05-18T00:16:04 https://maestrodatabase.com/blog/to-drive-down-insulin-prices-who-will-certify-generic-versions 2019-11-14T19:48:28 https://maestrodatabase.com/blog/scilex-announces-that-the-fda-has-granted-fast-track-designation-for-sp-103-lignocaine-5-dot-4-percent-topical-system-next-generation-triple-strength-formulation-of-ztlido-for-the-treatment-of-acute-low-back-pain 2022-08-31T09:54:31 https://maestrodatabase.com/blog/drug-makers-fight-trump-appellate-bid-to-restore-rule-exposing-drug-prices-in-tv-ads 2019-11-14T19:46:19 https://maestrodatabase.com/blog/pbac-rebukes-amgen-for-lodging-early-submission-for-repatha-under-tga-pbac-parallel-process 2016-01-06T05:19:09 https://maestrodatabase.com/blog/trump-officials-making-changes-to-signature-drug-pricing-proposal-azar-says 2019-11-14T18:54:32 https://maestrodatabase.com/blog/fda-approves-new-oral-therapy-to-treat-alk-positive-lung-cancer 2015-12-13T07:33:37 https://maestrodatabase.com/blog/omnix-medical-granted-fast-track-designation-by-us-fda-for-its-next-generation-anti-infective-omn6 2024-02-20T23:05:43 https://maestrodatabase.com/blog/anavex-life-sciences-receives-rare-paediatric-disease-designation-from-fda-for-anavex-2-73-blarcamesine-for-the-treatment-of-rett-syndrome 2019-11-14T19:59:44 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-27-may-2021 2021-05-27T05:22:54 https://maestrodatabase.com/blog/cadth-ruling-on-spinraza-nusinersen-extinguishes-hope-for-adults-needing-treatment-for-spinal-muscular-atrophy 2022-08-31T08:00:47 https://maestrodatabase.com/blog/pharmac-secures-significant-savings-for-dhbs-on-biologic-drug 2015-08-05T11:37:30 https://maestrodatabase.com/blog/nice-responds-to-criticisms-of-its-draft-guidance-on-statins 2015-08-05T11:37:17 https://maestrodatabase.com/blog/uk-drugs-watchdog-nice-approves-five-new-treatments-in-coup-for-big-pharma 2016-06-22T21:13:33 https://maestrodatabase.com/blog/researchers-call-on-fda-to-rethink-guidance-allowing-use-of-surrogate-outcomes 2019-11-14T19:56:01 https://maestrodatabase.com/blog/the-complex-math-behind-spiraling-prescription-drug-prices 2016-04-28T21:04:54 https://maestrodatabase.com/blog/mark-butler-says-pharmacy-guild-breached-nda-but-chemists-say-they-were-given-go-ahead-by-government 2023-06-01T21:18:43 https://maestrodatabase.com/blog/fda-approves-first-combination-pill-to-treat-hepatitis-c 2015-08-05T11:37:09 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-september-2022-update 2022-08-31T20:21:40 https://maestrodatabase.com/blog/cms-announces-plan-to-ensure-availability-of-new-alzheimers-drugs 2023-06-01T21:21:14 https://maestrodatabase.com/blog/even-greeks-can-get-more-medicines-than-brits-pfizer-boss-claims 2016-02-05T06:30:12 https://maestrodatabase.com/blog/nice-backs-nhs-use-of-benlysta-five-years-after-eu-nod 2016-05-11T14:15:17 https://maestrodatabase.com/blog/fda-approves-first-treatment-for-acid-sphingomyelinase-deficiency-a-rare-genetic-disease 2022-08-31T20:15:11 https://maestrodatabase.com/blog/gsk-files-ultra-rare-disease-application-with-ema 2015-08-05T11:37:13 https://maestrodatabase.com/blog/getting-effective-cancer-drugs-to-patients-faster 2016-05-18T11:44:08 https://maestrodatabase.com/blog/ucbs-new-epilepsy-drug-briviact-receives-eu-approval 2016-01-20T20:21:11 https://maestrodatabase.com/blog/bms-korea-wins-insurance-coverage-for-myelofibrosis-drug-inrebic 2023-06-01T09:00:29 https://maestrodatabase.com/blog/fda-approves-new-therapy-for-certain-types-of-advanced-soft-tissue-sarcoma 2015-10-26T09:53:20 https://maestrodatabase.com/blog/antengene-announces-xpovio-plus-bortezomib-and-dexamethasone-included-for-reimbursement-by-the-pbs-in-australia-for-the-treatment-of-relapsed-and-slash-or-refractory-multiple-myeloma 2023-06-01T08:46:09 https://maestrodatabase.com/blog/phrma-and-bio-offer-glowing-support-for-pdufa-vi-performance-goals 2016-08-25T21:22:29 https://maestrodatabase.com/blog/valeants-drug-price-strategy-enriches-it-but-infuriates-patients-and-lawmakers 2015-10-05T19:29:31 https://maestrodatabase.com/blog/breast-cancer-treatments-rare-disorders-venlafaxine 2019-05-27T05:22:56 https://maestrodatabase.com/blog/aquestive-therapeutics-receives-fda-tentative-approval-for-libervant-diazepam-buccal-film 2022-08-31T12:11:37 https://maestrodatabase.com/blog/nice-u-turn-backs-biologics-for-ulcerative-colitis 2015-08-05T11:37:11 https://maestrodatabase.com/blog/update-on-novartis-influenza-vaccines-acquisition 2015-08-05T11:37:06 https://maestrodatabase.com/blog/icer-publishes-evidence-report-on-treatments-for-obesity-management 2022-08-31T11:36:21 https://maestrodatabase.com/blog/chiasma-provides-update-regarding-fdas-complete-response-letter-for-mycapssa-new-drug-application 2016-04-18T18:29:23 https://maestrodatabase.com/blog/colorado-becomes-first-state-to-put-cap-on-rising-insulin-prices 2019-05-27T05:19:51 https://maestrodatabase.com/blog/committee-to-advise-on-medical-research-future-fund-health-technology-assessment-investments 2023-06-01T06:39:55 https://maestrodatabase.com/blog/nice-issues-final-draft-guidance-on-pomalidomide-for-blood-cancer 2015-08-05T11:37:24 https://maestrodatabase.com/blog/csl-haemophilia-drug-closer-to-market-after-positive-trials 2015-08-05T11:37:29 https://maestrodatabase.com/blog/fda-authorises-moderna-pfizer-biontech-bivalent-covid-19-vaccines-for-use-as-a-booster-dose 2022-08-31T21:09:27 https://maestrodatabase.com/blog/daiichi-sankyos-once-daily-lixiana-edoxaban-approved-in-the-eu-for-stroke-prevention-in-non-valvular-atrial-fibrillation-and-for-the-treatment-and-prevention-of-recurrent-dvt-and-pe 2015-08-05T11:37:14 https://maestrodatabase.com/blog/allergan-announces-fda-approves-revised-indication-for-ozurdex-dexamethasone-intravitreal-implant-07-mg-for-the-treatment-of-diabetic-macular-oedema 2015-08-05T11:37:08 https://maestrodatabase.com/blog/you-disappointed-us-why-is-canada-opposing-more-transparency-in-drug-prices 2019-05-27T11:33:32 https://maestrodatabase.com/blog/gsk-receives-fda-approval-of-an-additional-promacta-eltrombopag-indication-for-use-in-patients-with-severe-aplastic-anaemia-who-have-had-an-insufficient-response-to-immunosuppressive-therapy 2015-08-05T11:37:23 https://maestrodatabase.com/blog/these-republicans-campaigned-on-a-bold-drug-pricing-pledge-since-they-won-theyve-gone-silent 2019-05-27T11:04:45 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-september-2022 2022-08-31T20:40:46 https://maestrodatabase.com/blog/ema-publishes-epar-for-galafold-migalastat 2016-06-09T21:17:05 https://maestrodatabase.com/blog/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-for-keytuda-pembrolizumab-for-treatment-of-advanced-cervical-cancer 2018-03-14T03:41:56 https://maestrodatabase.com/blog/inflation-reduction-act-undermines-cancer-medicine-development 2023-06-01T21:28:05 https://maestrodatabase.com/blog/the-price-of-health-the-cost-of-developing-new-medicines 2016-03-31T20:44:49 https://maestrodatabase.com/blog/pharmaceutical-industry-ought-to-justify-drug-prices-on-value-not-r-and-d-costs 2023-06-01T21:32:19 https://maestrodatabase.com/blog/hundreds-of-cancer-drugs-to-enter-market-in-next-five-years-report 2016-04-04T01:03:39 https://maestrodatabase.com/blog/us-fda-grants-fast-track-designation-for-longeverons-lomecel-b-product-for-treatment-of-hypoplastic-left-heart-syndrome-in-infants 2022-08-31T20:33:04 https://maestrodatabase.com/blog/ema-publishes-epar-for-zinbryta-daclizumab 2016-07-19T21:28:21 https://maestrodatabase.com/blog/european-commission-approves-cabometyx-cabozantinib-tablets-for-the-treatment-of-advanced-renal-cell-carcinoma-following-vegf-targeted-therapy 2016-09-14T10:52:25 https://maestrodatabase.com/blog/nhs-england-funds-janssens-hiv-pill-rezolsta 2016-04-01T21:27:58 https://maestrodatabase.com/blog/us-fda-grants-priority-review-to-takedas-ixazomib-for-patients-with-relapsedrefractory-multiple-myeloma 2015-09-09T21:21:06 https://maestrodatabase.com/blog/another-nice-backing-for-mercks-keytruda-in-skin-cancer 2015-10-09T10:15:54 https://maestrodatabase.com/blog/nice-recommends-covering-sovaldi-hepatitis-c-pill 2015-08-05T11:37:14 https://maestrodatabase.com/blog/the-commercial-market-for-priority-review-vouchers 2016-05-02T22:32:58 https://maestrodatabase.com/blog/reproducibility-of-real-world-evidence-studies-using-clinical-practice-data-to-inform-regulatory-and-coverage-decisions 2022-08-31T21:36:58 https://maestrodatabase.com/blog/governor-ron-desantis-announces-lawsuit-against-biden-administrations-reckless-delay-of-canadian-prescription-drug-importation-program 2022-08-31T21:21:20 https://maestrodatabase.com/blog/nice-recommends-new-treatment-option-for-multiple-sclerosis-dimethyl-fumarate 2015-08-05T11:37:10 https://maestrodatabase.com/blog/saxenda-approved-in-europe-for-the-treatment-of-obesity 2015-08-05T11:37:29 https://maestrodatabase.com/blog/uk-patient-groups-urge-government-to-negotiate-drug-prices 2016-08-17T21:43:22 https://maestrodatabase.com/blog/amneal-announces-submission-of-new-drug-application-to-the-us-fda-for-ipx203-for-the-treatment-of-parkinsons-disease 2022-08-31T21:31:25 https://maestrodatabase.com/blog/pbac-submission-to-the-senate-inquiry-into-the-availability-of-new-innovative-and-specialist-cancer-drugs-in-australia 2015-08-05T11:37:14 https://maestrodatabase.com/blog/diabetes__glaucoma__cancer_and_growth_hormone_patients_benefit_from_pbs_changes 2015-08-05T11:37:08 https://maestrodatabase.com/blog/kidney-disease-drug-dapagliflozin-added-to-pharmaceutical-benefits-scheme 2022-08-31T21:17:11 https://maestrodatabase.com/blog/bis-nintedanib-gets-fda-breakthrough-status-for-ipf 2015-08-05T11:37:08 https://maestrodatabase.com/blog/amendments-to-the-conditions-of-approval-for-approved-pharmacists 2015-08-05T11:37:18 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---may-2014-update 2015-08-05T11:37:12 https://maestrodatabase.com/blog/cms-approves-arizonas-plan-to-re-open-chip-program 2016-07-25T21:23:25 https://maestrodatabase.com/blog/sunovion-pharmaceuticals-inc-announces-fda-acceptance-for-review-of-supplemental-new-drug-application-for-the-use-of-aptiom-eslicarbazepine-acetate-as-monotherapy-treatment-for-partial-onset-seizures 2015-08-05T11:37:21 https://maestrodatabase.com/blog/arcturus-therapeutics-receives-us-fda-fast-track-designation-for-arct-810-mrna-therapeutic-candidate-for-ornithine-transcarbamylase-deficiency 2023-06-01T23:10:07 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-approval-from-the-us-food-and-drug-administration-for-yervoy-ipilimumab-as-adjuvant-treatment-for-fully-resected-stage-iii-melanoma 2015-10-29T12:41:26 https://maestrodatabase.com/blog/tga-approves-odefsey 2016-09-14T03:02:57 https://maestrodatabase.com/blog/patients-fear-spike-in-price-of-old-drugs 2015-12-23T20:25:31 https://maestrodatabase.com/blog/is-valeant-pharmaceuticals-the-next-enron 2015-10-27T19:09:11 https://maestrodatabase.com/blog/tresiba-receives-positive-opinion-from-chmp-for-treatment-of-children-with-diabetes 2015-08-05T11:37:24 https://maestrodatabase.com/blog/samsung-bioepis-obtains-european-commission-approval-for-soliris-biosimilar 2023-06-01T23:04:44 https://maestrodatabase.com/blog/actavis-confirms-complete-response-letter-for-nebivololvalsartan-fixed-dose-combination-for-hypertension 2015-08-05T11:37:28 https://maestrodatabase.com/blog/more-gps-to-join-the-covid-19-vaccine-rollout 2021-05-27T06:01:19 https://maestrodatabase.com/blog/gsks-malaria-candidate-vaccine-mosquirix-rtss-receives-positive-opinion-from-european-regulators-for-the-prevention-of-malaria-in-young-children-in-sub-saharan-africa 2015-08-05T11:37:04 https://maestrodatabase.com/blog/nice_draft_guidance_recommend_the_use_of_ribavirin_with_peginterferon_to_treat_chronic_children_and_young_people_with_hepatitis_c_virus_infection 2015-08-05T11:37:26 https://maestrodatabase.com/blog/samsung-bioepis-marketing-authorization-application-for-sb5-adalimumab-biosimilar-candidate-accepted-for-review-by-the-european-medicines-agency 2016-07-18T21:21:41 https://maestrodatabase.com/blog/rocket-pharmaceuticals-receives-ema-priority-medicines-prime-designation-for-rp-a501-gene-therapy-for-danon-disease 2023-06-01T22:50:26 https://maestrodatabase.com/blog/agenda-for-18-february-2015-tc-meeting 2015-08-05T11:37:16 https://maestrodatabase.com/blog/mercks-keytruda-pembrolizumab-approved-by-the-european-commission-for-patients-with-advanced-non-small-cell-lung-cancer-nsclc-whose-tumors-express-pd-l1 2016-08-03T10:38:11 https://maestrodatabase.com/blog/february-2016-smc-decisions-news-release 2016-02-08T20:35:12 https://maestrodatabase.com/blog/pbs-listing-for-ovarian-cancer-and-kidney-disease 2022-09-01T01:36:44 https://maestrodatabase.com/blog/calls-for-uk-to-pilot-new-reimbursement-models-for-antibiotics 2015-08-05T11:37:15 https://maestrodatabase.com/blog/agenda-for-the-november-2015-pbac-meeting 2015-08-26T12:46:01 https://maestrodatabase.com/blog/fda-approves-expanded-use-of-gsk-hib-vaccine-from-booster-dose-to-full-series 2016-01-20T20:57:08 https://maestrodatabase.com/blog/statement-from-the-chair-of-the-pharmaceutical-benefits-advisory-committee-on-eculizumab-soliris 2015-08-05T11:37:11 https://maestrodatabase.com/blog/cancer-drug-that-the-nhs-refuses-to-pay-for-brought-me-back-from-the-dead 2016-07-09T23:43:29 https://maestrodatabase.com/blog/kyverna-therapeutics-granted-fda-fast-track-designation-for-kyv-101-in-lupus-nephritis 2023-06-02T00:06:25 https://maestrodatabase.com/blog/372m-to-ensure-timely-access-to-chemotherapy-drugs 2015-08-05T11:37:04 https://maestrodatabase.com/blog/mezzions-new-drug-application-for-its-orphan-drug-udenafil-for-the-treatment-of-single-ventricle-heart-disease-has-been-accepted-for-filing-by-the-fda 2021-05-27T06:57:05 https://maestrodatabase.com/blog/post-market-review-framework 2015-08-05T11:37:05 https://maestrodatabase.com/blog/mundipharma-and-orexo-announce-eu-regulatory-submission-for-zubsolv 2016-10-04T11:32:30 https://maestrodatabase.com/blog/grattan-institute-misses-the-point-again 2015-08-05T11:37:22 https://maestrodatabase.com/blog/brisbane-witnesses-30-drop-in-hiv-infections-in-5-years-hiv-drug-truvada-still-not-on-pbs 2016-08-23T21:20:38 https://maestrodatabase.com/blog/uniteds-withdrawal-from-exchanges-much-ado-about-the-wrong-things-1 2016-07-29T02:38:29 https://maestrodatabase.com/blog/nz-patients-with-alk-positive-non-small-cell-lung-cancer-score-a-minor-win 2018-10-23T05:01:05 https://maestrodatabase.com/blog/kythera-biopharmaceuticals-announces-health-canada-authorization-of-belkyra-a-submental-contouring-injectable-drug 2015-08-05T11:37:04 https://maestrodatabase.com/blog/nice-turns-down-celgenes-otezla-for-psoriatic-arthritis 2015-08-05T11:37:21 https://maestrodatabase.com/blog/cancer-flight-club 2016-08-20T21:35:29 https://maestrodatabase.com/blog/new-chair-elect-of-cadth-pcodr-expert-review-committee-appointed 2015-11-03T19:53:58 https://maestrodatabase.com/blog/fda-authorises-additional-monoclonal-antibody-for-treatment-of-covid-19 2021-05-27T07:09:46 https://maestrodatabase.com/blog/performance-statistics-report-july-2015-to-june-2016 2016-09-28T03:46:36 https://maestrodatabase.com/blog/sanofi-submits-new-drug-application-for-the-once-daily-fixed-ratio-combination-of-insulin-glargine-and-lixisenatide 2015-12-23T20:37:24 https://maestrodatabase.com/blog/secukinumab-for-active-ankylosing-spondylitis-or-psoriatic-arthritis-no-additional-clinical-benefit-says-germanys-iqwig 2016-03-15T18:52:33 https://maestrodatabase.com/blog/sprout-investors-say-valeant-overcharging-for-female-libido-pill 2016-03-28T20:47:32 https://maestrodatabase.com/blog/ontario-will-cover-cost-of-kalydeco-for-people-with-cystic-fibrosis 2015-08-05T11:37:04 https://maestrodatabase.com/blog/health-premium-increases-must-fall-greg-hunt 2019-05-27T21:04:31 https://maestrodatabase.com/blog/novartis-announces-robust-phase-iii-results-for-qva149-and-nva237-and-submits-regulatory-applications-to-us-fda 2015-08-05T11:37:14 https://maestrodatabase.com/blog/albiglutide-in-type-2-diabetes-hint-of-minor-added-benefit 2015-08-05T11:37:24 https://maestrodatabase.com/blog/eye-disease-drugs-added-to-the-pbs-to-benefit-thousands-of-australians 2018-10-23T19:48:27 https://maestrodatabase.com/blog/charlie-teo-cancer-specialist-questions-$120k-bills-for-surgeon-of-choice 2019-05-27T21:02:10 https://maestrodatabase.com/blog/ace-publishes-another-tranche-of-technology-guidances-august-2022 2022-09-01T02:54:26 https://maestrodatabase.com/blog/dbv-technologies-announces-submission-of-biologics-license-application-for-viaskin-peanut-to-the-u-dot-s-fda 2018-10-23T08:30:06 https://maestrodatabase.com/blog/flamel-technologies-receives-fda-approval-of-akovaz 2016-05-03T21:33:37 https://maestrodatabase.com/blog/novartis-cosentyx-receives-positive-chmp-opinion-for-first-line-treatment-of-moderate-to-severe-psoriasis-patients 2015-08-05T11:37:24 https://maestrodatabase.com/blog/australian-scientists-in-hunt-for-cutting-edge-treatments-medicine 2025-09-03T11:40:33 https://maestrodatabase.com/blog/fda-approves-new-diagnostic-imaging-agent-to-detect-recurrent-prostate-cancer 2016-05-28T12:21:22 https://maestrodatabase.com/blog/guyon-espiner-investigates-pharmac-nz-diabetes-drugs-third-world---doctor 2019-05-27T20:55:47 https://maestrodatabase.com/blog/fda-accepts-supplemental-new-drug-application-for-priority-review-of-rapamune-sirolimus-for-treatment-of-lymphangioleiomyomatosis 2015-08-05T11:37:21 https://maestrodatabase.com/blog/enoxaparin-sodium-and-plerixafor-proposal 2016-06-24T00:24:21 https://maestrodatabase.com/blog/budget-2015-federal-government-to-subsidise-13-billion-life-saving-drugs 2015-08-05T11:37:25 https://maestrodatabase.com/blog/biosimilar-adalimumab-a-landmark-for-nhs-medicines-optimisation 2018-10-23T19:58:16 https://maestrodatabase.com/blog/european-commission-approves-bristol-myers-squibbs-opdivo-nivolumab-for-previously-treated-advanced-renal-cell-carcinoma 2016-04-06T20:23:48 https://maestrodatabase.com/blog/battle-in-australia-over-access-to-cancer-drugs 2015-08-05T11:37:09 https://maestrodatabase.com/blog/call-for-patient-input-on-a-submission-from-raptor-pharmaceuticals-for-quinsair-levofloxacin 2016-05-02T21:18:35 https://maestrodatabase.com/blog/lynparza-olaparib-receives-positive-chmp-opinion-in-the-eu-for-the-maintenance-treatment-of-brca-mutated-platinum-sensitive-relapsed-ovarian-cancer 2015-08-05T11:37:10 https://maestrodatabase.com/blog/6-dollars-8-cents-billion-high-claim-health-cost-sparks-private-insurer-outcry 2018-10-23T19:53:35 https://maestrodatabase.com/blog/nice-says-yes-to-two-eye-treatments-for-treating-serious-diabetic-eye-condition-in-final-draft-guidance 2015-08-05T11:37:04 https://maestrodatabase.com/blog/ema-publishes-agenda-for-27-29-2019-may-chmp-meeting 2019-05-27T21:20:15 https://maestrodatabase.com/blog/fda-chief-becomes-point-man-on-drug-prices 2018-03-14T10:06:46 https://maestrodatabase.com/blog/proposal-relating-to-pembrolizumab-keytruda-nivolumab-opdivo-posaconazole-noxafil-and-raltegravir-isentress 2016-06-28T04:41:12 https://maestrodatabase.com/blog/menarini-groups-obicetrapib-and-obicetrapib-slash-ezetimibe-marketing-authorisation-applications-accepted-for-review-by-the-ema-for-the-treatment-of-adults-with-primary-hypercholesterolaemia-heterozygous-familial-and-non-familial-or-mixed-dyslipidaemia 2025-09-03T07:48:10 https://maestrodatabase.com/blog/health-canada-approves-ofev-nintedanib-for-the-treatment-of-idiopathic-pulmonary-fibrosis 2015-08-05T11:37:17 https://maestrodatabase.com/blog/drug-companies-not-middlemen-are-responsible-for-high-drug-prices 2018-10-23T20:24:52 https://maestrodatabase.com/blog/health-economic-assessment-of-opdivo-in-combination-with-yervoy-for-the-first-line-treatment-of-patients-with-renal-cell-carcinoma 2019-05-27T21:47:26 https://maestrodatabase.com/blog/u-dot-s-food-and-drug-administration-grants-bcma-car-t-cilta-cel-priority-review-for-the-treatment-for-relapsed-slash-refractory-multiple-myeloma 2021-05-27T07:39:55 https://maestrodatabase.com/blog/house-defeats-right-to-try-legislation-to-allow-expanded-use-of-experimental-drugs 2018-03-14T18:47:55 https://maestrodatabase.com/blog/pbac-dusc-meeting---june-2014 2015-08-05T11:37:13 https://maestrodatabase.com/blog/pharmaceutical-benefit-advisory-committee-guidelines-review 2016-02-19T02:50:42 https://maestrodatabase.com/blog/trump-ready-to-force-transparency-in-health-care-pricing-with-an-executive-order 2019-05-27T21:33:11 https://maestrodatabase.com/blog/novabiotics-lynovex-receives-fast-track-designation-for-cystic-fibrosis-exacerbations 2018-03-14T09:51:59 https://maestrodatabase.com/blog/relistor-approved-in-eu-to-treat-all-opioid-induced-constipation 2015-08-05T11:37:09 https://maestrodatabase.com/blog/b-dot-c-becomes-first-province-to-force-change-to-biosimilar-drugs 2019-05-27T21:28:43 https://maestrodatabase.com/blog/genmab-announces-submission-of-supplemental-biologics-license-application-to-fda-for-daratumumab-in-relapsed-multiple-myeloma 2016-08-17T20:59:12 https://maestrodatabase.com/blog/myr-pharma-announces-grant-of-breakthrough-therapy-designation-by-us-fda-for-myrcludex-the-first-in-class-entry-inhibitor-for-treatment-of-chronic-hepatitis-b-and-d-infections 2018-10-23T20:19:41 https://maestrodatabase.com/blog/cancer-patients-get-another-option-with-pharmac-eyeing-funding-for-keytruda 2016-06-28T05:04:11 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac---november-2021 2021-12-17T22:09:50 https://maestrodatabase.com/blog/why-drug-approval-needs-better-evidence 2016-06-29T02:57:27 https://maestrodatabase.com/blog/valeant-receives-health-canada-approval-of-siliq-brodalumab-for-moderate-to-severe-plaque-psoriasis 2018-03-14T20:03:54 https://maestrodatabase.com/blog/almost-half-of-new-us-cancer-patients-lose-their-entire-life-savings 2018-10-23T20:43:52 https://maestrodatabase.com/blog/drug-prices-in-advertisements-actually-hurt-consumers 2018-10-23T20:27:26 https://maestrodatabase.com/blog/the-eu-commission-approves-helsinns-akynzeo-netupitantpalonosetron-for-prevention-of-chemotherapy-induced-nausea-and-vomiting-in-european-union 2015-08-05T11:37:19 https://maestrodatabase.com/blog/single-payer-health-care-would-take-years-to-develop-in-california-legislative-report-says 2018-03-14T18:56:38 https://maestrodatabase.com/blog/medicine-agency-recommends-listing-of-life-saving-drugs-for-australian-men-with-deadly-forms-of-prostate-cancer 2021-12-17T22:14:02 https://maestrodatabase.com/blog/cadth-calls-for-patient-input-on-a-new-submission-from-celopharma-for-misogymiso 2016-01-18T21:13:47 https://maestrodatabase.com/blog/should-health-care-shift-toward-a-blockchain-based-efficiency-model 2018-10-23T20:32:56 https://maestrodatabase.com/blog/availability-of-new-medicines-in-the-us-and-germany-2004---2018 2022-09-01T03:49:08 https://maestrodatabase.com/blog/public-release-documents-dusc-october-2015-meeting 2016-03-06T00:21:47 https://maestrodatabase.com/blog/breast-cancer-drug-approved-for-nhs-use 2018-03-14T19:53:45 https://maestrodatabase.com/blog/pfizer-announces-european-medicines-agency-validates-marketing-authorisation-application-for-ibrance-palbociclib-in-combination-with-endocrine-therapy-for-the-treatment-of-hrher2-metastatic-breast-cancer 2015-08-20T21:11:33 https://maestrodatabase.com/blog/fda-approves-new-antibacterial-drug-to-treat-complicated-urinary-tract-infections-as-part-of-ongoing-efforts-to-address-antimicrobial-resistance 2019-11-14T23:50:00 https://maestrodatabase.com/blog/fda-approves-paediatric-indication-for-emend-aprepitant-capsules-in-combination-with-other-anti-emetic-agents 2015-09-02T21:07:28 https://maestrodatabase.com/blog/merck-intends-to-submit-cladribine-tablets-to-treat-multiple-sclerosis-for-registration-in-europe 2015-09-11T21:52:42 https://maestrodatabase.com/blog/fda-considers-new-efficacy-endpoint-for-diabetes-drugs 2023-06-02T02:03:12 https://maestrodatabase.com/blog/health-experts-worried-as-trans-pacific-partnership-negotiations-conclude 2015-08-05T11:37:18 https://maestrodatabase.com/blog/adempas_now_approved_for_second_rare_heart_and_lung_disease__offering_a_new_treatment_option_to_improve_patient_care_ 2015-08-05T11:37:16 https://maestrodatabase.com/blog/fda-approves-therapy-to-treat-patients-with-relapsed-and-refractory-mantle-cell-lymphoma-supported-by-clinical-trial-results-showing-high-response-rate-of-tumour-shrinkage 2019-11-14T23:46:16 https://maestrodatabase.com/blog/australian-statistics-on-medicines-2015 2016-09-05T08:42:43 https://maestrodatabase.com/blog/tga-publishes-another-6-auspars 2015-09-24T21:55:38 https://maestrodatabase.com/blog/nice-proposes-to-recommend-lenalidomide-for-myelodysplastic-syndromes 2015-08-05T11:37:29 https://maestrodatabase.com/blog/pharmac-september-2015-tender-notification 2015-09-30T03:33:58 https://maestrodatabase.com/blog/pharmac-to-widen-access-to-the-exceptional-circumstances-process-for-lamotrigine 2019-11-15T01:24:24 https://maestrodatabase.com/blog/eu-clears-german-scheme-to-exempt-pharma-groups-from-price-freezes 2015-08-05T11:37:14 https://maestrodatabase.com/blog/pfizer-and-protalix-biotherapeutics-announce-fda-approval-of-pediatric-indication-for-elelyso-taliglucerase-alfa-for-injection-for-intravenous-use-for-the-treatment-of-type-1-gaucher-disease 2015-08-05T11:37:25 https://maestrodatabase.com/blog/ema-publishes-epar-for-daratumumab-darzalex 2016-05-31T16:08:55 https://maestrodatabase.com/blog/health-system-wont-fund-dads-2000-a-week-cancer-treatment-despite-free-heart-transplant 2015-09-17T20:59:53 https://maestrodatabase.com/blog/heres-how-law-makers-can-slash-medicare-spending-without-cutting-benefits 2023-06-02T02:39:15 https://maestrodatabase.com/blog/ruxolitinib-phosphate-for-the-treatment-of-patients-with-polycythaemia-vera 2023-10-19T02:09:47 https://maestrodatabase.com/blog/ema-to-encourage-use-of-scientific-advice-for-post-authorisation-safety-studies 2015-08-05T11:37:28 https://maestrodatabase.com/blog/agenda-for-the-18-november-2015-tc-meeting 2015-11-18T05:10:20 https://maestrodatabase.com/blog/foslevodopa-foscarbidopa-for-treating-parkinsons-disease-with-motor-symptoms 2023-06-02T02:34:30 https://maestrodatabase.com/blog/high-prices-for-drugs-attacked-at-meeting 2015-08-05T11:37:12 https://maestrodatabase.com/blog/health-canada-approves-keytruda-pembrolizumab-as-first-line-treatment-for-patients-with-metastatic-or-unresectable-recurrent-head-and-neck-squamous-cell-carcinoma 2020-10-17T01:54:09 https://maestrodatabase.com/blog/five-cancer-drugs-back-on-nhs-list-after-deals-with-drug-companies 2015-11-13T06:45:21 https://maestrodatabase.com/blog/venclexta-venetoclax-receives-fda-full-approval-for-acute-myeloid-leukaemia 2020-10-17T01:30:10 https://maestrodatabase.com/blog/pharming-announces-sale-of-priority-review-voucher 2023-06-02T02:10:31 https://maestrodatabase.com/blog/linvoseltamab-bla-for-treatment-of-relapsed-slash-refractory-multiple-myeloma-accepted-for-fda-priority-review 2024-02-21T19:54:21 https://maestrodatabase.com/blog/afatinib-with-advanced-squamous-cell-carcinoma-of-the-lung-additional-benefits-not-covered 2016-08-02T04:43:53 https://maestrodatabase.com/blog/fda-approves-expanded-use-of-navideas-lymphoseek-for-lymphatic-mapping-in-solid-tumours 2015-08-05T11:37:03 https://maestrodatabase.com/blog/pharmac-backs-down-on-epilepsy-drug-brand-switch 2019-11-15T01:49:46 https://maestrodatabase.com/blog/fda-and-ema-accept-vorasidenib-regulatory-submissions-for-the-treatment-of-idh-mutant-diffuse-glioma 2024-02-21T01:39:39 https://maestrodatabase.com/blog/scoping-document-for-icer-review-of-abuse-deterrent-opioid-formulations-open-for-public-comment 2016-09-08T21:24:30 https://maestrodatabase.com/blog/icer-publishes-evidence-report-on-therapies-for-haemophilia-a 2020-10-17T01:43:02 https://maestrodatabase.com/blog/ad-treatment-dupixent-approved-for-use-in-china-for-young-children 2023-06-02T02:06:27 https://maestrodatabase.com/blog/stakeholder-engagement-session-phase-ii-of-the-transfer-of-pcodr-to-cadth 2015-08-05T11:37:02 https://maestrodatabase.com/blog/canada-wants-alexion-to-repay-sales-generated-by-excessive-pricing 2015-08-05T11:37:13 https://maestrodatabase.com/blog/meningitis-foundation-calls-for-pharmac-to-protect-everyone 2019-11-15T01:45:18 https://maestrodatabase.com/blog/new-biosimilar-can-offer-an-effective-and-lower-cost-treatment-option-for-canadians-living-with-rheumatoid-arthritis-and-ankylosing-spondylitis 2016-09-13T12:24:48 https://maestrodatabase.com/blog/abpi-responds-to-publication-of-government-consultation-on-statutory-scheme 2015-08-05T11:37:04 https://maestrodatabase.com/blog/statins-harms-exaggerated-benefits-underestimated-major-lancet-journal-review-shows 2016-09-09T05:00:12 https://maestrodatabase.com/blog/the-biden-administration-versus-medicare-advantage 2024-02-21T20:40:35 https://maestrodatabase.com/blog/ema-publishes-epa-for-ceftazidime-with-avibactam-zavicefta 2016-07-14T21:54:01 https://maestrodatabase.com/blog/drug-pricing-pay-for-benefits-not-pills 2016-08-16T11:09:51 https://maestrodatabase.com/blog/summary_of_1_april_2014_price_reductions_for_the_2014_main_cycle_by_drug_manner_of_administration_percentage_reduction 2015-08-05T11:37:08 https://maestrodatabase.com/blog/omidria-approved-for-commercialisation-throughout-the-european-union-and-additional-countries 2015-08-05T11:37:04 https://maestrodatabase.com/blog/united-therapeutics-starts-litigation-with-fda-over-rival-liquidias-drug-application 2024-02-21T20:30:09 https://maestrodatabase.com/blog/vertex-submits-supplemental-new-drug-application-snda-to-us-food-and-drug-administration-for-use-of-kalydeco-ivacaftor-in-people-18-and-older-with-cystic-fibrosis-who-have-the-r117h-mutation 2015-08-05T11:37:08 https://maestrodatabase.com/blog/call-for-patient-input-6 2015-08-05T11:37:12 https://maestrodatabase.com/blog/reducing-drug-waste-could-save-billions-of-dollars 2016-03-08T09:11:58 https://maestrodatabase.com/blog/tecvayli-teclistamab-cqyv-biweekly-dosing-approved-by-the-us-fda-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma 2024-02-21T20:24:48 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-positive-chmp-opinion-in-the-european-union-for-nivolumab-opdivo-for-the-treatment-of-advanced-squamous-non-small-cell-lung-cancer-in-previously-treated-patients 2015-08-05T11:37:11 https://maestrodatabase.com/blog/talazoparib-tosylate-for-the-treatment-of-patients-with-advanced-brca-mutation-positive-her2-negative-breast-cancer-final-guidance 2024-02-21T20:06:50 https://maestrodatabase.com/blog/meningitis-b-vaccine-extension-rejected 2016-07-14T10:30:38 https://maestrodatabase.com/blog/bristol-myers-squibb-and-abbvie-receive-fda-approval-of-empliciti-elotuzumab-for-the-treatment-of-patients-with-multiple-myeloma-who-have-received-one-to-three-prior-therapies 2015-12-01T19:12:22 https://maestrodatabase.com/blog/cdr-update-issue-111 2015-09-23T21:39:32 https://maestrodatabase.com/blog/price_cuts_mean_pbs_can_afford_new_medicines 2015-08-05T11:37:03 https://maestrodatabase.com/blog/business-gateway-to-ebusiness-services---launching-in-early-2015 2015-08-05T11:37:10 https://maestrodatabase.com/blog/fda-approves-anti-clotting-drug-savaysa 2015-08-05T11:37:08 https://maestrodatabase.com/blog/nice-defends-panels-over-conflict-of-interest-claim 2015-08-05T11:37:08 https://maestrodatabase.com/blog/summary_of_the_agenda_for_the_pbac_march_2014_meeting 2015-08-05T11:37:11 https://maestrodatabase.com/blog/novartis-buys-queensland-drug-developer-spinifex-for-us200m-plus 2015-08-05T11:37:07 https://maestrodatabase.com/blog/prescription-medicines-new-or-extended-uses-of-registered-medicines 2016-05-04T03:26:17 https://maestrodatabase.com/blog/proposal-to-reduce-medicare-drug-payments-is-widely-criticized 2016-05-23T10:10:55 https://maestrodatabase.com/blog/australias-most-common-and-expensive-drugs-revealed-by-pbs-data 2016-08-01T13:42:02 https://maestrodatabase.com/blog/ema-management-board-highlights-of-march-2015-meeting 2015-08-05T11:37:27 https://maestrodatabase.com/blog/launch-of-prime-paving-the-way-for-promising-medicines-for-patients 2016-03-07T19:52:20 https://maestrodatabase.com/blog/fda-approves-an-immunotherapy-drug-for-bladder-cancer 2016-05-19T12:29:17 https://maestrodatabase.com/blog/stimulating-the-development-of-medicines-for-children 2015-08-05T11:37:29 https://maestrodatabase.com/blog/new-advance-in-copd-maintenance-treatment-spiolto-respimat-approved-in-first-european-countries 2015-08-05T11:37:07 https://maestrodatabase.com/blog/improved-deal-means-new-treatment-for-a-type-of-advanced-breast-cancer-can-be-recommended-by-nice 2020-05-22T11:06:58 https://maestrodatabase.com/blog/just-look-but-dont-touch-ema-terms-of-use-for-clinical-study-data-are-impracticable 2015-08-05T11:37:16 https://maestrodatabase.com/blog/agenda-for-the-6-january-2016-tc-meeting 2015-12-30T23:37:12 https://maestrodatabase.com/blog/indicative-1-october-2014-prices---price-disclosure 2015-08-05T11:37:16 https://maestrodatabase.com/blog/ema-validates-bristol-myers-squibbs-applications-for-idecabtagene-vicleucel-and-cc-486 2020-05-22T11:14:01 https://maestrodatabase.com/blog/fda-approves-tevas-granix-tbo-filgrastim-injection-for-self-administration 2015-08-05T11:37:16 https://maestrodatabase.com/blog/progenics-announces-breakthrough-therapy-designation-for-azedra-in-pheochromocytoma-and-paraganglioma 2015-08-05T11:37:10 https://maestrodatabase.com/blog/basilea-announces-that-health-canada-approved-zevtera-for-the-treatment-of-bacterial-lung-infections 2015-10-13T11:19:21 https://maestrodatabase.com/blog/sunovion-announces-u-dot-s-fda-approval-of-kynmobi-apomorphine-hydrochloride-sublingual-film-for-the-treatment-of-parkinsons-disease-off-episodes 2020-05-22T11:23:57 https://maestrodatabase.com/blog/nice-recommends-ataluren-for-treating-duchenne-muscular-dystrophy-caused-by-a-nonsense-mutation 2016-04-15T21:21:16 https://maestrodatabase.com/blog/the-unstable-economics-in-obamas-health-law 2016-08-17T22:30:20 https://maestrodatabase.com/blog/nices-eylea-guideline-out-of-touch-with-clinical-practice 2016-06-09T10:56:10 https://maestrodatabase.com/blog/targeted-therapies-raise-the-number-of-subsidised-high-priced-drugs 2015-08-05T11:37:11 https://maestrodatabase.com/blog/the-life-saving-black-magic-pill-that-costs-140000-a-year 2015-09-06T02:44:50 https://maestrodatabase.com/blog/mayne-pharma-receives-fda-approval-for-dofetilide-capsules-and-awarded-180-days-market-exclusivity 2016-06-08T08:23:13 https://maestrodatabase.com/blog/hiv-positive-children-and-adolescents-additional-benefit-of-rilpivirine-not-proven 2016-04-02T00:37:08 https://maestrodatabase.com/blog/teva-canada-innovation-announces-approval-of-three-times-a-week-copaxone-40mgml-by-health-canada 2016-08-24T22:35:04 https://maestrodatabase.com/blog/antengene-announces-xpovia-included-for-reimbursement-by-the-pbs-in-australia-for-the-treatment-of-patients-with-relapsed-and-slash-or-refractory-multiple-myeloma 2022-09-01T08:39:31 https://maestrodatabase.com/blog/pcodr-expands-the-scope-of-its-review-of-keytruda-opdivo 2015-10-24T20:47:05 https://maestrodatabase.com/blog/biosimilar-awareness-consultation-on-implementation 2015-10-12T03:48:36 https://maestrodatabase.com/blog/proposal-for-sole-subsidised-supply-of-progestogen-only-long-acting-intra-uterine-system-mirena 2016-06-27T07:00:58 https://maestrodatabase.com/blog/galderma-receives-fda-approval-for-new-antibiotic-free-treatment-option-for-acne-patients 2015-08-05T11:37:19 https://maestrodatabase.com/blog/life-extending-cancer-drugs-to-be-axed-by-nhs 2015-09-04T05:30:45 https://maestrodatabase.com/blog/eu-us-collaboration-to-boost-medicine-development-for-rare-diseases 2016-09-26T20:51:21 https://maestrodatabase.com/blog/80-dollars-million-investment-in-eye-medication 2018-10-23T23:44:13 https://maestrodatabase.com/blog/csl-behring-receives-marketing-authorisation-for-respreeza-in-europe 2015-08-27T05:16:09 https://maestrodatabase.com/blog/immunotherapy-offers-hope-to-a-cancer-patient-but-no-certainty 2016-08-01T08:31:41 https://maestrodatabase.com/blog/lillys-lung-cancer-drug-portrazza-to-cost-11430-a-month 2015-12-14T06:37:57 https://maestrodatabase.com/blog/fda-approvals-for-the-first-6-months-of-2016 2016-07-30T01:29:11 https://maestrodatabase.com/blog/passage-bio-receives-rare-paediatric-disease-designation-for-pbgm01-for-patients-with-gm1-gangliosidosis 2020-05-22T11:33:54 https://maestrodatabase.com/blog/nice-reviews-guidance-on-imatinib-mesylate-for-digestive-system-tumours 2015-08-05T11:37:21 https://maestrodatabase.com/blog/fda-approves-new-treatment-for-myasthenia-gravis 2021-12-17T23:53:41 https://maestrodatabase.com/blog/valeo-pharma-announces-filing-of-a-new-drug-submission-for-low-molecular-weight-heparin-in-canada 2019-11-15T04:45:20 https://maestrodatabase.com/blog/aegerion_pharmaceuticals__juxtapid__lomitapide__capsules_approved_in_canada_for_the_treatment_of_homozygous_familial_hypercholesterolemia_ 2015-08-05T11:37:19 https://maestrodatabase.com/blog/eisai-outraged-by-iqwigs-failure-to-back-epilepsy-drug 2015-08-05T11:37:08 https://maestrodatabase.com/blog/icer-addresses-misconceptions-about-its-goals-and-methods-of-value-assessment 2016-08-09T21:06:10 https://maestrodatabase.com/blog/health_canada_approves_thrombogenics__jetrea__ocriplasmin__for_the_treatment_of_symptomatic_vitreomacular_adhesion 2015-08-05T11:37:26 https://maestrodatabase.com/blog/ema-sets-up-task-force-on-zika-virus 2016-02-08T19:46:09 https://maestrodatabase.com/blog/are-the-days-of-big-pharma-dominating-the-agenda-of-a-pbac-meeting-over 2016-05-02T12:07:39 https://maestrodatabase.com/blog/compass-pathways-receives-fda-breakthrough-therapy-designation-for-psilocybin-therapy-for-treatment-resistant-depression 2018-10-23T23:48:52 https://maestrodatabase.com/blog/scottish-cancer-sufferers-denied-life-saving-drugs 2015-08-05T11:37:23 https://maestrodatabase.com/blog/cancer-drugs-fund-is-not-sustainable-after-exceeding-its-budget-by-50-to-help-74000-patients-receive-life-saving-treatments-not-approved-by-nhs-watchdog 2015-09-18T21:51:06 https://maestrodatabase.com/blog/changes-to-the-conditions-under-which-eculizumab-may-be-prescribed-on-the-pbs 2015-12-18T10:13:43 https://maestrodatabase.com/blog/i-dont-want-to-die-i-still-have-things-to-do-keytruda-wins-ron-walkers-war-on-cancer 2015-08-05T11:37:27 https://maestrodatabase.com/blog/stivarga-regorafenib-from-bayer-approved-in-the-european-union-for-the-treatment-of-gastrointestinal-stromal-tumors 2015-08-05T11:37:30 https://maestrodatabase.com/blog/fda-approves-sandoz-erelzi-to-treat-multiple-inflammatory-diseases 2016-08-30T20:47:11 https://maestrodatabase.com/blog/esperion-announces-submission-of-supplemental-new-drug-applications-to-us-fda-for-nexletol-bempedoic-acid-tablet-and-nexlizet-bempedoic-acid-and-ezetimibe-tablet 2023-06-02T03:34:19 https://maestrodatabase.com/blog/a-comprehensive-and-fair-solution-to-the-price-of-medicines 2016-07-11T02:11:11 https://maestrodatabase.com/blog/janssens-stelara-gets-insurance-benefits-as-first-line-therapy-for-ulcerative-colitis 2022-09-01T09:22:59 https://maestrodatabase.com/blog/elotuzumab-in-multiple-myeloma-additional-clinical-benefit-is-not-proven 2016-09-01T20:47:52 https://maestrodatabase.com/blog/cdec-rejects-aubagio-teriflunomide-for-patients-with-relapsing-remitting-multiple-sclerosis 2015-08-05T11:37:21 https://maestrodatabase.com/blog/proposal-to-amend-or-remove-funding-restrictions-from-various-pharmaceuticals 2015-08-05T11:37:20 https://maestrodatabase.com/blog/critical-kidney-disease-medication-listed-on-the-pbs 2022-09-01T11:47:01 https://maestrodatabase.com/blog/merck-receives-breakthrough-therapy-designation-from-fda-and-prime-status-from-ema-for-investigational-ebola-zaire-vaccine-v920 2016-07-26T13:02:59 https://maestrodatabase.com/blog/seqirus-receives-fda-approval-of-afluria-quadrivalent-influenza-vaccine-for-people-six-months-of-age-and-older-in-the-u-dot-s 2018-10-24T05:26:13 https://maestrodatabase.com/blog/pfizer-announces-submission-of-biologics-license-application-to-the-fda-for-investigational-meningococcal-b-vaccine 2015-08-05T11:37:17 https://maestrodatabase.com/blog/europe-approves-novel-australian-drug-developed-for-rare-sun-disease 2015-08-05T11:37:08 https://maestrodatabase.com/blog/kythera-biopharmaceuticals-announces-fda-approval-of-kybella-also-known-as-atx-101--first-and-only-submental-contouring-injectable-drug 2015-08-05T11:37:14 https://maestrodatabase.com/blog/fda-approves-new-novartis-dual-combination-bronchodilator-utibron-neohaler-for-patients-with-chronic-obstructive-pulmonary-disease 2015-10-30T07:16:30 https://maestrodatabase.com/blog/nice-recommends-commissioning-of-eculizumab-soliris-for-all-patients-with-ahus-in-england 2015-08-05T11:37:24 https://maestrodatabase.com/blog/scotland-doubles-cash-for-new-medicines-fund 2015-08-05T11:37:03 https://maestrodatabase.com/blog/pembrolizumab-in-advanced-melanoma-added-benefit-for-certain-patients 2015-11-23T20:56:11 https://maestrodatabase.com/blog/call-for-feedback-summary-report-on-phase-ii-of-pcodr-transfer-to-cadth-from-stakeholder-engagement-sessions 2015-08-05T11:37:11 https://maestrodatabase.com/blog/further-update-on-proposal-to-fund-glecaprevir-with-pibrentasvir-maviret-for-hepatitis-c 2018-10-24T05:32:22 https://maestrodatabase.com/blog/baxalta-granted-eu-marketing-authorization-for-oncaspar-pegaspargase-as-a-component-of-combination-therapy-in-acute-lymphoblastic-leukaemia 2016-01-20T20:29:43 https://maestrodatabase.com/blog/dont-weaken-the-fdas-drug-approval-process 2015-08-05T11:37:30 https://maestrodatabase.com/blog/tezspire-tezepelumab-approved-in-the-us-for-severe-asthma 2021-12-18T00:02:08 https://maestrodatabase.com/blog/fda-approves-epclusa-for-treatment-of-chronic-hepatitis-c-virus-infection 2016-06-28T21:30:37 https://maestrodatabase.com/blog/abbvie-announces-us-fda-approval-of-duopa-carbidopa-and-levodopa-enteral-suspension-for-the-treatment-fo-motor-fluctuations-in-patients-with-advanced-parkinsons-disease 2015-08-05T11:37:09 https://maestrodatabase.com/blog/fda-approves-blincyto-to-treat-a-rare-form-of-acute-lymphoblastic-leukaemia 2015-08-05T11:37:16 https://maestrodatabase.com/blog/sussan-leys-private-health-committee-packed-with-lobby-groups 2016-09-22T20:30:53 https://maestrodatabase.com/blog/budget-2015-drug-firms-prepare-for-war 2015-08-05T11:37:09 https://maestrodatabase.com/blog/fda-approves-first-recombinant-von-willebrand-factor-to-treat-bleeding-episodes 2015-12-08T20:16:50 https://maestrodatabase.com/blog/pbac-creates-reference-group-for-eculizumab 2015-11-24T20:08:42 https://maestrodatabase.com/blog/ceo-raises-pills-price-from-us18-to-us750-overnight-calls-journalist-moron 2015-09-22T20:45:54 https://maestrodatabase.com/blog/brivaracetam-in-epilepsy-additional-benefits-not-covered-as-before 2016-08-06T05:48:05 https://maestrodatabase.com/blog/fda-approves-gazyva-obinutuzumab-supplemental-biologics-license-application-with-new-data-in-previously-untreated-chronic-lymphocytic-leukaemia 2015-08-05T11:37:25 https://maestrodatabase.com/blog/the-medicines-company-announces-fda-approval-of-ionsys-fentanyl-iontophoretic-transdermal-system-for-the-management-of-acute-post-pperative-pain-for-adult-patients-in-the-hospital 2015-08-05T11:37:06 https://maestrodatabase.com/blog/fda-approves-first-line-use-of-vectibix-panitumumab-plus-folfox-for-patients-with-wild-type-kras-metastatic-colorectal-cancer 2015-08-05T11:37:16 https://maestrodatabase.com/blog/fda-approves-new-diagnostic-imaging-agent-to-detect-rare-neuroendocrine-tumours 2016-06-02T05:36:59 https://maestrodatabase.com/blog/fda-approves-aristada-for-treatment-of-schizophrenia 2015-10-06T06:29:43 https://maestrodatabase.com/blog/new-multiple-sclerosis-treatment-plegridy-peginterferon-beta-1a-to-be-pbs-listed-in-australia 2015-08-05T11:37:17 https://maestrodatabase.com/blog/tga-approves-lesinurad-zurampic 2016-06-02T05:18:33 https://maestrodatabase.com/blog/flixabi-biogens-infliximab-biosimilar-referencing-remicade-approved-in-the-european-union 2016-05-31T14:19:15 https://maestrodatabase.com/blog/decision_criteria_consultation___proposal_for_change 2015-08-05T11:37:11 https://maestrodatabase.com/blog/what-negotiating-with-medicare-means-for-drug-makers-a-mixture-of-price-controls-and-actual-negotiations 2022-09-01T20:21:01 https://maestrodatabase.com/blog/actavis-and-gedeon-richter-announce-fda-receipt-of-nda-resubmission-for-cariprazine 2015-08-05T11:37:06 https://maestrodatabase.com/blog/ema-publishes-epar-for-nordimet 2016-09-29T10:21:36 https://maestrodatabase.com/blog/new_facet_added_to_maestro_australia___dusc_outcome_statements 2015-08-05T11:37:16 https://maestrodatabase.com/blog/fda-approves-new-drug-for-chronic-lymphocytic-leukemia-in-patients-with-a-specific-chromosomal-abnormality 2016-04-11T20:36:53 https://maestrodatabase.com/blog/first-adapted-covid-19-booster-vaccines-recommended-for-approval-in-the-eu 2022-09-01T20:17:18 https://maestrodatabase.com/blog/public_summary_documents_from_the_november_2013_pbac_meeting___risk_share_agreements 2015-08-05T11:37:19 https://maestrodatabase.com/blog/cdf-to-revisit-delisting-of-lillys-alimta 2015-08-05T11:37:16 https://maestrodatabase.com/blog/call-for-feedback-therapeutic-review-framework-and-process 2015-08-05T11:37:26 https://maestrodatabase.com/blog/fda-approves-new-indication-for-bayers-kogenate 2015-08-05T11:37:23 https://maestrodatabase.com/blog/tris-pharma-receives-fda-approval-of-dyanavel-xr-amphetamine-cii-as-once-daily-liquid-for-treatment-of-adhd-in-children 2015-10-21T05:13:50 https://maestrodatabase.com/blog/anger_as_life_saving_drugs_stuck_in_federal_bureaucratic_limbo 2015-08-05T11:37:04 https://maestrodatabase.com/blog/call-for-patient-input-on-a-submission-from-boehringer-ingelheim-for-jardiance-empagliflozin 2016-03-30T20:10:16 https://maestrodatabase.com/blog/janssen-submits-application-seeking-approval-of-sirukumab-in-united-states-for-rheumatoid-arthritis 2016-09-26T05:21:52 https://maestrodatabase.com/blog/call-for-patient-input-7 2015-08-05T11:37:06 https://maestrodatabase.com/blog/a-pill-too-hard-to-swallow-how-the-nhs-is-limiting-access-to-high-priced-drugs 2016-07-30T01:44:31 https://maestrodatabase.com/blog/sanofi-and-regeneron-announce-praluent-alirocumab-biologics-license-application-has-been-accepted-for-priority-review-by-us-fda 2015-08-05T11:37:09 https://maestrodatabase.com/blog/blood-cancer-drug-approved-for-use-on-scottish-nhs 2016-09-12T21:15:44 https://maestrodatabase.com/blog/landmark-nice-recommendation-for-lynparza-olaparib-for-ovarian-cancer 2015-12-13T20:37:34 https://maestrodatabase.com/blog/cadth-launches-post-market-drug-evaluation-program 2022-09-01T20:47:43 https://maestrodatabase.com/blog/fda-approves-new-drug-to-treat-influenza 2018-10-24T19:35:25 https://maestrodatabase.com/blog/applications-for-new-human-medicines-under-evaluation-by-the-chmp-april-2016-update 2016-04-21T09:35:10 https://maestrodatabase.com/blog/call-for-nominations-pcodr-expert-review-committee 2015-08-05T11:37:22 https://maestrodatabase.com/blog/international-agencies-crackdown-on-fake-medicines 2018-10-24T11:49:50 https://maestrodatabase.com/blog/recell-system-insurance-coverage-begins-in-japan-for-treatment-of-acute-burns 2022-09-01T20:36:01 https://maestrodatabase.com/blog/hospiras-inflectra-infliximab-now-available-in-canada 2015-08-05T11:37:10 https://maestrodatabase.com/blog/over-100000-people-set-to-benefit-from-pharmac-vaccines-decisions 2016-07-28T20:57:22 https://maestrodatabase.com/blog/vernalis-and-tris-pharma-receive-fda-approval-of-nda-for-tuzistra-xr-codeine-polistirex-and-chlorpheniramine-polistirex 2015-08-05T11:37:06 https://maestrodatabase.com/blog/chmp-grants-positive-opinion-for-idarucizumab-the-specific-reversal-agent-for-dabigatran-etexilate-pradaxa 2015-09-26T02:55:21 https://maestrodatabase.com/blog/prince-edward-island-adds-perjeta-herceptin-combo-pack-for-treatment-of-her2-positive-metastatic-breast-cancer-to-the-provincial-formulary 2015-08-05T11:37:29 https://maestrodatabase.com/blog/health-canada-authorises-first-bivalent-covid-19-booster-for-adults-18-years-and-older 2022-09-01T20:31:44 https://maestrodatabase.com/blog/biomarin-announces-ema-validation-of-brineura-cerliponase-alfa-marketing-authorization-application-for-treatment-of-cln2-disease-a-form-of-batten-disease 2016-09-16T08:17:10 https://maestrodatabase.com/blog/vabysmo-faricimab-injection-receives-positive-cadth-recommendation-for-the-treatment-of-neovascular-wet-age-related-macular-degeneration-in-adults 2022-09-01T20:24:47 https://maestrodatabase.com/blog/canadian-drug-expert-committee---call-for-nominations 2015-08-05T11:37:02 https://maestrodatabase.com/blog/us-justice-department-subpoenas-taro-over-generic-drug-pricing 2016-09-12T10:59:44 https://maestrodatabase.com/blog/lundbeck-and-takeda-receive-complete-response-letter-by-the-fda-for-brintellix-vortioxetine-snda 2016-03-29T20:12:39 https://maestrodatabase.com/blog/drug-makers-sidestep-barriers-on-pricing 2015-10-20T20:36:31 https://maestrodatabase.com/blog/cubist-announces-ema-acceptance-of-ceftolozanetazobactam-marketing-authorization-application-for-review 2015-08-05T11:37:04 https://maestrodatabase.com/blog/ms-and-cholesterol-drugs-picked-for-new-uk-rapid-uptake-push 2018-10-24T20:00:04 https://maestrodatabase.com/blog/european-medicines-agency-welcomes-new-head-of-administration 2015-08-05T11:37:27 https://maestrodatabase.com/blog/update-on-regulatory-submission-for-aducanumab-in-the-european-union 2022-04-24T08:12:44 https://maestrodatabase.com/blog/supply-of-insulin-glargine 2016-02-22T10:34:32 https://maestrodatabase.com/blog/european-medicines-agency-validates-bristol-myers-squibbs-type-ii-variation-application-for-opdivo-nivolumab-in-previously-treated-advanced-renal-cell-carcinoma 2015-11-06T22:08:10 https://maestrodatabase.com/blog/sigma-backs-productivity-commissions-federal-pharmacy-review 2016-07-28T21:32:26 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-ends-assessment-of-canakinumab-for-atherosclerosis 2018-10-24T19:43:56 https://maestrodatabase.com/blog/european-commission-approves-eliquis-apixaban-for-the-treatment-of-deep-vein-thrombosis-dvt-and-pulmonary-embolism-pe-and-prevention-of-recurrent-dvt-and-pe 2015-08-05T11:37:18 https://maestrodatabase.com/blog/fda-approves-baxters-rixubis-coagulation-factor-ix-recombinant-for-treatment-of-children-with-hemophilia-b 2015-08-05T11:37:21 https://maestrodatabase.com/blog/systematic-reviews-of-economic-evaluations-in-health-technology-assessment-a-review-of-characteristics-and-applied-methods 2018-10-24T20:15:58 https://maestrodatabase.com/blog/shire-announces-fda-acceptance-for-filing-with-priority-review-of-supplemental-new-drug-application-snda-for-vyvanse-lisdexamfetamine-dimesylate-capsules-for-adults-with-binge-eating-disorder 2015-08-05T11:37:30 https://maestrodatabase.com/blog/ema-chmp-adopts-positive-opinion-recommending-authorisation-for-the-use-of-modernas-omicron-targeting-bivalent-booster-in-the-european-union 2022-09-01T20:57:20 https://maestrodatabase.com/blog/novartis-announces-that-xolair-is-approved-in-canada-as-a-licensed-therapy-for-chronic-idiopathic-urticaria-patients-unresponsive-to-antihistamines 2015-08-05T11:37:15 https://maestrodatabase.com/blog/final_pbac_outcome_for_taliglucerase_alfa__elelyso_ 2015-08-05T11:37:15 https://maestrodatabase.com/blog/roche-ceo-slams-stupid-uk-decision-to-drop-some-cancer-drugs 2015-09-08T19:44:10 https://maestrodatabase.com/blog/amgen-cuts-price-of-cholesterol-drug-by-almost-60-percent-echoing-rivals-move 2018-10-24T20:10:00 https://maestrodatabase.com/blog/shire-submits-nda-to-fda-for-new-formulation-of-vyvanse-lisdexamphetamine-dimesylate-cii-as-chewable-tablets 2016-04-19T20:37:48 https://maestrodatabase.com/blog/covid-19-vaccine-available-in-march 2024-02-22T00:25:20 https://maestrodatabase.com/blog/simeprevir-in-hepatitis-c-additional-benefit-in-certain-patients 2015-08-05T11:37:03 https://maestrodatabase.com/blog/nova-scotia-funds-treatment-with-aubagio-for-relapsing-remitting-multiple-sclerosis 2015-08-05T11:37:08 https://maestrodatabase.com/blog/proposal-to-list-nitrolingual-pump-spray-glyceryl-trinitrate-oral-spray-and-azamun-azathioprine-tablets 2015-08-05T11:37:30 https://maestrodatabase.com/blog/sipuleucel-t-in-prostate-cancer-indication-of-added-benefit 2015-08-05T11:37:22 https://maestrodatabase.com/blog/first-treatment-to-target-heart-condition-set-to-benefit-thousands-as-nice-draft-guidance-approves-nhs-use 2023-06-02T08:57:39 https://maestrodatabase.com/blog/viacoram-now-approved-in-canada-as-a-new-first-line-treatment-in-hypertension 2016-02-01T06:53:46 https://maestrodatabase.com/blog/facilitating-the-development-of-advanced-therapies 2015-08-05T11:37:18 https://maestrodatabase.com/blog/state-regulators-probe-cvs-price-fluctuations 2018-10-24T20:23:17 https://maestrodatabase.com/blog/lawmakers-candidates-target-high-drug-prices 2015-11-16T19:36:43 https://maestrodatabase.com/blog/nice-asks-for-further-evidence-for-the-benefits-of-a-new-treatment-for-duchenne-muscular-dystrophy-to-justify-its-very-high-cost 2015-10-16T19:36:25 https://maestrodatabase.com/blog/reimbursing-wisely-cmss-trial-of-medicare-part-b-drug-payment-reform 2016-06-01T23:26:37 https://maestrodatabase.com/blog/tepmetko-tepotinib-receives-positive-chmp-opinion-for-patients-with-advanced-nsclc-with-metex14-skipping-alterations 2021-12-18T04:58:44 https://maestrodatabase.com/blog/nice_gives_green_light_to_treatment_for_wet_amd_in_final_draft_guidance 2015-08-05T11:37:10 https://maestrodatabase.com/blog/no-additional-benefit-for-umeclidiniumvilanterol-in-copd 2015-08-05T11:37:05 https://maestrodatabase.com/blog/allergan-and-adamas-announce-new-expanded-indication-for-namzaric-memantine-and-donepezil-hydrochlorides-extended-release-for-the-treatment-of-moderate-to-severe-alzheimers-disease 2016-07-20T21:39:26 https://maestrodatabase.com/blog/astellas-and-seagen-receive-positive-chmp-opinion-for-padcev-enfortumab-vedotin-in-locally-advanced-or-metastatic-urothelial-cancer 2021-12-18T05:07:55 https://maestrodatabase.com/blog/nice_has_recommended_the_use_of_jetrea__ocriplasmin__for_certain_patients_with_vitreomacular_traction 2015-08-05T11:37:07 https://maestrodatabase.com/blog/eisai-announces-fda-approval-of-fycompa-perampanel-oral-suspension-for-adjunctive-therapy-in-the-treatment-of-partial-onset-seizures-and-primary-generalized-tonic-clonic-seizures 2016-05-03T21:40:24 https://maestrodatabase.com/blog/sanofi-and-regeneron-announce-sarilumab-biologics-license-application-accepted-for-review-by-us-fda 2016-01-08T20:17:44 https://maestrodatabase.com/blog/novartis_pharmaceuticals_canada_inc__receives_health_canada_approval_for_ilaris_in_active_systemic_juvenile_idiopathic_arthritis__a_serious_form_of_rare_childhood_arthritis 2015-08-05T11:37:17 https://maestrodatabase.com/blog/1500-new-zealanders-access-a-cure-for-hepatitis-c 2019-05-28T03:55:40 https://maestrodatabase.com/blog/pharmaceutical-benefits-scheme-becoming-unsustainable-says-senate-committee 2015-09-21T12:42:44 https://maestrodatabase.com/blog/7-out-of-10-koreans-want-cheaper-drug-with-same-ingredient 2021-05-27T11:19:24 https://maestrodatabase.com/blog/drug-recommended-to-help-cut-drink-dependence 2015-08-05T11:37:11 https://maestrodatabase.com/blog/us-fda-expands-indication-for-type-2-diabetes-treatment-synjardy-empagliflozinmetformin-hydrochloride-to-include-treatment-naïve-adults 2016-07-19T12:25:27 https://maestrodatabase.com/blog/nice-publishes-appraisal-consultation-for-osimertinib-mesylata-tagrisso-for-patients-with-non-small-cell-lung-cancer 2016-06-24T22:37:10 https://maestrodatabase.com/blog/coherus-announces-industry-wide-lowest-list-price-for-adalimumab-biosimilar-yusimry-adalimumab-aqvh-launching-in-july-2023 2023-06-02T23:10:44 https://maestrodatabase.com/blog/amgens-bite-immunotherapy-blinatumomab-receives-fda-priority-review-designation-in-acute-lymphoblastic-leukaemia 2015-08-05T11:37:30 https://maestrodatabase.com/blog/lantheus-receives-u-dot-s-fda-approval-of-pylarify-piflufolastat-f-18-injection-the-first-and-only-commercially-available-psma-pet-imaging-agent-for-prostate-cancer 2021-05-27T12:32:44 https://maestrodatabase.com/blog/allergan-receives-positive-opinion-for-truberzi-eluxadoline-for-treatment-of-irritable-bowel-syndrome-with-diarrhoea-ibs-d-in-adults 2016-07-26T10:01:09 https://maestrodatabase.com/blog/santhera-submits-marketing-authorisation-application-to-the-european-medicines-agency-for-puldysa-idebenone-in-duchenne-muscular-dystrophy 2019-05-28T03:44:54 https://maestrodatabase.com/blog/health-officials-under-attack-over-pbs-deal 2015-08-30T02:53:39 https://maestrodatabase.com/blog/anticancer-drug-should-extend-life-for-22-months-to-get-insurance-benefits 2021-05-27T11:25:38 https://maestrodatabase.com/blog/shires-investigational-shp609-idursulfase-it-receives-fda-fast-track-designation-for-the-treatment-of-neurocognitive-decline-associated-with-hunter-syndrome 2015-08-05T11:37:08 https://maestrodatabase.com/blog/why-is-getting-the-abortion-pill-to-women-such-a-complicated-thing 2016-09-27T11:15:02 https://maestrodatabase.com/blog/post-market-review-of-products-used-for-diabetes-management 2015-08-05T11:37:10 https://maestrodatabase.com/blog/bc-pharmacares-biosimilars-initiative-an-important-step-towards-improving-patient-access-to-safe-and-effective-medicines 2019-05-28T05:06:53 https://maestrodatabase.com/blog/orphazymes-arimoclomol-receives-us-fast-track-designation-in-amyotrophic-lateral-sclerosis 2020-05-23T02:05:04 https://maestrodatabase.com/blog/publication-of-clinical-reports 2015-08-05T11:37:28 https://maestrodatabase.com/blog/tga-advice-on-2016-seasonal-influenza-vaccines 2016-04-08T12:05:50 https://maestrodatabase.com/blog/pharmac-head-defends-drug-agencys-funding 2019-05-28T03:59:25 https://maestrodatabase.com/blog/eisai-bewildered-as-german-institute-for-quality-and-efficiency-in-health-care-iqwig-fails-to-recognise-additional-benefit-of-halaven-eribulin-in-the-treatment-of-advanced-liposarcoma 2016-09-05T05:01:14 https://maestrodatabase.com/blog/foresee-pharmaceuticals-announces-fda-approval-of-camcevi-for-the-treatment-of-advanced-prostate-cancer-accord-biopharma-to-head-the-u-dot-s-commercialisation 2021-05-27T10:47:38 https://maestrodatabase.com/blog/fda-approves-new-type-of-sleep-drug-belsomra 2015-08-05T11:37:19 https://maestrodatabase.com/blog/knockoffs-of-biotech-drugs-bring-paltry-savings 2016-05-07T01:44:40 https://maestrodatabase.com/blog/express-scripts-and-cvs-health-cut-ties-with-a-pharmacy-linked-to-valeant 2015-10-30T08:24:55 https://maestrodatabase.com/blog/australia-breaks-with-biologic-prescribers-other-regulators-on-biosimilar-substitution 2015-08-05T11:37:23 https://maestrodatabase.com/blog/fda-approves-biohavens-nurtec-odt-rimegepant-for-prevention-now-the-first-and-only-migraine-medication-for-both-acute-and-preventive-treatment 2021-05-27T20:50:45 https://maestrodatabase.com/blog/the-european-medicines-agency-is-still-too-close-to-industry 2016-05-11T07:45:01 https://maestrodatabase.com/blog/cadth-issues-initial-perc-outcome-for-lynparza-olaparib 2016-08-12T23:42:19 https://maestrodatabase.com/blog/teva-receives-chmp-positive-opinion-for-cinqaero-reslizumab 2016-06-26T07:59:44 https://maestrodatabase.com/blog/democrats-promised-to-lower-drug-prices-but-plans-are-sputtering 2021-05-27T20:57:41 https://maestrodatabase.com/blog/tpp-a-missed-opportunity-for-the-australian-biopharmaceutical-community 2015-10-06T06:02:06 https://maestrodatabase.com/blog/fda-accepts-for-filing-supplemental-biologics-license-application-for-xeomin-incobotulinumtoxina-in-adult-patients-with-sialorrhoea 2018-03-15T10:47:09 https://maestrodatabase.com/blog/canadian-biosimilars-forum-applauds-b-dot-c-governments-landmark-decision-to-enhance-adoption-of-biosimilars-and-calls-on-remaining-provinces-to-follow 2019-05-28T05:49:58 https://maestrodatabase.com/blog/kaitaia-womans-medical-win 2016-02-17T19:24:20 https://maestrodatabase.com/blog/dusc-utilisation-analysis-public-release-documents-april-2025 2025-10-10T03:33:06 https://maestrodatabase.com/blog/pfizer-ceo-says-clinton-plan-to-curb-drug-prices-would-hurt-consumers 2016-09-08T21:19:21 https://maestrodatabase.com/blog/fda-grants-micro-interventional-devices-breakthrough-device-designation-for-the-mia-t-percutaneous-tricuspid-annuloplasty-system 2021-05-27T20:43:23 https://maestrodatabase.com/blog/us-fda-approves-synjardy-empagliflozinmetformin-hydrochloride-tablets-for-adults-with-type-2-diabetes-mellitus 2015-08-27T21:35:15 https://maestrodatabase.com/blog/regeneron-and-sanofi-announce-unitedhealth-group-selects-praluent-alirocumab-injection-for-preferred-access 2015-12-13T20:44:51 https://maestrodatabase.com/blog/fda-accepts-nda-for-bis-copd-combination 2015-08-05T11:37:18 https://maestrodatabase.com/blog/what-glaxosmithkline-ceo-andrew-witty-doesnt-get-about-drug-pricing 2016-03-23T02:03:21 https://maestrodatabase.com/blog/nice-recommends-serviers-lonsurf-trifluridine-with-tipiracil-hydrochloride 2016-08-25T05:01:55 https://maestrodatabase.com/blog/pharmac-publishes-indicative-agenda-for-may-2018-ptac-meeting 2018-03-15T11:06:27 https://maestrodatabase.com/blog/agenda-for-the-july-2016-pbac-meeting 2016-04-28T12:37:14 https://maestrodatabase.com/blog/nasp-applauds-the-introduction-of-bipartisan-legislation-to-reduce-drug-costs-and-support-medication-access-for-seniors-with-life-threatening-specialised-conditions 2021-05-27T21:14:32 https://maestrodatabase.com/blog/february_2014_tender_notification 2015-08-05T11:37:05 https://maestrodatabase.com/blog/the-inexplicable-and-relentless-rise-of-cancer-drug-prices 2016-05-02T22:45:39 https://maestrodatabase.com/blog/alemtuzumab__lemtrada____nice_says_yes_in_final_draft_guidance 2015-08-05T11:37:02 https://maestrodatabase.com/blog/drug_provides_new_hope_for_rare_lung_disease__but_cost_still_not_covered_in_canada 2015-08-05T11:37:27 https://maestrodatabase.com/blog/amazon-looking-at-opening-pharmacy-stores-in-us 2021-05-27T21:25:01 https://maestrodatabase.com/blog/fda-issues-complete-response-letter-for-digital-medicine-new-drug-application 2016-04-27T12:14:07 https://maestrodatabase.com/blog/ireland-an-outlier-without-access-to-new-cell-and-gene-therapy-report-says 2021-05-27T21:00:08 https://maestrodatabase.com/blog/former-republican-henry-waxman-says-lawmakers-derelict-if-they-dont-address-drug-prices 2018-03-15T20:23:40 https://maestrodatabase.com/blog/australian-first-website-to-connect-more-patients-with-clinical-trials 2015-08-05T11:37:30 https://maestrodatabase.com/blog/icer-finds-emicizumab-reduces-treatment-cost-while-improving-health-of-people-with-haemophilia-a 2018-03-15T20:26:13 https://maestrodatabase.com/blog/call-for-patient-input-on-a-submission-from-ferring-pharmaceuticals-for-budesonide 2016-04-26T20:33:19 https://maestrodatabase.com/blog/abbvie-prices-hepatitis-c-drug-12-below-gilead-rival 2015-08-05T11:37:28 https://maestrodatabase.com/blog/decision-to-open-list-montelukast-tablets 2018-03-15T11:14:02 https://maestrodatabase.com/blog/nice_unable_to_give_the_go_ahead_to_new_prostate_cancer_drug_in_preliminary_recommendations 2015-08-05T11:37:08 https://maestrodatabase.com/blog/nice-medtech-early-technical-assessment-tool-to-form-part-of-government-grant-application-process-for-health-care-product-developers 2018-03-15T20:14:38 https://maestrodatabase.com/blog/insufficient-data-on-use-of-inhaled-corticosteroids-to-treat-covid-19 2021-05-27T21:08:30 https://maestrodatabase.com/blog/behind_the_headlines___will_elderly_patients_miss_out_on_new_drugs_ 2015-08-05T11:37:14 https://maestrodatabase.com/blog/pfizer-receives-european-approval-to-expand-use-of-xalkori-crizotinib-to-first-line-treatment-of-adults-with-alk-positive-advanced-non-small-cell-lung-cancer 2015-11-25T20:56:01 https://maestrodatabase.com/blog/roches-marketing-applications-for-review-of-ocrevus-ocrelizumab-in-two-forms-of-multiple-sclerosis-accepted-by-ema-and-fda 2016-06-28T12:40:38 https://maestrodatabase.com/blog/janssen-announces-u-dot-s-fda-breakthrough-therapy-designation-for-erdafitinib-in-the-treatment-of-metastatic-urothelial-cancer 2018-03-15T20:37:12 https://maestrodatabase.com/blog/mps-find-no-evidence-that-cancer-drugs-fund-was-spent-wisely 2016-02-10T08:26:53 https://maestrodatabase.com/blog/u-dot-s-fda-approves-takedas-alunbrig-brigatinib-as-a-first-line-treatment-option-for-patients-diagnosed-with-rare-and-serious-form-of-lung-cance 2020-05-23T03:34:04 https://maestrodatabase.com/blog/delay-in-nhs-patients-access-to-cancer-drug-opdivo-labelled-a-disgrace 2015-08-10T05:34:49 https://maestrodatabase.com/blog/us-food-and-drug-administration-accepts-supplemental-biologics-license-application-for-opdivo-nivolumab-in-previously-treated-non-squamous-non-small-cell-lung-cancer-patients 2015-09-02T20:19:32 https://maestrodatabase.com/blog/post-market-review-of-opiate-dependence-treatment-program-medicines 2021-05-28T03:29:19 https://maestrodatabase.com/blog/the_just_price_of_cancer_drugs_and_the_growing_cost_of_cancer_care__oncologists_need_to_be_part_of_the_solution 2015-08-05T11:37:03 https://maestrodatabase.com/blog/us-fda-grants-breakthrough-therapy-designation-for-roches-investigational-medicine-ocrelizumab-in-primary-progressive-multiple-sclerosis 2016-02-17T11:06:39 https://maestrodatabase.com/blog/product-withdrawn-after-overseas-reports-of-inflammatory-brain-disorders 2018-03-15T20:50:45 https://maestrodatabase.com/blog/fda-approves-first-targeted-therapy-to-treat-patients-with-painful-complication-of-sickle-cell-disease 2019-11-15T21:51:48 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule-1-august-2016-update 2016-07-31T01:04:41 https://maestrodatabase.com/blog/ailing-obama-health-care-act-may-have-to-change-to-survive 2016-10-03T08:51:06 https://maestrodatabase.com/blog/nice-adoption-resource-on-the-use-of-biosimilars 2015-08-30T06:27:51 https://maestrodatabase.com/blog/saving_ashley__what_price_a_life_ 2015-08-05T11:37:04 https://maestrodatabase.com/blog/fdas-generic-drug-labelling-rule-delayed-again 2017-08-06T11:53:22 https://maestrodatabase.com/blog/roche_blasts_u_k__drug_watchdogs_for_limiting_use_of_tarceva_in_lung_cancer 2015-08-05T11:37:15 https://maestrodatabase.com/blog/pharmacare-and-the-chaotic-world-of-canadian-drug-prices 2018-03-15T20:45:04 https://maestrodatabase.com/blog/u-dot-s-fda-approves-evofem-biosciences-phexxi-lactic-acid-citric-acid-and-potassium-bitartrate-the-first-and-only-non-hormonal-prescription-gel-for-the-prevention-of-pregnancy 2020-05-23T03:23:40 https://maestrodatabase.com/blog/amag-pharmaceuticals-receives-complete-response-letter-from-fda-for-the-single-dose-vial-of-makena-hydroxyprogesterone-caproate-injection 2015-08-05T11:37:09 https://maestrodatabase.com/blog/gene-therapy-cure-has-money-back-guarantee 2016-08-09T11:48:06 https://maestrodatabase.com/blog/dutch-authorities-hand-over-final-building-to-ema-in-amsterdam 2019-11-15T21:57:22 https://maestrodatabase.com/blog/european-medicines-agency-accepts-samsung-bioepis-enbrel-biosimilar-candidate-sb4-for-regulatory-review 2015-08-05T11:37:08 https://maestrodatabase.com/blog/call-for-patient-input-27 2015-08-05T11:37:18 https://maestrodatabase.com/blog/tga-publishes-auspar-for-simoctocog-alfa-rhu-nuwiq 2016-06-17T11:39:25 https://maestrodatabase.com/blog/medical-research-future-fund-will-improve-australias-competitiveness-in-world-class-innovation 2015-08-05T11:37:04 https://maestrodatabase.com/blog/nice-gives-green-light-to-two-eye-treatments-for-treating-serious-eye-condition 2015-08-05T11:37:28 https://maestrodatabase.com/blog/perc_has_recommended_the_use_of_revlimid__lenalidomide__for_patients_with_newly_diagnosed_multiple_myeloma 2015-08-05T11:37:30 https://maestrodatabase.com/blog/uks-mhra-revokes-authorisation-for-novartis-sickle-cell-drug 2024-02-22T02:53:40 https://maestrodatabase.com/blog/health-canada-issues-a-notice-of-compliance-for-simponi-as-the-first-and-only-treatment-indicated-for-non-radiographic-axial-spondyloarthritis 2016-06-24T05:29:31 https://maestrodatabase.com/blog/controversial-cdf-revamp-launches 2016-07-30T00:57:06 https://maestrodatabase.com/blog/response-to-feedback-discussion-document-on-pharmacs-proposed-approach-to-managing-hospital-medical-devices 2015-08-05T11:37:14 https://maestrodatabase.com/blog/new_nhs_drugs__to_create__50m_black_hole_ 2015-08-05T11:37:14 https://maestrodatabase.com/blog/aptinyx-receives-fda-fast-track-designation-for-development-of-nyx-2925-as-treatment-for-neuropathic-pain-associated-with-diabetic-peripheral-neuropathy 2016-09-13T21:38:24 https://maestrodatabase.com/blog/highlights-from-the-chmp-11-14-november-2019-meeting 2019-11-15T22:00:24 https://maestrodatabase.com/blog/gsk-chief-says-pressure-on-us-drug-prices-to-rise 2016-04-27T21:32:15 https://maestrodatabase.com/blog/ema-publishes-epar-for-empliciti-elotuzumab 2016-05-19T21:04:39 https://maestrodatabase.com/blog/extrapolation-of-data-from-adults-to-children-can-facilitate-development-of-paediatric-medicines 2016-04-04T20:39:11 https://maestrodatabase.com/blog/busy-dad-with-leukaemia-getting-outdated-treatment 2024-02-22T20:20:00 https://maestrodatabase.com/blog/novo-nordisk-receives-health-canada-approval-for-saxenda-liraglutide-for-the-treatment-of-chronic-weight-management 2015-08-05T11:37:06 https://maestrodatabase.com/blog/medibank-calls-for-patient-consent-fee-disclosure 2017-08-06T21:04:03 https://maestrodatabase.com/blog/fda-approves-shires-xiidra-lifitegrast-5-ophthalmic-solution-the-only-treatment-indicated-for-the-signs-and-symptoms-of-dry-eye-disease 2016-07-12T10:20:29 https://maestrodatabase.com/blog/a-cancer-doctors-view-of-why-reform-of-pharmac-is-vital 2024-02-22T20:16:10 https://maestrodatabase.com/blog/sandoz-advances-its-biosimilars-program-with-european-medicines-agency-ema-acceptance-of-regulatory-submission-for-biosimilar-etanercept 2015-12-08T07:21:49 https://maestrodatabase.com/blog/public-scrutiny-mooted-for-private-hospitals 2017-08-06T21:00:32 https://maestrodatabase.com/blog/eu-green-light-for-lillys-lung-cancer-drug-portrazza 2016-02-24T08:09:03 https://maestrodatabase.com/blog/up-to-14-000-people-could-benefit-from-the-first-treatment-for-severe-alopecia-recommended-by-nice 2024-02-22T20:11:11 https://maestrodatabase.com/blog/breakthrough-status-for-bis-pradaxa-antidote 2015-08-05T11:37:10 https://maestrodatabase.com/blog/fda-accepts-mercks-nda-for-fixed-dose-combination-of-raltegravir-with-lamivudine 2015-08-05T11:37:24 https://maestrodatabase.com/blog/nice-issues-draft-guidance-on-almiralls-skilarence-for-psoriasis 2017-08-06T21:10:16 https://maestrodatabase.com/blog/nice-tackles-complex-health-issues-for-people-with-multimorbidity 2016-03-31T10:45:22 https://maestrodatabase.com/blog/why-adding-prices-to-tv-drug-ads-is-bad-for-patients 2019-05-28T11:38:16 https://maestrodatabase.com/blog/pharmas-allege-government-communication-breakdown-in-medicine-deferral-crisis 2024-11-11T02:39:31 https://maestrodatabase.com/blog/regulatory-submission-for-sandoz-proposed-biosimilar-pegfilgrastim-accepted-by-the-fda 2015-11-18T06:31:18 https://maestrodatabase.com/blog/overall-survival-for-oncology-drugs-approved-for-genomic-indications 2021-12-18T06:25:38 https://maestrodatabase.com/blog/terminally-ill-patients-despair-amid-price-war-over-car-t-cancer-therapy 2024-02-22T04:59:07 https://maestrodatabase.com/blog/necitumumab-in-nsclc-small-additional-benefit-for-patients-with-metastases 2016-07-02T03:43:21 https://maestrodatabase.com/blog/who-agrees-watered-down-resolution-on-transparency-in-drug-costs 2019-05-28T11:36:08 https://maestrodatabase.com/blog/progress-and-collaboration-on-clinical-trials 2016-01-27T22:35:16 https://maestrodatabase.com/blog/tga-publishes-auspar-for-xolair 2016-06-27T13:20:14 https://maestrodatabase.com/blog/feilding-woman-nervous-about-pharmacs-decision-to-change-epilepsy-medication-brands 2019-05-28T11:33:13 https://maestrodatabase.com/blog/bristol-myers-squibbs-immunotherapy-opdivo-nivolumab-approved-by-health-canada-for-the-treatment-of-previously-untreated-braf-v600-wild-type-metastatic-melanoma 2015-09-28T05:13:25 https://maestrodatabase.com/blog/world-leading-approach-to-protect-babies-from-rsv 2024-11-11T20:11:27 https://maestrodatabase.com/blog/insights-from-the-pbac-july-2016-meeting 2016-08-21T09:22:58 https://maestrodatabase.com/blog/new-treatment-for-sickle-cell-disease 2021-12-18T06:41:28 https://maestrodatabase.com/blog/cost-of-life-under-microscope-as-new-cancer-drug-on-wait-list 2015-08-05T11:37:09 https://maestrodatabase.com/blog/nice_consults_again_on_decision_to_recommend_new_prostate_cancer_drug 2015-08-05T11:37:14 https://maestrodatabase.com/blog/nice-recommends-jevtana-cabazitaxel-for-prostate-cancer 2016-04-22T10:59:59 https://maestrodatabase.com/blog/nice-will-re-review-ferring-pharmaceuticals-firmagon-in-prostate-cancer-following-appeal 2015-08-05T11:37:16 https://maestrodatabase.com/blog/fda-approves-farydak-for-treatment-of-multiple-myeloma 2015-08-05T11:37:05 https://maestrodatabase.com/blog/fda-approves-drug-to-treat-sickle-cell-disease-in-patients-aged-4-up-to-11-years 2021-12-18T08:16:55 https://maestrodatabase.com/blog/novartis-announces-fda-approval-for-jadenu-to-simplify-treatment-administration-for-patients-with-chronic-iron-overload 2015-08-05T11:37:02 https://maestrodatabase.com/blog/novartis-gains-fda-approval-for-signifor-lar-to-treat-patients-with-acromegaly-a-rare-and-life-threatening-hormonal-disorder 2015-08-05T11:37:06 https://maestrodatabase.com/blog/icers-assessment-highlights-the-risk-benefit-tradeoffs-of-investigational-treatments-for-peanut-allergy 2019-05-28T20:51:46 https://maestrodatabase.com/blog/icer-releases-addendum-to-draft-scoping-document-for-ms-review 2016-07-18T21:32:59 https://maestrodatabase.com/blog/new_agreement_provides_new_medicines__saves_millions 2015-08-05T11:37:16 https://maestrodatabase.com/blog/tga-approves-new-medication-for-treatment-of-endometriosis-symptoms 2024-02-22T20:33:24 https://maestrodatabase.com/blog/medicare-projects-relatively-stable-average-prescription-drug-premiums-in-2017 2016-07-31T22:59:33 https://maestrodatabase.com/blog/aflibercept-in-macular-oedema-after-branch-retinal-vein-occlusion-no-hint-of-added-benefit 2015-08-05T11:37:16 https://maestrodatabase.com/blog/why-government-patent-use-to-lower-drug-costs-wont-stifle-innovation 2016-07-30T01:23:59 https://maestrodatabase.com/blog/insulin-prices-were-capped-for-millions-but-many-still-struggle-to-afford-to-life-saving-medication 2024-02-22T20:25:32 https://maestrodatabase.com/blog/drug-trials-snapshots-uptravi 2016-01-27T20:47:48 https://maestrodatabase.com/blog/allergan-and-gedeon-richter-receive-u-dot-s-fda-approval-for-expanded-use-of-vraylar-cariprazine-in-the-treatment-of-bipolar-depression 2019-05-28T21:05:06 https://maestrodatabase.com/blog/artiva-biotherapeutics-receives-fda-fast-track-designation-for-allonk-in-lupus-nephritis 2024-02-22T23:09:55 https://maestrodatabase.com/blog/biosimilar-makers-lose-second-shot-at-shortening-biologics-exclusivity 2016-07-06T21:33:14 https://maestrodatabase.com/blog/us-fda-grants-priority-review-for-daklinza-daclatasvir-sndas 2015-10-06T18:16:30 https://maestrodatabase.com/blog/terminal-brain-cancer-patient-shares-painful-health-insurance-lesson-as-more-aussies-ditch-cover 2019-05-28T21:02:25 https://maestrodatabase.com/blog/state-election-2015-liberals-unveil-plan-for-no-gap-drugs-for-the-chronically-ill 2015-08-05T11:37:12 https://maestrodatabase.com/blog/charlie-teo-brain-surgeon-defends-six-figure-op-costs 2019-05-29T08:30:04 https://maestrodatabase.com/blog/lilly-receives-positive-chmp-opinion-for-ixekizumab-for-the-treatment-of-moderate-to-severe-plaque-psoriasis 2016-02-26T21:40:29 https://maestrodatabase.com/blog/america-will-struggle-to-pay-for-ultra-expensive-gene-therapies 2023-06-03T01:16:37 https://maestrodatabase.com/blog/bevespi-aerosphere-approved-by-the-us-fda-for-patients-with-copd 2016-04-26T06:13:22 https://maestrodatabase.com/blog/pbs_mobile_website 2015-08-05T11:37:24 https://maestrodatabase.com/blog/fda-approves-new-formulation-of-minocin-minocycline-for-injection 2015-08-05T11:37:13 https://maestrodatabase.com/blog/uk-refuses-to-back-game-changing-resolution-on-drug-pricing 2019-05-28T21:21:52 https://maestrodatabase.com/blog/bluebird-bio-announces-fda-priority-review-of-biologics-license-application-for-eli-cel-gene-therapy-for-cerebral-adrenoleukodystrophy-in-patients-without-a-matched-sibling-donor 2021-12-18T08:25:38 https://maestrodatabase.com/blog/proposal-for-various-pharmaceuticals 2015-08-05T11:37:26 https://maestrodatabase.com/blog/assessment-of-the-clinical-benefit-of-cancer-drugs-receiving-accelerated-approval 2019-05-28T21:13:34 https://maestrodatabase.com/blog/celator-pharmaceuticals-announces-vyxeos-granted-breakthrough-therapy-designation 2016-05-20T12:32:34 https://maestrodatabase.com/blog/two-new-appointments-to-pharmac-advisory-committee 2015-08-05T11:37:29 https://maestrodatabase.com/blog/consultation-open-on-pembrolizumab-funding 2016-06-29T02:02:21 https://maestrodatabase.com/blog/drug-prices-keep-rising-despite-intense-criticism 2016-04-26T20:48:51 https://maestrodatabase.com/blog/us-fda-grants-priority-to-abbvie-for-investigational-all-oral-interferon-free-therapy-for-the-treatment-of-genotype--4-chronic-hepatitis-c 2015-08-05T11:37:02 https://maestrodatabase.com/blog/recommendations-on-eligibility-to-prime-scheme 2016-09-21T13:18:09 https://maestrodatabase.com/blog/avidity-biosciences-receives-fda-rare-paediatric-disease-designation-for-aoc-1044-for-treatment-of-duchenne-muscular-dystrophy-in-people-with-mutations-amenable-to-exon-44-skipping 2024-02-22T23:29:52 https://maestrodatabase.com/blog/a-2-dollars-1-cents-million-drug-price-record-is-made-to-be-broken 2019-05-28T21:28:22 https://maestrodatabase.com/blog/novartis-receives-fda-fast-track-designation-for-sabatolimab-mbg453-in-myelodysplastic-syndromes 2021-05-28T04:24:50 https://maestrodatabase.com/blog/submissions-to-the-pbac-in-dwindling-supply 2016-05-01T00:57:20 https://maestrodatabase.com/blog/nice-says-no-to-daclizumab-zinbryta 2016-10-03T20:22:04 https://maestrodatabase.com/blog/german_proposal_to_report_drug_prices_has_roche_concerned 2015-08-05T11:37:28 https://maestrodatabase.com/blog/pbac-public-summary-documents---november-2014 2015-08-05T11:37:07 https://maestrodatabase.com/blog/the-hidden-formula-that-determines-how-much-you-pay-for-drugs 2019-05-28T21:23:56 https://maestrodatabase.com/blog/cadth-recommends-reimbursement-of-revestive 2016-07-30T01:52:43 https://maestrodatabase.com/blog/harvard-pilgrim-signs-value-based-contract-with-eli-lilly-for-trulicity 2016-06-28T21:41:55 https://maestrodatabase.com/blog/big-karma-hits-big-pharma-as-biotech-shares-plunge-after-price-gouging-accusations 2015-12-02T19:54:18 https://maestrodatabase.com/blog/simplified-price-disclosure 2015-08-05T11:37:10 https://maestrodatabase.com/blog/nice-appraisal-consultation-for-mepolizumab-nucala-for-patients-with-severe-eosinophilic-asthma 2016-04-08T11:45:51 https://maestrodatabase.com/blog/fda-releases-online-continuing-education-course-on-biosimilars 2016-02-24T20:41:16 https://maestrodatabase.com/blog/santhera-receives-european-marketing-authorisation-for-raxone-in-lebers-hereditary-optic-neuropathy-lhon 2015-09-10T05:30:23 https://maestrodatabase.com/blog/nice-to-advise-firms-on-how-to-speed-up-nhs-adoption-of-their-drugs 2015-08-05T11:37:18 https://maestrodatabase.com/blog/insulin-degludec-with-liraglutide-no-hint-of-an-additional-benefit-in-type-2-diabetes-mellitus-says-iqwig 2015-08-12T12:29:39 https://maestrodatabase.com/blog/germany_s_federal_joint_committee__g_ba__has_issued_its_final_benefit_assessment_report_for_pixuvri__pixantrone_ 2015-08-05T11:37:06 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits-update---1-september-2014 2015-08-05T11:37:21 https://maestrodatabase.com/blog/mylan-coming-under-increasing-pressure-to-review-price-of-epi-pen 2016-08-19T21:54:47 https://maestrodatabase.com/blog/toward-a-new-era-of-trust-and-transparency-in-clinical-trials 2016-09-16T23:42:42 https://maestrodatabase.com/blog/hepatitis-c-call-to-include-cures-on-pharmaceutical-benefits-scheme 2015-09-30T03:22:20 https://maestrodatabase.com/blog/daratumumab-receives-breakthrough-therapy-designation-from-us-food-and-drug-administration-in-combination-with-standard-of-care-regimens-for-previously-treated-multiple-myeloma 2016-07-26T08:50:44 https://maestrodatabase.com/blog/cms-finalizes-2017-payment-and-policy-updates-for-medicare-health-and-drug-plans 2016-04-05T07:54:16 https://maestrodatabase.com/blog/how-aligned-are-the-perspectives-of-eu-regulators-and-hta-bodies-a-comparative-analysis-of-regulatory-hta-parallel-scientific-advice 2016-09-10T04:14:41 https://maestrodatabase.com/blog/delivering-commercial-success-from-university-research-must-involve-the-innovative-research-based-medicines-industry 2015-08-05T11:37:04 https://maestrodatabase.com/blog/pbac-generic-medicines-working-group-work-plans 2016-04-21T05:46:28 https://maestrodatabase.com/blog/the-bottom-line 2016-07-08T23:22:48 https://maestrodatabase.com/blog/heart-patient-edgar-newman-living-proof-of-rorted-system 2016-09-24T03:05:59 https://maestrodatabase.com/blog/ema-publishes-assessment-report-for-vokanamet 2015-08-05T11:37:09 https://maestrodatabase.com/blog/xydalba-dalbavancin-receives-chmp-positive-opinion-for-the-treatment-of-acute-bacterial-skin-and-skin-structure-infections-absssi-in-adults 2015-08-05T11:37:20 https://maestrodatabase.com/blog/nice-recommends-another-new-treatment-for-lung-cancer 2015-08-05T11:37:16 https://maestrodatabase.com/blog/submissions-open-for-the-life-saving-drugs-programme-post-market-review-issues-paper 2015-08-05T11:37:21 https://maestrodatabase.com/blog/budget-2015-generic-drug-prices-expected-to-fall-as-government-redirects-health-spending 2015-08-05T11:37:10 https://maestrodatabase.com/blog/european-commission-grants-marketing-authorization-for-gileads-epclusa-sofosbuvirvelpatasvir-for-the-treatment-of-all-genotypes-of-chronic-hepatitis-c 2016-07-08T21:31:52 https://maestrodatabase.com/blog/radium_ra223_dichloride_in_prostate_cancer__major_added_benefit_for_certain_patients 2015-08-05T11:37:18 https://maestrodatabase.com/blog/future-of-drug-pricing-paying-for-benefits-not-per-pill 2016-08-10T12:26:06 https://maestrodatabase.com/blog/merck-receives-fda-breakthrough-therapy-designation-for-keytruda-pembrolizumab-in-advanced-non-small-cell-lung-cancer 2015-08-05T11:37:14 https://maestrodatabase.com/blog/124-million-increase-over-four-years-for-investment-in-new-medicines 2016-05-04T03:31:58 https://maestrodatabase.com/blog/submissions-published-for-review-of-authority-required-pbs-listings 2015-08-05T11:37:06 https://maestrodatabase.com/blog/ipsen-announces-fda-approval-of-dysport-abobotulinumtoxina-for-injection-for-the-treatment-of-lower-limb-spasticity-in-children-aged-two-and-older 2016-08-02T05:18:57 https://maestrodatabase.com/blog/pharmaceutical-industry-gets-high-on-fat-profits 2015-08-05T11:37:22 https://maestrodatabase.com/blog/the-rise-and-fall-in-out-of-pocket-costs-in-australia-an-analysis-of-the-strengthening-medicare-reforms 2017-07-12T10:22:42 https://maestrodatabase.com/blog/to-fix-high-drug-prices-stop-the-merger-madness 2016-05-17T21:52:48 https://maestrodatabase.com/blog/most-provincial-drug-plans-wont-cover-abortion-pills-in-canada-1 2016-09-26T11:19:22 https://maestrodatabase.com/blog/agenda-for-21-march-tc-meeting 2018-03-15T22:55:55 https://maestrodatabase.com/blog/first-medicine-for-hiv-pre-exposure-prophylaxis-recommended-for-approval-in-the-eu 2016-07-22T12:06:06 https://maestrodatabase.com/blog/smc-announces-more-forthcoming-submissions-1 2015-12-21T20:18:27 https://maestrodatabase.com/blog/gilead-announces-us-fda-priority-review-designation-for-sofosbuvirvelpatasvir-for-treatment-of-all-genotypes-of-chronic-hepatitis-c-infection 2016-01-05T20:22:42 https://maestrodatabase.com/blog/cadth-calls-for-patient-input-on-a-new-submission-from-eli-lilly-for-basaglar 2015-09-04T23:47:27 https://maestrodatabase.com/blog/nice-oks-trio-of-new-drugs-for-nhs-use 2015-08-05T11:37:26 https://maestrodatabase.com/blog/pfizer-and-biontech-submit-supplemental-biologics-license-application-for-u-dot-s-fda-approval-of-comirnaty-in-adolescents-12-through-15-years-of-age 2021-12-18T20:58:06 https://maestrodatabase.com/blog/fda-approves-trulicity-to-treat-type-2-diabetes 2015-08-05T11:37:15 https://maestrodatabase.com/blog/access-to-medicines-working-group-amwg-communique---december-2014 2015-08-05T11:37:05 https://maestrodatabase.com/blog/marathon-pharmaceuticals-announces-submission-of-deflazacort-new-drug-application-to-the-fda 2016-06-15T21:26:58 https://maestrodatabase.com/blog/canadas-erc-rejects-zykadia-for-metastatic-non-small-cell-lung-cancer 2015-12-13T06:53:25 https://maestrodatabase.com/blog/ema-management-board-highlights-of-october-2014-meeting 2015-08-05T11:37:29 https://maestrodatabase.com/blog/us-fda-grants-priority-review-to-harmony-biosciences-application-for-wakix-pitolisant-in-paediatric-narcolepsy 2024-02-23T02:37:36 https://maestrodatabase.com/blog/every-silver-lining-has-a-cloud 2015-10-08T20:22:44 https://maestrodatabase.com/blog/updated-agenda-for-the-november-2022-pbac-meeting 2022-09-02T04:50:20 https://maestrodatabase.com/blog/new_zealand_pharmaceutical_schedule___april_2014_update 2015-08-05T11:37:14 https://maestrodatabase.com/blog/nice-turns-down-childhood-neuroblastoma-drug 2015-11-05T20:38:20 https://maestrodatabase.com/blog/review-of-pharmacy-remuneration-and-regulation-1 2016-02-18T20:10:13 https://maestrodatabase.com/blog/european-scheme-to-develop-drugs-for-diseases-with-no-treatment-launched 2016-03-09T03:37:04 https://maestrodatabase.com/blog/passage-of-pbs-legislation-welcomed 2015-08-05T11:37:27 https://maestrodatabase.com/blog/update-on-procedures-for-the-cadth-common-drug-review-and-pan-canadian-oncology-drug-review-mandatory-disclosure-of-a-submitted-drug-price 2016-02-26T11:33:30 https://maestrodatabase.com/blog/cadth-recommends-reimbursement-of-truvada-for-prep 2016-08-28T10:03:16 https://maestrodatabase.com/blog/sobis-partner-biogen-submits-marketing-authorisation-application-for-alprolix-rfixfc-in-europe 2015-08-05T11:37:23 https://maestrodatabase.com/blog/actavis-receives-fda-approval-for-viberzi-eluxadoline-for-the-treatment-of-irritable-bowel-syndrome-with-diarrhoea-ibs-d-in-adults 2015-08-05T11:37:12 https://maestrodatabase.com/blog/express-scripts-says-valeant-lilly-bristol-drugs-to-lack-coverage 2016-08-04T21:44:04 https://maestrodatabase.com/blog/fda-approves-new-antibacterial-drug-avycaz 2015-08-05T11:37:22 https://maestrodatabase.com/blog/ovid-therapeutics-announces-ov101-granted-fast-track-designation-by-u-dot-s-fda-for-treatment-of-fragile-x-syndrome 2018-03-15T23:22:33 https://maestrodatabase.com/blog/call-for-patient-input-8 2015-08-05T11:37:22 https://maestrodatabase.com/blog/valeant-pharmaceuticals-announces-fda-approval-of-jublia-for-the-treatment-of-onychomycosis 2015-08-05T11:37:28 https://maestrodatabase.com/blog/new-leadership-new-members-for-pharmac-consumer-committee 2015-08-05T11:37:08 https://maestrodatabase.com/blog/first-oral-treatment-for-fabry-disease-recommended-for-approval-in-the-eu 2016-04-01T23:44:43 https://maestrodatabase.com/blog/roches-gazyvaro-approved-in-europe-in-combination-with-bendamustine-for-people-with-previously-treated-follicular-lymphoma 2016-06-16T09:33:37 https://maestrodatabase.com/blog/germany-mulls-limiting-prices-drug-firms-can-charge-to-health-system 2016-04-22T22:11:57 https://maestrodatabase.com/blog/what-would-a-republican-win-mean-for-health-policy 2016-09-15T01:11:37 https://maestrodatabase.com/blog/uk-cost-agency-rebuffs-sanofi-cholesterol-drug-but-backs-amgens 2016-02-08T20:31:06 https://maestrodatabase.com/blog/cadth-call-for-patient-input 2015-08-05T11:37:12 https://maestrodatabase.com/blog/using-expert-opinion-in-health-technology-assessment-a-guideline-review 2016-08-10T04:16:25 https://maestrodatabase.com/blog/fast-track-flu-vaccine-raises-hopes-for-quicker-drugs-approvals 2018-10-25T06:38:08 https://maestrodatabase.com/blog/canadians-with-multiple-sclerosis-one-step-closer-to-accessing-lemtrada 2015-08-05T11:37:28 https://maestrodatabase.com/blog/the-potential-for-postrandomization-confounding-in-randomized-clinical-trials 2016-06-07T20:58:14 https://maestrodatabase.com/blog/insurers-can-reduce-drug-prices-if-policy-makers-let-them 2016-07-15T11:54:48 https://maestrodatabase.com/blog/us-fda-approves-rockwells-triferic-for-iron-replacement-and-maintenance-of-haemoglobin-in-haemodialysis-patients 2015-08-05T11:37:13 https://maestrodatabase.com/blog/amag-pharmaceuticals-receives-complete-response-letter-from-fda-for-single-dose-preservative-free-vial-of-makena-hydroxyprogesterone-caproate-injection 2015-11-19T20:47:49 https://maestrodatabase.com/blog/the-fda-vs-austin-leclaire 2016-04-25T06:24:56 https://maestrodatabase.com/blog/european-commission-approves-expanded-use-of-opdivo-nivolumab-to-include-previously-treated-metastatic-non-squamous-non-small-cell-lung-cancer 2016-04-06T20:28:12 https://maestrodatabase.com/blog/pbs-changes-drug-prices-to-drop-push-for-generics 2015-08-05T11:37:24 https://maestrodatabase.com/blog/confirmed-1-april-2015-prices-resulting-from-2015-april-cycle-of-price-disclosure 2015-08-05T11:37:14 https://maestrodatabase.com/blog/november-2015-decisions-news-release 2015-11-12T09:46:41 https://maestrodatabase.com/blog/fda-grants-breakthrough-therapy-designation-for-genzymes-olipudase-alfa 2015-08-05T11:37:18 https://maestrodatabase.com/blog/duchesnay-announces-submission-of-supplemental-new-drug-application-for-osphena-ospemifene-to-u-dot-s-fda-seeking-approval-for-the-treatment-of-vaginal-dryness-a-symptom-of-vulvar-and-vaginal-atrophy-due-to-menopause 2018-10-25T06:42:48 https://maestrodatabase.com/blog/public_summary_documents_from_the_november_2013_pbac_meeting 2015-08-05T11:37:07 https://maestrodatabase.com/blog/biomarin-withdraws-submission-for-kyndrissa 2016-06-27T12:49:56 https://maestrodatabase.com/blog/ema-publishes-epar-for-odefsey 2016-07-08T23:48:19 https://maestrodatabase.com/blog/proposal-to-fund-denosumab-for-osteoporosis 2018-03-15T23:58:40 https://maestrodatabase.com/blog/fda-approves-revlimid-lenalidomide-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-previously-treated-follicular-lymphoma-or-marginal-zone-lymphoma 2019-05-29T01:06:06 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-to-ryanodex-for-treatment-of-exertional-heat-stroke-fast-track-designation-highlights-serious-unmet-medical-need-that-exists-for-patients-with-ehs 2016-02-02T07:41:57 https://maestrodatabase.com/blog/facts-speak-for-themselves-on-drug-listings 2015-09-23T23:31:42 https://maestrodatabase.com/blog/icer-releases-evidence-report-on-treatments-for-non-small-cell-lung-cancer 2016-09-29T20:38:41 https://maestrodatabase.com/blog/new-treatments-for-australians-with-endometrial-cancer-and-lennox-gastaut-syndrome 2023-06-05T00:21:43 https://maestrodatabase.com/blog/simeprevir_has_been_approved_in_canada_as_a_new_treatment_for_hepatitis_c 2015-08-05T11:37:15 https://maestrodatabase.com/blog/sermonix-receives-fda-fast-track-designation-for-investigational-drug-lasofoxifene 2019-05-29T01:00:54 https://maestrodatabase.com/blog/fda-approves-the-first-treatment-option-for-generalized-pustular-psoriasis-flares-in-adults 2022-09-02T10:30:37 https://maestrodatabase.com/blog/tga-supports-mhras-new-international-recognition-framework-for-medicines 2023-06-04T21:05:36 https://maestrodatabase.com/blog/dabrafenibtrametinib-considerable-added-benefit-for-men-with-advanced-melanoma 2016-03-19T05:55:41 https://maestrodatabase.com/blog/destiny-pharma-announces-fda-fast-track-designation-for-lead-clinical-candidate-exeporfinium-chloride 2018-03-15T23:50:51 https://maestrodatabase.com/blog/tagrisso-approved-in-the-eu-for-the-adjuvant-treatment-of-patients-with-early-stage-egfr-mutated-lung-cancer 2021-05-28T06:08:36 https://maestrodatabase.com/blog/budget-puts-patient-outcomes-at-centre-of-health-reform 2016-05-03T20:40:59 https://maestrodatabase.com/blog/achieve-life-sciences-announces-fda-acceptance-of-cytisinicline-new-drug-application-for-treatment-of-nicotine-dependence-for-smoking-cessation 2025-09-04T08:01:20 https://maestrodatabase.com/blog/summary-report-of-stakeholder-consultations-on-phase-ii-of-transfer-of-pcodr-to-cadth 2015-08-05T11:37:07 https://maestrodatabase.com/blog/pfizer-announces-fda-acceptance-for-review-of-new-drug-application-for-a-once-daily-formulation-of-xeljanz-tofacitinib-citrate-modified-release-rablets 2015-08-05T11:37:30 https://maestrodatabase.com/blog/shire-receives-fda-breakthrough-therapy-designation-for-shp621-and-shp625-investigational-products-for-rare-gastro-intestinal-conditions 2016-06-13T21:13:40 https://maestrodatabase.com/blog/janssen-submits-application-to-the-ema-to-expand-use-of-imbruvica-ibrutinib-in-previously-untreated-chronic-lymphocytic-leukaemia-patients 2015-11-04T20:59:42 https://maestrodatabase.com/blog/health-system-deserves-keener-scalpel-than-gp-co-payments 2015-08-05T11:37:27 https://maestrodatabase.com/blog/nice-issues-guidance-recommending-two-new-cancer-treatments 2015-08-05T11:37:06 https://maestrodatabase.com/blog/janssen-submits-applications-seeking-approval-of-stelara-in-united-states-and-european-union-for-crohns-disease 2015-12-01T19:43:27 https://maestrodatabase.com/blog/fda-grants-hernexeos-breakthrough-therapy-designation-for-first-line-use-in-her2-mutant-advanced-nsclc 2025-09-04T08:10:06 https://maestrodatabase.com/blog/why-do-drugs-cost-so-much-because-drug-makers-keep-raising-the-prices 2016-06-29T21:55:05 https://maestrodatabase.com/blog/who-adds-important-new-but-expensive-medicines-on-the-eml 2015-08-05T11:37:17 https://maestrodatabase.com/blog/genzymes-lemtrada-resubmission-accepted-for-review-by-fda 2015-08-05T11:37:21 https://maestrodatabase.com/blog/coverage-with-evidence-development-and-managed-entry-in-the-funding-of-personalized-medicine-practical-and-ethical-challenges-for-oncology 2015-10-13T20:54:34 https://maestrodatabase.com/blog/schedule_of_pharmaceutical_benefits___1_december_2013 2015-08-05T11:37:23 https://maestrodatabase.com/blog/new-treatment-option-for-canadians-living-with-multiple-myeloma 2016-08-09T11:14:14 https://maestrodatabase.com/blog/nice-publishes-draft-guidance-for-two-prostate-cancer-treatments 2015-08-05T11:37:14 https://maestrodatabase.com/blog/nice-recommends-more-options-for-tackling-anaemia-in-people-with-cancer 2015-08-05T11:37:04 https://maestrodatabase.com/blog/u-dot-s-food-and-drug-administration-approves-bristol-myers-squibbs-zeposia-ozanimod-an-oral-treatment-for-adults-with-moderately-to-severely-active-ulcerative-colitis 2021-05-28T08:27:16 https://maestrodatabase.com/blog/nice-recommends-bortezomib-for-newly-diagnosed-blood-cancer-multiple-myeloma 2015-08-05T11:37:04 https://maestrodatabase.com/blog/janssen-submits-marketing-authorisation-application-for-darunavir-based-single-tablet-regimen-for-treatment-of-hiv-1-to-european-medicines-agency 2016-09-13T21:15:30 https://maestrodatabase.com/blog/brexit-could-boost-drug-costs-for-britains-national-health-service 2016-06-30T05:34:11 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-cftr-modulator-therapies-for-cystic-fibrosis 2018-03-16T01:40:11 https://maestrodatabase.com/blog/feraccru-receives-marketing-authorisation-in-europe 2016-02-26T10:51:59 https://maestrodatabase.com/blog/prescription_charge_to_rise_in_england 2015-08-05T11:37:30 https://maestrodatabase.com/blog/abpi-comments-on-the-nhs-englands-decision-for-the-cancer-drugs-fund 2016-02-26T21:44:49 https://maestrodatabase.com/blog/european-medicines-agency-accepts-marketing-authorisation-application-for-prestige-biopharmas-trastuzumab-biosimilar-hd201-for-review 2019-05-29T01:40:22 https://maestrodatabase.com/blog/fda-approves-first-treatment-for-sexual-desire-disorder 2015-08-18T23:25:49 https://maestrodatabase.com/blog/lillys-cyramza-ramucirumab-in-combination-with-paclitaxel-granted-fda-approval-for-advanced-gastric-cancer-after-prior-chemotherapy 2015-08-05T11:37:05 https://maestrodatabase.com/blog/exelixis-submits-u-dot-s-supplemental-new-drug-application-for-cabometyx-cabozantinib-for-previously-treated-advanced-hepatocellular-carcinoma 2018-03-16T04:27:32 https://maestrodatabase.com/blog/nice-yes-for-pfizers-inlyta-no-for-provenge 2015-08-05T11:37:25 https://maestrodatabase.com/blog/chinese-official-a-hero-after-forcing-us-drug-maker-biogen-to-cut-cost-of-treatment-for-spinal-disease-with-gentle-but-firm-approach 2021-12-18T22:11:36 https://maestrodatabase.com/blog/proposal-to-remove-stat-dispensing-from-various-pharmaceuticals-not-proceeding 2015-08-05T11:37:30 https://maestrodatabase.com/blog/tg-therapeutics-announces-european-commission-approval-for-briumvi-ublituximab-xiiy-for-the-treatment-of-relapsing-forms-of-multiple-sclerosis-in-adults 2023-06-05T02:07:24 https://maestrodatabase.com/blog/alcons-simbrinza-approved-in-the-eu-to-treat-patients-living-with-glaucoma-a-chronic-sight-threatening-eye-disease 2015-08-05T11:37:21 https://maestrodatabase.com/blog/tga-groups-and-offices-now-called-divisions-and-branches 2015-08-05T11:37:20 https://maestrodatabase.com/blog/two_new_features_have_been_added_to_maestro_australia 2015-08-05T11:37:08 https://maestrodatabase.com/blog/lillys-olomorasib-receives-us-fdas-breakthrough-therapy-designation-for-the-treatment-of-certain-newly-diagnosed-metastatic-kras-g12c-mutant-lung-cancers 2025-09-04T10:55:05 https://maestrodatabase.com/blog/pfizers-xalkori-gets-speedy-review-for-ros1-nsclc 2015-12-09T20:27:37 https://maestrodatabase.com/blog/ipsen-announces-health-canada-approval-of-dysport-therapeutic-abobotulinumtoxina-for-the-treatment-of-lower-limb-spasticity-in-adults 2018-03-16T01:46:25 https://maestrodatabase.com/blog/updated-indicative-1-october-2015-prices-resulting-from-the-2015-october-cycle-of-price-disclosure 2015-08-11T21:55:04 https://maestrodatabase.com/blog/fda-approves-two-higher-dosage-strengths-of-zubsolv 2015-08-05T11:37:13 https://maestrodatabase.com/blog/fda-approves-bayers-gadavist-gadobutrol-injection-as-the-first-magnetic-resonance-contrast-agent-for-pediatric-patients-less-than-2-years-of-age 2015-08-05T11:37:15 https://maestrodatabase.com/blog/review-pharmac-model-urge-breast-cancer-petitioners 2018-10-25T10:28:13 https://maestrodatabase.com/blog/cadth-calls-for-patient-input-on-a-submission-from-takeda-for-entyvio-vedolizumab 2016-03-24T04:07:15 https://maestrodatabase.com/blog/call-for-patient-input-on-a-submission-from-hospira-for-a-subsequent-entry-biologic 2016-03-11T22:30:19 https://maestrodatabase.com/blog/pharmac-bundle-deal-life-giving-for-some-cancer-patients-but-medics-say-nz-still-playing-catch-up-for-best-treatments 2021-12-18T22:07:44 https://maestrodatabase.com/blog/once-disparaged-me-too-drugs-crucial-for-lower-costs-of-cholesterol-hepatitis-c-and-cancer-drugs 2015-08-15T01:33:10 https://maestrodatabase.com/blog/new-zealand-access-to-medicine-worst-in-oecd 2015-08-05T11:37:20 https://maestrodatabase.com/blog/drugmakers-split-on-whether-to-include-interchangeability-statement-in-biosimilar-labels-see-more-at-httprapsorgregulatory-focusnews2016080325512drugmakers-split-on-whether-to-include-interchangeability-statement-in-biosimilar-labels 2016-08-04T21:36:14 https://maestrodatabase.com/blog/nice-changes-tack-with-yes-for-janssens-stelara 2015-08-05T11:37:04 https://maestrodatabase.com/blog/smc_meetings_to_be_held_in_public 2015-08-05T11:37:18 https://maestrodatabase.com/blog/pharmac-funds-new-medicine-and-removes-renewal-criteria-for-adhd-and-narcolepsy-treatments 2024-11-11T23:05:26 https://maestrodatabase.com/blog/santheras-marketing-authorization-application-for-raxone-in-duchenne-muscular-dystrophy-validated-by-the-european-medicines-agency 2016-06-21T21:29:42 https://maestrodatabase.com/blog/hhs-advances-payment-model-to-lower-drug-costs-for-patients 2018-10-25T20:06:06 https://maestrodatabase.com/blog/novartis-receives-positive-chmp-opinion-for-mayzent-siponimod-for-the-treatment-of-adult-patients-with-active-secondary-progressive-multiple-sclerosis 2019-11-16T02:54:57 https://maestrodatabase.com/blog/nmpa-accepted-akesos-ebronucimab-pcsk9-marketing-application-in-two-cardiovascular-indications 2023-06-05T02:30:58 https://maestrodatabase.com/blog/proposal-to-widen-access-to-rituximab-to-include-children-with-nephrotic-syndrome 2016-05-05T05:07:00 https://maestrodatabase.com/blog/fda-approves-durvalumab-for-locally-advanced-or-metastatic-biliary-tract-cancer 2022-09-02T20:28:20 https://maestrodatabase.com/blog/election-2016-mediscare-makes-medicare-reform-harder 2016-07-03T21:39:02 https://maestrodatabase.com/blog/dupixent-dupilumab-sbla-accepted-for-fda-priority-review-for-treatment-of-copd-with-type-2-inflammation 2024-02-23T06:41:54 https://maestrodatabase.com/blog/fda-permits-marketing-of-a-diagnostic-test-to-aid-in-the-determination-of-menopausal-status 2018-10-25T19:53:34 https://maestrodatabase.com/blog/fda-accepts-amgens-biologics-license-application-for-ldl-cholesterol-lowering-medication-evolocumab 2015-08-05T11:37:11 https://maestrodatabase.com/blog/pbs-generic-medicines-working-group-communiques 2016-01-27T20:13:00 https://maestrodatabase.com/blog/sandoz-biosimilar-etanercept-recommended-by-fda-advisory-committee-for-approval-to-treat-multiple-inflammatory-diseases 2016-07-13T21:11:51 https://maestrodatabase.com/blog/first-de-novo-deuterated-drug-poised-for-approval 2022-09-02T11:57:30 https://maestrodatabase.com/blog/apotex-announces-fda-has-accepted-for-filing-its-biosimilar-application-for-pegfilgrastim 2015-08-05T11:37:12 https://maestrodatabase.com/blog/fda-grants-priority-review-for-ruxolitinib-jakafi-as-a-treatment-for-patients-with-acute-graft-versus-host-disease 2018-10-25T20:18:23 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-to-genzymes-investigational-substrate-reduction-therapy-for-the-treatment-of-fabry-disease 2015-08-05T11:37:25 https://maestrodatabase.com/blog/german-agency-criticizes-european-program-for-speeding-some-drug-approvals 2016-08-16T11:55:36 https://maestrodatabase.com/blog/curium-announces-submission-of-the-marketing-authorisation-application-for-pylclari-an-innovative-18f--psma-pet-tracer-indicated-in-adults-with-prostate-cancer-to-swissmedic 2024-02-23T05:51:54 https://maestrodatabase.com/blog/fda-grants-priority-review-to-boehringer-ingelheims-biologics-license-application-for-idarucizumab 2015-08-05T11:37:09 https://maestrodatabase.com/blog/abeona-therapeutics-receives-fda-rare-paediatric-disease-designation-for-abo-202-gene-therapy-program-in-cln1-disease 2018-03-16T04:45:29 https://maestrodatabase.com/blog/price-of-medicinal-cannabis-halves-but-still-too-expensive-for-many 2018-10-25T20:13:22 https://maestrodatabase.com/blog/azurity-pharmaceuticals-announces-fda-approval-of-konvomep-omeprazole-and-sodium-bicarbonate-for-oral-suspension 2022-09-02T11:49:32 https://maestrodatabase.com/blog/nice-recommends-the-reimbursement-of-imlygic 2016-09-28T21:23:41 https://maestrodatabase.com/blog/vertex-announces-u-dot-s-fda-approval-for-orkambi-lumacaftor-slash-ivacaftor-in-children-with-cystic-fibrosis-ages-12-to-<24-months 2022-09-02T20:51:14 https://maestrodatabase.com/blog/nice-greenlights-dabigatran-for-treatment-of-blood-clots 2015-08-05T11:37:04 https://maestrodatabase.com/blog/sprout-pharmaceuticals-receives-fda-approval-of-addyi-flibanserin-100-mg 2015-08-19T21:42:15 https://maestrodatabase.com/blog/discount-pbs-prescriptions-start-today 2016-01-01T00:05:07 https://maestrodatabase.com/blog/trump-outlines-new-plan-to-lower-medicare-drug-prices-end-rigged-system 2018-10-25T20:28:36 https://maestrodatabase.com/blog/nice_encourages_further_research_into_the_effectiveness_of_skin_cancer_drug 2015-08-05T11:37:07 https://maestrodatabase.com/blog/takeda-receives-positive-chmp-opinion-for-conditional-approval-of-ninlaro-ixazomib-the-first-oral-proteasome-inhibitor-for-use-in-patients-with-multiple-myeloma 2016-09-17T02:03:03 https://maestrodatabase.com/blog/nice-recommends-simeprevir-sodium-olysio-in-combination-with-peginterferon-alfa-and-ribavirin-for-treating-hepatitis-c-in-final-draft-guidance 2015-08-05T11:37:11 https://maestrodatabase.com/blog/early-access-to-medicines-scheme-eams-scientific-opinion-pembrolizumab-for-non-small-cell-lung-cancer 2016-08-25T05:07:19 https://maestrodatabase.com/blog/fda-declines-to-approve-pre-filled-syringe-version-of-regenerons-eylea 2018-10-25T20:24:32 https://maestrodatabase.com/blog/california-senator-withdraws-gutted-drug-price-transparency-bill 2016-08-17T21:40:10 https://maestrodatabase.com/blog/states-threaten-hospital-funding-war-over-$600m-recalculation 2018-10-25T20:49:42 https://maestrodatabase.com/blog/i-wouldnt-want-to-be-a-cancer-patient-in-england-drug-company-boss-slams-nhs-watchdog-for-denying-patients-life-changing-treatments 2016-02-11T20:37:37 https://maestrodatabase.com/blog/merck-receives-fda-approval-of-zepatier-elbasvir-and-grazoprevir-for-the-treatment-of-chronic-hepatitis-c-virus-genotype-1-or-4-infection-in-adults-following-priority-review 2016-01-30T06:11:05 https://maestrodatabase.com/blog/fda-approves-first-generic-esomeprazole 2015-08-05T11:37:14 https://maestrodatabase.com/blog/betting-on-hepatitis-c-how-financial-speculation-in-drug-development-influences-access-to-medicines 2016-07-28T21:44:09 https://maestrodatabase.com/blog/pharmaceutical-industry-challenges-trump-plan-forcing-companies-to-reveal-drug-prices-in-tv-ads 2018-10-25T20:33:59 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-ocaliva-obeticholic-acid-for-the-treatment-of-patients-with-primary-biliary-cirrhosis 2016-05-29T17:27:29 https://maestrodatabase.com/blog/new-four-strain-flu-vaccine-available-from-this-month 2016-04-08T02:48:15 https://maestrodatabase.com/blog/fdas-gottlieb-extremely-worried-on-car-t-reimbursement 2018-10-25T20:37:24 https://maestrodatabase.com/blog/fda-deals-setback-to-catalyst-in-race-for-drug-approval 2016-02-18T06:54:44 https://maestrodatabase.com/blog/how-can-we-encourage-cancer-patients-to-share-their-health-data 2016-08-10T12:29:26 https://maestrodatabase.com/blog/health-insurance-marketplace-open-enrollment-snapshot-1 2015-12-02T20:13:56 https://maestrodatabase.com/blog/fda-grants-advaxis-fast-track-designation-for-adxs-her2-for-patients-with-newly-diagnosed-non-metastatic 2016-04-29T07:03:39 https://maestrodatabase.com/blog/a-secretive-board-controls-access-to-prescription-drugs-for-millions-of-americans 2016-08-15T12:13:16 https://maestrodatabase.com/blog/nice-draft-guidance-recommends-vortioxetine-brintellix-for-treating-major-depressive-episodes 2015-10-16T19:40:19 https://maestrodatabase.com/blog/call-from-cadth-for-patient-input-on-submission-for-constella-linaclotide 2015-08-05T11:37:21 https://maestrodatabase.com/blog/fda-expands-approved-use-of-imbruvica-for-chronic-lymphocytic-leukemia 2015-08-05T11:37:16 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-positive-chmp-opinion-in-the-european-union-for-opdivo-nivolumab-for-the-treatment-of-advanced-melanoma-in-both-first-line-and-previously-treated-patients 2015-08-05T11:37:12 https://maestrodatabase.com/blog/senate-estimates-clearly-confirms-pbs-expenditure-flat 2015-08-05T11:37:26 https://maestrodatabase.com/blog/amgen-receives-positive-chmp-opinion-for-parsabiv-etelcalcetide-for-the-treatment-of-secondary-hyperparathyroidism-in-adult-patients-with-chronic-kidney-disease-on-hemodialysis 2016-09-17T01:58:27 https://maestrodatabase.com/blog/fda-accepts-supplemental-biologics-license-application-sbla-for-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-for-first-line-treatment-of-advanced-melanoma-and-grants-priority-review 2015-08-18T20:58:34 https://maestrodatabase.com/blog/fda-approves-eagle-pharmaceuticals-ryanodex-for-the-treatment-of-malignant-hyperthermia 2015-08-05T11:37:22 https://maestrodatabase.com/blog/top-officials-aim-to-reshape-the-fda-to-prepare-for-avalanche-of-cancer-products 2016-07-05T03:42:18 https://maestrodatabase.com/blog/new-conditions-of-approval-for-approved-pharmacists 2015-08-05T11:37:21 https://maestrodatabase.com/blog/fda-still-skeptical-of-als-drug-ahead-of-high-stakes-meeting 2022-09-02T21:59:11 https://maestrodatabase.com/blog/dolutegravir-sodium-with-abacavir-sulphate-and-lamivudine-significant-additional-benefits-for-treatment-nave-adults-with-hiv 2015-08-05T11:37:06 https://maestrodatabase.com/blog/biogen-completes-rolling-submission-of-new-drug-application-to-fda-for-nusinersen-as-a-treatment-for-spinal-muscular-atrophy 2016-09-26T21:12:40 https://maestrodatabase.com/blog/fda-approves-first-tissue-adhesive-for-internal-use 2015-08-05T11:37:18 https://maestrodatabase.com/blog/government-ought-to-keep-clear-on-medicines 2015-12-31T22:00:44 https://maestrodatabase.com/blog/call-for-keytruda-bay-of-plenty-couple-needs-help-funding-hefty-cancer-treatment 2022-09-02T21:42:45 https://maestrodatabase.com/blog/nice-recommends-three-new-treatment-options-for-hepatitis-c-in-draft-guidance 2015-08-05T11:37:16 https://maestrodatabase.com/blog/atagi-update-following-weekly-covid-19-meeting-15-december-2021 2021-12-19T19:27:14 https://maestrodatabase.com/blog/mark-cuban-cost-plus-drug-company-joins-forces-with-coherus-to-make-yusimry-a-humira-biosimilar-available-to-patients 2023-06-05T04:00:48 https://maestrodatabase.com/blog/keryx-receives-european-approval-for-fexericr-ferric-citrate-coordination-complex-for-the-treatment-of-hyperphosphatemia-in-adults-with-chronic-kidney-disease 2015-09-24T13:01:22 https://maestrodatabase.com/blog/what-does-it-mean-to-put-new-hepatitis-c-drugs-on-a-list-of-essential-medicines 2016-04-27T11:44:05 https://maestrodatabase.com/blog/fda-accepts-supplemental-biologics-license-application-sbla-for-keytruda-pembrolizumab-in-advanced-non-small-cell-lung-cancer 2016-03-08T07:04:50 https://maestrodatabase.com/blog/notification-of-delay-of-decision-on-melatonin-funding-proposal 2015-08-05T11:37:27 https://maestrodatabase.com/blog/mhra-grants-marketing-authorisation-for-balversa-erdafitinib-as-monotherapy-for-the-treatment-of-adults-with-unresectable-or-metastatic-urothelial-carcinoma-uc-harbouring-susceptible-fgfr3-genetic-alterations-who-have-previously-received-at-least-one-line-of-therapy-containing-a-pd-1-or-pd-l1-inhibitor-in-the-unresectable-or-metastatic-treatment-setting 2024-11-11T23:49:21 https://maestrodatabase.com/blog/amgen-and-daiichi-sankyo-announce-agreement-to-commercialize-biosimilars-in-japan 2016-07-14T03:56:20 https://maestrodatabase.com/blog/bayers-keredia-finerenone-receives-updated-label-to-include-findings-from-phase-3-figaro-dkd-cardiovascular-outcomes-study-in-patients-with-chronic-kidney-disease-and-type-2-diabetes 2022-09-02T21:08:18 https://maestrodatabase.com/blog/aussies-save-almost-100-dollars-million-on-medicines-in-just-five-months 2023-06-05T03:57:26 https://maestrodatabase.com/blog/adma-biologics-receives-complete-response-letter-from-fda-for-pending-biologics-license-application 2016-07-31T22:22:54 https://maestrodatabase.com/blog/us-approval-for-idt-brain-cancer-drug 2016-04-13T20:56:21 https://maestrodatabase.com/blog/alcon-treatment-travatan-receives-eu-approval-for-pediatric-glaucoma-patients 2015-08-05T11:37:13 https://maestrodatabase.com/blog/novavax-announces-submission-of-new-drug-application-in-japan-for-approval-of-covid-19-vaccine 2021-12-19T21:37:30 https://maestrodatabase.com/blog/cannabis-based-multiple-sclerosis-drug-divides-england-and-wales 2015-08-05T11:37:10 https://maestrodatabase.com/blog/sask-woman-calls-on-government-to-cover-cystic-fibrosis-drug 2017-08-07T06:06:18 https://maestrodatabase.com/blog/panel-recommends-fda-approval-of-remicade-knockoff 2016-02-11T00:46:25 https://maestrodatabase.com/blog/new-appointments-to-the-pharmaceutical-benefits-advisory-committee 2017-08-07T06:13:16 https://maestrodatabase.com/blog/nice-green-lights-tremfya-to-treat-active-psoriatic-arthritis 2021-05-28T11:56:41 https://maestrodatabase.com/blog/xalud-therapeutics-receives-fda-fast-track-designation-for-xt-150-for-the-treatment-of-pain-associated-with-osteoarthritis-of-the-knee 2021-12-19T21:51:14 https://maestrodatabase.com/blog/cda-welcomes-tga-review-recommendations 2015-08-05T11:37:19 https://maestrodatabase.com/blog/galderma-receives-fda-approval-to-market-restylane-lyft-with-lidocaine-to-correct-age-related-volume-loss-in-the-cheek-area 2015-08-05T11:37:29 https://maestrodatabase.com/blog/rfp---supply-of-a-first-line-enzyme-replacement-therapy-for-the-treatment-of-gaucher-disease 2017-08-07T06:10:50 https://maestrodatabase.com/blog/vemurafenib__despite_new_data_no_change_in_result 2015-08-05T11:37:23 https://maestrodatabase.com/blog/emerging-oral-combination-interferon-free-regimens-for-the-treatment-of-chronic-hepatitis-c-genotype-1 2015-08-05T11:37:23 https://maestrodatabase.com/blog/redesigned-pbs-website 2015-08-05T11:37:02 https://maestrodatabase.com/blog/breakthrough-hiv-drug-authorities-reconsider-decision-to-block-cheap-access 2017-08-07T09:24:56 https://maestrodatabase.com/blog/announcement_of_a_new_simplified_pbs_price_disclosure_process 2015-08-05T11:37:26 https://maestrodatabase.com/blog/desperately-seeking-price-reform-pharma-needs-to-embrace-transparency-value-to-protect-innovation 2015-08-15T11:39:06 https://maestrodatabase.com/blog/fury-over-cancer-setback-scots-denied-wonder-drug-that-extends-life-up-to-five-years 2015-08-05T11:37:11 https://maestrodatabase.com/blog/nice-consults-on-draft-guidance-for-new-cystic-fibrosis-treatment 2016-03-23T19:47:10 https://maestrodatabase.com/blog/fist-assist-devices-receives-fda-breakthrough-device-designation-for-the-worlds-first-wearable-vein-dilation-device-for-esrd-patients 2021-12-19T21:32:31 https://maestrodatabase.com/blog/the-ceo-of-goodrx-doesnt-think-mail-order-pharmacies-are-the-right-answer-to-lowering-prescription-drug-prices 2022-09-02T22:06:46 https://maestrodatabase.com/blog/amgen-provides-update-on-status-of-parsabiv-etelcalcetide-new-drug-application-submitted-to-the-u-dot-s-fda 2016-08-24T22:44:39 https://maestrodatabase.com/blog/take-the-generic-patients-are-told-until-they-are-not 2017-08-07T09:30:45 https://maestrodatabase.com/blog/ema-statement-on-the-outcome-of-the-uk-referendum 2016-07-06T21:12:03 https://maestrodatabase.com/blog/nice_says_yes_to_new_treatment_for_rare_autoimmune_disease_in_final_guidance 2015-08-05T11:37:28 https://maestrodatabase.com/blog/ynparza-olaparib-granted-breakthrough-therapy-designation-by-us-fda-for-treatment-of-brca12-or-atm-gene-mutated-metastatic-castration-resistant-prostate-cancer 2016-01-28T20:20:21 https://maestrodatabase.com/blog/fda-issues-a-complete-response-letter-on-ccp-08-nda 2017-08-10T00:31:24 https://maestrodatabase.com/blog/abpi-submits-its-response-to-nices-vba-consultation 2015-08-05T11:37:26 https://maestrodatabase.com/blog/nice-draft-guidance-extends-treatment-options-for-thousands-of-people-with-severe-rheumatoid-arthritis 2016-07-12T21:14:06 https://maestrodatabase.com/blog/jazz-pharmaceuticals-receives-fda-approval-for-intravenous-administration-of-erwinaze-asparaginase-erwinia-chrysanthemi 2015-08-05T11:37:26 https://maestrodatabase.com/blog/revised-cadth-procedure-for-voluntary-withdrawal-of-a-submission 2016-03-01T03:42:18 https://maestrodatabase.com/blog/fda-approves-telixs-prostate-cancer-imaging-product-illuccix 2021-12-19T22:43:13 https://maestrodatabase.com/blog/sebelipase-alfa-for-the-treatment-of-patients-with-wolman-disease-final-guidance 2024-01-15T03:29:21 https://maestrodatabase.com/blog/fda-approves-octapharmas-nuwiq-for-the-treatment-of-adults-and-children-with-haemophilia-a 2015-09-16T08:23:28 https://maestrodatabase.com/blog/costly-hepatitis-c-drugs-for-everyone 2015-09-02T08:25:45 https://maestrodatabase.com/blog/dropout-by-dartmouth-raises-questions-on-health-law-cost-savings-effort 2016-09-11T11:53:04 https://maestrodatabase.com/blog/roche-warns-on-uks-pricing-for-cancer-drugs 2015-11-16T19:40:08 https://maestrodatabase.com/blog/smc---august-2017-decisions 2017-08-07T21:08:05 https://maestrodatabase.com/blog/sanofi-receives-fda-approval-of-one-daily-basal-insulin-toujeo 2015-08-05T11:37:08 https://maestrodatabase.com/blog/agenda-for-17-december-2014-transparency-committee-meeting 2015-08-05T11:37:16 https://maestrodatabase.com/blog/platform-for-post-authorisation-studies-registered-as-eu-trade-mark 2017-08-07T20:58:21 https://maestrodatabase.com/blog/verrica-pharmaceuticals-announces-extension-of-fda-review-period-of-its-nda-for-vp-102-for-the-treatment-of-molluscum-contagiosum 2021-05-28T12:03:14 https://maestrodatabase.com/blog/fda-considers-temporary-cancer-drug-imports-from-unapproved-companies-to-ease-us-shortage 2023-06-05T05:12:04 https://maestrodatabase.com/blog/tga-approves-taltz 2016-09-14T02:48:38 https://maestrodatabase.com/blog/drugs-cleared-through-the-fdas-expedited-review-offer-greater-gains-than-drugs-approved-by-conventional-process 2017-08-07T21:17:19 https://maestrodatabase.com/blog/amarin-partner-eddingpharm-receives-regulatory-approval-for-vascepa-icosapent-ethyl-in-mainland-china 2023-06-05T04:56:58 https://maestrodatabase.com/blog/pbs-price-cuts-cruel-pharm-innovations 2016-04-11T21:21:58 https://maestrodatabase.com/blog/new-treatment-option-for-patients-with-advanced-lung-cancer 2015-08-05T11:37:09 https://maestrodatabase.com/blog/teva-announces-fda-approval-of-qvar-redihaler-beclomethasone-dipropionate-hfa-inhalation-aerosol 2017-08-07T21:12:18 https://maestrodatabase.com/blog/tga-approves-new-indication-for-perjeta 2016-06-01T14:29:50 https://maestrodatabase.com/blog/pfizer-receives-positive-chmp-opinion-for-lorviqua-lorlatinib-as-first-line-treatment-for-alk-positive-advanced-lung-cancer 2021-12-19T22:04:35 https://maestrodatabase.com/blog/companies-at-smc-meetings 2015-08-05T11:37:16 https://maestrodatabase.com/blog/new-treatment-for-heart-failure-to-support-thousands-of-australian-patients 2021-12-20T08:17:21 https://maestrodatabase.com/blog/cadth-calls-for-patient-input-on-submission-from-pierre-fabre-for-hemangiol-propranolol-hydrochloride 2016-07-27T21:16:05 https://maestrodatabase.com/blog/prep-hiv-game-changer-to-reach-nhs-in-england-from-september 2017-08-07T21:23:53 https://maestrodatabase.com/blog/fda-approves-first-targeted-therapy-for-lung-cancer-mutation-previously-considered-resistant-to-drug-therapy 2021-05-28T21:09:56 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-april-2015-update 2015-08-05T11:37:10 https://maestrodatabase.com/blog/bellafil-receives-fda-approval-for-treatment-of-acne-scars 2015-08-05T11:37:25 https://maestrodatabase.com/blog/april-2016-nce-registrations-tga 2016-05-02T11:42:56 https://maestrodatabase.com/blog/health-insurance-demands-robust-rethink-to-restore-value-for-consumers 2017-08-07T21:29:24 https://maestrodatabase.com/blog/chmp-issues-positive-opinion-for-pfizers-20-valent-pneumococcal-conjugate-vaccine-for-the-prevention-of-vaccine-type-pneumococcal-pneumonia-in-adults 2021-12-20T08:21:32 https://maestrodatabase.com/blog/novartis-announces-fda-approval-for-first-il-17a-antagonist-cosentyx-secukinumab-for-moderate-to-severe-plaque-psoriasis-patients 2015-08-05T11:37:17 https://maestrodatabase.com/blog/behind-the-sarepta-drug-approval-was-intense-fda-bickering 2016-09-20T21:15:23 https://maestrodatabase.com/blog/promoting-consumer-involvement-in-medicine-decisions-welcomed 2017-08-07T21:27:13 https://maestrodatabase.com/blog/united-therapeutics-sells-fda-priority-review-voucher-to-abbvie-for-350-million 2015-08-20T06:23:23 https://maestrodatabase.com/blog/tga-risk-management-plans 2015-08-05T11:37:02 https://maestrodatabase.com/blog/injectafer-ferric-carboxymaltose-injection-receives-fda-approval-for-the-treatment-of-paediatric-patients-with-iron-deficiency-anaemia 2021-12-19T23:02:19 https://maestrodatabase.com/blog/germanys-iqwig-finds-some-benefit-in-eisais-halaven-eribulin-mesylate 2015-08-05T11:37:11 https://maestrodatabase.com/blog/fda-grants-amgen-priority-review-designation-for-ivabradine-for-the-treatment-of-chronic-heart-failure 2015-08-05T11:37:29 https://maestrodatabase.com/blog/abbvie-wages-hcv-drug-price-war-on-gilead 2017-08-07T21:33:04 https://maestrodatabase.com/blog/saxagliptin-and-saxagliptin-metformin-in-type-2-diabetes-additional-benefits-not-covered 2016-10-05T20:05:57 https://maestrodatabase.com/blog/pharmacs-year-in-review 2021-12-20T08:10:52 https://maestrodatabase.com/blog/abbvies-humira-adalimumab-approved-by-european-commission-to-treat-children-and-adolescents-with-severe-chronic-plaque-psoriasis 2015-08-05T11:37:12 https://maestrodatabase.com/blog/provinces-taking-too-long-to-approve-potentially-life-saving-cancer-drugs-study 2015-08-05T11:37:07 https://maestrodatabase.com/blog/tough-choices-in-melanoma-drug-debate 2016-03-02T18:28:22 https://maestrodatabase.com/blog/blood-cancer-drug-accepted-for-nhs-use-in-scotland 2017-08-07T21:38:41 https://maestrodatabase.com/blog/new-nhs-cancer-drugs-deal-announced-by-welsh-ministers 2015-11-12T10:05:24 https://maestrodatabase.com/blog/saphnelo-recommended-for-approval-in-the-eu-by-chmp-for-the-treatment-of-patients-with-systemic-lupus-erythematosus 2021-12-20T08:40:24 https://maestrodatabase.com/blog/nice-publishes-final-draft-guidance-on-nab-paclitaxel-abraxane-for-pancreatic-cancer 2015-09-17T10:19:34 https://maestrodatabase.com/blog/improving-the-consumer-experience-at-healthcaregov 2015-10-24T05:40:40 https://maestrodatabase.com/blog/nipocalimab-is-the-first-and-only-investigational-therapy-granted-us-fda-breakthrough-therapy-designation-for-the-treatment-of-adults-living-with-moderate-to-severe-sjoegrens-disease 2024-11-12T00:30:04 https://maestrodatabase.com/blog/icer-weighs-in-on-diabetes-prevention-programs 2016-07-28T21:50:03 https://maestrodatabase.com/blog/harnessing-the-immune-system-to-fight-cancer 2016-07-31T22:45:09 https://maestrodatabase.com/blog/regulatory-information---further-guidance-on-adaptive-licensing-pilot-project-available 2015-08-05T11:37:30 https://maestrodatabase.com/blog/pharmac-decision-relating-to-filgrastim-and-methotrexate-pre-filled-syringes 2016-02-05T20:47:56 https://maestrodatabase.com/blog/even-talking-about-reducing-drug-prices-can-reduce-drug-prices 2016-01-18T20:56:12 https://maestrodatabase.com/blog/biotech-bodies-united-in-concern-over-un-report 2016-10-03T05:14:17 https://maestrodatabase.com/blog/pharmacy-trial-programme 2016-02-23T06:44:40 https://maestrodatabase.com/blog/fda-approves-troxyca-er-oxycodone-hydrochloride-and-naltrexone-hydrochloride-extended-release-capsules-cii-with-abuse-deterrent-properties-for-the-management-of-pain 2016-08-22T05:54:12 https://maestrodatabase.com/blog/tga-publishes-auspar-for-armodafinil-nuvigil 2016-06-09T11:19:32 https://maestrodatabase.com/blog/supplemental-new-drug-applications-for-invega-sustenna-paliperidone-palmitate-submitted-to-the-us-fda-for-the-treatment-of-schizoaffective-disorder 2015-08-05T11:37:13 https://maestrodatabase.com/blog/biosimilar-awareness-initiative-reference-group-communiqués 2016-06-06T07:16:23 https://maestrodatabase.com/blog/european-commission-approves-imbruvica-ibrutinib-for-first-line-treatment-of-patients-with-chronic-lymphocytic-leukaemia 2016-05-31T14:10:58 https://maestrodatabase.com/blog/progress-in-science-medicines-health 2015-08-05T11:37:05 https://maestrodatabase.com/blog/alexions-550000-bone-drug-too-expensive-for-britain-read-more-at-reuters 2015-12-03T20:42:03 https://maestrodatabase.com/blog/approval_of_proposals_for_atomoxetine_hydrochloride__sugammadex_and_baclofen_injection 2015-08-05T11:37:15 https://maestrodatabase.com/blog/allergan-announces-fda-approval-of-byvalson-nebivolol-and-valsartan 2016-06-06T21:57:40 https://maestrodatabase.com/blog/edenbridge-pharmaceuticals-announces-u-dot-s-fda-approval-of-dartisla-odt-glycopyrrolate-orally-disintegrating-tablets 2021-12-20T09:46:44 https://maestrodatabase.com/blog/indicative-1-october-2015-pbs-prices---2015-october-cycle 2015-08-05T11:37:26 https://maestrodatabase.com/blog/fda-approves-raplixa-to-help-control-bleeding-during-surgery 2015-08-05T11:37:18 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-infigratinib-for-metastatic-cholangiocarcinoma 2021-05-28T22:01:34 https://maestrodatabase.com/blog/daily_mail_admits__champagne_bar__story_was_wrong 2015-08-05T11:37:22 https://maestrodatabase.com/blog/first-covid-19-vaccine-approved-for-children-aged-12-to-15-in-eu 2021-05-28T21:57:28 https://maestrodatabase.com/blog/pharmacs-new-approach-for-people-with-rare-disorders 2016-05-16T03:41:44 https://maestrodatabase.com/blog/pbs-and-nip-cost-recovery---annual-indexation-of-fees 2018-06-30T11:36:55 https://maestrodatabase.com/blog/european-commission-grants-marketing-authorization-for-gileads-fixed-dose-combination-descovy-emtricitabine-tenofovir-alafenamide-for-treatment-of-hiv 2016-04-26T08:34:06 https://maestrodatabase.com/blog/us-fda-approves-csl-behrings-idevlion-the-first-and-only-haemophilia-b-therapy-with-up-to-14-day-dosing-intervals 2016-03-06T07:09:04 https://maestrodatabase.com/blog/call-for-patient-input-13 2015-08-05T11:37:22 https://maestrodatabase.com/blog/meeting-highlights-from-the-committee-for-medicinal-products-for-human-use-chmp-21-24-july-2014 2015-08-05T11:37:18 https://maestrodatabase.com/blog/bayer-receives-european-approval-for-gadovist-gadobutrol-for-use-in-pediatric-patients-less-than-2-years-of-age 2015-08-05T11:37:10 https://maestrodatabase.com/blog/ariad-and-sta-announce-approval-of-iclusig-ponatinib-in-australia 2015-08-05T11:37:13 https://maestrodatabase.com/blog/biogen-cuts-price-for-alzheimers-drug-aduhelm-by-half 2021-12-20T19:40:44 https://maestrodatabase.com/blog/pfizer-glaxosmithkline-astrazeneca-to-face-grilling-on-tax 2015-08-05T11:37:15 https://maestrodatabase.com/blog/bmj-reforming-the-cancer-drug-fund 2015-08-05T11:37:09 https://maestrodatabase.com/blog/nice-updates-guidance-on-the-use-of-cabazitaxel-for-hormone-relapsed-metastatic-prostate-cancer-treated-with-docetaxel 2016-05-25T12:35:17 https://maestrodatabase.com/blog/ema-recommends-nuvaxovid-for-authorisation-in-the-eu 2021-12-20T19:50:08 https://maestrodatabase.com/blog/fda-approves-sivextro-to-treat-skin-infections 2015-08-05T11:37:29 https://maestrodatabase.com/blog/health-canada-approves-inflectra-biosimilar-infliximab-for-three-additional-indications-crohns-disease-fistulising-crohns-disease-and-ulcerative-colitis 2016-06-15T06:22:45 https://maestrodatabase.com/blog/merck-receives-positive-eu-chmp-opinion-for-keytruda-pembrolizumab-in-combination-with-chemotherapy-as-neo-adjuvant-treatment-then-continued-as-monotherapy-as-adjuvant-treatment-for-the-treatment-of-resectable-nsclc-at-high-risk-of-recurrence 2024-02-24T00:38:24 https://maestrodatabase.com/blog/nice-consults-on-dry-eye-treatment-and-asks-for-more-information-from-the-company 2015-08-05T11:37:23 https://maestrodatabase.com/blog/bayer-receives-approval-for-haemophilia-a-treatment-jivi 2018-10-26T01:21:38 https://maestrodatabase.com/blog/baxalta-gains-health-canada-approval-for-obizur-to-treat-patients-with-acquired-haemophilia-a 2015-10-16T20:53:07 https://maestrodatabase.com/blog/ema-adopts-a-positive-chmp-opinion-for-pfizers-and-opkos-somatrogon-a-long-acting-treatment-for-paediatric-growth-hormone-deficiency 2021-12-20T10:08:27 https://maestrodatabase.com/blog/ema-publishes-epar-for-wakix 2016-04-13T20:39:38 https://maestrodatabase.com/blog/fda-statement-on-senate-confirmation-of-dr-robert-m-califf 2016-02-24T20:30:41 https://maestrodatabase.com/blog/pharmac-proposal-to-retain-first-line-biologic-access-for-adalimumab-in-dermatology-and-rheumatology-indications 2015-10-29T19:59:31 https://maestrodatabase.com/blog/nice-calls-for-a-new-approach-to-managing-the-entry-of-drugs-into-the-nhs 2015-08-05T11:37:09 https://maestrodatabase.com/blog/sun-pharma-launches-imatinib-mesylate-in-usa 2016-02-02T20:28:51 https://maestrodatabase.com/blog/pharmaceutical-benefits-advisory-committee-pbac-guidelines-review 2015-09-15T02:32:29 https://maestrodatabase.com/blog/guidance-for-reporting-real-world-evidence 2023-06-05T21:12:04 https://maestrodatabase.com/blog/gsk-announces-us-regulatory-submission-seeking-additional-indication-for-eltrombopag-promacta 2015-08-05T11:37:26 https://maestrodatabase.com/blog/executives-grapple-with-new-realities-in-drug-pricing 2019-05-29T05:32:15 https://maestrodatabase.com/blog/crossing-the-line-nices-value-for-money-threshold 2016-03-20T00:52:43 https://maestrodatabase.com/blog/specialty-drug-pricing-and-out-of-pocket-spending-on-orally-administered-anti-cancer-drugs-in-medicare-part-d-2010-to-2019 2019-05-29T05:29:22 https://maestrodatabase.com/blog/request-for-proposals---supply-of-recombinant-factor-viii-recombinant-factor-ix-recombinant-factor-viia-and-factor-viii-inhibitor-bypassing-fraction-for-haemophilia 2015-08-05T11:37:07 https://maestrodatabase.com/blog/hollow-victories-and-hepatitis-c 2016-07-30T01:34:42 https://maestrodatabase.com/blog/does-fast-track-drugs-approval-in-eu-run-too-fast 2018-10-26T01:27:44 https://maestrodatabase.com/blog/celgenes-vidaza-azacitidine-for-injection-approved-by-the-european-commission-as-new-treatment-for-elderly-patients-with-acute-myeloid-leukaemia 2015-10-30T20:33:54 https://maestrodatabase.com/blog/actavis-receives-fda-approval-for-viibryd-vilazodone-hydrochloride-20-mg-once-daily-as-a-therapeutic-dose 2015-08-05T11:37:29 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-report-finds-extended-release-treatments-for-opioid-use-disorder-provide-only-marginal-benefits-over-generic-alternatives-at-significantly-higher-prices 2018-10-26T01:30:24 https://maestrodatabase.com/blog/cancer-drug-not-cost-effective 2015-08-05T11:37:08 https://maestrodatabase.com/blog/biased-outcome-reporting-guidelines-for-underwhelming-studies-bogus-statement-and-checklist 2021-12-20T20:25:47 https://maestrodatabase.com/blog/fda-issues-final-decision-to-withdraw-approval-of-pepaxto-melphalan-flufenamide 2024-02-24T00:56:27 https://maestrodatabase.com/blog/prescription-medicines-tga-annual-report-for-2015-1 2016-05-24T13:42:15 https://maestrodatabase.com/blog/european-commission-approves-bristol-myers-squibbs-evotaz-atazanavir-and-cobicistat-fixed-dose-combination-for-the-treatment-of-hiv-1-infection-in-adults 2015-08-05T11:37:28 https://maestrodatabase.com/blog/cadths-25th-anniversary-lecture-series--dr-stirling-bryan 2015-08-05T11:37:18 https://maestrodatabase.com/blog/nice-recommends-monotherapy-for-adjuvant-treatment-of-stage-3-melanoma 2021-12-20T19:54:32 https://maestrodatabase.com/blog/2016-the-year-of-diversity-in-clinical-trials 2016-01-27T20:41:19 https://maestrodatabase.com/blog/flu-vaccine-shortage-amid-run-on-private-market-pharmacy-supplies 2019-05-29T05:38:58 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-positive-chmp-opinion-for-reblozyl-luspatercept-for-treatment-of-adults-with-transfusion-dependent-anaemia-due-to-low--to-intermediate-risk-myelodysplastic-syndromes 2024-02-24T00:51:08 https://maestrodatabase.com/blog/nice_consults_on_draft_guidance_recommending_new_drug_for_type_2_diabetes 2015-08-05T11:37:04 https://maestrodatabase.com/blog/cost-effectiveness-analysis-in-the-context-of-us-commercial-health-insurance 2019-05-29T05:35:11 https://maestrodatabase.com/blog/nice-rejects-roches-melanoma-combination 2016-09-06T14:26:10 https://maestrodatabase.com/blog/tax-cuts-and-other-tax-benefits-for-community-pharmacies 2016-05-03T20:51:49 https://maestrodatabase.com/blog/proposal-to-award-sole-supply-of-bortezomib-in-dhb-hospitals 2016-05-23T10:15:46 https://maestrodatabase.com/blog/confirmation_of_1_april_2014_price_disclosure_prices_and_new_price_disclosure_fact_sheet 2015-08-05T11:37:09 https://maestrodatabase.com/blog/celldexs-rindopepimut-rintega-receives-fda-breakthrough-therapy-designation-for-the-treatment-of-adult-patients-with-egfrviii-positive-glioblastoma 2015-08-05T11:37:10 https://maestrodatabase.com/blog/infliximab-biosimilars-are-safe-effective-and-cheap-uk-audit-shows 2016-09-23T03:28:03 https://maestrodatabase.com/blog/is-this-cancer-treatment-worth-it-new-tool-offers-patients-data 2015-10-14T19:47:39 https://maestrodatabase.com/blog/proposal-to-list-new-brands-of-zoledronic-acid-and-vecuronium-bromide 2016-07-12T10:07:18 https://maestrodatabase.com/blog/boehringer-ingelheim-submits-applications-for-approval-of-idarucizumab-specific-reversal-agent-to-dabigatran-etexilate-pradaxa-to-ema-fda-and-health-canada 2015-08-05T11:37:26 https://maestrodatabase.com/blog/tecfidera-a-first-line-oral-treatment-for-multiple-sclerosis-reimbursed-in-alberta 2015-08-05T11:37:03 https://maestrodatabase.com/blog/how-can-a-price-be-put-on-my-daughters-life 2016-04-26T20:17:59 https://maestrodatabase.com/blog/decisions-to-amend-or-remove-restrictions-on-various-funded-pharmaceuticals 2015-08-05T11:37:02 https://maestrodatabase.com/blog/the_final_round_of_public_summary_documents_from_the_july_2013_pbac_meeting_have_been_added_to_maestro_australia 2015-08-05T11:37:07 https://maestrodatabase.com/blog/upcoming-improvements-to-the-cadth-reimbursement-review-process 2023-06-05T21:28:34 https://maestrodatabase.com/blog/us-fda-approves-new-indications-for-harvoni-gileads-once-daily-single-tablet-regimen-for-chronic-hepatitis-c 2015-11-14T18:54:28 https://maestrodatabase.com/blog/cadth-common-drug-review-priority-review-process-on-hold 2015-08-05T11:37:21 https://maestrodatabase.com/blog/cancer-drugs-cant-stay-this-expensive-forever 2016-06-13T21:57:33 https://maestrodatabase.com/blog/icer-proposes-updates-to-value-assessment-framework-methods-and-procedures 2023-06-05T21:21:12 https://maestrodatabase.com/blog/sirtex-medical-shares-surge-on-liver-cancer-trial-results-and-strong-sales 2015-08-05T11:37:07 https://maestrodatabase.com/blog/u-dot-s-fda-grants-priority-review-for-vascepa-icosapent-ethyl-supplemental-new-drug-application-seeking-cardiovascular-risk-reduction-indication 2019-05-29T21:28:09 https://maestrodatabase.com/blog/cadth-calls-for-patient-input-on-a-new-submission-from-merck 2015-09-23T21:21:50 https://maestrodatabase.com/blog/therapeutic-goods-administration-of-australia-newest-ich-observer 2016-01-23T21:23:53 https://maestrodatabase.com/blog/charlie-teo-celebrity-surgeons-prices-challenged-by-insurers 2019-05-29T21:17:25 https://maestrodatabase.com/blog/sarepta-therapeutics-announces-plans-to-submit-rolling-nda-for-eteplirsen-following-todays-pre-nda-meeting-with-the-fda 2015-08-05T11:37:05 https://maestrodatabase.com/blog/2015-2025-projections-of-national-health-expenditures-data-released-by-cms 2016-07-13T21:40:01 https://maestrodatabase.com/blog/november-2024-decisions 2024-11-12T01:53:59 https://maestrodatabase.com/blog/nice_says_yes_to_non_hodgkin_s_lymphoma_treatment_in_final_draft_guidance 2015-08-05T11:37:27 https://maestrodatabase.com/blog/call-for-patient-input-31 2016-09-22T10:24:02 https://maestrodatabase.com/blog/highlights-from-the-chmp-27-29-may-2019-meeting 2019-05-29T21:14:40 https://maestrodatabase.com/blog/chmp-recommends-approval-of-dupixent-dupilumab-for-children-aged-6-to-11-years-with-severe-atopic-dermatitis 2020-10-18T02:11:52 https://maestrodatabase.com/blog/fda-approves-yervoy-to-reduce-the-risk-of-melanoma-returning-after-surgery 2015-10-29T20:09:25 https://maestrodatabase.com/blog/ema-fast-tracks-treatment-of-multiple-myeloma-for-approval-in-eu 2016-01-30T07:01:25 https://maestrodatabase.com/blog/prices-of-canadian-generic-medicines-below-international-average 2019-05-29T21:39:08 https://maestrodatabase.com/blog/fda-officials-call-for-patient-friendly-terminology-in-oncology 2019-05-29T21:35:19 https://maestrodatabase.com/blog/welsh-government-overrules-nice-rejection-of-celgenes-pancreatic-cancer-drug 2016-03-27T23:28:15 https://maestrodatabase.com/blog/health-advocate-says-fda-must-walk-a-fine-line-to-ensure-affordable-drugs-are-safe 2019-05-29T21:33:17 https://maestrodatabase.com/blog/sandoz-submits-biologics-license-application-for-proposed-biosimilar-trastuzumab-to-us-fda 2021-12-21T21:16:48 https://maestrodatabase.com/blog/pharmaceutical-benefits-scheme-to-be-reformed 2015-08-05T11:37:14 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-first-drug-for-duchenne-muscular-dystrophy 2016-09-19T20:20:18 https://maestrodatabase.com/blog/mylan-raised-epipens-price-before-the-expected-arrival-of-a-generic 2016-08-25T09:10:19 https://maestrodatabase.com/blog/valeants-ceo-was-key-force-on-pricing 2016-05-02T22:26:20 https://maestrodatabase.com/blog/new-indication-for-teijin-pharmas-febuxostat-in-europe 2015-08-05T11:37:08 https://maestrodatabase.com/blog/first-car-t-cell-medicine-for-mantle-cell-lymphoma 2020-10-18T02:27:11 https://maestrodatabase.com/blog/fda-accepts-supplemental-biologics-license-application-for-keytruda-pembrolizumab-in-recurrent-or-metastatic-head-and-neck-cancer-and-grants-priority-review 2016-04-13T12:26:12 https://maestrodatabase.com/blog/the-upcoming-u-dot-s-health-care-cost-debate----the-publics-views 2019-05-29T21:47:02 https://maestrodatabase.com/blog/community-engagement-in-health-technology-assessment-and-beyond-from-guests-in-the-process-to-hosts 2020-10-18T02:31:13 https://maestrodatabase.com/blog/drug-companies-wont-deny-australia-is-being-ripped-off-on-medicines 2015-08-05T11:37:08 https://maestrodatabase.com/blog/judge-denies-petition-by-supporters-of-california-drug-pricing-ballot 2016-08-16T21:21:25 https://maestrodatabase.com/blog/canada-told-drug-makers-it-would-limit-scope-of-some-new-price-rules 2019-05-29T21:42:55 https://maestrodatabase.com/blog/fda-approves-new-targeted-treatment-for-bladder-cancer 2016-05-18T20:56:21 https://maestrodatabase.com/blog/rft---supply-of-infliximab-to-dhb-hospitals 2015-08-05T11:37:13 https://maestrodatabase.com/blog/revamped-body-to-review-medical-devices-list 2016-09-08T12:51:48 https://maestrodatabase.com/blog/summary-of-the-agenda-for-the-pbac-november-2016-meeting 2016-08-24T21:34:24 https://maestrodatabase.com/blog/novartis-new-heart-failure-medicine-entresto-recommended-by-chmp-for-eu-approval 2015-09-25T05:29:29 https://maestrodatabase.com/blog/swissmedic-authorises-novavax-nuvaxovid-covid-19-vaccine-for-adolescents-aged-12-through-17-and-as-a-booster-in-adults-aged-18-and-older 2022-09-03T02:48:21 https://maestrodatabase.com/blog/mallinckrodt-pharmaceuticals-new-drug-application-accepted-for-review-by-fda 2015-08-05T11:37:14 https://maestrodatabase.com/blog/call-for-patient-input-12 2015-08-05T11:37:29 https://maestrodatabase.com/blog/first-long-acting-injectable-antiretroviral-therapy-for-hiv-recommended-for-approval 2020-10-18T02:14:57 https://maestrodatabase.com/blog/proposals_to_fund_melatonin_and_to_add_the_stat_dispensing_rule_to_buspirone 2015-08-05T11:37:15 https://maestrodatabase.com/blog/first-treatment-for-rare-condition-primary-hyperoxaluria-type-1 2020-10-18T02:18:32 https://maestrodatabase.com/blog/added-benefit-of-sucroferric-oxyhydroxide-is-not-proven 2015-08-05T11:37:29 https://maestrodatabase.com/blog/fda-approves-ofev-to-treat-idiopathic-pulmonary-fibrosis 2015-08-05T11:37:06 https://maestrodatabase.com/blog/pharmaceutical-benefits-scheme-listing-of-ivacaftor-kalydeco-for-cystic-fibrosis 2015-08-05T11:37:11 https://maestrodatabase.com/blog/summary-of-responses-to-pharmacs-consultation-on-future-funding-approach-to-blood-glucose-meters-and-test-strips 2015-08-05T11:37:21 https://maestrodatabase.com/blog/pharmaceutical_benefits_scheme_a_national_treasure__ma_chairman 2015-08-05T11:37:04 https://maestrodatabase.com/blog/az-bags-us-nod-for-xigduo-xr 2015-08-05T11:37:28 https://maestrodatabase.com/blog/nice-appraisal-consultation-for-azacitidine-vidaza-for-patients-with-acute-myeloid-leukaemia 2016-04-08T12:20:05 https://maestrodatabase.com/blog/novartis-launches-first-us-biosimilar-drug-at-15-percent-discount 2015-09-03T11:00:42 https://maestrodatabase.com/blog/benepali-the-first-etanercept-biosimilar-referencing-enbrel-approved-in-the-european-union 2016-01-17T20:03:20 https://maestrodatabase.com/blog/pfizer-announces-fda-acceptance-for-review-of-a-new-drug-application-for-alo-02-oxycodone-hydrochloride-and-naltrexone-hydrochloride 2015-08-05T11:37:15 https://maestrodatabase.com/blog/ipilimumab-in-advanced-melanoma-added-benefit-for-non-pretreated-patients-still-not-proven 2015-08-05T11:37:02 https://maestrodatabase.com/blog/martin-shkreli-all-but-gloated-over-huge-drug-price-increases-memos-show 2016-02-03T09:32:51 https://maestrodatabase.com/blog/pharmaceutical-benefits-advisory-committee-guidelines-review-2 2016-05-07T01:38:22 https://maestrodatabase.com/blog/brexit-could-relocate-eu-drug-and-banking-agencies 2016-06-20T01:12:24 https://maestrodatabase.com/blog/top-lobbyist-for-drug-makers-threads-a-thicket-of-outrage 2016-02-27T02:23:54 https://maestrodatabase.com/blog/rare-cancer-australia-report-a-deadly-discrepancy-in-cancer-care 2015-08-05T11:37:03 https://maestrodatabase.com/blog/new-zealand-public-help-improve-pharmac-decision-making 2016-07-05T23:27:42 https://maestrodatabase.com/blog/tga-approves-new-use-for-takedas-adcetris 2016-09-27T03:29:23 https://maestrodatabase.com/blog/avedro-announces-receipt-of-complete-response-letter-from-fda-for-corneal-cross-linking-nda 2015-08-05T11:37:14 https://maestrodatabase.com/blog/majority-in-us-wants-government-to-curb-prescription-costs-poll-finds 2015-08-21T21:19:16 https://maestrodatabase.com/blog/novartis-drug-afinitor-receives-eu-approval-to-treat-certain-types-of-advanced-gastro-intestinal-and-lung-neuroendocrine-tumours 2016-06-02T05:26:46 https://maestrodatabase.com/blog/daratumumab-with-bortezomib-and-dexamethasone-for-previously-treated-multiple-myeloma 2023-06-06T02:05:25 https://maestrodatabase.com/blog/data-uncertainties-mean-nice-does-not-recommend-leukaemia-drug-in-draft-guidance 2015-08-05T11:37:07 https://maestrodatabase.com/blog/obama-extends-controversial-program-for-rare-pediatric-drugs 2016-10-03T19:52:17 https://maestrodatabase.com/blog/nice-approves-first-drug-from-old-cancer-drugs-fund 2016-07-07T11:57:58 https://maestrodatabase.com/blog/agenda-for-the-3-february-2016-tc-meeting 2016-01-29T11:35:44 https://maestrodatabase.com/blog/pbac-public-summary-documents-november-2014 2015-08-05T11:37:18 https://maestrodatabase.com/blog/health-fund-premiums-soviet-way-boosts-health-costs 2016-01-28T23:01:15 https://maestrodatabase.com/blog/ahes-conference-and-ahed-workshop-abstract-submission-deadline-is-friday-18-july-2014 2015-08-05T11:37:21 https://maestrodatabase.com/blog/injectafer-approved-in-the-us-for-the-treatment-of-iron-deficiency-in-adult-patients-with-heart-failure 2023-06-06T01:44:11 https://maestrodatabase.com/blog/eribulin-mesylate-halaven-for-breast-cancer-positive-effects-predominate-in-certain-patients-negative-effects-in-others 2015-08-05T11:37:28 https://maestrodatabase.com/blog/european-chmp-adopts-positive-opinion-for-gileads-fixed-dose-combination-descovy-emtricitabinetenofovir-alafenamide-for-the-treatment-of-hiv 2016-02-26T21:24:56 https://maestrodatabase.com/blog/european-commission-approves-orfadin-oral-suspension 2015-08-05T11:37:02 https://maestrodatabase.com/blog/use-of-intermediate-endpoints-in-the-economic-evaluation-of-new-treatments-for-advanced-cancer-and-methods-adopted-when-suitable-overall-survival-data-are-not-available 2016-08-14T23:00:15 https://maestrodatabase.com/blog/booker-and-sanders-propose-a-new-federal-agency-to-set-drug-prices 2019-11-16T21:56:52 https://maestrodatabase.com/blog/top-us-doctors-say-pricey-cholesterol-drugs-best-for-limited-group 2015-09-29T21:17:47 https://maestrodatabase.com/blog/cancer-patient-in-16k-hit-to-stay-alive 2015-08-05T11:37:13 https://maestrodatabase.com/blog/changes-to-number-of-copies-of-the-economic-model-and-category-1-requirements-to-be-filed-with-cadth 2015-11-02T21:17:30 https://maestrodatabase.com/blog/australians-forced-to-wait-15-months-for-new-drugs-vs-us--europe-report 2015-08-05T11:37:12 https://maestrodatabase.com/blog/ema-fast-tracks-new-oral-treatment-for-non-small-cell-lung-cancer 2015-12-19T02:22:14 https://maestrodatabase.com/blog/glavine-urges-action-on-cf-drug-prices 2015-08-05T11:37:05 https://maestrodatabase.com/blog/nice-recommends-ovarian-cancer-treatments 2016-04-27T11:28:08 https://maestrodatabase.com/blog/springworks-therapeutics-announces-pdufa-date-extension-for-nirogacestat-nda 2023-06-06T03:35:29 https://maestrodatabase.com/blog/latest_pbs_listings_include_medicines_for_children 2015-08-05T11:37:14 https://maestrodatabase.com/blog/nhs-patients-missing-out-on-cancer-drugs 2016-08-15T11:40:14 https://maestrodatabase.com/blog/adaptive-pathways-to-drug-authorisation-adapting-to-industry 2016-08-19T06:46:57 https://maestrodatabase.com/blog/celebrating-20-years-ema-launches-anniversary-book 2015-08-05T11:37:15 https://maestrodatabase.com/blog/miracle-med-too-costly-for-patient 2016-02-28T20:02:51 https://maestrodatabase.com/blog/navigating-the-dermatological-drug-cost-curve 2016-06-28T21:36:46 https://maestrodatabase.com/blog/labour-will-exclude-the-nhs-and-medicines-from-trade-deals-with-the-us 2019-11-16T22:00:44 https://maestrodatabase.com/blog/life-saving-drug-for-adult-pompe-patients 2015-08-05T11:37:28 https://maestrodatabase.com/blog/smc-march-2016-decisions-news-release 2016-03-07T20:38:16 https://maestrodatabase.com/blog/costs-for-dementia-care-far-exceeding-other-diseases-study-finds 2015-10-27T19:13:23 https://maestrodatabase.com/blog/shortage-of-migraine-medication-crushing-for-chronic-pain-patients 2024-02-24T04:30:26 https://maestrodatabase.com/blog/pbs-listing-of-tamoxifen-citrate-projected-to-benefit-thousands-of-women 2016-04-29T21:34:11 https://maestrodatabase.com/blog/us-fda-accepts-nda-for-once-daily-formulation-of-anti-obesity-agent-belviq 2015-12-01T19:28:38 https://maestrodatabase.com/blog/fda-approves-first-injectable-treatment-for-hiv-pre-exposure-prevention 2021-12-21T23:29:24 https://maestrodatabase.com/blog/shire-receives-chmp-positive-opinion-in-europe-for-intiniv-guanfacine-hydrochloride-extended-release-as-a-non-stimulant-adhd-treatment-for-children-and-adolescents 2015-08-05T11:37:17 https://maestrodatabase.com/blog/new-cell-based-therapy-to-support-stem-cell-transplantation-in-patients-with-high-risk-blood-cancer 2016-06-24T22:43:14 https://maestrodatabase.com/blog/white-house-is-pressed-to-help-widen-access-to-hepatitis-c-drugs-via-medicaid 2015-08-26T11:01:11 https://maestrodatabase.com/blog/experimental-immunotherapy-drug-reduces-rare-tumour-size-dramatically 2016-06-26T21:46:26 https://maestrodatabase.com/blog/additional-benefit-of-crizotinib-for-the-first-line-treatment-of-bronchial-carcinoma-is-not-proven 2016-04-08T09:37:11 https://maestrodatabase.com/blog/nice-issues-draft-guidance-on-the-use-of-lesinurad 2016-08-04T21:19:02 https://maestrodatabase.com/blog/esketamine-hydrochloride-for-the-treatment-of-adults-with-major-depressive-disorder-at-imminent-risk-of-suicide 2023-06-06T03:44:07 https://maestrodatabase.com/blog/biomarin-announces-ema-grants-accelerated-assessment-for-cerliponase-alfa-experimental-treatment-for-a-form-of-batten-disease 2016-05-04T07:20:05 https://maestrodatabase.com/blog/expanded-pbs-safety-net-early-supply-arrangements-apply-from-1-january-2016 2016-01-04T01:43:06 https://maestrodatabase.com/blog/draft_guidance_from_nice_asks_for_more_information_on_multiple_sclerosis_treatment 2015-08-05T11:37:27 https://maestrodatabase.com/blog/biotech-gets-a-reality-check 2015-08-05T11:37:05 https://maestrodatabase.com/blog/new-fund-set-up-to-support-research-into-medicines-usage-in-nz 2016-06-08T06:35:04 https://maestrodatabase.com/blog/cost-of-cystic-fibrosis-treatment-too-high-for-benefit-offered-says-nice 2016-06-17T11:28:27 https://maestrodatabase.com/blog/outcomes_from_the_march_2014_pbac_meeting 2015-08-05T11:37:20 https://maestrodatabase.com/blog/rare-diseases-no-reason-for-lower-demands-for-studies 2015-08-05T11:37:05 https://maestrodatabase.com/blog/implementation-of-guidelines-for-manufacturers-on-application-fees-for-pcodr 2015-08-05T11:37:25 https://maestrodatabase.com/blog/neurotech-provides-update-on-bla-for-nt-501-as-a-treatment-for-macular-telangiectasia-type-2 2024-11-12T02:50:34 https://maestrodatabase.com/blog/daclatasvir-for-hepatitis-c-added-benefit-not-proven 2015-08-05T11:37:22 https://maestrodatabase.com/blog/letting-post-marketing-bridge-the-evidence-gap-the-case-of-orphan-drugs 2016-06-29T03:05:57 https://maestrodatabase.com/blog/chmp-chair-re-elected 2015-09-21T21:03:25 https://maestrodatabase.com/blog/fda-approves-xtoro-to-treat-swimmers-ear 2015-08-05T11:37:26 https://maestrodatabase.com/blog/doctors-hit-out-over-greater-care-role-for-pharmacists-under-new-19b-deal 2015-08-05T11:37:22 https://maestrodatabase.com/blog/cancer-drug-ads-vs-cancer-drug-reality 2016-08-09T10:56:58 https://maestrodatabase.com/blog/george_laking__talks_lose_lose_for_cancer_patients 2015-08-05T11:37:22 https://maestrodatabase.com/blog/patients-with-brvo-a-sight-threatening-eye-condition-now-have-first-line-access-to-eylea-aflibercept-solution-for-injection-on-the-nhs 2016-09-28T05:14:53 https://maestrodatabase.com/blog/agenda-for-11-june-2014-transparency-commission-meeting 2015-08-05T11:37:10 https://maestrodatabase.com/blog/nice-backs-ferrings-firmagon 2016-07-04T21:22:54 https://maestrodatabase.com/blog/fda-approves-drug-to-treat-help-prevent-types-of-blood-clots-in-certain-pediatric-populations 2021-12-22T00:15:03 https://maestrodatabase.com/blog/agenda-for-1-april-2015-tc-meeting 2015-08-05T11:37:14 https://maestrodatabase.com/blog/trade-negotiations-stall-over-drugs-and-dairy-extending-talks-another-day 2015-10-04T10:49:48 https://maestrodatabase.com/blog/first-oral-treatment-against-residual-haemolytic-anaemia-in-patients-with-paroxysmal-nocturnal-haemoglobinuria 2024-02-24T06:19:44 https://maestrodatabase.com/blog/astrazeneca-chief-warns-uk-falling-behind-in-cancer-care 2015-08-05T11:37:03 https://maestrodatabase.com/blog/pharmac-publishes-experts-advice-and-seeks-views-on-patient-access-criteria-for-covid-19-treatments 2021-12-22T04:00:19 https://maestrodatabase.com/blog/vertex-receives-european-approval-for-kalydeco-ivacaftor-in-eight-non-g551d-gating-mutations 2015-08-05T11:37:02 https://maestrodatabase.com/blog/health-minister-sussan-ley-says-cost-of-common-medicines-could-halve-under-new-generic-drug-deal 2015-08-05T11:37:12 https://maestrodatabase.com/blog/us-fda-accepts-for-priority-review-snda-for-eisais-anti-cancer-agent-lenvatinib-seeking-approval-for-renal-cell-carcinoma 2016-01-18T11:40:50 https://maestrodatabase.com/blog/chmp-recommends-eu-approval-of-roches-kadcyla-for-the-adjuvant-treatment-of-people-with-her2-positive-early-breast-cancer-with-residual-invasive-disease-after-neo-adjuvant-treatment 2019-11-17T02:28:28 https://maestrodatabase.com/blog/senate-committee-calls-for-medicine-review-1 2015-09-17T10:52:15 https://maestrodatabase.com/blog/new-treatment-for-rare-motor-neurone-disease-recommended-for-approval 2024-02-24T06:11:32 https://maestrodatabase.com/blog/lillys-alimta-wins-nice-support 2016-07-21T10:21:49 https://maestrodatabase.com/blog/psivida_reports_iluvien_to_be_funded_by_uk_s_national_health_service_for_treatment_of_pseudophakic_chronic_dme_patients_following_issuance_of_final_nice_guidance 2015-08-05T11:37:23 https://maestrodatabase.com/blog/aprecia-pharmaceuticals-receives-fda-acceptance-for-filing-for-first-product-using-advanced-zipdose-technology 2015-08-05T11:37:13 https://maestrodatabase.com/blog/chmp-recommends-conditional-eu-approval-of-roches-polivy-for-people-with-previously-treated-aggressive-lymphoma 2019-11-17T02:23:58 https://maestrodatabase.com/blog/fda-approves-new-product-to-treat-rare-genetic-disease 2015-08-05T11:37:09 https://maestrodatabase.com/blog/september-2016-decisions-news-release 2016-09-12T21:04:54 https://maestrodatabase.com/blog/fennec-pharmaceuticals-resubmits-new-drug-application-to-the-u-dot-s-fda-for-pedmark 2022-03-24T19:39:38 https://maestrodatabase.com/blog/gsk-receives-eu-marketing-authorisation-for-mekinist-trametinib-for-patients-with-unresectable-or-metastatic-melanoma-with-a-braf-v600-mutation 2015-08-05T11:37:20 https://maestrodatabase.com/blog/industry-calls-for-reform-at-cancer-medicines-inquiry 2015-08-05T11:37:09 https://maestrodatabase.com/blog/pfizer-expands-its-patient-assistance-program-doubling-the-income-eligibility-limit-to-benefit-even-more-patients-taking-pfizer-medicines 2015-11-05T20:20:26 https://maestrodatabase.com/blog/tricida-announces-fda-acceptance-of-new-drug-application-for-veverimer 2019-11-17T03:24:30 https://maestrodatabase.com/blog/stakeholder_forum_outcomes___asthma_post_market_review 2015-08-05T11:37:26 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-october-2014-update 2015-08-05T11:37:06 https://maestrodatabase.com/blog/janssen-submits-marketing-authorisation-application-for-daratumumab-for-european-patients-with-heavily-pre-treated-multiple-myeloma 2015-09-14T01:42:11 https://maestrodatabase.com/blog/france-to-back-roche-cancer-drug-as-cheaper-eye-treatment 2015-08-05T11:37:15 https://maestrodatabase.com/blog/cadth-assessment-of-the-interventions-for-the-management-of-patients-with-symptomatic-uterine-fibroids 2015-09-03T21:40:23 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule-1-september-2016-update 2016-08-31T11:45:09 https://maestrodatabase.com/blog/novartis-receives-european-approval-for-cosentyx-as-first-and-only-il-17a-inhibitor-for-hidradenitis-suppurativa 2023-06-06T05:38:45 https://maestrodatabase.com/blog/united-states-first-country-to-launch-saxenda 2015-08-05T11:37:18 https://maestrodatabase.com/blog/orexigens-mysimba-approved-in-europe-for-the-treatment-of-obesity 2015-08-05T11:37:28 https://maestrodatabase.com/blog/durvalumab-granted-breakthrough-therapy-designation-by-us-fda-for-treatment-of-patients-with-pd-l1-positive-urothelial-bladder-cancer 2016-02-17T11:13:56 https://maestrodatabase.com/blog/nice-consults-on-draft-guidance-recommending-treatments-for-types-of-arthritis-that-affect-the-spine 2015-08-05T11:37:13 https://maestrodatabase.com/blog/tesaro-receives-fda-fast-track-designation-for-niraparib-and-initiates-rolling-nda-submission 2016-09-12T20:42:14 https://maestrodatabase.com/blog/anger-over-decision-to-refuse-patients-ms-drugs 2015-08-05T11:37:18 https://maestrodatabase.com/blog/manitoba-adds-kadcyla-to-the-provincial-formulary-for-the-treatment-of-her2-positive-metastatic-breast-cancer 2015-08-05T11:37:06 https://maestrodatabase.com/blog/australian-cancer-patients-in-deadly-wait-for-new-medicines 2015-08-05T11:37:05 https://maestrodatabase.com/blog/ipsen-confirms-u-dot-s-fda-accepts-new-drug-application-for-palovarotene-as-the-first-potential-treatment-worldwide-for-fibrodysplasia-ossificans-progressiva 2021-05-29T02:51:58 https://maestrodatabase.com/blog/pacira-receives-complete-response-letter-from-fda-for-snda-seeking-approval-of-exparel-use-in-nerve-block-to-provide-post-surgical-analgesia 2015-08-05T11:37:22 https://maestrodatabase.com/blog/nice-approves-new-cancer-drugs-for-routine-nhs-use 2016-08-24T13:23:23 https://maestrodatabase.com/blog/health-sector-feedback-helps-make-the-most-of-government-funding-boost 2016-06-09T04:36:50 https://maestrodatabase.com/blog/venatorx-and-melinta-provide-update-on-status-of-us-new-drug-application-for-cefepime-taniborbactam 2024-02-24T07:03:25 https://maestrodatabase.com/blog/proposal-to-list-nivolumab-opdivo-for-advanced-melanoma 2016-05-04T00:42:35 https://maestrodatabase.com/blog/cadth-calls-for-feedback-antivascular-endothelial-growth-factor-drugs-for-retinal-conditions 2015-12-16T21:28:48 https://maestrodatabase.com/blog/the_outcomes_from_the_november_2013_ptac_meeting_are_now_in_the_public_domain 2015-08-05T11:37:07 https://maestrodatabase.com/blog/xtandi-enzalutamide-capsules-receive-positive-chmp-opinion-for-the-treatment-of-men-with-metastatic-castration-resistant-prostate-cancer-who-are-chemotherapy-naive 2015-08-05T11:37:15 https://maestrodatabase.com/blog/prices-for-new-us-drugs-rose-35-percent-in-2023-more-than-the-previous-year 2024-02-24T06:54:36 https://maestrodatabase.com/blog/anoro-ellipta-umeclidiniumvilanterol-to-be-reimbursed-in-australia-for-chronic-obstructive-pulmonary-disease 2015-08-05T11:37:03 https://maestrodatabase.com/blog/summary-of-the-agenda-for-the-pbac-november-2015-meeting 2015-08-26T21:37:01 https://maestrodatabase.com/blog/medicines-new-zealand-has-never-threatened-new-zealand 2016-04-27T20:56:03 https://maestrodatabase.com/blog/german_watchdog_deals_setback_to_bayer_eye_drug_eylea__aflibercept_ 2015-08-05T11:37:07 https://maestrodatabase.com/blog/drug-insurance-a-single-payer-pharmacare-program-would-jeopardise-coverage-quality-for-21-million-canadians 2024-02-24T06:42:41 https://maestrodatabase.com/blog/cadth-calls-for-patient-input-on-a-submission-from-gilead-for-sofosbuvir-with-velpatasvir 2016-03-23T20:45:34 https://maestrodatabase.com/blog/new-nice-knockback-for-celgene-myeloma-drug 2015-08-05T11:37:15 https://maestrodatabase.com/blog/pbs-expenditure-and-prescriptions-report-2014-15 2016-05-04T08:15:01 https://maestrodatabase.com/blog/janssen-receives-positive-chmp-opinion-for-carvykti-ciltacabtagene-autoleucel-for-treatment-in-earlier-lines-of-relapsed-and-refractory-multiple-myeloma 2024-02-24T06:36:48 https://maestrodatabase.com/blog/tga-publishes-auspar-for-opdivo-nivolumab 2016-09-07T06:59:11 https://maestrodatabase.com/blog/dasabuvir-and-ombitasvirparitaprevirritonavir-iqwig-finds-a-hint-of-an-additional-benefit-in-some-patients 2015-08-06T20:54:53 https://maestrodatabase.com/blog/value-can-we-afford-to-think-long-term-while-ignoring-budget-impact 2016-09-23T11:57:43 https://maestrodatabase.com/blog/novogen-anti-cancer-drug-trxe-009-crosses-blood-brain-barrier 2015-08-05T11:37:24 https://maestrodatabase.com/blog/pembrolizumab-has-an-additional-benefit-in-certain-patients-with-advanced-melanoma-says-iqwig 2015-11-16T20:28:09 https://maestrodatabase.com/blog/americas-health-care-prices-are-out-of-control-these-11-charts-prove-it 2016-07-19T21:51:30 https://maestrodatabase.com/blog/onivyde-receives-positive-chmp-opinion-for-treatment-of-patients-with-metastatic-adenocarcinoma-of-the-pancreas-who-have-progressed-following-gemcitabine-based-therapy 2016-07-25T09:04:48 https://maestrodatabase.com/blog/prescription-drugs-arent-the-largest-driver-of-premium-increases 2016-08-04T12:31:27 https://maestrodatabase.com/blog/brexit-to-cost-jobs-if-uk-loses-pharma-watchdog 2016-09-07T08:41:02 https://maestrodatabase.com/blog/vertex-receives-chmp-positive-opinion-for-kalydeco-for-the-treatment-of-infants-with-cystic-fibrosis-ages-1-month-and-older 2024-02-24T07:23:44 https://maestrodatabase.com/blog/merck-receives-breakthrough-therapy-designation-from-us-food-and-drug-administration-for-keytruda-pembrolizumab-in-advanced-colorectal-cancer 2015-11-02T20:58:48 https://maestrodatabase.com/blog/dying_doctor_s_dream__to_hold_his_baby_girl 2015-08-05T11:37:29 https://maestrodatabase.com/blog/unicycive-therapeutics-announces-us-fda-acceptance-of-the-new-drug-application-for-oxylanthanum-carbonate-for-the-treatment-of-hyperphosphataemia-in-patients-with-chronic-kidney-disease-on-dialysis 2024-11-12T05:06:16 https://maestrodatabase.com/blog/agenda-for-28-may-2014-transparency-commission-meeting 2015-08-05T11:37:15 https://maestrodatabase.com/blog/fda-grants-priority-review-for-asfotase-alfa-as-a-treatment-for-patients-with-hypophosphatasia 2015-08-05T11:37:29 https://maestrodatabase.com/blog/republicans-should-not-help-bernie-sanders-push-socialised-medicine 2023-06-06T06:13:42 https://maestrodatabase.com/blog/impax-receives-fda-approval-of-emverm-mebendazole-100-mg-chewable-tablets 2016-01-18T07:10:13 https://maestrodatabase.com/blog/every-life-is-worth-the-same-but-maybe-not-at-pharmac 2022-09-03T22:15:08 https://maestrodatabase.com/blog/sunovion-pharmaceuticals-canada-announces-health-canada-approval-of-aptiom-eslicarbazepine-acetate-as-a-once-daily-adjunctive-treatment-for-partial-onset-seizures-in-patients-with-epilepsy 2015-08-05T11:37:08 https://maestrodatabase.com/blog/access-to-medicines-at-risk 2015-08-05T11:37:11 https://maestrodatabase.com/blog/ulcerative-colitis-comparative-study-provides-important-insights 2025-09-05T05:44:22 https://maestrodatabase.com/blog/ron-walker-survived-skin-cancer-now-other-australians-can-get-the-wonder-drug-that-saved-him 2015-08-05T11:37:04 https://maestrodatabase.com/blog/jinarc-recommended-for-approval-in-rare-kidney-disease 2015-08-05T11:37:30 https://maestrodatabase.com/blog/prostheses-reform-a-priority-for-cheaper-health-premiums 2016-02-05T06:55:13 https://maestrodatabase.com/blog/us-and-european-regulators-accept-applications-for-abbvies-venetoclax-the-first-potential-bcl-2-inhibitor-for-chronic-lymphocytic-leukaemia 2016-01-12T19:53:22 https://maestrodatabase.com/blog/nice-welcomes-new-non-executive-director 2015-08-05T11:37:13 https://maestrodatabase.com/blog/nzers-getting-access-to-best-cancer-medicines-says-pharmac 2015-11-03T19:50:03 https://maestrodatabase.com/blog/innovation-focus-will-deliver-benefits-to-australia 2015-12-07T11:35:15 https://maestrodatabase.com/blog/2016-pbs-co-payment-and-safety-net-amounts 2016-01-04T02:23:45 https://maestrodatabase.com/blog/fda-approves-treatment-for-inhalation-anthrax 2015-08-05T11:37:27 https://maestrodatabase.com/blog/ultomiris-regulatory-submission-accepted-under-fda-priority-review-in-the-us-for-adults-with-generalised-myasthenia-gravis 2021-12-22T05:01:48 https://maestrodatabase.com/blog/abbvie-announces-submission-of-a-supplemental-new-drug-application-for-ibrutinib-imbruvica-for-treatment-of-marginal-zone-lymphoma 2016-09-26T11:22:56 https://maestrodatabase.com/blog/california-plans-to-shame-drug-makers-who-hike-prices 2016-07-11T21:28:16 https://maestrodatabase.com/blog/new-heart-medicine-for-18-000-new-zealanders 2024-11-12T06:25:37 https://maestrodatabase.com/blog/propranolol-in-proliferating-infantile-haemangioma-indication-of-major-added-benefit-in-certain-patients 2015-08-05T11:37:15 https://maestrodatabase.com/blog/baxalta-gains-eu-marketing-authorisation-to-provide-obizur-to-adult-patients-with-acquired-haemophilia-a 2015-11-14T19:28:45 https://maestrodatabase.com/blog/setting-the-bodys-serial-killers-loose-on-cancer 2016-08-02T08:26:05 https://maestrodatabase.com/blog/turnbull-government-invests-over-1-billion-to-cure-hepatitis-c 2015-12-21T20:22:14 https://maestrodatabase.com/blog/surrogate-endpoints-and-their-validation-in-oncology-clinical-trials 2016-04-20T22:47:26 https://maestrodatabase.com/blog/tga-approves-tagrisso-osimertinib-mesylate 2016-08-13T01:07:51 https://maestrodatabase.com/blog/agios-provides-update-on-us-pdufa-goal-date-for-pyrukynd-mitapivat-in-thalassemia 2025-09-05T05:18:28 https://maestrodatabase.com/blog/fda-approves-portrazza-to-treat-advanced-squamous-non-small-cell-lung-cancer 2015-11-25T09:15:31 https://maestrodatabase.com/blog/toujeo-approved-in-the-european-union-for-the-treatment-of-diabetes-in-adults 2015-08-05T11:37:03 https://maestrodatabase.com/blog/prescriptions-to-display-drug-cost 2015-08-05T11:37:13 https://maestrodatabase.com/blog/transitioning-of-herceptin-subsidy-to-the-pharmaceutical-benefits-scheme 2015-08-05T11:37:15 https://maestrodatabase.com/blog/price-disclosure-2016-october-cycle-outcomes-summary 2016-07-18T07:19:10 https://maestrodatabase.com/blog/telesta-receives-fda-bla-filing-notification-letter-and-priority-review-designation-for-mcna 2015-09-01T21:54:39 https://maestrodatabase.com/blog/health-minister-slams-panadol-osteo-maker-for-50-price-rise-plans 2015-12-30T22:53:44 https://maestrodatabase.com/blog/atagi-update-following-weekly-covid-19-meeting-31-august-2022 2022-09-03T22:28:12 https://maestrodatabase.com/blog/health-canada-approves-subcutaneous-actemra-tocilizumab-for-use-in-adult-patients-living-with-moderately-to-severely-active-rheumatoid-arthritis 2015-08-05T11:37:21 https://maestrodatabase.com/blog/ibrutinib-indication-of-an-additional-clinical-benefit-in-one-of-three-therapeutic-indications 2016-05-02T21:10:13 https://maestrodatabase.com/blog/agenda-for-25-june-2014-transparency-commission-meeting 2015-08-05T11:37:08 https://maestrodatabase.com/blog/justice-department-will-seek-to-block-2-health-insurance-mergers 2016-07-20T12:33:59 https://maestrodatabase.com/blog/post-market-review-of-pbs-medicines-used-to-treat-asthma-in-children-1 2015-08-05T11:37:18 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule-1-september-2015 2015-08-31T21:25:03 https://maestrodatabase.com/blog/novartis-multiproduct-proposal 2015-08-05T11:37:22 https://maestrodatabase.com/blog/pfizer-slash-biontech-bivalent-covid-19-booster-approved-by-uk-medicines-regulator 2022-09-03T23:04:36 https://maestrodatabase.com/blog/als-patients-press-fda-for-quick-access-to-controversial-biotech-drug 2015-08-05T11:37:18 https://maestrodatabase.com/blog/options-to-promote-competitive-generics-markets-in-the-united-states 2015-10-29T20:43:44 https://maestrodatabase.com/blog/ema-publishes-list-of-applications-for-new-human-medicines-under-evaluation-by-the-committee-for-medicinal-products-for-human-use 2016-06-16T20:59:19 https://maestrodatabase.com/blog/roche-gets-priority-review-for-melanoma-drug-cobimetinib 2015-08-05T11:37:02 https://maestrodatabase.com/blog/agenda-for-july-2016-chmp-meeting 2016-07-19T21:20:15 https://maestrodatabase.com/blog/fda-approves-wilate-license-supplement-peri-operative-management-of-bleeding-in-patients-with-von-willebrand-disease 2015-08-15T11:33:02 https://maestrodatabase.com/blog/datopotamab-deruxtecan-new-bla-submitted-for-accelerated-approval-in-the-us-for-patients-with-previously-treated-advanced-egfr-mutated-non-small-cell-lung-cancer 2024-11-12T10:04:16 https://maestrodatabase.com/blog/health_canada_approves_tudorza_genuair__aclidinium_bromide__as_a_new_treatment_for_patients_living_with_copd 2015-08-05T11:37:28 https://maestrodatabase.com/blog/why-gene-therapy-drugs-are-so-expensive 2016-08-04T21:08:34 https://maestrodatabase.com/blog/fda-approval-of-afstyla-rfviii-single-chain 2016-05-26T10:35:32 https://maestrodatabase.com/blog/fda-knocks-back-novartis-copy-of-amgens-drug-neulasta 2016-07-19T21:12:10 https://maestrodatabase.com/blog/agenda-for-the-17-june-2015-tc-meeting 2015-08-05T11:37:30 https://maestrodatabase.com/blog/novartis-lung-cancer-drug-zykadia-gains-eu-approval-providing-new-therapy-for-certain-patients-with-alk-nsclc 2015-08-05T11:37:30 https://maestrodatabase.com/blog/novartis-receives-eu-approval-for-revolade-as-first-in-class-therapy-for-children-aged-1-year-and-above-with-chronic-itp 2016-04-07T05:55:18 https://maestrodatabase.com/blog/shire-resubmits-new-drug-application-for-lifitegrast-to-us-fda 2016-01-26T01:43:50 https://maestrodatabase.com/blog/high-cost-of-new-drugs 2016-07-30T01:38:45 https://maestrodatabase.com/blog/what-they-are-saying-about-icers-scoping-document-for-non-small-cell-lung-cancer 2016-07-12T21:34:18 https://maestrodatabase.com/blog/alchemia-drug-sale-boosts-shares 2015-09-25T22:11:41 https://maestrodatabase.com/blog/health-canada-approves-varithena-polidocanol-injectable-foam-for-patients-with-varicose-veins 2015-08-11T21:19:51 https://maestrodatabase.com/blog/health-care-law-results-in-24-billion-in-consumer-rebates-on-premiums-since-2011 2015-11-19T20:58:48 https://maestrodatabase.com/blog/alprolix-rfixfc-approved-in-the-eu-for-the-treatment-of-haemophilia-b 2016-05-13T09:10:51 https://maestrodatabase.com/blog/five-new-drugs-given-approval-for-use-by-scottish-nhs 2015-08-05T11:37:30 https://maestrodatabase.com/blog/gsk-receives-us-fda-file-acceptance-for-jemperli-dostarlimab-plus-chemotherapy-for-the-treatment-of-dmmr-slash-msi-h-primary-advanced-or-recurrent-endometrial-cancer 2023-06-06T08:59:32 https://maestrodatabase.com/blog/nice-diabetes-guidelines-still-dont-add-up-say-doctors-and-pharma-company 2015-08-05T11:37:04 https://maestrodatabase.com/blog/us-fda-approves-henlius-and-organons-bildyos-denosumab-nxxp-and-bilprevda-denosumab-nxxp-biosimilars-to-prolia-denosumab-and-xgeva-denosumab-respectively 2025-09-05T06:00:47 https://maestrodatabase.com/blog/icer-to-review-treatments-for-rheumatoid-arthritis-and-psoriatic-arthritis 2016-07-11T21:06:45 https://maestrodatabase.com/blog/chemist-warehouse-makes-mockery-of-government-regulation 2016-01-08T00:04:15 https://maestrodatabase.com/blog/tga-approves-new-indication-for-gazyva 2016-09-05T08:26:43 https://maestrodatabase.com/blog/cdf-has-improved-drugs-access-but-is-not-sustainable-nao-finds 2015-09-17T10:41:00 https://maestrodatabase.com/blog/fda-shuffles-longtime-division-head-janet-woodcock-to-focus-exclusively-on-covid-19-vaccine-project 2020-05-24T21:14:16 https://maestrodatabase.com/blog/lung_cancer_treatment_takes_another_forward_step 2015-08-05T11:37:13 https://maestrodatabase.com/blog/senate-supports-cheaper-medicines-for-australians 2015-08-05T11:37:21 https://maestrodatabase.com/blog/decision-to-list-ferric-carboxymaltose-ferinject-for-use-in-dhb-hospitals 2015-08-05T11:37:29 https://maestrodatabase.com/blog/federal-scientists-finally-publish-remdesivir-data 2020-05-24T21:20:15 https://maestrodatabase.com/blog/martin-shkreli-the-bad-boy-of-pharmaceuticals-hits-back 2015-12-06T10:09:31 https://maestrodatabase.com/blog/exclusive-americans-overpaying-hugely-for-cancer-drugs-study 2015-09-23T11:14:01 https://maestrodatabase.com/blog/u-dot-s-is-ahead-of-china-in-vaccine-race-former-fda-chief-says 2020-05-24T21:24:37 https://maestrodatabase.com/blog/hepatitis-c-drug-maker-puts-profit-ahead-of-patients-us-senate-report-charges 2015-12-04T21:26:02 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-december-2014-update 2015-08-05T11:37:23 https://maestrodatabase.com/blog/zealand-pharma-announces-fda-acceptance-of-new-drug-application-for-the-dasiglucagon-hypopal-rescue-pen-for-treatment-of-severe-hypoglycemia 2020-05-24T21:04:14 https://maestrodatabase.com/blog/nice-supports-nhs-use-of-roches-gazyvaro-in-cll 2015-08-05T11:37:23 https://maestrodatabase.com/blog/european-commission-approves-amgens-blincyto-blinatumomab-for-the-treatment-of-adults-with-philadelphia-chromosome-negative-relapsed-or-refractory-b-precursor-acute-lymphoblastic-leukaemia 2015-11-24T20:45:57 https://maestrodatabase.com/blog/perc_finally_recommends_the_use_of_pazopanib_hydrochloride__votrient__in_patients_with_renal_cell_carcinoma 2015-08-05T11:37:05 https://maestrodatabase.com/blog/acelrx-pharmaceuticals-reports-that-the-european-commission-has-granted-marketing-authorization-for-zalviso-for-treatment-of-acute-moderate-to-severe-post-operative-pain-in-adult-patients 2015-09-23T08:18:01 https://maestrodatabase.com/blog/hikma-receives-fda-approval-for-its-generic-vascepa 2020-05-24T21:09:14 https://maestrodatabase.com/blog/teva-announces-fda-approval-of-qnasl-beclomethasone-dipropionate-nasal-aerosol-for-treatment-of-children-with-seasonal-and-perennial-allergic-rhinitis 2015-08-05T11:37:30 https://maestrodatabase.com/blog/call-for-patient-input-16 2015-08-05T11:37:06 https://maestrodatabase.com/blog/proposals-for-funding-in-the-neurology-immunosuppressants-diabetes-and-anti-thrombotic-therapy-areas 2019-05-30T04:47:34 https://maestrodatabase.com/blog/astellas-xtandi-approved-for-use-with-advanced-prostate-cancer-patients-prior-to-chemotherapy 2015-12-19T02:41:47 https://maestrodatabase.com/blog/melanoma-drug-keytruda-should-be-funded-here-labour-says 2016-03-06T20:16:07 https://maestrodatabase.com/blog/doh-publishes-agenda-for-november-2025-pbac-meeting-version-3 2025-09-05T07:05:48 https://maestrodatabase.com/blog/grade-evidence-to-decision-frameworks-a-systematic-and-transparent-approach-to-making-well-informed-health-care-choices-2-clinical-practice-guidelines 2016-07-07T04:37:50 https://maestrodatabase.com/blog/funding-new-cancer-drugs-extends-kiwis-lives-keep-patients-out-of-hospital 2016-08-23T04:13:35 https://maestrodatabase.com/blog/nice-draft-guidance-recommends-rivaroxaban-xarelto-to-prevent-blood-clots-in-people-who-have-had-a-heart-attack 2015-08-05T11:37:11 https://maestrodatabase.com/blog/back-to-the-health-policy-drawing-board 2018-03-18T19:52:18 https://maestrodatabase.com/blog/ovarian-cancer-patients-denied-innovative-drug-amid-cost-concerns 2015-08-05T11:37:22 https://maestrodatabase.com/blog/fda-approves-cinqair-to-treat-severe-asthma 2016-03-23T19:42:19 https://maestrodatabase.com/blog/nice-draft-guidance-recommends-apixaban-eliquis-for-treating-and-preventing-potentially-fatal-blood-clots 2015-08-05T11:37:29 https://maestrodatabase.com/blog/fast-track-routes-for-medicines-that-address-unmet-medical-needs 2015-08-05T11:37:09 https://maestrodatabase.com/blog/bayer-receives-eu-approval-for-stivarga-regorafenib-for-the-second-line-systemic-treatment-of-liver-cancer 2017-08-08T02:37:07 https://maestrodatabase.com/blog/cms-finalises-coverage-of-next-generation-sequencing-tests-ensuring-enhanced-access-for-cancer-patients 2018-03-18T20:01:17 https://maestrodatabase.com/blog/fresenius-kabis-regulatory-submission-for-pegfilgrastim-biosimilar-accepted-for-review-by-ema 2020-05-24T21:32:38 https://maestrodatabase.com/blog/raptor-pharmaceutical-receives-fda-approval-of-expanded-label-for-procysbi-to-treat-children-aged-2-6-years-with-nephropathic-cystinosis 2015-08-18T10:26:09 https://maestrodatabase.com/blog/medicines-new-zealand-statement-on-the-trans-pacific-partnership-negotiations 2015-10-06T06:09:37 https://maestrodatabase.com/blog/fda-approves-medicines360s-snda-for-liletta-levonorgestrel-releasing-intrauterine-system-52-mg-to-prevent-pregnancy-for-up-to-four-years 2017-08-08T02:31:11 https://maestrodatabase.com/blog/nice-says-ok-to-keytruda-for-bladder-cancer-via-the-cancer-drugs-fund 2018-03-18T20:06:02 https://maestrodatabase.com/blog/celgene-threatens-to-scale-back-uk-clinical-trial-investment-after-cdf-snub 2015-09-04T21:31:39 https://maestrodatabase.com/blog/hepatitis_c_treatments__australia_urged_to_subsidise__revolutionary__new_drugs 2015-08-05T11:37:24 https://maestrodatabase.com/blog/german-drug-companies-are-criticised-for-not-focusing-on-useful-therapeutic-areas 2015-09-16T03:47:12 https://maestrodatabase.com/blog/fda-approves-hizentra-immune-globulin-subcutaneous-human-20-percent-liquid-for-the-treatment-of-patients-with-chronic-inflammatory-demyelinating-polyneuropathy 2018-03-18T19:56:29 https://maestrodatabase.com/blog/ligand-partner-pfizer-receives-european-marketing-authorization-for-duavive-conjugated-oestrogensbazedoxifene-for-treatment-of-oestrogen-deficiency-symptoms-in-post-menopausal-women-with-a-uterus 2015-08-05T11:37:16 https://maestrodatabase.com/blog/trump-administration-announces-changes-to-medicare-advantage-and-part-d-to-provide-better-coverage-and-increase-access-for-medicare-beneficiaries 2020-05-24T21:38:10 https://maestrodatabase.com/blog/rd-tax-incentive-review 2016-09-28T08:55:07 https://maestrodatabase.com/blog/agenda-for-the-20-january-2016-tc-meeting 2016-01-18T20:48:25 https://maestrodatabase.com/blog/europe-clears-simponi-for-non-radiographic-axial-spondyloarthritis 2015-08-05T11:37:13 https://maestrodatabase.com/blog/policy-strategies-for-aligning-price-and-value-for-brand-name-pharmaceuticals 2018-03-18T20:33:00 https://maestrodatabase.com/blog/drug-utilisation-sub-committee-outcome-statement 2021-11-05T04:41:23 https://maestrodatabase.com/blog/cadth-calls-for-patient-input-on-a-new-submission-from-actelion-for-uptravi 2016-02-17T07:35:39 https://maestrodatabase.com/blog/pancreatic-cancer-drug-to-go-on-pbs 2015-08-05T11:37:28 https://maestrodatabase.com/blog/former-fda-commissioners-say-right-to-try-bills-could-endanger-vulnerable-patients 2018-03-18T20:23:41 https://maestrodatabase.com/blog/plea-to-fund-melanoma-drug 2016-03-01T19:49:34 https://maestrodatabase.com/blog/aclidinium-bromideformoterol-in-copd-added-benefit-for-certain-patient-groups 2015-08-05T11:37:30 https://maestrodatabase.com/blog/costco-under-investigation-by-ontario-forensic-team-over-drug-company-payments 2018-03-18T20:29:42 https://maestrodatabase.com/blog/health-care-tax-inversions-robbing-both-peter-and-paul 2016-03-20T01:18:55 https://maestrodatabase.com/blog/ema-fast-tracks-enzyme-replacement-therapy-for-lysosomal-acid-lipase-deficiency 2015-08-05T11:37:18 https://maestrodatabase.com/blog/lynparza-approved-in-the-european-union-as-first-in-class-treatment-for-advanced-brca-mutated-ovarian-cancer 2015-08-05T11:37:24 https://maestrodatabase.com/blog/government-urged-to-work-more-closely-with-cancer-community 2015-08-05T11:37:06 https://maestrodatabase.com/blog/drug-regulation-in-australia 2015-08-05T11:37:21 https://maestrodatabase.com/blog/measures-to-help-protect-patients-from-falsified-medicines 2016-02-09T19:36:21 https://maestrodatabase.com/blog/new_version_of_the_pbac_guidelines_are_now_available 2015-08-05T11:37:08 https://maestrodatabase.com/blog/us-fda-grants-priority-review-to-abbvie-for-investigational-all-oral-interferon-free-therapy-for-the-treatment-of-genotype-1-chronic-hepatitis-c 2015-08-05T11:37:14 https://maestrodatabase.com/blog/pbs-drugs-save-money-and-lives-report 2015-11-25T06:52:10 https://maestrodatabase.com/blog/eli-lilly-gets-european-approval-to-sell-trulicity-a-type-2-diabetes-drug 2015-08-05T11:37:24 https://maestrodatabase.com/blog/horizon-pharma-plc-receives-positive-chmp-opinion-for-ravicti-glycerol-phenylbutyrate-oral-liquid-for-the-treatment-of-urea-cycle-disorders-in-patients-greater-than-two-months-of-age 2015-09-26T05:26:00 https://maestrodatabase.com/blog/hospira-applauds-uks-nice-for-issuing-adoption-resource-to-help-drive-the-introduction-of-biosimilars 2015-08-15T11:20:35 https://maestrodatabase.com/blog/new-report-proposes-radical-reforms-for-rare-cancer-regulation 2017-08-09T12:50:51 https://maestrodatabase.com/blog/ema-and-ecdc-statement-on-updating-covid-19-vaccines-to-target-new-sars-cov-2-virus-variants 2023-06-06T21:08:05 https://maestrodatabase.com/blog/novartis-receives-eu-approval-for-jakavi-in-polycythemia-vera-first-targeted-therapy-approved-for-patients-with-this-rare-blood-cancer 2015-08-05T11:37:14 https://maestrodatabase.com/blog/thousands-more-people-could-be-offered-drugs-to-prevent-bone-fractures-because-of-osteoporosis 2017-08-09T12:47:21 https://maestrodatabase.com/blog/mallinckrodts-inomax-approved-in-australia-and-japan-for-pulmonary-hypertension-in-conjunction-with-heart-surgery 2015-11-02T06:22:30 https://maestrodatabase.com/blog/fennec-pharmaceuticals-announces-european-commission-marketing-authorisation-for-pedmarqsi-sodium-thiosulphate-to-reduce-the-risk-of-hearing-loss-in-paediatric-oncology-patients 2023-06-06T21:10:48 https://maestrodatabase.com/blog/servier-receives-positive-chmp-opinion-for-lonsulf-trifluridinetipiracil-for-refractory-metastatic-colorectal-cancer 2016-02-26T21:36:51 https://maestrodatabase.com/blog/applications-sought-for-consumer-advisory-committee 2015-08-05T11:37:06 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-posts-draft-scoping-document-on-car-t-therapies-for-public-comment 2017-08-09T20:41:38 https://maestrodatabase.com/blog/future-of-cancer-treatment-has-just-been-approved 2023-06-06T21:03:17 https://maestrodatabase.com/blog/insurers-pushing-for-higher-rates-challenge-key-component-of-health-law 2016-07-17T10:27:07 https://maestrodatabase.com/blog/nice-says-yes-to-another-hepatitis-c-drug 2016-09-23T09:50:54 https://maestrodatabase.com/blog/weve-got-a-health-system-thats-the-envy-of-the-world-minister-tells-cancer-charities 2017-08-09T13:00:07 https://maestrodatabase.com/blog/novo-nordisk-files-for-regulatory-approval-in-the-us-of-long-acting-factor-ix-for-the-treatment-of-haemophilia-b 2016-05-18T21:11:50 https://maestrodatabase.com/blog/neos-therapeutics-announces-fda-approval-of-adzenys-xr-odt-amphetamine-extended-release-orally-disintegrating-tablet-for-the-treatment-of-adhd-in-patients-6-years-and-older 2016-01-28T21:20:06 https://maestrodatabase.com/blog/drug-makers-hopes-for-gene-therapy-rise-despite-tiny-sales-in-europe 2017-08-09T20:51:00 https://maestrodatabase.com/blog/vyluma-announces-fda-acceptance-of-new-drug-application-for-nvk002-its-novel-investigational-treatment-for-paediatric-myopia 2023-06-06T12:13:50 https://maestrodatabase.com/blog/tga-publishes-auspar-for-lenvima-lenvatinib-mesylate 2016-09-09T04:51:59 https://maestrodatabase.com/blog/rare-cancer-drug-which-significantly-delays-progression-of-advanced-thyroid-cancer-is-left-off-relaunched-cancer-drugs-fund 2016-08-02T21:43:51 https://maestrodatabase.com/blog/june-2016-decisions-news-release 2016-06-13T21:04:42 https://maestrodatabase.com/blog/tga-finds-no-issue-with-bexsero-meningococcal-b-vaccine 2016-03-23T01:54:20 https://maestrodatabase.com/blog/gmia-welcomes-efficient-patient-access-to-affordable-medicines 2015-08-05T11:37:09 https://maestrodatabase.com/blog/valeant-pharmaceuticals-receives-complete-response-letter-from-the-fda-for-latanoprostene-bunod-ophthalmic-solution-0-dot-024-percent-nda 2017-08-09T20:53:34 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits-1-september-2015-update 2015-08-31T21:46:46 https://maestrodatabase.com/blog/abbvies-cll-drug-venclyxto-too-expensive-for-nhs-says-nice 2018-10-26T21:07:25 https://maestrodatabase.com/blog/sun-pharma-announces-successful-completion-of-opiates-business-acquisition-in-australia 2015-09-01T21:51:03 https://maestrodatabase.com/blog/fda-announces-additional-steps-to-modernise-clinical-trials 2023-06-06T21:28:08 https://maestrodatabase.com/blog/melanoma-drug-keytruda-denied-full-listing-on-pbs 2016-04-25T21:41:51 https://maestrodatabase.com/blog/registration-and-reimbursement-of-new-cancer-medicines-in-australia 2016-06-07T21:28:22 https://maestrodatabase.com/blog/european-medicines-agency-validates-gileads-marketing-application-for-tenofovir-alafenamide-taf-for-the-treatment-of-chronic-hepatitis-b 2016-02-26T11:07:04 https://maestrodatabase.com/blog/nhs-cancer-chief-further-funding-cuts-likely 2015-08-05T11:37:08 https://maestrodatabase.com/blog/merck-sues-hhs-over-drug-negotiation-claims-program-tantamount-to-extortion 2023-06-06T21:25:26 https://maestrodatabase.com/blog/nice_seeks_more_information_on_treatment_for_potentially_serious_liver_condition 2015-08-05T11:37:26 https://maestrodatabase.com/blog/the-other-canadian-drug-company-that-has-pushed-up-drug-pricess 2016-05-21T18:15:42 https://maestrodatabase.com/blog/ausbiotech-nominates-for-prostheses-list-advisory 2016-09-26T02:18:31 https://maestrodatabase.com/blog/nice-recommends-erbitux 2017-08-09T21:18:16 https://maestrodatabase.com/blog/anti-cancer-drug-ribomustin-added-to-pbs 2016-04-28T20:52:52 https://maestrodatabase.com/blog/us-fda-approves-new-indication-for-mercks-prevymis-letermovir-for-prevention-of-cytomegalovirus-disease-in-high-risk-adult-kidney-transplant-recipients 2023-06-06T21:17:31 https://maestrodatabase.com/blog/pfizer-receives-positive-chmp-opinion-for-ibrance-palbociclib-in-combination-with-endocrine-therapy-for-the-treatment-of-hrher2-metastatic-breast-cancer-in-europe 2016-09-17T01:55:00 https://maestrodatabase.com/blog/health-insurance-comparison-sites-dont-address-affordability-ombudsman 2017-08-09T21:11:34 https://maestrodatabase.com/blog/agenda-for-29-april-2015-tc-meeting 2015-08-05T11:37:16 https://maestrodatabase.com/blog/valuing_orphan_medicines_using_multi_criteria_decision_analysis 2015-08-05T11:37:05 https://maestrodatabase.com/blog/nice-publishes-final-guidance-for-baricitinib 2017-08-09T21:24:17 https://maestrodatabase.com/blog/european-medicines-agency-grants-accelerated-assessment-of-ixazomib-for-patients-with-relapsedrefractory-multiple-myeloma 2015-08-05T11:37:18 https://maestrodatabase.com/blog/celltrion-files-for-us-fda-approval-of-remsima 2015-08-05T11:37:09 https://maestrodatabase.com/blog/registration-of-new-chemical-entities-in-australia-2015 2016-01-13T20:18:36 https://maestrodatabase.com/blog/changes-to-pharmaceutical-benefits-advisory-committee 2015-08-05T11:37:23 https://maestrodatabase.com/blog/nice-gives-conditional-backing-for-gsks-benlysta-in-lupus 2016-06-22T21:36:03 https://maestrodatabase.com/blog/nice-supports-the-use-of-another-treatment-option-for-patients-with-renal-cell-carcinoma-on-the-nhs 2017-08-09T21:31:12 https://maestrodatabase.com/blog/deciphera-announces-approval-of-qinlock-in-the-united-kingdom-for-the-treatment-of-fourth-line-gastro-intestinal-stromal-tumour 2021-12-22T21:30:17 https://maestrodatabase.com/blog/regulatory-agencies-should-engage-in-drug-pricing 2016-09-03T11:32:33 https://maestrodatabase.com/blog/nice-to-research-patient-preferences-in-hta 2016-06-01T23:16:04 https://maestrodatabase.com/blog/repeal-replace-repair-retreat----republicans-health-care-quagmire 2017-08-09T21:46:59 https://maestrodatabase.com/blog/breakthrough-drugs-dony-always-break-through 2016-08-02T22:44:58 https://maestrodatabase.com/blog/heres-how-drug-prices-actually-work 2016-04-28T21:01:16 https://maestrodatabase.com/blog/unlicensed-and-off-label-uses-of-medicines-definitions-and-clarification-of-terminology 2017-08-09T21:43:48 https://maestrodatabase.com/blog/the-hazards-of-rapid-approval-of-new-drugs 2016-02-01T22:55:18 https://maestrodatabase.com/blog/health-insurance-coverage-and-health----what-the-recent-evidence-tells-us 2017-08-09T21:57:12 https://maestrodatabase.com/blog/pharmac-request-for-proposals-supply-of-progestagen-only-long-acting-intrauterine-systems 2015-09-11T06:28:27 https://maestrodatabase.com/blog/three-ways-president-trump-can-make-good-on-his-promise-to-bring-down-drug-prices 2017-08-09T21:52:47 https://maestrodatabase.com/blog/novartis-receives-positive-chmp-opinion-for-leqvio-inclisiran-a-potential-first-in-class-sirna-for-the-treatment-of-high-cholesterol 2020-10-18T10:58:31 https://maestrodatabase.com/blog/big-drugs-companies-vow-to-oppose-federal-budget-pbs-cuts 2015-08-05T11:37:02 https://maestrodatabase.com/blog/comprehensive-assessment-of-complex-technologies-integrating-various-aspects-in-health-technology-assessment 2017-08-09T22:12:14 https://maestrodatabase.com/blog/sunesis-pharmaceuticals-announces-european-medicines-agency-validates-marketing-authorization-application-for-vosaroxin-in-aml 2016-01-07T03:05:06 https://maestrodatabase.com/blog/inside-sussan-leys-billion-dollar-health-battle 2016-09-18T21:23:10 https://maestrodatabase.com/blog/breakthrough-melanoma-drug-approved 2016-04-29T21:24:15 https://maestrodatabase.com/blog/physicians-knowledge-about-fda-approval-standards-and-perceptions-of-the-breakthrough-therapy-designation 2016-04-12T21:15:46 https://maestrodatabase.com/blog/fda-approves-expanded-use-of-vonvendi-for-von-willebrand-disease-including-for-certain-uses-for-children 2025-09-05T23:13:18 https://maestrodatabase.com/blog/vertex-receives-chmp-positive-opinions-for-orkambi-lumacaftor-with-ivacaftor-and-kalydeco-ivacaftor-in-the-european-union 2015-09-26T05:11:48 https://maestrodatabase.com/blog/bio-statement-regarding-the-un-high-level-panel-on-access-to-medicines-report 2016-09-15T05:19:07 https://maestrodatabase.com/blog/fda-grants-priority-review-and-breakthrough-therapy-designation-for-zelboraf-vemurafenib-in-erdheim-chester-disease-with-braf-v600-mutation 2017-08-09T23:23:09 https://maestrodatabase.com/blog/intra-cellular-therapies-announces-u-dot-s-fda-approval-of-caplyta-lumateperone-for-the-treatment-of-bipolar-depression-in-adults 2021-12-22T21:56:01 https://maestrodatabase.com/blog/fda-rejects-avanirs-migraine-drug-device 2015-08-05T11:37:23 https://maestrodatabase.com/blog/nice-consults-on-further-draft-guidance-on-the-drug-sofosbuvir-sovaldi-for-treating-hepatitis-c 2015-08-05T11:37:15 https://maestrodatabase.com/blog/cero-therapeutics-receives-fda-fast-track-designation-for-cer-1236-in-acute-myeloid-leukaemia 2025-09-05T23:17:33 https://maestrodatabase.com/blog/the-challenge-of-costly-drugs 2016-06-01T23:07:52 https://maestrodatabase.com/blog/proposal-to-award-sole-supply-to-goserelin-zoladex-and-reference-price-leuprorelin-eligard-and-lucrin-pds 2016-07-07T04:07:16 https://maestrodatabase.com/blog/fda-approves-otezla-apremilast-for-the-treatment-of-adult-patients-with-plaque-psoriasis-regardless-of-severity-level 2021-12-22T21:34:24 https://maestrodatabase.com/blog/fda-approves-new-drug-to-treat-hyperkalaemia 2015-10-22T10:08:03 https://maestrodatabase.com/blog/pbs-and-rpbs-section-85-date-of-processing-and-date-of-supply-data-1 2016-08-12T22:05:40 https://maestrodatabase.com/blog/spectrum-pharmaceuticals-files-a-new-drug-application-with-the-fda-for-captisol-enabled-propylene-glycol-free-melphalan 2015-08-05T11:37:26 https://maestrodatabase.com/blog/pharmaceutical_benefits_scheme_prescription_prices_for_2014 2015-08-05T11:37:04 https://maestrodatabase.com/blog/novartis-receives-positive-chmp-opinion-for-the-first-il-17a-inhibitor-cosentyx-to-treat-ankylosing-spondylitis-and-psoriatic-arthritis 2015-10-23T11:41:03 https://maestrodatabase.com/blog/january-2016-smc-decisions-news-release 2016-01-11T20:19:39 https://maestrodatabase.com/blog/dabrafenib__also_no_added_benefit_over_vemurafenib 2015-08-05T11:37:29 https://maestrodatabase.com/blog/taming-drug-prices-by-pulling-back-the-curtain-online 2016-02-10T09:17:28 https://maestrodatabase.com/blog/fda-approves-velcade-bortezomib-for-injection-for-previously-untreated-patients-with-mantle-cell-lymphoma 2015-08-05T11:37:07 https://maestrodatabase.com/blog/smc_advice___september_2013 2015-08-05T11:37:18 https://maestrodatabase.com/blog/agenda-for-the-22-june-2016-tc-meeting 2016-06-16T04:04:03 https://maestrodatabase.com/blog/leo-pharma-announced-new-taclonex-calcipotriene-and-betamethasone-dipropionate-topical-suspension-00050064-indication-for-the-treatment-of-scalp-plaque-psoriasis-in-paediatric-patients-aged-12-17 2015-08-05T11:37:18 https://maestrodatabase.com/blog/changes-to-clone-and-extension-of-indications-no-data-application 2015-08-05T11:37:22 https://maestrodatabase.com/blog/european-commission-approves-amgens-imlygic-talimogene-laherparepvec-as-first-oncolytic-immunotherapy-in-europe 2015-12-19T01:32:58 https://maestrodatabase.com/blog/intercept-receives-complete-response-letter-from-fda-addressing-ocaliva-supplemental-new-drug-application 2024-11-12T21:14:10 https://maestrodatabase.com/blog/toward-an-integrated-federal-health-system-in-the-us 2016-04-28T21:09:56 https://maestrodatabase.com/blog/fda-approves-beleodaq-to-treat-rare-aggressive-form-of-non-hodgkin-lymphoma 2015-08-05T11:37:18 https://maestrodatabase.com/blog/express-scripts-aims-new-price-model-at-cancer-inflammation 2015-11-19T20:30:16 https://maestrodatabase.com/blog/pfizer-receives-us-fda-approval-of-new-quillichew-er-methylphenidate-hydrochloride-extended-release-chewable-tablets 2015-12-08T11:35:14 https://maestrodatabase.com/blog/australians-pay-thousands-more-for-private-health-cover 2016-09-21T08:43:49 https://maestrodatabase.com/blog/iqwig-publishes-english-translation-of-the-new-version-of-its-general-methods 2015-10-09T07:48:12 https://maestrodatabase.com/blog/cadth-recommends-against-the-reimbursement-of-egrifta-tesamorelin 2016-08-29T11:30:41 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-complete-response-letter-from-us-food-and-drug-administration-for-daclatasvir-an-investigational-treatment-for-hepatitis-c 2015-08-05T11:37:08 https://maestrodatabase.com/blog/highlights-from-12-15-october-chmp-meeting 2020-10-18T19:58:28 https://maestrodatabase.com/blog/grade-evidence-to-decision-etd-frameworks-a-systematic-and-transparent-approach-to-making-well-informed-healthcare-choices-1-introduction 2016-06-29T03:13:32 https://maestrodatabase.com/blog/helsinn-group-announces-ema-acceptance-for-review-of-the-marketing-authorisation-application-for-infigratinib-for-patients-with-cholangiocarcinoma-with-fibroblast-growth-factor-receptor-2-fusions-or-rearrangements 2021-12-22T22:32:42 https://maestrodatabase.com/blog/can-we-get-cheaper-cancer-drugs-more-than-100-experts-weigh-in 2015-08-05T11:37:16 https://maestrodatabase.com/blog/pbac-recommends-zeposia-for-patients-with-relapsing-remitting-multiple-sclerosis 2020-10-18T20:03:40 https://maestrodatabase.com/blog/pfizer-to-seek-fda-approval-for-covid-19-vaccine-in-november 2020-10-18T20:17:39 https://maestrodatabase.com/blog/ema-publishes-epar-for-flixabi-infliximab 2016-06-09T11:10:13 https://maestrodatabase.com/blog/pharmac-confirms-funding-of-rituximab-for-igg4-related-disease 2023-06-07T01:03:47 https://maestrodatabase.com/blog/first-specific-replacement-therapy-to-treat-rare-bleeding-disorder 2016-01-30T07:03:59 https://maestrodatabase.com/blog/tga-approves-new-indication-for-alprolix 2016-09-15T05:32:13 https://maestrodatabase.com/blog/department-of-health-begins-3-yearly-review-of-nice 2015-08-05T11:37:07 https://maestrodatabase.com/blog/post-market-reviews-of-copd-medicines-and-ezetimibe-public-consultation 2016-03-04T23:04:13 https://maestrodatabase.com/blog/shire-and-bms-secure-nice-recommendations-for-oncology-drugs 2016-07-27T12:25:29 https://maestrodatabase.com/blog/mid-life-women-being-let-down-by-pharmac-say-menopause-experts 2023-06-07T00:21:57 https://maestrodatabase.com/blog/factors-for-consideration 2016-07-05T04:17:12 https://maestrodatabase.com/blog/icer-publishes-final-report-and-policy-recommendations-for-targeted-immune-modulator-therapies-for-ulcerative-colitis 2020-10-18T19:52:33 https://maestrodatabase.com/blog/the-grim-prospect 2016-05-24T12:31:13 https://maestrodatabase.com/blog/call-for-patient-input-21 2015-08-05T11:37:26 https://maestrodatabase.com/blog/approval-of-novartis-multiproduct-proposal 2015-08-05T11:37:20 https://maestrodatabase.com/blog/novartis-receives-approval-for-cosentyx-label-update-in-europe-to-include-dosing-flexibility-in-psoriatic-arthritis 2018-10-28T10:16:15 https://maestrodatabase.com/blog/ibrutinib-in-cll-no-additional-clinical-benefits-for-treatment-naïve-patients 2016-10-04T20:30:12 https://maestrodatabase.com/blog/allarity-therapeutics-submits-new-drug-application-to-the-u-dot-s-fda-for-dovitinib-for-third-line-treatment-of-renal-cell-carcinoma 2021-12-23T10:48:01 https://maestrodatabase.com/blog/celgene-receives-positive-chmp-opinion-to-extend-revlimid-lenalidomide-for-continuous-use-in-patients-with-newly-diagnosed-multiple-myeloma-and-ineligible-for-transplant 2015-08-05T11:37:14 https://maestrodatabase.com/blog/the-answer-to-high-drug-prices-is-more-drugs-faster 2015-10-23T01:16:04 https://maestrodatabase.com/blog/medicare-drug-spending-dashboard 2015-12-22T20:43:07 https://maestrodatabase.com/blog/rip-off-prices-stop-cancer-patients-getting-new-drugs 2016-03-29T11:06:04 https://maestrodatabase.com/blog/potent-drugs-to-treat-lung-cancer-and-high-cholesterol-added-to-pbs 2018-10-28T10:05:17 https://maestrodatabase.com/blog/zykadia-recommended-for-approval-in-advanced-non-small-cell-lung-cancer 2015-08-05T11:37:09 https://maestrodatabase.com/blog/second_draft_nice_guidance_for_aggressive_non_hodgkin_lymphoma_treatment__pixuvri__pixantrone_ 2015-08-05T11:37:27 https://maestrodatabase.com/blog/scottish-medicines-consortium-forthcoming-submissions-1 2015-10-15T20:16:29 https://maestrodatabase.com/blog/pbac-public-summary-documents---july-2018-meeting 2018-10-28T10:37:49 https://maestrodatabase.com/blog/pfizers-inotuzumab-ozogamicin-receives-fda-breakthrough-therapy-designation-for-acute-lymphoblastic-leukaemia-all 2015-10-20T20:09:14 https://maestrodatabase.com/blog/pbac-drug-utilisation-sub-committee-outcome-statement 2016-03-20T09:47:40 https://maestrodatabase.com/blog/calls-for-pharmac-review-after-funds-made-available-to-offset-wage-settlements 2018-10-28T10:43:03 https://maestrodatabase.com/blog/proposal-relating-to-the-funding-of-tnf-inhibitors-humira-and-enbrel-and-gabapentin-neurontin 2015-08-05T11:37:04 https://maestrodatabase.com/blog/g_ba_confirms_that_jetrea__ocriplasmin__has_significant_added_benefit_for_patients_with_vitreomacular_traction 2015-08-05T11:37:06 https://maestrodatabase.com/blog/review-of-pharmacy-remuneration-and-regulation-message-from-the-chair 2016-03-24T23:57:12 https://maestrodatabase.com/blog/decision-to-widen-access-and-fund-adalimumab-and-etanercept-for-the-treatment-of-pyoderma-gangrenosum 2015-08-05T11:37:27 https://maestrodatabase.com/blog/agenda-for-the-6-july-2016-tc-meeting 2016-06-30T21:32:15 https://maestrodatabase.com/blog/fda-authorises-additional-oral-antiviral-for-treatment-of-covid-19-in-certain-adults 2021-12-23T20:27:55 https://maestrodatabase.com/blog/australia-among-worlds-best-in-treating-debilitating-and-often-fatal-muscle-disorder 2022-09-04T20:34:44 https://maestrodatabase.com/blog/osimertinib-in-lung-cancer-no-assigned-additional-benefits 2016-06-15T12:41:36 https://maestrodatabase.com/blog/biotech-stocks-in-the-wild-wild-west 2015-08-05T11:37:12 https://maestrodatabase.com/blog/fda-accepts-supplemental-new-drug-application-for-lonsurf-trifluridine-slash-tipiracil-for-the-treatment-of-metastatic-gastric-slash-gastro-oesophageal-junction-adenocarcinoma-grants-priority-review 2018-10-28T11:04:06 https://maestrodatabase.com/blog/proposal-to-award-sole-supply-of-venlafaxine-hydrochloride 2016-08-10T01:20:22 https://maestrodatabase.com/blog/secukinumab-in-plaque-psoriasis-manufacturer-dossier-provided-no-hint-of-an-added-benefit-english-version 2015-09-07T11:41:43 https://maestrodatabase.com/blog/new-medicine-funded-to-combat-multi-resistant-infections 2015-08-05T11:37:24 https://maestrodatabase.com/blog/a-potent-heart-drugs-price-cut-may-be-a-blueprint 2018-10-28T10:47:05 https://maestrodatabase.com/blog/fda-authorises-first-oral-antiviral-for-treatment-of-covid-19 2021-12-23T20:32:50 https://maestrodatabase.com/blog/additional-outcome-from-the-november-2015-pbac-meeting 2016-01-07T04:42:52 https://maestrodatabase.com/blog/ipsen-submits-marketing-authorization-applications-in-the-us-and-europe-for-somatuline-autogel-lanreotide-acetate-in-the-treatment-of-gastroenteropancreatic-neuroendocrine-tumours 2015-08-05T11:37:04 https://maestrodatabase.com/blog/u-dot-s-fda-approves-expansion-of-trintellix-vortioxetine-label 2018-10-28T10:57:21 https://maestrodatabase.com/blog/review-process-is-an-opportunity-for-pharmacy 2016-07-27T05:36:14 https://maestrodatabase.com/blog/update-on-proposal-to-move-to-one-funded-brand-of-lamotrigine-logem 2018-10-28T20:15:39 https://maestrodatabase.com/blog/new-indication-for-bayerregenerons-eylea-in-eu 2015-08-05T11:37:26 https://maestrodatabase.com/blog/government_agrees_breakthrough_drug_pricing_deal_with_pharmaceutical_firms 2015-08-05T11:37:09 https://maestrodatabase.com/blog/why-cancer-has-not-been-cured 2016-07-11T20:51:24 https://maestrodatabase.com/blog/legend-biotech-announces-submission-of-supplemental-application-to-the-us-fda-for-expanded-use-of-carvykti-ciltacabtagene-autoleucel 2023-06-07T03:57:10 https://maestrodatabase.com/blog/patient-safety-must-not-be-pushed-aside-in-government-quest-for-biosimilars-budget-savings 2015-08-05T11:37:23 https://maestrodatabase.com/blog/45-million-behind-new-pill-to-tackle-australias-number-one-killer 2016-06-15T02:04:31 https://maestrodatabase.com/blog/marketing-authorization-for-gileads-single-tablet-regimen-genvoya-elvitegravir-cobicistat-emtricitabine-and-tenofovir-alafenamide-for-the-treatment-of-hiv-1-infection 2015-11-23T20:45:07 https://maestrodatabase.com/blog/uk-nhs-cancer-patients-denied-drugs-due-to-inflated-prices-experts 2015-09-24T05:09:37 https://maestrodatabase.com/blog/smc_rejects_novartis__full_submission_for_everolimus__afinitor__for_women_with_breast_cancer_ 2015-08-05T11:37:14 https://maestrodatabase.com/blog/is-the-pbacs-stance-on-the-choice-of-the-main-comparator-changing 2018-10-28T20:47:30 https://maestrodatabase.com/blog/astrazenecas-tagrisso-to-cost-12750-for-a-months-supply 2015-11-17T20:56:52 https://maestrodatabase.com/blog/plegridy-peginterferon-beta-1a-approved-in-the-european-union-for-the-treatment-of-multiple-sclerosis 2015-08-05T11:37:03 https://maestrodatabase.com/blog/merck-and-ridgebacks-molnupiravir-an-investigational-oral-anti-viral-covid-19-treatment-receives-special-approval-for-emergency-in-japan 2021-12-26T00:40:56 https://maestrodatabase.com/blog/axicabtagene-ciloleucel-for-the-treatment-of-patients-with-relapsed-or-refractory-follicular-lymphoma 2023-06-07T04:34:03 https://maestrodatabase.com/blog/nice-rejects-united-therapeutics-cancer-drug 2016-07-15T22:43:45 https://maestrodatabase.com/blog/pbac-minutes-for-the-managed-access-program-framework---march-2015 2015-08-05T11:37:03 https://maestrodatabase.com/blog/trump-proposes-to-lower-drug-prices-by-basing-them-on-other-countries-costs 2018-10-28T20:27:47 https://maestrodatabase.com/blog/fda-accepts-sanofi-new-drug-application-for-once-daily-fixed-ratio-combination-of-insulin-glargine-and-lixisenatide 2016-02-22T10:38:14 https://maestrodatabase.com/blog/investigational-alzheimers-disease-therapy-lecanemab-granted-fda-fast-track-designation 2021-12-26T00:47:44 https://maestrodatabase.com/blog/bristol-myers-squibb-and-abbvie-announce-european-commission-approval-of-empliciti-elotuzumab-for-the-treatment-of-multiple-myeloma-in-adult-patients-who-have-received-at-least-one-prior-therapy 2016-05-11T22:03:29 https://maestrodatabase.com/blog/drug-lobby-compares-trump-drug-price-plan-to-socialised-system 2018-10-28T20:40:16 https://maestrodatabase.com/blog/nhs_england_to_fund_hepatitis_c_drug_sovaldi 2015-08-05T11:37:20 https://maestrodatabase.com/blog/nice-and-the-general-election-campaign 2015-08-05T11:37:02 https://maestrodatabase.com/blog/cadth-releases-report-on-cancer-biomarker-testing 2015-12-09T20:31:36 https://maestrodatabase.com/blog/drugmaker-raises-price-of-acne-cream-to-10000-a-tube 2016-09-21T13:14:47 https://maestrodatabase.com/blog/regulator-says-too-many-drugmakers-chasing-same-cancer-strategy 2016-06-10T21:50:45 https://maestrodatabase.com/blog/open-angle-glaucoma-poor-data-for-the-fixed-combination-tafluprosttimolol 2015-08-05T11:37:23 https://maestrodatabase.com/blog/nice-proposes-research-recommendation-for-dupuytrens-disease-finger-contracture-treatment 2015-08-05T11:37:24 https://maestrodatabase.com/blog/shire-receives-fda-complete-response-letter-for-lifitegrast-nda-and-plans-to-respond-with-opus-3-trial 2015-10-19T03:04:07 https://maestrodatabase.com/blog/nice_gives_green_light_to_treatment_for_macular_oedema_in_final_draft_guidance 2015-08-05T11:37:22 https://maestrodatabase.com/blog/nice-consults-on-draft-guidance-on-the-drug-sofosbuvir-sovaldi-for-treating-hepatitis-c 2015-08-05T11:37:12 https://maestrodatabase.com/blog/allergan-announces-ozurdex-dexamethasone-700-mcg-intravitreal-implant-in-applicator-now-approved-in-the-european-union-for-the-treatment-of-diabetic-macular-edema 2015-08-05T11:37:17 https://maestrodatabase.com/blog/fda-approves-kyprolis-carfilzomib-for-combination-use-in-the-treatment-of-patients-with-relapsed-multiple-myeloma 2015-08-05T11:37:02 https://maestrodatabase.com/blog/additional-benefit-of-vedolizumab-is-not-shown 2015-08-05T11:37:22 https://maestrodatabase.com/blog/medimmune-receives-fast-track-designation-in-the-us-for-medi8852-for-treatment-of-patients-hospitalised-with-influenza-a 2016-03-08T11:19:45 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits-1-june-2016-update 2016-05-31T15:35:04 https://maestrodatabase.com/blog/gsks-jemperli-dostarlimab-for-injection-approved-in-canada-as-an-anti-pd-1-therapy-for-recurrent-or-advanced-endometrial-cancer 2021-12-26T01:33:58 https://maestrodatabase.com/blog/call-for-patient-input-on-resubmission-from-biomarin-for-vimizim 2015-10-01T21:40:57 https://maestrodatabase.com/blog/japans-first-committee-on-new-drugs-of-the-pharmaceutical-affairs-and-food-sanitation-council-seeks-additional-data-aducanumab-remains-under-review 2021-12-26T01:03:32 https://maestrodatabase.com/blog/secret-rebates-why-patients-pay-600-for-drugs-that-cost-300 2016-10-05T20:13:17 https://maestrodatabase.com/blog/uk-likes-the-look-of-ema-quicker-approvals-pilot 2015-08-05T11:37:15 https://maestrodatabase.com/blog/nice-recommends-lubiprostone-to-treat-long-term-painful-constipation 2015-08-05T11:37:15 https://maestrodatabase.com/blog/mhra-approves-licence-extension-for-novartis-targeted-therapy-for-advanced-breast-cancer-patients-in-great-britain 2021-12-26T01:21:30 https://maestrodatabase.com/blog/tga-summary-of-fees-and-charges-at-1-july-2014 2015-08-05T11:37:28 https://maestrodatabase.com/blog/accrufer-assigned-priority-review-in-the-us-by-fda-in-children-with-iron-deficiency-anaemia 2025-09-06T05:05:16 https://maestrodatabase.com/blog/cadth-calls-for-patient-input-on-a-new-submission-from-novartis-for-ilaris 2015-11-24T20:49:54 https://maestrodatabase.com/blog/as-world-embraces-precision-medicine-canada-falls-behind 2016-10-04T10:54:06 https://maestrodatabase.com/blog/smc-says-no-to-copd-drugs-from-gsk-and-bi 2015-08-05T11:37:18 https://maestrodatabase.com/blog/biogen-and-abbvies-once-monthly-zinbryta-daclizumab-approved-in-european-union-for-treatment-of-multiple-sclerosis 2016-07-05T12:13:12 https://maestrodatabase.com/blog/negotiations-with-drug-maker-alexion-over-soliris-have-been-called-off-by-provinces 2016-02-18T06:47:14 https://maestrodatabase.com/blog/biogen-and-sobi-receive-positive-opinion-from-chmp-for-elocta-rfviiifc-for-the-treatment-of-haemophilia 2015-09-26T03:40:45 https://maestrodatabase.com/blog/pediapharm-receives-health-canada-approval-for-rupatadine 2016-07-22T10:52:37 https://maestrodatabase.com/blog/biotechs-plead-for-tax-break-for-start-ups 2015-08-05T11:37:08 https://maestrodatabase.com/blog/ticagrelor-for-prevention-after-myocardial-infarction-added-benefit-called-into-question-by-data-subsequently-submitted 2016-09-15T20:16:37 https://maestrodatabase.com/blog/tauranga-woman-fights-for-life-saving-drug 2016-02-29T20:12:57 https://maestrodatabase.com/blog/medicines-australia-agrees-to-federal-budget-savings-to-secure-a-5-year-strategic-agreement 2015-08-05T11:37:28 https://maestrodatabase.com/blog/crizotinib-xalkori-managed-entry-scheme-for-listing-on-the-pharmaceutical-benefits-scheme-information-for-patients 2015-08-06T20:50:57 https://maestrodatabase.com/blog/more-patients-get-access-to-medicines-within-the-high-cost-protection 2019-05-30T07:45:39 https://maestrodatabase.com/blog/dr-chris-jackson-cancer-sufferers-in-dark-over-drug 2016-01-07T20:16:31 https://maestrodatabase.com/blog/cms-acting-administrator-andy-slavitt-at-the-hhs-pharmaceutical-forum-innovation-access-affordability-and-better-health 2015-11-20T21:12:21 https://maestrodatabase.com/blog/fda-approves-akynzeo-for-nausea-and-vomiting-associated-with-cancer-chemotherapy 2015-08-05T11:37:22 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-august-2104-update 2015-08-05T11:37:05 https://maestrodatabase.com/blog/fda-approves-new-dosing-option-for-csl-behrings-hizentra 2015-08-05T11:37:13 https://maestrodatabase.com/blog/smc-may-2016-decisions 2016-05-09T13:16:19 https://maestrodatabase.com/blog/heart-of-bureaucratic-darkness 2016-08-11T11:33:16 https://maestrodatabase.com/blog/sharing-clinical-trial-data 2016-01-20T21:17:32 https://maestrodatabase.com/blog/pfizer-and-allergan-reach-150-billion-merger-deal 2015-11-23T20:49:10 https://maestrodatabase.com/blog/big-pharmaceutical-companies-hit-out-at-cancer-drug-approval-process 2015-08-05T11:37:23 https://maestrodatabase.com/blog/us-lawmakers-want-health-agencies-to-lower-prostate-cancer-drug-cost 2016-03-29T04:40:42 https://maestrodatabase.com/blog/us-health-care-system-begins-to-embrace-cost-effectiveness-as-a-central-component-of-value 2016-08-29T21:05:35 https://maestrodatabase.com/blog/gsk-to-allow-staggered-payments-for-ema-approved-gene-therapy 2016-04-02T21:46:33 https://maestrodatabase.com/blog/tga-key-performance-indicators-january-to-june-2015 2015-09-03T11:08:48 https://maestrodatabase.com/blog/prescription-medicines-new-or-extended-uses-approved-by-the-tga 2016-05-17T09:59:20 https://maestrodatabase.com/blog/genea-in-global-fertility-deal-with-merck 2015-08-05T11:37:27 https://maestrodatabase.com/blog/additional-dosage-strengths-of-otrexup-methotrexate-injection-approved-by-fda 2016-03-30T06:02:49 https://maestrodatabase.com/blog/agenda-for-the-22-july-2015-tc-meeting 2015-08-05T11:37:03 https://maestrodatabase.com/blog/ucb-receives-new-european-commission-approvals-for-bimzelx-bimekizumab-for-the-treatment-of-psoriatic-arthritis-and-axial-spondyloarthritis 2023-06-07T05:21:11 https://maestrodatabase.com/blog/proposal-to-list-ceftaroline-fosamil-in-section-h-of-the-pharmaceutical-schedule 2015-08-05T11:37:05 https://maestrodatabase.com/blog/gsk-receives-fda-approval-for-arnuity-ellipta-fluticasone-furoate-in-the-us-for-the-treatment-of-asthma 2015-08-05T11:37:27 https://maestrodatabase.com/blog/anti-psychotic-drug-plague-running-unchecked 2015-08-05T11:37:27 https://maestrodatabase.com/blog/behind_the_headlines___champagne_perks_of_nhs_watchdog 2015-08-05T11:37:27 https://maestrodatabase.com/blog/eusa-pharma-and-aveo-announce-submission-of-marketing-authorization-application-for-tivozanib-in-advanced-renal-cell-carcinoma 2016-03-01T20:18:29 https://maestrodatabase.com/blog/janssen-announces-health-canada-approval-of-tremfya-one-press-guselkumab---a-patient-controlled-injector-for-adults-with-moderate-to-severe-plaque-psoriasis 2019-05-30T10:27:38 https://maestrodatabase.com/blog/cadth-calls-for-feedback-on-draft-report-on-drugs-for-chronic-hepatitis-c-infection 2015-09-15T20:58:56 https://maestrodatabase.com/blog/aduro-biotech-receives-breakthrough-therapy-designation-from-fda-for-innovative-pancreatic-cancer-combination-immunotherapy 2015-08-05T11:37:02 https://maestrodatabase.com/blog/american-epipen-price-as-much-as-nine-times-higher-than-in-other-wealthy-countries-public-citizen-survey-shows 2016-09-21T00:05:34 https://maestrodatabase.com/blog/cancer-drug-fund-needs-more-radical-changes-say-experts 2015-08-05T11:37:09 https://maestrodatabase.com/blog/europe-gets-amgen-cholesterol-drug-for-50-60-pct-of-us-price 2015-09-02T08:19:23 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits-1-march-2016-update 2016-03-01T02:57:49 https://maestrodatabase.com/blog/agenda-for-the-july-2015-pbac-meeting 2015-08-05T11:37:24 https://maestrodatabase.com/blog/eu-approves-roches-avastin-for-platinum-resistant-recurrent-ovarian-cancer 2015-08-05T11:37:06 https://maestrodatabase.com/blog/novartis-lung-cancer-drug-zykadia-recommended-for-eu-approval-in-patients-with-alk-nsclc-previously-treated-with-crizotinib 2015-08-05T11:37:26 https://maestrodatabase.com/blog/saskatchewan-includes-lemtrada-alemtuzumab-on-ms-drugs-program-for-eligible-patients 2016-07-06T06:17:01 https://maestrodatabase.com/blog/health-economic-assessment-of-luxturna-in-the-treatment-of-visual-impairment-caused-by-hereditary-eye-disease 2019-05-30T11:26:42 https://maestrodatabase.com/blog/brexucabtagene-autoleucel-for-treating-relapsed-or-refractory-b-cell-acute-lymphoblastic-leukaemia-in-people-26-years-and-over 2023-06-07T06:18:47 https://maestrodatabase.com/blog/how-congress-can-make-drug-pricing-more-rational 2016-09-12T10:51:15 https://maestrodatabase.com/blog/health-canada-approves-tecentriq-atezolizumab-combination-therapy-for-first-line-treatment-of-metastatic-non-squamous-non-small-cell-lung-cancer 2019-05-30T10:32:00 https://maestrodatabase.com/blog/new-drug-for-pancreatic-cancer-turned-down 2015-08-05T11:37:12 https://maestrodatabase.com/blog/pharmac-confirms-chickenpox-vaccine-for-all-kids 2016-07-28T21:01:29 https://maestrodatabase.com/blog/arvinas-receives-fast-track-designation-for-its-targeted-protein-degrader-arv-110-as-a-treatment-for-men-with-metastatic-castration-resistant-prostate-cancer 2019-05-30T11:38:19 https://maestrodatabase.com/blog/us-food-and-drug-administration-extends-action-date-for-supplemental-biologics-license-application-for-opdivo-nivolumab-in-previously-untreated-advanced-melanoma 2015-08-13T05:05:02 https://maestrodatabase.com/blog/fda-approves-rapamune-to-treat-lam-a-very-rare-lung-disease 2015-08-05T11:37:14 https://maestrodatabase.com/blog/nice-issues-preliminary-guidance-on-pomalidomide-for-blood-cancer 2015-08-05T11:37:06 https://maestrodatabase.com/blog/sol-gel-announces-health-canada-approval-of-epsolay 2025-09-06T11:33:58 https://maestrodatabase.com/blog/nice-urges-new-approach-to-how-nhs-adopts-new-drugs 2015-08-05T11:37:22 https://maestrodatabase.com/blog/fda-approves-new-treatment-for-diabetic-retinopathy-in-patients-with-diabetic-macular-edema 2015-08-05T11:37:27 https://maestrodatabase.com/blog/imara-announces-fda-fast-track-designation-for-imr-687-for-the-treatment-of-sickle-cell-disease 2019-05-30T11:34:34 https://maestrodatabase.com/blog/accessing-key-ema-information-on-human-medicines 2016-05-20T13:39:57 https://maestrodatabase.com/blog/bayer-receives-u-dot-s-fda-breakthrough-therapy-designation-for-copanlisib-for-the-treatment-of-marginal-zone-lymphoma 2019-05-30T11:49:26 https://maestrodatabase.com/blog/this-drug-saved-my-life-cystic-fibrosis-patient-accuses-drug-company-canada-of-stalling-on-approval 2019-11-18T02:36:25 https://maestrodatabase.com/blog/prevenar-13-receives-chmp-positive-opinion-for-prevention-of-vaccine-type-pneumococcal-pneumonia-in-adults 2015-08-05T11:37:14 https://maestrodatabase.com/blog/zymeworks-lead-asset-zw25-granted-fast-track-designation-from-the-fda 2019-05-30T11:43:08 https://maestrodatabase.com/blog/us-fda-approves-expanded-indication-for-vonvendi-von-willebrand-factor-recombinant-for-adults-and-children-with-von-willebrand-disease 2025-09-06T12:23:54 https://maestrodatabase.com/blog/health-canada-approves-sale-of-carbaglu-for-deficient-liver-enzymes 2015-09-09T06:34:12 https://maestrodatabase.com/blog/final-report-for-the-post-market-review-of-pulmonary-arterial-hypertension-medicines 2020-05-25T05:07:05 https://maestrodatabase.com/blog/martin-shkrelis-latest-plan-to-sharply-raise-drug-price-prompts-outcry 2015-12-13T20:13:15 https://maestrodatabase.com/blog/new-gene-therapy-for-the-treatment-of-children-with-ultra-rare-immune-disorder-recommended-for-approval 2016-04-01T23:50:16 https://maestrodatabase.com/blog/contraceptive-pill-rationed-amid-countrywide-shortage 2020-05-25T05:14:00 https://maestrodatabase.com/blog/sobi-and-biogens-elocta-rfviiifc-approved-in-europe-for-the-treatment-of-haemophilia-a 2015-11-24T20:37:19 https://maestrodatabase.com/blog/fda-approves-new-oral-medication-to-treat-patients-with-advanced-colorectal-cancer 2015-09-22T20:40:12 https://maestrodatabase.com/blog/cancer-patients-sign-up-for-trials-of-new-drugs-with-too-high-hopes 2016-09-27T20:59:46 https://maestrodatabase.com/blog/the_outcomes_from_the_august_2013_special_pbac_meeting_have_been_added_to_maestro_australia 2015-08-05T11:37:22 https://maestrodatabase.com/blog/eu-nations-join-forces-against-exorbitant-hepatitis-c-drug 2015-08-05T11:37:08 https://maestrodatabase.com/blog/takeda-receives-complete-response-letter-from-the-u-dot-s-fda-for-tak-721 2021-12-26T04:23:42 https://maestrodatabase.com/blog/backlash-over-decision-by-australias-top-medical-journal-to-outsource-to-company-with-history-of-unethical-behaviour 2015-08-05T11:37:14 https://maestrodatabase.com/blog/bristol-myers-squibb-announces-us-food-and-drug-administration-approval-for-opdivo-nivolumab-as-a-single-agent-for-the-treatment-of-patients-with-previously-untreated-braf-wild-type-advanced-melanoma 2015-11-25T07:28:28 https://maestrodatabase.com/blog/fibrocell-receives-fda-regenerative-medicine-advanced-therapy-designation-for-fcx-007-gene-therapy-for-the-treatment-of-rdeb 2019-05-30T11:57:24 https://maestrodatabase.com/blog/siga-announces-health-canada-regulatory-approval-of-oral-tpoxx 2021-12-26T04:37:07 https://maestrodatabase.com/blog/expert-panel-to-review-medicines-and-medical-devices-regulation 2015-08-05T11:37:10 https://maestrodatabase.com/blog/picturing-elsi-plus-a-visual-representation-of-ethical-legal-and-social-issues-and-patient-experiences-in-health-technology-assessment-in-canada 2019-11-18T02:45:23 https://maestrodatabase.com/blog/an_audience_with_new_nice_chairman_david_haslam 2015-08-05T11:37:07 https://maestrodatabase.com/blog/implications-of-proposed-medicare-reforms-to-counteract-high-cancer-drug-prices-1 2016-07-19T21:06:12 https://maestrodatabase.com/blog/fda-advisory-committee-unanimously-recommends-accelerated-approval-of-ocaliva-obeticholic-acid-for-the-treatment-of-pbc 2016-04-08T05:46:11 https://maestrodatabase.com/blog/rockwell-medical-announces-submission-of-new-drug-application-for-i-dot-v-triferic 2019-05-30T12:14:21 https://maestrodatabase.com/blog/statement-from-sarah-yim-acting-director-of-the-office-of-therapeutic-biologics-and-biosimilars-in-the-fdas-center-for-drug-evaluation-and-research-on-fdas-continued-progress-facilitating-competition-in-the-biologic-marketplace-with-approval-of-25th-biosimilar-product 2019-11-18T03:04:16 https://maestrodatabase.com/blog/pharmac-decision-relating-to-a-number-of-respiratory-products 2016-02-03T04:57:15 https://maestrodatabase.com/blog/pbac-recommendation---august-2014-out-of-session-meeting 2015-08-05T11:37:21 https://maestrodatabase.com/blog/biostatistics-a-fundamental-discipline-at-the-core-of-modern-health-data-science 2019-11-18T03:00:41 https://maestrodatabase.com/blog/nonprofit-reacquires-rights-to-tuberculosis-drug-after-hefty-price-hike 2015-09-23T03:30:56 https://maestrodatabase.com/blog/fda-and-ema-accept-regulatory-applications-for-boehringer-ingelheims-giotrif-gilotrif-afatinib-dimaleate-for-treatment-of-advanced-squamous-cell-carcinoma-of-the-lung 2015-08-25T11:41:44 https://maestrodatabase.com/blog/nhs-england-stumps-up-190m-for-hepatitis-c-therapy 2015-08-05T11:37:29 https://maestrodatabase.com/blog/first-ever-treatment-approved-in-canada-for-adults-living-with-adpkd-a-life-threatening-kidney-disease 2015-08-05T11:37:29 https://maestrodatabase.com/blog/mesoblast-initiates-rolling-submission-of-biologics-license-application-to-u-dot-s-fda-for-remestemcel-l-in-the-treatment-of-acute-graft-versus-host-disease 2019-05-30T12:05:12 https://maestrodatabase.com/blog/calliditas-announces-submission-of-marketing-authorisation-application-for-nefecon-to-the-european-medicines-agency 2021-05-30T02:05:14 https://maestrodatabase.com/blog/experts-call-for-equal-access-to-cml-therapies-in-the-uk 2015-08-25T09:45:16 https://maestrodatabase.com/blog/cadth-recommends-reimbursement-of-sunvepra 2016-07-26T21:37:14 https://maestrodatabase.com/blog/use-of-real-world-data-sources-for-canadian-drug-pricing-and-reimbursement-decisions-stakeholder-views-and-lessons-for-other-countries 2019-05-30T21:17:55 https://maestrodatabase.com/blog/otsukas-jinarc-the-first-ever-treatment-approved-in-europe-for-adults-living-with-adpkd-a-chronic-genetic-kidney-disease 2015-08-05T11:37:13 https://maestrodatabase.com/blog/pharmac-fails-to-score-major-funding-boost-in-nz-budget 2019-05-30T21:00:29 https://maestrodatabase.com/blog/european-medicines-agency-validates-marketing-authorisation-application-for-zinbryta-daclizumab-high-yield-process-for-treatment-of-ms 2015-08-05T11:37:12 https://maestrodatabase.com/blog/european-commission-grants-marketing-authorisation-for-unituxin-dinutuximab-for-the-treatment-of-paediatric-high-risk-neuroblastoma 2015-08-17T21:48:27 https://maestrodatabase.com/blog/administration-is-seeking-ways-to-keep-prescription-drugs-affordable 2015-11-21T23:50:44 https://maestrodatabase.com/blog/cost-of-goods-information-pb11b-form-at-the-time-of-pbac-submission 2015-08-05T11:37:06 https://maestrodatabase.com/blog/genascence-granted-fda-fast-track-designation-for-gnsc-001-in-patients-with-osteoarthritis-of-the-knee 2024-11-12T23:44:36 https://maestrodatabase.com/blog/fda-approves-new-use-for-celgenes-cancer-drug-revlimid 2015-08-05T11:37:05 https://maestrodatabase.com/blog/hiv-prevention-pill-to-get-insurance-benefit-in-korea 2019-05-30T12:20:31 https://maestrodatabase.com/blog/actelion-receives-health-canada-approval-for-uptravi-selexipag-for-the-long-term-treatment-of-pulmonary-arterial-hypertension 2016-01-26T20:52:09 https://maestrodatabase.com/blog/igr-confirms-the-sustainability-of-the-pbs-into-the-future 2015-08-05T11:37:29 https://maestrodatabase.com/blog/uk-nhs-cancer-drug-approval-needs-radical-change 2015-08-10T21:57:55 https://maestrodatabase.com/blog/pharmac-decision-to-award-sole-supply-to-fentanyl-sandoz-fentanyl-transdermal-patch 2015-08-05T11:37:10 https://maestrodatabase.com/blog/implications-of-proposed-medicare-reforms-to-counteract-high-cancer-drug-prices 2016-05-05T20:30:15 https://maestrodatabase.com/blog/nice-backs-mercks-prevymis-for-cmv 2019-05-30T21:23:16 https://maestrodatabase.com/blog/fda-approves-jardiance-to-treat-type-2-diabetes 2015-08-05T11:37:16 https://maestrodatabase.com/blog/fda-approves-repatha-to-treat-certain-patients-with-high-cholesterol 2015-08-27T21:22:16 https://maestrodatabase.com/blog/fda-announces-real-time-release-of-complete-response-letters-posts-previously-unpublished-batch-of-89 2025-09-06T23:24:44 https://maestrodatabase.com/blog/ema-publishes-chmp-assessment-report-for-accofil-filgrastim 2015-08-05T11:37:24 https://maestrodatabase.com/blog/nice-issues-final-guidance-on-axitinib-inlyta-and-sipuleucel-t-provenge 2015-08-05T11:37:27 https://maestrodatabase.com/blog/breakthrough-lung-cancer-drug-must-be-available-on-nhs-astrazeneca-says 2016-07-20T21:56:25 https://maestrodatabase.com/blog/hep-c-cures-available-today-for-as-low-as-620-a-prescription 2016-03-01T19:58:18 https://maestrodatabase.com/blog/scottish-patients-get-access-to-roches-cll-drug-on-nhs 2015-08-05T11:37:14 https://maestrodatabase.com/blog/10-outrageous-cancer-drug-statistics 2016-06-12T00:40:11 https://maestrodatabase.com/blog/review-of-efficient-funding-of-chemotherapy-program---interim-report 2022-09-05T03:35:16 https://maestrodatabase.com/blog/rare-cancers-lodges-pbac-submission 2016-07-08T04:48:59 https://maestrodatabase.com/blog/proposal-relating-to-two-hiv-treatments-tivicay-and-kivexa 2016-09-09T04:29:06 https://maestrodatabase.com/blog/nice-oks-restricted-use-of-bayers-prostate-cancer-drug-xofigo 2015-11-19T20:35:54 https://maestrodatabase.com/blog/issues-of-price-exposed-by-knee-replacements-12bn-billion 2016-09-26T03:30:37 https://maestrodatabase.com/blog/collaboration-arrangement-between-the-department-of-health-and-aged-care-and-health-technology-assessment-bodies-in-the-united-kingdom-and-canada 2022-09-05T02:09:45 https://maestrodatabase.com/blog/information-about-the-new-hepatitis-c-treatments-from-1-march-2016 2016-02-10T08:30:33 https://maestrodatabase.com/blog/martin-shkreli-invokes-the-fifth-amendment-during-grilling-by-us-congress 2016-02-05T21:32:31 https://maestrodatabase.com/blog/hepatitis-c-drug-delayed-by-nhs-due-to-high-cost 2015-08-05T11:37:15 https://maestrodatabase.com/blog/sydney-mother-calls-for-cystic-fibrosis-drug-orkambi-to-be-accessible-for-daughter 2016-05-19T21:11:56 https://maestrodatabase.com/blog/abeona-therapeutics-announces-fda-acceptance-of-bla-resubmission-of-prademagene-zamikeracel-for-the-treatment-of-recessive-dystrophic-epidermolysis-bullosa 2024-11-12T23:58:33 https://maestrodatabase.com/blog/biodelivery-sciences-receives-fda-approval-for-bunavail-buprenorphine-with-naloxone-buccal-film-for-the-maintenance-treatment-of-opioid-dependence 2015-08-05T11:37:12 https://maestrodatabase.com/blog/smc---recently-added-forthcoming-submissions 2015-08-05T11:37:29 https://maestrodatabase.com/blog/fda-expands-approved-use-of-opdivo-in-advanced-lung-cancer 2015-10-09T20:31:16 https://maestrodatabase.com/blog/fda-approves-bayers-gadavist-gadobutrol-injection-as-first-contrast-agent-for-use-with-magnetic-resonance-angiography-of-supra-aortic-arteries 2016-05-02T11:14:33 https://maestrodatabase.com/blog/novartis-cosentyx-is-the-first-il-17-inhibitor-to-receive-eu-approval-for-first-line-treatment-of-moderate-to-severe-psoriasis-patients 2015-08-05T11:37:23 https://maestrodatabase.com/blog/medicare-items-review-backed-by-health-professionals-patients 2016-09-06T14:17:15 https://maestrodatabase.com/blog/fda-approves-new-antibacterial-drug-zerbaxa 2015-08-05T11:37:11 https://maestrodatabase.com/blog/aralez-announces-fda-approval-of-yosprala-for-secondary-prevention-of-cardiovascular-and-cerebrovascular-events-in-patients-at-risk-for-aspirin-associated-gastric-ulcers 2016-09-16T08:14:11 https://maestrodatabase.com/blog/charleston-laboratories-inc-and-daiichi-sankyo-inc-announce-fda-acceptance-of-new-drug-application-nda-for-cl-108 2016-06-16T21:29:28 https://maestrodatabase.com/blog/appointment-of-ceo-for-the-australian-digital-health-agency 2016-08-01T07:18:40 https://maestrodatabase.com/blog/actavis-and-medicines360-announce-fda-approval-of-liletta-levonorgestrel-releasing-intrauterine-system-52-mg-to-prevent-pregnancy-for-up-to-three-years 2015-08-05T11:37:21 https://maestrodatabase.com/blog/pbac-public-summary-documents---march-2015 2015-08-05T11:37:14 https://maestrodatabase.com/blog/did-the-fda-set-a-dangerous-precedent-with-its-latest-drug-approval 2016-09-20T21:20:47 https://maestrodatabase.com/blog/erc-recommends-jakavi-for-patients-with-polycythema-vera-who-are-resistant-to-or-intolerant-of-hydroxyurea 2016-01-13T20:58:05 https://maestrodatabase.com/blog/summary-of-fees-and-charges-from-1-july-2015 2015-08-05T11:37:14 https://maestrodatabase.com/blog/pcodr-final-recommendation-for-zaltrap-aflibercept 2015-08-05T11:37:26 https://maestrodatabase.com/blog/bristol-myers-bucks-trend-toward-precision-medicine 2016-03-15T04:05:31 https://maestrodatabase.com/blog/ema-to-further-clarify-safety-profile-of-human-papillomavirus-hpv-vaccines 2015-08-05T11:37:06 https://maestrodatabase.com/blog/european-medicines-agency-accepts-application-seeking-new-indication-for-prevenar-13-for-prevention-of-pneumococcal-pneumonia-in-adults 2015-08-05T11:37:27 https://maestrodatabase.com/blog/avanir-pharmaceuticals-announces-fda-approval-of-onzetra-xsail-avp-825-for-the-acute-treatment-of-migraine-in-adults 2016-01-29T23:03:57 https://maestrodatabase.com/blog/tesaro-announces-us-fda-approval-of-varubi-rolapitant-for-nausea-and-vomiting-associated-with-cancer-chemotherapy 2015-09-02T21:03:38 https://maestrodatabase.com/blog/forxiga-approved-in-china-for-the-treatment-of-chronic-kidney-disease-in-patients-at-risk-of-progression-with-and-without-type-2-diabetes 2022-09-05T07:06:01 https://maestrodatabase.com/blog/takeda-receives-european-commission-approval-of-adcetris-brentuximab-vedotin-for-consolidation-treatment-in-post-transplant-hodgkins-lymphoma 2016-07-06T21:23:25 https://maestrodatabase.com/blog/call-for-patient-input-5 2015-08-05T11:37:15 https://maestrodatabase.com/blog/fda-approves-pfizers-biosimilar-abrilada-adalimumab-afzb-for-multiple-inflammatory-conditions 2019-11-18T19:06:57 https://maestrodatabase.com/blog/health-minister-sussan-leys-retreat-on-higher-medicine-charges-to-put-1b-hole-in-budget 2015-08-05T11:37:07 https://maestrodatabase.com/blog/public-summary-documents-pbac-july-2015-meeting 2015-11-16T08:35:47 https://maestrodatabase.com/blog/improving-transparency-in-decision-models-current-issues-and-potential-solutions 2019-11-18T05:45:59 https://maestrodatabase.com/blog/pbac-guidelines-review-update-1 2016-08-05T04:26:47 https://maestrodatabase.com/blog/nice_says_yes_to_the_use_of_mabthera__rituximab__for_patients_with_rare_autoimmune_disease_in_draft_guidance 2015-08-05T11:37:09 https://maestrodatabase.com/blog/unrelated-future-costs-and-unrelated-future-benefits-reflections-on-nice-guide-to-the-methods-of-technology-appraisal 2016-07-05T04:23:35 https://maestrodatabase.com/blog/funding-breakthrough-therapies-a-systematic-review-and-recommendation 2018-03-19T04:51:09 https://maestrodatabase.com/blog/nice-in-confidence-an-assessment-of-redaction-to-obscure-confidential-information-in-single-technology-appraisals-by-the-national-institute-for-health-and-care-excellence 2019-11-18T05:42:33 https://maestrodatabase.com/blog/nice_gives_green_light_to_lucentis__ranibizumab__for_eye_condition_in_final_draft_guidance 2015-08-05T11:37:14 https://maestrodatabase.com/blog/promoting-high-quality-clinical-research-to-develop-more-and-better-medicines-for-children 2016-04-14T20:28:17 https://maestrodatabase.com/blog/eagle-pharmaceuticals-receives-fda-approval-for-vasopressin 2021-12-26T05:29:08 https://maestrodatabase.com/blog/ema-getting-ready-for-the-publication-of-clinical-data 2015-08-05T11:37:24 https://maestrodatabase.com/blog/how-the-worlds-premier-public-health-agency-was-handcuffed 2020-05-25T20:57:29 https://maestrodatabase.com/blog/promoting_competition_key_to_improving_patients__access_to_high_cost_medicines 2015-08-05T11:37:13 https://maestrodatabase.com/blog/calls-for-more-medicinal-cannabis-brands-to-be-added-to-pharmaceutical-benefits-scheme-as-costs-surge 2023-06-07T21:31:56 https://maestrodatabase.com/blog/national-ms-society-responds-to-price-of-new-biogen-slash-alkermes-ms-medication-vumerity 2019-11-18T19:12:56 https://maestrodatabase.com/blog/cadth-sees-green-for-beovu 2020-05-25T21:08:43 https://maestrodatabase.com/blog/new-drugs-pilot-to-tackle-obesity-and-cut-nhs-waiting-lists 2023-06-07T21:36:17 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-september-2014-update 2015-08-05T11:37:27 https://maestrodatabase.com/blog/families-to-save-hundreds-of-dollars-under-pbs-changes 2016-09-25T21:08:35 https://maestrodatabase.com/blog/forxiga-recommended-for-approval-in-the-eu-by-chmp-for-heart-failure 2020-10-19T07:09:40 https://maestrodatabase.com/blog/filgrastim-and-methotrexate-prefilled-syringe-proposal-with-novartis-new-zealand-ltd 2015-12-20T20:57:08 https://maestrodatabase.com/blog/fda-accepts-scenesse-clinical-data-package-for-nda-submission 2016-07-18T11:47:35 https://maestrodatabase.com/blog/tga-approves-rozlytrek 2020-05-25T21:19:10 https://maestrodatabase.com/blog/we-dont-agree-on-drug-pricing-policy-fda-chief-tells-biotech-leaders 2023-06-07T21:26:54 https://maestrodatabase.com/blog/sanofi-regeneron-praluent-alirocumab-marketing-authorization-application-accepted-for-review-by-ema 2015-08-05T11:37:29 https://maestrodatabase.com/blog/to-lower-costs-trump-to-force-hospitals-to-reveal-price-of-care 2019-11-18T19:31:33 https://maestrodatabase.com/blog/ucp-approves-policy-to-create-private-health-care-system-in-alberta 2020-10-19T04:02:19 https://maestrodatabase.com/blog/eisai-receives-license-for-new-indication-for-anticancer-agent-kisplyx-lenvatinib-mesylate-for-treatment-of-advanced-renal-cell-carcinoma 2016-09-15T09:57:13 https://maestrodatabase.com/blog/axicabtagene-ciloleucel-for-the-treatment-of-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-after-first-line-chemoimmunotherapy 2023-06-07T11:38:40 https://maestrodatabase.com/blog/fda-grants-priority-review-for-intercepts-obeticholic-acid-for-the-treatment-of-primary-biliary-cirrhosis 2015-08-31T21:00:30 https://maestrodatabase.com/blog/trixeo-aerosphere-recommended-for-approval-in-the-eu-by-chmp-for-the-maintenance-treatment-of-copd 2020-10-19T07:04:41 https://maestrodatabase.com/blog/call-for-feedback-new-drugs-for-type-2-diabetes-a-therapeutic-review-update 2016-02-23T02:39:08 https://maestrodatabase.com/blog/seelos-therapeutics-receives-fda-fast-track-designation-for-intranasal-racemic-ketamine-sls-002 2019-11-18T19:25:41 https://maestrodatabase.com/blog/ema-and-fda-reinforce-collaboration-on-patient-engagement 2016-06-22T21:20:32 https://maestrodatabase.com/blog/eu-collaboration-strengthens-safety-monitoring-of-medicines 2016-08-08T21:04:07 https://maestrodatabase.com/blog/pharmamar-and-luye-pharma-announce-the-acceptance-of-new-drug-application-for-lurbinectedin-in-china 2023-06-07T10:00:36 https://maestrodatabase.com/blog/fda-approves-new-treatment-for-rare-form-of-hemophilia 2015-08-05T11:37:30 https://maestrodatabase.com/blog/covid-19-csl-aims-to-cover-australia-with-vaccine 2020-05-25T20:55:02 https://maestrodatabase.com/blog/cerulean-receives-fda-fast-track-designation-for-crlx101-for-the-treatment-of-platinum-resistant-ovarian-cancer 2016-07-20T21:29:05 https://maestrodatabase.com/blog/nancy-brunnings-death-calls-for-pharmac-reform 2019-11-18T19:20:50 https://maestrodatabase.com/blog/giotrif-afatinib-approved-in-europe-as-new-oral-treatment-option-for-patients-with-squamous-cell-carcinoma-of-the-lung 2016-04-07T09:28:02 https://maestrodatabase.com/blog/ontario-and-quebec-provide-reimbursement-for-hiv-therapies-pifeltro-doravirine-and-delstrigo-doravirine-slash-lamivudine-slash-tenofovir-disoproxil-fumarate 2019-11-18T19:53:09 https://maestrodatabase.com/blog/first-generic-version-of-gileads-remdesivir-will-be-sold-by-a-bangladesh-drug-maker 2020-05-25T21:39:36 https://maestrodatabase.com/blog/aimmune-receives-positive-chmp-opinion-on-palforzia-for-the-treatment-of-patients-with-peanut-allergy-in-europe 2020-10-19T07:16:30 https://maestrodatabase.com/blog/methods-for-the-economic-evaluation-of-health-care-programmes-new-edition 2015-09-21T12:15:43 https://maestrodatabase.com/blog/lillys-taltz-cleared-in-the-eu-for-plaque-psoriasis 2016-04-27T11:53:07 https://maestrodatabase.com/blog/the-nhs-is-facing-shortages-of-lifesaving-treatments-says-internal-document 2019-11-18T19:47:02 https://maestrodatabase.com/blog/smc-response-to-covid-19 2020-05-25T21:54:44 https://maestrodatabase.com/blog/pharmac-releases-its-interim-response-following-pharmac-review 2022-09-05T20:48:12 https://maestrodatabase.com/blog/allergan-receives-fda-approval-of-teflaro-ceftaroline-fosamil-for-paediatric-patients 2016-05-31T18:05:59 https://maestrodatabase.com/blog/pfizer-and-biontech-submit-updated-longer-term-follow-up-data-of-comirnaty-in-adolescents-12-through-15-years-of-age-to-ema 2021-12-26T06:42:32 https://maestrodatabase.com/blog/the-pill-lower-income-women-locked-out-of-new-contraceptive-ranges 2016-09-22T20:32:34 https://maestrodatabase.com/blog/biosimilars-make-progress-in-the-canadian-market-but-stakeholders-see-more-work-ahead 2019-11-18T19:40:36 https://maestrodatabase.com/blog/novartis-cosentyx-receives-fda-approval-for-the-treatment-of-children-and-adolescents-with-enthesitis-related-arthritis-and-psoriatic-arthritis 2021-12-26T06:50:23 https://maestrodatabase.com/blog/fda-grants-priority-review-for-three-month-paliperidone-palmitate-for-the-treatment-of-schizophrenia 2015-08-05T11:37:22 https://maestrodatabase.com/blog/funding-orphan-medicinal-products-beyond-price-sustaining-an-ecosystem 2019-11-18T19:36:53 https://maestrodatabase.com/blog/draft-ema-reflection-paper-on-the-use-of-patient-reported-outcome-measures-in-oncology-studies 2015-08-05T11:37:28 https://maestrodatabase.com/blog/nice-rejects-trastuzumab-emtansine-for-use-on-nhs 2015-12-24T00:52:11 https://maestrodatabase.com/blog/us-fda-accepts-first-digital-medicine-new-drug-application-for-otsuka-and-proteus-digital-health 2015-09-10T20:59:49 https://maestrodatabase.com/blog/who-pauses-trial-of-hydroxychloroquine-in-covid-19-patients-due-to-safety-concerns 2020-05-25T21:30:55 https://maestrodatabase.com/blog/eye-specialists-call-for-nhs-to-use-avastin 2015-08-05T11:37:14 https://maestrodatabase.com/blog/cancer_patients_denied_30_medicines_available_overseas 2015-08-05T11:37:06 https://maestrodatabase.com/blog/group-launches-seven-figure-ad-buy-boosting-vulnerable-democrats-on-drug-prices 2019-11-18T19:59:18 https://maestrodatabase.com/blog/us-food-and-drug-administration-approves-bristol-myers-squibbs-evotaz-atazanavir-and-cobicistat-for-the-treatment-of-hiv-1-infection-in-adults 2015-08-05T11:37:07 https://maestrodatabase.com/blog/act-now-ama-urges-health-education-to-combat-growing-anti-vaxxer-movement 2020-05-25T21:34:54 https://maestrodatabase.com/blog/bulevirtide-acetate-for-the-treatment-of-adults-with-chronic-hepatitis-d-final-guidance 2023-06-07T21:49:29 https://maestrodatabase.com/blog/adaptive-pathways-key-learnings-and-next-steps 2016-08-04T12:26:52 https://maestrodatabase.com/blog/agenda-for-the-4-november-2015-tc-meeting 2015-10-30T21:44:05 https://maestrodatabase.com/blog/inside-the-science-companies-racing-to-develop-a-covid-19-vaccine 2020-05-25T21:36:57 https://maestrodatabase.com/blog/bristol-myers-squibb-statement-about-asunaprevir-in-the-us 2015-08-05T11:37:22 https://maestrodatabase.com/blog/international-work-sharing---first-medicines-approved-by-all-five-access-consortium-regulators 2022-09-05T11:40:13 https://maestrodatabase.com/blog/cost-to-nhs-of-providing-sipuleucel-t-too-high-to-be-recommended-in-draft-guidance 2015-08-05T11:37:05 https://maestrodatabase.com/blog/final-nice-yes-for-daiichis-bloodthinner-lixiana 2015-09-23T21:03:45 https://maestrodatabase.com/blog/janssen-receives-chmp-positive-opinion-for-expanded-use-of-tremfya-guselkumab-in-the-treatment-of-active-psoriatic-arthritis-in-the-european-union 2020-10-19T07:52:29 https://maestrodatabase.com/blog/outcome-statement---feb-2018-drug-utilisation-sub-committee-meeting 2018-03-19T05:19:13 https://maestrodatabase.com/blog/changes-to-the-national-diabetes-services-scheme-ndss 2016-03-22T06:01:46 https://maestrodatabase.com/blog/feedback-on-draft-rfp-for-medicines-for-rare-disorders 2015-08-05T11:37:27 https://maestrodatabase.com/blog/data-integrity-key-to-public-health-protection 2016-08-11T12:33:17 https://maestrodatabase.com/blog/fda-issues-draft-updated-recommendations-on-submitting-a-new-510k-for-device-modifications 2016-08-06T06:04:38 https://maestrodatabase.com/blog/fda-issues-draft-guidance-on-common-issues-in-drug-development-for-rare-diseases 2015-08-26T21:22:20 https://maestrodatabase.com/blog/decisions-to-list-and-amend-restrictions-on-various-pharmaceuticals 2015-08-05T11:37:09 https://maestrodatabase.com/blog/be-wary-of-canadas-drug-price-controls-and-lack-of-ip-protections 2018-03-19T20:03:03 https://maestrodatabase.com/blog/fda-approves-aspireassist-obesity-device 2016-06-14T21:02:29 https://maestrodatabase.com/blog/world-leaders-agree-at-un-on-steps-to-curb-rising-drug-resistance 2016-09-22T08:21:22 https://maestrodatabase.com/blog/coherus-announces-u-dot-s-fda-approval-of-yusimry-adalimumab-aqvh 2021-12-26T06:54:47 https://maestrodatabase.com/blog/cadth-issues-draft-guidelines-for-manufacturers-on-application-fees-for-the-cadth-common-drug-review 2015-08-05T11:37:09 https://maestrodatabase.com/blog/new-pm-will-inherit-an-nhs-in-its-most-challenging-state-for-decades 2022-09-05T21:13:52 https://maestrodatabase.com/blog/trump-promises-major-news-conference-on-u-dot-s-drug-prices 2018-03-20T20:30:06 https://maestrodatabase.com/blog/notification-of-outcomes-for-the-2016-october-cycle-of-price-disclosure 2016-06-20T07:28:03 https://maestrodatabase.com/blog/call-for-patient-input-24 2015-08-05T11:37:04 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-to-nintedanib-for-the-treatment-of-systemic-sclerosis-with-associated-interstitial-lung-disease 2018-03-19T19:56:19 https://maestrodatabase.com/blog/pharmac-promises-equity-boost-in-first-official-response-to-independent-review 2022-09-05T20:51:30 https://maestrodatabase.com/blog/its-a-very-good-start-funding-boost-for-pharmac-welcomed-but-is-it-enough 2016-05-04T21:29:13 https://maestrodatabase.com/blog/opdivo-approved-via-uks-early-drug-access-scheme 2015-08-05T11:37:23 https://maestrodatabase.com/blog/psivida-announces-fda-acceptance-for-filing-of-new-drug-application-for-durasert-three-year-treatment-for-posterior-segment-uveitis 2018-03-19T19:59:22 https://maestrodatabase.com/blog/clinical-trials-real-world-data-plays-early-role-in-efforts-to-increase-diversity 2022-09-05T21:00:48 https://maestrodatabase.com/blog/repros-announces-acceptance-for-filing-of-nda 2015-08-05T11:37:18 https://maestrodatabase.com/blog/promius-pharma-receives-fda-approval-for-sernivo-betamethasone-dipropionate-005-spray 2016-02-09T08:07:54 https://maestrodatabase.com/blog/germany_extends_drug_price_freeze_to_end_2017 2015-08-05T11:37:07 https://maestrodatabase.com/blog/shingrix-shingles-vaccine-for-older-adults-now-available-at-cvs 2018-03-19T20:13:55 https://maestrodatabase.com/blog/fda-approves-new-drug-application-for-rayaldee-to-treat-secondary-hyperparathyroidism-associated-with-vitamin-d-insufficiency-in-stage-3-4-chronic-kidney-disease 2016-06-21T21:09:59 https://maestrodatabase.com/blog/xultophy-insulin-degludecliraglutide-receives-european-approval-for-use-in-adults-with-type-2-diabetes-and-moderate-renal-impairment 2016-09-05T11:11:52 https://maestrodatabase.com/blog/fdas-new-pilot-program-aims-for-more-transparency-about-new-drug-approvals 2018-03-19T20:08:59 https://maestrodatabase.com/blog/teva-announces-fda-approval-of-proair-respiclick 2015-08-05T11:37:07 https://maestrodatabase.com/blog/biogen-idecs-plegridy-approved-for-australian-adults-with-relapsing-multiple-sclerosis 2015-08-05T11:37:17 https://maestrodatabase.com/blog/workshop-on-paediatric-regulation---stakeholders-to-discuss-how-to-boost-development-of-medicines-for-children 2018-03-19T20:11:07 https://maestrodatabase.com/blog/astrazeneca-receives-approval-in-the-eu-for-qtern-saxagliptin-and-dapagliflozin-for-treatment-of-type-2-diabetes-mellitus 2016-07-20T21:16:14 https://maestrodatabase.com/blog/pharmaxis-boosted-by-drug-sale 2015-08-05T11:37:16 https://maestrodatabase.com/blog/gsk-genmab-get-ec-marketing-authorization-for-new-indication-for-use-of-arzerra 2015-08-05T11:37:16 https://maestrodatabase.com/blog/new-guidance-from-nice-recommends-humira-adalimumab-the-only-licensed-biologic-for-treatment-of-hidradenitis-suppurativa-a-debilitating-and-disfiguring-skin-condition 2016-06-23T05:44:19 https://maestrodatabase.com/blog/levo-therapeutics-receives-fast-track-designation-from-fda-for-intranasal-carbetocin-for-the-treatment-of-prader-willi-syndrome 2019-11-18T23:28:52 https://maestrodatabase.com/blog/praxbind-idarucizumab-a-specific-antidote-for-immediate-reversal-of-pradaxa-dabigatran-etexilate-now-approved-in-canada-with-conditions 2016-05-17T10:08:03 https://maestrodatabase.com/blog/gsk-announces-eu-regulatory-submission-for-malaria-vaccine-candidate-rtss 2015-08-05T11:37:08 https://maestrodatabase.com/blog/thrombogenics__jetrea__ocriplasmin__receives_positive_common_drug_review_in_canada 2015-08-05T11:37:09 https://maestrodatabase.com/blog/lucentis__ranibizumab__accepted_for_use_within_nhs_scotland 2015-08-05T11:37:28 https://maestrodatabase.com/blog/aetna-backs-off-plans-to-expand-its-aca-business 2016-08-04T11:46:59 https://maestrodatabase.com/blog/public-summary-documents---november-2014-pbac-meeting 2015-08-05T11:37:15 https://maestrodatabase.com/blog/us-style-managed-healthcare-given-green-light-by-australian-consumer-watchdog 2021-05-30T21:10:21 https://maestrodatabase.com/blog/fda-approves-new-five-year-contraceptive-of-bayer 2016-09-20T12:52:50 https://maestrodatabase.com/blog/ema-virtual-conference-25-years-of-advancing-public-and-animal-health 2020-10-19T19:50:18 https://maestrodatabase.com/blog/amicus-therapeutics-announces-european-commission-for-galafold-migalastat-in-patients-with-fabry-disease-in-european-union 2016-05-31T14:04:00 https://maestrodatabase.com/blog/amgen-submits-marketing-authorization-application-for-talimogene-laherparepvec-to-the-european-medicines-agency 2015-08-05T11:37:25 https://maestrodatabase.com/blog/abbvie-submits-regulatory-applications-to-fda-and-ema-for-rinvoq-upadacitinib-in-atopic-dermatitis 2020-10-19T19:52:57 https://maestrodatabase.com/blog/agios-announces-withdrawal-of-european-marketing-authorisation-application-for-tibsovo-as-a-treatment-for-relapsed-or-refractory-idh1-mutant-acute-myeloid-leukaemia 2020-10-19T20:02:22 https://maestrodatabase.com/blog/pbs-listed-progesterone-pessary-slashes-preterm-birth-risk 2021-05-30T21:15:27 https://maestrodatabase.com/blog/access_to_new_cancer_drugs_must_come_from_a_more_rapid_process 2015-08-05T11:37:26 https://maestrodatabase.com/blog/dynavax-announces-fda-acceptance-for-review-of-biologics-license-application-and-pdufa-action-date-for-heplisav-b 2016-04-01T21:08:32 https://maestrodatabase.com/blog/cancer-patients-may-lose-vital-drug-in-crackdown-on-funding-watchdog-reviews-31-treatments-that-are-not-usually-available-on-the-nhs 2016-08-10T12:44:58 https://maestrodatabase.com/blog/cadth-recommends-nintedanib-mesylate-ofev-for-patients-with-idiopathic-pulmonary-fibrosis 2015-10-22T03:16:12 https://maestrodatabase.com/blog/fda-approves-first-and-only-single-monthly-injection-for-a-pcsk9-inhibitor 2016-07-11T21:13:56 https://maestrodatabase.com/blog/the-fda-approves-first-generic-version-of-widely-used-influenza-drug-tamiflu 2016-08-06T11:29:52 https://maestrodatabase.com/blog/nice-approval-of-new-hepatitis-drug-could-result-in-700m-bill-for-nhs 2015-10-22T03:02:14 https://maestrodatabase.com/blog/proposal-to-widen-funded-access-to-temozolomide-for-treatment-of-neuroendocrine-tumours-and-high-grade-gliomas 2016-05-05T05:09:58 https://maestrodatabase.com/blog/fda-should-stand-firm-on-stem-cell-treatments 2016-07-05T21:58:00 https://maestrodatabase.com/blog/empagliflozin-in-type-2-diabetes-added-benefit-not-proven 2015-08-05T11:37:26 https://maestrodatabase.com/blog/british-columbia-to-reimburse-tecfidera-a-first-line-oral-treatment-for-multiple-sclerosis 2015-08-05T11:37:23 https://maestrodatabase.com/blog/gilead-submits-new-drug-application-to-us-food-and-drug-administration-for-fixed-dose-combination-of-emtricitabinetenofovir-alafenamide-for-hiv-treatment 2015-08-05T11:37:08 https://maestrodatabase.com/blog/alvotech-and-teva-announce-us-approval-of-simlandi-adalimumab-ryvk-injection-the-first-interchangeable-high-concentration-citrate-free-biosimilar-to-humira 2024-02-26T02:32:37 https://maestrodatabase.com/blog/fda-approves-jj-diabetes-drug-invokamet 2015-08-05T11:37:29 https://maestrodatabase.com/blog/cdr_recommends_self_injectable_subcutaneous_formulation_of_first_non_anti_tnf_biological_treatment_available_in_both_intravenous_and_subcutaneous_formulations_to_be_reimbursed_for_canadians_with_moderately_to_severely_active_ra 2015-08-05T11:37:19 https://maestrodatabase.com/blog/fda-approves-first-treatment-for-rare-disease-in-patients-who-receive-stem-cell-transplant-from-blood-or-bone-marrow 2016-03-30T19:58:07 https://maestrodatabase.com/blog/the-trans-pacific-partnership-pacific-countries-agree-to-historic-trade-pact 2015-10-05T19:43:47 https://maestrodatabase.com/blog/2015-another-strong-year-for-patients-in-need-of-new-drug-therapies 2016-01-04T20:53:55 https://maestrodatabase.com/blog/industry-weighs-radical-shake-up-of-european-drug-pricing 2016-06-09T21:03:35 https://maestrodatabase.com/blog/versantis-receives-fda-rare-paediatric-disease-designation-for-vs-01-for-the-treatment-of-urea-cycle-disorders 2020-10-19T20:16:28 https://maestrodatabase.com/blog/fda-approves-uceris-budesonide-2-mg-rectal-foam-for-the-induction-of-remission-of-mild-to-moderate-distal-ulcerative-colitis 2015-08-05T11:37:23 https://maestrodatabase.com/blog/diurnal-receives-european-commission-approval-for-efmody 2021-05-30T21:21:56 https://maestrodatabase.com/blog/umeclidinium-for-symptom-relief-in-copd-additional-benefit-is-not-proven 2016-05-02T20:59:18 https://maestrodatabase.com/blog/department-of-health-to-conduct-a-post-market-review-of-authority-required-pbs-listings 2015-08-05T11:37:16 https://maestrodatabase.com/blog/is-lowest-cost-alternative-rapidly-becoming-the-most-common-main-comparator-accepted-by-the-pbac 2018-10-29T05:06:24 https://maestrodatabase.com/blog/richter-and-allergan-announce-fda-has-extended-the-review-period-for-cariprazine-to-september-2015 2015-08-05T11:37:04 https://maestrodatabase.com/blog/nice_set_not_to_recommend_ustekinumab_for_psoriatic_arthritis 2015-08-05T11:37:07 https://maestrodatabase.com/blog/uk-doctors-urge-use-of-roches-avastin-as-cheap-eye-drug 2015-08-05T11:37:03 https://maestrodatabase.com/blog/bmj___drug_companies_agree_to_cut_price_of_hpv_vaccine_to_developing_countries_to_increase_accessibility 2015-08-05T11:37:22 https://maestrodatabase.com/blog/claims-australia-in-danger-of-falling-out-of-trillion-dollar-pharmaceuticals-industry 2015-08-05T11:37:03 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-positive-chmp-opinion-recommending-opdivo-nivolumab-as-second-line-treatment-for-unresectable-advanced-recurrent-or-metastatic-oesophageal-squamous-cell-carcinoma 2020-10-19T20:11:17 https://maestrodatabase.com/blog/pharmac-funding-will-result-in-health-poverty-advocate 2021-05-30T21:26:26 https://maestrodatabase.com/blog/new-oecd-data-shows-australia-lagging-in-investing-in-medicines 2015-08-05T11:37:10 https://maestrodatabase.com/blog/inventiva-receives-fda-fast-track-designation-in-mps-vi-for-its-clinical-stage-asset-odiparcil 2020-10-19T20:44:42 https://maestrodatabase.com/blog/bristol-myers-squibb-announces-regulatory-update-for-opdivo-nivolumab-in-advanced-melanoma 2015-11-30T19:38:48 https://maestrodatabase.com/blog/voydeya-recommended-for-approval-in-the-eu-by-chmp-as-add-on-treatment-to-ravulizumab-or-eculizumab-for-adults-with-pnh-who-have-residual-haemolytic-anaemia 2024-02-26T07:38:58 https://maestrodatabase.com/blog/european-commission-grants-marketing-authorizations-for-abbvies-viekirax-ombitasvirparitepravirritonavir-tablets--exviera-dasabuvir-tablets-for-the-treatment-of-chronic-hepatitis-c 2015-08-05T11:37:14 https://maestrodatabase.com/blog/csl-vifor-and-travere-therapeutics-announce-sparsentan-receives-positive-chmp-opinion-for-the-treatment-of-iga-nephropathy 2024-02-26T03:48:52 https://maestrodatabase.com/blog/cheaper-medicines-from-1-october 2016-09-26T01:26:58 https://maestrodatabase.com/blog/heres-what-washington-could-do-to-combat-high-drug-prices 2015-10-14T19:58:41 https://maestrodatabase.com/blog/highlights-from-the-19-22-february-2024-chmp-meeting 2024-02-26T03:46:28 https://maestrodatabase.com/blog/pharmacy-lobby-in-conflict-row-over-it-firms-windfall 2015-08-05T11:37:13 https://maestrodatabase.com/blog/glenmark-pharmaceuticals-receives-anda-approval-for-sirolimus-0-dot-5-mg-1-mg-and-2-mg-tablets 2020-10-19T20:47:55 https://maestrodatabase.com/blog/ojjaara-momelotinib-approved-in-canada-for-the-treatment-of-myelofibrosis-in-adults-who-have-moderate-to-severe-anaemia 2024-11-13T02:21:33 https://maestrodatabase.com/blog/management-board-expected-to-nominate-ema-executive-director-on-1-october-2015 2015-09-29T21:31:13 https://maestrodatabase.com/blog/xeris-pharmaceuticals-announces-fda-acceptance-for-review-of-nda-for-its-ready-to-use-glucagon-rescue-pen 2018-10-29T05:25:00 https://maestrodatabase.com/blog/fda-approves-two-therapies-to-treat-ibs-d 2015-08-05T11:37:22 https://maestrodatabase.com/blog/novartis-receives-two-landmark-european-approvals-for-cosentyx-to-treat-patients-with-ankylosing-spondylitis-and-psoriatic-arthritis 2015-11-23T20:07:01 https://maestrodatabase.com/blog/neurocrine-submits-new-drug-application-for-valbenazine-for-treatment-of-tardive-dyskinesia 2016-08-31T20:53:23 https://maestrodatabase.com/blog/u-dot-s-food-and-drug-administration-accepts-for-priority-review-applications-for-opdivo-nivolumab-in-combination-with-cabometyx-cabozantinib-in-advanced-renal-cell-carcinoma 2020-10-19T20:20:43 https://maestrodatabase.com/blog/cadth-recommends-entyvio-for-patients-with-ulcerative-colitis 2015-11-04T20:50:25 https://maestrodatabase.com/blog/swissmedic-authorizes-novavax-nuvaxovid-covid-19-vaccine-for-adolescents-aged-12-through-17-and-as-a-booster-in-adults-aged-18-and-older 2022-09-06T08:02:59 https://maestrodatabase.com/blog/pragmatic-trials-practical-answers-to-real-world-questions 2016-09-20T20:56:30 https://maestrodatabase.com/blog/pfizer-glaxosmithkline-leaning-on-the-taxpayer 2015-08-05T11:37:03 https://maestrodatabase.com/blog/amgen-announces-repatha-preferred-position-on-cvs-health-commercial-formularies 2015-11-23T20:29:17 https://maestrodatabase.com/blog/neurelis-announces-fda-approval-of-extended-expiration-dating-for-valtoco-diazepam-nasal-spray 2020-10-19T20:30:51 https://maestrodatabase.com/blog/sydney_morning_herald___drug_giant_takes_state_cash__axes_jobs 2015-08-05T11:37:17 https://maestrodatabase.com/blog/as-clinton-trump-debate-looms-its-drug-prices-not-obamacare-taking-stage 2016-09-26T21:04:31 https://maestrodatabase.com/blog/octapharma-announces-fda-approval-of-updated-nuwiq-prescribing-information-to-include-immunogenicity-data-in-previously-untreated-patients 2020-10-19T20:34:45 https://maestrodatabase.com/blog/amazon-eyes-japans-online-prescription-drug-market 2022-09-06T07:09:53 https://maestrodatabase.com/blog/novartis-heart-failure-medicine-entresto-receives-eu-approval 2015-11-24T20:05:49 https://maestrodatabase.com/blog/medicines-new-zealand-consulting-on-a-new-generation-medicines-policy 2020-05-26T02:08:56 https://maestrodatabase.com/blog/standardizing-patient-outcomes-measurement 2016-02-11T00:50:49 https://maestrodatabase.com/blog/sanofi-sees-eu-regulatory-decision-on-its-covid-booster-in-weeks 2022-09-06T08:24:18 https://maestrodatabase.com/blog/proposal-to-list-a-range-of-wound-care-products-supplied-by-convatec-new-zealand-limited 2015-08-05T11:37:18 https://maestrodatabase.com/blog/new-biosimilar-trastuzumab-on-the-pbs---information-for-health-professionals-and-patients 2020-05-26T02:11:18 https://maestrodatabase.com/blog/beigene-receives-positive-chmp-opinion-for-tislelizumab-as-treatment-for-non-small-cell-lung-cancer 2024-02-26T20:28:58 https://maestrodatabase.com/blog/alectinib-hydrochloride-for-the-adjuvant-treatment-of-patients-with-alk-positive-non-small-cell-lung-cancer 2024-11-13T02:26:09 https://maestrodatabase.com/blog/fda-approves-the-first-antihemophilic-factor-fc-fusion-protein-for-patients-with-hemophilia-a 2015-08-05T11:37:27 https://maestrodatabase.com/blog/fda-approves-new-indication-for-spiriva-respimat 2015-09-17T05:46:00 https://maestrodatabase.com/blog/draft_nice_guidance_indicates_pertuzumab__perjeta__is_not_good_value_for_money 2015-08-05T11:37:30 https://maestrodatabase.com/blog/closure-of-beach-program-after-18-years 2016-04-11T09:47:32 https://maestrodatabase.com/blog/bayer-receives-us-fda-breakthrough-therapy-designation-for-bay-2927088-for-non-small-cell-lung-cancer-harbouring-her2-activating-mutations 2024-02-26T20:18:33 https://maestrodatabase.com/blog/sixth-community-pharmacy-agreement-delivers-for-patients 2015-08-05T11:37:30 https://maestrodatabase.com/blog/all-eyes-on-a-hurdle-race-for-a-sars-cov-2-vaccine 2020-10-19T20:54:13 https://maestrodatabase.com/blog/european-commission-authorises-gsks-arexvy-the-first-respiratory-syncytial-virus-rsv-vaccine-for-older-adults 2023-06-08T02:05:19 https://maestrodatabase.com/blog/pharmac-decision-puts-cancer-patients-at-risk-cancer-society 2015-12-04T01:43:01 https://maestrodatabase.com/blog/drug-cost-legislation-gets-a-push-from-white-house 2019-11-19T06:15:48 https://maestrodatabase.com/blog/nearly-a-fifth-of-cancer-patients-in-england-miss-62-day-target-for-starting-treatment 2015-08-05T11:37:14 https://maestrodatabase.com/blog/obamacares-skyrocketing-premiums-why-the-sky-isnt-falling 2016-07-20T21:44:19 https://maestrodatabase.com/blog/no_added_benefit_with_lisdexamfetamine_dimesylate__elvanse__due_to_an_absence_of_relevant_evidence 2015-08-05T11:37:17 https://maestrodatabase.com/blog/fda-nominee-califfs-ties-to-drug-makers-worry-some 2015-09-20T21:19:57 https://maestrodatabase.com/blog/lundbeck-takeda-file-cognitive-data-for-brintellix-with-fda 2015-08-11T11:28:18 https://maestrodatabase.com/blog/european-medicines-agency-grants-orchard-therapeutics-accelerated-assessment-of-otl-200-for-patients-with-metachromatic-leukodystrophy 2019-11-19T01:42:32 https://maestrodatabase.com/blog/treatment-for-chronic-painful-bowel-condition-to-get-nhs-funding-approval 2015-08-05T11:37:22 https://maestrodatabase.com/blog/strategic-agreement-recognises-the-important-role-of-generic-and-biosimilar-medicines-in-delivering-affordable-healthcare 2015-08-05T11:37:08 https://maestrodatabase.com/blog/ama-sharpens-policy-to-promote-reasonable-drug-prices 2019-11-19T10:51:10 https://maestrodatabase.com/blog/baxter-bioscience-and-merrimack-pharmaceuticals-announce-filing-for-european-approval-of-mm-398-an-investigational-treatment-for-post-gemcitabine-metastatic-pancreatic-cancer 2015-08-05T11:37:08 https://maestrodatabase.com/blog/fda-approves-targeted-therapy-for-first-line-treatment-of-patients-with-a-type-of-metastatic-lung-cancer 2015-08-05T11:37:29 https://maestrodatabase.com/blog/fresenius-kabi-receives-u-dot-s-fda-approval-for-biosimilar-stimufend-pegfilgrastim-fpgk 2022-09-06T21:00:22 https://maestrodatabase.com/blog/janssen-statement-update-on-the-scottish-medicines-consortium-smc-decision-on-the-use-of-zytiga-abiraterone-acetate-prior-to-chemotherapy 2015-08-05T11:37:29 https://maestrodatabase.com/blog/us-food-and-drug-administration-accepts-biologics-licensing-application-for-opdivo-nivolumab-for-the-treatment-of-advanced-squamous-non-small-cell-lung-cancer 2015-08-05T11:37:07 https://maestrodatabase.com/blog/pbac-public-summary-documents-july-2015-meeting 2015-11-02T09:57:15 https://maestrodatabase.com/blog/epilepsy-sufferer-says-victims-of-pharmac-drug-switch-should-be-compensated 2019-11-19T06:35:42 https://maestrodatabase.com/blog/italian-medicines-agency-approves-reimbursed-access-to-bylvay-odevixibat-for-patients-with-all-pfic-types 2022-09-06T20:51:27 https://maestrodatabase.com/blog/us-fda-accepts-biologics-license-application-for-paxvaxs-single-dose-oral-cholera-vaccine-vaxchora 2015-12-19T02:57:09 https://maestrodatabase.com/blog/reduction-of-tga-assessment-fees-for-medical-devices 2015-08-05T11:37:22 https://maestrodatabase.com/blog/elizabeth-warren-says-medicare-for-all-rollout-process-will-take-3-years 2019-11-19T06:18:20 https://maestrodatabase.com/blog/us-fda-acknowledges-receipt-of-resubmission-of-shires-new-drug-application-for-lifitegrast-for-dry-eye-disease-in-adults 2016-02-08T19:53:45 https://maestrodatabase.com/blog/boston-scientific-receives-fda-approval-for-expanded-labelling-of-watchman-flx-laac-device-for-dual-anti-platelet-therapy-as-post-procedural-medication-option 2022-09-06T20:46:00 https://maestrodatabase.com/blog/action-receives-approval-for-uptravi-selexipag-for-the-treatment-of-pulmonary-arterial-hypertension-in-australia-and-new-zealand 2016-03-23T06:40:59 https://maestrodatabase.com/blog/ama-develops-rx-for-drug-prices-that-are-high-and-rising 2019-11-19T19:50:34 https://maestrodatabase.com/blog/comparative-analysis-of-decision-maker-preferences-for-equityefficiency-attributes-in-reimbursement-decisions-in-three-european-countries 2016-08-08T21:29:04 https://maestrodatabase.com/blog/proposal-to-widen-access-to-intravenous-trastuzumab-and-change-the-funded-brand 2023-06-08T04:27:03 https://maestrodatabase.com/blog/heres-why-pharmaceutical-companies-raise-their-prices-so-much 2019-11-19T19:22:49 https://maestrodatabase.com/blog/fda-approves-lynparza-to-treat-advanced-ovarian-cancer 2015-08-05T11:37:20 https://maestrodatabase.com/blog/covid-19-a-global-opinion-on-bivalent-vaccines-in-mid-september 2022-09-06T12:04:58 https://maestrodatabase.com/blog/cadth-extends-consultations-deadline 2015-10-23T23:05:12 https://maestrodatabase.com/blog/lung-cancer-and-leukaemia-treatments-to-be-added-to-pbs 2019-11-19T19:19:57 https://maestrodatabase.com/blog/health-insurers-use-process-intended-to-curb-rate-increases-to-justify-them 2016-08-15T08:36:00 https://maestrodatabase.com/blog/pharmac-capable-of-managing-medical-devices-supply-chain-it-says 2022-09-06T12:13:41 https://maestrodatabase.com/blog/setmelanotide-acetate-for-the-treatment-of-people-with-obesity-and-hyperphagia-associated-with-bardet-biedl-syndrome-draft-guidance 2024-02-26T20:45:11 https://maestrodatabase.com/blog/fda-takes-important-step-to-increase-the-development-of-and-access-to-abuse-deterrent-opioids 2016-03-25T00:36:04 https://maestrodatabase.com/blog/duaklir-genuair-approved-in-the-european-union-for-chronic-obstructive-pulmonary-disease 2015-08-05T11:37:30 https://maestrodatabase.com/blog/janssen-files-four-times-a-year-schizophrenia-shot 2015-08-05T11:37:06 https://maestrodatabase.com/blog/withdrawal-from-the-drug-benefits-on-1-december 2019-11-19T20:52:54 https://maestrodatabase.com/blog/decision-to-list-galsulfase-naglazyme-for-mucopolysaccharidosis-mps-vi 2016-03-17T20:47:39 https://maestrodatabase.com/blog/update-to-pbs-listing-steps 2015-09-03T02:51:12 https://maestrodatabase.com/blog/innocare-announces-priority-review-of-orelabrutinib-for-the-treatment-of-relapsed-or-refractory-marginal-zone-lymphoma-by-nmpa 2022-09-06T21:40:26 https://maestrodatabase.com/blog/pharmac-announces-exciting-opportunities-for-improved-health-from-39-million-budget-boost 2016-05-04T00:52:57 https://maestrodatabase.com/blog/icr-criticises-nice-rejection-of-olaparib-for-advanced-prostate-cancer 2022-09-06T21:18:34 https://maestrodatabase.com/blog/fda-accepts-samsung-bioepis-bla-for-sb8-bevacizumab-biosimilar-candidate 2019-11-19T19:57:28 https://maestrodatabase.com/blog/protalix-announces-elelyso-taliglucerase-alfa-approved-in-canada-for-the-treatment-of-gaucher-disease-in-both-adult-and-pediatric-patients 2015-08-05T11:37:09 https://maestrodatabase.com/blog/worlds-most-expensive-medicine-is-it-worth-the-price 2015-08-05T11:37:25 https://maestrodatabase.com/blog/pharmac-to-fund-melanoma-drug 2016-06-12T11:46:03 https://maestrodatabase.com/blog/in-a-rare-political-move-prominent-biotech-venture-capitalists-speak-out-against-pelosis-drug-pricing-bill 2019-11-19T19:53:33 https://maestrodatabase.com/blog/bristol-myers-squibbs-acute-myeloid-leukaemia-oral-maintenance-therapy-recommended-by-nice 2022-09-06T21:30:40 https://maestrodatabase.com/blog/tga-key-performance-indicators-and-measures-regulator-performance-framework 2015-08-05T11:37:26 https://maestrodatabase.com/blog/viiv_healthcare_receives_approval_for_tivicay__dolutegravir__in_canada_for_the_treatment_of_hiv 2015-08-05T11:37:22 https://maestrodatabase.com/blog/ecdc-ema-statement-on-booster-vaccination-with-omicron-adapted-bivalent-covid-19-vaccines 2022-09-06T21:12:33 https://maestrodatabase.com/blog/tagrisso-azd9291-approved-by-the-us-fda-for-patients-with-egfr-t790m-mutation-positive-metastatic-non-small-cell-lung-cancer 2015-11-14T19:15:46 https://maestrodatabase.com/blog/new-browse-by-facet-option-for-maestro-new-zealand---listed-in-the-new-zealand-pharmaceutical-schedule 2015-08-05T11:37:24 https://maestrodatabase.com/blog/european-medicines-agency-validates-marketing-authorization-application-for-natpar-parathyroid-hormone-rdna-in-hypoparathyroidism 2015-08-05T11:37:05 https://maestrodatabase.com/blog/lomitapide-mesylate-in-hypercholesterolaemia-iqwig-finds-no-hint-of-added-clinical-benefit-english-version 2015-09-17T20:49:13 https://maestrodatabase.com/blog/nice-issues-revised-draft-guidance-on-ezetimibe-for-hypercholesterolaemia 2015-12-28T20:37:25 https://maestrodatabase.com/blog/children-and-young-people-set-to-benefit-from-new-treatment-for-peanut-allergy 2021-12-26T08:30:07 https://maestrodatabase.com/blog/fda-accepts-amgens-biosimilar-biologics-license-application-for-abp-501 2016-01-26T20:33:32 https://maestrodatabase.com/blog/biosimilars-how-can-payers-get-long-term-savings 2016-05-16T00:30:44 https://maestrodatabase.com/blog/patients-in-manitoba-and-saskatchewan-living-with-the-most-common-form-of-leukaemia-now-have-access-to-a-targeted-treatment-option 2015-08-05T11:37:08 https://maestrodatabase.com/blog/pharmaceutical-benefits-scheme-new-and-amended-listings 2016-05-04T03:48:39 https://maestrodatabase.com/blog/axovant-sciences-receives-fda-fast-track-designation-for-intepirdine-as-an-investigational-treatment-for-dementia-with-lewy-bodies 2016-09-27T21:02:36 https://maestrodatabase.com/blog/valeant-pharmaceuticals-receives-complete-response-letter-from-the-fda 2016-07-22T21:58:55 https://maestrodatabase.com/blog/nice-issues-draft-guidance-for-ibrutinib-imbruvica 2016-06-01T15:55:58 https://maestrodatabase.com/blog/more-information-needed-on-type-2-diabetes-drug-empagliflozin 2015-08-05T11:37:23 https://maestrodatabase.com/blog/trade-minister-andrew-robb-lashes-out-at-free-trade-scaremongering 2015-08-05T11:37:22 https://maestrodatabase.com/blog/approval_of_sole_supply_arrangement_for_nicotine_replacement_therapy_ 2015-08-05T11:37:26 https://maestrodatabase.com/blog/naswsi-and-project-orbis---are-they-essentially-the-same 2022-09-06T21:45:30 https://maestrodatabase.com/blog/mhra-publishes-eams-scientific-opinion-on-venetoclax-for-the-treatment-of-chronic-lymphocytic-leukaemia 2016-08-28T11:09:04 https://maestrodatabase.com/blog/health-secretary-warns-pharma-administration-will-push-ahead-with-drug-pricing-reforms 2018-10-29T10:53:49 https://maestrodatabase.com/blog/orphazyme-receives-breakthrough-therapy-designation-for-arimoclomol-in-niemann-pick-disease-type-c 2019-11-19T23:57:20 https://maestrodatabase.com/blog/novo-nordisk-files-for-regulatory-approval-of-long-acting-factor-ix-in-the-eu-for-the-treatment-of-haemophilia-b 2016-01-08T20:40:16 https://maestrodatabase.com/blog/nice-turns-down-hyperkalaemia-therapies 2018-10-29T10:58:32 https://maestrodatabase.com/blog/75-million-for-new-medicine-subsidies 2015-08-05T11:37:07 https://maestrodatabase.com/blog/valeant-style-price-hikes-targeted-for-review-by-drug-plan 2016-05-02T21:35:38 https://maestrodatabase.com/blog/trumps-proposed-medicare-drug-pricing-experiment-stokes-fears-of-price-controls 2018-10-29T08:49:59 https://maestrodatabase.com/blog/imbruvica-ibrutinib-approved-with-conditions-for-relapsed-or-refractory-mantle-cell-lymphoma-patients 2015-08-05T11:37:28 https://maestrodatabase.com/blog/game-changing-cancer-medicines-now-within-reach-for-2-200-australians 2019-11-19T23:52:42 https://maestrodatabase.com/blog/major-parties-clash-over-health 2016-05-23T10:21:22 https://maestrodatabase.com/blog/new-medicine-listings-improve-treatment-options-for-people-with-respiratory-conditions 2015-08-05T11:37:22 https://maestrodatabase.com/blog/medicare-negotiating-of-drug-prices-may-not-be-the-cure-to-high-costs 2016-08-16T11:06:15 https://maestrodatabase.com/blog/therapeuticsmd-announces-fda-approval-of-tx-001hr-bijuva-oestradiol-and-progesterone-capsules-for-the-treatment-of-moderate-to-severe-vasomotor-symptoms-due-to-menopause 2018-10-29T20:02:14 https://maestrodatabase.com/blog/benefits-of-new-drug-to-treat-rare-inherited-bone-disorder-too-uncertain-to-justify-its-high-cost-says-nice-in-draft-guidance 2015-12-05T02:43:36 https://maestrodatabase.com/blog/pharmac-in-negotiations-over-rare-disorders-medicines 2015-08-05T11:37:23 https://maestrodatabase.com/blog/medexus-granted-priority-review-status-for-gliolan-by-health-canada 2019-11-20T01:29:20 https://maestrodatabase.com/blog/pfizer-announces-european-medicines-agency-acceptance-for-review-of-marketing-authorization-application-for-trumenba-meningococcal-group-b-vaccine 2016-05-20T14:09:17 https://maestrodatabase.com/blog/merck-sues-to-stop-the-iras-extortion 2023-06-08T07:13:12 https://maestrodatabase.com/blog/agenda-for-the-21-october-2015-tc-meeting 2015-10-19T22:10:52 https://maestrodatabase.com/blog/ucb-announces-us-and-eu-regulatory-filings-for-the-investigational-antiepileptic-drug-brivaracetam 2015-08-05T11:37:27 https://maestrodatabase.com/blog/pfizer-merck-and-bristol-myers-squibb-report-solid-results 2015-08-05T11:37:16 https://maestrodatabase.com/blog/request-for-proposals-rfp-supply-of-progestogen-only-long-acting-intrauterine-systems-extension-to-due-date 2015-09-28T05:16:48 https://maestrodatabase.com/blog/mavenclad-cladribine-tablets-receives-positive-cadth-canadian-drug-expert-committee-recommendation 2018-10-29T19:54:41 https://maestrodatabase.com/blog/genmab-announces-european-marketing-authorization-for-darzalex-daratumumab-in-combination-with-lenalidomide-and-dexamethasone-in-frontline-multiple-myeloma 2019-11-20T01:08:08 https://maestrodatabase.com/blog/vanda-announces-fda-approval-of-the-fanapt-supplemental-new-drug-application-for-maintenance-treatment-of-schizophrenia-in-adults 2016-05-27T12:29:37 https://maestrodatabase.com/blog/cortiment-mmx-a-new-treatment-for-ulcerative-colitis-receives-european-approval 2015-08-05T11:37:02 https://maestrodatabase.com/blog/drug-companies-pushed-from-far-and-wide-to-explain-high-prices 2015-08-05T11:37:25 https://maestrodatabase.com/blog/life-saving-therapy-denied-to-dying-cop 2019-11-20T02:34:12 https://maestrodatabase.com/blog/uk-nice-to-hold-oral-appeal-hearing-for-firmagon-degarelix-for-the-treatment-of-advanced-hormone-dependent-prostate-cancer 2015-08-05T11:37:15 https://maestrodatabase.com/blog/alternative-state-level-financing-for-hepatitis-c-treatment--the-netflix-model 2018-10-29T20:13:37 https://maestrodatabase.com/blog/medicure-announces-approval-of-expanded-dosing-time-for-aggrastat 2015-08-05T11:37:10 https://maestrodatabase.com/blog/jazz-pharmaceuticals-announces-fda-approval-of-xyrem-sodium-oxybate-for-the-treatment-of-cataplexy-or-excessive-daytime-sleepiness-in-paediatric-narcolepsy-patients 2018-10-29T20:08:17 https://maestrodatabase.com/blog/private-health-premiums-tipped-to-soar-as-more-young-people-drop-cover 2019-11-20T02:12:48 https://maestrodatabase.com/blog/costs-and-concerns-in-cancer-care 2016-10-04T23:29:04 https://maestrodatabase.com/blog/nice-issues-final-draft-guidance-recommending-enzalutamide-for-prostate-cancer 2015-08-05T11:37:21 https://maestrodatabase.com/blog/generic-drug-approvals-soar-but-patients-still-go-without 2019-11-20T02:08:43 https://maestrodatabase.com/blog/fda-approves-a-second-vaccine-to-prevent-serogroup-b-meningococcal-disease 2015-08-05T11:37:18 https://maestrodatabase.com/blog/alkermes-submits-new-drug-application-to-u-dot-s-fda-for-alks-3831-for-treatment-of-schizophrenia-and-bipolar-i-disorder 2019-11-20T03:28:44 https://maestrodatabase.com/blog/us-congress-seeks-fda-documents-about-generic-drug-approvals 2016-02-09T20:16:30 https://maestrodatabase.com/blog/the-sickest-patients-are-fleeing-private-medicare-plans-costing-taxpayers-billions 2024-11-13T07:14:51 https://maestrodatabase.com/blog/s-fda-expands-indication-of-invokanamet-canagliflozinmetformin-hcl-to-include-first-line-treatment-of-adults-with-type-2-diabetes 2016-05-25T10:37:35 https://maestrodatabase.com/blog/public-opinion-divided-over-uk-drugs-spend 2015-08-05T11:37:27 https://maestrodatabase.com/blog/a-fair-plan-for-fairer-drug-prices 2016-07-12T21:39:57 https://maestrodatabase.com/blog/medical-device-makers-shut-out-of-value-based-care-without-kickback-rule-change 2018-10-29T20:20:47 https://maestrodatabase.com/blog/germany-tops-global-patient-table-for-access-to-medicines 2015-08-05T11:37:11 https://maestrodatabase.com/blog/phrma-statement-on-hhs-speech-and-part-b-proposal 2018-10-29T20:26:20 https://maestrodatabase.com/blog/newron-receives-fda-rare-paediatric-disease-designation-for-sarizotan-for-the-treatment-of-rett-syndrome 2019-11-20T02:58:14 https://maestrodatabase.com/blog/two-new-films-focus-on-how-smc-works-with-patient-groups 2016-06-14T12:35:32 https://maestrodatabase.com/blog/nice-publishes-final-guidance-on-the-use-of-nivolumab-in-combination-with-ipilimumab-for-treating-advanced-melanoma 2016-07-27T11:31:39 https://maestrodatabase.com/blog/ispor-europe-2018 2018-10-29T20:52:00 https://maestrodatabase.com/blog/price-disclosure-2015-october-cycle-outcomes-summary 2015-08-05T11:37:05 https://maestrodatabase.com/blog/cdec-recommends-tivicay-dolutegravir-for-patients-with-hiv-infection 2015-08-05T11:37:24 https://maestrodatabase.com/blog/patritumab-deruxtecan-granted-u-dot-s-fda-breakthrough-therapy-designation-in-patients-with-metastatic-egfr-mutated-non-small-cell-lung-cancer 2021-12-26T10:53:23 https://maestrodatabase.com/blog/staying-safe-when-buying-medicines-online 2015-08-05T11:37:13 https://maestrodatabase.com/blog/expanding-evidence-based-technology-assessment-for-coverage-in-washington-state 2016-08-08T07:14:00 https://maestrodatabase.com/blog/pharmac_s_proposed_approach_to_managing_hospital_medical_devices 2015-08-05T11:37:08 https://maestrodatabase.com/blog/eisai_withdraws_epilepsy_drug_fycompa_in_germany_over_price_disagreement 2015-08-05T11:37:15 https://maestrodatabase.com/blog/ema-publishes-epar-for-epclusa-sofosbuvir-with-velpatasvir 2016-07-28T21:19:53 https://maestrodatabase.com/blog/european-commission-approves-nivolumab-bms-the-first-pd-1-immune-checkpoint-inhibitor-in-europe-proven-to-extend-survival-for-patients-with-previously-treated-advanced-squamous--non-small-cell-lung-cancer 2015-08-05T11:37:16 https://maestrodatabase.com/blog/reform-pharmac-or-people-will-die-melanoma-survivor-tells-mps 2016-08-17T21:47:23 https://maestrodatabase.com/blog/first-in-class-epilepsy-treatment-fycompa-perampanel-launches-in-australia 2015-08-05T11:37:14 https://maestrodatabase.com/blog/european-commission-approves-two-new-regimens-of-mercks-keytruda-pembrolizumab-as-first-line-treatment-for-metastatic-or-unresectable-recurrent-head-and-neck-squamous-cell-carcinoma 2019-11-20T19:57:45 https://maestrodatabase.com/blog/kadcyla-price-too-high-for-routine-nhs-funding-says-nice-in-final-guidance 2015-12-16T20:08:40 https://maestrodatabase.com/blog/review-of-pharmacy-remuneration-and-regulation-submissions-closing-soon 2016-09-22T08:18:31 https://maestrodatabase.com/blog/aarp-price-hikes-doubled-average-drug-price-over-7-years 2016-02-29T20:53:15 https://maestrodatabase.com/blog/auckland-widows-wish-to-give-away-leftover-cancer-medication-illegal-under-medicines-act 2019-11-20T19:52:39 https://maestrodatabase.com/blog/outcomes-for-the-diabetes-post-market-review 2015-08-05T11:37:30 https://maestrodatabase.com/blog/nice-yes-for-genzymes-lemtrada-but-no-for-janssens-stelara 2015-08-05T11:37:18 https://maestrodatabase.com/blog/medical-devices-pushing-private-health-expenses 2019-11-20T19:49:28 https://maestrodatabase.com/blog/ledipasvir-plus-sofosbuvir-hint-of-added-benefit-in-certain-patients 2015-08-05T11:37:16 https://maestrodatabase.com/blog/ema-publishes-epar-for-selexipag-uptravi 2016-05-26T20:07:17 https://maestrodatabase.com/blog/nice-recommends-treatment-for-brain-condition-caused-by-liver-failure 2015-08-05T11:37:17 https://maestrodatabase.com/blog/fda-accepts-application-for-mercks-keytruda-pembrolizumab-plus-chemotherapy-as-treatment-for-advanced-or-unresectable-biliary-tract-cancer 2023-06-08T11:12:34 https://maestrodatabase.com/blog/improving-access-to-medicines-and-devices-in-primary-care-in-new-zealand 2015-09-18T02:44:16 https://maestrodatabase.com/blog/the-fix-for-american-health-care-can-be-found-in-europe 2017-08-10T20:55:15 https://maestrodatabase.com/blog/outcomes_from_the_november_2013_pbac_meeting 2015-08-05T11:37:18 https://maestrodatabase.com/blog/fda-approves-first-treatment-for-inherited-rare-disease 2019-11-20T20:04:17 https://maestrodatabase.com/blog/perc_has_recommended_the_funding_of_mekinist__trametinib__in_patients_with_braf_v600_mutation_positive_unresectable_or_metastatic_melanoma 2015-08-05T11:37:08 https://maestrodatabase.com/blog/universal-public-drug-coverage-would-save-canada-billions 2015-08-05T11:37:11 https://maestrodatabase.com/blog/nice-final-nod-for-msds-cholesterol-buster-ezetrol 2016-02-24T20:13:53 https://maestrodatabase.com/blog/patients-getting-faster-access-to-cancer-drugs-as-nice-approves-three-quarters-of-the-cancer-drugs-fund 2017-08-10T21:01:40 https://maestrodatabase.com/blog/toujeo-new-basal-insulin-option-for-adults-living-with-diabetes-approved-by-health-canada 2015-08-05T11:37:24 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits-1-august-2016-update 2016-07-31T10:49:16 https://maestrodatabase.com/blog/science-and-innovation-for-better-medicines 2017-08-10T20:58:34 https://maestrodatabase.com/blog/agenda-for-the-7-september-2016-tc-meeting 2016-08-30T21:15:42 https://maestrodatabase.com/blog/french-authorities-approve-national-reimbursement-of-orkambi-lumacaftor-slash-ivacaftor-for-eligible-people-ages-two-and-older-with-cystic-fibrosis 2019-11-20T20:20:04 https://maestrodatabase.com/blog/patient-reported-outcomes-labeling-for-products-approved-by-the-office-of-hematology-and-oncology-products-of-the-us-food-and-drug-administration-2010-2014 2016-05-24T11:06:30 https://maestrodatabase.com/blog/to-speed-access-to-compassionate-use-look-beyond-the-fda 2017-08-10T21:15:45 https://maestrodatabase.com/blog/top-gop-senator-drug-pricing-action-unlikely-before-end-of-year 2019-11-20T20:11:53 https://maestrodatabase.com/blog/drug-shortages-forcing-hard-decisions-on-rationing-treatments 2016-01-29T22:41:05 https://maestrodatabase.com/blog/novartis-xolair-backed-for-nhs-treatment-of-hives 2015-08-05T11:37:17 https://maestrodatabase.com/blog/berinert-approved-by-health-canada-for-the-treatment-of-hereditary-angioedema-in-paediatric-patients 2017-08-10T21:36:12 https://maestrodatabase.com/blog/request-for-information-relating-to-adrenaline-auto-injectors 2015-08-05T11:37:18 https://maestrodatabase.com/blog/investors-bet-100000-cancer-drug-prices-are-here-to-stay 2015-08-05T11:37:11 https://maestrodatabase.com/blog/trump-takes-issue-with-mcconnells-accusation-that-he-had-excessive-expectations-for-congress 2017-08-10T21:22:31 https://maestrodatabase.com/blog/chf-expresses-concern-on-biosimilars-plan 2015-08-05T11:37:13 https://maestrodatabase.com/blog/unfair-if-rare-should-the-pbs-change-the-way-it-lists-cancer-drugs 2016-05-12T21:54:24 https://maestrodatabase.com/blog/setting-the-record-straight-on-fda-approvals-in-oncology 2017-08-10T21:43:18 https://maestrodatabase.com/blog/valeant-and-progenics-announce-the-submission-of-us-new-drug-application-for-oral-resistor 2015-08-05T11:37:14 https://maestrodatabase.com/blog/smc-announces-more-forthcoming-submissions 2015-11-13T06:37:25 https://maestrodatabase.com/blog/china-to-promote-centralised-medicine-procurement-use-to-ease-patients-burden 2019-11-20T20:30:30 https://maestrodatabase.com/blog/call-for-feedback-anti-vegf-drugs-for-retinal-conditions 2015-08-05T11:37:13 https://maestrodatabase.com/blog/congress-misguided-plan-to-ban-qalys 2023-06-08T20:59:46 https://maestrodatabase.com/blog/obamacare-marketplaces-are-in-trouble-what-can-be-done 2016-08-30T08:55:44 https://maestrodatabase.com/blog/pharmacyclics-files-supplemental-new-drug-application-for-imbruciva-for-waldenstroms-macroglobulinaemia 2015-08-05T11:37:02 https://maestrodatabase.com/blog/lion-tcr-receives-fda-fast-track-designation-for-its-hbv-specific-tcr-t-cell-therapy-for-hepatocellular-carcinoma 2021-12-26T21:01:09 https://maestrodatabase.com/blog/novaliq-announces-fda-approval-of-vevye-cyclosporine-ophthalmic-solution-0-dot-1-percent-for-the-treatment-of-the-signs-and-symptoms-of-dry-eye-disease 2023-06-08T21:05:52 https://maestrodatabase.com/blog/toward-a-new-era-of-trust-and-transparency-in-clinical-trials-1 2016-10-04T21:15:42 https://maestrodatabase.com/blog/fda-issues-complete-response-letter-for-kyndrisa-for-duchenne-muscular-dystrophy-amenable-to-exon-51-skipping 2016-01-14T20:49:35 https://maestrodatabase.com/blog/brexit-spells-upheaval-for-eu-and-uk-drug-regulation 2016-06-26T11:03:30 https://maestrodatabase.com/blog/tga-approves-latisse-bimatoprost 2016-07-27T03:32:24 https://maestrodatabase.com/blog/future-funding-approach-for-blood-glucose-meters-and-test-strips 2015-08-05T11:37:22 https://maestrodatabase.com/blog/rocket-pharmaceuticals-receives-fda-fast-track-and-orphan-drug-designations-for-rp-a601-gene-therapy-for-pkp2-arrhythmogenic-cardiomyopathy 2023-06-08T12:08:06 https://maestrodatabase.com/blog/nice-recommends-vargatef-nintedanib-in-combination-with-docetaxel-as-an-option-for-patients-with-non-small-cell-lung-cancer-of-adenocarcinoma-histology-within-its-licensed-indication 2015-08-05T11:37:10 https://maestrodatabase.com/blog/fda-approves-first-buprenorphine-implant-for-treatment-of-opioid-dependence 2016-05-26T19:12:12 https://maestrodatabase.com/blog/sanofi-wins-appeal-in-spat-with-nice-over-sarclisa 2024-11-13T20:55:48 https://maestrodatabase.com/blog/call-for-patient-input-on-a-submission-from-teva-for-reslizumab 2016-05-04T20:56:59 https://maestrodatabase.com/blog/cheaper-scripts-for-millions 2022-09-07T02:16:40 https://maestrodatabase.com/blog/decision-regarding-funding-of-pembrolizumab-keytruda-nivolumab-opdivo-posaconazole-noxafil-and-raltegravir-isentress 2016-08-02T02:00:05 https://maestrodatabase.com/blog/sar443579-slash-iph6101-receives-fda-fast-track-designation-in-the-us-for-the-treatment-of-haematological-malignancies 2023-06-08T11:50:55 https://maestrodatabase.com/blog/focus-on-innovation-a-welcome-start-for-the-turnbull-government 2015-09-21T12:08:34 https://maestrodatabase.com/blog/specialty-based-global-payment-a-new-phase-in-payment-reform 2016-04-25T21:36:50 https://maestrodatabase.com/blog/allogeneic-hematopoietic-cell-transplantation-and-other-expensive-cellular-therapies-a-miracle-for-the-few-but-off-limits-to-many 2019-11-21T04:13:45 https://maestrodatabase.com/blog/real-world-evidence-a-comparison-of-the-australian-herceptin-program-and-clinical-trials-of-trastuzumab-for-her2-positive-metastatic-breast-cancer 2016-09-19T02:18:45 https://maestrodatabase.com/blog/antivascular-endothelial-growth-factor-drugs-for-retinal-conditions 2015-08-05T11:37:02 https://maestrodatabase.com/blog/fda-approves-gilotrif-afatinib-dimaleate-as-new-oral-treatment-option-for-patients-with-squamous-cell-carcinoma-of-the-lung 2016-04-18T06:26:07 https://maestrodatabase.com/blog/welcome-to-the-new-pharmac-dot-govt-dot-nz 2020-10-20T03:21:26 https://maestrodatabase.com/blog/cadth-calls-for-patient-input-on-a-new-submission-from-abbvie-for-humira 2015-08-28T20:52:01 https://maestrodatabase.com/blog/novartis-receives-three-fda-breakthrough-therapy-designations-for-ilaris-to-treat-rare-types-of-periodic-fever-syndromes 2016-04-27T05:56:13 https://maestrodatabase.com/blog/us-fda-grants-priority-review-for-ofatumumab-acetate-as-maintenance-therapy-for-relapsed-cll 2015-09-21T12:47:49 https://maestrodatabase.com/blog/tga-approves-new-indication-for-glypressin-terlipressin-acetate 2016-06-20T07:45:13 https://maestrodatabase.com/blog/ema-publishes-epar-for-pandemic-h5n1-influenza-vaccine 2016-06-07T21:20:14 https://maestrodatabase.com/blog/horizon-pharma-plc-receives-health-canada-approval-for-ravicti-glycerol-phenylbutyrate-oral-liquid-for-the-treatment-of-urea-cycle-disorders-in-patients-two-years-of-age-and-older 2016-03-22T06:10:16 https://maestrodatabase.com/blog/apotex-medicines-in-new-zealand 2021-05-31T06:12:41 https://maestrodatabase.com/blog/cadth-publishes-initial-recommendation-for-afinitor-everolimus 2016-10-01T01:25:45 https://maestrodatabase.com/blog/swissmedic-fast-tracks-second-anti-viral-vaccine 2020-10-20T03:13:23 https://maestrodatabase.com/blog/health-minister-abandons-strategic-agreement-with-medicines-australia--medicines-industry-stability-and-patient-safety-at-risk 2015-08-05T11:37:09 https://maestrodatabase.com/blog/us-presidential-candidates-proposals-to-reduce-drug-prices 2016-08-28T10:42:02 https://maestrodatabase.com/blog/cancer-drugs-fund-gets-160m-more-for-innovative-treatments 2015-08-05T11:37:10 https://maestrodatabase.com/blog/windtree-therapeutics-announces-fda-fast-track-designation-for-aerosurf 2016-09-19T20:46:52 https://maestrodatabase.com/blog/health-canada-has-approved-taltz-ixekizumab-for-the-treatment-of-non-radiographic-axial-spondyloarthritis 2020-10-20T03:15:46 https://maestrodatabase.com/blog/opdivo-nivolumab-granted-first-approval-of-a-pd-1-inhibitor-in-haematology-for-the-treatment-of-classical-hodgkins-lymphoma-patients-who-have-relapsed-or-progressed-after-auto-hsct-and-post-transplantation-brentuximab-vedotin-by-the-fda 2016-05-18T06:33:08 https://maestrodatabase.com/blog/summary_of_the_agenda_for_the_july_2013_pbac_meeting 2015-08-05T11:37:21 https://maestrodatabase.com/blog/cadth-calls-for-patient-input-on-a-new-submission-from-eli-lilly-for-ixekizumab 2016-02-17T23:23:30 https://maestrodatabase.com/blog/ema-publishes-epar-for-zepatier-elbasvir-with-grazoprevir 2016-07-28T21:24:44 https://maestrodatabase.com/blog/first-combination-covid-19-and-influenza-self-tests-approved-for-australia 2022-09-07T04:58:09 https://maestrodatabase.com/blog/call-for-vital-menieres-disease-medication-to-be-added-to-the-pbs 2016-06-16T21:18:37 https://maestrodatabase.com/blog/the-cost-of-nab-paclitaxel-is-not-justified-by-its-limited-benefit-says-nice-in-draft-guidance-1 2015-08-05T11:37:07 https://maestrodatabase.com/blog/call-for-patient-input-9 2015-08-05T11:37:03 https://maestrodatabase.com/blog/germany_s_iqwig_has_found_that_pertuzumab__perjeta__has_significant_added_value_in_certain_patients_with_advanced_breast_cancer 2015-08-05T11:37:15 https://maestrodatabase.com/blog/sacubitrilvalsartan-in-chronic-heart-failure-indication-of-a-considerable-additional-benefit 2016-04-06T20:44:01 https://maestrodatabase.com/blog/generic-medicines-working-group-gmwg-communique 2016-09-20T12:46:00 https://maestrodatabase.com/blog/viiv-healthcare-receives-approval-for-triumeq-dolutegravirabacavirlamivudine-in-canada---a-new-once-daily-single-pill-regimen-for-the-treatment-of-hiv 2015-08-05T11:37:27 https://maestrodatabase.com/blog/nice-appraisal-of-earlier-treatment-with-abiraterone-acetate-for-prostate-cancer 2015-08-05T11:37:17 https://maestrodatabase.com/blog/examining-the-impact-of-different-country-processes-for-appraising-rare-disease-treatments-a-case-study-analysis 2021-05-31T06:39:14 https://maestrodatabase.com/blog/incruse-ellipta-umeclidinium-to-be-reimbursed-in-australia-for-chronic-obstructive-pulmonary-disease 2015-08-05T11:37:17 https://maestrodatabase.com/blog/smc---september-2025-decisions 2025-09-08T23:08:30 https://maestrodatabase.com/blog/fda-approves-first-biosimilar-product-zarxio 2015-08-05T11:37:06 https://maestrodatabase.com/blog/latest-plan-to-cut-medicare-drug-payments-leaves-senators-skeptical 2016-06-29T10:48:59 https://maestrodatabase.com/blog/scotland-rejects-cancer-drugs-opdivo-and-perjeta 2016-03-08T20:15:42 https://maestrodatabase.com/blog/nice-joins-global-group-to-accelerate-access-to-new-drugs 2015-08-05T11:37:24 https://maestrodatabase.com/blog/cdec-recommends-galexos-simeprevir-sodium-for-patients-with-chronic-hepatitis-genotype-1-infection 2015-08-05T11:37:21 https://maestrodatabase.com/blog/u-dot-s-fda-grants-priority-review-for-a-supplemental-new-drug-application-for-xtandi-enzalutamide-in-non-metastatic-castration-resistant-prostate-cancer 2018-03-20T01:15:48 https://maestrodatabase.com/blog/thousands-more-patients-to-benefit-from-additional-160-million-for-cancer-drugs 2015-08-05T11:37:25 https://maestrodatabase.com/blog/ema-refused-rolling-review-of-sk-biosciences-covid-19-vaccine 2022-09-07T07:53:05 https://maestrodatabase.com/blog/specialised-therapeutics-australia-receives-tga-approval-for-abraxane-in-combination-with-gemcitabine-for-first-line-treatment-of-metastatic-pancreatic-cancer 2015-08-05T11:37:17 https://maestrodatabase.com/blog/fdas-expedited-programs-and-their-impact-on-the-availability-of-new-therapies 2016-09-14T02:36:17 https://maestrodatabase.com/blog/japan-weighs-further-clampdown-on-drug-pricing-with-opdivo-and-repatha-in-its-sights 2016-09-22T20:52:09 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule-1-april-2016-update 2016-03-31T06:03:15 https://maestrodatabase.com/blog/health-canada-approves-new-indication-for-jardiance-empagliflozin-tablets-for-adults-with-type-2-diabetes-and-established-cardiovascular-disease 2016-08-12T23:04:40 https://maestrodatabase.com/blog/kiwis-missing-out-on-innovative-medicines 2015-08-05T11:37:15 https://maestrodatabase.com/blog/celgene-receives-positive-chmp-opinion-for-abraxane-for-first-line-treatment-of-patients-with-non-small-cell-lung-cancer 2015-08-05T11:37:03 https://maestrodatabase.com/blog/great-voice-heard 2016-03-03T18:18:43 https://maestrodatabase.com/blog/reimbursement-delay-leaves-korean-patients-waiting-for-padcev-keytruda-first-line-therapy 2025-09-09T06:48:16 https://maestrodatabase.com/blog/pcodr_recommends_the_funding_of_dabrafenib_mesylate__tafinlar__for_patients_with_malignant_melanoma 2015-08-05T11:37:10 https://maestrodatabase.com/blog/call-for-inquiry-into-pharmacs-epilepsy-drug-switch 2019-11-21T05:41:22 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule-1-july-2016-update 2016-06-30T21:53:54 https://maestrodatabase.com/blog/nhs-england-consults-on-plans-for-cancer-drugs-fund 2015-08-05T11:37:28 https://maestrodatabase.com/blog/pbs-expenditure-and-prescriptions-report-2020-21 2021-12-26T23:22:03 https://maestrodatabase.com/blog/fda-issues-complete-response-letter-for-sequestox-new-drug-application 2016-07-18T07:34:42 https://maestrodatabase.com/blog/abbvies-humira-adalimumab-receives-health-canada-approval-for-the-extension-of-the-polyarticular-juvenile-idiopathic-arthritis-indication-for-patients-between-2-and-4-years 2015-12-10T20:22:24 https://maestrodatabase.com/blog/report-on-the-collection-of-under-co-payment-data-2020-21 2021-12-26T23:19:35 https://maestrodatabase.com/blog/white-house-asks-court-to-dismiss-lawsuit-over-drug-imports 2021-05-31T09:03:51 https://maestrodatabase.com/blog/new-national-plan-to-tackle-the-impact-of-asthma 2015-08-05T11:37:11 https://maestrodatabase.com/blog/direct-acting-anti-virals-for-chronic-hepatitis-c-genotype-1 2015-08-05T11:37:16 https://maestrodatabase.com/blog/nice-intends-to-recommend-olaparib-for-ovarian-fallopian-tube-and-peritoneal-cancer-after-company-provides-more-information 2015-12-14T20:18:58 https://maestrodatabase.com/blog/qol-medical-receives-fda-approval-of-sucraid-sacrosidase-oral-solution-single-use-containers-for-patients-with-congenital-sucrase-isomaltase-deficiency 2022-09-07T08:22:38 https://maestrodatabase.com/blog/fda-regulator-widowed-by-cancer-helps-speed-drug-approval 2016-01-03T07:00:15 https://maestrodatabase.com/blog/relevant_additions_and_changes_from_the_1_february_2014_issue_of_the_schedule_of_pharmaceutical_benefits_have_been_added_to_maestro_australia 2015-08-05T11:37:03 https://maestrodatabase.com/blog/bristol-myers-squibbs-opdivo-nivolumab-receives-breakthrough-therapy-designation-from-us-food-and-drug-administration-for-advanced-renal-cell-carcinoma 2015-09-16T20:02:52 https://maestrodatabase.com/blog/epizyme-submits-new-drug-application-to-the-u-dot-s-fda-for-tazemetostat-for-the-treatment-of-patients-with-epithelioid-sarcoma 2019-05-31T04:08:14 https://maestrodatabase.com/blog/u-dot-s-fda-approves-supplemental-new-drug-application-adding-overall-survival-data-for-xospata-gilteritinib 2019-05-31T03:58:54 https://maestrodatabase.com/blog/medical-device-makers-hit-back-on-prices 2016-09-27T20:43:14 https://maestrodatabase.com/blog/public-summary-documents---september-2021-pbac-meeting 2021-12-26T23:35:37 https://maestrodatabase.com/blog/nhs-abandoning-thousands-by-rationing-hepatitis-c-drugs 2016-07-28T21:35:45 https://maestrodatabase.com/blog/submissions-received-orphan-drugs-program 2015-08-05T11:37:30 https://maestrodatabase.com/blog/demonstrating-significant-benefit-of-orphan-medicines 2015-09-07T11:52:14 https://maestrodatabase.com/blog/type-2-diabetes-added-benefit-of-canagliflozin-plus-metformin-is-not-proven 2015-08-05T11:37:22 https://maestrodatabase.com/blog/pbs-process-improvements-webinar---information-forum 2019-05-31T04:19:01 https://maestrodatabase.com/blog/icer-publishes-evidence-report-on-treatment-for-non-cystic-fibrosis-bronchiectasis 2025-09-09T05:43:31 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits-1-october-2015-update 2015-09-30T10:30:35 https://maestrodatabase.com/blog/us-fda-accepts-for-priority-review-the-supplemental-biologics-license-application-for-epcoritamab-epkinly-for-difficult-to-treat-relapsed-or-refractory-follicular-lymphoma 2024-02-27T05:52:27 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule-1-january-2016-update 2015-12-31T01:03:31 https://maestrodatabase.com/blog/tafamidis-meglumine-for-the-treatment-of-patients-with-transthyretin-amyloidosis-with-cardiomyopathy 2024-02-27T04:39:00 https://maestrodatabase.com/blog/blood-cancer-patients-implore-pharmac-to-fund-desperately-needed-medicine 2022-09-07T08:00:43 https://maestrodatabase.com/blog/kiwi-mum-petitions-for-free-sunscreen-as-nz-overtakes-australias-melanoma-rate 2016-03-30T21:02:08 https://maestrodatabase.com/blog/b-dot-c-woman-receives-long-term-supply-of-life-saving-drug----but-vows-to-fight-for-coverage-for-all 2018-03-20T01:37:34 https://maestrodatabase.com/blog/pfenex-and-alvogen-announce-european-medicines-agency-accepts-marketing-authorisation-application-for-pf708 2019-05-31T04:13:52 https://maestrodatabase.com/blog/new-medicines-review-smc-event-on-march-21 2016-02-23T19:56:06 https://maestrodatabase.com/blog/marketing-approval-received-in-japan-for-ninlaro-as-a-maintenance-therapy-after-first-line-treatment-for-multiple-myeloma-without-prior-stem-cell-transplantation 2021-05-31T08:47:21 https://maestrodatabase.com/blog/fda-fast-track-designation-granted-to-luspatercept-for-the-treatment-of-patients-with-beta-thalassemia 2015-08-05T11:37:19 https://maestrodatabase.com/blog/promoting-high-quality-scientific-research-in-paediatric-medicines 2015-08-05T11:37:09 https://maestrodatabase.com/blog/minerva-neurosciences-receives-complete-response-letter-from-fda-for-new-drug-application-for-roluperidone-for-the-treatment-of-negative-symptoms-in-patients-with-schizophrenia 2024-02-27T20:31:21 https://maestrodatabase.com/blog/mirabegron-for-overactive-bladder-additional-benefits-not-covered 2015-08-05T11:37:26 https://maestrodatabase.com/blog/tarsus-submits-new-drug-application-to-the-fda-for-tp-03-for-the-treatment-of-demodex-blepharitis 2022-09-07T11:16:46 https://maestrodatabase.com/blog/pbac-public-summary-documents-march-2015 2015-09-15T02:34:36 https://maestrodatabase.com/blog/minister-consults-on-pharmaceutical-benefits-scheme-and-pharmacy-agreement 2015-08-05T11:37:28 https://maestrodatabase.com/blog/cadths-25th-anniversary-lecture-series--professor-christopher-mccabe 2015-08-05T11:37:09 https://maestrodatabase.com/blog/etrasimod-arginine-for-the-treatment-of-patients-with-moderate-to-severe-active-ulcerative-colitis 2024-02-27T20:21:44 https://maestrodatabase.com/blog/fda-approves-new-extended-release-oxycodone-with-abuse-deterrent-properties 2015-08-05T11:37:13 https://maestrodatabase.com/blog/voxelotor-for-the-treatment-of-patients-with-sickle-cell-disease-draft-guidance 2024-02-27T07:27:53 https://maestrodatabase.com/blog/the-boys-who-beat-the-fda 2016-09-20T22:08:04 https://maestrodatabase.com/blog/amgen-receives-fda-breakthrough-therapy-designation-for-investigational-bite-antibody-blinatumomab-in-acute-lymphoblastic-leukaemia 2015-08-05T11:37:07 https://maestrodatabase.com/blog/2015-cadth-symposium-abstract-submission-deadline-extended 2015-08-05T11:37:10 https://maestrodatabase.com/blog/bristol-myers-squibb-announces-availability-of-fda-approved-orencia-abatacept-clickject-a-self-administered-subcutaneous-autoinjector-for-adults-with-moderate-to-severe-rheumatoid-arthritis 2016-07-20T12:27:00 https://maestrodatabase.com/blog/tga-publishes-auspar-for-harvoni 2015-10-29T20:04:25 https://maestrodatabase.com/blog/european-imbruvica-approval-for-janssen 2015-08-05T11:37:14 https://maestrodatabase.com/blog/amplyx-pharmaceuticals-receives-fourth-qualified-infectious-disease-product-designation-from-the-fda-for-apx001 2018-03-20T01:56:58 https://maestrodatabase.com/blog/public-consultation-starts-on-prime-a-new-scheme-to-optimise-development-of-priority-medicines-and-facilitate-patients-access 2015-10-27T19:02:46 https://maestrodatabase.com/blog/highlights-from-the-chmp-18-21-july-2016-meeting 2016-07-22T21:43:36 https://maestrodatabase.com/blog/rhythm-pharmaceuticals-announces-imcivree-setmelanotide-granted-marketing-authorisation-by-european-commission-for-treatment-of-obesity-and-control-of-hunger-in-bardet-biedl-syndrome 2022-09-07T09:01:19 https://maestrodatabase.com/blog/gsks-rsv-vaccine-arexvy-accepted-for-review-by-health-canada-for-prevention-of-rsv-disease-in-adults-aged-50-59-at-increased-risk 2024-02-27T07:09:08 https://maestrodatabase.com/blog/cadth-publishes-its-final-report-on-interventions-for-the-management-of-symptomatic-uterine-fibroids 2016-01-08T21:16:32 https://maestrodatabase.com/blog/smc-july-2016-decisions 2016-07-11T21:18:13 https://maestrodatabase.com/blog/new-indication-for-vimpat-lacosamide-ucbs-anti-epileptic-drug-approved-by-fda-as-monotherapy-in-the-treatment-of-patients-with-partial-onset-seizures 2015-08-05T11:37:07 https://maestrodatabase.com/blog/orexigen-shares-tumble-as-fda-delays-weight-loss-drug-approval 2015-08-05T11:37:18 https://maestrodatabase.com/blog/if-the-fda-approves-biogens-alzheimers-treatment-i-wont-prescribe-it 2021-05-31T12:24:13 https://maestrodatabase.com/blog/new-layout-for-ema-scientific-guidelines 2016-08-03T10:34:14 https://maestrodatabase.com/blog/european-commission-grants-marketing-authorization-for-gileads-once-daily-truvada-for-reducing-the-risk-of-sexually-acquired-hiv-1 2016-08-22T20:02:40 https://maestrodatabase.com/blog/fda-grants-priority-review-for-lillys-olaratumab-an-investigational-medicine-for-advanced-soft-tissue-sarcoma 2016-05-05T11:53:02 https://maestrodatabase.com/blog/theratechnologies-receives-refusal-to-file-letter-for-trogarzo-intramuscular-method-of-administration-sbla-from-fda 2024-02-27T20:47:46 https://maestrodatabase.com/blog/new-biomedical-fund-to-capitalise-on-our-research-and-entrepreneurial-strengths 2016-08-03T10:31:07 https://maestrodatabase.com/blog/eton-pharmaceuticals-receives-complete-response-letter-from-u-dot-s-fda-for-dehydrated-alcohol-injection 2021-05-31T12:32:10 https://maestrodatabase.com/blog/allergan-launches-first-generic-version-of-crestor-rosuvastatin-calcium 2016-05-03T21:29:04 https://maestrodatabase.com/blog/denmark-joins-queue-for-london-based-european-medicines-agency 2016-09-14T05:31:09 https://maestrodatabase.com/blog/beigenes-biologics-license-application-for-tevimbra-tislelizumab-for-first-line-gastric-or-gastro-oesophageal-junction-cancers-accepted-by-fda 2024-02-27T20:38:21 https://maestrodatabase.com/blog/late-onset-pompe-disease-stakeholder-meeting 2015-08-05T11:37:08 https://maestrodatabase.com/blog/cost-of-cancer-drugs-should-be-part-of-treatment-decisions 2015-08-05T11:37:12 https://maestrodatabase.com/blog/external-reference-pricing-the-drug-pricing-reform-america-needs 2021-05-31T11:56:52 https://maestrodatabase.com/blog/hillary-clinton-vows-shes-going-after-valeant-in-new-campaign-ad 2016-03-02T01:02:22 https://maestrodatabase.com/blog/post-market-reviews-of-medicines-to-treat-copd-and-ezetimibe 2015-10-16T02:42:56 https://maestrodatabase.com/blog/state-slower-to-adopt-new-drugs-than-most-of-western-europe 2021-05-31T12:13:25 https://maestrodatabase.com/blog/agenda-for-the-2-december-2015-tc-meeting 2015-11-27T03:01:04 https://maestrodatabase.com/blog/fda-accepts-biologics-license-applications-for-exagamglogene-autotemcel-exa-cel-for-severe-sickle-cell-disease-and-transfusion-dependent-beta-thalassaemia 2023-06-09T00:36:58 https://maestrodatabase.com/blog/agenda-for-the-17-february-2016-tc-meeting 2016-02-11T01:11:35 https://maestrodatabase.com/blog/fda-grants-breakthrough-device-designation-for-smart-orthopaedic-implants 2021-05-31T12:06:46 https://maestrodatabase.com/blog/novartis-combination-therapy-tafinlar-and-mekinist-achieves-important-eu-and-us-regulatory-milestones 2015-08-05T11:37:05 https://maestrodatabase.com/blog/nintedanib-in-lung-cancer-added-benefit-depends-on-disease-severity 2015-08-05T11:37:28 https://maestrodatabase.com/blog/lillys-efient-tipped-for-expanded-nice-approval 2015-08-05T11:37:09 https://maestrodatabase.com/blog/ligands-partner-cstone-pharmaceuticals-receives-approval-in-china-for-sugemalimab-cejemly-for-the-first-line-treatment-of-advanced-non-small-cell-lung-cancer-in-combination-with-chemotherapy 2021-12-27T02:08:01 https://maestrodatabase.com/blog/fda-approves-labeling-with-abuse-deterrent-features-for-third-extended-release-opioid-analgesic 2015-08-05T11:37:17 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-june-2021-update 2021-05-31T21:00:53 https://maestrodatabase.com/blog/albiglutide-in-type-2-diabetes-mellitus-evidence-of-little-added-value 2015-08-05T11:37:22 https://maestrodatabase.com/blog/doctors-who-helped-develop-heart-drug-now-balk-at-$225-000-slash-year-price 2019-11-21T06:47:57 https://maestrodatabase.com/blog/fda-eyes-new-diabetes-end-points 2016-09-29T22:19:29 https://maestrodatabase.com/blog/abbvie-announces-submission-of-a-supplemental-new-drug-application-for-imbruvica-ibrutinib-for-treatment-naive-chronic-lymphocytic-leukemia 2015-09-15T09:55:01 https://maestrodatabase.com/blog/japan-to-slash-price-of-costly-cancer-drug-early 2016-10-03T20:16:35 https://maestrodatabase.com/blog/campaign-launched-for-life-sustaining-treatment-access-across-canada 2021-05-31T21:13:34 https://maestrodatabase.com/blog/pbac-guidelines-review-welcomed 2015-08-05T11:37:17 https://maestrodatabase.com/blog/ariad-announces-approval-of-iclusig-as-ponatinib-hydrochloride-in-canada 2015-08-05T11:37:22 https://maestrodatabase.com/blog/carrying-nice-over-the-threshold 2015-08-05T11:37:02 https://maestrodatabase.com/blog/gsk-announces-eu-regulatory-submission-seeking-extended-indication-for-ambrisentan-volibris-in-pulmonary-arterial-hypertension 2015-08-05T11:37:18 https://maestrodatabase.com/blog/brainsee-novel-software-is-breakthrough-for-non-invasive-detection-and-monitoring-of-alzheimers-disease-at-the-early-stage-of-mild-cognitive-impairment 2021-05-31T12:37:51 https://maestrodatabase.com/blog/scotland-doubles-funding-for-access-to-new-medicines 2015-08-05T11:37:29 https://maestrodatabase.com/blog/suspend-intellectual-property-rights-for-covid-19-vaccines 2021-05-31T20:54:26 https://maestrodatabase.com/blog/fda-grants-breakthrough-therapy-designation-to-pfizers-group-b-streptococcus-vaccine-candidate-to-help-prevent-infection-in-infants-via-immunisation-of-pregnant-women 2022-09-07T11:38:58 https://maestrodatabase.com/blog/changes-to-growth-hormone-and-botulinum-toxin-s100-programs 2015-08-26T11:07:36 https://maestrodatabase.com/blog/shire-submits-application-to-the-us-fda-for-approval-of-lifitegrast-for-treatment-of-dry-eye-disease-in-adults 2015-08-05T11:37:26 https://maestrodatabase.com/blog/how-similar-are-biosimilars 2016-05-18T02:37:39 https://maestrodatabase.com/blog/eu-approves-allergans-ibs-drug 2016-09-23T20:55:14 https://maestrodatabase.com/blog/new-gastric-cancer-medicine-approved-and-available-for-use-in-canada 2015-09-22T12:25:10 https://maestrodatabase.com/blog/ammax-bio-announces-amb-05x-granted-fda-fast-track-designation-for-the-treatment-of-tenosynovial-giant-cell-tumour 2022-09-07T21:05:19 https://maestrodatabase.com/blog/government-offers-funds-for-cancer-drug-trials 2016-05-23T10:33:53 https://maestrodatabase.com/blog/fda-approves-gardasil-9-for-prevention-of-certain-cancers-caused-by-five-additional-types-of-hpv 2015-08-05T11:37:06 https://maestrodatabase.com/blog/fda-approves-first-generic-abilify-to-treat-mental-illnesses 2015-08-05T11:37:12 https://maestrodatabase.com/blog/cder-and-cber-accept-first-submission-to-istand-pilot-program 2022-09-07T21:00:13 https://maestrodatabase.com/blog/merck-kgaa-threshold-win-fast-track-for-pancreatic-cancer-drug 2015-08-05T11:37:10 https://maestrodatabase.com/blog/nice_says_yes_to_a_new_treatment_for_blood_disorder_but_with_strings_attached 2015-08-05T11:37:26 https://maestrodatabase.com/blog/pharmacy-sector-leads-reform 2016-04-06T07:34:18 https://maestrodatabase.com/blog/smc-gives-green-light-for-bms-opdivo 2016-07-11T21:32:38 https://maestrodatabase.com/blog/fda-approves-add-on-therapy-to-lower-cholesterol-among-certain-high-risk-adults 2021-12-27T03:36:56 https://maestrodatabase.com/blog/rising-drug-costs-to-be-in-focus-at-congressional-hearing 2015-12-06T23:06:15 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-june-2021 2021-05-31T21:21:17 https://maestrodatabase.com/blog/the-fda-needs-to-be-more-flexible-in-assessing-treatments-for-rare-diseases-like-the-one-that-seemed-to-help-my-son 2022-09-07T20:57:30 https://maestrodatabase.com/blog/ferring-pharmaceuticals-announces-approval-for-nocdurna-a-new-therapeutic-option-for-the-treatment-of-adults-waking-multiple-times-to-urinate-at-night 2016-05-05T06:34:15 https://maestrodatabase.com/blog/pbac-world-first-biosimilar-drug-decision 2015-08-05T11:37:21 https://maestrodatabase.com/blog/new-eu-health-innovation-rules-edge-closer 2021-05-31T21:51:10 https://maestrodatabase.com/blog/nice-consults-again-on-updated-guidance-for-two-lung-cancer-drugs 2015-08-05T11:37:26 https://maestrodatabase.com/blog/updates-from-the-health-technology-assessment-policy-and-methods-review-reference-committee-june-2023 2023-06-09T03:26:14 https://maestrodatabase.com/blog/roche-canada-announces-collaboration-to-improve-access-to-personalised-health-care-with-real-world-evidence 2021-05-31T21:43:43 https://maestrodatabase.com/blog/no-subsidy-for-meningococcal-b-vaccine 2015-08-24T10:53:37 https://maestrodatabase.com/blog/seres-therapeutics-announces-completion-of-rolling-bla-submission-to-fda-for-investigational-microbiome-therapeutic-ser-109-for-recurrent-c-difficile-infection 2022-09-07T20:52:42 https://maestrodatabase.com/blog/european-commission-grants-marketing-authorisation-for-tevas-cinquaero-reslizumab 2016-08-19T06:34:29 https://maestrodatabase.com/blog/fdas-view-on-biosimilar-product-labeling 2016-04-01T21:02:13 https://maestrodatabase.com/blog/fda-accepts-supplemental-new-drug-application-for-jakafi-ruxolitinib-and-priority-review-granted 2015-08-05T11:37:22 https://maestrodatabase.com/blog/ofev-nintedanib-now-available-in-canada-for-adults-living-with-progressive-fibrosing-interstitial-lung-diseases 2020-05-26T07:29:07 https://maestrodatabase.com/blog/call-for-feedback-draft-guidelines-on-application-fees-for-pcodr 2015-08-05T11:37:07 https://maestrodatabase.com/blog/revisiting-the-fdas-accelerated-approval-pathway 2025-09-09T10:57:09 https://maestrodatabase.com/blog/gsk-found-uks-drug-pricing-changes-a-tough-sell 2015-08-05T11:37:14 https://maestrodatabase.com/blog/dabrafenib-in-combination-with-trametinib-in-advanced-melanoma-with-braf-v600-mutation-indication-of-added-benefit-says-iqwig 2016-01-12T20:32:52 https://maestrodatabase.com/blog/fda-accepts-integral-moleculars-letter-of-intent-on-membrane-proteome-array-antibody-specificity-test-into-istand-drug-development-tools-pilot-program 2022-09-07T21:30:11 https://maestrodatabase.com/blog/why-sareptas-300k-price-for-dmd-drug-invalidates-reasons-for-accelerated-approval 2016-09-28T21:16:44 https://maestrodatabase.com/blog/fda-approves-new-indication-for-novartis-drug-afinitor-for-progressive-non-functional-gastro-intestinal-and-lung-neuroendocrine-tumors 2016-02-26T19:57:04 https://maestrodatabase.com/blog/astellas-submits-new-drug-application-for-zolbetuximab-in-japan 2023-06-09T04:12:38 https://maestrodatabase.com/blog/mylan-and-biocon-announce-regulatory-submission-for-proposed-biosimilar-trastuzumab-accepted-for-review-by-european-medicines-agency 2016-08-25T20:40:32 https://maestrodatabase.com/blog/ongoing-uncertainty-about-prices-will-deter-new-drug-launches-in-canada 2022-09-07T21:23:17 https://maestrodatabase.com/blog/aspects-of-patient-reported-outcomes-in-rare-diseases-a-discussion-paper 2016-08-17T21:09:07 https://maestrodatabase.com/blog/tagrisso-granted-priority-review-in-the-us-for-the-adjuvant-treatment-of-patients-with-early-stage-egfr-mutated-lung-cancer 2020-10-20T06:21:11 https://maestrodatabase.com/blog/cell_therapeutics_provides_an_update_on_nice_s_appraisal_of_pixantrone_for_patients_with_non_hodgkin_s_lymphoma 2015-08-05T11:37:17 https://maestrodatabase.com/blog/alcon-achieves-us-approval-for-cypass-micro-stent-a-micro-invasive-surgical-device-to-treat-glaucoma 2016-08-02T05:34:29 https://maestrodatabase.com/blog/statement-by-president-biden-on-fda-and-cdc-authorising-updated-covid--19-vaccines 2022-09-07T21:12:02 https://maestrodatabase.com/blog/review-of-the-efficacy-and-safety-of-over-the-counter-codeine-combination-medicines 2016-03-24T04:12:50 https://maestrodatabase.com/blog/nice-recommends-edoxaban-lixiana-for-preventing-potentially-fatal-blood-clots-in-people-with-atrial-fibrillation 2015-09-24T12:48:14 https://maestrodatabase.com/blog/doctors-call-for-vaccine-u-turn-from-pharmac-after-surge-in-preventable-pneumococcal-cases 2022-09-07T21:16:38 https://maestrodatabase.com/blog/how-the-morrison-government-passed-over-an-australian-company-for-a-us-pharmaceutical-giant 2024-11-13T23:46:55 https://maestrodatabase.com/blog/fda-approves-keytruda-for-advanced-melanoma 2015-08-05T11:37:28 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac---march-2015 2015-08-05T11:37:27 https://maestrodatabase.com/blog/pharmac-proposal-to-list-asacol-800-mg-tablets 2015-10-22T03:43:53 https://maestrodatabase.com/blog/british-columbia-funds-treatment-with-aubagio-for-relapsing-remitting-multiple-sclerosis 2015-08-05T11:37:15 https://maestrodatabase.com/blog/uk-cost-agency-turns-down-bristol-immunotherapy-for-lung-cancer 2015-12-16T20:32:13 https://maestrodatabase.com/blog/fda-provides-final-guidance-on-breakthrough-product-designation 2015-08-05T11:37:16 https://maestrodatabase.com/blog/unitedhealth-unit-favors-sanofi-regeneron-cholesterol-drug 2015-12-01T19:20:00 https://maestrodatabase.com/blog/nice-u-turn-on-novartis-multiple-myeloma-drug 2015-12-03T20:34:01 https://maestrodatabase.com/blog/dna-on-drugs-how-genetic-tests-could-make-prescriptions-more-precise 2018-03-20T05:24:15 https://maestrodatabase.com/blog/drug-and-biotech-industry-trade-groups-give-martin-shkreli-the-boot 2015-09-26T07:13:08 https://maestrodatabase.com/blog/fda-takes-second-action-under-international-collaboration-approves-new-treatment-option-for-patients-with-chronic-lymphocytic-leukaemia 2019-11-21T19:44:27 https://maestrodatabase.com/blog/iroko-pharmaceuticals-receives-fda-approval-for-vivodex-first-low-dose-solumatrix-meloxicam-for-osteoarthritis-pain 2015-10-26T10:01:14 https://maestrodatabase.com/blog/twi-pharmaceuticals-receives-us-fda-final-approval-on-generic-megestrol-acetate-125mgml-oral-suspension 2015-08-05T11:37:03 https://maestrodatabase.com/blog/senators-press-mylan-labs-over-outrageous-epipen-pricing 2016-08-23T19:25:05 https://maestrodatabase.com/blog/paion-announces-submission-of-the-marketing-authorisation-application-for-remimazolam-in-procedural-sedation-to-the-european-medicines-agency 2019-11-21T07:38:21 https://maestrodatabase.com/blog/what-we-already-know-about-the-budget 2015-08-05T11:37:09 https://maestrodatabase.com/blog/1-april-2018-price-disclosure-confirmed-prices 2018-03-20T04:52:05 https://maestrodatabase.com/blog/saol-therapeutics-receives-complete-response-letter-from-fda-for-sl1009-dca-for-the-treatment-of-pyruvate-dehydrogenase-complex-feficiency 2025-09-09T10:31:09 https://maestrodatabase.com/blog/can-measuring-anticoagulant-activity-and-concentration-in-the-body-play-a-role-in-clinical-use-of-medicines-used-to-prevent-blood-clots 2015-10-16T19:45:33 https://maestrodatabase.com/blog/ipsen-announces-fda-approval-of-dysport-abobotulinumtoxina-for-injection-in-the-treatment-of-upper-limb-spasticity-in-adults-in-the-united-states 2015-08-05T11:37:22 https://maestrodatabase.com/blog/provisional-approval-pathway-prescription-medicines 2018-03-20T04:58:13 https://maestrodatabase.com/blog/fda-approves-roches-cotellic-cobimetinib-in-combination-with-zelboraf-vemurafenib-in-advanced-melanoma 2015-11-12T09:55:55 https://maestrodatabase.com/blog/invitation-to-access-the-community-service-obligation-cso-funding-pool-and-national-diabetes-service-scheme-ndss-to-supply-pbs-medicines-and-ndss-products 2016-09-29T04:00:30 https://maestrodatabase.com/blog/where-top-2020-democrats-stand-on-drug-pricing 2019-11-21T19:55:16 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-treatments-for-obesity 2025-09-09T23:51:33 https://maestrodatabase.com/blog/fda-approves-rapivab-to-treat-flu-infection 2015-08-05T11:37:30 https://maestrodatabase.com/blog/nice-publishes-evidence-summary-on-eculizumab-soliris-for-treating-rare-kidney-condition 2015-08-05T11:37:06 https://maestrodatabase.com/blog/us-fda-accepts-for-review-a-biologics-license-application-for-merck-and-sanofi-pasteurs-investigational-paediatric-hexavalent-vaccine 2015-08-05T11:37:06 https://maestrodatabase.com/blog/drug-for-ultra-rare-disease-comes-with-ultra-high-price-tag 2019-11-21T19:49:48 https://maestrodatabase.com/blog/drug-industry-must-address-image-problem-over-prices-teva-executive 2015-09-30T20:11:20 https://maestrodatabase.com/blog/nuvalent-receives-us-fda-breakthrough-therapy-designation-for-nvl-520 2024-02-27T23:23:26 https://maestrodatabase.com/blog/fda-approves-opdivo-for-advanced-melanoma 2015-08-05T11:37:18 https://maestrodatabase.com/blog/shes-coming-after-the-rest-of-you 2016-04-18T07:36:05 https://maestrodatabase.com/blog/superb-health-care-at-ultra-low-prices-how-singapore-does-it 2020-05-26T10:13:06 https://maestrodatabase.com/blog/nice-turns-down-opdivo-for-lung-cancer 2016-05-12T14:30:47 https://maestrodatabase.com/blog/u-dot-s-fda-grants-priority-review-for-daratumumab-in-combination-with-bortezomib-thalidomide-and-dexamethasone-in-frontline-multiple-myeloma 2019-05-31T05:16:11 https://maestrodatabase.com/blog/fujifilm-seeks-approval-for-avigan-as-covid-19-treatment-in-japan 2020-10-20T19:56:07 https://maestrodatabase.com/blog/teva-and-eagle-pharmaceuticals-announce-nda-for-bendamustine-rapid-infusion-product-accepted-for-filing 2015-08-05T11:37:30 https://maestrodatabase.com/blog/expert-review-of-medicines-and-medical-devices-regulation---first-report-released 2015-08-05T11:37:05 https://maestrodatabase.com/blog/fingolimod-in-rrms-indication-of-added-benefit-in-certain-patients 2015-08-05T11:37:26 https://maestrodatabase.com/blog/transparency-is-a-first-step-in-bringing-down-drug-costs-for-american-seniors-families 2019-11-21T20:05:15 https://maestrodatabase.com/blog/guild-launches-new-corporate-plan 2015-08-05T11:37:22 https://maestrodatabase.com/blog/edoxaban-has-considerable-additional-benefits-for-certain-patients-says-iqwig 2015-11-02T21:36:56 https://maestrodatabase.com/blog/trump-senators-push-for-drug-price-disclosures-despite-setbacks 2019-11-21T20:00:39 https://maestrodatabase.com/blog/horizon-pharma-plc-receives-fda-fast-track-designation-for-actimmune-in-the-treatment-of-friedreichs-ataxia 2015-08-05T11:37:03 https://maestrodatabase.com/blog/france-uses-tax-to-put-pressure-on-hepatitis-c-drug-prices 2015-08-05T11:37:21 https://maestrodatabase.com/blog/pricing-tactics-slow-uptake-of-generic-drugs-by-medicare-plans 2019-11-21T19:57:09 https://maestrodatabase.com/blog/axsome-therapeutics-announces-fda-fast-track-designation-for-axs-02-for-the-treatment-of-pain-associated-with-complex-regional-pain-syndrome 2015-08-05T11:37:29 https://maestrodatabase.com/blog/ionis-receives-us-fda-breakthrough-therapy-designation-for-ion582-in-angelman-syndrome 2025-09-10T01:23:37 https://maestrodatabase.com/blog/the-right-way-to-do-drugs 2016-02-11T20:16:41 https://maestrodatabase.com/blog/nice-rejects-rare-eye-disease-drug 2018-03-20T20:09:27 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-to-9mw2821 2024-02-28T00:11:50 https://maestrodatabase.com/blog/brady-says-gop-wont-allow-medicare-to-negotiate-drug-prices 2016-07-19T21:33:51 https://maestrodatabase.com/blog/biden-looks-to-germany-for-answers-on-how-to-tackle-high-u-dot-s-drug-prices 2020-10-20T20:07:52 https://maestrodatabase.com/blog/fda-approves-gemcitabine-intravesical-system-for-non-muscle-invasive-bladder-cancer 2025-09-09T21:58:59 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac-july-2015 2015-08-21T22:33:33 https://maestrodatabase.com/blog/fda-expands-approval-of-adcetris-for-first-line-treatment-of-stage-iii-or-iv-classical-hodgkin-lymphoma-in-combination-with-chemotherapy 2018-03-20T20:13:02 https://maestrodatabase.com/blog/tackling-americas-giant-hospital-bill 2019-11-21T20:24:56 https://maestrodatabase.com/blog/ptc-receives-refuse-to-file-letter-from-fda-for-translarna-ataluren 2016-02-23T20:01:37 https://maestrodatabase.com/blog/roche-ceo-warns-against-high-hopes-for-speedy-covid-vaccines 2020-10-20T20:16:17 https://maestrodatabase.com/blog/the-real-reason-you-wait-for-life-saving-medicine 2015-08-05T11:37:13 https://maestrodatabase.com/blog/optimizing-patient-access-to-medications-the-american-dermatological-associations-position-statement-on-pharmacy-benefit-managers-and-patient-access-to-affordable-and-appropriate-medications 2020-05-26T20:46:01 https://maestrodatabase.com/blog/covid-19-vaccines-time-to-talk-about-the-uncertainties 2020-10-20T20:22:36 https://maestrodatabase.com/blog/perc_has_issued_its_final_recommendation_for_brentuximab_vedotin__adcetris__for_patients_with_systemic_anaplastic_large_cell_lymphoma 2015-08-05T11:37:08 https://maestrodatabase.com/blog/nice-draft-guidance-recommends-eculizumab-soliris-for-treatment-of-very-rare-life-threatening-blood-disorder 2015-08-05T11:37:22 https://maestrodatabase.com/blog/mc2-therapeutics-announces-fda-acceptance-of-its-new-drug-application-for-wynzora-cream-for-treatment-of-plaque-psoriasis 2019-11-21T20:12:06 https://maestrodatabase.com/blog/tocilizumab-for-rheumatoid-arthritis--use-in-dhb-hospitals 2015-08-05T11:37:11 https://maestrodatabase.com/blog/new_zealand_pharmaceutical_schedule___march_2014_update 2015-08-05T11:37:20 https://maestrodatabase.com/blog/acer-therapeutics-submits-nda-for-edsivo-for-the-treatment-of-veds 2018-10-30T03:35:03 https://maestrodatabase.com/blog/breakthrough-drug-would-give-child-with-cystic-fibrosis-a-future 2020-10-20T19:58:39 https://maestrodatabase.com/blog/pharmac-breast-cancer-cost-saving-proposal-welcome-but-ignores-patients-facing-dead-end 2023-06-09T04:52:31 https://maestrodatabase.com/blog/runaway-drug-prices 2015-08-05T11:37:21 https://maestrodatabase.com/blog/high-drug-costs-lead-5-percent-of-seniors-to-skip-or-ration-medication-study-finds 2019-05-31T06:05:23 https://maestrodatabase.com/blog/france-to-call-for-lower-drug-prices-at-g7 2016-03-23T02:22:51 https://maestrodatabase.com/blog/how-an-essential-medicines-list-could-benefit-canadians 2016-06-14T21:08:22 https://maestrodatabase.com/blog/proposal-to-change-how-discarded-medicines-are-reimbursed 2018-10-30T03:31:45 https://maestrodatabase.com/blog/health_canada_approves_genzyme_s_aubagio__teriflunomide___a_once_daily__oral_treatment_for_relapsing_remitting_multiple_sclerosis 2015-08-05T11:37:04 https://maestrodatabase.com/blog/nice-recommends-abiraterone-for-prostate-cancer 2016-03-21T20:02:05 https://maestrodatabase.com/blog/australians-stick-with-malaria-drug-hydroxychoroquine-trial 2020-05-26T11:22:04 https://maestrodatabase.com/blog/health-charities-and-patient-groups-join-together-to-protect-access-to-breakthrough-medical-treatments-in-canada 2020-10-20T20:03:36 https://maestrodatabase.com/blog/portola-pharmaceuticals-announces-validation-of-marketing-authorization-application-maa-by-european-medicines-agency-ema-for-indexxa-andexanet-alfa-a-factor-xa-inhibitor-antidote 2016-08-22T08:45:11 https://maestrodatabase.com/blog/enhanced-access-to-generalised-myasthenia-gravis-treatments-ucb-canada-secures-pcpa-agreements-for-zilbrysq-and-rystiggo 2025-09-10T01:55:09 https://maestrodatabase.com/blog/b-dot-c-moms-drug-pricing-petition-on-behalf-of-son-garners-thousands-of-signatures 2020-05-26T20:58:47 https://maestrodatabase.com/blog/smc_rejects_sanofi_s_full_submission_for_aflibercept__zaltrap__for_patients_with_colorectal_cancer 2015-08-05T11:37:21 https://maestrodatabase.com/blog/eylea-aflibercept-injection-receives-fda-approval-for-the-treatment-of-diabetic-macular-edema 2015-08-05T11:37:07 https://maestrodatabase.com/blog/the-fda-isnt-afraid-to-yank-a-disappointing-drug 2024-02-28T02:13:19 https://maestrodatabase.com/blog/price-disclosure-2015-april-cycle-outcomes-summary 2015-08-05T11:37:09 https://maestrodatabase.com/blog/cadth-calls-for-patient-input-on-a-new-submission-from-abbvie-for-humira-1 2015-09-30T20:35:22 https://maestrodatabase.com/blog/partner-therapeutics-receives-ema-approval-of-imreplys-sargramostim-rhu-gm-csf-to-treat-exposure-to-myelosuppressive-doses-of-radiation-haematopoietic-sub-syndrome-of-acute-radiation-syndrome 2025-09-10T02:01:44 https://maestrodatabase.com/blog/dasabuvir-in-hepatitis-c-indication-of-added-benefit-in-certain-patients 2015-08-05T11:37:27 https://maestrodatabase.com/blog/protara-therapeutics-receives-fast-track-designation-from-u-dot-s-fda-for-intravenous-choline-chloride-for-the-treatment-of-intestinal-failure-associated-liver-disease 2020-05-26T21:02:56 https://maestrodatabase.com/blog/nhs_patients__should_be_more_pushy_to_get_drugs_ 2015-08-05T11:37:30 https://maestrodatabase.com/blog/bristol-myers-signs-deal-with-un-group-for-generic-hepatitis-c-drug 2015-11-24T20:11:47 https://maestrodatabase.com/blog/melbourne-woman-with-breast-cancer-forced-to-pay-4-500-dollars-a-month-for-pbs-listed-drug 2019-05-31T07:50:17 https://maestrodatabase.com/blog/tevas-emrusolmin-granted-us-fda-fast-track-designation-for-treatment-of-multiple-system-atrophy 2025-09-10T02:09:42 https://maestrodatabase.com/blog/15-years-of-nice 2015-08-05T11:37:13 https://maestrodatabase.com/blog/ema-calls-for-high-quality-observational-research-in-context-of-covid-19 2020-05-26T20:50:47 https://maestrodatabase.com/blog/smc---forthcoming-submissions 2015-08-05T11:37:12 https://maestrodatabase.com/blog/us-fda-approval-of-inlexzo-gemcitabine-intravesical-system-set-to-transform-how-certain-bladder-cancers-are-treated 2025-09-10T02:16:10 https://maestrodatabase.com/blog/breast-cancer-drug-costing-tens-of-thousands-of-pounds-more-than-other-treatments-unaffordable-for-nhs 2015-08-05T11:37:10 https://maestrodatabase.com/blog/nice-chairman-sharmila-nebhrajani-begins-her-new-role 2020-05-26T20:53:00 https://maestrodatabase.com/blog/celularity-receives-fast-track-designation-from-u-dot-s-fda-for-its-nk-cell-therapy-cynk-001-in-development-for-the-treatment-of-aml 2021-12-27T23:22:19 https://maestrodatabase.com/blog/immunization-policy-and-the-importance-of-sustainable-vaccine-pricing 2016-02-08T20:08:35 https://maestrodatabase.com/blog/roches-sc-mabthera-to-be-funded-on-nhs 2015-08-05T11:37:18 https://maestrodatabase.com/blog/who-pauses-hydroxycholoroquine-arm-in-covid-19-trial 2020-05-26T20:55:13 https://maestrodatabase.com/blog/us-cancer-doctors-drop-pricey-drugs-with-little-or-no-effect 2015-10-08T20:43:09 https://maestrodatabase.com/blog/abpi-president-nice-needs-political-reform 2015-08-05T11:37:27 https://maestrodatabase.com/blog/joint-statement-by-hon-peter-dutton-mp-minister-for-health-for-australia-and-hon-dr-jonathan-coleman-minister-of-health-for-new-zealand-regarding-anztpa 2015-08-05T11:37:06 https://maestrodatabase.com/blog/fast-track-approval-of-medicines-in-australia 2016-09-30T11:31:42 https://maestrodatabase.com/blog/row-over-cf-drug-funding-as-nhs-rejects-vertex-offer 2018-03-20T20:42:09 https://maestrodatabase.com/blog/pcodr-recommends-pomalyst-pomalidmide-for-patients-with-relapsed-or-refractory-multiple-myeloma 2015-08-05T11:37:02 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-us-fda-breakthrough-therapy-designation-for-investigational-hiv-1-attachment-inhibitor-for-heavily-treatment-experienced-patients 2015-08-05T11:37:15 https://maestrodatabase.com/blog/kirkland-family-lobbies-ottawa-for-help-with-750-000-dollars-medication 2018-03-20T20:45:35 https://maestrodatabase.com/blog/we-want-to-hear-from-you 2015-08-05T11:37:30 https://maestrodatabase.com/blog/fda-approves-dupixent-dupilumab-as-first-biologic-medicine-for-children-aged-6-to-11-years-with-moderate-to-severe-atopic-dermatitis 2020-05-26T21:26:51 https://maestrodatabase.com/blog/health-canada-approves-bylvay-odevixibat-for-the-treatment-of-cholestatic-pruritus-in-patients-with-alagille-syndrome 2025-09-10T01:33:32 https://maestrodatabase.com/blog/conflicts-of-interests-revised-ema-policy-reflects-more-balanced-approach 2015-08-05T11:37:24 https://maestrodatabase.com/blog/involving-general-practitioners-in-regulatory-decisions-on-medicines 2016-04-28T12:23:43 https://maestrodatabase.com/blog/thrombogenics-jetrea-gains-approval-in-australia 2015-08-05T11:37:10 https://maestrodatabase.com/blog/fda-industry-ponder-changes-to-clinical-trials-for-rare-disease-treatments 2018-03-20T20:32:34 https://maestrodatabase.com/blog/europe-pushes-back-verdict-on-bristol-immune-system-cancer-drug 2015-08-05T11:37:14 https://maestrodatabase.com/blog/president-trump-announces-lower-out-of-pocket-insulin-costs-for-medicares-seniors 2020-05-26T21:35:32 https://maestrodatabase.com/blog/update-for-patient-groups 2015-08-05T11:37:07 https://maestrodatabase.com/blog/fda-approves-new-orphan-drug-to-treat-rare-autosomal-recessive-disorder 2015-09-07T11:15:11 https://maestrodatabase.com/blog/kala-pharmaceuticals-announces-fda-acceptance-of-new-drug-application-for-eysuvis-for-dry-eye-disease 2020-05-26T21:09:11 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-to-ns-229-for-the-treatment-of-eosinophilic-granulomatosis-with-polyangiitis 2025-09-10T01:40:26 https://maestrodatabase.com/blog/nhs-england-drops-16-medicines-from-cancer-drugs-fund-bmj 2015-09-09T11:53:06 https://maestrodatabase.com/blog/contestable-fund-for-medicines-for-rare-disorders 2015-08-05T11:37:19 https://maestrodatabase.com/blog/proposed-new-drug-guidelines-for-the-pbs-put-cost-cutting-before-patients 2016-08-17T21:28:08 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-ulcerative-colitis-therapies 2020-05-26T21:17:04 https://maestrodatabase.com/blog/pfizers-prevnar-20-selected-for-pneumococcal-public-immunisation-program-in-british-columbia 2025-09-10T01:48:33 https://maestrodatabase.com/blog/the-world-could-end-aids-if-it-tried 2016-06-13T09:28:52 https://maestrodatabase.com/blog/fda-approves-the-medicines-cos-pain-drug-device-ionsys 2015-08-05T11:37:24 https://maestrodatabase.com/blog/patients-with-advanced-metastatic-colorectal-cancer-in-europe-now-have-a-new-treatment-option-as-lonsulf-trifluridinetipiracil-receives-eu-approval 2016-04-28T12:31:54 https://maestrodatabase.com/blog/aurinia-completes-submission-of-new-drug-application-to-the-u-dot-s-fda-for-voclosporin-for-the-treatment-of-lupus-nephritis 2020-05-26T21:21:32 https://maestrodatabase.com/blog/minister-announces-parallel-assessment-means-new-medicines-assessed-sooner 2024-02-28T02:24:29 https://maestrodatabase.com/blog/outcome-report-on-first-european-collaboration-between-regulators-and-hta-organisations-improving-the-contribution-of-regulatory-assessment-reports-to-health-technology-assessment 2015-08-05T11:37:06 https://maestrodatabase.com/blog/health-canada-approves-imbruvica-ibrutinib-for-the-treatment-of-waldenströms-macroglobulinemia 2016-05-13T05:13:54 https://maestrodatabase.com/blog/subsidised-access-to-new-melanoma-drugs-in-need-of-further-innovation 2016-08-18T21:53:23 https://maestrodatabase.com/blog/the-spectrum-effect-in-tests-for-risk-prediction-screening-and-diagnosis 2016-06-30T06:36:48 https://maestrodatabase.com/blog/fda-approves-new-orphan-drug-to-treat-pulmonary-arterial-hypertension 2015-12-22T20:26:04 https://maestrodatabase.com/blog/pbac-guidelines-review-update 2016-04-07T21:24:36 https://maestrodatabase.com/blog/hasty-cuts-may-make-it-harder-to-access-the-new-medicines-that-patients-need 2015-08-05T11:37:19 https://maestrodatabase.com/blog/alberta-man-pushes-feds-to-approve-new-alzheimers-drugs-leqembi-and-kinsula 2025-09-10T03:00:21 https://maestrodatabase.com/blog/european-commission-approves-bristol-myers-squibbs-daklinza-daclatasvir-across-multiple-genotypes-for-the-treatment-of-chronic-hepatitis-c-infection 2015-08-05T11:37:22 https://maestrodatabase.com/blog/nice-recommends-new-drug-osimertinib-for-hundreds-of-people-with-lung-cancer 2016-10-04T07:53:59 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-treatments-for-plaque-psoriasis 2016-09-29T23:02:10 https://maestrodatabase.com/blog/technivie-ombitasvir-paritaprevir-and-ritonavir-tablets-receives-fda-approval-as-the-first-and-only-all-oral-interferon-free-treatment-for-genotype-4-chronic-hepatitis-c-in-the-us 2015-08-05T11:37:23 https://maestrodatabase.com/blog/prescription-medicines-tga-pre-submission-pilot 2015-12-14T06:45:45 https://maestrodatabase.com/blog/astellas-receives-european-approval-for-xtandi-enzalutamide-for-adult-men-with-high-risk-non-metastatic-castration-resistant-prostate-cancer 2018-10-30T05:44:39 https://maestrodatabase.com/blog/how-to-improve-product-lifecycle-management 2015-10-27T19:05:48 https://maestrodatabase.com/blog/mallinckrodt-receives-fda-fast-track-designation-for-synacthen-depot-ind-application 2016-08-25T21:29:03 https://maestrodatabase.com/blog/fda-approves-cotellic-as-part-of-combination-treatment-for-advanced-melanoma 2015-11-12T09:51:34 https://maestrodatabase.com/blog/gene-tests-identify-breast-cancer-patients-who-can-skip-chemotherapy-study-says 2016-08-28T10:28:16 https://maestrodatabase.com/blog/analysis-of-base-case-icers-accepted-by-the-pbac-july-2018 2018-10-30T07:17:47 https://maestrodatabase.com/blog/actelion_receives_health_canada_approval_of_opsumit__macitentan__for_the_long_term_treatment_of_pulmonary_arterial_hypertension 2015-08-05T11:37:06 https://maestrodatabase.com/blog/first-treatment-recommended-for-rare-bone-disease 2015-08-05T11:37:27 https://maestrodatabase.com/blog/proposal-for-various-pharmaceuticals-1 2015-08-05T11:37:15 https://maestrodatabase.com/blog/apotex-announces-fda-has-accepted-for-filing-its-biosimilar-application-for-filgrastim-grastofil 2015-08-05T11:37:17 https://maestrodatabase.com/blog/additional-public-summary-documents-pbac-november-2015-meeting 2016-03-19T11:08:37 https://maestrodatabase.com/blog/pharmac-issues-rfp-for-intravenous-trastuzumab-a-medicine-used-to-treat-breast-cancer 2022-09-08T03:59:36 https://maestrodatabase.com/blog/us-fda-approves-supplemental-new-drug-applications-for-once-monthly-long-acting-therapy-invega-sutenna-paliperidone-palmitate-for-the-treatment-of-schizoaffective-disorder 2015-08-05T11:37:13 https://maestrodatabase.com/blog/ab-science-announces-that-health-canada-has-issued-a-notice-of-non-compliance-withdrawal-for-masitinib-in-als 2024-02-28T03:34:27 https://maestrodatabase.com/blog/va-extends-new-hepatitis-c-drugs-to-all-veterans-in-its-health-system-1 2016-09-07T09:36:18 https://maestrodatabase.com/blog/envarsus-receives-european-marketing-authorization-for-treatment-of-both-kidney-and-liver-transplant-patients 2015-08-05T11:37:23 https://maestrodatabase.com/blog/early-dialogue-to-support-development-of-medicines-for-children 2015-08-05T11:37:07 https://maestrodatabase.com/blog/australians-with-lymphoma-suffer-highest-financial-stress-in-the-world-survey-shows 2016-09-14T21:31:44 https://maestrodatabase.com/blog/generic-drug-approvals-since-the-1984-hatch-waxman-act-1 2016-09-07T08:35:43 https://maestrodatabase.com/blog/tga-publishes-auspar-for-nalfemene-hydrochloride-dihydrate-selincro 2016-09-03T10:46:11 https://maestrodatabase.com/blog/pharmaxis-shares-soar-45pc-on-750m-boehringer-ingelheim-deal 2015-08-05T11:37:28 https://maestrodatabase.com/blog/new-drugs-for-ovarian-cancer-patients 2016-09-06T01:14:09 https://maestrodatabase.com/blog/new-zealand-patients-call-for-cannabis 2016-04-11T21:01:38 https://maestrodatabase.com/blog/u-dot-s-fda-approves-invokana-canagliflozin-to-reduce-the-risk-of-heart-attack-stroke-or-cardiovascular-death-in-adults-with-type-2-diabetes-and-established-cardiovascular-disease 2018-10-30T20:20:31 https://maestrodatabase.com/blog/us-health-plans-slow-to-take-up-value-frameworks 2016-07-27T12:18:52 https://maestrodatabase.com/blog/teclistamab-for-the-treatment-of-patients-with-relapsed-and-refractory-multiple-myeloma-after-three-or-more-treatments-final-guidance 2024-11-14T01:48:37 https://maestrodatabase.com/blog/anoro-ellipta-approved-in-australia-for-chronic-obstructive-pulmonary-disease 2015-08-05T11:37:14 https://maestrodatabase.com/blog/why-im-not-worried-about-drug-prices-how-i-stopped-worrying-and-learned-to-love-the-100000-drug 2015-09-10T21:18:58 https://maestrodatabase.com/blog/fda-grants-genentechs-alectinib-priority-review-for-specific-type-of-alk-positive-lung-cancer 2015-09-09T12:08:47 https://maestrodatabase.com/blog/hope-for-regenerative-medicine-bonanza 2018-10-30T20:10:40 https://maestrodatabase.com/blog/prescription-medicines-registration-of-new-chemical-entities-in-australia 2015-08-05T11:37:02 https://maestrodatabase.com/blog/record-of-stakeholder-meeting-eculizumab-soliris-for-atypical-haemolytic-uraemic-syndrome-february-2016 2016-04-22T10:48:59 https://maestrodatabase.com/blog/jeanette-kusel-is-appointed-as-director-for-nice-scientific-advice 2018-10-30T20:13:02 https://maestrodatabase.com/blog/cadths-calls-for-patient-input 2015-08-26T20:47:33 https://maestrodatabase.com/blog/new-medicine-to-help-end-the-transmission-of-hiv 2018-03-21T00:28:55 https://maestrodatabase.com/blog/comparison-of-u-dot-s-and-international-prices-for-top-medicare-part-b-drugs-by-total-expenditures 2018-10-30T20:34:54 https://maestrodatabase.com/blog/health-canadas-approval-of-ibavyr 2015-08-05T11:37:28 https://maestrodatabase.com/blog/the-virtues-and-vices-of-single-payer-health-care-in-the-us 2016-04-13T21:52:47 https://maestrodatabase.com/blog/first-oncolytic-immunotherapy-medicine-recommended-for-approval 2015-10-23T11:21:31 https://maestrodatabase.com/blog/smc-announces-more-forthcoming-submissions-3 2016-03-19T11:26:18 https://maestrodatabase.com/blog/pharmas-support-of-trumps-drug-pricing-plan-is-fraying-heading-into-midterms 2018-10-30T20:26:29 https://maestrodatabase.com/blog/nice-says-no-to-personalised-bowel-cancer-drugs 2015-11-18T10:49:52 https://maestrodatabase.com/blog/reform-of-regulation-of-medicines-and-medical-devices 2016-09-15T00:37:04 https://maestrodatabase.com/blog/pharmas-come-to-jesus-moment-the-industry-braces-for-a-pelosi-speakership-and-democrats-drug-pricing-agenda 2018-10-30T20:29:28 https://maestrodatabase.com/blog/proposals-to-revise-guidance-on-first-in-human-clinical-trials 2016-07-21T21:05:31 https://maestrodatabase.com/blog/cadth-calls-for-patient-input-on-a-new-submission-from-janssen-cilag-for-canagliflozin-hemihydrate-with-metformin-hydrochloride 2016-02-03T20:26:19 https://maestrodatabase.com/blog/european-commission-approves-extended-indication-for-amgens-kyprolis-carfilzomib-for-the-treatment-of-relapsed-multiple-myeloma-patients 2016-07-04T09:03:35 https://maestrodatabase.com/blog/herald_sun___fears_aussie_cancer_patients_may_miss_out_on_drugs 2015-08-05T11:37:27 https://maestrodatabase.com/blog/savings-from-extended-roles-exceed-100m 2015-08-05T11:37:14 https://maestrodatabase.com/blog/the-health-202-the-trump-administration-is-planning-its-next-move-on-drug-prices 2018-10-30T20:49:52 https://maestrodatabase.com/blog/epipen-maker-mylan-quietly-steers-effort-to-protect-its-price 2016-09-16T08:20:45 https://maestrodatabase.com/blog/drug-appraisal-issues-must-be-resolved-at-policy-level 2016-09-03T11:30:11 https://maestrodatabase.com/blog/pharmacy-benefit-managers-must-face-lawsuit-over-epipen-prices---judge 2018-10-30T20:39:42 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-to-publish-upcoming-assessment-on-treatments-for-peanut-allergy 2018-10-30T20:42:53 https://maestrodatabase.com/blog/valeant-promised-price-breaks-on-drugs-heart-hospitals-are-still-waiting 2016-05-12T14:23:39 https://maestrodatabase.com/blog/viiv-healthcare-receives-eu-marketing-authorisation-for-triumeq 2015-08-05T11:37:27 https://maestrodatabase.com/blog/alexion_lifts_annual_guidance_after_positive_french_decision_on_soliris_reimbursement 2015-08-05T11:37:24 https://maestrodatabase.com/blog/genentech-submits-new-drug-application-to-fda-for-investigational-cobimetinib-used-in-combination-with-zelboraf-vemurafenib-in-advanced-melanoma 2015-08-05T11:37:05 https://maestrodatabase.com/blog/health-canada-approves-abecma-idecabtagene-vicleucel-the-first-and-only-anti-bcma-car-t-cell-therapy-for-relapsed-and-refractory-multiple-myeloma 2021-06-01T03:04:41 https://maestrodatabase.com/blog/bayer-receives-eu-approval-for-eylea-for-the-treatment-of-visual-impairment-secondary-to-myopic-choroidal-neovascularization 2015-10-30T20:23:23 https://maestrodatabase.com/blog/pharmacists-warn-against-cheaper-meds 2015-12-14T20:34:34 https://maestrodatabase.com/blog/updated-guidance-on-comparator-medicines-with-a-patient-access-scheme 2016-09-13T20:54:53 https://maestrodatabase.com/blog/cadth-drug-portfolio-information-sessions 2015-09-25T23:19:32 https://maestrodatabase.com/blog/flutiform_launched_in_france 2015-08-05T11:37:23 https://maestrodatabase.com/blog/fda-approves-two-new-drug-treatments-for-diabetes-mellitus 2015-09-25T23:09:50 https://maestrodatabase.com/blog/u_k__cost_agency_seeks_more_lemtrada_data_from_sanofi 2015-08-05T11:37:27 https://maestrodatabase.com/blog/nice-draft-guidance-recommends-treatments-for-types-of-arthritis-that-affect-the-spine-1 2015-09-14T20:51:24 https://maestrodatabase.com/blog/recently_added_forthcoming_submissions 2015-08-05T11:37:06 https://maestrodatabase.com/blog/medicines-australia-welcomes-government-proposal-to-cut-medical-red-tape 2015-08-05T11:37:18 https://maestrodatabase.com/blog/divestment-of-portfolio-of-branded-and-generic-products-to-strides-entities 2015-08-05T11:37:24 https://maestrodatabase.com/blog/amgens-first-biosimilar-marketing-authorization-application-submitted-to-european-medicines-agency-for-abp-501 2015-12-04T21:01:35 https://maestrodatabase.com/blog/ema-publishes-epar-for-albutrepenonacog-alfa-idelvion 2016-05-31T16:13:53 https://maestrodatabase.com/blog/nice-proposes-to-recommend-drug-for-psoriatic-arthritis 2015-08-05T11:37:29 https://maestrodatabase.com/blog/tga-business-services-site-replaces-ebs 2015-08-05T11:37:26 https://maestrodatabase.com/blog/pfizer-announces-submission-of-palbociclib-new-drug-application-to-the-fda 2015-08-05T11:37:29 https://maestrodatabase.com/blog/fda-approves-new-treatment-for-adults-with-partial-onset-seizures 2019-11-21T23:22:20 https://maestrodatabase.com/blog/pbac-guidelines-review-extension-of-public-consultation 2015-08-25T09:52:15 https://maestrodatabase.com/blog/fda-approves-avastin-for-ovarian-cancer 2015-08-05T11:37:06 https://maestrodatabase.com/blog/the-cost-of-this-drug-is-high-enough-to-question-its-value 2016-08-17T21:36:46 https://maestrodatabase.com/blog/higher-priced-drugs-are-not-cost-effective-for-diabetic-macular-edema-us-study-finds 2016-06-15T02:31:43 https://maestrodatabase.com/blog/effective-today-jinarc-is-now-commercially-available-for-use-in-canada 2015-08-05T11:37:21 https://maestrodatabase.com/blog/review-panel-backs-expanded-indications-for-keytruda-dupixent-imfinzi-sent-for-reconsideration 2025-09-10T05:19:08 https://maestrodatabase.com/blog/fda-approves-qbrelis-the-first-and-only-lisinopril-oral-solution-1-mgml-for-pediatric-patients-6-years-of-age-and-older 2016-08-01T06:58:27 https://maestrodatabase.com/blog/speeding-up-access-to-new-drugs-threatens-evidence-based-medicine-says-health-economist 2016-01-20T20:38:02 https://maestrodatabase.com/blog/the-fda-juno-therapeutics-and-the-ethical-imperative-of-transparency 2016-08-17T09:48:00 https://maestrodatabase.com/blog/us-fda-approves-foundationone-liquid-cdx-as-a-companion-diagnostic-for-pfizers-braftovi-encorafenib-in-combination-with-cetuximab-to-identify-patients-with-braf-v600e-alterations-in-metastatic-colorectal-cancer 2023-06-09T21:18:01 https://maestrodatabase.com/blog/nice-backs-novartis-glivec-for-gist 2015-08-05T11:37:10 https://maestrodatabase.com/blog/fda-approves-only-drug-in-u-dot-s-to-treat-severe-malaria 2020-05-27T01:52:57 https://maestrodatabase.com/blog/cadth-calls-for-feedback-on-drugs-for-the-management-of-rheumatoid-arthritis 2016-06-22T21:45:54 https://maestrodatabase.com/blog/tga-approves-afluria-quad 2016-07-28T21:57:01 https://maestrodatabase.com/blog/fda-seeks-49-billion-for-fy-2016-to-implement-the-fda-food-safety-modernization-act-and-improve-the-quality-and-safety-of-the-medical-products-americans-use 2015-08-05T11:37:07 https://maestrodatabase.com/blog/vivoryon-therapeutics-receives-fda-fast-track-designation-for-varoglutamstat-in-early-alzheimers-disease 2021-12-28T07:02:24 https://maestrodatabase.com/blog/new-treatment-option-recommended-for-patients-with-advanced-melanoma 2015-08-05T11:37:18 https://maestrodatabase.com/blog/tga-reforms-a-blueprint-for-tgas-future-progress-report-as-at-31-december-2014 2015-08-05T11:37:12 https://maestrodatabase.com/blog/fda-approves-first-treatment-for-a-form-of-bladder-dysfunction-in-paediatric-patients-as-young-as-2-years-of-age 2020-05-27T02:04:44 https://maestrodatabase.com/blog/nice_seeks_views_on_how_it_assesses_drugs_and_other_technologies_for_the_nhs 2015-08-05T11:37:28 https://maestrodatabase.com/blog/us-fda-has-granted-priority-review-for-olysio-in-combination-with-sofosbuvir-supplementary-new-drug-application 2015-08-05T11:37:08 https://maestrodatabase.com/blog/pbs-palliative-care-schedule 2016-06-01T14:35:08 https://maestrodatabase.com/blog/major-european-research-project-on-monitoring-and-evaluation-of-medicines-concludes 2015-08-05T11:37:30 https://maestrodatabase.com/blog/the-challenges-of-sharing-data-in-an-era-of-politicised-science 2019-11-21T23:34:32 https://maestrodatabase.com/blog/nice-issues-draft-guidance-on-alirocumab-for-lipid-disorder 2016-02-08T19:38:23 https://maestrodatabase.com/blog/bdmards-on-the-pbs-are-they-all-the-same 2016-04-27T21:57:18 https://maestrodatabase.com/blog/statement-from-lilly-chairman-and-ceo-dave-ricks-on-the-new-medicare-part-d-senior-savings-model 2020-05-27T01:49:17 https://maestrodatabase.com/blog/kiniksa-announces-breakthrough-therapy-designation-for-rilonacept-for-the-treatment-of-recurrent-pericarditis 2019-11-21T23:29:30 https://maestrodatabase.com/blog/decision-to-not-accept-any-proposals-for-the-insulin-glargine-rfp 2016-09-28T00:59:31 https://maestrodatabase.com/blog/nivolumab-in-melanoma-additional-benefit-in-certain-patients-according-to-the-iqwig 2015-10-15T20:50:19 https://maestrodatabase.com/blog/us-fda-grants-priority-review-to-lifitegrast-nda-for-the-treatment-of-dry-eye-disease-in-adults 2015-08-05T11:37:09 https://maestrodatabase.com/blog/fighting-antimicrobial-resistance-globally 2016-09-08T12:43:58 https://maestrodatabase.com/blog/keytruda-should-be-funded-in-nz-andrew-little 2015-12-06T22:28:27 https://maestrodatabase.com/blog/venetoclax-receives-third-breakthrough-therapy-designation-from-the-fda-for-the-combination-treatment-of-patients-with-untreated-acute-myeloid-leukaemia-not-eligible-for-standard-induction-chemotherapy 2016-01-28T20:31:57 https://maestrodatabase.com/blog/consultation-now-open-on-plans-to-reform-cancer-drugs-fund 2015-11-20T04:40:47 https://maestrodatabase.com/blog/nice-publishes-appraisal-consultation-for-cobimetinib-hemifumarate-cotellic-for-patients-with-malignant-melanoma 2016-06-16T11:57:36 https://maestrodatabase.com/blog/inflation-reduction-act-continues-to-lower-out-of-pocket-prescription-drug-costs-for-drugs-with-price-increases-above-inflation 2023-09-14T10:23:39 https://maestrodatabase.com/blog/queensland-government-partners-with-johnson-johnson-to-lure-medical-tech-firms 2015-09-24T12:58:10 https://maestrodatabase.com/blog/applied-therapeutics-announces-fda-acceptance-and-priority-review-of-new-drug-application-for-govorestat-for-the-treatment-of-classic-galactosaemia 2024-02-28T20:22:19 https://maestrodatabase.com/blog/sovaldi-unaffordable-says-nhs-documents 2015-08-05T11:37:26 https://maestrodatabase.com/blog/incyte-announces-us-fda-grants-priority-review-for-axatilimab-for-the-treatment-of-chronic-graft-versus-host-disease 2024-02-28T10:37:17 https://maestrodatabase.com/blog/bayer-wins-cancer-drugs-fund-appeal 2015-08-05T11:37:29 https://maestrodatabase.com/blog/cadth-calls-for-patient-input-on-a-new-submission-from-eli-lilly-for-trulicity 2015-11-17T20:35:40 https://maestrodatabase.com/blog/smc-forthcoming-submissions 2015-08-05T11:37:09 https://maestrodatabase.com/blog/basilea-submits-isavuconazole-european-marketing-authorization-application-for-the-treatment-of-invasive-mold-infections 2015-08-05T11:37:02 https://maestrodatabase.com/blog/at-last-nice-to-take-over-the-cancer-drugs-fund 2016-03-09T03:34:05 https://maestrodatabase.com/blog/tga-half-yearly-performance-reports---july-to-december-2014 2015-08-05T11:37:13 https://maestrodatabase.com/blog/call-for-patient-input-10 2015-08-05T11:37:18 https://maestrodatabase.com/blog/icer-announces-updates-to-timeline-for-review-of-ms-therapies 2016-09-17T08:05:44 https://maestrodatabase.com/blog/scottish-medicines-consortium-forthcoming-submissions 2015-09-15T10:08:34 https://maestrodatabase.com/blog/us-fda-approves-botox-onabotulinumtoxina-for-the-treatment-of-lower-limb-spasticity-in-adults 2016-01-25T20:29:48 https://maestrodatabase.com/blog/cancer-drugs-fund-changes-deeply-concerning-say-charities 2016-05-16T10:23:32 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits-1-november-2015-update 2015-11-01T20:32:48 https://maestrodatabase.com/blog/chmp-issues-positive-opinion-to-include-new-data-in-european-label-for-xtandi-enzalutamide 2016-04-07T21:18:25 https://maestrodatabase.com/blog/edoxaban-tosylate-considerable-additional-benefit-for-certain-patients 2015-11-05T10:21:33 https://maestrodatabase.com/blog/evolocumab-no-evidence-of-additional-clinical-benefits-says-iqwig 2015-12-15T20:38:38 https://maestrodatabase.com/blog/valley-of-death-journey-for-australian-biotech-to-pharmacy-shelves 2015-09-25T23:05:15 https://maestrodatabase.com/blog/agenda-for-18-march-2015-tc-meeting 2015-08-05T11:37:04 https://maestrodatabase.com/blog/msac-publishes-agenda-for-jun-2024-esc-meeting 2024-02-28T20:50:03 https://maestrodatabase.com/blog/degarelix-the-prostate-cancer-lifeline-drug-finally-approved-after-three-year-wait 2016-07-12T21:24:49 https://maestrodatabase.com/blog/amicus-therapeutics-submits-marketing-authorisation-application-maa-for-full-approval-of-fabry-monotherapy-galafold-migalastat-in-european-union 2015-08-05T11:37:28 https://maestrodatabase.com/blog/us-fda-grants-priority-review-to-janssens-new-drug-application-for-chewable-mebendazole-tablets-intended-to-treat-soil-transmitted-helminthiasis 2016-07-14T08:49:52 https://maestrodatabase.com/blog/trastuzumab-deruxtecan-type-ii-variation-application-validated-by-ema-for-patients-with-her2-positive-metastatic-breast-cancer-treated-with-a-prior-anti-her2-based-regimen 2021-12-28T07:22:03 https://maestrodatabase.com/blog/bernie-sanders-wants-to-rein-in-drug-prices-is-he-asking-the-right-questions 2024-02-28T20:42:57 https://maestrodatabase.com/blog/smc-recently-added-forthcoming-submissions 2015-08-05T11:37:08 https://maestrodatabase.com/blog/considering-tomorrows-patients-in-todays-drug-approvals 2023-06-09T22:33:06 https://maestrodatabase.com/blog/meeting-highlights-from-the-committee-for-medicinal-products-for-human-use-chmp-20-23-july-2015 2015-08-05T11:37:29 https://maestrodatabase.com/blog/ceritinib-in-advanced-lung-cancer-no-evidence-of-additional-benefits-says-iqwig 2015-10-01T11:52:30 https://maestrodatabase.com/blog/canadas-cdec-recommends-gsks-breo-ellipta 2015-08-05T11:37:18 https://maestrodatabase.com/blog/uk-cost-agency-nice-rejects-another-roche-cancer-drug 2015-08-05T11:37:23 https://maestrodatabase.com/blog/fda-accepts-biologics-license-application-for-sobis-nasp-for-patients-with-uncontrolled-gout 2025-09-10T10:31:25 https://maestrodatabase.com/blog/from-obamacare-to-hillarycare-democrats-health-care-reform-agenda 2016-09-15T00:44:18 https://maestrodatabase.com/blog/amarin-provides-update-on-anchor-trial-spa-agreement-rescission-appeal 2015-08-05T11:37:09 https://maestrodatabase.com/blog/recommendations-for-conduct-methodological-practices-and-reporting-of-cost-effectiveness-analyses-second-panel-on-cost-effectiveness-in-health-and-medicine 2016-09-13T21:21:25 https://maestrodatabase.com/blog/it-really-seems-cruel-drug-giants-brutal-blow-to-australian-breast-cancer-patients 2020-10-21T01:23:50 https://maestrodatabase.com/blog/nice-recommends-treatment-for-severe-crohns-disease 2015-08-05T11:37:21 https://maestrodatabase.com/blog/fda-approves-inflectra-a-biosimilar-to-remicade 2016-04-05T20:39:05 https://maestrodatabase.com/blog/update-for-patient-groups-2 2016-09-14T03:10:53 https://maestrodatabase.com/blog/the-fda-did-the-right-thing-by-approving-a-novel-drug-for-a-disabling-disease 2016-09-22T20:59:08 https://maestrodatabase.com/blog/valeant-drops-philidor-mail-order-pharmacy 2015-11-01T11:06:40 https://maestrodatabase.com/blog/fda-approves-new-drug-to-treat-schizophrenia-and-bipolar-disorder 2015-09-18T02:26:34 https://maestrodatabase.com/blog/nivolumab-in-non-small-cell-lung-cancer-evidence-of-considerable-additional-benefit-in-patients-under-75-years-of-age 2015-11-16T20:45:05 https://maestrodatabase.com/blog/abbott-government-extends-pharmacy-location-rules-for-another-five-years 2015-08-05T11:37:23 https://maestrodatabase.com/blog/quebec-becomes-first-province-to-reimburse-sovaldi-for-the-treatment-of-chronic-hepatitis-c 2015-08-05T11:37:28 https://maestrodatabase.com/blog/more-than-10-million-people-with-medicare-have-saved-over-20-billion-on-prescription-drugs-since-2010 2016-02-08T20:13:22 https://maestrodatabase.com/blog/proposal-to-list-icatibant-acetate-solution-for-injection 2015-08-05T11:37:05 https://maestrodatabase.com/blog/perc_has_issued_its_final_recommendation_for_cetuximab__erbitux__for_patients_with_egfr_expressing_k_ras_wild_type_metastatic_colorectal_carcinoma 2015-08-05T11:37:05 https://maestrodatabase.com/blog/nice-u-turn-on-boehringers-vargatef-for-lung-cancer 2015-08-05T11:37:02 https://maestrodatabase.com/blog/alnylam-announces-u-dot-s-fda-has-granted-priority-review-of-the-lumasiran-new-drug-application-for-the-treatment-of-primary-hyperoxaluria-type-1 2020-05-27T04:01:01 https://maestrodatabase.com/blog/improving-safety-of-first-in-human-clinical-trials 2016-05-27T12:52:34 https://maestrodatabase.com/blog/agenda-for-1-october-2014-transparency-commission-meeting 2015-08-05T11:37:22 https://maestrodatabase.com/blog/legislation-to-increase-generic-drug-alternatives 2016-08-09T21:24:34 https://maestrodatabase.com/blog/outcomes_from_the_february_2014_dusc_meeting 2015-08-05T11:37:28 https://maestrodatabase.com/blog/health-canada-approves-pluvicto-as-first-targeted-radioligand-therapy-for-progressive-psma-positive-metastatic-castration-resistant-prostate-cancer 2022-09-08T07:32:18 https://maestrodatabase.com/blog/medicines-banned-from-the-us-and-canada-are-on-sale-in-australia 2015-08-05T11:37:18 https://maestrodatabase.com/blog/dusc-utilisation-analysis-public-release-documents---february-2015 2015-08-05T11:37:30 https://maestrodatabase.com/blog/court-tells-canadian-feds-you-cannot-control-generic-drug-prices 2015-08-05T11:37:24 https://maestrodatabase.com/blog/fda-approves-vaccine-for-use-after-known-or-suspected-anthrax-exposure 2015-11-25T07:05:09 https://maestrodatabase.com/blog/listening-to-the-publics-views-on-the-safety-of-medicines 2016-04-15T21:17:23 https://maestrodatabase.com/blog/stemline-therapeutics-receives-breakthrough-therapy-designation-from-us-food-and-drug-administration-for-sl-401 2016-08-23T21:50:26 https://maestrodatabase.com/blog/rockwell-medical-files-new-drug-submission-with-health-canada-for-marketing-approval-of-triferic-avnu 2020-05-27T03:19:13 https://maestrodatabase.com/blog/pharmac_continues_expanding_medicines_within_budget 2015-08-05T11:37:12 https://maestrodatabase.com/blog/european-chmp-adopts-positive-opinion-for-gileads-single-tablet-regimen-genvoya-elvitegravir-cobicistat-emtricitabine-and-tenofovir-alafenamide-for-the-treatment-of-hiv 2015-09-26T04:06:21 https://maestrodatabase.com/blog/european-medicines-agency-validates-gileads-marketing-application-for-single-tablet-regimen-containing-rilpivirine-emtricitabine-and-tenofovir-alafenamide-rftaf-for-hiv-treatment 2015-08-21T02:34:12 https://maestrodatabase.com/blog/actuate-announces-fda-rare-paediatric-disease-designation-granted-to-elraglusib-for-treatment-of-ewing-sarcoma 2024-11-14T03:16:50 https://maestrodatabase.com/blog/cost-to-nhs-of-providing-sipuleucel-t-too-high-to-be-recommended-in-draft-guidance-1 2015-08-05T11:37:19 https://maestrodatabase.com/blog/fda-approves-gardasil-9-for-prevention-of-certain-cancers-caused-by-five-additional-types-of-hpv-1 2015-08-05T11:37:08 https://maestrodatabase.com/blog/canadian-baby-with-spinal-muscular-atrophy-to-get-worlds-most-expensive-drug 2020-10-21T02:47:00 https://maestrodatabase.com/blog/affordable-access-to-innovative-cancer-medicines-dont-forget-the-prices 2016-04-03T22:40:04 https://maestrodatabase.com/blog/high-price-of-epipens-spurs-consumers-emts-to-resort-to-syringes-for-allergic-reactions 2016-07-13T21:20:16 https://maestrodatabase.com/blog/tga-approves-targin-for-new-indication 2016-07-27T05:31:05 https://maestrodatabase.com/blog/nice-no-for-novartis-farydak-a-blow-for-multiple-myeloma-patients 2015-09-15T20:53:30 https://maestrodatabase.com/blog/california-plans-to-review-coronavirus-vaccine-independently 2020-10-21T02:50:09 https://maestrodatabase.com/blog/cadth-calls-for-patient-input-on-a-resubmission-for-xolair 2015-10-06T20:42:57 https://maestrodatabase.com/blog/adjusted-fees-for-applications-to-european-medicines-agency-from-1-april-2015 2015-08-05T11:37:18 https://maestrodatabase.com/blog/biomarin-submits-marketing-authorisation-application-to-ema-for-valoctocogene-roxaparvovec-to-treat-severe-haemophilia-a 2019-11-22T01:28:38 https://maestrodatabase.com/blog/public-summary-documents-from-the-march-2014-pbac-meeting 2015-08-05T11:37:26 https://maestrodatabase.com/blog/ptc-therapeutics-announces-fda-approval-of-aadc-deficiency-gene-therapy 2024-11-14T02:50:51 https://maestrodatabase.com/blog/fda-approves-entyvio-to-treat-ulcerative-colitis-and-crohns-disease 2015-08-05T11:37:13 https://maestrodatabase.com/blog/fda-approves-expanded-indication-for-mercks-keytruda-pembrolizumab-for-the-treatment-of-patients-with-advanced-melanoma 2017-06-04T00:52:24 https://maestrodatabase.com/blog/health-canada-approves-lonsurf-trifluridine-slash-tipiracil-for-adults-with-metastatic-gastric-cancer-during-stomach-cancer-awareness-month 2019-11-22T01:23:02 https://maestrodatabase.com/blog/international-collaboration-for-the-evaluation-of-generic-drugs 2015-08-05T11:37:21 https://maestrodatabase.com/blog/mitsubishi-tanabe-pharma-submits-new-drug-application-for-edaravone-to-treat-als-in-the-united-states 2016-06-21T11:08:57 https://maestrodatabase.com/blog/nice_joins_the_smc_in_recommending_the_use_of_lucentis__ranibizumab__for_macular_oedema_due_to_retinal_vein_occlusion 2015-08-05T11:37:20 https://maestrodatabase.com/blog/chinese-pharmacists-plan-to-share-1600-billion-pie-with-australia 2016-05-03T06:14:40 https://maestrodatabase.com/blog/the-medicines-company-receives-european-commission-approval-for-three-hospital-acute-care-products-kengrexal-cangrelor-orbactiv-oritavancin-and-raplixa-sealant-powder 2015-08-05T11:37:11 https://maestrodatabase.com/blog/painted-as-epipen-villain-mylans-chief-says-shes-no-such-thing 2016-08-28T10:25:24 https://maestrodatabase.com/blog/devices-savings-to-help-hospitals-manage-budgets 2016-07-05T03:50:00 https://maestrodatabase.com/blog/calgary-boy-needs-400k-drug-to-treat-rare-form-of-muscular-dystrophy 2016-02-03T20:48:06 https://maestrodatabase.com/blog/grifols-enters-into-agreement-with-canadian-blood-services-to-accelerate-self-sufficiency-in-immunoglobulins-for-canada 2022-09-08T08:29:31 https://maestrodatabase.com/blog/us-officials-move-to-end-duplicate-health-care-coverage 2016-08-20T08:12:15 https://maestrodatabase.com/blog/aerie-pharmaceuticals-receives-european-commission-approval-for-rhokiinsa-netarsudil-0-dot-02-percent-ophthalmic-solution 2019-11-22T01:40:27 https://maestrodatabase.com/blog/roches-roactemra-receives-eu-approval-for-use-in-patients-with-early-rheumatoid-arthritis 2015-08-05T11:37:15 https://maestrodatabase.com/blog/trans-pacific-partnership-whats-the-deal-being-negotiated-in-our-name 2015-08-05T11:37:08 https://maestrodatabase.com/blog/fda-expands-approval-of-pernixs-migraine-therapy-treximet-in-paediatric-patients 2015-08-05T11:37:19 https://maestrodatabase.com/blog/hep-c-cures-now-as-cheap-as-620 2016-02-29T20:49:21 https://maestrodatabase.com/blog/nice-asks-company-for-further-information-on-drug-for-rare-inherited-disease-in-draft-guidance 2015-08-05T11:37:23 https://maestrodatabase.com/blog/fact-sheet-2015-price-disclosure-changes 2015-08-09T12:15:00 https://maestrodatabase.com/blog/old-pharma-sees-new-profit-cure-in-cancer-drugs 2016-07-19T21:55:22 https://maestrodatabase.com/blog/eu-expands-use-of-novos-diabetes-drug-tresiba 2015-08-05T11:37:09 https://maestrodatabase.com/blog/nice-recommends-three-diabetes-treatments 2016-05-25T10:52:02 https://maestrodatabase.com/blog/medicines_scheme_overhaul_raises_health_concerns 2015-08-05T11:37:24 https://maestrodatabase.com/blog/antivascular-endothelial-growth-factor-drugs-for-retinal-conditions-1 2015-10-08T20:29:10 https://maestrodatabase.com/blog/health-canada-approves-first-treatment-for-schizophrenia-dosed-four-times-a-year 2016-06-27T21:34:37 https://maestrodatabase.com/blog/health-canada-issues-notice-of-compliance-for-gileads-single-tablet-regimen-genvoya-elvitegravir-cobicistat-emtricitabine-and-tenofovir-alafenamide-for-treatment-of-hiv-1-infection 2015-12-08T20:30:40 https://maestrodatabase.com/blog/fda-approves-lymphoseek-to-help-determine-the-extent-of-head-and-neck-cancer-in-the-body 2015-08-05T11:37:06 https://maestrodatabase.com/blog/nice-guidance-recommends-apixaban-eliquis-for-treating-and-preventing-potentially-fatal-blood-clots 2015-08-05T11:37:29 https://maestrodatabase.com/blog/cadth-canadian-drug-expert-committee-recommends-cosentyx-secukinumab 2015-11-02T06:31:47 https://maestrodatabase.com/blog/fda-grants-breakthrough-therapy-designation-for-urogen-pharmas-ugn-101-for-the-treatment-of-patients-with-low-grade-upper-tract-urothelial-cancer 2018-10-31T00:44:19 https://maestrodatabase.com/blog/merck-announces-fda-acceptance-of-biologics-license-application-for-bezlotoxumab-an-investigational-anti-toxin-for-prevention-of-clostridium-difficile-infection-recurrence 2016-01-28T20:39:37 https://maestrodatabase.com/blog/abbvie-racks-up-three-more-indications-for-humira 2016-07-27T06:05:33 https://maestrodatabase.com/blog/release-of-the-201415-pharmac-invitation-to-tender 2015-08-05T11:37:07 https://maestrodatabase.com/blog/nice-backs-new-hepatitis-c-melanoma-drugs 2015-08-05T11:37:03 https://maestrodatabase.com/blog/european-commission-approves-additional-indication-for-velcade-bortezomib-in-mantle-cell-lymphoma 2015-08-05T11:37:03 https://maestrodatabase.com/blog/european-medicines-agency-validates-bristol-myers-squibbs-application-for-opdivo-nivolumab-for-the-treatment-of-classical-hodgkins-lymphoma-patients 2016-04-02T00:08:16 https://maestrodatabase.com/blog/us-fda-grants-priority-review-status-to-snda-for-anti-cancer-agent-halaven-as-treatment-for-soft-tissue-sarcoma 2015-09-29T21:24:58 https://maestrodatabase.com/blog/idalopirdine-granted-fast-track-designation-by-us-fda 2016-07-08T07:53:12 https://maestrodatabase.com/blog/bc-cancer-agency-adds-kadcyla-to-the-provincial-formulary-for-the-treatment-of-her2-positive-metastatic-breast-cancer 2015-08-05T11:37:11 https://maestrodatabase.com/blog/selecta-biosciences-and-askbio-receive-fda-rare-paediatric-disease-designation-for-their-gene-therapy-for-methylmalonic-acidemia 2020-10-21T05:28:46 https://maestrodatabase.com/blog/nice-publishes-draft-guidance-on-two-prostate-cancer-treatments 2015-12-13T07:08:00 https://maestrodatabase.com/blog/sixty-seconds-on-the-cancer-drugs-fund 2016-02-10T08:24:33 https://maestrodatabase.com/blog/sprout-pharmaceuticals-resubmits-flibanserin-new-drug-application-for-the-treatment-of-hypoactive-sexual-desire-disorder-in-pre-menopausal-women 2015-08-05T11:37:27 https://maestrodatabase.com/blog/silence-therapeutics-announces-fda-fast-track-designation-for-sln124-a-novel-investigational-sirna-therapy-for-the-treatment-of-polycythemia-vera 2022-09-08T11:07:35 https://maestrodatabase.com/blog/cobimetinib-in-advanced-melanoma-with-braf-v600-mutation-little-additional-value-says-germanys-iqwig 2016-03-16T20:50:59 https://maestrodatabase.com/blog/addition-of-therapeutic-area-as-a-filter 2015-08-05T11:37:17 https://maestrodatabase.com/blog/tga-presentations-given-at-the-arcs-rmp-workshop-12-march-2015 2015-08-05T11:37:22 https://maestrodatabase.com/blog/how-the-fda-stood-up-to-the-president 2020-10-21T08:14:56 https://maestrodatabase.com/blog/roches-gazyvaro-approved-in-europe-for-patients-with-the-most-common-type-of-leukaemia 2015-08-05T11:37:06 https://maestrodatabase.com/blog/charlie-teo-brain-surgery-controversy-society-gives-assurances 2019-06-01T00:23:38 https://maestrodatabase.com/blog/humira_is_now_available_for_canadian_children_living_with_severely_active_crohn_s_disease 2015-08-05T11:37:06 https://maestrodatabase.com/blog/melanoma_treatment_among_50_new_medicines_added_to_pbs_list 2015-08-05T11:37:13 https://maestrodatabase.com/blog/xeris-pharmaceuticals-granted-fast-track-designation-by-the-fda-for-its-novel-concentrated-diazepam-formulation-xp-0863-for-injection 2020-10-21T08:19:03 https://maestrodatabase.com/blog/thrombogenics-jetrea-receives-positive-recommendation-from-scottish-medicines-consortium 2015-08-05T11:37:02 https://maestrodatabase.com/blog/pomalyst-pomalidomide-label-update-including-progression-free-and-overall-survival-benefits-approved-by-us-fda 2015-08-05T11:37:28 https://maestrodatabase.com/blog/recently-added-forthcoming-submissions---september-2014-update 2015-08-05T11:37:24 https://maestrodatabase.com/blog/perc-isses-final-recommendation-for-ibrutinib-imbruvica 2016-07-21T21:15:38 https://maestrodatabase.com/blog/ocular-therapeutix-receives-complete-response-letter-from-fda-for-its-nda-for-dextenza-for-the-treatment-of-post-surgical-ocular-pain 2016-07-25T21:07:55 https://maestrodatabase.com/blog/pfizer-announces-fda-acceptance-for-review-of-supplemental-new-drug-application-for-oral-xeljanz-tofacitinib-citrate-for-adult-patients-with-moderate-to-severe-chronic-plaque-psoriasis 2015-08-05T11:37:21 https://maestrodatabase.com/blog/employers-battle-drug-costs 2015-12-21T20:29:52 https://maestrodatabase.com/blog/smc-forthcoming-submissions-1 2015-08-05T11:37:29 https://maestrodatabase.com/blog/mepolizumab-in-severe-asthma-additional-benefit-is-not-proven 2016-05-02T20:52:47 https://maestrodatabase.com/blog/pfizer-receives-complete-response-letter-from-fda-for-oral-xeljanz-tofacitinib-citrate-supplemental-new-drug-application-for-moderate-to-severe-chronic-plaque-psoriasis 2015-10-15T11:17:23 https://maestrodatabase.com/blog/combination-drug-therapies-for-cancer-show-promise-at-higher-potential-cost 2016-06-06T06:04:45 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-23-december-2021 2021-12-28T22:27:00 https://maestrodatabase.com/blog/mhra-approves-olaparib-for-high-risk-early-stage-breast-cancer 2022-09-08T12:04:32 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits-update---1-august-2014 2015-08-05T11:37:27 https://maestrodatabase.com/blog/ema-and-eunethta-take-stock-of-their-co-operation 2021-06-01T08:28:17 https://maestrodatabase.com/blog/cms-proposes-improvements-for-the-2017-marketplace 2015-11-22T06:51:23 https://maestrodatabase.com/blog/premiums-for-healthcare-dot-gov-plans-are-lower-for-third-consecutive-year 2020-10-21T08:48:56 https://maestrodatabase.com/blog/national-health-spending-to-surpass-10000-a-person-in-2016 2016-07-14T21:22:18 https://maestrodatabase.com/blog/access-to-the-latest-and-most-effective-diabetes-drugs-depends-on-where-you-live-and-what-you-earn 2020-10-21T10:59:42 https://maestrodatabase.com/blog/revance-announces-fda-approval-of-daxxify-daxibotulinumtoxina-lanm-for-injection-the-first-and-only-peptide-formulated-neuromodulator-with-long-lasting-results 2022-09-08T11:38:25 https://maestrodatabase.com/blog/beyondspring-announces-u-dot-s-fda-acceptance-and-priority-review-of-new-drug-application-for-plinabulin-and-g-csf-combination-for-the-prevention-of-chemotherapy-induced-neutropenia 2021-06-01T11:35:03 https://maestrodatabase.com/blog/when-right-to-try-isnt-enough-congress-wants-a-single-als-patient-to-get-a-therapy-never-tested-in-humans 2019-06-01T00:56:07 https://maestrodatabase.com/blog/big-pharmas-had-a-gutful-of-pbs-report 2015-09-23T07:41:45 https://maestrodatabase.com/blog/pharmaceutical_benefits_scheme_listing_of_kalydeco__ivacaftor_ 2015-08-05T11:37:30 https://maestrodatabase.com/blog/revised-process-for-cell-and-gene-therapies 2019-11-22T04:10:17 https://maestrodatabase.com/blog/janssen-submits-application-seeking-approval-of-stelara-in-european-union-for-paediatric-plaque-psoriasis 2015-08-05T11:37:15 https://maestrodatabase.com/blog/abbvie-receives-us-fda-approval-of-once-daily-viekira-xr-dasabuvir-ombitasvir-paritaprevir-and-ritonavir-for-the-treatment-of-genotype-1-chronic-hepatitis-c 2016-07-25T21:18:15 https://maestrodatabase.com/blog/some-biosimilars-are-just-as-good-as-some-pricey-biologics 2016-08-03T11:46:12 https://maestrodatabase.com/blog/viewray-announces-china-nmpa-approval-of-its-mridian-mri-guided-radiation-therapy-for-cancer-patients 2022-09-08T11:27:44 https://maestrodatabase.com/blog/cancer-sufferers-may-lose-access-to-effective-drugs-says-support-group 2016-07-30T01:06:50 https://maestrodatabase.com/blog/pharmac-to-seek-further-advice-on-melatonin-funding-proposal 2015-08-05T11:37:13 https://maestrodatabase.com/blog/status-of-the-adaptive-pathways-pilot-project 2015-08-05T11:37:07 https://maestrodatabase.com/blog/covid-19-vaccine-safety-report-8-august-2022 2022-09-08T11:14:27 https://maestrodatabase.com/blog/cadth-calls-for-patient-input-on-two-submissions-from-novartis-for-cosentyx 2016-01-21T20:30:24 https://maestrodatabase.com/blog/keryx-biopharmaceuticals-receives-fda-approval-of-ferric-citrate-a-new-oral-iron-based-treatment-for-dialysis-patients-with-hyperphosphataemia 2015-08-05T11:37:13 https://maestrodatabase.com/blog/biomarins-vimizim-elosulfase-alfa-approved-in-australia-for-treatment-of-morquio-a-syndrome 2015-08-05T11:37:09 https://maestrodatabase.com/blog/fda-accepts-sandoz-regulatory-submission-for-a-proposed-biosimilar-etanercept 2015-10-02T05:24:13 https://maestrodatabase.com/blog/esketamine-nices-appraisal-was-unfair-appeal-panel-rules 2022-09-08T20:47:53 https://maestrodatabase.com/blog/nice-draft-guidance-recommends-treatments-for-types-of-arthritis-that-affect-the-spine 2015-09-11T21:46:12 https://maestrodatabase.com/blog/drugmakers-pricing-power-remains-strong 2016-07-14T21:17:10 https://maestrodatabase.com/blog/portola-pharmaceuticals-receives-complete-response-letter-from-fda-for-biologics-license-application-for-andexxa-andexanet-alfa 2016-08-18T20:46:48 https://maestrodatabase.com/blog/alkermes-announces-fda-approval-of-lybalvi-for-the-treatment-of-schizophrenia-and-bipolar-i-disorder 2021-06-01T11:56:58 https://maestrodatabase.com/blog/is-iqwigs-15-percent-threshold-universally-applicable-in-assessing-the-clinical-relevance-of-patient-reported-outcomes-changes-an-ispor-special-interest-group-report 2022-09-08T20:58:30 https://maestrodatabase.com/blog/nice-widens-scope-of-bayers-eylea 2016-08-24T13:27:58 https://maestrodatabase.com/blog/mycovia-pharmaceuticals-submits-new-drug-application-to-the-u-dot-s-fda-for-oteseconazole-for-the-treatment-of-recurrent-vulvovaginal-candidiasis 2021-06-01T12:04:11 https://maestrodatabase.com/blog/bayer_s_adempas__riociguat__approved_for_the_treatment_of_two_life_threatening_forms_of_pulmonary_hypertension_in_the_eu 2015-08-05T11:37:20 https://maestrodatabase.com/blog/british-colombia-expands-childrens-access-to-transformational-cystic-fibrosis-drug 2022-09-08T20:42:50 https://maestrodatabase.com/blog/health-canada-approves-jardiance-empagliflozin-tablets-for-adults-with-type-2-diabetes 2015-12-01T20:11:42 https://maestrodatabase.com/blog/fda-approves-selumetinib-for-pediatric-patients-1-year-of-age-and-older-with-neurofibromatosis-type-1-with-symptomatic-inoperable-plexiform-neurofibromas 2025-09-10T23:34:14 https://maestrodatabase.com/blog/valeant-and-progenics-announce-fda-approves-relistor-tablets-for-the-treatment-of-opioid-induced-constipation-in-adults-with-chronic-non-cancer-pain 2016-07-20T21:11:57 https://maestrodatabase.com/blog/cancer-charities-concerned-at-drug-fund-cuts 2015-08-05T11:37:29 https://maestrodatabase.com/blog/navigating-the-tga-website 2015-08-05T11:37:06 https://maestrodatabase.com/blog/pharmac-hits-back-at-claims-australia-has-better-access-to-high-cost-cancer-drugs 2015-11-04T02:00:35 https://maestrodatabase.com/blog/ceribell-receives-fda-breakthrough-device-designation-for-delirium-indication 2022-09-08T20:37:12 https://maestrodatabase.com/blog/new-alternatives-to-statins-add-to-a-quandary-on-cholesterol 2015-08-30T08:20:37 https://maestrodatabase.com/blog/greenwich-lifesciences-glsi-100-granted-us-fda-fast-track-designation 2025-09-10T23:39:00 https://maestrodatabase.com/blog/amgen-submits-biologics-license-application-for-novel-investigational-ldl-cholesterol-lowering-medication-evolocumab-to-the-fda 2015-08-05T11:37:12 https://maestrodatabase.com/blog/submitting-documents-using-real-world-data-and-real-world-evidence-to-fda-for-drug-and-biological-products 2022-09-08T20:33:15 https://maestrodatabase.com/blog/continuing-the-shift-from-volume-to-results-in-american-healthcare 2015-11-24T20:28:00 https://maestrodatabase.com/blog/cadth-recommends-reimbursement-of-secukinumab-cosentyx-for-ankylosing-spondylitis 2016-08-28T10:18:44 https://maestrodatabase.com/blog/akebia-and-otsuka-announce-fda-acceptance-for-filing-of-new-drug-application-for-vadadustat-for-the-treatment-of-anaemia-due-to-chronic-kidney-disease-in-adult-patients-on-dialysis-and-not-on-dialysis 2021-06-01T11:42:38 https://maestrodatabase.com/blog/uk-pharmaceutical-industry-reforms-delayed-until-after-eu-referendum 2016-04-15T21:13:35 https://maestrodatabase.com/blog/speaker-pelosis-drug-pricing-plan-could-result-in-56-fewer-new-medicines-over-10-years 2019-11-22T06:11:52 https://maestrodatabase.com/blog/methods-used-in-early-value-assessments-for-nice-a-scoping-review 2025-09-11T00:00:02 https://maestrodatabase.com/blog/pharma-and-docs-up-in-arms-over-cancer-drugs-fund-cuts 2015-08-05T11:37:10 https://maestrodatabase.com/blog/pharmac-decision-relating-to-the-funding-of-tnf-inhibitors-humira-and-enbrel-and-gabapentin-neurontin 2015-09-09T06:40:12 https://maestrodatabase.com/blog/ema-workshop-on-single-arm-trials-in-oncology 2016-06-23T21:31:29 https://maestrodatabase.com/blog/large-scale-population-based-surveys-linked-to-administrative-health-databases-as-a-source-of-data-on-health-utilities-in-australia 2022-09-08T21:41:53 https://maestrodatabase.com/blog/the-solution-to-drug-prices 2015-09-09T11:49:41 https://maestrodatabase.com/blog/biogens-top-scientist-nearly-dares-fda-not-to-approve-alzheimers-drug 2019-11-22T20:50:20 https://maestrodatabase.com/blog/imbruvica-ibrutinib-now-approved-to-treat-waldenstroms-macroglobulinemia-in-europe 2015-08-05T11:37:09 https://maestrodatabase.com/blog/launch-prices-tackling-the-next-drug-pricing-challenge 2022-09-08T21:30:18 https://maestrodatabase.com/blog/actavis-and-adamas-announce-fda-approval-of-namzaric-a-fixed-dose-combination-of-memantine-hydrochloride-extended-release-and-donepezil-hydrochloride 2015-08-05T11:37:20 https://maestrodatabase.com/blog/trump-says-drug-importation-plan-coming-soon 2019-11-22T20:42:55 https://maestrodatabase.com/blog/janssen-announces-u-dot-s-fda-breakthrough-therapy-designation-granted-for-teclistamab-for-the-treatment-of-relapsed-or-refractory-multiple-myeloma 2021-06-01T12:40:09 https://maestrodatabase.com/blog/nice-consults-on-the-use-of-a-new-lung-cancer-drug 2015-08-05T11:37:11 https://maestrodatabase.com/blog/zosano-pharma-receives-complete-response-letter-from-fda-for-qtrypta 2020-10-21T19:42:45 https://maestrodatabase.com/blog/bridgebio-pharma-receives-fda-fast-track-designation-for-encaleret-for-the-treatment-of-autosomal-dominant-hypocalcaemia-type-1 2021-06-01T12:35:25 https://maestrodatabase.com/blog/fda-approves-new-psoriasis-drug-taltz-ixekizumab 2016-03-22T20:46:28 https://maestrodatabase.com/blog/corbyn-pledges-to-create-state-run-generics-firm-to-cut-drug-prices 2019-11-22T20:40:23 https://maestrodatabase.com/blog/cellectar-receives-fda-fast-track-designation-for-clr-131-in-lymphoplasmacytic-lymphoma-slash-waldenstroms-macroglobulinaemia 2020-05-27T06:07:54 https://maestrodatabase.com/blog/long-term-harm-for-diabetics-unable-to-access-medication 2022-09-08T21:32:29 https://maestrodatabase.com/blog/eu-approves-sanofis-new-gardasil-jab 2015-08-05T11:37:26 https://maestrodatabase.com/blog/the-yukon-to-fund-treatment-with-aubagio-for-relapsing-remitting-multiple-sclerosis 2015-08-05T11:37:13 https://maestrodatabase.com/blog/the-life-improvement-value-a-new-measure-of-cost-efficiency 2019-11-22T22:18:52 https://maestrodatabase.com/blog/icer-to-assess-treatments-for-alzheimers-disease 2021-12-28T23:26:07 https://maestrodatabase.com/blog/perc-issues-final-recommendation-for-cobimetinib-hemifumarate-cotellic 2016-06-30T21:46:07 https://maestrodatabase.com/blog/drug-combination-for-treating-skin-cancer-approved-for-nhs-use 2016-06-18T01:43:51 https://maestrodatabase.com/blog/paratek-pharmaceuticals-announces-fda-approval-of-nuzyra-omadacycline-oral-only-dosing-regimen-for-the-treatment-of-community-acquired-bacterial-pneumonia 2021-06-01T12:14:56 https://maestrodatabase.com/blog/us-food-and-drug-administration-and-representation-of-older-adults-in-clinical-trials 2016-03-22T05:40:29 https://maestrodatabase.com/blog/novartis-snares-spinifex-in-1bn-pharmaceuticals-deal 2015-08-05T11:37:23 https://maestrodatabase.com/blog/moderna-announces-initiation-of-rolling-submission-of-biologics-license-application-with-us-fda-for-the-moderna-covid-19-vaccine 2021-06-01T12:29:32 https://maestrodatabase.com/blog/us-gao-generic-drugs-under-medicare-part-d-generic-drug-prices-declined-overall-but-some-had-extraordinary-price-increases 2016-09-13T12:28:35 https://maestrodatabase.com/blog/fda-grants-breakthrough-therapy-designation-to-usona-institutes-psilocybin-program-for-major-depressive-disorder 2019-11-22T20:53:55 https://maestrodatabase.com/blog/lannett-announces-fda-acceptance-as-a-priority-original-anda-of-the-generic-advair-diskus-filing 2021-06-01T12:20:15 https://maestrodatabase.com/blog/basilea-gets-fda-request-for-more-data-on-pneumonia-drug 2015-08-05T11:37:25 https://maestrodatabase.com/blog/tg-therapeutics-announces-fast-track-designation-granted-by-the-fda-to-ublituximab-in-combination-with-umbralisib-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia 2020-10-21T19:52:03 https://maestrodatabase.com/blog/pharmac-petition-tabled-at-parliament 2021-06-01T12:55:47 https://maestrodatabase.com/blog/federal-budget-2015-side-effect-means-sickest-patients-are-to-pay-more-for-drugs 2015-08-05T11:37:22 https://maestrodatabase.com/blog/tga-approves-new-diagnostic-agent 2016-08-31T21:13:39 https://maestrodatabase.com/blog/iqwig-commences-4-new-assessments 2015-08-05T11:37:15 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-november-2018-update 2018-10-31T02:51:44 https://maestrodatabase.com/blog/fda-approves-ibrance-for-post-menopausal-women-with-advanced-breast-cancer 2015-08-05T11:37:03 https://maestrodatabase.com/blog/additional-manufacturing-capacity-for-biontech-slash-pfizers-covid-19-vaccine 2021-06-01T20:45:20 https://maestrodatabase.com/blog/celltrion-steps-up-global-expansion-with-biosimilar-drug-and-gains-tga-approval-for-remsima 2015-08-12T20:55:07 https://maestrodatabase.com/blog/hillarys-new-generic-drug-price-proposal-better-than-expected 2016-09-06T01:09:44 https://maestrodatabase.com/blog/government-announces-funding-available-for-soliris 2015-08-05T11:37:22 https://maestrodatabase.com/blog/nice-recommended-use-of-opdivo-for-another-indication 2020-10-21T20:00:10 https://maestrodatabase.com/blog/review-of-nhs-drugs-assessment-ordered 2016-02-02T07:59:24 https://maestrodatabase.com/blog/cti-biopharma-announces-acceptance-of-nda-granted-with-priority-review-of-pacritinib-for-treatment-of-patients-with-myelofibrosis 2021-06-01T12:46:44 https://maestrodatabase.com/blog/from-our-perspective-expedited-oncology-drug-approvals 2016-01-20T10:47:52 https://maestrodatabase.com/blog/novartis-zykadia-clears-first-step-in-uk-early-access-scheme 2015-08-05T11:37:11 https://maestrodatabase.com/blog/regorafenib__hint_of_minor_added_benefit 2015-08-05T11:37:06 https://maestrodatabase.com/blog/bms-withdraws-submission-for-opdivo-for-urothelial-carcinoma 2018-03-21T11:43:38 https://maestrodatabase.com/blog/why-are-private-health-insurers-losing-money-on-obamacare 2016-10-04T21:18:37 https://maestrodatabase.com/blog/nice-u-turn-on-roches-tarceva 2015-08-05T11:37:03 https://maestrodatabase.com/blog/medicines-nz-calls-for-government-funding-of-melanoma-wonder-drug 2016-02-26T00:27:35 https://maestrodatabase.com/blog/gardasil-9-offers-wider-protection-against-cancers-caused-by-human-papillomavirus 2015-08-05T11:37:24 https://maestrodatabase.com/blog/pharmac-proposal-to-fund-a-multivitamin-for-renal-patients 2015-08-08T01:15:42 https://maestrodatabase.com/blog/covid-19-vaccines-to-be-stored-secretly-under-tight-security 2020-10-21T20:23:51 https://maestrodatabase.com/blog/novartis-drug-pkc412-midostaurin-receives-breakthrough-therapy-designation-from-the-fda-for-newly-diagnosed-flt3-mutated-acute-myeloid-leukaemia 2016-02-19T06:52:35 https://maestrodatabase.com/blog/nice-in-favour-of-another-highly-specialised-technology 2020-10-21T20:27:14 https://maestrodatabase.com/blog/nice-draft-guidance-conditionally-recommends-elosulfase-alfa-vimizim-for-treatment-of-very-rare-life-limiting-genetic-disorder 2015-09-02T21:25:31 https://maestrodatabase.com/blog/cancer-drugs-fund-a-missed-opportunity-says-mp 2015-08-05T11:37:09 https://maestrodatabase.com/blog/new-guidance-to-speed-up-development-of-antibiotics 2015-09-28T21:39:26 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---july-2014-update 2015-08-05T11:37:08 https://maestrodatabase.com/blog/a-prescription-for-americas-drug-pricing-problem 2020-10-21T20:39:21 https://maestrodatabase.com/blog/fda-approves-first-coagulation-factor-albumin-fusion-protein-to-treat-patients-with-hemophilia-b 2016-03-05T03:46:32 https://maestrodatabase.com/blog/icer-posts-draft-scoping-document-for-the-assessment-of-alzheimers-disease 2020-10-21T20:06:02 https://maestrodatabase.com/blog/eight-year-experience-of-using-hta-in-drug-reimbursement-in-south-korea 2016-06-18T02:37:31 https://maestrodatabase.com/blog/a-10-dollars-test-that-could-save-the-lives-of-five-aussie-babies-a-day-not-delivered-as-promised 2023-06-10T01:30:31 https://maestrodatabase.com/blog/heres-another-threat-to-affordable-drugs 2016-10-05T20:17:22 https://maestrodatabase.com/blog/bernie-sanders-says-price-of-alzheimers-treatment-is-unconscionable-calls-on-hhs-to-take-action 2023-06-10T01:34:58 https://maestrodatabase.com/blog/senator-criticizes-fda-delays-in-approving-generic-drugs 2016-03-08T20:53:18 https://maestrodatabase.com/blog/fda-grants-priority-review-for-sanofis-dengue-vaccine-candidate 2018-10-31T03:24:05 https://maestrodatabase.com/blog/novo-nordisk-resubmits-once-weekly-semaglutide-2-mg-for-the-treatment-of-type-2-diabetes-for-us-regulatory-approval 2021-06-01T20:52:29 https://maestrodatabase.com/blog/nice-published-draft-guidance-on-a-new-use-for-keytruda 2016-10-04T20:10:15 https://maestrodatabase.com/blog/trumps-antibody-cure-will-be-in-short-supply 2020-10-21T20:18:26 https://maestrodatabase.com/blog/confusion-over-ongoing-pbs-supply-of-life-saving-drug-soliris-to-treat-rare-condition 2015-09-18T22:17:01 https://maestrodatabase.com/blog/european-commission-approves-bristol-myers-squibbs-opdivo-nivolumab-the-first-and-only-pd-1-checkpoint-inhibitor-approved-in-europe-for-both-first-line-and-previously-treated-advanced-melanoma-patients 2015-08-05T11:37:10 https://maestrodatabase.com/blog/ema-publishes-epar-for-neparvis-sacubitril-with-valsartan 2016-06-13T10:51:28 https://maestrodatabase.com/blog/iqwig-autumn-symposium-2015-presentations-now-online 2016-01-05T20:36:01 https://maestrodatabase.com/blog/users-of-hiv-prevention-prep-urge-nhs-to-fund-life-changing-medicine 2016-08-03T03:43:55 https://maestrodatabase.com/blog/ema-commissions-independent-research-to-prepare-for-real-world-monitoring-of-covid-19-vaccines 2020-05-27T08:28:06 https://maestrodatabase.com/blog/biosimilar-names-may-affect-pharmacist-dispensing-habits 2016-08-16T11:57:32 https://maestrodatabase.com/blog/ema-publishes-agenda-for-25-28-may-2020-chmp-meeting 2020-05-27T08:30:39 https://maestrodatabase.com/blog/value-framework-initiatives-not-yet-used-in-health-plan-decision-making 2016-08-16T11:53:18 https://maestrodatabase.com/blog/more-insights-from-the-first-tranche-of-public-summary-documents-from-the-july-2018-pbac-meeting 2018-10-31T03:56:26 https://maestrodatabase.com/blog/nice_responds_to_telegraph_article_on_value_based_assessment 2015-08-05T11:37:27 https://maestrodatabase.com/blog/trends-in-utilization-of-fda-expedited-drug-development-and-approval-programs-1987-2014-cohort-study 2015-09-30T04:55:53 https://maestrodatabase.com/blog/u-dot-s-fda-approves-opdivo-nivolumab-and-yervoy-ipilimumab-combined-with-limited-chemotherapy-as-first-line-treatment-of-metastatic-or-recurrent-non-small-cell-lung-cancer 2020-05-27T07:20:09 https://maestrodatabase.com/blog/tga-fees-and-charges-summary-from-1-july-2016 2016-07-01T07:37:17 https://maestrodatabase.com/blog/novartis-cosentyx-receives-fda-approval-for-treatment-of-children-and-adolescents-with-moderate-to-severe-plaque-psoriasis 2021-06-01T21:02:39 https://maestrodatabase.com/blog/nice-issues-preliminary-recommendations-on-earlier-treatment-with-abiraterone-acetate-for-prostate-cancer 2015-08-05T11:37:21 https://maestrodatabase.com/blog/doctor-treating-patients-with-neurofibromatosis-calls-for-rectifying-inconsistent-reimbursement-standards-for-koselugo 2025-09-11T04:32:45 https://maestrodatabase.com/blog/agenda-for-3-december-2014-transparency-committee-meeting 2015-08-05T11:37:14 https://maestrodatabase.com/blog/tga-consultation-forecast 2016-04-04T07:18:19 https://maestrodatabase.com/blog/fda-files-corcepts-new-drug-application-for-relacorilant-as-a-treatment-for-patients-with-platinum-resistant-ovarian-cancer 2025-09-11T04:37:04 https://maestrodatabase.com/blog/mercks-keytruda-pembrolizumab-receives-conditional-approval-in-canada-for-the-treatment-of-advanced-melanoma 2015-08-05T11:37:13 https://maestrodatabase.com/blog/drug-prices-too-high-sometimes-theyre-not-costly-enough 2016-06-06T21:14:04 https://maestrodatabase.com/blog/santen-receives-cadth-canadian-drug-expert-committee-reimbursement-recommendation-for-verkazia-cyclosporin-0-dot-1-percent-eye-drops 2019-11-23T06:46:57 https://maestrodatabase.com/blog/a-review-of-labeling-based-on-patient-reported-outcome-endpoints-for-new-oncology-drugs-approved-by-the-ema-2017-2021 2023-06-10T02:59:04 https://maestrodatabase.com/blog/fast-thinking 2016-07-18T21:41:04 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-european-commission-approval-for-zeposia-ozanimod-for-the-treatment-of-adult-patients-with-relapsing-remitting-multiple-sclerosis-with-active-disease 2020-05-27T21:03:01 https://maestrodatabase.com/blog/france-gets-g7-to-discuss-global-regulation-of-medicine-prices 2016-05-02T21:39:30 https://maestrodatabase.com/blog/shkreli-was-right-everyones-hiking-drug-prices 2016-02-02T20:15:34 https://maestrodatabase.com/blog/nice_has_issued_new_preliminary_draft_guidance_that_does_not_recommend_bosutinib__bosulif__for_previously_treated_cml 2015-08-05T11:37:17 https://maestrodatabase.com/blog/prospective-dialogue-between-developers-and-regulators-makes-for-better-evidence-generation 2020-05-27T21:08:01 https://maestrodatabase.com/blog/caldolor-launched-in-australia-for-treatment-of-pain-and-fever 2015-11-24T07:23:42 https://maestrodatabase.com/blog/paediatric-drug-and-other-shortages-in-the-age-of-supply-chain-disruption 2023-06-10T02:52:52 https://maestrodatabase.com/blog/roche-receives-eu-approval-of-cotellic-for-use-in-combination-with-zelboraf-in-advanced-melanoma 2015-11-26T20:42:04 https://maestrodatabase.com/blog/cut-cost-of-vital-breast-cancer-drug-before-nhs-stops-funding-its-70000-a-year-price-charity-begs-drug-giant 2015-10-29T20:20:39 https://maestrodatabase.com/blog/hiv-prevention-drug-truvada-wont-be-subsidised-in-australia-anytime-soon 2016-08-19T20:58:46 https://maestrodatabase.com/blog/nice-recommends-treatment-for-type-of-small-cell-lung-cancer 2020-05-27T20:54:21 https://maestrodatabase.com/blog/integrating-randomized-comparative-effectiveness-research-with-patient-care 2016-06-01T23:21:27 https://maestrodatabase.com/blog/using-real-world-data-in-health-technology-assessment-hta-practice-a-comparative-study-of-five-hta-agencies 2018-03-21T19:49:34 https://maestrodatabase.com/blog/nice-issues-draft-guidance-on-the-use-of-talimogene-laherparepvec 2016-08-09T11:36:24 https://maestrodatabase.com/blog/health-canada-approves-slenyto---extended-release-melatonin-formulation---as-a-prescription-drug-for-insomnia-in-children-with-autism-spectrum-disorder-and-smith-magenis-syndrome 2025-09-11T05:45:28 https://maestrodatabase.com/blog/transfer_of_the_pan_canadian_oncology_drug_review__pcodr__to_cadth 2015-08-05T11:37:26 https://maestrodatabase.com/blog/new-tools-for-assessing-drug-value-havent-caught-on-with-payers-yet 2016-07-27T12:14:56 https://maestrodatabase.com/blog/fda-approves-mercks-keytruda-pembrolizumab-in-combination-with-carboplatin-and-either-paclitaxel-or-nab-paclitaxel-for-the-first-line-treatment-of-patients-with-metastatic-squamous-non-small-cell-lung-cancer 2018-10-31T05:53:50 https://maestrodatabase.com/blog/cancer-drugs-arent-as-cost-effective-as-they-used-to-be 2015-09-30T20:29:28 https://maestrodatabase.com/blog/nice-issues-final-guidance-on-nhs-use-of-bayers-vitrakvi 2020-05-27T20:58:22 https://maestrodatabase.com/blog/pharmac-updates-its-list-of-funding-applications 2016-08-04T12:15:56 https://maestrodatabase.com/blog/proposal-for-supply-of-diltiazem-hydrochloride-apo-diltiazem-cd 2015-08-05T11:37:21 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits-1-july-2016-update 2016-06-30T21:59:10 https://maestrodatabase.com/blog/activists-urge-ottawa-to-fund-$1-million-treatment-for-rare-disease 2018-03-21T20:13:35 https://maestrodatabase.com/blog/accc-should-inspect-medical-devices-list 2016-09-25T11:40:09 https://maestrodatabase.com/blog/fda-grants-amgen-priority-review-for-kyprolis-carfilzomib-supplemental-new-drug-application-for-the-treatment-of-relapsed-multiple-myeloma 2015-08-05T11:37:17 https://maestrodatabase.com/blog/summary-of-responses-to-pharmacs-consultation-on-improving-access-to-medicines-and-devices-in-primary-care 2016-02-11T02:33:20 https://maestrodatabase.com/blog/dbv-technologies-receives-fda-breakthrough-therapy-designation-for-viaskin-peanut-for-the-treatment-of-peanut-allergy-in-children 2015-08-05T11:37:30 https://maestrodatabase.com/blog/we-need-to-have-a-difficult-conversation-about-albertas-health-care-costs 2018-03-21T20:01:54 https://maestrodatabase.com/blog/csl-completes-novartis-flu-vaccine-deal 2015-08-05T11:37:12 https://maestrodatabase.com/blog/pfizer-ceo-business-as-normal-on-drug-prices-next-year-despite-trump-pressure 2018-10-31T06:03:53 https://maestrodatabase.com/blog/ema-publishes-agenda-for-march-19-22-chmp-meeting 2018-03-21T20:04:54 https://maestrodatabase.com/blog/cadth-calls-for-patient-input-on-submissions-from-daiichi-sankyo-for-edoxaban-tosylate 2016-06-08T21:47:35 https://maestrodatabase.com/blog/nice-nod-for-bis-lung-scarring-drug-ofev 2015-09-11T22:12:22 https://maestrodatabase.com/blog/record-flu-vaccines-in-2020-to-protect-australians 2020-05-27T21:13:15 https://maestrodatabase.com/blog/health-canada-approves-imbruvica-by-priority-review-giving-physicians-and-patients-a-much-needed-option-in-the-fight-against-cll 2015-08-05T11:37:26 https://maestrodatabase.com/blog/covid-19-uk-authorises-anti-viral-drug-remdesivir 2020-05-27T21:17:09 https://maestrodatabase.com/blog/fda-and-access-to-medications 2016-09-21T21:25:58 https://maestrodatabase.com/blog/summary_of_outcomes_from_the_march_2013_pbac_meeting 2015-08-05T11:37:20 https://maestrodatabase.com/blog/nice-backs-non-surgical-option-for-fibroids 2016-08-26T11:32:59 https://maestrodatabase.com/blog/trump-tries-to-convince-voters-hes-lowered-drug-prices-based-only-on-a-modest-tweak-to-medicare 2020-05-27T21:19:37 https://maestrodatabase.com/blog/fda-approves-first-hpv-test-for-use-with-surepath-preservative-fluid 2016-07-08T23:42:34 https://maestrodatabase.com/blog/sun-pharma-announces-u-dot-s-fda-approval-of-ilumya-tildrakizumab-asmn-for-the-treatment-of-moderate-to-severe-plaque-psoriasis 2018-03-21T20:25:02 https://maestrodatabase.com/blog/medical-groups-call-on-mps-to-back-60-day-prescribing-as-labor-backbench-wobbles 2023-06-10T04:24:57 https://maestrodatabase.com/blog/elafibranor-for-the-treatment-of-patients-with-primary-biliary-cholangitis 2024-11-14T04:56:38 https://maestrodatabase.com/blog/us-fda-grants-breakthrough-therapy-designation-for-roches-investigational-cancer-immunotherapy-mpdl3280a-anti-pdl1-in-non-small-cell-lung-cancer 2015-08-05T11:37:23 https://maestrodatabase.com/blog/insulin-degludec-no-hint-of-added-benefit-in-children-and-adolescents 2015-08-05T11:37:03 https://maestrodatabase.com/blog/revised-procedure-for-providing-cadth-review-teams-responses 2016-02-28T22:17:02 https://maestrodatabase.com/blog/cadth-calls-for-feedback-on-cancer-biomarker-testing 2015-11-04T20:44:41 https://maestrodatabase.com/blog/trump-admin-keeping-drug-price-info-under-wraps 2018-03-21T20:42:11 https://maestrodatabase.com/blog/us-drug-company-sues-canada-for-trying-to-lower-cost-of-700k-a-year-drug 2015-09-26T07:06:21 https://maestrodatabase.com/blog/nice-consults-on-draft-guidance-on-the-drug-simeprevir-sodium-olysio-for-treating-hepatitis-c 2015-08-05T11:37:29 https://maestrodatabase.com/blog/cvs-taps-an-eli-lilly-exec-to-run-its-pbm-glaxo-pharma-chief-cuts-his-budget 2018-03-21T20:45:13 https://maestrodatabase.com/blog/tga-publishes-auspar-for-emtricitabine-with-elvitegravir-and-cobicistat-and-tenofovir-alafenamide-fumarate-genvoya 2016-07-05T21:53:13 https://maestrodatabase.com/blog/fennec-pharmaceuticals-receives-fast-track-designation-by-fda-for-pedmark 2018-03-21T20:31:23 https://maestrodatabase.com/blog/european-commission-approves-esmya-5-mg-for-intermittent-treatment-in-the-long-term-management-of-uterine-fibroids-myomas 2015-08-05T11:37:17 https://maestrodatabase.com/blog/fda-approves-differin-gel-01-for-over-the-counter-use-to-treat-acne 2016-07-08T23:38:02 https://maestrodatabase.com/blog/intermune-announces-resubmission-of-nda-for-pirfenidone-for-the-treatment-of-patients-with-ipf 2015-08-05T11:37:21 https://maestrodatabase.com/blog/medical-research-future-fund-bill-passes 2015-08-12T12:26:05 https://maestrodatabase.com/blog/fda-approves-pradaxa-dabigatran-etexilate-mesylate-for-prophylaxis-of-deep-venous-thrombosis-and-pulmonary-embolism-after-hip-replacement-surgery 2015-11-24T20:22:00 https://maestrodatabase.com/blog/cadth-calls-for-patient-input-on-two-submissions 2015-08-08T04:10:09 https://maestrodatabase.com/blog/cancer-drugs-fund-makes-no-sense 2015-08-05T11:37:04 https://maestrodatabase.com/blog/ema-publishes-agenda-for-11-14-november-2024-chmp-meeting 2024-11-14T06:49:59 https://maestrodatabase.com/blog/quebec-becomes-the-first-province-to-fund-gazyva-for-patients-with-most-common-form-of-leukaemia 2015-08-05T11:37:17 https://maestrodatabase.com/blog/pbs-medicines-save-7-billion-in-hospital-costs 2015-11-25T06:44:51 https://maestrodatabase.com/blog/this-cancer-doctor-is-leading-the-attack-on-astronomical-drug-prices 2015-08-05T11:37:08 https://maestrodatabase.com/blog/the-economics-of-alternative-payment-models-for-pharmaceuticals 2021-06-02T01:22:00 https://maestrodatabase.com/blog/prostate-cancer-treatment-to-be-funded-from-1-may 2015-08-05T11:37:02 https://maestrodatabase.com/blog/agenda-for-the-8-june-2016-tc-meeting 2016-06-02T00:08:24 https://maestrodatabase.com/blog/enhertu-type-ii-variation-application-validated-in-the-eu-for-previously-treated-patients-with-her2-positive-metastatic-solid-tumours 2025-09-11T06:53:04 https://maestrodatabase.com/blog/takeda-announces-european-medicines-agency-acceptance-of-ixazomibs-marketing-authorisation-application-for-patients-with-relapsedrefractory-multiple-myeloma 2015-08-21T10:52:40 https://maestrodatabase.com/blog/dbv-technologies-receives-fda-fast-track-designation-for-viaskin-milk-for-the-treatment-of-cows-milk-protein-allergy 2016-09-21T21:03:45 https://maestrodatabase.com/blog/the-story-and-the-numbers 2015-10-29T20:49:04 https://maestrodatabase.com/blog/european-chmp-adopts-positive-opinion-for-genzymes-cerdelga-eliglustat-capsules 2015-08-05T11:37:30 https://maestrodatabase.com/blog/antiviral_drug_stockpile_a_waste_of_money__says_study 2015-08-05T11:37:04 https://maestrodatabase.com/blog/canadas-erc-recommends-the-funding-of-revlimid-lenalidomide-for-patients-with-newly-diagnosed-multiple-myeloma 2015-12-15T20:09:05 https://maestrodatabase.com/blog/diabetics-fear-for-health-after-government-removes-blood-sugar-test-subsidy 2016-07-17T08:25:18 https://maestrodatabase.com/blog/pharmac-decision-criteria-review-final-decision 2015-08-05T11:37:29 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-jun-2019-update 2019-06-01T03:27:46 https://maestrodatabase.com/blog/agenda-for-the-march-2015-pbac-meeting 2015-08-05T11:37:14 https://maestrodatabase.com/blog/statement-by-the-pbac---safety-of-biosimilar-medicines 2015-08-05T11:37:26 https://maestrodatabase.com/blog/nice-to-retire-guidance-app 2018-10-31T11:44:24 https://maestrodatabase.com/blog/the-next-chapter-in-cost-effectiveness-analysis 2016-09-13T21:29:12 https://maestrodatabase.com/blog/nice-issues-draft-guidance-on-evolocumab-for-lipid-disorder 2015-11-19T10:15:18 https://maestrodatabase.com/blog/us-health-insurers-push-to-tie-drug-prices-to-outcomes 2016-05-11T21:46:23 https://maestrodatabase.com/blog/how-nice-can-get-innovative-cancer-meds-into-nhs-1 2015-08-05T11:37:19 https://maestrodatabase.com/blog/us-fda-accepts-eisais-nda-for-banzel-rufinamide-as-adjunctive-treatment-in-paediatric-patients-with-lennox-gastaut-syndrome 2015-08-05T11:37:07 https://maestrodatabase.com/blog/cadth-lecture-series--dr-jeffrey-hoch 2015-08-05T11:37:11 https://maestrodatabase.com/blog/patients-with-rare-disease-get-free-access-to-life-saving-wonder-drug 2018-10-31T19:44:39 https://maestrodatabase.com/blog/added-benefit-and-revenues-of-oncology-drugs-approved-by-the-ema-between-1995-and-2020-retrospective-cohort-study 2024-02-29T02:43:17 https://maestrodatabase.com/blog/stakeholder-engagement-session-phase-ii-of-the-transfer-of-pcodr-to-cadth-1 2015-08-05T11:37:14 https://maestrodatabase.com/blog/strengthening-interaction-with-academia 2016-06-30T21:08:35 https://maestrodatabase.com/blog/fda-approves-expanded-indication-for-two-transcatheter-heart-valves-for-patients-at-intermediate-risk-for-death-or-complications-associated-with-open-heart-surgery 2016-08-18T20:55:53 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-november-2018-update 2018-10-31T12:13:20 https://maestrodatabase.com/blog/fda-grants-priority-review-for-roches-cancer-immunotherapy-atezolizumab-in-specific-type-of-lung-cancer 2016-04-11T10:14:24 https://maestrodatabase.com/blog/cadth-calls-for-patient-input-on-a-new-submission-from-sanofi-for-praluent 2015-12-07T19:49:48 https://maestrodatabase.com/blog/us-fda-approves-juvederm-ultra-xc-for-use-in-lips 2015-10-02T00:18:20 https://maestrodatabase.com/blog/hospira-submits-new-biologics-license-application-to-us-fda-for-proposed-epoetin-alfa-biosimilar 2015-08-05T11:37:02 https://maestrodatabase.com/blog/sandoz-receives-us-fda-approval-for-biosimilar-hyrimoz-adalimumab-adaz 2018-10-31T19:57:51 https://maestrodatabase.com/blog/2-valeant-dermatology-drugs-lead-steep-price-increases-study-finds 2015-11-26T11:14:21 https://maestrodatabase.com/blog/qubec-becomes-first-canadian-province-to-add-victoza-to-the-drug-benefit-formulary-for-the-treatment-of-type-2-diabetes 2015-08-05T11:37:10 https://maestrodatabase.com/blog/tga-publishes-auspar-for-xiaflex 2016-08-05T01:18:40 https://maestrodatabase.com/blog/infringement-procedure-against-roche-ema-update 2016-07-04T12:40:30 https://maestrodatabase.com/blog/cancer-patients-call-for-vitamin-c-infusion-to-be-affordable 2018-10-31T19:49:50 https://maestrodatabase.com/blog/leo-pharma-announces-fda-approval-of-adbry-tralokinumab-as-the-first-and-only-treatment-specifically-targeting-il-13-for-adults-with-moderate-to-severe-atopic-dermatitis 2021-12-29T07:12:43 https://maestrodatabase.com/blog/samsung-targets-us-drug-market-with-remicade-knockoff 2016-05-24T10:48:25 https://maestrodatabase.com/blog/fda-accepts-bla-filing-for-synagevas-kanuma-sebelipase-alfa-grants-priority 2015-08-05T11:37:04 https://maestrodatabase.com/blog/working-with-stakeholders-to-improve-availability-of-medicines-in-the-eu 2018-10-31T19:55:10 https://maestrodatabase.com/blog/vertex-receives-eu-approval-for-orkambi-lumacaftorivacaftor-the-first-medicine-to-treat-the-underlying-cause-of-cystic-fibrosis-in-people-ages-12-and-older-with-two-copies-of-the-f508del-mutation 2015-11-23T20:11:34 https://maestrodatabase.com/blog/added_benefit_of_saxagliptin_hydrochloride_as_monotherapy_is_not_proven 2015-08-05T11:37:18 https://maestrodatabase.com/blog/fda-approves-bayers-finacea-azelaic-acid-15-foam-for-the-topical-treatment-of-the-inflammatory-papules-and-pustules-of-mild-to-moderate-rosacea 2015-08-05T11:37:25 https://maestrodatabase.com/blog/fda-approves-new-pill-to-treat-certain-patients-with-non-small-cell-lung-cancer 2015-11-14T19:02:15 https://maestrodatabase.com/blog/icer-posts-draft-scoping-document-for-the-assessment-of-esketamine-for-treatment-resistant-depression 2018-10-31T20:09:49 https://maestrodatabase.com/blog/access-to-medicines-working-group-amwg-communique---28-october-2014 2015-08-05T11:37:19 https://maestrodatabase.com/blog/icer-posts-draft-scoping-document-for-the-assessment-of-siponimod-for-the-treatment-of-secondary-progressive-multiple-sclerosis 2018-10-31T20:04:59 https://maestrodatabase.com/blog/moventig-approved-in-the-european-union-for-opioid-induced-constipation 2015-08-05T11:37:22 https://maestrodatabase.com/blog/priority-review-granted-to-ascentage-pharmas-new-drug-application-for-olverembatinib-hqp1351-the-first-third-generation-bcr-abl-inhibitor-in-china 2020-10-21T23:42:16 https://maestrodatabase.com/blog/_lift_unfair_ban_on_prostate_cancer_drug___says_tv_s_sir_michael_parkinson 2015-08-05T11:37:11 https://maestrodatabase.com/blog/va-extends-new-hepatitis-c-drugs-to-all-veterans-in-its-health-system 2016-08-11T21:28:12 https://maestrodatabase.com/blog/nice-to-seek-greater-access-to-clinical-trial-data-when-appraising-drugs 2015-08-05T11:37:12 https://maestrodatabase.com/blog/decision-to-list-tobramycin-powder-and-widen-access-to-clarithromycin-infusion 2015-08-05T11:37:15 https://maestrodatabase.com/blog/industry-group-wants-fda-to-stop-drug-importation-study 2018-10-31T20:19:52 https://maestrodatabase.com/blog/post-market-review-of-authority-required-pbs-listings 2015-09-04T12:34:38 https://maestrodatabase.com/blog/fda-grants-priority-review-of-nucala-for-patients-with-hypereosinophilic-syndrome 2020-05-27T23:27:44 https://maestrodatabase.com/blog/drug-prices-tweaking-the-formula 2016-04-25T21:48:15 https://maestrodatabase.com/blog/new-fda-documents-reveal-history-breakthrough-therapy-designation-for-epclusa 2016-08-08T21:51:39 https://maestrodatabase.com/blog/fda-fails-to-adequately-track-safety-of-expedited-drugs 2016-03-08T20:50:05 https://maestrodatabase.com/blog/oral_cancer_drugs__group_pushes_for_universal_coverage 2015-08-05T11:37:24 https://maestrodatabase.com/blog/acadia-pharmaceuticals-submits-new-drug-application-for-nuplazid-for-the-treatment-of-parkinsons-disease-psychosis 2015-09-03T21:19:49 https://maestrodatabase.com/blog/medical-cannabis-user-finds-prescription-unaffordable-now-that-recreational-weed-is-legal 2018-10-31T20:15:32 https://maestrodatabase.com/blog/u-dot-s-fda-grants-fast-track-designation-for-asp0367-slash-ma-0211-a-selective-ppard-modulator-being-developed-for-the-treatment-of-primary-mitochondrial-myopathies 2020-10-21T23:10:13 https://maestrodatabase.com/blog/drug-companies-really-dont-care-about-the-price-hike-backlash 2016-07-14T21:41:00 https://maestrodatabase.com/blog/qalsody-has-update 2024-11-14T21:30:15 https://maestrodatabase.com/blog/request-for-proposal-supply-of-anti-vascular-endothelial-growth-factor-agents 2016-05-05T11:45:44 https://maestrodatabase.com/blog/smc_advice___march_2014 2015-08-05T11:37:15 https://maestrodatabase.com/blog/10-000-dollars-on-new-drugs-every-four-months-keeps-melanoma-patient-alive 2020-10-22T00:29:09 https://maestrodatabase.com/blog/europe-approves-jjs-imbruvica-for-blood-cancers 2015-08-05T11:37:12 https://maestrodatabase.com/blog/insiders-say-nice-is-being-encouraged-to-be-more-favourable-to-industry 2015-08-05T11:37:11 https://maestrodatabase.com/blog/fda-authorises-first-direct-to-consumer-test-for-detecting-genetic-variants-that-may-be-associated-with-medication-metabolism 2018-10-31T22:06:18 https://maestrodatabase.com/blog/aggressive-stance-to-health-reform-will-backfire-warns-ley 2016-09-28T20:42:04 https://maestrodatabase.com/blog/specialized-therapeutics-grants-sublicense-for-anti-emetic-products-to-mundipharma 2016-03-08T07:13:10 https://maestrodatabase.com/blog/medicine-for-rare-disease-made-free-on-the-life-saving-drugs-program 2018-10-31T22:09:29 https://maestrodatabase.com/blog/sage-receives-fda-breakthrough-therapy-designation-for-sage-547-for-the-treatment-of-postpartum-depression 2016-09-07T21:39:57 https://maestrodatabase.com/blog/mylan-epipen-us-prices-hikes-unlikely-to-be-experienced-in-australia-experts-say 2016-08-25T07:38:15 https://maestrodatabase.com/blog/fda-approves-fewer-generics-in-fy2020-ending-record-streak 2020-10-21T23:54:15 https://maestrodatabase.com/blog/tga-regulation-of-biosimilar-medicines 2015-12-17T20:28:53 https://maestrodatabase.com/blog/pfizer-announces-fda-acceptance-of-palbociclib-new-drug-application-with-priority-review 2015-08-05T11:37:27 https://maestrodatabase.com/blog/nice-consults-on-ovarian-cancer-treatments-draft-guidance 2015-11-25T06:58:34 https://maestrodatabase.com/blog/update--6th-community-pharmacy-agreement 2015-08-05T11:37:16 https://maestrodatabase.com/blog/fda-expands-use-of-xalkori-to-treat-rare-form-of-advanced-non-small-cell-lung-cancer 2016-03-11T21:13:02 https://maestrodatabase.com/blog/new-anti-cancer-drugs-associated-with-large-increases-in-costs-and-life-expectancy 2016-09-07T21:48:00 https://maestrodatabase.com/blog/sta-announces-breakthrough-cancer-drug-abraxane-to-be-pbs-listed-for-metastatic-pancreatic-cancer 2015-08-05T11:37:16 https://maestrodatabase.com/blog/boehringer-ingelheims-new-lung-drug-to-cost-96000 2015-08-05T11:37:24 https://maestrodatabase.com/blog/fda-nominee-sails-through-senate-committee-but-could-a-fish-stand-in-his-way 2016-01-14T20:58:47 https://maestrodatabase.com/blog/public-advises-nice-on-value-of-care 2015-08-05T11:37:20 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-june-2019 2019-06-01T04:16:59 https://maestrodatabase.com/blog/alkermes-submits-new-drug-application-to-fda-for-aripiprazole-lauroxil-for-treatment-of-schizophrenia 2015-08-05T11:37:20 https://maestrodatabase.com/blog/heron-announces-fda-submission-of-htx-011-nda-for-post-operative-pain-management 2018-10-31T23:56:32 https://maestrodatabase.com/blog/nivolumab-in-advanced-lung-cancer-evidence-for-significant-additional-benefits 2016-08-03T04:09:52 https://maestrodatabase.com/blog/merck-criticises-nice-no-to-personalised-bowel-cancer-drugs 2015-11-19T20:39:17 https://maestrodatabase.com/blog/tga-approves-alirocumab-praluent 2016-05-19T21:24:23 https://maestrodatabase.com/blog/us-fda-approves-belviq-xr-a-once-daily-formulation-of-lorcaserin-for-chronic-weight-management 2016-07-20T21:22:58 https://maestrodatabase.com/blog/patients-health-organisations-band-together-to-bring-breakthrough-treatments-to-canada-sooner 2020-10-22T04:57:10 https://maestrodatabase.com/blog/nice-ok-for-biogen-ms-pill-tecfidera 2015-08-05T11:37:23 https://maestrodatabase.com/blog/consultation-on-draft-type-2-diabetes-medicines-report 2015-08-05T11:37:26 https://maestrodatabase.com/blog/abbvies-venetoclax-receives-breakthrough-therapy-designation-from-fda-in-combination-with-rituximab-for-the-treatment-of-patients-with-relapsedrefractory-chronic-lymphocytic-leukaemia 2016-01-20T19:59:09 https://maestrodatabase.com/blog/eylea-aflibercept-injection-receives-eu-approval-for-the-treatment-of-diabetic-macular-oedema 2015-08-05T11:37:02 https://maestrodatabase.com/blog/nice-kadcyla-price-still-too-high 2015-11-17T11:04:11 https://maestrodatabase.com/blog/fda-approves-stelara-ustekinumab-for-treatment-of-adults-with-moderately-to-severely-active-crohns-disease 2016-09-27T05:15:32 https://maestrodatabase.com/blog/haemophilia-treatments-funding-proposal 2015-08-05T11:37:30 https://maestrodatabase.com/blog/proposal-to-list-cholic-acid-cholebiol-for-rare-disorder 2016-06-28T04:36:43 https://maestrodatabase.com/blog/pharma-and-nice-reject-view-nhs-pays-too-much-for-meds 2015-08-05T11:37:07 https://maestrodatabase.com/blog/idelvion-now-registered-by-australia 2016-09-27T11:23:23 https://maestrodatabase.com/blog/scynexis-announces-fda-approval-of-brexafemme-ibrexafungerp-tablets-as-the-first-and-only-oral-non-azole-treatment-for-vaginal-yeast-infections 2021-06-02T20:40:41 https://maestrodatabase.com/blog/appliedvr-receives-fda-breakthrough-device-designation-to-treat-pain-with-digital-therapeutic 2020-10-22T05:24:12 https://maestrodatabase.com/blog/pcodr_recommends_the_funding_of_regorafenib__stivarga__for_patients_with_metastatic_gist 2015-08-05T11:37:05 https://maestrodatabase.com/blog/g_ba_finds_that_constella__linaclotide__provides_no_added_benefit_as_a_treatment_for_adults_with_irritable_bowel_syndrome_with_constipation__ibs_c_ 2015-08-05T11:37:16 https://maestrodatabase.com/blog/liquidia-announces-fda-acceptance-of-new-drug-application-resubmission-for-liq861-treprostinil-inhalation-powder 2021-06-02T20:46:57 https://maestrodatabase.com/blog/rockwell-medical-announces-fda-acceptance-for-filing-of-triferic-new-drug-application 2015-08-05T11:37:30 https://maestrodatabase.com/blog/praluent-recommended-for-approval-to-lower-cholesterol 2015-08-05T11:37:09 https://maestrodatabase.com/blog/nivolumab-in-non-small-cell-lung-cancer-indication-of-major-added-benefit-for-under-75-year-olds 2015-11-18T10:32:50 https://maestrodatabase.com/blog/funding-of-abiraterone-and-other-products-supplied-by-janssen 2015-08-05T11:37:29 https://maestrodatabase.com/blog/pharmac-works-well-unless-youre-sick 2021-06-02T08:54:43 https://maestrodatabase.com/blog/meeting-highlights-from-the-committee-for-medicinal-products-for-human-use-chmp-19-22-october-2015 2015-10-24T01:49:18 https://maestrodatabase.com/blog/amarin-corporation-announces-anchor-complete-response-letter-from-fda-on-vascepa 2015-08-05T11:37:03 https://maestrodatabase.com/blog/fearing-drugs-rare-side-effects-millions-take-their-chances-with-osteoporosis 2016-06-02T22:55:00 https://maestrodatabase.com/blog/fda-approves-first-automated-insulin-delivery-device-for-type-1-diabetes 2016-09-28T20:51:57 https://maestrodatabase.com/blog/fda-approves-new-antifungal-drug-cresemba 2015-08-05T11:37:18 https://maestrodatabase.com/blog/pancreatic-cancer-patients-denied-life-extending-drug-by-spending-watchdog 2015-09-17T20:55:17 https://maestrodatabase.com/blog/nice-draft-guidance-does-not-recommend-risdiplam-for-treating-spinal-muscular-atrophy 2021-06-02T08:58:18 https://maestrodatabase.com/blog/health_canada_approves_stivarga__regorafenib__as_a_new_treatment_option_for_patients_with_gist__a_rare_form_of_sarcoma 2015-08-05T11:37:25 https://maestrodatabase.com/blog/how_much_should_the_nhs_pay_for_a_qaly_ 2015-08-05T11:37:10 https://maestrodatabase.com/blog/boehringer-ingelheim-and-zealand-pharma-receive-fda-fast-track-designation-for-investigational-treatment-for-nash 2021-06-02T21:01:22 https://maestrodatabase.com/blog/new-zealand-budget-2016-extra-22-billion-pumped-into-health 2016-05-26T11:25:52 https://maestrodatabase.com/blog/migalastat-galafold-included-on-the-life-saving-drugs-program 2018-11-01T00:28:22 https://maestrodatabase.com/blog/health-insurers-hit-back-after-minister-rejects-premium-rise 2019-11-24T20:22:46 https://maestrodatabase.com/blog/more-on-nice-recommendation-of-imlygic 2016-09-29T05:34:33 https://maestrodatabase.com/blog/originator-list-for-pbs-medicines-on-f2-formulary---stakeholder-consultation 2015-08-05T11:37:16 https://maestrodatabase.com/blog/today-is-rare-disease-day 2024-02-29T10:10:15 https://maestrodatabase.com/blog/propaganda-or-the-cost-of-innovation-challenging-the-high-price-of-new-drugs 2016-03-20T00:59:19 https://maestrodatabase.com/blog/bausch-health-and-clearside-biomedical-announce-u-dot-s-fda-filing-acceptance-for-xipere-triamcinolone-acetonide-suprachoroidal-injectable-suspension 2021-06-02T21:05:21 https://maestrodatabase.com/blog/pcodr-recommends-pomalyst-pomalidmide-for-patients-with-relapsed-or-refractory-multiple-myeloma-final 2015-08-05T11:37:21 https://maestrodatabase.com/blog/many-need-to-shop-around-on-healthcaregov-as-prices-jump-us-says 2015-11-01T11:03:05 https://maestrodatabase.com/blog/drugs-for-chronic-hepatitis-c 2015-08-05T11:37:09 https://maestrodatabase.com/blog/update-on-the-australia-canada-mutual-recognition-agreement 2018-11-01T00:25:24 https://maestrodatabase.com/blog/australia-avoids-risky-business-of-coronavirus-vaccine-sweepstakes 2020-05-28T01:10:57 https://maestrodatabase.com/blog/fda-approves-first-mri-guided-focused-ultrasound-device-to-treat-essential-tremor 2016-07-11T20:54:53 https://maestrodatabase.com/blog/amryt-announces-fda-acceptance-of-new-drug-application-for-oleogel-s10-for-the-treatment-of-epidermolysis-bullosa 2021-06-02T20:51:01 https://maestrodatabase.com/blog/tga-approves-ida 2016-05-20T01:45:30 https://maestrodatabase.com/blog/agenda-for-the-7-october-2015-tc-meeting 2015-10-03T22:00:20 https://maestrodatabase.com/blog/eu-court-advised-to-quash-german-prescription-drug-price-floor 2016-06-02T21:38:55 https://maestrodatabase.com/blog/david-camerons-flagship-cancer-drugs-fund-is-a-waste-of-nhs-cash 2015-08-05T11:37:13 https://maestrodatabase.com/blog/kedrion-and-kamada-announce-fda-approval-of-kedrab-label-update-confirming-safety-and-effectiveness-in-children 2021-06-02T20:56:09 https://maestrodatabase.com/blog/abbvies-holkira-pak-now-reimbursed-in-all-four-atlantic-provinces 2015-10-22T07:09:29 https://maestrodatabase.com/blog/promoting-therapeutic-innovation-what-do-we-do-about-drug-device-combinations 2016-03-01T23:08:30 https://maestrodatabase.com/blog/i-would-not-want-to-be-a-cancer-patient-in-england-says-pfizer-boss 2016-02-11T20:41:44 https://maestrodatabase.com/blog/agenda-for-23-26-march-2015-chmp-meeting 2015-08-05T11:37:30 https://maestrodatabase.com/blog/experts-expect-to-see-second-wave-of-biosimilars-approvals 2021-06-02T21:25:23 https://maestrodatabase.com/blog/cancer-drugs-fund-cuts-23-treatments 2015-09-04T21:11:58 https://maestrodatabase.com/blog/amgen-submits-application-to-fda-for-new-delivery-option-for-monthly-administration-of-repatha-evolocumab 2015-09-11T21:56:31 https://maestrodatabase.com/blog/generic-crestor-wins-approval-dealing-a-blow-to-astrazeneca 2016-07-24T21:29:07 https://maestrodatabase.com/blog/allergan-confirms-generic-abraxane-patent-challenge 2016-03-19T21:35:18 https://maestrodatabase.com/blog/summit-therapeutics-receives-fda-fast-track-designation-for-novel-antibiotic-smt19969-in-the-treatment-of-c-difficile-infection 2015-08-05T11:37:11 https://maestrodatabase.com/blog/swiss-regulator-approves-roche-regeneron-covid-19-drug 2021-12-29T20:46:24 https://maestrodatabase.com/blog/bristol-myers-squibb-announces-multiple-regulatory-milestones-for-opdivo-nivolumab-in-the-us-and-the-european-union 2015-08-05T11:37:06 https://maestrodatabase.com/blog/proposal-to-list-lidocaine-4-cream 2015-08-05T11:37:22 https://maestrodatabase.com/blog/lupin-announces-u-dot-s-fda-acceptance-for-pegfilgrastim-biosimilar-application 2021-06-02T21:29:29 https://maestrodatabase.com/blog/cadth-report-on-drugs-for-pulmonary-arterial-hypertension 2015-08-05T11:37:17 https://maestrodatabase.com/blog/nice-no-to-roches-risdiplam-for-sma-not-unexpected-says-patient-group 2021-06-02T21:11:39 https://maestrodatabase.com/blog/dutton-wont-intervene-in-cf-drug-listing 2015-08-05T11:37:21 https://maestrodatabase.com/blog/janssen-covid-19-booster-shot-approved-in-switzerland 2021-12-29T20:27:55 https://maestrodatabase.com/blog/amgens-cholesterol-buster-repatha-turned-down-for-nhs-use 2015-11-18T12:25:15 https://maestrodatabase.com/blog/private-healthcare-australia-blames-steep-health-premiums-on-fixed-prices-for-medical-devices 2016-08-22T11:31:17 https://maestrodatabase.com/blog/fda-accepts-bpls-amended-bla-submission-for-coagadex-coagulation-factor-x-human 2015-08-05T11:37:29 https://maestrodatabase.com/blog/enzalutamide-to-be-reimbursed-via-pbs-for-the-management-of-castration-resistant-metastatic-prostate-cancer-for-men-whose-disease-has-progressed-on-or-after-docetaxel-therapy 2015-08-05T11:37:20 https://maestrodatabase.com/blog/roche-seeks-to-avoid-cancer-drug-drama-with-uk-price-talks 2016-04-04T20:59:33 https://maestrodatabase.com/blog/twenty-five-years-of-prescription-opioid-use-in-australia-a-whole-of-population-analysis-using-pharmaceutical-claims 2016-03-24T06:03:33 https://maestrodatabase.com/blog/health-canada-approves-opdivo-nivolumab-plus-yervoy-ipilimumab-as-the-first-and-only-immunotherapy-treatment-for-previously-untreated-unresectable-malignant-pleural-mesothelioma 2021-06-02T21:18:12 https://maestrodatabase.com/blog/fda-approves-orbactiv-to-treat-skin-infections 2015-08-05T11:37:25 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-march-2024 2024-02-29T20:23:49 https://maestrodatabase.com/blog/jardiance-recommended-by-cadth-for-use-in-combination-with-metformin-hydrochloride-and-a-sulphonylurea 2015-10-22T03:25:10 https://maestrodatabase.com/blog/call-for-patient-input-4 2015-08-05T11:37:07 https://maestrodatabase.com/blog/pharmac-to-seek-further-advice-on-azithromycin-funding-proposal 2016-06-10T00:32:48 https://maestrodatabase.com/blog/pharmaceutical-policy-reform-balancing-affordability-with-incentives-for-innovation 2016-02-28T22:12:42 https://maestrodatabase.com/blog/prescription-medicines-tga-annual-report-for-2015-part-3-timelines 2016-05-26T12:26:28 https://maestrodatabase.com/blog/indapta-therapeutics-receives-us-fda-fast-track-designation-for-lead-clinical-drug-candidate-idp-023-for-non-hodgkins-lymphoma-and-myeloma 2024-02-29T20:18:57 https://maestrodatabase.com/blog/the-future-of-cardiovascular-medicine-from-the-regulatory-perspective 2016-08-11T01:39:38 https://maestrodatabase.com/blog/new-drugs-available-after-cancer-drugs-fund-revamp 2016-07-30T01:03:34 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1--july-2015-update 2015-08-05T11:37:13 https://maestrodatabase.com/blog/valemetostat-new-drug-application-submitted-in-japan-for-treatment-of-patients-with-adult-t-cell-leukaemia-slash-lymphoma 2021-12-29T20:58:21 https://maestrodatabase.com/blog/house-looks-to-weaken-medicare-negotiation 2024-02-29T20:15:28 https://maestrodatabase.com/blog/outcomes-from-the-pbac-20152-meeting 2015-08-30T03:18:20 https://maestrodatabase.com/blog/regulator-acts-to-close-loophole-enabling-australian-pharmacists-to-make-copycat-ozempic-drug 2024-02-29T20:09:11 https://maestrodatabase.com/blog/sanofis-sar402663-earns-fast-track-designation-in-the-us-for-neovascular-age-related-macular-degeneration 2025-09-12T00:24:41 https://maestrodatabase.com/blog/speeding-up-access-to-innovative-drugs-devices-and-diagnostics 2015-08-05T11:37:19 https://maestrodatabase.com/blog/fda-authorises-marketing-of-diagnostic-aid-for-autism-spectrum-disorder 2021-06-02T21:35:08 https://maestrodatabase.com/blog/cms-finalizes-improvements-for-the-2017-health-insurance-marketplace 2016-03-01T03:37:27 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-march-2024 2024-02-29T20:00:27 https://maestrodatabase.com/blog/sanofi-and-regeneron-announce-dupilumab-biologics-license-application-accepted-for-priority-review-by-u-dot-s-fda 2016-09-26T11:27:59 https://maestrodatabase.com/blog/genmab-announces-us-fda-approval-of-arzerra-ofatumumab-as-extended-treatment-for-recurrent-or-progressive-cll 2016-01-20T20:14:29 https://maestrodatabase.com/blog/fda-approves-pricey-pill-to-treat-vaginal-yeast-infections 2021-06-02T21:43:48 https://maestrodatabase.com/blog/leo-pharmas-anzupgo-delgocitinib-cream-achieves-marketing-approval-in-switzerland 2024-11-15T02:16:55 https://maestrodatabase.com/blog/uk-cost-agency-rejects-bristols-opdivo-for-kidney-cancer 2016-07-05T21:19:35 https://maestrodatabase.com/blog/pharmac-decision-pending-on-life-changing-diabetes-medications 2020-10-22T20:08:03 https://maestrodatabase.com/blog/call-for-patient-input-1 2015-08-05T11:37:29 https://maestrodatabase.com/blog/painkiller-packs-cut-down-to-size-as-opioid-crackdown-intensifies 2020-05-28T02:54:57 https://maestrodatabase.com/blog/pharmac_tender_reveals_vibrant_market_for_pharmaceuticals 2015-08-05T11:37:23 https://maestrodatabase.com/blog/secretive-system-for-vetting-cancer-drug-use-needs-an-overhaul 2016-09-06T01:17:17 https://maestrodatabase.com/blog/health-canada-approves-birth-control-arm-implant-nexplanon 2020-05-28T03:34:00 https://maestrodatabase.com/blog/maestro_australia_to_go_live_on_monday_27_may_2013 2015-08-05T11:37:14 https://maestrodatabase.com/blog/icer-draft-report-on-cardiomems-and-entresto-for-management-of-congestive-heart-failure-posted-for-public-comment 2015-09-14T21:11:22 https://maestrodatabase.com/blog/budget-is-why-pharmac-is-letting-down-new-zealanders-ceo-says 2020-10-22T20:11:14 https://maestrodatabase.com/blog/replace-the-prostheses-insurance-gouge-with-reasonable-pricing 2016-09-22T10:55:31 https://maestrodatabase.com/blog/cancer-sufferers-waiting-years-for-pbs-drug-approvals 2015-08-05T11:37:12 https://maestrodatabase.com/blog/remdesivirs-hefty-price-tag-ignores-nih-investment-in-its-creation 2020-10-22T20:15:33 https://maestrodatabase.com/blog/f2g-receives-second-us-fda-breakthrough-therapy-designation-for-olorofim 2020-10-22T08:53:04 https://maestrodatabase.com/blog/governments-need-better-guidance-to-maximise-value-for-money-the-case-of-australias-pharmaceutical-benefits-advisory-committee 2016-07-12T09:56:42 https://maestrodatabase.com/blog/unitedhealth-plans-to-exit-obamacare-exchanges 2016-04-20T21:11:23 https://maestrodatabase.com/blog/update-on-recruitment-of-new-members-for-pcodr-expert-review-committee 2015-08-05T11:37:13 https://maestrodatabase.com/blog/tax-payers-paid-to-develop-remdesivir-but-will-have-no-say-when-gilead-sets-the-price 2020-05-28T02:38:09 https://maestrodatabase.com/blog/perc-initial-outcome-for-ramucirumab-cyramza 2015-09-03T21:52:33 https://maestrodatabase.com/blog/velphoro-receives-eu-marketing-authorisation-for-treatment-of-hyperphosphatemia-in-adult-ckd-patients-on-dialysis 2015-08-05T11:37:16 https://maestrodatabase.com/blog/leo-pharma-announces-u-dot-s-fda-approval-for-enstilar-calcipotriene-and-betamethasone-dipropionate-foam-u-dot-s-prescribing-information-update-to-include-data-in-long-term-use-in-plaque-psoriasis-treatment 2020-10-22T19:57:20 https://maestrodatabase.com/blog/vismodegib-for-basal-cell-carcinoma-additional-benefits-not-seen-says-germanys-iqwig 2016-05-17T21:03:19 https://maestrodatabase.com/blog/collaborating-to-help-improve-access-to-drugs-for-rare-diseases 2024-02-29T20:37:34 https://maestrodatabase.com/blog/health-canada-grants-priority-review-for-novartis-heart-failure-medicine-lcz696 2015-08-05T11:37:18 https://maestrodatabase.com/blog/rilpivirine_combination_product_in_hiv_1_patients_with_previous_antiretroviral_treatment__added_benefit_not_proven 2015-08-05T11:37:24 https://maestrodatabase.com/blog/nexplanon-recommended-after-second-submission 2020-10-22T20:32:35 https://maestrodatabase.com/blog/more-rare-conditions-considered-for-newborn-bloodspot-screening-and-new-treatment-option-for-spinal-muscular-atrophy 2024-03-01T01:09:30 https://maestrodatabase.com/blog/xalkori-crizotinib-receives-approval-in-european-union-for-the-treatment-of-patients-with-ros1-positive-advanced-non-small-cell-lung-cancer 2016-08-31T12:51:16 https://maestrodatabase.com/blog/nice_says_yes_to_xtanda__enzalutamide___a_new_medicine_for_adult_men_with_prostate_cancer 2015-08-05T11:37:30 https://maestrodatabase.com/blog/pbs-listing-for-braftovi-and-cetuximab-for-metastatic-bowel-cancer-patients-with-brafv600-mutation 2021-12-30T04:45:22 https://maestrodatabase.com/blog/us-food-and-drug-administration-approves-gileads-second-taf-based-single-tablet-regimen-odefsey-emtricitabine-rilpivirine-tenofovir-alafenamide-for-the-treatment-of-hiv-1-infection 2016-03-02T06:16:57 https://maestrodatabase.com/blog/pbac-public-summary-documents-first-time-rejections-and-deferrals---may-2022-meeting 2022-09-09T07:31:59 https://maestrodatabase.com/blog/iroko-pharmaceuticals-gains-fda-approval-of-zorvolex-for-management-of-osteoarthritis-pain 2015-08-05T11:37:18 https://maestrodatabase.com/blog/sunovion-resubmits-new-drug-application-for-apomorphine-sublingual-film 2019-11-24T21:49:15 https://maestrodatabase.com/blog/new-pharmacy-guild-policy-on-substitution-of-biosimilar-medicine 2015-10-28T20:37:44 https://maestrodatabase.com/blog/nice-recommends-edoxaban-tosylate-lixiana-for-treating-and-preventing-potentially-fatal-blood-clots 2015-08-05T11:37:24 https://maestrodatabase.com/blog/cadth-recommends-invokamet 2016-08-30T01:47:27 https://maestrodatabase.com/blog/oxford-developed-covid-19-vaccine-then-scholars-clashed-over-money 2020-10-22T20:39:28 https://maestrodatabase.com/blog/cms-finalises-2016-medicare-payment-rules-for-physicians-hospitals-other-providers 2015-10-30T20:39:44 https://maestrodatabase.com/blog/trump-promised-seniors-drug-discount-cards-they-may-be-illegal 2020-10-22T20:19:18 https://maestrodatabase.com/blog/approval-of-amendments-to-the-listing-of-some-respiratory-products 2016-02-12T01:31:48 https://maestrodatabase.com/blog/breast_cancer_drug_not_cost_effective_for_nhs__says_draft_nice_guidance 2015-08-05T11:37:23 https://maestrodatabase.com/blog/cadth-in-favour-of-new-indication-for-soliris 2020-10-22T20:22:14 https://maestrodatabase.com/blog/scotland-oks-seven-new-drugs-for-nhs-use 2015-08-05T11:37:23 https://maestrodatabase.com/blog/teriflunomide_in_multiple_sclerosis__added_benefit_not_proven 2015-08-05T11:37:15 https://maestrodatabase.com/blog/hhs-announces-physician-groups-selected-for-an-initiative-promoting-better-cancer-care 2016-06-30T02:06:52 https://maestrodatabase.com/blog/vanda-receives-positive-chmp-opinion-for-hetlioz-tasimelteon-for-the-treatment-of-non-24-hour-sleep-wake-disorder-in-the-european-union 2015-08-05T11:37:18 https://maestrodatabase.com/blog/us-fda-approves-zubsolv-for-induction-of-buprenorphine-maintenance-therapy-in-patients-suffering-from-opioid-dependence 2015-08-11T21:38:12 https://maestrodatabase.com/blog/will-hira-resume-talk-to-grant-benefits-for-anti-diabetic-combo-drugs 2020-10-22T20:28:57 https://maestrodatabase.com/blog/fda-approves-first-of-its-kind-product-for-the-treatment-of-melanoma 2015-10-27T20:57:30 https://maestrodatabase.com/blog/fda-and-ema-accept-regulatory-submission-for-pfizers-ritlecitinib-for-individuals-12-years-and-older-with-alopecia-areata 2022-09-09T11:07:00 https://maestrodatabase.com/blog/pbac-guidelines-review 2016-02-24T08:02:15 https://maestrodatabase.com/blog/biogen-idecs-plegridy-peginterferon-beta-1a-approved-in-the-us-for-the-treatment-of-multiple-sclerosis 2015-08-05T11:37:12 https://maestrodatabase.com/blog/knight-therapeutics-announces-health-canada-approval-for-jornay-pm-to-treat-attention-deficit-hyperactivity-disorder 2024-11-15T04:25:27 https://maestrodatabase.com/blog/update-for-patient-groups-1 2015-08-05T11:37:20 https://maestrodatabase.com/blog/health-canadas-approval-of-taltz-ixekizumab-brings-targeted-therapy-to-canadians-living-with-moderate-to-severe-plaque-psoriasi 2016-06-22T05:29:30 https://maestrodatabase.com/blog/rare-cancer-sufferers-fight-to-get-drugs-on-pbs 2022-09-09T07:54:42 https://maestrodatabase.com/blog/springworks-therapeutics-announces-ema-validation-for-marketing-authorisation-application-of-nirogacestat-for-the-treatment-of-adults-with-desmoid-tumours 2024-03-01T01:29:35 https://maestrodatabase.com/blog/nice_proposes_to_recommend_a_new_treatment_for_some_people_with_advanced_kidney_cancer 2015-08-05T11:37:12 https://maestrodatabase.com/blog/teva-announces-fda-approval-of-proair-respiclick-salbutamol-sulphate-inhalation-powder-for-paediatric-asthma-patients-ages-4-to-11 2016-05-01T01:53:19 https://maestrodatabase.com/blog/iqwig-invites-to-its-autumn-symposium-2014 2015-08-05T11:37:27 https://maestrodatabase.com/blog/government-recognises-value-of-pbs-and-vaccines-in-federal-budget 2015-08-05T11:37:14 https://maestrodatabase.com/blog/faster-access-to-effective-cancer-treatments-through-new-cancer-drugs-fund 2016-03-16T20:35:22 https://maestrodatabase.com/blog/tga-approves-briviact-brivaracetam 2016-08-13T01:13:38 https://maestrodatabase.com/blog/janssen-submits-biologics-license-application-to-u-dot-s-fda-seeking-approval-of-teclistamab-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma 2021-12-30T05:28:15 https://maestrodatabase.com/blog/pbs-delisting-of-otc-medicines 2015-10-14T06:02:50 https://maestrodatabase.com/blog/johnson-and-johnson-seeks-first-ema-approval-for-icotrokinra-aiming-to-transform-the-plaque-psoriasis-treatment-paradigm 2025-09-12T02:20:19 https://maestrodatabase.com/blog/fda-approves-new-kyprolis-carfilzomib-combination-therapy-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma 2016-01-23T00:53:44 https://maestrodatabase.com/blog/biologic-treatment-entyvio-vedolizumab-approved-by-health-canada-to-treat-crohns-disease 2016-05-20T05:15:20 https://maestrodatabase.com/blog/abbvie-receives-european-commission-approval-of-venclyxto-venetoclax-plus-rituximab-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia-who-have-received-at-least-one-prior-therapy 2018-11-01T05:07:05 https://maestrodatabase.com/blog/oecd-warns-high-priced-drugs-are-stretching-health-budgets 2015-11-05T10:52:02 https://maestrodatabase.com/blog/b-dot-c-family-grateful-for-expanded-funding-to-cystic-fibrosis-drug-but-questions-why-it-took-so-long 2022-09-09T07:45:33 https://maestrodatabase.com/blog/smc-accepts-medicines-for-multiple-myeloma-and-lung-cancer 2015-12-07T20:36:17 https://maestrodatabase.com/blog/request-for-proposals-influenza-vaccine 2016-02-03T06:09:58 https://maestrodatabase.com/blog/baxalta-submits-marketing-authorization-application-to-the-european-medicines-agency-for-adynovi-for-treatment-of-haemophilia-a-patients 2016-03-03T18:34:22 https://maestrodatabase.com/blog/ema-fast-tracks-antidote-to-anticoagulant-pradaxa 2015-09-26T02:52:34 https://maestrodatabase.com/blog/meeting-highlights-from-the-chmp-14-17-december-2015 2015-12-19T02:25:33 https://maestrodatabase.com/blog/director-of-the-fdas-center-for-devices-and-radiological-health-and-director-of-the-fdas-center-for-drug-evaluation-and-research-on-agencys-warning-to-consumers-about-genetic-tests-that-claim-to-predict-patients-responses-to-specific-medications 2018-11-01T19:48:58 https://maestrodatabase.com/blog/vertex-announces-european-authorisation-for-third-cystic-fibrosis-medicine-symkevi-tezacaftor-slash-ivacaftor-to-be-used-in-combination-with-ivacaftor-kalydeco-for-people-with-cf-aged-12-and-older-with-certain-mutations-in-the-cftr-gene 2018-11-01T19:40:38 https://maestrodatabase.com/blog/take-home-naloxone-pilot-to-launch-1-december-2019 2019-11-24T23:04:16 https://maestrodatabase.com/blog/biden-harris-administration-issues-final-guidance-to-help-people-with-medicare-prescription-drug-coverage-manage-prescription-drug-costs 2024-03-01T02:24:15 https://maestrodatabase.com/blog/the_listing_of_soliris__eculizumab__on_the_pharmaceutical_benefits_scheme_or_life_saving_drugs_programme_for_the_treatment_of_patients_with_atypical_haemolytic_uraemic_syndrome__ahus_ 2015-08-05T11:37:03 https://maestrodatabase.com/blog/us-fda-approves-avastin-as-ovarian-cancer-treatment 2015-08-05T11:37:16 https://maestrodatabase.com/blog/cheating-death 2016-08-11T21:51:56 https://maestrodatabase.com/blog/cancer-patients-lose-free-lifesaving-drugs 2015-08-05T11:37:26 https://maestrodatabase.com/blog/novartis-drug-struck-off-cancer-drugs-fund 2015-08-05T11:37:22 https://maestrodatabase.com/blog/abbvie-offers-a-huge-discount-on-humira-to-fend-off-european-rivals 2018-11-01T19:58:25 https://maestrodatabase.com/blog/health-canada-accepts-new-drug-submission-for-reduvo-as-a-treatment-for-patients-with-chemotherapy-induced-nausea-and-vomiting 2021-06-03T03:00:16 https://maestrodatabase.com/blog/25-billion-drugs-recommended-for-pbs 2015-08-05T11:37:02 https://maestrodatabase.com/blog/orphan-drug-expenditures-in-the-united-states-a-historical-and-prospective-analysis-200718 2016-09-07T23:15:53 https://maestrodatabase.com/blog/novartis-receives-health-canada-approval-for-the-combination-therapy-of-tafinlar-dabrafenib-plus-mekinist-trametinib-for-adjuvant-treatment-of-patients-with-braf-v600-mutation-melanoma 2018-11-01T20:05:47 https://maestrodatabase.com/blog/imbruvica-ibrutinib-approved-by-us-fda-for-the-first-line-treatment-of-chronic-lymphocytic-leukaemia 2016-03-06T23:18:13 https://maestrodatabase.com/blog/establishing-the-effectiveness-of-procedural-interventions-the-limited-role-of-randomised-trials 2018-12-18T23:57:20 https://maestrodatabase.com/blog/will-the-fda-approve-all-3-of-these-cancer-drugs-in-october 2015-09-25T22:37:29 https://maestrodatabase.com/blog/representativeness-of-studies-required-under-medicares-coverage-with-evidence-development-program 2024-11-15T05:06:52 https://maestrodatabase.com/blog/government-reaches-19-billion-deal-with-pharmacy-guild-to-dispense-taxpayer-subsidised-medicine 2015-08-05T11:37:29 https://maestrodatabase.com/blog/alk-obtains-european-approval-for-its-house-dust-mite-sublingual-allergy-immunotherapy-tablet-against-allergic-rhinitis-and-allergic-asthma 2015-08-31T21:15:23 https://maestrodatabase.com/blog/model-validation-has-its-time-come 2016-08-11T01:05:18 https://maestrodatabase.com/blog/the-white-house-makes-a-last-minute-proposal-on-drug-prices 2018-11-01T20:13:24 https://maestrodatabase.com/blog/several_new_features_are_currently_in_development_and_will_be_added_soon 2015-08-05T11:37:20 https://maestrodatabase.com/blog/eagle-pharmaceuticals-receives-complete-response-letter-from-fda-on-kangio-rtu-bivalirudin-application 2016-03-19T21:49:14 https://maestrodatabase.com/blog/tga-approves-brenzys-etanercept 2016-07-28T21:13:28 https://maestrodatabase.com/blog/sorry-we-dont-take-obamacare 2016-05-15T08:51:34 https://maestrodatabase.com/blog/fda-approves-first-treatment-for-covid-19 2020-10-22T22:18:06 https://maestrodatabase.com/blog/csl-executive-gordon-naylor-on-how-to-create-advanced-manufacturing-success 2015-08-09T00:11:00 https://maestrodatabase.com/blog/ema-publishes-epar-for-cinqaero-reslizumab 2016-09-03T11:09:36 https://maestrodatabase.com/blog/fda-accepts-csl-behrings-bla-for-first-subcutaneous-prophylactic-therapy-to-prevent-hereditary-angioedema-attacks 2016-08-30T08:48:30 https://maestrodatabase.com/blog/the-us-pays-a-lot-more-for-top-drugs-than-other-countries 2015-12-19T02:51:04 https://maestrodatabase.com/blog/timelines-for-new-pbs-listings 2018-11-01T20:38:10 https://maestrodatabase.com/blog/lilly-merck-receive-inquiries-from-justice-department-over-drug-pricing 2015-11-06T22:18:19 https://maestrodatabase.com/blog/lifecycle-regulation-of-artificial-intelligence-and-machine-learning-based-software-devices-in-medicine 2019-11-24T23:36:59 https://maestrodatabase.com/blog/price-disclosure-drugs-and-manners-of-administration-that-meet-the-f2multi-branded-criteria-30-month-clock-for-originator-removal-calculation-for-the-2016-october-cycle 2016-04-12T10:23:43 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---june-2014-update 2015-08-05T11:37:28 https://maestrodatabase.com/blog/allergan-receives-positive-opinion-through-european-decentralised-procedure-for-belkyra-deoxycholic-acid-for-patients-with-submental-fullness 2016-07-04T21:12:54 https://maestrodatabase.com/blog/ferring-receives-acceptance-of-marketing-authorisation-filing-from-ema-for-personalised-fertility-treatment-with-rekovelle-follitropin-delta 2015-11-03T19:41:28 https://maestrodatabase.com/blog/call-for-patient-input-28 2015-08-05T11:37:08 https://maestrodatabase.com/blog/prescription-drug-prices-a-bitter-pill-in-the-midterm-elections 2018-11-01T20:20:20 https://maestrodatabase.com/blog/nice-draft-guidance-recommends-new-drugs-for-cholesterol-disorder 2016-05-07T00:51:42 https://maestrodatabase.com/blog/fda-approves-expanded-age-indication-for-gardasil-9-in-males 2015-12-16T20:40:33 https://maestrodatabase.com/blog/dupixent-dupilumab-sbla-accepted-for-fda-review-for-the-treatment-of-chronic-spontaneous-urticaria 2024-11-15T11:18:54 https://maestrodatabase.com/blog/oral-otezla-apremilast-approved-by-the-european-commission-for-the-treatment-of-both-patients-with-psoriasis-and-psoriatic-arthritis 2015-08-05T11:37:06 https://maestrodatabase.com/blog/janssen-offers-nhs-to-pay-for-olysio-failures 2015-08-05T11:37:29 https://maestrodatabase.com/blog/cystic-fibrosis-patients-campaign-for-drug-orkambi-to-be-listed-on-pharmaceutical-benefits-scheme 2016-05-02T20:44:58 https://maestrodatabase.com/blog/agenda-for-the-20-july-2016-tc-meeting 2016-07-16T04:01:33 https://maestrodatabase.com/blog/sandoz-receives-european-commission-approval-for-afqlir-aflibercept-further-strengthening-leading-biosimilar-portfolio 2024-11-15T11:13:54 https://maestrodatabase.com/blog/norgine-close-to-final-yes-from-nice-on-targaxan 2015-08-05T11:37:06 https://maestrodatabase.com/blog/landmark-medicinal-cannabis-legislation-introduced-today 2016-02-10T20:03:05 https://maestrodatabase.com/blog/post-market-review-of-pharmaceutical-benefits-scheme-medicines-used-to-treat-asthma-in-children 2015-08-05T11:37:04 https://maestrodatabase.com/blog/children-with-cancer-denied-lifesaving-drugs-by-out-of-date-eu-regulations 2016-07-05T21:44:54 https://maestrodatabase.com/blog/leqembi-recommended-for-treatment-of-early-alzheimers-disease 2024-11-15T11:06:49 https://maestrodatabase.com/blog/apremilast-in-plaque-psoriasis-and-psoriatic-arthritis-no-added-benefit-can-be-derived 2015-08-05T11:37:04 https://maestrodatabase.com/blog/quebec-extends-public-reimbursement-of-dupixent-dupilumab-for-the-treatment-of-moderate-to-severe-atopic-dermatitis-to-include-adolescents 2021-06-03T03:57:47 https://maestrodatabase.com/blog/germany-plans-to-extend-price-brake-for-drugs-under-statutory-insurance 2016-08-03T20:07:52 https://maestrodatabase.com/blog/nice_moves_closer_to_a_final_decision_on_jetrea_whereas_iqwig_has_just_started_its_rapid_benefit_assessment 2015-08-05T11:37:14 https://maestrodatabase.com/blog/new-cervical-cancer-vaccine-may-almost-eliminate-disease-research-shows 2017-08-12T07:03:25 https://maestrodatabase.com/blog/unitedhealth-raises-doubts-about-its-participation-in-affordable-care-act 2015-11-20T08:23:28 https://maestrodatabase.com/blog/seamless-oncology-drug-development 2016-04-13T21:57:02 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-to-evaluate-comparative-clinical-effectiveness-and-value-of-emicizumab-for-haemophilia-a 2017-08-12T07:15:33 https://maestrodatabase.com/blog/novartis-launches-novartis-access-a-portfolio-of-affordable-medicines-to-treat-chronic-diseases-in-lower-income-countries 2015-09-24T14:30:53 https://maestrodatabase.com/blog/patients-struggle-with-high-drug-prices 2016-01-01T00:31:14 https://maestrodatabase.com/blog/acalabrutinib-receives-tga-approval-for-cll-and-sll-cancers 2019-11-25T01:44:14 https://maestrodatabase.com/blog/ema-publishes-epa-for-lutetium-177-lu-chloride-endolucin-beta 2016-07-14T21:48:05 https://maestrodatabase.com/blog/gilead-announces-us-fda-priority-review-designation-for-fixed-dose-combination-of-bictegravir-emtricitabine-and-tenofovir-alafenamide-for-treatment-of-hiv 2017-08-12T07:07:43 https://maestrodatabase.com/blog/medicine-prices-will-rise-by-up-to-5-a-script-from-january-next-year 2015-08-05T11:37:06 https://maestrodatabase.com/blog/sandoz-canada-regulatory-submission-for-subsequent-entry-biologic-etanercept-accepted-for-review-by-health-canada 2016-06-29T11:00:19 https://maestrodatabase.com/blog/nice_confirms_agnss_positive_assessment_that_eculizumab__soliris__is_a_very_effective_treatment_for_ahus_patients_and_produces_substantial_quality_adjusted_life_year_gains_of_a_magnitude_rarely_seen_for_a_new_drug 2015-08-05T11:37:09 https://maestrodatabase.com/blog/ireland_passes_reference_pricing__pro_generics_law 2015-08-05T11:37:07 https://maestrodatabase.com/blog/next-president-should-attack-drug-prices-obama-says-in-jama 2016-07-13T03:27:01 https://maestrodatabase.com/blog/nice-recommends-laser-device-to-help-thousands-of-men-with-an-enlarged-prostate 2016-06-14T09:55:35 https://maestrodatabase.com/blog/qa-is-nz-lagging-in-cancer-drug-funding 2016-08-31T12:37:50 https://maestrodatabase.com/blog/drug-regulation-and-pricing-can-regulators-influence-affordability 2016-05-11T21:53:33 https://maestrodatabase.com/blog/highlights-from-the-11-14-november-2024-chmp-meeting 2024-11-15T20:04:21 https://maestrodatabase.com/blog/drug-companies-paying-doctors-millions-medicines-australia-report-reveals 2016-09-01T21:22:06 https://maestrodatabase.com/blog/public-summary-documents-first-time-decisions-not-to-recommend-and-deferrals---july-2024-pbac-meeting 2024-11-15T20:01:09 https://maestrodatabase.com/blog/nih-wont-cut-price-of-taxpayer-funded-prostate-cancer-drug 2016-06-21T10:58:49 https://maestrodatabase.com/blog/swissmedic-approves-novartis-new-heart-failure-medicine-entresto 2015-09-18T21:57:30 https://maestrodatabase.com/blog/trump-draws-ire-after-retreat-on-drug-prices-pledge 2019-11-25T02:37:20 https://maestrodatabase.com/blog/dolutegravir-in-hiv-1-infection-additional-benefit-in-adult-patients 2015-08-05T11:37:06 https://maestrodatabase.com/blog/spectrum-pharmaceuticals-receives-fda-approval-for-rolvedon-eflapegrastim-xnst-injection 2022-09-09T21:35:28 https://maestrodatabase.com/blog/european_medicines_agency_and_eunethta_review_progress_of_their_cooperation 2015-08-05T11:37:19 https://maestrodatabase.com/blog/medicine-prices-in-australia-among-the-cheapest-in-the-world-research-shows 2019-11-25T02:31:49 https://maestrodatabase.com/blog/fda-approves-us-product-labeling-update-for-sprycel-dasatinib-monohydrate-to-include-five-year-first-line-and-seven-year-second-line-efficacy-and-safety-data-in-chronic-myeloid-leukaemia-in-chronic-phase 2015-08-13T20:38:01 https://maestrodatabase.com/blog/cancer-drugs-fund-seems-to-help-pharmaceuticals-giant-roche-most 2015-08-05T11:37:11 https://maestrodatabase.com/blog/march_2014_tender_notification 2015-08-05T11:37:22 https://maestrodatabase.com/blog/cadth-calls-for-patient-input-on-submissions-from-shire-and-vertex 2015-10-30T22:07:43 https://maestrodatabase.com/blog/fda-fails-to-monitor-fast-tracked-drugs-after-approval-says-us-watchdog 2016-01-27T04:50:35 https://maestrodatabase.com/blog/cancer-drugs-first-to-take-advantage-of-uk-early-access-scheme 2015-08-05T11:37:14 https://maestrodatabase.com/blog/dr-reddys-laboratories-ltd-receives-fda-approval-for-zembrace-symtouch-sumatriptan-succinate-injection-for-the-acute-treatment-of-migraines-in-adults 2016-02-05T22:02:35 https://maestrodatabase.com/blog/fda-approves-aquestives-als-treatment 2019-11-25T07:20:18 https://maestrodatabase.com/blog/us-fda-approves-the-labeling-update-of-abilify-maintena-aripiprazole-for-extended-release-injectable-suspension-to-describe-new-clinical-data-for-the-treatment-of-acutely-relapsed-adults-with-schizophrenia 2015-08-05T11:37:04 https://maestrodatabase.com/blog/merck-kgaa-darmstadt-germany-and-pfizer-announce-investigational-immunotherapy-avelumab-receives-fda-fast-track-designation-for-metastatic-merkel-cell-carcinoma 2015-10-08T04:30:23 https://maestrodatabase.com/blog/pharma-decision-to-list-multivitamin-for-renal-patients 2015-09-11T08:13:50 https://maestrodatabase.com/blog/proposed-ontario-drug-regulation-changes-worry-policy-experts 2019-11-25T07:12:10 https://maestrodatabase.com/blog/intercept-announces-fda-acceptance-of-supplemental-new-drug-application-for-ocaliva-obeticholic-acid-for-the-treatment-of-pbc 2024-03-01T04:09:14 https://maestrodatabase.com/blog/sanofi-and-regeneron-announce-approval-of-praluent-alirocumab-for-the-treatment-of-hypercholesterolemia-in-the-european-union 2015-09-28T10:18:11 https://maestrodatabase.com/blog/novartis-chief-backs-shake-up-in-drug-pricing 2015-08-05T11:37:27 https://maestrodatabase.com/blog/are-government-efforts-to-lower-drug-prices-violating-the-first-amendment 2019-11-25T02:40:12 https://maestrodatabase.com/blog/immunisation-policy-and-the-importance-of-sustainable-vaccine-pricing 2016-03-08T20:24:59 https://maestrodatabase.com/blog/praxbind-idarucizumab-reimbursed-in-england-ireland-and-wales 2016-02-25T20:43:05 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1--june-2015-update 2015-08-05T11:37:06 https://maestrodatabase.com/blog/sellas-life-sciences-receives-fda-fast-track-designation-of-galinpepimut-s-for-the-treatment-of-malignant-pleural-mesothelioma 2016-09-19T20:39:43 https://maestrodatabase.com/blog/fda-approves-genentechs-lucentis-ranibizumab-injection-0-dot-3-mg-pre-filled-syringe-for-diabetic-macular-oedema-and-diabetic-retinopathy 2018-03-22T05:00:35 https://maestrodatabase.com/blog/fda-providing-2-million-in-new-grants-for-natural-history-studies-in-rare-diseases 2016-02-29T20:07:08 https://maestrodatabase.com/blog/adaptive-pathways-ema-still-leaves-open-questions-unanswered 2016-08-09T11:42:23 https://maestrodatabase.com/blog/kite-pharma-receives-fda-breakthrough-therapy-designation-for-kte-c19-for-the-treatment-of-refractory-aggressive-non-hodgkins-lymphoma 2015-12-07T19:28:36 https://maestrodatabase.com/blog/pharmac-decision-to-widen-access-to-budesonide-with-eformoterol-symbicort-turbuhaler-and-vannair 2016-02-03T06:07:02 https://maestrodatabase.com/blog/drug-price-demagoguery-could-hurt-patients 2015-09-30T20:24:43 https://maestrodatabase.com/blog/changes-to-the-requirements-for-submitting-to-the-pbac-that-take-effect-july-2015 2015-08-05T11:37:14 https://maestrodatabase.com/blog/public-consultation-on-the-post-market-review-of-authority-required-pbs-listings 2015-08-05T11:37:10 https://maestrodatabase.com/blog/call-for-nominations-to-the-pcodr-expert-review-committee-1 2015-08-05T11:37:14 https://maestrodatabase.com/blog/eisai-launches-anticancer-agent-halaven-eribulin-mesylate-in-australia 2015-08-05T11:37:24 https://maestrodatabase.com/blog/fda-approves-taros-keveyis-dichlorphenamide-50-mg-tablets-for-primary-hyperkalemic-and-hypokalemic-periodic-paralysis 2015-08-11T21:08:13 https://maestrodatabase.com/blog/nice-reform-plans-a-step-back-for-cancer-patients 2015-08-05T11:37:03 https://maestrodatabase.com/blog/department-of-health-submission-to-the-senate-inquiry-on-the-availability-of-new-innovative-and-specialised-cancer-drugs-in-australia 2015-08-05T11:37:22 https://maestrodatabase.com/blog/european-commission-grants-marketing-authorization-for-gileads-single-tablet-regimen-odefsey-emtricitabine-rilpivirine-tenofovir-alafenamide-for-the-treatment-of-hiv 2016-06-24T05:34:19 https://maestrodatabase.com/blog/european-commission-approves-trevicta-paliperidone-palmitate-a-3-monthly-injection-for-maintenance-treatment-of-schizophrenia 2016-06-01T17:04:45 https://maestrodatabase.com/blog/medicines-sector-reforms-deliver-consumer-benefits-and-a-sustainable-pbs 2016-04-04T09:12:28 https://maestrodatabase.com/blog/as-prices-soar-us-drugmakers-say-they-bear-an-unfair-burden 2016-05-16T10:30:14 https://maestrodatabase.com/blog/ema-and-australian-regulatory-authority-strengthen-collaboration-in-the-area-of-orphan-medicines 2015-08-05T11:37:14 https://maestrodatabase.com/blog/ema-publishes-epar-for-empliciti-omentys 2016-07-02T07:52:59 https://maestrodatabase.com/blog/drug-companies-give-their-tax-affairs-a-clean-bill-of-health-ahead-of-senate-grilling 2015-08-05T11:37:27 https://maestrodatabase.com/blog/differences-in-availability-of-cancer-drugs-across-europe 2016-07-29T08:51:42 https://maestrodatabase.com/blog/drug-firms-turn-to-orphan-medicines-as-generics-eat-into-profits 2015-10-05T02:08:37 https://maestrodatabase.com/blog/giotrif__afatinib__approved_by_health_canada_as_a_treatment_for_patients_with_metastatic_adenocarcinoma_of_the_lung_with_activating_egfr_mutation_s__who_are_tyrosine_kinase_inhibitor_na_ve 2015-08-05T11:37:16 https://maestrodatabase.com/blog/fda-grants-priority-review-to-roches-risdiplam-for-spinal-muscular-atrophy 2019-11-25T11:22:06 https://maestrodatabase.com/blog/when-the-drugs-dont-work 2016-05-19T21:29:37 https://maestrodatabase.com/blog/smc-april-2016-decisions-news-release 2016-04-11T21:55:32 https://maestrodatabase.com/blog/allergan-announces-fda-approval-of-supplemental-new-drug-application-for-avycaz-ceftazidime-and-avibactam 2016-06-24T08:40:37 https://maestrodatabase.com/blog/nice-recommends-daklinza-daclatasvir-for-treatment-of-certain-patients-with-chronic-hepatitis-c-genotypes-1-3-and-4 2015-10-16T20:28:30 https://maestrodatabase.com/blog/nz-2nd-last-in-class-for-first-in-class-medicines 2015-08-05T11:37:24 https://maestrodatabase.com/blog/tga-publishes-auspar-for-repatha-evolocumab 2016-05-16T04:13:35 https://maestrodatabase.com/blog/responses-to-feedback-on-pharmacs-proposed-approach-to-market-share-procurement-of-hospital-medical-devices 2015-08-19T00:24:34 https://maestrodatabase.com/blog/new-cancer-immunotherapy-indication-for-canadian-patients-with-untreated-metastatic-melanoma 2016-05-31T17:51:20 https://maestrodatabase.com/blog/aflibercept-in-diabetic-macular-oedema-added-benefit-not-proven 2015-08-05T11:37:30 https://maestrodatabase.com/blog/baxalta-to-advance-care-for-hemophilia-a-patients-with-fda-approval-of-adynovate-a-simple-twice-weekly-treatment-to-reduce-bleeds 2015-11-14T19:32:47 https://maestrodatabase.com/blog/otonomy-announces-fda-approval-of-otiprio-for-the-treatment-of-pediatric-patients-undergoing-tympanostomy-tube-placement-surgery 2015-12-15T20:44:17 https://maestrodatabase.com/blog/melanoma-drug-could-be-funded-after-boost-in-funding 2016-05-04T03:40:37 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-3-june-2021 2021-06-03T10:48:51 https://maestrodatabase.com/blog/safinamide-in-parkinson-disease-no-hint-of-added-benefit-says-iqwig 2015-08-19T09:40:06 https://maestrodatabase.com/blog/fda-awards-18-grants-to-stimulate-product-development-for-rare-diseases 2015-09-21T21:07:21 https://maestrodatabase.com/blog/nice-asks-for-more-information-on-xolair-for-hives 2015-08-05T11:37:07 https://maestrodatabase.com/blog/smc_advice___april_2014 2015-08-05T11:37:02 https://maestrodatabase.com/blog/pbs-hospital-medication-charts---phase-one-trials 2015-08-05T11:37:23 https://maestrodatabase.com/blog/recommendations-alone-will-not-avert-a-liver-disease-epidemic 2015-08-24T01:57:09 https://maestrodatabase.com/blog/addressing-challenges-of-innovative-cancer-immunotherapy-medicines 2016-08-16T21:16:15 https://maestrodatabase.com/blog/caladrius-biosciences-receives-fda-fast-track-designation-for-clbs03-to-treat-recent-onset-type-1-diabetes 2016-07-31T22:54:00 https://maestrodatabase.com/blog/dolutegravirabacavirlamivudine-considerable-added-benefit-for-treatment-naive-adults-with-hiv 2015-08-05T11:37:14 https://maestrodatabase.com/blog/why-the-price-is-right-for-drug-companies 2016-07-20T21:50:10 https://maestrodatabase.com/blog/ospemifene-in-vulvovaginal-atrophy-additional-benefits-not-covered 2016-08-02T04:14:31 https://maestrodatabase.com/blog/scottish-cost-regulators-ok-nhs-use-of-7-new-drugs 2015-08-05T11:37:25 https://maestrodatabase.com/blog/nabriva-therapeutics-completes-submission-of-new-drug-application-to-u-dot-s-fda-for-intravenous-contepo-to-treat-complicated-urinary-tract-infections 2018-11-02T00:43:02 https://maestrodatabase.com/blog/uk-government-tables-bill-on-medicine-pricing-reforms 2016-09-16T23:57:59 https://maestrodatabase.com/blog/amylyx-pharmaceuticals-announces-fda-acceptance-and-priority-review-of-new-drug-application-for-amx0035-for-the-treatment-of-als 2021-12-31T02:40:51 https://maestrodatabase.com/blog/intercept-announces-voluntary-withdrawal-of-ocaliva-for-primary-biliary-cholangitis-from-the-us-market 2025-09-12T05:51:50 https://maestrodatabase.com/blog/relevant_additions_and_changes_from_the_1_march_2014_issue_of_the_schedule_of_pharmaceutical_benefits_have_been_added_to_maestro_australia 2015-08-05T11:37:18 https://maestrodatabase.com/blog/ipilimumab_in_advanced_melanoma__added_benefit_for_non_pretreated_patients_not_proven 2015-08-05T11:37:12 https://maestrodatabase.com/blog/agenda-for-the-16-march-2016-tc-meeting 2016-03-09T21:06:34 https://maestrodatabase.com/blog/on-target 2016-06-13T21:50:07 https://maestrodatabase.com/blog/public-summary-documents---november-2023-pbac-meeting-round-1 2024-03-01T05:43:49 https://maestrodatabase.com/blog/german-evaluation-says-new-drug-for-alcohol-dependence-is-no-better-than-old-one 2015-08-05T11:37:04 https://maestrodatabase.com/blog/statement-from-the-panel-for-the-review-of-pharmacy-remuneration-and-regulation 2016-05-11T14:27:14 https://maestrodatabase.com/blog/budget-providing-the-answers-in-fight-against-cancers 2015-08-05T11:37:02 https://maestrodatabase.com/blog/fda-grants-priority-review-for-new-drug-application-for-oleogel-s10-for-the-treatment-of-epidermolysis-bullosa 2021-06-03T10:55:28 https://maestrodatabase.com/blog/shires-shp626-volixibat-receives-fda-fast-track-designation-for-an-investigational-treatment-for-adults-who-have-nonalcoholic-steatohepatitis-nash-with-liver-fibrosis 2016-07-30T00:26:51 https://maestrodatabase.com/blog/constellation-pharmaceuticals-receives-fda-fast-track-designation-for-cpi-0610-in-treatment-of-myelofibrosis 2018-11-02T00:52:37 https://maestrodatabase.com/blog/the-rise-of-drug-resistance 2016-09-23T21:02:39 https://maestrodatabase.com/blog/comparable-overseas-reports-pathway---first-registration-decision 2018-11-02T00:58:06 https://maestrodatabase.com/blog/proposal-to-fund-novorapid-flexpen-insulin-aspart 2015-08-05T11:37:18 https://maestrodatabase.com/blog/post-market-review-of-biological-disease-modifying-anti-rheumatic-drugs-to-treat-severe-chronic-plaque-psoriasis-and-of-pulmonary-arterial-hypertension-medicines 2016-08-19T23:40:45 https://maestrodatabase.com/blog/eu-dcp-international-collaboration-for-the-evaluation-of-generic-drugs 2015-08-05T11:37:09 https://maestrodatabase.com/blog/us-food-and-drug-administration-accepts-supplemental-biologics-license-application-for-opdivoyervoy-regimen-in-patients-with-previously-untreated-advanced-melanoma 2015-08-05T11:37:10 https://maestrodatabase.com/blog/amgen-biosimilar-gets-thumbs-up-from-fda-panel 2016-07-13T21:15:30 https://maestrodatabase.com/blog/no-evidence-that-1bn-cancer-drugs-fund-has-helped-patients-says-watchdog 2015-09-23T03:25:20 https://maestrodatabase.com/blog/most-americans-support-medicare-negotiation-despite-claims-it-would-hurt-innovation 2021-06-03T11:19:05 https://maestrodatabase.com/blog/drug-utilisation-sub-committee-outcome-statement---september-2018 2018-11-02T01:05:11 https://maestrodatabase.com/blog/novartis-drug-tasigna-approved-by-fda-to-treat-children-with-rare-form-of-leukaemia 2018-03-22T20:12:29 https://maestrodatabase.com/blog/agenda-for-the-6-april-2016-tc-meeting 2016-03-31T05:52:24 https://maestrodatabase.com/blog/selincro-receives-positive-draft-guidance-from-uks-nice 2015-08-05T11:37:03 https://maestrodatabase.com/blog/nice-backs-restricted-use-of-heart-drug-entresto 2016-04-27T21:05:07 https://maestrodatabase.com/blog/pharmac-welcomes-appointments-to-clinical-committee 2015-08-05T11:37:29 https://maestrodatabase.com/blog/new-inn-publication-biological-qualifier-an-inn-proposal 2015-08-05T11:37:26 https://maestrodatabase.com/blog/new-medicine-to-treat-heart-failure-recommended-for-approval 2015-09-26T02:39:26 https://maestrodatabase.com/blog/psoriasis-patients-get-nhs-access-to-leo-pharmas-kyntheum 2018-03-22T20:07:11 https://maestrodatabase.com/blog/protagonist-therapeutics-receives-fda-breakthrough-therapy-designation-for-rusfertide-in-polycythemia-vera 2021-06-03T11:39:00 https://maestrodatabase.com/blog/roche-expects-cancer-treatments-to-be-spared-us-pricing-curbs 2016-01-29T23:20:30 https://maestrodatabase.com/blog/public_summary_documents_from_the_august_2013_pbac_meeting 2015-08-05T11:37:22 https://maestrodatabase.com/blog/house-approves-right-to-try-bill-giving-seriously-ill-patients-access-to-experimental-drugs 2018-03-22T20:28:16 https://maestrodatabase.com/blog/pbs-price-disclosure-2016-april-cycle-outcomes-summary 2015-12-16T20:02:45 https://maestrodatabase.com/blog/call-for-patient-input-11 2015-08-05T11:37:26 https://maestrodatabase.com/blog/cadth-calls-for-patient-input-on-submission-from-sanofi-for-sarilumab 2016-09-13T21:10:30 https://maestrodatabase.com/blog/getting-sick-can-be-really-expensive-even-for-the-insured 2018-03-22T20:35:59 https://maestrodatabase.com/blog/servier-receives-health-canada-approval-of-folotyn-for-the-treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma 2018-11-02T05:20:24 https://maestrodatabase.com/blog/nice-changes-position-on-second-line-treatment-for-nsclc 2015-08-05T11:37:25 https://maestrodatabase.com/blog/harmonised-health-technology-assessment-in-europe-theres-a-long-way-to-go 2018-03-22T20:19:23 https://maestrodatabase.com/blog/approval-of-funding-for-flecainide-acetate-and-beclometasone-dipropionate 2015-08-05T11:37:14 https://maestrodatabase.com/blog/were-not-just-all-about-the-money----pharmac-defends-why-it-still-wont-fund-drug-for-rare-childrens-disorder 2021-06-03T11:13:58 https://maestrodatabase.com/blog/how-to-reduce-medicare-drug-costs 2016-03-10T10:25:13 https://maestrodatabase.com/blog/fda-wants-to-help-unproductive-drug-makers 2018-03-22T20:23:07 https://maestrodatabase.com/blog/clinton-urges-us-regulators-to-examine-daraprim-price-hike 2015-10-22T06:04:14 https://maestrodatabase.com/blog/public-summary-documents-first-time-decisions-not-to-recommend-and-deferrals---may-2025-pbac-meeting 2025-09-12T07:13:46 https://maestrodatabase.com/blog/pfizer-drug-wins-uk-support-following-overhaul-of-cancer-fund 2016-07-07T11:51:29 https://maestrodatabase.com/blog/first-generic-version-of-viagra-approved-by-fda 2016-03-10T19:59:23 https://maestrodatabase.com/blog/resolving-the-cost-effective-but-unaffordable-paradox-estimating-the-health-opportunity-costs-of-non-marginal-budget-impacts 2018-03-22T20:49:29 https://maestrodatabase.com/blog/trevena-receives-complete-response-letter-for-oliceridine-from-fda 2018-11-02T21:00:28 https://maestrodatabase.com/blog/drug-makers-pharmac-should-be-doing-more 2015-08-05T11:37:29 https://maestrodatabase.com/blog/call-for-patient-input-20 2015-08-05T11:37:10 https://maestrodatabase.com/blog/what-is-the-evidence-from-past-nice-single-technology-appraisals-regarding-company-submissions-with-base-case-incremental-cost-effectiveness-ratios-of-less-than-ps10-000-slash-qaly 2018-03-22T20:53:38 https://maestrodatabase.com/blog/takedas-entyvio-available-in-uk-for-ulcerative-colitis-and-crohns-disease 2015-08-05T11:37:22 https://maestrodatabase.com/blog/drug-firms-will-be-barred-from-extortionately-raising-nhs-drug-prices-as-jeremy-hunt-acts-to-close-loophole 2016-09-20T20:47:33 https://maestrodatabase.com/blog/affordability-of-new-technologies-the-next-frontier 2018-03-22T20:41:00 https://maestrodatabase.com/blog/european-medicines-regulatory-network-fully-mobilised-in-fight-against-covid-19 2020-05-28T11:22:11 https://maestrodatabase.com/blog/bausch-health-responds-to-norwich-pharmaceuticals-tentative-fda-approval-for-a-200-mg-rifaximin 2022-09-09T22:57:23 https://maestrodatabase.com/blog/the-personalisation-of-cancer-treatments-is-leading-to-better-outcomes-for-patients 2016-06-06T21:20:34 https://maestrodatabase.com/blog/affordability-challenges-to-value-based-pricing-mass-diseases-orphan-diseases-and-cures 2018-03-22T20:44:10 https://maestrodatabase.com/blog/fda-permits-marketing-of-two-devices-that-detect-parathyroid-tissue-in-real-time-during-surgery 2018-11-02T20:51:02 https://maestrodatabase.com/blog/statement-from-fda-commissioner-on-agencys-approval-of-dsuvia-and-the-fdas-future-consideration-of-new-opioids 2018-11-02T21:19:08 https://maestrodatabase.com/blog/vertex-receives-two-eu-approvals-for-kalydeco-ivacaftor-for-people-with-cystic-fibrosis 2015-11-19T07:47:16 https://maestrodatabase.com/blog/meeting-highlights-from-the-committee-for-medicinal-products-for-human-use-chmp-23-26-march-2015 2015-08-05T11:37:29 https://maestrodatabase.com/blog/u-dot-s-fda-approves-udenyca-pegfilgrastim-cbqv 2018-11-02T21:22:48 https://maestrodatabase.com/blog/pfizer-announces-fda-acceptance-of-methylphenidate-hydrochloride-extended-release-chewable-tablet-nda-as-adhd-treatment 2015-08-05T11:37:12 https://maestrodatabase.com/blog/a-consultancy-firm-was-paid-660-000-dollars-to-advise-on-australias-covid-19-vaccine-strategy-but-a-government-official-said-they-provided-no-specific-advice 2021-06-03T12:18:56 https://maestrodatabase.com/blog/fda-approves-zinbryta-to-treat-multiple-sclerosis 2016-05-28T13:35:32 https://maestrodatabase.com/blog/europe-to-boost-cooperation-with-international-partners-on-generics 2015-08-05T11:37:17 https://maestrodatabase.com/blog/nz-pm-keytruda-debate-very-emotional 2015-12-06T22:36:09 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-pharmaessentias-bla-resubmission-for-ropeginterferon-alfa-2b-njft-for-the-treatment-of-polycythemia-vera 2021-06-03T20:43:39 https://maestrodatabase.com/blog/lexicon-submits-new-drug-application-for-sotagliflozin-for-the-treatment-of-heart-failure-in-adults-with-type-2-diabetes 2021-12-31T03:10:08 https://maestrodatabase.com/blog/lucentis-ranibizumab-approved-by-health-canada-to-treat-vision-loss-resulting-from-choroidal-neovascularization-in-pathologic-myopia 2015-08-05T11:37:06 https://maestrodatabase.com/blog/dermavant-submits-new-drug-application-to-fda-for-tapinarof-cream-for-the-treatment-of-adults-with-plaque-psoriasis 2021-06-03T12:24:30 https://maestrodatabase.com/blog/meeting-highlights-from-the-committee-for-medicinal-products-for-human-use-chmp-12-15-september-2016 2016-09-17T01:49:19 https://maestrodatabase.com/blog/hospital-in-the-home-revolution-hunts-plan-to-shake-up-private-health-insurance 2019-11-25T19:38:44 https://maestrodatabase.com/blog/life-saving-drug-for-young-pompe-patients 2015-08-05T11:37:22 https://maestrodatabase.com/blog/a-cancer-conundrum-too-many-drug-trials-too-few-patients 2017-08-13T00:21:49 https://maestrodatabase.com/blog/cardiff-oncology-announces-fast-track-designation-granted-by-the-fda-to-onvansertib-for-second-line-treatment-of-kras-mutated-colorectal-cancer 2020-05-28T20:59:56 https://maestrodatabase.com/blog/kythera-biopharmaceuticals-submits-marketing-authorisation-application-in-the-european-union-for-atx-101-as-first-in-class-treatment-for-the-reduction-of-submental-fat 2015-08-18T21:15:10 https://maestrodatabase.com/blog/federal-office-decides-drug-price-cuts 2018-11-02T21:34:52 https://maestrodatabase.com/blog/department-of-health-publishes-revised-agenda-for-the-july-2021-pbac-meeting 2021-06-03T21:09:25 https://maestrodatabase.com/blog/breast-cancer-sufferer-claire-mclintock-fundraising-for-new-drug-palbociclib 2017-08-13T00:16:24 https://maestrodatabase.com/blog/the-voice-of-the-patient 2016-09-15T01:23:30 https://maestrodatabase.com/blog/statement-on-efforts-to-help-make-development-of-biosimilar-and-interchangeable-insulin-products-more-efficient 2019-11-25T19:32:46 https://maestrodatabase.com/blog/fda-approves-imlygic-talimogene-laherparepvec-as-first-oncolytic-viral-therapy-in-the-us 2015-10-28T20:23:23 https://maestrodatabase.com/blog/protalix-biotherapeutics-and-chiesi-global-rare-diseases-announce-submission-of-biologics-license-application-to-u-dot-s-fda-for-pegunigalsidase-alfa-for-the-treatment-of-fabry-disease 2020-05-28T21:05:11 https://maestrodatabase.com/blog/sarepta-therapeutics-announces-fda-request-for-dystrophin-data-prior-to-making-a-decision-on-eteplirsen-nda 2016-06-07T09:20:42 https://maestrodatabase.com/blog/diabetes-drugs-cost-the-nhs-in-scotland-almost-90-million-last-year 2016-07-18T09:37:56 https://maestrodatabase.com/blog/private-health-insurance-tactics-to-lure-young-people-ineffective-senate-told 2017-08-13T00:28:49 https://maestrodatabase.com/blog/health-canada-approves-pfizer-biontech-covid-19-vaccine-for-kids-under-5 2022-09-09T23:10:02 https://maestrodatabase.com/blog/humanfirst-joins-the-fda-hhs-and-more-than-20-organisations-and-leading-health-companies-to-launch-the-digital-health-measurement-collaborative-community 2021-06-03T21:28:49 https://maestrodatabase.com/blog/us-fda-approves-two-supplemental-indications-for-harvoni-in-chronic-hepatitis-c-patients-with-advanced-liver-disease 2016-02-17T20:22:22 https://maestrodatabase.com/blog/biden-health-official-taking-a-look-at-trump-drug-pricing-proposal 2021-06-03T20:56:06 https://maestrodatabase.com/blog/ispor-publishes-new-global-health-care-systems-road-map-australia-medical-devices 2016-05-03T00:24:23 https://maestrodatabase.com/blog/technegas---us-fda-new-drug-application---next-milestone-in-approval-process-successfully-achieved 2020-05-28T11:27:26 https://maestrodatabase.com/blog/abbvie-receives-fda-approval-of-supplemental-new-drug-application-for-viekira-pak-ombitasvir-paritaprevir-and-ritonavir-tablets-dasabuvir-tablets-without-ribavirin-in-genotype-1b-chronic-hepatitis-c-patients-with-compensated-cirrhosis 2016-04-26T12:02:26 https://maestrodatabase.com/blog/eu-regulators-develop-recommendations-to-forecast-demand-of-medicines 2021-06-03T20:51:40 https://maestrodatabase.com/blog/2015-cadth-symposium---request-to-attend 2015-08-05T11:37:19 https://maestrodatabase.com/blog/zogenix-announces-fda-acceptance-for-filing-of-new-drug-application-and-priority-review-for-fintelpa-for-the-treatment-of-dravet-syndrome 2019-11-25T19:54:41 https://maestrodatabase.com/blog/off-label-drugs-a-risky-business 2020-05-28T11:38:49 https://maestrodatabase.com/blog/a-drug-cartel-at-the-fda 2016-09-27T20:55:46 https://maestrodatabase.com/blog/astrazeneca-receives-complete-response-letter-from-us-fda-for-sodium-zirconium-cyclosilicate-zs-9-for-oral-suspension-for-treatment-of-hyperkalaemia 2016-05-28T12:45:44 https://maestrodatabase.com/blog/adamis-pharmaceuticals-receives-a-complete-response-letter-from-the-fda-regarding-zimhi 2020-11-16T12:02:35 https://maestrodatabase.com/blog/amgen-receives-chmp-positive-opinions-for-two-new-treatment-options-for-patients-with-blood-cancer-in-europe 2015-09-26T02:35:10 https://maestrodatabase.com/blog/nhs-chief-further-cancer-cuts-likely 2015-08-05T11:37:24 https://maestrodatabase.com/blog/the-big-pharma-firm-that-saw-the-future 2021-06-03T21:00:33 https://maestrodatabase.com/blog/pharmaceutical-benefits-advisory-committee-guidelines-review 2015-08-05T11:37:12 https://maestrodatabase.com/blog/worlds-most-hated-man-martin-shkreli-faces-critics-over-drug-price-rise 2015-10-26T08:15:48 https://maestrodatabase.com/blog/public-summary-documents-from-the-march-2014-pbac-meeting-rejections 2015-08-05T11:37:20 https://maestrodatabase.com/blog/modelling-epidemics-with-compartmental-models 2020-05-28T21:30:20 https://maestrodatabase.com/blog/hepatitis-c-drug-buyers-club-aims-to-set-up-new-source-of-support 2015-09-25T22:30:01 https://maestrodatabase.com/blog/fda-approves-revumenib-for-relapsed-or-refractory-acute-leukaemia-with-a-kmt2a-translocation 2024-11-15T23:16:43 https://maestrodatabase.com/blog/federal-budget-2015-nearly-2-billion-in-cuts-to-health-system 2015-08-05T11:37:02 https://maestrodatabase.com/blog/nonparametric-statistical-analysis 2020-05-28T21:33:20 https://maestrodatabase.com/blog/nice-recommends-rivaroxaban-xarelto-to-prevent-blood-clots-in-people-who-have-had-a-heart-attack-in-final-draft-guidance 2015-08-05T11:37:30 https://maestrodatabase.com/blog/cancer_overtakes_heart_disease_as_biggest_killer_in_australia__world_health_organisation 2015-08-05T11:37:08 https://maestrodatabase.com/blog/tlv-has-decided-to-reconsider-the-subsidy-status-for-certain-drugs 2020-05-28T21:39:52 https://maestrodatabase.com/blog/updated-label-for-daklinza-daclatasvir-for-the-12-week-treatment-of-non-cirrhotic-patients-with-chronic-hepatitis-c-genotype-3-approved-by-the-european-commission 2015-09-11T08:33:42 https://maestrodatabase.com/blog/fda-accepts-intercepts-new-drug-application-for-oca-for-the-treatment-of-liver-fibrosis-due-to-nash-and-grants-priority-review 2019-11-25T20:05:17 https://maestrodatabase.com/blog/gsk_announces_approval_in_canada_for_incruse_ellipta__umeclidinium_bromide__as_a_treatment_for_copd 2015-08-05T11:37:11 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac---april-2015-pbac-special-meeting 2015-08-05T11:37:17 https://maestrodatabase.com/blog/us-fda-approves-invega-trinza-first-and-only-four-times-a-year-treatment-for-schizophrenia 2015-08-05T11:37:06 https://maestrodatabase.com/blog/calls-to-fast-track-pfizer-for-victoria-amid-phenomenal-demand-for-vaccine 2021-06-03T21:56:54 https://maestrodatabase.com/blog/bill-ferris-defends-rd-reform-proposals 2016-10-05T19:50:56 https://maestrodatabase.com/blog/mei-pharmas-pracinostat-receives-breakthrough-therapy-designation-from-fda-for-treatment-in-combination-with-azacitidine-of-patients-with-newly-diagnosed-acute-myeloid-leukaemia-unfit-for-intensive-chemotherapy 2016-08-01T23:46:23 https://maestrodatabase.com/blog/novartis-receives-two-new-fda-approvals-for-cosentyx-to-treat-patients-with-ankylosing-spondylitis-and-psoriatic-arthritis-in-the-us 2017-06-08T03:14:16 https://maestrodatabase.com/blog/cancer-experts-write-to-government-to-demand-life-saving-drug-be-used-on-nhs 2016-07-24T21:22:33 https://maestrodatabase.com/blog/covid-19-researchers-halt-patient-recruitment-for-hydroxychloroquine-trial 2020-05-28T21:22:54 https://maestrodatabase.com/blog/vertex-receives-australian-approval-for-orkambi-lumacaftorivacaftor-the-first-medicine-to-treat-the-underlying-cause-of-cystic-fibrosis-in-people-ages-12-and-older-with-two-copies-of-the-f508del-mutation 2016-03-09T07:03:54 https://maestrodatabase.com/blog/humira-adalimumab-approved-by-european-commission-for-moderate-to-severe-hidradenitis-suppurativa-hs 2015-08-05T11:37:28 https://maestrodatabase.com/blog/waste-in-cancer-drugs-costs-3-billion-a-year-a-study-says-1 2016-03-01T11:22:29 https://maestrodatabase.com/blog/health-canada-approves-pradaxa-for-the-treatment-of-venous-thromboembolism-events-deep-vein-thrombosis-dvt-and-pulmonary-embolism-pe-and-for-the-prevention-of-recurrent-dvt-and-pe 2015-08-05T11:37:21 https://maestrodatabase.com/blog/decision-to-widen-access-to-a-brand-of-long-acting-methylphenidate 2020-10-23T03:35:08 https://maestrodatabase.com/blog/pfizer-and-merck-join-500-million-california-ballot-stampede 2016-05-31T18:00:47 https://maestrodatabase.com/blog/cms-releases-2014-national-health-expenditures 2015-12-02T22:07:56 https://maestrodatabase.com/blog/european-commission-grants-marketing-authorization-for-gileads-zydelig-idelalisib-for-the-treatment-of-chronic-lymphocytic-leukemia-and-follicular-lymphoma 2015-08-05T11:37:08 https://maestrodatabase.com/blog/fda-approves-first-intraocular-lens-with-extended-range-of-vision-for-cataract-patients 2016-07-15T22:16:15 https://maestrodatabase.com/blog/chemotherapy-mortality-study-could-help-improve-cancer-care-in-england 2016-08-31T21:05:50 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-positive-chmp-opinion-for-opdivo-nivolumab-plus-yervoy-ipilimumab-for-the-first-line-treatment-of-adult-patients-with-microsatellite-instability-high-or-mismatch-repair-deficient-metastatic-colorectal-cancer 2024-11-15T23:36:45 https://maestrodatabase.com/blog/fda-approves-new-treatment-for-cystic-fibrosis 2015-08-05T11:37:30 https://maestrodatabase.com/blog/vaccine-nationalism-a-new-dynamic-in-the-race-to-quash-coronavirus 2020-05-28T21:46:56 https://maestrodatabase.com/blog/how-parents-harnessed-the-power-of-social-media-to-challenge-epipen-prices 2016-08-28T10:37:16 https://maestrodatabase.com/blog/trametinib-mekinist-managed-entry-scheme-for-listing-on-the-pharmaceutical-benefits-scheme-information-for-patients 2015-08-06T20:45:50 https://maestrodatabase.com/blog/fauci-warns-about-hydroxychloroquine 2020-05-28T21:49:59 https://maestrodatabase.com/blog/eisai-receives-european-commission-approval-of-anti-cancer-agent-lenvima-for-treatment-of-advanced-thyroid-cancer-refractory-to-radio-active-iodine 2015-08-05T11:37:18 https://maestrodatabase.com/blog/allergan-announces-fda-approval-of-aczone-dapsone-75-topical-gel-for-treatment-of-acne-vulgaris 2016-02-26T07:17:10 https://maestrodatabase.com/blog/keytruda-pembrolizumab-receives-new-draft-recommendation-from-national-institute-for-health-and-care-excellence-nice-in-uk-for-first-line-treatment-for-advanced-melanoma 2015-10-09T20:44:02 https://maestrodatabase.com/blog/fda-approves-anacor-pharmaceuticals-kerydin-tavaborole-5-topical-solution-for-the-treatment-of-onychomycosis-of-the-toenails 2015-08-05T11:37:10 https://maestrodatabase.com/blog/submissions-to-the-review-of-pharmacy-remuneration-and-regulation 2016-08-25T11:24:44 https://maestrodatabase.com/blog/cms-releases-new-prescription-drug-cost-data 2016-08-19T06:51:21 https://maestrodatabase.com/blog/sun-pharma-gets-fda-approval-for-generic-of-novartis-gleevec 2015-12-07T11:21:03 https://maestrodatabase.com/blog/sandoz-decides-not-to-pursue-us-biosimilar-rituximab-will-focus-on-robust-biosimilar-portfolio-for-unmet-access-and-sustainability-needs 2018-11-02T22:06:16 https://maestrodatabase.com/blog/ema-started-the-evaluation-of-richters-marketing-authorisation-application-for-biosimilar-teriparatide 2016-01-07T02:32:14 https://maestrodatabase.com/blog/fda-approves-amivantamab-vmjw-for-egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer-indications 2024-03-01T21:25:50 https://maestrodatabase.com/blog/pharmaceutical-benefit-advisory-committee-pbac-guidelines-review 2015-08-17T07:10:17 https://maestrodatabase.com/blog/icer-to-review-abuse-deterrent-opioids-in-upcoming-report 2016-08-17T21:15:31 https://maestrodatabase.com/blog/fda-permits-marketing-of-balloon-device-to-treat-persistent-eustachian-tube-dysfunction 2016-09-16T23:53:46 https://maestrodatabase.com/blog/ptac-rare-disorders-subcommittee-meeting---20-june-2014 2015-08-05T11:37:25 https://maestrodatabase.com/blog/cadth-recommends-reimbursement-of-secukinumab-cosentyx-for-psoriatic-arthritis 2016-08-25T21:35:02 https://maestrodatabase.com/blog/government_to_extend_cancer_drugs_fund_until_2016 2015-08-05T11:37:29 https://maestrodatabase.com/blog/fda-approves-voxelotor-for-sickle-cell-disease 2019-11-25T21:06:41 https://maestrodatabase.com/blog/fda-approves-boehringer-ingelheims-stiolto--respimat-as-once-daily-maintenance-treatment-for-copd 2015-08-05T11:37:30 https://maestrodatabase.com/blog/the-ethics-of-expanding-access-to-cheaper-less-effective-treatments 2016-08-28T10:43:51 https://maestrodatabase.com/blog/summary-of-the-outcomes-from-the-pbac-july-2016-meeting 2016-08-21T08:02:36 https://maestrodatabase.com/blog/boris-johnson-pledges-ps500-million-for-cutting-edge-medicine-as-pm-plans-to-expand-cancer-drugs-fund-to-fight-dementia-and-motor-neurone-disease 2019-11-25T21:04:25 https://maestrodatabase.com/blog/nice-says-yes-to-new-class-of-drug-for-adults-with-leukaemia 2015-09-24T12:51:21 https://maestrodatabase.com/blog/call-for-feedback-drugs-for-chronic-hepatitis-c-infection 2015-08-05T11:37:18 https://maestrodatabase.com/blog/cdr-update--issue-105 2015-08-05T11:37:02 https://maestrodatabase.com/blog/proposal_for_paliperidone_depot_injection__risperidone_depot_injection_and_olanzapine_depot_injection 2015-08-05T11:37:05 https://maestrodatabase.com/blog/decisions-to-list-delist-and-amend-restrictions-on-various-pharmaceuticals 2015-08-05T11:37:12 https://maestrodatabase.com/blog/radius-health-provides-update-on-chmp-opinion-for-abaloparatide-sc 2018-03-23T02:10:26 https://maestrodatabase.com/blog/how-to-make-us-health-care-more-equitable-and-less-costly-begin-by-replacing-employment-based-insurance 2018-11-02T23:44:28 https://maestrodatabase.com/blog/how-valeant-cashed-in-twice-on-higher-drug-prices 2016-08-01T11:57:53 https://maestrodatabase.com/blog/relevant_additions_and_changes_to_the_1_april_2014_issue_of_the_schedule_of_pharmaceutical_benefits_have_been_added_to_maestro_australia 2015-08-05T11:37:20 https://maestrodatabase.com/blog/perc-recommends-yervoy-ipilimumab-for-first-line-use-by-adults-with-metastatic-melanoma 2015-08-05T11:37:02 https://maestrodatabase.com/blog/cancer-drugs-may-start-the-next-drug-price-wars 2016-06-28T21:59:21 https://maestrodatabase.com/blog/health-canada-approves-rituxan-subcutaneous-formulation-for-canadians-with-chronic-lymphocytic-leukaemia 2018-03-23T01:40:19 https://maestrodatabase.com/blog/cadth-issues-final-perc-recommendation-for-yondelis-trabectedin 2016-08-08T21:23:55 https://maestrodatabase.com/blog/summary-of-submissions-and-outcomes-from-the-july-2015-pbac-meeting 2015-08-23T05:58:33 https://maestrodatabase.com/blog/nice-issues-final-ok-for-novartis-hives-therapy 2015-08-05T11:37:14 https://maestrodatabase.com/blog/medicares-cancer-drug-experiment-annoys-specialists 2016-04-11T21:28:03 https://maestrodatabase.com/blog/us-fda-commissioner-margaret-hamburg-to-step-down 2015-08-05T11:37:11 https://maestrodatabase.com/blog/xadago-safinamide-new-drug-application-accepted-for-filing-by-the-us-food-and-drug-administration 2015-08-05T11:37:24 https://maestrodatabase.com/blog/rfp--supply-of-national-vaccine-storage-and-distribution-services 2015-08-05T11:37:17 https://maestrodatabase.com/blog/call-for-patient-input 2015-08-05T11:37:07 https://maestrodatabase.com/blog/vaccinex-receives-fda-fast-track-designation-for-vx15-antibody-for-the-treatment-of-huntingtons-disease 2016-08-02T00:30:05 https://maestrodatabase.com/blog/added-benefit-of-idelalisib-is-not-proven 2015-08-05T11:37:03 https://maestrodatabase.com/blog/dont-delay-news-of-medical-breakthroughs 2015-09-18T21:43:12 https://maestrodatabase.com/blog/listing-of-intravenous-nicardipine 2015-08-05T11:37:26 https://maestrodatabase.com/blog/why-the-who-plans-a-fair-pricing-model-for-drugs 2016-07-09T02:47:11 https://maestrodatabase.com/blog/considerable-additional-benefit-of-eisais-halaven-eribulin-confirmed-by-german-federal-joint-committee-g-ba 2015-08-05T11:37:23 https://maestrodatabase.com/blog/introducing-a-common-cadth-recommendation-framework-and-establishing-a-minimum-period-of-120-calendar-days-for-advance-notification-of-anticipated-submissions-and-resubmissions-for-cadth-common-drug-review-and-pan-canadian-oncology-drug-review-programs 2016-03-25T00:59:36 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-positive-chmp-opinion-for-repotrectinib-for-the-treatment-of-advanced-ros1-positive-non-small-cell-lung-cancer-and-advanced-ntrk-positive-solid-tumours 2024-11-16T00:30:15 https://maestrodatabase.com/blog/plans-for-measles-vaccinations-to-be-distributed-back-through-pharmac 2019-11-26T01:53:43 https://maestrodatabase.com/blog/abbvie-and-eisai-obtain-additional-approval-for-new-indication-of-fully-human-anti-tnf-α-monoclonal-antibody-humira-in-the-treatment-of-non-infectious-uveitis 2016-09-29T20:58:11 https://maestrodatabase.com/blog/response-to-consultation-comments-price-disclosure-originator-brand-removal 2015-09-21T12:02:48 https://maestrodatabase.com/blog/new-study-shows-nice-advice-support-can-reduce-appraisal-timelines-by-3-months 2024-11-16T00:24:07 https://maestrodatabase.com/blog/cardiome-announces-xydalba-single-dose-infusion-approval-by-european-medicines-agency 2016-08-10T05:51:46 https://maestrodatabase.com/blog/recently_added_forthcoming_submissions___april_2014_update 2015-08-05T11:37:08 https://maestrodatabase.com/blog/drug-costs-up-in-201314-for-canadian-public-drug-plans-due-to-increased-spending-on-high-cost-drugs-reduced-savings-from-generics 2016-05-26T10:49:39 https://maestrodatabase.com/blog/ron-walkers-150000-cancer-drug-keytruda-approved-for-melanoma-patients 2015-08-05T11:37:06 https://maestrodatabase.com/blog/at-heart-medical-device-prices-in-australia-are-unhealthily-high 2016-10-03T20:01:17 https://maestrodatabase.com/blog/progenics-pharmaceuticals-announces-three-month-extension-of-pdufa-date-for-azedra-iobenguane-i-131 2018-03-23T03:20:39 https://maestrodatabase.com/blog/abc_tv_show_catalyst_could_cause_3000_heart_attacks 2015-08-05T11:37:26 https://maestrodatabase.com/blog/smc-oks-five-new-drugs-for-routine-use-in-scotland 2015-08-05T11:37:27 https://maestrodatabase.com/blog/why-do-health-costs-keep-rising-these-people-know 2016-06-10T23:41:48 https://maestrodatabase.com/blog/government-likely-to-fund-melanoma-drug-judith-collins 2015-12-04T01:37:00 https://maestrodatabase.com/blog/cancer-drugs-fund-makes-no-sense-says-head-of-drugs-rationing-body-nice 2015-08-05T11:37:29 https://maestrodatabase.com/blog/nice_gives_green_light_to_jetrea__ocriplasmin__in_final_draft_guidance 2015-08-05T11:37:04 https://maestrodatabase.com/blog/verastem-oncology-announces-submission-of-a-marketing-authorisation-application-to-the-european-medicines-agency-for-copiktra-duvelisib 2019-11-26T02:11:24 https://maestrodatabase.com/blog/changes-to-the-funding-access-criteria-for-some-vaccines 2015-08-05T11:37:07 https://maestrodatabase.com/blog/outrageous-banned-breast-implant-maker-flouts-tga-and-safety-concerns 2019-11-26T02:09:21 https://maestrodatabase.com/blog/health_canada_approves_pomalyst_for_patients_with_multiple_myeloma 2015-08-05T11:37:26 https://maestrodatabase.com/blog/us-fda-expands-imbruvica-ibrutinib-label-to-include-overall-survival-data-in-previously-untreated-chronic-lymphocytic-leukaemia-and-new-indication-for-small-lymphocytic-lymphoma-patients 2016-05-10T05:33:53 https://maestrodatabase.com/blog/the-european-commission-approves-aloxi-palonosetron-hydrochloride-injection-to-prevent-nausea-and-vomiting-due-to-chemotherapy-in-children-as-young-as-one-month 2015-08-05T11:37:10 https://maestrodatabase.com/blog/probing-our-moral-values-in-health-care-the-pricing-of-specialty-drugs 2015-09-08T20:36:49 https://maestrodatabase.com/blog/pharmac-proposal-to-list-pheburane-sodium-phenylbutyrate 2015-10-23T01:26:02 https://maestrodatabase.com/blog/phathom-pharmaceuticals-provides-corporate-update 2019-11-26T02:23:56 https://maestrodatabase.com/blog/gw_pharma_reaches_an_agreement_on_the_pricing_of_sativex__nabiximols__in_germany 2015-08-05T11:37:06 https://maestrodatabase.com/blog/walking-the-tightrope-between-treatment-efficacy-and-price 2015-09-09T07:09:55 https://maestrodatabase.com/blog/fda-accepts-arcutis-biotherapeutics-new-drug-application-for-roflumilast-cream-for-adults-and-adolescents-with-plaque-psoriasis 2021-12-31T05:59:19 https://maestrodatabase.com/blog/tpp__no_threat_to_medicine_ 2015-08-05T11:37:25 https://maestrodatabase.com/blog/tga-website-update 2016-04-15T05:14:56 https://maestrodatabase.com/blog/more-value-from-payment-reform-in-health-care-and-biomedical-innovation 2016-09-27T11:25:27 https://maestrodatabase.com/blog/new_features_have_been_added_to_maestro_australia 2015-08-05T11:37:18 https://maestrodatabase.com/blog/celltrion-healthcare-receives-eu-marketing-authorisation-for-worlds-first-subcutaneous-formulation-of-infliximab-remsima-sc-for-the-treatment-of-people-with-rheumatoid-arthritis 2019-11-26T02:16:48 https://maestrodatabase.com/blog/european-commission-approves-halaven-eribulin-mesylate-for-treatment-of-advanced-liposarcoma-in-europe 2016-05-05T12:18:08 https://maestrodatabase.com/blog/government-must-take-action-now-on-cancer-drug-availability 2015-09-22T12:28:13 https://maestrodatabase.com/blog/zejula-is-included-in-the-high-cost-protection-with-limitation 2019-11-26T02:47:01 https://maestrodatabase.com/blog/seizure-inducing 2016-09-01T21:16:01 https://maestrodatabase.com/blog/eliquis-approved-for-treatment-of-venous-thromboembolic-events-and-the-prevention-of-recurrent-deep-vein-thrombosis-and-pulmonary-embolism 2015-08-05T11:37:28 https://maestrodatabase.com/blog/pharmacy-agreement-offers-pills-with-a-sugar-coating 2015-08-05T11:37:06 https://maestrodatabase.com/blog/your-money-or-your-life-cancers-crushing-cost 2022-09-10T05:01:38 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-january-2022-update 2021-12-31T23:04:39 https://maestrodatabase.com/blog/dasabuvir-and-ombitasvirparitaprevirritonavir-iqwig-finds-a-hint-of-added-benefit-in-further-patients 2015-08-10T13:38:42 https://maestrodatabase.com/blog/when-health-insurers-merge-consumers-often-lose 2016-07-25T08:59:02 https://maestrodatabase.com/blog/pembrolizumab-information-for-patients 2015-08-31T21:30:31 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-january-2022 2021-12-31T22:58:26 https://maestrodatabase.com/blog/thousands-of-cancer-patients-to-be-denied-treatment 2015-09-04T21:16:29 https://maestrodatabase.com/blog/new-price-cuts-to-medicines-demonstrate-pbs-sustainability 2015-08-05T11:37:12 https://maestrodatabase.com/blog/using-grade-methodology-to-assess-innovation-of-new-medicinal-products-in-italy 2019-11-26T07:09:07 https://maestrodatabase.com/blog/celltrion-acquires-approval-for-its-new-humira-yuflyma-in-canada 2021-12-31T06:15:49 https://maestrodatabase.com/blog/eu-agrees-tighter-standards-for-medical-devices 2016-06-08T08:34:31 https://maestrodatabase.com/blog/cadth-rejects-submission-from-actavis-for-constella-linaclotide-for-patients-with-ibs 2015-09-29T21:43:45 https://maestrodatabase.com/blog/epipen-outrage-the-us-senators-daughter-who-raised-price-of-anti-allergy-medication-by-400 2016-08-25T07:31:15 https://maestrodatabase.com/blog/vertex-submits-applications-in-the-us-and-europe-for-approval-of-lumacaftor-in-combination-with-ivacaftor-for-people-with-cystic-fibrosis-who-have-two-copies-of-the-f508del-mutation 2015-08-05T11:37:24 https://maestrodatabase.com/blog/meet-the-health-crusader-saving-lives-with-cheap-drugs 2015-08-21T02:14:52 https://maestrodatabase.com/blog/fda-approves-esbriet-to-treat-idiopathic-pulmonary-fibrosis 2015-08-05T11:37:21 https://maestrodatabase.com/blog/seattle-genetics-announces-health-canada-approval-of-adcetris-brentuximab-vedotin-in-combination-with-chemotherapy-in-frontline-cd30-expressing-peripheral-t-cell-lymphoma 2019-11-26T04:31:33 https://maestrodatabase.com/blog/spending-on-drugs-will-drop-as-top-sellers-go-generic 2016-04-14T21:29:04 https://maestrodatabase.com/blog/dispensing-frequency-amendment-approved 2015-08-05T11:37:20 https://maestrodatabase.com/blog/prescription-medicines-submissions-in-the-ectd-format-now-in-australia 2015-08-05T11:37:10 https://maestrodatabase.com/blog/canberra-to-increase-hiv-funding-list-groundbreaking-drug-treatment 2019-11-26T20:24:35 https://maestrodatabase.com/blog/independent-review-of-tga-provides-sensible-solutions-to-accelerate-access-to-new-medicines 2015-08-05T11:37:09 https://maestrodatabase.com/blog/novartis-canada-disappointed-with-outcome-of-pcpa-negotiations-for-metastatic-castration-resistant-prostate-cancer-treatment-pluvicto 2024-11-16T01:23:56 https://maestrodatabase.com/blog/could-australia-become-global-cannabis-leader 2016-02-11T20:28:25 https://maestrodatabase.com/blog/icer-releases-evidence-report-on-jak-inhibitors-to-treat-rheumatoid-arthritis 2019-11-26T20:18:20 https://maestrodatabase.com/blog/xeris-biopharma-announces-u-dot-s-fda-approval-of-recorlev-levoketoconazole-for-the-treatment-of-endogenous-hypercortisolemia-in-adult-patients-with-cushings-syndrome 2022-01-01T01:17:42 https://maestrodatabase.com/blog/perc_has_recommended_the_funding_of_brentuximab_vedotin__adcetris__for_patients_with_hodgkin_s_lymphoma 2015-08-05T11:37:23 https://maestrodatabase.com/blog/even-insured-can-face-crushing-medical-debt-study-finds 2016-01-06T22:32:34 https://maestrodatabase.com/blog/mavenclad-granted-accelerated-access-by-nice 2019-11-26T10:33:24 https://maestrodatabase.com/blog/tlv-reconsiders-the-subsidy-of-rinvoq 2020-10-23T20:50:58 https://maestrodatabase.com/blog/the-pcodr-program-is-moving 2015-08-05T11:37:19 https://maestrodatabase.com/blog/efficiency-ratio-and-rocketing-drug-prices-old-concerns-and-new-possibilities 2020-10-23T08:16:54 https://maestrodatabase.com/blog/dabrafenib_in_melanoma__added_benefit_not_proven 2015-08-05T11:37:19 https://maestrodatabase.com/blog/us-drug-makers-have-imposed-big-price-rises-for-top-selling-drugs-study-finds 2016-04-06T07:29:32 https://maestrodatabase.com/blog/amgen-submits-marketing-authorization-application-for-novel-investigational-ldl-cholesterol-lowering-medication-evolocumab-to-the-european-medicines-agency 2015-08-05T11:37:29 https://maestrodatabase.com/blog/pharmac-proposals-regarding-multiple-sclerosis-treatments 2015-10-19T11:58:27 https://maestrodatabase.com/blog/outcome-statement---october-2024-dusc-meeting 2024-11-16T01:04:43 https://maestrodatabase.com/blog/actelion-is-granted-market-authorisation-for-uptravi-selexipag-in-pulmonary-arterial-hypertension-by-the-european-commission 2016-05-17T10:37:43 https://maestrodatabase.com/blog/teva-drug-makers-in-talks-with-u-dot-s-to-end-generics-probes 2019-11-26T20:42:09 https://maestrodatabase.com/blog/evaluation-of-health-care-interventions-and-big-data-review-of-associated-data-issues 2017-08-13T12:51:14 https://maestrodatabase.com/blog/newron-receives-complete-response-letter-from-us-fda-for-xadago-safinamide 2016-03-30T20:47:59 https://maestrodatabase.com/blog/the-wrong-way-to-control-drug-prices 2016-04-20T21:02:05 https://maestrodatabase.com/blog/ema-adopts-eu-ombudsman-recommendations-to-avoid-bias-concerns-over-drug-approvals 2019-11-26T20:28:20 https://maestrodatabase.com/blog/decision-to-award-sole-supply-of-progestogen-only-long-acting-intra-uterine-system-lius-in-the-community-and-dhb-hospitals 2016-07-20T20:59:33 https://maestrodatabase.com/blog/nice-green-light-for-sankyos-bloodthinner-lixiana 2015-08-26T20:38:05 https://maestrodatabase.com/blog/cancer-drug-a-long-time-coming 2016-06-09T21:43:46 https://maestrodatabase.com/blog/pharmac-seeking-community-views-on-changes-to-funding-application-process 2016-08-18T01:45:31 https://maestrodatabase.com/blog/harvoni-passed-common-drug-review 2015-08-05T11:37:03 https://maestrodatabase.com/blog/regulatory-decision-making-in-canadaexploring-new-frontiers-in-patient-involvement 2016-10-04T02:32:13 https://maestrodatabase.com/blog/eu-oks-gardasil-update-on-long-term-hpv-protection 2015-08-05T11:37:06 https://maestrodatabase.com/blog/updated-pbac-outcomes-for-march-and-july-2015 2015-12-12T01:48:00 https://maestrodatabase.com/blog/cadth-calls-for-patient-input-on-a-new-submission-from-genzyme-for-cerdelga 2016-02-01T20:55:47 https://maestrodatabase.com/blog/meeting-highlights-from-the-committee-for-medicinal-products-for-human-use-chmp-22-25-june-2015 2015-08-05T11:37:03 https://maestrodatabase.com/blog/labour-pledges-cancer-therapy-fund 2015-08-05T11:37:23 https://maestrodatabase.com/blog/strengthening-global-collaboration-on-covid-19-real-world-evidence-and-observational-studies 2020-10-23T20:55:41 https://maestrodatabase.com/blog/us-food-and-drug-administration-approves-sotyktu-deucravacitinib-oral-treatment-for-adults-with-moderate-to-severe-plaque-psoriasis 2022-09-10T11:39:25 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac-march-2016 2016-04-23T23:50:59 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac-november-2015 2015-12-20T20:50:37 https://maestrodatabase.com/blog/review-of-pharmacy-remuneration-and-regulation 2016-10-31T08:08:26 https://maestrodatabase.com/blog/fda-approves-roches-lucentis-ranibizumab-injection-for-treatment-of-diabetic-retinopathy-in-people-with-diabetic-macular-oedema 2015-08-05T11:37:26 https://maestrodatabase.com/blog/proposal-to-reinstate-monthly-dispensing-on-various-pharmaceuticals-remove-stat-dispensing 2015-08-05T11:37:22 https://maestrodatabase.com/blog/health-canada-approves-opdivo-nivolumab-for-the-treatment-of-advanced-or-metastatic-non-small-cell-lung-cancer 2016-03-02T06:24:29 https://maestrodatabase.com/blog/development-of-medicines-to-treat-tuberculosis 2016-08-01T23:31:25 https://maestrodatabase.com/blog/more-options-to-be-made-available-to-treat-hepatitis-c 2016-09-09T08:30:00 https://maestrodatabase.com/blog/acelrx-announces-fda-approval-of-dsuvia 2018-11-03T08:29:45 https://maestrodatabase.com/blog/rethinking-the-appraisal-and-approval-of-drugs-for-type-2-diabetes 2015-10-14T07:34:26 https://maestrodatabase.com/blog/call-for-patient-input-25 2015-08-05T11:37:07 https://maestrodatabase.com/blog/cadth-calls-for-patient-input 2015-08-12T21:13:08 https://maestrodatabase.com/blog/capivasertib-in-combination-with-faslodex-granted-priority-review-in-the-us-for-patients-with-advanced-hormone-receptor-positive-breast-cancer 2023-06-12T06:57:35 https://maestrodatabase.com/blog/interpretation-of-clinical-trials-that-stopped-rarly 2016-04-19T20:31:33 https://maestrodatabase.com/blog/paion-submits-extension-application-of-marketing-authorisation-for-remimazolam-in-the-indication-general-anaesthesia-to-the-european-medicines-agency 2022-01-01T03:34:57 https://maestrodatabase.com/blog/cadth-posts-final-recommendation-for-zydelig 2016-09-29T21:11:49 https://maestrodatabase.com/blog/nice-confirms-support-for-novartis-heart-drug-entresto 2016-03-21T09:47:13 https://maestrodatabase.com/blog/the-arm-wrestle-over-drugs-inside-the-tpp-deal 2015-10-06T20:24:49 https://maestrodatabase.com/blog/nice-draft-guidance-recommends-treatments-for-arthritis-in-children 2015-10-22T03:52:15 https://maestrodatabase.com/blog/iqwig_finds_that_vismodegib__erivedge__provides_no_additional_benefit_for_patients_with_basal_cell_carcinoma 2015-08-05T11:37:22 https://maestrodatabase.com/blog/fda-approves-briviact-to-treat-partial-onset-seizures 2016-02-19T21:10:39 https://maestrodatabase.com/blog/funding-prep-for-hiv-prevention 2016-07-06T02:39:41 https://maestrodatabase.com/blog/working-to-lower-drug-costs-by-challenging-questionable-patents 2015-11-29T10:10:13 https://maestrodatabase.com/blog/humana-unitedhealthcare-join-new-value-based-prescription-drug-model 2016-10-04T21:24:41 https://maestrodatabase.com/blog/cancer-drug-saves-masterton-war-veteran 2016-04-22T04:30:49 https://maestrodatabase.com/blog/cadth-recommends-the-reimbursement-of-four-new-products 2015-09-24T13:17:12 https://maestrodatabase.com/blog/it-feels-dodgy-parents-bypass-tga-to-buy-sleep-drug-from-overseas 2018-11-03T21:04:04 https://maestrodatabase.com/blog/agenda-for-the-3-june-2015-tc-meeting 2015-08-05T11:37:22 https://maestrodatabase.com/blog/acelrx-pharmaceuticals-receives-complete-response-letter-from-fda-for-nda-for-zalviso 2015-08-05T11:37:26 https://maestrodatabase.com/blog/proposal_to_fund_adalimumab_and_etanercept_for_the_treatment_of_pyoderma_gangrenosum 2015-08-05T11:37:08 https://maestrodatabase.com/blog/alveogene-receives-rare-paediatric-disease-designation-from-fda-for-avg-002-its-novel-inhaled-gene-therapy-for-lethal-neonatal-surfactant-protein-b-deficiency 2024-11-16T02:57:45 https://maestrodatabase.com/blog/eu-clears-enbrel-for-early-axial-spondyloarthritis 2015-08-05T11:37:16 https://maestrodatabase.com/blog/the_age___judge_refuses_to_approve_vioxx_settlement 2015-08-05T11:37:06 https://maestrodatabase.com/blog/vm-biopharma-announces-fda-fast-track-designation-granted-for-investigational-gene-therapy-vm202-for-patients-with-amyotrophic-lateral-sclerosis 2016-05-18T07:54:34 https://maestrodatabase.com/blog/valeant-chief-at-senate-hearing-concedes-mistakes-on-steep-drug-prices 2016-04-28T12:54:50 https://maestrodatabase.com/blog/cadth-calls-for-patient-input-on-a-new-submission-from-astrazeneca-for-brilinta 2016-01-16T04:22:41 https://maestrodatabase.com/blog/amgen-receives-chmp-positive-opinion-for-imlygic-talimogene-laherparepvec 2015-10-23T11:36:22 https://maestrodatabase.com/blog/chmp-issues-positive-opinion-for-futibatinib-for-the-treatment-of-adults-with-cholangiocarcinoma 2023-04-28T02:15:15 https://maestrodatabase.com/blog/sudbury-ontario-family-finally-gets-coverage-for-drug-to-treat-daughters-rare-epilepsy 2024-01-18T04:05:12 https://maestrodatabase.com/blog/a-caravan-of-americans-is-crossing-the-canadian-border-to-get-affordable-health-care 2019-05-07T18:00:09 https://maestrodatabase.com/blog/health-canada-approves-first-and-only-oral-targeted-treatment-for-brain-cancer 2024-10-23T02:09:21 https://maestrodatabase.com/blog/cothera-bioscience-announces-fda-fast-track-designation-for-clinical-program-pc-002 2024-10-23T02:03:44 https://maestrodatabase.com/blog/us-fda-approves-prevnar-20-pfizers-20-valent-pneumococcal-conjugate-vaccine-for-infants-and-children 2023-04-28T01:13:52 https://maestrodatabase.com/blog/shield-therapeutics-announces-submission-of-a-new-drug-application-for-feraccru-with-the-us-fda 2018-10-01T10:54:44 https://maestrodatabase.com/blog/tga-provisional-approval-of-roche-covid-19-treatment-tocilizumab-actemra 2021-12-02T00:21:13 https://maestrodatabase.com/blog/utilitytherapeutics-announces-fda-acceptance-of-pivya-new-drug-application-with-priority-review 2024-01-18T20:45:02 https://maestrodatabase.com/blog/ucb-announces-mhra-approval-for-ucbs-zilbrysq 2024-01-18T20:39:09 https://maestrodatabase.com/blog/novartis-twice-yearly-leqvio-inclisiran-receives-fda-approval-for-new-indication-enabling-first-line-use 2025-08-01T02:07:13 https://maestrodatabase.com/blog/drug-makers-raise-prices-of-ozempic-mounjaro-and-hundreds-of-other-drugs 2024-01-18T20:34:26 https://maestrodatabase.com/blog/nhs-england-agrees-to-fund-janssens-symtuza 2018-10-01T13:35:27 https://maestrodatabase.com/blog/new-orphan-drug-for-a-sub-type-of-acute-myeloid-leukaemia-g-ba-sees-significant-additional-benefit 2024-01-18T20:29:17 https://maestrodatabase.com/blog/trump-takes-aim-at-foreign-freeloading-nations-over-drug-prices-in-new-threat-to-pbs 2025-08-01T02:11:52 https://maestrodatabase.com/blog/us-fda-declines-to-approve-shin-nippon-biomedicals-migraine-drug 2024-01-18T20:24:14 https://maestrodatabase.com/blog/updates-to-the-hta-policy-and-methods-review-reference-committee-18-january-2024 2024-01-18T06:38:13 https://maestrodatabase.com/blog/doing-nothing-on-drug-prices-unacceptable 2019-05-07T21:25:09 https://maestrodatabase.com/blog/antares-receives-fda-approval-of-xyosted-testosterone-enanthate-injection-for-testosterone-replacement-therapy-in-adult-males 2018-10-01T20:12:56 https://maestrodatabase.com/blog/who-says-it-will-engage-us-to-make-remdesivir-coronavirus-treatment-more-widely-available 2020-05-05T08:43:43 https://maestrodatabase.com/blog/beyondspring-pharmaceuticals-receives-complete-response-letter-from-the-fda-for-plinabulin-new-drug-application-for-prevention-of-chemotherapy-induced-neutropenia 2021-12-02T03:24:51 https://maestrodatabase.com/blog/pertuzumab-in-early-breast-cancer-no-proof-of-an-additional-benefit-despite-exemplary-surrogate-validation 2018-10-01T20:04:07 https://maestrodatabase.com/blog/pfizer-canada-initiates-submission-to-health-canada-for-covid-19-oral-anti-viral-candidate 2021-12-02T02:44:00 https://maestrodatabase.com/blog/agenda-for-the-may-2023-intracycle-meeting 2023-04-28T07:23:46 https://maestrodatabase.com/blog/statement-from-fda-commissioner-on-fdas-efforts-to-strengthen-the-agencys-medical-device-cybersecurity-program-as-part-of-its-mission-to-protect-patients 2018-10-01T21:54:36 https://maestrodatabase.com/blog/norgine-welcomes-pbs-listing-in-australia-of-ifinwil-eflornithine-for-patients-with-high-risk-neuroblastoma 2025-08-01T02:23:48 https://maestrodatabase.com/blog/couple-move-to-america-to-afford-life-saving-treatment 2020-09-27T05:09:13 https://maestrodatabase.com/blog/abbvie-receives-chmp-positive-opinion-for-upadacitinib-rinvoq-for-the-treatment-of-adults-with-moderate-to-severe-active-rheumatoid-arthritis 2019-10-18T11:57:50 https://maestrodatabase.com/blog/global-regulators-work-towards-alignment-on-policy-approaches-and-regulatory-flexibility-during-covid-19 2020-05-05T20:35:25 https://maestrodatabase.com/blog/takeda-announces-fda-acceptance-of-bla-resubmission-for-investigational-subcutaneous-administration-of-entyvio-vedolizumab-for-maintenance-therapy-in-moderately-to-severely-active-ulcerative-colitis 2023-04-28T09:15:59 https://maestrodatabase.com/blog/genetx-and-ultragenyx-announce-gtx-102-granted-fast-track-designation-by-us-fda-for-treatment-of-angelman-syndrome 2020-05-05T20:43:09 https://maestrodatabase.com/blog/lenz-therapeutics-announces-us-fda-approval-of-vizz-for-the-treatment-of-presbyopia 2025-08-01T03:29:18 https://maestrodatabase.com/blog/atara-biotherapeutics-announces-us-fda-acceptance-and-priority-review-of-the-biologics-license-application-for-tabelecleucel-tab-cel-for-the-treatment-of-epstein-barr-virus-positive-post-transplant-lymphoproliferative-disease 2025-08-01T03:38:03 https://maestrodatabase.com/blog/nice-ok-for-bayers-xarelto 2019-10-18T20:09:13 https://maestrodatabase.com/blog/bill-gates-donates-10-dollars-million-to-australian-trial-of-immune-boosting-vaccine 2020-05-05T09:15:39 https://maestrodatabase.com/blog/pfizer-and-biontech-dose-first-participants-in-the-u-dot-s-as-part-of-global-covid-19-mrna-vaccine-development-program 2020-05-05T21:23:58 https://maestrodatabase.com/blog/world-leaders-donate-to-covid-19-vaccine-funding-drive 2020-05-05T21:40:03 https://maestrodatabase.com/blog/health-canada-approves-tresiba-for-children-with-type-1-diabetes 2018-10-02T05:04:56 https://maestrodatabase.com/blog/overlap-weighting-a-propensity-score-method-that-mimics-attributes-of-a-randomised-clinical-trial 2020-05-05T20:51:22 https://maestrodatabase.com/blog/ema-publishes-minutes-of-joint-meeting-with-eunethta---november-2019 2020-05-05T21:13:26 https://maestrodatabase.com/blog/verastem-oncology-granted-fast-track-designation-for-combination-of-avutometinib-and-sotorasib-for-the-treatment-of-kras-g12c-mutant-non-small-cell-lung-cancer 2024-01-18T23:27:29 https://maestrodatabase.com/blog/fda-grants-rare-paediatric-disease-designation-to-pegzilarginase-for-arginase-1-deficiency 2018-10-02T05:15:52 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-2-december-2021 2021-12-02T05:08:40 https://maestrodatabase.com/blog/new-ministerial-discretion-guidance-for-first-new-brand-statutory-price-reductions 2018-10-02T05:11:54 https://maestrodatabase.com/blog/reimbursement-for-oral-fabry-disease-drug-galafold-expanded-to-first-line-treatment 2025-08-01T08:37:20 https://maestrodatabase.com/blog/fda-approves-otsuka-and-lundbecks-abilify-asimtufii-aripiprazole-the-first-once-every-two-months-long-acting-injectable-for-the-treatment-of-schizophrenia-or-maintenance-monotherapy-treatment-of-bipolar-i-disorder-in-adults 2023-04-28T22:03:07 https://maestrodatabase.com/blog/fda-approves-kyprolis-carfilzomib-once-weekly-70-mg-slash-m2-in-combination-with-dexamethasone-for-patients-with-relapsed-or-refractory-multiple-myeloma 2018-10-02T05:22:24 https://maestrodatabase.com/blog/a-real-world-example-of-coverage-with-evidence-development-in-australia---ipilimumab-for-the-treatment-of-metastatic-melanoma 2018-02-19T03:38:15 https://maestrodatabase.com/blog/august-2018-pbac-special-meeting 2018-02-19T03:26:10 https://maestrodatabase.com/blog/beone-medicines-receives-prime-designation-from-the-ema-for-bgb-16673-in-waldenstroems-macroglobulinaemia 2025-08-01T09:33:23 https://maestrodatabase.com/blog/challenges-of-health-technology-assessment-in-pluralistic-healthcare-systems-an-ispor-council-report 2022-08-09T21:29:19 https://maestrodatabase.com/blog/introducing-cadths-rwe-guidance-working-group 2022-08-09T21:08:43 https://maestrodatabase.com/blog/paladin-labs-announces-health-canadas-filing-acceptance-of-cenobamate-tablets-as-an-adjunctive-therapy-for-the-management-of-partial-onset-seizures-in-adults-with-epilepsy 2022-08-09T21:16:40 https://maestrodatabase.com/blog/cormedix-announces-regulatory-and-manufacturing-updates 2022-08-09T20:54:45 https://maestrodatabase.com/blog/relmada-therapeutics-receives-fda-fast-track-designation-for-rel-1017-as-a-monotherapy-for-the-treatment-of-major-depressive-disorder 2022-08-09T20:59:07 https://maestrodatabase.com/blog/reata-pharmaceuticals-announces-three-month-extension-of-the-review-period-for-new-drug-application-for-omaveloxolone-for-the-treatment-of-friedreichs-ataxia 2022-08-09T20:49:17 https://maestrodatabase.com/blog/redhill-biopharma-submits-new-drug-application-for-talicia-for-h-pylori-infection 2019-05-08T14:28:41 https://maestrodatabase.com/blog/precision-biosciences-receives-fast-track-designation-from-u-dot-s-fda-for-pbcar269a-an-investigational-allogeneic-car-t-therapy-for-relapsed-slash-refractory-multiple-myeloma 2020-09-27T11:21:25 https://maestrodatabase.com/blog/fda-grants-cytodyn-fast-track-designation-for-leronlimab-pro-140-in-metastatic-triple-negative-breast-cancer-an-unmet-medical-need 2019-05-08T14:41:00 https://maestrodatabase.com/blog/kidney-cancer-therapy-works-but-cost-is-a-killer 2018-10-02T20:59:05 https://maestrodatabase.com/blog/cytodyn-submits-cmc-manufacturing-section-of-hiv-bla-to-fda-under-previously-authorised-rolling-review-last-clinical-section-will-complete-full-bla-submission 2021-12-02T05:57:17 https://maestrodatabase.com/blog/has-the-innovative-pharmaceutical-industry-essential-given-up-trying-to-list-new-medicines-in-new-zealand 2022-08-09T21:48:27 https://maestrodatabase.com/blog/statement-from-fda-commissioner-on-new-agency-actions-to-further-deter-gaming-of-the-generic-drug-approval-process-by-the-use-of-citizen-petitions 2018-10-02T20:48:34 https://maestrodatabase.com/blog/network-collaborators-announced-for-cadths-post-market-drug-evaluation-network 2022-08-09T21:46:01 https://maestrodatabase.com/blog/nplate-romiplostim-now-approved-for-earlier-use-in-adults-with-immune-thrombocytopenia 2019-10-18T22:04:48 https://maestrodatabase.com/blog/will-usmca-affect-canadas-drug-prices-depends-on-what-happens-next-experts-say 2018-10-02T21:11:43 https://maestrodatabase.com/blog/ema-starts-rolling-review-of-valnevas-covid-19-vaccine-vla2001 2021-12-02T19:32:31 https://maestrodatabase.com/blog/clovis-oncology-receives-breakthrough-therapy-designation-for-rubraca-rucaparib-for-treatment-of-brca1-slash-2-mutated-metastatic-castration-resistant-prostate-cancer 2018-10-02T21:14:59 https://maestrodatabase.com/blog/strengthening-patient-access-to-new-medicines-through-new-landmark-bill 2021-12-02T19:30:10 https://maestrodatabase.com/blog/serplulimab-in-combination-with-carboplatin-and-etoposide-phosphate-for-the-first-line-treatment-of-patients-with-extensive-stage-small-cell-lung-cancer 2025-08-01T10:40:12 https://maestrodatabase.com/blog/boosting-the-development-of-medicines-for-children 2018-10-02T21:03:29 https://maestrodatabase.com/blog/evenity-romosozumab-receives-positive-chmp-opinion-for-the-treatment-of-severe-osteoporosis-in-postmenopausal-women-at-high-risk-of-fracture 2019-10-18T21:47:11 https://maestrodatabase.com/blog/investors-say-drug-pricing-measure-may-shift-incentives-for-biotech-venture-funding 2021-12-02T19:42:24 https://maestrodatabase.com/blog/better-data-will-serve-as-the-foundation-in-modernising-the-medicaid-program 2018-10-02T21:06:58 https://maestrodatabase.com/blog/akcea-and-ionis-announce-approval-of-waylivra-volanesorsen-in-the-european-union 2019-05-08T15:06:50 https://maestrodatabase.com/blog/doh-revises-agenda-for-march-2022-pbac-meeting-twice-in-one-day 2021-12-02T06:09:36 https://maestrodatabase.com/blog/new-hope-for-cancer-patients-accessing-leading-edge-unfunded-drugs 2019-05-08T15:03:41 https://maestrodatabase.com/blog/pharmac-welcomes-interim-report 2021-12-02T06:05:10 https://maestrodatabase.com/blog/swissmedic-approves-ameluz-in-combination-with-daylight-photodynamic-therapy-in-switzerland 2018-10-02T21:29:10 https://maestrodatabase.com/blog/blood-cancer-patients-advocate-pleads-for-treatment-funding 2019-05-08T15:02:02 https://maestrodatabase.com/blog/pharmac-review-damning-interim-report-reveals-fortress-mentality-maori-equity-progress-slow 2021-12-02T06:20:48 https://maestrodatabase.com/blog/medicines-australia-welcomes-alp-r-and-d-investment-pledge 2019-05-08T14:58:49 https://maestrodatabase.com/blog/this-startup-wants-to-score-you-cheap-prescription-drugs-now-its-offering-home-delivery 2018-10-02T21:20:42 https://maestrodatabase.com/blog/denmark-funds-vertexs-cystic-fibrosis-drug-orkambi-uk-talks-deadlocked 2018-10-02T21:42:05 https://maestrodatabase.com/blog/us-eu-regulators-discuss-tailoring-biosimilar-approvals 2021-05-11T08:32:30 https://maestrodatabase.com/blog/sequoia-sciences-receives-fda-fast-track-designation-for-vaccine-for-urinary-tract-infections-caused-by-multidrug-resistant-bacteria 2017-07-27T02:14:55 https://maestrodatabase.com/blog/a-payers-perspective-on-value-based-contracting 2018-10-02T21:36:13 https://maestrodatabase.com/blog/pharmac-in-review-2021---part-2 2021-12-02T19:48:30 https://maestrodatabase.com/blog/european-commission-approves-lorviqua-lorlatinib-for-certain-adult-patients-with-previously-treated-alk-positive-advanced-non-small-cell-lung-cancer 2019-05-08T15:53:27 https://maestrodatabase.com/blog/call-for-a-central-portal-for-clinical-study-reports 2021-12-02T19:46:15 https://maestrodatabase.com/blog/mhra-grants-conditional-marketing-authorisation-for-covid-19-treatment-xevudy-sotrovimab 2021-12-02T20:08:14 https://maestrodatabase.com/blog/dupixent-dupilumab-approved-for-severe-asthma-by-european-commission 2019-05-08T15:47:53 https://maestrodatabase.com/blog/harmonisation-of-health-technology-assessment-across-the-european-union-lessons-for-the-united-states 2021-12-02T19:51:22 https://maestrodatabase.com/blog/fda-approves-alhemo-as-once-daily-prophylactic-treatment-to-prevent-or-reduce-the-frequency-of-bleeding-episodes-for-adults-and-children-12-years-of-age-and-older-with-haemophilia-a-or-b-without-inhibitors 2025-08-01T21:02:53 https://maestrodatabase.com/blog/graham-says-senate-should-vote-on-generic-drug-bill 2019-05-08T16:04:55 https://maestrodatabase.com/blog/medicine-shortage-fears-amid-mua-pay-dispute 2020-09-27T21:17:07 https://maestrodatabase.com/blog/a-2-dollars-million-drug-is-about-to-hit-the-market 2019-05-08T16:11:31 https://maestrodatabase.com/blog/in-canada-a-little-known-drug-regulator-shows-its-teeth 2019-05-08T16:09:09 https://maestrodatabase.com/blog/danicopan-in-combination-with-ravulizumab-or-eculizumab-for-the-treatment-of-patients-with-paroxysmal-nocturnal-haemoglobinuria-final-guidance 2024-10-23T05:08:47 https://maestrodatabase.com/blog/ablynx-receives-fast-track-designation-from-the-fda-for-caplacizumab-for-the-treatment-of-acquired-ttp 2017-07-27T02:48:14 https://maestrodatabase.com/blog/us-fda-grants-mesoblast-rare-paediatric-disease-designation-for-revascor-rexlemestrocel-l-in-children-with-congenital-heart-disease 2024-01-19T02:32:54 https://maestrodatabase.com/blog/bms-withdraws-application-for-opdivo-slash-yervoy-combination 2021-05-11T08:37:45 https://maestrodatabase.com/blog/avenda-health-granted-fda-breakthrough-device-designation-for-technology-to-treat-prostate-cancer 2021-05-11T13:41:01 https://maestrodatabase.com/blog/hospitals-again-defeat-medicare-reimbursement-drug-rate-cut 2019-05-08T16:26:52 https://maestrodatabase.com/blog/they-were-supposed-to-talk-about-the-patent-system-driving-up-drug-prices-but-most-lawmakers-got-distracted-by-small-tweaks 2019-05-08T16:23:14 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-to-cerc-002-for-treatment-of-hospitalised-patients-with-covid-19 2021-05-11T13:47:38 https://maestrodatabase.com/blog/drug-prices-will-soon-appear-in-many-us-tv-ads 2019-05-08T16:20:02 https://maestrodatabase.com/blog/additional-measures-to-allow-experts-to-focus-on-covid-19-activities 2021-05-11T09:23:31 https://maestrodatabase.com/blog/mhra-approves-label-extension-for-vertexs-kaftrio-combo 2021-05-11T09:26:34 https://maestrodatabase.com/blog/alberta-faces-shortage-of-covid-19-drug-as-global-demand-spikes 2021-05-11T21:03:03 https://maestrodatabase.com/blog/budget-2021--22-generational-change-and-record-investment-in-the-health-of-australians 2021-05-11T20:57:25 https://maestrodatabase.com/blog/fda-approves-new-treatment-for-a-type-of-heart-failure 2020-05-05T23:52:26 https://maestrodatabase.com/blog/fda-approves-eisais-fycompa-perampanel-for-use-as-monotherapy-for-the-treatment-of-partial-onset-seizures 2017-07-27T03:08:12 https://maestrodatabase.com/blog/cms-expanding-efforts-to-grow-covid-19-vaccine-confidence-and-uptake-amongst-nations-most-vulnerable 2021-05-11T21:06:57 https://maestrodatabase.com/blog/expensive-migraine-drug-emgality-added-to-pbs 2021-05-11T20:47:37 https://maestrodatabase.com/blog/health-front-and-centre-of-economic-recovery 2021-05-11T13:50:50 https://maestrodatabase.com/blog/arcutis-announces-canadian-approval-of-zoryve-roflumilast-cream-0-dot-3-percent-for-treatment-of-plaque-psoriasis-in-individuals-12-years-and-older 2023-04-29T07:53:53 https://maestrodatabase.com/blog/merck-receives-positive-eu-chmp-opinion-for-two-new-regimens-of-keytruda-pembrolizumab-as-first-line-treatment-for-metastatic-or-unresectable-recurrent-head-and-neck-squamous-cell-carcinoma 2019-10-18T23:19:10 https://maestrodatabase.com/blog/icer-publishes-final-evidence-report-and-policy-recommendations-on-therapies-for-multiple-myeloma 2021-05-11T20:52:03 https://maestrodatabase.com/blog/what-hcf-and-hbfs-plan-to-merge-means-for-health-insurance-customers 2018-02-19T19:50:37 https://maestrodatabase.com/blog/new-alzheimers-treatment-donanemab-does-not-currently-demonstrate-value-for-the-nhs-says-nice 2024-10-23T11:08:36 https://maestrodatabase.com/blog/medication-for-rare-soft-bone-disease-to-be-covered-by-public-drug-plans-in-canada 2018-02-19T19:56:26 https://maestrodatabase.com/blog/pelosi-finds-a-way-to-save-billions-by-cutting-drug-prices-but-big-pharma-pushes-back 2019-10-18T23:29:27 https://maestrodatabase.com/blog/should-the-nhs-fund-a-new-drug-costing-ps1million-for-ollie-and-amelia 2018-02-19T20:05:45 https://maestrodatabase.com/blog/the-pharma-industry-needs-to-measure-patient-experience-from-the-patients-perspectives 2021-05-11T21:18:47 https://maestrodatabase.com/blog/international-ip-protection-at-risk-for-covid-19-vaccines 2021-05-11T21:13:48 https://maestrodatabase.com/blog/mtaa-optimistic-as-government-rejects-insurer-led-push-to-abolish-prosthesis-list 2021-05-11T21:30:55 https://maestrodatabase.com/blog/new-patented-medicine-prices-review-board-chairperson-announced 2018-02-19T20:00:07 https://maestrodatabase.com/blog/a-shot-at-vaccine-self-reliance-via-biocina-and-university-of-adelaide-partnership 2021-05-11T21:21:31 https://maestrodatabase.com/blog/drug-companies-are-blackmailing-us-with-expensive-drugs-health-care-chief 2018-02-19T20:17:29 https://maestrodatabase.com/blog/fda-approves-osmotica-pharmaceuticals-once-daily-osmolex-er-amantadine-extended-release-tablets-for-the-treatment-of-parkinsons-disease-and-drug-induced-extrapyramidal-reactions-in-adults 2018-02-19T20:10:58 https://maestrodatabase.com/blog/us-fda-approves-pfizers-rsv-vaccine-abrysvo-for-adults-aged-18-to-59-at-increased-risk-for-disease 2024-10-23T20:11:42 https://maestrodatabase.com/blog/new-zealand-cancer-survival-rate-worse-than-australias 2018-02-19T20:28:15 https://maestrodatabase.com/blog/lillys-kisunla-donanemab-azbt-receives-marketing-authorisation-in-great-britain-for-the-treatment-of-mild-cognitive-impairment-and-mild-dementia-due-to-alzheimers-disease-in-adult-patients-who-are-apolipoprotein-e-e4-heterozygotes-or-non-carriers 2024-10-23T19:51:34 https://maestrodatabase.com/blog/voydeya-danicopan-granted-first-ever-regulatory-approval-in-japan-for-adults-with-pnh-to-be-used-in-combination-with-c5-inhibitor-therapy 2024-01-19T21:11:20 https://maestrodatabase.com/blog/teva-and-medincell-announce-fda-approval-of-uzedy-risperidone-extended-release-injectable-suspension-a-long-acting-subcutaneous-atypical-antipsychotic-injection-for-the-treatment-of-schizophrenia-in-adults 2023-04-30T03:01:02 https://maestrodatabase.com/blog/foamix-receives-fda-approval-of-amzeeq-topical-minocycline-treatment-for-millions-of-moderate-to-severe-acne-sufferers 2019-10-19T01:12:46 https://maestrodatabase.com/blog/alexion-receives-fda-approval-for-ultomiris-ravulizumab-cwvz-for-atypical-haemolytic-uremic-syndrome 2019-10-19T01:42:03 https://maestrodatabase.com/blog/atagi-update-following-weekly-covid-19-meeting-1-december-2021 2021-12-03T00:38:08 https://maestrodatabase.com/blog/cipher-pharmaceuticals-receives-health-canada-approval-for-trulance-plecanatide 2019-10-19T01:36:36 https://maestrodatabase.com/blog/abbvie-receives-health-canada-approval-for-the-combination-of-venclexta-venetoclax-with-obinutuzumab-for-patients-with-previously-untreated-chronic-lymphocytic-leukaemia 2020-05-06T01:15:53 https://maestrodatabase.com/blog/fda-approves-ngs-based-companion-diagnostic-for-first-targeted-therapy-for-patients-with-grade-2-idh-mutant-glioma 2024-10-23T20:58:54 https://maestrodatabase.com/blog/zetamet-receives-breakthrough-device-designation-from-u-dot-s-fda-for-treatment-of-metastatic-bone-cancers 2021-12-03T01:01:44 https://maestrodatabase.com/blog/csl-ramps-up-development-of-covid-19-plasma-treatment 2020-05-06T00:40:18 https://maestrodatabase.com/blog/kyverna-therapeutics-granted-fda-fast-track-designation-for-kyv-101-in-the-treatment-of-patients-with-refractory-progressive-multiple-sclerosis 2024-01-19T21:50:06 https://maestrodatabase.com/blog/merck-receives-eu-chmp-positive-opinion-for-investigational-v920-ebola-zaire-vaccine-for-protection-against-ebola-virus-disease 2019-10-19T01:51:50 https://maestrodatabase.com/blog/300-people-to-benefit-from-new-treatment-for-advanced-breast-cancer-recommended-by-nice-following-price-deal 2024-01-19T21:40:02 https://maestrodatabase.com/blog/anti-epileptic-drug-fycompa-injection-formulation-approved-in-japan 2024-01-19T22:52:02 https://maestrodatabase.com/blog/halozyme-announces-argenx-received-approval-in-japan-for-vyvdura-efgartigimod-alfa-and-hyaluronidase-qvfc-co-formulated-with-enhanze-for-generalised-myasthenia-gravis 2024-01-19T22:40:25 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-may-2023 2023-04-30T11:32:23 https://maestrodatabase.com/blog/medicare-patients-on-pricey-drugs-are-saving-big-this-year 2024-01-19T22:32:54 https://maestrodatabase.com/blog/fda-approves-erdafitinib-for-locally-advanced-or-metastatic-urothelial-carcinoma 2024-01-19T21:59:25 https://maestrodatabase.com/blog/fda-authorises-emergency-use-of-jynneos-vaccine-to-increase-vaccine-supply 2022-08-10T11:11:13 https://maestrodatabase.com/blog/rmat-vs-breakthrough-vs-fast-track-companies-seek-clarity-on-fda-draft-guidance 2018-02-19T23:10:36 https://maestrodatabase.com/blog/overall-survival-progression-free-survival-and-tumour-response-benefit-supporting-initial-us-fda-approval-and-indication-extension-of-new-cancer-drugs-2003-2021 2022-08-10T21:03:44 https://maestrodatabase.com/blog/paratek-announces-fda-approval-of-nuzyra-omadacycline 2018-10-03T05:26:52 https://maestrodatabase.com/blog/eu-regulator-begins-review-of-pfizer-biontechs-variant-adapted-covid-shot 2022-08-10T11:22:53 https://maestrodatabase.com/blog/few-u-dot-s-patients-with-hepatitis-c-get-timely-treatment-cdc-says 2022-08-10T11:19:01 https://maestrodatabase.com/blog/adma-biologics-resubmits-biologics-license-application-for-ri-002 2018-10-03T05:19:27 https://maestrodatabase.com/blog/fda-undercuts-375-000-dollars-drug-in-surprise-move 2019-05-08T20:35:42 https://maestrodatabase.com/blog/failed-covidsafe-app-deleted 2022-08-10T21:54:06 https://maestrodatabase.com/blog/eu-report-more-evidence-on-link-between-antibiotic-use-and-antibiotic-resistance 2017-07-27T11:02:08 https://maestrodatabase.com/blog/fda-sets-inaugural-meeting-of-first-ever-patient-engagement-advisory-committee 2017-07-27T11:11:51 https://maestrodatabase.com/blog/real-world-data-can-help-expedite-drug-approvals-for-serious-diseases-with-few-options 2022-08-10T21:43:56 https://maestrodatabase.com/blog/fda-approves-seysara-sarecycline-for-the-treatment-of-moderate-to-severe-acne 2018-10-03T05:33:06 https://maestrodatabase.com/blog/statins-should-be-offered-to-everyone-who-has-chronic-kidney-disease-says-nice 2017-07-27T11:05:58 https://maestrodatabase.com/blog/the-situation-in-new-zealand-can-only-be-described-as-dire 2022-08-10T21:15:53 https://maestrodatabase.com/blog/the-expanded-access-navigator---helping-patients-in-need-of-potentially-life-saving-drug-treatments 2017-07-27T11:16:22 https://maestrodatabase.com/blog/ptac-recommends-the-use-of-pembrolizumab-as-a-first-line-treatment-for-patients-with-advanced-non-small-cell-lung-cancer 2019-05-08T20:38:53 https://maestrodatabase.com/blog/chiesi-group-receives-the-european-marketing-authorisation-for-trimbow-inhaled-corticosteroid-slash-long-acting-b2-agonist-slash-long-acting-muscarinic-antagonist 2017-07-27T11:35:24 https://maestrodatabase.com/blog/cure-rare-disease-receives-fda-approval-to-administer-first-in-human-crispr-therapeutic 2022-08-10T21:10:20 https://maestrodatabase.com/blog/half-yearly-performance-snapshot-july-to-december-2019 2020-05-06T05:11:25 https://maestrodatabase.com/blog/cancer-drug-secures-$400m-royalty-deal 2017-07-27T13:06:04 https://maestrodatabase.com/blog/medibank-mulls-refunds-as-covid-19-cuts-costs 2020-05-06T05:15:07 https://maestrodatabase.com/blog/we-have-been-waiting-for-this-moment-for-so-long-hepatitis-c-patients-have-access-to-cure-with-epclusa-pbs-listing 2017-07-27T20:55:58 https://maestrodatabase.com/blog/tot-biopharm-announces-nmpa-granted-marketing-approval-for-pusintin-tab008-bevacizumab-in-china 2021-12-03T02:45:04 https://maestrodatabase.com/blog/priority-review-vouchers-for-tropical-disease-drugs-simply-arent-working 2017-07-27T13:10:25 https://maestrodatabase.com/blog/ps3-a-day-drug-for-irritable-bowel-syndrome-gets-nice-approval 2017-07-27T21:03:59 https://maestrodatabase.com/blog/fda-announces-new-steps-to-empower-consumers-and-advance-digital-health-care 2017-07-27T21:09:33 https://maestrodatabase.com/blog/seladelpar-lysine-dihydrate-for-the-treatment-of-patients-with-primary-biliary-cholangitis 2025-08-02T06:41:35 https://maestrodatabase.com/blog/eagle-pharmaceuticals-receives-complete-response-letter-from-fda-on-ryanodex-for-exertional-heat-stroke-application 2017-07-27T21:25:14 https://maestrodatabase.com/blog/fda-accepts-new-drug-application-and-grants-priority-review-for-tlx101-cdx-pixclara-brain-cancer-imaging-agent 2024-10-23T23:21:23 https://maestrodatabase.com/blog/challenges-in-international-comparison-of-health-care-systems 2017-07-27T21:17:42 https://maestrodatabase.com/blog/update-on-us-regulatory-review-of-supplemental-biologics-license-application 2025-08-02T10:14:43 https://maestrodatabase.com/blog/fda-approves-bausch-and-lomb-alaway-preservative-free-ketotifen-fumarate-0-dot-035-percent-ophthalmic-solution 2020-09-28T00:41:15 https://maestrodatabase.com/blog/axumin-fluciclovine-18f-receives-positive-recommendation-from-transparency-committee-of-the-french-has-for-use-in-pet-imaging-of-suspected-recurrent-prostate-cancer 2018-10-03T07:11:14 https://maestrodatabase.com/blog/chiesi-files-resubmission-to-address-fda-bronchitol-mannitol-inhalation-powder-complete-response-letter 2020-05-06T11:03:23 https://maestrodatabase.com/blog/bristol-myers-squibb-provides-update-on-biologics-license-application-for-lisocabtagene-maraleucel 2020-05-06T11:08:21 https://maestrodatabase.com/blog/advanced-melanoma-treatment-to-be-added-to-pharmaceutical-benefits-scheme 2024-01-21T20:26:21 https://maestrodatabase.com/blog/medicines-australia-joins-forces-with-15-health-care-organisations-to-highlight-continuity-of-care 2020-05-06T06:33:46 https://maestrodatabase.com/blog/covid-19-potentially-life-saving-immunoglobulin-treatment-for-seriously-ill-australians 2020-05-06T06:38:00 https://maestrodatabase.com/blog/kala-pharmaceuticals-resubmits-new-drug-application-for-eysuvis-for-dry-eye-disease 2020-05-06T10:47:50 https://maestrodatabase.com/blog/hibercell-receives-fda-fast-track-designation-for-hc-7366-for-the-treatment-of-relapsed-or-refractory-acute-myeloid-leukaemia 2024-10-24T01:46:50 https://maestrodatabase.com/blog/janssen-receives-positive-chmp-opinion-for-spravato-esketamine-nasal-spray-for-adults-with-treatment-resistant-major-depressive-disorder 2019-10-19T03:10:48 https://maestrodatabase.com/blog/fda-issues-draft-guidance-to-industry-on-submitting-real-world-evidence-in-new-drug-and-biologic-applications 2019-05-09T05:12:18 https://maestrodatabase.com/blog/proposal-for-changes-to-funded-vaccines-in-the-national-immunisation-schedule 2019-05-09T04:09:57 https://maestrodatabase.com/blog/fda-approves-first-targeted-therapy-to-treat-aggressive-form-of-lung-cancer 2020-05-06T20:41:45 https://maestrodatabase.com/blog/first-and-only-parp-inhibitor-lynparza-olaparib-approved-as-a-first-line-maintenance-therapy-treatment-in-brca-mutated-advanced-ovarian-cancer 2019-05-09T04:03:24 https://maestrodatabase.com/blog/first-ever-treatment-for-ultra-rare-rapid-ageing-disease-progeria-receives-approval-in-japan 2024-01-21T20:29:54 https://maestrodatabase.com/blog/preliminary-nice-no-for-takedas-alunbrig 2018-10-03T11:03:45 https://maestrodatabase.com/blog/botannix-pharmaceuticals-resubmission-of-sofdra-nda-accepted-by-fda 2024-01-22T20:11:38 https://maestrodatabase.com/blog/australians-save-250-dollars-million-thanks-to-albanese-government-cheaper-medicines 2024-01-22T02:14:55 https://maestrodatabase.com/blog/criticism-wont-slow-targeted-cancer-drug-reviews-fda-official 2019-10-19T03:54:05 https://maestrodatabase.com/blog/immunicum-receives-regenerative-medicine-advanced-therapy-designation-from-fda-for-ilixadencel-in-kidney-cancer 2020-05-06T20:57:49 https://maestrodatabase.com/blog/nabriva-therapeutics-announces-submission-of-marketing-authorisation-application-for-lefamulin-to-treat-community-acquired-pneumonia-in-adults-by-european-medicines-agency 2019-05-09T05:15:34 https://maestrodatabase.com/blog/eu-nod-for-lillys-new-breast-cancer-drug 2018-10-03T11:11:23 https://maestrodatabase.com/blog/submissions-to-the-march-2025-pbac-meeting 2024-10-24T01:57:10 https://maestrodatabase.com/blog/antabio-receives-fda-qualified-infectious-disease-product-designation-for-mem-ant3310-a-novel-broad-spectrum-combination-therapy-targeting-whos-priority-pathogens 2020-05-06T20:52:17 https://maestrodatabase.com/blog/cms-accelerates-innovation-and-promotes-patient-access-to-medical-technology 2018-10-03T20:20:01 https://maestrodatabase.com/blog/new-arthritis-drug-to-be-slashed-with-taxpayer-pbs-subsidy 2018-10-03T20:25:44 https://maestrodatabase.com/blog/agenda-for-the-december-2021-pbac-intracycle-meeting 2021-12-03T03:54:48 https://maestrodatabase.com/blog/novartis-confident-of-zolgensma-supply-calls-2-dollars-million-price-speculation 2019-05-09T05:37:50 https://maestrodatabase.com/blog/nice-issues-draft-guidance-for-use-of-remdesivir-and-also-for-tixagevimab-cilgavimab-for-treatment-of-covid-19 2024-01-22T20:42:01 https://maestrodatabase.com/blog/generic-drugs-in-the-us-are-too-cheap-to-be-sustainable-experts-say 2024-01-22T20:28:08 https://maestrodatabase.com/blog/remdesivir-helps-coronavirus-patients----but-at-what-cost 2020-05-06T21:04:49 https://maestrodatabase.com/blog/hope-for-multiple-sclerosis-sufferers-after-green-light-for-drug-which-can-delay-wheelchair-use-by-seven-years 2019-05-09T06:21:06 https://maestrodatabase.com/blog/biogen-canada-and-pan-canadian-pharmaceutical-alliance-reach-agreement-on-access-to-first-and-only-approved-treatment-for-spinal-muscular-atrophy-in-canada 2018-10-03T20:40:58 https://maestrodatabase.com/blog/sitting-in-limbo----obamacare-under-divided-government 2019-05-09T05:52:49 https://maestrodatabase.com/blog/will-gilead-price-its-coronavirus-drug-for-public-good-or-company-profit 2020-05-06T21:08:59 https://maestrodatabase.com/blog/in-march-in-rights-some-see-a-tool-to-lower-drug-prices-others-see-a-threat-to-intellectual-property 2024-01-22T20:25:16 https://maestrodatabase.com/blog/life-saving-drug-out-of-reach-for-queensland-mum-at-$100k-a-year 2018-10-03T20:31:52 https://maestrodatabase.com/blog/jaguar-health-says-recent-drug-price-hikes-not-tied-to-covid-19-pandemic 2020-05-06T21:18:17 https://maestrodatabase.com/blog/ema-publishes-agenda-for-22-25-january-2024-chmp-meeting 2024-01-22T20:19:23 https://maestrodatabase.com/blog/what-the-last-trade-debate-over-drug-prices-can-tell-us-about-the-new-one 2018-10-03T20:49:43 https://maestrodatabase.com/blog/pfizer-launches-biosimilar-filgrastim-nivestym-at-a-substantial-discount 2018-10-03T20:55:03 https://maestrodatabase.com/blog/why-desperate-americans-are-driving-to-canada-in-caravans-for-insulin 2019-05-09T06:38:50 https://maestrodatabase.com/blog/cancer-specialists-wont-increase-fees-under-labor-plan 2019-05-09T06:30:08 https://maestrodatabase.com/blog/did-canada-agree-to-a-trump-veto-and-costlier-drugs-in-usmca 2018-10-03T20:47:09 https://maestrodatabase.com/blog/us-fda-accepts-for-priority-review-supplemental-biologics-license-application-and-ema-validates-application-for-reblozyl-luspatercept-aamt-as-first-line-treatment-of-anaemia-in-adults-with-lower-risk-myelodysplastic-syndromes 2023-05-01T20:54:56 https://maestrodatabase.com/blog/us-fda-issues-complete-response-letter-for-transcon-pth-in-hypoparathyroidism 2023-05-01T21:12:01 https://maestrodatabase.com/blog/rebuilding-medicare-for-the-21st-century 2023-05-01T06:51:32 https://maestrodatabase.com/blog/australia-lacks-vaccine-making-capacity-defence-report-warns 2020-05-06T22:30:57 https://maestrodatabase.com/blog/pharmac-amends-funding-rules-on-dispensing-of-adhd-medicines 2023-05-01T20:51:32 https://maestrodatabase.com/blog/importing-prescription-drugs-from-canada----legal-and-practical-problems-with-the-trump-administrations-proposal 2020-05-06T22:40:22 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-may-2023 2023-05-01T06:46:25 https://maestrodatabase.com/blog/quizartinib-dihydrochloride-for-the-induction-consolidation-and-maintenance-treatment-of-adults-with-newly-diagnosed-flt3-itd-positive-acute-myeloid-leukaemia 2024-10-24T03:10:17 https://maestrodatabase.com/blog/erasca-granted-fda-fast-track-designation-for-cns-penetrant-egfr-inhibitor-eras-801-in-patients-with-glioblastoma 2023-05-02T01:04:31 https://maestrodatabase.com/blog/cabaletta-bio-receives-fda-fast-track-designation-for-caba-201 2023-05-02T01:01:44 https://maestrodatabase.com/blog/impacts-to-medicine-supply-from-india 2021-05-12T03:44:05 https://maestrodatabase.com/blog/canadas-health-minister-denies-interfering-in-agencys-efforts-to-lower-drug-costs 2023-05-01T21:43:27 https://maestrodatabase.com/blog/decision-to-fund-tacrolimus-ointment-for-people-with-facial-eczema 2021-05-12T03:48:22 https://maestrodatabase.com/blog/dutch-ministry-of-health-will-not-reimburse-gileads-breast-cancer-drug-trodelvy 2023-05-01T21:39:13 https://maestrodatabase.com/blog/smc-approves-nhs-funding-for-ucbs-vimpat-in-children 2018-02-20T09:55:34 https://maestrodatabase.com/blog/vertex-offers-portfolio-approach-to-secure-access-to-cf-meds 2018-02-20T10:03:43 https://maestrodatabase.com/blog/cabaletta-bio-receives-fda-fast-track-designation-for-dsg3-caart-for-the-treatment-of-mucosal-pemphigus-vulgaris 2020-05-06T23:18:43 https://maestrodatabase.com/blog/pfizer-asks-uk-to-clear-vaccine-for-teens 2021-05-12T06:44:10 https://maestrodatabase.com/blog/scientific-research-on-the-coronavirus-is-being-released-in-a-torrent 2020-05-06T23:39:11 https://maestrodatabase.com/blog/blueprint-medicines-announces-european-commission-approval-of-ayvakyt-avapritinib-for-the-treatment-of-adults-with-unresectable-or-metastatic-pdgfra-d842v-mutant-gastro-intestinal-stromal-tumours 2020-09-28T02:18:41 https://maestrodatabase.com/blog/pharmacy-guild-want-alternative-epipen-added-to-the-pbs 2018-02-20T20:01:13 https://maestrodatabase.com/blog/lower-price-for-ms-drug-paves-the-way-for-positive-recommendation-from-nice 2019-05-09T07:47:03 https://maestrodatabase.com/blog/public-availability-of-results-of-clinicaltrials-dot-gov-registered-expanded-access-studies 2021-05-12T08:19:25 https://maestrodatabase.com/blog/pharmac-funding-affects-all-new-zealanders 2021-05-12T08:16:01 https://maestrodatabase.com/blog/dermasensor-granted-fda-breakthrough-device-designation 2021-05-12T08:23:46 https://maestrodatabase.com/blog/acorda-announces-fda-acceptance-of-new-drug-application-for-inbrija-levodopa-inhalation-powder 2018-02-20T20:27:18 https://maestrodatabase.com/blog/the-use-of-budget-impact-analysis-in-the-economic-evaluation-of-new-medicines-in-australia-england-france-and-the-united-states-relationship-to-cost-effectiveness-analysis-and-methodological-challenges 2018-02-20T20:08:12 https://maestrodatabase.com/blog/beyond-qalys-multi-criteria-based-estimation-of-maximum-willingness-to-pay-for-health-technologies 2018-02-20T20:13:20 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-reviews-evidence-report-finds-esketamine-may-benefit-patients-with-treatment-resistant-depression-but-exceeds-cost-effectiveness-thresholds 2019-05-10T01:36:06 https://maestrodatabase.com/blog/does-the-usa-need-a-national-health-technology-assessor 2018-02-20T20:38:38 https://maestrodatabase.com/blog/does-employment-based-insurance-make-the-us-medical-care-system-unfair-and-inefficient 2019-05-10T01:31:19 https://maestrodatabase.com/blog/minerva-neurosciences-announces-the-nda-filing-for-roluperidone-for-the-treatment-of-negative-symptoms-in-schizophrenia 2023-05-02T12:44:10 https://maestrodatabase.com/blog/as-some-got-free-health-care-gwen-got-squeezed-an-obamacare-dilemma 2018-02-20T20:43:21 https://maestrodatabase.com/blog/many-hospitals-charge-double-or-even-triple-what-medicare-would-pay 2019-05-10T01:57:32 https://maestrodatabase.com/blog/trastuzumab-deruxtecan-benefits-also-in-her2-low-breast-cancer 2023-05-02T12:39:31 https://maestrodatabase.com/blog/trump-administration-wants-to-shame-big-pharma-into-lowering-drug-prices 2019-05-10T01:54:18 https://maestrodatabase.com/blog/what-do-transformational-shifts-mean-in-terms-of-ultimate-outcomes-and-value-of-medicines 2019-05-10T01:42:46 https://maestrodatabase.com/blog/trump-seeks-boost-from-seniors-with-200-dollars-drug-discount-coupons 2020-09-28T03:28:09 https://maestrodatabase.com/blog/icmra-and-who-map-out-flexibilities-used-by-regulators-to-respond-to-the-covid-19-pandemic 2021-12-03T23:03:09 https://maestrodatabase.com/blog/vertex-announces-reimbursement-of-cystic-fibrosis-medicines-symdeko-tezacaftor-slash-ivacaftor-and-ivacaftor-for-eligible-patients-ages-12-and-older-and-orkambi-lumacaftor-slash-ivacaftor-in-children-ages-2-to-5-with-certain-cftr-mutations-in-australia 2019-10-20T03:00:02 https://maestrodatabase.com/blog/medicares-coverage-with-evidence-development-a-barrier-to-patient-access-and-innovation 2023-05-02T13:09:36 https://maestrodatabase.com/blog/fda-approves-pembrolizumab-for-adjuvant-treatment-of-stage-iib-or-iic-melanoma 2021-12-03T23:26:02 https://maestrodatabase.com/blog/pharmac-publishes-agenda-for-next-months-ptac-meeting 2024-01-22T23:07:35 https://maestrodatabase.com/blog/the-breakthrough-cancer-mental-health-and-arthritis-medicines-that-will-never-be-subsidised 2019-10-20T02:29:01 https://maestrodatabase.com/blog/libtayo-cemiplimab-in-combination-with-chemotherapy-now-approved-in-canada-for-the-first-line-treatment-of-advanced-non-small-cell-lung-cancer 2023-05-02T13:03:07 https://maestrodatabase.com/blog/fda-approves-rituximab-plus-chemotherapy-for-paediatric-cancer-indications 2021-12-03T22:51:40 https://maestrodatabase.com/blog/avadel-pharmaceuticals-announces-final-fda-approval-of-lumryz-sodium-oxybate-for-extended-release-oral-suspension-as-the-first-and-only-once-at-bedtime-oxybate-for-cataplexy-or-excessive-daytime-sleepiness-in-adults-with-narcolepsy 2023-05-02T12:56:07 https://maestrodatabase.com/blog/driving-down-the-cost-of-biologics-lessons-from-a-nationalised-health-care-system 2024-10-24T06:52:34 https://maestrodatabase.com/blog/fda-expands-authorisation-of-two-monoclonal-antibodies-for-treatment-and-post-exposure-prevention-of-covid-19-to-younger-paediatric-patients-including-newborns 2021-12-04T00:17:07 https://maestrodatabase.com/blog/mercks-keytruda-pembrolizumab-receives-30th-approval-from-european-commission-with-two-new-indications-in-gynaecologic-cancers 2024-10-24T20:05:42 https://maestrodatabase.com/blog/voclosporin-with-mycophenolate-mofetil-for-treating-lupus-nephritis 2023-05-03T01:59:47 https://maestrodatabase.com/blog/ripretinib-for-treating-advanced-gastro-intestinal-stromal-tumour-after-three-or-more-treatments 2023-05-03T01:51:43 https://maestrodatabase.com/blog/abbvie-provides-update-on-rinvoq-upadacitinib-for-the-treatment-of-rheumatoid-arthritis-in-the-u-dot-s 2021-12-03T23:34:36 https://maestrodatabase.com/blog/nice-rejects-pfizers-rare-heart-disease-treatment-vyndaqel 2021-05-12T11:16:54 https://maestrodatabase.com/blog/us-fda-grants-breakthrough-therapy-designation-for-spesolimab-for-the-prevention-of-flares-in-adults-with-generalised-pustular-psoriasis 2023-05-03T01:43:04 https://maestrodatabase.com/blog/international-experience-with-performance-based-risk-sharing-arrangements-implications-for-the-chinese-innovative-pharmaceutical-market 2020-09-28T05:40:50 https://maestrodatabase.com/blog/amgens-acute-lymphoblastic-leukaemia-drug-blincyto-passes-reimbursement-review 2022-08-11T10:35:49 https://maestrodatabase.com/blog/european-commission-approves-imbruvica-ibrutinib-fixed-duration-combination-for-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia 2022-08-11T10:22:46 https://maestrodatabase.com/blog/menarini-groups-elacestrant-granted-priority-review-by-the-us-fda-for-patients-with-er-plus-slash-her2--advanced-or-metastatic-breast-cancer 2022-08-11T10:28:15 https://maestrodatabase.com/blog/tenaya-therapeutics-receives-fda-fast-track-designation-for-tn-201 2023-05-03T02:16:58 https://maestrodatabase.com/blog/roche-receives-fda-approval-for-ventana-mmr-rxdx-panel-to-identify-dmmr-solid-tumour-patients-and-pmmr-endometrial-cancer-patients-eligible-for-keytruda 2022-08-11T07:52:47 https://maestrodatabase.com/blog/opdivo-and-yervoy-combination-therapy-approved-in-japan-to-expand-use-for-the-treatment-of-microsatellite-instability-high-colorectal-cancer-and-opdivo-for-additional-dosage-and-administration-in-monotherapy-dosing-regimen 2020-09-28T05:28:39 https://maestrodatabase.com/blog/reforms-needed-for-fdas-regulation-of-medical-devices 2021-12-04T01:13:18 https://maestrodatabase.com/blog/canadas-drug-agency-announces-recipients-of-funding-to-enhance-rare-disease-registries 2024-10-24T20:57:21 https://maestrodatabase.com/blog/atyr-pharma-receives-fda-fast-track-designation-for-efzofitimod-atyr1923-for-treatment-of-pulmonary-sarcoidosis 2022-08-11T20:53:47 https://maestrodatabase.com/blog/u-dot-s-food-and-drug-administration-accepts-for-priority-review-supplemental-biologics-license-application-for-reblozyl-luspatercept-aamt-in-adults-with-non-transfusion-dependent-beta-thalassaemia 2021-12-04T02:14:10 https://maestrodatabase.com/blog/astellas-xtandi-bags-additional-mhra-approval-in-prostate-cancer 2021-05-12T11:21:04 https://maestrodatabase.com/blog/genentech-announces-fda-approval-of-xofluza-to-treat-influenza-in-children-aged-five-and-older 2022-08-11T20:49:25 https://maestrodatabase.com/blog/the-fdas-breakthrough-medical-devices-are-finally-hitting-the-market-in-numbers 2022-08-11T20:46:43 https://maestrodatabase.com/blog/memo-therapeutics-receives-fda-fast-track-designation-for-antibkv-as-treatment-of-bkv-infection-in-renal-transplant-patients 2023-05-03T02:23:53 https://maestrodatabase.com/blog/european-medicines-agency-validates-amicus-therapeutics-marketing-authorisation-applications-for-at-gaa-for-the-treatment-of-pompe-disease 2021-12-04T02:06:33 https://maestrodatabase.com/blog/understanding-the-democrats-drug-pricing-package 2022-08-11T11:03:40 https://maestrodatabase.com/blog/covid-19-vaccine-safety-report-11-august-2022 2022-08-11T21:12:29 https://maestrodatabase.com/blog/nice-lung-cancer-treatment-pathways 2022-08-11T21:19:34 https://maestrodatabase.com/blog/fda-approves-capmatinib-for-metastatic-non-small-cell-lung-cancer 2022-08-11T21:08:10 https://maestrodatabase.com/blog/khondrion-receives-rare-paediatric-disease-designation-for-sonlicromanol-from-us-fda 2020-09-28T11:37:43 https://maestrodatabase.com/blog/smc-approve-johnson-and-johnsons-systemic-light-chain-amyloidosis-therapy 2022-08-11T21:04:57 https://maestrodatabase.com/blog/remdesivir-and-the-combination-of-tixagevimab-and-cilgavimab-for-the-treatment-of-patients-with-covid-19-disease 2024-01-23T01:28:13 https://maestrodatabase.com/blog/enhertu-approved-in-japan-for-the-treatment-of-patients-with-her2-positive-metastatic-gastric-cancer 2020-09-28T06:50:37 https://maestrodatabase.com/blog/mhra-grants-marketing-authorisation-for-novartis-radioligand-therapy-pluvicto-lutetium-lu-177-vipivotide-tetraxetan-in-advanced-prostate-cancer-in-great-britain 2022-08-11T20:59:29 https://maestrodatabase.com/blog/ultomiris-ravulizumab-receives-approval-in-japan-for-atypical-haemolytic-uraemic-syndrome-in-adults-and-children 2020-09-28T06:57:34 https://maestrodatabase.com/blog/u-dot-s-fda-approves-haegarda-c1-esterase-inhibitor-subcutaneous-human-for-prevention-of-hereditary-angioedema-attacks-in-paediatric-patients 2020-09-28T20:58:59 https://maestrodatabase.com/blog/drug-makers-cut-prices-by-62-percent-on-average-to-get-china-state-insurance-listing 2021-12-04T04:14:58 https://maestrodatabase.com/blog/shionogi-receives-us-fda-fast-track-designation-for-the-novel-anti-respiratory-syncytial-virus-drug-candidate-s-337395 2024-10-25T00:05:15 https://maestrodatabase.com/blog/ispor-introduces-new-competencies-framework-for-health-economics-and-outcomes-research-professionals 2020-09-28T21:08:04 https://maestrodatabase.com/blog/janssen-seeks-approval-of-imbruvica-ibrutinib-in-a-fixed-duration-regimen-for-patients-with-untreated-chronic-lymphocytic-leukaemia 2021-12-04T02:48:51 https://maestrodatabase.com/blog/icer-publishes-white-paper-on-cornerstones-for-fair-patient-access-to-prescription-drugs-launches-annual-assessment-of-us-payer-policies 2020-09-28T20:48:22 https://maestrodatabase.com/blog/pembrolizumab-plus-chemotherapy-with-or-without-bevacizumab-for-persistent-recurrent-or-metastatic-cervical-cancer 2023-05-03T12:15:28 https://maestrodatabase.com/blog/abbvie-receives-orphan-drug-and-fast-track-designations-from-the-u-dot-s-fda-for-elezanumab-an-investigational-monoclonal-antibody-rgma-inhibitor-for-the-treatment-of-spinal-cord-injury 2020-09-28T20:51:29 https://maestrodatabase.com/blog/lynparza-receives-health-canada-approval-as-adjuvant-treatment-for-patients-with-germline-brca-mutated-her2-negative-high-risk-early-breast-cancer 2022-08-11T21:24:27 https://maestrodatabase.com/blog/orchard-therapeutics-receives-ema-prime-designation-for-otl-203-for-the-treatment-of-mps-i 2020-09-28T21:25:54 https://maestrodatabase.com/blog/lenz-therapeutics-announces-fda-acceptance-of-new-drug-application-for-lnz100-for-the-treatment-of-presbyopia 2024-10-26T02:17:04 https://maestrodatabase.com/blog/fda-approves-first-respiratory-syncytial-virus-vaccine 2023-05-03T21:18:07 https://maestrodatabase.com/blog/sophisticated-purchasing-of-pharmaceuticals-learning-from-other-countries 2020-09-28T21:13:47 https://maestrodatabase.com/blog/worst-rank-score-methods--a-non-parametric-approach-to-informatively-missing-data 2020-09-28T21:17:18 https://maestrodatabase.com/blog/maritime-union-rejects-claims-medical-supplies-and-food-are-being-held-up-in-pay-dispute 2020-09-28T21:22:59 https://maestrodatabase.com/blog/pfizers-covid-19-vaccine-comirnaty-provisionally-approved-for-use-in-individuals-5-years-and-over 2021-12-04T23:25:05 https://maestrodatabase.com/blog/evofem-biosciences-receives-fast-track-designation-for-evo100-for-prevention-of-gonorrhoea-in-women 2021-05-12T20:50:12 https://maestrodatabase.com/blog/alume-biosciences-granted-fda-fast-track-designation-of-alm-488-for-surgical-nerve-visualisation 2021-05-12T20:45:33 https://maestrodatabase.com/blog/vertex-announces-us-fda-approval-for-kalydeco-ivacaftor-to-treat-eligible-infants-with-cf-ages-1-month-and-older 2023-05-03T21:35:46 https://maestrodatabase.com/blog/moderna-announces-new-supply-agreement-with-australia-for-25-million-doses-of-its-covid-19-vaccine 2021-05-12T20:53:44 https://maestrodatabase.com/blog/liquidia-resubmits-new-drug-application-for-liq861-treprostinil-inhalation-powder-for-the-treatment-of-pulmonary-arterial-hypertension 2021-05-12T12:21:53 https://maestrodatabase.com/blog/iterum-therapeutics-receives-us-fda-approval-of-orlynvah-oral-sulopenem-for-the-treatment-of-uncomplicated-urinary-tract-infections 2024-10-26T02:30:16 https://maestrodatabase.com/blog/new-drug-to-help-over-200-000-australians 2017-07-28T04:24:36 https://maestrodatabase.com/blog/agenda-items-scheduled-for-review-by-the-pbac-under-the-process-for-reviewing-recommendations-not-accepted-by-applicants 2021-05-12T21:22:32 https://maestrodatabase.com/blog/biocryst-receives-uk-approval-of-orladeyo-berotralstat-first-oral-once-daily-therapy-to-prevent-attacks-in-hereditary-angioedema-patients 2021-05-12T21:05:07 https://maestrodatabase.com/blog/autolus-therapeutics-announces-acceptance-of-biologics-license-application-for-obecabtagene-autoleucel-as-a-potential-treatment-for-relapsed-slash-refractory-adult-b-cell-acute-lymphoblastic-leukaemia 2024-01-23T02:33:53 https://maestrodatabase.com/blog/allow-medicare-to-negotiate-on-behalf-of-patients-to-lower-drug-prices 2021-05-12T20:58:51 https://maestrodatabase.com/blog/pharmac---2023-in-review-part-2 2024-01-23T02:18:16 https://maestrodatabase.com/blog/tga-approves-octapharmas-cutaquig 2021-05-12T21:10:07 https://maestrodatabase.com/blog/fda-grants-rare-paediatric-disease-designation-to-omeros-masp-3-inhibitor-zaltenibart-for-treatment-of-c3-glomerulopathy 2024-10-26T02:44:39 https://maestrodatabase.com/blog/mylan-receives-tentative-approval-for-combination-hiv-treatment-dtg-slash-ftc-slash-taf-under-fdas-pepfar-program 2018-02-21T02:11:57 https://maestrodatabase.com/blog/lower-drug-costs-are-just-a-federal-license-away-but-they-require-biden-administration-leadership 2024-01-23T20:40:32 https://maestrodatabase.com/blog/theratechnologies-receives-update-from-fda-on-tesamorelin-f8-supplemental-biologics-license-application 2024-01-23T20:21:49 https://maestrodatabase.com/blog/4dmt-receives-rare-paediatric-disease-designation-from-fda-for-aerosolised-4d-710-for-treatment-of-cystic-fibrosis-lung-disease 2024-01-23T20:17:31 https://maestrodatabase.com/blog/fda-grants-paediatric-disease-designation-for-mateons-ca4p 2020-05-07T07:47:30 https://maestrodatabase.com/blog/ensysce-biosciences-announces-fda-breakthrough-therapy-designation-granted-for-pf614-mpar 2024-01-23T20:14:02 https://maestrodatabase.com/blog/private-health-insurance-premiums-are-scheduled-for-october-medibank-boss-says 2020-05-07T07:54:58 https://maestrodatabase.com/blog/fasenra-approved-in-the-eu-for-eosinophilic-granulomatosis-with-polyangiitis 2024-10-28T09:21:00 https://maestrodatabase.com/blog/enhertu-approved-in-the-u-dot-s-as-the-first-her2-directed-therapy-for-patients-with-previously-treated-her2-mutant-metastatic-non-small-cell-lung-cancer 2022-08-12T02:17:55 https://maestrodatabase.com/blog/astellas-provides-update-on-marketing-authorisation-application-for-avacincaptad-pegol-in-the-european-union 2024-10-28T21:16:43 https://maestrodatabase.com/blog/tga-approves-rsv-vaccine-for-use-through-private-prescription-for-australians-over-60 2024-01-23T20:44:12 https://maestrodatabase.com/blog/pbs-in-review-2021 2021-12-05T02:00:32 https://maestrodatabase.com/blog/u-dot-s-fda-approves-pfizers-xeljanz-tofacitinib-for-the-treatment-of-active-polyarticular-course-juvenile-idiopathic-arthritis 2020-09-29T02:04:09 https://maestrodatabase.com/blog/provisional-determination-granted-to-pfizer-in-relation-to-covid-19-vaccine-comirnaty---for-use-in-individuals-12-years-of-age-and-older 2021-05-13T06:13:49 https://maestrodatabase.com/blog/eiger-announces-fda-fast-track-designation-granted-for-pegylated-interferon-lambda-in-hepatitis-delta-virus-infection 2017-07-28T05:40:41 https://maestrodatabase.com/blog/thousands-to-benefit-from-spinal-arthritis-medication-listing-on-pbs 2018-10-04T20:45:10 https://maestrodatabase.com/blog/private-health-fund-changes-to-push-patients-back-to-public-hospitals 2018-10-04T20:49:43 https://maestrodatabase.com/blog/election-campaign-2020-jacinda-ardern-unveils-1-dollars-billion-health-policy 2020-09-29T03:41:20 https://maestrodatabase.com/blog/vistagen-therapeutics-receives-fda-fast-track-designation-for-development-of-av-101-as-a-non-opioid-treatment-for-neuropathic-pain 2018-10-04T11:54:42 https://maestrodatabase.com/blog/us-fda-seeks-boxed-warning-for-car-t-cancer-therapies 2024-01-24T20:43:11 https://maestrodatabase.com/blog/urogen-initiates-submission-of-a-rolling-nda-to-the-fda-for-ugn-102 2024-01-24T20:18:17 https://maestrodatabase.com/blog/icer-final-report-highlights-uncertainty-in-long-term-safety-and-effectiveness-of-new-treatments-for-hereditary-transthyretin-amyloidosis-discusses-options-for-insurance-coverage-criteria 2018-10-04T21:28:59 https://maestrodatabase.com/blog/shionogi-announces-fda-approval-of-fetroja-cefiderocol-for-the-treatment-of-hospital-acquired-bacterial-pneumonia-and-ventilator-associated-bacterial-pneumonia 2020-09-29T02:11:15 https://maestrodatabase.com/blog/heron-therapeutics-announces-fda-approval-of-zynrelef-indication-expansion-to-include-additional-orthopaedic-and-soft-tissue-procedures 2024-01-24T20:09:12 https://maestrodatabase.com/blog/fda-approves-new-prophylactic-treatment-for-haemophilia-a-without-factor-viii-inhibitors 2018-10-04T21:34:55 https://maestrodatabase.com/blog/icer-review-highlights-the-clinical-benefits-of-using-anti-androgen-therapies-to-treat-earlier-stage-prostate-cancer 2018-10-04T21:24:38 https://maestrodatabase.com/blog/jardiance-empagliflozin-receives-authorisation-from-health-canada-for-the-treatment-of-adults-with-chronic-kidney-disease 2024-01-24T05:38:26 https://maestrodatabase.com/blog/this-brand-new-advocacy-group-is-an-unapologetic-defender-of-high-drug-prices 2018-10-04T21:42:47 https://maestrodatabase.com/blog/fulcrum-therapeutics-announces-u-dot-s-fda-grants-fast-track-designation-to-losmapimod-for-the-potential-treatment-of-facioscapulohumeral-muscular-dystrophy 2021-05-13T06:50:45 https://maestrodatabase.com/blog/babies-with-spinal-muscular-atrophy-to-be-covered-for-life-saving-but-costly-spinraza-drug 2018-10-04T21:46:46 https://maestrodatabase.com/blog/daiichi-sankyo-submits-application-for-additional-indication-of-mirogabalin-in-japan 2021-05-13T07:08:29 https://maestrodatabase.com/blog/heron-therapeutics-receives-european-commission-authorisation-for-zynrelef-htx-011-for-the-treatment-of-post-operative-pain 2020-09-29T04:58:45 https://maestrodatabase.com/blog/merck-acknowledges-the-u-dot-s-department-of-veterans-affairs-for-adopting-biosimilar-medicines-to-increase-treatment-options-for-veterans 2018-10-04T21:38:58 https://maestrodatabase.com/blog/nice-publishes-draft-guidance-for-idelalisib 2018-10-04T21:56:08 https://maestrodatabase.com/blog/pbs-summary-of-changes-for-1-june-2019 2019-05-10T20:51:36 https://maestrodatabase.com/blog/aradigm-submits-new-drug-application-to-fda-for-u-dot-s-marketing-approval-of-linhaliq-in-non-cystic-fibrosis-bronchiectasis 2017-07-28T06:12:11 https://maestrodatabase.com/blog/statement-from-acting-fda-commissioner-on-policy-advancements-to-help-bring-interchangeable-biosimilars-to-market 2019-05-10T20:47:59 https://maestrodatabase.com/blog/nice-oks-pfizers-xeljanz-for-new-indication 2018-10-04T21:51:15 https://maestrodatabase.com/blog/speed-up-cancer-funding-alp-told 2019-05-10T21:45:10 https://maestrodatabase.com/blog/house-democrats-pass-bill-to-roll-back-trump-guidance-related-to-obamacare 2019-05-10T21:34:15 https://maestrodatabase.com/blog/allegations-of-widespread-fraud-raise-questions-about-the-safety-of-generic-drugs-made-overseas 2019-05-10T21:28:11 https://maestrodatabase.com/blog/taxpayers-are-funding-expensive-drug-development-report-says 2019-05-10T21:04:26 https://maestrodatabase.com/blog/fdas-istand-pilot-program-accepts-submission-of-first-artificial-intelligence-based-and-digital-health-technology-for-neuroscience 2024-01-24T23:27:17 https://maestrodatabase.com/blog/us-senate-rejects-measure-to-partly-repeal-affordable-care-act-dealing-gop-leaders-a-major-setback 2017-07-28T06:48:44 https://maestrodatabase.com/blog/csl-behring-australia-commences-development-of-treatment-for-serious-cases-of-covid-19 2020-05-07T11:32:26 https://maestrodatabase.com/blog/the-equitable-distribution-of-covid-19-therapeutics-and-vaccines 2020-05-07T20:44:56 https://maestrodatabase.com/blog/japan-approves-gilead-sciences-remdesivir-as-covid-19-drug 2020-05-07T20:52:15 https://maestrodatabase.com/blog/manufacturer-of-cystic-fibrosis-drug-offers-it-for-free-during-pandemic-if-feds-negotiate-on-pricing 2020-05-07T10:43:19 https://maestrodatabase.com/blog/nice-draft-guidance-recommends-new-treatment-option-for-people-with-early-breast-cancer 2020-05-07T11:08:00 https://maestrodatabase.com/blog/generic-drug-maker-admits-to-fixing-prices-for-cholesterol-medication 2020-05-07T21:05:32 https://maestrodatabase.com/blog/capmatinib-for-treating-advanced-non-small-cell-lung-cancer-with-met-exon-14-skipping 2023-05-04T00:48:31 https://maestrodatabase.com/blog/eisai-korea-to-stop-supply-of-blood-cancer-drug-symbenda-this-year 2021-05-13T07:55:45 https://maestrodatabase.com/blog/covid-19-pharmac-warns-of-significant-shortage-of-surgery-drug-propofol 2020-05-07T20:55:25 https://maestrodatabase.com/blog/hospital-prices-for-physician-administered-drugs-for-patients-with-private-insurance 2024-01-25T00:27:38 https://maestrodatabase.com/blog/dr-reddys-laboratories-received-approval-for-their-nda-elyxyb-celecoxib-25-mg-slash-ml-oral-solution-in-the-u-dot-s 2020-05-07T21:01:17 https://maestrodatabase.com/blog/ema-publishes-agenda-for-19-22-february-chmp-meeting 2018-02-21T20:00:07 https://maestrodatabase.com/blog/palisade-bio-receives-fda-fast-track-designation-for-lb1148-for-reduction-of-adhesions-following-abdominal-and-pelvic-surgery 2021-05-13T20:45:42 https://maestrodatabase.com/blog/charity-upset-pre-election-pledge-for-separate-fund-for-rare-diseases-off-the-table 2018-02-21T19:49:24 https://maestrodatabase.com/blog/pharmacy-benefit-managers-are-the-sole-check-against-drug-manufacturers-pricing-power 2019-05-10T22:27:01 https://maestrodatabase.com/blog/strongbridge-biopharma-announces-u-dot-s-fda-filing-acceptance-of-new-drug-application-for-recorlev-levoketoconazole-for-the-treatment-of-endogenous-cushings-syndrome 2021-05-13T20:53:27 https://maestrodatabase.com/blog/mandatory-requirements-for-an-effective-application 2018-02-21T19:55:47 https://maestrodatabase.com/blog/industrys-experiences-with-the-scientific-advice-offered-by-the-federal-joint-committee-within-the-early-benefit-assessment-of-pharmaceuticals-in-germany 2018-02-21T20:21:35 https://maestrodatabase.com/blog/daiichi-sankyo-receives-negative-chmp-opinion-for-flt3-inhibitor-quizartinib-for-treatment-of-patients-with-relapsed-slash-refractory-flt3-itd-aml 2019-10-21T01:08:54 https://maestrodatabase.com/blog/australia-secures-moderna-vaccines 2021-05-13T10:15:53 https://maestrodatabase.com/blog/unitedhealth-commits-1-dollars-5-cents-billion-for-premium-rebates-and-new-cost-sharing-waivers 2020-05-07T21:20:23 https://maestrodatabase.com/blog/increase-transparency-at-the-fda-we-need-sunlight-to-fight-the-pandemic 2020-09-29T11:34:15 https://maestrodatabase.com/blog/american-society-of-clinical-oncology-statement-biosimilars-in-oncology 2018-02-21T20:31:41 https://maestrodatabase.com/blog/how-are-incremental-cost-effectiveness-contextual-considerations-and-other-benefits-viewed-in-health-technology-assessment-recommendations-in-the-united-states 2020-05-07T21:32:13 https://maestrodatabase.com/blog/nice-nod-for-gileads-pan-genotypic-hepatitis-c-therapy 2018-02-21T20:09:54 https://maestrodatabase.com/blog/heron-therapeutics-announces-u-dot-s-fda-approval-of-zynrelef-for-the-management-of-post-operative-pain-for-up-to-72-hours 2021-05-13T20:40:20 https://maestrodatabase.com/blog/bausch-health-announces-updated-health-canada-safety-information-for-elidel 2019-10-21T01:26:40 https://maestrodatabase.com/blog/pfizer-warns-that-ip-waiver-for-covid-19-vaccines-may-invite-copycat-medicines 2021-05-13T21:29:47 https://maestrodatabase.com/blog/california-to-use-market-power-in-bid-to-lower-prescription-drug-costs 2020-09-29T20:46:57 https://maestrodatabase.com/blog/ptc-therapeutics-receives-formal-dispute-resolution-request-decision-from-the-fdas-office-of-new-drugs 2018-02-21T20:56:52 https://maestrodatabase.com/blog/china-wants-big-pharma-to-bend-the-knee-in-new-health-care-system 2019-10-21T01:23:40 https://maestrodatabase.com/blog/the-estimation-of-health-state-utility-values-in-rare-diseases-overview-of-existing-techniques 2020-09-29T20:49:49 https://maestrodatabase.com/blog/annual-performance-statistics-report-july-2018-to-june-2019 2019-10-21T01:17:16 https://maestrodatabase.com/blog/labours-promised-pharmac-boost-not-enough 2020-09-29T20:53:29 https://maestrodatabase.com/blog/trump-pushing-ahead-on-koch-backed-experimental-drugs-right-to-try-agenda 2018-02-21T20:38:19 https://maestrodatabase.com/blog/epidyolex-oral-solution-is-not-included-in-the-high-cost-protection 2020-09-29T20:56:22 https://maestrodatabase.com/blog/health-canada-approves-otsuka-and-lundbecks-rexulti-brexpiprazole-for-the-symptomatic-management-of-agitation-associated-with-alzheimers-dementia 2024-01-25T02:09:42 https://maestrodatabase.com/blog/modernising-medicare-coverage-pathways-for-prescription-digital-therapeutics 2021-05-16T20:54:55 https://maestrodatabase.com/blog/icer-to-assess-treatment-for-alzheimers-disease 2020-09-29T20:43:42 https://maestrodatabase.com/blog/pilot-of-new-health-technology-evaluation-process-for-antimicrobials 2021-05-13T21:27:11 https://maestrodatabase.com/blog/sunovion-and-psychogenics-announce-that-sep-363856-has-received-fda-breakthrough-therapy-designation-for-the-treatment-of-people-with-schizophrenia 2019-05-10T23:07:39 https://maestrodatabase.com/blog/long-waits-for-life-saving-drugs-harming-canadians-report 2021-05-13T21:08:09 https://maestrodatabase.com/blog/ascentage-pharmas-core-drug-candidate-hqp1351-granted-fast-track-designation-by-the-us-fda-marking-another-milestone-in-its-development 2020-05-07T23:09:26 https://maestrodatabase.com/blog/germany-has-not-fully-realised-its-biosimilar-potential 2020-09-29T21:21:05 https://maestrodatabase.com/blog/pfizer-ceo-on-the-pressures-of-creating-a-covid-19-vaccine-what-is-at-stake-is-beyond-imagination 2020-09-29T21:29:49 https://maestrodatabase.com/blog/fda-chief-stands-by-vaccine-approval-criteria-despite-trump-pressure 2020-09-29T21:41:30 https://maestrodatabase.com/blog/victoza-has-been-approved-in-the-eu-as-the-only-glp-1-with-a-label-to-include-prevention-of-cardiovascular-events 2017-07-28T11:44:00 https://maestrodatabase.com/blog/assessing-claims-of-clinical-superiority-what-do-the-guidelines-say 2020-09-29T21:03:11 https://maestrodatabase.com/blog/trumps-drug-pricing-ideas-would-cost-taxpayers-a-bundle 2020-09-29T21:07:06 https://maestrodatabase.com/blog/voters-beware-national-pharmacare-is-unnecessary-bad-for-privately-insured-canadians-and-costly-for-taxpayers 2019-10-21T02:14:06 https://maestrodatabase.com/blog/pharmac-joins-global-health-technology-assessment-network 2024-01-25T02:31:00 https://maestrodatabase.com/blog/bridgebio-pharma-and-affiliate-origin-biosciences-announces-fda-acceptance-of-its-new-drug-application-for-fosdenopterin-for-the-treatment-of-mocd-type-a 2020-09-29T21:11:15 https://maestrodatabase.com/blog/cystic-fibrosis-medicines-listings-on-the-pharmaceutical-benefits-scheme 2019-10-21T05:18:53 https://maestrodatabase.com/blog/health-canada-approves-quviviq-daridorexant-for-the-management-of-adult-patients-with-insomnia 2023-05-04T11:20:54 https://maestrodatabase.com/blog/breast-cancer-canada-progress-report-reveals-major-gaps-in-screening-and-treatment-delays-across-canada 2024-10-29T04:55:46 https://maestrodatabase.com/blog/healthscope-to-slug-bupa-patients-100-dollars-for-overnight-hospital-stays 2024-10-29T04:49:06 https://maestrodatabase.com/blog/european-medicines-agency-validates-type-ii-variation-application-for-padcev-enfortumab-vedotin-with-keytruda-pembrolizumab-for-first-line-treatment-of-advanced-bladder-cancer 2024-01-26T20:51:15 https://maestrodatabase.com/blog/gene-therapies-are-still-hampered-by-substantial-delays-between-approval-and-launch 2023-05-04T11:30:28 https://maestrodatabase.com/blog/aurinia-pharmaceuticals-announces-swissmedic-approval-of-lupkynis-voclosporin 2023-05-04T12:58:32 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-european-commission-approval-for-car-t-cell-therapy-breyanzi-lisocabtagene-maraleucel-for-relapsed-or-refractory-large-b-cell-lymphoma-after-one-prior-therapy 2023-05-04T11:25:02 https://maestrodatabase.com/blog/theratechnologies-receives-complete-response-letter-from-the-fda-for-the-f8-formulation-of-tesamorelin-sbla 2024-01-26T21:09:14 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-takedas-biologics-license-application-for-a-subcutaneous-formulation-of-vedolizumab-entyvio-for-maintenance-therapy-in-moderately-to-severely-active-ulcerative-colitis 2019-05-12T20:57:17 https://maestrodatabase.com/blog/fda-approves-prior-approval-supplement-for-bivigam 2019-05-12T20:51:24 https://maestrodatabase.com/blog/united-therapeutics-announces-fda-approval-of-updated-label-for-orenitram-reflecting-results-of-freedom-ev-study 2019-10-21T11:46:09 https://maestrodatabase.com/blog/2022-2023-cost-recovery-implementation-statement 2022-08-12T08:15:37 https://maestrodatabase.com/blog/dupixent-dupilumab-fda-approved-as-first-and-only-treatment-indicated-for-children-aged-1-year-and-older-with-eosinophilic-oesophagitis 2024-01-26T21:57:14 https://maestrodatabase.com/blog/biosimilar-medicines-regulation 2018-02-22T10:53:07 https://maestrodatabase.com/blog/intellipharmaceutics-announces-fda-approval-for-generic-pristiq 2019-05-13T03:57:28 https://maestrodatabase.com/blog/minutes-from-november-2017-ptac-meeting-provide-interesting-insights-on-roches-submission-for-kadcyla 2018-02-22T10:59:31 https://maestrodatabase.com/blog/farxiga-approved-in-the-us-to-reduce-the-risk-of-hospitalisation-for-heart-failure-in-patients-with-type-2-diabetes 2019-10-21T11:41:33 https://maestrodatabase.com/blog/teva-and-other-generic-drug-makers-inflated-prices-up-to-1-000-percent-state-prosecutors-say 2019-05-12T21:12:54 https://maestrodatabase.com/blog/its-absurd---allergy-sufferers-beg-pharmac-to-fund-epipens 2019-05-12T21:03:50 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-asciminib-for-newly-diagnosed-chronic-myeloid-leukaemia 2024-10-29T20:02:48 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-positive-chmp-opinion-for-car-t-cell-therapy-abecma-idecabtagene-vicleucel-in-earlier-lines-of-therapy-for-triple-class-exposed-relapsed-and-refractory-multiple-myeloma 2024-01-26T21:41:19 https://maestrodatabase.com/blog/nice-sticks-with-no-for-earlier-use-of-halaven 2018-02-22T20:03:54 https://maestrodatabase.com/blog/chmp-issues-negative-opinion-for-renewal-of-conditional-marketing-authorisation-for-translarna-ataluren-following-re-examination-procedure 2024-01-26T21:32:59 https://maestrodatabase.com/blog/people-with-a-rare-form-of-blood-cancer-are-set-to-benefit-after-nice-recommends-new-targeted-therapy 2024-10-29T10:20:25 https://maestrodatabase.com/blog/janssen-announces-u-dot-s-fda-approval-of-stelara-ustekinumab-for-the-treatment-of-adults-with-moderately-to-severely-active-ulcerative-colitis 2019-10-21T19:37:13 https://maestrodatabase.com/blog/new-insights-on-pharmacs-tardiness-in-funding-keytruda-for-patients-with-nsclc 2018-02-22T11:18:57 https://maestrodatabase.com/blog/enhancing-consistency-in-wording-of-therapeutic-indications-to-support-health-care-decision-making 2019-10-21T19:33:45 https://maestrodatabase.com/blog/the-ceo-of-merck-on-race-leadership-and-high-drug-prices 2018-02-22T20:31:19 https://maestrodatabase.com/blog/assertio-therapeutics-provides-regulatory-update-on-long-acting-cosyntropin 2019-10-21T19:57:33 https://maestrodatabase.com/blog/medibank-to-be-first-health-insurer-to-make-potential-out-of-pocket-costs-publicly-available 2019-10-21T19:54:16 https://maestrodatabase.com/blog/outcomes-from-the-december-2023-pbac-intracycle-meeting 2024-01-26T22:23:57 https://maestrodatabase.com/blog/developing-anti-cancer-drugs-in-orphan-molecular-entities----a-paradigm-under-construction 2018-02-22T20:38:52 https://maestrodatabase.com/blog/after-10-hours-and-a-pile-of-rejected-amendments-democrats-advance-their-drug-pricing-bill-out-of-two-key-committees 2019-10-21T19:46:50 https://maestrodatabase.com/blog/fda-acceptance-of-medicines360s-filing-for-supplemental-new-drug-application-for-liletta-levonorgestrel-releasing-intrauterine-system-52-mg 2018-02-22T20:28:38 https://maestrodatabase.com/blog/liquidia-provides-update-on-new-drug-application-for-yutrepia-treprostinil-inhalation-powder 2024-01-26T22:16:35 https://maestrodatabase.com/blog/fda-approves-new-breakthrough-therapy-for-cystic-fibrosis 2019-10-21T19:42:26 https://maestrodatabase.com/blog/trump-tries-to-kill-obamacare-by-a-thousand-cuts 2018-02-22T20:55:44 https://maestrodatabase.com/blog/international-pricing-index-accomplishes-nothing-it-sets-out-to-do 2019-10-21T20:07:12 https://maestrodatabase.com/blog/fda-approves-new-kyprolis-carfilzomib-combination-regimen-with-darzalex-faspro-daratumumab-and-hyaluronidase-fihj-and-dexamethasone-for-patients-with-multiple-myeloma-at-first-or-subsequent-relapse 2021-12-05T21:49:56 https://maestrodatabase.com/blog/bayer-submits-supplemental-new-drug-application-to-fda-for-intrauterine-device-mirena-levonorgestrel-releasing-intrauterine-system-52-mg 2019-10-21T20:02:44 https://maestrodatabase.com/blog/a-health-economics-approach-to-us-value-frameworks-serving-the-needs-of-decision-making 2018-02-22T20:43:06 https://maestrodatabase.com/blog/australian-patients-to-benefit-from-ongoing-collaboration-between-peak-medicine-bodies 2020-09-29T23:21:30 https://maestrodatabase.com/blog/eton-pharmaceuticals-announces-fda-approval-of-orphan-drug-alkindi-sprinkle-hydrocortisone-as-replacement-therapy-in-paediatric-patients-with-adrenocortical-insufficiency 2020-09-29T23:04:48 https://maestrodatabase.com/blog/reflexion-receives-breakthrough-device-designation-for-lung-cancer-treatment 2021-12-05T22:30:28 https://maestrodatabase.com/blog/the-pandemic-is-a-chance-to-revamp-indias-pharmaceutical-industry 2020-05-08T00:56:10 https://maestrodatabase.com/blog/infinity-receives-fast-track-designation-for-eganelisib-in-combination-with-a-checkpoint-inhibitor-and-chemotherapy-for-first-line-treatment-of-advanced-triple-negative-breast-cancer 2020-09-29T23:16:04 https://maestrodatabase.com/blog/japans-ministry-of-health-labour-and-welfare-grants-priority-review-for-enfortumab-vedotin-new-drug-application 2021-05-14T01:16:55 https://maestrodatabase.com/blog/mps-call-for-life-changing-kuvan-to-be-made-affordable 2019-05-13T11:02:56 https://maestrodatabase.com/blog/nice-recommendation-expands-patient-eligibility-for-abbvies-ozurdex 2022-08-12T22:39:49 https://maestrodatabase.com/blog/statement-on-60-day-medicine-dispensing 2023-05-04T17:06:42 https://maestrodatabase.com/blog/access-to-cancer-medicines-in-the-uk 2023-05-04T17:01:40 https://maestrodatabase.com/blog/lillys-cyramza-ramucirumab-becomes-first-fda-approved-biomarker-driven-therapy-in-patients-with-hepatocellular-carcinoma 2019-05-13T10:53:07 https://maestrodatabase.com/blog/two-words-to-help-ned-sharpless-revolutionise-clinical-trials-data-standards 2019-05-13T12:00:38 https://maestrodatabase.com/blog/federal-funding-for-discovery-and-development-of-costly-hiv-drugs-was-far-more-than-previously-estimated 2023-05-04T15:42:23 https://maestrodatabase.com/blog/grandstanding-not-real-change-why-drug-prices-in-tv-ads-will-be-confusing-and-irrelevant 2019-05-13T11:22:53 https://maestrodatabase.com/blog/the-uks-new-medicines-pricing-deal---opportunities-and-risks-for-pharma 2019-05-13T11:17:20 https://maestrodatabase.com/blog/for-the-second-time-pfizer-tries-a-warranty-in-response-to-concerns-over-high-drug-costs 2022-08-12T11:41:49 https://maestrodatabase.com/blog/smc---may-2019-decisions 2019-05-13T21:02:24 https://maestrodatabase.com/blog/migraine-drug-emgality-to-be-listed-on-pbs-saving-sufferers-thousands-of-dollars 2021-05-14T02:16:48 https://maestrodatabase.com/blog/us-move-to-negotiate-drug-prices-a-rare-defeat-for-big-pharma 2022-08-12T23:22:53 https://maestrodatabase.com/blog/considerations-in-demonstrating-interchangeability-with-a-reference-product-guidance-for-industry 2019-05-13T20:58:57 https://maestrodatabase.com/blog/safety-efficacy-and-quality-remain-top-priorities-as-we-continue-our-work-to-expand-access-to-cost-saving-generic-drugs-for-the-american-public 2019-05-13T20:53:31 https://maestrodatabase.com/blog/hta-frameworks-for-ra-therapies-need-improvement-researchers-say 2019-05-13T21:26:33 https://maestrodatabase.com/blog/health-canada-approves-reblozyl-luspatercept-new-class-of-treatment-for-adult-patients-living-with-beta-thalassaemia 2020-09-30T01:17:59 https://maestrodatabase.com/blog/australias-gbma-launches-hub-for-biosimilar-education 2019-05-13T21:23:11 https://maestrodatabase.com/blog/molzym-announces-fda-breakthrough-device-designation-for-its-molecular-diagnostic-test-system---sepsis-ioint-and-implant-infections-infective-endocarditis-bacterial-meningitis 2021-05-14T01:45:56 https://maestrodatabase.com/blog/four-dose-mounjaro-kwikpen-approved-by-mhra-for-diabetes-and-weight-management 2024-01-26T23:39:25 https://maestrodatabase.com/blog/new-cancer-drugs-approved-for-nhs-use-in-scotland 2019-05-13T21:12:14 https://maestrodatabase.com/blog/study-identifies-shortcomings-in-fda-evaluations-for-new-opioid-drug-approvals-over-two-decades 2020-09-30T02:21:22 https://maestrodatabase.com/blog/house-budget-committee-announces-hearing-on-single-payer-health-care 2019-05-13T21:07:07 https://maestrodatabase.com/blog/msac-publishes-agenda-for-upcoming-esc-meeting 2021-05-14T02:00:47 https://maestrodatabase.com/blog/dismay-as-uk-drags-its-heels-on-azs-covid-antibody-evusheld 2022-08-12T23:35:16 https://maestrodatabase.com/blog/novartis-pitches-discounts-on-pricey-gene-therapy-for-deadly-muscle-disorder 2019-05-13T21:53:50 https://maestrodatabase.com/blog/japan-health-ministry-orders-ono-pharmaceutical-to-add-warning-to-opdivo-cancer-drug-after-death 2019-05-13T21:40:35 https://maestrodatabase.com/blog/nice-publishes-first-draft-guidance-from-its-early-value-assessment-pilot-project-recommending-smartphone-linked-ecg-device 2022-08-12T23:53:57 https://maestrodatabase.com/blog/congress-should-revive-the-office-of-technology-assessment 2019-05-13T21:30:55 https://maestrodatabase.com/blog/vaccine-patent-waivers-deserve-a-warning-label 2021-05-14T04:55:04 https://maestrodatabase.com/blog/act-would-ensure-an-independent-review-of-pharmac 2020-09-30T04:29:17 https://maestrodatabase.com/blog/celltrions-remsima-sc-launches-in-netherlands 2020-05-08T06:30:47 https://maestrodatabase.com/blog/saxenda-is-not-included-in-the-high-cost-protection 2020-09-30T05:38:35 https://maestrodatabase.com/blog/new-dual-therapy-pbs-restrictions-for-pulmonary-arterial-hypertension-medicines 2020-09-30T11:23:31 https://maestrodatabase.com/blog/patrick-admits-no-medical-shortages-from-wharf-dispute---yet 2020-09-30T11:41:31 https://maestrodatabase.com/blog/health-care-leaders-question-how-remdesivir-is-being-distributed 2020-05-08T06:42:31 https://maestrodatabase.com/blog/trump-claims-his-policies-made-insulin-so-cheap-its-like-water-dot-but-for-most-people-it-costs-just-as-much-as-before 2020-09-30T11:08:15 https://maestrodatabase.com/blog/bridgebio-pharma-receives-fda-fast-track-designation-for-investigational-gene-therapy-for-congenital-adrenal-hyperplasia 2021-05-14T20:53:30 https://maestrodatabase.com/blog/proposal-to-widen-access-to-bortezomib-for-multiple-myeloma-and-amyloidosis 2019-10-22T00:01:21 https://maestrodatabase.com/blog/simponi-aria-golimumab-approved-by-the-u-dot-s-fda-for-active-polyarticular-juvenile-idiopathic-arthritis-and-extension-of-its-active-psoriatic-arthritis-indication-in-patients-2-years-of-age-and-older 2020-09-30T21:05:50 https://maestrodatabase.com/blog/proposal-to-award-sole-supply-for-fluticasone-and-fluticasone-with-salmeterol-metered-dose-inhalers 2019-10-21T23:56:31 https://maestrodatabase.com/blog/colorectal-cancer-patients-with-rare-mutations-to-benefit-from-life-extending-treatment 2021-05-14T20:59:18 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-october-2020-update 2020-09-30T21:12:25 https://maestrodatabase.com/blog/janssen-submits-new-drug-application-to-u-dot-s-fda-for-uptravi-selexipag-injection-for-intravenous-use-to-treat-pulmonary-arterial-hypertension 2020-09-30T21:23:05 https://maestrodatabase.com/blog/internationally-respected-medical-specialist-slams-pharmac-urges-pm-to-investigate 2020-09-30T20:52:59 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-october-2020 2020-09-30T20:55:53 https://maestrodatabase.com/blog/house-panel-says-drug-makers-inflated-prices-to-boost-profits-and-reap-bonuses 2020-09-30T21:01:25 https://maestrodatabase.com/blog/pharmaessentia-resubmits-application-to-the-u-dot-s-fda-for-ropeginterferon-alfa-2b-njft-to-treat-polycythemia-vera 2021-05-14T13:18:32 https://maestrodatabase.com/blog/allogene-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-designation-for-allo-316-an-allocar-t-investigational-product-for-adult-patients-with-advanced-or-metastatic-renal-cell-carcinoma 2024-10-29T23:55:01 https://maestrodatabase.com/blog/funding-battle-over-a-critical-medicine-is-the-latest-front-in-private-health-war 2024-10-29T23:50:38 https://maestrodatabase.com/blog/highlights-from-the-22-25-january-2024-chmp-meeting 2024-01-27T01:27:39 https://maestrodatabase.com/blog/nice-says-final-no-to-bms-zeposia-for-multiple-sclerosis 2021-05-14T21:11:41 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-therapies-for-atopic-dermatitis 2021-05-14T21:03:06 https://maestrodatabase.com/blog/fda-approves-first-ngs-based-companion-diagnostic-to-aid-in-selecting-non-small-cell-lung-cancer-patients-with-her2-erbb2-activating-mutations-snvs-and-exon-20-insertions-for-treatment-with-enhertu 2022-08-13T03:53:11 https://maestrodatabase.com/blog/humacytes-human-acellular-vessel-receives-fdas-regenerative-medicine-advanced-therapy-designation-for-urgent-arterial-repair-following-vascular-trauma 2023-05-04T23:43:32 https://maestrodatabase.com/blog/sanders-and-klobuchar-reintroduce-legislation-to-cut-drug-prices-in-half 2023-05-04T21:10:17 https://maestrodatabase.com/blog/eu-actions-to-support-availability-of-medicines-during-covid-19-pandemic---update-number-5 2020-05-08T22:03:32 https://maestrodatabase.com/blog/fda-approves-first-therapy-for-patients-with-lung-and-thyroid-cancers-with-a-certain-genetic-mutation-or-fusion 2020-05-08T22:05:38 https://maestrodatabase.com/blog/paratek-announces-acceptance-of-european-marketing-authorisation-application-for-oral-and-intravenous-omadacycline 2018-10-05T06:59:37 https://maestrodatabase.com/blog/chmp-adopts-positive-opinion-recommending-hepcludex-bulevirtide-for-full-marketing-authorization-for-the-treatment-of-hepatitis-delta-virus 2023-05-05T01:13:16 https://maestrodatabase.com/blog/akcea-and-ionis-announce-approval-of-tegsedi-inotersen-injection-in-canada 2018-10-05T07:10:01 https://maestrodatabase.com/blog/orchard-therapeutics-receives-ema-prime-designation-for-otl-300-an-investigational-lentiviral-gene-therapy-for-the-treatment-of-transfusion-dependent-beta-thalassaemia 2018-10-05T07:03:13 https://maestrodatabase.com/blog/roche-app-allows-access-to-latest-cancer-guidelines 2019-10-22T02:32:02 https://maestrodatabase.com/blog/pharmac-negotiates-deal-with-pfizer-for-its-promising-new-oral-antiviral-treatment-for-covid-19 2021-12-06T20:21:29 https://maestrodatabase.com/blog/icer-publishes-evidence-report-on-treatment-for-schizophrenia 2024-01-27T22:06:04 https://maestrodatabase.com/blog/ema-recommends-approval-for-use-of-roactemra-in-adults-with-severe-covid-19 2021-12-06T20:28:58 https://maestrodatabase.com/blog/health-canada-approves-radicava-edaravone-for-the-treatment-of-als 2018-10-05T07:31:45 https://maestrodatabase.com/blog/tga-provisional-approval-of-celltrion-covid-19-treatment-regdanvimab-regkirona 2021-12-06T20:25:05 https://maestrodatabase.com/blog/chiesi-global-rare-diseases-announces-updated-u-dot-s-prescribing-information-for-ferriprox-deferiprone 2021-12-06T20:10:26 https://maestrodatabase.com/blog/dupixent-dupilumab-injection-is-now-approved-in-canada-for-the-treatment-of-adult-and-adolescent-patients-12-plus-with-eosinophilic-esophagitis 2023-05-05T01:29:17 https://maestrodatabase.com/blog/the-fda-and-the-importance-of-trust 2020-09-30T23:41:20 https://maestrodatabase.com/blog/extension-to-image-based-prescription-special-arrangement 2021-12-22T04:42:07 https://maestrodatabase.com/blog/secura-bio-announces-copiktra-duvelisib-strategic-focus-on-t-cell-lymphoma-and-voluntary-u-dot-s-withdrawal-of-the-relapsed-or-refractory-follicular-lymphoma-indication 2021-12-06T20:14:33 https://maestrodatabase.com/blog/theratechnologies-submits-supplemental-biologics-license-application-to-fda-advancing-development-of-iv-push-trogarzo-for-patients-living-with-hiv 2021-12-06T20:41:51 https://maestrodatabase.com/blog/celgene-corporation-announces-pomalyst-granted-breakthrough-therapy-designation-from-fda-for-hiv-positive-and-negative-kaposi-sarcoma 2019-05-14T03:09:44 https://maestrodatabase.com/blog/hyqvia-gets-a-higher-price 2020-05-08T22:41:33 https://maestrodatabase.com/blog/making-cancer-treatments-affordable-today-wont-hurt-tomorrows-innovation 2021-05-14T22:51:24 https://maestrodatabase.com/blog/hcf-calls-for-independent-regulator-of-medical-devices 2021-12-06T20:33:49 https://maestrodatabase.com/blog/cellectar-receives-fda-fast-track-designation-for-clr-131-in-relapsed-or-refractory-multiple-myeloma 2019-05-14T03:15:10 https://maestrodatabase.com/blog/sapience-therapeutics-receives-fda-fast-track-designation-for-st101-for-the-treatment-of-recurrent-glioblastoma-multiforme 2021-12-06T20:37:39 https://maestrodatabase.com/blog/updated-agenda-for-the-july-2023-pbac-meeting 2023-05-05T09:15:10 https://maestrodatabase.com/blog/apellis-announces-u-dot-s-fda-approval-of-empaveli-pegcetacoplan-for-adults-with-paroxysmal-nocturnal-hemoglobinuria 2021-05-15T01:15:53 https://maestrodatabase.com/blog/nices-office-for-digital-health-opens-its-doors 2021-05-15T01:36:20 https://maestrodatabase.com/blog/fda-approves-broadened-indication-for-xeomin-incobotulinumtoxina-as-first-line-treatment-for-blepharospasm-involuntary-blinking-in-adult-patients 2019-05-14T04:08:09 https://maestrodatabase.com/blog/helping-canadians-get-faster-access-to-the-prescription-drugs-they-need-to-live-healthier-lives 2019-05-14T04:06:05 https://maestrodatabase.com/blog/lilly-canada-and-the-pan-canadian-pharmaceutical-alliance-successfully-complete-negotiations-for-verzenio-abemaciclib-in-expanded-early-breast-cancer-indication 2024-10-30T02:30:35 https://maestrodatabase.com/blog/more-reimbursement-needed-for-hepatocellular-carcinoma 2021-05-14T23:12:48 https://maestrodatabase.com/blog/process-for-managing-the-march-2025-pbac-meeting-agenda 2024-10-30T02:59:04 https://maestrodatabase.com/blog/eplontersen-for-the-treatment-of-patients-with-hereditary-transthyretin-related-amyloidosis 2024-10-30T02:51:15 https://maestrodatabase.com/blog/osimertinib-mesylate-in-combination-with-pemetrexed-and-platinum-based-chemotherapy-for-the-first-line-treatment-of-patients-with-advanced-egfr-mutation-positive-non-small-cell-lung-cancer 2024-10-30T10:42:02 https://maestrodatabase.com/blog/mhra-consults-on-new-regulatory-framework-for-no-deal-scenario 2018-10-05T22:28:03 https://maestrodatabase.com/blog/lynparza-olaparib-approved-by-fda-as-first-line-maintenance-treatment-with-bevacizumab-for-hrd-positive-advanced-ovarian-cancer 2020-05-09T02:34:32 https://maestrodatabase.com/blog/fda-approves-expanded-use-of-gardasil-9-to-include-individuals-27-through-45-years-old 2018-10-05T22:30:25 https://maestrodatabase.com/blog/pharmacist-prescribers-able-to-prescribe-special-authority-medicines 2020-10-01T00:43:57 https://maestrodatabase.com/blog/pharmac-expands-access-to-meningococcal-b-vaccine-for-children-under-5 2025-08-04T02:01:35 https://maestrodatabase.com/blog/european-commission-approves-subcutaneous-formulation-of-entyvio-vedolizumab-for-use-as-maintenance-therapy-in-adults-with-moderately-to-severely-active-ulcerative-colitis-or-crohns-disease 2020-05-09T02:42:10 https://maestrodatabase.com/blog/australians-now-take-drastic-steps-to-pay-for-vital-medicines-not-on-the-pbs 2025-08-04T02:12:56 https://maestrodatabase.com/blog/pbs-listing-of-parkinsons-drug-a-life-changing-move-for-father-of-two-craig-gillespie 2025-08-04T02:17:37 https://maestrodatabase.com/blog/akcea-and-ionis-receive-fda-approval-of-tegsedi-inotersen-for-the-treatment-of-the-polyneuropathy-of-hereditary-transthyretin-mediated-amyloidosis-in-adults 2018-10-05T22:50:04 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-for-omecamtiv-mecarbil-in-heart-failure 2020-05-08T23:40:05 https://maestrodatabase.com/blog/gilead-strikes-deal-with-nhs-england-on-car-t-yescarta 2018-10-05T22:45:04 https://maestrodatabase.com/blog/evolution-or-revolution-the-latest-review-of-nice-methods 2019-10-22T10:35:10 https://maestrodatabase.com/blog/trump-urges-quicker-action-to-allow-imported-drugs-from-canada 2019-10-22T05:20:32 https://maestrodatabase.com/blog/us-to-widen-inquiry-into-astrazeneca-covid-vaccine-destined-for-australia 2020-10-01T00:59:19 https://maestrodatabase.com/blog/biogen-plans-regulatory-filing-for-aducanumab-in-alzheimers-disease-based-on-new-analysis-of-larger-dataset-from-phase-3-studies 2019-10-22T10:45:37 https://maestrodatabase.com/blog/a-bipartisan-way-to-make-prescription-drugs-affordable 2019-10-22T10:40:56 https://maestrodatabase.com/blog/evaluating-progression-free-survival-as-a-surrogate-outcome-for-health-related-quality-of-life-in-oncology 2018-10-05T23:01:25 https://maestrodatabase.com/blog/a-pac-is-using-the-midterms-to-spotlight-high-drug-prices-why-is-it-sinking-millions-into-unwinnable-races 2018-10-05T23:06:43 https://maestrodatabase.com/blog/how-joe-grogan-a-former-pharma-lobbyist-upended-trumps-drug-pricing-agenda 2019-10-22T10:38:43 https://maestrodatabase.com/blog/express-scripts-offers-prescription-cost-relief-for-newly-uninsured-americans 2020-05-09T03:47:19 https://maestrodatabase.com/blog/eton-pharmaceuticals-announces-u-dot-s-fda-approval-of-biorphen-phenylephrine-hci-injection 2019-10-22T19:51:46 https://maestrodatabase.com/blog/health-insurance-premiums-to-rise-after-government-deal-fails-to-reduce-costs 2019-10-22T19:43:57 https://maestrodatabase.com/blog/bergenbio-receives-fda-approval-of-fast-track-designation-for-bemcentinib 2019-10-22T20:05:26 https://maestrodatabase.com/blog/heron-announces-fda-approval-of-supplemental-new-drug-application-to-expand-cinvanti-label-for-single-dose-regimen-for-patients-receiving-moderately-emetogenic-chemotherapy 2019-10-22T19:58:26 https://maestrodatabase.com/blog/which-health-care-promises-will-the-liberals-realistically-be-able-to-keep 2019-10-22T20:24:42 https://maestrodatabase.com/blog/why-drug-prices-for-some-big-medicines-will-remain-high-for-a-longer-time 2025-08-04T05:19:51 https://maestrodatabase.com/blog/microsoft-humana-partner-to-reimagine-health-care-for-ageing-boomers 2019-10-22T20:21:11 https://maestrodatabase.com/blog/update-from-the-pbac-july-2025 2025-08-04T06:32:02 https://maestrodatabase.com/blog/americans-deserve-better-than-speaker-nancy-pelosis-drug-pricing-plan 2019-10-22T20:16:30 https://maestrodatabase.com/blog/drugstore-drones-ups-will-fly-cvs-prescriptions-to-u-dot-s-customers 2019-10-22T20:12:00 https://maestrodatabase.com/blog/moderna-receives-fda-fast-track-designation-for-propionic-acidemia-program-mrna-3927 2019-10-22T23:42:47 https://maestrodatabase.com/blog/bluebird-bio-announces-emas-acceptance-of-marketing-authorisation-application-for-lentiglobin-gene-therapy-for-the-treatment-of-transfusion-dependent-b-thalassemia 2018-10-06T01:06:28 https://maestrodatabase.com/blog/can-we-stop-the-medicine-arms-race 2019-10-22T23:29:52 https://maestrodatabase.com/blog/fda-approves-revcovi-a-new-enzyme-replacement-therapy-developed-by-leadiant-biosciences-for-the-treatment-of-ada-scid-in-paediatric-and-adult-patients 2018-10-06T01:15:32 https://maestrodatabase.com/blog/fda-approves-eylea-aflibercept-injection-for-diabetic-retinopathy 2019-05-14T07:22:55 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-karyopharms-new-drug-application-for-selinexor-and-grants-priority-review 2018-10-06T01:32:39 https://maestrodatabase.com/blog/new-procedures-for-cadth-drug-reimbursement-reviews 2020-10-01T02:07:42 https://maestrodatabase.com/blog/the-district-court-rejected-an-appeal-against-darzalex 2019-10-23T00:35:37 https://maestrodatabase.com/blog/us-fda-grants-rare-paediatric-disease-designation-to-atl1102-for-the-treatment-of-dmd 2020-10-01T01:40:08 https://maestrodatabase.com/blog/health-canada-approves-bavencio-avelumab-for-injection-for-the-treatment-of-metastatic-merkel-cell-carcinoma-in-previously-treated-adult-patients 2018-02-23T05:12:50 https://maestrodatabase.com/blog/evofem-biosciences-receives-fast-track-designation-for-amphora-for-prevention-of-chlamydia 2018-02-23T05:22:01 https://maestrodatabase.com/blog/junshi-biosciences-announces-two-additional-indications-for-toripalimab-included-in-chinas-national-reimbursement-drug-list 2021-12-07T00:44:31 https://maestrodatabase.com/blog/dyne-therapeutics-announces-fda-breakthrough-therapy-designation-for-dyne-251-in-duchenne-muscular-dystrophy 2025-08-04T23:26:18 https://maestrodatabase.com/blog/patients-in-quebec-now-have-access-to-dupixent-for-the-treatment-of-moderate-to-severe-atopic-dermatitis 2019-10-23T01:14:57 https://maestrodatabase.com/blog/global-moves-to-reduce-the-future-cost-of-publicly-funded-medicines 2018-10-06T02:05:28 https://maestrodatabase.com/blog/beigene-announces-inclusion-in-the-china-national-reimbursement-drug-list-nrdl-of-tislelizumab-in-three-new-indications-brukinsa-zanubrutinib-in-one-new-indication-and-the-first-listing-for-pamiparib 2021-12-07T01:23:33 https://maestrodatabase.com/blog/critics-blame-diabetes-deaths-on-pharmac-taking-years-to-fund-new-drug 2021-12-07T01:59:09 https://maestrodatabase.com/blog/european-commission-grants-abbvies-maviret-glecaprevir-slash-pibrentasvir-marketing-authorisation-for-the-treatment-of-chronic-hepatitis-c-in-all-major-genotypes-gt1-6 2017-07-29T02:18:19 https://maestrodatabase.com/blog/surrogate-endpoints-in-oncology-when-are-they-acceptable-for-regulatory-and-clinical-decisions-and-are-they-currently-overused 2017-07-29T02:28:10 https://maestrodatabase.com/blog/the-2019-who-essential-medicine-list-narrowing-the-access-gap-to-innovative-cancer-treatments 2019-10-23T01:32:56 https://maestrodatabase.com/blog/its-very-frustrating-ovarian-cancer-patient-waiting-on-potential-approval-of-new-treatment 2017-07-29T02:33:30 https://maestrodatabase.com/blog/you-cant-ignore-cost-pharmac-bosses-recognise-drug-buying-constraints-promise-transparency 2019-10-23T01:27:24 https://maestrodatabase.com/blog/shining-a-light-on-pharmac 2021-12-07T00:57:03 https://maestrodatabase.com/blog/national-health-amendment-pharmaceutical-benefits---budget-and-other-measures-act-2018 2018-02-23T06:14:59 https://maestrodatabase.com/blog/abilify-maintena-r-aripiprazole-for-extended-release-injectable-suspension-approved-by-the-u-dot-s-fda-for-maintenance-monotherapy-treatment-of-bipolar-i-disorder 2017-07-29T02:39:55 https://maestrodatabase.com/blog/nusinersen-stakeholder-meeting-outcome-statement 2018-02-23T06:17:51 https://maestrodatabase.com/blog/us-fda-grants-prolong-pharmaceuticals-fda-fast-track-designation-for-novel-stroke-therapy-pp-007-in-hemera-1-clinical-study 2024-10-30T23:13:38 https://maestrodatabase.com/blog/genetron-health-receives-u-dot-s-fda-breakthrough-device-designation-for-its-blood-based-ngs-test-for-early-detection-of-hepatocellular-carcinoma 2020-10-01T05:49:23 https://maestrodatabase.com/blog/abbvie-receives-health-canada-approval-of-orilissa-elagolix-for-the-treatment-of-moderate-to-severe-pain-associated-with-endometriosis 2018-10-06T02:55:01 https://maestrodatabase.com/blog/fda-grants-priority-review-for-amgens-supplemental-biologics-license-application-for-repatha-evolocumab-to-include-data-on-reducing-risk-of-cardiovascular-events 2017-07-29T02:49:51 https://maestrodatabase.com/blog/kadmon-announces-submission-of-new-drug-application-to-the-u-dot-s-fda-for-belumosudil-in-patients-with-chronic-graft-versus-host-disease 2020-10-01T05:42:06 https://maestrodatabase.com/blog/the-trump-administration-still-has-the-power-to-wreak-havoc-on-obamacare 2017-07-29T02:58:10 https://maestrodatabase.com/blog/patients-lose-access-to-free-medicines-amid-spat-between-drugmakers-health-plans 2023-05-05T18:01:42 https://maestrodatabase.com/blog/fibristal-ulipristal-acetate-5-mg-tablets-voluntary-withdrawal-in-canada-due-to-risk-of-drug-induced-liver-injury 2020-10-01T07:11:21 https://maestrodatabase.com/blog/pharmaceutical-companies-policies-on-access-to-trial-data-results-and-methods-audit-study 2017-07-29T03:02:31 https://maestrodatabase.com/blog/clarametyx-biosciences-announces-fda-grant-of-fast-track-and-qualified-infectious-disease-product-designations-for-cmtx-101 2025-08-04T23:37:08 https://maestrodatabase.com/blog/bristol-myers-squibbs-application-for-breyanzi-lisocabtagene-maraleucel-accepted-for-priority-review-by-us-fda-in-fifth-cancer-type-for-relapsed-or-refractory-marginal-zone-lymphoma 2025-08-04T23:41:26 https://maestrodatabase.com/blog/cytodyn-clarifies-status-of-biologics-license-application 2020-05-10T01:58:56 https://maestrodatabase.com/blog/commemorating-40-years-of-medicare 2024-01-29T09:04:54 https://maestrodatabase.com/blog/nice-backs-shionogis-rizmoic 2020-10-01T12:05:43 https://maestrodatabase.com/blog/make-drug-companies-partners----not-adversaries----to-expand-global-covid-19-vaccine-access 2021-05-16T21:03:04 https://maestrodatabase.com/blog/covid-19-health-minister-david-clark-announces-more-medicines-vaccines-in-160-dollars-million-pharmac-budget-boost 2020-05-10T02:03:30 https://maestrodatabase.com/blog/a-million-americans-need-this-drug-trumps-deal-wont-help-enough-of-them 2019-05-14T10:59:58 https://maestrodatabase.com/blog/ema-starts-first-rolling-review-of-a-covid-19-vaccine-in-the-eu 2020-10-01T20:42:10 https://maestrodatabase.com/blog/enhertu-granted-priority-review-in-the-us-for-patients-with-metastatic-her2-positive-solid-tumours 2024-01-29T07:19:50 https://maestrodatabase.com/blog/health-technology-assessment-again-a-transparent-evidence-based-approach-for-cms-drug-price-negotiations 2025-08-05T02:27:10 https://maestrodatabase.com/blog/updates-to-the-hta-review-options-paper-for-consultation-2-published 2024-01-29T07:17:20 https://maestrodatabase.com/blog/centus-biotherapeutics-receives-european-marketing-authorisation-for-equidacent-biosimilar-avastin 2020-10-01T08:59:07 https://maestrodatabase.com/blog/product-approval-and-public-health-at-the-us-food-and-drug-administration 2021-12-07T03:52:54 https://maestrodatabase.com/blog/rezzayo-approved-to-treat-adult-patients-with-invasive-candidiasis 2024-01-29T20:16:47 https://maestrodatabase.com/blog/biosimilar-follitropin-alfa-on-the-pbs---information-for-health-care-professionals-and-patients 2021-12-07T05:03:41 https://maestrodatabase.com/blog/fostamatinib-in-chronic-immune-thrombocytopenia-added-benefit-not-proven-due-to-lack-of-comparison 2020-10-01T20:49:02 https://maestrodatabase.com/blog/ema-reminds-physicians-to-use-tecentriq-with-nab-paclitaxel-for-treating-breast-cancer 2020-10-01T20:53:50 https://maestrodatabase.com/blog/ascletis-announces-inclusion-in-new-catalogue-of-china-national-reimbursement-drug-list-of-asclevir-slash-ganovo-regimen-an-all-oral-direct-anti-hcv-therapy 2021-12-07T02:40:22 https://maestrodatabase.com/blog/celltrion-usa-completes-submission-of-biologics-license-application-for-ct-p47-a-biosimilar-candidate-of-actemra-tocilizumab 2024-01-29T09:31:12 https://maestrodatabase.com/blog/takedas-hyqvia-approved-by-european-commission-as-maintenance-therapy-in-patients-with-chronic-inflammatory-demyelinating-polyneuropathy 2024-01-30T07:48:18 https://maestrodatabase.com/blog/gsks-rsv-vaccine-arexvy-accepted-for-regulatory-review-by-the-ema-for-the-prevention-of-rsv-disease-in-adults-aged-50-59-at-increased-risk 2024-01-30T07:43:18 https://maestrodatabase.com/blog/at-40-medicares-a-marvel-but-its-time-for-a-health-check 2024-01-29T20:36:38 https://maestrodatabase.com/blog/icmra-high-level-meeting-on-global-health-emergencies-and-regulatory-approaches 2021-12-07T05:09:10 https://maestrodatabase.com/blog/canadian-health-care-stuck-in-the-60s-expert-says 2019-05-14T21:20:50 https://maestrodatabase.com/blog/will-medicare-push-drug-prices-down-in-2024 2024-01-29T20:32:19 https://maestrodatabase.com/blog/merck-johnson-and-johnson-ceos-agree-to-testify-in-senate-hearing-on-high-drug-prices 2024-01-29T20:28:43 https://maestrodatabase.com/blog/ema-begins-search-for-next-executive-director 2019-05-14T21:15:00 https://maestrodatabase.com/blog/cracks-in-the-system-without-a-national-pharmacare-strategy-who-is-left-behind 2019-05-14T21:31:01 https://maestrodatabase.com/blog/patients-avoid-paying-hundreds-of-dollars-in-out-of-pocket-fees-after-ramsay-and-bupa-end-stalemate 2022-08-13T21:32:28 https://maestrodatabase.com/blog/treosulphan-in-combination-with-fludarabine-phosphate-before-allogeneic-stem-cell-transplantation-for-patients-aged-1-month-to-17-years-with-non-malignant-diseases 2024-01-30T19:47:11 https://maestrodatabase.com/blog/dont-buy-pharmas-lies 2019-05-14T21:22:37 https://maestrodatabase.com/blog/restrictions-put-on-diabetes-drug-ozempic-leave-users-feeling-fat-shamed 2022-08-13T21:36:39 https://maestrodatabase.com/blog/pharmac-publishes-list-of-applications-to-be-considered-by-ptac-later-this-month 2019-05-14T21:43:33 https://maestrodatabase.com/blog/european-commission-authorises-gsks-omjjara-momelotinib 2024-01-30T11:00:10 https://maestrodatabase.com/blog/takedas-gammagard-liquid-approved-by-us-fda-for-adults-with-chronic-inflammatory-demyelinating-polyneuropathy 2024-01-30T07:54:13 https://maestrodatabase.com/blog/analysis-of-sponsor-hearings-on-pbac-decision-making 2019-05-14T21:35:59 https://maestrodatabase.com/blog/fda-approves-first-medicine-under-new-project-optimus 2022-08-14T02:57:16 https://maestrodatabase.com/blog/a-new-study-sparks-a-war-of-words-over-the-drug-industrys-commitment-to-research 2019-05-14T21:54:21 https://maestrodatabase.com/blog/regulatory-applications-accepted-in-the-us-and-japan-for-bristol-myers-squibbs-breyanzi-lisocabtagene-maraleucel-in-relapsed-or-refractory-follicular-lymphoma-and-relapsed-or-refractory-mantle-cell-lymphoma 2024-01-30T20:18:31 https://maestrodatabase.com/blog/pharma-price-cut-proposals-from-us-government-could-be-steep-analysts-say 2024-01-30T20:15:47 https://maestrodatabase.com/blog/ascidian-therapeutics-announces-fast-tracks-acdn-01-in-stargardt-disease-and-other-abca4-retinopathies 2024-01-30T20:00:38 https://maestrodatabase.com/blog/leniolisib-phosphate-for-the-treatment-of-patients-12-years-of-age-and-older-with-activated-phosphoinositide-3-kinase-delta-syndrome 2024-10-31T02:28:34 https://maestrodatabase.com/blog/how-australia-is-getting-tangled-in-trumps-fight-with-big-pharma 2025-08-06T02:10:50 https://maestrodatabase.com/blog/italy-continues-protest-against-ema-move-to-amsterdam 2018-02-24T00:46:06 https://maestrodatabase.com/blog/highlights-from-february-2018-chmp-meeting 2018-02-24T00:39:25 https://maestrodatabase.com/blog/fda-approves-drugs-before-ema-and-swissmedic-comparison-finds 2018-02-24T00:43:28 https://maestrodatabase.com/blog/revealed-sick-state-of-bulk-billing 2022-08-14T21:07:08 https://maestrodatabase.com/blog/ptc-therapeutics-announces-fda-acceptance-of-translarna-nda-resubmission 2024-10-31T09:43:58 https://maestrodatabase.com/blog/pfizer-announces-update-on-european-marketing-authorisation-application-for-sutent-sunitinib-in-adult-patients-at-high-risk-of-recurrent-renal-cell-carcinoma 2018-02-24T01:03:14 https://maestrodatabase.com/blog/foresee-pharmaceuticals-announces-submission-of-the-nda-to-the-us-fda-for-the-3-month-version-of-camcevi-for-the-treatment-of-advanced-prostate-cancer 2024-10-31T04:15:20 https://maestrodatabase.com/blog/pfizer-receives-positive-chmp-opinion-for-two-haematology-medicines-mylotarg-and-bosulif 2018-02-24T00:57:01 https://maestrodatabase.com/blog/premiums-for-healthcare-dot-gov-plans-are-down-4-percent-but-remain-unaffordable-to-non-subsidised-consumers 2019-10-23T06:44:45 https://maestrodatabase.com/blog/puma-biotechnology-receives-results-of-chmp-formal-decision-for-neratinib-for-extended-adjuvant-treatment-of-her2-positive-early-stage-breast-cancer 2018-02-24T01:17:13 https://maestrodatabase.com/blog/premiums-for-aca-health-plans-are-set-to-drop-in-2020 2019-10-23T05:16:32 https://maestrodatabase.com/blog/fda-approves-bavencio-avelumab-plus-axitinib-combination-for-patients-with-advanced-renal-cell-carcinoma 2019-05-15T00:25:33 https://maestrodatabase.com/blog/kye-pharmaceuticals-announces-the-approval-of-dynavel-xr-amphetamine-extended-release-tablets-and-oral-suspension-for-the-treatment-of-adults-and-children-with-adhd 2025-08-06T01:51:56 https://maestrodatabase.com/blog/middlemen-play-gatekeeper-in-battle-to-curb-soaring-drug-costs 2018-02-24T01:13:32 https://maestrodatabase.com/blog/fda-approves-fiasp-for-use-in-insulin-infusion-pumps-for-adults-with-type-1-or-type-2-diabetes 2019-10-23T05:11:54 https://maestrodatabase.com/blog/pfizer-receives-fda-fast-track-designation-for-duchenne-muscular-dystrophy-investigational-gene-therapy 2020-10-02T00:20:12 https://maestrodatabase.com/blog/homology-medicines-announces-fda-fast-track-designation-for-hmi-102-gene-therapy-development-candidate-for-adults-with-pku 2019-05-15T00:32:29 https://maestrodatabase.com/blog/concept-paper-on-development-and-lifecycle-of-personalised-medicines-and-companion-diagnostic 2017-07-29T05:57:45 https://maestrodatabase.com/blog/economic-cost-and-sustainability-of-oral-therapies-in-precision-oncology 2022-08-14T21:47:11 https://maestrodatabase.com/blog/ema-accepts-regulatory-submission-for-olipudase-alfa-the-first-potential-therapy-for-asmd 2021-12-07T08:17:57 https://maestrodatabase.com/blog/sugemalimab-approved-to-treat-adult-patients-with-non-small-cell-lung-cancer 2024-10-31T09:56:26 https://maestrodatabase.com/blog/fda-grants-fast-track-status-to-aegle-therapeutics-agle-102-for-the-treatment-of-dystrophic-epidermolysis-bullosa 2020-10-02T00:02:51 https://maestrodatabase.com/blog/spectrum-pharmaceuticals-submits-new-drug-application-for-poziotinib 2021-12-07T08:22:42 https://maestrodatabase.com/blog/abeona-therapeutics-completes-pz-cel-biologics-license-application-resubmission-to-us-fda 2024-10-31T09:49:04 https://maestrodatabase.com/blog/lantheus-submits-new-drug-application-to-the-u-dot-s-fda-for-pyl-18f-dcfpyl-a-psma-targeted-prostate-cancer-imaging-agent 2020-10-02T01:39:43 https://maestrodatabase.com/blog/vertex-prices-cystic-fibrosis-combo-treatment-at-$311-000-per-year 2019-10-23T19:31:58 https://maestrodatabase.com/blog/dont-back-away-from-cancer-drug-plan-breast-cancer-foundation-begs 2020-05-10T21:09:43 https://maestrodatabase.com/blog/covid-19-raises-questions-about-the-value-of-personalised-medicine 2020-05-10T21:18:20 https://maestrodatabase.com/blog/proposal-to-widen-access-to-sirolimus-for-lymphovascular-malformations-and-tuberous-sclerosis-complex-complications 2020-10-02T01:44:58 https://maestrodatabase.com/blog/janssen-seeks-to-expand-use-of-tremfya-guselkumab-in-the-treatment-of-adults-with-active-psoriatic-arthritis 2019-10-23T19:25:09 https://maestrodatabase.com/blog/private-health-insurers-say-cost-of-medical-devices-putting-pressure-on-premiums 2019-10-23T19:50:01 https://maestrodatabase.com/blog/pharmac-looks-to-fund-a-medicine-to-keep-bones-strong 2024-10-31T10:22:59 https://maestrodatabase.com/blog/blair-had-private-health-insurance----but-his-cancer-treatment-still-cost-almost-1-000-dollars-a-week 2019-10-23T19:46:33 https://maestrodatabase.com/blog/cystic-fibrosis-nhs-patients-in-england-to-get-life-transforming-drugs-within-weeks 2019-10-23T19:40:43 https://maestrodatabase.com/blog/nancy-pelosis-drug-pricing-plan-passes-to-house-floor-for-full-vote-this-month 2019-10-23T19:37:36 https://maestrodatabase.com/blog/u-dot-s-plans-to-fast-track-revamped-covid-19-vaccines 2021-12-07T09:26:18 https://maestrodatabase.com/blog/china-clears-insurance-coverage-for-kainos-medicines-hiv-drug 2021-12-07T09:20:40 https://maestrodatabase.com/blog/canadian-election-clears-path-for-universal-drug-plan 2019-10-23T19:53:01 https://maestrodatabase.com/blog/zai-lab-announces-inclusion-of-zejula-niraparib-in-chinas-national-reimbursement-drug-list-for-first-line-ovarian-cancer 2021-12-07T19:21:57 https://maestrodatabase.com/blog/patients-to-receive-medicines-3-to-6-months-faster-under-10-year-health-plan 2025-08-06T11:19:50 https://maestrodatabase.com/blog/remarks-by-president-biden-on-prescription-drug-costs 2021-12-07T19:48:30 https://maestrodatabase.com/blog/cystic-fibrosis-drug-campaign-makes-no-progress-in-year 2019-05-15T08:58:20 https://maestrodatabase.com/blog/trump-bucks-his-own-party-again-this-time-its-on-importing-drugs-from-canada 2019-05-15T10:26:58 https://maestrodatabase.com/blog/linus-biotechnology-receives-fda-breakthrough-device-designation-for-stranddx-asd-exposome-sequencing-diagnostic 2021-12-07T19:29:25 https://maestrodatabase.com/blog/mesoblast-receives-complete-response-letter-from-the-fda-for-biologics-license-application-for-steroid-refractory-acute-graft-versus-host-disease-in-children 2020-10-02T02:11:21 https://maestrodatabase.com/blog/fda-approves-octapharmas-cutaquig-16-dot-5-percent-for-paediatric-pi-patients-providing-flexible-treatment-options 2021-12-07T19:34:59 https://maestrodatabase.com/blog/adalimumab-and-the-challenges-for-biosimilars 2019-10-23T22:23:27 https://maestrodatabase.com/blog/u-dot-s-fda-grants-priority-review-for-an-epinephrine-auto-injector-in-development-by-kaleo-specifically-for-infants-and-small-children 2017-07-29T07:35:33 https://maestrodatabase.com/blog/nice-recommends-first-ever-treatment-for-children-with-rare-muscle-wasting-condition 2019-05-15T10:10:28 https://maestrodatabase.com/blog/abbvie-announces-us-fda-approval-of-venclexta-venetoclax-as-a-chemotherapy-free-combination-regimen-for-previously-untreated-chronic-lymphocytic-leukaemia-patients 2019-05-15T20:43:23 https://maestrodatabase.com/blog/lipocine-announces-tlando-nda-pdufa-action-date-of-9-november-2019 2019-05-15T10:57:54 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-dordaviprone-for-diffuse-midline-glioma 2025-08-06T20:59:39 https://maestrodatabase.com/blog/sigma-healthcare-to-face-investor-questions-over-claims-it-mishandled-prescription-drugs 2019-05-15T21:04:55 https://maestrodatabase.com/blog/nhs-chief-hails-sma-drug-deal---and-was-that-a-swipe-at-vertex 2019-05-15T21:01:08 https://maestrodatabase.com/blog/cms-issues-new-guidance-addressing-spread-pricing-in-medicaid-ensures-pharmacy-benefit-managers-are-not-up-charging-taxpayers 2019-05-15T20:49:27 https://maestrodatabase.com/blog/drug-prices-in-tv-ads-how-transparent-are-they 2019-05-15T21:26:09 https://maestrodatabase.com/blog/nivolumab-and-ipilimumab-drug-combination-has-added-benefit-in-advanced-renal-cell-carcinoma 2019-05-15T21:14:10 https://maestrodatabase.com/blog/novartis-gets-approval-to-sell-kymriah-in-japan-for-306-000-dollars 2019-05-15T21:09:36 https://maestrodatabase.com/blog/hospital-drug-making-venture-picks-antibiotics-as-first-products 2019-05-15T21:50:42 https://maestrodatabase.com/blog/knight-therapeutics-and-sifi-announce-approval-of-netildex-in-canada 2019-10-24T01:46:43 https://maestrodatabase.com/blog/proposal-to-widen-access-to-pertussis-whooping-cough-vaccine 2019-05-15T21:43:23 https://maestrodatabase.com/blog/trump-touts-democratic-playbook-in-crackdown-on-drug-costs 2019-05-15T21:29:11 https://maestrodatabase.com/blog/verastem-oncology-completes-rolling-nda-submission-to-the-fda-for-avutometinib-plus-defactinib-as-a-treatment-for-recurrent-kras-mutant-low-grade-serous-ovarian-cancer 2024-10-31T23:35:57 https://maestrodatabase.com/blog/biogen-ceo-reasonably-confident-once-doomed-alzheimers-drug-will-be-granted-fda-approval 2019-10-24T01:55:22 https://maestrodatabase.com/blog/quality-access-and-the-use-of-real-world-data-by-payers-where-are-we-now-where-do-we-want-to-be-in-the-future 2021-05-17T02:42:51 https://maestrodatabase.com/blog/women-living-with-metastatic-breast-cancer-in-british-columbia-now-have-public-access-to-kisqali 2019-10-24T01:49:38 https://maestrodatabase.com/blog/gsk-announces-u-dot-s-fda-approval-of-additional-indication-for-zejula-niraparib-for-late-line-treatment-for-women-with-recurrent-ovarian-cancer 2019-10-24T02:25:23 https://maestrodatabase.com/blog/2024-pbs-post-market-review-framework 2024-01-30T23:55:33 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-to-calibrs-switchable-car-t-cell-cancer-therapy-clbr001-plus-swi019 2020-10-02T05:48:15 https://maestrodatabase.com/blog/glaukos-announces-fda-acceptance-of-nda-submission-for-idose-tr 2023-05-06T14:57:21 https://maestrodatabase.com/blog/hhs-says-gilead-distributor-can-directly-sell-covid-19-drug-in-u-dot-s 2020-10-02T05:55:50 https://maestrodatabase.com/blog/nice-approves-first-immunotherapy-combination-for-endometrial-cancer 2025-08-06T21:17:59 https://maestrodatabase.com/blog/ema-accepts-regulatory-submission-for-avalglucosidase-alfa-a-potentially-new-standard-of-care-enzyme-replacement-therapy-for-pompe-disease 2020-10-02T05:39:09 https://maestrodatabase.com/blog/development-of-covid-19-vaccine-wont-be-affected-by-politics-pfizer-ceo-says 2020-10-02T06:34:28 https://maestrodatabase.com/blog/patients-users-caregivers-and-citizens-involvement-in-local-health-technology-assessment-unit-in-quebec-a-survey 2020-10-02T07:15:01 https://maestrodatabase.com/blog/gsk-canadas-submission-for-momelotinib-for-the-treatment-of-myelofibrosis-accepted-for-review-by-health-canada 2024-01-31T01:34:35 https://maestrodatabase.com/blog/pharmac-shares-update-on-its-assessment-of-trikafta 2022-08-15T03:39:01 https://maestrodatabase.com/blog/farxiga-granted-breakthrough-therapy-designation-in-us-for-chronic-kidney-disease 2020-10-02T06:15:49 https://maestrodatabase.com/blog/xtandi-enzalutamide-receives-health-canada-approval-as-the-first-and-only-treatment-for-high-risk-patients-with-non-metastatic-castration-sensitive-prostate-cancer 2024-01-31T02:02:15 https://maestrodatabase.com/blog/farxiga-extended-in-the-us-to-reduce-risk-of-cardiovascular-death-and-hospitalisation-for-heart-failure-to-a-broader-range-of-patients 2023-05-09T09:22:14 https://maestrodatabase.com/blog/beigene-receives-new-approvals-for-brukinsa-zanubrutinib-in-china 2023-05-08T09:53:49 https://maestrodatabase.com/blog/10-000-new-zealanders-set-to-benefit-from-pharmac-budget-increase 2024-11-01T00:13:47 https://maestrodatabase.com/blog/koselugo-approved-in-china-for-paediatric-patients-with-neurofibromatosis-type-1-and-plexiform-neurofibromas 2023-05-08T09:49:50 https://maestrodatabase.com/blog/how-drug-treatment-in-hong-kong-changed-aussie-cancer-sufferers-life 2018-10-07T02:37:19 https://maestrodatabase.com/blog/dare-announces-fda-approval-of-xaciato-clindamycin-phosphate-vaginal-gel-as-a-treatment-for-bacterial-vaginosis 2021-12-07T22:23:16 https://maestrodatabase.com/blog/ezharmia-supplemental-new-drug-application-submitted-in-japan-for-patients-with-peripheral-t-cell-lymphoma 2024-01-31T04:14:17 https://maestrodatabase.com/blog/atagi-recommends-covid-19-vaccine-use-in-some-children-aged-6-months-to-4-years 2022-08-15T04:15:30 https://maestrodatabase.com/blog/ema-and-ecdc-recommendations-on-heterologous-vaccination-courses-against-covid-19 2021-12-07T23:02:49 https://maestrodatabase.com/blog/eyenovia-announces-fda-approval-of-mydcombi-the-first-ophthalmic-spray-for-mydriasis-which-also-leverages-the-companys-proprietary-optejet-device-platform 2023-05-09T09:37:42 https://maestrodatabase.com/blog/calls-for-decision-on-trikafta-as-new-advice-shows-health-system-savings-and-decades-more-life-for-patients 2022-08-15T04:47:31 https://maestrodatabase.com/blog/loncastuximab-tesirine-for-treating-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-and-high-grade-b-cell-lymphoma-after-2-or-more-systemic-treatments 2024-01-31T03:27:37 https://maestrodatabase.com/blog/rhythm-pharmaceuticals-announces-health-canada-approval-of-imcivree-setmelanotide-injection-for-weight-management-in-bardet-biedl-syndrome-or-genetically-confirmed-biallelic-pomc-pcsk1-or-lepr-deficiency 2023-05-09T09:30:06 https://maestrodatabase.com/blog/lillys-olumiant-baricitinib-now-authorised-in-canada-for-adults-with-severe-alopecia-areata 2024-01-31T03:06:25 https://maestrodatabase.com/blog/vedanta-biosciences-receives-fast-track-designation-for-ve303 2023-05-09T09:26:00 https://maestrodatabase.com/blog/astellas-submits-supplemental-new-drug-application-in-japan-for-padcev-enfortumab-vedotin-with-keytruda-pembrolizumab-for-first-line-treatment-of-advanced-bladder-cancer 2024-01-31T02:20:07 https://maestrodatabase.com/blog/argenx-announces-european-commission-approval-of-vyvgart-efgartigimod-alfa-fcab-for-the-treatment-of-generalised-myasthenia-gravis 2022-08-15T06:43:16 https://maestrodatabase.com/blog/chiesi-global-rare-diseases-and-protalix-biotherapeutics-announce-european-commission-authorisation-of-prx-102-pegunigalsidase-alfa-for-the-treatment-of-fabry-disease 2023-05-09T10:03:15 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-february-2024 2024-01-31T20:37:38 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-february-2024 2024-01-31T20:13:37 https://maestrodatabase.com/blog/the-us-fda-granted-fast-track-designation-to-dizals-birelentinib-for-relapsed-slash-refractory-chronic-lymphocytic-leukaemia-or-small-lymphocytic-lymphoma 2025-08-06T23:36:12 https://maestrodatabase.com/blog/galapagos-announces-us-fda-regenerative-medicine-advanced-therapy-designation-granted-to-glpg5101-for-the-treatment-of-relapsed-slash-refractory-mantle-cell-lymphoma 2025-08-06T23:43:33 https://maestrodatabase.com/blog/nirmatrelvir-and-ritonavir-for-treating-covid-19 2023-05-09T09:58:18 https://maestrodatabase.com/blog/belantamab-mafodotin-for-treating-relapsed-or-refractory-multiple-myeloma-after-4-or-more-therapies 2023-05-09T09:53:24 https://maestrodatabase.com/blog/opdivo-to-get-reimbursement-soon-as-primary-treatment-of-stomach-cancer 2023-05-09T09:44:57 https://maestrodatabase.com/blog/statement-from-emer-cooke-on-the-end-of-the-covid-19-public-health-emergency 2023-05-09T09:49:36 https://maestrodatabase.com/blog/defender-pharmaceuticals-receives-complete-response-letter-from-the-us-fda-for-its-intranasal-scopolamine-new-drug-application-for-the-prevention-of-nausea-and-vomiting-induced-by-motion-in-adults 2024-01-31T21:18:48 https://maestrodatabase.com/blog/novavax-submits-application-to-the-u-dot-s-fda-for-emergency-use-authorisation-for-novavax-covid-19-vaccine-adjuvanted-as-a-booster-in-adults-aged-18-and-older 2022-08-15T20:41:02 https://maestrodatabase.com/blog/biden-harris-administration-announces-action-to-increase-access-to-sickle-cell-disease-treatments 2024-01-31T21:13:28 https://maestrodatabase.com/blog/a-doctor-says-a-patient-saved-over-1-000-dollars-a-month-by-ordering-prescriptions-through-mark-cubans-online-pharmacy 2022-08-15T08:30:27 https://maestrodatabase.com/blog/value-assessment-on-anti-cancer-drugs-hotly-discussed 2019-10-24T08:54:37 https://maestrodatabase.com/blog/proposed-new-classification-rule-for-medical-devices-that-administer-medicines-or-biologicals-by-inhalation 2019-10-24T06:40:35 https://maestrodatabase.com/blog/smc---may-2023-decisions 2023-05-09T10:08:23 https://maestrodatabase.com/blog/post-market-review-of-medicines-for-smoking-cessation 2019-10-24T06:35:25 https://maestrodatabase.com/blog/pbs-wait-times-a-more-urgent-issue-than-donald-trumps-potential-pharmaceutical-tariffs-peak-medicines-body-warns 2025-08-08T00:38:28 https://maestrodatabase.com/blog/budget-2023--24-building-a-stronger-medicare 2023-05-09T10:11:28 https://maestrodatabase.com/blog/newly-launched-us-drugs-head-toward-record-high-prices-in-2022 2022-08-15T20:56:50 https://maestrodatabase.com/blog/pharmac-drugs-stretching-southern-dhb-budget 2020-05-11T02:03:47 https://maestrodatabase.com/blog/fda-approves-expanded-indication-for-avtozma-tocilizumab-anoh-intravenous-formulation-in-cytokine-release-syndrome 2025-08-08T00:09:59 https://maestrodatabase.com/blog/european-commission-approves-opdivo-nivolumab-four-week-dosing-schedule-for-the-adjuvant-treatment-of-adult-patients-with-melanoma-with-involvement-of-lymph-nodes-or-metastatic-disease-who-have-undergone-complete-resection 2019-10-24T11:13:37 https://maestrodatabase.com/blog/brainstorm-to-seek-fda-approval-for-als-stem-cell-treatment-despite-agency-objections 2022-08-15T21:03:23 https://maestrodatabase.com/blog/fda-accepts-application-for-genentechs-vabysmo-for-the-treatment-of-retinal-vein-occlusion 2023-05-09T10:49:58 https://maestrodatabase.com/blog/exploration-of-the-visibility-of-patient-input-in-final-recommendation-documentation-for-three-health-technology-assessment-bodies 2020-05-11T03:21:09 https://maestrodatabase.com/blog/benefit-payments-for-australian-father-cut-while-son-receives-cancer-treatment 2019-10-24T10:27:29 https://maestrodatabase.com/blog/kempharm-announces-fda-approval-of-apadaz-benzhydrocodone-and-paracetamol-for-the-short-term-management-of-acute-pain 2018-02-24T22:22:55 https://maestrodatabase.com/blog/unitedhealth-customers-will-see-a-discount-on-next-months-bill 2020-05-11T03:29:44 https://maestrodatabase.com/blog/ensuring-a-future-for-gene-therapy-for-rare-diseases 2022-08-15T20:53:33 https://maestrodatabase.com/blog/mhra-authorises-modernas-omicron-containing-bivalent-booster-in-the-uk 2022-08-15T20:46:19 https://maestrodatabase.com/blog/the-price-of-insulin-has-soared-these-biohackers-have-a-plan-to-fix-it 2019-10-24T19:29:59 https://maestrodatabase.com/blog/novartis-receives-approval-for-cosentyx-label-update-in-europe-to-include-dosing-flexibility-in-ankylosing-spondylitis 2019-10-24T12:25:27 https://maestrodatabase.com/blog/fda-accepts-shires-biologics-license-application-and-grants-priority-review-for-lanadelumab-for-the-prevention-of-attacks-in-hereditary-angioedema-patients 2018-02-24T22:31:45 https://maestrodatabase.com/blog/oia-response-medicines-from-china 2020-05-11T01:57:28 https://maestrodatabase.com/blog/nhse-signs-definitive-agreement-for-vertex-cf-drugs 2019-10-24T12:03:58 https://maestrodatabase.com/blog/access-to-multiple-sclerosis-treatments-inadequate-in-british-columbia 2025-08-08T02:35:50 https://maestrodatabase.com/blog/fda-approves-botox-onabotulinumtoxina-for-paediatric-patients-with-lower-limb-spasticity-excluding-spasticity-caused-by-cerebral-palsy 2019-10-24T19:38:09 https://maestrodatabase.com/blog/alexion-astrazeneca-rare-disease-reaches-an-agreement-with-the-pan-canadian-pharmaceutical-alliance-for-ultomiris-for-the-treatment-of-adults-with-neuromyelitis-optica-spectrum-disorder-and-adults-with-generalised-myasthenia-gravis 2025-08-08T03:02:03 https://maestrodatabase.com/blog/mallinckrodt-receives-fda-acceptance-of-stannsoporfin-new-drug-application-filing 2018-02-24T22:42:06 https://maestrodatabase.com/blog/trump-set-to-nominate-texas-cancer-doctor-to-head-fda 2019-10-24T19:34:33 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-zongertinib-for-non-squamous-nsclc-with-her2-tkd-activating-mutations 2025-08-08T18:57:21 https://maestrodatabase.com/blog/oia-response-security-of-supply-of-medicines 2020-05-11T03:58:12 https://maestrodatabase.com/blog/patients-eagerly-awaited-a-generic-drug-then-they-saw-the-price 2018-02-25T00:35:07 https://maestrodatabase.com/blog/china-approves-novartis-multiple-sclerosis-treatment-mayzent 2020-05-11T05:33:13 https://maestrodatabase.com/blog/provention-bio-files-clinical-module-for-teplizumab-for-the-delay-or-prevention-of-clinical-type-1-diabetes-in-at-risk-individuals 2020-10-02T22:37:19 https://maestrodatabase.com/blog/lundbeck-and-takeda-receive-complete-response-letter-from-the-fda-for-trintellix-vortioxetine-snda 2017-07-29T23:13:36 https://maestrodatabase.com/blog/mother-fears-daughters-death-linked-to-pharmacs-epilepsy-drug-switch 2019-10-24T19:47:24 https://maestrodatabase.com/blog/enhertu-granted-breakthrough-therapy-designation-in-the-u-dot-s-for-her2-positive-metastatic-gastric-cancer 2020-05-11T06:38:01 https://maestrodatabase.com/blog/saol-therapeutics-announces-fda-approval-of-lyvispah-baclofen-oral-granules 2021-12-08T02:20:46 https://maestrodatabase.com/blog/one-stop-shop-in-medicare-shake-up 2022-08-15T21:11:53 https://maestrodatabase.com/blog/novavax-covid-19-vaccine-could-be-approved-very-soon-says-ema-chief 2021-12-08T03:04:29 https://maestrodatabase.com/blog/improvements-to-clinical-trials-will-strengthen-australias-economy-and-benefit-patients 2021-12-08T02:58:19 https://maestrodatabase.com/blog/fortress-biotech-cyprium-therapeutics-and-sentynl-therapeutics-announce-the-initiation-of-rolling-submission-of-a-new-drug-application-for-cutx-101-copper-histidinate-for-treatment-of-menkes-disease 2021-12-08T02:47:11 https://maestrodatabase.com/blog/eisai-completes-rolling-submission-to-us-fda-for-leqembi-lecanemab-irmb-biologics-license-application-for-subcutaneous-maintenance-dosing-for-the-treatment-of-early-alzheimers-disease-under-the-fast-track-status 2024-11-01T03:34:46 https://maestrodatabase.com/blog/trump-and-pelosi-are-still-working-on-a-drug-pricing-deal-despite-impeachment-drama 2019-10-24T22:57:48 https://maestrodatabase.com/blog/older-patients-still-left-out-of-cancer-clinical-trials 2019-10-24T22:35:41 https://maestrodatabase.com/blog/new-therapies-for-a-range-of-conditions-are-coming-in-2022 2021-12-08T02:55:17 https://maestrodatabase.com/blog/amgen-to-make-repatha-evolocumab-available-exclusively-at-its-lower-list-price-option-in-2020 2019-10-25T05:37:54 https://maestrodatabase.com/blog/reforming-eu-and-national-orphan-drug-regulations-to-improve-outcomes-for-patients-with-rare-diseases 2023-05-10T09:37:01 https://maestrodatabase.com/blog/making-new-drugs-is-hard-so-is-pricing-them 2019-10-25T05:34:17 https://maestrodatabase.com/blog/arvinas-announces-fda-acceptance-of-the-new-drug-application-for-vepdegestrant-for-the-treatment-of-esr1m-er-plus-slash-her2--advanced-breast-cancer 2025-08-09T20:44:55 https://maestrodatabase.com/blog/lung-cancer-victims-miss-out-in-drug-funding-boost---advocates 2020-05-11T11:33:49 https://maestrodatabase.com/blog/federal-budget-government-confirms-commitment-to-build-a-21st-century-health-system 2023-05-10T09:39:43 https://maestrodatabase.com/blog/biotech-industry-pushes-trump-administration-to-release-new-vaccine-guidelines 2020-10-02T23:09:59 https://maestrodatabase.com/blog/acrivon-therapeutics-announces-fda-grants-fast-track-designation-for-development-of-acr-368-in-platinum-resistant-ovarian-cancer-and-endometrial-cancer 2023-05-10T09:32:06 https://maestrodatabase.com/blog/covid-19-pharmacists-and-gps-brawl-over-powers-to-dispense-medicines 2020-05-11T11:41:21 https://maestrodatabase.com/blog/pharmac-funding-increase-extremely-disappointing 2020-05-11T12:03:11 https://maestrodatabase.com/blog/proposal-to-award-sole-supply-for-apomorphine-hydrochloride 2019-10-25T05:25:34 https://maestrodatabase.com/blog/new-zealands-medicines-system-still-on-life-support-but-can-be-saved 2020-05-11T07:25:24 https://maestrodatabase.com/blog/johnson-and-johnson-submits-supplemental-biologics-license-application-to-us-fda-seeking-approval-of-darzalex-faspro-daratumumab-and-hyaluronidase-fihj--based-regimen-for-the-treatment-of-patients-with-transplant-eligible-newly-diagnosed-multiple-myeloma 2024-01-31T23:10:56 https://maestrodatabase.com/blog/labor-vows-to-fight-as-trump-threatens-pharma-tariffs 2025-08-09T20:55:51 https://maestrodatabase.com/blog/health-canada-has-authorised-csls-andembry-garadacimab-as-once-monthly-treatment-for-hereditary-angioedema 2025-08-09T21:04:56 https://maestrodatabase.com/blog/ema-publishes-agenda-for-17-20-may-chmp-meeting 2021-05-17T10:08:34 https://maestrodatabase.com/blog/reforming-opioid-dependence-treatment-access 2023-05-10T09:58:00 https://maestrodatabase.com/blog/recommendations-made-out-of-session-by-the-pbac-between-march-2023-and-july-2023-meetings 2023-05-10T09:53:10 https://maestrodatabase.com/blog/adamis-pharmaceuticals-resubmits-zimhi-new-drug-application-to-fda-for-the-treatment-of-opioid-overdose 2021-05-17T11:45:10 https://maestrodatabase.com/blog/ema-recommends-expanding-remdesivir-compassionate-use-to-patients-not-on-mechanical-ventilation 2020-05-11T20:44:06 https://maestrodatabase.com/blog/pharmacy-guild-unleashes-robocalls-text-messages-and-posters-opposing-pbs-changes 2023-05-10T09:45:50 https://maestrodatabase.com/blog/ultomiris-approved-in-the-eu-for-adults-with-neuromyelitis-optica-spectrum-disorder 2023-05-10T09:48:25 https://maestrodatabase.com/blog/pricing-of-covid-19-treatments-and-coronavirus-vaccines 2020-05-11T20:52:27 https://maestrodatabase.com/blog/health-canada-approves-abbvies-rinvoq-upadacitinib-for-the-treatment-of-adults-with-active-non-radiographic-axial-spondyloarthritis 2023-05-10T09:42:19 https://maestrodatabase.com/blog/crispr-therapeutics-and-vertex-pharmaceuticals-announce-fda-regenerative-medicine-advanced-therapy-designation-granted-to-ctx001-for-the-treatment-of-severe-hemoglobinopathies 2020-05-11T20:56:02 https://maestrodatabase.com/blog/us-supreme-court-denies-sandoz-petition-to-review-biosimilar-erelzi-etanercept-szzs-case 2021-05-17T21:05:30 https://maestrodatabase.com/blog/chiesi-global-rare-diseases-and-protalix-biotherapeutics-announce-fda-approval-of-elfabrio-pegunigalsidase-alfa-iwxj-for-the-treatment-of-fabry-disease 2023-05-11T09:58:22 https://maestrodatabase.com/blog/fda-approves-drug-combination-for-treating-mesothelioma 2020-10-02T23:35:00 https://maestrodatabase.com/blog/may-2023-updates-from-the-health-technology-assessment-policy-and-methods-review-reference-committee 2023-05-11T09:51:50 https://maestrodatabase.com/blog/new-zealanders-living-with-cystic-fibrosis-wait-for-life-changing-drug 2021-05-17T21:16:21 https://maestrodatabase.com/blog/labor-very-concerned-by-trump-pharma-threat 2025-08-09T22:40:49 https://maestrodatabase.com/blog/more-medicine-for-less 2023-05-11T09:54:31 https://maestrodatabase.com/blog/the-national-health-data-registers-are-the-way-forward 2021-05-17T21:11:23 https://maestrodatabase.com/blog/optimising-managed-access-lessons-from-the-cancer-drugs-fund 2021-05-17T12:01:36 https://maestrodatabase.com/blog/cases-of-invasive-pneumococcal-disease-sharply-rose-after-pharmac-downgraded-vaccine-programme---study 2023-05-10T10:10:53 https://maestrodatabase.com/blog/adaptimmune-announces-us-fda-acceptance-of-biologics-license-application-for-afami-cel-for-the-treatment-of-advanced-synovial-sarcoma-with-priority-review 2024-02-01T10:37:18 https://maestrodatabase.com/blog/health-economic-assessment-of-gene-therapy-zynteglo-in-transfusion-dependent-beta-thalassemia 2020-05-11T21:11:07 https://maestrodatabase.com/blog/tga-weighs-over-the-counter-contraceptive-pill-plan 2021-05-17T11:58:35 https://maestrodatabase.com/blog/terminal-cancer-patient-denied-access-to-life-extending-chemo-drug 2018-02-25T01:57:03 https://maestrodatabase.com/blog/hhs-announces-shipments-of-donated-remdesivir-for-hospitalised-patients-with-covid-19 2020-05-11T21:17:40 https://maestrodatabase.com/blog/more-flexible-storage-conditions-for-biontech-slash-pfizers-covid-19-vaccine 2021-05-17T20:58:58 https://maestrodatabase.com/blog/olaparib-for-adjuvant-treatment-of-brca-mutation-positive-her2-negative-high-risk-early-breast-cancer-after-chemotherapy 2023-05-10T10:00:31 https://maestrodatabase.com/blog/biontech-and-dualitybio-receive-fda-fast-track-designation-for-next-generation-antibody-drug-conjugate-candidate-bnt325-slash-db-1305 2024-02-01T06:48:14 https://maestrodatabase.com/blog/biogen-hopes-alzheimers-drug-mired-in-controversy-earns-fda-nod 2021-05-17T12:22:58 https://maestrodatabase.com/blog/medicines-for-chronic-illnesses-soon-accessible-before-european-authorisation 2025-08-09T21:31:58 https://maestrodatabase.com/blog/australian-medical-association-urges-over-50s-to-not-wait-for-pfizer-covid-19-vaccine 2021-05-17T21:39:02 https://maestrodatabase.com/blog/one-in-four-covid-vaccine-doses-distributed-in-australia-not-yet-administered-figures-show 2021-05-17T21:36:37 https://maestrodatabase.com/blog/lawmakers-press-cms-to-release-new-breakthrough-device-coverage-rule 2023-05-11T10:26:35 https://maestrodatabase.com/blog/public-summary-documents---july-2024-pbac-meeting 2024-11-01T05:22:54 https://maestrodatabase.com/blog/international-study-on-authorisation-times-confirms-swissmedics-competitiveness 2025-08-09T22:03:35 https://maestrodatabase.com/blog/fda-approval-clinical-trial-evidence-efficacy-epidemiology-and-price-for-non-orphan-and-ultra-rare-rare-and-common-orphan-cancer-drug-indications-cross-sectional-analysis 2023-05-11T10:16:47 https://maestrodatabase.com/blog/icer-publishes-evidence-report-on-treatment-for-epstein-barr-virus-positive-post-transplant-lymphoproliferative-disease 2024-11-01T05:08:33 https://maestrodatabase.com/blog/eisai-submits-new-drug-application-for-mecobalamin-ultra-high-dose-formulation-in-japan-for-the-indication-of-amyotrophic-lateral-sclerosis 2024-02-01T20:20:17 https://maestrodatabase.com/blog/imfinzi-approved-in-canada-as-first-and-only-peri-operative-immunotherapy-for-muscle-invasive-bladder-cancer 2025-08-09T22:16:55 https://maestrodatabase.com/blog/statement-on-leronlimab 2021-05-17T21:24:00 https://maestrodatabase.com/blog/servier-receives-european-commission-approval-of-tibsovo-ivosidenib-tablets-in-idh1-mutated-acute-myeloid-leukaemia-and-idh1-mutated-cholangiocarcinoma 2023-05-11T10:11:38 https://maestrodatabase.com/blog/significant-additional-benefit-of-mavacamten-in-hypertrophic-obstructive-cardiomyopathy 2024-02-01T20:16:38 https://maestrodatabase.com/blog/sandoz-canada-launches-its-6th-biosimilar-with-inclunox-and-inclunox-hp-enoxaparin-sodium-solution-for-injection-100-mg-slash-ml-and-150-mg-slash-ml-high-potency 2021-05-17T21:28:17 https://maestrodatabase.com/blog/otsuka-and-lundbeck-announce-us-fda-approval-of-supplemental-new-drug-application-for-rexulti-brexpiprazole-for-the-treatment-of-agitation-associated-with-dementia-due-to-alzheimers-disease 2023-05-11T10:05:10 https://maestrodatabase.com/blog/miracle-opdivo-cancer-drug-that-saved-jarryd-rougheads-life-discounted-for-patients 2017-07-30T00:31:57 https://maestrodatabase.com/blog/ivosidenib-for-the-treatment-of-patients-with-advanced-idh1-r132-mutation-positive-cholangiocarcinoma-after-one-or-more-systemic-treatments 2024-02-01T20:06:33 https://maestrodatabase.com/blog/roche-leukaemia-drug-gets-fda-breakthrough-therapy-designation 2017-07-30T00:38:49 https://maestrodatabase.com/blog/biden-harris-administration-to-make-first-offer-for-drug-price-negotiation-program-launches-new-resource-hub-to-help-people-access-lower-cost-drugs 2024-02-01T20:47:07 https://maestrodatabase.com/blog/akcea-announces-its-access-and-distribution-strategy-for-tegsedi-inotersen 2018-10-08T00:09:17 https://maestrodatabase.com/blog/federal-budget-2023-doctors-praise-1-dollars-5-cents-billion-cash-injection 2023-05-11T13:03:00 https://maestrodatabase.com/blog/icer-publishes-evidence-report-on-treatments-for-paroxysmal-nocturnal-haemoglobinuria 2024-02-01T20:36:30 https://maestrodatabase.com/blog/tga-approves-booster-doses-of-the-moderna-covid-19-vaccine-spikevax 2021-12-08T05:41:09 https://maestrodatabase.com/blog/why-buzzy-weight-loss-drugs-such-as-ozempic-and-wegovy-cost-so-much-more-in-the-us 2023-05-11T10:31:07 https://maestrodatabase.com/blog/valneva-announces-fda-approval-of-accelerated-ixiario-vaccination-schedule 2018-10-08T01:37:54 https://maestrodatabase.com/blog/medicines-australia-welcomes-investment-in-medicines 2019-10-26T02:08:39 https://maestrodatabase.com/blog/affyimmune-therapeutics-aic100-granted-fast-track-designation-for-treating-thyroid-cancer 2021-05-17T23:04:37 https://maestrodatabase.com/blog/americas-drug-regulator-is-in-turmoil 2025-08-10T20:26:48 https://maestrodatabase.com/blog/lynparza-in-combination-with-abiraterone-granted-priority-review-in-the-us-for-patients-with-metastatic-castration-resistant-prostate-cancer 2022-08-16T07:51:00 https://maestrodatabase.com/blog/pfizer-will-submit-full-data-on-covid-treatment-pill-to-the-fda-in-a-few-days-ceo-says 2021-12-08T19:43:17 https://maestrodatabase.com/blog/nice-terminates-appraisal-of-yet-another-cancer-medicine 2021-12-08T19:33:05 https://maestrodatabase.com/blog/phrma-statement-on-white-house-drug-pricing-event 2021-12-08T20:02:09 https://maestrodatabase.com/blog/fda-takes-new-steps-aimed-at-advancing-development-of-individualised-medicines-to-treat-genetic-diseases 2021-12-08T19:56:35 https://maestrodatabase.com/blog/european-commission-approves-astellas-xospata-gilteritinib-as-a-monotherapy-for-patients-with-relapsed-or-refractory-acute-myeloid-leukaemia-with-a-flt3-mutation 2019-10-26T02:48:23 https://maestrodatabase.com/blog/dont-destroy-future-drug-development 2021-12-08T20:18:54 https://maestrodatabase.com/blog/ema-and-european-medicines-regulatory-network-lift-covid-19-business-continuity-status 2023-05-11T20:25:38 https://maestrodatabase.com/blog/biosyngen-announces-fda-fast-track-designation-for-bst02-in-treatment-of-liver-cancer 2024-02-01T23:11:30 https://maestrodatabase.com/blog/insulin-companies-pbms-pass-the-blame-as-they-face-bipartisan-ire-on-pricing 2023-05-11T20:28:56 https://maestrodatabase.com/blog/dialogue-with-chinese-authorities-on-medicine-regulation 2019-10-26T02:45:32 https://maestrodatabase.com/blog/foundationone-cdx-receives-fda-approval-as-a-companion-diagnostic-for-braf-inhibitor-therapeutics-in-melanoma 2021-12-08T20:09:32 https://maestrodatabase.com/blog/$56k-alzheimers-drug-avoiding-bidens-cost-curbs-for-now 2021-12-08T19:46:22 https://maestrodatabase.com/blog/differences-in-drug-shortages-in-the-us-and-canada 2024-11-01T06:10:40 https://maestrodatabase.com/blog/trumps-trade-war-is-not-the-only-threat-to-cheap-pbs-medicines 2025-08-11T02:29:23 https://maestrodatabase.com/blog/artificial-intelligence-was-supposed-to-transform-health-care-it-hasnt 2022-08-16T08:21:19 https://maestrodatabase.com/blog/melinta-therapeutics-announces-u-dot-s-fda-approval-of-supplemental-new-drug-application-for-baxdela-delafloxacin-for-the-treatment-of-community-acquired-bacterial-pneumonia 2019-10-26T04:06:32 https://maestrodatabase.com/blog/funding-keytruda-for-melanoma-but-not-for-lung-cancer-is-racist-health-advocates-say 2021-12-08T19:51:24 https://maestrodatabase.com/blog/fda-accepts-supplemental-biologics-license-application-for-genentechs-polivy-combination-for-people-with-previously-untreated-diffuse-large-b-cell-lymphoma 2022-08-16T08:32:00 https://maestrodatabase.com/blog/real-time-benefit-tools-for-drug-prices 2019-10-26T02:58:07 https://maestrodatabase.com/blog/kidney-patients-cite-insurance-and-payment-issues-as-critical-barriers-to-fda-approved-care-innovations 2022-08-16T20:57:26 https://maestrodatabase.com/blog/visibly-becomes-first-fda-cleared-online-vision-test-in-the-united-states 2022-08-16T20:52:59 https://maestrodatabase.com/blog/public-sector-financial-support-for-late-stage-discovery-of-new-drugs-in-the-united-states-cohort-study 2019-10-26T04:13:14 https://maestrodatabase.com/blog/gps-demand-action-to-fix-disintegrating-medicare 2022-08-16T20:50:39 https://maestrodatabase.com/blog/lantheus-announces-fda-acceptance-of-nda-for-new-formulation-for-market-leading-psma-pet-imaging-agent 2025-08-11T01:28:40 https://maestrodatabase.com/blog/otsuka-canada-pharmaceutical-announces-health-canada-approval-of-korsuva-difelikefalin-for-the-treatment-of-moderate-to-severe-pruritus-associated-with-chronic-kidney-disease-in-adult-haemodialysis-patients 2022-08-16T21:22:53 https://maestrodatabase.com/blog/smc---august-2025-decisions 2025-08-11T22:59:03 https://maestrodatabase.com/blog/chugai-obtains-regulatory-approval-for-osteoporosis-treatment-edirol 2022-08-16T21:02:29 https://maestrodatabase.com/blog/gepotidacin-accepted-for-priority-review-by-the-us-fda-for-the-oral-treatment-of-uncomplicated-urogenital-gonorrhoea 2025-08-11T23:02:46 https://maestrodatabase.com/blog/outcome-in-relation-to-fluticasone-propionate---may-2023-pbac-intracycle-meeting 2023-05-12T11:20:41 https://maestrodatabase.com/blog/pbac-backs-ongoing-access-to-low-dose-asthma-puffer-for-aussie-kids 2023-05-12T11:23:58 https://maestrodatabase.com/blog/pharmac-to-update-access-and-supply-of-covid-19-treatments 2025-08-11T03:29:07 https://maestrodatabase.com/blog/committee-recommends-against-funding-$250-000-a-year-orkambi-cystic-fibrosis-drug 2018-10-08T05:06:29 https://maestrodatabase.com/blog/ovarian-cancer-bay-of-plenty-mother-spends-more-than-130-000-dollars-on-treatments 2023-05-11T21:30:38 https://maestrodatabase.com/blog/sales-from-controversial-drug-discount-program-rose-to-44-dollars-billion-last-year 2022-08-16T21:43:20 https://maestrodatabase.com/blog/unpacking-the-drug-pricing-policies-that-congress-just-approved 2022-08-16T21:27:12 https://maestrodatabase.com/blog/cancer-patient-who-devoted-six-years-to-drug-pricing-reform-isnt-done-yet 2022-08-16T21:32:02 https://maestrodatabase.com/blog/fda-approves-novel-drug-to-treat-moderate-to-severe-hot-flashes-caused-by-menopause 2023-05-12T21:11:38 https://maestrodatabase.com/blog/novartis-announces-fda-and-ema-filing-acceptance-of-siponimod-the-first-and-only-drug-shown-to-meaningfully-delay-disability-progression-in-typical-spms-patients 2018-10-08T05:23:27 https://maestrodatabase.com/blog/ideas-about-resourcing-health-care-in-the-united-states-can-economic-evaluation-achieve-meaningful-use 2020-10-03T07:32:44 https://maestrodatabase.com/blog/fda-allows-marketing-of-first-self-fitting-hearing-aid-controlled-by-the-user 2018-10-08T10:14:30 https://maestrodatabase.com/blog/acacia-pharma-provides-update-on-fda-regulatory-review-of-barhemsys 2018-10-08T10:25:31 https://maestrodatabase.com/blog/fdas-drug-approval-system-is-more-open-than-australias 2020-05-12T01:23:46 https://maestrodatabase.com/blog/nice-expands-backing-for-pfizers-mylotarg 2018-10-08T10:11:00 https://maestrodatabase.com/blog/covid-19-update-fda-takes-new-actions-to-accelerate-development-of-novel-prevention-treatment-options-for-covid-19 2020-05-12T01:26:29 https://maestrodatabase.com/blog/cms-delays-medicare-payments-for-breakthrough-devices-until-december 2021-05-18T05:00:43 https://maestrodatabase.com/blog/fda-approves-brinsupri-brensocatib-as-the-first-and-only-treatment-for-non-cystic-fibrosis-bronchiectasis-a-serious-chronic-lung-disease 2025-08-12T17:23:35 https://maestrodatabase.com/blog/pbs-win-to-bring-relief-for-people-with-migraine-but-concerns-over-limitations-remain 2021-05-18T04:52:20 https://maestrodatabase.com/blog/decision-to-fund-pancreatic-enzymes-modified-release-granules-creon-micro 2020-05-12T02:46:56 https://maestrodatabase.com/blog/nrx-pharmaceuticals-granted-fda-fast-track-designation-for-nrx-100-for-suicidal-ideation-in-patients-with-depression-including-bipolar-depression 2025-08-12T00:12:16 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-november-2024 2024-11-01T09:00:57 https://maestrodatabase.com/blog/new-and-expanded-pbs-listings-for-endometrial-cancer-neuroblastoma-parkinsons-disease-and-melanoma 2025-08-12T05:55:39 https://maestrodatabase.com/blog/sandoz-canada-congratulates-the-quebec-government-on-implementing-a-shift-towards-biosimilars 2021-05-18T20:54:30 https://maestrodatabase.com/blog/biden-pledges-to-export-millions-of-fda-authorised-vaccines 2021-05-18T20:48:06 https://maestrodatabase.com/blog/pharmaceutical-company-abbvie-inflated-prices-for-two-major-drugs-house-oversight-report-says 2021-05-18T20:57:40 https://maestrodatabase.com/blog/pharmac-dental-funding-crucial-in-budget---national-party 2021-05-18T06:14:38 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-november-2024-update 2024-11-01T10:18:28 https://maestrodatabase.com/blog/almost-one-third-of-adult-australians-say-theyre-unlikely-to-get-covid-vaccination-survey 2021-05-18T20:43:30 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-regulatory-submission-for-sintilimab-in-combination-with-pemetrexed-and-platinum-chemotherapy-for-the-first-line-treatment-of-people-with-non-squamous-non-small-cell-lung-cancer 2021-05-18T08:32:08 https://maestrodatabase.com/blog/essilor-receives-fda-breakthrough-device-designation-for-essilor-stellest-its-new-generation-of-spectacle-lens-solutions-in-the-fight-against-myopia 2021-05-18T21:43:59 https://maestrodatabase.com/blog/belgium-seeks-to-encourage-generic-drugs-with-new-prescription-reimbursement-structure 2021-05-18T21:02:04 https://maestrodatabase.com/blog/northern-ireland-faces-huge-rise-in-generic-medicine-prices 2021-05-18T21:41:54 https://maestrodatabase.com/blog/quebec-announces-intention-to-implement-a-biosimilar-switching-policy 2021-05-18T21:10:01 https://maestrodatabase.com/blog/restart-of-the-national-medicines-policy-review---further-consultation-on-a-revised-draft 2022-08-17T01:31:52 https://maestrodatabase.com/blog/aavantgarde-bio-announces-fda-fast-track-designation-for-aavb-039-for-the-treatment-of-stargardt-disease 2025-08-13T01:36:04 https://maestrodatabase.com/blog/pbac-dismisses-pharmacy-guild-concerns-on-60-day-dispensing 2023-05-13T11:05:51 https://maestrodatabase.com/blog/public-consultation-draft-2023-24-cost-recovery-implementation-statement-cris-for-listing-medicines-on-the-pbs-and-designated-vaccines-on-the-nip 2023-05-12T23:27:54 https://maestrodatabase.com/blog/sigma-healthcare-leadership-says-it-has-received-no-worker-reports-of-medicine-mishandling 2019-05-16T06:21:35 https://maestrodatabase.com/blog/tetra-bio-pharma-cancels-new-drug-submission-to-health-canada 2023-05-13T11:32:00 https://maestrodatabase.com/blog/family-pleads-with-pharmac-to-help-save-toddlers-life-by-funding-cystic-fibrosis-wonder-drug 2018-10-08T11:34:52 https://maestrodatabase.com/blog/feliqs-receives-us-fda-fast-track-designation-for-flq-101-a-first-in-class-small-molecule-to-prevent-retinopathy-of-prematurity 2024-11-01T23:07:30 https://maestrodatabase.com/blog/tyra-biosciences-receives-fda-rare-paediatric-disease-designation-for-tyra-300-for-the-treatment-of-achondroplasia 2024-02-02T05:38:09 https://maestrodatabase.com/blog/request-for-proposals-for-pharmac-and-hrc-research-partnership-2019 2018-10-08T19:43:16 https://maestrodatabase.com/blog/new-zealand-women-with-advanced-breast-cancer-are-dying-faster-than-in-other-countries 2018-10-08T19:48:34 https://maestrodatabase.com/blog/a-majority-of-locals-in-nsw-rural-towns-want-rules-changed-to-allow-discount-chemists 2019-10-27T02:10:48 https://maestrodatabase.com/blog/who-knows-the-true-cost-of-medicines 2018-10-08T19:57:53 https://maestrodatabase.com/blog/smc---october-2018-decisions 2018-10-08T20:02:13 https://maestrodatabase.com/blog/making-life-saving-medical-treatments-more-affordable 2019-10-27T02:04:15 https://maestrodatabase.com/blog/the-high-cost-of-living-for-advanced-breast-cancer-patients 2018-10-08T19:53:05 https://maestrodatabase.com/blog/im-the-director-of-the-center-for-medicare-heres-how-we-executed-the-first-round-of-drug-price-negotiation 2024-11-01T23:48:31 https://maestrodatabase.com/blog/fda-authorises-new-long-acting-monoclonal-antibodies-for-pre-exposure-prevention-of-covid-19-in-certain-individuals 2021-12-09T19:18:24 https://maestrodatabase.com/blog/spectrum-pharmaceuticals-announces-submission-to-the-u-dot-s-fda-of-updated-biologics-license-application-for-rolontis 2019-10-27T01:58:21 https://maestrodatabase.com/blog/bausch-healths-bryhali-halobetasol-propionate-0-dot-01-percent-lotion-receives-tentative-fda-approval-for-plaque-psoriasis-in-adults 2018-10-08T20:13:21 https://maestrodatabase.com/blog/revised-process-for-ultra-orphan-medicines 2018-10-08T20:06:38 https://maestrodatabase.com/blog/non-partisan-congressional-report-suggests-pelosis-drug-pricing-bill-could-be-found-unconstitutional 2019-10-27T02:16:05 https://maestrodatabase.com/blog/fda-approves-first-anticoagulant-blood-thinner-for-paediatric-patients-to-treat-potentially-life-threatening-blood-clots 2019-05-16T20:40:38 https://maestrodatabase.com/blog/us-drug-pricing-is-in-need-of-an-overhaul 2019-05-16T11:54:16 https://maestrodatabase.com/blog/pharmac-estimates-trikafta-could-give-people-with-cf-another-27-years 2022-08-17T07:23:53 https://maestrodatabase.com/blog/alvotech-and-teva-announce-us-fda-approval-of-additional-presentation-of-selarsdi-ustekinumab-aekn-expanding-its-label-to-include-further-indications-approved-for-reference-product-stelara-ustekinumab 2024-11-02T02:27:14 https://maestrodatabase.com/blog/upadacitinib-in-atopic-dermatitis-additional-benefit-for-adults-at-high-dose 2021-12-09T19:35:46 https://maestrodatabase.com/blog/house-to-vote-on-bills-to-lower-drug-prices-but-republicans-balk-at-obamacare-protections 2019-05-16T11:50:15 https://maestrodatabase.com/blog/heron-therapeutics-announces-fda-approval-of-a-significant-indication-expansion-for-zynrelef 2021-12-09T19:45:34 https://maestrodatabase.com/blog/will-drugs-companies-follow-eu-agency-from-london-to-amsterdam 2019-05-16T11:45:00 https://maestrodatabase.com/blog/handoks-rare-blood-disorder-treatment-empaveli-wins-insurance-coverage 2024-11-02T02:16:31 https://maestrodatabase.com/blog/liberals-accused-of-caving-on-drug-concession-at-request-of-u-dot-s 2018-10-08T20:23:04 https://maestrodatabase.com/blog/canadas-national-strategy-for-drugs-for-rare-diseases-needs-a-holistic-approach 2021-12-09T19:40:00 https://maestrodatabase.com/blog/creative-medical-technology-secures-fda-fast-track-designation-for-celz-201-ddt---advancing-breakthrough-therapy-for-chronic-lower-back-pain 2025-08-13T23:33:41 https://maestrodatabase.com/blog/mum-delivers-65-roses-to-downing-street-in-bid-to-speed-up-nhs-availability-of-vital-cystic-fibrosis-drugs 2019-05-16T21:07:09 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-9-december-2021 2021-12-09T19:24:00 https://maestrodatabase.com/blog/a-1-dollars-discount-on-prescription-medicines-is-under-threat 2019-05-16T21:03:57 https://maestrodatabase.com/blog/budget-to-deliver-better-access-to-life-changing-medicines-for-liver-cancer-eye-conditions-and-parkinsons-disease 2020-10-04T03:21:51 https://maestrodatabase.com/blog/cms-takes-action-to-lower-prescription-drug-prices-and-increase-transparency 2019-05-16T20:47:40 https://maestrodatabase.com/blog/nice-publish-final-guidance-recommending-aspaveli-in-adults-with-ultra-rare-blood-disorder 2021-12-09T19:29:56 https://maestrodatabase.com/blog/in-washington-a-partisan-approach-to-lowering-drug-costs-leaves-democrats-doubting-their-own-party-leadership 2019-05-16T20:44:31 https://maestrodatabase.com/blog/fda-expands-eligibility-for-pfizer-biontech-covid-19-booster-dose-to-16-and-17-year-olds 2021-12-09T20:05:41 https://maestrodatabase.com/blog/pharma-industry-improves-access-to-medicines-in-developing-world 2019-05-16T21:33:34 https://maestrodatabase.com/blog/fda-issues-draft-guidance-for-industry-considerations-for-the-use-of-real-world-data-and-real-world-evidence-to-support-regulatory-decision-making-for-drugs-and-biological-products 2021-12-09T20:23:08 https://maestrodatabase.com/blog/consensus-lacking-on-value-for-new-anti-cancer-drugs 2021-12-09T19:50:49 https://maestrodatabase.com/blog/nivolumab-for-the-adjuvant-treatment-of-oesophageal-carcinoma-indication-of-minor-added-benefit 2021-12-09T20:02:40 https://maestrodatabase.com/blog/instalment-payments-could-be-used-across-gene-therapy-space-spark-ceo-says 2019-05-16T21:36:32 https://maestrodatabase.com/blog/supernus-resubmits-nda-for-spn-830-apomorphine-infusion-device 2024-08-02T12:54:08 https://maestrodatabase.com/blog/uk-will-not-buy-evusheld-owing-to-insufficient-data-on-protection-government-says 2022-08-17T08:13:41 https://maestrodatabase.com/blog/linvoseltamab-receives-ema-filing-acceptance-for-treatment-of-relapsed-slash-refractory-multiple-myeloma 2024-02-02T22:13:22 https://maestrodatabase.com/blog/fenfluramine-hydrochloride-for-the-treatment-of-patients-with-lennox-gastaut-seizures 2024-02-02T09:36:30 https://maestrodatabase.com/blog/prioritising-pills-for-the-people-getting-new-medicines-on-schedule-a-complex-process-by-new-zealand-doctor 2024-02-02T09:32:32 https://maestrodatabase.com/blog/why-your-pharmacist-cant-tell-you-that-20-dollars-prescription-could-cost-only-8-dollars 2018-02-26T02:23:47 https://maestrodatabase.com/blog/orphan-drugs-early-generation-of-evidence-urgently-needed 2023-05-13T14:45:14 https://maestrodatabase.com/blog/health-canada-approves-keytruda-for-patients-with-resectable-locally-advanced-head-and-neck-squamous-cell-carcinoma-tumours-that-are-pd-l1-cps-positive-as-neo-adjuvant-treatment-continued-as-adjuvant-treatment-combined-with-radiotherapy-with-or-without-cisplatin-then-as-monotherapy 2025-08-14T16:34:30 https://maestrodatabase.com/blog/brii-bio-announces-amubarvimab-slash-romlusevimab-combination-received-approval-from-nmpa-as-first-covid-19-neutralising-antibody-combination-therapy-in-china 2021-12-09T21:41:01 https://maestrodatabase.com/blog/henlius-fourth-biologic-bevacizumab-biosimilar-approved-by-national-medical-products-administration 2021-12-09T22:34:59 https://maestrodatabase.com/blog/us-fda-accepts-new-drug-application-for-gsks-momelotinib-for-the-treatment-of-myelofibrosis 2022-08-17T08:36:44 https://maestrodatabase.com/blog/contribution-of-nih-funding-to-new-drug-approvals-2010-2016 2018-02-26T02:43:08 https://maestrodatabase.com/blog/lynparza-receives-positive-eu-chmp-opinion-in-platinum-sensitive-relapsed-ovarian-cancer 2018-02-26T06:36:00 https://maestrodatabase.com/blog/innocare-announces-inclusion-of-orelabrutinib-in-china-national-reimbursement-drug-list 2021-12-09T21:48:16 https://maestrodatabase.com/blog/pfizer-ceo-calls-us-drug-price-plan-negotiation-with-a-gun-to-your-head 2023-05-13T15:11:54 https://maestrodatabase.com/blog/legend-biotech-announces-submission-of-new-drug-application-to-japanese-regulatory-authority-for-bcma-car-t-therapy-cilta-cel-for-the-treatment-of-relapsed-or-refractory-multiple-myeloma-by-janssen 2021-12-09T22:09:31 https://maestrodatabase.com/blog/eu-clears-rare-musculoskeletal-disorder-drug 2018-02-26T19:57:14 https://maestrodatabase.com/blog/samsung-bioepis-and-organon-announce-fda-approval-of-citrate-free-high-concentration-humira-biosimilar-hadlima-adalimumab-bwwd 2022-08-17T11:46:19 https://maestrodatabase.com/blog/would-they-run-out-of-viagra-pharmac-slammed-for-huge-shortage-of-hrt 2023-05-14T22:22:57 https://maestrodatabase.com/blog/the-finose-collaboration-is-extended-and-strengthened-by-the-entry-of-the-danish-medicines-council 2023-05-14T22:24:59 https://maestrodatabase.com/blog/third-evaluation-within-the-finose-collaboration 2020-05-12T10:41:50 https://maestrodatabase.com/blog/covid-vaccine-rollout-too-slow-poorly-planned-audit-finds 2022-08-17T11:14:42 https://maestrodatabase.com/blog/akorn-announces-fda-has-approved-generic-cetrorelix-acetate 2022-08-17T09:29:52 https://maestrodatabase.com/blog/taking-new-steps-to-meet-the-challenges-of-rare-diseases----fda-marks-the-11th-rare-disease-day 2018-02-26T20:16:16 https://maestrodatabase.com/blog/nhs-could-claw-back-ps502m-if-lyrica-ruling-upheld-study-finds 2018-02-26T20:00:18 https://maestrodatabase.com/blog/final-decision-on-cerliponase-alfa-for-batten-disease-treatment-confirmed 2025-08-14T17:24:19 https://maestrodatabase.com/blog/esperion-targets-10-dollars-a-day-for-heart-pill-to-undercut-rivals 2018-02-26T20:06:26 https://maestrodatabase.com/blog/alzheimers-treatment-leqembi-could-cost-medicare-up-to-5-dollars-billion-per-year-study-estimates 2023-05-15T21:10:14 https://maestrodatabase.com/blog/accelerated-approval-of-cancer-drugs-no-economic-reward-for-drug-makers-that-conduct-confirmatory-trials 2022-08-17T20:59:32 https://maestrodatabase.com/blog/medicare-fda-urged-to-press-ahead-with-new-alzheimers-drug-leqembi 2023-05-15T21:13:12 https://maestrodatabase.com/blog/icer-to-assess-treatment-for-pulmonary-arterial-hypertension 2023-05-15T21:02:21 https://maestrodatabase.com/blog/a-new-regulatory-threat-to-cancer-patients 2018-02-26T20:22:07 https://maestrodatabase.com/blog/statement-from-fda-commissioner-on-fdas-ongoing-efforts-to-help-improve-effectiveness-of-influenza-vaccines 2018-02-26T20:38:21 https://maestrodatabase.com/blog/kyowa-kirin-announces-european-commission-approval-of-crysvita-burosumab-for-the-treatment-of-x-linked-hypophosphataemia-in-older-adolescents-and-adults 2020-10-04T21:23:01 https://maestrodatabase.com/blog/fda-approves-first-cell-based-gene-therapy-to-treat-adult-and-paediatric-patients-with-beta-thalassaemia-who-require-regular-blood-transfusions 2022-08-17T20:51:18 https://maestrodatabase.com/blog/cancer-drugs-among-top-5-most-affected-by-shortages-in-the-us 2023-05-14T22:41:57 https://maestrodatabase.com/blog/pharmacy-guild-rebuked-over-scare-campaign-on-medicine-shortages 2023-05-14T22:28:59 https://maestrodatabase.com/blog/fears-for-patient-safety-with-hundreds-of-medicines-in-short-supply 2022-08-17T11:53:40 https://maestrodatabase.com/blog/negotiations-begin-for-a-new-medicine-pricing-scheme 2023-05-14T22:34:48 https://maestrodatabase.com/blog/intercept-announces-withdrawal-of-ema-marketing-authorisation-application-for-obeticholic-acid-for-advanced-liver-fibrosis-due-to-nash 2021-12-10T03:21:29 https://maestrodatabase.com/blog/evaluation-of-the-impact-of-patient-involvement-in-health-technology-assessments-a-scoping-review 2020-05-12T10:54:46 https://maestrodatabase.com/blog/iqwig-annual-report-for-2021-is-available 2022-08-17T21:12:57 https://maestrodatabase.com/blog/caldolor-now-fda-approved-for-treatment-of-fever-and-pain-in-infants 2023-05-15T22:17:17 https://maestrodatabase.com/blog/early-phase-oncology-trials-why-so-many-designs 2022-08-17T21:24:39 https://maestrodatabase.com/blog/covid-19-vaccines-in-the-rush-for-regulatory-approval-do-we-need-more-data 2021-05-19T02:24:42 https://maestrodatabase.com/blog/drug-companies-are-minting-billions-on-unproven-treatments-with-fda-shortcut 2023-05-15T21:31:07 https://maestrodatabase.com/blog/thermo-fisher-receives-fda-approval-for-ngs-based-companion-diagnostic-for-new-non-small-cell-lung-cancer-treatment 2025-08-15T19:10:13 https://maestrodatabase.com/blog/biomarin-receives-fda-fast-track-designation-for-investigational-gene-therapy-bmn-307 2020-10-04T21:30:38 https://maestrodatabase.com/blog/bluebird-bio-announces-u-dot-s-commercial-infrastructure-to-enable-patient-access-to-zynteglo-the-first-and-only-fda-approved-gene-therapy-for-people-with-beta-thalassaemia-who-require-regular-red-blood-cell-transfusions 2022-08-17T21:04:19 https://maestrodatabase.com/blog/fda-flexibility-okay-for-gaps-in-gene-therapy-trials 2021-05-19T03:10:11 https://maestrodatabase.com/blog/migraine-sufferers-devastated-drug-wont-be-listed-on-pbs 2019-10-28T01:16:15 https://maestrodatabase.com/blog/proposal-to-transition-funded-access-to-dornase-alfa-to-a-standard-special-authority 2020-10-04T22:09:06 https://maestrodatabase.com/blog/pbs-listings 2019-10-28T01:11:39 https://maestrodatabase.com/blog/top-fda-official-says-fully-vaccinated-people-could-need-covid-booster-shots-within-a-year 2021-05-19T03:05:29 https://maestrodatabase.com/blog/tonix-pharmaceuticals-announces-fda-approval-of-tonmya-cyclobenzaprine-hydrochloride-sublingual-tablets-for-the-treatment-of-fibromyalgia 2025-08-16T23:02:17 https://maestrodatabase.com/blog/nice-to-support-new-valuation-study-for-england-for-eq-5d-5l-questionnaire 2019-10-28T04:22:39 https://maestrodatabase.com/blog/halda-therapeutics-receives-fda-fast-track-designation-for-hld-0915-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer 2025-08-16T16:07:13 https://maestrodatabase.com/blog/zolpimist-update 2020-05-12T11:00:26 https://maestrodatabase.com/blog/ruzurgi-now-available-to-canadian-lambert-eaton-myasthenic-syndrome-patients 2020-10-04T22:17:14 https://maestrodatabase.com/blog/bluebird-bio-announces-european-medicines-agencys-acceptance-of-marketing-authorisation-application-for-elivaldogene-autotemcel-eli-cel-lenti-d-gene-therapy-for-cerebral-adrenoleukodystrophy 2020-10-04T22:38:11 https://maestrodatabase.com/blog/tisotumab-vedotin-marketing-authorisation-application-validated-by-ema-for-treatment-of-recurrent-or-metastatic-cervical-cancer 2024-02-03T01:08:46 https://maestrodatabase.com/blog/fda-launches-crowdsourcing-challenge-to-solicit-input-on-research-questions-to-be-addressed-through-fdas-oncologic-clinical-trial-data 2021-05-19T03:59:12 https://maestrodatabase.com/blog/national-disgrace-why-australia-is-still-waiting-for-proton-therapy 2025-08-16T23:44:10 https://maestrodatabase.com/blog/fda-accepts-biologics-license-application-for-aimovig-erenumab 2017-07-30T23:59:58 https://maestrodatabase.com/blog/fda-approves-first-immunotherapy-for-recurrent-respiratory-papillomatosis 2025-08-16T23:08:11 https://maestrodatabase.com/blog/price-disclosure-2022-april-cycle-outcomes-summary 2021-12-10T05:56:28 https://maestrodatabase.com/blog/mhra-approves-teplizumab-to-delay-progression-of-type-1-diabetes 2025-08-16T23:15:53 https://maestrodatabase.com/blog/pfizer-withdraws-evidence-submission-for-staquis 2021-05-19T10:18:35 https://maestrodatabase.com/blog/vabysmo-faricimab-injection-now-publicly-funded-for-macular-oedema-secondary-to-retinal-vein-occlusion-and-pre-filled-syringe-in-quebec 2025-08-16T23:29:10 https://maestrodatabase.com/blog/use-effective-drugs-in-early-multiple-myeloma-to-prevent-relapse 2021-05-19T10:59:57 https://maestrodatabase.com/blog/innovent-receives-nmpa-breakthrough-designation-for-ibi351-krasg12c-inhibitor-as-monotherapy-for-previously-treated-advanced-colorectal-carcinoma 2023-05-16T00:09:48 https://maestrodatabase.com/blog/beigene-announces-u-dot-s-fda-acceptance-and-priority-review-of-supplemental-new-drug-application-for-brukinsa-zanubrutinib-in-marginal-zone-lymphoma 2021-05-19T11:25:45 https://maestrodatabase.com/blog/radiopharmaceutical-lutathera-now-reimbursed-in-quebec-for-cancer-patients-with-advanced-gastro-enteropancreatic-neuroendocrine-tumours 2020-10-05T00:20:01 https://maestrodatabase.com/blog/immpact-bio-granted-fda-fast-track-designation-for-impt-314-in-patients-with-relapsed-or-refractory-aggressive-b-cell-lymphoma 2023-05-15T23:57:19 https://maestrodatabase.com/blog/physician-patient-shared-decision-making-patient-satisfaction-and-adoption-of-new-health-technology-in-china 2020-10-05T00:24:41 https://maestrodatabase.com/blog/vbi-vaccines-announces-filing-of-new-drug-submission-for-3-antigen-hepatitis-b-vaccine-to-health-canada 2021-12-10T06:22:44 https://maestrodatabase.com/blog/where-next-for-randomised-controlled-trials-in-global-health 2019-10-28T06:43:15 https://maestrodatabase.com/blog/tga-considering-changing-storage-rules-of-pfizer-jab-could-allow-aussies-to-get-dose-at-gps-or-pharmacists-hunt 2021-05-19T21:13:33 https://maestrodatabase.com/blog/roche-launches-mysugr-pump-control-within-the-mysugr-app-to-simplify-insulin-pump-therapy-via-smartphone 2021-05-19T21:27:55 https://maestrodatabase.com/blog/bioxcel-therapeutics-announces-fda-acceptance-for-filing-of-nda-for-bxcl501-for-the-acute-treatment-of-agitation-associated-with-schizophrenia-and-bipolar-disorders-i-and-ii 2021-05-19T11:53:51 https://maestrodatabase.com/blog/health-canada-accepts-new-drug-submission-for-lecanemab-as-treatment-for-early-alzheimers-disease 2023-05-16T02:16:11 https://maestrodatabase.com/blog/government-to-introduce-new-law-for-vaccine-after-legal-challenge 2021-05-19T20:51:02 https://maestrodatabase.com/blog/wegovy-approved-in-the-us-for-the-treatment-of-mash 2025-08-17T02:39:20 https://maestrodatabase.com/blog/will-abbvie-maker-of-the-worlds-best-selling-drug-finally-face-the-music-over-its-price-hikes 2021-05-19T20:45:52 https://maestrodatabase.com/blog/racgp-welcomes-asthma-puffer-decision-saving-aussie-families-time-and-money 2023-05-16T05:44:47 https://maestrodatabase.com/blog/marketing-authorisation-application-for-ct001-has-been-submitted-to-the-ema-for-acute-pain-management-in-children 2025-08-18T01:00:27 https://maestrodatabase.com/blog/pharmac-makes-cancer-treatment-available-to-more-people 2022-08-18T00:38:53 https://maestrodatabase.com/blog/fda-grants-sisafs-innovative-sirna-therapy-sis-101-ado-orphan-drug-designation-and-rare-paediatric-disease-designation-for-the-treatment-of-autosomal-dominant-osteopetrosis 2023-05-16T02:46:16 https://maestrodatabase.com/blog/leading-real-world-data-and-analytics-organisations-form-industry-coalition-to-advance-policies-to-support-regulatory-use-of-real-world-evidence 2021-05-19T21:33:58 https://maestrodatabase.com/blog/its-time-for-canada-to-embrace-universal-pharmacare-and-protect-drug-coverage-from-corporate-erosion 2019-10-28T10:04:43 https://maestrodatabase.com/blog/democrats-new-logic-on-drug-pricing-developing-slightly-fewer-medicines-is-ok-if-it-means-lower-prices 2019-10-28T10:02:15 https://maestrodatabase.com/blog/doorstop-interview-in-launceston 2019-10-28T09:57:27 https://maestrodatabase.com/blog/u-dot-s-food-and-drug-administration-issues-complete-response-letter-for-byondis-trastuzumab-duocarmazine 2023-05-16T09:26:02 https://maestrodatabase.com/blog/most-of-the-medicine-subsidies-the-government-claims-are-not-new-and-cost-them-nothing 2019-10-28T10:10:49 https://maestrodatabase.com/blog/the-decline-of-science-at-the-fda-has-become-unmanageable 2023-05-16T08:39:44 https://maestrodatabase.com/blog/bayer-receives-us-fda-fast-track-designation-for-asundexian-atrial-fibrillation-program 2023-05-17T00:07:50 https://maestrodatabase.com/blog/protega-pharmaceuticals-receives-fda-approval-for-roxybond-oxycodone-hydrochloride-immediate-release-10-mg-tablet-with-abuse-deterrent-technology-for-management-of-pain 2024-11-03T01:29:54 https://maestrodatabase.com/blog/eu-cancer-drugs-rejection-shows-contrasts-with-fda 2018-02-27T01:27:31 https://maestrodatabase.com/blog/pfizers-bosulif-for-leukaemia-gains-insurance-coverage-patients-urge-inclusion-for-children-first-line-use 2024-02-03T23:12:19 https://maestrodatabase.com/blog/lilly-receives-additional-fda-approval-for-verzenio-abemaciclib-as-initial-treatment-for-advanced-breast-cancer 2018-02-27T01:19:02 https://maestrodatabase.com/blog/shionogi-announces-fda-new-drug-application-and-ema-marketing-authorisation-application-acceptances-for-lusutrombopag-s-888711 2018-02-27T01:30:58 https://maestrodatabase.com/blog/european-commission-grants-approval-of-ogsiveo 2025-08-18T17:04:43 https://maestrodatabase.com/blog/stealth-biotherapeutics-resubmits-new-drug-application-for-elamipretide-for-the-treatment-of-barth-syndrome 2025-08-18T22:52:35 https://maestrodatabase.com/blog/intraparty-disputes-dim-outlook-for-drug-price-legislation 2019-10-28T11:13:02 https://maestrodatabase.com/blog/migraine-drug-subsidy-knocked-back-leaving-sufferers-paying-800-dollars-a-month-for-aimovig 2019-10-28T11:02:58 https://maestrodatabase.com/blog/risankizumab-for-previously-treated-moderately-to-severely-active-crohns-disease 2023-05-17T00:30:05 https://maestrodatabase.com/blog/free-sunscreen-and-skin-checks-health-insurer-seeks-to-reward-good-behaviour 2019-10-28T20:22:08 https://maestrodatabase.com/blog/let-private-health-funds-cover-all-gp-bills 2019-10-28T20:16:42 https://maestrodatabase.com/blog/chembio-diagnostics-receives-fda-approval-for-dpp-hiv-syphilis-system 2020-10-05T08:52:55 https://maestrodatabase.com/blog/european-commission-approves-bavencio-avelumab-plus-axitinib-combination-for-first-line-treatment-of-patients-with-advanced-renal-cell-carcinoma 2019-10-28T20:11:20 https://maestrodatabase.com/blog/outdated-public-funding-model-failing-new-zealand-patients 2018-10-09T06:27:02 https://maestrodatabase.com/blog/heron-therapeutics-announces-fda-acceptance-of-new-drug-application-resubmission-for-htx-011-for-management-of-post-operative-pain 2019-10-28T20:31:44 https://maestrodatabase.com/blog/medicine-shortages-in-australia---what-are-we-doing-about-them 2018-10-09T06:16:09 https://maestrodatabase.com/blog/epilepsy-sufferers-not-happy-with-pharmac-drug-change 2019-10-28T20:25:45 https://maestrodatabase.com/blog/tga-business-plan-2018-19 2018-10-09T06:19:27 https://maestrodatabase.com/blog/u-dot-s-fda-grants-fast-track-designation-to-astellas-for-the-development-of-asp1128-for-patients-at-risk-for-acute-kidney-injury 2019-10-28T23:21:17 https://maestrodatabase.com/blog/health-canada-approves-injectable-hydromorphone-to-treat-opioid-addiction 2019-05-17T01:22:45 https://maestrodatabase.com/blog/fda-approves-medicines360s-liletta-levonorgestrel-releasing-intrauterine-system-52-mg-to-prevent-pregnancy-for-up-to-six-years-the-longest-approved-duration-of-use-of-any-hormonal-iuds 2019-10-28T20:41:11 https://maestrodatabase.com/blog/a-comparison-of-the-eq-5d-3l-and-eq-5d-5l 2020-05-12T20:42:08 https://maestrodatabase.com/blog/carsgen-announces-investigational-car-t-therapy-ct053-granted-rmat-designation-by-the-u-dot-s-fda-for-relapsed-slash-refractory-multiple-myeloma 2019-10-28T23:26:29 https://maestrodatabase.com/blog/doctors-face-nearly-an-impossible-situation-as-they-ration-remdesivir 2020-05-12T20:52:16 https://maestrodatabase.com/blog/investigators-propose-different-measures-for-biosimilar-equivalence 2020-05-12T20:55:33 https://maestrodatabase.com/blog/health-canada-has-approved-fasenra-benralizumab-injection-for-patients-with-severe-eosinophilic-asthma 2018-02-27T06:01:17 https://maestrodatabase.com/blog/battle-for-life-saving-drugs-now-harder-as-pharmac-absorbs-$5m-rare-disorders-fund 2019-10-29T00:50:24 https://maestrodatabase.com/blog/mirum-pharmaceuticals-announces-breakthrough-therapy-designation-for-maralixibat-for-the-treatment-of-pruritus-associated-with-alagille-syndrome 2019-10-28T23:29:58 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-astellas-new-drug-application-for-fezolinetant 2022-08-18T07:28:41 https://maestrodatabase.com/blog/moderna-receives-fda-fast-track-designation-for-mrna-vaccine-mrna-1273-against-novel-voronavirus 2020-05-12T20:33:19 https://maestrodatabase.com/blog/lenvatinib-with-pembrolizumab-for-untreated-advanced-renal-cell-carcinoma 2022-08-18T08:44:29 https://maestrodatabase.com/blog/blueprint-medicines-announces-fda-intent-to-split-avapritinib-new-drug-application-into-separate-submissions-for-pdgfra-exon-18-mutant-gist-and-fourth-line-gist 2019-10-29T02:18:40 https://maestrodatabase.com/blog/regenxbio-announces-fda-review-extension-of-bla-for-rgx-121-to-treat-patients-with-mps-ii 2025-08-18T23:43:42 https://maestrodatabase.com/blog/costly-prescription-eye-treatment-highlights-a-loophole-in-canadas-drug-price-regulation-process 2019-10-29T02:06:03 https://maestrodatabase.com/blog/breast-cancer-mri-added-to-medicare 2019-10-29T02:01:37 https://maestrodatabase.com/blog/eu-regulators-fully-uphold-transparency-and-independence-standards-for-covid-19-treatments-and-vaccines 2020-10-05T19:55:54 https://maestrodatabase.com/blog/omeros-corporation-initiates-bla-submission-for-narsoplimab-for-the-treatment-of-hsct-tma 2019-10-29T04:53:06 https://maestrodatabase.com/blog/racing-getting-more-from-budget-than-pharmac 2020-05-12T21:07:08 https://maestrodatabase.com/blog/addressing-the-challenge-of-common-chronic-diseases----a-view-from-the-fda 2024-02-04T20:06:12 https://maestrodatabase.com/blog/japan-to-set-price-of-sma-drug-zolgensma-at-167-million-yen 2020-05-12T21:11:40 https://maestrodatabase.com/blog/import-german-drug-prices-to-the-united-states-nein-danke 2020-10-05T20:15:39 https://maestrodatabase.com/blog/csl-vifor-plans-uk-launch-after-nice-backs-rare-disease-drug-tavneos 2022-08-18T20:59:54 https://maestrodatabase.com/blog/immunogen-announces-fda-breakthrough-therapy-designation-for-imgn632-in-relapsed-or-refractory-blastic-plasmacytoid-dendritic-cell-neoplasm 2020-10-05T20:21:24 https://maestrodatabase.com/blog/prescription-charge-in-england-to-rise 2018-02-27T19:59:59 https://maestrodatabase.com/blog/ema-starts-review-of-conditional-marketing-authorisation-application-for-skycovion-covid-19-vaccine 2022-08-18T20:47:03 https://maestrodatabase.com/blog/de-adopting-low-value-care-evidence-eminence-and-economics 2020-10-05T20:26:21 https://maestrodatabase.com/blog/chiesis-trimbow-recommended-for-use-within-nhs-scotland 2022-08-18T20:50:07 https://maestrodatabase.com/blog/ifinatamab-deruxtecan-granted-breakthrough-therapy-designation-by-us-fda-for-patients-with-pre-treated-extensive-stage-small-cell-lung-cancer 2025-08-18T23:19:58 https://maestrodatabase.com/blog/patients-say-generic-pharmac-funded-version-of-anti-depressant-venlafaxine-left-them-depressed-anxious 2018-02-27T19:52:11 https://maestrodatabase.com/blog/sobis-orfadin-nitisinone-receives-positive-reimbursement-recommendation-for-the-treatment-of-ht-1-from-cadth-canadian-drug-expert-committee 2018-02-27T20:14:27 https://maestrodatabase.com/blog/real-world-evidence-from-a-narrow-therapeutic-index-product-levothyroxine-reflects-the-therapeutic-equivalence-of-generic-drug-product 2020-10-05T19:59:08 https://maestrodatabase.com/blog/cder-proposes-withdrawal-of-approval-for-makena 2020-10-05T20:01:58 https://maestrodatabase.com/blog/restart-of-national-medicines-policy-review-is-welcome-but-assurances-needed-over-further-consultation-and-feedback-processes 2022-08-18T20:43:48 https://maestrodatabase.com/blog/ema-grants-accelerated-assessment-for-shires-lanadelumab-being-evaluated-for-the-prevention-of-attacks-in-hereditary-angioedema-patients-aged-12-years-and-older 2018-02-27T20:06:08 https://maestrodatabase.com/blog/celgene-receives-european-commission-approvals-for-revlimid-lenalidomide-and-imnovid-pomalidomide--based-triplet-combination-regimens-for-patients-with-multiple-myeloma 2019-05-17T05:45:55 https://maestrodatabase.com/blog/fda-label-update-reflects-bayers-commitment-to-providing-options-for-long-acting-contraception 2022-08-18T20:36:23 https://maestrodatabase.com/blog/health-technology-assessment-challenges-in-oncology-20-years-of-value-in-health 2019-05-17T04:14:21 https://maestrodatabase.com/blog/eu-regulator-starts-safety-review-of-coronavirus-drug 2020-10-05T20:06:27 https://maestrodatabase.com/blog/valneva-initiates-rolling-submission-of-fda-biologics-license-application-for-its-single-shot-chikungunya-vaccine-candidate 2022-08-18T20:39:43 https://maestrodatabase.com/blog/canadians-seek-diabetes-medication-as-replacement-for-weight-loss-drug-during-arrival-delays 2022-08-18T21:13:45 https://maestrodatabase.com/blog/tetraphase-pharmaceuticals-announces-fda-acceptance-for-filing-of-its-nda-submission-for-eravacycline-for-the-treatment-of-complicated-intra-abdominal-infections 2018-02-27T20:22:49 https://maestrodatabase.com/blog/stability-of-changes-in-health-status-next-step-in-comprehensively-assessing-patient-reported-outcomes 2022-08-18T21:22:14 https://maestrodatabase.com/blog/aarp-pennsylvania-convenes-discussion-on-lower-prescription-drug-costs-after-inflation-reduction-act-signed-into-law 2022-08-18T21:10:00 https://maestrodatabase.com/blog/nova-scotia-sets-up-program-to-help-pay-for-take-home-cancer-drugs 2018-02-27T20:40:46 https://maestrodatabase.com/blog/moderna-ceo-says-covid-19-vaccine-will-be-ready-for-fda-submission-in-late-november 2020-10-05T20:32:17 https://maestrodatabase.com/blog/on-drug-pricing-states-step-in-where-washington-fails 2018-02-27T20:51:04 https://maestrodatabase.com/blog/caps-on-prescription-drug-price-hikes-most-popular-aspect-of-inflation-reduction-act-poll 2022-08-18T21:04:57 https://maestrodatabase.com/blog/twenty-states-sue-federal-government-seeking-end-to-obamacare 2018-02-27T20:33:25 https://maestrodatabase.com/blog/private-health-premiums-could-rise-by-12-per-cent-next-year-leaked-modelling-shows 2018-10-09T19:57:47 https://maestrodatabase.com/blog/update-on-emas-brexit-preparedness 2018-10-09T20:03:45 https://maestrodatabase.com/blog/health-canada-approves-new-indications-for-xeljanz-in-ulcerative-colitis-and-psoriatic-arthritis 2018-10-09T20:23:24 https://maestrodatabase.com/blog/statement-from-fda-commissioner-on-new-efforts-to-advance-the-development-of-generic-copies-of-complex-drugs-to-improve-patient-access-to-medicines 2018-10-09T20:08:33 https://maestrodatabase.com/blog/recro-pharma-announces-pdufa-date-for-iv-meloxicam 2018-10-09T20:12:06 https://maestrodatabase.com/blog/wa-family-forced-to-pay-$40k-a-year-for-sons-medicinal-cannabis 2018-10-09T20:43:01 https://maestrodatabase.com/blog/aerie-pharmaceuticals-announces-drug-application-for-regulatory-approval-accepted-for-review-in-europe 2018-10-09T20:47:01 https://maestrodatabase.com/blog/health-minister-greg-hunt-tells-health-funds-to-reduce-price-rises 2021-12-10T21:20:53 https://maestrodatabase.com/blog/us-fda-grants-priority-review-of-tak-755-for-the-treatment-of-congenital-thrombotic-thrombocytopenic-purpura 2023-05-17T02:08:47 https://maestrodatabase.com/blog/international-regulators-stress-continued-need-for-covid-19-therapeutics 2021-12-10T21:58:07 https://maestrodatabase.com/blog/seattle-genetics-announces-the-approval-of-tukysa-tucatinib-in-switzerland-for-the-treatment-of-patients-with-metastatic-her2-positive-breast-cancer 2020-05-13T03:28:55 https://maestrodatabase.com/blog/cheaper-medicines-for-advanced-melanoma-and-multiple-sclerosis 2024-02-05T05:28:21 https://maestrodatabase.com/blog/ruxolitinib-phosphate-for-the-treatment-of-patients-with-non-segmental-vitiligo 2024-02-04T22:34:47 https://maestrodatabase.com/blog/new-opioid-overdose-antidote-to-gain-pbs-listing 2019-10-29T19:54:39 https://maestrodatabase.com/blog/life-changing-multi-cancer-drug-funding-proposal-in-jeopardy 2024-11-03T23:26:17 https://maestrodatabase.com/blog/valnevas-chikungunya-vaccine-ixchiq-now-authorised-in-canada-for-individuals-aged-12-and-plder 2025-08-19T01:17:04 https://maestrodatabase.com/blog/statement-on-fdas-new-report-regarding-root-causes-and-potential-solutions-to-drug-shortages 2019-10-29T20:10:06 https://maestrodatabase.com/blog/how-the-prescription-drug-pricing-reduction-act-can-reduce-drug-costs 2019-10-29T20:05:12 https://maestrodatabase.com/blog/iovances-amtagvi-lifileucel-receives-health-canada-approval-for-advanced-melanoma 2025-08-19T02:00:19 https://maestrodatabase.com/blog/uk-officials-discussed-nhs-at-secret-meetings-with-us-drug-companies-as-part-of-trade-talks 2019-10-29T20:03:00 https://maestrodatabase.com/blog/gilead-strikes-deal-to-make-remdesivir-coronavirus-treatment-in-127-countries 2020-05-13T05:22:26 https://maestrodatabase.com/blog/pharmac-political-theatre-grotesque 2021-05-20T03:48:43 https://maestrodatabase.com/blog/we-need-a-cure-for-the-arrogance-of-drug-price-control-advocates 2019-10-29T20:00:07 https://maestrodatabase.com/blog/pfizer-canada-and-biontech-receive-health-canada-approval-of-lp-dot-8-1-variant-adapted-covid-19-vaccine 2025-08-19T06:54:27 https://maestrodatabase.com/blog/nhs-bill-for-us-drugs-could-soar-under-post-brexit-trade-deal 2019-10-29T20:34:07 https://maestrodatabase.com/blog/ultragenyx-initiates-rolling-submission-of-niologics-license-application-to-us-fda-for-dtx401-aav-gene-therapy-for-the-treatment-of-glycogen-storage-disease-type-ia 2025-08-19T07:40:07 https://maestrodatabase.com/blog/in-generic-drug-plants-in-china-and-india-data-falsification-is-still-a-problem 2019-10-29T20:20:24 https://maestrodatabase.com/blog/fda-issues-new-recommendations-to-combat-drug-shortages-but-can-it-really-fix-the-problem 2019-10-29T20:16:36 https://maestrodatabase.com/blog/bristol-myers-squibb-and-bluebird-bio-provide-regulatory-update-on-idecabtagene-vicleucel-ide-cel-bb2121-for-the-treatment-of-patients-with-multiple-myeloma 2020-05-13T11:20:01 https://maestrodatabase.com/blog/be-thankful-for-high-drug-prices 2024-02-05T19:50:58 https://maestrodatabase.com/blog/call-for-time-limits-on-pharmacs-drug-assessment-process 2024-02-05T10:30:00 https://maestrodatabase.com/blog/aeglea-biotherapeutics-announces-european-medicines-agency-validation-of-marketing-authorisation-application-for-pegzilarginase-for-the-treatment-of-arginase-1-deficiency 2022-08-19T02:29:55 https://maestrodatabase.com/blog/selinexor-in-combination-with-bortezomib-and-dexamethasone-for-the-treatment-of-patients-with-relapsed-slash-refractory-multiple-myeloma 2024-02-05T06:04:08 https://maestrodatabase.com/blog/canadas-change-to-pfizer-vaccine-storage-temperature-has-major-implications-on-rollout 2021-05-20T03:54:36 https://maestrodatabase.com/blog/ciltacabtagene-autoleucel-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma 2023-05-17T02:58:08 https://maestrodatabase.com/blog/further-strengthening-the-covid-19-vaccine-rollout-through-primary-care 2021-05-20T05:27:28 https://maestrodatabase.com/blog/nice-final-guidance-backs-pfizers-lorviqua 2020-05-13T09:04:26 https://maestrodatabase.com/blog/boring-budget-2021-reinforces-two-tier-medicines-access-system-in-new-zealand 2021-05-20T05:21:07 https://maestrodatabase.com/blog/sustainability-of-healthcare-systems-in-asia-exploring-the-roles-of-horizon-scanning-and-reassessment-in-the-health-technology-assessment-landscape 2020-05-13T21:03:31 https://maestrodatabase.com/blog/arbor-pharmaceuticals-announces-fda-filing-acceptance-of-new-drug-application-for-ar19-an-investigational-adhd-prescription-stimulant-treatment-specifically-designed-to-resist-physical-manipulation-for-non-medical-misuse-or-abuse 2020-05-13T21:12:53 https://maestrodatabase.com/blog/ultimovacs-receives-fda-fast-track-designation-for-uv1-cancer-vaccine-for-the-treatment-of-patients-with-unresectable-mesothelioma 2024-02-05T20:16:34 https://maestrodatabase.com/blog/last-hope-why-its-costing-me-20-000-dollars-a-month-to-stay-alive 2024-11-04T02:35:13 https://maestrodatabase.com/blog/medicare-patient-access-to-humira-biosimilars-still-falls-woefully-short 2024-02-05T20:11:05 https://maestrodatabase.com/blog/brighter-future-for-blood-cancer-patients-battling-rare-condition 2024-11-04T02:15:26 https://maestrodatabase.com/blog/newamsterdam-announces-acceptance-of-marketing-authorisation-applications-for-review-by-ema-for-obicetrapib 2025-08-19T16:47:00 https://maestrodatabase.com/blog/rhythm-pharmaceuticals-announces-fda-acceptance-of-new-drug-application-for-setmelanotide-for-the-treatment-of-pomc-and-lepr-deficiency-obesities 2020-05-13T20:39:58 https://maestrodatabase.com/blog/ns-parents-dismayed-by-lack-of-access-to-new-rsv-vaccines-for-infants 2024-11-04T01:51:06 https://maestrodatabase.com/blog/vanda-pharmaceuticals-announces-agreement-with-fda-on-resubmission-of-the-application-for-hetlioz-for-the-treatment-of-patients-with-smith-magenis-syndrome 2020-05-13T20:46:18 https://maestrodatabase.com/blog/nice-backs-drug-for-lymphoma-from-roche 2020-05-13T20:55:58 https://maestrodatabase.com/blog/linzagolix-choline-for-the-treatment-of-patients-with-moderate-to-severe-symptoms-of-uterine-fibroids-final-guidance 2024-08-14T11:07:06 https://maestrodatabase.com/blog/katie-porter-brings-her-whiteboard-to-accuse-pharma-ceo-of-inflating-drug-prices 2021-05-20T10:42:41 https://maestrodatabase.com/blog/gileads-remdesivir-tested-with-other-drugs-to-fight-covid-19 2020-05-13T21:45:49 https://maestrodatabase.com/blog/budget-2021-health-boost-for-pharmac-and-funding-for-maori-health-authority 2021-05-20T08:42:51 https://maestrodatabase.com/blog/digby-n-dot-s-dad-obtains-high-priced-drug-to-fight-rare-cancer 2018-02-28T01:24:54 https://maestrodatabase.com/blog/difelikefalin-acetate-for-the-treatment-of-patients-with-pruritus-undergoing-haemodialysis 2023-05-17T04:21:27 https://maestrodatabase.com/blog/publication-of-ema-annual-report-2022 2023-05-17T04:48:40 https://maestrodatabase.com/blog/altimmune-announces-fda-fast-track-designation-for-pemvidutide-in-alcohol-use-disorder 2025-08-20T02:31:24 https://maestrodatabase.com/blog/nice-turns-down-janssens-erleada 2021-05-20T10:48:24 https://maestrodatabase.com/blog/cytokinetics-announces-receipt-of-breakthrough-therapy-designation-from-fda-for-aficamten 2021-12-10T23:49:21 https://maestrodatabase.com/blog/mail-order-drug-delivery-rises-during-coronavirus-lockdowns 2020-05-13T21:18:33 https://maestrodatabase.com/blog/patients-with-rare-blood-disorders-to-receive-new-treatment-option-says-nice 2021-05-20T07:56:16 https://maestrodatabase.com/blog/covid-19-exposes-drug-supply-gaps-as-made-in-canada-solution-proposed 2020-05-13T21:29:55 https://maestrodatabase.com/blog/the-pandemic-will-recast-americas-health-care-industrial-complex 2020-05-13T21:33:27 https://maestrodatabase.com/blog/medicare-part-d-and-insulin-affordability---the-devil-is-in-the-details 2020-05-13T21:42:18 https://maestrodatabase.com/blog/fda-approves-nivolumab-for-resected-oesophageal-or-gej-cancer 2021-05-20T20:49:34 https://maestrodatabase.com/blog/omeros-announces-extension-of-fda-review-period-for-narsoplimab-in-hsct-tma 2021-05-20T20:57:03 https://maestrodatabase.com/blog/drug-shortages-near-an-all-time-high-leading-to-rationing 2023-05-17T20:56:14 https://maestrodatabase.com/blog/ema-mhra-to-review-vertex-kaftrio-for-children-with-cystic-fibrosis 2021-05-20T11:18:37 https://maestrodatabase.com/blog/nice-nod-for-bms-opdivo-in-advanced-oesophageal-cancer 2021-05-20T11:09:52 https://maestrodatabase.com/blog/astellas-seeks-to-expand-reimbursement-for-prostate-cancer-drug-xtandi 2023-05-17T06:36:49 https://maestrodatabase.com/blog/fda-authorises-longer-time-for-refrigerator-storage-of-thawed-pfizer-biontech-covid-19-vaccine-prior-to-dilution-making-vaccine-more-widely-available 2021-05-20T11:59:37 https://maestrodatabase.com/blog/european-commission-approves-roches-hemlibra-for-people-with-haemophilia-a-with-inhibitors 2018-02-28T06:05:26 https://maestrodatabase.com/blog/1-september-2022-updates-as-part-of-the-digital-transformation-of-authority-required-written-pbs-listings 2022-08-19T02:37:05 https://maestrodatabase.com/blog/ptc-therapeutics-receives-complete-response-letter-for-vatiquinone-nda 2025-08-20T07:06:32 https://maestrodatabase.com/blog/thousands-of-astrazeneca-shots-pile-up-in-federal-run-clinics-as-gps-wait 2021-05-20T21:05:25 https://maestrodatabase.com/blog/health-canada-approves-ozempic-to-reduce-the-risk-of-sustained-egfr-decline-end-stage-kidney-disease-and-cardiovascular-death-in-adults-with-type-2-diabetes-and-chronic-kidney-disease 2025-08-20T07:25:40 https://maestrodatabase.com/blog/lumen-bioscience-receives-fast-track-designation-from-us-fda-for-lmn-201 2023-05-17T21:06:49 https://maestrodatabase.com/blog/health-canada-approves-dual-immunotherapy-opdivo-plus-yervoy-for-colorectal-and-liver-cancers 2025-08-20T07:46:26 https://maestrodatabase.com/blog/government-calls-for-pitches-for-mrna-vaccine-production-facilities 2021-05-20T21:13:25 https://maestrodatabase.com/blog/evidence-based-approach-to-funding-choices-more-important-than-ever 2018-10-09T23:48:17 https://maestrodatabase.com/blog/management-board-initiates-building-approval-process-for-ema-premises-in-amsterdam 2018-02-28T19:57:07 https://maestrodatabase.com/blog/celgene-provides-regulatory-update-on-ozanimod-for-the-treatment-of-relapsing-multiple-sclerosis 2018-02-28T10:37:28 https://maestrodatabase.com/blog/drug-makers-lobby-for-antibiotic-incentives-in-pandemic-preparedness-bill 2018-02-28T20:07:14 https://maestrodatabase.com/blog/pharmacare-wont-be-free-for-all-canadians-bill-morneau-says 2018-02-28T20:21:53 https://maestrodatabase.com/blog/novo-nordisk-files-for-regulatory-approval-of-long-acting-factor-viii-n8-gp-in-the-us-and-the-eu-for-treatment-of-haemophilia-a 2018-02-28T20:01:39 https://maestrodatabase.com/blog/ozempic-is-hard-to-find-some-pharmacies-are-offering-unauthorised-alternatives 2023-05-17T22:45:04 https://maestrodatabase.com/blog/sumitomo-pharma-and-pfizer-canada-announce-availability-of-myfembree-in-canada 2024-02-05T23:51:30 https://maestrodatabase.com/blog/all-i-want-for-christmas-is-higher-prices-congressional-report-accuses-pharma-of-manipulating-americans-for-profit 2021-12-11T01:05:06 https://maestrodatabase.com/blog/europe-follows-fda-with-plans-to-help-early-alzheimers-drugs 2018-02-28T20:39:15 https://maestrodatabase.com/blog/affordable-pharmacare-the-goal-of-study-launched-in-federal-budget 2018-02-28T20:24:11 https://maestrodatabase.com/blog/how-bad-is-celgenes-fda-foul-up-two-decades-of-biotech-history-say-it-cant-be-good 2018-02-28T20:27:20 https://maestrodatabase.com/blog/terns-pharmaceuticals-receives-fast-track-designation-from-the-fda-for-tern-101-an-fxr-agonist-for-the-treatment-of-nash 2019-10-29T23:01:52 https://maestrodatabase.com/blog/fda-grants-glycomimetics-rare-paediatric-disease-designation-for-rivipansel-for-treatment-of-sickle-cell-disease 2020-10-06T04:15:14 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-march-2018 2018-02-28T20:44:42 https://maestrodatabase.com/blog/fda-announces-all-time-low-rates-for-fy2021-priority-review-vouchers 2020-10-06T07:11:24 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-march-2018-update 2018-02-28T20:50:29 https://maestrodatabase.com/blog/1-october-2020-price-disclosure---confirmed-prices 2020-10-06T07:20:39 https://maestrodatabase.com/blog/pixcell-medical-announces-regulatory-approval-from-australian-tga-for-hemoscreen-point-of-care-hematology-analyser 2020-10-06T03:12:29 https://maestrodatabase.com/blog/fda-accepts-krystal-biotechs-biologics-license-application-for-dystrophic-epidermolysis-bullosa 2022-08-19T05:04:28 https://maestrodatabase.com/blog/european-commission-grants-marketing-authorisation-for-gileads-vosevi-sofosbuvir-slash-velpatasvir-slash-voxilaprevir-for-the-treatment-of-all-genotypes-of-chronic-hepatitis-c 2017-07-31T11:14:29 https://maestrodatabase.com/blog/nice-recommends-revlimid-as-multiple-myeloma-alternative 2019-05-18T02:55:17 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-august-2017 2017-07-31T11:32:00 https://maestrodatabase.com/blog/aldeyra-therapeutics-receives-fast-track-designation-for-adx-2191-for-the-treatment-of-retinitis-pigmentosa 2025-08-20T15:54:23 https://maestrodatabase.com/blog/ultragenyx-receives-prime-designation-from-ema-for-gtx-102-for-the-treatment-of-angelman-syndrome 2024-02-06T01:38:53 https://maestrodatabase.com/blog/nice-bars-obesity-pill-from-routine-nhs-use 2017-07-31T11:24:03 https://maestrodatabase.com/blog/agile-therapeutics-resubmits-new-drug-application-for-its-transdermal-low-dose-contraceptive-patch-twirla 2019-05-18T03:25:10 https://maestrodatabase.com/blog/improving-access-to-medicines 2020-10-06T09:25:21 https://maestrodatabase.com/blog/ema-starts-second-rolling-review-of-a-covid-19-vaccine 2020-10-06T09:47:18 https://maestrodatabase.com/blog/guidance-for-industry-to-prevent-and-mitigate-medicine-shortages 2023-05-18T00:31:02 https://maestrodatabase.com/blog/updates-on-nice-and-smc-collaboration-on-mta-for-cystic-fibrosis 2024-02-06T01:07:50 https://maestrodatabase.com/blog/u-dot-s-fda-approves-gattex-teduglutide-for-children-1-year-of-age-and-older-with-short-bowel-syndrome 2019-05-18T03:01:51 https://maestrodatabase.com/blog/eylea-hd-aflibercept-injection-8-mg-applications-for-expanded-us-label-and-pre-filled-syringe-receive-fda-review-period-extension 2025-08-20T16:11:06 https://maestrodatabase.com/blog/trump-just-pulled-his-punch-on-drug-prices 2019-05-18T03:37:22 https://maestrodatabase.com/blog/madrigal-receives-european-commission-approval-for-rezdiffra-resmetirom-for-the-treatment-of-mash-with-moderate-to-advanced-liver-fibrosis 2025-08-20T15:31:14 https://maestrodatabase.com/blog/demystifying-the-estimand-framework-a-case-study-using-patient-reported-outcomes-in-oncology 2020-10-06T19:54:48 https://maestrodatabase.com/blog/fda-discloses-vaccine-guidelines-blocked-by-white-house 2020-10-06T19:58:14 https://maestrodatabase.com/blog/first-of-its-kind-ozempic-listing-for-kidney-disease 2025-08-20T15:38:11 https://maestrodatabase.com/blog/athersys-announces-fast-track-designation-from-fda-for-multistem-program-for-acute-respiratory-distress-syndrome 2019-05-18T03:30:12 https://maestrodatabase.com/blog/y-mabs-provides-regulatory-update-on-omburtamab-for-the-treatment-of-patients-with-neuroblastoma 2020-10-06T20:02:22 https://maestrodatabase.com/blog/hope-for-ovarian-cancer-patients-with-new-drug-listed-on-pbs 2020-10-06T10:06:02 https://maestrodatabase.com/blog/valneva-announces-sale-of-priority-review-voucher-for-103-dollars-million 2024-02-06T02:38:34 https://maestrodatabase.com/blog/landmark-funding-and-long-term-certainty-for-innovative-medicines-for-australian-patients-the-community-and-the-economy 2020-10-06T10:17:28 https://maestrodatabase.com/blog/update-on-smc-remobilisation 2020-10-06T10:48:01 https://maestrodatabase.com/blog/ispors-real-world-evidence-transparency-initiative-creating-a-road-map-that-builds-trust 2020-10-06T20:31:08 https://maestrodatabase.com/blog/bridgebio-pharma-announces-us-fda-acceptance-of-new-drug-application-for-acoramidis-for-the-treatment-of-patients-with-transthyretin-amyloid-cardiomyopathy 2024-02-06T04:15:20 https://maestrodatabase.com/blog/department-publishes-yet-another-revised-agenda-for-november-pbac-meeting 2020-10-06T20:10:06 https://maestrodatabase.com/blog/supreme-court-wary-of-letting-states-regulate-prescription-drug-middlemen 2020-10-06T20:17:51 https://maestrodatabase.com/blog/next-generation-wet-amd-therapy-beovu-now-available-in-canada-receives-positive-recommendation-from-cadth-drug-expert-committee 2020-10-06T20:22:54 https://maestrodatabase.com/blog/collaboration-creates-roadmap-in-canada-to-report-real-world-evidence-studies 2023-05-18T21:11:50 https://maestrodatabase.com/blog/fda-approves-first-oral-treatment-for-moderately-to-severely-active-crohns-disease 2023-05-18T20:57:10 https://maestrodatabase.com/blog/helping-with-health-costs-prescription-charge-scrapped-providing-cheaper-medicine 2023-05-18T21:08:18 https://maestrodatabase.com/blog/ontario-family-of-toddler-with-rare-disorder-seeks-funding-for-expensive-drug 2018-03-01T04:55:42 https://maestrodatabase.com/blog/nice-draft-guidance-recommends-new-treatment-for-chronic-heart-failure 2023-05-18T20:52:44 https://maestrodatabase.com/blog/elevar-therapeutics-submits-new-drug-application-to-fda-for-combination-of-rivoceranib-and-camrelizumab-as-first-line-treatment-option-for-unresectable-hepatocellular-carcinoma 2023-05-18T03:14:35 https://maestrodatabase.com/blog/updates-to-the-hta-review-consultation-2-survey 2024-02-06T20:31:19 https://maestrodatabase.com/blog/private-health-insurance-tipped-to-be-a-luxury-for-one-in-five 2017-07-31T20:57:44 https://maestrodatabase.com/blog/arvinas-and-pfizers-vepdegestrant-arv-471-receives-fda-fast-track-designation-for-the-treatment-of-patients-with-er-positive-slash-her2-negative-metastatic-breast-cancer 2024-02-06T20:13:48 https://maestrodatabase.com/blog/abbvie-to-remain-cautious-on-drug-pricing 2017-07-31T21:15:59 https://maestrodatabase.com/blog/japan-oks-public-insurance-coverage-for-sma-drug-zolgensma 2020-05-14T02:55:41 https://maestrodatabase.com/blog/chiesi-global-rare-diseases-announces-health-canada-approval-of-myalepta-metreleptin-for-injection-for-the-treatment-of-patients-with-lipodystrophy 2024-02-06T05:37:23 https://maestrodatabase.com/blog/izalontamab-brengitecan-egfrxher3-adc-granted-breakthrough-therapy-designation-by-us-fda-for-patients-with-previously-treated-advanced-egfr-mutated-non-small-cell-lung-cancer 2025-08-20T17:07:00 https://maestrodatabase.com/blog/bupas-call-to-scrap-approval-process-for-health-cover-premiums 2017-07-31T21:00:47 https://maestrodatabase.com/blog/amgen-submits-supplemental-biologics-license-application-for-prolia-denosumab-in-glucocorticoid-induced-osteoporosis 2017-07-31T21:25:25 https://maestrodatabase.com/blog/friction-in-the-path-to-use-of-biosimilar-drugs 2018-03-01T05:22:03 https://maestrodatabase.com/blog/amgen-and-allergan-submit-biosimilar-biologics-license-application-for-abp-980-to-us-food-and-drug-administration 2017-07-31T21:21:33 https://maestrodatabase.com/blog/nice-position-statement-chemotherapy-dose-standardisation 2018-03-01T05:26:51 https://maestrodatabase.com/blog/bioaegis-therapeutics-awarded-second-fda-fast-track-designation-for-recombinant-human-gelsolin-to-treat-inflammasome-driven-decompression-sickness 2025-08-21T00:21:58 https://maestrodatabase.com/blog/celltrion-and-teva-announce-u-dot-s-fda-acceptance-of-biologics-license-application-for-proposed-biosimilar-to-herceptin-trastuzumab 2017-07-31T21:29:15 https://maestrodatabase.com/blog/swissmedic-approves-carbetocin-ferring-for-the-prevention-of-postpartum-haemorrhage-in-all-births 2020-05-14T03:33:51 https://maestrodatabase.com/blog/express-scripts-to-cover-mylans-epipen-exclude-rivals 2017-07-31T21:35:05 https://maestrodatabase.com/blog/galera-therapeutics-receives-fda-breakthrough-therapy-designation-for-gc4419-for-the-reduction-of-severe-oral-mucositis 2018-03-01T06:38:02 https://maestrodatabase.com/blog/imfinzi-granted-breakthrough-therapy-designation-by-us-fda-for-patients-with-locally-advanced-unresectable-non-small-cell-lung-cancer 2017-07-31T21:42:36 https://maestrodatabase.com/blog/pharmac-to-work-with-others-to-improve-communication 2021-05-21T01:34:02 https://maestrodatabase.com/blog/eu-states-set-for-squabble-over-who-gets-londons-agencies-after-brexit 2017-07-31T21:39:06 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-august-2017 2017-07-31T21:51:15 https://maestrodatabase.com/blog/new-system-speeds-fda-import-decisions 2017-07-31T21:47:57 https://maestrodatabase.com/blog/rhythm-pharmaceuticals-announces-fda-acceptance-of-snda-for-setmelanotide-in-acquired-hypothalamic-obesity 2025-08-21T01:14:28 https://maestrodatabase.com/blog/oia-response-effect-of-covid-19-on-medicine-supply 2020-05-14T04:11:43 https://maestrodatabase.com/blog/sorrento-therapeutics-subsidiary-scilex-receives-us-fda-approval-for-non-opioid-ztlido-lignocaine-topical-system-1-dot-8-percent-for-phn-pain 2018-03-01T06:52:20 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac---july-2022 2022-08-19T08:39:39 https://maestrodatabase.com/blog/consumer-comments-needed-for-proposed-new-listings-on-the-pbs 2020-05-14T04:08:05 https://maestrodatabase.com/blog/serious-shortages-substitution-notice 2020-05-14T05:18:26 https://maestrodatabase.com/blog/fda-grants-priority-review-of-sutimlimab-potential-first-approved-treatment-of-haemolysis-in-adult-patients-with-cold-agglutinin-disease 2020-05-14T05:10:15 https://maestrodatabase.com/blog/tga-evaluating-first-monoclonal-antibody-treatment-for-covid-19-sotrovimab---glaxosmithkline 2021-05-21T02:26:35 https://maestrodatabase.com/blog/four-more-eu-member-states-benefit-from-eu-us-mutual-recognition-agreement-for-inspections 2018-03-01T20:11:28 https://maestrodatabase.com/blog/ionis-announces-fda-acceptance-of-new-drug-application-for-donidalorsen-for-prophylactic-treatment-of-hae 2024-11-04T23:14:44 https://maestrodatabase.com/blog/samsung-bioepis-and-biogen-announce-ema-filing-acceptance-of-sb11-a-proposed-biosimilar-referencing-lucentis-ranibizumab 2020-10-07T01:24:25 https://maestrodatabase.com/blog/gsks-rsv-vaccine-arexvy-accepted-under-priority-review-in-us-for-the-prevention-of-rsv-disease-in-adults-aged-50-59-at-increased-risk 2024-02-07T02:58:09 https://maestrodatabase.com/blog/four-new-rare-disease-treatments-awaiting-nice-review 2018-03-01T20:30:10 https://maestrodatabase.com/blog/nice-nod-for-merck-slash-pfizers-bavencio 2018-03-01T20:14:08 https://maestrodatabase.com/blog/electra-therapeutics-receives-fda-fast-track-designation-for-ela026-in-secondary-haemophagocytic-lymphohistiocytosis 2024-11-05T00:08:24 https://maestrodatabase.com/blog/allergan-announces-fda-has-extended-the-ulipristal-acetate-nda-review-period-to-august-2018 2018-03-01T20:18:24 https://maestrodatabase.com/blog/european-commission-approves-oncopeptides-pepaxti-for-the-treatment-of-patients-with-relapsed-refractory-multiple-myeloma 2022-08-19T09:17:19 https://maestrodatabase.com/blog/dawnzera-donidalorsen-approved-in-the-us-as-first-and-only-rna-targeted-prophylactic-treatment-for-hereditary-angioedema 2025-08-21T20:20:38 https://maestrodatabase.com/blog/under-trump-the-pace-of-fda-regulations-slowed-to-a-trickle 2018-03-01T20:43:49 https://maestrodatabase.com/blog/russia-says-search-for-a-coronavirus-treatment-should-not-be-a-medical-arms-race 2020-05-14T11:01:07 https://maestrodatabase.com/blog/fibrogen-granted-fast-track-designation-by-u-dot-s-fda-for-pamrevlumab-treatment-of-patients-with-locally-advanced-unresectable-pancreatic-cancer 2018-03-01T20:35:07 https://maestrodatabase.com/blog/swissmedic-reviewing-astrazenecas-covid-19-vaccine 2020-10-07T02:14:15 https://maestrodatabase.com/blog/dupilumab-in-atopic-dermatitis-indication-of-added-benefit-in-adults 2018-03-01T20:53:49 https://maestrodatabase.com/blog/european-medicines-agency-confirms-acceptance-of-marketing-authorisation-application-for-avt05-a-proposed-biosimilar-to-simponi-golimumab 2024-11-05T01:15:35 https://maestrodatabase.com/blog/veongen-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-designation-for-vg801-gene-therapy-for-stargardt-disease 2025-08-21T22:44:59 https://maestrodatabase.com/blog/will-personalised-medicine-mean-higher-costs-for-consumers 2018-03-01T20:46:39 https://maestrodatabase.com/blog/icers-cost-model-is-not-only-wrong-its-also-dangerous 2020-05-14T11:33:23 https://maestrodatabase.com/blog/health-economic-assessment-of-spravato-in-treatment-resistant-depression 2020-05-14T11:53:53 https://maestrodatabase.com/blog/cost-of-epipens-putting-children-at-risk-specialists-say 2019-05-19T02:45:56 https://maestrodatabase.com/blog/drug-authority-decision-wipes-dozens-of-lifesaving-new-medicines-from-pipeline 2024-11-05T02:11:34 https://maestrodatabase.com/blog/stealth-biotherapeutics-announces-fda-acceptance-of-elamipretide-nda-resubmission 2025-08-21T20:59:12 https://maestrodatabase.com/blog/aegle-therapeutics-receives-rare-paediatric-disease-designation-from-the-fda-for-agle-102-for-patients-with-dystrophic-epidermolysis-bullosa 2020-10-07T03:00:17 https://maestrodatabase.com/blog/eton-pharmaceuticals-submits-new-drug-application-to-the-fda-for-topiramate-oral-solution 2020-10-07T03:26:40 https://maestrodatabase.com/blog/terminally-ill-kiwi-mum-forced-to-pay-nearly-6-500-dollars-a-month-for-unfunded-drugs-for-her-lung-cancer 2018-10-10T10:18:40 https://maestrodatabase.com/blog/ineffective-treatments-to-be-removed-from-basic-health-insurance-package 2020-10-07T04:16:10 https://maestrodatabase.com/blog/xlh-patients-to-get-routine-access-to-first-new-therapy-in-30-years 2018-10-10T08:25:00 https://maestrodatabase.com/blog/australians-want-cheaper-medicines-quicker 2019-05-19T20:49:12 https://maestrodatabase.com/blog/oncternal-therapeutics-receives-rare-paediatric-disease-designation-from-u-dot-s-fda-for-tk216-for-treatment-of-ewing-sarcoma 2020-10-07T03:06:58 https://maestrodatabase.com/blog/pharmac-confirms-their-new-way-of-contracting-for-medicines 2020-10-07T03:11:08 https://maestrodatabase.com/blog/digital-technology-could-revolutionise-drug-reimbursement-in-spain 2018-10-10T10:24:41 https://maestrodatabase.com/blog/santhera-to-discontinue-phase-3-sideros-trial-and-development-of-puldysa-in-duchenne-muscular-dystrophy-and-focus-on-vamorolone 2020-10-07T03:18:02 https://maestrodatabase.com/blog/trump-administration-backs-off-medicare-drug-pricing-rule 2019-05-19T21:05:13 https://maestrodatabase.com/blog/biosimilar-bevacizumab-on-the-pbs---information-for-health-professionals-and-patients 2021-05-21T05:09:26 https://maestrodatabase.com/blog/house-passes-legislation-aiming-to-shore-up-health-law-and-lower-drug-costs 2019-05-19T21:02:48 https://maestrodatabase.com/blog/new-listings-for-opioid-medications-on-the-palliative-care-schedule-for-the-management-of-severe-disabling-pain-from-1-june-2021 2021-05-21T06:22:31 https://maestrodatabase.com/blog/coronavirus-vaccine-could-be-ready-in-a-year-eu-medicine-agency 2020-05-14T21:02:09 https://maestrodatabase.com/blog/push-for-drug-pricing-transparency-strikes-a-nerve-with-industry 2019-05-19T20:54:30 https://maestrodatabase.com/blog/icer-appoints-new-members-to-each-of-its-three-independent-evidence-appraisal-councils 2020-05-14T20:42:35 https://maestrodatabase.com/blog/gileads-21-000-dollars-drug-is-being-blamed-for-a-plateau-in-hiv-prevention 2019-05-19T21:15:41 https://maestrodatabase.com/blog/camurus-buvidal-reimbursed-in-sweden-for-the-treatment-of-opioid-dependence 2020-05-14T20:46:18 https://maestrodatabase.com/blog/san-francisco-santa-clara-alameda-counties-join-governor-newsom-to-lower-drug-prices 2019-05-19T21:07:21 https://maestrodatabase.com/blog/sunovion-discontinues-dasotraline-program 2020-05-14T20:52:01 https://maestrodatabase.com/blog/funding-for-eye-drug-decreases-wait-times-and-treatment-costs 2018-10-10T20:08:06 https://maestrodatabase.com/blog/dont-write-us-off-advanced-breast-cancer-patients-lobby-for-access-to-drugs 2018-10-10T20:04:36 https://maestrodatabase.com/blog/trump-administration-caves-to-pharma-on-medicare-part-d-protected-classes-reform 2019-05-19T21:20:56 https://maestrodatabase.com/blog/u-dot-s-fda-grants-priority-review-of-maribavir-for-the-treatment-of-post-transplant-recipients-with-cytomegalovirus-infection-in-those-resistant-and-slash-or-refractory-to-prior-anti-cmv-treatment 2021-05-21T13:10:12 https://maestrodatabase.com/blog/27-million-americans-may-lose-health-insurance-coverage 2020-05-14T21:06:05 https://maestrodatabase.com/blog/questions-about-funding-and-purpose-loom-over-a-foundation-congress-created-to-help-the-fda 2018-10-10T20:21:38 https://maestrodatabase.com/blog/nice-recommends-rinvoq-upadacitinib-as-a-treatment-option-for-moderately-to-severely-active-crohns-disease 2023-05-19T08:00:31 https://maestrodatabase.com/blog/china-nmpa-approves-optune-for-the-treatment-of-newly-diagnosed-and-recurrent-glioblastoma 2020-05-14T21:13:04 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-to-publish-upcoming-assessments-on-treatments-for-secondary-progressive-multiple-sclerosis-treatment-resistant-depression 2018-10-10T20:15:39 https://maestrodatabase.com/blog/belimumab-in-active-systemic-lupus-erythematosus-additional-benefit-for-children-and-adolescents 2020-05-14T21:23:34 https://maestrodatabase.com/blog/japans-pmda-had-shortest-review-times-for-new-drugs-half-of-drugs-submitted-to-us-first 2025-08-21T23:42:13 https://maestrodatabase.com/blog/junshi-biosciences-announces-nmpa-accepted-supplemental-new-drug-application-for-toripalimab-in-combination-with-chemotherapy-as-first-line-treatment-of-advanced-nsclc 2021-12-11T09:17:17 https://maestrodatabase.com/blog/cure-for-cancer-would-become-more-likely-if-fda-streamlined-the-drug-approval-process 2018-10-10T20:34:46 https://maestrodatabase.com/blog/medicare-provides-continued-access-to-high-quality-health-coverage-choices-in-2019 2018-10-10T20:24:00 https://maestrodatabase.com/blog/kapruvia-approved-in-switzerland-with-additional-regulatory-decisions-expected-in-h2-2022 2022-08-20T04:01:42 https://maestrodatabase.com/blog/picking-winners-and-losers-among-cystic-fibrosis-patients 2018-10-10T20:31:07 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-amivantamab-vmjw-for-metastatic-non-small-cell-lung-cancer 2021-05-21T21:55:10 https://maestrodatabase.com/blog/fresenius-kabi-announces-acceptance-of-its-marketing-authorisation-application-by-the-european-medicines-agency-for-msb11456-a-tocilizumab-biosimilar-candidate 2022-08-20T03:50:48 https://maestrodatabase.com/blog/aetna-sued-for-systematically-denying-care-to-patients 2018-10-10T20:42:06 https://maestrodatabase.com/blog/why-its-not-so-simple-to-standardise-the-guides-insurers-use-to-pay-for-off-label-cancer-drugs 2018-10-10T20:47:02 https://maestrodatabase.com/blog/implementation-of-stage-2-pbs-process-improvements-from-1-january-2021 2020-10-07T05:15:46 https://maestrodatabase.com/blog/trump-signs-bills-aimed-at-increasing-drug-price-transparency 2018-10-10T20:37:31 https://maestrodatabase.com/blog/fda-approves-first-topical-gene-therapy-for-treatment-of-wounds-in-patients-with-dystrophic-epidermolysis-bullosa 2023-05-19T20:47:34 https://maestrodatabase.com/blog/new-drugs-how-much-are-governments-paying-for-innovation 2018-10-10T20:54:44 https://maestrodatabase.com/blog/european-commission-approves-celltrion-healthcares-vegzelma-ct-p16-biosimilar-bevacizumab-for-the-treatment-of-multiple-types-of-cancer 2022-08-20T04:37:21 https://maestrodatabase.com/blog/bausch-plus-lomb-and-novaliq-announce-fda-approval-of-miebo-perfluorohexyloctane-ophthalmic-solution-for-the-treatment-of-the-signs-and-symptoms-of-dry-eye-disease 2023-05-19T21:04:09 https://maestrodatabase.com/blog/belumosudil-mesylate-for-the-treatment-of-patients-with-chronic-graft-versus-host-disease 2024-02-07T06:02:25 https://maestrodatabase.com/blog/health-canada-grants-marketing-authorisation-for-an-additional-indication-of-bayers-nubeqa-darolutamide-for-the-treatment-of-metastatic-castration-sensitive-prostate-cancer 2025-08-22T01:31:29 https://maestrodatabase.com/blog/private-health-insurance-simpler-and-cheaper-for-everyday-australians 2018-10-11T00:15:24 https://maestrodatabase.com/blog/axsome-therapeutics-announces-fda-approval-of-auvelity-the-first-and-only-oral-nmda-receptor-antagonist-for-the-treatment-of-major-depressive-disorder-in-adults 2022-08-20T05:38:38 https://maestrodatabase.com/blog/vaxzevria-further-advice-on-blood-clots-and-low-blood-platelets 2021-05-21T22:21:46 https://maestrodatabase.com/blog/health-canada-approves-covid-19-booster-dose-for-kids-5-to-11 2022-08-20T05:32:02 https://maestrodatabase.com/blog/update-on-fda-review-of-vtama-tapinarof-cream-1-percent-for-the-treatment-of-atopic-dermatitis-in-adults-and-children-2-years-of-age-and-older 2024-11-05T20:40:18 https://maestrodatabase.com/blog/leqvio-advances-toward-broader-access-with-agreement-between-novartis-and-the-pan-canadian-pharmaceutical-alliance 2025-08-22T03:01:57 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-epcoritamab-bysp-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-and-high-grade-b-cell-lymphoma 2023-05-19T21:25:27 https://maestrodatabase.com/blog/ema-issues-advice-on-use-of-sotrovimab-vir-7831-for-treating-covid-19 2021-05-21T23:03:00 https://maestrodatabase.com/blog/fda-and-ema-launch-parallel-scientific-advice-pilot-program-for-complex-generics 2024-02-07T20:20:56 https://maestrodatabase.com/blog/pbac-drug-utilisation-sub-committee-utilisation-analysis-public-release-documents 2018-03-02T01:20:09 https://maestrodatabase.com/blog/new-reforms-to-prescription-drug-pricing-in-the-us-opportunities-and-challenges 2022-08-20T07:06:08 https://maestrodatabase.com/blog/fda-grants-latozinemab-breakthrough-therapy-designation-for-frontotemporal-dementia-due-to-a-progranulin-gene-mutation 2024-02-07T20:15:10 https://maestrodatabase.com/blog/olaparib-in-combination-with-abiraterone-acetate-for-the-treatment-of-patients-with-hormone-relapsed-metastatic-prostate-cancer 2024-02-07T10:06:51 https://maestrodatabase.com/blog/nivolumab-with-relatlimab-for-the-treatment-of-patients-with-unresectable-or-metastatic-melanoma 2024-02-07T06:49:49 https://maestrodatabase.com/blog/breakthrough-life-extending-combination-treatment-for-advanced-bladder-cancer-recommended-by-nice 2025-08-22T02:30:11 https://maestrodatabase.com/blog/regulatory-considerations-to-keep-pace-with-innovation-in-digital-health-products 2022-08-20T07:01:31 https://maestrodatabase.com/blog/growing-medicines-waiting-list-an-international-disgrace 2019-10-30T05:45:53 https://maestrodatabase.com/blog/dupixent-dupilumab-now-approved-in-european-union-for-severe-chronic-rhinosinusitis-with-nasal-polyposis 2019-10-30T05:33:52 https://maestrodatabase.com/blog/intravenous-benlysta-is-the-first-biologic-treatment-to-be-approved-for-children-with-lupus-in-europe 2019-10-30T05:30:27 https://maestrodatabase.com/blog/rhythm-pharmaceuticals-announces-positive-reimbursement-decision-in-italy-for-imcivree-setmelanotide-for-the-treatment-of-obesity-and-control-of-hunger-in-bardet-biedl-syndrome 2024-02-07T20:34:24 https://maestrodatabase.com/blog/bristol-myers-squibb-announces-acceptance-of-us-and-eu-regulatory-filings-for-neo-adjuvant-opdivo-nivolumab-and-chemotherapy-followed-by-surgery-and-adjuvant-opdivo-in-resectable-non-small-cell-lung-cancer 2024-02-07T20:26:51 https://maestrodatabase.com/blog/swiss-drug-prices-still-much-higher-than-abroad 2023-05-19T21:56:24 https://maestrodatabase.com/blog/ema-validates-marketing-authorisation-application-for-efanesoctocog-alfa-for-treatment-of-haemophilia-a 2023-05-20T01:08:41 https://maestrodatabase.com/blog/eli-lilly-asks-fda-to-authorise-covid-19-antibody-drug 2020-10-07T19:44:39 https://maestrodatabase.com/blog/new-online-platform-for-scientific-advice 2020-10-07T19:51:13 https://maestrodatabase.com/blog/double-dippers-drive-up-drug-costs 2020-10-07T19:58:21 https://maestrodatabase.com/blog/doh-publishes-revised-agenda-for-november-2025-pbac-meeting-version-2 2025-08-22T04:55:38 https://maestrodatabase.com/blog/emergency-use-authorisation-of-remdesivir-the-need-for-a-transparent-distribution-process 2020-05-14T23:15:20 https://maestrodatabase.com/blog/fda-issues-guidance-on-emergency-use-authorisation-for-covid-19-vaccines 2020-10-07T19:39:47 https://maestrodatabase.com/blog/health-insurers-sit-on-pot-of-gold-say-private-hospitals 2021-05-21T23:38:34 https://maestrodatabase.com/blog/pharmas-likely-to-sue-over-medicare-negotiation-here-are-the-arguments-they-might-use 2022-08-20T23:17:01 https://maestrodatabase.com/blog/private-health-insurance-still-confuses-australian-customers-despite-reforms-choice-finds 2019-10-30T06:59:55 https://maestrodatabase.com/blog/father-invents-balance-treatment-device-for-daughter-makes-history-with-fda-clearance-and-breakthrough-device-designation 2022-08-20T23:00:47 https://maestrodatabase.com/blog/health-insurance-how-much-will-you-pay-to-boost-specialists-incomes 2019-10-30T06:57:22 https://maestrodatabase.com/blog/improving-the-use-of-fda-advisory-committees 2022-08-20T22:57:01 https://maestrodatabase.com/blog/european-countries-face-shortages-of-covid-19-drug-remdesivir 2020-10-07T20:12:23 https://maestrodatabase.com/blog/janssen-submits-european-marketing-authorisation-application-for-esketamine-nasal-spray-for-treatment-resistant-depression 2018-10-11T05:11:05 https://maestrodatabase.com/blog/countries-pledge-nearly-us$1-billion-to-support-equitable-access-to-covid-19-vaccines 2020-10-07T20:31:34 https://maestrodatabase.com/blog/icer-posts-draft-scoping-document-for-the-assessment-of-treatments-for-non-alcoholic-steatohepatitis 2019-10-30T09:25:25 https://maestrodatabase.com/blog/the-hidden-wave-what-happens-when-everything-else-is-put-on-hold 2020-05-15T02:24:28 https://maestrodatabase.com/blog/ema-and-fda-accept-marketing-applications-for-chugais-satralizumab-in-neuromyelitis-optica-spectrum-disorder 2019-10-30T10:45:57 https://maestrodatabase.com/blog/donald-trump-back-in-oval-office-pledges-drugs-he-got-to-all-for-free 2020-10-08T01:18:30 https://maestrodatabase.com/blog/the-cancer-growing-in-cancer-medicine-pharma-money-paid-to-doctors 2019-10-30T10:30:34 https://maestrodatabase.com/blog/inaugural-chief-advisor-maori-appointed-to-pharmac 2020-10-08T01:23:55 https://maestrodatabase.com/blog/nda-submission-for-polareans-hyperpolarised-129-xenon-gas-drug-device-diagnostic-for-lung-imaging 2020-10-08T03:48:42 https://maestrodatabase.com/blog/biogen-and-alkermes-announce-fda-approval-of-vumerity-diroximel-fumarate-for-multiple-sclerosis 2019-10-30T19:30:20 https://maestrodatabase.com/blog/mapping-of-health-technology-assessment-in-china-situation-analysis-and-international-comparison 2019-10-30T19:25:26 https://maestrodatabase.com/blog/model-assisted-designs-for-early-phase-clinical-trials-simplicity-meets-superiority 2019-10-30T10:57:26 https://maestrodatabase.com/blog/house-democrats-clash-over-pelosis-drug-pricing-bill 2019-10-30T19:48:55 https://maestrodatabase.com/blog/health-canada-approves-zeposia-an-oral-treatment-for-relapsing-remitting-multiple-sclerosis 2020-10-08T03:26:32 https://maestrodatabase.com/blog/forced-drug-prices-are-not-the-answer-to-health-care-costs 2019-10-30T19:46:19 https://maestrodatabase.com/blog/to-maintain-trust-and-respectability-digital-health-companies-must-commit-to-the-highest-standards 2020-10-08T03:30:48 https://maestrodatabase.com/blog/democrats-continue-to-have-concerns-about-fda-program-to-streamline-regulation-of-medical-software 2019-10-30T19:41:33 https://maestrodatabase.com/blog/budget-2020-21-improving-access-to-medicines---improving-administration-of-the-pbs-and-patient-support-programs 2020-10-08T03:42:37 https://maestrodatabase.com/blog/mental-illness-costs-180-dollars-billion-study-reveals 2019-10-30T19:36:46 https://maestrodatabase.com/blog/australian-government-finalises-university-of-queensland-csl-covid-19-vaccine-agreement 2020-10-08T05:01:29 https://maestrodatabase.com/blog/sma-patients-protest-inconsistent-reimbursement-standards-for-spinraza 2023-05-20T06:33:21 https://maestrodatabase.com/blog/neuraptive-therapeutics-announces-fda-has-granted-fast-track-designation-to-ntx-001-clinical-development-program-for-treatment-of-patients-with-peripheral-nerve-injuries 2020-05-15T03:59:42 https://maestrodatabase.com/blog/y-mabs-nivatrotamab-for-the-treatment-of-patients-with-neuroblastoma-granted-orphan-drug-designation-and-rare-paediatric-disease-designation-by-fda 2020-10-08T06:44:25 https://maestrodatabase.com/blog/gilead-inks-supply-agreement-with-the-european-commission-for-remdesivir 2020-10-08T09:45:58 https://maestrodatabase.com/blog/new-alzheimers-drug-rejected-for-pbs-listing-leaving-patients-to-pay-up-to-$80k-a-year 2025-08-24T18:12:56 https://maestrodatabase.com/blog/health-insurance-reform-to-make-winners-and-losers 2018-10-11T11:13:09 https://maestrodatabase.com/blog/leukaemia-treatment-patients-cured-by-new-car-t-therapy 2018-10-11T20:15:15 https://maestrodatabase.com/blog/injectable-form-of-ocrevus-for-relapsing-remitting-multiple-sclerosis-recommended-for-pbs-listing 2025-08-25T01:49:42 https://maestrodatabase.com/blog/abpi-tells-mps-brexit-deal-on-medicines-regulation-urgently-needed 2018-10-11T10:18:12 https://maestrodatabase.com/blog/committee-rejects-application-for-medication-keytruda-to-be-subsidised-for-aussies-with-cancer 2025-08-25T02:04:47 https://maestrodatabase.com/blog/accounting-for-us-public-funding-in-drug-development-how-can-we-better-balance-access-affordability-and-innovation 2020-10-08T10:21:26 https://maestrodatabase.com/blog/icer-finds-treatments-prevent-hereditary-angioedema-attacks-but-cost-effectiveness-uncertain-and-sensitive-to-frequency-of-attacks 2018-10-11T20:24:16 https://maestrodatabase.com/blog/ethics-in-health-technology-assessment-a-systematic-review 2018-10-11T20:30:43 https://maestrodatabase.com/blog/rigel-receives-ema-validation-of-the-marketing-authorisation-application-for-fostamatinib-disodium-hexahydrate-in-chronic-immune-thrombocytopenia-in-adult-patients 2018-10-11T20:18:10 https://maestrodatabase.com/blog/vaccine-suppliers-given-indemnity-for-inevitable-side-effects 2020-10-08T10:41:41 https://maestrodatabase.com/blog/csl-confirms-uq-vaccine-production-trials-set-for-december 2020-10-08T19:41:11 https://maestrodatabase.com/blog/new-value-assessment-framework-needed-for-biosimilars-white-paper-argues 2018-10-11T20:49:26 https://maestrodatabase.com/blog/regeneron-asks-fda-for-emergency-approval-for-drug-that-trump-claimed-cured-him 2020-10-08T09:58:16 https://maestrodatabase.com/blog/association-between-fda-and-ema-expedited-approval-programs-and-therapeutic-value-of-new-medicines-retrospective-cohort-study 2020-10-08T10:07:05 https://maestrodatabase.com/blog/fda-again-approves-record-breaking-number-of-generic-drugs 2018-10-11T20:35:14 https://maestrodatabase.com/blog/hls-announces-that-vascepa-is-now-reimbursed-by-british-columbias-provincial-drug-plan 2024-02-08T01:38:59 https://maestrodatabase.com/blog/sandoz-announces-global-resolution-of-biosimilar-adalimumab-patent-disputes-securing-patient-access 2018-10-11T20:39:26 https://maestrodatabase.com/blog/china-approves-17-anti-cancer-drugs-for-medical-insurance-coverage 2018-10-11T20:55:47 https://maestrodatabase.com/blog/insurance-pharma-figures-spar-over-drug-price-legislations-innovation-impact 2019-10-31T00:15:12 https://maestrodatabase.com/blog/fda-approves-new-dna-based-test-to-determine-blood-compatibility 2018-10-11T20:58:07 https://maestrodatabase.com/blog/ozempic-restrictions-for-weight-loss-unfair-obesity-expert-says 2022-08-21T08:46:46 https://maestrodatabase.com/blog/secret-health-fund-benefit-list-reveals-the-lowest-paying-insurers 2019-10-31T00:12:36 https://maestrodatabase.com/blog/a-new-era-for-drug-pricing-the-accountable-choice 2018-10-11T20:53:25 https://maestrodatabase.com/blog/proposal-to-widen-access-to-rituximab-and-change-the-funded-brand-for-all-funded-indications-excluding-rheumatoid-arthritis 2019-10-31T00:06:25 https://maestrodatabase.com/blog/is-the-quality-of-evidence-in-health-technology-assessment-deteriorating-over-time-a-case-study-on-cancer-drugs-in-australia 2023-05-21T01:29:41 https://maestrodatabase.com/blog/use-of-real-world-evidence-to-support-fda-approval-of-oncology-drugs 2020-10-08T19:44:09 https://maestrodatabase.com/blog/astrazeneca-vaccine-document-shows-limit-of-no-profit-pledge 2020-10-08T19:52:19 https://maestrodatabase.com/blog/seattle-genetics-announces-adcetris-brentuximab-vedotin-receives-european-commission-approval-for-treatment-of-adult-patients-with-previously-untreated-systemic-anaplastic-large-cell-lymphoma 2020-05-15T06:05:43 https://maestrodatabase.com/blog/atagi-statement-on-the-omicron-variant-and-timing-of-covid-19-booster-vaccination 2021-12-12T00:05:01 https://maestrodatabase.com/blog/janssen-announces-health-canada-approval-of-darzalex-daratumumab-in-combination-with-lenalidomide-and-dexamethasone-for-newly-diagnosed-patients-with-multiple-myeloma-who-are-transplant-ineligible 2019-10-31T01:54:30 https://maestrodatabase.com/blog/recommendations-made-the-pbac---july-2025 2025-08-25T02:25:31 https://maestrodatabase.com/blog/bewildering-pbac-decision-a-missed-opportunity-to-ensure-australian-cancer-patients-not-left-behind 2025-08-25T02:27:20 https://maestrodatabase.com/blog/european-commission-approves-tablet-formulation-of-beone-medicines-brukinsa-for-all-approved-indications 2025-08-25T02:39:37 https://maestrodatabase.com/blog/new-opioid-overdose-tool-added-to-pbs-will-save-australian-lives 2019-10-31T02:11:03 https://maestrodatabase.com/blog/health-canada-approves-roches-columvi-glofitamab-as-the-first-bi-specific-antibody-in-canada-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-after-initial-therapy 2025-08-25T02:44:23 https://maestrodatabase.com/blog/response-to-media-on-new-mbs-items-for-eating-disorders 2019-10-31T02:07:33 https://maestrodatabase.com/blog/fdas-strengthened-global-inspection-program-helps-ensure-generic-drug-safety 2019-05-20T02:33:58 https://maestrodatabase.com/blog/knight-therapeutics-announces-launch-of-bijuva-in-canada 2024-02-08T02:24:10 https://maestrodatabase.com/blog/moderna-receives-health-canada-approval-for-updated-covid-19-vaccine-targeting-sars-cov-2-variant-lp-dot-8-1 2025-08-25T02:53:25 https://maestrodatabase.com/blog/pbs-pharmaceuticals-in-hospitals-review 2019-05-20T04:21:13 https://maestrodatabase.com/blog/korean-government-to-reduce-biopharmaceutical-approval-period-to-half 2019-05-20T11:11:54 https://maestrodatabase.com/blog/health-technology-assessment-consumer-consultative-committee-march-2019-meeting-communique 2019-05-20T07:56:39 https://maestrodatabase.com/blog/health-canada-approves-brukinsa-zanubrutinib-for-the-treatment-of-relapsed-or-refractory-follicular-lymphoma 2024-02-08T10:38:01 https://maestrodatabase.com/blog/pharmac-to-fully-fund-testosterone-gel-for-all-who-need-it 2024-02-08T05:52:39 https://maestrodatabase.com/blog/icer-plans-cloud-based-tools-to-accelerate-the-use-of-value-assessments-in-the-us-health-care-system 2019-05-20T11:15:57 https://maestrodatabase.com/blog/merus-receives-fda-extension-of-pdufa-for-zenocutuzumab 2024-11-06T00:23:54 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-november-2019 2019-10-31T10:53:36 https://maestrodatabase.com/blog/crovalimab-approved-in-china-as-the-first-country-for-the-treatment-of-paroxysmal-nocturnal-haemoglobinuria 2024-02-08T20:21:28 https://maestrodatabase.com/blog/u-dot-s-food-and-drug-administration-approves-bristol-myers-squibbs-pomalyst-pomalidomide-for-aids-related-and-hiv-negative-kaposi-sarcoma 2020-05-15T21:12:04 https://maestrodatabase.com/blog/in-a-showy-hearing-bernie-sanders-gets-few-answers-about-lower-drug-prices 2024-02-08T20:15:30 https://maestrodatabase.com/blog/j-and-j-merck-and-bristol-myers-ceos-defend-high-drug-prices-in-senate-hearing-as-biden-tries-to-cut-costs 2024-02-08T20:11:36 https://maestrodatabase.com/blog/eplontersen-granted-us-fda-fast-track-designation-for-patients-with-transthyretin-mediated-amyloid-cardiomyopathy 2024-02-08T20:04:46 https://maestrodatabase.com/blog/datroway-approved-in-china-for-patients-with-previously-treated-metastatic-hr-positive-her2-negative-breast-cancer 2025-08-26T01:04:50 https://maestrodatabase.com/blog/journey-medical-announces-us-fda-approval-of-emrosi-minocycline-hydrochloride-extended-release-capsules-40-mg-for-the-treatment-of-rosacea 2024-11-06T01:04:41 https://maestrodatabase.com/blog/the-role-of-disclosures-helping-to-understand-oncology-clinical-trial-endpoints 2023-05-22T20:56:12 https://maestrodatabase.com/blog/ema-publishes-agenda-for-22-25-may-2023-chmp-meeting 2023-05-22T21:00:40 https://maestrodatabase.com/blog/sangamo-therapeutics-receives-us-fda-fast-track-designation-for-isaralgagene-civaparvovec-for-the-treatment-of-fabry-disease 2023-05-22T20:48:41 https://maestrodatabase.com/blog/a-drug-company-wagers-the-u-dot-s-wont-dare-charge-it-with-crimes 2020-05-15T21:40:08 https://maestrodatabase.com/blog/ucb-announces-nayzilam-midazolam-nasal-spray-now-approved-by-fda-to-treat-intermittent-stereotypic-episodes-of-frequent-seizure-activity-in-people-living-with-epilepsy-in-the-us 2019-05-20T20:54:59 https://maestrodatabase.com/blog/fda-approves-ayvakit-avapritinib-as-the-first-and-only-treatment-for-indolent-systemic-mastocytosis 2023-05-22T20:43:42 https://maestrodatabase.com/blog/international-coordination-needed-to-encourage-conduct-of-large-decision-relevant-covid-19-clinical-trials 2020-05-15T21:19:17 https://maestrodatabase.com/blog/satsuma-pharmaceuticals-announces-fda-acceptance-of-505-b-2-nda-for-sts101-a-novel-and-investigational-dihydroergotamine-nasal-powder-product-for-the-acute-treatment-of-migraine 2023-05-22T02:11:33 https://maestrodatabase.com/blog/the-new-definition-of-health-technology-assessment-a-milestone-in-international-collaboration 2020-05-15T21:25:06 https://maestrodatabase.com/blog/rusfertide-receives-breakthrough-therapy-designation-for-treatment-of-erythrocytosis-in-patients-with-polycythemia-vera 2025-08-26T00:45:51 https://maestrodatabase.com/blog/u-dot-s-fda-approves-opdivo-nivolumab-plus-yervoy-ipilimumab-as-first-line-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-whose-tumours-express-pd-l1-1-percent 2020-05-15T21:29:24 https://maestrodatabase.com/blog/expanded-age-indication-for-gsks-arexvy-the-first-respiratory-syncytial-virus-vaccine-approved-in-canada-for-adults-aged-50-59-at-increased-risk 2024-11-06T01:28:31 https://maestrodatabase.com/blog/europe-responding-to-gene-therapy-challenge-but-picture-remains-fragmented 2019-05-20T21:13:10 https://maestrodatabase.com/blog/putting-a-dollar-value-on-life-governments-already-do 2020-05-15T21:52:56 https://maestrodatabase.com/blog/trump-administration-postpones-some-medicare-drug-cost-proposals 2019-05-20T21:05:47 https://maestrodatabase.com/blog/fda-approves-first-drug-for-fourth-line-treatment-of-advanced-gastro-intestinal-stromal-tumours 2020-05-15T21:55:19 https://maestrodatabase.com/blog/medicine-access-debacle-deepens-with-invoices-for-delayed-services 2024-11-06T02:09:23 https://maestrodatabase.com/blog/event-billed-as-national-pharmacare-forum-dominated-by-groups-opposed-to-universal-drug-plan 2019-05-20T21:33:43 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-rucaparib-for-brca-mutated-metastatic-castration-resistant-prostate-cancer 2020-05-15T21:43:56 https://maestrodatabase.com/blog/ema-urgently-reviewing-multiple-sclerosis-medicine-zinbryta-following-cases-of-inflammatory-brain-disorders 2018-03-02T12:14:35 https://maestrodatabase.com/blog/a-leading-hiv-drug-is-way-overpriced-in-the-us 2019-05-20T21:26:09 https://maestrodatabase.com/blog/australian-technical-advisory-group-on-immunisation-recommendations-on-the-use-of-spikevax-moderna-as-a-covid-19-booster-vaccine 2021-12-12T02:44:10 https://maestrodatabase.com/blog/theresa-may-urges-us-makers-of-cystic-fibrosis-drug-to-strike-crucial-deal-with-nhs 2019-05-20T21:22:28 https://maestrodatabase.com/blog/fenfluramine-hydrochloride-for-the-treatment-of-patients-2-years-of-age-and-older-with-seizures-associated-with-lennox-gastaut-syndrome 2024-11-06T01:52:05 https://maestrodatabase.com/blog/enhertu-approved-in-japan-as-first-her2-directed-medicine-for-patients-with-her2-low-or-her2-ultra-low-metastatic-breast-cancer-following-at-least-one-endocrine-therapy 2025-08-26T01:11:02 https://maestrodatabase.com/blog/fda-to-review-dupixent-dupilumab-as-potential-treatment-for-moderate-to-severe-asthma 2018-03-02T12:19:02 https://maestrodatabase.com/blog/fda-grants-appeal-to-recro-pharma-for-iv-meloxicam-new-drug-application 2019-10-31T11:53:16 https://maestrodatabase.com/blog/biogen-and-abbvie-announce-the-voluntary-worldwide-withdrawal-of-marketing-authorisations-for-zinbryta-daclizumab-for-relapsing-multiple-sclerosis 2018-03-02T20:17:29 https://maestrodatabase.com/blog/where-were-the-women-gender-parity-in-clinical-trials 2019-10-31T11:46:59 https://maestrodatabase.com/blog/ayrmid-announces-fda-acceptance-and-priority-review-for-omidubicel-for-the-treatment-of-severe-aplastic-anaemia 2025-08-26T06:16:55 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-november-2019-update 2019-10-31T11:39:27 https://maestrodatabase.com/blog/european-commission-authorises-twice-yearly-yeytuo-lenacapavir-for-hiv-prevention 2025-08-26T20:07:07 https://maestrodatabase.com/blog/repatha-now-indicated-for-adults-at-increased-risk-for-major-adverse-cardiovascular-events-due-to-uncontrolled-ldl-c 2025-08-26T20:12:56 https://maestrodatabase.com/blog/despite-responsible-price-regeneron-drug-kept-out-of-many-patients-hands-by-payers 2018-03-02T20:25:39 https://maestrodatabase.com/blog/spero-therapeutics-receives-qidp-designation-from-the-u-dot-s-fda-for-the-development-of-spr206 2018-10-12T02:17:51 https://maestrodatabase.com/blog/centessa-pharmaceuticals-receives-fast-track-designation-from-the-us-fda-for-serpinpc-for-haemophilia-b 2023-05-23T00:22:39 https://maestrodatabase.com/blog/tga-fees-and-charges-summary-from-1-july-2018 2018-10-12T02:24:54 https://maestrodatabase.com/blog/tga-grants-provisional-determination-for-sabizabulin-for-the-treatment-of-covid-19 2022-08-22T06:48:36 https://maestrodatabase.com/blog/pierre-fabre-announces-start-of-eu-marketing-authorization-application-procedure-for-vibegron-in-overactive-bladder 2023-05-23T02:36:44 https://maestrodatabase.com/blog/acadia-pharmaceuticals-enters-into-an-agreement-to-sell-its-rare-paediatric-disease-priority-review-voucher-for-150-dollars-million 2024-11-06T03:16:59 https://maestrodatabase.com/blog/gruenenthals-resiniferatoxin-receives-breakthrough-therapy-designation-from-us-fda-for-pain-associated-with-osteoarthritis-of-the-knee 2023-05-23T02:22:27 https://maestrodatabase.com/blog/x4-pharmaceuticals-announces-fast-track-designation-granted-by-the-fda-to-mavorixafor-for-the-treatment-of-whim-syndrome 2020-10-09T00:09:31 https://maestrodatabase.com/blog/allarity-therapeutics-granted-fda-fast-track-designation-for-stenoparib-for-the-treatment-of-advanced-ovarian-cancer 2025-08-26T23:46:22 https://maestrodatabase.com/blog/u-dot-s-fda-approves-xarelto-rivaroxaban-to-reduce-the-risk-of-major-cardiovascular-events-in-patients-with-chronic-coronary-artery-disease-or-peripheral-artery-disease 2018-10-12T05:12:10 https://maestrodatabase.com/blog/kyowa-kirin-receives-european-commission-approval-for-use-of-crysvita-burosumab-for-the-treatment-of-tumour-induced-osteomalacia 2022-08-22T07:43:31 https://maestrodatabase.com/blog/national-medicines-policy-review---registrations-for-targeted-stakeholder-consultation-sessions-and-open-public-forum 2022-08-22T07:22:44 https://maestrodatabase.com/blog/avapritinib-for-the-treatment-of-patients-with-advanced-systemic-mastocytosis 2024-11-06T03:56:16 https://maestrodatabase.com/blog/u-dot-s-fda-grants-rare-paediatric-disease-designation-to-cerecins-investigational-drug-tricaprilin-for-the-treatment-of-infantile-spasms 2020-10-09T01:26:51 https://maestrodatabase.com/blog/genmab-receives-fda-breakthrough-therapy-designation-for-rinatabart-sesutecan-in-advanced-endometrial-cancer 2025-08-27T00:19:21 https://maestrodatabase.com/blog/emas-emergency-task-force-advises-on-intradermal-use-of-imvanex-slash-jynneos-against-monkeypox 2022-08-22T08:06:39 https://maestrodatabase.com/blog/fda-approves-new-buprenorphine-treatment-option-for-opioid-use-disorder 2023-05-23T20:52:57 https://maestrodatabase.com/blog/biomarin-receives-fda-approval-of-label-expansion-to-allow-maximum-dose-of-60-mg-for-palynziq-pegvaliase-pqpz-injection-for-treatment-of-adults-with-pku 2020-10-09T02:00:59 https://maestrodatabase.com/blog/to-improve-access-and-equity-move-vaccine-coverage-to-medicare-part-b 2022-08-22T10:48:30 https://maestrodatabase.com/blog/monkeypox-vaccines-not-expected-until-december 2022-08-22T08:49:52 https://maestrodatabase.com/blog/lumicell-announces-fda-acceptance-and-priority-review-of-new-drug-application-for-lumisight-optical-imaging-agent-for-breast-cancer 2023-05-23T03:59:10 https://maestrodatabase.com/blog/leo-pharma-announces-health-canada-approval-of-anzupgo-for-treatment-of-moderate-to-severe-chronic-hand-eczema 2025-08-27T01:27:47 https://maestrodatabase.com/blog/drug-pricing-reforms-can-hurt-innovation-here-are-3-ways-to-prevent-that 2022-08-22T20:51:07 https://maestrodatabase.com/blog/cereno-scientific-granted-fda-fast-track-designation-for-cs1-in-rare-disease-pulmonary-arterial-hypertension 2025-08-27T00:57:01 https://maestrodatabase.com/blog/european-medicines-agency-accepts-rezafungin-marketing-authorisation-application-for-the-treatment-of-invasive-candidiasis 2022-08-22T20:54:13 https://maestrodatabase.com/blog/health-canadas-position-on-the-cadth-guidance-for-reporting-rwe-to-support-decision-making 2023-05-23T21:16:38 https://maestrodatabase.com/blog/minerva-neurosciences-submits-new-drug-application-to-fda-for-roluperidone-for-the-treatment-of-negative-symptoms-in-patients-with-schizophrenia 2022-08-22T20:44:49 https://maestrodatabase.com/blog/bayers-nubeqa-combination-recommended-by-nice-to-treat-metastatic-prostate-cancer 2023-05-23T21:11:47 https://maestrodatabase.com/blog/johnson-and-johnson-announces-european-commission-approval-of-agreement-to-supply-200-million-doses-of-janssens-covid-19-vaccine-candidate 2020-10-09T02:58:47 https://maestrodatabase.com/blog/gilead-announces-first-global-regulatory-approval-of-sunlenca-lenacapavir-the-only-twice-yearly-hiv-treatment-option 2022-08-22T20:37:23 https://maestrodatabase.com/blog/satsuma-pharmaceuticals-and-snbl-resubmits-the-new-drug-application-for-sts101-dihydroergotamine-nasal-powder-for-the-acute-treatment-of-migraine-with-or-without-aura 2024-11-06T10:01:07 https://maestrodatabase.com/blog/dupixent-dupilumab-approved-in-the-european-union-as-the-first-and-only-medicine-for-young-children-with-eosinophilic-oesophagitis 2024-11-06T06:32:20 https://maestrodatabase.com/blog/mhra-to-join-project-orbis 2020-10-09T03:14:08 https://maestrodatabase.com/blog/pfizer-and-biontech-submit-application-to-u-dot-s-fda-for-emergency-use-authorisation-of-omicron-ba-dot-4-slash-ba-dot-5-adapted-bivalent-covid-19-vaccine 2022-08-22T20:33:04 https://maestrodatabase.com/blog/fda-approves-prescription-nasal-spray-to-reverse-opioid-overdose 2023-05-23T20:58:09 https://maestrodatabase.com/blog/the-fda-and-the-clinical-community 2022-08-22T21:09:56 https://maestrodatabase.com/blog/hansa-biopharma-and-medison-pharma-announce-positive-reimbursement-decision-in-poland-for-idefirix-in-highly-sensitised-kidney-transplant-patients 2022-08-22T21:02:29 https://maestrodatabase.com/blog/eton-pharmaceuticals-announces-acceptance-for-filing-of-new-drug-application-for-orphan-drug-dehydrated-alcohol-injection 2020-10-09T06:09:40 https://maestrodatabase.com/blog/amneal-announces-complete-response-resubmission-for-ipx203-new-drug-application 2024-02-09T22:10:55 https://maestrodatabase.com/blog/csl-vifor-and-travere-therapeutics-announce-ema-has-accepted-for-review-the-conditional-marketing-authorisation-application-for-sparsentan-for-the-treatment-of-iga-nephropathy 2022-08-22T20:58:34 https://maestrodatabase.com/blog/new-transparency-measures-for-prescription-medicines 2020-10-09T06:17:10 https://maestrodatabase.com/blog/nomenclature-of-biological-medicines 2017-08-01T08:09:28 https://maestrodatabase.com/blog/hhs-secretary-azar-says-u-dot-s-could-have-enough-coronavirus-vaccine-doses-for-every-american-by-march 2020-10-09T06:22:07 https://maestrodatabase.com/blog/rocket-pharmaceuticals-receives-fda-regenerative-medicine-advanced-therapy-designation-for-rp-l301-gene-therapy-for-pyruvate-kinase-deficiency 2023-05-23T22:05:14 https://maestrodatabase.com/blog/acalabrutinib-granted-breakthrough-therapy-designation-by-us-fda-for-the-treatment-of-patients-with-mantle-cell-lymphoma 2017-08-01T08:14:15 https://maestrodatabase.com/blog/three-imperatives-for-r-and-d-in-biosimilars 2022-08-22T21:14:16 https://maestrodatabase.com/blog/public-summary-documents---november-2017-pbac-meeting 2018-03-18T20:36:33 https://maestrodatabase.com/blog/kite-files-the-industrys-first-car-t-marketing-authorisation-application-in-europe-for-axicabtagene-ciloleucel 2017-08-01T09:25:32 https://maestrodatabase.com/blog/nice-terminates-another-two-assessments-for-cancer-medicines 2019-10-31T14:24:32 https://maestrodatabase.com/blog/johnson-and-johnsons-nipocalimab-granted-us-fda-breakthrough-therapy-designation-for-the-treatment-of-individuals-at-high-risk-for-severe-haemolytic-disease-of-the-foetus-and-newborn 2024-02-09T23:13:33 https://maestrodatabase.com/blog/akebia-announces-uk-mhra-approval-of-vafseo-vadadustat-for-the-treatment-of-symptomatic-anaemia-associated-with-chronic-kidney-disease-in-adults-on-chronic-maintenance-dialysis 2023-05-23T22:34:31 https://maestrodatabase.com/blog/where-to-now-for-pharmac 2021-12-12T20:00:11 https://maestrodatabase.com/blog/otonomy-announces-fda-approval-of-otiprio-for-acute-otitis-externa 2018-03-03T04:33:42 https://maestrodatabase.com/blog/fda-approves-ngs-based-companion-diagnostic-for-egfr-exon20-insertion-mutant-non-small-cell-lung-cancer-tumour-tissue 2021-12-12T19:55:50 https://maestrodatabase.com/blog/free-pricing-in-the-uk-the-influence-of-nice-and-nhs-england 2018-03-03T00:03:54 https://maestrodatabase.com/blog/ema-confirms-move-to-amsterdam 2018-03-03T00:06:11 https://maestrodatabase.com/blog/parallel-distributed-or-parallel-imported-maviret-and-viekirax-remain-in-high-cost-protection 2019-10-31T14:44:17 https://maestrodatabase.com/blog/nda-filing-for-luye-pharmas-anti-depressant-drug-ly03005-accepted-by-the-u-dot-s-fda 2020-10-09T21:50:21 https://maestrodatabase.com/blog/removing-the-blindfold-on-medicines-pricing 2018-03-03T23:55:52 https://maestrodatabase.com/blog/fda-approves-new-treatment-for-pneumonia-caused-by-certain-difficult-to-treat-bacteria 2023-05-23T22:49:19 https://maestrodatabase.com/blog/report-clearly-demonstrates-the-value-of-vaccines 2019-11-01T11:02:39 https://maestrodatabase.com/blog/us-biotech-novavax-could-make-covid-vaccine-onshore-in-australia 2021-05-22T08:45:57 https://maestrodatabase.com/blog/health-canada-approves-inqovi-decitabine-and-cedazuridine-oral-therapy-for-two-types-of-blood-cancers-mds-and-cmml 2020-10-10T02:41:23 https://maestrodatabase.com/blog/why-wont-they-help-him-broken-mother-pleads-for-pharmac-funding-for-toddlers-rare-disorder 2019-11-01T11:11:17 https://maestrodatabase.com/blog/gadoquatrane-new-drug-application-accepted-for-review-by-us-fda 2025-08-27T18:55:11 https://maestrodatabase.com/blog/feilding-epilepsy-sufferer-feared-increased-seizures-following-pharmacs-drug-brand-switch 2019-11-01T11:08:18 https://maestrodatabase.com/blog/indivior-rbp-6000-nda-acceptance-with-priority-review-designation 2017-08-01T11:06:40 https://maestrodatabase.com/blog/biden-harris-administration-announces-proposal-to-advance-prescription-drug-transparency-in-medicaid 2023-05-23T23:23:38 https://maestrodatabase.com/blog/pbac-public-summary-documents---may-2019-meeting 2019-11-01T11:05:04 https://maestrodatabase.com/blog/italfarmaco-receives-fda-rare-paediatric-disease-designation-for-givinostat-in-duchenne-muscular-dystrophy-announces-completed-enrolment-in-epidys-phase-3-trial 2020-10-09T23:15:29 https://maestrodatabase.com/blog/regenxbio-receives-fda-regenerative-medicine-advanced-therapy-designation-for-rgx-121-gene-therapy-for-hunter-syndrome 2023-05-23T23:07:41 https://maestrodatabase.com/blog/zemcelpro-um171-cell-therapy-receives-ec-authorisation-as-the-first-and-only-cell-therapy-for-blood-cancer-patients-without-access-to-suitable-donor-cells 2025-08-27T19:04:19 https://maestrodatabase.com/blog/us-fda-approves-the-cyltezo-pen-a-new-auto-injector-option-ahead-of-1-july-commercial-launch 2023-05-23T23:02:05 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-fda-approval-for-opdivo-nivolumab-in-msi-h-or-dmmr-metastatic-colorectal-cancer-that-has-progressed-following-treatment-with-a-fluoropyrimidine-oxaliplatin-and-irinotecan 2017-08-01T11:17:11 https://maestrodatabase.com/blog/pfizer-canada-and-biontech-initiate-rolling-submission-to-health-canada-for-sars-cov-2-vaccine-candidate-bnt162b2 2020-10-10T02:35:37 https://maestrodatabase.com/blog/icer-report-finds-oral-glp-1-semaglutide-at-estimated-net-price-less-cost-effective-than-sglt-2-competitor-empagliflozin-as-add-on-therapy-for-type-2-diabetes 2019-11-01T11:33:15 https://maestrodatabase.com/blog/spark-therapeutics-submits-marketing-authorisation-application-to-european-medicines-agency-for-investigational-luxturna-voretigene-neparvovec 2017-08-01T11:24:32 https://maestrodatabase.com/blog/ema-prepares-for-brexit 2017-08-01T20:51:43 https://maestrodatabase.com/blog/private-health-cover-forecast-to-become-more-unaffordable-as-insurers-doctors-point-finger 2017-08-01T20:47:38 https://maestrodatabase.com/blog/ema-encourages-tailored-development-of-medicines-for-older-people 2017-08-01T20:54:04 https://maestrodatabase.com/blog/in-landmark-international-program-hta-agencies-around-the-world-access-icers-customisable-covid-19-cost-effectiveness-model 2020-10-10T03:22:11 https://maestrodatabase.com/blog/fda-approves-new-targeted-treatment-for-relapsed-or-refractory-acute-myeloid-leukaemia 2017-08-01T20:58:37 https://maestrodatabase.com/blog/janssen-submits-type-ii-extension-of-indication-application-to-the-ema-seeking-approval-of-rybrevant-amivantamab-in-combination-with-lazertinib-for-first-line-treatment-of-patients-with-egfr-mutated-non-small-cell-lung-cancer 2024-02-10T01:39:13 https://maestrodatabase.com/blog/sanders-to-unveil-rule-requiring-drug-companies-to-set-fair-prices 2017-08-01T21:07:49 https://maestrodatabase.com/blog/vertex-announces-ema-marketing-authorisation-application-validation-for-vx-445-elexacaftor-tezacaftor-and-ivacaftor-triple-combination-treatment-in-cystic-fibrosis 2019-11-01T11:44:20 https://maestrodatabase.com/blog/abbvies-vyalev-foslevodopa-slash-foscarbidopa-solution-available-for-the-treatment-of-advanced-parkinsons-disease-in-canada 2024-02-10T01:11:38 https://maestrodatabase.com/blog/proposed-revisions-to-cadths-biosimilar-review-process 2017-08-01T21:13:14 https://maestrodatabase.com/blog/pbac-public-summary-documents---july-2019-meeting 2019-11-16T05:38:57 https://maestrodatabase.com/blog/express-scripts-will-exclude-more-drugs-next-year-limiting-patient-choice-to-save-health-plans-millions 2017-08-01T21:10:05 https://maestrodatabase.com/blog/health-products-portal-has-a-new-website 2022-08-23T01:31:49 https://maestrodatabase.com/blog/the-americans-who-saved-health-insurance 2017-08-01T21:33:55 https://maestrodatabase.com/blog/sharing-patient-input-submissions-for-the-cdr-program 2017-08-01T21:30:41 https://maestrodatabase.com/blog/revolutionising-ms-treatment-new-form-of-tysabri-recommended-for-pbs-listing 2023-05-24T02:38:13 https://maestrodatabase.com/blog/theresa-may-reveals-uk-willing-to-pay-to-remain-part-of-european-agencies-for-medicine-chemicals-and-aviation 2018-03-04T05:44:01 https://maestrodatabase.com/blog/ema-started-the-evaluation-of-resubmitted-marketing-authorisation-application-for-biosimilar-pegfilgrastim 2018-03-04T05:46:04 https://maestrodatabase.com/blog/lykos-therapeutics-announces-fda-acceptance-and-priority-review-of-new-drug-application-for-mdma-assisted-therapy-for-ptsd 2024-02-10T02:55:12 https://maestrodatabase.com/blog/emergent-biosolutions-announces-granting-of-marketing-authorisation-in-five-eu-countries-for-its-oral-typhoid-vaccine-expands-availability-across-europe 2019-05-21T08:13:26 https://maestrodatabase.com/blog/menarini-groups-elacestrant-marketing-authorisation-application-accepted-for-review-by-the-ema-for-the-treatment-of-er-plus-slash-her2--advanced-or-metastatic-breast-cancer 2022-08-23T02:41:25 https://maestrodatabase.com/blog/new-life-changing-treatment-for-dwarfism-added-to-pbs 2023-05-24T02:45:27 https://maestrodatabase.com/blog/human-acellular-vessel-biologics-license-application-granted-priority-review-by-us-fda-for-the-treatment-of-vascular-trauma 2024-02-10T03:09:27 https://maestrodatabase.com/blog/new-made-in-canada-technique-could-revolutionise-vaccine-transportation 2019-05-21T21:07:32 https://maestrodatabase.com/blog/americans-coming-north-to-fill-prescriptions-on-the-rise-again 2019-05-21T21:01:22 https://maestrodatabase.com/blog/pharmacare---not-all-canadians-not-all-drugs 2019-05-21T20:58:23 https://maestrodatabase.com/blog/the-global-battle-over-high-drug-prices 2019-05-21T20:55:14 https://maestrodatabase.com/blog/could-drug-price-transparency-raise-prices-these-lobbyists-and-lawmakers-think-so 2019-05-21T21:18:59 https://maestrodatabase.com/blog/framework-for-the-regulation-of-regenerative-medicine-products 2019-05-21T21:15:00 https://maestrodatabase.com/blog/south-africas-aspen-sells-australian-prescription-portfolio-to-mylan 2019-05-21T21:11:39 https://maestrodatabase.com/blog/novartis-ceo-gene-therapy-offers-hope-of-cures-in-one-treatment-but-us-needs-new-pricing-and-payment-model 2019-05-21T21:33:42 https://maestrodatabase.com/blog/google-sister-company-verily-is-teaming-with-big-pharma-on-clinical-trials 2019-05-21T21:25:48 https://maestrodatabase.com/blog/isatuximab-in-combination-with-pomalidomide-and-dexamethasone-for-the-treatment-of-patients-with-relapsed-and-refractory-multiple-myeloma 2024-02-10T03:20:13 https://maestrodatabase.com/blog/spinraza-a-life-saving-drug-for-spinal-muscular-atrophy-remains-out-of-reach 2018-03-04T20:20:08 https://maestrodatabase.com/blog/extremely-high-drug-prices-should-be-reviewed-for-appropriateness 2019-05-21T21:21:34 https://maestrodatabase.com/blog/roches-breast-cancer-drug-gains-more-insurance-benefits 2019-05-21T21:47:55 https://maestrodatabase.com/blog/louisiana-is-creating-a-drug-price-revolution 2019-05-21T21:40:07 https://maestrodatabase.com/blog/meiragtx-receives-ema-prime-designation-for-achromatopsia-gene-therapy-candidate 2018-03-04T20:27:47 https://maestrodatabase.com/blog/fda-replaces-withdrawn-biosimilar-guidance-with-new-one-on-quality-related-considerations 2019-05-21T21:36:02 https://maestrodatabase.com/blog/official-information-act-response-prep-data 2019-05-21T21:56:29 https://maestrodatabase.com/blog/official-information-act-response-adrenaline-auto-injector-cost-utility-analysis 2019-05-21T21:51:19 https://maestrodatabase.com/blog/pbac-public-summary-document---may-2023 2023-05-24T06:32:43 https://maestrodatabase.com/blog/premiums-for-most-popular-type-of-obamacare-plan-will-drop-next-year 2018-10-13T07:23:22 https://maestrodatabase.com/blog/quizartinib-marketing-authorisation-application-validated-by-ema-for-treatment-of-adult-patients-with-newly-diagnosed-flt3--itd-positive-acute-myeloid-leukaemia 2022-08-23T06:07:36 https://maestrodatabase.com/blog/fda-approves-stiolto-respimat-supplemental-new-drug-application-to-add-data-on-copd-exacerbation-reduction 2018-10-13T07:27:06 https://maestrodatabase.com/blog/rinvoq-upadacitinib-receives-health-canada-notice-of-compliance-for-giant-cell-arteritis-in-adults 2025-08-28T02:30:59 https://maestrodatabase.com/blog/medicaid-plans-to-audit-the-prices-of-costliest-drugs 2023-05-24T20:53:32 https://maestrodatabase.com/blog/mums-battle-for-life-saving-drug 2018-10-13T07:56:58 https://maestrodatabase.com/blog/can-trump-really-speed-approval-of-covid-treatments 2020-10-11T01:59:50 https://maestrodatabase.com/blog/long-term-survival-and-value-of-chimeric-antigen-receptor-t-cell-therapy-for-paediatric-patients-with-relapsed-or-refractory-leukaemia 2018-10-13T08:22:45 https://maestrodatabase.com/blog/trump-signs-2-drug-pricing-bills-hhs-secretary-promises-more-to-come 2018-10-13T09:00:13 https://maestrodatabase.com/blog/integrative-review-of-managed-entry-agreements-chances-and-limitations 2020-10-11T20:01:46 https://maestrodatabase.com/blog/telix-provides-regulatory-update-on-tlx250-cdx 2025-08-28T18:47:57 https://maestrodatabase.com/blog/moderna-vows-to-not-enforce-covid-19-vaccine-patents-during-pandemic 2020-10-11T20:06:28 https://maestrodatabase.com/blog/veru-granted-expedited-provisional-registration-regulatory-pathway-for-sabizabulin-treatment-in-hospitalised-covid-19-patients-by-australias-tga 2022-08-23T10:18:43 https://maestrodatabase.com/blog/mhra-approves-zuranolone-to-treat-postnatal-depression-in-adults-following-childbirth 2025-08-28T19:03:59 https://maestrodatabase.com/blog/mhra-approves-uks-first-new-type-of-antibiotic-for-urinary-tract-infections-in-nearly-30-years 2025-08-28T19:10:17 https://maestrodatabase.com/blog/european-commission-approves-tevimbra-as-neo-adjuvant-slash-adjuvant-nsclc-treatment 2025-08-28T19:16:04 https://maestrodatabase.com/blog/iecure-receives-fda-rare-paediatric-disease-designation-for-gtp-506-an-investigational-gene-editing-product-candidate-for-the-treatment-of-ornithine-transcarbamylase-deficiency 2022-08-23T20:37:33 https://maestrodatabase.com/blog/synlogic-granted-fda-fast-track-designation-for-synb1353-for-the-treatment-of-homocystinuria 2022-08-23T11:23:45 https://maestrodatabase.com/blog/merck-receives-fast-track-designation-from-the-us-fda-for-mk-2060-an-investigational-anti-coagulant-therapy 2022-08-23T11:15:42 https://maestrodatabase.com/blog/sarepta-therapeutics-announces-update-on-regulatory-review-of-srp-9001 2023-05-24T22:17:41 https://maestrodatabase.com/blog/outlook-therapeutics-provides-regulatory-update-on-us-fda-review-of-ons-5010-slash-lytenava-bevacizumab-vikg-for-the-treatment-of-wet-amd 2025-08-28T18:40:59 https://maestrodatabase.com/blog/health-canada-approves-opdivo-nivolumab-with-chemotherapy-as-neo-adjuvant-treatment-for-adult-patients-with-resectable-non-small-cell-lung-cancer 2022-08-23T21:05:04 https://maestrodatabase.com/blog/hiring-and-data-how-the-us-will-set-up-new-medicare-drug-price-talks 2022-08-23T20:56:36 https://maestrodatabase.com/blog/rapid-qualitative-evidence-syntheses-in-health-technology-assessment-experiences-challenges-and-lessons 2020-10-11T22:11:24 https://maestrodatabase.com/blog/astrazenecas-soriot-warns-new-us-drug-price-law-will-hurt-innovation 2022-08-23T20:53:42 https://maestrodatabase.com/blog/european-medicines-agency-commences-review-of-oral-fixed-dose-combination-of-decitabine-and-cedazuridine-for-the-treatment-of-adults-with-acute-myeloid-leukaemia 2022-08-23T20:48:52 https://maestrodatabase.com/blog/axovant-gene-therapies-receives-rare-paediatric-disease-designation-for-axo-aav-gm1-for-gm1-gangliosidosis 2020-10-11T23:12:36 https://maestrodatabase.com/blog/phathom-pharmaceuticals-resubmits-erosive-gerd-new-drug-application-to-fda 2023-05-24T22:54:08 https://maestrodatabase.com/blog/the-eu-hta-regulation-a-new-frontier-for-access-to-innovative-technologies 2022-08-23T21:21:01 https://maestrodatabase.com/blog/pillar-biosciences-receives-china-national-medical-products-administration-approval-for-oncoreveal-dx-colon-cancer-assay 2022-08-23T21:39:01 https://maestrodatabase.com/blog/fda-approves-abbotts-new-spinal-cord-stimulation-device-provides-tailored-relief-to-multiple-pain-areas-and-adds-more-treatment-options-for-evolving-pain-conditions 2022-08-23T21:10:32 https://maestrodatabase.com/blog/moderna-completes-application-to-us-fda-for-emergency-use-authorisation-of-omicron-targeting-bivalent-covid-19-booster-vaccine-mrna-1273-dot-222 2022-08-23T23:09:33 https://maestrodatabase.com/blog/extra-ordinary-meeting-of-the-chmp-1-september-2022 2022-08-23T21:56:23 https://maestrodatabase.com/blog/radiopharmaceutical-cancer-treatment-lutathera-now-available-to-ontario-patients-with-midgut-neuroendocrine-tumours 2020-10-12T00:17:09 https://maestrodatabase.com/blog/d3-bio-announces-fda-breakthrough-therapy-designation-and-orphan-drug-designation-for-d3s-001-for-the-treatment-of-patients-with-kras-g12c-mutated-cancers 2025-08-28T23:46:16 https://maestrodatabase.com/blog/janssen-emea-receives-conditional-marketing-authorisation-for-rybrevant-amivantamab-the-first-treatment-approved-for-patients-with-advanced-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations 2021-12-13T06:26:47 https://maestrodatabase.com/blog/dying-to-survive-gets-real-china-cuts-price-of-life-saving-cancer-drugs 2018-10-14T02:29:24 https://maestrodatabase.com/blog/avalglucosidase-alfa-for-treating-pompe-disease 2022-08-24T04:58:55 https://maestrodatabase.com/blog/tauranga-cancer-sufferer-tracy-barr-smiths-fighting-for-a-longer-life 2018-10-14T02:31:58 https://maestrodatabase.com/blog/cancer-patients-demand-ono-bms-msd-share-immunotherapy-cost 2020-05-16T23:16:17 https://maestrodatabase.com/blog/ambrisentan-diazepam-and-dexamethasone-new-exchange-groups 2020-10-12T02:04:53 https://maestrodatabase.com/blog/accc-helps-to-protect-australians-against-medicine-shortages-caused-by-covid-19 2021-12-13T19:18:00 https://maestrodatabase.com/blog/pharmac-publishes-agenda-for-the-november-2024-ptac-meeting 2024-11-07T01:48:37 https://maestrodatabase.com/blog/tga-grants-provisional-determination-for-covid-19-vaccine 2020-10-12T01:51:52 https://maestrodatabase.com/blog/cancer-patients-fight-for-life-extending-drugs-everyone-deserves-a-decent-chance 2018-10-14T19:22:10 https://maestrodatabase.com/blog/new-diabetes-medicine-funded-by-pharmac-not-what-the-doctors-ordered 2018-10-14T19:19:51 https://maestrodatabase.com/blog/lifesaving-cancer-treatment-out-of-reach-for-rural-people 2022-08-24T21:16:18 https://maestrodatabase.com/blog/smc---december-2021-decisions 2021-12-13T19:39:32 https://maestrodatabase.com/blog/pharmac-apologises-for-contraceptive-pill-shortages 2020-10-12T02:21:32 https://maestrodatabase.com/blog/government-scrambles-after-medicines-delay-outrage 2024-11-07T02:37:29 https://maestrodatabase.com/blog/moderna-vaccine-deal-to-produce-100-million-doses-in-melbourne-reached-by-federal-and-victorian-governments 2021-12-13T19:36:10 https://maestrodatabase.com/blog/roche-withdraws-application-for-tecentriq 2022-08-24T20:55:01 https://maestrodatabase.com/blog/intervenes-blueleaf-endovenous-valve-formation-system-granted-breakthrough-device-designation-by-the-fda 2021-12-13T19:42:45 https://maestrodatabase.com/blog/independent-pharmacies-sue-major-pbm-over-alleged-illegal-price-discrimination-and-reimbursement-violations 2020-05-16T23:20:54 https://maestrodatabase.com/blog/european-commission-approves-pfizers-cibinqo-abrocitinib-for-the-treatment-of-adults-with-moderate-to-severe-atopic-dermatitis 2021-12-13T19:23:10 https://maestrodatabase.com/blog/fda-approves-ibrutinib-for-paediatric-patients-with-chronic-graft-versus-host-disease-including-a-new-oral-suspension 2022-08-24T20:48:54 https://maestrodatabase.com/blog/international-regulators-recommend-use-of-remote-inspections-as-complementary-tool-beyond-pandemic 2021-12-13T19:20:25 https://maestrodatabase.com/blog/how-a-long-overlooked-protein-could-remake-neuroscience-drug-discovery----or-plunge-the-fda-into-controversy 2022-08-24T20:37:55 https://maestrodatabase.com/blog/forecast-2-for-the-2021-rebate-from-side-agreements 2021-12-13T19:29:02 https://maestrodatabase.com/blog/celltrion-usa-announces-us-fda-approval-of-yuflyma-adalimumab-aaty-a-high-concentration-and-citrate-free-formulation-of-humira-adalimumab-biosimilar 2023-05-25T00:00:10 https://maestrodatabase.com/blog/access-criteria-for-new-covid-19-treatment-announced 2022-08-24T20:44:57 https://maestrodatabase.com/blog/free-market-activists-slam-trumps-international-drug-pricing-index 2019-05-22T07:40:11 https://maestrodatabase.com/blog/polypid-receives-a-second-qidp-designation-for-d-plex100-in-abdominal-surgery 2019-05-22T07:32:32 https://maestrodatabase.com/blog/asthma-stakeholder-meeting-december-2018---outcome-statement 2019-05-22T06:50:30 https://maestrodatabase.com/blog/veru-announces-fda-approval-of-entadfi-a-new-treatment-for-benign-prostatic-hyperplasia 2021-12-13T19:48:49 https://maestrodatabase.com/blog/pfizer-slash-biontech-vaccine-approved-for-children-by-swiss-regulator 2021-12-13T19:45:39 https://maestrodatabase.com/blog/ema-publishes-agenda-for-13-16-chmp-meeting 2021-12-13T19:56:51 https://maestrodatabase.com/blog/tama-is-deteriorating-fast-but-the-drug-that-can-help-him-is-too-expensive 2019-11-03T07:11:22 https://maestrodatabase.com/blog/desperate-pharmac-plea-from-family-selling-cans-for-unfunded-myeloma-cancer-drugs 2024-02-11T20:27:46 https://maestrodatabase.com/blog/tolremo-therapeutics-receives-two-fda-fast-track-designations-for-tt125-802-in-pretreated-advanced-or-metastatic-nsclc-with-either-an-egfr-or-a-kras-g12c-mutation 2025-08-29T01:20:44 https://maestrodatabase.com/blog/pelosi-calls-pharmas-bluff-on-drug-prices 2019-11-03T07:24:47 https://maestrodatabase.com/blog/lilly-selling-half-price-version-of-popular-humalog-insulin 2019-05-22T21:02:33 https://maestrodatabase.com/blog/sometimes-drug-prices-are-too-low 2019-11-03T07:22:40 https://maestrodatabase.com/blog/agenda-for-the-september-2025-pbac-intracycle-meeting 2025-08-29T05:49:14 https://maestrodatabase.com/blog/guyon-espiner-investigates-pharmac-the-nz-buyers-club 2019-05-22T20:50:02 https://maestrodatabase.com/blog/innovative-drugs-save-lives-only-if-people-can-afford-them 2019-11-03T07:18:54 https://maestrodatabase.com/blog/public-summary-documents---may-2025-pbac-meeting 2025-08-29T05:58:34 https://maestrodatabase.com/blog/the-health-system-in-my-native-australia-has-a-lot-to-learn-from-the-u-dot-s 2019-11-03T07:15:59 https://maestrodatabase.com/blog/international-impact-of-external-reference-pricing-should-national-policy-makers-care 2019-11-03T07:35:20 https://maestrodatabase.com/blog/u-dot-s-fda-grants-priority-review-of-invokana-canagliflozin-snda-for-the-treatment-of-chronic-kidney-disease-in-patients-with-type-2-diabetes 2019-05-22T21:06:35 https://maestrodatabase.com/blog/white-house-distances-itself-from-pelosi-plan-to-lower-drug-prices 2019-11-03T07:27:29 https://maestrodatabase.com/blog/agile-therapeutics-announces-fda-acceptance-of-the-nda-resubmission-of-twirla 2019-05-22T21:18:44 https://maestrodatabase.com/blog/te-awamutu-mother-fights-for-cancer-drug-dollars-as-clock-winds-down 2018-10-15T07:02:00 https://maestrodatabase.com/blog/fda-approves-sorilux-for-adolescent-plaque-psoriasis 2019-05-22T21:15:23 https://maestrodatabase.com/blog/house-committee-proposes-6-percent-increase-in-fda-funding-for-fy-2020 2019-05-22T21:12:46 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-treatments-for-duchenne-muscular-dystrophy 2019-05-22T21:38:55 https://maestrodatabase.com/blog/extending-vbp-models-into-medicaid-drug-purchasing-challenges-and-opportunities 2019-05-22T21:32:32 https://maestrodatabase.com/blog/hhs-marches-forward-to-enhance-drug-price-transparency 2019-05-22T21:23:22 https://maestrodatabase.com/blog/blueprint-medicines-receives-complete-response-letter-from-fda-for-avapritinib-new-drug-application-for-the-fourth-line-treatment-of-gastro-intestinal-stromal-tumour 2020-05-17T09:57:54 https://maestrodatabase.com/blog/how-patent-law-and-medicine-regulations-could-affect-new-zealands-access-to-a-covid-19-vaccine 2020-10-12T05:20:11 https://maestrodatabase.com/blog/less-than-a-movie-ticket-or-impossible-to-overpay-experts-name-their-price-for-remdesivir 2020-05-17T20:53:06 https://maestrodatabase.com/blog/pfizer-and-biontech-to-supply-the-european-union-with-up-to-1-dot-8-billion-additional-doses-of-comirnaty 2021-05-23T10:53:40 https://maestrodatabase.com/blog/mylan-to-introduce-two-new-cost-saving-hiv-combination-treatments-in-the-u-dot-s 2018-03-05T08:15:16 https://maestrodatabase.com/blog/guided-by-the-research-design-choosing-the-right-statistical-test 2018-03-05T04:13:57 https://maestrodatabase.com/blog/radical-dental-plan-highlights-need-for-change 2018-03-05T04:19:45 https://maestrodatabase.com/blog/new-treatment-for-obesity-caused-by-rare-genetic-disorders 2021-05-23T20:47:02 https://maestrodatabase.com/blog/eyepoint-pharmaceuticals-receives-fda-approval-of-yutiq-fluocinolone-acetonide-0-dot-18-mg-intravitreal-implant 2018-10-15T20:12:34 https://maestrodatabase.com/blog/innovent-and-lilly-jointly-announce-the-nmpa-granted-marketing-approval-for-halpryza-rituximab-injection-in-china 2020-10-12T05:25:53 https://maestrodatabase.com/blog/health-canada-approves-mylan-and-biocons-ogivri-the-first-trastuzumab-biosimilar-for-the-treatment-of-her2-positive-breast-and-gastric-cancers 2019-05-23T08:47:21 https://maestrodatabase.com/blog/nhs-prescription-charges-are-rising---heres-how-to-keep-them-down 2018-03-05T08:22:45 https://maestrodatabase.com/blog/statement-by-fda-commissioner-on-fdas-new-steps-to-modernise-drug-development-improve-efficiency-and-promote-innovation-of-targeted-therapies 2018-10-15T20:08:28 https://maestrodatabase.com/blog/tga-fees-and-charges-summary-from-1-july-2019 2019-05-23T08:40:47 https://maestrodatabase.com/blog/congress-loves-a-big-pharma-villain-but-will-that-lead-to-any-real-policy-changes-on-drug-prices 2021-05-23T10:35:01 https://maestrodatabase.com/blog/nice-on-the-hunt-for-a-director-to-lead-the-centre-for-health-technology-evaluation 2018-03-05T09:34:05 https://maestrodatabase.com/blog/avadel-pharmaceuticals-announces-fda-acceptance-of-new-drug-application-for-av001 2019-05-23T08:34:09 https://maestrodatabase.com/blog/covid-19-vaccine-rollout-aussies-could-get-covid-19-jabs-by-christmas 2021-05-23T10:23:58 https://maestrodatabase.com/blog/the-ema-accepts-regulatory-submission-for-forxiga-in-adults-with-type-1-diabetes 2018-03-05T19:56:47 https://maestrodatabase.com/blog/new-findings-confirm-australians-place-high-value-on-the-pbs-but-acknowledge-its-shortfalls 2019-05-23T09:08:28 https://maestrodatabase.com/blog/new-tracking-tool-for-emas-relocation-to-amsterdam 2018-03-05T10:46:48 https://maestrodatabase.com/blog/drug-industry-will-use-ads-to-point-consumers-to-price-information 2018-10-15T20:25:19 https://maestrodatabase.com/blog/the-uk-pharmaceutical-industry-response-to-the-prime-ministers-road-to-brexit-speech 2018-03-05T10:49:50 https://maestrodatabase.com/blog/australians-battling-with-prostate-cancer-to-benefit-from-new-pbs-listing 2023-05-25T02:05:14 https://maestrodatabase.com/blog/iovance-biotherapeutics-announces-breakthrough-therapy-designation-for-ln-145-for-treatment-of-advanced-cervical-cancer-patients-who-have-progressed-on-or-after-chemotherapy 2019-05-23T08:53:58 https://maestrodatabase.com/blog/uk-government-pharma-industry-fail-to-agree-on-medicines-payment-scheme 2025-08-29T06:45:12 https://maestrodatabase.com/blog/forus-therapeutics-and-the-pan-canadian-pharmaceutical-alliance-complete-negotiations-for-xpovio-selinexor 2023-05-25T01:33:11 https://maestrodatabase.com/blog/accelerated-approval-in-oncology-fda-touts-successes-responds-to-criticism 2018-03-05T20:35:12 https://maestrodatabase.com/blog/first-gene-therapy-to-treat-children-with-rare-inherited-neurological-disease 2021-05-23T20:52:08 https://maestrodatabase.com/blog/record-30-per-cent-increase-in-complaints-about-health-insurance 2018-03-05T20:03:05 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-new-drug-application-for-prucalopride-shp555-for-chronic-idiopathic-constipation 2018-03-05T20:27:57 https://maestrodatabase.com/blog/positive-chmp-opinion-for-bayers-new-symptomatic-chronic-heart-failure-treatment-vericiguat 2021-05-23T20:58:12 https://maestrodatabase.com/blog/nice-proposes-simplifying-how-medicines-and-medical-devices-are-selected-for-evaluation 2020-10-12T11:07:03 https://maestrodatabase.com/blog/mhra-approvals-for-comirnaty-pfizer-slash-biontech-and-nuvaxovid-novavax-covid-19-vaccines 2024-02-12T05:51:42 https://maestrodatabase.com/blog/avenue-therapeutics-receives-complete-response-letter-from-the-fda-for-intravenous-tramadol 2021-06-15T04:22:03 https://maestrodatabase.com/blog/case-of-the-21-dollars-million-medicaid-patient-shows-how-drug-prices-soar-for-rare-diseases 2018-03-05T20:42:08 https://maestrodatabase.com/blog/smc---october-2020-decisions 2020-10-12T19:46:01 https://maestrodatabase.com/blog/fda-approves-first-oral-anti-viral-for-treatment-of-covid-19-in-adults 2023-05-25T21:16:57 https://maestrodatabase.com/blog/health-economic-assessment-of-tegsedi-in-hereditary-transthyretin-amyloidosis 2019-05-23T10:46:58 https://maestrodatabase.com/blog/mrna-manufacturing-facility-will-deliver-long-term-health-benefits-for-australians 2021-12-14T00:37:18 https://maestrodatabase.com/blog/vanflyta-first-flt3-inhibitor-approved-in-japan-for-patients-with-newly-diagnosed-flt3-itd-positive-aml 2023-05-25T06:43:09 https://maestrodatabase.com/blog/sandoz-marketing-authorisation-applications-for-proposed-biosimilar-denosumab-accepted-by-ema 2023-05-25T05:35:58 https://maestrodatabase.com/blog/b-dot-c-eye-doctors-warn-province-of-spike-in-glaucoma-cases-linked-to-injections-of-eye-drug 2019-05-23T20:59:51 https://maestrodatabase.com/blog/smc-accepts-bavencio-avelumab-in-combination-with-axitinib-for-the-first-line-treatment-of-adult-patients-with-advanced-or-metastatic-renal-cell-carcinoma 2020-10-12T20:11:54 https://maestrodatabase.com/blog/prescription-medicines-applications-under-evaluation-may-2021-update 2021-05-23T22:53:21 https://maestrodatabase.com/blog/i-would-be-able-to-live-into-my-thirties-nova-scotia-woman-has-high-hopes-for-new-cancer-treatment 2021-05-23T22:48:27 https://maestrodatabase.com/blog/drugs-and-money 2019-05-23T20:53:03 https://maestrodatabase.com/blog/seelos-therapeutics-receives-rare-paediatric-disease-designation-for-sls-005-trehalose-in-sanfilippo-syndrome 2020-05-18T02:04:23 https://maestrodatabase.com/blog/fda-accepts-xspray-pharmas-nda-resubmission-for-dasynoc 2024-02-12T19:37:48 https://maestrodatabase.com/blog/guyon-espiner-investigates-pharmac-the-secret-list 2019-05-23T20:49:22 https://maestrodatabase.com/blog/efficacy-trials-cost-more-take-longer-for-biosimilars-than-originators 2020-10-12T20:17:20 https://maestrodatabase.com/blog/eu-actions-to-support-availability-of-medicines-during-covid-19-pandemic---update-number-6 2020-05-18T02:18:01 https://maestrodatabase.com/blog/fda-approves-takedas-eohilia-budesonide-oral-suspension-the-first-and-only-oral-treatment-in-the-us-for-eosinophilic-oesophagitis 2024-02-12T19:32:36 https://maestrodatabase.com/blog/a-drug-with-a-multi-million-dollar-price-tag-is-making-a-mockery-of-washingtons-efforts-to-rein-in-prices 2019-05-23T10:50:16 https://maestrodatabase.com/blog/ema-publishes-agenda-for-12-15-october-chmp-meeting 2020-10-12T20:29:17 https://maestrodatabase.com/blog/eu-regulator-backs-extending-approval-for-remdesivir-for-another-year 2021-05-23T23:05:29 https://maestrodatabase.com/blog/fda-permits-marketing-of-first-diagnostic-test-to-aid-in-detecting-prosthetic-joint-infections 2019-05-23T21:14:09 https://maestrodatabase.com/blog/alexion-receives-fda-approval-for-new-advanced-formulation-of-ultomiris-ravulizumab-cwvz-with-significantly-reduced-infusion-time 2020-10-12T19:51:43 https://maestrodatabase.com/blog/biosimilars-no-longer-reviewed-through-the-cadth-cdr-and-pcodr-processes 2019-05-23T21:10:12 https://maestrodatabase.com/blog/novartis-ceo-plans-gene-therapy-price-far-lower-than-4-dollars-million-to-5-dollars-million-range 2019-05-23T21:03:26 https://maestrodatabase.com/blog/pfizer-trying-to-defuse-critics-amid-push-for-vaccine-before-election-day 2020-10-12T20:08:11 https://maestrodatabase.com/blog/warren-health-plan-tightens-democrats-embrace-of-tax-increases 2019-11-03T18:11:13 https://maestrodatabase.com/blog/republicans-are-struggling-to-fix-americas-dysfunctional-health-care-system 2019-05-23T21:28:34 https://maestrodatabase.com/blog/a-new-senate-health-package-includes-surprisingly-aggressive-drug-pricing-reforms 2019-05-23T21:21:02 https://maestrodatabase.com/blog/hundreds-of-kiwis-battling-leukaemia-given-hope-with-funding-of-new-drug 2019-11-03T18:05:34 https://maestrodatabase.com/blog/who-drug-pricing-talks-may-fail-to-end-secrecy-activists-fear 2019-05-23T21:17:39 https://maestrodatabase.com/blog/icer-publishes-final-evidence-report-on-treatments-for-non-alcoholic-steatohepatitis 2023-05-25T22:10:06 https://maestrodatabase.com/blog/gsk-receives-us-fda-fast-track-designation-for-bepirovirsen-in-chronic-hepatitis-b 2024-02-12T20:16:56 https://maestrodatabase.com/blog/cymabay-announces-fda-acceptance-of-nda-and-priority-review-for-seladelpar-for-the-treatment-of-primary-biliary-cholangitis 2024-02-12T20:09:25 https://maestrodatabase.com/blog/radiomedix-and-orano-med-receive-fda-breakthrough-therapy-designation-for-alphamedix-in-gastro-enteropancreatic-neuroendocrine-tumours 2024-02-12T20:29:46 https://maestrodatabase.com/blog/house-of-representatives-passes-bill-to-ban-use-of-qalys-in-federally-funded-health-care-programs 2024-02-12T20:26:17 https://maestrodatabase.com/blog/bioxcel-therapeutics-receives-fda-fast-track-designation-for-bxcl701-for-treatment-of-small-cell-neuroendocrine-prostate-cancer 2024-02-12T20:19:48 https://maestrodatabase.com/blog/loxo-oncology-announces-receipt-of-breakthrough-therapy-designation-from-u-dot-s-fda-for-loxo-292-for-the-treatment-of-ret-fusion-positive-thyroid-cancer 2018-10-16T01:44:47 https://maestrodatabase.com/blog/inventiva-receives-fda-breakthrough-therapy-designation-for-lead-drug-candidate-lanifibranor-in-nash 2020-10-12T23:40:13 https://maestrodatabase.com/blog/review-fundamentally-flawed 2017-08-02T05:43:52 https://maestrodatabase.com/blog/global-regulators-work-towards-alignment-on-policy-approaches-and-regulatory-flexibility-during-covid-19---update-number-2 2020-05-18T11:07:22 https://maestrodatabase.com/blog/covid-19-vaccine-frontrunners-emerge-as-rollout-debate-rages 2020-05-18T11:14:34 https://maestrodatabase.com/blog/gilead-and-teva-defend-antitrust-claims-that-prices-for-hiv-medicines-were-unfairly-kept-high 2023-05-25T23:18:22 https://maestrodatabase.com/blog/enhertu-granted-breakthrough-therapy-designation-in-the-u-dot-s-for-her2-mutant-metastatic-non-small-cell-lung-cancer 2020-05-18T06:01:02 https://maestrodatabase.com/blog/milvexian-granted-us-fda-fast-track-designation-for-all-three-indications-under-evaluation-in-phase-3-librexia-program-ischaemic-stroke-acute-coronary-syndrome-and-atrial-fibrillation 2023-05-25T23:09:16 https://maestrodatabase.com/blog/veozah-fezolinetant-film-coated-tablets-receives-health-canada-approval-as-first-and-only-non-hormonal-treatment-for-vasomotor-symptoms-associated-with-menopause 2024-12-07T06:58:13 https://maestrodatabase.com/blog/besponsa-approved-by-health-canada-for-the-treatment-of-adults-with-relapsed-or-refractory-b-cell-precursor-acute-lymphoblastic-leukaemia 2018-04-07T03:37:10 https://maestrodatabase.com/blog/evolus-provides-update-of-nuceiva-marketing-authorisation-application-in-europe 2019-06-11T07:08:03 https://maestrodatabase.com/blog/pif-partners-granted-fda-rare-paediatric-disease-designation-for-its-proprietary-small-molecule-in-treating-systemic-juvenile-idiopathic-arthritis-flares 2024-12-07T06:49:35 https://maestrodatabase.com/blog/novavax-covid-19-vaccine-to-be-available-in-coming-weeks 2022-01-24T06:40:28 https://maestrodatabase.com/blog/icer-to-assess-vaccines-for-covid-19 2025-09-29T22:48:42 https://maestrodatabase.com/blog/pacira-announces-fda-approval-of-supplemental-new-drug-application-for-exparel-as-a-nerve-block-to-produce-regional-analgesia 2018-04-07T03:43:44 https://maestrodatabase.com/blog/saol-therapeutics-announces-submission-of-new-drug-application-to-the-us-fda-for-sl1009 2024-12-07T06:40:36 https://maestrodatabase.com/blog/duchesnay-is-seeking-health-canadas-approval-for-ospemifene-for-the-treatment-of-moderate-to-severe-dyspareunia-and-vaginal-dryness-symptoms-of-vulvar-and-vaginal-atrophy-a-component-of-genitourinary-syndrome-of-menopause 2019-06-11T07:18:59 https://maestrodatabase.com/blog/ingredient-name-changes-a-medicine-ingredient-by-any-other-name-dot-dot-dot 2019-06-11T07:14:47 https://maestrodatabase.com/blog/rubraca-rucaparib-approved-in-the-u-dot-s-as-maintenance-treatment-of-recurrent-ovarian-cancer 2018-04-07T03:54:02 https://maestrodatabase.com/blog/imfinzi-granted-priority-review-in-the-us-for-patients-with-muscle-invasive-bladder-cancer 2024-12-07T08:21:27 https://maestrodatabase.com/blog/chugais-actemra-approved-for-additional-indication-of-sars-cov-2-pneumonia-in-japan 2022-01-24T07:19:14 https://maestrodatabase.com/blog/drug-makers-have-to-post-policies-for-patients-seeking-experimental-medicines-not-all-do 2018-04-07T04:01:17 https://maestrodatabase.com/blog/fda-approves-durvalumab-for-limited-stage-small-cell-lung-cancer 2024-12-07T08:13:40 https://maestrodatabase.com/blog/new-leaders-for-medicines-and-medical-services-committees 2024-03-21T02:25:48 https://maestrodatabase.com/blog/new-drugs-patient-hope-or-harm 2018-04-07T04:04:13 https://maestrodatabase.com/blog/tga-approves-msds-vaxneuvance 2022-01-24T06:44:52 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-zenocutuzumab-zbco-for-non-small-cell-lung-cancer-and-pancreatic-adenocarcinoma 2024-12-07T08:07:14 https://maestrodatabase.com/blog/2023-24-financial-results-for-cost-recovery-activities-for-listing-medicines-on-the-pbs-and-designated-vaccines-on-the-nip 2024-12-07T07:12:55 https://maestrodatabase.com/blog/health-canada-approves-ipsens-sohonos-palovarotene-as-the-first-approved-treatment-for-fibrodysplasia-ossificans-progressiva 2022-01-24T20:19:13 https://maestrodatabase.com/blog/fda-rejects-teva-slash-celltrion-biosimilars 2018-04-07T04:10:56 https://maestrodatabase.com/blog/alnylam-receives-approval-in-europe-for-amvuttra-vutrisiran-for-the-treatment-of-hereditary-transthyretin-mediated-amyloidosis-in-adult-patients-with-stage-1-or-stage-2-polyneuropathy 2022-09-21T08:17:38 https://maestrodatabase.com/blog/people-with-chronic-myeloid-leukaemia-granted-early-access-to-novartis-investigational-treatment 2022-01-24T20:07:39 https://maestrodatabase.com/blog/ema-publishes-agenda-for-24-27-jan-chmp-meeting 2022-01-24T19:59:47 https://maestrodatabase.com/blog/merck-provides-us-and-japan-regulatory-update-for-gefapixant 2022-01-24T20:12:40 https://maestrodatabase.com/blog/fda-accepts-supplemental-biologics-license-application-for-roches-columvi-combination-for-people-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma 2024-12-07T08:39:33 https://maestrodatabase.com/blog/breast-cancer-patients-in-scotland-are-set-to-receive-tumour-blasting-wonder-drug-that-starts-working-in-weeks---sparking-hopes-of-a-wider-rollout-for-nhs-patients-across-the-rest-of-the-uk 2022-01-24T20:36:10 https://maestrodatabase.com/blog/fda-approves-nucala-mepolizumab-40-mg-pre-filled-syringe-for-children-with-severe-eosinophilic-asthma 2022-01-24T20:48:13 https://maestrodatabase.com/blog/codexis-announces-fda-orphan-drug-and-rare-paediatric-disease-designations-for-cdx-6512-for-the-treatment-of-homocystinuria 2022-01-24T20:24:24 https://maestrodatabase.com/blog/method-paper-new-version-6-dot-1-comes-into-force 2022-01-24T20:31:30 https://maestrodatabase.com/blog/cook-medical-receives-fda-breakthrough-designation-for-new-drug-eluting-stent 2022-01-24T20:28:57 https://maestrodatabase.com/blog/momelotinib-dihydrochloride-monohydrate-for-the-treatment-of-patients-with-myelofibrosis-related-splenomegaly-or-symptoms 2024-03-21T03:45:03 https://maestrodatabase.com/blog/vertex-announces-european-commission-approval-for-kalydeco-ivacaftor-in-infants-with-cystic-fibrosis-ages-6-months-to-less-than-12-months-with-certain-mutations-in-the-cftr-gene 2019-12-11T06:07:44 https://maestrodatabase.com/blog/decision-to-award-sole-supply-for-apomorphine-hydrochloride 2019-12-11T05:33:57 https://maestrodatabase.com/blog/strategic-need-for-large-prospective-studies-in-different-populations 2019-12-11T06:25:00 https://maestrodatabase.com/blog/use-of-real-world-evidence-in-regulatory-decision-making---ema-publishes-review-of-its-studies 2023-06-25T21:42:32 https://maestrodatabase.com/blog/guerbet-announces-us-fda-approval-of-elucirem-gadopiclenol 2022-09-21T21:05:33 https://maestrodatabase.com/blog/astrazeneca-caps-patient-out-of-pocket-costs-at-35-dollars-per-month-for-its-us-inhaled-respiratory-portfolio 2024-03-21T04:36:53 https://maestrodatabase.com/blog/us-fda-approves-tremfya-guselkumab-for-the-treatment-of-paediatric-plaque-psoriasis-and-active-psoriatic-arthritis-marking-a-first-and-only-approval-for-an-il-23-inhibitor 2025-09-30T01:19:18 https://maestrodatabase.com/blog/public-hospitals-going-backwards 2019-12-11T19:45:02 https://maestrodatabase.com/blog/health-insurers-call-for-federal-crackdown-on-public-hospital-fraud 2019-12-11T19:42:55 https://maestrodatabase.com/blog/kedrion-biopharma-receives-fda-approval-for-qivigy-immune-globulin-10-percent-iv-for-treatment-of-primary-humoral-immunodeficiency-in-adults 2025-09-30T01:30:10 https://maestrodatabase.com/blog/innovative-medicines-canada-bans-members-from-paying-doctors-fees-for-iv-infusions 2019-12-11T20:06:26 https://maestrodatabase.com/blog/fda-approves-mylotarg-for-treatment-of-acute-myeloid-leukaemia 2017-09-01T21:11:25 https://maestrodatabase.com/blog/fda-accepts-supplemental-biologics-license-application-for-xolair-omalizumab-for-the-treatment-of-nasal-polyps 2019-12-11T19:58:21 https://maestrodatabase.com/blog/fda-approves-guardant360-cdx-as-companion-diagnostic-for-eli-lilly-and-companys-inluriyo-imlunestrant-for-treatment-of-esr1-mutated-advanced-breast-cancer 2025-09-30T02:17:14 https://maestrodatabase.com/blog/pelosi-agrees-to-expand-drug-price-bill-to-win-support-from-aoc-other-democrats 2019-12-11T19:54:44 https://maestrodatabase.com/blog/six-year-review-shows-success-of-the-eu-signal-management-system-in-improving-safe-use-of-medicines 2019-12-11T19:48:07 https://maestrodatabase.com/blog/expanding-use-of-multi-criteria-decision-analysis-for-health-technology-assessment 2019-12-11T20:27:12 https://maestrodatabase.com/blog/venturing-a-perspective-on-the-drug-pricing-debate 2019-12-11T20:22:57 https://maestrodatabase.com/blog/biosimilar-stakeholders-praise-removal-of-biologic-exclusivity-provisions-from-usmca 2019-12-11T20:16:15 https://maestrodatabase.com/blog/nice-says-benefits-of-breast-cancer-drug-fulvestrant-too-uncertain-to-make-it-cost-effective 2017-09-01T21:26:54 https://maestrodatabase.com/blog/trudeau-vague-on-scope-of-national-pharmacare-plan 2019-12-11T20:13:56 https://maestrodatabase.com/blog/argenx-submits-biologics-license-application-to-us-food-and-drug-administration-for-subcutaneous-efgartigimod-for-treatment-of-generalised-myasthenia-gravis 2022-09-21T21:12:07 https://maestrodatabase.com/blog/fda-approves-two-new-indications-for-mercks-keytruda-pembrolizumab 2019-06-11T20:58:06 https://maestrodatabase.com/blog/bipartisan-group-of-governors-calls-on-congress-to-shore-up-elements-of-affordable-care-act 2017-09-01T21:33:41 https://maestrodatabase.com/blog/a-475-000-dollars-price-tag-for-a-new-cancer-drug-crazy-or-meh 2017-09-01T21:40:43 https://maestrodatabase.com/blog/more-than-60-000-back-petition-calling-for-dr-charlie-teo-to-operate-in-public-hospitals 2019-06-11T20:52:49 https://maestrodatabase.com/blog/weighing-costs-and-benefits-in-the-economics-of-cancer-care 2019-12-11T20:52:51 https://maestrodatabase.com/blog/profit-on-475-000-dollars-novartis-cancer-drug-could-be-a-while-coming 2017-09-01T21:35:36 https://maestrodatabase.com/blog/pharma-agrees-to-2-percent-cap-on-branded-meds-growth 2018-11-27T20:50:57 https://maestrodatabase.com/blog/novartis-ceos-dilemma-is-475-000-dollars-too-much-for-a-leukaemia-breakthrough-or-is-it-not-enough 2017-09-01T21:48:44 https://maestrodatabase.com/blog/customers-ditch-downgrade-private-health-insurance-as-premium-increases-bite-accc 2018-11-26T07:45:16 https://maestrodatabase.com/blog/mps-to-debate-cystic-fibrosis-drug-orkambi-in-parliament 2019-06-11T21:11:20 https://maestrodatabase.com/blog/u-dot-s-benefits-manager-baulks-after-novartis-values-gene-therapy-at-$4-5-million 2018-11-27T20:48:21 https://maestrodatabase.com/blog/orkambi-row-government-now-considering-crown-use-licensing 2019-06-11T21:07:50 https://maestrodatabase.com/blog/systematic-literature-review-calls-economic-impact-of-switching-to-biosimilars-uncertain 2019-06-11T21:25:27 https://maestrodatabase.com/blog/were-paying-834-dollars-million-more-for-health-insurance-but-getting-less 2018-11-26T19:58:07 https://maestrodatabase.com/blog/biosimilar-proposal-for-medicare-will-depend-on-the-details 2019-06-11T21:22:00 https://maestrodatabase.com/blog/why-prescription-drug-prices-have-skyrocketed 2018-11-26T20:05:26 https://maestrodatabase.com/blog/magnesium-development-company-announces-fda-breakthrough-device-designation-for-resorbable-hc-screw 2022-01-25T00:33:06 https://maestrodatabase.com/blog/government-orders-urgent-meningococcal-vaccination-programme-for-northland 2018-11-26T10:42:50 https://maestrodatabase.com/blog/jacobus-prices-its-rare-disease-drug-at-half-of-what-catalyst-charges-but-will-doctors-prescribe-it 2019-06-11T21:15:15 https://maestrodatabase.com/blog/novartis-ceo-sees-tougher-u-dot-s-drug-pricing-over-next-three-five-years 2016-10-26T16:08:38 https://maestrodatabase.com/blog/seizing-on-rising-costs-trump-says-health-law-is-over 2016-10-26T16:16:04 https://maestrodatabase.com/blog/specialists-must-also-think-of-patients-financial-health 2019-06-11T21:45:26 https://maestrodatabase.com/blog/big-pharma-is-gearing-up-to-defend-drug-prices 2016-10-26T16:04:00 https://maestrodatabase.com/blog/slavitt-says-tackling-drug-spending-will-be-top-priority-for-next-cms-leader 2016-10-26T16:06:13 https://maestrodatabase.com/blog/why-trumps-tariffs-could-raise-the-cost-of-a-hip-replacement 2018-04-07T09:22:09 https://maestrodatabase.com/blog/novartis-ceo-says-four-factors-can-help-with-pricing-and-payment-of-life-saving-cell-and-gene-therapies 2018-11-26T20:22:45 https://maestrodatabase.com/blog/ispor-announces-2019-2020-board-of-directors 2019-06-11T21:37:55 https://maestrodatabase.com/blog/nhs-drug-suppliers-investigated-over-prices 2016-10-26T20:07:59 https://maestrodatabase.com/blog/update-to-cadth-guidelines-for-the-economic-evaluation-of-health-technologies 2016-10-26T20:15:59 https://maestrodatabase.com/blog/sk-biopharmaceuticals-submits-epilepsy-drug-candidate-for-approval-to-us-fda 2018-11-26T20:09:07 https://maestrodatabase.com/blog/affordable-care-act-premium-increases-are-a-fixable-problem 2016-10-26T16:18:48 https://maestrodatabase.com/blog/should-the-fda-disclose-new-filings-for-drugs-biologics-and-biosimilars 2019-06-11T21:28:16 https://maestrodatabase.com/blog/crunch-time-for-obamacare 2016-10-26T20:03:07 https://maestrodatabase.com/blog/statement-from-fda-commissioner-and-director-of-the-center-for-devices-and-radiological-health-on-transformative-new-steps-to-modernize-fdas-510-k-program-to-advance-the-review-of-the-safety-and-effectiveness-of-medical-devices 2018-11-26T20:13:28 https://maestrodatabase.com/blog/coronavirus-covid-19-update-fda-limits-use-of-certain-monoclonal-antibodies-to-treat-covid-19-due-to-the-omicron-variant 2022-01-25T00:23:15 https://maestrodatabase.com/blog/nhs-saves-record-ps300-million-by-switching-to-cheaper-arthritis-drug 2018-11-27T20:43:47 https://maestrodatabase.com/blog/medicare-for-all-wont-work-this-might 2019-06-11T21:50:50 https://maestrodatabase.com/blog/revise-pharmaceutical-legislation-or-long-term-access-to-medical-breakthroughs-for-europeans-will-be-harmed 2023-06-26T00:06:07 https://maestrodatabase.com/blog/the-cost-of-cancer-to-australias-economy 2018-04-07T12:33:07 https://maestrodatabase.com/blog/gsk-announces-cap-of-35-dollars-per-month-on-us-patient-out-of-pocket-costs-for-its-entire-portfolio-of-asthma-and-copd-inhalers 2024-03-21T20:21:08 https://maestrodatabase.com/blog/roche-cops-another-rejection-from-nice 2018-04-07T12:37:05 https://maestrodatabase.com/blog/china-pharma-crackdown-leads-to-flu-vaccine-shortage 2018-11-27T20:46:19 https://maestrodatabase.com/blog/free-daily-hiv-prevention-pills-will-soon-be-available-to-private-insurance-holders 2019-06-11T21:47:26 https://maestrodatabase.com/blog/medicare-opens-door-for-covering-obesity-drugs 2024-03-21T20:17:38 https://maestrodatabase.com/blog/gilead-receives-chmp-positive-opinion-for-trodelvy-in-pre-treated-hr-plus-slash-her2--metastatic-breast-cancer 2023-06-26T01:57:00 https://maestrodatabase.com/blog/jardiance-recommended-for-the-treatment-of-adults-with-chronic-kidney-disease-in-the-eu 2023-06-26T01:46:00 https://maestrodatabase.com/blog/equity-and-obesity-treatment---expanding-medicaid-covered-interventions 2023-06-26T01:38:56 https://maestrodatabase.com/blog/midostaurin-for-treating-advanced-systemic-mastocytosis 2020-11-08T20:25:00 https://maestrodatabase.com/blog/fda-approves-an-oncology-drug-that-targets-a-key-genetic-driver-of-cancer-rather-than-a-specific-type-of-tumour 2018-11-26T23:20:24 https://maestrodatabase.com/blog/novo-nordisk-submits-biologics-license-application-to-fda-for-mim8-an-investigational-prophylaxis-treatment-for-people-living-with-haemophilia-a-with-or-without-inhibitors 2025-09-30T03:52:27 https://maestrodatabase.com/blog/made-in-melbourne-lab-to-start-producing-promising-coronavirus-vaccine 2020-11-08T20:10:11 https://maestrodatabase.com/blog/new-zealanders-to-benefit-from-partnership-to-enhance-responsible-use-of-medicines 2016-10-27T05:53:36 https://maestrodatabase.com/blog/2021-medicare-part-b-premiums-remain-steady 2020-11-08T20:18:51 https://maestrodatabase.com/blog/soliris-recommended-for-approval-in-the-eu-by-chmp-for-children-and-adolescents-with-refractory-generalised-myasthenia-gravis 2023-06-26T06:21:24 https://maestrodatabase.com/blog/more-essential-support-for-australian-patients-through-community-pharmacy 2020-06-12T06:50:32 https://maestrodatabase.com/blog/the-inflation-reduction-act-aims-to-lower-drug-costs----but-heres-how-big-pharma-could-get-around-it 2022-09-21T23:01:40 https://maestrodatabase.com/blog/pfizer-reaches-landmark-agreement-with-us-government-to-lower-drug-costs-for-american-patients 2025-09-30T20:20:03 https://maestrodatabase.com/blog/the-on--and-off-ramps-of-oncology-accelerated-approval 2022-09-21T22:47:37 https://maestrodatabase.com/blog/fda-approves-selpercatinib-for-locally-advanced-or-metastatic-ret-fusion-positive-non-small-cell-lung-cancer 2022-09-21T22:53:42 https://maestrodatabase.com/blog/update-on-proposed-changes-to-2nd-and-3rd-line-anti-vegf-treatments-for-ophthalmic-use 2016-10-28T06:01:27 https://maestrodatabase.com/blog/novartis-receives-fda-approval-for-rhapsido-remibrutinib-the-only-oral-targeted-btki-treatment-for-chronic-spontaneous-urticaria 2025-09-30T20:36:11 https://maestrodatabase.com/blog/pharmac-outlines-changes-at-tauranga-public-forum 2016-10-28T06:03:30 https://maestrodatabase.com/blog/fda-approves-selpercatinib-for-locally-advanced-or-metastatic-ret-fusion-positive-solid-tumours 2022-09-21T22:36:56 https://maestrodatabase.com/blog/health-canada-issues-notice-of-compliance-for-bausch-healths-duobrii 2020-06-12T06:44:14 https://maestrodatabase.com/blog/autopsy-of-a-drug-withdrawal----the-case-of-melphalan-flufenamide 2024-12-08T20:27:26 https://maestrodatabase.com/blog/pbac-public-summary-documents---july-2016-meeting 2016-10-28T07:59:40 https://maestrodatabase.com/blog/in-washingtons-drug-price-fight-plenty-of-blame-to-go-around 2016-10-28T08:02:53 https://maestrodatabase.com/blog/health-law-tax-penalty-ill-take-it-millions-say 2016-10-28T07:52:39 https://maestrodatabase.com/blog/post-market-review-of-ezetimibe---targeted-stakeholder-forum 2016-10-28T07:55:33 https://maestrodatabase.com/blog/ruxolitinib-phosphate-for-the-treatment-of-patients-with-acute-graft-versus-host-disease-that-responds-inadequately-to-corticosteroids 2024-12-08T21:17:04 https://maestrodatabase.com/blog/humana-spells-out-its-conditional-exondys-51-coverage-policy----strings-attached 2016-10-28T08:36:22 https://maestrodatabase.com/blog/the-best-way-to-save-obamacare 2016-10-28T08:23:14 https://maestrodatabase.com/blog/drug-prices-not-the-health-law-top-voters-health-priorities-for-2017 2016-10-28T08:33:27 https://maestrodatabase.com/blog/fda-approves-non-steroidal-treatment-for-duchenne-muscular-dystrophy 2024-03-21T22:50:04 https://maestrodatabase.com/blog/fda-approves-new-device-for-prevention-of-recurrent-strokes-in-certain-patients 2016-10-29T06:43:51 https://maestrodatabase.com/blog/cancer-drugs-fund-the-bigger-picture 2016-10-29T07:59:01 https://maestrodatabase.com/blog/sanofi-and-regeneron-receive-complete-response-letter-from-fda-for-sarilumab-an-investigational-treatment-for-rheumatoid-arthritis 2016-10-29T06:32:49 https://maestrodatabase.com/blog/expensive-brain-cancer-drug-no-longer-an-option-under-medicare 2021-06-20T04:02:21 https://maestrodatabase.com/blog/united-states-to-spend-4-dollars-2-cents-billion-on-anti-viral-pills-and-other-treatments-for-covid-19 2021-06-20T03:55:36 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-october-2025 2025-09-30T20:47:14 https://maestrodatabase.com/blog/abbvie-submits-biologics-license-application-to-us-fda-for-pivekimab-sunirine---an-investigational-antibody-drug-conjugate-to-treat-rare-cancer-with-limited-treatment-options 2025-09-30T21:30:11 https://maestrodatabase.com/blog/oncopeptides-withdraws-withdrawal-of-first-marketed-drug 2022-01-25T21:00:13 https://maestrodatabase.com/blog/regulatory-harmonisation-of-clinical-trials-in-the-eu-clinical-trials-regulation-to-enter-into-application-and-new-clinical-trials-information-system-to-be-launched 2022-01-25T21:05:49 https://maestrodatabase.com/blog/mylan-and-biocon-announce-u-dot-s-fda-approval-of-semglee-insulin-glargine-injection 2020-06-12T07:42:58 https://maestrodatabase.com/blog/vyepti-eptinezumab-approved-by-the-eu-commission-for-the-preventive-treatment-of-migraine-in-adults 2022-01-25T07:40:34 https://maestrodatabase.com/blog/lisata-therapeutics-announces-us-fda-rare-paediatric-disease-designation-granted-to-lsta1-for-the-treatment-of-osteosarcoma 2024-03-22T00:11:47 https://maestrodatabase.com/blog/bimzelx-bimekizumab-approved-in-japan-for-the-treatment-of-plaque-psoriasis-generalised-pustular-psoriasis-and-psoriatic-erythroderma 2022-01-25T07:48:42 https://maestrodatabase.com/blog/icer-to-assess-treatments-for-high-cholesterol 2020-06-12T23:14:58 https://maestrodatabase.com/blog/genentechs-evrysdi-risdiplam-granted-fda-priority-review-for-treatment-of-presymptomatic-babies-under-2-months-of-age-with-spinal-muscular-atrophy 2022-01-25T21:33:43 https://maestrodatabase.com/blog/orphan-drug-reimbursements-create-tough-situation-for-south-korean-public-budget 2020-06-12T23:17:37 https://maestrodatabase.com/blog/nice-rejects-sanofis-cablivi-in-draft-guidelines 2020-06-12T23:21:10 https://maestrodatabase.com/blog/kyowa-kirin-announces-poteligeo-receives-marketing-authorisation-in-europe-for-the-treatment-of-mycosis-fungoides-and-sezary-syndrome 2018-11-27T01:33:58 https://maestrodatabase.com/blog/fda-approves-drug-to-treat-infants-and-children-with-hiv 2020-06-12T22:54:13 https://maestrodatabase.com/blog/fda-approves-the-actpen-for-genentechs-actemra-a-single-dose-pre-filled-auto-injector-for-the-treatment-of-rheumatoid-arthritis-giant-cell-arteritis-and-two-forms-of-juvenile-arthritis 2018-11-27T01:26:28 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-novel-agents-to-prevent-chemotherapy-induced-neutropenia 2022-01-25T21:18:52 https://maestrodatabase.com/blog/18-dollars-3-cents-billion-deal-struck-to-fund-pharmaceutical-benefits-scheme-improve-indigenous-health 2020-06-12T22:59:56 https://maestrodatabase.com/blog/new-report-from-the-kings-fund-shows-the-uk-underperforming-on-treatable-health-conditions-says-the-abpi 2023-06-26T10:20:29 https://maestrodatabase.com/blog/snipr-biome-announces-us-fda-grants-fast-track-designation-for-snipr001-for-prevention-of-bloodstream-infections-in-haematologic-cancer-patients 2022-01-25T23:57:38 https://maestrodatabase.com/blog/senhwas-pidnarulex-receives-us-fda-fast-track-designation-for-the-treatment-of-solid-tumours-with-brca1-slash-2-palb2-and-other-hr-gene-mutations 2022-01-25T23:52:39 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-for-cs-1103-a-first-in-class-small-molecule-to-reverse-acute-intoxication-from-methamphetamine 2025-09-30T23:03:39 https://maestrodatabase.com/blog/new-drugs-patients-are-needlessly-waiting-15-months-too-long 2018-04-07T23:55:58 https://maestrodatabase.com/blog/new-health-technologies-need-new-approaches 2023-06-26T21:46:07 https://maestrodatabase.com/blog/aft-welcomes-us-fda-complete-response-letter 2020-11-09T01:13:25 https://maestrodatabase.com/blog/biopharma-facing-two-major-crises---a-huge-patent-cliff-and-price-controls 2023-06-26T21:40:00 https://maestrodatabase.com/blog/makena-indication-may-fall-based-on-post-approval-data 2020-11-09T00:31:31 https://maestrodatabase.com/blog/gsk-receives-positive-chmp-opinion-recommending-authorisation-of-daprodustat-for-symptomatic-anaemia-associated-with-chronic-kidney-disease-in-adults-on-chronic-maintenance-dialysis 2023-06-26T11:56:38 https://maestrodatabase.com/blog/japans-ministry-of-health-labour-and-welfare-approves-shingrix-for-the-prevention-of-shingles-in-at-risk-adults-aged-18-and-over 2023-06-26T11:46:21 https://maestrodatabase.com/blog/umoja-biopharma-announces-that-ub-vv111-receives-fda-fast-track-designation-for-relapsed-slash-refractory-b-cell-malignancies 2025-09-30T23:08:04 https://maestrodatabase.com/blog/zz-biotech-announces-fda-fast-track-designation-for-stroke-program 2020-06-13T01:32:42 https://maestrodatabase.com/blog/fda-permits-marketing-of-new-device-designed-to-reduce-sleep-disturbance-related-to-nightmares-in-certain-adults 2020-11-09T01:25:03 https://maestrodatabase.com/blog/antimicrobials-benefited-from-expedited-fda-programs-more-than-other-drugs 2020-06-13T01:36:05 https://maestrodatabase.com/blog/liminal-biosciences-announces-fda-extension-of-review-period-for-ryplazim-plasminogen-bla 2020-11-09T03:19:14 https://maestrodatabase.com/blog/cladribine-for-the-treatment-of-patients-with-relapsing-multiple-sclerosis 2024-12-09T21:01:52 https://maestrodatabase.com/blog/awiqli-once-weekly-basal-insulin-icodec-recommended-for-approval-for-the-treatment-of-diabetes-by-the-european-regulatory-authorities 2024-03-22T06:47:30 https://maestrodatabase.com/blog/ucb-receives-positive-chmp-opinion-for-bimzelx-bimekizumab-for-the-treatment-of-adults-with-moderate-to-severe-hidradenitis-suppurativa 2024-03-22T06:38:46 https://maestrodatabase.com/blog/fda-approves-mercks-gardasil-9-for-the-prevention-of-certain-hpv-related-head-and-neck-cancers 2020-06-13T02:09:17 https://maestrodatabase.com/blog/new-drug-helps-extend-survival-rate-of-men-with-advanced-prostate-cancer-b-dot-c-cancer-agency-study 2019-06-12T07:00:13 https://maestrodatabase.com/blog/behind-the-scenes-at-the-pbac 2019-06-12T06:05:57 https://maestrodatabase.com/blog/catalyst-biosciences-receives-rare-paediatric-disease-designation-for-cb-4332-for-the-treatment-of-cfi-deficiency 2022-01-26T08:15:22 https://maestrodatabase.com/blog/pharmac-confirms-access-criteria-for-covid-19-treatments 2022-01-26T19:39:44 https://maestrodatabase.com/blog/bridgebio-pharma-and-sentynl-therapeutics-receive-marketing-authorisation-in-the-eu-for-nulibry-fosdenopterin-for-the-treatment-of-mocd-type-a 2022-09-22T01:47:46 https://maestrodatabase.com/blog/incyte-provides-update-on-parsaclisib-and-mcla-145 2022-01-26T08:06:21 https://maestrodatabase.com/blog/outcome-statement---february-2024-dusc-meeting 2024-03-22T06:56:04 https://maestrodatabase.com/blog/julia-would-breathe-easier-if-living-with-asthma-wasnt-quite-so-costly 2019-06-12T07:07:30 https://maestrodatabase.com/blog/sask-cancer-agency-started-chemotherapy-drug-trial-without-required-health-canada-approval 2019-06-12T07:04:15 https://maestrodatabase.com/blog/post-market-review-of-medicines-for-smoking-cessation---targeted-stakeholder-forum 2020-11-09T05:24:45 https://maestrodatabase.com/blog/pfizer-pushes-to-intervene-in-lawsuit-seeking-covid-vaccine-information-from-fda 2022-01-26T19:58:02 https://maestrodatabase.com/blog/novartis-fabhalta-iptacopan-receives-positive-chmp-opinion-as-first-oral-monotherapy-for-adult-patients-with-paroxysmal-nocturnal-hemoglobinuria 2024-03-22T20:55:36 https://maestrodatabase.com/blog/tirzepatide-for-the-treatment-of-patients-with-type-2-diabetes-mellitus 2023-10-25T02:12:41 https://maestrodatabase.com/blog/immunocore-announces-fda-approval-of-kimmtrak-tebentafusp-tebn-for-the-treatment-of-unresectable-or-metastatic-uveal-melanoma 2022-01-26T19:50:34 https://maestrodatabase.com/blog/cadth-recommendation-to-not-reimburse-new-treatment-a-failure-for-people-living-with-schizophrenia 2022-09-22T02:13:31 https://maestrodatabase.com/blog/former-bowel-cancer-patient-calls-for-nz-to-fund-drug-she-says-saved-her-life 2022-01-26T19:47:41 https://maestrodatabase.com/blog/sun-pharma-announces-health-canada-approval-of-absorica-ld-isotretinoin-capsules-for-treatment-of-severe-nodular-acne 2023-06-27T05:03:25 https://maestrodatabase.com/blog/calquence-approved-in-the-eu-for-the-treatment-of-chronic-lymphocytic-leukaemia 2020-11-09T07:04:27 https://maestrodatabase.com/blog/biohaven-announces-fda-acceptance-of-505-b-2-nda-filing-for-bhv-0223-a-novel-sublingual-form-of-riluzole-for-the-treatment-of-amyotrophic-lateral-sclerosis 2018-11-27T03:05:02 https://maestrodatabase.com/blog/outlook-therapeutics-receives-european-union-positive-chmp-opinion-for-ons-5010-as-a-treatment-for-wet-amd 2024-03-22T21:17:24 https://maestrodatabase.com/blog/nice-issues-positive-final-appraisal-determination-for-abbvies-rinvoq-upadacitinib-in-severe-active-rheumatoid-arthritis 2020-11-09T06:15:55 https://maestrodatabase.com/blog/janssen-submits-marketing-authorisation-application-to-the-ema-seeking-approval-of-single-tablet-combination-therapy-of-macitentan-and-tadalafil-for-treatment-of-patients-with-pulmonary-arterial-hypertension 2023-06-27T04:33:15 https://maestrodatabase.com/blog/ucb-announces-us-fda-approval-of-rystiggo-rozanolixizumab-noli-for-the-treatment-of-adults-with-generalised-myasthenia-gravis 2023-06-27T05:30:36 https://maestrodatabase.com/blog/novo-nordisk-resubmits-awiqli-to-the-fda-with-potential-to-be-the-first-once-weekly-basal-insulin-treatment-for-adults-with-type-2-diabetes 2025-10-01T02:22:52 https://maestrodatabase.com/blog/vary-drug-prices-for-different-conditions-say-health-experts 2020-11-09T09:08:19 https://maestrodatabase.com/blog/roche-announces-fda-approval-for-ventana-pd-l1-sp142-assay-to-support-immunotherapy-treatment-decisions-in-lung-cancer 2016-10-30T09:38:17 https://maestrodatabase.com/blog/cadth-recommends-the-reimbursement-of-taltz 2016-10-30T20:22:17 https://maestrodatabase.com/blog/pbac-drug-utilisation-sub-committee-public-release-documents 2016-10-30T09:29:31 https://maestrodatabase.com/blog/impel-neuropharma-announces-fda-submission-of-new-drug-application-for-inp104-for-the-acute-treatment-of-migraine 2020-11-09T19:57:11 https://maestrodatabase.com/blog/fda-approves-liquid-biopsy-ngs-companion-diagnostic-test-for-multiple-cancers-and-biomarkers 2020-11-09T20:02:50 https://maestrodatabase.com/blog/global-covid-19-cases-pass-50-million-as-vaccine-proven-to-be-90-per-cent-effective 2020-11-09T19:45:42 https://maestrodatabase.com/blog/novavax-covid-19-vaccine-granted-fast-track-designation-by-u-dot-s-fda 2020-11-09T19:48:10 https://maestrodatabase.com/blog/fda-grants-rare-paediatric-disease-designation-to-amo-pharma-for-amo-02-for-treatment-of-congenital-myotonic-dystrophy 2020-11-09T19:52:49 https://maestrodatabase.com/blog/proposal-to-list-and-award-sole-supply-to-celecoxib-pfizer 2016-10-31T08:11:23 https://maestrodatabase.com/blog/smc---november-2020-decisions 2020-11-09T20:07:55 https://maestrodatabase.com/blog/tga-approves-yet-another-use-for-humira-adalimumab 2016-10-31T08:56:50 https://maestrodatabase.com/blog/new-osteoporosis-drug-for-women-approved-for-use-on-nhs-in-scotland 2020-11-09T20:12:33 https://maestrodatabase.com/blog/eligible-patients-living-with-rare-debilitating-genetic-disorder-are-one-step-closer-to-having-access-to-first-of-its-kind-treatment-option 2020-11-09T20:16:02 https://maestrodatabase.com/blog/cadth-recommends-epclusa 2016-10-31T10:24:30 https://maestrodatabase.com/blog/tga-approves-new-combination-product-for-type-2-diabetes 2016-10-31T09:17:07 https://maestrodatabase.com/blog/otezla-finally-recommended-for-use-by-patients-with-psoriasis 2016-10-31T13:06:38 https://maestrodatabase.com/blog/chiesi-global-rare-diseases-and-protalix-biotherapeutics-announce-validation-of-variation-submission-by-ema-for-pegunigalsidase-alfa 2024-12-10T04:51:10 https://maestrodatabase.com/blog/disc-medicine-announces-submission-of-new-drug-application-to-us-fda-for-accelerated-approval-of-bitopertin-for-patients-with-erythropoietic-protoporphyria 2025-10-01T02:42:10 https://maestrodatabase.com/blog/us-fda-accepts-gsks-submission-for-the-use-of-nucala-mepolizumab-in-copd 2024-12-10T04:23:50 https://maestrodatabase.com/blog/xigduo-xr-approved-in-china-for-adults-with-type-2-diabetes 2023-06-27T06:07:05 https://maestrodatabase.com/blog/as-health-premiums-jump-obama-wields-an-imperfect-shield 2016-10-31T20:15:53 https://maestrodatabase.com/blog/perrigo-announces-tentative-fda-approval-for-the-first-to-file-generic-version-of-ultravate-lotion-0-dot-05-percent 2018-11-27T04:35:48 https://maestrodatabase.com/blog/alprolix-approved-in-switzerland-for-the-treatment-of-haemophilia-b 2016-10-31T20:20:45 https://maestrodatabase.com/blog/sacubitril-slash-valsartan-entresto-utilisation-and-prescribing-patterns-in-the-context-of-a-reimbursement-application-system 2020-06-14T06:19:41 https://maestrodatabase.com/blog/sandoz-receives-eighth-european-commission-approval-for-a-biosimilar-with-ziextenzo-pegfilgrastim 2018-11-27T06:28:28 https://maestrodatabase.com/blog/olaparib-in-combination-with-bevacizumab-for-the-maintenance-treatment-of-adults-with-advanced-ovarian-fallopian-tube-and-peritoneal-cancer-after-response-to-first-line-platinum-based-chemotherapy 2023-06-27T06:34:00 https://maestrodatabase.com/blog/greg-hunt-says-no-to-health-insurers-creep-into-us-style-managed-care 2021-06-20T21:15:19 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-november-2016-update 2016-10-31T20:50:23 https://maestrodatabase.com/blog/the-implant-files-how-the-therapeutic-goods-administration-regulates-medical-devices 2018-11-27T11:32:13 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-november-2016-update 2016-10-31T20:56:06 https://maestrodatabase.com/blog/cms-takes-action-to-lower-prescription-drug-costs-by-modernising-medicare 2018-11-27T11:38:19 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-october-2025 2025-10-01T03:38:37 https://maestrodatabase.com/blog/trump-moves-to-lower-medicare-drug-costs-by-relaxing-some-patient-protections 2018-11-27T19:37:40 https://maestrodatabase.com/blog/loxo-and-bayers-amazing-drug-has-an-expensive-price 2018-11-27T19:40:13 https://maestrodatabase.com/blog/2022-april-price-disclosure-cycle---indicative-prices 2022-01-27T00:16:52 https://maestrodatabase.com/blog/ac-immune-receives-fda-fast-track-designation-for-anti-amyloid-beta-active-immunotherapy-aci-24-dot-060-to-treat-alzheimers-disease 2023-06-27T12:53:41 https://maestrodatabase.com/blog/celebrity-brain-surgeon-faces-threat-of-disciplinary-action 2019-06-12T12:36:58 https://maestrodatabase.com/blog/pharma-backed-group-attacks-a-controversial-cost-shifting-insurance-tool-by-scaring-employers 2018-11-27T20:18:18 https://maestrodatabase.com/blog/public-prostate-cancer-patients-told-treatment-provided-by-public-hospitals-no-longer-available 2025-10-01T04:20:17 https://maestrodatabase.com/blog/fda-accepts-pfizers-application-for-haemophilia-b-gene-therapy-fidanacogene-elaparvovec 2023-06-27T12:48:53 https://maestrodatabase.com/blog/astellas-receives-positive-chmp-opinion-for-xtandi-in-additional-recurrent-early-prostate-cancer-treatment-setting 2024-03-22T23:55:17 https://maestrodatabase.com/blog/fda-promised-a-lower-cost-option-to-epipen-but-the-price-isnt-any-lower 2018-11-27T20:13:20 https://maestrodatabase.com/blog/novartis-lee011-ribociclib-granted-fda-priority-review-for-first-line-treatment-of-hr-plus--slash-her2--advanced-breast-cancer 2016-11-01T08:00:58 https://maestrodatabase.com/blog/gsk-receives-us-fda-fast-track-designation-for-investigational-vaccine-against-gonorrhoea 2023-06-27T12:45:52 https://maestrodatabase.com/blog/is-high-deductible-health-insurance-worth-the-risk 2016-11-01T08:16:15 https://maestrodatabase.com/blog/cadth-supports-the-use-of-entyvio-in-crohns-disease 2016-11-01T10:12:06 https://maestrodatabase.com/blog/accc-issues-fresh-warning-to-health-insurance-firms-over-failures 2016-11-01T10:42:36 https://maestrodatabase.com/blog/capping-seniors-out-of-pocket-prescription-drug-costs-could-increase-medicare-prices----and-premiums 2019-06-12T12:46:50 https://maestrodatabase.com/blog/60-day-drug-dispensing-subject-of-new-pharmacy-guild-attack 2023-06-27T07:06:19 https://maestrodatabase.com/blog/imfinzis-bid-for-coverage-faces-keytrudas-double-edged-impact-in-korea 2025-10-01T05:48:29 https://maestrodatabase.com/blog/european-medicines-agency-validates-the-marketing-authorization-application-for-avelumab-for-the-treatment-of-metastatic-merkel-cell-carcinoma 2016-11-01T08:51:32 https://maestrodatabase.com/blog/how-pharma-could-benefit-from-one-of-congress-signature-drug-pricing-ideas 2019-06-12T12:43:43 https://maestrodatabase.com/blog/more-evidence-needed-to-recommend-type-2-diabetes-treatment-tirzepatide 2023-06-27T12:42:02 https://maestrodatabase.com/blog/icer-releases-final-report-with-pricing-and-coverage-implications-for-treatment-of-advanced-non-small-cell-lung-cancer-with-tki-and-pd-1-drugs 2016-11-01T16:31:47 https://maestrodatabase.com/blog/ispor-annual-european-congress---vienna 2016-11-01T16:51:33 https://maestrodatabase.com/blog/head-and-neck-cancer-drug-is-not-cost-effective 2016-11-01T15:10:45 https://maestrodatabase.com/blog/nice-issues-draft-guidance-on-the-use-of-ixekizumab 2016-11-01T16:17:25 https://maestrodatabase.com/blog/allecra-therapeutics-submits-new-drug-application-to-the-us-fda-for-exblifep-for-the-treatment-of-complicated-urinary-tract-infections 2023-06-27T21:37:02 https://maestrodatabase.com/blog/canada-will-move-on-new-drug-price-rules-in-very-near-future-minister 2019-06-12T21:39:37 https://maestrodatabase.com/blog/nice-launches-public-consultation-on-updates-to-health-technology-evaluations-manual 2023-06-27T13:16:29 https://maestrodatabase.com/blog/catalyst-pharma-sues-fda-over-approval-of-cheaper-rival-drug 2019-06-12T21:01:38 https://maestrodatabase.com/blog/fda-issues-complete-response-letter-for-aflibercept-8-mg-biologics-license-application-solely-due-to-an-on-going-review-of-inspection-findings-at-a-third-party-filler 2023-06-27T21:27:08 https://maestrodatabase.com/blog/ucb-provides-update-on-us-fda-review-of-the-biologics-license-application-for-bimekizumab 2023-06-27T13:09:40 https://maestrodatabase.com/blog/the-cancer-drugs-fund-in-practice-and-under-the-new-framework 2019-06-12T13:15:55 https://maestrodatabase.com/blog/statement-from-fda-commissioner-on-how-modern-predicates-can-promote-innovation-and-advance-safety-and-effectiveness-of-medical-devices-that-use-510-k-pathway 2018-11-27T21:47:28 https://maestrodatabase.com/blog/ford-government-to-fund-spinraza-worlds-most-expensive-drug---with-age-caps 2019-06-12T21:45:16 https://maestrodatabase.com/blog/senate-judiciary-committee-plans-markup-of-drug-pricing-bill-this-month 2019-06-12T21:41:43 https://maestrodatabase.com/blog/13-million-novavax-doses-due-to-expire-as-australians-stick-to-mrna-boosters 2022-09-22T20:43:56 https://maestrodatabase.com/blog/pharmac-plans-switch-back-to-broader-pneumococcal-vaccine-following-surge-in-deadly-disease-cases 2022-09-22T20:30:30 https://maestrodatabase.com/blog/incorporating-future-medical-costs-impact-on-cost-effectiveness-analysis-in-cancer-patients 2019-06-12T21:51:16 https://maestrodatabase.com/blog/cstone-announces-gavreto-pralsetinib-snda-approval-by-china-nmpa-for-first-line-treatment-of-patients-with-locally-advanced-or-metastatic-ret-fusion-positive-non-small-cell-lung-cancer 2023-06-27T21:57:05 https://maestrodatabase.com/blog/hightide-therapeutics-receives-fast-track-designation-from-the-u-dot-s-fda-for-htd1801-treating-non-alcoholic-steatohepatitis 2018-11-27T23:10:47 https://maestrodatabase.com/blog/white-house-unveils-trumprx-drug-buying-site-and-a-pfizer-pricing-deal 2025-10-01T06:11:36 https://maestrodatabase.com/blog/datopotamab-deruxtecan-granted-breakthrough-therapy-designation-in-us-for-patients-with-previously-treated-advanced-egfr-mutated-non-small-cell-lung-cancer 2024-12-10T08:28:41 https://maestrodatabase.com/blog/how-to-make-us-health-care-more-equitable-and-less-costly 2018-11-27T23:02:19 https://maestrodatabase.com/blog/orphazyme-submits-european-marketing-authorisation-application-for-arimoclomol-for-treatment-of-niemann-pick-disease-type-c 2020-11-10T01:05:48 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-27-january-2022 2022-01-27T06:13:13 https://maestrodatabase.com/blog/lillys-neutralising-antibody-bamlanivimab-ly-cov555-receives-fda-emergency-use-authorisation-for-the-treatment-of-recently-diagnosed-covid-19 2020-11-10T01:11:00 https://maestrodatabase.com/blog/do-federal-price-transparency-regulations-neglect-oncology-patients 2022-01-27T02:43:58 https://maestrodatabase.com/blog/bayer-submits-marketing-authorization-applications-for-finerenone-in-the-u-dot-s-and-the-eu-for-patients-with-chronic-kidney-disease-and-type-2-diabetes 2020-11-10T01:30:11 https://maestrodatabase.com/blog/pharmac-seeks-feedback-to-fund-medicines-for-liver-and-ovarian-cancer 2024-12-10T09:07:04 https://maestrodatabase.com/blog/how-health-care-hurts-your-paycheck 2016-11-02T08:31:40 https://maestrodatabase.com/blog/fda-grants-breakthrough-therapy-designation-to-seres-therapeutics-ser-155-for-reduction-of-bloodstream-infections-in-adults-undergoing-allogeneic-haematopoietic-stem-cell-transplantation 2024-12-10T08:59:56 https://maestrodatabase.com/blog/sanders-takes-aim-at-insulin-makers-in-latest-price-attack 2016-11-02T08:36:50 https://maestrodatabase.com/blog/modernas-mrna-vaccines-to-be-exempted-from-advisory-committee-scrutiny-under-2-dollars-billion-morrison-era-deal 2024-12-10T08:52:28 https://maestrodatabase.com/blog/celltrion-seeks-ema-approval-of-herceptin-biosimilar 2016-11-02T09:56:29 https://maestrodatabase.com/blog/decision-to-award-sole-supply-for-fluticasone-and-fluticasone-with-salmeterol-metered-dose-inhalers 2019-12-12T03:27:08 https://maestrodatabase.com/blog/lantern-pharma-receives-rare-paediatric-disease-and-orphan-drug-designations-for-lp-184-for-the-treatment-of-atypical-teratoid-rhabdoid-tumour 2022-01-27T08:15:16 https://maestrodatabase.com/blog/jardiance-recommended-by-cadth-for-use-by-patients-with-type-2-diabetes-mellitus-at-high-risk-of-cardiovascular-disease 2016-11-02T10:40:30 https://maestrodatabase.com/blog/health-canada-approves-alecensaro---a-targeted-oral-treatment---for-patients-with-aggressive-and-rare-form-of-lung-cancer 2016-11-02T09:50:30 https://maestrodatabase.com/blog/generic-drug-backlog-at-the-fda-a-dive-into-the-confusing-numbers 2016-11-02T15:08:31 https://maestrodatabase.com/blog/mirum-pharmaceuticals-broadens-expanded-access-program-for-maralixibat-in-alagille-syndrome-to-europe-and-australia 2020-11-10T01:20:59 https://maestrodatabase.com/blog/give-and-take-us-pharma-and-payers-forge-risk-sharing-deals-for-new-heart-drugs 2016-11-02T14:58:53 https://maestrodatabase.com/blog/new-expensive-anti-cancer-agents-which-role-is-played-by-quality-adjusted-life-years-in-the-selection-of-a-specific-treatment 2016-11-02T15:17:06 https://maestrodatabase.com/blog/enhertu-followed-by-thp-supplemental-biologics-license-application-accepted-in-the-us-for-patients-with-high-risk-her2-positive-early-stage-breast-cancer-prior-to-surgery 2025-10-01T11:01:20 https://maestrodatabase.com/blog/confounding-by-indication-in-clinical-research 2016-11-02T15:39:43 https://maestrodatabase.com/blog/costs-keep-women-from-taking-drugs-to-prevent-cancers-return 2016-11-02T15:11:21 https://maestrodatabase.com/blog/analysis-of-pbac-submissions-and-outcomes-for-medicines-2010-2018 2020-06-14T21:10:46 https://maestrodatabase.com/blog/kite-submits-biologics-license-application-to-u-dot-s-fda-for-companys-second-car-t-cell-therapy 2019-12-12T03:39:08 https://maestrodatabase.com/blog/californias-proposition-61-will-direct-democracy-impact-prescription-drug-pricing 2016-11-02T15:13:54 https://maestrodatabase.com/blog/30-day-limit-on-prescription-refills-lifted-in-most-provinces 2020-06-14T21:16:26 https://maestrodatabase.com/blog/2019-20-cost-recovery-implementation-statement-for-pbs-slash-nip-updated-for-2018-19-financial-outcome 2019-12-12T03:32:17 https://maestrodatabase.com/blog/tga-publishes-auspar-for-esmya 2016-11-02T15:44:01 https://maestrodatabase.com/blog/ema-management-board-backs-rolling-review-fees-covid-19-transparency-measures 2020-06-14T21:22:50 https://maestrodatabase.com/blog/fda-approves-mirvetuximab-soravtansine-gynx-for-fra-positive-platinum-resistant-epithelial-ovarian-fallopian-tube-or-primary-peritoneal-cancer 2024-03-23T01:04:11 https://maestrodatabase.com/blog/bristol-myers-squibbs-anti-mtbr-tau-targeting-antibody-bms-986446-granted-fast-track-designation-by-us-fda-for-the-treatment-of-alzheimers-disease 2025-10-01T11:23:44 https://maestrodatabase.com/blog/health-reform-and-the-changing-safety-net-in-the-united-states 2016-11-03T06:08:14 https://maestrodatabase.com/blog/the-disappearing-doctor-how-mega-mergers-are-changing-the-business-of-medical-care 2018-04-08T11:21:56 https://maestrodatabase.com/blog/seqirus-announces-health-canada-approval-of-first-cell-based-seasonal-influenza-vaccine 2019-12-12T03:53:03 https://maestrodatabase.com/blog/these-new-pharma-bros-are-wreaking-havoc-on-prescription-drug-prices 2018-04-08T20:53:28 https://maestrodatabase.com/blog/icer-opens-nominations-for-new-members-of-its-voting-panels 2020-12-04T07:41:58 https://maestrodatabase.com/blog/avenue-therapeutics-announces-submission-of-new-drug-application-for-iv-tramadol 2019-12-12T03:46:00 https://maestrodatabase.com/blog/ending-the-postcode-lottery-in-newborn-health-screening 2023-06-28T04:39:27 https://maestrodatabase.com/blog/maestro-daily-maintenance 2016-11-06T09:57:10 https://maestrodatabase.com/blog/dementia-drug-choline-alfoscerate-to-get-limited-insurance-benefit 2020-06-14T21:07:19 https://maestrodatabase.com/blog/tesaro-announces-submission-of-niraparib-new-drug-application-for-platinum-sensitive-recurrent-ovarian-cancer 2016-11-03T06:19:04 https://maestrodatabase.com/blog/verona-pharma-submits-new-drug-application-to-us-fda-for-ensifentrine-for-the-maintenance-treatment-of-copd 2023-06-28T04:23:26 https://maestrodatabase.com/blog/meiragtx-granted-fda-regenerative-medicine-advanced-therapy-designation-for-aav2-haqp1-for-the-treatment-of-grade-2-slash-3-radiation-induced-xerostomia 2024-12-10T09:12:52 https://maestrodatabase.com/blog/eusa-pharma-and-beigene-announce-acceptance-of-a-biologics-license-application-for-qarziba-dinutuximab-beta-in-chin 2020-11-10T01:34:05 https://maestrodatabase.com/blog/covid-19-ema-recommends-conditional-marketing-authorisation-for-paxlovid 2022-01-27T19:36:55 https://maestrodatabase.com/blog/swedish-prices-for-medicines-among-the-lowest-in-europe 2019-12-12T05:50:56 https://maestrodatabase.com/blog/its-a-bonanza-with-drug-pricing-bill-up-for-a-vote-d-dot-c-news-outlets-are-drowning-in-advocacy-ads 2019-12-12T04:08:02 https://maestrodatabase.com/blog/the-price-of-cystic-fibrosis-drugs-is-still-too-high 2022-01-27T19:40:39 https://maestrodatabase.com/blog/commonwealth-of-australia-v-sanofi-hearing-of-commonwealths-claim-commences-in-federal-court-of-australia 2017-09-02T02:37:43 https://maestrodatabase.com/blog/new-price-deal-paves-way-for-nice-approval-of-treatment-for-rare-genetic-condition 2024-12-10T10:19:59 https://maestrodatabase.com/blog/apricus-biosciences-announces-fda-acknowledgement-of-vitaros-class-2-nda-resubmission 2017-09-02T02:43:12 https://maestrodatabase.com/blog/iovance-biotherapeutics-announces-fda-fast-track-designation-for-ln-144-for-treatment-of-advanced-melanoma 2017-09-02T02:49:50 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-treatment-for-acute-pain 2024-12-10T11:04:25 https://maestrodatabase.com/blog/fda-grants-breakthrough-therapy-designation-for-dizal-pharmaceuticals-dzd9008-in-patients-with-locally-advanced-or-metastatic-non-small-cell-lung-cancer-harbouring-egfr-exon-20-insertion 2022-01-27T19:55:47 https://maestrodatabase.com/blog/positive-early-access-to-medicines-scheme-eams-scientific-opinion-awarded-to-gbts-voxelotor-for-the-treatment-of-haemolytic-anaemia-due-to-sickle-cell-disease 2022-01-27T20:11:36 https://maestrodatabase.com/blog/shortage-of-prescription-infant-formula-worries-parents 2022-01-27T20:08:23 https://maestrodatabase.com/blog/sentynl-therapeutics-updates-on-its-nda-for-cutx-101 2025-10-01T21:16:51 https://maestrodatabase.com/blog/tga-approves-tepmetko-for-patients-with-non-small-cell-lung-cancer 2022-01-27T19:44:58 https://maestrodatabase.com/blog/deucravacitinib-for-the-treatment-of-patients-with-moderate-to-severe-plaque-psoriasis 2023-06-28T07:01:48 https://maestrodatabase.com/blog/ema-publishes-agenda-for-9-12-december-2024-chmp-meeting 2024-12-10T20:28:08 https://maestrodatabase.com/blog/astrazeneca-welcomes-court-ruling-on-supply-of-its-covid-19-vaccine-to-europe 2021-06-20T23:17:24 https://maestrodatabase.com/blog/moderna-aims-to-deliver-omicron-covid-19-vaccine-by-september 2022-01-27T20:44:25 https://maestrodatabase.com/blog/december-2024-decisions 2024-12-10T20:23:14 https://maestrodatabase.com/blog/drug-shortages-in-canada-why-they-happen-and-what-you-can-do-about-it 2019-06-13T03:45:57 https://maestrodatabase.com/blog/the-certainty-of-uncertainty-in-health-technology-assessment 2022-01-27T20:18:14 https://maestrodatabase.com/blog/us-plays-catch-up-with-europe-over-biosimilar-patents 2021-06-20T23:14:56 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-european-commission-approval-of-camzyos-mavacamten-for-the-treatment-of-symptomatic-obstructive-hypertrophic-cardiomyopathy 2023-06-28T06:38:21 https://maestrodatabase.com/blog/fda-enforces-clinicaltrials-dot-gov-results-posting-requirements-including-threats-of-financial-penalty 2022-01-27T20:23:04 https://maestrodatabase.com/blog/pfizers-covid-19-vaccine-comirnaty-provisionally-approved-for-use-as-a-booster-in-individuals-aged-16-17-years-old 2022-01-28T04:42:27 https://maestrodatabase.com/blog/pfizers-and-biontechs-vaccine-is-the-start-of-the-end-of-the-pandemic 2020-11-10T02:40:28 https://maestrodatabase.com/blog/deliberations-at-the-chmp-regarding-the-marketing-authorisation-application-in-the-eu-for-lecanemab-have-been-rescheduled-due-to-procedural-reasons-at-the-ema 2024-03-23T01:51:25 https://maestrodatabase.com/blog/australians-deserve-fast-access-to-the-latest-medicines-vaccines-and-treatments 2022-01-28T04:46:56 https://maestrodatabase.com/blog/fda-approves-bayers-ultravist-iopromide-injection-for-contrast-enhanced-mammography 2023-06-28T07:29:25 https://maestrodatabase.com/blog/additional-public-summary-documents-from-the-pbac-july-2016-meeting 2016-11-13T06:03:51 https://maestrodatabase.com/blog/highlights-from-chmp-24-27-january-2022-meeting 2022-01-28T20:55:34 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac---december-2021-intracycle-meeting 2022-01-28T05:05:25 https://maestrodatabase.com/blog/i-feel-like-im-drowning-thousands-with-cystic-fibrosis-wait-to-hear-if-life-saving-drug-will-be-listed-on-pbs 2022-01-28T04:57:01 https://maestrodatabase.com/blog/icer-to-review-drug-treatments-for-osteoporosis-in-upcoming-report 2016-11-13T06:38:09 https://maestrodatabase.com/blog/hhs-watchdog-office-steps-up-focus-on-drug-pricing 2016-11-13T06:46:24 https://maestrodatabase.com/blog/organon-canada-announces-the-availability-of-nduvra-1-percent-tapinarof-cream-for-the-topical-treatment-of-plaque-psoriasis-in-adults 2025-10-02T02:27:55 https://maestrodatabase.com/blog/price-cuts-pave-the-way-for-routine-access-to-breast-and-lung-cancer-drugs 2016-11-13T07:05:16 https://maestrodatabase.com/blog/life-extending-breast-cancer-drug-approved-by-nice-in-draft-guidance 2016-11-13T07:08:52 https://maestrodatabase.com/blog/cystic-fibrosis-life-altering-drug-nearing-patient-access-across-the-country-health-canada 2021-06-21T01:16:31 https://maestrodatabase.com/blog/health-equity-and-medicaid-transformation----operationalising-president-bidens-agenda 2021-06-21T00:20:50 https://maestrodatabase.com/blog/regeneron-and-sanofi-provide-regulatory-update-on-libtayo-cemiplimab-rwlc-in-advanced-cervical-cancer 2022-01-28T21:13:34 https://maestrodatabase.com/blog/nice-and-the-smc-have-published-recommendations-on-shionogis-mulpleo-lusutrombopag-approving-its-use-for-the-treatment-of-severe-thrombocytopenia-in-adult-patients-with-chronic-liver-disease-undergoing-invasive-procedures 2019-12-12T20:01:06 https://maestrodatabase.com/blog/fda-issues-draft-guidance-to-foster-oncology-product-development-for-paediatric-populations 2019-12-12T19:54:48 https://maestrodatabase.com/blog/tlv-publishes-first-joint-report-within-the-finose-co-operation 2019-06-13T04:45:11 https://maestrodatabase.com/blog/after-a-long-fight-progressives-secure-small-tweaks-to-pelosis-drug-pricing-package 2019-12-12T09:16:46 https://maestrodatabase.com/blog/merck-ridgeback-withdraw-covid-drug-application-in-eu 2023-06-28T07:52:30 https://maestrodatabase.com/blog/highlights-from-the-18-21-march-2024-chmp-meeting 2024-03-24T20:38:34 https://maestrodatabase.com/blog/house-votes-to-give-the-government-the-power-to-negotiate-drug-prices 2019-12-12T20:13:50 https://maestrodatabase.com/blog/breast-cancer-survivor-wants-7-000-dollars-a-month-wonder-drug-to-be-more-readily-available-to-patients 2023-06-28T11:01:29 https://maestrodatabase.com/blog/bracco-announces-fda-approval-of-gadopiclenol-injection-a-new-macrocyclic-high-relaxivity-gadolinium-based-contrast-agent-which-will-be-commercialised-as-vueway 2022-09-23T02:01:48 https://maestrodatabase.com/blog/krystal-biotech-provides-update-on-emas-on-going-regulatory-review-of-b-vec-for-dystrophic-epidermolysis-bullosa 2024-12-11T00:17:09 https://maestrodatabase.com/blog/kinnate-biopharma-receives-fast-track-designation-from-the-us-food-and-drug-administration-for-kin-2787-an-investigational-pan-raf-inhibitor 2022-09-23T00:56:14 https://maestrodatabase.com/blog/cyltezo-first-interchangeable-biosimilar-to-humira-receives-preferred-formulary-status-with-optum-rx-for-commercially-insured-patients 2023-06-28T10:47:21 https://maestrodatabase.com/blog/biocryst-submits-new-drug-application-for-oral-once-daily-berotralstat-bcx7353-to-prevent-hae-attacks 2019-12-12T20:06:42 https://maestrodatabase.com/blog/alimera-sciences-announces-canadian-regulatory-approval-for-iluvien 2018-11-28T01:32:42 https://maestrodatabase.com/blog/value-based-pricing-for-gene-therapy-maybe-not-ready-for-haemophilia 2019-12-12T20:34:08 https://maestrodatabase.com/blog/2023-24-cost-recovery-implementation-statement-for-listing-medicines-on-the-pbs-and-designated-vaccines-on-the-nip 2023-06-28T08:08:46 https://maestrodatabase.com/blog/updates-on-olumiant-baricitinib-fda-review-for-atopic-dermatitis 2022-01-28T21:31:38 https://maestrodatabase.com/blog/koreas-drug-pricing-policies-for-the-second-half-of-2023 2023-06-28T10:24:19 https://maestrodatabase.com/blog/canadian-study-shows-substantial-savings-possible-with-use-of-biosimilar-filgrastim 2019-12-12T20:30:03 https://maestrodatabase.com/blog/health-canada-has-now-authorised-adynovate-anti-haemophilic-factor-recombinant-pegylated-in-paediatrics-for-treatment-of-children-under-12-with-haemophilia-a 2018-11-28T01:26:24 https://maestrodatabase.com/blog/alberta-will-force-patients-to-switch-from-biologics-to-cheaper-biosimilar-medications 2019-12-12T20:24:46 https://maestrodatabase.com/blog/review-of-rotarix 2019-06-13T05:02:41 https://maestrodatabase.com/blog/glaucoma-drug-vyzulta-psoriasis-remedy-skilarence-win-insurance-benefit 2022-01-28T21:37:38 https://maestrodatabase.com/blog/lynparza-approved-in-china-as-first-line-maintenance-treatment-with-bevacizumab-for-hrd-positive-advanced-ovarian-cancer 2022-09-23T00:46:07 https://maestrodatabase.com/blog/canada-should-have-universal-single-payer-public-pharmacare-says-advisory-council 2019-06-13T05:22:01 https://maestrodatabase.com/blog/european-commission-approves-evenity-romosozumab-for-the-treatment-of-severe-osteoporosis-in-post-menopausal-women-at-high-risk-of-fracture 2019-12-12T20:43:34 https://maestrodatabase.com/blog/fda-grants-priority-review-to-genentechs-rituxan-rituximab-in-children-with-two-rare-blood-vessel-disorders 2019-06-13T05:59:10 https://maestrodatabase.com/blog/how-the-shortage-of-a-15-dollars-cancer-drug-is-upending-treatment 2023-06-28T11:06:26 https://maestrodatabase.com/blog/pharming-group-announces-us-fda-acceptance-and-priority-review-of-supplemental-new-drug-application-for-leniolisib-in-children-with-apds-aged-4-to-11-years 2025-10-02T02:47:07 https://maestrodatabase.com/blog/facilitating-review-of-real-world-data-studies-the-oncology-qcard-initiative 2023-06-28T11:42:08 https://maestrodatabase.com/blog/fda-approves-acetadote-snda 2024-12-11T01:59:22 https://maestrodatabase.com/blog/how-big-data-can-be-used-for-the-development-and-regulation-of-medicines 2016-11-13T10:05:07 https://maestrodatabase.com/blog/pfizer-applies-to-swissmedic-for-authorisation-of-another-covid-19-vaccine 2022-09-23T03:02:15 https://maestrodatabase.com/blog/bristol-myers-squibbs-opdivo-nivolumab-is-the-first-immuno-oncology-treatment-to-receive-fda-approval-based-on-overall-survival-in-head-and-neck-cancer 2017-06-06T03:00:29 https://maestrodatabase.com/blog/highlights-from-chmp-november-2016-meeting 2016-11-13T10:07:00 https://maestrodatabase.com/blog/donald-trump-says-he-may-keep-parts-of-obama-health-care-act 2016-11-13T10:57:05 https://maestrodatabase.com/blog/drug-prices-threaten-the-nhs 2016-11-25T09:49:35 https://maestrodatabase.com/blog/smc---november-2016-decisions 2016-11-13T12:01:34 https://maestrodatabase.com/blog/beigene-announces-china-nmpa-approval-of-brukinsa-zanubrutinib-for-the-treatment-of-patients-with-relapsed-or-refractory-waldenstroems-macroglobulinaemia 2021-06-21T05:07:02 https://maestrodatabase.com/blog/u-dot-s-fda-approves-gileads-vemlidy-tenofovir-alafenamide-fumarate-for-the-treatment-of-chronic-hepatitis-b-virus-infection 2016-11-13T11:36:51 https://maestrodatabase.com/blog/covid-19-pfizer-vaccine-could-roll-out-in-new-zealand-at-the-start-of-2021-if-success-continues 2020-11-10T05:22:40 https://maestrodatabase.com/blog/tga-not-expecting-novavax-quality-data-until-september 2021-06-21T04:39:42 https://maestrodatabase.com/blog/brexits-effect-on-access-to-new-medicines 2016-11-13T11:50:39 https://maestrodatabase.com/blog/a-precision-medicine-approach-to-clinical-trials 2016-11-13T19:37:35 https://maestrodatabase.com/blog/european-commission-approves-alunbrig-brigatinib-for-alk-positive-non-small-cell-lung-cancer-in-patients-previously-treated-with-crizotinib-advancing-treatment-paradigm-in-europe 2018-11-28T01:46:14 https://maestrodatabase.com/blog/14-000-new-flu-vaccine-doses-available-for-high-needs-patients 2019-06-13T08:14:11 https://maestrodatabase.com/blog/promotion-of-drugs-for-off-label-uses-the-us-food-and-drug-administration-at-a-crossroads 2017-02-07T20:09:53 https://maestrodatabase.com/blog/knowing-when-and-how-to-use-medical-products-a-shared-responsibility-for-the-fda-and-cms 2016-11-13T12:12:38 https://maestrodatabase.com/blog/rocket-pharmaceuticals-receives-fda-regenerative-medicine-advanced-therapy-and-fast-track-designations-for-rp-l102-gene-therapy-for-fanconi-anaemia 2018-11-28T01:57:03 https://maestrodatabase.com/blog/theratechnologies-receives-march-2025-pdufa-goal-date-for-updated-tesamorelin-f8-formulation-sbla 2024-12-11T09:54:38 https://maestrodatabase.com/blog/delgocitinib-approved-to-treat-adult-patients-with-moderate-to-severe-chronic-hand-eczema 2024-12-11T09:49:23 https://maestrodatabase.com/blog/icer-announces-leadership-transition 2023-06-28T21:33:13 https://maestrodatabase.com/blog/the-next-big-challenge-after-a-covid-19-vaccine-is-giving-it-to-enough-people 2020-11-10T06:35:43 https://maestrodatabase.com/blog/are-drugs-priced-in-accordance-with-value-a-comparison-of-value-based-and-net-prices-using-institute-for-clinical-and-economic-review-reports 2021-06-21T07:11:13 https://maestrodatabase.com/blog/fda-approves-pfizers-ngenla-a-long-acting-once-weekly-treatment-for-paediatric-growth-hormone-deficiency 2023-06-28T21:22:32 https://maestrodatabase.com/blog/us-fda-approves-broad-new-labels-for-esperions-nexletol-and-nexlizet-to-prevent-heart-attacks-and-cardiovascular-procedures-in-both-primary-and-secondary-prevention-patients-regardless-of-statin-use 2024-03-25T01:46:18 https://maestrodatabase.com/blog/health-canada-approves-celltrions-omlyclo-ct-p39-the-first-and-only-omalizumab-biosimilar-in-canada 2024-12-11T20:55:12 https://maestrodatabase.com/blog/taho-pharma-announces-submission-of-new-drug-application-to-the-us-fda-for-tah3311---the-worlds-first-apixaban-oral-dissolving-film---represents-a-transformational-advancement-in-anti-coagulant-therapy 2025-10-02T04:15:04 https://maestrodatabase.com/blog/octapharma-receives-swissmedic-approval-for-fibryga-to-treat-congenital-and-acquired-fibrinogen-deficiencies 2018-11-28T02:26:45 https://maestrodatabase.com/blog/sensome-receives-fda-breakthrough-device-designation-for-its-ai-powered-stroke-guidewire 2021-06-21T09:48:23 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-positive-chmp-opinion-for-car-t-cell-therapy-breyanzi-lisocabtagene-maraleucel-for-relapsed-or-refractory-dlbcl-pmbcl-and-fl3b 2022-01-29T06:39:18 https://maestrodatabase.com/blog/medsafe-approves-pfizer-vaccine-for-new-zealand-12-15-year-olds 2021-06-21T10:08:48 https://maestrodatabase.com/blog/fda-grants-argenica-rare-paediatric-disease-designation-for-arg-007-in-the-treatment-of-hie 2024-03-25T03:42:33 https://maestrodatabase.com/blog/factors-associated-with-generic-drug-uptake-in-the-united-states-2012-to-2017 2021-06-21T08:42:02 https://maestrodatabase.com/blog/vedolizumab-for-the-treatment-of-patients-with-chronic-refractory-pouchitis 2022-09-23T04:25:38 https://maestrodatabase.com/blog/novartis-cosentyx-wins-nice-backing-for-non-radiographic-axial-spondyloarthritis 2021-06-21T09:40:44 https://maestrodatabase.com/blog/us-fda-approves-opsynvi-macitentan-and-tadalafil-as-the-first-and-only-once-daily-single-tablet-combination-therapy-for-patients-with-pulmonary-arterial-hypertension 2024-03-25T01:53:41 https://maestrodatabase.com/blog/supernus-provides-regulatory-updates-for-spn-812-and-spn-830 2020-11-10T19:57:30 https://maestrodatabase.com/blog/ultomiris-approved-in-europe-for-the-treatment-of-adults-with-generalised-myasthenia-gravis 2022-09-23T07:10:41 https://maestrodatabase.com/blog/agios-submits-new-drug-application-to-fda-for-mitapivat-for-treatment-of-adults-with-pyruvate-kinase-deficiency 2021-06-21T11:24:14 https://maestrodatabase.com/blog/atopic-dermatitis-patients-demand-reimbursement-for-sanofis-biological-drug 2019-06-13T12:52:34 https://maestrodatabase.com/blog/aimmune-wins-over-icer-for-peanut-allergy-product 2019-06-13T12:45:49 https://maestrodatabase.com/blog/nice-recommends-new-chemotherapy-free-treatment-option-for-people-with-untreated-chronic-lymphocytic-leukaemia 2020-11-10T19:44:47 https://maestrodatabase.com/blog/patients-in-other-countries-are-getting-access-to-breakthrough-cancer-drugs-faster-than-aussies 2020-11-10T19:53:00 https://maestrodatabase.com/blog/fda-approves-first-oral-blood-thinning-medication-for-children 2021-06-21T21:02:52 https://maestrodatabase.com/blog/trump-picks-show-over-substance-with-drug-price-for-veterans 2019-06-13T21:07:36 https://maestrodatabase.com/blog/ema-publishes-agenda-for-21-24-june-chmp-meeting 2021-06-21T20:56:51 https://maestrodatabase.com/blog/role-of-health-technology-assessment-in-drug-policies-korea 2019-06-13T21:03:48 https://maestrodatabase.com/blog/pharmaceutical-policy-reforms-to-regulate-drug-prices-in-the-asia-pacific-region-the-case-of-australia-china-india-malaysia-new-zealand-and-south-korea 2019-06-13T21:00:54 https://maestrodatabase.com/blog/health-canada-approves-maviret-8-week-treatment-duration-for-treatment-naive-patients-with-genotype-3-compensated-cirrhosis 2020-11-10T20:24:58 https://maestrodatabase.com/blog/realigning-incentives-to-optimise-generic-and-biosimilar-prescribing 2019-06-13T20:52:05 https://maestrodatabase.com/blog/bayer-submits-regulatory-applications-for-oncology-treatment-combination-of-copanlisib-and-rituximab-in-the-u-dot-s-and-eu 2021-06-21T21:10:19 https://maestrodatabase.com/blog/state-efforts-to-lower-health-care-prices-paid-by-private-insurers 2019-06-13T21:23:02 https://maestrodatabase.com/blog/rafael-pharmaceuticals-receives-fda-fast-track-designation-for-cpi-613-devimistat-for-the-treatment-of-pancreatic-cancer 2020-11-10T20:05:48 https://maestrodatabase.com/blog/1-500-people-set-to-receive-new-skin-cancer-treatment-that-reduces-the-risk-of-it-returning-and-spreading 2022-09-23T11:24:17 https://maestrodatabase.com/blog/amgen-wins-fda-approval-for-kanjinti-injection-for-treatment-of-breast-cancer-gastro-esophageal-junction-adenocarcinoma 2019-06-13T21:13:03 https://maestrodatabase.com/blog/wockhardt-submits-new-drug-application-to-us-fda-for-zidebactam-cefepime-wck-5222-for-treatment-of-serious-gram-negative-infections 2025-10-02T05:48:13 https://maestrodatabase.com/blog/nice-approves-routine-use-of-drug-combination-for-advanced-breast-cancer 2022-09-23T10:23:56 https://maestrodatabase.com/blog/bausch-health-canada-receives-a-positive-recommendation-from-the-cadth-canadian-drug-expert-committee-for-duobrii---a-novel-topical-anti-psoriatic-prescription-drug 2020-11-10T20:19:44 https://maestrodatabase.com/blog/covid-19-vaccine-safety-report-23-september-2022 2022-09-23T10:58:46 https://maestrodatabase.com/blog/pixuvri-approved-for-use-in-eu 2019-06-13T21:29:38 https://maestrodatabase.com/blog/nice-20th-anniversary-parliamentary-reception-and-awards 2019-06-13T21:25:58 https://maestrodatabase.com/blog/manufacturer-moves-to-bring-life-changing-cystic-fibrosis-drugs-to-canada 2020-11-10T20:30:50 https://maestrodatabase.com/blog/notice-of-compliance-with-conditions-granted-for-retevmo-selpercatinib-the-first-therapy-in-canada-specifically-for-patients-with-advanced-ret-driven-lung-and-thyroid-cancers 2021-06-21T21:19:30 https://maestrodatabase.com/blog/new-cancer-drugs-to-be-covered-by-national-health-insurance 2020-11-10T20:34:46 https://maestrodatabase.com/blog/novartis-drug-pkc412-midostaurin-granted-fda-priority-review-for-newly-diagnosed-flt3-mutated-aml-and-advanced-systemic-mastocytosis 2016-11-14T06:52:18 https://maestrodatabase.com/blog/ontario-to-publicly-reimburse-albrioza-for-the-treatment-of-als 2023-06-29T04:58:49 https://maestrodatabase.com/blog/chmp-recommendation-for-csls-afstyla-rfviii-sc 2016-11-14T07:10:05 https://maestrodatabase.com/blog/decision-to-list-enzyme-replacement-therapies-for-some-rare-disorders 2016-11-14T06:59:08 https://maestrodatabase.com/blog/esperion-announces-submission-of-application-for-expanded-indication-with-the-ema-for-nilemdo-bempedoic-acid-tablet-and-nustendi-bempedoic-acid-and-ezetimibe-tablet 2023-06-29T04:37:49 https://maestrodatabase.com/blog/tga-key-performance-indicators-july-2015-to-june-2016 2016-11-14T07:03:37 https://maestrodatabase.com/blog/how-to-facilitate-development-of-cancer-treatment-based-on-genetically-modified-t-cells 2016-11-14T07:25:19 https://maestrodatabase.com/blog/graeme-samuel-urges-cuts-to-price-fixing-prostheses-list 2016-11-14T07:19:37 https://maestrodatabase.com/blog/medibanks-drummond-prostheses-savings-just-the-start 2016-11-14T07:22:40 https://maestrodatabase.com/blog/beigene-announces-acceptance-of-supplemental-new-drug-application-in-china-for-brukinsa-zanubrutinib-in-chronic-lymphocytic-leukaemia-with-breakthrough-therapy-designation 2022-01-30T00:14:10 https://maestrodatabase.com/blog/too-much-chemotherapy 2016-11-14T19:43:24 https://maestrodatabase.com/blog/clinical-trials-for-authorized-biosimilars-in-the-european-union-a-systematic-review 2016-11-14T19:49:08 https://maestrodatabase.com/blog/ultomiris-approved-in-the-us-for-the-treatment-of-adults-with-neuromyelitis-optica-spectrum-disorder 2024-03-25T07:03:55 https://maestrodatabase.com/blog/abbvies-humira-adalimumab-receives-chmp-positive-opinion-to-treat-adolescents-with-hidradenitis-suppurativa-a-chronic-inflammatory-skin-disease 2016-11-14T19:34:48 https://maestrodatabase.com/blog/european-commission-approves-parsabiv-etelcalcetide-for-the-treatment-of-secondary-hyperparathyroidism-in-adults-on-haemodialysis 2016-11-14T20:10:09 https://maestrodatabase.com/blog/bayer-warns-planned-german-price-curbs-may-restrict-drug-access 2016-11-14T20:00:06 https://maestrodatabase.com/blog/modelling-and-simulation-in-the-development-of-medicines 2016-11-14T20:04:48 https://maestrodatabase.com/blog/why-big-data-should-make-insurance-cheaper 2016-11-14T20:22:54 https://maestrodatabase.com/blog/pharmas-not-off-the-hook-for-high-drug-prices 2016-11-14T20:25:12 https://maestrodatabase.com/blog/medical-research-caught-in-cross-fire-of-r-and-d-tax-overhaul 2018-04-09T03:06:52 https://maestrodatabase.com/blog/regeneron-provides-update-on-biologics-license-application-for-odronextamab 2024-03-25T21:38:18 https://maestrodatabase.com/blog/fda-grants-rare-paediatric-disease-designation-to-dovitinib-for-osteosarcoma 2022-09-24T08:22:40 https://maestrodatabase.com/blog/melinta-therapeutics-granted-european-commission-marketing-authorisation-for-vabomere-meropenem-with-vaborbactam 2018-11-28T06:18:30 https://maestrodatabase.com/blog/icer-provides-second-update-to-pricing-models-for-remdesivir-as-a-treatment-for-covid-19 2020-11-10T23:54:07 https://maestrodatabase.com/blog/pharmac-to-fund-new-haemophilia-medicine 2020-11-10T23:57:55 https://maestrodatabase.com/blog/bayer-receives-eu-approval-for-its-haemophilia-a-treatment-jivi 2018-11-28T06:14:23 https://maestrodatabase.com/blog/bausch-health-and-glenmark-announce-the-approval-of-ryaltris-in-canada 2022-09-24T08:15:47 https://maestrodatabase.com/blog/drug-makers-gain-more-access-to-china-but-at-a-price 2018-11-28T06:30:36 https://maestrodatabase.com/blog/genprex-receives-us-fda-fast-track-designation-for-reqorsa-immunogene-therapy-in-combination-with-tecentriq-for-the-treatment-of-small-cell-lung-cancer 2023-06-29T07:13:20 https://maestrodatabase.com/blog/lymphoma-therapy-now-approved-for-australian-patients-with-diffuse-large-b-cell-lymphoma 2023-06-29T07:05:10 https://maestrodatabase.com/blog/amazon-muscles-into-health-care-with-patient-record-software 2018-11-28T10:09:58 https://maestrodatabase.com/blog/secukinumab-for-the-treatment-of-patients-with-moderate-to-severe-hidradenitis-suppurativa 2023-06-29T06:55:52 https://maestrodatabase.com/blog/decision-to-widen-access-to-treatments-for-juvenile-idiopathic-arthritis 2020-11-11T03:23:06 https://maestrodatabase.com/blog/trump-medicare-plan-targets-drugs-from-astrazeneca-to-roche 2018-11-28T06:42:35 https://maestrodatabase.com/blog/first-children-set-to-receive-novartis-kymriah 2018-11-28T08:12:46 https://maestrodatabase.com/blog/fda-approves-first-biosimilar-for-treatment-of-adult-patients-with-non-hodgkins-lymphoma 2018-11-28T19:02:39 https://maestrodatabase.com/blog/commonwealth-loses-appeal-in-clopidogrel-pbs-damages-undertaking-case-important-lessons-for-patentees-and-generics-alike 2023-06-29T10:10:19 https://maestrodatabase.com/blog/moderna-asks-fda-to-authorise-omicron-covid-boosters-for-children-as-young-as-6-years-old 2022-09-24T21:47:56 https://maestrodatabase.com/blog/zai-lab-announces-nda-acceptance-of-repotrectinib-for-patients-with-ros1-positive-nsclc-by-chinas-nmpa 2023-06-29T10:18:04 https://maestrodatabase.com/blog/trump-medicare-plan-promises-lower-prescription-prices-for-seniors-but-also-risks-losing-coverage-of-some-critical-cancer-hiv-depression-drugs 2018-11-28T10:14:33 https://maestrodatabase.com/blog/novartis-announces-eu-approval-of-gilenya-for-children-and-adolescents-with-ms-making-it-the-first-and-only-oral-disease-modifying-treatment-for-these-patients-in-europe 2018-11-29T10:43:38 https://maestrodatabase.com/blog/prostate-cancer-tauranga-man-spends-212-000-dollars-on-treatment 2022-09-24T09:27:11 https://maestrodatabase.com/blog/fda-approves-first-cellular-therapy-to-treat-patients-with-type-1-diabetes 2023-06-29T08:17:08 https://maestrodatabase.com/blog/pharmac-proposes-changes-to-make-it-easier-to-access-hiv-medicines 2025-10-02T07:47:25 https://maestrodatabase.com/blog/therapeutic-goods-administration-gives-green-light-for-early-pfizer-vaccine 2020-11-11T03:34:50 https://maestrodatabase.com/blog/sebela-pharmaceuticals-receives-fda-approval-for-sutab-tablets-for-colonoscopy-preparation 2020-11-11T03:38:32 https://maestrodatabase.com/blog/nice-publishes-fad-for-new-indication-for-xeljanz 2018-11-28T19:42:24 https://maestrodatabase.com/blog/eton-pharmaceuticals-receives-complete-response-letter-for-dehydrated-alcohol-injection 2023-06-29T07:33:49 https://maestrodatabase.com/blog/proposal-to-remove-the-funding-restrictions-for-candesartan 2018-04-09T04:09:15 https://maestrodatabase.com/blog/cms-takes-steps-to-ensure-medicare-beneficiaries-have-wide-access-to-covid-19-antibody-treatment 2020-11-11T03:43:30 https://maestrodatabase.com/blog/sarepta-hit-with-call-to-drop-duchenne-drug-costs 2018-04-09T05:04:35 https://maestrodatabase.com/blog/fda-approves-first-treatment-for-lambert-eaton-myasthenic-syndrome-a-rare-auto-immune-disorder 2018-11-29T10:56:46 https://maestrodatabase.com/blog/support-for-ending-and-managing-hiv 2018-11-29T11:04:48 https://maestrodatabase.com/blog/fda-approves-treatment-for-adult-patients-who-have-relapsed-or-refractory-acute-myeloid-leukaemia-with-a-certain-genetic-mutation 2018-11-29T10:52:55 https://maestrodatabase.com/blog/ensuring-innovation-and-competition-for-biologics-leads-to-more-timely-products-for-patients 2019-06-14T01:08:58 https://maestrodatabase.com/blog/novartis-completes-certification-of-initial-sites-in-ontario-for-first-approved-canadian-car-t-therapy-kymriah-tisagenlecleucel 2019-12-13T02:06:22 https://maestrodatabase.com/blog/galapagos-receives-fast-track-designation-from-fda-for-glpg1972-slash-s201086-in-osteoarthritis 2018-11-29T11:35:37 https://maestrodatabase.com/blog/nice-u-turn-sees-roches-tecentriq-backed-for-lung-cancer 2018-04-09T11:18:13 https://maestrodatabase.com/blog/european-commission-approves-mercks-delstrigo-doravirine-slash-lamivudine-slash-tenofovir-disoproxil-fumarate-a-once-daily-fixed-dose-combination-tablet-as-a-complete-regimen-and-pifeltro-doravirine-an-nnrti-both-for-the-treatment-of-hiv-1-in-appropriate-patients 2018-11-29T11:29:15 https://maestrodatabase.com/blog/tonix-pharmaceuticals-receives-rare-paediatric-disease-designation-from-the-fda-for-tnx-2900-for-the-treatment-of-prader-willi-syndrome 2024-03-26T02:43:57 https://maestrodatabase.com/blog/doctors-patients-protest-at-plans-to-cap-medicine-prices 2022-09-24T21:57:44 https://maestrodatabase.com/blog/life-extending-treatment-for-patients-with-advanced-liver-cancer-recommended-by-nice 2018-11-29T19:54:00 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-treatment-for-post-traumatic-stress-disorder 2024-03-26T20:24:26 https://maestrodatabase.com/blog/five-new-medicines-accepted-by-smc-for-use-by-nhsscotland 2018-04-09T20:46:32 https://maestrodatabase.com/blog/elranatamab-for-treating-relapsed-and-refractory-multiple-myeloma-after-three-or-more-treatments-final-guidance 2024-12-12T00:35:14 https://maestrodatabase.com/blog/acceleron-receives-fda-fast-track-designation-for-ace-083-in-charcot-marie-tooth-disease 2018-11-29T11:52:30 https://maestrodatabase.com/blog/public-hearing-on-13-june-2018 2018-04-09T11:58:07 https://maestrodatabase.com/blog/icer-appoints-athelia-tia-tilson-as-vice-president-of-development 2018-11-29T19:51:20 https://maestrodatabase.com/blog/y-mabs-gd2-gd3-vaccine-granted-rare-paediatric-disease-designation 2019-12-13T02:12:22 https://maestrodatabase.com/blog/why-do-new-medicines-cost-so-much-and-what-can-we-do-about-it 2018-04-09T12:04:18 https://maestrodatabase.com/blog/ontario-grants-broader-access-to-spinraza-nusinersen-for-patients-living-with-spinal-muscular-atrophy 2019-06-14T01:44:30 https://maestrodatabase.com/blog/merck-raised-prices-five-drugs-including-keytruda-in-november 2018-11-29T20:13:34 https://maestrodatabase.com/blog/health-canada-approves-tecentriq-atezolizumab-for-the-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer 2018-04-09T21:41:19 https://maestrodatabase.com/blog/submissions-received-scope-of-regulated-software-based-medical-devices 2020-08-16T21:30:27 https://maestrodatabase.com/blog/cms-issues-final-2019-payment-notice-rule-to-increase-access-to-affordable-health-plans-for-americans-suffering-from-high-obamacare-premiums 2018-04-09T21:16:01 https://maestrodatabase.com/blog/five-additional-countries-to-benefit-from-eu-us-mutual-recognition-agreement-for-inspections 2018-11-29T19:57:22 https://maestrodatabase.com/blog/fda-offers-guidance-to-enhance-diversity-in-clinical-trials-encourage-inclusivity-in-medical-product-development 2020-11-11T05:07:40 https://maestrodatabase.com/blog/fda-accepts-new-drug-application-for-duvelisib-and-grants-priority-review 2018-04-09T21:19:46 https://maestrodatabase.com/blog/hhs-allocates-lilly-therapeutic-to-treat-patients-with-mild-to-moderate-covid-19 2020-11-11T05:11:19 https://maestrodatabase.com/blog/five-more-cancer-drugs-go-on-the-pbs 2018-11-29T20:10:20 https://maestrodatabase.com/blog/decision-to-remove-funding-restrictions-for-alendronate-70-mg-products-decrease-price-and-award-sole-supply 2018-11-29T20:31:44 https://maestrodatabase.com/blog/amgen-cuts-repathas-price-by-60-percent-will-value-based-pricing-support-value-based-patient-access 2018-11-29T20:41:11 https://maestrodatabase.com/blog/the-pandemic-claims-new-victims-prestigious-medical-journals 2020-06-15T11:37:37 https://maestrodatabase.com/blog/billionaire-philanthropist-john-arnold-on-drug-prices-congress-needs-to-act 2018-11-29T20:17:53 https://maestrodatabase.com/blog/biogens-fda-application-for-alzheimers-drug-drags-on 2020-06-15T11:45:59 https://maestrodatabase.com/blog/the-evolution-of-adaptiveness-balancing-speed-and-evidence 2018-11-29T20:29:17 https://maestrodatabase.com/blog/astellas-vyloy-zolbetuximab-approved-in-japan-for-treatment-of-gastric-cancer 2024-03-26T20:40:06 https://maestrodatabase.com/blog/cost-and-value-of-cancer-medicines-in-a-single-payer-public-health-system-in-ontario-canada-a-cross-sectional-study 2024-03-26T20:34:17 https://maestrodatabase.com/blog/johnson-and-johnsons-nipocalimab-granted-us-fda-fast-track-designation-to-reduce-the-risk-of-foetal-neonatal-allo-immune-thrombocytopenia-in-allo-immunised-pregnant-adults 2024-03-26T20:30:05 https://maestrodatabase.com/blog/nice-backs-rozlytrek-for-subset-of-nsclc-patients 2020-06-15T11:32:06 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-european-commission-approval-for-onureg-azacitidine-tablets-as-frontline-oral-maintenance-therapy-for-adults-with-acute-myeloid-leukaemia 2021-06-22T01:24:36 https://maestrodatabase.com/blog/once-daily-anticoagulant-lixiana-edoxaban-tosylate-approved-in-canada-for-stroke-prevention-in-atrial-fibrillation-and-for-the-treatment-and-prevention-of-recurrent-deep-vein-thrombosis-and-pulmonary-embolism 2016-11-15T04:14:06 https://maestrodatabase.com/blog/global-regulators-work-towards-alignment-on-policy-approaches-and-regulatory-flexibility-during-covid-19---update-number-4 2020-06-15T20:54:23 https://maestrodatabase.com/blog/eagle-pharmaceuticals-initiates-rolling-submission-of-nda-for-ryanodex-in-exertional-heat-stroke 2016-11-15T02:54:08 https://maestrodatabase.com/blog/fda-approves-mercks-winrevair-sotatercept-csrk-a-first-in-class-treatment-for-adults-with-pulmonary-arterial-hypertension-who-group-1 2024-03-26T22:26:38 https://maestrodatabase.com/blog/teen-with-spinal-muscular-atrophy-campaigns-for-wonder-drug-to-survive 2020-06-15T20:57:48 https://maestrodatabase.com/blog/fda-may-require-post-marketing-studies-to-analyse-long-term-effects-of-breast-cancer-drugs 2021-06-22T01:32:59 https://maestrodatabase.com/blog/dynavax-receives-complete-response-letter-from-u-dot-s-fda-for-biologics-license-application-for-heplisav-b 2016-12-20T06:27:35 https://maestrodatabase.com/blog/pfizer-vaccine-will-be-shipped-in-eskies-as-vaccines-get-preliminary-approval 2020-11-11T06:56:45 https://maestrodatabase.com/blog/rising-costs-explain-why-canada-is-switching-to-biosimilars 2020-06-15T21:01:33 https://maestrodatabase.com/blog/calico-life-sciences-announces-us-fda-fast-track-designation-for-investigational-treatment-of-autosomal-dominant-polycystic-kidney-disease 2025-10-02T23:57:26 https://maestrodatabase.com/blog/update-to-pbs-pricing-fact-sheet-on-setting-an-approved-ex-manufacturer-price-for-new-or-extended-listings 2016-11-15T05:53:07 https://maestrodatabase.com/blog/pharmaceutical-companies-strategies-for-reaching-the-poor-are-maturing-but-expansion-is-gradual 2016-11-15T06:31:34 https://maestrodatabase.com/blog/a-rare-loss-for-u-dot-s-pharma-lobby-will-cost-the-industry-billions 2018-04-10T04:35:25 https://maestrodatabase.com/blog/covid-19-and-remdesivir-rethinking-how-we-measure-a-drugs-value 2020-06-15T12:24:20 https://maestrodatabase.com/blog/clinigens-totect-dexrazoxane-receives-fda-approval-for-new-indication-to-treat-incidence-and-severity-of-cardiomyopathy-associated-with-doxorubicin-in-women-with-metastatic-breast-cancer 2020-11-11T06:01:04 https://maestrodatabase.com/blog/stada-receives-positive-opinion-from-the-ema-for-teriparatide-biosimilar 2016-11-15T06:25:22 https://maestrodatabase.com/blog/the-unprecedented-challenge-of-pricing-a-coronavirus-vaccine 2020-06-15T12:28:45 https://maestrodatabase.com/blog/covid-19-update-fda-revokes-emergency-use-authorisation-for-chloroquine-and-hydroxychloroquine 2020-06-15T20:50:55 https://maestrodatabase.com/blog/nice-publishes-draft-guidance-on-the-use-of-cinqaero-reslizumab 2016-11-15T09:18:48 https://maestrodatabase.com/blog/baudax-bio-announces-full-commercial-launch-of-anjeso-and-receipt-of-unique-c-code-and-pass-through-payment-status-effective-1-july-2020 2020-06-15T21:16:35 https://maestrodatabase.com/blog/trump-just-dropped-a-big-hint-to-the-pharmaceutical-industry 2016-11-15T20:14:12 https://maestrodatabase.com/blog/what-could-be-worse-than-repealing-all-of-obamacare 2016-11-15T09:16:28 https://maestrodatabase.com/blog/the-european-commission-launches-a-public-consultation-on-the-paediatric-regulation 2016-11-15T20:28:36 https://maestrodatabase.com/blog/romosozumab-in-osteoporosis-considerable-added-benefit-for-women-after-menopause 2020-06-15T21:22:19 https://maestrodatabase.com/blog/taysha-gene-therapies-announces-fda-breakthrough-therapy-designation-and-provides-positive-regulatory-update-on-tsha-102-in-rett-syndrome 2025-10-03T00:36:10 https://maestrodatabase.com/blog/nice-says-pancreatic-cancer-treatment-considered-not-cost-effective-for-routine-nhs-use 2016-11-15T20:20:28 https://maestrodatabase.com/blog/swedens-cost-of-medicines-is-increasing 2021-06-16T12:01:49 https://maestrodatabase.com/blog/revising-the-guideline-on-first-in-human-clinical-trials 2016-11-15T20:26:25 https://maestrodatabase.com/blog/jazz-pharmaceuticals-announces-u-dot-s-fda-accelerated-approval-of-zepzelca-lurbinectedin-for-the-treatment-of-metastatic-small-cell-lung-cancer 2020-06-15T21:05:42 https://maestrodatabase.com/blog/fda-approves-lurbinectedin-in-combination-with-atezolizumab-or-atezolizumab-and-hyaluronidase-tqjs-for-extensive-stage-small-cell-lung-cancer 2025-10-03T00:42:25 https://maestrodatabase.com/blog/pharma-blockchains-ai-for-drug-development 2019-06-14T23:23:30 https://maestrodatabase.com/blog/chmp-issues-positive-opinion-to-expand-jardiance-empagliflozin-indication-based-on-unprecedented-benefit-in-adult-heart-failure-patients-with-preserved-ejection-fraction 2022-01-30T03:34:47 https://maestrodatabase.com/blog/fda-permits-marketing-of-first-game-based-digital-therapeutic-to-improve-attention-function-in-children-with-adhd 2020-06-15T21:11:19 https://maestrodatabase.com/blog/blueprint-medicines-ayvakyt-avapritinib-receives-positive-chmp-opinion-for-the-treatment-of-adults-with-advanced-systemic-mastocytosis 2022-01-30T03:41:56 https://maestrodatabase.com/blog/we-either-buy-insulin-or-we-die 2019-06-14T23:19:42 https://maestrodatabase.com/blog/sarepta-therapeutics-announces-fda-approval-of-vyondys-golodirsen-injection-for-the-treatment-of-duchenne-muscular-dystrophy-in-patients-amenable-to-skipping-exon-53 2019-12-13T03:54:16 https://maestrodatabase.com/blog/sunovion-announces-health-canada-approval-of-kynmobi-apomorphine-hydrochloride-soluble-film-for-the-treatment-of-parkinsons-disease-off-episodes 2020-06-15T21:36:01 https://maestrodatabase.com/blog/patient-advocates-clash-over-wisdom-of-approving-drugs-faster-and-faster 2024-03-27T01:20:00 https://maestrodatabase.com/blog/proposal-involving-treatments-for-multiple-sclerosis-narcolepsy-and-attention-deficit-hyperactivity-disorder 2018-11-30T08:04:58 https://maestrodatabase.com/blog/outcome-statements-for-october-2024-stakeholder-meetings-oral-contraceptives-and-migraine 2024-12-12T03:04:07 https://maestrodatabase.com/blog/nacuity-pharmaceuticals-granted-us-fda-breakthrough-therapy-designation-for-npi-001-n-acetylcysteine-amide-tablets-for-the-treatment-of-retinitis-pigmentosa 2025-10-03T00:58:27 https://maestrodatabase.com/blog/decision-to-fund-ceftriaxone-in-the-community-for-suspected-meningococcal-disease 2018-11-30T01:19:18 https://maestrodatabase.com/blog/surface-oncology-announces-fda-fast-track-designation-granted-by-u-dot-s-food-and-drug-administration-for-srf388-to-treat-liver-cancer 2020-11-11T19:20:00 https://maestrodatabase.com/blog/eu-recommendations-for-2024-slash-2025-seasonal-flu-vaccine-composition 2024-03-27T01:33:56 https://maestrodatabase.com/blog/vertex-announces-european-commission-approval-for-kalydeco-ivacaftor-to-treat-patients-with-cystic-fibrosis-aged-12-to-<24-months-with-certain-mutations-in-the-cftr-gene 2018-11-30T11:45:23 https://maestrodatabase.com/blog/health-canada-approves-agamree-vamorolone-as-the-first-treatment-for-duchenne-muscular-dystrophy-in-canada 2025-10-03T01:57:11 https://maestrodatabase.com/blog/nice-u-turn-on-opdivo-for-skin-cancer-recurrence 2018-11-30T08:14:04 https://maestrodatabase.com/blog/nice-publishes-draft-guidance-on-new-treatment-for-patients-with-immune-thrombocytopenia 2020-11-11T19:46:55 https://maestrodatabase.com/blog/ritlecitinib-tosylate-for-the-treatment-of-people-12-years-and-over-with-alopecia-areata 2024-03-27T02:03:07 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-december-2018-update 2018-11-30T23:40:00 https://maestrodatabase.com/blog/obamacares-very-stable-genius 2018-04-10T11:06:16 https://maestrodatabase.com/blog/fda-announces-pilot-program-with-who-to-expedite-review-of-hiv-drug-applications 2018-11-30T23:33:55 https://maestrodatabase.com/blog/the-health-202-trumps-latest-move-to-lower-drug-spending-pits-patients-versus-insurers 2018-11-30T23:56:16 https://maestrodatabase.com/blog/european-commission-approves-lorviqua-lorlatinib-as-a-first-line-treatment-for-alk-positive-advanced-lung-cancer 2022-01-30T04:04:53 https://maestrodatabase.com/blog/revised-guideline-to-assess-risk-of-human-medicines-for-the-environment 2018-11-30T23:49:20 https://maestrodatabase.com/blog/angiocrine-bioscience-announces-fda-regenerative-medicine-advanced-therapy-designation-granted-to-ab-205-universal-e-cel-cell-therapy-to-treat-organ-vascular-niche-injuries-for-the-prevention-of-severe-toxicities-in-lymphoma-patients-undergoing-curative-high-dose-therapy-with-autologous-stem-cell-transplantation 2020-11-11T19:24:34 https://maestrodatabase.com/blog/data-from-patient-registries-to-replace-clinical-trials-in-previously-untreated-haemophilia-patients 2018-11-30T23:51:31 https://maestrodatabase.com/blog/fda-accepts-filing-of-new-oestrogen-free-oral-contraceptive-developed-by-exeltis 2018-12-01T00:21:02 https://maestrodatabase.com/blog/intra-cellular-therapies-submits-supplemental-new-drug-application-to-fda-for-caplyta-lumateperone-for-the-treatment-of-major-depressive-disorder-as-adjunctive-therapy 2024-12-12T04:42:49 https://maestrodatabase.com/blog/novartis-ceo-vas-narasimhan-on-the-price-of-gene-therapies-its-a-challenge-we-have-to-solve 2018-12-01T00:01:15 https://maestrodatabase.com/blog/daratumumab-in-combination-with-bortezomib-cyclophosphamide-and-dexamethasone-for-the-treatment-of-adults-with-newly-diagnosed-systemic-light-chain-amyloidosis 2024-03-27T02:18:35 https://maestrodatabase.com/blog/italfarmaco-group-completes-fda-submission-of-new-drug-application-for-givinostat-in-duchenne-muscular-dystrophy-and-receives-priority-review 2023-06-29T21:33:33 https://maestrodatabase.com/blog/us-fda-approves-biomarins-roctavian-valoctocogene-roxaparvovec-rvox-the-first-and-only-gene-therapy-for-adults-with-severe-haemophilia-a 2023-06-29T21:25:49 https://maestrodatabase.com/blog/takeda-announces-approval-of-adzynma-intravenous-injection-1500-apadamtase-alfa-slash-cinaxadamtase-alfa-in-japan-for-patients-with-congenital-thrombotic-thrombocytopenic-purpura 2024-03-27T02:11:05 https://maestrodatabase.com/blog/alvotech-provides-regulatory-update-on-second-biologics-license-application-for-avt02 2023-06-29T12:31:37 https://maestrodatabase.com/blog/abbvie-and-neurocrine-biosciences-announce-pdufa-target-date-of-q3-2018-for-elagolix-in-endometriosis-associated-pain 2018-04-10T12:35:59 https://maestrodatabase.com/blog/how-are-child-specific-utility-instruments-used-in-decision-making-in-australia-a-review-of-pharmaceutical-benefits-advisory-committee-public-summary-documents 2022-01-30T04:35:02 https://maestrodatabase.com/blog/syndax-announces-fda-priority-review-of-nda-for-revumenib-for-the-treatment-of-relapsed-slash-refractory-kmt2ar-acute-leukaemia 2024-03-27T03:25:06 https://maestrodatabase.com/blog/fda-grants-revescor-rexlemestrocel-l-regenerative-medicine-advanced-therapy-designation-in-children-with-congenital-heart-disease 2024-12-12T04:59:02 https://maestrodatabase.com/blog/innovative-drugs-need-a-new-regulatory-approach 2018-04-10T20:36:27 https://maestrodatabase.com/blog/takeda-warns-new-drugs-at-risk-if-countries-push-deep-price-cuts 2023-06-29T21:51:58 https://maestrodatabase.com/blog/trump-administration-rewrites-aca-insurance-rules-to-give-more-power-to-states 2018-04-10T20:41:49 https://maestrodatabase.com/blog/amicus-therapeutics-announces-approval-and-launch-of-new-pompe-disease-therapy-in-the-european-union 2023-06-29T21:44:33 https://maestrodatabase.com/blog/epicentrxs-oncolytic-virus-delivered-tgfb-inhibitor-adapt-001-receives-fda-fast-track-designation-for-recurrent-or-refractory-soft-tissue-sarcoma-treatment 2024-12-12T05:17:29 https://maestrodatabase.com/blog/icer-publishes-guidance-on-improving-the-development-and-use-of-real-world-evidence-for-drug-coverage-and-formulary-decisions 2018-04-10T21:21:28 https://maestrodatabase.com/blog/feds-broaden-the-definition-of-pharmacy-in-a-bid-to-level-playing-field-for-startup 2018-04-10T21:37:29 https://maestrodatabase.com/blog/armo-biosciences-immunotherapy-am0010-receives-orphan-drug-and-fast-track-designations-from-the-u-dot-s-fda-for-the-treatment-of-pancreatic-cancer 2016-11-16T05:41:16 https://maestrodatabase.com/blog/wasteful-wrong-headed 2018-04-10T20:45:05 https://maestrodatabase.com/blog/alberta-changes-coverage-of-biologic-drugs-for-people-with-crohns-diabetes-arthritis 2019-12-13T05:12:35 https://maestrodatabase.com/blog/acadia-pharmaceuticals-submits-supplemental-new-drug-application-to-u-dot-s-fda-for-nuplazid-pimavanserin-for-the-treatment-of-hallucinations-and-delusions-associated-with-dementia-related-psychosis 2020-06-16T01:12:52 https://maestrodatabase.com/blog/fda-clears-first-contact-lens-with-light-adaptive-technology 2018-04-10T20:52:39 https://maestrodatabase.com/blog/a-loss-for-the-rest-of-us-an-fda-approval-is-a-boon-for-a-drug-maker-but-could-come-at-a-major-cost-for-patients 2018-12-01T01:09:13 https://maestrodatabase.com/blog/study-shows-promise-for-expensive-cholesterol-drugs-but-they-are-still-hard-to-obtain 2016-11-16T19:47:27 https://maestrodatabase.com/blog/ama-embraces-value-based-drug-pricing 2016-11-16T19:51:07 https://maestrodatabase.com/blog/proposal-to-list-oral-betaine-for-rare-disorder 2016-11-16T05:59:44 https://maestrodatabase.com/blog/pbs-expenditure-and-prescriptions-report-2018-19 2019-12-13T05:26:52 https://maestrodatabase.com/blog/republican-lawmakers-are-scrambling-to-find-an-alternative-to-obamacare 2016-11-16T19:44:25 https://maestrodatabase.com/blog/trump-used-to-rail-against-drug-prices-now-the-industrys-allies-are-helping-shape-his-agenda 2016-11-16T19:55:48 https://maestrodatabase.com/blog/how-can-clinical-research-networks-support-developers-of-medicines-for-children 2016-11-16T20:05:40 https://maestrodatabase.com/blog/trump-should-be-good-medicine-for-the-pharmaceutical-industry-heres-why 2016-11-16T19:53:46 https://maestrodatabase.com/blog/how-drug-price-pressure-helped-sink-novos-insulin-pill 2016-11-16T20:15:46 https://maestrodatabase.com/blog/drug-makers-to-fda-let-us-share-off-label-study-data-with-payers 2016-11-16T20:19:59 https://maestrodatabase.com/blog/japan-government-panel-halves-price-of-cancer-drug-opdivo 2016-11-16T20:09:26 https://maestrodatabase.com/blog/how-to-make-drug-prices-fair-to-u-dot-s-consumers 2016-11-16T20:12:54 https://maestrodatabase.com/blog/blurring-boundaries-how-jacinda-ardern-challenges-journalisms-ethics 2022-09-25T10:51:16 https://maestrodatabase.com/blog/amgen-and-allergan-submit-biosimilar-biologics-license-application-for-abp-215-to-u-dot-s-fda 2016-11-16T20:23:08 https://maestrodatabase.com/blog/my-brother-is-dying-while-theres-a-drug-that-could-stop-this 2022-09-25T20:32:10 https://maestrodatabase.com/blog/fda-approves-genentechs-vabysmo-the-first-bispecific-antibody-for-the-eye-to-treat-two-leading-causes-of-vision-loss 2022-01-30T05:06:46 https://maestrodatabase.com/blog/zenocutuzumab-granted-breakthrough-therapy-designation-by-the-us-fda-for-the-treatment-of-nrg1-plus-pancreatic-cancer 2023-06-29T23:24:39 https://maestrodatabase.com/blog/pharmac-funds-new-treatments-for-breast-and-blood-cancer 2024-03-27T04:41:08 https://maestrodatabase.com/blog/satralizumab-for-the-prevention-of-relapse-in-patients-with-a-neuromyelitis-optica-spectrum-disorder 2024-03-27T04:37:05 https://maestrodatabase.com/blog/pfizer-receives-positive-chmp-opinion-for-vyndaqel-for-use-in-patients-with-transthyretin-amyloid-cardiomyopathy-a-rare-and-fatal-disease 2019-12-13T21:20:53 https://maestrodatabase.com/blog/trifluridine-tipiracil-combination-in-colorectal-cancer-additional-benefit-only-for-some-patients 2016-11-16T21:39:40 https://maestrodatabase.com/blog/cystic-fibrosis-canada-says-life-changing-drug-coming-to-canada-but-approval-months-away 2020-11-12T01:10:33 https://maestrodatabase.com/blog/koselugo-approved-in-the-eu-for-children-with-neurofibromatosis-type-1-and-plexiform-neurofibromas 2021-06-22T06:24:57 https://maestrodatabase.com/blog/novartis-receives-positive-chmp-opinion-for-beovu-brolucizumab-for-the-treatment-of-wet-amd 2019-12-13T21:13:47 https://maestrodatabase.com/blog/highlights-from-the-december-9-12-chmp-meeting 2019-12-13T21:10:39 https://maestrodatabase.com/blog/coronavirus-vaccine-rollout-for-five-million-aussies-tipped-for-march 2020-11-12T01:13:00 https://maestrodatabase.com/blog/jardiance-empagliflozin-approved-in-europe-for-the-treatment-of-heart-failure-with-reduced-ejection-fraction 2021-06-22T06:09:15 https://maestrodatabase.com/blog/chmp-grants-positive-opinion-for-expanded-use-of-darzalex-daratumumab-in-combination-with-bortezomib-thalidomide-and-dexamethasone-for-patients-with-newly-diagnosed-multiple-myeloma-who-are-transplant-eligible 2019-12-13T21:26:27 https://maestrodatabase.com/blog/the-challenges-ahead-with-monoclonal-antibodies-from-authorisation-to-access 2020-11-12T00:57:42 https://maestrodatabase.com/blog/pembrolizumab-in-lung-cancer-evidence-of-considerable-additional-benefit 2016-11-16T22:47:43 https://maestrodatabase.com/blog/proposal-to-widen-access-to-valganciclovir-for-transplant-patients 2020-11-12T05:35:55 https://maestrodatabase.com/blog/european-commission-approves-stelara-ustekinumab-for-treatment-of-adults-with-moderately-to-severely-active-crohns-disease 2016-11-16T23:39:32 https://maestrodatabase.com/blog/proposal-for-the-supply-of-primidone-and-gabapentin 2021-06-22T06:57:14 https://maestrodatabase.com/blog/norgine-receives-positive-chmp-opinion-recommending-approval-of-npj5008-dantrolene-sodium-hemiheptahydrate-for-the-treatment-of-malignant-hyperthermia 2024-03-27T05:47:24 https://maestrodatabase.com/blog/two-combination-vaccine-candidates-for-prevention-of-influenza-and-covid-19-granted-fast-track-designation-in-the-us 2024-12-12T21:27:30 https://maestrodatabase.com/blog/icer-announces-most-significant-drug-price-hikes-unsupported-by-new-clinical-evidence-in-us 2024-12-12T21:05:21 https://maestrodatabase.com/blog/beyfortus-approved-in-japan-for-the-prevention-of-rsv-disease-in-infants 2024-03-27T09:14:57 https://maestrodatabase.com/blog/centrexion-therapeutics-announces-fast-track-designation-granted-by-fda-to-cntx-4975-for-treatment-of-mortons-neuroma 2016-11-17T03:38:30 https://maestrodatabase.com/blog/bioxcel-therapeutics-announces-completion-of-pre-nda-meeting-with-fda-for-bxcl501-for-the-acute-treatment-of-agitation-in-patients-with-schizophrenia-and-bipolar-disorders 2020-11-12T07:17:40 https://maestrodatabase.com/blog/fennec-pharmaceuticals-announces-fda-acceptance-of-new-drug-application-resubmission-for-pedmark 2021-06-22T10:07:27 https://maestrodatabase.com/blog/ema-publishes-agenda-for-9-12-november-chmp-meeting 2020-11-12T19:29:56 https://maestrodatabase.com/blog/maintaining-insurance-access-under-trump----a-strategy 2016-11-17T04:22:15 https://maestrodatabase.com/blog/the-end-of-obamacare 2016-11-17T04:24:08 https://maestrodatabase.com/blog/hira-gives-leclaza-benefits-easily-but-delays-decision-on-tagrisso 2021-06-22T10:50:19 https://maestrodatabase.com/blog/expertise-experience-and-excellence-twenty-years-of-patient-involvement-in-health-technology-assessment-at-nice-an-evolving-story 2020-11-12T19:49:23 https://maestrodatabase.com/blog/pharmac-wont-release-the-data-that-changed-its-mind-on-diabetes 2020-11-12T19:53:33 https://maestrodatabase.com/blog/azar-says-trumps-drug-price-shake-up-is-working 2020-11-12T19:59:14 https://maestrodatabase.com/blog/new-pbs-listing-vital-to-australians-living-with-acute-myeloid-leukaemia 2018-12-01T04:28:12 https://maestrodatabase.com/blog/acrux-receives-approval-from-the-fda-for-its-generic-version-of-jublia 2021-06-22T11:03:56 https://maestrodatabase.com/blog/nice-recommends-innovative-treatment-for-severe-blood-disorder-for-nhs-use 2020-11-12T19:33:58 https://maestrodatabase.com/blog/drug-prices-dont-budge-even-after-pressure-from-congress 2016-11-17T06:18:24 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-treatments-for-high-cholesterol 2020-11-12T19:41:33 https://maestrodatabase.com/blog/us-government-announces-covid-19-vaccine-agreement-with-pharmacies 2020-11-12T19:44:33 https://maestrodatabase.com/blog/medtronic-receives-fda-expanded-approval-for-arctic-front-family-of-cardiac-cryoablation-catheters-for-initial-use-for-recurrent-symptomatic-paroxysmal-atrial-fibrillation 2021-06-22T10:37:05 https://maestrodatabase.com/blog/truqap-plus-faslodex-approved-in-japan-for-patients-with-advanced-hr-positive-breast-cancer 2024-03-27T09:18:12 https://maestrodatabase.com/blog/two-additional-manufacturing-sites-for-biontech-slash-pfizers-covid-19-vaccine 2021-06-22T21:01:05 https://maestrodatabase.com/blog/moderna-initiates-rolling-submission-to-health-canada-for-updated-covid-19-vaccine 2023-06-30T01:57:47 https://maestrodatabase.com/blog/after-nice-okay-scots-denied-access-to-vifors-veltassa 2020-11-12T20:22:36 https://maestrodatabase.com/blog/bluebird-bio-ceo-defends-1-dollars-8-cents-million-price-for-gene-therapy----its-really-thinking-about-it-differently 2019-06-15T05:28:29 https://maestrodatabase.com/blog/price-discount-helps-give-green-light-for-breast-cancer-drug-pertuzumab 2016-11-17T10:31:11 https://maestrodatabase.com/blog/fda-grants-a-breakthrough-device-designation-for-spiderwort-spinal-cord-technology 2020-11-12T20:28:29 https://maestrodatabase.com/blog/tga-approves-ninlaro 2016-11-17T10:40:51 https://maestrodatabase.com/blog/new-drug-could-cost-the-government-as-much-as-it-spends-on-nasa 2021-06-22T21:19:35 https://maestrodatabase.com/blog/nice-approves-three-quarters-of-cdf-group-1-drugs-for-routine-use 2016-11-17T10:27:25 https://maestrodatabase.com/blog/covid-19-delta-strain-requires-two-vaccine-doses-for-protection-therapeutic-goods-administration-boss-says 2021-06-22T21:09:12 https://maestrodatabase.com/blog/promising-new-therapy-for-covid-19-cleared-by-u-dot-s-still-under-review-by-health-canada 2020-11-12T20:05:50 https://maestrodatabase.com/blog/meningococcal-b-vaccine-petition-to-lobby-for-pbs-inclusion-receives-thousands-of-signatures 2016-11-17T10:57:07 https://maestrodatabase.com/blog/janssen-submits-applications-in-u-dot-s-and-eu-seeking-approval-of-darzalex-faspro-daratumumab-and-hyaluronidase-fihj-slash-darzalex-daratumumab-subcutaneous-formulation-in-combination-with-pomalidomide-and-dexamethasone-for-patients-with-relapsed-or-refractory-multiple-myeloma 2020-11-12T20:15:12 https://maestrodatabase.com/blog/endo-announces-approval-of-xcopri-cenobamate-tablets-in-canada 2023-06-30T01:43:17 https://maestrodatabase.com/blog/immuneering-granted-fda-fast-track-designation-for-imm-1-104-in-advanced-melanoma 2024-12-12T23:12:40 https://maestrodatabase.com/blog/update-of-handbook-for-companies-applying-for-a-subsidy 2021-06-22T11:51:46 https://maestrodatabase.com/blog/medicines-regulator-pilot-probes-pharma-delays-in-market-launches 2022-01-30T20:43:24 https://maestrodatabase.com/blog/targovax-receives-fast-track-designation-for-oncos-102-in-melanoma 2021-06-22T20:54:24 https://maestrodatabase.com/blog/blueprint-medicines-submits-new-drug-application-to-u-dot-s-fda-for-avapritinib-for-the-treatment-of-pdgfra-exon-18-mutant-gist-and-fourth-line-gist 2019-06-15T05:33:56 https://maestrodatabase.com/blog/nib-launches-new-product-providing-greater-access-to-unfunded-medicines 2021-06-22T20:50:19 https://maestrodatabase.com/blog/facing-progressive-pressure-pelosi-could-expand-her-drug-pricing-plan-to-negotiate-prices-for-118-dollars-billion-worth-of-medicines 2019-06-15T05:48:53 https://maestrodatabase.com/blog/fda-approves-intrarosa-for-postmenopausal-women-experiencing-pain-during-sex 2016-11-17T19:40:37 https://maestrodatabase.com/blog/drug-makers-sue-to-block-requirement-for-listing-prices-in-tv-ads 2019-06-15T05:46:24 https://maestrodatabase.com/blog/pbs-listings-to-support-patients-with-mesothelioma 2021-06-23T05:36:50 https://maestrodatabase.com/blog/fda-research-to-help-speed-development-of-zika-virus-vaccines-and-therapeutics 2016-11-17T19:46:19 https://maestrodatabase.com/blog/trump-administration-expands-pre-tax-accounts-for-health-insurance 2019-06-15T05:41:44 https://maestrodatabase.com/blog/australia-canada-singapore-switzerland-united-kingdom-access-consortium 2021-06-22T21:24:33 https://maestrodatabase.com/blog/experts-agree-private-health-insurance-is-broken-but-how-can-it-be-fixed 2016-11-17T20:01:41 https://maestrodatabase.com/blog/exciting-new-maestro-feature 2016-11-17T20:15:39 https://maestrodatabase.com/blog/mercks-tepmetko-gsk-janssens-vocabria-plus-rekambys-combo-move-closer-to-reimbursement-in-korea 2024-12-12T23:28:35 https://maestrodatabase.com/blog/bristol-myers-squibb-plans-to-launch-cobenfy-xanomeline-and-trospium-chloride-in-the-uk-at-a-list-price-equal-to-the-us-launch-price 2025-10-03T21:23:47 https://maestrodatabase.com/blog/fda-approved-biogen-alzheimers-drug-despite-some-staff-concerns 2021-06-22T21:35:24 https://maestrodatabase.com/blog/trade-offs-and-policy-options---using-insights-from-economics-to-inform-public-health-policy 2022-01-30T22:47:26 https://maestrodatabase.com/blog/drug-price-setting-is-selfishly-shortsighted 2022-01-30T22:43:03 https://maestrodatabase.com/blog/building-a-model-of-health-technology-assessment-co-operation-lessons-learned-from-eunethta-joint-action-3 2022-01-30T23:33:18 https://maestrodatabase.com/blog/abbvie-announces-humira-adalimumab-global-patent-license-with-pfizer 2018-12-01T23:39:22 https://maestrodatabase.com/blog/orpathys-approved-in-china-for-patients-with-lung-cancer-and-met-gene-alterations 2021-06-23T06:03:38 https://maestrodatabase.com/blog/toripalimab-in-combination-with-chemotherapy-for-the-first-line-treatment-of-patients-with-advanced-oesophageal-squamous-cell-cancer 2024-12-12T23:47:23 https://maestrodatabase.com/blog/fda-approves-roches-tecentriq-plus-lurbinectedin-as-first-line-maintenance-therapy-for-extensive-stage-small-cell-lung-cancer 2025-10-04T01:14:59 https://maestrodatabase.com/blog/pbs-listing-to-benefit-australians-with-rare-type-of-non-hodgkin-lymphoma 2022-01-30T22:11:06 https://maestrodatabase.com/blog/does-big-pharma-gouge-americans 2025-10-04T02:00:39 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-december-2018 2018-12-02T00:05:51 https://maestrodatabase.com/blog/baqsimi-nasal-glucagon-rescue-treatment-for-severe-hypoglycaemia-now-covered-in-ontario 2022-01-30T22:36:58 https://maestrodatabase.com/blog/atagi-recommend-the-covid-19-vaccination-for-some-children-aged-6-months-to-under-5-years 2022-09-26T03:55:16 https://maestrodatabase.com/blog/alto-neuroscience-receives-fda-fast-track-designation-for-alto-101-for-the-treatment-of-cognitive-impairment-associated-with-schizophrenia 2025-10-03T23:08:02 https://maestrodatabase.com/blog/national-medicines-policy-draft-strides-ahead-but-still-room-for-improvement 2022-09-26T03:48:12 https://maestrodatabase.com/blog/vir-biotechnology-receives-fda-breakthrough-therapy-designation-and-ema-prime-designation-for-tobevibart-and-elebsiran-in-chronic-hepatitis-delta 2024-12-13T00:35:57 https://maestrodatabase.com/blog/shire-receives-european-approval-for-takhzyro-lanadelumab-subcutaneous-injection-for-the-preventive-treatment-of-hereditary-angioedema 2018-12-02T07:26:47 https://maestrodatabase.com/blog/botanix-submission-of-fda-new-drug-application-for-sofpironium-bromide 2022-09-26T03:33:43 https://maestrodatabase.com/blog/leo-pharma-announces-european-commission-approval-of-adtralza-tralokinumab-as-the-first-and-only-treatment-specifically-targeting-il-13-for-adults-with-moderate-to-severe-atopic-dermatitis 2021-06-23T06:11:48 https://maestrodatabase.com/blog/formycon-announces-submission-of-the-biologics-license-application-for-fyb203-an-aflibercept-biosimilar-candidate-to-the-us-fda 2023-06-30T03:44:42 https://maestrodatabase.com/blog/genmab-announces-that-janssen-has-received-european-marketing-authorisations-for-darzalex-daratumumab-subcutaneous-formulation-including-for-the-treatment-of-patients-with-newly-diagnosed-light-chain-amyloidosis 2021-06-23T06:17:51 https://maestrodatabase.com/blog/health-technology-assessment-of-paediatric-medicines-european-landscape-challenges-and-opportunities-inside-the-conect4children-project 2022-01-31T00:04:55 https://maestrodatabase.com/blog/novavax-appeals-to-atagi-to-change-advice-as-vaccine-uptake-falls-behind 2022-09-26T07:05:33 https://maestrodatabase.com/blog/ezharmia-approved-in-japan-as-first-dual-ezh1-and-ezh2-inhibitor-therapy-for-patients-with-adult-t-cell-leukaemia-slash-lymphoma 2022-09-26T06:57:51 https://maestrodatabase.com/blog/sanofi-receives-tentative-fda-approval-of-admelog-insulin-lispro-100-units-slash-ml 2017-09-03T06:30:30 https://maestrodatabase.com/blog/australians-have-access-to-more-affordable-and-life-changing-medicines-on-pbs 2022-09-26T05:12:39 https://maestrodatabase.com/blog/fda-accepts-amgens-filing-of-a-supplemental-new-drug-application-to-add-overall-survival-results-to-kyprolis-carfilzomib-label 2017-09-03T06:35:36 https://maestrodatabase.com/blog/pfizer-and-biontech-submit-application-to-u-dot-s-fda-for-emergency-use-authorisation-of-omicron-ba-dot-4-slash-ba-dot-5-adapted-bivalent-vaccine-booster-in-children-5-through-11-years-of-age 2022-09-26T20:48:36 https://maestrodatabase.com/blog/fda-approves-xeljanz-xr-tofacitinib-extended-release-tablets-for-the-treatment-of-ulcerative-colitis 2019-12-14T02:05:48 https://maestrodatabase.com/blog/ensem-therapeutics-announces-etx-636-granted-fast-track-designation-by-the-fda-for-advanced-breast-cancer 2025-10-04T03:16:51 https://maestrodatabase.com/blog/european-commission-approves-expanded-use-of-mimpara-cinacalcet-for-the-treatment-of-secondary-hyperparathyroidism-in-children-with-end-stage-renal-disease-on-dialysis 2017-09-03T06:40:03 https://maestrodatabase.com/blog/novartis-afinitor-disperz-wins-new-tsc-related-approval 2018-04-11T11:08:00 https://maestrodatabase.com/blog/theresa-may-tells-drugs-firm-to-make-a-deal-and-end-misery 2019-06-15T08:40:53 https://maestrodatabase.com/blog/fintepla-fenfluramine-approved-in-japan-for-the-treatment-of-seizures-associated-with-dravet-syndrome 2022-09-26T11:51:35 https://maestrodatabase.com/blog/bayer-submits-biologics-license-application-in-the-u-dot-s-for-bay94-9027---a-long-acting-factor-viii-for-the-treatment-of-haemophilia-a 2017-09-03T06:45:16 https://maestrodatabase.com/blog/kineret-anakinra-approved-in-the-eu-for-the-treatment-of-stills-disease 2018-04-11T10:59:07 https://maestrodatabase.com/blog/new-cost-effectiveness-methods-to-determine-value-based-prices-for-potential-cures-what-are-the-options 2019-06-15T08:35:04 https://maestrodatabase.com/blog/atea-pharmaceuticals-announces-u-dot-s-fda-fast-track-designation-granted-to-at-752-for-treatment-of-dengue 2022-09-26T11:45:29 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac---may-2019-intracycle-meeting 2019-06-28T12:04:30 https://maestrodatabase.com/blog/use-of-mercks-bavencio-avelumab-on-nhs-supported-by-nice 2018-04-11T11:47:43 https://maestrodatabase.com/blog/celltrion-seeks-european-approval-for-remsima-sc 2018-12-03T02:21:50 https://maestrodatabase.com/blog/karyopharms-selinexor-receives-fast-track-designation-from-fda-for-the-treatment-of-patients-with-penta-refractory-multiple-myeloma 2018-04-11T11:12:07 https://maestrodatabase.com/blog/penthrox-receives-marketing-authorisation-from-health-canada-for-adult-patients-requiring-relief-from-moderate-to-severe-acute-pain-associated-with-trauma-or-interventional-medical-procedures 2018-04-11T11:22:10 https://maestrodatabase.com/blog/novartis-announces-fda-filing-acceptance-and-priority-review-of-avxs-101-a-one-time-treatment-designed-to-address-the-genetic-root-cause-of-sma-type-1 2018-12-03T07:21:10 https://maestrodatabase.com/blog/fda-permits-marketing-of-artificial-intelligence-based-device-to-detect-certain-diabetes-related-eye-problems 2018-04-11T20:36:24 https://maestrodatabase.com/blog/cvs-pharmacists-will-have-new-tools-to-help-patients-save-money-on-drugs 2018-04-11T20:46:41 https://maestrodatabase.com/blog/santen-and-ube-received-fda-approval-for-omlonti-omidenepag-isopropyl-0-dot-002-percent-ophthalmic-solution-for-the-reduction-of-elevated-intra-ocular-pressure-in-patients-with-primary-open-angle-glaucoma-or-ocular-hypertension 2022-09-26T20:53:31 https://maestrodatabase.com/blog/fda-faulted-for-lapses-in-orphan-drug-program 2018-12-03T02:25:36 https://maestrodatabase.com/blog/redistribution-of-uks-portfolio-of-centrally-authorised-products 2018-04-11T20:30:38 https://maestrodatabase.com/blog/allay-therapeutics-receives-fda-breakthrough-therapy-designation-for-atx101-for-the-treatment-of-post-surgical-pain-following-total-knee-replacement-surgery 2024-12-13T01:16:14 https://maestrodatabase.com/blog/zambon-announces-approval-and-artg-listing-of-safinamide-in-australia-for-treatment-of-patients-with-parkinsons-disease 2018-12-03T07:29:51 https://maestrodatabase.com/blog/atagi-update-following-weekly-covid-19-meeting-27-january-2022 2022-01-31T06:18:57 https://maestrodatabase.com/blog/the-fda-breakthrough-drug-designation----four-years-of-experience 2018-04-11T21:49:41 https://maestrodatabase.com/blog/janssens-imbruvica-passes-reimbursement-review-beigenes-brukinsa-fails 2022-09-26T21:21:53 https://maestrodatabase.com/blog/additional-92-dollars-million-or-5-percent-government-funding-for-pharmaceutical-wholesalers 2020-06-16T07:39:36 https://maestrodatabase.com/blog/health-canada-authorises-verzenio-abemaciclib-as-the-first-and-only-cdk4-slash-6-inhibitor-for-patients-with-hr-plus-her2--high-risk-early-breast-cancer 2022-01-31T06:48:09 https://maestrodatabase.com/blog/asthma-and-allergy-foundation-of-america-elevates-patient-voice-in-icer-review-of-new-peanut-allergy-treatments 2019-06-15T23:30:32 https://maestrodatabase.com/blog/better-therapeutics-submits-de-novo-request-to-us-fda-for-bt-001-investigational-prescription-digital-therapy-for-type-2-diabetes 2022-09-26T21:12:57 https://maestrodatabase.com/blog/engaging-stakeholders-along-health-technology-assessment-pathways-a-scoping-review-of-international-practice 2025-10-04T05:12:50 https://maestrodatabase.com/blog/trevena-announces-submission-of-new-drug-application-in-china-for-olinvyk-by-its-partner-jiangsu-nhwa-pharmaceutical 2022-01-31T03:42:00 https://maestrodatabase.com/blog/price-disclosure-2021-october-cycle-outcomes-summary 2021-06-23T09:00:01 https://maestrodatabase.com/blog/breakthrough-therapy-designation----an-fda-perspective 2018-04-11T21:52:12 https://maestrodatabase.com/blog/chmp-recommends-approval-of-dupixent-dupilumab-for-children-aged-6-to-11-years-with-severe-asthma-with-type-2-inflammation 2022-01-31T06:08:03 https://maestrodatabase.com/blog/patients-will-pay-less-for-critical-medicines-including-miracle-cancer-drug 2022-09-26T21:08:49 https://maestrodatabase.com/blog/phanes-therapeutics-pt217-granted-fast-track-designation-by-the-fda-for-nepc 2024-12-13T01:38:55 https://maestrodatabase.com/blog/canadians-with-rare-lung-disease-are-relieved-to-now-have-publicly-funded-access-to-potentially-life-extending-treatment 2018-12-03T07:36:02 https://maestrodatabase.com/blog/aducanumab-aduhelm-information 2021-06-23T09:08:06 https://maestrodatabase.com/blog/msac-publishes-updated-agenda-for-upcoming-meeting 2022-01-31T03:46:24 https://maestrodatabase.com/blog/nice-publishes-new-combined-methods-and-processes-manual-and-topic-selection-manual-for-its-health-technology-evaluation-programmes 2022-01-31T20:11:23 https://maestrodatabase.com/blog/stoke-therapeutics-receives-fda-breakthrough-therapy-designation-for-zorevunersen-for-the-treatment-of-dravet-syndrome 2024-12-13T02:09:06 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-february-2022-update 2022-01-31T20:06:27 https://maestrodatabase.com/blog/biosimilar-pegfilgrastim-co-developed-by-biocon-receives-approval-in-eu 2018-12-03T09:03:58 https://maestrodatabase.com/blog/a-stronger-role-for-ema 2022-01-31T20:13:09 https://maestrodatabase.com/blog/fables-and-misperceptions-about-drug-makers-and-drug-pricing-are-misleading-customers-about-the-value-the-industry-provides 2022-01-31T06:52:38 https://maestrodatabase.com/blog/express-scripts-miller-says-washington-at-incredible-moment-on-drug-pricing 2018-12-03T20:05:39 https://maestrodatabase.com/blog/astrazeneca-to-be-phased-out-of-aussie-jab-rollout 2021-06-23T10:12:38 https://maestrodatabase.com/blog/tga-approves-first-generic-pomalidomide 2021-06-23T09:36:41 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-february-2022-update 2022-01-31T19:54:21 https://maestrodatabase.com/blog/canadian-r-and-d-to-sales-ratio-for-brand-name-drug-companies-less-than-half-of-10-percent-commitment 2018-12-03T19:56:13 https://maestrodatabase.com/blog/andexanet-alfa-for-haemorrhage-hope-not-fulfilled 2025-10-04T21:38:36 https://maestrodatabase.com/blog/recognition-where-its-due-the-access-to-medicines-index-and-the-pharma-industry 2018-12-03T20:26:43 https://maestrodatabase.com/blog/pharmac---2018-in-review 2018-12-03T20:33:51 https://maestrodatabase.com/blog/gop-balks-at-trump-drug-pricing-plan 2018-12-03T20:07:53 https://maestrodatabase.com/blog/australias-first-telehealth-cancer-drug-trial 2018-12-03T20:11:18 https://maestrodatabase.com/blog/fda-issues-new-analysis-linking-greater-generic-competition-and-lower-generic-drug-prices 2019-12-14T02:44:24 https://maestrodatabase.com/blog/fda-approves-lyumjev-insulin-lispro-aabc-injection-lillys-new-rapid-acting-insulin 2020-06-16T09:28:44 https://maestrodatabase.com/blog/va-and-icer-at-three-years-critics-concerns-answered 2020-06-16T09:34:41 https://maestrodatabase.com/blog/fees-and-charges-summary-from-1-july-2021 2021-06-23T20:38:31 https://maestrodatabase.com/blog/supreme-court-will-not-hear-generic-drug-price-fixing-discovery-dispute 2020-06-16T11:45:29 https://maestrodatabase.com/blog/rare-disease-patient-advocates-continue-battle-for-affordable-drugs 2021-06-23T20:32:18 https://maestrodatabase.com/blog/public-summary-documents---march-2023-pbac-meeting 2023-06-30T06:03:11 https://maestrodatabase.com/blog/evio-pharmacy-solutions-established-to-tackle-affordability-outcomes-and-experience-with-medications 2021-06-23T20:43:32 https://maestrodatabase.com/blog/1-in-10-americans-skipping-doses-as-prescription-drug-prices-rise 2019-06-16T02:05:29 https://maestrodatabase.com/blog/advancing-structured-decision-making-in-drug-regulation-at-the-fda-and-ema 2020-06-16T21:10:05 https://maestrodatabase.com/blog/access-to-medicine-the-states-with-the-most-and-least-pharmacies-per-capita 2021-06-23T21:15:49 https://maestrodatabase.com/blog/fda-chief-under-fire-over-alzheimers-drug-decision 2021-06-23T21:09:43 https://maestrodatabase.com/blog/fda-approves-first-treatment-for-adult-onset-stills-disease-a-severe-and-rare-disease 2020-06-16T21:16:34 https://maestrodatabase.com/blog/coronavirus-australia-is-the-vaccine-rollout-designed-to-be-slow-and-ineffective 2021-06-23T21:31:15 https://maestrodatabase.com/blog/first-drug-proves-able-to-improve-survival-from-covid-19-trial-shows 2020-06-16T20:50:31 https://maestrodatabase.com/blog/coronavirus-covid-19-update-fda-takes-key-action-by-approving-second-covid-19-vaccine 2022-01-31T23:28:59 https://maestrodatabase.com/blog/drug-makers-raised-prices-by-6-dot-6-percent-on-average-early-this-year 2022-01-31T23:55:34 https://maestrodatabase.com/blog/fda-approves-gemtuzumab-ozogamicin-for-cd33-positive-aml-in-paediatric-patients 2020-06-16T20:53:48 https://maestrodatabase.com/blog/fda-should-lead-the-way-on-new-als-treatments-not-canada-and-europe 2021-06-23T21:00:33 https://maestrodatabase.com/blog/tga-grants-provisional-determination-for-the-moderna-covid-19-vaccine-elasomeran 2021-06-24T07:20:24 https://maestrodatabase.com/blog/cder-establishes-new-center-for-real-world-evidence-innovation 2024-12-13T04:19:15 https://maestrodatabase.com/blog/national-medicines-policy-review-to-begin-in-august-2021 2021-06-24T07:16:41 https://maestrodatabase.com/blog/lynparza-approved-in-china-for-the-treatment-of-brca-mutated-metastatic-castration-resistant-prostate-cancer 2021-06-24T09:35:16 https://maestrodatabase.com/blog/novavax-submits-request-to-the-u-dot-s-fda-for-emergency-use-authorisation-of-covid-19-vaccine 2022-02-01T00:27:36 https://maestrodatabase.com/blog/moving-patient-stories-highlight-opportunities-to-strengthen-our-health-care-systems-for-all-australians 2021-06-24T07:23:38 https://maestrodatabase.com/blog/why-pfizers-trump-deal-is-good-news-for-all-of-big-pharma 2025-10-05T06:14:43 https://maestrodatabase.com/blog/40-house-democrats-push-for-swift-action-to-lower-drug-prices 2022-02-01T00:08:30 https://maestrodatabase.com/blog/nivolumab-in-squamous-cell-carcinoma-in-the-head-and-neck-area-additional-benefit-for-certain-patients 2017-09-03T09:24:01 https://maestrodatabase.com/blog/89bio-receives-ema-prime-status-for-pegozafermin-in-the-treatment-of-metabolic-dysfunction-associated-steatohepatitis-mash-with-fibrosis-and-compensated-cirrhosis 2024-03-28T02:58:16 https://maestrodatabase.com/blog/chinas-first-car-t-cell-therapy-approved-fosun-kite-axicabtagene-ciloleucel-fkc876 2021-06-24T09:50:33 https://maestrodatabase.com/blog/cder-explores-series-of-draft-guidances-on-real-world-data-real-world-evidence---drug-information-update 2022-02-01T01:04:23 https://maestrodatabase.com/blog/fda-accepts-application-for-genentechs-port-delivery-system-with-ranibizumab-for-treatment-of-wet-age-related-macular-degeneration 2021-06-24T10:03:04 https://maestrodatabase.com/blog/alzinova-receives-fast-track-designation-from-us-fda-for-alz-101-in-alzheimers-disease 2025-10-04T23:26:04 https://maestrodatabase.com/blog/anticancer-agent-tazverik-200-mg-tablets-tazemetostat-hydrobromide-approved-in-japan-for-ezh2-gene-mutation-positive-follicular-lymphoma 2021-06-24T09:39:46 https://maestrodatabase.com/blog/hikma-and-richter-announce-fda-submission-acceptance-for-denosumab-biosimilar-products 2024-12-13T04:22:57 https://maestrodatabase.com/blog/applaud-medical-receives-fda-breakthrough-device-designation-for-the-companys-acoustic-enhancer-for-use-in-conjunction-with-ureteroscopy-with-laser-lithotripsy-for-the-fragmentation-of-calcium-based-kidney-stones 2022-02-01T01:41:00 https://maestrodatabase.com/blog/celltrion-healthcare-announces-canadian-approval-of-yuflyma-a-high-concentration-low-volume-citrate-free-and-latex-free-humira-adalimumab-biosimilar 2022-02-01T01:48:23 https://maestrodatabase.com/blog/eisai-and-biogen-announce-u-dot-s-fda-grants-breakthrough-therapy-designation-for-lecanemab-ban2401-an-anti-amyloid-beta-antibody-for-the-treatment-of-alzheimers-disease 2021-06-24T10:29:21 https://maestrodatabase.com/blog/uk-mhra-grants-innovation-passport-designation-to-iliad-biotechnologies-bpze1-next-generation-intranasal-pertussis-vaccine 2024-12-13T05:33:10 https://maestrodatabase.com/blog/lifesaving-cystic-fibrosis-drug-trikafta-recommended-for-inclusion-on-pbs 2022-02-01T02:13:38 https://maestrodatabase.com/blog/janssen-submits-marketing-authorisation-application-to-the-ema-seeking-approval-of-bispecific-antibody-teclistamab-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma 2022-02-01T02:00:41 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-provides-policy-recommendations-for-extended-release-treatments-for-opioid-use-disorder 2018-12-03T23:16:05 https://maestrodatabase.com/blog/four-million-additional-australians-eligible-for-their-booster-dose 2022-02-01T02:09:20 https://maestrodatabase.com/blog/u-dot-s-fda-grants-fast-track-designation-for-the-development-of-eisais-bace-inhibitor-e2609-for-early-alzheimers-disease 2016-11-18T22:54:12 https://maestrodatabase.com/blog/seattle-genetics-receives-fda-breakthrough-therapy-designation-for-adcentis-brentuximab-vedotin-in-mycosis-fungoides-and-primary-cutaneous-anaplastic-large-cell-lymphoma 2016-11-18T23:07:03 https://maestrodatabase.com/blog/workshop-towards-new-treatments-for-tuberculosis 2016-11-19T06:44:17 https://maestrodatabase.com/blog/lillys-donanemab-receives-u-dot-s-fdas-breakthrough-therapy-designation-for-treatment-of-alzheimers-disease 2021-06-24T11:23:27 https://maestrodatabase.com/blog/akebia-receives-fda-approval-of-vafseo-vadadustat-tablets-for-the-treatment-of-anaemia-due-to-chronic-kidney-disease-in-adult-patients-on-dialysis 2024-03-28T21:29:31 https://maestrodatabase.com/blog/spectrum-pharmaceuticals-says-fda-rejects-its-bladder-cancer-drug 2016-11-19T06:51:38 https://maestrodatabase.com/blog/will-nice-go-commercial 2016-11-19T06:57:55 https://maestrodatabase.com/blog/amgen-makes-repatha-available-though-amgennow-a-direct-to-patient-program-in-the-us 2025-10-06T23:19:43 https://maestrodatabase.com/blog/pharmac-seeking-feedback-on-nusinersen-sodium-and-adrenaline-auto-injectors-funding 2022-09-27T20:23:14 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-european-commission-approval-for-opdivo-nivolumab-with-chemotherapy-as-neo-adjuvant-treatment-of-resectable-non-small-cell-lung-cancer-at-high-risk-of-recurrence-in-patients-with-tumour-cell-pd-l1-expression-1-percent 2023-06-30T07:52:59 https://maestrodatabase.com/blog/reata-pharmaceuticals-initiates-rolling-submission-of-new-drug-application-with-u-dot-s-fda-for-omaveloxolone-for-the-treatment-of-patients-with-friedreichs-ataxia 2022-02-01T03:13:27 https://maestrodatabase.com/blog/nice-recommends-nhs-collects-real-world-evidence-on-devices-that-monitor-people-with-parkinsons-disease 2022-09-27T08:28:35 https://maestrodatabase.com/blog/halton-review-into-vaccine-and-treatment-procurement 2022-09-27T06:20:21 https://maestrodatabase.com/blog/santen-receives-fda-approval-for-verkazia-cyclosporin-0-dot-1-percent-ophthalmic-emulsion-for-the-treatment-of-vernal-keratoconjunctivitis-in-children-and-adults 2021-06-24T11:31:05 https://maestrodatabase.com/blog/koselugo-approved-in-japan-for-paediatric-patients-with-plexiform-neurofibromas-in-neurofibromatosis-type-1 2022-09-27T06:22:40 https://maestrodatabase.com/blog/tezspire-approved-in-japan-for-the-treatment-of-severe-asthma 2022-09-27T06:14:10 https://maestrodatabase.com/blog/european-commission-approves-mercks-keytruda-pembrolizumab-plus-chemotherapy-as-neo-adjuvant-treatment-then-continued-as-monotherapy-as-adjuvant-treatment-for-resectable-non-small-cell-lung-cancer-at-high-risk-of-recurrence-in-adults 2024-03-28T21:44:47 https://maestrodatabase.com/blog/mercks-keytruda-pembrolizumab-receives-four-new-approvals-in-japan-including-in-high-risk-early-stage-triple-negative-breast-cancer 2022-09-27T20:48:05 https://maestrodatabase.com/blog/health-canada-approves-xtandi-enzalutamide-for-the-treatment-of-metastatic-castration-sensitive-prostate-cancer 2020-06-17T02:12:42 https://maestrodatabase.com/blog/eg-427-receives-us-fda-fast-track-designation-for-eg110a-dna-medicine-in-neurogenic-bladder-patients 2025-10-07T00:26:43 https://maestrodatabase.com/blog/intrabio-announces-us-fda-accepts-new-dug-application-for-ib1001-for-the-treatment-of-niemann-pick-disease-type-c 2024-03-28T22:23:13 https://maestrodatabase.com/blog/blue-earth-diagnostics-announces-fda-acceptance-of-new-drug-application-for-18f-rhpsma-7-dot-3-a-radiohybrid-prostate-specific-membrane-antigen-targeted-pet-imaging-agent-for-prostate-cancer 2022-09-27T20:42:31 https://maestrodatabase.com/blog/carvykti-ciltacabtagene-autoleucel-receives-approval-from-japans-mhlw-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma 2022-09-27T20:34:07 https://maestrodatabase.com/blog/abilify-maintena-960-mg-aripiprazole-approved-in-the-eu-as-the-first-once-every-two-months-long-acting-injectable-for-the-maintenance-treatment-of-schizophrenia 2024-03-28T23:41:11 https://maestrodatabase.com/blog/call-to-fund-$5000-a-month-drug-that-gives-people-time 2017-09-03T22:28:16 https://maestrodatabase.com/blog/pmprb-risks-harming-the-health-of-canadians-by-reducing-access-to-new-medicines 2021-06-24T21:48:32 https://maestrodatabase.com/blog/evrysdi-approved-in-japan-for-the-treatment-of-spinal-muscular-atrophy 2021-06-24T21:43:13 https://maestrodatabase.com/blog/ayala-pharmaceuticals-announces-fast-track-designation-granted-by-us-fda-for-al102-in-progressing-desmoid-tumours 2022-09-27T21:08:49 https://maestrodatabase.com/blog/chinas-national-medical-products-administration-accepts-astellas-and-pfizers-supplemental-biologics-license-application-for-enfortumab-vedotin-with-keytruda-pembrolizumab-for-first-line-treatment-of-advanced-bladder-cancer 2024-03-28T23:25:10 https://maestrodatabase.com/blog/health-insurers-blamed-for-rising-health-care-costs 2017-09-03T22:32:47 https://maestrodatabase.com/blog/alnylam-announces-u-dot-s-fda-acceptance-of-new-drug-application-for-investigational-vutrisiran-for-the-treatment-of-the-polyneuropathy-of-hereditary-attr-amyloidosis 2021-06-24T21:29:47 https://maestrodatabase.com/blog/covid-19-vaccine-procurement-review-says-rapid-access-to-vaccines-and-treatments-key-to-on-going-protection-of-australians 2022-09-27T20:59:30 https://maestrodatabase.com/blog/biogen-expects-slow-alzheimers-drug-uptake-may-reset-price 2021-06-24T21:24:11 https://maestrodatabase.com/blog/more-medicines-for-new-zealanders-thanks-to-governments-budget-boost 2022-09-27T21:01:55 https://maestrodatabase.com/blog/teva-announces-ministry-of-health-labour-and-welfare-approves-ajovy-fremanezumab-injection-in-japan-for-the-preventive-treatment-of-migraine-in-adults 2021-06-24T21:39:31 https://maestrodatabase.com/blog/why-health-funds-are-prevented-from-paying-for-this-lifesaving-medical-device 2017-09-03T22:37:55 https://maestrodatabase.com/blog/proposal-relating-to-schedule-changes-made-in-response-to-covid-19 2020-06-17T02:39:08 https://maestrodatabase.com/blog/half-of-gps-say-staying-open-is-financially-unsustainable-as-medicare-rebate-fails 2022-09-27T20:56:53 https://maestrodatabase.com/blog/european-marketing-application-for-avt23-a-proposed-biosimilar-to-xolair-omalizumab-accepted-by-the-ema 2025-10-07T02:21:01 https://maestrodatabase.com/blog/the-value-of-medicines-a-crucial-but-vague-concept 2016-11-19T22:39:50 https://maestrodatabase.com/blog/paladin-labs-announces-approval-of-wakix-pitolisant-hydrochloride-tablets-for-use-in-paediatric-patients-in-canada 2024-03-29T01:30:59 https://maestrodatabase.com/blog/ptc-announces-submission-of-sepiapterin-maa-for-treatment-of-pku-to-ema 2024-03-29T01:09:35 https://maestrodatabase.com/blog/orca-bio-announces-fda-acceptance-and-priority-review-of-the-biologics-license-application-for-orca-t-to-treat-haematological-malignancies 2025-10-07T04:12:01 https://maestrodatabase.com/blog/kashiv-biosciences-announces-submission-of-biologics-license-application-to-us-fda-and-acceptance-of-market-authorisation-application-by-ema-for-adl-018-a-proposed-biosimilar-to-xolair-omalizumab 2025-10-07T04:20:29 https://maestrodatabase.com/blog/als-association-wants-more-commitment-from-the-fda 2021-06-24T21:55:47 https://maestrodatabase.com/blog/korean-drug-for-metabolism-related-steatohepatitis-gets-fdas-fast-track-designation 2024-03-29T00:32:13 https://maestrodatabase.com/blog/health-canada-accepts-mitsubishi-tanabe-pharma-corporations-nds-filing-for-edaravone-to-treat-als-grants-priority-review 2018-04-12T03:07:10 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-cgrp-inhibitors-for-migraine-prevention 2018-04-12T02:25:18 https://maestrodatabase.com/blog/chemotherapy-compounder-id-mandatory-within-pbs-claims 2018-04-12T02:39:42 https://maestrodatabase.com/blog/fda-approves-arup-laboratories-aav5-detectcdx-a-first-ever-companion-diagnostic-immunoassay-for-a-gene-therapy 2023-06-30T10:57:21 https://maestrodatabase.com/blog/spruce-biosciences-receives-us-fda-breakthrough-therapy-designation-for-tralesinidase-alfa-enzyme-replacement-therapy-in-sanfilippo-syndrome-type-b 2025-10-07T01:17:51 https://maestrodatabase.com/blog/fda-approves-arcutis-zoryve-roflumilast-cream-0-dot-05-percent-for-the-treatment-of-atopic-dermatitis-in-children-ages-2-to-5 2025-10-07T01:25:40 https://maestrodatabase.com/blog/why-we-may-lose-generic-drugs 2018-04-12T06:18:02 https://maestrodatabase.com/blog/ohara-cuts-price-of-generic-drug-for-leukaemia 2018-04-12T06:21:04 https://maestrodatabase.com/blog/jesses-dad-who-walked-canada-for-his-son-cheers-approval-of-new-duchenne-drug 2025-10-07T04:34:34 https://maestrodatabase.com/blog/mallinckrodt-shares-slide-on-whistleblower-lawsuit-involving-its-best-selling-drug 2018-04-12T20:52:20 https://maestrodatabase.com/blog/enhertu-plus-pertuzumab-supplemental-new-drug-application-submitted-in-japan-as-first-line-therapy-for-patients-with-her2-positive-metastatic-breast-cancer 2025-10-07T07:28:44 https://maestrodatabase.com/blog/fda-approves-prophylactic-treatment-with-vonvendi-von-willebrand-factor-recombinant-for-adult-patients-living-with-severe-type-3-von-willebrand-disease 2022-02-01T10:41:57 https://maestrodatabase.com/blog/demand-cancer-drugs-that-truly-help-patients 2018-04-12T20:58:27 https://maestrodatabase.com/blog/fda-finalises-guidances-to-accelerate-the-development-of-reliable-beneficial-next-generation-sequencing-based-tests 2018-04-12T21:05:23 https://maestrodatabase.com/blog/ocular-therapeutix-announces-fda-approval-of-dextenza-for-the-treatment-of-ocular-pain-following-ophthalmic-surgery 2018-12-04T01:17:30 https://maestrodatabase.com/blog/chmp-recommends-renewal-of-translarnas-marketing-authorisation-for-nonsense-mutation-duchenne-muscular-dystrophy-based-on-continued-positive-benefit-risk-assessment 2016-11-20T02:12:53 https://maestrodatabase.com/blog/as-cancer-drug-prices-climb-value-not-keeping-pace 2018-04-12T20:54:49 https://maestrodatabase.com/blog/tga-approves-grifols-prolastin-c 2016-11-20T01:24:16 https://maestrodatabase.com/blog/private-health-insurance-industry-says-australian-system-affordable 2016-11-20T03:32:11 https://maestrodatabase.com/blog/viiv-healthcare-files-submissions-to-the-fda-and-ema-for-the-first-ever-dispersible-formulation-of-dolutegravir-for-children-living-with-hiv 2019-12-14T05:40:45 https://maestrodatabase.com/blog/icer-posts-draft-scoping-document-on-therapies-for-prevention-of-hereditary-angioedema-attacks 2018-04-12T21:29:40 https://maestrodatabase.com/blog/viiv-healthcare-announces-us-fda-approval-of-cabenuva-cabotegravir-rilpivirine-for-use-every-two-months-expanding-the-label-of-the-first-and-only-complete-long-acting-hiv-treatment 2022-02-01T20:14:05 https://maestrodatabase.com/blog/angelini-pharma-and-sunovion-pharmaceutical-europe-receive-ema-approval-for-latuda-first-atypical-antipsychotic-for-the-treatment-of-adolescent-schizophrenia-in-patients-starting-from-13-years-of-age 2020-11-13T01:40:52 https://maestrodatabase.com/blog/byannli-authorised-in-britain-for-schizophrenia-treatment 2022-02-01T20:05:59 https://maestrodatabase.com/blog/medicines-for-severe-asthma-and-growth-hormone-deficiency-listed-on-the-pbs 2018-12-04T02:04:21 https://maestrodatabase.com/blog/u-dot-s-fda-approves-new-label-update-for-car-t-cell-therapy-yescarta-showing-prophylactic-steroid-use-improves-management-of-cytokine-release-syndrome 2022-02-01T20:29:44 https://maestrodatabase.com/blog/agenda-for-april-18-meeting 2018-04-12T22:50:44 https://maestrodatabase.com/blog/liscure-biosciences-receives-us-fda-fast-track-designation-for-lb-p8-for-the-treatment-of-primary-sclerosing-cholangitis 2024-03-29T23:10:45 https://maestrodatabase.com/blog/novartis-cosentyx-receives-fda-approval-for-new-indication-to-treat-active-non-radiographic-axial-spondyloarthritis 2020-06-17T05:42:37 https://maestrodatabase.com/blog/blue-note-therapeutics-receives-breakthrough-device-designation-for-prescription-only-digital-therapeutic-for-acute-myeloid-leukaemia 2022-02-01T20:21:33 https://maestrodatabase.com/blog/gsk-receives-fda-approval-for-expanded-indication-for-flulaval-quadrivalent-influenza-vaccine-for-infants-6-months-and-older 2016-11-21T06:26:31 https://maestrodatabase.com/blog/ema-publishes-epar-for-kisplyx 2016-11-21T11:05:34 https://maestrodatabase.com/blog/gsk-files-regulatory-submission-in-us-for-once-daily-closed-triple-combination-therapy-ff-slash-umec-slash-vi-for-patients-with-copd 2016-11-21T11:25:35 https://maestrodatabase.com/blog/regulators-discuss-accelerated-approvals-project-orbis-at-dia 2020-06-17T06:47:28 https://maestrodatabase.com/blog/health-canada-extends-approval-of-imvamune-to-immunisation-against-monkeypox-and-orthopox-viruses 2020-11-13T04:59:36 https://maestrodatabase.com/blog/the-future-of-health-care-mergers-under-trump 2016-11-21T10:58:44 https://maestrodatabase.com/blog/many-insured-children-lack-essential-health-care-study-finds 2016-11-21T11:01:13 https://maestrodatabase.com/blog/public-summary-documents---pbac-july-2020-meeting 2020-11-13T05:29:31 https://maestrodatabase.com/blog/is-the-investment-in-private-health-insurance-worthwhile 2016-11-21T19:58:07 https://maestrodatabase.com/blog/amgen-eyes-spending-caps-to-win-payer-nods-on-migraine-prospect-erenumab 2016-11-21T20:03:46 https://maestrodatabase.com/blog/pfizer-sues-texas-health-agency-for-releasing-confidential-pricing-information 2016-11-21T11:37:15 https://maestrodatabase.com/blog/consultation-on-cadths-proposed-process-for-the-assessment-of-companion-diagnostics 2016-11-21T19:49:43 https://maestrodatabase.com/blog/aussie-device-that-gives-eyes-to-the-blind-fast-tracked-in-us 2022-02-01T23:28:20 https://maestrodatabase.com/blog/fda-approves-medexuss-supplemental-biologics-license-application-for-ixinity-to-treat-haemophilia-b-in-paediatric-patients 2024-03-30T03:11:27 https://maestrodatabase.com/blog/intarcia-submits-new-drug-application-to-fda-for-u-dot-s-marketing-approval-of-itca-650-in-type-2-diabetes 2016-11-21T20:21:29 https://maestrodatabase.com/blog/us-fda-approves-simponi-golimumab-for-the-treatment-of-paediatric-ulcerative-colitis 2025-10-08T01:14:59 https://maestrodatabase.com/blog/regeneron-ceo-a-few-bad-actors-are-raising-drug-prices-for-no-reason 2016-11-21T20:07:07 https://maestrodatabase.com/blog/teva-secures-european-approval-of-trisenox-for-first-line-treatment-of-low-to-intermediate-risk-acute-promyelocytic-leukaemia 2016-11-21T20:11:15 https://maestrodatabase.com/blog/veru-announces-fda-grant-of-fast-track-designation-for-sabizabulin-for-the-treatment-of-hospitalised-covid-19-patients-at-high-risk-for-acute-respiratory-distress-syndrome 2022-02-01T23:06:55 https://maestrodatabase.com/blog/coronavirus-the-vaccine-is-coming-so-who-should-get-it-first 2020-11-13T04:57:16 https://maestrodatabase.com/blog/pfizer-and-biontech-initiate-rolling-submission-for-emergency-use-authorisation-of-their-covid-19-vaccine-in-children-6-months-through-4-years-of-age-following-request-from-u-dot-s-fda 2022-02-01T23:45:49 https://maestrodatabase.com/blog/how-to-deal-with-the-inevitable-generating-real-world-data-and-using-real-world-evidence-for-hta-purposes---from-theory-to-action 2019-06-16T20:53:47 https://maestrodatabase.com/blog/universal-health-care-bill-fails-to-pass-in-california 2022-02-02T00:08:57 https://maestrodatabase.com/blog/government-crackdown-on-abuse-of-antibiotics 2019-06-16T20:49:49 https://maestrodatabase.com/blog/steadymed-receives-refusal-to-file-letter-from-fda-for-trevyent-new-drug-application 2017-09-03T23:54:00 https://maestrodatabase.com/blog/review-of-the-national-medicines-policy---consultation-on-the-draft-closes-16-february-2022 2022-02-02T00:59:56 https://maestrodatabase.com/blog/equity-in-cancer-drug-access-in-the-uk 2022-02-02T00:24:08 https://maestrodatabase.com/blog/vericiguat-approved-in-japan-to-treat-patients-with-chronic-heart-failure 2021-06-25T00:53:45 https://maestrodatabase.com/blog/rivaroxaban-application-submitted-to-u-dot-s-fda-for-approval-to-treat-vte-and-to-prevent-vte-in-children 2021-06-25T01:03:48 https://maestrodatabase.com/blog/changes-to-cost-recovery-arrangements-from-1-july-2021 2021-06-25T00:57:54 https://maestrodatabase.com/blog/ontario-connecting-patients-to-life-saving-cancer-drugs-faster 2025-10-08T02:59:50 https://maestrodatabase.com/blog/global-consequences-of-the-us-fdas-accelerated-approval-of-cancer-drugs 2022-02-02T01:03:48 https://maestrodatabase.com/blog/cost-recovery-implementation-statement-2016---2017 2016-11-22T04:30:42 https://maestrodatabase.com/blog/new-eu-regulation-on-health-technology-assessment-of-cancer-medicines 2022-02-02T01:30:39 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-pembrolizumab-for-locally-recurrent-unresectable-or-metastatic-triple-negative-breast-cancer 2020-11-13T19:59:58 https://maestrodatabase.com/blog/allergan-announces-receipt-of-additional-health-canada-approval-for-fibristal 2016-11-22T10:28:06 https://maestrodatabase.com/blog/genmab-announces-u-dot-s-fda-approval-of-darzalex-daratumumab-for-relapsed-multiple-myeloma 2016-11-22T10:12:43 https://maestrodatabase.com/blog/u-dot-s-fda-grants-fast-track-designation-for-the-development-of-oragenics-ag013-for-oral-mucositis 2016-11-22T10:40:05 https://maestrodatabase.com/blog/novo-nordisk-receives-us-fda-approval-for-xultophy-100-slash-3-dot-6 2016-11-22T10:32:31 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-july-2023 2023-07-01T00:20:23 https://maestrodatabase.com/blog/high-prices-for-some-leukaemia-drugs-will-make-them-less-cost-effective 2016-11-22T11:07:41 https://maestrodatabase.com/blog/japan-eyes-annual-revamp-of-drug-prices-to-slash-costs 2016-11-22T20:07:57 https://maestrodatabase.com/blog/statistical-and-clinical-significance 2017-09-04T01:17:23 https://maestrodatabase.com/blog/mallinckrodt-will-initiate-company-sponsored-clinical-trial-of-h-dot-p-acthar-gel-in-treatment-of-amyotropic-lateral-sclerosis 2016-11-22T10:47:22 https://maestrodatabase.com/blog/pharmacy-price-wars-heat-up 2016-11-22T20:34:48 https://maestrodatabase.com/blog/sanofi-receives-fda-approval-of-soliqua-100-slash-33-for-the-treatment-of-adults-with-type-2-diabetes 2016-11-22T20:18:37 https://maestrodatabase.com/blog/abpi-analysis-on-nices-changes-for-evaluating-new-medicines-next-steps 2022-02-02T10:23:12 https://maestrodatabase.com/blog/european-commission-approves-bristol-myers-squibbs-opdivo-nivolumab-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma-after-autologous-stem-cell-transplant-and-treatment-with-brentuximab-vedotin 2016-11-22T20:22:06 https://maestrodatabase.com/blog/jazz-pharmaceuticals-completes-u-dot-s-fda-supplemental-biologics-license-application-for-rylaze-asparaginase-erwinia-chrysanthemi-recombinant--rywn-monday-slash-wednesday-slash-friday-dosing-schedule 2022-02-02T20:07:50 https://maestrodatabase.com/blog/new-order-european-cancer-coalition-calls-for-cancer-treatment-overhaul 2022-02-02T20:01:19 https://maestrodatabase.com/blog/fda-approves-use-of-drug-to-reduce-risk-of-cardiovascular-events-in-certain-adult-patient-groups 2019-12-14T08:05:56 https://maestrodatabase.com/blog/register-study-on-gene-therapy-with-zolgensma-starts 2022-02-02T11:13:41 https://maestrodatabase.com/blog/eu-secures-300-million-doses-of-biontech-pfizers-covid-19-vaccine 2020-11-13T20:13:01 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-april-2024 2024-03-31T22:57:47 https://maestrodatabase.com/blog/fda-approves-cemiplimab-rwlc-for-adjuvant-treatment-of-cutaneous-squamous-cell-carcinoma 2025-10-08T22:28:27 https://maestrodatabase.com/blog/fresenius-kabi-announces-new-approval-and-immediate-availability-of-daptomycin-for-injection 2018-04-13T01:09:06 https://maestrodatabase.com/blog/uks-early-access-to-medicines-scheme-now-to-be-put-on-a-legal-footing 2022-02-02T11:19:41 https://maestrodatabase.com/blog/madrigal-pharmaceuticals-announces-rolling-submission-of-new-drug-application-to-us-fda-seeking-accelerated-approval-of-resmetirom-for-the-treatment-of-nash-with-liver-fibrosis 2023-07-01T00:28:59 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-april-2024 2024-03-31T22:46:39 https://maestrodatabase.com/blog/lillys-omvoh-mirikizumab-recommended-by-chmp-for-approval-in-the-european-union-for-adults-with-moderately-to-severely-active-crohns-disease 2024-12-13T23:07:21 https://maestrodatabase.com/blog/highlights-from-9-12-november-chmp-meeting 2020-11-13T20:16:10 https://maestrodatabase.com/blog/most-coronavirus-tests-cost-about-$100-why-did-one-cost-$2-315 2020-06-17T09:08:39 https://maestrodatabase.com/blog/us-fda-accepts-astellas-supplemental-new-drug-application-for-izervay-avacincaptad-pegol-intravitreal-solution-for-geographic-atrophy 2024-04-01T05:38:05 https://maestrodatabase.com/blog/final-nice-green-light-for-janssens-stelara-in-ulcerative-colitis 2020-06-17T09:13:45 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-treatments-for-multiple-sclerosis 2022-10-17T19:50:16 https://maestrodatabase.com/blog/fda-approves-first-generic-of-restasis 2022-02-02T20:27:09 https://maestrodatabase.com/blog/biden-promised-500-million-free-covid-tests-then-he-had-to-find-them 2022-02-02T21:52:51 https://maestrodatabase.com/blog/qsam-biosciences-receives-rare-paediatric-disease-designation-from-fda-for-cyclosam-in-the-treatment-of-osteosarcoma 2022-02-02T20:12:46 https://maestrodatabase.com/blog/auspar-user-survey-results 2016-11-23T05:27:11 https://maestrodatabase.com/blog/tga-approves-another-opdivo-for-another-cancer-type 2016-11-23T06:44:54 https://maestrodatabase.com/blog/halaven-cleared-by-tga-for-sarcoma 2016-11-23T07:52:41 https://maestrodatabase.com/blog/olaparib-a-no-go-for-patients-with-breast-cancer-in-england 2022-02-02T20:19:31 https://maestrodatabase.com/blog/fda-approves-cosibelimab-ipdl-for-metastatic-or-locally-advanced-cutaneous-squamous-cell-carcinoma 2024-12-13T23:16:39 https://maestrodatabase.com/blog/new-zealands-slow-medicine-uptake-leads-to-800-diabetes-deaths-each-year 2020-06-17T11:06:13 https://maestrodatabase.com/blog/aquestive-therapeutics-resubmits-new-drug-application-for-libervant-diazepam-buccal-film 2021-06-25T03:30:11 https://maestrodatabase.com/blog/intercept-provides-regulatory-update 2020-05-23T03:30:12 https://maestrodatabase.com/blog/tolebrutinib-designated-breakthrough-therapy-by-the-fda-for-non-relapsing-secondary-progressive-multiple-sclerosis 2024-12-13T23:35:57 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-first-targeted-treatment-for-rare-duchenne-muscular-dystrophy-mutation 2019-12-14T08:35:56 https://maestrodatabase.com/blog/nice-recommends-extra-triple-therapy-drug-for-treating-type-2-diabetes 2016-11-23T11:07:41 https://maestrodatabase.com/blog/belsomra-finally-approved-by-tga 2016-11-23T11:13:50 https://maestrodatabase.com/blog/atagi-recommendations-for-use-of-pfizer-covid-19-vaccine-as-a-booster-dose-in-adolescents-aged-16-17-years 2022-02-02T23:02:23 https://maestrodatabase.com/blog/nice-reviews-multiple-myeloma-drug-and-approves-for-routine-use 2016-11-23T11:05:17 https://maestrodatabase.com/blog/understanding-innovation-of-health-technology-assessment-methods-the-ihtam-framework 2022-02-02T22:44:10 https://maestrodatabase.com/blog/an-america-first-pharma-supply-chain-sounds-good-but-it-wont-work 2020-06-17T11:03:46 https://maestrodatabase.com/blog/chmp-adopts-positive-opinion-for-zinplava 2016-11-23T11:23:58 https://maestrodatabase.com/blog/ema-publishes-epar-for-lartruvo 2016-11-23T19:45:51 https://maestrodatabase.com/blog/to-help-patients-reform-the-drug-pricing-system-dont-impose-price-controls 2019-12-14T08:47:39 https://maestrodatabase.com/blog/cadth-recommends-listing-of-quinsair 2016-11-23T20:17:21 https://maestrodatabase.com/blog/nice-publishes-final-guidance-on-the-use-of-nivolumab-for-rcc 2016-11-23T20:25:09 https://maestrodatabase.com/blog/disagreement-on-cancer-drug-decisions-in-europe 2020-06-17T20:54:23 https://maestrodatabase.com/blog/changes-to-the-national-immunisation-program-effective-1-july-2023 2023-07-01T07:45:59 https://maestrodatabase.com/blog/a-mad-scramble-to-stock-millions-of-malaria-pills-likely-for-nothing 2020-06-17T20:57:12 https://maestrodatabase.com/blog/atezolizumab-for-adjuvant-treatment-of-resected-non-small-cell-lung-cancer 2022-09-28T06:26:37 https://maestrodatabase.com/blog/sandoz-to-launch-hyrimoz-adalimumab-adaz-high-concentration-formulation-marking-sandoz-entrance-into-us-immunology-space 2023-07-01T07:37:39 https://maestrodatabase.com/blog/tga-approves-extended-use-of-harvoni 2016-11-23T20:30:28 https://maestrodatabase.com/blog/enstilar-is-now-covered-by-the-alberta-drug-benefit-list-for-adults-with-psoriasis-vulgaris 2018-12-04T07:53:21 https://maestrodatabase.com/blog/fda-approves-pembrolizumab-for-adults-and-children-with-tmb-h-solid-tumours 2020-06-17T21:00:22 https://maestrodatabase.com/blog/pharming-announces-us-fda-acceptance-for-priority-review-of-its-new-drug-application-for-leniolisib 2022-09-28T08:21:47 https://maestrodatabase.com/blog/zealand-pharma-submits-new-drug-application-to-us-fda-for-dasiglucagon-in-congenital-hyperinsulinism 2023-07-01T07:31:46 https://maestrodatabase.com/blog/voydeya-approved-in-the-us-as-add-on-therapy-to-ravulizumab-or-eculizumab-for-treatment-of-extravascular-haemolysis-in-adults-with-the-rare-disease-pnh 2024-04-01T06:08:22 https://maestrodatabase.com/blog/high-cost-has-many-diabetics-cutting-back-on-insulin 2018-12-04T07:57:53 https://maestrodatabase.com/blog/nice-backs-cimzia-for-psoriasis-but-rejects-ilumetri 2018-12-04T10:11:31 https://maestrodatabase.com/blog/csl-receives-manufacturing-and-marketing-authorisation-in-japan-for-berinert-sc-injection-2000-as-a-medicine-for-prevention-of-acute-hereditary-angioedema-attacks 2022-09-28T06:20:02 https://maestrodatabase.com/blog/eisai-completes-submission-of-leqembi-lecanemab-irmb-supplemental-biologics-license-application-for-iv-maintenance-dosing-for-the-treatment-of-early-alzheimers-disease-to-the-us-fda 2024-04-01T05:50:25 https://maestrodatabase.com/blog/fda-takes-new-action-to-advance-the-development-of-reliable-and-beneficial-genetic-tests-that-can-improve-patient-care 2018-12-04T19:55:22 https://maestrodatabase.com/blog/donald-trumps-cure-for-drug-prices-is-worse-than-the-disease 2025-10-09T00:25:41 https://maestrodatabase.com/blog/fda-promotes-the-development-and-adoption-of-innovations-that-can-ensure-the-continued-safety-of-the-u-dot-s-blood-supply 2018-12-04T19:57:47 https://maestrodatabase.com/blog/delay-in-decision-on-modifying-funded-access-to-mifepristone-and-misoprostol-proposal 2020-06-17T21:42:26 https://maestrodatabase.com/blog/mulholland-supports-calls-for-pharmac-inquiry 2018-12-04T10:18:15 https://maestrodatabase.com/blog/in-new-guidance-fda-says-ai-tools-to-warn-of-sepsis-should-be-regulated-as-devices 2022-09-28T09:13:46 https://maestrodatabase.com/blog/new-cancer-drugs-taking-longer-to-reach-nhs-patients 2018-12-04T10:24:58 https://maestrodatabase.com/blog/the-eortc-quality-of-life-questionnaire-for-cancer-patients-qlq-c30-australian-general-population-reference-values 2019-06-17T00:51:26 https://maestrodatabase.com/blog/cmss-proposed-rule-on-value-based-purchasing-for-prescription-drugs-new-tools-for-negotiating-prices-for-the-next-generation-of-therapies 2020-06-17T21:08:04 https://maestrodatabase.com/blog/the-trump-administration-has-a-new-idea-for-changing-drug-rebates-that-doesnt-mean-its-abandoning-its-earlier-proposals 2018-12-04T20:21:23 https://maestrodatabase.com/blog/thermo-fisher-scientific-announces-fda-approval-of-oncomine-dx-target-test-as-the-first-ngs-based-companion-diagnostic-to-aid-in-therapy-selection-for-patients-with-ret-mutations-slash-fusions-in-thyroid-cancers 2022-09-28T08:41:51 https://maestrodatabase.com/blog/analysis-of-the-agenda-for-the-pbac-2017-slash-3-meeting 2017-09-04T05:11:48 https://maestrodatabase.com/blog/fda-proposes-improvements-to-the-de-novo-pathway-for-novel-medical-devices-to-advance-safe-effective-and-innovative-treatments-for-patients 2018-12-04T20:00:31 https://maestrodatabase.com/blog/ipsen-receives-fda-fast-track-designation-for-liposomal-irinotecan-onivyde-as-a-first-line-combination-treatment-for-metastatic-pancreatic-cancer 2020-06-17T21:12:28 https://maestrodatabase.com/blog/harrow-announces-us-fda-approval-of-iheezo-chloroprocaine-hydrochloride-3-percent-ophthalmic-gel-for-ocular-surface-anaesthesia 2022-09-28T08:32:56 https://maestrodatabase.com/blog/shield-therapeutics-announces-the-new-drug-application-for-feraccru-has-been-accepted-for-filing-and-review-by-the-fda 2018-12-04T20:13:00 https://maestrodatabase.com/blog/identifying-the-risks-of-unproven-regenerative-medicine-therapies 2020-06-17T21:20:51 https://maestrodatabase.com/blog/decision-to-award-sole-supply-for-nicotine-replacement-therapy 2017-09-04T05:03:51 https://maestrodatabase.com/blog/crispr-therapeutics-announces-fda-regenerative-medicine-advanced-therapy-designation-granted-to-ctx130-for-the-treatment-of-cutaneous-t-cell-lymphomas 2022-09-28T21:05:46 https://maestrodatabase.com/blog/britain-prepares-nhs-drug-spending-hike-to-stave-off-trump-tariffs 2025-10-08T23:12:02 https://maestrodatabase.com/blog/the-biosimilars-forum-joins-calls-for-fda-action-on-biosimilar-communications 2018-12-04T20:33:46 https://maestrodatabase.com/blog/flexibility-on-cancer-drugs-approval-will-foster-innovation 2018-12-04T20:26:58 https://maestrodatabase.com/blog/vivace-therapeutics-vt3989-granted-fast-track-designation-by-the-us-fda-for-the-treatment-of-mesothelioma 2025-10-08T23:15:42 https://maestrodatabase.com/blog/us-biotech-kite-set-to-be-first-to-launch-one-time-cancer-gene-therapy-in-britain 2017-09-04T11:23:31 https://maestrodatabase.com/blog/celltrion-usa-receives-us-fda-approval-for-its-oncology-biosimilar-vegzelma-bevacizumab-adcd-for-the-treatment-of-six-types-of-cancer 2022-09-28T11:24:56 https://maestrodatabase.com/blog/werewolf-therapeutics-receives-fast-track-designation-from-the-us-fda-for-wtx-124-an-investigational-therapy-for-the-treatment-of-cancer 2025-10-08T23:36:44 https://maestrodatabase.com/blog/mercks-erbitux-backed-by-nice-for-head-and-neck-cancer 2017-09-04T11:27:27 https://maestrodatabase.com/blog/xspray-pharma-provides-update-on-the-fda-process-for-dasynoc---observations-at-contract-manufacturer-delay-approval 2025-10-08T23:57:45 https://maestrodatabase.com/blog/citius-pharmaceuticals-submits-biologics-license-application-to-the-us-food-and-drug-administration-for-denileukin-diftitox-for-the-treatment-of-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma 2022-09-28T21:32:26 https://maestrodatabase.com/blog/ascendis-submits-marketing-authorisation-application-to-the-ema-for-transcon-cnp-for-treatment-of-children-with-achondroplasia 2025-10-09T01:40:01 https://maestrodatabase.com/blog/toray-receives-approval-from-chinas-nmpa-for-careload-to-treat-pulmonary-arterial-hypertension 2022-09-28T21:24:36 https://maestrodatabase.com/blog/news-hyperbole-in-government-media-releases-on-new-drugs-can-undermine-confidence-in-nhs-says-editor 2022-09-28T21:20:13 https://maestrodatabase.com/blog/at-475-000-dollars-new-cancer-drug-raises-thorny-questions-about-drug-pricing----and-value 2017-09-04T21:01:46 https://maestrodatabase.com/blog/addressing-uncertainty-in-relative-effectiveness-assessments-by-hta-organisations 2022-02-03T01:11:59 https://maestrodatabase.com/blog/dupixent-dupilumab-approved-by-fda-as-the-first-and-only-treatment-indicated-for-prurigo-nodularis 2022-09-28T21:50:53 https://maestrodatabase.com/blog/pharmac-publishes-agenda-for-may-2024-ptac-meeting 2024-04-01T21:22:37 https://maestrodatabase.com/blog/richter-and-hikma-receive-fda-approval-for-denosumab-biosimilars-enoby-and-xtrenbo-referencing-prolia-and-xgeva 2025-10-09T01:29:15 https://maestrodatabase.com/blog/vamorolone-for-the-treatment-of-patients-with-duchenne-muscular-dystrophy 2024-04-02T05:26:45 https://maestrodatabase.com/blog/fda-accepts-ascendis-pharmas-supplemental-biologics-license-application-for-transcon-hgh-for-the-treatment-of-adults-with-growth-hormone-deficiency 2024-12-14T07:02:37 https://maestrodatabase.com/blog/eligible-australian-kids-16-plus-can-now-get-a-booster 2022-02-03T01:28:26 https://maestrodatabase.com/blog/roche-canada-and-the-pan-canadian-pharmaceutical-alliance-successfully-complete-negotiations-for-tecentriq-sc-atezolizumab-solution-for-subcutaneous-injection 2024-12-14T06:54:14 https://maestrodatabase.com/blog/bms-oral-plaque-psoriasis-drug-sotyktu-gets-reimbursement-starting-april 2024-04-02T02:15:21 https://maestrodatabase.com/blog/relugolix-estradiol-norethisterone-acetate-for-the-treatment-of-patients-with-pain-associated-with-endometriosis 2024-04-02T01:42:25 https://maestrodatabase.com/blog/deal-struck-to-secure-place-of-eczema-drug-on-pbs 2024-12-14T06:39:04 https://maestrodatabase.com/blog/mercks-superovulation-induction-drug-pergoveris-gets-expanded-coverage 2024-04-02T01:13:05 https://maestrodatabase.com/blog/all-payer-claims-databases----uses-and-expanded-prospects-after-gobeille 2016-11-24T01:34:13 https://maestrodatabase.com/blog/trouble-on-the-exchanges----does-the-united-states-owe-billions-to-health-insurers 2016-11-24T01:37:01 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-july-2023 2023-07-01T11:26:26 https://maestrodatabase.com/blog/cms-releases-revised-guidance-for-historic-medicare-drug-price-negotiation-program 2023-07-01T11:22:12 https://maestrodatabase.com/blog/auckland-toddler-may-be-able-to-dance-again-after-pharmac-proposes-funding-drug 2022-09-29T01:18:59 https://maestrodatabase.com/blog/datopotamab-deruxtecan-biologics-license-application-accepted-in-the-us-for-patients-with-previously-treated-metastatic-hr-positive-her2-negative-breast-cancer 2024-04-02T06:17:54 https://maestrodatabase.com/blog/mirum-pharmaceuticals-livmarli-maralixibat-oral-solution-receives-positive-reimbursement-recommendation-by-canadas-cadth-for-patients-with-cholestatic-pruritus-in-alagille-syndrome 2024-04-02T20:26:11 https://maestrodatabase.com/blog/promise-of-genetic-sequencing-frustrated-by-the-cost-of-medicines-for-rare-cancer-patients 2016-11-24T07:32:54 https://maestrodatabase.com/blog/eli-lillys-experimental-alzheimers-drug-fails-in-large-trial 2016-11-24T19:51:48 https://maestrodatabase.com/blog/cancer-experts-urge-pharmac-to-fast-track-life-saving-keytruda 2024-04-02T20:19:47 https://maestrodatabase.com/blog/federal-government-changes-mean-some-skin-cancer-operations-are-off-the-table-for-private-health-funds 2016-11-24T19:58:48 https://maestrodatabase.com/blog/clinical-data-for-two-more-medicines-now-available-online 2017-02-01T20:03:08 https://maestrodatabase.com/blog/updated-submission-form-and-guide-for-patient-group-partners 2016-11-24T19:46:55 https://maestrodatabase.com/blog/new-website-offers-prescription-drugs-at-cost-prices-undercutting-pharmacies 2016-11-24T20:07:12 https://maestrodatabase.com/blog/europes-generic-drugmakers-say-they-may-cut-output-due-to-energy-bills 2022-09-29T05:36:34 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-3-february-2022 2022-02-03T07:29:19 https://maestrodatabase.com/blog/private-health-insurers-should-wind-back-aggressive-tactics---ama-head 2016-11-24T20:03:57 https://maestrodatabase.com/blog/usas-bio-slams-japans-pharma-reimbursement-and-pricing-system 2016-11-24T20:29:36 https://maestrodatabase.com/blog/cadth-issues-second-final-recommendation-for-ibrance-palbociclib 2016-11-24T20:36:36 https://maestrodatabase.com/blog/petition-to-pressure-pharmac-over-hiv-meds 2016-11-24T20:18:04 https://maestrodatabase.com/blog/european-medicines-agency-accepts-modernas-conditional-marketing-authorisation-filing-for-its-omicron-ba-dot-4-slash-ba-dot-5-targeting-bivalent-covid-19-vaccine 2022-09-29T05:33:07 https://maestrodatabase.com/blog/pancreatic-cancer-new-treatment-could-see-advanced-patients-live-twice-as-long 2016-11-24T20:24:07 https://maestrodatabase.com/blog/catalyst-pharmaceuticals-announces-fda-approval-of-supplemental-new-drug-application-for-firdapse-expanding-patient-population-to-include-paediatric-patients 2022-09-29T20:21:47 https://maestrodatabase.com/blog/proposed-cap-on-the-r-and-d-tax-incentive-will-hamper-clinical-trials 2016-11-24T20:49:02 https://maestrodatabase.com/blog/why-the-government-must-urgently-raise-the-nice-cost-effectiveness-threshold 2025-10-09T04:20:36 https://maestrodatabase.com/blog/mhra-appoints-first-new-uk-approved-body-to-certify-medical-devices-since-brexit 2022-09-29T11:42:51 https://maestrodatabase.com/blog/fore-biotherapeutics-announces-fast-track-designation-granted-by-fda-to-fore8394-for-the-treatment-of-cancers-harbouring-braf-class-1-and-class-2-alterations 2022-09-29T11:30:26 https://maestrodatabase.com/blog/tga-provisionally-approves-pfizers-covid-19-vaccine-comirnaty-tozinameran-for-use-in-children-aged-6-months-to-less-than-5-years 2022-09-29T09:28:48 https://maestrodatabase.com/blog/joe-bidens-assault-on-the-900-dollars-child-eczema-cream 2024-04-02T20:39:09 https://maestrodatabase.com/blog/novo-nordisk-rejects-u-dot-s-report-on-aggressive-insulin-price-hikes 2022-02-03T10:38:50 https://maestrodatabase.com/blog/polatuzumab-vedotin-in-untreated-diffuse-large-b-cell-lymphoma-one-step-forward-two-steps-back 2024-04-02T21:41:18 https://maestrodatabase.com/blog/ema-pilot-offers-enhanced-support-to-academic-and-non-profit-developers-of-advanced-therapy-medicinal-products 2022-09-29T20:31:02 https://maestrodatabase.com/blog/weak-krona-exchange-rates-result-in-lower-drug-prices 2022-02-03T19:57:23 https://maestrodatabase.com/blog/icer-to-assess-treatments-for-amyotrophic-lateral-sclerosis 2022-02-03T20:00:59 https://maestrodatabase.com/blog/stakeholder-consultation-forum-post-market-review-of-opiate-dependence-treatment-program-medicines 2022-02-03T10:51:33 https://maestrodatabase.com/blog/timely-intervention-first-chronic-kidney-disease-treatment-in-20-years 2022-02-03T19:54:12 https://maestrodatabase.com/blog/novavax-covid-19-vaccine-nuvaxovid-approved-by-mhra 2022-02-03T20:30:56 https://maestrodatabase.com/blog/why-non-funding-of-cystic-fibrosis-treatment-is-unacceptable 2022-09-29T21:42:53 https://maestrodatabase.com/blog/biomarin-resubmits-biologics-license-application-for-valoctocogene-roxaparvovec-aav-gene-therapy-for-severe-haemophilia-a-to-the-fda 2022-09-29T21:38:20 https://maestrodatabase.com/blog/bargaining-with-cancer-patients-about-treatment 2017-09-04T23:17:32 https://maestrodatabase.com/blog/fda-approves-new-treatment-for-congenital-adrenal-hyperplasia 2024-12-14T08:39:15 https://maestrodatabase.com/blog/democrats-must-get-their-act-together-starting-with-drug-prices 2022-02-03T20:13:33 https://maestrodatabase.com/blog/novartis-and-the-pan-canadian-pharmaceutical-alliance-achieve-milestone-agreement-for-pluvicto 2024-12-14T08:32:43 https://maestrodatabase.com/blog/agenda-for-30-november-2016-tc-meeting 2016-11-25T02:13:59 https://maestrodatabase.com/blog/fda-approves-new-treatment-option-for-patients-with-als 2022-09-29T21:34:26 https://maestrodatabase.com/blog/lipocine-announces-its-partner-received-fda-acceptance-of-nda-resubmission-for-tlando 2022-02-03T20:08:02 https://maestrodatabase.com/blog/britain-fines-firms-47-dollars-million-over-price-surge-for-nhs-nausea-pill 2022-02-03T20:24:50 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-treatments-for-covid-19 2022-02-03T20:15:40 https://maestrodatabase.com/blog/life-or-death-under-pharmac---part-one 2019-06-17T04:51:56 https://maestrodatabase.com/blog/solid-biosciences-receives-rare-paediatric-disease-designation-from-the-fda-for-duchenne-muscular-dystrophy-gene-therapy-candidate-sgt-003 2024-04-02T23:24:49 https://maestrodatabase.com/blog/cadth-calls-for-input-on-submission-for-new-medicine-for-patients-with-biliary-cirrhosis 2016-11-25T03:00:02 https://maestrodatabase.com/blog/tme-pharma-receives-us-fda-fast-track-designation-for-lead-asset-nox-a12-in-brain-cancer 2024-04-02T23:17:51 https://maestrodatabase.com/blog/drug-prices-are-a-populist-campaign-issue-here-are-the-latest-proposals-to-lower-costs 2019-06-17T06:29:05 https://maestrodatabase.com/blog/plan-for-australians-living-with-pain 2019-06-17T06:26:37 https://maestrodatabase.com/blog/roches-vabysmo-pre-filled-syringe-approved-in-the-eu-for-three-retinal-conditions-that-can-cause-blindness 2024-12-14T09:21:28 https://maestrodatabase.com/blog/us-fda-approves-boehringers-jascayd-nerandomilast-tablets-as-first-new-treatment-option-for-adults-with-ipf-in-over-a-decade 2025-10-10T02:17:02 https://maestrodatabase.com/blog/europes-drug-regulator-is-backing-away-from-the-u-dot-k 2018-12-05T03:27:58 https://maestrodatabase.com/blog/nice-reverses-decision-on-cdf-leukaemia-drug-after-price-drop 2016-11-25T10:01:48 https://maestrodatabase.com/blog/ninlaro-ixazomib-citrate-receives-conditional-approval-from-the-european-commission-to-treat-multiple-myeloma 2016-11-25T07:28:10 https://maestrodatabase.com/blog/a-battle-to-change-medicare-is-brewing-whether-trump-wants-it-or-not 2016-11-25T09:55:04 https://maestrodatabase.com/blog/ema-publishes-epar-for-ibrance 2016-11-25T21:13:50 https://maestrodatabase.com/blog/us-court-nixes-drug-maker-price-disclosure 2020-06-18T04:25:20 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-for-amg-420 2018-12-05T05:39:05 https://maestrodatabase.com/blog/rhizen-pharmaceuticals-receives-fda-fast-track-designation-for-tenalisib-rp6530-a-highly-selective-dual-pi3k-delta-slash-gamma-inhibitor-for-the-treatment-of-patients-with-relapsed-and-slash-or-refractory-cutaneous-t-cell-lymphoma 2018-04-13T23:22:41 https://maestrodatabase.com/blog/biden-harris-administration-will-cover-free-over-the-counter-covid-19-tests-through-medicare 2022-02-04T00:40:44 https://maestrodatabase.com/blog/heron-therapeutics-resubmits-new-drug-application-to-fda-for-htx-011-for-the-treatment-of-post-operative-pain 2020-11-13T23:32:03 https://maestrodatabase.com/blog/trump-administration-seeks-to-encourage-value-based-drug-pricing-deals-with-new-proposal 2020-06-18T05:34:22 https://maestrodatabase.com/blog/biocardia-receives-fda-breakthrough-device-designation-for-cardiamp-cell-therapy-system-for-heart-failure 2022-02-04T00:14:53 https://maestrodatabase.com/blog/celltrion-receives-us-fda-approval-for-eydenzelt-aflibercept-boav-biosimilar-referencing-eylea-aflibercept 2025-10-10T03:06:23 https://maestrodatabase.com/blog/decision-components-of-nices-technology-appraisals-assessment-framework 2018-04-13T23:34:35 https://maestrodatabase.com/blog/uk-launches-worlds-first-subscription-style-payment-model-for-antibiotics 2020-06-18T09:31:34 https://maestrodatabase.com/blog/vertex-announces-new-drug-submission-for-exagamglogene-autotemcel-exa-cel-has-been-accepted-for-priority-review-by-health-canada-for-the-treatment-of-sickle-cell-disease-and-transfusion-dependent-beta-thalassaemia 2024-04-03T01:06:34 https://maestrodatabase.com/blog/lawmakers-grill-key-fda-official-over-controversial-alzheimers-drug-approval 2022-02-04T01:14:59 https://maestrodatabase.com/blog/government-authorises-use-of-dexamethasone-for-covid-19 2020-06-18T09:34:05 https://maestrodatabase.com/blog/european-commission-expands-approval-of-bristol-myers-squibbs-reblozyl-luspatercept-to-include-first-line-treatment-of-transfusion-dependent-anaemia-in-adults-with-lower-risk-myelodysplastic-syndromes 2024-04-03T00:49:20 https://maestrodatabase.com/blog/international-regulators-stress-value-of-safe-and-effective-vaccines 2020-06-18T09:15:51 https://maestrodatabase.com/blog/bipartisan-senators-introduce-new-drug-pricing-bill 2018-12-05T10:59:23 https://maestrodatabase.com/blog/csls-improved-flu-vaccine-wont-reach-australia-until-2021 2018-12-05T19:52:52 https://maestrodatabase.com/blog/zanidatamab-biologics-license-application-for-previously-treated-her2-positive-metastatic-biliary-tract-cancer-completed 2024-04-03T03:33:14 https://maestrodatabase.com/blog/international-price-index-for-medicine-will-harm-patients 2018-12-05T10:50:57 https://maestrodatabase.com/blog/gsk-announces-eu-regulatory-submission-of-candidate-vaccine-for-prevention-of-shingles---follows-regulatory-submissions-in-us-and-canada 2016-11-26T03:03:57 https://maestrodatabase.com/blog/johnson-and-johnson-ceo-says-fix-the-drug-pricing-process-but-not-too-much 2018-12-05T10:57:13 https://maestrodatabase.com/blog/fda-issues-complete-response-letter-for-sutimlimab-an-investigational-treatment-for-haemolysis-in-adults-with-cold-agglutinin-disease 2020-11-14T02:39:49 https://maestrodatabase.com/blog/dostarlimab-in-combination-with-platinum-based-chemotherapy-for-the-treatment-of-patients-with-advanced-or-recurrent-high-microsatellite-instability-or-mismatch-repair-deficiency-endometrial-cancer 2024-04-03T01:40:38 https://maestrodatabase.com/blog/chi-med-announces-fruquintinib-granted-u-dot-s-fda-fast-track-designation-for-metastatic-colorectal-cancer 2020-06-18T10:49:47 https://maestrodatabase.com/blog/fda-approves-new-treatment-for-paediatric-patients-with-type-2-diabetes 2019-06-17T20:45:59 https://maestrodatabase.com/blog/cvs-health-promises-a-new-drug-plan-to-pass-all-rebates-along-to-consumers 2018-12-05T20:04:53 https://maestrodatabase.com/blog/samsung-bioepis-announces-health-canada-approval-of-150-mg-single-use-vial-and-440-mg-multi-dose-vial-of-ontruzant-sb3-trastuzumab-biosimilar-for-the-treatment-of-adults-with-early-breast-cancer-metastatic-breast-cancer-and-metastatic-gastric-cancer 2022-02-04T01:32:13 https://maestrodatabase.com/blog/msac-publishes-agenda-for-1-2-august-2024-msac-meeting 2024-04-03T01:33:56 https://maestrodatabase.com/blog/population-adjustment-methods-for-indirect-comparisons-a-review-of-nice-technology-appraisals 2019-06-17T12:35:17 https://maestrodatabase.com/blog/fda-grants-priority-review-to-genentechs-tecentriq-in-combination-with-chemotherapy-for-the-initial-treatment-of-extensive-stage-small-cell-lung-cancer 2018-12-05T20:08:31 https://maestrodatabase.com/blog/melinta-therapeutics-submits-baxdela-new-drug-application-for-hospital-treated-skin-infections 2016-11-26T05:19:39 https://maestrodatabase.com/blog/arog-pharmaceuticals-receives-fda-fast-track-designation-for-crenolanib-for-advanced-gastro-intestinal-stromal-tumours-with-a-d842v-mutation-in-the-pdgfra-gene 2016-11-26T05:27:29 https://maestrodatabase.com/blog/updated-pbac-calendar-and-publication-of-stage-1-pbs-process-improvements---procedure-guidance-and-supporting-documents 2019-06-17T12:31:20 https://maestrodatabase.com/blog/nhs-to-save-ps1-billion-on-its-medicines-bill-in-2019 2018-12-05T19:57:52 https://maestrodatabase.com/blog/tg-therapeutics-completes-rolling-submission-of-new-drug-application-to-the-u-dot-s-fda-for-umbralisib-as-a-treatment-for-patients-with-previously-treated-marginal-zone-lymphoma-or-follicular-lymphoma 2020-06-18T11:18:33 https://maestrodatabase.com/blog/autolus-therapeutics-announces-acceptance-of-marketing-authorisation-application-by-the-ema-for-obecabtagene-autoleucel-for-patients-with-relapsed-slash-refractory-adult-b-cell-acute-lymphoblastic-leukaemia 2024-04-03T01:12:35 https://maestrodatabase.com/blog/nice-terminates-two-appraisals 2018-12-05T20:24:07 https://maestrodatabase.com/blog/medicare-for-all-plan-faces-steep-hurdles-in-massachusetts 2019-06-17T20:56:52 https://maestrodatabase.com/blog/pharmac---2018-in-review-update 2018-12-05T20:39:57 https://maestrodatabase.com/blog/emmaus-new-drug-application-for-sickle-cell-disease-accepted-for-review-by-fda 2016-11-26T08:02:52 https://maestrodatabase.com/blog/government-could-have-bought-more-vaccines-for-northland-national 2019-06-17T20:53:47 https://maestrodatabase.com/blog/eu-watchdog-says-supports-fast-development-of-omicron-only-vaccine 2022-02-04T04:24:29 https://maestrodatabase.com/blog/agenda-for-the-july-2024-pbac-meeting 2024-04-03T07:43:23 https://maestrodatabase.com/blog/generic-drug-prices-strongly-predictive-of-shortages-study-finds 2018-12-05T20:14:40 https://maestrodatabase.com/blog/life-or-death-under-pharmac---part-two 2019-06-17T20:50:21 https://maestrodatabase.com/blog/many-in-florida-count-on-obamas-health-law-even-amid-talk-of-its-demise 2016-11-26T10:25:54 https://maestrodatabase.com/blog/canada-already-has-a-pharmacare-system----and-its-working 2019-06-17T21:16:18 https://maestrodatabase.com/blog/patient-with-rare-disease-pleads-for-life-saving-drug-funding 2019-06-17T21:13:24 https://maestrodatabase.com/blog/trump-says-he-will-roll-out-new-health-care-plan-in-next-couple-of-months 2019-06-17T21:00:03 https://maestrodatabase.com/blog/eiger-announces-breakthrough-therapy-designation-granted-by-fda-for-avexitide-for-treatment-of-post-bariatric-hypoglycemia 2019-06-17T21:29:09 https://maestrodatabase.com/blog/fda-approves-first-therapy-for-rare-disease-that-causes-low-phosphate-blood-levels-bone-softening 2020-06-18T20:50:15 https://maestrodatabase.com/blog/european-medicines-agency-accepts-astellas-marketing-authorisation-application-for-fezolinetant 2022-09-30T00:25:48 https://maestrodatabase.com/blog/as-global-markets-for-generic-drugs-fail-poor-people-pay-the-price 2019-06-17T21:23:17 https://maestrodatabase.com/blog/as-price-of-insulin-soars-americans-caravan-to-canada-for-lifesaving-medicine 2019-06-17T21:19:46 https://maestrodatabase.com/blog/remegens-telitacicept-rc18-granted-fast-track-designation-by-us-fda-for-treatment-of-primary-sjoegrens-syndrome 2024-04-03T20:46:23 https://maestrodatabase.com/blog/fda-granted-accelerated-approval-to-tazemetostat-for-follicular-lymphoma 2020-06-18T20:55:41 https://maestrodatabase.com/blog/important-new-cancer-treatments-approved-by-health-canada-marred-by-major-provincial-reality-disconnect-for-patients 2016-11-26T23:06:51 https://maestrodatabase.com/blog/linnaeus-therapeutics-granted-u-dot-s-fda-fast-track-designation-for-lns8801-for-the-treatment-of-patients-with-metastatic-or-unresectable-melanoma-who-have-progressed-on-anti-pd-1-slash-l1-therapy 2020-06-18T21:09:10 https://maestrodatabase.com/blog/fees-and-charges-summary-from-1-july-2020 2020-06-18T21:16:09 https://maestrodatabase.com/blog/harnessing-the-power-of-health-taxes 2020-06-18T21:22:12 https://maestrodatabase.com/blog/public-summary-documents---december-2017-pbac-meeting 2018-04-27T22:18:06 https://maestrodatabase.com/blog/adcendo-aps-announces-fda-fast-track-designation-granted-to-adce-d01-for-the-treatment-of-soft-tissue-sarcoma 2025-10-10T03:56:54 https://maestrodatabase.com/blog/cidara-therapeutics-receives-us-fda-breakthrough-therapy-designation-for-cd388-in-seasonal-influenza-prevention 2025-10-10T04:02:11 https://maestrodatabase.com/blog/tlv-has-decided-to-change-the-subsidy-status-for-certain-drugs 2020-06-18T21:05:41 https://maestrodatabase.com/blog/fda-approves-new-antibiotic-for-three-different-uses 2024-04-03T22:13:01 https://maestrodatabase.com/blog/clinical-trial-costs-to-develop-a-new-drug-may-actually-be-rather-modest----or-so-one-study-suggests 2020-06-18T21:33:33 https://maestrodatabase.com/blog/vertex-and-canada-hold-talks-over-cystic-fibrosis-drug-but-a-deal-for-newer-medicine-remains-out-of-reach 2020-06-18T21:35:43 https://maestrodatabase.com/blog/fda-takes-additional-action-to-harness-real-world-data-to-inform-covid-19-response-efforts 2020-06-18T21:47:31 https://maestrodatabase.com/blog/pressure-on-meningococcal-vaccine-for-wa 2016-11-27T12:05:42 https://maestrodatabase.com/blog/janssen-submits-application-to-ema-seeking-approval-of-anti-interleukin-23-monoclonal-antibody-guselkumab-for-the-treatment-of-moderate-to-severe-plaque-psoriasis 2016-11-27T12:11:25 https://maestrodatabase.com/blog/drug-makers-find-competition-doesnt-keep-a-lid-on-prices 2016-11-27T20:15:15 https://maestrodatabase.com/blog/therapeuticsmd-announces-fda-acceptance-of-new-drug-application-and-pdufa-date-for-yuvvexy-tx-004hr 2016-11-27T21:38:25 https://maestrodatabase.com/blog/neurocrine-announces-ingrezza-valbenazine-new-drug-application-for-the-treatment-of-tardive-dyskinesia-has-been-accepted-for-priority-review-by-u-dot-s-fda 2016-11-27T21:25:58 https://maestrodatabase.com/blog/beigene-announces-european-medicines-agency-acceptance-of-its-marketing-authorisation-application-for-brukinsa-zanubrutinib-for-the-treatment-of-patients-with-waldenstroems-macroglobulinaemia 2020-06-19T01:06:14 https://maestrodatabase.com/blog/japan-drug-pricing-reform-to-get-blueprint-by-year-end 2016-11-27T22:03:26 https://maestrodatabase.com/blog/cancer-prevention-pharmaceuticals-submits-eu-marketing-authorisation-application-for-cpp-1x-slash-sul-for-treatment-of-familial-adenomatous-polyposis 2020-06-19T01:59:19 https://maestrodatabase.com/blog/first-gene-therapy-for-rare-genetic-neurodegenerative-disorder-in-children-recommended-in-nice-draft-guidance 2022-02-04T09:50:21 https://maestrodatabase.com/blog/libmedly-worlds-most-expensive-drug-recommended-for-nhs-use 2022-02-04T07:31:21 https://maestrodatabase.com/blog/auspars-questions-and-answers 2016-11-28T05:43:42 https://maestrodatabase.com/blog/the-g-dot-o-p-and-health-care-chaos 2016-11-28T10:37:07 https://maestrodatabase.com/blog/republicans-reach-deal-to-pass-cures-act-by-end-of-year-but-democrats-pushing-for-changes 2016-11-28T19:44:21 https://maestrodatabase.com/blog/updating-medicine-ingredient-names 2016-11-28T05:46:25 https://maestrodatabase.com/blog/astrazeneca-announces-historic-agreement-with-us-government-to-lower-the-cost-of-medicines-for-american-patients 2025-10-10T22:06:48 https://maestrodatabase.com/blog/workshop-measuring-the-impact-of-pharmacovigilance-activities 2016-11-28T10:30:06 https://maestrodatabase.com/blog/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-seeking-approval-for-keytruda-pembrolizumab-for-new-indication-in-microsatellite-instability-high-cancer 2016-11-28T19:55:47 https://maestrodatabase.com/blog/pfizer-fears-rough-ride-with-nice-over-breast-cancer-drug 2016-11-28T20:06:32 https://maestrodatabase.com/blog/many-medicare-cancer-patients-hit-by-high-out-of-pocket-costs 2016-11-28T19:46:40 https://maestrodatabase.com/blog/fda-approves-treatment-for-adults-with-rare-type-of-anaemia 2022-02-04T22:52:45 https://maestrodatabase.com/blog/could-the-fda-be-dismantled-under-trump 2016-11-28T19:48:51 https://maestrodatabase.com/blog/why-regulators-must-move-with-the-science-if-were-to-get-innovative-new-treatments-to-patients-more-quickly 2018-12-06T01:40:10 https://maestrodatabase.com/blog/tandem-drug-price-increases-for-viagra-and-cialis-hurt-patients 2016-11-28T20:27:47 https://maestrodatabase.com/blog/tga-grants-third-provisional-approval-to-covid-19-vaccine-janssen 2021-06-26T01:01:49 https://maestrodatabase.com/blog/the-future-of-the-aca-and-health-care-policy-in-the-united-states 2016-11-28T20:15:14 https://maestrodatabase.com/blog/the-affordable-care-act-moving-forward-in-the-coming-years 2016-11-28T20:21:18 https://maestrodatabase.com/blog/to-hell-and-back-devices-meant-to-ease-pain-are-causing-trauma 2022-02-04T23:01:11 https://maestrodatabase.com/blog/dicerna-receives-rare-paediatric-disease-designation-from-u-dot-s-fda-for-nedosiran-for-the-treatment-of-primary-hyperoxaluria 2020-06-19T04:21:58 https://maestrodatabase.com/blog/advanced-accelerator-applications-reports-feedback-from-the-fda-for-lutathera-an-investigational-treatment-for-neuroendocrine-tumours 2016-11-28T20:32:18 https://maestrodatabase.com/blog/widened-eligibility-for-oral-antiviral-paxlovid-plus-new-medicines-on-pbs 2023-07-02T21:32:02 https://maestrodatabase.com/blog/first-medicine-to-treat-rare-genetic-disorder-causing-cysts-and-tumours 2024-12-14T22:39:34 https://maestrodatabase.com/blog/utilisation-and-cost-model-workbook-to-accompany-pbac-guidelines 2016-11-28T23:07:10 https://maestrodatabase.com/blog/fda-publishes-post-crl-guidance-for-generic-companies 2018-12-06T09:09:43 https://maestrodatabase.com/blog/mirati-therapeutics-adagrasib-receives-breakthrough-therapy-designation-from-u-dot-s-fda-for-patients-with-advanced-non-small-cell-lung-cancer-harbouring-the-krasg12c-mutation 2021-06-26T01:07:30 https://maestrodatabase.com/blog/alofisel-withdrawn-from-the-eu-market 2024-12-14T22:30:09 https://maestrodatabase.com/blog/highlights-from-the-9-12-december-2024-chmp-meeting 2024-12-14T22:25:58 https://maestrodatabase.com/blog/epizyme-announces-fast-track-designation-for-tazemetostat-in-dlbcl-and-provides-solid-tumour-program-update 2016-11-29T01:27:19 https://maestrodatabase.com/blog/statement-from-fda-commissioner-on-fdas-new-strategic-framework-to-advance-use-of-real-world-evidence-to-support-development-of-drugs-and-biologics 2018-12-06T19:54:54 https://maestrodatabase.com/blog/hodgkins-patients-have-keytruda-cost-cut 2018-04-15T00:30:55 https://maestrodatabase.com/blog/fda-approves-expanded-indication-for-uzedy-risperidone-extended-release-injectable-suspension-as-a-treatment-for-adults-living-with-bipolar-i-disorder 2025-10-10T23:53:54 https://maestrodatabase.com/blog/long-waits-push-surgeries-onto-private-health-insurance-list 2018-12-06T20:01:30 https://maestrodatabase.com/blog/trapped-abroad-nz-a-death-sentence-if-she-comes-home 2018-12-06T10:56:10 https://maestrodatabase.com/blog/statement-from-fda-commissioner-on-the-fdas-new-effort-for-developing-and-class-labelling-of-in-vitro-companion-diagnostics-for-classes-of-oncology-therapeutic-products 2018-12-06T19:51:57 https://maestrodatabase.com/blog/galderma-receives-us-fda-approval-for-nemluvio-nemolizumab-for-patients-with-moderate-to-severe-atopic-dermatitis 2024-12-14T23:27:29 https://maestrodatabase.com/blog/pfizer-and-merck-are-raising-drug-prices-again-showing-that-their-price-cuts-were-just-a-sham-to-mollify-trump 2018-12-06T20:14:54 https://maestrodatabase.com/blog/chinas-drug-makers-plunge-most-since-2009-on-price-concerns 2018-12-06T20:18:04 https://maestrodatabase.com/blog/first-treatment-for-peripheral-thyrotoxicosis-in-patients-with-allan-herndon-dudley-syndrome 2024-12-14T22:51:57 https://maestrodatabase.com/blog/federal-officials-call-out-fda-over-lapses-in-rare-disease-drug-approval 2018-12-06T20:09:10 https://maestrodatabase.com/blog/first-treatment-recommended-for-rare-progressive-lung-conditions-in-children-and-adolescents 2024-12-14T22:45:03 https://maestrodatabase.com/blog/6-dollars-3-cents-billion-measure-aims-to-cure-ailing-health-care-policies 2016-11-29T11:58:53 https://maestrodatabase.com/blog/tom-price-obamacare-critic-is-said-to-be-trumps-choice-for-health-secretary 2016-11-29T12:01:37 https://maestrodatabase.com/blog/critical-drugs-could-be-rationed-following-epipen-shortage 2018-04-15T01:18:55 https://maestrodatabase.com/blog/tga-publishes-auspar-for-spiriva-respimat 2016-11-29T06:31:12 https://maestrodatabase.com/blog/tga-business-plan-2016-17 2016-11-29T07:13:00 https://maestrodatabase.com/blog/ultragenyx-and-kyowa-kirin-announce-health-canada-approval-of-crysvita-burosumab-injection-for-the-treatment-of-x-linked-hypophosphataemia-in-adults-and-children 2018-12-06T20:39:43 https://maestrodatabase.com/blog/amicus-therapeutics-announces-u-dot-s-regulatory-pathway-for-migalastat-hydrochloride-for-fabry-disease 2016-11-29T12:09:54 https://maestrodatabase.com/blog/fda-breaks-nme-approval-record-in-2018 2018-12-06T20:23:47 https://maestrodatabase.com/blog/precision-medicine-and-the-changing-role-of-regulatory-agencies 2016-11-29T19:55:41 https://maestrodatabase.com/blog/nice-recommends-4p-a-day-breast-cancer-drug 2016-11-29T12:05:59 https://maestrodatabase.com/blog/alberta-boy-with-thyroid-cancer-runs-plays-after-taking-u-dot-s-approved-drug 2018-12-06T20:32:34 https://maestrodatabase.com/blog/drug-company-shenanigans-to-block-generics-come-under-federal-scrutiny 2018-04-15T01:08:01 https://maestrodatabase.com/blog/quality-of-life-overall-survival-and-costs-of-cancer-drugs-approved-based-on-surrogate-endpoints 2016-11-29T20:06:22 https://maestrodatabase.com/blog/cutting-edge-cancer-drug-hobbled-by-diagnostic-test-confusion 2018-04-15T01:55:48 https://maestrodatabase.com/blog/why-cant-device-makers-and-insurers-get-along 2016-11-29T20:13:58 https://maestrodatabase.com/blog/cancer-immunology-community-seeks-better-end-points 2016-11-29T19:59:27 https://maestrodatabase.com/blog/improving-the-accelerated-pathway-to-cancer-drug-approvals 2016-11-29T20:02:57 https://maestrodatabase.com/blog/insurers-look-to-pass-drug-price-breaks-straight-to-consumer 2018-04-15T02:00:09 https://maestrodatabase.com/blog/development-challenges-for-medicines-for-central-nervous-system-disorders 2016-11-29T20:47:25 https://maestrodatabase.com/blog/ironed-out 2018-04-15T01:36:11 https://maestrodatabase.com/blog/fda-accepts-the-biologics-license-application-for-avelumab-for-the-treatment-of-metastatic-merkel-cell-carcinoma-for-priority-review 2016-11-29T20:20:00 https://maestrodatabase.com/blog/doctors-drug-and-tech-experts-converge-on-halifax-for-symposium 2018-04-15T01:39:54 https://maestrodatabase.com/blog/fair-vaccine-pricing-please-not-random-acts-of-charity 2016-11-29T20:38:07 https://maestrodatabase.com/blog/hospital-docs-weigh-in-on-car-t-reimbursement-its-very-complicated 2018-12-06T20:45:38 https://maestrodatabase.com/blog/fda-accepts-supplemental-biologics-license-applications-for-bimzelx-bimekizumab-bkzx-for-moderate-to-severe-hidradenitis-suppurativa-and-additional-2-ml-device-presentations 2024-04-04T05:02:47 https://maestrodatabase.com/blog/rocket-pharmaceuticals-announces-ema-acceptance-of-rp-l102-marketing-authorisation-application-for-the-treatment-of-fanconi-anaemia 2024-04-04T02:47:04 https://maestrodatabase.com/blog/tga-grants-provisional-determination-to-modernas-covid-19-bivalent-original-plus-omicron-ba-dot-4-slash-ba-dot-5-booster-dose-vaccine 2022-09-30T05:49:06 https://maestrodatabase.com/blog/vanda-pharmaceuticals-fanapt-iloperidone-receives-us-fda-approval-for-the-acute-treatment-of-bipolar-i-disorder 2024-04-04T01:24:33 https://maestrodatabase.com/blog/introduction-of-mandatory-arrangements-for-pbs-efficient-funding-of-chemotherapy-claims 2017-09-05T05:25:55 https://maestrodatabase.com/blog/medicare-coverage-of-weight-loss-drugs-could-save-the-us-billions-of-dollars 2024-04-04T06:37:10 https://maestrodatabase.com/blog/nice-review-does-not-recommend-routine-funding-for-duchenne-muscular-dystrophy-gene-therapy-ataluren-in-draft-guidance 2022-09-30T09:18:32 https://maestrodatabase.com/blog/abbvie-provides-update-regarding-rinvoq-upadacitinib-in-psoriatic-arthritis-and-ankylosing-spondylitis-in-the-u-dot-s 2021-06-26T05:54:15 https://maestrodatabase.com/blog/biogen-announced-ema-filing-acceptance-of-biib800-a-biosimilar-candidate-referencing-roactemra-tocilizumab 2022-09-30T11:28:29 https://maestrodatabase.com/blog/fda-frants-rmat-designation-to-avobis-bios-implantable-cell-therapy-avb-114-for-crohns-perianal-fistulas 2025-10-11T21:23:10 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-october-2022 2022-09-30T10:54:47 https://maestrodatabase.com/blog/ariad-announces-fda-full-approval-and-label-update-for-iclusig-ponatinib-based-on-long-term-efficacy-and-safety-data-from-phase-2-pace-clinical-trial 2016-11-30T01:07:03 https://maestrodatabase.com/blog/debut-of-abortion-pill-mifegymiso-in-canada-delayed-to-january 2016-11-30T01:26:17 https://maestrodatabase.com/blog/south-australia-to-commence-prep-trials 2016-11-30T02:06:36 https://maestrodatabase.com/blog/nice-publishes-second-draft-guidance-for-ixazomib-citrate 2017-09-05T20:55:48 https://maestrodatabase.com/blog/curis-announces-full-approval-of-roches-erivedge-in-the-european-union 2016-11-30T01:18:12 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-december-2016 2016-11-30T06:20:35 https://maestrodatabase.com/blog/nice-says-people-with-osteoporosis-should-be-assessed-for-their-fracture-risk 2016-11-30T10:58:09 https://maestrodatabase.com/blog/pharmacies-need-6cpa-risk-share 2016-11-30T03:45:44 https://maestrodatabase.com/blog/donald-trump-taps-obamacare-critic-to-overhaul-health-system 2016-11-30T03:51:41 https://maestrodatabase.com/blog/drug-approval-by-regulators-who-watches-the-watchers 2016-11-30T11:05:46 https://maestrodatabase.com/blog/amylyx-pharmaceuticals-announces-formal-intention-to-remove-relyvrio-slash-albrioza-from-the-market 2024-04-04T20:13:55 https://maestrodatabase.com/blog/in-the-real-world 2016-11-30T20:07:35 https://maestrodatabase.com/blog/chmp-recommends-approval-of-rinvoq-upadacitinib-for-the-treatment-of-atopic-dermatitis 2021-06-26T06:00:58 https://maestrodatabase.com/blog/f-dot-d-a-agrees-to-new-trials-for-ecstasy-as-relief-for-ptsd-patients 2016-11-30T11:02:56 https://maestrodatabase.com/blog/new-model-validation-tool-to-support-economic-evaluations-of-health-technologies 2024-04-04T20:10:33 https://maestrodatabase.com/blog/expensive-thyroid-cancer-drug-now-38-dollars 2016-11-30T20:25:22 https://maestrodatabase.com/blog/why-drugs-cost-less-in-the-u-dot-k-than-in-the-u-dot-s 2017-09-05T21:10:10 https://maestrodatabase.com/blog/vertex-announces-new-portfolio-reimbursement-agreement-in-italy-including-kaftrio-symkevi-and-additional-indications-of-orkambi-and-kalydeco-for-eligible-patients-with-cystic-fibrosis 2021-06-26T06:16:35 https://maestrodatabase.com/blog/tom-price-a-radical-choice-for-health-secretary 2016-11-30T20:15:23 https://maestrodatabase.com/blog/87-per-cent-of-aussies-believe-private-health-insurance-is-expensive 2016-11-30T20:22:10 https://maestrodatabase.com/blog/novartis-charged-much-more-in-the-u-dot-s-for-some-drugs-than-in-other-countries 2017-09-05T21:16:49 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-december-2016-update 2016-11-30T20:37:15 https://maestrodatabase.com/blog/interoperability-fdas-final-guidance-on-smart-safe-medical-device-interactions 2017-09-05T21:13:54 https://maestrodatabase.com/blog/cadth-publishes-final-outcome-for-opdivo-for-head-and-neck-cancer 2017-09-05T21:35:49 https://maestrodatabase.com/blog/mhra-and-nice-invite-early-adopters-to-trial-accelerated-aligned-pathway---six-months-ahead-of-schedule 2025-10-11T21:51:49 https://maestrodatabase.com/blog/cancer-survivors-more-likely-to-skip-drugs-due-to-cost 2017-09-05T21:20:30 https://maestrodatabase.com/blog/cyltezo-first-and-only-fda-approved-interchangeable-biosimilar-to-humira-now-commercially-available-in-the-us 2023-07-03T07:28:40 https://maestrodatabase.com/blog/novartis-scemblix-gets-benefit-to-treat-chronic-myeloid-leukaemia-third-or-more-times 2023-07-03T02:16:01 https://maestrodatabase.com/blog/ira-extends-insulin-cost-caps-to-medicare-part-b-and-medicare-advantage-starting-1-july 2023-07-03T01:32:25 https://maestrodatabase.com/blog/cadth-recommends-olaparib-following-supply-of-results-from-phase-3-trial 2017-09-05T21:45:59 https://maestrodatabase.com/blog/sq-innovation-announces-fda-approval-of-lasix-onyu-for-treatment-of-edema-in-heart-failure 2025-10-11T21:37:18 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-futibatinib-for-cholangiocarcinoma 2022-09-30T20:43:18 https://maestrodatabase.com/blog/patients-gain-subsidised-access-to-expensive-new-medicines 2016-11-30T23:29:46 https://maestrodatabase.com/blog/emmaus-life-sciences-receives-notice-of-fda-pdufa-date-for-investigational-l-glutamine-treatment-for-sickle-cell-disease 2016-12-01T01:24:28 https://maestrodatabase.com/blog/health-canada-authorises-tecentriq-atezolizumab-for-canadians-with-early-non-small-cell-lung-cancer 2022-02-05T06:08:23 https://maestrodatabase.com/blog/coherus-marketing-authorisation-application-to-european-medicines-agency-for-chs-1701-pegfilgrastim-biosimilar-candidate-accepted 2016-12-01T01:35:17 https://maestrodatabase.com/blog/life-saving-spinal-muscular-atrophy-medicine-to-be-made-available-to-australian-babies 2020-11-15T03:20:33 https://maestrodatabase.com/blog/house-passes-health-bill-to-speed-drug-approvals-boost-biomedical-research 2016-12-01T06:31:39 https://maestrodatabase.com/blog/price-of-covid-treatments-from-pfizer-merck-gsk-align-with-patient-benefits 2022-02-05T06:18:12 https://maestrodatabase.com/blog/simpler-website-navigation-for-regulatory-information-on-human-medicines 2016-12-01T19:51:12 https://maestrodatabase.com/blog/gsk-gets-green-light-to-sell-breakthrough-asthma-treatment-to-the-nhs 2016-12-01T03:50:45 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-for-review-a-supplemental-new-drug-application-to-expand-labelling-of-abilify-maintena-aripiprazole-for-the-treatment-of-bipolar-i-disorder 2016-12-01T20:15:12 https://maestrodatabase.com/blog/fda-grants-priority-review-to-supplemental-biologics-license-application-for-mercks-keytruda-pembrolizumab-in-relapsed-or-refractory-classical-hodgkins-lymphoma 2016-12-01T19:57:09 https://maestrodatabase.com/blog/tga-approves-provisional-determination-for-gilead-for-covid-19-treatment-veklury-remdesivir-for-proposed-use-in-children-and-adults-who-are-at-risk-of-progressing-to-severe-covid-19 2022-02-05T08:48:54 https://maestrodatabase.com/blog/prep-advocates-call-for-greater-affordability-and-access-to-new-preventative-hiv-method 2016-12-01T20:28:51 https://maestrodatabase.com/blog/my-mother-bought-me-prep-for-christmas-how-far-weve-come-in-the-fight-against-aids 2016-12-01T20:33:47 https://maestrodatabase.com/blog/scientific-evidence-and-financial-obligations-to-ensure-access-to-biosimilars-for-cancer-treatment 2016-12-01T20:49:17 https://maestrodatabase.com/blog/biosimilar-therapy-for-erbb2-her2--positive-breast-cancer 2016-12-01T20:52:57 https://maestrodatabase.com/blog/cadth-publishes-initial-recommendation-for-venclexta-venetoclax 2016-12-01T20:41:28 https://maestrodatabase.com/blog/agenda-for-7-december-2016-tc-meeting 2016-12-01T23:11:10 https://maestrodatabase.com/blog/older-americans-can-get-rsv-vaccine-this-fall-after-consulting-their-doctor-cdc-says 2023-07-03T06:00:02 https://maestrodatabase.com/blog/celltrion-applies-for-approval-in-us-for-eye-treatment-biosimilar 2023-07-03T05:54:32 https://maestrodatabase.com/blog/innovent-and-iaso-bio-announce-the-nmpa-approval-of-fucaso-the-first-fully-human-bcma-car-t-therapy-for-the-treatment-of-relapsed-or-refractory-multiple-myeloma 2023-07-03T05:32:44 https://maestrodatabase.com/blog/celltrion-usa-launches-yuflyma-adalimumab-aaty-a-humira-adalimumab-biosimilar-in-the-us 2023-07-03T06:24:55 https://maestrodatabase.com/blog/securing-cheaper-medicines-for-people-with-severe-eczema 2024-12-15T21:20:30 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac---may-2020-intracycle-meeting 2020-06-19T23:12:38 https://maestrodatabase.com/blog/genentech-withdraws-use-of-gavreto-in-us-for-a-type-of-thyroid-cancer-says-partner-blueprint 2023-07-03T06:12:50 https://maestrodatabase.com/blog/review-of-pharmacy-remuneration-and-regulation---pharmacy-financial-survey 2016-12-02T03:52:25 https://maestrodatabase.com/blog/arsanis-receives-fda-fast-track-designation-for-asn100-for-the-prevention-of-staphylococcus-aureus-pneumonia 2016-12-02T03:55:43 https://maestrodatabase.com/blog/vaccines-including-for-covid-19-will-be-made-in-new-australian-plant 2020-11-15T19:33:41 https://maestrodatabase.com/blog/updated-pbs-cost-recovery-arrangements-for-2020-21 2020-06-19T23:15:30 https://maestrodatabase.com/blog/fda-approves-jardiance-to-reduce-cardiovascular-death-in-adults-with-type-2-diabetes 2016-12-02T19:46:52 https://maestrodatabase.com/blog/icers-final-report-on-targeted-immunomodulators-for-plaque-psoriasis-offers-guidance-for-policy-and-practice 2016-12-02T19:56:57 https://maestrodatabase.com/blog/proposal-to-widen-funded-access-to-lenalidomide-for-multiple-myeloma 2019-12-16T07:07:44 https://maestrodatabase.com/blog/ars-pharmaceuticals-announces-filings-for-approval-of-neffy-in-china-japan-and-australia 2024-12-15T22:19:57 https://maestrodatabase.com/blog/agilent-receives-expanded-fda-approval-for-pd-l1-ihc-22c3-pharmdx-in-triple-negative-breast-cancer 2020-11-15T19:49:27 https://maestrodatabase.com/blog/u-dot-s-fda-grants-fast-track-designation-for-her2-targeting-antibody-drug-conjugate-ds-8201-for-her2-positive-metastatic-breast-cancer 2016-12-02T04:39:24 https://maestrodatabase.com/blog/the-four-legs-of-a-new-health-care-system 2016-12-02T20:16:03 https://maestrodatabase.com/blog/chmp-recommends-eu-approval-of-roches-xofluza-baloxavir-marboxil-for-the-treatment-of-influenza 2020-11-15T19:54:32 https://maestrodatabase.com/blog/nice-recommends-new-lung-cancer-drug-pembrolizumab 2016-12-02T20:19:22 https://maestrodatabase.com/blog/trump-may-be-more-vicious-on-drug-prices-pharma-ceo-says 2016-12-02T20:07:17 https://maestrodatabase.com/blog/legislation-will-improve-access-to-medicines-and-cut-red-tape 2016-12-02T20:11:34 https://maestrodatabase.com/blog/new-drug-gives-normal-life-to-haemophiliac-who-thought-he-would-never-study-surf-or-be-on-stage 2020-11-15T19:37:36 https://maestrodatabase.com/blog/cancer-drugs-may-remain-approved-despite-lack-of-benefit 2016-12-02T20:29:53 https://maestrodatabase.com/blog/underuse-of-innovative-medicines-in-germany-a-justification-for-government-intervention 2018-12-07T02:32:23 https://maestrodatabase.com/blog/api-calls-off-pursuit-of-pharmacy-rival-sigma 2019-12-16T07:17:52 https://maestrodatabase.com/blog/drug-makers-offer-canada-1-billion-dollars-to-scrap-some-pending-pricing-rules 2020-11-15T19:43:04 https://maestrodatabase.com/blog/drug-companys-affiliate-cashing-in-on-opioid-overdoses-with-new-cure---subsidised-by-australian-government 2019-12-16T07:15:21 https://maestrodatabase.com/blog/flawed-forecasting-why-new-zealand-ran-out-of-mmr-vaccine 2019-12-16T07:10:55 https://maestrodatabase.com/blog/surviving-niche-busters-main-strategies-employed-by-canadian-private-insurers-facing-the-arrival-of-high-cost-specialty-drugs 2018-12-07T03:08:59 https://maestrodatabase.com/blog/proposal-to-list-a-new-presentation-of-raltegravir-and-amend-arrangements-for-raltegravir-and-posaconazole 2018-12-07T02:34:52 https://maestrodatabase.com/blog/cms-office-of-the-actuary-releases-2017-national-health-expenditures 2018-12-07T03:04:03 https://maestrodatabase.com/blog/chmp-issues-positive-opinion-to-expand-cyramza-ramucirumab-label-to-include-results-from-relay-study-in-patients-with-metastatic-egfr-mutated-non-small-cell-lung-cancer 2019-12-16T07:28:00 https://maestrodatabase.com/blog/gsk-files-eu-regulatory-submission-for-once-daily-closed-triple-combination-therapy-ff-slash-umec-slash-vi-for-patients-with-copd 2016-12-02T22:42:16 https://maestrodatabase.com/blog/health-minister-concedes-dhbs-are-under-pressure---i-want-to-put-more-money-in 2019-06-18T04:48:39 https://maestrodatabase.com/blog/private-health-insurance-analysis-shows-double-digit-rise-in-some-premiums 2018-04-16T02:07:47 https://maestrodatabase.com/blog/improved-payment-administration-for-pbs-listed-medicines 2018-12-07T05:39:19 https://maestrodatabase.com/blog/amgen-and-allergan-submit-biosimilar-marketing-authorisation-application-to-ema-for-abp-215-a-biosimilar-candidate-to-bevacizumab 2016-12-02T23:04:55 https://maestrodatabase.com/blog/an-evidence-based-framework-for-identifying-technologies-of-no-or-low-added-value 2019-12-16T07:53:27 https://maestrodatabase.com/blog/medicare-lays-out-the-bureaucracy-it-will-need-to-negotiate-drug-prices 2022-09-30T22:07:50 https://maestrodatabase.com/blog/chinas-cancer-patients-hit-by-new-law-on-experimental-drug-treatments-not-approved-by-government 2019-12-16T07:40:12 https://maestrodatabase.com/blog/plakous-therapeutics-receives-rare-paediatric-disease-and-orphan-drug-designations-for-protego-pdtm-for-the-prevention-of-necrotising-enterocolitis 2020-06-20T03:28:59 https://maestrodatabase.com/blog/zai-lab-and-argenx-announce-approval-of-vyvgart-efgartigimod-alfa-injection-for-generalised-myasthenia-gravis-in-china 2023-07-03T10:28:44 https://maestrodatabase.com/blog/mylan-ceo-accepts-full-responsibility-for-epipen-price-hikes-but-offers-little-explanation 2016-12-03T00:36:19 https://maestrodatabase.com/blog/fda-approves-evokes-gimoti 2020-06-20T03:45:44 https://maestrodatabase.com/blog/cadth-publishes-final-outcome-for-darzalex-daratumumab 2016-12-02T23:53:43 https://maestrodatabase.com/blog/cadth-publishes-final-outcome-for-afinitor-everolimus 2016-12-03T00:20:08 https://maestrodatabase.com/blog/g-dot-o-p-plans-immediate-repeal-of-health-law-then-a-delay 2016-12-03T22:02:49 https://maestrodatabase.com/blog/ovid-therapeutics-receives-fda-rare-paediatric-disease-designation-for-ov101-for-the-treatment-of-angelman-syndrome 2020-06-20T03:22:36 https://maestrodatabase.com/blog/fda-approves-genentechs-tecentriq-in-combination-with-avastin-and-chemotherapy-for-the-initial-treatment-of-people-with-a-specific-type-of-metastatic-lung-cancer 2018-12-07T06:10:49 https://maestrodatabase.com/blog/roche-receives-fda-clearance-for-additional-alzheimers-disease-cerebrospinal-fluid-assays-supporting-timely-diagnosis-and-treatment-decision-making 2023-07-03T07:23:05 https://maestrodatabase.com/blog/novartis-presents-results-from-first-global-registration-trial-of-ctl019-in-paediatric-and-young-adult-patients-with-r-slash-r-b-all 2016-12-04T00:42:52 https://maestrodatabase.com/blog/senate-confirms-stephen-hahn-to-head-fda 2019-12-16T08:01:22 https://maestrodatabase.com/blog/nice-oks-nhs-funding-for-gileads-car-t-cell-therapy 2018-12-07T11:47:13 https://maestrodatabase.com/blog/vertex-and-republic-of-ireland-expand-long-term-cystic-fibrosis-medicines-reimbursement-agreement-to-include-triple-combination-therapy-for-all-eligible-patients-ages-12-and-over-once-licensed 2019-12-16T08:15:44 https://maestrodatabase.com/blog/immune-system-unleashed-by-cancer-therapies-can-attack-organs 2016-12-04T11:00:17 https://maestrodatabase.com/blog/patent-abuse-is-driving-up-drug-prices-just-look-at-lantus 2018-12-08T00:22:06 https://maestrodatabase.com/blog/this-drug-can-treat-90-per-cent-of-cystic-fibrosis-patients-but-its-not-available-in-canada 2020-06-20T03:56:18 https://maestrodatabase.com/blog/gsks-anne-belcher-says-certainty-on-government-policy-is-crucial 2016-12-04T19:37:25 https://maestrodatabase.com/blog/organon-and-samsung-bioepis-announce-us-launch-of-humira-biosimilar-hadlima-adalimumab-bwwd-in-multiple-presentations-consistent-with-originator 2023-07-03T11:01:15 https://maestrodatabase.com/blog/a-global-accountability-mechanism-for-access-to-essential-medicines 2018-12-07T12:02:07 https://maestrodatabase.com/blog/tom-price-is-eager-to-lead-h-dot-h-s-dot-and-reduce-its-clout 2016-12-05T10:21:00 https://maestrodatabase.com/blog/hepatitis-c-drugs-australias-most-expensive-cost-taxpayers-1-dollars-billion-in-four-months 2016-12-05T10:27:55 https://maestrodatabase.com/blog/amnog-as-a-learning-system-new-study-on-ingenol-mebutate-in-actinic-keratosis-shows-added-benefit 2018-12-08T00:25:55 https://maestrodatabase.com/blog/approval-of-multi-product-funding-proposal-with-roche 2016-12-04T23:31:34 https://maestrodatabase.com/blog/tga-approves-abbvies-technivie 2016-12-05T10:02:28 https://maestrodatabase.com/blog/nabriva-therapeutics-receives-complete-response-letter-from-fda-on-nda-for-contepo-fosfomycin-for-injection 2020-06-20T09:34:27 https://maestrodatabase.com/blog/merck-ceo-says-drug-maker-is-restrained-on-price-increases 2016-12-05T10:57:17 https://maestrodatabase.com/blog/how-perceptions-of-high-drug-prices-do-not-necessarily-match-reality 2018-12-09T06:31:36 https://maestrodatabase.com/blog/pharmac-funds-breast-cancer-drug-perjeta 2016-12-05T19:53:45 https://maestrodatabase.com/blog/nice-to-co-host-2021-htai-annual-meeting-in-manchester 2019-06-18T08:48:51 https://maestrodatabase.com/blog/cadth-establishes-new-post-market-drug-evaluation-program 2022-02-05T11:24:03 https://maestrodatabase.com/blog/online-booking-tool-could-be-the-key-to-sweeping-public-health-reforms 2016-12-05T10:34:42 https://maestrodatabase.com/blog/congress-to-drug-makers-why-stock-buybacks-over-lowered-drug-prices 2018-12-09T20:15:56 https://maestrodatabase.com/blog/nocdurna-approved-by-tga 2016-12-05T10:46:30 https://maestrodatabase.com/blog/private-health-fund-members-stuck-with-outdated-treatments-due-to-loophole 2016-12-05T20:21:59 https://maestrodatabase.com/blog/company-brings-unapproved-life-saving-drugs-to-australia-but-is-it-medicine-for-the-rich 2016-12-05T20:26:39 https://maestrodatabase.com/blog/can-the-government-really-protect-your-privacy-when-it-de-identifies-public-data 2016-12-05T20:14:17 https://maestrodatabase.com/blog/eddingpharm-announces-approval-of-mulpleta-lusutrombopag-in-china 2023-07-03T11:29:00 https://maestrodatabase.com/blog/world-first-clinical-trial-of-cannabis-for-chemotherapy-patients-kicks-off-in-nsw 2016-12-05T20:17:39 https://maestrodatabase.com/blog/medical-device-price-differentials-in-the-u-dot-s-and-europe---rethinking-price-regulation 2018-12-09T20:26:39 https://maestrodatabase.com/blog/itf-pharma-announces-fda-approval-of-supplemental-new-drug-application-for-tiglutik-riluzole-oral-suspension-for-the-treatment-of-amyotrophic-lateral-sclerosis-with-a-percutaneous-endoscopic-gastronomy-feeding-tube 2019-12-16T08:29:06 https://maestrodatabase.com/blog/transparency-commission-publishes-its-opinion-for-yescarta 2018-12-09T20:33:04 https://maestrodatabase.com/blog/zaxine-rifaximin---now-indicated-in-canada-for-patients-with-irritable-bowel-syndrome-with-diarrhoea 2018-12-09T20:19:15 https://maestrodatabase.com/blog/provisional-approval-pathway---first-determination-decision 2018-04-16T06:29:37 https://maestrodatabase.com/blog/buyers-club-wants-government-support-on-orkambi-imports 2019-06-18T08:52:46 https://maestrodatabase.com/blog/wa-accuses-canberra-of-1-dollars-billion-health-care-rip-off 2018-04-16T20:16:15 https://maestrodatabase.com/blog/chinese-vice-premier-calls-for-centralised-medicine-procurement-to-cut-prices 2018-12-09T20:45:12 https://maestrodatabase.com/blog/icers-final-report-on-emicizumab-shows-new-treatment-improves-health-while-lowering-costs-for-certain-people-with-haemophilia-a 2018-04-16T20:18:43 https://maestrodatabase.com/blog/kite-pharma-initiates-rolling-submission-of-u-dot-s-biologics-license-application-for-kte-c19-its-investigational-anti-cd19-car-t-therapy-for-the-treatment-of-patients-with-relapsed-slash-refractory-aggressive-b-cell-non-hodgkin-lymphoma 2016-12-06T10:06:03 https://maestrodatabase.com/blog/icer-posts-draft-scoping-document-on-treatments-for-osteoporosis 2016-12-06T10:30:40 https://maestrodatabase.com/blog/kite-pharma-receives-fda-breakthrough-therapy-designation-for-kte-c19-for-the-treatment-of-refractory-aggressive-non-hodgkin-lymphoma 2016-12-06T03:37:14 https://maestrodatabase.com/blog/clostridium-botulinum-type-a-toxin-botox-in-dhb-hospitals 2016-12-06T06:58:12 https://maestrodatabase.com/blog/considerable-additional-benefit-of-eisais-halaven-eribulin-mesylate-in-advanced-liposarcoma-confirmed-by-the-german-federal-joint-committee 2016-12-06T11:04:55 https://maestrodatabase.com/blog/novo-nordisk-becomes-second-major-drug-maker-to-limit-price-hikes 2016-12-06T20:06:27 https://maestrodatabase.com/blog/u-dot-s-fda-approves-opdivo-nivolumab-plus-yervoy-ipilimumab-combination-as-first-line-treatment-for-patients-with-intermediate--and-poor-risk-advanced-renal-cell-carcinoma 2018-04-16T20:28:08 https://maestrodatabase.com/blog/twelfth-joint-ema-slash-eunethta-dialogue-meeting 2016-12-06T10:42:59 https://maestrodatabase.com/blog/in-new-survey-of-eleven-countries-us-adults-still-struggle-with-access-to-and-affordability-of-health-care 2016-12-06T10:54:07 https://maestrodatabase.com/blog/heartless-to-deny-breast-cancer-drug 2016-12-06T20:20:09 https://maestrodatabase.com/blog/failure-of-investigational-drugs-in-late-stage-clinical-development-and-publication-of-trial-results 2016-12-06T20:29:22 https://maestrodatabase.com/blog/foreign-visa-holders-leaving-millions-in-hospital-debts 2016-12-06T20:14:36 https://maestrodatabase.com/blog/u-dot-s-disappointed-by-japanese-plan-to-cut-drug-costs 2016-12-06T20:16:49 https://maestrodatabase.com/blog/eagle-pharmaceuticals-vasopressin-anda-accepted-for-filing-by-the-fda 2018-04-16T20:52:48 https://maestrodatabase.com/blog/nice-u-turn-backs-nhs-use-of-veltassa 2019-12-16T19:45:47 https://maestrodatabase.com/blog/antizol-approved-by-tga 2016-12-06T20:34:24 https://maestrodatabase.com/blog/coronavirus-attacks-the-lungs-a-federal-agency-just-halted-funding-for-new-lung-treatments 2020-06-21T07:34:32 https://maestrodatabase.com/blog/this-is-what-life-could-be-like-a-miracle-migraine-drug-is-changing-sufferers-lives-but-most-cant-afford-the-exorbitant-800-dollars-a-month-price-tag 2020-06-21T07:39:46 https://maestrodatabase.com/blog/cadth-2018-2021-strategic-plan 2018-04-16T20:34:30 https://maestrodatabase.com/blog/confirming-the-next-fda-commissioner-is-a-matter-of-national-preparedness 2022-02-05T23:39:04 https://maestrodatabase.com/blog/fda-approves-new-dupixent-dupilumab-pre-filled-pen-designed-to-support-more-convenient-self-administration 2020-06-21T07:53:51 https://maestrodatabase.com/blog/fourth-circuit-appeals-court-strikes-down-marylands-drug-price-gouging-law 2018-04-16T20:47:08 https://maestrodatabase.com/blog/pharmac-knew-of-epilepsy-deaths-for-weeks-but-stayed-silent 2019-12-16T19:58:39 https://maestrodatabase.com/blog/eu-hta-g-ba-coordinates-parallel-scientific-consultations-for-manufacturers-from-september 2023-07-03T21:29:20 https://maestrodatabase.com/blog/private-health-care-in-australia-health-policys-wicked-problem 2018-04-16T21:08:30 https://maestrodatabase.com/blog/diurnal-submits-marketing-application-to-european-regulators-for-congenital-adrenal-hyperplasia-treatment 2019-12-16T19:51:50 https://maestrodatabase.com/blog/alkermes-announces-fda-acceptance-for-review-of-new-drug-application-for-alks-5461-for-the-adjunctive-treatment-of-major-depressive-disorder 2018-04-16T20:58:23 https://maestrodatabase.com/blog/amneal-receives-us-fda-complete-response-letter-for-ipx203 2023-07-03T21:19:05 https://maestrodatabase.com/blog/avadel-pharmaceuticals-receives-u-dot-s-fda-approval-for-nouress-av001-a-cysteine-hydrochloride-injection-for-treating-neonate-patients-requiring-total-parental-nutrition 2019-12-16T20:08:08 https://maestrodatabase.com/blog/high-prescription-costs-are-just-one-way-the-big-pharma-drug-companies-rip-us-off 2019-12-16T20:04:23 https://maestrodatabase.com/blog/opposition-turns-its-sights-on-pharmac-funding 2019-06-18T20:44:08 https://maestrodatabase.com/blog/desperate-for-lifesaving-insulin-americans-head-to-canada 2019-06-18T20:57:09 https://maestrodatabase.com/blog/better-ways-than-trumps-plan-to-address-prescription-drug-prices 2018-12-10T02:07:45 https://maestrodatabase.com/blog/biomarins-next-roctavian-challenge-is-how-to-successfully-commercialise-its-gene-therapy-warranties-may-be-an-option 2023-07-03T21:46:03 https://maestrodatabase.com/blog/proposal-to-open-access-to-atomoxetine-and-change-funded-brand 2018-12-10T02:11:56 https://maestrodatabase.com/blog/statement-on-a-new-effort-to-improve-transparency-and-predictability-for-generic-drug-applicants-to-help-increase-timely-access-to-high-quality-lower-cost-generic-drugs 2019-06-18T20:52:18 https://maestrodatabase.com/blog/the-reimbursement-for-medicines-will-continue-to-increase-in-2019 2019-12-16T22:27:23 https://maestrodatabase.com/blog/surgery-is-a-very-costly-business 2019-06-18T20:50:08 https://maestrodatabase.com/blog/ema-closes-out-the-year-with-66-positive-opinions-for-new-medicines 2019-12-16T20:36:07 https://maestrodatabase.com/blog/pharmacies-get-major-financial-boost-from-1-july 2023-07-03T21:37:29 https://maestrodatabase.com/blog/fda-releases-new-data-to-help-generic-drug-competitors 2019-06-18T21:13:24 https://maestrodatabase.com/blog/net-prices-for-medicines-fell-considerably-in-2023s-last-quarter-mostly-thanks-to-humira-biosimilars 2024-04-05T22:19:10 https://maestrodatabase.com/blog/advisory-council-supports-biosimilars-in-call-for-universal-public-drug-coverage-in-canada 2019-06-18T21:10:45 https://maestrodatabase.com/blog/importing-oncology-trials-from-china-a-bridge-over-troubled-waters 2022-02-06T01:05:34 https://maestrodatabase.com/blog/ema-to-reinstate-some-activities-halted-by-brexit 2019-06-18T21:07:11 https://maestrodatabase.com/blog/theravance-biopharma-receives-fda-fast-track-designation-for-velusetrag-td-5108-for-idiopathic-and-diabetic-gastroparesis 2016-12-07T02:00:45 https://maestrodatabase.com/blog/us-fda-approves-bristol-myers-squibb-and-2seventy-bios-abecma-for-triple-class-exposed-relapsed-or-refractory-multiple-myeloma-after-two-prior-lines-of-therapy 2024-04-05T22:09:21 https://maestrodatabase.com/blog/pelosi-democrats-will-fight-relentlessly-against-trumps-obamacare-repeal-attempts 2019-06-18T21:01:36 https://maestrodatabase.com/blog/correcting-the-record-australia-financial-review-story-on-medicinal-cannabis 2016-12-07T02:57:54 https://maestrodatabase.com/blog/spinraza-funding-application-reviewed-by-the-rare-disorders-subcommittee 2019-12-17T00:09:15 https://maestrodatabase.com/blog/public-summary-documents---december-2023-pbac-meeting 2024-04-05T04:29:01 https://maestrodatabase.com/blog/novo-nordisk-files-for-regulatory-approval-of-once-weekly-semaglutide-in-the-us-and-eu-for-the-treatment-of-type-2-diabetes 2016-12-07T04:42:25 https://maestrodatabase.com/blog/bausch-health-canada-announces-first-public-drug-plan-listings-for-uceris-budesonide-aerosol-foam-to-help-address-the-unmet-need-for-the-treatment-of-mild-to-moderate-distal-ulcerative-colitis-in-adults 2024-04-05T04:24:33 https://maestrodatabase.com/blog/lynparza-olaparib-approved-in-the-eu-for-use-as-first-line-maintenance-therapy-in-patients-with-brca-mutated-advanced-ovarian-cancer 2019-06-18T21:17:15 https://maestrodatabase.com/blog/fda-approves-genentechs-avastin-bevacizumab-plus-chemotherapy-for-a-specific-type-of-advanced-ovarian-cancer 2016-12-07T06:32:02 https://maestrodatabase.com/blog/roche-wins-japan-approval-for-personalised-cancer-drug-rozlytrek 2019-06-18T21:31:08 https://maestrodatabase.com/blog/dupixent-dupilumab-approved-in-china-for-adults-with-moderate-to-severe-atopic-dermatitis 2020-06-21T21:25:13 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-fam-trastuzumab-deruxtecan-nxki-for-unresectable-or-metastatic-her2-positive-solid-tumours 2024-04-05T22:34:06 https://maestrodatabase.com/blog/novartis-lucentis-receives-eu-approval-in-new-indication 2016-12-07T06:23:39 https://maestrodatabase.com/blog/lamotrigine-nppa-change 2019-12-17T00:13:04 https://maestrodatabase.com/blog/fda-approves-mercks-keytruda-pembrolizumab-as-monotherapy-for-patients-with-metastatic-small-cell-lung-cancer-with-disease-progression-on-or-after-platinum-based-chemotherapy-and-at-least-one-other-prior-line-of-therapy 2019-06-18T21:22:59 https://maestrodatabase.com/blog/pharma-calls-for-more-detail-on-plan-for-post-brexit-medicines-access 2018-12-10T19:49:48 https://maestrodatabase.com/blog/breast-cancer-sufferer-fighting-for-life-extending-drugs-wants-pharmac-inquiry 2018-12-10T19:53:19 https://maestrodatabase.com/blog/zolgensma-a-remarkable-new-treatment-an-icer-analysis-and-a-poorly-justified-price 2019-06-18T21:41:30 https://maestrodatabase.com/blog/asthma-care-in-korea-reminds-me-of-canada-8-years-ago 2023-07-03T23:47:12 https://maestrodatabase.com/blog/ema-publishes-epar-for-ninlaro 2016-12-07T19:58:31 https://maestrodatabase.com/blog/nice-to-be-sovereign-u-dot-k-rejects-trump-suggestion-to-include-nhs-in-possible-trade-deal 2019-06-18T21:38:56 https://maestrodatabase.com/blog/report-on-the-collection-of-under-co-payment-data-2018-19 2019-12-17T00:24:04 https://maestrodatabase.com/blog/nevakar-injectables-announces-fda-approval-of-cyclophosphamide-rtd-solution 2023-07-03T22:39:43 https://maestrodatabase.com/blog/japan-pms-advisers-urge-annual-review-of-drug-prices 2016-12-07T20:16:35 https://maestrodatabase.com/blog/review-of-pharmacy-remuneration-and-regulation---pharmacy-financial-survey-update 2016-12-07T19:53:35 https://maestrodatabase.com/blog/calls-to-review-pharmac-model-after-more-drug-shortages 2020-06-21T21:16:34 https://maestrodatabase.com/blog/moderna-submits-regulatory-application-to-the-ema-for-its-updated-covid-19-vaccine 2023-07-04T07:16:40 https://maestrodatabase.com/blog/tech-giants-waiting-in-wings-to-give-health-care-a-shake-up 2018-12-10T20:04:22 https://maestrodatabase.com/blog/senate-leaders-offer-bipartisan-plan-to-lower-drug-costs-speed-patient-access-to-generic-medicines 2016-12-07T20:32:52 https://maestrodatabase.com/blog/donald-trump-sent-biotech-stocks-plummeting-with-these-16-words 2016-12-07T20:22:32 https://maestrodatabase.com/blog/nice-turns-down-opdivo-slash-yervoy-combo-for-kidney-cancer 2018-12-10T20:10:23 https://maestrodatabase.com/blog/health-insurers-list-demands-if-affordable-care-act-is-killed 2016-12-07T20:28:42 https://maestrodatabase.com/blog/biomarker-tests-for-targeted-oncology-therapies-pose-tricky-regulatory-challenges 2023-07-04T00:45:12 https://maestrodatabase.com/blog/decision-regarding-pharmacs-implementation-of-trans-pacific-partnership-provisions-and-other-amendments-to-application-processes 2016-12-08T02:24:51 https://maestrodatabase.com/blog/health-insurance-cap-may-advantage-youth 2018-12-10T19:59:20 https://maestrodatabase.com/blog/perjeta-given-green-light-in-scotland-as-early-stage-breast-cancer-treatment 2018-12-10T20:22:31 https://maestrodatabase.com/blog/salarius-pharmaceuticals-receives-fda-fast-track-designation-for-lead-drug-candidate-seclidemstat-in-relapsed-or-refractory-ewing-sarcoma 2019-12-17T00:43:27 https://maestrodatabase.com/blog/smc---december-2018-decisions 2018-12-10T20:16:30 https://maestrodatabase.com/blog/in-an-about-face-health-canada-allows-a-controversial-rare-disease-drug-back-on-the-market 2021-06-27T02:07:37 https://maestrodatabase.com/blog/european-medicines-agency-validates-application-for-bavencio-avelumab-for-first-line-maintenance-treatment-of-locally-advanced-or-metastatic-urothelial-carcinoma 2020-06-22T07:47:26 https://maestrodatabase.com/blog/house-set-to-vote-on-bill-cracking-down-on-drug-companies-overcharging-medicaid 2018-12-10T20:32:02 https://maestrodatabase.com/blog/the-rise-of-use-of-medical-devices-force-fda-to-change-the-rules 2018-12-10T20:37:40 https://maestrodatabase.com/blog/anti-covid-drug-may-be-ready-in-australia-by-the-end-of-the-year 2020-06-22T11:17:58 https://maestrodatabase.com/blog/kura-oncology-receives-fast-track-designation-for-tipifarnib-in-hras-mutant-hnscc-and-provides-enrolment-guidance-for-aim-hn-trial 2019-12-17T00:48:27 https://maestrodatabase.com/blog/fda-accepts-supplemental-biologics-license-application-for-botox-onabotulinumtoxina-for-the-treatment-of-paediatric-patients-with-neurogenic-detrusor-overactivity 2020-06-22T12:30:57 https://maestrodatabase.com/blog/investigation-of-generic-cartel-expands-to-300-drugs 2018-12-10T20:29:30 https://maestrodatabase.com/blog/european-commission-grants-conditional-marketing-approval-for-abbvies-venclyxto-venetoclax-monotherapy-for-appropriate-patients-with-difficult-to-treat-chronic-lymphocytic-leukaemia 2016-12-08T07:34:37 https://maestrodatabase.com/blog/cytokinetics-announces-fda-acceptance-of-new-drug-application-for-omecamtiv-mecarbil-for-the-treatment-of-heart-failure-with-reduced-ejection-fraction 2022-02-06T20:36:49 https://maestrodatabase.com/blog/us-senate-clears-bill-to-ease-fda-drug-and-device-approvals 2016-12-08T07:52:32 https://maestrodatabase.com/blog/pfenex-submits-new-drug-application-to-u-dot-s-fda-seeking-approval-of-pf708-for-the-treatment-of-osteoporosis 2018-12-10T20:44:49 https://maestrodatabase.com/blog/china-drug-prices-were-cut-more-than-expected-credit-suisse-says 2018-12-10T20:49:21 https://maestrodatabase.com/blog/blue-earth-diagnostics-announces-u-dot-s-fda-filing-acceptance-of-supplemental-new-drug-application-for-18f-fluciclovine-pet-imaging-in-glioma 2018-12-10T20:40:08 https://maestrodatabase.com/blog/its-time-to-put-fairness-into-focus 2020-06-22T07:32:08 https://maestrodatabase.com/blog/neovacs-obtains-fda-fast-track-designation-for-ifna-kinoid-in-lupus-sle 2016-12-08T07:59:02 https://maestrodatabase.com/blog/rocket-pharmaceuticals-receives-ema-prime-eligibility-for-rp-l102-gene-therapy-for-fanconi-anaemia 2019-12-17T00:58:39 https://maestrodatabase.com/blog/sanofi-and-regeneron-announce-marketing-authorisation-application-for-dupixent-dupilumab-accepted-for-review-by-the-ema 2016-12-08T09:04:44 https://maestrodatabase.com/blog/u-dot-s-fda-grants-fast-track-designation-to-asana-biosciences-oral-dual-jak-syk-inhibitor-asn002-for-the-treatment-of-atopic-dermatitis 2018-12-10T23:13:41 https://maestrodatabase.com/blog/how-to-cut-drug-prices-experts-weigh-in 2018-12-10T20:51:37 https://maestrodatabase.com/blog/nurtec-odt-is-now-available-in-canada-for-the-treatment-of-acute-migraine 2024-04-06T02:06:29 https://maestrodatabase.com/blog/alternative-payment-models--victims-of-their-own-success 2020-06-22T21:23:46 https://maestrodatabase.com/blog/single-drug-technology-assessment-processes-across-health-technology-assessment-organisations 2016-12-08T19:59:17 https://maestrodatabase.com/blog/european-commission-ema-and-fda-agree-new-priorities-to-strengthen-their-collaboration-on-medicines 2020-06-22T21:12:29 https://maestrodatabase.com/blog/trump-team-said-to-consider-thiel-associate-oneill-for-fda 2016-12-08T20:11:50 https://maestrodatabase.com/blog/stealth-biotherapeutics-granted-fast-track-designation-for-elamipretide-for-the-treatment-of-dry-age-related-macular-degeneration-with-geographic-atrophy 2018-12-10T23:18:13 https://maestrodatabase.com/blog/1-patient-7-tumours-and-100-billion-cells-equal-1-striking-recovery 2016-12-08T20:15:27 https://maestrodatabase.com/blog/fda-approves-selinexor-for-relapsed-slash-refractory-diffuse-large-b-cell-lymphoma 2020-06-22T21:15:14 https://maestrodatabase.com/blog/high-price-tags-for-new-medicines-are-about-to-come-under-renewed-pressure 2016-12-08T20:06:44 https://maestrodatabase.com/blog/real-world-evidence----what-is-it-and-what-can-it-tell-us 2016-12-08T20:45:35 https://maestrodatabase.com/blog/celltrion-receives-positive-chmp-opinion-for-three-biosimilars-in-the-european-union 2024-12-16T02:36:50 https://maestrodatabase.com/blog/interpreting-geographic-variations-in-results-of-randomised-controlled-trials 2016-12-08T20:52:18 https://maestrodatabase.com/blog/first-stage-of-prostheses-benefit-reform-commences 2016-12-08T20:27:33 https://maestrodatabase.com/blog/agenda-for-14-december-2016-tc-meeting 2016-12-08T20:31:16 https://maestrodatabase.com/blog/samsung-bioepis-and-biogen-receive-positive-chmp-opinion-for-ranibizumab-biosimilar-byooviz 2021-06-27T03:17:42 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-positive-chmp-opinion-for-anti-bcma-car-t-cell-therapy-abecma-idecabtagene-vicleucel-for-relapsed-and-refractory-multiple-myeloma 2021-06-27T03:25:53 https://maestrodatabase.com/blog/new-medicare-data-show-steep-increases-in-drug-prices 2016-12-08T21:00:23 https://maestrodatabase.com/blog/trump-administration-proposes-medicaid-reforms-to-encourage-innovative-contracting-models 2020-06-22T21:31:23 https://maestrodatabase.com/blog/proposed-legislation-to-stabilise-aca-threatens-health-care-innovation 2020-06-22T21:33:50 https://maestrodatabase.com/blog/pfizers-vyndaqel-vyndamax-do-not-deserve-rare-disease-pricing 2020-06-22T21:38:51 https://maestrodatabase.com/blog/highlights-from-21-24-june-chmp-meeting 2021-06-27T03:13:27 https://maestrodatabase.com/blog/eiger-initiates-rolling-submission-of-new-drug-application-with-fda-for-lonafarnib-for-treatment-of-progeria-and-progeroid-laminopathies 2019-12-17T06:19:44 https://maestrodatabase.com/blog/pmprb-publishes-new-draft-guidelines-launches-30-day-consultation 2020-06-22T21:46:01 https://maestrodatabase.com/blog/emas-chmp-recommends-approval-of-biocon-biologics-yesintek-biosimilar-to-j-and-js-stelara 2024-12-16T01:13:45 https://maestrodatabase.com/blog/proposal-to-amend-listings-in-the-national-immunisation-schedule 2016-12-08T23:40:03 https://maestrodatabase.com/blog/health-canada-approves-new-indication-for-erleada-apalutamide-for-the-treatment-of-metastatic-castration-sensitive-prostate-cancer 2019-12-17T06:33:13 https://maestrodatabase.com/blog/insmed-receives-priority-medicines-prime-designation-from-ema-for-brensocatib-in-patients-with-non-cystic-fibrosis-bronchiectasis 2020-11-15T23:32:48 https://maestrodatabase.com/blog/proposal-to-list-orthopaedic-hip-and-knee-implants-cement-and-associated-products-on-the-pharmaceutical-schedule 2017-02-02T04:59:04 https://maestrodatabase.com/blog/decision-to-list-a-new-brand-of-iron-polymaltose-ferrosig 2018-12-11T06:50:14 https://maestrodatabase.com/blog/deciphera-pharmaceuticals-announces-submission-of-new-drug-application-to-u-dot-s-fda-for-ripretinib-in-patients-with-advanced-gastro-intestinal-stromal-tumours 2019-12-17T06:26:21 https://maestrodatabase.com/blog/statement-from-fda-commissioner-on-new-actions-advancing-the-agencys-biosimilars-policy-framework 2018-12-11T19:55:45 https://maestrodatabase.com/blog/better-together-when-buying-medicines-taking-stock-of-the-beneluxa-initiative 2018-12-11T20:03:21 https://maestrodatabase.com/blog/proposal-to-decline-inactive-funding-applications 2020-10-01T02:11:16 https://maestrodatabase.com/blog/amneal-launches-authorised-generic-for-xyrem-sodium-oxybate-and-receives-fda-approval-for-five-complex-generics-in-the-second-quarter 2023-07-04T10:54:30 https://maestrodatabase.com/blog/dozens-of-groups-attack-trump-plan-to-peg-drug-prices-to-what-other-countries-pay 2018-12-11T11:40:25 https://maestrodatabase.com/blog/us-fda-approves-updated-indication-statement-for-rinvoq-upadacitinib-for-the-treatment-of-inflammatory-bowel-disease 2025-10-13T19:44:43 https://maestrodatabase.com/blog/us-solicitor-general-calls-on-supreme-court-to-review-six-month-delays-to-biosimilar-launches 2016-12-09T20:41:41 https://maestrodatabase.com/blog/abbvie-submits-new-drug-application-to-u-dot-s-fda-for-investigational-oral-treatment-elagolix-for-the-management-of-endometriosis-with-associated-pain 2017-09-06T12:41:22 https://maestrodatabase.com/blog/biogen-and-abbvie-receive-health-canada-approval-of-once-monthly-zinbryta-daclizumab-beta-for-multiple-sclerosis 2016-12-09T20:45:50 https://maestrodatabase.com/blog/sweden-launches-campaign-to-host-eu-drugs-agency-instead-of-uk-after-brexit 2016-12-09T02:50:53 https://maestrodatabase.com/blog/washington-price-choppers 2016-12-09T09:28:27 https://maestrodatabase.com/blog/intra-cellular-therapies-announces-fda-acceptance-of-new-drug-application-for-lumateperone-for-the-treatment-of-schizophrenia 2018-12-11T20:21:24 https://maestrodatabase.com/blog/cipla-receives-final-fda-approval-for-generic-baraclude-tablets 2016-12-09T21:04:48 https://maestrodatabase.com/blog/australians-set-to-be-slugged-for-skin-cancer-removal-under-medicare-changes 2016-12-09T21:11:20 https://maestrodatabase.com/blog/european-commission-approves-mercks-keytruda-pembrolizumab-for-the-treatment-of-certain-patients-with-locally-advanced-or-metastatic-urothelial-carcinoma-a-type-of-bladder-cancer 2017-09-06T12:52:42 https://maestrodatabase.com/blog/labor-kickstarts-inquiry-into-private-health-insurance 2018-12-11T20:06:35 https://maestrodatabase.com/blog/when-the-price-is-right-drug-costing-and-nice-approval 2016-12-09T20:51:41 https://maestrodatabase.com/blog/glatect-added-to-public-drug-plan-in-british-columbia-as-sole-rrms-treatment-of-its-type 2018-12-11T20:15:05 https://maestrodatabase.com/blog/democratic-group-plans-attacks-on-g-dot-o-p-efforts-to-undermine-obama-health-care-law 2017-09-06T20:54:42 https://maestrodatabase.com/blog/medical-devices-sponsor-information-day---2017 2017-09-06T20:37:50 https://maestrodatabase.com/blog/we-may-soon-learn-just-how-flexible-scott-gottliebs-fda-is 2017-09-06T21:05:41 https://maestrodatabase.com/blog/xtandi-enzalutamide-approved-by-u-dot-s-fda-for-the-treatment-of-metastatic-castration-sensitive-prostate-cancer 2019-12-17T07:14:35 https://maestrodatabase.com/blog/nice-publishes-updated-guidance-on-the-use-of-nexavar-on-the-nhs 2017-09-06T21:17:23 https://maestrodatabase.com/blog/us-fda-accepts-first-biologics-license-application-for-astrazenecas-durvalumab-in-bladder-cancer 2016-12-09T23:16:28 https://maestrodatabase.com/blog/findings-from-the-eunethta-21-project-for-eu-hta-from-2025 2024-12-16T03:46:08 https://maestrodatabase.com/blog/short-seller-citron-calls-express-scripts-drug-price-culprit 2016-12-09T22:20:07 https://maestrodatabase.com/blog/insurers-doctors-battle-over-new-heart-disease-drugs 2017-09-06T21:09:36 https://maestrodatabase.com/blog/the-drug-industry-is-headed-back-to-congress-to-make-its-case-will-democrats-keep-the-door-open 2018-12-11T20:45:53 https://maestrodatabase.com/blog/aerie-pharmaceuticals-receives-positive-chmp-opinion-for-roclanda-in-the-european-union 2020-11-16T01:33:24 https://maestrodatabase.com/blog/malcolm-turnbull-in-new-funding-fight-with-the-powerful-pharmacy-guild 2016-12-10T20:01:59 https://maestrodatabase.com/blog/randomised-controlled-trials-in-health-insurance-systems 2017-09-06T21:57:12 https://maestrodatabase.com/blog/new-diabetes-guidelines-imminent-jardiance-sales-may-surge 2016-12-10T20:07:33 https://maestrodatabase.com/blog/patent-term-extensions-in-australia-under-pressure-but-safe-for-now 2017-09-06T21:30:21 https://maestrodatabase.com/blog/fda-approves-vtama-tapinarof-cream-1-percent-for-the-treatment-of-atopic-dermatitis-in-adults-and-children-2-years-of-age-and-older 2024-12-16T22:02:13 https://maestrodatabase.com/blog/non-cystic-fibrosis-bronchiectasis-fda-grants-fast-track-and-qipd-to-zambon-for-colistimethate-sodium-powder-for-nebuliser-solution-delivered-by-the-i-neb-aad-system 2018-12-11T23:44:28 https://maestrodatabase.com/blog/how-will-brexit-affect-the-supply-of-medicines 2020-11-16T02:25:02 https://maestrodatabase.com/blog/ema-publishes-agenda-for-13-16-october-2025-chmp-meeting 2025-10-13T20:06:09 https://maestrodatabase.com/blog/should-nices-cost-effectiveness-thresholds-change 2024-12-16T04:48:40 https://maestrodatabase.com/blog/gilead-submits-new-drug-application-to-u-dot-s-fda-for-the-investigational-single-tablet-regimen-sofosbuvir-slash-velpatasvir-slash-voxilaprevir 2016-12-11T01:08:31 https://maestrodatabase.com/blog/medicines-australia-calls-for-new-national-medicines-policy-to-be-pushed-back-until-after-the-federal-election 2022-02-07T04:53:48 https://maestrodatabase.com/blog/patients-will-die-if-they-dont-fix-this-hospitals-rationing-stockpiling-first-line-antibiotics-amid-drug-shortage 2016-12-10T22:15:38 https://maestrodatabase.com/blog/big-price-hikes-seen-in-drug-that-prevents-overdose-deaths 2016-12-10T22:30:46 https://maestrodatabase.com/blog/ema-starts-rolling-review-of-mrna-covid-19-vaccine-by-moderna-biotech-spain 2020-11-16T11:58:32 https://maestrodatabase.com/blog/blacksmith-medicines-receives-fda-qualified-infectious-disease-product-and-fast-track-designation-for-fg-2101-a-novel-antibiotic-targeting-lpxc 2025-10-13T23:06:56 https://maestrodatabase.com/blog/denali-therapeutics-announces-fda-review-extension-of-bla-for-tividenofusp-alfa-for-the-treatment-of-mps-ii-hunter-syndrome 2025-10-13T23:14:16 https://maestrodatabase.com/blog/eisai-receives-approval-for-indication-expansion-of-anti-epileptic-agent-fycompa-for-use-in-paediatric-patients 2020-11-16T06:15:50 https://maestrodatabase.com/blog/emer-cooke-takes-office-as-head-of-ema 2020-11-16T19:24:07 https://maestrodatabase.com/blog/governments-must-speed-up-access-to-approved-cancer-drugs 2018-04-17T01:15:49 https://maestrodatabase.com/blog/the-chmp-has-adopted-a-negative-opinion-for-emapalumab-in-europe-for-the-treatment-of-primary-hlh 2020-11-16T19:28:04 https://maestrodatabase.com/blog/acss---nce-work-sharing-pilot 2018-04-17T01:37:52 https://maestrodatabase.com/blog/chmp-recommends-approval-of-galdermas-nemolizumab-for-moderate-to-severe-atopic-dermatitis-and-prurigo-nodularis-in-the-european-union 2024-12-16T23:50:54 https://maestrodatabase.com/blog/csl-receives-positive-chmp-opinion-for-garadacimab-in-hereditary-angioedema 2024-12-16T23:47:04 https://maestrodatabase.com/blog/chmp-adopted-positive-opinion-for-elzonris-tagraxofusp-for-the-treatment-of-blastic-plasmacytoid-dendritic-cell-neoplasm 2020-11-16T19:42:54 https://maestrodatabase.com/blog/seventh-community-pharmacy-agreement 2020-06-23T04:21:14 https://maestrodatabase.com/blog/arca-biopharma-receives-fda-fast-track-designation-for-gencaro-atrial-fibrillation-development-in-a-genetically-targeted-heart-failure-population 2016-12-11T10:30:33 https://maestrodatabase.com/blog/zostavax-listed-on-the-nip 2016-12-11T09:37:24 https://maestrodatabase.com/blog/submissions-received-fees-and-charges-proposal-2020-21 2020-06-23T04:28:23 https://maestrodatabase.com/blog/icer-publishes-final-evidence-report-on-treatment-for-epstein-barr-virus-positive-post-transplant-lymphoproliferative-disease 2024-12-17T03:42:52 https://maestrodatabase.com/blog/deciphera-announces-health-canadas-authorisation-of-qinlock-ripretinib-for-the-treatment-of-fourth-line-gastro-intestinal-stromal-tumour 2020-06-23T06:55:14 https://maestrodatabase.com/blog/mannkind-announces-us-fda-accepts-for-review-its-supplemental-biologics-license-application-for-inhaled-ansulin-afrezza-in-children-and-adolescents-aged-4-17-years-living-with-diabetes 2025-10-14T04:01:12 https://maestrodatabase.com/blog/final-minutes-of-december-2017-ema-slash-eunethta-meeting 2018-04-17T05:59:25 https://maestrodatabase.com/blog/cardiorentis-ularitide-receives-fda-fast-track-designation-for-the-treatment-of-acute-decompensated-heart-failure 2016-12-11T20:11:55 https://maestrodatabase.com/blog/swissmedic-begins-rolling-review-of-modernas-mrna-vaccine-against-covid-19-mrna-1273 2020-11-16T19:33:13 https://maestrodatabase.com/blog/chmp-recommends-eu-approval-of-roches-phesgo-fixed-dose-combination-of-perjeta-and-herceptin-for-subcutaneous-injection-for-her2-positive-breast-cancer 2020-11-16T19:37:20 https://maestrodatabase.com/blog/underlying-guilt-turns-to-delight-after-pharmac-decision 2022-10-03T00:22:49 https://maestrodatabase.com/blog/myovant-sciences-announces-priority-review-and-fda-acceptance-of-new-drug-application-for-once-daily-oral-relugolix-for-advanced-prostate-cancer 2020-06-23T04:14:27 https://maestrodatabase.com/blog/listing-of-life-saving-cancer-medicine-to-save-patients-more-than-200-000-dollars 2018-04-17T04:11:33 https://maestrodatabase.com/blog/fda-grants-breakthrough-therapy-designation-to-sunvozertinib-for-the-first-line-treatment-of-patients-with-advanced-non-small-cell-lung-cancer-harboring-egfr-exon-20-insertion-mutations 2024-04-07T23:10:42 https://maestrodatabase.com/blog/lives-and-profits-in-the-balance-the-high-stakes-of-medical-patents 2016-12-12T10:10:01 https://maestrodatabase.com/blog/draft-agenda-for-december-2016-chmp-meeting 2016-12-12T19:02:19 https://maestrodatabase.com/blog/should-i-lie-about-my-beliefs-to-get-health-insurance 2016-12-11T21:38:31 https://maestrodatabase.com/blog/beone-medicines-sonrotoclax-granted-breakthrough-therapy-designation-by-us-fda 2025-10-13T23:32:45 https://maestrodatabase.com/blog/insurers-step-up-lobbying-with-an-eye-to-health-law-changes 2016-12-12T10:05:23 https://maestrodatabase.com/blog/chmp-extends-review-period-for-portola-pharmaceuticals-ondexxya-andexanet-alfa 2018-12-12T02:58:24 https://maestrodatabase.com/blog/under-30s-turning-their-backs-on-private-health-cover 2016-12-12T19:23:16 https://maestrodatabase.com/blog/scots-miss-out-on-breast-cancer-drug-withheld-from-nhs-use 2016-12-12T19:27:08 https://maestrodatabase.com/blog/pay-for-performance-drug-pricing-drug-makers-asked-to-eat-costs-when-products-dont-deliver 2016-12-12T19:11:34 https://maestrodatabase.com/blog/smc---december-2016-decisions 2016-12-12T19:15:36 https://maestrodatabase.com/blog/mayne-pharma-receives-fda-approval-of-tolsura-suba-itraconazole-capsules-for-the-treatment-of-certain-fungal-infections 2018-12-12T02:47:50 https://maestrodatabase.com/blog/camurus-announces-pdufa-date-for-brixadi-for-the-treatment-of-opioid-use-disorder-in-the-us 2021-06-27T12:00:55 https://maestrodatabase.com/blog/lupin-announces-fda-filing-acceptance-of-supplemental-new-drug-application-for-solosec-secnidazole-for-the-treatment-of-trichomoniasis 2020-11-16T19:52:49 https://maestrodatabase.com/blog/doh-publishes-revised-agenda-for-next-months-pbac-meeting 2022-02-07T06:00:46 https://maestrodatabase.com/blog/bicara-therapeutics-announces-ficerafusp-alfa-granted-breakthrough-therapy-designation-by-us-fda-for-first-line-hpv-negative-metastatic-or-with-unresectable-recurrent-head-and-neck-squamous-cell-carcinoma 2025-10-13T23:48:11 https://maestrodatabase.com/blog/cholesterol-drugs-offer-fresh-hope-in-fight-against-alzheimers-disease 2016-12-12T19:50:25 https://maestrodatabase.com/blog/apellis-announces-fda-acceptance-and-priority-review-of-the-new-drug-application-for-pegcetacoplan-for-the-treatment-of-pnh 2020-11-16T19:58:15 https://maestrodatabase.com/blog/fda-awards-fast-track-designation-to-epion-therapeutics-for-its-epismart-epithelium-on-cross-linking-system 2025-10-13T23:55:02 https://maestrodatabase.com/blog/calls-for-answers-about-pharmac-delay-after-epilepsy-deaths 2019-12-17T19:34:47 https://maestrodatabase.com/blog/mercks-keytruda-pembrolizumab-approved-in-china-for-second-line-treatment-of-patients-with-locally-advanced-or-metastatic-oesophageal-squamous-cell-carcinoma-whose-tumours-express-pd-l1-cps-10 2020-06-23T07:31:20 https://maestrodatabase.com/blog/the-menarini-group-announces-meropenem-slash-vaborbactam-european-marketing-authorisation 2018-12-12T03:07:54 https://maestrodatabase.com/blog/imbruvica-ibrutinib-seeks-to-expand-u-dot-s-label-with-long-term-data-in-waldenstroems-macroglobulinaemia 2020-06-23T11:37:17 https://maestrodatabase.com/blog/hhs-secretary-azar-says-the-fda-will-move-as-quickly-as-possible-to-clear-moderna-and-pfizers-covid-19-vaccines 2020-11-16T20:08:36 https://maestrodatabase.com/blog/bayesian-hierarchical-models 2018-12-12T05:00:36 https://maestrodatabase.com/blog/comparison-of-pharmac-with-uk-agency-was-misleading 2019-12-17T19:41:51 https://maestrodatabase.com/blog/u-dot-s-fda-approves-synjardy-xr-empagliflozin-slash-metformin-hydrochloride-extended-release-tablets-for-adults-with-type-2-diabetes 2016-12-12T20:43:12 https://maestrodatabase.com/blog/u-dot-s-states-race-to-buy-ultra-cold-vaccine-freezers-fuelling-supply-worries 2020-11-16T20:13:20 https://maestrodatabase.com/blog/pharmac-brand-switch-man-driving-through-waterview-tunnel-blacked-out 2019-12-17T19:37:19 https://maestrodatabase.com/blog/expansion-of-the-medicare-340b-payment-program-hospital-participation-prescribing-patterns-and-reimbursement-and-legal-challenges 2018-12-12T04:55:57 https://maestrodatabase.com/blog/trump-officials-preparing-to-move-forward-with-major-step-to-lower-medicare-drug-prices 2020-11-16T20:15:35 https://maestrodatabase.com/blog/metastasis-free-survival-in-prostate-cancer-faster-drug-approvals-better-drugs 2018-12-12T09:23:40 https://maestrodatabase.com/blog/academia-developing-medicines-for-rare-diseases-to-receive-free-ema-scientific-advice 2020-06-23T21:09:02 https://maestrodatabase.com/blog/mhra-extends-access-to-santheras-dmd-drug-via-the-eams 2020-06-23T21:12:39 https://maestrodatabase.com/blog/fda-investigating-possible-increased-risk-of-death-with-lymphoma-medicine-ukoniq-umbralisib 2022-02-07T10:48:42 https://maestrodatabase.com/blog/pharmamar-announces-the-approval-of-aplidin-in-australia-for-the-treatment-of-multiple-myeloma 2018-12-12T06:07:38 https://maestrodatabase.com/blog/biomarin-receives-positive-chmp-opinion-in-europe-for-vosoritide-for-the-treatment-of-children-with-achondroplasia-from-age-2-until-growth-plates-close 2021-06-27T12:10:00 https://maestrodatabase.com/blog/pricing-remdesivir-a-domestic-reference-price-approach 2020-06-23T12:02:11 https://maestrodatabase.com/blog/law-makers-push-covid-19-bills-to-prevent-price-gouging-track-federal-funds-used-to-discover-drugs 2020-06-23T12:05:00 https://maestrodatabase.com/blog/health-organisations-join-calls-for-a-review-into-government-drug-buying-agency 2018-12-12T09:48:20 https://maestrodatabase.com/blog/fda-announces-first-of-its-kind-pilot-program-to-communicate-patient-reported-outcomes-from-cancer-clinical-trials 2020-06-23T21:05:01 https://maestrodatabase.com/blog/polynoma-receives-fda-fast-track-designation-for-its-melanoma-cancer-vaccine-seviprotimut-l 2020-06-23T21:40:21 https://maestrodatabase.com/blog/analysis-of-consumer-comments-into-pbac-decision-making-2014-9 2022-02-07T11:03:05 https://maestrodatabase.com/blog/akamis-bio-receives-fda-fast-track-designation-for-ng-350a-for-the-treatment-of-mismatch-repair-proficient-locally-advanced-rectal-cancer 2025-10-14T23:26:19 https://maestrodatabase.com/blog/not-so-nice-cancer-patients-miss-out-on-innovative-new-treatments 2022-02-07T19:45:44 https://maestrodatabase.com/blog/carvykti-is-the-first-and-only-bcma-targeted-treatment-approved-by-the-us-fda-for-patients-with-relapsed-or-refractory-multiple-myeloma-who-have-received-at-least-one-prior-line-of-therapy 2024-04-08T01:04:03 https://maestrodatabase.com/blog/smc---february-2022-decisions 2022-02-07T19:40:26 https://maestrodatabase.com/blog/fda-maintains-the-pace-of-meeting-its-goals-on-applications-for-medical-products-during-the-pandemic 2020-06-23T21:22:55 https://maestrodatabase.com/blog/bladder-cancer-technology-new-improved-blue-light-cystoscopy-system-receives-fda-approval-for-use-in-non-muscle-invasive-bladder-cancer-in-the-u-dot-s 2022-02-07T10:53:48 https://maestrodatabase.com/blog/unfunded-drug-the-final-lifeline-for-27-year-old-with-bowel-cancer 2020-06-23T21:29:19 https://maestrodatabase.com/blog/the-case-for-using-novel-value-elements-when-assessing-covid-19-vaccines-and-therapeutics 2020-06-23T21:33:38 https://maestrodatabase.com/blog/morrison-government-unveils-1-dollars-25-cents-billion-health-funding-fix 2018-12-12T10:11:29 https://maestrodatabase.com/blog/azurity-pharmaceuticals-announces-fda-approval-of-fleqsuvy-baclofen-oral-suspension 2022-02-07T20:06:31 https://maestrodatabase.com/blog/overcharging-doctors-exposed-under-medical-cost-finder-revamp 2021-06-27T21:24:34 https://maestrodatabase.com/blog/bernie-sanders-drug-price-controls-would-stifle-medical-innovation 2018-12-12T10:32:55 https://maestrodatabase.com/blog/health-economic-assessment-of-opdivo-in-cancer-of-the-oesophagus-or-upper-gastro-intestinal-tract 2022-02-07T19:49:20 https://maestrodatabase.com/blog/fda-approves-first-therapy-for-rare-inherited-form-of-rickets-x-linked-hypophosphataemia 2018-04-17T20:44:14 https://maestrodatabase.com/blog/everest-medicines-announces-first-drug-approval-of-trodelvy-in-singapore-for-second-line-metastatic-triple-negative-breast-cancer 2022-02-07T20:00:36 https://maestrodatabase.com/blog/life-or-death-under-pharmac---part-three 2019-06-19T01:49:13 https://maestrodatabase.com/blog/fda-grants-breakthrough-therapy-designation-for-roches-hemlibra-in-haemophilia-a-without-inhibitors 2018-04-17T20:52:02 https://maestrodatabase.com/blog/why-so-few-value-assessments-on-health-services-and-procedures-and-what-should-be-done 2022-02-07T20:30:39 https://maestrodatabase.com/blog/chmp-opined-on-fewer-new-medicines-in-2019 2019-12-17T20:38:39 https://maestrodatabase.com/blog/mentoring-as-a-potential-means-to-assist-consumer-representatives-contribute-effectively-to-the-assessment-of-health-technologies-in-australia-a-pragmatic-review 2022-02-07T20:43:25 https://maestrodatabase.com/blog/ngm-bios-ngm621-receives-fast-track-designation-from-the-fda-for-the-treatment-of-patients-with-geographic-atrophy-secondary-to-age-related-macular-degeneration 2022-02-07T20:19:17 https://maestrodatabase.com/blog/cadth-to-review-car-t-cell-therapies 2018-04-17T21:04:43 https://maestrodatabase.com/blog/fda-takes-aim-at-pharmas-biosimilar-delaying-tactics 2018-12-12T19:33:07 https://maestrodatabase.com/blog/atomoxetine---delay-in-change-of-funded-brand-and-open-access 2019-06-19T01:54:30 https://maestrodatabase.com/blog/new-nice-standards-to-improve-digital-health-tech-uptake 2018-12-12T19:17:16 https://maestrodatabase.com/blog/flexion-therapeutics-submits-new-drug-application-for-zilretta-to-treat-knee-osteoarthritis-pain 2016-12-12T23:05:40 https://maestrodatabase.com/blog/amazon-has-shelved-a-plan-to-sell-drugs-to-hospitals-and-insiders-say-there-are-two-reasons-why 2018-04-17T20:59:03 https://maestrodatabase.com/blog/this-is-not-the-trump-hearing---pharmac-deny-accusations-by-national-mp-of-tampering-with-northland-vaccine-order 2019-06-19T01:51:48 https://maestrodatabase.com/blog/eqrx-seeks-to-establish-a-more-competitive-market-for-oncology-drugs-in-the-u-dot-s 2022-02-07T20:25:49 https://maestrodatabase.com/blog/nice-says-no-to-rival-alnylam-and-akcea-amyloidosis-drugs---but-deal-could-be-done 2018-12-12T19:21:52 https://maestrodatabase.com/blog/corcept-submits-marketing-authorisation-application-to-ema-for-relacorilant-as-a-treatment-for-patients-with-platinum-resistant-ovarian-cancer 2025-10-15T01:29:09 https://maestrodatabase.com/blog/trump-to-give-speech-on-lowering-drug-prices-this-month 2018-04-17T21:01:31 https://maestrodatabase.com/blog/health-canada-approves-hemlibra-for-haemophilia-a-patients-without-factor-viii-inhibitors 2019-06-19T02:03:58 https://maestrodatabase.com/blog/pbs---2018-in-review 2018-12-12T19:59:07 https://maestrodatabase.com/blog/rigel-announces-fda-approval-of-tavalisse-fostamatinib-disodium-hexahydrate-for-chronic-immune-thrombocytopenia-in-adult-patients 2018-04-17T21:17:47 https://maestrodatabase.com/blog/low-prices-of-some-lifesaving-drugs-make-them-impossible-to-get 2019-06-19T01:59:40 https://maestrodatabase.com/blog/mallinckrodts-specgx-receives-fda-complete-response-letter-for-abuse-deterrent-immediate-release-reformulation-of-roxicodone-oxycodone-hydrochloride 2018-12-12T20:12:01 https://maestrodatabase.com/blog/emergent-biosolutions-receives-health-canada-approval-for-botulism-anti-toxin 2016-12-13T01:16:55 https://maestrodatabase.com/blog/remarks-from-fda-commissioner-scott-gottlieb-on-fiscal-year-2019-budget-request-for-fda 2018-04-17T21:33:29 https://maestrodatabase.com/blog/faster-information-from-fda-means-improved-drug-safety-for-patients 2016-12-13T01:13:08 https://maestrodatabase.com/blog/fda-approves-vonvendi-von-willebrand-factor-recombinant-for-peri-operative-management-of-bleeding-in-adult-patients-with-von-willebrand-disease 2018-04-17T21:41:31 https://maestrodatabase.com/blog/lilly-announces-program-to-provide-insulin-at-discounted-prices 2016-12-13T18:58:57 https://maestrodatabase.com/blog/children-of-woman-with-rare-disease-ask-santa-for-mummys-medicine 2016-12-13T19:03:56 https://maestrodatabase.com/blog/abeona-therapeutics-receives-fda-fast-track-designation-for-abo-202-aav9-gene-therapy-in-cln1-disease 2019-06-19T05:33:40 https://maestrodatabase.com/blog/fda-medical-device-safety-action-plan-now-available 2018-04-17T21:29:38 https://maestrodatabase.com/blog/pediapharm-receives-health-canada-approval-for-otixal 2016-12-13T01:25:32 https://maestrodatabase.com/blog/european-commission-grants-marketing-authorization-for-arzerra-ofatumumab-in-combination-with-fludarabine-and-cyclophosphamide-in-relapsed-cll 2016-12-13T19:23:12 https://maestrodatabase.com/blog/ema-hosts-workshop-on-adaptive-pathways 2016-12-13T19:28:39 https://maestrodatabase.com/blog/sa-health-university-of-adelaide-roll-out-meningococcal-b-vaccine-trial 2016-12-13T19:13:31 https://maestrodatabase.com/blog/provinces-to-receive-health-transfer-details-ahead-of-key-meeting 2016-12-13T19:18:05 https://maestrodatabase.com/blog/review-of-the-national-medicines-policy---consultation-on-draft-national-medicines-policy-extended 2022-02-07T23:40:17 https://maestrodatabase.com/blog/lets-work-with-trump-to-reduce-drug-prices-sen-klobuchar 2016-12-13T19:55:58 https://maestrodatabase.com/blog/china-nmpa-approves-rarestones-pitolisant-wakix-for-the-treatment-of-narcolepsy 2023-07-05T06:36:44 https://maestrodatabase.com/blog/olaparib-for-the-maintenance-treatment-of-adults-with-relapsed-platinum-sensitive-ovarian-fallopian-tube-or-peritoneal-cancer-after-two-or-more-courses-of-platinum-based-chemotherapy 2023-07-05T06:44:27 https://maestrodatabase.com/blog/we-need-to-tame-the-price-of-new-cancer-drugs 2016-12-13T20:19:11 https://maestrodatabase.com/blog/fda-approves-first-autologous-cellularized-scaffold-for-the-repair-of-cartilage-defects-of-the-knee 2016-12-13T23:19:18 https://maestrodatabase.com/blog/somatropin-for-patients-under-2-years-with-prader-willi-syndrome 2016-12-14T01:32:31 https://maestrodatabase.com/blog/patients-call-for-funding-of-drugs-for-rare-disorders 2016-12-14T19:29:16 https://maestrodatabase.com/blog/new-formulation-of-rituxan-now-available-to-canadians-living-with-non-hodgkins-lymphoma 2016-12-14T01:27:22 https://maestrodatabase.com/blog/express-scripts-announces-enhancements-to-industry-leading-safeguardrx-programs 2016-12-14T19:57:17 https://maestrodatabase.com/blog/express-scripts-sees-no-let-up-in-drug-pricing-chatter 2016-12-14T20:05:03 https://maestrodatabase.com/blog/clinical-benefit-and-regulatory-outcomes-of-cancer-drugs-receiving-accelerated-approval 2024-05-07T21:21:13 https://maestrodatabase.com/blog/nice-and-the-fda-working-together 2016-12-14T19:39:11 https://maestrodatabase.com/blog/nice-publishes-final-guidance-on-the-use-of-astrazenecas-brilique 2016-12-14T19:42:13 https://maestrodatabase.com/blog/european-commission-grants-conditional-marketing-authorisation-for-taihos-lytgobi-tablets-for-the-treatment-of-adults-with-cholangiocarcinoma 2023-07-05T06:50:45 https://maestrodatabase.com/blog/life-saving-cancer-drug-restricted 2016-12-14T20:26:41 https://maestrodatabase.com/blog/drug-makers-push-back-on-data-requirements-in-australias-provisional-approval-pathway 2017-09-07T01:32:03 https://maestrodatabase.com/blog/two-executives-charged-in-generic-drug-price-fixing-federal-investigation 2016-12-14T20:15:19 https://maestrodatabase.com/blog/obama-signs-6-dollars-3-cents-billion-law-for-cancer-research-drug-treatment 2016-12-14T20:22:57 https://maestrodatabase.com/blog/authorized-generic-for-evzio-naloxone-hydrochloride-injection-to-be-available-at-a-reduced-list-price-of-178-dollars 2018-12-13T08:46:32 https://maestrodatabase.com/blog/rimegepant-sulphate-for-the-prevention-of-migraine 2023-07-05T10:35:52 https://maestrodatabase.com/blog/novartis-receives-european-commission-approval-for-self-administration-of-xolair-across-all-indications 2018-12-13T08:38:58 https://maestrodatabase.com/blog/australians-benefit-from-cheaper-medicines-on-the-pbs 2024-04-08T03:41:20 https://maestrodatabase.com/blog/fda-approves-eucrisa-for-eczema 2016-12-14T20:49:18 https://maestrodatabase.com/blog/global-regulators-confirm-good-safety-profile-of-covid-19-vaccines 2023-07-05T10:31:51 https://maestrodatabase.com/blog/ema-says-it-will-consider-conditional-approval-for-nash-drugs-using-intermediate-outcomes 2024-04-08T03:33:35 https://maestrodatabase.com/blog/all-women-go-through-menopause-so-why-is-treatment-so-expensive 2024-04-08T03:08:59 https://maestrodatabase.com/blog/european-commission-approves-orkambi-lumacaftor-slash-ivacaftor-for-the-treatment-of-children-with-cystic-fibrosis-ages-1-to-2-years-old 2023-07-05T07:17:09 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-to-the-baricitinib-development-program-for-the-treatment-of-systemic-lupus-erythematosus 2018-12-13T11:58:47 https://maestrodatabase.com/blog/calithera-receives-fda-fast-track-designation-for-sapanisertib-for-the-treatment-of-nrf2-mutated-squamous-lung-cancer 2022-10-03T20:14:39 https://maestrodatabase.com/blog/the-health-202-phrmas-top-priority-pushed-to-sidelines-by-border-wall-fight 2018-12-13T20:06:43 https://maestrodatabase.com/blog/frustrated-at-cancer-treatment-inequity 2018-12-13T19:54:36 https://maestrodatabase.com/blog/statement-from-fda-commissioner-and-director-of-fdas-center-for-drug-evaluation-and-research-on-efforts-to-modernise-generic-drug-labels-while-maintaining-the-efficiency-of-generic-development 2018-12-13T20:01:20 https://maestrodatabase.com/blog/brexit-contributes-to-surge-in-generic-drug-prices 2018-12-13T20:24:31 https://maestrodatabase.com/blog/value-based-pricing-and-reimbursement-still-more-promise-than-reality 2018-12-13T20:33:25 https://maestrodatabase.com/blog/senate-democrats-introduce-bill-to-allow-government-to-block-drug-price-rises 2018-12-13T20:12:45 https://maestrodatabase.com/blog/the-little-known-way-pharma-companies-hook-people-on-their-costly-drugs 2018-12-13T20:21:03 https://maestrodatabase.com/blog/mhra-puts-supporting-patient-access-to-innovation-at-the-heart-of-its-new-corporate-plan-2023-26 2023-07-05T10:47:04 https://maestrodatabase.com/blog/outcomes-from-the-november-2018-pbac-meeting 2018-12-13T20:53:53 https://maestrodatabase.com/blog/a-method-for-approximating-future-entry-of-generic-drugs 2018-12-13T20:39:31 https://maestrodatabase.com/blog/hhs-price-of-more-than-1-200-drugs-outpaced-inflation 2022-10-03T20:50:28 https://maestrodatabase.com/blog/ferring-receives-eu-approval-for-rekovelle-follitropin-delta 2016-12-14T23:30:52 https://maestrodatabase.com/blog/prescription-drugs-innovation-spending-and-patient-access 2016-12-14T22:45:45 https://maestrodatabase.com/blog/viewpoint-molecular-targeting-announces-vmt-alfa-net-granted-us-fda-fast-track-destination-for-the-treatment-of-neuroendocrine-tumours 2022-10-03T20:26:17 https://maestrodatabase.com/blog/the-21st-century-cures-act----a-view-from-the-nih 2016-12-14T23:41:13 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-october-2022 2022-10-03T20:20:37 https://maestrodatabase.com/blog/transforming-evidence-generation-to-support-health-and-health-care-decisions 2016-12-15T00:14:23 https://maestrodatabase.com/blog/health-canada-approves-csl-behrings-afstyla-for-the-treatment-of-haemophilia-a 2016-12-15T01:21:55 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-to-publish-upcoming-assessment-on-treatments-for-duchenne-muscular-dystrophy 2018-12-13T21:27:39 https://maestrodatabase.com/blog/european-commission-grants-intercepts-ocaliva-obeticholic-acid-marketing-authorisation-for-the-treatment-of-primary-biliary-cholangitis 2016-12-15T01:08:51 https://maestrodatabase.com/blog/arcutis-submits-zorvye-roflumilast-cream-0-dot-05-percent-supplemental-new-drug-application-to-the-fda-for-the-treatment-of-children-aged-2-to-5-with-mild-to-moderate-atopic-dermatitis 2024-12-17T22:43:35 https://maestrodatabase.com/blog/sarepta-therapeutics-announces-sale-of-priority-review-voucher-for-102-dollars-million 2023-07-05T21:36:32 https://maestrodatabase.com/blog/health-canada-approves-stelara-for-the-treatment-of-adults-with-moderately-to-severely-active-crohns-disease 2016-12-15T01:29:09 https://maestrodatabase.com/blog/review-must-avoid-change-for-the-sake-of-change 2016-12-15T02:21:59 https://maestrodatabase.com/blog/decision-relating-to-anti-vegf-treatments-for-ophthalmic-use 2016-12-15T03:14:01 https://maestrodatabase.com/blog/tlv-is-tasked-with-carrying-out-health-economic-assessments-of-new-drugs-against-cancer 2023-07-05T21:29:55 https://maestrodatabase.com/blog/nice-publishes-second-appraisal-consultation-document-for-brentuximab-vedotin 2016-12-15T19:40:55 https://maestrodatabase.com/blog/update-on-us-regulatory-review-of-subcutaneous-amivantamab 2024-12-17T22:05:07 https://maestrodatabase.com/blog/us-states-sue-mylan-teva-others-for-allegedly-fixing-drug-prices 2016-12-15T19:49:36 https://maestrodatabase.com/blog/price-disclosure-2017-april-cycle-outcomes-summary 2016-12-15T06:06:28 https://maestrodatabase.com/blog/icer-to-assess-treatment-for-schizophrenia 2023-07-05T11:55:41 https://maestrodatabase.com/blog/tlv-does-not-extend-hemlibras-current-subsidy 2019-06-19T09:00:45 https://maestrodatabase.com/blog/a-new-type-of-molecular-medicine-may-be-needed-to-halt-cancers 2016-12-15T19:32:16 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-for-torques-first-deep-primed-t-cell-cancer-immunotherapy-program-trq-1501 2019-06-19T09:44:20 https://maestrodatabase.com/blog/nice-nod-for-blincyto 2019-06-19T20:51:25 https://maestrodatabase.com/blog/us-fda-grants-breakthrough-therapy-designation-to-trodelvy-sacituzumab-govitecan-hziy-for-second-line-treatment-of-extensive-stage-small-cell-lung-cancer 2024-12-17T23:33:02 https://maestrodatabase.com/blog/why-the-coalition-must-adopt-labors-cancer-plans 2019-06-19T20:47:57 https://maestrodatabase.com/blog/melinta-therapeutics-announces-u-dot-s-fda-acceptance-of-supplemental-new-drug-application-for-baxdela-delafloxacin-for-the-treatment-of-community-acquired-bacterial-pneumonia 2019-06-19T21:02:11 https://maestrodatabase.com/blog/2018-influenza-vaccines-now-available 2018-04-18T01:01:23 https://maestrodatabase.com/blog/with-eyes-on-gilead-law-makers-want-details-on-how-hhs-reviews-possible-patent-infringement 2019-06-19T20:55:08 https://maestrodatabase.com/blog/johnson-and-johnson-submits-application-seeking-us-fda-approval-of-simponi-golimumab-for-the-treatment-of-paediatric-ulcerative-colitis 2024-12-17T23:17:38 https://maestrodatabase.com/blog/icer-describes-for-patients-and-policy-makers-why-the-qaly-is-considered-the-best-way-to-reward-the-care-that-improves-patients-lives 2018-12-13T22:05:49 https://maestrodatabase.com/blog/game-changing-cancer-drugs-which-can-attack-all-tumours-will-be-fast-tracked-by-nhs 2019-06-19T21:21:24 https://maestrodatabase.com/blog/german-patients-get-the-latest-drugs-for-just-$11-can-such-a-model-work-in-the-u-dot-s 2019-06-19T21:14:34 https://maestrodatabase.com/blog/grassley-announces-opposition-to-key-trump-proposal-to-lower-drug-prices 2019-06-19T21:11:25 https://maestrodatabase.com/blog/cannabis-based-medicine-among-batch-of-new-drugs-approved-for-use-in-scotland 2022-02-08T10:32:12 https://maestrodatabase.com/blog/global-blood-therapeutics-receives-rare-paediatric-disease-designation-from-fda-for-gbt440-for-treatment-of-sickle-cell-disease 2017-09-07T04:17:59 https://maestrodatabase.com/blog/tonix-pharmaceuticals-announces-fda-acceptance-of-the-new-drug-application-for-tnx-102-sl-for-fibromyalgia 2024-12-18T00:22:27 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-to-lipocine-for-lpcn-1148-as-a-treatment-for-sarcopenia-in-patients-with-decompensated-cirrhosis 2024-12-18T00:14:28 https://maestrodatabase.com/blog/sobi-receives-approval-from-health-canada-for-once-daily-dosing-of-orfadin-nitisinone-for-the-treatment-of-ht-1 2018-04-18T02:10:18 https://maestrodatabase.com/blog/nice-recommends-new-drug-for-people-living-with-obesity 2022-02-08T10:35:12 https://maestrodatabase.com/blog/fda-provides-full-approval-to-praxbind-specific-reversal-agent-for-pradaxa 2018-04-18T02:17:10 https://maestrodatabase.com/blog/kiniksa-announces-breakthrough-therapy-designation-granted-to-vixarelimab-for-the-treatment-of-pruritus-associated-with-prurigo-nodularis 2020-11-17T02:16:19 https://maestrodatabase.com/blog/roches-elecsys-ptau181-becomes-the-only-fda-cleared-blood-test-for-use-in-primary-care-to-rule-out-alzheimers-related-amyloid-pathology 2025-10-15T22:27:52 https://maestrodatabase.com/blog/trumps-fda-chief-may-implement-progressive-approval-for-drugs 2016-12-16T01:28:18 https://maestrodatabase.com/blog/why-did-new-drug-approvals-in-the-u-dot-s-plunge-this-year 2016-12-16T01:30:52 https://maestrodatabase.com/blog/advanced-accelerator-applications-announces-european-commission-approval-of-somakit-toc 2016-12-16T01:22:11 https://maestrodatabase.com/blog/pivotal-dreamm-2-study-demonstrated-a-clinically-meaningful-overall-response-rate-with-belantamab-mafodotin-gsk2857916-for-patients-with-relapsed-slash-refractory-multiple-myeloma 2019-12-18T02:44:53 https://maestrodatabase.com/blog/anthem-humana-united-push-back-on-sareptas-fda-approved-dmd-drug 2016-12-16T01:33:49 https://maestrodatabase.com/blog/plx-pharma-submits-supplemental-new-drug-applications-for-vazalore-325-mg-and-81-mg-to-u-dot-s-fda 2020-11-17T03:37:45 https://maestrodatabase.com/blog/health-economic-assessment-of-kyprolis-in-combination-with-revlimid-and-dexamethasone 2019-12-18T02:41:05 https://maestrodatabase.com/blog/santhera-submits-marketing-authorisation-application-to-the-european-medicines-agency-for-vamorolone-in-duchenne-muscular-dystrophy 2022-10-04T06:16:30 https://maestrodatabase.com/blog/landmark-pbs-listing-for-treatment-of-gastro-oesophageal-cancers 2022-10-04T01:51:51 https://maestrodatabase.com/blog/agios-receives-fda-breakthrough-therapy-designation-for-tibsovo-ivosidenib-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-myelodysplastic-syndrome-with-an-idh1-mutation 2019-12-18T02:53:22 https://maestrodatabase.com/blog/theratechnologies-trogarzo-approved-by-fda-for-30-second-intravenous-push-simplifying-hiv-treatment-for-heavily-treatment-experienced-population 2022-10-04T02:02:25 https://maestrodatabase.com/blog/pharmamar-has-filed-new-drug-application-for-lurbinectedin-with-the-fda-for-the-treatment-of-relapsed-small-cell-lung-cancer 2019-12-18T02:48:37 https://maestrodatabase.com/blog/funding-of-vitamin-a-oral-liquid 2019-12-18T03:08:43 https://maestrodatabase.com/blog/proposal-to-fund-mepolizumab-for-the-treatment-of-severe-refractory-eosinophilic-asthma 2019-12-18T03:04:35 https://maestrodatabase.com/blog/viiv-healthcare-announces-chmp-positive-opinion-for-vocabria-plus-rekambys-the-first-and-only-complete-long-acting-hiv-treatment-for-adolescents-in-europe 2024-12-18T02:43:56 https://maestrodatabase.com/blog/renibus-therapeutics-receives-fda-fast-track-designation-for-rbt-9-treatment-in-covid-19 2020-06-24T05:36:56 https://maestrodatabase.com/blog/statement-from-anna-abram-fdas-deputy-commissioner-for-policy-legislation-and-international-affairs-and-janet-woodcock-m-dot-d-director-of-fdas-center-for-drug-evaluation-and-research-on-low-cost-biosimilar-and-interchangeable-protein-products 2019-12-18T03:01:13 https://maestrodatabase.com/blog/italy-serves-cautionary-lesson-for-new-trump-drug-plan 2018-04-18T05:48:49 https://maestrodatabase.com/blog/geron-announces-positive-chmp-opinion-for-rytelo-imetelstat-for-the-treatment-of-adults-with-transfusion-dependent-anaemia-due-to-lower-risk-mds 2024-12-18T01:08:40 https://maestrodatabase.com/blog/enzyvant-receives-fda-rare-paediatric-disease-designation-for-investigational-therapy-rvt-802 2017-09-07T05:37:22 https://maestrodatabase.com/blog/price-disclosure-2020-april-cycle-outcomes-summary 2019-12-18T08:53:29 https://maestrodatabase.com/blog/pbs-growth-hormone-program---1-january-2020-listing-changes 2019-12-18T03:26:39 https://maestrodatabase.com/blog/novimmune-receives-rare-paediatric-disease-designation-from-the-fda-for-its-lead-drug-emapalumab 2017-09-07T07:38:21 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-24-june-2021 2021-06-28T03:47:04 https://maestrodatabase.com/blog/gsks-b7-h3-targeted-antibody-drug-conjugate-gsk227-receives-ema-priority-medicines-prime-designation-in-relapsed-extensive-stage-small-cell-lung-cancer 2024-12-18T02:50:19 https://maestrodatabase.com/blog/verastem-expands-duvelisib-development-program-to-include-peripheral-t-cell-lymphoma 2017-09-07T08:03:55 https://maestrodatabase.com/blog/abbvie-receives-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of-adults-with-moderate-to-severe-active-rheumatoid-arthritis 2019-12-18T19:08:41 https://maestrodatabase.com/blog/roche-receives-fda-approval-for-first-companion-diagnostic-to-identify-patients-with-her2-low-metastatic-breast-cancer-eligible-for-enhertu 2022-10-04T11:52:18 https://maestrodatabase.com/blog/therapeutic-value-of-first-versus-supplemental-indications-of-drugs-in-us-and-europe-2011-20-retrospective-cohort-study 2023-07-06T03:48:52 https://maestrodatabase.com/blog/cymabay-therapeutics-announces-that-mbx-8025-has-received-european-medicines-agency-priority-medicines-prime-designation-for-the-treatment-of-primary-biliary-cholangitis 2016-12-16T04:30:51 https://maestrodatabase.com/blog/ema-evaluating-data-on-booster-dose-of-covid-19-vaccine-comirnaty-in-adolescents 2022-02-08T19:40:01 https://maestrodatabase.com/blog/fda-survey-finds-americans-dont-really-understand-drug-approvals 2019-12-18T11:11:12 https://maestrodatabase.com/blog/auvelity-newly-approved-drug-for-major-depressive-disorder-to-face-payer-pricing-and-reimbursement-challenges 2022-10-04T20:03:58 https://maestrodatabase.com/blog/libtayo-cemiplimab-approved-by-the-european-commission-as-the-first-immunotherapy-indicated-for-patients-with-advanced-basal-cell-carcinoma 2021-06-28T05:37:41 https://maestrodatabase.com/blog/leqvio-therapy-to-lower-cholesterol-approved-by-fda-ivx-health-now-accepting-new-leqvio-patients 2022-02-08T19:51:20 https://maestrodatabase.com/blog/eli-lilly-receives-marketing-authorisation-for-baricitinib 2022-10-04T11:49:31 https://maestrodatabase.com/blog/post-marketing-modifications-of-drug-labels-for-cancer-drugs-approved-by-the-us-fda-between-2006-and-2016-with-and-without-supporting-randomized-controlled-trials 2018-04-18T08:21:08 https://maestrodatabase.com/blog/sage-547-granted-prime-designation-by-ema-for-the-treatment-of-post-partum-depression 2016-12-16T04:38:10 https://maestrodatabase.com/blog/global-regulators-discuss-data-requirements-for-phase-3-trials-of-covid-19-vaccines 2020-06-24T11:57:58 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-and-grants-priority-review-to-snda-for-braftovi-encorafenib-in-combination-with-erbitux-cetuximab-braftovi-doublet-for-the-treatment-of-braf-v600e-mutant-metastatic-colorectal-cancer-after-prior-therapy 2019-12-18T19:24:59 https://maestrodatabase.com/blog/libtayo-cemiplimab-approved-by-the-european-commission-for-first-line-treatment-of-patients-with-advanced-non-small-cell-lung-cancer-with-50-percent-pd-l1-expression 2021-06-28T04:05:33 https://maestrodatabase.com/blog/pickering-mother-with-cystic-fibrosis-pleads-for-miracle-drug-to-come-to-canada 2019-12-18T19:21:40 https://maestrodatabase.com/blog/ars-pharmaceuticals-submits-response-to-fda-complete-response-letter-for-neffy-epinephrine-nasal-spray 2024-04-08T22:27:26 https://maestrodatabase.com/blog/trump-administration-takes-historic-steps-to-lower-u-dot-s-prescription-drug-prices 2019-12-18T19:14:13 https://maestrodatabase.com/blog/big-pharma-is-taking-big-money-from-u-dot-s-tax-payers-to-find-a-coronavirus-vaccine----and-charge-whatever-they-want-for-it 2020-06-24T12:29:07 https://maestrodatabase.com/blog/rare-disease-endpoint-advancement-pilot-program 2022-10-04T20:25:41 https://maestrodatabase.com/blog/terminally-ill-dad-saves-more-than-$200k-bringing-in-cancer-drugs-from-india 2018-04-18T20:47:25 https://maestrodatabase.com/blog/neurorx-and-relief-therapeutics-announce-fast-track-designation-granted-by-the-fda-to-rlf-100-aviptadil-for-the-treatment-of-respiratory-distress-in-covid-19 2020-06-24T12:31:47 https://maestrodatabase.com/blog/eagle-pharmaceuticals-announces-fda-maintains-prioritisation-of-anda-for-vasopressin 2021-06-28T05:57:07 https://maestrodatabase.com/blog/three-million-novavax-doses-touch-down-in-australia-ahead-of-final-tga-approval 2022-02-08T20:18:17 https://maestrodatabase.com/blog/the-use-of-mcda-in-hta-great-potential-but-more-effort-needed 2018-04-18T20:53:58 https://maestrodatabase.com/blog/u-dot-s-fda-acknowledges-receipt-of-evofem-biosciences-new-drug-application-resubmission-for-amphora-for-the-prevention-of-pregnancy 2019-12-18T19:33:52 https://maestrodatabase.com/blog/towards-greater-impact-in-health-technology-assessment-horizon-scanning-for-new-and-emerging-technologies-in-singapore 2020-06-24T12:39:40 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-supplemental-biologics-license-application-for-opdivo-nivolumab-in-previously-treated-patients-with-small-cell-lung-cancer-and-grants-priority-review 2018-04-18T20:36:58 https://maestrodatabase.com/blog/cvs-adds-eliquis-other-vital-drugs-to-formulary-exclusions 2022-02-08T20:25:43 https://maestrodatabase.com/blog/split-real-time-application-review-star 2022-10-04T20:20:45 https://maestrodatabase.com/blog/the-new-janet-the-fda-turns-to-a-quiet-problem-solver-who-brings-expertise----and-a-little-controversy 2020-06-24T12:48:38 https://maestrodatabase.com/blog/canada-moves-one-step-closer-to-universal-pharmacare 2018-04-18T21:00:46 https://maestrodatabase.com/blog/seattle-genetics-announces-u-dot-s-fda-grants-breakthrough-therapy-designation-for-tucatinib-in-locally-advanced-or-metastatic-her2-positive-breast-cancer 2019-12-18T19:42:00 https://maestrodatabase.com/blog/free-epipen-campaign-returns-in-response-to-overwhelming-demand 2022-02-08T19:57:36 https://maestrodatabase.com/blog/fda-official-insists-u-dot-s-is-catching-up-to-europe-on-biosimilar-regulations-approvals 2018-04-18T21:10:12 https://maestrodatabase.com/blog/nice-begins-phased-restart-of-non-covid-19-guidance 2020-06-24T12:02:38 https://maestrodatabase.com/blog/mayne-pharma-announces-fda-filing-acceptance-of-new-drug-application-for-e4-slash-drsp-in-the-us 2020-06-24T12:25:03 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-positive-chmp-opinion-for-opdivo-nivolumab-as-adjuvant-treatment-for-oesophageal-or-gastro-oesophageal-junction-cancer-patients-with-residual-pathologic-disease-following-chemoradiotherapy 2021-06-28T05:43:51 https://maestrodatabase.com/blog/nice-misses-golden-opportunity-to-enhance-access-to-innovative-cancer-drugs 2022-02-08T20:05:06 https://maestrodatabase.com/blog/jemperli-dostarlimab-receives-us-fda-breakthrough-therapy-designation-for-locally-advanced-dmmr-slash-msi-h-rectal-cancer 2024-12-18T03:01:46 https://maestrodatabase.com/blog/neurorx-awarded-fda-fast-track-designation-for-first-drug-regimen-targeting-suicide-in-bipolar-depression 2017-09-07T11:56:02 https://maestrodatabase.com/blog/us-painkiller-to-be-sold-in-australian-pharmacies-to-shore-up-supply 2020-06-24T21:20:36 https://maestrodatabase.com/blog/science-hinted-that-cancer-patients-could-take-less-of-a-$148-000-a-year-drug-its-maker-tripled-the-price-of-a-pill 2018-04-18T21:27:33 https://maestrodatabase.com/blog/astellas-receives-positive-chmp-opinion-for-evrenzo-roxadustat-for-adult-patients-with-symptomatic-anaemia-of-chronic-kidney-disease 2021-06-28T06:49:09 https://maestrodatabase.com/blog/new-pharmac-funded-drug-will-help-in-the-cancer-battle---but-its-still-not-enough 2022-10-05T08:27:22 https://maestrodatabase.com/blog/fdas-plan-to-engage-the-public-in-the-agencys-new-effort-to-strengthen-and-modernise-fdas-regulatory-framework 2017-09-07T20:55:28 https://maestrodatabase.com/blog/nice-publishes-final-guidance-for-sobis-avatrombopag-maleate 2020-06-24T21:26:24 https://maestrodatabase.com/blog/in-the-costly-us-health-care-market-mark-cubans-company-has-a-plan-to-reduce-prescription-drug-costs 2022-10-04T20:49:07 https://maestrodatabase.com/blog/calithera-biosciences-announces-fda-fast-track-designation-granted-to-cb-839-in-combination-with-cabozantinib-for-treatment-of-patients-with-advanced-renal-cell-carcinoma 2018-04-18T21:15:06 https://maestrodatabase.com/blog/newly-approved-als-drug-relyvrio-to-face-its-next-challenge-pricing-and-reimbursement 2022-10-04T20:44:14 https://maestrodatabase.com/blog/icer-provides-first-update-to-pricing-models-for-remdesivir-as-a-treatment-for-covid-19 2020-06-24T20:55:58 https://maestrodatabase.com/blog/forxiga-recommended-for-approval-in-the-eu-by-chmp-for-the-treatment-of-patients-with-chronic-kidney-disease 2021-06-28T06:13:48 https://maestrodatabase.com/blog/statement-from-fda-commissioner-scott-gottlieb-on-a-new-qualified-health-claim-advising-that-early-introduction-of-peanuts-to-certain-high-risk-infants-may-reduce-risk-of-peanut-allergy 2017-09-07T20:57:44 https://maestrodatabase.com/blog/fda-approves-pembrolizumab-for-cutaneous-squamous-cell-carcinoma 2020-06-24T20:59:05 https://maestrodatabase.com/blog/cue-biopharma-granted-fda-fast-track-designation-for-cue-101-for-the-treatment-of-recurrent-slash-metastatic-head-and-neck-squamous-cell-carcinoma 2022-10-04T20:39:03 https://maestrodatabase.com/blog/moderna-announces-global-regulatory-submissions-for-its-respiratory-syncytial-virus-rsv-vaccine-mrna-1345 2023-07-06T04:30:49 https://maestrodatabase.com/blog/deputy-ministers-call-out-patient-engagement-as-key-to-transforming-health-care 2018-04-18T21:42:16 https://maestrodatabase.com/blog/a-gop-senate-leader-calls-for-bipartisan-compromise-on-aca-marketplaces 2017-09-07T21:42:18 https://maestrodatabase.com/blog/continued-development-of-the-national-health-data-registers-leads-to-better-follow-up-of-medicines 2022-10-05T20:11:29 https://maestrodatabase.com/blog/tecentriq-atezolizumab-receives-cadth-reimbursement-recommendations-for-the-adjuvant-treatment-of-early-stage-non-small-cell-lung-cancer-and-the-treatment-of-extensive-stage-small-cell-lung-cancer 2022-10-05T20:14:37 https://maestrodatabase.com/blog/ucb-receives-positive-chmp-opinion-recommending-approval-of-bimzelx-bimekizumab-in-the-eu-for-the-treatment-of-adults-with-moderate-to-severe-plaque-psoriasis 2021-06-28T07:14:46 https://maestrodatabase.com/blog/ozanimod-hydrochloride-for-treating-moderate-to-severe-active-ulcerative-colitis 2022-10-05T19:54:37 https://maestrodatabase.com/blog/germany-first-in-eu-to-get-novartis-sma-gene-therapy-costing-almost-2-million-euros 2020-06-24T21:37:15 https://maestrodatabase.com/blog/bristol-myers-squibb-provides-regulatory-update-on-lisocabtagene-maraleucel 2020-11-17T06:12:10 https://maestrodatabase.com/blog/incyte-canada-announces-health-canada-approval-of-opzelura-ruxolitinib-cream-for-the-treatment-of-atopic-dermatitis-in-children-ages-2-11 2025-10-16T02:27:17 https://maestrodatabase.com/blog/looking-back-uk-patients-unhappy-with-adalimumab-biosimilar-switch 2020-06-24T21:46:38 https://maestrodatabase.com/blog/incyte-and-morphosys-announce-positive-chmp-opinion-for-tafasitamab-in-combination-with-lenalidomide-for-the-treatment-of-adults-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma 2021-06-28T07:06:28 https://maestrodatabase.com/blog/pharmac-cuts-red-tape-to-improve-access-to-medicines-for-thousands-of-new-zealanders 2025-10-16T02:37:43 https://maestrodatabase.com/blog/health-canada-grants-market-authorisation-for-orkambi-lumacaftor-slash-ivacaftor-for-children-with-cystic-fibrosis-aged-2-to-5-years-old-with-most-common-form-of-the-disease 2018-12-14T02:48:11 https://maestrodatabase.com/blog/immutep-receives-fda-fast-track-designation-for-lag-3-therapeutic-eftilagimod-alfa-for-first-line-non-small-cell-lung-cancer 2022-10-05T08:30:56 https://maestrodatabase.com/blog/rocket-pharmaceuticals-announces-fda-acceptance-of-bla-resubmission-of-kresladi-for-the-treatment-of-severe-leukocyte-adhesion-deficiency-i 2025-10-16T02:44:04 https://maestrodatabase.com/blog/innocare-announces-breakthrough-therapy-designation-of-orelabrutinib-by-us-fda-for-treatment-of-relapsed-or-refractory-mantle-cell-lymphoma 2021-06-28T10:40:07 https://maestrodatabase.com/blog/uk-strikes-deal-for-five-million-doses-of-modernas-covid-19-vaccine 2020-11-17T10:27:46 https://maestrodatabase.com/blog/pharmac-and-diabetes-foundation-aotearoa-locked-in-stand-off-over-drug-funding-decision 2020-11-17T10:35:49 https://maestrodatabase.com/blog/stealth-biotherapeutics-announces-fda-acceptance-of-new-drug-application-for-elamipretide-for-the-treatment-of-barth-syndrome 2024-04-08T23:18:01 https://maestrodatabase.com/blog/phanes-therapeutics-pt217-granted-fast-track-designation-by-the-fda 2024-04-08T23:13:50 https://maestrodatabase.com/blog/success-rate-for-marketing-authorisation-applications-from-smes-doubles-between-2016-and-2020 2021-06-28T10:34:16 https://maestrodatabase.com/blog/olaparib-for-previously-treated-brca-mutation-positive-hormone-relapsed-metastatic-prostate-cancer 2023-05-10T10:04:32 https://maestrodatabase.com/blog/industry-fears-disruption-as-eu-excludes-uk-from-drug-approvals 2018-04-19T01:09:55 https://maestrodatabase.com/blog/ucbs-vimpat-lacosamide-now-approved-by-fda-in-u-dot-s-for-primary-generalised-tonic-clonic-seizures-and-expanded-paediatric-use-for-people-living-with-epilepsy 2020-11-17T19:35:07 https://maestrodatabase.com/blog/astrazeneca-available-to-all-australians-vaccines-mandated-for-quarantine-aged-care-workers 2021-06-28T21:31:36 https://maestrodatabase.com/blog/fda-accepts-cingulates-new-drug-application-for-ctx-1301-in-attention-deficit-hyperactivity-disorder-and-sets-a-31-may-2026-pdufa-date 2025-10-16T19:50:27 https://maestrodatabase.com/blog/askbio-receives-fda-fast-track-designation-for-lion-101-a-novel-investigational-aav-gene-therapy-for-the-treatment-of-limb-girdle-muscular-dystrophy-type-2i-slash-r9-lgmd2i-slash-r9 2021-06-28T11:25:51 https://maestrodatabase.com/blog/technegas-receives-complete-response-letter-from-the-us-fda---requirement-to-address-outstanding-technical-elements 2021-06-28T10:55:10 https://maestrodatabase.com/blog/us-fda-approves-tagrisso-as-first-line-treatment-for-egfr-mutated-non-small-cell-lung-cancer 2018-04-19T01:12:12 https://maestrodatabase.com/blog/sndx-5613-granted-fda-fast-track-designation-for-the-treatment-of-relapsed-slash-refractory-acute-leukemias 2021-06-28T11:18:33 https://maestrodatabase.com/blog/fdas-ongoing-commitment-to-transparency-for-covid-19-euas 2020-11-17T19:58:30 https://maestrodatabase.com/blog/boston-drug-pricing-watchdog-group-has-pharma-companies-attention 2019-06-20T06:14:08 https://maestrodatabase.com/blog/amazon-jumps-into-the-pharmacy-business-with-online-prescription-fulfilment-free-delivery-for-prime-members 2020-11-17T19:42:58 https://maestrodatabase.com/blog/catalyst-biosciences-receives-fda-fast-track-designation-for-subcutaneous-marzaa-for-the-treatment-of-episodic-bleeding-in-factor-vii-deficiency 2021-06-28T21:34:19 https://maestrodatabase.com/blog/senate-committee-to-vote-on-health-package-with-ambitious-plan-to-reduce-drug-prices 2019-06-20T06:07:55 https://maestrodatabase.com/blog/tracon-pharmaceuticals-announces-submission-for-approval-of-envafolimab-kn035-with-the-nmpa-in-china-by-its-corporate-partners-alphamab-oncology-and-3d-medicine 2020-11-17T19:51:11 https://maestrodatabase.com/blog/smc---april-2024-decisions 2024-04-08T23:53:15 https://maestrodatabase.com/blog/why-the-pharmacy-guild-is-the-most-powerful-lobby-group-youve-never-heard-of 2019-06-20T10:19:16 https://maestrodatabase.com/blog/innovative-treatment-for-inflammatory-eye-condition-recommended-for-use-on-the-nhs 2019-06-20T10:13:16 https://maestrodatabase.com/blog/decision-in-relation-to-infliximab-tocilizumab-and-rituximab 2018-12-14T05:00:20 https://maestrodatabase.com/blog/genentech-files-to-block-marketing-of-centus-bevacizumab-biosimilar 2020-11-17T20:51:34 https://maestrodatabase.com/blog/us-fda-accepts-takedas-supplemental-biologics-license-application-for-use-of-takzyro-lanadelumab-flyo-to-prevent-hereditary-angioedema-attacks-in-children-2-years-of-age-and-older 2022-10-06T06:53:14 https://maestrodatabase.com/blog/health-canada-approves-additional-indication-for-nubeqa-darolutamide-for-the-treatment-of-metastatic-castration-sensitive-prostate-cancer-in-combination-with-docetaxel 2022-10-06T06:43:14 https://maestrodatabase.com/blog/mhra-grants-marketing-authorisation-for-opzelura-ruxolitinib-cream-for-the-treatment-of-non-segmental-vitiligo-with-facial-involvement-in-adults-and-adolescents 2023-07-06T06:03:56 https://maestrodatabase.com/blog/astellas-announces-us-fda-grants-priority-review-for-zolbetuximab-biologics-license-application 2023-07-06T06:08:03 https://maestrodatabase.com/blog/viiv-healthcare-announces-us-fda-approval-of-dovato-dolutegravir-slash-lamivudine-for-adolescents-living-with-hiv 2024-04-09T06:09:44 https://maestrodatabase.com/blog/agenda-for-the-may-2025-pbac-meeting 2024-12-18T07:28:02 https://maestrodatabase.com/blog/shorla-oncology-announces-fda-filing-acceptance-of-new-drug-application-to-treat-certain-forms-of-leukaemia-and-other-cancers 2024-04-09T02:53:52 https://maestrodatabase.com/blog/hhs-implements-inflationary-rebates-for-list-prices-of-medicare-part-d-outpatient-drugs 2022-10-06T08:23:02 https://maestrodatabase.com/blog/supernus-provides-regulatory-update-for-spn-830 2024-04-09T02:48:52 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac---september-2025 2025-10-16T23:18:11 https://maestrodatabase.com/blog/bristol-myers-squibb-announces-submission-of-biologics-license-application-for-car-t-cell-therapy-lisocabtagene-maraleucel-liso-cel-to-fda 2019-12-18T22:29:07 https://maestrodatabase.com/blog/merck-announces-fda-acceptance-of-biologics-license-application-for-clesrovimab-an-investigational-long-acting-monoclonal-antibody-designed-to-protect-infants-from-rsv-disease-during-their-first-rsv-season 2024-12-18T06:52:07 https://maestrodatabase.com/blog/palbociclib-combination-in-advanced-breast-cancer-again-only-disadvantages 2022-10-06T19:39:37 https://maestrodatabase.com/blog/santen-announces-health-canada-approval-for-cationorm-plus-to-relieve-the-symptoms-of-dry-eye-and-ocular-allergy 2022-10-06T19:35:03 https://maestrodatabase.com/blog/lilly-receives-us-fda-fast-track-designation-for-tirzepatide-for-the-treatment-of-adults-with-obesity-or-overweight-with-weight-related-co-morbidities 2022-10-06T11:11:07 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-issues-final-report-and-policy-recommendations-on-siponimod-for-secondary-progressive-multiple-sclerosis 2019-06-20T20:47:43 https://maestrodatabase.com/blog/ublituximab-for-the-treatment-of-patients-with-relapsing-multiple-sclerosis 2024-12-18T19:24:31 https://maestrodatabase.com/blog/sustainable-discovery-and-development-of-antibiotics----is-a-non-profit-approach-the-future 2019-06-20T12:55:55 https://maestrodatabase.com/blog/what-is-nices-severity-modifier 2024-12-18T19:21:30 https://maestrodatabase.com/blog/pwc-says-us-companies-are-expected-to-spend-6-percent-more-on-employee-health-care-next-year-as-drug-prices-rise 2019-06-20T12:53:20 https://maestrodatabase.com/blog/icer-publishes-2024-research-protocol-for-assessing-unsupported-price-increases-on-prescription-drugs 2024-04-09T21:23:32 https://maestrodatabase.com/blog/polatuzumab-vedotin-in-combination-for-untreated-diffuse-large-b-cell-lymphoma 2022-10-06T10:26:33 https://maestrodatabase.com/blog/drug-prices-and-innovation 2019-06-20T12:50:58 https://maestrodatabase.com/blog/health-canada-approves-xeomin-incobotulinumtoxina-for-treatment-of-adults-with-post-stroke-lower-limb-spasticity-in-the-ankle-and-foot 2024-12-18T07:30:06 https://maestrodatabase.com/blog/novelwise-pharmaceutical-receives-fda-fast-track-designation-for-nbm-bmx-in-metastatic-uveal-melanoma 2025-10-16T23:54:10 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-supplemental-biologics-license-application-for-ultomiris-ravulizumab-cwvz-under-priority-review-for-the-treatment-of-atypical-haemolytic-uremic-syndrome 2019-06-20T20:55:59 https://maestrodatabase.com/blog/gruenenthal-receives-breakthrough-therapy-designation-from-u-dot-s-fda-for-neridronic-acid-for-the-treatment-of-complex-regional-pain-syndrome-a-debilitating-orphan-disease-with-high-medical-need 2016-12-17T00:37:56 https://maestrodatabase.com/blog/combatting-misinformation-on-biosimilars-and-preparing-the-market-for-them-can-save-the-u-dot-s-billions 2019-06-20T21:14:37 https://maestrodatabase.com/blog/dexcom-g7-receives-health-canada-approval-next-generation-continuous-glucose-monitoring-system-with-unmatched-accuracy-coming-to-canadians 2023-07-06T06:53:17 https://maestrodatabase.com/blog/chmp-recommends-eu-conditional-approval-of-roches-alecensa-alectinib-for-people-with-previously-treated-alk-positive-nsclc 2016-12-17T01:11:34 https://maestrodatabase.com/blog/drug-pricing-should-reflect-value-not-recoupment-of-investment 2019-06-20T21:11:05 https://maestrodatabase.com/blog/pathway-to-us-approval-clarified-after-fda-issues-complete-response-letter-on-use-of-bronchitol-for-adult-cf-patients 2019-06-20T21:03:01 https://maestrodatabase.com/blog/fda-approves-new-type-of-therapy-to-treat-advanced-urothelial-cancer 2019-12-18T23:07:06 https://maestrodatabase.com/blog/maribavir-for-treating-refractory-or-resistant-cytomegalovirus-infection-after-transplant 2022-10-06T19:47:49 https://maestrodatabase.com/blog/orphazymes-arimoclomol-receives-us-fast-track-designation-in-sporadic-inclusion-body-myositis 2019-12-18T23:16:12 https://maestrodatabase.com/blog/novel-approaches-to-value-assessment-within-the-cost-effectiveness-framework 2019-06-20T21:29:07 https://maestrodatabase.com/blog/more-than-100-people-a-year-in-england-could-benefit-from-new-endometrial-cancer-treatment-within-the-cancer-drugs-fund 2022-02-09T03:14:05 https://maestrodatabase.com/blog/icer-issues-final-report-and-policy-recommendations-on-esketamine-for-treatment-resistant-depression 2019-06-20T21:20:06 https://maestrodatabase.com/blog/pharmacy-benefit-manager-reform-lessons-from-ohio 2019-06-20T21:17:28 https://maestrodatabase.com/blog/women-in-dobell-cant-afford-medicine 2022-02-09T03:35:50 https://maestrodatabase.com/blog/chmp-recommends-approval-of-lillys-baricitinib-for-the-treatment-of-adults-with-moderate-to-severe-active-rheumatoid-arthritis 2016-12-17T02:25:27 https://maestrodatabase.com/blog/statement-on-the-fdas-benefit-risk-framework-for-evaluating-opioid-analgesics 2019-06-20T21:36:26 https://maestrodatabase.com/blog/atai-life-sciences-and-beckley-psytech-announce-us-fda-breakthrough-therapy-designation-granted-to-bpl-003-underscoring-its-potential-in-treatment-resistant-depression 2025-10-16T23:45:24 https://maestrodatabase.com/blog/xultophy-approved-in-canada-for-the-treatment-of-adults-with-type-2-diabetes 2018-04-19T07:07:58 https://maestrodatabase.com/blog/price-tag-for-newly-approved-crysvita-is-responsible-says-pbm-express-scripts 2018-04-19T08:18:07 https://maestrodatabase.com/blog/chondrial-therapeutics-announces-dosing-of-first-patients-in-phase-1-clinical-program-of-cti-1601-for-treatment-of-friedreichs-ataxia-cti-1601-granted-rare-pediatric-disease-designation-and-fast-track-designation-by-u-dot-s-fda 2019-12-18T23:22:44 https://maestrodatabase.com/blog/evolus-receives-acceptance-of-submission-in-australia-a-pivotal-step-in-approval-process-for-nuceiva 2022-02-09T03:41:37 https://maestrodatabase.com/blog/swissmedic-validates-shires-marketing-authorisation-application-for-investigational-hereditary-angioedema-treatment-lanadelumab 2018-04-19T07:14:16 https://maestrodatabase.com/blog/merck-announces-unprecedented-agreement-with-us-government-to-expand-access-to-ivf-therapies 2025-10-17T01:38:19 https://maestrodatabase.com/blog/fda-staff-raises-safety-concerns-over-lilly-slash-incyte-arthritis-drug 2018-04-19T20:03:44 https://maestrodatabase.com/blog/kazias-paxalisib-receives-fast-track-designation-from-fda-for-treatment-of-solid-tumour-brain-metastases-harbouring-pi3k-pathway-mutations-in-combination-with-radiation-therapy 2023-07-06T12:11:44 https://maestrodatabase.com/blog/using-effect-scores-to-characterise-heterogeneity-of-treatment-effects 2024-04-09T22:48:44 https://maestrodatabase.com/blog/final-nhs-nod-for-roches-roactemra 2018-04-19T11:57:31 https://maestrodatabase.com/blog/universal-pharmacare-the-right-prescription-for-canada 2018-04-19T21:00:39 https://maestrodatabase.com/blog/four-canadian-provinces-add-erelzi-etanercept-to-provincial-drug-plans-for-the-treatment-of-multiple-inflammatory-diseases 2018-04-19T20:09:54 https://maestrodatabase.com/blog/sommetrics-receives-fda-breakthrough-device-designation-for-its-aersleep-ii-product-to-treat-sleep-apnea 2020-11-17T23:04:22 https://maestrodatabase.com/blog/extension-of-indications-in-drug-approval-often-without-proof-of-additional-benefit 2023-07-06T21:39:42 https://maestrodatabase.com/blog/ips-heart-receives-us-fda-rare-paediatric-drug-designation-for-isx9-cpc-stem-cell-therapy-for-treatment-of-cardiomyopathy-associated-with-danon-disease 2023-07-06T21:30:31 https://maestrodatabase.com/blog/immunotherapy-for-patients-with-advanced-cancers 2025-10-17T03:35:03 https://maestrodatabase.com/blog/fda-converts-novel-alzheimers-disease-treatment-to-traditional-approval 2023-07-06T21:18:32 https://maestrodatabase.com/blog/syros-receives-fast-track-designation-from-the-fda-for-tamibarotene-for-the-treatment-of-newly-diagnosed-unfit-aml-with-rara-gene-over-expression 2024-04-09T23:31:53 https://maestrodatabase.com/blog/same-time-decisions-on-licensing-and-value---what-pharmaceutical-companies-need-to-know 2025-10-17T01:47:39 https://maestrodatabase.com/blog/a-mother-shaped-by-tragedy-embarks-on-a-mission-to-advance-custom-medicines 2022-02-09T10:49:11 https://maestrodatabase.com/blog/first-hiv-prevention-injection-for-people-unable-to-have-daily-prep-recommended 2025-10-17T01:49:42 https://maestrodatabase.com/blog/hira-mulls-therapeutic-outcome-based-benefits-for-ultra-expensive-drugs 2022-02-09T10:41:23 https://maestrodatabase.com/blog/viiv-healthcare-receives-fda-breakthrough-therapy-designation-for-investigational-long-acting-cabotegravir-for-hiv-prevention 2020-11-17T23:49:05 https://maestrodatabase.com/blog/price-disclosure-october-2020-cycle-outcomes-summary 2020-06-25T11:40:18 https://maestrodatabase.com/blog/hls-therapeutics-announces-health-canada-approval-of-perseris-for-the-treatment-of-schizophrenia 2020-11-18T01:37:42 https://maestrodatabase.com/blog/does-remdesivir-actually-work-against-covid-19 2020-11-18T01:44:30 https://maestrodatabase.com/blog/sinovac-receives-approval-from-china-for-its-quadrivalent-influenza-vaccine 2020-06-25T11:55:07 https://maestrodatabase.com/blog/cancer-patients-to-benefit-from-new-histology-independent-treatment 2020-06-25T11:32:03 https://maestrodatabase.com/blog/johnson-and-johnson-submits-application-to-the-ema-seeking-approval-of-a-new-indication-for-imbruvica-ibrutinib-in-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-eligible-for-autologous-stem-cell-transplant 2024-12-18T21:57:34 https://maestrodatabase.com/blog/fda-approves-ensartinib-for-alk-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer 2024-12-18T21:21:36 https://maestrodatabase.com/blog/who-pays-in-medicare-part-d-giving-plans-more-skin-in-the-game 2019-12-19T00:18:38 https://maestrodatabase.com/blog/nice-draft-guidance-does-not-recommend-siponimod-for-treating-secondary-progressive-multiple-sclerosis 2020-06-25T11:36:05 https://maestrodatabase.com/blog/dupixent-dupilumab-injection-now-approved-by-health-canada-for-patients-with-severe-asthma 2020-11-18T01:34:19 https://maestrodatabase.com/blog/us-fda-approves-celltrions-steqeyma-ustekinumab-stba-a-biosimilar-to-stelara-ustekinumab 2024-12-18T21:15:45 https://maestrodatabase.com/blog/emer-cooke-nominated-as-new-ema-executive-director 2020-06-25T20:57:05 https://maestrodatabase.com/blog/rare-cancer-lifeline-comes-with-dual-drug-discounts 2025-10-17T04:15:10 https://maestrodatabase.com/blog/first-covid-19-treatment-recommended-for-eu-authorisation 2020-06-25T20:59:06 https://maestrodatabase.com/blog/the-impact-of-drug-quality-ratings-from-health-technology-assessments-on-the-adoption-of-new-drugs-by-physicians-in-germany 2020-06-25T21:03:20 https://maestrodatabase.com/blog/how-orphan-drug-policy-could-impede-access-to-covid-19-treatments 2020-06-25T21:09:44 https://maestrodatabase.com/blog/federal-prosecutors-allege-regeneron-used-a-charity-to-pay-kickbacks-to-medicare-patients 2020-06-25T12:00:40 https://maestrodatabase.com/blog/gilead-submits-new-drug-application-to-u-dot-s-fda-for-lenacapavir-an-investigational-long-acting-capsid-inhibitor-for-the-treatment-of-hiv-1-in-people-with-limited-therapy-options 2021-06-29T00:18:11 https://maestrodatabase.com/blog/sandoz-canada-launches-the-biosimilars-generation 2020-06-25T12:19:12 https://maestrodatabase.com/blog/consultation-on-cadths-drug-reimbursement-review-procedures 2020-06-25T21:22:13 https://maestrodatabase.com/blog/angelini-pharmas-ontozry-available-for-patients-in-scotland-with-drug-resistant-epilepsy 2022-02-09T20:08:31 https://maestrodatabase.com/blog/initiation-of-darwin-eu-coordination-centre-advances-integration-of-real-world-evidence-into-assessment-of-medicines-in-the-eu 2022-02-09T20:05:37 https://maestrodatabase.com/blog/open-dialogue-needed-with-htas-to-improve-access 2020-06-25T21:38:32 https://maestrodatabase.com/blog/maia-biotechnology-granted-fda-rare-paediatric-disease-designation-for-thio-as-a-treatment-for-paediatric-high-grade-gliomas 2024-12-19T06:31:01 https://maestrodatabase.com/blog/tga-provisionally-approves-astrazenecas-covid-19-vaccine-as-booster-dose 2022-02-09T20:12:59 https://maestrodatabase.com/blog/partnering-with-the-european-union-and-global-regulators-on-covid-19 2020-06-25T21:13:06 https://maestrodatabase.com/blog/aadi-bioscience-initiates-rolling-submission-of-nda-to-fda-for-nab-sirolimus-abi-009-fyarro-for-the-treatment-of-advanced-malignant-pecoma 2020-06-25T21:16:19 https://maestrodatabase.com/blog/topic-selection-process-in-health-technology-assessment-agencies-around-the-world-a-systematic-review 2022-02-09T20:44:10 https://maestrodatabase.com/blog/esperoct-turoctocog-alfa-pegol-n8-gp-approved-in-the-eu 2019-06-21T05:32:28 https://maestrodatabase.com/blog/nova-scotia-becomes-fifth-canadian-province-to-implement-a-biosimilar-switching-program 2022-02-09T20:39:33 https://maestrodatabase.com/blog/fda-authorises-first-covid-19-test-for-self-testing-at-home 2020-11-18T03:20:01 https://maestrodatabase.com/blog/novavax-underdelivers-on-covid-vaccine-promises 2022-02-09T20:50:55 https://maestrodatabase.com/blog/eu-ramps-up-collection-of-public-health-data-to-improve-drug-reviews 2022-02-09T20:26:07 https://maestrodatabase.com/blog/pfizer-has-enough-safety-data-about-its-coronavirus-vaccine-and-is-preparing-to-submit-for-fda-authorisation-ceo-says 2020-11-18T03:03:37 https://maestrodatabase.com/blog/fda-raises-concerns-about-china-developed-drugs 2022-02-09T20:17:26 https://maestrodatabase.com/blog/cost-recovery-implementation-statement 2019-06-21T05:37:37 https://maestrodatabase.com/blog/fda-awards-qidp-designation-for-prevention-of-chlamydia-to-evofem-biosciences 2022-02-09T20:33:13 https://maestrodatabase.com/blog/lib-therapeutics-submits-a-biologic-license-application-to-fda-for-lerodalcibep-for-the-treatment-of-adults-with-elevated-ldl-cholesterol 2024-12-19T06:50:24 https://maestrodatabase.com/blog/alkermes-receives-fda-complete-response-letter-related-to-alks-3831-manufacturing-records-review 2020-11-18T05:56:55 https://maestrodatabase.com/blog/savara-initiates-rolling-submission-of-a-biologics-license-application-to-the-us-fda-for-molbreevi-for-the-potential-treatment-of-auto-immune-pulmonary-alveolar-proteinosis 2024-12-19T07:42:50 https://maestrodatabase.com/blog/desktop-health-receives-fda-clearance-for-smileguard-resin-for-durable-and-comfortable-orthodontic-and-dental-appliances 2022-10-07T01:59:44 https://maestrodatabase.com/blog/regulatory-agency-expands-cooperation-with-european-counterparts 2019-12-19T02:34:57 https://maestrodatabase.com/blog/fda-approves-remestemcel-l-rknd-for-steroid-refractory-acute-graft-versus-host-disease-in-paediatric-patients 2024-12-19T08:05:40 https://maestrodatabase.com/blog/atara-bio-granted-access-to-priority-medicines-prime-regulatory-support-for-allogeneic-epstein-barr-virus-ebv--specific-cytotoxic-t-lymphocytes-ctl-for-treatment-of-ebv-associated-post-transplant-lymphoproliferative-disorder-ebv-ptld 2016-12-17T06:23:04 https://maestrodatabase.com/blog/soaring-medication-prices-in-remote-australian-chemists-have-families-going-online 2019-12-19T02:24:57 https://maestrodatabase.com/blog/cabozantinib-maleate-in-combination-with-nivolumab-for-the-first-line-treatment-of-patients-with-advanced-renal-cell-carcinoma 2024-04-10T01:51:29 https://maestrodatabase.com/blog/making-tender-decisions-how-does-pharmac-allocate-its-fixed-budget 2024-04-10T01:47:01 https://maestrodatabase.com/blog/rilzabrutinib-granted-fda-fast-track-designation-for-treatment-of-immune-thrombocytopenia 2020-11-18T06:33:12 https://maestrodatabase.com/blog/gileads-seladelpar-receives-positive-chmp-opinion-for-primary-biliary-cholangitis 2024-12-19T07:53:43 https://maestrodatabase.com/blog/albireos-lead-product-candidate-for-orphan-paediatric-liver-disease-accepted-into-european-medicines-agencys-prime-program 2016-12-17T06:40:11 https://maestrodatabase.com/blog/fda-grants-priority-review-for-avalglucosidase-alfa-a-potential-new-therapy-for-pompe-disease 2020-11-18T06:05:50 https://maestrodatabase.com/blog/samsung-bioepis-and-biogen-announce-fda-filing-acceptance-of-sb11-a-proposed-biosimilar-referencing-lucentis-ranibizumab 2020-11-18T19:56:44 https://maestrodatabase.com/blog/the-vaccines-will-probably-work-making-them-fast-will-be-the-hard-part 2020-11-18T20:06:48 https://maestrodatabase.com/blog/pfizer-will-seek-regulatory-review-within-days-for-its-vaccine 2020-11-18T20:11:40 https://maestrodatabase.com/blog/covid-19-vaccine-safety-report-6-october-2022 2022-10-07T05:10:56 https://maestrodatabase.com/blog/nice-backs-lillys-emgality-for-migraine-adding-pressure-on-novartis 2020-11-18T19:46:59 https://maestrodatabase.com/blog/european-commission-approves-supemtek-quadrivalent-recombinant-influenza-vaccine-for-the-prevention-of-influenza-in-adults-aged-18-years-and-older 2020-11-18T19:50:58 https://maestrodatabase.com/blog/covid-19-nirmatrelvir-slash-ritonavir-reduces-the-risk-of-a-severe-course-in-patients-at-risk 2022-10-07T02:34:30 https://maestrodatabase.com/blog/epizyme-submits-new-drug-application-to-the-u-dot-s-fda-for-tazemetostat-for-the-treatment-of-patients-with-follicular-lymphoma 2019-12-19T03:24:17 https://maestrodatabase.com/blog/the-critical-role-of-academic-clinical-trials-in-paediatric-cancer-drug-approvals-design-conduct-and-fit-for-purpose-data-for-positive-regulatory-decisions 2022-10-07T05:38:19 https://maestrodatabase.com/blog/novartis-receives-positive-chmp-recommendation-for-ilaris-to-treat-rare-diseases-in-adults-and-children-called-periodic-fever-syndromes 2016-12-17T20:32:49 https://maestrodatabase.com/blog/fda-approves-new-therapy-for-dravet-syndrome 2020-06-26T01:10:43 https://maestrodatabase.com/blog/pembrolizumab-in-combination-with-platinum-based-chemotherapy-for-treating-recurrent-persistent-or-metastatic-cervical-cancer 2022-10-07T05:46:17 https://maestrodatabase.com/blog/tga-grants-third-provisional-determination-for-a-covid-19-vaccine 2020-11-18T20:20:46 https://maestrodatabase.com/blog/calls-for-supplement-to-treat-rare-metabolic-disorder-to-be-relisted-on-pbs 2024-04-10T02:35:46 https://maestrodatabase.com/blog/mums-plea-im-dying-but-7-dollars-70-cents-could-save-my-kids 2024-04-10T02:24:14 https://maestrodatabase.com/blog/government-subsidises-two-$5000-slash-month-breast-cancer-drugs 2018-04-21T00:01:17 https://maestrodatabase.com/blog/knight-therapeutics-announces-filing-of-supplement-to-a-new-drug-submission-for-nerlynx-neratinib-to-treat-her2-positive-metastatic-breast-cancer 2020-11-18T22:31:59 https://maestrodatabase.com/blog/fda-accepts-filing-of-new-drug-application-for-nalmefene-auto-injector-for-the-treatment-of-known-or-suspected-opioid-overdose 2024-04-10T03:06:02 https://maestrodatabase.com/blog/lundbeck-and-otsuka-submit-snda-for-fda-review-of-brexpiprazole-and-sertraline-combination-as-potential-treatment-for-ptsd 2024-04-10T02:55:06 https://maestrodatabase.com/blog/chiasma-announces-submission-of-marketing-authorisation-application-for-mycapssa-to-the-european-medicines-agency 2021-06-29T03:25:31 https://maestrodatabase.com/blog/european-medicines-agencys-chmp-recommends-mercks-keytruda-pembrolizumab-for-the-first-line-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-whose-tumours-have-high-pd-l1-expression-with-no-egfr-or-alk-positive-tumour-mutations 2016-12-17T21:09:30 https://maestrodatabase.com/blog/a-new-way-to-contain-unaffordable-medication-costs---exercising-the-governments-existing-rights 2022-02-10T01:48:39 https://maestrodatabase.com/blog/biomarin-resubmits-marketing-authorisation-application-to-european-medicines-agency-for-valoctocogene-roxaparvovec-to-treat-severe-haemophilia-a 2021-06-29T03:47:10 https://maestrodatabase.com/blog/viiv-healthcare-announces-chmp-positive-opinion-to-lower-the-age-and-weight-limit-for-tivicay-dolutegravir-in-children-and-adolescents-living-with-hiv-in-europe 2016-12-17T23:38:22 https://maestrodatabase.com/blog/national-medicines-policy-too-important-to-be-rushed-before-federal-election 2022-02-10T01:42:52 https://maestrodatabase.com/blog/price-disclosure-2019-october-cycle-outcomes-summary 2019-06-21T08:46:32 https://maestrodatabase.com/blog/allergan-and-molecular-partners-receive-complete-response-letter-from-fda-on-biologics-license-application-for-abicipar-pegol 2020-06-26T07:07:08 https://maestrodatabase.com/blog/new-asthma-treatments-to-be-listed-on-pharmaceutical-benefits-scheme 2016-12-18T01:21:32 https://maestrodatabase.com/blog/janssen-submits-application-seeking-fda-approval-of-stelara-ustekinumab-for-the-treatment-of-adolescents-with-moderate-to-severe-plaque-psoriasis 2016-12-18T01:25:23 https://maestrodatabase.com/blog/novartis-drug-votubia-recommended-by-chmp-for-eu-approval-to-treat-refractory-partial-onset-seizures-in-patients-with-tsc 2016-12-17T23:58:47 https://maestrodatabase.com/blog/novartis-scemblix-receives-positive-chmp-opinion-for-the-treatment-of-adults-with-newly-diagnosed-cml 2025-10-17T21:26:55 https://maestrodatabase.com/blog/merck-ceo-sees-legal-challenge-if-u-dot-s-adopts-drug-pricing-based-on-other-countries 2019-06-21T08:50:48 https://maestrodatabase.com/blog/alnylam-announces-fda-approval-of-supplemental-new-drug-application-for-oxlumo-lumasiran-in-advanced-primary-hyperoxaluria-type-1 2022-10-07T06:43:13 https://maestrodatabase.com/blog/libtayo-cemiplimab-recommended-for-eu-approval-by-the-chmp-for-adjuvant-treatment-of-cutaneous-squamous-cell-carcinoma-with-a-high-risk-of-recurrence-after-surgery-and-radiation 2025-10-17T21:31:46 https://maestrodatabase.com/blog/pbs-expenditure-and-prescriptions-for-2015-16 2016-12-18T04:30:02 https://maestrodatabase.com/blog/proposal-to-list-a-range-of-orthopaedic-implants-and-associated-products-supplied-by-zimmer-biomet-new-zealand 2016-12-18T04:23:44 https://maestrodatabase.com/blog/saphnelo-subcutaneous-self-administration-recommended-for-approval-in-eu-by-chmp-for-systemic-lupus-erythematosus 2025-10-17T21:39:43 https://maestrodatabase.com/blog/icer-to-assess-treatment-for-narcolepsy 2025-10-17T21:46:28 https://maestrodatabase.com/blog/u-dot-s-group-says-novartis-ms-drug-price-out-of-line-with-benefit 2019-06-21T12:31:12 https://maestrodatabase.com/blog/tezspire-approved-in-the-us-for-chronic-rhinosinusitis-with-nasal-polyps 2025-10-17T22:02:58 https://maestrodatabase.com/blog/health-economics-methods-advisory-group-releases-draft-report-asssessing-treatment-benefits-in-health-technology-assessment-decision-making 2025-10-17T22:50:55 https://maestrodatabase.com/blog/silver-creek-pharmaceuticals-receives-fda-fast-track-designation-for-scp776-in-acute-ischaemic-stroke 2025-10-17T23:11:18 https://maestrodatabase.com/blog/sanofis-wayrilz-recommended-for-eu-approval-by-the-chmp-to-treat-immune-thrombocytopenia 2025-10-18T05:26:41 https://maestrodatabase.com/blog/fda-expands-approval-of-treatment-for-cystic-fibrosis-to-include-patients-ages-6-and-older 2019-06-21T21:46:04 https://maestrodatabase.com/blog/pbs-subsidy-arrangements-for-insulin-degludec-and-insulin-aspart 2023-07-07T10:12:14 https://maestrodatabase.com/blog/ab-science-announces-that-health-canada-has-granted-eligibility-for-reconsideration-request-for-masitinib-in-als 2024-04-10T04:50:15 https://maestrodatabase.com/blog/phasing-out-of-extraordinary-covid-19-regulatory-flexibilities 2023-07-07T10:15:13 https://maestrodatabase.com/blog/chmp-recommends-eu-approval-of-brinsupri-brensocatib-for-the-treatment-of-non-cystic-fibrosis-bronchiectasis 2025-10-18T05:35:13 https://maestrodatabase.com/blog/kyowa-kirin-announces-approval-for-partial-change-of-rituximab-biosimilar-received-by-sandoz-in-japan 2020-11-19T07:24:04 https://maestrodatabase.com/blog/omeros-submits-its-biologics-license-application-to-u-dot-s-fda-for-narsoplimab-in-hsct-tma 2020-11-19T06:40:13 https://maestrodatabase.com/blog/highlights-from-the-13-16-october-2025-chmp-meeting 2025-10-17T22:48:20 https://maestrodatabase.com/blog/pacira-receives-european-commission-approval-for-exparel-bupivacaine-liposome-injectable-suspension-for-the-treatment-of-post-surgical-pain 2020-11-19T06:47:14 https://maestrodatabase.com/blog/broader-medicare-coverage-of-leqembi-available-following-fda-traditional-approval 2023-07-07T10:57:10 https://maestrodatabase.com/blog/biomarin-sells-priority-review-voucher-for-110-dollars-million 2022-02-10T02:24:34 https://maestrodatabase.com/blog/agios-submits-marketing-authorisation-application-to-european-medicines-agency-for-mitapivat-for-treatment-of-adults-with-pyruvate-kinase-deficiency 2021-06-29T05:08:18 https://maestrodatabase.com/blog/chmp-recommends-eu-approval-of-roches-gazyva-slash-gazyvaro-for-lupus-nephritis 2025-10-18T05:42:13 https://maestrodatabase.com/blog/alvotech-announces-that-the-u-dot-s-fda-and-ema-have-accepted-regulatory-submissions-for-avt02-a-proposed-biosimilar-to-humira-adalimumab 2020-11-19T19:49:19 https://maestrodatabase.com/blog/alnylam-receives-approval-for-oxlumo-lumasiran-in-the-european-union-for-the-treatment-of-primary-hyperoxaluria-type-1-in-all-age-groups 2020-11-19T19:53:50 https://maestrodatabase.com/blog/fda-approves-novo-nordisks-oral-semaglutide-for-cardiovascular-risk-reduction-in-adults-with-type-2-diabetes-who-are-at-high-risk-including-those-who-have-not-had-a-prior-cv-event 2025-10-18T05:53:50 https://maestrodatabase.com/blog/ema-organises-public-meeting-on-covid-19-vaccines 2020-11-19T19:37:18 https://maestrodatabase.com/blog/hugel-resubmits-bla-for-its-botulinum-toxin-botulax-to-the-us-fda 2022-10-07T08:17:47 https://maestrodatabase.com/blog/nice-is-getting-ready-for-the-end-of-the-transition-period-after-brexit 2020-11-19T19:39:39 https://maestrodatabase.com/blog/trifarotene-in-moderate-acne-no-study-data-for-the-assessment-of-the-added-benefit 2020-11-19T19:42:32 https://maestrodatabase.com/blog/new-target-zero-initiative-aims-to-help-improve-access-to-new-drugs 2024-04-10T08:36:31 https://maestrodatabase.com/blog/brickell-biotech-announces-launch-date-for-sofpironium-bromide-5-percent-gel-ecclock-in-japan-by-its-development-partner-kaken-pharmaceutical 2020-11-19T20:11:47 https://maestrodatabase.com/blog/health-officials-say-every-state-will-have-covid-vaccine-doses-within-24-hours-after-fda-green-light 2020-11-19T20:22:31 https://maestrodatabase.com/blog/lantheus-announces-fda-approval-of-definity-room-temperature 2020-11-19T20:32:27 https://maestrodatabase.com/blog/consideration-of-value-based-pricing-for-treatments-and-vaccines-is-important-even-in-the-covid-19-pandemic 2020-11-19T20:05:34 https://maestrodatabase.com/blog/gamida-cell-initiates-rolling-submission-of-biologics-license-application-for-omidubicel 2022-02-10T03:21:16 https://maestrodatabase.com/blog/why-the-new-amazon-pharmacy-could-pose-a-real-threat-to-drugstores 2020-11-19T20:08:55 https://maestrodatabase.com/blog/update-of-eu-recommendations-for-2021-2022-seasonal-flu-vaccine-composition 2021-06-29T06:14:18 https://maestrodatabase.com/blog/a-priority-review-voucher-program-to-fuel-generic-drug-development 2023-07-07T11:31:51 https://maestrodatabase.com/blog/fda-approves-vaccine-for-use-during-third-trimester-of-pregnancy-to-prevent-whooping-cough-in-infants-younger-than-two-months-of-age 2022-10-07T20:33:33 https://maestrodatabase.com/blog/nice-recommends-another-medicine-for-patients-with-multiple-myeloma 2020-11-19T20:41:49 https://maestrodatabase.com/blog/weekly-growth-hormone-injection-hits-pbs-newcastles-griffin-carters-first-in-australia-to-receive-life-changing-medication 2022-10-07T20:41:24 https://maestrodatabase.com/blog/innovent-announces-the-china-nmpa-approval-of-tyvyt-sintilimab-injection-in-combination-with-byvasda-bevacizumab-biosimilar-injection-as-first-line-therapy-for-people-with-hepatocellular-carcinoma 2021-06-29T06:02:06 https://maestrodatabase.com/blog/fda-grants-rare-paediatric-disease-designation-to-ns-089-slash-ncnp-02-for-the-treatment-of-duchenne-muscular-dystrophy 2023-07-07T13:02:04 https://maestrodatabase.com/blog/medexus-receives-notice-of-compliance-to-commercialise-treosulfan-in-canada 2021-06-29T06:49:50 https://maestrodatabase.com/blog/aft-to-re-apply-for-heart-medicine-contract-after-shortages 2016-12-18T19:55:41 https://maestrodatabase.com/blog/obama-administration-scraps-controversial-drug-pricing-proposal 2016-12-18T20:01:40 https://maestrodatabase.com/blog/summary-of-submissions-and-outcomes-from-the-november-2016-pbac-meeting 2016-12-18T20:37:47 https://maestrodatabase.com/blog/lumicell-granted-fast-track-designation-approval-by-the-fda-for-breast-cancer-treatment 2020-11-20T01:40:13 https://maestrodatabase.com/blog/fda-accepts-dupixent-dupilumab-for-priority-review-in-children-aged-6-months-to-5-years-with-moderate-to-severe-atopic-dermatitis 2022-02-10T06:06:45 https://maestrodatabase.com/blog/ptc-therapeutics-announces-key-regulatory-designations-for-ptc596-to-advance-treatment-of-two-rare-oncology-indications 2020-11-20T01:46:27 https://maestrodatabase.com/blog/roches-enspryng-approved-by-european-commission-as-first-and-only-at-home-subcutaneous-treatment-for-neuromyelitis-optica-spectrum-disorder 2021-06-29T08:56:53 https://maestrodatabase.com/blog/new-life-extending-drug-for-advanced-womb-cancer-to-be-rolled-out-on-the-nhs 2022-02-10T05:57:11 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-10-february-2022 2022-02-10T05:47:46 https://maestrodatabase.com/blog/fulfilment-of-post-market-commitments-and-requirements-for-new-drugs-approved-by-the-fda-2013-2016 2022-10-07T21:29:24 https://maestrodatabase.com/blog/fda-authorises-drug-combination-for-treatment-of-covid-19 2020-11-20T01:33:26 https://maestrodatabase.com/blog/inside-project-onyx-how-biogen-used-an-fda-back-channel-to-win-approval-of-its-polarising-alzheimers-drug 2021-06-29T12:28:23 https://maestrodatabase.com/blog/atagi-update-following-weekly-covid-19-meeting---9-february-2022 2022-02-10T10:39:29 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-treatment-for-chronic-obstructive-pulmonary-disease 2024-04-10T12:22:52 https://maestrodatabase.com/blog/mediwound-receives-complete-response-letter-from-us-fda-for-nexobrid-biologics-license-application 2021-06-29T21:29:19 https://maestrodatabase.com/blog/eli-lilly-promises-40-percent-discount-for-innovents-pd-1-in-last-ditch-bid-to-shift-fda-review-to-drug-pricing 2022-02-10T20:17:02 https://maestrodatabase.com/blog/health-canada-authorises-covid-19-vaccine-booster-targeting-the-omicron-ba-dot-4-slash-ba-dot-5-sub-variants 2022-10-08T02:04:31 https://maestrodatabase.com/blog/pharmacies-enter-covid-19-vaccine-frontline 2021-06-29T21:27:03 https://maestrodatabase.com/blog/enterome-receives-fda-fast-track-designation-in-follicular-lymphoma-for-lead-oncomimics-immunotherapy-eo2463 2025-10-19T20:24:25 https://maestrodatabase.com/blog/biden-wont-end-cancer----or-any-other-disease----by-importing-drug-price-controls-from-europe 2021-06-29T21:35:09 https://maestrodatabase.com/blog/biden-puts-focus-on-drug-prices-in-fight-against-inflation 2022-02-10T19:52:38 https://maestrodatabase.com/blog/walmart-unveils-low-price-insulin-as-more-patients-with-diabetes-struggle-to-pay-for-drug 2021-06-29T12:39:15 https://maestrodatabase.com/blog/neuros-medical-receives-fda-breakthrough-device-designation-for-its-novel-altius-high-frequency-nerve-block-system 2021-06-29T12:33:30 https://maestrodatabase.com/blog/bayer-receives-u-dot-s-fda-fast-track-designation-for-asundexian-stroke-program 2022-02-10T10:46:59 https://maestrodatabase.com/blog/south-africas-antitrust-regulator-wants-roche-penalised-for-excessive-cancer-drug-pricing 2022-02-10T20:12:51 https://maestrodatabase.com/blog/tailored-scientific-advice-to-support-step-by-step-development-of-new-biosimilars 2016-12-18T21:52:40 https://maestrodatabase.com/blog/three-doses-to-be-up-to-date-as-national-cabinet-prepares-for-winter-waves 2022-02-10T20:05:14 https://maestrodatabase.com/blog/doctors-stand-firm-on-pfizer-for-under-60s 2021-06-29T12:48:16 https://maestrodatabase.com/blog/smc-approves-biogens-vumerity-for-patients-with-multiple-sclerosis 2022-02-10T20:40:34 https://maestrodatabase.com/blog/azurity-pharmaceuticals-announces-the-fda-approval-of-ferabright-ferumoxytol-injection-the-first-and-only-iron-based-contrast-agent-indicated-for-magnetic-resonance-imaging-of-the-brain 2025-10-19T01:47:55 https://maestrodatabase.com/blog/costly-new-alzheimers-drug-could-force-medicare-to-restrict-access 2021-06-29T21:39:44 https://maestrodatabase.com/blog/theragnostics-announces-that-its-radiotherapeutic-for-treatment-of-glioblastoma-multiforme-has-been-awarded-uks-mhra-innovation-passport 2022-02-10T20:28:21 https://maestrodatabase.com/blog/senate-republican-bill-would-repeal-democratic-drug-pricing-law 2022-10-08T02:20:16 https://maestrodatabase.com/blog/biogen-urges-medicare-to-reverse-proposed-limits-on-coverage-of-alzheimers-drug 2022-02-10T20:34:07 https://maestrodatabase.com/blog/new-anniversary-price-reductions-and-ministerial-discretion-guidance-material-available 2018-04-21T03:30:57 https://maestrodatabase.com/blog/sunovion-announces-health-canada-approval-of-latuda-lurasidone-hydrochloride-to-treat-adolescents-13-to-17-years-of-age-wth-bipolar-depression 2018-04-21T04:20:03 https://maestrodatabase.com/blog/price-disclosure-2019-april-cycle-outcomes-summary 2018-12-15T23:03:57 https://maestrodatabase.com/blog/fda-commissioner-to-drug-middlemen-youre-part-of-the-problem 2018-04-21T03:35:36 https://maestrodatabase.com/blog/more-talk-about-universal-pharmacare-in-canada-but-still-no-action 2018-04-21T03:41:38 https://maestrodatabase.com/blog/fda-grants-breakthrough-designation-to-4d-path-for-novel-cancer-diagnostic-solution 2020-11-20T03:19:42 https://maestrodatabase.com/blog/european-commission-approves-reblozyl-luspatercept-for-the-treatment-of-transfusion-dependent-anaemia-in-adult-patients-with-myelodysplastic-syndromes-or-beta-thalassaemia 2020-06-28T00:19:18 https://maestrodatabase.com/blog/fda-approves-nplate-romiplostim-for-use-in-paediatric-patients-with-immune-thrombocytopenia 2018-12-15T23:16:43 https://maestrodatabase.com/blog/indivior-announces-new-drug-submission-to-health-canada-for-sublocade-buprenorphine-extended-release-injection-for-the-treatment-of-moderate-to-severe-opioid-use-disorder 2018-04-21T07:34:11 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac---november-2018 2018-12-15T23:06:08 https://maestrodatabase.com/blog/helsinn-group-announces-the-fda-approval-of-the-iv-formulation-of-akynzeo-fosnetupitant-slash-palonosetron-in-the-united-states 2018-04-21T07:10:53 https://maestrodatabase.com/blog/novartis-cosentyx-gains-positive-chmp-opinion-for-paediatric-psoriasis-reinforcing-established-efficacy-and-safety-profile 2020-06-28T00:26:41 https://maestrodatabase.com/blog/highlights-from-the-chmp-10-13-december-2018-meeting 2018-12-15T23:10:33 https://maestrodatabase.com/blog/texas-judge-strikes-down-obamas-affordable-care-act-as-unconstitutional 2018-12-15T23:28:19 https://maestrodatabase.com/blog/knight-therapeutics-announces-canadian-regulatory-approval-for-probuphine-for-opioid-drug-dependence 2018-04-21T07:53:04 https://maestrodatabase.com/blog/court-rules-affordable-care-acts-individual-insurance-mandate-is-unconstitutional 2019-12-19T07:06:17 https://maestrodatabase.com/blog/eu-drugs-agency-says-brexit-move-to-eat-into-2019-budget 2018-12-15T23:30:45 https://maestrodatabase.com/blog/celltrion-and-teva-announce-fda-approval-of-herzuma-trastuzumab-pkrb-a-biosimilar-to-herceptin-for-the-treatment-of-her2-over-expressing-breast-cancer-for-certain-indications 2018-12-15T23:22:03 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac---march-2018 2018-04-21T11:22:07 https://maestrodatabase.com/blog/supernus-announces-fda-approval-of-snda-to-expand-oxtellar-xr-label-to-include-monotherapy 2018-12-15T23:35:12 https://maestrodatabase.com/blog/bible-hill-firm-has-plan-to-lower-drug-prices 2018-04-21T11:19:15 https://maestrodatabase.com/blog/request-for-information-on-lamotrigine-brand-change 2019-12-19T07:10:40 https://maestrodatabase.com/blog/lillys-kisunla-donanemab-azbt-approved-in-china-for-the-treatment-of-early-symptomatic-alzheimers-disease 2024-12-19T20:48:35 https://maestrodatabase.com/blog/imfinzi-approved-in-the-us-for-less-frequent-fixed-dose-use 2020-11-20T08:09:17 https://maestrodatabase.com/blog/artiva-biotherapeutics-announces-refractory-rheumatoid-arthritis-as-lead-indication 2025-10-19T21:14:22 https://maestrodatabase.com/blog/patent-box-legislation-to-promote-australian-innovation 2022-02-10T22:53:33 https://maestrodatabase.com/blog/fda-approves-new-treatment-for-hypoactive-sexual-desire-disorder-in-pre-menopausal-women 2019-06-22T01:35:09 https://maestrodatabase.com/blog/why-wont-health-insurance-companies-pay-for-new-drugs 2024-04-10T23:20:05 https://maestrodatabase.com/blog/pushing-value-harvard-pilgrim-tests-outcomes-deals 2018-04-21T23:05:34 https://maestrodatabase.com/blog/new-cancer-gene-test-are-you-eligible 2021-06-29T23:27:36 https://maestrodatabase.com/blog/sanofi-and-regeneron-announce-that-cemiplimab-regn2810-has-received-fda-breakthrough-therapy-designation-for-advanced-cutaneous-squamous-cell-carcinoma 2017-09-09T02:49:56 https://maestrodatabase.com/blog/adrenomed-receives-fda-fast-track-designation-for-enibarcimab-for-treatment-of-septic-shock 2024-04-10T23:13:25 https://maestrodatabase.com/blog/three-steps-toward-a-more-sustainable-path-for-targeted-cancer-drugs 2018-04-21T23:02:10 https://maestrodatabase.com/blog/u-dot-s-fda-grants-fast-track-designation-for-polyphors-innovative-immuno-oncology-candidate-balixafortide-in-combination-with-eribulin-as-third-line-therapy-for-metastatic-breast-cancer 2018-04-21T23:15:28 https://maestrodatabase.com/blog/fda-approves-botox-onabotulinumtoxina-for-paediatric-patients-with-upper-limb-spasticity 2019-06-22T01:43:03 https://maestrodatabase.com/blog/should-value-frameworks-take-a-societal-perspective 2017-09-09T03:00:26 https://maestrodatabase.com/blog/can-a-new-value-framework-help-ease-friction-over-orphan-drug-prices 2017-09-09T02:57:38 https://maestrodatabase.com/blog/the-most-expensive-drugs-of-2016 2016-12-19T01:12:52 https://maestrodatabase.com/blog/safety-related-label-changes-for-new-drugs-after-approval-in-the-us-through-expedited-regulatory-pathways-retrospective-cohort-study 2017-09-09T03:10:45 https://maestrodatabase.com/blog/national-health-amendment-pharmaceutical-benefits-bill-2016 2016-12-19T02:38:49 https://maestrodatabase.com/blog/g-dot-o-p-plans-to-replace-health-care-law-with-universal-access 2016-12-19T03:33:40 https://maestrodatabase.com/blog/ocular-therapeutix-announces-fda-approval-of-supplemental-new-drug-application-for-dextenza-dexamethasone-intracanalicular-insert-for-ophthalmic-use-for-the-treatment-of-ocular-inflammation-following-ophthalmic-surgery 2019-06-22T01:50:00 https://maestrodatabase.com/blog/post-market-review-of-the-use-of-biologics-in-the-treatment-of-severe-chronic-plaque-psoriasis 2018-08-17T02:15:55 https://maestrodatabase.com/blog/should-the-fda-speed-up-or-slow-down-approval-of-new-cancer-drugs 2019-06-22T01:47:23 https://maestrodatabase.com/blog/20-states-accuse-generic-drug-companies-of-price-fixing 2016-12-19T03:39:10 https://maestrodatabase.com/blog/boehringer-ingelheim-and-lilly-welcome-new-recommendation-for-jardiance-empagliflozin-tablets-in-updated-american-diabetes-associations-2017-standards 2016-12-19T03:41:39 https://maestrodatabase.com/blog/hhs-announces-actions-to-protect-consumers-and-lower-health-care-costs 2023-07-08T00:47:43 https://maestrodatabase.com/blog/chiasma-announces-fda-approval-of-mycappsa-octreotide-capsules-the-first-and-only-oral-somatostatin-analogue 2020-06-28T01:23:23 https://maestrodatabase.com/blog/a-message-from-the-panel---review-of-pharmacy-remuneration-and-regulation 2016-12-19T04:24:26 https://maestrodatabase.com/blog/nices-evaluations-of-medicines-authorized-by-ema-with-conditional-marketing-authorization-or-under-exceptional-circumstances 2020-06-28T01:45:20 https://maestrodatabase.com/blog/abbvie-submits-new-drug-application-to-u-dot-s-fda-for-its-investigational-regimen-of-glecaprevir-slash-pibrentasvir-for-the-treatment-of-all-major-genotypes-of-chronic-hepatitis-c 2016-12-19T19:04:20 https://maestrodatabase.com/blog/novartis-receives-positive-chmp-opinion-for-new-xolair-indication-to-treat-severe-chronic-rhinosinusitis-with-nasal-polyps 2020-06-28T01:10:19 https://maestrodatabase.com/blog/review-of-access-to-new-medicines-report 2016-12-19T05:24:08 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-new-treatment-for-advanced-ovarian-cancer 2016-12-19T18:50:02 https://maestrodatabase.com/blog/aussie-mums-shunning-private-hospitals-due-to-obscene-obstetrics-charges 2016-12-19T19:48:11 https://maestrodatabase.com/blog/why-drug-costs-will-keep-rising-in-2017 2016-12-19T19:50:31 https://maestrodatabase.com/blog/vertex-announces-german-reimbursement-agreement-for-orkambi-lumacaftor-with-ivacaftor-the-first-medicine-to-treat-the-underlying-cause-of-cystic-fibrosis-in-people-ages-12-and-older-with-two-copies-of-the-f508del-mutation 2016-12-19T19:18:41 https://maestrodatabase.com/blog/japan-to-review-drug-prices-annually-rather-than-every-two-years 2016-12-19T19:28:06 https://maestrodatabase.com/blog/novartis-pulls-dry-eye-drug-xiidras-bid-for-approval-in-europe 2020-06-28T01:15:37 https://maestrodatabase.com/blog/averitas-pharma-announces-fda-acceptance-of-snda-filing-for-qutenza-capsaicin-8-percent-patch-for-the-treatment-of-neuropathic-pain-associated-with-diabetic-peripheral-neuropathy 2019-12-19T11:21:50 https://maestrodatabase.com/blog/healthy-lottery-fears-as-novartis-plans-to-give-away-worlds-most-expensive-drug 2019-12-19T11:08:12 https://maestrodatabase.com/blog/urogen-pharma-announces-fda-fling-acceptance-and-priority-review-of-u-dot-s-new-drug-application-for-ugn-101 2019-12-19T19:53:24 https://maestrodatabase.com/blog/obamacare-faces-unprecedented-test-as-economy-sinks 2020-06-28T01:51:49 https://maestrodatabase.com/blog/north-america-trade-pact-deals-rare-setback-to-big-pharma 2019-12-19T19:48:35 https://maestrodatabase.com/blog/lilly-launches-campaign-to-increase-awareness-of-insulin-cost-saving-options 2019-12-19T11:47:42 https://maestrodatabase.com/blog/tonix-pharmaceuticals-ptsd-phase-3-ready-drug-candidate-tnx-102-sl-granted-breakthrough-therapy-designation-by-the-fda 2016-12-20T03:28:20 https://maestrodatabase.com/blog/u-dot-s-fda-advisers-call-for-new-trial-of-lilly-innovent-lung-cancer-drug 2022-02-11T00:44:09 https://maestrodatabase.com/blog/prometic-initiates-rolling-submission-of-its-biologics-license-application-for-plasminogen-with-u-dot-s-fda 2016-12-20T03:54:13 https://maestrodatabase.com/blog/disaster-tipped-after-vital-medicine-cut-off 2022-10-08T08:31:40 https://maestrodatabase.com/blog/sarepta-therapeutics-announces-ema-validation-of-eteplirsen-authorisation-application-for-treatment-of-duchenne-muscular-dystrophy-amenable-to-exon-skipping-51 2016-12-20T04:12:34 https://maestrodatabase.com/blog/merry-christmas-and-happy-new-year-to-all-maestro-daily-readers 2019-12-19T20:02:50 https://maestrodatabase.com/blog/celltrions-biosimilar-granted-marketing-approval-recommendation-in-europe 2016-12-20T04:29:30 https://maestrodatabase.com/blog/really-expensive-migraine-expert-calls-for-more-funded-treatments 2024-04-11T01:38:38 https://maestrodatabase.com/blog/proposal-to-maintain-full-subsidy-for-gefitinib-iressa-from-1-april-2017 2016-12-20T05:06:32 https://maestrodatabase.com/blog/tga-approves-new-uses-for-janssens-imbruvica 2016-12-20T05:11:27 https://maestrodatabase.com/blog/ipsens-bylvay-launches-in-korea-with-national-coverage-for-a-rare-childhood-liver-disease 2025-10-20T10:08:32 https://maestrodatabase.com/blog/the-government-could-force-a-price-cut-for-this-prostate-cancer-drug-by-as-much-as-80-percent-why-hasnt-it-acted 2022-02-11T07:23:57 https://maestrodatabase.com/blog/fda-approves-roches-gazyva-slash-gazyvaro-for-the-treatment-of-lupus-nephritis 2025-10-20T19:39:11 https://maestrodatabase.com/blog/proposal-to-harmonise-streamline-and-transition-the-cancer-drug-implementation-advisory-committee-to-cadth 2018-12-16T01:08:14 https://maestrodatabase.com/blog/ptc-therapeutics-announces-vatiquinone-nda-submission-to-fda-for-the-treatment-of-children-and-adults-living-with-friedreich-ataxia 2024-12-20T04:51:28 https://maestrodatabase.com/blog/2019-oncology-drugs-in-pipeline----survey 2018-12-16T00:56:34 https://maestrodatabase.com/blog/abbvie-announces-first-provincial-reimbursements-for-venclexta-venetoclax-in-combination-with-azacitidine-for-acute-myeloid-leukaemia-patients 2022-02-11T01:52:12 https://maestrodatabase.com/blog/new-advice-to-keep-australians-up-to-date-with-covid-19-vaccinations 2022-02-11T01:36:16 https://maestrodatabase.com/blog/hansa-biopharma-receives-positive-chmp-opinion-for-idefirix-imlifidase-for-kidney-transplant-in-eu 2020-06-28T03:44:32 https://maestrodatabase.com/blog/lillys-bebtelovimab-receives-emergency-use-authorisation-for-the-treatment-of-mild-to-moderate-covid-19 2022-02-11T20:18:48 https://maestrodatabase.com/blog/health-economic-assessment-of-adakveo-for-the-treatment-of-sickle-cell-anaemia 2022-02-11T20:28:37 https://maestrodatabase.com/blog/a-drug-that-was-once-inexpensive-gets-a-new-price-tag-375-000-dollars 2018-12-16T05:21:24 https://maestrodatabase.com/blog/ascendis-pharma-announces-submission-of-biologics-license-application-to-fda-for-transcon-hgh-in-paediatric-growth-hormone-deficiency 2020-06-28T03:50:09 https://maestrodatabase.com/blog/pharmac-proposes-greater-transparency-for-medicine-funding-decisions 2025-10-20T04:19:16 https://maestrodatabase.com/blog/new-agreement-to-ensure-medicines-stay-cheaper-and-on-pharmacy-shelves 2024-12-20T05:04:42 https://maestrodatabase.com/blog/agenda-for-the-may-2022-pbac-intracycle-meeting 2022-02-11T07:28:26 https://maestrodatabase.com/blog/fda-grants-conatus-fast-track-designation-for-development-of-emricasan-in-nash-cirrhosis 2016-12-20T06:53:05 https://maestrodatabase.com/blog/pfizer-and-biontech-provide-update-on-rolling-submission-for-emergency-use-authorisation-of-their-covid-19-vaccine-in-children-6-months-through-4-years-of-age 2022-02-12T06:04:05 https://maestrodatabase.com/blog/harnessing-the-u-dot-s-taxpayer-to-fight-cancer-and-make-profits 2016-12-20T10:20:45 https://maestrodatabase.com/blog/novo-nordisk-receives-fda-approval-of-tresiba-insulin-degludec-injection-100-u-slash-ml-200-u-slash-ml-for-use-in-children-and-adolescents-with-diabetes 2016-12-20T10:32:18 https://maestrodatabase.com/blog/pfizer-receives-approval-in-the-european-union-for-nimenrix-meningococcal-group-a-c-w-135-and-y-conjugate-vaccine-in-infants-six-weeks-of-age-and-older 2016-12-20T10:25:42 https://maestrodatabase.com/blog/transparency-commission-publishes-its-opinion-for-kymriah 2018-12-16T06:31:13 https://maestrodatabase.com/blog/liberals-fail-to-clinch-10-year-health-deal-with-provinces 2016-12-20T11:28:51 https://maestrodatabase.com/blog/productivity-commissions-report-recommendations-would-hurt-australian-innovation-and-delay-access-to-breakthrough-medicines 2016-12-20T12:18:55 https://maestrodatabase.com/blog/hma-slash-ema-statement-on-approval-of-vaccines 2020-11-20T21:55:52 https://maestrodatabase.com/blog/update-on-remdesivir---ema-will-evaluate-new-data-from-solidarity-trial 2020-11-20T22:01:33 https://maestrodatabase.com/blog/industry-cites-outdated-standards-as-flaw-in-fdas-real-world-data-draft-guidance 2022-02-12T20:28:13 https://maestrodatabase.com/blog/trump-administration-announces-prescription-drug-payment-model-to-put-american-patients-first 2020-11-20T22:04:37 https://maestrodatabase.com/blog/health-economic-assessment-of-jemperli-in-endometrial-cancer 2022-02-12T20:37:19 https://maestrodatabase.com/blog/faced-with-unaffordable-drug-prices-tens-of-millions-buy-medicine-outside-u-dot-s 2016-12-20T19:56:34 https://maestrodatabase.com/blog/japan-to-step-up-drug-price-reviews-in-bid-to-curb-healthcare-costs 2016-12-20T19:51:58 https://maestrodatabase.com/blog/democrats-seek-trumps-cooperation-on-drug-price-reform 2016-12-20T19:53:45 https://maestrodatabase.com/blog/lillys-neutralising-antibody-bamlanivimab-ly-cov555-receives-interim-authorisation-from-health-canada-as-a-treatment-for-covid-19 2020-11-20T21:50:53 https://maestrodatabase.com/blog/cadth-calls-for-patient-input-on-submission-from-allergan-for-fetzima-levomilnacipran-hydrochloride 2016-08-03T03:29:12 https://maestrodatabase.com/blog/china-approves-use-of-pfizers-covid-drug-paxlovid 2022-02-12T20:24:03 https://maestrodatabase.com/blog/proposal-to-list-a-range-of-interventional-cardiology-products-supplied-by-abbott-laboratories-nz-ltd 2015-08-05T11:37:02 https://maestrodatabase.com/blog/pharmaceuticals-requiring-companion-diagnostics 2015-08-05T11:37:25 https://maestrodatabase.com/blog/patient-group-submissions-to-the-smc 2016-04-21T09:10:53 https://maestrodatabase.com/blog/fda-approves-new-treatment-for-hiv 2015-11-05T20:23:45 https://maestrodatabase.com/blog/evolution-of-evidence-underpins-pharmacs-pembrolizumab-funding-decision 2016-08-02T01:57:54 https://maestrodatabase.com/blog/bristol-myers-squibb-and-abbvie-receive-us-fda-breakthrough-therapy-designation-for-elotuzumab-an-investigational-humanized-monoclonal-antibody-for-multiple-myeloma 2015-08-05T11:37:06 https://maestrodatabase.com/blog/nhs-cost-watchdog-in-favour-of-bayers-xofigo 2015-08-05T11:37:08 https://maestrodatabase.com/blog/medicago-signs-agreements-with-the-government-of-canada-to-supply-up-to-76-million-doses-of-its-recombinant-plant-derived-covid-19-vaccine 2020-10-24T02:57:15 https://maestrodatabase.com/blog/pbs-statutory-pricing-changes 2016-03-11T09:41:30 https://maestrodatabase.com/blog/health_canada_approves_actemra__tocilizumab__for_children_with_a_rare_form_of_arthritis 2015-08-05T11:37:04 https://maestrodatabase.com/blog/nice-says-novartis-certican-costs-too-much-for-nhs 2015-08-05T11:37:19 https://maestrodatabase.com/blog/pbac-to-conduct-post-market-reviews-of-medicines-to-treat-pah-and-bdmards-to-treat-chronic-plaque-psoriasis 2016-04-22T11:07:46 https://maestrodatabase.com/blog/health_canada_issues_notice_of_compliance_for_sovaldi__sofosbuvir__for_the_treatment_of_chronic_hepatitis_c 2015-08-05T11:37:19 https://maestrodatabase.com/blog/pharmaceutical-benefits-scheme-listing-of-eculizumab-soliris-for-atypical-haemolytic-uraemic-syndrome 2015-08-05T11:37:26 https://maestrodatabase.com/blog/move-to-six-pbs-price-change-points 2015-08-05T11:37:05 https://maestrodatabase.com/blog/ema-tightens-rules-on-revolving-door-for-committee-members-and-experts 2015-08-05T11:37:23 https://maestrodatabase.com/blog/fda-files-supplemental-new-drug-application-for-boehringer-ingelheims-pradaxa-dabigatran-etexilate-mesylate-for-the-prophylaxis-of-deep-venous-thrombosis-and-pulmonary-embolism-after-hip-replacement-surgery 2015-08-05T11:37:10 https://maestrodatabase.com/blog/nice-opens-consultation-on-three-drugs-for-chronic-bowel-condition 2015-08-05T11:37:06 https://maestrodatabase.com/blog/major-step-forward-for-multiple-sclerosis-treatment 2015-08-05T11:37:05 https://maestrodatabase.com/blog/obamacares-kindest-critic 2016-07-17T10:33:51 https://maestrodatabase.com/blog/accelerated-drug-approval-and-health-inequality 2016-06-13T21:27:31 https://maestrodatabase.com/blog/fda-approves-additional-antibacterial-treatment-for-plague 2015-08-05T11:37:06 https://maestrodatabase.com/blog/impending-approval-of-a-dangerous-amphetamine-drug-for-use-in-weight-control-an-unacceptable-ema-recommendation-that-must-be-overturned 2015-08-05T11:37:10 https://maestrodatabase.com/blog/nice-recommends-cancer-drugs-fund-treatment-for-prostate-cancer-for-routine-nhs-use 2016-09-03T11:05:14 https://maestrodatabase.com/blog/mylan-confirms-fda-submission-of-anda-for-generic-advair-diskus 2016-01-12T20:06:29 https://maestrodatabase.com/blog/fda-accepts-supplemental-biologics-license-application-sbla-for-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-advanced-non-small-cell-lung-cancer-and-grants-priority-review 2015-08-05T11:37:26 https://maestrodatabase.com/blog/fda-shows-signs-of-cold-feet-over-emergency-authorisation-of-covid-19-vaccines 2020-10-24T03:00:38 https://maestrodatabase.com/blog/vermont-to-become-first-state-to-require-drug-makers-to-explain-price-increases 2016-05-15T08:58:25 https://maestrodatabase.com/blog/merck-and-pfizer-receive-fda-breakthrough-therapy-designation-for-avelumab-in-metastatic-merkel-cell-carcinoma 2015-11-18T20:46:23 https://maestrodatabase.com/blog/smc---june-2023-decisions 2023-06-12T21:02:17 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-march-2015-update 2015-08-05T11:37:20 https://maestrodatabase.com/blog/counting-the-cost-of-offering-better-care 2015-08-05T11:37:08 https://maestrodatabase.com/blog/ema-publishes-epar-for-sialanar 2016-09-30T21:37:16 https://maestrodatabase.com/blog/innovation-in-medicine-and-device-development-regulatory-review-and-use-of-clinical-advances 2016-09-27T11:27:16 https://maestrodatabase.com/blog/access-to-medicines-working-group-amwg-communique---16-june-2014 2015-08-05T11:37:04 https://maestrodatabase.com/blog/critics-target-institute-that-evaluates-price-value-of-drugs 2016-07-30T01:17:42 https://maestrodatabase.com/blog/simoctocog-alfa-for-haemophilia-a-no-suitable-data 2015-08-05T11:37:27 https://maestrodatabase.com/blog/kineret-receives-australian-regulatory-approval-for-use-in-systemic-juvenile-idiopathic-arthritis 2015-08-20T08:32:51 https://maestrodatabase.com/blog/budesonide-with-eformoterol-symbicort-turbuhaler-and-vannair-proposal-with-astra-zeneca 2015-12-14T20:14:14 https://maestrodatabase.com/blog/aflibercept-in-myopic-choroidal-neovascularisation-additional-benefits-not-covered 2016-03-01T20:39:45 https://maestrodatabase.com/blog/public-consultation-on-lsdp-review-issues-paper-extended-to-18-may-2015 2015-08-05T11:37:29 https://maestrodatabase.com/blog/medical-implant-reform-could-save-private-patients-millions 2015-08-05T11:37:03 https://maestrodatabase.com/blog/fast-tracked-skin-cancer-drug-pembrolizumab-gets-approval 2015-10-07T09:34:27 https://maestrodatabase.com/blog/changes_to_the_national_immunisation_schedule 2015-08-05T11:37:07 https://maestrodatabase.com/blog/industry_supports_greater_pbac_transparency 2015-08-05T11:37:27 https://maestrodatabase.com/blog/tga-publishes-2-new-australian-public-assessment-reports-auspars 2016-03-31T04:22:38 https://maestrodatabase.com/blog/agenda-for-the-2-march-2016-tc-meeting 2016-02-29T22:55:43 https://maestrodatabase.com/blog/poliovirus-therapy-against-cancer-given-breakthrough-status-by-fda 2016-05-20T03:20:06 https://maestrodatabase.com/blog/tga-publishes-2-new-auspars-1 2016-06-06T06:12:03 https://maestrodatabase.com/blog/eylea-aflibercept-injection-receives-fda-approval-for-macular-oedema-following-retinal-vein-occlusion 2015-08-05T11:37:17 https://maestrodatabase.com/blog/company-creates-bioethics-panel-on-trial-drugs 2015-08-05T11:37:22 https://maestrodatabase.com/blog/shortage-of-meningococcal-b-vaccine-reaches-australia 2016-07-14T10:24:18 https://maestrodatabase.com/blog/nhs_england_commissions_soliris__eculizumab__for_the_treatment_of_patients_with_atypical_haemolytic_uraemic_syndrome__ahus_ 2015-08-05T11:37:21 https://maestrodatabase.com/blog/relevant_additions_and_changes_from_the_1_october_2013_issue_of_the_schedule_of_pharmaceutical_benefits_have_been_added_to_maestro_australia 2015-08-05T11:37:28 https://maestrodatabase.com/blog/intercept-pharmaceuticals-files-for-oca-in-us-and-europe 2015-08-05T11:37:02 https://maestrodatabase.com/blog/improving-transparency-in-the-pharmaceutical-industry 2016-08-01T23:09:58 https://maestrodatabase.com/blog/biomarin-to-stop-developing-current-drugs-for-duchenne-muscular-dystrophy 2016-06-01T16:39:28 https://maestrodatabase.com/blog/submissions-open-for-the-life-saving-drugs-programme-post-market-review 2015-08-05T11:37:27 https://maestrodatabase.com/blog/fast-acting-insulin-now-available-on-pbs 2019-06-02T05:30:59 https://maestrodatabase.com/blog/nice-draft-guidance-recommends-nivolumab-for-advanced-skin-cancer 2016-01-23T01:33:34 https://maestrodatabase.com/blog/fda-approves-first-treatment-for-paediatric-functional-constipation 2023-06-12T22:21:43 https://maestrodatabase.com/blog/pfizer-just-jacked-up-prices-for-all-of-these-drugs 2016-01-11T20:34:06 https://maestrodatabase.com/blog/phathom-pharmaceuticals-announces-fda-acceptance-of-nda-resubmission-for-erosive-gerd 2023-06-12T22:41:03 https://maestrodatabase.com/blog/health-insurers-promises-of-quick-premium-relief-are-fantasy 2016-09-27T20:46:39 https://maestrodatabase.com/blog/how-long-can-cancer-patients-afford-to-wait 2015-08-05T11:37:08 https://maestrodatabase.com/blog/ventirx-pharmaceuticals-announces-fast-track-designation-granted-for-motolimod-vtx-2337-a-novel-immunotherapy-for-women-with-ovarian-cancer 2015-08-05T11:37:12 https://maestrodatabase.com/blog/is-canada-missing-out-an-assessment-of-drugs-approved-internationally-between-2016-and-2020-and-not-submitted-for-health-canada-review 2023-06-12T22:08:37 https://maestrodatabase.com/blog/cancer-drugs-fund-is-papering-over-the-cracks-say-campaigners 2015-08-05T11:37:03 https://maestrodatabase.com/blog/abbvies-investigational-hcv-regimen-receives-us-fda-breakthrough-therapy-designation 2016-09-30T12:24:26 https://maestrodatabase.com/blog/one-stop-shop-for-ai-and-digital-regulations-for-health-and-social-care-launched 2023-06-12T22:17:40 https://maestrodatabase.com/blog/valeant-makes-distribution-deal-with-walgreens 2015-12-16T06:11:47 https://maestrodatabase.com/blog/roches-ocrevus-ocrelizumab-shorter-2-hour-infusion-time-approved-in-europe 2020-05-29T07:38:50 https://maestrodatabase.com/blog/fda-approves-technivie-for-treatment-of-chronic-hepatitis-c-genotype-4 2015-08-05T11:37:26 https://maestrodatabase.com/blog/icer-releases-final-report-on-diabetes-prevention-programs 2016-07-26T00:15:26 https://maestrodatabase.com/blog/raludotatug-deruxtecan-granted-breakthrough-therapy-designation-by-us-fda-for-patients-with-cdh6-expressing-platinum-resistant-ovarian-primary-peritoneal-or-fallopian-tube-cancers-previously-treated-with-bevacizumab 2025-09-15T11:12:46 https://maestrodatabase.com/blog/recently-added-forthcoming-submissions---may-2014-update 2015-08-05T11:37:22 https://maestrodatabase.com/blog/for-prescription-drug-makers-price-increases-drive-revenue 2015-10-06T22:19:33 https://maestrodatabase.com/blog/nice-updated-guidance-recommends-imatinib-for-digestive-system-cancers 2015-08-05T11:37:09 https://maestrodatabase.com/blog/genmab-announces-european-conditional-marketing-authorization-for-darzalex-daratumumab-for-multiple-myeloma 2016-05-24T10:33:40 https://maestrodatabase.com/blog/fda-approves-modified-antihemophilic-factor-for-hemophilia-a 2015-11-14T19:23:31 https://maestrodatabase.com/blog/nalmefene-for-alcohol-dependence-added-benefit-not-proven 2015-08-05T11:37:06 https://maestrodatabase.com/blog/tc-opinion-on-lyxumia-finally-published 2016-09-27T21:16:35 https://maestrodatabase.com/blog/agenda-for-the-1-july-2015-tc-meeting 2015-08-05T11:37:24 https://maestrodatabase.com/blog/company-withholds-life-saving-drug-in-row-with-australian-government-over-its-use 2015-08-05T11:37:02 https://maestrodatabase.com/blog/fda-accepts-for-review-fresenius-kabis-first-biosimilar-regulatory-submission-for-msb11455-a-biosimilar-candidate-of-pegfilgrastim 2020-05-29T07:05:41 https://maestrodatabase.com/blog/adapt-pharma-submits-nda-to-fda-for-narcan-naloxone-nasal-spray 2015-08-05T11:37:06 https://maestrodatabase.com/blog/the-rise-of-patient-reported-outcomes-in-oncology 2016-06-06T07:22:57 https://maestrodatabase.com/blog/onivyde-irinotecan-liposome-for-injection-has-received-approval-in-canada-for-the-treatment-of-metastatic-adenocarcinoma-of-the-pancreas-in-the-post-gemcitabine-setting 2017-08-14T08:52:17 https://maestrodatabase.com/blog/fda-approves-first-drug-to-image-tau-pathology-in-patients-being-evaluated-for-alzheimers-disease 2020-05-29T07:11:51 https://maestrodatabase.com/blog/health-canada-releases-final-version-of-controversial-regulations-for-controlling-drug-prices 2020-10-24T03:49:19 https://maestrodatabase.com/blog/dems-v-gop-on-new-drugs 2016-08-14T22:40:58 https://maestrodatabase.com/blog/abbvies-humira-adalimumab-receives-us-fda-approval-for-extension-of-polyarticular-juvenile-idiopathic-arthritis-indication-to-patients-ages-2-years-and-older 2015-08-05T11:37:19 https://maestrodatabase.com/blog/single-payer-or-bust 2017-08-14T09:11:34 https://maestrodatabase.com/blog/fda-approves-first-blood-test-to-detect-gene-mutation-associated-with-non-small-cell-lung-cancer 2016-06-03T01:03:13 https://maestrodatabase.com/blog/smc-industry-engagement-event-1 2016-04-12T12:09:19 https://maestrodatabase.com/blog/health-insurers-get-more-time-to-calculate-increases-for-2018 2017-08-14T09:08:49 https://maestrodatabase.com/blog/world-aids-day-1-december-2019---more-support-for-australians-living-with-hiv 2019-11-26T23:51:52 https://maestrodatabase.com/blog/novartis-heart-failure-medicine-lcz696-granted-fda-priority-review 2015-08-05T11:37:05 https://maestrodatabase.com/blog/nice-set-to-recommend-type-2-diabetes-drug-empagliflozin 2015-08-05T11:37:28 https://maestrodatabase.com/blog/rare-disorders-process-yields-first-funding-decision 2015-09-16T04:25:20 https://maestrodatabase.com/blog/costs-eat-into-private-health-incentives 2017-08-14T09:16:23 https://maestrodatabase.com/blog/commission_of_audit_must_look_forward_on_pbs 2015-08-05T11:37:04 https://maestrodatabase.com/blog/a-new-name-for-a-new-era 2015-08-05T11:37:04 https://maestrodatabase.com/blog/new-cancer-treatment-with-the-precision-drug-vitrakvi-is-included-in-the-high-cost-protection 2020-10-24T03:26:31 https://maestrodatabase.com/blog/nice-asks-for-more-information-on-vortioxetine-hydrobromide-brintellix-for-major-depressive-disorder 2015-08-05T11:37:02 https://maestrodatabase.com/blog/kiwis-hit-by-medication-shortages 2020-10-24T03:29:57 https://maestrodatabase.com/blog/chmp-grants-positive-opinion-for-clovis-oncologys-rubraca-rucaparib-tablets 2018-03-23T23:34:34 https://maestrodatabase.com/blog/review_of_life_saving_drugs_programme 2015-08-05T11:37:07 https://maestrodatabase.com/blog/cdec-recommends-stiripentol-dravit-for-severe-myoclonic-epilepsy-in-infancy-dravet-syndrome 2015-08-05T11:37:22 https://maestrodatabase.com/blog/fda-approves-foundationonecdx-as-companion-diagnostic-for-vitrakvi-larotrectinib-to-aid-in-identifying-ntrk-fusion-positive-patients 2020-10-24T03:35:47 https://maestrodatabase.com/blog/anika-therapeutics-announces-health-canada-approval-of-cingal-for-the-treatment-of-pain-associated-with-osteoarthritis-of-the-knee 2015-11-04T06:04:42 https://maestrodatabase.com/blog/better-monitoring-of-biological-medicines 2016-08-15T21:08:21 https://maestrodatabase.com/blog/nice-sets-out-proposed-technology-assessment-fees 2016-09-27T21:07:04 https://maestrodatabase.com/blog/viiv-healthcare-gains-chmp-positive-opinion-for-juluca-dolutegravir-slash-rilpivirine-in-europe 2018-03-23T23:29:36 https://maestrodatabase.com/blog/csl-chief-paul-perreault-thinking-outside-the-square 2015-08-05T11:37:06 https://maestrodatabase.com/blog/expert-committee-hits-back-at-industry-push-to-fast-track-listings-for-cancer-drugs 2015-08-05T11:37:17 https://maestrodatabase.com/blog/sandoz-receives-positive-chmp-opinion-for-proposed-biosimilar-infliximab 2018-03-23T23:42:46 https://maestrodatabase.com/blog/fda-approves-first-prescription-drug-made-through-3d-printing 2015-08-05T11:37:15 https://maestrodatabase.com/blog/astrazeneca-withdraws-cancer-drug-after-differences-of-opinion-with-regulator 2016-09-21T13:10:20 https://maestrodatabase.com/blog/abbvies-vraylar-cariprazine-now-publicly-reimbursed-in-alberta 2025-09-16T02:49:01 https://maestrodatabase.com/blog/hepatitis-c-drug-sofosbuvir-approved-for-use-on-nhs 2015-08-05T11:37:29 https://maestrodatabase.com/blog/tga-publishes-auspars-for-etanercept-enbrel-and-secukinumab-cosentyx 2015-10-26T20:53:29 https://maestrodatabase.com/blog/arbor-pharmaceuticals-announces-fda-approval-of-sotylize 2015-08-05T11:37:03 https://maestrodatabase.com/blog/patisiran-sodium-in-hereditary-transthyretin-amyloidosis-less-benefit-than-vutrisiran 2024-03-02T02:22:28 https://maestrodatabase.com/blog/astrazeneca-pushes-to-protect-crestor-from-generic-competition 2016-06-28T12:19:46 https://maestrodatabase.com/blog/amgen-receives-positive-chmp-opinion-recognising-that-repatha-evolocumab-prevents-heart-attacks-and-strokes 2018-03-24T00:01:07 https://maestrodatabase.com/blog/erytech-submits-ema-marketing-authorisation-application-for-graspa-to-treat-acute-lymphoblastic-leukaemia 2015-09-15T05:17:33 https://maestrodatabase.com/blog/meeting-highlights-from-the-committee-for-medicinal-products-for-human-use-chmp-20-23-april-2015 2015-08-05T11:37:30 https://maestrodatabase.com/blog/maestro___now_housed_on_local_server 2015-08-05T11:37:11 https://maestrodatabase.com/blog/same-data-different-interpretations 2016-08-30T01:22:49 https://maestrodatabase.com/blog/the-brave-new-world-of-biosimilars 2016-06-02T01:59:22 https://maestrodatabase.com/blog/amgen-and-allergan-receive-positive-chmp-opinion-for-abp-980-biosimilar-herceptin-for-the-treatment-of-three-types-of-cancer 2018-03-23T23:48:30 https://maestrodatabase.com/blog/fda-grants-breakthrough-therapy-designation-to-eisais-lenvatinib-for-the-potential-treatment-of-metastatic-renal-cell-carcinoma 2015-08-05T11:37:08 https://maestrodatabase.com/blog/decision-to-award-sole-supply-to-zoladex-and-reference-price-eligard-and-lucrin 2016-08-30T03:34:28 https://maestrodatabase.com/blog/tga-intends-to-update-medicine-ingredient-names-to-align-with-international-usage 2016-04-06T07:19:46 https://maestrodatabase.com/blog/cosentyx-first-il-17a-antagonist-for-moderate-to-severe-plaque-psoriasis-now-approved-in-canada 2015-08-05T11:37:10 https://maestrodatabase.com/blog/loxo-oncology-receives-breakthrough-therapy-designation-from-u-dot-s-food-and-drug-administration-for-loxo-101 2016-07-18T07:43:16 https://maestrodatabase.com/blog/icer-final-report-on-car-t-therapies-highlights-need-for-systemwide-changes-to-ensure-affordability-and-access-to-innovative-one-time-therapies 2018-03-24T00:17:51 https://maestrodatabase.com/blog/actelion-receives-therapeutic-goods-administration-approval-in-australia-for-opsumit-macitentan-in-pulmonary-arterial-hypertension 2015-08-05T11:37:16 https://maestrodatabase.com/blog/us-fda-approves-once-daily-jentadueto-xr-linagliptin-and-metformin-hydrochloride-extended-release-tablets-for-adults-with-type-2-diabetes 2016-06-01T16:53:30 https://maestrodatabase.com/blog/eu-approval-makes-novo-nordisks-oral-semaglutide-the-first-and-only-oral-glp-1-ra-to-reduce-cardiovascular-death-heart-attack-and-stroke 2025-09-15T20:48:21 https://maestrodatabase.com/blog/nice_proposes_to_recommend_another_treatment_for_people_with_multiple_myeloma 2015-08-05T11:37:19 https://maestrodatabase.com/blog/petition-targets-access-to-life-saving-cancer-drug 2015-12-31T22:03:34 https://maestrodatabase.com/blog/fdas-foray-into-big-data-still-maturing 2016-04-20T20:48:31 https://maestrodatabase.com/blog/icer-to-undertake-special-report-on-crohns-disease-and-ulcerative-colitis-for-cms-as-part-of-public-comment-process-on-medicare-drug-price-negotiations 2025-09-15T21:05:32 https://maestrodatabase.com/blog/trump-policy-change-is-a-win-for-drug-makers 2018-03-24T00:07:54 https://maestrodatabase.com/blog/fda-grants-priority-review-for-amgens-supplemental-biologics-license-application-for-blinctyo-blinatumomab 2016-05-04T11:08:05 https://maestrodatabase.com/blog/making-the-most-of-clinical-trial-data 2016-04-12T08:37:53 https://maestrodatabase.com/blog/uk-government-reaches-deal-with-gsk-for-menb-jab 2015-08-05T11:37:18 https://maestrodatabase.com/blog/proposals-to-list-hepatitis-c-treatments 2016-05-04T00:55:41 https://maestrodatabase.com/blog/merck-announces-fda-acceptance-of-biologics-license-application-for-investigational-house-dust-mite-sublingual-allergy-immunotherapy-tablet 2016-04-13T12:21:32 https://maestrodatabase.com/blog/revance-submits-biologics-license-application-to-the-fda-for-daxi-to-treat-glabellar-frown-lines 2019-11-27T03:38:52 https://maestrodatabase.com/blog/parliamentary_budget_office_confirms_pbs_spending_not_the_villain 2015-08-05T11:37:10 https://maestrodatabase.com/blog/proposal-for-azacitidine-lenalidomide-and-thalidomide 2015-08-05T11:37:02 https://maestrodatabase.com/blog/baxter-submits-application-for-us-fda-approval-of-bax-855-extended-half-life-recombinant-fviii-based-on-advate-for-hemophilia-a 2015-08-05T11:37:09 https://maestrodatabase.com/blog/costly-cancer-drugs-may-be-cut-from-special-funding-list 2015-08-05T11:37:20 https://maestrodatabase.com/blog/maestro-australia-pbac---links-to-msac-assessments 2015-08-05T11:37:20 https://maestrodatabase.com/blog/meeting-highlights-from-the-committee-for-medicinal-products-for-human-use-16-19-november-2015 2015-11-21T05:33:20 https://maestrodatabase.com/blog/how-to-navigate-specialist-fees-in-the-private-health-system 2019-11-27T08:04:09 https://maestrodatabase.com/blog/improving-safety-of-medicines-across-europe 2015-08-05T11:37:16 https://maestrodatabase.com/blog/advancing-international-collaboration-on-covid-19-real-world-evidence-and-observational-studies 2021-06-04T20:53:57 https://maestrodatabase.com/blog/smc-allows-wider-use-of-gedeon-richters-esmya-ulipristal-acetate 2016-03-23T19:55:55 https://maestrodatabase.com/blog/pharmac-threatened-with-legal-action-to-fund-life-saving-drug 2019-06-02T10:56:35 https://maestrodatabase.com/blog/decision-to-fund-febuxostat-adenuric-for-treatment-resistant-gout 2015-08-05T11:37:24 https://maestrodatabase.com/blog/well-well-well---heres-a-way-to-make-health-insurance-affordable 2019-11-27T08:00:49 https://maestrodatabase.com/blog/newron-parkinsons-drug-xadago-gets-europe-okay 2015-08-05T11:37:19 https://maestrodatabase.com/blog/alks-partner-msd-submits-us-license-application-for-investigational-house-dust-mite-slit-tablet 2016-02-10T20:26:06 https://maestrodatabase.com/blog/changes-to-wastage-funding 2019-11-27T07:51:26 https://maestrodatabase.com/blog/roches-gazyvaro-bayers-eylea-backed-for-nhs-use 2015-08-05T11:37:02 https://maestrodatabase.com/blog/cancer-drugs-fund-shake-up-could-put-thousands-at-risk-experts-claim-reforms-would-have-devastating-consequences-amid-fears-life-saving-treatment-could-be-restricted 2016-01-19T20:16:00 https://maestrodatabase.com/blog/access-to-medicines-working-group-communiques 2016-09-08T02:38:42 https://maestrodatabase.com/blog/mercks-keytruda-pembrolizumab-now-approved-in-china-for-first-line-treatment-of-metastatic-squamous-non-small-cell-lung-cancer-in-combination-with-chemotherapy 2019-11-27T19:58:55 https://maestrodatabase.com/blog/health-canada-approves-daklinza-daclatasvir-for-the-treatment-of-chronic-hepatitis-c-infection-across-multiple-genotypes-including-genotype-3 2015-08-20T21:50:18 https://maestrodatabase.com/blog/vertex-receives-complete-response-letter-from-us-fda-for-use-of-kalydeco-ivacaftor-in-people-with-cystic-fibrosis-ages-2-and-older-with-one-of-23-residual-function-mutations 2016-02-05T21:44:33 https://maestrodatabase.com/blog/january_tender_notification 2015-08-05T11:37:16 https://maestrodatabase.com/blog/evofem-biosciences-resubmits-new-drug-application-to-u-dot-s-fda-for-amphora-for-the-prevention-of-pregnancy 2019-11-27T19:52:19 https://maestrodatabase.com/blog/nice-group-publishes-final-report-on-which-values-influence-decisions-on-how-health-and-social-care-resources-are-shared-out 2015-08-05T11:37:09 https://maestrodatabase.com/blog/pbac-guidelines-review-1 2016-03-11T08:19:46 https://maestrodatabase.com/blog/how-president-trump-is-delivering-results-on-drug-prices 2019-06-02T11:06:00 https://maestrodatabase.com/blog/our-drug-policy-often-prioritises-eliminating-rare-disease-one-researcher-asks-is-that-the-right-goal 2019-11-27T19:48:59 https://maestrodatabase.com/blog/nice-gives-green-light-to-innovative-drug-for-common-heart-condition 2015-12-13T07:05:24 https://maestrodatabase.com/blog/how-a-billionaire-couple-greased-the-skids-for-nancy-pelosis-drug-pricing-bill 2019-11-27T20:07:46 https://maestrodatabase.com/blog/price-cut-call-as-cancer-drug-rejected-for-routine-nhs-use 2015-08-05T11:37:14 https://maestrodatabase.com/blog/petition-calls-on-roche-to-cut-breast-cancer-drug-price 2015-08-05T11:37:06 https://maestrodatabase.com/blog/blincyto-is-the-first-and-only-bispecific-cd19-directed-cd3-t-cell-engager-bite-immunotherapy-approved-by-health-canada 2016-01-13T06:26:25 https://maestrodatabase.com/blog/viagra-for-women-is-backed-by-an-fda-panel 2015-08-05T11:37:15 https://maestrodatabase.com/blog/ipsen-announces-the-acceptance-by-the-european-medicines-agency-of-the-marketing-authorization-application-for-telotristat-etiprate-to-treat-carcinoid-syndrome-caused-by-neuroendocrine-tumors-in-combination-with-somatostatin-analogues 2016-07-19T07:05:30 https://maestrodatabase.com/blog/astellas-announces-the-approval-of-xtandi-enzalutamide-by-the-china-national-medical-products-administration-approval-based-on-asian-prevail-study-of-men-with-metastatic-castration-resistant-prostate-cancer 2019-11-27T20:03:28 https://maestrodatabase.com/blog/biomarin-completes-rolling-nda-submission-to-fda-for-drisapersen-for-treatment-of-duchenne-muscular-dystrophy-amenable-to-exon-51-skipping 2015-08-05T11:37:17 https://maestrodatabase.com/blog/public-summary-documents-pbac-november-2015-meeting 2016-03-06T00:25:54 https://maestrodatabase.com/blog/pfizer-australia-lipitor-case-dismissed 2015-08-05T11:37:13 https://maestrodatabase.com/blog/sanofi-new-drug-application-for-lixisenatide-accepted-for-review-by-fda 2015-09-29T09:38:45 https://maestrodatabase.com/blog/agenda-for-the-may-2016-chmp-meeting 2016-05-23T16:36:45 https://maestrodatabase.com/blog/additional-benefits-of-canagliflozin-are-not-occupied 2015-08-05T11:37:14 https://maestrodatabase.com/blog/first-in-class-treatment-to-lower-cholesterol 2015-08-05T11:37:04 https://maestrodatabase.com/blog/call-for-nhs-to-haggle-with-drug-companies-over-price-of-new-treatments 2016-08-02T05:26:46 https://maestrodatabase.com/blog/nice-turns-down-gsks-iv-benlysta-for-systemic-lupus 2021-06-04T21:06:32 https://maestrodatabase.com/blog/early-benefit-assessment-increases-transparency-for-study-data 2015-08-05T11:37:14 https://maestrodatabase.com/blog/pharma-execs-tell-researchers-that-multiple-sclerosis-drug-pricing-is-based-on-competition-not-r-and-d-costs 2019-11-27T20:12:55 https://maestrodatabase.com/blog/takedas-adcetris-brentuximab-vedotin-is-the-first-ultra-orphan-medicine-to-be-accepted-by-the-smc-via-the-new-assessment-process 2015-08-05T11:37:06 https://maestrodatabase.com/blog/different-models-same-results-considerations-when-choosing-between-approaches-to-model-cost-effectiveness-of-chimeric-antigen-receptor-t-cell-therapy-versus-standard-of-care 2024-11-16T06:43:40 https://maestrodatabase.com/blog/cancer-drugs-the-case-for-keytruda 2016-03-03T18:22:09 https://maestrodatabase.com/blog/apricus-biosciences-announces-approval-of-vitaros-for-the-treatment-of-erectile-dysfunction-in-twelve-additional-countries 2015-08-11T21:15:50 https://maestrodatabase.com/blog/mhra-grants-first-approval-via-the-new-international-recognition-procedure-in-30-days 2024-03-02T22:13:40 https://maestrodatabase.com/blog/survey-of-healthcare-experiences-of-australian-adults-living-with-rare-diseases 2016-04-19T05:45:01 https://maestrodatabase.com/blog/obamas-pointless-cancer-moonshot 2016-05-27T12:44:21 https://maestrodatabase.com/blog/campaign-wants-patients-to-have-more-influence-on-pbs 2019-06-02T21:22:47 https://maestrodatabase.com/blog/drug-industry-group-starts-advertising-campaign-to-defend-its-pricing 2016-09-07T21:34:51 https://maestrodatabase.com/blog/new-medicine-approval-process-to-allow-quicker-access-to-breakthrough-drugs 2016-09-14T21:33:54 https://maestrodatabase.com/blog/nice-rejects-celgenes-revlimid-again 2015-08-05T11:37:08 https://maestrodatabase.com/blog/fda-approves-oxycontin-for-children-as-young-as-11 2015-08-15T01:36:25 https://maestrodatabase.com/blog/fda-approves-praluent-to-treat-certain-patients-with-high-cholesterol 2015-08-05T11:37:23 https://maestrodatabase.com/blog/government-slams-big-drug-companies-for-pushing-costly-cancer-drugs-with-limited-benefits 2015-08-05T11:37:10 https://maestrodatabase.com/blog/ema-publishes-annual-report-on-its-interaction-with-patients-consumers-health-care-professionals-and-their-organisations 2016-06-21T21:55:07 https://maestrodatabase.com/blog/nice_has_issued_new_draft_guidance_that_does_not_recommend_lenalidomide__revlimid__for_treating_myelodysplastic_syndromes 2015-08-05T11:37:25 https://maestrodatabase.com/blog/fda-approves-nucala-to-treat-severe-asthma 2015-11-05T10:27:47 https://maestrodatabase.com/blog/government-review-describes-nice-as-a-respected-trusted-high-performing-organisation 2015-08-05T11:37:24 https://maestrodatabase.com/blog/fda-accepts-marathon-pharmaceuticals-new-drug-applications-for-deflazacort-for-the-treatment-of-duchenne-muscular-dystrophy-and-grants-priority-review 2016-08-11T11:47:56 https://maestrodatabase.com/blog/drug-companies-in-us-spent-millions-pushing-for-weight-loss-drug-approvals-investigative-report-finds 2015-08-05T11:37:02 https://maestrodatabase.com/blog/improving-bioequivalence-studies 2015-08-05T11:37:02 https://maestrodatabase.com/blog/scottish_medicines_consortium_accepts_iluvien_for_national_health_service_scotland 2015-08-05T11:37:18 https://maestrodatabase.com/blog/public-summary-documents-march-2016-meeting 2016-07-15T06:52:25 https://maestrodatabase.com/blog/time-to-fess-up-that-panadol-osteo-de-listing-was-a-mistake 2016-01-11T20:46:42 https://maestrodatabase.com/blog/shire-announces-fda-approval-of-adynovate-with-baxject-iii-reconstitution-system 2016-08-01T23:19:56 https://maestrodatabase.com/blog/cadth-calls-for-patient-input-on-submissions-from-boehringer-ingelheim-servier 2016-04-04T21:40:42 https://maestrodatabase.com/blog/fda-authorises-lower-1-200-mg-intravenous-and-subcutaneous-dose-of-regen-cov-casirivimab-and-imevimab-antibody-cocktail-to-treat-patients-with-covid-19 2021-06-04T22:06:16 https://maestrodatabase.com/blog/updates-to-the-guidelines-for-the-economic-evaluation-of-health-technologies-canada 2015-12-07T23:21:40 https://maestrodatabase.com/blog/inflation-reduction-act-and-us-drug-pricing 2022-09-11T21:05:35 https://maestrodatabase.com/blog/independent-group-finds-multiple-myeloma-drugs-too-costly-in-us 2016-05-09T13:38:55 https://maestrodatabase.com/blog/pharmac-201516-invitation-to-tender-medical 2015-08-05T11:37:16 https://maestrodatabase.com/blog/health-canada-approves-prorkambi-lumacaftorivacaftor-the-first-medicine-to-treat-the-underlying-cause-of-cystic-fibrosis-for-people-ages-12-and-older-with-two-copies-of-the-f508del-mutation 2016-01-27T20:22:05 https://maestrodatabase.com/blog/2016-marketplace-affordability-snapshot 2015-10-26T23:54:32 https://maestrodatabase.com/blog/tagrisso-osimertinib-approved-in-eu-as-first-in-class-treatment-for-patients-with-egfr-t790m-mutation-positive-metastatic-non-small-cell-lung-cancer 2016-02-03T10:56:37 https://maestrodatabase.com/blog/cadth-publishes-final-recommendation-for-lenvima-lenvatinib-mesylate 2016-09-24T03:12:39 https://maestrodatabase.com/blog/nice-turns-down-kidney-cancer-drugs 2017-08-14T11:19:22 https://maestrodatabase.com/blog/you-can-call-it-the-female-viagra-but-the-libido-pill-addyi-wont-come-close-to-viagras-impact 2015-08-19T21:32:23 https://maestrodatabase.com/blog/call-for-patient-input-18 2015-08-05T11:37:05 https://maestrodatabase.com/blog/2016-october-price-disclosure-cycle-indicative-prices 2016-07-28T12:12:02 https://maestrodatabase.com/blog/smc-introductory-industry-engagement-event-september-2016 2016-09-14T03:08:44 https://maestrodatabase.com/blog/fda-accepts-amgens-supplemental-biologics-license-application-for-the-expanded-use-of-enbrel-etanercept-to-treat-paediatric-patients-with-chronic-severe-plaque-psoriasis 2016-03-11T21:23:31 https://maestrodatabase.com/blog/seeking-tga-statutory-advisory-committee-members 2015-08-05T11:37:05 https://maestrodatabase.com/blog/fda-approves-first-treatment-for-patients-with-plasminogen-deficiency-a-rare-genetic-disorder 2021-06-04T23:06:24 https://maestrodatabase.com/blog/new-treatment-funded-for-severe-gout 2015-08-05T11:37:06 https://maestrodatabase.com/blog/updated-submission-deadlines-and-pbs-price-change-fact-sheet 2015-08-05T11:37:15 https://maestrodatabase.com/blog/insulin-degludec-plus-liraglutide-again-no-hint-of-added-benefit-in-type-2-diabetes 2015-11-18T20:29:23 https://maestrodatabase.com/blog/ms-patients-granted-lifeline-with-effective-drug-listed-on-pbs 2020-10-24T21:29:09 https://maestrodatabase.com/blog/empagliflozin-in-type-2-diabetes-additional-benefits-not-covered 2015-08-05T11:37:01 https://maestrodatabase.com/blog/novartis-heart-failure-medicine-lcz696-granted-accelerated-assessment-by-chmp-in-europe 2015-08-05T11:37:10 https://maestrodatabase.com/blog/fda-approves-new-antiplatelet-drug-used-during-heart-procedure 2015-08-05T11:37:13 https://maestrodatabase.com/blog/europe-to-boost-international-co-operation-on-generics 2015-08-05T11:37:24 https://maestrodatabase.com/blog/cadth-recommends-the-reimbursement-of-descovy-emtricitabine-with-tenofovir-alafenamide-fumarate 2016-08-29T11:25:45 https://maestrodatabase.com/blog/nice-recommends-novartis-lung-cancer-drug-zykadia 2016-05-20T21:31:15 https://maestrodatabase.com/blog/health-movement-in-south-korea-fights-for-universal-access-to-medicines 2022-09-11T21:20:26 https://maestrodatabase.com/blog/smc-announces-more-forthcoming-submissions-4 2016-04-14T21:07:04 https://maestrodatabase.com/blog/nice-nhs-england-consult-on-cancer-drugs-fund-revamp 2015-11-19T20:53:34 https://maestrodatabase.com/blog/seres-therapeutics-receives-fda-breakthrough-therapy-designation-for-its-lead-product-candidate-ser-109 2015-08-05T11:37:29 https://maestrodatabase.com/blog/exits-from-pharmaceutical-benefits-on-1-october-2022 2022-09-11T21:33:42 https://maestrodatabase.com/blog/australians-with-hepatitis-c-hope-new-drugs-will-be-approved-by-pharmaceutical-benefits-scheme 2015-08-05T11:37:05 https://maestrodatabase.com/blog/tga-approves-promethium-progesterone 2016-07-07T23:35:53 https://maestrodatabase.com/blog/nice_says_yes_to_dapagliflozin_for_some_people_with_type_2_diabetes_in_final_draft_guidance 2015-08-05T11:37:27 https://maestrodatabase.com/blog/microbion-corporation-announces-fda-has-granted-fast-track-designation-to-mbn-101-for-the-adjunctive-treatment-of-moderate-and-severe-diabetic-foot-ulcer-infections 2016-08-04T21:28:30 https://maestrodatabase.com/blog/pilot-expert-committee-to-support-decision-making-across-the-drug-life-cycle 2023-06-13T03:50:31 https://maestrodatabase.com/blog/australian_statistics_on_medicines_2011 2015-08-05T11:37:12 https://maestrodatabase.com/blog/pbs-hospital-medication-charts 2016-06-24T08:08:23 https://maestrodatabase.com/blog/u-dot-s-fda-approves-lorbrena-lorlatinib-for-previously-treated-alk-positive-metastatic-non-small-cell-lung-cancer 2018-11-04T01:22:26 https://maestrodatabase.com/blog/nice-recommends-the-use-of-canagliflozin-hemihydrate-invokana-when-used-in-combination-with-other-anti-diabetic-drugs 2015-08-05T11:37:19 https://maestrodatabase.com/blog/cancer-patient-pays-5000-every-two-weeks-for-treatment-costing-others-just-620 2016-05-09T07:35:33 https://maestrodatabase.com/blog/house-conservatives-hope-to-revive-obamacare-repeal-vote 2017-08-15T05:35:54 https://maestrodatabase.com/blog/fda-approves-new-drug-treatment-for-chronic-weight-management-first-since-2014 2021-06-05T01:21:59 https://maestrodatabase.com/blog/takedas-investigational-oral-proteasome-inhibitor-ixazomib-citrate-granted-breakthrough-therapy-designation-by-us-fda-for-relapsed-or-refractory-systemic-light-chain-amyloidosis 2015-08-05T11:37:11 https://maestrodatabase.com/blog/incyte-announces-acceptance-and-priority-review-of-nda-for-pemigatinib-as-a-treatment-for-patients-with-cholangiocarcinoma 2019-11-28T11:41:32 https://maestrodatabase.com/blog/access-to-unregistered-drugs-in-australia 2017-08-15T07:28:51 https://maestrodatabase.com/blog/victoza-receives-positive-chmp-opinion-for-use-in-adults-with-type-2-diabetes-and-moderate-renal-impairment 2015-08-05T11:37:07 https://maestrodatabase.com/blog/accelerated-drug-approval-and-health-inequality-1 2016-07-05T21:10:27 https://maestrodatabase.com/blog/posting-of-key-milestones-for-cdr-projects 2017-08-15T06:35:32 https://maestrodatabase.com/blog/health-canada-approves-ofev-nintedanib-the-first-and-only-therapy-in-canada-to-slow-the-rate-of-decline-in-pulmonary-function-in-patients-with-systemic-sclerosis-associated-ild 2019-11-28T11:37:47 https://maestrodatabase.com/blog/nhs-watchdog-ready-to-impose-hefty-fees-for-approving-drugs 2016-10-03T11:20:13 https://maestrodatabase.com/blog/characteristics-of-pre-approval-and-post-approval-studies-for-drugs-granted-accelerated-approval-by-the-us-food-and-drug-administration 2017-08-15T20:48:27 https://maestrodatabase.com/blog/health-overhaul-after-policy-review 2016-09-22T21:04:56 https://maestrodatabase.com/blog/icer-opens-national-call-for-proposed-improvements-to-its-value-assessment-framework 2016-07-14T21:09:17 https://maestrodatabase.com/blog/amgen-submits-new-drug-application-for-novel-intravenous-calcimimetic-etelcalcetide-amg-416 2015-08-25T22:41:38 https://maestrodatabase.com/blog/shire-announces-submission-of-lifitegrast-marketing-authorisation-application-for-treatment-of-dry-eye-disease-in-europe 2017-08-15T13:53:13 https://maestrodatabase.com/blog/which-drug-prices-should-medicare-negotiate-a-too-little-or-too-late-approach 2019-11-28T20:01:19 https://maestrodatabase.com/blog/us-fda-approves-new-indication-for-the-use-of-xtandi-enzalutamide-capsules-for-patients-with-metastatic-castration-resistant-prostate-cancer 2015-08-05T11:37:22 https://maestrodatabase.com/blog/novartis-announces-fda-approval-of-xolair-omalizumab-for-paediatric-allergic-asthma 2016-07-08T05:14:01 https://maestrodatabase.com/blog/are-rumours-of-abbvies-humira-price-cuts-what-they-seem 2018-11-04T20:53:39 https://maestrodatabase.com/blog/outcomes-from-the-july-2014-pbac-meeting 2015-08-05T11:37:11 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-releases-draft-evidence-report-on-cognitive-and-mind-body-therapies-for-treatment-of-chronic-low-back-and-neck-pain 2017-08-15T20:53:23 https://maestrodatabase.com/blog/advancing-legislation-on-drug-pricing----is-there-a-path-forward 2019-11-28T19:58:52 https://maestrodatabase.com/blog/tga-approves-zepatier 2016-08-31T07:15:09 https://maestrodatabase.com/blog/hikma-completes-its-fda-response-for-generic-advair 2019-11-28T11:45:24 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-november-2014-update 2015-08-05T11:37:27 https://maestrodatabase.com/blog/why-drug-prices-in-america-are-so-high 2016-09-13T21:02:45 https://maestrodatabase.com/blog/fda-extends-use-of-promacta-in-young-children-with-rare-blood-disorder 2015-08-24T21:28:02 https://maestrodatabase.com/blog/nice-issues-final-guidance-on-pomalidomide-imnovid-for-blood-cancer 2015-08-05T11:37:03 https://maestrodatabase.com/blog/heart-failure-treatment-entresto-lcz696-shown-to-reduce-the-risk-of-cardiovascular-death-and-hospitalisation-approved-by-health-canada 2015-10-07T20:34:53 https://maestrodatabase.com/blog/new-class-of-cholesterol-drugs-should-cost-much-less-report-says 2015-09-10T05:25:58 https://maestrodatabase.com/blog/fda-clears-first-test-to-detect-specific-genetic-markers-for-certain-antibiotic-resistant-bacteria-directly-from-clinical-specimens 2016-06-29T22:31:26 https://maestrodatabase.com/blog/verrica-pharmaceuticals-announces-fda-filing-acceptance-of-new-drug-application-for-vp-102-for-the-treatment-of-molluscum-contagiosum 2019-11-28T20:14:34 https://maestrodatabase.com/blog/fda-grants-genentechs-avastin-priority-review-for-certain-types-of-cervical-cancer 2015-08-05T11:37:18 https://maestrodatabase.com/blog/smc-august-2016-decisions 2016-08-08T21:12:29 https://maestrodatabase.com/blog/smc-october-2015-decisions-news-release 2015-10-12T20:34:49 https://maestrodatabase.com/blog/fda-approves-baxters-hyqvia-for-treatment-of-adults-with-primary-immunodeficiency 2015-08-05T11:37:06 https://maestrodatabase.com/blog/pfizers-ibrance-scores-second-line-breast-cancer-approval-via-nices-cancer-drugs-fund 2019-11-28T20:06:37 https://maestrodatabase.com/blog/call-for-patient-input-30 2015-08-05T11:37:15 https://maestrodatabase.com/blog/health-canada-approves-ocrevus-ocrelizumab-for-canadians-living-with-relapsing-remitting-multiple-sclerosis 2017-08-16T05:28:37 https://maestrodatabase.com/blog/nice-to-recommend-new-drug-to-treat-rare-inherited-bone-disorder-in-children 2016-09-22T20:37:14 https://maestrodatabase.com/blog/agneta-karlsson-new-director-general-at-tlv 2019-11-28T20:30:12 https://maestrodatabase.com/blog/pfizer-receives-european-approval-for-new-indication-for-prevenar-13-for-prevention-of-vaccine-type-pneumococcal-pneumonia-in-adults 2015-08-05T11:37:05 https://maestrodatabase.com/blog/gsk-and-theravance-announce-submission-to-us-regulatory-authorities-for-fluticasone-furoatevilanterol-in-asthma 2015-08-05T11:37:18 https://maestrodatabase.com/blog/impax-receives-positive-chmp-opinion-for-numient-levodopa-with-carbidopa-modified-release-capsules-for-the-symptomatic-treatment-of-adult-patients-with-parkinsons-disease 2015-09-26T04:54:32 https://maestrodatabase.com/blog/amicus-therapeutics-announces-approval-for-galafold-migalastat-for-treatment-of-fabry-disease-in-australia 2017-08-16T05:22:11 https://maestrodatabase.com/blog/harvard-pilgrim-strikes-pay-for-performance-deal-for-cholesterol-drug 2015-11-12T11:13:57 https://maestrodatabase.com/blog/australians-may-pay-more-for-medicines-under-trade-deal 2015-08-05T11:37:29 https://maestrodatabase.com/blog/ema-publishes-agenda-for-14-17-august-chmp-meeting 2017-08-16T05:36:02 https://maestrodatabase.com/blog/takhzyro-lanadelumab-injection-receives-positive-recommendation-from-cadths-canadian-drug-expert-committee-for-the-routine-prevention-of-hereditary-angioedema-attacks 2019-11-28T20:25:49 https://maestrodatabase.com/blog/nice-recommends-edoxaban-lixiana-for-preventing-potentially-fatal-blood-clots-in-people-with-common-heart-problem 2015-08-09T21:16:20 https://maestrodatabase.com/blog/fda-grants-priority-review-for-abbvie-for-supplemental-new-drug-application-for-viekira-pak-ombitasvir-paritaprevir-ritonavir-tablets-dasabuvir-tablets-without-ribavirin-in-genotype-1b-chronic-hepatitis-c-virus-patients-with-compensated-cirrhosis 2016-01-07T20:05:34 https://maestrodatabase.com/blog/medicare-bill-puts-every-australian-at-risk 2019-11-28T20:22:58 https://maestrodatabase.com/blog/us-drug-watchdog-refuses-apotex-medicines--but-theyre-still-approved-by-australias-tga 2015-08-05T11:37:08 https://maestrodatabase.com/blog/early-dialogue-with-regulators-and-hta-bodies 2016-03-31T19:45:14 https://maestrodatabase.com/blog/independence-and-trustworthiness-remain-core-to-nps-medicinewise 2016-08-31T06:59:18 https://maestrodatabase.com/blog/decoding-big-pharmas-secret-drug-pricing-practices 2016-06-29T21:57:33 https://maestrodatabase.com/blog/chi-meds-elunate-fruquintinib-capsules-included-in-the-national-reimbursement-drug-list-in-china 2019-11-28T20:37:00 https://maestrodatabase.com/blog/novo-nordisk-receives-fda-approval-for-saxenda-for-the-treatment-of-obesity 2015-08-05T11:37:29 https://maestrodatabase.com/blog/fda-approves-first-drug-to-show-survival-benefit-in-liposarcoma 2016-01-28T20:47:42 https://maestrodatabase.com/blog/asco-explains-its-opposition-to-medicare-part-b-demo-during-key-congressional-hearing 2016-05-25T16:25:15 https://maestrodatabase.com/blog/drug-makers-including-roche-and-novartis-slash-medicine-prices-in-china-to-get-on-reimbursement-list 2019-11-28T20:34:18 https://maestrodatabase.com/blog/fda-approves-lenvima-for-a-type-of-thyroid-cancer 2015-08-05T11:37:08 https://maestrodatabase.com/blog/sosei-heptares-announces-that-the-copd-treatment-ultibro-breezhaler-has-been-included-in-the-national-reimbursement-drug-list-in-china 2019-11-28T20:55:29 https://maestrodatabase.com/blog/meeting-highlights-from-the-committee-for-medicinal-products-for-human-use-chmp-15-18-december-2014 2015-08-05T11:37:17 https://maestrodatabase.com/blog/cadth-recommends-brilinta 2016-08-30T02:00:02 https://maestrodatabase.com/blog/nice-recommends-another-new-skin-cancer-drug 2015-08-05T11:37:17 https://maestrodatabase.com/blog/bristol-myers-squibbs-opdivo-nivolumab-receives-breakthrough-therapy-designation-from-us-fda-for-advanced-form-of-bladder-cancer 2016-06-27T21:28:10 https://maestrodatabase.com/blog/nice-seeks-more-information-on-treatment-for-adults-with-leukaemia 2015-08-05T11:37:26 https://maestrodatabase.com/blog/tyvyt-sintilimab-injection-an-innovative-pd-1-inhibitor-jointly-developed-by-innovent-and-lilly-is-included-in-the-new-catalogue-of-national-reimbursement-drug-list 2019-11-28T20:51:33 https://maestrodatabase.com/blog/lipocine-announces-fda-acknowledgement-of-tlando-lpcn-1021-nda-resubmission-pdufa-goal-date-8-february-2018 2017-08-16T05:50:28 https://maestrodatabase.com/blog/ema-publishes-epar-for-qtern-saxagliptin-hydrochloride-with-dapagliflozin-propanediol-monohydrate 2016-07-27T21:39:26 https://maestrodatabase.com/blog/relypsa-submits-new-drug-application-to-us-fda-seeking-approval-for-patiromer-for-oral-suspension-to-treat-hyperkalaemia 2015-08-05T11:37:07 https://maestrodatabase.com/blog/pharma-group-under-pressure-punches-back-on-prices 2016-06-09T11:36:02 https://maestrodatabase.com/blog/harper-competition-review-finds-bitter-pills-in-pharmacy-industry 2015-08-05T11:37:29 https://maestrodatabase.com/blog/three_more_drugs_make_england_s_cancer_drugs_fund 2015-08-05T11:37:25 https://maestrodatabase.com/blog/thousands-of-patients-missing-out-on-targeted-cancer-drugs 2015-08-21T10:49:25 https://maestrodatabase.com/blog/lokelma-approved-in-the-eu-for-the-treatment-of-adults-with-hyperkalaemia 2018-03-25T20:22:31 https://maestrodatabase.com/blog/cms-proposes-new-standards-to-strengthen-the-marketplace-for-2018 2016-08-29T20:58:19 https://maestrodatabase.com/blog/2015-seasonal-influenza-vaccines 2015-08-05T11:37:30 https://maestrodatabase.com/blog/pride-of-australia-family-wins-fight-to-get-life-saving-drug-eculizumab-on-pharmaceutical-benefits-scheme 2015-08-05T11:37:14 https://maestrodatabase.com/blog/tigenix-and-takeda-announce-alofisel-darvadstrocel-receives-approval-to-treat-complex-perianal-fistulas-in-crohns-disease-in-europe 2018-03-24T02:05:12 https://maestrodatabase.com/blog/cadth-posts-final-recommendation-for-lynparza 2016-09-29T21:21:33 https://maestrodatabase.com/blog/roche-receives-us-fda-breakthrough-therapy-designation-for-actemraroactemra-in-systemic-sclerosis-and-will-present-new-study-results-at-eular-2015 2015-08-05T11:37:29 https://maestrodatabase.com/blog/new-treatment-for-rare-white-blood-cell-cancer 2016-05-01T01:25:30 https://maestrodatabase.com/blog/portola-pharmaceuticals-receives-and-plans-to-appeal-negative-chmp-opinion-regarding-marketing-authorisation-for-betrixaban-in-the-european-union 2018-03-25T20:33:39 https://maestrodatabase.com/blog/biomarkers-and-surrogate-endpoints 2016-03-16T22:38:45 https://maestrodatabase.com/blog/eisai-receives-health-canada-approval-for-antiepileptic-agent-fycompa-as-adjunctive-treatment-for-patients-with-primary-generalized-tonic-clonic-seizures 2015-12-04T20:41:36 https://maestrodatabase.com/blog/prescription-medicines-new-or-extended-uses-approved-by-the-tga-may-2016 2016-05-19T08:33:06 https://maestrodatabase.com/blog/cheaper-medicines-with-twice-as-many-medicines-now-available-for-a-60-day-prescription 2024-03-03T20:15:59 https://maestrodatabase.com/blog/new-zealands-medicines-landscape 2016-04-08T01:46:56 https://maestrodatabase.com/blog/cdec_recommends_that_inspra_not_be_listed_for_patients_with_nyha_class_ii_systolic_heart_failure 2015-08-05T11:37:09 https://maestrodatabase.com/blog/medicines-to-treat-asthma-diabetes-arthritis-cancer-and-eye-disease-added-to-pbs 2018-03-25T20:25:56 https://maestrodatabase.com/blog/new-medicines-for-australians-with-multiple-sclerosis-lymphoma-carcinoma-and-reproductive-cancers 2020-10-25T02:37:07 https://maestrodatabase.com/blog/nice_issues_final_guidance_aflibercept_for_colorectal_cancer 2015-08-05T11:37:24 https://maestrodatabase.com/blog/no-justification-for-high-drug-prices 2015-12-21T20:34:04 https://maestrodatabase.com/blog/ipsen-receives-positive-chmp-opinion-for-cabometyx-cabozantinib-for-the-first-line-treatment-of-adults-with-intermediate--or-poor-risk-advanced-renal-cell-carcinoma 2018-03-25T20:53:56 https://maestrodatabase.com/blog/cadth-announces-new-chair-and-vice-chair-of-the-canadian-drug-expert-committee 2015-08-05T11:37:11 https://maestrodatabase.com/blog/australian-statistics-on-medicines-2012-2013-and-2014 2015-08-19T12:16:40 https://maestrodatabase.com/blog/nice-rejects-celgenes-otezla-for-psoriasis 2015-09-30T09:29:48 https://maestrodatabase.com/blog/pbs-publications---design-changes-to-pdf-documents 2015-08-05T11:37:15 https://maestrodatabase.com/blog/fresh-hopes-that-breast-cancer-drug-perjeta-will-be-made-available-in-scotland 2018-03-25T20:40:21 https://maestrodatabase.com/blog/fda-approves-zomig-zolmitriptan-nasal-spray-for-migraine-in-paediatric-patients-ages-12-17 2015-08-05T11:37:24 https://maestrodatabase.com/blog/neoadjuvant-use-of-pertuzumab-in-her2-positive-breast-cancer-hint-of-lesser-benefit 2015-12-04T21:45:07 https://maestrodatabase.com/blog/european-commission-grants-marketing-authorisation-for-kanuma-sebelipase-alfa-for-the-treatment-of-patients-of-all-ages-with-lysosomal-acid-lipase-deficiency-lal-d 2015-09-01T12:11:11 https://maestrodatabase.com/blog/australians-with-chronic-heart-failure-benefit-from-cheaper-medicines-on-the-pbs 2024-03-03T20:06:36 https://maestrodatabase.com/blog/nice-issues-draft-guidance-on-the-use-of-otezla-apremilast 2016-08-03T10:51:27 https://maestrodatabase.com/blog/health_canada_approves_new_strength_for_tecfidera__a_first_line_oral_treatment_for_multiple_sclerosis 2015-08-05T11:37:29 https://maestrodatabase.com/blog/decision-relating-to-enoxaparin-sodium-and-plerixafor 2016-08-08T20:55:45 https://maestrodatabase.com/blog/proposal-to-award-sole-supply-of-metoprolol-tartrate-injection-in-the-community-and-dhb-hospitals 2016-07-12T10:13:54 https://maestrodatabase.com/blog/non-stimulant-for-adhd-approved-in-europe 2015-09-21T20:55:33 https://maestrodatabase.com/blog/nice-publishes-second-appraisal-consultation-for-nucala-mepolizumab 2016-06-09T21:10:00 https://maestrodatabase.com/blog/pcodr_expert_review_committee_has_recommended_the_use_of_pertuzumab__perjeta__for_use_in_certain_women_with_breast_cancer 2015-08-05T11:37:09 https://maestrodatabase.com/blog/nice_is_moving_onward_according_to_sir_michael_rawlins 2015-08-05T11:37:12 https://maestrodatabase.com/blog/fda-approves-new-medication-for-dry-eye-disease 2016-07-12T21:08:42 https://maestrodatabase.com/blog/value-in-cancer-care 2015-08-05T11:37:23 https://maestrodatabase.com/blog/astrazeneca-receives-complete-response-letter-from-us-fda-for-saxagliptin-dapagliflozin-fixed-dose-combination 2015-10-16T20:35:43 https://maestrodatabase.com/blog/us-fda-grants-priority-review-status-to-nda-for-anticancer-agent-lenvatinib 2015-08-05T11:37:19 https://maestrodatabase.com/blog/flimsy-evidence-behind-many-fda-approvals 2017-08-16T20:29:52 https://maestrodatabase.com/blog/seven-new-medicines-approved-for-nhs-scotland 2015-09-07T20:52:17 https://maestrodatabase.com/blog/consultation-on-recommendation-framework-for-cadth-common-drug-review-and-pan-canadian-oncology-drug-review-programs 2015-10-09T21:03:06 https://maestrodatabase.com/blog/trump-threat-on-obamacare-would-boost-deficit-by-194-dollars-billion 2017-08-16T20:26:39 https://maestrodatabase.com/blog/breast-cancer-drug-tamoxifen-listed-on-pharmaceutical-benefits-scheme-from-today 2016-10-01T11:57:39 https://maestrodatabase.com/blog/australian-manufacturers-of-medical-devices-given-a-level-playing-field 2015-08-05T11:37:03 https://maestrodatabase.com/blog/trump-tweets-up-a-storm-on-drug-prices-but-delivers-little-change 2017-08-16T20:40:06 https://maestrodatabase.com/blog/bristol-myers-cancer-drug-combination-to-cost-256000-a-year 2015-10-01T21:54:17 https://maestrodatabase.com/blog/government-puts-new-cancer-drug-on-pbs 2015-08-05T11:37:04 https://maestrodatabase.com/blog/novel-rosacea-treatment-approved-by-health-canada-for-adult-patients 2015-08-05T11:37:10 https://maestrodatabase.com/blog/whats-harder-than-making-copycat-biotech-drugs-selling-them 2017-08-16T20:32:19 https://maestrodatabase.com/blog/fda-takes-multiple-actions-to-expand-use-of-pfizer-biontech-covid-19-vaccine 2022-01-03T22:44:38 https://maestrodatabase.com/blog/senate-committee-calls-for-medicine-review 2015-09-17T10:32:50 https://maestrodatabase.com/blog/association-of-reference-pricing-with-drug-selection-and-spending 2017-08-17T05:33:09 https://maestrodatabase.com/blog/improved-specificity-with-respect-to-diseasecondition 2015-08-05T11:37:29 https://maestrodatabase.com/blog/the-use-of-real-world-evidence-among-health-care-payers-a-scoping-review 2025-09-16T21:28:29 https://maestrodatabase.com/blog/decision-to-list-bedaquiline-sirturo-and-siltuximab-sylvant-for-rare-disorders 2016-05-12T14:15:56 https://maestrodatabase.com/blog/us-chamber-of-commerce-sues-over-governments-drug-pricing-power 2023-06-13T04:59:57 https://maestrodatabase.com/blog/bms_pulls_diabetes_drug_from_germany_in_price_fight 2015-08-05T11:37:21 https://maestrodatabase.com/blog/melanoma-drug-given-low-funding-priority 2015-12-03T06:12:41 https://maestrodatabase.com/blog/impax-receives-european-commission-marketing-authorization-for-numient-levodopa-and-carbidopa-modified-release-capsules-for-the-symptomatic-treatment-of-adult-patients-with-parkinsons-disease 2015-11-26T20:48:39 https://maestrodatabase.com/blog/valeant-provides-update-regarding-government-inquiries 2015-10-15T19:59:36 https://maestrodatabase.com/blog/portola-pharmaceuticals-announces-andexxa-andexanet-alfa-biologics-license-application-resubmission-accepted-for-review-by-u-dot-s-fda 2017-08-17T05:43:15 https://maestrodatabase.com/blog/nice-proposes-ipilimumab-as-a-first-treatment-for-advanced-skin-cancer 2015-08-05T11:37:24 https://maestrodatabase.com/blog/the-gouge-factor-big-companies-want-transparency-in-drug-price-negotiations 2016-08-03T11:48:59 https://maestrodatabase.com/blog/report-on-the-collection-of-under-co-payment-data-2014-15 2016-07-18T07:24:01 https://maestrodatabase.com/blog/drug-makers-price-medicines-unfairly-uk-patient-groups-say 2015-08-05T11:37:08 https://maestrodatabase.com/blog/updated-price-disclosure-arrangements-procedural-and-operational-guidelines 2016-06-29T10:43:27 https://maestrodatabase.com/blog/us-fda-approves-invokamet-xr-canagliflozin-metformin-hydrochloride-extended-release-for-the-treatment-of-adults-with-type-2-diabetes 2016-09-21T21:14:06 https://maestrodatabase.com/blog/cancer-campaigner-and-melanoma-patient-jeffrey-paterson-dies-aged-23 2016-08-28T21:23:39 https://maestrodatabase.com/blog/uk-proposal-to-fight-drug-resistant-bacteria-has-some-doubters 2016-05-19T21:34:30 https://maestrodatabase.com/blog/japans-eisai-weighs-legal-action-in-uk-cancer-drug-row 2016-07-08T21:26:54 https://maestrodatabase.com/blog/the-supreme-administrative-court-did-not-test-mayzent 2023-06-13T08:34:51 https://maestrodatabase.com/blog/ema-explains-its-redaction-rules 2015-08-05T11:37:18 https://maestrodatabase.com/blog/smc-accepts-rinvoq-upadacitinib-as-a-treatment-option-for-adults-with-moderately-to-severely-active-crohns-disease-in-scotland 2023-06-13T08:16:31 https://maestrodatabase.com/blog/novartis-receives-eu-approval-for-tafinlar-and-mekinist-first-combination-approved-for-patients-with-aggressive-form-of-melanoma 2015-09-01T12:23:37 https://maestrodatabase.com/blog/market_access_granted_in_france_for_pixuvri__pixantrone__for_patients_with_aggressive_non_hodgkin_lymphoma 2015-08-05T11:37:08 https://maestrodatabase.com/blog/call_for_submissions__stage_3_of_the_pbac_post_market_review_of_products_used_in_the_management_of_patients_with_diabetes_mellitus 2015-08-05T11:37:19 https://maestrodatabase.com/blog/exelixis-submits-u-dot-s-supplemental-new-drug-application-for-cabometyx-cabozantinib-for-the-treatment-of-previously-untreated-advanced-kidney-cancer 2017-08-17T05:52:54 https://maestrodatabase.com/blog/biofrontera-announces-us-fda-approval-of-ameluz-and-activating-bf-rhodoled-device-for-treatment-of-actinic-keratosis 2016-05-18T02:46:06 https://maestrodatabase.com/blog/soliris-approved-in-china-for-the-treatment-of-adults-with-refractory-generalised-myasthenia-gravis 2023-06-13T06:06:02 https://maestrodatabase.com/blog/australian_pbs__pay_for_performance__deals_slammed 2015-08-05T11:37:16 https://maestrodatabase.com/blog/ask-your-doctor-if-this-ad-is-right-for-you 2016-02-28T10:06:43 https://maestrodatabase.com/blog/direct-acting-antivirals-for-chronic-hepatitis-c-genotype-1 2015-08-05T11:37:22 https://maestrodatabase.com/blog/steady-increase-in-prices-for-oral-anti-cancer-drugs-after-market-launch-suggests-a-lack-of-competitive-pressure 2016-05-03T00:33:23 https://maestrodatabase.com/blog/new-report-shows-how-badly-big-pharma-is-ripping-off-american-people-with-publicly-funded-medications 2023-06-13T05:44:02 https://maestrodatabase.com/blog/medicines-australia-welcomes-new-chair-and-members-of-the-pharmaceutical-benefits-advisory-committee 2015-08-05T11:37:09 https://maestrodatabase.com/blog/cadth-calls-for-patient-input-on-a-resubmission-from-biomarin-for-kuvan 2016-01-04T20:39:13 https://maestrodatabase.com/blog/iqwig_rebuffs_gilead_s_stribild__tenofovir_disoproxil_fumarate_with_emtricitabine_and_elvitegravir_and_cobicistat_ 2015-08-05T11:37:29 https://maestrodatabase.com/blog/agenda-for-the-5-november-2014-transparency-commission-meeting 2015-08-05T11:37:26 https://maestrodatabase.com/blog/santhera-updates-on-us-regulatory-filing-for-raxone-idebenone-in-duchenne-muscular-dystrophy 2016-07-14T21:31:00 https://maestrodatabase.com/blog/patients-left-in-lurch-as-bayer-pulls-free-anti-coagulant 2016-02-17T20:13:55 https://maestrodatabase.com/blog/agenda-for-14-may-2014-transparency-commission-meeting 2015-08-05T11:37:23 https://maestrodatabase.com/blog/the-31-breakthrough-medicines-australians-cant-get-according-to-medicines-australia-report 2015-08-05T11:37:14 https://maestrodatabase.com/blog/decision-to-fund-rifaximin-xifaxan-for-hepatic-encephalopathy 2015-08-05T11:37:10 https://maestrodatabase.com/blog/new-medicine-to-help-in-the-fight-against-antimicrobial-resistance 2016-05-01T01:28:25 https://maestrodatabase.com/blog/tiotropiumolodaterol-in-copd-disadvantages-in-patients-with-more-severe-disease-advantages-for-some-women 2015-11-19T20:10:05 https://maestrodatabase.com/blog/mark-zuckerberg-and-priscilla-chan-pledge-3-billion-to-fighting-disease 2016-09-22T08:25:49 https://maestrodatabase.com/blog/ramucirumab-in-colorectal-and-lung-cancer-some-additional-benefits-some-reductions-in-benefits 2016-06-01T16:17:46 https://maestrodatabase.com/blog/fda-grants-iliad-biotechnologies-fast-track-designation-for-next-generation-pertussis-vaccine-bpze1 2022-01-03T23:35:27 https://maestrodatabase.com/blog/lawmakers-criticize-medicare-plan-for-costly-drugs 2016-05-09T06:31:23 https://maestrodatabase.com/blog/aflibercept_in_macular_oedema__added_benefit_not_proven 2015-08-05T11:37:03 https://maestrodatabase.com/blog/fda-approves-natpara-to-control-low-blood-calcium-levels-in-patients-with-hypoparathyroidism 2015-08-05T11:37:28 https://maestrodatabase.com/blog/planned-revision-of-eu-pharmaceutical-legislation-early-market-access-and-robust-evidence-need-not-remain-a-contradiction-in-terms 2023-06-13T10:54:56 https://maestrodatabase.com/blog/enanta-announces-us-fda-grants-priority-review-for-abbvies-investigational-all-oral-interferon-free-treatment-regimen-for-genotype-4-chronic-hepatitis-c-infection 2015-08-05T11:37:29 https://maestrodatabase.com/blog/smc-recently-added-forthcoming-submissions-1 2015-08-13T20:46:50 https://maestrodatabase.com/blog/agenda-for-the-23-july-2014-transparency-commission-meeting 2015-08-05T11:37:15 https://maestrodatabase.com/blog/us-fda-approves-bylvay-for-patients-living-with-cholestatic-pruritus-due-to-alagille-syndrome 2023-06-13T21:12:32 https://maestrodatabase.com/blog/removal-of-originator-brand-data-from-the-price-disclosure-calculation-worked-example 2015-11-02T05:04:52 https://maestrodatabase.com/blog/thousands-to-benefit-as-nice-set-to-recommend-drug-to-prevent-heart-attacks-and-strokes 2016-08-12T22:40:19 https://maestrodatabase.com/blog/smc-rejects-the-use-of-remicade-infliximab-for-patients-with-ulcerative-colitis 2015-08-05T11:37:23 https://maestrodatabase.com/blog/cancer-drugs-are-the-least-likely-to-receive-fda-approval 2016-05-27T12:24:01 https://maestrodatabase.com/blog/teva-announces-fda-acceptance-of-the-biologics-license-application-for-reslizumab 2015-08-05T11:37:12 https://maestrodatabase.com/blog/uncertainty-for-masterton-mother-after-drug-trial-ditched 2016-07-11T08:19:24 https://maestrodatabase.com/blog/fda-approves-new-indication-for-faslodex-fulvestrant 2016-03-03T18:55:07 https://maestrodatabase.com/blog/pharmac-simplifies-criteria-for-covid-19-anti-viral-treatments 2022-09-12T05:07:07 https://maestrodatabase.com/blog/provinces-push-for-more-federal-health-spending-as-senior-population-grows 2016-09-29T10:16:33 https://maestrodatabase.com/blog/sarepta-to-charge-300k-for-duchenne-drug-we-tried-to-be-reasonable-ceo-says 2016-09-20T21:34:20 https://maestrodatabase.com/blog/decision-relating-to-idarucizumab-and-dabigatran 2016-08-08T07:21:54 https://maestrodatabase.com/blog/pharmaceutical-benefits-advisory-committee-pbac-guidelines-review-1 2016-09-29T08:26:05 https://maestrodatabase.com/blog/tga-updates-prescription-medicine-clinical-units 2016-05-26T11:14:03 https://maestrodatabase.com/blog/therapeutic-substitutionshould-it-be-systematic-or-automatic 2016-05-10T04:57:18 https://maestrodatabase.com/blog/makers-of-humira-and-enbrel-using-new-drug-patents-to-delay-generic-versions 2016-07-16T23:38:57 https://maestrodatabase.com/blog/multiple-provinces-align-to-provide-public-funding-for-harvoni-the-first-single-tablet-regimen-for-the-treatment-of-genotype-1-chronic-hepatitis-c-virus-infection 2015-08-05T11:37:12 https://maestrodatabase.com/blog/usa-grapples-with-high-drug-costs 2015-11-29T20:33:36 https://maestrodatabase.com/blog/eupraxia-pharmaceuticals-receives-us-fda-fast-track-designation-for-ep-104iar-in-treatment-of-osteoarthritis 2023-06-13T22:19:06 https://maestrodatabase.com/blog/trimel-receives-fda-approval-for-natesto-nasal-gel-to-treat-men-with-low-testosterone 2015-08-05T11:37:22 https://maestrodatabase.com/blog/genprex-receives-u-dot-s-fda-fast-track-designation-for-reqorsa-immunogene-therapy-in-combination-with-keytruda-for-the-treatment-of-non-small-cell-lung-cancer 2022-01-04T00:40:04 https://maestrodatabase.com/blog/actavis-receives-fda-approval-of-saphris-for-paediatric-patients-age-10-17-for-acute-treatment-of-manic-or-mixed-episodes-of-bipolar-i-disorder 2015-08-05T11:37:06 https://maestrodatabase.com/blog/nice_draft_guidance_recommends_new_treatment_for_lung_cancer 2015-08-05T11:37:23 https://maestrodatabase.com/blog/fda-approves-use-of-menactra-vaccine-for-booster-immunization-against-potentially-deadly-disease 2015-08-05T11:37:04 https://maestrodatabase.com/blog/how-patent-troll-legislation-can-increase-timely-access-to-generic-drugs 2016-05-16T23:46:09 https://maestrodatabase.com/blog/amgen-receives-positive-chmp-opinion-for-use-of-repatha-evolocumab-for-the-treatment-of-high-cholesterol 2015-08-05T11:37:08 https://maestrodatabase.com/blog/over-the-counter-items-recommended-for-de-listing-or-amendment-from-1-january-2016 2015-11-02T20:30:04 https://maestrodatabase.com/blog/proposal-to-list-intravenous-nicardipine 2015-08-05T11:37:24 https://maestrodatabase.com/blog/iqwig_publishes_new_version_of_its_general_methods__german_ 2015-08-05T11:37:10 https://maestrodatabase.com/blog/new-drug-listed-with-pbs-to-help-australians-with-bone-marrow-cancer 2015-08-06T21:04:13 https://maestrodatabase.com/blog/sunovion-announces-fda-approval-of-a-new-indication-for-aptiom-eslicarbazepine-acetate-as-monotherapy-for-partial-onset-seizures 2015-08-30T21:16:37 https://maestrodatabase.com/blog/european-medicines-agency-validates-bristol-myers-squibbs-type-ii-variation-application-for-opdivo-nivolumab-in-advanced-form-of-bladder-cancer 2016-09-20T12:43:20 https://maestrodatabase.com/blog/australias-first-bivalent-covid-19-vaccine-to-join-rollout 2022-09-12T06:43:16 https://maestrodatabase.com/blog/supporting-innovative-smes-as-major-drivers-of-new-pharmaceutical-developments 2016-05-11T14:31:10 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule-1-june-2016-update 2016-05-31T14:35:17 https://maestrodatabase.com/blog/novavax-submits-final-data-packages-to-u-dot-s-fda-as-prerequisite-to-emergency-use-authorisation-application-request-for-covid-19-vaccine 2022-01-04T00:10:11 https://maestrodatabase.com/blog/new-treatment-for-patients-with-multiple-myeloma 2016-04-01T23:40:27 https://maestrodatabase.com/blog/juventas-therapeutics-granted-fda-fast-track-designation-and-phase-2b-protocol-allowance-for-novel-heart-failure-gene-therapy 2015-08-05T11:37:23 https://maestrodatabase.com/blog/tga-publishes-3-new-auspars 2015-08-25T12:42:13 https://maestrodatabase.com/blog/decision-to-widen-access-to-tocilizumab-actemra-for-rheumatoid-arthritis-in-patients-who-are-unable-to-be-treated-with-methotrexate 2015-08-05T11:37:07 https://maestrodatabase.com/blog/fda-allows-marketing-of-clot-retrieval-devices-to-reduce-disability-in-stroke-patients 2016-09-03T11:21:58 https://maestrodatabase.com/blog/fda-approves-new-treatment-for-adults-with-relapsed-or-refractory-acute-lymphoblastic-leukaemia 2017-08-17T20:45:36 https://maestrodatabase.com/blog/report-on-the-collection-of-under-co-payment-data-2017-18 2018-11-05T02:16:09 https://maestrodatabase.com/blog/call-for-nominations-to-the-pcodr-expert-review-committee 2015-08-05T11:37:29 https://maestrodatabase.com/blog/a-start-up-suggests-a-fix-to-the-health-care-morass 2017-08-17T21:07:45 https://maestrodatabase.com/blog/fda-accepts-biologics-license-application-for-zinbryta-daclizumab-high-yield-process-for-treatment-of-ms 2015-08-05T11:37:18 https://maestrodatabase.com/blog/atagi-statement-on-use-of-the-moderna-bivalent-original-slash-omicron-vaccine 2022-09-12T10:28:11 https://maestrodatabase.com/blog/cdec-recommends-adempas-riociguat-for-certain-patients-with-chronic-thromboembolic-pulmonary-hypertension 2015-08-05T11:37:09 https://maestrodatabase.com/blog/novartis-files-submission-to-cadth-for-jakavi-for-patients-with-polycythemia-vera 2015-08-27T22:19:08 https://maestrodatabase.com/blog/iqwig-celebrates-its-10th-anniversary 2015-08-05T11:37:06 https://maestrodatabase.com/blog/nomination-for-an-early-re-entry-resubmission---what-exactly-does-it-mean 2022-09-12T08:23:24 https://maestrodatabase.com/blog/nice_requests_more_data_on_velcade__bortezomib__for_multiple_myeloma 2015-08-05T11:37:06 https://maestrodatabase.com/blog/two-terminal-cancer-patients-she-gets-treatment-funded-he-doesnt 2018-11-05T19:38:50 https://maestrodatabase.com/blog/pbac-public-summary-documents---august-2019-intracycle-meeting 2020-01-31T08:29:56 https://maestrodatabase.com/blog/new-fda-guidelines-ease-access-to-abortion-pill 2016-03-31T08:36:35 https://maestrodatabase.com/blog/lynparza-receives-additional-and-broad-approval-in-the-us-for-ovarian-cancer 2017-08-17T21:21:14 https://maestrodatabase.com/blog/saskatchewan-government-to-cover-new-hepatitis-c-drug 2015-08-05T11:37:24 https://maestrodatabase.com/blog/impax-pharmaceuticals-announce-fda-approval-of-rytary-carbidopa-and-levodopa-extended-release-capsules-for-the-treatment-of-parkinsons-disease 2015-08-05T11:37:20 https://maestrodatabase.com/blog/generic-drug-makers-feel-pinch-as-prices-crumble 2017-08-17T21:38:05 https://maestrodatabase.com/blog/hundreds-of-people-set-to-benefit-after-life-extending-lung-cancer-treatment-given-green-light 2025-09-17T00:45:24 https://maestrodatabase.com/blog/drug-goes-from-1350-a-tablet-to-750-overnight 2015-09-21T21:50:14 https://maestrodatabase.com/blog/rfp---supply-of-etanercept 2018-11-05T05:44:45 https://maestrodatabase.com/blog/revised-risperidone-pbs-listings-for-behavioural-and-psychological-symptoms-of-dementia-from-1-january-2020 2019-11-30T04:42:30 https://maestrodatabase.com/blog/pbs-hospital-medication-chart 2015-08-05T11:37:17 https://maestrodatabase.com/blog/hepatitis-c-treatment-coming-to-pbs 2016-02-22T20:14:50 https://maestrodatabase.com/blog/house-democrats-start-multiple-sclerosis-drug-price-probe 2017-08-17T21:32:09 https://maestrodatabase.com/blog/policy-makers-are-taking-the-wrong-approach-to-health-care-reform 2019-11-30T04:40:03 https://maestrodatabase.com/blog/fda-approves-mercks-single-dose-emend-fosaprepitant-dimeglumine-for-injection-in-combination-with-other-anti-emetic-agents-for-the-prevention-of-delayed-nausea-and-vomiting-in-adults-receiving-moderately-emetogenic-chemotherapy 2016-02-05T06:38:45 https://maestrodatabase.com/blog/y-mabs-initiates-rolling-submission-of-biologics-license-application-to-u-dot-s-fda-for-naxitamab-for-treatment-of-neuroblastoma 2019-11-30T04:55:50 https://maestrodatabase.com/blog/tga-approves-akynzeo-netupitantpalonosetron-for-the-prevention-of-chemotherapy-induced-nausea-and-vomiting 2015-08-05T11:37:18 https://maestrodatabase.com/blog/bitter-pill-over-pbs-savings-shortfall 2018-11-05T19:48:40 https://maestrodatabase.com/blog/confirmed-1-october-2016-prices-2016-october-cycle 2016-09-09T04:55:25 https://maestrodatabase.com/blog/fda-approves-treatment-for-aids-symptoms 2016-07-05T21:26:38 https://maestrodatabase.com/blog/17-million-australians-to-be-automatically-enrolled-in-my-health-record 2018-11-05T20:06:28 https://maestrodatabase.com/blog/mersana-therapeutics-announces-fda-fast-track-designation-granted-to-xmt-1660-for-the-treatment-of-triple-negative-breast-cancer 2022-09-12T20:15:43 https://maestrodatabase.com/blog/bayer-submits-marketing-authorization-application-in-europe-for-recombinant-factor-viii-product-bay-81-8973-for-the-treatment-of-hemophilia-a-in-adults-and-children 2015-08-05T11:37:10 https://maestrodatabase.com/blog/1-dollars-million-treatment-could-save-our-infants-from-the-orphan-disease 2018-11-05T19:45:08 https://maestrodatabase.com/blog/gsk-receives-positive-chmp-opinion-in-europe-for-novel-anti-il5-biological-nucala-mepolizumab-for-the-treatment-of-patients-with-severe-refractory-eosinophilic-asthma 2015-09-24T20:54:03 https://maestrodatabase.com/blog/imfinzi-granted-fda-priority-review-for-the-treatment-of-patients-with-extensive-stage-small-cell-lung-cancer 2019-11-30T04:52:02 https://maestrodatabase.com/blog/an-antidote-for-escalating-drug-prices-reciprocity-of-regulatory-approvals 2015-10-14T19:55:05 https://maestrodatabase.com/blog/chimerix-receives-u-dot-s-fda-approval-for-tembexa-brincidofovir-for-the-treatment-of-smallpox 2021-06-05T03:28:53 https://maestrodatabase.com/blog/medicines-to-drop-in-price-for-conditions-including-leukaemia-cardiovascular-disease 2016-04-02T21:41:35 https://maestrodatabase.com/blog/big-data 2019-11-30T04:48:45 https://maestrodatabase.com/blog/fda-grants-breakthrough-device-designation-for-curvebeam-ais-ossview-bone-fragility-software 2022-09-12T20:10:45 https://maestrodatabase.com/blog/lundbeck-announces-health-canada-approval-of-trintellix-vortioxetine-hydrobromide-for-treatment-of-adults-with-major-depressive-disorder 2015-08-05T11:37:14 https://maestrodatabase.com/blog/eylea-aflibercept-injection-receives-fda-breakthrough-therapy-designation-for-diabetic-retinopathy-in-patients-with-diabetic-macular-oedema 2015-08-05T11:37:30 https://maestrodatabase.com/blog/cadth-publishes-initial-recommendation-for-lenvima 2018-11-05T20:22:00 https://maestrodatabase.com/blog/performance-of-uk-national-health-service-compared-with-other-high-income-countries-observational-study 2019-11-30T23:11:38 https://maestrodatabase.com/blog/chiesi-global-rare-diseases-announces-fda-acceptance-of-bla-filing-for-velmanase-alfa-for-the-proposed-treatment-of-alfa-mannosidosis 2022-09-12T20:06:08 https://maestrodatabase.com/blog/pcodr-fails-to-recommend-zaltrap-aflibercept-for-patients-with-metastatic-colorectal-cancer 2015-08-05T11:37:28 https://maestrodatabase.com/blog/a-push-to-lower-drug-prices-that-hit-insurers-and-employers-the-hardest 2016-09-09T08:19:51 https://maestrodatabase.com/blog/nhs-and-drug-prices-could-be-included-in-us-uk-trade-deal-leaked-documents-suggest 2019-11-30T23:09:16 https://maestrodatabase.com/blog/ensuring-australians-get-most-from-community-pharmacy 2016-07-27T06:11:25 https://maestrodatabase.com/blog/biolinerx-announces-submission-of-new-drug-application-to-fda-for-motixafortide-in-stem-cell-mobilisation 2022-09-12T11:05:59 https://maestrodatabase.com/blog/qubec-government-covers-lemtrada-alemtuzumab-for-ms-patients 2015-08-05T11:37:12 https://maestrodatabase.com/blog/aquestive-therapeutics-announces-u-dot-s-fda-approval-for-sympazan-clobazam-oral-film 2018-11-05T20:15:05 https://maestrodatabase.com/blog/pharmac-notification-of-decision-to-fund-cinacalcet-sensipar-for-parathyroid-carcinoma-and-calciphylaxis 2016-04-12T01:48:14 https://maestrodatabase.com/blog/federal-govt-keen-to-get-biosimilar-drugs-onto-pbs 2015-08-05T11:37:28 https://maestrodatabase.com/blog/two-new-combination-therapies-against-chronic-hepatitis-c 2016-05-27T12:48:11 https://maestrodatabase.com/blog/novartis-says-sma-gene-therapy-is-cost-effective-at-$4-5-million-per-patient 2018-11-05T20:45:19 https://maestrodatabase.com/blog/amitiza-lubiprostone-receives-nice-recommendation 2015-08-05T11:37:16 https://maestrodatabase.com/blog/nivolumab-in-melanoma-data-subsequently-submitted-improve-assessment-result 2016-01-13T20:27:44 https://maestrodatabase.com/blog/daratumumab-in-multiple-myeloma-reassessment-results-in-hint-of-considerable-added-benefit 2022-01-04T02:11:24 https://maestrodatabase.com/blog/adapted-vaccine-targeting-ba-dot-4-and-ba-dot-5-omicron-variants-and-original-sars-cov-2-recommended-for-approval 2022-09-12T20:35:38 https://maestrodatabase.com/blog/medicine_prescribing_hits_new_high_as_pharmac_role_expands 2015-08-05T11:37:27 https://maestrodatabase.com/blog/ptac-recommended-the-listing-of-perjeta-pertuzumab-for-patients-with-metastatic-breast-cancer 2015-08-05T11:37:28 https://maestrodatabase.com/blog/cadth-publishes-initial-recommendation-for-tagrisso 2018-11-05T20:32:36 https://maestrodatabase.com/blog/ruxolitinib-phosphate-in-polycythaemia-vera-iqwig-finds-a-hint-of-a-non-quantifiable-added-benefit 2015-08-08T01:10:58 https://maestrodatabase.com/blog/the-role-of-the-tga 2015-08-05T11:37:21 https://maestrodatabase.com/blog/nice_issues_draft_guidance_for_new_medicine_for_patients_with_non_small_cell_lung_cancer 2015-08-05T11:37:29 https://maestrodatabase.com/blog/spero-therapeutics-announces-fda-acceptance-and-priority-review-of-new-drug-application-for-tebipenem-hydrobromide-for-the-treatment-of-complicated-urinary-tract-infections-including-pyelonephritis 2022-01-04T02:15:47 https://maestrodatabase.com/blog/cancer-drug-prices-vary-widely-even-among-countries-with-curbs 2015-12-04T20:54:44 https://maestrodatabase.com/blog/acadia-pharmaceuticals-announces-trofinetide-new-drug-application-for-the-treatment-of-rett-syndrome-has-been-accepted-for-filing-and-review-by-us-fda 2022-09-12T20:23:25 https://maestrodatabase.com/blog/release-of-final-report-of-review-of-medicines-and-medical-devices-regulation 2015-11-20T01:27:53 https://maestrodatabase.com/blog/fda-approves-relistor-subcutaneous-injection-for-the-treatment-of-opioid-induced-constipation-in-patients-with-chronic-non-cancer-pain 2015-08-05T11:37:29 https://maestrodatabase.com/blog/cadth-to-conduct-a-therapeutic-review-of-new-drugs-for-type-2-diabetes-mellitus 2016-08-11T01:15:55 https://maestrodatabase.com/blog/expensive-new-hep-c-drugs-may-be-cost-effective-even-for-early-disease 2015-11-24T20:32:11 https://maestrodatabase.com/blog/express-scripts-champions-1-per-pill-access-to-an-alternative-for-daraprim 2015-12-01T19:53:10 https://maestrodatabase.com/blog/fda-accepts-mitsubishi-tanabe-pharmas-nda-filing-for-edaravone-to-treat-als 2016-09-01T21:04:48 https://maestrodatabase.com/blog/epipen-price-rises-could-mean-more-riches-for-mylan-executives 2016-09-04T13:33:59 https://maestrodatabase.com/blog/updates-to-the-cadth-therapeutic-review-framework 2015-08-05T11:37:14 https://maestrodatabase.com/blog/brilique-ticagrelor-approved-in-eu-for-extended-treatment-of-patients-with-history-of-heart-attack 2016-02-19T23:36:30 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-to-corbus-pharmaceuticals-nectin-4-targeting-adc-crb-701-in-head-and-neck-squamous-cell-carcinoma 2025-09-17T01:57:50 https://maestrodatabase.com/blog/why-cancer 2016-06-13T21:37:00 https://maestrodatabase.com/blog/skin-disease-treatment-now-on-pbs 2015-08-31T21:56:59 https://maestrodatabase.com/blog/ema-publishes-agenda-for-12-15-september-2022-chmp-meeting 2022-09-12T20:51:17 https://maestrodatabase.com/blog/us-fda-accepts-for-review-otsuka-and-lundbecks-snda-filing-for-labeling-update-of-rexulti-brexpiprazole-for-maintenance-treatment-of-schizophrenia 2016-02-09T20:42:17 https://maestrodatabase.com/blog/adamis-pharmaceuticals-receives-complete-response-letter-from-fda-for-its-epinephrine-pre-filled-syringe-nda 2016-06-06T23:31:01 https://maestrodatabase.com/blog/genzyme_s_lemtrada__alemtuzumab__approved_in_canada_for_treatment_of_multiple_sclerosis 2015-08-05T11:37:15 https://maestrodatabase.com/blog/health-canada-approves-yervoy-ipilimumab-for-first-line-treatment-of-adults-with-malignant-melanoma-the-most-deadly-form-of-skin-cancer 2015-08-05T11:37:06 https://maestrodatabase.com/blog/celgene-bet-1-billion-that-this-biotechs-science-can-cure-deadly-cancers 2015-08-05T11:37:29 https://maestrodatabase.com/blog/blood-cancer-patient-charity-campaigns-for-pharmac-to-fund-medicine 2022-09-12T20:45:34 https://maestrodatabase.com/blog/sanofi-pasteur-announces-fda-approval-of-quadracel-dtap-ipv-vaccine-for-children-4-through-6-years-of-age 2015-08-05T11:37:17 https://maestrodatabase.com/blog/registration-of-nces-by-the-tga-august-2015 2015-09-03T11:35:53 https://maestrodatabase.com/blog/kaitaia-mum-fights-pharmac-for-chance-to-live 2018-11-06T01:04:01 https://maestrodatabase.com/blog/samsung-bioepis-submits-marketing-authorization-application-for-sb2--a-remicade-infliximab-biosimilar-candidate-to-the-european-medicines-agency 2015-08-05T11:37:17 https://maestrodatabase.com/blog/selexipag-in-pulmonary-arterial-hypertension-additional-clinical-benefit-is-not-proven 2016-09-17T00:01:09 https://maestrodatabase.com/blog/vaxxinity-initiates-rolling-submission-for-ub-612-covid-19-vaccine-with-mhra 2022-09-12T20:39:38 https://maestrodatabase.com/blog/abpi-comments-on-scottish-new-medicines-fund 2015-08-05T11:37:30 https://maestrodatabase.com/blog/nice-issues-final-guidance-recommending-7drugs-for-rheumatoid-arthritis 2016-01-26T20:25:28 https://maestrodatabase.com/blog/european-commission-approves-daklinza-daclatasvir-for-the-treatment-of-genotype-1-3-and-4-chronic-hepatitis-c-patients-with-hiv-co-infection-advanced-cirrhosis-and-post-liver-transplant-recurrence-of-hcv 2016-01-28T23:07:53 https://maestrodatabase.com/blog/charity-urges-drug-firms-to-reduce-price-of-pneumonia-vaccine 2015-11-20T03:39:43 https://maestrodatabase.com/blog/supply-of-gonadotropin-releasing-hormone-analogues 2016-03-09T00:57:06 https://maestrodatabase.com/blog/nice-consults-on-no-recommendation-for-skin-cancer-drug-talimogene-laherparepvec 2016-03-16T20:43:01 https://maestrodatabase.com/blog/sankyos-flt3-inhibitor-quizartinib-for-treatment-of-patients-with-relapsed-slash-refractory-flt3-itd-aml 2018-11-06T01:13:34 https://maestrodatabase.com/blog/belatacept-after-kidney-transplantation-indication-of-significant-added-value-says-iqwig 2015-10-15T20:34:28 https://maestrodatabase.com/blog/fda-grants-tentative-approval-for-lilly-and-boehringer-ingelheims-basaglar-insulin-glargine-injection 2015-08-05T11:37:12 https://maestrodatabase.com/blog/subsidy_for_cystic_fibrosis_kalydeco_approved_by_pbac_with_conditions 2015-08-05T11:37:13 https://maestrodatabase.com/blog/seattle-genetics-submits-supplemental-biologics-license-application-for-adcetris-brentuximab-vedotin-in-front-line-treatment-of-cd30-expressing-peripheral-t-cell-lymphomas 2018-11-06T01:08:35 https://maestrodatabase.com/blog/nice_seeks_views_on_how_it_assesses_new_drugs_and_other_technologies_for_the_nhs 2015-08-05T11:37:02 https://maestrodatabase.com/blog/us-fda-approves-prezista-darunavir-for-use-in-pregnant-women-with-hiv 2016-07-19T05:21:35 https://maestrodatabase.com/blog/the-top-10-challenges-for-health-technology-assessment-inahta-viewpoint 2019-12-01T01:24:11 https://maestrodatabase.com/blog/ema-updates-published-list-of-new-medicines-under-review-by-the-chmp 2016-08-09T21:33:39 https://maestrodatabase.com/blog/ema-publishes-epar-for-aerivio-spiromax 2016-09-05T04:23:10 https://maestrodatabase.com/blog/my-health-record-system-crashes-as-australians-rush-to-opt-out 2018-11-06T01:30:59 https://maestrodatabase.com/blog/enzalutamide_in_prostate_cancer__hints_of_added_benefit 2015-08-05T11:37:08 https://maestrodatabase.com/blog/u-dot-s-food-and-drug-administration-anticancer-drug-approval-trends-from-2016-to-2018-for-lung-colorectal-breast-and-prostate-cancer 2019-12-01T00:34:02 https://maestrodatabase.com/blog/will-the-biden-administration-use-march-in-to-protect-prostate-cancer-patients-from-excessive-drug-prices 2022-01-04T02:28:07 https://maestrodatabase.com/blog/a-healthier-medicare-for-chronically-ill-patients 2016-03-31T04:16:17 https://maestrodatabase.com/blog/japan-health-ministry-panel-backs-pfizer-and-moderna-omicron-boosters 2022-09-12T21:23:30 https://maestrodatabase.com/blog/a-novel-uk-approach-to-cancer-access-yes-no-or-maybe 2016-08-11T23:33:58 https://maestrodatabase.com/blog/cheaper-medicine-for-thousands-of-australian-patients 2018-03-26T01:00:41 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-december-2019-update 2019-12-01T00:25:48 https://maestrodatabase.com/blog/poseida-therapeutics-receives-regenerative-medicine-advanced-therapy-designation-from-fda-for-p-bcma-101 2018-11-06T01:21:34 https://maestrodatabase.com/blog/pfizer-announces-european-medicines-agency-accepted-for-review-its-marketing-authorisation-application-for-xeljanz-tofacitinib-citrate-for-the-treatment-of-moderate-to-severe-rheumatoid-arthritis 2016-03-24T21:21:39 https://maestrodatabase.com/blog/icer-to-assess-therapies-for-hereditary-angioedema-in-upcoming-assessment 2018-03-26T01:09:25 https://maestrodatabase.com/blog/vertex-seeks-deal-after-nice-rejects-cf-drug-orkambi 2016-07-27T21:07:03 https://maestrodatabase.com/blog/the-smc-recommends-use-of-hansa-biopharmas-idefirix-imlifidase-as-desensitisation-treatment-for-highly-sensitised-kidney-transplant-patients 2022-09-12T21:28:43 https://maestrodatabase.com/blog/access-to-medicines-working-group-communique---7-august-2014 2015-08-05T11:37:27 https://maestrodatabase.com/blog/quebec-government-to-cover-tecfidera-as-a-first-line-oral-treatment-for-multiple-sclerosis 2015-08-05T11:37:28 https://maestrodatabase.com/blog/besremi-gains-reimbursement-as-second-line-therapy-for-polycythemia-vera-in-korea 2025-09-17T03:19:04 https://maestrodatabase.com/blog/a-medicare-option-for-the-uninsured 2016-05-12T14:26:58 https://maestrodatabase.com/blog/novartis-wins-eu-approval-for-multiple-myeloma-drug-farydak 2015-09-04T12:23:03 https://maestrodatabase.com/blog/laws-to-shed-light-on-drug-pricing-strategies-probably-wont-work 2016-08-16T11:11:52 https://maestrodatabase.com/blog/simponi__golimumab__receives_health_canada_approval_for_patients_with_ulcerative_colitis 2015-08-05T11:37:05 https://maestrodatabase.com/blog/pharmac-proposes-funding-a-new-brand-of-adhd-medicine 2025-09-17T05:11:55 https://maestrodatabase.com/blog/nice_draft_guidance_asks_genzyme_for_more_information_for_teriflunomide__aubagio_ 2015-08-05T11:37:23 https://maestrodatabase.com/blog/cadth-calls-for-patient-input-on-a-submission-from-gilead-on-new-combination-treatment-for-patients-with-hiv-infection 2016-01-05T06:24:55 https://maestrodatabase.com/blog/court-blocks-novartis-copy-of-amgen-cancer-care-drug 2015-08-05T11:37:20 https://maestrodatabase.com/blog/merck-canada-inc-to-enter-new-area-of-medicine-with-biosimilars-in-canada 2015-12-04T20:37:12 https://maestrodatabase.com/blog/ahrq-report-shows-gains-in-access-to-and-affordability-of-health-insurance 2016-05-03T21:18:25 https://maestrodatabase.com/blog/cadth-common-drug-review-backlog-cleared--effective-february-24-2015 2015-08-05T11:37:26 https://maestrodatabase.com/blog/us-fda-approves-eisais-anti-epileptic-agent-fycompa-as-adjunctive-treatment-for-primary-generalised-tonic-clonic-seizures 2015-08-05T11:37:04 https://maestrodatabase.com/blog/fda-panel-turns-down-fast-track-approval-of-astrazeneca-cancer-drug 2015-08-05T11:37:05 https://maestrodatabase.com/blog/pbs-software-developers-website-redesign 2016-05-25T10:47:55 https://maestrodatabase.com/blog/pbac-holds-hepatitis-c-virus-stakeholder-meeting 2015-08-05T11:37:12 https://maestrodatabase.com/blog/nivolumab-in-melanoma-added-benefit-in-certain-patients-says-german-iqwig 2015-10-20T20:32:26 https://maestrodatabase.com/blog/acelrx-provides-regulatory-update-on-zalviso 2015-08-05T11:37:07 https://maestrodatabase.com/blog/fda-approves-empliciti-a-new-immune-stimulating-therapy-to-treat-multiple-myeloma 2015-11-30T19:58:02 https://maestrodatabase.com/blog/fda-approves-zydelig-for-three-types-of-blood-cancers 2015-08-05T11:37:02 https://maestrodatabase.com/blog/alexion-receives-chmp-positive-opinions-for-strensiq-asfotase-alfa-and-kanuma-sebelipase-alfa-in-the-european-union 2015-08-05T11:37:15 https://maestrodatabase.com/blog/fda-approves-new-treatment-for-inhalation-anthrax 2016-03-21T19:58:17 https://maestrodatabase.com/blog/prezcobix-darunavircobicistat-approved-in-the-us-for-the-treatment-of-adults-living-with-hiv-1 2015-08-05T11:37:29 https://maestrodatabase.com/blog/drug-spend-a-hard-pill-to-swallow 2016-03-06T20:19:02 https://maestrodatabase.com/blog/us-fda-accepts-supplemental-biologics-license-application-for-yervoy-ipilimumab-as-adjuvant-treatment-for-patients-with-stage-3-melanoma-who-are-at-high-risk-of-recurrence 2015-08-05T11:37:02 https://maestrodatabase.com/blog/endo-announces-updated-xiaflex-label-with-recurrence-and-retreatment-data-in-patients-with-dupuytrens-contracture 2015-08-05T11:37:12 https://maestrodatabase.com/blog/three-new-drugs-green-lighted-by-smc-for-nhs-scotland 2015-08-10T23:48:13 https://maestrodatabase.com/blog/cms-proposes-2017-payment-and-policy-updates-for-medicare-health-and-drug-plans 2016-02-19T23:39:06 https://maestrodatabase.com/blog/grazoprevirelbasvir-mercks-investigational-chronic-hepatitis-c-therapy-granted-fda-breakthrough-therapy-designations 2015-08-05T11:37:22 https://maestrodatabase.com/blog/flucelvax-quadrivalent-influenza-vaccine-fda-approval 2016-05-24T19:30:10 https://maestrodatabase.com/blog/approval_of_proposal_for_paliperidone__risperidone_and_olanzapine_depot_injections 2015-08-05T11:37:08 https://maestrodatabase.com/blog/nice-recommends-rivaroxaban-xarelto-to-prevent-blood-clots-in-people-who-have-had-a-heart-attack 2015-08-05T11:37:02 https://maestrodatabase.com/blog/patients-suffer-when-nhs-buys-expensive-new-drugs-says-report 2015-08-05T11:37:03 https://maestrodatabase.com/blog/pharmac-seeks-comment-on-levetiracetam-and-lamotrigine-proposal 2015-10-13T20:07:51 https://maestrodatabase.com/blog/pozens-yosprala-receives-complete-response-letter-from-the-fda 2015-08-05T11:37:06 https://maestrodatabase.com/blog/pbs-legislative-amendments 2018-03-26T02:28:10 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-may-2015-update 2015-08-05T11:37:22 https://maestrodatabase.com/blog/proposed_changes_to_the_brand_and_distribution_of_growth_hormone 2015-08-05T11:37:12 https://maestrodatabase.com/blog/proposal-to-award-sole-supply-of-leflunomide 2016-08-09T11:21:50 https://maestrodatabase.com/blog/nice-guidance-on-ramucirumab-for-previously-treated-locally-advanced-or-metastatic-non-small-cell-lung-cancer 2016-08-25T00:05:50 https://maestrodatabase.com/blog/nice-gives-green-light-to-pembrolizumab-for-advanced-skin-cancer 2015-10-07T20:13:54 https://maestrodatabase.com/blog/rejected-by-the-government-ive-spent-160-000-dollars-just-to-keep-myself-alive 2018-03-26T02:05:49 https://maestrodatabase.com/blog/pharmac-tender-for-generic-medicines-contributes-38-million-savings 2015-08-05T11:37:13 https://maestrodatabase.com/blog/call-for-patient-input-on-a-submission-from-ucb-for-brivaracetam 2016-03-17T20:43:54 https://maestrodatabase.com/blog/what-drugs-really-cost-gao-wants-cms-to-find-out 2016-08-04T12:21:05 https://maestrodatabase.com/blog/consultation-paper-on-proposal-to-introduce-a-cost-recovered-pathway-for-medical-services-advisory-committee-applications 2022-01-04T03:36:54 https://maestrodatabase.com/blog/listing-of-various-contrast-media 2015-08-05T11:37:10 https://maestrodatabase.com/blog/cadth-calls-for-patient-input-on-submissions-for-2-new-medicines-for-use-by-patients-with-hiv-infection 2016-02-06T06:11:03 https://maestrodatabase.com/blog/nice-launches-initiative-to-speed-up-adoption-of-health-technologies 2015-10-13T11:34:31 https://maestrodatabase.com/blog/nhs-plan-to-reassess-value-of-cancer-drugs-alarms-patient-groups 2016-02-25T20:51:48 https://maestrodatabase.com/blog/new-hope-for-psoriasis-sufferers-as-new-drug-skyrizi-added-to-pbs 2019-12-01T02:01:48 https://maestrodatabase.com/blog/modelling-and-simulation-in-the-development-and-regulatory-review-of-medicines 2016-07-31T23:03:42 https://maestrodatabase.com/blog/zogenix-submits-type-ii-variation-application-to-the-ema-to-expand-the-use-of-fintepla-fenfluramine-for-the-treatment-of-seizures-associated-with-lennox-gastaut-syndrome 2022-01-04T03:40:28 https://maestrodatabase.com/blog/no-matter-what-the-fda-decides-new-diabetes-drugs-will-still-require-cv-outcomes-trials 2018-11-06T20:13:48 https://maestrodatabase.com/blog/ipsen-announces-fda-acceptance-of-filing-for-dysport-in-the-treatment-of-upper-limb-spasticity-in-adult-patients 2015-08-05T11:37:06 https://maestrodatabase.com/blog/merck-submits-us-new-drug-application-for-grazoprevirelbasvir-an-investigational-once-daily-single-tablet-combination-therapy-for-treatment-of-chronic-hepatitis-c-genotypes-1-4-and-6-infection 2015-08-05T11:37:09 https://maestrodatabase.com/blog/should-a-drugs-value-depend-on-the-disease-or-population-it-treats-insights-from-icers-value-assessments 2018-11-06T20:22:26 https://maestrodatabase.com/blog/collecting-high-quality-information-on-medicines-through-patient-registries 2015-10-13T11:37:48 https://maestrodatabase.com/blog/australians-could-get-different-covid-vaccines-csl-may-need-an-extra-year-for-a-non-protein-covid-vaccine 2020-10-26T00:58:48 https://maestrodatabase.com/blog/cadth-recommends-2-new-treatments-for-patients-with-overactive-bladder 2015-08-05T11:37:05 https://maestrodatabase.com/blog/pbs-biosimilar-awareness-updated-implementation-framework 2016-01-29T03:45:49 https://maestrodatabase.com/blog/ema-to-review-marketing-authorisation-application-for-sarilumab 2016-08-01T10:57:05 https://maestrodatabase.com/blog/health-canada-accepts-cardiomes-xydalba-new-drug-submission-and-grants-priority-review 2018-03-26T03:59:49 https://maestrodatabase.com/blog/health-minister-greg-hunt-to-announce-my-health-record-changes 2018-11-06T19:51:55 https://maestrodatabase.com/blog/cdr-update-issue-112 2015-09-30T20:43:04 https://maestrodatabase.com/blog/fda-approves-novel-single-vial-formulation-of-egrifta 2018-11-06T20:37:30 https://maestrodatabase.com/blog/iqwig-invites-to-its-autumn-symposium-2015 2015-09-07T20:44:19 https://maestrodatabase.com/blog/compulsory-licenses-for-cancer-drugs-does-circumventing-patent-rights-improve-access-to-oncology-medications 2016-06-30T04:18:03 https://maestrodatabase.com/blog/call-for-patient-input-on-a-submission-from-merck-for-a-subsequent-entry-biologic 2016-03-09T20:13:34 https://maestrodatabase.com/blog/smc-rejects-roches-avastin-for-ovarian-cancer-but-six-new-drugs-are-in 2015-08-05T11:37:29 https://maestrodatabase.com/blog/final-nice-nod-for-sovaldi-but-patients-left-waiting 2015-08-05T11:37:29 https://maestrodatabase.com/blog/trans-pacific-partnership-trade-deal-is-reached 2015-10-06T08:26:53 https://maestrodatabase.com/blog/pharma-makes-lobbying-push-to-roll-back-seniors-drug-discounts 2018-11-06T20:26:43 https://maestrodatabase.com/blog/the-drug-pipeline-flows-again 2015-08-05T11:37:19 https://maestrodatabase.com/blog/merck-receives-complete-response-letter-from-the-us-fda-for-zetia-ezetimibe-and-vytorin-ezetimibe-and-simvastatin 2016-02-16T19:53:48 https://maestrodatabase.com/blog/update-of-the-cost-resource-manual 2018-11-07T02:43:02 https://maestrodatabase.com/blog/trial-reporting-in-clinicaltrialsgov-the-final-rule 2016-09-16T23:45:46 https://maestrodatabase.com/blog/cyramza-now-approved-in-the-u-dot-s-for-use-with-folfiri-in-second-line-treatment-of-metastatic-colorectal-cancer 2015-08-05T11:37:21 https://maestrodatabase.com/blog/shingrix-approved-in-europe-and-japan-for-the-prevention-of-shingles-in-adults-aged-50-and-over 2018-03-26T07:12:41 https://maestrodatabase.com/blog/innovation-in-the-pharmaceutical-industry-new-estimates-of-rd-costs 2016-04-18T09:55:47 https://maestrodatabase.com/blog/nice-recommends-bayers-nubeqa-darolutamide-a-new-treatment-option-for-non-metastatic-castration-resistant-prostate-cancer 2020-10-26T05:18:47 https://maestrodatabase.com/blog/u-dot-s-fda-approves-empliciti-elotuzumab-plus-pomalidomide-and-dexamethasone-a-new-immunotherapy-combination-for-certain-patients-with-relapsed-or-refractory-multiple-myeloma 2018-11-07T02:32:51 https://maestrodatabase.com/blog/corstasis-therapeutics-announces-fda-approval-of-enbumyst-bumetanide-nasal-spray-for-the-treatment-of-oedema-associated-with-congestive-heart-failure-liver-disease-and-kidney-disease 2025-09-17T21:30:02 https://maestrodatabase.com/blog/nice-says-no-to-expanding-scope-of-roches-ipf-drug 2016-09-19T11:46:13 https://maestrodatabase.com/blog/ifhp-publishes-2013-price-report 2015-09-28T21:14:50 https://maestrodatabase.com/blog/tga-publishes-auspar-for-pertuzumab-perjeta 2016-08-23T04:20:39 https://maestrodatabase.com/blog/ema-ready-to-address-challenges-ahead 2015-12-09T20:21:45 https://maestrodatabase.com/blog/eu-recommendations-for-2018-slash-2019-seasonal-flu-vaccine-composition 2018-03-26T20:09:52 https://maestrodatabase.com/blog/nice-set-to-recommend-another-leukaemia-drug 2015-08-05T11:37:18 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-december-2019-update 2019-12-01T03:18:58 https://maestrodatabase.com/blog/epipen-maker-dispenses-outsize-pay 2016-09-14T05:01:58 https://maestrodatabase.com/blog/eisai-confirms-life-extending-breast-cancer-treatment-halaven-eribulin-to-remain-on-cancer-drugs-fund-pending-reconsideration 2015-08-05T11:37:18 https://maestrodatabase.com/blog/octapharma-usa-fda-approves-wilate-license-supplement-peri-operative-management-of-bleeding-in-patients-with-von-willebrand-disease 2015-08-16T05:16:30 https://maestrodatabase.com/blog/fda-grants-priority-review-for-dupixent-dupilumab-as-potential-treatment-for-adolescents-with-uncontrolled-moderate-to-severe-atopic-dermatitis 2018-11-07T03:01:02 https://maestrodatabase.com/blog/more-than-health-on-line-in-patent-debate 2016-09-24T05:27:21 https://maestrodatabase.com/blog/european-union-would-apply-lower-threshold-in-assessing-covid-19-vaccine 2020-10-26T02:05:50 https://maestrodatabase.com/blog/political-parties-commit-support-for-community-pharmacy-model 2016-06-18T03:43:16 https://maestrodatabase.com/blog/doctors-name-and-shame-health-insurers-as-profits-and-complaints-soar 2018-03-26T20:07:34 https://maestrodatabase.com/blog/agenda-for-the-29-june-2016-tc-meeting 2016-06-23T21:44:40 https://maestrodatabase.com/blog/fda-approves-new-treatment-for-most-common-form-of-advanced-skin-cancer 2015-08-05T11:37:23 https://maestrodatabase.com/blog/cadth-publishes-final-report-for-antivascular-endothelial-growth-factor-drugs-for-retinal-conditions 2016-05-17T21:11:57 https://maestrodatabase.com/blog/auspars-user-survey 2016-05-02T06:35:57 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-positive-chmp-opinion-recommending-approval-of-opdivo-four-week-dosing-schedule-for-advanced-melanoma-and-previously-treated-renal-cell-carcinoma 2018-03-26T20:22:11 https://maestrodatabase.com/blog/adaptive-design-clinical-trials-for-drugs-and-biologics-guidance-for-industry 2019-12-01T20:34:29 https://maestrodatabase.com/blog/mesoblast-to-accelerate-research-on-promising-kidney-treatment 2015-08-05T11:37:11 https://maestrodatabase.com/blog/the-high-cost-of-prescription-drugs-in-the-united-states-origins-and-prospects-for-reform-1 2016-08-24T21:27:58 https://maestrodatabase.com/blog/trumps-drug-importation-plan-faces-resistance-in-us-canada 2019-12-01T20:28:16 https://maestrodatabase.com/blog/biomarin-announces-health-canada-approval-of-vimizim-elosulfase-alfa-for-the-treatment-of-morquio-a-syndrome 2015-08-05T11:37:11 https://maestrodatabase.com/blog/multiple-sclerosis-treatments-funding-proposal 2015-08-05T11:37:18 https://maestrodatabase.com/blog/private-health-system-in-a-death-spiral-says-expert-but-what-can-be-done-to-save-it 2019-12-01T20:24:50 https://maestrodatabase.com/blog/emas-medical-literature-monitoring-enters-into-full-operation 2015-09-01T20:40:53 https://maestrodatabase.com/blog/canada-probes-horizon-pharma-over-efforts-to-boost-sales-of-a-rare-disease-drug 2018-03-26T20:36:54 https://maestrodatabase.com/blog/early-nice-rejection-for-lillys-gastric-cancer-drug-cyramza 2015-09-15T11:56:32 https://maestrodatabase.com/blog/chinese-policies-fail-to-curb-soaring-drug-prices 2019-06-03T05:12:16 https://maestrodatabase.com/blog/a-market-based-proposal-for-controlling-drug-prices 2016-06-20T21:26:55 https://maestrodatabase.com/blog/nice-publishes-final-drug-recommendations-for-the-treatment-of-3-separate-medical-conditions 2015-10-28T20:13:14 https://maestrodatabase.com/blog/young-canadians-feeling-the-pinch-of-sky-high-prescription-drug-prices 2018-03-26T20:40:03 https://maestrodatabase.com/blog/tga-key-performance-indicators-july-to-december-2014 2015-08-05T11:37:06 https://maestrodatabase.com/blog/poll-finds-majority-of-americans-want-restraints-on-drug-prices 2016-09-29T21:32:40 https://maestrodatabase.com/blog/novo-nordisk-files-for-regulatory-approval-of-faster-acting-insulin-aspart-in-the-us-for-the-treatment-of-type-1-and-2-diabetes 2015-12-13T20:20:27 https://maestrodatabase.com/blog/industry-welcomes-progress-on-brexit 2018-03-26T20:33:48 https://maestrodatabase.com/blog/insurers-dont-want-to-pay-for-pricey-cancer-medicines 2015-11-29T20:44:34 https://maestrodatabase.com/blog/icr-urges-change-as-nice-rejects-keytruda-plus-chemotherapy 2020-10-26T07:04:16 https://maestrodatabase.com/blog/abbvies-humira-adalimumab-receives-first-and-only-us-food-and-drug-administration-approval-for-moderate-to-severe-hidradenitis-suppurativa 2015-09-11T08:17:06 https://maestrodatabase.com/blog/seattle-genetics-and-astellas-receive-fda-breakthrough-therapy-designation-for-enfortumab-vedotin-in-locally-advanced-or-metastatic-urothelial-cancer 2018-03-26T20:50:46 https://maestrodatabase.com/blog/how-medical-science-hopes-to-slow-down-ageing 2016-08-15T21:04:27 https://maestrodatabase.com/blog/saving-antibiotics-so-that-antibiotics-can-save-lives 2016-09-16T04:49:11 https://maestrodatabase.com/blog/pbs-listing-with-strings-for-melanoma-drug 2015-08-05T11:37:24 https://maestrodatabase.com/blog/gmia-welcomes-the-pbac-consideration-of-a-flagging-biosimilars-and-the-pbs-listing-of-the-first-biosimilar-insulin 2015-08-05T11:37:16 https://maestrodatabase.com/blog/novartis-shows-growing-strength-in-lung-cancer-innovation-with-new-capmatinib-investigational-data 2019-06-03T06:20:37 https://maestrodatabase.com/blog/shire-receives-extension-of-market-authorization-in-europe-for-revestive-teduglutide-for-the-treatment-of-paediatric-patients-with-short-bowel-syndrome 2016-07-07T11:45:30 https://maestrodatabase.com/blog/alnylam-receives-ema-prime-designation-for-accelerated-assessment-of-lumasiran-an-investigational-rnai-therapeutic-for-the-treatment-of-primary-hyperoxaluria-type-1 2018-03-26T20:43:56 https://maestrodatabase.com/blog/tlv-is-reconsidering-the-subsidy-for-hepatitis-c-drugs-with-side-agreements 2020-10-26T09:24:53 https://maestrodatabase.com/blog/nice-and-janssen-urged-to-end-zytiga-fiasco 2015-08-05T11:37:23 https://maestrodatabase.com/blog/no-end-in-sight-to-rising-drug-prices-study-finds 2019-06-03T05:14:28 https://maestrodatabase.com/blog/relevant_additions_and_changes_from_the_1_september_2013_issue_of_the_schedule_of_pharmaceutical_benefits_have_been_added_to_maestro_australia 2015-08-05T11:37:05 https://maestrodatabase.com/blog/a-billionaire-couple-is-pumping-money-into-the-drug-pricing-debate-can-they-loosen-pharmas-grip 2018-03-26T20:59:39 https://maestrodatabase.com/blog/fda-european-commission-and-ema-reinforce-collaboration-to-advance-medicine-development-and-evaluation 2015-08-05T11:37:09 https://maestrodatabase.com/blog/fda-approves-bayers-gadavist-gadobutrol-injection-as-the-first-magnetic-resonance-contrast-agent-for-evaluation-of-breast-cancer-in-the-united-states 2015-08-05T11:37:07 https://maestrodatabase.com/blog/vertex-receives-us-food-and-drug-administration-approval-of-kalydeco-ivacaftor-for-children-with-cystic-fibrosis-ages-2-to-5-who-have-specific-mutations-in-the-cftr-gene 2015-08-05T11:37:11 https://maestrodatabase.com/blog/improving-price-transparency-in-cancer-care 2016-02-03T00:55:43 https://maestrodatabase.com/blog/process_changes_for_end_of_life_and_very_rare_conditions 2015-08-05T11:37:15 https://maestrodatabase.com/blog/make-new-chemo-drugs-more-accessible-by-passing-the-cancer-drug-coverage-parity-act 2018-03-26T20:57:20 https://maestrodatabase.com/blog/australia-among-top-10-healthiest-countries-in-the-world-global-burden-of-disease-study-shows 2016-09-23T10:20:09 https://maestrodatabase.com/blog/could-big-pharma-actually-lose-this-fight-over-drug-prices-its-bidens-call 2021-06-05T20:55:01 https://maestrodatabase.com/blog/decision_to_award_sole_supply_to_tacrolimus_sandoz 2015-08-05T11:37:12 https://maestrodatabase.com/blog/abbvie-announces-humira-adalimumab-global-patent-license-with-momenta 2018-11-07T04:18:26 https://maestrodatabase.com/blog/fda-approves-the-first-oral-medication-for-the-management-of-heavy-menstrual-bleeding-due-to-uterine-fibroids-in-pre-menopausal-women 2020-05-31T00:44:34 https://maestrodatabase.com/blog/agenda-for-7-may-2014-transparency-commission-meeting 2015-08-05T11:37:08 https://maestrodatabase.com/blog/fda-approves-ninlaro-new-oral-medication-to-treat-multiple-myeloma 2015-11-20T20:57:32 https://maestrodatabase.com/blog/ipsens-somatuline-depot-is-the-first-therapy-approved-by-the-fda-in-the-united-states-for-the-treatment-of-patients-with-locally-advanced-or-metastatic-gastroenteropancreatic-neuroendocrine-tumors 2015-08-05T11:37:03 https://maestrodatabase.com/blog/cdec-recommends-simponi-iv 2015-08-05T11:37:22 https://maestrodatabase.com/blog/global-regulators-work-towards-alignment-on-policy-approaches-and-regulatory-flexibility-during-covid-19---update-number-3 2020-05-31T00:49:03 https://maestrodatabase.com/blog/anti-mtbr-microtubule-binding-region-tau-antibody-etalanetug-granted-fda-fast-track-designation 2025-09-18T00:38:12 https://maestrodatabase.com/blog/alcon-receives-fda-approval-of-pazeo-solution-for-ocular-allergy-itch-relief 2015-08-05T11:37:22 https://maestrodatabase.com/blog/fda-commissioner-calls-for-sarepta-drug-study-to-be-retracted 2016-09-22T20:55:57 https://maestrodatabase.com/blog/covid-19-reminder-of-the-risks-of-chloroquine-and-hydroxychloroquine 2020-05-31T00:53:37 https://maestrodatabase.com/blog/nice-consults-on-treatment-for-finger-contracture-caused-by-dupuytrens-disease 2015-08-05T11:37:29 https://maestrodatabase.com/blog/mhra-approves-adapted-nuvaxovid-jn-dot-1-covid-19-vaccine-for-adults-and-children-aged-12-plus 2024-11-17T04:02:22 https://maestrodatabase.com/blog/final-reports-on-drugs-for-chronic-hepatitis-c-infection 2016-01-05T20:30:47 https://maestrodatabase.com/blog/cancer-drugs-fund-delisting-september-2015 2015-09-04T05:51:10 https://maestrodatabase.com/blog/evidence-of-clinical-benefit-of-cancer-medicines-considered-for-funding-in-australia 2024-11-17T03:57:18 https://maestrodatabase.com/blog/pbs_expenditure_is_contained_and_sustainable 2015-08-05T11:37:08 https://maestrodatabase.com/blog/biogen-receives-european-commission-approval-for-zurzuvae-zuranolone-the-first-and-only-treatment-approved-for-women-with-postpartum-depression-in-europe 2025-09-18T01:13:12 https://maestrodatabase.com/blog/merck-receives-european-medicines-agency-acceptance-for-review-of-marketing-authorization-application-for-cladribine-tablets 2016-07-18T21:13:52 https://maestrodatabase.com/blog/pharmacist-army-ready-to-jab-australians-with-covid-19-vaccine 2020-10-26T09:29:49 https://maestrodatabase.com/blog/why-the-us-pays-more-than-other-countries-for-drugs 2015-12-01T19:59:18 https://maestrodatabase.com/blog/lillys-cyramza-ramucirumab-receives-fda-approval-as-first-line-treatment-for-metastatic-egfr-mutated-non-small-cell-lung-cancer 2020-05-31T00:40:14 https://maestrodatabase.com/blog/adaptive-designs-for-clinical-trials 2016-07-06T22:00:14 https://maestrodatabase.com/blog/james-raftery-nice-and-value-based-pricing---is-this-the-end 2015-08-05T11:37:10 https://maestrodatabase.com/blog/hepatitis-c-sufferers-ire-at-activist-website-ban 2016-06-15T21:38:57 https://maestrodatabase.com/blog/european-commission-grants-marketing-authorization-for-cerdelga-eliglustat-genzymes-oral-therapy-for-gaucher-disease-type-1 2015-08-05T11:37:07 https://maestrodatabase.com/blog/fda-approves-extended-release-single-entity-hydrocodone-product-with-abuse-deterrent-properties 2015-08-05T11:37:07 https://maestrodatabase.com/blog/belatacept-after-a-kidney-transplant-indication-of-considerable-added-benefit-iqwig 2015-10-21T22:39:12 https://maestrodatabase.com/blog/forte-biosciences-announces-the-fda-has-granted-fast-track-designation-to-fb-401-for-the-treatment-of-atopic-dermatitis 2020-10-26T19:46:57 https://maestrodatabase.com/blog/sanofi-and-regeneron-announce-chmp-recommends-european-approval-of-praluent-alirocumab-for-the-treatment-of-hypercholesterolaemia 2015-08-05T11:37:07 https://maestrodatabase.com/blog/upgrade-to-tga-website 2015-08-05T11:37:09 https://maestrodatabase.com/blog/agenda-for-the-22-october-2014-transparency-commission-meeting 2015-08-05T11:37:16 https://maestrodatabase.com/blog/uk-cost-agency-queries-value-of-700000-a-year-alexion-drug 2016-02-18T20:15:19 https://maestrodatabase.com/blog/highlights-from-the-may-25-28-chmp-meeting 2020-05-31T00:56:08 https://maestrodatabase.com/blog/spectrum-pharmaceuticals-receives-complete-response-letter-from-us-food-and-drug-administration-for-evomela-melphalan-for-injection 2015-10-23T09:51:56 https://maestrodatabase.com/blog/canada-to-limit-scope-of-new-drug-price-rules 2019-06-03T07:07:29 https://maestrodatabase.com/blog/promise-and-peril-for-generic-drugs 2016-05-10T04:54:14 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-to-nkt-therapeutics-nktt120-for-the-treatment-of-sickle-cell-disease 2015-08-05T11:37:24 https://maestrodatabase.com/blog/spectrum-pharmaceuticals-announces-that-the-fda-is-deferring-its-action-on-the-bla-for-rolontis-eflapegrastim 2020-10-26T19:35:34 https://maestrodatabase.com/blog/ema-accepts-eisais-request-for-accelerated-assessment-of-anticancer-agent-lenvatinib 2015-08-05T11:37:05 https://maestrodatabase.com/blog/the-impact-of-innovative-pharmaceuticals-on-new-zealand-cancer-patients 2016-08-21T21:50:29 https://maestrodatabase.com/blog/janssen-submits-application-to-u-dot-s-fda-for-new-indication-to-expand-use-of-xarelto-rivaroxaban-in-patients-with-peripheral-artery-disease 2020-10-26T19:41:14 https://maestrodatabase.com/blog/experimental-cancer-therapy-holds-great-promise-but-at-great-cost 2016-08-23T19:22:42 https://maestrodatabase.com/blog/i-thought-melanoma-would-kill-me-heres-why-it-didnt 2016-07-19T21:02:13 https://maestrodatabase.com/blog/public_summary_documents_from_the_november_2013_pbac_meeting__rejections_ 2015-08-05T11:37:07 https://maestrodatabase.com/blog/establishing-genomics-australia 2024-11-17T04:47:50 https://maestrodatabase.com/blog/statement-by-chip-davis-president-and-ceo-gpha-regarding-the-trans-pacific-partnership-agreement 2015-10-06T06:37:42 https://maestrodatabase.com/blog/addendum-on-regorafenib-in-metastatic-colorectal-cancer-added-benefit-no-longer-proven 2016-03-19T05:59:40 https://maestrodatabase.com/blog/merck-receives-breakthrough-therapy-designation-from-us-fda-for-keytruda-pembrolizumab-in-classical-hodgkins-lymphoma-chl 2016-04-18T18:22:37 https://maestrodatabase.com/blog/alzheimers-drug-poses-a-dilemma-for-the-fda 2021-06-05T22:25:47 https://maestrodatabase.com/blog/brukinsa-gets-reimbursement-to-treat-rare-blood-cancer-patients 2023-06-14T03:34:20 https://maestrodatabase.com/blog/health-system-cares-for-big-insurers-big-pharma 2016-06-06T21:01:57 https://maestrodatabase.com/blog/request-for-proposals-for-biological-qualifier-impact-assessment-study 2016-02-05T21:37:53 https://maestrodatabase.com/blog/single-payer-reform---medicare-for-all 2019-06-03T07:09:45 https://maestrodatabase.com/blog/agenda-for-the-20-april-2016-tc-meeting 2016-04-13T21:31:35 https://maestrodatabase.com/blog/delay-in-decision-on-ferric-carboxymaltose-ferinject-funding-proposal 2015-08-05T11:37:23 https://maestrodatabase.com/blog/what-can-europe-learn-from-the-managed-care-backlash-in-the-united-states 2016-05-09T06:47:02 https://maestrodatabase.com/blog/santen-announces-u-dot-s-fda-filing-acceptance-of-new-drug-application-for-cyclosporin-0-dot-1-percent-topical-ophthalmic-emulsion-for-the-treatment-of-severe-vernal-keratoconjunctivitis-in-patients-ages-4-18 2020-10-26T19:52:51 https://maestrodatabase.com/blog/put-canadians-first-by-suspending-the-implementation-of-harmful-drug-pricing-regulations 2021-06-05T22:16:08 https://maestrodatabase.com/blog/rfp-supply-of-bortezomib 2016-03-16T20:14:14 https://maestrodatabase.com/blog/pharmac-expands-into-new-medical-device-category 2015-08-05T11:37:16 https://maestrodatabase.com/blog/zurampic-lesinurad-approved-in-the-european-union-for-patients-with-gout 2016-02-19T23:32:14 https://maestrodatabase.com/blog/pbac-guidelines-website-design-update 2016-02-11T06:48:44 https://maestrodatabase.com/blog/nice_recommends_nhs_funding_for_new_cancer_treatment 2015-08-05T11:37:19 https://maestrodatabase.com/blog/newly-approved-obesity-drug-wegovy-holds-promise-but-faces-reimbursement-challenges 2021-06-05T22:20:15 https://maestrodatabase.com/blog/nice-rejects-lillys-portrazza 2016-09-29T05:05:04 https://maestrodatabase.com/blog/availability-and-dissemination-of-results-from-us-fdamandated-post-approval-studies-for-medical-devices 2016-06-29T00:17:16 https://maestrodatabase.com/blog/sacubitril-valsartan-in-heart-failure-differentiated-value-added 2016-06-16T21:59:02 https://maestrodatabase.com/blog/galt-pharmaceuticals-answers-the-call-for-better-practices-in-pain-management-with-a-non-opioid-therapeutic-alternative 2019-06-03T13:08:25 https://maestrodatabase.com/blog/novartis-receives-fda-regular-approval-for-tafinlar-mekinist-to-treat-aggressive-form-of-melanoma-based-on-long-term-survival-data 2015-11-23T20:16:09 https://maestrodatabase.com/blog/abbvie-announces-u-dot-s-fda-granted-breakthrough-therapy-designation-to-telisotuzumab-vedotin-for-previously-treated-non-small-cell-lung-cancer 2022-01-04T21:02:08 https://maestrodatabase.com/blog/vorasidenib-approved-to-treat-patients-12-years-and-older-with-grade-2-astrocytoma-or-oligodendroglioma-with-a-susceptible-idh1-or-idh2-mutation 2025-09-18T01:31:48 https://maestrodatabase.com/blog/sofosbuvir_shows_an_indication_of_additional_benefit_for_certain_patients 2015-08-05T11:37:26 https://maestrodatabase.com/blog/agenda-for-21-september-2016-tc-meeting 2016-09-19T12:12:07 https://maestrodatabase.com/blog/turing-ceo-martin-shkreli-backflips-on-daraprim-price-following-backlash-from-hillary-clinton 2015-09-23T07:51:11 https://maestrodatabase.com/blog/ema-celebrates-ten-years-of-its-patients-and-consumers-working-party 2016-06-10T23:45:37 https://maestrodatabase.com/blog/alteogen-receives-european-commission-approval-for-aflibercept-biosimilar-eyluxvi-alt-l9 2025-09-18T01:43:13 https://maestrodatabase.com/blog/registration-of-nces-by-the-tga-september-2015 2015-10-01T11:15:56 https://maestrodatabase.com/blog/health-canada-approves-amgens-new-multiple-myeloma-treatment-kyprolis-carfilzomib 2016-01-29T23:16:23 https://maestrodatabase.com/blog/fda-blueprint-for-helping-children-with-rare-diseases 2015-08-05T11:37:11 https://maestrodatabase.com/blog/surgeons-face-sanction-for-imposing-severe-financial-pain 2019-06-03T21:00:26 https://maestrodatabase.com/blog/fda-accepts-lundbeck-resubmission-of-new-drug-application-for-carnexiv-carbamazepine 2016-04-25T21:03:08 https://maestrodatabase.com/blog/gsk-receives-european-marketing-authorisation-for-nucala-mepolizumab-in-31-countries 2015-12-03T06:35:20 https://maestrodatabase.com/blog/australians-lives-have-a-price---a-quality-adjusted-life-year-worth-about-50-000-dollars 2019-06-03T20:56:35 https://maestrodatabase.com/blog/dulaglutide-in-type-2-diabetes-hint-of-an-added-benefit-in-combination-with-short-acting-insulin 2015-08-05T11:37:16 https://maestrodatabase.com/blog/fda-announces-project-facilitate-to-assist-physicians-seeking-access-to-unapproved-therapies-for-patients-with-cancer 2019-06-03T20:51:42 https://maestrodatabase.com/blog/new-drug-application-for-iressa-accepted-by-us-food-and-drug-administration 2015-08-05T11:37:04 https://maestrodatabase.com/blog/junshi-biosciences-announces-uk-mhra-approval-for-marketing-of-toripalimab 2024-11-17T08:33:20 https://maestrodatabase.com/blog/are-you-paying-the-nhs-for-more-drugs-than-you-need-billions-worth-of-life-saving-cancer-remedies-are-poured-down-the-drain-every-year 2016-07-26T21:27:25 https://maestrodatabase.com/blog/fda-approves-genentechs-tecentriq-in-combination-with-avastin-for-people-with-the-most-common-form-of-liver-cancer 2020-05-31T01:23:38 https://maestrodatabase.com/blog/scripps-study-claims-rebate-system-does-inflate-drug-prices 2019-06-03T21:16:37 https://maestrodatabase.com/blog/drug-utilisation-sub-committee-outcome-statement-2 2016-08-10T06:09:47 https://maestrodatabase.com/blog/highlights-from-the-chmp-meeting-22-25-february-2016 2016-02-27T03:09:55 https://maestrodatabase.com/blog/widening_of_funding_restrictions_for_rituximab_and_eltrombopag 2015-08-05T11:37:04 https://maestrodatabase.com/blog/first-in-class-type-2-diabetes-medication-approved-in-canada 2015-08-05T11:37:17 https://maestrodatabase.com/blog/health-reform-agenda-to-maintain-momentum 2015-09-22T12:30:38 https://maestrodatabase.com/blog/sandoz-receives-ec-approval-for-subcutaneous-route-of-administration-in-biosimilar-binocrits-nephrology-indication 2016-04-08T05:34:20 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule-1-february-2016-update 2016-01-31T20:59:45 https://maestrodatabase.com/blog/fda-approves-new-treatment-for-hospital-acquired-and-ventilator-associated-bacterial-pneumonia 2019-06-03T21:08:38 https://maestrodatabase.com/blog/takeda-and-orexigen-announce-availability-of-contrave-naltrexone-hcl-and-bupropion-hcl--extended-release-tablets-for-chronic-weight-management-in-obese-adults 2015-08-05T11:37:24 https://maestrodatabase.com/blog/hancock-says-nhs-not-for-sale-in-post-brexit-us-trade-talks 2019-06-03T21:45:18 https://maestrodatabase.com/blog/information-specialist-collaboration-in-europe-collaborative-methods-processes-and-infrastructure-through-eunethta 2020-10-27T00:37:54 https://maestrodatabase.com/blog/simponi_i_v___golimumab__becomes_first_fully_human_anti_tnf_infusion_therapy_approved_for_treatment_of_moderately_to_severely_active_rheumatoid_arthritis 2015-08-05T11:37:09 https://maestrodatabase.com/blog/relevant_additions_and_changes_from_the_1_may_2014_issue_of_the_schedule_of_pharmaceutical_benefits_have_been_added_to_maestro_australia 2015-08-05T11:37:26 https://maestrodatabase.com/blog/heritage-pharmaceuticals-to-pay-7-dollars-million-to-settle-price-fixing-allegations 2019-06-03T21:39:30 https://maestrodatabase.com/blog/therabron-therapeutics-receives-fda-fast-track-designation-for-rhcc10-for-the-prevention-of-chronic-lung-disease-related-to-premature-birth 2016-04-29T23:05:17 https://maestrodatabase.com/blog/tax-avoidance-inquiry-calls-on-nine-big-pharma-bosses-to-explain-tax-contribution 2015-08-05T11:37:19 https://maestrodatabase.com/blog/valeants-high-price-drug-strategy 2015-10-04T10:55:13 https://maestrodatabase.com/blog/cadth-publishes-initial-recommendation-for-darzalex-daratumumab 2016-09-30T23:06:53 https://maestrodatabase.com/blog/biosimilar-pegfilgrastim-can-increase-access-but-patient-perception-remains-a-biosimilar-barrier 2019-06-03T21:26:01 https://maestrodatabase.com/blog/incyte-announces-health-canada-acceptance-of-the-new-drug-submission-for-pemigatinib-as-a-treatment-for-patients-with-cholangiocarcinoma 2020-10-27T01:26:04 https://maestrodatabase.com/blog/sussan-ley-confirms-pharmaceutical-benefits-scheme-crackdown-in-may-budget 2015-08-05T11:37:14 https://maestrodatabase.com/blog/shire-announces-us-fda-approval-of-cuvitra-immune-globulin-subcutaneous-human-20-solution-treatment-for-primary-immunodeficiency 2016-09-15T05:10:10 https://maestrodatabase.com/blog/how-to-facilitate-development-of-cancer-immunotherapies 2016-02-02T20:36:03 https://maestrodatabase.com/blog/acacia-pharma-resubmits-barhemsys-new-drug-application 2018-11-07T09:20:25 https://maestrodatabase.com/blog/pharmac-responds-to-concerns-about-medication-shortages 2020-10-27T06:07:40 https://maestrodatabase.com/blog/new-brunswick-includes-lemtrada-alemtuzumab-on-provincial-drug-program-for-eligible-patients 2016-08-26T07:06:50 https://maestrodatabase.com/blog/health-economic-assessment-of-pluvicto-in-advanced-prostate-cancer 2023-06-14T05:41:25 https://maestrodatabase.com/blog/chmp-grants-positive-opinions-of-abbvies-viekirax-ombitasvir-with-paritepravir-and-ritonavir-and-exviera-dasabuvir-sodium-for-the-treatment-of-chronic-hepatitis-c-in-europe 2015-08-05T11:37:26 https://maestrodatabase.com/blog/smc-no-for-zytiga-but-four-new-meds-are-in 2015-08-05T11:37:09 https://maestrodatabase.com/blog/american-voters-have-a-simple-health-care-message-for-2020-just-fix-it 2019-06-03T21:51:08 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-june-2020 2020-05-31T20:59:21 https://maestrodatabase.com/blog/fda-grants-priority-review-and-ema-accepts-regulatory-submission-for-pfizers-abrocitinib-an-oral-once-daily-jak1-inhibitor-for-patients-12-and-up-with-moderate-to-severe-atopic-dermatitis 2020-10-27T11:25:42 https://maestrodatabase.com/blog/update-on-publication-of-clinical-data-1 2015-09-22T20:35:47 https://maestrodatabase.com/blog/the-drug-industry-can-help-reduce-cancer-drug-costs 2016-03-23T02:39:06 https://maestrodatabase.com/blog/health-law-improved-access-to-cancer-treatment-studies-show 2019-06-03T21:48:02 https://maestrodatabase.com/blog/novartis-piqray-receives-positive-chmp-opinion-to-treat-hr-plus-slash-her2--advanced-breast-cancer-with-a-pik3ca-mutation 2020-05-31T21:07:52 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-may-2015-update 2015-08-05T11:37:08 https://maestrodatabase.com/blog/ema-recommends-treatment-for-rare-cancer-in-children 2015-08-05T11:37:03 https://maestrodatabase.com/blog/fda-moves-quickly-to-approve-easy-to-use-nasal-spray-to-treat-opioid-overdose 2015-11-19T09:59:52 https://maestrodatabase.com/blog/post-market-review-of-authority-required-pbs-listings---opioids-roundtable-meeting 2015-08-05T11:37:14 https://maestrodatabase.com/blog/fda-approves-genzymes-cerdelga-eliglustat-capsules 2015-08-05T11:37:19 https://maestrodatabase.com/blog/darzalex-daratumumab-approved-by-health-canada-as-the-first-human-anti-cd38-monoclonal-antibody-for-the-treatment-of-multiple-myeloma 2016-06-30T21:03:18 https://maestrodatabase.com/blog/pharmac-calls-on-tauranga-for-advice 2016-08-18T02:01:47 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-october-2014 2015-08-05T11:37:30 https://maestrodatabase.com/blog/without-it-i-dont-imagine-id-still-be-here-or-be-a-mum-breast-cancer-sufferers-get-new-hope-as-two-new-life-saving-drugs-are-approved-for-subsidy-scheme 2015-08-05T11:37:18 https://maestrodatabase.com/blog/biosimilars-in-inflammatory-bowel-disease 2016-10-02T22:13:03 https://maestrodatabase.com/blog/fda-grants-roches-cancer-immunotherapy-atezolizumab-priority-review-for-advanced-bladder-cancer 2016-03-15T10:15:21 https://maestrodatabase.com/blog/gw-pharmaceuticals-announces-epidiolex-receives-fast-track-designation-from-fda-for-the-treatment-of-dravet-syndrome 2015-08-05T11:37:10 https://maestrodatabase.com/blog/greater-flexibility-for-australians-with-severe-asthma-with-reimbursement-of-at-home 2020-05-31T21:21:12 https://maestrodatabase.com/blog/dracen-pharmaceuticals-drp-104-granted-u-dot-s-fda-fast-track-designation-for-the-treatment-of-non-small-cell-lung-cancer 2020-10-27T19:41:55 https://maestrodatabase.com/blog/expanding-the-cadth-drug-review-process-to-receive-patient-input-submissions-from-individual-patients-and-caregivers 2015-10-06T20:49:29 https://maestrodatabase.com/blog/jj-bristol-myers-battle-california-drug-discount-proposal 2015-10-08T20:35:14 https://maestrodatabase.com/blog/johnson-and-johnson-receives-positive-chmp-opinion-for-janssens-investigational-preventive-ebola-vaccine-regimen 2020-05-31T21:23:58 https://maestrodatabase.com/blog/nice-proposes-further-research-for-dupuytrens-contracture-treatment 2015-09-16T10:13:42 https://maestrodatabase.com/blog/fda-approves-first-therapy-for-high-risk-neuroblastoma 2015-08-05T11:37:21 https://maestrodatabase.com/blog/nice-set-to-eject-two-medicines-from-cdf 2016-08-18T21:11:48 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-june-2020 2020-05-31T21:29:57 https://maestrodatabase.com/blog/mavenclad-cladribine-tablets-is-available-through-public-drug-plans-for-the-majority-of-eligible-canadians-with-relapsing-remitting-multiple-sclerosis 2020-10-27T19:56:57 https://maestrodatabase.com/blog/agenda-for-the-13-april-2016-tc-meeting 2016-04-12T21:32:54 https://maestrodatabase.com/blog/statement-by-chip-davis-president-and-ceo-gpha-regarding-generic-drug-costs 2015-09-24T14:36:31 https://maestrodatabase.com/blog/chmp-recommends-eu-approval-of-roches-rozlytrek-for-people-with-ntrk-fusion-positive-solid-tumours-and-for-people-with-ros1-positive-advanced-non-small-cell-lung-cancer 2020-05-31T21:12:03 https://maestrodatabase.com/blog/prevail-therapeutics-receives-u-dot-s-fda-fast-track-designation-for-pr001-for-the-treatment-of-neuronopathic-gaucher-disease 2020-10-27T11:32:14 https://maestrodatabase.com/blog/fda-advisors-vote-against-clovis-rociletinib 2016-04-13T21:10:18 https://maestrodatabase.com/blog/cadth-lecture-series--choosing-wisely-canada-evidence-based-medicine-and-changing-the-canadian-health-care-environment 2015-08-05T11:37:10 https://maestrodatabase.com/blog/fda-approves-new-foundationone-liquid-cdx-companion-diagnostic-indications-for-three-targeted-therapies-that-treat-advanced-ovarian-breast-and-non-small-cell-lung-cancer 2020-10-27T11:37:04 https://maestrodatabase.com/blog/dabrafenib-mesylate-and-trametinib-dimethyl-sulphoxide-for-the-treatment-of-patients-with-advanced-braf-v600-mutation-positive-non-small-cell-lung-cancer 2023-06-14T10:34:56 https://maestrodatabase.com/blog/drugs-for-pulmonary-arterial-hypertension 2015-08-05T11:37:13 https://maestrodatabase.com/blog/innovent-biologics-announces-fda-acceptance-of-nda-for-pemigatinib-in-patients-with-previously-treated-locally-advanced-or-metastatic-cholangiocarcinoma-with-fgfr2-fusions-or-rearrangements 2019-12-02T02:07:35 https://maestrodatabase.com/blog/kala-pharmaceuticals-announces-fda-approval-of-eysuvis-for-the-short-term-treatment-of-the-signs-and-symptoms-of-dry-eye-disease 2020-10-27T11:41:38 https://maestrodatabase.com/blog/new-research-shows-australia-lags-far-behind-other-countries-in-access-to-new-medicines 2015-08-05T11:37:21 https://maestrodatabase.com/blog/celgenes-abraxane-authorised-by-health-canada 2015-08-05T11:37:05 https://maestrodatabase.com/blog/oral-sma-drug-evrysdi-passes-reimbursement-review 2023-06-14T06:02:50 https://maestrodatabase.com/blog/nexavar-sorafenib-tablets-now-approved-in-canada-for-the-treatment-of-differentiated-thyroid-cancer 2015-08-05T11:37:06 https://maestrodatabase.com/blog/cvs-health-to-replace-higher-cost-drugs-on-covered-medication-list-for-2017 2016-08-04T11:54:57 https://maestrodatabase.com/blog/fda-approves-lotion-for-non-prescription-use-to-treat-head-lice 2020-10-27T20:29:26 https://maestrodatabase.com/blog/talimogene-laherparepvec-in-melanoma-added-benefit-not-proven 2016-09-19T11:49:32 https://maestrodatabase.com/blog/accelerated-assessment-fast-tracks-lenvima-to-benefit-patients-with-thyroid-cancer 2015-08-05T11:37:07 https://maestrodatabase.com/blog/genvoya-in-hiv-positive-effects-predominate-in-some-adults-negative-effects-in-others-says-germanys-iqwig 2016-04-06T20:34:16 https://maestrodatabase.com/blog/dual-attack-lobbyists-target-sussan-ley-over-pbs-and-prostheses 2016-09-21T20:52:55 https://maestrodatabase.com/blog/approval-of-multiproduct-proposal-with-biocsl-nz-ltd 2015-08-05T11:37:30 https://maestrodatabase.com/blog/fda-approves-new-treatment-for-rare-metabolic-disorder 2015-10-23T22:48:03 https://maestrodatabase.com/blog/top-10-drugs-2018-19 2019-12-02T02:20:23 https://maestrodatabase.com/blog/nice-bars-celgenes-imnovid-from-nhs-funding 2015-08-05T11:37:19 https://maestrodatabase.com/blog/tga-approves-simponi-for-axial-spondyloarthritis 2016-09-15T05:56:41 https://maestrodatabase.com/blog/fda-approves-basaglar-the-first-follow-on-insulin-glargine-product-to-treat-diabetes 2015-12-17T20:33:02 https://maestrodatabase.com/blog/nabriva-therapeutics-receives-positive-eu-chmp-opinion-for-xenleta-lefamulin-for-the-treatment-of-community-acquired-pneumonia 2020-05-31T21:37:47 https://maestrodatabase.com/blog/nice-turns-down-celgenes-otezla-for-psoriasis 2015-08-05T11:37:09 https://maestrodatabase.com/blog/fda-accepts-bla-for-biomarins-cerliponase-alfa-for-cln2-disease-form-of-batten-disease 2016-08-02T01:40:03 https://maestrodatabase.com/blog/nhs-england-in-legal-battle-with-american-firm-over-medicine-procurement 2018-11-07T19:57:06 https://maestrodatabase.com/blog/sales-of-cancer-medicines-in-canada-nearly-tripled-over-the-past-decade 2020-10-27T20:01:49 https://maestrodatabase.com/blog/fda-expands-uses-of-vyvanse-to-treat-binge-eating-disorder 2015-08-05T11:37:08 https://maestrodatabase.com/blog/cadth-calls-for-patient-input-on-a-new-submission-from-celgene-for-otezla 2016-01-30T01:13:18 https://maestrodatabase.com/blog/nice-publishes-appraisal-consultation-document-for-avapritinib 2020-10-27T20:04:25 https://maestrodatabase.com/blog/covid-19-vaccine-rollout-calls-for-supply-chain-collaboration-logistics-chief-says 2020-10-27T20:10:40 https://maestrodatabase.com/blog/health-canada-approves-amgens-cholesterol-lowering-medication-repatha-evolocumab 2015-09-16T08:04:14 https://maestrodatabase.com/blog/additional-benefit-of-sucroferric-oxyhydroxide-is-not-occupied 2015-08-05T11:37:17 https://maestrodatabase.com/blog/smc_advice___february_2014 2015-08-05T11:37:07 https://maestrodatabase.com/blog/chmp-recommends-eu-approval-for-roches-combination-of-cotellic-cobimetinib-and-zelboraf-vemurafenib-in-advanced-melanoma 2015-09-26T03:33:22 https://maestrodatabase.com/blog/tga-publishes-auspar-for-adalimumab-humira 2016-07-25T06:59:15 https://maestrodatabase.com/blog/springworks-therapeutics-receives-fda-fast-track-designation-for-nirogacestat-for-the-treatment-of-adult-patients-with-desmoid-tumours 2018-11-07T20:15:32 https://maestrodatabase.com/blog/resmed-shares-slump-on-shock-heart-failure-trial-result 2015-08-05T11:37:10 https://maestrodatabase.com/blog/cadth-calls-for-patient-input-on-a-new-submission-from-gsk-for-mepolizumab 2015-11-20T21:38:08 https://maestrodatabase.com/blog/fda-releases-real-world-data-collection-app 2018-11-07T20:02:55 https://maestrodatabase.com/blog/spain_to_guarantee_government_s_payments_to_drugmakers__report_suggests 2015-08-05T11:37:30 https://maestrodatabase.com/blog/cancer-drug-websites-more-likely-to-offer-data-on-benefits-than-risks 2016-09-13T12:31:16 https://maestrodatabase.com/blog/nice-public-board-meeting-and-nice-question-time-salisbury 2016-01-04T20:57:00 https://maestrodatabase.com/blog/cvs-to-test-stores-with-added-health-services-early-next-year-after-aetna-deal-closes 2018-11-07T20:06:30 https://maestrodatabase.com/blog/indicative-1-april-2015-prices---2015-april-cycle 2015-08-05T11:37:24 https://maestrodatabase.com/blog/novimmunes-ni-0501-granted-breakthrough-therapy-designation-by-us-fda-for-treatment-of-patients-with-primary-haemophagocytic-lymphohistiocytosis 2016-03-17T07:10:52 https://maestrodatabase.com/blog/pelosi-sees-possible-common-ground-with-trump-on-drug-prices 2018-11-07T20:37:36 https://maestrodatabase.com/blog/agenda-for-the-chmp-meeting-to-be-held-on-19-22-january-2015 2015-08-05T11:37:26 https://maestrodatabase.com/blog/novartis-ceo-predicts-drug-pricing-overhaul-in-us-after-the-election-whoever-wins 2016-07-20T21:53:09 https://maestrodatabase.com/blog/beyond-the-political-noise-3-policy-proposals-on-drug-prices-that-have-a-fighting-chance----and-make-the-industry-shudder 2018-11-07T20:44:17 https://maestrodatabase.com/blog/tga-publishes-paper-on-transparency-in-medicines-regulation 2016-08-05T04:21:55 https://maestrodatabase.com/blog/australias-medicine-labels-are-becoming-clearer 2016-08-09T11:25:38 https://maestrodatabase.com/blog/rotavirus-vaccine-now-free-for-all-babies 2015-08-05T11:37:04 https://maestrodatabase.com/blog/eribulin-in-liposarcoma-added-benefit-not-proven 2016-09-07T21:01:18 https://maestrodatabase.com/blog/mcconnell-says-drug-prices-are-on-the-agenda-obamacare-is-off 2018-11-07T20:20:22 https://maestrodatabase.com/blog/us-investigates-drug-maker-contracts-with-pharmacy-benefit-managers 2016-05-11T07:50:04 https://maestrodatabase.com/blog/quebec-adds-perjeta-pertuzumab-for-treatment-of-her2-positive-metastatic-breast-cancer-to-the-provinces-hospital-formulary 2015-08-05T11:37:03 https://maestrodatabase.com/blog/fighting-for-a-streamlined-european-hta-scheme 2018-11-07T20:54:38 https://maestrodatabase.com/blog/fda-grants-breakthrough-therapy-designation-for-cullinan-oncologys-cln-081-in-patients-with-locally-advanced-or-metastatic-egfr-mutated-non-small-cell-lung-cancer 2022-01-05T00:01:15 https://maestrodatabase.com/blog/nps_radar___december_2013 2015-08-05T11:37:29 https://maestrodatabase.com/blog/with-a-new-congress-a-window-opens-to-finally-bring-down-drug-prices 2018-11-07T20:47:07 https://maestrodatabase.com/blog/prostate-cancer-drug-decision-grossly-unfair 2016-06-13T22:01:17 https://maestrodatabase.com/blog/pharma-exceptional-circumstances-framework-go-live-notification 2015-08-30T23:52:01 https://maestrodatabase.com/blog/ema-will-review-amgenonyx-myeloma-drug 2015-08-05T11:37:07 https://maestrodatabase.com/blog/eylea__aflibercept__offers_new_hope_for_patients_suffering_from_wet_age_related_macular_degeneration 2015-08-05T11:37:19 https://maestrodatabase.com/blog/apixaban-in-deep-vein-thrombosis-and-pulmonary-embolism-patients-with-high-bmi-benefit-considerably 2015-08-05T11:37:02 https://maestrodatabase.com/blog/tga-grants-provisional-determination-to-astrazeneca-for-covid-19-prophylaxis-and-treatment-tixagevimab-and-cilgavimab-evusheld 2022-01-04T23:56:38 https://maestrodatabase.com/blog/canberra-women-travelling-to-queanbeyan-to-access-medical-abortion-drugs-through-mail 2016-05-23T17:06:16 https://maestrodatabase.com/blog/iqwig-commences-an-assessment-of-triumeq-for-patients-with-hiv-infection 2015-08-05T11:37:05 https://maestrodatabase.com/blog/nice-asks-company-for-more-information-on-olaparib-for-ovarian-fallopian-tube-and-peritoneal-cancer 2015-08-06T20:57:19 https://maestrodatabase.com/blog/pharmaxis-has-a-new-business-model-is-it-now-the-least-risky-biotech-stock 2015-09-25T23:01:24 https://maestrodatabase.com/blog/1-september-2016-changes-to-pbs-efficient-funding-of-chemotherapy 2016-08-11T11:55:04 https://maestrodatabase.com/blog/flixabi-an-infliximab-biosimilar-candidate-referencing-remicade-receives-positive-chmp-opinion 2016-04-03T01:42:52 https://maestrodatabase.com/blog/acorda-files-marketing-authorisation-application-for-inbrija-levodopa-inhalation-powder 2018-03-27T01:16:51 https://maestrodatabase.com/blog/response_to_daily_mail_article_on_credit_card_usage 2015-08-05T11:37:19 https://maestrodatabase.com/blog/nice-proposes-to-recommend-another-new-drug-for-people-with-lymphocytic-leukaemia 2015-08-05T11:37:06 https://maestrodatabase.com/blog/patients-set-to-pay-thousands-more-as-rebates-cut-in-raft-of-radical-medicare-changes 2021-06-06T11:42:38 https://maestrodatabase.com/blog/merck-ceo-ken-frazier-on-keytruda-and-why-australians-miss-out-on-new-drugs 2015-08-05T11:37:17 https://maestrodatabase.com/blog/pbac-stakeholder-meeting---nitisinone-for-tyrosinaemia-type-1-february-2015 2015-08-05T11:37:06 https://maestrodatabase.com/blog/tasmanian-man-robert-mitchell-welcomes-rollout-of-new-drug-dovato-on-pbs 2019-12-02T03:22:37 https://maestrodatabase.com/blog/eagle-pharmaceuticals-receives-fda-qualified-infectious-disease-product-and-fast-track-designation-for-cal02 2023-06-14T21:12:05 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule-1-october-2015-update 2015-09-30T09:22:10 https://maestrodatabase.com/blog/tga-publishes-auspar-for-orkambi 2016-09-21T08:29:43 https://maestrodatabase.com/blog/fda-launches-competition-to-spur-innovative-technologies-to-help-reduce-opioid-overdose-deaths 2016-09-19T20:23:32 https://maestrodatabase.com/blog/fdas-decision-on-biogen-alzheimers-drug-will-be-a-watershed-moment-for-the-agency----and-the-biotech-industry 2021-06-06T11:49:22 https://maestrodatabase.com/blog/family-of-baby-spending-first-birthday-in-hospital-with-pneumococcal-complications-calls-for-vaccine-switch 2022-09-13T03:21:25 https://maestrodatabase.com/blog/european-commission-approves-reconciliation-of-indications-for-nivolumab-under-the-opdivo-european-marketing-authorization-application 2015-11-25T07:40:42 https://maestrodatabase.com/blog/gp-bulk-billing-services-at-record-highs 2021-06-06T11:45:20 https://maestrodatabase.com/blog/experience-with-the-priority-review-voucher-program-for-drug-development-1 2015-10-27T20:51:22 https://maestrodatabase.com/blog/ombitasvirparitaprevirritonavir-in-hepatitis-c-indication-of-added-benefit-in-certain-patients 2015-08-05T11:37:04 https://maestrodatabase.com/blog/saskatchewan-to-fund-treatment-with-aubagio-for-relapsing-remitting-multiple-sclerosis 2015-08-05T11:37:10 https://maestrodatabase.com/blog/bayer-announces-completion-of-rolling-submission-of-new-drug-application-in-the-u-dot-s-for-larotrectinib-for-the-treatment-of-trk-fusion-cancer 2018-03-27T03:22:46 https://maestrodatabase.com/blog/april-2015-tender-notification 2015-08-05T11:37:28 https://maestrodatabase.com/blog/cancer-medicines-inquiry-recommendations-are-good-news-for-consumers 2015-09-18T02:31:59 https://maestrodatabase.com/blog/ucb-receives-positive-eu-chmp-opinion-for-cimzia-certolizumab-pegol-to-treat-severe-active-and-progressive-rheumatoid-arthritis-in-dmard-naïve-patients 2015-11-21T06:12:40 https://maestrodatabase.com/blog/samsung-bioepis-seeks-europe-approval-for-copy-of-herceptin-breast-cancer-drug 2016-10-04T10:59:40 https://maestrodatabase.com/blog/proposal-to-fund-aflibercept-and-rivaroxaban 2018-03-27T01:27:13 https://maestrodatabase.com/blog/astrazenecas-lung-cancer-drug-tagrisso-gets-fdas-approval 2015-11-16T08:31:31 https://maestrodatabase.com/blog/acerus-receives-health-canada-approval-for-natesto 2016-01-08T06:51:02 https://maestrodatabase.com/blog/value-frameworks-are-expanding-for-drugs-devices 2016-07-27T00:28:26 https://maestrodatabase.com/blog/palatin-technologies-announces-submission-of-bremelanotide-nda-to-fda-for-treatment-of-hypoactive-sexual-desire-disorder-in-premenopausal-women 2018-03-27T03:30:08 https://maestrodatabase.com/blog/two-datopotamab-deruxtecan-applications-validated-in-the-eu-for-patients-with-advanced-non-squamous-non-small-cell-lung-cancer-or-hr-positive-her2-negative-breast-cancer 2024-03-04T07:18:44 https://maestrodatabase.com/blog/nivolumab-in-renal-cell-carcinoma-recalling-additional-benefits 2016-08-03T03:39:45 https://maestrodatabase.com/blog/gsks-nucala-mepolizumab-receives-approval-from-us-fda 2015-11-05T10:33:18 https://maestrodatabase.com/blog/tebentafusp-in-uveal-melanoma-indication-of-a-considerable-additional-benefit 2024-03-04T05:36:05 https://maestrodatabase.com/blog/nice-joins-project-to-make-development-of-new-treatments-more-efficient 2015-09-04T21:04:06 https://maestrodatabase.com/blog/us-to-test-ways-to-cut-drug-prices-in-medicare 2016-03-09T20:54:24 https://maestrodatabase.com/blog/1bn-saving-goes-begging-in-public-private-health-cost-shift 2016-09-28T20:44:02 https://maestrodatabase.com/blog/snap-spanish-elections-throw-health-reimbursement-reform-into-doubt 2023-06-14T21:26:08 https://maestrodatabase.com/blog/investigation-medicine-venetoclax-receives-breakthrough-therapy-designation-in-relapsed-or-refractory-chronic-lymphocytic-leukaemia-in-previously-treated-patients-with-the-17p-deletion-genetic-mutation 2015-08-05T11:37:08 https://maestrodatabase.com/blog/tixagevimab-and-cilgavimab-for-the-prevention-of-covid-19-disease 2023-06-14T21:30:05 https://maestrodatabase.com/blog/cadth-calls-for-patient-input-on-a-new-submission-from-astrazeneca-for-xigduo 2015-12-01T20:31:36 https://maestrodatabase.com/blog/hugel-receives-us-fda-approval-for-its-botulinum-toxin-letybo 2024-03-04T04:12:38 https://maestrodatabase.com/blog/sustainable-financing-of-innovative-therapies-a-review-of-approaches 2016-09-19T02:21:51 https://maestrodatabase.com/blog/actavis-announces-fda-acceptance-of-snda-for-saphris-asenapine-maleate-for-the-treatment-of-bipolar-i-disorder-in-paediatric-patients 2015-08-05T11:37:22 https://maestrodatabase.com/blog/and-then-there-were-five 2015-08-05T11:37:10 https://maestrodatabase.com/blog/covid-19-2024-vaccine-advice 2024-03-04T03:34:57 https://maestrodatabase.com/blog/otsuka_and_lundbeck_announce_once_monthly_abilify_maintena_approved_in_canada_for_the_maintenance_treatment_of_schizophrenia_in_stabilized_adult_patients 2015-08-05T11:37:06 https://maestrodatabase.com/blog/new-nice-website 2015-08-05T11:37:19 https://maestrodatabase.com/blog/pharmacist-claiming-of-paracetamol-500-mg-with-codeine-30-mg-tablet-prescriptions-from-1-june-2020 2020-06-01T01:12:21 https://maestrodatabase.com/blog/marketing-authorisation-application-for-gout-treatment-lesinurad-accepted-by-european-medicines-agency 2015-08-05T11:37:16 https://maestrodatabase.com/blog/horizon-pharma-plc-receives-european-commission-approval-for-ravicti-glycerol-phenylbutyrate-oral-liquid-for-the-treatment-of-urea-cycle-disorders-in-patients-two-months-of-age-and-older 2015-12-01T20:06:43 https://maestrodatabase.com/blog/ipsen-announces-us-fda-submission-acceptance-of-its-supplemental-new-drug-application-for-onivyde-regimen-in-first-line-metastatic-pancreatic-ductal-adenocarcinoma 2023-06-14T21:19:48 https://maestrodatabase.com/blog/drug-utilisation-sub-committee-outcome-statements---february-2015 2015-08-05T11:37:15 https://maestrodatabase.com/blog/summary_of_the_agenda_for_the_pbac_july_2014_meeting 2015-08-05T11:37:13 https://maestrodatabase.com/blog/fda-approves-visumax-femtosecond-laser-to-surgically-treat-nearsightedness 2016-09-13T20:58:13 https://maestrodatabase.com/blog/patents-vs-market-exclusivity-why-does-it-take-so-long-to-bring-generics-to-market 2016-08-18T21:43:56 https://maestrodatabase.com/blog/nonproprietary-naming-of-biological-products 2015-08-27T21:10:40 https://maestrodatabase.com/blog/valeant-canada-announces-health-canada-approval-of-contrave-extended-release-tablets-for-chronic-weight-management-in-adults 2018-03-27T05:25:20 https://maestrodatabase.com/blog/the-parents-hoped-an-existing-drug-might-keep-their-kids-from-having-seizures-then-they-saw-the-price 2021-06-06T21:14:21 https://maestrodatabase.com/blog/how-obamas-fda-keeps-generic-drugs-off-the-market 2016-08-22T06:03:35 https://maestrodatabase.com/blog/13-billion-to-list-life-saving-medicines 2015-08-05T11:37:09 https://maestrodatabase.com/blog/more-treatments-funded-by-pharmac-for-respiratory-disease 2016-02-09T01:05:59 https://maestrodatabase.com/blog/amylyx-pharmaceuticals-submits-marketing-authorisation-application-for-amx0035-for-the-treatment-of-als 2022-01-05T01:22:32 https://maestrodatabase.com/blog/health-consumer-choice-drives-better-care 2018-03-27T06:31:16 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits-1-may-2016-update 2016-05-01T00:06:50 https://maestrodatabase.com/blog/insights-from-the-agenda-for-the-pbac-november-2016-meeting 2016-08-24T21:56:21 https://maestrodatabase.com/blog/pharmacy-guild-asks-for-right-to-give-jab 2021-06-06T20:56:59 https://maestrodatabase.com/blog/amicus-therapeutics-fabry-monotherapy-granted-accelerated-assessment-by-european-regulators 2015-08-05T11:37:30 https://maestrodatabase.com/blog/smc-industry-engagement-event 2017-07-03T11:52:24 https://maestrodatabase.com/blog/post-market-reviews-of-pulmonary-arterial-hypertension-medicines-and-biological-dmards-to-treat-severe-chronic-plaque-psoriasis 2016-05-02T06:16:05 https://maestrodatabase.com/blog/cadth-calls-for-patient-input-on-submissions-requesting-advice-on-recent-recommendations-from-new-hepatitis-c-medicines 2016-01-07T04:31:43 https://maestrodatabase.com/blog/cellcentric-receives-fda-fast-track-designation-for-relapsed-refractory-multiple-myeloma-drug 2023-06-14T21:43:09 https://maestrodatabase.com/blog/patients-could-suffer-as-drug-costs-threaten-to-bankrupt-nhs 2016-04-04T06:30:47 https://maestrodatabase.com/blog/2018-seasonal-influenza-vaccines 2018-03-27T06:20:29 https://maestrodatabase.com/blog/doctors-hail-drug-that-can-turn-off-cancer-once-a-day-tablet-could-spare-blood-cancer-patients-effects-of-traditional-chemotherapy 2015-08-05T11:37:30 https://maestrodatabase.com/blog/nice-publishes-appraisal-consultation-document-for-medicine-for-excessive-daytime-sleepiness 2021-06-06T21:06:15 https://maestrodatabase.com/blog/nice-draft-guidance-recommends-a-treatment-for-prostate-cancer 2015-08-05T11:37:22 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits-1-october-2016-update 2016-10-02T20:42:05 https://maestrodatabase.com/blog/european-commission-approves-bristol-myers-squibbs-orencia-abatacept-for-the-treatment-of-highly-active-and-progressive-disease-in-adult-patients-with-rheumatoid-arthritis-not-previously-treated-with-methotrexate 2016-09-06T14:40:58 https://maestrodatabase.com/blog/agreement-for-supply-of-influenza-vaccine-approved 2016-08-05T04:42:51 https://maestrodatabase.com/blog/government-to-remove-paracetamol-aspirin-other-common-drugs-from-pharmaceutical-benefits-scheme 2015-11-03T01:12:41 https://maestrodatabase.com/blog/lexicon-pharmaceuticals-announces-regulatory-submissions-for-sotagliflozin-to-treat-adults-with-type-1-diabetes 2018-03-27T06:35:37 https://maestrodatabase.com/blog/novartis-heart-failure-pill-hits-hurdles-with-doctors 2016-03-17T07:05:12 https://maestrodatabase.com/blog/the_outcomes_from_the_october_2013_cdec_meeting_have_been_added_to_maestro_canada 2015-08-05T11:37:27 https://maestrodatabase.com/blog/u-dot-s-fda-approves-immix-biopharma-rare-paediatric-disease-designation-for-imx-110-as-a-treatment-for-life-threatening-paediatric-cancer 2022-01-05T03:18:35 https://maestrodatabase.com/blog/vertex-announces-casgevy-reimbursement-agreement-for-the-treatment-of-transfusion-dependent-beta-thalassaemia-and-sickle-cell-disease-in-italy 2025-09-18T22:03:04 https://maestrodatabase.com/blog/new_features_added_to_maestro_australia 2015-08-05T11:37:23 https://maestrodatabase.com/blog/bristol-myers-squibb-announces-acceptance-of-new-drug-application-for-investigational-daclatasvir-for-fda-review-for-the-treatment-of-hepatitis-c-genotype-3 2015-08-05T11:37:10 https://maestrodatabase.com/blog/cadth-issues-final-recommendation-for-nivolumab-opdivo-for-use-in-patients-with-non-small-cell-lung-cancer 2016-06-04T00:42:56 https://maestrodatabase.com/blog/lilly-receives-fda-breakthrough-therapy-designation-for-abemaciclib-a-cdk-4-and-6-inhibitor-in-advanced-breast-cancer 2015-10-08T20:54:17 https://maestrodatabase.com/blog/new-combination-therapy-now-reimbursed-for-australians-living-with-incurable-blood-cancer 2020-06-01T02:02:43 https://maestrodatabase.com/blog/cancer-drug-move-a-victory 2016-07-04T21:28:33 https://maestrodatabase.com/blog/family-asking-for-help-to-purchase-the-most-expensive-drug-in-the-world 2019-12-02T06:01:02 https://maestrodatabase.com/blog/government-moves-on-dispensing-from-unapproved-pharmacies 2015-08-05T11:37:26 https://maestrodatabase.com/blog/we-cant-all-have-it-all-the-economic-limits-of-pharmaceutical-innovation 2016-05-10T23:49:56 https://maestrodatabase.com/blog/pharmacy-guild-accord-to-dispense-6bn-savings 2015-08-05T11:37:05 https://maestrodatabase.com/blog/regulatory-information--update-of-ema-recommendations-for-20152016-seasonal-flu-vaccine-composition 2015-08-05T11:37:14 https://maestrodatabase.com/blog/bayer_receives_health_canada_approval_for_adempas__riociguat__to_treat_patients_with_rare_heart_and_lung_disease 2015-08-05T11:37:03 https://maestrodatabase.com/blog/pharmacs-credibility-questioned-by-labour 2016-06-30T21:16:10 https://maestrodatabase.com/blog/actelion-sees-uptravi-price-of-160000-170000patient 2016-01-06T20:42:42 https://maestrodatabase.com/blog/revamp-national-cancer-mental-health-groups-panel-tells-minister 2018-03-27T20:13:50 https://maestrodatabase.com/blog/agenda-for-15-april-2015-tc-meeting 2015-08-05T11:37:10 https://maestrodatabase.com/blog/taiho-submits-tas-102-marketing-authorization-application-to-the-european-medicines-agency-for-the-treatment-of-refractory-metastatic-colorectal-cancer 2015-08-05T11:37:30 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-treatments-for-non-small-cell-lung-cancer 2016-08-20T02:21:14 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-bristol-myers-squibbs-application-for-opdivo-nivolumab-plus-yervoy-ipilimumab-for-previously-treated-patients-with-msi-h-or-dmmr-metastatic-colorectal-cancer-for-priority-review 2018-03-27T11:21:17 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac---july-2017 2017-08-20T06:41:53 https://maestrodatabase.com/blog/cooperation-between-regulators-and-hta-bodies-creates-synergies 2016-04-14T11:04:56 https://maestrodatabase.com/blog/make-drug-makers-pay-englands-strategy-for-cancer-medicines 2016-08-01T06:51:00 https://maestrodatabase.com/blog/hiv-preventative-drug-subsidy-negotiations-have-stalled 2017-08-20T06:50:48 https://maestrodatabase.com/blog/merck-provides-regulatory-update-on-biologics-licensing-application-for-investigational-agent-bezlotoxumab 2016-07-22T21:50:10 https://maestrodatabase.com/blog/agenda-for-4-february-2015-tc-meeting 2015-08-05T11:37:27 https://maestrodatabase.com/blog/nice-sets-price-too-high-for-nhs-medicines 2015-08-05T11:37:18 https://maestrodatabase.com/blog/aetna-will-pass-along-discounts-as-drug-price-scrutiny-increases 2018-03-27T20:31:36 https://maestrodatabase.com/blog/treatment-for-cystic-fibrosis-sufferers-still-out-of-reach 2017-08-20T06:48:01 https://maestrodatabase.com/blog/evolocumab-no-hint-of-added-clinical-benefit-according-the-iqwig-in-germany 2015-12-22T20:16:45 https://maestrodatabase.com/blog/ticagrelor-prevention-after-myocardial-infarction-little-added-value 2016-07-02T00:33:18 https://maestrodatabase.com/blog/an-update-on-the-clinical-evidence-that-supports-biosimilar-approvals-in-europe 2018-03-27T20:19:51 https://maestrodatabase.com/blog/u-dot-s-house-democrats-launch-probe-into-ms-drug-pricing 2017-08-20T06:59:51 https://maestrodatabase.com/blog/request-for-information-on-anti-diabetic-agents 2015-08-05T11:37:18 https://maestrodatabase.com/blog/federal-judge-rules-against-astrazeneca-in-lawsuit-challenging-medicare-drug-price-negotiation 2024-03-04T09:51:44 https://maestrodatabase.com/blog/minovia-therapeutics-receives-fda-fast-track-designation-for-mnv-201-in-myelodysplastic-syndrome 2025-09-18T23:14:50 https://maestrodatabase.com/blog/restrictions_on_skin_cancer_drug 2015-08-05T11:37:15 https://maestrodatabase.com/blog/top-funds-said-to-tell-pharma-leaders-to-defend-drug-pricing 2016-05-10T07:03:16 https://maestrodatabase.com/blog/fda-authorises-first-fully-interoperable-continuous-glucose-monitoring-system-streamlines-review-pathway-for-similar-devices 2018-03-27T20:26:19 https://maestrodatabase.com/blog/together-for-high-standards-in-the-assessment-of-health-technologies-in-europe-from-2025 2024-03-04T09:39:34 https://maestrodatabase.com/blog/medical-cannabis-first 2016-02-10T19:57:19 https://maestrodatabase.com/blog/public-register-of-parallel-distribution-now-available 2015-08-05T11:37:07 https://maestrodatabase.com/blog/trump-quietly-signs-new-fda-user-fee-agreement-into-law 2017-08-20T07:03:24 https://maestrodatabase.com/blog/nmpa-approves-the-nda-for-carsgens-bcma-car-t-therapy-zevorcabtagene-autoleucel-for-relapsed-or-refractory-multiple-myeloma 2024-03-04T20:07:24 https://maestrodatabase.com/blog/tagrisso-osimertinib-approved-by-health-canada-as-treatment-for-patients-with-locally-advanced-or-metastatic-egfr-t790m-mutation-positive-non-small-cell-lung-cancer 2016-07-12T10:42:52 https://maestrodatabase.com/blog/french-legislation-undermines-eu-regulatory-framework-by-endorsing-off-label-use-of-medicines-for-economic-reasons 2015-08-05T11:37:14 https://maestrodatabase.com/blog/findings-from-the-lean-review-of-our-drug-reimbursement-review-program 2024-03-04T20:00:23 https://maestrodatabase.com/blog/health-insurance-marketplace-open-enrollment-snapshot-week-3-update 2015-11-27T05:01:10 https://maestrodatabase.com/blog/prices-for-widely-prescribed-medicare-part-d-drugs-rose-12-percent-annually-but-mind-the-caveat 2018-03-27T20:34:50 https://maestrodatabase.com/blog/gsk-receives-approval-for-nucala-mepolizumab-in-canada-for-the-treatment-of-severe-eosinophilic-asthma 2015-12-13T20:31:09 https://maestrodatabase.com/blog/biocon-pulls-application-for-eu-approval-of-two-drugs 2017-08-20T18:14:17 https://maestrodatabase.com/blog/bayer-submits-application-for-us-fda-approval-for-recombinant-factor-viii-product-bay-81-8973-for-the-treatment-of-hemophilia-a-in-adults-and-children 2015-08-05T11:37:09 https://maestrodatabase.com/blog/medicare-weighing-changes-to-doctor-drug-payments-memo-shows 2016-02-10T20:11:20 https://maestrodatabase.com/blog/free-visits-to-the-doctor-reach-a-record-high-new-medicare-statistics-show 2017-08-20T18:10:41 https://maestrodatabase.com/blog/time-to-reassess-the-cancer-compendia-for-off-label-drug-coverage-in-oncology 2016-10-18T20:04:45 https://maestrodatabase.com/blog/novartis-drug-farydak-recommended-by-chmp-for-eu-approval-to-treat-multiple-myeloma-providing-patients-a-new-mechanism-of-action 2015-08-05T11:37:10 https://maestrodatabase.com/blog/pharmac-tender-savings-top-600-million 2015-08-05T11:37:07 https://maestrodatabase.com/blog/nice-no-takes-gloss-off-besponsas-fda-nod 2017-08-20T18:18:04 https://maestrodatabase.com/blog/brilinta-receives-us-fda-approval-for-new-administration-option 2015-08-05T11:37:19 https://maestrodatabase.com/blog/scientific-advice-leads-to-stronger-applications-from-industry 2015-08-05T11:37:30 https://maestrodatabase.com/blog/gilead-receives-approval-in-canada-for-vosevi-sofosbuvir-slash-velpatasvir-slash-voxilaprevir-for-re-treatment-of-certain-patients-with-chronic-hepatitis-c-virus-infection 2017-08-20T18:32:56 https://maestrodatabase.com/blog/european-medicines-agency-selects-first-two-medicines-to-be-included-in-its-adaptive-licensing-pilot-project 2015-08-05T11:37:30 https://maestrodatabase.com/blog/alert-on-drug-prices-came-two-years-ago 2016-08-16T11:13:52 https://maestrodatabase.com/blog/cystic-fibrosis-patients-families-angry-over-latest-refusal-to-subsidise-drug-orkambi 2017-08-20T18:26:28 https://maestrodatabase.com/blog/cms-announces-32-million-to-help-get-eligible-children-enrolled-in-health-coverage 2015-11-16T21:56:33 https://maestrodatabase.com/blog/cadth-calls-for-patient-input-1 2015-08-27T21:50:52 https://maestrodatabase.com/blog/trastuzumab_emtansine__indication_of_major_added_benefit_in_metastatic_breast_cancer_with_previous_anthracycline_therapy 2015-08-05T11:37:24 https://maestrodatabase.com/blog/celltrion-seeks-fda-approval-for-biosimilar-remsima 2015-08-05T11:37:04 https://maestrodatabase.com/blog/expanded-pbs-medicines-listings-to-provide-new-treatment-options-for-over-170-000-asthmatics-and-new-hope-for-blood-cancer-patients 2020-06-01T03:44:24 https://maestrodatabase.com/blog/us-drug-spending-climbs 2016-04-14T21:23:56 https://maestrodatabase.com/blog/new_zealand_pharmaceutical_schedule___february_2014_update 2015-08-05T11:37:15 https://maestrodatabase.com/blog/pfizer_s_crizotinib_is_not_good_value_for_nhs_money__says_nice 2015-08-05T11:37:29 https://maestrodatabase.com/blog/takeda-receives-positive-chmp-opinion-for-pre-filled-syringe-presentation-of-takhzyro-lanadelumab-for-use-as-a-preventive-treatment-for-hereditary-angioedema-attacks 2020-06-01T03:48:42 https://maestrodatabase.com/blog/esketamine-receives-breakthrough-therapy-designation-from-us-food-and-drug-administration-for-major-depressive-disorder-with-imminent-risk-for-suicide 2016-08-17T20:48:15 https://maestrodatabase.com/blog/theravance-biopharma-announces-health-canada-approval-for-vibativ-telavancin-for-treatment-of-hapvap-caused-by-gram-positive-bacteria-including-mrsa 2015-08-05T11:37:13 https://maestrodatabase.com/blog/health-canada-approves-lynparza-for-the-treatment-of-ovarian-cancer-in-patients-with-brca-mutations 2016-05-04T07:10:59 https://maestrodatabase.com/blog/private-health-insurance-junk-policies-ripping-australians-off-ama-says 2017-08-21T04:44:16 https://maestrodatabase.com/blog/fda-approves-first-drug-to-treat-a-rare-enzyme-disorder-in-pediatric-and-adult-patients 2015-12-08T20:03:19 https://maestrodatabase.com/blog/boehringer-ingelheim-statement-on-hepatitis-c-drug-development 2015-08-05T11:37:19 https://maestrodatabase.com/blog/national-medical-products-administration-approves-chipscreen-biosciences-chidamide-epidaza-for-breast-cancer-indication 2019-12-02T09:50:31 https://maestrodatabase.com/blog/generic-drug-approvals-since-the-1984-hatch-waxman-act 2016-07-18T21:48:36 https://maestrodatabase.com/blog/springworks-therapeutics-initiates-rolling-submission-of-new-drug-application-to-the-fda-for-mirdametinib-for-the-treatment-of-children-and-adults-with-nf1-pn 2024-03-04T23:12:39 https://maestrodatabase.com/blog/nice-to-reject-humira-for-inflammatory-skin-disease 2016-03-08T22:37:36 https://maestrodatabase.com/blog/record-number-of-australians-receiving-medicare-benefits 2017-08-21T04:54:41 https://maestrodatabase.com/blog/human-medicines-ema-highlights-of-2015 2016-01-12T20:27:44 https://maestrodatabase.com/blog/efpia-welcomes-member-states-sharing-experience-on-new-models-for-patient-access 2015-10-07T21:11:41 https://maestrodatabase.com/blog/private-health-insurance-not-junk-nib-boss-rejects-doctors-paternalistic-proposal 2017-08-21T04:45:59 https://maestrodatabase.com/blog/engaging-patients-in-medicines-regulation-a-tale-of-two-agencies 2019-12-02T09:43:14 https://maestrodatabase.com/blog/itms-subsidiary-itg-receives-drug-approval-for-endolucin-beta 2016-08-06T05:20:07 https://maestrodatabase.com/blog/amgen-and-humana-partner-for-improved-health-outcomes-and-efficiency 2017-08-21T06:26:06 https://maestrodatabase.com/blog/new-managed-access-process-for-cancer-drugs-fund-to-go-ahead-nhs-england-confirms 2016-03-02T06:00:51 https://maestrodatabase.com/blog/seqirus-receives-fda-approval-for-afluria-quadrivalent-influenza-vaccine-for-people-18-years-of-age-and-older 2016-08-30T00:48:09 https://maestrodatabase.com/blog/orchard-therapeutics-announces-the-filing-and-validation-of-marketing-authorisation-application-by-ema-for-otl-200-for-the-treatment-of-metachromatic-leukodystrophy 2019-12-02T20:01:44 https://maestrodatabase.com/blog/abbvies-maviret-approved-by-health-canada-for-the-treatment-of-chronic-hepatitis-c-in-all-major-genotypes 2017-08-21T06:20:05 https://maestrodatabase.com/blog/sobi-and-biogen-receive-positive-opinion-from-chmp-for-alprolix-rfixfc-for-the-treatment-of-haemophilia-b 2016-02-26T21:18:53 https://maestrodatabase.com/blog/the-role-of-single-arm-trials-in-the-authorisation-of-new-cancer-medicines-update 2016-06-27T21:50:11 https://maestrodatabase.com/blog/fdara-making-a-difference-for-industry-and-patients 2017-08-21T17:27:59 https://maestrodatabase.com/blog/australia-a-treasure-island-for-medical-device-giants-ex-hospital-boss 2019-12-02T19:57:53 https://maestrodatabase.com/blog/france-pegs-gilead-hepatitis-c-drug-at-lowest-price-in-europe 2015-08-05T11:37:28 https://maestrodatabase.com/blog/a-step-closer-to-accessing-harvoni-as-tga-approves-use 2015-08-05T11:37:02 https://maestrodatabase.com/blog/fda-approves-expanded-indication-for-qudexy-xr-topiramate-extended-release-capsules-within-the-paediatric-population 2015-08-05T11:37:18 https://maestrodatabase.com/blog/nice-grants-lynparza-expansion-for-advanced-ovarian-cancer 2019-12-02T19:50:17 https://maestrodatabase.com/blog/abpi_statement_in_response_to_the__pharmaceutical_price_regulation_scheme_twelfth_report_to_parliament_ 2015-08-05T11:37:20 https://maestrodatabase.com/blog/diurnal-files-adrenal-insufficiency-drug-alkindi-in-us 2019-12-02T20:16:16 https://maestrodatabase.com/blog/moves-to-protect-availability-of-haemophilia-treatments 2015-08-05T11:37:27 https://maestrodatabase.com/blog/boehringer-ingelheim-receives-positive-chmp-opinion-for-a-third-nintedanib-indication-in-pulmonary-fibrosis 2020-06-01T04:43:42 https://maestrodatabase.com/blog/2000-medicine-prices-to-fall-by-up-to-50 2015-08-05T11:37:13 https://maestrodatabase.com/blog/pfizer-objects-to-nice-methods-in-leukaemia-drug-rejection 2017-08-21T17:32:30 https://maestrodatabase.com/blog/fda-approves-praxbind-the-first-reversal-agent-for-the-anticoagulant-pradaxa 2015-10-16T19:58:16 https://maestrodatabase.com/blog/janssen-submits-new-drug-application-for-yondelis-trabectedin-to-us-fda-for-the-treatment-of-patients-with-advanced-soft-tissue-sarcoma 2015-08-05T11:37:23 https://maestrodatabase.com/blog/turnbull-struggles-to-deal-with-funding-the-nations-soaring-health-care-demands 2017-08-21T17:43:48 https://maestrodatabase.com/blog/summary-of-the-agenda-for-the-march-2016-pbac-meeting 2016-01-11T20:42:14 https://maestrodatabase.com/blog/lexicon-pharmaceuticals-receives-formal-dispute-resolution-request-decision-from-fdas-office-of-new-drugs-for-sotagliflozin-in-type-1-diabetes 2019-12-02T20:09:11 https://maestrodatabase.com/blog/hikma-hikes-price-of-us-medicines-by-up-to-430-percent 2017-08-21T17:37:25 https://maestrodatabase.com/blog/accelerating-global-innovation-to-address-antibacterial-resistance-introducing-carb-x 2016-08-31T07:01:28 https://maestrodatabase.com/blog/menlo-therapeutics-receives-fda-approval-of-zilxi-minocycline-1-dot-5-percent-topical-foam-the-first-topical-minocycline-treatment-for-rosacea 2020-06-01T04:48:23 https://maestrodatabase.com/blog/pbs-and-rpbs-section-85-date-of-processing-and-date-of-supply-data 2016-04-29T06:52:37 https://maestrodatabase.com/blog/alexion-completes-rolling-bla-submission-to-us-fda-for-asfotase-alfa-as-a-treatment-for-patients-with-pypophosphatasia 2015-08-05T11:37:08 https://maestrodatabase.com/blog/fda-approves-avastin-to-treat-patients-with-aggressive-and-late-stage-cervical-cancer 2015-08-05T11:37:27 https://maestrodatabase.com/blog/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-for-keytruda-pembrolizumab-in-certain-patients-with-high-risk-non-muscle-invasive-bladder-cancer-nmibc 2019-12-02T20:29:36 https://maestrodatabase.com/blog/chmp-issues-positive-opinion-to-extend-invokana-canagliflozin-indication-to-reflect-improved-renal-outcomes-in-patients-with-diabetic-kidney-disease-and-type-2-diabetes 2020-06-01T05:09:56 https://maestrodatabase.com/blog/commission-proposal-for-a-european-regulation-on-hta 2019-12-02T20:26:26 https://maestrodatabase.com/blog/european-commission-grants-marketing-authorization-for-gileads-harvoni-ledipasvirsofosbuvir-the-first-single-tablet-regimen-to-treat-the-majority-of-chronic-hepatitis-c-patients-with-genotype-1-and-4 2015-08-05T11:37:04 https://maestrodatabase.com/blog/alkermes-initiates-rolling-submission-of-alks-5461-new-drug-application-for-major-depressive-disorder 2017-08-22T05:37:48 https://maestrodatabase.com/blog/confirmation-of-1-october-2014-price-disclosure-prices 2015-08-05T11:37:24 https://maestrodatabase.com/blog/public-consultation-on-lsdp-review-issues-paper-closed 2015-08-05T11:37:04 https://maestrodatabase.com/blog/china-updates-drug-reimbursement-list-agrees-price-cuts 2019-12-02T20:22:56 https://maestrodatabase.com/blog/biocon-biologics-yesafili-aflibercept-now-publicly-funded-in-ontario-canada-for-the-advanced-treatment-of-patients-with-retinal-diseases 2025-09-19T02:41:03 https://maestrodatabase.com/blog/federal-budget-2016-commitment-to-the-pbs 2016-05-03T20:45:08 https://maestrodatabase.com/blog/ironwood-pharmaceuticals-announces-fda-approval-of-duzallo-lesinurad-and-allopurinol-for-the-treatment-of-hyperuricaemia-in-patients-with-uncontrolled-gout 2017-08-22T05:27:37 https://maestrodatabase.com/blog/medunik-canada-is-pleased-to-announce-that-health-canada-has-granted-market-authorization-for-pheburane 2015-08-05T11:37:29 https://maestrodatabase.com/blog/sanofi-and-regeneron-announce-that-dupilumab-has-received-fda-breakthrough-therapy-designation-in-atopic-dermatitis 2015-08-05T11:37:13 https://maestrodatabase.com/blog/nice-issues-draft-guidance-recommending-drugs-for-rheumatoid-arthritis 2015-09-03T11:13:18 https://maestrodatabase.com/blog/zevra-therapeutics-provides-fda-update-on-the-pdufa-action-date-for-arimoclomol-as-a-treatment-for-niemann-pick-disease-type-c 2024-03-05T05:14:59 https://maestrodatabase.com/blog/biological-qualifier-an-inn-proposal-published 2016-01-23T01:48:26 https://maestrodatabase.com/blog/premiers-want-ottawa-to-allow-opt-out-for-proposed-pharmacare-plan 2019-12-02T20:40:56 https://maestrodatabase.com/blog/report-on-the-collection-of-under-co-payment-data-2013-14 2015-08-05T11:37:19 https://maestrodatabase.com/blog/biocon-biologics-receives-us-fda-approval-for-bosaya-and-aukelso-denosumab-biosimilars 2025-09-19T03:14:23 https://maestrodatabase.com/blog/trevena-receives-fda-breakthrough-therapy-designation-for-oliceridine 2016-02-22T20:23:03 https://maestrodatabase.com/blog/european-commission-grants-new-indication-for-soliris-eculizumab-for-the-treatment-of-patients-with-refractory-generalised-myasthenia-gravis 2017-08-22T06:03:33 https://maestrodatabase.com/blog/rare-disease-day-2015 2015-08-05T11:37:29 https://maestrodatabase.com/blog/what-should-patients-be-told-about-non-inferiority-studies 2017-08-22T05:58:24 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits-1-april-2016-update 2016-03-31T07:41:18 https://maestrodatabase.com/blog/european-medicines-agencys-management-board-nominates-guido-rasi-as-executive-director 2015-10-01T21:23:18 https://maestrodatabase.com/blog/australia-eyes-biotechnology-start-ups-to-remedy-resources-slump 2015-09-17T05:35:26 https://maestrodatabase.com/blog/hanmi-pharmaceutical-scores-its-first-fda-approval 2022-09-13T09:02:23 https://maestrodatabase.com/blog/novartis-ceo-opens-door-to-cancer-patient-demanding-fair-car-t-pricing 2017-08-22T06:31:27 https://maestrodatabase.com/blog/eisai-receives-european-commission-approval-of-indication-expansion-for-anticancer-agent-halaven-for-advanced-breast-cancer-only-one-prior-chemotherapy 2015-08-05T11:37:07 https://maestrodatabase.com/blog/praluent-recommended-for-reimbursement-by-cadth 2016-07-25T21:42:42 https://maestrodatabase.com/blog/taysha-gene-therapies-receives-rare-paediatric-disease-designation-and-orphan-drug-designation-for-tsha-104-to-treat-surf1-associated-leigh-syndrome 2020-10-28T04:55:28 https://maestrodatabase.com/blog/new-therapeutic-option-now-available-for-select-treatment-resistant-lung-cancer-patients 2015-08-05T11:37:10 https://maestrodatabase.com/blog/forxiga-cardiovascular-outcomes-benefit-approved-in-china 2020-10-28T10:09:44 https://maestrodatabase.com/blog/price-cuts-mean-pbs-is-sustainable-and-can-afford-new-medicines 2015-08-05T11:37:02 https://maestrodatabase.com/blog/heron-therapeutics-announces-us-fda-approval-of-sustol-granisetron-extended-release-injection-for-the-prevention-of-chemotherapy-induced-nausea-and-vomiting 2016-08-10T21:01:09 https://maestrodatabase.com/blog/meeting-highlights-from-the-committee-for-medicinal-products-for-human-use-chmp-19-22-january-2015 2015-08-05T11:37:21 https://maestrodatabase.com/blog/more-on-fda-breakthrough-therapies 2016-08-04T12:48:36 https://maestrodatabase.com/blog/amgen-sanofi-cholesterol-drugs-not-cost-effective-study-says 2016-08-16T21:25:32 https://maestrodatabase.com/blog/revlimid-lenalidomide-approved-by-the-european-commission-for-the-treatment-of-relapsedrefractory-patients-with-mantle-cell-lymphoma 2016-07-15T08:52:30 https://maestrodatabase.com/blog/nice-cancer-drugs-fund-must-use-our-processes 2015-08-05T11:37:06 https://maestrodatabase.com/blog/clovis-oncology-receives-breakthrough-therapy-designation-for-co-1686-for-the-second-line-treatment-of-egfr-mutant-non-small-cell-lung-cancer-in-patients-with-the-t790m-mutation 2015-08-05T11:37:09 https://maestrodatabase.com/blog/azurity-pharmaceuticals-announces-fda-approval-of-danziten-nilotinib-tablets-the-first-and-only-nilotinib-with-no-mealtime-restrictions 2024-11-17T23:46:53 https://maestrodatabase.com/blog/us-senators-urge-fda-to-take-action-over-wasted-cancer-drugs 2016-06-01T17:49:41 https://maestrodatabase.com/blog/fda-approves-striverdi-respimat-to-treat-chronic-obstructive-pulmonary-disease 2015-08-05T11:37:13 https://maestrodatabase.com/blog/tga-consultation-orphan-drugs-program 2015-08-05T11:37:28 https://maestrodatabase.com/blog/health-canada-authorises-akeega-niraparib-and-abiraterone-acetate-dual-action-tablets-for-targeted-treatment-of-patients-with-metastatic-castration-resistant-prostate-cancer-with-brca-1-slash-2-gene-mutations 2023-06-15T01:57:35 https://maestrodatabase.com/blog/drug-that-saved-ron-walker-could-help-wide-range-of-cancer-patients 2016-05-13T23:58:55 https://maestrodatabase.com/blog/fdas-foray-into-big-data-still-maturing-1 2016-05-10T23:46:13 https://maestrodatabase.com/blog/cerdelga-recommended-for-approval-in-type-1-gaucher-disease 2015-08-05T11:37:19 https://maestrodatabase.com/blog/pharmaxis-announces-positive-recommendation-for-broader-bronchitol-access-in-australia 2017-08-22T07:47:42 https://maestrodatabase.com/blog/mylan-and-biocon-receive-approvals-from-the-european-commission-and-tga-australia-for-semglee-biosimilar-insulin-glargine 2018-03-28T04:45:09 https://maestrodatabase.com/blog/iqwig-internationally-health-economic-evaluations-are-a-fixed-component-of-reimbursement-decisions 2015-08-05T11:37:18 https://maestrodatabase.com/blog/nice-rejects-thyroid-cancer-drugs 2017-08-23T17:51:09 https://maestrodatabase.com/blog/prostate-cancer-symptoms-as-new-treatment-given-green-light-in-scotland 2022-09-13T10:46:33 https://maestrodatabase.com/blog/european-commission-approves-scenesse 2015-08-05T11:37:23 https://maestrodatabase.com/blog/enhertu-granted-priority-review-in-the-us-for-the-treatment-of-her2-positive-metastatic-gastric-cancer 2020-10-28T11:05:31 https://maestrodatabase.com/blog/fda-approves-new-drug-treatment-for-nausea-and-vomiting-from-chemotherapy 2015-09-02T20:15:52 https://maestrodatabase.com/blog/mcconnell-next-steps-on-obamacare-are-somewhat-murky 2017-08-22T13:22:11 https://maestrodatabase.com/blog/lilly-announces-agreement-with-u-dot-s-government-to-supply-300-000-vials-of-investigational-neutralising-antibody-bamlanivimab-ly-cov555-in-an-effort-to-fight-covid-19 2020-10-28T11:09:07 https://maestrodatabase.com/blog/new-treatment-for-cancer-approved-for-pbs-listing 2015-08-05T11:37:19 https://maestrodatabase.com/blog/tender-still-important-to-maintain-nzers-access-to-medicines 2015-08-05T11:37:16 https://maestrodatabase.com/blog/nice-nod-for-jazz-aml-chemo 2018-11-09T10:41:08 https://maestrodatabase.com/blog/agenda-for-the-november-2017-pbac-meeting 2017-08-23T17:53:16 https://maestrodatabase.com/blog/bristol-myers-squibb-announces-us-food-and-drug-administration-regulatory-filing-update-for-the-opdivoyervoy-regimen-in-patients-with-previously-untreated-advanced-melanoma 2015-09-27T00:31:05 https://maestrodatabase.com/blog/scottish-medicines-consortium-accepts-theramex-bijuve-hrt-on-nhs-scotland 2022-09-13T10:34:04 https://maestrodatabase.com/blog/cadth-lecture-series--dr-murray-krahn 2015-08-05T11:37:15 https://maestrodatabase.com/blog/ispors-initiative-on-us-value-assessment-frameworks-conference-draws-key-health-care-stakeholders-and-thought-leaders 2016-10-04T21:22:08 https://maestrodatabase.com/blog/cadth-recommends-reimbursement-of-eylea 2016-07-31T23:11:55 https://maestrodatabase.com/blog/breakthrough-cancer-drug-could-be-astronomical-in-price 2017-08-23T18:08:47 https://maestrodatabase.com/blog/novavax-nuvaxovid-covid-19-vaccine-granted-expanded-conditional-marketing-authorisation-in-the-european-union-for-use-as-a-booster-for-adults-aged-18-and-older 2022-09-13T09:07:44 https://maestrodatabase.com/blog/health-canada-approves-strensiq-asfotase-alfa-the-first-therapy-for-patients-with-hypophosphatasia-hpp-an-ultra-rare-life-threatening-disease 2015-08-18T10:18:54 https://maestrodatabase.com/blog/combination-drugs-taking-flow-on-price-deductions-for-1-october-2016 2016-08-01T07:25:51 https://maestrodatabase.com/blog/strengthening-eu-us-cooperation-in-medicine-inspections 2017-08-23T17:57:03 https://maestrodatabase.com/blog/parents-take-battle-for-life-saving-drug-to-parliament 2018-03-28T04:53:07 https://maestrodatabase.com/blog/pharmac-invites-proposals-for-the-supply-of-various-vaccines-in-new-zealand 2016-02-15T10:49:38 https://maestrodatabase.com/blog/perc-recommends-abraxane-for-patients-with-metastatic-adenocarcinoma-of-the-pancreas 2015-08-05T11:37:07 https://maestrodatabase.com/blog/sanofi-and-gsk-to-support-covax-with-200-million-doses-of-adjuvanted-recombinant-protein-based-covid-19-vaccine 2020-10-28T11:22:22 https://maestrodatabase.com/blog/us-food-and-drug-administration-accepts-for-priority-review-the-supplemental-biologics-license-application-for-opdivo-nivolumab-in-patients-with-advanced-renal-cell-carcinoma 2015-11-17T06:49:21 https://maestrodatabase.com/blog/fda-approves-toujeo-max-solostar 2018-03-28T05:10:39 https://maestrodatabase.com/blog/uk-trailing-europe-on-access-to-cancer-drugs 2016-06-23T21:19:00 https://maestrodatabase.com/blog/senate-health-panel-announces-hearings-on-obamacare-markets 2017-08-23T19:25:28 https://maestrodatabase.com/blog/vertex-announces-a-signed-letter-of-intent-to-enable-public-reimbursement-of-kalydeco-ivacaftor-in-canada-for-eligible-people-with-cystic-fibrosis 2015-08-05T11:37:12 https://maestrodatabase.com/blog/legislation-to-make-private-health-insurance-simpler-and-more-affordable 2018-03-28T05:51:51 https://maestrodatabase.com/blog/icer-publishes-final-evidence-report-and-policy-recommendations-on-treatments-for-amyotrophic-lateral-sclerosis 2022-09-13T20:41:40 https://maestrodatabase.com/blog/shield-receives-eu-commission-approval-for-the-broadening-of-the-indication-for-feraccru-ferric-maltol-to-the-treatment-of-iron-deficiency-in-adults 2018-03-28T05:03:31 https://maestrodatabase.com/blog/debate-are-doctors-or-insurers-to-blame-for-health-insurance-price-hikes 2017-08-23T19:37:14 https://maestrodatabase.com/blog/chmp-issues-positive-opinion-for-orencia-abatacept-in-the-treatment-of-highly-active-and-progressive-disease-in-adult-patients-with-rheumatoid-arthritis-not-previously-treated-with-methotrexate-in-the-eu 2016-07-25T12:01:44 https://maestrodatabase.com/blog/a-multi-stakeholder-platform-for-improving-access-to-medicines-in-the-european-region 2022-09-13T20:38:26 https://maestrodatabase.com/blog/another-drug-pricing-ripoff 2016-08-25T09:13:13 https://maestrodatabase.com/blog/astellas-receives-u-dot-s-fda-fast-track-designation-for-asp5354-an-investigational-near-infrared-fluorescence-imaging-agent 2020-10-28T19:40:09 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule-1-may-2016-update 2016-04-30T23:25:13 https://maestrodatabase.com/blog/health-minister-hears-consumer-case-for-health-reform 2017-08-23T19:31:09 https://maestrodatabase.com/blog/new-drug-listing-keytruda-to-treat-melanoma 2015-08-05T11:37:23 https://maestrodatabase.com/blog/us-food-and-drug-administration-approves-descovy-emtricitabine-tenofovir-alafenamide-gileads-third-taf-based-hiv-therapy 2016-04-05T02:20:18 https://maestrodatabase.com/blog/abbvies-humira-adalimumab-receives-positive-chmp-opinion-to-treat-adult-patients-with-active-moderate-to-severe-hidradenitis-suppurativa-a-chronic-inflammatory-skin-disease 2015-08-05T11:37:21 https://maestrodatabase.com/blog/hetlioz-receives-european-commission-approval-for-the-treatment-of-non-24-hour-sleep-wake-disorder-in-the-totally-blind 2015-08-05T11:37:18 https://maestrodatabase.com/blog/major-new-measures-to-help-combat-rare-cancers 2017-08-24T01:57:42 https://maestrodatabase.com/blog/bwxt-medical-submits-tc-99m-generator-new-drug-application-to-fda 2022-09-13T20:32:18 https://maestrodatabase.com/blog/opal-biosciences-takes-on-the-superbugs 2015-08-05T11:37:14 https://maestrodatabase.com/blog/private-health-insurance-premiums-rise-less-than-wages-pensions-and-inflation 2024-03-05T06:00:22 https://maestrodatabase.com/blog/europe-approves-hololcar-the-first-stem-cell-based-medicinal-product 2015-08-05T11:37:03 https://maestrodatabase.com/blog/federal-health-minister-urged-to-get-new-hep-c-drugs-listed-on-pbs 2015-09-30T03:25:05 https://maestrodatabase.com/blog/uks-mhra-starts-rolling-review-of-modernas-covid-19-vaccine 2020-10-28T11:12:30 https://maestrodatabase.com/blog/otsuka-and-lundbeck-announce-u-dot-s-fda-acceptance-of-new-drug-application-for-aripiprazole-2-month-ready-to-use-long-acting-injectable-to-treat-schizophrenia-and-bipolar-i-disorder-in-adults 2022-09-13T20:27:51 https://maestrodatabase.com/blog/european-biotech-firms-head-to-wall-street 2015-08-05T11:37:05 https://maestrodatabase.com/blog/nice-rejects-takeda-crohns-disease-drug 2015-08-05T11:37:29 https://maestrodatabase.com/blog/using-discrete-choice-experiments-to-inform-the-benefit-risk-assessment-of-medicines-are-we-ready-yet 2017-08-24T03:19:31 https://maestrodatabase.com/blog/tlv-reconsiders-the-subsidy-of-cosentyx 2020-10-28T11:14:25 https://maestrodatabase.com/blog/smc_advice___december_2013 2015-08-05T11:37:28 https://maestrodatabase.com/blog/cardiome-provides-u-dot-s-regulatory-update-for-brinavess 2017-08-24T04:19:28 https://maestrodatabase.com/blog/us-food-and-drug-administration-accepts-supplemental-biologics-license-application-for-opdivo-nivolumab-in-patients-with-previously-untreated-advanced-melanoma 2015-08-05T11:37:12 https://maestrodatabase.com/blog/leo-pharma-is-withdrawing-the-drug-picato-ingenol-mebutate-used-to-treat-skin-lesions-due-to-the-potential-increased-risk-of-skin-cancer 2020-10-28T20:27:30 https://maestrodatabase.com/blog/abbvie-receives-health-canada-approval-of-holkira-pak-for-the-treatment-of-chronic-genotype-1-hepatitis-c 2015-08-05T11:37:12 https://maestrodatabase.com/blog/cadth-partners-with-international-health-technology-assessment-bodies-to-boost-collaboration-on-shared-challenges 2022-09-13T21:01:41 https://maestrodatabase.com/blog/call-for-patient-input-2 2015-08-05T11:37:30 https://maestrodatabase.com/blog/first-fda-breakthrough-therapy-designation-for-klh-conjugate-immunotherapy-signals-key-step-for-novel-carrier-molecule 2015-08-05T11:37:30 https://maestrodatabase.com/blog/alk-obtains-european-approval-for-its-house-dust-mite-sublingual-allergy-immunotherapy-tablet-against-allergic-rhinitis-and-allergic-asthma-1 2015-09-03T04:38:42 https://maestrodatabase.com/blog/amneal-receives-nda-approval-from-fda-for-pemrydi-rtu-a-ready-to-use-oncology-injectable 2023-06-15T02:18:41 https://maestrodatabase.com/blog/pbs-listing-for-kalydeco-and-soliris 2015-08-05T11:37:07 https://maestrodatabase.com/blog/medicare-and-medicaid-to-cover-early-covid-19-vaccine 2020-10-28T20:37:55 https://maestrodatabase.com/blog/explainer-how-the-us-drug-pricing-law-affects-medicare-and-its-members 2022-09-13T20:56:47 https://maestrodatabase.com/blog/ariad-initiates-submission-of-new-drug-application-for-brigatinib-to-the-us-fda-ahead-of-plan 2016-06-20T21:15:20 https://maestrodatabase.com/blog/post-market-review-of-pbs-medicines-used-to-treat-asthma-in-children 2015-08-05T11:37:13 https://maestrodatabase.com/blog/kye-pharmaceuticals-announces-commercial-availability-of-firdapse-in-canada 2020-10-28T19:57:37 https://maestrodatabase.com/blog/health-industry-forum-outlines-opportunities-for-investment-and-growth-in-australias-innovative-medicines-sector 2015-08-05T11:37:14 https://maestrodatabase.com/blog/updated-agenda-for-the-march-2022-pbac-meeting 2022-01-06T02:10:33 https://maestrodatabase.com/blog/novartis_pharmaceuticals_canada_receives_health_canada_approval_for_ultibro_breezhaler__a_once_daily_dual_bronchodilator_for_copd 2015-08-05T11:37:16 https://maestrodatabase.com/blog/coalition-quietly-shelves-13b-drugs-initiative 2015-08-05T11:37:13 https://maestrodatabase.com/blog/fda-finalises-guidance-on-submitting-rwd-slash-rwe-in-application-cover-letters 2022-09-13T20:51:39 https://maestrodatabase.com/blog/health-departments-jane-halton-nabs-finance-post 2015-08-05T11:37:02 https://maestrodatabase.com/blog/nice-conflicts-of-interest-call-for-mps-to-investigate 2015-08-05T11:37:03 https://maestrodatabase.com/blog/orphazyme-initiates-rolling-submission-of-new-drug-application-for-arimoclomol-with-us-fda-in-niemann-pick-disease-type-c 2020-06-01T06:36:43 https://maestrodatabase.com/blog/fda-issues-final-guidance-on-the-evaluation-and-labeling-of-abuse-deterrent-opioids 2015-08-05T11:37:03 https://maestrodatabase.com/blog/agenda-for-19-november-2014-transparency-commission-meeting 2015-08-05T11:37:03 https://maestrodatabase.com/blog/covid-19-vaccine-attitudes-differ-in-australia-as-experts-say-were-at-a-precarious-time 2020-10-28T20:22:18 https://maestrodatabase.com/blog/clovis-oncology-submits-applications-for-rubraca-label-expansion-in-the-us-and-european-union-as-first-line-maintenance-treatment-in-women-with-advanced-ovarian-cancer 2022-09-13T20:46:13 https://maestrodatabase.com/blog/fda-grants-genentechs-avastin-priority-review-for-recurrent-platinum-resistant-ovarian-cancer 2015-08-05T11:37:24 https://maestrodatabase.com/blog/pembrolizumab-in-combination-with-chemotherapy-for-the-treatment-of-patients-with-advanced-her2-negative-gastric-or-gastro-oesophageal-junction-adenocarcinoma 2024-03-05T20:04:25 https://maestrodatabase.com/blog/novartis-kisqali-ribociclib-receives-eu-approval-as-first-line-treatment-for-hr-plus-slash-her2--locally-advanced-or-metastatic-breast-cancer-in-combination-with-any-aromatase-inhibitor 2017-08-24T07:41:33 https://maestrodatabase.com/blog/cadth-calls-for-patient-input-on-submission-from-duchesnay-for-mictoryl-propiverine-hydrochloride 2016-09-11T12:01:32 https://maestrodatabase.com/blog/fda-approves-expanded-indications-for-ilaris-for-three-rare-diseases 2016-09-23T21:08:00 https://maestrodatabase.com/blog/shkreli-laughs-off-questions-from-lawmakers-calls-them-imbeciles 2016-02-04T20:46:54 https://maestrodatabase.com/blog/final-nice-green-light-for-ipsens-cometriq 2018-03-28T10:03:27 https://maestrodatabase.com/blog/agenda-for-17-september-2014-transparency-commission-meeting 2015-08-05T11:37:28 https://maestrodatabase.com/blog/first-medicine-recommended-for-approval-for-hidradenitis-suppurativa 2015-08-05T11:37:06 https://maestrodatabase.com/blog/anthos-therapeutics-announces-that-abelacimab-has-received-fda-fast-track-designation-for-the-prevention-of-stroke-and-systemic-embolism-in-patients-with-atrial-fibrillation 2022-09-13T21:24:56 https://maestrodatabase.com/blog/sandoz-receives-fda-approval-for-first-and-only-denosumab-biosimilars 2024-03-05T19:58:10 https://maestrodatabase.com/blog/two-new-medicines-recommended-for-the-treatment-of-chronic-hepatitis-c 2017-06-23T11:28:44 https://maestrodatabase.com/blog/dymista-approved-in-children-6-to-11-years-of-age-with-seasonal-allergic-rhinitis 2015-08-05T11:37:16 https://maestrodatabase.com/blog/ipsen-announces-ema-validation-of-filing-of-a-new-application-for-additional-indication-for-cabometyx 2018-03-28T10:10:10 https://maestrodatabase.com/blog/changes-needed-to-selection-of-pbs-cancer-medicines-experts 2016-05-09T13:32:34 https://maestrodatabase.com/blog/cstone-announces-chinas-nmpa-has-accepted-and-granted-priority-review-to-the-supplemental-new-drug-application-for-sugemalimab-in-the-treatment-of-patients-with-relapsed-or-refractory-extranodal-natural-killer-slash-t-cell-lymphoma 2022-09-13T21:12:08 https://maestrodatabase.com/blog/us-fda-approves-expanded-indication-for-brilinta-to-include-long-term-use-in-patients-with-a-history-of-heart-attack 2015-09-04T01:02:59 https://maestrodatabase.com/blog/to-make-copycat-drugs-more-competitive-the-fda-is-taking-a-harder-look-at-the-originals 2018-03-28T20:19:42 https://maestrodatabase.com/blog/statement-from-fda-commissioner-on-new-efforts-to-strengthen-fdas-expanded-access-program 2018-11-09T11:24:21 https://maestrodatabase.com/blog/are-insurance-policies-saving-patients-money-or-keeping-them-from-the-treatment-they-need 2016-08-22T11:50:46 https://maestrodatabase.com/blog/bitter-pill-to-swallow-potentially-life-saving-drugs-remain-unfunded-for-more-than-a-decade 2017-08-24T07:52:59 https://maestrodatabase.com/blog/agenda-for-the-16-december-2015-tc-meeting 2015-12-10T05:34:25 https://maestrodatabase.com/blog/adjustment-of-application-fees-for-cadth-pharmaceutical-reviews 2018-03-28T20:28:54 https://maestrodatabase.com/blog/new-treatment-option-available-today-for-womb-cancer 2024-03-05T09:51:09 https://maestrodatabase.com/blog/dont-complain-about-tpp-pharmaceuticals-we-already-free-ride-off-us-consumers 2015-10-07T20:20:03 https://maestrodatabase.com/blog/us-australia-agree-on-complicated-compromise-on-biologic-drugs 2015-10-05T06:10:42 https://maestrodatabase.com/blog/ema-to-raise-mah-and-applicant-fees-by-1-dot-7-percent-in-april 2018-03-28T20:03:59 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-gene-therapies-for-haemophilia-a-and-b 2022-09-13T21:04:52 https://maestrodatabase.com/blog/nice-recommends-crizotinib-first-pill-for-lung-cancer 2016-08-18T09:11:09 https://maestrodatabase.com/blog/first-statistics-on-prime-are-released 2016-06-01T16:01:01 https://maestrodatabase.com/blog/in-battle-to-cut-drug-prices-outcome-based-pricing-carries-big-risks-for-biopharma 2018-03-28T20:07:02 https://maestrodatabase.com/blog/ispor-expands-leadership-team-with-chief-science-officer 2016-04-21T11:28:43 https://maestrodatabase.com/blog/review-of-pharmacy-remuneration-and-regulation-release-of-discussion-paper 2016-07-27T03:23:42 https://maestrodatabase.com/blog/unprecedented-stock-management-and-cashflow-challenges 2016-03-09T03:01:00 https://maestrodatabase.com/blog/novo-nordisk-to-cease-distribution-of-tresiba-in-germany 2015-08-05T11:37:18 https://maestrodatabase.com/blog/coherus-prices-biosimilar-to-amgens-neulasta-at-33-percent-discount 2018-11-09T11:46:32 https://maestrodatabase.com/blog/post-market-review-of-medicines-for-smoking-cessation---public-consultation-on-the-draft-report 2021-06-07T02:05:29 https://maestrodatabase.com/blog/novartis-cdk46-inhibitor-lee011-ribociclib-receives-fda-breakthrough-therapy-designation-as-first-line-treatment-for-hrher2-advanced-breast-cancer 2016-08-03T10:27:36 https://maestrodatabase.com/blog/zionexa-usa-and-petnet-solutions-announce-fda-approval-of-cerianna-fluoroestradiol-f-18 2020-06-01T08:26:56 https://maestrodatabase.com/blog/merck-receives-eu-approval-to-extend-kuvan-use-to-children-with-pku-below-4-years-of-age 2015-08-05T11:37:15 https://maestrodatabase.com/blog/abpi-responds-to-the-international-comparisons-of-health-technology-assessment-report-and-claims-that-patients-are-being-denied-life-prolonging-treatments 2016-08-15T12:20:40 https://maestrodatabase.com/blog/lenvima-backed-for-nhs-use-to-treat-liver-cancer 2018-11-09T11:43:06 https://maestrodatabase.com/blog/new-model-needed-to-relieve-hepatitis-c-medicines-pressure-on-pharmacies 2016-04-20T04:13:04 https://maestrodatabase.com/blog/ab-science-today-announces-that-health-canada-has-issued-a-screening-acceptance-letter-for-the-application-of-masitinib-in-the-treatment-of-amyotrophic-lateral-sclerosis 2024-03-05T20:35:16 https://maestrodatabase.com/blog/nice-backs-gileads-harvoni-for-hepatitis-c 2015-08-05T11:37:28 https://maestrodatabase.com/blog/pbac-generic-medicines-working-group-communique 2016-04-21T05:51:35 https://maestrodatabase.com/blog/drug-makers-send-counter-offers-for-us-medicare-price-negotiations-biden-says 2024-03-05T20:18:52 https://maestrodatabase.com/blog/post-market-reviews-of-copd-medicines-and-ezetimibe-extension-of-public-consultation-on-draft-terms-of-reference 2015-11-02T00:52:34 https://maestrodatabase.com/blog/trump-administration-acts-to-ensure-coverage-of-life-saving-covid-19-vaccines-and-therapeutics 2020-10-28T21:58:10 https://maestrodatabase.com/blog/medlab-shares-up-on-cannabis-approval 2015-08-05T11:37:10 https://maestrodatabase.com/blog/fda-approves-amgens-cholesterol-lowering-drug-repatha 2015-08-30T08:27:22 https://maestrodatabase.com/blog/iqwig-autumn-symposium-2016-programme-is-now-online 2016-09-07T09:45:03 https://maestrodatabase.com/blog/nine-drug-formularies-in-canada-list-evenity-for-reimbursement-for-the-treatment-of-osteoporosis-in-post-menopausal-women-as-high-risk-of-fracture 2024-03-05T20:13:03 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac-august-2016 2016-09-30T02:56:11 https://maestrodatabase.com/blog/u-dot-s-fda-approves-new-paediatric-formulation-of-sirturo-bedaquiline-as-part-of-combination-therapy-to-treat-children-with-pulmonary-multidrug-resistant-tuberculosis 2020-06-01T08:06:59 https://maestrodatabase.com/blog/afatinib-added-benefit-in-certain-mutations-confirmed-by-iqwig 2015-08-20T21:05:49 https://maestrodatabase.com/blog/epipen-price-rise-sparks-concern-for-allergy-sufferers 2016-08-23T19:20:50 https://maestrodatabase.com/blog/ema-started-the-evaluation-of-richters-marketing-authorisation-application-for-biosimilar-pegfilgrastim 2015-12-09T06:18:03 https://maestrodatabase.com/blog/lillys-taltz-ixekizumab-is-the-first-il-17a-antagonist-to-receive-u-dot-s-fda-approval-for-the-treatment-of-non-radiographic-axial-spondyloarthritis 2020-06-01T11:19:55 https://maestrodatabase.com/blog/us-fda-approves-update-of-simponi-aria-golimumab-for-infusion-label-to-include-improvement-in-both-physical-and-emotional-measures-of-health-when-treating-moderately-to-severely-active-rheumatoid-arthritis 2015-09-03T21:12:55 https://maestrodatabase.com/blog/fda-approves-cholbam-to-treat-rare-bile-acid-synthesis-disorders 2015-08-05T11:37:30 https://maestrodatabase.com/blog/type-2-diabetes-boost-new-treatment-will-save-money-and-multiple-injections 2016-08-14T01:18:14 https://maestrodatabase.com/blog/tpp-finalised-with-no-extension-to-data-exclusivity-for-medicines-gbma 2015-10-06T07:48:24 https://maestrodatabase.com/blog/omeros-receives-fda-approval-of-omidria-for-use-in-cataract-and-other-intraocular-lens-replacement-procedures 2015-08-05T11:37:26 https://maestrodatabase.com/blog/us-fda-review-for-scenesse-extended-by-three-months 2019-06-04T06:14:26 https://maestrodatabase.com/blog/ema-publishes-epar-for-autologous-cd34-enriched-cell-fraction-strimvelis 2016-06-08T21:14:21 https://maestrodatabase.com/blog/this-vote-could-finally-make-a-difference-in-crazy-drug-prices 2016-09-14T21:39:25 https://maestrodatabase.com/blog/cadth-calls-for-patient-input-on-a-new-submission-from-eisai-for-fycompa 2015-09-28T21:22:02 https://maestrodatabase.com/blog/health-economic-assessment-of-vimizim-in-mucopolysaccharidosis-type-iva-morquio-a-syndrome 2020-06-01T09:06:18 https://maestrodatabase.com/blog/the-trans-pacific-partnership-agreement-and-implications-for-access-to-essential-medicines 2015-10-20T20:51:03 https://maestrodatabase.com/blog/fda-statement-on-medical-device-user-fee-agreement-mdufa 2016-08-22T21:08:49 https://maestrodatabase.com/blog/roche-receives-eu-approval-of-avastin-in-combination-with-tarceva-for-patients-with-a-specific-type-of-advanced-lung-cancer 2016-06-08T11:06:11 https://maestrodatabase.com/blog/fdas-breakthrough-therapy-designation-and-expedited-review-programs-part-i 2016-04-20T21:27:08 https://maestrodatabase.com/blog/springworks-therapeutics-announces-fda-fast-track-designation-for-pd-0325901-for-the-treatment-of-a-severe-form-of-neurofibromatosis-type-1 2019-06-04T06:10:43 https://maestrodatabase.com/blog/agenda-for-the-23-september-2015-tc-meeting 2015-09-26T00:47:59 https://maestrodatabase.com/blog/mylan-and-biocon-announce-regulatory-submission-for-proposed-biosimilar-pegfilgrastim-accepted-for-review-by-european-medicines-agency 2016-07-22T10:31:22 https://maestrodatabase.com/blog/biosimilar-uptake-drivers---etanercept 2019-06-04T06:23:26 https://maestrodatabase.com/blog/alirocumab-hypercholesterolemia-or-mixed-dyslipidaemia-additional-benefits-not-covered-says-iqwig 2016-02-15T20:17:45 https://maestrodatabase.com/blog/simponi-receives-european-commission-approval-for-treatment-of-non-radiographic-axial-spondyloarthritis 2015-08-05T11:37:09 https://maestrodatabase.com/blog/scoping-document-for-icer-review-of-drugs-for-rheumatoid-arthritis-posted-for-public-comment 2016-08-01T21:23:05 https://maestrodatabase.com/blog/drugs_access_review_speeds_help_for_scots 2015-08-05T11:37:18 https://maestrodatabase.com/blog/octapharma-usa-announces-fda-approval-of-nuwiq-new-product-strengths-expanding-haemophilia-a-patient-treatment-options 2017-08-24T10:45:51 https://maestrodatabase.com/blog/new-regulatory-arrangements-support-businesses-and-health-care-professionals-to-communicate-and-incentivise-covid-19-vaccination 2021-06-07T04:23:50 https://maestrodatabase.com/blog/fda-expands-approved-use-of-opdivo-to-treat-lung-cancer 2017-06-08T04:13:40 https://maestrodatabase.com/blog/passage-bios-pbkr03-receives-orphan-drug-and-rare-paediatric-disease-designations-from-fda-for-treatment-of-krabbe-disease 2020-10-29T03:57:08 https://maestrodatabase.com/blog/the-gop-needs-to-tackle-the-high-price-of-prescription-drugs 2016-07-13T21:45:48 https://maestrodatabase.com/blog/novartis-roche-find-outcome-based-drug-pricing-an-elusive-dream 2015-11-14T18:24:46 https://maestrodatabase.com/blog/do-the-american-society-of-clinical-oncology-value-framework-and-the-european-society-of-medical-oncology-magnitude-of-clinical-benefit-scale-measure-the-same-construct-of-clinical-benefit 2017-08-24T10:52:49 https://maestrodatabase.com/blog/cytodyn-files-request-with-fda-for-priority-review-of-bla-for-first-approval 2020-06-01T11:27:56 https://maestrodatabase.com/blog/decision-to-list-eplerenone-for-the-treatment-of-heart-failure 2018-03-29T00:09:47 https://maestrodatabase.com/blog/abpi-comments-on-nices-response-to-value-based-assessment-consultation 2015-08-05T11:37:25 https://maestrodatabase.com/blog/industry_calls_on_government_to_save_the_pbs 2015-08-05T11:37:28 https://maestrodatabase.com/blog/iqwig-welcomes-who-statement-on-public-disclosure-of-clinical-trial-results 2015-08-05T11:37:02 https://maestrodatabase.com/blog/multidimensional-evidence-generation-and-fda-regulatory-decision-making 2017-08-24T11:04:32 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-approval-from-the-us-food-and-drug-administration-for-the-opdivo-nivolumab-yervoy-ipilimumab-regimen-in-braf-v600-wild-type-unresectable-or-metastatic-melanoma 2015-10-01T11:21:29 https://maestrodatabase.com/blog/brilinta-approved-in-the-us-to-reduce-the-risk-of-a-first-heart-attack-or-stroke-in-high-risk-patients-with-coronary-artery-disease 2020-06-01T11:38:30 https://maestrodatabase.com/blog/novartis-chief-sees-lasting-price-pressure-as-the-new-reality 2016-01-29T04:03:44 https://maestrodatabase.com/blog/icer-publishes-evidence-report-on-tirzepatide-for-type-2-diabetes 2022-01-06T19:59:34 https://maestrodatabase.com/blog/exelixis-provides-update-on-genentechs-pending-new-drug-application-for-cobimetinib-an-exelixis-discovered-compound 2015-08-05T11:37:18 https://maestrodatabase.com/blog/guidance-for-the-publication-of-clinical-data 2016-03-03T18:28:10 https://maestrodatabase.com/blog/bluebird-bio-announces-eu-conditional-marketing-authorisation-for-zynteglo-autologous-cd34-plus-cells-encoding-ba-t87q-globin-gene-gene-therapy-for-patients-12-years-and-older-with-transfusion-dependent-b-thalassemia-who-do-not-have-b0-slash-b0-genotype 2019-06-04T06:27:24 https://maestrodatabase.com/blog/australian-public-assessment-report-auspar-guidance-document-version-15-march-2015 2015-08-05T11:37:08 https://maestrodatabase.com/blog/pcsk9-inhibitors-and-the-choice-between-innovation-efficiency-and-affordability 2017-08-24T11:09:11 https://maestrodatabase.com/blog/ema-accepts-biomarins-marketing-application-for-pegvaliase-maa-for-treatment-of-phenylketonuria 2018-03-29T01:07:14 https://maestrodatabase.com/blog/lilly-snaps-up-regulatory-fast-pass-for-bargain-price 2018-11-09T13:21:37 https://maestrodatabase.com/blog/ema-raises-awareness-of-clinical-care-recommendations-to-manage-suspected-thrombosis-with-thrombocytopenia-syndrome 2021-06-07T09:02:29 https://maestrodatabase.com/blog/cancer-drug-prices-highest-in-us-least-affordable-in-india-china-study 2016-06-06T21:08:23 https://maestrodatabase.com/blog/tga-investigating-pfizer-jabs-for-children-over-12 2021-06-07T08:33:12 https://maestrodatabase.com/blog/eu-council-conclusions-on-strengthening-the-balance-in-the-pharmaceutical-systems-in-the-eu-and-its-member-states 2016-06-20T09:10:46 https://maestrodatabase.com/blog/after-repeated-losses-in-the-u-dot-s-catalyst-wins-a-victory-in-canada-over-a-rare-disease-drug 2021-06-07T09:08:47 https://maestrodatabase.com/blog/how-much-should-cancer-drugs-cost 2015-08-05T11:37:17 https://maestrodatabase.com/blog/abbvie-submits-regulatory-applications-to-fda-and-ema-for-rinvoq-upadacitinib-for-the-treatment-of-adults-with-active-psoriatic-arthritis 2020-06-01T21:10:07 https://maestrodatabase.com/blog/amgen-submits-applications-in-the-us-and-europe-for-kyprolis-carfilzomib-for-the-treatment-of-relapsed-multiple-myeloma 2015-08-05T11:37:23 https://maestrodatabase.com/blog/health-canada-approves-new-first-line-treatment-for-women-living-with-metastatic-breast-cancer 2016-05-11T14:23:18 https://maestrodatabase.com/blog/what-is-the-medical-technology-association-and-how-does-it-wield-its-power 2016-09-28T11:35:32 https://maestrodatabase.com/blog/citing_unreasonable_price__pharmac_declines_eculizumab_funding_proposal 2015-08-05T11:37:26 https://maestrodatabase.com/blog/new_pricing_deal_swings_into_action_this_month_with_industry_making_first_payments 2015-08-05T11:37:04 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-august-2015-update 2015-08-05T11:37:25 https://maestrodatabase.com/blog/nice-welcomes-governments-innovation-review 2015-08-05T11:37:19 https://maestrodatabase.com/blog/ceritinib-in-advanced-lung-cancer-no-hint-of-added-benefit 2015-10-06T11:09:35 https://maestrodatabase.com/blog/summary-of-submissions-and-outcomes-from-the-march-2016-pbac-meeting 2016-04-25T21:57:34 https://maestrodatabase.com/blog/post-market-review-of-the-life-saving-drugs-programme 2015-08-05T11:37:25 https://maestrodatabase.com/blog/nhs-england-hands-over-cancer-drugs-fund-remit-to-nice-1 2015-08-15T01:29:42 https://maestrodatabase.com/blog/formosa-pharmaceuticals-and-aimmax-therapeutics-receive-fda-approval-for-clobetasol-propionate-0-dot-05-percent-ophthalmic-suspension-for-the-treatment-of-post-operative-inflammation-and-pain-following-ocular-surgery 2024-03-05T23:25:24 https://maestrodatabase.com/blog/drugmakers-point-finger-at-middlemen-for-rising-drug-prices 2016-10-03T12:14:21 https://maestrodatabase.com/blog/mylan-introduces-symfi-triple-combo-once-daily-hiv-treatment-in-the-u-dot-s 2018-03-29T01:37:22 https://maestrodatabase.com/blog/nice-says-no-to-expanding-use-of-astrazenecas-lynparza 2018-11-10T03:57:46 https://maestrodatabase.com/blog/fda-approves-use-of-eliquis-to-treat-leg-lung-clots 2015-08-05T11:37:07 https://maestrodatabase.com/blog/innovative-regenerative-medicine-therapies---patient-safety-comes-first 2021-06-07T11:15:03 https://maestrodatabase.com/blog/tga-approves-descovy-emtricitabine-with-tenofovir-alafenamide-fumarate 2016-07-07T12:46:18 https://maestrodatabase.com/blog/netupitantpalonosetron-for-prevention-of-nausea-and-vomiting-added-benefit-not-proven-says-iqwig 2015-11-25T23:12:51 https://maestrodatabase.com/blog/ellipses-next-generation-selective-ret-inhibitor-ep0031-slash-a400-granted-fast-track-designation-by-us-fda 2024-03-05T23:12:28 https://maestrodatabase.com/blog/pharmac-moving-to-next-stage-of-medical-devices-activity 2015-08-05T11:37:18 https://maestrodatabase.com/blog/pharmac-notification-of-delay-of-decision-on-proposal-to-reinstate-monthly-dispensing-on-various-pharmaceuticals-remove-stat-dispensing 2015-08-05T11:37:19 https://maestrodatabase.com/blog/walgreens-to-buy-rite-aid-for-94-billion 2015-10-28T20:46:46 https://maestrodatabase.com/blog/gsks-pd-1-inhibitor-jemperli-approved-in-the-uk 2021-06-07T09:12:19 https://maestrodatabase.com/blog/final-budget-outcome-confirms-pbs-is-sustainable 2015-09-21T12:12:24 https://maestrodatabase.com/blog/sandoz-introduces-act4biosimilars-action-plan-to-accelerate-patient-access-to-biosimilar-medicines 2023-06-15T06:30:31 https://maestrodatabase.com/blog/fda-continues-steady-reduction-of-generic-drug-application-backlog 2016-07-27T00:36:27 https://maestrodatabase.com/blog/merck-receives-positive-chmp-opinion-for-keytruda-pembrolizumab-for-the-treatment-of-advanced-melanoma 2015-08-05T11:37:22 https://maestrodatabase.com/blog/canadas-new-drug-price-rules-pushed-to-next-year 2020-06-01T21:14:37 https://maestrodatabase.com/blog/us-fda-accepts-botox-onabotulinumtoxina-resubmission-for-the-treatment-of-lower-limb-spasticity-in-adults 2015-08-21T02:23:30 https://maestrodatabase.com/blog/mhra-authorises-pfizer-slash-biontechs-covid-19-vaccine-for-12-to-15-year-olds 2021-06-07T09:16:14 https://maestrodatabase.com/blog/medcac-meeting-27-april-2016-treatment-resistant-depression 2016-04-26T02:07:07 https://maestrodatabase.com/blog/us-breakthrough-status-for-genentechs-lucentis 2015-08-05T11:37:19 https://maestrodatabase.com/blog/fda-approves-mercks-keytruda-pembrolizumab-for-the-treatment-of-patients-with-hepatocellular-carcinoma-who-have-been-previously-treated-with-sorafenib 2018-11-10T04:00:53 https://maestrodatabase.com/blog/gsk-announces-regulatory-submissions-for-mepolizumab-in-severe-eosinophilic-asthma 2015-08-05T11:37:23 https://maestrodatabase.com/blog/roches-perjeta-regimen-approved-in-europe-for-use-before-surgery-in-early-stage-aggressive-breast-cancer 2015-08-05T11:37:26 https://maestrodatabase.com/blog/health-canada-approves-somatuline-autogel-lanreotide-injection-for-the-treatment-of-enteropancreatic-neuroendocrine-tumours 2015-10-07T21:30:46 https://maestrodatabase.com/blog/gsk-announces-eu-regulatory-submission-for-sirukumab-in-rheumatoid-arthritis 2016-09-12T20:36:31 https://maestrodatabase.com/blog/pfizer-receives-us-fda-breakthrough-therapy-designation-for-xalkori-crizotinib-for-the-treatment-of-patients-with-ros1-positive-non-small-cell-lung-cancer 2015-08-05T11:37:25 https://maestrodatabase.com/blog/call-for-patient-input-22 2015-08-05T11:37:18 https://maestrodatabase.com/blog/secukinumab-in-psoriasis-now-an-indication-of-an-additional-clinical-benefit-for-certain-patients 2015-12-04T21:20:27 https://maestrodatabase.com/blog/fda-highlights-record-breaking-number-of-generic-drug-approvals-in-october 2018-11-10T04:06:38 https://maestrodatabase.com/blog/secukinumab-with-plaque-psoriasis-manufacturer-dossier-provides-no-evidence-of-an-additional-clinical-enefit-according-to-the-iqwig 2015-09-01T20:53:21 https://maestrodatabase.com/blog/call-for-patient-input-3 2015-08-05T11:37:23 https://maestrodatabase.com/blog/how-pfizer-set-the-cost-of-its-new-drug-at-9850-a-month 2015-12-09T20:06:44 https://maestrodatabase.com/blog/qrxpharma-receives-complete-response-letter-from-fda-regarding-moxduo-nda 2015-08-05T11:37:03 https://maestrodatabase.com/blog/atyr-pharma-receives-fda-fast-track-designation-for-efzofitimod-for-treatment-of-systemic-sclerosis-associated-interstitial-lung-disease 2022-09-14T00:14:05 https://maestrodatabase.com/blog/ema-reviews-cancer-medicine-zydelig 2016-03-11T20:58:32 https://maestrodatabase.com/blog/pcodr_recommends_the_funding_of_vismodegib__erivedge__for_patients_with_basal_cell_carcinoma 2015-08-05T11:37:27 https://maestrodatabase.com/blog/fda-seeks-51-billion-total-for-fy-2017-including-funds-to-implement-food-safety-law-improve-medical-product-safety-and-quality 2016-02-09T20:12:46 https://maestrodatabase.com/blog/agenda-for-chmp-meeting---june-2014 2015-08-05T11:37:13 https://maestrodatabase.com/blog/fda-expands-approval-of-blincyto-for-treatment-of-a-type-of-leukaemia-in-patients-who-have-a-certain-risk-factor-for-relapse 2018-03-29T20:54:26 https://maestrodatabase.com/blog/five-ideas-for-the-new-nz-health-minister 2015-08-05T11:37:09 https://maestrodatabase.com/blog/better_information_needed_on_multiple_myeloma_drug 2015-08-05T11:37:09 https://maestrodatabase.com/blog/fda-accepts-supplemental-new-drug-application-snda-for-dalvance-dalbavancin 2015-10-09T20:49:29 https://maestrodatabase.com/blog/bayer-receives-eu-approval-of-kovaltry-for-treatment-of-haemophilia-a 2016-02-22T20:01:07 https://maestrodatabase.com/blog/fda-grants-priority-review-to-genentechs-emicizumab-for-haemophilia-a-with-inhibitors 2017-08-24T23:23:38 https://maestrodatabase.com/blog/muscular-dystrophy-day-at-the-fda 2016-05-27T12:18:29 https://maestrodatabase.com/blog/fda-ema-and-ec-sign-new-confidentiality-commitment 2017-08-24T11:44:27 https://maestrodatabase.com/blog/leo-pharma-announces-us-approval-of-enstilar-foam-for-plaque-psoriasis 2015-10-21T03:33:48 https://maestrodatabase.com/blog/madrigal-pharmaceuticals-announces-ema-validation-of-its-marketing-authorisation-application-for-resmetirom-for-the-treatment-of-nash-slash-mash-with-liver-fibrosis 2024-03-06T01:13:17 https://maestrodatabase.com/blog/harper-review-pharmacists-slam-proposal-to-lift-restrictions 2015-08-05T11:37:18 https://maestrodatabase.com/blog/merck-receives-positive-eu-chmp-opinion-for-keytruda-pembrolizumab-plus-chemotherapy-as-first-line-treatment-for-adult-patients-with-unresectable-non-epithelioid-malignant-pleural-mesothelioma 2024-11-18T07:39:22 https://maestrodatabase.com/blog/sandoz-advances-its-biosimilars-program-with-ema-acceptance-of-regulatory-submission-for-biosimilar-pegfilgrastim 2016-02-11T06:54:38 https://maestrodatabase.com/blog/as-insurers-balk-us-makes-new-push-to-boost-health-care-act 2016-08-18T08:15:55 https://maestrodatabase.com/blog/us-drug-costs-are-rising-faster-than-overall-health-spending-officials-report 2016-03-20T00:45:13 https://maestrodatabase.com/blog/cystic-fibrosis-drug-approved-for-pbs-listing-heralding-better-quality-of-life-for-sufferers 2015-08-05T11:37:19 https://maestrodatabase.com/blog/shires-cinryze-c1-esterase-inhibitor-human-receives-fda-fast-track-designation-for-investigation-in-the-treatment-of-antibody-mediated-rejection-amr-in-patients-receiving-kidney-transplants 2015-10-14T00:59:55 https://maestrodatabase.com/blog/agenda-for-4-april-tc-meeting 2018-03-29T21:19:34 https://maestrodatabase.com/blog/proposal-for-the-supply-of-influenza-vaccine 2016-06-02T23:29:04 https://maestrodatabase.com/blog/european-commission-approves-kyprolis-carfilzomib-for-combination-use-in-the-treatment-of-patients-with-relapsed-multiple-myeloma 2015-11-20T21:17:46 https://maestrodatabase.com/blog/revision-therapeutics-announces-us-fda-grant-of-rare-paediatric-disease-and-orphan-drug-designation-for-rev-0100-for-the-treatment-of-stargardt-disease 2020-10-29T06:41:15 https://maestrodatabase.com/blog/tagrisso-recommended-for-approval-in-the-eu-by-chmp-for-patients-with-unresectable-egfr-mutated-lung-cancer 2024-11-18T07:32:58 https://maestrodatabase.com/blog/european-commission-grants-marketing-authorisation-for-arikayce-liposomal-590-mg-nebuliser-dispersion-for-the-treatment-of-ntm-lung-infections-caused-by-mac-in-adult-non-cf-patients-with-limited-treatment-options 2020-10-29T06:45:23 https://maestrodatabase.com/blog/new-drug-deal-will-sweeten-pbs-fix 2015-08-05T11:37:26 https://maestrodatabase.com/blog/fda-approves-pembrolizumab-and-berahyaluronidase-alfa-pmph-for-subcutaneous-injection 2025-09-19T22:27:24 https://maestrodatabase.com/blog/2016-april-price-disclosure-cycle-indicative-prices 2016-02-03T04:49:24 https://maestrodatabase.com/blog/abbvie-receives-european-commission-approval-of-elahere-mirvetuximab-soravtansine-for-the-treatment-of-platinum-resistant-ovarian-cancer 2024-11-18T07:22:01 https://maestrodatabase.com/blog/updated-treatment-algorithm-for-the-treatment-of-her2-metastatic-breast-cancer 2016-05-09T07:12:16 https://maestrodatabase.com/blog/tryngolza-olezarsen-approved-in-the-european-union-for-familial-chylomicronaemia-syndrome 2025-09-19T22:31:39 https://maestrodatabase.com/blog/pacific-trade-deal-could-limit-affordable-drugs-world-health-chief 2015-11-14T18:30:46 https://maestrodatabase.com/blog/public-release-of-linkable-10-sample-of-medicare-benefits-scheme-medicare-and-pharmaceutical-benefits-scheme-pbs-data 2016-08-11T11:59:29 https://maestrodatabase.com/blog/nice-calls-for-more-research-into-promising-new-drug-to-treat-inherited-rare-enzyme-deficiency 2016-02-19T23:18:05 https://maestrodatabase.com/blog/roche-receives-fda-approval-for-the-cobas-egfr-mutation-test-v2-as-the-first-companion-diagnostic-test-for-expanded-egfr-tki-therapies-in-patients-with-non-small-cell-lung-cancer 2020-10-29T19:46:12 https://maestrodatabase.com/blog/fda-accepts-for-review-medexuss-ixinity-supplemental-biological-license-application-for-paediatric-patients 2023-06-15T21:40:51 https://maestrodatabase.com/blog/supernus-receives-fda-tentative-approval-for-expanded-label-of-trokendi-xr-to-include-migraine-prophylaxis-in-adults 2016-08-22T06:00:42 https://maestrodatabase.com/blog/cms-proposes-to-test-new-medicare-part-b-prescription-drug-models-to-improve-quality-of-care-and-deliver-better-value-for-medicare-beneficiaries 2016-03-08T23:34:12 https://maestrodatabase.com/blog/additional-benefit-of-idelalisib-is-not-occupied 2015-08-05T11:37:09 https://maestrodatabase.com/blog/these-20-recently-approved-cancer-drugs-essentially-have-1-thing-in-common 2016-07-03T21:46:46 https://maestrodatabase.com/blog/pharmac-announces-medicines-bundle-to-provide-more-treatment-options-for-new-zealanders 2022-09-14T05:49:05 https://maestrodatabase.com/blog/cymabay-announces-ema-accepts-for-review-the-marketing-authorisation-application-for-seladelpar-for-the-treatment-of-primary-biliary-cholangitis 2024-03-06T01:38:01 https://maestrodatabase.com/blog/allergans-rapastinel-receives-fda-breakthrough-therapy-designation-for-adjunctive-treatment-of-major-depressive-disorder 2016-01-30T06:25:06 https://maestrodatabase.com/blog/the-fda-will-not-inspect-vaccine-production-plants 2020-10-29T19:51:47 https://maestrodatabase.com/blog/amylyx-pharmaceuticals-completes-negotiation-process-and-signs-letter-of-intent-with-the-pcpa-for-albrioza-for-the-treatment-of-als 2023-06-15T21:28:31 https://maestrodatabase.com/blog/two-new-treatments-funded-for-blood-disorders-and-cancers 2015-08-05T11:37:05 https://maestrodatabase.com/blog/updating-the-american-society-of-clinical-oncology-value-framework-revisions-and-reflections-in-response-to-comments-received 2016-06-01T17:43:47 https://maestrodatabase.com/blog/investigational-pd-1-immune-checkpoint-inhibitor-nivolumab-receives-us-fda-breakthrough-therapy-designation-for-hodgkin-lymphoma 2015-08-05T11:37:17 https://maestrodatabase.com/blog/fda-accepts-for-priority-review-libtayo-cemiplimab-rwlc-for-advanced-non-small-cell-lung-cancer-with-pd-l1-expression-of-50-percent 2020-10-29T11:19:34 https://maestrodatabase.com/blog/nice-says-yes-to-dexamethasone-for-the-treatment-of-common-diabetic-eye-condition-in-draft-guidance 2015-08-05T11:37:25 https://maestrodatabase.com/blog/independent-review-of-paracetamol-overdose 2022-09-14T05:46:12 https://maestrodatabase.com/blog/coherus-resolves-part-of-dispute-with-abbvie-over-humira-biosimilar 2023-06-15T21:21:40 https://maestrodatabase.com/blog/us-insurers-drugmakers-want-to-exchange-information-on-specialty-drugs 2016-04-21T20:54:10 https://maestrodatabase.com/blog/nice_consults_on_updated_guidance_for_two_lung_cancer_drugs 2015-08-05T11:37:30 https://maestrodatabase.com/blog/fda-should-reject-accelerated-approval-of-gene-therapy-srp-9001 2023-06-15T21:10:06 https://maestrodatabase.com/blog/nice-issues-draft-guidance-on-apremilast-for-psoriatic-arthritis 2015-09-03T11:22:50 https://maestrodatabase.com/blog/nice-announces-start-of-review-of-nusinersen-managed-access-agreement 2020-10-29T19:27:31 https://maestrodatabase.com/blog/new-alzheimers-drug-is-a-problem-for-fdas-pass-fail-approach 2023-06-15T21:14:21 https://maestrodatabase.com/blog/sipuleucel-t-in-prostate-cancer-added-benefit-is-not-proven 2015-08-05T11:37:13 https://maestrodatabase.com/blog/cadth-calls-for-patient-input-on-submission-from-janssen-for-stelara-ustekinumab 2016-08-12T22:33:49 https://maestrodatabase.com/blog/the-regions-have-applied-for-a-price-change-for-cimzia-and-simponi 2020-10-29T20:17:38 https://maestrodatabase.com/blog/health-canada-approves-keytruda-pembrolizumab-as-adjuvant-treatment-for-adults-and-children-with-stage-iib-or-iic-melanoma-following-complete-resection 2022-09-14T06:07:18 https://maestrodatabase.com/blog/a-cure-for-swelling-drug-prices-competition 2016-08-31T21:03:09 https://maestrodatabase.com/blog/merck-announces-u-dot-s-fda-filing-acceptance-of-new-drug-application-for-mk-1293-an-investigational-follow-on-biologic-insulin-glargine 2016-08-08T05:33:03 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-for-alzheimers-drug 2021-06-07T20:45:58 https://maestrodatabase.com/blog/decisions-relating-to-multiple-sclerosis-treatments 2015-12-05T02:39:20 https://maestrodatabase.com/blog/camurus-announces-fda-acceptance-of-nda-submission-for-oclaiz-for-treatment-of-acromegaly 2024-03-06T04:04:05 https://maestrodatabase.com/blog/novartis-cell-treatment-named-breakthrough-therapy-in-us 2015-08-05T11:37:28 https://maestrodatabase.com/blog/public-summary-documents---july-2018-pbac-meeting 2018-11-10T07:58:37 https://maestrodatabase.com/blog/covid-19-border-closures-worry-americans-who-come-to-canada-to-buy-insulin 2020-06-02T01:40:10 https://maestrodatabase.com/blog/cadth-publishes-final-recommendation-for-blincyto 2020-10-29T20:32:13 https://maestrodatabase.com/blog/icer-issues-statement-on-the-fdas-approval-of-aducanumab-for-alzheimers-disease 2021-06-07T20:52:04 https://maestrodatabase.com/blog/wezlana-ustekinumab-a-biosimilar-to-stelara-now-available-in-canada-for-certain-chronic-inflammatory-diseasee 2024-03-06T03:57:18 https://maestrodatabase.com/blog/aralez-receives-health-canada-approval-for-blexten 2016-04-26T08:41:48 https://maestrodatabase.com/blog/cancer-drugs-approved-on-the-basis-of-a-surrogate-end-point-and-subsequent-overall-survival 2015-10-19T21:37:33 https://maestrodatabase.com/blog/public-summary-documents---april-2018-pbac-meeting 2018-11-10T08:04:05 https://maestrodatabase.com/blog/lynparza-recommended-for-approval-in-eu-by-chmp-for-brca-mutated-metastatic-pancreatic-cancer 2020-06-02T01:50:59 https://maestrodatabase.com/blog/updated-agenda-for-march-2024-pbac-meeting-6-march-2024 2024-03-06T03:49:58 https://maestrodatabase.com/blog/fda-approves-dalvance-to-treat-skin-infections 2015-08-05T11:37:14 https://maestrodatabase.com/blog/nice-backs-bmspfizer-bloodthinner-eliquis-for-vte 2015-08-05T11:37:17 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-april-2015-update 2015-08-05T11:37:23 https://maestrodatabase.com/blog/pharmac-needs-a-short-sharp-dose-of-reality 2020-10-29T19:54:37 https://maestrodatabase.com/blog/proposal-to-fund-preservative-free-minims-prednisolone-sodium-phosphate-05-eye-drops 2015-08-05T11:37:18 https://maestrodatabase.com/blog/praxbind-idarucizumab-approved-in-european-union-for-the-specific-reversal-of-pradaxa-dabigatran-etexilate 2015-11-26T22:34:29 https://maestrodatabase.com/blog/white-house-to-require-insurers-to-post-negotiated-prices-for-medical-care 2020-10-29T19:58:24 https://maestrodatabase.com/blog/bayer__roche_and_gsk_cancer_meds_win_nod_for_special_u_k__funding 2015-08-05T11:37:15 https://maestrodatabase.com/blog/vertex-announces-acceptance-of-its-applications-for-review-of-the-tezacaftor-slash-ivacaftor-combination-treatment-in-people-with-cystic-fibrosis-by-the-fda-and-ema 2017-08-25T02:52:49 https://maestrodatabase.com/blog/incruse-ellipta-umeclidinium-approved-in-australia-for-chronic-obstructive-pulmonary-disease 2015-08-05T11:37:05 https://maestrodatabase.com/blog/sales-of-cancer-fighting-drugs-soared-in-canada-over-the-past-decade 2020-10-29T20:01:42 https://maestrodatabase.com/blog/entyvio-first-biologic-to-get-nice-backing-for-uc 2015-08-05T11:37:19 https://maestrodatabase.com/blog/price-transparency-press-call-remarks-by-administrator-seema-verma 2020-10-29T20:10:20 https://maestrodatabase.com/blog/eribulin-mesylate-for-advanced-breast-cancer-positive-effects-in-some-patients 2015-08-05T11:37:05 https://maestrodatabase.com/blog/fda-approves-breo-ellipta-for-the-treatment-of-adults-with-asthma-in-the-us 2015-08-05T11:37:11 https://maestrodatabase.com/blog/proposed-refinements-to-the-regulation-of-personalised-medical-devices 2021-06-07T21:10:29 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-new-drug-application-for-triple-combination-tablet-for-adults-with-type-2-diabetes 2019-06-04T21:00:34 https://maestrodatabase.com/blog/decision-to-retain-first-line-biologic-access-for-adalimumab-in-dermatology-and-rheumatology-indications 2015-12-02T19:57:09 https://maestrodatabase.com/blog/lupin-receives-health-canada-approval-for-rymti-biosimilar-etanercept 2022-09-14T06:30:59 https://maestrodatabase.com/blog/consultation-on-draft-guideline-on-quality-requirements-for-medical-devices-in-combination-products 2019-06-04T10:03:45 https://maestrodatabase.com/blog/cadth-common-drug-review-and-pan-canadian-oncology-drug-review-engagement-with-the-pan-canadian-pharmaceutical-alliance 2016-05-26T15:42:01 https://maestrodatabase.com/blog/smc---june-2021-decisions 2021-06-07T21:06:41 https://maestrodatabase.com/blog/dusc-utilisation-analysis-public-release-documents-october-2022 2022-10-25T04:05:49 https://maestrodatabase.com/blog/nice-gives-green-light-to-aflibercept-for-the-treatment-of-common-eye-condition-in-draft-guidance 2015-08-05T11:37:04 https://maestrodatabase.com/blog/incyte-announces-additional-fda-approval-of-opzelura-ruxolitinib-cream-in-children-ages-2-11-with-atopic-dermatitis 2025-09-19T22:37:26 https://maestrodatabase.com/blog/cancer-drugs-fund-20-a-missed-opportunity 2016-06-13T21:43:03 https://maestrodatabase.com/blog/medicare-rebate-changes-for-surgeries-kick-in-next-month-but-doctors-say-more-time-is-needed 2021-06-07T21:24:28 https://maestrodatabase.com/blog/pomalidomide-in-multiple-myeloma-no-sign-of-an-additional-clinical-benefit 2016-01-12T20:37:33 https://maestrodatabase.com/blog/public-disclosure-of-the-filing-of-new-drug-and-therapeutic-biologics-applications-with-the-us-food-and-drug-administration 2019-06-04T09:10:16 https://maestrodatabase.com/blog/limiting-coverage-based-on-efficacy-and-safety-a-path-forward-for-medicare-regarding-the-alzheimers-treatment-aducanumab 2021-06-07T21:13:36 https://maestrodatabase.com/blog/olysio-simeprevir-gains-additional-fda-approval-as-once-daily-all-oral-interferon--and-ribavirin-free-treatment-option-in-combination-with-sofosbuvir-for-adults-with-genotype-1-chronic-hepatitis-c-infection 2015-08-05T11:37:30 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-first-treatment-for-barth-syndrome 2025-09-19T22:48:02 https://maestrodatabase.com/blog/european-patent-office-rules-in-favour-of-sanofi-and-regeneron-concerning-praluent-alirocumab 2020-10-29T20:41:15 https://maestrodatabase.com/blog/fda-to-make-it-easier-for-doctors-to-get-unapproved-cancer-drugs-for-patients 2019-06-04T21:10:04 https://maestrodatabase.com/blog/new-treatment-option-for-patients-with-rare-blood-cancer 2015-09-26T02:24:48 https://maestrodatabase.com/blog/theres-a-possible-cure-for-bubble-boy-disease-it-will-cost-665000 2016-08-04T12:34:27 https://maestrodatabase.com/blog/safer-and-more-effective-shingles-vaccine-will-be-available-to-aussies---but-it-wont-come-cheap 2021-06-07T20:57:58 https://maestrodatabase.com/blog/viiv-healthcare-receives-fda-approval-for-triumeq 2015-08-05T11:37:04 https://maestrodatabase.com/blog/ema-to-review-sotagliflozin-as-potential-treatment-for-type-1-diabetes 2018-03-29T22:50:05 https://maestrodatabase.com/blog/fda-launches-openfda-to-provide-easy-access-to-valuable-fda-public-data 2015-08-05T11:37:30 https://maestrodatabase.com/blog/traditional-cost-effectiveness-formulas-and-precision-medicines 2020-06-02T01:56:33 https://maestrodatabase.com/blog/fda-awards-grants-to-stimulate-drug-device-development-for-rare-diseases 2015-08-05T11:37:28 https://maestrodatabase.com/blog/celgene-corporation-and-acceleron-pharma-announce-u-dot-s-fda-accepts-luspatercept-biologics-license-application-in-myelodysplastic-syndromes-and-beta-thalassemia 2019-06-04T21:05:21 https://maestrodatabase.com/blog/ptac-recommends-the-reimbursement-of-osimertinib-mesylate-for-the-first-line-treatment-of-patients-with-locally-advanced-or-metastatic-epidermal-growth-factor-receptor-mutated-non-small-cell-lung-cancer 2020-10-29T20:49:34 https://maestrodatabase.com/blog/queensland-pharmacies-join-rollout-1-million-regional-vaccines-delivered 2021-06-07T21:02:56 https://maestrodatabase.com/blog/icer-convenes-broad-group-of-stakeholders-to-inform-update-to-value-assessment-framework 2016-10-04T19:56:57 https://maestrodatabase.com/blog/canadas-health-technology-assessment-agency-gives-positive-recommendation-for-opdivo-to-treat-non-small-cell-lung-cancer 2016-06-09T10:49:29 https://maestrodatabase.com/blog/nice-publishes-final-draft-guidance-on-enhertu-after-commercial-discussions-conclude-without-a-price-to-make-it-a-cost-effective-use-of-nhs-resources 2024-03-06T20:08:24 https://maestrodatabase.com/blog/shire-reports-regulatory-milestones-for-investigational-hereditary-angioedema-treatment-lanadelumab 2018-03-29T22:41:19 https://maestrodatabase.com/blog/nice-consults-on-draft-guidance-recommending-ledipasvir-sofosbuvir-harvoni-for-treating-chronic-hepatitis-c 2015-08-05T11:37:19 https://maestrodatabase.com/blog/lilly-and-incyte-announce-submission-of-new-drug-application-to-fda-for-oral-once-daily-baricitinib-for-treatment-of-moderate-to-severe-rheumatoid-arthritis 2016-01-19T19:56:33 https://maestrodatabase.com/blog/theravance-biopharma-and-mylan-receive-fda-approval-for-yuperli-revefenacin-in-adults-with-chronic-obstructive-pulmonary-disease 2018-11-10T15:00:59 https://maestrodatabase.com/blog/chinas-revolutionary-cancer-drugs-undercut-american-competitors 2019-06-04T21:30:07 https://maestrodatabase.com/blog/nice-recommends-ustekinumab-stelara-for-psoriatic-arthritis 2015-08-05T11:37:11 https://maestrodatabase.com/blog/biosimilar-drugs-could-save-up-to-110-billion-by-2020 2016-03-30T20:41:05 https://maestrodatabase.com/blog/seattle-genetics-announces-fda-regular-approval-of-adcetris-brentuximab-vedotin-for-classical-hodgkin-lymphoma-patients-at-high-risk-of-relapse-or-progression-as-post-autologous-haematopoietic-stem-cell-transplantation-consolidation 2015-08-18T09:04:22 https://maestrodatabase.com/blog/pbm-launches-oncology-biosimilar-medical-pharmacy-initiative 2019-06-04T21:26:54 https://maestrodatabase.com/blog/hospira-receives-us-fda-approval-of-proprietary-analgesic-dyloject-diclofenac-sodium-injection 2015-08-05T11:37:09 https://maestrodatabase.com/blog/sumitovant-biopharma-announces-myovant-sciences-submission-of-new-drug-application-to-the-fda-for-once-daily-relugolix-combination-tablet-for-the-treatment-of-women-with-uterine-fibroids 2020-06-02T03:13:55 https://maestrodatabase.com/blog/hiding-in-plain-sight-the-fdas-approach-to-disclosing-new-drug-applications-is-a-disservice-to-public-health 2019-06-04T21:19:58 https://maestrodatabase.com/blog/applications-for-orphan-drug-designation 2015-08-05T11:37:15 https://maestrodatabase.com/blog/atagi-update-following-covid-19-meeting-7-september-2022 2022-09-14T06:57:24 https://maestrodatabase.com/blog/bio-products-laboratory-receives-european-approval-for-coagadex-human-coagulation-factor-x-first-ever-treatment-for-rare-bleeding-disorder-hereditary-factor-x-deficiency 2016-04-01T21:32:00 https://maestrodatabase.com/blog/the-european-medicines-agencys-goals-for-regulatory-science-to-2025 2019-06-04T21:12:59 https://maestrodatabase.com/blog/azar-taps-former-cvs-executive-to-help-lower-drug-prices 2018-03-29T23:33:52 https://maestrodatabase.com/blog/fda-approves-first-generic-versions-of-celecoxib 2015-08-05T11:37:06 https://maestrodatabase.com/blog/fda-accepts-shionogis-supplemental-new-drug-application-with-priority-review-for-fetroja-cefiderocol-for-the-treatment-of-hospital-acquired-bacterial-pneumonia-and-ventilator-associated-bacterial-pneumonia 2020-06-02T03:01:57 https://maestrodatabase.com/blog/new-treatment-options-for-patients-with-multiple-sclerosis 2015-12-09T06:07:23 https://maestrodatabase.com/blog/originator-list-for-pbs-medicines-on-f2-formulary-stakeholder-consultation-brand-of-octreotide-added 2015-08-12T12:34:28 https://maestrodatabase.com/blog/budget-criteria-and-drug-value-assessments-a-case-of-apples-and-oranges 2016-09-23T11:59:43 https://maestrodatabase.com/blog/fda-approves-lillys-migraine-drug-as-first-ever-cluster-headache-treatment 2019-06-04T21:40:51 https://maestrodatabase.com/blog/draft-clinical-evidence-guidelines-medical-devices 2016-03-15T04:08:09 https://maestrodatabase.com/blog/conservative-group-launches-ads-against-obama-medicare-experiment 2016-08-09T11:56:43 https://maestrodatabase.com/blog/us-takes-aim-at-the-uks-national-health-service 2019-06-04T21:33:46 https://maestrodatabase.com/blog/aveo-oncology-announces-fda-acceptance-for-filing-of-a-new-drug-application-for-tivozanib-as-a-treatment-of-relapsed-or-refractory-renal-cell-carcinoma 2020-06-02T03:08:49 https://maestrodatabase.com/blog/amgens-shameful-silence-covers-up-reasons-for-fda-drug-rejection 2016-08-28T10:31:27 https://maestrodatabase.com/blog/actelion-submits-us-fda-new-drug-application-for-selexipag-uptravi-in-patients-with-pulmonary-arterial-hypertension 2015-08-05T11:37:26 https://maestrodatabase.com/blog/2015-pwc-pharma-industry-survey-highlights-challenges-for-innovative-medicines-sector 2015-09-23T04:01:24 https://maestrodatabase.com/blog/novartis-drug-afinitor-recommended-by-chmp-for-european-union-approval-to-treat-select-gi-and-lung-neuroendocrine-tumors 2016-05-01T01:02:38 https://maestrodatabase.com/blog/astrazeneca-chief-says-the-us-drugs-market-is-under-pressure-and-changes-are-coming 2018-11-10T15:20:11 https://maestrodatabase.com/blog/pbac-public-summary-documents-july-2015-meeting-1 2016-02-19T23:21:13 https://maestrodatabase.com/blog/mundipharma-receives-positive-european-commission-decision-on-targin-oxycodonenaloxone-for-the-treatment-of-restless-legs-syndrome 2015-08-05T11:37:14 https://maestrodatabase.com/blog/big-pharma-gaming-patents-for-extra-cash-productivity-commission 2016-04-28T20:56:31 https://maestrodatabase.com/blog/jazz-pharmaceuticals-submits-marketing-authorisation-application-to-ema-for-solriamfetol-as-a-treatment-to-improve-wakefulness-and-reduce-excessive-daytime-sleepiness-in-adult-patients-with-narcolepsy-or-obstructive-sleep-apnoea 2018-11-10T15:11:25 https://maestrodatabase.com/blog/eagle-pharmaceuticals-rtu-bivalirudin-nda-accepted-for-filing 2015-08-05T11:37:15 https://maestrodatabase.com/blog/ema-accepts-for-review-marketing-authorisation-application-for-amarins-icosapent-ethyl-vascepa-for-reduction-of-cardiovascular-risk-in-high-risk-patients-as-reflected-in-reduce-it-study 2019-12-03T02:23:29 https://maestrodatabase.com/blog/canadas-erc-recommends-panitumumab-vectibix-for-use-by-patients-with-metastatic-ras-colorectal-cancer 2015-12-14T06:54:35 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule-1-november-2015-update 2015-11-01T20:41:03 https://maestrodatabase.com/blog/provinces-to-cover-costs-of-cystic-fibrosis-drug 2015-08-05T11:37:10 https://maestrodatabase.com/blog/cumberland-pharmaceuticals-receives-fda-approval-for-reditrex-product-line 2019-12-03T02:19:27 https://maestrodatabase.com/blog/bristol-myers-squibbs-opdivo-nivolumab-receives-breakthrough-therapy-designation-from-us-fda-for-previously-treated-recurrent-or-metastatic-squamous-cell-carcinoma-of-the-head-and-neck 2016-04-26T12:18:31 https://maestrodatabase.com/blog/potrero-medical-receives-fda-breakthrough-device-designation-for-accuryn-aki-predict-algorithm 2022-09-14T07:46:36 https://maestrodatabase.com/blog/pharmac-request-for-information-for-hepatitis-c-treatments 2015-08-10T21:07:33 https://maestrodatabase.com/blog/basilea-announces-that-chmp-recommends-approval-of-isavuconazole-cresemba-as-a-treatment-for-invasive-aspergillosis-and-mucormycosis-in-the-european-union 2015-08-05T11:37:05 https://maestrodatabase.com/blog/mayne-pharma-secures-us125m-refinancing 2015-08-05T11:37:28 https://maestrodatabase.com/blog/psoriasis-sufferers-asthmatics-ucd-patients-to-save-thousands-as-key-medicines-are-added-expanded-on-the-pbs 2019-12-03T02:14:32 https://maestrodatabase.com/blog/would-a-breakthrough-therapy-by-any-other-name-be-as-promising 2015-09-21T21:28:18 https://maestrodatabase.com/blog/abbvies-holkira-pak-now-reimbursed-in-ontario 2015-08-05T11:37:15 https://maestrodatabase.com/blog/ultragenyx-and-kyowa-hakko-kirin-announce-submission-of-burosumabs-biologics-license-application-in-the-us 2017-08-25T03:33:01 https://maestrodatabase.com/blog/us-fda-grants-breakthrough-therapy-designation-for-roches-investigational-medicine-ace910-for-people-with-haemophilia-a-with-factor-viii-inhibitors 2015-09-04T12:19:40 https://maestrodatabase.com/blog/the_price_government_puts_on_a_year_of_your_life_is__50_000 2015-08-05T11:37:18 https://maestrodatabase.com/blog/novartis-ms-pill-heads-stream-of-smc-approvals 2015-08-05T11:37:02 https://maestrodatabase.com/blog/cost-barrier-emerges-for-breakthrough-alzheimers-drug-in-australia 2025-09-20T03:15:55 https://maestrodatabase.com/blog/fact-sheets---administration-handling-and-infrastructure-fee--premium-free-dispensing-incentive 2015-08-05T11:37:24 https://maestrodatabase.com/blog/furor-over-drug-prices-puts-patient-advocacy-groups-in-bind 2016-09-28T21:05:47 https://maestrodatabase.com/blog/ema-recommends-approval-of-treatment-for-attention-deficit-hyperactivity-disorder 2015-08-05T11:37:19 https://maestrodatabase.com/blog/fda-approves-first-generic-copaxone-to-treat-multiple-sclerosis 2015-08-05T11:37:11 https://maestrodatabase.com/blog/karyopharms-selinexor-receives-fast-track-designation-from-fda-for-the-treatment-of-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma 2018-11-10T15:33:28 https://maestrodatabase.com/blog/samsung-bioepis-first-to-obtain-european-commission-approval-for-a-third-anti-tnf-a-biosimilar-with-imraldi-adalimumab 2017-08-25T03:40:33 https://maestrodatabase.com/blog/european-commission-approves-the-first-and-only-immuno-oncology-combination-bristol-myers-squibbs-opdivo-nivolumab-and-yervoy-ipilimumab-regimen-for-treatment-of-advanced-melanoma 2016-05-12T14:10:04 https://maestrodatabase.com/blog/puma-biotechnology-licensing-partner-specialised-therapeutics-receives-marketing-approval-in-singapore-for-nerlynx-neratinib-for-extended-adjuvant-treatment-of-early-stage-hormone-receptor-positive-her2-positive-breast-cancer 2019-12-03T02:36:53 https://maestrodatabase.com/blog/what-does-the-future-hold-for-the-cancer-drugs-fund 2015-08-05T11:37:29 https://maestrodatabase.com/blog/novo-nordisk-changes-strategy-in-germany-launches-diabetes-drug 2015-08-05T11:37:15 https://maestrodatabase.com/blog/keryx-receives-chmp-positive-opinion-for-fexeric-ferric-citrate-coordination-complex-for-the-treatment-of--hyperphosphatemia-in-adults-with-kidney-disease 2015-08-05T11:37:18 https://maestrodatabase.com/blog/nivolumab-plus-ipilimumab-in-melanoma-added-benefit-in-certain-patients 2016-09-26T13:10:34 https://maestrodatabase.com/blog/cancer-drugs-fund-costly-mistake-as-re-evaluation-begins 2015-08-05T11:37:17 https://maestrodatabase.com/blog/inflammatory-conditions-care-value-program-makes-americas-costliest-medication-class-more-affordable 2016-09-08T21:51:14 https://maestrodatabase.com/blog/otsuka-and-lundbeck-announce-fda-approval-of-supplemental-new-drug-application-for-rexulti-brexpiprazole-to-treat-schizophrenia-in-paediatric-patients-ages-13-17 2022-01-07T02:06:39 https://maestrodatabase.com/blog/section-100-ivf-program-updated-claiming-arrangements 2016-06-17T11:51:18 https://maestrodatabase.com/blog/heart-failure-drug-gets-onto-uks-early-access-scheme 2015-09-02T21:31:34 https://maestrodatabase.com/blog/best-practices-for-communication-between-ind-sponsors-and-fda-during-drug-development 2015-12-05T01:38:58 https://maestrodatabase.com/blog/catalyst-pharmaceuticals-announces-fda-acceptance-of-nda-and-priority-review-status-for-firdapse-amifampridine-phosphate-for-lambert-eaton-myasthenic-syndrome 2018-05-30T02:49:04 https://maestrodatabase.com/blog/health-technology-assessment-and-its-use-in-drug-policies-singapore 2019-12-03T02:47:07 https://maestrodatabase.com/blog/vanda-pharmaceuticals-announces-fda-update-for-supplemental-nda-for-hetlioz-in-the-treatment-of-insomnia 2024-03-06T21:30:30 https://maestrodatabase.com/blog/drug-pricing-debate-looking-past-big-pharmas-nightmare-scenario 2016-05-23T10:29:59 https://maestrodatabase.com/blog/adamas-announces-fda-approval-of-gocovri-as-first-and-only-medication-for-the-treatment-of-dyskinesia-in-parkinsons-disease-patients 2017-08-25T03:45:14 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits-1-september-2016-update 2016-08-31T12:25:51 https://maestrodatabase.com/blog/clarifying-the-meaning-of-clinically-meaningful-benefit-in-clinical-research-noticeable-change-vs-valuable-change 2019-12-03T02:43:45 https://maestrodatabase.com/blog/nice-recommends-nalmefene-to-help-people-reduce-their-dependence-on-alcohol 2015-08-05T11:37:09 https://maestrodatabase.com/blog/recently_added_forthcoming_submissions___march_2014_update 2015-08-05T11:37:02 https://maestrodatabase.com/blog/seven-new-drugs-okd-for-nhs-scotland 2015-08-05T11:37:22 https://maestrodatabase.com/blog/pressure-grows-on-roche-to-lower-breast-cancer-drug-price 2015-08-05T11:37:28 https://maestrodatabase.com/blog/abbott-government-to-deliver-a-healthier-medicare 2015-08-05T11:37:08 https://maestrodatabase.com/blog/strimvelis-receives-european-marketing-authorisation-to-treat-very-rare-disease-ada-scid 2016-05-29T17:21:32 https://maestrodatabase.com/blog/nice-inks-another-early-full-stop-on-the-appraisal-of-a-cancer-medicine 2022-09-14T09:35:45 https://maestrodatabase.com/blog/the-assault-on-drug-innovation 2015-09-23T22:14:48 https://maestrodatabase.com/blog/victoza-approved-in-the-us-as-the-only-type-2-diabetes-treatment-indicated-to-reduce-the-risk-of-major-adverse-cardiovascular-events 2017-08-27T01:49:01 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-amended-us-fda-breakthrough-therapy-designation-for-investigational-daclatasvir-based-hepatitis-c-regimen 2015-08-05T11:37:29 https://maestrodatabase.com/blog/orexigens-mysimba-naltrexone-hcl--bupropion-hcl-prolonged-release-receives-positive-chmp-opinion-recommending-approval-for-weight-management-in-the-european-union 2015-08-05T11:37:29 https://maestrodatabase.com/blog/eylea-aflibercept-injection-accepted-for-priority-review-by-fda-for-diabetic-retinopathy-in-patients-with-diabetic-macular-oedema 2015-08-05T11:37:25 https://maestrodatabase.com/blog/cadth-recognition-awards--nominations-being-accepted 2015-08-05T11:37:07 https://maestrodatabase.com/blog/payer-and-policy-maker-steps-to-support-value-based-pricing-for-drugs 2015-11-30T19:48:17 https://maestrodatabase.com/blog/us-food-and-drug-administration-grants-breakthrough-therapy-designation-for-mogamulizumab-for-the-treatment-of-mycosis-fungoides-and-sezary-syndrome 2017-08-27T02:12:14 https://maestrodatabase.com/blog/alexion-announces-fda-approval-of-ultomiris-ravulizumab-cwvz-for-children-and-adolescents-with-paroxysmal-nocturnal-haemoglobinuria 2021-06-07T23:32:32 https://maestrodatabase.com/blog/fda-approves-new-drug-to-treat-schizophrenia-and-as-an-add-on-to-an-antidepressant-to-treat-major-depressive-disorder 2015-08-05T11:37:29 https://maestrodatabase.com/blog/tracon-pharmaceuticals-announces-fast-track-designation-by-the-fda-for-envafolimab-for-the-treatment-of-the-soft-tissue-sarcoma-subtypes-of-ups-and-mfs 2022-09-14T20:55:47 https://maestrodatabase.com/blog/califf-fda-top-officials-call-for-sweeping-review-of-agency-opioids-policies 2016-02-04T22:57:37 https://maestrodatabase.com/blog/will-your-prescription-medicines-be-covered-next-year-better-check 2016-08-15T12:01:11 https://maestrodatabase.com/blog/local-mother-daughter-getting-loud-for-cystic-fibrosis-and-the-need-for-lifesaving-medication 2020-06-02T04:13:43 https://maestrodatabase.com/blog/smc_advice___november_2013 2015-08-05T11:37:30 https://maestrodatabase.com/blog/nice-reverses-stance-on-takedas-adcetris 2017-08-27T10:42:53 https://maestrodatabase.com/blog/londoners-crowdfunding-bid-for-200000-vital-cancer-drug 2016-07-17T21:30:00 https://maestrodatabase.com/blog/estimating-the-cost-of-delayed-generic-drug-entry-to-medicaid 2020-06-02T04:23:29 https://maestrodatabase.com/blog/ibrutinib-imbruvica-granted-breakthrough-therapy-designation-by-us-fda-for-the-development-of-a-treatment-for-chronic-graft-versus-host-disease 2016-06-29T21:30:04 https://maestrodatabase.com/blog/jazz-pharmaceuticals-receives-smc-approval-for-reimbursement-of-sativex 2022-09-14T20:51:17 https://maestrodatabase.com/blog/journal_of_health_economics___preference_heterogeneity_and_selection_in_private_health_insurance__the_case_of_australia 2015-08-05T11:37:26 https://maestrodatabase.com/blog/americas-wary-approval-of-an-alzheimers-drug-offers-hope-to-millions 2021-06-07T23:46:17 https://maestrodatabase.com/blog/teva-pharmaceuticals-and-eagle-pharmaceuticals-announce-fda-approval-of-bendeka-bendamustine-hydrochloride-injection 2015-12-09T06:27:30 https://maestrodatabase.com/blog/fda-approves-inotuzumab-ozogamicin-for-paediatric-patients-with-acute-lymphoblastic-leukaemia 2024-03-06T21:47:47 https://maestrodatabase.com/blog/call-for-patient-input-15 2015-08-05T11:37:18 https://maestrodatabase.com/blog/ramucirumab-in-gastric-cancer-additional-benefits-not-covered 2016-08-03T04:39:10 https://maestrodatabase.com/blog/agenda-for-the-20-may-2015-tc-meeting 2015-08-05T11:37:05 https://maestrodatabase.com/blog/the_scotsman___smc_decisions_on_drugs_must_improve__nhs_agencies_told 2015-08-05T11:37:07 https://maestrodatabase.com/blog/expansion-of-hepatitis-c-drug-coverage-in-massachusetts 2016-07-01T00:16:34 https://maestrodatabase.com/blog/lomitapide-mesylate-for-hypercholesterolemia-no-evidence-of-additional-benefits 2015-09-15T21:15:55 https://maestrodatabase.com/blog/breast-cancer-drug-perjeta-at-risk-in-price-wrangle 2017-08-27T10:49:25 https://maestrodatabase.com/blog/agenda-for-the-25-may-2016-tc-meeting 2016-05-21T18:02:05 https://maestrodatabase.com/blog/health-canada-approves-invokamet-for-the-treatment-of-adults-with-type-2-diabetes-mellitus 2016-07-21T06:43:23 https://maestrodatabase.com/blog/fda-approves-first-absorbable-stent-for-coronary-artery-disease 2016-07-05T21:06:16 https://maestrodatabase.com/blog/improving-dose-optimisation-processes-used-in-oncology-drug-development-to-minimise-toxicity-and-maximise-benefit-to-patients 2022-09-14T21:28:23 https://maestrodatabase.com/blog/proposals-to-widen-funding-access-to-important-vaccines 2016-05-30T16:39:14 https://maestrodatabase.com/blog/european-commission-grants-approval-for-mavenclad-cladribine-tablets 2017-08-27T10:56:29 https://maestrodatabase.com/blog/insmed-submits-new-drug-application-to-fda-for-alis-in-ntm-lung-disease-caused-by-mac 2018-03-30T03:11:14 https://maestrodatabase.com/blog/aquestive-therapeutics-completes-rolling-submission-of-new-drug-application-to-u-dot-s-food-and-drug-administration-for-libervant-diazepam-buccal-film-for-management-of-seizure-clusters 2019-12-03T03:20:24 https://maestrodatabase.com/blog/nice-gives-green-light-to-dry-eye-disease-treatment-in-final-draft-guidance 2015-11-04T20:19:58 https://maestrodatabase.com/blog/europes-first-stem-cell-therapy-backed-by-nice 2017-08-28T08:41:32 https://maestrodatabase.com/blog/orfadin-20-mg-capsules-approved-in-the-us 2016-06-15T12:17:59 https://maestrodatabase.com/blog/health-canada-approves-abbvies-rinvoq-upadacitinib-for-the-treatment-of-adults-with-active-psoriatic-arthritis 2021-06-08T02:08:39 https://maestrodatabase.com/blog/sanofi-receives-fda-approval-of-priftin-rifapentine-tablets-for-the-treatment-of-latent-tuberculosis-infection 2015-08-05T11:37:30 https://maestrodatabase.com/blog/minoryxs-marketing-authorisation-application-for-its-lead-candidate-leriglitazone-validated-by-ema-for-orphan-indication-x-linked-adrenoleukodystrophy 2022-09-14T21:20:48 https://maestrodatabase.com/blog/gsk-receives-approval-for-arnuity-ellipta-fluticasone-furoate-in-canada-for-the-treatment-of-asthma 2015-10-06T11:56:34 https://maestrodatabase.com/blog/fda-grants-priority-review-to-sarepta-drug-candidate 2015-08-26T12:49:06 https://maestrodatabase.com/blog/genetic-profiling-the-cancer-game-changer 2017-08-27T11:07:43 https://maestrodatabase.com/blog/agreement-with-biotronik-australia-pty-limited-for-the-supply-of-interventional-cardiology-devices 2016-06-23T05:04:42 https://maestrodatabase.com/blog/guilty-health-department-breached-privacy-laws-publishing-data-of-2-dot-5-million-people 2018-03-30T03:15:45 https://maestrodatabase.com/blog/health-canada-advises-canadians-to-help-support-the-continued-supply-of-medications 2020-06-02T06:00:05 https://maestrodatabase.com/blog/has-there-actually-been-early-resolution-for-early-resolution-resubmissions 2022-09-14T21:11:28 https://maestrodatabase.com/blog/ema-publishes-epar-for-truberzi 2016-09-30T21:38:45 https://maestrodatabase.com/blog/statement-on-governments-response-to-productivity-commissions-inquiry-in-intellectual-property 2017-08-28T08:45:29 https://maestrodatabase.com/blog/the-nice-medline-and-embase-ovid-health-apps-search-filters-development-of-validated-filters-to-retrieve-evidence-about-health-apps 2020-10-30T01:26:57 https://maestrodatabase.com/blog/hint_of_minor_added_benefit_for_caprelsa__vandetanib__in_people_aged_under_65_years_but_greater_harm_in_people_aged_over_65_years 2015-08-05T11:37:22 https://maestrodatabase.com/blog/public-summary-documents---pbac-july-2020 2020-10-30T05:23:44 https://maestrodatabase.com/blog/is-drug-price-negotiation-a-concept-whose-time-has-come 2022-09-14T21:15:15 https://maestrodatabase.com/blog/genmab-announces-submission-of-supplemental-biologics-license-application-to-fda-for-ofatumumab-in-combination-with-fludarabine-and-cyclophosphamide-for-relapsed-cll 2016-03-11T21:40:45 https://maestrodatabase.com/blog/cadth-calls-for-patient-input-on-submission-from-horizon-for-ravicti-glycerol-phenylbutyrate 2016-08-03T03:50:17 https://maestrodatabase.com/blog/novartis-announces-extension-to-fda-review-period-for-multiple-myeloma-investigational-compound-lbh589 2015-08-05T11:37:28 https://maestrodatabase.com/blog/growing-financial-burden-from-high-cost-targeted-oral-anti-cancer-medicines-among-medicare-beneficiaries-with-cancer 2022-09-14T21:05:40 https://maestrodatabase.com/blog/nice-issues-draft-guidance-for-necitumumab-portrazza 2016-05-26T11:03:58 https://maestrodatabase.com/blog/abbvie-files-new-drug-submission-to-health-canada-for-its-investigational-all-oral-interferon-free-therapy-for-the-treatment-of-hepatitis-c 2015-08-05T11:37:13 https://maestrodatabase.com/blog/nice-terminates-appraisal-of-another-cancer-medicine 2017-08-28T08:50:36 https://maestrodatabase.com/blog/final-nice-nod-for-opdivo-in-skin-cancer 2016-02-23T20:15:14 https://maestrodatabase.com/blog/summary-of-pbs-opioid-listings-for-the-treatment-of-pain-as-of-1-june-2020 2020-06-02T06:26:54 https://maestrodatabase.com/blog/update-on-publication-of-clinical-data 2015-08-05T11:37:29 https://maestrodatabase.com/blog/cadth-to-provide-drug-plans-with-copies-of-cdr-submission-or-resubmission-materials 2016-03-01T23:28:29 https://maestrodatabase.com/blog/ron-walkers-cancer-crusade-pays-dividends 2015-08-05T11:37:24 https://maestrodatabase.com/blog/streamlined_pbs_pricing_processes_to_improve_access_to_medicines 2015-08-05T11:37:16 https://maestrodatabase.com/blog/regeneron-ceo-optimistic-will-strike-deals-to-lower-14-000-dollars-per-year-cholesterol-drug 2018-03-30T05:10:09 https://maestrodatabase.com/blog/unique-pay-if-you-clear-proposal-for-new-hepatitis-drug 2015-08-05T11:37:30 https://maestrodatabase.com/blog/five-facts-about-deductibles 2015-11-18T01:01:43 https://maestrodatabase.com/blog/alentis-receives-fda-fast-track-designation-for-ale-dot-p02-for-the-treatment-of-cldn1-positive-squamous-solid-tumours 2024-11-18T23:11:56 https://maestrodatabase.com/blog/how-the-nhs-can-deal-with-soaring-drugs-prices 2015-08-05T11:37:05 https://maestrodatabase.com/blog/fda-approves-new-option-for-certain-people-with-previously-treated-follicular-lymphoma 2016-02-27T01:07:58 https://maestrodatabase.com/blog/abortion_drug_subsidies_blasted__cancer_treatments_welcomed 2015-08-05T11:37:27 https://maestrodatabase.com/blog/health-canada-approves-new-indications-for-promnitrope-somatropin-canadas-first-subsequent-entry-biologic-biosimilar 2015-09-03T22:25:42 https://maestrodatabase.com/blog/emtricitabine-with-tenofovir-alafenamid-in-hiv-infection-additional-benefits-not-covered 2016-08-15T11:49:50 https://maestrodatabase.com/blog/epcoritamab-for-the-treatment-of-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-after-two-or-more-systemic-treatments 2024-03-06T22:14:43 https://maestrodatabase.com/blog/statement-regarding-the-german-federal-joint-committees-decision-on-anti-epileptic-drug-fycompa 2015-08-05T11:37:18 https://maestrodatabase.com/blog/idelalisib-zydelig-100-mg-and-150-mg-tablets 2016-03-16T20:19:21 https://maestrodatabase.com/blog/smc-announces-more-forthcoming-submissions-2 2016-01-13T20:44:49 https://maestrodatabase.com/blog/keytruda-pembrolizumab-plus-lenvima-lenvatinib-approved-in-japan-for-patients-with-unresectable-advanced-or-recurrent-endometrial-carcinoma-that-progressed-after-cancer-chemotherapy 2022-01-07T03:03:51 https://maestrodatabase.com/blog/dexamethasone-intravitreal-implant-for-treating-diabetic-macular-oedema 2022-09-14T21:53:03 https://maestrodatabase.com/blog/high-court-decision-could-undermine-development-of-innovative-medicine 2015-10-07T09:40:49 https://maestrodatabase.com/blog/call-for-feedback-drugs-for-chronic-hepatitis-c-infection-1 2015-08-05T11:37:22 https://maestrodatabase.com/blog/european-commission-approves-amgens-vectibix-panitumumab-as-first-line-treatment-in-combination-with-folfiri-chemotherapy-for-metastatic-colorectal-cancer 2015-08-05T11:37:03 https://maestrodatabase.com/blog/need-for-a-national-evaluation-system-for-health-technology 2016-07-11T21:00:15 https://maestrodatabase.com/blog/exelixis-announces-fda-approval-of-cabometyx-cabozantinib-maleate-tablets-for-patients-with-advanced-renal-cell-carcinoma-who-have-received-prior-anti-angiogenic-therapy 2016-04-26T08:20:46 https://maestrodatabase.com/blog/novartis-provides-update-on-fda-review-of-ofatumumab-a-self-administered-targeted-b-cell-therapy-for-patients-with-relapsing-multiple-sclerosis 2020-06-02T20:58:30 https://maestrodatabase.com/blog/ema-goes-electronic-for-pdco-opinions-and-subsequent-ema-decisions 2016-07-06T10:22:53 https://maestrodatabase.com/blog/proposal-to-list-cinacalcet-sensipar-on-the-pharmaceutical-schedule-for-parathyroid-carcinoma-and-calciphylaxis 2016-03-11T08:25:44 https://maestrodatabase.com/blog/fda-grants-breakthrough-therapy-designation-to-exelixis-cabozantinib-for-the-treatment-of-renal-cell-carcinoma-in-patients-who-received-one-prior-therapy 2015-08-25T11:46:19 https://maestrodatabase.com/blog/cancer-drugs-fund-plans-to-speed-up-access-to-drugs 2015-11-20T21:08:42 https://maestrodatabase.com/blog/biden-pledges-faster-us-approval-for-cancer-drug-cocktails 2016-01-19T20:07:53 https://maestrodatabase.com/blog/fda-approves-zurampic-to-treat-high-blood-uric-acid-levels-associated-with-gout 2015-12-22T23:40:14 https://maestrodatabase.com/blog/novartis-sets-heart-drug-price-with-two-insurers-based-on-health-outcome 2016-02-09T20:55:04 https://maestrodatabase.com/blog/us-insurers-dragging-feet-on-covering-new-drugs-novartis-says 2016-01-29T04:00:26 https://maestrodatabase.com/blog/nice-published-draft-guidance-on-new-use-for-gazyva 2016-09-15T20:07:26 https://maestrodatabase.com/blog/promise-and-plausibility-health-technology-adoption-decisions-with-limited-evidence 2016-08-17T23:41:58 https://maestrodatabase.com/blog/professor-lloyd-sansom-to-head-prosthetics-crackdown 2016-02-08T21:30:09 https://maestrodatabase.com/blog/review-of-pharmacy-remuneration-and-regulation-live-national-webcast 2016-09-01T05:19:10 https://maestrodatabase.com/blog/cdk-4-slash-6-inhibitor-market-to-heat-up-on-insurance-benefits 2020-06-02T21:24:51 https://maestrodatabase.com/blog/merck-receives-positive-eu-chmp-opinion-for-enflonsia-clesrovimab-for-the-prevention-of-respiratory-syncytial-virus-in-infants-during-their-first-rsv-season 2025-09-20T05:12:42 https://maestrodatabase.com/blog/prescription-medicines-tga-annual-report-for-2015 2016-05-23T17:25:27 https://maestrodatabase.com/blog/canada_s_rx_drug_coverage_system__unsustainable_ 2015-08-05T11:37:29 https://maestrodatabase.com/blog/aclidinium-bromide-in-copd-evidence-of-significant-additional-value-in-certain-patients 2016-01-16T05:44:02 https://maestrodatabase.com/blog/y-mabs-announces-u-dot-s-fda-acceptance-of-biologics-license-application-for-danyelza-naxitamab-for-the-treatment-of-neuroblastoma-for-priority-review 2020-06-02T21:29:43 https://maestrodatabase.com/blog/germany_extends_drug_price_freeze 2015-08-05T11:37:05 https://maestrodatabase.com/blog/chmp-recommends-eu-approval-of-roches-subcutaneous-formulation-of-lunsumio-for-people-with-relapsed-or-refractory-follicular-lymphoma 2025-09-20T06:09:25 https://maestrodatabase.com/blog/ontario-to-fund-700000-a-year-drug-for-rare-life-threatening-illness 2015-08-05T11:37:29 https://maestrodatabase.com/blog/novo-nordisk-receives-positive-opinion-from-the-european-regulatory-authorities-for-saxenda-liraglutide-3-mg-for-the-treatment-of-obesity 2015-08-05T11:37:24 https://maestrodatabase.com/blog/elinzanetant-recommended-for-approval-in-eu-as-treatment-of-moderate-to-severe-vasomotor-symptoms 2025-09-20T06:17:44 https://maestrodatabase.com/blog/proposal_to_widen_access_to_tocilizumab__actemra__for_rheumatoid_arthritis_in_patients_who_are_unable_to_be_treated_with_methotrexate 2015-08-05T11:37:07 https://maestrodatabase.com/blog/clinical-trials-are-safe-effective-and-provide-benefits-to-australian-patients 2015-09-17T10:25:48 https://maestrodatabase.com/blog/fda-expands-approved-use-of-imbruvica-for-rare-form-of-non-hodgkin-lymphoma 2015-08-05T11:37:19 https://maestrodatabase.com/blog/european-commission-approves-sarclisa-isatuximab-for-adults-with-relapsed-and-refractory-multiple-myeloma 2020-06-02T21:05:13 https://maestrodatabase.com/blog/dynacure-receives-fast-track-designation-for-dyn101-an-investigational-antisense-oligonucleotide-for-the-treatment-of-myotubular-and-centronuclear-myopathies 2022-01-07T03:39:09 https://maestrodatabase.com/blog/german-drug-industry-says-pricing-law-is-restricting-access-to-some-drugs 2015-11-20T03:35:34 https://maestrodatabase.com/blog/roches-subcutaneous-formulation-of-mabthera-receives-approval-in-europe-for-people-with-chronic-lymphocytic-leukaemia 2016-05-31T13:57:08 https://maestrodatabase.com/blog/trans-pacific-partnership-a-mixed-bag-for-new-zealand-patients 2015-11-20T03:49:40 https://maestrodatabase.com/blog/more-patients-have-access-to-medicines-within-the-high-cost-protection-system 2020-06-02T21:14:15 https://maestrodatabase.com/blog/daclatasvir-dihydrochloride-for-hepatitis-c-hint-of-added-benefit-in-genotype-4 2015-08-05T11:37:09 https://maestrodatabase.com/blog/takeda-and-hutchmed-announce-marketing-authorisation-application-of-fruquintinib-for-previously-treated-metastatic-colorectal-cancer-validated-by-the-european-medicines-agency 2023-06-16T01:29:40 https://maestrodatabase.com/blog/vaderis-receives-fda-fast-track-designation-for-vad044-for-the-treatment-of-hereditary-haemorrhagic-telangiectasia 2024-11-18T23:27:26 https://maestrodatabase.com/blog/proposal-to-list-various-respiratory-aerosol-inhalers-supplied-by-rex-medical-ltd 2015-08-05T11:37:14 https://maestrodatabase.com/blog/ribociclib-succinate-in-breast-cancer-added-benefit-for-certain-post-menopausal-women 2020-06-02T21:15:58 https://maestrodatabase.com/blog/agenda-for-the-march-2016-pbac-meeting 2015-12-23T08:15:52 https://maestrodatabase.com/blog/pbac-public-summary-documents---march-2015-meeting 2015-08-05T11:37:11 https://maestrodatabase.com/blog/abbvie-submits-applications-for-upadacitinib-rinvoq-in-non-radiographic-axial-spondyloarthritis-to-u-dot-s-fda-and-ema 2022-01-07T20:35:56 https://maestrodatabase.com/blog/experience-with-the-priority-review-voucher-program-for-drug-development 2015-09-29T03:32:51 https://maestrodatabase.com/blog/merck_announces_canadian_approval_of_grastek__standardized_allergenic_extract__timothy_grass__phleum_pratense__sublingual_tablet_ 2015-08-05T11:37:07 https://maestrodatabase.com/blog/icer-announces-new-program-to-make-available-draft-executable-economic-models-during-drug-assessment-review-process 2018-03-30T21:27:24 https://maestrodatabase.com/blog/eu-marketing-approval-granted-for-vivagel-bv 2015-09-25T05:06:25 https://maestrodatabase.com/blog/nice-recommends-msds-keytruda-in-combination-with-chemotherapy-for-routine-treatment-of-lung-cancer 2022-01-07T20:30:19 https://maestrodatabase.com/blog/specialised-therapeutics-breakthrough-brain-tumour-visualisation-drug-gliolan-approved-for-use-in-new-zealand 2015-09-21T12:39:38 https://maestrodatabase.com/blog/ensuring-access-to-the-best-pbs 2015-08-05T11:37:21 https://maestrodatabase.com/blog/nice_hits_back_at_pharma_accusations_that_it_s_blocking_nhs_drugs 2015-08-05T11:37:13 https://maestrodatabase.com/blog/nice-recommends-pembrolizumab-for-advanced-skin-cancer-in-final-draft-guidance 2015-09-07T20:40:09 https://maestrodatabase.com/blog/statement-from-fda-commissioner-on-fdas-efforts-to-enhance-the-patient-perspective-and-experience-in-drug-development-and-review 2018-03-30T21:16:13 https://maestrodatabase.com/blog/open-letter-cancer-drugs--sanity-required 2015-08-05T11:37:30 https://maestrodatabase.com/blog/moderna-files-for-conditional-marketing-approval-for-its-covid-19-vaccine-in-adolescents-in-the-european-union 2021-06-08T03:28:01 https://maestrodatabase.com/blog/reforms-to-fast-track-access-to-new-drugs 2015-08-05T11:37:22 https://maestrodatabase.com/blog/cobimetinib-in-advanced-melanoma-with-braf-v600-mutation-added-benefit-now-considerable 2016-06-02T21:45:55 https://maestrodatabase.com/blog/health-canada-approves-celltrions-stoboclo-and-osenvelt-ct-p41-denosumab-biosimilars-for-the-treatment-of-all-indications-approved-for-the-reference-products-prolia-and-xgeva-respectively 2025-09-20T04:52:49 https://maestrodatabase.com/blog/pharmaceutical-benefits-scheme-not-always-cost-effective-for-the-chronically-ill 2016-09-05T04:27:59 https://maestrodatabase.com/blog/proposal-to-fund-abiraterone-acetate-list-additional-presentations-of-epoetin-alfa-and-reduce-expenditure-on-methylphenidate-hydrochloride-extended-release-and-topiramate 2015-08-05T11:37:28 https://maestrodatabase.com/blog/walmart-humana-sounds-wild-but-makes-sense 2018-03-30T21:43:09 https://maestrodatabase.com/blog/trellis-biosciences-trl1068-receives-fda-fast-track-and-qidp-designations-amplifying-commitment-to-combat-infectious-diseases 2024-03-06T23:09:05 https://maestrodatabase.com/blog/a-new-era-of-dementia-treatment-is-coming-we-are-not-ready 2025-09-20T05:04:28 https://maestrodatabase.com/blog/nice-says-yes-to-dry-eye-disease-treatment-in-final-guidance 2015-12-16T20:05:56 https://maestrodatabase.com/blog/pharmac-considering-new-price-offer-for-melanoma-drug-keytruda 2016-01-08T20:06:35 https://maestrodatabase.com/blog/new-breast--lung-cancer-drugs-available-from-today 2015-08-05T11:37:03 https://maestrodatabase.com/blog/high_cost_of_treatment_for_rare_blood_disorder_needs_to_be_clarified__says_nice_in_draft_guidance 2015-08-05T11:37:04 https://maestrodatabase.com/blog/trends-in-the-price-per-median-and-mean-life-year-gained-among-newly-approved-cancer-therapies-1995-to-2017 2019-12-03T07:18:22 https://maestrodatabase.com/blog/nice_gives_green_light_to_treatment_for_macular_oedema_in_final_guidance 2015-08-05T11:37:16 https://maestrodatabase.com/blog/fda-approves-a-new-ultrasound-imaging-agent 2015-08-05T11:37:08 https://maestrodatabase.com/blog/does-the-institute-for-clinical-and-economic-review-revise-its-findings-in-response-to-industry-comments 2019-12-03T07:01:39 https://maestrodatabase.com/blog/cancer-drug-appraisal-needs-to-be-reviewed 2016-08-18T21:31:12 https://maestrodatabase.com/blog/trump-surrenders-to-european-welfare-states-on-drug-prices 2018-11-11T20:32:42 https://maestrodatabase.com/blog/patient-advocacy-group-demands-doubling-of-pharmac-budget-to-fund-life-saving-treatments 2019-12-03T06:50:15 https://maestrodatabase.com/blog/decision-relating-to-the-listing-of-diltiazem-hydrochloride-apo-diltiazem 2015-08-05T11:37:15 https://maestrodatabase.com/blog/spark-therapeutics-and-pfizer-announce-receipt-of-fda-breakthrough-therapy-designation-for-spk-9001-for-the-treatment-of-hemophilia-b 2016-07-22T22:24:55 https://maestrodatabase.com/blog/novartis-erenumab-proving-to-be-a-headache-for-the-pbac 2018-11-11T20:36:05 https://maestrodatabase.com/blog/eagle-pharmaceuticals-announces-fda-approval-of-docetaxel-injection-non-alcohol-formula 2016-01-04T20:46:00 https://maestrodatabase.com/blog/lurasidone-in-schizophrenia-added-benefit-is-not-proven 2015-08-05T11:37:15 https://maestrodatabase.com/blog/could-or-should-we-use-mcda-in-the-french-hta-process 2019-12-03T20:00:23 https://maestrodatabase.com/blog/ministers-scramble-to-introduce-new-nhs-cancer-drugs-scheme 2016-02-11T20:34:29 https://maestrodatabase.com/blog/sunovion-submits-new-drug-application-to-the-fda-for-apomorphine-sublingual-film-apl-130277-for-the-treatment-of-off-episodes-associated-with-parkinsons-disease 2018-03-30T23:41:41 https://maestrodatabase.com/blog/once-daily-trelegy-ellipta-gains-expanded-copd-indication-in-europe 2018-11-12T16:03:22 https://maestrodatabase.com/blog/smc_advice___january_2014 2015-08-05T11:37:18 https://maestrodatabase.com/blog/in-china-desperate-patients-smuggle-drugs-or-make-their-own 2018-11-12T16:07:49 https://maestrodatabase.com/blog/donald-trump-says-us-would-never-take-over-any-part-of-britains-nhs 2019-12-03T19:54:43 https://maestrodatabase.com/blog/alkeus-pharmaceuticals-receives-fda-rare-paediatric-disease-and-fast-track-designations-for-gildeuretinol-as-a-treatment-for-stargardt-disease 2024-11-19T00:02:27 https://maestrodatabase.com/blog/obamacare-will-survive-aetnas-retreat 2016-08-17T08:20:07 https://maestrodatabase.com/blog/proposal-related-to-2nd-3rd-line-anti-vegf-treatments-for-ophthalmic-use 2016-09-05T04:04:35 https://maestrodatabase.com/blog/cancer-control-agency-open-prime-minister-hails-blair-vinings-tireless-advocacy 2019-12-03T19:52:07 https://maestrodatabase.com/blog/merck-receives-two-positive-eu-chmp-opinions-for-keytruda-pembrolizumab-for-subcutaneous-administration-and-for-new-indication-for-earlier-stage-head-and-neck-cancer 2025-09-20T21:54:19 https://maestrodatabase.com/blog/shire-receives-european-approval-to-use-resolor-prucalopride-succinate-in-men-for-the-symptomatic-treatment-of-chronic-constipation 2015-08-05T11:37:25 https://maestrodatabase.com/blog/availability-of-orkambi-on-the-nhs 2018-11-12T13:57:07 https://maestrodatabase.com/blog/recently-added-forthcoming-submissions---june-2014-update 2015-08-05T11:37:02 https://maestrodatabase.com/blog/icr-welcomes-nices-decision-to-reassess-abiraterone-acetate-as-first-line-treatment-for-advanced-prostate-cancer 2020-10-30T06:54:38 https://maestrodatabase.com/blog/f1-5-statutory-price-reduction-fact-sheet 2015-08-19T04:12:29 https://maestrodatabase.com/blog/smc---november-2018-decisions 2018-11-12T16:00:16 https://maestrodatabase.com/blog/epipen-jr 2019-12-03T08:24:11 https://maestrodatabase.com/blog/only_3_in_20_new_drugs_approved_in_germany_in_2011_were_an_improvement__report_says 2015-08-05T11:37:17 https://maestrodatabase.com/blog/billion-dollar-drug-company-wants-to-be-reimbursed-with-taxpayer-funding 2018-11-12T16:19:55 https://maestrodatabase.com/blog/mesalazine-asacol-800-mg-tablets-approved-in-nz 2015-12-13T20:34:38 https://maestrodatabase.com/blog/regenerative-medicine-advanced-therapy-designation-granted-by-fda-to-adp-a2m4-for-the-treatment-of-synovial-sarcoma 2019-12-03T20:10:18 https://maestrodatabase.com/blog/novartis-drug-signifor-approved-in-eu-marking-an-advance-for-patients-with-inadequately-controlled-acromegaly 2015-08-05T11:37:02 https://maestrodatabase.com/blog/progress-made-in-the-operation-of-eu-pharmacovigilance-legislation 2016-09-14T21:25:07 https://maestrodatabase.com/blog/drug-prices-on-ads-as-relevant-as-percent-daily-value-on-food-labels 2018-11-12T16:12:29 https://maestrodatabase.com/blog/restricted-drug-treatments-for-people-with-ms-justified 2017-08-28T10:03:42 https://maestrodatabase.com/blog/tga-approves-belkyra-deoxycholic-acid 2016-07-28T21:08:02 https://maestrodatabase.com/blog/nice-publishes-final-drug-recommendations-for-5-separate-medical-conditions 2016-01-27T12:15:02 https://maestrodatabase.com/blog/the-use-of-risk-sharing-contracts-in-health-care-theoretical-and-empirical-assessments 2019-12-03T20:05:41 https://maestrodatabase.com/blog/democrats-won-a-mandate-on-health-care-how-will-they-use-it 2018-11-12T16:16:39 https://maestrodatabase.com/blog/_early_access__drugs_scheme_launched_for_severely_ill 2015-08-05T11:37:17 https://maestrodatabase.com/blog/cadth-seeks-input-on-submission-from-amgen-for-prolia 2015-10-26T20:34:48 https://maestrodatabase.com/blog/kedrion-biopharma-and-kamada-receive-fda-approval-of-kedrab-for-post-exposure-prophylaxis-against-rabies-infection 2017-08-28T09:48:07 https://maestrodatabase.com/blog/call-for-britain-to-over-ride-patents-on-roche-cancer-drug 2015-10-01T21:30:52 https://maestrodatabase.com/blog/help-shape-the-way-pharmac-implements-tpp-changes 2016-09-05T04:00:54 https://maestrodatabase.com/blog/pbac-shows-no-propensity-to-support-amgens-innovative-method-of-analysis 2018-11-12T16:36:26 https://maestrodatabase.com/blog/pfizer-announces-fda-approval-of-xeljanz-xr-tofacitinib-citrate-extended-release-tablets-the-first-and-only-once-daily-oral-jak-inhibitor-treatment-for-rheumatoid-arthritis 2016-02-25T20:20:54 https://maestrodatabase.com/blog/gsk-announces-regulatory-submissions-for-subcutaneous-formulation-of-benlysta-belimumab-for-patients-with-systemic-lupus-disease 2016-09-26T20:53:35 https://maestrodatabase.com/blog/paying-for-car-t-therapy-amidst-limited-health-system-resources 2019-06-05T08:10:13 https://maestrodatabase.com/blog/breast-cancer-drug-kadcyla-to-remain-on-nhs-after-manufacturer-lowers-price 2015-11-05T07:35:02 https://maestrodatabase.com/blog/pharmac-to-change-how-it-makes-funding-decisions 2015-08-05T11:37:10 https://maestrodatabase.com/blog/biosimilar-drugs-promise-to-slash-health-care-costs-in-rich-countries 2018-11-12T16:24:28 https://maestrodatabase.com/blog/apra-warns-health-insurers-of-forced-mergers-if-risks-not-tackled 2019-06-05T08:07:27 https://maestrodatabase.com/blog/abbvies-humira-adalimumab-receives-us-fda-approval-to-treat-adults-with-non-infectious-intermediate-posterior-and-panuveitis 2016-07-01T22:07:38 https://maestrodatabase.com/blog/costly-cancer-drugs-face-chop-from-cdf 2015-08-05T11:37:19 https://maestrodatabase.com/blog/oversight-gap-at-private-infusion-clinics-poses-health-risk-ontario-documents-say 2018-11-12T16:31:54 https://maestrodatabase.com/blog/pfizer-knew-drug-may-prevent-alzheimers-why-didnt-it-tell-us 2019-06-05T08:03:47 https://maestrodatabase.com/blog/cancer-drugs-fund-requires-further-reform 2016-09-29T20:53:27 https://maestrodatabase.com/blog/new-weapon-in-push-to-lower-us-biotech-drug-prices 2015-09-23T22:10:36 https://maestrodatabase.com/blog/fda-approves-daklinza-daclatasvir-for-the-treatment-of-patients-with-chronic-hepatitis-c-genotype-3 2015-08-05T11:37:05 https://maestrodatabase.com/blog/pharmac-decision-to-fund-azacitidine-and-lenalidomide 2015-08-05T11:37:30 https://maestrodatabase.com/blog/icr-responds-to-nice-decision-on-olaparib-for-women-with-advanced-ovarian-cancer 2018-11-13T15:10:32 https://maestrodatabase.com/blog/fda-accepts-sandoz-application-for-biosimilar-filgrastim 2015-08-05T11:37:19 https://maestrodatabase.com/blog/efpia-statement-on-the-un-hlp-report-on-access-to-medicines 2016-09-16T07:56:12 https://maestrodatabase.com/blog/us-fda-accepts-regulatory-submission-for-lynparza-maintenance-therapy-in-newly-diagnosed-brca-mutated-advanced-ovarian-cancer-and-grants-priority-review 2018-11-12T17:05:00 https://maestrodatabase.com/blog/the-medicines-company-announces-fda-approval-of-kengreal-cangrelor-as-an-adjunct-to-percutaneous-coronary-intervention-for-reducing-thrombotic-events 2015-08-05T11:37:20 https://maestrodatabase.com/blog/smart-buys-and-pbs-shift-pay-off-for-sigma 2015-09-10T21:16:02 https://maestrodatabase.com/blog/rare-blood-cancer-therapy-oncaspar-gets-nice-green-light 2016-08-23T21:13:08 https://maestrodatabase.com/blog/2015-pbs-co-payment-and-safety-net-amounts 2015-08-05T11:37:23 https://maestrodatabase.com/blog/nice_gives_the_green_light_to_aflibercept__eylea__for_patients_with_wet_amd_in_final_guidance 2015-08-05T11:37:23 https://maestrodatabase.com/blog/canadas-hta-agency-releases-report-on-international-biosimilar-policies 2018-11-13T15:27:15 https://maestrodatabase.com/blog/agenda-for-4-march-2015-tc-meeting 2015-08-05T11:37:16 https://maestrodatabase.com/blog/drug-utilisation-sub-committee-outcome-statement-1 2015-11-17T01:15:55 https://maestrodatabase.com/blog/something-happened-to-u-dot-s-drug-costs-in-the-1990s 2018-11-13T15:16:26 https://maestrodatabase.com/blog/fda-approves-rexulti-brexpiprazole-as-adjunctive-treatment-for-adults-with-major-depressive-disorder-and-as-a-treatment-for-adults-with-schizophrenia 2015-08-05T11:37:29 https://maestrodatabase.com/blog/european-commission-approves-mercks-anti-pd-1-therapy-keytruda-pembrolizumab-for-both-first-line-and-previously-treated-patients-with-advanced-melanoma 2015-08-05T11:37:15 https://maestrodatabase.com/blog/fda-grants-priority-review-to-roches-tecentriq-in-combination-with-abraxane-for-the-initial-treatment-of-people-with-pd-l1-positive-metastatic-triple-negative-breast-cancer 2018-11-13T15:19:38 https://maestrodatabase.com/blog/european-medicines-agency-validates-two-parallel-type-ii-variation-applications-to-extend-the-opdivo-nivolumab-indication-in-europe 2015-08-05T11:37:07 https://maestrodatabase.com/blog/fda-grants-breakthrough-therapy-designation-to-huahui-healths-libevitug-hh-003-for-treatment-of-chronic-hepatitis-d-virus-infection 2024-11-19T00:29:54 https://maestrodatabase.com/blog/nice-guidance-recommends-sofosbuvir-sovaldi-gilead-sciences-and-simeprevir-olysio-janssen-for-treating-hepatitis-c 2015-08-05T11:37:21 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-april-2018 2018-03-31T00:20:53 https://maestrodatabase.com/blog/presentations-from-ispor-australian-chapter-predicting-future-evidence-workshop 2015-08-05T11:37:08 https://maestrodatabase.com/blog/fda-permits-marketing-of-first-system-of-mobile-medical-apps-for-continuous-glucose-monitoring 2015-08-05T11:37:13 https://maestrodatabase.com/blog/alimera-sciences-iluvien-receives-marketing-authorization-in-denmark-for-the-treatment-of-chronic-diabetic-macular-edema 2015-08-05T11:37:26 https://maestrodatabase.com/blog/fda-takes-steps-to-allow-greater-flexibility-for-clinical-investigators-about-informed-consent-in-minimal-risk-situations 2018-11-13T18:04:12 https://maestrodatabase.com/blog/highlights-from-the-15-18-september-2025-chmp-meeting 2025-09-20T22:04:23 https://maestrodatabase.com/blog/fda-approves-vaccine-to-prevent-cholera-for-travelers 2016-06-10T21:31:46 https://maestrodatabase.com/blog/merck-cancer-drug-is-first-approved-under-uk-early-access-scheme 2015-08-05T11:37:21 https://maestrodatabase.com/blog/us-food-and-drug-administration-accepts-for-priority-review-the-biologics-license-application-for-empliciti-elotuzumab-for-the-treatment-of-multiple-myeloma-in-patients-who-have-received-one-or-more-prior-therapies 2015-09-01T13:04:14 https://maestrodatabase.com/blog/nice-recommends-prasugrel-hydrochloride-efient-for-preventing-blood-clots-in-people-with-acute-coronary-syndromes 2015-08-05T11:37:22 https://maestrodatabase.com/blog/protesters-take-anger-over-insulin-prices-to-drug-makers-some-bearing-childrens-ashes 2018-11-13T15:59:23 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-january-2015-update 2015-08-05T11:37:24 https://maestrodatabase.com/blog/call-for-nz-government-to-fund-hpv-vaccine-for-boys 2016-03-21T21:09:49 https://maestrodatabase.com/blog/fda-approves-new-injectable-drug-to-treat-schizophrenia 2015-10-06T18:31:57 https://maestrodatabase.com/blog/perc-rejects-arzerra-ofatumumab-acetate-for-patients-with-chronic-lymphocytic-leukaemia 2015-08-05T11:37:21 https://maestrodatabase.com/blog/lilly-submits-new-drug-application-to-the-fda-for-lasmiditan-for-acute-treatment-of-migraine-receives-breakthrough-therapy-designation-for-emgality-galcanezumab-gnlm-for-prevention-of-episodic-cluster-headache 2018-11-14T15:13:56 https://maestrodatabase.com/blog/fda-shortens-interval-for-booster-dose-of-moderna-covid-19-vaccine-to-five-months 2022-01-08T00:16:08 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits-1-january-2016-update 2015-12-31T00:39:18 https://maestrodatabase.com/blog/cms-takes-action-to-lower-out-of-pocket-medicare-part-d-prescription-drug-costs 2022-01-08T04:33:04 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-november-2014-update 2015-08-05T11:37:19 https://maestrodatabase.com/blog/express-scripts-introduces-novel-formulary-built-for-evolution-of-drug-pricing 2018-11-13T18:11:04 https://maestrodatabase.com/blog/new_facet_added_to_maestro_australia___risk_sharing_agreement 2015-08-05T11:37:16 https://maestrodatabase.com/blog/a-new-parkinsons-drug-is-a-long-acting-version-of-a-cheap-generic-should-it-cost-30-000-dollars-a-year 2017-08-28T20:57:46 https://maestrodatabase.com/blog/emas-brexit-plans-ensure-agencys-focus-on-medicines-evaluation-and-supervision 2018-11-13T19:20:08 https://maestrodatabase.com/blog/agreement-with-smith-and-nephew-for-the-supply-of-orthopaedic-trauma-implants 2016-06-21T02:34:18 https://maestrodatabase.com/blog/2014-budget-information-on-the-pharmaceutical-benefits-scheme 2015-08-05T11:37:25 https://maestrodatabase.com/blog/reinsurance-obamacare-fix-wins-bipartisan-support-in-senate 2018-11-14T15:29:26 https://maestrodatabase.com/blog/diabetes-breakthrough-part-of-70m-pbs-medicines-listings 2016-08-14T21:09:57 https://maestrodatabase.com/blog/faslodex-receives-us-fda-approval-as-monotherapy-for-expanded-use-in-breast-cancer 2017-08-28T21:28:02 https://maestrodatabase.com/blog/productivity-commission-draft-report-on-intellectual-property-arrangements 2016-04-29T21:15:18 https://maestrodatabase.com/blog/afterpay-added-to-radiology-pharmacy-and-gp-services 2019-06-05T08:45:15 https://maestrodatabase.com/blog/allergan-and-gedeon-richter-plc-receive-fda-approval-of-vraylar-cariprazine-for-treatment-of-manic-or-mixed-episodes-of-bipolar-i-disorder-and-schizophrenia-in-adults 2015-09-18T22:04:56 https://maestrodatabase.com/blog/nsw-minister-for-health-brad-hazzard-says-more-competition-needed-in-medical-device-sector 2017-08-28T21:21:01 https://maestrodatabase.com/blog/fda-approves-genentechs-columvi-the-first-and-only-bispecific-antibody-with-a-fixed-duration-treatment-for-people-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma 2023-06-16T03:34:43 https://maestrodatabase.com/blog/ofev-nintedanib-approved-in-the-eu-for-the-treatment-of-ipf 2015-08-05T11:37:07 https://maestrodatabase.com/blog/the-worst-solution-to-high-drug-prices-is-political-interference-says-former-pharma-ceo 2017-08-28T21:34:39 https://maestrodatabase.com/blog/invega_sustenna_now_reimbursed_in_newfoundland 2015-08-05T11:37:12 https://maestrodatabase.com/blog/statement-from-fda-commissioner-scott-gottlieb-m-dot-d-on-the-fdas-new-policy-steps-and-enforcement-efforts-to-ensure-proper-oversight-of-stem-cell-therapies-and-regenerative-medicine 2017-08-28T21:31:34 https://maestrodatabase.com/blog/fingolimod-in-multiple-sclerosis-no-evidence-of-additional-benefits-in-the-new-application 2016-03-01T20:55:03 https://maestrodatabase.com/blog/my-health-record-opt-out-deadline-extended-after-system-crash 2018-11-14T15:22:24 https://maestrodatabase.com/blog/how-nice-can-get-innovative-cancer-meds-into-nhs 2015-08-05T11:37:24 https://maestrodatabase.com/blog/rotorua-toddler-faces-being-trapped-in-his-own-body-parents-plead-for-spinraza-drug-funding 2019-06-05T08:39:23 https://maestrodatabase.com/blog/zilucoplan-sodium-for-the-treatment-of-patients-with-antibody-positive-generalised-myasthenia-gravis-revised-draft-guidance 2024-11-19T02:09:11 https://maestrodatabase.com/blog/role-of-the-fda-in-affordability-of-off-patent-pharmaceuticals 2016-01-04T20:42:03 https://maestrodatabase.com/blog/sandoz-biosimilar-rituximab-regulatory-submission-accepted-by-european-medicines-agency 2016-05-24T10:19:42 https://maestrodatabase.com/blog/pain-therapeutics-appeals-fda-decision-on-remoxy 2018-11-14T15:38:30 https://maestrodatabase.com/blog/helsinn-group-announces-fda-approval-of-a-new-liquid-formulation-of-akynzeo-fosnetupitant-slash-palonosetron-injection-in-the-united-states 2020-06-03T03:06:35 https://maestrodatabase.com/blog/lilly-and-astrazeneca-receive-fda-fast-track-designation-for-azd3293-an-investigational-treatment-for-early-alzheimers-disease 2016-08-22T11:19:27 https://maestrodatabase.com/blog/fda-grants-priority-review-for-genentechs-gazyva-in-previously-untreated-follicular-lymphoma 2017-08-28T21:37:15 https://maestrodatabase.com/blog/icer-report-finds-biologic-treatments-for-uncontrolled-asthma-would-require-more-than-a-50-percent-price-discount-to-reach-common-thresholds-for-cost-effectiveness 2018-11-14T15:43:55 https://maestrodatabase.com/blog/fda-approves-jakafi-to-treat-patients-with-a-chronic-type-of-bone-marrow-disease 2015-08-05T11:37:29 https://maestrodatabase.com/blog/palvella-therapeutics-announces-fda-fast-track-designation-for-ptx-022-for-treatment-of-pachyonychia-congenita 2018-11-14T15:33:34 https://maestrodatabase.com/blog/ema-publishes-epa-for-eftrenonacog-alfa-alprolix 2016-05-25T15:58:44 https://maestrodatabase.com/blog/first-nice-highly-specialised-technologies-guidance-recommends-eculizumab-soliris-for-treating-very-rare-life-threatening-blood-disorder 2015-08-05T11:37:25 https://maestrodatabase.com/blog/fda-approves-corlanor-to-treat-heart-failure 2015-08-05T11:37:19 https://maestrodatabase.com/blog/breo-ellipta-fluticasone-furoatevilanterol-to-be-pbs-listed-as-reimbursed-treatment-for-asthma-and-copd 2015-08-05T11:37:02 https://maestrodatabase.com/blog/new_cancer_medicines_available_through_the_pbs 2015-08-05T11:37:08 https://maestrodatabase.com/blog/rejected-prostate-cancer-drug-extends-life 2015-08-05T11:37:15 https://maestrodatabase.com/blog/gilead-abbvie-asked-by-us-for-hepatitis-c-pricing-options 2015-11-06T21:53:50 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-for-filing-shires-supplemental-new-drug-application-for-gattex-teduglutide-rdna-origin-for-children-with-short-bowel-syndrome 2018-11-14T20:46:01 https://maestrodatabase.com/blog/gsks-nucala-wins-european-panel-thumbs-up-for-self-administration 2019-06-05T09:11:02 https://maestrodatabase.com/blog/new-nhs-cancer-drugs-fund-approved 2016-02-26T07:34:44 https://maestrodatabase.com/blog/gigantism-sufferers-to-benefit-from-new-miracle-drug-subsidy 2016-08-14T01:24:30 https://maestrodatabase.com/blog/retrophin-announces-u-dot-s-fda-acceptance-of-nda-filing-for-the-new-formulation-of-thiola-tiopronin-in-the-treatment-of-cystinuria 2018-11-14T20:38:52 https://maestrodatabase.com/blog/abortion-drug-company-open-to-restarting-reimbursement-review-process 2016-10-04T09:19:27 https://maestrodatabase.com/blog/i-am-paying-for-your-expensive-medicine 2015-11-12T09:14:00 https://maestrodatabase.com/blog/janssen-seeks-to-expand-use-of-erleada-apalutamide-in-the-treatment-of-patients-with-metastatic-hormone-sensitive-prostate-cancer 2019-06-05T09:06:13 https://maestrodatabase.com/blog/update-to-examples-for-no-reduction-low-volumelow-discount-items-in-fact-sheet-2015-price-disclosure-changes 2015-09-03T02:47:36 https://maestrodatabase.com/blog/pfizer-launches-epoetin-alfa-biosimilar-retacrit-at-33-dot-5-percent-discount-to-reference-epogen 2018-11-14T20:53:56 https://maestrodatabase.com/blog/cancer_drug_divide_between_england_and_wales 2015-08-05T11:37:21 https://maestrodatabase.com/blog/why-drug-makers-charge-outrageous-prices 2016-08-29T21:19:26 https://maestrodatabase.com/blog/us-fda-approves-first-in-class-glyxambi-empagliflozinlinagliptin-tablets-for-adults-with-type-2-diabetes 2015-08-05T11:37:22 https://maestrodatabase.com/blog/fda-approves-viekira-pak-to-treat-hepatitis-c 2015-08-05T11:37:30 https://maestrodatabase.com/blog/how-to-design-the-cost-effectiveness-appraisal-process-of-new-health-care-technologies-to-maximise-population-health-a-conceptual-framework 2017-08-28T21:55:20 https://maestrodatabase.com/blog/big-pharmas-delicate-dance-on-drug-prices 2016-02-22T20:17:36 https://maestrodatabase.com/blog/evaluating-fdas-approach-to-cancer-clinical-trials 2016-09-21T21:20:37 https://maestrodatabase.com/blog/incoming-democrat-chairman-medicare-negotiating-drug-prices-is-a-priority 2018-11-14T20:51:08 https://maestrodatabase.com/blog/unitedhealth-trims-drug-coverage-including-sanofi-insulin 2016-09-22T08:30:00 https://maestrodatabase.com/blog/fda-approves-opdivo-to-treat-advanced-form-of-kidney-cancer 2015-11-23T20:53:32 https://maestrodatabase.com/blog/nice-approves-serviers-lonsurf-as-third-line-cancer-therapy 2016-07-25T12:07:51 https://maestrodatabase.com/blog/us-panel-would-make-insurers-help-contain-rising-drug-costs 2016-04-19T09:46:49 https://maestrodatabase.com/blog/call-for-patient-input-on-a-submission-from-boehringer-ingelheim-for-praxbind 2016-05-17T22:44:19 https://maestrodatabase.com/blog/immunesensor-therapeutics-receives-orphan-drug-and-rare-paediatric-disease-designations-from-the-us-fda-for-cgas-inhibitor-drug-candidate-imsb301-for-the-treatment-of-aicardi-goutieres-syndrome 2024-11-21T02:49:53 https://maestrodatabase.com/blog/f1-5-statutory-price-reductions-on-1-april-2016-list-of-affected-drugs 2015-12-18T10:11:10 https://maestrodatabase.com/blog/disclosing-prescription-drug-prices-in-advertisements----legal-and-public-health-issues 2018-11-15T07:19:14 https://maestrodatabase.com/blog/turning-medical-research-into-commercial-reality 2015-12-07T04:26:19 https://maestrodatabase.com/blog/bristol-myers-squibb-announces-regulatory-updates-for-opdivo-nivolumab-in-previously-treated-recurrent-or-metastatic-squamous-cell-carcinoma-of-the-head-and-neck 2016-07-18T11:57:31 https://maestrodatabase.com/blog/many-say-high-deductibles-make-their-health-law-insurance-all-but-useless 2015-11-16T08:46:36 https://maestrodatabase.com/blog/dyax-corp-receives-fda-breakthrough-therapy-designation-for-dx-2930-for-prevention-of-attacks-of-hereditary-angioedema 2015-08-05T11:37:23 https://maestrodatabase.com/blog/agenda-for-the-3-september-2014-transparency-commission-meeting 2015-08-05T11:37:22 https://maestrodatabase.com/blog/progesterone-to-be-fully-funded-for-all-who-need-it 2022-09-15T03:02:59 https://maestrodatabase.com/blog/call-for-nominations-canadian-drug-expert-committee 2015-08-05T11:37:22 https://maestrodatabase.com/blog/added-benefit-of-the-fixed-combination-of-dapagliflozin-and-metformin-is-not-proven 2015-08-05T11:37:16 https://maestrodatabase.com/blog/2015-an-important-year-for-advancing-generic-drugs-at-fda 2016-04-13T21:22:03 https://maestrodatabase.com/blog/inclusion-of-data-on-treatment-discontinuation-in-the-tasigna-product-monograph-approved-by-health-canada-for-cml-patients-who-achieve-a-sustained-molecular-response 2018-11-15T07:32:27 https://maestrodatabase.com/blog/cadth-calls-for-patient-input-on-a-submission-from-cipher-pharmaceuticals-for-actikerall-5-fluorouracil-with-salicylic-acid 2016-08-06T05:13:52 https://maestrodatabase.com/blog/health-canada-approves-daklinza-daclatasvir-for-difficult-to-treat-hepatitis-c-patient-populations 2016-05-25T10:44:03 https://maestrodatabase.com/blog/fear-mongering-jeopardising-21st-century-trade-deal 2015-08-05T11:37:29 https://maestrodatabase.com/blog/pbac-decision-to-approve-biosimilars-for-pharmacy-substitution-is-a-safety-concern-for-patients 2015-08-21T10:36:36 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits-1-december-2015-update 2015-11-30T20:24:56 https://maestrodatabase.com/blog/public-consultation-on-pbac-post-market-reviews-of-chronic-obstructive-pulmonary-disease-medicines-and-ezetimibe 2016-08-05T04:34:26 https://maestrodatabase.com/blog/teva-announces-fda-acceptance-for-review-of-nda-for-its-investigational-twice-daily-hydrocodone-bitartrate-extended-release-tablets-with-proprietary-abuse-deterrence-technology 2015-08-05T11:37:27 https://maestrodatabase.com/blog/juno-t-cell-therapy-for-leukaemia-granted-fda-breakthrough-therapy-designation 2015-08-05T11:37:17 https://maestrodatabase.com/blog/pill-boxes-and-kneehab-apps-johnson-johnson-hackathon 2016-09-26T03:17:00 https://maestrodatabase.com/blog/pbac-to-consider-first-submission-for-a-cellular-therapy-in-july 2016-04-28T12:02:37 https://maestrodatabase.com/blog/cynapsus-receives-fda-fast-track-designation-for-apl-130277-for-the-treatment-of-off-episodes-in-patients-with-parkinsons-disease 2016-08-29T21:25:23 https://maestrodatabase.com/blog/government-announces-new-drug-funding-including-for-advanced-melanoma 2016-06-09T20:56:19 https://maestrodatabase.com/blog/ema-publishes-epar-for-zalmoxis 2016-09-05T22:21:43 https://maestrodatabase.com/blog/stallergenes-greer-announces-u-dot-s-fda-approval-of-paediatric-indication-extension-for-oralair-sublingual-immunotherapy-tablet-for-the-treatment-of-grass-pollen-allergy 2018-11-15T07:51:34 https://maestrodatabase.com/blog/pfizer-receives-expanded-fda-approval-for-ibrance-palbociclib-in-hr-her2-metastatic-breast-cancer 2016-02-25T20:29:44 https://maestrodatabase.com/blog/drug-companies-and-patient-groups-want-faster-approval-for-cancer-drugs 2015-08-05T11:37:30 https://maestrodatabase.com/blog/nice-backs-bayers-eylea-after-discount-deal 2015-08-05T11:37:15 https://maestrodatabase.com/blog/the-epipen-outrage-continues 2016-09-22T08:24:09 https://maestrodatabase.com/blog/2016-medicare-parts-a-b-premiums-and-deductibles-announced 2015-11-16T19:57:12 https://maestrodatabase.com/blog/nice-recommends-new-treatment-option-for-adults-with-obesity-and-non-diabetic-hyperglycaemia-who-have-a-high-risk-of-cardiovascular-disease 2020-10-30T09:49:17 https://maestrodatabase.com/blog/four-new-drugs-approved-for-nhs-use-in-scotland 2015-08-05T11:37:06 https://maestrodatabase.com/blog/arrowhead-pharmaceuticals-submits-new-drug-application-to-us-fda-for-plozasiran-for-the-treatment-of-familial-chylomicronemia-syndrome 2024-11-21T03:14:44 https://maestrodatabase.com/blog/outcomes-from-the-may-2016-ptac-meeting 2016-07-16T23:50:33 https://maestrodatabase.com/blog/astellas-provides-update-on-izervay-avacincaptad-pegol-intravitreal-solution-supplemental-new-drug-application 2024-11-27T10:32:17 https://maestrodatabase.com/blog/european-medicines-agency-recommends-39-medicines-for-human-use-for-marketing-authorisation-in-first-half-of-2014 2015-08-05T11:37:28 https://maestrodatabase.com/blog/fdas-decision-to-approve-new-treatment-for-alzheimers-disease 2021-06-08T07:37:16 https://maestrodatabase.com/blog/streamlined-approvals-means-faster-access-to-medicines-for-patients 2016-09-15T06:08:06 https://maestrodatabase.com/blog/fda-approves-nivolumab-in-combination-with-cisplatin-and-gemcitabine-for-unresectable-or-metastatic-urothelial-carcinoma 2024-03-07T19:55:46 https://maestrodatabase.com/blog/health_canada_approves_kadcyla__trastuzumab_emtansine__for_the_treatment_of_women_with_her2_positive_metastatic_breast_cancer 2015-08-05T11:37:03 https://maestrodatabase.com/blog/moderna-files-for-authorisation-with-health-canada-for-its-covid-19-vaccine-in-adolescents 2021-06-08T07:27:50 https://maestrodatabase.com/blog/sparsentan-approved-to-treat-adult-patients-with-primary-immunoglobulin-a-nephropathy 2024-11-27T10:02:00 https://maestrodatabase.com/blog/updated-new-product-assessment-form-and-guidance 2016-04-12T22:30:17 https://maestrodatabase.com/blog/nice-recommends-tecentriq-for-first-line-nsclc 2021-06-08T07:42:57 https://maestrodatabase.com/blog/coagulation-factor-ix-fc-fusion-protein-alprolix-treatment-cost-comparison-and-budget-impact-analysis 2015-11-12T09:36:50 https://maestrodatabase.com/blog/us-food-and-drug-administration-accepts-filing-of-new-drug-application-for-empagliflozinmetformin-fixed-dose-combination 2015-08-05T11:37:15 https://maestrodatabase.com/blog/european-commission-grants-lilly-and-boehringer-ingelheims-insulin-glargine-product-marketing-authorisation-in-europe 2015-08-05T11:37:17 https://maestrodatabase.com/blog/merck-begins-rolling-submission-of-licensure-application-for-v920-rvsv-g-zebov-gp-to-u-dot-s-fda 2018-11-15T08:00:17 https://maestrodatabase.com/blog/how-will-a-covid-vaccine-be-distributed-once-its-approved-by-fda 2020-10-30T19:37:19 https://maestrodatabase.com/blog/johnson-and-johnson-submits-application-to-the-ema-for-darzalex-daratumumab--based-quadruplet-therapy-for-the-treatment-of-patients-with-transplant-eligible-newly-diagnosed-multiple-myeloma 2024-03-07T07:43:48 https://maestrodatabase.com/blog/meeting-highlights-from-the-committee-for-medicinal-products-for-human-use-chmp-23-26-june-2014 2015-08-05T11:37:23 https://maestrodatabase.com/blog/agenda-for-9-july-2014-transparency-commission-meeting 2015-08-05T11:37:24 https://maestrodatabase.com/blog/neurorx-receives-fda-breakthrough-therapy-designation-for-nrx-101-first-oral-drug-targeting-suicidal-bipolar-depression 2018-11-15T08:11:37 https://maestrodatabase.com/blog/fda-approves-genentechs-tecentriq-plus-chemotherapy-abraxane-and-carboplatin-for-the-initial-treatment-of-metastatic-non-squamous-non-small-cell-lung-cancer 2019-12-04T02:17:50 https://maestrodatabase.com/blog/nice_consults_on_a_new_treatment_for_myelodysplastic_syndromes 2015-08-05T11:37:09 https://maestrodatabase.com/blog/new-medicine-for-lupus-now-available-in-australia 2015-08-05T11:37:22 https://maestrodatabase.com/blog/cannot-be-trusted-dot-dot-dot-causing-harm-top-medical-journal-takes-on-big-pharma 2019-12-04T02:13:38 https://maestrodatabase.com/blog/fda-approves-radiation-medical-countermeasure 2015-08-05T11:37:17 https://maestrodatabase.com/blog/new-skyrizi-risankizumab-150-mg-presentation-pre-filled-pen-and-pre-filled-syringe-approved-by-the-mhra 2021-06-08T07:08:28 https://maestrodatabase.com/blog/fda-approves-implantable-device-that-changes-the-shape-of-the-cornea-to-correct-near-vision 2016-06-29T21:42:43 https://maestrodatabase.com/blog/salix-announces-fda-approval-of-xifaxan-550-mg-for-the-treatment-of-ibs-d-irritable-bowel-syndrome-with-diarrhoea 2015-08-05T11:37:22 https://maestrodatabase.com/blog/public-consultation-on-the-post-market-review-of-authority-required-pbs-listings---update 2015-08-05T11:37:02 https://maestrodatabase.com/blog/aerie-pharmaceuticals-submits-marketing-authorisation-application-for-roclanda-netarsudil-and-latanoprost-ophthalmic-solution-0-dot-02-percent-slash-0-dot-005-percent-in-europe 2019-12-04T02:03:17 https://maestrodatabase.com/blog/making_medicines_cheaper_for_consumers 2015-08-05T11:37:20 https://maestrodatabase.com/blog/pharmaceutical-reform-agreement-review-report 2024-03-07T20:30:27 https://maestrodatabase.com/blog/fda-rescinds-breakthrough-status-for-mercks-hepatitis-c-drug 2015-08-05T11:37:07 https://maestrodatabase.com/blog/immunomedics-resubmits-biologics-license-application-to-the-fda-for-sacituzumab-govitecan 2019-12-04T02:51:52 https://maestrodatabase.com/blog/lilly-canada-remains-steadfast-in-commitment-to-access-options-for-patients-amidst-controversial-cda-amc-recommendation-for-ebglyss-lebrikizumab 2024-11-27T22:22:22 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-for-priority-review-bristol-myers-squibbs-supplemental-biologics-license-application-for-opdivo-nivolumab-for-the-treatment-of-classical-hodgkins-lymphoma-patients 2016-04-14T20:41:40 https://maestrodatabase.com/blog/first-malaria-vaccine-receives-positive-scientific-opinion-from-ema 2015-08-05T11:37:21 https://maestrodatabase.com/blog/nz-govt-should-subsidise-more-drugs 2015-08-05T11:37:28 https://maestrodatabase.com/blog/biden-says-medicare-should-negotiate-prices-for-at-least-50-drugs-each-year-up-from-a-target-of-20 2024-03-07T20:21:49 https://maestrodatabase.com/blog/meeting-highlights-from-the-chmp-25-28-april-2016 2016-05-01T01:33:51 https://maestrodatabase.com/blog/health-canada-grants-priority-review-status-for-heron-therapeutics-new-drug-submission-for-htx-011-for-management-of-post-operative-pain 2019-12-04T02:30:58 https://maestrodatabase.com/blog/abpi-comments-on-scottish-new-medicines-fund-1 2015-08-05T11:37:15 https://maestrodatabase.com/blog/death-sentence-one-in-a-million-rare-cancers-get-the-sorting-hat-treatment 2018-11-15T08:22:23 https://maestrodatabase.com/blog/fda-accepts-supplemental-biologics-license-application-assigns-priority-review-and-grants-breakthrough-therapy-designation-to-mercks-keytruda-pembrolizumab-for-first-line-treatment-of-patients-with-advanced-non-small-cell-lung-cancer 2016-09-07T21:08:40 https://maestrodatabase.com/blog/despite-its-high-price-tag-the-new-alzheimers-drug-isnt-reigniting-the-drug-pricing-debate 2021-06-08T11:52:23 https://maestrodatabase.com/blog/profits-from-unproven-supplements-a-conflict-for-pharmacists 2016-09-24T03:02:06 https://maestrodatabase.com/blog/clovis-oncology-initiates-rolling-nda-submission-to-the-fda-for-rolicetinib-in-the-treatment-of-advanced-egfr-mutant-non-small-cell-lung-cancer 2015-08-05T11:37:22 https://maestrodatabase.com/blog/early-impact-of-the-inflation-reduction-act-on-drug-discovery 2024-03-07T20:18:21 https://maestrodatabase.com/blog/pharma-bizarre-pricing-shrug 2015-11-16T21:13:54 https://maestrodatabase.com/blog/ivosidenib-with-azacitidine-for-untreated-acute-myeloid-leukaemia-with-an-idh1-r132-mutation 2024-03-07T20:08:47 https://maestrodatabase.com/blog/tevas-copaxone-patent-again-struck-down-by-us-court 2015-08-05T11:37:02 https://maestrodatabase.com/blog/bridgebio-pharmas-origin-biosciences-initiates-rolling-submission-of-new-drug-application-with-the-u-dot-s-fda-for-bbp-870-for-the-treatment-of-mocd-type-a 2019-12-04T03:23:43 https://maestrodatabase.com/blog/robertson-says-pharmacs-bulk-buying-model-is-different-not-worse-than-other-oecd-countries 2021-06-08T07:52:38 https://maestrodatabase.com/blog/nice-turns-down-alexions-366k-a-year-bone-disease-drug 2015-12-03T20:37:36 https://maestrodatabase.com/blog/fund-to-bridge-biomedical-research-to-market-gaps 2015-12-10T06:06:58 https://maestrodatabase.com/blog/bergenbio-receives-fda-fast-track-designation-for-bemcentinib-slash-anti-pd--l-1-combination-in-nsclc 2021-06-08T11:37:35 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-january-2015-update 2015-08-05T11:37:19 https://maestrodatabase.com/blog/zogenix-receives-fda-approval-of-new-formulation-of-zohydro-er 2015-08-05T11:37:21 https://maestrodatabase.com/blog/the-problem-of-medical-drug-prices 2015-08-05T11:37:05 https://maestrodatabase.com/blog/radical-plan-to-overhaul-private-health-insurance-put-forward-by-grattan-institute 2019-12-04T19:55:52 https://maestrodatabase.com/blog/the-folly-of-targeting-big-pharma 2015-12-14T06:43:27 https://maestrodatabase.com/blog/uk-cost-agency-rejects-leukaemia-drug-from-jj-and-abbvie 2016-03-02T18:23:25 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-march-2015-update 2015-08-05T11:37:12 https://maestrodatabase.com/blog/fda-approves-movantik-naloxegol-tablets-c-ii-for-the-treatment-of-opioid-induced-constipation-in-adult-patients-with-chronic-non-cancer-pain 2015-08-05T11:37:10 https://maestrodatabase.com/blog/allergan-announces-fda-approval-of-updated-label-for-teflaro-ceftaroline-fosamil 2015-09-02T21:22:13 https://maestrodatabase.com/blog/bristol-myers-squibb-announces-u-dot-s-fda-breakthrough-therapy-designation-for-orencia-abatacept-to-help-prevent-acute-graft-versus-host-disease-a-potentially-life-threatening-complication-after-stem-cell-transplant 2019-12-04T12:08:55 https://maestrodatabase.com/blog/summary_of_1_august_2014_price_reductions 2015-08-05T11:37:13 https://maestrodatabase.com/blog/biogen-ceo-says-56-000-dollars-annually-for-alzheimers-drug-is-fair-promises-not-to-hike-price-for-at-least-4-years 2021-06-08T12:14:18 https://maestrodatabase.com/blog/australians-benefit-from-new-and-expanded-medicines-on-the-pbs 2024-11-27T23:24:31 https://maestrodatabase.com/blog/zinbryta-approved-by-tga 2016-09-27T11:19:54 https://maestrodatabase.com/blog/fda-nominee-clears-senate-panel 2019-12-04T11:29:47 https://maestrodatabase.com/blog/novartis-submits-application-to-the-fda-for-meningitis-b-vaccine-candidate-bexsero-to-help-protect-us-adolescents-and-young-adults 2015-08-05T11:37:27 https://maestrodatabase.com/blog/meningococcal-disease-survivors-want-bexsero-listed-on-the-pharmaceutical-benefits-scheme 2015-08-05T11:37:03 https://maestrodatabase.com/blog/more-on-transparency-in-drug-regulation-public-assessment-reports-in-europe-and-australia 2016-08-06T09:12:54 https://maestrodatabase.com/blog/immunitybio-granted-fda-breakthrough-therapy-designation-for-n-803-il-15-superagonist-in-non-muscle-invasive-bladder-cancer 2019-12-04T20:06:34 https://maestrodatabase.com/blog/galderma-receives-fda-approval-of-novel-treatment-option-for-rosacea-patients 2015-08-05T11:37:05 https://maestrodatabase.com/blog/lundbeck_canada_launches_a_new_treatment_for_a_rare_form_of_acute_leukemia__acute_promyelocytic_leukemia_ 2015-08-05T11:37:09 https://maestrodatabase.com/blog/abbvies-technivie-receives-health-canada-approval-for-genotype-4-chronic-hepatitis-c-infection 2015-11-25T09:30:21 https://maestrodatabase.com/blog/avastin_on_cdf_list_for_advanced_cervical_cancer 2015-08-05T11:37:14 https://maestrodatabase.com/blog/drug-makers-strongly-oppose-post-approval-evaluation 2019-12-04T19:59:37 https://maestrodatabase.com/blog/ucb-receives-us-fda-approval-for-bimzelx-bimekizumab-bkzx-as-the-first-il-17a-and-il-17f-inhibitor-for-adults-with-moderate-to-severe-hidradenitis-suppurativa 2024-11-27T22:42:41 https://maestrodatabase.com/blog/us-fda-approves-expanded-use-of-bristol-myers-squibbs-daklinza-daclatasvir-for-additional-challenging-to-treat-patients-with-genotype-1-or-genotype-3-chronic-hepatitis-c 2016-02-08T19:49:50 https://maestrodatabase.com/blog/biogen-and-eisai-launch-multiple-initiatives-to-help-patients-with-alzheimers-disease-access-aduhelm 2021-06-08T11:59:03 https://maestrodatabase.com/blog/access-to-medicinesthe-status-quo-is-no-longer-an-option 2016-09-24T03:35:54 https://maestrodatabase.com/blog/sierra-announces-momelotinib-granted-fda-fast-track-designation 2019-06-05T21:06:31 https://maestrodatabase.com/blog/alpha-tau-receives-breakthrough-device-designation-from-the-fda-for-alpha-dart 2021-06-08T21:04:43 https://maestrodatabase.com/blog/white-house-claims-speaker-nancy-pelosis-drug-pricing-bill-would-result-in-100-fewer-drugs-over-a-decade 2019-12-04T20:24:35 https://maestrodatabase.com/blog/with-biosimilars-big-pharma-fights-itself 2016-07-13T21:31:37 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule-1-december-2015-update 2015-11-30T20:19:03 https://maestrodatabase.com/blog/lowering-the-price-of-new-drugs-comes-with-too-high-a-cost----canadians-health 2018-11-15T08:49:41 https://maestrodatabase.com/blog/unapproved-lilly-lung-cancer-drug-stirs-price-debate 2015-08-27T22:10:58 https://maestrodatabase.com/blog/doctors-call-for-shake-up-of-private-health-insurance-rules 2019-12-04T20:22:17 https://maestrodatabase.com/blog/doctors-diary-cancer-drugs-hope-or-hype 2016-06-14T12:53:49 https://maestrodatabase.com/blog/novartis-new-heart-failure-medicine-lcz696-now-called-entresto-approved-by-fda-to-reduce-risk-of-cardiovascular-death-and-heart-failure-hospitalization 2015-08-05T11:37:05 https://maestrodatabase.com/blog/labor-unions-team-up-with-drug-makers-to-defeat-drug-price-proposals 2019-12-04T20:14:23 https://maestrodatabase.com/blog/dad-pushing-for-a-subsidy-on-epipens 2016-02-01T20:27:31 https://maestrodatabase.com/blog/update-to-listing-requirements-for-new-brands-and-new-items-on-the-pbs 2015-08-24T08:54:36 https://maestrodatabase.com/blog/biogen-faces-tough-questions-over-56-000-dollars-a-year-price-of-newly-approved-alzheimers-drug 2021-06-08T21:10:30 https://maestrodatabase.com/blog/eisais-epilepsy-treatment-zonegran-zonisamide-approved-for-use-in-children-and-adolescents-in-france 2015-08-05T11:37:21 https://maestrodatabase.com/blog/ema-seeks-feedback-on-using-registries-for-regulatory-purposes 2018-11-15T17:05:44 https://maestrodatabase.com/blog/could-the-nhs-be-part-of-a-us-uk-trade-deal 2019-06-05T21:20:23 https://maestrodatabase.com/blog/protalix-announces-elelyso-taliglucerase-alfa-approved-in-australia-for-the-treatment-of-gaucher-disease-in-both-adult-and-paediatric-patients 2015-08-05T11:37:11 https://maestrodatabase.com/blog/titan-pharmaceuticals-announces-resubmission-of-the-new-drug-application-for-probuphine-for-the-maintenance-treatment-of-opioid-addiction 2015-08-31T21:10:28 https://maestrodatabase.com/blog/incyte-announces-u-dot-s-fda-has-extended-the-snda-review-period-for-ruxolitinib-jakafi-in-chronic-graft-versus-host-disease 2021-06-08T20:48:20 https://maestrodatabase.com/blog/call-for-patient-input-23 2015-08-05T11:37:28 https://maestrodatabase.com/blog/alexion-receives-notification-of-pdufa-date-extension-for-kanuma-sebelipase-alfa 2015-09-04T21:19:34 https://maestrodatabase.com/blog/b-dot-c-wants-federal-health-funding-lift-before-national-pharmacare-program 2019-12-04T20:34:21 https://maestrodatabase.com/blog/vbi-vaccines-granted-fda-fast-track-designation-for-vbi-1901-for-the-treatment-of-recurrent-gbm 2021-06-08T20:55:28 https://maestrodatabase.com/blog/novartis-receives-eu-approval-for-new-revolade-use-as-first-in-class-therapy-for-patients-with-severe-aplastic-anemia 2015-09-03T00:18:41 https://maestrodatabase.com/blog/families-create-buyers-club-for-cut-price-cystic-fibrosis-drug 2019-06-05T21:15:01 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-zanubrutinib-for-relapsed-or-refractory-follicular-lymphoma 2024-03-07T20:38:26 https://maestrodatabase.com/blog/us-fda-approves-foundationone-liquid-cdx-as-a-companion-diagnostic-for-tepmetko-tepotinib-to-identify-patients-with-met-exon-14-skipping-alterations-in-non-small-cell-lung-cancer 2024-11-28T05:48:18 https://maestrodatabase.com/blog/fda-approves-amgens-new-cholesterol-lowering-medication-repatha-evolocumab 2015-08-27T23:04:56 https://maestrodatabase.com/blog/a-path-forward-for-lowering-prescription-drug-prices 2016-07-20T13:20:42 https://maestrodatabase.com/blog/final-nice-green-light-for-pfizers-mylotarg 2018-11-15T16:59:45 https://maestrodatabase.com/blog/trump-says-uks-national-health-service-not-on-table-in-trade-talks 2019-06-05T21:11:17 https://maestrodatabase.com/blog/pharmacy-benefits-manager-abarca-inks-discount-deal-for-amgens-enbrel 2019-12-04T20:28:51 https://maestrodatabase.com/blog/european-commission-approves-pfizers-hympavzi-marstacimab-for-the-treatment-of-adults-and-adolescents-with-severe-haemophilia-a-or-b-without-inhibitors 2024-11-28T05:40:58 https://maestrodatabase.com/blog/drugmakers-raise-prices-despite-criticisms 2016-01-11T20:28:13 https://maestrodatabase.com/blog/kalvista-pharmaceuticals-announces-european-commission-and-swissmedic-approval-of-ekterly-sebetralstat-first-and-only-oral-on-demand-treatment-for-hereditary-angioedema 2025-09-21T03:27:58 https://maestrodatabase.com/blog/nice-proposes-to-recommend-a-new-treatment-for-some-people-with-advanced-kidney-cancer 2015-08-05T11:37:14 https://maestrodatabase.com/blog/lower-drug-prices-get-an-assist-from-a-big-player 2018-11-15T17:17:36 https://maestrodatabase.com/blog/nice-issues-guidance-not-recommending-apremilast-for-psoriatic-arthritis 2015-12-16T20:11:24 https://maestrodatabase.com/blog/high-drug-prices-a-target-of-opportunity-for-divided-congress 2018-11-15T17:20:57 https://maestrodatabase.com/blog/advocates-welcome-pharmacs-removal-of-barriers-to-menopausal-symptoms-treatment 2022-09-15T08:52:08 https://maestrodatabase.com/blog/opean-commission-grants-marketing-authorisation-for-strensiq-asfotase-alfa-for-the-treatment-of-patients-with-paediatric-onset-hypophosphatasia-hpp 2015-09-01T12:19:45 https://maestrodatabase.com/blog/new-antibiotic-zavicefta-approved-in-the-european-union-for-patients-with-serious-bacterial-infections 2016-06-29T10:54:24 https://maestrodatabase.com/blog/modis-therapeutics-announces-prime-designation-granted-by-the-ema-to-mt1621-for-the-treatment-of-tk2-deficiency 2018-11-15T17:09:25 https://maestrodatabase.com/blog/mallinckrodt-receives-us-fda-approval-for-terlivaz-terlipressin-for-injection-for-the-treatment-of-hepatorenal-syndrome 2022-09-15T08:32:40 https://maestrodatabase.com/blog/molmed-receives-positive-chmp-opinion-recommending-conditional-marketing-authorisation-for-zalmoxis-the-first-immunogene-therapy-to-treat-high-risk-haematological-malignancies-in-patients-receiving-haplo-identical-haematopoietic-stem-cell-transplantation 2016-06-26T02:01:24 https://maestrodatabase.com/blog/pharma-groups-combine-to-promote-drug-discovery-with-ai 2019-06-05T21:53:57 https://maestrodatabase.com/blog/ema-weighs-covid-19-data-transparency-not-ready-to-resume-full-clinical-data-publication 2020-06-03T07:32:00 https://maestrodatabase.com/blog/generic-medicine-prices-to-drop-by-up-to-1-under-budget-savings-measure-that-helps-consumers 2015-08-05T11:37:25 https://maestrodatabase.com/blog/nhs-publishes-update-on-the-use-of-biosimilars 2019-06-05T21:23:07 https://maestrodatabase.com/blog/moderna-produces-its-first-canadian-mrna-vaccines-in-its-new-state-of-the-art-quebec-facility 2025-09-21T03:34:09 https://maestrodatabase.com/blog/sanaria-pfspz-vaccine-against-malaria-receives-fda-fast-track-designation 2016-09-22T20:41:57 https://maestrodatabase.com/blog/south-korea-approves-emergency-use-of-gileads-anti-viral-drug-to-treat-covid-19 2020-06-03T08:41:36 https://maestrodatabase.com/blog/nice-publishes-appraisal-consultation-for-crizotinib-xalkori-for-patients-with-non-small-cell-lung-cancer 2016-06-03T23:57:39 https://maestrodatabase.com/blog/fda-official-hints-at-a-tough-road-ahead-for-right-to-try 2018-11-15T17:32:19 https://maestrodatabase.com/blog/az-pulls-lynparzas-application-for-cdf-funding 2015-08-05T11:37:22 https://maestrodatabase.com/blog/eisai-submits-marketing-approval-applications-for-anticancer-agent-lenvatinib-simultaneously-in-europe-and-us 2015-08-05T11:37:23 https://maestrodatabase.com/blog/icer-to-assess-treatment-for-secondary-progressive-multiple-sclerosis 2024-11-28T06:45:35 https://maestrodatabase.com/blog/brand-name-drug-makers-wary-of-letting-generic-rival-join-their-club 2016-07-04T08:41:20 https://maestrodatabase.com/blog/tga-cost-recovery-implementation-statement-2016-17 2016-07-18T07:50:13 https://maestrodatabase.com/blog/china-to-set-the-bar-high-for-new-health-technologies 2018-11-15T17:25:06 https://maestrodatabase.com/blog/anoro_ellipta_approved_for_copd_treatment_in_canada 2015-08-05T11:37:29 https://maestrodatabase.com/blog/97-per-cent-of-aussies-want-new-cancer-medicines-subsidised-through-pbs 2015-08-05T11:37:19 https://maestrodatabase.com/blog/german-health-minister-calls-for-faster-adoption-of-biosimilar-drugs 2018-11-15T17:28:59 https://maestrodatabase.com/blog/nice-publishes-final-guidance-recommending-ataluren-for-children-with-duchenne-muscular-dystrophy-1 2016-07-20T13:04:32 https://maestrodatabase.com/blog/cadth-is-now-accepting-applications-for-scientific-advice 2015-08-05T11:37:12 https://maestrodatabase.com/blog/how-to-decrease-prices-for-an-expensive-class-of-drugs 2015-11-16T19:49:24 https://maestrodatabase.com/blog/outcomes-of-the-may-2023-pbac-intracycle-meeting 2023-06-16T06:07:44 https://maestrodatabase.com/blog/first-treatment-recommended-for-rare-immunoglobulin-related-autoimmune-disease 2025-09-21T00:08:50 https://maestrodatabase.com/blog/ema-publishes-monthly-statistics 2016-06-23T21:38:37 https://maestrodatabase.com/blog/guild-asks-pbac-to-review-pbs-de-listings 2016-01-01T00:13:39 https://maestrodatabase.com/blog/fda-grants-breakthrough-therapy-designation-to-adcetris-brentuximab-vedotin-for-frontline-peripheral-t-cell-lymphomas 2018-11-16T07:45:16 https://maestrodatabase.com/blog/hahn-fda-will-make-some-changes-amid-covid-19-permanent 2020-06-03T09:07:58 https://maestrodatabase.com/blog/big-pharma-vs-big-pharma-in-court-battles-over-biosimilar-drugs 2016-10-04T00:07:25 https://maestrodatabase.com/blog/tga-publishes-2-new-auspars 2016-04-12T07:49:00 https://maestrodatabase.com/blog/in-michigan-medicaid-can-now-pay-for-drugs-based-on-how-well-they-work 2018-11-15T17:34:22 https://maestrodatabase.com/blog/european-commission-approves-ipsens-cabometyx-cabozantinib-for-the-treatment-of-hepatocellular-carcinoma-in-adults-previously-treated-with-sorafenib 2018-11-16T07:39:52 https://maestrodatabase.com/blog/last-call-for-commenting-on-biological-qualifier-an-inn-proposal 2015-08-05T11:37:23 https://maestrodatabase.com/blog/otsuka-and-lundbeck-receive-complete-response-letter-from-us-fda-for-snda-of-rexulti-brexpiprazole-in-combination-with-sertraline-for-the-treatment-of-adults-with-post-traumatic-stress-disorder 2025-09-21T01:11:13 https://maestrodatabase.com/blog/nice-recommends-infliximab-biosimilars-ahead-of-remicade 2015-08-05T11:37:03 https://maestrodatabase.com/blog/jasper-therapeutics-announces-fda-fast-track-designation-for-jsp191-a-novel-monoclonal-antibody-targeting-cd117-in-the-treatment-of-patients-with-severe-combined-immunodeficiency-undergoing-allogeneic-haematopoietic-stem-cell-transplantation 2022-09-15T12:15:25 https://maestrodatabase.com/blog/us-fda-accepts-otsuka-and-lundbecks-filing-for-review-of-brexpiprazole-for-the-treatment-of-schizophrenia-and-as-adjunctive-therapy-for-the-treatment-of-major-depression 2015-08-05T11:37:29 https://maestrodatabase.com/blog/fda-grants-priority-review-for-amgens-supplemental-new-drug-application-for-expanded-labeling-of-kyprolis-carfilzomib-in-relapsed-multiple-myeloma 2015-09-21T12:58:07 https://maestrodatabase.com/blog/fda-issues-final-rule-on-right-to-try-reporting-requirements 2022-09-15T10:40:42 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-june-2015-update 2015-08-05T11:37:11 https://maestrodatabase.com/blog/the-cdc-waited-its-entire-existence-for-this-moment-what-went-wrong 2020-06-03T08:47:25 https://maestrodatabase.com/blog/big-pharma-shuffles-the-tax-pill 2015-08-05T11:37:25 https://maestrodatabase.com/blog/xiapex-approved-by-the-eu-commission-for-the-treatment-of-peyronies-disease 2015-08-05T11:37:23 https://maestrodatabase.com/blog/zoloft-falls-into-shortage-as-virus-anxiety-strains-supplies 2020-06-03T08:50:55 https://maestrodatabase.com/blog/united-states-health-care-reform-progress-to-date-and-next-steps 2016-07-12T08:23:26 https://maestrodatabase.com/blog/fdas-drug-industry-fees-fuel-concerns-over-influence 2022-09-15T10:33:13 https://maestrodatabase.com/blog/idorsias-jeraygo-aprocitentan-approved-in-switzerland-for-the-treatment-of-resistant-hypertension 2025-09-21T02:01:30 https://maestrodatabase.com/blog/fda-approves-amgens-xgeva-denosumab-for-the-treatment-of-hypercalcemia-of-malignancy-refractory-to-bisphosphonate-therapy 2015-08-05T11:37:05 https://maestrodatabase.com/blog/biosimilar-awareness-initiative-literature-review-and-project-plan 2016-09-30T05:23:09 https://maestrodatabase.com/blog/actavis-receives-approval-from-the-european-commission-for-xydalba-dalbavancin 2015-08-05T11:37:15 https://maestrodatabase.com/blog/tga-devices-sponsor-information-day-2015 2015-09-17T05:31:08 https://maestrodatabase.com/blog/integrating-patients-views-in-clinical-studies-of-anti-cancer-medicines 2016-04-22T12:32:52 https://maestrodatabase.com/blog/ariad-completes-rolling-submission-of-new-drug-application-for-brigatinib-to-the-us-food-and-drug-administration 2016-09-01T05:16:55 https://maestrodatabase.com/blog/law-makers-government-watchdog-blast-fda-for-poor-oversight-of-u-dot-s-drug-supply-chain 2020-06-03T10:28:51 https://maestrodatabase.com/blog/nice-draft-guidance-recommends-eculizumab-soliris-for-treating-very-rare-life-threatening-blood-disorder 2015-08-05T11:37:29 https://maestrodatabase.com/blog/genzymes-lemtrada-approved-by-the-fda 2015-08-05T11:37:04 https://maestrodatabase.com/blog/nhs-england-push-to-rein-in-cancer-drug-prices 2015-08-05T11:37:06 https://maestrodatabase.com/blog/advicenne-updates-on-availability-of-sibnayal-to-patients-and-caregivers-in-great-britain 2022-09-15T20:44:05 https://maestrodatabase.com/blog/determining-value-and-price-in-health-care 2016-07-14T21:12:57 https://maestrodatabase.com/blog/ptc-therapeutics-begins-rolling-nda-submission-to-the-fda-for-translarna-to-treat-duchenne-muscular-dystrophy 2015-08-05T11:37:22 https://maestrodatabase.com/blog/medicare-and-other-government-payments-to-be-privatised 2016-02-09T19:48:58 https://maestrodatabase.com/blog/mylan-taking-immediate-action-to-further-enhance-access-to-epipen-epinephrine-injection-usp-auto-injector 2016-08-25T12:03:20 https://maestrodatabase.com/blog/opsens-announces-fda-clearance-for-the-savvywire-for-use-in-transcatheter-aortic-valve-replacement-procedures 2022-09-15T20:33:22 https://maestrodatabase.com/blog/pharmac-approves-largest-single-deal 2015-08-05T11:37:26 https://maestrodatabase.com/blog/what-constitutes-a-new-medicine 2016-07-25T21:59:35 https://maestrodatabase.com/blog/pfizers-investigational-vaccine-candidate-for-clostridium-difficile-receives-us-food-and-drug-administration-fast-track-designation 2015-08-05T11:37:29 https://maestrodatabase.com/blog/aro-biotherapeutics-receives-fda-rare-paediatric-drug-designation-for-abx1100-for-the-treatment-of-pompe-disease 2022-09-15T20:26:06 https://maestrodatabase.com/blog/biosimilar-infliximab-on-the-pbs-information-for-health-professionals-and-patients 2015-12-01T09:00:04 https://maestrodatabase.com/blog/iroko-pharmaceuticals-announces-acceptance-of-us-filing-for-solumatrix-meloxicam-in-osteoarthritis-pain 2015-08-05T11:37:19 https://maestrodatabase.com/blog/health-canada-issues-notice-of-compliance-for-gileads-harvoni-ledipasvirsofosbuvir-the-first-once-daily-single-tablet-regimen-for-the-treatment-of-genotype-1-chronic-hepatitis-c 2015-08-05T11:37:12 https://maestrodatabase.com/blog/why-the-drug-development-pipeline-is-not-delivering-better-medicines 2015-10-29T09:01:30 https://maestrodatabase.com/blog/public-summary-documents-march-2016-pbac-meeting 2016-07-01T07:29:13 https://maestrodatabase.com/blog/real-urgent-plight-for-melanoma-patients-hoping-for-better-keytruda-funding 2016-03-07T02:00:38 https://maestrodatabase.com/blog/european-commission-approves-rezolsta-a-new-once-daily-fixed-dose-hiv-therapy-combining-darunavir-and-cobicistat 2015-08-05T11:37:22 https://maestrodatabase.com/blog/the-miracle-cure-with-a-billion-dollar-price-tag 2015-08-05T11:37:25 https://maestrodatabase.com/blog/new-treatment-for-breast-cancer 2016-09-17T01:52:38 https://maestrodatabase.com/blog/health-canada-approves-plegridy-peginterferon-beta-1a-for-adults-with-relapsing-remitting-multiple-sclerosis 2015-08-15T11:27:18 https://maestrodatabase.com/blog/amgens-first-biosimilar-biologics-license-application-for-abp-501-submitted-to-us-fda 2015-11-26T03:54:23 https://maestrodatabase.com/blog/fda-accepts-and-grants-priority-review-for-avycaz-ceftazidime-and-avibactam-supplemental-new-drug-application 2016-02-24T21:01:02 https://maestrodatabase.com/blog/fda-approves-treatment-to-improve-kidney-function-in-adults-with-hepatorenal-syndrome 2022-09-15T21:48:51 https://maestrodatabase.com/blog/pfizer-announces-fda-acceptance-of-and-priority-review-designation-for-biologics-license-application-for-investigational-meningococcal-b-vaccine 2015-08-05T11:37:19 https://maestrodatabase.com/blog/proposal-for-sole-supply-of-erythropoietin 2015-08-05T11:37:21 https://maestrodatabase.com/blog/can-the-proposed-listing-of-two-medicines-from-the-same-supplier-really-be-called-a-bundle-deal 2022-09-15T20:57:17 https://maestrodatabase.com/blog/the-primary-outcome-fails-what-next 2016-09-01T05:02:42 https://maestrodatabase.com/blog/pharmac_seeking_public_views_on_proposed_new_decision_criteria 2015-08-05T11:37:11 https://maestrodatabase.com/blog/bayer-receives-fda-approval-for-kovaltry-for-the-treatment-of-children-and-adults-with-haemophilia-a 2016-03-17T20:56:12 https://maestrodatabase.com/blog/agenda-for-june-2016-chmp-meeting 2016-06-20T21:07:47 https://maestrodatabase.com/blog/ignoring-drug-costs-risks-nhs-crash-nice-warns 2015-08-05T11:37:14 https://maestrodatabase.com/blog/watchdog_rejects__societal_benefit__test_on_nhs_medicines 2015-08-05T11:37:29 https://maestrodatabase.com/blog/cancer_doctors_say_drugs_system_is_unfit_for_purpose 2015-08-05T11:37:17 https://maestrodatabase.com/blog/new-judicial-decisions-at-odds-with-emas-efforts-to-allow-access-to-documents-on-medicines 2016-09-29T21:00:20 https://maestrodatabase.com/blog/cancer-drugs-fund-should-be-managed-better-say-mps 2016-02-05T08:11:05 https://maestrodatabase.com/blog/imprimis-pharmaceuticals-to-make-compounded-and-customisable-formulation-of-pyrimethamine-and-leucovorin-available-for-physicians-to-prescribe-for-their-patients-as-an-alternative-to-daraprim 2015-10-22T19:44:44 https://maestrodatabase.com/blog/two-new-medicines-for-advanced-kidney-cancer 2016-07-22T12:42:13 https://maestrodatabase.com/blog/us-food-and-drug-administration-approves-orkambi-lumacaftorivacaftor-for-use-in-children-with-cystic-fibrosis-ages-6-through-11-who-have-two-copies-of-the-f508del-mutation 2016-09-29T05:03:33 https://maestrodatabase.com/blog/us-fda-approves-belbuca-buprenorphine-buccal-film-for-chronic-pain-management 2015-10-26T20:11:42 https://maestrodatabase.com/blog/fda-approves-first-generic-crestor 2016-05-01T01:11:08 https://maestrodatabase.com/blog/nice_recommends_new_treatment_option_for_multiple_sclerosis 2015-08-05T11:37:27 https://maestrodatabase.com/blog/nhs-increases-budget-for-cancer-drugs-fund-from-280-million-in-201415-to-an-expected-340-million-in-201516 2015-08-05T11:37:13 https://maestrodatabase.com/blog/fda-approves-aloxi-palonosetron-hydrochloride-to-prevent-nausea-and-vomiting-due-to-chemotherapy-in-children-as-young-as-1-month 2015-08-05T11:37:04 https://maestrodatabase.com/blog/outrage-at-nhs-cancer-drugs-move 2015-08-05T11:37:10 https://maestrodatabase.com/blog/nice_responds_to_article_in_the_times 2015-08-05T11:37:30 https://maestrodatabase.com/blog/fda-expands-approved-use-of-cyramza-to-treat-aggressive-non-small-cell-lung-cancer 2015-08-05T11:37:09 https://maestrodatabase.com/blog/merck-co-discounts-remicade-by-25-in-uk-to-fend-off-rivals 2015-10-23T10:09:25 https://maestrodatabase.com/blog/viagra-slows-the-spread-of-malaria-study-finds 2015-08-05T11:37:21 https://maestrodatabase.com/blog/government-looks-to-health-department-for-savings 2015-08-05T11:37:08 https://maestrodatabase.com/blog/fda-expands-approval-of-drug-to-treat-pompe-disease-to-patients-of-all-ages-removes-risk-mitigation-strategy-requirements 2015-08-05T11:37:12 https://maestrodatabase.com/blog/new-tga-business-services-site---launching-next-week 2015-08-05T11:37:26 https://maestrodatabase.com/blog/medicines-australia-wants-new-154-billion-pharmacy-agreement-to-be-value-for-money 2015-08-05T11:37:13 https://maestrodatabase.com/blog/cancer-drugs-provide-positive-value-in-nine-countries-but-the-united-states-lags-in-health-gains-per-dollar-spent 2016-05-03T21:47:04 https://maestrodatabase.com/blog/how-an-84000-drug-got-its-price-lets-hold-our-position-whatever-the-headlines 2015-12-02T19:44:46 https://maestrodatabase.com/blog/coherus-biosciences-submits-351k-biologics-license-application-to-us-food-and-drug-administration-for-chs-1701-pegfilgrastim-biosimilar-candidate 2016-08-10T05:38:51 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-july-2015-update 2015-08-05T11:37:23 https://maestrodatabase.com/blog/nice_consults_on_belimumab__benlysta__for_patients_with_systemic_lupus_erythematosus 2015-08-05T11:37:22 https://maestrodatabase.com/blog/fda-approves-keytruda-for-advanced-non-small-cell-lung-cancer 2015-10-03T11:57:54 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule-1-october-2016-update 2016-10-02T20:36:04 https://maestrodatabase.com/blog/replimune-receives-breakthrough-therapy-designation-for-rp1-and-submits-rp1-biologics-license-application-to-the-fda-under-the-accelerated-approval-pathway 2024-11-29T11:17:05 https://maestrodatabase.com/blog/agenda-for-the-11-may-2016-tc-meeting 2016-05-05T09:28:21 https://maestrodatabase.com/blog/fda-approves-mercks-keytruda-pembrolizumab-for-patients-with-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma-with-disease-progression-on-or-after-platinum-containing-chemotherapy 2017-06-04T00:40:00 https://maestrodatabase.com/blog/gsk-receives-chmp-positive-opinion-to-expand-indication-for-volibris-in-pulmonary-arterial-hypertension 2015-10-26T19:59:55 https://maestrodatabase.com/blog/medicines-information-factsheet-developed-for-patients-and-the-public 2016-06-14T12:46:37 https://maestrodatabase.com/blog/novartis-receives-positive-chmp-opinion-to-expand-kisqali-combination-therapy-to-all-women-with-hr-plus-slash-her2--locally-advanced-or-metastatic-breast-cancer 2018-11-16T16:57:33 https://maestrodatabase.com/blog/fda-approves-first-line-treatment-for-peripheral-t-cell-lymphoma-under-new-review-pilot 2018-11-16T17:04:28 https://maestrodatabase.com/blog/funding_for_new_drug_to_treat_rare_bleeding_condition 2015-08-05T11:37:04 https://maestrodatabase.com/blog/scotland-rejects-celgene-myeloma-drug-imnovid 2015-08-05T11:37:05 https://maestrodatabase.com/blog/the-cancer-drugs-fund 2016-06-08T11:14:02 https://maestrodatabase.com/blog/what-can-we-expect-from-value-based-funding-of-medicines-a-retrospective-study 2016-03-22T05:49:37 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-august-2015-update 2015-08-05T11:37:30 https://maestrodatabase.com/blog/pharmacy-guild-wins-28b-at-the-cost-of-drug-makers 2015-08-05T11:37:23 https://maestrodatabase.com/blog/german-insurers-win-discounts-on-gileads-sovaldi 2015-08-05T11:37:20 https://maestrodatabase.com/blog/biosimilar-awareness-initiative-reference-group-communique 2016-09-20T06:21:56 https://maestrodatabase.com/blog/gsk-announces-extension-of-fda-review-period-for-momelotinib 2023-06-16T09:12:52 https://maestrodatabase.com/blog/nice-recommends-combined-drug-therapy-proven-to-extend-life-for-skin-cancer 2016-04-29T13:21:17 https://maestrodatabase.com/blog/john-key-hints-at-funding-boost-for-melanoma-drug-keytruda 2015-12-07T19:10:06 https://maestrodatabase.com/blog/icer-issues-final-report-on-long-term-prophylaxis-for-hereditary-angioedema-provides-policy-recommendations-to-improve-cost-effectiveness 2018-11-16T17:12:16 https://maestrodatabase.com/blog/nice_citizens_council_to_discuss_what_influences_how_health_and_social_care_resources_are_shared_out 2015-08-05T11:37:29 https://maestrodatabase.com/blog/eu-green-light-for-lillys-cyramza 2015-08-05T11:37:30 https://maestrodatabase.com/blog/government_congratulated_on_new_cabinet_threshold 2015-08-05T11:37:17 https://maestrodatabase.com/blog/nice-reviews-guidance-to-ensure-ovarian-cancer-patients-benefit-from-the-best-treatments 2015-08-05T11:37:03 https://maestrodatabase.com/blog/nice-recommends-cutting-edge-therapy-for-young-people-with-blood-cancer 2018-11-16T17:07:18 https://maestrodatabase.com/blog/decline_in_placebo_controlled_trial_results_suggests_new_directions_for_comparative_effectiveness_research 2015-08-05T11:37:10 https://maestrodatabase.com/blog/us-fda-approves-prevnar-20-pfizers-pneumococcal-20-valent-conjugate-vaccine-for-adults-ages-18-years-or-older 2021-06-09T00:29:26 https://maestrodatabase.com/blog/abpi-responds-to-labours-plan-to-create-cancer-treatment-fund 2015-08-05T11:37:06 https://maestrodatabase.com/blog/france_s_transparency_commission_issues_positive_opinion_for_reimbursement_of_jetrea__ocriplasmin_ 2015-08-05T11:37:30 https://maestrodatabase.com/blog/european-medicines-agency-agrees-policy-on-publication-of-clinical-trial-data-with-more-user-friendly-amendments 2015-08-05T11:37:23 https://maestrodatabase.com/blog/jadelle-levonorgestrel-2-x-75-mg-rods-funding-proposal-approved 2015-08-05T11:37:24 https://maestrodatabase.com/blog/u-dot-s-food-and-drug-administration-approves-addition-of-positive-data-from-phase-3-valor-hcm-study-to-camzyos-mavacamten-label 2023-06-16T22:37:06 https://maestrodatabase.com/blog/bill-shortens-1b-promise-to-keep-medicine-costs-down 2016-05-21T18:10:47 https://maestrodatabase.com/blog/crizotinib-in-cancer-new-data-inconclusive 2016-10-04T20:37:05 https://maestrodatabase.com/blog/health-insurance-marketplace-open-enrollment-snapshot 2015-11-16T20:50:28 https://maestrodatabase.com/blog/statement-by-fda-commissioner-scott-gottlieb-on-the-fdas-efforts-to-hold-industry-accountable-for-fulfilling-critical-post-marketing-studies-of-the-benefits-safety-of-new-drugs 2018-11-16T20:49:14 https://maestrodatabase.com/blog/womans-death-during-drug-trial-questioned 2015-08-05T11:37:30 https://maestrodatabase.com/blog/all-about-the-base 2016-06-27T22:11:48 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-zanidatamab-hrii-for-previously-treated-unresectable-or-metastatic-her2-positive-biliary-tract-cancer 2024-11-29T21:54:27 https://maestrodatabase.com/blog/record-number-of-medicines-for-rare-diseases-recommended-for-approval-in-2014 2015-08-05T11:37:11 https://maestrodatabase.com/blog/first-long-acting-drug-for-haemophilia-a-approved-by-therapeutic-goods-administration 2015-08-05T11:37:03 https://maestrodatabase.com/blog/health_canada_approves_humira__adalimumab__for_the_treatment_of_ulcerative_colitis 2015-08-05T11:37:24 https://maestrodatabase.com/blog/chugai-files-new-drug-application-in-japan-for-crovalimab-for-paroxysmal-nocturnal-hemoglobinuria 2023-06-16T12:24:05 https://maestrodatabase.com/blog/new_york_times___the_outrageous_cost_of_a_gene_test_in_the_us 2015-08-05T11:37:06 https://maestrodatabase.com/blog/fycompa__perampanel__to_be_resubmitted_early_to_german_federal_joint_committee__g_ba__for_additional_benefit_assessment 2015-08-05T11:37:30 https://maestrodatabase.com/blog/gilead-receives-approval-in-canada-for-epclusa-sofosbuvirvelpatasvir-the-first-once-daily-pan-genotypic-genotypes-1-6-single-tablet-regimen-for-the-treatment-of-chronic-hepatitis-c 2016-07-15T05:35:11 https://maestrodatabase.com/blog/pharmacs-implementation-of-trans-pacific-partnership-tpp-provisions-and-other-amendments-to-application-processes 2016-09-05T04:09:22 https://maestrodatabase.com/blog/amicus-therapeutics-announces-united-kingdoms-mhra-grants-early-access-to-at-gaa 2021-06-09T01:16:18 https://maestrodatabase.com/blog/spectrum-pharmaceuticals-announces-fdas-acceptance-of-nda-filing-for-eoquin-apaziquone-for-intravesical-instillation 2016-02-22T05:49:47 https://maestrodatabase.com/blog/glaukos-announces-australias-tga-regulatory-approval-for-preserflo-microshunt 2021-06-09T00:48:05 https://maestrodatabase.com/blog/allergan-receives-fda-approval-for-ozurdex-dexamethasone-intravitreal-implant-07-mg-as-treatment-option-for-diabetic-macular-oedema-in-certain-patients 2015-08-05T11:37:12 https://maestrodatabase.com/blog/bristol-myers-hepatitis-c-drug-to-lose-special-status-from-fda 2015-08-05T11:37:23 https://maestrodatabase.com/blog/update-from-the-pbac-november-2024 2024-11-29T22:19:19 https://maestrodatabase.com/blog/early_access_to_medicines_scheme__eams_ 2015-08-05T11:37:29 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule-1-march-2016-update 2016-03-01T04:06:56 https://maestrodatabase.com/blog/prescription-medicines-pre-submission-pilot 2016-06-29T04:26:43 https://maestrodatabase.com/blog/vortioxetine-hydrobromide-in-depression-iqwig-finds-no-hint-of-an-additional-benefit 2015-08-11T12:58:40 https://maestrodatabase.com/blog/valuing-trial-designs-from-a-pharmaceutical-perspective-using-value-based-pricing 2015-10-07T09:45:45 https://maestrodatabase.com/blog/vivus-and-auxilium-announce-fda-approval-of-stendra-snda-stendra-now-first-and-only-oral-erectile-dysfunction-treatment-approved-to-be-taken-approximately-15-minutes-before-sexual-activity 2015-08-05T11:37:23 https://maestrodatabase.com/blog/fda-approves-new-drug-to-treat-travelers-diarrhoea 2018-11-17T06:31:43 https://maestrodatabase.com/blog/economist-visits-new-zealand-to-present-ground-breaking-cancer-research 2016-08-21T21:42:40 https://maestrodatabase.com/blog/fda-approves-first-drug-to-treat-hallucinations-and-delusions-associated-with-parkinsons-disease 2016-05-01T01:18:11 https://maestrodatabase.com/blog/slashed-drug-prices-could-mean-hundreds-more-for-families-every-year-even-beyond-the-pbs 2015-08-05T11:37:09 https://maestrodatabase.com/blog/valuing-the-benefits-of-new-anticancer-drugs 2016-06-20T01:19:16 https://maestrodatabase.com/blog/invokana-set-for-nice-recommendation 2015-08-05T11:37:02 https://maestrodatabase.com/blog/us-senators-probe-five-drug-makers-on-price-of-overdose-antidote 2016-06-07T21:05:33 https://maestrodatabase.com/blog/how-a-us-uk-trade-agreement-could-affect-nhs-drug-prices 2020-06-03T20:56:51 https://maestrodatabase.com/blog/sanofi-and-renegeron-announce-fda-approval-of-praluent-alirocumab-injection-the-first-pcsk9-inhibitor-in-the-us-for-the-treatment-of-high-ldl-cholesterol-in-adult-patients 2015-08-05T11:37:24 https://maestrodatabase.com/blog/antimicrobial-approvals-are-not-bottlenecked-by-fda 2020-06-03T21:00:29 https://maestrodatabase.com/blog/new-browse-by-facet-option-for-maestro-new-zealand 2015-08-05T11:37:21 https://maestrodatabase.com/blog/fda-approves-bridion-to-reverse-effects-of-neuromuscular-blocking-drugs-used-during-surgery 2015-12-15T21:17:53 https://maestrodatabase.com/blog/regorafenib-in-metastatic-colorectal-cancer-still-only-a-hint-of-a-minor-additional-benefit 2016-01-14T01:23:00 https://maestrodatabase.com/blog/biosimilars-guidances 2015-08-05T11:37:26 https://maestrodatabase.com/blog/pharmac-decision-to-list-epoprostenol-injection 2015-08-13T01:35:40 https://maestrodatabase.com/blog/cuts-to-cancer-treatments-announced 2015-08-05T11:37:22 https://maestrodatabase.com/blog/hikmas-anda-for-generic-advair-diskus-accepted-for-filing-by-fda 2016-04-08T08:04:34 https://maestrodatabase.com/blog/fda-approves-new-psoriasis-drug-cosentyx 2015-08-05T11:37:20 https://maestrodatabase.com/blog/xenoscope-the-revolutionary-cost-effective-laparoscope-wins-fda-fast-track-clearance 2016-10-05T20:24:25 https://maestrodatabase.com/blog/european-medicines-agency-accepts-basileas-isavuconazole-marketing-authorization-application-for-review 2015-08-05T11:37:14 https://maestrodatabase.com/blog/fda-approves-novartis-drug-promacta-for-first-line-saa-and-grants-breakthrough-therapy-designation-for-additional-new-indication 2018-11-17T06:43:37 https://maestrodatabase.com/blog/pharmac-to-fund-more-cancer-medicines-march-2025 2025-03-12T22:32:35 https://maestrodatabase.com/blog/originator-list-for-pbs-medicines-on-f2-formulary-stakeholder-consultation 2015-08-09T12:18:16 https://maestrodatabase.com/blog/first-vaccine-approved-by-fda-to-prevent-serogroup-b-meningococcal-disease 2015-08-05T11:37:05 https://maestrodatabase.com/blog/novartis-can-sell-copycat-of-amgens-neupogen-in-september-court-rules 2015-08-05T11:37:23 https://maestrodatabase.com/blog/brivaracetam-in-epilepsy-additional-benefits-not-seen 2016-05-17T21:27:44 https://maestrodatabase.com/blog/decision_to_award_sole_supply_to_imatinib_aft_for_indications_other_than_gastro_intestinal_stromal_tumours 2015-08-05T11:37:29 https://maestrodatabase.com/blog/paying-for-value-from-costly-medical-technologies-a-framework-for-applying-value-based-payment-reforms 2020-06-03T21:28:41 https://maestrodatabase.com/blog/nhs-england-hands-over-cancer-drugs-fund-remit-to-nice 2015-08-05T11:37:22 https://maestrodatabase.com/blog/clovis-oncology-receives-breakthrough-therapy-designation-for-rucaparib-for-monotherapy-treatment-of-advanced-ovarian-cancer-in-patients-with-brca-mutated-tumours-inclusive-of-both-germline-and-somatic-brca-mutations 2015-08-05T11:37:18 https://maestrodatabase.com/blog/cell_therapeutics_and_gkv_sv_reach_agreement_on_pricing_of_pixuvri__pixantrone__in_germany 2015-08-05T11:37:02 https://maestrodatabase.com/blog/bha-abpi-welcome-uks-eu-withdrawal-agreement 2018-11-17T07:02:24 https://maestrodatabase.com/blog/revised-category-1-requirements-for-new-combination-products-that-are-eligible-for-a-tailored-cdr-review 2015-08-05T11:37:30 https://maestrodatabase.com/blog/the-fda-should-not-rush-a-covid-19-vaccine 2020-06-03T21:34:10 https://maestrodatabase.com/blog/us-fda-approves-additional-indication-for-eisais-anti-cancer-agent-lenvima-in-combination-with-everolimus-as-treatment-for-advanced-renal-cell-carcinoma 2016-05-16T06:13:06 https://maestrodatabase.com/blog/fda-approves-afrezza-to-treat-diabetes 2015-08-05T11:37:16 https://maestrodatabase.com/blog/fda-approves-amgens-amjevita-adalimumab-atto-for-treatment-of-seven-inflammatory-diseases 2016-09-24T02:57:21 https://maestrodatabase.com/blog/pfizer-to-raise-prices-on-41-prescription-drugs-next-year-despite-pressure-from-trump 2018-11-17T06:51:13 https://maestrodatabase.com/blog/cadth-publishes-final-recommendation-for-crysvita 2020-06-03T21:37:24 https://maestrodatabase.com/blog/final-nice-green-light-for-takedas-entyvio 2015-08-26T20:34:39 https://maestrodatabase.com/blog/poll-finds-backing-for-cancer-drug-subsidies 2015-08-05T11:37:26 https://maestrodatabase.com/blog/why-cancer-can-cost-more-the-rarer-it-is 2016-06-15T09:50:13 https://maestrodatabase.com/blog/extra-transparency-measures-for-covid-19-vaccines-and-therapeutics 2020-10-31T00:01:30 https://maestrodatabase.com/blog/narcolepsy-treatment-recommended-for-approval 2015-11-21T05:29:48 https://maestrodatabase.com/blog/clarity-pharmaceuticals-announces-that-the-us-fda-grants-rare-paediatric-disease-designation-to-copper-cu-67-sartate-for-the-treatment-of-neuroblastoma 2020-06-03T21:08:49 https://maestrodatabase.com/blog/meeting-highlights-from-the-chmp-29-march-1-april-2016 2016-04-02T00:03:58 https://maestrodatabase.com/blog/tga-publishes-auspar-for-asfotase-alfa-strensiq 2016-07-05T22:05:29 https://maestrodatabase.com/blog/highlights-from-chmp-12-15-november-2018-meeting 2018-11-17T07:04:54 https://maestrodatabase.com/blog/ema-management-board-highlights-of-october-2015-meeting 2015-10-06T11:13:59 https://maestrodatabase.com/blog/janssen-receives-positive-chmp-opinion-for-erleada-apalutamide-for-patients-with-non-metastatic-castration-resistant-prostate-cancer-who-are-at-high-risk-of-developing-metastatic-disease 2018-11-17T07:08:57 https://maestrodatabase.com/blog/nice-publishes-final-drug-recommendations-for-the-treatment-of-four-separate-medical-conditions 2015-11-25T20:40:57 https://maestrodatabase.com/blog/covid-19-and-the-us-health-insurance-conundrum 2020-06-03T21:24:09 https://maestrodatabase.com/blog/good-news-for-allergy-sufferers-dymista-is-approved-by-health-canada-for-the-treatment-of-seasonal-allergic-rhinitis 2015-10-23T10:16:32 https://maestrodatabase.com/blog/dusc-public-release-documents-june-2015-meeting 2015-10-30T20:43:53 https://maestrodatabase.com/blog/government-to-continue-inborn-error-of-metabolism-programme 2015-08-05T11:37:04 https://maestrodatabase.com/blog/call-for-patient-input-26 2015-08-05T11:37:13 https://maestrodatabase.com/blog/genmab-announces-u-dot-s-fda-approval-of-arzerra-ofatumumab-in-combination-with-fludarabine-and-cyclophosphamide-for-relapsed-cll 2016-09-01T05:05:26 https://maestrodatabase.com/blog/nhs-england-ptc-reach-agreement-on-duchenne-drug 2016-07-08T23:32:16 https://maestrodatabase.com/blog/xtandi-enzalutamide-now-approved-europe-for-the-treatment-of-men-with-metastatic-castration-resistant-prostate-cancer-who-are-chemotherapy-naive 2015-08-05T11:37:16 https://maestrodatabase.com/blog/raptors-procysbi-new-drug-submission-accepted-by-health-canada-with-priority-review 2016-03-22T06:15:45 https://maestrodatabase.com/blog/jama___advances_in_regulatory_science_at_the_us_fda 2015-08-05T11:37:18 https://maestrodatabase.com/blog/amgen-submits-supplemental-new-drug-application-for-kyprolis-carfilzomib-in-relapsed-multiple-myeloma 2015-08-05T11:37:21 https://maestrodatabase.com/blog/regulation-of-advanced-therapy-medicines 2016-06-03T22:01:23 https://maestrodatabase.com/blog/lower-prices-and-greater-patient-access----lessons-from-germanys-drug-purchasing-structure 2020-06-03T21:45:20 https://maestrodatabase.com/blog/charity-calls-on-nice-to-reverse-rejection-of-amgens-pcsk9-inhibitor 2015-12-07T11:28:57 https://maestrodatabase.com/blog/fda-approves-new-drug-to-treat-heart-failure 2015-08-05T11:37:16 https://maestrodatabase.com/blog/agenda-for-the-22-july-2015-tc-meeting-1 2015-09-10T09:48:52 https://maestrodatabase.com/blog/nice_rules_that_afinitor_is_not_cost_effective_in_patients_with_breast_cancer 2015-08-05T11:37:14 https://maestrodatabase.com/blog/gsk-announces-eu-regulatory-submission-seeking-additional-indication-for-eltrombopag-revolade 2015-08-05T11:37:13 https://maestrodatabase.com/blog/fda-approves-new-treatment-for-chronic-hepatitis-c-genotype-3-infections 2015-08-05T11:37:27 https://maestrodatabase.com/blog/non-profit-seeks-to-dispel-myths-about-how-it-assesses-drug-values 2016-08-12T23:10:04 https://maestrodatabase.com/blog/tga-approves-truvada-for-prep-next-put-it-on-the-pbs-say-hiv-advocates 2016-05-09T13:24:26 https://maestrodatabase.com/blog/changes-to-certain-s100-programs 2015-08-05T11:37:30 https://maestrodatabase.com/blog/nice-u-turn-as-entyvio-is-backed-for-crohns 2015-08-05T11:37:29 https://maestrodatabase.com/blog/uniteds-withdrawal-from-exchanges-much-ado-about-the-wrong-things 2016-06-22T21:51:17 https://maestrodatabase.com/blog/agenda-for-the-5-october-2016-tc-meeting 2016-09-28T21:11:10 https://maestrodatabase.com/blog/zytiga__abiraterone_acetate__now_available_for_men_with_metastatic_prostate_cancer_in_british_columbia_prior_to_chemotherapy 2015-08-05T11:37:13 https://maestrodatabase.com/blog/european-commission-approves-surgical-patch-tachosil-human-thrombinhuman-fibrogen-for-use-in-neurological-surgery 2016-04-28T13:02:14 https://maestrodatabase.com/blog/rfp___supply_of_contraceptive_implants 2015-08-05T11:37:11 https://maestrodatabase.com/blog/ama-and-australian-government-agree-to-strengthening-the-mbs-review-process-and-informed-financial-consent 2021-06-09T02:30:22 https://maestrodatabase.com/blog/sipuleucel-t-in-prostate-cancer-additional-benefit-has-not-been-established 2015-08-05T11:37:22 https://maestrodatabase.com/blog/prescription-medicines-ppf-only-pre-submission-phase-option 2016-09-19T02:09:27 https://maestrodatabase.com/blog/acorda-therapeutics-announces-notification-of-anda-filing-for-ampyra 2015-08-05T11:37:10 https://maestrodatabase.com/blog/relevant-additions-and-changes-from-the-1-july-2014-issue-of-the-schedule-of-pharmaceutical-benefits-have-been-added-to-maestro-australia 2015-08-05T11:37:05 https://maestrodatabase.com/blog/new-indication-for-spiriva-tiotropium-respimat-in-the-eu-may-offer-millions-of-adults-a-significant-advance-in-asthma-care 2015-08-05T11:37:10 https://maestrodatabase.com/blog/expert-review-of-medicines-and-medical-devices-regulation 2015-08-05T11:37:13 https://maestrodatabase.com/blog/ema-receives-application-for-conditional-marketing-authorisation-for-paxlovid-pf-07321332-and-ritonavir-for-treating-patients-with-covid-19 2022-01-10T19:34:10 https://maestrodatabase.com/blog/jadenu-deferasirox-for-the-management-of-chronic-iron-overload-is-now-available-in-canada 2016-05-09T06:36:03 https://maestrodatabase.com/blog/eisai-submits-new-drug-application-in-europe-for-in-house-developed-anti-cancer-agent-lenvatinib-seeking-approval-for-indication-covering-renal-cell-carcinoma 2016-01-12T20:19:28 https://maestrodatabase.com/blog/outcomes-from-the-ptac-february-2016-meeting 2016-04-24T00:00:48 https://maestrodatabase.com/blog/abbvies-humira-adalimumab-receives-first-and-only-health-canada-approval-for-moderate-to-severe-hidradenitis-suppurativa 2016-01-07T06:43:00 https://maestrodatabase.com/blog/cadth-announces-new-members-to-its-health-technology-expert-review-panel 2015-08-05T11:37:27 https://maestrodatabase.com/blog/both-pcsk9-inhibitors-included-on-national-preferred-formulary 2015-10-07T20:27:13 https://maestrodatabase.com/blog/governments-hands-off-stance-is-fine-if-people-arent-dying 2016-03-01T19:53:53 https://maestrodatabase.com/blog/fda-approves-first-factor-x-concentrate-to-treat-patients-with-rare-hereditary-bleeding-disorder 2015-10-20T20:20:12 https://maestrodatabase.com/blog/a-golden-ticket-that-fast-tracks-a-drug-through-the-fda 2016-10-03T20:13:13 https://maestrodatabase.com/blog/biomarin-submits-drisapersen-maa-to-ema-for-the-treatment-of-duchenne-muscular-dystrophy-amenable-to-exon-51-skipping 2015-08-05T11:37:03 https://maestrodatabase.com/blog/veloxis-announces-us-fda-approval-of-envarsus-xr-for-treatment-of-kidney-transplant-patients 2015-08-05T11:37:16 https://maestrodatabase.com/blog/professor-sir-michael-rawlins-appointed-chair-of-medicines-and-healthcare-products-regulatory-agency 2015-08-05T11:37:19 https://maestrodatabase.com/blog/june-2015-decisions-news-release 2015-08-05T11:37:14 https://maestrodatabase.com/blog/nice-consults-on-draft-guidance-on-olaparib-for-ovarian-fallopian-tube-and-peritoneal-cancer 2015-08-05T11:37:11 https://maestrodatabase.com/blog/nice-issues-draft-guidance-on-ezetimibe-for-primary-hypercholesterolaemia 2015-10-22T03:49:18 https://maestrodatabase.com/blog/ledipasvir-plus-sofosbuvir-hint-of-added-benefit-in-further-patient-group 2015-08-05T11:37:10 https://maestrodatabase.com/blog/sanofi-provides-update-on-new-drug-application-for-investigational-once-daily-fixed-ratio-combination-of-insulin-glargine-and-lixisenatide 2016-08-22T05:57:53 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-february-2015-update 2015-08-05T11:37:15 https://maestrodatabase.com/blog/gileads-covid-19-drug-is-mediocre-it-will-be-a-blockbuster-anyway 2020-10-31T02:15:07 https://maestrodatabase.com/blog/tga-publishes-auspar-for-pirfenidone-esbriet 2016-08-29T08:04:47 https://maestrodatabase.com/blog/the-drug-that-costs-more-than-1200-and-sells-for-5-in-india 2016-01-03T06:40:07 https://maestrodatabase.com/blog/health-economics-update-and-call-for-feedback-on-costing-document 2015-08-05T11:37:13 https://maestrodatabase.com/blog/merlion-announces-fda-approval-of-finafloxacin-otic-suspension 2015-08-05T11:37:09 https://maestrodatabase.com/blog/nice-issues-draft-guidance-onfirst-line-use-of-sorafenib-nexavar-in-advancedmetastatic-hepatocellular-carcinoma 2016-08-19T21:26:05 https://maestrodatabase.com/blog/us-food-and-drug-administration-approves-kalydeco-ivacaftor-for-use-in-people-with-cystic-fibrosis-ages-6-and-older-who-have-the-r117h-mutation 2015-08-05T11:37:14 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits-1-february-2016-update 2016-01-31T12:03:47 https://maestrodatabase.com/blog/new-drug-listing-keytruda-to-treat-melanoma-1 2015-09-01T03:28:24 https://maestrodatabase.com/blog/american-regulators-approve-first-female-viagra-drug-addyi 2015-08-19T21:18:39 https://maestrodatabase.com/blog/millions-of-j-and-j-covid-19-vaccines-are-at-risk-of-expiring-in-june 2021-06-09T03:32:41 https://maestrodatabase.com/blog/use-medicares-muscle-to-lower-drug-prices 2015-09-21T12:29:11 https://maestrodatabase.com/blog/biogen-idec-and-sobi-announce-european-medicines-agency-validates-elocta-rfviiifc-marketing-authorization-application-for-review 2015-08-05T11:37:09 https://maestrodatabase.com/blog/iressa-approved-by-us-fda-for-first-line-treatment-of-patients-with-advanced-egfr-mutation-positive-non-small-cell-lung-cancer 2015-08-05T11:37:06 https://maestrodatabase.com/blog/social-media-disinformation-campaigns-tied-to-vaccine-hesitancy 2020-10-31T02:04:26 https://maestrodatabase.com/blog/tremfya-guselkumab-achieves-us-approval-for-subcutaneous-induction-in-adults-with-ulcerative-colitis-now-the-first-and-only-il-23-inhibitor-with-a-fully-subcutaneous-regimen 2025-09-22T01:24:55 https://maestrodatabase.com/blog/efmoroctocog-alfa-for-haemophilia-a-iqwig-says-an-additional-benefit-is-not-proven 2016-04-04T20:35:32 https://maestrodatabase.com/blog/us-ophthalmologists-plead-with-drug-regulator-not-to-restrict-access-to-avastin 2015-08-05T11:37:25 https://maestrodatabase.com/blog/heat-biologics-inc-receives-us-fda-fast-track-designation-for-hs-410-vesigenurtacel-l-in-combination-with-bcg-for-the-treatment-of-non-muscle-invasive-bladder-cancer 2015-08-05T11:37:18 https://maestrodatabase.com/blog/guido-rasi-takes-office-as-head-of-ema 2015-11-16T11:15:58 https://maestrodatabase.com/blog/smc_advice___october_2013 2015-08-05T11:37:04 https://maestrodatabase.com/blog/proposal-to-widen-access-to-tocilizumab-for-treatment-of-rheumatoid-arthritis-in-dhb-hospitals 2015-08-05T11:37:10 https://maestrodatabase.com/blog/nice-told-to-back-off-national-policy-issues 2015-12-24T00:56:01 https://maestrodatabase.com/blog/cost_of_prescription_drugs_increases_by__6_7m_in_scotland 2015-08-05T11:37:21 https://maestrodatabase.com/blog/2021-federal-health-insurance-exchange-open-enrolment-period-starts-on-1-november-on-healthcare-dot-gov 2020-10-31T03:04:46 https://maestrodatabase.com/blog/us-fda-issues-complete-response-letter-to-snda-seeking-to-expand-the-label-for-invega-sustenna 2015-08-05T11:37:06 https://maestrodatabase.com/blog/summary-of-fees-and-charges-from-1-january-2016 2015-12-14T03:59:39 https://maestrodatabase.com/blog/gormleys-take-road-to-launching-biosimilar-drugs-just-got-longer 2016-07-14T00:37:21 https://maestrodatabase.com/blog/call-for-patient-input-14 2015-08-05T11:37:27 https://maestrodatabase.com/blog/facilitating-global-development-of-biosimilars 2015-08-05T11:37:17 https://maestrodatabase.com/blog/nurix-therapeutics-receives-prime-designation-from-the-ema-for-nx-5948-for-the-treatment-of-relapsed-or-refractory-chronic-lymphocytic-leukaemia 2024-11-30T01:52:12 https://maestrodatabase.com/blog/sandoz-launches-zarxio-filgrastim-sndz-the-first-biosimilar-in-the-united-states 2015-09-03T10:57:45 https://maestrodatabase.com/blog/la-jolla-pharmaceutical-company-announces-u-dot-s-fda-acceptance-of-new-drug-application-for-ljpc-501 2017-08-29T03:14:55 https://maestrodatabase.com/blog/meeting-highlights-from-the-chmp-20-23-june-2016 2016-06-24T22:46:12 https://maestrodatabase.com/blog/mindmed-receives-fda-breakthrough-therapy-designation-for-mm120-for-generalized-anxiety-disorder 2024-03-08T01:08:01 https://maestrodatabase.com/blog/statement-from-fda-commissioner-announcing-the-acting-director-of-the-fda-oncology-center-of-excellence 2016-06-29T21:49:15 https://maestrodatabase.com/blog/fda-approves-weight-management-drug-contrave 2015-08-05T11:37:06 https://maestrodatabase.com/blog/pharmac-melatonin-funding-proposal-not-proceeding-at-this-time 2015-08-05T11:37:04 https://maestrodatabase.com/blog/fda-approves-first-treatment-to-reduce-risk-of-serious-heart-problems-specifically-in-adults-with-obesity-or-overweight 2024-03-08T22:53:33 https://maestrodatabase.com/blog/pcodr_recommends_the_funding_of_trastuzumab_emtansine__kadcyla__for_female_patients_with_her_2_positive_breast_cancer 2015-08-05T11:37:11 https://maestrodatabase.com/blog/nice_proposes_green_light_for_the_use_of_iluvien_in_people_with_diabetes_in_final_draft_guidance 2015-08-05T11:37:03 https://maestrodatabase.com/blog/nice-draft-guidance-recommends-elosulfase-alfa-vimizim-for-treatment-of-very-rare-life-limiting-genetic-disorder-under-managed-access-agreement 2015-11-25T06:56:04 https://maestrodatabase.com/blog/removal-of-blood-glucose-test-strips-from-the-pbs-on-1-july-2016 2016-06-21T06:58:52 https://maestrodatabase.com/blog/boehringer-ingelheim-caps-patient-out-of-pocket-costs-for-its-inhaler-portfolio-at-35-dollars-per-month 2024-03-08T07:22:26 https://maestrodatabase.com/blog/may-2015-tender-notification 2015-08-05T11:37:27 https://maestrodatabase.com/blog/bristol-myers-squibb-announces-plans-for-third-quarter-submission-of-a-biologics-license-application-for-opdivo-nivolumab-an-investigational-pd-1-immune-checkpoint-inhibitor-for-previously-treated-advanced-melanoma 2015-08-05T11:37:08 https://maestrodatabase.com/blog/enzalutamide-indication-of-major-added-benefit-for-over-75-year-olds 2015-08-05T11:37:19 https://maestrodatabase.com/blog/can-pharma-learn-to-stop-worrying-and-love-biosimilars 2016-02-11T20:48:46 https://maestrodatabase.com/blog/icer-to-assess-treatments-for-transthyretin-amyloidosis-cardiomyopathy 2024-03-08T07:16:58 https://maestrodatabase.com/blog/tga-publishes-auspar-for-proshaeos-alprostadil 2016-06-28T12:52:50 https://maestrodatabase.com/blog/antihaemophilic-factor-recombinant-bdd-fc-fusion-protein-eloctate-treatment-cost-comparison-and-budget-impact-analysis 2015-11-12T10:15:57 https://maestrodatabase.com/blog/ahrq-director-sets-course-for-agencys-health-services-research 2016-10-01T03:09:31 https://maestrodatabase.com/blog/agenda-for-the-september-chmp-meeting 2016-09-12T21:27:19 https://maestrodatabase.com/blog/asco-urges-fda-to-provide-clear-distinctions-between-biosimilars-and-approved-biological-products 2015-10-29T12:34:21 https://maestrodatabase.com/blog/monitoring-for-atrial-fibrillation-in-discharged-stroke-and-transient-ischaemic-attack-patients 2015-09-21T21:01:09 https://maestrodatabase.com/blog/janssen-submits-application-seeking-approval-of-simponi-in-european-union-for-non-radiographic-axial-spondyloarthritis 2015-08-05T11:37:03 https://maestrodatabase.com/blog/us-fda-grants-priority-review-for-potential-new-indication-for-brilinta 2015-08-05T11:37:16 https://maestrodatabase.com/blog/idelalisib-in-the-second-line-treatment-in-cll-additional-benefits-still-no-seen 2016-07-02T04:39:50 https://maestrodatabase.com/blog/basilea-announces-that-european-commission-approves-isavuconazole-crescemba-as-a-treatment-for-invasive-aspergillosis-and-mucormycosis-in-the-european-union 2015-10-19T06:20:04 https://maestrodatabase.com/blog/meeting-highlights-from-the-committee-for-medicinal-products-for-human-use-chmp-20-23-october-2014 2015-08-05T11:37:05 https://maestrodatabase.com/blog/mp_accused_of_misleading_public 2015-08-05T11:37:10 https://maestrodatabase.com/blog/us-fda-approves-dual-chamber-syringe-for-abilify-maintena-aripiprazole-extended-release-injectable-suspension-for-the-treatment-of-schizophrenia 2015-08-05T11:37:07 https://maestrodatabase.com/blog/call-for-patient-input-29 2015-08-05T11:37:16 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-for-medicinovas-mn-001-tipelukast-for-the-treatment-of-idiopathic-pulmonary-fibrosis 2015-09-10T20:36:59 https://maestrodatabase.com/blog/humulin-r-u-500-kwikpen-may-improve-glycemic-control-in-people-with-severely-insulin-resistant-diabetes 2016-01-23T01:18:54 https://maestrodatabase.com/blog/fingolimod-hydrochloride-in-a-new-field-of-application-additional-benefits-not-covered 2015-08-05T11:37:22 https://maestrodatabase.com/blog/decision-to-fund-two-new-cancer-treatments-olaparib-and-fulvestrant 2019-12-05T03:09:47 https://maestrodatabase.com/blog/fda-approves-new-treatment-for-advanced-pancreatic-cancer 2015-10-22T19:56:41 https://maestrodatabase.com/blog/perampanel-for-epilepsy-still-no-proof-of-added-benefit 2015-08-05T11:37:27 https://maestrodatabase.com/blog/my-vision-for-universal-quality-affordable-health-care 2016-09-29T05:08:29 https://maestrodatabase.com/blog/higher_drug_prices_will_boost_development_of_personalised_medicine__says_new_report 2015-08-05T11:37:07 https://maestrodatabase.com/blog/fda-allows-marketing-of-first-of-kind-computerized-cognitive-tests-to-help-assess-cognitive-skills-after-a-head-injuryfda-allows-marketing-of-first-of-kind-computerized-cognitive-tests-to-help-assess-cognitive-skills-after-a-head-injury 2016-08-22T21:06:36 https://maestrodatabase.com/blog/ge-healthcare-announces-european-union-approval-of-vizamyl-flutemetamol-18f-solution-for-injection-for-pet-imaging-of-beta-amyloid-plaque-in-suspected-alzheimers-disease 2015-08-05T11:37:10 https://maestrodatabase.com/blog/ariads-ap26113-receives-fda-breakthrough-therapy-designation-for-alk-non-small-cell-lung-cancer-resistant-to-crizotinib 2015-08-05T11:37:11 https://maestrodatabase.com/blog/cancer-patients-hurt-by-lack-of-informed-choice-on-costs-options 2016-06-19T21:12:54 https://maestrodatabase.com/blog/confirmed-1-april-2016-prices-resulting-from-2016-april-cycle-of-price-disclosure 2016-03-22T05:43:15 https://maestrodatabase.com/blog/updated-nice-quality-standard-identifies-areas-for-breast-cancer-improvement 2016-06-16T10:39:02 https://maestrodatabase.com/blog/tpp-no-reason-big-pharma-supply-would-stop 2016-04-26T20:25:50 https://maestrodatabase.com/blog/vildagliptin-for-type-2-diabetes-no-suitable-data-for-combination-with-a-sulphonylurea 2015-08-05T11:37:02 https://maestrodatabase.com/blog/complementary-medicines-testing-the-claims-of-the-billion-dollar-industry-isnt-easy 2015-08-05T11:37:26 https://maestrodatabase.com/blog/decision-to-widen-access-to-bortezomib-for-multiple-myeloma-and-al-amyloidosis 2019-12-05T03:17:03 https://maestrodatabase.com/blog/nice_draft_guidance_rejects_sanofi_s_zaltrap_for_metastatic_colorectal_cancer 2015-08-05T11:37:22 https://maestrodatabase.com/blog/pbs_funds_botox_to_prevent_migraines 2015-08-05T11:37:22 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-december-2014-update 2015-08-05T11:37:14 https://maestrodatabase.com/blog/european-commission-approval-of-csls-idelvion 2016-05-12T21:48:32 https://maestrodatabase.com/blog/agenda-for-the-20-23-october-2014-chmp-meeting 2015-08-05T11:37:26 https://maestrodatabase.com/blog/commission_of_audit_report_flawed_on_pbs 2015-08-05T11:37:19 https://maestrodatabase.com/blog/medical-red-tape-next-on-abbotts-hit-list 2015-08-05T11:37:28 https://maestrodatabase.com/blog/the-fda-is-basically-approving-everything-heres-the-data-to-prove-it 2015-08-25T00:03:27 https://maestrodatabase.com/blog/merck-announces-european-medicines-agency-acceptance-of-marketing-authorization-application-for-grazoprevirelbasvir-an-investigational-therapy-for-treatment-of-chronic-hepatitis-c-infection 2015-08-05T11:37:08 https://maestrodatabase.com/blog/fresenius-kabis-biosimilar-tyenne-tocilizumab-aazg-becomes-the-first-intravenous-and-subcutaneous-tocilizumab-biosimilar-approved-by-the-fda 2024-03-09T02:03:26 https://maestrodatabase.com/blog/updated-price-disclosure-guidelines-july-2014-and-cycles-table-are-now-available 2015-08-05T11:37:07 https://maestrodatabase.com/blog/aquestive-therapeutics-receives-complete-response-letter-from-u-dot-s-fda-for-tadalafil-oral-film 2018-11-18T06:59:41 https://maestrodatabase.com/blog/nice-draft-guidance-recommends-new-drug-for-people-with-ankylosing-spondylitis 2016-08-04T21:12:33 https://maestrodatabase.com/blog/information-on-efficient-funding-of-chemotherapy-reviewed 2019-12-05T05:00:10 https://maestrodatabase.com/blog/medicare-open-enrollment-starts-today 2015-10-15T20:03:16 https://maestrodatabase.com/blog/pharmac-announces-faster-assessment-of-cancer-medicines 2019-12-05T04:54:07 https://maestrodatabase.com/blog/2000-price-hike-for-infant-seizure-drug-called-absurd 2015-11-19T20:24:47 https://maestrodatabase.com/blog/european-medicines-agency-validates-and-grants-accelerated-assessment-of-marketing-authorization-application-for-empliciti-elotuzumab-for-the-treatment-of-multiple-myeloma-in-patients-who-have-received-one-or-more-prior-therapies 2015-08-05T11:37:11 https://maestrodatabase.com/blog/european-commission-approves-amgens-new-cholesterol-lowering-medication-repatha-evolocumab-the-first-pcsk9-inhibitor-to-be-approved-in-the-world-for-treatment-of-high-cholesterol 2015-08-05T11:37:08 https://maestrodatabase.com/blog/decision-to-widen-access-to-rituximab-and-award-sole-supply 2019-12-05T04:31:46 https://maestrodatabase.com/blog/abpi-extremely-disappointed-with-nhse-cdf-delisting-decision 2015-08-05T11:37:14 https://maestrodatabase.com/blog/breakthrough-cystic-fibrosis-drug-rejected-by-australian-authorities 2016-04-23T06:09:09 https://maestrodatabase.com/blog/pharmac-funded-video-downplays-side-effects-of-drug-linked-to-four-unexplained-deaths-epilepsy-patients-say 2019-12-05T20:20:32 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-positive-chmp-opinion-for-opdivo-nivolumab-in-combination-with-yervoy-ipilimumab-for-treatment-of-advanced-melanoma 2016-04-02T00:18:13 https://maestrodatabase.com/blog/bid-to-get-hiv-pill-programme-introduced-to-new-zealand 2015-08-05T11:37:28 https://maestrodatabase.com/blog/auxilium-pharmaceuticals-inc-announces-xiaflex-now-approved-for-the-concurrent-treatment-of-up-to-two-affected-joints-in-the-same-hand-in-dupuytrens-contracture-patients 2015-08-05T11:37:14 https://maestrodatabase.com/blog/the-health-202-the-most-viable-drug-pricing-bill-in-congress-is-getting-a-makeover 2019-12-05T20:18:08 https://maestrodatabase.com/blog/australian-government-spending-on-health-driven-down-thanks-to-pbs 2015-08-05T11:37:29 https://maestrodatabase.com/blog/pharmac-cant-progress-cystic-fibrosis-drug-trikafta---cf-new-zealand 2022-09-16T04:07:38 https://maestrodatabase.com/blog/phrma-statement-on-the-transpacific-partnership-negotiations 2015-10-06T06:47:19 https://maestrodatabase.com/blog/fda-authorises-marketing-of-diagnostic-test-that-uses-novel-technology-to-detect-mrsa-bacteria 2019-12-05T20:14:43 https://maestrodatabase.com/blog/ruxolitinib-for-myelofibrosis-indication-of-considerable-added-benefit 2015-08-05T11:37:20 https://maestrodatabase.com/blog/auckland-asbestos-victim-rises-from-death-bed-after-keytruda-treatment 2016-08-31T12:47:38 https://maestrodatabase.com/blog/hospital-groups-sue-to-block-price-transparency-rule 2019-12-05T06:25:05 https://maestrodatabase.com/blog/nice-recommends-dabigatran-etexilate-mesylate-pradaxa-for-treating-and-preventing-potentially-fatal-blood-clots 2015-08-05T11:37:30 https://maestrodatabase.com/blog/apha-welcomes-government-decision-regarding-chemotherapy-funding 2016-03-09T00:04:59 https://maestrodatabase.com/blog/valeant-pharmaceuticals-announces-fda-approval-of-onexton-gel-for-the-treatment-of-acne-vulgaris 2015-08-05T11:37:04 https://maestrodatabase.com/blog/fda-declines-to-approve-enzyvant-regenerative-therapy-on-manufacturing-concerns 2019-12-05T20:29:45 https://maestrodatabase.com/blog/european-medicines-agency-accepts-biogens-aducanumab-marketing-authorisation-application-for-alzheimers-disease 2020-10-31T05:00:04 https://maestrodatabase.com/blog/us-fda-grants-breakthrough-therapy-designation-for-roches-alecensa-alectinib-for-first-line-treatment-of-people-with-alk-positive-nsclc 2016-10-04T09:26:48 https://maestrodatabase.com/blog/type-2-diabetes-synjardy-empagliflozinmetformin-hydrochloride-approved-in-the-european-union 2015-08-05T11:37:12 https://maestrodatabase.com/blog/eisai-resubmits-fycompa-to-german-federal-joint-committee-for-additional-benefit-assessment 2015-08-05T11:37:18 https://maestrodatabase.com/blog/epilepsy-patients-angry-at-being-told-symptoms-all-in-their-heads 2019-12-05T20:24:50 https://maestrodatabase.com/blog/health-canada-approves-new-indication-for-the-use-of-xtandi-enzalutamide-capsules-for-patients-with-metastatic-castration-resistant-prostate-cancer 2015-08-05T11:37:12 https://maestrodatabase.com/blog/economic-nonsense-from-the-un-on-drugs 2016-09-20T20:31:35 https://maestrodatabase.com/blog/is-it-time-to-look-beyond-price-with-biosimilars 2019-12-05T20:54:47 https://maestrodatabase.com/blog/43p-drug-that-prevents-spread-of-breast-cancer-denied-to-thousands 2016-09-22T20:46:19 https://maestrodatabase.com/blog/why-this-bristol-myers-cancer-drug-is-crushing-its-rivals 2016-03-14T20:06:10 https://maestrodatabase.com/blog/cadth-drug-portfolio-information-sessions-1 2016-09-16T23:48:57 https://maestrodatabase.com/blog/fda-launches-app-for-health-care-professionals-to-report-novel-uses-of-existing-medicines-for-patients-with-difficult-to-treat-infectious-diseases 2019-12-05T20:37:29 https://maestrodatabase.com/blog/meeting-highlights-from-the-chmp-23-26-may-2016-meeting 2016-05-27T12:56:22 https://maestrodatabase.com/blog/fda-approves-bincyto-blinatumomab-for-use-in-paediatric-patients-with-philadelphia-chromosome-negative-relapsed-or-refractory-b-cell-precursor-acute-lymphoblastic-leukemia 2016-09-03T10:31:33 https://maestrodatabase.com/blog/fda-approves-adlyxin-to-treat-type-2-diabetes 2016-07-28T12:17:43 https://maestrodatabase.com/blog/gilead-agrees-price-cut-for-sovaldi-in-germany 2015-08-05T11:37:10 https://maestrodatabase.com/blog/viiv-healthcare-submits-new-drug-application-to-the-fda-for-fostemsavir-an-investigational-first-in-class-attachment-inhibitor-for-the-treatment-of-hiv-in-adults-with-few-treatment-options-available 2019-12-05T20:32:27 https://maestrodatabase.com/blog/guild-member-delegation-calls-for-fairer-s100-arrangements 2016-04-20T04:17:10 https://maestrodatabase.com/blog/confirmed-1-october-2015-prices-resulting-from-the-2015-october-cycle-of-price-disclosure 2015-09-18T21:33:33 https://maestrodatabase.com/blog/efpia-response-to-reuters-article-industry-weighs-radical-shake-up-of-european-drug-pricing 2016-06-13T05:16:10 https://maestrodatabase.com/blog/cour-pharmaceuticals-receives-fda-fast-track-designation-for-cnp-104-for-the-treatment-of-primary-biliary-cholangitis 2022-01-11T05:47:11 https://maestrodatabase.com/blog/the-cost-of-nab-paclitaxel-is-not-justified-by-its-limited-benefit-says-nice-in-draft-guidance 2015-08-05T11:37:21 https://maestrodatabase.com/blog/prestige-biopharma-voluntary-withdraws-eu-license-application-for-herceptin-biosimilar 2022-09-16T06:18:55 https://maestrodatabase.com/blog/mercks-investigational-anti-pd-1-antibody-pembrolizumab-under-regulatory-review-in-europe-for-the-treatment-of-advanced-melanoma 2015-08-05T11:37:05 https://maestrodatabase.com/blog/pompe-disease-sufferers-offered-life-saving-drug-by-sussan-ley 2015-08-05T11:37:14 https://maestrodatabase.com/blog/australian-health-insurers-and-pharmaceutical-companies-reckon-with-new-psychedelic-mental-health-treatments 2023-06-17T05:14:49 https://maestrodatabase.com/blog/nice-publishes-report-on-approaches-to-assessing-innovative-regenerative-medicines 2016-03-29T20:07:48 https://maestrodatabase.com/blog/alzheimers-drug-is-bonanza-for-biogen-most-likely-at-taxpayer-expense 2021-06-09T07:39:08 https://maestrodatabase.com/blog/icer-release-final-reports-on-obeticholic-acid-for-treatment-of-pbc-and-nash 2016-07-26T21:13:11 https://maestrodatabase.com/blog/cadth-symposium-deadline-reminder-call-for-abstracts 2015-10-20T20:54:47 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-april-2018-update 2018-04-01T04:05:59 https://maestrodatabase.com/blog/nice-publishes-appraisal-consultation-for-pirfenidone-esbriet-for-patients-with-idiopathic-pulmonary-fibrosis 2016-06-03T23:36:16 https://maestrodatabase.com/blog/fda-approves-first-generics-of-gilenya 2019-12-05T22:30:08 https://maestrodatabase.com/blog/call-for-patient-input-19 2015-08-05T11:37:18 https://maestrodatabase.com/blog/chmp-recommends-approval-of-beyfortus-nirsevimab-for-prevention-of-rsv-disease-in-infants 2022-09-16T06:10:49 https://maestrodatabase.com/blog/janssen-submits-application-to-the-european-medicines-agency-ema-to-expand-use-of-darzalex-daratumumab-to-include-combination-with-standard-of-care-regimens 2016-08-24T21:11:17 https://maestrodatabase.com/blog/agenda-for-7-january-2015-transparency-committee-meeting 2015-08-05T11:37:03 https://maestrodatabase.com/blog/bristol-myers-squibbs-opdivo-nivolumab-yervoy-ipilimumab-regimen-receives-expanded-fda-approval-in-unresectable-or-metastatic-melanoma-across-braf-status 2016-01-25T12:15:04 https://maestrodatabase.com/blog/actavis-announces-fda-approval-of-expanded-label-for-botox-onabotulinumtoxina-for-the-treatment-of-upper-limb-spasticity-in-adults 2015-08-05T11:37:24 https://maestrodatabase.com/blog/cancer-experts-slam-pharmac-report 2015-11-27T03:44:53 https://maestrodatabase.com/blog/new-national-standard-established-by-canadian-insurers-and-rheumatologists-to-provide-access-to-biologic-drugs 2015-09-03T22:18:45 https://maestrodatabase.com/blog/shire-and-kamada-announce-fda-approval-of-expanded-label-for-self-infusion-of-glassia-for-the-treatment-of-emphysema-due-to-severe-aat-deficiency 2016-06-16T05:37:47 https://maestrodatabase.com/blog/drug-that-cures-rare-disease-hereditary-tyrosinaemia-type-1-gets-approval-on-life-saving-drugs-program 2016-07-09T23:23:42 https://maestrodatabase.com/blog/clinical-studies-broad-definition-of-commercially-confidential-information-endangers-transparency 2015-08-05T11:37:18 https://maestrodatabase.com/blog/nhs-will-not-fund-anti-hiv-prep-drug-plan 2016-06-02T23:07:41 https://maestrodatabase.com/blog/new-small-cell-lung-cancer-drug-accepted-for-tga-evaluation-under-project-orbis 2020-06-04T03:23:18 https://maestrodatabase.com/blog/relevant-additions-and-changes-from-the-1-june-2014-issue-of-the-schedule-of-pharmaceutical-benefits-have-been-added-to-maestro-australia 2015-08-05T11:37:06 https://maestrodatabase.com/blog/veru-announces-fda-grant-of-fast-track-designation-for-enobosarm-for-the-treatment-of-androgen-receptor-positive-oestrogen-receptor-positive-human-epidermal-growth-factor-receptor-2-negative-metastatic-breast-cancer 2022-01-11T06:16:14 https://maestrodatabase.com/blog/symplmed-announces-fda-approval-of-prestalia-for-treatment-of-hypertension 2015-08-05T11:37:18 https://maestrodatabase.com/blog/the-improvisational-oncologist 2016-05-15T08:46:36 https://maestrodatabase.com/blog/drug-price-controls-are-vital-in-a-market-thats-not-free 2015-09-23T21:17:39 https://maestrodatabase.com/blog/abraxane-approved-by-european-commission-for-first-line-treatment-of-patients-with-non-small-cell-lung-cancer 2015-08-05T11:37:29 https://maestrodatabase.com/blog/uceris-budesonide-2mg-rectal-foam-for-the-induction-of-remission-of-mild-to-moderate-distal-ulcerative-colitis-granted-tentative-approval-by-fda 2015-08-05T11:37:17 https://maestrodatabase.com/blog/novartis-gains-fda-approval-for-promacta-providing-new-option-for-children-ages-6-and-older-with-chronic-itp-a-rare-blood-disorder 2015-08-05T11:37:06 https://maestrodatabase.com/blog/hospira-wins-french-biosimilar-drug-tender-at-45-percent-discount 2015-08-05T11:37:13 https://maestrodatabase.com/blog/september-2015-smc-decisions-news-release 2015-09-08T19:39:11 https://maestrodatabase.com/blog/evusheld-long-acting-antibody-combination-recommended-for-approval-in-the-eu-for-the-treatment-of-covid-19 2022-09-16T07:02:04 https://maestrodatabase.com/blog/pbac-guidelines-review-2 2016-04-12T10:19:10 https://maestrodatabase.com/blog/actelions-new-drug-application-for-selexipag-uptravi-is-accepted-for-review-by-the-us-fda-with-a-standard-review-time 2015-08-05T11:37:18 https://maestrodatabase.com/blog/pierre-fabre-receives-european-approval-for-braftovi-encorafenib-in-combination-with-cetuximab-for-the-treatment-of-adult-patients-with-braf-v600e-mutant-metastatic-colorectal-cancer 2020-06-04T04:16:28 https://maestrodatabase.com/blog/sitagliptin-and-sitagliptin-metformin-in-type-2-diabetes-additional-benefit-compared-to-sulfonylurea-plus-metformin 2016-10-05T20:08:34 https://maestrodatabase.com/blog/icer-draft-report-on-effectiveness-value-and-pricing-benchmarks-for-pcsk9-inhibitors-for-high-cholesterol-posted-for-public-comment 2015-09-09T21:15:22 https://maestrodatabase.com/blog/bill-to-speed-drug-development-passes-house-despite-opposition 2015-08-05T11:37:28 https://maestrodatabase.com/blog/call-for-patient-input-17 2015-08-05T11:37:02 https://maestrodatabase.com/blog/merck-receives-approval-of-zepatier-elbasvirgrazoprevir-in-canada-for-the-treatment-of-chronic-hepatitis-c-for-patients-with-genotype-1-3-or-4-infection-following-priority-review 2016-02-04T07:40:25 https://maestrodatabase.com/blog/german-body-calls-for-pause-in-european-plan-for-fast-track-drug-approval 2016-08-17T10:13:37 https://maestrodatabase.com/blog/novartis-receives-eu-approval-for-farydak-the-first-in-its-class-of-anticancer-agents-approved-for-patients-with-multiple-myeloma 2015-09-04T21:25:54 https://maestrodatabase.com/blog/prescription-drug-price-increases-continue-to-outpace-inflation 2021-06-09T08:51:03 https://maestrodatabase.com/blog/biosimilars-whats-in-a-name 2015-08-05T11:37:12 https://maestrodatabase.com/blog/siga-technologies-receives-approval-from-the-european-medicines-agency-for-tecovirimat 2022-01-11T06:34:13 https://maestrodatabase.com/blog/mylan-to-launch-first-generic-to-epipen-auto-injector-at-a-list-price-of-300-per-two-pack-carton-a-more-than-50-discount-to-the-brand-product 2016-08-29T11:59:01 https://maestrodatabase.com/blog/fixhepc-the-buyers-club-for-hepatitis-c-drug-inundated-with-inquiries 2015-10-03T06:36:09 https://maestrodatabase.com/blog/science-medicines-health-patients-at-the-heart-of-future-innovation 2015-08-05T11:37:28 https://maestrodatabase.com/blog/4d-molecular-therapeutics-announces-fda-fast-track-designation-granted-to-4d-125-for-the-treatment-of-x-linked-retinitis-pigmentosa 2022-01-11T06:23:57 https://maestrodatabase.com/blog/hhs-considering-action-on-drug-patents-over-high-prices 2016-02-12T21:19:52 https://maestrodatabase.com/blog/medicare-dataset-pulled-after-academics-find-breach-of-doctor-details-possible 2016-09-29T21:04:33 https://maestrodatabase.com/blog/carsgen-announces-ct041-car-t-cell-product-candidate-granted-rmat-designation-by-the-fda 2022-01-11T06:39:54 https://maestrodatabase.com/blog/fda-accepts-clovis-oncologys-new-drug-application-for-rucaparib-for-priority-review-for-the-treatment-of-advanced-mutant-brca-ovarian-cancer 2016-08-23T21:31:01 https://maestrodatabase.com/blog/private-health-insurers-speak-their-minds-on-unhealthy-system 2016-09-26T21:01:47 https://maestrodatabase.com/blog/beigene-announces-acceptance-of-a-supplemental-biologics-license-application-in-china-for-tislelizumab-in-microsatellite-instability-high-or-mismatch-repair-deficient-solid-tumours 2021-06-09T10:41:59 https://maestrodatabase.com/blog/pfizer-receives-fda-approval-for-prevnar-13-in-adults-age-18-through-49 2016-07-13T05:45:20 https://maestrodatabase.com/blog/lawmakers-grill-mylan-ceo-over-epipen-steep-price-increases 2016-09-21T21:33:51 https://maestrodatabase.com/blog/pharmacist-conflicts-of-interest-and-up-selling-patients-flagged-in-major-federal-government-review 2016-07-28T21:30:11 https://maestrodatabase.com/blog/smc-august-2015-decisions-news-release 2015-08-24T10:43:54 https://maestrodatabase.com/blog/new-expensive-anticancer-agents-which-role-is-played-by-quality-adjusted-life-years-in-the-selection-of-a-specific-treatment 2016-08-11T03:36:44 https://maestrodatabase.com/blog/asias-pharma-investment-shows-the-benefit-of-patent-protection 2016-08-16T22:23:42 https://maestrodatabase.com/blog/pharmac-decision-to-award-sole-supply-to-eprex-erythropoietin-alfa 2015-08-05T11:37:16 https://maestrodatabase.com/blog/cadth-calls-for-patient-input-on-submission-from-teva-for-fentora-fentanyl-citrate 2016-06-11T00:32:36 https://maestrodatabase.com/blog/nice-reform-put-on-hold--for-now 2015-08-05T11:37:24 https://maestrodatabase.com/blog/march-2016-nce-registrations-tga 2016-04-06T21:45:40 https://maestrodatabase.com/blog/nice-responds-to-failure-of-talks-to-reach-price-agreement-on-enhertu 2024-11-30T07:31:45 https://maestrodatabase.com/blog/progress-in-science-medicine-and-health 2016-05-18T09:12:22 https://maestrodatabase.com/blog/outcomes_from_the_july_2013_pbac_meeting 2015-08-05T11:37:17 https://maestrodatabase.com/blog/valeant-outlines-heart-drug-discounts-after-heavy-scrutiny 2016-05-17T04:56:29 https://maestrodatabase.com/blog/pharmac-decision-to-award-sole-supply-to-remicade-infliximab 2015-08-05T11:37:18 https://maestrodatabase.com/blog/merck-files-for-fda-approval-of-keytruda-in-lung-cancer 2015-08-05T11:37:27 https://maestrodatabase.com/blog/pcodr-recommends-iclusig-for-patients-with-cml-and-all 2015-10-04T11:14:30 https://maestrodatabase.com/blog/fda-approves-darzalex-for-patients-with-previously-treated-multiple-myeloma 2015-11-16T20:57:48 https://maestrodatabase.com/blog/important_next_steps_for_kalydeco__ivacaftor_ 2015-08-05T11:37:17 https://maestrodatabase.com/blog/preliminary-data-indicate-covid-19-vaccines-remain-effective-against-severe-disease-and-hospitalisation-caused-by-the-omicron-variant 2022-01-11T20:05:39 https://maestrodatabase.com/blog/establishment-of-pharmac-labelling-preferences 2015-08-05T11:37:28 https://maestrodatabase.com/blog/consumers-big-winners-from-medicines-deals 2015-08-05T11:37:14 https://maestrodatabase.com/blog/cancer-unpronounceable-drugs-incomprehensible-prices 2015-08-05T11:37:05 https://maestrodatabase.com/blog/using-health-technology-assessment-to-inform-insurance-reimbursement-of-high-technology-medicines-in-china-an-example-of-cancer-immunotherapy 2023-06-17T23:49:42 https://maestrodatabase.com/blog/what-cancer-doctors-dont-know-about-cancer-drugs 2015-09-23T22:17:41 https://maestrodatabase.com/blog/nice-recommends-rinvoq-for-psoriatic-arthritis-patients 2022-01-11T20:10:21 https://maestrodatabase.com/blog/novartis_is_yet_to_commit_to_the_possible_withdrawal_of_galvus__vildagliptin__following_g_ba_benefit_assessment 2015-08-05T11:37:26 https://maestrodatabase.com/blog/did-it-matter-that-the-cancer-drugs-fund-was-not-nice-a-retrospective-review 2016-10-04T02:34:56 https://maestrodatabase.com/blog/cadth-calls-for-patient-input-on-a-new-submission-from-bayer-for-eylea 2015-11-16T20:11:56 https://maestrodatabase.com/blog/fda-approves-novartis-drug-odomzo-sonidegib-for-locally-advanced-basal-cell-carcinoma-labcc-a-form-of-skin-cancer 2015-08-05T11:37:10 https://maestrodatabase.com/blog/european-commission-approves-lumykras-sotorasib-for-patients-with-kras-g12c-mutated-advanced-non-small-cell-lung-cancer 2022-01-11T07:52:55 https://maestrodatabase.com/blog/appointments-to-the-pharmaceutical-benefits-advisory-committee 2015-08-05T11:37:14 https://maestrodatabase.com/blog/new_treatment_option_for_women_with_breast_cancer_is_not_cost_effective_for_nhs__says_draft_nice_guidance 2015-08-05T11:37:09 https://maestrodatabase.com/blog/health-canada-approves-tresiba-a-new-basal-insulin-for-type-1-and-2-diabetes 2017-08-29T12:31:59 https://maestrodatabase.com/blog/vertex-provides-update-on-the-reimbursement-of-ivacaftor-kalydeco-in-canada 2015-08-05T11:37:25 https://maestrodatabase.com/blog/european-commission-approves-kaftrio-ivacaftor-slash-tezacaftor-slash-elexacaftor-in-combination-with-ivacaftor-to-treat-children-with-cystic-fibrosis-ages-6-to-11-years 2022-01-11T20:00:59 https://maestrodatabase.com/blog/australian-anti-cancer-company-sirtex-in-bayers-sights 2015-08-05T11:37:07 https://maestrodatabase.com/blog/nice-reviews-guidance-on-imatinib-mesylate-for-digestive-system-tumours-1 2015-08-05T11:37:18 https://maestrodatabase.com/blog/bayer-receives-fda-approval-for-betaconnect-first-and-only-electronic-autoinjector-in-relapsing-remitting-multiple-sclerosis-rrms-treatment 2015-09-28T20:54:16 https://maestrodatabase.com/blog/novartis-drug-odomzo-gains-eu-approval-for-locally-advanced-basal-cell-carcinoma-providing-new-non-invasive-therapy-for-patients 2015-08-20T11:26:49 https://maestrodatabase.com/blog/fotivda-tivozanib-now-licensed-in-the-european-union-for-the-first-line-treatment-of-advanced-renal-cell-carcinoma 2017-08-29T12:38:24 https://maestrodatabase.com/blog/medicine-exports-fall-30-per-cent-sparking-calls-for-policy-change 2015-08-08T01:08:18 https://maestrodatabase.com/blog/chmp-recommends-approval-of-lillys-olaratumab-in-combination-with-doxorubicin-for-advanced-soft-tissue-sarcoma 2016-09-17T00:11:30 https://maestrodatabase.com/blog/how-abbvies-humira-undercuts-the-drug-industry-price-defense 2016-07-21T21:28:52 https://maestrodatabase.com/blog/fda-approves-first-emergency-treatment-for-overdose-of-certain-types-of-chemotherapy 2015-12-13T07:13:22 https://maestrodatabase.com/blog/crohns-disease-sufferers-get-life-changing-medication-cheaper-after-stelara-is-listed-on-the-pbs 2017-08-29T12:53:25 https://maestrodatabase.com/blog/novartis-says-cdf-proposals-place-unreasonable-risk-on-pharma 2016-02-10T20:16:02 https://maestrodatabase.com/blog/biogens-investigational-alzheimers-disease-treatment-aducanumab-granted-fda-fast-track-designation 2016-09-01T21:27:36 https://maestrodatabase.com/blog/vargatef-nintedanib-approved-in-the-eu-for-lung-cancer-patients-with-advanced-adenocarcinoma-after-first-line-chemotherapy 2015-08-05T11:37:14 https://maestrodatabase.com/blog/acorda-receives-refusal-to-file-letter-from-fda-for-inbrija-cvt-301-levodopa-inhalation-powder-new-drug-application 2017-08-29T20:58:46 https://maestrodatabase.com/blog/pharmaceutical-benefits-advisory-committee-guidelines-review-1 2015-11-04T01:56:19 https://maestrodatabase.com/blog/drug-companies-oppose-moves-to-reimburse-off-label-medicine 2015-08-05T11:37:28 https://maestrodatabase.com/blog/teva-receives-complete-response-letter-for-nda-for-sd-809-for-the-treatment-of-chorea-associated-with-huntington-disease 2016-06-01T16:26:57 https://maestrodatabase.com/blog/u-dot-s-fda-and-ema-accept-regulatory-submissions-for-bosulif-bosutinib-for-the-treatment-of-patients-with-newly-diagnose-ph-plus-chronic-myeloid-leukaemia 2017-08-29T21:26:26 https://maestrodatabase.com/blog/opko-health-receives-complete-response-letter-from-fda-for-rayaldee-new-drug-application 2016-03-30T20:31:35 https://maestrodatabase.com/blog/california-drug-price-plan-is-criticized-by-patient-advocates 2016-07-05T10:31:30 https://maestrodatabase.com/blog/fda-approves-first-u-dot-s-treatment-for-chagas-disease 2017-08-29T21:17:46 https://maestrodatabase.com/blog/health-insurance-marketplace-open-enrollment-snapshot-week-2-update 2015-11-18T20:53:41 https://maestrodatabase.com/blog/proposal_to_fund_febuxostat__adenuric__for_treatment_resistant_gout 2015-08-05T11:37:08 https://maestrodatabase.com/blog/ispor-comments-on-the-asco-value-framework 2016-08-16T21:07:09 https://maestrodatabase.com/blog/new-drug-price-questions-loom-after-gileads-cancer-purchase 2017-08-29T21:34:18 https://maestrodatabase.com/blog/nice-backs-use-of-abbvies-humira-for-hidradenitis-suppurativa 2016-05-09T13:10:17 https://maestrodatabase.com/blog/poor-value-sees-younger-people-dropping-private-health-insurance 2018-11-19T18:13:32 https://maestrodatabase.com/blog/dupixent-dupilumab-to-treat-chronic-spontaneous-urticaria-advances-in-eu-with-positive-chmp-opinion 2025-09-22T05:47:55 https://maestrodatabase.com/blog/nice-recommends-elosulfase-alfa-vimizim-for-treatment-of-very-rare-life-limiting-genetic-disorder-under-managed-access-agreement 2015-12-16T20:17:26 https://maestrodatabase.com/blog/as-new-therapies-arrive-pressure-builds-on-the-health-care-system-to-figure-out-how-to-pay-for-them 2018-11-18T19:11:56 https://maestrodatabase.com/blog/vertex-receives-european-chmp-positive-opinion-for-orkambi-lumacaftor-slash-ivacaftor-for-treatment-of-children-with-cystic-fibrosis-aged-2-to-5-years-old-with-most-common-form-of-the-disease 2018-11-19T18:22:35 https://maestrodatabase.com/blog/innovative-skin-cancer-drug-available-on-cancer-drugs-fund 2018-11-19T18:16:24 https://maestrodatabase.com/blog/fda-approves-updated-drug-labelling-for-fludarabine-phosphate-under-project-renewal 2024-11-30T10:39:40 https://maestrodatabase.com/blog/novartis-joins-call-asking-fda-to-stop-biosimilar-trash-talkers 2018-11-19T18:37:20 https://maestrodatabase.com/blog/ibex-granted-fda-breakthrough-device-designation 2021-06-09T12:14:35 https://maestrodatabase.com/blog/ema-recommends-fexinidazole-the-first-all-oral-treatment-for-sleeping-sickness 2018-11-19T18:30:13 https://maestrodatabase.com/blog/icer-to-assess-gene-therapy-for-beta-thalassaemia 2021-11-24T20:41:20 https://maestrodatabase.com/blog/scandals-catch-up-to-private-chinese-hospitals-after-fortunes-are-made 2018-11-19T18:59:47 https://maestrodatabase.com/blog/gottlieb-pushes-for-funding-to-speed-gene-therapy-reviews 2018-11-19T18:41:08 https://maestrodatabase.com/blog/health-economic-assessment-of-carvykti-in-the-treatment-of-multiple-myeloma 2023-06-18T00:35:00 https://maestrodatabase.com/blog/which-databases-should-be-used-to-identify-studies-for-systematic-reviews-of-economic-evaluations 2018-11-19T18:45:15 https://maestrodatabase.com/blog/gop-law-maker-pushes-back-on-trump-drug-pricing-proposal 2018-11-19T19:11:23 https://maestrodatabase.com/blog/australia-tipped-to-approve-pfizer-vaccine-for-children-this-year 2021-06-09T21:03:57 https://maestrodatabase.com/blog/pharma-funded-more-than-2-400-state-law-maker-campaigns-in-2020-new-stat-analysis-finds 2021-06-09T20:58:44 https://maestrodatabase.com/blog/pharma-ignores-the-squabbling-and-prepares-for-a-hard-brexit 2018-11-19T19:15:16 https://maestrodatabase.com/blog/new-alzheimers-drug-unlikely-to-be-approved-in-australia-soon-say-experts 2021-06-09T21:07:02 https://maestrodatabase.com/blog/fda-approved-more-first-in-class-drugs-gave-more-accelerated-approvals-in-2021 2022-01-11T21:17:42 https://maestrodatabase.com/blog/tezspire-recommended-for-approval-in-the-eu-by-chmp-for-chronic-rhinosinusitis-with-nasal-polyps 2025-09-22T06:07:41 https://maestrodatabase.com/blog/the-bizarre-world-of-drug-pricing 2018-11-19T19:07:32 https://maestrodatabase.com/blog/vertex-announces-u-dot-s-fda-approval-for-trikafta-elexacaftor-slash-tezacaftor-slash-ivacaftor-and-ivacaftor-in-children-with-cystic-fibrosis-ages-6-through-11-with-certain-mutations 2021-06-09T12:23:20 https://maestrodatabase.com/blog/wound-care-decision-points-to-future-direction-of-devices-work 2016-10-06T23:48:08 https://maestrodatabase.com/blog/another-drug-company-that-raises-prices-like-crazy 2016-10-06T23:51:36 https://maestrodatabase.com/blog/unitedhealth-accused-of-gouging-customers-on-prescription-drugs 2016-10-06T23:22:36 https://maestrodatabase.com/blog/fda-approves-first-treatment-specifically-for-patients-with-rare-and-life-threatening-type-of-immune-disease 2018-11-20T23:51:33 https://maestrodatabase.com/blog/abbvies-new-oral-therapy-venclexta-now-available-for-canadians-with-a-difficult-to-treat-blood-cancer 2016-10-06T23:36:14 https://maestrodatabase.com/blog/secret-rebates-why-patients-pay-600-dollars-for-drugs-that-cost-300-dollars 2016-10-07T00:10:22 https://maestrodatabase.com/blog/mylan-accused-by-u-dot-s-of-overcharging-medicaid-for-epipen 2016-10-07T00:15:59 https://maestrodatabase.com/blog/why-the-drug-industry-and-its-critics-are-both-wrong-about-how-r-and-d-spending-affects-pricing 2016-10-06T23:54:47 https://maestrodatabase.com/blog/fda-grants-breakthrough-therapy-designation-for-roches-actemra-slash-roactemra-in-giant-cell-arteritis-a-form-of-vasculitis 2016-10-06T23:59:29 https://maestrodatabase.com/blog/cadth-calls-for-patient-input-on-a-submission-from-celopharma-for-mifegymiso 2016-10-07T00:21:28 https://maestrodatabase.com/blog/paladin-labs-announces-approval-of-wakix-pitolisant-in-canada 2021-06-09T21:17:56 https://maestrodatabase.com/blog/end-vaccine-frustration-and-let-pharmacies-join-the-rollout-pharmacy-guild 2021-06-09T21:12:33 https://maestrodatabase.com/blog/stop-blaming-pharmac---wed-be-worse-off-without-it 2021-06-09T21:27:17 https://maestrodatabase.com/blog/sanofi-plans-to-change-hospital-drug-discount-program 2024-11-30T23:04:24 https://maestrodatabase.com/blog/us-fda-accepts-supplemental-new-drug-application-for-nubeqa-darolutamide-for-the-treatment-of-patients-with-metastatic-hormone-sensitive-prostate-cancer 2024-11-30T22:56:39 https://maestrodatabase.com/blog/idorsia-receives-us-fda-approval-of-quviviq-daridorexant-25-and-50-mg-for-the-treatment-of-adults-with-insomnia 2022-01-12T00:00:49 https://maestrodatabase.com/blog/broken-promises-and-lies-people-like-me-dont-matter 2019-06-06T07:27:44 https://maestrodatabase.com/blog/health-canada-authorises-carvykti-ciltacabtagene-autoleucel-for-patients-with-relapsed-or-refractory-multiple-myeloma-who-have-received-one-to-three-prior-lines-of-therapy 2024-11-30T22:31:24 https://maestrodatabase.com/blog/decision-to-widen-access-to-etanercept-and-award-sole-supply 2019-06-06T07:19:38 https://maestrodatabase.com/blog/celltrion-usa-completes-submission-of-biologics-license-application-to-us-fda-for-ct-p39-an-interchangeable-biosimilar-candidate-of-xolair-omalizumab 2024-03-11T07:01:55 https://maestrodatabase.com/blog/koselugo-recommended-for-approval-in-the-eu-by-chmp-for-plexiform-neurofibromas-in-adults-with-neurofibromatosis-type-1 2025-09-22T07:02:40 https://maestrodatabase.com/blog/request-for-proposals---supply-of-various-vaccines-and-influenza-vaccines 2018-11-21T02:05:52 https://maestrodatabase.com/blog/notice-of-information-no-further-rfps-to-be-released-by-pharmac-in-2018 2018-11-21T02:10:26 https://maestrodatabase.com/blog/johnson-and-johnson-seeks-us-fda-approval-for-subcutaneous-induction-regimen-of-tremfya-guselkumab-in-ulcerative-colitis-a-first-for-an-il-23-inhibitor 2024-11-30T23:08:42 https://maestrodatabase.com/blog/sanders-unveils-aggressive-new-bill-targeting-drug-prices 2018-11-21T02:03:10 https://maestrodatabase.com/blog/insurer-greed-to-inflict-more-financial-pain-on-patients 2024-11-30T23:47:00 https://maestrodatabase.com/blog/alector-announces-fda-fast-track-designation-granted-to-al001-for-the-treatment-of-patients-with-frontotemporal-dementia 2019-12-06T03:17:00 https://maestrodatabase.com/blog/praluent-alirocumab-injection-receives-fda-approval-to-treat-children-with-genetic-form-of-high-cholesterol 2024-03-11T20:04:15 https://maestrodatabase.com/blog/a-cder-study-of-factors-that-may-predict-the-likelihood-of-generic-drug-marketing-applications 2020-11-01T00:55:59 https://maestrodatabase.com/blog/covid-19-vaccine-australias-rollout-plan-and-who-will-receive-it-first 2020-11-01T01:00:59 https://maestrodatabase.com/blog/dusc-utilisation-analysis-public-release-documents-june-2024-update 2024-12-01T00:11:51 https://maestrodatabase.com/blog/the-health-202-express-scripts-takes-on-rebates-in-plan-it-says-will-lower-drug-prices 2018-11-21T03:13:39 https://maestrodatabase.com/blog/a-drug-maker-boosted-the-price-of-its-opioid-overdose-antidote-by-600-percent-and-taxpayers-suffered 2018-11-21T03:10:22 https://maestrodatabase.com/blog/enzyvant-announces-fda-acceptance-of-biologics-license-application-and-priority-review-status-for-rvt-802-a-novel-investigational-tissue-based-regenerative-therapy-for-paediatric-congenital-athymia 2019-06-06T11:21:30 https://maestrodatabase.com/blog/attruby-acoramidis-a-near-complete-ttr-stabiliser-90-percent-approved-by-fda-to-reduce-cardiovascular-death-and-cardiovascular-related-hospitalisation-in-attr-cm-patients 2024-12-01T00:22:10 https://maestrodatabase.com/blog/alnylam-completes-rolling-submission-of-new-drug-application-to-u-dot-s-fda-for-givosiran-for-the-treatment-of-acute-hepatic-porphyria 2019-06-06T11:14:55 https://maestrodatabase.com/blog/icer-publishes-final-evidence-report-on-treatment-for-schizophrenia 2024-03-11T21:06:06 https://maestrodatabase.com/blog/strengthening-engagement-between-ema-and-general-practitioners 2019-06-06T20:41:00 https://maestrodatabase.com/blog/specialist-groups-appalled-by-egregious-billers-within-their-ranks 2019-06-06T11:34:02 https://maestrodatabase.com/blog/amneal-resubmits-dhe-auto-injector-new-drug-application-and-receives-us-fda-approval-of-exenatide-its-first-generic-injectable-glp-1-agonist 2024-12-01T00:51:27 https://maestrodatabase.com/blog/liberals-rip-democratic-leaders-for-writing-drug-pricing-bill-in-secret 2019-06-06T11:30:01 https://maestrodatabase.com/blog/bridgebio-selects-pantherx-rare-specialty-pharmacy-for-distribution-of-attruby-acoramidis 2024-12-01T00:40:52 https://maestrodatabase.com/blog/xeris-pharmaceuticals-receives-notification-of-pdufa-date-extension-for-gvoke 2019-06-06T20:59:59 https://maestrodatabase.com/blog/us-fda-and-ema-accept-applications-for-ozanimod-for-the-treatment-of-relapsing-forms-of-multiple-sclerosis 2019-06-06T20:51:59 https://maestrodatabase.com/blog/private-insurers-are-afraid-of-medicare-for-all-they-should-be-excited 2019-06-06T20:48:43 https://maestrodatabase.com/blog/fdas-woodcock-defends-accelerated-approvals-and-talks-of-culture-shift-in-clinical-trials 2019-06-06T21:13:02 https://maestrodatabase.com/blog/soaring-insurance-deductibles-and-high-drug-prices-hit-sick-americans-with-a-double-whammy 2019-06-06T21:08:21 https://maestrodatabase.com/blog/gop-senators-ask-phrma-for-solutions-to-lower-drug-prices 2019-06-06T21:05:18 https://maestrodatabase.com/blog/nice-publishes-final-guidance-backing-tevas-ajovy-for-migraine 2020-06-04T10:45:59 https://maestrodatabase.com/blog/cms-seeks-public-input-on-patients-over-paperwork-initiative-to-further-reduce-administrative-regulatory-burden-to-lower-health-care-costs 2019-06-06T21:25:35 https://maestrodatabase.com/blog/patients-physicians-raise-concerns-with-bc-biosimilar-non-medical-switching-policy 2019-06-06T21:21:50 https://maestrodatabase.com/blog/pfizer-denies-report-it-hid-possible-alzheimers-breakthrough 2019-06-06T21:15:25 https://maestrodatabase.com/blog/icer-posts-draft-scoping-document-for-the-assessment-of-treatments-for-peanut-allergy 2018-11-21T04:19:57 https://maestrodatabase.com/blog/biden-harris-administration-requires-insurance-companies-and-group-health-plans-to-cover-the-cost-of-at-home-covid-19-tests-increasing-access-to-free-tests 2022-01-12T05:02:01 https://maestrodatabase.com/blog/bc-man-calls-on-federal-provincial-governments-to-cover-his-costly-life-saving-cancer-treatment 2024-12-01T01:23:40 https://maestrodatabase.com/blog/health-insurers-offer-premium-discounts 2020-06-04T11:06:50 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-november-2020 2020-11-01T03:39:18 https://maestrodatabase.com/blog/proposed-changes-to-research-and-development-tax-incentive-will-discourage-investment-and-undermine-innovation 2019-12-06T05:39:13 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-november-2020 2020-11-01T03:52:32 https://maestrodatabase.com/blog/pelosi-sets-medicare-showdown-on-drug-costs-and-new-benefits 2019-12-06T21:01:39 https://maestrodatabase.com/blog/pharmac-says-it-welcomes-a-joint-inquiry-into-four-deaths---which-have-all-been-linked-to-the-anti-epileptic-drug-logem 2019-12-06T06:04:56 https://maestrodatabase.com/blog/life-changing-endometriosis-treatment-now-cheaper 2024-12-01T08:19:20 https://maestrodatabase.com/blog/fda-approves-amgens-avsola-infliximab-axxq-for-the-same-indications-as-remicade-infliximab 2019-12-06T23:18:20 https://maestrodatabase.com/blog/voters-clamour-for-affordable-health-in-election-lead-up 2024-12-01T08:14:53 https://maestrodatabase.com/blog/as-trump-looks-overseas-for-drug-pricing-ideas-one-expert-says-france-has-some-useful-approaches 2019-12-06T23:12:27 https://maestrodatabase.com/blog/pharmacy-chains-sue-bausch-health-other-drug-makers-for-overcharging-for-diabetes-drug 2019-12-06T21:06:17 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-december-2024 2024-12-01T10:08:57 https://maestrodatabase.com/blog/janssen-seeks-expanded-use-of-imbruvica-ibrutinib-in-two-indications-in-europe 2018-11-21T05:32:17 https://maestrodatabase.com/blog/tvax-biomedical-receives-fast-track-designation-from-the-fda-for-brain-cancer 2020-06-04T20:59:24 https://maestrodatabase.com/blog/agenda-for-the-march-2025-pbac-meeting-version-1 2024-12-01T10:05:03 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-pharmaessentias-application-for-ropeginterferon-alfa-2b-to-treat-polycythemia-vera 2020-06-04T21:03:59 https://maestrodatabase.com/blog/john-ivison-the-math-of-saving-lives----canadas-drug-battle-leaves-patients-caught-in-the-middle 2020-11-01T04:36:01 https://maestrodatabase.com/blog/roche-pulls-eu-tecentriq-slash-avastin-filing-in-kidney-cancer 2018-11-21T05:47:38 https://maestrodatabase.com/blog/patients-and-health-care-professionals-organisations-updated-on-emas-response-to-covid-19 2020-06-04T20:52:55 https://maestrodatabase.com/blog/beigene-announces-the-approval-of-brukinsa-zanubrutinib-in-china-for-patients-with-relapsed-slash-refractory-chronic-lymphocytic-leukaemia-or-small-lymphocytic-lymphoma-and-relapsed-slash-refractory-mantle-cell-lymphoma 2020-06-04T21:24:16 https://maestrodatabase.com/blog/two-members-of-u-dot-s-fda-advisory-panel-resign-over-alzheimers-drug-approval 2021-06-10T02:41:03 https://maestrodatabase.com/blog/integrating-early-economic-evaluation-into-target-product-profile-development-for-medical-tests-advantages-and-potential-applications 2021-06-10T02:37:23 https://maestrodatabase.com/blog/malaria-drug-promoted-by-trump-did-not-prevent-covid-19-infections-study-finds 2020-06-04T21:28:45 https://maestrodatabase.com/blog/who-set-to-resume-hydroxychloroquine-trial-in-battle-against-covid-19 2020-06-04T21:30:59 https://maestrodatabase.com/blog/the-lancet-new-england-journal-retract-covid-19-studies-including-one-that-raised-safety-concerns-about-malaria-drugs 2020-06-04T21:33:08 https://maestrodatabase.com/blog/fda-approves-antibiotic-to-treat-hospital-acquired-bacterial-pneumonia-and-ventilator-associated-bacterial-pneumonia 2020-06-04T21:10:54 https://maestrodatabase.com/blog/adamas-announces-fda-filing-acceptance-of-snda-to-modify-the-indication-statement-for-gocovri-to-include-treatment-for-parkinsons-disease-patients-receiving-levodopa-and-experiencing-off-episodes 2020-06-04T21:14:18 https://maestrodatabase.com/blog/wholesale-drug-prices----and-net-prices----keep-falling-for-most-drugs 2020-06-04T21:20:04 https://maestrodatabase.com/blog/changes-to-the-pbs-listings-for-opdualag-and-vyxeos 2024-12-01T10:13:01 https://maestrodatabase.com/blog/trump-administration-selects-five-coronavirus-vaccine-candidates-as-finalists 2020-06-04T21:41:25 https://maestrodatabase.com/blog/fda-re-evaluates-user-fees-for-biosimilar-reviews 2020-06-04T21:48:38 https://maestrodatabase.com/blog/copiktra-duvelisib-receives-european-union-marketing-authorisation-for-the-treatment-of-relapsed-or-refractory-cll-and-refractory-fl 2021-06-10T05:13:42 https://maestrodatabase.com/blog/viatris-and-mapi-pharma-statement-regarding-new-drug-application-for-glatiramer-acetate-depot 2024-03-12T02:41:22 https://maestrodatabase.com/blog/adamis-provides-update-on-zimhi 2021-06-10T06:07:53 https://maestrodatabase.com/blog/cymedica-orthopedics-announces-fda-clearance-for-intellihab-a-novel-drug-free-non-invasive-modality-for-treatment-of-knee-osteoarthritis-pain 2021-06-10T05:45:46 https://maestrodatabase.com/blog/update-on-the-us-regulatory-review-of-tolebrutinib-in-non-relapsing-secondary-progressive-multiple-sclerosis 2025-09-22T22:40:41 https://maestrodatabase.com/blog/making-more-life-changing-medicines-available-to-all-australians 2017-08-30T03:40:48 https://maestrodatabase.com/blog/cms-proposes-medicare-coverage-policy-for-monoclonal-antibodies-directed-against-amyloid-for-the-treatment-of-alzheimers-disease 2022-01-13T00:31:57 https://maestrodatabase.com/blog/fda-grants-breakthrough-therapy-designation-for-mdma-assisted-psychotherapy-for-ptsd-agrees-on-special-protocol-assessment-for-phase-3-trials 2017-08-30T03:44:28 https://maestrodatabase.com/blog/janssen-announces-bcma-car-t-therapy-jnj-4528-granted-u-dot-s-fda-breakthrough-therapy-designation-for-the-treatment-of-relapsed-or-refractory-multiple-myeloma 2019-12-07T01:17:12 https://maestrodatabase.com/blog/jamp-and-alvotech-announce-canadian-approval-of-simlandi-a-high-concentration-biosimilar-to-humira-providing-access-to-previously-unavailable-versions-in-canada 2022-01-13T01:02:17 https://maestrodatabase.com/blog/atagi-update-following-weekly-covid-19-meeting---9-june-2021 2021-06-10T06:16:29 https://maestrodatabase.com/blog/mavrix-bio-receives-fda-fast-track-designation-for-mvx-220-for-treatment-of-angelman-syndrome 2025-09-23T00:15:05 https://maestrodatabase.com/blog/fda-takes-action-to-make-a-treatment-available-for-autism-symptoms 2025-09-23T00:21:08 https://maestrodatabase.com/blog/quebec-to-impose-health-tax-on-unvaccinated-canadians 2022-01-13T01:06:59 https://maestrodatabase.com/blog/european-commission-approves-lillys-emgality-for-migraine 2018-11-21T07:08:21 https://maestrodatabase.com/blog/workshop-on-how-to-better-support-medicine-developers-in-the-generation-and-preparation-of-quality-data-packages-for-prime-and-breakthrough-therapy-application 2018-11-21T06:57:45 https://maestrodatabase.com/blog/gsk-submits-us-regulatory-filing-to-expand-the-use-of-nucala-in-children-with-severe-eosinophilic-asthma 2018-11-21T07:01:17 https://maestrodatabase.com/blog/european-commission-approves-serviers-voranigo-vorasidenib-as-the-first-targeted-therapy-for-grade-2-idh-mutant-glioma-in-the-eu 2025-09-23T01:41:58 https://maestrodatabase.com/blog/travere-therapeutics-submits-supplemental-new-drug-application-to-the-us-fda-seeking-full-approval-of-filspari-sparsentan-for-the-treatment-of-iga-nephropathy 2024-03-12T03:52:25 https://maestrodatabase.com/blog/fda-approves-new-treatment-for-patients-with-acute-myeloid-leukaemia 2018-11-21T19:03:14 https://maestrodatabase.com/blog/gsk-retains-leading-position-on-access-to-medicines-list 2018-11-21T12:04:04 https://maestrodatabase.com/blog/national-paracetamol-shortage-leads-to-restrictions 2018-11-21T12:19:03 https://maestrodatabase.com/blog/genmab-announces-european-marketing-authorisation-for-the-subcutaneous-formulation-of-darzalex-daratumumab-for-the-treatment-of-patients-with-multiple-myeloma 2020-06-05T02:04:11 https://maestrodatabase.com/blog/heron-therapeutics-announces-us-fda-approval-of-aponvie-htx-019-for-the-prevention-of-post-operative-nausea-and-vomiting 2022-09-17T04:23:59 https://maestrodatabase.com/blog/25-000-people-to-benefit-after-nice-recommends-new-ulcerative-colitis-treatment 2024-03-12T04:08:04 https://maestrodatabase.com/blog/abbvie-receives-us-fda-accelerated-approval-for-venclexta-venetoclax-for-treatment-of-newly-diagnosed-acute-myeloid-leukaemia-patients-ineligible-for-intensive-chemotherapy 2018-11-21T19:24:30 https://maestrodatabase.com/blog/update-on-the-march-2025-meeting 2024-12-01T21:08:15 https://maestrodatabase.com/blog/mitsubishi-tanabe-pharma-america-announces-fda-acceptance-of-new-drug-application-for-oral-edaravone-formulation-for-the-treatment-of-als 2022-01-13T02:30:32 https://maestrodatabase.com/blog/muscular-dystrophy-drug-looks-set-for-commercial-success-despite-clinical-doubts 2016-10-09T03:20:25 https://maestrodatabase.com/blog/thousands-of-european-melanoma-patients-lack-access-to-new-drugs 2016-10-09T03:31:30 https://maestrodatabase.com/blog/johnson-and-johnson-submits-supplemental-biologics-license-application-to-us-fda-seeking-approval-of-tremfya-guselkumab-for-the-treatment-of-adults-with-moderately-to-severely-active-ulcerative-colitis 2024-03-12T04:26:17 https://maestrodatabase.com/blog/personal-health-spending-boom-in-vitamins-supplements-painkillers 2016-10-09T03:42:04 https://maestrodatabase.com/blog/ema-management-board-highlights-of-october-2016-meeting 2016-10-09T03:47:04 https://maestrodatabase.com/blog/ema-recommends-marketing-authorisation-of-avt03-alvotechs-proposed-biosimilar-to-prolia-and-xgeva 2025-09-23T03:27:47 https://maestrodatabase.com/blog/nice-backs-use-of-forxiga-in-triple-therapy-for-diabetes 2016-10-09T03:36:09 https://maestrodatabase.com/blog/guild-submission-to-pharmacy-review 2016-10-09T03:38:40 https://maestrodatabase.com/blog/human-medicines-highlights---september-2016 2016-10-09T08:11:27 https://maestrodatabase.com/blog/lexicon-pharmaceuticals-announces-update-on-submission-of-additional-data-to-us-fda-supporting-the-benefit-risk-profile-of-zynquista-in-type-1-diabetes 2025-09-23T03:54:59 https://maestrodatabase.com/blog/cant-find-a-plan-on-healthcare-dot-gov-one-may-be-picked-for-you 2016-10-09T08:16:54 https://maestrodatabase.com/blog/coherus-biosciences-announces-fda-acceptance-of-351-k-biologics-license-application-to-u-dot-s-fda-for-chs-1701-pegfilgrastim-biosimilar-candidate 2016-10-09T03:54:31 https://maestrodatabase.com/blog/mylan-to-settle-epipen-overpricing-case-for-465-dollars-million 2016-10-09T03:59:53 https://maestrodatabase.com/blog/reimbursable-drug-classes-and-ceilings-in-italy-why-not-only-one 2016-10-09T10:29:45 https://maestrodatabase.com/blog/ramsay-ceo-chris-rex-says-claimed-prosthetic-savings-are-ridiculous 2016-10-09T19:50:55 https://maestrodatabase.com/blog/leading-rheumatologist-appointed-new-chair-of-smc 2016-10-09T08:21:53 https://maestrodatabase.com/blog/teva-and-celltrion-announce-exclusive-biosimilar-commercial-partnership 2016-10-09T08:30:12 https://maestrodatabase.com/blog/cbmg-receives-fda-regenerative-medicine-advanced-therapy-and-fast-track-designations-for-bi-specific-anti-cd19-slash-cd20-car-t-cell-therapy-for-relapsed-slash-refractory-b-cell-non-hodgkin-lymphoma 2022-01-13T05:11:40 https://maestrodatabase.com/blog/abbvie-reaches-an-agreement-with-the-pan-canadian-pharmaceutical-alliance-for-skyrizi-risankizumab-for-the-treatment-of-moderate-to-severe-plaque-psoriasis 2019-12-07T03:41:29 https://maestrodatabase.com/blog/idebenone-accepted-by-fda-for-priority-review-for-leber-hereditary-optic-neuropathy 2025-09-23T02:45:05 https://maestrodatabase.com/blog/international-collaboration-among-canadian-u-dot-s-and-australian-regulators-leads-to-new-options-for-the-treatment-of-cancer 2019-12-07T03:38:10 https://maestrodatabase.com/blog/independent-review-of-lamotrigine-sole-supply-decision-by-pharmac 2020-06-05T02:30:13 https://maestrodatabase.com/blog/fda-approves-new-antibacterial-drug 2017-08-30T05:53:41 https://maestrodatabase.com/blog/quizartinib-approved-to-treat-adult-patients-with-a-type-of-blood-cancer 2024-03-12T09:58:18 https://maestrodatabase.com/blog/bluebird-bio-announces-first-outcomes-based-agreement-with-medicaid-for-sickle-cell-disease-gene-therapy 2024-03-12T09:51:46 https://maestrodatabase.com/blog/we-dodged-a-bullet-biotech-and-pharma-react-to-selection-of-marty-makary-for-fda-commissioner 2024-12-02T07:14:03 https://maestrodatabase.com/blog/us-pharma-companies-really-do-want-britain-to-pay-more-for-drugs 2019-12-07T06:45:46 https://maestrodatabase.com/blog/government-announces-lowest-health-insurance-premium-increase-in-19-years 2019-12-07T06:40:55 https://maestrodatabase.com/blog/kites-car-t-cell-therapy-yescarta-first-in-europe-to-receive-positive-chmp-opinion-for-use-in-second-line-diffuse-large-b-cell-lymphoma-and-high-grade-b-cell-lymphoma 2022-09-17T04:57:22 https://maestrodatabase.com/blog/yuhans-leclaza-to-be-cheaper-than-astrazenecas-tagrisso 2021-06-10T11:56:15 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-10-june-2021 2021-06-10T07:53:56 https://maestrodatabase.com/blog/astellas-xtandi-bags-nice-approval-in-prostate-cancer 2021-06-10T11:38:47 https://maestrodatabase.com/blog/nice-recommends-several-treatment-options-to-help-thousands-with-moderate-rheumatoid-arthritis 2021-06-10T07:57:46 https://maestrodatabase.com/blog/smc---march-2024-decisions 2024-03-12T10:02:48 https://maestrodatabase.com/blog/americas-approval-of-an-alzheimers-drug-is-premature 2021-06-10T21:05:23 https://maestrodatabase.com/blog/orphan-drugs-privilege-of-fictitious-additional-benefit-not-justified 2022-01-13T20:23:14 https://maestrodatabase.com/blog/biogens-new-alzheimers-drug-could-cost-medicare-billions-of-dollars-a-year-report-finds 2021-06-10T21:11:46 https://maestrodatabase.com/blog/blenrep-combinations-accepted-for-review-by-the-us-fda-for-the-treatment-of-relapsed-slash-refractory-multiple-myeloma 2024-12-02T20:19:26 https://maestrodatabase.com/blog/the-us-fda-issues-a-complete-response-letter-for-the-biologics-license-application-for-insulin-aspart 2022-01-13T21:40:55 https://maestrodatabase.com/blog/gileads-trodelvy-awaits-re-deliberation-for-reimbursement-in-korea-following-patient-petitions-price-cut-proposal 2024-12-02T20:12:44 https://maestrodatabase.com/blog/core-patient-reported-outcomes-in-cancer-clinical-trials 2021-06-10T12:34:48 https://maestrodatabase.com/blog/health-canada-grants-interim-order-authorisation-for-casirivimab-and-imdevimab-for-the-treatment-of-mild-to-moderate-covid-19 2021-06-10T20:58:33 https://maestrodatabase.com/blog/fda-accepts-filing-of-abbreviated-new-drug-application-and-grants-priority-review-for-nalmefene-hydrochloride-injection-for-the-treatment-of-known-or-suspected-opioid-overdose 2021-06-10T20:49:57 https://maestrodatabase.com/blog/insurer-nib-wants-access-to-members-genetic-information 2019-12-07T07:30:49 https://maestrodatabase.com/blog/u-dot-s-fda-approves-carnexiv-carbamazepine-injection-as-intravenous-replacement-therapy-for-oral-carbamazepine-formulations 2016-10-10T07:12:47 https://maestrodatabase.com/blog/updated-agenda-for-march-2024-pbac-meeting-12-march-2024 2024-03-12T20:10:02 https://maestrodatabase.com/blog/new-electronic-portal-for-bidding-on-pharmacs-annual-tender 2016-10-10T19:24:15 https://maestrodatabase.com/blog/smc---october-2016-decisions 2016-10-10T19:42:54 https://maestrodatabase.com/blog/anthem-says-will-not-cover-sareptas-approved-duchenne-drug 2016-10-10T19:47:55 https://maestrodatabase.com/blog/panadol-osteo-price-hike-statement-ambiguous-but-not-misleading-accc 2016-10-10T19:29:13 https://maestrodatabase.com/blog/draft-agenda-for-chmp-october-meeting 2016-10-10T19:33:48 https://maestrodatabase.com/blog/eu-options-for-improving-access-to-medicines 2016-10-10T20:02:08 https://maestrodatabase.com/blog/immunomolecular-therapeutics-awarded-sbir-grant-and-receives-rare-paediatric-disease-designation-from-fda-for-imt-002 2018-11-21T21:42:17 https://maestrodatabase.com/blog/health-and-aged-care-are-the-new-productivity-reform-frontier-parkinson-says 2016-10-10T20:13:32 https://maestrodatabase.com/blog/life-extending-lung-cancer-drug-approved-for-use-in-scotland 2016-10-10T19:53:00 https://maestrodatabase.com/blog/elbit-imaging-announces-that-gamida-cell-has-received-fda-breakthrough-therapy-designation-for-nicord 2016-10-10T19:58:05 https://maestrodatabase.com/blog/leo-pharma-receives-positive-chmp-opinion-of-adtralza-tralokinumab-for-the-treatment-of-adolescents-with-moderate-to-severe-atopic-dermatitis 2022-09-17T05:36:39 https://maestrodatabase.com/blog/chmp-adopts-positive-opinion-to-extend-indication-of-veklury-remdesivir-for-the-treatment-of-paediatric-patients-with-covid-19 2022-09-17T05:21:39 https://maestrodatabase.com/blog/the-choices-on-health-reform-in-the-us-presidential-and-congressional-elections 2016-10-10T20:16:50 https://maestrodatabase.com/blog/finance-ministry-wants-japans-elderly-to-foot-more-medical-costs 2016-10-10T20:28:43 https://maestrodatabase.com/blog/novartis-sickle-cell-medicine-adakveo-approved-in-europe-to-prevent-recurrent-vaso-occlusive-crises 2020-11-01T19:44:41 https://maestrodatabase.com/blog/us-fda-approves-aop-healths-rapiblyk-landiolol-for-atrial-fibrillation-and-atrial-flutter-in-the-critical-care-setting 2024-12-02T21:14:49 https://maestrodatabase.com/blog/abeona-therapeutics-receives-fda-breakthrough-therapy-designation-for-eb-101-autologous-cell-therapy-in-epidermolysis-bullosa 2017-08-30T09:21:30 https://maestrodatabase.com/blog/mhra-grants-hae-patients-early-access-to-biocrysts-berotralstat-in-united-kingdom 2020-11-01T22:11:19 https://maestrodatabase.com/blog/intelgenx-announces-fdas-acceptance-of-resubmission-of-new-drug-application-for-rizaport 2018-11-21T22:41:16 https://maestrodatabase.com/blog/urogen-pharma-receives-fda-fast-track-designation-for-mitogel-for-the-treatment-of-upper-tract-urothelial-carcinoma 2017-08-30T09:45:06 https://maestrodatabase.com/blog/cadth-recommends-new-treatment-option-for-patients-with-plaque-psoriasis 2020-11-01T23:48:37 https://maestrodatabase.com/blog/the-fdas-digital-health-center-of-excellence-why-it-matters-and-what-it-means-to-you 2020-11-01T22:16:35 https://maestrodatabase.com/blog/bms-appeals-final-appraisal-document-for-nivolumab-for-non-small-cell-lung-cancer 2020-11-01T23:30:19 https://maestrodatabase.com/blog/fda-approves-bronchitol-for-us-market 2020-11-01T23:39:49 https://maestrodatabase.com/blog/on-the-integration-of-early-health-technology-assessment-in-the-innovation-process-reflections-from-five-stakeholders 2020-11-02T01:05:31 https://maestrodatabase.com/blog/msac-publishes-agenda-for-upcoming-meeting 2021-11-25T04:49:44 https://maestrodatabase.com/blog/lilly-to-file-baricitinib-resubmission-to-u-dot-s-fda-before-end-of-january-2018 2017-08-30T10:53:58 https://maestrodatabase.com/blog/adc-therapeutics-and-sobi-announce-zylonta-loncastuximab-tesirine-receives-positive-chmp-opinion-in-europe-for-the-treatment-of-relapsed-or-refractory-diffuse-large-b-cell-lymphoma 2022-09-17T06:23:48 https://maestrodatabase.com/blog/prometic-receives-rare-paediatric-disease-designation-from-u-dot-s-fda-for-its-plasminogen-replacement-therapy 2017-08-30T11:00:04 https://maestrodatabase.com/blog/merck-receives-positive-chmp-opinion-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-in-infants-and-children 2022-09-17T06:11:59 https://maestrodatabase.com/blog/shorla-oncology-announces-fda-approval-of-imkeldi-imatinib-oral-solution-an-oral-liquid-for-the-treatment-of-certain-forms-of-leukaemia-and-other-cancers 2024-12-03T02:17:09 https://maestrodatabase.com/blog/tga-boss-warns-about-streamlining-approvals 2016-10-11T03:23:28 https://maestrodatabase.com/blog/insulin-prices-soar-while-drug-makers-share-stays-flat 2016-10-11T03:27:00 https://maestrodatabase.com/blog/fda-grants-breakthrough-therapy-designation-to-daiichi-sankyos-ds-8201-for-her2-positive-metastatic-breast-cancer 2017-08-30T11:10:08 https://maestrodatabase.com/blog/a-comparative-study-of-drug-listing-recommendations-and-the-decision-making-process-in-australia-the-netherlands-sweden-and-the-uk 2016-10-11T03:14:02 https://maestrodatabase.com/blog/decision-regarding-funding-of-the-hiv-treatments-dolutegravir-tivicay-and-abacavir-sulphate-with-lamivudine-kivexa 2016-10-11T04:14:49 https://maestrodatabase.com/blog/multi-product-proposal-involving-nine-pharmaceuticals 2016-10-11T04:18:07 https://maestrodatabase.com/blog/preferences-for-speed-of-access-versus-certainty-of-the-survival-benefit-of-new-cancer-drugs-a-discrete-choice-experiment 2024-12-03T03:25:49 https://maestrodatabase.com/blog/icer-releases-corrected-evidence-report-on-treatments-for-non-small-cell-lung-cancer 2016-10-11T03:40:07 https://maestrodatabase.com/blog/dbv-technologies-announces-filing-and-validation-of-marketing-authorisation-application-for-viaskin-peanut-by-european-medicines-agency 2020-11-02T10:13:37 https://maestrodatabase.com/blog/highlights-from-the-12-15-september-2022-chmp-meeting 2022-09-17T06:42:14 https://maestrodatabase.com/blog/the-trade-off-between-accelerated-cancer-drug-approvals-and-patient-preferences 2024-12-03T03:22:34 https://maestrodatabase.com/blog/people-with-an-advanced-form-of-thyroid-cancer-now-able-to-benefit-from-lenvima-lenvatinib-mesylate-in-scotland 2016-10-11T04:57:42 https://maestrodatabase.com/blog/swiss-regulator-gives-green-light-to-first-drug-to-prevent-covid-19 2022-09-17T06:34:13 https://maestrodatabase.com/blog/fda-accepts-biomarins-pegvaliase-biologics-license-application-and-grants-priority-review-designation 2017-08-30T11:22:09 https://maestrodatabase.com/blog/glp-1-drugs-ozempic-and-mounjaro-close-to-reimbursement-in-diabetes-care 2025-09-23T08:17:25 https://maestrodatabase.com/blog/fda-grants-priority-review-to-roches-lucentis-for-mcnv 2016-10-11T10:32:17 https://maestrodatabase.com/blog/cutting-through-the-numbers-on-health-care-funding 2016-10-11T10:43:13 https://maestrodatabase.com/blog/non-inferiority-trials-are-they-inferior-a-systematic-review-of-reporting-in-major-medical-journals 2016-10-11T06:30:39 https://maestrodatabase.com/blog/biotech-sector-crafts-response-to-r-and-d-tax-incentive-review 2016-10-11T06:33:21 https://maestrodatabase.com/blog/breast-cancer-chemotherapy-costs-vary-despite-similar-effectiveness 2016-10-11T20:05:11 https://maestrodatabase.com/blog/battling-rising-drug-prices-is-like-whac-a-mole-says-hospital-executive 2016-10-11T20:14:42 https://maestrodatabase.com/blog/janssen-submits-paliperidone-palmitate-6-month-supplemental-new-drug-application-to-u-dot-s-fda-for-treatment-of-schizophrenia-in-adults 2020-11-02T20:06:10 https://maestrodatabase.com/blog/nice-publishes-draft-guidance-on-the-use-of-otezla-on-the-nhs 2016-10-11T11:07:37 https://maestrodatabase.com/blog/cost-effectiveness-and-value-how-to-judge 2016-10-11T19:57:49 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-december-2024 2024-12-03T03:43:28 https://maestrodatabase.com/blog/breakthrough-drug-that-cures-eczema-knocked-back-by-pbs 2019-12-08T02:58:51 https://maestrodatabase.com/blog/european-commission-approves-roches-tecentriq-in-combination-with-avastin-for-the-treatment-of-people-with-the-most-common-form-of-liver-cancer 2020-11-02T20:13:38 https://maestrodatabase.com/blog/novartis-monaleesa-7-kisqali-ribociclib-succinate-study-demonstrated-statistically-significant-improvement-in-overall-survival-in-pre--and-peri-menopausal-women-with-hr-plus-slash-her2--advanced-breast-cancer 2020-11-02T20:17:45 https://maestrodatabase.com/blog/icer-names-leigh-purvis-to-governance-board-mark-mcclellan-to-advisory-board 2020-11-02T19:48:10 https://maestrodatabase.com/blog/takeda-price-hikes-for-a-gi-drug-may-give-some-patients-another-kind-of-stomachache 2020-11-02T19:54:04 https://maestrodatabase.com/blog/aicuris-was-granted-breakthrough-therapy-designation-by-u-dot-s-fda-for-pritelivir-for-the-treatment-of-hsv-infections-in-immunocompromised-patients 2020-06-06T23:22:18 https://maestrodatabase.com/blog/nice-talking-to-you-trends-in-early-hta-engagement 2020-11-02T19:58:41 https://maestrodatabase.com/blog/boehringer-ingelheim-pharmaceuticals-receives-fda-approval-for-cyltezo-adalimumab-adbm-a-biosimilar-to-humira-for-the-treatment-of-multiple-chronic-inflammatory-diseases 2017-08-30T11:52:19 https://maestrodatabase.com/blog/gsk-nucala-mepolizumab-filings-accepted-by-european-medicines-agency-for-three-additional-eosinophil-driven-diseases 2020-11-02T20:42:42 https://maestrodatabase.com/blog/dupilumab-for-the-treatment-of-adults-with-moderate-to-severe-prurigo-nodularis 2024-03-13T20:15:41 https://maestrodatabase.com/blog/fluocinolone-acetonide-for-the-treatment-of-patients-with-chronic-diabetic-macular-oedema 2024-03-13T20:10:25 https://maestrodatabase.com/blog/european-commission-approves-zejula-niraparib-as-first-line-monotherapy-maintenance-treatment-in-advanced-ovarian-cancer 2020-11-02T21:02:02 https://maestrodatabase.com/blog/sumitomo-pharma-announces-availability-of-orgovyx-relugolix-in-canada-the-first-and-only-oral-androgen-deprivation-therapy-treatment-for-men-with-advanced-prostate-cancer 2024-03-13T01:55:08 https://maestrodatabase.com/blog/pbac-recommends-price-increase-for-paracetamol 2020-11-02T20:22:24 https://maestrodatabase.com/blog/pharmacs-decision-over-diabetes-drugs-could-see-up-to-140-000-miss-out-doctor-says 2021-06-11T05:33:38 https://maestrodatabase.com/blog/sanofis-sar446268-earns-us-fast-track-designation-for-the-treatment-of-non-congenital-myotonic-dystrophy-type-1 2025-09-23T23:20:52 https://maestrodatabase.com/blog/gsk-and-vir-submit-emergency-use-authorisation-application-to-fda-for-intramuscular-administration-of-sotrovimab-for-the-early-treatment-of-covid-19 2022-01-14T20:42:34 https://maestrodatabase.com/blog/u-dot-s-fda-approves-new-formulation-of-epclusa-expanding-paediatric-indication-to-treat-children-ages-3-and-older-with-chronic-hepatitis-c 2021-06-11T06:07:59 https://maestrodatabase.com/blog/celltrion-wins-conditional-nod-for-regkirona-in-switzerland 2022-01-14T20:49:43 https://maestrodatabase.com/blog/senate-panel-advances-bidens-fda-pick-in-13-8-vote 2022-01-14T20:46:49 https://maestrodatabase.com/blog/pbac-public-summary-documents---september-2021-meeting-first-time-rejections-and-deferrals 2022-01-14T06:20:44 https://maestrodatabase.com/blog/bupa-takes-first-steps-into-world-of-genomics 2025-09-24T00:03:11 https://maestrodatabase.com/blog/fda-issues-complete-response-letter-for-apitegromab-as-a-treatment-for-patients-with-spinal-muscular-atrophy 2025-09-23T22:48:23 https://maestrodatabase.com/blog/more-canadians-have-access-to-humira-adalimumab-for-the-treatment-of-ulcerative-colitis 2017-08-30T12:49:18 https://maestrodatabase.com/blog/u-dot-s-fda-approves-rinvoq-upadacitinib-to-treat-adults-and-children-12-years-and-older-with-refractory-moderate-to-severe-atopic-dermatitis 2022-01-14T21:08:18 https://maestrodatabase.com/blog/fda-approval-brings-first-gene-therapy-to-the-united-states 2017-08-30T20:59:30 https://maestrodatabase.com/blog/delytact-oncolytic-virus-g47-approved-in-japan-for-treatment-of-patients-with-malignant-glioma 2021-06-11T06:49:39 https://maestrodatabase.com/blog/push-for-taxpayers-to-fund-weight-loss-drugs-for-500-000-australians 2025-09-24T03:53:14 https://maestrodatabase.com/blog/novartis-receives-first-ever-fda-approval-for-a-car-t-cell-therapy-kymriah-ctl019-for-children-and-young-adults-with-b-cell-all-that-is-refractory-or-has-relapsed-at-least-twice 2017-08-30T21:09:56 https://maestrodatabase.com/blog/biogen-prepares-to-fight-medicare-over-alzheimers-drug-limits 2022-01-14T21:13:26 https://maestrodatabase.com/blog/consolidated-health-economic-evaluation-reporting-standards-2022-cheers-2022-statement-updated-reporting-guidance-for-health-economic-evaluations 2022-01-14T21:18:14 https://maestrodatabase.com/blog/innovative-treatments-call-for-innovative-payment-models-and-arrangements 2017-08-30T21:15:00 https://maestrodatabase.com/blog/controversial-alzheimers-drug-approved-in-u-dot-s-where-does-canada-stand 2021-06-11T07:15:06 https://maestrodatabase.com/blog/u-dot-s-fda-approves-pfizers-cibinqo-abrocitinib-for-adults-with-moderate-to-severe-atopic-dermatitis 2022-01-15T01:23:00 https://maestrodatabase.com/blog/teva-and-medincells-risperidone-lai-approved-in-canada-as-longavo 2025-09-24T03:43:18 https://maestrodatabase.com/blog/novartis-gene-therapy-approval-signals-new-cancer-treatment-era 2017-08-30T21:20:48 https://maestrodatabase.com/blog/advancing-health-through-innovation-new-drug-therapy-approvals-2021 2022-01-14T21:59:08 https://maestrodatabase.com/blog/medibank-warns-of-health-insurance-crisis 2019-12-09T02:32:02 https://maestrodatabase.com/blog/pharmac-funding-resources-to-focus-on-medicines-access-equity 2020-11-03T03:38:39 https://maestrodatabase.com/blog/cancer-costs-can-be-unbearable---a-special-centrelink-payment-is-needed-couple-say 2019-12-09T02:29:13 https://maestrodatabase.com/blog/european-medicines-agency-validates-marketing-application-for-filgotinib-for-the-treatment-of-ulcerative-colitis 2020-11-03T03:54:00 https://maestrodatabase.com/blog/base-drug-prices-on-value-rather-than-r-and-d 2019-12-09T03:03:08 https://maestrodatabase.com/blog/provention-bio-completes-rolling-submission-of-the-biologics-license-application-for-teplizumab-for-the-delay-or-prevention-of-clinical-type-1-diabetes-in-at-risk-individuals 2020-11-03T03:34:20 https://maestrodatabase.com/blog/health-funds-call-for-urgent-reform-after-government-caps-price-hikes 2019-12-09T02:35:10 https://maestrodatabase.com/blog/pharmac-proposes-funding-five-medicines-and-more-convenient-treatment-options-to-ease-pressure-on-health-services 2025-09-24T05:06:49 https://maestrodatabase.com/blog/fda-use-of-real-world-evidence-in-regulatory-decision-making 2025-09-24T04:35:31 https://maestrodatabase.com/blog/hta-policy-and-methods-review-update 2024-12-03T05:20:37 https://maestrodatabase.com/blog/new-subcutaneous-formulation-of-opdivo-receives-positive-inesss-recommendation-for-multiple-tumour-types 2025-09-24T04:40:28 https://maestrodatabase.com/blog/gilead-faces-pressure-to-relinquish-valuable-fda-voucher-awarded-with-remdesivir-approval 2020-11-03T03:58:34 https://maestrodatabase.com/blog/eisai-submits-supplemental-new-drug-application-to-fda-for-fycompa-perampanel-paediatric-indications 2018-04-03T04:26:13 https://maestrodatabase.com/blog/alkermes-receives-refusal-to-file-letter-from-fda-for-alks-5461 2018-04-03T04:17:05 https://maestrodatabase.com/blog/pbac-guidelines 2016-10-12T04:50:26 https://maestrodatabase.com/blog/fda-grants-priority-review-for-daiichi-sankyos-new-drug-application-for-flt3-inhibitor-quizartinib-for-treatment-of-patients-with-relapsed-slash-refractory-flt3-itd-aml 2018-11-22T02:20:46 https://maestrodatabase.com/blog/how-health-technology-reassessment-can-support-disinvestment-in-chinas-national-drug-reimbursement-list 2023-06-19T21:22:19 https://maestrodatabase.com/blog/moderna-files-for-emergency-use-authorisation-for-its-covid-19-vaccine-in-adolescents-in-the-united-states 2021-06-11T09:00:04 https://maestrodatabase.com/blog/sanofi-provides-update-on-aubagio-teriflunomide-submission-for-children-and-adolescents-with-relapsing-remitting-multiple-sclerosis-in-the-u-dot-s 2021-06-11T11:54:48 https://maestrodatabase.com/blog/smc-publishes-a-collaborative-advice-document-for-tixagevimab-cilgavimab-evusheld-for-prevention-of-covid-19 2023-06-19T21:19:20 https://maestrodatabase.com/blog/ema-publishes-agenda-for-19-22-june-chmp-meeting 2023-06-19T11:14:18 https://maestrodatabase.com/blog/cadth-calls-for-patient-input-on-submission-from-servier-for-corlovan 2016-10-12T05:15:02 https://maestrodatabase.com/blog/f2g-receives-complete-response-letter-from-fda-for-new-drug-application-for-olorofim-for-the-treatment-of-invasive-fungal-infections-plans-resubmission-with-additional-data-and-analyses 2023-06-19T21:15:11 https://maestrodatabase.com/blog/international-regulators-and-who-address-need-to-boost-covid-19-vaccine-confidence 2021-06-11T08:42:07 https://maestrodatabase.com/blog/take-whatever-covid-booster-you-can-get-says-head-of-eu-drugs-watchdog 2022-09-17T20:46:27 https://maestrodatabase.com/blog/ema-recommends-standard-marketing-authorisations-for-comirnaty-and-spikevax-covid-19-vaccines 2022-09-17T20:52:25 https://maestrodatabase.com/blog/global-regulators-discuss-path-towards-regulatory-alignment-on-response-to-omicron-variant 2022-01-16T21:53:49 https://maestrodatabase.com/blog/new-life-extending-lung-cancer-treatment-approved-by-nice 2018-11-22T02:33:06 https://maestrodatabase.com/blog/glenmark-receives-nda-approval-by-the-united-states-fda-for-ryaltris-nasal-spray-for-the-treatment-of-symptoms-of-seasonal-allergic-rhinitis-in-adults-and-paediatric-patients-12-years-of-age-and-older 2022-01-16T21:58:50 https://maestrodatabase.com/blog/decision-to-award-sole-supply-of-venlafaxine 2016-10-12T05:37:35 https://maestrodatabase.com/blog/incyte-announces-u-dot-s-fda-has-extended-the-new-drug-application-review-period-for-ruxolitinib-cream-for-the-treatment-of-atopic-dermatitis 2021-06-11T21:23:35 https://maestrodatabase.com/blog/third-member-of-prestigious-fda-panel-resigns-over-approval-of-biogens-alzheimers-drug 2021-06-11T12:03:11 https://maestrodatabase.com/blog/more-measures-are-needed-to-curb-the-development-cost-of-pharmaceuticals 2023-06-19T21:25:05 https://maestrodatabase.com/blog/bayer-submits-vericiguat-for-marketing-authorization-in-the-eu-and-japan-for-the-treatment-of-chronic-heart-failure 2020-06-07T03:31:47 https://maestrodatabase.com/blog/the-university-of-queensland-cepi-and-csl-partner-to-advance-development-and-manufacture-of-covid-19-vaccine-candidate 2020-06-07T03:36:48 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-6-january-2022 2022-01-16T23:21:21 https://maestrodatabase.com/blog/accelerating-clinical-trials-in-the-eu-for-better-clinical-trials-that-address-patients-need 2022-01-16T22:12:02 https://maestrodatabase.com/blog/kiwis-affected-by-epilepsy-drug-switch-feel-let-down-by-pharmac-review 2020-06-07T03:20:13 https://maestrodatabase.com/blog/proposals-for-funding-in-the-blood-alimentary-and-immunosuppressant-therapy-areas 2019-12-09T03:46:38 https://maestrodatabase.com/blog/lilly-bags-expanded-eu-approval-for-taltz 2020-06-07T03:24:12 https://maestrodatabase.com/blog/health-canada-greenlights-mendelikabs-for-the-commercialisation-of-prmdk-nitisinone 2016-10-12T07:18:30 https://maestrodatabase.com/blog/ontario-plans-new-treatment-for-opioid-addiction 2016-10-12T11:07:57 https://maestrodatabase.com/blog/cybin-receives-fda-breakthrough-therapy-designation-for-its-novel-psychedelic-molecule-cyb003 2024-03-14T01:42:24 https://maestrodatabase.com/blog/enhertu-plus-pertuzumab-granted-priority-review-in-the-us-as-first-line-treatment-for-patients-with-her2-positive-metastatic-breast-cancer 2025-09-24T06:38:13 https://maestrodatabase.com/blog/aetna-merck-reach-value-based-deal-on-diabetes-medicines-and-collaborate-on-wellness 2016-10-12T20:08:48 https://maestrodatabase.com/blog/what-experimental-drug-most-companies-dont-post-compassionate-use-policies 2016-10-12T20:15:37 https://maestrodatabase.com/blog/department-publishes-revised-agenda-for-november-2020-pbac-meeting 2020-11-03T05:18:38 https://maestrodatabase.com/blog/reform-critical-in-healthcare-but-lacking-clear-direction 2016-10-12T19:58:45 https://maestrodatabase.com/blog/the-medical-tests-and-treatments-you-should-think-twice-about 2016-10-12T20:03:03 https://maestrodatabase.com/blog/terminal-breast-cancer-patients-denied-life-extending-drugs-available-in-australia 2016-10-12T20:29:22 https://maestrodatabase.com/blog/european-commission-approves-pfizers-prevenar-20-to-help-protect-infants-and-children-against-pneumococcal-disease 2024-03-14T01:31:43 https://maestrodatabase.com/blog/fda-grants-qidp-and-fast-track-designations-to-vt-1161-for-treatment-of-recurrent-vulvovaginal-candidiasis 2016-10-12T20:31:47 https://maestrodatabase.com/blog/improved-quality-of-medicare-health-and-drug-plans-means-great-news-for-medicare-beneficiaries 2016-10-12T20:17:59 https://maestrodatabase.com/blog/ema-publishes-epar-for-cabometyx-cabozantinib-maleate 2016-10-12T20:22:39 https://maestrodatabase.com/blog/undermining-value-based-purchasing----lessons-from-the-pharmaceutical-industry 2016-10-12T22:25:49 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-13-january-2022 2022-01-16T23:25:50 https://maestrodatabase.com/blog/wholesale-drug-prices-may-be-rising-but-rebates-are-taking-a-bigger-bite 2018-04-03T04:54:58 https://maestrodatabase.com/blog/basilea-announces-approval-of-antifungal-cresemba-isavuconazole-for-invasive-aspergillosis-in-china 2022-01-16T23:58:47 https://maestrodatabase.com/blog/cms-lowers-the-cost-of-prescription-drugs-for-medicare-beneficiaries 2018-04-03T04:57:32 https://maestrodatabase.com/blog/allergan-announces-fda-acceptance-of-supplemental-new-drug-application-for-avycaz-ceftazidime-and-avibactam 2018-11-22T05:46:52 https://maestrodatabase.com/blog/ascendis-pharma-receives-european-approval-for-transcon-hgh-for-paediatric-growth-hormone-deficiency 2022-01-16T23:43:51 https://maestrodatabase.com/blog/fda-charts-path-forward-for-biosimilars----but-drug-makers-arent-all-on-board 2018-04-03T04:53:11 https://maestrodatabase.com/blog/massachusetts-a-health-pioneer-turns-its-focus-to-drug-prices-its-in-for-a-fight 2018-04-03T05:05:00 https://maestrodatabase.com/blog/half-yearly-performance-snapshot-july-to-december-2017 2018-04-03T05:09:18 https://maestrodatabase.com/blog/pharmac---2021-in-review 2022-01-17T00:57:18 https://maestrodatabase.com/blog/atagi-update-following-weekly-covid-19-meeting-12-january-2022 2022-01-17T04:07:22 https://maestrodatabase.com/blog/tga-approves-game-changing-ovarian-cancer-drug-bringing-new-hope-to-patients 2022-01-17T20:04:22 https://maestrodatabase.com/blog/421-000-dollars-cancer-drug-kymriah-becomes-eligible-for-reimbursement 2022-01-17T19:59:08 https://maestrodatabase.com/blog/keytruda-reimbursement-boosts-msds-r-and-d-of-follow-up-drug 2022-01-17T20:07:07 https://maestrodatabase.com/blog/pharmac-publishes-annual-report-for-the-year-ending-30-june-2016 2016-10-13T05:21:37 https://maestrodatabase.com/blog/agenda-for-19-october-transparency-commission-meeting 2016-10-13T04:57:06 https://maestrodatabase.com/blog/valeant-hiked-lead-poisoning-drug-price-by-2-700-per-cent-report 2016-10-13T05:02:01 https://maestrodatabase.com/blog/enhertu-granted-priority-review-in-the-u-dot-s-for-patients-with-her2-positive-metastatic-breast-cancer-treated-with-a-prior-anti-her2-based-regimen 2022-01-17T10:15:09 https://maestrodatabase.com/blog/substantial-rebates-negotiated-in-medicare-part-d 2016-10-13T20:01:45 https://maestrodatabase.com/blog/first-comprehensive-overview-of-global-initiatives-on-medicine-regulation-published 2016-10-13T20:05:14 https://maestrodatabase.com/blog/smc---january-2022-decisions 2022-01-17T19:53:22 https://maestrodatabase.com/blog/breast-cancer-sufferers-crusade-for-more-medicine 2016-10-13T10:41:53 https://maestrodatabase.com/blog/patients-to-get-faster-access-to-the-most-cost-effective-treatments-under-proposed-changes-to-nices-process 2016-10-13T19:54:47 https://maestrodatabase.com/blog/tga-recognises-the-gamaleya-institute-vaccine-sputnik-v-russian-federation-for-international-travel-to-australia 2022-01-17T19:50:31 https://maestrodatabase.com/blog/fda-fast-track-designation-and-first-subject-dosing-with-lead-candidate-cc8464-slash-asp1807-for-the-management-of-neuropathic-pain-associated-with-isfn 2016-10-13T20:28:46 https://maestrodatabase.com/blog/fy-2016-generic-approvals-by-fda-a-new-record-under-gdufa 2016-10-13T20:30:55 https://maestrodatabase.com/blog/novel-drugs-for-depression 2016-10-13T20:08:12 https://maestrodatabase.com/blog/drug-coupons-helping-a-few-at-the-expense-of-everyone 2016-10-13T20:14:24 https://maestrodatabase.com/blog/swissmedic-grants-temporary-authorisation-to-xevudy-for-covid-19-patients 2022-01-17T20:19:17 https://maestrodatabase.com/blog/serb-receives-eu-approval-for-voraxaze-glucarpidase-as-rescue-therapy-for-high-dose-methotrexate-toxicity 2022-01-17T20:11:47 https://maestrodatabase.com/blog/sun-pharma-announces-health-canada-approval-of-winlevi-clascoterone-cream-1-percent-for-topical-treatment-of-acne 2023-06-20T01:26:33 https://maestrodatabase.com/blog/icer-publishes-final-evidence-report-on-treatments-for-paroxysmal-nocturnal-haemoglobinuria 2024-03-14T03:08:11 https://maestrodatabase.com/blog/the-cost-of-asthma-medicines 2018-04-03T06:59:07 https://maestrodatabase.com/blog/legacy-healthcare-announces-ema-validation-of-marketing-authorisation-application-for-coacillium-for-the-treatment-of-moderate-and-severe-alopecia-areata-in-children-and-adolescents 2023-06-20T01:15:11 https://maestrodatabase.com/blog/pepgen-receives-us-fda-orphan-drug-and-rare-paediatric-disease-designations-for-pgn-edo51-for-the-treatment-of-duchenne-muscular-dystrophy 2024-03-14T03:04:00 https://maestrodatabase.com/blog/ema-to-review-cemiplimab-as-a-potential-treatment-for-advanced-cutaneous-squamous-cell-carcinoma 2018-04-03T10:21:13 https://maestrodatabase.com/blog/atopic-dermatitis-patients-to-be-denied-nhs-access-to-dupixent 2018-04-03T10:11:28 https://maestrodatabase.com/blog/ema-to-review-dupixent-dupilumab-as-potential-treatment-for-inadequately-controlled-moderate-to-severe-asthma 2018-04-03T10:17:01 https://maestrodatabase.com/blog/getting-the-price-right-how-some-countries-control-spending-in-a-fee-for-service-system 2020-11-03T08:16:07 https://maestrodatabase.com/blog/drugs-and-manners-of-administration-that-meet-the-f2-slash-multi-brand-criteria-30-month-clock-for-originator-removal-calculation-for-the-2017-april-cycle 2016-10-13T23:36:28 https://maestrodatabase.com/blog/40-million-people-with-diabetes-will-be-left-without-insulin-by-2030-study-predicts 2018-11-22T19:19:14 https://maestrodatabase.com/blog/food-and-drug-administration-accepts-biomarins-new-drug-application-for-vosoritide-to-treat-children-with-achondroplasia 2020-11-03T07:58:37 https://maestrodatabase.com/blog/towards-electronic-product-information-for-eu-medicines 2018-11-22T19:24:38 https://maestrodatabase.com/blog/most-americans-dont-trust-the-government-to-lower-prescription-drug-costs 2018-11-22T19:05:12 https://maestrodatabase.com/blog/canadians-giving-up-necessities-going-into-debt-to-pay-for-prescriptions-study-finds 2018-11-22T19:10:06 https://maestrodatabase.com/blog/relief-for-sufferers-of-neuroendocrine-cancer-after-pharmac-funding-decision 2018-04-03T10:37:02 https://maestrodatabase.com/blog/fda-oks-new-administration-options-for-gsks-nucala 2019-06-08T01:54:39 https://maestrodatabase.com/blog/tga-publishes-auspar-for-entresto 2016-10-14T00:58:03 https://maestrodatabase.com/blog/tga-publishes-auspar-for-zurampic 2016-10-14T00:59:59 https://maestrodatabase.com/blog/cemiplimab-for-the-treatment-of-patients-with-recurrent-or-metastatic-cervical-cancer 2023-06-20T02:29:43 https://maestrodatabase.com/blog/the-fdas-cutoff-for-covid-19-vaccine-effectiveness-is-50-percent-what-does-that-mean 2020-11-03T10:42:27 https://maestrodatabase.com/blog/families-seek-access-to-life-changing-drug 2018-04-03T10:42:11 https://maestrodatabase.com/blog/fda-permits-marketing-of-first-medical-device-for-relief-of-pain-associated-with-irritable-bowel-syndrome-in-patients-11-18-years-of-age 2019-06-08T01:58:34 https://maestrodatabase.com/blog/state-coverage-and-reimbursement-of-anti-obesity-medications-in-medicaid 2024-03-14T20:26:11 https://maestrodatabase.com/blog/political-battle-over-private-health-insurance-rebate-heats-up 2018-04-03T20:52:05 https://maestrodatabase.com/blog/bluebird-bio-receives-fda-accelerated-approval-for-skysona-gene-therapy-for-early-active-cerebral-adrenoleukodystrophy 2022-09-18T02:16:40 https://maestrodatabase.com/blog/fda-approves-first-treatment-for-patients-with-liver-scarring-due-to-fatty-liver-disease 2024-03-14T20:17:40 https://maestrodatabase.com/blog/ema-accepts-regulatory-submission-for-lynparza-in-brca-mutated-her2-negative-metastatic-breast-cancer 2018-04-03T20:55:23 https://maestrodatabase.com/blog/exagamglogene-autotemcel-for-the-treatment-of-patients-with-sickle-cell-disease 2024-03-14T20:03:38 https://maestrodatabase.com/blog/securing-cheaper-medicines-and-improved-patient-outcomes-through-8th-community-pharmacy-agreement 2024-03-14T19:59:19 https://maestrodatabase.com/blog/alk-obtains-european-approval-for-its-tree-slit-tablet-against-allergic-rhinitis 2019-06-08T03:46:23 https://maestrodatabase.com/blog/is-it-time-for-the-fda-to-be-independent 2020-11-03T19:07:51 https://maestrodatabase.com/blog/us-fda-accepts-biologics-license-application-for-moxetumomab-pasudotox-in-hairy-cell-leukaemia 2018-04-03T21:07:58 https://maestrodatabase.com/blog/fda-approves-updated-label-for-endari 2020-11-03T19:10:52 https://maestrodatabase.com/blog/equity-issue-saskatchewan-to-fully-cover-cost-of-abortion-drug-mifegymiso 2019-06-08T03:42:16 https://maestrodatabase.com/blog/uk-germany-dissociate-from-who-drug-pricing-resolution 2019-06-08T03:40:26 https://maestrodatabase.com/blog/icer-to-assess-treatments-for-acute-migraine 2019-06-08T04:04:23 https://maestrodatabase.com/blog/tga-publishes-auspar-for-actemra 2016-10-14T01:46:12 https://maestrodatabase.com/blog/ptc-therapeutics-receives-fda-approval-for-the-expansion-of-the-emflaza-deflazacort-labeling-to-include-patients-2-5-years-of-age 2019-06-08T03:54:42 https://maestrodatabase.com/blog/nice-publishes-draft-guidance-on-the-use-of-opdivo-by-patients-with-nsclc 2016-10-14T10:44:13 https://maestrodatabase.com/blog/regulatory-policy-may-not-stop-comparative-efficacy-trials 2020-11-03T19:34:07 https://maestrodatabase.com/blog/nice-publishes-draft-guidance-on-the-use-of-imbruvica 2016-10-14T10:48:06 https://maestrodatabase.com/blog/intellia-therapeutics-announces-fda-regenerative-medicine-advanced-therapy-designation-granted-to-nexiguran-ziclumeran-for-the-treatment-of-hereditary-transthyretin-amyloidosis-with-polyneuropathy 2024-12-03T23:22:49 https://maestrodatabase.com/blog/biogen-provides-regulatory-update-on-high-dose-regimen-of-nusinersen 2025-09-24T20:33:46 https://maestrodatabase.com/blog/how-people-in-china-with-rare-diseases-afford-outrageously-expensive-medicines 2020-11-03T19:14:57 https://maestrodatabase.com/blog/chemocentryx-and-vfmcrp-announce-european-medicines-agency-has-accepted-to-review-the-marketing-authorisation-application-for-avacopan 2020-11-03T19:18:24 https://maestrodatabase.com/blog/gensight-biologics-reports-validation-of-lumevoq-marketing-authorisation-application-by-european-medicines-agency 2020-11-03T19:24:13 https://maestrodatabase.com/blog/complaints-about-private-health-insurance-rule-changes-jump 2019-12-09T19:39:16 https://maestrodatabase.com/blog/court-rules-against-fdas-finding-that-a-device-was-a-drug 2019-12-09T19:52:47 https://maestrodatabase.com/blog/china-to-strengthen-medicine-price-monitoring 2019-12-09T19:50:22 https://maestrodatabase.com/blog/if-vaccine-apartheid-exists-vaccine-billionaires-shouldnt 2021-06-13T07:10:01 https://maestrodatabase.com/blog/ema-publishes-agenda-for-9-12-december-chmp-meeting 2019-12-09T19:42:03 https://maestrodatabase.com/blog/galderma-investigational-therapy-nemolizumab-granted-fda-breakthrough-therapy-designation-for-the-treatment-of-patients-suffering-from-prurigo-nodularis 2019-12-09T20:03:55 https://maestrodatabase.com/blog/abbvie-receives-chmp-positive-opinion-for-venclyxto-venetoclax-tablets-for-appropriate-patients-with-difficult-to-treat-chronic-lymphocytic-leukaemia 2016-10-14T22:19:01 https://maestrodatabase.com/blog/canada-approves-pfizer-covid-drug 2022-01-18T01:52:01 https://maestrodatabase.com/blog/the-quest-for-a-vaccine-could-restore-faith-in-big-pharma 2020-06-08T01:17:44 https://maestrodatabase.com/blog/sesen-bio-initiates-rolling-submission-of-bla-for-vicinium-to-fda 2019-12-09T19:58:43 https://maestrodatabase.com/blog/pharmac-switching-anti-depressants-too-frequently---advocates 2020-06-08T02:04:52 https://maestrodatabase.com/blog/alnylam-announces-us-fda-acceptance-of-supplemental-new-drug-application-for-vutrisiran-for-the-treatment-of-attr-amyloidosis-with-cardiomyopathy 2024-12-04T00:04:01 https://maestrodatabase.com/blog/fda-approving-drugs-at-breakneck-speed-raising-alarm 2019-12-09T19:55:57 https://maestrodatabase.com/blog/hyposensitisation-with-ar101-in-peanut-allergy-proof-of-lesser-benefit 2022-01-17T23:25:49 https://maestrodatabase.com/blog/medicare-costs-for-seniors-lowered-in-senate-drug-price-bill 2019-12-09T20:24:25 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-positive-chmp-opinion-for-opdivo-nivolumab-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma-after-autologous-stem-cell-transplant-and-treatment-with-brentuximab-vedotin 2016-10-14T22:47:52 https://maestrodatabase.com/blog/unaffordable-treatment-for-severe-malaria-highlights-u-dot-s-drug-market-pitfalls 2021-06-13T07:22:37 https://maestrodatabase.com/blog/icer-issues-final-report-and-policy-recommendations-for-add-on-therapies-to-treat-type-2-diabetes 2019-12-09T20:16:58 https://maestrodatabase.com/blog/leqembi-lecanemab-approved-for-the-treatment-of-alzheimers-disease-in-australia 2025-09-24T20:49:53 https://maestrodatabase.com/blog/smc---december-2019-decisions 2019-12-09T20:35:12 https://maestrodatabase.com/blog/novartis-kisqali-receives-european-commission-approval-in-a-broad-population-of-patients-with-hr-positive-slash-her2-negative-early-breast-cancer-at-high-risk-of-recurrence 2024-12-04T00:23:59 https://maestrodatabase.com/blog/prescription-drug-prices-down-slightly-last-year 2019-12-09T20:26:50 https://maestrodatabase.com/blog/u-dot-k-lab-to-sidestep-pharma-industry-to-sell-potential-virus-vaccine 2020-06-08T02:08:22 https://maestrodatabase.com/blog/biden-harris-administration-announces-medicare-advantage-and-medicare-part-d-prescription-drug-proposals-that-aim-to-improve-care-and-access-for-enrollees 2024-12-04T00:19:25 https://maestrodatabase.com/blog/insurers-pay-more-for-multiple-sclerosis-drug-because-rebates-dont-help-report-says 2016-10-15T01:54:46 https://maestrodatabase.com/blog/why-losing-the-european-medicines-agency-is-bad-news-for-patients-jobs---and-the-nhs 2016-10-15T01:58:23 https://maestrodatabase.com/blog/anavex-life-sciences-announces-submission-of-blarcamesine-maa-for-treatment-of-alzheimers-disease-to-ema 2024-12-04T00:36:08 https://maestrodatabase.com/blog/highlights-from-chmp-october-2016-meeting 2016-10-15T02:12:30 https://maestrodatabase.com/blog/medical-devices-3d-pioneer-paul-durso-calls-for-level-field 2016-10-15T02:08:09 https://maestrodatabase.com/blog/soleno-therapeutics-announces-fda-extension-of-review-period-for-dccr-diazoxide-choline-extended-release-tablets-in-prader-willi-syndrome 2024-12-04T04:09:04 https://maestrodatabase.com/blog/fury-as-life-changing-eczema-drug-fails-to-make-pbs 2020-11-03T20:35:13 https://maestrodatabase.com/blog/keros-therapeutics-announces-us-fda-fast-track-designation-for-ker-050-in-lower-risk-myelodysplastic-syndromes 2024-03-14T23:12:50 https://maestrodatabase.com/blog/valneva-submits-label-extension-application-for-its-chikungunya-vaccine-ixchiq-to-the-us-fda 2024-12-04T04:18:29 https://maestrodatabase.com/blog/theratechnologies-submits-updated-tesamorelin-f8-formulation-sbla-for-fda-review 2024-12-04T04:36:16 https://maestrodatabase.com/blog/health-care-laws-beneficiaries-reflect-its-strengths-and-its-faults 2016-10-15T10:27:40 https://maestrodatabase.com/blog/gilead-withdraws-use-of-zydelig-to-treat-two-types-of-cancer 2022-01-18T19:36:47 https://maestrodatabase.com/blog/csl-behring-announces-the-first-patient-has-received-fda-approved-hemgenix-etranacogene-dezaparvovec-drlb-for-haemophilia-b 2023-06-20T11:37:34 https://maestrodatabase.com/blog/bms-joins-merck-in-challenge-to-medicare-price-negotiation 2023-06-20T09:10:11 https://maestrodatabase.com/blog/satsuma-pharmaceuticals-and-snbl-receive-fda-acceptance-of-nda-resubmission-of-sts101-for-the-acute-treatment-of-migraine-with-or-without-aura 2024-12-04T04:55:08 https://maestrodatabase.com/blog/tga-knowingly-putting-pharmacists-in-serious-danger 2022-01-18T20:29:20 https://maestrodatabase.com/blog/geron-announces-submission-of-new-drug-application-to-fda-for-first-in-class-telomerase-inhibitor-imetelstat 2023-06-20T20:53:27 https://maestrodatabase.com/blog/tga-in-review-2021 2022-01-18T20:03:33 https://maestrodatabase.com/blog/precigen-receives-breakthrough-therapy-designation-for-prgn-2012-adenoverse-immunotherapy-for-the-treatment-of-recurrent-respiratory-papillomatosis 2023-06-20T12:19:23 https://maestrodatabase.com/blog/bluebird-provides-update-on-fda-review-timelines-for-betibeglogene-autotemcel-for-beta-thalasszemia-and-elivaldogene-autotemcel-for-cerebral-adrenoleukodystrophy 2022-01-18T19:40:20 https://maestrodatabase.com/blog/celularity-receives-fast-track-designation-from-u-dot-s-fda-for-its-nk-cell-therapy-cynk-101-in-development-for-the-first-line-treatment-of-advanced-her2-slash-neu-positive-gastric-and-gastro-oesophageal-junction-cancers 2022-01-18T19:52:50 https://maestrodatabase.com/blog/us-fda-approves-first-anti-inflammatory-drug-for-cardiovascular-disease 2023-06-20T12:14:24 https://maestrodatabase.com/blog/covid-19-latest-safety-data-provide-reassurance-about-use-of-mrna-vaccines-during-pregnancy 2022-01-18T19:44:36 https://maestrodatabase.com/blog/fda-launches-pilot-program-to-help-reduce-risks-associated-with-using-laboratory-developed-tests-to-identify-cancer-biomarkers 2023-06-20T21:25:31 https://maestrodatabase.com/blog/discussion-paper-and-online-questionnaire-for-information-session-on-a-potential-pan-canadian-formulary 2022-01-18T20:49:21 https://maestrodatabase.com/blog/evidence-of-lack-of-treatment-efficacy-derived-from-statistically-non-significant-results-of-randomised-clinical-trials 2023-06-20T21:20:45 https://maestrodatabase.com/blog/antares-pharma-receives-fda-fast-track-designation-for-atrs-1902-for-adrenal-crisis-rescue 2022-01-18T20:32:51 https://maestrodatabase.com/blog/fedratinib-dihydrochloride-monohydrate-for-the-treatment-of-adults-with-disease-related-splenomegaly-or-symptoms-in-myelofibrosis 2024-12-04T05:26:29 https://maestrodatabase.com/blog/fda-approves-new-class-of-medicines-to-treat-paediatric-type-2-diabetes 2023-06-20T21:09:55 https://maestrodatabase.com/blog/akebia-announces-swissmedic-approval-of-vafseo-vadadustat 2023-06-21T06:00:30 https://maestrodatabase.com/blog/novo-nordisk-takes-actions-to-help-protect-us-patients-from-unlawful-sales-of-non-fda-approved-medicines-claiming-to-contain-semaglutide 2023-06-21T06:10:27 https://maestrodatabase.com/blog/fda-approves-talazoparib-with-enzalutamide-for-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer 2023-06-20T22:07:17 https://maestrodatabase.com/blog/artios-receives-us-fda-fast-track-designation-for-alnodesertib-in-atm-negative-metastatic-colorectal-cancer 2025-11-12T21:38:31 https://maestrodatabase.com/blog/a-brand-new-era-in-alzheimers-therapy-drug-cleared-by-regulator 2025-09-25T00:32:38 https://maestrodatabase.com/blog/argenx-announces-us-fda-approval-of-vyvgart-hytrulo-efgartigimod-alfa-and-hyaluronidase-qvfc-injection-for-subcutaneous-use-in-generalised-myasthenia-gravis 2023-06-21T06:52:12 https://maestrodatabase.com/blog/dapagliflozin-propanediol-monohydrate-for-the-treatment-of-adults-with-chronic-heart-failure-with-preserved-or-mildly-reduced-ejection-fraction 2023-06-21T06:21:46 https://maestrodatabase.com/blog/health-economic-assessment-of-polivy-in-combination-with-bendamustine-and-rituximab 2020-06-08T10:23:05 https://maestrodatabase.com/blog/rare-cancer-sufferers-face-long-waits-high-costs-for-treatment 2016-10-16T19:51:19 https://maestrodatabase.com/blog/ema-receives-application-for-conditional-authorisation-of-first-covid-19-treatment-in-the-eu 2020-06-08T21:02:15 https://maestrodatabase.com/blog/eu-actions-to-support-availability-of-medicines-during-covid-19-pandemic---update-number-7 2020-06-08T21:04:15 https://maestrodatabase.com/blog/bad-medicine 2016-10-16T19:54:13 https://maestrodatabase.com/blog/us-fda-approves-bristol-myers-squibbs-breyanzi-as-the-first-and-only-car-t-cell-therapy-for-adults-with-relapsed-or-refractory-chronic-lymphocytic-leukaemia-or-small-lymphocytic-lymphoma 2024-03-15T01:45:59 https://maestrodatabase.com/blog/cytodyn-receives-bla-acknowledgment-letter-from-the-fda 2020-06-08T10:19:08 https://maestrodatabase.com/blog/bimzelx-bimekizumab-now-approved-for-adults-with-active-psoriatic-arthritis-and-for-adults-with-axial-spondyloarthritis 2024-03-15T01:30:05 https://maestrodatabase.com/blog/ascendis-pharma-announces-extension-of-u-dot-s-fda-review-period-for-transcon-hgh-onapegsomatropin-for-paediatric-growth-hormone-deficiency 2021-06-14T05:26:54 https://maestrodatabase.com/blog/nice-publishes-appraisal-consultation-for-isatuximab-in-combination-with-pomalidomide-and-dexamethasone-for-treating-patients-with-relapsed-and-refractory-multiple-myeloma 2020-06-08T21:08:38 https://maestrodatabase.com/blog/public-hospital-cost-shifting-gets-reform-priority 2016-10-16T21:46:06 https://maestrodatabase.com/blog/fate-of-pharmas-reputation-lies-in-gileads-hands-on-pricing-of-covid-19-drug-remdesivir 2020-06-08T21:15:32 https://maestrodatabase.com/blog/neurometrix-receives-fda-breakthrough-device-designation-for-treatment-of-chronic-chemotherapy-induced-peripheral-neuropathy-with-its-wearable-neurostimulation-technology 2022-01-19T00:40:54 https://maestrodatabase.com/blog/pregabalin-supply-issue 2020-11-04T04:12:16 https://maestrodatabase.com/blog/darolutamide-in-combination-with-androgen-deprivation-therapy-and-docetaxel-for-the-treatment-of-patients-with-hormone-sensitive-metastatic-prostate-cancer 2023-06-21T08:35:18 https://maestrodatabase.com/blog/public-summary-documents-first-time-rejections-and-deferrals---november-2023-pbac-meeting 2024-03-15T06:40:31 https://maestrodatabase.com/blog/health-canada-approves-canadas-first-hiv-self-test 2020-11-04T01:55:45 https://maestrodatabase.com/blog/msac-publishes-agenda-for-october-2023-esc-meeting 2023-06-21T08:15:24 https://maestrodatabase.com/blog/nice-to-reassess-kyowa-kirins-poteligeo 2021-06-14T11:32:14 https://maestrodatabase.com/blog/fda-grants-breakthrough-device-designation-to-diadems-alzosure-predict-prognostic-blood-test-for-the-early-prediction-of-alzheimers-disease 2022-01-19T01:18:54 https://maestrodatabase.com/blog/gsks-fully-liquid-menveo-meningococcal-vaccine-approved-by-european-commission 2024-12-05T00:27:12 https://maestrodatabase.com/blog/opdivo-plus-yervoy-scores-nice-backing-for-certain-bowel-cancer-patients 2021-06-14T11:37:29 https://maestrodatabase.com/blog/bluebird-bio-announces-fda-priority-review-of-the-biologics-license-application-for-lovotibeglogene-autotemcel-lovo-cel-for-patients-with-sickle-cell-disease-12-years-and-older-with-a-history-of-vaso-occlusive-events 2023-06-21T12:44:07 https://maestrodatabase.com/blog/european-commission-approves-beigenes-tevimbra-for-first-line-treatment-of-advanced-slash-metastatic-oesophageal-squamous-cell-carcinoma-and-gastric-or-gastro-oesophageal-junction-cancer 2024-12-05T00:24:41 https://maestrodatabase.com/blog/icer-receives-grant-from-the-commonwealth-fund-for-annual-assessment-of-coverage-policies-that-present-barriers-to-fair-access 2023-06-21T12:39:40 https://maestrodatabase.com/blog/xbrance-announce-us-fda-filing-acceptance-for-a-lucentis-ranibizumab-biosimilar-candidate 2023-06-21T10:14:07 https://maestrodatabase.com/blog/imbruvica-is-included-in-the-high-cost-protection-with-a-changed-benefit-limitation 2023-06-21T21:23:17 https://maestrodatabase.com/blog/the-fda-still-lacks-a-permanent-chief-despite-pressing-weighty-problems 2021-06-14T21:16:48 https://maestrodatabase.com/blog/valeant-sets-price-increases-for-some-drugs 2016-10-17T05:08:05 https://maestrodatabase.com/blog/proposal-to-list-enzyme-replacement-therapies-for-some-rare-disorders 2016-10-17T04:22:09 https://maestrodatabase.com/blog/vaxzevria-ema-advises-against-use-in-people-with-history-of-capillary-leak-syndrome 2021-06-14T21:21:38 https://maestrodatabase.com/blog/fda-approves-genentechs-lucentis-ranibizumab-injection-pre-filled-syringe 2016-10-17T04:59:29 https://maestrodatabase.com/blog/sofosbuvir-with-velpatasvir-in-chronic-hepatitis-c-hint-of-added-benefit-in-two-of-ten-subindications 2016-10-17T19:52:25 https://maestrodatabase.com/blog/decision-to-list-cholic-acid-cholebiol-for-rare-disorder 2016-10-17T19:54:19 https://maestrodatabase.com/blog/pasc-to-consider-comprehensive-genomic-profiling-of-non-small-cell-lung-cancer-tumour-tissue-specimens-using-next-generation-sequencing-assays 2020-11-04T08:39:51 https://maestrodatabase.com/blog/b-dot-c-regulators-plan-to-let-pharmacists-distribute-abortion-pills 2016-10-17T10:23:19 https://maestrodatabase.com/blog/emtricitabine-slash-rilpivirine-slash-tenofovir-alafenamide-in-hiv-added-benefit-not-proven 2016-10-17T19:50:50 https://maestrodatabase.com/blog/fda-awards-21-grants-to-stimulate-product-development-for-rare-diseases 2016-10-17T20:06:23 https://maestrodatabase.com/blog/salvia-bioelectronics-receives-fda-breakthrough-device-designation-for-innovative-neurostimulation-solution 2020-11-04T09:00:33 https://maestrodatabase.com/blog/abe-orders-study-of-specific-steps-to-curb-medical-spending 2016-10-17T20:09:26 https://maestrodatabase.com/blog/sussan-leys-new-push-on-prosthesis-pricing 2016-10-17T20:01:11 https://maestrodatabase.com/blog/private-health-insurance-ombudsman-report-shows-record-complaints-driven-by-medibank 2016-10-17T20:03:23 https://maestrodatabase.com/blog/fda-ema-officials-regulators-must-adapt-to-effectively-regulate-precision-medicine 2016-10-17T20:28:55 https://maestrodatabase.com/blog/mhra-starts-rolling-review-of-astrazenecas-coronavirus-vaccine 2020-11-04T10:22:48 https://maestrodatabase.com/blog/teikoku-pharma-granted-fda-fast-track-designation-for-tpu-006-a-novel-4-day-dexmedetomidine-transdermal-system-for-post-operative-pain-management 2023-06-21T22:15:16 https://maestrodatabase.com/blog/immviras-oncolytic-product-mvr-t3011-it-intratumoral-injection-receives-fda-fast-track-designation-for-hnscc-treatment 2024-03-16T00:39:37 https://maestrodatabase.com/blog/exelixis-provides-regulatory-update-related-to-supplemental-new-drug-application-for-cabozantinib-cabometyx-for-the-treatment-of-patients-with-previously-treated-advanced-neuroendocrine-tumors 2024-12-05T06:00:08 https://maestrodatabase.com/blog/fda-approves-imlunestrant-for-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast-cancer 2025-09-25T21:00:53 https://maestrodatabase.com/blog/pembrolizumab-with-lenvatinib-for-previously-treated-advanced-or-recurrent-endometrial-cancer 2023-06-21T22:20:27 https://maestrodatabase.com/blog/upadacitinib-monohydrate-for-the-treatment-of-patients-with-previously-treated-moderately-to-severely-active-crohns-disease 2023-06-22T05:54:18 https://maestrodatabase.com/blog/calliditas-therapeutics-submits-supplemental-new-drug-application-to-us-fda-for-full-approval-of-tarpeyo 2023-06-22T05:44:18 https://maestrodatabase.com/blog/pharmac-considers-widening-access-to-treatments-for-multiple-sclerosis-and-haemophilia-a 2023-06-22T05:33:42 https://maestrodatabase.com/blog/motif-bio-initiates-nda-rolling-submission-for-iclaprim 2018-04-04T08:04:59 https://maestrodatabase.com/blog/u-dot-s-fda-grants-fast-track-designation-to-taris-for-tar-200-gemris-in-muscle-invasive-bladder-cancer 2018-04-04T07:59:36 https://maestrodatabase.com/blog/fda-grants-full-approval-for-blincyto-blinatumomab-to-treat-minimal-residual-disease-positive-b-cell-precursor-acute-lymphoblastic-leukaemia 2023-06-21T22:37:03 https://maestrodatabase.com/blog/early-benefit-assessment-for-new-drugs-2021-g-ba-sets-a-record-with-146-completed-procedures 2022-01-19T03:57:30 https://maestrodatabase.com/blog/aldeyra-therapeutics-provides-regulatory-update-on-adx-2191 2023-06-22T09:44:19 https://maestrodatabase.com/blog/roches-alecensa-approved-in-switzerland 2018-04-04T08:38:36 https://maestrodatabase.com/blog/beigene-receives-fda-approval-for-tevimbra-for-the-treatment-of-advanced-or-metastatic-oesophageal-squamous-cell-carcinoma-after-prior-chemotherapy 2024-03-17T20:17:20 https://maestrodatabase.com/blog/european-commission-approves-expanded-indication-for-amgens-xgeva-denosumab-for-the-prevention-sf-skeletal-related-events-in-patients-with-multiple-myeloma 2018-04-04T20:53:31 https://maestrodatabase.com/blog/funding-process-for-child-cancer-medicines-to-remain 2024-03-17T20:10:54 https://maestrodatabase.com/blog/ars-pharmaceuticals-announces-pdufa-date-extension-for-neffy-intranasal-epinephrine-for-the-treatment-of-allergic-reactions-type-1-including-anaphylaxis 2023-06-22T06:12:03 https://maestrodatabase.com/blog/lin-bioscience-receives-us-fda-fast-track-designation-for-lbs-007 2024-12-05T06:33:01 https://maestrodatabase.com/blog/us-fda-approves-bydureon-for-use-with-basal-insulin-in-patients-with-type-2-diabetes-with-inadequate-glycemic-control 2018-04-04T08:20:23 https://maestrodatabase.com/blog/perth-dads-desperate-bid-to-fund-$100k-life-saving-drug-for-son 2018-04-04T21:00:06 https://maestrodatabase.com/blog/clearing-dense-drug-patent-thickets 2024-12-05T07:22:41 https://maestrodatabase.com/blog/fda-approves-first-gene-therapy-for-treatment-of-certain-patients-with-duchenne-muscular-dystrophy 2023-06-22T20:52:34 https://maestrodatabase.com/blog/australia-now-has-four-covid-19-vaccine-options-expected-to-be-ready-in-2021 2020-11-04T19:34:14 https://maestrodatabase.com/blog/u-dot-s-fda-and-european-medicines-agency-accept-regulatory-submissions-for-review-of-dacomitinib-to-treat-metastatic-non-small-cell-lung-cancer-with-egfr-activating-mutations 2018-04-04T21:18:34 https://maestrodatabase.com/blog/phrma-sues-biden-administration-over-medicare-drug-price-negotiations 2023-06-22T10:16:03 https://maestrodatabase.com/blog/applied-therapeutics-receives-complete-response-letter-from-us-fda-regarding-new-drug-application-for-govorestat-for-classic-galactosaemia 2024-12-05T07:11:53 https://maestrodatabase.com/blog/patients-grappling-with-10-000-dollars-out-of-pocket-medical-bills-survey-reveals 2018-04-04T21:07:49 https://maestrodatabase.com/blog/rare-cancer-patients-push-for-better-medication-access-say-current-pbs-framework-is-unfair 2016-10-18T07:26:16 https://maestrodatabase.com/blog/the-biggest-pharma-election-risk-is-in-california 2016-10-18T06:55:43 https://maestrodatabase.com/blog/prices-of-generic-prescription-drugs-fall-by-25-40-percent 2018-04-04T21:15:26 https://maestrodatabase.com/blog/tga-publishes-auspar-for-keytruda 2016-10-18T06:59:04 https://maestrodatabase.com/blog/ottawa-wont-boost-provincial-health-transfers-without-reform-plan-philpott 2016-10-18T10:46:53 https://maestrodatabase.com/blog/medicare-puts-off-decision-on-lowering-drug-prices-patients-pay-at-the-pharmacy 2018-04-04T21:35:12 https://maestrodatabase.com/blog/health-cost-cuts-to-ease-pain-on-premiums 2016-10-18T19:49:25 https://maestrodatabase.com/blog/proteostasis-therapeutics-receives-fda-fast-track-designation-for-triple-combination-program-in-patients-with-cystic-fibrosis 2018-04-04T21:39:15 https://maestrodatabase.com/blog/fda-accepts-for-review-new-drug-application-for-sodium-zirconium-cyclosilicate-for-the-treatment-of-hyperkalaemia 2016-10-18T09:43:34 https://maestrodatabase.com/blog/cadth-calls-for-patient-input-on-a-submission-for-zinbryta-daclizumab 2016-10-18T20:18:20 https://maestrodatabase.com/blog/lillys-kisunla-donanemab-receives-marketing-authorization-by-european-commission-for-the-treatment-of-early-symptomatic-alzheimers-disease 2025-09-25T22:48:50 https://maestrodatabase.com/blog/senators-launch-probe-into-why-price-of-cancer-drug-increased-1400-percent 2018-04-04T21:33:15 https://maestrodatabase.com/blog/transitional-coverage-for-emerging-technologies 2023-06-22T21:16:12 https://maestrodatabase.com/blog/nice-publishes-evaluation-consultation-document-for-for-migalastat-hydrochloride 2016-10-18T19:56:01 https://maestrodatabase.com/blog/nice-proposes-faster-process-to-appraise-cheaper-drugs 2016-10-18T20:11:07 https://maestrodatabase.com/blog/agios-receives-positive-chmp-opinion-for-pyrukynd-mitapivat-for-the-treatment-of-pyruvate-kinase-deficiency-in-adult-patients 2022-09-18T21:15:38 https://maestrodatabase.com/blog/logicbio-therapeutics-receives-fda-fast-track-designation-for-lb-001-for-the-treatment-of-methylmalonic-acidemia 2020-11-04T19:44:04 https://maestrodatabase.com/blog/what-should-and-shouldnt-be-covered-by-medicare 2018-04-04T21:55:26 https://maestrodatabase.com/blog/can-doctors-choose-between-saving-lives-and-saving-a-fortune 2018-04-04T21:43:38 https://maestrodatabase.com/blog/ovarian-cancer-drug-olaparib-approved-in-scotland-as-new-treatment 2019-12-10T02:56:13 https://maestrodatabase.com/blog/istari-oncology-announces-fda-granted-fast-track-designation-to-pvsripo-for-the-treatment-of-advanced-melanoma 2021-06-15T04:33:13 https://maestrodatabase.com/blog/nice-publishes-first-technology-assessment-guidance-for-oesophageal-cancer 2020-11-04T19:54:39 https://maestrodatabase.com/blog/moderna-seeks-vaccine-approval-for-adolescents 2021-06-15T04:42:49 https://maestrodatabase.com/blog/uptake-of-medicines-for-type-2-diabetes-mellitus 2021-06-15T04:38:23 https://maestrodatabase.com/blog/nice-updates-guidance-for-nivolumab-for-melanoma 2020-11-04T20:18:35 https://maestrodatabase.com/blog/where-clinton-will-take-obamacare 2016-10-19T00:12:13 https://maestrodatabase.com/blog/medtronic-announces-fda-approval-of-its-next-generation-recharge-free-spinal-cord-stimulation-platform 2021-06-15T07:11:25 https://maestrodatabase.com/blog/parateks-new-drug-applications-for-oral-and-intravenous-omadacycline-accepted-for-priority-review-by-fda 2018-04-04T23:25:04 https://maestrodatabase.com/blog/fda-approves-genentechs-cancer-immunotherapy-tecentriq-atezolizumab-for-people-with-a-specific-type-of-metastatic-lung-cancer 2016-10-19T01:37:01 https://maestrodatabase.com/blog/levo-therapeutics-receives-complete-response-letter-from-fda-for-its-new-drug-application-for-lv-101-intranasal-carbetocin-for-the-treatment-of-prader-willi-syndrome 2022-01-19T09:40:01 https://maestrodatabase.com/blog/cidara-therapeutics-receives-us-fda-fast-track-designation-for-cd388-a-novel-drug-fc-conjugate-targeting-influenza-a-and-b 2023-06-22T23:05:33 https://maestrodatabase.com/blog/fda-accepts-for-review-libtayo-cemiplimab-rwlc-in-combination-with-chemotherapy-for-first-line-treatment-of-advanced-nsclc 2022-01-19T19:49:38 https://maestrodatabase.com/blog/canbridge-pharmaceuticals-can108-new-drug-application-for-alagille-syndrome-accepted-by-chinas-national-medical-products-administration 2022-01-19T07:27:00 https://maestrodatabase.com/blog/vertex-announces-key-advancements-across-kidney-portfolio 2025-09-26T01:47:39 https://maestrodatabase.com/blog/update-on-proposal-to-fund-two-new-medicines-for-type-2-diabetes-mellitus 2020-11-04T22:13:39 https://maestrodatabase.com/blog/first-adjuvanted-quadrivalent-influenza-vaccine-by-seqirus-receives-eu-approval 2020-06-09T05:24:00 https://maestrodatabase.com/blog/sensydia-receives-fda-breakthrough-device-designation-for-cps-non-invasive-cardiac-monitoring-device 2022-01-19T20:05:30 https://maestrodatabase.com/blog/gbts-voxelotor-is-first-sickle-cell-disease-treatment-to-receive-promising-innovative-medicine-designation-in-the-uk 2021-06-15T07:39:57 https://maestrodatabase.com/blog/tga-provisionally-approves-two-oral-covid-19-treatments-molnupiravir-lagevrio-and-nirmatrelvir-and-ritonavir-paxlovid 2022-01-19T20:25:00 https://maestrodatabase.com/blog/lamotrigine-concerns-not-addressed 2020-06-09T05:33:19 https://maestrodatabase.com/blog/lieutenant-general-john-frewen-says-he-expects-tga-approval-of-novavax-vaccine-is-imminent 2022-01-19T20:19:04 https://maestrodatabase.com/blog/amylyx-pharmaceuticals-files-new-drug-submission-for-amx0035-for-the-treatment-of-als-in-canada 2021-06-15T07:24:24 https://maestrodatabase.com/blog/emerging-healthcare-interventions-patient-centered-outcomes-research-institutes-programmatic-initiative 2023-06-23T00:14:09 https://maestrodatabase.com/blog/hira-calls-for-insurance-overhaul-to-ensure-access-to-high-cost-orphan-drugs 2025-09-26T07:55:23 https://maestrodatabase.com/blog/insmed-receives-fda-breakthrough-therapy-designation-for-brensocatib-in-patients-with-non-cystic-fibrosis-bronchiectasis 2020-06-09T04:38:04 https://maestrodatabase.com/blog/uks-nice-to-launch-sweeping-changes-to-drug-assessments-to-be-faster-more-agile 2022-01-19T19:58:24 https://maestrodatabase.com/blog/anumana-receives-us-fda-breakthrough-device-designation-for-its-cardiac-amyloidosis-algorithm 2023-06-22T23:24:57 https://maestrodatabase.com/blog/eton-pharmaceuticals-announces-fda-approval-of-rezipres-ephedrine-hydrochloride-injection 2021-06-15T20:55:23 https://maestrodatabase.com/blog/hugel-america-announces-u-dot-s-fda-acceptance-of-biologics-license-application-for-letibotulinumtoxina-for-injection-to-treat-glabellar-frown-lines 2021-06-15T21:01:05 https://maestrodatabase.com/blog/kelun-biotechs-trop2-adc-sacituzumab-tirumotecan-approved-for-marketing-by-nmpa-of-china-for-second-line-advanced-or-metastatic-triple-negative-breast-cancer 2024-12-05T21:15:58 https://maestrodatabase.com/blog/results-of-health-technology-assessments-of-orphan-drugs-in-germany--lack-of-added-benefit-evidence-gaps-and-persisting-unmet-medical-needs 2024-12-05T21:00:05 https://maestrodatabase.com/blog/cerevel-therapeutics-announces-fast-track-designation-granted-by-the-us-fda-to-cvl-871-for-the-treatment-of-dementia-related-apathy 2021-06-15T11:36:53 https://maestrodatabase.com/blog/beyond-survival-the-us-fda-confirms-surrogate-end-points-for-patients-with-newly-diagnosed-acute-myeloid-leukaemia-treated-with-intensive-chemotherapy 2022-01-19T20:36:35 https://maestrodatabase.com/blog/health-canada-approves-wegovy-semaglutide-injection-to-reduce-the-risk-of-non-fatal-myocardial-infarction 2024-12-05T20:12:19 https://maestrodatabase.com/blog/pharmac-funds-more-cancer-and-respiratory-medicines-for-new-zealanders 2024-12-05T23:12:24 https://maestrodatabase.com/blog/evkeeza-evinacumab-dgnb-angptl3-antibody-approved-in-the-us-for-children-as-young-as-1-year-old-with-ultra-rare-form-of-high-cholesterol 2025-09-26T11:54:55 https://maestrodatabase.com/blog/health-care-funding-decisions-and-real-world-benefits-reducing-bias-by-matching-untreated-patients 2021-06-15T21:38:40 https://maestrodatabase.com/blog/canadas-drug-agency-launches-consultation-on-methods-guide 2024-12-05T23:07:57 https://maestrodatabase.com/blog/msac-publishes-agenda-for-april-2025-msac-meeting 2024-12-05T22:59:33 https://maestrodatabase.com/blog/abbvie-submits-new-drug-application-to-us-fda-for-tavapadon-for-the-treatment-of-parkinsons-fisease 2025-09-26T20:54:41 https://maestrodatabase.com/blog/shire-granted-eu-marketing-authorisation-of-onivyde-in-combination-with-5-fluorouracil-and-leucovorin-for-the-treatment-of-metastatic-adenocarcinoma-of-the-pancreas-in-adult-patients-who-have-progressed-following-gemcitabine-based-therapy 2016-10-19T04:56:25 https://maestrodatabase.com/blog/fda-approves-stratagraft-for-the-treatment-of-adults-with-thermal-burns 2021-06-15T21:06:47 https://maestrodatabase.com/blog/how-the-patient-voice-is-becoming-vital-for-drug-approval 2021-06-15T21:23:45 https://maestrodatabase.com/blog/orphelia-pharma-provides-update-on-the-regulatory-submission-of-kizfizo-with-the-ema 2024-12-05T22:47:07 https://maestrodatabase.com/blog/6-ways-the-fdas-approval-of-aduhelm-does-more-harm-than-good 2021-06-15T21:13:17 https://maestrodatabase.com/blog/mhra-approves-new-diagnostic-agent-for-adult-patients-showing-signs-of-cognitive-impairment-for-alzheimers-disease 2024-12-06T00:53:41 https://maestrodatabase.com/blog/2022-october-price-disclosure-cycle---confirmed-prices-and-patient-savings-reports 2022-10-04T00:49:58 https://maestrodatabase.com/blog/ascendis-pharma-submits-transcon-pth-new-drug-application-to-the-us-fda-for-adult-patients-with-hypoparathyroidism 2022-09-19T05:24:14 https://maestrodatabase.com/blog/otsuka-submits-new-drug-application-in-japan-for-bempedoic-acid-in-the-treatment-of-hypercholesterolaemia 2024-12-06T00:41:33 https://maestrodatabase.com/blog/mylan-and-lupin-receive-european-marketing-authorisation-for-nepexto-biosimilar-etanercept 2020-06-09T06:37:22 https://maestrodatabase.com/blog/medicare-must-study-unproven-expensive-alzheimers-drug 2021-06-16T07:47:15 https://maestrodatabase.com/blog/co-design-of-an-enhanced-consumer-engagement-process 2024-03-18T04:38:26 https://maestrodatabase.com/blog/braeburn-resubmits-new-drug-application-for-brixadi-buprenorphine-extended-release-subcutaneous-injection-for-moderate-to-severe-opioid-use-disorder 2021-06-16T10:52:06 https://maestrodatabase.com/blog/registry-based-randomised-trials-the-best-of-both-worlds 2022-09-19T05:41:45 https://maestrodatabase.com/blog/zymfentra-infliximab-dyyb-the-first-and-only-fda-approved-subcutaneous-infliximab-now-commercially-available-in-the-u-dot-s 2024-03-18T04:23:00 https://maestrodatabase.com/blog/emmaus-life-sciences-announces-submission-of-marketing-authorisation-application-to-swissmedic-ideogen-to-manage-early-access-program 2021-06-16T07:37:20 https://maestrodatabase.com/blog/novartis-prostate-cancer-drug-receives-u-dot-s-fda-breakthrough-designation 2021-06-16T20:59:33 https://maestrodatabase.com/blog/alberta-canada-sees-early-success-from-switching-patients-to-biosimilars 2020-11-05T06:09:06 https://maestrodatabase.com/blog/fda-approves-avapritinib-for-advanced-systemic-mastocytosis 2021-06-16T21:04:19 https://maestrodatabase.com/blog/crinetics-announces-fda-approval-of-palsonify-paltusotine-for-the-treatment-of-adults-with-acromegaly 2025-09-26T21:12:24 https://maestrodatabase.com/blog/jessica-lawrences-meds-cost-her-family-$75k-a-year-because-theyre-not-listed-on-the-pbs 2024-12-06T01:46:22 https://maestrodatabase.com/blog/united-therapeutics-announces-fda-acceptance-of-tyvaso-dpi-new-drug-application-for-priority-review 2021-06-16T11:39:11 https://maestrodatabase.com/blog/sobi-launch-doptelet-avatrombopag-in-europe 2020-11-05T06:05:13 https://maestrodatabase.com/blog/msac-technical-guidelines---release-of-guidelines-for-preparing-assessments-for-the-medical-services-advisory-committee-version-1-dot-0-may-2021 2021-06-16T12:23:10 https://maestrodatabase.com/blog/government-of-canada-signs-bilateral-agreement-with-alberta-to-improve-access-to-drugs-for-rare-diseases 2024-12-06T01:40:14 https://maestrodatabase.com/blog/australias-progress-in-genomic-medicine-too-slow-says-international-health-chief 2025-09-26T21:27:04 https://maestrodatabase.com/blog/tlv-receives-a-new-assignment-for-precision-medicine-and-advanced-therapy-drugs 2021-06-16T21:26:43 https://maestrodatabase.com/blog/uk-post-brexit-drug-stockpiles-at-risk-amid-virus 2020-06-09T21:16:31 https://maestrodatabase.com/blog/msac-consultation-process---changes-to-take-effect-from-1-july-2021 2021-06-16T21:23:29 https://maestrodatabase.com/blog/abbvie-secures-positive-chmp-opinion-for-risankizumab-skyrizi-for-the-treatment-of-adults-with-moderate-to-severe-crohns-disease 2022-09-19T07:04:13 https://maestrodatabase.com/blog/desloratadine-new-exchange-groups 2020-06-09T21:19:31 https://maestrodatabase.com/blog/tackling-the-3-big-challenges-confronting-health-technology-assessment-development-in-asia-a-commentary 2020-06-09T21:31:34 https://maestrodatabase.com/blog/hhs-proposes-rescinding-trump-era-insulin-epinephrine-rule 2021-06-16T21:34:24 https://maestrodatabase.com/blog/a-litany-of-flaws-advocacy-group-urges-hhs-to-boot-fda-officials-over-alzheimers-drug-approval 2021-06-16T21:31:21 https://maestrodatabase.com/blog/the-development-of-health-technology-assessment-in-asia-current-status-and-future-trends 2020-06-09T21:38:51 https://maestrodatabase.com/blog/celcuity-receives-fda-fast-track-designation-for-gedatolisib-in-hr-positive-her2-negative-metastatic-breast-cancer 2022-01-20T00:43:52 https://maestrodatabase.com/blog/the-coronavirus-pandemic-is-reigniting-a-fierce-debate-over-compounded-drugs 2020-06-09T20:54:09 https://maestrodatabase.com/blog/tga-provisionally-approves-novavax-biocelect-covid-19-vaccine-nuvaxovid 2022-01-20T00:35:48 https://maestrodatabase.com/blog/biocryst-announces-berotralstat-expanded-access-program-for-patients-with-hereditary-angioedema-in-united-states 2020-06-09T21:12:19 https://maestrodatabase.com/blog/sanders-delighted-desantis-asked-white-house-to-import-canadian-prescription-drugs 2021-06-16T21:19:47 https://maestrodatabase.com/blog/pasc-to-consider-methods-for-the-detection-of-beta-amyloid-pathology-in-patients-with-early-stage-alzheimers-disease-to-determine-eligibility-for-aducanumab 2020-11-05T07:52:10 https://maestrodatabase.com/blog/german-law-makers-seek-to-ease-reimbursement-for-advanced-therapies 2021-06-16T21:46:01 https://maestrodatabase.com/blog/forxiga-approved-in-the-eu-for-heart-failure 2020-11-05T07:21:47 https://maestrodatabase.com/blog/europe-wants-to-make-its-own-drugs-but-it-needs-american-blood-plasma 2020-06-09T21:44:17 https://maestrodatabase.com/blog/xhance-approved-by-fda-as-first-and-only-medication-indicated-for-treatment-of-adults-with-chronic-rhinosinusitis-without-nasal-polyps 2024-03-18T06:20:36 https://maestrodatabase.com/blog/the-us-governments-supply-of-the-only-proven-covid-19-drug-runs-out-at-the-end-of-the-month 2020-06-09T21:47:29 https://maestrodatabase.com/blog/volumetrixs-niva|hf-for-heart-failure-patients-designated-as-breakthrough-device-by-u-dot-s-fda 2021-06-16T21:40:10 https://maestrodatabase.com/blog/lynparza-approved-in-the-eu-for-the-treatment-of-brca-mutated-metastatic-castration-resistant-prostate-cancer 2020-11-05T07:25:12 https://maestrodatabase.com/blog/lynparza-approved-in-the-eu-as-first-line-maintenance-treatment-with-bevacizumab-for-hrd-positive-advanced-ovarian-cancer 2020-11-05T07:45:20 https://maestrodatabase.com/blog/expanded-pbs-listing-to-save-australians-around-120-000-dollars-a-year 2021-06-17T06:57:32 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-17-june-2021 2021-06-17T06:47:46 https://maestrodatabase.com/blog/vertex-announces-european-commission-approval-for-kalydeco-ivacaftor-as-first-and-only-cftr-modulator-to-treat-eligible-infants-with-cystic-fibrosis-as-early-as-four-months-of-age 2020-11-05T09:20:37 https://maestrodatabase.com/blog/skin-cancer-drug-not-cost-effective-for-routine-nhs-use 2020-11-05T10:43:29 https://maestrodatabase.com/blog/analysing-data-from-patient-reported-outcome-and-quality-of-life-endpoints-for-cancer-clinical-trials-a-start-in-setting-international-standards 2016-10-19T07:45:52 https://maestrodatabase.com/blog/australia-secures-a-further-50-million-doses-of-covid-19-vaccine 2020-11-05T11:14:13 https://maestrodatabase.com/blog/pharmac-unlikely-to-get-back-up-flu-vaccines-before-season-over 2019-06-09T06:11:06 https://maestrodatabase.com/blog/camurus-receives-eu-approval-for-weekly-and-monthly-buvidal-cam2038-for-opioid-dependence 2018-11-23T08:12:12 https://maestrodatabase.com/blog/value-assessment-of-antimicrobials-and-the-implications-for-development-access-and-funding-of-effective-treatments-australian-stakeholder-perspective 2020-11-05T20:19:33 https://maestrodatabase.com/blog/ema-will-assess-potential-covid-19-vaccine-on-case-by-case-basis 2020-11-05T20:25:33 https://maestrodatabase.com/blog/cutting-medical-device-and-prostheses-costs-should-lower-health-premiums-says-minister 2016-10-19T09:34:46 https://maestrodatabase.com/blog/australians-should-expect-a-marathon-on-vaccine-distribution-experts-warn 2020-11-05T20:30:36 https://maestrodatabase.com/blog/ema-updates-list-of-prime-priority-medicines 2016-10-19T19:55:44 https://maestrodatabase.com/blog/timely-and-full-6cpa-delivery-the-highest-priority-for-pharmacy-guild 2016-10-19T08:17:45 https://maestrodatabase.com/blog/step-in-the-right-direction-on-private-health-costs 2016-10-19T08:50:00 https://maestrodatabase.com/blog/australias-world-renowned-brain-surgeon-charlie-teo-says-his-critics-will-eventually-get-me 2019-06-09T06:14:08 https://maestrodatabase.com/blog/eu-court-quashes-german-prescription-drug-price-floor 2016-10-19T20:02:04 https://maestrodatabase.com/blog/icer-to-review-treatments-for-atopic-dermatitis-in-upcoming-report 2016-10-19T20:05:03 https://maestrodatabase.com/blog/fda-approves-lillys-lartruvo-olaratumab-in-combination-with-doxorubicin-for-soft-tissue-sarcoma 2016-10-19T19:57:43 https://maestrodatabase.com/blog/iqwig-publishes-a-new-version-of-its-general-methods 2020-11-05T20:08:44 https://maestrodatabase.com/blog/chemocentryx-announces-eu-approval-of-tavneos-avacopan-for-the-treatment-of-anca-associated-vasculitis 2022-01-20T01:30:48 https://maestrodatabase.com/blog/aspen-fined-over-huge-price-hikes 2016-10-19T20:18:35 https://maestrodatabase.com/blog/cost-effectiveness-of-cancer-drugs-comparative-analysis-of-the-united-states-and-england 2020-11-05T20:11:40 https://maestrodatabase.com/blog/treat-pharma-as-a-utility-and-10-other-ways-states-can-lower-drug-prices 2016-10-19T20:08:34 https://maestrodatabase.com/blog/oasmia-pharmaceutical-receives-approval-from-european-commission-for-apealea-paclitaxel-micellar-in-the-european-union 2018-11-23T08:18:51 https://maestrodatabase.com/blog/pharma-may-avoid-worst-case-drug-pricing-scenario-as-us-elections-deadlocked 2020-11-05T20:15:04 https://maestrodatabase.com/blog/medicare-shouldnt-pay-more-for-drugs-when-others-pay-less 2016-10-19T20:25:48 https://maestrodatabase.com/blog/fda-approves-first-gene-therapy-for-children-with-metachromatic-leukodystrophy 2024-03-18T21:23:57 https://maestrodatabase.com/blog/statement-in-response-to-latest-atagi-advice-regarding-covid-19-vaccines 2021-06-17T07:43:28 https://maestrodatabase.com/blog/u-dot-s-government-purchases-additional-200-million-doses-of-modernas-covid-19-vaccine 2021-06-17T07:34:19 https://maestrodatabase.com/blog/trouble-on-the-exchanges---does-the-united-states-owe-billions-to-health-insurers 2016-10-19T23:17:22 https://maestrodatabase.com/blog/us-fda-approves-stemcyte-biologics-license-application-for-regenecyte-cord-blood-cell-therapy-product 2024-12-06T04:00:36 https://maestrodatabase.com/blog/fda-grants-radiopharm-theranostics-dunp19-product-rare-paediatric-disease-designation 2022-09-19T08:24:58 https://maestrodatabase.com/blog/final-nhs-green-light-for-allergans-ibs-d-drug 2017-08-31T10:49:44 https://maestrodatabase.com/blog/public-opinion-about-the-future-of-the-affordable-care-act 2017-08-31T10:53:35 https://maestrodatabase.com/blog/two-anti-viral-covid-19-treatments-approved 2022-01-20T02:32:17 https://maestrodatabase.com/blog/seagen-announces-tukysa-tucatinib-in-combination-with-trastuzumab-granted-priority-review-by-fda-for-previously-treated-her2-positive-metastatic-colorectal-cancer 2022-09-19T20:16:50 https://maestrodatabase.com/blog/fda-approves-genentechs-actemra-tocilizumab-for-the-treatment-of-car-t-cell-induced-cytokine-release-syndrome 2017-08-31T11:04:19 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-september-2017 2017-08-31T11:43:42 https://maestrodatabase.com/blog/agenda-for-the-december-2024-pbac-intracycle-meeting 2024-12-06T05:23:45 https://maestrodatabase.com/blog/advanced-accelerator-applications-announces-new-prescription-drug-user-fee-act-date-of-26-january-2018-for-lutetium-lu-177-dotatate-lutathera 2017-08-31T11:13:07 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-report-finds-inadequate-evidence-to-compare-parp-inhibitors-across-key-ovarian-cancer-indications 2017-08-31T11:52:15 https://maestrodatabase.com/blog/woman-in-limbo-over-rare-cancer-treatment 2016-10-20T19:45:18 https://maestrodatabase.com/blog/opening-up-clinical-data-on-new-medicines 2016-10-20T19:52:15 https://maestrodatabase.com/blog/oral-otezla-apremilast-receives-positive-nice-recommendation-for-adults-with-chronic-plaque-psoriasis 2016-10-20T08:05:12 https://maestrodatabase.com/blog/pharmac-publishes-minutes-from-february-2023-ptac-meeting 2023-06-23T06:04:17 https://maestrodatabase.com/blog/ottawas-gloves-come-off-over-health-care-funding 2016-10-20T20:11:24 https://maestrodatabase.com/blog/a-life-saving-new-drug-for-covid-19-is-found 2021-06-17T11:37:55 https://maestrodatabase.com/blog/celgene-skips-the-placebo-fails-drug-development-101 2016-10-20T20:14:35 https://maestrodatabase.com/blog/european-commission-approves-roches-vabysmo-the-first-bispecific-antibody-for-the-eye-for-two-leading-causes-of-vision-loss 2022-09-19T20:39:38 https://maestrodatabase.com/blog/mylans-settlement-with-doj-not-tough-enough-senator-says 2016-10-20T20:04:01 https://maestrodatabase.com/blog/oncologists-knock-icers-lung-cancer-cost-effectiveness-review 2016-10-20T20:06:24 https://maestrodatabase.com/blog/members-unite-in-response-to-r-and-d-tax-incentive-review 2016-10-20T20:23:45 https://maestrodatabase.com/blog/applied-therapeutics-granted-fast-track-designation-by-fda-for-at-007-for-galactosaemia 2021-06-17T11:45:43 https://maestrodatabase.com/blog/pathogenomix-granted-fda-breakthrough-device-designation 2022-01-20T03:38:32 https://maestrodatabase.com/blog/beigene-receives-positive-chmp-opinion-for-brukinsa-zanubrutinib-for-the-treatment-of-adults-with-marginal-zone-lymphoma 2022-09-19T20:34:04 https://maestrodatabase.com/blog/binding-arbitration-a-flawed-approach-to-tackling-drug-pricing 2016-10-20T20:16:52 https://maestrodatabase.com/blog/pharmaceuticals-and-public-health 2016-10-20T20:20:09 https://maestrodatabase.com/blog/shared-decision-making-underpins-good-health-care 2021-06-17T11:42:16 https://maestrodatabase.com/blog/ontozry-scores-mhra-authorisation-for-focal-onset-seizures 2021-06-17T09:53:54 https://maestrodatabase.com/blog/biosimilar-medicines-can-be-interchanged 2022-09-19T20:24:42 https://maestrodatabase.com/blog/speeding-access-to-new-and-innovative-cancer-treatments 2019-12-10T05:57:48 https://maestrodatabase.com/blog/changes-to-pbs-eligibility-criteria-for-paxlovid 2023-06-23T06:40:29 https://maestrodatabase.com/blog/eagle-pharmaceuticals-submits-response-to-complete-response-letter-from-fda-for-vasopressin 2021-06-17T11:09:58 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-european-commission-approval-for-lag-3-blocking-antibody-combination-opdualag-nivolumab-and-relatlimab-for-the-treatment-of-unresectable-or-metastatic-melanoma-with-tumour-cell-pd-l1-expression-<-1-percent 2022-09-19T20:29:33 https://maestrodatabase.com/blog/fda-expands-use-of-tevas-austedo-in-parkinsons 2017-08-31T12:59:03 https://maestrodatabase.com/blog/esperion-announces-new-drug-submissions-in-canada-for-nexletol-bempedoic-acid-and-nexlizet-bempedoic-acid-and-ezetimibe-treatments-to-reduce-ldl-cholesterol-and-cardiovascular-risk 2024-12-06T06:40:30 https://maestrodatabase.com/blog/amneal-announces-u-dot-s-fda-filing-acceptance-of-biologics-license-application-for-bevacizumab 2021-06-17T20:58:37 https://maestrodatabase.com/blog/does-nices-severity-modifier-for-assessing-diseases-need-to-change 2024-12-06T06:34:34 https://maestrodatabase.com/blog/statement-from-center-for-drug-evaluation-and-research-director-janet-woodcock-regarding-safety-concerns-related-to-investigational-use-of-keytruda-in-multiple-myeloma 2017-08-31T20:51:13 https://maestrodatabase.com/blog/usfda-target-action-date-for-trastuzumab-reset-to-3-december-2017 2017-08-31T20:56:23 https://maestrodatabase.com/blog/fda-approves-a-nasal-anti-histamine-for-non-prescription-use 2021-06-17T20:43:34 https://maestrodatabase.com/blog/health-minister-mark-butler-says-pbs-not-for-negotiation-donald-trump-announced-100-pc-tariff-on-pharmaceutical-goods 2025-09-27T02:19:50 https://maestrodatabase.com/blog/agenus-announces-u-dot-s-fda-acceptance-and-priority-review-of-balstilimab-biologics-license-application-for-the-treatment-of-recurrent-or-metastatic-cervical-cancer 2021-06-17T20:48:03 https://maestrodatabase.com/blog/pharmacists-can-now-prescribe-paxlovid-but-barriers-persist 2022-09-19T20:45:21 https://maestrodatabase.com/blog/intercept-receives-complete-response-letter-from-fda-for-obeticholic-acid-as-a-treatment-for-pre-cirrhotic-fibrosis-due-to-nash 2023-06-23T10:36:21 https://maestrodatabase.com/blog/ema-publishes-agenda-for-18-21-march-2024-chmp-meeting 2024-03-18T23:02:21 https://maestrodatabase.com/blog/furore-rages-over-fda-approval-of-controversial-alzheimers-drug 2021-06-17T21:16:46 https://maestrodatabase.com/blog/find-common-ground-on-health-roxon 2017-08-31T21:12:20 https://maestrodatabase.com/blog/sana-biotechnology-announces-fast-track-designation-for-sc291-in-relapsed-slash-refractory-systemic-lupus-erythematosus 2024-12-06T07:14:01 https://maestrodatabase.com/blog/vaccine-confusion-as-clots-force-jab-switch-for-two-million 2021-06-17T21:09:20 https://maestrodatabase.com/blog/a-cancer-doctor-weighs-in-on-car-t-precision-medicine-and-pricing-debates 2017-08-31T21:20:59 https://maestrodatabase.com/blog/the-fda-is-in-desperate-need-of-some-soul-searching 2021-06-17T21:03:45 https://maestrodatabase.com/blog/positive-chmp-opinion-for-the-extension-of-indication-of-palforzia-for-the-treatment-of-toddlers-with-confirmed-peanut-allergy 2024-12-06T07:04:26 https://maestrodatabase.com/blog/is-475-000-dollars-too-high-a-price-for-novartiss-historic-cancer-gene-therapy 2017-08-31T21:25:38 https://maestrodatabase.com/blog/dupixent-dupilumab-pre-filled-pen-now-available-in-canada-providing-convenient-self-administration-option-for-people-with-type-2-inflammatory-diseases 2021-06-17T21:13:14 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-september-2017 2017-08-31T21:32:12 https://maestrodatabase.com/blog/fda-grants-breakthrough-therapy-designation-to-sacituzumab-tirumotecan-for-the-treatment-of-certain-patients-with-previously-treated-advanced-or-metastatic-non-squamous-non-small-cell-lung-cancer-with-egfr-mutations 2024-12-06T11:04:44 https://maestrodatabase.com/blog/promise-and-reality-of-price-transparency 2018-04-05T04:48:16 https://maestrodatabase.com/blog/johnson-and-johnson-seeks-us-fda-approval-for-first-paediatric-indications-for-tremfya-guselkumab 2024-12-06T08:10:38 https://maestrodatabase.com/blog/teva-announces-fda-acceptance-of-resubmitted-new-drug-application-for-sd-809-for-treatment-of-chorea-associated-with-huntington-disease 2016-10-21T04:58:19 https://maestrodatabase.com/blog/new-treatment-recommended-for-kidney-cancer 2016-10-21T21:31:41 https://maestrodatabase.com/blog/lords-ask-minister-for-clarity-on-access-to-medicine-after-brexit 2018-11-23T21:01:50 https://maestrodatabase.com/blog/differential-pricing-of-pharmaceuticals-theory-evidence-and-emerging-issues 2018-11-23T21:05:15 https://maestrodatabase.com/blog/rigel-announces-r289-granted-fast-track-designation-by-the-fda-for-lower-risk-myelodysplastic-syndrome 2024-12-06T19:40:52 https://maestrodatabase.com/blog/fda-official-warns-other-drug-makers-not-to-copy-sarepta 2016-10-21T21:47:25 https://maestrodatabase.com/blog/bernie-sanders-wants-to-know-why-this-cancer-drug-costs-nearly-200-000-a-year 2016-10-21T21:50:32 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-for-priority-review-the-supplemental-biologics-license-application-for-opdivo-nivolumab-in-previously-treated-patients-with-advanced-form-of-bladder-cancer 2016-10-21T21:34:49 https://maestrodatabase.com/blog/top-scientist-wants-to-bring-big-data-analysis-to-health-care 2016-10-21T21:44:22 https://maestrodatabase.com/blog/chiesi-group-receives-the-european-marketing-authorisation-for-lamzede-velmanase-alfa 2018-04-05T05:10:32 https://maestrodatabase.com/blog/health-rebate-battle-is-brewing 2018-11-23T21:15:52 https://maestrodatabase.com/blog/omeros-confirms-submission-of-response-to-fda-regarding-the-bla-for-narsoplimab-in-the-treatment-of-hsct-tma 2022-01-20T04:20:55 https://maestrodatabase.com/blog/faster-access-to-groundbreaking-medicines-as-major-milestones-reached-in-deal-with-pharmaceutical-industry 2018-11-23T21:20:07 https://maestrodatabase.com/blog/multi-indication-pricing-nice-in-theory-but-can-it-work-in-practice 2018-11-23T21:07:30 https://maestrodatabase.com/blog/statement-on-the-arrival-of-the-novavax-vaccine-and-covid-19-pills 2022-01-20T04:27:15 https://maestrodatabase.com/blog/fda-is-advancing-new-efforts-to-address-drug-shortages 2018-11-23T21:10:08 https://maestrodatabase.com/blog/nice-signals-commitment-to-greater-flexibility-in-its-evaluation-of-promising-new-health-technologies-and-making-patient-access-fairer 2022-01-20T19:28:58 https://maestrodatabase.com/blog/novartis-announces-landmark-eu-approval-for-one-time-gene-therapy-luxturna-to-restore-vision-in-people-with-rare-inherited-retinal-disease 2018-11-23T21:30:18 https://maestrodatabase.com/blog/frances-high-authority-of-health-is-in-favour-of-delisting-alzheimers-disease-drugs 2016-10-22T12:53:32 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-20-january-2022 2022-01-20T19:37:45 https://maestrodatabase.com/blog/a-biotechs-depression-drug-returns-from-dead-setting-up-test-for-fda 2016-10-22T13:10:12 https://maestrodatabase.com/blog/faster-access-to-drugs 2016-10-22T12:39:32 https://maestrodatabase.com/blog/lessons-for-canada-from-pharmacare-systems-around-the-world 2018-11-23T21:24:56 https://maestrodatabase.com/blog/nice-moves-increased-accessibility-and-flexibility-for-health-tech 2022-01-20T19:34:16 https://maestrodatabase.com/blog/deal-or-delay-nices-new-negotiating-chip 2016-10-22T12:43:35 https://maestrodatabase.com/blog/private-health-insurers-victims-of-rising-healthcare-costs-too 2016-10-23T19:58:06 https://maestrodatabase.com/blog/kite-pharmas-ceo-on-bringing-cancer-killing-t-cells-to-the-fda 2016-10-22T13:12:24 https://maestrodatabase.com/blog/woman-battling-rare-cancer-gets-pharmac-funding-for-drug 2016-10-23T19:54:03 https://maestrodatabase.com/blog/novartiss-pricing-might-be-tested-with-costly-eye-therapy 2018-11-23T21:35:28 https://maestrodatabase.com/blog/gsk-announces-us-regulatory-submission-of-candidate-vaccine-for-prevention-of-shingles 2016-10-24T13:41:30 https://maestrodatabase.com/blog/health-funds-say-billions-in-savings-needed-to-curb-premiums 2016-10-24T13:38:42 https://maestrodatabase.com/blog/moderna-files-for-fda-authorisation-of-its-updated-covid-19-vaccine 2023-06-23T11:25:12 https://maestrodatabase.com/blog/how-to-make-better-use-of-patient-registries-to-collect-high-quality-data-on-medicines 2016-10-24T14:02:07 https://maestrodatabase.com/blog/lumakras-sotorasib-receives-approval-in-japan-for-patients-with-kras-g12c-mutated-advanced-non-small-cell-lung-cancer 2022-01-20T19:54:11 https://maestrodatabase.com/blog/taking-the-initiative-in-healthcare-will-california-voters-cap-drug-prices 2016-10-24T14:07:24 https://maestrodatabase.com/blog/genmab-announces-that-janssen-has-submitted-a-type-ii-variation-application-to-the-european-medicines-agency-for-use-of-subcutaneous-darzalex-daratumumab-in-patients-with-light-chain-amyloidosis 2020-11-06T01:09:56 https://maestrodatabase.com/blog/major-breast-cancer-treatment-cost-slashed-under-new-pbs-listing 2025-09-27T21:26:35 https://maestrodatabase.com/blog/fda-approves-mercks-zinplava-bezlotoxumab-to-reduce-recurrence-of-clostridium-difficile-infection-cdi-in-adult-patients-receiving-antibacterial-drug-treatment-for-cdi-who-are-at-high-risk-of-cdi-recurrence 2016-10-24T13:49:08 https://maestrodatabase.com/blog/fda-approves-supplemental-new-drug-application-for-xtandi-in-advanced-prostate-cancer 2016-10-24T13:53:29 https://maestrodatabase.com/blog/atyr-pharma-receives-fda-fast-track-designation-for-resolaris-to-treat-facioscapulohumeral-muscular-dystrophy 2016-10-24T14:19:56 https://maestrodatabase.com/blog/clinical-trial-exemption-ctx-scheme-renamed-as-clinical-trial-approval-cta-scheme 2020-11-06T01:18:06 https://maestrodatabase.com/blog/uk-government-publishes-findings-of-accelerated-access-review 2016-10-24T14:32:49 https://maestrodatabase.com/blog/sanders-urges-californians-to-approve-drug-price-ballot-measure 2016-10-24T14:10:51 https://maestrodatabase.com/blog/approving-a-problematic-muscular-dystrophy-drug-implications-for-fda-policy 2016-12-13T19:34:51 https://maestrodatabase.com/blog/some-health-plan-costs-to-increase-by-an-average-of-25-percent-u-dot-s-says 2016-10-25T10:52:23 https://maestrodatabase.com/blog/billionaire-mark-cuban-opens-online-pharmacy-to-provide-affordable-generic-drugs 2022-01-20T19:43:34 https://maestrodatabase.com/blog/asbestos-cancer-patient-seeking-government-funding 2016-10-25T10:36:41 https://maestrodatabase.com/blog/all-clear-for-hep-c-after-australian-medication 2016-10-25T10:38:42 https://maestrodatabase.com/blog/nice-publishes-draft-guidance-on-the-use-of-certolizumab-pegol-and-secukinumab-for-treating-active-psoriatic-arthritis-after-inadequate-response-to-dmards 2016-10-25T19:36:21 https://maestrodatabase.com/blog/ema-encourages-companies-to-submit-type-i-variations-for-2016-by-end-of-november 2016-10-25T10:57:56 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-approval-for-abecma-idecabtagene-vicleucel-the-first-car-t-therapy-approved-for-the-treatment-of-multiple-myeloma-in-japan 2022-01-20T19:50:00 https://maestrodatabase.com/blog/fda-approves-mercks-keytruda-pembrolizumab-in-metastatic-nsclc-for-first-line-treatment-of-patients-whose-tumours-have-high-pd-l1-expression-tumour-proportion-score-of-50-percent-or-more-with-no-egfr-or-alk-genomic-tumour-aberrations 2016-10-25T19:19:55 https://maestrodatabase.com/blog/proposal-to-list-mercaptopurine-oral-suspension 2018-04-05T07:15:24 https://maestrodatabase.com/blog/portola-pharmaceuticals-submits-new-drug-application-to-u-dot-s-fda-for-betrixaban-for-extended-duration-prophylaxis-of-venous-thromboembolism-in-acute-medically-ill-patients 2016-10-26T04:25:42 https://maestrodatabase.com/blog/investors-fear-pelosis-drug-price-plan-will-kill-small-biotech-firms 2019-12-10T19:45:39 https://maestrodatabase.com/blog/new-drug-for-gastro-intestinal-stromal-tumours-to-be-launched-in-australia-new-zealand-and-south-east-asia-following-distribution-agreement 2020-11-06T01:21:45 https://maestrodatabase.com/blog/the-g-ba-classifies-three-drugs-as-reserve-antibiotics 2022-01-20T20:06:55 https://maestrodatabase.com/blog/house-gop-unveils-alternative-drug-pricing-measure-ahead-of-pelosi-vote 2019-12-10T19:42:58 https://maestrodatabase.com/blog/immunotherapy-with-blinatumomab-improves-the-chances-of-survival-in-very-rare-childhood-blood-cancer 2022-01-20T20:02:13 https://maestrodatabase.com/blog/abeona-therapeutics-announces-fast-track-designation-from-fda-for-abo-102-in-sanfilippo-syndrome-type-a 2016-10-26T05:36:24 https://maestrodatabase.com/blog/do-large-pharma-companies-provide-drug-development-innovation-our-analysis-says-no 2019-12-10T19:39:13 https://maestrodatabase.com/blog/jyseleca-filgotinib-licensed-for-the-treatment-of-adult-patients-with-moderately-to-severely-active-ulcerative-colitis-in-great-britain 2022-01-20T20:23:37 https://maestrodatabase.com/blog/citius-pharmaceuticals-announces-fda-acceptance-of-the-bla-resubmission-of-lymphir-denileukin-diftitox-for-the-treatment-of-adults-with-relapsed-or-refractory-cutaneous-t-cell-lymphoma 2024-03-19T04:27:19 https://maestrodatabase.com/blog/americans-are-still-pretty-happy-with-their-private-health-insurance 2019-12-10T19:35:40 https://maestrodatabase.com/blog/woman-with-brain-tumour-wants-natural-therapies-subsidised-by-pharmac 2018-04-05T11:15:36 https://maestrodatabase.com/blog/dermira-receives-fast-track-designation-from-fda-for-lebrikizumab-for-the-treatment-of-atopic-dermatitis 2019-12-10T19:55:40 https://maestrodatabase.com/blog/u-dot-s-fda-grants-vistagen-therapeutics-fast-track-designation-for-ph94b-for-treatment-of-social-anxiety-disorder 2019-12-10T19:50:25 https://maestrodatabase.com/blog/first-and-only-medication-approved-in-canada-for-the-treatment-of-binge-eating-disorder 2016-10-26T06:06:56 https://maestrodatabase.com/blog/new-report-calls-for-measurement-of-outcomes-and-federal-funding-for-research-and-increased-capacity-at-fda-to-advance-safe-and-effective-regenerative-cell-therapies 2019-12-10T20:16:21 https://maestrodatabase.com/blog/endo-launches-generic-version-of-afinitor-everolimus-tablets-in-the-united-states 2019-12-10T20:04:58 https://maestrodatabase.com/blog/pharmacare-with-no-new-medicines 2019-12-10T20:25:05 https://maestrodatabase.com/blog/molnupiravir-for-the-treatment-of-patients-with-covid-19-infection 2024-12-06T22:04:52 https://maestrodatabase.com/blog/biotech-companies-defend-prices-of-one-off-gene-therapy 2019-12-10T20:20:05 https://maestrodatabase.com/blog/nice-describes-how-weight-loss-drug-tirzepatide-will-be-rolled-out 2024-12-06T21:58:55 https://maestrodatabase.com/blog/pickering-mom-fights-for-life-changing-cf-medicine-to-come-to-canada 2019-12-10T20:28:22 https://maestrodatabase.com/blog/aradigm-announces-the-ema-has-completed-its-validation-of-the-maa-submission 2018-04-05T20:52:42 https://maestrodatabase.com/blog/equillium-granted-u-dot-s-fda-fast-track-designation-for-itolizumab-for-the-treatment-of-lupus-nephritis 2019-12-10T20:47:14 https://maestrodatabase.com/blog/fda-approves-etectrx-digital-pill-as-rivals-struggle 2019-12-10T20:40:22 https://maestrodatabase.com/blog/national-pharmacare-must-come-even-if-some-provincial-governments-are-against-it 2019-12-10T20:34:49 https://maestrodatabase.com/blog/ohio-regulator-orders-insurers-benefit-managers-to-give-lowest-drug-price 2018-04-05T21:07:30 https://maestrodatabase.com/blog/the-health-202-trumps-tariffs-could-defeat-his-goal-of-lowering-drug-prices 2018-04-05T21:10:37 https://maestrodatabase.com/blog/pharmac-initiated-lengthy-review-a-waste-of-valuable-time-and-resources-says-rare-disorders-nz 2024-03-19T20:17:59 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-ponatinib-with-chemotherapy-for-newly-diagnosed-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia 2024-03-19T20:08:21 https://maestrodatabase.com/blog/icer-to-assess-medication-assisted-therapy-for-treatment-of-opioid-use-disorder 2018-04-05T21:01:36 https://maestrodatabase.com/blog/nice-set-to-reject-roches-ocrevus-ocrelizumab 2018-04-05T21:22:28 https://maestrodatabase.com/blog/specialised-therapeutics-initiates-early-access-program-for-neratinib-maleate 2018-04-05T21:12:55 https://maestrodatabase.com/blog/european-medicine-agency-accepts-marketing-authorisation-applications-for-bimekizumab-in-psoriatic-arthritis-and-axial-spondyloarthritis 2022-09-20T05:36:19 https://maestrodatabase.com/blog/the-alternative-to-private-health-insurance-proposed-by-dentists 2018-04-05T21:37:58 https://maestrodatabase.com/blog/lets-have-permanently-quicker-drug-approvals 2021-06-18T02:13:40 https://maestrodatabase.com/blog/nice-recommends-beigenes-brukinsa-zanubrutinib-for-patients-with-waldenstroems-macroglobulinaemia-who-have-had-at-least-one-treatment 2022-09-20T05:53:26 https://maestrodatabase.com/blog/mallinckrodt-completes-rolling-submission-of-biologics-license-application-for-stratagraft-regenerative-skin-tissue-to-u-dot-s-fda 2020-06-10T05:20:03 https://maestrodatabase.com/blog/cardiff-oncology-announces-expanded-access-program-for-onvansertib-in-kras-mutated-metastatic-colorectal-cancer-as-follow-on-to-fast-track-designation 2020-06-10T06:27:13 https://maestrodatabase.com/blog/sandoz-canada-receives-health-canada-approval-to-launch-two-oncology-biosimilars-ziextenzo-and-riximyo 2020-06-10T06:42:59 https://maestrodatabase.com/blog/evusheld-long-acting-antibody-combination-approved-in-the-eu-for-the-treatment-of-covid-19 2022-09-20T06:58:54 https://maestrodatabase.com/blog/indivior-announces-health-canada-approval-of-sublocade-buprenorphine-extended-release-injection-for-patients-with-moderate-to-severe-opioid-use-disorder 2018-11-24T01:10:41 https://maestrodatabase.com/blog/eu-expands-reach-of-vertex-cf-drug-kalydeco 2020-06-10T11:27:55 https://maestrodatabase.com/blog/efficient-funding-of-chemotherapy-review---submissions-on-discussion-paper 2021-06-18T04:12:50 https://maestrodatabase.com/blog/international-regulators-and-who-join-forces-to-address-covid-19-challenges 2020-11-06T19:37:46 https://maestrodatabase.com/blog/canada-has-found-the-key-to-lowering-drug-prices-but-it-wont-be-used-any-time-soon 2018-11-25T10:46:32 https://maestrodatabase.com/blog/helsinn-announces-launch-of-oral-formulation-of-akynzeo-in-china 2020-06-10T11:55:08 https://maestrodatabase.com/blog/avrobio-receives-rare-paediatric-disease-designation-from-us-fda-for-first-gene-therapy-in-development-for-cystinosis 2022-09-20T11:45:06 https://maestrodatabase.com/blog/aurinia-announces-european-commission-approval-of-lupkynis-voclosporin-for-the-treatment-of-lupus-nephritis 2022-09-20T08:38:18 https://maestrodatabase.com/blog/f2gs-olorofim-receives-both-fda-orphan-drug-designation-for-coccidioidomycosis-valley-fever-and-fda-qidp-designation-for-multiple-fungal-infections 2020-06-10T20:58:41 https://maestrodatabase.com/blog/abbvie-secures-positive-chmp-opinion-for-atogepant-for-the-preventive-treatment-of-adults-with-migraine 2023-06-24T01:01:05 https://maestrodatabase.com/blog/european-commission-approves-pelmeg-pegfilgrastim-as-a-biosimilar-treatment-to-reduce-the-duration-of-neutropenia-and-incidence-of-febrile-neutropenia-in-adults-treated-with-chemotherapy 2018-11-25T09:11:24 https://maestrodatabase.com/blog/ema-accepts-mediwounds-application-for-extended-indication-for-nexobrid-to-treat-paediatric-patients-with-severe-thermal-burns 2022-09-20T11:40:39 https://maestrodatabase.com/blog/final-nhs-green-light-for-roches-kadcyla 2020-06-10T11:32:27 https://maestrodatabase.com/blog/xtandi-enzalutamide-soft-capsules-approved-by-china-nmpa-for-the-treatment-of-non-metastatic-castration-resistant-prostate-cancer 2020-11-06T07:17:12 https://maestrodatabase.com/blog/leo-pharma-receives-positive-chmp-opinion-for-new-adtralza-tralokinumab-injection-device 2023-06-24T00:52:41 https://maestrodatabase.com/blog/trump-administration-invites-health-care-industry-to-help-rewrite-ban-on-kickbacks 2018-11-25T10:54:23 https://maestrodatabase.com/blog/price-limits-will-scare-off-covid-19-vaccine-makers-fauci-warns 2020-06-10T11:43:51 https://maestrodatabase.com/blog/brilinta-approved-in-the-us-to-reduce-the-risk-of-stroke-in-patients-with-an-acute-ischaemic-stroke-or-high-risk-transient-ischaemic-attack 2020-11-06T07:22:02 https://maestrodatabase.com/blog/dangerous-medical-devices-let-through-by-loopholes-and-lax-regulation 2018-11-25T20:39:59 https://maestrodatabase.com/blog/hawkes-bay-mums-heartbreak-as-pharmac-refuses-spinal-muscular-atrophy-drug-for-her-two-kids 2020-06-10T11:47:57 https://maestrodatabase.com/blog/highlights-from-the-19-22-june-2023-chmp-meeting 2023-06-24T00:24:52 https://maestrodatabase.com/blog/outcomes-of-the-may-2021-pbac-intracycle-meeting 2021-06-18T06:31:12 https://maestrodatabase.com/blog/fda-approves-pfizers-litfulo-ritlecitinib-for-adults-and-adolescents-with-severe-alopecia-areata 2023-06-24T10:01:01 https://maestrodatabase.com/blog/medicare-offers-details-on-reimbursement-for-new-alzheimers-drugs 2023-06-24T01:12:15 https://maestrodatabase.com/blog/coalition-of-attorneys-general-file-third-lawsuit-against-generic-drug-price-fixing 2020-06-10T21:04:44 https://maestrodatabase.com/blog/cidara-therapeutics-announces-fda-acceptance-for-priority-review-of-new-drug-application-for-rezafungin-for-the-treatment-of-candidemia-and-invasive-candidiasis 2022-09-20T20:27:21 https://maestrodatabase.com/blog/amylyx-pharmaceuticals-receives-chmp-negative-opinion-on-its-conditional-marketing-authorisation-application-for-amx0035-for-the-treatment-of-als-in-the-european-union 2023-06-24T01:05:37 https://maestrodatabase.com/blog/akcea-announces-approval-for-reimbursement-of-tegsedi-inotersen-in-italy-for-treatment-of-hereditary-transthyretin-amyloidosis-with-polyneuropathy 2020-06-10T21:31:16 https://maestrodatabase.com/blog/xvivo-granted-breakthrough-device-designation-from-the-fda-for-the-liver-assist-device 2022-09-20T11:53:10 https://maestrodatabase.com/blog/stemline-therapeutics-announces-start-of-rolling-bla-submission-for-sl-401 2018-04-06T01:30:16 https://maestrodatabase.com/blog/the-us-medicaid-program-coverage-financing-reforms-and-implications-for-health-equity 2022-09-20T21:07:05 https://maestrodatabase.com/blog/trelegy-ellipta-approved-in-canada-as-the-first-single-inhaler-triple-therapy-for-the-treatment-of-appropriate-patients-with-copd 2018-04-06T01:25:48 https://maestrodatabase.com/blog/junshi-biosciences-receives-nmpa-approval-of-snda-for-toripalimab-in-combination-with-chemotherapy-as-first-line-treatment-for-advanced-non-squamous-non-small-cell-lung-cancer 2022-09-20T20:53:52 https://maestrodatabase.com/blog/stryker-receives-fda-clearance-for-optablate-bone-tumour-ablation-system 2022-09-20T20:36:09 https://maestrodatabase.com/blog/lower-medicine-costs-for-chronic-health-conditions 2023-06-24T10:08:54 https://maestrodatabase.com/blog/chmp-adopts-positive-opinion-for-mycapssa-for-the-treatment-of-acromegaly 2022-09-20T20:48:44 https://maestrodatabase.com/blog/icer-publishes-evidence-report-on-new-therapies-for-bladder-cancer 2020-11-06T21:12:51 https://maestrodatabase.com/blog/insurer-to-return-40-dollars-million-in-health-care-claims-to-600-000-aussies 2022-09-20T21:23:45 https://maestrodatabase.com/blog/nices-methods-of-technology-evaluation---presenting-a-case-for-change 2020-11-06T21:01:14 https://maestrodatabase.com/blog/icer-publishes-evidence-report-on-digital-therapeutics-for-opioid-use-disorder 2020-11-06T21:03:34 https://maestrodatabase.com/blog/additional-analysis-of-kyprolis-in-the-treatment-of-multiple-myeloma 2020-11-06T21:07:55 https://maestrodatabase.com/blog/national-medicines-policy-review---publication-of-submissions 2022-01-21T01:45:45 https://maestrodatabase.com/blog/uk-regulator-oks-celltrions-avastin-biosimilar 2022-09-20T21:10:46 https://maestrodatabase.com/blog/deverra-therapeutics-granted-fda-regenerative-medicine-advanced-therapy-and-orphan-drug-designations-for-dvx101-dilanubicel-for-the-treatment-of-acute-myeloid-leukaemia 2024-03-19T23:57:07 https://maestrodatabase.com/blog/fda-approves-sodium-thiosulfate-to-reduce-the-risk-of-ototoxicity-associated-with-cisplatin-in-paediatric-patients-with-localised-non-metastatic-solid-tumours 2022-09-20T21:50:39 https://maestrodatabase.com/blog/conservatives-claim-vindication-despite-losing-bid-to-overturn-obamacare-in-the-us-supreme-court 2021-06-18T09:15:50 https://maestrodatabase.com/blog/us-fda-approves-idorsias-once-daily-tryvio-aprocitentan---the-first-and-only-endothelin-receptor-antagonist-for-the-treatment-of-high-blood-pressure-not-adequately-controlled-in-combination-with-other-antihypertensives 2024-03-20T10:54:57 https://maestrodatabase.com/blog/orphazyme-provides-regulatory-update-from-fda-on-arimoclomol-for-niemann-pick-disease-type-c 2021-06-18T08:16:58 https://maestrodatabase.com/blog/ptc-therapeutics-provides-key-regulatory-updates-march-2024 2024-03-20T06:48:40 https://maestrodatabase.com/blog/donald-trump-is-waging-war-on-sky-high-drug-prices-can-he-win 2025-09-28T23:53:04 https://maestrodatabase.com/blog/european-commission-approves-aubagio-teriflunomide-as-the-first-oral-ms-therapy-for-first-line-treatment-of-children-and-adolescents-living-with-relapsing-remitting-multiple-sclerosis 2021-06-18T21:09:03 https://maestrodatabase.com/blog/ema-recommends-marketing-approval-of-gobivaz-alvotechs-proposed-biosimilar-to-simponi-golimumab-with-advanz-pharma-as-commercialisation-partner 2025-09-29T00:52:23 https://maestrodatabase.com/blog/u-dot-s-fda-approves-second-indication-for-skyrizi-risankizumab-rzaa-to-treat-adults-with-active-psoriatic-arthritis 2022-01-21T22:15:11 https://maestrodatabase.com/blog/pfizer-and-opko-provide-update-on-the-biologics-license-application-for-somatrogon-for-paediatric-growth-hormone-deficiency 2022-01-21T22:31:06 https://maestrodatabase.com/blog/international-regulators-recommendations-on-covid-19-vaccines-and-the-omicron-variant 2022-01-21T22:20:55 https://maestrodatabase.com/blog/japans-mhlw-approves-pfizer-and-opkos-ngenla-somatrogon-a-new-long-acting-treatment-for-paediatric-growth-hormone-deficiency 2022-01-21T07:00:03 https://maestrodatabase.com/blog/pfizer-and-biontech-submit-applications-to-us-fda-for-omicron-xbb-dot-1-5-adapted-monovalent-covid-19-vaccine 2023-06-24T23:26:24 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-european-commission-approval-for-opdivo-nivolumab-plus-yervoy-ipilimumab-with-two-cycles-of-chemotherapy-for-first-line-treatment-of-metastatic-non-small-cell-lung-cancer 2020-11-07T01:10:39 https://maestrodatabase.com/blog/ligands-partner-sedor-pharmaceuticals-receives-fda-approval-for-sesquient-for-the-treatment-of-status-epilepticus-in-adult-and-paediatric-patients 2020-11-07T01:20:03 https://maestrodatabase.com/blog/fda-takes-actions-to-expand-use-of-treatment-for-outpatients-with-mild-to-moderate-covid-19 2022-01-22T01:06:19 https://maestrodatabase.com/blog/new-life-changing-medicines-listed-on-the-pbs 2025-09-29T04:25:56 https://maestrodatabase.com/blog/covid-19-vaccines-and-treatments-we-must-have-raw-data-now 2022-01-22T03:12:07 https://maestrodatabase.com/blog/covid-19-early-access-granted-to-paxlovid-as-a-curative-treatment 2022-01-22T21:41:29 https://maestrodatabase.com/blog/patent-thickets-are-thwarting-u-dot-s-availability-of-lower-cost-biosimilar-medicines-study-finds 2022-01-22T02:29:45 https://maestrodatabase.com/blog/accelerating-stakeholder-collaboration-to-enhance-the-clinical-trials-environment-in-the-eu 2024-03-20T21:26:20 https://maestrodatabase.com/blog/rezolute-receives-rare-paediatric-disease-designation-for-rz358-phase-2b-candidate-for-the-treatment-of-congenital-hyperinsulinism-enabling-eligibility-for-priority-review-voucher 2020-06-11T05:41:32 https://maestrodatabase.com/blog/health-canada-grants-marketing-authorisation-for-trikafta-elexacaftor-slash-tezacaftor-slash-ivacaftor-and-ivacaftor-in-people-ages-12-and-older-who-have-at-least-one-f508del-mutation 2021-06-18T21:48:58 https://maestrodatabase.com/blog/thousands-to-benefit-from-decision-to-subsidise-eczema-treatment 2022-01-23T19:56:45 https://maestrodatabase.com/blog/us-fda-approves-updated-novartis-beovu-label-to-include-additional-safety-information 2020-06-11T05:19:28 https://maestrodatabase.com/blog/bristol-myers-squibbs-abecma-idecabtagene-vicleucel-becomes-first-car-t-cell-therapy-approved-in-the-european-union-in-earlier-lines-for-triple-class-exposed-relapsed-and-refractory-multiple-myeloma 2024-03-20T21:07:21 https://maestrodatabase.com/blog/a-health-opportunity-cost-threshold-for-cost-effectiveness-analysis-in-the-united-state 2020-11-07T02:52:14 https://maestrodatabase.com/blog/pharmacists-struggle-to-meet-demand-for-free-covid-test-kits-amid-stock-shortage 2022-01-23T20:07:31 https://maestrodatabase.com/blog/database-tracks-faulty-medical-devices-across-the-globe 2018-11-25T23:08:59 https://maestrodatabase.com/blog/u-dot-s-food-and-drug-administration-approves-opdivo-nivolumab-for-the-treatment-of-patients-with-advanced-oesophageal-squamous-cell-carcinoma-after-prior-fluoropyrimidine--and-platinum-based-chemotherapy 2020-06-11T05:23:46 https://maestrodatabase.com/blog/manchin-wants-biden-to-oust-fda-chief-over-controversial-alzheimers-drug-approval 2021-06-18T22:06:48 https://maestrodatabase.com/blog/atagi-statement-on-the-use-of-novavax-covid-19-vaccine-nuvaxovid 2022-01-23T23:41:39 https://maestrodatabase.com/blog/morphosys-announces-approvals-for-tremfya-guselkumab-for-the-treatment-of-moderate-to-severe-plaque-psoriasis-in-brazil-and-australia 2018-04-06T05:04:57 https://maestrodatabase.com/blog/us-fda-approves-biocon-biologics-yesintek-biosimilar-to-j-and-js-stelara-ustekinumab 2024-12-07T04:17:38 https://maestrodatabase.com/blog/greg-hunt-warns-of-excessive-medical-fees-amid-dr-charlie-teo-debate 2019-06-10T08:24:59 https://maestrodatabase.com/blog/spevigo-approved-for-expanded-indications-in-china-and-the-us 2024-03-20T22:28:27 https://maestrodatabase.com/blog/a-lifesaving-therapy-for-children-with-a-rare-disease-is-now-the-worlds-most-expensive-drug-raising-questions-about-access 2024-03-20T22:21:10 https://maestrodatabase.com/blog/senator-patty-murray-introduces-bipartisan-bills-aimed-at-lowering-prescription-drug-prices 2019-06-10T08:30:56 https://maestrodatabase.com/blog/not-playing-nice-uk-drugs-gatekeeper-in-us-crosshairs 2019-06-10T11:01:06 https://maestrodatabase.com/blog/australians-with-severe-dermatitis-to-benefit-from-pbs-listing 2022-01-24T00:27:42 https://maestrodatabase.com/blog/uk-pharma-industry-reacts-to-outcome-of-european-council-meeting 2018-11-26T01:33:13 https://maestrodatabase.com/blog/fda-approves-first-chemoimmunotherapy-regimen-for-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma 2019-06-10T20:39:14 https://maestrodatabase.com/blog/the-2-dollars-1-cents-million-question-what-are-the-medical-ethical-implications-of-the-worlds-priciest-drug 2019-06-10T20:59:36 https://maestrodatabase.com/blog/tga-provisionally-approves-pfizers-covid-19-vaccine-comirnaty-tozinameran-for-use-as-a-booster-dose-in-individuals-5-years-and-older 2022-09-21T02:00:57 https://maestrodatabase.com/blog/smc---june-2019-decisions 2019-06-10T20:47:27 https://maestrodatabase.com/blog/3d-bioprinting-can-help-end-organ-transplant-waitlists----if-the-fda-stops-delaying 2021-06-18T23:01:49 https://maestrodatabase.com/blog/migraine-patients-coverage-headache-fda-ok-doesnt-mean-insurance-will-pay 2018-11-26T01:44:34 https://maestrodatabase.com/blog/rival-treatments-may-help-justify-fda-gamble-with-biogen-alzheimers-drug 2021-06-18T22:53:17 https://maestrodatabase.com/blog/leo-pharma-announces-european-medicines-agency-acceptance-of-marketing-authorisation-application-for-tralokinumab-for-the-treatment-of-adults-with-moderate-to-severe-atopic-dermatitis 2020-06-11T20:51:10 https://maestrodatabase.com/blog/patients-to-receive-new-cancer-drugs-faster-under-brexit-rules-shake-up 2022-01-24T01:11:10 https://maestrodatabase.com/blog/the-fda-grants-a-breakthrough-device-designation-to-the-miscoli-an-innovative-vertebral-body-tethering-device-to-treat-idiopathic-scoliosis 2021-06-18T23:05:06 https://maestrodatabase.com/blog/charlie-teo-frenzy-likened-to-lindy-chamberlain 2019-06-10T21:03:39 https://maestrodatabase.com/blog/new-treatment-for-essential-tremor-now-available-through-medicare 2024-03-20T23:14:09 https://maestrodatabase.com/blog/phanes-therapeutics-pt886-granted-fast-track-designation-for-the-treatment-of-patients-with-metastatic-claudin-18-dot-2-positive-pancreatic-adenocarcinoma-by-the-fda 2024-03-20T23:10:30 https://maestrodatabase.com/blog/rare-disease-therapy-development-and-access-remain-top-fda-priorities-during-covid-19 2020-06-11T21:05:48 https://maestrodatabase.com/blog/fda-approves-new-therapy-for-rare-disease-affecting-optic-nerve-spinal-cord 2020-06-11T21:08:22 https://maestrodatabase.com/blog/antares-pharma-provides-xyosted-regulatory-update 2018-04-06T09:10:19 https://maestrodatabase.com/blog/health-canada-approves-takedas-livtencity-maribavir-the-first-and-only-treatment-for-adults-with-post-transplant-cytomegalovirus-infection 2022-09-21T04:07:55 https://maestrodatabase.com/blog/fda-approves-pfizers-oncology-supportive-care-biosimilar-nyvepria-pegfilgrastim-apgf 2020-06-11T21:12:06 https://maestrodatabase.com/blog/health-economic-assessment-of-waylivra-in-familial-chylomicronaemia 2020-06-11T20:55:44 https://maestrodatabase.com/blog/tafamidis-for-treating-transthyretin-amyloid-cardiomyopathy 2020-06-11T21:00:36 https://maestrodatabase.com/blog/abbvie-announces-uk-pricing-strategy-for-elahere-mirvetuximab-soravtansine-gynx 2025-09-29T20:35:23 https://maestrodatabase.com/blog/singapore-approves-ebola-drug-remdesivir-for-treatment-of-coronavirus 2020-06-11T21:36:57 https://maestrodatabase.com/blog/cell-and-gene-therapies-fda-official-on-covid-19-impact 2020-06-11T21:48:44 https://maestrodatabase.com/blog/imfinzi-changed-treatment-paradigm-for-non-resectable-non-small-cell-lung-cancer 2020-06-11T21:21:12 https://maestrodatabase.com/blog/u-dot-s-fda-commissioner-says-agency-seeks-fast-review-of-covid-19-products 2020-06-11T21:30:50 https://maestrodatabase.com/blog/fda-considers-limiting-authorisation-of-certain-monoclonal-antibody-treatments 2022-01-24T03:38:38 https://maestrodatabase.com/blog/hutchmed-announces-nmpa-approval-of-surufatinib-sulanda-in-china-for-advanced-pancreatic-neuroendocrine-tumours 2021-06-19T03:30:50 https://maestrodatabase.com/blog/novartis-and-the-pan-canadian-pharmaceutical-alliance-conclude-negotiations-for-luxturna-a-gene-therapy-for-previously-untreatable-inherited-vision-loss 2022-09-21T06:49:04 https://maestrodatabase.com/blog/health-canada-accepts-for-review-new-drug-submission-for-tofersen-for-treatment-of-rare-genetic-form-of-als 2024-03-21T01:30:24 https://maestrodatabase.com/blog/tezspire-approved-in-the-eu-for-the-treatment-of-severe-asthma 2022-09-21T06:36:49 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-to-crb-701-for-the-treatment-of-relapsed-or-refractory-metastatic-cervical-cancer 2024-12-07T06:05:57 https://maestrodatabase.com/blog/ferinject-approved-by-health-canada-for-the-treatment-of-iron-deficiency-anaemia-in-adult-and-paediatric-patients-and-iron-deficiency-in-adult-patients-with-heart-failure 2024-03-21T01:20:44 https://maestrodatabase.com/blog/eu-health-regulator-says-covid-pandemic-not-over 2022-09-21T06:41:17 https://maestrodatabase.com/blog/biden-harris-administration-takes-next-steps-to-increase-access-to-sickle-cell-disease-treatments 2024-12-07T05:49:16 https://maestrodatabase.com/blog/lantern-pharmas-investigational-drug-candidate-lp-184-receives-second-fast-track-designation-from-fda-for-treatment-of-triple-negative-breast-cancer 2024-12-07T06:23:35 https://maestrodatabase.com/blog/european-regulator-ema-says-it-wont-set-50-percent-efficacy-threshold-for-covid-shots 2021-06-19T05:26:46 https://maestrodatabase.com/blog/scynexis-oral-scy-078-receives-fda-qidp-and-fast-track-designations-for-the-treatment-of-vvc-and-prevention-of-recurrent-vvc 2018-05-01T23:19:11 https://maestrodatabase.com/blog/acceleron-receives-fda-fast-track-designation-for-ace-083-in-facioscapulohumeral-muscular-dystrophy 2018-05-01T23:25:36 https://maestrodatabase.com/blog/patients-take-outdated-drugs-because-of-pbs-restrictions-uq-doctor 2019-07-03T03:08:44 https://maestrodatabase.com/blog/j-and-j-bms-lose-challenges-to-us-drug-price-negotiation-program 2024-04-30T21:28:06 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-may-2024 2024-04-30T21:21:06 https://maestrodatabase.com/blog/astria-therapeutics-receives-fast-track-designation-for-star-0215-for-the-treatment-of-hereditary-angioedema 2023-07-24T00:47:33 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-may-2024 2024-04-30T21:08:31 https://maestrodatabase.com/blog/gefitinib-in-new-exchange-group 2019-07-03T03:24:03 https://maestrodatabase.com/blog/prescription-medicines-applications-under-evaluation-february-2022 2022-02-28T05:09:08 https://maestrodatabase.com/blog/joint-evaluation-report-of-sotagliflozin-zynquista 2019-07-03T03:20:08 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-january-2019-update 2019-01-02T03:13:50 https://maestrodatabase.com/blog/drug-makers-raise-prices-on-hundreds-of-medicines 2019-01-02T05:57:42 https://maestrodatabase.com/blog/federal-judge-blocks-trump-administrations-cuts-to-discount-drug-program 2019-01-02T02:02:26 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-january-2019-update 2019-01-02T02:55:54 https://maestrodatabase.com/blog/gc-pharma-receives-complete-response-letter-from-the-u-dot-s-fda-for-alyglo 2022-02-28T05:32:23 https://maestrodatabase.com/blog/nhs-england-to-fund-actelions-uptravi 2019-01-02T13:13:16 https://maestrodatabase.com/blog/department-update-implementation-of-the-improved-payment-administration-arrangements 2019-01-02T07:59:35 https://maestrodatabase.com/blog/nhs-to-fund-afinitor-for-tsc-related-epilepsy 2019-01-02T13:06:32 https://maestrodatabase.com/blog/pharmac-ensures-earlier-access-to-key-covid-19-treatment 2022-02-28T05:17:57 https://maestrodatabase.com/blog/atagi-update-following-weekly-covid-19-meeting-23-february-2022 2022-02-28T05:21:53 https://maestrodatabase.com/blog/new-treatment-approved-in-canada-for-most-common-type-of-leukaemia 2020-01-09T01:20:46 https://maestrodatabase.com/blog/rhythm-pharmaceuticals-announces-public-reimbursement-for-imcivree-setmelanotide-in-canada-in-five-provinces-and-under-the-federal-non-insured-health-benefits-program 2025-11-09T20:41:27 https://maestrodatabase.com/blog/new-hope-for-patients-with-rare-diseases-with-the-launching-of-a-new-fund 2019-07-03T05:21:54 https://maestrodatabase.com/blog/ethics-information-retrieval-in-hta-state-of-current-practice 2023-07-24T04:50:14 https://maestrodatabase.com/blog/mark-cuban-cost-plus-drug-company-expands-access-with-addition-of-starjemza-ustekinumab-hmny-to-give-patients-more-power-over-prescription-costs 2025-11-09T20:49:59 https://maestrodatabase.com/blog/first-rsv-vaccine-to-protect-infants-up-to-6-months-of-age-and-older-adults 2023-07-24T05:02:29 https://maestrodatabase.com/blog/strengthening-australias-immunisation-program 2020-12-06T08:41:04 https://maestrodatabase.com/blog/government-promises-independent-pharmac-review-after-labour-mps-veto-health-select-committee-inquiry 2020-12-06T08:44:05 https://maestrodatabase.com/blog/bio-to-file-lawsuit-today-to-block-trump-international-drug-pricing-policy 2020-12-06T10:44:33 https://maestrodatabase.com/blog/what-is-the-price-of-comfort-oncologist-raises-concerns-about-newly-approved-cancer-treatment-in-canada 2024-05-01T01:38:42 https://maestrodatabase.com/blog/sandoz-receives-positive-chmp-opinion-for-multiple-sclerosis-biosimilar-natalizumab 2023-07-24T05:26:00 https://maestrodatabase.com/blog/amylyx-pharmaceuticals-announces-ema-validation-of-marketing-authorisation-application-for-amx0035-for-the-treatment-of-als 2022-02-28T06:54:23 https://maestrodatabase.com/blog/bristol-myers-squibbs-sprycel-dasatinib-tablets-now-approved-in-combination-with-chemotherapy-in-certain-paediatric-patients-with-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia 2019-01-02T21:41:50 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-positive-chmp-opinion-recommending-approval-for-opdivo-nivolumab-as-adjuvant-treatment-for-patients-with-radically-resected-high-risk-muscle-invasive-urothelial-carcinoma-with-tumour-cell-pd-l1-expression-1-percent 2022-02-28T07:09:53 https://maestrodatabase.com/blog/proqr-receives-fast-track-designation-from-fda-for-qr-421a-for-usher-syndrome-type-2 2019-01-02T23:48:05 https://maestrodatabase.com/blog/jazz-pharmaceuticals-receives-chmp-positive-opinion-for-jzp458-a-recombinant-erwinia-asparaginase-or-crisantaspase-for-the-treatment-of-acute-lymphoblastic-leukaemia-and-lymphoblastic-lymphoma 2023-07-24T07:08:15 https://maestrodatabase.com/blog/biocon-biologics-announces-positive-chmp-opinion-for-yesafili-biosimilar-aflibercept 2023-07-24T06:00:11 https://maestrodatabase.com/blog/aruvant-receives-fda-rare-paediatric-disease-designation-for-aru-1801-for-the-treatment-of-sickle-cell-disease 2020-01-09T04:09:22 https://maestrodatabase.com/blog/hhss-alex-azar-says-pfizer-vaccine-could-receive-green-light-within-days 2020-12-06T20:06:40 https://maestrodatabase.com/blog/immusant-secures-fast-track-designation-for-lead-therapeutic-vaccine-candidate-nexvax2-for-patients-with-celiac-disease 2019-01-03T00:27:52 https://maestrodatabase.com/blog/viiv-healthcares-cabotegravir-for-hiv-prevention-receives-positive-chmp-opinion-from-european-medicines-agency 2023-07-24T08:40:08 https://maestrodatabase.com/blog/pembrolizumab-for-the-treatment-of-patients-3-years-and-older-with-relapsed-or-refractory-classical-hodgkins-lymphoma 2024-05-01T04:38:00 https://maestrodatabase.com/blog/the-elderly-vs-essential-workers-who-should-get-the-coronavirus-vaccine-first 2020-12-06T21:20:22 https://maestrodatabase.com/blog/eton-pharmaceuticals-announces-submission-to-fda-of-new-drug-application-for-et-400-hydrocortisone-oral-solution 2024-05-01T04:13:45 https://maestrodatabase.com/blog/how-covid-19-vaccines-are-being-approved-in-canada 2020-12-06T21:24:12 https://maestrodatabase.com/blog/strategies-that-delay-market-entry-of-generic-drugs 2017-09-18T21:23:39 https://maestrodatabase.com/blog/biosimilar-cancer-drug-threat-closing-in-for-roche 2017-09-18T21:30:57 https://maestrodatabase.com/blog/why-are-drug-prices-so-high-were-curious-too 2017-09-18T21:27:58 https://maestrodatabase.com/blog/the-best-health-care-system-in-the-world-which-one-would-you-pick 2017-09-18T21:40:41 https://maestrodatabase.com/blog/republicans-demand-another-vote-to-repeal-the-affordable-care-act 2017-09-18T21:37:50 https://maestrodatabase.com/blog/viiv-healthcare-receives-eu-marketing-authorisation-for-dovato-dolutegravir-slash-lamivudine-a-new-once-daily-single-pill-two-drug-regimen-for-the-treatment-of-hiv-1-infection 2019-07-03T11:12:25 https://maestrodatabase.com/blog/validation-of-patient-reported-outcomes-a-low-bar 2019-07-03T07:28:14 https://maestrodatabase.com/blog/new-pbs-process-improvements 2019-07-03T07:06:08 https://maestrodatabase.com/blog/selpercatinib-for-the-treatment-of-patients-with-advanced-thyroid-cancer-with-ret-alterations-that-has-not-been-treated-with-systemic-therapy 2024-05-01T05:43:28 https://maestrodatabase.com/blog/some-insurers-are-pushing-back-on-the-high-price-for-a-novartis-gene-therapy 2019-07-03T21:01:56 https://maestrodatabase.com/blog/u-dot-s-fda-approves-supplemental-new-drug-application-for-expanded-indication-of-mycamine-micafungin-for-injection-for-the-treatment-of-invasive-candidiasis-in-paediatric-patients-less-than-4-months-of-age 2020-01-09T06:09:35 https://maestrodatabase.com/blog/these-two-brothers-are-living-healthier-lives-thanks-to-gene-therapy 2019-07-03T20:59:13 https://maestrodatabase.com/blog/call-for-all-sponsors-to-publish-clinical-trial-results-in-eu-database 2019-07-03T20:53:40 https://maestrodatabase.com/blog/fda-approves-new-treatment-for-refractory-multiple-myeloma 2019-07-03T21:06:06 https://maestrodatabase.com/blog/nabriva-therapeutics-receives-fda-acknowledgement-of-new-drug-application-resubmission-for-intravenous-contepo-fosfomycin-for-injection 2020-01-09T06:21:23 https://maestrodatabase.com/blog/update-on-funding-decision-for-two-new-diabetes-medicines 2020-12-07T05:05:10 https://maestrodatabase.com/blog/fda-releases-theratechnologies-from-post-approval-commitments-related-to-egrifta-tesamorelin-for-injection 2018-05-02T03:52:27 https://maestrodatabase.com/blog/jw-therapeutics-announces-nmpa-acceptance-of-the-supplemental-new-drug-application-for-carteyva-in-patients-with-relapsed-or-refractory-follicular-lymphoma 2022-02-28T12:17:21 https://maestrodatabase.com/blog/trump-fixates-on-drug-prices-as-campaign-looms 2019-07-03T21:23:24 https://maestrodatabase.com/blog/pbs---2019-in-review 2020-01-09T06:40:48 https://maestrodatabase.com/blog/fda-accepts-new-drug-application-for-insys-therapeutics-naloxone-nasal-spray-for-the-emergency-treatment-of-known-or-suspected-opioid-overdose 2019-07-03T21:14:02 https://maestrodatabase.com/blog/bavarian-nordic-initiates-rolling-submission-of-biologics-license-application-with-fda-for-its-chikungunya-vaccine-candidate 2024-05-01T21:21:31 https://maestrodatabase.com/blog/novartis-korea-to-continue-discussing-reimbursement-plan-for-sma-drug-zolgensma 2021-07-11T05:52:26 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-positive-chmp-opinion-for-opdivo-nivolumab-plus-chemotherapy-for-first-line-treatment-of-patients-with-unresectable-advanced-recurrent-or-metastatic-oesophageal-squamous-cell-carcinoma-with-tumour-cell-pd-l1-expression-1-percent 2022-02-28T19:56:48 https://maestrodatabase.com/blog/drug-prices-are-one-focus-of-bidens-push-to-boost-competition 2021-07-11T05:33:45 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-march-2022 2022-02-28T19:45:57 https://maestrodatabase.com/blog/lagevrio-molnupiravir-pbs-listing 2022-02-28T20:01:43 https://maestrodatabase.com/blog/reducing-drug-costs-is-more-than-slashing-prices 2020-01-09T07:10:03 https://maestrodatabase.com/blog/iterum-therapeutics-resubmits-new-drug-application-to-us-fda-for-oral-sulopenem 2024-05-01T22:26:37 https://maestrodatabase.com/blog/eli-lilly-korea-gains-further-reimbursement-for-psoriasis-treatment-taltz 2019-07-03T21:48:41 https://maestrodatabase.com/blog/aquestive-therapeutics-receives-us-fda-approval-and-market-access-for-libervant-diazepam-buccal-film-in-paediatric-patients-ages-2-to-5 2024-05-01T21:52:48 https://maestrodatabase.com/blog/nice-backing-for-takedas-adcetris-for-rare-lymphoma 2020-07-11T04:26:34 https://maestrodatabase.com/blog/ema-advises-against-use-of-covid-19-vaccine-janssen-in-people-with-history-of-capillary-leak-syndrome 2021-07-11T03:26:46 https://maestrodatabase.com/blog/revance-submits-supplemental-biologics-license-application-for-daxxify-daxibotulinumtoxina-lanm-for-injection-for-the-treatment-of-cervical-dystonia 2022-10-21T03:31:24 https://maestrodatabase.com/blog/covid-vaccine-rollout-chemists-brought-in-to-fast-track-jabs 2021-07-11T03:41:40 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-positive-chmp-opinion-recommending-approval-for-opdivo-nivolumab-plus-yervoy-ipilimumab-for-first-line-treatment-of-patients-with-unresectable-advanced-recurrent-or-metastatic-oesophageal-squamous-cell-carcinoma 2022-02-28T19:39:45 https://maestrodatabase.com/blog/bias-operational-bias-and-generalisability-in-phase-ii-slash-iii-trials 2018-06-28T08:48:07 https://maestrodatabase.com/blog/astellas-and-seagen-announce-chmp-confirms-positive-opinion-for-padcev-enfortumab-vedotin-in-locally-advanced-or-metastatic-urothelial-cancer 2022-02-28T21:18:54 https://maestrodatabase.com/blog/shingles-can-be-deadly-so-why-is-the-vaccine-only-free-for-one-year-of-life 2023-07-24T21:06:16 https://maestrodatabase.com/blog/australias-first-covid-treatment-approved 2020-07-11T04:55:15 https://maestrodatabase.com/blog/drug-pricing-and-the-impossible-trinity-for-patients 2023-07-24T21:02:11 https://maestrodatabase.com/blog/human-medicines-highlights-of-2019 2020-01-09T19:55:18 https://maestrodatabase.com/blog/health-canada-approves-kisqali-for-the-treatment-of-hr-positive-and-her2-negative-metastatic-breast-cancer-in-post-menopausal-women-in-combination-with-letrozole-as-an-initial-endocrine-based-therapy 2018-05-02T12:54:54 https://maestrodatabase.com/blog/failing-mental-and-dental-health-resources-driving-hospital-congestion 2020-01-09T19:52:16 https://maestrodatabase.com/blog/ontario-ndp-promise-take-home-cancer-drug-coverage-ahead-of-election 2018-05-02T08:33:27 https://maestrodatabase.com/blog/icer-issues-final-report-and-policy-recommendations-on-jak-inhibitors-for-rheumatoid-arthritis 2020-01-09T19:45:38 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-march-2022 2022-02-28T20:26:57 https://maestrodatabase.com/blog/u-dot-s-health-care-system-costs-four-times-more-to-run-than-canadas-single-payer-system 2020-01-09T11:53:16 https://maestrodatabase.com/blog/amryt-receives-complete-response-letter-from-the-fda-for-oleogel-s10-nda 2022-02-28T21:38:53 https://maestrodatabase.com/blog/california-eyes-selling-its-own-brand-of-generic-prescription-drugs-to-battle-high-costs 2020-01-09T20:09:06 https://maestrodatabase.com/blog/neurocrine-biosciences-announces-us-fda-approval-of-ingrezza-sprinkle-valbenazine-capsules 2024-05-02T01:41:51 https://maestrodatabase.com/blog/trump-should-do-more-to-bolster-senate-drug-pricing-effort-grassley-says 2020-01-09T20:06:02 https://maestrodatabase.com/blog/sandoz-receives-complete-response-letter-from-the-us-fda-for-proposed-biosimilar-rituximab 2018-05-02T20:40:05 https://maestrodatabase.com/blog/pharmac-epilepsy-drug-process-questions 2020-01-09T19:59:27 https://maestrodatabase.com/blog/fda-approves-the-first-targeted-therapy-to-treat-a-rare-mutation-in-patients-with-gastro-intestinal-stromal-tumours 2020-01-09T21:06:02 https://maestrodatabase.com/blog/fda-real-world-evidence-to-be-made-available-on-google-cloud 2020-01-09T20:29:56 https://maestrodatabase.com/blog/overland-adct-biopharma-announces-nmpa-accepts-biologics-license-application-and-grants-priority-review-for-zylonta-for-treatment-of-relapsed-or-refractory-diffuse-large-b-cell-lymphoma 2023-07-24T21:15:24 https://maestrodatabase.com/blog/california-plan-would-upend-drug-prices-though-obstacles-abound 2020-01-09T20:11:35 https://maestrodatabase.com/blog/flu-vaccine-price-increase 2022-02-28T23:41:19 https://maestrodatabase.com/blog/johnson-and-johnson-submits-regulatory-applications-to-ema-for-tremfya-guselkumab-for-treatment-of-patients-with-ulcerative-colitis-and-crohns-disease 2024-05-02T02:06:51 https://maestrodatabase.com/blog/ema-2017-annual-report-published 2018-05-02T20:49:01 https://maestrodatabase.com/blog/nice-publishes-draft-guidance-on-the-use-of-libmeldy 2021-07-11T12:19:11 https://maestrodatabase.com/blog/the-growing-problem-of-out-of-pocket-costs-and-affordability-in-employer-sponsored-insurance 2021-07-11T21:36:48 https://maestrodatabase.com/blog/president-trump-wants-to-go-much-further-to-attack-high-drug-prices-hhs-secretary-says 2018-05-02T22:45:43 https://maestrodatabase.com/blog/too-many-cancer-drugs-crowded-market-gives-investors-pause 2018-05-02T22:48:33 https://maestrodatabase.com/blog/icer-releases-draft-scope-on-vaccines-for-covid-19 2025-11-10T20:01:53 https://maestrodatabase.com/blog/u-dot-s-fda-grants-fast-track-designation-to-pluristems-plx-pad-for-the-treatment-of-critical-limb-ischemia 2017-09-19T00:07:05 https://maestrodatabase.com/blog/fda-grants-fast-track-status-to-cancer-prevention-pharmaceuticals-lead-drug-cpp-1x-slash-sul-for-treatment-of-familial-adenomatous-polyposis 2017-09-19T02:01:42 https://maestrodatabase.com/blog/theres-a-nation-wide-shortage-of-the-hpv-vaccine 2018-05-02T22:41:24 https://maestrodatabase.com/blog/abbvie-seeks-new-indication-for-imbruvica-ibrutinib-in-paediatric-patients-with-chronic-graft-versus-host-disease 2022-02-28T23:34:55 https://maestrodatabase.com/blog/uks-mhra-accepts-humanigens-submission-of-lenzilumab-for-marketing-authorisation-in-covid-19-for-expedited-rolling-review 2021-07-11T12:09:41 https://maestrodatabase.com/blog/can-we-please-stop-fighting-about-medicare-for-all 2020-01-09T21:31:55 https://maestrodatabase.com/blog/new-cadth-process-for-cell-and-gene-therapies 2020-01-09T21:28:18 https://maestrodatabase.com/blog/fda-acceptance-of-nda-for-cam2038-for-opioid-use-disorder 2017-09-19T02:06:20 https://maestrodatabase.com/blog/jacinda-ardern-defends-labours-perfectly-reasonable-decision-to-veto-mp-led-pharmac-inquiry 2020-12-07T07:48:03 https://maestrodatabase.com/blog/pharmac-publishes-minutes-from-february-2024-ptac-meeting 2024-05-02T03:21:16 https://maestrodatabase.com/blog/pharmac-diabetes-drugs-delay-bewildering-worse-than-disappointing---doctors 2020-12-07T07:53:44 https://maestrodatabase.com/blog/how-can-cancer-drug-prices-better-match-their-benefits-germany-offers-a-cost-saving-model 2020-07-11T05:28:30 https://maestrodatabase.com/blog/fda-finalises-multiple-endpoints-guidance 2022-10-21T05:28:32 https://maestrodatabase.com/blog/fda-approves-symbiomix-therapeutics-solosec-secnidazole-oral-granules-for-the-treatment-of-bacterial-vaginosis-in-adult-women 2017-09-19T02:14:00 https://maestrodatabase.com/blog/what-a-waste-the-national-academy-of-medicines-report-on-oversized-vials-of-expensive-drugs 2021-07-11T21:42:50 https://maestrodatabase.com/blog/avenzo-therapeutics-granted-fast-track-designation-for-avzo-1418-a-potential-best-in-class-egfr-slash-her3-bispecific-antibody-drug-conjugate-for-the-treatment-of-patients-with-egfr-mutated-tki-pretreated-nsclc 2025-11-10T23:17:17 https://maestrodatabase.com/blog/abbvie-provides-update-regarding-skyrizi-risankizumab-rzaa-for-the-treatment-of-moderate-to-severe-crohns-disease-in-the-u-dot-s 2022-03-01T00:37:45 https://maestrodatabase.com/blog/janssen-seeks-eu-approval-for-twice-yearly-schizophrenia-treatment 2020-12-07T20:13:45 https://maestrodatabase.com/blog/scpharmaceuticals-receives-complete-response-letter-from-fda-for-furoscix 2020-12-07T20:19:25 https://maestrodatabase.com/blog/glucophage-is-the-first-oral-diabetes-treatment-approved-in-europe-for-use-during-pregnancy 2022-03-01T01:53:23 https://maestrodatabase.com/blog/u-dot-s-fda-approves-new-indication-for-ipsens-somatuline-depot-lanreotide-injection-for-the-treatment-of-carcinoid-syndrome 2017-09-19T02:27:34 https://maestrodatabase.com/blog/trump-will-sign-three-executive-orders-on-lowering-drug-prices-chief-of-staff 2020-07-11T05:31:03 https://maestrodatabase.com/blog/health-economic-assessment-of-beovu-in-wet-age-related-macular-degeneration 2020-12-07T11:22:31 https://maestrodatabase.com/blog/trelegy-ellipta-approved-as-the-first-once-daily-single-inhaler-triple-therapy-for-the-treatment-of-appropriate-patients-with-copd-in-the-us 2017-09-19T02:36:21 https://maestrodatabase.com/blog/should-access-to-life-saving-medicines-be-determined-by-economic-evaluations 2020-01-09T23:10:47 https://maestrodatabase.com/blog/minoryx-therapeutics-receives-us-fda-fast-track-designation-for-leriglitazone-in-the-treatment-of-x-ald 2020-01-09T23:04:15 https://maestrodatabase.com/blog/immunicum-receives-fda-fast-track-designation-for-ilixadencel-in-gastro-intestinal-stromal-tumours 2020-12-07T20:33:36 https://maestrodatabase.com/blog/trump-officials-push-ambitious-vaccine-timeline-as-california-locks-down 2020-12-07T20:37:24 https://maestrodatabase.com/blog/new-pbs-listings-from-1-march-2022 2022-03-01T03:46:35 https://maestrodatabase.com/blog/fda-could-authorise-pfizers-covid-19-vaccine-this-week-as-u-dot-s-deaths-surge 2020-12-07T20:40:14 https://maestrodatabase.com/blog/chimerix-announces-fda-acceptance-of-new-drug-application-for-brincidofovir-as-a-medical-countermeasure-for-smallpox 2020-12-07T20:23:02 https://maestrodatabase.com/blog/scynexis-announces-fda-acceptance-and-priority-review-of-new-drug-application-for-oral-ibrexafungerp-for-the-treatment-of-vaginal-yeast-infections 2020-12-07T20:26:47 https://maestrodatabase.com/blog/kiwis-call-on-government-to-increase-pharmac-funding-to-help-fund-spinraza-treatment 2022-03-01T03:42:02 https://maestrodatabase.com/blog/u-dot-s-food-and-drug-administration-accepts-for-priority-review-bristol-myers-squibbs-application-for-opdivo-nivolumab-plus-chemotherapy-as-neo-adjuvant-treatment-for-resectable-non-small-cell-lung-cancer 2022-03-01T04:09:30 https://maestrodatabase.com/blog/leo-pharma-announces-european-commission-approval-of-adtralza-tralokinumab-for-the-treatment-of-moderate-to-severe-atopic-dermatitis-in-adolescents 2022-10-21T07:09:04 https://maestrodatabase.com/blog/alignment-of-terminology 2020-01-09T23:38:54 https://maestrodatabase.com/blog/smc---december-2020-decisions 2020-12-07T20:46:11 https://maestrodatabase.com/blog/lexicon-voluntarily-withdraws-sotagliflozin-new-drug-application-and-plans-prompt-resubmission-targeted-early-q2-2022 2022-03-01T03:55:04 https://maestrodatabase.com/blog/ema-publishes-agenda-for-7-10-december-chmp-meeting 2020-12-07T20:48:54 https://maestrodatabase.com/blog/new-report-on-tlvs-medical-technology-assignment 2020-12-07T20:57:35 https://maestrodatabase.com/blog/akesos-ivonescimab-granted-breakthrough-therapy-designation-by-china-nmpa-for-the-treatment-of-advanced-nsclc 2022-10-21T10:42:27 https://maestrodatabase.com/blog/ema-publishes-agenda-for-10-13-november-2025-chmp-meeting 2025-11-11T01:21:39 https://maestrodatabase.com/blog/pbs-minimum-stockholding-requirements 2022-10-21T07:52:41 https://maestrodatabase.com/blog/aadi-bioscience-receives-breakthrough-therapy-designation-for-tarzifyx-abi-009-in-pecoma-indication 2019-01-03T23:15:39 https://maestrodatabase.com/blog/treatment-for-families-battling-a-devastating-rare-disease 2018-05-03T04:10:21 https://maestrodatabase.com/blog/blueprint-medicines-initiates-rolling-nda-submission-to-fda-for-pralsetinib-for-the-treatment-of-patients-with-ret-fusion-positive-non-small-cell-lung-cancer 2020-01-10T03:05:39 https://maestrodatabase.com/blog/pfizer-covid-vaccine-price-hike-to-boost-revenue-for-years-rivals-may-follow 2022-10-21T20:41:54 https://maestrodatabase.com/blog/akcea-announces-filing-of-new-drug-submission-for-volanesorsen-to-health-canada 2017-09-19T07:21:56 https://maestrodatabase.com/blog/heres-how-tripling-prices-could-save-you-40-percent-on-your-medications 2020-01-10T03:02:03 https://maestrodatabase.com/blog/defending-transparency-at-european-drug-regulator 2020-01-10T01:12:26 https://maestrodatabase.com/blog/regenxbio-receives-fda-fast-track-designation-for-rgx-121-gene-therapy-for-the-treatment-of-mucopolysaccharidosis-type-ii 2018-05-03T04:15:33 https://maestrodatabase.com/blog/silverback-therapeutics-announces-the-fdas-acceptance-of-ars-pharmaceuticals-nda-for-neffy-epinephrine-nasal-spray-for-the-treatment-of-allergic-reactions-type-i-including-anaphylaxis 2022-10-21T20:13:55 https://maestrodatabase.com/blog/cti-biopharma-announces-fda-accelerated-approval-of-vonjo-pacritinib-for-the-treatment-of-adult-patients-with-myelofibrosis-and-thrombocytopenia 2022-03-01T04:38:16 https://maestrodatabase.com/blog/us-fda-accepts-supplemental-new-drug-application-for-camzyos-mavacamten-in-symptomatic-obstructive-hypertrophic-cardiomyopathy-to-reduce-the-need-for-septal-reduction-therapy 2022-10-21T20:08:51 https://maestrodatabase.com/blog/janssen-welcomes-nice-final-appraisal-determination-for-tremfya-guselkumab-to-treat-moderate-to-severe-plaque-psoriasis-janssen 2018-05-03T06:28:29 https://maestrodatabase.com/blog/cellectar-receives-rare-paediatric-disease-designation-for-clr-131-to-treat-neuroblastoma 2018-05-03T04:23:36 https://maestrodatabase.com/blog/migraine-drug-delay-would-compound-tevas-troubles 2018-05-03T14:05:24 https://maestrodatabase.com/blog/fda-updates-trintellix-vortioxetine-label-to-include-data-showing-improvement-in-processing-speed-an-important-aspect-of-cognitive-function-in-acute-major-depressive-disorder 2018-05-03T14:11:27 https://maestrodatabase.com/blog/changes-to-pbs-payment-arrangements-for-certain-medicines 2018-05-03T13:59:02 https://maestrodatabase.com/blog/for-expensive-new-drugs-biopharma-should-make-money-back-guarantees-mandatory 2018-05-03T14:21:44 https://maestrodatabase.com/blog/eagle-pharmaceuticals-resubmits-nda-for-ryanodex-for-exertional-heat-stroke 2020-01-10T03:46:23 https://maestrodatabase.com/blog/white-house-drug-price-initiative-to-include-negotiation-tools-list-prices-azar-says 2018-05-03T14:24:52 https://maestrodatabase.com/blog/wesfarmers-lobs-687-dollars-million-takeover-of-australian-pharmaceutical-industries 2021-07-12T06:32:57 https://maestrodatabase.com/blog/rinvoq-upadacitinib-receives-its-sixth-us-fda-approval 2022-10-21T21:16:49 https://maestrodatabase.com/blog/march-sends-cf-message-to-minister 2018-05-03T14:17:40 https://maestrodatabase.com/blog/drug-prices-weigh-on-older-americans 2021-07-12T06:43:40 https://maestrodatabase.com/blog/cadth-is-now-canadas-drug-agency 2024-05-02T06:18:53 https://maestrodatabase.com/blog/herzuma-trastuzumab-a-biosimilar-for-the-treatment-of-breast-cancer-now-available-in-europe 2018-05-03T14:39:47 https://maestrodatabase.com/blog/express-scripts-the-good-guy-on-drug-prices-not-exactly 2018-05-03T14:27:54 https://maestrodatabase.com/blog/coherus-biosciences-re-submits-biologics-license-application-for-chs-1701-pegfilgrastim-biosimilar-candidate 2018-05-03T14:32:23 https://maestrodatabase.com/blog/drug-development-at-the-portfolio-level-is-important-for-policy-care-decisions-and-human-protections 2017-09-19T21:28:31 https://maestrodatabase.com/blog/prescription-medicines-under-evaluation-april-2024 2024-05-02T06:49:17 https://maestrodatabase.com/blog/ema-validates-bristol-myers-squibbs-type-ii-variation-application-for-opdivo-plus-yervoy-combination-for-treatment-of-first-line-metastatic-non-small-cell-lung-cancer 2018-05-03T14:57:36 https://maestrodatabase.com/blog/fdas-expansive-alzheimers-drug-approval-surprised-even-top-agency-officials 2021-07-12T12:27:23 https://maestrodatabase.com/blog/msd-korea-proposed-unprecedented-offer-for-keytruda-reimbursement 2021-07-12T11:47:12 https://maestrodatabase.com/blog/nivolumab-now-available-for-lung-cancer-after-company-offers-nice-new-cdf-deal 2017-09-20T16:09:09 https://maestrodatabase.com/blog/medicines-australia-welcomes-more-money-in-the-pbs 2018-05-03T14:49:19 https://maestrodatabase.com/blog/brand-name-drug-prices-are-still-rising-just-not-as-fast-as-before 2017-09-20T16:11:58 https://maestrodatabase.com/blog/health-data-governance-enforceable-undertaking-for-re-identification-of-mbs-slash-pbs-data 2018-05-04T05:28:40 https://maestrodatabase.com/blog/decision-to-fund-aflibercept-and-rivaroxaban 2018-05-04T05:34:02 https://maestrodatabase.com/blog/leukaemia-patients-demand-reimbursement-for-novartis-kymriah 2021-07-12T11:27:37 https://maestrodatabase.com/blog/novartis-drug-rydapt-midostaurin-receives-eu-approval-for-newly-diagnosed-flt3-mutated-acute-myeloid-leukaemia-and-three-types-of-advanced-systemic-mastocytosis 2017-09-20T16:18:59 https://maestrodatabase.com/blog/how-the-u-dot-s-compares-to-europe-on-biosimilar-approvals-and-products-in-the-pipeline 2018-05-03T15:05:17 https://maestrodatabase.com/blog/3-dot-6-million-kiwis-benefit-from-pharmacs-model 2017-09-20T16:15:25 https://maestrodatabase.com/blog/experts-warn-full-fda-covid-19-vaccine-approval-is-no-quick-fix-for-hesitancy 2021-07-12T11:41:29 https://maestrodatabase.com/blog/why-its-time-to-abandon-the-icer 2020-07-12T00:43:32 https://maestrodatabase.com/blog/fda-approves-daratumumab-and-hyaluronidase-fihj-with-pomalidomide-and-dexamethasone-for-multiple-myeloma 2021-07-12T21:15:11 https://maestrodatabase.com/blog/fda-approves-new-uses-for-two-drugs-administered-together-for-the-treatment-of-braf-positive-anaplastic-thyroid-cancer 2018-05-05T05:47:45 https://maestrodatabase.com/blog/teplizumab-awarded-innovation-passport-in-the-united-kingdom-for-the-delay-of-onset-of-clinical-type-1-diabetes-in-at-risk-individuals 2021-07-12T21:22:08 https://maestrodatabase.com/blog/icer-finds-that-at-current-prices-cftr-modulators-for-cystic-fibrosis-improve-patient-outcomes-at-costs-that-far-exceed-standard-cost-effectiveness-levels 2018-05-04T05:39:19 https://maestrodatabase.com/blog/long-term-benefit-of-neuroblastoma-treatment-is-too-uncertain-says-nice 2018-05-05T05:53:12 https://maestrodatabase.com/blog/hundreds-of-people-with-blood-cancer-given-more-treatment-options-after-nice-recommends-three-drugs 2018-05-05T05:56:36 https://maestrodatabase.com/blog/minister-for-health-announces-hse-approval-to-reimburse-patisiran-onpattro 2021-07-12T21:09:56 https://maestrodatabase.com/blog/does-cost-effectiveness-analysis-really-need-to-abandon-the-incremental-cost-effectiveness-ratio-to-embrace-net-benefit 2020-07-12T00:53:20 https://maestrodatabase.com/blog/us-fda-accepts-supplemental-new-drug-application-for-ofev-nintedanib-for-children-and-adolescents-aged-6-17-years-old-with-fibrosing-interstitial-lung-disease 2023-07-25T20:37:53 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-elagolix-for-endometriosis 2018-05-05T06:05:34 https://maestrodatabase.com/blog/carvykti-ciltacabtagene-autoleucel-bcma-directed-car-t-therapy-receives-u-dot-s-fda-approval-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-multiple-myeloma 2022-03-01T07:30:10 https://maestrodatabase.com/blog/health-canada-approves-abbvies-rinvoq-upadacitinib-for-the-treatment-of-adults-with-moderately-to-severely-active-ulcerative-colitis 2023-07-25T11:04:02 https://maestrodatabase.com/blog/smc---july-2021-decisions 2021-07-12T21:52:27 https://maestrodatabase.com/blog/icer-releases-evidence-report-on-acute-treatments-for-migraine 2020-01-10T21:33:00 https://maestrodatabase.com/blog/fda-to-announce-new-warning-on-j-and-j-covid-vaccine-related-to-a-rare-auto-immune-disorder-report-says 2021-07-12T21:36:14 https://maestrodatabase.com/blog/in-a-sweeping-executive-order-biden-endorses-importing-drugs-from-canada-and-orders-a-bigger-drug-pricing-plan-by-late-august 2021-07-12T21:33:44 https://maestrodatabase.com/blog/remdesivir-us-purchase-of-world-stocks-sparks-new-hunger-games-warn-observers 2020-07-12T00:50:08 https://maestrodatabase.com/blog/cms-opens-national-coverage-determination-analysis-on-treatment-for-alzheimers-disease 2021-07-12T21:40:36 https://maestrodatabase.com/blog/us-fda-approves-high-concentration-citrate-free-formulation-of-cyltezo-adalimumab-adbm-injection-boehringer-ingelheims-interchangeable-biosimilar-to-humira 2024-05-02T09:03:31 https://maestrodatabase.com/blog/pharmac-funding-will-not-stretch-to-new-medicines---chief-executive 2024-05-02T08:59:33 https://maestrodatabase.com/blog/watchdog-says-vertex-cystic-fibrosis-drugs-are-not-cost-effective-but-company-calls-analysis-a-sham 2018-05-05T06:22:30 https://maestrodatabase.com/blog/paving-the-way-towards-coordinated-clinical-trials-in-public-health-emergencies-in-the-eu 2023-07-25T21:01:27 https://maestrodatabase.com/blog/chmp-recommends-idorsias-dual-acting-treatment-quviviq-for-insomnia-patients 2022-03-01T19:54:34 https://maestrodatabase.com/blog/launch-of-arthritis-drug-biosimilars-ramps-up-us-pressure-on-pricing-middlemen 2023-07-25T21:06:21 https://maestrodatabase.com/blog/labcorp-receives-fda-approval-for-first-companion-diagnostic-for-use-with-pfizers-newly-approved-gene-therapy-to-treat-patients-with-haemophilia-b 2024-05-02T21:04:26 https://maestrodatabase.com/blog/icer-to-assess-treatments-for-paroxysmal-nocturnal-haemoglobinuria 2023-07-25T20:56:16 https://maestrodatabase.com/blog/gilead-receives-complete-response-letter-from-u-dot-s-fda-for-investigational-lenacapavir-due-to-vial-compatability-issues 2022-03-01T20:07:32 https://maestrodatabase.com/blog/abpi-response-to-england-rare-diseases-action-plan 2022-03-01T19:58:40 https://maestrodatabase.com/blog/pharmac-to-fund-five-medicines-for-multiple-sclerosis-breast-cancer-eye-conditions-and-lung-cancer 2025-11-12T02:19:52 https://maestrodatabase.com/blog/market-approval-for-drugs-in-the-eu-time-to-change-direction 2017-09-22T10:16:03 https://maestrodatabase.com/blog/fda-approves-xdemvy-lotilaner-ophthalmic-solution-0-dot-25-percent-for-the-treatment-of-demodex-blepharitis 2023-07-25T20:51:02 https://maestrodatabase.com/blog/fda-chief-questions-protections-on-drug-rebates 2018-05-05T06:33:44 https://maestrodatabase.com/blog/gilead-sciences-announces-its-largest-commitment-to-health-equity-for-australian-and-canadian-indigenous-communities 2023-07-25T20:42:07 https://maestrodatabase.com/blog/last-hope-eager-germans-are-prepared-to-pay-for-weight-loss-drug 2023-07-25T20:45:48 https://maestrodatabase.com/blog/ema-highlights-of-2018 2019-01-04T22:00:13 https://maestrodatabase.com/blog/third-biological-treatment-gives-more-choice-for-people-with-severe-asthma 2019-01-04T22:02:37 https://maestrodatabase.com/blog/lies-damn-lies-and-drug-price-increases 2020-01-10T21:56:19 https://maestrodatabase.com/blog/kaitaia-womans-life-and-death-choice-as-pharmac-says-no-to-funding-drug 2019-01-04T01:00:48 https://maestrodatabase.com/blog/regulation-on-emas-extended-mandate-becomes-applicable 2022-03-01T21:24:26 https://maestrodatabase.com/blog/march-biosciences-receives-fda-regenerative-medicine-advanced-therapy-designation-for-mb-105-in-relapsed-slash-refractory-cd5-positive-t-cell-lymphoma 2025-11-12T00:11:06 https://maestrodatabase.com/blog/mhra-releases-response-to-consultation-on-eu-exit-no-deal-legislative-proposals 2019-01-04T01:07:39 https://maestrodatabase.com/blog/meissa-vaccines-receives-u-dot-s-fda-fast-track-designation-for-respiratory-syncytial-virus-vaccine-mv-012-968 2020-01-10T21:51:18 https://maestrodatabase.com/blog/chinas-national-medical-products-administration-approves-vyloy-zolbetuximab-for-first-line-treatment-of-advanced-gastric-or-gastro-oesophageal-junction-adenocarcinoma 2025-01-06T01:16:31 https://maestrodatabase.com/blog/astrazenecas-imfinzi-imjudo-and-ultomiris-clear-reimbursement-panel-review 2025-11-12T00:41:09 https://maestrodatabase.com/blog/bausch-and-lomb-announces-health-canada-approval-of-vyzulta-latanoprostene-bunod-ophthalmic-solution-0-dot-024-percent-for-the-treatment-of-glaucoma 2019-01-04T22:28:17 https://maestrodatabase.com/blog/ema-accepts-marketing-authorisation-application-for-daprodustat 2022-03-01T20:18:57 https://maestrodatabase.com/blog/icer-to-assess-treatment-for-epstein-barr-virus-positive-post-transplant-lymphoproliferative-disease 2024-05-02T21:10:36 https://maestrodatabase.com/blog/peter-mac-increases-manufacturing-centre-for-gene-therapy-bringing-new-hope-to-cancer-patients 2023-07-25T21:20:22 https://maestrodatabase.com/blog/payers-expect-drug-prices-to-rise-3-to-5-percent-annually-over-the-next-three-years 2019-01-04T22:13:04 https://maestrodatabase.com/blog/decision-criteria-that-influence-managed-entry-agreements 2019-01-04T23:07:05 https://maestrodatabase.com/blog/price-must-be-right-to-put-obesity-pill-on-the-pbs 2025-01-06T02:47:21 https://maestrodatabase.com/blog/global-pharma-giants-push-for-weight-loss-drugs-to-be-added-to-pbs 2025-01-06T02:27:54 https://maestrodatabase.com/blog/triple-negative-breast-cancer-survival-benefit-with-sacituzumab-govitecan 2022-03-01T22:22:15 https://maestrodatabase.com/blog/new-fact-sheets---infliximab-biosimilars 2017-09-22T15:26:01 https://maestrodatabase.com/blog/alnylam-initiates-rolling-submission-of-new-drug-application-to-u-dot-s-fda-for-lumasiran-for-the-treatment-of-primary-hyperoxaluria-type-1 2020-01-10T23:16:00 https://maestrodatabase.com/blog/ultomiris-ravulizumab-receives-marketing-authorisation-from-european-commission-for-adults-with-paroxysmal-nocturnal-hemoglobinuria 2019-07-04T09:04:16 https://maestrodatabase.com/blog/fda-approval-of-tisagenlecleucel 2017-11-21T20:53:20 https://maestrodatabase.com/blog/redhill-biopharma-announces-fda-acceptance-of-new-drug-application-for-talicia 2019-07-04T08:32:12 https://maestrodatabase.com/blog/spinraza-access-agreement-extended 2019-07-04T09:51:44 https://maestrodatabase.com/blog/criminal-and-civil-actions-filed-against-aegerion-pharmaceuticals 2017-09-22T23:40:27 https://maestrodatabase.com/blog/fda-clears-biotech-drug-copycats-but-buying-them-isnt-so-easy 2017-09-23T00:08:31 https://maestrodatabase.com/blog/costly-drugs-to-weigh-on-u-dot-s-employers-expenses-in-2018-survey 2017-09-23T00:05:22 https://maestrodatabase.com/blog/karyopharm-therapeutics-prices-blood-cancer-treatment-after-fda-approval 2019-07-04T09:48:04 https://maestrodatabase.com/blog/crispr-therapeutics-and-vertex-announce-fda-fast-track-designation-for-ctx001-for-the-treatment-of-sickle-cell-disease 2019-01-06T21:34:26 https://maestrodatabase.com/blog/bristol-myers-squibbs-opdivo-nivolumab-receives-fda-approval-for-the-treatment-of-hepatocellular-carcinoma-patients-previously-treated-with-sorafenib 2017-09-23T00:13:59 https://maestrodatabase.com/blog/fda-approves-mercks-keytruda-pembrolizumab-for-previously-treated-patients-with-recurrent-locally-advanced-or-metastatic-gastric-or-gastro-oesophageal-junction-cancer-whose-tumours-express-pd-l1-cps-greater-than-or-equal-to-1 2017-09-23T01:31:33 https://maestrodatabase.com/blog/lenvima-lenvatinib-plus-keytruda-pembrolizumab-approved-in-japan-for-radically-unresectable-or-metastatic-renal-cell-carcinoma 2022-03-02T00:32:27 https://maestrodatabase.com/blog/viiv-healthcare-submits-regulatory-application-to-the-european-medicines-agency-for-fostemsavir-an-investigational-first-in-class-attachment-inhibitor-for-the-treatment-of-hiv-in-adults-with-few-treatment-options-available 2020-01-11T01:07:38 https://maestrodatabase.com/blog/attempt-to-replicate-clinical-trials-with-real-world-data-generates-real-world-criticism-too 2019-07-04T12:33:03 https://maestrodatabase.com/blog/pharmaceutical-benefits-scheme-pharmacy-guild-of-australia-say-medication-becoming-unaffordable 2022-03-02T02:53:08 https://maestrodatabase.com/blog/japan-health-minister-to-consider-u-dot-s-drug-firms-views-in-pricing-overhaul 2017-09-23T02:40:00 https://maestrodatabase.com/blog/shionogi-files-for-approval-of-s-217622-a-therapeutic-drug-for-covid-19-in-japan 2022-03-02T01:34:14 https://maestrodatabase.com/blog/enfortumab-vedotin-plus-pembrolizumab-in-advanced-bladder-cancer-evidence-of-a-significant-additional-benefit 2025-01-06T04:14:35 https://maestrodatabase.com/blog/smc---november-2025-decisions 2025-11-12T19:47:23 https://maestrodatabase.com/blog/cormedix-announces-resubmission-of-new-drug-application-for-defencath 2022-03-02T03:33:45 https://maestrodatabase.com/blog/dynamicare-health-digital-therapeutic-receives-fda-breakthrough-device-designation-for-treatment-of-smoking-during-pregnancy 2022-03-02T03:14:08 https://maestrodatabase.com/blog/nabriva-therapeutics-announces-acceptance-of-the-new-drug-application-for-intravenous-contepo-to-treat-complicated-urinary-tract-infections-by-fda 2019-01-06T21:59:43 https://maestrodatabase.com/blog/mirums-livmarli-now-authorised-in-canada-for-cholestatic-pruritus-in-patients-with-alagille-syndrome 2023-07-26T02:46:07 https://maestrodatabase.com/blog/als-canada-marks-rare-disease-day-2022-by-calling-on-ontario-to-champion-expedited-access-to-als-therapies 2022-03-02T03:04:56 https://maestrodatabase.com/blog/mccain-announces-opposition-to-republican-health-bill-likely-dooming-it 2017-09-23T11:33:18 https://maestrodatabase.com/blog/janssen-receives-complete-response-letter-from-u-dot-s-fda-for-sirukumab-biologics-license-application 2017-09-23T11:49:54 https://maestrodatabase.com/blog/banner-receives-fda-tentative-approval-for-bafiertam-for-the-treatment-of-relapsing-forms-of-multiple-sclerosis 2019-01-06T22:11:51 https://maestrodatabase.com/blog/assessing-unexpected-circumstances-that-lead-to-modifications-in-clinical-trial-design-conduct-or-analysis-application-of-the-conserve-reporting-guideline 2022-03-02T04:47:25 https://maestrodatabase.com/blog/u-dot-s-law-makers-seek-answers-on-troubling-drug-price-increases 2022-03-02T05:53:16 https://maestrodatabase.com/blog/progression-free-survival-it-is-time-for-a-new-name 2022-03-02T05:40:12 https://maestrodatabase.com/blog/cancer-treatment-in-this-country-is-a-national-shame 2019-07-04T21:21:14 https://maestrodatabase.com/blog/expert-slams-successive-governments-approach-to-cancer 2019-07-04T21:18:32 https://maestrodatabase.com/blog/grifols-announces-fda-approval-of-xembify-20-percent-subcutaneous-immunoglobulin-for-primary-immunodeficiencies 2019-07-04T21:32:34 https://maestrodatabase.com/blog/trumps-bully-pulpit-didnt-stop-drug-price-hikes 2019-07-04T21:29:39 https://maestrodatabase.com/blog/medicine-shortages-eu-network-takes-steps-to-improve-reporting-and-communication 2019-07-04T21:26:38 https://maestrodatabase.com/blog/labour-is-failing-to-deliver-for-cancer-patients 2019-07-04T21:23:10 https://maestrodatabase.com/blog/slayback-pharma-announces-fda-approval-of-hydroxyprogesterone-caproate-injection-usp-1-250-mg-slash-5-ml-in-a-multi-dose-vial-the-first-generic-equivalent-of-makena-injection-1-250-mg-slash-5-ml-multi-dose-vial 2019-01-06T22:50:52 https://maestrodatabase.com/blog/ema-confirms-wework-as-new-sub-tenant-for-30-churchill-place-ema-also-settles-court-case-with-canary-wharf-group 2019-07-04T21:45:10 https://maestrodatabase.com/blog/teva-canada-welcomes-public-drug-plan-reimbursement-by-alberta-saskatchewan-quebec-veteran-affairs-canada-and-the-non-insured-health-benefits-program-for-patients-prescribed-ajovy-fremanezumab-for-the-preventive-treatment-of-migraine-in-adults 2022-03-02T20:12:08 https://maestrodatabase.com/blog/the-model-for-acquiring-oncology-drugs-must-change-say-kaiser-permanente-experts 2019-07-04T21:42:21 https://maestrodatabase.com/blog/australian-vaccine-trial-starts-today 2020-07-12T21:04:21 https://maestrodatabase.com/blog/trump-goes-after-pharma-on-twitter-as-companies-increase-prices 2019-01-06T23:00:49 https://maestrodatabase.com/blog/pharmacies-could-hand-out-prescriptions-for-medicines-under-major-wa-healthcare-reforms 2019-07-04T21:37:51 https://maestrodatabase.com/blog/bill-gates-calls-for-covid-19-meds-to-go-to-people-who-need-them-not-highest-bidder 2020-07-12T21:18:15 https://maestrodatabase.com/blog/atagi-recommends-novavax-for-use-as-a-covid-19-booster 2022-03-02T20:20:25 https://maestrodatabase.com/blog/pbac---2018-in-review 2019-01-07T06:26:19 https://maestrodatabase.com/blog/pfizer-granted-fda-breakthrough-therapy-designation-for-respiratory-syncytial-virus-rsv-vaccine-candidate-for-the-prevention-of-rsv-in-infants-from-birth-up-to-six-months-of-age-by-active-immunisation-of-pregnant-women 2022-03-02T19:53:38 https://maestrodatabase.com/blog/democrats-look-to-unlikely-ally-on-drug-pricing-donald-trump 2019-01-07T11:11:59 https://maestrodatabase.com/blog/advanced-innovative-partners-announces-designation-for-rare-paediatric-disease-drug 2022-03-02T07:24:52 https://maestrodatabase.com/blog/celgene-boosted-the-price-of-its-top-cancer-drug-on-the-same-day-of-mega-deal 2019-01-07T06:08:28 https://maestrodatabase.com/blog/beigene-hits-major-milestone-with-first-pbs-approved-cancer-treatment 2022-03-02T20:01:36 https://maestrodatabase.com/blog/the-9-dollars-billion-upcharge-how-insurers-kept-extra-cash-from-medicare 2019-01-07T06:18:24 https://maestrodatabase.com/blog/amolyt-pharma-granted-fda-fast-track-designation-for-eneboparatide-for-the-treatment-of-hypoparathyroidism 2024-05-02T23:13:31 https://maestrodatabase.com/blog/janssen-files-stelara-in-europe-for-ulcerative-colitis 2019-01-07T20:05:26 https://maestrodatabase.com/blog/drug-pricing-is-pharmas-top-concern-in-2019 2019-01-07T11:14:33 https://maestrodatabase.com/blog/big-pharma-is-caught-between-wall-street-and-trump-on-drug-prices 2019-01-07T11:17:18 https://maestrodatabase.com/blog/real-world-evidence-use-in-assessments-of-cancer-drugs-by-nice 2020-07-12T21:21:54 https://maestrodatabase.com/blog/kempharm-announces-fda-approval-of-snda-for-two-additional-strengths-of-apadaz-4-dot-08-mg-benzhydrocodone-slash-325-mg-apap-and-8-dot-16-mg-benzhydrocodone-slash-325-mg-apap 2019-01-07T20:08:54 https://maestrodatabase.com/blog/msac-secretariat-publishes-agenda-for-november-2023-msac-meeting 2023-07-26T05:33:09 https://maestrodatabase.com/blog/doh-publishes-agenda-for-november-2023-pbac-meeting 2023-07-26T05:53:35 https://maestrodatabase.com/blog/covid-19-is-forcing-us-to-rethink-clinical-trials-for-cancer-treatments 2020-07-12T21:27:55 https://maestrodatabase.com/blog/cheaper-cancer-and-chronic-conditions-medicines-now-on-pbs 2025-11-13T04:58:26 https://maestrodatabase.com/blog/paying-it-forward-man-pledges-$1million-to-get-life-saving-cancer-treatment-in-nz 2019-01-07T20:29:34 https://maestrodatabase.com/blog/2018-a-year-of-innovation-efficiency-and-new-advances-in-drug-therapy-for-the-american-public 2019-01-07T20:32:30 https://maestrodatabase.com/blog/jardiance-empagliflozin-approved-in-the-eu-for-the-treatment-of-adults-with-chronic-kidney-disease 2023-07-26T12:42:57 https://maestrodatabase.com/blog/adma-biologics-submits-response-and-provides-supplemental-information-to-fda-for-bivigam-complete-response-letter 2019-01-07T20:14:25 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-treatment-for-metachromatic-leukodystrophy 2023-07-26T12:11:54 https://maestrodatabase.com/blog/afamelanotide-acetate-for-the-treatment-of-patients-with-erythropoietic-protoporphyria 2023-07-26T12:21:52 https://maestrodatabase.com/blog/parabilis-medicines-receives-fda-fast-track-designation-for-fog-001-the-first-and-only-direct-inhibitor-of-the-b-catenin-tcf-interaction-for-the-treatment-of-desmoid-tumours 2025-11-12T23:09:21 https://maestrodatabase.com/blog/selpercatinib-for-untreated-ret-fusion-positive-advanced-non-small-cell-lung-cancer 2023-07-26T09:42:57 https://maestrodatabase.com/blog/pharma-firms-face-shake-up-with-chinas-plan-to-bulk-buy-drugs 2019-01-07T20:44:56 https://maestrodatabase.com/blog/generics-industry-calls-fda-draft-guidance-on-priority-reviews-basically-inoperable 2017-09-24T02:01:07 https://maestrodatabase.com/blog/novartis-matches-gilead-on-price-in-new-car-t-use 2018-05-05T10:46:34 https://maestrodatabase.com/blog/labor-fulfils-vow-to-cut-cost-of-scripts 2022-10-22T04:33:14 https://maestrodatabase.com/blog/gottlieb-pushes-back-against-criticism-of-breakthrough-designation 2018-05-05T10:41:17 https://maestrodatabase.com/blog/octapharmas-prothrombin-complex-concentrate-balfaxar-receives-fda-approval-for-warfarin-reversal-in-urgent-surgery-and-invasive-procedures 2023-07-26T20:38:37 https://maestrodatabase.com/blog/fda-grants-paxvax-fast-track-designation-for-its-chikungunya-vaccine 2018-05-05T11:02:24 https://maestrodatabase.com/blog/powerful-house-democrats-demand-documents-from-biogen-about-co-ordination-with-fda-on-new-alzheimers-drug 2021-07-13T03:24:50 https://maestrodatabase.com/blog/jemperli-approved-by-the-tga 2022-03-03T02:42:31 https://maestrodatabase.com/blog/fda-approves-kaleos-naloxone-auto-injector-10-mg-for-the-treatment-of-known-or-potential-exposure-to-ultra-potent-weaponised-opioids 2022-03-03T03:25:22 https://maestrodatabase.com/blog/cystic-fibrosis-drug-orkambi-in-pbs-decision-moree-family-share-story 2018-05-06T06:03:10 https://maestrodatabase.com/blog/allergan-receives-refusal-to-file-letter-from-fda-for-vraylar-cariprazine-supplemental-new-drug-application-for-the-treatment-of-negative-symptoms-in-schizophrenia 2017-09-24T02:30:49 https://maestrodatabase.com/blog/ferring-signs-global-agreement-to-commercialise-novel-gene-therapy-for-bladder-cancer-patients 2018-05-06T06:18:37 https://maestrodatabase.com/blog/amneal-enters-u-dot-s-biosimilars-market-with-approval-of-releuko-filgrastim-ayow 2022-03-03T05:01:50 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-3-march-2022 2022-03-03T05:32:29 https://maestrodatabase.com/blog/fda-accepts-alvotechs-bla-supporting-interchangeability-for-atv02-a-high-concentration-citrate-free-biosimilar-candidate-for-humira 2022-03-03T03:42:51 https://maestrodatabase.com/blog/roche-receives-eu-approval-of-gazyvaro-for-people-with-previously-untreated-advanced-follicular-lymphoma 2017-09-24T12:57:26 https://maestrodatabase.com/blog/roche-receives-eu-approval-of-tecentriq-atezolizumab-in-a-specific-type-of-metastatic-lung-cancer-and-two-types-of-metastatic-bladder-cancer 2017-09-24T13:08:48 https://maestrodatabase.com/blog/rainier-therapeutics-announces-fast-track-designation-granted-by-fda-for-vofatamab-in-treatment-of-fgfr3-positive-urothelial-cell-carcinoma 2019-01-07T23:38:09 https://maestrodatabase.com/blog/altpep-receives-fda-breakthrough-device-designation-for-soba-ad-a-simple-blood-test-for-the-detection-of-alzheimers-disease 2022-03-03T06:35:59 https://maestrodatabase.com/blog/harpoon-therapeutics-receives-fda-fast-track-designation-for-hpn217 2022-03-03T06:01:22 https://maestrodatabase.com/blog/stemline-therapeutics-announces-submission-of-european-marketing-authorisation-application-for-elzonris 2019-01-08T02:53:15 https://maestrodatabase.com/blog/fda-grants-revalesio-fast-track-status-for-als-investigational-drug-rns60 2019-01-07T23:43:49 https://maestrodatabase.com/blog/fda-approves-new-interchangeable-biosimilar-to-perjeta 2025-11-13T19:54:16 https://maestrodatabase.com/blog/amgen-makes-all-repatha-evolocumab-device-options-available-in-the-us-at-a-60-percent-reduced-list-price 2019-01-08T06:04:16 https://maestrodatabase.com/blog/marius-pharmaceuticals-expands-global-footprint-with-health-canada-approval-of-kyzatrex-testosterone-undecanoate-ciii-capsules 2025-11-13T06:50:53 https://maestrodatabase.com/blog/fda-approves-ziftomenib-for-relapsed-or-refractory-acute-myeloid-leukaemia-with-a-npm1-mutation 2025-11-13T19:39:20 https://maestrodatabase.com/blog/cder-focuses-on-novel-drug-development-tools-to-help-speed-creation-of-new-therapies 2020-12-08T08:35:57 https://maestrodatabase.com/blog/if-medicare-part-d-redesign-ever-happens-it-could-lead-to-lower-prescription-drug-prices 2022-03-03T07:05:16 https://maestrodatabase.com/blog/pharmac-to-fund-alternative-treatment-for-tooth-decay 2025-11-13T22:05:28 https://maestrodatabase.com/blog/digital-therapeutics-should-be-regulated-with-gold-standard-evidence 2022-03-03T07:10:56 https://maestrodatabase.com/blog/novartis-investigational-therapy-crizanlizumab-seg101-receives-fda-breakthrough-therapy-designation-for-the-prevention-of-vaso-occlusive-crises-in-sickle-cell-disease 2019-01-08T06:20:39 https://maestrodatabase.com/blog/statement-on-litigation-challenging-legality-of-the-administrations-most-favoured-nation-rule 2020-12-08T07:59:42 https://maestrodatabase.com/blog/amgen-receives-positive-chmp-opinion-for-abp-501-biosimilar-adalimumab-for-the-treatment-of-certain-inflammatory-diseases 2017-01-30T10:48:30 https://maestrodatabase.com/blog/merck-will-release-average-drug-price-increases-to-provide-greater-transparency 2017-01-30T10:54:38 https://maestrodatabase.com/blog/britain-begins-vaccine-rollout-first-person-vaccinated 2020-12-08T08:21:16 https://maestrodatabase.com/blog/less-than-a-third-of-americans-will-definitely-get-the-covid-vaccine-poll 2020-12-08T08:31:15 https://maestrodatabase.com/blog/cancer-drugs-price-rise-costing-nhs-millions 2017-01-30T10:44:52 https://maestrodatabase.com/blog/fda-approves-allergans-snda-for-avycaz-ceftazidime-and-avibactam-to-include-new-phase-iii-data-in-patients-with-complicated-urinary-tract-infections-including-pyelonephritis 2017-01-30T20:02:17 https://maestrodatabase.com/blog/heres-why-trump-will-struggle-to-control-murderous-drug-prices 2017-01-30T20:21:36 https://maestrodatabase.com/blog/rise-in-deadly-w-strain-of-meningococcal-disease-prompts-calls-for-national-approach 2017-01-30T11:25:38 https://maestrodatabase.com/blog/teva-announces-fda-approval-of-two-new-respiclick-maintenance-inhalers-for-the-treatment-of-asthma 2017-01-30T19:53:33 https://maestrodatabase.com/blog/cadth-recommends-ucbs-brivlera 2017-01-30T20:46:05 https://maestrodatabase.com/blog/celgene-receives-positive-chmp-opinion-to-expand-revlimid-lenalidomide-indication-as-monotherapy-for-the-maintenance-treatment-of-patients-with-newly-diagnosed-multiple-myeloma-after-autologous-stem-cell-transplantation 2017-01-30T20:24:58 https://maestrodatabase.com/blog/big-drug-companies-should-secede-from-the-pharmaceutical-research-and-manufacturers-of-america 2017-01-30T20:31:24 https://maestrodatabase.com/blog/over-500-people-a-year-can-access-a-new-life-extending-lung-cancer-treatment-after-nice-recommends-its-use-within-the-cancer-drugs-fund 2022-03-03T11:19:07 https://maestrodatabase.com/blog/fda-approves-promega-oncomate-msi-dx-analysis-system-as-companion-diagnostic-for-keytruda-in-combination-with-lenvima-in-advanced-endometrial-carcinoma 2025-11-13T20:06:20 https://maestrodatabase.com/blog/stryker-announces-the-fda-clearance-of-the-first-biodegradable-subacromial-balloon-spacer-filling-a-gap-in-the-shoulder-continuum-of-care 2021-07-13T20:54:19 https://maestrodatabase.com/blog/arcutis-canada-announces-health-canada-approval-of-zorvye-0-dot-3-percent-topical-foam-the-first-steroid-free-topical-foam-for-scalp-and-body-psoriasis-for-adults-and-adolescents-ages-12-and-older 2025-11-14T01:40:51 https://maestrodatabase.com/blog/uniqure-announces-fda-breakthrough-therapy-designation-for-amt-060-in-haemophilia-b 2017-01-31T00:31:47 https://maestrodatabase.com/blog/biden-wants-a-drug-pricing-plan-in-45-days-whos-going-to-write-it 2021-07-13T20:58:19 https://maestrodatabase.com/blog/phrma-statement-on-the-state-of-the-union-address 2022-03-03T19:37:38 https://maestrodatabase.com/blog/biocryst-announces-the-acceptance-of-peramivir-maa-filing-by-the-european-medicines-agency 2017-01-31T01:25:31 https://maestrodatabase.com/blog/u-dot-s-fda-approves-portola-pharmaceuticals-andexxa-first-and-only-antidote-for-the-reversal-of-factor-xa-inhibitors 2018-05-06T21:12:56 https://maestrodatabase.com/blog/prime-enables-earlier-availability-of-life-changing-medicines 2022-03-03T19:31:04 https://maestrodatabase.com/blog/its-magic-families-advocates-celebrate-lifesaving-drug-announcement 2018-05-06T21:05:35 https://maestrodatabase.com/blog/atagi-statement-on-use-of-covid-19-vaccines-in-an-outbreak-setting 2021-07-13T12:01:43 https://maestrodatabase.com/blog/tg-therapeutics-announces-extension-of-u-dot-s-fda-bla-slash-snda-pdufa-date-for-ublituximab-plus-ukoniq-to-treat-patients-with-cll-and-sll 2022-03-03T19:41:09 https://maestrodatabase.com/blog/cders-work-to-ensure-drug-safety-is-an-ongoing-top-priority 2019-01-08T20:17:22 https://maestrodatabase.com/blog/new-california-governor-tackles-drug-prices-in-first-act 2019-01-08T20:24:46 https://maestrodatabase.com/blog/tecentriq-kesimpta-lead-latest-smc-decisions 2021-07-13T21:29:17 https://maestrodatabase.com/blog/icer-to-develop-a-california-state-unsupported-price-increase-report-funded-by-the-california-health-care-foundation 2022-03-03T19:53:18 https://maestrodatabase.com/blog/fda-plans-to-create-a-new-office-to-leverage-cutting-edge-science 2019-01-08T20:10:47 https://maestrodatabase.com/blog/criticism-of-study-planning-patient-reported-endpoints-are-often-collected-far-too-briefly 2022-03-03T19:58:18 https://maestrodatabase.com/blog/nhs-rolls-out-life-changing-treatment-for-thousands-with-sickle-cell-disease 2024-05-03T05:28:13 https://maestrodatabase.com/blog/understanding-statistical-principles-in-linear-and-logistic-regression 2018-05-07T05:07:30 https://maestrodatabase.com/blog/all-seven-of-the-fdas-recent-commissioners-agree-it-should-be-independent----but-not-on-how-to-accomplish-it 2019-01-08T20:13:01 https://maestrodatabase.com/blog/start-up-proposes-third-way-to-cut-us-drug-prices 2020-01-12T20:05:01 https://maestrodatabase.com/blog/european-efforts-to-assess-russias-sputnik-v-vaccine-stymied-by-data-gaps 2021-07-13T21:10:08 https://maestrodatabase.com/blog/enhertu-to-get-insurance-coverage-for-metastatic-breast-slash-stomach-cancer-from-april 2024-05-03T05:24:58 https://maestrodatabase.com/blog/a-price-on-your-life-toronto-cystic-fibrosis-patients-slam-review-process-while-waiting-for-access-to-life-saving-treatment 2021-07-13T21:01:37 https://maestrodatabase.com/blog/the-drug-price-control-threat 2019-01-08T20:56:13 https://maestrodatabase.com/blog/drug-maker-wont-put-price-in-tv-ads-but-patients-can-look-it-up 2019-01-08T20:27:12 https://maestrodatabase.com/blog/molnupiravir-will-remain-available-for-people-who-need-it 2023-07-27T03:18:36 https://maestrodatabase.com/blog/allterum-therapeutics-receives-fda-fast-track-designation-for-4a10-in-acute-lymphoblastic-leukaemia 2025-11-14T00:31:41 https://maestrodatabase.com/blog/biden-in-standoff-with-democratic-senators-over-who-should-lead-fda 2021-07-13T21:24:08 https://maestrodatabase.com/blog/itm-announces-fda-acceptance-of-new-drug-application-and-pdufa-date-for-lutetium-lu-177-edotreotide-itm-11-in-gastro-enteropancreatic-neuroendocrine-tumours 2025-11-14T01:19:13 https://maestrodatabase.com/blog/tlv-wants-to-go-further-with-combination-treatments-in-the-field-of-cancer 2020-12-08T10:38:23 https://maestrodatabase.com/blog/european-commission-approves-bavencio-avelumab-for-metastatic-merkel-cell-carcinoma 2017-09-25T03:25:54 https://maestrodatabase.com/blog/registration-of-new-chemical-entities-in-australia-2016 2017-01-31T19:57:14 https://maestrodatabase.com/blog/nice-backs-astrazenecas-calquence-for-chronic-lymphocytic-leukaemia 2020-12-08T10:49:27 https://maestrodatabase.com/blog/ucbs-anti-epileptic-drug-vimpat-lacosamide-receives-eu-approval-for-paediatric-use 2017-09-25T03:20:03 https://maestrodatabase.com/blog/trump-order-on-regulations-could-create-hurdles-for-fda-cures-act 2017-01-31T20:17:19 https://maestrodatabase.com/blog/life-saving-medicine-listed-for-spinal-muscular-atrophy 2018-05-07T05:25:30 https://maestrodatabase.com/blog/novartis-drug-votubia-receives-eu-approval-to-treat-refractory-partial-onset-seizures-in-patients-with-tsc 2017-01-31T20:21:52 https://maestrodatabase.com/blog/kiadis-pharma-receives-fda-regenerative-medicine-advanced-therapy-designation-for-atir101 2017-09-25T03:34:18 https://maestrodatabase.com/blog/medicines-australia-welcomes-reform-efforts-to-speed-up-clinical-trials 2022-03-03T20:05:05 https://maestrodatabase.com/blog/patients-battling-deadly-ovarian-lung-cancer-to-have-affordable-access-to-new-drugs 2017-01-31T20:03:28 https://maestrodatabase.com/blog/trump-pushes-drug-makers-for-lower-prices-more-u-dot-s-production 2017-01-31T20:13:49 https://maestrodatabase.com/blog/reality-tv-star-john-cocksy-cocks-brave-battle-with-terminal-cancer 2018-05-07T05:32:30 https://maestrodatabase.com/blog/roche-receives-european-approval-for-actemra-slash-roactemra-in-giant-cell-arteritis 2017-09-25T03:42:43 https://maestrodatabase.com/blog/trump-health-pick-tom-price-pressed-over-purchase-of-shares-in-asx-listed-biotech-innate 2017-01-31T20:39:34 https://maestrodatabase.com/blog/tom-price-steve-mnuchin-nominations-blocked-by-democratic-boycott 2017-01-31T20:42:34 https://maestrodatabase.com/blog/pfizer-ceo-says-no-need-to-alter-its-drug-pricing-practices 2017-01-31T20:32:53 https://maestrodatabase.com/blog/many-drug-companies-fail-to-conduct-timely-safety-checks-on-medicines-after-fda-approval 2017-09-25T03:39:15 https://maestrodatabase.com/blog/bernie-sanders-seeks-trumps-support-in-cutting-drug-costs 2017-01-31T20:35:52 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-february-2017-update 2017-01-31T20:54:52 https://maestrodatabase.com/blog/biocrysts-rapivab-peramivir-injection-receives-fda-approval-for-a-paediatric-indication 2017-09-25T03:46:09 https://maestrodatabase.com/blog/drug-makers-accused-of-fixing-prices-on-insulin 2017-01-31T20:47:53 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-february-2017 2017-01-31T20:51:07 https://maestrodatabase.com/blog/challenges-in-the-assessment-of-medical-devices-the-medtechta-project 2017-02-01T00:11:42 https://maestrodatabase.com/blog/acerus-provides-update-on-natesto-approval-process-in-europe 2020-01-12T21:20:01 https://maestrodatabase.com/blog/star-therapeutics-receives-fda-fast-track-designation-for-vga039-in-von-willebrand-disease 2025-01-06T23:39:25 https://maestrodatabase.com/blog/at-16-shes-a-pioneer-in-the-fight-to-cure-sickle-cell-disease 2020-01-12T21:35:51 https://maestrodatabase.com/blog/intellipharmaceutics-receives-complete-response-letter-from-the-fda-for-rexista-nda 2017-09-25T12:46:04 https://maestrodatabase.com/blog/sentynl-therapeutics-announces-us-fda-acceptance-and-priority-review-of-new-drug-application-for-cutx-101-copper-histidinate-product-candidate-for-treatment-of-menkes-disease 2025-01-06T23:56:15 https://maestrodatabase.com/blog/karyopharm-announces-submission-of-marketing-authorisation-application-to-the-european-medicines-agency-for-selinexor-for-the-treatment-of-patients-with-penta-refractory-multiple-myeloma 2019-01-09T07:00:37 https://maestrodatabase.com/blog/medicares-national-coverage-determination-for-aducanumab---a-one-off-or-a-pragmatic-path-forward 2022-10-22T22:56:31 https://maestrodatabase.com/blog/u-dot-s-fda-grants-fast-track-designation-for-amicus-therapeutics-migalastat-for-treatment-of-fabry-disease 2017-09-25T13:34:28 https://maestrodatabase.com/blog/advanced-ovarian-cancer-treatment-placed-on-the-pbs-a-move-praised-by-doctors-and-patients 2017-02-01T02:53:36 https://maestrodatabase.com/blog/the-fda-is-in-trouble-heres-how-to-fix-it 2020-01-12T21:50:38 https://maestrodatabase.com/blog/trump-pledges-to-work-with-big-pharma-to-lower-drug-prices 2017-02-01T02:51:03 https://maestrodatabase.com/blog/european-commission-approves-keytruda-pembrolizumab-for-first-line-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-whose-tumours-have-high-pd-l1-expression-with-no-egfr-or-alk-positive-tumour-mutations 2017-02-01T06:23:34 https://maestrodatabase.com/blog/biotech-proposes-paying-for-pricey-drugs-by-instalment 2019-01-09T07:18:22 https://maestrodatabase.com/blog/soliris-approved-in-the-eu-for-children-and-adolescents-with-refractory-generalised-myasthenia-gravis 2023-07-27T06:47:57 https://maestrodatabase.com/blog/three-reasons-the-drug-industry-should-be-worried-about-bidens-hhs-pick-xavier-becerra 2020-12-08T11:11:26 https://maestrodatabase.com/blog/new-brunswick-to-publicly-reimburse-albrioza-for-the-treatment-of-als 2023-07-27T07:02:34 https://maestrodatabase.com/blog/can-a-butterfly-cause-a-typhoon-just-ask-innate-immunotherapeutics 2017-02-01T06:17:25 https://maestrodatabase.com/blog/british-columbia-to-publicly-reimburse-albrioza-for-the-treatment-of-als 2023-07-27T05:22:34 https://maestrodatabase.com/blog/first-in-class-brca-positive-ovarian-cancer-medicine-lynparza-olaparib-receives-positive-pan-canadian-oncology-drug-review-recommendation-for-provincial-reimbursement 2017-09-25T14:02:02 https://maestrodatabase.com/blog/agenda-for-the-may-2024-pbac-meeting 2024-05-03T06:24:53 https://maestrodatabase.com/blog/performance-based-risk-sharing-arrangements-an-updated-international-review 2017-09-25T13:54:42 https://maestrodatabase.com/blog/defender-pharmaceuticals-announces-submission-of-new-drug-application-to-fda-with-intranasal-scopolamine-for-prevention-of-nausea-and-vomiting-induced-by-motion-in-adults 2023-07-27T05:06:31 https://maestrodatabase.com/blog/gilead-receives-approval-in-canada-for-expanded-indication-of-epclusa-sofosbuvir-slash-velpatasvir-for-the-treatment-of-chronic-hepatitis-c-in-patients-co-infected-with-hiv 2017-09-25T14:09:38 https://maestrodatabase.com/blog/as-trump-prepares-plan-to-lower-drug-prices-big-pharma-girds-for-a-fight 2018-05-07T08:40:38 https://maestrodatabase.com/blog/fda-grants-priority-review-to-roches-cancer-immunotherapy-tecentriq-atezolizumab-for-initial-treatment-of-people-with-a-specific-type-of-metastatic-lung-cancer 2018-05-07T13:20:48 https://maestrodatabase.com/blog/camurus-announces-that-fda-grants-priority-review-of-nda-for-weekly-and-monthly-cam2038-buprenorphine-depots-for-treatment-of-opioid-use-disorder 2017-09-25T14:35:55 https://maestrodatabase.com/blog/stivarga-final-nice-recommendation-for-hepatocellular-carcinoma 2019-01-09T19:47:47 https://maestrodatabase.com/blog/turf-war-pharmacists-will-deliver-covid-19-vaccine-despite-gp-concerns 2020-12-08T19:46:09 https://maestrodatabase.com/blog/pfizers-vaccine-offers-covid-19-protection-after-first-dose-fda-says 2020-12-08T19:48:18 https://maestrodatabase.com/blog/turning-point-therapeutics-granted-fda-breakthrough-therapy-designation-for-repotrectinib-treatment-in-patients-with-ros1-positive-metastatic-non-small-cell-lung-cancer-who-have-not-been-treated-with-a-ros1-tyrosine-kinase-inhibitor 2020-12-08T20:04:42 https://maestrodatabase.com/blog/nuvation-bio-receives-approval-from-chinas-national-medical-products-administration-for-taletrectinib-for-patients-with-advanced-ros1-positive-non-small-cell-lung-cancer 2025-01-07T00:30:12 https://maestrodatabase.com/blog/novartis-car-t-drug-needs-new-payment-model-says-express-scripts 2017-09-25T14:55:20 https://maestrodatabase.com/blog/public-summary-documents-first-time-decisions-not-to-recommend-and-deferrals---july-2025-pbac-meeting 2025-11-14T10:15:28 https://maestrodatabase.com/blog/the-future-of-fdas-electronic-safety-surveillance 2019-01-09T19:59:17 https://maestrodatabase.com/blog/outcome-statement---dusc-october-2025-meeting 2025-11-14T10:18:10 https://maestrodatabase.com/blog/nice-nod-for-new-eylea-indication 2017-09-25T15:00:38 https://maestrodatabase.com/blog/new-drug-to-halve-heart-patients-cholesterol-levels 2019-01-09T20:08:32 https://maestrodatabase.com/blog/house-democrats-tempt-trump-with-legislation-to-allow-medicare-to-negotiate-drug-prices 2019-01-09T19:50:52 https://maestrodatabase.com/blog/trump-summons-advisers-to-white-house-over-drug-price-hikes 2019-01-09T19:54:06 https://maestrodatabase.com/blog/joint-strategy-sets-direction-for-ema-and-eu-medicines-regulatory-agencies-to-2025 2020-12-08T19:41:32 https://maestrodatabase.com/blog/nice-publishes-final-guidance-on-the-use-of-darvadstrocel-on-the-nhs 2019-01-09T20:22:17 https://maestrodatabase.com/blog/indication-specific-drug-pricing---simple-in-theory-complex-in-reality 2018-05-07T13:48:25 https://maestrodatabase.com/blog/price-drugs-according-to-what-they-do 2019-01-09T20:29:28 https://maestrodatabase.com/blog/trump-administration-passed-on-chance-to-secure-more-of-pfizer-vaccine 2020-12-08T20:32:37 https://maestrodatabase.com/blog/smc---may-2018-decisions 2018-05-07T13:40:39 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-posts-revised-value-assessment-framework-for-public-comment 2017-02-01T20:18:39 https://maestrodatabase.com/blog/can-the-record-breaking-number-of-fda-new-drug-approvals-continue 2019-01-09T20:12:54 https://maestrodatabase.com/blog/the-tories-must-learn-from-the-orkambi-victory-and-keep-drug-pricing-off-the-table 2020-01-12T22:40:51 https://maestrodatabase.com/blog/sanofi-and-regeneron-announce-first-approval-of-kevzara-sarilumab-for-the-treatment-of-moderately-to-severely-active-rheumatoid-arthritis-in-adult-patients-by-health-canada 2017-02-01T20:25:08 https://maestrodatabase.com/blog/democrats-say-cabinet-choice-tom-price-misled-the-public-heres-what-we-know 2017-02-01T20:13:47 https://maestrodatabase.com/blog/this-bottle-of-pills-costs-20-dollars-in-one-state-and-130-dollars-in-another 2019-01-09T20:17:11 https://maestrodatabase.com/blog/who-gets-covid-19-vaccine-first-hospitals-assess-how-to-divvy-up-shots 2020-12-08T20:39:49 https://maestrodatabase.com/blog/trump-wants-to-blow-up-the-fda-the-drug-industry-not-so-much 2017-02-01T20:15:58 https://maestrodatabase.com/blog/senate-inquiry-on-prostheses-pricing-urged-to-consider-implications 2017-02-01T20:47:09 https://maestrodatabase.com/blog/us-government-is-talking-to-companies-about-drug-price-negotiations 2022-10-22T23:45:05 https://maestrodatabase.com/blog/two-years-of-prime 2018-05-08T06:21:17 https://maestrodatabase.com/blog/atomoxetine---further-delay-in-change-of-funded-brand-and-open-access 2020-05-20T04:22:01 https://maestrodatabase.com/blog/eli-lilly-ceo-were-not-jacking-up-our-drug-costs-for-profit 2017-02-01T20:33:42 https://maestrodatabase.com/blog/roche-remains-committed-to-us-despite-trumps-crackdown-on-drug-prices 2017-02-01T20:41:46 https://maestrodatabase.com/blog/genmab-announces-u-dot-s-fda-approval-of-darzalex-daratumumab-in-newly-diagnosed-multiple-myeloma 2018-05-08T06:24:17 https://maestrodatabase.com/blog/new-cancer-medicines-added-to-the-pbs 2022-10-23T02:19:05 https://maestrodatabase.com/blog/carlsmed-aprevo-granted-unprecedented-decision-by-fda 2020-12-08T20:18:46 https://maestrodatabase.com/blog/pbac---2018-in-review-cancer 2019-01-09T20:32:35 https://maestrodatabase.com/blog/sanofi-secures-expanded-european-approval-for-toujeo-in-type-1-diabetes 2020-01-12T22:53:38 https://maestrodatabase.com/blog/patient-centred-health-technology-assessment-a-perspective-on-engagement-in-health-technology-assessment-by-three-patient-organisations-and-a-health-technology-assessment-body 2022-10-22T23:34:36 https://maestrodatabase.com/blog/icer-to-assess-treatments-for-obesity-management 2022-03-03T23:07:53 https://maestrodatabase.com/blog/telix-granted-tga-priority-review-for-prostate-cancer-imaging 2020-12-08T20:26:05 https://maestrodatabase.com/blog/notification-of-delay-of-decision-on-denosumab-funding-proposal 2018-05-08T06:17:48 https://maestrodatabase.com/blog/pharmaceutical-patent-challenges-company-strategies-and-litigation-outcomes 2017-02-01T20:51:01 https://maestrodatabase.com/blog/senate-panel-advances-pbm-reform---but-sidesteps-anything-controversial 2023-07-27T21:13:40 https://maestrodatabase.com/blog/doctors-and-patients-anxious-after-pharma-giant-apotex-quits-new-zealand 2020-07-13T10:55:48 https://maestrodatabase.com/blog/pfizer-and-biontech-granted-fda-fast-track-designation-for-two-investigational-mrna-based-vaccine-candidates-against-sars-cov-2 2020-07-13T11:02:01 https://maestrodatabase.com/blog/trump-vaccine-executive-order-raises-questions-after-pfizer-offer-declined 2020-12-08T20:50:43 https://maestrodatabase.com/blog/fda-grants-breakthrough-therapy-designation-to-ns-089-slash-ncnp-02-for-the-treatment-of-duchenne-muscular-dystrophy 2023-07-27T20:59:36 https://maestrodatabase.com/blog/salix-receives-fda-approval-for-plenvu-next-generation-1-litre-bowel-cleansing-preparation-for-colonoscopies 2018-05-08T06:36:20 https://maestrodatabase.com/blog/request-for-information---covid-19-vaccine-research-manufacture-and-supply 2020-07-13T06:51:00 https://maestrodatabase.com/blog/ipsen-announces-updated-indication-for-dysport-abobotulinumtoxina-for-the-treatment-of-spasticity-in-children 2020-07-13T06:59:37 https://maestrodatabase.com/blog/fda-approves-supplemental-new-drug-application-for-myrbetriq-mirabegron-for-use-in-combination-with-solifenacin-succinate-for-the-treatment-of-overactive-bladder-symptoms 2018-05-08T06:45:56 https://maestrodatabase.com/blog/pharmac-cruel-for-failing-to-fund-drugs-for-rare-illnesses----advocate 2021-07-14T10:24:21 https://maestrodatabase.com/blog/antengene-announces-xpovio-regulatory-approval-in-singapore-for-the-treatment-of-relapsed-and-slash-or-refractory-multiple-myeloma-and-relapsed-slash-refractory-diffuse-large-b-cell-lymphoma-in-three-indications 2022-03-03T23:32:07 https://maestrodatabase.com/blog/hhs-allocates-gileads-covid-19-drug-remdesivir-to-four-hardest-hit-states 2020-07-13T21:20:20 https://maestrodatabase.com/blog/eunethta-is-extended-for-one-year-and-focuses-on-covid-19 2020-07-13T21:25:32 https://maestrodatabase.com/blog/u-dot-s-food-and-drug-administration-grants-cabaletta-bio-fast-track-designation-for-musk-caart 2022-03-03T23:41:05 https://maestrodatabase.com/blog/tga-publishes-more-details-on-its-approval-of-covid-19-medicine-veklury 2020-07-13T11:39:34 https://maestrodatabase.com/blog/first-us-drug-priced-at-more-than-1-dollars-million-may-be-on-the-horizon 2018-05-08T08:27:51 https://maestrodatabase.com/blog/pharmac-has-for-decades-refused-to-fund-synagis-drug-that-could-save-vulnerable-babies-from-rsv 2021-07-14T09:12:55 https://maestrodatabase.com/blog/obesity-drugs-dont-make-whos-essential-list-but-ebola-ms-drugs-added 2023-07-27T21:24:22 https://maestrodatabase.com/blog/are-high-cost-drug-funding-mechanisms-fit-for-purpose-a-retrospective-study-of-individual-funding-requests-in-an-nhs-tertiary-hospital 2020-07-13T21:03:32 https://maestrodatabase.com/blog/harvard-doctor-urges-fda-reforms-after-biogen-alzheimer-nod 2021-07-14T10:18:13 https://maestrodatabase.com/blog/precision-medicines-have-faster-approvals-based-on-fewer-and-smaller-trials-than-other-medicines 2018-05-08T06:54:06 https://maestrodatabase.com/blog/access-and-availability-why-are-europeans-finding-it-hard-to-get-the-new-medicines-they-need 2023-07-27T21:17:52 https://maestrodatabase.com/blog/fda-advises-cytodyn-its-application-is-incomplete 2020-07-13T21:11:11 https://maestrodatabase.com/blog/gnawing-away-at-health-care 2018-05-08T08:17:24 https://maestrodatabase.com/blog/world-health-organization-publishes-updated-essential-medicines-list 2023-07-27T21:20:50 https://maestrodatabase.com/blog/norgine-submits-marketing-authorisation-application-to-the-ema-for-eflornithine-difluoromethylornithine-in-high-risk-neuroblastoma 2025-01-07T01:20:18 https://maestrodatabase.com/blog/radiomedix-and-curium-announce-fda-fast-track-designation-for-64cu-dotatate 2019-01-09T23:27:51 https://maestrodatabase.com/blog/generic-price-competition-for-specialty-drugs-too-little-too-late 2018-05-08T08:40:10 https://maestrodatabase.com/blog/six-months-into-the-pandemic-how-much-closer-are-we-to-a-vaccine 2020-07-13T21:38:54 https://maestrodatabase.com/blog/onconano-receives-authorisation-to-proceed-from-fda-for-ind-application-and-fast-track-designation-for-onm-100-intra-operative-imaging-agent-to-detect-tumours-and-metastatic-lymph-nodes-that-often-go-undetected-during-surgery 2019-01-09T23:52:46 https://maestrodatabase.com/blog/aquestive-therapeutics-receives-fda-response-to-citizens-petition 2020-01-13T01:21:51 https://maestrodatabase.com/blog/ema-commences-review-of-donidalorsen-in-hereditary-angioedema 2025-01-07T01:30:39 https://maestrodatabase.com/blog/texas-v-united-states-the-affordable-care-act-is-constitutional-and-will-remain-so 2019-01-10T00:12:18 https://maestrodatabase.com/blog/asp3772-receives-fda-breakthrough-therapy-designation 2021-07-14T11:35:53 https://maestrodatabase.com/blog/senator-bernie-sanders-potential-2020-candidate-to-introduce-bills-on-prescription-drug-costs 2019-01-10T06:53:47 https://maestrodatabase.com/blog/fda-approves-59-novel-drugs-in-2018 2019-01-10T06:57:41 https://maestrodatabase.com/blog/decision-to-list-a-new-presentation-of-raltegravir-and-amend-arrangements-for-raltegravir-and-posaconazole 2019-01-10T00:33:59 https://maestrodatabase.com/blog/sarepta-announces-fdas-approval-of-updated-elevidys-prescribing-information 2025-11-15T03:58:20 https://maestrodatabase.com/blog/pharmac-updates-access-criteria-for-remdesivir 2022-03-04T01:43:50 https://maestrodatabase.com/blog/prescription-medicines-applications-under-evaluation-july-2021-update 2021-07-14T12:04:06 https://maestrodatabase.com/blog/2018-in-a-nutshell-new-edition-with-facts-and-graphics-from-the-iqwig 2019-01-10T20:01:49 https://maestrodatabase.com/blog/approved-first-generic-for-apokyn-injection-cartridges-requires-separately-packaged-pen 2022-03-04T01:52:36 https://maestrodatabase.com/blog/new-migraine-drug-not-cost-effective-nice-says-in-draft-guidance 2019-01-10T12:54:20 https://maestrodatabase.com/blog/nice-feedback 2021-07-14T21:02:05 https://maestrodatabase.com/blog/nice-publishes-final-guidance-on-another-use-of-keytruda-for-patients-with-nsclc 2019-01-10T19:51:27 https://maestrodatabase.com/blog/pm-speaks-about-covid-19-fiji-and-pharmac-funding 2021-07-14T12:08:19 https://maestrodatabase.com/blog/grassley-says-not-in-favour-of-government-negotiating-with-companies-on-drug-prices 2019-01-10T20:22:44 https://maestrodatabase.com/blog/kesimpta-ofatumumab-approved-for-relapsing-remitting-ms-in-scotland 2021-07-14T11:43:37 https://maestrodatabase.com/blog/fda-grants-alkeus-pharmaceuticals-breakthrough-therapy-designation-for-alk-001-c20-d3-vitamin-a-for-the-treatment-of-stargardt-disease 2021-07-14T11:55:14 https://maestrodatabase.com/blog/trump-inspired-tweets-signal-more-drug-price-pressure 2019-01-10T20:12:59 https://maestrodatabase.com/blog/diabetes-drug-that-cuts-sugar-will-also-reduce-heart-problems 2017-02-01T22:52:32 https://maestrodatabase.com/blog/no-more-sending-kiwis-across-the-ditch-as-new-national-neuroendocrine-cancer-treatment-service-opens 2021-07-14T21:32:10 https://maestrodatabase.com/blog/fda-chief-tells-reporter-move-on-when-pressed-on-biogen-alzheimers-drug-approval 2021-07-14T21:23:48 https://maestrodatabase.com/blog/nymox-announces-submission-of-new-drug-application-to-the-fda-for-fexapotide-triflutate 2022-03-04T04:18:46 https://maestrodatabase.com/blog/science-hasnt-shown-these-medications-work-theyre-being-sold-anyway 2022-03-04T03:42:00 https://maestrodatabase.com/blog/fda-chief-janet-woodcock-acknowledges-agency-may-have-misstepped-in-process-leading-up-to-alzheimers-drug-approval 2021-07-14T21:12:11 https://maestrodatabase.com/blog/sanofis-teizeild-recommended-for-eu-approval-by-the-chmp-for-patients-with-stage-2-type-1-diabetes 2025-11-15T04:17:48 https://maestrodatabase.com/blog/patient-impact-statement-fda-approval-of-kerendia-to-help-slow-kidney-disease-and-failure-associated-with-type-2-diabetes 2021-07-14T21:17:59 https://maestrodatabase.com/blog/beigene-announces-health-canada-approval-for-brukinsa-zanubrutinib-in-relapsed-or-refractory-marginal-zone-lymphoma 2022-03-04T03:58:49 https://maestrodatabase.com/blog/government-commits-to-pbs-time-to-unpack-the-detail 2018-05-08T21:32:10 https://maestrodatabase.com/blog/federal-budget-2018-1-dollars-3-cents-billion-plan-to-make-australia-a-medical-technology-leader 2018-05-08T21:40:20 https://maestrodatabase.com/blog/public-summary-documents---november-2021-pbac-meeting 2022-03-04T05:29:48 https://maestrodatabase.com/blog/guaranteeing-essential-services---record-investment-in-health 2018-05-08T10:31:46 https://maestrodatabase.com/blog/minister-to-talk-to-novartis-after-five-fold-cancer-drug-price-hike 2019-01-10T21:17:23 https://maestrodatabase.com/blog/trump-often-goes-off-script-what-does-that-mean-for-his-drug-pricing-speech 2018-05-08T21:51:28 https://maestrodatabase.com/blog/heres-what-to-expect-when-trump-outlines-his-policy-to-bring-down-drug-prices 2018-05-08T21:53:50 https://maestrodatabase.com/blog/hundreds-of-patients-to-benefit-from-revolutionary-lung-cancer-drug-on-the-nhs 2022-03-04T04:27:48 https://maestrodatabase.com/blog/lynparza-tablets-receive-eu-approval-for-the-treatment-of-platinum-sensitive-relapsed-ovarian-cancer 2018-05-08T21:45:50 https://maestrodatabase.com/blog/ausbiotech-consults-biotech-ceos-on-industry-advocacy 2017-02-02T01:13:41 https://maestrodatabase.com/blog/icer-to-assess-treatments-for-spinal-muscular-atrophy 2025-01-07T01:59:52 https://maestrodatabase.com/blog/optinose-announces-fda-acceptance-for-filing-of-the-new-drug-application-for-opn-375 2017-02-02T02:51:51 https://maestrodatabase.com/blog/drug-development-challenges-for-small-biopharmaceutical-companies 2017-02-02T02:17:31 https://maestrodatabase.com/blog/japans-takeda-committed-to-single-digit-u-dot-s-drug-price-rises 2017-02-02T02:47:34 https://maestrodatabase.com/blog/mind-the-gap---an-analysis-of-cancer-medicines-in-new-zealand-and-australia 2017-02-02T07:10:47 https://maestrodatabase.com/blog/quality-over-quantity-more-important-in-health-outcomes 2017-02-02T04:55:32 https://maestrodatabase.com/blog/u-dot-s-fda-grants-priority-review-to-abbvie-for-its-investigational-regimen-of-glecaprevir-slash-pibrentasvir-for-the-treatment-of-chronic-hepatitis-c-in-all-major-genotypes 2017-02-02T19:45:59 https://maestrodatabase.com/blog/potential-drug-price-hike-could-be-a-hard-pill-to-swallow 2017-02-02T19:58:04 https://maestrodatabase.com/blog/biomarin-receives-access-to-priority-medicines-prime-regulatory-support-from-ema-for-bmn-270-gene-therapy-in-haemophilia-a 2017-02-02T10:58:36 https://maestrodatabase.com/blog/teva-confirms-generic-victoza-patent-challenge-in-the-united-states 2017-02-02T20:21:19 https://maestrodatabase.com/blog/trump-pledges-to-gut-fda-which-regulations-need-to-go 2017-02-02T20:05:52 https://maestrodatabase.com/blog/health-and-science-health-insurers-warn-of-wider-defections-from-aca-marketplaces-for-2018 2017-02-02T20:10:35 https://maestrodatabase.com/blog/outcomes-of-early-health-technology-assessment-dialogues-in-medicinal-product-development 2017-02-02T20:43:03 https://maestrodatabase.com/blog/critics-wary-over-plans-to-fast-track-uk-drug-approval-model 2023-07-28T03:47:08 https://maestrodatabase.com/blog/highlights-from-the-10-13-november-2025-chmp-meeting 2025-11-15T04:53:18 https://maestrodatabase.com/blog/could-more-medicines-be-recommended-for-routine-commissioning-rather-than-spending-time-in-the-cancer-drugs-fund 2022-10-23T19:59:26 https://maestrodatabase.com/blog/tga-and-pbac-parallel-process-now-available-for-vaccines 2017-09-26T13:10:20 https://maestrodatabase.com/blog/improved-deal-signals-nice-recommendation-of-sickle-cell-treatment-voxelotor 2024-05-03T12:55:33 https://maestrodatabase.com/blog/pbs-cost-recovery-implementation-statement-2017-2018 2017-09-26T13:07:28 https://maestrodatabase.com/blog/european-commission-approves-symtuza-for-the-treatment-of-hiv-1-in-adults-and-adolescents-in-europe 2017-09-26T13:20:22 https://maestrodatabase.com/blog/pharmac-publishes-agenda-for-november-2022-ptac-meeting 2022-10-23T19:47:01 https://maestrodatabase.com/blog/update-on-ema-relocation-preparedness 2017-09-26T13:14:13 https://maestrodatabase.com/blog/aradigm-announces-fda-acceptance-of-nda-for-linhaliq-with-priority-review-status 2017-09-26T13:27:20 https://maestrodatabase.com/blog/partial-government-shutdowns-impact-on-fda-drug-approvals 2019-01-11T02:03:28 https://maestrodatabase.com/blog/drug-pricing-advocates-to-spend-$1m-on-ads-supporting-trump-proposal 2019-01-11T05:05:35 https://maestrodatabase.com/blog/health-bill-appears-dead-as-pivotal-g-dot-o-p-senator-declares-opposition 2017-09-26T14:23:33 https://maestrodatabase.com/blog/drugs-watchdog-nice-attacks-pharmaceutical-industry-in-pricing-dispute 2017-09-26T14:16:14 https://maestrodatabase.com/blog/us-fda-sets-pdufa-date-for-scenesse 2019-01-11T06:00:31 https://maestrodatabase.com/blog/miracle-drug-keytruda-should-be-funded-patients-say 2017-09-26T14:25:46 https://maestrodatabase.com/blog/fda-conducts-major-global-operation-to-protect-consumers-from-potentially-dangerous-prescription-drugs-sold-online 2017-09-26T14:37:57 https://maestrodatabase.com/blog/notification-of-decision-involving-treatments-for-multiple-sclerosis-narcolepsy-and-attention-deficit-hyperactivity-disorder 2019-01-11T06:06:03 https://maestrodatabase.com/blog/final-budget-outcomes-reveal-industry-efforts-to-take-pressure-off-pbs 2017-09-26T14:32:46 https://maestrodatabase.com/blog/everyone-wants-to-reduce-drug-prices-so-why-cant-we-do-it 2017-09-26T14:46:01 https://maestrodatabase.com/blog/how-patient-preferences-contribute-to-regulatory-decisions-for-medical-devices 2017-09-26T14:39:47 https://maestrodatabase.com/blog/governors-association-plans-a-big-strategy-session-over-drug-pricing 2017-09-26T14:48:24 https://maestrodatabase.com/blog/icer-posts-draft-scoping-document-for-the-assessment-of-treatments-for-duchenne-muscular-dystrophy 2019-01-11T22:24:08 https://maestrodatabase.com/blog/talazoparib-tosylate-for-the-treatment-of-patients-with-advanced-germline-brca-mutation-positive-her2-negative-breast-cancer 2023-07-28T04:20:46 https://maestrodatabase.com/blog/regeneron-ceo-we-need-a-carrot-and-stick-system-to-balance-pricing-and-innovation 2019-01-11T22:32:46 https://maestrodatabase.com/blog/agenda-for-8-february-2017-tc-meeting 2017-02-03T01:01:03 https://maestrodatabase.com/blog/pbs-expenditure-and-prescriptions-report-2017-18 2019-01-11T22:36:28 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-fda-approval-for-opdivo-nivolumab-in-previously-treated-locally-advanced-or-metastatic-urothelial-carcinoma-a-type-of-bladder-cancer 2017-02-03T00:42:25 https://maestrodatabase.com/blog/updated-financial-estimates-workbook 2021-08-06T02:00:58 https://maestrodatabase.com/blog/j-and-j-raises-u-dot-s-prices-on-around-two-dozen-drugs 2019-01-11T22:29:33 https://maestrodatabase.com/blog/life-extending-lung-cancer-treatment-recommended-for-use-on-the-nhs 2019-07-05T10:20:24 https://maestrodatabase.com/blog/pbac-public-summary-documents---march-2019-meeting 2019-07-05T10:34:05 https://maestrodatabase.com/blog/sanofi-and-novo-nordisk-press-ahead-with-us-insulin-prices-rises 2019-01-11T22:52:00 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-15-july-2021 2021-07-15T05:41:31 https://maestrodatabase.com/blog/fda-approves-grifols-prolastin-c-liquid-alpha-1-proteinase-inhibitor-liquid-for-the-treatment-of-alpha-1-anti-trypsin-deficiency 2017-09-26T15:14:17 https://maestrodatabase.com/blog/government-breaks-promises-to-pompe-disease-sufferers 2019-07-05T10:30:10 https://maestrodatabase.com/blog/facing-legal-action-insurer-now-will-cover-people-taking-truvada-an-h-dot-i-v-prevention-drug 2019-01-11T22:43:02 https://maestrodatabase.com/blog/agenda-for-27-september-tc-meeting 2017-09-26T15:21:39 https://maestrodatabase.com/blog/device-for-preventing-and-relieving-pain-of-cluster-headaches-approved-by-nice-in-draft-guidance 2019-07-05T12:41:17 https://maestrodatabase.com/blog/making-advances-against-sickle-cell-disease 2017-09-27T03:11:36 https://maestrodatabase.com/blog/fda-selects-participants-for-new-digital-health-software-pre-certification-pilot-program 2017-09-27T03:08:21 https://maestrodatabase.com/blog/mother-of-threes-life-has-5900-dollars-a-month-price-tag 2017-09-27T03:26:05 https://maestrodatabase.com/blog/nz-behind-rest-of-modern-world-in-medicines-funding 2017-09-27T03:32:36 https://maestrodatabase.com/blog/ema-staff-favour-move-to-amsterdam 2017-09-27T11:51:40 https://maestrodatabase.com/blog/even-before-year-end-2020s-new-drug-approvals-match-fdas-2019-stats 2020-12-09T01:59:25 https://maestrodatabase.com/blog/u-dot-s-health-care-bills-collapse-escalates-republican-infighting 2017-09-27T12:14:58 https://maestrodatabase.com/blog/abbvie-insists-its-keeping-its-pricing-pledge-calling-earlier-reports-incorrect 2017-09-27T12:06:09 https://maestrodatabase.com/blog/chmp-positive-opinion-for-waskyra-a-gene-therapy-for-the-treatment-of-wiskott-aldrich-syndrome 2025-11-15T21:42:25 https://maestrodatabase.com/blog/application-for-additional-indication-of-lenvima-for-hepatocellular-carcinoma-accepted-for-review-by-u-dot-s-fda 2017-09-27T12:28:40 https://maestrodatabase.com/blog/the-swiss-also-have-a-private-health-care-system-but-theirs-works 2017-09-27T12:16:58 https://maestrodatabase.com/blog/switzerland-secures-three-million-doses-of-pfizer-slash-biontech-vaccine 2020-12-09T02:13:40 https://maestrodatabase.com/blog/first-coronavirus-vaccine-shots-could-be-doled-out-in-canada-next-week 2020-12-09T02:22:54 https://maestrodatabase.com/blog/time-running-out-for-no-deal-brexit-medicines-laws 2019-01-12T02:42:40 https://maestrodatabase.com/blog/us-fda-accepts-for-priority-review-the-biologics-license-application-for-pfizers-investigational-20-valent-pneumococcal-conjugate-vaccine-for-adults-18-years-of-age-and-older 2020-12-09T03:39:03 https://maestrodatabase.com/blog/lynparza-olaparib-tablets-receive-approval-as-maintenance-therapy-treatment-for-ovarian-cancer-regardless-of-brca-status 2018-05-09T05:46:01 https://maestrodatabase.com/blog/ocular-therapeutix-submits-supplemental-new-drug-application-for-dextenza-dexamethasone-ophthalmic-insert-for-the-treatment-of-ocular-inflammation-following-ophthalmic-surgery 2019-01-12T05:25:23 https://maestrodatabase.com/blog/wegovy-semaglutide-injection-available-in-canada 2024-05-04T01:03:24 https://maestrodatabase.com/blog/fdas-new-plausible-mechanism-pathway 2025-11-15T21:47:04 https://maestrodatabase.com/blog/mercks-met-inhibitor-tepotinib-gains-positive-opinion-from-mhra 2021-07-15T10:51:51 https://maestrodatabase.com/blog/health-economic-assessment-of-oncotype-dx-in-breast-cancer 2021-07-15T11:04:32 https://maestrodatabase.com/blog/influenza-vaccine-in-pharmacies 2017-02-03T05:09:18 https://maestrodatabase.com/blog/outcomes-of-the-consultation-on-the-draft-list-of-permitted-indications 2018-05-09T10:20:24 https://maestrodatabase.com/blog/exploring-opportunities-for-collaboration-between-regulators-and-health-care-payers 2017-09-27T18:44:29 https://maestrodatabase.com/blog/the-impact-of-moving-from-the-eq-5d-3l-to-the--5l-in-nice-technology-appraisals 2019-01-13T05:35:21 https://maestrodatabase.com/blog/relypsa-announces-fda-approval-of-supplemental-new-drug-application-to-enable-the-usage-of-veltassa-patiromer-with-or-without-food 2018-05-09T10:36:36 https://maestrodatabase.com/blog/ascelia-pharma-announces-fda-acceptance-of-orviglance-new-drug-application-for-review 2025-11-16T10:49:04 https://maestrodatabase.com/blog/right-after-trump-blamed-high-drug-prices-on-campaign-cash-drug-makers-gave-more 2017-09-27T18:18:20 https://maestrodatabase.com/blog/aligning-price-and-value-for-drugs--potential-disrupters-of-the-pbm-model 2018-05-09T10:28:02 https://maestrodatabase.com/blog/transparency-on-quality-and-price-will-transform-medicine 2018-05-09T10:31:09 https://maestrodatabase.com/blog/trump-falsely-claims-drug-prices-declined-in-2018 2019-01-13T04:11:55 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-to-debiopharms-debio-1347-for-the-treatment-of-patients-with-unresectable-or-metastatic-tumours-with-a-specific-fgfr-gene-alteration 2018-05-09T10:44:58 https://maestrodatabase.com/blog/fda-approves-first-continuous-glucose-monitoring-system-for-adults-not-requiring-blood-sample-calibration 2017-09-28T01:36:57 https://maestrodatabase.com/blog/new-advance-value-framework-offered-as-a-decision-support-tool-for-reimbursement 2017-09-27T18:51:12 https://maestrodatabase.com/blog/breast-cancer-drug-costs-too-high-in-relation-to-benefits-for-routine-nhs-funding 2017-02-03T08:33:45 https://maestrodatabase.com/blog/the-graham-cassidy-plan----the-most-harmful-aca-repeal-bill-yet 2017-09-28T01:42:40 https://maestrodatabase.com/blog/china-has-a-very-unhealthy-interest-in-our-medical-data 2019-01-13T20:17:56 https://maestrodatabase.com/blog/albireo-submits-for-u-dot-s-fda-and-ema-product-approval-of-once-daily-odevixibat-for-pfic 2020-12-09T04:15:42 https://maestrodatabase.com/blog/affordable-medicines-to-treat-skin-cancer-lung-cancer-and-alh 2022-10-23T23:42:52 https://maestrodatabase.com/blog/lannett-receives-fda-approval-for-oxycodone-and-acetaminophen-tablets-5-mg-slash-325-mg-and-10-mg-slash-325-mg 2017-09-28T01:49:15 https://maestrodatabase.com/blog/b-dot-c-where-access-to-a-wait-list-is-considered-access-to-health-care 2018-05-09T11:03:48 https://maestrodatabase.com/blog/stallergenes-greer-advances-its-house-dust-mite-allergy-pipeline-with-acceptance-of-regulatory-submission-and-new-market-approval 2017-09-28T01:55:28 https://maestrodatabase.com/blog/european-medicines-agency-grants-prime-designation-to-bit-pharmas-nicaplant-for-treatment-of-non-traumatic-subarachnoid-haemorrhage-in-patients-undergoing-surgery 2022-10-24T00:55:56 https://maestrodatabase.com/blog/evaluating-and-valuing-drugs-for-rare-conditions-no-easy-answers 2018-05-09T15:40:55 https://maestrodatabase.com/blog/lipocine-receives-complete-response-letter-for-tlando-from-u-dot-s-fda 2019-11-11T16:43:17 https://maestrodatabase.com/blog/rare-diseases-addressing-the-challenges-in-diagnosis-drug-approval-and-patient-access 2018-05-09T15:36:34 https://maestrodatabase.com/blog/fda-accepts-two-sblas-for-mercks-keytruda-pembrolizumab-for-locally-advanced-or-metastatic-urothelial-cancer-in-cisplatin-ineligible-first-line-and-second-line-post-platinum-failure-treatment-settings 2017-02-03T23:24:38 https://maestrodatabase.com/blog/u-dot-s-house-panel-to-take-up-bill-to-spur-generic-drug-development 2017-02-03T23:13:23 https://maestrodatabase.com/blog/g-dot-o-p-campaign-to-repeal-obamacare-stalls-on-the-details 2017-02-03T23:16:37 https://maestrodatabase.com/blog/biogen-alzheimers-drug-hits-roadblocks-with-some-hospitals-insurers 2021-07-15T20:59:44 https://maestrodatabase.com/blog/pharma-companies-fined-after-10-000-percent-price-rise-for-life-saving-drug 2021-07-15T21:08:29 https://maestrodatabase.com/blog/cystic-fibrosis-patients-upset-over-recommended-restrictive-criteria-for-life-saving-drug 2021-07-15T21:03:40 https://maestrodatabase.com/blog/intellipharmaceutics-announces-fda-acceptance-for-filing-of-nda-for-rexista-oxycodone-hydrochloride-extended-release-an-abuse-deterrent-opioid-analgesic-for-the-treatment-of-moderate-to-severe-pain 2017-02-04T01:30:26 https://maestrodatabase.com/blog/aduhelm-may-not-cure-alzheimers-but-it-might-help-fix-drug-prices 2021-07-15T20:55:43 https://maestrodatabase.com/blog/in-home-care-plan-to-cut-hospital-costs 2020-01-13T19:39:47 https://maestrodatabase.com/blog/pharmacies-are-ready-to-go-chemists-in-hotspots-fast-tracked-to-deliver-jabs 2021-07-15T21:48:40 https://maestrodatabase.com/blog/ensuring-continued-access-to-affordable-pbs-medicines-for-those-impacted-by-bushfires 2020-01-13T19:36:21 https://maestrodatabase.com/blog/g-ba-sees-considerable-additional-benefit-in-two-active-ingredients---eu-hta-analysis-is-coming 2021-07-15T21:38:32 https://maestrodatabase.com/blog/fda-approves-second-over-the-counter-naloxone-nasal-spray-product 2023-07-28T22:00:18 https://maestrodatabase.com/blog/alnylam-announces-that-the-united-kingdoms-mhra-grants-early-access-to-lumasiran 2020-07-14T08:09:57 https://maestrodatabase.com/blog/atagi-update-following-weekly-covid-19-meeting-14-july-2021 2021-07-15T21:20:02 https://maestrodatabase.com/blog/smc---january-2020-decisions 2020-01-13T19:47:31 https://maestrodatabase.com/blog/myeloma-nz-calls-on-pharmac-to-make-good-on-access-deal 2020-01-13T19:42:12 https://maestrodatabase.com/blog/another-month-another-terminated-appraisal-of-a-cancer-medicine 2021-07-15T21:25:35 https://maestrodatabase.com/blog/drug-makers-test-new-ways-to-pay-for-six-figure-treatments 2020-01-13T19:59:08 https://maestrodatabase.com/blog/lynparza-regulatory-submission-granted-priority-review-in-the-us-for-first-line-maintenance-treatment-with-bevacizumab-in-advanced-ovarian-cancer 2020-01-13T19:51:09 https://maestrodatabase.com/blog/restem-receives-fda-fast-track-designation-for-restem-l-for-idiopathic-inflammatory-myopathy 2025-01-07T23:34:31 https://maestrodatabase.com/blog/atagi-recommendations-for-a-booster-dose-of-the-paediatric-pfizer-covid-19-vaccine-in-children-aged-5-to-11-years 2022-10-24T03:47:25 https://maestrodatabase.com/blog/novartis-strikes-deal-with-uk-to-provide-cholesterol-drug-to-high-risk-patients 2020-01-13T20:15:08 https://maestrodatabase.com/blog/pmprb-changes-within-scope-of-patent-act-rules-federal-court-in-judicial-review 2020-07-14T08:27:42 https://maestrodatabase.com/blog/teva-announces-availability-of-proair-digihaler-salbutamol-sulphate-117-mcg-inhalation-powder-for-patients-with-asthma-and-copd 2020-07-14T08:32:57 https://maestrodatabase.com/blog/intarcia-provides-corporate-update 2017-09-28T11:31:23 https://maestrodatabase.com/blog/neurelis-announces-fda-approval-for-seizure-rescue-treatment-valtoco-diazepam-nasal-spray-that-incorporates-the-science-of-intravail-for-consistent-and-reliable-absoption 2020-01-13T20:06:58 https://maestrodatabase.com/blog/high-cost-of-multiple-sclerosis-medicines-is-forcing-many-patients-to-take-drastic-actions 2020-01-13T20:03:40 https://maestrodatabase.com/blog/cder-collaborates-with-global-regulators-on-pharmaceutical-quality-assessments-and-inspections 2023-07-28T22:06:57 https://maestrodatabase.com/blog/healthcare-bravery-needed-says-hbf-boss-bransby 2017-02-04T02:57:42 https://maestrodatabase.com/blog/sanofi-and-regeneron-announce-approval-of-dupixent-dupilumab-to-treat-adult-patients-with-moderate-to-severe-atopic-dermatitis-in-the-european-union 2017-09-28T11:56:08 https://maestrodatabase.com/blog/imjudo-tremelimumab-in-combination-with-imfinzi-approved-in-the-us-for-patients-with-unresectable-liver-cancer 2022-10-24T06:05:27 https://maestrodatabase.com/blog/gsks-b7-h3-targeted-antibody-drug-conjugate-gsk227-receives-us-fda-breakthrough-therapy-designation-in-late-line-relapsed-or-refractory-osteosarcoma 2025-01-07T23:45:53 https://maestrodatabase.com/blog/quizartinib-granted-priority-review-in-the-us-for-patients-with-newly-diagnosed-flt3-itd-positive-acute-myeloid-leukaemia 2022-10-24T19:46:26 https://maestrodatabase.com/blog/aspen-offers-to-cut-cancer-drug-prices-may-avoid-eu-antitrust-fine 2020-07-14T12:27:11 https://maestrodatabase.com/blog/eisai-initiates-submission-of-application-data-under-the-prior-assessment-consultation-system-in-japan-with-the-aim-of-obtaining-early-approval-for-investigational-anti-amyloid-beta-protofibril-antibody-lecanemab 2022-03-06T05:39:34 https://maestrodatabase.com/blog/symbicort-granted-paediatric-exclusivity-in-the-us 2017-02-04T04:35:00 https://maestrodatabase.com/blog/dupixent-dupilumab-receives-positive-recommendation-from-inesss-for-the-treatment-of-moderate-to-severe-atopic-dermatitis-in-adolescents 2020-07-14T12:30:09 https://maestrodatabase.com/blog/novaliq-announces-fda-acceptance-of-the-new-drug-application-for-cyclasol-for-the-treatment-of-dry-eye-disease 2022-10-24T19:38:47 https://maestrodatabase.com/blog/most-important-breast-cancer-drug-in-two-decades-will-not-get-nhs-funding 2017-02-04T05:05:08 https://maestrodatabase.com/blog/bernie-sanders-will-trump-have-the-guts-to-stand-up-to-drug-companies 2017-02-04T05:23:09 https://maestrodatabase.com/blog/abbvie-announces-global-resolution-of-humira-adalimumab-patent-disputes-with-amgen 2017-09-28T12:11:42 https://maestrodatabase.com/blog/u-dot-s-food-and-drug-administration-approves-opdivo-nivolumab-with-chemotherapy-as-neo-adjuvant-treatment-for-certain-adult-patients-with-resectable-non-small-cell-lung-cancer 2022-03-06T01:53:22 https://maestrodatabase.com/blog/verrica-pharmaceuticals-receives-complete-response-letter-from-the-fda-for-its-new-drug-application-for-vp-102-for-the-treatment-of-molluscum-contagiosum 2020-07-14T12:21:31 https://maestrodatabase.com/blog/janssen-submits-supplemental-new-drug-application-to-us-fda-seeking-expanded-paediatric-indication-for-hiv-1-therapy-edurant 2023-07-28T22:33:44 https://maestrodatabase.com/blog/forty-seven-granted-fast-track-designation-for-5f9-for-the-treatment-of-diffuse-large-b-cell-lymphoma-and-follicular-lymphoma 2018-05-09T18:32:03 https://maestrodatabase.com/blog/new-minister-for-health-needs-better-pharmaceutical-advisers 2022-10-24T20:07:56 https://maestrodatabase.com/blog/proposed-changes-to-pharmac-model-could-ease-brand-switch-issues 2020-07-14T21:08:58 https://maestrodatabase.com/blog/saskatchewan-becomes-sixth-canadian-province-to-implement-a-biosimilar-switching-policy 2022-10-24T20:43:10 https://maestrodatabase.com/blog/pharmac-asks-covid-19-vaccine-developers-to-let-kiwi-businesses-make-doses-under-contract-in-new-zealand 2020-07-14T21:13:33 https://maestrodatabase.com/blog/rezolute-receives-breakthrough-therapy-designation-from-fda-for-ersodetug-in-the-treatment-of-hypoglycaemia-due-to-congenital-hyperinsulinism 2025-01-08T00:39:34 https://maestrodatabase.com/blog/invivoscribe-files-spma-with-the-fda-for-use-of-the-leukostrat-cdx-flt3-mutation-assay-to-select-patients-with-newly-diagnosed-flt3-itd-positive-aml 2022-10-24T19:59:14 https://maestrodatabase.com/blog/nice-partners-with-flatiron-health-to-develop-real-world-evidence-research-methodologies 2020-07-14T21:18:19 https://maestrodatabase.com/blog/tremfya-guselkumab-approved-by-u-dot-s-food-and-drug-administration-as-the-first-selective-interleukin-23-inhibitor-for-active-psoriatic-arthritis 2020-07-14T20:53:24 https://maestrodatabase.com/blog/acumens-acu193-an-anti-amyloid-beta-oligomer-antibody-granted-fda-fast-track-designation-for-alzheimers-disease 2022-10-24T19:55:41 https://maestrodatabase.com/blog/biosimilar-awareness-week-proves-successful-for-australia 2020-07-14T21:05:31 https://maestrodatabase.com/blog/paediatric-rare-disease-drug-koselugo-fails-to-get-insurance-benefits 2022-03-06T06:29:41 https://maestrodatabase.com/blog/we-cant-pass-up-the-opportunity-to-lower-drug-prices 2022-03-06T06:34:47 https://maestrodatabase.com/blog/gilead-rushes-to-meet-remdesivir-demand-as-virus-pressures-grow 2020-07-14T21:41:32 https://maestrodatabase.com/blog/nice-knocks-back-janssens-imbruvica-in-mantle-cell-lymphoma 2017-09-28T12:59:35 https://maestrodatabase.com/blog/trump-says-he-may-sign-executive-order-allowing-interstate-purchase-of-health-insurance 2017-09-28T12:57:06 https://maestrodatabase.com/blog/canadian-regulator-orders-price-cut-of-expensive-u-dot-s-drug-soliris 2017-09-28T13:06:14 https://maestrodatabase.com/blog/not-giving-up-trump-insists-he-has-votes-to-repeal-obamacare 2017-09-28T13:10:27 https://maestrodatabase.com/blog/us-fda-granted-priority-review-to-dizals-sunvozertinib-new-drug-application 2025-01-08T01:11:01 https://maestrodatabase.com/blog/vergent-bioscience-receives-fda-fast-track-designation-for-abenacianine-for-injection-vgt-309-to-help-surgeons-visualise-tumours-in-the-lung-during-surgery 2025-01-08T01:51:04 https://maestrodatabase.com/blog/deciphera-announces-australian-therapeutic-goods-administrations-approval-of-qinlock-ripretinib-for-the-treatment-of-fourth-line-gastro-intestinal-stromal-tumour 2020-07-15T01:11:25 https://maestrodatabase.com/blog/to-lower-drug-costs-at-home-trump-wants-higher-prices-abroad 2018-05-10T04:59:10 https://maestrodatabase.com/blog/acelrx-resubmits-new-drug-application-for-dsuvia 2018-05-10T05:04:49 https://maestrodatabase.com/blog/blunders-eroded-u-dot-s-confidence-in-early-vaccine-front-runner 2020-12-09T19:09:50 https://maestrodatabase.com/blog/audentes-therapeutics-announces-rare-paediatric-disease-and-fast-track-designations-for-at132-for-the-treatment-of-x-linked-myotubular-myopathy 2017-09-28T14:35:10 https://maestrodatabase.com/blog/pfizer-biontech-covid-19-vaccine-warning-after-uk-allergic-reactions 2020-12-09T19:13:01 https://maestrodatabase.com/blog/covid-19-vaccine-trial-deaths-were-not-related-to-treatment-pfizer 2020-12-09T19:16:19 https://maestrodatabase.com/blog/cf-canada-launches-campaign-to-make-orkambi-accessible-to-more-patients 2018-05-10T05:25:48 https://maestrodatabase.com/blog/first-and-only-immuno-oncology-treatment-imfinzi-durvalumab-for-stage-iii-unresectable-non-small-cell-lung-cancer-now-approved-in-canada 2018-05-10T05:19:26 https://maestrodatabase.com/blog/affordable-care-act-sign-ups-dip-amid-uncertainty-and-trump-attacks 2017-02-04T21:03:33 https://maestrodatabase.com/blog/were-feeling-broken-taranaki-father-of-six-dies-after-battle-for-cancer-drug-funding 2020-12-09T19:38:02 https://maestrodatabase.com/blog/hope-for-cystic-fibrosis-sufferers-as-health-minister-commits-to-listing-of-breakthrough-drug 2018-05-10T05:38:16 https://maestrodatabase.com/blog/drug-game-changer-for-thousands-suffering-from-cystic-fibrosis-headed-for-the-pbs 2017-02-04T20:55:04 https://maestrodatabase.com/blog/funding-cuts-threat-for-radiation-patients 2017-02-06T05:35:25 https://maestrodatabase.com/blog/charleston-laboratories-and-daiichi-sankyo-receive-complete-response-letter-from-fda-for-new-drug-application-for-cl-108-hydrocodone-acetaminophen-promethazine-tablets-for-oral-use 2017-02-06T06:18:29 https://maestrodatabase.com/blog/riverina-mother-to-tackle-government-over-pbs-refusal-to-list-cystic-fibrosis-drug 2017-02-05T20:11:42 https://maestrodatabase.com/blog/mental-health-cover-a-battleground-for-private-health-insurers 2017-02-05T20:29:26 https://maestrodatabase.com/blog/regeltec-receives-fda-breakthrough-designation-for-its-hydrafil-system 2020-12-09T19:42:30 https://maestrodatabase.com/blog/canada-health-regulator-approves-pfizers-covid-19-vaccine 2020-12-09T19:20:51 https://maestrodatabase.com/blog/intarcia-announces-fda-filing-acceptance-of-new-drug-application-for-itca-650-for-the-treatment-of-type-2-diabetes 2017-02-06T06:28:21 https://maestrodatabase.com/blog/the-kiwi-patients-that-new-zealands-health-system-wont-help 2018-05-10T05:52:51 https://maestrodatabase.com/blog/amgens-sotorasib-granted-breakthrough-therapy-designation-for-advanced-or-metastatic-non-small-cell-lung-cancer-patients-with-kras-g12c-mutation 2020-12-09T19:32:22 https://maestrodatabase.com/blog/imago-receives-fast-track-designation-from-u-dot-s-fda-for-bomedemstat-for-treatment-of-essential-thrombocythemia 2020-01-13T23:03:03 https://maestrodatabase.com/blog/fda-approves-new-treatment-for-certain-advanced-or-metastatic-breast-cancers 2017-09-28T18:30:20 https://maestrodatabase.com/blog/hutchmeds-marketing-authorisation-application-for-surufatinib-submitted-and-validated-by-the-european-medicines-agency 2021-07-16T02:01:43 https://maestrodatabase.com/blog/european-commission-approves-gileads-trodelvy-for-pre-treated-hr-positive-her2-negative-metastatic-breast-cancer 2023-07-29T01:10:38 https://maestrodatabase.com/blog/cost-recovery-and-pharmaceutical-benefits-scheme-process-improvements-information-forums 2019-01-14T00:31:00 https://maestrodatabase.com/blog/thousands-of-new-zealanders-will-benefit-from-advances-in-treatment 2018-05-10T05:46:48 https://maestrodatabase.com/blog/games-and-greed-delay-the-market-entry-of-money-saving-biosimilars 2018-05-10T21:17:59 https://maestrodatabase.com/blog/prisoners-and-the-obese-priority-groups-for-covid-19-vaccine 2020-12-09T20:01:16 https://maestrodatabase.com/blog/hospitals-stock-up-on-covid-19-drugs-to-prepare-for-second-wave-in-fall 2020-07-15T21:12:30 https://maestrodatabase.com/blog/call-for-scottish-breast-cancer-drug-deal 2018-05-10T21:24:00 https://maestrodatabase.com/blog/beigene-announces-the-approval-in-china-of-blincyto-blinatumomab-for-injection-for-adult-patients-with-relapsed-or-refractory-b-cell-precursor-acute-lymphoblastic-leukaemia 2020-12-09T20:05:09 https://maestrodatabase.com/blog/the-covid-19-vaccine-development-multiverse 2020-07-15T21:38:52 https://maestrodatabase.com/blog/efpia-welcomes-hta-proposals-from-commission 2018-05-10T21:14:53 https://maestrodatabase.com/blog/improving-clinical-trial-enrollment----in-the-covid-19-era-and-beyond 2020-07-15T21:49:50 https://maestrodatabase.com/blog/america-is-subsidising-europes-socialist-medicine----with-higher-drug-prices-here 2020-12-09T19:50:19 https://maestrodatabase.com/blog/drug-makers-answer-on-drug-prices-hold-free-riding-foreign-governments-accountable 2018-05-11T07:01:35 https://maestrodatabase.com/blog/the-impact-of-managed-entry-agreements-on-pharmaceutical-prices 2020-07-15T11:45:34 https://maestrodatabase.com/blog/most-favoured-nation-drug-pricing-rule-will-harm-patient-access-and-jeopardise-practice-stability-rheumatology-leaders-warn 2020-12-09T19:54:31 https://maestrodatabase.com/blog/fda-improves-access-to-reports-of-adverse-drug-reactions 2017-09-29T02:12:09 https://maestrodatabase.com/blog/lynparza-olaparib-receives-new-indication-for-brca-mutated-metastatic-breast-cancer 2018-05-11T06:51:17 https://maestrodatabase.com/blog/fda-grants-breakthrough-therapy-designation-for-roches-cd20xcd3-bispecific-cancer-immunotherapy-mosunetuzumab-recognising-its-potential-in-follicular-lymphoma 2020-07-15T21:05:58 https://maestrodatabase.com/blog/ocugen-announces-initiation-of-rolling-submission-to-health-canada-for-covaxin 2021-07-16T03:24:01 https://maestrodatabase.com/blog/business-council-urges-unlocking-aladdins-cave-of-medicare-data-to-save-lives-health-system 2025-11-17T07:56:44 https://maestrodatabase.com/blog/trumps-f-dot-d-a-pick-could-undo-decades-of-drug-safeguards 2017-02-06T09:42:05 https://maestrodatabase.com/blog/entasis-therapeutics-to-present-phase-1-data-on-etx2514-at-idweek-2017 2017-09-29T02:23:42 https://maestrodatabase.com/blog/fda-expands-approval-of-gilenya-to-treat-multiple-sclerosis-in-paediatric-patients 2018-05-12T06:21:03 https://maestrodatabase.com/blog/parliament-house-rally-to-call-for-potentially-life-saving-drugs-for-cystic-fibrosis-patients-to-be-listed-on-the-pbs 2017-02-06T19:47:08 https://maestrodatabase.com/blog/statement-from-fda-commissioner-on-the-trump-administrations-plan-to-lower-drug-prices 2018-05-12T06:29:02 https://maestrodatabase.com/blog/ema-validates-biomarins-marketing-authorisation-application-for-valoctocogene-roxaparvovec-to-treat-severe-haemophilia-a 2021-07-16T02:43:43 https://maestrodatabase.com/blog/australian-families-reconsider-having-health-insurance-with-premiums-tipped-to-rise 2017-02-06T19:51:38 https://maestrodatabase.com/blog/medicines-evaluation-not-keeping-pace-with-scientific-progress-says-abpi 2017-02-06T20:10:01 https://maestrodatabase.com/blog/drug-prices-rose-11-percent-last-year-providing-fuel-for-both-sides-of-price-debate 2017-02-06T20:20:09 https://maestrodatabase.com/blog/advanced-therapy-medicines-towards-increased-development-and-patient-access 2017-02-06T19:59:14 https://maestrodatabase.com/blog/express-scripts-says-prescription-drug-spending-slowed-in-2016 2017-02-06T20:06:33 https://maestrodatabase.com/blog/nice-to-bring-hta-processes-to-mobile-health-apps 2017-02-06T20:32:24 https://maestrodatabase.com/blog/big-pharmas-offer-to-trump-discounts-when-drugs-dont-work 2017-02-06T20:56:33 https://maestrodatabase.com/blog/trump-acknowledges-that-the-replacement-of-obamacare-will-span-years 2017-02-06T20:25:36 https://maestrodatabase.com/blog/decision-to-fund-mercaptopurine-oral-suspension 2018-05-12T06:58:36 https://maestrodatabase.com/blog/ashp-response-to-president-trumps-speech-on-prescription-drug-prices 2018-05-12T06:46:01 https://maestrodatabase.com/blog/greg-hunts-innovation-fund-sent-back-to-drawing-board 2017-02-06T23:55:54 https://maestrodatabase.com/blog/cystic-fibrosis-sufferers-to-get-lifesaving-medication-for-free-after-government-intervention 2017-02-06T23:58:36 https://maestrodatabase.com/blog/phrma-statement-on-president-trumps-drug-pricing-blueprint 2018-05-12T07:04:12 https://maestrodatabase.com/blog/ariad-announces-submission-of-marketing-authorisation-application-for-brigatinib-to-the-european-medicines-agency 2017-02-07T01:26:45 https://maestrodatabase.com/blog/pharmac-considers-funding-meningococcal-b-vaccine-to-be-part-of-childhood-immunisations 2022-10-25T03:09:20 https://maestrodatabase.com/blog/americans-tired-of-high-priced-drugs-are-fighting-back 2018-05-12T07:25:15 https://maestrodatabase.com/blog/the-shortfalls-of-pharmac-and-why-the-public-system-simply-cant-shoulder-it-alone 2022-03-06T20:26:24 https://maestrodatabase.com/blog/ablynx-submits-a-marketing-authorisation-application-to-the-ema-for-caplacizumab-its-anti-vwf-nanobody-for-the-treatment-of-attp 2017-02-07T01:40:43 https://maestrodatabase.com/blog/v-dot-a-seeks-to-redirect-billions-of-dollars-into-private-care 2019-01-14T02:46:56 https://maestrodatabase.com/blog/australian-covid-nasal-spray-not-on-shop-shelves-amid-tga-dispute 2022-03-06T20:30:50 https://maestrodatabase.com/blog/fda-grants-priority-review-for-roches-perjeta-pertuzumab-for-adjuvant-treatment-of-her2-positive-early-breast-cancer 2017-09-29T11:19:11 https://maestrodatabase.com/blog/the-five-most-expensive-drugs-in-the-united-states 2018-05-12T07:43:30 https://maestrodatabase.com/blog/roches-ocrevus-ocrelizumab-approved-in-switzerland-for-primary-progressive-and-relapsing-forms-of-multiple-sclerosis 2017-09-29T11:14:09 https://maestrodatabase.com/blog/a-revolutionary-drug-that-could-treat-a-rare-and-devastating-disease-is-prohibitively-expensive-but-one-state-has-a-plan-to-pay-for-its-potential-5-dollars-million-price-tag 2019-01-14T06:03:42 https://maestrodatabase.com/blog/president-donald-j-trumps-blueprint-to-lower-drug-prices 2018-05-12T07:32:29 https://maestrodatabase.com/blog/revised-guideline-aims-to-strengthen-global-approach-to-development-of-new-antibacterial-medicines 2019-01-14T19:19:19 https://maestrodatabase.com/blog/ema-approves-flutiform-for-children-with-asthma 2019-01-14T19:23:01 https://maestrodatabase.com/blog/why-pharmaceutical-companies-are-on-a-shopping-binge 2019-01-14T19:16:32 https://maestrodatabase.com/blog/knopp-biosciences-receives-rare-paediatric-disease-designation-for-kv7-activator-kb-3061-for-treatment-of-kcnq2-epileptic-encephalopathy 2020-07-16T00:11:58 https://maestrodatabase.com/blog/health-insurers-poor-prognosis 2019-01-14T19:35:39 https://maestrodatabase.com/blog/congresss-pbm-reforms-wont-end-americas-drug-pricing-woes-heres-what-they-would-do 2023-07-29T06:41:22 https://maestrodatabase.com/blog/life-extending-drug-perjeta-approved-for-secondary-breast-cancer 2019-01-14T19:38:56 https://maestrodatabase.com/blog/pbac-public-summary-documents-first-time-rejections-and-deferrals---march-2021-meeting 2021-07-16T08:16:27 https://maestrodatabase.com/blog/smc---january-2019-decisions 2019-01-14T19:26:25 https://maestrodatabase.com/blog/congressman-urges-president-trump-to-take-action-on-90-000-dollars-multiple-sclerosis-drug 2017-09-29T11:35:39 https://maestrodatabase.com/blog/samsung-faces-resistance-from-big-pharma-in-the-u-dot-s 2019-01-14T19:57:04 https://maestrodatabase.com/blog/us-fda-accepts-regulatory-submissions-for-review-of-tafamidis-to-treat-transthyretin-amyloid-cardiomyopathy 2019-01-14T19:43:41 https://maestrodatabase.com/blog/price-deal-sees-nice-back-imbruvica-for-one-indication-but-not-another 2017-09-29T11:42:27 https://maestrodatabase.com/blog/eu-health-technology-assessment-needs-to-move-up-a-gear-says-pressure-group 2019-01-14T20:15:45 https://maestrodatabase.com/blog/perrigo-expects-complete-response-letter-on-generic-version-of-proair 2018-05-13T05:27:19 https://maestrodatabase.com/blog/trumps-plan-to-lower-drug-prices-diverges-from-campaign-promise 2018-05-12T08:33:06 https://maestrodatabase.com/blog/democrats-roll-out-big-health-care-proposals-in-the-states 2019-01-14T20:00:25 https://maestrodatabase.com/blog/reforming-the-world-health-organizations-essential-medicines-list-essential-but-unaffordable 2022-10-25T05:41:07 https://maestrodatabase.com/blog/mandatory-or-voluntary-a-sticking-point-for-european-hta 2019-01-14T20:11:47 https://maestrodatabase.com/blog/rexgeneros-lead-product-rex-001-selected-for-the-eunethta-prioritisation-list-for-joint-assessments 2019-01-14T20:20:20 https://maestrodatabase.com/blog/international-regulators-work-towards-alignment-on-development-and-authorisation-of-second-generation-covid-19-vaccines 2021-07-16T10:19:09 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac---august-2017 2017-11-03T13:50:35 https://maestrodatabase.com/blog/agenda-for-16-may-tc-meeting 2018-05-13T05:34:10 https://maestrodatabase.com/blog/statutory-authority-for-medicare-coverage-decisions---cms-is-an-independent-federal-agency 2023-07-29T06:50:44 https://maestrodatabase.com/blog/senior-clinicians-appointed-to-pharmac-clinical-committee 2017-02-07T03:27:59 https://maestrodatabase.com/blog/koreas-only-ret-inhibitor-retevmo-seeks-insurance-coverage-again 2025-01-08T05:19:27 https://maestrodatabase.com/blog/economists-say-health-insurance-premium-hikes-well-above-cpi-are-unwarranted 2017-02-07T19:39:20 https://maestrodatabase.com/blog/price-of-prescription-medicines-likely-to-rise-by-5-dollars 2017-02-07T19:45:03 https://maestrodatabase.com/blog/trumps-new-vision-for-health-care 2019-01-14T20:28:59 https://maestrodatabase.com/blog/european-commission-approves-third-nintedanib-indication-in-pulmonary-fibrosis 2020-07-16T01:16:02 https://maestrodatabase.com/blog/the-problem-with-prescription-drug-prices 2018-05-13T05:53:37 https://maestrodatabase.com/blog/european-commission-approves-opdivo-nivolumab-plus-low-dose-yervoy-ipilimumab-for-first-line-treatment-of-patients-with-intermediate--and-poor-risk-advanced-renal-cell-carcinoma 2019-01-14T21:33:45 https://maestrodatabase.com/blog/aussie-kids-given-immediate-access-to-life-changing-cystic-fibrosis-drug 2017-02-07T19:35:39 https://maestrodatabase.com/blog/perrigo-confirms-patent-challenge-for-generic-version-of-onexton-gel 2017-02-07T19:58:42 https://maestrodatabase.com/blog/assessing-the-value-of-drugs-for-rare-conditions-institute-for-clinical-and-economic-review-to-host-orphan-drug-assessment-and-pricing-summit 2017-02-07T20:04:07 https://maestrodatabase.com/blog/alexion-extremely-disappointed-with-nice-ruling-on-costly-strensiq 2017-02-07T19:54:25 https://maestrodatabase.com/blog/distressed-and-appalled-eye-doctor-sees-red-at-overcharging-by-peers 2022-10-25T06:41:30 https://maestrodatabase.com/blog/health-insurers-seek-a-halt-to-$800m-prosthetics-wastage 2017-02-07T20:30:14 https://maestrodatabase.com/blog/health-canada-approves-gazyva-for-patients-with-previously-treated-follicular-lymphoma 2017-02-08T01:41:47 https://maestrodatabase.com/blog/privatised-pharmaceutical-innovation-vs-access-to-essential-medicines-a-global-framework-for-equitable-sharing-of-benefits 2017-02-07T20:16:43 https://maestrodatabase.com/blog/from-repeal-to-repair-campaign-talk-on-health-law-meets-reality 2017-02-07T20:24:30 https://maestrodatabase.com/blog/flexion-therapeutics-announces-new-drug-application-for-zilretta-fx006-accepted-by-u-dot-s-food-and-drug-administration 2017-02-08T02:03:44 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-to-angionetics-generx-product-candidate-a-one-time-gene-therapy-for-coronary-heart-disease 2017-02-08T06:14:09 https://maestrodatabase.com/blog/decision-relating-to-nicotine-replacement-therapy-rfp 2017-02-08T04:06:15 https://maestrodatabase.com/blog/prescription-medicine-for-cancer-cholesterol-and-contraception-is-about-to-get-cheaper 2017-09-29T23:49:09 https://maestrodatabase.com/blog/trump-sinks-pharma-stocks-on-medicare-drug-price-negotiation 2017-02-08T06:26:23 https://maestrodatabase.com/blog/nices-decision-not-to-approve-zytiga-frustrating-says-icr 2021-07-16T11:20:28 https://maestrodatabase.com/blog/fda-approves-amgens-parsabiv-etelcalcetide-first-new-treatment-in-more-than-a-decade-for-secondary-hyperparathyroidism-in-adult-patients-on-hemodialysis 2017-02-08T07:24:22 https://maestrodatabase.com/blog/ledaga-recommended-by-nice-for-rare-type-of-lymphoma 2021-07-16T11:37:54 https://maestrodatabase.com/blog/government-to-change-policy-on-medicinal-cannabis 2017-02-08T19:43:08 https://maestrodatabase.com/blog/lillys-trulicity-dulaglutide-label-updated-to-include-use-in-combination-with-basal-insulin-for-adults-with-type-2-diabetes 2017-02-08T20:00:14 https://maestrodatabase.com/blog/can-donald-trump-really-change-the-cost-of-new-zealand-drugs 2018-05-13T07:42:49 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-to-review-treatments-for-ovarian-cancer-in-upcoming-report 2017-02-08T20:12:35 https://maestrodatabase.com/blog/bupa-head-tackles-government-for-further-reductions-on-costly-prostheses 2017-02-08T19:51:03 https://maestrodatabase.com/blog/trump-promises-lower-drug-prices-but-drops-populist-solutions 2018-05-13T19:19:22 https://maestrodatabase.com/blog/ausbiotech-to-initiate-clinical-trials-advisory-group 2017-02-08T19:53:52 https://maestrodatabase.com/blog/advance-notice-of-a-request-for-proposals---permanent-coronary-drug-eluting-stents 2017-09-30T21:15:54 https://maestrodatabase.com/blog/merck-cancer-drug-brings-cost-competition-to-japanese-rival 2017-02-08T20:50:30 https://maestrodatabase.com/blog/one-third-dont-know-obamacare-and-affordable-care-act-are-the-same 2017-02-08T20:22:23 https://maestrodatabase.com/blog/issues-facing-republicans-in-replacing-affordable-care-act 2017-02-08T20:36:05 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-october-2017 2017-09-30T21:22:25 https://maestrodatabase.com/blog/president-promises-to-attack-high-drug-prices 2018-05-13T19:25:25 https://maestrodatabase.com/blog/republicans-have-lost-the-plot-on-their-obamacare-repeal 2017-02-08T23:53:59 https://maestrodatabase.com/blog/copenhagen-joins-crowded-brexit-fight-for-medicines-agency 2017-02-09T01:07:49 https://maestrodatabase.com/blog/european-commission-publishes-assessment-of-offers-to-host-european-medicines-agency-but-declines-to-rank-them 2017-09-30T21:59:14 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-october-2017-update 2017-09-30T21:47:56 https://maestrodatabase.com/blog/fda-approves-bio-products-laboratorys-gammaplex-10-percent-for-treatment-of-primary-immunodeficiency-and-chronic-immune-thrombocytopenic-purpura 2017-02-09T00:11:19 https://maestrodatabase.com/blog/fda-approves-belumosudil-for-chronic-graft-versus-host-disease 2021-07-16T22:44:15 https://maestrodatabase.com/blog/blacked-out-information-reveals-secret-world-of-drug-prices 2017-09-30T22:08:24 https://maestrodatabase.com/blog/miracle-drug-keytruda-approved-for-use-earlier-in-melanoma-treatment 2019-07-07T00:25:18 https://maestrodatabase.com/blog/decision-to-widen-access-and-change-the-funded-brand-of-tenofovir-disoproxil-and-entecavir 2018-05-14T04:35:57 https://maestrodatabase.com/blog/improved-access-the-reality-of-the-pprs 2017-09-30T22:02:33 https://maestrodatabase.com/blog/health-research-and-consumers-good-thinking 2018-05-14T04:40:35 https://maestrodatabase.com/blog/cancer-campaign-coverage-puts-heat-on-pharmac 2019-07-07T00:22:30 https://maestrodatabase.com/blog/fast-track-drug-approval-designed-for-emergencies-is-now-routine 2019-07-07T00:19:42 https://maestrodatabase.com/blog/trump-suggests-executive-order-on-drug-prices-with-a-scope-that-is-unclear 2019-07-07T00:08:16 https://maestrodatabase.com/blog/seven-drugs-available-in-england-but-not-scotland-holyrood-hears 2018-05-14T05:08:43 https://maestrodatabase.com/blog/thousands-more-doses-of-the-flu-jab-are-on-the-way 2019-07-07T04:47:48 https://maestrodatabase.com/blog/hugel-aesthetics-receives-fda-acceptance-of-bla-resubmission-for-letibotulinumtoxina-for-injection-for-glabellar-lines 2022-10-25T19:29:56 https://maestrodatabase.com/blog/novo-nordisks-new-fast-acting-mealtime-insulin-fiasp-approved-in-the-us 2017-09-30T22:18:48 https://maestrodatabase.com/blog/the-scottish-medicines-consortium-accepts-use-of-kyntheum-brodalumab-for-eligible-patients-with-moderate-to-severe-plaque-psoriasis 2018-05-14T05:11:17 https://maestrodatabase.com/blog/jaws-of-death-health-insurance-faces-its-crisis-moment 2019-07-07T04:44:53 https://maestrodatabase.com/blog/jacinda-ardern-pharmac-will-be-protected-in-trade-deals-after-trump-threats 2018-05-14T04:44:32 https://maestrodatabase.com/blog/president-donald-trump-wants-to-build-a-drug-cartel---and-wants-new-zealand-to-pay-for-it 2018-05-14T04:48:29 https://maestrodatabase.com/blog/chinas-national-medical-products-administration-approves-padcev-in-combination-with-keytruda-pembrolizumab-for-the-treatment-of-advanced-bladder-cancer 2025-01-08T20:35:17 https://maestrodatabase.com/blog/price-cuts-secure-nhs-place-for-ms-drugs 2018-05-14T11:55:35 https://maestrodatabase.com/blog/fda-approves-new-use-of-transplant-drug-based-on-real-world-evidence 2021-07-16T22:56:41 https://maestrodatabase.com/blog/massachussetts-could-shake-up-drug-pricing 2017-09-30T22:33:42 https://maestrodatabase.com/blog/cystic-fibrosis-drug-orkambi-should-be-on-pbs-wagga-teen-bella-ingram-wants-to-help-others-to-access-pink-pills-of-hope 2018-05-15T07:25:42 https://maestrodatabase.com/blog/fda-grants-priority-review-to-mercks-new-drug-application-for-vericiguat 2020-07-16T11:31:45 https://maestrodatabase.com/blog/federal-budget-2022-pensioners-to-pay-more-for-prescription-drugs 2022-10-25T19:41:25 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-reviews-final-report-confirms-inadequate-evidence-to-compare-outcomes-of-parp-inhibitors-for-ovarian-cancer-highlights-poor-cost-effectiveness-particularly-for-maintenance-therapy 2017-09-30T22:39:51 https://maestrodatabase.com/blog/terminal-cancer-patient-priced-out-of-life-prolonging-medication 2017-02-09T19:42:18 https://maestrodatabase.com/blog/ispor-launches-center-for-health-technology-assessment 2018-05-14T12:05:33 https://maestrodatabase.com/blog/health-fund-premiums-rise-200-dollars-a-year----how-state-governments-are-to-blame 2017-02-09T19:47:02 https://maestrodatabase.com/blog/life-changing-drug-not-accessible-for-new-zealanders-living-with-cystic-fibrosis 2020-07-16T20:57:30 https://maestrodatabase.com/blog/endostim-receives-fda-breakthrough-device-designation-for-the-endostim-system-for-the-treatment-of-drug-refractory-gerd 2022-10-25T19:35:50 https://maestrodatabase.com/blog/cancer-drug-prices-must-come-down-say-leading-research-institutes 2017-02-09T20:13:22 https://maestrodatabase.com/blog/promoting-high-quality-clinical-research-in-children-through-strengthened-international-collaboration 2017-02-09T19:50:24 https://maestrodatabase.com/blog/fda-approves-drug-to-treat-duchenne-muscular-dystrophy 2017-02-09T19:53:27 https://maestrodatabase.com/blog/conservatives-in-congress-call-for-obamacare-repeal-in-the-next-few-months 2017-02-09T20:44:58 https://maestrodatabase.com/blog/americans-thought-they-would-get-a-pharmac-from-trump 2018-05-15T07:57:55 https://maestrodatabase.com/blog/as-obamacare-repeal-stalls-republicans-face-new-challenges 2017-02-09T20:48:04 https://maestrodatabase.com/blog/cvs-health-says-it-is-not-to-blame-for-skyrocketing-drug-costs 2017-02-09T20:15:51 https://maestrodatabase.com/blog/amid-flurry-of-new-cancer-drugs-how-many-offer-real-benefits 2017-02-09T20:26:20 https://maestrodatabase.com/blog/how-to-make-a-dent-in-crazy-high-drug-prices 2018-05-15T08:02:24 https://maestrodatabase.com/blog/ucb-announces-briviact-brivaracetam-now-approved-by-fda-to-treat-partial-onset-focal-seizures-in-paediatric-epilepsy-patients 2018-05-15T08:20:49 https://maestrodatabase.com/blog/mallinckrodt-and-terumo-bct-announce-positive-recommendations-for-public-funding-of-uvadex-methoxsalen-for-ecp-administration-with-the-therakos-ce 2020-07-16T21:31:11 https://maestrodatabase.com/blog/october-budget-2022-23-a-no-surprise-budget-for-health 2022-10-25T20:04:10 https://maestrodatabase.com/blog/actual-and-potential-harm-caused-by-medical-software 2020-07-16T21:38:13 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-for-yamo-pharmaceuticals-l1-79-in-autism-spectrum-disorder 2018-05-15T08:09:27 https://maestrodatabase.com/blog/new-fda-approved-labelling-for-petros-pharmaceuticals-stendra-avanafil-now-includes-efficacy-data-regarding-use-in-men-who-have-undergone-radical-prostatectomy 2022-10-25T19:59:11 https://maestrodatabase.com/blog/the-trump-plan-to-reduce-prescription-drug-prices-will-have-a-major-impact 2018-05-15T08:17:40 https://maestrodatabase.com/blog/assessing-quantitative-comparisons-of-health-and-social-care-between-countries 2020-07-16T21:47:15 https://maestrodatabase.com/blog/would-drug-price-controls-kill-innovation 2019-01-15T06:10:21 https://maestrodatabase.com/blog/budget-october-2022-23-strengthening-medicare 2022-10-25T19:51:45 https://maestrodatabase.com/blog/remarks-on-drug-pricing-blueprint 2018-05-15T08:41:46 https://maestrodatabase.com/blog/deep-dive-into-big-pharma-ai-productivity-one-study-shaking-the-pharmaceutical-industry 2020-07-16T21:14:05 https://maestrodatabase.com/blog/health-canada-approves-xtandi-enzalutamide---the-first-and-only-oral-treatment-for-men-with-non-metastatic-and-metastatic-castration-resistant-prostate-cancer 2019-01-15T07:13:05 https://maestrodatabase.com/blog/fda-approves-subcutaneous-formulation-of-actemra-for-use-in-active-polyarticular-juvenile-idiopathic-arthritis-a-rare-form-of-juvenile-arthritis 2018-05-15T08:25:26 https://maestrodatabase.com/blog/us-fda-approves-tecvayli-teclistamab-cqyv-the-first-bispecific-t-cell-engager-antibody-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma 2022-10-25T19:46:00 https://maestrodatabase.com/blog/hanmis-fatty-liver-drug-won-fdas-fast-track-designation 2020-07-16T21:17:59 https://maestrodatabase.com/blog/fda-to-name-companies-accused-of-hindering-generic-drug-development 2018-05-15T11:49:58 https://maestrodatabase.com/blog/fda-panel-vote-highlights-accelerated-approval-concerns 2022-10-25T20:34:16 https://maestrodatabase.com/blog/house-democrats-launch-drug-pricing-probe-into-a-dozen-major-health-care-companies 2019-01-15T07:24:02 https://maestrodatabase.com/blog/az-appeals-against-nice-rejection-of-tagrisso-in-untreated-lung-cancer 2019-07-07T06:25:29 https://maestrodatabase.com/blog/trump-administration-defends-plan-to-lower-prescription-drug-prices 2018-05-15T08:50:45 https://maestrodatabase.com/blog/exelixis-announces-u-dot-s-fda-approval-of-cabometyx-cabozantinib-tablets-for-previously-treated-hepatocellular-carcinoma 2019-01-15T07:18:30 https://maestrodatabase.com/blog/a-perspective-on-life-cycle-health-technology-assessment-and-real-world-evidence-for-precision-oncology-in-canada 2022-10-25T20:15:05 https://maestrodatabase.com/blog/intelgenx-receives-fda-gdufa-date-for-xiromed-partnered-development-candidate-buprenorphine-buccal-film 2022-10-25T20:17:54 https://maestrodatabase.com/blog/fda-approves-expanded-use-of-adacel-tdap-vaccine-for-repeat-vaccination 2019-01-15T07:28:33 https://maestrodatabase.com/blog/pharmac-to-consider-funding-the-meningococcal-b-vaccine-but-concerns-remain 2022-10-25T20:07:19 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-to-dewpoint-therapeutics-dptx3186-for-the-treatment-of-gastric-cancer 2025-11-17T23:16:16 https://maestrodatabase.com/blog/post-market-review-of-pulmonary-arterial-hypertension-medicines---public-consultation 2017-02-10T00:53:28 https://maestrodatabase.com/blog/us-fda-confirms-class-1-resubmission-of-the-supplemental-new-drug-application-for-izervay-avacincaptad-pegol-intravitreal-solution-for-geographic-atrophy 2025-01-09T01:36:29 https://maestrodatabase.com/blog/u-dot-s-senators-question-kaleos-4-500-dollars-tag-on-opioid-overdose-treatment 2017-02-10T07:10:26 https://maestrodatabase.com/blog/an-old-drug-gets-a-new-price-to-fight-a-rare-disease-89-000-dollars-a-year 2017-02-10T21:49:12 https://maestrodatabase.com/blog/lowest-health-insurance-premium-increases-in-a-decade 2017-02-10T01:09:38 https://maestrodatabase.com/blog/decision-to-maintain-full-subsidy-for-gefitinib-iressa-from-1-april-2017 2017-02-10T01:19:43 https://maestrodatabase.com/blog/over-1-000-studies-now-recorded-in-eu-register-of-post-authorisation-studies 2017-02-11T03:43:18 https://maestrodatabase.com/blog/cost-shifting-by-public-hospitals-blamed-for-pushing-up-the-cost-of-private-health-insurance 2017-02-11T03:48:59 https://maestrodatabase.com/blog/tom-price-is-confirmed-as-health-secretary 2017-02-11T03:36:09 https://maestrodatabase.com/blog/henlius-and-organon-announce-us-fda-approval-of-poherdy-pertuzumab-dpzb-the-first-perjeta-pertuzumab-biosimilar-in-the-us 2025-11-18T01:21:54 https://maestrodatabase.com/blog/a-ted-cruz-proposal-to-speed-fda-approvals-may-have-limited-impact 2017-02-11T03:38:33 https://maestrodatabase.com/blog/prostheses-list-insurers-and-health-care-majors-square-off 2017-02-11T03:52:01 https://maestrodatabase.com/blog/celcuity-announces-completion-of-submission-of-its-new-drug-application-to-the-us-fda-for-gedatolisib-in-hr-plus-slash-her2--slash-pik3ca-wild-type-advanced-breast-cancer 2025-11-17T23:42:55 https://maestrodatabase.com/blog/cancer-drugs-may-be-delayed-after-brexit-say-experts 2017-02-11T07:45:22 https://maestrodatabase.com/blog/health-minister-greg-hunt-steps-in-to-ensure-meningococcal-b-vaccine-supply 2017-02-11T23:37:35 https://maestrodatabase.com/blog/denali-therapeutics-announces-us-fda-breakthrough-therapy-designation-granted-to-tividenofusp-alfa-for-the-treatment-of-hunter-syndrome 2025-01-09T02:14:05 https://maestrodatabase.com/blog/agenda-for-22-february-2017-tc-meeting 2017-02-12T00:15:16 https://maestrodatabase.com/blog/proposal-to-widen-access-to-febuxostat-for-prevention-of-tumour-lysis-syndrome 2020-12-10T02:26:47 https://maestrodatabase.com/blog/tga-approval-timelines-for-new-cancer-medicines 2017-02-12T01:00:39 https://maestrodatabase.com/blog/marathon-dystrophy-drugs-approval-sends-cost-sky-high 2017-02-12T20:07:16 https://maestrodatabase.com/blog/fda-accepts-gsks-filing-of-nucala-mepolizumab-for-use-in-chronic-rhinosinusitis-with-nasal-polyps 2020-12-10T07:26:49 https://maestrodatabase.com/blog/farxiga-granted-fast-track-designation-in-the-us-for-heart-failure-following-acute-myocardial-infarction-leveraging-an-innovative-registry-based-trial-design 2020-07-16T23:21:17 https://maestrodatabase.com/blog/lantheus-holdings-announces-acceptance-and-priority-review-of-new-drug-application-for-pyltm-18f-dcfpyl-a-psma-targeted-prostate-cancer-pet-imaging-agent 2020-12-10T07:30:13 https://maestrodatabase.com/blog/vyndamax-tafamidis-pbs-listed-for-adult-patients-with-wild-type-or-hereditary-transthyretin-amyloid-cardiomyopathy-with-new-york-heart-association-class-i-ii-heart-failure 2024-05-05T02:15:09 https://maestrodatabase.com/blog/high-dose-regimen-of-nusinersen-receives-positive-chmp-opinion-for-the-treatment-of-spinal-muscular-atrophy 2025-11-18T01:39:28 https://maestrodatabase.com/blog/valeo-pharma-announces-health-canada-approval-for-redesca-and-redesca-hp 2020-12-10T07:03:10 https://maestrodatabase.com/blog/hackers-steal-pfizer-slash-biontech-covid-19-vaccine-data-in-europe-companies-say 2020-12-10T07:11:20 https://maestrodatabase.com/blog/outcomes-from-the-november-2016-ptac-meeting 2017-02-13T19:50:40 https://maestrodatabase.com/blog/australian-covid-vaccine-terminated-due-to-hiv-false-positives 2020-12-10T20:08:08 https://maestrodatabase.com/blog/could-uks-post-brexit-regulator-evaluate-value-as-well 2017-02-13T20:07:43 https://maestrodatabase.com/blog/ultragenyx-and-kyowa-kirin-announce-submission-of-supplemental-biologics-license-application-to-u-dot-s-fda-for-crysvita-burosumab-for-tumour-induced-osteomalacia 2020-01-14T04:25:06 https://maestrodatabase.com/blog/nice-approves-incytes-leukaemia-drug-for-routine-nhs-use 2017-02-13T10:30:13 https://maestrodatabase.com/blog/republicans-aiming-to-kill-health-law-also-work-to-shore-it-up 2017-02-13T10:38:18 https://maestrodatabase.com/blog/ptc-therapeutics-provides-corporate-update 2020-01-14T04:44:02 https://maestrodatabase.com/blog/the-challenges-of-generating-evidence-to-support-precision-medicine 2017-02-13T20:20:58 https://maestrodatabase.com/blog/one-in-three-teens-at-risk-of-cancer-because-of-lost-vaccination-papers 2017-02-13T20:31:26 https://maestrodatabase.com/blog/policies-in-play-as-health-insurance-premium-hike-looms-survey-finds 2017-02-13T20:12:28 https://maestrodatabase.com/blog/smc---february-2017-decisions 2017-02-13T20:15:17 https://maestrodatabase.com/blog/switzerland-ramps-up-covid-19-vaccine-order 2020-12-10T07:43:39 https://maestrodatabase.com/blog/citius-pharmaceuticals-receives-a-complete-response-letter-from-the-us-fda-for-lymphir-denileukin-diftitox-for-the-treatment-of-patients-with-relapsed-or-refractory-cutaneous-t-cell-lymphoma 2023-07-30T09:43:51 https://maestrodatabase.com/blog/botox-to-be-prescribed-on-nhs-in-scotland-for-migraine-patients 2017-02-13T20:35:18 https://maestrodatabase.com/blog/grassley-launches-inquiry-into-orphan-drugs-after-khn-investigation 2017-02-13T20:41:29 https://maestrodatabase.com/blog/x4-pharmaceuticals-receives-rare-paediatric-disease-designation-from-fda-for-mavorixafor-for-the-treatment-of-whim-syndrome 2020-12-10T20:00:16 https://maestrodatabase.com/blog/incidental-imaging-findings-in-clinical-trials 2020-01-14T07:40:41 https://maestrodatabase.com/blog/coffin-drawn-through-timaru-draws-attention-to-health-care-truth 2020-01-14T07:26:28 https://maestrodatabase.com/blog/supreme-court-rules-that-states-can-regulate-pharmacy-benefit-managers 2020-12-10T20:31:46 https://maestrodatabase.com/blog/tga---2019-in-review 2020-01-14T06:34:18 https://maestrodatabase.com/blog/medicare-bulk-billing-rates-surge-across-our-health-system 2022-03-07T04:06:10 https://maestrodatabase.com/blog/atagi-update-following-weekly-covid-19-meeting-2-march-2022 2022-03-07T01:57:25 https://maestrodatabase.com/blog/ontario-to-begin-vaccinations-next-week-in-toronto-ottawa 2020-12-10T20:41:31 https://maestrodatabase.com/blog/chiasma-announces-fda-acceptance-of-mycapssa-new-drug-application-resubmission 2020-01-14T11:16:52 https://maestrodatabase.com/blog/only-half-in-us-want-shots-as-vaccine-nears 2020-12-10T20:13:19 https://maestrodatabase.com/blog/icer-to-assess-treatments-for-atopic-dermatitis 2020-12-10T20:17:49 https://maestrodatabase.com/blog/why-is-keytruda-funded-for-melanoma-but-not-lung-cancer 2017-10-02T06:10:43 https://maestrodatabase.com/blog/pharmacs-funding-model-creating-an-ethical-dilemma---specialist 2023-07-30T20:52:09 https://maestrodatabase.com/blog/lupron-depot-new-strength-receives-health-canada-approval-for-the-treatment-of-advanced-prostate-cancer 2025-11-18T02:22:39 https://maestrodatabase.com/blog/governments-will-want-to-track-who-has-had-a-covid-19-vaccine 2020-12-10T20:25:16 https://maestrodatabase.com/blog/health-secretary-tom-price-resigns-after-drawing-ire-for-chartered-flights 2017-10-02T17:08:51 https://maestrodatabase.com/blog/revised-procedure-for-advance-notification-of-pending-cdr-submissions-and-resubmissions 2017-10-02T17:14:36 https://maestrodatabase.com/blog/reducing-the-hurdles-for-complex-generic-drug-development 2017-10-02T17:35:28 https://maestrodatabase.com/blog/pharmac-seeking-views-on-new-breast-cancer-medicine 2020-01-14T20:02:54 https://maestrodatabase.com/blog/fda-holds-advisory-committee-meeting-to-discuss-authorisation-of-covid-19-vaccine-candidate-as-part-of-agencys-review-of-safety-and-effectiveness-data 2020-12-10T20:44:05 https://maestrodatabase.com/blog/medicare-offers-more-health-coverage-choices-and-decreased-premiums-in-2018 2017-10-02T17:28:38 https://maestrodatabase.com/blog/fda-approves-first-epoetin-alfa-biosimilar-for-the-treatment-of-anemia 2018-05-15T17:13:39 https://maestrodatabase.com/blog/lilly-expands-insulin-affordability-options-with-lower-priced-versions-of-humalog-mix75-slash-25-kwikpen-and-humalog-junior-kwikpen 2020-01-14T11:48:00 https://maestrodatabase.com/blog/pfizer-plans-to-file-for-full-fda-approval-of-covid-19-vaccine-in-april-2021 2020-12-10T20:48:38 https://maestrodatabase.com/blog/statement-from-fda-commissioner-scott-gottlieb-on-the-fdas-adverse-event-reporting-system-and-new-search-tool 2017-10-02T17:37:15 https://maestrodatabase.com/blog/federal-watchdog-urged-to-investigate-the-fdas-handling-of-biogen-alzheimers-drug 2020-12-10T20:52:04 https://maestrodatabase.com/blog/chmp-endorses-tresiba-label-update-in-the-eu---new-label-reflects-significant-reduction-in-the-risk-of-severe-hypoglycaemia 2017-10-02T17:43:14 https://maestrodatabase.com/blog/its-given-me-so-much-hope-pharmac-announces-breast-cancer-drug-deal 2020-01-14T20:15:15 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-releases-draft-evidence-report-on-treatments-for-tardive-dyskinesia 2017-10-03T08:10:15 https://maestrodatabase.com/blog/european-commission-approves-once-daily-olumiant-tablets-for-treatment-of-adults-with-moderate-to-severe-active-rheumatoid-arthritis 2017-02-13T23:12:57 https://maestrodatabase.com/blog/basket-cases-how-real-world-testing-for-drugs-approved-based-on-basket-trials-might-lead-to-false-diagnoses-patient-risks-and-squandered-resources 2020-01-14T20:09:42 https://maestrodatabase.com/blog/jardiance-empagliflozin-becomes-the-first-and-only-approved-treatment-in-europe-for-adults-with-symptomatic-chronic-heart-failure-regardless-of-ejection-fraction 2022-03-07T20:00:50 https://maestrodatabase.com/blog/do-pharmas-claims-on-drug-prices-pass-the-smell-test-we-found-5-stinkers 2017-10-02T17:54:17 https://maestrodatabase.com/blog/statement-from-fda-commissioner-and-director-of-the-center-for-biologics-evaluation-and-research-on-new-policies-to-advance-development-of-safe-and-effective-cell-and-gene-therapies 2019-01-15T19:15:06 https://maestrodatabase.com/blog/roche-aims-to-underwhelm-on-sma-drug-price-to-challenge-rivals 2020-01-14T20:27:43 https://maestrodatabase.com/blog/breakthrough-cancer-treatments-raise-difficult-questions 2017-10-03T08:22:14 https://maestrodatabase.com/blog/progressive-squamous-cell-carcinoma-of-the-head-and-neck-pembrolizumab-prolongs-survival 2019-01-15T19:18:39 https://maestrodatabase.com/blog/approval-for-seqirus-flu-vaccine 2019-01-15T19:11:12 https://maestrodatabase.com/blog/indivior-submits-new-drug-application-to-u-dot-s-fda-for-rbp-7000-risperidone-monthly-depot-for-treatment-of-schizophrenia 2017-10-03T08:56:42 https://maestrodatabase.com/blog/fda-approves-drugs-faster-than-ever-but-relies-on-weaker-evidence-researchers-find 2020-01-14T20:24:01 https://maestrodatabase.com/blog/what-makes-singapores-health-care-so-cheap 2017-10-03T08:31:04 https://maestrodatabase.com/blog/sydney-breast-cancer-patients-welcome-better-access-to-life-changing-drug 2020-01-14T20:19:42 https://maestrodatabase.com/blog/novavaxs-covid-19-vaccine-moves-closer-to-fda-authorisation-decision 2022-03-07T20:22:22 https://maestrodatabase.com/blog/health-insurance-industry-pooling-mechanism-makes-high-cost-drugs-accessible-for-record-number-of-canadians 2020-01-14T20:36:42 https://maestrodatabase.com/blog/if-the-shutdown-drags-on-at-fda-it-will-put-anticipated-new-treatments-in-jeopardy 2019-01-15T19:39:30 https://maestrodatabase.com/blog/rezafungin-awarded-promising-innovation-medicine-designation-by-the-uks-medicines-and-healthcare-products-regulatory-agency-for-the-treatment-of-invasive-candidiasis 2022-03-07T20:19:05 https://maestrodatabase.com/blog/smc---march-2022-decisions 2022-03-07T20:28:08 https://maestrodatabase.com/blog/how-a-regulatory-dead-zone-may-be-holding-up-copycat-insulin 2019-01-15T19:34:46 https://maestrodatabase.com/blog/horizon-therapeutics-announces-fda-has-granted-priority-review-of-the-supplemental-biologics-license-application-for-the-concomitant-use-of-krystexxa-pegloticase-injection-plus-methotrexate-for-people-living-with-uncontrolled-gout 2022-03-07T20:11:32 https://maestrodatabase.com/blog/heres-why-many-prescription-drugs-in-the-us-cost-so-much--and-its-not-innovation-or-improvement 2019-01-15T19:48:42 https://maestrodatabase.com/blog/servier-announces-fda-filing-acceptance-and-priority-review-for-tibsovo-ivosidenib-tablets-in-combination-with-azacitidine-for-patients-with-previously-untreated-idh1-mutated-acute-myeloid-leukaemia 2022-03-07T20:06:32 https://maestrodatabase.com/blog/pressure-on-private-health-as-thousands-dump-hospital-cover 2017-02-14T19:48:42 https://maestrodatabase.com/blog/beigene-receives-u-dot-s-fda-breakthrough-therapy-designation-for-zanubrutinib-in-mantle-cell-lymphoma 2019-01-15T19:43:01 https://maestrodatabase.com/blog/tga-bill-to-cut-red-tape-stalls-for-inquiry 2017-02-14T19:50:47 https://maestrodatabase.com/blog/b-dot-c-funding-decision-on-pricey-drug-leaves-teen-with-rare-disease-facing-scary-future 2020-01-14T20:41:15 https://maestrodatabase.com/blog/fda-drug-trials-snapshots-and-diversity-when-testing-new-drugs 2017-02-14T01:25:13 https://maestrodatabase.com/blog/valeo-pharma-and-zambon-announce-the-approval-of-onstryv-safinamide-for-canada 2019-01-15T20:10:32 https://maestrodatabase.com/blog/aetna-and-humana-mutually-end-merger-agreement 2017-02-14T20:08:13 https://maestrodatabase.com/blog/merit-medical-receives-fda-breakthrough-device-designation-for-embosphere-microspheres-for-use-in-genicular-artery-embolisation-for-symptomatic-knee-osteoarthritis 2022-03-07T20:43:15 https://maestrodatabase.com/blog/an-open-letter-to-the-duchenne-community 2017-02-14T20:01:41 https://maestrodatabase.com/blog/atox-bio-announces-fda-acceptance-to-file-the-nda-for-reltecimod-to-treat-suspected-organ-dysfunction-or-failure-in-patients-with-necrotising-soft-tissue-infection-flesh-eating-disease 2020-12-10T23:11:32 https://maestrodatabase.com/blog/angry-town-hall-meetings-on-health-care-law-and-few-answers 2017-02-14T20:23:32 https://maestrodatabase.com/blog/azar-vows-to-go-beyond-administration-blueprint-if-drug-prices-dont-go-down 2019-01-15T19:50:39 https://maestrodatabase.com/blog/breast-cancer-pill-denied-to-500-000-women 2017-02-14T20:28:41 https://maestrodatabase.com/blog/lawmakers-slam-new-89-000-dollars-price-tag-on-rare-disease-treatment-unconscionable 2017-02-14T20:12:18 https://maestrodatabase.com/blog/why-brexit-could-make-the-u-dot-s-a-refuge-for-sick-europeans-lacking-drug-access 2017-10-03T09:14:18 https://maestrodatabase.com/blog/new-21st-century-cures-legislation-speed-and-ease-vs-science 2017-02-14T20:18:11 https://maestrodatabase.com/blog/health-canada-restricts-allergans-esmya 2019-01-15T20:02:16 https://maestrodatabase.com/blog/seattle-genetics-receives-fda-breakthrough-therapy-designation-for-adcetris-brentuximab-vedotin-in-front-line-advanced-hodgkin-lymphoma 2017-10-03T09:23:37 https://maestrodatabase.com/blog/american-patients-can-access-far-more-new-cancer-drugs-than-others-can 2017-02-14T20:38:46 https://maestrodatabase.com/blog/teva-announces-launch-of-a-first-generic-version-of-revlimid-lenalidomide-capsules-in-the-u-dot-s 2022-03-07T20:34:02 https://maestrodatabase.com/blog/key-democrat-moves-to-crack-down-on-fda-accelerated-approvals 2022-03-07T20:40:32 https://maestrodatabase.com/blog/xenleta-lefamulin-receives-health-canada-approval-for-treatment-of-community-acquired-pneumonia 2020-07-17T01:22:56 https://maestrodatabase.com/blog/merck-announces-u-dot-s-fda-approval-of-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-the-prevention-of-invasive-pneumococcal-disease-in-adults-18-years-and-older-caused-by-15-serotypes 2021-07-17T03:16:02 https://maestrodatabase.com/blog/cms-unveils-enhanced-drug-dashboards-to-increase-transparency-on-drug-prices 2018-05-15T20:25:24 https://maestrodatabase.com/blog/icer-posts-draft-scoping-document-on-biologic-treatments-for-asthma 2018-05-15T18:56:08 https://maestrodatabase.com/blog/sonivie-receives-fda-breakthrough-device-designation-for-the-tivus-system-for-renal-artery-denervation 2020-12-10T23:45:54 https://maestrodatabase.com/blog/us-could-see-lower-drug-prices-if-europe-pays-more-of-its-fair-share 2018-05-15T20:58:31 https://maestrodatabase.com/blog/aerie-pharmaceuticals-submits-new-drug-application-to-u-dot-s-fda-for-roclatan-netarsudil-slash-latanoprost-ophthalmic-solution-0-dot-02-percent-slash-0-dot-005-percent 2018-05-15T21:41:47 https://maestrodatabase.com/blog/johnson-and-johnsons-posdinemab-and-tau-active-immunotherapy-receive-us-fda-fast-track-designations-for-the-treatment-of-alzheimers-disease 2025-01-09T04:01:57 https://maestrodatabase.com/blog/trumps-big-campaign-promise-on-drug-prices-wouldnt-have-worked-health-and-human-services-secretary-says 2018-05-15T20:36:02 https://maestrodatabase.com/blog/aduhelm-pros-and-cons-debated-at-icer-meeting 2021-07-17T03:26:38 https://maestrodatabase.com/blog/fda-approves-epcoritamab-bysp-for-follicular-lymphoma-indications 2025-11-18T19:27:41 https://maestrodatabase.com/blog/after-outcry-drug-makers-decide-not-to-triple-the-price-of-a-cancer-pill 2018-05-16T06:17:02 https://maestrodatabase.com/blog/u-dot-s-fda-approves-expanded-indication-for-truvada-emtricitabine-and-tenofovir-disoproxil-fumarate-for-reducing-the-risk-of-acquiring-hiv-1-in-adolescents 2018-05-16T06:06:31 https://maestrodatabase.com/blog/arrowhead-pharmaceuticals-announces-fda-approval-of-redemplo-plozasiran-to-reduce-triglycerides-in-adults-with-familial-chylomicronaemia-syndrome 2025-11-18T19:36:42 https://maestrodatabase.com/blog/patient-empowerment-in-europe-is-no-further-research-needed 2018-05-16T06:24:45 https://maestrodatabase.com/blog/trump-threatens-to-use-us-trade-talks-to-force-nhs-to-pay-more-for-drugs 2018-05-16T06:28:53 https://maestrodatabase.com/blog/hoping-and-praying-prime-minister-will-promise-to-deliver-on-prostate-cancer 2018-05-16T06:20:45 https://maestrodatabase.com/blog/marengos-first-in-class-invikafusp-alfa-star0602-receives-us-fda-fast-track-designation-for-treatment-of-unresectable-locally-advanced-or-metastatic-colorectal-cancers-with-high-tumour-mutational-burden 2025-01-09T04:13:32 https://maestrodatabase.com/blog/grifols-receives-expanded-indication-for-thrombate-iii-antithrombin-iii-human-label-in-us-strengthening-treatment-options-for-pediatric-patients 2025-11-19T05:49:54 https://maestrodatabase.com/blog/high-costs-big-gaps-driving-australians-away-from-health-insurance 2018-05-16T09:54:49 https://maestrodatabase.com/blog/evolving-landscape-of-us-fda-drug-approval-in-the-era-of-precision-oncology-finding-the-right-balance-between-access-and-safety 2018-05-16T09:58:58 https://maestrodatabase.com/blog/mc2-therapeutics-announces-submission-of-marketing-authorisation-application-in-eu-for-wynzora-cream-50-ug-slash-g-calcipotriol-and-0-dot-5-mg-slash-g-betamethasone-as-dipropionate 2020-07-17T03:13:55 https://maestrodatabase.com/blog/rosemary-wants-to-be-the-uber-of-electronic-scripts 2019-07-07T20:52:51 https://maestrodatabase.com/blog/sound-fury-and-prescription-drugs 2019-07-07T12:25:40 https://maestrodatabase.com/blog/pharmac-proposes-widened-access-to-the-flu-vaccine-for-maori-and-pacific-peoples-for-2022-season 2022-03-07T23:01:38 https://maestrodatabase.com/blog/life-changing-drug-spinraza-still-not-covered-for-many-canadians-with-spinal-muscular-atrophy 2019-07-07T21:01:14 https://maestrodatabase.com/blog/kamala-harris-says-medicare-for-all-wouldnt-end-private-insurance-it-would 2019-07-07T20:55:58 https://maestrodatabase.com/blog/vasa-therapeutics-granted-fda-fast-track-designation-for-vs-041-a-novel-investigational-treatment-of-heart-failure-with-preserved-ejection-fraction 2025-11-18T23:37:30 https://maestrodatabase.com/blog/advanced-accelerator-applications-announces-european-approval-of-lutetium-177lu-oxodotreotide-lutathera-for-gastro-enteropancreatic-neuroendocrine-tumours 2017-10-03T10:28:06 https://maestrodatabase.com/blog/european-commission-approves-brinsupri-brensocatib-as-the-first-and-only-treatment-approved-for-non-cystic-fibrosis-bronchiectasis-in-the-european-union 2025-11-19T05:13:29 https://maestrodatabase.com/blog/agenda-for-the-march-2026-pbac-meeting-19-november-2025 2025-11-19T06:08:30 https://maestrodatabase.com/blog/tga-approves-sogroya 2022-03-07T23:13:15 https://maestrodatabase.com/blog/pharmac-funds-ramipril-for-people-with-high-blood-pressure 2022-10-26T05:28:41 https://maestrodatabase.com/blog/cder-brings-many-safe-and-effective-therapies-to-patients-and-consumers-in-2024 2025-01-09T05:10:27 https://maestrodatabase.com/blog/sucampo-pharmaceuticals-announces-fda-acceptance-of-snda-for-amitiza-in-children-with-paediatric-functional-constipation-with-priority-review-designation 2017-10-03T15:15:42 https://maestrodatabase.com/blog/fresenius-kabi-canada-has-received-a-health-canada-notice-of-compliance-for-otulfi-an-ustekinumab-biosimilar 2025-01-09T05:03:37 https://maestrodatabase.com/blog/general-court-finds-no-fault-in-2011-appointment-procedure-of-ema-executive-director 2017-10-03T15:23:40 https://maestrodatabase.com/blog/pharmac-and-health-nz-weigh-up-future-of-covid-19-vaccines-and-treatments 2024-05-05T21:26:45 https://maestrodatabase.com/blog/nabriva-therapeutics-provides-update-on-pdufa-date-for-intravenous-contepo 2019-01-15T23:18:06 https://maestrodatabase.com/blog/esperion-partner-hls-therapeutics-announces-approval-of-nilemdo-for-the-reduction-of-ldl-cholesterol-in-canadians-at-risk-of-cardiovascular-disease 2025-11-19T07:50:09 https://maestrodatabase.com/blog/public-summary-documents---march-2020-meeting 2020-07-17T07:29:57 https://maestrodatabase.com/blog/csl-university-of-queensland-coronavirus-vaccine-trials-halted 2020-12-11T07:05:22 https://maestrodatabase.com/blog/pfizer-and-biontech-receive-fda-advisory-committee-vote-supporting-potential-first-emergency-use-authorisation-for-vaccine-to-combat-covid-19-in-the-u-dot-s 2020-12-11T07:12:44 https://maestrodatabase.com/blog/paracetamol-500-mg-tablets-in-short-supply-at-pharmacies 2020-07-17T07:35:38 https://maestrodatabase.com/blog/fda-grants-traditional-approval-to-daratumumab-and-hyaluronidase-fihj-for-newly-diagnosed-light-chain-amyloidosis 2025-11-19T19:33:14 https://maestrodatabase.com/blog/nice-backing-for-astellas-xospata 2020-07-17T08:43:35 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-sevabertinib-for-non-squamous-non-small-cell-lung-cancer 2025-11-19T19:50:53 https://maestrodatabase.com/blog/fda-grants-traditional-approval-to-tarlatamab-dlle-for-extensive-stage-small-cell-lung-cancer 2025-11-19T20:00:46 https://maestrodatabase.com/blog/fda-approves-selumetinib-for-adults-with-neurofibromatosis-type-1-with-symptomatic-inoperable-plexiform-neurofibromas 2025-11-19T19:05:09 https://maestrodatabase.com/blog/alunbrig-scores-nice-backing-for-alk-positive-lung-cancer 2020-12-11T11:19:00 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-for-db102-in-patients-with-newly-diagnosed-glioblastoma 2020-07-17T21:27:20 https://maestrodatabase.com/blog/determination-of-the-target-population-in-early-benefit-assessments-in-germany-challenges-for-non-small-cell-lung-cancer 2020-07-17T09:24:31 https://maestrodatabase.com/blog/corvista-health-receives-breakthrough-device-designation-for-the-corvista-system 2022-10-26T07:13:26 https://maestrodatabase.com/blog/european-commission-approves-roches-lunsumio-subcutaneous-for-relapsed-or-refractory-follicular-lymphoma 2025-11-19T19:21:23 https://maestrodatabase.com/blog/ema-validates-bristol-myers-squibbs-application-for-car-t-cell-therapy-lisocabtagene-maraleucel 2020-07-17T12:38:59 https://maestrodatabase.com/blog/lynkuet-elinzanetant-approved-in-the-eu-for-the-treatment-of-moderate-to-severe-vasomotor-symptoms-associated-with-menopause-or-endocrine-therapy-for-breast-cancer 2025-11-19T22:00:58 https://maestrodatabase.com/blog/bavencio-avelumab-receives-positive-chmp-opinion-for-first-line-maintenance-treatment-of-locally-advanced-or-metastatic-urothelial-carcinoma 2020-12-11T20:46:33 https://maestrodatabase.com/blog/fda-explores-requiring-drug-price-disclosures-in-commercials 2018-05-16T15:45:42 https://maestrodatabase.com/blog/libtayo-cemiplimab-approved-in-the-european-union-as-first-and-only-immunotherapy-for-adjuvant-treatment-of-cutaneous-squamous-cell-carcinoma-with-high-risk-of-recurrence-after-surgery-and-radiation 2025-11-19T20:30:33 https://maestrodatabase.com/blog/pm-urged-to-back-access-to-life-saving-drug-for-children-with-cystic-fibrosis 2018-05-16T16:00:08 https://maestrodatabase.com/blog/proposal-to-list-a-range-of-medical-thermometer-products-and-medical-devices-used-in-the-prevention-of-venous-thromboembolisms-supplied-by-medtronic 2017-10-04T15:47:22 https://maestrodatabase.com/blog/funding-rejected-for-breast-cancer-testing 2017-10-04T15:58:49 https://maestrodatabase.com/blog/eylea-hd-aflibercept-injection-8-mg-approved-by-fda-for-the-treatment-of-macular-oedema-following-retinal-vein-occlusion-and-for-monthly-dosing-across-approved-indications 2025-11-19T22:13:04 https://maestrodatabase.com/blog/agenda-for-the-december-2017-pbac-meeting 2017-10-04T15:54:32 https://maestrodatabase.com/blog/the-health-system-is-still-awaiting-modernisation 2017-10-04T16:03:02 https://maestrodatabase.com/blog/health-canada-approves-astellas-xospata-gilteritinib-for-patients-with-relapsed-or-refractory-acute-myeloid-leukaemia-with-a-flt3-mutation 2020-01-15T01:49:01 https://maestrodatabase.com/blog/ema-publishes-comments-on-member-states-hosting-bids 2017-10-04T16:21:11 https://maestrodatabase.com/blog/amneal-announces-approval-of-rivastigmine-transdermal-system 2019-01-16T02:46:58 https://maestrodatabase.com/blog/countdown-to-launch-of-new-eudravigilance-system 2017-10-04T16:23:39 https://maestrodatabase.com/blog/msac-secretariat-tweaks-the-agenda-for-dec-2022-pasc-meeting 2022-10-26T08:47:22 https://maestrodatabase.com/blog/fda-accepts-supplemental-new-drug-application-filing-for-avycaz-ceftazidime-and-avibactam 2017-10-04T16:41:42 https://maestrodatabase.com/blog/pharmac-budget-2018-slash-19 2018-05-17T09:25:47 https://maestrodatabase.com/blog/proposal-to-widen-access-and-change-the-funded-enzyme-replacement-therapy-for-gaucher-disease 2018-05-17T09:28:32 https://maestrodatabase.com/blog/fda-approves-the-first-non-opioid-treatment-for-management-of-opioid-withdrawal-symptoms-in-adults 2018-05-17T09:20:15 https://maestrodatabase.com/blog/tlv-has-decided-to-reconsider-the-subsidy-for-olumiant 2020-01-15T02:20:15 https://maestrodatabase.com/blog/budget-2018-pharmac-to-buy-all-medicines-for-dhbs 2018-05-17T09:42:40 https://maestrodatabase.com/blog/eu-oks-first-line-use-of-ipsens-cabometyx 2018-05-17T09:34:34 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-and-acknowledges-coherus-biosciences-biologics-license-application-of-chs-1701-pegfilgrastim-biosimilar-candidate-for-review 2018-05-17T09:54:58 https://maestrodatabase.com/blog/fda-approves-botox-cosmetic-onabotulinumtoxina-for-the-temporary-improvement-in-the-appearance-of-moderate-to-severe-forehead-lines-associated-with-frontalis-muscle-activity-in-adults 2017-10-04T17:07:02 https://maestrodatabase.com/blog/evolus-announces-progress-with-dwp-450-regulatory-submissions 2018-05-17T09:48:31 https://maestrodatabase.com/blog/new-members-appointed-to-cadth-expert-committees 2017-10-04T17:13:34 https://maestrodatabase.com/blog/addressing-generic-drug-market-failures---the-case-for-establishing-a-non-profit-manufacturer 2018-05-17T10:11:24 https://maestrodatabase.com/blog/european-medicines-agency-validates-oasmia-pharmaceuticals-application-to-add-efficacy-data-to-the-approved-apealea-product-information 2019-01-16T03:17:05 https://maestrodatabase.com/blog/ema-to-lose-25-percent-of-staff-as-hard-brexit-approaches 2019-01-16T03:20:09 https://maestrodatabase.com/blog/mylan-announces-u-dot-s-fda-approval-of-first-generic-for-copaxone-40-mg-slash-ml-3-times-a-week-and-may-be-eligible-for-180-day-exclusivity 2017-10-04T20:00:08 https://maestrodatabase.com/blog/fda-faster-than-global-peers-at-approving-new-drugs 2018-05-17T10:01:02 https://maestrodatabase.com/blog/takeda-announces-fda-approval-of-alunbrig-brigatinib-180-mg-tablets 2017-10-04T20:18:12 https://maestrodatabase.com/blog/puretech-receives-fda-fast-track-designation-for-lyt-200-in-acute-myeloid-leukaemia 2025-01-09T23:44:02 https://maestrodatabase.com/blog/myonexus-therapeutics-receives-fda-rare-paediatric-drug-designation-for-pioneering-treatment-of-limb-girdle-muscular-dystrophy-type-2e 2018-05-17T10:29:17 https://maestrodatabase.com/blog/expanded-access-fda-describes-efforts-to-ease-application-process 2017-10-04T20:07:58 https://maestrodatabase.com/blog/novartis-seeks-outcomes-based-pricing-in-japan-for-cancer-drug 2017-10-04T20:28:02 https://maestrodatabase.com/blog/castle-creek-pharmaceuticals-receives-fda-rare-paediatric-disease-designation-for-diacerein-1-percent-ointment-for-epidermolysis-bullosa 2018-05-17T10:19:03 https://maestrodatabase.com/blog/scottish-medicines-consortium-update 2022-03-08T07:23:37 https://maestrodatabase.com/blog/amgen-receives-european-commission-approval-for-repatha-evolocumab-to-prevent-heart-attack-and-stroke-in-adults-with-established-cardiovascular-disease 2018-05-17T10:45:11 https://maestrodatabase.com/blog/the-uks-new-five-year-pricing-agreement 2019-01-16T11:09:19 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-evidence-report-finds-cognitive-and-mind-body-therapies-for-treatment-of-back-pain-provide-added-benefit-at-reasonable-cost 2017-10-04T20:42:07 https://maestrodatabase.com/blog/j-and-j-ceo-warns-of-unintended-consequences-of-trumps-drug-price-reduction-plan 2018-05-17T11:07:05 https://maestrodatabase.com/blog/one-in-six-britons-considers-stockpiling-food-and-medicine-for-brexit 2019-01-16T11:13:00 https://maestrodatabase.com/blog/amazon-australia-signals-pharmacy-foray-with-new-trademark-application 2020-01-15T03:02:09 https://maestrodatabase.com/blog/prescription-for-pharmacy-talks-add-consumers 2018-05-17T10:40:10 https://maestrodatabase.com/blog/rfp---supply-of-diabetes-agents-sglt-2-inhibitors-glp-1-agonists-and-dpp-4-inhibitors 2020-01-15T02:57:08 https://maestrodatabase.com/blog/efpia-response-to-the-uk-parliaments-decision-to-reject-the-brexit-withdrawal-agreement-and-political-declaration 2019-01-16T11:41:45 https://maestrodatabase.com/blog/nice-draft-guidance-does-not-recommend-pembrolizumab-plus-chemotherapy-for-triple-negative-breast-cancer 2022-03-08T19:32:18 https://maestrodatabase.com/blog/ispor-launches-about-real-world-evidence-content 2022-03-08T19:47:01 https://maestrodatabase.com/blog/dublin-warns-medicine-supply-threatened-by-no-deal-brexit 2019-01-16T11:20:16 https://maestrodatabase.com/blog/fda-effort-to-improve-clinical-trial-diversity-failed-to-make-a-difference-for-black-patients-study-finds 2022-03-08T19:42:17 https://maestrodatabase.com/blog/pharmaceutical-industry-responds-to-brexit-vote-outcome 2019-01-16T11:37:38 https://maestrodatabase.com/blog/germany-significantly-tightens-drug-pricing-and-reimbursement-laws 2022-10-26T19:40:01 https://maestrodatabase.com/blog/nice-backs-roches-tecentriq-for-pre-treated-bladder-cancer 2018-05-17T20:35:47 https://maestrodatabase.com/blog/pharmaceutical-companies-spent-$34m-on-patient-advocacy-groups-research-finds 2019-01-16T20:18:41 https://maestrodatabase.com/blog/seres-therapeutics-announces-fda-acceptance-of-biologics-license-application-for-investigational-microbiome-therapeutic-ser-109-for-recurrent-c-difficile-infection-for-priority-review 2022-10-26T19:43:59 https://maestrodatabase.com/blog/fda-offers-funding-for-biosimilar-regulatory-science-pilot 2022-03-08T19:27:41 https://maestrodatabase.com/blog/sweet-smell-of-success-for-patients-taking-the-sugar-pill 2019-01-16T12:00:53 https://maestrodatabase.com/blog/the-meningitis-foundation-says-pharmac-proposal-to-partially-fund-a-meningococcal-b-vaccine-will-not-work 2022-10-26T19:31:36 https://maestrodatabase.com/blog/fda-approves-first-generic-version-of-sabril-to-help-treat-seizures-in-adults-and-paediatric-patients-with-epilepsy 2019-01-16T20:14:12 https://maestrodatabase.com/blog/cancer-patients-given-new-drugs-that-wont-help-them 2017-10-05T07:45:22 https://maestrodatabase.com/blog/nipocalimab-granted-us-fda-priority-review-for-the-treatment-of-generalized-myasthenia-gravis 2025-01-10T02:54:35 https://maestrodatabase.com/blog/vermont-signs-law-to-allow-import-of-prescription-drugs-from-canada 2018-05-17T22:58:46 https://maestrodatabase.com/blog/trump-administration-throws-down-gauntlet-on-drug-prices 2019-01-16T20:31:28 https://maestrodatabase.com/blog/statement-from-fda-commissioner-on-new-agency-efforts-to-shine-light-on-situations-where-drug-makers-may-be-pursuing-gaming-tactics-to-delay-generic-competition 2018-05-17T21:56:33 https://maestrodatabase.com/blog/vaccine-approval-before-phase-3-trial-results-a-consequence-of-vaccine-access-inequity 2022-03-08T20:36:57 https://maestrodatabase.com/blog/fda-accepts-agios-supplemental-new-drug-application-for-pyrukynd-mitapivat-in-adult-patients-with-non-transfusion-dependent-and-transfusion-dependent-alpha--or-beta-thalassemia 2025-01-10T02:35:30 https://maestrodatabase.com/blog/the-slow-death-of-our-health-insurance-system 2019-01-16T20:25:26 https://maestrodatabase.com/blog/abpi-update-on-application-for-judicial-review 2017-10-05T07:52:55 https://maestrodatabase.com/blog/this-12-year-old-leukaemia-survivor-is-fighting-for-equal-access-to-medicine-for-all-canadians 2018-05-17T22:50:16 https://maestrodatabase.com/blog/the-fda-has-five-weeks-till-money-runs-out-for-approving-new-drugs 2019-01-16T20:28:37 https://maestrodatabase.com/blog/key-considerations-in-the-health-technology-assessment-of-advanced-therapy-medicinal-products-in-scotland-the-netherlands-and-england 2022-03-08T20:19:04 https://maestrodatabase.com/blog/us-fda-delays-panel-meet-on-perrigos-otc-birth-control-pill 2022-10-26T19:56:07 https://maestrodatabase.com/blog/acurx-receives-fda-fast-track-designation-for-acx-362e-for-the-treatment-of-c-difficile-infection 2019-01-17T05:04:57 https://maestrodatabase.com/blog/nice-yet-to-support-the-use-of-pralsetinib-on-the-nhs 2022-03-08T19:57:01 https://maestrodatabase.com/blog/astellas-receives-health-canada-approval-for-vyloy-zolbetuximab-in-combination-with-chemotherapy-for-advanced-gastric-and-gastro-oesophageal-junction-cancer 2025-01-10T02:20:17 https://maestrodatabase.com/blog/menlo-therapeutics-serlopitant-granted-breakthrough-therapy-designation-by-fda-for-the-treatment-of-pruritus-associated-with-prurigo-nodularis 2019-01-17T05:00:54 https://maestrodatabase.com/blog/saluda-medical-receives-fda-approval-for-the-evoke-spinal-cord-stimulation-system-to-treat-chronic-intractable-pain 2022-03-08T20:08:46 https://maestrodatabase.com/blog/fda-review-of-aimmune-drug-put-on-hold-due-to-government-shutdown 2019-01-17T05:28:46 https://maestrodatabase.com/blog/alex-azar-calls-democratic-reforms-to-lower-drug-prices-gimmicks-and-ineffective 2018-05-17T23:16:10 https://maestrodatabase.com/blog/new-drug-application-for-insomnia-disorder-treatment-lemborexant-submitted-in-the-united-states 2019-01-17T05:11:19 https://maestrodatabase.com/blog/rising-drug-prices-said-to-strain-hospitals-force-budget-cuts 2019-01-17T05:20:46 https://maestrodatabase.com/blog/fda-approves-aimovig-erenumab-aooe-a-novel-treatment-developed-specifically-for-migraine-prevention 2018-05-17T23:29:50 https://maestrodatabase.com/blog/tebentafusp-for-the-treatment-of-patients-with-advanced-uveal-melanoma 2025-01-10T21:02:09 https://maestrodatabase.com/blog/vigeneron-announces-fda-rare-paediatric-disease-designation-for-vg901 2025-01-10T20:44:27 https://maestrodatabase.com/blog/why-biosimilar-approval-applications-break-down 2020-07-18T01:56:05 https://maestrodatabase.com/blog/proposal-to-fund-betamethasone-dipropionate-with-calcipotriol-enstilar-foam-spray-for-psoriasis 2020-01-15T04:23:07 https://maestrodatabase.com/blog/mersana-therapeutics-announces-additional-fda-fast-track-designation-granted-to-emiltatug-ledadotin-xmt-1660 2025-01-12T04:26:22 https://maestrodatabase.com/blog/us-fda-accepts-biologics-license-application-for-gc-biopharmas-gc5107b-immune-globulin-intravenous-human-10-percent-liquid 2023-07-31T06:36:38 https://maestrodatabase.com/blog/erdafitinib-for-the-treatment-of-patients-with-metastatic-or-unresectable-fgfr-altered-urothelial-cancer 2025-01-10T21:22:09 https://maestrodatabase.com/blog/international-harmonisation-of-ingredient-names---changes-to-the-pbs-schedule-effective-1-august-2023 2023-07-31T10:44:19 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-to-ivs-3001-a-car-t-cell-therapy-in-the-treatment-of-renal-cell-carcinoma 2023-07-31T10:27:29 https://maestrodatabase.com/blog/lexicon-pharmaceuticals-receives-fast-track-designation-from-the-fda-for-lx9211-for-diabetic-peripheral-neuropathic-pain 2020-12-12T02:16:25 https://maestrodatabase.com/blog/bridgebio-oncology-therapeutics-granted-us-fda-fast-track-designation-for-bbo-8520-for-krasg12c-mutated-metastatic-non-small-cell-lung-cancer 2025-01-12T04:37:17 https://maestrodatabase.com/blog/nuvalent-announces-fda-acceptance-of-new-drug-application-for-zidesamtinib-for-the-treatment-of-tki-pre-treated-patients-with-advanced-ros1-positive-nsclc 2025-11-20T19:49:58 https://maestrodatabase.com/blog/gene-therapy-drug-kymriah-should-be-publicly-covered-if-manufacturer-drops-price-report-recommends 2019-01-17T07:47:52 https://maestrodatabase.com/blog/democrat-chairman-cummings-meets-with-trump-health-chief-to-discuss-drug-prices 2019-01-17T07:58:19 https://maestrodatabase.com/blog/aeterna-zentaris-receives-european-marketing-clearance-for-macimorelin 2019-01-17T08:01:11 https://maestrodatabase.com/blog/heartbreaking-alberta-families-describe-waiting-for-life-changing-drug-to-be-made-available-in-canada 2020-07-18T02:54:47 https://maestrodatabase.com/blog/fda-is-urged-to-mandate-disclosure-of-clinical-trial-summaries-as-pilot-program-stalls 2019-01-17T08:10:20 https://maestrodatabase.com/blog/nice-approval-for-verzenios-in-metastatic-breast-cancer 2019-01-17T19:52:33 https://maestrodatabase.com/blog/considering-and-communicating-uncertainty-in-health-technology-assessment 2021-07-18T05:09:41 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-august-2023 2023-07-31T20:57:06 https://maestrodatabase.com/blog/tlv-has-decided-to-reconsider-the-subsidy-for-xeljanz 2020-01-15T05:40:24 https://maestrodatabase.com/blog/fda-updates-guidance-on-development-of-rare-disease-therapies 2019-01-17T20:00:35 https://maestrodatabase.com/blog/bavencio-gets-coverage-as-first-line-maintenance-therapy-for-urothelial-cancer 2023-07-31T20:52:12 https://maestrodatabase.com/blog/icer-to-assess-whether-the-most-significant-prescription-drug-price-increases-are-supported-by-new-clinical-evidence 2020-06-20T04:10:20 https://maestrodatabase.com/blog/pharmac-considering-new-medicines-for-type-2-diabetes-mellitus 2020-01-15T05:47:04 https://maestrodatabase.com/blog/fda-takes-key-action-in-fight-against-covid-19-by-issuing-emergency-use-authorisation-for-first-covid-19-vaccine 2020-12-12T02:48:36 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-august-2023 2023-07-31T20:43:48 https://maestrodatabase.com/blog/welcoming-natalie-mcmurtry-chief-executive-of-pharmac 2025-11-20T22:28:12 https://maestrodatabase.com/blog/after-37-years-of-trying-this-biotech-nears-a-first-drug-approval-in-breast-cancer 2019-01-17T19:56:31 https://maestrodatabase.com/blog/a-chance-to-cure-americas-drug-price-sickness 2019-01-17T20:30:08 https://maestrodatabase.com/blog/puahoaho-clarity-around-pharmacs-priority-lists 2022-03-09T00:12:14 https://maestrodatabase.com/blog/fda-issues-letter-about-paclitaxel-coated-balloons-and-eluting-stents 2019-01-17T20:11:49 https://maestrodatabase.com/blog/u-dot-s-fda-grants-priority-review-for-the-biologics-license-application-for-pfizer-biontech-covid-19-vaccine 2021-07-18T05:13:29 https://maestrodatabase.com/blog/how-to-integrate-evidence-from-patient-preference-studies-into-health-technology-assessment-a-critical-review-and-recommendations 2021-07-18T05:28:07 https://maestrodatabase.com/blog/7-hills-pharmas-clinical-stage-novel-immunostimulant-7hp349-granted-fda-fast-track-designation-for-anti-pd-1-resistant-metastatic-melanoma 2022-03-09T00:06:25 https://maestrodatabase.com/blog/pfizer-agrees-to-pay-345-dollars-million-to-resolve-epipen-pricing-lawsuit 2021-07-18T06:55:10 https://maestrodatabase.com/blog/hta-review-and-chair-committee 2022-10-27T01:01:39 https://maestrodatabase.com/blog/fda-approves-dostarlimab-gxly-with-chemotherapy-for-endometrial-cancer 2023-07-31T21:21:55 https://maestrodatabase.com/blog/fair-allocation-of-scarce-car-t-cell-therapies-for-relapsed-slash-refractory-multiple-myeloma 2023-07-31T21:16:54 https://maestrodatabase.com/blog/agreements-for-the-supply-of-orthopaedic-implants-and-associated-products 2017-10-06T11:45:00 https://maestrodatabase.com/blog/states-urging-hospitals-to-bill-health-insurers-is-pushing-up-premiums-analysis-shows 2017-10-06T11:52:02 https://maestrodatabase.com/blog/unitedhealth-seeks-more-clarity-on-biogens-56-000-dollars-alzheimers-drug-coverage 2021-07-18T07:00:25 https://maestrodatabase.com/blog/australias-health-care-spending-rises-above-10-percent-of-gdp-for-first-time 2017-10-06T11:49:05 https://maestrodatabase.com/blog/cms-releases-2024-projected-medicare-part-d-premium-and-bid-information 2023-07-31T22:15:13 https://maestrodatabase.com/blog/drug-makers-go-under-the-skin-skirting-early-us-medicare-price-negotiations 2023-07-31T21:45:42 https://maestrodatabase.com/blog/emas-painful-departure 2017-10-06T11:59:23 https://maestrodatabase.com/blog/ema-takes-yet-another-step-in-public-engagement-with-its-first-public-hearing 2017-10-06T11:54:58 https://maestrodatabase.com/blog/fda-awards-six-grants-for-natural-history-studies-in-rare-diseases 2017-10-07T00:53:17 https://maestrodatabase.com/blog/fda-awards-15-grants-for-clinical-trials-to-stimulate-product-development-for-rare-diseases 2017-10-07T00:50:30 https://maestrodatabase.com/blog/flexion-therapeutics-announces-fda-approval-of-zilretta-triamcinolone-acetonide-extended-release-injectable-suspension-for-osteoarthritis-knee-pain 2017-10-07T01:01:56 https://maestrodatabase.com/blog/fda-approval-and-regulation-of-pharmaceuticals-1983-2018 2020-01-15T08:28:01 https://maestrodatabase.com/blog/fda-approves-implantable-device-to-treat-moderate-to-severe-central-sleep-apnea 2017-10-07T00:56:13 https://maestrodatabase.com/blog/withdrawals-from-the-drug-benefits---august-2019 2019-07-08T09:36:57 https://maestrodatabase.com/blog/astrazeneca-boss-calls-for-nhs-drug-approval-shake-up 2019-07-08T05:50:54 https://maestrodatabase.com/blog/health-canada-approves-kerendia-finerenone-as-an-adjunct-to-standard-of-care-therapy-in-adults-with-chronic-kidney-disease-and-type-2-diabetes 2022-10-27T02:14:42 https://maestrodatabase.com/blog/taysha-gene-therapies-announces-regenerative-medicine-advanced-therapy-designation-granted-by-us-fda-for-tsha-102-in-rett-syndrome 2024-05-06T06:36:48 https://maestrodatabase.com/blog/guido-rasi-elected-chair-of-international-coalition-of-medicines-regulatory-authorities 2019-07-08T10:49:20 https://maestrodatabase.com/blog/nhs-england-scraps-7-more-drugs-on-prescription 2019-07-08T12:46:48 https://maestrodatabase.com/blog/plan-on-more-pharma-mega-mergers 2019-07-08T12:41:29 https://maestrodatabase.com/blog/more-government-regulation-of-biopharma-would-harm-patients-and-the-economy 2022-03-09T04:26:10 https://maestrodatabase.com/blog/independent-chair-of-health-technology-assessment-review-will-drive-major-reform-of-australias-health-system 2022-10-27T03:21:50 https://maestrodatabase.com/blog/pharma-giant-wants-vaccination-reform 2019-07-08T20:49:57 https://maestrodatabase.com/blog/nice-unable-to-provide-guidance-on-a-new-use-of-lenalidomide 2022-03-09T05:01:41 https://maestrodatabase.com/blog/chmp-recommends-the-approvals-of-rinvoq-upadacitinib-for-the-treatment-of-adults-with-active-psoriatic-arthritis-and-ankylosing-spondylitis 2020-12-12T04:12:36 https://maestrodatabase.com/blog/democrats-zero-in-on-high-drug-prices-in-iowa-debate 2020-01-15T11:27:15 https://maestrodatabase.com/blog/prevail-therapeutics-receives-u-dot-s-fda-fast-track-designation-for-pr001-for-the-treatment-of-parkinsons-disease-patients-with-a-gba1-mutation 2019-07-08T21:03:13 https://maestrodatabase.com/blog/nice-rejects-keytruda-asks-for-more-information 2020-01-15T11:19:28 https://maestrodatabase.com/blog/family-to-stay-in-australia-after-son-with-cystic-fibrosis-initially-deemed-a-burden 2019-07-08T20:54:46 https://maestrodatabase.com/blog/fda-accepts-roches-supplemental-biologics-license-application-for-tecentriq-plus-chemotherapy-abraxane-and-carboplatin-for-the-initial-treatment-of-metastatic-non-squamous-non-small-cell-lung-cancer 2019-01-18T00:38:42 https://maestrodatabase.com/blog/vandas-letter-to-fda-commissioner-highlights-faulty-gastroparesis-nda-review 2025-01-12T22:07:11 https://maestrodatabase.com/blog/cystic-fibrosis-scandal-drugs-boss-tells-boy-9-he-wants-nhs-deal-to-save-lives 2019-07-08T21:15:01 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-for-priority-review-bristol-myers-squibbs-application-for-opdivo-nivolumab-plus-yervoy-ipilimumab-in-first-line-non-small-cell-lung-cancer 2020-01-15T19:31:31 https://maestrodatabase.com/blog/us-pharma-ramps-up-attack-on-australias-discriminatory-drug-pricing 2025-11-21T02:13:51 https://maestrodatabase.com/blog/adma-biologics-receives-fda-approval-for-license-transfers-for-bivigam-and-nabi-hb 2019-07-08T21:07:11 https://maestrodatabase.com/blog/reform-at-the-fda--in-need-of-reform 2020-01-15T11:43:02 https://maestrodatabase.com/blog/chinas-national-medical-products-administration-accepts-astellas-biologics-license-application-for-zolbetuximab 2023-08-01T02:03:39 https://maestrodatabase.com/blog/priority-review-granted-to-beigenes-supplemental-new-drug-application-in-china-for-tislelizumab-in-urothelial-carcinoma 2019-07-08T21:37:43 https://maestrodatabase.com/blog/report-calls-for-european-funding-reform-for-gene-therapies 2019-07-08T21:27:17 https://maestrodatabase.com/blog/speaker-pelosi-seize-the-moment-to-make-history-on-drug-pricing 2019-07-08T21:24:15 https://maestrodatabase.com/blog/stakeholders-want-clearer-terms-in-fdas-generally-accepted-scientific-knowledge-guidance 2023-08-01T01:30:08 https://maestrodatabase.com/blog/smc---july-2019-decisions 2019-07-08T21:19:43 https://maestrodatabase.com/blog/cheaper-medicines-legislation-passed 2022-10-27T03:45:31 https://maestrodatabase.com/blog/2019-april-price-disclosure-cycle---indicative-prices 2019-01-18T03:42:10 https://maestrodatabase.com/blog/new-treatment-approved-for-patients-with-breast-cancer-in-scotland 2019-07-08T21:49:56 https://maestrodatabase.com/blog/itm-receives-fda-fast-track-designation-for-radionuclide-therapy-candidate-itm-11-lutetium-lu-177-edotreotide-in-neuroendocrine-tumours-gep-nets 2022-10-27T10:03:45 https://maestrodatabase.com/blog/us-fda-accepts-bristol-myers-squibbs-application-for-subcutaneous-nivolumab-nivolumab-and-hyaluronidase 2024-05-06T11:55:25 https://maestrodatabase.com/blog/doctors-slow-to-adopt-tech-tools-that-might-save-patients-money-on-drugs 2019-07-08T21:44:26 https://maestrodatabase.com/blog/santhera-and-reveragen-complete-nda-submission-to-fda-for-vamorolone-in-duchenne-muscular-dystrophy 2022-10-27T09:54:51 https://maestrodatabase.com/blog/merck-canada-and-the-pan-canadian-pharmaceutical-alliance-successfully-complete-negotiations-for-winrevair-sotatercept 2025-11-21T01:42:09 https://maestrodatabase.com/blog/ema-validates-bristol-myers-squibbs-application-for-opdivo-nivolumab-plus-yervoy-ipilimumab-for-the-first-line-treatment-of-adult-patients-with-microsatellite-instability-high-or-mismatch-repair-deficient-metastatic-colorectal-cancer 2024-05-06T11:51:49 https://maestrodatabase.com/blog/thousands-of-adults-with-chronic-lymphocytic-leukaemia-to-benefit-from-new-treatment-option 2019-01-18T11:31:03 https://maestrodatabase.com/blog/clovis-oncologys-rubraca-rucaparib-granted-fda-priority-review-for-advanced-prostate-cancer 2020-01-15T19:48:53 https://maestrodatabase.com/blog/china-unveils-pilot-group-buying-plan-to-cut-drug-prices 2019-01-18T03:51:04 https://maestrodatabase.com/blog/actelion-receives-complete-response-letter-from-u-dot-s-fda-for-opsumit-macitentan-supplemental-new-drug-application 2019-01-18T11:22:39 https://maestrodatabase.com/blog/nice-recommends-ibrance-and-lynparza-rejects-keytruda-and-xospata 2020-01-15T19:44:47 https://maestrodatabase.com/blog/thousands-to-benefit-as-pharmac-set-to-fund-better-diabetes-drugs 2020-01-15T20:01:21 https://maestrodatabase.com/blog/fda-grants-qidp-designation-for-kinnears-csa-131-drug-for-life-threatening-pseudomonas-bacterial-infections-in-cf 2023-08-01T02:38:41 https://maestrodatabase.com/blog/important-milestone-for-biotest-biologics-license-application-for-fibrinogen-submitted-to-the-us-fda 2025-01-12T22:49:25 https://maestrodatabase.com/blog/immunomedics-receives-complete-response-letter-from-fda-for-sacituzumab-govitecan-biologics-license-application 2019-01-18T11:34:14 https://maestrodatabase.com/blog/reducing-the-expert-halo-effect-on-pharmacy-and-therapeutics-committees 2019-01-18T20:22:20 https://maestrodatabase.com/blog/global-sarcoma-therapy-now-listed-on-pharmaceutical-benefits-scheme 2023-08-01T02:25:44 https://maestrodatabase.com/blog/lilly-reports-results-of-phase-3-soft-tissue-sarcoma-study-of-lartruvo 2019-01-18T20:07:13 https://maestrodatabase.com/blog/differences-in-health-technology-assessment-recommendations-among-european-jurisdictions-the-role-of-practice-variations 2020-01-15T20:08:11 https://maestrodatabase.com/blog/canadas-drug-pricing-regulator-brings-rare-allegation-of-excessive-pricing-against-horizon-pharma 2019-01-18T20:36:43 https://maestrodatabase.com/blog/patient-groups-fail-to-declare-financial-interests-during-nice-assessments 2019-01-18T20:29:50 https://maestrodatabase.com/blog/nice-ok-for-bravtovi-skin-cancer-drug 2019-01-18T20:47:45 https://maestrodatabase.com/blog/marinus-pharmaceuticals-announces-european-commission-approval-of-ztalmy-ganaxolone-for-the-adjunctive-treatment-of-epileptic-seizures-associated-with-cdkl5-deficiency-disorder 2023-08-01T02:59:45 https://maestrodatabase.com/blog/european-medicines-agency-accepts-marketing-authorisation-application-for-cinfa-biotechs-pegfilgrastim-biosimilar-b12019-for-review 2017-10-07T10:46:49 https://maestrodatabase.com/blog/prescription-drug-companies-are-raising-prices-on-older-medicines 2019-01-18T20:57:46 https://maestrodatabase.com/blog/trump-administration-proposes-higher-obamacare-premiums 2019-01-18T20:44:03 https://maestrodatabase.com/blog/neurocrine-announces-fda-approval-of-80-mg-ingrezza-valbenazine-capsules-for-the-treatment-of-adults-with-tardive-dyskinesia 2017-10-07T11:04:34 https://maestrodatabase.com/blog/2-000-people-to-benefit-from-medicine-for-osteoporosis-and-people-with-high-blood-calcium-and-cancer 2025-01-12T23:42:15 https://maestrodatabase.com/blog/taiho-oncology-taiho-pharmaceutical-and-cullinan-therapeutics-initiate-rolling-submission-of-new-drug-application-to-us-fda-for-zipalertinib-for-treatment-of-locally-advanced-or-metastatic-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations 2025-11-21T03:50:39 https://maestrodatabase.com/blog/avrobio-receives-rare-paediatric-disease-designation-from-the-us-fda-for-first-in-class-gene-therapy-for-gaucher-disease 2022-10-27T19:27:57 https://maestrodatabase.com/blog/ema-review-of-zinbryta-confirms-medicines-risks-outweigh-its-benefits 2018-05-18T23:17:33 https://maestrodatabase.com/blog/mannkind-receives-us-fda-fast-track-designation-for-clofazimine-inhalation-suspension-for-the-treatment-of-non-tuberculous-mycobacterial-lung-disease 2024-05-06T23:09:51 https://maestrodatabase.com/blog/leukaemia-patients-to-get-access-to-abbvies-venclyxto-via-cancer-drugs-fund 2017-10-07T22:33:54 https://maestrodatabase.com/blog/fda-approves-pembrolizumab-with-enfortumab-vedotin-ejfv-for-muscle-invasive-bladder-cancer 2025-11-21T20:50:31 https://maestrodatabase.com/blog/mylan-in-partnership-with-synthon-receives-marketing-authorisation-approval-in-europe-for-first-generic-for-copaxone-40-mg-slash-ml 2017-10-07T22:43:28 https://maestrodatabase.com/blog/pmprb-finds-ultra-rare-drug-procysbi-is-excessively-priced 2022-10-27T19:49:20 https://maestrodatabase.com/blog/f-dot-d-a-approves-first-drug-designed-to-prevent-migraines 2018-05-18T23:22:28 https://maestrodatabase.com/blog/athersys-to-present-at-2017-cell-and-gene-meeting-on-the-mesa-and-announces-regenerative-medicine-advanced-therapy-designation-from-fda 2017-10-08T03:52:14 https://maestrodatabase.com/blog/msds-zerbaxa-becomes-koreas-newest-antibiotic-to-receive-reimbursement 2022-10-27T19:45:12 https://maestrodatabase.com/blog/adynxx-completes-enrolment-in-adyx-004-a-phase-2-study-of-brivoligide-lead-compound-for-the-treatment-of-post-surgical-pain 2017-10-08T04:14:26 https://maestrodatabase.com/blog/remedy-for-high-drug-costs-let-medicare-negotiate 2018-05-18T23:38:54 https://maestrodatabase.com/blog/fda-looking-at-ways-to-include-price-info-in-drug-ads-gottlieb-says-as-questions-loom 2018-05-18T23:41:40 https://maestrodatabase.com/blog/doctors-in-canada-and-us-call-for-fundamental-reform-on-prescription-drug-prices 2018-05-18T23:32:43 https://maestrodatabase.com/blog/health-technology-assessment-review---frequently-asked-questions 2022-10-27T20:29:05 https://maestrodatabase.com/blog/how-a-migraine-drug-is-easing-the-headache-of-high-prices 2018-05-18T23:35:56 https://maestrodatabase.com/blog/fda-continues-to-advance-medicines-for-children 2022-10-27T20:13:45 https://maestrodatabase.com/blog/turnbull-government-subsidy-gives-hope-to-cancer-sufferers 2017-10-08T19:12:33 https://maestrodatabase.com/blog/evidence-based-drug-delivery-for-rare-diseases-the-role-of-digitisation 2022-10-27T20:19:20 https://maestrodatabase.com/blog/supercharged-gardasil-cervical-cancer-vaccine-provides-extra-protection-for-teens 2017-10-08T19:17:32 https://maestrodatabase.com/blog/drug-maker-raises-the-price-of-an-old-chemo-medicine-tenfold-amid-persistent-shortages 2022-10-27T20:03:24 https://maestrodatabase.com/blog/decision-to-widen-access-to-rituximab-for-people-with-b-cell-acute-lymphoblastic-leukaemia-slash-lymphoma 2021-07-19T03:09:23 https://maestrodatabase.com/blog/samsung-bioepis-biosimilar-to-roches-herceptin-wins-fda-nod 2019-01-19T01:12:41 https://maestrodatabase.com/blog/international-collaboration-provides-new-guidance-on-the-use-of-surrogate-endpoints-in-cost-effectiveness-analysis 2025-01-13T01:57:18 https://maestrodatabase.com/blog/marstacimab-for-the-treatment-of-patients-12-years-of-age-and-older-with-severe-haemophilia-a-or-severe-haemophilia-b 2025-01-13T01:45:40 https://maestrodatabase.com/blog/fda-accepts-new-drug-application-submission-for-cosmo-pharmaceuticals-rifamycin-sv-mmx-and-sets-pdufa-date 2018-05-19T03:05:11 https://maestrodatabase.com/blog/gsks-shingrix-new-pre-filled-syringe-presentation-accepted-for-review-by-us-fda 2025-01-13T03:27:16 https://maestrodatabase.com/blog/merus-announces-us-fda-acceptance-and-priority-review-of-biologics-license-application-for-zenocutuzumab-for-the-treatment-of-nrg1-positive-nsclc-and-pdac 2024-05-06T23:47:38 https://maestrodatabase.com/blog/bayer-submits-application-to-us-fda-and-to-chinas-cde-for-new-indication-of-finerenone-for-patients-with-common-form-of-heart-failure-with-high-unmet-medical-need 2025-01-13T03:12:55 https://maestrodatabase.com/blog/imfinzi-approved-in-china-for-the-treatment-of-extensive-stage-small-cell-lung-cancer 2021-07-19T06:34:46 https://maestrodatabase.com/blog/lokelma-approved-in-the-us-for-the-treatment-of-adults-with-hyperkalaemia 2018-05-19T14:27:40 https://maestrodatabase.com/blog/myeloid-therapeutics-announces-fda-fast-track-designation-for-mt-101-for-the-treatment-of-cd5-positive-relapsed-slash-refractory-ptcl 2022-10-27T23:18:41 https://maestrodatabase.com/blog/datopotamab-deruxtecan-granted-priority-review-in-the-us-for-patients-with-previously-treated-advanced-egfr-mutated-non-small-cell-lung-cancer 2025-01-13T07:03:06 https://maestrodatabase.com/blog/pharmac-ensuring-supply-of-prednisolone-to-treat-children-with-respiratory-conditions 2021-07-19T07:23:47 https://maestrodatabase.com/blog/alnylams-attr-cardiomyopathy-drug-backed-for-nhs-use 2025-11-21T21:52:50 https://maestrodatabase.com/blog/lilly-and-incyte-provide-update-on-supplemental-new-drug-application-for-baricitinib-for-the-treatment-of-moderate-to-severe-atopic-dermatitis 2021-07-19T07:27:21 https://maestrodatabase.com/blog/decision-to-fund-rasagiline 2021-07-19T07:10:32 https://maestrodatabase.com/blog/abbvie-provides-update-regarding-rinvoq-upadacitinib-for-the-treatment-of-moderate-to-severe-atopic-dermatitis-in-the-u-dot-s 2021-07-19T07:18:03 https://maestrodatabase.com/blog/smc-approval-welcome-news-for-breast-cancer-patients 2022-03-09T19:35:24 https://maestrodatabase.com/blog/insightec-receives-fda-ide-approval-and-breakthrough-designation-for-nsclc-brain-mets-study 2022-03-09T19:50:15 https://maestrodatabase.com/blog/health-canada-approves-rebinyn-coagulation-factor-ix-recombinant-pegylated-for-the-treatment-of-routine-prophylaxis-to-prevent-or-reduce-frequency-of-bleeding-episodes-in-children-with-haemophilia-b 2022-10-28T01:18:55 https://maestrodatabase.com/blog/time-to-ask-companies-why-they-dont-submit-to-nice 2022-03-09T19:58:51 https://maestrodatabase.com/blog/sangamo-therapeutics-announces-fda-acceptance-of-bla-rolling-submission-request-for-st-920-in-fabry-disease 2025-11-21T23:38:31 https://maestrodatabase.com/blog/bayer-submits-applications-in-the-u-dot-s-and-eu-for-additional-indication-of-nubeqa-darolutamide 2022-03-09T19:41:09 https://maestrodatabase.com/blog/janssen-seeks-expanded-use-of-spravato-esketamine-nasal-spray-in-europe-as-a-treatment-for-depressive-symptoms-in-adults-with-major-depressive-disorder-who-have-current-suicidal-ideation-with-intent 2020-01-16T01:09:51 https://maestrodatabase.com/blog/cimzia-certolizumab-pegol-now-approved-in-canada-for-the-treatment-of-non-radiographic-axial-spondyloarthritis 2020-01-16T01:19:44 https://maestrodatabase.com/blog/empagliflozin-for-treating-chronic-heart-failure-with-reduced-ejection-fraction 2022-03-09T20:25:34 https://maestrodatabase.com/blog/dapagliflozin-for-treating-chronic-kidney-disease 2022-03-09T20:34:52 https://maestrodatabase.com/blog/novavax-granted-fast-track-designation-for-nanoflu-in-older-adults 2020-01-16T01:24:24 https://maestrodatabase.com/blog/peters-prostate-cancer-diagnosis-came-as-a-shock-now-he-wants-to-protect-his-kids 2025-01-13T21:09:16 https://maestrodatabase.com/blog/zanubrutinib-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia 2023-08-01T06:20:16 https://maestrodatabase.com/blog/pharmac-considers-access-criteria-for-covid-19-anti-viral-treatments 2023-08-01T06:27:22 https://maestrodatabase.com/blog/march-2017-pbs-schedule 2017-02-15T02:54:49 https://maestrodatabase.com/blog/proposed-changes-to-accessing-unapproved-therapeutic-goods-through-the-authorised-prescriber-and-special-access-schemes 2017-02-15T05:11:32 https://maestrodatabase.com/blog/amgen-submits-supplemental-biologics-license-application-for-blincyto-blinatumomab-in-relapsed-or-refractory-b-cell-precursor-acute-lymphoblastic-leukaemia 2017-02-15T05:18:56 https://maestrodatabase.com/blog/larotrectinib-in-tumours-with-ntrk-gene-fusion-data-are-not-yet-sufficient-for-derivation-of-an-added-benefit 2020-01-16T02:00:34 https://maestrodatabase.com/blog/quality-of-life-overall-survival-and-costs-of-cancer-drugs-approved-based-on-surrogate-outcomes 2017-02-15T04:02:18 https://maestrodatabase.com/blog/g1-therapeutics-receives-fast-track-designation-from-u-dot-s-food-and-drug-administration-for-cosela-trilaciclib-in-combination-with-chemotherapy-for-the-treatment-of-locally-advanced-or-metastatic-triple-negative-breast-cancer 2021-07-19T21:07:06 https://maestrodatabase.com/blog/bluerock-therapeutics-receives-fda-fast-track-designation-for-da01-in-the-treatment-of-advanced-parkinsons-disease 2021-07-19T12:32:27 https://maestrodatabase.com/blog/former-fda-chief-cites-5-things-to-watch-on-drug-approvals-and-keeping-drugs-safe 2017-02-15T05:38:27 https://maestrodatabase.com/blog/drug-regulators-remain-united-on-covid-19-says-eu-agency-boss 2020-07-19T02:52:58 https://maestrodatabase.com/blog/ema-starts-evaluating-the-use-of-kineret-in-adult-covid-19-patients-at-increased-risk-of-severe-respiratory-failure 2021-07-19T09:14:36 https://maestrodatabase.com/blog/axsome-therapeutics-receives-fda-fast-track-designation-for-axs-05-for-treatment-resistant-depression 2017-02-15T05:45:05 https://maestrodatabase.com/blog/generic-and-biosimilar-manufacturers-launch-new-brand-and-campaign-to-expand-access-to-medicines 2017-02-15T06:09:58 https://maestrodatabase.com/blog/making-sense-of-the-fdas-indefensible-decision-to-approve-aduhelm 2021-07-19T11:33:06 https://maestrodatabase.com/blog/nevro-announces-fda-approval-of-its-10-khz-high-frequency-spinal-cord-stimulation-therapy-for-treatment-of-chronic-pain-associated-with-painful-diabetic-neuropathy 2021-07-19T21:21:13 https://maestrodatabase.com/blog/aquestive-therapeutics-announces-fda-acceptance-of-new-drug-application-resubmission-for-libervant-diazepam-buccal-film 2021-07-19T21:13:07 https://maestrodatabase.com/blog/gilead-receives-complete-response-letter-from-us-fda-for-bulevirtide-for-the-treatment-of-adults-with-hepatitis-delta-virus 2022-10-28T03:14:51 https://maestrodatabase.com/blog/tga-provisionally-approves-pfizer-bivalent-covid-19-vaccine-for-use-as-a-booster-dose-in-adults 2022-10-28T02:58:08 https://maestrodatabase.com/blog/endologix-receives-fda-breakthrough-device-designation-for-chevas-system 2021-07-19T21:17:01 https://maestrodatabase.com/blog/foundation-medicine-expands-indication-for-foundationone-liquid-cdx-to-be-used-as-a-companion-diagnostic-for-tabrecta-capmatinib 2021-07-19T21:40:21 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-to-spinogenixs-spg601-for-treatment-of-fragile-x-syndrome-a-common-inherited-form-of-autism 2025-01-13T23:17:37 https://maestrodatabase.com/blog/public-summary-documents---july-2022-pbac-meeting 2022-10-28T05:06:38 https://maestrodatabase.com/blog/private-health-insurance-rises-prompt-launch-of-tool-aimed-at-reducing-costs 2017-02-15T19:56:34 https://maestrodatabase.com/blog/nice-publishes-draft-guidance-for-venclyxto 2017-02-15T20:10:16 https://maestrodatabase.com/blog/humana-plans-to-pull-out-of-obamacares-insurance-exchanges 2017-02-15T11:03:06 https://maestrodatabase.com/blog/u-dot-s-targets-drug-pricing-no-poach-deals-for-anti-trust-action-in-2020 2020-01-16T08:43:13 https://maestrodatabase.com/blog/will-cms-find-aducanumab-reasonable-and-necessary-for-alzheimer-disease-after-fda-approval 2021-07-19T21:30:41 https://maestrodatabase.com/blog/nice-rejects-alexions-rare-disease-therapy-kanuma 2017-02-15T20:25:19 https://maestrodatabase.com/blog/drug-makers-riled-amid-calls-for-yearly-review-of-drug-costs 2017-02-15T20:31:27 https://maestrodatabase.com/blog/pharma-industry-shuns-trump-push-for-radical-shift-at-fda 2017-02-15T20:18:14 https://maestrodatabase.com/blog/prices-of-ms-medications-keep-soaring 2020-01-16T08:33:10 https://maestrodatabase.com/blog/tga-approves-provisional-determination-for-biocelect-for-covid-19-vaccine-nuvaxovid 2022-03-09T23:45:30 https://maestrodatabase.com/blog/ryan-faces-major-test-in-selling-obamacare-repeal-and-replacement 2017-02-15T20:21:31 https://maestrodatabase.com/blog/cms-proposes-rule-to-increase-price-transparency-access-to-care-safety-and-health-equity 2021-07-19T21:34:55 https://maestrodatabase.com/blog/europe-ready-to-embrace-first-copies-of-biotech-cancer-drugs 2017-02-15T20:36:13 https://maestrodatabase.com/blog/iecure-receives-fda-fast-track-designation-for-ecur-506-for-the-treatment-of-neonatal-onset-ornithine-transcarbamylase-deficiency 2024-05-07T13:11:00 https://maestrodatabase.com/blog/azurity-pharmaceuticals-announces-fda-approval-of-myhibbin-mycophenolate-mofetil-oral-suspension 2024-05-07T13:07:31 https://maestrodatabase.com/blog/fda-approves-new-psoriasis-drug 2017-02-15T23:50:11 https://maestrodatabase.com/blog/fda-regulation-of-prescription-drugs 2017-02-15T23:59:50 https://maestrodatabase.com/blog/adaptimmune-announces-us-fda-breakthrough-therapy-designation-granted-to-letetresgene-autoleucel-for-treatment-of-myxoid-slash-round-cell-liposarcoma 2025-01-14T00:23:52 https://maestrodatabase.com/blog/nice-ok-for-lynparza 2020-01-16T10:36:02 https://maestrodatabase.com/blog/european-medicines-agency-validates-viiv-healthcares-marketing-authorisation-application-for-cabotegravir-long-acting-injectable-for-hiv-prevention 2022-10-28T10:18:00 https://maestrodatabase.com/blog/us-purchases-world-stocks-of-remdesivir-why-the-rest-of-the-world-should-be-glad-to-be-at-the-back-of-the-queue 2020-07-19T21:23:41 https://maestrodatabase.com/blog/trump-rule-requiring-drug-prices-in-tv-ads-blocked 2019-07-09T06:02:11 https://maestrodatabase.com/blog/advanced-therapy-medicinal-products-regulations-in-the-eu 2020-07-19T21:26:40 https://maestrodatabase.com/blog/nektar-issues-statement-regarding-fda-advisory-committee-vote-for-oxycodegol 2020-01-16T10:48:23 https://maestrodatabase.com/blog/gsk-marketing-authorisation-application-for-respiratory-syncytial-virus-older-adult-vaccine-candidate-accepted-by-european-medicines-agency-under-accelerated-assessment 2022-10-28T10:15:42 https://maestrodatabase.com/blog/tg-therapeutics-initiates-rolling-submission-of-new-drug-application-to-u-dot-s-fda-for-umbralisib-as-a-treatment-for-patients-with-previously-treated-marginal-zone-lymphoma-or-follicular-lymphoma 2020-01-16T20:25:18 https://maestrodatabase.com/blog/epilepsy-deaths-level-of-risk-in-medication-brand-switch-unclear-study-says 2020-01-16T20:18:16 https://maestrodatabase.com/blog/health-is-more-important-than-ever-for-aussies 2020-07-19T20:54:50 https://maestrodatabase.com/blog/pbac-asks-roche-for-another-comparison-for-tecentriq 2020-07-19T20:57:11 https://maestrodatabase.com/blog/requiring-prices-in-drug-ads-would-it-do-any-good-is-it-even-legal 2018-05-20T11:25:20 https://maestrodatabase.com/blog/withdrawal-from-the-drug-benefits-on-1-february-2020 2020-01-16T20:45:42 https://maestrodatabase.com/blog/abbvie-announces-submissions-of-regulatory-applications-for-epcoritamab-duobody-cd3xcd20-for-the-treatment-of-relapsed-slash-refractory-diffuse-large-b-cell-lymphoma-and-large-b-cell-lymphoma 2022-10-28T20:22:53 https://maestrodatabase.com/blog/breast-cancer-specialists-throw-their-weight-behind-long-running-fight-for-increased-government-drug-funding 2019-07-09T06:49:14 https://maestrodatabase.com/blog/eqrx-wants-to-make-high-end-medicines-less-costly 2020-01-16T20:39:03 https://maestrodatabase.com/blog/car-t-cell-therapy-breyanzi-lisocabtagene-maraleucel-approved-for-second-line-relapsed-or-refractory-diffuse-large-b-cell-lymphoma 2025-01-14T01:41:40 https://maestrodatabase.com/blog/3l-5l-what-the-l-a-nice-conundrum 2018-05-20T01:15:11 https://maestrodatabase.com/blog/fda-to-speed-review-of-generic-versions-of-opioid-overdose-antidote 2019-07-09T06:42:34 https://maestrodatabase.com/blog/pharma-execs-pitch-ideas-at-jpm20-to-lower-drug-costs-none-of-them-include-dropping-their-own-prices 2020-01-16T20:34:46 https://maestrodatabase.com/blog/students-join-push-for-lifesaving-drug-after-young-siblings-both-diagnosed-with-cystic-fibrosis 2018-05-20T21:02:14 https://maestrodatabase.com/blog/why-canada-wont-end-up-as-the-drugstore-to-the-u-dot-s 2020-01-16T20:52:42 https://maestrodatabase.com/blog/fda-accepts-leqembi-lecanemab-irmb-biologics-license-application-for-subcutaneous-maintenance-dosing-for-the-treatment-of-early-alzheimers-disease 2025-01-14T01:16:51 https://maestrodatabase.com/blog/asfotase-alfa-in-hypophosphatasia-in-children-and-adolescents-survival-advantage-for-small-children 2020-01-16T20:49:34 https://maestrodatabase.com/blog/drug-prices-drive-many-americans-to-black-market-for-medicines 2018-05-20T21:10:13 https://maestrodatabase.com/blog/ema-recommends-measures-to-minimise-risk-of-serious-side-effects-with-janus-kinase-inhibitors-for-chronic-inflammatory-disorders 2022-10-28T20:43:59 https://maestrodatabase.com/blog/first-patient-begins-newly-approved-sickle-cell-gene-therapy 2024-05-08T01:39:40 https://maestrodatabase.com/blog/innovent-receives-nmpa-breakthrough-therapy-designation-for-ibi34-anti-claudin18-dot-2-antibody-drug-conjugate-as-monotherapy-for-advanced-gastric-cancer 2024-05-07T23:38:07 https://maestrodatabase.com/blog/lokon-pharma-receives-fda-fast-track-designation-for-load703-for-the-treatment-of-pancreatic-cancer 2025-01-14T02:03:03 https://maestrodatabase.com/blog/outlook-therapeutics-announces-acceptance-of-biologics-license-application-by-fda-for-ons-5010-as-a-treatment-for-wet-amd 2025-11-14T09:47:52 https://maestrodatabase.com/blog/when-desperate-patients-go-to-court-for-unproven-treatments---the-battle-for-hospital-independence 2022-03-10T03:53:06 https://maestrodatabase.com/blog/filing-of-humanised-anti-cd20-monoclonal-antibody-gazyva-for-additional-indication-of-chronic-lymphocytic-leukaemia 2022-03-10T04:07:53 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-10-march-2022 2022-03-10T03:45:55 https://maestrodatabase.com/blog/design-and-features-of-pricing-and-payment-schemes-for-health-technologies-a-scoping-review-and-a-proposal-for-a-flexible-need-driven-classification 2025-01-14T03:04:35 https://maestrodatabase.com/blog/legislation-would-set-expiration-for-fdas-accelerated-approvals 2022-03-10T04:33:41 https://maestrodatabase.com/blog/botulinum-toxin-for-spasticity-a-case-for-change-to-the-pharmaceutical-benefits-scheme 2018-05-21T04:04:35 https://maestrodatabase.com/blog/thirty-six-medicines-added-to-pharmacs-waiting-list-as-new-zealands-medicines-crisis-worsens 2022-03-10T04:36:16 https://maestrodatabase.com/blog/august-2018-pbac-special-meeting---invitation-for-submissions-open-and-background-paper-available 2018-05-21T04:16:12 https://maestrodatabase.com/blog/pegcetacoplan-for-treating-paroxysmal-nocturnal-haemoglobinuria 2022-03-10T04:14:53 https://maestrodatabase.com/blog/flu-vaccine-supply-shortfall-triggered-by-unprecedented-demand 2018-05-21T04:09:26 https://maestrodatabase.com/blog/landmark-pbs-listing-for-australians-with-bowel-cancer 2021-07-20T03:17:35 https://maestrodatabase.com/blog/clinical-trial-national-approach-will-benefit-patients-and-our-economy 2021-07-20T03:14:55 https://maestrodatabase.com/blog/us-fda-defers-action-on-filing-for-at-gaa-in-late-onset-pompe-disease 2022-10-28T22:30:06 https://maestrodatabase.com/blog/draft-report-for-the-post-market-review-of-medicines-for-pulmonary-arterial-hypertension 2018-05-21T04:20:54 https://maestrodatabase.com/blog/revance-resubmits-biologics-license-application-for-daxibotulinumtoxina-for-injection-for-glabellar-lines-to-the-fda 2022-03-10T10:24:00 https://maestrodatabase.com/blog/almirall-receives-european-commission-approval-of-klisyri-tirbanibulin-an-innovative-topical-treatment-for-actinic-keratosis 2021-07-20T03:03:08 https://maestrodatabase.com/blog/pharmac-proposes-funding-another-adhd-medicine-to-improve-supply 2025-11-22T21:47:54 https://maestrodatabase.com/blog/ardelyx-provides-regulatory-update-on-new-drug-application-for-tenapanor-for-the-control-of-serum-phosphorus-in-adult-patients-with-ckd-on-dialysis 2021-07-20T03:08:57 https://maestrodatabase.com/blog/streamlining-proprietary-ingredient-categories 2021-07-20T05:10:41 https://maestrodatabase.com/blog/aarp-launches-new-ad-showing-the-impact-of-congress-failure-to-act-on-prescription-drug-prices 2022-03-10T19:49:42 https://maestrodatabase.com/blog/servier-submits-a-marketing-authorisation-application-to-the-ema-for-tibsovo-ivosidenib-for-patients-with-idh1-mutated-acute-myeloid-leukaemia-and-cholangiocarcinoma 2022-03-10T19:55:28 https://maestrodatabase.com/blog/albireo-receives-european-marketing-authorisation-of-bylvay-odevixibat-the-first-drug-treatment-for-progressive-familial-intrahepatic-cholestasis 2021-07-20T05:15:25 https://maestrodatabase.com/blog/selinexor-with-dexamethasone-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma-after-4-or-more-treatments 2024-05-08T04:35:23 https://maestrodatabase.com/blog/reimbursement-from-pharmaceutical-companies-decreases-by-288-million 2020-12-13T19:53:51 https://maestrodatabase.com/blog/how-will-reimbursement-for-tecentriq-in-liver-cancer-affect-biosimilars 2022-03-10T10:38:37 https://maestrodatabase.com/blog/smc-accepts-lumykras-sotorasib-for-locally-advanced-or-metastatic-non-small-cell-lung-cancer-for-use-on-an-interim-basis-by-nhs-scotland 2022-03-10T10:42:24 https://maestrodatabase.com/blog/though-promising-gene-therapies-face-durability-and-reimbursement-headwinds 2020-12-13T20:22:11 https://maestrodatabase.com/blog/seagen-announces-positive-chmp-opinion-for-tukysa-tucatinib-for-the-treatment-of-patients-with-locally-advanced-or-metastatic-her2-positive-breast-cancer 2020-12-13T20:46:13 https://maestrodatabase.com/blog/health-canada-approves-samsung-bioepis-and-biogens-byooviz-sb11-lucentis-biosimilar-ranibizumab 2022-03-10T20:10:42 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-positive-chmp-opinion-for-inrebic-fedratinib-for-adult-patients-with-newly-diagnosed-and-previously-treated-myelofibrosis 2020-12-13T20:51:37 https://maestrodatabase.com/blog/ronapreve-first-covid-19-therapeutic-drug-to-get-medsafes-approval-not-effective-against-omicron 2022-03-10T20:26:36 https://maestrodatabase.com/blog/pitolisant-hydrochloride-for-treating-excessive-daytime-sleepiness-caused-by-obstructive-sleep-apnoea 2022-03-10T20:04:55 https://maestrodatabase.com/blog/first-coronavirus-vaccines-head-to-states-starting-historic-effort 2020-12-13T20:01:02 https://maestrodatabase.com/blog/avidity-biosciences-receives-fda-breakthrough-therapy-designation-for-delpacibart-etedesiran-aoc-1001-for-treatment-of-myotonic-dystrophy-type-1 2024-05-08T23:14:13 https://maestrodatabase.com/blog/us-fda-approves-fexinidazole-as-the-first-all-oral-treatment-for-sleeping-sickness 2021-07-20T05:21:40 https://maestrodatabase.com/blog/walgreens-statement-regarding-fda-emergency-use-authorisation-of-covid-19-vaccine 2020-12-13T20:06:57 https://maestrodatabase.com/blog/japan-becomes-first-country-to-approve-regeneron-antibody-cocktail-casirivimab-and-imdevimab-for-the-treatment-of-mild-to-moderate-covid-19 2021-07-20T05:27:17 https://maestrodatabase.com/blog/qualitative-comparative-analysis-of-health-economic-evaluation-guidelines-for-health-technology-assessment-in-european-countries 2020-12-13T20:12:02 https://maestrodatabase.com/blog/changes-in-the-number-of-continuation-patents-on-drugs-approved-by-the-fda 2023-08-02T08:45:56 https://maestrodatabase.com/blog/pyc-therapeutics-gets-fast-track-status-from-fda-for-retinitis-pigmentosa-treatment 2023-08-02T08:48:32 https://maestrodatabase.com/blog/upadacitinib-in-active-crohns-disease-no-additional-benefit-proven-due-to-a-lack-of-comparative-studies 2023-08-02T07:14:59 https://maestrodatabase.com/blog/nice-onpattro-approval-puts-alnylam-back-in-hattr-running 2019-07-09T10:57:01 https://maestrodatabase.com/blog/the-fragility-of-phase-3-trials-supporting-fda-approved-anti-cancer-medicines-a-retrospective-analysis 2019-07-09T10:52:09 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-to-arena-pharmaceuticals-apd418-for-development-in-decompensated-heart-failure-patients 2020-01-16T23:42:27 https://maestrodatabase.com/blog/solriamfetol-for-treating-excessive-daytime-sleepiness-caused-by-obstructive-sleep-apnoea 2022-03-10T20:31:55 https://maestrodatabase.com/blog/ganaxolone-for-the-treatment-of-patients-with-seizures-caused-by-cdkl5-deficiency-disorder 2023-08-02T10:06:10 https://maestrodatabase.com/blog/uk-launches-subscription-style-payment-pilot-to-incentivise-pharma-antibiotics-r-and-d 2019-07-09T11:05:11 https://maestrodatabase.com/blog/white-house-proposes-new-rules-to-steady-insurance-markets-under-health-law 2017-02-16T20:11:37 https://maestrodatabase.com/blog/pharmacists-v-doctors-fiery-prescription-debate-rages-in-wa 2019-07-09T21:11:38 https://maestrodatabase.com/blog/why-drug-companies-dont-want-president-trump-to-deregulate-the-fda 2017-02-16T20:14:14 https://maestrodatabase.com/blog/pharma-giant-using-loophole-to-falsely-promote-opioid-pain-relief-product-across-australia 2019-07-09T21:06:51 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-biologics-license-application-for-mylan-and-biocons-proposed-biosimilar-pegfilgrastim-for-review 2017-02-16T19:59:44 https://maestrodatabase.com/blog/families-lawmakers-demand-transparency-for-89-000-dollars-drug 2017-02-16T20:33:14 https://maestrodatabase.com/blog/pharmac-has-spent-tens-of-millions-on-oxycontin-blamed-for-americas-opioid-crisis 2019-07-09T21:01:40 https://maestrodatabase.com/blog/pressed-on-drug-prices-nominee-to-head-medicare-and-medicaid-praises-competition 2017-02-16T20:36:34 https://maestrodatabase.com/blog/aetna-chief-executive-says-obamacare-is-in-a-death-spiral 2017-02-16T20:17:02 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-lists-potential-topics-for-assessments-in-2020 2019-07-09T20:56:35 https://maestrodatabase.com/blog/kyowa-kirin-announces-eu-approval-for-the-self-administration-of-crysvita-burosumab-to-treat-x-linked-hypophosphataemia 2021-07-20T06:07:01 https://maestrodatabase.com/blog/ceo-under-fire-for-89-000-dollars-drug-has-a-history-of-steep-price-hikes 2017-02-16T20:29:47 https://maestrodatabase.com/blog/time-for-a-change-in-how-new-antibiotics-are-reimbursed-development-of-an-insurance-framework-for-funding-new-antibiotics-based-on-a-policy-of-risk-mitigation 2017-10-09T06:35:43 https://maestrodatabase.com/blog/australian-covid-researchers-warn-vaccines-will-have-to-be-made-overseas 2020-07-20T07:13:21 https://maestrodatabase.com/blog/fda-accepts-mercks-supplemental-biologics-license-applications-for-keytruda-pembrolizumab-six-week-dosing-schedule-for-melanoma-and-multiple-other-indications 2019-07-09T21:21:54 https://maestrodatabase.com/blog/pbs-listing-opens-up-a-new-medication-era-for-leukaemia-patients 2017-10-09T06:42:42 https://maestrodatabase.com/blog/give-paediatric-cancer-sufferers-the-help-they-need 2018-05-21T20:49:26 https://maestrodatabase.com/blog/fda-approves-trifluridine-and-tipiracil-with-bevacizumab-for-previously-treated-metastatic-colorectal-cancer 2023-08-02T20:21:29 https://maestrodatabase.com/blog/fda-leverages-private-sector-technology-based-tools-in-its-embrace-of-real-world-evidence 2019-07-09T21:18:15 https://maestrodatabase.com/blog/fda-approves-new-drug-for-patients-with-chronic-liver-disease-who-have-low-blood-platelets-and-are-undergoing-a-medical-procedure 2018-05-21T20:52:21 https://maestrodatabase.com/blog/etranacogene-dezaparvovec-for-the-treatment-of-patients-with-moderately-severe-or-severe-haemophilia-b 2023-08-02T11:17:50 https://maestrodatabase.com/blog/amazing-gene-silencing-drugs-reach-nhs 2019-07-09T21:36:05 https://maestrodatabase.com/blog/viiv-healthcare-announces-start-of-first-ever-study-to-identify-and-evaluate-approaches-to-implementing-its-once-monthly-injectable-hiv-treatment-in-clinical-practice 2019-07-09T21:30:34 https://maestrodatabase.com/blog/updates-from-the-health-technology-assessment-policy-and-methods-review-reference-committee-july-2023 2023-08-02T10:11:30 https://maestrodatabase.com/blog/gsk-welcomes-the-uk-trial-of-subscription-style-payment-system-for-pharma-companies-to-incentivise-creation-of-new-antibiotics 2019-07-09T21:27:58 https://maestrodatabase.com/blog/rare-disease-drove-two-women-on-a-mission-to-change-fda-drug-review-process 2020-07-20T10:14:02 https://maestrodatabase.com/blog/glenmark-pharmaceuticals-announces-the-companys-first-new-drug-application-for-ryaltris-for-patients-with-seasonal-allergic-rhinitis 2018-05-21T21:19:11 https://maestrodatabase.com/blog/cmss-international-pricing-model-for-medicare-part-b-drugs-implementation-issues 2019-07-09T21:39:46 https://maestrodatabase.com/blog/government-signs-deals-with-biontech-slash-pfizer-and-valneva-for-covid-vaccines 2020-07-20T09:56:28 https://maestrodatabase.com/blog/health-canada-approves-zoladex-la-for-the-management-of-oestrogen-receptor-positive-early-breast-cancer-with-a-high-risk-of-recurrence-or-advanced-breast-cancer-in-pre--and-peri-menopausal-women 2024-05-09T01:38:19 https://maestrodatabase.com/blog/orphazyme-completes-rolling-submission-of-new-drug-application-to-u-dot-s-fda-for-arimoclomol-for-niemann-pick-disease-type-c 2020-07-20T10:05:09 https://maestrodatabase.com/blog/icer-posts-draft-scoping-document-for-the-assessment-of-anaemia-in-chronic-kidney-disease-treatments 2020-07-20T20:46:53 https://maestrodatabase.com/blog/actemra-iv-tocilizumab-for-injection-receives-authorisation-for-additional-indication-from-health-canada-for-the-treatment-of-covid-19 2022-10-29T06:54:57 https://maestrodatabase.com/blog/acadia-pharmaceuticals-announces-u-dot-s-fda-accepted-for-filing-the-supplemental-new-drug-application-for-nuplazid-pimavanserin-for-the-treatment-of-hallucinations-and-delusions-associated-with-dementia-related-psychosis 2020-07-20T20:50:58 https://maestrodatabase.com/blog/private-patients-foot-the-bill-for-health-insurance-rebate-cuts 2017-10-09T10:07:51 https://maestrodatabase.com/blog/a-health-care-plan-thats-universal-and-bipartisan 2017-10-09T10:02:36 https://maestrodatabase.com/blog/european-medicines-agency---payer-community-meeting 2017-10-09T19:53:13 https://maestrodatabase.com/blog/government-adds-two-new-heart-disease-treatments-on-the-pbs 2024-05-09T02:19:10 https://maestrodatabase.com/blog/study-identifies-122-orthopaedic-surgeons-having-troubles 2017-10-09T19:46:03 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-treatment-for-anaemia-in-myelodysplastic-syndrome 2024-05-09T12:44:19 https://maestrodatabase.com/blog/ema-publishes-agenda-for-9-12-october-chmp-meeting 2017-10-09T19:56:44 https://maestrodatabase.com/blog/tagrisso-granted-breakthrough-therapy-designation-by-us-fda-for-the-first-line-treatment-of-patients-with-egfr-mutation-positive-non-small-cell-lung-cancer 2017-10-09T20:03:39 https://maestrodatabase.com/blog/cadth-publishes-final-recommendation-for-stelara 2020-07-20T21:06:09 https://maestrodatabase.com/blog/osmotica-pharmaceutical-announces-fda-user-fee-goal-date-of-29-december-2020-for-arbaclofen-extended-release-tablets 2020-07-20T20:58:20 https://maestrodatabase.com/blog/pharmac-secures-supply-of-vaccines-for-new-zealanders 2023-08-03T02:28:30 https://maestrodatabase.com/blog/almirall-announces-ema-acceptance-for-filing-of-marketing-authorisation-application-for-lebrikizumab-in-atopic-dermatitis 2022-10-29T07:01:53 https://maestrodatabase.com/blog/aspaveli-pegcetacoplan-approved-in-europe-for-use-among-treatment-naive-adult-patients-with-pnh 2024-05-09T05:41:42 https://maestrodatabase.com/blog/how-much-is-preventing-a-heart-attack-worth 2019-01-20T19:53:38 https://maestrodatabase.com/blog/trials-of-a-vaccine-and-new-drug-raise-hope-of-beating-covid-19 2020-07-20T21:31:41 https://maestrodatabase.com/blog/expensive-lung-cancer-drug-added-to-pbs 2019-01-20T19:48:42 https://maestrodatabase.com/blog/developing-nice-guidelines 2020-07-20T21:36:32 https://maestrodatabase.com/blog/janssen-seeks-approval-of-a-new-indication-for-imbruvica-ibrutinib-for-use-in-patients-with-untreated-mantle-cell-lymphoma 2022-03-11T01:30:48 https://maestrodatabase.com/blog/gene-therapy-shows-promise-for-haemophilia-but-could-be-most-expensive-u-dot-s-drug-ever 2020-07-20T21:10:49 https://maestrodatabase.com/blog/the-european-medicines-agency-accepts-marketing-authorisation-application-for-imfinzi-in-locally-advanced-unresectable-non-small-cell-lung-cancer 2017-10-09T20:15:48 https://maestrodatabase.com/blog/many-drug-companies-working-on-covid-19-vaccines-and-treatments-are-lobbying-harder-than-usual 2020-07-20T21:12:54 https://maestrodatabase.com/blog/grieving-families-lobby-parliament-to-reverse-epilepsy-drug-brand-switch 2020-07-20T21:17:12 https://maestrodatabase.com/blog/health-canada-authorises-tecvayli-teclistamab-injection-a-first-in-class-bispecific-antibody-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma 2023-08-03T02:56:41 https://maestrodatabase.com/blog/hls-therapeutics-welcomes-both-cadths-recommendation-to-reimburse-vascepa-icosapent-ethyl-for-patients-with-established-cardiovascular-disease-and-pmprbs-notification-on-its-introductory-price 2020-07-20T21:21:43 https://maestrodatabase.com/blog/pharmamar-has-filed-lurbinectedin-for-temporary-marketing-authorisation-with-the-swiss-agency-for-therapeutic-products 2020-07-21T07:15:51 https://maestrodatabase.com/blog/is-the-nhs-being-held-to-ransom-by-big-pharma 2017-10-09T20:32:41 https://maestrodatabase.com/blog/smc---october-2017-decisions 2017-10-09T20:43:42 https://maestrodatabase.com/blog/legal-fight-looms-with-new-california-drug-price-law 2017-10-09T20:39:38 https://maestrodatabase.com/blog/china-nmpa-accepts-nda-submission-of-ripretinib-for-advanced-gastro-intestinal-stromal-tumour 2020-07-21T06:48:37 https://maestrodatabase.com/blog/patients-in-scotland-first-to-get-new-blood-cancer-drug-daratumumab-on-nhs 2017-10-09T20:46:25 https://maestrodatabase.com/blog/viiv-healthcare-announces-positive-chmp-opinion-for-rukobia-fostemsavir-a-first-in-class-attachment-inhibitor-for-the-treatment-of-adults-with-multidrug-resistant-hiv-with-few-treatment-options-available 2020-12-13T23:50:15 https://maestrodatabase.com/blog/advicenne-receives-positive-chmp-opinion-recommending-approval-of-adv7103-sibnayal-for-the-treatment-of-distal-renal-tubular-acidosis 2020-12-14T00:56:38 https://maestrodatabase.com/blog/pharmac-covid-19-health-response-get-slice-of-302-dollars-million-fund 2020-07-21T07:23:26 https://maestrodatabase.com/blog/tga-publishes-auspar-for-vemlidy 2020-07-21T07:28:33 https://maestrodatabase.com/blog/immunomedics-submits-biologics-license-application-for-sacituzumab-govitecan-to-the-u-dot-s-food-and-drug-administration 2018-05-21T23:12:59 https://maestrodatabase.com/blog/pbs-botulinum-toxin-program-changes 2017-02-17T06:22:50 https://maestrodatabase.com/blog/trastuzumab-deruxtecan-recommended-for-approval-in-the-eu-by-chmp-for-her2-positive-metastatic-breast-cancer 2020-12-14T02:07:39 https://maestrodatabase.com/blog/qulipta-atogepant-now-approved-by-health-canada-for-the-preventive-treatment-of-chronic-migraine-in-adults 2024-05-10T01:04:11 https://maestrodatabase.com/blog/gilead-receives-approval-in-canada-for-odefsey-for-the-treatment-of-hiv-1-infection 2017-02-17T06:29:35 https://maestrodatabase.com/blog/fda-expands-approval-of-spriva-respimat-tiotropium-bromide-inhalation-spray-for-maintenance-treatment-of-asthma-in-children 2017-02-17T06:36:36 https://maestrodatabase.com/blog/ozempic-approved-in-the-us-for-cv-risk-reduction-in-people-with-type-2-diabetes-and-established-cvd 2020-01-17T02:44:20 https://maestrodatabase.com/blog/isturisa-osilodrostat-approved 2020-01-17T03:01:51 https://maestrodatabase.com/blog/white-house-weighs-resurrecting-key-drug-price-initiatives 2020-07-21T09:46:07 https://maestrodatabase.com/blog/janssen-receives-positive-chmp-opinion-for-spravato-esketamine-nasal-spray-for-the-rapid-reduction-of-depressive-symptoms-in-a-psychiatric-emergency-for-patients-with-major-depressive-disorder 2020-12-14T03:05:45 https://maestrodatabase.com/blog/merck-receives-positive-eu-chmp-opinion-for-keytruda-pembrolizumab-as-first-line-treatment-in-adult-patients-with-metastatic-microsatellite-instability-high-or-mismatch-repair-deficient-colorectal-cancer 2020-12-14T02:50:04 https://maestrodatabase.com/blog/the-democratic-majority-depends-on-slashing-drug-prices 2021-07-20T11:33:28 https://maestrodatabase.com/blog/jazz-pharmaceuticals-enters-into-letter-of-intent-with-the-pan-canadian-pharmaceutical-alliance-for-rylaze-helping-address-the-unmet-need-of-acute-lymphoblastic-leukaemia-and-lymphoblastic-lymphoma-patients-across-canada 2023-08-03T05:13:22 https://maestrodatabase.com/blog/molecular-partners-provides-regulatory-update-of-european-and-japanese-filings-of-abicipar-pegol 2020-07-21T12:28:04 https://maestrodatabase.com/blog/agenda-for-the-july-2024-pbac-meeting-version-3 2024-05-10T06:33:32 https://maestrodatabase.com/blog/icer-publishes-evidence-report-on-obeticholic-acid-for-the-treatment-of-non-alcoholic-steatohepatitis 2020-07-21T21:00:31 https://maestrodatabase.com/blog/celltrion-usas-adalimumab-aaty-biosimilar-to-humira-now-available-at-low-wholesale-acquisition-cost 2024-05-10T06:10:17 https://maestrodatabase.com/blog/gruenenthal-and-averitas-pharma-announce-u-dot-s-fda-approval-of-qutenza-for-the-treatment-of-neuropathic-pain-associated-with-diabetic-peripheral-neuropathy-of-the-feet 2020-07-21T21:16:17 https://maestrodatabase.com/blog/trumps-pick-to-lead-health-agency-calls-epipen-issue-disturbing 2017-02-18T01:46:43 https://maestrodatabase.com/blog/ema-starts-rolling-review-of-covid-19-vaccine-vidprevtyn 2021-07-20T21:03:18 https://maestrodatabase.com/blog/use-of-risk-evaluation-and-mitigation-strategies-by-the-us-food-and-drug-administration-2008-2019 2020-07-21T21:22:33 https://maestrodatabase.com/blog/house-gop-discusses-obamacare-replacement-ideas----but-doesnt-call-them-a-plan 2017-02-18T01:49:43 https://maestrodatabase.com/blog/when-is-applying-for-listing-on-the-pharmaceutical-benefits-scheme-not-an-infringement 2017-02-18T01:56:14 https://maestrodatabase.com/blog/consultation-on-revised-policy-on-access-to-documents 2017-02-18T02:01:28 https://maestrodatabase.com/blog/trump-says-hell-submit-healthcare-reforms-in-early-or-mid-march 2017-02-18T01:52:39 https://maestrodatabase.com/blog/ema-sets-up-infrastructure-for-real-world-monitoring-of-covid-19-treatments-and-vaccines 2020-07-21T21:05:50 https://maestrodatabase.com/blog/covid-19-pharmac-warns-pandemic-could-disrupt-supply-of-paracetamol-other-medicines 2020-07-21T21:10:00 https://maestrodatabase.com/blog/will-drug-companies-price-transparency-efforts-fall-short 2017-02-18T02:19:47 https://maestrodatabase.com/blog/pharma-execs-say-fda-will-not-lower-standards-for-coronavirus-vaccine 2020-07-21T21:13:05 https://maestrodatabase.com/blog/harnessing-real-world-data-for-regulatory-use-and-applying-innovative-applications 2020-07-21T21:43:35 https://maestrodatabase.com/blog/albireo-announces-fda-approval-of-bylvay-odevixibat-the-first-drug-treatment-for-patients-with-progressive-familial-intrahepatic-cholestasis 2021-07-20T21:18:21 https://maestrodatabase.com/blog/white-house-considers-drug-pricing-executive-order-prompting-gop-pushback 2020-07-21T21:27:50 https://maestrodatabase.com/blog/fda-approves-octapharmas-octagam-10-percent-for-adult-dermatomyositis 2021-07-20T21:07:41 https://maestrodatabase.com/blog/novartis-receives-fda-breakthrough-therapy-designation-for-scemblix-in-first-line-cml 2024-05-10T23:28:08 https://maestrodatabase.com/blog/executive-order-on-drug-price-controls-would-backfire 2020-07-21T21:30:06 https://maestrodatabase.com/blog/when-will-canada-have-national-pharmacare 2024-05-10T10:39:08 https://maestrodatabase.com/blog/a-lot-left-to-be-desired-private-health-insurers-get-covid-19-report-card 2020-07-21T21:36:47 https://maestrodatabase.com/blog/neurometrix-receives-fda-breakthrough-device-designation-for-treatment-of-fibromyalgia-with-its-wearable-neurostimulation-technology 2021-07-20T21:13:42 https://maestrodatabase.com/blog/the-u-dot-s-should-assess-the-economic-value-of-drugs-rather-than-leave-it-up-to-other-countries 2019-01-20T23:50:32 https://maestrodatabase.com/blog/cms-announces-new-model-to-lower-drug-prices-in-medicare-part-d-and-transformative-updates-to-existing-model-for-medicare-advantage 2019-01-20T23:53:03 https://maestrodatabase.com/blog/biden-administration-seeks-higher-penalties-for-hospitals-that-dont-publish-prices 2021-07-20T21:40:55 https://maestrodatabase.com/blog/the-health-202-hhs-secretary-azar-is-courting-capitol-hill-on-drug-prices 2019-01-21T00:02:19 https://maestrodatabase.com/blog/tauranga-women-fighting-cancer-and-fighting-the-system 2019-01-20T23:57:59 https://maestrodatabase.com/blog/pharma-ceos-lobbyists-showered-democrat-with-cash-after-his-attempt-to-torpedo-pelosis-drug-pricing-bill 2021-07-20T21:29:48 https://maestrodatabase.com/blog/allogene-therapeutics-receives-fda-fast-track-designation-for-its-first-solid-tumour-candidate-allo-316-in-the-treatment-of-renal-cell-carcinoma 2022-03-11T11:47:58 https://maestrodatabase.com/blog/diabetes-nz-to-kick-start-campaign-for-pharmac-funding-for-glucose-monitors 2022-03-11T19:54:05 https://maestrodatabase.com/blog/aurinia-announces-u-dot-s-fda-acceptance-of-the-filing-of-new-drug-application-and-priority-review-for-voclosporin-for-the-treatment-of-lupus-nephritis 2020-07-21T23:46:29 https://maestrodatabase.com/blog/sn-bioscience-receives-fda-fast-track-designation-for-small-cell-lung-cancer 2024-05-10T23:56:20 https://maestrodatabase.com/blog/tests-could-lead-to-fewer-people-having-unnecessary-chemotherapy-after-surgery-for-early-breast-cancer 2024-05-10T23:52:34 https://maestrodatabase.com/blog/coronavirus-pharmaceutical-giants-split-on-vaccine-profits 2020-07-22T07:29:36 https://maestrodatabase.com/blog/first-covid-19-vaccine-may-be-approved-in-2020-eu-regulator-says 2020-07-22T07:37:41 https://maestrodatabase.com/blog/atagi-update-following-weekly-covid-19-meeting-9-march-2022 2022-03-11T20:05:06 https://maestrodatabase.com/blog/acadia-pharmaceuticals-submits-marketing-authorisation-application-to-the-ema-for-trofinetide-for-the-treatment-of-rett-syndrome 2025-01-15T01:30:06 https://maestrodatabase.com/blog/will-price-be-a-barrier-to-new-cancer-immunotherapy 2019-01-21T02:20:07 https://maestrodatabase.com/blog/viiv-healthcare-receives-eu-marketing-authorisation-for-juluca-dolutegravir-slash-rilpivirine-the-first-2-drug-regimen-once-daily-single-pill-for-the-treatment-of-hiv 2018-05-22T01:17:59 https://maestrodatabase.com/blog/health-canada-approves-otsuka-and-lundbecks-rexulti-brexpiprazole-as-a-treatment-for-schizophrenia-in-adults 2017-02-18T05:41:52 https://maestrodatabase.com/blog/health-canada-approves-keytruda-for-adult-patients-with-locally-advanced-unresectable-or-metastatic-biliary-tract-carcinoma-in-combination-with-gemcitabine-based-chemotherapy 2024-05-11T01:05:49 https://maestrodatabase.com/blog/capivasertib-in-combination-with-fulvestrant-for-the-treatment-of-patients-with-advanced-hormone-receptor-positive-her2-negative-breast-cancer-after-endocrine-treatment 2025-01-15T01:58:31 https://maestrodatabase.com/blog/fortress-biotech-announces-rare-paediatric-disease-designation-for-cutx-101-for-the-treatment-of-menkes-disease 2020-01-17T04:58:28 https://maestrodatabase.com/blog/australia-left-in-the-dark-as-manufacturers-race-to-make-oxford-covid-19-vaccine 2020-07-22T07:52:04 https://maestrodatabase.com/blog/in-new-york-appearance-cms-administrator-pushes-for-congress-to-act-on-drug-prices 2022-03-11T20:09:44 https://maestrodatabase.com/blog/epilepsy-medicine-linked-to-deaths-not-same-as-previous-funded-drug----advocacy-group 2020-07-22T08:14:04 https://maestrodatabase.com/blog/merck-takes-patient-directed-approach-to-bring-innovation-to-the-treatment-of-rare-neuromuscular-disorder-generalised-myasthenia-gravis 2025-11-24T20:20:38 https://maestrodatabase.com/blog/fda-approves-prolia-denosumab-for-glucocorticoid-induced-osteoporosis 2018-05-22T05:04:35 https://maestrodatabase.com/blog/from-publication-bias-to-lost-in-information 2020-12-14T07:44:40 https://maestrodatabase.com/blog/harmony-biosciences-receives-breakthrough-therapy-and-fast-track-designations-for-pitolisant 2018-05-22T05:34:12 https://maestrodatabase.com/blog/lynparza-approved-in-the-us-as-adjuvant-treatment-for-patients-with-germline-brca-mutated-her2-negative-high-risk-early-breast-cancer 2022-03-11T21:28:22 https://maestrodatabase.com/blog/utility-receives-qualified-infectious-disease-product-designation-from-the-u-dot-s-fda 2018-05-22T11:32:39 https://maestrodatabase.com/blog/pandemic-creating-potential-for-drug-shortages-that-canada-isnt-equipped-to-deal-with 2020-07-22T21:11:44 https://maestrodatabase.com/blog/gsk-receives-us-approval-of-arnuity-ellipta-for-use-in-children-from-5-years-old-who-suffer-from-asthma 2018-05-22T11:16:43 https://maestrodatabase.com/blog/japan-approves-dexamethasone-as-second-drug-for-coronavirus-treatment 2020-07-22T21:31:38 https://maestrodatabase.com/blog/lillys-taltz-ixekizumab-receives-the-first-u-dot-s-fda-approval-for-label-update-to-include-data-for-psoriasis-involving-the-genital-area 2018-05-22T21:04:35 https://maestrodatabase.com/blog/diabetes-drugs-delay-shows-problem-with-pharmacs-funding-model-doctor-claims 2020-12-14T07:47:05 https://maestrodatabase.com/blog/pfizer-vaccine-deal-at-20-dollars-a-dose-sets-ceiling-for-rivals 2020-07-22T21:01:09 https://maestrodatabase.com/blog/for-cancer-patients-trumps-drug-pricing-proposal-falls-short 2018-05-22T11:48:45 https://maestrodatabase.com/blog/jazz-pharmaceuticals-announces-u-dot-s-fda-approval-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-for-cataplexy-or-excessive-daytime-sleepiness-associated-with-narcolepsy 2020-07-22T21:04:47 https://maestrodatabase.com/blog/working-together-for-people-with-rare-and-complex-diseases 2018-05-22T21:19:27 https://maestrodatabase.com/blog/make-drugs-cheaper-by-encouraging-generics 2018-05-22T21:25:13 https://maestrodatabase.com/blog/okanagan-mla-pushes-province-drug-company-to-provide-compassionate-coverage-for-pricey-drug 2018-05-22T21:12:21 https://maestrodatabase.com/blog/us-fda-approves-mercks-ervebo-ebola-zaire-vaccine-live-for-use-in-children-12-months-of-age-and-older 2023-08-03T11:39:19 https://maestrodatabase.com/blog/ema-report-makes-recommendations-for-car-t-patient-registries 2018-05-22T21:16:34 https://maestrodatabase.com/blog/the-swiss-government-must-make-lifesaving-drugs-affordable 2018-05-22T21:33:13 https://maestrodatabase.com/blog/covid-19---implications-for-the-health-care-system 2020-07-22T21:42:09 https://maestrodatabase.com/blog/chinas-nmpa-accepts-and-grants-priority-review-designation-to-the-new-drug-application-for-luye-pharmas-rotigotine-extended-release-microspheres 2023-08-03T11:21:25 https://maestrodatabase.com/blog/gop-chairman-in-talks-with-big-pharma-on-moving-drug-pricing-bill 2018-05-22T21:27:57 https://maestrodatabase.com/blog/americas-backwards-coronavirus-strategy 2020-07-22T21:48:55 https://maestrodatabase.com/blog/congress-goes-home-and-constituents-fired-up-over-health-care-are-waiting 2017-02-18T09:23:08 https://maestrodatabase.com/blog/cellectar-receives-fda-fast-track-designation-for-clr-131-in-diffuse-large-b-cell-lymphoma 2019-07-10T09:47:22 https://maestrodatabase.com/blog/vaccine-crisis-leaves-australias-immunisation-record-in-tatters 2019-07-10T09:45:20 https://maestrodatabase.com/blog/biomarin-explores-pricing-experimental-gene-therapy-at-2-dollars-million-to-3-dollars-million 2020-01-17T06:09:19 https://maestrodatabase.com/blog/janssen-questions-literature-review-on-biosimilar-switching-studies-as-authors-defend-it 2018-05-22T21:42:08 https://maestrodatabase.com/blog/holistic-approach-to-palliative-care-required-for-consumers-and-carers 2018-05-22T21:49:01 https://maestrodatabase.com/blog/largest-pharmacy-benefit-managers-hiked-up-drug-prices-ftc-says 2025-01-15T07:42:02 https://maestrodatabase.com/blog/drug-makers-boost-prices-up-to-909-percent-defying-political-pressure 2019-07-10T09:57:02 https://maestrodatabase.com/blog/fda-to-review-isatuximab-as-a-potential-treatment-for-relapsed-slash-refractory-multiple-myeloma 2019-07-10T12:14:36 https://maestrodatabase.com/blog/swiss-medical-authority-approves-pharmamars-zepzelca-lurbinectedin-and-atezolizumab-tecentriq-combination-as-first-line-maintenance-therapy-for-extensive-stage-small-cell-lung-cancer 2025-11-24T20:49:37 https://maestrodatabase.com/blog/why-disclosing-drug-prices-in-tv-ads-wont-lower-costs 2019-07-10T11:17:18 https://maestrodatabase.com/blog/spravato-esketamine-nasal-spray-is-available-for-canadian-patients 2020-07-23T06:54:57 https://maestrodatabase.com/blog/pbac-statement-of-endorsement-for-transparency-measures-and-standardised-redactions-to-public-summary-documents 2020-07-23T07:01:32 https://maestrodatabase.com/blog/amazons-alexa-to-offer-nhs-health-care-advice 2019-07-10T12:43:50 https://maestrodatabase.com/blog/fda-approves-katerzia-the-first-and-only-amlodipine-oral-suspension-for-paediatric-patients-6-years-of-age-and-older 2019-07-10T12:23:37 https://maestrodatabase.com/blog/pharming-announces-ema-validates-its-marketing-authorisation-application-under-accelerated-assessment-for-leniolisib 2022-10-30T01:24:39 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-approval-from-the-european-commission-to-expand-use-of-car-t-cell-therapy-breyanzi-for-relapsed-or-refractory-mantle-cell-lymphoma 2025-11-24T22:32:00 https://maestrodatabase.com/blog/novartis-launches-adamis-allergy-shots-in-u-dot-s-pharmacies-amid-epipen-shortage 2019-07-10T20:55:23 https://maestrodatabase.com/blog/europe-and-norway-discuss-improving-affordable-access-to-innovative-medicines 2020-01-17T06:31:57 https://maestrodatabase.com/blog/severe-atopic-dermatitis-drug-too-expensive-for-adolescents 2020-07-23T12:25:22 https://maestrodatabase.com/blog/novartis-receives-fda-approval-for-itvisma-the-only-gene-replacement-therapy-for-children-two-years-and-older-teens-and-adults-with-spinal-muscular-atrophy 2025-11-24T22:38:02 https://maestrodatabase.com/blog/icers-final-report-on-peanut-allergy-treatments-clinical-evidence-does-not-yet-demonstrate-that-long-term-benefits-of-desensitisation-outweigh-short-term-risks 2019-07-10T20:49:52 https://maestrodatabase.com/blog/potential-risks-of-treatment-with-unapproved-regenerative-medicine-products 2020-07-23T12:30:44 https://maestrodatabase.com/blog/a-supreme-court-ruling-may-have-made-it-harder-to-get-some-info-from-the-fda 2019-07-10T21:12:14 https://maestrodatabase.com/blog/mc2-therapeutics-announces-u-dot-s-food-and-drug-administration-approval-of-wynzora-calcipotriene-0-dot-005-percent-and-betamethasone-dipropionate-0-dot-064-percent-cream-for-adults-with-plaque-psoriasis 2020-07-23T07:08:52 https://maestrodatabase.com/blog/gop-senators-raise-concerns-over-potential-deal-to-lower-drug-prices 2019-07-10T21:10:05 https://maestrodatabase.com/blog/u-dot-s-appeals-court-signals-sympathy-to-bid-to-strike-down-obamacare 2019-07-10T21:06:31 https://maestrodatabase.com/blog/new-committee-brings-diverse-patient-family-and-caregiver-voices-to-cadth 2019-07-10T21:01:09 https://maestrodatabase.com/blog/aardvark-therapeutics-announces-receipt-of-fda-rare-paediatric-disease-designation-for-prader-willi-syndrome 2023-08-03T21:52:40 https://maestrodatabase.com/blog/elsalys-biotech-announces-submission-of-biologics-license-application-to-fda-for-leukotac-inolimomab-for-the-treatment-of-graft-versus-host-disease-in-adult-patients 2020-07-23T12:18:43 https://maestrodatabase.com/blog/canadas-labour-leaders-encourage-premiers-to-embrace-universal-pharmacare 2019-07-10T21:26:48 https://maestrodatabase.com/blog/fda-proposes-new-rule-on-reporting-requirements 2020-07-23T21:15:48 https://maestrodatabase.com/blog/biomarker-based-cancer-diagnostics-german-pricing-regulator-sets-high-validation-and-reimbursement-standards-for-novel-diagnostic-methods 2019-07-10T21:22:38 https://maestrodatabase.com/blog/delays-to-the-commencement-of-certain-medical-device-regulatory-changes 2020-07-23T21:20:55 https://maestrodatabase.com/blog/fda-announces-new-efforts-to-expedite-generic-drug-development-and-marketing-to-improve-patient-access-to-medicines 2019-07-10T21:17:39 https://maestrodatabase.com/blog/vertex-and-nhs-wales-agree-on-kaftrio-reimbursement 2020-07-23T21:28:43 https://maestrodatabase.com/blog/cadth-publishes-final-recommendation-for-mayzent 2020-07-23T21:00:13 https://maestrodatabase.com/blog/trump-likely-to-sign-executive-orders-on-drug-pricing-friday 2020-07-23T21:07:40 https://maestrodatabase.com/blog/how-to-lower-drug-prices-without-killing-research-and-development 2020-07-23T21:10:07 https://maestrodatabase.com/blog/fda-approves-lillys-omvoh-mirikizumab-mrkz-for-crohns-disease-expanding-its-use-to-the-second-major-type-of-inflammatory-bowel-disease 2025-01-15T21:16:58 https://maestrodatabase.com/blog/the-drug-lobby-is-getting-touchy-about-drug-prices 2017-02-18T22:13:59 https://maestrodatabase.com/blog/the-refusal-of-medicare-to-fund-a-60-dollars-blood-test-means-cancer-patients-miss-out-on-treatment 2017-02-18T22:09:13 https://maestrodatabase.com/blog/nice-encourages-further-data-collection-on-game-changing-histology-independent-cancer-drugs 2020-01-17T09:04:22 https://maestrodatabase.com/blog/avenzo-therapeutics-granted-fast-track-designation-for-avzo-103-a-potential-best-in-class-nectin4-slash-trop2-bispecific-antibody-drug-conjugate-for-the-treatment-of-patients-with-urothelial-cancer-previously-treated-with-enfortumab-vedotin 2025-11-25T06:42:35 https://maestrodatabase.com/blog/defining-the-concept-of-fair-pricing-for-medicines 2020-01-17T11:29:47 https://maestrodatabase.com/blog/dupixent-dupilumab-approved-as-the-first-targeted-medicine-in-the-european-union-in-over-a-decade-for-chronic-spontaneous-urticaria 2025-11-25T06:47:53 https://maestrodatabase.com/blog/confusion-abounds-around-health-insurance-reforms 2019-01-21T19:39:13 https://maestrodatabase.com/blog/horizon-therapeutics-submits-teprotumumab-biologics-license-application-for-the-treatment-of-active-thyroid-eye-disease 2019-07-11T01:05:48 https://maestrodatabase.com/blog/use-of-patient-preference-studies-in-hta-decision-making-a-nice-perspective 2020-01-17T11:16:43 https://maestrodatabase.com/blog/contraceptive-pill-levlen-ed-rationed-as-supply-runs-low-across-new-zealand 2019-01-21T19:34:01 https://maestrodatabase.com/blog/rx-drug-prices-continue-to-rise----heres-what-you-can-do 2019-01-21T19:55:38 https://maestrodatabase.com/blog/millennials-turn-to-afterpay-to-cover-dental-costs 2019-01-21T19:42:44 https://maestrodatabase.com/blog/reforming-the-orphan-drug-act-for-the-21st-century 2019-07-11T01:11:25 https://maestrodatabase.com/blog/drug-utilisation-subcommittee-outcome-statement 2022-07-11T00:51:07 https://maestrodatabase.com/blog/fdas-banner-year-for-approvals-will-market-access-to-new-drugs-follow-suit 2019-01-21T19:52:07 https://maestrodatabase.com/blog/new-agreement-on-branded-drugs-for-the-nhs 2019-01-21T20:09:37 https://maestrodatabase.com/blog/china-pharma-must-swallow-that-jagged-little-pill-called-r-and-d-as-government-slashes-profit-margins-of-generic-drugs 2019-01-21T20:12:21 https://maestrodatabase.com/blog/mesoblast-receives-complete-response-from-us-fda-for-biologics-license-application-for-steroid-refractory-acute-graft-versus-host-disease-in-children 2023-08-04T01:58:59 https://maestrodatabase.com/blog/canadian-payer-reports-a-successful-switch-to-biosimilars 2019-01-21T20:01:59 https://maestrodatabase.com/blog/new-whitepaper-identifies-limitations-in-using-icers-potential-budget-impact-work-to-guide-private-payer-budget-decisions 2019-01-21T20:22:17 https://maestrodatabase.com/blog/health-canada-approves-pomalyst-based-triplet-combination-for-patients-with-multiple-myeloma 2019-07-11T01:37:56 https://maestrodatabase.com/blog/myokardia-announces-receipt-of-breakthrough-therapy-designation-from-fda-for-mavacamten-for-the-treatment-of-symptomatic-obstructive-hypertrophic-cardiomyopathy 2020-07-24T09:34:27 https://maestrodatabase.com/blog/trixeo-aerosphere-approved-in-the-eu-for-maintenance-treatment-of-copd 2020-12-14T11:17:02 https://maestrodatabase.com/blog/myriad-genetics-receives-fda-approval-of-bracanalysis-cdx-as-a-companion-diagnostic-for-lynparza-in-early-breast-cancer 2022-03-12T07:28:30 https://maestrodatabase.com/blog/europe-closer-to-biosimilar-rule-change-despite-fierce-resistance-from-pharma 2019-01-21T20:28:33 https://maestrodatabase.com/blog/nhs-england-sees-off-abbvies-hepatitis-c-legal-challenge 2019-01-21T20:16:13 https://maestrodatabase.com/blog/excellthera-receives-priority-medicines-prime-designation-from-european-medicines-agency-for-ect-001-cell-therapy 2020-12-14T11:26:29 https://maestrodatabase.com/blog/biosimilar-impact-on-oncology-clinical-trial-design-and-operations 2022-03-12T08:17:52 https://maestrodatabase.com/blog/catalyst-pharmaceuticals-and-kye-pharmaceuticals-announce-a-second-favourable-canadian-federal-court-ruling-setting-aside-approval-of-ruzurgi 2022-03-12T03:08:31 https://maestrodatabase.com/blog/new-treatment-authorised-and-available-for-canadians-with-her2-positive-breast-cancer 2021-07-21T02:01:56 https://maestrodatabase.com/blog/nice-u-turn-on-novartis-migraine-drug-aimovig 2020-12-14T11:13:30 https://maestrodatabase.com/blog/moderna-announces-update-on-investigational-rsv-vaccine 2024-05-12T01:06:31 https://maestrodatabase.com/blog/fda-approves-durvalumab-for-resectable-gastric-or-gastro-oesophageal-junction-adenocarcinoma 2025-11-25T22:05:15 https://maestrodatabase.com/blog/u-dot-s-fda-expands-indication-for-prograf-for-prevention-of-organ-rejection-in-adult-and-paediatric-lung-transplant-recipients 2021-07-21T02:09:12 https://maestrodatabase.com/blog/novartis-receives-eu-approval-for-leqvio-inclisiran-a-first-in-class-sirna-to-lower-cholesterol-with-two-doses-a-year 2020-12-14T19:45:26 https://maestrodatabase.com/blog/ema-publishes-agenda-for-19-22-july-chmp-meeting 2021-07-21T05:47:24 https://maestrodatabase.com/blog/pharmacy-trial-program-implementation-review 2020-07-24T12:40:36 https://maestrodatabase.com/blog/antengene-announces-xpovio-approved-by-the-tga-in-australia-for-the-treatment-of-relapsed-and-slash-or-refractory-multiple-myeloma-and-triple-class-refractory-multiple-myeloma 2022-03-12T21:11:42 https://maestrodatabase.com/blog/gannex-received-u-dot-s-fda-fast-track-designation-for-its-nash-drug-candidate-asc42-an-fxr-agonist 2020-12-14T19:54:16 https://maestrodatabase.com/blog/france-removes-state-funding-for-dementia-drugs 2020-01-17T22:10:52 https://maestrodatabase.com/blog/acadia-pharmaceuticals-announces-4-august-2022-action-date-for-resubmitted-supplemental-new-drug-application-for-nuplazid-pimavanserin-for-the-treatment-of-alzheimers-disease-psychosis 2022-03-12T10:33:01 https://maestrodatabase.com/blog/venetoclax-venclexta-granted-us-fda-breakthrough-therapy-designation-in-higher-risk-myelodysplastic-syndrome 2021-07-21T05:24:13 https://maestrodatabase.com/blog/eisai-completes-rolling-submission-to-us-fda-for-leqembi-iqlik-lecanemab-irmb-supplemental-biologics-license-pplication-as-a-subcutaneous-starting-dose-for-the-treatment-of-early-alzheimers-disease-under-fast-track-status 2025-11-26T00:50:14 https://maestrodatabase.com/blog/avelas-receives-fda-breakthrough-therapy-designation-for-pegloprastide-avb-620-for-use-during-breast-cancer-surgery 2020-12-14T20:15:59 https://maestrodatabase.com/blog/airing-frustrations-with-pharma-a-republican-ftc-commissioner-just-endorsed-medicare-negotiation 2020-01-17T22:23:26 https://maestrodatabase.com/blog/pricing-of-pharmaceuticals-is-becoming-a-major-challenge-for-health-systems 2020-01-17T22:19:24 https://maestrodatabase.com/blog/sarclisa-obtains-first-approval-in-china-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-multiple-myeloma 2025-01-15T22:52:38 https://maestrodatabase.com/blog/australia-secures-20-million-extra-astra-zeneca-vaccines 2020-12-14T20:25:38 https://maestrodatabase.com/blog/highlights-from-the-20-23-july-chmp-meeting 2020-07-24T12:44:25 https://maestrodatabase.com/blog/public-posting-of-a-comprehensive-surrogate-endpoint-table-for-cder-and-cber-regulated-products 2020-12-14T20:03:13 https://maestrodatabase.com/blog/biomarin-submits-marketing-authorisation-application-to-european-medicines-agency-for-vosoritide-to-treat-children-with-achondroplasia 2020-07-24T12:49:20 https://maestrodatabase.com/blog/u-dot-s-government-exercises-first-option-for-additional-100-million-doses-of-modernas-covid-19-vaccine-candidate 2020-12-14T20:09:36 https://maestrodatabase.com/blog/sorrento-announces-its-partner-mabpharm-has-received-marketing-approval-in-china-for-infliximab-biobetter 2021-07-21T06:07:50 https://maestrodatabase.com/blog/adaptimmune-granted-access-to-priority-medicines-prime-regulatory-support-by-the-european-medicines-agency-for-adp-a2m4-for-the-treatment-of-synovial-sarcoma 2020-07-24T12:54:26 https://maestrodatabase.com/blog/uk-set-to-raise-prices-of-drugs-in-us-agreement 2025-11-26T01:46:54 https://maestrodatabase.com/blog/fda-approves-a-new-treatment-for-primary-immunoglobulin-a-nephropathy 2025-11-26T01:49:40 https://maestrodatabase.com/blog/public-hospital-funding-crisis-highlights-need-for-reforms 2017-02-19T20:27:29 https://maestrodatabase.com/blog/request-for-supply---supply-of-nicotine-replacement-therapy 2017-02-19T20:23:08 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-for-hanmi-laps-triple-agonist 2020-07-24T23:06:39 https://maestrodatabase.com/blog/another-example-of-a-shkrelian-drug-price-increase 2022-10-30T20:00:53 https://maestrodatabase.com/blog/how-an-unproven-alzheimers-drug-got-approved 2021-07-21T10:09:15 https://maestrodatabase.com/blog/new-drug-application-initiated-with-us-fda-for-tar-200-the-first-and-only-intravesical-drug-releasing-system-for-patients-with-bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer 2025-01-15T23:16:49 https://maestrodatabase.com/blog/health-canada-has-authorised-vyvanse-lisdexamphetamine-dimesylate-the-first-and-only-chewable-tablet-for-the-treatment-of-attention-deficit-slash-hyperactivity-disorder 2019-07-11T02:06:24 https://maestrodatabase.com/blog/myovant-sciences-announces-european-commission-approval-for-ryeqo-for-the-treatment-of-women-with-uterine-fibroids 2021-07-21T08:36:22 https://maestrodatabase.com/blog/australia-is-on-target-to-eliminate-hepatitis-c-by-2026 2017-02-20T20:02:51 https://maestrodatabase.com/blog/the-european-medicines-agency-and-publication-of-clinical-study-reports-a-challenge-for-the-us-fda 2017-02-20T20:08:23 https://maestrodatabase.com/blog/pharmac-considers-funding-womens-hygiene-products 2017-02-20T19:47:22 https://maestrodatabase.com/blog/big-pharma-funding-biases-drug-trials-in-favour-of-a-sponsors-product-review 2017-02-20T19:52:39 https://maestrodatabase.com/blog/ausbiotech-suggests-fsanz-amend-cost-recovery-plan 2017-02-21T19:52:03 https://maestrodatabase.com/blog/agenda-for-chmp-20-23-february-2017-meeting 2017-02-21T19:57:18 https://maestrodatabase.com/blog/milan-mayor-sees-eu-picking-new-home-for-drugs-agency-by-june 2017-02-20T20:22:05 https://maestrodatabase.com/blog/sarepta-therapeutics-receives-fast-track-designation-for-srp-9001-micro-dystrophin-gene-therapy-for-the-treatment-of-duchenne-muscular-dystrophy 2020-07-24T23:21:14 https://maestrodatabase.com/blog/amphastar-announces-the-receipt-of-a-complete-response-letter-for-intranasal-naloxone-for-the-emergency-treatment-of-opioid-overdose 2017-02-21T20:15:30 https://maestrodatabase.com/blog/nice-draft-guidelines-reject-ipsens-cabometyx 2017-02-21T20:02:34 https://maestrodatabase.com/blog/fda-approves-first-cell-based-gene-therapy-for-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma 2020-07-24T23:27:47 https://maestrodatabase.com/blog/roche-receives-eu-approval-of-alecensa-alectinib-for-people-with-previously-treated-alk-positive-non-small-cell-lung-cancer 2017-02-21T20:10:13 https://maestrodatabase.com/blog/massive-support-for-nz-drug-buying-agency-pharmac-to-fund-pads-and-tampons 2017-02-21T20:34:20 https://maestrodatabase.com/blog/americans-medical-debts-are-bigger-than-was-known-totalling-140-dollars-billion 2021-07-21T10:20:24 https://maestrodatabase.com/blog/trump-says-obamacare-repeal-moving-fast 2017-02-21T20:24:19 https://maestrodatabase.com/blog/bps-804-accepted-for-ema-adaptive-pathways-programme 2017-02-21T21:12:09 https://maestrodatabase.com/blog/nice-publishes-draft-guidance-for-eluxadoline 2017-02-21T20:45:31 https://maestrodatabase.com/blog/vericel-receives-fda-fast-track-designation-for-ixmyelocel-t-an-investigational-product-for-the-treatment-of-patients-with-advanced-heart-failure-due-to-ischaemic-dilated-cardiomyopathy 2017-02-21T23:53:49 https://maestrodatabase.com/blog/neurocrine-biosciences-announces-fda-acceptance-of-new-drug-application-for-opicapone-as-an-adjunctive-treatment-for-patients-with-parkinsons-disease 2019-07-11T03:05:11 https://maestrodatabase.com/blog/nice-says-no-to-chiesis-rare-disease-drug 2018-05-23T12:14:14 https://maestrodatabase.com/blog/the-medicines-company-announces-fda-filing-acceptance-of-new-drug-application-for-intravenous-antibiotic-carbavance-meropenem-vaborbactam 2017-02-21T23:41:59 https://maestrodatabase.com/blog/rationing-medicines-by-stealth-with-government-budget-announcement 2018-05-23T09:36:53 https://maestrodatabase.com/blog/orchard-therapeutics-completes-submission-of-biologics-license-application-for-otl-200-in-mld-to-us-fda 2023-08-04T03:26:22 https://maestrodatabase.com/blog/gene-therapies-that-could-transform-diseases-get-easier-fda-path 2018-05-23T09:42:04 https://maestrodatabase.com/blog/deal-reduces-price-of-life-saving-hepatitis-c-drugs-for-canadians 2017-02-22T19:56:45 https://maestrodatabase.com/blog/repatha-evolocumab-receives-european-commission-approval-for-new-420-mg-single-dose-delivery-option 2017-02-22T20:05:42 https://maestrodatabase.com/blog/we-price-drugs-in-line-with-innovation-potential-says-bayer-ceo 2017-02-22T20:30:56 https://maestrodatabase.com/blog/harvard-pilgrim-expands-use-of-novel-drug-purchasing-deals 2017-02-22T20:36:13 https://maestrodatabase.com/blog/new-drug-costs-are-still-high-but-putting-prices-in-tv-ads-offers-little-value 2018-05-23T12:19:16 https://maestrodatabase.com/blog/decision-for-funding-in-the-neurology-immunosuppression-diabetes-and-anti-thrombotic-therapy-areas 2019-07-11T03:12:57 https://maestrodatabase.com/blog/pfizer-announces-acceptance-of-regulatory-submission-for-inotuzumab-ozogamicin-by-the-u-dot-s-fda 2017-02-22T20:12:29 https://maestrodatabase.com/blog/lawsuit-accuses-drug-makers-of-conspiring-to-hike-insulin-prices 2017-02-22T20:28:37 https://maestrodatabase.com/blog/novartis-adakveo-receives-positive-chmp-opinion-for-the-prevention-of-recurrent-vaso-occlusive-crises-in-patients-with-sickle-cell-disease 2020-07-25T00:49:50 https://maestrodatabase.com/blog/republicans-postpone-settling-obamacare-subsidies-lawsuit 2017-02-22T20:39:40 https://maestrodatabase.com/blog/fdas-pazdur-and-blumenthal-the-march-of-checkpoint-inhibitors-will-continue 2017-02-22T23:43:22 https://maestrodatabase.com/blog/otsuka-pharmaceutical-submits-new-drug-application-to-us-fda-for-centanafadine-for-the-treatment-of-adhd-in-children-adolescents-and-adults 2025-11-26T04:35:08 https://maestrodatabase.com/blog/a-flawed-study-depicts-drug-companies-as-profiteers 2017-10-10T04:55:50 https://maestrodatabase.com/blog/lead-cancer-immunotherapy-candidate-receives-fda-fast-track-designation 2017-02-22T23:47:06 https://maestrodatabase.com/blog/fda-accepts-supplemental-biologics-license-application-for-prolia-denosumab-in-glucocorticoid-induced-osteoporosis 2017-10-10T05:05:49 https://maestrodatabase.com/blog/trumps-plan-wont-lower-prescription-drug-prices-ours-would 2018-05-23T20:54:56 https://maestrodatabase.com/blog/sun-pharma-announces-usfda-approval-of-yonsa-abiraterone-acetate-to-treat-metastatic-castration-resistant-prostate-cancer-in-combination-with-methylprednisolone 2018-05-23T21:28:47 https://maestrodatabase.com/blog/pharmac-consulting-on-widening-access-to-venetoclax-azacitidine-and-upadacitinib-monohydrate 2025-01-16T00:39:25 https://maestrodatabase.com/blog/right-to-try-legislation-heads-to-the-white-house 2018-05-23T20:51:07 https://maestrodatabase.com/blog/doughnuts-and-discounts----changes-to-medicare-part-d-under-the-bipartisan-budget-act-of-2018 2018-05-23T21:47:20 https://maestrodatabase.com/blog/rationale-opportunities-and-reality-of-biosimilar-medications 2018-05-23T21:44:14 https://maestrodatabase.com/blog/immunitybio-provides-regulatory-update-on-global-submission-for-anktiva-plus-bcg-in-bcg-unresponsive-non-muscle-invasive-bladder-cancer-with-carcinoma-in-situ-in-europe-and-united-kingdom 2025-01-16T01:41:15 https://maestrodatabase.com/blog/health-report-confirms-consumers-want-control-of-their-own-health-data 2018-05-23T21:56:07 https://maestrodatabase.com/blog/inflarx-receives-european-commission-approval-for-gohibic-vilobelimab-for-the-treatment-of-sars-cov-2-induced-acute-respiratory-distress-syndrome 2025-01-16T01:23:47 https://maestrodatabase.com/blog/agenda-for-11-october-tc-meeting 2017-10-10T07:24:00 https://maestrodatabase.com/blog/cytodyn-announces-voluntary-withdrawal-of-bla-for-hiv-mdr-due-to-cro-data-management-issues 2022-10-30T22:27:47 https://maestrodatabase.com/blog/fda-expands-indication-for-revlimid-lenalidomide-as-a-maintenance-treatment-for-patients-with-multiple-myeloma-following-autologous-haematopoietic-stem-cell-transplant-auto-hsct 2017-02-23T03:19:35 https://maestrodatabase.com/blog/alzheimers-patient-groups-pressure-u-dot-s-to-pay-for-biogen-drug 2022-03-13T20:35:57 https://maestrodatabase.com/blog/are-prescription-drugs-the-next-target-for-amazon 2017-10-10T07:53:39 https://maestrodatabase.com/blog/celltrions-rituxan-biosimilar-wins-european-approval 2017-02-23T01:53:50 https://maestrodatabase.com/blog/us-fda-issues-complete-response-letter-for-proposed-biosimilar-pegfilgrastim 2017-10-10T09:45:13 https://maestrodatabase.com/blog/novartis-drug-zykadia-receives-fda-priority-review-for-first-line-use-in-patients-with-alk-plus-metastatic-nsclc 2017-02-23T07:05:18 https://maestrodatabase.com/blog/can-the-u-dot-s-repair-its-health-care-while-keeping-its-innovation-edge 2017-10-10T10:10:52 https://maestrodatabase.com/blog/pfizer-provides-update-on-u-dot-s-fda-review-of-abrocitinib-and-xeljanz-filings 2021-07-21T21:05:13 https://maestrodatabase.com/blog/department-of-health-tweaks-the-agenda-for-this-weeks-pbac-meeting 2022-10-31T01:23:39 https://maestrodatabase.com/blog/a-systematic-review-on-the-appropriate-discounting-rates-for-the-economic-evaluation-of-gene-therapies-whether-a-specific-approach-is-justified-to-tackle-the-challenges 2024-05-13T01:46:01 https://maestrodatabase.com/blog/australians-benefit-from-new-life-changing-medicines-added-to-the-pbs 2024-05-13T01:29:53 https://maestrodatabase.com/blog/fit-for-purpose-real-world-data-assessments-in-oncology-a-call-for-cross-stakeholder-collaboration 2021-07-21T21:26:04 https://maestrodatabase.com/blog/allergan-ceo-pushes-for-trump-to-lead-drug-price-discussions 2017-02-23T20:10:13 https://maestrodatabase.com/blog/uncertainty-on-r-and-d-tax-incentive-causing-real-harm 2017-02-23T19:42:57 https://maestrodatabase.com/blog/support-for-obamacare-is-rising 2017-02-23T20:33:52 https://maestrodatabase.com/blog/remdesivir-and-the-combination-of-tixagevimab-and-cilgavimab-for-the-treatment-of-patients-with-covid-19-disease-final-guidance 2024-05-13T02:30:39 https://maestrodatabase.com/blog/vaccine-mandates-more-likely-once-fda-grants-full-approvals-health-experts-say 2021-07-21T21:36:12 https://maestrodatabase.com/blog/prep-the-hiv-prevention-pill-must-now-be-totally-free-under-almost-all-insurance-plans 2021-07-21T21:32:49 https://maestrodatabase.com/blog/billionaire-philanthropist-john-arnold-goes-after-drug-prices 2017-02-23T20:13:18 https://maestrodatabase.com/blog/many-u-dot-s-cancer-patients-struggle-to-afford-life-saving-medications 2017-02-23T20:28:57 https://maestrodatabase.com/blog/biogen-alzheimers-drug-slow-to-take-off-as-u-dot-s-medicare-wrestles-with-coverage 2021-07-21T21:16:09 https://maestrodatabase.com/blog/recently-approved-alzheimer-drug-raises-questions-that-might-never-be-answered 2021-07-21T21:20:21 https://maestrodatabase.com/blog/breztri-aerosphere-approved-in-the-us-for-the-maintenance-treatment-of-copd 2020-07-25T06:15:09 https://maestrodatabase.com/blog/incyte-and-syndax-announce-us-fda-approval-of-niktimvo-axatilimab-csfr-9-mg-and-22-mg-vial-sizes 2025-01-16T05:17:35 https://maestrodatabase.com/blog/were-seeing-what-happens-when-the-fda-loses-credibility 2021-07-21T21:40:39 https://maestrodatabase.com/blog/clovis-oncology-submits-supplemental-new-drug-application-for-rucaparib-as-maintenance-treatment-for-patients-with-platinum-sensitive-recurrent-ovarian-cancer 2017-10-10T19:47:29 https://maestrodatabase.com/blog/setmelanotide-acetate-for-the-treatment-of-people-with-obesity-and-hyperphagia-associated-with-bardet-biedl-syndrome 2023-08-04T07:46:17 https://maestrodatabase.com/blog/cancer-drug-prices-are-at-a-tipping-point 2017-10-10T19:42:19 https://maestrodatabase.com/blog/trumps-executive-order-on-health-care----can-it-undermine-the-aca-if-congress-fails-to-act 2017-02-23T22:42:23 https://maestrodatabase.com/blog/alarmed-by-popularity-of-ozempic-and-wegovy-insurers-wage-multi-front-battle 2023-08-05T01:05:02 https://maestrodatabase.com/blog/fda-approves-first-oral-treatment-for-post-partum-depression 2023-08-05T01:00:03 https://maestrodatabase.com/blog/mundipharma-to-launch-truxima-rituximab-the-first-biosimilar-monoclonal-antibody-for-the-treatment-of-cancer-in-seven-european-markets 2017-02-24T06:00:06 https://maestrodatabase.com/blog/repeal-of-health-law-faces-obstacles-in-house-not-just-in-senate 2017-02-24T10:29:51 https://maestrodatabase.com/blog/tocagen-receives-breakthrough-therapy-designation-from-u-dot-s-fda-for-toca-511-and-toca-fc-in-recurrent-high-grade-glioma 2017-02-24T01:56:53 https://maestrodatabase.com/blog/hundreds-could-benefit-from-life-saving-blood-cancer-treatment-recommended-by-nice 2025-11-26T10:08:00 https://maestrodatabase.com/blog/can-the-california-law-on-drug-pricing-transparency-make-a-difference 2017-10-10T20:15:42 https://maestrodatabase.com/blog/chmp-recommends-eu-conditional-marketing-authorisation-for-natpar-parathyroid-hormone-for-patients-with-chronic-hypoparathyroidism 2017-02-24T21:11:15 https://maestrodatabase.com/blog/zs-9-sodium-zirconium-cyclosilicate-receives-positive-chmp-opinion-for-the-treatment-of-hyperkalaemia 2017-02-24T21:00:12 https://maestrodatabase.com/blog/gatekeeping-strategies-for-avoiding-false-positive-results-in-clinical-trials-with-many-comparisons 2017-10-10T20:18:55 https://maestrodatabase.com/blog/iveric-bio-receives-us-fda-approval-for-izervay-avacincaptad-pegol-intravitreal-solution-a-new-treatment-for-geographic-atrophy 2023-08-05T02:37:11 https://maestrodatabase.com/blog/the-lifecycle-of-a-rare-disease-cancer-drug 2017-10-10T20:22:39 https://maestrodatabase.com/blog/drug-makers-brace-for-list-of-first-10-drugs-for-us-price-negotiations 2023-08-05T01:10:21 https://maestrodatabase.com/blog/ascendis-announces-extension-of-fda-review-period-for-transcon-cnp-navepegritide-for-children-with-achondroplasia 2025-11-26T21:03:11 https://maestrodatabase.com/blog/basilea-announces-submission-of-a-new-drug-application-to-the-us-fda-for-its-antibiotic-ceftobiprole 2023-08-05T03:38:56 https://maestrodatabase.com/blog/gsks-arexvy-the-first-respiratory-syncytial-virus-vaccine-for-older-adults-approved-in-canada 2023-08-05T03:35:09 https://maestrodatabase.com/blog/us-negotiates-lower-prices-for-ozempic-and-14-other-drugs 2025-11-26T10:46:49 https://maestrodatabase.com/blog/chinese-pharma-is-on-the-cusp-of-going-global 2025-11-26T10:50:34 https://maestrodatabase.com/blog/chmp-issues-positive-opinion-recommending-darzalex-daratumumab-for-relapsed-or-refractory-multiple-myeloma 2017-02-24T22:11:08 https://maestrodatabase.com/blog/ensuring-patient-safety-and-drug-manufacturing-quality-through-partnership-with-european-union-regulators 2019-07-11T20:55:56 https://maestrodatabase.com/blog/dupixent-dupilumab-sbla-accepted-for-fda-priority-review-for-treatment-of-adolescents-with-chronic-rhinosinusitis-with-nasal-polyposis 2024-05-13T05:15:32 https://maestrodatabase.com/blog/trump-abandons-drug-pricing-proposal-that-would-have-ended-certain-drug-rebates 2019-07-11T11:39:23 https://maestrodatabase.com/blog/how-australia-could-almost-eradicate-h-dot-i-v-transmissions 2019-07-11T09:32:10 https://maestrodatabase.com/blog/biosimilars-continue-to-exhibit-market-failure 2019-07-11T21:12:34 https://maestrodatabase.com/blog/new-drugs-where-did-we-go-wrong-and-what-can-we-do-better 2019-07-11T21:09:14 https://maestrodatabase.com/blog/trumps-losses-in-drug-pricing-battle-should-be-a-free-market-wake-up-call-to-him 2019-07-11T21:06:23 https://maestrodatabase.com/blog/novartis-receives-positive-chmp-opinion-for-tafinlar-plus-mekinist-in-braf-positive-non-small-cell-lung-cancer-patients 2017-02-24T22:33:28 https://maestrodatabase.com/blog/over-the-counter-access-to-low-dose-cannabidiol 2020-12-15T03:01:02 https://maestrodatabase.com/blog/gillibrand-unveils-plan-to-lower-drug-prices 2019-07-11T21:03:43 https://maestrodatabase.com/blog/icer-publishes-evidence-report-on-treatments-for-duchenne-muscular-dystrophy 2019-07-11T21:21:20 https://maestrodatabase.com/blog/bernie-sanders-to-join-people-with-type-1-diabetes-on-canada-trip-for-cheaper-insulin 2019-07-11T21:17:46 https://maestrodatabase.com/blog/covid-19-vaccine-codes-updated-effective-date-for-pfizer-biontech 2020-12-15T05:19:23 https://maestrodatabase.com/blog/proposals-for-funding-in-the-immunosuppressant-oncology-vasodilator-and-smoking-cessation-therapeutic-areas 2019-07-11T21:34:23 https://maestrodatabase.com/blog/novo-nordisk-files-for-fda-approval-of-a-higher-dose-of-wegovy-injection-7-dot-2-mg 2025-11-26T21:43:13 https://maestrodatabase.com/blog/sanofi-uk-marketing-authorisation-granted-for-sanofi-pasteurs-trivalent-influenza-vaccine-split-virion-inactivated-high-dose-tiv-high-dose 2019-01-22T04:10:42 https://maestrodatabase.com/blog/amag-pharmaceuticals-files-submission-in-response-to-the-fdas-notice-of-opportunity-for-a-hearing-and-proposal-to-withdraw-approval-of-makena-hydroxyprogesterone-caproate-injection 2020-12-15T03:35:08 https://maestrodatabase.com/blog/china-nmpa-approves-tislelizumab-for-patients-with-microsatellite-instability-high-or-mismatch-repair-deficient-solid-tumours 2022-03-14T06:09:32 https://maestrodatabase.com/blog/update-on-us-regulatory-review-of-fasenra-in-chronic-rhinosinusitis-with-nasal-polyps 2022-03-14T07:06:57 https://maestrodatabase.com/blog/european-chmp-adopts-positive-opinion-for-heplisav-b-dynavaxs-two-dose-adult-hepatitis-b-adjuvanted-vaccine 2020-12-15T06:32:08 https://maestrodatabase.com/blog/sandoz-canada-receives-health-canada-approval-for-erelzi-etanercept-in-the-treatment-of-psoriatic-arthritis-in-adult-patients 2019-01-22T04:15:35 https://maestrodatabase.com/blog/fda-approves-genentechs-ocrevus-ocrelizumab-shorter-2-hour-infusion-for-relapsing-and-primary-progressive-multiple-sclerosis 2020-12-15T06:09:56 https://maestrodatabase.com/blog/zai-lab-announces-approval-of-augtyro-repotrectinib-for-patients-with-ros1-positive-nsclc-by-chinas-nmpa 2024-05-13T09:29:34 https://maestrodatabase.com/blog/first-ever-life-saving-treatment-for-rare-heart-condition-available-on-the-nhs 2024-05-13T09:18:23 https://maestrodatabase.com/blog/digital-contraceptive-gets-approval-by-australian-health-authorities 2020-12-15T06:21:23 https://maestrodatabase.com/blog/obesity-related-diseases-expected-to-cost-australia-21-dollars-billion 2017-10-11T03:56:36 https://maestrodatabase.com/blog/innocare-announces-acceptance-of-supplemental-new-drug-application-for-orelabrutinib-in-relapsed-or-refractory-waldenstroems-macroglobulinemia-in-china 2022-03-14T09:49:44 https://maestrodatabase.com/blog/phathom-pharmaceuticals-submits-vonoprazan-nda-to-fda-for-the-treatment-of-erosive-oesophagitis 2022-03-14T19:40:52 https://maestrodatabase.com/blog/free-the-prep---over-the-counter-access-to-hiv-pre-exposure-prophylaxis 2023-08-06T01:54:47 https://maestrodatabase.com/blog/auris-medical-receives-fda-fast-track-designation-for-am-111-in-acute-sensorineural-hearing-loss 2017-02-25T00:10:28 https://maestrodatabase.com/blog/corium-receives-fda-approval-of-adlarity-donepezil-transdermal-system-for-treatment-of-patients-with-alzheimers-disease 2022-03-14T19:46:15 https://maestrodatabase.com/blog/imfinzi-recommended-for-approval-in-the-eu-by-chmp-for-less-frequent-fixed-dose-use-in-unresectable-non-small-cell-lung-cancer 2020-12-15T07:05:50 https://maestrodatabase.com/blog/incyte-announces-u-dot-s-fda-has-extended-the-supplemental-new-drug-application-review-period-for-ruxolitinib-cream-opzelura-for-the-treatment-of-vitiligo 2022-03-14T19:52:09 https://maestrodatabase.com/blog/how-much-australians-spend-on-health 2017-02-25T00:54:50 https://maestrodatabase.com/blog/revlimid-lenalidomide-approved-by-the-european-commission-as-monotherapy-for-the-maintenance-treatment-of-patients-with-newly-diagnosed-multiple-myeloma-after-autologous-stem-cell-transplantation 2017-02-25T00:42:00 https://maestrodatabase.com/blog/the-importance-of-swiss-style-claims-in-australia 2017-02-25T00:48:25 https://maestrodatabase.com/blog/without-rare-disease-policy-patients-in-canada-face-steep-costs-for-drugs 2017-02-25T01:10:08 https://maestrodatabase.com/blog/imlifidase-for-preventing-kidney-transplant-rejection-in-people-with-chronic-kidney-disease 2022-03-14T20:10:28 https://maestrodatabase.com/blog/food-and-drug-chief-gottlieb-skirts-health-secretary-talk-says-most-effective-at-fda 2017-10-11T04:29:01 https://maestrodatabase.com/blog/teduglutide-for-treating-short-bowel-syndrome 2022-03-14T20:26:17 https://maestrodatabase.com/blog/ansun-biopharma-announces-breakthrough-designation-for-its-experimental-drug-das181 2017-10-11T04:36:32 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-to-cothera-biosciences-zotiraciclib-for-treatment-of-recurrent-high-grade-glioma-with-idh1-slash-2-mutations 2025-11-26T23:44:27 https://maestrodatabase.com/blog/boehringer-ingelheim-expands-access-to-adalimumab-adbm-injection-the-companys-biosimilar-to-humira 2024-05-13T22:28:31 https://maestrodatabase.com/blog/fda-approves-acalabrutinib-with-bendamustine-and-rituximab-for-previously-untreated-mantle-cell-lymphoma 2025-01-16T22:57:00 https://maestrodatabase.com/blog/us-fda-grants-priority-review-to-sonrotoclax-for-the-treatment-of-relapsed-or-refractory-mantle-cell-lymphoma 2025-11-27T00:25:41 https://maestrodatabase.com/blog/ultragenyx-and-kyowa-hakko-kirin-announce-fda-acceptance-and-priority-review-designation-of-burosumabs-biologics-license-application 2017-10-11T05:13:44 https://maestrodatabase.com/blog/foresee-pharmaceuticals-announces-the-pdufa-goal-date-for-the-3-month-version-of-camcevi-is-29-august-2025 2025-01-16T23:10:12 https://maestrodatabase.com/blog/almirall-announces-fda-approval-of-klisyri-tirbanibulin-a-new-innovative-topical-treatment-for-actinic-keratosis 2020-12-15T11:24:02 https://maestrodatabase.com/blog/fda-awards-genetesis-breakthrough-device-designation-for-cardioflux-imaging-technology 2020-12-15T20:18:12 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-new-drug-application-for-review-grants-priority-review-for-takedas-tak-721-budesonide-oral-suspension-for-the-treatment-of-eosinophilic-oesophagitis 2020-12-15T20:23:34 https://maestrodatabase.com/blog/u-dot-s-fda-grants-fast-track-designation-to-astellas-for-development-of-gilteritinib-in-relapsed-or-refractory-acute-myeloid-leukaemia 2017-10-11T05:28:02 https://maestrodatabase.com/blog/28-state-attorneys-general-demand-hhs-secretary-azar-enforce-laws-on-340b-drug-pricing 2020-12-15T20:01:02 https://maestrodatabase.com/blog/update-on-assessment-of-the-biontech-and-pfizer-bnt162b2-vaccine-marketing-authorisation-application 2020-12-15T20:12:27 https://maestrodatabase.com/blog/fda-approves-sotorasib-with-panitumumab-for-kras-g12c-mutated-colorectal-cancer 2025-01-16T23:57:56 https://maestrodatabase.com/blog/fda-grants-breakthrough-therapy-designation-for-tafamidis-for-the-treatment-of-patients-with-transthyretin-cardiomyopathy 2018-05-24T05:39:28 https://maestrodatabase.com/blog/big-pharmas-new-ceos-must-step-up-to-erase-inequities-in-drug-access 2020-12-15T20:43:02 https://maestrodatabase.com/blog/smc---may-2024-decisions 2024-05-14T00:28:35 https://maestrodatabase.com/blog/rafael-pharmaceuticals-receives-fda-fast-track-designation-for-cpi-613-devimistat-for-the-treatment-of-acute-myeloid-leukaemia 2020-12-15T20:31:45 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-22-july-2021 2021-07-22T04:05:27 https://maestrodatabase.com/blog/trumps-plan-for-200-dollars-medicare-drug-cards-advances-though-hurdles-remain 2020-12-15T20:36:58 https://maestrodatabase.com/blog/republicans-want-you-in-a-health-savings-account-so-now-what 2017-02-25T21:52:07 https://maestrodatabase.com/blog/fda-committee-to-meet-again-thursday-for-modernas-covid-19-vaccine 2020-12-15T20:38:52 https://maestrodatabase.com/blog/petosemtamab-granted-breakthrough-therapy-designation-by-the-us-fda 2024-05-13T23:15:14 https://maestrodatabase.com/blog/fda-to-review-zynquista-sotagliflozin-as-potential-treatment-for-type-1-diabetes 2018-05-24T05:53:19 https://maestrodatabase.com/blog/ptac-recommends-keytruda-for-patients-with-non-small-cell-lung-cancer 2019-01-22T06:41:50 https://maestrodatabase.com/blog/fda-grants-breakthrough-therapy-designation-to-lenti-d-for-the-treatment-of-cerebral-adrenoleukodystrophy 2018-05-24T05:48:17 https://maestrodatabase.com/blog/vertex-announces-european-commission-approval-for-orkambi-lumacaftor-slash-ivacaftor-for-treatment-of-children-with-cystic-fibrosis-aged-2-to-5-years-old-with-most-common-form-of-the-disease 2019-01-22T06:28:20 https://maestrodatabase.com/blog/alvotech-announces-approval-of-avt03-a-biosimilar-to-prolia-and-xgeva-denosumab-in-the-european-economic-area 2025-11-27T05:41:03 https://maestrodatabase.com/blog/fda-grants-priority-review-to-gilotrif-for-uncommon-egfr-mutations-in-advanced-non-small-cell-lung-cancer 2017-10-11T05:57:54 https://maestrodatabase.com/blog/access-value-and-investment-making-the-right-choices-for-a-healthy-australia 2019-01-22T06:56:03 https://maestrodatabase.com/blog/innovent-receives-nmpa-breakthrough-therapy-designation-for-ibi343-anti-cldn18-dot-2-adc-as-monotherapy-for-advanced-pancreatic-cancer 2025-01-17T00:03:02 https://maestrodatabase.com/blog/fda-officials-defend-agencys-flexibility-under-current-regulatory-framework 2017-02-26T01:09:14 https://maestrodatabase.com/blog/mhra-approves-inavolisib-for-the-treatment-of-breast-cancer 2025-11-27T10:01:25 https://maestrodatabase.com/blog/trump-proposals-could-increase-health-costs-for-consumers 2019-01-22T08:27:59 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-november-2022 2022-10-31T11:01:22 https://maestrodatabase.com/blog/sandoz-receives-european-commission-approval-for-zessly-infliximab-in-gastroenterological-rheumatological-and-dermatological-diseases 2018-05-24T07:13:18 https://maestrodatabase.com/blog/rarestone-announces-submission-of-new-drug-application-of-wakix-pitolisant-for-narcolepsy-with-and-without-cataplexy-in-china 2021-07-22T05:11:38 https://maestrodatabase.com/blog/effect-of-project-orbis-participation-by-the-swiss-regulator-on-submission-gaps-review-times-and-drug-approval-decisions-between-2020-and-2022-a-comparative-analysis 2024-05-14T02:10:05 https://maestrodatabase.com/blog/pharmac-publishes-ptac-outcome-for-nivolumab-in-renal-cell-carcinoma 2019-01-22T07:05:28 https://maestrodatabase.com/blog/fda-accepts-supplemental-biologics-license-application-and-grants-priority-review-for-prophylactic-and-paediatric-use-for-bio-products-laboratorys-coagadex-coagulation-factor-x-human-for-treatment-of-hereditary-factor-x-deficiency 2018-05-24T06:01:29 https://maestrodatabase.com/blog/1-april-2022-price-disclosure-confirmed-prices 2022-03-15T02:21:34 https://maestrodatabase.com/blog/outlook-therapeutics-announces-uk-submission-of-marketing-authorisation-application-for-ons-5010-as-a-treatment-for-wet-amd 2024-05-14T02:04:07 https://maestrodatabase.com/blog/teva-confirms-september-pdufa-date-for-fremanezumab 2018-05-24T07:17:06 https://maestrodatabase.com/blog/fda-chief-scott-gottlieb-warns-we-have-many-hard-decisions-ahead-of-us-if-government-shutdown-persists 2019-01-22T08:30:59 https://maestrodatabase.com/blog/vaccination-strategy-against-sars-cov-2 2020-12-15T22:05:40 https://maestrodatabase.com/blog/development-of-antibiotics-for-children---towards-a-global-approach 2018-05-24T20:58:57 https://maestrodatabase.com/blog/trajectories-of-injectable-cancer-drug-costs-after-launch-in-the-united-states 2017-10-11T08:49:54 https://maestrodatabase.com/blog/what-does-patient-choice-really-mean-for-most-of-us 2017-10-11T08:44:17 https://maestrodatabase.com/blog/sumitomo-pharma-announces-fda-acceptance-of-supplemental-new-drug-application-for-vibegron-in-men-with-overactive-bladder-symptoms-receiving-pharmacological-therapy-for-benign-prostatic-hyperplasia 2024-05-14T06:59:39 https://maestrodatabase.com/blog/cancer-drug-spending-doubles-in-5-years 2018-05-24T21:11:51 https://maestrodatabase.com/blog/xeljanz-receives-positive-reimbursement-decision-in-england 2017-10-11T19:51:42 https://maestrodatabase.com/blog/fda-accepts-for-priority-review-ascendis-pharmas-nda-for-transcon-pth-in-adult-patients-with-hypoparathyroidism 2022-10-31T20:21:12 https://maestrodatabase.com/blog/new-melanoma-guidelines-recommend-150-000-dollars-a-year-treatment-thats-not-subsidised 2018-05-24T21:29:57 https://maestrodatabase.com/blog/statement-by-fda-commissioner-scott-gottlieb-on-new-steps-by-fda-to-advance-patient-engagement-in-the-agencys-regulatory-work 2017-10-11T19:57:13 https://maestrodatabase.com/blog/single-dose-kozenis-tafenoquine-approved-for-children-with-plasmodium-vivax-malaria-by-australian-therapeutic-goods-administration 2022-03-15T10:15:40 https://maestrodatabase.com/blog/drug-industry-says-emas-prime-scheme-useful-but-could-be-improved 2022-03-15T10:21:54 https://maestrodatabase.com/blog/medicare-offers-improved-access-to-high-quality-health-coverage-choices-in-2018 2017-10-11T20:01:50 https://maestrodatabase.com/blog/northland-dad-with-brain-tumour-needs-$60k-to-fund-drug-to-extend-his-life 2019-01-22T19:05:27 https://maestrodatabase.com/blog/study-finds-significant-overlap-in-the-drugs-covered-by-canadian-public-drug-plans 2017-10-11T20:12:15 https://maestrodatabase.com/blog/collider-bias 2022-03-15T03:38:22 https://maestrodatabase.com/blog/here-come-more-gene-therapies----and-more-pricing-debates 2017-10-11T20:16:43 https://maestrodatabase.com/blog/statement-from-fda-commissioner-and-director-of-the-center-for-devices-and-radiological-health-on-latest-steps-to-strengthen-fdas-510-k-program-for-premarket-review-of-medical-devices 2019-01-22T19:01:38 https://maestrodatabase.com/blog/celgene-sold-for-74-dollars-billion-leaves-a-legacy-of-chutzpah-in-science-and-drug-pricing 2019-01-22T19:50:00 https://maestrodatabase.com/blog/an-fda-program-to-approve-old-drugs-causes-higher-prices-and-shortages 2017-10-11T20:30:34 https://maestrodatabase.com/blog/new-criteria-changes-wholl-get-covid-19-vaccine-first 2020-12-15T23:06:32 https://maestrodatabase.com/blog/beigene-and-medison-announce-approval-and-national-reimbursement-in-israel-for-brukinsa-zanubrutinib-for-the-treatment-of-waldenstroems-macroglobulinaemia 2022-03-15T19:54:05 https://maestrodatabase.com/blog/the-future-of-drug-pricing-value-over-volume 2017-10-11T20:20:17 https://maestrodatabase.com/blog/icer-publishes-evidence-report-on-treatment-for-post-traumatic-stress-disorder 2024-05-14T21:30:14 https://maestrodatabase.com/blog/key-republican-in-health-laws-fate-hails-from-a-state-that-embraced-it 2017-02-26T21:25:08 https://maestrodatabase.com/blog/shutdown-risks-delaying-fda-approval-of-potentially-life-saving-drugs-and-therapies 2019-01-22T19:11:20 https://maestrodatabase.com/blog/prolonged-price-negotiation-for-kymriah-devastates-leukaemia-patients 2022-03-15T19:59:19 https://maestrodatabase.com/blog/all-high-earners-to-pay-medicare-levy-surcharge-under-budget-proposal 2017-02-26T21:30:33 https://maestrodatabase.com/blog/grassley-to-test-gop-on-lowering-drug-prices 2019-01-22T19:15:08 https://maestrodatabase.com/blog/roche-launches-cobas-pik3ca-mutation-test-for-patients-with-advanced-or-metastatic-breast-cancer-in-countries-accepting-the-ce-mark 2020-12-15T23:54:27 https://maestrodatabase.com/blog/cvs-walmart-reach-an-agreement-on-a-pharmacy-contract-after-impasse 2019-01-22T20:54:52 https://maestrodatabase.com/blog/forget-the-banks---health-insurance-makes-them-look-like-amateurs 2017-02-27T19:48:48 https://maestrodatabase.com/blog/additional-listings-on-the-pharmaceutical-schedule-of-a-range-of-orthopaedic-implants-and-associated-products-with-smith-and-nephew-limited 2017-02-27T03:36:18 https://maestrodatabase.com/blog/myrtelle-receives-fda-fast-track-rare-paediatric-disease-and-orphan-drug-designations-for-its-proprietary-gene-therapy-for-the-treatment-of-canavan-disease 2022-03-15T19:36:52 https://maestrodatabase.com/blog/fda-approves-updated-altuviiio-label-with-expanded-paediatric-data-confirming-highly-effective-bleed-protection-in-children-with-haemophilia-a 2024-05-14T10:45:05 https://maestrodatabase.com/blog/us-drug-firms-limit-price-hikes-but-still-cost-health-system-billions 2017-02-27T20:04:20 https://maestrodatabase.com/blog/budget-2024--25-cheaper-medicines-new-medicare-urgent-care-clinics-and-more-free-mental-health-services-in-a-stronger-medicare 2024-05-14T10:32:17 https://maestrodatabase.com/blog/johnson-and-johnson-lifts-lid-on-drug-pricing-data-shows-3-dot-5-percent-net-hike-in-2016 2017-02-27T20:07:11 https://maestrodatabase.com/blog/in-oversight-inquiry-key-democrat-seeking-10-years-worth-of-pricing-sales-research-data-from-drug-companies 2019-01-22T19:52:19 https://maestrodatabase.com/blog/2016-a-record-setting-year-for-generic-drugs 2017-02-27T19:55:03 https://maestrodatabase.com/blog/secretive-rebate-trap-keeps-generic-drugs-for-diabetes-and-other-ills-out-of-reach 2019-01-22T20:06:07 https://maestrodatabase.com/blog/whats-really-driving-drug-costs 2022-03-15T19:46:01 https://maestrodatabase.com/blog/expanded-access-to-covid-19-oral-antiviral-treatments-on-the-pbs 2022-10-31T20:41:31 https://maestrodatabase.com/blog/the-risk-of-expanding-the-uninsured-population-by-repealing-the-affordable-care-act 2017-04-11T21:21:57 https://maestrodatabase.com/blog/new-access-tool-launched-as-part-of-smcs-joint-work-on-streamlining-patient-access-to-innovative-medicines 2022-03-15T20:39:19 https://maestrodatabase.com/blog/abbvie-receives-chmp-positive-opinion-for-eight-week-treatment-option-with-viekirax-ombitasvir-slash-paritaprevir-slash-ritonavir-tablets-plus-exviera-dasabuvir-tablets-for-patients-with-genotype-1b-chronic-hepatitis-c 2017-02-27T20:27:03 https://maestrodatabase.com/blog/what-allergans-ceo-thinks-about-donald-trump-and-drug-prices 2017-02-27T20:09:39 https://maestrodatabase.com/blog/better-care-and-treatment-for-australians-with-blood-cancer 2022-03-15T20:34:27 https://maestrodatabase.com/blog/achieving-universal-coverage-without-turning-to-a-single-payer 2017-02-27T20:13:00 https://maestrodatabase.com/blog/gsk-real-world-study-offers-new-model-for-drug-trials 2017-02-27T20:48:40 https://maestrodatabase.com/blog/who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed 2017-02-27T23:02:46 https://maestrodatabase.com/blog/spark-biomedical-receives-fda-breakthrough-device-designation-for-infant-transcutaneous-auricular-neurostimulation-device-the-roo-system 2020-12-16T01:09:33 https://maestrodatabase.com/blog/leaked-draft-shows-gop-plan-will-not-only-replace-obamacare-but-transform-medicaid 2017-02-27T20:42:35 https://maestrodatabase.com/blog/with-obamacare-in-jeopardy-california-considers-going-it-alone-with-single-payer-system 2017-02-27T20:45:26 https://maestrodatabase.com/blog/us-fda-approves-worlds-first-rapid-covid-test-from-brisbanes-ellume 2020-12-16T00:36:32 https://maestrodatabase.com/blog/fda-approves-first-generic-of-symbicort-to-treat-asthma-and-copd 2022-03-15T20:08:22 https://maestrodatabase.com/blog/hansa-biopharma-and-german-payer-head-association-agree-on-reimbursement-price-for-idefirix-imlifidase-as-desensitisation-treatment-for-highly-sensitised-kidney-transplant-patients 2022-03-15T20:14:19 https://maestrodatabase.com/blog/exero-medicals-smart-sensor-granted-fda-breakthrough-designation 2020-12-16T00:42:03 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-march-2017 2017-02-28T00:39:46 https://maestrodatabase.com/blog/ptc-therapeutics-announces-fda-acceptance-and-priority-review-of-the-bla-for-upstaza 2024-05-15T03:38:51 https://maestrodatabase.com/blog/trump-urges-insurers-to-work-together-to-save-americans-from-obamacare 2017-02-27T23:42:51 https://maestrodatabase.com/blog/how-to-fight-a-soaring-drug-price-innovate 2017-02-28T11:58:13 https://maestrodatabase.com/blog/pbs-website-update---1-march-2017 2017-02-28T19:45:55 https://maestrodatabase.com/blog/clinical-evidence-guidelines-documents-for-medical-devices 2017-02-28T04:21:18 https://maestrodatabase.com/blog/trump-concedes-health-law-overhaul-is-unbelievably-complex 2017-02-28T11:56:13 https://maestrodatabase.com/blog/us-insurers-balk-at-expensive-miracle-drugs 2017-02-28T20:10:02 https://maestrodatabase.com/blog/baxter-secures-fda-approval-of-clinolipid-lipid-injectable-emulsion-neonatal-and-paediatric-indication 2024-05-14T23:50:14 https://maestrodatabase.com/blog/fda-approves-once-daily-qtern-dapagliflozin-and-saxagliptin-tablets-for-adults-with-type-2-diabetes-mellitus 2017-02-28T20:18:42 https://maestrodatabase.com/blog/health-canada-approves-venclexta-venetoclax-in-combination-with-azacitidine-or-low-dose-cytarabine-for-untreated-acute-myeloid-leukaemia 2020-12-16T01:28:47 https://maestrodatabase.com/blog/sinodinos-announces-intention-for-womens-advisory-roundtable 2017-02-28T19:49:03 https://maestrodatabase.com/blog/nice-publishes-draft-guidance-on-keytruda 2017-02-28T19:57:51 https://maestrodatabase.com/blog/universal-public-coverage-of-essential-drugs-would-improve-health-care-research-suggests 2017-02-28T20:33:14 https://maestrodatabase.com/blog/pathology-providers-guarantee-to-continue-to-provide-pap-tests-for-australian-women 2017-02-28T20:43:33 https://maestrodatabase.com/blog/fortress-biotech-announces-breakthrough-therapy-designation-for-cutx-101-copper-histidinate-for-the-treatment-of-menkes-disease 2020-12-16T02:06:43 https://maestrodatabase.com/blog/viiv-healthcare-welcomes-european-commission-approval-of-dolutegravir-paediatric-type-ii-variation-and-extension-applications 2017-02-28T20:22:02 https://maestrodatabase.com/blog/fda-approves-xermelo-for-carcinoid-syndrome-diarrhoea 2017-02-28T23:02:13 https://maestrodatabase.com/blog/pharma-company-gives-up-on-pharmac-gives-drug-free-to-new-zealand-patients 2017-02-28T20:50:58 https://maestrodatabase.com/blog/oncosec-granted-fda-fast-track-designation-for-immunopulse-il-12-for-the-treatment-of-metastatic-melanoma-following-progression-on-pembrolizumab-or-nivolumab 2017-02-28T23:16:36 https://maestrodatabase.com/blog/ascendis-pharma-announces-extension-of-us-fda-review-period-for-transcon-pth-for-adults-with-hypoparathyroidism 2024-05-15T04:07:05 https://maestrodatabase.com/blog/eisai-initiates-rolling-biologics-license-application-to-us-fda-for-leqembi-lecanemab-irmb-for-subcutaneous-maintenance-dosing 2024-05-15T04:00:02 https://maestrodatabase.com/blog/viiv-healthcare-announces-health-canada-approval-for-apretude-cabotegravir-tablets-and-extended-release-injectable-suspension-for-pre-exposure-prophylaxis-to-reduce-the-risk-of-sexually-acquired-hiv 2024-05-15T03:52:57 https://maestrodatabase.com/blog/public-private-partnership-speeds-investigator-access-to-cancer-drugs 2017-03-01T06:11:08 https://maestrodatabase.com/blog/pressure-mounts-on-eu-drug-regulator-to-approve-pfizer-covid-19-vaccine 2020-12-16T05:42:35 https://maestrodatabase.com/blog/year-in-review 2020-12-16T05:53:50 https://maestrodatabase.com/blog/fda-accepts-the-biologics-license-application-for-avelumab-for-the-treatment-of-metastatic-urothelial-carcinoma-for-priority-review 2017-03-01T20:03:30 https://maestrodatabase.com/blog/teva-announces-priority-review-granted-by-fda-for-sd-809-for-treatment-of-tardive-dyskinesia 2017-03-01T20:10:55 https://maestrodatabase.com/blog/recommendations-on-eligibility-to-prime-scheme---february-2017 2017-03-01T19:47:02 https://maestrodatabase.com/blog/palbociclib-in-advanced-breast-cancer-disadvantages-in-certain-patients 2017-03-01T19:51:45 https://maestrodatabase.com/blog/orphan-drug-sales-will-outpace-all-other-meds-thanks-to-high-prices 2017-03-01T20:27:23 https://maestrodatabase.com/blog/trump-opposes-required-health-benefits-but-reveals-few-details-of-his-plan-to-end-the-aca 2017-03-01T20:31:26 https://maestrodatabase.com/blog/trump-derides-slow-and-burdensome-approval-process-at-fda 2017-03-01T20:25:05 https://maestrodatabase.com/blog/bluebird-bio-receives-ec-approval-for-skysona-elivaldogene-autotemcel-lenti-d-gene-therapy-for-patients-less-than-18-years-of-age-with-early-cerebral-adrenoleukodystrophy-without-matched-sibling-donor 2021-07-22T07:31:29 https://maestrodatabase.com/blog/give-us-the-chance-to-live-mum-suffering-from-breast-cancer-begs-for-life-extending-drug-kadcyla-to-be-available-on-nhs 2017-03-01T20:39:36 https://maestrodatabase.com/blog/bernie-sanders-takes-another-swing-at-big-pharma-with-bill-to-allow-drug-imports 2017-03-01T20:33:32 https://maestrodatabase.com/blog/insurer-windfalls-arent-a-solution-to-drug-prices 2017-03-01T20:36:29 https://maestrodatabase.com/blog/who-stresses-urgent-need-for-r-and-d-for-drug-resistant-tb-alongside-newly-prioritized-antibiotic-resistant-pathogens 2017-03-01T22:25:26 https://maestrodatabase.com/blog/gilead-and-galapagos-announce-new-commercialisation-and-development-agreement-for-jyseleca-filgotinib 2020-12-16T10:06:56 https://maestrodatabase.com/blog/drug-benefit-managers-need-more-oversight-pharmacists-say 2017-03-01T20:53:03 https://maestrodatabase.com/blog/fda-approves-odactra-for-house-dust-mite-allergies 2017-03-01T22:18:42 https://maestrodatabase.com/blog/nice-recommends-novartis-wet-amd-drug-beovu 2020-12-16T10:21:05 https://maestrodatabase.com/blog/cdr-update----issue-129 2017-10-11T22:38:18 https://maestrodatabase.com/blog/burdensome-fda-drug-approval-process-fuels-innovation-saves-lives 2017-03-02T01:15:20 https://maestrodatabase.com/blog/health-canada-approves-zolgensma-the-one-time-gene-therapy-for-paediatric-patients-with-spinal-muscular-atrophy 2020-12-16T20:16:52 https://maestrodatabase.com/blog/grant-winners-announced-for-new-joint-pharmaceuticals-research-fund 2017-03-02T01:24:58 https://maestrodatabase.com/blog/dynavax-announces-fda-acceptance-for-review-of-its-complete-response-to-november-2016-crl-and-pdufa-action-date-for-heplisav-b 2017-03-02T01:18:40 https://maestrodatabase.com/blog/in-a-petition-boehringer-warns-fda-its-definition-of-strength-threatens-biosimilar-competition 2020-12-16T19:54:35 https://maestrodatabase.com/blog/durect-corporation-announces-dur-928-granted-fda-fast-track-designation-for-treatment-of-alcoholic-hepatitis 2020-12-16T19:59:10 https://maestrodatabase.com/blog/rybrevant-plus-chemotherapy-approved-in-canada-as-first-and-only-targeted-treatment-to-reduce-risk-of-disease-progression-or-death-by-more-than-half-in-second-line-egfr-mutated-advanced-lung-cancer 2025-01-17T03:43:15 https://maestrodatabase.com/blog/fda-authorises-marketing-of-new-implant-to-repair-a-torn-anterior-cruciate-ligament 2020-12-16T20:04:44 https://maestrodatabase.com/blog/1-november-2022-updates-as-part-of-the-digital-transformation-of-authority-required-written-pbs-listings 2022-11-01T00:30:49 https://maestrodatabase.com/blog/fda-approves-datopotamab-deruxtecan-dlnk-for-unresectable-or-metastatic-hr-positive-her2-negative-breast-cancer 2025-01-17T20:13:55 https://maestrodatabase.com/blog/nice-recommends-innovative-treatment-for-type-1-diabetes 2019-07-12T11:39:47 https://maestrodatabase.com/blog/improving-affordability-of-new-essential-cancer-medicines 2019-07-12T11:27:02 https://maestrodatabase.com/blog/pharmac-to-fund-new-treatments-for-lung-and-ovarian-cancer 2022-03-16T01:00:53 https://maestrodatabase.com/blog/atara-biotherapeutics-provides-regulatory-and-business-update-on-ebvallo-tabelecleucel 2026-01-12T21:58:11 https://maestrodatabase.com/blog/astrazeneca-biopharma-president-talks-drug-rebates-pricing 2019-07-12T12:02:29 https://maestrodatabase.com/blog/biomarin-receives-standard-approval-for-palynziq-pegvaliase-pqpz-injection-for-treatment-of-adults-with-phenylketonuria-a-rare-enetic-disease 2018-05-25T03:06:31 https://maestrodatabase.com/blog/aimmune-statement-on-icer-final-report-on-ar101-for-peanut-allergy 2019-07-12T11:57:28 https://maestrodatabase.com/blog/patients-with-rare-bile-duct-cancer-set-to-benefit-from-life-extending-treatment 2021-07-22T11:20:29 https://maestrodatabase.com/blog/life-extending-injection-for-blood-cancer-available-on-the-nhs 2022-03-16T06:32:20 https://maestrodatabase.com/blog/tg-therapeutics-receives-breakthrough-therapy-designation-from-the-u-dot-s-fda-for-umbralisib-for-the-treatment-of-marginal-zone-lymphoma 2019-01-23T04:00:20 https://maestrodatabase.com/blog/atogepant-monohydrate-for-the-prevention-of-migraine 2024-05-15T05:17:12 https://maestrodatabase.com/blog/submission-of-oral-edarvarone-formulation-mt-1186-new-drug-application-in-japan-for-als 2022-03-16T02:06:54 https://maestrodatabase.com/blog/seladelpar-approved-to-treat-adult-patients-in-the-uk-with-liver-illness 2025-01-17T20:30:09 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-for-review-astellas-supplemental-new-drug-application-for-mirabegron-for-use-in-combination-with-solifenacin-succinate-5-mg-for-the-treatment-of-overactive-bladder 2017-10-12T00:03:09 https://maestrodatabase.com/blog/roche-is-discussing-alzheimers-drug-with-fda-following-regulators-controversial-approval-of-biogens-aduhelm-ceo-says 2021-07-22T11:52:58 https://maestrodatabase.com/blog/u-dot-s-fda-grants-fast-track-designation-for-krystal-biotechs-kb103-for-the-treatment-of-dystrophic-epidermolysis-bullosa 2018-05-25T04:16:37 https://maestrodatabase.com/blog/european-commission-approves-blincyto-blinatumomab-in-patients-with-philadelphia-chromosome-negative-minimal-residual-disease-positive-b-cell-precursor-acute-lymphoblastic-leukaemia 2019-01-23T07:37:00 https://maestrodatabase.com/blog/bayers-new-symptomatic-chronic-heart-failure-treatment-verquvo-vericiguat-approved-in-eu 2021-07-22T11:36:30 https://maestrodatabase.com/blog/dynavax-provides-regulatory-update-on-sbla-for-four-dose-heplisav-b-regimen-for-adults-on-haemodialysis-in-the-us 2024-05-15T21:07:42 https://maestrodatabase.com/blog/fda-accepts-new-drug-application-and-grants-priority-review-for-enasidenib-in-relapsed-or-refractory-aml-with-an-idh2-mutation 2017-03-02T09:32:53 https://maestrodatabase.com/blog/fda-approves-keytruda-pembrolizumab-plus-lenvima-lenvatinib-combination-for-patients-with-certain-types-of-advanced-endometrial-carcinoma 2021-07-22T11:45:38 https://maestrodatabase.com/blog/trumps-drug-ad-price-transparency-contains-huge-loophole-researchers-identify 2019-01-23T07:56:40 https://maestrodatabase.com/blog/european-and-us-regulators-agree-on-mutual-recognition-of-inspections-of-medicines-manufacturers 2017-03-02T19:47:23 https://maestrodatabase.com/blog/recro-pharma-receives-complete-response-letter-from-the-fda 2018-05-25T04:33:25 https://maestrodatabase.com/blog/europe-begins-reviewing-application-for-astrazeneca-covid-drug 2022-03-16T19:51:07 https://maestrodatabase.com/blog/nice-recommends-ocaliva-obeticholic-acid-for-the-treatment-of-patients-with-primary-biliary-cholangitis-in-england-wales-and-northern-ireland 2017-03-02T19:53:31 https://maestrodatabase.com/blog/nice-says-patients-accessing-more-cancer-drugs-following-price-drops 2017-03-02T09:58:17 https://maestrodatabase.com/blog/health-funds-hit-list-to-save-members-$1-dot-5bn-a-year 2017-03-02T19:44:05 https://maestrodatabase.com/blog/dostarlimab-for-previously-treated-advanced-or-recurrent-endometrial-cancer-with-high-microsatellite-instability-or-mismatch-repair-deficiency 2022-03-16T19:43:47 https://maestrodatabase.com/blog/republicans-in-washington-are-in-control-but-not-in-agreement 2017-03-02T20:21:11 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-therapies-for-myasthenia-gravis 2021-07-22T12:21:28 https://maestrodatabase.com/blog/pfizer-and-biontech-submit-for-u-dot-s-emergency-use-authorisation-of-an-additional-booster-dose-of-their-covid-19-vaccine-for-older-adults 2022-03-16T19:55:26 https://maestrodatabase.com/blog/nice-expands-positive-recommendation-for-erbitux-as-first-line-treatment-for-ras-wild-type-mcrc 2017-03-02T20:04:20 https://maestrodatabase.com/blog/republican-unity-on-health-care-is-elusive-despite-trumps-support 2017-03-02T20:17:11 https://maestrodatabase.com/blog/out-of-pocket-costs-undermining-health-system 2018-05-25T04:49:12 https://maestrodatabase.com/blog/alk-announces-fda-approval-for-its-house-dust-mite-sublingual-allergy-immunotherapy-tablet-acarizax-in-europe 2017-03-02T20:30:04 https://maestrodatabase.com/blog/more-government-is-not-the-remedy-for-high-drug-prices 2017-03-02T20:38:31 https://maestrodatabase.com/blog/flu-vaccine-to-be-reserved-for-most-vulnerable-as-supplies-dry-up 2018-05-25T04:46:05 https://maestrodatabase.com/blog/senaparib-approved-by-nmpa-for-first-line-maintenance-therapy-in-ovarian-cancer 2025-01-17T21:01:20 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-lisocabtagene-maraleucel-for-follicular-lymphoma 2024-05-15T21:45:15 https://maestrodatabase.com/blog/anonymous-ghost-ship-is-among-groups-flooding-drug-pricing-debate 2019-01-23T10:21:51 https://maestrodatabase.com/blog/fda-drafts-guidance-on-genome-editing-car-t-cell-therapies 2022-03-16T20:22:20 https://maestrodatabase.com/blog/future-costs-in-cost-effectiveness-analyses-past-present-future 2019-01-23T10:40:09 https://maestrodatabase.com/blog/nhs-england-unveils-new-innovative-medicine-fund 2021-07-22T12:38:58 https://maestrodatabase.com/blog/first-young-children-now-taking-life-changing-cystic-fibrosis-treatment-on-nhs 2022-02-13T10:44:53 https://maestrodatabase.com/blog/consequences-of-lack-of-funding-for-efforts-to-combat-covid--19-if-congress-does-not-act 2022-03-16T20:33:45 https://maestrodatabase.com/blog/pharmac-deal-good-news-for-new-zealanders 2022-03-16T20:00:57 https://maestrodatabase.com/blog/sk-bioscience-submits-a-rolling-review-for-covid-19-vaccine-gbp510-to-british-pharmaceutical-authority 2022-03-16T20:09:34 https://maestrodatabase.com/blog/how-is-nice-supporting-digital-health-technology-developers 2022-02-13T20:06:56 https://maestrodatabase.com/blog/first-batch-of-oxford-universitys-vaccine-for-covid-19-ready-by-new-years-day 2020-11-20T22:15:43 https://maestrodatabase.com/blog/highlights-from-the-june-22-25-chmp-meeting 2020-06-28T05:10:07 https://maestrodatabase.com/blog/the-fda-and-its-new-commissioner-must-follow-the-science 2022-02-13T19:59:39 https://maestrodatabase.com/blog/novavax---first-protein-vaccine-now-available 2022-02-13T19:50:24 https://maestrodatabase.com/blog/fast-track-granted-by-fda-for-nnz-2591-in-phelan-mcdermid-syndrome 2025-10-20T23:43:42 https://maestrodatabase.com/blog/juno-therapeutics-and-celgene-corporations-investigational-drug-jcar017-granted-breakthrough-therapy-designation-from-fda-and-priority-medicines-eligibility-from-ema-for-relapsed-slash-refractory-diffuse-large-b-cell-lymphoma 2016-12-20T23:18:54 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac---november-2024 2024-12-20T06:35:36 https://maestrodatabase.com/blog/spectrum-pharmaceuticals-announces-acceptance-of-new-drug-application-filing-for-poziotinib 2022-02-14T01:05:10 https://maestrodatabase.com/blog/cogent-biosciences-announces-fda-breakthrough-therapy-designation-for-bezuclastinib 2025-10-20T23:27:59 https://maestrodatabase.com/blog/pharmac-proposing-to-widen-access-to-funded-medicines 2022-02-14T00:41:59 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-treatment-for-smoking-cessation 2025-10-20T23:32:27 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-to-cns-pharmaceuticals-for-berubicin-for-the-treatment-of-recurrent-glioblastoma-multiforme 2021-06-30T00:57:10 https://maestrodatabase.com/blog/cend-therapeutics-cend-1-granted-fast-track-designation-for-pancreatic-cancer 2021-06-30T01:55:35 https://maestrodatabase.com/blog/170-000-people-in-england-to-have-further-treatment-choice-for-preventing-migraine-attacks 2024-04-11T11:21:24 https://maestrodatabase.com/blog/apellis-announces-fda-fast-track-designation-for-apl-2-in-pnh 2016-12-21T03:25:14 https://maestrodatabase.com/blog/children-and-young-adults-to-benefit-after-nice-recommends-personalised-immunotherapy-to-treat-blood-cancer-be-made-routinely-available-on-the-nhs 2024-04-11T11:18:52 https://maestrodatabase.com/blog/decision-to-list-oral-betaine-for-rare-disorder 2016-12-21T03:09:46 https://maestrodatabase.com/blog/manual-of-resource-items-and-their-associated-unit-costs 2016-12-21T03:13:23 https://maestrodatabase.com/blog/new-federal-incentives-for-diversity-in-clinical-trials 2022-10-09T00:08:12 https://maestrodatabase.com/blog/free-medicines-under-proposed-plan-to-slash-pbs-co-payment 2022-10-08T23:10:18 https://maestrodatabase.com/blog/the-inflation-reduction-act-lowers-health-care-costs-for-millions-of-americans 2022-10-08T23:20:09 https://maestrodatabase.com/blog/kempharm-granted-fast-track-designation-for-kp201-slash-ir 2016-12-21T03:57:23 https://maestrodatabase.com/blog/astellas-announces-fda-fast-track-designation-for-asp0892-dna-vaccine-for-mitigation-of-severe-hypersensitivity-reactions-due-to-peanut-allergy 2016-12-21T04:28:26 https://maestrodatabase.com/blog/fda-extends-review-of-application-for-ocrevus-ocrelizumab 2016-12-21T04:52:19 https://maestrodatabase.com/blog/spravato-esketamine-nasal-spray-approved-in-europe-for-adults-with-treatment-resistant-major-depressive-disorder 2019-12-20T01:56:02 https://maestrodatabase.com/blog/european-commission-approves-mercks-keytruda-pembrolizumab-plus-chemotherapy-for-certain-patients-with-oesophageal-cancer-or-her2-negative-gastro-oesophageal-junction-adenocarcinoma 2021-06-30T02:50:01 https://maestrodatabase.com/blog/medicares-plan-for-drug-price-negotiation---the-importance-of-defining-generic-entry 2023-07-09T03:25:46 https://maestrodatabase.com/blog/tesaro-announces-priority-review-designation-for-niraparib-nda 2016-12-21T05:04:41 https://maestrodatabase.com/blog/canada-again-delays-overhaul-to-patented-medicine-pricing-system 2021-06-30T02:44:22 https://maestrodatabase.com/blog/tryngolza-olezarsen-approved-in-us-as-first-ever-treatment-for-adults-living-with-familial-chylomicronemia-syndrome-as-an-adjunct-to-diet 2024-12-20T20:39:43 https://maestrodatabase.com/blog/ono-warns-on-profit-after-government-halves-price-of-cancer-drug-opdivo 2016-12-21T10:36:53 https://maestrodatabase.com/blog/senate-aims-to-stop-firms-from-buying-up-drugs-and-jacking-up-prices 2016-12-21T10:48:58 https://maestrodatabase.com/blog/ucbs-anti-epileptic-drug-vimpat-lacosamide-approved-as-monotherapy-by-european-commission 2016-12-21T07:58:51 https://maestrodatabase.com/blog/summary-of-the-agenda-for-the-pbac-march-2017-meeting 2016-12-21T20:28:16 https://maestrodatabase.com/blog/fda-accepts-supplemental-new-drug-application-for-pfizers-ibrance-palbociclib-in-hr-plus-her2--metastatic-breast-cancer 2016-12-21T20:33:56 https://maestrodatabase.com/blog/janssen-submits-two-applications-to-fda-seeking-approval-of-simponi-aria-golimumab-for-the-treatment-of-active-psoriatic-arthritis-and-active-ankylosing-spondylitis 2016-12-21T10:58:18 https://maestrodatabase.com/blog/trump-is-going-after-health-care-will-democrats-push-back 2016-12-21T11:08:34 https://maestrodatabase.com/blog/first-fda-approved-vaccine-for-the-prevention-of-ebola-virus-disease-marking-a-critical-milestone-in-public-health-preparedness-and-response 2019-12-20T02:17:52 https://maestrodatabase.com/blog/us-fda-issues-complete-response-letter-for-the-glepaglutide-new-drug-application-for-the-treatment-of-short-bowel-syndrome 2024-12-20T20:21:02 https://maestrodatabase.com/blog/medunik-canada-once-again-receives-notice-of-compliance-from-health-canada-for-ruzurgi-amifampridine-following-review-ordered-by-court-ruling 2021-06-30T02:38:48 https://maestrodatabase.com/blog/care-for-the-vulnerable-vs-cash-for-the-powerful----trumps-pick-for-hhs 2016-12-21T23:59:25 https://maestrodatabase.com/blog/macrogenics-announces-submission-of-margetuximab-biologics-license-application-to-u-dot-s-fda 2019-12-20T03:34:08 https://maestrodatabase.com/blog/as-the-coronavirus-spreads-drug-pricing-legislation-remains-stalled 2020-06-28T12:18:29 https://maestrodatabase.com/blog/fda-officials-call-for-including-adolescents-in-adult-oncology-trials 2016-12-22T00:08:34 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-encorafenib-with-cetuximab-and-mfolfox6-for-metastatic-colorectal-cancer-with-a-braf-v600e-mutation 2024-12-20T21:34:25 https://maestrodatabase.com/blog/amgen-and-allergan-submit-biologics-license-application-for-abp-798-biosimilar-candidate-to-rituxan-rituximab-to-u-dot-s-fda 2019-12-20T04:12:18 https://maestrodatabase.com/blog/icer-publishes-fourth-annual-assessment-of-barriers-to-fair-access-within-us-commercial-insurance-prescription-drug-coverage 2024-12-20T20:47:08 https://maestrodatabase.com/blog/high-cost-high-value-oral-specialty-drugs-more-evidence-on-the-impact-of-cost-sharing-in-medicare-part-d 2016-12-22T03:05:40 https://maestrodatabase.com/blog/gpha-to-president-elect-trump-generic-drug-and-biosimilar-competition-key-to-lowering-drug-prices-expanding-access-to-affordable-medicines 2016-12-22T03:45:49 https://maestrodatabase.com/blog/richter-withdraws-marketing-application-for-biosimilar-drug 2016-12-22T04:04:54 https://maestrodatabase.com/blog/the-reimbursement-for-medicines-is-expected-to-decrease-by-sek-185-million-in-2020 2020-06-28T21:35:23 https://maestrodatabase.com/blog/erc-belgium-submits-marketing-authorisation-application-to-european-medicines-agency-for-glioblastoma-immunotherapy-sitoiganap 2020-06-28T21:19:46 https://maestrodatabase.com/blog/axsome-therapeutics-receives-fda-breakthrough-therapy-designation-for-axs-05-for-the-treatment-of-alzheimers-disease-agitation 2020-06-28T21:25:23 https://maestrodatabase.com/blog/pfizer-and-biontech-to-submit-emergency-use-authorisation-request-today-to-the-u-dot-s-fda-for-covid-19-vaccine 2020-11-21T05:34:05 https://maestrodatabase.com/blog/sen-klobuchar-on-drug-pricing-this-is-going-to-be-one-of-the-top-priorities-of-the-year 2016-12-22T20:37:45 https://maestrodatabase.com/blog/adc-therapeutics-announces-fda-accepts-biologics-license-application-and-grants-priority-review-for-loncastuximab-tesirine-for-treatment-of-relapsed-or-refractory-diffuse-large-b-cell-lymphoma 2020-11-21T06:08:44 https://maestrodatabase.com/blog/tga-approves-new-lung-cancer-drug-osimertinib-for-patients-dealt-cruel-double-blow 2016-12-22T20:40:05 https://maestrodatabase.com/blog/fda-awards-first-ever-national-priority-vouchers-to-nine-sponsors 2025-10-21T03:45:21 https://maestrodatabase.com/blog/u-dot-s-consumer-agency-schedules-meeting-on-drug-prices 2022-02-14T05:28:55 https://maestrodatabase.com/blog/ema-publishes-epar-for-venclyxto 2016-12-22T20:46:54 https://maestrodatabase.com/blog/merry-christmas-and-a-happy-new-year-to-all 2023-12-21T20:30:12 https://maestrodatabase.com/blog/ema-starts-safety-review-of-janus-kinase-inhibitors-for-inflammatory-disorders 2022-02-14T07:02:15 https://maestrodatabase.com/blog/fda-approves-first-treatment-for-hutchinson-gilford-progeria-syndrome-and-some-progeroid-laminopathies 2020-11-21T07:45:40 https://maestrodatabase.com/blog/singapore-is-the-latest-country-to-approve-novavaxs-covid-vaccine-while-the-u-dot-s-reviews-application 2022-02-14T10:36:55 https://maestrodatabase.com/blog/glaukos-announces-fda-approval-of-epioxa 2025-10-21T05:17:11 https://maestrodatabase.com/blog/the-australian-managed-entry-scheme-are-we-getting-it-right 2018-04-22T21:56:08 https://maestrodatabase.com/blog/bavarian-nordic-announces-breakthrough-therapy-designation-for-its-rsv-vaccine-candidate-for-the-prevention-of-respiratory-syncytial-virus-in-older-adults 2022-02-14T19:46:24 https://maestrodatabase.com/blog/replimune-announces-fda-acceptance-of-bla-resubmission-of-rp1-for-the-treatment-of-advanced-melanoma 2025-10-21T04:12:48 https://maestrodatabase.com/blog/fasenra-approved-for-treatment-of-children-aged-6-to-11-with-severe-asthma 2024-04-11T21:15:40 https://maestrodatabase.com/blog/axcella-therapeutics-announces-fda-fast-track-designation-for-axa1125-in-nash 2022-02-14T19:41:14 https://maestrodatabase.com/blog/avion-pharmaceuticals-an-alora-pharmaceuticals-company-announces-the-fda-approval-and-availability-of-dhivy-for-the-treatment-of-parkinsons-disease 2022-02-14T19:53:05 https://maestrodatabase.com/blog/us-fda-grants-the-coveted-breakthrough-designation-for-early-stage-prostate-cancer-detection-blood-test-developed-in-india-by-datar-cancer-genetics 2022-02-14T19:34:20 https://maestrodatabase.com/blog/peter-paid-60-000-dollars-to-boost-his-cancer-survival-chances-but-others-miss-out 2022-02-14T20:11:21 https://maestrodatabase.com/blog/nice-issues-final-draft-guidance-for-use-of-remdesivir-and-also-for-tixagevimab-cilgavimab-evusheld-for-treatment-of-covid-19 2024-04-11T21:37:47 https://maestrodatabase.com/blog/puretech-receives-fda-fast-track-designation-for-lyt-200-in-head-and-neck-cancers 2024-04-11T21:26:27 https://maestrodatabase.com/blog/new-cgm-device-for-australians-with-diabetes 2022-02-14T20:13:38 https://maestrodatabase.com/blog/nurse-prescribers-now-able-to-initiate-special-authority-medicines 2021-06-30T04:51:36 https://maestrodatabase.com/blog/who-prequalifies-first-monoclonal-antibody---tocilizumab---to-treat-covid-19 2022-02-14T19:58:10 https://maestrodatabase.com/blog/novelion-therapeutics-subsidiary-files-for-european-approval-for-metreleptin-as-a-treatment-for-generalised-lipodystrophy-and-a-subset-of-patients-with-partial-lipodystrophy 2016-12-23T01:09:56 https://maestrodatabase.com/blog/members-of-congress-ask-cdc-to-cut-cost-of-new-hiv-prevention-drug 2022-02-14T20:02:22 https://maestrodatabase.com/blog/medscape-awarded-contract-from-fda-to-develop-educational-programming-focused-on-biosimilars 2022-02-14T20:20:05 https://maestrodatabase.com/blog/confirmation-fight-over-bidens-fda-nominee-comes-to-a-head 2022-02-14T20:17:05 https://maestrodatabase.com/blog/anxiety-mounts-for-australian-patients-as-supply-chain-crunch-hits-another-arthritis-drug 2022-02-14T20:25:02 https://maestrodatabase.com/blog/wonder-drug-for-sufferers-given-green-light-for-nhs-use 2016-12-23T08:33:05 https://maestrodatabase.com/blog/after-five-years-of-successful-experience-internationally-biocon-biologics-hulio-biosimilar-to-humira-now-available-in-the-united-states 2023-07-09T23:22:27 https://maestrodatabase.com/blog/ultragenyx-submits-biologics-license-application-to-the-us-fda-for-ux111-aav-gene-therapy-for-the-treatment-of-sanfilippo-syndrome-type-a 2024-12-21T04:54:02 https://maestrodatabase.com/blog/novavax-files-for-conditional-marketing-authorisation-of-covid-19-vaccine-in-switzerland 2022-02-14T22:15:02 https://maestrodatabase.com/blog/azars-plan-to-tie-u-dot-s-drug-prices-to-foreign-ones-will-impact-investments-in-r-and-d 2019-06-22T21:13:33 https://maestrodatabase.com/blog/maori-council-calls-for-inquiry-into-pharmac 2019-06-22T21:09:01 https://maestrodatabase.com/blog/great-help-20-000-dollars-brain-cancer-drug-set-to-be-listed-on-pbs 2019-06-22T21:05:45 https://maestrodatabase.com/blog/gilead-submits-new-drug-application-to-us-fda-for-twice-yearly-lenacapavir-for-hiv-prevention 2024-12-21T05:26:20 https://maestrodatabase.com/blog/eli-lilly-ceo-says-drug-maker-will-keep-looking-for-ways-to-cut-insulin-costs-as-walmart-debuts-lower-price-rival 2021-06-30T12:32:21 https://maestrodatabase.com/blog/sobi-receives-approval-from-the-fda-for-once-daily-dosing-frequency-of-orfadin-for-the-treatment-of-ht-1 2017-09-10T01:23:36 https://maestrodatabase.com/blog/allogene-therapeutics-granted-fda-fast-track-designation-for-allo-605-the-first-turbocar-t-cell-therapy-for-the-treatment-of-relapsed-slash-refractory-multiple-myeloma 2021-06-30T12:47:59 https://maestrodatabase.com/blog/pharmac-funding-decision-gives-kiwis-with-hepatitis-c-access-to-a-potential-cure 2018-12-17T02:03:38 https://maestrodatabase.com/blog/states-step-up-push-to-regulate-pharmacy-drug-brokers 2021-06-30T11:24:25 https://maestrodatabase.com/blog/new-hope-breakthrough-cystic-fibrosis-treatment-to-be-listed-on-pbs 2022-02-15T01:46:48 https://maestrodatabase.com/blog/decision-to-fund-a-new-hepatitis-c-treatment-maviret-and-to-widen-access-to-adalimumab-humira-for-psoriasis 2018-12-17T02:00:02 https://maestrodatabase.com/blog/in-revised-evidence-report-icer-confirms-judgment-that-evidence-is-insufficient-to-demonstrate-net-health-benefit-of-aducanumab-for-patients-with-alzheimers-disease 2021-06-30T12:10:18 https://maestrodatabase.com/blog/icer-to-assess-treatment-for-type-2-diabetes 2021-06-30T21:33:42 https://maestrodatabase.com/blog/biosimilar-education-grant 2018-04-23T03:14:54 https://maestrodatabase.com/blog/will-biogens-new-alzheimers-drugs-burden-on-medicare-be-big-huge-or-catastrophic 2021-06-30T21:42:45 https://maestrodatabase.com/blog/they-make-a-difference---modern-medicines-not-being-funded-for-kiwis-industry-group-says 2018-04-23T03:27:43 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-july-2021 2021-06-30T13:04:49 https://maestrodatabase.com/blog/cost-effectiveness-thresholds-the-past-the-present-and-the-future 2018-04-23T03:31:21 https://maestrodatabase.com/blog/all-aged-care-homes-must-offer-staff-flu-vaccinations-turnbull-government-orders 2018-04-23T03:19:45 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-july-2021-update 2021-06-30T21:28:16 https://maestrodatabase.com/blog/man-31-dying-of-cancer-is-forced-to-pay-thousands-for-miracle-drug 2018-04-23T03:23:44 https://maestrodatabase.com/blog/sanofis-praluent-provides-solution-for-korean-dyslipidaemia-patients 2021-06-30T21:23:23 https://maestrodatabase.com/blog/fda-approves-first-drug-for-spinal-muscular-atrophy 2016-12-23T22:30:19 https://maestrodatabase.com/blog/donald-trumps-pick-for-health-secretary-traded-medical-stocks-while-in-house 2016-12-23T23:00:11 https://maestrodatabase.com/blog/celltrions-truxima-approved-in-australia 2018-04-23T05:34:00 https://maestrodatabase.com/blog/portola-pharmaceuticals-announces-fda-accepts-new-drug-application-for-priority-review-and-ema-validates-marketing-authorisation-application-for-oral-factor-xa-inhibitor-anticoagulant-betrixaban 2016-12-23T23:05:01 https://maestrodatabase.com/blog/ruling-striking-down-obamacare-moves-health-debate-to-centre-stage 2018-12-17T03:43:50 https://maestrodatabase.com/blog/trump-officials-say-drug-prices-are-inflated-so-are-some-of-their-claims-on-a-solution 2018-12-17T03:57:25 https://maestrodatabase.com/blog/fda-authorises-monoclonal-antibodies-for-treatment-of-covid-19 2021-02-10T01:36:02 https://maestrodatabase.com/blog/ab-science-announces-that-the-chmp-has-adopted-a-negative-opinion-for-the-marketing-authorization-of-masitinib-in-amyotrophic-lateral-sclerosis 2018-04-23T08:31:39 https://maestrodatabase.com/blog/company-urged-to-lower-cost-of-life-changing-drug-for-cystic-fibrosis 2018-04-23T09:21:24 https://maestrodatabase.com/blog/painful-consolidation-ahead-for-chinas-generic-drug-makers-as-beijing-gets-behind-procurement-revamp 2018-12-17T04:01:05 https://maestrodatabase.com/blog/pfizer-granted-fda-breakthrough-therapy-designation-for-trumenba-meningococcal-group-b-vaccine-for-the-prevention-of-invasive-meningococcal-b-disease-in-children-aged-1-to-9-years 2018-04-23T20:45:43 https://maestrodatabase.com/blog/takeda-receives-positive-chmp-opinion-for-adcetris-brentuximab-vedotin-for-the-treatment-of-adult-patients-with-previously-untreated-cd30-positive-stage-iv-hodgkin-lymphoma-in-combination-with-avd 2018-12-17T04:06:11 https://maestrodatabase.com/blog/mylotarg-approved-in-the-eu-for-the-treatment-of-previously-untreated-de-novo-cd33-positive-acute-myeloid-leukaemia-in-combination-with-chemotherapy 2018-04-23T20:59:04 https://maestrodatabase.com/blog/fda-declines-to-approve-daiichi-sankyos-blood-cancer-treatment 2019-06-22T22:33:49 https://maestrodatabase.com/blog/pfizer-provides-update-on-proposed-trastuzumab-biosimilar 2018-04-23T20:54:33 https://maestrodatabase.com/blog/ema-validates-type-ii-variation-for-mercks-keytruda-pembrolizumab-in-combination-with-pemetrexed-and-platinum-chemotherapy-as-first-line-therapy-in-metastatic-non-squamous-nsclc-based-on-phase-3-keynote-189-trial 2018-04-23T21:17:01 https://maestrodatabase.com/blog/like-winning-the-lottery-why-william-will-now-have-access-to-life-changing-drug 2018-04-23T21:10:15 https://maestrodatabase.com/blog/pfizer-receives-positive-chmp-opinion-for-oncology-biosimilar-zirabev-bevacizumab 2018-12-17T04:30:44 https://maestrodatabase.com/blog/myopax-receives-rare-paediatric-disease-designation-from-fda-for-breakthrough-regenerative-cell-product-in-exstrophy-epispadias-complex 2023-07-10T11:29:32 https://maestrodatabase.com/blog/summary-of-submissions-and-outcomes-from-the-march-2018-pbac-meeting 2018-04-23T21:38:55 https://maestrodatabase.com/blog/synthetic-biologics-provides-update-on-development-of-syn-004-ribaxamase-for-the-prevention-of-c-difficile-infection 2018-04-23T21:26:04 https://maestrodatabase.com/blog/delayed-patient-access-to-innovative-medical-technologies-in-south-korea-a-lead-time-analysis-of-reimbursement-coverage-determinations 2019-06-22T22:45:19 https://maestrodatabase.com/blog/chmp-grants-positive-opinion-for-new-indication-of-clovis-oncologys-rubraca-rucaparib-tablets-as-maintenance-treatment-for-women-with-relapsed-ovarian-cancer 2018-12-17T04:46:18 https://maestrodatabase.com/blog/prime-designation-granted-by-european-medicines-agency-for-roches-risdiplam-for-treatment-of-spinal-muscular-atrophy 2018-12-17T10:31:17 https://maestrodatabase.com/blog/in-cancer-trials-minorities-face-extra-hurdles 2016-12-24T09:30:10 https://maestrodatabase.com/blog/republicans-are-in-denial-on-health-care 2016-12-24T09:34:35 https://maestrodatabase.com/blog/immusoft-receives-fda-fast-track-designation-for-isp-001-a-first-in-class-engineered-b-cell-therapy-for-mps-i 2025-10-22T01:29:35 https://maestrodatabase.com/blog/novartis-pulls-eu-filing-for-canakinumab 2018-12-17T11:23:20 https://maestrodatabase.com/blog/with-no-votes-to-spare-senate-advances-califfs-fda-nomination-toward-final-vote 2022-02-15T07:23:48 https://maestrodatabase.com/blog/gondolabio-receives-us-fda-orphan-drug-and-fast-track-designations-for-port-77-for-the-treatment-of-erythropoietic-protoporphyria-and-x-linked-protoporphyria 2025-10-22T02:01:08 https://maestrodatabase.com/blog/medicines-australia-welcomes-the-governments-recognition-of-the-importance-of-medicines 2018-12-17T10:50:41 https://maestrodatabase.com/blog/pfizer-canada-announces-health-canada-approval-of-abrysvo-for-adults-18-plus 2025-10-22T02:08:15 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-positive-chmp-opinion-recommending-sprycel-dasatinib-for-paediatric-patients-with-newly-diagnosed-philadelphia-chromosome-positive-acute-lymphoblastic-leukaemia 2018-12-17T19:28:27 https://maestrodatabase.com/blog/us-fda-approves-expanded-indication-for-novartis-leqvio-inclisiran-to-include-treatment-of-adults-with-high-ldl-c-and-who-are-at-increased-risk-of-heart-disease 2023-07-10T11:36:07 https://maestrodatabase.com/blog/nice-recommends-new-diagnostic-devices-for-men-with-suspected-prostate-cancer-in-draft-guidance 2022-02-15T10:10:10 https://maestrodatabase.com/blog/novartis-weighs-reinsurance-tie-up-to-fund-ultra-expensive-drugs 2018-12-17T19:41:02 https://maestrodatabase.com/blog/health-canada-approves-darzalex-daratumumab-for-newly-diagnosed-patients-with-multiple-myeloma-who-are-transplant-ineligible 2018-12-17T19:53:59 https://maestrodatabase.com/blog/blumenthal-pushes-for-legislation-to-curb-medication-prices 2018-12-17T20:00:26 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-1-july-2021 2021-07-01T07:20:10 https://maestrodatabase.com/blog/pbs---2018-in-review-listing-timelines 2018-12-17T20:14:22 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-filing-of-hutchmeds-nda-for-surufatinib-for-the-treatment-of-advanced-neuroendocrine-tumours 2021-07-01T10:57:40 https://maestrodatabase.com/blog/n-dot-j-governor-murphy-outlines-plan-to-lower-prescription-drug-prices 2022-02-15T19:35:12 https://maestrodatabase.com/blog/pembrolizumab-in-combination-with-chemotherapy-significant-additional-benefit-in-advanced-squamous-cell-carcinoma-of-the-oesophagus 2022-02-15T19:39:20 https://maestrodatabase.com/blog/icer-publishes-final-report-and-policy-recommendations-for-haemophilia-a-therapies 2020-11-22T20:02:47 https://maestrodatabase.com/blog/guaranteeing-medicare 2021-07-01T07:23:32 https://maestrodatabase.com/blog/device-vital-for-monitoring-diabetes-should-be-funded-immediately 2020-11-22T20:12:27 https://maestrodatabase.com/blog/additional-treatment-option---tremfya---now-available-on-the-pbs-for-australians-with-active-psoriatic-arthritis 2021-07-01T08:00:36 https://maestrodatabase.com/blog/icer-publishes-final-evidence-report-and-policy-recommendations-on-tirzepatide-for-type-2-diabetes 2022-02-15T19:30:14 https://maestrodatabase.com/blog/pharmac-is-seeking-views-on-declining-funding-applications 2021-07-01T07:55:56 https://maestrodatabase.com/blog/new-breast-cancer-drug-could-buy-greerton-woman-time 2017-09-10T03:18:00 https://maestrodatabase.com/blog/fda-approves-component-of-treatment-regimen-for-most-common-childhood-cancer 2021-07-01T12:13:07 https://maestrodatabase.com/blog/mtaa-welcomes-patent-box-legislation 2022-02-15T20:00:21 https://maestrodatabase.com/blog/fda-approves-dose-escalation-label-update-for-puma-biotechnologys-nerlynx-neratinib-in-her2-positive-early-stage-and-metastatic-breast-cancer 2021-07-01T13:19:08 https://maestrodatabase.com/blog/maine-could-lower-cost-of-prescription-drugs-under-new-bill 2022-02-15T19:56:27 https://maestrodatabase.com/blog/sanofis-tzield-accepted-for-expedited-review-in-the-us-for-stage-3-type-1-diabetes-through-fda-commissioners-national-priority-voucher-pilot-program 2025-10-22T03:00:35 https://maestrodatabase.com/blog/senate-confirms-califf-as-fda-chief-in-tight-vote 2022-02-15T19:44:34 https://maestrodatabase.com/blog/lyvdelzi-seladelpar-receives-health-canada-approval-for-the-treatment-of-primary-biliary-cholangitis 2025-10-22T03:04:15 https://maestrodatabase.com/blog/the-fdas-christmas-breakthrough 2016-12-25T01:06:50 https://maestrodatabase.com/blog/neuroelectrics-granted-fda-breakthrough-device-designation-for-new-therapeutic-neuromodulation-platform-to-treat-refractory-focal-epilepsy 2021-07-01T11:02:44 https://maestrodatabase.com/blog/china-nmpa-approves-selpercatinib-for-the-treatment-of-patients-with-ret-driven-lung-and-thyroid-cancers 2022-10-10T01:35:14 https://maestrodatabase.com/blog/to-stop-price-spikes-on-prescription-drugs-a-widening-radar 2016-12-25T19:15:03 https://maestrodatabase.com/blog/biogen-alzheimer-drug-row-augers-flux-in-fast-fda-approvals 2022-02-15T19:52:57 https://maestrodatabase.com/blog/meiragtx-announces-aav-rpgr-granted-fast-track-designation-by-u-dot-s-fda-for-treatment-of-x-linked-retinitis-pigmentosa-due-to-rpgr-deficiency 2018-04-23T23:07:10 https://maestrodatabase.com/blog/daiichi-sankyo-provides-update-on-chmp-review-of-pexidartinib-a-csf1r-inhibitor-for-the-treatment-of-patients-with-tgct 2020-06-29T02:30:03 https://maestrodatabase.com/blog/lexeo-therapeutics-receives-rare-paediatric-disease-designation-and-orphan-drug-designation-for-lx2006-for-the-treatment-of-friedreichs-ataxia 2021-07-01T11:43:51 https://maestrodatabase.com/blog/drug-makers-lose-choline-alfoscerate-suit-against-government 2022-02-15T19:49:52 https://maestrodatabase.com/blog/calls-grow-for-an-investigation-into-fda-approval-of-biogens-alzheimers-drug 2021-07-01T21:24:57 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac---november-2019 2019-12-21T04:59:35 https://maestrodatabase.com/blog/abeona-announces-fda-grants-rmat-designation-to-abo-102-gene-therapy-in-mps-iiia 2018-04-23T23:21:10 https://maestrodatabase.com/blog/theradaptive-wins-additional-fda-breakthrough-designation-for-spinal-fusion 2022-02-15T20:24:47 https://maestrodatabase.com/blog/sage-therapeutics-submits-new-drug-application-to-u-dot-s-fda-for-intravenous-brexanolone-in-the-treatment-of-post-partum-depression 2018-04-23T23:12:54 https://maestrodatabase.com/blog/ground-breaking-platform-launched-for-aboriginal-and-torres-strait-islander-people-affected-by-cancer 2022-10-10T02:55:48 https://maestrodatabase.com/blog/analysis-of-launch-and-post-approval-cancer-drug-pricing-clinical-benefit-and-policy-implications-in-the-us-and-europe 2021-07-01T21:31:11 https://maestrodatabase.com/blog/tezspire-approved-in-the-eu-for-chronic-rhinosinusitis-with-nasal-polyps 2025-10-22T06:50:25 https://maestrodatabase.com/blog/fda-approves-new-treatment-option-for-patients-with-her2-positive-breast-cancer-who-have-progressed-on-available-therapies 2019-12-21T05:22:00 https://maestrodatabase.com/blog/whos-new-international-classification-of-diseases-icd-11-comes-into-effect 2022-02-15T20:13:38 https://maestrodatabase.com/blog/clascoterone-for-the-treatment-of-patients-12-years-of-age-and-older-with-acne-vulgaris 2025-10-22T10:38:01 https://maestrodatabase.com/blog/fda-approves-supplemental-new-drug-application-for-adhansia-xr-methylphenidate-hydrochloride-extended-release-capsules 2021-07-01T13:31:47 https://maestrodatabase.com/blog/sarilumab-for-the-treatment-of-children-slash-adolescents-2-17-years-of-age-with-polyarticular-or-oligoarticular-juvenile-idiopathic-arthritis 2025-10-22T10:44:52 https://maestrodatabase.com/blog/amgen-submits-biologics-license-application-for-abp-710-biosimilar-infliximab-to-us-food-and-drug-administration 2018-12-17T22:34:56 https://maestrodatabase.com/blog/office-of-generic-drugs-2021-annual-report 2022-02-15T20:21:01 https://maestrodatabase.com/blog/foundationone-cdx-receives-fda-approval-as-a-companion-diagnostic-for-alunbrig-brigatinib-to-identify-patients-with-alk-positive-metastatic-non-small-cell-lung-cancer 2021-07-01T13:39:03 https://maestrodatabase.com/blog/human-medicines-highlights-of-2021 2022-02-15T20:18:43 https://maestrodatabase.com/blog/knight-therapeutics-announces-filing-of-new-drug-submission-for-qelbree-viloxazine-in-canada 2024-12-21T20:22:23 https://maestrodatabase.com/blog/smc---july-2023-decisions 2023-07-10T21:35:04 https://maestrodatabase.com/blog/formycon-announces-commercial-launch-of-fyb201-ranibizumab-in-canada-ranopto-and-switzerland-ranivisio 2024-04-12T01:49:46 https://maestrodatabase.com/blog/2021s-first-forecast-of-savings-from-side-agreements 2021-07-01T21:53:58 https://maestrodatabase.com/blog/waiting-for-new-medicines-in-canada-europe-and-the-united-states-study-finds-americans-get-better-and-faster-access-to-innovative-drugs 2024-04-12T01:35:26 https://maestrodatabase.com/blog/lexicon-announces-receipt-of-complete-response-letter-for-zynquista-sotagliflozin 2024-12-21T20:46:21 https://maestrodatabase.com/blog/who-calls-for-lower-prices-on-gilead-drug-for-covid-linked-black-fungus 2021-07-01T21:35:52 https://maestrodatabase.com/blog/australian-adults-can-now-get-modernas-omicron-covid-19-booster-heres-what-we-know 2022-10-10T04:11:12 https://maestrodatabase.com/blog/lupin-announces-fda-approval-of-supplemental-new-drug-application-for-solosec-secnidazole-for-the-treatment-of-trichomoniasis 2021-07-01T21:47:40 https://maestrodatabase.com/blog/association-of-advisory-committee-votes-with-us-fda---a-decision-making-on-prescription-drugs-2010-2021 2023-07-10T22:08:13 https://maestrodatabase.com/blog/recommendations-made-out-of-session-by-the-pbac-march-2023-and-july-2023-meetings---changes-to-ms-2-step-pbs-listing 2023-07-10T21:45:52 https://maestrodatabase.com/blog/tga-decision-on-access-to-medical-terminations 2023-07-10T21:42:26 https://maestrodatabase.com/blog/eiger-announces-breakthrough-therapy-designation-granted-by-fda-for-lonafarnib-for-treatment-of-hepatitis-delta-virus-infection 2018-12-17T23:08:19 https://maestrodatabase.com/blog/gilead-submits-filgotinib-new-drug-application-to-u-dot-s-fda-under-priority-review-for-rheumatoid-arthritis-treatment 2019-12-21T06:16:23 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-european-commission-approval-for-revlimid-lenalidomide-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-previously-treated-follicular-lymphoma 2019-12-21T06:50:20 https://maestrodatabase.com/blog/challenges-of-non-intention-to-treat-analyses 2019-01-16T02:43:46 https://maestrodatabase.com/blog/official-complaints 2020-06-29T06:18:25 https://maestrodatabase.com/blog/pluvicto-receives-positive-recommendations-from-cadth-and-inesss-for-progressive-psma-positive-metastatic-castration-resistant-prostate-cancer 2023-07-11T02:27:41 https://maestrodatabase.com/blog/updated-information-about-pharmacs-priority-lists-september-2025 2025-10-22T21:43:20 https://maestrodatabase.com/blog/samsung-bioepis-receives-positive-chmp-opinion-for-aybintio-bevacizumab 2020-06-29T06:22:44 https://maestrodatabase.com/blog/idacio-adalimumab-aacf-now-available-in-the-united-states 2023-07-10T23:10:43 https://maestrodatabase.com/blog/evoke-resubmits-gimoti-new-drug-application-to-fda 2019-12-21T21:30:46 https://maestrodatabase.com/blog/its-about-private-healthcare-not-just-health-insurance 2017-09-10T20:52:50 https://maestrodatabase.com/blog/nanoscope-therapeutics-receives-fast-track-designation-by-the-fda-for-mco-010-for-the-treatment-of-retinitis-pigmentosa 2022-10-10T19:26:23 https://maestrodatabase.com/blog/health-insurers-demand-reforms-to-keep-premium-increases-low 2017-09-10T20:56:54 https://maestrodatabase.com/blog/new-medicine-for-cystic-fibrosis-patients 2020-06-29T10:02:04 https://maestrodatabase.com/blog/zai-lab-announces-acceptance-by-chinas-nmpa-of-the-bla-for-efgartigimod-alfa-injection-subcutaneous-injection-for-patients-with-generalised-myasthenia-gravis 2023-07-11T09:01:51 https://maestrodatabase.com/blog/successful-eloctaq-bid-should-widen-access-to-the-drug-in-the-uk 2020-06-29T10:07:03 https://maestrodatabase.com/blog/mhra-authorises-gsks-arexvy-the-first-respiratory-syncytial-virus-vaccine-for-older-adults 2023-07-11T08:56:11 https://maestrodatabase.com/blog/more-treatments-available-to-30-000-new-zealanders 2024-04-12T03:27:10 https://maestrodatabase.com/blog/nabriva-therapeutics-resubmits-new-drug-application-for-intravenous-contepo-fosfomycin-for-injection 2019-12-21T21:41:49 https://maestrodatabase.com/blog/smc---october-2022-decisions 2022-10-10T19:56:52 https://maestrodatabase.com/blog/pharmac-publishes-experts-advice-and-seeks-views-on-access-criteria-for-covid-19-treatments 2022-02-16T01:51:19 https://maestrodatabase.com/blog/ema-publishes-agenda-for-10-13-october-2022-chmp-meeting 2022-10-10T19:44:40 https://maestrodatabase.com/blog/at-least-three-people-in-running-to-head-fda 2019-06-23T02:27:17 https://maestrodatabase.com/blog/rapid-medical-receives-fda-breakthrough-device-designation-for-vasospasm-treatment 2022-02-16T01:45:03 https://maestrodatabase.com/blog/mental-health-funding-of-ps1-dot-8-million-welcomed-by-nice-and-mhra-to-explore-regulation-of-digital-mental-health-tools 2022-10-10T19:52:15 https://maestrodatabase.com/blog/sunovion-announces-fda-filing-acceptance-of-resubmitted-new-drug-application-for-apomorphine-sublingual-film 2019-12-21T21:55:13 https://maestrodatabase.com/blog/ge-healthcares-stress-agent-rapiscan-approved-for-use-in-stress-cardiac-magnetic-resonance-imaging 2022-02-16T01:39:51 https://maestrodatabase.com/blog/high-quality-data-to-empower-data-driven-medicines-regulation-in-the-european-union 2022-10-10T19:34:08 https://maestrodatabase.com/blog/fda-to-import-more-chinese-cancer-drugs-amid-shortage 2023-07-11T10:52:29 https://maestrodatabase.com/blog/scpharmaceuticals-announces-fda-approval-of-furoscix-furosemide-the-first-and-only-self-administered-subcutaneous-loop-diuretic-for-the-at-home-treatment-of-congestion-in-chronic-heart-failure 2022-10-10T19:37:46 https://maestrodatabase.com/blog/fda-approves-ortho-dermatologics-arazlo-tazarotene-0-dot-045-percent-lotion-for-acne-vulgaris 2019-12-21T22:04:41 https://maestrodatabase.com/blog/health-economic-assessment-of-ondexxya-in-life-threatening-or-uncontrolled-bleeding 2020-06-29T11:14:03 https://maestrodatabase.com/blog/saphnelo-approved-in-the-eu-for-the-treatment-of-moderate-to-severe-systemic-lupus-erythematosus 2022-02-16T09:20:33 https://maestrodatabase.com/blog/intercept-receives-complete-response-letter-from-fda-for-obeticholic-acid-for-the-treatment-of-fibrosis-due-to-nash 2020-06-29T11:58:05 https://maestrodatabase.com/blog/pfizer-and-opkos-once-weekly-ngenla-somatrogon-injection-receives-marketing-authorisation-in-european-union-for-treatment-of-paediatric-growth-hormone-deficiency 2022-02-16T09:25:38 https://maestrodatabase.com/blog/supernus-provides-regulatory-update-on-spn-830 2022-10-10T20:09:28 https://maestrodatabase.com/blog/icer-to-assess-treatments-for-anaemia-in-chronic-kidney-disease 2020-06-29T10:41:53 https://maestrodatabase.com/blog/european-medicines-agency-approves-pfizers-20-valent-pneumococcal-conjugate-vaccine-against-invasive-pneumococcal-disease-and-pneumonia-in-adults 2022-02-16T06:42:49 https://maestrodatabase.com/blog/federal-drug-price-watchdog-consulting-public-on-proposed-changes-to-its-pricing-guidelines 2022-10-10T20:02:14 https://maestrodatabase.com/blog/myosin-therapeutics-receives-fda-fast-track-designation-for-mt-125-in-glioblastoma 2025-10-22T23:37:22 https://maestrodatabase.com/blog/novartis-receives-simultaneous-approval-for-five-new-products-from-japanese-ministry-of-health-labour-and-welfare-offering-japanese-patients-a-broad-range-of-novel-treatment-options 2020-06-29T11:00:19 https://maestrodatabase.com/blog/monkeypox-vaccine-not-expected-in-nz-until-december-as-community-spread-confirmed 2022-10-10T20:05:39 https://maestrodatabase.com/blog/cardiosense-receives-fda-breakthrough-device-designation-for-algorithm-to-identify-patients-at-risk-of-decompensated-heart-failure 2022-02-16T01:57:32 https://maestrodatabase.com/blog/fda-approves-first-line-immunotherapy-for-patients-with-msi-h-slash-dmmr-metastatic-colorectal-cancer 2020-06-29T21:06:20 https://maestrodatabase.com/blog/gilead-sets-price-for-coronavirus-drug-remdesivir-at-2-340-dollars-sparking-criticism 2020-06-29T21:11:11 https://maestrodatabase.com/blog/cancer-prevention-pharmaceuticals-submits-new-drug-application-to-the-fda-for-cpp-1x-slash-sul-for-treatment-of-familial-adenomatous-polyposis 2020-06-29T21:20:12 https://maestrodatabase.com/blog/foundation-medicines-ctdna-monitoring-assay-foundationone-tracker-granted-breakthrough-device-designation-by-u-dot-s-food-and-drug-administration 2022-02-16T09:43:24 https://maestrodatabase.com/blog/fda-approves-combination-of-pertuzumab-trastuzumab-and-hyaluronidase-zzxf-for-her2-positive-breast-cancer 2020-06-29T20:57:35 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-mirati-therapeutics-new-drug-application-for-adagrasib-as-treatment-of-previously-treated-kras-g12c-mutated-non-small-cell-lung-cancer 2022-02-16T10:04:05 https://maestrodatabase.com/blog/demand-for-dexamethasone-soars-after-promising-findings-in-uk 2020-06-29T21:03:23 https://maestrodatabase.com/blog/poxel-announces-fda-fast-track-status-for-pxl065-in-x-linked-adrenoleukodystrophy 2022-02-16T19:37:22 https://maestrodatabase.com/blog/electra-therapeutics-receives-fda-breakthrough-therapy-and-ema-priority-medicines-designations-for-ela026-in-secondary-haemophagocytic-lymphohistiocytosis 2025-10-23T00:04:41 https://maestrodatabase.com/blog/bonalive-biomaterials-granted-fda-breakthrough-device-designation-for-a-bone-graft-substitute-that-potentially-protects-against-microbial-colonisation 2022-02-16T19:42:49 https://maestrodatabase.com/blog/government-should-lower-prices-of-generic-drugs 2020-06-29T21:25:57 https://maestrodatabase.com/blog/imc-responds-to-federal-court-decision-regarding-pmprb-regulatory-changes 2020-06-29T21:30:31 https://maestrodatabase.com/blog/3d-printing-medical-devices-stakeholders-weigh-in-on-fdas-discussion-paper 2022-02-16T10:22:59 https://maestrodatabase.com/blog/alkermes-and-biogen-announce-submission-of-a-new-drug-application-to-u-dot-s-fda-for-diroximel-fumarate-in-multiple-sclerosis 2018-12-18T00:37:06 https://maestrodatabase.com/blog/acadia-pharmaceuticals-announces-resubmission-of-supplemental-new-drug-application-to-u-dot-s-fda-for-nuplazid-pimavanserin-to-treat-alzheimers-disease-psychosis 2022-02-16T19:58:13 https://maestrodatabase.com/blog/european-commission-approves-oxbryta-voxelotor-for-the-treatment-of-haemolytic-anaemia-in-patients-with-sickle-cell-disease-age-12-years-and-older 2022-02-16T20:19:38 https://maestrodatabase.com/blog/merck-struggles-to-win-european-approval-for-covid-antiviral-pill 2022-02-16T19:48:22 https://maestrodatabase.com/blog/padcev-enfortumab-vedotin-ejfv-plus-keytruda-pembrolizumab-sbla-granted-fda-priority-review-for-treatment-of-certain-patients-with-muscle-invasive-bladder-cancer 2025-10-23T01:15:10 https://maestrodatabase.com/blog/charting-a-new-drug-review-pathway 2016-12-26T23:47:34 https://maestrodatabase.com/blog/the-new-lightning-rod-in-the-fight-over-high-drug-prices 2022-02-16T19:53:19 https://maestrodatabase.com/blog/stage-2-pbs-process-improvements-and-revised-cost-recovery-arrangements---information-forum 2020-11-22T23:50:58 https://maestrodatabase.com/blog/ethinyloestradiol-20-mcg-with-desogestrel-150-mcg-and-7-inert-tablets-mercilon-28 2020-11-23T01:03:14 https://maestrodatabase.com/blog/alexion-receives-marketing-authorisation-from-european-commission-for-new-formulation-of-ultomiris-ravulizumab-with-significantly-reduced-infusion-time 2020-11-23T01:27:43 https://maestrodatabase.com/blog/fda-approves-shires-motegrity-prucalopride-the-only-serotonin-4-receptor-agonist-for-adults-with-chronic-idiopathic-constipation 2018-12-18T01:05:26 https://maestrodatabase.com/blog/funding-changes-to-dornase-alfa-for-cystic-fibrosis 2020-11-23T00:32:41 https://maestrodatabase.com/blog/biogencell-receives-fda-fast-track-designation-with-expanded-access-for-bgc101 2024-12-22T01:19:00 https://maestrodatabase.com/blog/politics-science-and-the-remarkable-race-for-a-coronavirus-vaccine 2020-11-23T02:36:40 https://maestrodatabase.com/blog/fda-approves-alhemo-injection-as-once-daily-prophylactic-treatment-to-prevent-or-reduce-the-frequency-of-bleeding-episodes-for-adults-and-children-12-years-of-age-and-older-with-haemophilia-a-or-b-with-inhibitors 2024-12-22T01:12:37 https://maestrodatabase.com/blog/woman-trying-to-raise-110-000-dollars-a-month-for-life-extending-breast-cancer-treatment 2020-11-23T04:03:32 https://maestrodatabase.com/blog/fda-approves-first-acellular-tissue-engineered-vessel-to-treat-vascular-trauma-in-extremities 2024-12-22T01:35:10 https://maestrodatabase.com/blog/value-based-healthcare-summit-looks-at-a-new-health-paradigm 2018-04-24T04:02:57 https://maestrodatabase.com/blog/fda-advisory-committee-recommends-the-approval-of-baricitinib-2-mg-but-not-4-mg-for-the-treatment-of-moderately-to-severely-active-rheumatoid-arthritis 2018-04-24T03:53:52 https://maestrodatabase.com/blog/trump-delays-drug-pricing-speech-no-set-date-yet 2018-04-24T05:05:59 https://maestrodatabase.com/blog/australias-health-panel-your-chance-to-influence-the-health-system 2018-04-24T04:07:22 https://maestrodatabase.com/blog/european-commission-approves-menquadfi-the-latest-innovation-in-meningococcal-vaccination-for-individuals-12-months-of-age-and-older 2020-11-23T09:07:32 https://maestrodatabase.com/blog/vertex-announces-us-fda-approval-of-alyftrek-a-once-daily-next-in-class-cftr-modulator-for-the-treatment-of-cystic-fibrosis 2024-12-22T01:59:20 https://maestrodatabase.com/blog/nordic-nanovectors-betalutin-receives-fast-track-designation-from-us-fda-for-marginal-zone-lymphoma 2020-06-30T01:04:48 https://maestrodatabase.com/blog/pfizers-cibinqo-affordable-at-77-dollars-slash-month-with-reimbursement-for-severe-atopic-dermatitis 2023-07-11T12:03:49 https://maestrodatabase.com/blog/vertex-announces-us-fda-approval-for-trikafta-elexacaftor-slash-tezacaftor-slash-ivacaftor-and-ivacaftor-to-include-additional-non-f508del-trikafta-responsive-variants 2024-12-22T01:51:11 https://maestrodatabase.com/blog/synlogic-granted-fast-track-designation-from-fda-for-labafenogene-marselecobac-synb1934-for-treatment-of-phenylketonuria 2023-07-11T11:50:19 https://maestrodatabase.com/blog/argenx-enters-into-agreement-to-acquire-priority-review-voucher 2022-11-30T08:23:54 https://maestrodatabase.com/blog/givinostat-conditionally-approved-to-treat-patients-with-duchenne-muscular-dystrophy 2024-12-22T01:47:49 https://maestrodatabase.com/blog/dupixent-dupilumab-injection-approved-in-canada-for-adults-with-inadequately-controlled-chronic-obstructive-pulmonary-disease 2025-10-23T01:54:05 https://maestrodatabase.com/blog/fda-approves-first-medication-for-obstructive-sleep-apnoea 2024-12-22T01:40:16 https://maestrodatabase.com/blog/viiv-healthcare-receives-complete-response-letter-from-us-fda-for-use-of-investigational-cabotegravir-and-rilpivirine-long-acting-regimen-in-the-treatment-of-hiv 2019-12-22T03:11:05 https://maestrodatabase.com/blog/express-scripts-adds-three-biosimilars-to-largest-formulary-to-promote-competition-and-advance-affordability-choices-for-patients 2023-07-11T21:27:40 https://maestrodatabase.com/blog/bevacizumab-on-the-pbs 2021-07-02T06:04:48 https://maestrodatabase.com/blog/european-commission-approves-roches-fixed-duration-columvi-glofitamab-for-people-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma 2023-07-11T21:24:02 https://maestrodatabase.com/blog/limmatech-awarded-fda-fast-track-designation-for-vaccine-candidate-against-staphylococcus-aureus 2024-12-22T03:01:42 https://maestrodatabase.com/blog/nurix-therapeutics-receives-us-fda-fast-track-designation-for-nx-5948-for-the-treatment-of-relapsed-or-refractory-waldenstroms-macroglobulinaemia 2024-12-22T02:54:53 https://maestrodatabase.com/blog/takeda-withdraws-us-application-for-dengue-vaccine-candidate 2023-07-11T21:18:29 https://maestrodatabase.com/blog/nice-recommends-new-treatment-to-prevent-and-reduce-hearing-loss-in-people-being-treated-for-cancer 2024-12-22T02:37:58 https://maestrodatabase.com/blog/icer-launches-a-patient-council-to-amplify-the-patient-voice-in-value-assessment 2023-07-11T21:12:36 https://maestrodatabase.com/blog/the-european-medicines-agency-and-the-netherlands-agree-on-seat-agreement 2018-04-24T10:49:10 https://maestrodatabase.com/blog/xspray-pharma-receives-request-for-additional-information-concerning-dasynoc-from-fda 2023-07-11T22:02:02 https://maestrodatabase.com/blog/make-medicines-affordable---without-going-to-court 2023-07-11T21:42:02 https://maestrodatabase.com/blog/modernas-covid-19-vaccine-spikevax-provisionally-approved-for-use-in-individuals-6-years-and-older 2022-02-16T23:59:24 https://maestrodatabase.com/blog/fda-accepts-veloxiss-supplemental-new-drug-application-for-the-de-novo-indication-for-envarsus-xr 2018-04-24T21:01:23 https://maestrodatabase.com/blog/swiss-drugs-regulator-approves-one-of-pfizers-covid-19-booster-shots 2022-10-11T00:39:49 https://maestrodatabase.com/blog/ema-publishes-agenda-for-23-26-april-chmp-meeting 2018-04-24T20:45:09 https://maestrodatabase.com/blog/ema-statement-on-on-going-review-of-glp-1-receptor-agonists 2023-07-11T21:32:23 https://maestrodatabase.com/blog/express-scripts-targets-amgen-lilly-migraine-drugs-in-pricing-shift 2018-04-24T20:56:49 https://maestrodatabase.com/blog/icer-developing-special-report-for-submission-to-cms-as-part-of-public-comment-process-on-medicare-drug-price-negotiations 2023-07-11T21:37:08 https://maestrodatabase.com/blog/emergent-biosolutions-receives-health-canada-approval-of-biothrax-anthrax-vaccine-adsorbed 2018-12-18T01:54:17 https://maestrodatabase.com/blog/solutions-for-the-future-a-new-medicines-landscape 2020-06-30T03:58:29 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-to-assess-biologic-treatments-for-asthma-in-upcoming-assessment 2018-04-24T21:12:18 https://maestrodatabase.com/blog/catalent-signs-commercial-supply-agreement-with-blueprint-medicines-following-fda-approval-of-gavreto-pralsetinib 2020-11-23T19:43:05 https://maestrodatabase.com/blog/lorlatinib-for-the-treatment-of-adults-with-advanced-alk-positive-non-small-cell-lung-cancer 2023-07-12T06:30:51 https://maestrodatabase.com/blog/canada-federal-court-dismisses-drug-makers-plea-challenging-drug-price-rules 2020-06-30T04:04:15 https://maestrodatabase.com/blog/kiniksa-announces-u-dot-s-fda-acceptance-of-sbla-and-priority-review-for-rilonacept-in-recurrent-pericarditis 2020-11-23T19:47:49 https://maestrodatabase.com/blog/pbac-public-summary-documents---march-2021-meeting 2021-07-02T08:00:57 https://maestrodatabase.com/blog/lupin-announces-health-canada-approval-of-tiotropium-bromide-inhalation-powder-for-treatment-of-copd 2023-07-12T05:44:46 https://maestrodatabase.com/blog/beigene-announces-the-approval-of-xgeva-denosumab-in-china-for-the-prevention-of-skeletal-related-events-in-patients-with-bone-metastases-from-solid-tumours-and-in-patients-with-multiple-myeloma 2020-11-23T11:34:50 https://maestrodatabase.com/blog/ruzurgi-is-now-available-and-covered-by-the-vast-majority-of-public-health-and-private-insurance-plans 2023-07-12T05:19:23 https://maestrodatabase.com/blog/cipher-pharmaceuticals-announces-plecanatide-accepted-for-review-by-health-canada 2018-12-18T01:58:01 https://maestrodatabase.com/blog/a-letter-to-donald-trump-about-health-care 2016-12-27T09:39:18 https://maestrodatabase.com/blog/fda-expands-approval-of-influenza-treatment-to-post-exposure-prevention 2020-11-23T19:38:36 https://maestrodatabase.com/blog/negative-control-outcomes-a-tool-to-detect-bias-in-randomised-trials 2016-12-27T21:29:27 https://maestrodatabase.com/blog/renibus-therapeutics-announces-breakthrough-therapy-designation-from-us-fda-for-rbt-1-for-the-reduction-in-risk-of-post-operative-complications-in-patients-undergoing-cardiothoracic-surgery 2023-07-12T05:03:11 https://maestrodatabase.com/blog/idefirix-imlifidase-receives-provisional-approval-in-australia-as-desensitisation-treatment-in-highly-sensitised-patients-prior-to-kidney-transplantation 2023-07-12T05:11:11 https://maestrodatabase.com/blog/trumps-health-secretary-pick-leaves-nations-doctors-divided 2016-12-27T09:20:10 https://maestrodatabase.com/blog/shire-announces-fda-approval-of-adynovate-anti-haemophilic-factor-recombinant-pegylated-for-use-in-children-and-surgical-settings 2016-12-28T01:24:48 https://maestrodatabase.com/blog/covid-19-shots-could-reach-first-americans-by-mid-december-top-health-official-says 2020-11-23T20:07:49 https://maestrodatabase.com/blog/workshop-on-regulatory-support-for-development-of-orphan-medicines 2020-11-23T20:10:10 https://maestrodatabase.com/blog/ab201-development-as-a-potential-treatment-for-covid-19-receives-u-dot-s-fda-fast-track-designation 2020-11-23T19:52:33 https://maestrodatabase.com/blog/formycon-and-bioeq-announce-submission-of-the-marketing-authorisation-application-for-fyb201-a-biosimilar-candidate-to-lucentis-ranibizumab-to-the-ema 2021-07-02T08:05:00 https://maestrodatabase.com/blog/new-life-saving-medicine-free-for-rare-disease 2025-10-23T02:32:28 https://maestrodatabase.com/blog/companies-have-raised-prices-on-245-drugs-during-pandemic-advocacy-group-says 2020-06-30T04:37:26 https://maestrodatabase.com/blog/theralase-granted-fda-fast-track-designation-for-nmibc-phase-2-clinical-study 2020-11-23T19:57:49 https://maestrodatabase.com/blog/enhertu-approved-in-china-as-the-first-her2-directed-therapy-for-patients-with-her2-low-metastatic-breast-cancer 2023-07-12T11:27:38 https://maestrodatabase.com/blog/better-therapeutics-receives-fda-authorisation-for-aspyrerx-to-treat-adults-with-type-2-diabetes 2023-07-12T07:47:32 https://maestrodatabase.com/blog/junshi-biosciences-announces-acceptance-of-the-supplemental-new-drug-application-for-toripalimab 2023-07-12T08:21:57 https://maestrodatabase.com/blog/vbi-vaccines-announces-submission-of-marketing-authorisation-application-for-3-antigen-prophylactic-hepatitis-b-vaccine-to-the-european-medicines-agency 2020-11-24T05:11:22 https://maestrodatabase.com/blog/medicare-drug-price-negotiations-policy-implications-of-the-first-10-drugs-features 2024-04-12T23:10:05 https://maestrodatabase.com/blog/fda-issues-complete-response-letter-for-ryaltris-olopatadine-hydrochloride-and-mometasone-furoate 2019-06-23T23:47:03 https://maestrodatabase.com/blog/rigel-and-medison-announce-health-canada-approval-of-tavalisse-an-oral-medication-for-the-treatment-of-adults-with-chronic-immune-thrombocytopenia 2020-11-24T05:16:37 https://maestrodatabase.com/blog/proposal-to-amend-the-distribution-and-access-criteria-for-dasatinib-sprycel 2018-12-18T02:45:57 https://maestrodatabase.com/blog/epilepsy-medicine-worry 2019-06-23T23:04:40 https://maestrodatabase.com/blog/fda-approves-first-drug-to-treat-rare-metabolic-disorder 2020-11-24T05:42:28 https://maestrodatabase.com/blog/beigene-announces-fda-acceptance-of-snda-for-fifth-brukinsa-indication 2023-07-12T12:23:00 https://maestrodatabase.com/blog/statement-on-agencys-efforts-to-increase-transparency-in-medical-device-reporting 2019-06-23T23:58:17 https://maestrodatabase.com/blog/ema-and-korean-ministry-of-food-and-drug-safety-to-share-confidential-covid-19-information 2020-06-30T20:59:20 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-july-2020 2020-06-30T21:02:29 https://maestrodatabase.com/blog/fda-takes-action-to-help-facilitate-timely-development-of-safe-effective-covid-19-vaccines 2020-06-30T21:07:58 https://maestrodatabase.com/blog/telix-new-drug-application-for-prostate-cancer-imaging-product-accepted-by-us-fda 2020-11-24T07:04:50 https://maestrodatabase.com/blog/urogen-pharma-initiates-rolling-submission-of-new-drug-application-for-ugn-101-for-the-treatment-of-low-grade-upper-tract-urothelial-cancer 2018-12-18T05:36:45 https://maestrodatabase.com/blog/merck-submits-applications-for-licensure-of-v114-the-companys-investigational-15-valent-pneumococcal-conjugate-vaccine-for-use-in-adults-to-the-us-fda-and-ema 2020-11-24T06:00:47 https://maestrodatabase.com/blog/european-medicines-agency-accepted-first-china-developed-biosimilar---henlius-hlx02-marketing-authorisation-application-for-review 2019-06-24T00:15:26 https://maestrodatabase.com/blog/success-for-a-third--and-perhaps-most-important--covid-19-vaccine 2020-11-24T06:21:47 https://maestrodatabase.com/blog/fda-approves-new-treatment-for-adults-with-migraine 2019-12-24T00:07:07 https://maestrodatabase.com/blog/mediwound-announces-submission-of-biologics-license-application-to-the-us-fda-for-nexobrid-for-the-treatment-of-severe-thermal-burns 2020-06-30T21:31:25 https://maestrodatabase.com/blog/finose---nordic-cooperation-extended-to-promote-patients-access-to-medicines 2020-06-30T21:36:23 https://maestrodatabase.com/blog/jw-therapeutics-announces-nmpa-approval-of-relmacabtagene-autoleucel-injection-in-patients-with-relapsed-or-refractory-follicular-lymphoma 2022-10-11T06:16:39 https://maestrodatabase.com/blog/expansion-of-continued-dispensing-arrangements---covid-19 2020-06-30T21:11:16 https://maestrodatabase.com/blog/ultragenyx-announces-u-dot-s-fda-approval-of-dojolvi-ux007-slash-triheptanoin-the-first-fda-approved-therapy-for-the-treatment-of-long-chain-fatty-acid-oxidation-disorders 2020-06-30T21:25:00 https://maestrodatabase.com/blog/european-commission-approves-mercks-keytruda-pembrolizumab-as-adjuvant-therapy-for-adults-with-resected-stage-iii-melanoma 2018-12-18T06:17:43 https://maestrodatabase.com/blog/pharmac-considering-more-options-for-people-with-inflammatory-bowel-disease 2022-10-11T06:00:36 https://maestrodatabase.com/blog/nivolumab-in-combination-for-untreated-advanced-unresectable-recurrent-or-metastatic-oesophageal-squamous-cell-carcinoma 2022-10-11T05:53:43 https://maestrodatabase.com/blog/karyopharm-submits-new-drug-application-to-u-dot-s-fda-for-xpovio-selinexor-as-a-treatment-for-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma 2019-12-24T01:30:41 https://maestrodatabase.com/blog/fda-approves-first-generics-of-eliquis 2019-12-24T01:25:56 https://maestrodatabase.com/blog/obseva-submits-marketing-authorisation-application-to-the-european-medicines-agency-for-yselty-linzagolix-for-the-treatment-of-women-with-uterine-fibroids 2020-11-24T19:49:51 https://maestrodatabase.com/blog/empaveli-approved-by-the-tga 2022-02-17T04:10:09 https://maestrodatabase.com/blog/nice-backs-braftovi-for-braf-positive-colorectal-cancer 2020-11-24T19:55:12 https://maestrodatabase.com/blog/european-medicines-agency-validates-biomarins-marketing-authorisation-application-for-valoctocogene-roxaparvovec-to-treat-severe-haemophilia-a 2019-12-24T01:47:48 https://maestrodatabase.com/blog/funding-applications-declined 2020-06-30T21:39:23 https://maestrodatabase.com/blog/nearly-a-fifth-of-australias-covid-vaccine-stock-binned-amid-warning-of-fresh-wave-of-cases 2022-10-11T07:23:16 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-july-2020 2020-06-30T21:43:05 https://maestrodatabase.com/blog/first-adalimumab-biosimilar-gains-approval-in-japan 2020-06-30T21:52:26 https://maestrodatabase.com/blog/time-to-consider-changing-prescription-criteria-for-adhd-medication---pharmac-chief-medical-officer 2022-10-11T06:39:52 https://maestrodatabase.com/blog/new-option-for-people-with-difficult-to-treat-multiple-myeloma-is-recommended-for-use-in-cancer-drugs-fund-by-nice 2020-11-24T11:11:41 https://maestrodatabase.com/blog/after-years-of-feuds-vertex-and-the-u-dot-k-government-reach-a-deal-over-cystic-fibrosis-medicines 2020-06-30T21:55:22 https://maestrodatabase.com/blog/hospitals-in-safety-net-brace-for-health-care-laws-repeal 2016-12-28T21:17:27 https://maestrodatabase.com/blog/gps-frustrated-by-pharmacs-lack-of-progress-on-better-meds-for-type-2-diabetics 2020-11-24T20:19:18 https://maestrodatabase.com/blog/biosyngens-first-in-class-cell-therapy-brg01-receives-fda-fast-track-designation 2023-07-12T23:32:52 https://maestrodatabase.com/blog/how-donald-trumps-health-secretary-pick-endangers-women 2016-12-28T21:14:39 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-to-sbt101-the-first-investigational-aav-based-gene-therapy-for-patients-with-adrenomyeloneuropathy 2022-02-17T07:08:04 https://maestrodatabase.com/blog/disappointing-delay-for-new-type-2-diabetes-drugs-that-stop-kidney-failure-and-save-lives 2020-11-24T20:23:28 https://maestrodatabase.com/blog/polypid-granted-breakthrough-therapy-designation-from-fda-for-d-plex-for-the-prevention-of-surgical-site-infections-in-colorectal-surgery 2020-11-24T20:08:12 https://maestrodatabase.com/blog/which-pricey-drugs-will-trumps-international-pricing-policy-target 2020-11-24T20:12:41 https://maestrodatabase.com/blog/lilly-and-the-government-of-canada-sign-an-agreement-for-the-supply-of-bamlanivimab-to-treat-covid-19-in-canada 2020-11-24T20:15:48 https://maestrodatabase.com/blog/u-dot-s-fda-approves-eisais-dayvigo-lemborexant-for-treatment-of-insomnia-in-adult-patients 2019-12-24T02:00:01 https://maestrodatabase.com/blog/revolutionary-cancer-drug-using-genetically-modified-cells-approved 2018-12-18T20:05:26 https://maestrodatabase.com/blog/fda-approves-intra-cellular-therapies-novel-anti-psychotic-caplyta-lumateperone-for-the-treatment-of-schizophrenia-in-adults 2019-12-24T02:21:43 https://maestrodatabase.com/blog/our-door-is-open-fda-puts-patients-first 2018-12-18T20:21:26 https://maestrodatabase.com/blog/doctors-say-cdc-should-warn-people-the-side-effects-from-covid-vaccine-shots-wont-be-a-walk-in-the-park 2020-11-24T20:29:14 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-17-february-2022 2022-02-17T07:13:12 https://maestrodatabase.com/blog/eiger-announces-prime-designation-granted-by-european-medicines-agency-for-lonafarnib-for-treatment-of-hepatitis-delta-virus-infection 2018-12-18T20:30:30 https://maestrodatabase.com/blog/australias-coronavirus-vaccination-program-to-start-from-march 2020-11-24T20:42:19 https://maestrodatabase.com/blog/statement-from-fda-commissioner-and-director-of-the-center-for-devices-and-radiological-health-on-new-steps-to-promote-innovations-in-medical-devices-that-help-advance-patient-safety 2018-12-18T20:12:30 https://maestrodatabase.com/blog/agenda---pbac-2019-slash-1-meeting 2018-12-18T20:16:03 https://maestrodatabase.com/blog/warren-unveils-bill-to-lower-drug-prices-by-letting-government-manufacture-them 2018-12-18T20:35:56 https://maestrodatabase.com/blog/biomarin-submits-biologics-license-application-to-u-dot-s-fda-for-valoctocogene-roxaparvovec-to-treat-haemophilia-a 2019-12-24T03:38:44 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-for-priority-review-bristol-myers-squibbs-supplemental-biologics-license-application-for-breyanzi-lisocabtagene-maraleucel-as-a-second-line-therapy-for-relapsed-or-refractory-large-b-cell-lymphoma 2022-02-17T19:33:22 https://maestrodatabase.com/blog/seattle-genetics-announces-submission-of-tucatinib-new-drug-application-to-the-u-dot-s-fda-for-patients-with-locally-advanced-or-metastatic-her2-positive-breast-cancer 2019-12-24T02:43:45 https://maestrodatabase.com/blog/dong-a-st-secures-european-approval-for-stelara-biosimilar-imuldosa 2024-12-22T10:58:05 https://maestrodatabase.com/blog/european-commission-approves-talzenna-talazoparib-for-patients-with-inherited-germ-line-brca-mutated-locally-advanced-or-metastatic-breast-cancer 2019-06-24T05:04:09 https://maestrodatabase.com/blog/fibrogen-submits-new-drug-application-to-the-u-dot-s-fda-for-roxadustat-in-patients-with-anaemia-of-chronic-kidney-disease 2019-12-24T03:51:16 https://maestrodatabase.com/blog/eu-drug-regulator-could-rule-on-covid-19-vaccines-by-year-end 2020-11-25T10:35:52 https://maestrodatabase.com/blog/lupin-announces-fda-approval-of-supplemental-new-drug-application-for-solosec-secnidazole-in-adolescents-for-both-the-treatment-of-bacterial-vaginosis-in-females-and-trichomoniasis 2022-02-17T20:03:54 https://maestrodatabase.com/blog/zosano-announces-fda-submission-of-new-drug-application-for-qtrypta 2019-12-24T03:47:38 https://maestrodatabase.com/blog/pfizer-vaccine-distribution-could-kick-off-within-weeks-pending-fda-approval-azar-says 2020-11-25T10:40:30 https://maestrodatabase.com/blog/agios-wins-fda-approval-for-pill-to-treat-rare-blood-disease 2022-02-17T20:15:11 https://maestrodatabase.com/blog/third-major-covid-19-vaccine-shown-to-be-effective-and-cheaper 2020-11-25T10:52:27 https://maestrodatabase.com/blog/nirsevimab-ema-regulatory-submission-accepted-under-accelerated-assessment-for-rsv-protection-in-all-infants 2022-02-17T19:41:24 https://maestrodatabase.com/blog/meningococcal-b-vaccine-rejected-for-inclusion-on-free-schedule 2019-12-24T03:55:15 https://maestrodatabase.com/blog/how-big-pharma-suppresses-biosimilars 2019-06-24T05:45:12 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-european-commission-approval-for-opdivo-nivolumab-as-second-line-treatment-for-unresectable-advanced-recurrent-or-metastatic-oesophageal-squamous-cell-carcinoma 2020-11-25T10:26:00 https://maestrodatabase.com/blog/health-canada-authorises-novavaxs-nuvaxovid-covid-19-vaccine 2022-02-17T19:58:52 https://maestrodatabase.com/blog/liquidia-receives-complete-response-letter-from-fda-for-liq861-treprostinil-inhalation-powder-for-the-treatment-of-pulmonary-arterial-hypertension 2020-11-25T20:04:03 https://maestrodatabase.com/blog/fda-approves-belantamab-mafodotin-blmf-for-relapsed-or-refractory-multiple-myeloma 2025-10-23T21:21:42 https://maestrodatabase.com/blog/new-icer-report-shows-significant-jump-in-launch-prices-exceeding-inflation-and-gdp-growth 2025-10-23T21:27:34 https://maestrodatabase.com/blog/medical-trial-delays-see-australians-wait-for-rare-disease-treatment 2020-11-25T11:08:00 https://maestrodatabase.com/blog/dr-robert-califf-returns-as-fdas-commissioner 2022-02-17T20:24:38 https://maestrodatabase.com/blog/nice-terminates-yet-another-appraisal-of-a-cancer-medicine 2021-05-19T02:18:51 https://maestrodatabase.com/blog/u-dot-s-officials-plan-to-release-6-dot-4-million-covid-19-vaccine-doses-in-first-distribution 2020-11-25T19:53:48 https://maestrodatabase.com/blog/hospitals-charge-double-for-drugs---specialty-pharmacies-more-affordable 2022-02-17T20:44:51 https://maestrodatabase.com/blog/remdesivir-veklury-approval-for-the-treatment-of-covid-19--the-evidence-for-safety-and-efficacy 2020-11-25T20:00:06 https://maestrodatabase.com/blog/veterans-agency-to-offer-new-depression-drug-despite-cost-and-safety-concerns 2019-06-24T11:53:43 https://maestrodatabase.com/blog/astrazenecas-triple-combination-therapy-approved-in-china-for-patients-with-copd 2019-12-24T06:28:32 https://maestrodatabase.com/blog/nice-publishes-final-guidance-on-nubeqa 2020-11-25T20:26:30 https://maestrodatabase.com/blog/publication-of-stage-1-pbs-process-improvements---cost-recovery-administrative-guidelines-and-forms 2019-06-24T08:01:41 https://maestrodatabase.com/blog/rinvoq-continues-to-be-part-of-the-high-cost-protection-with-limited-subsidy-after-reconsideration 2020-11-25T20:33:43 https://maestrodatabase.com/blog/sun-biopharma-receives-fda-fast-track-designation-for-sbp-101 2020-07-01T06:24:35 https://maestrodatabase.com/blog/five-dying-a-day-pharmac-failing-on-nzs-deadliest-cancer 2019-06-24T07:55:49 https://maestrodatabase.com/blog/heidelberg-pharmas-lead-adc-candidate-hdp-101-granted-fast-track-designation-by-us-fda-for-the-treatment-of-multiple-myeloma 2025-10-23T23:24:53 https://maestrodatabase.com/blog/astrazeneca-gears-up-to-vaccinate-the-world-against-covid-19 2020-11-25T20:12:16 https://maestrodatabase.com/blog/correvio-resubmits-brinavess-vernakalant-new-drug-application-to-u-dot-s-fda-for-the-treatment-of-patients-with-recent-onset-atrial-fibrillation 2019-06-24T11:59:52 https://maestrodatabase.com/blog/russia-looks-to-undercut-rivals-with-cut-price-covid-19-vaccine 2020-11-25T20:20:18 https://maestrodatabase.com/blog/oncopeptides-submits-a-new-drug-application-to-the-fda-for-accelerated-approval-of-melflufen-in-triple-class-refractory-multiple-myeloma-patients 2020-07-01T06:19:29 https://maestrodatabase.com/blog/its-pioneer-institute-vs-icer-drug-pricing-watchdog-comes-under-fire-for-a-one-size-fits-all-approach 2019-06-24T21:43:42 https://maestrodatabase.com/blog/ardelyx-announces-submission-of-new-drug-application-to-the-u-dot-s-fda-for-tenapanor-for-the-control-of-serum-phosphorus-in-adult-patients-with-ckd-on-dialysis 2020-07-01T07:08:22 https://maestrodatabase.com/blog/forcing-patients-to-switch-to-biosimilars-puts-them-in-uncharted-waters 2019-06-24T12:19:47 https://maestrodatabase.com/blog/merck-racks-up-another-nice-recommendation-for-keytruda 2020-11-25T20:39:27 https://maestrodatabase.com/blog/y-mabs-announces-initiation-of-submission-of-omburtamab-rolling-biologics-license-application-to-the-fda 2020-07-01T07:13:10 https://maestrodatabase.com/blog/england-to-fast-track-tumour-agnostic-drugs-like-vitrakvi---if-the-price-is-right 2019-06-24T12:14:42 https://maestrodatabase.com/blog/fda-approves-bavencio-as-first-line-maintenance-treatment-for-patients-with-locally-advanced-or-metastatic-urothelial-carcinoma 2020-07-01T07:18:31 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-for-aj201-a-first-in-class-therapy-for-kennedys-disease 2025-10-23T23:07:11 https://maestrodatabase.com/blog/incorporating-patient-preferences-in-non-inferiority-trials 2019-06-24T21:52:12 https://maestrodatabase.com/blog/mezzion-announces-submission-of-new-drug-application-for-its-orphan-drug-udenafil-to-treat-patients-who-have-undergone-the-fontan-operation-for-single-ventricle-heart-disease 2020-07-01T06:31:54 https://maestrodatabase.com/blog/the-fda-erred-in-approving-new-womens-libido-drug-dont-reward-palatin-technologies 2019-06-24T21:49:16 https://maestrodatabase.com/blog/zenocutuzumab-zbco-granted-fda-breakthrough-therapy-designation-for-nrg1-positive-cholangiocarcinoma 2025-10-23T23:15:48 https://maestrodatabase.com/blog/trump-administration-pushes-to-make-health-care-pricing-more-transparent 2019-06-24T21:45:57 https://maestrodatabase.com/blog/astrazeneca-chief-says-nhs-drug-approval-process-hurts-patients 2016-12-30T01:06:56 https://maestrodatabase.com/blog/pbs-listings-to-benefit-australians-with-type-2-diabetes-and-small-cell-lung-cancer-emergency-dispensing-measures-of-pbs-medicines-extended 2020-07-01T07:58:08 https://maestrodatabase.com/blog/should-medicare-value-based-purchasing-take-social-risk-into-account 2016-12-29T23:59:37 https://maestrodatabase.com/blog/maintaining-insurance-access-under-trump---a-strategy 2016-12-30T00:02:00 https://maestrodatabase.com/blog/the-head-of-the-fda-defends-the-importance-of-drug-effectiveness 2016-12-30T01:28:36 https://maestrodatabase.com/blog/cempra-receives-complete-response-letter-from-fda-for-solithromycin-ndas 2016-12-30T01:12:14 https://maestrodatabase.com/blog/coverage-denial-for-therapy-unconscionable 2016-12-30T01:25:29 https://maestrodatabase.com/blog/icer-cancels-public-meeting-for-non-alcoholic-steatohepatitis-assessment 2020-07-01T20:58:32 https://maestrodatabase.com/blog/scotland-backs-three-new-uses-for-msds-keytruda 2022-10-11T19:57:21 https://maestrodatabase.com/blog/medicines-australia-welcomes-support-for-national-harmonisation-of-clinical-trials 2020-07-01T21:07:06 https://maestrodatabase.com/blog/international-regulators-provide-guiding-principles-for-covid-19-clinical-trials 2020-07-01T21:08:59 https://maestrodatabase.com/blog/pharmac-looking-to-fund-ulcerative-colitis-crohns-medicine-ustekinumab-following-four-year-fight 2022-10-11T19:51:43 https://maestrodatabase.com/blog/us-gets-almost-all-of-the-worlds-supply-of-key-covid-19-drug 2020-07-01T21:14:56 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-treatment-for-vasomotor-symptoms-associated-with-menopause 2022-10-11T19:40:09 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-for-priority-review-the-supplemental-biologics-license-application-for-gileads-trodelvy-for-pre-treated-hr-plus-slash-her2--metastatic-breast-cancer 2022-10-11T19:34:56 https://maestrodatabase.com/blog/pharmac-consulting-on-six-medicines-for-new-zealanders 2024-12-22T23:34:28 https://maestrodatabase.com/blog/assessment-of-overall-survival-quality-of-life-and-safety-benefits-associated-with-new-cancer-medicines 2016-12-30T20:22:34 https://maestrodatabase.com/blog/nice-publishes-final-guidance-for-tecentriq-for-2-indications 2020-07-01T21:44:24 https://maestrodatabase.com/blog/trying-to-survive-to-access-lifesaving-drugs-young-cancer-patients-face-huge-hurdles 2022-10-11T20:26:29 https://maestrodatabase.com/blog/ema-publishes-minutes-of-bilateral-ema---eunethta-meeting-june-2022 2022-10-11T20:11:50 https://maestrodatabase.com/blog/some-u-dot-s-government-contracts-for-covid-19-research-could-skirt-affordable-pricing-laws 2020-07-01T21:52:38 https://maestrodatabase.com/blog/fda-completes-guidance-on-the-development-of-biosimilars 2016-12-30T20:28:20 https://maestrodatabase.com/blog/the-china-nmpa-approved-cyramza-ramucirumab-for-the-treatment-in-patients-with-hepatocellular-carcinoma 2022-10-11T20:19:06 https://maestrodatabase.com/blog/new-generation-of-weight-loss-medications-offer-promise----but-at-a-price 2022-10-11T20:08:46 https://maestrodatabase.com/blog/life-changing-drug-remains-unfunded 2020-07-01T21:17:58 https://maestrodatabase.com/blog/cipher-pharmaceuticals-announces-a-101-40-percent-topical-solution-accepted-for-review-by-health-canada 2018-12-18T23:39:50 https://maestrodatabase.com/blog/why-states-netflix-model-prescription-drug-arrangements-are-no-silver-bullet 2020-07-01T21:22:27 https://maestrodatabase.com/blog/eligo-bioscience-receives-fda-orphan-drug-designation-and-rare-paediatric-disease-designation-for-eb003-for-the-prevention-of-haemolytic-uraemic-syndrome-with-first-in-class-crispr-based-medicine 2022-10-11T20:02:50 https://maestrodatabase.com/blog/takeda-receives-complete-response-letter-from-u-dot-s-fda-for-the-investigational-subcutaneous-formulation-of-entyvio-vedolizumab-as-a-maintenance-therapy-in-adults-with-moderate-to-severe-ulcerative-colitis 2019-12-24T11:10:45 https://maestrodatabase.com/blog/dr-reddys-proposed-rituximab-biosimilar-application-accepted-for-review-by-us-fda-ema-and-mhra 2023-07-13T03:53:03 https://maestrodatabase.com/blog/blueprint-medicines-announces-submission-of-new-drug-application-to-fda-for-pralsetinib-for-the-treatment-of-advanced-ret-mutant-and-ret-fusion-positive-thyroid-cancers 2020-07-01T21:29:14 https://maestrodatabase.com/blog/private-health-insurance-premiums-to-rise-3-dot-25pc-in-april 2018-12-19T07:09:36 https://maestrodatabase.com/blog/agenda-for-the-march-2019-pbac-meeting 2018-12-19T07:12:17 https://maestrodatabase.com/blog/correvio-receives-complete-response-letter-from-u-dot-s-fda-for-brinavess-and-provides-update-on-recent-events 2019-12-25T09:15:28 https://maestrodatabase.com/blog/20-000-dollars-on-allergy-meds-families-ask-for-help-with-astronomical-costs 2019-12-24T11:48:42 https://maestrodatabase.com/blog/pharming-submits-a-marketing-authorisation-application-to-the-european-medicines-agency-for-leniolisib 2022-10-11T20:34:31 https://maestrodatabase.com/blog/teligent-announces-fda-request-for-further-data-on-complex-drug 2019-12-24T11:29:15 https://maestrodatabase.com/blog/rhovacs-prostate-cancer-drug-candidate-rv001-is-granted-fast-track-designation-by-the-fda 2020-11-25T23:14:50 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-naxitamab-for-high-risk-neuroblastoma-in-bone-or-bone-marrow 2020-11-25T23:19:23 https://maestrodatabase.com/blog/comparative-assessment-of-clinical-benefit-using-the-esmo-magnitude-of-clinical-benefit-scale-version-1-dot-1-and-the-asco-value-framework-net-health-benefit-score 2018-12-19T09:07:29 https://maestrodatabase.com/blog/biocon-biologics-receives-health-canada-spproval-for-yesintek-and-yesintek-i-dot-v-ustekinumab-a-biosimilar-to-stelara 2025-10-24T02:01:04 https://maestrodatabase.com/blog/otsukas-jynarque-tolvaptan-approved-by-u-dot-s-fda-as-the-first-treatment-to-slow-kidney-function-decline-in-adults-at-risk-of-rapidly-progressing-autosomal-dominant-polycystic-kidney-disease 2018-04-25T02:08:42 https://maestrodatabase.com/blog/nice-authorises-msds-keytruda-for-stage-iii-melanoma 2018-12-19T19:14:08 https://maestrodatabase.com/blog/fda-advances-new-scientific-framework-to-promote-greater-predictability-efficiency-in-oncology-drug-development 2018-12-19T19:18:22 https://maestrodatabase.com/blog/apotex-receives-health-canada-approval-for-loqtorzi---the-first-and-only-immuno-therapy-for-recurrent-unresectable-or-metastatic-nasopharyngeal-cancer 2025-10-24T01:29:26 https://maestrodatabase.com/blog/nice-appraisal-fees-to-be-introduced-despite-opposition 2018-12-19T10:52:18 https://maestrodatabase.com/blog/as-health-insurance-premiums-rise-again-consumer-focus-will-be-on-value 2018-12-19T11:19:14 https://maestrodatabase.com/blog/aridis-ar-301-monoclonal-antibody-is-among-the-first-biologics-to-receive-fdas-qualified-infectious-diseases-product-designation 2023-07-13T07:40:03 https://maestrodatabase.com/blog/jubilant-over-drug-funding 2018-12-19T19:24:43 https://maestrodatabase.com/blog/the-fdas-rigged-drug-committees 2016-12-31T01:24:54 https://maestrodatabase.com/blog/women-who-petitioned-parliament-get-nothing-from-pharmac 2018-12-19T19:22:21 https://maestrodatabase.com/blog/bio-thera-solutions-submits-marketing-authorisation-application-for-bat1706-a-proposed-biosimilar-to-avastin-to-european-medicines-agency 2020-11-26T01:42:29 https://maestrodatabase.com/blog/european-commission-approves-tepmetko-tepotinib-for-patients-with-advanced-nsclc-with-metex14-skipping-alterations 2022-02-18T20:31:05 https://maestrodatabase.com/blog/more-lawsuits-equals-higher-drug-prices 2018-12-19T19:42:46 https://maestrodatabase.com/blog/equillium-granted-u-dot-s-fda-fast-track-designation-for-eq001-for-the-treatment-of-acute-graft-versus-host-disease 2018-12-19T19:31:53 https://maestrodatabase.com/blog/lynparza-olaparib-receives-health-canada-approval-for-the-treatment-of-brca-or-atm-gene-mutated-metastatic-castration-resistant-prostate-cancer 2020-11-26T01:27:30 https://maestrodatabase.com/blog/semaglutide-for-the-treatment-of-overweight-and-obese-adolescents 2023-07-13T08:08:38 https://maestrodatabase.com/blog/lynparza-approved-by-us-fda-for-first-line-maintenance-therapy-in-brca-mutated-advanced-ovarian-cancer 2018-12-19T19:57:10 https://maestrodatabase.com/blog/roxadustat-approved-in-china-for-the-treatment-of-anaemia-in-chronic-kidney-disease-patients-on-dialysis 2018-12-19T19:53:24 https://maestrodatabase.com/blog/costly-drug-for-fatal-muscular-disease-wins-fda-approval 2016-12-31T21:36:46 https://maestrodatabase.com/blog/breast-cancer-drug-rejected-for-nhs-use-on-cost-benefit-grounds 2016-12-31T21:42:08 https://maestrodatabase.com/blog/european-commission-approves-janssens-tremfya-guselkumab-a-first-in-class-treatment-for-active-psoriatic-arthritis 2020-11-26T01:46:45 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-january-2017-update 2016-12-31T22:13:37 https://maestrodatabase.com/blog/brexit-is-nhs-already-finding-it-hard-to-get-medicines 2018-12-19T20:14:21 https://maestrodatabase.com/blog/dizal-pharmaceutical-receives-u-dot-s-fda-fast-track-designation-for-dzd4205-golidocitinib-for-the-treatment-of-refractory-or-relapsed-peripheral-t-cell-lymphoma 2022-02-18T20:54:08 https://maestrodatabase.com/blog/agios-announces-fda-approval-of-pyrukynd-mitapivat-as-first-disease-modifying-therapy-for-haemolytic-anaemia-in-adults-with-pyruvate-kinase-deficiency 2022-02-18T21:44:14 https://maestrodatabase.com/blog/sandoz-launches-generic-lenalidomide-in-19-countries-across-europe-expanding-access-to-essential-oncology-medicine 2022-02-18T21:16:24 https://maestrodatabase.com/blog/fda-grants-priority-review-for-keytruda-pembrolizumab-and-keytruda-qlex-pembrolizumab-and-berahyaluronidase-alfa-pmph-each-in-combination-with-padcev-enfortumab-vedotin-ejfv-for-certain-patients-with-muscle-invasive-bladder-cancer 2025-10-24T02:38:45 https://maestrodatabase.com/blog/fda-defers-approval-of-daxibotulinumtoxina-for-injection-in-glabellar-lines-due-to-covid-19-related-travel-restrictions-impacting-manufacturing-site-inspection 2020-11-26T11:15:19 https://maestrodatabase.com/blog/immune-onc-therapeutics-receives-fda-fast-track-designation-for-io-202-the-first-anti-lilrb4-myeloid-checkpoint-inhibitor-for-the-treatment-of-relapsed-or-refractory-acute-myeloid-leukaemia 2022-02-18T21:54:24 https://maestrodatabase.com/blog/moderna-signs-deal-with-eu-for-160-million-covid-19-vaccine-doses 2020-11-26T11:27:02 https://maestrodatabase.com/blog/regulatory-decisions-diverge-over-aducanumab-for-alzheimers-disease 2022-02-18T22:38:56 https://maestrodatabase.com/blog/generic-drug-companies-to-face-first-charges-in-u-dot-s-probe 2018-04-25T05:43:40 https://maestrodatabase.com/blog/medical-industry-advocates-urge-ontario-to-offer-cheaper-versions-of-prescription-medications 2022-10-12T01:26:48 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-january-2017 2017-01-01T01:55:27 https://maestrodatabase.com/blog/once-daily-trelegy-ellipta-gains-expanded-indication-in-the-us-for-the-treatment-of-patients-with-copd 2018-04-25T05:46:52 https://maestrodatabase.com/blog/fda-will-begin-accepting-breakthrough-devices-for-tap-pilot-in-2023 2022-10-12T02:30:50 https://maestrodatabase.com/blog/fda-approves-first-non-prescription-daily-oral-contraceptive 2023-07-13T12:40:44 https://maestrodatabase.com/blog/icer-publishes-evidence-report-on-gene-therapies-for-sickle-cell-disease 2023-07-13T12:05:42 https://maestrodatabase.com/blog/european-medicines-agency-validates-application-for-tepotinib-for-the-treatment-of-advanced-nsclc-with-metex14-skipping-alterations 2020-11-26T19:45:40 https://maestrodatabase.com/blog/takhzyro-is-not-included-in-the-high-cost-protection 2020-11-26T20:06:19 https://maestrodatabase.com/blog/uninsured-us-patients-pay-up-to-330-dollars-for-eli-lillys-25-dollars-insulin-senator-warren-says 2023-07-13T21:04:33 https://maestrodatabase.com/blog/job-no-1-for-a-new-congress-undoing-obamas-health-law 2017-01-01T11:22:31 https://maestrodatabase.com/blog/slynd-drospirenone-is-now-covered-by-the-regie-de-lassurance-maladie-du-quebec 2023-07-13T20:59:45 https://maestrodatabase.com/blog/hta-review---is-today-d-day 2024-04-14T21:10:18 https://maestrodatabase.com/blog/cost-based-pricing-for-innovative-medicines-is-unviable-and-harmful 2024-04-14T21:03:09 https://maestrodatabase.com/blog/ipsen-receives-validation-from-european-medicines-agency-for-the-application-of-a-new-indication-for-cabometyx-cabozantinib-for-first-line-treatment-of-advanced-renal-cell-carcinoma-in-adults 2017-09-11T07:44:39 https://maestrodatabase.com/blog/agenda-for-13-september-tc-meeting 2017-09-11T07:55:05 https://maestrodatabase.com/blog/bowel-disease-patients-to-march-on-pharmac-and-parliament-to-present-30-000-plus-signature-petition 2020-11-26T20:19:15 https://maestrodatabase.com/blog/after-admitting-mistake-astrazeneca-faces-difficult-questions-about-its-vaccine 2020-11-26T20:25:13 https://maestrodatabase.com/blog/insights-from-the-march-2018-pbac-meeting 2018-04-25T07:42:45 https://maestrodatabase.com/blog/tga-announces-approval-of-new-medicine-from-asx-listed-company 2020-11-26T20:34:46 https://maestrodatabase.com/blog/medical-technology-investment-to-improve-lives 2017-09-11T11:10:49 https://maestrodatabase.com/blog/abbvie-submits-biologics-license-application-to-u-dot-s-fda-for-investigational-treatment-risankizumab-for-moderate-to-severe-plaque-psoriasis 2018-04-25T22:20:04 https://maestrodatabase.com/blog/how-the-eu-regulates-medicines 2017-09-11T11:27:51 https://maestrodatabase.com/blog/ose-immunotherapeutics-is-pleased-to-announce-that-veloxis-pharmaceuticals-its-partner-in-transplantation-has-obtained-fda-fast-track-designation-for-cd28-antagonist-vel-101-slash-fr104 2022-02-18T23:36:24 https://maestrodatabase.com/blog/drug-makers-question-idea-to-shake-up-how-medicare-pays-for-certain-drugs 2018-04-25T22:40:22 https://maestrodatabase.com/blog/bayers-lynkuet-elinzanetant-approved-in-the-us-for-treatment-of-moderate-to-severe-vasomotor-symptoms-due-to-menopause 2025-10-24T21:00:24 https://maestrodatabase.com/blog/beigene-announces-approval-for-brukinsa-zanubrutinib-by-swissmedic-for-treatment-of-adult-patients-with-waldenstroems-macroglobulinaemia 2022-02-19T05:20:33 https://maestrodatabase.com/blog/efficacy-safety-and-regulatory-approval-of-fda-designated-breakthrough-and-non-breakthrough-cancer-medicines 2018-04-25T22:34:51 https://maestrodatabase.com/blog/up-to-6-000-patients-to-benefit-from-nice-approved-life-extending-prostate-cancer-drug 2025-10-24T21:28:46 https://maestrodatabase.com/blog/nabriva-therapeutics-announces-ema-validation-of-marketing-authorisation-application-for-lefamulin 2019-06-25T02:47:26 https://maestrodatabase.com/blog/fda-authorises-moderna-and-pfizer-biontech-bivalent-covid-19-vaccines-for-use-as-a-booster-dose-in-younger-age-groups 2022-10-12T19:44:12 https://maestrodatabase.com/blog/european-commission-approves-bristol-myers-squibbs-opdivo-nivolumab-four-week-dosing-schedule-for-advanced-melanoma-and-previously-treated-renal-cell-carcinoma 2018-04-25T22:46:30 https://maestrodatabase.com/blog/thousands-could-be-affected-by-shortage-of-diabetes-drug 2022-10-12T08:44:46 https://maestrodatabase.com/blog/lung-cancer-advocates-feel-disease-is-being-ignored-by-government 2019-06-25T02:44:46 https://maestrodatabase.com/blog/new-very-high-prices-on-old-drugs 2017-09-11T20:37:22 https://maestrodatabase.com/blog/nice-partners-with-international-health-technology-assessment-bodies-to-boost-collaboration-on-shared-opportunities-and-challenges 2022-10-12T09:17:51 https://maestrodatabase.com/blog/a-much-needed-corrective-on-drug-development-costs 2017-09-11T20:45:41 https://maestrodatabase.com/blog/how-digital-therapeutics-platforms-are-revolutionising-health-care-delivery 2022-02-19T05:29:17 https://maestrodatabase.com/blog/sydnexis-receives-complete-response-letter-from-fda-for-syd-101-to-slow-paediatric-myopia-progression 2025-10-24T20:04:48 https://maestrodatabase.com/blog/research-and-development-spending-to-bring-a-single-cancer-drug-to-market-and-revenues-after-approval 2017-09-11T20:41:31 https://maestrodatabase.com/blog/premium-cost-hopes-resting-on-knees-hips 2017-09-11T20:54:24 https://maestrodatabase.com/blog/fda-approves-revumenib-for-relapsed-or-refractory-acute-myeloid-leukaemia-with-a-susceptible-npm1-mutation 2025-10-24T20:12:04 https://maestrodatabase.com/blog/meningococcal-vaccine-approved-for-infants 2017-09-11T20:49:57 https://maestrodatabase.com/blog/fdas-califf-shares-priority-list-with-agency-staff 2022-02-19T05:38:01 https://maestrodatabase.com/blog/current-standard-for-stopping-insurance-benefits-for-sma-treatment-harsh-on-adult-patients 2022-10-12T08:23:19 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-posts-updated-economic-analyses-for-pcsk9-inhibitor-evolocumab-finds-less-favourable-cost-effectiveness 2017-09-11T21:04:39 https://maestrodatabase.com/blog/thousands-of-kiwi-with-severe-asthma-given-access-to-newly-funded-medicine 2022-10-12T20:29:08 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-posts-draft-scoping-document-to-guide-review-of-emicizumab-for-haemophilia-a 2017-09-11T21:09:31 https://maestrodatabase.com/blog/cystic-fibrosis-rotorua-mother-gives-pharmac-a-year-to-fund-trikafta-before-moving-overseas 2022-10-12T20:12:54 https://maestrodatabase.com/blog/what-does-it-cost-to-create-a-cancer-drug-less-than-youd-think 2017-09-11T21:18:16 https://maestrodatabase.com/blog/lutetium-lu-177-vipivotide-tetraxetan-for-treating-psma-positive-hormone-relapsed-metastatic-prostate-cancer-after-two-or-more-therapies 2022-10-12T20:06:23 https://maestrodatabase.com/blog/smc---september-2017-decisions 2017-09-11T21:14:52 https://maestrodatabase.com/blog/fda-issues-complete-response-letter-for-pdp-716-nda-due-to-inspection-findings-at-third-party-api-manufacturing-facility 2023-07-14T00:18:44 https://maestrodatabase.com/blog/nice-were-the-institute-of-yes 2017-09-11T21:24:01 https://maestrodatabase.com/blog/european-medicines-agency-accepts-astellas-marketing-authorisation-application-for-zolbetuximab 2023-07-14T00:04:59 https://maestrodatabase.com/blog/eylea-aflibercept-injection-sbla-for-treatment-of-retinopathy-of-prematurity-accepted-for-fda-priority-review 2022-10-12T19:58:09 https://maestrodatabase.com/blog/ipsen-announces-u-dot-s-fda-approval-for-newly-designed-pre-filled-syringe-for-somatuline-depot-lanreotide 2019-06-25T03:02:53 https://maestrodatabase.com/blog/agitated-solutions-receives-fast-track-designation-for-investigational-drug-asi-02 2025-10-25T00:57:34 https://maestrodatabase.com/blog/revolution-medicines-awarded-voucher-for-daraxonrasib-rmc-6236-under-fda-commissioners-national-priority-voucher-pilot-program 2025-10-25T05:30:52 https://maestrodatabase.com/blog/sq-hdm-slit-for-the-treatment-of-patients-with-allergic-rhinitis-and-allergic-asthma-caused-by-house-dust-mites 2022-10-12T20:32:46 https://maestrodatabase.com/blog/krystal-biotech-receives-regenerative-medicine-advanced-therapy-designation-from-fda-for-kb103 2019-06-25T03:08:44 https://maestrodatabase.com/blog/dbv-technologies-provides-update-on-viaskin-peanut-for-children-four-to-11-years-of-age 2018-12-20T05:22:08 https://maestrodatabase.com/blog/breast-cancer-drug-buying-time-for-terminal-women-amid-push-for-pbs-subsidy 2022-02-19T22:25:00 https://maestrodatabase.com/blog/theracosbio-announces-commercial-availability-of-brenzavvy-bexagliflozin-for-the-treatment-of-adults-with-type-2-diabetes 2023-07-14T01:15:56 https://maestrodatabase.com/blog/receipt-of-complete-response-ketter-from-us-fda-for-investigational-nd0612 2025-10-25T10:21:39 https://maestrodatabase.com/blog/fda-eyes-second-covid-19-booster-shot 2022-02-19T22:31:20 https://maestrodatabase.com/blog/astellas-submits-new-drug-applications-for-approval-of-gilteritinib-for-the-treatment-of-flt3-mutation-positive-relapsed-or-refractory-acute-myeloid-leukaemia 2018-04-26T02:13:11 https://maestrodatabase.com/blog/health-canada-approves-lynparza-in-combination-with-abiraterone-and-prednisone-or-prednisolone-for-patients-with-brca-mutated-metastatic-castration-resistant-prostate-cancer 2023-07-14T02:29:10 https://maestrodatabase.com/blog/proposals-for-prescription-drug-transparency 2018-04-26T02:22:20 https://maestrodatabase.com/blog/fda-approves-mercks-keytruda-pembrolizumab-for-the-treatment-of-adult-and-paediatric-patients-with-recurrent-locally-advanced-or-metastatic-merkel-cell-carcinoma-a-rare-form-of-skin-cancer 2018-12-20T05:45:53 https://maestrodatabase.com/blog/biontech-plans-to-make-vaccines-in-shipping-containers 2022-02-20T01:17:41 https://maestrodatabase.com/blog/fda-approves-new-indication-for-envarsus-xr-tacrolimus-extended-release-tablets 2018-12-20T05:56:15 https://maestrodatabase.com/blog/uks-mhra-renews-eams-scientific-opinion-for-santheras-idebenone-in-duchenne-muscular-dystrophy 2019-06-25T04:12:59 https://maestrodatabase.com/blog/proposal-for-funded-multiple-sclerosis-treatments 2020-11-27T05:36:01 https://maestrodatabase.com/blog/dr-crawshaw-takes-over-as-pharmacs-medical-director-after-covid-challenges-in-the-uk 2020-11-27T05:38:37 https://maestrodatabase.com/blog/stabilising-health-cares-share-of-the-gdp 2022-02-20T20:08:16 https://maestrodatabase.com/blog/new-pbs-listing-to-help-fight-chronic-graft-versus-host-disease 2022-02-20T20:21:21 https://maestrodatabase.com/blog/assessing-transferability-in-systematic-reviews-of-health-economic-evaluations---a-review-of-methodological-guidance 2022-02-20T20:16:56 https://maestrodatabase.com/blog/radical-plan-for-bigger-medicare-rebates-in-the-bush 2017-01-02T20:28:48 https://maestrodatabase.com/blog/new-drug-approvals-fall-to-six-year-low-in-2016 2017-01-02T20:31:04 https://maestrodatabase.com/blog/health-canada-grants-authorisation-for-leqembi-lecanemab-for-the-treatment-of-early-alzheimers-disease 2025-10-27T01:22:59 https://maestrodatabase.com/blog/bronchial-carcinoma-additional-use-of-crizotinib-not-seen 2017-01-02T20:19:20 https://maestrodatabase.com/blog/global-regulators-urge-continuation-of-covid-19-vaccine-trials-for-longer-term-safety-and-efficacy-follow-up 2020-11-27T22:13:44 https://maestrodatabase.com/blog/coalition-to-simplify-private-health-policies 2017-01-02T20:34:41 https://maestrodatabase.com/blog/reduced-annual-charges-for-medical-devices-listed-on-the-prostheses-list 2020-07-02T11:18:26 https://maestrodatabase.com/blog/scpharmaceuticals-announces-furoscix-nda-resubmission 2020-07-02T11:21:33 https://maestrodatabase.com/blog/rhythm-pharmaceuticals-announces-submission-of-marketing-authorization-application-to-the-european-medicines-agency-for-setmelanotide-in-pomc-and-lepr-deficiency-obesities 2020-07-02T11:26:11 https://maestrodatabase.com/blog/theres-no-backup-baby-formula-crisis-hits-prescription-market 2018-04-26T08:06:49 https://maestrodatabase.com/blog/european-commission-approves-daurisma-glasdegib-for-certain-adult-patients-with-newly-diagnosed-acute-myeloid-leukaemia 2020-07-02T11:58:08 https://maestrodatabase.com/blog/enzychem-lifesciences-fast-track-designation-for-chemo-radiation-induced-oral-mucositis-had-been-granted-by-the-fda 2018-04-26T08:21:36 https://maestrodatabase.com/blog/tagrisso-approved-in-the-eu-for-patients-with-unresectable-egfr-mutated-lung-cancer 2024-12-23T10:04:05 https://maestrodatabase.com/blog/rhythm-pharmaceuticals-receives-rare-paediatric-disease-designation-from-u-dot-s-fda-for-setmelanotide-for-treatment-of-pomc-and-lepr-deficiency-obesities 2020-07-02T11:31:08 https://maestrodatabase.com/blog/chamber-of-commerce-asks-judge-to-block-medicare-drug-price-negotiations-before-october 2023-07-14T04:20:37 https://maestrodatabase.com/blog/johnson-and-johnson-announces-european-commission-approval-for-janssens-preventive-ebola-vaccine 2020-07-02T11:34:40 https://maestrodatabase.com/blog/flaws-in-the-fdas-new-priority-voucher-program 2025-10-27T03:02:58 https://maestrodatabase.com/blog/delivering-better-access-to-contraception-for-australian-women 2025-10-27T02:13:06 https://maestrodatabase.com/blog/two-key-fda-decisions-to-watch-out-for-in-january-2017 2017-01-03T02:00:38 https://maestrodatabase.com/blog/gilead-donates-covid-19-drug-remdesivir-to-australias-medical-stockpile-after-us-buys-up-supply 2020-07-02T12:11:44 https://maestrodatabase.com/blog/long-lasting-contraceptive-gets-new-pbs-listing 2025-10-27T02:34:13 https://maestrodatabase.com/blog/incorporating-the-patient-experience-into-regulatory-decision-making-in-the-usa-europe-and-canada 2018-04-26T09:22:41 https://maestrodatabase.com/blog/acacia-pharma-announces-us-fda-approval-of-byfavo-remimazolam-for-injection-for-the-induction-and-maintenance-of-procedural-sedation 2020-07-02T21:15:47 https://maestrodatabase.com/blog/pbs-arrangements-for-medicines-for-the-treatment-of-paroxysmal-nocturnal-haemoglobinuria 2022-02-21T08:07:30 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-for-orphomeds-orp-101-for-treatment-of-ibs-d 2018-04-26T10:31:07 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-gsks-application-for-zejula-niraparib-in-late-stage-ovarian-cancer-with-priority-review 2019-06-25T06:52:40 https://maestrodatabase.com/blog/cochlear-calls-for-low-risk-health-apps-to-be-exempt-from-tga-register 2020-07-02T21:26:27 https://maestrodatabase.com/blog/synlogic-receives-fast-track-designation-for-synb1618-a-synthetic-biotic-medicine-for-the-treatment-of-phenylketonuria 2018-04-26T10:26:49 https://maestrodatabase.com/blog/vertex-announces-expansion-of-reimbursement-agreement-with-nhs-england-to-include-kaftrio-ivacaftor-slash-tezacaftor-slash-elexacaftor-in-combination-with-kalydeco-ivacaftor 2020-07-02T21:32:13 https://maestrodatabase.com/blog/icer-publishes-white-paper-on-alternative-policies-for-drug-and-vaccine-pricing-during-a-pandemic-announces-cross-stakeholder-discussion-series 2020-07-02T20:58:18 https://maestrodatabase.com/blog/pharmac-says-us-cant-prevent-us-accessing-medicines 2020-07-02T21:06:14 https://maestrodatabase.com/blog/allarity-therapeutics-receives-refusal-to-file-letters-from-u-dot-s-fda 2022-02-21T07:59:35 https://maestrodatabase.com/blog/600-dollars-or-$3-120-gilead-puts-a-price-tag-on-covid-19-relief 2020-07-02T21:10:20 https://maestrodatabase.com/blog/covid-19-pandemic-sends-clear-message-that-australia-must-value-the-long-term-health-of-all-australians 2022-02-21T07:56:39 https://maestrodatabase.com/blog/updates-to-the-hta-policy-and-methods-review-reference-committee-15-april-2024 2024-04-15T05:42:01 https://maestrodatabase.com/blog/u-dot-s-fda-approves-foundationone-cdx-as-a-companion-diagnostic-for-keytruda-pembrolizumab-to-identify-patients-with-microsatellite-instability-high-solid-tumours 2022-02-21T19:39:59 https://maestrodatabase.com/blog/drug-funded-for-people-with-spinal-muscular-atrophy 2022-02-21T19:52:22 https://maestrodatabase.com/blog/fda-accepts-biomarins-biologics-license-application-for-valoctocogene-roxaparvovec-aav-gene-therapy-for-adults-with-severe-haemophilia-a 2022-10-13T00:31:54 https://maestrodatabase.com/blog/fda-approves-veklury-remdesivir-for-covid-19-treatment-in-patients-with-severe-renal-impairment-including-those-on-dialysis 2023-07-14T12:43:00 https://maestrodatabase.com/blog/nice-says-liver-cancer-treatment-to-stay-within-the-cancer-drugs-fund-but-not-recommended-for-routine-nhs-use 2017-01-03T06:32:27 https://maestrodatabase.com/blog/annual-performance-statistics-report-july-2016-to-june-2017 2017-09-12T09:04:54 https://maestrodatabase.com/blog/regression-discontinuity-design 2020-07-02T21:41:31 https://maestrodatabase.com/blog/bayers-new-treatment-kerendia-finerenone-approved-in-eu-for-adult-patients-with-chronic-kidney-disease-associated-with-type-2-diabetes 2022-02-21T20:34:59 https://maestrodatabase.com/blog/chugais-satralizumab-receives-fda-breakthrough-therapy-designation-for-neuromyelitis-optica-and-neuromyelitis-optica-spectrum-disorders 2018-12-20T06:58:24 https://maestrodatabase.com/blog/sandoz-proposed-biosimilar-rituximab-accepted-for-review-by-the-fda 2017-09-12T09:08:24 https://maestrodatabase.com/blog/proposed-pmprb-regulations-requires-focused-dialogue-with-all-players 2022-02-21T20:13:21 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-european-commission-approval-for-opdivo-nivolumab-plus-yervoy-ipilimumab-for-the-first-line-treatment-of-adult-patients-with-microsatellite-instability-high-or-mismatch-repair-deficient-metastatic-colorectal-cancer 2024-12-23T20:46:59 https://maestrodatabase.com/blog/the-nice-year-in-review 2017-01-03T19:55:41 https://maestrodatabase.com/blog/lillys-omvoh-mirikizumab-mrkz-approved-by-us-fda-as-a-single-injection-maintenance-regimen-in-adults-with-ulcerative-colitis 2025-10-27T20:27:55 https://maestrodatabase.com/blog/fda-accepts-adellos-biosimilar-biologics-license-application-for-a-proposed-filgrastim-biosimilar 2017-09-12T09:14:41 https://maestrodatabase.com/blog/ebola-vaccine-fast-tracked-after-proven-100-percent-effective-in-trials 2017-01-03T20:03:19 https://maestrodatabase.com/blog/petition-for-national-cancer-agency-gathers-steam 2019-06-25T07:21:28 https://maestrodatabase.com/blog/morally-bankrupt-government-stalls-funding-for-life-saving-cystic-fibrosis-drug-for-children 2017-01-03T12:16:59 https://maestrodatabase.com/blog/allergan-and-others-raise-medicine-prices-just-under-10-percent-hoping-to-avoid-public-outcry 2017-01-03T20:14:31 https://maestrodatabase.com/blog/australia-proves-national-drug-plan-is-possible-for-canada 2017-09-12T10:37:02 https://maestrodatabase.com/blog/amicus-therapeutics-set-for-share-of-fabry-market-after-nice-approval 2017-01-03T20:19:14 https://maestrodatabase.com/blog/responses-to-prostheses-list-reform 2022-02-21T20:05:18 https://maestrodatabase.com/blog/us-fda-approves-updated-indication-for-winrevair-sotatercept-csrk-in-adults-with-pulmonary-arterial-hypertension-who-group-1-pulmonary-hypertension-based-on-phase-3-zenith-study 2025-10-27T20:42:30 https://maestrodatabase.com/blog/adma-biologics-provides-regulatory-update-on-bivigam-pas-submissions 2018-12-20T07:05:39 https://maestrodatabase.com/blog/new-gene-therapy-treatments-will-carry-whopping-price-tags 2017-09-12T09:21:21 https://maestrodatabase.com/blog/donald-trump-mulls-public-private-care-for-veterans 2017-01-03T20:07:34 https://maestrodatabase.com/blog/germanys-model-for-drug-price-regulation-could-work-in-the-us 2017-01-03T20:10:14 https://maestrodatabase.com/blog/tga-rejects-fetzima 2017-01-03T20:35:14 https://maestrodatabase.com/blog/2016-in-review 2017-01-03T20:57:24 https://maestrodatabase.com/blog/over-1-000-people-with-advanced-breast-cancer-set-to-benefit-from-new-once-a-day-tablet 2024-12-23T11:30:28 https://maestrodatabase.com/blog/why-world-beating-tropical-drugs-are-so-hard-to-get-in-canada 2017-01-03T20:27:05 https://maestrodatabase.com/blog/after-obama-some-health-reforms-may-prove-lasting 2017-01-03T20:30:03 https://maestrodatabase.com/blog/apple-iphone-game-changing-new-health-feature-cleared-by-fda-coming-in-weeks 2022-02-21T20:08:36 https://maestrodatabase.com/blog/update-from-the-pbac-december-2024 2024-12-23T11:18:05 https://maestrodatabase.com/blog/cytokinetics-announces-ema-validation-of-marketing-authorisation-application-for-aficamten-for-the-treatment-of-obstructive-hypertrophic-cardiomyopathy 2024-12-24T02:54:03 https://maestrodatabase.com/blog/humira-gets-ec-approval-for-anterior-uveitis 2017-09-12T20:42:37 https://maestrodatabase.com/blog/pharmac-turns-down-dhb-request-for-free-flu-vaccine-for-super-spreader-kids 2018-04-26T12:22:16 https://maestrodatabase.com/blog/chronic-kidney-treatment-made-cheaper-for-people-like-franki 2025-10-27T20:19:01 https://maestrodatabase.com/blog/raising-awareness-of-the-perils-of-antimicrobial-resistance 2017-09-12T20:38:15 https://maestrodatabase.com/blog/updated-rules-for-clinical-development-of-vaccines 2018-04-26T20:38:04 https://maestrodatabase.com/blog/price-gouge-on-private-patients-for-medical-devices 2017-09-12T20:58:15 https://maestrodatabase.com/blog/nice-appoints-new-head-of-health-technology-evaluation 2018-04-26T11:57:15 https://maestrodatabase.com/blog/biosimilar-trastuzumab-co-developed-by-biocon-receives-approval-in-the-eu 2018-12-20T07:13:41 https://maestrodatabase.com/blog/war-on-drugs-big-pharma-fights-nhs-bill-curbs 2017-09-12T21:04:00 https://maestrodatabase.com/blog/exodus-from-private-health-care-saves-$1bn-but-states-carry-can 2017-09-12T21:00:32 https://maestrodatabase.com/blog/why-is-the-fda-chief-so-worried-about-pharma-profits 2017-09-12T21:07:51 https://maestrodatabase.com/blog/tonix-pharmaceuticals-announces-pdufa-goal-date-of-15-august-2025-for-fda-decision-on-us-marketing-approval-for-tnx-102-sl-for-fibromyalgia 2024-12-24T02:10:23 https://maestrodatabase.com/blog/california-moves-closer-to-adopting-a-drug-pricing-transparency-law 2017-09-12T21:14:06 https://maestrodatabase.com/blog/streamlined-fda-reviews-fail-to-catch-dangerous-glitches-in-health-software-study-finds 2017-09-12T21:11:02 https://maestrodatabase.com/blog/generic-chemo-is-too-expensive-to-help-curb-cancer-spending-study-says 2017-09-12T21:19:17 https://maestrodatabase.com/blog/fda-is-advancing-the-goals-of-the-orphan-drug-act 2017-09-12T21:37:37 https://maestrodatabase.com/blog/blarcamesine-receives-ema-filing-acceptance-for-treatment-of-alzheimers-disease 2024-12-24T02:58:48 https://maestrodatabase.com/blog/mission-possible-moving-the-needle-forward-to-advance-health-equity 2018-04-26T20:54:31 https://maestrodatabase.com/blog/clarity-around-pharmacs-priority-lists-october-2022 2022-10-13T02:55:09 https://maestrodatabase.com/blog/health-canada-approves-keytruda-pembrolizumab-as-monotherapy-for-the-adjuvant-treatment-of-adults-with-renal-cell-carcinoma-rcc-at-intermediate-high-or-high-risk-of-recurrence-following-nephrectomy-or-following-nephrectomy-and-resection-of-metastatic-lesions 2022-10-13T03:13:43 https://maestrodatabase.com/blog/european-medicine-agency-accepts-intas-marketing-authorisation-application-for-dmb-3115-a-proposed-biosimilar-to-stelara-ustekinumab 2023-07-15T01:16:15 https://maestrodatabase.com/blog/iterum-therapeutics-provides-regulatory-update 2021-07-03T13:43:22 https://maestrodatabase.com/blog/cellectar-biosciences-receives-rare-paediatric-disease-designation-from-us-fda-for-iopofosine-i-131-in-relapsed-or-refractory-paediatric-high-grade-glioma 2025-10-28T03:28:19 https://maestrodatabase.com/blog/us-fda-accepts-for-priority-review-nuvation-bios-new-drug-application-for-taletrectinib-for-the-treatment-of-advanced-ros1-positive-non-small-cell-lung-cancer 2024-12-24T03:35:28 https://maestrodatabase.com/blog/health-economic-assessment-of-kymriah-in-diffuse-large-b-cell-lymphoma 2019-06-25T11:04:51 https://maestrodatabase.com/blog/do-cancer-treatments-have-option-value-real-world-evidence-from-metastatic-melanoma 2019-06-25T10:56:57 https://maestrodatabase.com/blog/koselugo-approved-in-the-eu-for-plexiform-neurofibromas-in-adults-with-neurofibromatosis-type-1 2025-10-28T09:56:35 https://maestrodatabase.com/blog/president-donald-j-trump-is-putting-american-patients-first-by-making-healthcare-more-transparent 2019-06-25T08:20:34 https://maestrodatabase.com/blog/random-effects-meta-analysis-summarising-evidence-with-caveats 2019-01-23T04:05:12 https://maestrodatabase.com/blog/donald-trump-could-lower-the-bar-for-fda-drug-approvals-but-payers-will-limit-access 2017-01-04T02:10:52 https://maestrodatabase.com/blog/decisions-relating-to-the-funded-brands-of-some-anti-retroviral-treatments-for-hiv 2018-12-20T08:11:13 https://maestrodatabase.com/blog/drop-in-fda-approvals-and-new-administration-rekindles-fears-for-the-future-of-pharma 2017-01-04T02:15:15 https://maestrodatabase.com/blog/london-based-regulator-for-eu-drugs-fears-staff-exodus 2017-01-04T02:19:36 https://maestrodatabase.com/blog/nice-explores-extending-its-use-of-real-world-data-to-inform-its-guidance 2019-06-25T12:01:19 https://maestrodatabase.com/blog/louisianas-experiment-paying-for-hepatitis-c-drugs-lessons-for-other-states-other-treatments 2019-06-25T11:40:39 https://maestrodatabase.com/blog/patient-planning-to-remortgage-house-to-fund-costly-cancer-drug-strikes-miracle-scheme 2019-06-25T21:10:31 https://maestrodatabase.com/blog/amgens-annual-trends-report-finds-competition-created-by-biosimilars-contributed-21-dollars-billion-in-us-health-care-system-savings 2022-10-13T19:58:59 https://maestrodatabase.com/blog/tga-approves-rybelsus 2022-02-22T02:02:23 https://maestrodatabase.com/blog/diabetics-wont-be-made-to-pay-for-alternative-medicines-pharmac-says 2022-10-13T19:44:01 https://maestrodatabase.com/blog/hhs-announces-cost-savings-for-64-prescription-drugs-thanks-to-the-medicare-prescription-drug-inflation-rebate-program-established-by-the-biden-harris-administrations-lower-cost-prescription-drug-law 2024-12-24T04:11:39 https://maestrodatabase.com/blog/nevro-announces-fda-approval-of-hfx-iq-spinal-cord-stimulation-system-to-personalise-the-treatment-of-chronic-pain 2022-10-13T19:35:19 https://maestrodatabase.com/blog/ema-publishes-agenda-for-24-27-june-chmp-meeting 2019-06-25T21:24:08 https://maestrodatabase.com/blog/its-a-big-week-for-debates-about-drug-prices-whether-pharma-likes-it-or-not 2019-06-25T21:18:26 https://maestrodatabase.com/blog/shire-receives-fda-fast-track-designation-for-shp607-for-the-prevention-of-chronic-lung-disease-in-extremely-premature-infants 2017-09-12T23:16:23 https://maestrodatabase.com/blog/expert-advice-on-lung-cancer-screening 2022-10-13T19:29:45 https://maestrodatabase.com/blog/new-zealand-lacking-best-treatment-options-for-blood-cancer-patients-warns-myeloma-nz 2019-06-25T21:13:49 https://maestrodatabase.com/blog/public-summary-documents-first-time-decisions-not-to-recommend-and-deferrals---march-2023-pbac-meeting 2023-07-16T21:17:34 https://maestrodatabase.com/blog/datopotamab-deruxtecan-application-in-the-eu-for-patients-with-advanced-non-squamous-non-small-sell-lung-cancer-voluntarily-withdrawn 2024-12-24T08:05:45 https://maestrodatabase.com/blog/cheaper-medicine-for-kidney-disease-patients 2025-10-28T20:37:07 https://maestrodatabase.com/blog/pharmac-publishes-agenda-for-february-2025-ptac-meeting 2024-12-24T04:27:20 https://maestrodatabase.com/blog/public-summary-documents---september-2024-pbac-meeting 2024-12-24T04:22:59 https://maestrodatabase.com/blog/metvital-announces-fda-fast-track-designation-of-anhydrous-enol-oxaloacetate-for-the-treatment-of-patients-with-newly-diagnosed-glioblastoma-multiforme 2020-07-03T02:01:54 https://maestrodatabase.com/blog/harmonized-protocol-template-to-enhance-reproducibility-of-hypothesis-evaluating-real-world-evidence-studies-on-treatment-effects-a-good-practices-report-of-a-joint-ispe-slash-ispor-task-force 2022-10-13T20:04:59 https://maestrodatabase.com/blog/abbvie-submits-new-drug-application-to-u-dot-s-fda-and-marketing-authorisation-application-to-ema-for-upadacitinib-for-treatment-of-adults-with-moderate-to-severe-rheumatoid-arthritis 2018-12-20T19:29:17 https://maestrodatabase.com/blog/celltrions-auto-immune-disease-biosimilar-wins-further-approval-in-europe 2022-02-22T04:56:29 https://maestrodatabase.com/blog/pharmaxis-announces-resubmission-of-bronchitol-nda-in-usa 2018-12-20T19:25:12 https://maestrodatabase.com/blog/dengvaxia-vaccine-approved-for-prevention-of-dengue-in-europe 2018-12-20T19:35:46 https://maestrodatabase.com/blog/the-truth-about-patient-access-and-fda-fast-tracking 2022-02-22T04:22:38 https://maestrodatabase.com/blog/despite-challenges-health-exchange-enrolment-falls-only-slightly 2018-12-20T19:50:07 https://maestrodatabase.com/blog/fda-approves-first-treatment-for-weight-management-for-people-with-certain-rare-genetic-conditions 2020-11-28T11:07:23 https://maestrodatabase.com/blog/regorafenib-granted-priority-review-in-the-u-dot-s-for-second-line-treatment-of-liver-cancer 2017-01-04T21:53:51 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-provides-policy-recommendations-for-biologic-treatments-for-uncontrolled-asthma 2018-12-20T19:41:11 https://maestrodatabase.com/blog/norgine-submits-marketing-authorisation-application-via-project-orbis-for-eflornithine-difluoromethylornithine-in-high-risk-neuroblastoma 2024-04-16T01:35:40 https://maestrodatabase.com/blog/u-dot-s-fda-approves-supplemental-new-drug-applications-to-include-landmark-data-in-product-labels-for-synjardy-empagliflozin-slash-metformin-hydrochloride-synjardy-xr-empagliflozin-slash-metformin-hydrochloride-extended-release-and-glyxambi-empagliflozin-slash-linagliptin-tablets 2017-01-04T22:15:17 https://maestrodatabase.com/blog/warning-of-rising-drug-prices-as-britain-prepares-for-no-deal-brexit 2018-12-20T20:05:00 https://maestrodatabase.com/blog/senate-moves-to-dismantle-health-law 2017-01-04T22:19:18 https://maestrodatabase.com/blog/fda-accepts-for-filing-supplemental-new-drug-application-for-lilletta-levonorgestrel-releasing-intrauterine-system 2017-01-04T22:01:19 https://maestrodatabase.com/blog/merry-christmas-and-a-happy-new-year-to-all-maestro-daily-readers 2018-12-20T20:16:43 https://maestrodatabase.com/blog/provinces-seek-end-to-health-funding-standoff-with-ottawa 2017-01-04T22:10:20 https://maestrodatabase.com/blog/breast-cancer-drug-lobbyists-let-down-by-pharmacs-response-to-funding 2018-12-20T19:58:20 https://maestrodatabase.com/blog/protalix-biotherapeutics-and-chiesi-global-rare-diseases-announce-extension-of-pdufa-date-for-pegunigalsidase-alfa-for-the-proposed-treatment-of-fabry-disease 2020-11-28T10:59:24 https://maestrodatabase.com/blog/biosimilar-and-generic-cancer-drugs-unlikely-to-bend-cost-curve-in-the-usa 2017-01-04T22:24:46 https://maestrodatabase.com/blog/decision-to-list-a-range-of-medical-devices-supplied-by-biotronik 2022-10-14T00:10:48 https://maestrodatabase.com/blog/gops-health-law-attack-spurs-messaging-battle 2017-01-04T23:13:33 https://maestrodatabase.com/blog/the-changing-face-of-clinical-trials-the-large-pharmaceutical-company-perspective 2017-01-04T22:55:39 https://maestrodatabase.com/blog/a-review-of-cders-novel-drug-approvals-for-2016 2017-01-04T22:58:58 https://maestrodatabase.com/blog/polaryx-therapeutics-receives-both-rare-paediatric-disease-and-orphan-drug-designations-for-the-treatment-of-gm2-gangliosidosis-with-plx-300 2020-11-28T11:28:30 https://maestrodatabase.com/blog/vertex-announces-european-commission-approval-for-symkevi-tezacaftor-slash-ivacaftor-with-kalydeco-ivacaftor-for-eligible-children-with-cystic-fibrosis-ages-6-11-years 2020-11-28T11:40:42 https://maestrodatabase.com/blog/fda-approves-new-hiv-treatment-for-patients-with-limited-treatment-options 2020-07-03T04:58:38 https://maestrodatabase.com/blog/canadas-health-care-is-abysmal-why-would-we-copy-it 2018-04-27T02:25:23 https://maestrodatabase.com/blog/icer-posts-draft-scoping-document-on-medication-assisted-treatments-for-opioid-use-disorder 2018-04-27T02:27:42 https://maestrodatabase.com/blog/universal-health-care-worldwide-is-within-reach 2018-04-27T02:42:17 https://maestrodatabase.com/blog/fda-grants-breakthrough-therapy-designation-to-omeros-masp-2-inhibitor-oms721-for-the-treatment-of-high-risk-haematopoietic-stem-cell-transplant-associated-thrombotic-microangiopathy 2018-04-27T02:49:39 https://maestrodatabase.com/blog/cms-administrator-verma-unveils-new-strategy-to-fuel-data-driven-patient-care-transparency 2018-04-27T02:37:17 https://maestrodatabase.com/blog/gsks-5-in-1-meningococcal-abcwy-vaccine-candidate-accepted-for-regulatory-review-by-us-fda 2024-04-16T21:05:07 https://maestrodatabase.com/blog/tlx101-cdx-pixclara-granted-fda-fast-track-designation 2024-04-16T04:13:19 https://maestrodatabase.com/blog/alphamab-oncology-announces-biparatopic-her2-targeting-adc-jskn003-was-granted-fast-track-designation-by-fda-for-the-treatment-of-platinum-resistant-recurrent-epithelial-ovarian-cancer-primary-peritoneal-cancer-or-fallopian-tube-cancer 2025-10-29T01:57:48 https://maestrodatabase.com/blog/glaukos-submits-new-drug-application-to-us-fda-for-epioxa 2024-12-25T22:43:19 https://maestrodatabase.com/blog/icer-to-test-principle-of-fair-access-to-fairly-priced-pharmaceuticals 2021-07-04T01:45:17 https://maestrodatabase.com/blog/array-biopharma-announces-fda-acceptance-for-review-of-binimetinib-and-encorafenib-new-drug-applications-for-patients-with-advanced-braf-mutant-melanoma 2017-09-13T02:47:33 https://maestrodatabase.com/blog/alnylam-announces-innovative-value-based-agreement-framework-for-oxlumo-lumasiran-to-accelerate-access-for-patients-with-primary-hyperoxaluria-type-1-and-deliver-ultra-rare-orphan-disease-pricing-solutions-to-u-dot-s-payers 2020-11-28T22:51:46 https://maestrodatabase.com/blog/doh-published-revised-agenda-for-july-2024-pbac-meeting-12-april-2024 2024-04-16T21:27:35 https://maestrodatabase.com/blog/lexeo-therapeutics-granted-fda-fast-track-designation-for-lx2006-an-aav-based-gene-therapy-candidate-for-the-treatment-of-friedreichs-ataxia-cardiomyopathy 2024-04-16T21:13:14 https://maestrodatabase.com/blog/health-canada-approves-illuccix-for-prostate-cancer-imaging 2022-10-14T02:28:53 https://maestrodatabase.com/blog/iqwig-in-dialogue-on-15-june-2018-do-the-new-estimand-strategies-threaten-the-standards-of-benefit-assessment 2018-04-27T03:58:13 https://maestrodatabase.com/blog/galderma-receives-fda-approval-for-restylane-contour-for-cheek-augmentation-and-correction-of-midface-contour-deficiencies 2021-07-04T02:20:50 https://maestrodatabase.com/blog/public-summary-documents---march-2020-pbac-meeting 2020-07-03T06:52:44 https://maestrodatabase.com/blog/fda-approves-first-generic-of-once-daily-glp-1-injection-to-lower-blood-sugar-in-patients-with-type-2-diabetes 2024-12-26T00:17:47 https://maestrodatabase.com/blog/sonic-healthcare-usa-to-offer-assay-to-aid-in-the-selection-of-jemperli-dostarlimab-gxly-therapy-in-endometrial-cancer 2021-07-04T03:13:00 https://maestrodatabase.com/blog/acer-therapeutics-receives-complete-response-letter-from-u-dot-s-fda-for-use-of-edsivo-celiprolol-in-veds-patients 2019-06-26T02:05:42 https://maestrodatabase.com/blog/the-million-dollar-cancer-treatment-who-will-pay 2018-04-27T04:37:22 https://maestrodatabase.com/blog/medicare-coverage-with-evidence-development-for-aducanumab-how-might-it-work 2021-07-04T03:31:08 https://maestrodatabase.com/blog/fda-moves-to-encourage-a-dot-i-in-medicine-drug-development 2018-04-27T04:59:08 https://maestrodatabase.com/blog/new-zealand-falling-behind-rest-of-world-in-cancer-treatment 2019-06-26T01:48:58 https://maestrodatabase.com/blog/medicines-should-be-more-affordable-for-all-australians 2019-06-26T01:42:38 https://maestrodatabase.com/blog/pacira-biosciences-announces-validation-of-exparel-marketing-authorisation-application-from-european-medicines-agency 2019-06-26T02:12:03 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-to-enantas-fxr-agonist-candidate-edp-305-for-the-treatment-of-nash-with-liver-fibrosis 2017-01-05T04:44:40 https://maestrodatabase.com/blog/dova-pharmaceuticals-announces-european-union-marketing-authorisation-for-doptelet-avatrombopag-for-the-treatment-of-thrombocytopenia-in-patients-with-chronic-liver-disease 2019-06-26T02:18:23 https://maestrodatabase.com/blog/neurelis-intra-nasal-diazepam-treatment-for-epilepsy-granted-fast-track-designation-by-fda 2017-01-05T05:13:46 https://maestrodatabase.com/blog/health-canada-approves-orfadin-capsules-for-treatment-of-hereditary-tyrosinaemia-type-1 2017-01-05T05:09:06 https://maestrodatabase.com/blog/enigma-biomedical-usa-announces-fda-acceptance-of-new-drug-application-for-florquinitau-f-18-mk-6240-a-tau-pet-alzheimers-disease-radiodiagnostic 2025-10-29T23:49:46 https://maestrodatabase.com/blog/kempharm-announces-fdrr-process-completion-and-resubmission-of-the-apadaz-nda 2017-09-13T12:29:31 https://maestrodatabase.com/blog/fda-accepts-biomarins-palynziq-pegvaliase-pqpz-supplemental-biologics-license-application-for-priority-review-to-expand-use-to-adolescents-aged-12-17-with-phenylketonuria 2025-10-30T00:28:43 https://maestrodatabase.com/blog/bernie-sanders-why-we-need-medicare-for-all 2017-09-13T12:41:00 https://maestrodatabase.com/blog/drug-companies-tie-costs-to-outcomes 2017-09-13T20:16:17 https://maestrodatabase.com/blog/icer-publishes-evidence-report-on-treatments-for-obesity 2025-10-29T20:47:48 https://maestrodatabase.com/blog/fdas-gottlieb-plans-to-close-an-orphan-drug-loophole 2017-09-13T20:14:10 https://maestrodatabase.com/blog/ema-publishes-agenda-for-11-14-september-chmp-meeting 2017-09-13T21:11:49 https://maestrodatabase.com/blog/medicare-for-all-or-state-control-health-care-plans-go-to-extremes 2017-09-14T12:20:46 https://maestrodatabase.com/blog/confirmed-1-october-2017-prices---2017-october-cycle 2017-09-14T04:28:12 https://maestrodatabase.com/blog/independent-hospital-pricing-authority-data-on-medical-devices---apples-and-oranges 2017-09-14T20:48:31 https://maestrodatabase.com/blog/private-health-insurance-claims-on-medical-device-pricing-debunked 2017-09-14T20:46:07 https://maestrodatabase.com/blog/fintempla-fenfluramine-oral-solution-approved-in-japan-for-adjunctive-treatment-of-seizures-associated-with-lennox-gastaut-syndrome 2024-04-17T06:15:36 https://maestrodatabase.com/blog/fda-approves-first-biosimilar-for-the-treatment-of-cancer 2017-09-14T20:57:39 https://maestrodatabase.com/blog/closing-in-on-cancer 2017-09-14T20:54:44 https://maestrodatabase.com/blog/fda-approves-new-treatment-for-adults-with-relapsed-follicular-lymphoma 2017-09-14T21:25:57 https://maestrodatabase.com/blog/teva-receives-fda-priority-review-for-first-line-use-of-trisenox-arsenic-trioxide-in-patients-with-low-to-intermediate-risk-acute-promyelocytic-leukaemia 2017-09-14T21:33:59 https://maestrodatabase.com/blog/fda-moves-to-accelerate-biosimilar-development-and-lower-drug-costs 2025-10-30T01:21:42 https://maestrodatabase.com/blog/pharma-keeps-ignoring-its-price-problem 2017-09-14T21:47:15 https://maestrodatabase.com/blog/fda-permits-marketing-of-mobile-medical-application-for-substance-use-disorder 2017-09-14T21:40:29 https://maestrodatabase.com/blog/tragedy-perseverance-and-chance----the-story-of-car-t-therapy 2017-09-14T21:52:59 https://maestrodatabase.com/blog/agenda-for-the-july-2018-pbac-meeting 2018-04-27T23:44:09 https://maestrodatabase.com/blog/the-breakthrough-therapy-designation-for-promising-cancer-drugs-is-good-for-patients 2018-04-27T23:31:49 https://maestrodatabase.com/blog/icer-releases-draft-condition-update-report-on-treatments-for-plaque-psoriasis 2018-04-27T23:36:45 https://maestrodatabase.com/blog/alvotech-and-teva-announce-us-fda-approval-of-selarsdi-ustekinumab-aekn-biosimilar-to-stelara-ustekinumab 2024-04-18T01:07:06 https://maestrodatabase.com/blog/what-is-the-evidence-for-the-performance-of-generic-preference-based-measures-a-systematic-overview-of-reviews 2018-04-27T23:55:25 https://maestrodatabase.com/blog/rhythm-pharmaceuticals-announces-fda-approval-of-imcivree-setmelanotide-for-patients-as-young-as-2-years-old 2024-12-26T07:51:20 https://maestrodatabase.com/blog/car-t-therapy-could-be-available-to-nhs-patients-this-year 2018-04-28T00:11:43 https://maestrodatabase.com/blog/forward-into-the-past-with-fdas-new-history-exhibit 2019-06-26T05:16:54 https://maestrodatabase.com/blog/use-real-world-data-not-international-reference-pricing-to-set-us-drug-prices 2019-06-26T05:10:43 https://maestrodatabase.com/blog/fda-approves-genentechs-alecensa-as-first-adjuvant-treatment-for-people-with-alk-positive-early-stage-lung-cancer 2024-04-18T21:21:11 https://maestrodatabase.com/blog/pharmacs-perpetually-stretched-budget 2024-04-18T21:18:12 https://maestrodatabase.com/blog/finose-now-covers-all-nordic-countries 2024-04-18T21:14:57 https://maestrodatabase.com/blog/green-cross-resubmits-bla-for-its-immunoglobulin-blood-product-to-fda 2023-07-17T09:46:03 https://maestrodatabase.com/blog/covid-19-vaccine-strain-updates-global-regulators-agree-on-timing-and-data-requirements 2024-04-18T21:12:52 https://maestrodatabase.com/blog/moderna-submits-authorisation-application-for-coronavirus-vaccine-spikevax-xbb-dot-1-5 2023-07-17T07:52:40 https://maestrodatabase.com/blog/pbs-support-for-australians-living-with-leukaemia 2020-11-29T03:19:22 https://maestrodatabase.com/blog/pbs-expenditure-and-prescriptions-report-2023-24 2024-12-26T08:07:05 https://maestrodatabase.com/blog/report-on-pbs-slash-rpbs-under-co-payment-prescriptions-data-2023-24 2024-12-26T08:03:56 https://maestrodatabase.com/blog/ema-publishes-agenda-for-17-20-july-chmp-meeting 2023-07-17T10:21:44 https://maestrodatabase.com/blog/first-jabs-could-take-place-within-days-in-the-uk 2020-11-29T03:43:26 https://maestrodatabase.com/blog/lumicells-cutting-edge-imaging-platform-receives-historic-fda-approval-to-illuminate-residual-breast-cancer 2024-04-18T21:34:28 https://maestrodatabase.com/blog/fda-starts-review-of-hlbs-hcc-drug-rivoceranib 2023-07-17T10:07:09 https://maestrodatabase.com/blog/askbio-receives-fda-fast-track-designation-for-ab-1002-investigational-gene-therapy-program-in-congestive-heart-failure 2024-04-18T21:31:06 https://maestrodatabase.com/blog/immunotherapy-keytruda-gets-insurance-benefits 2022-02-22T09:42:01 https://maestrodatabase.com/blog/medicare-official-says-breakthrough-device-reimbursement-rule-coming-in-early-summer 2024-04-19T23:15:18 https://maestrodatabase.com/blog/national-pharmacare-will-reduce-access-to-new-medicines-for-27-million-privately-insured-canadians 2024-04-19T01:25:02 https://maestrodatabase.com/blog/us-fda-approves-subcutaneous-administration-of-takedas-entyvio-vedolizumab-for-maintenance-therapy-in-moderately-to-severely-active-crohns-disease 2024-04-19T00:39:50 https://maestrodatabase.com/blog/novel-alzheimer-disease-treatments-and-reconsideration-of-us-pharmaceutical-reimbursement-policy 2023-07-17T21:13:34 https://maestrodatabase.com/blog/pharmacies-are-a-true-partnership-with-the-public 2017-01-05T19:49:19 https://maestrodatabase.com/blog/publication-of-stage-1-and-stage-2-pbs-process-improvements-metrics-report-for-2022-23 2024-04-19T00:15:50 https://maestrodatabase.com/blog/health-insurers-warning-dont-drive-young-people-away 2017-01-05T19:52:57 https://maestrodatabase.com/blog/biden-to-tackle-broad-range-of-cancer-issues-including-drug-prices-after-leaving-white-house 2017-01-05T20:13:50 https://maestrodatabase.com/blog/gop-wins-first-obamacare-fight-in-senate-budget-vote 2017-01-05T20:20:02 https://maestrodatabase.com/blog/controversial-alzheimers-drug-under-tga-review-should-not-be-approved 2022-02-22T08:01:58 https://maestrodatabase.com/blog/european-health-union-eu-steps-up-action-to-prevent-shortages-of-antibiotics-for-next-winter 2023-07-17T21:00:27 https://maestrodatabase.com/blog/new-21st-century-cures-legislation-speed-and-ease-versus-science 2017-01-05T20:01:20 https://maestrodatabase.com/blog/fda-approves-new-drug-to-prevent-rsv-in-babies-and-toddlers 2023-07-17T21:04:20 https://maestrodatabase.com/blog/how-republicans-might-replace-obamacare 2017-01-05T20:09:44 https://maestrodatabase.com/blog/republicans-are-courting-disaster-on-health-care 2017-01-05T20:37:15 https://maestrodatabase.com/blog/dying-mum-begs-nhs-to-keep-cancer-drug-free-so-she-can-live-to-see-son-go-to-school 2017-01-05T20:45:34 https://maestrodatabase.com/blog/obamacare-sign-ups-reach-8-dot-8-million-as-repeal-efforts-start 2017-01-05T20:22:49 https://maestrodatabase.com/blog/republicans-4-step-plan-to-repeal-the-affordable-care-act 2017-01-05T20:34:40 https://maestrodatabase.com/blog/nice-publishes-second-appraisal-consultation-for-certolizumab-pegol-and-secukinumab 2017-01-05T20:58:54 https://maestrodatabase.com/blog/nora-pharma-receives-health-canada-approval-for-niopeg-a-biosimilar-of-neulasta 2024-04-20T02:33:34 https://maestrodatabase.com/blog/health-canada-approves-keytruda-as-a-first-line-treatment-for-adult-patients-with-locally-advanced-unresectable-or-metastatic-her2-negative-gastric-or-gastro-oesophageal-junction-adenocarcinoma-in-combination-with-fluoropyrimidine--and-platinum-containing-chemotherapy 2024-04-20T02:22:23 https://maestrodatabase.com/blog/libtayo-cemiplimab-receives-positive-chmp-opinion-recommending-approval-to-treat-advanced-cervical-cancer 2022-10-14T11:31:57 https://maestrodatabase.com/blog/novartis-receives-positive-chmp-opinion-for-pluvicto-for-patients-with-progressive-psma-positive-metastatic-castration-resistant-prostate-cancer 2022-10-14T11:37:57 https://maestrodatabase.com/blog/ucb-receives-european-commission-approval-for-bimzelx-bimekizumab-as-the-first-il-17a-and-il-17f-biologic-for-moderate-to-severe-hidradenitis-suppurativa 2024-04-22T05:21:11 https://maestrodatabase.com/blog/outcomes-from-the-september-2022-pbac-intracycle-meeting 2022-10-14T09:12:21 https://maestrodatabase.com/blog/the-myth-of-the-free-market-for-pharmaceuticals 2024-04-21T21:38:40 https://maestrodatabase.com/blog/will-covid-19-vaccines-be-cost-effective--and-does-it-matter 2020-11-29T06:02:46 https://maestrodatabase.com/blog/abbvie-submits-supplemental-new-drug-application-to-u-dot-s-fda-for-cariprazine-vraylar-for-the-adjunctive-treatment-of-major-depressive-disorder 2022-02-22T19:27:04 https://maestrodatabase.com/blog/boost-for-pharmacists-for-flu-season 2024-04-22T06:18:57 https://maestrodatabase.com/blog/mallinckrodt-provides-a-regulatory-update-on-terlipressin 2022-02-22T19:35:30 https://maestrodatabase.com/blog/u-dot-s-fda-grants-fast-track-designation-to-empagliflozin-for-the-treatment-of-chronic-heart-failure 2019-06-26T12:27:31 https://maestrodatabase.com/blog/immunomedics-announces-fda-acceptance-for-filing-of-biologics-license-application-resubmission-for-sacituzumab-govitecan-to-treat-metastatic-triple-negative-breast-cancer 2019-12-26T23:41:53 https://maestrodatabase.com/blog/why-transparency-on-medical-prices-could-actually-make-them-go-higher 2019-06-26T08:13:45 https://maestrodatabase.com/blog/sandoz-confirms-european-commission-approval-of-pyzchiva-ustekinumab-further-strengthening-immunology-offering 2024-04-22T05:31:52 https://maestrodatabase.com/blog/novartis-wins-gilenya-reprieve-as-judge-blocks-generics-for-now 2019-06-26T21:26:10 https://maestrodatabase.com/blog/neurosigma-receives-fda-breakthrough-device-designation-for-monarch-etns-system 2022-02-22T20:01:46 https://maestrodatabase.com/blog/fda-seeks-public-feedback-on-new-drug-approval-transparency-efforts 2019-06-26T21:21:06 https://maestrodatabase.com/blog/key-pbs-listing-to-save-australians-with-severe-back-and-neck-pain-more-than-20-000-dollars 2020-11-29T19:51:17 https://maestrodatabase.com/blog/fda-approves-first-treatment-for-chronic-rhinosinusitis-with-nasal-polyps 2019-06-26T21:18:08 https://maestrodatabase.com/blog/nice-recommends-albireos-bylvay-odevixibat-for-all-pfic-types 2022-02-22T20:06:27 https://maestrodatabase.com/blog/drug-change-not-ruled-out-as-factor-in-epilepsy-death-neurologists-report-says 2020-11-29T19:57:33 https://maestrodatabase.com/blog/fibrocell-announces-fda-fast-track-designation-of-fcx-007-for-treatment-of-recessive-dystrophic-epidermolysis-bullosa 2017-01-05T23:25:58 https://maestrodatabase.com/blog/does-the-doh-favour-some-pharmaceutical-companies-over-others 2022-02-22T19:46:41 https://maestrodatabase.com/blog/new-fda-drug-approvals-breaking-down-the-numbers 2017-01-05T23:20:34 https://maestrodatabase.com/blog/cms-approves-louisiana-state-plan-amendment-for-supplemental-rebate-agreements-using-a-modified-subscription-model-for-hepatitis-c-therapies-in-medicaid 2019-06-26T21:49:35 https://maestrodatabase.com/blog/beigene-announces-european-medicines-agency-acceptance-of-applications-for-brukinsa-zanubrutinib-in-chronic-lymphocytic-leukaemia-and-marginal-zone-lymphoma 2022-02-22T19:41:53 https://maestrodatabase.com/blog/nice-to-make-changes-to-health-technology-evaluation 2019-06-26T21:38:18 https://maestrodatabase.com/blog/beigene-announces-u-dot-s-fda-acceptance-of-supplemental-new-drug-application-for-brukinsa-zanubrutinib-in-chronic-lymphocytic-leukaemia 2022-02-22T19:57:28 https://maestrodatabase.com/blog/nices-backing-of-the-prostate-cancer-drug-abiraterone-could-help-thousands-and-save-the-nhs-millions 2025-10-31T04:49:59 https://maestrodatabase.com/blog/pharmacare-in-canada-remains-an-idealistic-pitch-without-a-realistic-plan 2019-06-26T21:30:26 https://maestrodatabase.com/blog/european-medicines-regulatory-network-adopts-eu-common-standard-for-electronic-product-information 2022-02-22T20:36:02 https://maestrodatabase.com/blog/real-world-evidence-the-future-is-here 2019-06-26T21:55:19 https://maestrodatabase.com/blog/sudden-epilepsy-deaths-grieving-mum-speaks-out-ahead-of-coronial-inquest 2020-11-29T20:00:43 https://maestrodatabase.com/blog/canada-bans-mass-exports-of-prescription-drugs 2020-11-29T20:04:38 https://maestrodatabase.com/blog/is-the-senate-gearing-up-to-actually-pass-drug-pricing-legislation 2022-02-22T20:09:57 https://maestrodatabase.com/blog/america-will-be-the-first-country-to-roll-out-a-covid-19-vaccine 2020-11-29T20:11:46 https://maestrodatabase.com/blog/karyopharm-receives-fda-fast-track-designation-for-selinexor-for-the-treatment-of-myelofibrosis 2023-07-17T23:16:50 https://maestrodatabase.com/blog/enhertu-approved-in-canada-as-the-first-and-only-her2-directed-therapy-for-patients-with-hr-positive-her2-low-or-her2-ultra-low-metastatic-breast-cancer-following-disease-progression-after-one-or-more-endocrine-therapies 2025-10-31T05:53:34 https://maestrodatabase.com/blog/health-economic-assessment-of-the-gene-therapy-libmeldy-in-metachromatic-leukodystrophy 2022-02-22T20:31:31 https://maestrodatabase.com/blog/new-pmprb-report-shows-significant-consistency-in-public-drug-plan-coverage-across-canada-for-drugs-subject-to-common-drug-review-process 2022-02-22T20:29:08 https://maestrodatabase.com/blog/covid-19-indemnity-scheme-to-protect-health-professionals-and-patients 2021-07-04T21:34:37 https://maestrodatabase.com/blog/madrigal-pharmaceuticals-completes-submission-of-new-drug-application-seeking-accelerated-approval-of-resmetirom-for-the-treatment-of-nash-with-liver-fibrosis 2023-07-18T00:00:59 https://maestrodatabase.com/blog/alvotech-signs-us-agreement-to-expand-access-for-newly-approved-high-concentration-interchangeable-biosimilar-to-humira-adalimumab 2024-04-22T07:35:23 https://maestrodatabase.com/blog/flexion-therapeutics-announces-fda-approval-of-snda-to-revise-zilretta-triamcinolone-acetonide-extended-release-injectable-suspension-product-label 2019-12-27T02:07:10 https://maestrodatabase.com/blog/fda-approves-genentechs-lucentis-ranibizumab-for-myopic-choroidal-neovascularisation 2017-01-06T01:16:52 https://maestrodatabase.com/blog/japans-push-to-cut-drug-costs-risks-u-dot-s-trade-friction 2017-09-15T01:22:09 https://maestrodatabase.com/blog/carvykti-ciltacabtagene-autoleucel-is-the-first-bcma-targeted-treatment-approved-by-the-european-commission-for-patients-with-relapsed-and-refractory-multiple-myeloma-who-have-received-at-least-one-prior-line-of-therapy 2024-04-22T22:02:20 https://maestrodatabase.com/blog/public-summary-documents---july-2025-pbac-meeting 2025-10-31T06:23:14 https://maestrodatabase.com/blog/melinta-therapeutics-new-drug-application-for-baxdela-accepted-for-filing-by-us-fda 2017-01-06T02:28:37 https://maestrodatabase.com/blog/solasia-announces-submission-of-new-drug-application-for-anti-cancer-drug-darinaparsin-for-peripheral-t-cell-lymphoma-in-japan 2021-07-04T21:37:37 https://maestrodatabase.com/blog/ema-publishes-agenda-for-22-25-april-2024-chmp-meeting 2024-04-22T21:14:07 https://maestrodatabase.com/blog/icer-publishes-final-evidence-report-on-treatment-for-non-cystic-fibrosis-bronchiectasis 2025-10-31T06:11:00 https://maestrodatabase.com/blog/post-market-review-of-ezetimibe---draft-report 2017-01-27T06:21:08 https://maestrodatabase.com/blog/2016-financial-year-report-from-the-director 2017-01-06T03:09:57 https://maestrodatabase.com/blog/meeting-highlights---chmp-23-26-april-2018-meeting 2018-04-28T02:30:03 https://maestrodatabase.com/blog/fda-approves-nogapendekin-alfa-inbakicept-pmln-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer 2024-04-22T22:51:09 https://maestrodatabase.com/blog/fda-approves-device-for-treatment-of-osteoid-osteoma-in-the-extremities 2020-11-30T04:44:15 https://maestrodatabase.com/blog/kura-oncology-receives-breakthrough-therapy-designation-for-ziftomenib-in-npm1-mutant-aml 2024-04-22T23:30:58 https://maestrodatabase.com/blog/deploying-big-data-to-determine-how-well-vaccines-work 2020-11-30T05:21:35 https://maestrodatabase.com/blog/european-commission-approves-pfizers-emblaveo-for-patients-with-multidrug-resistant-infections-and-limited-treatment-options 2024-04-23T01:14:36 https://maestrodatabase.com/blog/gps-tell-inquest-they-were-unaware-pharmac-changed-their-patients-epilepsy-drugs 2020-11-30T05:28:13 https://maestrodatabase.com/blog/we-cant-wait-life-saving-cystic-fibrosis-drugs-hard-to-access-advocates-say 2019-12-27T05:59:47 https://maestrodatabase.com/blog/bureaucratic-deficiencies-in-medicine-funding-underscore-access-crisis 2024-12-27T03:22:33 https://maestrodatabase.com/blog/u-dot-s-spending-more-on-specialty-drugs-via-medicare 2017-01-06T06:02:50 https://maestrodatabase.com/blog/pharmacies-add-freezers-train-staff-to-handle-covid-19-vaccination-drive 2020-11-30T06:14:18 https://maestrodatabase.com/blog/german-iqwig-confirms-additional-benefit-for-kisplyx-lenvatinib-mesylate-in-combination-with-everolimus-for-the-treatment-of-advanced-renal-cell-carcinoma 2017-01-06T06:07:35 https://maestrodatabase.com/blog/datroway-approved-in-japan-as-the-first-trop-2-directed-therapy-for-patients-with-previously-treated-unresectable-or-recurrent-hormone-receptor-positive-her2-negative-breast-cancer 2024-12-27T07:07:05 https://maestrodatabase.com/blog/dupixent-dupilumab-approved-by-european-commission-as-first-and-only-biologic-medicine-for-children-aged-6-to-11-years-with-severe-atopic-dermatitis 2020-11-30T06:25:48 https://maestrodatabase.com/blog/luye-pharma-submits-new-drug-application-in-the-u-dot-s-for-its-anti-depressant-drug-ly03005 2019-12-28T04:11:07 https://maestrodatabase.com/blog/acadia-pharmaceuticals-announces-trofinetide-new-drug-submission-for-treatment-of-rett-syndrome-has-been-accepted-for-filing-and-priority-review-by-health-canada 2024-04-23T01:59:21 https://maestrodatabase.com/blog/biden-pushes-hhs-to-do-more-on-drug-pricing 2022-10-15T02:08:54 https://maestrodatabase.com/blog/health-canada-approves-new-indication-for-mercks-prevymis-letermovir-for-prevention-of-cytomegalovirus-disease-in-high-risk-adult-kidney-transplant-recipients 2024-04-23T01:49:40 https://maestrodatabase.com/blog/associations-between-surrogate-markers-and-clinical-outcomes-for-non-oncologic-chronic-disease-treatments 2024-04-23T01:42:04 https://maestrodatabase.com/blog/beigene-receives-positive-chmp-opinion-for-brukinsa-zanubrutinib-for-the-treatment-of-adults-with-cll 2022-10-15T01:28:13 https://maestrodatabase.com/blog/takeda-receives-positive-chmp-opinion-recommending-approval-of-dengue-vaccine-candidate-in-eu-and-dengue-endemic-countries 2022-10-15T01:15:35 https://maestrodatabase.com/blog/gottlieb-mcclellan-push-for-fda-regulatory-reforms 2022-10-15T02:28:02 https://maestrodatabase.com/blog/chmp-recommends-conditional-marketing-authorisation-for-spesolimab-as-first-in-class-treatment-option-for-generalised-pustular-psoriasis-flares 2022-10-15T02:15:27 https://maestrodatabase.com/blog/forxiga-approved-in-japan-for-chronic-heart-failure 2020-11-30T07:21:30 https://maestrodatabase.com/blog/fda-approves-nivolumab-and-hyaluronidase-nvhy-for-subcutaneous-injection 2024-12-27T21:17:11 https://maestrodatabase.com/blog/janssen-announces-european-commission-approval-of-darzalex-daratumumab-split-dosing-regimen 2018-12-21T03:09:23 https://maestrodatabase.com/blog/nabriva-therapeutics-submits-new-drug-applications-to-u-dot-s-fda-for-intravenous-and-oral-lefamulin-to-treat-community-acquired-bacterial-pneumonia-in-adults 2018-12-21T03:02:27 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-releases-draft-evidence-report-on-treatments-for-spinal-muscular-atrophy 2018-12-21T03:13:40 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-november-2025 2025-10-31T20:53:00 https://maestrodatabase.com/blog/pharmacs-clinical-experts-recommend-funding-trikafta 2022-02-23T05:40:33 https://maestrodatabase.com/blog/provention-bio-announces-biologics-license-application-resubmission-for-teplizumab-to-address-complete-response-letter 2022-02-23T04:29:47 https://maestrodatabase.com/blog/more-treatment-options-proposed-for-people-with-multiple-myeloma-and-myelodysplastic-syndrome 2024-04-23T03:55:27 https://maestrodatabase.com/blog/trump-administration-defends-rule-requiring-drug-prices-in-tv-ads 2019-06-27T05:53:27 https://maestrodatabase.com/blog/ucb-announces-eu-regulatory-filing-for-bimekizumab-for-the-treatment-of-moderate-to-severe-hidradenitis-suppurativa 2023-07-18T05:46:30 https://maestrodatabase.com/blog/bevespi-aerosphere-approved-in-the-eu-for-chronic-obstructive-pulmonary-disease 2018-12-21T07:00:01 https://maestrodatabase.com/blog/msac-secretariat-publishes-agenda-for-june-2022-esc-meeting 2022-02-23T06:33:01 https://maestrodatabase.com/blog/merck-provides-update-on-keytruda-pembrolizumab-supplemental-biologics-license-application-for-keynote-042-trial 2018-12-21T05:13:14 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-november-2025 2025-10-31T20:27:23 https://maestrodatabase.com/blog/trastuzumab-emtansine-and-cost-based-decision-making 2017-01-06T11:01:52 https://maestrodatabase.com/blog/fda-approves-first-treatment-for-rare-blood-disease 2018-12-21T20:09:50 https://maestrodatabase.com/blog/pharmac-recommends-funding-cystic-fibrosis-medicine-trikafta-but-needs-more-funding 2022-02-23T08:27:48 https://maestrodatabase.com/blog/nice-recommends-lenvima-for-advanced-liver-cancer 2018-12-21T12:41:11 https://maestrodatabase.com/blog/grumpy-tga-boss-unloads-over-people-downplaying-covids-effect-on-kids 2022-02-23T08:32:18 https://maestrodatabase.com/blog/fda-approves-new-treatment-for-adult-patients-with-rare-life-threatening-blood-disease 2018-12-21T20:18:48 https://maestrodatabase.com/blog/alnylam-canada-signs-letter-of-intent-from-pan-canadian-pharmaceutical-alliance-for-the-public-reimbursement-of-amvuttra-for-the-treatment-of-hereditary-transthyretin-mediated-amyloidosis-in-adults 2024-12-27T21:49:33 https://maestrodatabase.com/blog/elahere-receives-positive-reimbursement-recommendation-by-canadas-drug-agency-for-certain-types-of-platinum-resistant-ovarian-cancers 2025-11-01T01:07:11 https://maestrodatabase.com/blog/johnson-and-johnson-submits-application-to-us-fda-for-stelara-ustekinumab-in-the-treatment-of-paediatric-ulcerative-colitis 2025-11-01T01:13:26 https://maestrodatabase.com/blog/tga-checks-need-for-another-vax-booster 2022-02-23T19:57:55 https://maestrodatabase.com/blog/outcome-statement---june-2023-dusc-meeting 2023-07-18T06:09:17 https://maestrodatabase.com/blog/fda-permits-marketing-of-first-condom-specifically-indicated-for-anal-intercourse 2022-02-23T20:16:58 https://maestrodatabase.com/blog/theragnostics-announces-us-fda-approval-for-its-radiodiagnostic-imaging-drug-nephroscan-kit-for-the-preparation-of-technetium-tc-99m-succimer-injection 2022-02-23T20:05:20 https://maestrodatabase.com/blog/medtronic-receives-fda-approval-for-interstim-x-system-the-next-generation-of-the-most-personalised-sacral-nerve-stimulation-therapy-for-bladder-and-bowel-control 2022-02-23T09:26:01 https://maestrodatabase.com/blog/agenda-for-the-august-2019-pbac-intracycle-meeting 2019-06-27T10:30:22 https://maestrodatabase.com/blog/annual-report-2021-more-government-assignments-and-increased-eu-cooperation-on-tlv 2022-02-23T19:50:08 https://maestrodatabase.com/blog/statement-for-health-care-professionals-how-covid-19-vaccines-are-regulated-for-safety-and-effectiveness 2021-07-05T05:46:21 https://maestrodatabase.com/blog/roche-withdraws-type-ii-variation-for-gazyvaro 2023-07-18T08:04:28 https://maestrodatabase.com/blog/abeona-therapeutics-provides-regulatory-update-on-pz-cel 2024-04-23T05:14:37 https://maestrodatabase.com/blog/medical-devices-reforms-enhancements-to-post-market-monitoring 2021-07-05T05:04:19 https://maestrodatabase.com/blog/doh-publishes-revised-agenda-version-4-for-july-2023-pbac-meeting 2023-07-18T06:31:48 https://maestrodatabase.com/blog/fda-approves-nalmefene-hydrochloride-2-mg-slash-2-ml-injection-for-the-treatment-of-known-or-suspected-opioid-overdose-with-natural-or-synthetic-opioids 2022-02-23T20:50:56 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-december-2020 2020-11-30T10:55:17 https://maestrodatabase.com/blog/knight-announces-filing-of-new-drug-submission-for-ibsrela-in-canada 2019-06-27T11:35:56 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-december-2020-update 2020-11-30T11:01:28 https://maestrodatabase.com/blog/icer-analytics-launched-to-accelerate-the-real-world-application-of-icer-reports-helping-payers-the-life-science-industry-and-health-care-policy-makers-move-from-insight-to-action 2020-11-30T20:04:26 https://maestrodatabase.com/blog/fda-takes-steps-to-spark-development-of-heart-failure-drugs 2019-06-27T21:02:09 https://maestrodatabase.com/blog/one-additional-country-to-benefit-from-eu-us-mutual-recognition-agreement-for-inspections 2019-06-27T20:59:19 https://maestrodatabase.com/blog/a-million-kiwis-to-be-impacted-by-major-pharmaceutical-company-leaving-new-zealand 2020-07-05T03:07:08 https://maestrodatabase.com/blog/sneaky-deals-are-keeping-cheaper-generic-medicines-off-the-market 2019-06-27T11:44:19 https://maestrodatabase.com/blog/clock-ticking-on-edmonton-familys-hope-for-2-dollars-8-cents-million-drug-treatment-for-toddler-son 2020-07-05T03:12:15 https://maestrodatabase.com/blog/uk-secures-another-two-million-doses-of-modernas-covid-19-vaccine 2020-11-30T10:51:25 https://maestrodatabase.com/blog/canada-to-trump-you-cant-take-our-prescription-drugs 2020-11-30T20:41:04 https://maestrodatabase.com/blog/beyond-the-numbers-a-critique-of-quantitative-multi-criteria-decision-analysis 2020-07-05T04:26:32 https://maestrodatabase.com/blog/astellas-receives-approval-of-evrenzo-roxadustat-in-japan-for-the-treatment-of-anaemia-of-chronic-kidney-disease-in-adult-patients-not-on-dialysis 2020-11-30T20:43:25 https://maestrodatabase.com/blog/fda-approves-first-treatment-for-neuromyelitis-optica-spectrum-disorder-a-rare-auto-immune-disease-of-the-central-nervous-system 2019-06-27T21:08:30 https://maestrodatabase.com/blog/fda-takes-new-step-to-help-advance-the-transition-of-certain-biological-products 2019-06-27T21:05:11 https://maestrodatabase.com/blog/moderna-submits-vaccine-for-fda-regulatory-approval 2020-11-30T20:24:23 https://maestrodatabase.com/blog/dova-pharmaceuticals-announces-fda-approval-of-supplemental-new-drug-application-for-doptelet-avatrombopag-for-treatment-of-chronic-immune-thrombocytopenia 2019-06-27T21:27:39 https://maestrodatabase.com/blog/new-recommendations-to-strengthen-supply-chains-of-critical-medicines 2024-04-23T21:08:37 https://maestrodatabase.com/blog/european-commission-approves-extended-invokana-canagliflozin-indication-to-reflect-improved-renal-outcomes-in-patients-with-diabetic-kidney-disease-and-type-2-diabetes-seen-in-credence-study 2020-07-05T03:34:21 https://maestrodatabase.com/blog/pfizer-names-former-fda-chief-gottlieb-to-board-of-directors 2019-06-27T21:22:55 https://maestrodatabase.com/blog/icer-and-newdigs-release-white-paper-analysing-the-challenges-and-potential-policy-options-for-paying-for-gene-therapies 2024-04-23T21:02:42 https://maestrodatabase.com/blog/labor-leaves-genetics-loophole-for-life-insurers 2024-12-27T23:22:47 https://maestrodatabase.com/blog/lynparza-approved-in-the-us-as-a-first-line-maintenance-treatment-of-germline-brca-mutated-metastatic-pancreatic-cancer 2019-12-30T21:04:06 https://maestrodatabase.com/blog/senate-health-committee-advances-bipartisan-package-to-lower-health-costs 2019-06-27T21:15:38 https://maestrodatabase.com/blog/oxford-university-is-leading-in-the-vaccine-race 2020-07-05T03:58:34 https://maestrodatabase.com/blog/zymeworks-receives-fda-breakthrough-therapy-designation-for-her2-targeted-bispecific-antibody-zanidatamab-in-patients-with-biliary-tract-cancer 2020-11-30T20:32:07 https://maestrodatabase.com/blog/canadas-pharmacare-idea-will-face-the-same-obstacles-as-obamacare 2019-06-27T21:41:12 https://maestrodatabase.com/blog/dealing-with-drug-pricing-not-just-one-solution 2018-12-22T00:04:53 https://maestrodatabase.com/blog/pbac-public-summary-document-for-risdiplam---march-2021-meeting 2021-07-05T07:25:25 https://maestrodatabase.com/blog/ceftolozane-slash-tazobactam-new-treatment-option-for-severe-infections-but-no-proof-of-superiority 2020-07-05T12:23:33 https://maestrodatabase.com/blog/switzerland-fast-tracks-anti-viral-medication-against-covid-19 2020-07-05T12:30:51 https://maestrodatabase.com/blog/now-more-than-ever-the-fight-against-hiv-must-continue 2020-11-30T20:56:37 https://maestrodatabase.com/blog/democrats-clash-over-medicare-for-all-in-first-debate 2019-06-27T21:53:39 https://maestrodatabase.com/blog/aimmune-therapeutics-submits-bla-to-fda-for-ar101-for-the-treatment-of-peanut-allergy-in-children-and-adolescents-ages-4-17 2018-12-22T00:12:40 https://maestrodatabase.com/blog/pharma-frustration-mounts-as-johnson-toys-with-no-deal-brexit-pronouncements 2019-06-27T21:48:21 https://maestrodatabase.com/blog/diurnal-receives-marketing-authorisation-for-efmody-in-great-britain-from-the-mhra 2021-07-05T06:58:58 https://maestrodatabase.com/blog/britain-nears-625-dollars-million-sanofi-slash-gsk-covid-19-vaccine-deal 2020-07-05T21:46:41 https://maestrodatabase.com/blog/fda-commissioner-says-he-cant-predict-when-vaccine-will-be-ready-after-trumps-timeline-claims 2020-07-05T21:18:52 https://maestrodatabase.com/blog/the-health-of-private-insurance-in-the-us-during-covid-19 2020-07-05T21:29:32 https://maestrodatabase.com/blog/assessment-of-technical-errors-and-validation-processes-in-economic-models-submitted-by-the-company-for-nice-technology-appraisals 2020-07-05T21:37:13 https://maestrodatabase.com/blog/xbrane-provides-regulatory-update-on-fda-review-of-its-ranibizumab-biosimilar-candidate 2025-10-20T09:57:21 https://maestrodatabase.com/blog/voydeya-approved-in-the-eu-as-add-on-treatment-to-ravulizumab-or-eculizumab-for-adults-with-the-rare-disease-pnh-who-have-residual-haemolytic-anaemia 2024-04-23T22:10:38 https://maestrodatabase.com/blog/morphosys-announces-submission-of-biologics-license-application-for-tafasitamab-in-r-slash-r-dlbcl-to-the-fda 2019-12-31T04:41:16 https://maestrodatabase.com/blog/merck-provides-update-on-keytruda-pembrolizumab-indication-in-third-line-gastric-cancer-in-the-us 2021-07-05T10:58:08 https://maestrodatabase.com/blog/its-time-for-the-fda-to-fully-approve-the-mrna-vaccines 2021-07-05T11:26:24 https://maestrodatabase.com/blog/fda-approves-lutetium-lu-177-dotatate-for-paediatric-patients-12-years-and-older-with-gep-nets 2024-04-23T22:25:37 https://maestrodatabase.com/blog/urovant-sciences-announces-submission-of-new-drug-application-for-vibegron-for-the-treatment-of-overactive-bladder 2019-12-31T04:54:39 https://maestrodatabase.com/blog/cheating-death-can-cost-us$200-000-as-cancer-tops-pharma-sales 2017-01-07T07:29:08 https://maestrodatabase.com/blog/ottawa-vows-prudent-health-spending-as-federal-report-projects-decades-of-deficits 2017-01-07T07:37:36 https://maestrodatabase.com/blog/repealing-the-aca-without-a-replacement----the-risks-to-american-health-care 2017-01-07T07:20:50 https://maestrodatabase.com/blog/new-cancer-drugs-are-expensive-and-often-ineffective 2021-07-05T11:33:15 https://maestrodatabase.com/blog/democrats-appeal-for-compromise-alter-but-dont-gut-the-health-law 2017-01-07T07:41:19 https://maestrodatabase.com/blog/the-politics-of-trumpcare 2017-01-07T07:47:40 https://maestrodatabase.com/blog/chmp-recommends-approval-of-atara-biotherapeutics-ebvallo-tabelecleucel-for-the-treatment-of-epstein-barr-virus-positive-post-transplant-lymphoproliferative-disease 2022-10-15T11:16:40 https://maestrodatabase.com/blog/savara-granted-breakthrough-therapy-designation-for-molgradex-for-the-treatment-of-auto-immune-pulmonary-alveolar-proteinosis 2019-12-31T05:11:05 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-tovorafenib-for-patients-with-relapsed-or-refractory-braf-altered-paediatric-low-grade-glioma 2024-04-23T23:40:38 https://maestrodatabase.com/blog/astellas-xtandi-enzalutamide-granted-european-commission-approval-for-use-in-additional-recurrent-early-prostate-cancer-treatment-setting 2024-04-23T23:35:58 https://maestrodatabase.com/blog/medicure-receives-us-fda-fast-track-designation-for-mc-1-for-pnpo-deficiency 2024-04-23T23:29:11 https://maestrodatabase.com/blog/utilisation-analysis-of-heart-failure-medicines-listed-on-the-pbs 2024-12-28T05:11:41 https://maestrodatabase.com/blog/reflection-paper-on-the-use-of-artificial-intelligence-in-the-lifecycle-of-medicines 2023-07-19T11:37:06 https://maestrodatabase.com/blog/averoa-submits-marketing-authorisation-application-to-the-european-medicines-agency-seeking-approval-of-ava1014-for-treating-complications-associated-with-chronic-kidney-disease 2024-04-24T01:11:15 https://maestrodatabase.com/blog/protecting-the-healthcare-innovation-ecosystem 2023-07-19T21:38:10 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-for-ambrxs-arx517-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer 2023-07-19T20:37:32 https://maestrodatabase.com/blog/severe-asthma-treatment-cinqair-passes-drug-review-6-years-after-approval 2023-07-19T11:45:09 https://maestrodatabase.com/blog/health-canada-authorizes-tecentriq-sc-atezolizumab-solution-for-subcutaneous-injection-the-first-cancer-immunotherapy-subcutaneous-injection-for-multiple-cancer-types 2024-04-24T01:20:38 https://maestrodatabase.com/blog/what-price-is-society-willing-to-pay-for-new-drugs 2024-12-28T05:57:15 https://maestrodatabase.com/blog/better-protection-against-meningococcal-and-pneumococcal-diseases 2020-07-06T01:27:59 https://maestrodatabase.com/blog/astellas-pharma-us-statement-on-legal-action-regarding-the-inflation-reduction-act 2023-07-19T20:33:30 https://maestrodatabase.com/blog/agenda-for-11-january-2017-tc-meeting 2017-01-08T06:46:51 https://maestrodatabase.com/blog/taste-of-their-own-medicine 2017-01-08T07:56:48 https://maestrodatabase.com/blog/major-step-in-covid-19-vaccine-rollout 2021-07-05T21:16:58 https://maestrodatabase.com/blog/pembrolizumab-in-combination-with-gemcitabine-and-cisplatin-for-the-first-line-treatment-of-patients-with-advanced-biliary-tract-cancer 2024-04-24T02:49:18 https://maestrodatabase.com/blog/highlights-from-the-10-13-october-2022-chmp-meeting 2022-10-15T20:43:41 https://maestrodatabase.com/blog/remdesivir-in-covid-19-indication-of-considerable-added-benefit-for-a-part-of-the-patients 2021-07-05T21:43:56 https://maestrodatabase.com/blog/atagi-recommendations-on-the-use-of-spikevax-moderna-covid-19-vaccine-in-children-aged-6-to-11-years 2022-02-24T03:56:23 https://maestrodatabase.com/blog/time-for-corporate-health-insurers-to-front-up-on-savings 2021-07-05T21:39:39 https://maestrodatabase.com/blog/government-of-canada-signs-new-covid-19-antibody-therapy-agreement 2022-02-24T04:13:35 https://maestrodatabase.com/blog/impending-relief-for-medicare-beneficiaries---the-inflation-reduction-act 2022-10-15T20:49:07 https://maestrodatabase.com/blog/karolinska-developments-portfolio-company-aprea-therapeutics-receives-fda-fast-track-designation-for-eprenetapopt-in-aml 2020-12-01T01:09:05 https://maestrodatabase.com/blog/fda-approves-new-treatment-for-uncomplicated-urinary-tract-infections 2024-04-25T00:58:08 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-january-2020-update 2020-01-02T01:26:09 https://maestrodatabase.com/blog/children-and-teenagers-with-an-aggressive-form-of-brain-cancer-set-to-benefit-after-nice-recommends-new-life-extending-drug-combination-treatment 2024-04-25T01:33:54 https://maestrodatabase.com/blog/janssen-announces-u-dot-s-fda-approval-of-darzalex-daratumumab-in-combination-with-lenalidomide-and-dexamethasone-for-newly-diagnosed-patients-with-multiple-myeloma-who-are-transplant-ineligible 2019-06-28T01:23:55 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-24-february-2022 2022-02-24T07:10:32 https://maestrodatabase.com/blog/velsipity-receives-health-canada-approval-for-adults-with-moderately-to-severely-active-ulcerative-colitis 2024-04-25T01:26:05 https://maestrodatabase.com/blog/earlier-access-to-cheaper-medicines-for-1-dot-6-million-australians 2020-01-02T02:28:55 https://maestrodatabase.com/blog/deverra-therapeutics-granted-fda-fast-track-designation-for-dvx101-dilanubicel-for-the-treatment-of-acute-myeloid-leukaemia 2024-04-25T01:18:24 https://maestrodatabase.com/blog/new-laws-that-affect-australians-from-january-1-2020 2020-01-02T02:19:27 https://maestrodatabase.com/blog/dont-thank-big-government-for-medical-breakthroughs 2017-01-08T23:07:26 https://maestrodatabase.com/blog/bashing-accelerated-approval-isnt-supported-by-the-data 2024-04-25T01:13:21 https://maestrodatabase.com/blog/does-an-orphan-drug-policy-make-a-difference-in-access-a-comparison-of-canada-and-australia 2020-01-02T02:14:45 https://maestrodatabase.com/blog/travere-therapeutics-and-csl-vifor-announce-european-commission-approves-filspari-sparsentan-for-the-treatment-of-iga-nephropathy 2024-04-25T01:08:46 https://maestrodatabase.com/blog/updated-pbac-outcomes-for-november-2016 2017-02-07T00:41:55 https://maestrodatabase.com/blog/biocryst-receives-health-canada-approval-for-rapivab-for-the-treatment-of-influenza 2017-01-09T01:06:33 https://maestrodatabase.com/blog/fda-approves-treatment-for-wider-range-of-patients-with-heart-failure 2022-02-24T19:46:00 https://maestrodatabase.com/blog/us-fda-accepts-for-priority-review-gsks-application-for-an-expanded-indication-of-jemperli-dostarlimab-plus-chemotherapy-to-include-all-adult-patients-with-primary-advanced-or-recurrent-endometrial-cancer 2024-04-25T02:47:54 https://maestrodatabase.com/blog/arrowhead-pharmaceuticals-receives-fast-track-designation-for-aro-aat-for-treatment-of-alfa-1-liver-disease 2019-06-28T02:23:07 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-therapies-for-anaemia-in-chronic-kidney-disease 2020-12-01T01:52:39 https://maestrodatabase.com/blog/biosimilar-trastuzumab-and-rituximab-on-the-pbs---information-for-health-professionals-and-patients 2020-01-02T02:57:50 https://maestrodatabase.com/blog/seeking-thought-leaders-new-advisory-council-to-medicines-australia 2017-01-09T03:27:13 https://maestrodatabase.com/blog/ema-recommends-approval-of-spikevax-for-children-aged-6-to-11 2022-02-24T19:42:25 https://maestrodatabase.com/blog/fda-grants-roches-cancer-immunotherapy-tecentriq-atezolizumab-priority-review-in-additional-type-of-advanced-bladder-cancer 2017-01-09T19:54:51 https://maestrodatabase.com/blog/fda-grants-bi-1015550-breakthrough-therapy-designation-for-idiopathic-pulmonary-fibrosis 2022-02-24T20:06:01 https://maestrodatabase.com/blog/dusc-utilisation-analysis-public-release-documents-february-2023 2023-07-20T01:41:31 https://maestrodatabase.com/blog/senate-looks-to-move-fast-on-trump-administration-hearings-health-law 2017-01-09T06:13:16 https://maestrodatabase.com/blog/health-insurers-offer-parents-a-rebate-for-bexsero-meningococcal-b-vaccine-which-is-not-on-the-pbs 2017-01-09T19:45:46 https://maestrodatabase.com/blog/ema-recommends-authorisation-of-booster-doses-of-comirnaty-from-12-years-of-age 2022-02-24T20:10:22 https://maestrodatabase.com/blog/medicare-to-cover-infliximab-biosimilar 2017-01-09T20:11:18 https://maestrodatabase.com/blog/senate-majority-leader-mitch-mcconnell-we-will-replace-obamacare-very-rapidly-after-repeal 2017-01-09T20:19:27 https://maestrodatabase.com/blog/once-a-day-capsule-for-people-with-some-forms-of-ovarian-fallopian-tube-and-peritoneal-cancer-recommended-for-routine-use-in-the-nhs 2022-02-24T19:54:22 https://maestrodatabase.com/blog/cost-of-older-australians-with-diabetes-to-hit-2-dollars-9-cents-billion-by-2030-new-research-shows 2017-01-09T20:41:09 https://maestrodatabase.com/blog/pharmac-joins-international-collaboration-to-advance-use-of-health-technology-assessments 2023-07-20T01:16:01 https://maestrodatabase.com/blog/afstyla-rfviii-for-haemophilia-a-receives-european-commission-approval 2017-01-09T20:24:28 https://maestrodatabase.com/blog/rhythm-pharmaceuticals-announces-fda-extension-of-review-period-for-imcivree-setmelanotide-for-patients-with-bardet-biedl-syndrome-and-alstroem-syndrome 2022-02-24T20:00:57 https://maestrodatabase.com/blog/nice-takes-key-role-in-new-european-project-for-faster-access-to-alzheimers-disease-drugs 2017-01-09T20:31:58 https://maestrodatabase.com/blog/egalet-receives-fda-approval-for-arymo-er-morphine-sulphate-c-ii-an-extended-release-morphine-product-formulated-with-abuse-deterrent-properties-for-treatment-of-chronic-pain 2017-01-10T19:58:34 https://maestrodatabase.com/blog/fiasp-fast-acting-insulin-aspart-approved-in-europe 2017-01-10T20:04:09 https://maestrodatabase.com/blog/australian-approval-for-drug-that-melts-leukaemia 2017-01-10T19:47:24 https://maestrodatabase.com/blog/european-commission-grants-conditional-marketing-authorization-for-gileads-veklury-remdesivir-for-the-treatment-of-covid-19 2020-07-06T07:52:25 https://maestrodatabase.com/blog/abbvie-announces-provincial-reimbursement-for-venclexta-venetoclax-with-obinutuzumab-for-patients-with-previously-untreated-chronic-lymphocytic-leukaemia-in-alberta-saskatchewan-british-columbia-and-manitoba 2022-02-24T20:25:58 https://maestrodatabase.com/blog/the-real-health-care-change-we-need-strong-leadership 2017-01-10T20:17:47 https://maestrodatabase.com/blog/biden-vows-to-push-pharmaceutical-companies-to-ensure-patients-can-afford-treatments 2017-01-10T20:22:05 https://maestrodatabase.com/blog/hhs-secretary-give-medicare-authority-to-negotiate-drug-prices 2017-01-10T20:07:53 https://maestrodatabase.com/blog/muted-response-from-health-lobby-as-affordable-care-act-faces-repeal 2017-01-10T20:11:18 https://maestrodatabase.com/blog/united-therapeutics-corporation-reports-fourth-quarter-and-full-year-2021-financial-results 2022-02-24T20:31:17 https://maestrodatabase.com/blog/viracyte-granted-u-dot-s-fda-fast-track-designation-for-viralym-c 2017-01-11T02:20:13 https://maestrodatabase.com/blog/merck-receives-fda-acceptance-of-supplemental-biologics-license-application-for-keytruda-pembrolizumab-in-combination-with-chemotherapy-for-first-line-treatment-of-metastatic-non-squamous-non-small-cell-lung-cancer 2017-01-11T02:27:20 https://maestrodatabase.com/blog/kadmon-announces-fda-acceptance-of-nda-for-belumosudil-in-patients-with-chronic-graft-versus-host-disease 2020-12-01T03:55:24 https://maestrodatabase.com/blog/abbvie-withdraws-submission-for-venclexta 2017-01-10T20:50:15 https://maestrodatabase.com/blog/foamix-submits-new-drug-application-to-u-dot-s-fda-seeking-approval-of-fmx101-in-treatment-of-moderate-to-severe-acne 2018-12-22T06:48:37 https://maestrodatabase.com/blog/innovation-through-hta-theme-for-htai-2021-annual-meeting-announced 2020-07-06T07:05:22 https://maestrodatabase.com/blog/insulin-cost-cap-splits-democrats-seeking-broad-drug-price-curbs 2022-02-24T20:14:58 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-biologics-license-application-for-mylan-and-biocons-proposed-biosimilar-trastuzumab 2017-01-11T19:54:47 https://maestrodatabase.com/blog/alexion-submits-u-dot-s-and-eu-applications-seeking-approval-of-soliris-eculizumab-as-a-treatment-for-patients-with-refractory-generalised-myasthenia-gravis 2017-01-11T02:34:58 https://maestrodatabase.com/blog/valeo-pharma-obtains-public-reimbursement-for-enerzair-breezhaler-and-atectura-breezhaler-in-ontario-manitoba-and-new-brunswick 2022-02-24T20:20:01 https://maestrodatabase.com/blog/national-cancer-institute-and-drug-companies-aim-to-speed-up-clinical-trials 2017-01-11T20:06:40 https://maestrodatabase.com/blog/drug-stocks-plunge-as-trump-threatens-to-force-price-bidding 2017-01-11T20:15:26 https://maestrodatabase.com/blog/johnson-and-johnson-to-reveal-average-drug-price-increases 2017-01-11T20:03:45 https://maestrodatabase.com/blog/trump-tells-congress-to-repeal-and-replace-health-care-law-very-quickly 2017-01-11T20:52:51 https://maestrodatabase.com/blog/some-republicans-try-to-head-off-a-health-care-calamity 2017-01-11T20:56:22 https://maestrodatabase.com/blog/abbvie-vows-to-keep-drug-price-increases-below-10-percent 2017-01-11T20:18:13 https://maestrodatabase.com/blog/nice-publishes-final-guidance-on-the-use-of-keytruda-for-non-small-cell-lung-cancer 2017-01-11T20:22:09 https://maestrodatabase.com/blog/battle-over-pregnancy-drug-highlights-risks-of-fda-expediting-drugs-to-market 2022-10-16T20:40:09 https://maestrodatabase.com/blog/viz-dot-ai-receives-fda-510-k-clearance-for-viz-aneurysm 2022-02-24T20:36:45 https://maestrodatabase.com/blog/seven-questions-about-health-reform 2017-01-11T20:59:45 https://maestrodatabase.com/blog/mirum-pharmaceuticals-announces-positive-chmp-opinion-for-livmarli-maralixibat-oral-solution-for-cholestatic-pruritus-in-patients-with-alagille-syndrome-two-months-of-age-and-older 2022-10-16T20:34:03 https://maestrodatabase.com/blog/nice-approves-kidney-cancer-drug-for-nhs-use 2017-01-12T11:39:39 https://maestrodatabase.com/blog/european-commission-grants-marketing-authorisation-for-gileads-vemlidy-tenofovir-alafenamide-fumarate-for-the-treatment-of-chronic-hepatitis-b-virus-infection 2017-01-12T11:45:20 https://maestrodatabase.com/blog/cystic-fibrosis-community-disappointed-with-ptac-recommendations 2022-02-24T20:49:31 https://maestrodatabase.com/blog/aussie-pharmaceuticals-whacked-by-donald-trump 2017-01-12T11:31:16 https://maestrodatabase.com/blog/health-canada-approves-new-heart-failure-treatment-lancora-to-reduce-mortality-and-hospitalisations 2017-01-12T12:02:29 https://maestrodatabase.com/blog/mtpconnect-reveals-final-10-year-plan-for-medical-technology-biotechnology-and-pharmaceutical-sector 2017-01-12T11:54:56 https://maestrodatabase.com/blog/ema-validates-and-grants-accelerated-assessment-for-trastuzumab-deruxtecan-for-the-treatment-of-her2-positive-metastatic-breast-cancer 2020-07-06T12:09:50 https://maestrodatabase.com/blog/additional-listings-on-the-pharmaceutical-schedule-of-a-range-of-orthopaedic-joint-implants-additional-cmf-implants-associated-products-and-bone-cement-with-stryker 2017-01-12T19:59:10 https://maestrodatabase.com/blog/pressure-on-house-to-back-obamacare-repeal-bid-after-senate-vote 2017-01-12T20:03:59 https://maestrodatabase.com/blog/biopharma-needs-to-stop-getting-blindsided-by-donald-trump 2017-01-12T19:52:25 https://maestrodatabase.com/blog/pharma-industry-seizes-on-pandemic-as-a-shot-at-redemption 2020-07-06T12:39:08 https://maestrodatabase.com/blog/donald-trump-says-pharmaceutical-industry-getting-away-with-murder-stocks-slide 2017-01-12T19:54:37 https://maestrodatabase.com/blog/what-trump-gets-wrong-about-drug-companies 2017-01-12T20:12:13 https://maestrodatabase.com/blog/pharma-company-executives-debate-drug-pricing-increases 2017-01-12T20:20:03 https://maestrodatabase.com/blog/cigna-is-no-longer-covering-pricey-epipen 2017-01-12T20:06:33 https://maestrodatabase.com/blog/will-we-be-hostages-to-drug-makers-covid-vaccine-pricing 2020-07-06T11:52:02 https://maestrodatabase.com/blog/pharmacists-get-power-to-alter-prescriptions-under-controversial-trial 2017-01-13T02:08:34 https://maestrodatabase.com/blog/tesaro-receives-complete-response-letter-for-rolapitant-iv-from-u-dot-s-fda 2017-01-13T03:14:56 https://maestrodatabase.com/blog/esperare-receives-fda-breakthrough-therapy-designation-for-investigational-prenatal-treatment-er-004-in-x-linked-hypohidrotic-ectodermal-dysplasia 2020-07-06T11:56:02 https://maestrodatabase.com/blog/vivagel-bv-granted-qidp-and-fast-track-designation-by-us-fda 2017-01-13T03:49:00 https://maestrodatabase.com/blog/developing-a-sars-cov-2-vaccine-at-warp-speed 2020-07-06T21:09:11 https://maestrodatabase.com/blog/the-development-of-covid-19-vaccines-safeguards-needed 2020-07-06T21:11:27 https://maestrodatabase.com/blog/heron-announces-submission-of-cinvanti-nda-for-the-prevention-of-chemotherapy-induced-nausea-and-vomiting 2017-01-13T21:17:57 https://maestrodatabase.com/blog/durect-announces-submission-to-fda-of-a-full-response-to-the-posimir-complete-response-letter 2019-06-28T04:19:54 https://maestrodatabase.com/blog/mylan-prices-its-generic-remdesivir-in-india-at-64-dollars-per-100-mg-vial 2020-07-06T21:18:22 https://maestrodatabase.com/blog/interpretation-of-surrogate-endpoints-in-the-era-of-the-21st-century-cures-act 2017-01-13T21:04:51 https://maestrodatabase.com/blog/fda-finalises-guidance-on-non-proprietary-naming-of-biologics-and-biosimilars 2017-01-13T22:18:29 https://maestrodatabase.com/blog/cmss-proposed-medicaid-best-price-loophole-for-value-based-purchasing-of-drugs 2020-07-06T13:00:37 https://maestrodatabase.com/blog/ars-announces-acceptance-of-market-authorisation-application-submission-to-european-medicines-agency-for-neffy-ars-1-epinephrine-nasal-spray 2020-12-01T04:32:12 https://maestrodatabase.com/blog/u-dot-s-fda-extends-review-period-for-baricitinib 2017-01-13T22:23:44 https://maestrodatabase.com/blog/house-expected-to-follow-senates-lead-on-rush-to-repeal-health-law 2017-01-13T21:34:14 https://maestrodatabase.com/blog/nearly-12-million-people-with-medicare-have-saved-over-26-dollars-billion-on-prescription-drugs-since-2010 2017-01-13T22:10:34 https://maestrodatabase.com/blog/launch-of-public-consultation-on-joint-network-strategy-to-2025 2020-07-06T20:51:38 https://maestrodatabase.com/blog/two-silicon-valley-insiders-meet-with-trump-about-heading-fda 2017-01-13T22:43:44 https://maestrodatabase.com/blog/icer-posts-draft-scoping-document-on-high-cholesterol 2020-07-06T20:54:20 https://maestrodatabase.com/blog/paul-ryan-repeal-and-replace-of-obamacare-to-come-at-the-same-time 2017-01-13T22:33:06 https://maestrodatabase.com/blog/cvs-slashes-price-of-impaxs-epipen-rival 2017-01-13T22:40:26 https://maestrodatabase.com/blog/canadians-demand-access-to-miracle-cystic-fibrosis-drug-already-approved-in-u-dot-s-and-u-dot-k 2020-07-06T21:02:37 https://maestrodatabase.com/blog/mirum-pharmaceuticals-announces-european-medicines-agency-validation-of-the-marketing-authorisation-application-for-maralixibat-in-patients-with-pfic2 2020-12-01T06:10:21 https://maestrodatabase.com/blog/health-products-portal---outcomes-from-the-2021-22-federal-budget 2021-07-06T00:58:25 https://maestrodatabase.com/blog/redhill-biopharma-announces-qidp-fast-track-designation-granted-by-fda-to-rhb-104-for-non-tuberculous-mycobacteria-infections 2017-01-13T23:32:04 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-january-2020-update 2020-01-02T04:49:38 https://maestrodatabase.com/blog/doh-publishes-revised-agenda-for-november-2025-pbac-meeting-version-6 2025-11-02T00:14:50 https://maestrodatabase.com/blog/access-to-hiv-medicines-severely-impacted-by-covid-19-as-aids-response-stalls 2020-07-06T21:22:37 https://maestrodatabase.com/blog/highlights-from-the-24-27-june-chmp-meeting 2019-06-28T12:22:09 https://maestrodatabase.com/blog/the-slow-release-dose 2025-11-02T01:12:43 https://maestrodatabase.com/blog/who-takes-stock-of-global-covid-19-r-and-d-progress 2020-07-06T21:34:51 https://maestrodatabase.com/blog/negotiating-drug-prices-without-restricting-patient-access-lessons-from-germany 2019-06-28T12:13:48 https://maestrodatabase.com/blog/compass-therapeutics-receives-fda-fast-track-designation-for-the-investigation-of-ctx-009-in-combination-with-paclitaxel-for-the-treatment-of-patients-with-metastatic-or-locally-advanced-biliary-tract-tumours-that-have-been-previously-treated 2024-04-25T23:27:35 https://maestrodatabase.com/blog/doh-publishes-revised-agenda-for-july-2021-pbac-meeting 2021-07-06T03:52:48 https://maestrodatabase.com/blog/hls-therapeutics-announces-health-canada-approval-for-vascepa-to-reduce-the-risk-of-cardiovascular-events 2020-01-02T04:56:55 https://maestrodatabase.com/blog/the-controversial-approval-of-an-alzheimers-drug-reignites-the-battle-over-the-underlying-cause-of-the-disease 2021-07-06T01:44:20 https://maestrodatabase.com/blog/toronto-parents-of-baby-needing-2-dollars-8-cents-million-drug-turn-to-swiss-drug-makers-dose-lottery-as-a-last-resort 2020-01-02T05:02:09 https://maestrodatabase.com/blog/novartis-receives-ec-approval-for-enerzair-breezhaler-including-the-first-digital-companion-sensor-and-app-that-can-be-prescribed-alongside-a-treatment-for-uncontrolled-asthma-in-the-eu 2020-07-07T07:44:11 https://maestrodatabase.com/blog/private-health-insurance-nears-crisis-point-as-costs-soar 2017-01-14T03:28:31 https://maestrodatabase.com/blog/melphalan-flufenamide-hydrochloride-in-combination-with-dexamethasone-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma 2024-04-26T00:04:20 https://maestrodatabase.com/blog/innovative-technology-to-detect-abnormal-heart-rhythms-recommended-by-nice-for-nhs-use-while-further-data-is-collected 2020-12-01T09:40:49 https://maestrodatabase.com/blog/fda-approves-pralsetinib-for-ret-altered-thyroid-cancers 2020-12-01T19:59:56 https://maestrodatabase.com/blog/ema-receives-application-for-conditional-marketing-authorisation-of-moderna-covid-19-vaccine 2020-12-01T19:46:11 https://maestrodatabase.com/blog/unsustainable-low-prices-causing-generic-drug-market-failure-leading-to-supply-chain-disruptions-and-shortages 2020-07-07T09:17:48 https://maestrodatabase.com/blog/fda-approves-first-psma-targeted-pet-imaging-drug-for-men-with-prostate-cancer 2020-12-01T19:49:38 https://maestrodatabase.com/blog/more-drug-makers-hike-u-dot-s-prices-as-new-year-begins 2020-01-02T19:45:36 https://maestrodatabase.com/blog/ema-receives-application-for-conditional-marketing-authorisation-of-covid-19-mrna-vaccine-bnt162b2 2020-12-01T19:54:28 https://maestrodatabase.com/blog/ipsen-announces-european-commission-decision-on-palovarotene-for-the-treatment-of-fop 2023-07-20T03:25:49 https://maestrodatabase.com/blog/genentech-announces-fda-approval-of-xolair-omalizumab-for-adults-with-nasal-polyps 2020-12-01T20:16:29 https://maestrodatabase.com/blog/ema-starts-rolling-review-of-janssens-covid-19-vaccine-ad26-dot-cov2-dot-s 2020-12-01T20:20:27 https://maestrodatabase.com/blog/tecentriq-hit-with-draft-nice-rejection 2020-01-02T21:31:24 https://maestrodatabase.com/blog/us-hopeful-of-pre-christmas-covid-jab-australia-still-has-long-wait 2020-12-01T20:06:33 https://maestrodatabase.com/blog/outraged-patients-to-present-petition-with-over-30-000-signatures-to-ask-for-funding-for-desperately-needed-medication 2020-12-01T20:10:14 https://maestrodatabase.com/blog/australias-10-most-commonly-prescribed-medicines-revealed-by-pbs-data 2020-12-01T20:14:24 https://maestrodatabase.com/blog/vbi-vaccines-announces-submission-of-biologics-license-application-to-fda-for-3-antigen-prophylactic-hepatitis-b-vaccine 2020-12-01T20:23:59 https://maestrodatabase.com/blog/optheas-opt-302-granted-fda-fast-track-designation-for-wet-age-related-macular-degeneration 2021-07-06T06:21:21 https://maestrodatabase.com/blog/house-clears-path-for-repeal-of-health-law 2017-01-15T02:02:15 https://maestrodatabase.com/blog/fda-approves-oral-combination-of-decitabine-and-cedazuridine-for-myelodysplastic-syndromes 2020-07-07T20:51:49 https://maestrodatabase.com/blog/fda-approves-expanded-indication-for-mercks-keytruda-pembrolizumab-in-locally-advanced-cutaneous-squamous-cell-carcinoma 2021-07-06T11:12:09 https://maestrodatabase.com/blog/provention-bio-receives-complete-response-letter-to-biologics-license-application-for-teplizumab-for-the-delay-of-clinical-type-1-diabetes-in-at-risk-individuals 2021-07-06T12:02:02 https://maestrodatabase.com/blog/athenex-provides-update-from-fda-type-a-meeting-regarding-oral-paclitaxel-plus-encequidar-for-the-treatment-of-metastatic-breast-cancer 2021-07-06T11:05:44 https://maestrodatabase.com/blog/fda-grants-priority-review-for-levo-therapeutics-new-drug-application-for-lv-101-intranasal-carbetocin-for-the-treatment-of-prader-willi-syndrome 2021-07-06T12:29:09 https://maestrodatabase.com/blog/without-obamacare-i-will-get-sicker-faster-until-i-die 2017-01-15T21:31:16 https://maestrodatabase.com/blog/ani-pharmaceuticals-announces-refiling-of-cortrophin-snda-with-fda 2021-07-06T12:14:31 https://maestrodatabase.com/blog/senhwa-biosciencess-silmitasertib-receives-rare-paediatric-disease-designation-from-u-dot-s-fda-for-treatment-of-recurrent-sonic-hedgehog-medulloblastoma 2020-07-07T21:10:03 https://maestrodatabase.com/blog/multiple-sclerosis-drug-mavenclad-to-be-heavily-subsidised-in-the-new-year-under-pbs 2018-12-22T23:21:34 https://maestrodatabase.com/blog/tiny-asx-listed-pharma-popular-with-trump-team 2017-01-16T06:46:57 https://maestrodatabase.com/blog/lessons-from-the-impact-of-price-regulation-on-the-pricing-of-anti-cancer-drugs-in-germany 2020-07-07T21:17:42 https://maestrodatabase.com/blog/network-meta-analyses-no-compensation-for-weak-evidence 2020-07-07T21:05:08 https://maestrodatabase.com/blog/donald-trump-vows-health-insurance-for-all 2017-01-16T19:46:49 https://maestrodatabase.com/blog/health-insurance-premiums-set-to-rise 2017-01-16T19:48:49 https://maestrodatabase.com/blog/remove-the-disincentives-and-biosimilars-will-flourish-policy-expert-says 2020-07-07T21:41:44 https://maestrodatabase.com/blog/health-minister-vows-to-save-canadians-billions-on-drug-prices 2017-01-16T20:00:06 https://maestrodatabase.com/blog/pause-on-nices-cost-recovery-plans 2017-01-16T20:05:08 https://maestrodatabase.com/blog/mhra-releases-guidance-in-collaboration-with-health-canada-to-improve-patient-safety-in-clinical-trials-through-improving-the-quality-of-development-safety-update-reports 2021-07-06T21:37:07 https://maestrodatabase.com/blog/precision-medicine-promises-new-hope-for-cancer-sufferers 2017-01-16T19:52:50 https://maestrodatabase.com/blog/costco-could-have-saved-medicare-2-dollars-6-cents-billion-in-drug-spending-analysis-shows 2021-07-06T21:19:37 https://maestrodatabase.com/blog/rare-public-hearing-highlights-concerns-over-explosion-of-high-priced-specialty-drugs-in-canada 2017-01-16T19:57:52 https://maestrodatabase.com/blog/ispor-working-group-provides-a-first-ever-cross-stakeholder-consensus-definition-of-patient-engagement-in-research 2020-07-07T21:48:03 https://maestrodatabase.com/blog/repeal-and-replace-words-still-hanging-over-g-dot-o-p-dot-s-health-care-strategy 2017-01-16T20:22:44 https://maestrodatabase.com/blog/the-assault-on-health-and-safety-begins 2017-01-16T20:25:51 https://maestrodatabase.com/blog/abandoning-list-prices-in-medicaid-drug-reimbursement-did-not-affect-spending 2020-07-07T21:20:49 https://maestrodatabase.com/blog/smc---january-2017-decisions 2017-01-16T20:11:26 https://maestrodatabase.com/blog/breast-cancer-patients-distress-at-withdrawal-of-kadcyla 2017-01-16T20:19:07 https://maestrodatabase.com/blog/did-a-pharma-trade-group-try-to-sabotage-a-dutch-government-report-on-compulsory-licensing 2020-07-07T21:27:17 https://maestrodatabase.com/blog/u-dot-s-commits-2-dollars-billion-for-covid-19-vaccine-drug-supplies 2020-07-07T21:32:44 https://maestrodatabase.com/blog/knight-therapeutics-announces-health-canada-approval-for-nerlynx-neratinib-to-treat-her2-positive-metastatic-breast-cancer 2021-07-06T21:06:37 https://maestrodatabase.com/blog/how-pharmac-stole-my-holiday 2017-01-16T20:36:39 https://maestrodatabase.com/blog/novartis-tries-to-rescue-stalled-inclisiran-filing-with-fda 2021-07-06T12:45:45 https://maestrodatabase.com/blog/use-of-infliximab-biosimilar-in-medicare-population-is-low-but-growing 2020-07-07T21:38:53 https://maestrodatabase.com/blog/mhra-outlines-two-year-delivery-plan-with-patient-first-focus 2021-07-06T21:43:31 https://maestrodatabase.com/blog/fda-grants-medivirs-miv-711-rare-paediatric-disease-designation-and-orphan-drug-designation-for-the-treatment-of-legg-calve-perthes-disease 2024-04-26T02:46:28 https://maestrodatabase.com/blog/cures-for-many-rare-diseases-might-already-exist-why-arent-we-using-them 2021-07-06T21:52:41 https://maestrodatabase.com/blog/ipsen-receives-fda-fast-track-designation-for-investigational-irinotecan-liposome-injection-onivyde-as-a-second-line-monotherapy-treatment-for-small-cell-lung-cancer 2020-12-01T23:10:30 https://maestrodatabase.com/blog/covid-19-vaccines-undergoing-evaluation-3-august-2022 2022-08-03T05:06:02 https://maestrodatabase.com/blog/alvotech-provides-update-on-the-status-of-us-biologics-license-application-for-avt05 2025-11-03T09:48:17 https://maestrodatabase.com/blog/janssen-submits-application-to-u-dot-s-fda-seeking-approval-of-stelara-ustekinumab-for-treatment-of-moderately-to-severely-active-ulcerative-colitis 2018-12-23T00:54:28 https://maestrodatabase.com/blog/lynparza-approved-in-the-eu-for-brca-mutated-metastatic-pancreatic-cancer 2020-07-08T10:22:44 https://maestrodatabase.com/blog/yikaida-car-t-cell-therapy-approved-as-a-second-line-therapy-for-new-indication 2023-07-20T07:34:23 https://maestrodatabase.com/blog/concert-pharmaceuticals-receives-fda-breakthrough-therapy-designation-for-ctp-543-for-the-treatment-of-alopecia-areata 2020-07-08T12:33:29 https://maestrodatabase.com/blog/acorda-therapeutics-announces-fda-approval-of-inbrija-levodopa-inhalation-powder 2018-12-23T01:35:43 https://maestrodatabase.com/blog/tlv-is-reviewing-the-subsidy-of-sglt-2-inhibitors 2020-07-08T12:39:52 https://maestrodatabase.com/blog/a-flawed-covid-19-study-gets-the-white-houses-attention----and-the-fda-may-pay-the-price 2020-07-08T20:57:52 https://maestrodatabase.com/blog/bavarian-nordic-announces-fda-acceptance-and-priority-review-of-biologics-license-application-for-mva-bn-smallpox-vaccine 2018-12-23T01:40:58 https://maestrodatabase.com/blog/merck-and-eisai-receive-complete-response-letter-for-keytruda-pembrolizumab-plus-lenvima-lenvatinib-combination-as-first-line-treatment-for-unresectable-hepatocellular-carcinoma 2020-07-08T12:10:48 https://maestrodatabase.com/blog/map-offers-new-online-pathway-for-accessing-cancer-treatments 2022-02-25T05:08:41 https://maestrodatabase.com/blog/biogen-completes-submission-of-biologics-license-application-to-fda-for-aducanumab-as-a-treatment-for-alzheimers-disease 2020-07-08T12:16:15 https://maestrodatabase.com/blog/icer-reschedules-cystic-fibrosis-public-meeting-for-27-august-2020 2020-07-08T12:22:54 https://maestrodatabase.com/blog/tga-provisionally-approves-astrazenecas-combination-therapy-tixagevimab-and-cilgavimab-evusheld---for-pre-exposure-prevention-prophylaxis-of-covid-19 2022-02-25T05:33:58 https://maestrodatabase.com/blog/advent-therapeutics-receives-fda-rare-paediatric-disease-designation-for-retinol-palmitate-for-prevention-of-bronchopulmonary-dysplasia-in-premature-infants 2023-07-20T12:07:40 https://maestrodatabase.com/blog/drug-prices-steadily-rise-amid-pandemic-data-shows 2020-07-08T21:02:44 https://maestrodatabase.com/blog/house-proposes-3-dollars-2-cents-billion-for-fda-in-fy-2021 2020-07-08T21:06:20 https://maestrodatabase.com/blog/so-just-who-do-we-think-qualifies-for-any-covid-19-vaccine 2020-07-08T21:12:36 https://maestrodatabase.com/blog/new-government-consultation-on-medicine-clawbacks-will-harm-investment-says-abpi 2023-07-20T11:16:41 https://maestrodatabase.com/blog/aerie-pharmaceuticals-announces-acceptance-for-review-of-the-roclanda-netarsudil-and-latanoprost-ophthalmic-solution-0-dot-02-percent-slash-0-dot-005-percent-marketing-authorisation-application-in-europe 2020-01-03T06:00:38 https://maestrodatabase.com/blog/changes-to-cadths-rapid-response-service 2023-07-20T21:04:36 https://maestrodatabase.com/blog/open-framework-extended-to-a-wider-range-of-medicines 2023-07-20T21:07:09 https://maestrodatabase.com/blog/t2-biosystems-receives-fda-breakthrough-device-designation-for-candida-auris-diagnostic-test 2023-07-20T20:57:33 https://maestrodatabase.com/blog/tesaro-receives-positive-chmp-opinion-for-zejula 2017-09-16T12:23:40 https://maestrodatabase.com/blog/noninvasix-receives-fda-breakthrough-device-designation-for-non-invasive-monitoring-technology-for-sepsis 2022-02-25T06:03:17 https://maestrodatabase.com/blog/trelegy-ellipta-once-daily-single-inhaler-triple-therapy-receives-positive-opinion-from-the-chmp-in-europe-for-appropriate-patients-with-copd 2017-09-16T12:18:51 https://maestrodatabase.com/blog/protalix-biotherapeutics-and-chiesi-global-rare-diseases-announce-the-submission-of-a-marketing-authorisation-application-to-the-european-medicines-agency-for-prx-102-for-the-treatment-of-fabry-disease 2022-02-25T06:31:36 https://maestrodatabase.com/blog/janssen-receives-chmp-positive-opinion-for-guselkumab-recommending-approval-for-the-treatment-of-moderate-to-severe-plaque-psoriasis-in-the-european-union 2017-09-16T12:28:47 https://maestrodatabase.com/blog/ema-accepts-regulatory-submission-for-lumoxiti-in-relapsed-or-refractory-hairy-cell-leukaemia 2020-01-03T06:07:34 https://maestrodatabase.com/blog/fda-approves-quizartinib-for-newly-diagnosed-acute-myeloid-leukaemia 2023-07-20T21:21:20 https://maestrodatabase.com/blog/proposal-to-fund-zoster-vaccine 2017-09-16T12:33:49 https://maestrodatabase.com/blog/greg-hunt-flags-dramatic-reductions-in-private-health-insurance-prices 2017-09-16T12:40:30 https://maestrodatabase.com/blog/total-costs-of-chimeric-antigen-receptor-t-cell-immunotherapy 2018-04-28T12:41:37 https://maestrodatabase.com/blog/assertio-therapeutics-announces-submission-of-nda-for-fda-approval-of-cosyntropin-depot 2018-12-23T20:47:56 https://maestrodatabase.com/blog/proposal-to-fund-dexamethasone-ocular-implants-for-dmo 2017-09-16T12:37:08 https://maestrodatabase.com/blog/meeting-highlights-from-the-chmp-11-to-14-september-2017-meeting 2017-09-16T12:43:56 https://maestrodatabase.com/blog/additional-evidence-needed-to-assess-histology-independent-cancer-drugs-says-paper-co-authored-by-nice-staff 2020-01-03T07:01:41 https://maestrodatabase.com/blog/pharmac---2019-in-review 2020-01-03T06:37:23 https://maestrodatabase.com/blog/fennec-pharmaceuticals-initiates-rolling-submission-new-drug-application-to-us-fda-for-pedmark 2018-12-23T21:16:36 https://maestrodatabase.com/blog/pbac-recommendation-for-molnupiravir-lagevrio 2022-02-25T06:45:45 https://maestrodatabase.com/blog/gritstone-oncology-announces-fda-fast-track-designation-for-granite-001-for-the-treatment-of-colorectal-cancer 2018-12-23T21:36:51 https://maestrodatabase.com/blog/updating-the-bayh-dole-act-march-in-rights-and-transparency 2022-02-25T06:43:36 https://maestrodatabase.com/blog/uk-approves-pfizer-slash-biontechs-covid-19-vaccine 2020-12-02T10:58:44 https://maestrodatabase.com/blog/britain-becomes-the-first-country-to-license-a-fully-tested-covid-19-vaccine 2020-12-02T11:02:47 https://maestrodatabase.com/blog/viridian-therapeutics-announces-successful-october-submission-of-biologics-license-application-to-us-fda-for-veligrotug-in-thyroid-eye-disease 2025-11-03T23:26:30 https://maestrodatabase.com/blog/tg-therapeutics-initiates-rolling-submission-of-biologics-license-application-to-u-dot-s-fda-for-ublituximab-in-combination-with-umbralisib-as-a-treatment-for-patients-with-chronic-lymphocytic-leukaemia 2020-12-02T11:08:33 https://maestrodatabase.com/blog/us-fda-approves-kygevvi-doxecitine-and-doxribtimine-the-first-and-only-treatment-for-adults-and-children-living-with-thymidine-kinase-2-deficiency 2025-11-03T21:08:58 https://maestrodatabase.com/blog/pharmac-boss-to-talk-with-crohns-sufferers-protesting-for-drug-funding 2020-12-02T11:27:38 https://maestrodatabase.com/blog/the-g-dot-o-p-dot-s-health-care-death-spiral 2017-01-17T19:56:06 https://maestrodatabase.com/blog/health-laws-repeal-could-raise-costs-and-number-of-uninsured-new-report-says 2017-01-17T19:59:06 https://maestrodatabase.com/blog/tga-statement-on-uk-government-emergency-use-authorisation-related-to-the-covid-19-vaccine-bnt162b2-supplied-by-pfizer-and-biontech 2020-12-02T19:50:35 https://maestrodatabase.com/blog/covid-19-australia-on-track-for-pfizer-vaccine-in-march 2020-12-02T19:58:00 https://maestrodatabase.com/blog/trump-vows-insurance-for-everybody-in-obamacare-replacement-plan 2017-01-17T19:53:33 https://maestrodatabase.com/blog/composite-endpoints-and-the-distortion-of-risk-benefit-analysis 2017-01-17T20:11:53 https://maestrodatabase.com/blog/notification-of-a-new-drug-application-for-hp-3070-transdermal-patch-for-the-treatment-of-schizophrenia-in-the-u-dot-s 2018-12-23T22:11:39 https://maestrodatabase.com/blog/human-medicines-highlights-of-2016 2017-01-17T20:15:28 https://maestrodatabase.com/blog/fear-spurs-support-for-health-law-as-republicans-work-to-repeal-it 2017-01-17T20:01:54 https://maestrodatabase.com/blog/fda-approves-hetlioz-tasimelteon-for-the-treatment-of-nighttime-sleep-disturbances-in-smith-magenis-syndrome 2020-12-02T11:15:13 https://maestrodatabase.com/blog/drug-makers-manipulate-orphan-drug-rules-to-create-prized-monopolies 2017-01-17T20:05:04 https://maestrodatabase.com/blog/nice-draft-guidance-recommends-tucatinib-for-advanced-breast-cancer 2022-02-25T11:29:39 https://maestrodatabase.com/blog/the-netherlands-joins-battle-for-ema 2017-01-17T20:40:25 https://maestrodatabase.com/blog/introducing-imeds-a-public-private-resource-for-evidence-generation 2017-01-17T20:18:54 https://maestrodatabase.com/blog/trump-links-keep-healthcare-stock-healthy 2017-01-17T20:29:45 https://maestrodatabase.com/blog/health-canada-licenses-xeomin-incobotulinumtoxina-for-adult-patients-with-sialorrhea 2020-12-02T11:20:25 https://maestrodatabase.com/blog/amicus-therapeutics-initiates-rolling-biologic-license-application-to-the-u-dot-s-fda-for-at-gaa-in-late-onset-pompe-disease 2020-12-02T20:15:37 https://maestrodatabase.com/blog/bridgebio-pharma-and-affiliate-qed-therapeutics-announce-fda-acceptance-of-new-drug-application-for-infigratinib-for-the-treatment-of-cholangiocarcinoma 2020-12-02T20:20:56 https://maestrodatabase.com/blog/international-reference-pricing-a-lazy-misguided-bi-partisan-plan-to-lower-us-drug-prices 2020-12-02T20:02:59 https://maestrodatabase.com/blog/what-the-uks-covid-19-vaccine-means-for-australia 2020-12-02T20:08:08 https://maestrodatabase.com/blog/ctd-holdings-receives-fda-fast-track-designation-for-development-of-trappsol-cyclo-to-treat-niemann-pick-disease-type-c 2017-01-17T23:06:30 https://maestrodatabase.com/blog/will-cardiovascular-outcomes-data-on-newer-diabetes-drugs-bury-the-older-agents 2017-01-18T00:57:58 https://maestrodatabase.com/blog/patient-advocacy-groups-should-disclose-pharma-sponsors-say-experts 2017-01-17T23:01:34 https://maestrodatabase.com/blog/trump-to-meet-next-week-with-industry-government-officials-on-covid-vaccine 2020-12-02T20:27:55 https://maestrodatabase.com/blog/benitec-biopharma-receives-fda-fast-track-designation-for-bb-301 2025-11-04T00:31:02 https://maestrodatabase.com/blog/iqwig-publishes-1-000th-report 2020-12-02T20:33:21 https://maestrodatabase.com/blog/us-fda-approves-pfizers-beqvez-fidanacogene-elaparvovec-dzkt-a-one-time-gene-therapy-for-adults-with-hemophilia-b 2024-04-26T22:42:58 https://maestrodatabase.com/blog/excision-biotherapeutics-receives-fda-fast-track-designation-for-ebt-101-a-first-in-class-crispr-based-gene-therapy-candidate-to-functionally-cure-hiv-1 2023-07-21T03:42:59 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac-march-2024 2024-04-26T22:39:36 https://maestrodatabase.com/blog/new-medicine-for-rare-type-of-eye-cancer 2022-02-25T22:10:38 https://maestrodatabase.com/blog/chemocentryx-announces-filing-of-amendment-to-nda-submission-and-extension-of-the-pdufa-review-period-for-avacopan-in-the-treatment-of-anca-associated-vasculitis 2021-07-07T03:31:17 https://maestrodatabase.com/blog/vertex-announces-european-commission-approval-for-kalydeco-to-treat-infants-with-cystic-fibrosis-ages-1-month-and-older 2024-04-26T22:50:49 https://maestrodatabase.com/blog/emergent-biosolutions-receives-us-fda-approval-of-cyfendus-anthrax-vaccine-adsorbed-adjuvanted-previously-known-as-av7909-a-two-dose-anthrax-vaccine-for-post-exposure-prophylaxis-use 2023-07-21T04:08:40 https://maestrodatabase.com/blog/nivolumab-for-advanced-non-squamous-non-small-cell-lung-cancer-after-chemotherapy 2021-07-07T07:45:24 https://maestrodatabase.com/blog/assessment-of-public-opinion-on-transparency-at-the-us-food-and-drug-administration 2022-02-25T22:45:02 https://maestrodatabase.com/blog/hutchmed-receives-breakthrough-therapy-designation-in-china-for-fruquintinib-combination-with-sintilimab-for-treatment-of-advanced-endometrial-cancer 2023-07-21T04:52:37 https://maestrodatabase.com/blog/samsung-bioepis-first-to-receive-positive-chmp-opinion-on-a-trastuzumab-biosimilar-with-ontruzant 2017-09-17T00:54:07 https://maestrodatabase.com/blog/suliqua-approved-in-the-european-union-for-the-treatment-of-adults-with-type-2-diabetes-mellitus 2017-01-18T05:58:01 https://maestrodatabase.com/blog/csl-behring-announces-fda-approval-of-privigen-immune-globulin-intravenous-human-10-percent-liquid-for-the-treatment-of-chronic-inflammatory-demyelinating-polyneuropathy-in-adults 2017-09-17T01:00:20 https://maestrodatabase.com/blog/pharmaceutical-industry-financial-ties-linked-to-positive-outcomes-in-clinical-trials-for-new-drugs 2017-01-18T07:19:47 https://maestrodatabase.com/blog/enzalutamide-for-men-with-hormone-sensitive-metastatic-prostate-cancer 2021-07-07T11:22:18 https://maestrodatabase.com/blog/statement-from-fda-commissioner-announcing-new-draft-guidances-on-medical-product-communications 2017-01-18T19:59:07 https://maestrodatabase.com/blog/fda-advisory-committees-independent-informed-essential-and-evolving 2017-01-18T20:01:47 https://maestrodatabase.com/blog/icer-to-assess-gene-therapy-for-haemophilia-a 2020-01-04T00:10:57 https://maestrodatabase.com/blog/cheaper-drug-trials-would-lower-prices-fda-chief 2017-09-17T01:05:31 https://maestrodatabase.com/blog/health-industry-issues-warning-for-greg-hunt 2017-01-18T19:51:59 https://maestrodatabase.com/blog/choice-launches-do-i-need-health-insurance-to-cut-through-advertising-campaigns 2017-01-18T19:54:53 https://maestrodatabase.com/blog/fda-issues-long-awaited-biosimilar-interchangeability-guidance 2017-01-18T20:23:34 https://maestrodatabase.com/blog/nice-refuses-akceas-waylivra 2020-01-04T00:07:12 https://maestrodatabase.com/blog/us-fda-grants-interchangeability-designation-to-celltrions-denosumab-biosimilars-stoboclo-denosumab-bmwo-and-ozenvelt-denosumab-bmwo 2025-11-04T03:22:38 https://maestrodatabase.com/blog/health-law-repeal-could-cost-18-million-their-insurance-study-finds 2017-01-18T20:27:20 https://maestrodatabase.com/blog/fda-approves-a-generic-of-xyrem-with-a-rems-program 2017-01-18T20:05:31 https://maestrodatabase.com/blog/teva-receives-fda-approval-for-vantrela-er-hydrocodone-bitartrate-extended-release-tablets-formulated-with-proprietary-abuse-deterrence-technology 2017-01-18T20:11:35 https://maestrodatabase.com/blog/cystic-fibrosis-sufferers-put-their-hope-in-a-change-of-government 2017-09-17T01:10:17 https://maestrodatabase.com/blog/trump-can-lower-drug-prices-by-u-dot-s-government-purchase-of-drug-companies 2017-01-18T20:30:54 https://maestrodatabase.com/blog/europes-oncologists-back-biosimilar-versions-of-cancer-drugs 2017-01-18T20:35:02 https://maestrodatabase.com/blog/valneva-awarded-fda-breakthrough-designation-for-its-single-shot-chikungunya-vaccine-candidate 2021-07-07T20:51:22 https://maestrodatabase.com/blog/innovative-health-technologies-need-special-subsidy 2021-07-07T12:22:36 https://maestrodatabase.com/blog/australias-pfizer-doses-are-coming-from-europe-as-us-limits-supply 2021-07-07T21:08:29 https://maestrodatabase.com/blog/pfizer-receives-u-dot-s-fda-approval-for-its-first-biosimilar-zirabev-bevacizumab-bvzr 2019-06-29T05:14:27 https://maestrodatabase.com/blog/this-will-shut-us-down-hiv-prevention-clinics-brace-for-gilead-reimbursement-cuts 2021-07-07T21:03:13 https://maestrodatabase.com/blog/agenda-for-25-january-2017-meeting 2017-01-18T22:12:34 https://maestrodatabase.com/blog/bernie-sanders-on-drug-costs 2019-06-29T05:11:23 https://maestrodatabase.com/blog/pushed-to-rush-fda-head-says-feds-will-get-vaccine-right 2020-12-03T03:07:56 https://maestrodatabase.com/blog/access-to-miracle-drug-trikafta-a-lifeline-for-cystic-fibrosis-patients-with-no-other-hope 2021-07-07T21:16:01 https://maestrodatabase.com/blog/icer-posts-draft-scoping-document-for-the-assessment-of-treatments-for-acute-migraine 2019-06-29T05:26:17 https://maestrodatabase.com/blog/it-looks-like-health-insurance-but-its-not-just-trust-god-buyers-are-told 2020-01-04T01:02:02 https://maestrodatabase.com/blog/incomplete-data-stalls-swiss-authorisation-of-covid-19-vaccines 2020-12-03T02:42:51 https://maestrodatabase.com/blog/hyalex-orthopaedics-receives-fda-breakthrough-device-designation-for-novel-hyalex-cartilage-system 2021-07-07T20:55:46 https://maestrodatabase.com/blog/three-drug-pricing-policy-experiments-to-watch-in-2020 2020-01-04T00:51:19 https://maestrodatabase.com/blog/tom-prices-dubious-trades-in-health-care-stocks 2017-01-18T22:55:52 https://maestrodatabase.com/blog/nice-explores-extending-its-use-of-data-to-inform-its-guidance 2019-06-29T05:19:36 https://maestrodatabase.com/blog/sanders-progressives-face-split-with-centrists-over-plan-to-cut-drug-prices-in-medicare 2021-07-07T20:59:50 https://maestrodatabase.com/blog/janssen-seeks-health-canada-approval-for-its-covid-19-vaccine 2020-12-03T05:01:06 https://maestrodatabase.com/blog/patients-to-save-thousands-as-kidney-drug-goes-on-pbs-list 2018-12-24T07:10:33 https://maestrodatabase.com/blog/mereo-biopharma-receives-fda-fast-track-designation-for-alvelestat-for-treatment-of-alpha-1-antitrypsin-deficiency-associated-lung-disease 2022-10-17T11:32:11 https://maestrodatabase.com/blog/us-fda-approves-menveo-in-a-new-single-vial-presentation-to-help-prevent-disease-caused-by-meningococcal-bacteria-serogroups-a-c-y-and-w 2022-10-17T10:06:13 https://maestrodatabase.com/blog/aimmune-submits-marketing-authorisation-application-to-ema-for-ar101-for-peanut-allergy 2019-06-29T05:37:10 https://maestrodatabase.com/blog/firm-says-senator-klobuchar-overstates-trumps-lack-of-success-lowering-drug-prices 2019-06-29T05:33:03 https://maestrodatabase.com/blog/who-recommends-life-saving-interleukin-6-receptor-blockers-for-covid-19-and-urges-producers-to-join-efforts-to-rapidly-increase-access 2021-07-07T21:29:44 https://maestrodatabase.com/blog/change-to-pbs-closing-the-gap-program-sees-aboriginal-patients-inadvertently-charged-more-for-medication 2021-07-07T21:24:14 https://maestrodatabase.com/blog/medicare-reports 2022-10-17T08:38:52 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-for-atyrs-resolaris-to-treat-limb-girdle-muscular-dystrophy-2b-and-removes-partial-clinical-hold-for-resolaris 2017-01-18T23:22:21 https://maestrodatabase.com/blog/braeburn-announces-tentative-fda-approval-of-brixadi-buprenorphine-extended-release-injection-for-the-treatment-of-moderate-to-severe-opioid-use-disorder 2018-12-24T07:26:49 https://maestrodatabase.com/blog/generic-medicines-working-group---1-december-2016 2017-01-19T00:19:22 https://maestrodatabase.com/blog/hospitals-often-charge-uninsured-people-the-highest-prices-new-data-show 2021-07-07T21:36:57 https://maestrodatabase.com/blog/amryt-receives-reimbursement-approval-from-the-dutch-ministry-of-health-for-myalepta-metreleptin 2022-10-17T20:03:07 https://maestrodatabase.com/blog/valneva-awarded-fda-fast-track-designation-for-chikungunya-vaccine-candidate 2018-12-25T22:57:41 https://maestrodatabase.com/blog/gene-therapy-luxturna-now-reimbursed-in-quebec-for-people-with-previously-untreatable-inherited-vision-loss 2022-10-17T19:59:07 https://maestrodatabase.com/blog/telix-files-tlx250-cdx-zircaix-bla-for-kidney-cancer-imaging 2024-12-30T07:26:47 https://maestrodatabase.com/blog/fda-pushes-to-remove-pregnancy-drug-company-pushes-back 2022-10-17T19:54:19 https://maestrodatabase.com/blog/medicare-rorts-expose-inflated-bulk-billing-rates 2022-10-17T19:48:02 https://maestrodatabase.com/blog/can-state-prescription-drug-affordability-boards-address-high-cost-drug-prices 2022-10-17T20:25:15 https://maestrodatabase.com/blog/powerful-ideas-for-global-access-to-medicines 2017-02-08T23:48:18 https://maestrodatabase.com/blog/minerva-neurosciences-receives-refusal-to-file-letter-from-fda-for-its-new-drug-application-for-roluperidone-for-the-treatment-of-negative-symptoms-in-schizophrenia 2022-10-17T20:31:58 https://maestrodatabase.com/blog/outlook-therapeutics-resubmits-biologics-license-application-for-ons-5010 2025-11-04T09:57:48 https://maestrodatabase.com/blog/cost-effectiveness-analysis-2-dot-0 2017-01-19T00:36:36 https://maestrodatabase.com/blog/biogen-announces-fdas-3-month-extension-of-review-period-for-the-new-drug-application-for-tofersen 2022-10-17T20:17:18 https://maestrodatabase.com/blog/calls-for-tga-to-withdraw-covid-drug-approval 2022-10-17T20:13:36 https://maestrodatabase.com/blog/fda-accepts-for-review-pfizers-supplemental-application-for-abrilada-adalimumab-afzb-interchangeability 2022-02-26T00:10:14 https://maestrodatabase.com/blog/chiesi-global-rare-diseases-and-protalix-biotherapeutics-seek-re-examination-from-the-ema-for-the-negative-opinion-for-elfabrio-pegunigalsidase-alfa-alternative-dosing-regimen-of-every-four-weeks-in-the-eu 2025-11-04T19:49:43 https://maestrodatabase.com/blog/boehringer-ingelheim-biosimilar-candidate-to-humira-accepted-for-ema-and-fda-regulatory-review 2017-01-19T01:16:57 https://maestrodatabase.com/blog/fdas-deadline-problem 2020-01-04T07:57:15 https://maestrodatabase.com/blog/drug-cost-saving-plans-may-hit-patients 2017-01-19T19:34:24 https://maestrodatabase.com/blog/six-month-market-exclusivity-extensions-to-promote-research-offer-substantial-returns-for-many-drug-makers 2017-01-19T10:40:05 https://maestrodatabase.com/blog/statement-from-fda-commissioner-announcing-fda-oncology-center-of-excellence-launch 2017-01-19T20:07:51 https://maestrodatabase.com/blog/online-calculator-aims-to-help-people-decide-if-private-health-insurance-is-worth-the-cost 2017-01-19T20:12:02 https://maestrodatabase.com/blog/u-dot-s-fda-approves-imbruvica-ibrutinib-as-first-treatment-specifically-indicated-for-relapsed-slash-refractory-marginal-zone-lymphoma---a-rare-type-of-non-hodgkins-lymphoma 2017-01-19T19:37:47 https://maestrodatabase.com/blog/what-trumps-libertarian-pals-dont-understand-about-the-fda----or-reality 2017-01-19T19:57:28 https://maestrodatabase.com/blog/canada-reaches-health-funding-agreement-with-saskatchewan 2017-01-19T20:16:25 https://maestrodatabase.com/blog/cadth-style-guide 2017-01-19T20:26:40 https://maestrodatabase.com/blog/australia-ahead-of-schedule-on-covid-19-vaccine-plan 2020-12-03T06:24:07 https://maestrodatabase.com/blog/the-dawn-of-digital-medicine 2020-12-03T06:30:13 https://maestrodatabase.com/blog/novartis-merck-and-allergan-join-those-raising-u-dot-s-drug-prices-for-2020 2020-01-04T21:43:54 https://maestrodatabase.com/blog/new-drug-added-to-pbs-can-double-life-expectancy-for-breast-cancer 2020-01-04T21:51:52 https://maestrodatabase.com/blog/2020-is-three-days-old-and-drug-prices-are-already-jumping 2020-01-04T21:47:22 https://maestrodatabase.com/blog/multivariate-and-network-meta-analysis-of-multiple-outcomes-and-multiple-treatments-rationale-concepts-and-examples 2017-09-17T04:13:29 https://maestrodatabase.com/blog/aeglea-biotherapeutics-receives-fda-rare-paediatric-disease-designation-for-acn00177-for-the-treatment-of-homocystinuria 2020-12-03T08:32:21 https://maestrodatabase.com/blog/protagonists-hepcidin-mimetic-candidate-ptg-300-receives-fast-track-designation-from-the-u-dot-s-fda-for-development-in-the-treatment-of-polycythemia-vera 2020-12-03T08:55:25 https://maestrodatabase.com/blog/fda-grant-fast-track-designation-for-remestemcel-l-in-the-treatment-of-acute-respiratory-distress-syndrome-due-to-covid-19 2020-12-03T08:16:52 https://maestrodatabase.com/blog/fda-approves-trulance-for-chronic-idiopathic-constipation 2017-01-20T03:39:23 https://maestrodatabase.com/blog/moleculin-announces-fda-approves-3-rare-paediatric-disease-designations-for-wp1066 2020-12-03T08:23:07 https://maestrodatabase.com/blog/the-real-worth-of-cancer-drugs 2020-12-03T19:55:39 https://maestrodatabase.com/blog/lilly-announces-650-000-additional-doses-of-neutralising-antibody-bamlanivimab-ly-cov555-purchased-by-u-dot-s-government-to-treat-covid-19 2020-12-03T20:02:34 https://maestrodatabase.com/blog/allergan-announces-fda-approval-of-rhofade-oxymetazoline-hydrochloride-1-percent-cream-for-the-topical-treatment-of-persistent-facial-erythema-associated-with-rosacea-in-adults 2017-01-20T03:59:15 https://maestrodatabase.com/blog/benefit-risk-assessments-at-the-us-food-and-drug-administration-finding-the-balance 2017-01-21T22:04:28 https://maestrodatabase.com/blog/ausbiotech-submits-to-tga-on-medical-device-reform 2017-01-21T21:34:02 https://maestrodatabase.com/blog/trump-issues-executive-order-scaling-back-parts-of-obamacare 2017-01-21T22:01:11 https://maestrodatabase.com/blog/how-the-u-dot-k-beat-the-u-dot-s-and-europe-to-a-covid-19-vaccine 2020-12-03T20:10:30 https://maestrodatabase.com/blog/health-canada-approves-vyxeos-the-first-chemotherapy-advance-in-over-40-years-for-adults-with-high-risk-acute-myeloid-leukaemia 2021-07-08T05:00:31 https://maestrodatabase.com/blog/abbvie-receives-positive-chmp-opinion-for-epcoritamab-tepkinly-for-the-treatment-of-adults-with-relapsed-slash-refractory-diffuse-large-b-cell-lymphoma 2023-07-21T08:39:32 https://maestrodatabase.com/blog/new-health-technologies-managing-access-value-and-sustainability 2017-01-21T22:11:25 https://maestrodatabase.com/blog/u-dot-s-fda-acknowledges-receipt-of-shires-new-drug-application-for-shp465-for-adhd 2017-01-21T22:17:41 https://maestrodatabase.com/blog/genmab-announces-that-janssen-has-submitted-a-biologics-license-application-to-u-dot-s-fda-for-amivantamab-in-non-small-cell-lung-cancer 2020-12-03T20:27:59 https://maestrodatabase.com/blog/obamacare-replacement-may-improve-patient-access-novartis-says 2017-01-22T00:38:17 https://maestrodatabase.com/blog/pharmac-probe-unlikely-to-examine-commercial-details---little 2020-12-03T20:15:25 https://maestrodatabase.com/blog/call-for-feedback-on-a-therapeutic-review-update-of-new-second-line-therapies-for-type-2-diabetes-mellitus 2017-01-22T00:41:25 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-treatments-for-rheumatoid-arthritis 2017-01-22T00:31:01 https://maestrodatabase.com/blog/fate-of-250-000-diabetics-in-pharmacs-hands 2020-12-03T20:18:29 https://maestrodatabase.com/blog/epipen-competitor-to-launch-in-february 2017-01-22T00:35:55 https://maestrodatabase.com/blog/ucb-files-briviact-brivaracetam-cv-in-the-u-dot-s-as-monotherapy-treatment-for-adult-epilepsy-patients-with-partial-onset-seizures 2017-01-22T01:37:16 https://maestrodatabase.com/blog/secukinumab-in-children-with-plaque-psoriasis-study-unsuitable-for-benefit-assessment 2020-12-03T20:24:26 https://maestrodatabase.com/blog/cystic-fibrosis-sufferer-scarlet-fox-1-million-dollars-away-from-access-to-life-changing-drug-kalydeco 2017-01-22T19:53:00 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-8-july-2021 2021-07-08T05:36:15 https://maestrodatabase.com/blog/in-brad-walls-deal-clues-for-medicares-future 2017-01-22T20:02:58 https://maestrodatabase.com/blog/what-does-trumps-executive-order-against-obamacare-actually-do 2017-01-22T20:07:28 https://maestrodatabase.com/blog/fda-issues-complete-response-letter-for-biohavens-vyglyxia-troriluzole-new-drug-application-for-spinocerebellar-ataxia 2025-11-05T02:38:55 https://maestrodatabase.com/blog/the-republican-health-care-con 2017-01-22T21:27:46 https://maestrodatabase.com/blog/advancing-the-needs-of-patients-in-the-trump-era 2017-01-22T22:08:35 https://maestrodatabase.com/blog/bristol-myers-squibb-provides-regulatory-update-in-first-line-lung-cancer 2017-01-23T06:35:33 https://maestrodatabase.com/blog/indicative-1-april-2017-prices---2017-april-cycle 2017-01-23T06:40:43 https://maestrodatabase.com/blog/medicare-levy-increase-on-the-table-as-turnbull-budget-speculation-begins 2017-01-22T23:14:23 https://maestrodatabase.com/blog/specialists-fees-drive-up-out-of-pocket-costs-for-patients 2017-01-22T23:16:29 https://maestrodatabase.com/blog/trumps-health-plan-would-convert-medicaid-to-block-grants-aide-says 2017-01-23T10:05:37 https://maestrodatabase.com/blog/conditional-marketing-authorisations-give-patients-access-to-important-new-medicines-earlier 2017-01-23T20:22:15 https://maestrodatabase.com/blog/nice-seeks-positive-future-with-life-sciences-industry 2017-01-23T09:26:42 https://maestrodatabase.com/blog/trumps-vow-to-repeal-health-law-revives-talk-of-high-risk-pools 2017-01-23T09:57:31 https://maestrodatabase.com/blog/astrazenecas-ultomiris-gets-insurance-benefits-for-neuromyelitis-optica-spectrum-disorders 2025-11-05T02:14:03 https://maestrodatabase.com/blog/high-prices-for-drugs-with-generic-alternatives-the-curious-case-of-duexis 2017-01-23T22:16:01 https://maestrodatabase.com/blog/uk-pharma-slams-new-drug-evaluation-plans 2017-01-23T20:29:13 https://maestrodatabase.com/blog/investors-gird-for-impact-of-trump-health-care-measures 2017-01-23T20:35:25 https://maestrodatabase.com/blog/ocular-therapeutix-resubmits-nda-for-dextenza-for-the-treatment-of-ocular-pain-occurring-after-ophthalmic-surgery 2017-01-23T22:25:06 https://maestrodatabase.com/blog/tezepelumab-regulatory-submission-accepted-and-granted-fda-priority-review-in-the-us-for-the-treatment-of-patients-with-asthma 2021-07-08T06:18:52 https://maestrodatabase.com/blog/novelion-therapeutics-announces-acceptance-of-marketing-authorisation-application-for-metreleptin-by-european-medicines-agency 2017-01-24T01:31:12 https://maestrodatabase.com/blog/advicenne-has-submitted-to-us-fda-the-registration-application-for-sibnayal-in-drta-treatment 2025-11-05T03:37:06 https://maestrodatabase.com/blog/americas-biopharmaceutical-companies-launch-groundbreaking-multi-year-initiative-heralding-new-era-of-medicine 2017-01-24T06:00:26 https://maestrodatabase.com/blog/european-commission-initiative-improves-information-for-patients-on-biosimilar-medicines 2017-01-24T06:58:05 https://maestrodatabase.com/blog/affordable-orphan-drugs-a-role-for-not-for-profit-organisations 2017-01-24T03:22:12 https://maestrodatabase.com/blog/mtpconnect-and-medicines-australia-sign-mou-to-boost-australias-innovative-medicines-sector 2017-01-24T03:48:39 https://maestrodatabase.com/blog/judge-blocks-aetnas-37-dollars-billion-deal-for-humana 2017-01-24T09:22:29 https://maestrodatabase.com/blog/the-fight-trump-faces-over-drug-prices 2017-01-24T19:58:30 https://maestrodatabase.com/blog/european-medicines-agency-grants-accelerated-assessment-validates-marketing-authorisation-application-for-abbvies-investigational-regimen-of-glecaprevir-slash-pibrentasvir-for-the-treatment-of-chronic-hepatitis-c-in-all-major-genotypes 2017-01-24T09:08:15 https://maestrodatabase.com/blog/blame-technology-not-longer-life-spans-for-health-spending-increases 2017-01-24T09:19:09 https://maestrodatabase.com/blog/government-seeks-further-comment-on-productivity-commissions-intellectual-property-report 2017-01-24T20:22:17 https://maestrodatabase.com/blog/ema-validates-gileads-marketing-authorisation-application-for-investigational-chronic-hepatitis-c-therapy-sofosbuvir-slash-velpatasvir-slash-voxilaprevir 2017-01-24T20:28:29 https://maestrodatabase.com/blog/express-scripts-cigna-opt-out-of-paying-for-epipen-competitor-auvi-q 2017-01-24T20:00:44 https://maestrodatabase.com/blog/roche-says-fda-grants-priority-review-for-actemra 2017-01-24T20:05:25 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-july-2019-update 2019-06-30T12:17:27 https://maestrodatabase.com/blog/why-it-takes-five-years-for-life-saving-medicines-to-get-funded 2019-06-30T21:39:07 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-july-2019-update 2019-06-30T12:25:30 https://maestrodatabase.com/blog/covid-19-vaccines-individual-patient-data-should-be-submitted-to-the-european-medicines-agency 2022-02-26T02:36:25 https://maestrodatabase.com/blog/boehringer-ingelheim-receives-positive-chmp-opinion-for-adalimumab-biosimilar-cyltezo 2017-09-17T10:27:24 https://maestrodatabase.com/blog/overwhelming-support-for-blair-vinings-petition-to-set-up-national-cancer-agency 2019-06-30T12:22:20 https://maestrodatabase.com/blog/landmark-pbs-listing-for-australians-with-leukaemia 2022-02-26T02:15:53 https://maestrodatabase.com/blog/trump-considers-an-entrepreneur-with-sweeping-reform-plans-to-run-the-fda 2017-01-25T01:09:34 https://maestrodatabase.com/blog/atlantic-healthcare-receives-fda-agreement-to-initiate-rolling-submission-of-its-new-drug-application-for-alicaforsen-in-the-treatment-of-pouchitis 2017-01-25T03:55:04 https://maestrodatabase.com/blog/catalyst-biosciences-receives-fda-fast-track-designation-for-subcutaneous-marzaa-for-the-treatment-of-episodic-bleeding-in-haemophilia-a-or-b-with-inhibitors 2020-12-03T23:30:09 https://maestrodatabase.com/blog/fda-approves-vaxelis-sanofi-and-msds-paediatric-hexavalent-combination-vaccine 2018-12-27T01:16:26 https://maestrodatabase.com/blog/eams-scientific-opinion-atezolizumab-for-locally-advanced-or-metastatic-urothelial-carcinoma 2017-01-25T05:41:27 https://maestrodatabase.com/blog/verastem-oncology-announces-fda-acceptance-and-priority-review-of-new-drug-application-for-avutometinib-in-combination-with-defactinib-for-the-treatment-of-recurrent-kras-mutant-low-grade-serous-ovarian-cancer 2024-12-31T02:44:41 https://maestrodatabase.com/blog/health-canada-approves-revlimid-plus-dexamethasone-as-a-first-line-treatment-for-patients-newly-diagnosed-with-multiple-myeloma-not-eligible-for-transplant 2017-01-25T06:07:30 https://maestrodatabase.com/blog/woman-plans-to-sell-home-to-pay-for-pancreatic-cancer-treatment 2017-01-25T06:21:29 https://maestrodatabase.com/blog/tom-prices-heated-hearing-is-unlikely-to-derail-his-nomination 2017-01-25T10:17:15 https://maestrodatabase.com/blog/nice-guidance-on-ibrutinib-for-previously-treated-chronic-lymphocytic-leukaemia-and-untreated-chronic-lymphocytic-leukaemia-in-the-presence-of-17p-deletion-or-tp53-mutation 2017-01-25T20:14:43 https://maestrodatabase.com/blog/novartis-says-court-battle-will-delay-its-enbrel-copy-until-2018-at-least 2017-01-25T20:36:02 https://maestrodatabase.com/blog/are-new-drugs-for-hepatitis-c-safe-a-report-raises-concerns 2017-01-25T10:20:26 https://maestrodatabase.com/blog/bupa-warns-health-insurers-face-unsustainable-cost-increases 2017-01-25T20:02:23 https://maestrodatabase.com/blog/fda-approves-updated-aduhelm-prescribing-information-to-emphasise-population-studied-in-clinical-trials 2021-07-08T11:36:04 https://maestrodatabase.com/blog/johnson-and-johnson-receives-positive-chmp-opinion-for-rybrevant-amivantamab-in-combination-with-chemotherapy-for-the-first-line-treatment-of-patients-with-advanced-non-small-cell-lung-cancer-with-activating-egfr-exon-20-insertion-mutations 2024-04-27T10:44:21 https://maestrodatabase.com/blog/abbvie-initiates-phase-2-clinical-trial-programs-for-abbv-8e12-an-investigational-anti-tau-antibody-in-early-alzheimers-disease-and-progressive-supranuclear-palsy 2017-01-25T22:13:30 https://maestrodatabase.com/blog/chmp-adopts-positive-opinion-recommending-approval-of-bristol-myers-squibbs-opdivo-nivolumab-in-combination-with-cisplatin-and-gemcitabine-for-the-first-line-treatment-of-adult-patients-with-unresectable-or-metastatic-urothelial-carcinoma 2024-04-27T10:39:43 https://maestrodatabase.com/blog/approval-of-proposal-for-clostridium-botulinum-type-a-toxin-botox-in-dhb-hospitals 2017-01-26T01:15:57 https://maestrodatabase.com/blog/chimerix-submits-dordaviprone-new-drug-application-for-accelerated-approval-to-us-fda-for-patients-with-recurrent-h3-k27m-mutant-diffuse-glioma 2024-12-31T04:01:18 https://maestrodatabase.com/blog/kites-yescarta-first-car-t-cell-therapy-to-receive-european-marketing-authorisation-for-use-in-second-line-diffuse-large-b-cell-lymphoma-and-high-grade-b-cell-lymphoma 2022-10-18T11:45:55 https://maestrodatabase.com/blog/narcan-naloxone-hydrochloride-2-mg-nasal-spray-approved-by-fda 2017-01-26T10:34:52 https://maestrodatabase.com/blog/final-yes-from-nice-for-gileads-epclusa 2017-01-26T20:12:32 https://maestrodatabase.com/blog/precigen-completes-submission-of-bla-with-request-for-priority-review-to-the-fda-for-prgn-2012-for-the-treatment-of-adults-with-recurrent-respiratory-papillomatosis 2024-12-31T03:57:40 https://maestrodatabase.com/blog/tom-price-cracks-the-drug-price-negotiation-door 2017-01-26T20:32:43 https://maestrodatabase.com/blog/cancer-hepatitis-treatments-set-for-boost-as-china-overhauls-drugs-list 2017-01-26T20:40:59 https://maestrodatabase.com/blog/u-dot-s-fda-approves-72-mcg-dose-of-linzess-linaclotide-for-adults-with-chronic-idiopathic-constipation 2017-01-26T20:16:48 https://maestrodatabase.com/blog/republicans-lay-out-plans-for-obamacare-repeal 2017-01-26T20:29:04 https://maestrodatabase.com/blog/msac-finally-recommends-genomic-testing-for-certain-women-with-breast-cancer 2022-10-18T19:45:49 https://maestrodatabase.com/blog/australia-day-celebration-of-the-life-sciences-industry 2017-01-26T20:48:00 https://maestrodatabase.com/blog/biogen-receives-positive-chmp-opinion-for-tofidence-tocilizumab-a-biosimilar-referencing-roactemra 2024-04-27T22:50:35 https://maestrodatabase.com/blog/noema-pharma-receives-fda-fast-track-designation-for-basimglurant-noe-101-in-trigeminal-neuralgia 2022-10-18T19:37:03 https://maestrodatabase.com/blog/biogen-sees-gradual-spinraza-launch-eyes-mid-year-eu-approval 2017-01-26T21:30:39 https://maestrodatabase.com/blog/pierre-fabre-laboratories-receive-positive-chmp-opinion-for-obgemsa-vibegron-in-overactive-bladder-syndrome 2024-04-27T22:46:59 https://maestrodatabase.com/blog/adding-patient-reported-outcomes-to-medicares-oncology-value-based-payment-model 2020-01-05T21:51:52 https://maestrodatabase.com/blog/takeda-receives-positive-chmp-opinion-for-fruquintinib-in-previously-treated-metastatic-colorectal-cancer 2024-04-27T22:41:43 https://maestrodatabase.com/blog/the-public-deserves-to-know-why---national-intensifies-calls-for-inquiry-into-pharmac-after-fifth-death-linked-to-epilepsy-drug-logem 2020-01-05T21:27:20 https://maestrodatabase.com/blog/tissue-agnostic-drug-development-in-oncology 2022-10-18T11:58:00 https://maestrodatabase.com/blog/dunedin-couple-towing-coffin-to-parliament-in-bid-to-double-pharmac-budget 2020-01-05T21:25:00 https://maestrodatabase.com/blog/avrobio-granted-ilap-designation-from-uk-mhra-for-first-in-class-gene-therapy-for-gaucher-disease 2022-10-18T12:07:31 https://maestrodatabase.com/blog/intelgenx-submits-response-to-crl-from-fda-for-rizaport-versafilm 2022-10-18T20:20:10 https://maestrodatabase.com/blog/china-national-medical-products-administration-approves-beigenes-tislelizumab-for-patients-with-classical-hodgkins-lymphoma-who-have-received-at-least-two-prior-therapies 2020-01-05T21:58:26 https://maestrodatabase.com/blog/health-insurance-prices-set-for-takeoff 2022-10-18T20:15:55 https://maestrodatabase.com/blog/highlights-from-the-22-25-april-2024-chmp-meeting 2024-04-27T23:16:25 https://maestrodatabase.com/blog/is-obamacare-really-unconstitutional 2020-01-05T22:12:59 https://maestrodatabase.com/blog/use-evidence-to-support-early-coverage-of-gene-therapy-after-accelerated-approval 2024-04-27T23:08:40 https://maestrodatabase.com/blog/carsgen-announces-nda-acceptance-of-bcma-car-t-zevor-cel-ct053-by-china-nmpa 2022-10-18T20:10:36 https://maestrodatabase.com/blog/a-milestone-in-facilitating-the-development-of-safe-and-effective-biosimilars 2024-04-27T23:05:25 https://maestrodatabase.com/blog/new-hope-for-aussies-battling-early-stage-breast-cancer 2024-04-27T22:58:09 https://maestrodatabase.com/blog/department-of-health-and-aged-care-publishes-revised-agenda-for-november-2022-pbac-meeting 2022-10-18T19:56:38 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac---december-2016 2017-01-27T01:05:11 https://maestrodatabase.com/blog/new-hope-for-breast-cancer-patients-with-key-drug-added-to-pbs 2020-01-06T00:00:25 https://maestrodatabase.com/blog/pharmac-to-remove-medicine-dispensing-restrictions 2020-07-09T05:26:29 https://maestrodatabase.com/blog/beyond-intent-to-treat-and-per-protocol-improving-assessment-of-treatment-effects-in-clinical-trials-through-the-specification-of-an-estimand 2020-01-05T23:01:14 https://maestrodatabase.com/blog/cormedix-reports-submission-of-defencath-new-drug-application 2020-07-09T05:29:44 https://maestrodatabase.com/blog/canadian-parents-of-babies-with-rare-deadly-disease-look-to-novartis-treatment-lottery 2020-01-06T01:16:03 https://maestrodatabase.com/blog/3-in-10-uninsured-americans-with-diabetes-may-ration-insulin 2022-10-18T20:35:55 https://maestrodatabase.com/blog/novel-drug-approvals-for-2019 2020-01-06T00:43:51 https://maestrodatabase.com/blog/pbac-goes-pc 2020-01-06T00:06:44 https://maestrodatabase.com/blog/axoft-brain-implant-technology-is-granted-fda-breakthrough-device-designation 2022-10-18T20:25:18 https://maestrodatabase.com/blog/democrats-and-republicans-promised-to-lower-drug-prices-instead-theyve-gone-up-again 2020-01-06T06:31:07 https://maestrodatabase.com/blog/analysis-of-the-agenda-for-the-march-2020-pbac-meeting 2020-01-06T05:40:21 https://maestrodatabase.com/blog/acer-therapeutics-announces-fda-acceptance-of-nda-and-priority-review-for-edsivo-for-the-treatment-of-veds 2018-12-27T22:50:18 https://maestrodatabase.com/blog/reata-pharmaceuticals-receives-complete-response-letter-from-the-fda-for-bardoxolone-for-the-treatment-of-patients-with-chronic-kidney-disease-caused-by-alport-syndrome 2022-02-26T12:29:12 https://maestrodatabase.com/blog/kala-pharmaceuticals-announces-new-drug-application-for-kpi-121-0-dot-25-percent-for-dry-eye-disease-has-been-accepted-for-review-by-the-u-dot-s-fda 2018-12-27T23:00:24 https://maestrodatabase.com/blog/proposal-to-widen-access-to-rituximab-for-treatment-of-membranous-nephropathy 2020-12-04T01:17:23 https://maestrodatabase.com/blog/highlights-from-chmp-21-24-february-2022-meeting 2022-02-26T22:47:54 https://maestrodatabase.com/blog/sarclisa-isatuximab-for-injection-now-available-in-canada-for-patients-with-relapsed-and-refractory-multiple-myeloma 2020-07-09T07:38:42 https://maestrodatabase.com/blog/u-dot-s-fda-approves-qwo-collagenase-clostridium-histolyticum-aaes-the-first-injectable-treatment-for-cellulite 2020-07-09T08:15:54 https://maestrodatabase.com/blog/brilinta-granted-fda-priority-review-for-the-reduction-of-subsequent-stroke-in-patients-who-had-an-acute-ischaemic-stroke-or-transient-ischaemic-attack 2020-07-09T12:45:22 https://maestrodatabase.com/blog/bioxcel-therapeutics-receives-fda-fast-track-designation-for-bxcl501-for-acute-treatment-of-agitation 2018-12-27T23:24:49 https://maestrodatabase.com/blog/astex-pharmaceuticals-taiho-oncology-and-otsuka-pharmaceutical-announce-health-canada-approval-of-inqovi-decitabine-and-cedazuridine-tablets-oral-hypomethylating-agent-therapy-for-intermediate-and-high-risk-mds-and-c 2020-07-09T07:25:04 https://maestrodatabase.com/blog/international-regulators-align-positions-on-phase-3-covid-19-vaccine-trials 2020-07-09T20:49:45 https://maestrodatabase.com/blog/corcept-submits-new-drug-application-for-relacorilant-as-a-treatment-for-patients-with-hypercortisolism 2025-01-01T22:41:35 https://maestrodatabase.com/blog/big-pharmas-return-to-business-as-usual-galvanizes-trump-administration-divided-congress 2018-12-27T23:29:10 https://maestrodatabase.com/blog/nice-signs-agreement-with-colombias-institute-of-health-technology-assessment-to-forge-closer-working-ties 2020-07-09T20:51:54 https://maestrodatabase.com/blog/assembly-biosciences-announces-fda-fast-track-designation-granted-to-abi-h2158-for-the-treatment-of-chronic-hepatitis-b-virus-infection 2020-07-09T20:54:52 https://maestrodatabase.com/blog/sotatercept-approved-to-treat-adult-patients-with-pulmonary-arterial-hypertension 2025-01-01T22:34:47 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-releases-evidence-report-on-disease-modifying-therapies-for-multiple-sclerosis-including-daclizumab-and-ocrelizumab 2017-01-27T05:56:08 https://maestrodatabase.com/blog/mylan-and-fujifilm-kyowa-kirin-biologics-announce-u-dot-s-fda-approval-of-hulio-adalimumab-fkjp 2020-07-09T12:52:03 https://maestrodatabase.com/blog/health-insurers-customers-hope-for-a-win-on-premium-increases 2017-01-27T06:26:26 https://maestrodatabase.com/blog/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-for-keytruda-pembrolizumab-for-second-line-treatment-of-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma 2020-07-09T12:59:01 https://maestrodatabase.com/blog/horizon-pharma-announces-fda-approval-to-expand-the-age-range-for-ravicti-glycerol-phenylbutyrate-oral-liquid-to-include-newborns 2018-12-28T01:05:31 https://maestrodatabase.com/blog/life-prolonging-drug-for-rare-cancer-sufferers-to-be-made-more-affordable-with-pbs-listing 2018-12-28T02:04:22 https://maestrodatabase.com/blog/chemocentryx-submits-new-drug-application-to-the-u-dot-s-fda-for-avacopan-in-anca-associated-vasculitis 2020-07-09T21:04:05 https://maestrodatabase.com/blog/tarlatamab-approved-to-treat-adult-patients-with-small-cell-lung-cancer 2025-01-01T22:54:58 https://maestrodatabase.com/blog/merck-receives-positive-european-union-chmp-opinion-for-gefapixant 2023-07-22T01:23:29 https://maestrodatabase.com/blog/despite-the-pandemic-prices-for-many-drugs-keep-rising 2020-07-09T21:11:26 https://maestrodatabase.com/blog/pharmac-inquiry-nothing-should-be-off-the-table 2020-12-04T02:34:21 https://maestrodatabase.com/blog/us-fda-requests-further-data-for-vivagel-bv-approval 2018-12-28T01:17:01 https://maestrodatabase.com/blog/xolairs-reimbursement-will-change-treatment-paradigm-for-asthma-patients 2020-07-09T21:16:58 https://maestrodatabase.com/blog/rare-lung-cancer-medication-made-available-on-the-pbs 2018-12-28T02:10:20 https://maestrodatabase.com/blog/osmotica-pharmaceuticals-receives-fda-approval-for-upneeq-oxymetazoline-hydrochloride-ophthalmic-solution-0-dot-1-percent-for-acquired-blepharoptosis-droopy-eyelid-in-adults 2020-07-09T20:58:01 https://maestrodatabase.com/blog/spectrum-pharmaceuticals-announces-submission-of-biologics-license-application-to-the-fda-for-rolontis-eflapegrastim-as-a-treatment-for-chemotherapy-induced-neutropenia 2018-12-28T06:26:44 https://maestrodatabase.com/blog/in-a-reversal-fda-calls-for-limits-on-who-gets-alzheimers-drug 2021-07-08T21:02:40 https://maestrodatabase.com/blog/drugmakers-appeal-limited-insurance-benefit-for-dementia-drug-choline-alfoscerate 2020-07-09T21:47:45 https://maestrodatabase.com/blog/cheaper-medicines-stay-cheaper-as-australians-save-1-dollars-1-cents-billion 2025-01-02T02:46:24 https://maestrodatabase.com/blog/lysogene-announces-fda-fast-track-designation-for-lys-gm101-gene-therapy-for-the-treatment-of-gm1-gangliosidosis 2021-07-08T21:06:58 https://maestrodatabase.com/blog/new-and-expanded-pbs-listings-for-breast-and-prostate-cancer 2025-01-02T02:41:47 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-january-2025 2025-01-01T23:34:45 https://maestrodatabase.com/blog/covid-19-flood-of-pfizer-doses-finally-here 2021-07-08T13:47:30 https://maestrodatabase.com/blog/european-commission-approves-rybrevant-amivantamab-in-combination-with-lazcluze-lazertinib-for-the-first-line-treatment-of-patients-with-egfr-mutated-advanced-non-small-cell-lung-cancer 2025-01-01T23:21:06 https://maestrodatabase.com/blog/beigene-announces-acceptance-of-a-supplemental-biologics-license-application-in-china-for-tislelizumab-in-oesophageal-squamous-cell-carcinoma 2021-07-08T21:46:32 https://maestrodatabase.com/blog/atagi-update-following-weekly-covid-19-meeting---7-july-2021 2021-07-08T21:31:00 https://maestrodatabase.com/blog/house-report-drug-companies-spent-more-on-buybacks-dividends-than-research 2021-07-08T21:17:40 https://maestrodatabase.com/blog/y-mabs-announces-nmpa-submission-of-bla-for-danyelza-naxitamab-gqgk-in-china 2021-07-08T21:38:15 https://maestrodatabase.com/blog/la-jolla-pharmaceutical-company-receives-positive-chmp-opinion-for-giapreza-angiotensin-ii-for-the-treatment-of-refractory-hypotension-in-adults-with-septic-or-other-distributive-shock 2019-07-01T03:12:54 https://maestrodatabase.com/blog/days-before-a-deadline-trump-team-cancels-ads-for-obama-health-plan 2017-01-28T23:30:27 https://maestrodatabase.com/blog/former-deputy-prime-minister-paula-bennett-appointed-new-chair-of-pharmac 2024-04-28T21:02:21 https://maestrodatabase.com/blog/sunovions-aptiom-eslicarbazepine-acetate-receives-fda-approval-for-expanded-indication-to-treat-partial-onset-seizures-in-children-and-adolescents-4-years-of-age-and-older 2017-09-17T21:42:00 https://maestrodatabase.com/blog/emas-chmp-rejects-another-drug-approved-by-us-fda 2019-07-01T03:24:49 https://maestrodatabase.com/blog/behind-closed-doors-republicans-fret-about-how-to-repeal-obamacare 2017-01-28T23:34:23 https://maestrodatabase.com/blog/meeting-highlights-from-the-chmp-23-26-january-2017-meeting 2017-01-28T23:50:49 https://maestrodatabase.com/blog/menarini-group-receives-positive-chmp-opinion-recommending-ec-approval-of-orserdu-elacestrant-for-the-treatment-of-patients-with-er-plus-her2--locally-advanced-or-metastatic-breast-cancer-with-an-activating-esr1-mutation 2023-07-22T01:45:40 https://maestrodatabase.com/blog/ema-recommends-two-amgen-humira-biosimilars 2017-01-28T23:55:41 https://maestrodatabase.com/blog/amgen-and-ucb-provide-regulatory-update-on-status-of-evenity-romosozumab-in-the-eu 2019-07-01T03:18:42 https://maestrodatabase.com/blog/new-treatment-for-children-with-type-2-diabetes-mellitus 2019-07-01T12:19:22 https://maestrodatabase.com/blog/the-gop-grapples-with-creating-a-better-obamacare 2017-01-29T00:00:05 https://maestrodatabase.com/blog/pharmac-welcome-new-financial-year-with-no-major-new-listings 2019-07-01T03:39:05 https://maestrodatabase.com/blog/international-work-sharing-initiative---niraparib-zejula 2019-07-01T03:32:28 https://maestrodatabase.com/blog/uks-drug-buying-agency-ceo-why-we-like-to-say-yes 2019-07-01T13:14:23 https://maestrodatabase.com/blog/1-july-medicare-rebate-increases 2019-07-01T13:09:46 https://maestrodatabase.com/blog/diabetes-lung-cancer-acne-and-depression-medicines-listed-on-the-pbs 2019-07-01T12:23:13 https://maestrodatabase.com/blog/retrophin-announces-fda-approval-of-thiola-ec-tiopronin-100-mg-and-300-mg-tablets-for-the-treatment-of-cystinuria 2019-07-01T13:32:10 https://maestrodatabase.com/blog/ethical-challenges-related-to-patient-involvement-in-health-technology-assessment 2019-07-01T13:26:15 https://maestrodatabase.com/blog/argenx-announces-vvygart-sc-pre-filled-syringe-for-self-injection-in-chronic-inflammatory-demyelinating-polyneuropathy-authorised-for-sale-by-health-canada 2025-11-06T03:58:52 https://maestrodatabase.com/blog/american-caravan-arrives-in-canadian-birthplace-of-insulin-for-cheaper-medicine 2019-07-01T13:21:25 https://maestrodatabase.com/blog/nrx-pharmaceuticals-files-initial-section-of-us-new-drug-application-to-the-fda-for-nrx-100-iv-ketamine-for-the-treatment-of-suicidal-depression 2025-01-02T22:59:01 https://maestrodatabase.com/blog/quitting-eu-regulator-would-leave-uk-waiting-longer-for-new-drugs 2017-01-29T01:05:35 https://maestrodatabase.com/blog/nancy-pelosis-latest-medicare-proposal-would-pass-drug-discounts-to-all-consumers 2019-07-01T21:37:07 https://maestrodatabase.com/blog/puma-biotechnology-submits-a-supplemental-new-drug-application-to-u-dot-s-fda-for-neratinib-to-treat-her2-positive-metastatic-breast-cancer 2019-07-01T21:31:52 https://maestrodatabase.com/blog/sunovions-latuda-lurasidone-hydrochloride-receives-fda-approval-to-treat-adolescents-with-schizophrenia 2017-01-29T01:09:45 https://maestrodatabase.com/blog/delays-a-matter-of-life-and-death 2019-07-01T21:27:57 https://maestrodatabase.com/blog/save-the-food-and-drug-administration-by-breaking-it-up 2025-01-02T23:20:23 https://maestrodatabase.com/blog/drug-prices-in-2019-are-surging-with-hikes-at-5-times-inflation 2019-07-01T21:39:08 https://maestrodatabase.com/blog/women-call-for-life-changing-medicinal-cannabis-oil-to-be-added-to-pharmaceutical-benefits-scheme 2022-10-19T02:39:21 https://maestrodatabase.com/blog/senator-collins-representative-eshoo-decry-medicare-coverage-rejection-of-alzheimers-drugs 2022-10-19T03:59:31 https://maestrodatabase.com/blog/access-consortium-statement-on-covid-19-vaccines-evidence 2020-12-04T07:05:08 https://maestrodatabase.com/blog/covid-19-vaccine-will-be-free-of-charge-1-million-inoculations-set-for-january-french-pm-say 2020-12-04T06:47:21 https://maestrodatabase.com/blog/evusheld-receives-health-canada-approval-for-treatment-of-covid-19 2022-10-19T03:33:50 https://maestrodatabase.com/blog/engene-receives-fast-track-designation-for-eg-70-for-the-treatment-of-non-muscle-invasive-bladder-cancer 2020-12-04T06:55:02 https://maestrodatabase.com/blog/life-prolonging-breast-cancer-drug-recommended-for-pbs-subsidy-but-it-is-not-time-to-celebrate 2024-04-29T03:08:01 https://maestrodatabase.com/blog/farxiga-granted-fda-priority-review-for-patients-with-heart-failure-with-reduced-ejection-fraction 2020-01-06T19:14:42 https://maestrodatabase.com/blog/bridgebio-pharmas-qed-therapeutics-receives-fast-track-designation-for-infigratinib-in-adults-with-first-line-advanced-or-metastatic-cholangiocarcinoma-and-orphan-drug-designation-for-infigratinib-for-treatment-of-cholangiocarcinoma 2020-01-06T19:27:25 https://maestrodatabase.com/blog/pfizer-receives-positive-chmp-opinion-in-europe-for-xeljanz-tofacitinib-citrate-for-the-treatment-of-moderate-to-severe-active-rheumatoid-arthritis 2017-01-29T01:55:33 https://maestrodatabase.com/blog/msac-publishes-agenda-for-february-2023-esc-meeting 2022-10-19T05:01:51 https://maestrodatabase.com/blog/fda-approves-fiasp-for-treatment-of-children-with-diabetes 2020-01-06T19:41:45 https://maestrodatabase.com/blog/fight-over-pharmacs-switch-to-generic-anti-depressant-brand-continues 2018-04-30T00:52:18 https://maestrodatabase.com/blog/european-chmp-adopts-positive-opinion-for-gileads-biktarvy-bictegravir-emtricitabine-tenofovir-alafenamide 2018-04-30T00:44:05 https://maestrodatabase.com/blog/a-new-incentive-to-encourage-the-prescription-of-biosimilars 2018-04-30T00:59:46 https://maestrodatabase.com/blog/chmp-recommends-roches-evrysdi-for-babies-under-two-months-old-with-spinal-muscular-atrophy 2023-07-22T03:33:17 https://maestrodatabase.com/blog/acelrx-receives-positive-chmp-opinion-for-dzuveo-for-management-of-acute-moderate-to-severe-pain-in-medically-monitored-settings 2018-04-30T01:04:54 https://maestrodatabase.com/blog/idebenone-for-the-treatment-of-patients-12-years-and-older-with-visual-impairment-associated-with-lebers-hereditary-optic-neuropathy 2024-04-29T03:13:24 https://maestrodatabase.com/blog/kyowa-kirin-announces-marketing-authorisation-application-for-istradefylline-validated-by-european-medicines-agency 2020-01-06T20:02:54 https://maestrodatabase.com/blog/access-to-biosimilars-in-eu-expected-to-continue-to-outpace-us-and-canada 2018-04-30T00:54:53 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-may-2018 2018-04-30T02:21:55 https://maestrodatabase.com/blog/tagrisso-receives-positive-eu-chmp-opinion-for-first-line-treatment-of-egfr-mutated-non-small-cell-lung-cancer 2018-04-30T05:00:14 https://maestrodatabase.com/blog/brexit-diagnosis-predicts-drug-delay-for-uk-patients 2018-04-30T01:10:39 https://maestrodatabase.com/blog/chmp-recommends-eu-approval-of-roches-tecentriq-in-combination-with-abraxane-as-an-initial-treatment-for-people-with-pd-l1-positive-metastatic-triple-negative-breast-cancer 2019-07-02T01:14:41 https://maestrodatabase.com/blog/fda-approves-daratumumab-and-hyaluronidase-fihj-for-high-risk-smoldering-multiple-myeloma 2025-11-06T20:49:11 https://maestrodatabase.com/blog/statement-on-steps-to-make-health-care-professional-and-patient-labelling-information-for-prescription-medications-consistent-and-clear 2019-07-02T01:09:08 https://maestrodatabase.com/blog/jardiance-empagliflozin-becomes-first-type-2-diabetes-medicine-in-the-eu-to-include-cardiovascular-death-reduction-data-in-label 2017-01-29T04:05:54 https://maestrodatabase.com/blog/zanubrutinib-for-the-treatment-of-patients-with-waldenstroems-macroglobulinaemia 2022-10-19T19:54:03 https://maestrodatabase.com/blog/hikma-pharmaceuticals-announces-the-launch-of-starjemza-ustekinumab-hmny-injection-a-biosimilar-referencing-stelara-ustekinumab-injection 2025-11-06T22:10:24 https://maestrodatabase.com/blog/fda-continues-to-encourage-ongoing-education-about-the-benefits-and-risks-associated-with-prep-including-additional-steps-to-help-reduce-the-risk-of-getting-hiv 2019-07-02T01:02:18 https://maestrodatabase.com/blog/ema-recommends-approval-of-second-adapted-spikevax-vaccine 2022-10-19T19:50:22 https://maestrodatabase.com/blog/oestradiol-hemifumarate-with-norethisterone-acetate-and-relugolix-for-the-treatment-of-moderate-to-severe-symptoms-of-uterine-fibroids 2022-10-19T19:42:53 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-to-tvardi-therapeutics-tti-101-for-hepatocellular-carcinoma 2022-10-19T19:37:41 https://maestrodatabase.com/blog/ipsen-provides-update-on-eu-marketing-authorisation-application-for-bylvay-for-cholestatic-pruritus-in-patients-with-alagille-syndrome 2023-07-22T03:43:57 https://maestrodatabase.com/blog/msac-publishes-outcome-for-mackenzies-mission 2022-10-19T20:26:04 https://maestrodatabase.com/blog/democratic-states-appeal-obamacare-ruling-to-supreme-court 2020-01-06T21:37:32 https://maestrodatabase.com/blog/ema-recommends-approval-of-comirnaty-and-spikevax-covid-19-vaccines-for-children-from-6-months-of-age 2022-10-19T20:11:46 https://maestrodatabase.com/blog/fostamatinib-disodium-hexahydrate-for-the-treatment-of-patients-with-refractory-chronic-immune-thrombocytopenia 2022-10-19T20:18:36 https://maestrodatabase.com/blog/lilly-and-us-government-agree-to-expand-access-to-obesity-medicines-to-millions-of-americans 2025-11-06T23:53:53 https://maestrodatabase.com/blog/advancing-real-world-evidence-program 2022-10-19T20:07:33 https://maestrodatabase.com/blog/emergent-biosolutions-announces-submission-to-fda-of-application-covering-emergency-use-authorisation-for-nuthrax 2018-12-29T01:11:03 https://maestrodatabase.com/blog/alnylam-submits-marketing-authorisation-application-to-the-ema-for-givosiran-for-the-treatment-of-acute-hepatic-porphyria 2019-07-02T02:03:16 https://maestrodatabase.com/blog/fda-approval-of-caplyta-lumateperone-has-the-potential-to-reset-treatment-expectations-offering-hope-for-remission-in-adults-with-major-depressive-disorder 2025-11-06T23:15:28 https://maestrodatabase.com/blog/challenges-to-the-reproducibility-of-machine-learning-models-in-health-care 2020-01-06T21:43:13 https://maestrodatabase.com/blog/generic-makers-will-appeal-ruling-that-allows-california-to-proceed-with-law-banning-pay-to-delay-deals 2020-01-06T21:40:06 https://maestrodatabase.com/blog/innovation-in-new-drug-approvals-of-2019-advances-patient-care-across-a-broad-range-of-diseases 2020-01-06T21:46:39 https://maestrodatabase.com/blog/libtayo-cemiplimab-approved-for-advanced-cutaneous-squamous-cell-carcinoma-in-the-european-union 2019-07-02T02:09:00 https://maestrodatabase.com/blog/invivoscribe-announces-fda-approval-of-the-leukostrat-cdx-flt3-mutation-assay-to-select-patients-with-flt3-itd-positive-aml-for-treatment-with-vanflyta 2023-07-22T05:10:15 https://maestrodatabase.com/blog/novo-nordisk-files-for-us-fda-regulatory-approval-of-once-weekly-semaglutide-2-dot-4-mg-for-weight-management 2020-12-04T20:38:43 https://maestrodatabase.com/blog/truqap-plus-faslodex-recommended-for-approval-in-the-eu-by-chmp-for-patients-with-advanced-er-positive-breast-cancer 2024-04-29T06:37:23 https://maestrodatabase.com/blog/rezurock-now-covered-in-quebec-for-people-living-with-chronic-graft-versus-host-disease 2025-11-07T01:57:34 https://maestrodatabase.com/blog/janssen-submits-supplemental-new-drug-application-to-u-dot-s-fda-for-zytiga-abiraterone-acetate-to-treat-men-with-earlier-stages-of-metastatic-prostate-cancer 2017-09-18T04:09:48 https://maestrodatabase.com/blog/beigene-announces-positive-chmp-opinion-for-tislelizumab-as-a-treatment-for-advanced-or-metastatic-oesophageal-squamous-cell-carcinoma 2023-07-22T04:13:18 https://maestrodatabase.com/blog/celltrion-usa-signs-agreement-with-express-scripts-for-its-therapy-for-autoimmune-diseases-including-the-first-fda-approved-subcutaneous-infliximab-zymfentra 2024-04-29T05:51:08 https://maestrodatabase.com/blog/evernorth-announces-humira-biosimilar-available-at-0-dollars-out-of-pocket-for-accredo-patients-in-june 2024-04-29T05:37:00 https://maestrodatabase.com/blog/biocryst-announces-fda-approval-of-orladeyo-berotralstat-first-oral-once-daily-therapy-to-prevent-attacks-in-hereditary-angioedema-patients 2020-12-04T11:48:10 https://maestrodatabase.com/blog/merck-receives-positive-eu-chmp-opinion-for-keytruda-pembrolizumab-plus-trastuzumab-and-chemotherapy-as-first-line-treatment-for-her2-positive-advanced-gastric-or-gastro-oesophageal-junction-adenocarcinoma-expressing-pd-l1-cps-1 2023-07-22T04:05:06 https://maestrodatabase.com/blog/government-boosts-pharmac-funding-by-1-dollars-7-cents-billion-as-inaugural-medicines-summit-begins 2024-04-29T05:07:59 https://maestrodatabase.com/blog/janssen-receives-positive-chmp-opinions-for-novel-bispecific-antibodies-talvey-talquetamab-and-tecvayli-teclistamab-for-the-treatment-of-patients-with-relapsed-and-refractory-multiple-myeloma 2023-07-22T05:47:46 https://maestrodatabase.com/blog/capricor-therapeutics-completes-submission-of-biologics-license-application-to-the-us-fda-for-deramiocel-for-the-treatment-of-duchenne-muscular-dystrophy 2025-01-03T04:06:14 https://maestrodatabase.com/blog/icer-posts-draft-scoping-document-for-the-assessment-of-treatments-for-beta-thalassaemia 2020-01-06T21:50:31 https://maestrodatabase.com/blog/check-your-health-insurance-because-extras-cover-may-not-be-worth-it-say-experts 2017-01-29T20:25:38 https://maestrodatabase.com/blog/verrica-pharmaceuticals-announces-fda-approval-of-ycanth-cantharidin-topical-solution-as-the-first-fda-approved-treatment-of-paediatric-and-adult-patients-with-molluscum-contagiosum 2023-07-22T05:22:12 https://maestrodatabase.com/blog/fda-approves-first-drug-for-whim-syndrome-a-rare-disorder-that-can-lead-to-recurrent-life-threatening-infections 2024-04-29T21:32:07 https://maestrodatabase.com/blog/new-indication-for-briviact-brivaracetam-ucbs-newest-anti-epileptic-drug-approved-by-fda-as-monotherapy-treatment-of-partial-onset-seizures-in-adults 2017-09-18T04:23:42 https://maestrodatabase.com/blog/gileads-vemlidy-now-reimbursed-as-initial-therapy-for-chronic-hepatitis-b-in-korea 2025-11-07T01:37:55 https://maestrodatabase.com/blog/highlights-from-the-17-20-july-2023-chmp-meeting 2023-07-22T05:18:58 https://maestrodatabase.com/blog/fda-approves-tisotumab-vedotin-tftv-for-recurrent-or-metastatic-cervical-cancer 2024-04-29T21:26:32 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-may-2018-update 2018-04-30T11:59:16 https://maestrodatabase.com/blog/rebalancing-high-prescription-drug-prices-with-innovation-incentive 2019-07-02T09:29:59 https://maestrodatabase.com/blog/fda-to-conduct-priority-review-of-cemiplimab-as-a-potential-treatment-for-advanced-cutaneous-squamous-cell-carcinoma 2018-04-30T12:38:18 https://maestrodatabase.com/blog/health-minister-david-clark-taking-time-to-consider-draft-national-cancer-plan-after-long-fought-campaign 2019-07-02T09:26:09 https://maestrodatabase.com/blog/final-nice-nod-for-keytruda-in-bladder-cancer 2018-04-30T09:03:54 https://maestrodatabase.com/blog/changes-to-wholesale-mark-up-arrangements-for-pbs-section-85-medicines-dispensed-in-public-and-private-hospitals-to-come-into-effect-on-1-october-2019 2019-07-02T09:21:21 https://maestrodatabase.com/blog/schedule-of-fees-and-charges 2019-07-02T09:17:48 https://maestrodatabase.com/blog/amicus-therapeutics-announces-approval-for-galafold-migalastat-for-treatment-of-fabry-disease-in-canada 2017-09-18T04:43:46 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-january-2025 2025-01-03T05:52:31 https://maestrodatabase.com/blog/innovent-announces-second-new-drug-pplication-of-dovbleron-taletrectinib-adipate-capsule-ros1-inhibitor-was-approved-by-chinas-national-medical-products-administration 2025-01-03T05:12:28 https://maestrodatabase.com/blog/drug-prices-persistently-rising-despite-trump-efforts 2019-07-02T09:36:22 https://maestrodatabase.com/blog/dieppe-mom-wants-$350k-drug-covered-for-son 2018-04-30T13:32:03 https://maestrodatabase.com/blog/novartis-receives-fda-approval-of-tafinlar-and-mekinist-for-adjuvant-treatment-of-braf-v600-mutant-melanoma 2018-04-30T20:45:38 https://maestrodatabase.com/blog/proposal-to-modify-pharmacs-approach-to-competitive-procurement 2020-07-10T03:02:31 https://maestrodatabase.com/blog/agenda-for-the-july-2018-pbac-meeting-update 2018-04-30T13:42:50 https://maestrodatabase.com/blog/hunter-cystic-fibrosis-patients-rally-for-access-to-wonder-drug-orkambi 2018-04-30T21:01:11 https://maestrodatabase.com/blog/hiv-diagnoses-in-australia-hit-18-year-low-but-there-is-still-a-way-go 2019-07-02T21:27:29 https://maestrodatabase.com/blog/drug-price-tv-ad-rule-will-cause-consumer-confusion-drug-makers-argue 2019-07-02T13:12:16 https://maestrodatabase.com/blog/update-of-eu-recommendations-for-2018-slash-2019-seasonal-flu-vaccine-composition 2018-04-30T21:05:52 https://maestrodatabase.com/blog/pfizer-plans-to-request-fda-approval-for-covid-booster-shot-in-august 2021-07-09T06:35:24 https://maestrodatabase.com/blog/innovation-prizes-to-support-cell-and-gene-therapy 2019-07-02T21:47:46 https://maestrodatabase.com/blog/immediately-after-eu-nod-englands-nhs-funds-sanofi-skin-cancer-drug 2019-07-02T21:42:16 https://maestrodatabase.com/blog/summary-of-submissions-and-outcomes-from-the-november-2019-pbac-meeting 2020-01-07T02:34:08 https://maestrodatabase.com/blog/will-transparent-pricing-make-americas-health-care-cheaper 2019-07-02T21:34:02 https://maestrodatabase.com/blog/trump-advisers-pursue-democratic-drug-price-ideas-as-campaign-looms 2019-07-02T21:31:19 https://maestrodatabase.com/blog/lokelma-approved-in-china-for-the-treatment-of-adult-patients-with-hyperkalaemia 2020-01-07T06:55:33 https://maestrodatabase.com/blog/leo-pharma-announces-u-dot-s-fda-acceptance-of-biologics-license-application-for-tralokinumab-for-the-treatment-of-adults-with-moderate-to-severe-atopic-dermatitis 2020-07-10T03:29:35 https://maestrodatabase.com/blog/new-fda-approved-cystic-fibrosis-medicine-trikafta-among-other-specialty-drugs-available-through-alliancerx-walgreens-prime 2020-01-07T02:43:14 https://maestrodatabase.com/blog/soleno-therapeutics-receives-breakthrough-therapy-designation-from-us-fda-for-diazoxide-choline-extended-release-tablets-in-prader-willi-syndrome 2024-04-29T23:09:02 https://maestrodatabase.com/blog/comirnaty-and-spikevax-possible-link-to-very-rare-cases-of-myocarditis-and-pericarditis 2021-07-09T23:08:08 https://maestrodatabase.com/blog/tga-provisionally-approves-modernas-covid-19-vaccine-for-use-as-a-booster-dose-in-individuals-12-years-and-older 2022-10-20T04:44:55 https://maestrodatabase.com/blog/fda-grants-regular-approval-to-enfortumab-vedotin-ejfv-for-locally-advanced-or-metastatic-urothelial-cancer 2021-07-09T23:17:08 https://maestrodatabase.com/blog/radiomedix-and-curium-announce-fda-filing-of-copper-cu-64-dotatate-injection-new-drug-application 2020-01-07T11:57:39 https://maestrodatabase.com/blog/icer-publishes-evidence-report-on-therapies-for-atopic-dermatitis 2021-07-09T23:12:04 https://maestrodatabase.com/blog/antibiotics-need-a-special-place-in-the-drug-pricing-debate 2020-01-07T20:12:21 https://maestrodatabase.com/blog/washington-took-a-decade-to-approve-an-obscure-drug-pricing-bill-thats-a-bad-omen-for-more-ambitious-reforms 2020-01-07T20:10:10 https://maestrodatabase.com/blog/conservative-group-with-pharma-ties-makes-clear-there-are-drug-pricing-reforms-they-can-support 2020-01-07T20:05:58 https://maestrodatabase.com/blog/congress-seeks-drug-pricing-deal-in-spite-of-2020-rancor 2020-01-07T19:55:19 https://maestrodatabase.com/blog/obamacare-market-stable-and-profitable-despite-loss-of-individual-mandate 2020-01-07T20:29:34 https://maestrodatabase.com/blog/public-hospital-system-being-stretched-to-the-limit 2020-01-07T20:23:40 https://maestrodatabase.com/blog/as-brexit-nears-fears-of-an-nhs-sell-out-resurface 2020-01-07T20:16:32 https://maestrodatabase.com/blog/how-digital-health-innovators-can-successfully-navigate-evolving-fda-regulations 2022-10-20T07:02:52 https://maestrodatabase.com/blog/pfizer-slashes-its-original-covid-19-vaccine-rollout-target-after-supply-chain-obstacles 2020-12-05T06:28:40 https://maestrodatabase.com/blog/fda-approves-expanded-botox-onabotulinumtoxina-label-for-the-treatment-of-paediatric-patients-with-spasticity 2020-07-10T06:19:16 https://maestrodatabase.com/blog/us-fda-grants-emergency-use-authorisation-for-novavax-covid-19-vaccine-adjuvanted-as-a-booster-for-adults 2022-10-20T08:29:46 https://maestrodatabase.com/blog/sinaptica-therapeutics-announces-fda-breakthrough-device-designation-for-its-novel-non-invasive-neurostimulation-treatment-for-alzheimers-disease 2022-10-20T06:19:43 https://maestrodatabase.com/blog/seqirus-receives-fda-approval-of-afluria-quadrivalent-influenza-vaccine-for-people-five-years-of-age-and-older-in-the-u-dot-s 2017-09-18T07:27:25 https://maestrodatabase.com/blog/incyte-announces-the-validation-by-the-european-medicines-agency-of-its-marketing-authorisation-application-for-pemigatinib-in-patients-with-cholangiocarcinoma 2020-01-08T01:17:57 https://maestrodatabase.com/blog/rhythm-pharmaceuticals-announces-fda-extension-of-review-period-for-imcivree-setmelanotide-for-patients-with-acquired-hypothalamic-obesity 2025-11-07T20:53:34 https://maestrodatabase.com/blog/collaborative-consultation-on-medicines-policy-closes 2020-07-10T06:25:33 https://maestrodatabase.com/blog/johnson-and-johnson-receives-positive-chmp-opinion-recommending-full-approval-for-sirturo-bedaquiline-for-treatment-of-multidrug-resistant-tuberculosis 2024-04-30T01:17:34 https://maestrodatabase.com/blog/abbvie-receives-health-canada-approval-of-rinvoq-upadacitinib-an-oral-medication-for-the-treatment-of-adults-with-moderate-to-severe-active-rheumatoid-arthritis 2020-01-08T01:29:34 https://maestrodatabase.com/blog/dutch-may-approve-insurance-cover-for-weight-loss-drugs 2025-11-07T06:37:02 https://maestrodatabase.com/blog/neos-therapeutics-receives-u-dot-s-fda-approval-of-adzenys-er-amphetamine-extended-release-oral-suspension-for-the-treatment-of-adhd-in-patients-6-years-and-older 2017-09-18T08:39:08 https://maestrodatabase.com/blog/irelands-cancer-survival-rates-lag-behind-other-eu-countries-with-access-to-new-drugs-limited 2022-10-20T10:12:43 https://maestrodatabase.com/blog/cms-announces-new-drug-payment-model-to-strengthen-medicaid-and-better-serve-vulnerable-americans 2025-11-07T20:00:03 https://maestrodatabase.com/blog/what-the-makena-vote-means-about-accelerated-approval-trust-and-the-fda 2022-10-20T10:28:25 https://maestrodatabase.com/blog/fda---2019-in-review 2020-01-08T07:14:52 https://maestrodatabase.com/blog/the-fda-is-a-mess-but-dont-blame-it-for-everything 2025-11-07T20:06:53 https://maestrodatabase.com/blog/gop-sen-grassley-turns-to-house-speaker-pelosi-for-help-selling-his-bipartisan-drug-pricing-bill 2020-01-08T06:56:15 https://maestrodatabase.com/blog/oh-canada-us-patients-dont-want-your-health-policies 2024-04-30T01:40:23 https://maestrodatabase.com/blog/pbac---2019-in-review 2020-01-08T02:29:03 https://maestrodatabase.com/blog/mark-cuban-is-trying-to-shake-up-biosimilar-pricing-with-a-version-of-j-and-js-best-selling-stelara-drug 2025-11-07T20:19:06 https://maestrodatabase.com/blog/fda-approves-pembrolizumab-for-bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer 2020-01-08T19:35:31 https://maestrodatabase.com/blog/application-for-cystic-fibrosis-medicine-received-by-pharmac 2021-07-10T07:45:45 https://maestrodatabase.com/blog/why-humiras-price-keeps-rising-despite-fda-approval-of-generic-competition 2020-01-08T19:53:42 https://maestrodatabase.com/blog/adamis-pharmaceuticals-submits-new-drug-application-to-fda-for-its-tadalafil-sublingual-tablet 2018-12-30T05:33:24 https://maestrodatabase.com/blog/fda-is-grappling-with-digital-health-regulation 2020-01-08T19:51:00 https://maestrodatabase.com/blog/boehringer-awarded-fda-commissioners-national-priority-voucher-for-hernexeos-in-her2-lung-cancer 2025-11-08T00:00:56 https://maestrodatabase.com/blog/medicine-for-the-treatment-of-seizures-listed-on-the-pbs 2018-12-29T23:49:21 https://maestrodatabase.com/blog/hospital-overload-fuelled-by-gp-rebate 2020-01-08T20:04:46 https://maestrodatabase.com/blog/renetx-bio-receives-fast-track-designation-from-u-dot-s-fda 2020-01-08T19:58:45 https://maestrodatabase.com/blog/health-canada-authorises-medicago-covid-19-vaccine-for-adults-18-to-64-years-of-age 2022-02-27T20:23:26 https://maestrodatabase.com/blog/starpharma-completes-us-new-drug-application-for-vivagel-bv 2018-05-01T00:03:11 https://maestrodatabase.com/blog/amcp-format-for-formulary-submissions-version-4-dot-1-includes-new-dossiers-for-submitting-evidence-on-unapproved-medicines-and-unapproved-indications-submitted-for-fda-approval 2020-01-08T20:24:05 https://maestrodatabase.com/blog/bayers-kerendia-finerenone-receives-u-dot-s-fda-approval-for-treatment-of-patients-with-chronic-kidney-disease-associated-with-type-2-diabetes 2021-07-10T07:52:41 https://maestrodatabase.com/blog/gsks-nucala-mepolizumab-approved-in-china-for-treatment-of-adults-with-chronic-rhinosinusitis-with-nasal-polyps 2025-01-03T22:31:35 https://maestrodatabase.com/blog/focus-needed-not-just-on-drugs-but-hospital-expenses-to-impact-health-care-costs 2020-01-08T20:12:40 https://maestrodatabase.com/blog/medicare-findings-support-need-for-continuing-review 2018-05-01T00:18:39 https://maestrodatabase.com/blog/icer-publishes-final-evidence-report-and-policy-recommendations-on-treatments-for-obesity-management 2022-10-20T20:08:10 https://maestrodatabase.com/blog/icer-evaluates-drug-price-increases-in-california 2022-10-20T20:02:34 https://maestrodatabase.com/blog/update-on-tyvaso-dpi-new-drug-application 2022-02-27T21:39:18 https://maestrodatabase.com/blog/consultation-on-the-revised-pbs-post-market-review-framework 2022-10-20T20:05:47 https://maestrodatabase.com/blog/actelion-submits-supplemental-new-drug-application-to-us-fda-seeking-approval-of-opsumit-macitentan-for-the-treatment-of-chronic-thromboembolic-pulmonary-hypertension 2018-05-01T01:08:43 https://maestrodatabase.com/blog/nhs-treats-first-sickle-cell-disease-patients-with-life-changing-drug 2022-02-27T20:33:24 https://maestrodatabase.com/blog/department-of-health-tweaks-the-agenda-for-november-2022-pbac-meeting 2022-10-20T19:56:43 https://maestrodatabase.com/blog/vera-therapeutics-submits-biologics-license-application-to-us-fda-through-accelerated-approval-program-for-atacicept-for-the-treatment-of-adults-with-iga-nephropathy 2025-11-08T03:42:02 https://maestrodatabase.com/blog/new-zealand-its-time-to-put-fairness-in-focus 2022-10-20T19:50:13 https://maestrodatabase.com/blog/gefapixant-for-the-treatment-of-patients-with-refractory-or-unexplained-chronic-cough 2024-04-30T02:21:38 https://maestrodatabase.com/blog/frustrated-cystic-fibrosis-patients-await-pbs-subsidy-to-life-changing-drug 2021-07-10T08:16:19 https://maestrodatabase.com/blog/covid-19-vaccine-safety-report-20-october-2022 2022-10-20T19:53:42 https://maestrodatabase.com/blog/health-canada-approves-trodelvy-sacituzumab-govitecan-in-pre-treated-hr-plus-slash-her2--metastatic-breast-cancer 2023-07-23T11:17:01 https://maestrodatabase.com/blog/drug-makers-look-to-limit-medicares-new-power-to-negotiate-lower-drug-prices 2022-10-20T20:38:09 https://maestrodatabase.com/blog/drugs-should-be-priced-based-on-one-factor---value 2022-10-20T20:34:58 https://maestrodatabase.com/blog/fda-grants-priority-review-to-mercks-sbla-for-keytruda-pembrolizumab-in-combination-with-pemetrexed-and-platinum-chemotherapy-based-on-results-from-phase-3-keynote-189-trial-as-first-line-treatment-of-metastatic-non-squamous-nsclc 2018-05-01T02:09:47 https://maestrodatabase.com/blog/fda-approves-weight-management-drug-for-patients-aged-12-and-older 2020-12-05T08:24:23 https://maestrodatabase.com/blog/abbvies-skyrizi-risankizumab-receives-health-canada-approval-as-the-first-and-only-specific-interleukin-23-to-treat-moderately-to-severely-active-crohns-disease-in-adults 2022-10-20T20:30:41 https://maestrodatabase.com/blog/msac-recommends-targeted-carrier-testing-of-certain-ethic-people-for-severe-monogenic-conditions 2022-10-20T20:14:52 https://maestrodatabase.com/blog/a-comparative-review-of-marketing-authorisation-decisions-in-switzerland-the-eu-and-the-usa 2018-05-01T02:01:42 https://maestrodatabase.com/blog/new-treatment-for-australians-with-rare-blood-disease 2022-02-28T01:12:11 https://maestrodatabase.com/blog/fda-awards-second-batch-of-national-priority-vouchers 2025-11-08T20:46:33 https://maestrodatabase.com/blog/biohaven-and-pfizer-receive-positive-chmp-opinion-for-migraine-treatment 2022-02-28T01:52:32 https://maestrodatabase.com/blog/adamis-pharmaceuticals-submits-new-drug-application-to-fda-for-its-naloxone-pre-filled-syringe 2019-01-01T21:27:49 https://maestrodatabase.com/blog/how-a-drug-maker-profited-by-slow-walking-a-promising-hiv-therapy 2023-07-23T20:48:26 https://maestrodatabase.com/blog/dermavant-announces-fda-acceptance-of-supplemental-new-drug-application-for-vtama-tapinarof-1-percent-cream-for-the-treatment-of-atopic-dermatitis-in-adults-and-children-2-years-of-age-and-older 2024-04-30T03:34:01 https://maestrodatabase.com/blog/crowd-inundates-sunrise-set-holding-red-balloons-and-orkambi-signs 2018-05-01T02:43:18 https://maestrodatabase.com/blog/population-health-impact-of-new-drugs-recommended-by-nice-in-england-during-2000-20-a-retrospective-analysis 2025-01-03T23:51:05 https://maestrodatabase.com/blog/abuses-of-fda-regulatory-procedures---the-case-of-suboxone 2020-01-08T22:52:30 https://maestrodatabase.com/blog/minimally-invasive-epilepsy-treatment-easee-receives-fda-breakthrough-device-designation 2022-02-28T02:27:00 https://maestrodatabase.com/blog/value-based-pricing-for-drugs 2018-05-01T11:30:30 https://maestrodatabase.com/blog/pharmac-consults-on-changes-to-simplify-biologic-medicine-funding-criteria 2025-11-08T20:36:20 https://maestrodatabase.com/blog/opdivo-nivolumab-is-the-first-and-only-anti-pd-1-therapy-approved-by-tga-for-adjuvant-treatment-of-melanoma 2018-05-01T02:50:33 https://maestrodatabase.com/blog/fda-grants-priority-review-designation-for-heron-therapeutics-nda-for-htx-011-a-non-opioid-for-post-operative-pain-management 2019-01-01T21:33:45 https://maestrodatabase.com/blog/novo-nordisk-announces-agreement-with-the-us-administration-to-bring-glp-1s-to-more-americans-at-a-lower-cost 2025-11-08T20:40:43 https://maestrodatabase.com/blog/abbvie-submits-marketing-authorisation-application-to-the-ema-for-investigational-treatment-risankizumab-for-moderate-to-severe-plaque-psoriasis 2018-05-01T20:39:35 https://maestrodatabase.com/blog/the-consequences-and-future-of-prior-authorisation-reform 2023-07-23T23:18:33 https://maestrodatabase.com/blog/fda-seeks-to-probe-talks-between-staff-and-biogen-on-alzheimers-drug 2021-07-10T08:47:39 https://maestrodatabase.com/blog/as-specialty-drugs-gain-share-trump-looks-to-curb-prices 2018-05-01T21:01:43 https://maestrodatabase.com/blog/regeneron-slash-sanofi-cut-heart-drug-price-to-$4-500-$6-600-for-express-scripts 2018-05-01T21:06:33 https://maestrodatabase.com/blog/u-dot-s-fda-approves-portola-pharmaceuticals-prior-approval-supplement-for-andexxa-generation-2-manufacturing-process 2019-01-02T00:59:46 https://maestrodatabase.com/blog/nice-rejects-first-line-use-of-roches-gazyvaro 2017-09-18T11:05:09 https://maestrodatabase.com/blog/the-icer-appoints-new-members-to-each-of-its-three-independent-evidence-appraisal-councils 2018-05-01T20:54:24 https://maestrodatabase.com/blog/new-prostheses-list-reforms-a-step-towards-health-insurance-affordability 2017-09-18T11:23:37 https://maestrodatabase.com/blog/biocryst-receives-european-medicines-agency-approval-for-alpivab-for-the-treatment-of-influenza 2018-05-01T21:11:24 https://maestrodatabase.com/blog/new-cheaper-medicine-for-chronic-liver-disease 2025-11-09T00:27:07 https://maestrodatabase.com/blog/unparalleled-access-to-clinical-data---one-year-on 2017-10-20T23:25:59 https://maestrodatabase.com/blog/hundreds-of-canadians-die-every-year-because-they-cant-afford-medication-nurses-union 2018-05-01T21:19:06 https://maestrodatabase.com/blog/kymriah-tisagenlecleucel-first-in-class-car-t-therapy-from-novartis-receives-second-fda-approval-to-treat-appropriate-r-slash-r-patients-with-large-b-cell-lymphoma 2018-05-01T21:22:05 https://maestrodatabase.com/blog/antares-pharma-receives-complete-response-letter-from-the-fda-for-xyosted 2017-10-20T23:30:45 https://maestrodatabase.com/blog/audentes-announces-prime-designation-granted-by-the-ema-to-at132-for-the-treatment-of-x-linked-myotubular-myopathy 2018-06-06T12:09:26 https://maestrodatabase.com/blog/sanofi-merck-and-j-and-j-tout-lower-drug-prices 2018-06-06T10:42:54 https://maestrodatabase.com/blog/pharma-giant-merck-is-planning-for-a-brexit-supply-blackout 2018-06-06T20:58:26 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-correvios-resubmitted-new-drug-application-for-brinavess-vernakalant 2019-07-25T12:02:11 https://maestrodatabase.com/blog/nice-recommends-another-revolutionary-car-t-cell-therapy-for-adults-with-lymphoma 2019-02-01T21:47:05 https://maestrodatabase.com/blog/private-health-insurers-already-using-labor-policy-as-a-threat-in-negotiations 2018-06-06T21:02:37 https://maestrodatabase.com/blog/astellas-announces-acceptance-by-the-ema-of-a-variation-application-for-regulatory-review-for-use-of-xtandi-enzalutamide-in-metastatic-hormone-sensitive-prostate-cancer 2019-07-25T11:52:11 https://maestrodatabase.com/blog/public-consultation---draft-cost-recovery-implementation-statement-for-listing-medicines-on-the-pbs-and-designated-vaccines-on-the-nip 2019-02-01T21:41:57 https://maestrodatabase.com/blog/mhra-approves-first-immunotherapy-treatment-for-mesothelioma 2021-08-04T02:04:07 https://maestrodatabase.com/blog/fda-approves-mercks-dificid-fidaxomicin-to-treat-clostridioides-difficile-in-children-aged-six-months-and-older 2020-01-27T19:31:30 https://maestrodatabase.com/blog/regulating-digital-health-apps-needs-user-centered-reform 2021-08-04T02:08:01 https://maestrodatabase.com/blog/nohla-receives-ema-prime-designation-for-dilanubicel-nla101-to-treat-haematopoietic-stem-cell-transplant-patients 2018-06-06T21:05:51 https://maestrodatabase.com/blog/pharmacy-benefit-managers-are-not-the-cause-of-high-prescription-drug-prices 2018-06-06T21:24:48 https://maestrodatabase.com/blog/quebecs-public-private-pharmacare-model-provides-more-generous--and-timely--access-to-new-drugs 2019-07-25T12:34:47 https://maestrodatabase.com/blog/white-house-trumps-drug-pricing-plan-will-make-the-rest-of-the-world-pay-its-fair-share 2018-06-06T21:27:16 https://maestrodatabase.com/blog/trump-administration-proposes-big-changes-in-how-prescription-drugs-are-priced 2019-02-01T22:21:28 https://maestrodatabase.com/blog/being-sold-a-dud-health-insurance-death-spiral-getting-worse-data-shows 2019-07-25T12:25:59 https://maestrodatabase.com/blog/nice-rejections-continue-hitting-novos-saxenda-next 2020-01-27T19:41:23 https://maestrodatabase.com/blog/canadas-drug-shortage-problem-needs-action-say-medical-experts 2018-06-06T21:14:12 https://maestrodatabase.com/blog/drug-pricing-policy-means-deciding-when-to-say-no 2019-07-25T12:23:29 https://maestrodatabase.com/blog/fdas-new-efforts-to-advance-biotechnology-innovation 2018-06-06T21:22:13 https://maestrodatabase.com/blog/white-house-preparing-order-that-would-cut-drug-prices-for-medicare 2019-07-25T12:19:48 https://maestrodatabase.com/blog/clinical-trial-participants-views-of-the-risks-and-benefits-of-data-sharing 2018-06-06T21:47:01 https://maestrodatabase.com/blog/epizyme-announces-fda-filing-acceptance-of-new-drug-application-and-priority-review-for-tazemetostat-for-the-treatment-of-epithelioid-sarcoma 2019-07-25T21:21:29 https://maestrodatabase.com/blog/senate-panel-schedules-vote-on-controversial-drug-pricing-bill 2018-06-06T21:29:35 https://maestrodatabase.com/blog/sunovion-receives-complete-response-letter-from-fda-for-apomorphine-sublingual-film-apl-130277 2019-02-01T22:25:04 https://maestrodatabase.com/blog/abbott-receives-fda-clearance-for-its-imaging-technology-using-artificial-intelligence-for-vessels-in-the-heart 2021-08-04T02:10:59 https://maestrodatabase.com/blog/day-of-celebration-for-blair-vining-as-cancer-petition-handed-to-parliament 2019-07-25T21:14:12 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-31-march-2022 2022-03-31T05:40:21 https://maestrodatabase.com/blog/big-pharma-wants-to-invest-more-in-australian-biotech-says-greg-hunt 2018-06-06T21:35:47 https://maestrodatabase.com/blog/the-value-of-affordable-care 2019-07-25T13:38:02 https://maestrodatabase.com/blog/asc-therapeutics-receives-key-regulatory-designations-in-u-dot-s-and-europe-to-advance-its-second-generation-gene-therapy-for-haemophilia-a 2022-03-31T05:10:46 https://maestrodatabase.com/blog/eylea-hd-aflibercept-8-mg-injection-approved-by-fda-for-treatment-of-wet-age-related-macular-degeneration-diabetic-macular-oedema-and-diabetic-retinopathy 2023-08-19T05:33:35 https://maestrodatabase.com/blog/u-dot-s-food-and-drug-administration-approves-lampit-nifurtimox-for-the-treatment-of-chagas-disease-in-children 2020-08-08T23:09:53 https://maestrodatabase.com/blog/aveo-oncology-announces-nda-timing-update 2019-02-01T22:50:26 https://maestrodatabase.com/blog/cutting-edge-500-000-dollars-treatment-for-aggressive-blood-cancers 2020-01-27T20:13:18 https://maestrodatabase.com/blog/senate-panel-advances-bipartisan-bill-to-lower-drug-prices-amid-gop-blowback 2019-07-25T21:36:43 https://maestrodatabase.com/blog/ema-starts-review-of-sanofi-gsk-covid-vaccine-application 2022-03-31T07:10:33 https://maestrodatabase.com/blog/aptars-nasal-unidose-device-approved-by-us-fda-for-first-needle-free-rescue-treatment-for-severe-hypoglycaemia 2019-07-25T21:31:41 https://maestrodatabase.com/blog/intellectual-property-law-amends-will-add-to-business-uncertainty 2019-07-26T09:41:22 https://maestrodatabase.com/blog/medicare-generations-pass-up-health-insurance 2019-07-25T21:46:40 https://maestrodatabase.com/blog/hard-questions-as-scientists-and-governments-seek-covid-19-vaccines 2020-08-08T23:32:34 https://maestrodatabase.com/blog/viiv-healthcare-announces-us-fda-approval-of-triumeq-pd-the-first-dispersible-single-tablet-regimen-containing-dolutegravir-a-once-daily-treatment-for-children-living-with-hiv 2022-03-31T07:05:47 https://maestrodatabase.com/blog/trump-meets-with-pharma-executives-amid-drug-pricing-push 2019-07-25T21:39:57 https://maestrodatabase.com/blog/federal-health-minister-announces-new-treatment-options-for-children 2019-07-26T10:09:18 https://maestrodatabase.com/blog/first-vaccine-to-protect-adults-from-chikungunya 2024-06-01T04:26:29 https://maestrodatabase.com/blog/tears-of-joy-as-new-drug-ready-for-cystic-fibrosis-patient 2020-08-09T01:46:53 https://maestrodatabase.com/blog/fda-approves-feraccru-with-a-broad-label-of-treating-iron-deficiency-in-adults 2019-07-26T10:03:08 https://maestrodatabase.com/blog/innovative-treatment-for-gynaecological-cancers-approved-for-cancer-drugs-fund 2019-07-26T09:54:59 https://maestrodatabase.com/blog/fda-approves-fam-trastuzumab-deruxtecan-nxki-with-pertuzumab-for-unresectable-or-metastatic-her2-positive-breast-cancer 2025-12-15T20:02:40 https://maestrodatabase.com/blog/fda-grants-breakthrough-device-designation-status-for-hancock-jaffes-venovalve 2021-08-04T02:17:02 https://maestrodatabase.com/blog/matinas-biopharma-receives-qualified-infectious-disease-product-and-fast-track-designations-from-u-dot-s-fda-for-mat2203-for-the-treatment-of-cryptococcal-meningitis 2019-07-26T10:54:26 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-june-2024 2024-06-01T03:21:57 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-positive-chmp-opinion-recommending-approval-of-empliciti-elotuzumab-plus-pomalidomide-and-low-dose-dexamethasone-for-treatment-of-patients-with-relapsed-and-refractory-multiple-myeloma 2019-07-26T11:18:34 https://maestrodatabase.com/blog/surrogate-endpoints-in-randomised-controlled-trials-a-reality-check 2019-07-26T11:09:52 https://maestrodatabase.com/blog/cancer-is-capsizing-americans-finances-i-was-losing-everything-dot 2024-06-01T05:02:18 https://maestrodatabase.com/blog/breakthrough-drugs-raise-worries-over-higher-costs 2019-07-26T11:03:32 https://maestrodatabase.com/blog/new-gene-therapy-treatment-for-haemophilia-b 2024-06-01T04:43:09 https://maestrodatabase.com/blog/medicare-paid-for-medicines-that-three-other-wealthy-nations-decided-had-little-value 2019-07-26T11:23:43 https://maestrodatabase.com/blog/us-payers-struggle-to-keep-up-with-high-rate-of-fda-drug-approvals 2017-10-21T04:01:10 https://maestrodatabase.com/blog/february-2025-decisions 2025-02-10T21:47:49 https://maestrodatabase.com/blog/big-pharma-steps-up-push-for-taxpayer-funded-weight-loss-drugs 2025-02-10T04:05:34 https://maestrodatabase.com/blog/new-analysis-examines-role-of-conditional-approvals-on-access-to-promising-oncology-therapies 2024-06-01T05:19:03 https://maestrodatabase.com/blog/dupixent-recommended-for-eu-approval-by-the-chmp-to-treat-patients-with-copd 2024-06-02T04:22:56 https://maestrodatabase.com/blog/fda-regulation-and-approval-of-medical-devices-1976-2020 2021-08-04T03:57:10 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-treatment-for-advanced-retinitis-pigmentosa 2025-02-10T22:27:28 https://maestrodatabase.com/blog/abbvie-receives-positive-chmp-opinion-for-risankizumab-skyrizi-for-the-treatment-of-adults-with-moderately-to-severely-active-ulcerative-colitis 2024-06-02T04:16:21 https://maestrodatabase.com/blog/icer-publishes-evidence-report-on-treatment-for-acute-pain 2025-02-10T22:15:20 https://maestrodatabase.com/blog/statement-from-rare-disorders-nz-re-minister-littles-comments-on-pharmac-funding 2022-03-31T09:56:23 https://maestrodatabase.com/blog/rising-cancer-drug-costs-in-the-usa 2017-10-21T08:25:03 https://maestrodatabase.com/blog/tempest-granted-fast-track-designation-from-the-us-fda-for-amezalpat-to-treat-patients-with-hepatocellular-carcinoma 2025-02-10T23:14:32 https://maestrodatabase.com/blog/fda-releases-flurry-of-new-revised-drug-specific-guidance-documents 2017-10-21T08:31:47 https://maestrodatabase.com/blog/shingrix-approved-in-the-us-for-prevention-of-shingles-in-adults-aged-50-and-over 2017-10-21T08:36:23 https://maestrodatabase.com/blog/janssen-receives-two-u-dot-s-fda-approvals-for-simponi-aria-golimumab-for-the-treatment-of-adults-with-active-psoriatic-arthritis-or-active-ankylosing-spondylitis 2017-10-21T08:40:09 https://maestrodatabase.com/blog/nivolumab-and-ipilimumab-for-the-first-line-treatment-of-patients-with-metastatic-colorectal-cancer-with-high-microsatellite-instability-or-mismatch-repair-deficiency 2025-02-11T00:06:02 https://maestrodatabase.com/blog/biodexa-receives-us-fda-fast-track-designation-for-erapa-in-familial-adenomatous-polyposis 2025-02-10T23:38:21 https://maestrodatabase.com/blog/health-canada-authorises-polivy-polatuzumab-vedotin-for-the-first-line-treatment-of-adults-with-large-b-cell-lymphoma 2022-11-25T01:29:41 https://maestrodatabase.com/blog/nektar-therapeutics-receives-fast-track-designation-for-rezpegaldesleukin-for-the-treatment-of-moderate-to-severe-atopic-dermatitis 2025-02-10T23:26:46 https://maestrodatabase.com/blog/bayer-files-for-approval-of-extended-6-month-treatment-interval-for-eylea-8-mg-in-the-eu 2025-02-11T01:12:47 https://maestrodatabase.com/blog/gileads-breast-cancer-treatment-trodelvy-passes-drug-reimbursement-panel 2025-02-11T00:43:49 https://maestrodatabase.com/blog/novartis-receives-positive-chmp-opinion-for-lucentis-treatment-in-preterm-infants-with-retinopathy-of-prematurity-a-disease-causing-visual-impairment-and-blindness 2019-07-26T12:15:46 https://maestrodatabase.com/blog/australia-pledges-to-share-coronavirus-vaccine-pm 2020-08-09T20:58:39 https://maestrodatabase.com/blog/junshi-biosciences-announces-submission-of-a-marketing-authorisation-application-for-toripalimab-to-the-uk-mhra 2022-11-25T03:33:40 https://maestrodatabase.com/blog/interpreting-the-results-of-intention-to-treat-per-protocol-and-as-treated-analyses-of-clinical-trials 2021-08-04T04:43:55 https://maestrodatabase.com/blog/ensuring-access-to-emerging-covid-19-treatments-through-medicare-reimbursement-policy 2020-08-09T21:05:51 https://maestrodatabase.com/blog/immix-biopharma-receives-fda-regenerative-medicine-advanced-therapy-designation-for-nxc-201-sterically-optimised-car-t-for-relapsed-slash-refractory-al-amyloidosis 2025-02-11T03:15:02 https://maestrodatabase.com/blog/fda-reportedly-hopes-to-fully-approve-pfizers-covid-vaccine-by-labor-day 2021-08-04T04:52:05 https://maestrodatabase.com/blog/fda-accepts-alkermes-resubmission-of-new-drug-application-for-alks-3831 2020-12-29T21:58:27 https://maestrodatabase.com/blog/collecting-patient-reported-outcomes-in-cancer-clinical-trials 2021-08-04T04:57:34 https://maestrodatabase.com/blog/takeda-receives-positive-chmp-opinion-for-recombinant-adamts13-radamts13-in-congenital-thrombotic-thrombocytopenic-purpura 2024-06-02T21:08:49 https://maestrodatabase.com/blog/spectrum-pharmaceuticals-receives-complete-response-letter-from-us-food-and-drug-administration-for-poziotinib 2022-11-25T19:41:11 https://maestrodatabase.com/blog/linvoseltamab-bla-accepted-for-fda-review-for-the-treatment-of-relapsed-slash-refractory-multiple-myeloma 2025-02-11T22:15:53 https://maestrodatabase.com/blog/hugels-letybo-first-in-korea-to-obtain-marketing-approval-from-australia 2022-11-25T06:56:22 https://maestrodatabase.com/blog/new-drug-application-resubmission 2022-03-31T11:13:04 https://maestrodatabase.com/blog/weight-loss-and-diabetes-drugs-cost-more-in-the-us-than-in-other-countries-kff-analysis-finds 2023-08-19T21:58:15 https://maestrodatabase.com/blog/ono-receives-supplemental-approval-of-opdivo-nivolumab-for-adjuvant-treatment-of-urothelial-carcinoma-in-japan 2022-03-31T12:03:54 https://maestrodatabase.com/blog/kestra-medical-technologies-receives-fda-premarket-approval-for-assure-wearable-cardioverter-defibrillator 2021-08-04T05:13:21 https://maestrodatabase.com/blog/sentynl-therapeutics-announces-fda-acceptance-of-cutx-101-nda-resubmission 2025-12-15T23:36:04 https://maestrodatabase.com/blog/taiho-pharmaceutical-obtains-additional-indication-of-post-operative-adjuvant-chemotherapy-for-hormone-receptor-positive-and-her2-negative-breast-cancer-at-high-risk-of-recurrence-for-oral-anti-cancer-agent-ts-1 2022-11-25T20:12:42 https://maestrodatabase.com/blog/neurocrine-biosciences-announces-fda-approval-of-ingrezza-valbenazine-capsules-for-the-treatment-of-chorea-associated-with-huntingtons-disease 2023-08-19T11:50:04 https://maestrodatabase.com/blog/reform-of-the-orphan-drug-program---end-of-transition-arrangements 2018-06-07T02:24:12 https://maestrodatabase.com/blog/novavax-submits-request-to-expand-conditional-marketing-authorisation-of-covid-19-vaccine-in-the-european-union-to-adolescents-ages-12-17 2022-03-31T19:51:15 https://maestrodatabase.com/blog/canada-trails-us-in-patient-access-to-rare-disease-therapies-cord-president-says 2018-06-07T02:17:43 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule--1-april-2022 2022-03-31T19:42:47 https://maestrodatabase.com/blog/tecvayli-and-darzalex-faspro-combination-selected-for-commissioners-national-priority-voucher-pilot-program 2025-12-16T00:54:20 https://maestrodatabase.com/blog/bayer-receives-positive-chmp-opinion-for-precision-oncology-treatment-larotrectinib-with-first-ever-tumour-agnostic-indication-in-in-europe 2019-07-26T23:35:15 https://maestrodatabase.com/blog/fda-approves-mirdametinib-for-adult-and-pediatric-patients-with-neurofibromatosis-type-1-who-have-symptomatic-plexiform-neurofibromas-not-amenable-to-complete-resection 2025-02-11T22:52:51 https://maestrodatabase.com/blog/partner-therapeutics-announces-us-fda-approval-of-leukine-sargramostim-for-the-treatment-of-acute-radiation-syndrome 2018-06-07T02:29:57 https://maestrodatabase.com/blog/outlook-therapeutics-submits-biologics-license-application-to-the-u-dot-s-food-and-drug-administration-for-ons-5010-as-a-treatment-for-wet-amd 2022-03-31T19:37:14 https://maestrodatabase.com/blog/agenda-for-july-2022-pbac-meeting 2022-03-31T20:16:25 https://maestrodatabase.com/blog/ema-establishes-cancer-medicines-forum-with-academia-to-optimise-cancer-treatments-in-clinical-practice 2022-03-31T20:37:36 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-april-2022 2022-03-31T19:57:22 https://maestrodatabase.com/blog/us-fda-approves-lib-therapeutics-lerochol-lerodalcibep-liga-for-adults-with-elevated-ldl-cholesterol 2025-12-16T00:34:27 https://maestrodatabase.com/blog/fda-grants-rare-paediatric-disease-designation-to-cellectar-biosciences-clr-131-for-the-treatment-of-rhabdomyosarcoma 2018-06-07T03:03:06 https://maestrodatabase.com/blog/chugai-obtains-regulatory-approval-for-perjeta-and-herceptin-for-additional-indication-of-her2-positive-colorectal-cancer 2022-03-31T20:10:32 https://maestrodatabase.com/blog/us-fda-acknowledges-astellas-resubmission-of-biologics-license-application-for-zolbetuximab-and-sets-new-action-date 2024-06-02T22:50:08 https://maestrodatabase.com/blog/intra-cellular-therapies-initiates-rolling-submission-of-new-drug-application-for-lumateperone-for-treatment-of-schizophrenia 2018-06-07T03:12:49 https://maestrodatabase.com/blog/heart-drug-beyonttra-acoramidis-approved-in-eu-for-treatment-of-transthyretin-amyloidosis-in-adults-with-cardiomyopathy 2025-02-11T23:23:49 https://maestrodatabase.com/blog/genentech-submits-supplemental-biologics-license-application-to-the-fda-for-tecentriq-in-combination-with-avastin-for-the-most-common-form-of-liver-cancer 2020-01-28T01:52:46 https://maestrodatabase.com/blog/ema-celebrates-25-years-advancing-public-and-animal-health 2020-01-28T01:21:44 https://maestrodatabase.com/blog/biohaven-announces-fda-acceptance-and-priority-review-of-troriluzole-new-drug-application-for-the-treatment-of-spinocerebellar-ataxia 2025-02-11T23:50:13 https://maestrodatabase.com/blog/eyenovia-submits-new-drug-application-to-fda-for-pharmacologic-mydriasis-with-mydcombi-targeting-80-million-patient-encounters-in-the-u-dot-s-annually 2020-12-30T01:51:40 https://maestrodatabase.com/blog/health-canada-approves-new-indication-for-stelara-ustekinumab-for-the-treatment-of-adults-with-moderately-to-severely-active-ulcerative-colitis 2020-01-28T02:41:33 https://maestrodatabase.com/blog/zealand-pharma-announces-positive-chmp-opinion-for-dasiglucagon-for-treatment-of-severe-hypoglycemia-in-diabetes-from-european-medicines-agency 2024-06-03T00:12:39 https://maestrodatabase.com/blog/us-eyes-battle-with-drug-giants-over-10-costly-medications-for-seniors 2023-08-20T00:01:41 https://maestrodatabase.com/blog/turning-cms-into-a-health-technology-assessment-organisation 2023-08-19T23:49:01 https://maestrodatabase.com/blog/sanofi-provides-update-on-tolebrutinib-regulatory-submission-in-non-relapsing-secondary-progressive-multiple-sclerosis 2025-12-24T09:57:02 https://maestrodatabase.com/blog/mirum-pharmaceuticals-announces-positive-chmp-opinion-for-livmarli-maralixibat-oral-solution-for-the-treatment-of-pfic-in-patients-three-months-of-age-and-older 2024-06-02T23:56:57 https://maestrodatabase.com/blog/leo-pharma-submits-adolescent-label-expansion-application-for-anzupgo-to-ema 2025-12-16T03:46:48 https://maestrodatabase.com/blog/blue-shield-of-california-looks-to-cut-reliance-on-cvs-taps-amazon 2023-08-19T23:46:11 https://maestrodatabase.com/blog/cms-expands-coverage-of-next-generation-sequencing-as-a-diagnostic-tool-for-patients-with-breast-and-ovarian-cancer 2020-01-28T05:07:15 https://maestrodatabase.com/blog/us-fda-approves-only-triple-combination-tablet-with-jardiance-for-adults-with-type-2-diabetes 2020-01-28T02:53:31 https://maestrodatabase.com/blog/chugai-obtains-regulatory-approval-for-vabysmo-the-first-bispecific-antibody-in-ophthalmology-for-neovascular-age-related-macular-degeneration-and-diabetic-macular-oedema 2022-03-31T22:52:15 https://maestrodatabase.com/blog/the-right-to-try-law-says-yes-the-drug-company-says-no 2018-06-07T04:45:58 https://maestrodatabase.com/blog/novo-nordisk-files-for-eu-regulatory-approval-of-once-weekly-semaglutide-2-mg-for-the-treatment-of-type-2-diabetes-mellitus 2020-12-30T02:33:37 https://maestrodatabase.com/blog/expanded-access-to-cutting-edge-car-t-cell-therapy 2020-01-28T05:11:55 https://maestrodatabase.com/blog/zanidatamab-granted-priority-review-for-her2-positive-metastatic-biliary-tract-cancer 2024-06-03T00:23:08 https://maestrodatabase.com/blog/an-important-overview-of-the-pros-cons-and-questions-about-my-health-record 2018-06-07T05:16:35 https://maestrodatabase.com/blog/rapid-rise-in-anti-hiv-prep-pills-linked-to-drop-in-condom-use 2018-06-07T05:20:20 https://maestrodatabase.com/blog/liquidia-submits-new-drug-application-for-liq861-treprostinil-inhalation-powder-to-u-dot-s-fda-for-the-treatment-of-pulmonary-arterial-hypertension 2020-01-28T05:17:17 https://maestrodatabase.com/blog/the-icr-responds-to-decision-by-nice-not-to-recommend-abiraterone-as-first-line-treatment-for-advanced-prostate-cancer 2018-06-07T05:05:56 https://maestrodatabase.com/blog/historic-first-in-womens-sexual-health-fda-grants-approval-for-addyi-flibanserin-in-post-menopausal-women 2025-12-16T21:29:43 https://maestrodatabase.com/blog/teva-announces-austedo-xr-deutetrabenazine-extended-release-tablets-now-us-fda-approved-as-a-one-pill-once-daily-treatment-option-for-clinically-therapeutic-doses-24-mg-48-mg-slash-day 2024-06-03T01:34:26 https://maestrodatabase.com/blog/pharmac-funds-medicines-for-liver-ovarian-and-neuroendocrine-cancers 2025-02-12T01:15:36 https://maestrodatabase.com/blog/aldeyra-therapeutics-announces-pdufa-extension-of-the-new-drug-application-of-reproxalap-for-the-treatment-of-dry-eye-disease 2025-12-16T21:39:36 https://maestrodatabase.com/blog/takeda-pioneers-nices-new-service-for-economic-model-review 2018-06-07T12:33:32 https://maestrodatabase.com/blog/jubilant-radiopharma-receives-approval-from-health-canada-for-drax-exametazime 2020-01-28T06:15:30 https://maestrodatabase.com/blog/u-dot-s-fda-and-ema-accept-regulatory-submissions-for-review-of-tazaloparib-for-metastatic-breast-cancer-patients-with-an-inherited-brca-mutation 2018-06-07T21:16:12 https://maestrodatabase.com/blog/uk-health-spends-lags-behind-eu-peers 2018-06-07T12:37:51 https://maestrodatabase.com/blog/saphnelo-approved-in-the-eu-for-subcutaneous-self-administration-as-a-new-pre-filled-pen-for-systemic-lupus-erythematosus 2025-12-16T07:44:35 https://maestrodatabase.com/blog/new-collaboration-between-nice-and-the-academic-health-science-network-will-help-embed-innovations-into-the-healthcare-system-for-the-benefit-of-patients 2021-08-04T10:19:03 https://maestrodatabase.com/blog/icers-final-report-on-cftr-modulators-for-cystic-fibrosis-calls-for-manufacturer-restraint-and-increased-transparency-in-pricing-decisions 2018-06-07T21:37:40 https://maestrodatabase.com/blog/calliditas-partner-stada-receives-positive-chmp-opinion-recommending-full-approval-for-kinpeygo-for-the-treatment-of-iga-nephropathy 2024-06-03T02:13:38 https://maestrodatabase.com/blog/cerus-corporation-announces-cms-has-granted-new-technology-add-on-payment-for-intercept-fibrinogen-complex 2021-08-04T10:29:33 https://maestrodatabase.com/blog/pfizer-wins-appeal-against-ps84m-uk-fine-over-epilepsy-drug-price 2018-06-07T21:24:43 https://maestrodatabase.com/blog/public-hearing-on-quinolones-and-fluoroquinolones-23-speakers-from-11-eu-countries-to-share-experience 2018-06-07T21:29:42 https://maestrodatabase.com/blog/adagene-announces-fda-fast-track-designation-for-muzastotug-adg126 2025-12-16T23:12:20 https://maestrodatabase.com/blog/palvella-therapeutics-granted-fda-fast-track-designation-for-qtorin-3-dot-9-percent-rapamycin-anhydrous-gel-for-the-treatment-of-angiokeratomas 2025-12-16T23:18:25 https://maestrodatabase.com/blog/fda-approves-genentechs-rituxan-rituximab-for-pemphigus-vulgaris 2018-06-07T21:48:09 https://maestrodatabase.com/blog/project-orbis-quicker-access-to-promising-cancer-treatments 2024-06-03T03:01:58 https://maestrodatabase.com/blog/icer-publishes-final-evidence-report-on-treatments-for-obesity 2025-12-16T23:34:21 https://maestrodatabase.com/blog/factorial-clinical-trial-designs 2025-02-12T02:20:10 https://maestrodatabase.com/blog/updated-information-about-pharmacs-priority-lists-as-at-15-december-2025 2025-12-16T21:46:09 https://maestrodatabase.com/blog/agenda-for-25-october-tc-meeting 2017-10-21T23:19:10 https://maestrodatabase.com/blog/health-canada-approves-mercks-keytruda-pembrolizumab-for-the-treatment-of-adult-patients-with-resectable-stage-ii-iiia-or-iiib-t3-4n2-non-small-cell-lung-carcinoma-nsclc-in-combination-with-platinum-containing-chemotherapy-as-neo-adjuvant-treatment-and-then-continued-as-monotherapy-as-adjuvant-treatment-after-surgery 2025-02-12T02:04:07 https://maestrodatabase.com/blog/tris-pharma-receives-us-fda-approval-for-once-daily-onyda-xr-clonidine-hydrochloride-extended-release-oral-suspension-the-first-and-only-liquid-non-stimulant-adhd-medication 2024-06-03T03:34:31 https://maestrodatabase.com/blog/funding-trikafta-for-kiwis-with-cystic-fibrosis---setting-the-record-straight 2022-04-01T01:32:42 https://maestrodatabase.com/blog/pfizers-besponsa-takedas-zejula-likely-to-get-insurance-coverage 2019-07-27T21:29:47 https://maestrodatabase.com/blog/ganaxolone-for-the-treatment-of-patients-2-years-of-age-and-older-with-seizures-caused-by-cdkl5-deficiency-disorder 2025-02-12T02:34:38 https://maestrodatabase.com/blog/australian-study-evaluates-real-world-evidence-of-botox-to-prevent-migraine 2019-07-27T21:41:06 https://maestrodatabase.com/blog/stories-of-patient-involvement-impact-in-health-technology-assessments-a-discussion-paper 2019-07-27T21:37:41 https://maestrodatabase.com/blog/a-non-inferiority-framework-for-cost-effectiveness-analysis 2019-07-27T21:34:27 https://maestrodatabase.com/blog/fda-eliminates-major-barrier-to-using-real-world-evidence-in-drug-and-device-application-reviews 2025-12-17T00:06:37 https://maestrodatabase.com/blog/cancer-patients-to-benefit-from-subsidies-for-new-medicines 2019-07-28T09:55:36 https://maestrodatabase.com/blog/update-on-fda-priority-review-of-dupixent-dupilumab-for-the-treatment-of-copd-patients-with-type-2-inflammation 2024-06-03T04:49:52 https://maestrodatabase.com/blog/fda-approves-brentuximab-vedotin-with-lenalidomide-and-rituximab-for-relapsed-or-refractory-large-b-cell-lymphoma 2025-02-12T22:02:55 https://maestrodatabase.com/blog/ace-releases-latest-trance-of-drug-guidances-april-2022 2022-04-01T03:49:25 https://maestrodatabase.com/blog/exdensur-depemokimab-approved-by-us-fda-for-the-treatment-of-severe-asthma 2025-12-17T01:29:46 https://maestrodatabase.com/blog/federal-watchdog-will-review-the-controversial-fda-approval-of-biogens-alzheimers-drug 2021-08-04T21:01:58 https://maestrodatabase.com/blog/how-to-balance-the-patient-voice-atop-the-shifting-plates-of-hta 2021-08-04T21:33:21 https://maestrodatabase.com/blog/big-drug-purchasers-predict-price-hikes-driven-by-expensive-new-therapies 2020-01-28T09:24:49 https://maestrodatabase.com/blog/nasal-spray-medicine-for-treatment-resistant-depression-not-recommended-by-nice 2020-09-11T10:04:52 https://maestrodatabase.com/blog/court-topples-canadian-ruling-that-one-of-worlds-most-expensive-drugs-is-excessively-priced 2021-08-04T21:15:02 https://maestrodatabase.com/blog/new-car-t-cell-therapy-option-now-available-in-australia-for-patients-with-aggressive-blood-cancer 2021-08-04T21:07:01 https://maestrodatabase.com/blog/ecdc-and-ema-update-on-covid-19 2021-08-04T21:20:52 https://maestrodatabase.com/blog/johnson-and-johnson-submits-application-to-the-ema-seeking-approval-of-subcutaneous-formulation-of-rybrevant-amivantamab-for-the-treatment-of-patients-with-egfr-mutated-non-small-cell-lung-cancer 2024-06-03T05:51:55 https://maestrodatabase.com/blog/b-dot-c-family-nearing-finish-in-race-to-raise-2-dollars-8-cents-million-to-treat-babys-rare-disease 2020-08-10T05:38:17 https://maestrodatabase.com/blog/oncusp-therapeutics-receives-fda-fast-track-designation-for-cusp06-for-the-treatment-of-platinum-resistant-ovarian-cancer 2025-02-12T23:36:04 https://maestrodatabase.com/blog/vanda-announces-submission-of-biologics-license-application-to-the-fda-for-imsidolimab-for-the-treatment-of-generalised-pustular-psoriasis 2025-12-17T03:39:28 https://maestrodatabase.com/blog/fda-accepts-for-priority-review-dupixent-dupilumab-for-children-aged-6-to-11-years-with-moderate-to-severe-atopic-dermatitis 2020-01-28T11:07:58 https://maestrodatabase.com/blog/tagrisso-with-the-addition-of-chemotherapy-recommended-for-approval-in-the-eu-by-chmp-for-patients-with-egfr-mutated-advanced-lung-cancer 2024-06-03T06:25:24 https://maestrodatabase.com/blog/cti-biopharma-receives-results-of-the-chmp-oral-explanation-for-pacritinib-in-the-treatment-of-myelofibrosis-and-provides-development-update 2019-02-02T11:28:02 https://maestrodatabase.com/blog/public-summary-documents---december-2021-pbac-meeting 2022-04-01T04:41:43 https://maestrodatabase.com/blog/wegovy-semaglutide-injection-receives-conditional-marketing-authorisation-from-health-canada-as-the-first-and-only-treatment-for-adults-with-non-cirrhotic-mash-a-serious-liver-disease 2025-12-17T06:29:38 https://maestrodatabase.com/blog/lundbecks-potential-treatment-amlenetug-for-multiple-system-atrophy-receives-fast-track-designation-from-the-fda 2025-02-12T23:47:35 https://maestrodatabase.com/blog/will-the-fda-add-suffixes-to-approved-biologics-names 2017-10-22T02:00:52 https://maestrodatabase.com/blog/us-fda-approves-expanded-label-for-astellas-izervay-avacincaptad-pegol-intravitreal-solution-for-geographic-atrophy 2025-02-13T01:17:01 https://maestrodatabase.com/blog/nkgen-biotech-receives-us-fda-fast-track-designation-for-troculeucel-for-the-treatment-of-moderate-alzheimers-disease 2025-02-13T00:52:38 https://maestrodatabase.com/blog/its-the-insulin-stupid-how-drug-pricings-simplest-case-study-became-a-top-issue-for-2020-democrats 2020-01-28T11:20:21 https://maestrodatabase.com/blog/fda-grants-regular-approval-to-rucaparib-for-metastatic-castration-resistant-prostate-cancer 2025-12-17T20:11:42 https://maestrodatabase.com/blog/selpercatinib-for-the-treatment-of-patients-with-advanced-thyroid-cancer-with-a-ret-alteration-after-treatment-with-a-targeted-cancer-medicine-final-guidance 2025-02-13T02:01:42 https://maestrodatabase.com/blog/stephen-hahn-md-fda-chief-is-caught-between-scientists-and-the-president 2020-08-10T10:00:54 https://maestrodatabase.com/blog/australian-start-ups-push-for-bigger-role-in-vaccine-making 2020-08-10T10:08:35 https://maestrodatabase.com/blog/fda-continues-strong-support-of-innovation-in-development-of-gene-therapy-products 2020-01-28T19:44:17 https://maestrodatabase.com/blog/olaparib-for-the-treatment-of-patients-with-advanced-brca-mutation-positive-her2-negative-breast-cancer-after-chemotherapy 2025-02-13T02:47:43 https://maestrodatabase.com/blog/aquestive-therapeutics-receives-fda-fast-track-designation-for-aqst-108-sublingual-film-formulation-delivering-systemic-epinephrine-for-treatment-of-allergic-reactions-including-anaphylaxis 2020-08-10T21:09:38 https://maestrodatabase.com/blog/nice-joins-international-collaboration-on-hta-methods-research 2025-02-13T02:45:12 https://maestrodatabase.com/blog/alkermes-announces-u-dot-s-fda-acceptance-of-alks-3831-new-drug-application-for-treatment-of-schizophrenia-and-bipolar-i-disorder 2020-01-28T19:50:12 https://maestrodatabase.com/blog/return-some-excess-drug-revenues-to-employers-clhia-says-in-submission-to-pmprb 2020-08-10T21:17:31 https://maestrodatabase.com/blog/coming-of-age-emerging-health-preference-research-based-on-established-scientific-standards 2020-08-10T21:21:43 https://maestrodatabase.com/blog/communication-at-ema 2020-08-10T20:52:05 https://maestrodatabase.com/blog/selpercatinib-for-the-treatment-of-patients-with-advanced-thyroid-cancer-with-a-ret-alteration-untreated-with-a-targeted-cancer-medicine 2025-02-13T02:37:29 https://maestrodatabase.com/blog/icer-to-assess-treatments-for-lupus-nephritis 2020-08-10T20:54:02 https://maestrodatabase.com/blog/mallinckrodt-announces-u-dot-s-fda-filing-acceptance-of-biologics-license-application-for-stratagraft-regenerative-skin-tissue-for-treatment-of-adults-with-deep-partial-thickness-thermal-burns 2020-08-10T21:03:47 https://maestrodatabase.com/blog/smc---august-2020-decisions 2020-08-10T21:50:51 https://maestrodatabase.com/blog/can-multi-criteria-decision-analysis-be-implemented-into-real-world-drug-decision-making-processes-a-canadian-provincial-experience 2020-08-10T21:53:35 https://maestrodatabase.com/blog/gilead-submits-new-drug-application-to-u-dot-s-food-and-drug-administration-for-veklury-remdesivir-for-the-treatment-of-covid-19 2020-08-10T21:25:43 https://maestrodatabase.com/blog/coronavirus-cancer-patients-urgent-plea-for-treatment-in-new-zealand 2020-08-10T21:39:16 https://maestrodatabase.com/blog/fda-approves-roches-evrysdi-tablet-as-first-and-only-tablet-for-spinal-muscular-atrophy 2025-02-13T20:41:17 https://maestrodatabase.com/blog/new-pharmacy-agreement-delivers-cheaper-medicines 2024-06-03T21:18:51 https://maestrodatabase.com/blog/medical-imaging-agent-gozetotide-approved-for-diagnosis-of-prostate-cancer 2025-02-13T22:09:39 https://maestrodatabase.com/blog/bavarian-nordic-submits-supplemental-bla-seeking-us-fda-approval-of-freeze-dried-formulation-of-smallpox-and-mpox-vaccine 2024-06-03T22:03:41 https://maestrodatabase.com/blog/biogen-receives-european-commission-approval-for-qalsody-tofersen-the-first-therapy-to-treat-a-rare-genetic-form-of-als 2024-06-03T21:43:34 https://maestrodatabase.com/blog/gsk-canada-submits-respiratory-syncytial-virus-vaccine-candidate-for-regulatory-review 2022-11-26T05:15:52 https://maestrodatabase.com/blog/astrazenecas-covid-19-vaccine-authorised-for-emergency-supply-in-the-uk 2020-12-30T07:55:03 https://maestrodatabase.com/blog/lymphoma-patients-to-benefit-from-new-cancer-therapy 2021-08-05T01:48:59 https://maestrodatabase.com/blog/keytruda-gets-expanded-coverage-for-11-indications-at-cancer-disease-panel 2025-02-13T22:51:18 https://maestrodatabase.com/blog/health-canada-approves-arazlo-lotion-for-acne-vulgaris-treatment 2021-08-05T01:42:19 https://maestrodatabase.com/blog/decision-to-fund-denosumab-for-osteoporosis 2018-06-08T03:57:19 https://maestrodatabase.com/blog/allergans-restatis-multidose-cyclosporin-0-dot-05-percent-ophthalmic-emulsion-approved-in-canada 2018-06-08T03:51:37 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-to-pleopharmas-investigational-new-drug-pp-01-for-the-mitigation-of-cannabis-withdrawal-symptoms-in-patients-with-cannabis-use-disorder-a-potential-first-in-class-treatment 2025-02-13T23:12:54 https://maestrodatabase.com/blog/large-pbms-should-mean-lower-drug-prices 2018-06-08T05:33:25 https://maestrodatabase.com/blog/paediatric-rare-disease-drug-qarziba-gets-green-light-for-coverage 2024-06-03T23:08:01 https://maestrodatabase.com/blog/ombudsman-report-on-bupa-highlights-regional-divide 2018-06-08T12:13:21 https://maestrodatabase.com/blog/reata-pharmaceuticals-completes-rolling-submission-of-new-drug-application-for-omaveloxolone-for-the-treatment-of-patients-with-friedreichs-ataxia 2022-04-01T07:55:27 https://maestrodatabase.com/blog/lupus-drug-will-be-game-changer 2021-08-05T02:42:09 https://maestrodatabase.com/blog/thousands-of-people-set-to-benefit-from-first-new-treatment-for-osteoporosis-for-over-a-decade 2022-04-01T20:11:39 https://maestrodatabase.com/blog/osmotica-pharmaceuticals-receives-complete-response-letter-from-u-dot-s-food-and-drug-administration-for-arbaclofen-extended-release-tablets 2020-12-30T09:36:14 https://maestrodatabase.com/blog/making-medicines-more-affordable-for-more-australians 2022-04-01T11:31:08 https://maestrodatabase.com/blog/price-slashed-for-revolutionary-78-000-dollars-a-year-prostate-cancer-treatment-lynparza 2022-04-01T19:54:27 https://maestrodatabase.com/blog/merck-provides-update-on-fda-review-of-supplemental-biologics-license-application-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-use-in-infants-and-children 2022-04-01T21:09:41 https://maestrodatabase.com/blog/tlv-is-reviewing-the-subsidy-of-factor-viii-drugs-with-side-agreements 2020-01-28T23:44:36 https://maestrodatabase.com/blog/fda-approves-axicabtagene-ciloleucel-for-second-line-treatment-of-large-b-cell-lymphoma 2022-04-01T21:31:57 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-5-august-2021 2021-08-05T07:49:15 https://maestrodatabase.com/blog/viiv-healthcare-and-the-pan-canadian-pharmaceutical-alliance-successfully-finalise-negotiations-for-apretude-for-hiv-1-pre-exposure-prophylaxis 2025-02-14T01:48:25 https://maestrodatabase.com/blog/mt-3921-granted-fda-fast-track-designation-for-treatment-of-spinal-cord-injury 2021-08-05T08:24:25 https://maestrodatabase.com/blog/health-canada-approves-new-indication-for-invokana-canagliflozin-to-reduce-the-risks-associated-with-diabetic-kidney-disease-in-patients-with-type-2-diabetes 2020-01-29T02:43:57 https://maestrodatabase.com/blog/novartis-receives-health-canada-approval-for-fabhalta-oral-treatment-for-adult-patients-with-paroxysmal-nocturnal-haemoglobinuria 2025-02-14T01:41:11 https://maestrodatabase.com/blog/b-dot-c-eye-injection-program-clouded-in-secrecy 2020-01-29T02:41:21 https://maestrodatabase.com/blog/y-mabs-announces-submission-of-omburtamab-biologics-license-application-to-fda 2022-04-02T03:31:32 https://maestrodatabase.com/blog/national-to-roll-back-free-prescription-fees-to-pay-for-13-cancer-treatments 2023-08-21T05:54:24 https://maestrodatabase.com/blog/new-drug-application-for-penpulimab-monoclonal-antibody-pd-1-for-third-line-treatment-of-metastatic-nasopharyngeal-carcinoma-accepted-by-nmpa 2021-08-05T09:49:01 https://maestrodatabase.com/blog/chiesi-global-rare-diseases-announces-health-canada-approval-of-elfabrio-pegunigalsidase-alfa-for-fabry-disease 2025-12-18T01:04:15 https://maestrodatabase.com/blog/children-in-the-uk-are-having-their-lives-saved-by-a-new-meningococcal-b-vaccine-our-government-wont-fund 2019-07-29T01:59:38 https://maestrodatabase.com/blog/european-commission-approves-csls-andembry-garadacimab-for-the-prevention-of-recurrent-attacks-of-hereditary-angioedema 2025-02-14T05:56:29 https://maestrodatabase.com/blog/junshi-biosciences-announces-inclusion-of-toripalimab-in-the-china-national-reimbursement-drug-list 2020-12-30T11:03:22 https://maestrodatabase.com/blog/roche-receives-chmp-positive-opinion-for-new-tecentriq-based-combination-therapy-as-an-initial-treatment-for-most-common-form-of-advanced-lung-cancer 2019-07-29T01:53:34 https://maestrodatabase.com/blog/treasury-wanted-labour-to-break-all-health-election-promises-bar-one 2021-08-05T09:58:38 https://maestrodatabase.com/blog/beigene-announces-inclusion-of-three-innovative-oncology-products-in-china-national-reimbursement-drug-list 2020-12-30T11:12:19 https://maestrodatabase.com/blog/g1-therapeutics-granted-new-technology-add-on-payment-for-cosela-trilaciclib-by-cms 2021-08-05T08:34:15 https://maestrodatabase.com/blog/abbvie-announces-u-dot-s-fda-approval-of-venclexta-venetoclax-tablets-in-combination-with-rituximab-as-a-fixed-duration-treatment-for-chronic-lymphocytic-leukaemia-or-small-lymphocytic-lymphoma-patients-who-have-received-one-prior-therapy 2018-06-09T01:04:21 https://maestrodatabase.com/blog/platelet-rich-plasma-treatment-is-not-classified-as-a-drug-health-canada-says 2019-07-29T02:25:12 https://maestrodatabase.com/blog/chmp-recommends-eu-approval-of-roches-tecentriq-in-combination-with-chemotherapy-as-an-initial-treatment-of-adults-with-extensive-stage-small-cell-lung-cancer 2019-07-29T02:02:54 https://maestrodatabase.com/blog/from-our-perspective-fda-approval-demonstrates-the-role-of-real-world-evidence-in-regulatory-decision-making-on-drug-effectiveness 2021-08-05T09:03:40 https://maestrodatabase.com/blog/lib-therapeutics-announces-fda-acceptance-of-biologics-license-application-for-lerodalcibep-to-lower-ldl-cholesterol-across-broad-patient-population 2025-02-14T03:52:51 https://maestrodatabase.com/blog/alnylam-announces-health-canada-approval-of-amvuttra-vutrisiran-the-first-and-only-rnai-therapeutic-for-the-treatment-of-cardiomyopathy-in-adult-patients-with-attr-amyloidosis 2025-12-18T02:02:42 https://maestrodatabase.com/blog/easier-drug-approval-isnt-cutting-drug-prices 2018-06-09T01:25:13 https://maestrodatabase.com/blog/pillar-biosciences-receives-premarket-approval-from-fda-for-its-oncoreveal-dx-lung-and-colon-cancer-assay 2021-08-05T20:54:56 https://maestrodatabase.com/blog/califf-admits-controversy-over-fdas-alzheimers-drug-decision-impacted-experts-trust-in-the-agency 2022-04-02T04:15:38 https://maestrodatabase.com/blog/bristol-myers-squibb-statement-on-opdivo-nivolumab-small-cell-lung-cancer-u-dot-s-indication 2020-12-30T19:50:47 https://maestrodatabase.com/blog/two-weeks-after-trump-unveiled-plan-to-lower-drug-prices-two-cancer-drugs-got-a-1-000-dollars-slash-month-price-hike 2018-06-09T01:27:55 https://maestrodatabase.com/blog/tiered-drug-pricing-policy-widens-price-difference-among-generic-drugs 2020-12-30T20:02:59 https://maestrodatabase.com/blog/exelixis-announces-u-dot-s-fda-accepts-for-priority-review-the-supplemental-new-drug-application-for-cabometyx-cabozantinib-for-patients-with-previously-treated-radioactive-iodine-refractory-differentiated-thyroid-cancer 2021-08-05T21:01:25 https://maestrodatabase.com/blog/trump-administration-wont-defend-aca-in-case-brought-by-gop-states 2018-06-09T01:16:03 https://maestrodatabase.com/blog/patients-get-antsy-amid-protracted-price-bargaining-for-spinraza-evrysdi 2023-08-21T08:43:01 https://maestrodatabase.com/blog/icer-publishes-final-evidence-report-and-policy-recommendations-on-aducanumab-for-alzheimers-disease 2021-08-05T12:09:09 https://maestrodatabase.com/blog/european-commission-approves-reduced-dosing-frequency-for-janssens-bispecific-antibody-tecvayli-teclistamab 2023-08-21T08:17:55 https://maestrodatabase.com/blog/zai-lab-announces-inclusion-of-zejula-niraparib-in-chinas-national-reimbursement-drug-list 2020-12-30T19:45:36 https://maestrodatabase.com/blog/fda-approves-vimseltinib-for-symptomatic-tenosynovial-giant-cell-tumour 2025-02-14T23:12:10 https://maestrodatabase.com/blog/eiger-announces-fda-breakthrough-therapy-designation-for-avexitide-for-treatment-of-congenital-hyperinsulinism 2021-08-05T12:17:47 https://maestrodatabase.com/blog/u-dot-s-health-care-system-ranks-last-among-11-high-income-countries-researchers-say 2021-08-05T21:19:09 https://maestrodatabase.com/blog/pfizer-epilepsy-drug-prices-were-unfairly-high-uk-review-finds 2021-08-05T21:11:27 https://maestrodatabase.com/blog/canadian-agency-loses-a-battle-in-effort-to-force-a-drug-maker-to-lower-excessive-pricing 2021-08-05T21:24:24 https://maestrodatabase.com/blog/rfp---supply-of-fluticasone-and-fluticasone-with-salmeterol-metered-dose-inhalers 2019-07-29T03:29:51 https://maestrodatabase.com/blog/clinical-trial-design-and-dissemination-comprehensive-analysis-of-clinicaltrials-dot-gov-and-pubmed-data-since-2005 2018-06-09T03:07:01 https://maestrodatabase.com/blog/teva-announces-fda-approval-of-ajovy-fremanezumab-vfrm-injection-auto-injector 2020-01-29T03:43:12 https://maestrodatabase.com/blog/fda-approves-first-rapid-acting-insulin-biosimilar-product-for-treatment-of-diabetes 2025-02-14T23:42:00 https://maestrodatabase.com/blog/janssen-receives-chmp-positive-opinion-for-stelara-ustekinumab-recommending-approval-for-the-treatment-of-moderately-to-severely-active-ulcerative-colitis-in-the-eu 2019-07-29T03:38:59 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac-july-2023 2023-08-21T12:13:32 https://maestrodatabase.com/blog/bernie-sanders-goes-to-canada-to-make-a-point-about-drug-prices 2019-07-29T03:37:15 https://maestrodatabase.com/blog/national-would-establish-a-national-cancer-agency---but-government-says-new-anti-cancer-measures-are-already-being-finalised 2019-07-29T03:34:19 https://maestrodatabase.com/blog/fda-approves-amivantamab-and-hyaluronidase-lpuj-for-subcutaneous-injection 2025-12-18T19:40:16 https://maestrodatabase.com/blog/fdas-sharpless-outlines-fdas-4-top-priorities-tech-hiring-modernisation-and-increased-safety 2019-07-29T03:49:13 https://maestrodatabase.com/blog/innovent-announces-the-nmpa-approval-of-sintbilo-tafolecimab-injection-for-the-treatment-of-adult-patients-with-primary-hypercholesterolaemia-and-mixed-dyslipidaemia 2023-08-21T10:54:15 https://maestrodatabase.com/blog/harms-from-uninformative-clinical-trials 2019-07-29T03:46:45 https://maestrodatabase.com/blog/novo-nordisk-files-for-fda-approval-of-cagrisema-the-first-onceweekly-combination-of-glp-1-and-amylin-analogues-for-weight-management 2025-12-18T19:48:16 https://maestrodatabase.com/blog/fda-approves-first-vaccine-for-pregnant-individuals-to-prevent-rsv-in-infants 2023-08-21T22:25:46 https://maestrodatabase.com/blog/datroway-type-ii-variation-application-validated-in-the-eu-as-first-line-treatment-for-patients-with-metastatic-triple-negative-breast-cancer-who-are-not-candidates-for-immunotherapy 2025-12-18T08:20:15 https://maestrodatabase.com/blog/geron-announces-fda-acceptance-of-new-drug-application-for-imetelstat-for-the-treatment-of-lower-risk-mds 2023-08-21T19:57:21 https://maestrodatabase.com/blog/icer-publishes-final-evidence-report-on-gene-therapies-for-sickle-cell-disease 2023-08-21T12:17:19 https://maestrodatabase.com/blog/erenumab-in-migraine-indication-of-a-significant-added-benefit-for-certain-patients 2019-02-03T04:39:15 https://maestrodatabase.com/blog/alkindi-approved-in-australia 2020-08-11T02:15:52 https://maestrodatabase.com/blog/cms-issues-draft-guidance-on-new-program-to-allow-people-with-medicare-to-pay-out-of-pocket-prescription-drug-costs-in-monthly-payments 2023-08-22T06:09:34 https://maestrodatabase.com/blog/update-on-rolling-review-of-astrazenecas-covid-19-vaccine 2020-12-30T21:06:47 https://maestrodatabase.com/blog/pfizer-receives-positive-chmp-opinion-for-vizimpro-dacomitinib-for-the-first-line-treatment-of-adult-patients-with-locally-advanced-or-metastatic-non-small-cell-lung-cancer-with-egfr-activating-mutations 2019-02-03T04:49:58 https://maestrodatabase.com/blog/swiss-drug-review-times-trail-fda-and-ema-increased-due-to-covid 2023-08-22T05:26:17 https://maestrodatabase.com/blog/suggestions-nats-cancer-drug-funding-promise-has-put-pharmac-in-a-difficult-position 2023-08-22T05:53:54 https://maestrodatabase.com/blog/european-commission-approves-csl-and-arcturus-therapeutics-kostaive-the-first-self-amplifying-mrna-covid-19-vaccine 2025-02-15T05:39:29 https://maestrodatabase.com/blog/highlights-from-the-chmp-28-31-january-2019-meeting 2019-02-03T04:46:45 https://maestrodatabase.com/blog/is-this-the-year-the-ama-finally-joins-the-single-payer-movement 2018-06-09T23:22:13 https://maestrodatabase.com/blog/gw-pharmaceuticals-receives-positive-chmp-opinion-for-epidyolex-cannabidiol-oral-solution-for-the-treatment-of-seizures-in-patients-with-two-rare-severe-forms-of-childhood-onset-epilepsy 2019-07-29T05:01:59 https://maestrodatabase.com/blog/high-cost-of-prescription-drugs-equals-age-discrimination-on-steroids 2020-01-29T10:53:08 https://maestrodatabase.com/blog/dupixent-revolutionary-atopic-dermatitis-drug-to-end-lack-of-fundamental-treatment 2020-01-29T08:19:46 https://maestrodatabase.com/blog/krystal-biotech-announces-sale-of-priority-review-voucher-for-100-dollars-million 2023-08-22T07:40:10 https://maestrodatabase.com/blog/key-principles-for-the-use-of-electronic-product-information-for-eu-medicines 2020-01-29T20:02:01 https://maestrodatabase.com/blog/lilly-receives-fda-priority-review-for-the-selpercatinib-new-drug-application 2020-01-29T12:03:17 https://maestrodatabase.com/blog/lonsurf-trifluridine-slash-tipiracil-receives-positive-opinion-from-chmp-in-the-eu-for-patients-with-previously-treated-metastatic-gastric-cancer 2019-07-29T05:12:28 https://maestrodatabase.com/blog/the-fda-wants-to-know-how-instagram-influencers-sway-patient-views-on-medicines 2020-01-29T11:14:17 https://maestrodatabase.com/blog/janssen-announces-european-commission-approval-for-expanded-use-of-erleada-apalutamide-for-treatment-of-patients-with-metastatic-hormone-sensitive-prostate-cancer 2020-01-29T20:07:38 https://maestrodatabase.com/blog/cancer-patients-facing-delays-in-getting-innovative-drugs 2020-01-29T20:05:22 https://maestrodatabase.com/blog/drug-prices-to-skyrocket-with-new-health-insurance-company-policy-according-to-coalition-of-state-rheumatology-organizations 2020-01-29T20:21:31 https://maestrodatabase.com/blog/multi-criteria-decision-analysis-for-health-technology-assessment-addressing-methodological-challenges-to-improve-the-state-of-the-art 2019-07-29T05:25:59 https://maestrodatabase.com/blog/with-new-rules-fda-aims-to-spark-competition-lower-prices-for-expensive-gene-therapies 2020-01-29T20:18:12 https://maestrodatabase.com/blog/efanesoctocog-alfa-approved-to-prevent-and-treat-bleeding-in-children-and-adults-with-severe-or-moderate-haemophilia-a 2025-02-15T10:25:39 https://maestrodatabase.com/blog/monoferric-ferric-derisomaltose-injection-is-approved-by-the-fda-in-the-us-for-the-treatment-of-iron-deficiency-anaemia 2020-01-29T20:43:08 https://maestrodatabase.com/blog/penmenvy-gsks-5-in-1-meningococcal-vaccine-approved-by-us-fda-to-help-protect-against-menabcwy 2025-02-15T23:51:09 https://maestrodatabase.com/blog/fda-launches-mobile-friendly-database-with-information-on-life-saving-hiv-drugs-as-part-of-ongoing-mission-to-empower-the-public-through-increased-access-to-information-and-data 2020-01-29T20:38:04 https://maestrodatabase.com/blog/documents-disclosed-to-the-ema-as-part-of-an-ma-application-process-are-not-presumed-to-be-confidential 2020-01-29T20:31:15 https://maestrodatabase.com/blog/the-cruellest-tax-clipping-the-ticket-on-unfunded-cancer-drugs 2022-11-27T19:49:54 https://maestrodatabase.com/blog/cost-of-life-saving-heart-disease-drugs-slashed-saving-patients-thousands 2022-11-27T20:06:52 https://maestrodatabase.com/blog/1-dollars-a-day-for-half-your-life-the-cost-of-contraception-is-a-bitter-pill-to-swallow 2023-08-23T04:19:20 https://maestrodatabase.com/blog/enhertu-approved-in-japan-as-first-her2-directed-therapy-for-patients-with-her2-mutant-metastatic-non-small-cell-lung-cancer 2023-08-23T14:41:46 https://maestrodatabase.com/blog/futility-in-clinical-trials 2023-08-23T04:13:06 https://maestrodatabase.com/blog/boehringer-latest-to-sue-us-over-drug-price-negotiation-plan 2023-08-22T12:58:33 https://maestrodatabase.com/blog/cdc-pharmacies-try-to-speed-up-covid-vaccine-program-for-the-uninsured 2023-08-22T13:02:18 https://maestrodatabase.com/blog/pharmac-confirms-transition-to-a-trastuzumab-biosimilar-and-widens-access-to-other-types-of-cancer 2023-08-23T15:06:39 https://maestrodatabase.com/blog/new-prostate-cancer-treatment-helping-patients-live-longer-better 2022-11-27T20:18:49 https://maestrodatabase.com/blog/dupilumab-for-the-treatment-of-patients-with-prurigo-nodularis 2023-08-23T14:59:33 https://maestrodatabase.com/blog/updates-to-the-health-technology-assessment-policy-and-methods-review-including-consultation-1-responses-published 2023-08-23T14:47:42 https://maestrodatabase.com/blog/mounjaro-is-second-obesity-drug-to-be-approved-for-use-in-england 2024-06-04T21:02:02 https://maestrodatabase.com/blog/high-demand-of-popular-obesity-drug-saxenda-may-be-going-to-wrong-patients 2022-11-27T20:14:06 https://maestrodatabase.com/blog/fda-grants-priority-review-for-xtandi-in-non-metastatic-castration-sensitive-prostate-cancer-with-high-risk-biochemical-recurrence 2023-08-23T14:52:08 https://maestrodatabase.com/blog/geron-announces-pdufa-date-for-imetelstat-nda-in-lower-risk-mds 2023-08-23T23:27:51 https://maestrodatabase.com/blog/would-a-single-payer-system-require-painful-sacrifices-from-doctors 2018-06-10T10:44:33 https://maestrodatabase.com/blog/fda-approves-samsung-bioepis-ospomyv-xbryk-denosumab-dssb-a-biosimilar-to-prolia-and-xgeva 2025-02-16T06:04:24 https://maestrodatabase.com/blog/understanding-the-rewards-of-successful-drug-development----thinking-inside-the-box 2020-01-29T23:33:45 https://maestrodatabase.com/blog/taxpayer-funded-drugs-too-expensive-for-patients 2017-10-23T01:54:48 https://maestrodatabase.com/blog/european-medicines-agency-validates-kites-marketing-application-for-companys-second-car-t-cell-therapy 2020-01-29T23:15:16 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-european-commission-approval-for-opdivo-nivolumab-as-an-adjuvant-treatment-for-patients-with-completely-resected-stage-iib-or-iic-melanoma 2023-08-23T16:59:20 https://maestrodatabase.com/blog/britain-approves-astrazenecas-covid-19-jab 2020-12-31T00:46:46 https://maestrodatabase.com/blog/cheaper-health-plans-promoted-by-trump-have-a-history-of-fraud 2017-10-23T01:51:30 https://maestrodatabase.com/blog/galdermas-nemluvio-nemolizumab-approved-in-the-european-union-for-moderate-to-severe-atopic-dermatitis-and-prurigo-nodularis 2025-02-16T21:20:14 https://maestrodatabase.com/blog/european-commission-approves-egetis-emcitate-tiratricol-as-the-first-and-only-treatment-for-patients-with-mct8-deficiency 2025-02-16T21:08:23 https://maestrodatabase.com/blog/cstone-announces-european-medicine-agency-chmp-recommends-approval-of-cejemly-sugemalimab-anti-pd-l1-as-first-line-treatment-for-nsclc 2024-06-04T23:32:44 https://maestrodatabase.com/blog/proposal-for-new-calcineurin-inhibitor-listings-on-the-pharmaceutical-schedule 2020-08-11T05:05:30 https://maestrodatabase.com/blog/comanche-biopharma-receives-us-fda-fast-track-designation-for-cbp-4888-for-the-treatment-of-sflt-1-mediated-pre-term-preeclampsia 2023-08-23T23:39:02 https://maestrodatabase.com/blog/health-canada-authorises-tnkase-tenecteplase-for-the-treatment-of-acute-ischaemic-stroke 2025-12-19T01:38:25 https://maestrodatabase.com/blog/repare-therapeutics-announces-fast-track-designation-granted-by-the-fda-for-lunresertib-in-combination-with-camonsertib-for-the-treatment-of-platinum-resistant-ovarian-cancer 2024-06-04T23:09:23 https://maestrodatabase.com/blog/tetra-bio-pharma-files-new-drug-submission-for-reduvo-in-canada 2020-12-31T04:30:33 https://maestrodatabase.com/blog/teva-receives-positive-chmp-opinion-for-ajovy-fremanezumab-for-the-prophylaxis-of-migraine-in-adults 2019-02-03T09:51:47 https://maestrodatabase.com/blog/altoida-awarded-fda-breakthrough-designation-for-development-of-worlds-first-precision-neurology-device-for-prediction-of-alzheimers-disease 2021-08-06T01:19:42 https://maestrodatabase.com/blog/takedas-zejula-poised-to-change-local-ovarian-cancer-treatment-market 2019-07-29T09:29:08 https://maestrodatabase.com/blog/trump-administration-pressures-congress-to-lower-medicare-drug-prices-by-ending-industrys-backdoor-deals 2019-02-03T10:07:08 https://maestrodatabase.com/blog/beone-medicines-granted-us-fda-fast-track-designation-for-bgb-b2033-as-treatment-for-hepatocellular-carcinoma 2025-12-19T00:57:00 https://maestrodatabase.com/blog/iterum-therapeutics-receives-fda-acceptance-of-resubmission-of-nda-for-oral-sulopenem-for-the-treatment-of-uncomplicated-urinary-tract-infections 2024-06-04T23:42:10 https://maestrodatabase.com/blog/world-leading-breast-cancer-expert-calls-on-pharmac-to-make-two-new-breast-cancer-drugs-more-affordable 2019-02-03T10:01:11 https://maestrodatabase.com/blog/rheumatoid-arthritis-few-indications-of-the-benefits-of-certain-biologics-over-others 2018-06-11T01:34:33 https://maestrodatabase.com/blog/bavarian-nordic-receives-us-fda-approval-of-chikungunya-vaccine-for-persons-aged-12-and-older 2025-02-16T22:15:24 https://maestrodatabase.com/blog/pmprb-report-reveals-most-new-medicines-come-to-market-with-high-treatment-costs 2023-08-24T04:39:46 https://maestrodatabase.com/blog/rinvoq-upadacitinib-now-available-for-paediatric-patients-two-years-and-older-with-polyarticular-juvenile-idiopathic-arthritis-and-psoriatic-arthritis 2024-06-05T01:09:18 https://maestrodatabase.com/blog/sangamo-therapeutics-initiates-rolling-submission-of-bla-to-us-fda-for-st-920-in-fabry-disease 2025-12-19T04:12:03 https://maestrodatabase.com/blog/formycon-and-bioeq-announce-submission-of-the-biologics-license-application-for-fyb201-a-biosimilar-candidate-to-lucentis-ranibizumab-to-the-u-dot-s-fda 2021-08-06T08:20:19 https://maestrodatabase.com/blog/telix-completes-tlx250-cdx-zircaix-bla-submission-for-kidney-cancer-imaging 2024-06-05T02:09:44 https://maestrodatabase.com/blog/the-eu-approves-tagrisso-for-first-line-treatment-of-egfr-mutated-non-small-cell-lung-cancer 2018-06-11T06:56:13 https://maestrodatabase.com/blog/cancer-treatment-uncertainty-european-nations-struggle-with-drug-shortages 2023-08-24T06:00:08 https://maestrodatabase.com/blog/spectrum-pharmaceuticals-receives-complete-response-letter-from-fda-for-rolontis-eflapegrastim 2021-08-06T21:24:58 https://maestrodatabase.com/blog/pharmac-seeking-bids-from-suppliers-for-multiple-myeloma-treatments 2023-08-24T05:17:00 https://maestrodatabase.com/blog/interoperability-of-track-and-trace-systems-key-to-public-health-protection 2021-08-06T08:46:57 https://maestrodatabase.com/blog/nidlegy-marketing-authorisation-application-submitted-to-ema 2024-06-05T01:22:23 https://maestrodatabase.com/blog/european-commission-approves-prolia-denosumab-for-patients-with-glucocorticoid-induced-osteoporosis 2018-06-11T07:02:21 https://maestrodatabase.com/blog/cytrx-issues-statement-regarding-u-dot-s-regulatory-review-of-arimoclomol-for-niemann-pick-disease-type-c 2021-01-01T02:11:46 https://maestrodatabase.com/blog/mercks-keytruda-pembrolizumab-significantly-prolonged-recurrence-free-survival-compared-to-placebo-as-adjuvant-therapy-for-patients-with-stage-ii-resected-high-risk-melanoma-in-phase-3-keynote-716-trial 2021-08-06T11:25:04 https://maestrodatabase.com/blog/novavax-delays-covid-vaccine-emergency-authorisation-submission-to-fda-until-fourth-quarter 2021-08-06T10:29:44 https://maestrodatabase.com/blog/health-minister-promises-dying-dad-that-nz-will-improve-cancer-treatment 2019-02-03T19:52:52 https://maestrodatabase.com/blog/protalix-biotherapeutics-and-chiesi-global-rare-diseases-announce-u-dot-s-fda-acceptance-of-biologics-license-application-for-pegunigalsidase-alfa-for-the-proposed-treatment-of-fabry-disease-and-grants-priority-review 2020-08-11T12:01:47 https://maestrodatabase.com/blog/smc---june-2018-decisions 2018-06-11T13:15:55 https://maestrodatabase.com/blog/northland-father-of-three-forced-to-sell-dream-home-to-fund-cancer-treatment 2019-02-03T19:55:32 https://maestrodatabase.com/blog/petitioner-demands-insurance-benefit-for-breast-cancer-drug-kadcyla 2020-08-11T20:55:49 https://maestrodatabase.com/blog/international-heath-technology-assessment-collaboration-expands 2023-08-24T15:09:37 https://maestrodatabase.com/blog/cvs-health-launches-company-to-produce-cheaper-biosimilar-versions-of-expensive-biotech-drug 2023-08-24T15:01:12 https://maestrodatabase.com/blog/fda-head-pledges-we-will-not-cut-corners-on-coronavirus-vaccine 2020-08-11T09:49:55 https://maestrodatabase.com/blog/soliris-approved-in-japan-for-paediatric-patients-with-generalised-myasthenia-gravis 2023-08-24T15:05:18 https://maestrodatabase.com/blog/lynparza-plus-abiraterone-approved-in-japan-for-the-treatment-of-brca-mutated-metastatic-castration-resistant-prostate-cancer 2023-08-24T06:04:46 https://maestrodatabase.com/blog/heres-the-evidence---time-to-play-fair-pharmac 2018-06-11T21:25:17 https://maestrodatabase.com/blog/fennec-pharmaceuticals-receives-complete-response-letter-from-the-fda-for-its-new-drug-application-for-pedmark-to-prevent-ototoxicity-associated-with-cisplatin-in-paediatric-patients-with-localised-non-metastatic-solid-tumours 2020-08-11T11:55:30 https://maestrodatabase.com/blog/novavax-and-european-commission-finalise-advance-purchase-agreement-for-up-to-200-million-doses-of-covid-19-vaccine 2021-08-06T21:38:12 https://maestrodatabase.com/blog/cheaper-medicines-for-high-cholesterol-and-chronic-heart-failure 2022-11-27T23:05:22 https://maestrodatabase.com/blog/chmp-recommends-eu-approval-of-roches-tecentriq-in-combination-with-avastin-and-chemotherapy-as-an-initial-treatment-for-lung-cancer 2019-02-03T20:07:32 https://maestrodatabase.com/blog/cenobamate-designated-promising-innovative-medicine-by-the-uks-mhra-for-treatment-of-drug-resistant-focal-onset-seizures-in-adults 2020-08-11T21:13:05 https://maestrodatabase.com/blog/taysha-gene-therapies-announces-fast-track-designation-granted-by-us-fda-for-tsha-102-in-rett-syndrome 2023-08-24T23:37:25 https://maestrodatabase.com/blog/johnson-and-johnson-submits-supplemental-new-drug-application-to-us-fda-seeking-expanded-paediatric-indication-for-hiv-1-therapy-prezcobix 2024-06-05T04:08:19 https://maestrodatabase.com/blog/european-medicines-agency-accepts-novaliqs-marketing-authorisation-application-for-cyclasol-cyclosporin-ophthalmic-solution-0-dot-1-percent-for-the-treatment-of-dry-eye-disease 2023-08-25T01:39:16 https://maestrodatabase.com/blog/chmp-recommends-eu-approval-of-roches-hemlibra-for-people-with-severe-haemophilia-a-without-factor-viii-inhibitors 2019-02-03T20:12:47 https://maestrodatabase.com/blog/trumps-call-for-essential-drugs-to-be-made-in-us-threatens-innovation-says-trade-group 2020-08-11T21:17:27 https://maestrodatabase.com/blog/novartis-combination-adjuvant-therapy-tafinlar-and-mekinist-receives-fda-breakthrough-therapy-designation-for-stage-iii-braf-v600-mutation-positive-melanoma-patients 2017-10-23T05:19:34 https://maestrodatabase.com/blog/china-national-medical-products-administration-approves-truvada-for-hiv-pre-exposure-prophylaxis 2020-08-11T21:27:48 https://maestrodatabase.com/blog/alentis-therapeutics-receives-fda-fast-track-designation-for-ale-dot-c04-for-the-treatment-of-claudin-1-positive-hnscc 2023-08-24T23:33:09 https://maestrodatabase.com/blog/eton-pharmaceuticals-provides-update-on-the-fda-review-of-em-100 2020-09-17T10:00:31 https://maestrodatabase.com/blog/mersana-therapeutics-receives-fda-fast-track-designation-for-xmt-1536-for-the-treatment-of-patients-with-platinum-resistant-ovarian-cancer 2020-08-11T21:04:07 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-january-2021-update 2021-01-01T03:53:45 https://maestrodatabase.com/blog/nectero-medical-receives-fda-fast-track-designation-for-nectero-east-system 2023-08-24T23:21:58 https://maestrodatabase.com/blog/fda-approves-first-biosimilar-to-treat-multiple-sclerosis 2023-08-24T23:27:20 https://maestrodatabase.com/blog/quince-therapeutics-receives-us-fda-fast-track-designation-for-erydex-system 2024-06-05T03:12:31 https://maestrodatabase.com/blog/nhs-to-fund-gene-therapy-for-bubble-babies 2017-10-23T07:07:25 https://maestrodatabase.com/blog/australia-pins-hopes-on-potential-oxford-university-covid-19-vaccine 2020-08-11T21:56:00 https://maestrodatabase.com/blog/mid-year-drug-price-hikes-are-back-despite-inflation-reduction-act 2023-08-25T21:26:58 https://maestrodatabase.com/blog/european-commission-approves-pfizers-abrysvo-to-help-protect-infants-through-maternal-immunisation-and-older-adults-from-rsv 2023-08-25T21:32:03 https://maestrodatabase.com/blog/viiv-healthcare-submits-regulatory-application-to-european-medicines-agency-for-investigational-cabotegravir-to-be-used-in-combination-with-rilpivirine-as-the-first-monthly-injectable-treatment-for-hiv 2019-07-29T21:09:48 https://maestrodatabase.com/blog/public-summary-documents---may-2023-pbac-meeting 2023-08-25T21:16:36 https://maestrodatabase.com/blog/fda-approves-veklury-remdesivir-to-treat-covid-19-in-people-with-mild-to-severe-hepatic-impairment-with-no-dose-adjustment 2023-08-25T01:45:13 https://maestrodatabase.com/blog/russias-approval-of-coronavirus-vaccine-greeted-with-some-alarm 2020-08-11T21:34:45 https://maestrodatabase.com/blog/an-open-letter-to-doctors-from-the-tga 2022-11-28T04:16:21 https://maestrodatabase.com/blog/local-doctor-may-have-breakthrough-coronavirus-cure 2020-08-11T21:43:18 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-january-2021 2021-01-01T05:50:28 https://maestrodatabase.com/blog/fda-updates-draft-guidance-on-rare-paediatric-disease-priority-review-voucher-program 2019-07-29T21:37:58 https://maestrodatabase.com/blog/uniqure-receives-fda-regenerative-medicine-advanced-therapy-designation-for-investigational-gene-therapy-amt-130-in-huntingtons-disease 2024-06-05T05:08:28 https://maestrodatabase.com/blog/nice-approves-gene-therapy-for-rare-bubble-baby-syndrome 2017-10-23T08:41:16 https://maestrodatabase.com/blog/european-medicines-agency-staff-could-live-in-london-and-commute-to-france-after-brexit 2017-10-23T11:06:22 https://maestrodatabase.com/blog/gsk-wins-u-dot-s-shingles-vaccine-approval-uk-nod-for-gene-therapy 2017-10-23T09:47:35 https://maestrodatabase.com/blog/cms-announces-landmark-price-transparency-proposals-that-benefit-consumers 2019-07-30T00:11:44 https://maestrodatabase.com/blog/health-and-wealth-in-the-united-states-and-england--two-very-different-countries-with-similar-findings 2017-10-23T20:01:46 https://maestrodatabase.com/blog/dublin-ramps-up-bid-to-lure-post-brexit-european-medical-agency 2017-10-23T11:10:50 https://maestrodatabase.com/blog/novo-nordisk-expands-product-offerings-in-canada-for-the-treatment-of-haemophilia-a-in-both-children-and-adults-with-availability-of-esperoct-and-zonovate 2022-04-02T23:25:30 https://maestrodatabase.com/blog/health-care-underfunded-for-too-long 2017-10-23T20:22:38 https://maestrodatabase.com/blog/nice-bars-nhs-access-to-lenvima-nexavar-for-thyroid-cancer 2017-10-23T20:12:19 https://maestrodatabase.com/blog/the-serious-flaw-in-canadas-health-care-system-prescription-drugs-arent-free 2017-10-23T20:24:53 https://maestrodatabase.com/blog/fda-approves-new-treatment-for-pompe-disease 2021-08-06T23:05:25 https://maestrodatabase.com/blog/dt-216-granted-fda-fast-track-designation-for-patients-with-friedreichs-ataxia 2022-04-02T23:20:22 https://maestrodatabase.com/blog/actuate-therapeutics-announces-fda-fast-track-designation-for-9-ing-41-for-treatment-of-pancreatic-cancer 2021-08-06T23:31:00 https://maestrodatabase.com/blog/car-t-cell-therapy-a-microcosm-for-the-challenges-ahead-in-medicare 2019-07-30T00:38:19 https://maestrodatabase.com/blog/nivolumab-for-the-adjuvant-treatment-of-patients-12-years-and-older-with-completely-resected-melanoma-at-high-risk-of-recurrence 2024-06-05T06:35:33 https://maestrodatabase.com/blog/fda-requires-box-warnings-for-pfizer-drug-xeljanz 2019-07-30T00:44:43 https://maestrodatabase.com/blog/cost-sharing-for-preferred-branded-drugs-in-medicare-part-d 2025-02-17T03:29:13 https://maestrodatabase.com/blog/moving-from-substantial-equivalence-to-substantial-improvement-for-510-k-ddevevices 2019-07-30T00:41:59 https://maestrodatabase.com/blog/sarepta-therapeutics-announces-that-us-fda-has-accepted-for-filing-and-granted-priority-review-for-the-biologics-license-application-for-srp-9001-sareptas-gene-therapy-for-the-treatment-of-ambulant-individuals-with-duchenne-muscular-dystrophy 2022-11-28T19:27:13 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac---november-2025 2025-12-19T07:38:35 https://maestrodatabase.com/blog/kintara-therapeutics-granted-fast-track-designation-from-fda-for-rem-001-for-cutaneous-metastatic-breast-cancer 2022-11-28T19:23:20 https://maestrodatabase.com/blog/bunbury-mothers-fight-to-get-drug-that-would-give-her-two-year-old-son-the-chance-to-grow-old 2018-06-12T01:38:09 https://maestrodatabase.com/blog/janssen-submits-supplemental-biologics-license-application-to-the-us-fda-seeking-approval-of-rybrevant-amivantamab-vmjw-in-combination-with-chemotherapy-for-the-first-line-treatment-of-patients-with-locally-advanced-or-metastatic-egfr-exon-20-insertion-mutation-positive-non-small-cell-lung-cancer 2023-08-25T23:23:22 https://maestrodatabase.com/blog/adicet-bio-receives-fda-fast-track-designation-for-adi-001-in-lupus-nephritis 2024-06-05T20:55:14 https://maestrodatabase.com/blog/joint-statement-nice-and-smc-slash-his-collaboration 2022-11-28T19:38:45 https://maestrodatabase.com/blog/unravelling-the-association-between-uncertainties-in-model-based-economic-analysis-and-funding-recommendations-of-medicines-in-australia 2025-02-17T06:44:25 https://maestrodatabase.com/blog/bayers-nubeqa-receives-mhra-approval-to-treat-metastatic-prostate-cancer 2022-11-28T19:46:18 https://maestrodatabase.com/blog/nice-recommends-rinvoq-upadacitinib-as-treatment-option-for-moderately-to-severely-active-ulcerative-colitis-in-adults 2022-11-28T19:34:29 https://maestrodatabase.com/blog/out-of-pocket-getting-out-of-hand---reducing-the-financial-toxicity-of-rapidly-approved-drugs 2025-02-17T06:06:11 https://maestrodatabase.com/blog/samsung-bioepis-gains-european-commission-approval-for-denosumab-biosimilar-obodence-xbryk 2025-02-17T06:01:52 https://maestrodatabase.com/blog/ivosidenib-in-combination-with-azacitidine-for-the-first-line-treatment-of-patients-with-idh1-r132-mutation-positive-acute-myeloid-leukaemia-final-guidance 2024-06-05T08:09:38 https://maestrodatabase.com/blog/tscan-therapeutics-receives-fdas-regenerative-medicine-advanced-therapy-designation-for-its-two-lead-tcr-t-therapy-candidates-for-the-treatment-of-heme-malignancies 2024-06-05T07:03:04 https://maestrodatabase.com/blog/ferinject-approved-in-china-for-the-treatment-of-iron-deficiency-in-adult-patients 2022-11-28T20:06:57 https://maestrodatabase.com/blog/medicare-for-all-instead-of-private-health-insurance-question-vexes-2020-democrats 2019-07-30T01:19:04 https://maestrodatabase.com/blog/frustrated-cancer-patients-husband-mulls-new-political-party 2019-07-30T01:28:59 https://maestrodatabase.com/blog/neurovives-neurostat-project-receives-fda-fast-track-designation 2019-07-30T01:21:45 https://maestrodatabase.com/blog/reimbursement-criteria-for-cgrp-inhibiting-migraine-drugs-not-realistic 2022-11-28T20:01:29 https://maestrodatabase.com/blog/lantheus-announces-the-approval-of-definity-perflutren-lipid-microsphere-by-chinas-nmpa 2022-11-28T19:54:10 https://maestrodatabase.com/blog/is-competitive-licensing-proposed-in-hr-1046-practical-for-lowering-drug-prices 2019-07-30T01:30:57 https://maestrodatabase.com/blog/type-2-diabetes-drug-shortage-victorias-ozempic-trulicity-supplies-limited-until-march 2022-11-28T20:32:05 https://maestrodatabase.com/blog/croma-australia-a-subsidiary-of-hugel-aesthetics-receives-tga-approval-in-australia-for-letybo-letibotulinumtoxina-for-the-treatment-of-glabellar-lines 2022-11-28T20:15:01 https://maestrodatabase.com/blog/why-should-the-fda-focus-on-pragmatic-clinical-research 2024-06-05T21:26:31 https://maestrodatabase.com/blog/blood-cancer-doctors-urge-government-dont-break-drug-promise-to-our-patients 2024-06-05T21:21:50 https://maestrodatabase.com/blog/agenda-for-the-september-2023-pbac-intracycle-meeting 2023-08-26T00:44:40 https://maestrodatabase.com/blog/ama-submission---government-proposals-to-increase-biosimilar-prescribing 2017-10-24T02:25:17 https://maestrodatabase.com/blog/pelosis-drug-price-controls-are-dangerous--but-so-are-trumps 2020-01-30T11:22:26 https://maestrodatabase.com/blog/cystic-fibrosis-patient-backs-campaign-to-make-medicines-available-on-nhs 2018-06-12T04:49:50 https://maestrodatabase.com/blog/cummings-plans-to-call-pharma-executives-to-testify-about-drug-costs 2019-07-30T01:57:00 https://maestrodatabase.com/blog/fda-approves-addition-of-positive-overall-survival-data-from-phase-3-aspire-trial-to-kyprolis-carfilzomib-label 2018-06-12T05:05:22 https://maestrodatabase.com/blog/themis-receives-ema-prime-designation-for-chikungunya-vaccine 2018-06-12T04:56:52 https://maestrodatabase.com/blog/ema-grants-prime-access-to-proqrs-sepofarsen-for-lebers-congenital-amaurosis-10 2019-07-30T02:29:50 https://maestrodatabase.com/blog/the-uk-national-institute-for-health-and-care-excellence-to-undertake-a-partial-review-of-the-iluvien-reimbursement-guidance-allowing-broader-availability 2018-06-12T05:12:14 https://maestrodatabase.com/blog/us-outspends-on-health-care-but-has-lower-life-expectancy 2020-01-30T19:55:37 https://maestrodatabase.com/blog/nice-publishes-updated-principles 2020-01-30T19:47:33 https://maestrodatabase.com/blog/corium-announces-fda-filing-acceptance-of-new-drug-application-for-adlarity-donepezil-transdermal-system-for-the-treatment-of-alzheimers-disease 2020-01-30T19:42:50 https://maestrodatabase.com/blog/cook-medical-receives-fda-breakthrough-device-designation-for-zenith-thoraco-plus-endovascular-system 2022-04-03T20:57:37 https://maestrodatabase.com/blog/proqr-receives-rare-paediatric-disease-designation-from-fda-for-qr-421a 2020-01-30T20:05:14 https://maestrodatabase.com/blog/house-passes-bill-to-limit-cost-of-insulin-to-35-dollars-a-month 2022-04-03T21:00:42 https://maestrodatabase.com/blog/survey-finds-87-percent-of-pharmacists-concerned-about-medicine-supply-post-brexit 2020-01-30T19:59:33 https://maestrodatabase.com/blog/innate-pharma-announces-us-fda-granted-breakthrough-therapy-designation-to-lacutamab-for-relapsed-or-refractory-sezary-syndrome 2025-02-17T23:09:34 https://maestrodatabase.com/blog/the-life-saving-medicine-she-needs-is-cheap-common-and-unavailable-in-canadian-pharmacies 2020-01-30T20:19:14 https://maestrodatabase.com/blog/aprea-therapeutics-receives-fda-breakthrough-therapy-designation-for-apr-246-in-combination-with-azacitidine-for-the-treatment-of-myelodysplastic-syndromes-with-a-tp53-mutation 2020-01-30T20:12:00 https://maestrodatabase.com/blog/nrdl-list-could-lead-to-increased-access-to-innovative-drugs-in-china 2020-01-30T20:42:43 https://maestrodatabase.com/blog/cvs-to-offer-diabetes-drugs-at-no-out-of-pocket-costs-for-pbm-members 2020-01-30T20:32:18 https://maestrodatabase.com/blog/brexit-d-day 2020-01-30T20:25:58 https://maestrodatabase.com/blog/catalyst-pharmaceuticals-receives-us-fda-approval-for-increased-maximum-daily-dose-for-firdapse 2024-06-05T23:34:29 https://maestrodatabase.com/blog/fda-updates-prioritization-policy-for-original-abbreviated-new-drug-applications-amendments-and-supplements-to-maximise-impact-on-public-health 2020-01-30T20:52:21 https://maestrodatabase.com/blog/cms-payment-policy-plays-role-in-biosimilar-uptake 2020-01-30T20:46:24 https://maestrodatabase.com/blog/innovent-receives-second-fast-track-designation-from-the-us-fda-for-ibi363-pd-1-slash-il-2a-bias-bipspecific-antibody-fusion-protein-in-squamous-non-small-cell-lung-cancer 2025-02-17T23:19:06 https://maestrodatabase.com/blog/who-should-pay-for-hta 2018-06-12T08:43:42 https://maestrodatabase.com/blog/egetis-therapeutics-initiates-new-drug-application-in-the-usa-for-emcitate-tiratricol-for-mct8-deficiency 2025-12-19T23:31:47 https://maestrodatabase.com/blog/the-health-care-stalkers 2018-06-12T09:48:06 https://maestrodatabase.com/blog/cytokinetics-announces-fda-approval-of-myqorzo-aficamten-for-the-treatment-of-adults-with-symptomatic-obstructive-hypertrophic-cardiomyopathy-to-improve-functional-capacity-and-symptoms 2025-12-19T23:44:38 https://maestrodatabase.com/blog/85-percent-of-canadians-now-have-publicly-funded-access-to-a-potentially-life-extending-treatment-for-patients-with-rare-lung-disease 2018-06-12T13:11:50 https://maestrodatabase.com/blog/smc-approves-funding-for-six-new-therapies-on-the-nhs 2018-06-12T09:50:36 https://maestrodatabase.com/blog/trump-officials-meet-with-drug-companies-to-push-for-voluntary-price-cuts 2018-06-12T13:06:26 https://maestrodatabase.com/blog/statement-from-fda-commissioner-on-new-agency-efforts-to-advance-the-patient-voice-in-medical-product-development-and-fda-regulatory-decision-making 2018-06-12T20:59:35 https://maestrodatabase.com/blog/statement-from-fda-commissioner-on-new-efforts-to-advance-medical-product-communications-to-support-drug-competition-and-value-based-health-care 2018-06-12T21:01:58 https://maestrodatabase.com/blog/drug-maker-revives-female-libido-pill-at-half-the-price 2018-06-12T21:13:29 https://maestrodatabase.com/blog/novartis-zolgensma-joins-growing-list-of-medicines-to-lose-accelerated-assessment-status-in-eu 2019-07-30T04:29:44 https://maestrodatabase.com/blog/fda-grants-two-national-priority-vouchers 2025-12-20T00:19:35 https://maestrodatabase.com/blog/statement-from-fda-commissioner-on-fdas-efforts-to-foster-discovery-and-development-of-new-tools-to-fight-antimicrobial-resistant-infections 2018-06-12T21:18:26 https://maestrodatabase.com/blog/fda-looks-to-modelling-and-simulation-tools-to-streamline-product-reviews 2022-11-29T00:49:37 https://maestrodatabase.com/blog/bms-announces-agreement-with-us-government-to-improve-affordability-and-access-to-critical-medicines-for-americans 2025-12-19T23:59:07 https://maestrodatabase.com/blog/trump-health-chief-renews-call-to-end-key-drug-pricing-tactic 2018-06-12T21:52:25 https://maestrodatabase.com/blog/us-fda-approves-new-easy-to-use-once-weekly-bydureon-bcise-injectable-medicine-for-patients-with-type-2-diabetes 2017-10-24T04:53:55 https://maestrodatabase.com/blog/the-iqwig-methods-new-version-is-effective-immediately 2025-12-20T00:12:11 https://maestrodatabase.com/blog/united-therapeutics-announces-fda-approval-of-third-generation-nebuliser-for-the-tyvaso-inhalation-system 2017-10-24T04:49:25 https://maestrodatabase.com/blog/can-ad-hoc-analyses-of-clinical-trials-help-personalise-treatment-decisions 2017-10-24T05:01:40 https://maestrodatabase.com/blog/us-fda-approves-jascayd-nerandomilast-tablets-for-the-treatment-of-progressive-pulmonary-fibrosis-in-adults 2025-12-20T01:06:53 https://maestrodatabase.com/blog/european-commission-approves-tremfya-guselkumab-for-the-treatment-of-children-with-plaque-psoriasis-marking-the-first-paediatric-indication-for-an-il-23-inhibitor 2025-12-20T01:19:15 https://maestrodatabase.com/blog/health-canada-approves-opdivo-nivolumab-plus-yervoy-ipilimumab-combined-with-limited-chemotherapy-for-the-treatment-of-metastatic-non-small-cell-lung-cancer 2020-08-12T03:35:01 https://maestrodatabase.com/blog/eli-lilly-cuts-price-of-diabetes-weight-loss-drugs-in-canada 2025-12-20T00:34:49 https://maestrodatabase.com/blog/novartis-and-us-government-reach-agreement-on-lowering-drug-prices-in-the-us 2025-12-20T00:38:16 https://maestrodatabase.com/blog/health-canada-has-approved-sotyku-deucravacitinib-tablets-an-oral-treatment-for-adults-with-moderate-to-severe-plaque-psoriasis 2022-11-29T02:50:45 https://maestrodatabase.com/blog/here-comes-yet-another-new-medicine-for-patients-with-ms 2022-04-04T04:15:49 https://maestrodatabase.com/blog/astrazeneca-sues-us-over-medicare-drug-price-negotiation-plans 2023-08-28T16:42:14 https://maestrodatabase.com/blog/moderna-vaccine-set-to-be-available-in-australia-by-september 2021-08-08T01:33:10 https://maestrodatabase.com/blog/cadth-to-establish-industry-task-force-on-real-world-data-for-post-market-drug-evaluations 2023-08-28T16:28:52 https://maestrodatabase.com/blog/abbvie-submits-regulatory-applications-to-fda-and-ema-for-risankizumab-skyrizi-in-ulcerative-colitis 2023-08-28T16:32:55 https://maestrodatabase.com/blog/efficient-funding-of-chemotherapy-review---final-report 2023-08-28T16:24:08 https://maestrodatabase.com/blog/novavax-booster-doses-to-soon-join-stockpile 2021-08-08T01:28:15 https://maestrodatabase.com/blog/icers-updated-assessment-of-new-targeted-therapies-for-plaque-psoriasis-notes-minor-distinctions-in-effectiveness-while-recent-price-hikes-have-made-entire-drug-class-less-cost-effective 2018-06-12T23:52:30 https://maestrodatabase.com/blog/pharmac-announcement-of-more-blood-cancer-medicines-welcomed 2023-08-27T15:36:05 https://maestrodatabase.com/blog/us-fda-approves-bristol-myers-squibbs-reblozyl-luspatercept-aamt-as-first-line-treatment-of-anaemia-in-adults-with-lower-risk-myelodysplastic-syndromes-who-may-require-transfusions 2023-08-29T07:26:43 https://maestrodatabase.com/blog/australia-knocks-back-application-for-diabetes-drug-that-could-overshadow-ozempic 2023-08-29T01:41:10 https://maestrodatabase.com/blog/bluebird-bio-has-serious-cash-flow-concerns-inability-to-strike-reimbursement-deals-in-europe-partly-to-blame 2022-04-04T04:28:05 https://maestrodatabase.com/blog/janssen-submits-supplemental-new-drug-application-to-the-us-fda-seeking-full-approval-of-balversa-erdafitinib-for-the-treatment-of-patients-with-locally-advanced-or-metastatic-urothelial-carcinoma-and-selected-fibroblast-growth-factor-receptor-gene-alterations 2023-08-29T01:51:07 https://maestrodatabase.com/blog/two-new-treatments-recommended-for-people-with-breast-cancer 2025-12-20T02:13:25 https://maestrodatabase.com/blog/knight-therapeutics-announces-health-canada-approval-for-wynzora-to-treat-psoriasis-vulgaris 2025-12-20T02:17:55 https://maestrodatabase.com/blog/mylifematters-calls-for-new-medicines-urgent-pharmac-investment 2023-08-28T18:21:51 https://maestrodatabase.com/blog/pharmac-taking-action-to-ensure-supply-of-type-2-diabetes-medicine-amid-worldwide-shortage 2023-08-29T16:02:12 https://maestrodatabase.com/blog/rznomics-liver-cancer-drug-candidate-secures-fast-track-designation 2025-02-18T05:53:24 https://maestrodatabase.com/blog/platform-clinical-trials-for-the-efficient-evaluation-of-multiple-treatments 2025-04-03T03:24:53 https://maestrodatabase.com/blog/alkermes-receives-complete-response-letter-from-u-dot-s-fda-for-alks-5461-new-drug-application 2019-02-04T02:26:10 https://maestrodatabase.com/blog/we-could-be-paying-too-much-for-knee-and-hip-replacements 2025-02-18T01:24:43 https://maestrodatabase.com/blog/hhs-selects-the-first-drugs-for-medicare-drug-price-negotiation 2023-08-29T15:24:34 https://maestrodatabase.com/blog/pulmatrix-receives-fast-track-designation-for-pulmazole-for-the-treatment-of-asthma-abpa 2020-01-31T00:01:28 https://maestrodatabase.com/blog/weight-loss-drug-wegovy-close-to-pbs-approval 2025-12-20T02:02:46 https://maestrodatabase.com/blog/jw-therapeutics-announces-receipt-of-breakthrough-therapy-designation-for-carteyva-in-mantle-cell-lymphoma-in-china 2022-04-04T04:33:59 https://maestrodatabase.com/blog/evolus-receives-fda-approval-for-jeuveau-prabotulinumtoxina-xvfs-for-injection 2019-02-04T02:42:18 https://maestrodatabase.com/blog/theranexus-and-bbdf-obtain-orphan-drug-designation-and-rare-paediatric-disease-designation-from-the-fda-for-bbdf-101-for-batten-disease 2020-08-12T04:33:24 https://maestrodatabase.com/blog/fda-approves-soliris-eculizumab-for-the-treatment-of-patients-with-generalised-myasthenia-gravis 2017-10-24T07:15:41 https://maestrodatabase.com/blog/european-commission-approves-keytruda-pembrolizumab-plus-trastuzumab-and-chemotherapy-as-first-line-treatment-for-her2-positive-advanced-gastric-or-gastro-oesophageal-junction-adenocarcinoma-expressing-pd-l1-cps-1 2023-08-30T06:00:10 https://maestrodatabase.com/blog/hundreds-of-people-with-diabetes-are-set-to-benefit-from-the-funding-of-a-new-treatment-that-will-help-prevent-blindness 2017-10-24T07:11:26 https://maestrodatabase.com/blog/additional-covid-19-treatment-for-australia 2021-08-08T07:54:55 https://maestrodatabase.com/blog/fda-accepts-dupixent-dupilumab-for-priority-review-in-patients-aged-12-years-and-older-with-eosinophilic-oesophagitis 2022-04-04T05:27:23 https://maestrodatabase.com/blog/americas-plan-to-cut-drug-prices-comes-with-unpleasant-side-effects 2023-08-30T00:01:35 https://maestrodatabase.com/blog/roches-tecentriq-becomes-the-first-subcutaneous-anti-pd--l-1-cancer-immunotherapy-available-to-patients-in-great-britain-reducing-treatment-time-to-just-minutes 2023-08-29T23:52:45 https://maestrodatabase.com/blog/dupixent-dupilumab-sbla-accepted-for-fda-priority-review-for-the-targeted-treatment-of-bullous-pemphigoid 2025-02-18T06:21:17 https://maestrodatabase.com/blog/top-celgene-cancer-drugs-now-20-percent-more-expensive-after-latest-price-hikes 2017-10-24T07:24:00 https://maestrodatabase.com/blog/health-canada-accepts-valnevas-chikungunya-vaccine-license-application-for-review 2023-08-29T23:16:25 https://maestrodatabase.com/blog/new-cancer-drug-funding-to-be-announced-this-year-christopher-luxon 2024-06-06T06:42:53 https://maestrodatabase.com/blog/nemolizumab-approved-to-treat-prurigo-nodularis-and-atopic-dermatitis-for-patients-in-the-uk 2025-02-18T06:15:23 https://maestrodatabase.com/blog/california-just-passed-a-law-to-rein-in-drug-prices-heres-why-its-unlikely-to-make-much-difference 2017-10-24T07:46:57 https://maestrodatabase.com/blog/biden-yet-to-nominate-new-fda-chief-even-as-delta-surges 2021-08-08T21:00:40 https://maestrodatabase.com/blog/european-commission-approves-roches-evrysdi-for-babies-under-two-months-old-with-spinal-muscular-atrophy 2023-08-30T16:23:58 https://maestrodatabase.com/blog/us-tropical-disease-priority-review-vouchers-lessons-in-promoting-drug-development-and-access 2021-08-08T20:57:42 https://maestrodatabase.com/blog/updates-to-the-health-technology-assessment-policy-and-methods-review-reference-committee---august-2023 2023-08-30T06:24:43 https://maestrodatabase.com/blog/uk-oncology-approvals-in-2022-global-regulatory-collaboration-and-new-regulatory-pathways-deliver-new-anti-cancer-therapies 2023-08-30T16:03:02 https://maestrodatabase.com/blog/bloomsbury-genetic-therapies-receives-rare-paediatric-disease-designation-from-the-us-fda-for-bgt-inad-for-the-treatment-of-infantile-neuroaxonal-dystrophy 2023-08-30T06:10:36 https://maestrodatabase.com/blog/new-contraceptive-pill-safer-slinda-pill-with-no-blood-clot-risk-no-periods-available-in-australia 2021-08-08T09:40:04 https://maestrodatabase.com/blog/spero-announces-nda-resubmission-of-tebipenem-hydrobromide-by-gsk-to-the-fda-for-the-treatment-of-complicated-urinary-tract-infections-including-pyelonephritis 2025-12-20T07:13:58 https://maestrodatabase.com/blog/2020-slash-21-invitation-to-tender-for-suppliers 2020-08-12T05:30:36 https://maestrodatabase.com/blog/mepolizumab-for-the-treatment-of-patients-with-eosinophilic-granulomatosis-with-polyangiitis 2022-11-29T06:03:50 https://maestrodatabase.com/blog/denali-therapeutics-announces-fda-has-selected-dnl126-for-mps-iiia-sanfilippo-syndrome-type-a-for-start-pilot-program-intended-to-accelerate-development-of-rare-disease-therapies 2024-06-06T21:12:55 https://maestrodatabase.com/blog/mepolizumab-for-the-treatment-of-patients-with-severe-hypereosinophilic-syndrome 2022-11-29T06:28:49 https://maestrodatabase.com/blog/withdrawn-accelerated-approvals-for-cancer-indications-in-the-us-what-is-the-marketing-authorisation-status-in-the-eu 2023-08-30T18:18:21 https://maestrodatabase.com/blog/modernas-investigational-therapeutic-for-methylmalonic-acidaemia-mrna-3705-selected-by-us-fda-for-start-pilot-program 2024-06-06T21:01:04 https://maestrodatabase.com/blog/fda-issues-final-guidance-on-considerations-for-the-use-of-real-world-data-and-real-world-evidence-to-support-regulatory-decision-making-for-drugs-and-biological-products 2023-08-30T18:01:29 https://maestrodatabase.com/blog/fda-accepts-for-review-treosulfan-nda-resubmission 2024-06-06T20:56:42 https://maestrodatabase.com/blog/mitsubishi-tanabe-pharma-canada-announces-that-companys-oral-treatment-formulation-for-amyotrophic-lateral-sclerosis-has-been-added-to-the-provincial-drug-plans-in-new-brunswick-and-nova-scotia 2023-08-30T17:52:39 https://maestrodatabase.com/blog/fda-approves-mercks-keytruda-pembrolizumab-for-previously-treated-patients-with-recurrent-or-metastatic-cervical-cancer-whose-tumours-express-pd-l1-cps-greater-than-or-equal-to-1 2018-06-13T01:46:02 https://maestrodatabase.com/blog/ivonescimab-in-combination-with-chemotherapy-approved-in-china-by-nmpa-for-2l-plus-egfrm-nsclc-based-on-harmoni-a-clinical-trial-positive-trend-observed-in-overall-survival-towards-ivonescimab-plus-chemotherapy 2024-06-06T21:32:16 https://maestrodatabase.com/blog/outlook-therapeutics-provides-regulatory-update-on-fda-review-of-ons-5010-slash-lytenava-bevacizumab-vikg-for-the-treatment-of-wet-amd 2023-08-30T18:46:49 https://maestrodatabase.com/blog/bluerock-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-designation-for-parkinsons-disease-cell-therapy-candidate-bemdaneprocel 2024-06-06T21:22:40 https://maestrodatabase.com/blog/hansa-biopharma-submits-bla-to-fda-for-imlifidase-in-desensitisation-for-kidney-transplantation 2025-12-20T07:04:37 https://maestrodatabase.com/blog/neurogene-announces-ngn-401-gene-therapy-for-rett-syndrome-selected-by-fda-for-start-pilot-program 2024-06-06T21:17:25 https://maestrodatabase.com/blog/medical-device-development-tools-helping-to-speed-medical-device-evaluation-and-approval 2017-10-24T19:39:09 https://maestrodatabase.com/blog/statement-from-fda-commissioner-scott-gottlieb-m-dot-d-on-new-steps-to-advance-medical-device-innovation-and-help-patients-gain-faster-access-to-beneficial-technologies 2017-10-24T19:34:55 https://maestrodatabase.com/blog/we-need-to-remove-barriers-for-high-cost-cancer-drugs 2017-10-24T19:42:56 https://maestrodatabase.com/blog/novartis-kisqali-granted-mhra-approval-to-treat-early-breast-cancer-patients 2025-02-18T22:05:43 https://maestrodatabase.com/blog/regenxbio-receives-fda-fast-track-designation-for-rgx-111-gene-therapy-for-the-treatment-of-mucopolysaccharidosis-type-i 2018-06-13T02:27:22 https://maestrodatabase.com/blog/takeda-expects-more-effective-ibd-treatment-with-kynteles-expanded-reimbursement 2020-08-12T10:47:00 https://maestrodatabase.com/blog/nordic-nanovector-announces-betalutin-has-been-granted-fast-track-designation-in-the-us-for-follicular-lymphoma 2018-06-13T02:33:50 https://maestrodatabase.com/blog/beren-through-its-subsidiary-mandos-submits-new-drug-application-to-us-fda-for-adrabetadex-in-infantile-pnset-npc 2025-12-20T20:46:30 https://maestrodatabase.com/blog/moderna-announces-supply-agreement-with-u-dot-s-government-for-initial-100-million-doses-of-mrna-vaccine-against-covid-19-mrna-1273 2020-08-12T11:16:31 https://maestrodatabase.com/blog/bio-statement-on-new-proposal-for-lowering-out-of-pocket-costs-for-medicines 2019-02-04T06:33:36 https://maestrodatabase.com/blog/phrma-statement-on-the-administrations-proposed-rule-to-reform-the-rebate-system 2019-02-04T06:36:54 https://maestrodatabase.com/blog/fda-grants-rare-paediatric-disease-designation-to-a4250-albireo-eligible-to-apply-for-priority-review-voucher 2018-06-13T03:05:05 https://maestrodatabase.com/blog/dont-blame-drug-prices-on-big-pharma 2019-02-04T06:28:17 https://maestrodatabase.com/blog/fresenius-kabi-receives-positive-chmp-opinion-for-msb11022-a-biosimilar-candidate-of-adalimumab 2019-02-04T06:46:06 https://maestrodatabase.com/blog/caribou-biosciences-announces-the-fda-granted-regenerative-medicine-advanced-therapy-and-fast-track-designations-to-cb-010-an-allogeneic-anti-cd19-car-t-cell-therapy 2022-11-29T19:39:39 https://maestrodatabase.com/blog/optum-to-cover-amgen-eli-lilly-migraine-drugs-exclude-teva 2019-02-04T06:39:46 https://maestrodatabase.com/blog/voclosporin-with-immunosuppressives-for-the-treatment-of-patients-with-lupus-nephritis 2022-11-29T19:32:40 https://maestrodatabase.com/blog/aravive-announces-fast-track-designation-of-batiraxcept-for-treatment-of-clear-cell-renal-cell-carcinoma 2022-11-29T19:27:30 https://maestrodatabase.com/blog/capstone-announces-authorisation-of-biosimilar-human-insulin-for-iv-infusion-in-canada-and-eu 2022-11-29T20:11:56 https://maestrodatabase.com/blog/leo-pharmas-adtralza-approved-by-mhra-ec-for-adolescent-atopic-dermatitis 2022-11-29T20:16:36 https://maestrodatabase.com/blog/external-consultation-on-the-draft-revised-post-market-review-framework-deadline-extension 2022-11-29T20:06:02 https://maestrodatabase.com/blog/us-fda-accepts-gileads-new-drug-applications-for-twice-yearly-lenacapavir-for-hiv-prevention-under-priority-review 2025-02-18T23:25:45 https://maestrodatabase.com/blog/mother-of-four-is-denied-cancer-drug-that-could-save-her-life 2019-02-04T07:18:24 https://maestrodatabase.com/blog/calls-for-action-on-patients-denied-ps100-000-cystic-fibrosis-drug 2019-02-04T07:13:47 https://maestrodatabase.com/blog/nices-new-methods-putting-innovation-first-but-at-what-cost 2022-11-29T19:49:00 https://maestrodatabase.com/blog/chimerix-announces-fda-acceptance-and-priority-review-of-new-drug-application-for-dordaviprone-as-treatment-for-recurrent-h3-k27m-mutant-diffuse-glioma 2025-02-18T23:11:18 https://maestrodatabase.com/blog/roche-withdraws-tecentriq-from-us-bladder-cancer-indication 2022-11-29T19:55:38 https://maestrodatabase.com/blog/ema-recommends-approval-of-adapted-covid-19-vaccine-targeting-omicron-xbb-dot-1-5 2023-08-30T20:17:13 https://maestrodatabase.com/blog/time-for-inquiry-into-pharmacs-funding-of-cancer-drugs 2019-02-04T09:30:57 https://maestrodatabase.com/blog/zealand-pharma-announces-designation-of-priority-review-by-the-us-fda-for-dasiglucagon-in-congenital-hyperinsulinism 2023-08-31T06:17:21 https://maestrodatabase.com/blog/first-oral-add-on-treatment-to-insulin-for-treatment-of-certain-patients-with-type-1-diabetes 2019-02-04T09:09:54 https://maestrodatabase.com/blog/inflarxs-marketing-authorisation-application-for-vilobelimab-for-treatment-of-critically-ill-covid-19-patients-under-review-by-european-medicines-agency 2023-08-31T01:54:01 https://maestrodatabase.com/blog/digital-health-to-transform-australias-health-system-and-save-lives 2018-06-13T07:02:40 https://maestrodatabase.com/blog/welireg-belzutifan-receives-first-european-commission-approval-for-two-indications 2025-02-18T23:46:02 https://maestrodatabase.com/blog/medicare-should-negotiate-with-drug-makers-but-not-set-prices 2023-08-30T23:18:32 https://maestrodatabase.com/blog/petosemtamab-granted-breakthrough-therapy-designation-by-the-us-fda-for-first-line-pd-l1-positive-head-and-neck-squamous-cell-carcinoma 2025-02-18T23:33:27 https://maestrodatabase.com/blog/mepolizumab-for-the-treatment-of-patients-with-severe-chronic-rhinosinusitis-with-nasal-polyps 2022-11-29T20:20:19 https://maestrodatabase.com/blog/zai-lab-announces-breakthrough-therapy-designation-granted-for-repotrectinib-for-treatment-of-patients-with-ntrk-positive-tki-pretreated-advanced-solid-tumours-in-china 2023-08-30T23:11:47 https://maestrodatabase.com/blog/drug-approved-for-leukaemia-treatment 2018-06-13T21:29:40 https://maestrodatabase.com/blog/mylan-ceo-promises-neulasta-biosimilar-will-offer-significant-savings-for-patients 2018-06-13T21:33:13 https://maestrodatabase.com/blog/us-hoses-down-russian-vaccine-says-it-will-have-millions-of-doses-ready-years-end 2020-08-12T12:45:25 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-september-2023 2023-08-31T15:28:16 https://maestrodatabase.com/blog/public-backs-nhs-spending-increases 2018-06-13T12:00:55 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-september-2023 2023-08-31T15:08:00 https://maestrodatabase.com/blog/hhs-secretary-says-several-drug-companies-looking-at-substantial-price-cuts 2018-06-13T21:26:07 https://maestrodatabase.com/blog/u-dot-s-fda-grants-priority-review-to-roches-actemra-slash-roactemra-for-the-treatment-of-covid-19-in-hospitalised-adults 2022-04-04T11:05:37 https://maestrodatabase.com/blog/enhertu-granted-two-breakthrough-therapy-designations-in-us-for-patients-across-multiple-her2-expressing-cancers 2023-08-31T15:21:21 https://maestrodatabase.com/blog/janssens-tremfya-guselkumab-receives-its-first-two-positive-health-technology-assessments-in-europe 2018-06-13T21:39:15 https://maestrodatabase.com/blog/fda-accepts-evinacumab-biologics-license-application-for-priority-review-as-a-treatment-for-patients-with-hofh-an-ultra-rare-inherited-form-of-high-cholesterol 2020-08-12T12:37:37 https://maestrodatabase.com/blog/changes-to-funded-vaccines-in-the-national-immunisation-schedule 2019-07-30T10:28:17 https://maestrodatabase.com/blog/when-a-lottery-wins-sick-babies-life-saving-drugs 2020-01-31T02:34:46 https://maestrodatabase.com/blog/fda-approves-targeted-treatment-for-rare-duchenne-muscular-dystrophy-mutation 2021-02-25T19:55:43 https://maestrodatabase.com/blog/amcp-applauds-fda-for-final-guidance-on-payer-and-manufacturer-communications-to-improve-patient-access-to-emerging-therapies 2018-06-13T21:45:59 https://maestrodatabase.com/blog/covid-19-vaccine-international-collaboration 2021-08-09T00:58:37 https://maestrodatabase.com/blog/fda-approves-genentechs-avastin-bevacizumab-plus-chemotherapy-as-a-treatment-for-women-with-advanced-ovarian-cancer-following-initial-surgery 2018-06-13T21:54:57 https://maestrodatabase.com/blog/acer-therapeutics-edsivo-celiprolol-granted-fda-breakthrough-therapy-designation-for-vascular-ehlers-danlos-syndrome 2022-04-04T20:28:24 https://maestrodatabase.com/blog/a-massive-u-dot-s-drug-price-fixing-probe-has-hit-major-roadblocks 2019-07-30T10:47:25 https://maestrodatabase.com/blog/department-publishes-revised-agenda-for-the-september-2023-pbac-meeting 2023-09-01T01:29:03 https://maestrodatabase.com/blog/lets-make-2019-the-year-canada-finally-gets-pharmacare 2019-02-04T19:47:46 https://maestrodatabase.com/blog/emergent-biosolutions-narcan-nasal-spray-launches-over-the-counter-making-it-possible-for-everyone-to-help-save-a-life-from-an-opioid-overdose-emergency 2023-09-01T03:46:40 https://maestrodatabase.com/blog/metastatic-breast-cancer-highly-selective-post-hoc-analysis-rather-than-complete-publication-of-quality-of-life-data 2018-06-13T22:35:41 https://maestrodatabase.com/blog/biocon-biologics-partner-receives-positive-eu-chmp-opinion-for-biosimilar-human-insulin-for-iv-infusion 2022-04-04T11:37:43 https://maestrodatabase.com/blog/sunovion-announces-fda-acceptance-of-new-drug-application-for-apomorphine-sublingual-film 2018-06-13T21:59:41 https://maestrodatabase.com/blog/celltrion-applies-for-australian-approval-for-stelara-biosimilar 2023-09-01T01:12:35 https://maestrodatabase.com/blog/meningococcal-disease-mother-wants-vaccine-to-be-free-for-all 2019-07-30T10:36:52 https://maestrodatabase.com/blog/reforms-to-the-generic-medicine-market-authorisation-process 2019-07-30T10:32:42 https://maestrodatabase.com/blog/what-is-it-going-to-be-tto-or-sg-a-direct-test-of-the-validity-of-health-state-valuation 2020-08-12T20:53:02 https://maestrodatabase.com/blog/this-once-free-drug-for-a-rare-condition-now-costs-375-000-dollars 2019-02-04T19:59:22 https://maestrodatabase.com/blog/uk-patient-activist-group-takes-aim-at-orkambi-patent 2019-02-04T20:12:01 https://maestrodatabase.com/blog/difficult-situation-cancer-patient-leads-pleas-for-better-government-funding-of-treatments 2019-02-04T19:52:00 https://maestrodatabase.com/blog/pharma-leaders-support-the-social-contract-on-drug-prices 2019-07-30T10:51:42 https://maestrodatabase.com/blog/quality-assurance-requirements-of-the-g-ba-also-apply-to-new-car-t-cell-therapy 2021-08-09T04:30:52 https://maestrodatabase.com/blog/bristol-myers-squibb-withdraws-european-application-of-opdivo-nivolumab-plus-yervoy-ipilimumab-for-the-first-line-treatment-of-advanced-non-small-cell-lung-cancer 2020-01-31T21:25:10 https://maestrodatabase.com/blog/australian-scientists-say-too-early-to-pick-covid-19-vaccine-race-winner-in-advice-to-federal-government 2020-08-12T21:11:39 https://maestrodatabase.com/blog/alnylam-announces-three-month-extension-of-review-period-for-new-drug-application-for-vutrisiran 2022-04-04T20:33:07 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-to-alzheons-alz-801-development-program-for-the-treatment-of-alzheimers-disease 2017-10-24T23:57:14 https://maestrodatabase.com/blog/rare-disease-drugs-strategy-standard-coverage-in-clhias-2020-budget-wish-list 2020-08-12T21:17:13 https://maestrodatabase.com/blog/pharmacy-guild-suspends-campaign-as-60-day-dispensing-begins 2023-09-01T04:47:10 https://maestrodatabase.com/blog/rebates-to-the-dustbin-of-history 2019-02-04T20:25:40 https://maestrodatabase.com/blog/cms-proposes-changes-to-medicaid-best-price-rule-a-potential-boost-to-value-based-contracting 2020-08-12T21:31:11 https://maestrodatabase.com/blog/efgartigimod-for-the-treatment-of-patients-with-generalised-myasthenia-gravis 2023-09-01T04:50:57 https://maestrodatabase.com/blog/medivir-receives-fda-fast-track-designation-for-miv-711-for-the-treatment-of-osteoarthritis 2017-10-25T00:02:05 https://maestrodatabase.com/blog/mystery-solved-over-hansard-change-to-hide-budgets-missing-10-dollars-drug-price-cut 2022-04-04T20:54:52 https://maestrodatabase.com/blog/durvalumab-in-combination-with-etoposide-phosphate-and-either-carboplatin-or-cisplatin-for-the-first-line-treatment-of-patients-with-extensive-stage-small-cell-lung-cancer 2025-02-19T05:14:59 https://maestrodatabase.com/blog/digital-medicine-society-launches-toolkit-to-support-reimbursement-for-new-drugs-developed-using-digital-outcomes 2022-04-04T20:58:12 https://maestrodatabase.com/blog/galdermas-nemluvio-nemolizumab-granted-marketing-authorisation-in-the-united-kingdom-and-switzerland-for-moderate-to-severe-atopic-dermatitis-and-prurigo-nodularis 2025-02-19T02:32:25 https://maestrodatabase.com/blog/barriers-to-us-biosimilar-market-growth-lessons-from-biosimilar-patent-litigation 2021-08-09T06:12:42 https://maestrodatabase.com/blog/competition-from-biosimilars-drives-price-reductions-for-biologics-in-the-french-single-payer-health-system 2021-08-09T05:14:54 https://maestrodatabase.com/blog/alecensaro-alectinib-approved-by-health-canada-for-first-line-treatment-of-alk-positive-lung-cancer 2018-06-14T01:13:10 https://maestrodatabase.com/blog/version-4-and-counting 2021-08-09T05:04:40 https://maestrodatabase.com/blog/fda-approves-nobelpharmas-hyftor-sirolimus-0-dot-2-percent-topical-gel 2022-04-04T20:43:20 https://maestrodatabase.com/blog/ultragenyx-announces-fda-acceptance-and-priority-review-of-the-biologics-license-application-for-ux111-aav-gene-therapy-to-treat-sanfilippo-syndrome-type-a 2025-02-19T02:27:56 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-february-2020 2020-01-31T21:43:20 https://maestrodatabase.com/blog/precigen-receives-fast-track-designation-for-prgn-3006-ultracar-t-in-patients-with-relapsed-or-refractory-acute-myeloid-leukaemia 2022-04-04T20:49:42 https://maestrodatabase.com/blog/japan-drug-maker-shionogi-to-seek-approval-for-oral-covid-19-drug 2021-08-09T05:43:15 https://maestrodatabase.com/blog/uk-withdrawal-from-the-eu-on-31-january-2020 2020-01-31T21:34:45 https://maestrodatabase.com/blog/fda-shuts-out-its-own-experts-in-authorising-another-vaccine-booster 2022-04-04T21:20:36 https://maestrodatabase.com/blog/locally-made-medicines 2022-04-04T21:26:21 https://maestrodatabase.com/blog/u-dot-s-fda-approves-moxidectin-for-the-treatment-of-river-blindness 2018-06-14T01:17:56 https://maestrodatabase.com/blog/tga-provisionally-approves-modernas-covid-19-vaccine 2021-08-09T06:22:24 https://maestrodatabase.com/blog/forxiga-approved-in-the-eu-for-the-treatment-of-chronic-kidney-disease-in-patients-with-and-without-type-2-diabetes-mellitus 2021-08-09T06:17:56 https://maestrodatabase.com/blog/novartis-announces-european-commission-approval-of-beovu-for-people-living-with-diabetic-macular-oedema 2022-04-04T21:08:26 https://maestrodatabase.com/blog/european-commission-approves-biocon-biologics-ustekinumab-biosimilar 2025-02-19T06:41:44 https://maestrodatabase.com/blog/upper-hutt-dads-plea-to-pharmac-to-cover-familys-5-200-dollars-a-year-bill-for-life-changing-diabetes-devices 2022-04-04T21:12:20 https://maestrodatabase.com/blog/selpercatinib-for-the-treatment-of-patients-with-advanced-ret-fusion-positive-non-small-cell-lung-cancer 2025-02-19T06:15:21 https://maestrodatabase.com/blog/calliditas-receives-fda-fast-track-designation-for-setanaxib-in-pbc 2021-08-09T10:42:21 https://maestrodatabase.com/blog/why-you-cannot-win-with-private-health-insurance-thanks-to-a-50-year-old-quirk 2023-09-02T18:04:59 https://maestrodatabase.com/blog/lisocabtagene-maraleucel-in-second-line-b-cell-lymphoma-additional-benefit-for-certain-patients 2023-09-02T03:11:36 https://maestrodatabase.com/blog/skyrizi-risankizumab-rzaa-now-available-in-the-u-dot-s-as-a-single-150-mg-injection-for-adults-with-moderate-to-severe-plaque-psoriasis 2021-08-09T20:31:18 https://maestrodatabase.com/blog/us-senators-push-drug-makers-for-details-on-low-cost-insulin-programs 2023-09-02T03:03:13 https://maestrodatabase.com/blog/department-publishes-revised-agenda-for-november-2023-pbac-meeting 2023-09-01T06:39:11 https://maestrodatabase.com/blog/hugel-resubmits-bla-for-its-botulinum-toxin-letybo-to-the-us-fda 2023-09-01T20:34:48 https://maestrodatabase.com/blog/alphamab-oncology-announces-biparatopic-her2-targeting-adc-jskn003-was-granted-breakthrough-therapy-designation-by-the-fda-for-the-treatment-of-proc 2025-12-20T23:32:40 https://maestrodatabase.com/blog/hhs-proposes-nixing-trump-rule-tying-drug-costs-to-foreign-rates 2021-08-09T20:54:22 https://maestrodatabase.com/blog/ophthalmologist-group-wants-u-dot-s-government-to-push-back-against-avastin-biosimilars 2021-08-09T21:09:04 https://maestrodatabase.com/blog/dare-bioscience-announces-fda-acceptance-and-priority-review-of-new-drug-application-for-dare-bv1-for-the-treatment-of-bacterial-vaginosis 2021-08-09T20:35:45 https://maestrodatabase.com/blog/fda-approves-imetelstat-for-low--to-intermediate-1-risk-myelodysplastic-syndromes-with-transfusion-dependent-anaemia 2024-06-07T05:05:20 https://maestrodatabase.com/blog/smc---august-2021-decisions 2021-08-09T20:48:30 https://maestrodatabase.com/blog/additional-covid-19-vaccine-dose-recommended-for-adults-75-years-and-over 2023-09-02T18:09:09 https://maestrodatabase.com/blog/scotland-backs-bavencio-for-bladder-cancer-after-nice-says-no 2021-08-09T21:21:02 https://maestrodatabase.com/blog/pharnext-announces-fda-fast-track-designation-for-pleodrug-pxt3003-for-the-treatment-of-charcot-marie-tooth-disease-type-1a 2019-02-05T01:14:53 https://maestrodatabase.com/blog/u-dot-s-fda-approves-darolutamide-a-new-treatment-for-men-with-non-metastatic-castration-resistant-prostate-cancer 2019-07-31T01:14:33 https://maestrodatabase.com/blog/als-patients-and-advocates-say-canada-needs-better-access-to-new-treatments 2021-01-04T03:57:16 https://maestrodatabase.com/blog/health-canada-approves-vitrakvi-larotrectinib-the-first-tumour-agnostic-cancer-treatment-for-advanced-solid-tumours-harbouring-an-ntrk-gene-fusion 2019-07-31T01:47:48 https://maestrodatabase.com/blog/janssen-announces-health-canada-approval-of-rybrevant-amivantamab-the-first-and-only-targeted-treatment-for-patients-with-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations 2022-04-05T02:08:52 https://maestrodatabase.com/blog/could-quebecs-public-drug-plan-work-for-national-pharmacare 2019-07-31T01:57:01 https://maestrodatabase.com/blog/sk-life-science-announces-fda-acceptance-of-nda-submission-for-cenobamate-an-investigational-anti-epileptic-drug 2019-02-05T03:43:17 https://maestrodatabase.com/blog/european-commission-approves-kimmtrak-tebentafusp-for-the-treatment-of-unresectable-or-metastatic-uveal-melanoma 2022-04-05T01:11:35 https://maestrodatabase.com/blog/pharmac-funds-first-treatment-for-primary-progressive-multiple-sclerosis 2023-09-04T01:30:58 https://maestrodatabase.com/blog/the-changing-landscape-of-clinical-trials-in-australia 2023-09-04T01:27:12 https://maestrodatabase.com/blog/to-pay-for-weight-loss-drugs-some-take-second-jobs-ring-up-credit-card-debts 2023-09-03T21:07:44 https://maestrodatabase.com/blog/boehringers-zongertinib-receives-priority-review-from-us-fda-for-the-treatment-of-her2-erbb2--mutant-advanced-non-small-cell-lung-cancer 2025-02-20T03:46:49 https://maestrodatabase.com/blog/clarity-receives-us-fda-fast-track-designation-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer-patients-with-copper-cu-67-sar-bispsma 2025-02-20T03:41:35 https://maestrodatabase.com/blog/european-commission-grants-expanded-marketing-authorisation-for-gileads-biktarvy-for-the-treatment-of-hiv-in-paediatric-populations 2022-11-30T06:38:17 https://maestrodatabase.com/blog/what-to-expect-from-the-emerging-battle-royale-over-drug-prices 2023-09-04T07:16:12 https://maestrodatabase.com/blog/tga-still-waiting-for-further-data-on-astrazeneca-vaccine 2021-01-04T07:16:55 https://maestrodatabase.com/blog/nice-collaboration-on-streamlined-licensing-and-patient-access-process-for-new-medicines-opened-on-january-1st 2021-01-04T20:43:46 https://maestrodatabase.com/blog/ripretinib-for-the-treatment-of-patients-with-an-advanced-gastro-intestinal-stromal-tumour-after-three-or-more-therapies 2022-11-30T01:51:34 https://maestrodatabase.com/blog/us-fda-accepts-regulatory-submission-from-pfizer-and-opko-for-review-of-somatrogon-to-treat-pediatric-patients-with-growth-hormone-deficiency 2021-01-04T20:47:01 https://maestrodatabase.com/blog/calquence-approved-in-china-for-chronic-lymphocytic-leukaemia 2023-09-04T06:45:26 https://maestrodatabase.com/blog/act-calls-for-productivity-focus-for-pharmac 2023-09-04T01:40:00 https://maestrodatabase.com/blog/pharmac-widens-access-to-treatment-for-life-long-bleeding-disorder-severe-haemophilia-a 2023-09-04T02:10:35 https://maestrodatabase.com/blog/jason-falinski-slams-tgas-slow-moderna-covid-vaccine-approval 2021-08-10T01:02:07 https://maestrodatabase.com/blog/aquipta-atogepant-receives-mhra-marketing-authorisation-for-the-prevention-of-migraines-in-adults 2023-09-05T08:08:03 https://maestrodatabase.com/blog/fda-grants-arx788-fast-track-designation-for-her2-positive-metastatic-breast-cancer 2021-01-04T21:05:38 https://maestrodatabase.com/blog/trump-administration-drives-down-drug-costs-for-seniors 2019-07-31T02:26:03 https://maestrodatabase.com/blog/moderna-covid-19-vaccine-gets-swiss-approval-for-12-to-17-year-olds 2021-08-10T02:11:42 https://maestrodatabase.com/blog/sk-bioscience-withdraws-conditional-marketing-authorisation-for-covid-19-vaccine-in-eu 2023-09-05T07:40:30 https://maestrodatabase.com/blog/oncologists-pen-open-letter-to-pharmac-asking-for-more-life-saving-cancer-drugs 2023-09-05T07:17:59 https://maestrodatabase.com/blog/the-government-may-have-taken-money-from-the-dhb-hospital-budget-to-increase-pharmacs-funding 2022-11-30T08:44:48 https://maestrodatabase.com/blog/provention-bio-announces-u-dot-s-fda-filing-of-a-biologics-license-application-and-priority-review-for-teplizumab-for-the-delay-or-prevention-of-clinical-type-1-diabetes-in-at-risk-individuals 2021-01-04T20:55:24 https://maestrodatabase.com/blog/mum-vows-to-keep-pushing-for-fenfluramine-pbs-listing-for-dravet-syndrome-a-severe-form-of-epilepsy 2023-09-05T07:28:32 https://maestrodatabase.com/blog/ptc-therapeutics-announces-fda-acceptance-and-priority-review-for-vatiquinone-nda-for-the-treatment-of-children-and-adults-with-friedreichs-ataxia 2025-02-20T04:16:34 https://maestrodatabase.com/blog/aldeyra-therapeutics-submits-new-drug-application-to-the-us-fda-for-reproxalap-for-the-treatment-of-signs-and-symptoms-of-dry-eye-disease 2022-11-30T06:48:05 https://maestrodatabase.com/blog/working-with-te-whatu-ora-to-enable-better-access-to-vaccines 2023-09-04T07:20:59 https://maestrodatabase.com/blog/fast-track-granted-by-fda-for-nnz-2591-in-pitt-hopkins-syndrome 2025-02-20T04:08:18 https://maestrodatabase.com/blog/essential-medicines-lists-are-for-high-income-countries-too 2023-09-05T21:14:53 https://maestrodatabase.com/blog/acer-therapeutics-and-relief-therapeutics-announce-submission-of-a-new-drug-application-to-the-u-dot-s-fda-for-acer-001-for-treatment-of-urea-cycle-disorders 2021-08-10T03:06:58 https://maestrodatabase.com/blog/novartis-sues-us-government-over-medicare-drug-price-regulation 2023-09-05T20:45:56 https://maestrodatabase.com/blog/nice-recommends-chiesis-elfabrio-for-adults-with-fabry-disease 2023-09-05T20:49:57 https://maestrodatabase.com/blog/ibrutinib-with-rituximab-in-previously-untreated-chronic-lymphocytic-leukaemia-indication-of-added-benefit-over-fcr 2021-01-04T21:32:44 https://maestrodatabase.com/blog/medicines-access-for-cancer-must-also-be-fair-for-rare 2019-07-31T02:52:59 https://maestrodatabase.com/blog/liminal-biosciences-announces-sale-of-priority-review-voucher-for-usd105-million 2021-08-10T02:17:38 https://maestrodatabase.com/blog/unacceptable-dads-cancer-treatment-denied 2023-09-05T20:41:50 https://maestrodatabase.com/blog/ablivas-lead-candidate-kl1333-receives-fda-fast-track-designation 2023-09-05T08:13:57 https://maestrodatabase.com/blog/sunovion-announces-acceptance-by-the-u-dot-s-fda-of-the-new-drug-application-for-dasotraline-for-the-treatment-of-adults-with-moderate-to-severe-binge-eating-disorder 2019-07-31T02:58:30 https://maestrodatabase.com/blog/korea-to-implement-new-drug-pricing-policy-that-rewards-innovation 2025-02-20T08:16:24 https://maestrodatabase.com/blog/fda-approves-mercks-keytruda-pembrolizumab-for-treatment-of-refractory-or-relapsed-primary-mediastinal-large-b-cell-lymphoma 2018-06-14T07:31:23 https://maestrodatabase.com/blog/doron-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-designation-for-motys-for-treatment-of-symptoms-associated-with-osteoarthritis 2025-02-20T08:09:29 https://maestrodatabase.com/blog/momenta-pharmaceuticals-announces-fast-track-designation-for-m281-nipocalimab-in-haemolytic-disease-of-the-foetus-and-newborn 2019-07-31T03:18:43 https://maestrodatabase.com/blog/harmony-biosciences-provides-update-on-the-status-of-the-supplemental-new-drug-application-for-pitolisant-in-idiopathic-hypersomnia 2025-02-20T19:59:30 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-december-2022 2022-11-30T19:14:22 https://maestrodatabase.com/blog/mylan-provides-statement-on-generic-advair-diskus 2018-06-14T07:40:06 https://maestrodatabase.com/blog/after-court-defeat-fda-shifts-to-regulating-some-drugs-as-devices 2021-08-10T04:16:54 https://maestrodatabase.com/blog/evkeeza-evinacumab-dgnb-sbla-for-children-with-ultra-rare-inherited-form-of-high-cholesterol-accepted-for-fda-priority-review 2022-11-30T19:24:43 https://maestrodatabase.com/blog/swiss-national-council-votes-to-accept-fda-approved-medical-devices 2022-11-30T18:58:21 https://maestrodatabase.com/blog/are-kiwis-dying-because-the-government-wont-fund-cancer-drugs 2019-02-05T08:27:20 https://maestrodatabase.com/blog/jacinda-ardern-not-fair-to-compare-pharmac-with-australias-system 2019-02-05T08:30:41 https://maestrodatabase.com/blog/pbs-growth-hormone-program-paediatric-use---1-february-2019-listing-changes 2019-02-05T09:15:31 https://maestrodatabase.com/blog/roche-submits-supplemental-biologics-license-application-to-the-us-fda-for-kadcyla-for-adjuvant-treatment-of-people-with-her2-positive-early-breast-cancer-with-residual-disease-after-neo-adjuvant-treatment 2019-02-05T09:40:45 https://maestrodatabase.com/blog/how-csl-priced-the-worlds-most-expensive-drug 2022-11-30T20:20:01 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-december-2022 2022-11-30T20:08:05 https://maestrodatabase.com/blog/askbio-receives-fda-regenerative-medicine-advanced-therapy-designation-for-parkinsons-disease-investigational-gene-therapy 2025-02-20T21:56:24 https://maestrodatabase.com/blog/final-guidance-on-metastasis-free-survival-in-non-metastatic-castration-resistant-prostate-cancer-released-by-the-fda 2021-08-10T07:02:55 https://maestrodatabase.com/blog/companion-diagnostics-are-growing-rapidly-worldwide-what-about-in-korea 2021-08-10T08:46:37 https://maestrodatabase.com/blog/life-changing-ms-drug-costs-ps600-a-month-in-england-but-is-free-on-nhs-in-scotland 2021-08-10T05:29:11 https://maestrodatabase.com/blog/us-fda-grants-breakthrough-therapy-designation-for-potential-next-generation-rsv-medicine-medi8897 2019-02-05T18:07:08 https://maestrodatabase.com/blog/risk-classification-of-antimicrobials-used-in-animals-opens-for-public-consultation 2019-02-05T18:00:39 https://maestrodatabase.com/blog/tga-approves-new-gene-therapy-from-novartis 2020-08-13T03:17:45 https://maestrodatabase.com/blog/ema-grants-prime-eligibility-for-potential-next-generation-rsv-medicine-medi8897 2019-02-05T18:04:21 https://maestrodatabase.com/blog/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-for-gardasil-9-in-women-and-men-ages-27-to-45-for-the-prevention-of-certain-hpv-related-cancers-and-diseases 2018-06-14T10:12:26 https://maestrodatabase.com/blog/drug-makers-blame-middlemen-for-high-prices-but-still-make-huge-profits 2019-02-05T18:20:23 https://maestrodatabase.com/blog/effect-of-cross-over-in-oncology-clinical-trials-on-evidence-levels-in-early-benefit-assessment-in-germany 2018-06-14T10:00:40 https://maestrodatabase.com/blog/pain-therapeutics-announces-feedback-from-recent-meeting-with-fda-on-remoxy 2019-02-05T18:14:32 https://maestrodatabase.com/blog/current-prescription-drug-pricing-practices-lessons-in-obfuscation 2018-06-14T21:18:52 https://maestrodatabase.com/blog/from-epipens-to-antibiotics-report-finds-canadas-drug-shortages-could-be-getting-worse 2018-06-14T21:24:40 https://maestrodatabase.com/blog/arcturus-therapeutics-and-csl-announce-european-medicines-agency-validates-marketing-authorisation-application-for-arct-154-vaccine-to-prevent-covid-19 2023-09-06T01:28:01 https://maestrodatabase.com/blog/big-pharma-firms-criticise-dutch-campaign-to-slash-drug-prices 2019-02-05T18:26:29 https://maestrodatabase.com/blog/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-for-keytruda-pembrolizumab-as-adjuvant-therapy-in-certain-patients-with-renal-cell-carcinoma-following-surgery 2021-08-10T11:21:10 https://maestrodatabase.com/blog/building-synergy-between-regulatory-and-hta-agencies-beyond-processes-and-procedures--can-we-effectively-align-the-evidentiary-requirements-a-survey-of-stakeholder-perceptions 2018-06-14T12:26:38 https://maestrodatabase.com/blog/fda-accepts-for-review-new-drug-application-for-mercks-investigational-combination-of-imipenem-slash-cilastatin-and-relebactam-and-supplemental-nda-for-zerbaxa-ceftolozane-and-tazobactam 2019-02-05T18:31:38 https://maestrodatabase.com/blog/chimeric-antigen-receptor-car-t-cell-therapy-and-patient-reported-outcomes 2018-06-14T21:40:17 https://maestrodatabase.com/blog/relief-but-at-what-cost-the-steep-price-of-modern-psoriasis-medications 2019-02-05T19:21:07 https://maestrodatabase.com/blog/fda-approves-first-generic-versions-of-suboxone-sublingual-film-which-may-increase-access-to-treatment-for-opioid-dependence 2018-06-14T21:44:00 https://maestrodatabase.com/blog/drug-prices 2019-02-05T19:18:42 https://maestrodatabase.com/blog/scpharmaceuticals-receives-complete-response-letter-from-the-fda-for-furoscix 2018-06-14T21:30:56 https://maestrodatabase.com/blog/vivagel-bv-granted-marketing-approval-in-australia 2017-10-25T11:16:24 https://maestrodatabase.com/blog/health-care-system-performs-well-but-faces-challenges 2018-06-14T21:53:46 https://maestrodatabase.com/blog/alp-2-percent-health-insurance-premium-cap-to-hit-margins 2018-06-14T21:55:56 https://maestrodatabase.com/blog/worlds-first-potential-target-therapy-for-diffuse-gastric-cancer-granted-fast-track-designation-by-the-us-fda 2025-02-20T23:14:15 https://maestrodatabase.com/blog/fda-accepts-application-for-mercks-keytruda-pembrolizumab-as-single-agent-for-certain-patients-with-msi-h-slash-dmmr-advanced-endometrial-carcinoma 2021-08-10T11:51:28 https://maestrodatabase.com/blog/quentin-bryce-in-canberra-to-support-getting-breast-cancer-drug-listed-on-pbs 2017-10-25T11:22:56 https://maestrodatabase.com/blog/gw-pharmaceuticals-receives-approval-for-epidyolex-cannabidiol-from-the-mhra-for-the-treatment-of-seizures-associated-with-tuberous-sclerosis-complex 2021-08-10T11:34:22 https://maestrodatabase.com/blog/better-health-care-helps-fiscal-health 2017-10-25T11:32:38 https://maestrodatabase.com/blog/seattle-genetics-announces-tukysa-tucatinib-approved-within-months-for-all-countries-participating-in-fdas-project-orbis-initiative 2020-08-13T04:12:14 https://maestrodatabase.com/blog/fda-approves-first-drug-for-treatment-of-peanut-allergy-for-children 2020-02-01T01:55:06 https://maestrodatabase.com/blog/merck-ceo-frazier-to-testify-at-senate-drug-pricing-hearing 2019-02-05T23:44:53 https://maestrodatabase.com/blog/biosimilar-rituximab-on-the-pbs---information-for-health-professionals-and-patients 2020-02-01T01:52:31 https://maestrodatabase.com/blog/mr-quixote-goes-to-washington-a-bill-would-allow-medicare-to-negotiate-drug-prices 2017-10-25T19:50:01 https://maestrodatabase.com/blog/characterisation-of-the-pharmaceutical-risk-sharing-arrangement-process-in-catalonia 2021-08-10T11:47:08 https://maestrodatabase.com/blog/dear-jacinda-ardern-my-mother-could-die-because-of-you 2019-02-05T23:37:22 https://maestrodatabase.com/blog/highlights-from-the-chmp-27-30-january-2020-meeting 2020-02-01T01:44:51 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-opens-nominations-for-new-members-of-its-voting-panels 2017-10-25T19:45:32 https://maestrodatabase.com/blog/european-medicines-agency-validates-bristol-myers-squibbs-application-for-opdivo-nivolumab-as-adjuvant-treatment-for-resected-oesophageal-or-gastro-oesophageal-junction-cancer-following-chemoradiotherapy 2021-01-05T03:16:12 https://maestrodatabase.com/blog/co-pay-method-helps-drive-up-drug-prices 2017-10-25T20:30:46 https://maestrodatabase.com/blog/bipartisan-group-of-law-makers-introduces-bill-to-fight-high-drug-prices 2019-02-06T04:24:55 https://maestrodatabase.com/blog/polaritybio-receives-us-fda-breakthrough-therapy-designation-for-treatment-of-wagner-grade-i-diabetic-foot-ulcers 2025-02-20T23:47:46 https://maestrodatabase.com/blog/u-dot-s-lawmakers-will-not-tackle-healthcare-this-year-ryan-says 2017-10-25T20:19:03 https://maestrodatabase.com/blog/the-best-way-to-lower-drug-prices-end-the-medicaid-program-that-blocks-discounts 2019-02-06T04:52:59 https://maestrodatabase.com/blog/trumps-medicaid-changes-offer-states-new-powers-to-lower-drug-costs----with-a-catch 2020-02-01T01:59:58 https://maestrodatabase.com/blog/we-must-reduce-drug-prices-with-policies-that-work-not-more-regulation 2019-02-05T23:55:45 https://maestrodatabase.com/blog/enhertu-granted-breakthrough-therapy-designation-in-the-us-as-post-neo-adjuvant-therapy-for-patients-with-her2-positive-early-breast-cancer 2025-12-22T08:16:57 https://maestrodatabase.com/blog/pear-therapeutics-announces-formulary-availability-for-its-three-fda-authorised-prescription-digital-therapeutics-at-optumrx 2021-08-10T21:02:27 https://maestrodatabase.com/blog/fda-grants-priority-review-for-daiichi-sankyos-new-drug-application-for-csf1r-inhibitor-pexidartinib-for-treatment-of-patients-with-tgct-a-rare-debilitating-tumour 2019-02-06T04:18:41 https://maestrodatabase.com/blog/biorestorative-receives-fda-fast-track-designation-for-brtx-100-chronic-lumbar-disc-disease-program 2025-02-20T23:35:08 https://maestrodatabase.com/blog/implementing-outcomes-based-managed-entry-agreements-for-rare-disease-treatments-nusinersen-and-tisagenlecleucel 2021-08-10T20:50:10 https://maestrodatabase.com/blog/dermavant-announces-fda-acceptance-for-filing-of-new-drug-application-for-tapinarof-cream-for-the-treatment-of-adults-with-plaque-psoriasis 2021-08-10T20:53:41 https://maestrodatabase.com/blog/how-trumps-latest-plan-to-cut-drug-prices-will-affect-you 2019-02-06T09:35:02 https://maestrodatabase.com/blog/what-are-the-obligations-of-pharmaceutical-companies-in-a-global-health-emergency 2021-08-10T21:19:56 https://maestrodatabase.com/blog/italfarmaco-group-receives-ema-validation-of-marketing-authorisation-application-for-givinostat-in-duchenne-muscular-dystrophy 2023-09-06T02:10:32 https://maestrodatabase.com/blog/novartis-and-vertex-battle-the-netherlands-government-over-pricing 2019-02-06T10:07:59 https://maestrodatabase.com/blog/fda-finalises-new-policy-to-encourage-widespread-innovation-and-development-of-new-buprenorphine-treatments-for-opioid-use-disorder 2019-02-06T19:31:11 https://maestrodatabase.com/blog/how-to-think-about-medicare-for-all 2017-10-25T22:10:29 https://maestrodatabase.com/blog/more-affordable-medicines-for-all-australians 2019-02-06T09:39:26 https://maestrodatabase.com/blog/new-opportunity-parallel-scientific-advice-from-cadth-and-nice 2019-02-06T19:39:28 https://maestrodatabase.com/blog/which-road-to-universal-coverage 2017-10-25T22:14:24 https://maestrodatabase.com/blog/nice-collaborates-with-the-canadian-agency-for-drugs-and-technology-in-health-to-offer-parallel-scientific-advice 2019-02-06T19:44:08 https://maestrodatabase.com/blog/fda-approves-first-therapy-for-the-treatment-of-adult-patients-with-a-rare-blood-clotting-disorder 2019-02-06T19:33:42 https://maestrodatabase.com/blog/innovent-and-eli-lilly-announce-acceptance-of-a-supplemental-new-drug-application-of-tyvyt-sintilimab-injection-in-combination-with-gemcitabine-and-platinum-as-first-line-therapy-in-squamous-non-small-cell-lung-cancer-in-china 2020-08-13T07:33:38 https://maestrodatabase.com/blog/fda-approves-first-faecal-microbiota-product 2022-12-01T01:32:17 https://maestrodatabase.com/blog/comparing-pharmacs-outcomes-with-those-of-australia 2019-02-06T19:56:32 https://maestrodatabase.com/blog/trump-appeals-for-lower-drug-prices-this-is-wrong-unfair-and-together-we-can-stop-it 2019-02-06T20:25:10 https://maestrodatabase.com/blog/cancer-group-demands-inquiry-into-pharmac 2019-02-06T19:48:27 https://maestrodatabase.com/blog/novartis-announces-fda-filing-acceptance-of-xolair-omalizumab-pre-filled-syringe-for-self-administration-across-all-indications 2020-08-13T09:52:48 https://maestrodatabase.com/blog/ema-validates-indication-extension-application-for-aspaveli-for-treatment-of-c3g-and-primary-ic-mpgn 2025-02-21T02:09:59 https://maestrodatabase.com/blog/daiichi-sankyo-submits-application-for-oncolytic-virus-teserpaturev-g47-for-treatment-of-patients-with-malignant-glioma-in-japan 2021-01-05T05:56:30 https://maestrodatabase.com/blog/elusys-therapeutics-receives-health-canada-approval-for-anthim-for-the-treatment-of-inhalation-anthrax 2020-08-13T08:09:18 https://maestrodatabase.com/blog/x4-pharmaceuticals-announces-submission-of-new-drug-application-to-us-fda-for-mavorixafor-in-whim-syndrome 2023-09-06T04:13:27 https://maestrodatabase.com/blog/update-on-us-regulatory-review-of-ultomiris-in-nmosd 2023-09-06T06:06:58 https://maestrodatabase.com/blog/tesaro-announces-u-dot-s-fda-approval-of-varubi-iv-for-delayed-nausea-and-vomiting-associated-with-cancer-chemotherapy 2017-10-26T01:56:35 https://maestrodatabase.com/blog/two-powerful-canadian-provinces-argued-against-federal-drug-price-crackdown 2019-07-31T07:08:59 https://maestrodatabase.com/blog/ptc-therapeutics-receives-complete-response-letter-for-atalurens-nda 2017-10-26T02:00:22 https://maestrodatabase.com/blog/fda-approves-roches-lunsumio-velo-for-subcutaneous-use-in-relapsed-or-refractory-follicular-lymphoma 2025-12-22T21:26:17 https://maestrodatabase.com/blog/strengthening-the-assessment-of-medical-devices-and-information-for-consumers 2017-10-26T02:22:25 https://maestrodatabase.com/blog/moderna-files-fda-application-for-the-jn-dot-1-targeting-covid-19-vaccine 2024-06-08T02:52:17 https://maestrodatabase.com/blog/trump-administration-is-drafting-plan-to-allow-us-consumers-to-import-drugs-from-canada 2019-07-31T07:15:02 https://maestrodatabase.com/blog/updated-covid-19-vaccines-for-use-in-the-united-states-beginning-in-fall-2024 2024-06-08T02:42:46 https://maestrodatabase.com/blog/eli-lilly-ceo-to-2020-candidates-capping-drug-prices-would-not-lead-to-lower-health-care-costs 2019-07-31T07:10:59 https://maestrodatabase.com/blog/consultation-now-open---review-of-base-case-discount-rate-at-3a-dot-1-of-the-pbac-guidelines 2022-04-05T07:28:34 https://maestrodatabase.com/blog/tg-therapeutics-announces-fda-acceptance-of-new-drug-application-for-umbralisib-as-a-treatment-for-patients-with-previously-treated-marginal-zone-lymphoma-and-follicular-lymphoma 2020-08-13T11:47:07 https://maestrodatabase.com/blog/once-we-have-it-will-we-use-it-a-european-survey-on-willingness-to-be-vaccinated-against-covid-19 2020-08-13T11:56:20 https://maestrodatabase.com/blog/4d-molecular-therapeutics-receives-fda-fast-track-designation-for-4d-310-gene-therapy-for-treatment-of-fabry-disease 2020-08-13T12:16:05 https://maestrodatabase.com/blog/drug-prices-fall-in-switzerland-but-generics-remain-expensive 2020-08-13T21:00:13 https://maestrodatabase.com/blog/cemiplimab-for-the-first-line-treatment-of-patients-wth-advanced-or-metastatic-pd-l1-positive-non-small-cell-lung-cancer 2022-12-01T02:41:53 https://maestrodatabase.com/blog/nice-recommends-adcetris-for-first-line-use-for-patients-with-a-rare-form-of-non-hodgkins-lymphoma 2020-08-13T21:31:40 https://maestrodatabase.com/blog/for-company-behind-coronavirus-drug-sharp-questions-over-pricing-potentially-cheaper-option 2020-08-13T21:43:11 https://maestrodatabase.com/blog/impact-of-rarity-on-canadian-oncology-health-technology-assessment-and-funding 2020-08-13T21:05:20 https://maestrodatabase.com/blog/eylea-hd-pre-filled-syringe-with-ocuclick-dosing-system-granted-marketing-authorisation-in-canada 2025-02-21T05:28:49 https://maestrodatabase.com/blog/predictors-of-negotiated-prices-for-new-drugs-in-germany 2020-08-13T21:08:56 https://maestrodatabase.com/blog/disney-official-others-talk-about-switch-to-biosimilars 2020-08-13T21:15:14 https://maestrodatabase.com/blog/gileads-seladelpar-granted-conditional-european-marketing-authorisation-for-the-treatment-of-primary-biliary-cholangitis 2025-02-21T05:21:51 https://maestrodatabase.com/blog/european-medicines-agency-validates-biomarins-marketing-authorisation-application-for-vosoritide-to-treat-children-with-achondroplasia 2020-08-13T21:20:57 https://maestrodatabase.com/blog/innoviva-announces-fda-acceptance-and-priority-review-of-new-drug-application-for-sulbactam-durlobactam 2022-12-01T05:26:33 https://maestrodatabase.com/blog/watchdog-urged-to-probe-mckinsey-over-work-with-fda-opioid-manufacturers 2022-04-05T20:13:17 https://maestrodatabase.com/blog/danicopan-in-combination-with-ravulizumab-or-eculizumab-for-the-treatment-of-patients-with-paroxysmal-nocturnal-haemoglobinuria 2024-06-08T08:25:53 https://maestrodatabase.com/blog/mhra-approves-pfizer-slash-biontechs-adapted-covid-19-vaccine-comirnaty-that-targets-omicron-xbb-dot-1-5 2023-09-06T08:03:10 https://maestrodatabase.com/blog/epkinly-epcoritamab-approved-by-japan-ministry-of-health-labour-and-welfare-for-additional-indication-as-a-treatment-for-relapsed-or-refractory-follicular-lymphoma 2025-02-21T06:54:39 https://maestrodatabase.com/blog/rights-watchdog-urges-quick-reimbursement-of-expensive-new-drugs 2022-04-05T20:18:58 https://maestrodatabase.com/blog/ezetimibe-reduces-the-risk-of-heart-attacks-and-strokes 2019-07-31T10:32:39 https://maestrodatabase.com/blog/the-covid-19-pandemic-could-be-the-last-straw-for-high-drug-costs 2020-08-13T21:46:28 https://maestrodatabase.com/blog/fda-approves-first-treatment-for-cerebrotendinous-xanthomatosis-a-rare-lipid-storage-disease 2025-02-21T20:46:50 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-european-commission-approval-for-car-t-cell-therapy-breyanzi-lisocabtagene-maraleucel-for-certain-forms-of-relapsed-or-refractory-large-b-cell-lymphoma 2022-04-05T20:45:23 https://maestrodatabase.com/blog/cadth-strategy-2022-2025-anticipate-innovate-and-transform 2022-04-05T20:29:58 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-european-commission-approval-for-opdivo-nivolumab-plus-yervoy-ipilimumab-as-first-line-treatment-for-patients-with-unresectable-advanced-recurrent-or-metastatic-oesophageal-squamous-cell-carcinoma-with-tumour-cell-pd-l1-expression-1-percent 2022-04-05T20:58:22 https://maestrodatabase.com/blog/aurinia-announces-the-great-britain-marketing-authorisation-of-lupkynis-voclosporin-for-the-treatment-of-lupus-nephritis 2022-12-01T06:16:19 https://maestrodatabase.com/blog/european-medicines-agency-validates-bristol-myers-squibbs-application-for-opdivo-nivolumab-combined-with-chemotherapy-as-first-line-treatment-in-metastatic-gastric-cancer-gastro-oesophageal-junction-cancer-and-oesophageal-adenocarcinoma 2021-01-05T20:59:52 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-august-2019 2019-07-31T10:48:39 https://maestrodatabase.com/blog/curium-announces-fda-approval-of-a-generic-version-of-datscan-ioflupane-i-123-injection-in-the-u-dot-s 2022-04-05T20:26:08 https://maestrodatabase.com/blog/reimbursed-access-to-bylvay-odevixibat-approved-in-france-for-patients-with-pfic-1-and-2 2022-12-01T05:43:24 https://maestrodatabase.com/blog/patient-preferences-studies-how-nice-aims-to-make-use-of-them 2019-07-31T11:25:36 https://maestrodatabase.com/blog/green-light-for-groundbreaking-personalised-cancer-therapy-that-reprogrammes-immune-system 2025-02-21T21:01:44 https://maestrodatabase.com/blog/harmonising-hta-evidence-needs-and-expectations-challenges-and-opportunities-to-improve-evidence-generation-ensure-access-and-affordability 2025-02-21T20:57:02 https://maestrodatabase.com/blog/fda-approves-new-monotherapy-indication-for-mercks-keytruda-pembrolizumab 2019-07-31T11:01:56 https://maestrodatabase.com/blog/use-of-surrogate-endpoints-in-health-technology-assessment-a-review-of-selected-nice-technology-appraisals-in-oncology 2025-02-21T20:53:37 https://maestrodatabase.com/blog/motif-bio-submits-nda-for-iclaprim 2018-06-16T05:59:15 https://maestrodatabase.com/blog/adding-pertuzumab-to-existing-treatments-after-surgery-for-early-breast-cancer-not-cost-effective-says-nice-in-draft-guidance 2018-06-16T05:40:25 https://maestrodatabase.com/blog/rare-disease-therapy-crysvita-to-be-barred-from-nhs 2018-06-16T05:49:20 https://maestrodatabase.com/blog/icer-report-questions-the-adequacy-of-evidence-on-overall-health-benefit-of-elagolix-given-limitations-of-information-on-safety-and-limited-evidence-comparing-to-other-treatment-options 2018-06-16T06:05:44 https://maestrodatabase.com/blog/fda-accepts-application-for-genentechs-crovalimab-for-the-treatment-of-pnh-a-rare-life-threatening-blood-condition 2023-09-06T11:51:07 https://maestrodatabase.com/blog/mavacamten-for-the-treatment-of-patients-with-symptomatic-obstructive-hypertrophic-cardiomyopathy 2023-09-06T20:58:41 https://maestrodatabase.com/blog/joint-reimbursement-of-opdivo-cdx-platform-marks-milestone-in-gastric-cancer-but-challenges-remain 2023-09-06T11:18:24 https://maestrodatabase.com/blog/broad-health-care-coalition-opposes-administration-stance-in-anti-aca-lawsuit 2018-06-16T06:11:19 https://maestrodatabase.com/blog/tga-grants-provisional-determination-to-msds-anti-viral-covid-19-treatment-molnupiravir 2021-08-11T00:42:55 https://maestrodatabase.com/blog/alvotech-and-teva-announce-filing-acceptance-of-us-biologics-license-application-for-avt06-a-proposed-biosimilar-to-eylea-aflibercept 2025-02-21T23:08:49 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-august-2019 2019-07-31T21:12:52 https://maestrodatabase.com/blog/genentechs-novel-anti-tigit-tiragolumab-granted-fda-breakthrough-therapy-designation-in-combination-with-tecentriq-for-pd-l1-high-non-small-cell-lung-cancer 2021-01-05T23:20:29 https://maestrodatabase.com/blog/supporting-medicine-developers-in-generating-quality-data-packages-in-early-access-approaches-prime-and-breakthrough-therapies 2019-07-31T21:31:02 https://maestrodatabase.com/blog/us-fda-approves-expanded-age-indication-for-gsks-arexvy-the-first-respiratory-syncytial-virus-vaccine-for-adults-aged-50-59-at-increased-risk 2024-06-09T01:20:07 https://maestrodatabase.com/blog/nightstar-therapeutics-receives-regenerative-medicine-advanced-therapy-designation-for-nsr-rep1-in-choroideremia 2018-06-17T00:03:51 https://maestrodatabase.com/blog/fda-approves-novo-nordisks-wegovy-pill-the-first-and-only-oral-glp-1-for-weight-loss-in-adults 2025-12-23T01:27:35 https://maestrodatabase.com/blog/health-canada-authorizes-itovebi-inavolisib-film-coated-tablets-a-targeted-treatment-for-advanced-hormone-receptor-positive-her2-negative-breast-cancer-with-a-pik3ca-mutation 2025-02-22T22:20:46 https://maestrodatabase.com/blog/scynexis-announces-fda-approval-of-second-indication-for-brexafemme-ibrexafungerp-for-reduction-in-incidence-of-recurrent-vulvovaginal-candidiasis 2022-12-01T19:15:36 https://maestrodatabase.com/blog/oncolytics-biotech-receives-fda-fast-track-designation-for-the-treatment-of-advanced-slash-metastatic-pancreatic-cancer 2022-12-01T19:11:17 https://maestrodatabase.com/blog/viridian-therapeutics-announces-bla-acceptance-and-priority-review-for-veligrotug-for-the-treatment-of-thyroid-eye-disease 2025-12-23T21:06:25 https://maestrodatabase.com/blog/icer-publishes-evidence-report-on-fezolinetant-for-vasomotor-symptoms-associated-with-menopause 2022-12-01T19:30:52 https://maestrodatabase.com/blog/citius-pharmaceuticals-announces-us-fda-acceptance-of-biologics-license-application-of-denileukin-diftitox-for-the-treatment-of-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma 2022-12-01T19:25:19 https://maestrodatabase.com/blog/trumps-plan-to-lower-drug-prices-tests-limits-of-the-law 2018-06-17T01:20:37 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-to-nuvectis-pharmas-nxp800-for-the-treatment-of-platinum-resistant-arid1a-mutated-ovarian-carcinoma 2022-12-01T19:21:11 https://maestrodatabase.com/blog/drug-patents-could-be-canadas-special-weapon-in-u-dot-s-trade-dispute 2018-06-17T01:24:03 https://maestrodatabase.com/blog/livtencity-maribavir-receives-positive-cadth-recommendation-for-adults-with-post-transplant-cytomegalovirus-infection 2022-12-01T19:53:06 https://maestrodatabase.com/blog/marius-pharmaceuticals-submits-new-drug-application-to-u-dot-s-fda-for-next-generation-oral-testosterone-replacement-therapy-in-male-patients-with-hypogonadism 2021-01-06T00:56:09 https://maestrodatabase.com/blog/you-can-spend-your-super-on-boob-jobs-and-weight-loss-surgery-but-not-operations-to-fix-crippling-back-pain 2018-06-17T01:45:29 https://maestrodatabase.com/blog/names-of-liposomal-medicines-to-be-changed-to-avoid-medication-errors 2019-07-31T23:49:31 https://maestrodatabase.com/blog/takeda-koreas-kynteles-sc-wins-insurance-benefit 2022-12-01T19:48:11 https://maestrodatabase.com/blog/lenvatinib-mesylate-in-combination-with-pembrolizumab-for-the-first-line-treatment-of-patients-with-advanced-renal-cell-carcinoma 2022-12-01T19:35:08 https://maestrodatabase.com/blog/morphosys-and-incyte-announce-the-acceptance-of-the-swissmedic-marketing-authorisation-application-for-tafasitamab 2021-01-06T04:16:00 https://maestrodatabase.com/blog/afraid-of-pharma-pushback-a-health-data-broker-puts-up-a-barrier-to-drug-pricing-information 2022-12-01T20:13:55 https://maestrodatabase.com/blog/medicare-expansion-and-a-lower-eligibility-age-are-included-in-democrats-3-dollars-5-cents-trillion-budget-plan 2021-08-11T03:37:40 https://maestrodatabase.com/blog/kye-pharmaceuticals-announces-approval-of-corzyna-in-canada-ranolazine-extended-release-tablets 2021-01-06T01:45:06 https://maestrodatabase.com/blog/phrmas-misleading-description-of-medicare-drug-price-legislation 2021-08-11T03:33:31 https://maestrodatabase.com/blog/early-breast-cancer-indication-of-a-minor-additional-clinical-benefit-of-adjuvant-therapy-with-olaparib 2022-12-01T20:06:26 https://maestrodatabase.com/blog/tga-head-john-skerritt-says-nsw-death-toll-would-be-much-higher-without-astrazeneca-vaccine 2021-08-11T03:41:14 https://maestrodatabase.com/blog/good-news-for-kiwi-women-as-pharmac-funds-utrogestan-from-today 2022-12-01T19:58:47 https://maestrodatabase.com/blog/pressure-builds-for-full-fda-approval-of-vaccines 2021-08-11T10:53:05 https://maestrodatabase.com/blog/dialectic-therapeutics-announces-dt2216-has-received-fast-track-designation-from-the-fda-for-adult-patients-with-relapsed-or-refractory-peripheral-and-cutaneous-t-cell-lymphoma 2022-04-06T07:54:29 https://maestrodatabase.com/blog/luxa-biotechnology-announces-fda-regenerative-medicine-advanced-therapy-designation-granted-to-rpesc-rpe-4w-transplantation-for-the-treatment-of-dry-age-related-macular-degeneration 2025-02-23T22:10:49 https://maestrodatabase.com/blog/fda-approves-novartis-vijoice-alpelisib-as-first-and-only-treatment-for-select-patients-with-pik3ca-related-overgrowth-spectrum 2022-04-06T07:35:37 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-european-commission-approval-for-opdivo-nivolumab-with-chemotherapy-as-first-line-treatment-for-patients-with-unresectable-advanced-recurrent-or-metastatic-oesophageal-squamous-cell-carcinoma-with-tumour-cell-pd-l1-expression-1-percent 2022-04-06T07:41:37 https://maestrodatabase.com/blog/hira-to-remove-17-medicines-from-group-2-anti-cancer-list-update-reimbursement-criteria 2025-02-23T22:34:51 https://maestrodatabase.com/blog/farxiga-granted-priority-review-in-the-us-for-the-treatment-of-patients-with-chronic-kidney-disease 2021-01-06T07:07:20 https://maestrodatabase.com/blog/fast-track-pathways-for-drug-approvals-the-australian-experience-so-far 2019-08-01T01:27:43 https://maestrodatabase.com/blog/scientific-development-of-hta--a-proposal-by-the-health-technology-assessment-international-scientific-development-and-capacity-building-committee 2019-08-01T01:24:11 https://maestrodatabase.com/blog/turning-point-therapeutics-granted-sixth-regulatory-designation-for-repotrectinib 2021-08-11T20:50:13 https://maestrodatabase.com/blog/anti-pd-1-slash-ctla-4-bi-specific-antibody-ak104-of-akeso-granted-fda-fast-track-designation-for-recurrent-and-metastatic-cervical-cancer 2020-08-14T03:54:32 https://maestrodatabase.com/blog/swing-therapeutics-receives-fda-breakthrough-device-designation-for-digital-therapeutic-for-the-management-of-fibromyalgia-launches-real-world-study 2021-08-11T20:41:33 https://maestrodatabase.com/blog/new-alzheimers-drug-aducanumab-is-dividing-doctors-and-patients-as-the-tga-weighs-up-its-risk-benefit-profile 2021-08-11T21:14:31 https://maestrodatabase.com/blog/groups-make-own-drugs-to-fight-high-drug-prices-shortages 2021-08-11T21:21:53 https://maestrodatabase.com/blog/veterans-affairs-declines-to-cover-biogens-alzheimers-drug-over-effectiveness-safety-concerns 2021-08-11T20:57:31 https://maestrodatabase.com/blog/withdrawals-from-the-pharmaceutical-benefits-on-1-september-2021 2021-08-11T21:08:56 https://maestrodatabase.com/blog/zogenix-submits-new-drug-application-to-u-dot-s-fda-and-marketing-authorisation-application-to-ema-for-fintepla-for-the-treatment-of-dravet-syndrome 2019-02-07T01:16:16 https://maestrodatabase.com/blog/vulnerable-senate-democrats-escalate-a-push-for-medicare-to-negotiate-drug-prices 2021-08-11T21:04:12 https://maestrodatabase.com/blog/personalised-medicine-and-pay-for-performance-should-pharmaceutical-firms-be-fully-penalised-when-treatment-fails 2018-06-17T21:05:49 https://maestrodatabase.com/blog/u-dot-s-fda-aims-to-decide-on-strain-selection-for-covid-boosters-by-june 2022-04-06T20:50:55 https://maestrodatabase.com/blog/ecdc-and-ema-issue-advice-on-fourth-doses-of-mrna-covid-19-vaccines 2022-04-06T20:38:29 https://maestrodatabase.com/blog/we-dont-unlearn-what-the-pandemic-has-taught-regulators-about-real-world-data 2021-08-11T21:30:24 https://maestrodatabase.com/blog/bioxcel-therapeutics-announces-fda-approval-of-igalmi-dexmedetomidine-sublingual-film-for-acute-treatment-of-agitation-associated-with-schizophrenia-or-bipolar-i-or-ii-disorder-in-adults 2022-04-06T20:43:37 https://maestrodatabase.com/blog/pbs-listing-for-cystic-fibrosis-drug-an-absolute-game-changer 2020-02-01T12:02:05 https://maestrodatabase.com/blog/some-hoped-fda-approval-of-pfizers-covid-vaccine-would-convince-unvaccinated-americans-it-didnt-study-finds 2022-04-06T21:44:05 https://maestrodatabase.com/blog/inside-a-campaign-to-get-medicare-coverage-for-a-new-alzheimers-drug 2022-04-06T21:22:10 https://maestrodatabase.com/blog/eligible-individuals-can-receive-second-covid-19-booster-shot-at-no-cost 2022-04-06T21:29:07 https://maestrodatabase.com/blog/invivyd-earns-fast-track-designation-for-vyd2311-a-vaccine-alternative-antibody-to-prevent-covid 2025-12-23T23:49:34 https://maestrodatabase.com/blog/astellas-withdraws-lawsuit-after-evading-medicare-drug-price-negotiations 2023-09-07T10:27:12 https://maestrodatabase.com/blog/korea-pharma-groups-warn-price-reform-will-cut-3-dot-6-trillion-won-and-cost-jobs 2025-12-24T00:41:14 https://maestrodatabase.com/blog/splisense-receives-fda-fast-track-designation-for-spl84-for-the-treatment-of-cystic-fibrosis 2024-06-10T02:58:23 https://maestrodatabase.com/blog/fda-accepts-for-priority-review-the-new-drug-application-for-mirabegron-for-oral-suspension-and-supplemental-new-drug-application-for-myrbetriq-mirabegron-tablets-in-paediatric-patients 2021-01-06T21:03:35 https://maestrodatabase.com/blog/fda-may-approve-new-covid-boosters-by-friday-as-deaths-spike 2023-09-07T21:12:53 https://maestrodatabase.com/blog/sanofis-wayrilz-approved-in-the-eu-as-the-first-btk-inhibitor-to-treat-immune-thrombocytopenia 2025-12-24T02:01:54 https://maestrodatabase.com/blog/fda-accepts-filing-of-leqembi-lecanemab-irmb-sbla-for-iv-maintenance-dosing-for-the-treatment-of-early-alzheimers-disease 2024-06-10T03:26:48 https://maestrodatabase.com/blog/public-summary-documents---september-2025-pbac-meeting 2025-12-24T02:35:20 https://maestrodatabase.com/blog/babys-brain-tumour-highlights-nightmare-experience-with-private-health-insurance 2019-08-01T03:36:05 https://maestrodatabase.com/blog/the-trouble-with-nationals-cancer-plan 2019-08-01T03:32:14 https://maestrodatabase.com/blog/agenda-for-the-december-2022-pbac-intracycle-meeting 2022-12-02T05:13:19 https://maestrodatabase.com/blog/department-tweaks-the-agenda-for-the-november-2023-pbac-meeting 2023-09-07T21:37:55 https://maestrodatabase.com/blog/lillys-jaypirca-wins-korea-reimbursement-for-relapsed-mantle-cell-lymphoma 2025-12-24T01:03:44 https://maestrodatabase.com/blog/ozempic-and-wegovy-maker-just-scratching-the-surface-in-meeting-demand-for-weight-loss-drugs-ceo-says 2023-09-07T21:33:29 https://maestrodatabase.com/blog/inflation-reduction-act-may-accelerate-generic-and-biosimilar-market-entry-but-questions-remain-around-cms-guidance 2023-09-07T21:22:27 https://maestrodatabase.com/blog/boehringer-and-lillys-jardiance-granted-mhra-approval-to-treat-chronic-kidney-disease 2023-09-07T21:29:01 https://maestrodatabase.com/blog/beigene-announces-european-medicines-agency-acceptance-of-marketing-authorisation-applications-for-tislelizumab-for-the-treatment-of-patients-with-escc-and-nsclc 2022-04-07T02:32:56 https://maestrodatabase.com/blog/us-fda-accepts-marketing-authorisation-application-for-immunoglobulin-yimmugo 2023-09-07T21:15:50 https://maestrodatabase.com/blog/call-for-anti-hiv-drug-to-be-funded 2017-10-26T13:06:53 https://maestrodatabase.com/blog/eu-scientific-opinion-how-to-assess-progress-on-reduction-of-antimicrobial-resistance-and-antimicrobial-consumption 2017-10-26T12:52:38 https://maestrodatabase.com/blog/ema-recommends-moderna-covid-19-vaccine-for-authorisation-in-the-eu 2021-01-06T23:10:45 https://maestrodatabase.com/blog/taking-patient-heterogeneity-and-preferences-into-account-in-health-technology-assessments 2017-10-26T20:27:19 https://maestrodatabase.com/blog/new-shingles-vaccine-endorsed-over-competitor-by-expert-panel-a-boost-for-gsk 2017-10-26T20:21:21 https://maestrodatabase.com/blog/hhs-secretary-azar-meets-with-health-insurance-leaders 2018-06-18T06:43:16 https://maestrodatabase.com/blog/congress-invites-7-drug-makers-to-testify-at-potentially-hostile-hearing-on-drug-prices-heres-what-theyre-saying 2019-02-07T08:55:41 https://maestrodatabase.com/blog/americans-want-to-see-a-bipartisan-fix-for-obamacare-reuters-slash-ipsos-poll 2017-10-26T20:36:55 https://maestrodatabase.com/blog/vertex-fears-its-triplet-will-also-face-uk-reimbursement-battle 2019-02-07T08:58:40 https://maestrodatabase.com/blog/exploration-and-preferential-ranking-of-patient-benefits-of-medical-devices-a-new-and-generic-instrument-for-health-economic-assessments 2017-10-26T20:53:14 https://maestrodatabase.com/blog/cvs-health-is-in-talks-to-buy-aetna 2017-10-26T20:46:32 https://maestrodatabase.com/blog/eli-lilly-ceo-its-time-for-a-change-in-the-drug-pricing-system 2018-06-18T06:46:06 https://maestrodatabase.com/blog/pharma-industry-pushes-back-against-generic-drug-price-cuts 2025-12-24T10:08:44 https://maestrodatabase.com/blog/millions-need-new-year-medicines-price-cut 2025-12-24T10:20:04 https://maestrodatabase.com/blog/diabetics-in-britain-worry-a-no-deal-brexit-could-put-their-lives-at-risk 2019-02-07T20:12:13 https://maestrodatabase.com/blog/dad-travels-to-canada-for-sons-medicine-that-would-cost-$53k-in-u-dot-s 2019-02-07T11:04:59 https://maestrodatabase.com/blog/fda-approves-keytruda-pembrolizumab-plus-lenvima-lenvatinib-combination-for-first-line-treatment-of-adult-patients-with-advanced-renal-cell-carcinoma 2021-08-12T02:07:48 https://maestrodatabase.com/blog/facing-crackdown-in-canada-drug-makers-offered-billions-in-price-cuts 2019-02-07T11:07:05 https://maestrodatabase.com/blog/trump-claims-drug-prices-have-fallen-but-hes-cherry-picking-that-data 2019-02-07T20:25:06 https://maestrodatabase.com/blog/pfizers-best-selling-drug-is-actually-a-vaccine--and-its-price-keeps-increasing 2019-02-07T20:27:18 https://maestrodatabase.com/blog/ema-publishes-agenda-for-24-27-february-2025-chmp-meeting 2025-02-24T21:18:16 https://maestrodatabase.com/blog/thousands-more-people-with-advanced-bowel-cancer-to-benefit-as-nice-approves-bevacizumab-biosimilars 2025-12-24T09:46:34 https://maestrodatabase.com/blog/novartis-and-lilly-ceos-back-trump-plans-to-cut-drug-prices 2019-02-07T20:16:14 https://maestrodatabase.com/blog/dupixent-dupilumab-approved-by-european-commission-for-children-aged-6-to-11-years-with-severe-asthma-with-type-2-inflammation 2022-04-07T05:10:09 https://maestrodatabase.com/blog/medicare-part-d-no-match-for-runaway-specialty-drug-costs 2019-02-07T20:22:27 https://maestrodatabase.com/blog/prime-minister-reveals-ps20-billion-a-year-boost-for-nhs 2018-06-18T10:43:51 https://maestrodatabase.com/blog/pharma-lashes-out-at-the-netherlands-over-drug-pricing-policies 2019-02-07T20:38:50 https://maestrodatabase.com/blog/us-fda-accepts-bmss-supplemental-biologics-license-application-for-opdivo-plus-yervoy-for-patients-with-unresectable-or-metastatic-microsatellite-instability-high-or-mismatch-repair-deficient-colorectal-cancer 2025-02-24T21:59:20 https://maestrodatabase.com/blog/celltrion-completes-resubmission-to-fda-for-proposed-trastuzumab-biosimilar 2018-06-18T10:49:37 https://maestrodatabase.com/blog/vertex-calls-for-changes-to-nice-as-cystic-fibrosis-drug-profits-soar 2019-02-07T20:43:37 https://maestrodatabase.com/blog/what-is-a-biosimilar-exactly 2019-02-07T20:30:54 https://maestrodatabase.com/blog/adalimumab-biosimilars-face-product-obsolescence-before-launch 2021-01-07T02:54:13 https://maestrodatabase.com/blog/the-ema-has-approved-an-additional-subcutaneous-administration-option-for-takhzyro-lanadelumab-for-patients-aged-12-years-and-above-with-recurrent-attacks-of-hereditary-angioedema 2025-02-24T21:51:22 https://maestrodatabase.com/blog/what-will-a-no-deal-brexit-mean-for-pharma-and-health-care 2019-02-07T20:36:35 https://maestrodatabase.com/blog/incyte-announces-u-dot-s-fda-has-extended-the-review-period-for-ruxolitinib-jakafi-in-acute-graft-versus-host-disease 2019-02-07T20:52:41 https://maestrodatabase.com/blog/tga-approves-yet-another-new-medicine-for-patients-with-psoriasis 2022-04-07T05:21:56 https://maestrodatabase.com/blog/is-asco-sending-mixed-messages-on-cancer-drug-value 2018-06-18T11:06:45 https://maestrodatabase.com/blog/chinas-vaccine-tourists-drain-hong-kongs-supply-of-cancer-drug 2018-06-18T11:10:07 https://maestrodatabase.com/blog/tagrisso-granted-priority-review-in-the-us-for-patients-with-unresectable-stage-iii-egfr-mutated-lung-cancer 2024-06-10T06:28:21 https://maestrodatabase.com/blog/almost-half-of-diabetics-skip-medical-care-due-to-costs 2018-06-18T11:02:24 https://maestrodatabase.com/blog/cigna-eclipses-50-percent-in-value-based-care-pay-to-providers 2019-02-07T20:48:30 https://maestrodatabase.com/blog/redhill-biopharmas-rhb-204-granted-fda-fast-track-designation-for-non-tuberculous-mycobacteria-disease 2021-01-07T01:10:33 https://maestrodatabase.com/blog/fda-issues-complete-response-letter-for-duobrii-halobetasol-propionate-and-tazarotene-lotion 2018-06-18T21:14:22 https://maestrodatabase.com/blog/organogenesis-announces-initiation-of-biologics-license-application-for-renu 2025-12-24T11:50:29 https://maestrodatabase.com/blog/icer-to-assess-canakinumab-for-atherosclerosis 2018-06-18T21:05:51 https://maestrodatabase.com/blog/auron-therapeutics-announces-autx-703-granted-fast-track-designation-by-the-fda-for-relapsed-or-refractory-acute-myelogenous-leukaemia 2025-02-24T23:06:54 https://maestrodatabase.com/blog/european-commission-approves-roches-alecensa-as-the-first-and-only-targeted-adjuvant-treatment-for-people-with-alk-positive-early-stage-lung-cance 2024-06-10T21:07:10 https://maestrodatabase.com/blog/inovio-announces-us-fda-breakthrough-therapy-designation-granted-for-ino-3107-for-the-treatment-of-recurrent-respiratory-papillomatosis 2023-09-08T00:44:26 https://maestrodatabase.com/blog/us-fda-grants-fast-track-designation-to-coherent-biopharmas-cbp-1019 2025-02-24T23:32:42 https://maestrodatabase.com/blog/health-canada-approves-tevimbra-tislelizumab-for-injection-in-combination-with-gemcitabine-and-cisplatin-for-the-first-line-treatment-of-adult-patients-with-recurrent-or-metastatic-nasopharyngeal-carcinoma 2025-12-25T01:12:28 https://maestrodatabase.com/blog/private-health-insurance-at-a-tipping-point-with-australians-dropping-cover-in-droves 2019-08-01T06:20:35 https://maestrodatabase.com/blog/fda-approves-almiralls-klisyri-tirbanibulin-for-the-treatment-of-actinic-keratosis-on-expanded-area-of-face-or-scalp-up-to-100-cm2 2024-06-10T07:51:38 https://maestrodatabase.com/blog/immunogen-announces-fda-fast-track-designation-for-mirvetuximab-soravtansine-in-patients-with-platinum-resistant-ovarian-cancer 2018-06-18T23:08:19 https://maestrodatabase.com/blog/trump-administration-weighs-allowing-drug-imports-for-cheaper-prescriptions 2019-08-01T06:23:13 https://maestrodatabase.com/blog/fda-approves-omeros-yartemlea---first-and-only-therapy-indicated-for-transplant-associated-thrombotic-microangiopathy 2025-12-24T23:32:45 https://maestrodatabase.com/blog/smc---june-2024-decisions 2024-06-10T21:16:13 https://maestrodatabase.com/blog/problems-with-paying-people-to-be-vaccinated-against-covid-19 2021-01-07T04:30:05 https://maestrodatabase.com/blog/octapharma-announces-approval-of-new-nuwiq-product-strengths-in-europe-increasing-dosing-flexibility-for-patients-with-haemophilia-a 2018-06-19T01:18:39 https://maestrodatabase.com/blog/glaukos-announces-fda-acceptance-of-nda-submission-for-epioxa 2025-02-25T05:26:34 https://maestrodatabase.com/blog/morphosys-receives-fda-breakthrough-therapy-designation-for-its-antibody-mor208-in-relapsed-slash-refractory-dlbcl 2017-10-27T00:13:36 https://maestrodatabase.com/blog/ema-validates-gileads-marketing-authorisation-application-and-eu-medicines-for-all-application-for-twice-yearly-lenacapavir-for-hiv-prevention 2025-02-25T05:19:13 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-7-april-2022 2022-04-07T06:40:59 https://maestrodatabase.com/blog/y-mabs-announces-complete-response-letter-for-omburtamab-biologics-license-application 2022-12-02T21:53:50 https://maestrodatabase.com/blog/tax-rises-on-the-horizon-for-nhs-budget-hike 2018-06-19T09:30:14 https://maestrodatabase.com/blog/valuing-innovative-drugs-based-on-their-cost-of-manufacturing-will-prolong-the-covid-19-pandemic 2020-08-15T04:59:59 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-12-august-2021 2021-08-12T04:57:13 https://maestrodatabase.com/blog/fda-approves-genentechs-enspryng-for-neuromyelitis-optica-spectrum-disorder 2020-08-15T05:03:36 https://maestrodatabase.com/blog/bipartisan-group-of-senators-asks-fda-to-examine-drug-shortages 2018-06-19T11:41:50 https://maestrodatabase.com/blog/fda-approves-olutasidenib-for-relapsed-or-refractory-acute-myeloid-leukaemia-with-a-susceptible-idh1-mutation 2022-12-02T22:34:33 https://maestrodatabase.com/blog/patients-call-for-end-to-two-year-row-over-cystic-fibrosis-drug-funding 2018-06-19T11:45:33 https://maestrodatabase.com/blog/trump-clears-way-for-health-plans-with-lower-costs-and-fewer-benefits 2018-06-19T11:26:11 https://maestrodatabase.com/blog/fda-accepts-genentechs-supplemental-biologics-license-application-for-avastin-as-a-front-line-treatment-for-women-with-advanced-ovarian-cancer 2017-10-27T01:07:51 https://maestrodatabase.com/blog/tezepelumab-for-the-treatment-of-patients-with-severe-asthma 2023-04-20T20:32:56 https://maestrodatabase.com/blog/commentary-on-the-ema-guideline-on-strategies-to-identify-and-mitigate-risks-for-first-in-human-and-early-clinical-trials-with-investigational-medicinal-products 2018-06-19T11:32:42 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-to-gcbp-and-novel-pharmas-gc1130a 2024-06-10T23:47:04 https://maestrodatabase.com/blog/number-needed-to-treat-conveying-the-likelihood-of-a-therapeutic-effect 2019-02-08T01:01:49 https://maestrodatabase.com/blog/fda-grants-priority-review-to-mercks-application-for-keytruda-pembrolizumab-plus-standard-of-care-as-peri-operative-treatment-for-resectable-locally-advanced-head-and-neck-squamous-cell-carcinoma 2025-02-25T22:13:20 https://maestrodatabase.com/blog/fda-takes-new-steps-to-adopt-more-modern-technologies-for-improving-the-security-of-the-drug-supply-chain-through-innovations-that-improve-tracking-and-tracing-of-medicines 2019-02-08T00:34:35 https://maestrodatabase.com/blog/what-is-driving-hta-decision-making-evidence-from-cancer-drug-reimbursement-decisions-from-6-european-countries 2019-02-08T00:37:22 https://maestrodatabase.com/blog/sandoz-canada-becomes-the-first-canadian-pharmaceutical-company-to-enter-the-medical-cannabis-field 2018-06-19T11:55:13 https://maestrodatabase.com/blog/statement-from-deputy-center-director-for-regulatory-programs-in-fdas-center-for-drug-evaluation-and-research-on-the-agencys-response-to-ongoing-drug-shortages-for-critical-products 2018-06-19T21:06:41 https://maestrodatabase.com/blog/leo-pharma-announces-u-dot-s-fda-expanded-regulatory-approvals-for-enstilar-foam-and-taclonex-topical-suspension-in-treatment-of-plaque-psoriasis 2019-08-01T12:12:57 https://maestrodatabase.com/blog/korea-to-expand-keytruda-reimbursement-to-11-new-cancer-uses-starting-2026 2025-12-25T22:30:27 https://maestrodatabase.com/blog/health-care-at-critical-point-says-medibank 2018-06-19T21:11:07 https://maestrodatabase.com/blog/family-battles-pharmac-and-eyes-australian-move-to-get-miracle-drug 2020-08-15T05:09:23 https://maestrodatabase.com/blog/guidance-for-pharmaceutical-companies-to-prepare-for-uks-withdrawal-from-eu 2018-06-19T21:00:46 https://maestrodatabase.com/blog/many-psoriasis-patients-are-paying-higher-prices-than-ever-at-the-pharmacy-counter 2020-08-15T05:12:54 https://maestrodatabase.com/blog/covid-19-vaccine-safety-report-1-december-2022 2022-12-03T00:37:17 https://maestrodatabase.com/blog/modernising-the-orphan-designation-process 2018-06-19T21:03:39 https://maestrodatabase.com/blog/google-is-training-machines-to-predict-when-a-patient-will-die 2018-06-19T21:29:24 https://maestrodatabase.com/blog/mps-told-meningitis-vaccines-were-always-available 2019-08-01T12:21:57 https://maestrodatabase.com/blog/vertex-reaches-agreement-in-sweden-for-reimbursement-of-orkambi 2018-06-19T21:23:13 https://maestrodatabase.com/blog/nice-backs-bayers-xarelto-in-new-stroke-and-heart-attack-prevention-use 2019-08-01T12:18:07 https://maestrodatabase.com/blog/advanced-accelerator-applications-announces-health-canada-approval-for-lutathera-a-treatment-for-gastro-enteropancreatic-neuroendocrine-tumours 2019-02-08T07:21:21 https://maestrodatabase.com/blog/ultragenyx-announces-submission-of-new-drug-application-to-fda-for-ux007-triheptanoin-for-treatment-of-long-chain-fatty-acid-oxidation-disorders 2019-08-01T13:03:21 https://maestrodatabase.com/blog/expensive-gilead-novartis-cancer-therapies-losing-patients-to-experimental-treatments 2019-08-01T12:59:39 https://maestrodatabase.com/blog/proposal-to-enhance-the-transparency-of-cadths-review-reports-and-recommendations 2019-08-01T12:28:55 https://maestrodatabase.com/blog/shortages-feared-as-u-dot-s-looks-to-canada-for-cheaper-prescription-drugs 2019-08-01T12:26:11 https://maestrodatabase.com/blog/when-cancer-is-political 2019-02-08T10:56:46 https://maestrodatabase.com/blog/fda-grants-priority-review-to-precigens-bla-for-prgn-2012-for-the-treatment-of-adults-with-recurrent-respiratory-papillomatosis-with-pdufa-target-action-date-set-for-27-august-2025 2025-02-25T23:06:54 https://maestrodatabase.com/blog/review-of-cancer-related-surrogate-outcomes-used-for-pbac-decision-making 2023-09-08T04:06:27 https://maestrodatabase.com/blog/new-safety-features-for-medicines-sold-in-the-eu 2019-02-08T22:30:16 https://maestrodatabase.com/blog/eton-pharmaceuticals-announces-fda-acceptance-of-new-drug-application-for-et-105 2019-08-01T21:02:06 https://maestrodatabase.com/blog/prometic-receives-fast-track-designation-for-pbi-4050-in-development-for-idiopathic-pulmonary-fibrosis 2017-10-27T03:40:51 https://maestrodatabase.com/blog/nektar-therapeutics-and-bristol-myers-squibb-announce-u-dot-s-fda-breakthrough-therapy-designation-for-bempegaldesleukin-nktr-214-in-combination-with-opdivo-nivolumab-for-the-treatment-of-patients-with-untreated-advanced-melanoma 2019-08-01T20:54:03 https://maestrodatabase.com/blog/abbvie-announces-provincial-reimbursement-for-rinvoq-upadacitinib-for-the-treatment-of-rheumatoid-arthritis-and-psoriatic-arthritis-in-alberta-new-brunswick-ontario-quebec-and-saskatchewan 2022-12-03T04:51:45 https://maestrodatabase.com/blog/generic-drug-approvals-surge-but-hundreds-still-arent-for-sale 2019-02-08T10:38:02 https://maestrodatabase.com/blog/hopes-$55k-breast-cancer-drug-keytruda-will-get-pbs-listing 2022-12-03T04:45:08 https://maestrodatabase.com/blog/democrats-unveil-bill-for-medicare-to-negotiate-drug-prices 2019-02-08T22:40:57 https://maestrodatabase.com/blog/ema-launches-checklist-to-facilitate-validation-for-initial-marketing-authorisation-applications 2019-02-08T22:32:31 https://maestrodatabase.com/blog/j-and-j-becomes-first-drug-maker-to-add-prices-to-television-ads 2019-02-08T22:37:43 https://maestrodatabase.com/blog/eqrx-announces-acceptance-of-marketing-authorisation-application-by-the-european-medicines-agency-for-aumolertinib-in-egfr-mutated-non-small-cell-lung-cancer 2022-12-03T04:31:56 https://maestrodatabase.com/blog/alex-azar-how-team-trump-is-bringing-drug-prices-down 2019-02-08T22:52:53 https://maestrodatabase.com/blog/innovent-announces-the-approval-of-pemazyre-pemigatinib-by-the-nmpa-for-the-treatment-of-adults-with-locally-advanced-or-metastatic-cholangiocarcinoma-with-a-fgfr2-fusion-or-rearrangement-as-confirmed-by-a-validated-diagnostic-test-that-have-progressed-after-at-least-one-prior-line-of-systemic-therapy 2022-04-07T08:26:52 https://maestrodatabase.com/blog/wellbeing-budget-total-nonsense-when-too-many-are-dying-early 2019-02-08T22:46:09 https://maestrodatabase.com/blog/warning-of-shortages-researchers-look-to-stretch-vaccine-supply 2021-01-07T10:07:03 https://maestrodatabase.com/blog/drug-prices-increase-and-biopharma-bashing-returns 2021-01-07T11:02:04 https://maestrodatabase.com/blog/european-medicines-agency-accepts-marketing-authorisation-application-for-momelotinib-for-the-treatment-of-myelofibrosis 2022-12-03T05:18:20 https://maestrodatabase.com/blog/most-governments-are-not-yet-on-track-to-hit-their-vaccine-roll-out-targets 2021-01-07T06:32:30 https://maestrodatabase.com/blog/orchard-therapeutics-announces-swissmedic-validation-of-the-marketing-authorisation-application-for-libmeldy-atidarsagene-autotemcel 2022-12-03T06:21:02 https://maestrodatabase.com/blog/kidney-disease-drug-added-to-pbs-hunt 2020-02-02T02:55:14 https://maestrodatabase.com/blog/hundreds-of-people-with-some-forms-of-urothelial-cancer-to-receive-new-treatment 2022-04-07T09:12:12 https://maestrodatabase.com/blog/nice-committee-recommends-tirzepatide-as-new-treatment-option-for-people-with-type-2-diabetes 2023-09-08T05:44:42 https://maestrodatabase.com/blog/sandoz-proposed-biosimilar-pegfilgrastim-accepted-by-ema-for-regulatory-review 2017-10-27T05:28:22 https://maestrodatabase.com/blog/nice-says-new-triple-negative-advanced-breast-cancer-drug-too-expensive-for-nhs-use 2022-04-07T11:42:37 https://maestrodatabase.com/blog/shire-receives-european-approval-for-label-extension-of-firazyr-icatibant-injection-for-the-symptomatic-treatment-of-acute-hereditary-angioedema-attacks-in-paediatric-patients 2017-10-27T05:51:11 https://maestrodatabase.com/blog/tga-receives-application-for-an-increased-dose-of-glaxosmithklines-covid-19-treatment-sotrovimab-xevudy-for-the-ba-dot-2-omicron-sublineage 2022-04-07T09:17:00 https://maestrodatabase.com/blog/a-radical-treatment-for-insulin-pricing 2022-04-07T09:27:04 https://maestrodatabase.com/blog/fda-to-authorise-third-vaccine-dose-for-people-with-weak-immune-systems 2021-08-12T10:48:14 https://maestrodatabase.com/blog/nice-draft-guidance-recommends-abemaciclib-for-advanced-breast-cancer 2021-08-12T10:37:04 https://maestrodatabase.com/blog/osimertinib-mesylate-for-the-adjuvant-treatment-of-patients-with-egfr-mutation-positive-non-small-cell-lung-cancer-after-complete-tumour-resection-final-guidance 2025-02-26T01:58:02 https://maestrodatabase.com/blog/grin-therapeutics-receives-fda-breakthrough-therapy-designation-for-radiprodil 2025-02-26T00:31:42 https://maestrodatabase.com/blog/mhra-nod-for-janssens-relapsing-multiple-sclerosis-drug-ponvory 2021-08-12T20:16:42 https://maestrodatabase.com/blog/omicron-xbb-dot-1-5-adapted-covid-19-vaccine-ds-5670-supplemental-new-drug-application-submitted-in-japan 2023-09-08T07:43:26 https://maestrodatabase.com/blog/reclassification-of-software-based-medical-devices 2021-08-12T06:27:34 https://maestrodatabase.com/blog/merus-granted-fda-fast-track-designation-of-zenocutuzumab-for-the-treatment-of-patients-with-neuregulin-1-fusion-cancers 2021-01-07T21:54:30 https://maestrodatabase.com/blog/junshi-biosciences-and-coherus-announce-u-dot-s-fda-breakthrough-therapy-designation-granted-for-toripalimab-for-first-line-treatment-of-nasopharyngeal-carcinoma 2021-08-12T20:31:44 https://maestrodatabase.com/blog/ipsens-iqirvo-receives-us-fda-accelerated-approval-as-a-first-in-class-ppar-treatment-for-primary-biliary-cholangitis 2024-06-11T05:23:58 https://maestrodatabase.com/blog/trifluridine-with-tipiracil-hydrochloride-in-combination-with-bevacizumab-for-the-treatment-of-patients-with-metastatic-colorectal-cancer-after-two-systemic-treatments 2024-06-11T05:13:46 https://maestrodatabase.com/blog/jazz-pharmaceuticals-announces-u-dot-s-fda-approval-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-for-idiopathic-hypersomnia-in-adults 2021-08-12T20:24:23 https://maestrodatabase.com/blog/icer-publishes-white-paper-evaluating-reforms-to-orphan-drug-development-pricing-and-coverage 2022-04-07T12:01:53 https://maestrodatabase.com/blog/drug-shortages-putting-patients-at-risk 2021-08-12T20:20:20 https://maestrodatabase.com/blog/fda-grants-first-of-its-kind-indication-for-chronic-sleep-disorder-treatment 2021-08-12T21:03:32 https://maestrodatabase.com/blog/ema-accepts-marketing-authorisation-application-for-nd0612-an-investigational-treatment-for-motor-fluctuations-in-parkinsons-disease 2025-02-26T21:08:44 https://maestrodatabase.com/blog/second-u-dot-s-fda-breakthrough-device-designation-granted-to-cytosorbents-drugsorb-atr-anti-thrombotic-removal-system-adding-the-removal-of-market-leading-direct-oral-anti-coagulants-during-urgent-cardiothoracic-surgery 2021-08-12T21:08:13 https://maestrodatabase.com/blog/government-ignored-funding-process-with-cancer-drug-promise---former-pharmac-chair 2024-06-11T05:40:09 https://maestrodatabase.com/blog/ellis-unger-an-outspoken-fda-veteran-retires 2021-08-12T20:54:16 https://maestrodatabase.com/blog/vtx-801-receives-u-dot-s-fda-fast-track-designation-for-the-treatment-of-wilson-disease 2021-08-12T20:47:10 https://maestrodatabase.com/blog/thousands-of-south-aucklanders-could-benefit-from-medsafe-approving-new-diabetes-drug 2021-08-12T20:58:46 https://maestrodatabase.com/blog/value-for-private-health-insurance 2025-02-26T08:28:13 https://maestrodatabase.com/blog/exagamglogene-autotemcel-for-the-treatment-of-patients-with-severe-sickle-cell-disease 2025-02-26T02:22:02 https://maestrodatabase.com/blog/biden-urges-congress-to-lower-prescription-drug-costs 2021-08-12T21:20:38 https://maestrodatabase.com/blog/updates-to-the-health-technology-assessment-policy-and-methods-review-reference-committee-7-september-2023 2023-09-08T08:22:03 https://maestrodatabase.com/blog/australian-technical-advisory-group-on-immunisation-weekly-covid-19-meeting---11-august-2021-update 2021-08-12T21:34:05 https://maestrodatabase.com/blog/alexion-submits-application-for-priority-review-and-approval-of-alxn1210-as-a-treatment-for-patients-with-paroxysmal-nocturnal-haemoglobinuria-in-the-u-dot-s 2018-06-20T03:07:10 https://maestrodatabase.com/blog/public-summary-documents---july-2017-pbac-meeting 2017-10-27T07:35:55 https://maestrodatabase.com/blog/the-4-arguments-you-will-hear-against-drug-price-negotiation 2023-09-08T12:55:39 https://maestrodatabase.com/blog/caladrius-receives-fda-regenerative-medicine-advanced-therapy-designation-for-cd34-plus-cell-therapy-for-treating-refractory-angina 2018-06-20T03:39:55 https://maestrodatabase.com/blog/amgen-receives-european-commission-approval-to-add-overall-survival-data-to-blincyto-blinatumomab-label 2018-06-20T06:06:20 https://maestrodatabase.com/blog/novartis-receives-fda-approval-for-inclusion-of-new-evidence-that-cosentyx-inhibits-progression-of-joint-structural-damage-in-psoriatic-arthritis 2018-06-20T06:02:42 https://maestrodatabase.com/blog/beigenes-brukinsa-quickly-passes-hiras-reimbursement-review 2022-04-07T20:44:21 https://maestrodatabase.com/blog/audit-of-medicines-listed-on-the-pbs-with-a-special-pricing-arrangement 2018-06-20T06:50:56 https://maestrodatabase.com/blog/health-canada-approves-amgens-repatha-evolocumab-to-reduce-the-risk-of-cardiovascular-events-in-adults-with-atherosclerotic-cardiovascular-disease 2018-06-20T06:11:52 https://maestrodatabase.com/blog/cms-finalises-medicare-coverage-policy-for-monoclonal-antibodies-directed-against-amyloid-for-the-treatment-of-alzheimers-disease 2022-04-07T21:12:51 https://maestrodatabase.com/blog/health-savings-accounts-for-everyone 2018-06-20T12:16:32 https://maestrodatabase.com/blog/cadth-launches-consultations-on-proposals-to-enhance-drug-review-processes 2022-04-07T21:02:31 https://maestrodatabase.com/blog/minister-rings-up-healthy-dinner-bill-for-conference-delegates 2018-06-20T12:24:21 https://maestrodatabase.com/blog/what-is-the-solution-to-americas-deepening-access-to-medicines-crisis 2022-04-07T21:22:49 https://maestrodatabase.com/blog/new-trump-rule-rolls-back-protections-of-the-affordable-care-act 2018-06-20T08:49:56 https://maestrodatabase.com/blog/cvs-introduces-prescription-drug-delivery-as-it-braces-for-amazons-possible-disruption 2018-06-20T21:27:17 https://maestrodatabase.com/blog/gemini-therapeutics-announces-fda-fast-track-designation-granted-for-gem103-for-the-treatment-of-dry-age-related-macular-degeneration-in-patients-with-complement-factor-h-loss-of-function-gene-variants 2021-01-07T23:39:40 https://maestrodatabase.com/blog/budget-matters-infrastructure-to-support-robust-generic-drug-competition 2018-06-20T21:36:19 https://maestrodatabase.com/blog/concerns-two-different-flu-vaccines-create-two-tier-system-for-65-and-overs 2022-04-07T20:51:08 https://maestrodatabase.com/blog/clayton-pharmaceuticals-and-vistapharm-receive-fda-approval-for-sucralfate-oral-suspension 2022-04-07T20:58:36 https://maestrodatabase.com/blog/whats-holding-back-market-uptake-of-biosimilars 2018-06-20T21:20:17 https://maestrodatabase.com/blog/finding-cancer-patients-is-the-pharma-industrys-unlikely-challenge 2018-06-20T21:39:38 https://maestrodatabase.com/blog/exit-from-obamacare 2018-06-20T21:48:51 https://maestrodatabase.com/blog/inversago-pharma-receives-rare-paediatric-disease-designation-from-the-fda-for-inv-101-for-the-treatment-of-prader-willi-syndrome 2021-01-08T00:37:32 https://maestrodatabase.com/blog/odronextamab-bla-accepted-for-fda-review-for-the-treatment-of-relapsed-slash-refractory-follicular-lymphoma 2025-02-26T22:58:00 https://maestrodatabase.com/blog/kevzara-sarilumab-approved-by-fda-for-the-treatment-of-active-polyarticular-juvenile-idiopathic-arthritis 2024-06-11T11:10:05 https://maestrodatabase.com/blog/novartis-ceo-lauds-trump-administration-plan-to-overhaul-rebates 2019-02-09T22:35:21 https://maestrodatabase.com/blog/u-dot-s-phrmas-fight-to-prevent-lower-canadian-drug-prices 2019-02-09T22:32:02 https://maestrodatabase.com/blog/patient-involvement-in-reflective-multi-criteria-decision-analysis-to-assist-decision-making-in-oncology 2019-02-10T20:05:53 https://maestrodatabase.com/blog/opus-genetics-announces-fda-fast-track-and-enrollment-updates-for-phentolamine-ophthalmic-solution-0-dot-75-percent-programs 2025-02-26T23:13:11 https://maestrodatabase.com/blog/how-procurement-judges-the-value-of-medical-technologies-a-review-of-health-care-tenders 2019-02-10T20:09:05 https://maestrodatabase.com/blog/fda-statement-on-following-the-authorised-dosing-schedules-for-covid-19-vaccines 2021-01-08T01:23:09 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-february-2020-update 2020-02-02T05:30:50 https://maestrodatabase.com/blog/pyxis-oncology-granted-fda-fast-track-designation-for-pyx-201-monotherapy-in-patients-with-recurrent-or-metastatic-head-and-neck-cancer 2025-02-26T23:40:07 https://maestrodatabase.com/blog/calico-life-sciences-announces-that-fosigotifator-abbv-cls-7262-for-vanishing-white-matter-disease-has-been-selected-for-the-fda-start-pilot-program 2024-06-11T20:57:39 https://maestrodatabase.com/blog/protecting-medicares-discretion-to-say-no-to-unproven-therapies 2023-09-08T23:13:51 https://maestrodatabase.com/blog/swissmedic-approves-csl-behrings-andembry-garadacimab-for-the-prevention-of-recurrent-attacks-of-hereditary-angioedema 2025-02-27T03:05:54 https://maestrodatabase.com/blog/kashiv-biosciences-obtains-marketing-authorisation-for-pegfilgrastim-injection-from-health-canada 2025-02-27T02:59:37 https://maestrodatabase.com/blog/mendus-receives-us-fda-fast-track-designation-for-vididencel-in-acute-myeloid-leukaemia 2023-09-08T23:30:12 https://maestrodatabase.com/blog/health-insurers-worried-about-court-order-to-cover-expensive-cancer-medicines 2025-02-27T03:22:14 https://maestrodatabase.com/blog/nice-no-for-bms-opdivo-for-head-and-neck-cancer 2021-01-08T22:01:58 https://maestrodatabase.com/blog/the-right-to-try-could-cost-dying-patients-a-fortune 2018-06-21T06:08:33 https://maestrodatabase.com/blog/modernas-covid-19-vaccine-granted-authorisation-in-uk 2021-01-08T22:11:58 https://maestrodatabase.com/blog/health-canada-approves-taltz-ixekizumab-for-treatment-of-active-psoriatic-arthritis 2018-06-21T06:02:55 https://maestrodatabase.com/blog/price-disclosure-2018-october-cycle-outcomes-summary 2018-06-21T06:35:10 https://maestrodatabase.com/blog/how-the-government-can-lower-drug-prices 2018-06-21T08:50:45 https://maestrodatabase.com/blog/extra-dose-from-vials-of-comirnaty-covid-19-vaccine 2021-01-08T21:57:43 https://maestrodatabase.com/blog/acurxs-lead-antibiotic-product-candidate-acx-362e-for-clostridium-difficile-infection 2018-06-21T06:29:17 https://maestrodatabase.com/blog/shire-announces-fda-approval-for-label-expansion-of-cinryze-c1-esterase-inhibitor-human-for-prevention-of-attacks-in-paediatric-hereditary-angioedema-patients 2018-06-21T10:49:52 https://maestrodatabase.com/blog/ramsays-profit-downgrade-a-sign-of-trouble-in-health 2018-06-21T12:54:04 https://maestrodatabase.com/blog/skyrocketing-insulin-prices-provoke-new-outrage 2018-06-21T13:04:13 https://maestrodatabase.com/blog/australian-stage-3-melanoma-patients-forced-to-self-fund-recurrent-treatment-while-pbs-makes-decision-on-listing 2018-06-21T11:52:55 https://maestrodatabase.com/blog/praxis-precision-medicines-receives-rare-paediatric-disease-and-orphan-drug-designations-for-severe-paediatric-epilepsy-programs 2021-01-08T23:00:14 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-application-for-opdivo-plus-low-dose-yervoy-for-treatment-of-first-line-non-small-cell-lung-cancer-in-patients-with-tumour-mutational-burden-10-mut-slash-mb 2018-06-21T20:41:16 https://maestrodatabase.com/blog/brenzys-lists-on-the-australian-pbs-and-pfizer-denied-discovery-of-documents-to-establish-grounds-for-patent-infringement 2017-04-04T21:39:20 https://maestrodatabase.com/blog/abbvie-announces-ibrutinib-imbruvica-supplemental-new-drug-application-for-previously-treated-chronic-graft-versus-host-disease-accepted-for-review-by-u-dot-s-fda 2017-04-04T21:44:55 https://maestrodatabase.com/blog/script-for-a-healthier-australia-small-steps-and-big-savings 2018-06-21T14:02:42 https://maestrodatabase.com/blog/changes-to-nice-drug-appraisals-what-you-need-to-know 2017-04-04T21:42:18 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-for-priority-review-bristol-myers-squibbs-application-for-opdivo-nivolumab-in-previously-treated-dmmr-or-msi-h-metastatic-colorectal-cancer 2017-04-04T21:50:52 https://maestrodatabase.com/blog/white-house-proposes-a-narrowing-of-fdas-mission----and-a-new-name 2018-06-21T21:40:07 https://maestrodatabase.com/blog/amneal-announces-fda-approval-of-denosumab-biosimilars-referencing-prolia-and-xgeva 2025-12-27T02:03:09 https://maestrodatabase.com/blog/fda-takes-steps-to-foster-greater-efficiency-in-biosimilar-development-by-reconsidering-draft-guidance-on-evaluating-analytical-studies 2018-06-21T20:46:59 https://maestrodatabase.com/blog/confirmatory-versus-explorative-endpoint-analysis-decision-making-on-the-basis-of-evidence-available-from-market-authorisation-and-early-benefit-assessment-for-oncology-drugs 2018-06-21T20:51:00 https://maestrodatabase.com/blog/finch-therapeutics-investigational-drug-cp101-granted-breakthrough-therapy-designation-from-fda-for-recurrent-c-difficile-infection 2019-02-11T00:01:59 https://maestrodatabase.com/blog/whistler-woman-forced-to-fundraise-for-cancer-drugs 2018-06-21T21:58:33 https://maestrodatabase.com/blog/janssen-submits-marketing-authorisation-application-to-the-ema-seeking-approval-of-erdafitinib-for-the-treatment-of-patients-with-locally-advanced-or-metastatic-urothelial-cancer-with-susceptible-fgfr-alterations 2023-09-09T01:42:22 https://maestrodatabase.com/blog/regenxbio-receives-rare-paediatric-disease-designation-for-rgx-181-gene-therapy-for-the-treatment-of-cln2-form-of-batten-disease 2019-02-11T00:29:25 https://maestrodatabase.com/blog/icer-finalises-2020-updates-to-methods-and-public-meeting-procedures-for-value-assessment-framework 2020-02-02T09:51:50 https://maestrodatabase.com/blog/how-chaos-at-chain-pharmacies-is-putting-patients-at-risk 2020-02-02T09:44:38 https://maestrodatabase.com/blog/health-canada-postpones-overhaul-of-drug-pricing-for-6-months 2021-01-09T22:23:44 https://maestrodatabase.com/blog/humana-executives-say-trumps-drug-rebate-proposal-would-raise-premiums-restrict-consumer-choice 2019-02-11T06:37:44 https://maestrodatabase.com/blog/vaccines-and-the-trump-administration 2017-04-05T00:34:04 https://maestrodatabase.com/blog/fake-drugs-could-put-patients-at-risk-after-no-deal-brexit 2019-02-11T06:40:10 https://maestrodatabase.com/blog/gottlieb-as-fda-commissioner-would-be-music-to-pharmas-ears 2017-04-05T01:08:38 https://maestrodatabase.com/blog/two-additional-countries-to-benefit-from-eu-us-mutual-recognition-agreement-for-inspections 2019-06-11T20:55:14 https://maestrodatabase.com/blog/government-should-spend-money-on-cancer-treatment-not-gender-reassignment 2019-02-11T06:51:00 https://maestrodatabase.com/blog/express-scripts-saved-plans-45-dollars-billion-on-prescription-drugs-in-2018 2019-02-11T07:14:12 https://maestrodatabase.com/blog/listing-on-the-pharmaceutical-schedule-of-a-range-of-orthopaedic-implants-and-associated-products-with-lmt-surgical-pty-ltd 2017-04-05T08:13:16 https://maestrodatabase.com/blog/report-on-the-collection-of-under-co-payment-data---2015-16 2017-04-05T08:09:05 https://maestrodatabase.com/blog/white-house-report-tries-to-shift-trump-health-care-rhetoric 2019-02-11T19:30:36 https://maestrodatabase.com/blog/australian-medtech-industry-to-help-add-18-dollars-billion-and-28-000-new-jobs-by-2025 2017-04-05T08:18:10 https://maestrodatabase.com/blog/european-commission-approves-bristol-myers-squibbs-sprycel-dasatinib-in-combination-with-chemotherapy-for-treatment-of-paediatric-patients-with-newly-diagnosed-philadelphia-chromosome-positive-acute-lymphoblastic-leukaemia 2019-02-11T19:34:13 https://maestrodatabase.com/blog/brexucabtagene-autoleucel-for-the-treatment-of-adults-with-relapsed-or-refractory-b-cell-acute-lymphoblastic-leukaemia 2022-12-04T01:40:22 https://maestrodatabase.com/blog/claims-of-skyrocketing-prostheses-costs-challenged 2017-04-05T11:28:10 https://maestrodatabase.com/blog/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-for-keytruda-pembrolizumab-for-the-first-line-treatment-of-patients-with-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma 2019-02-11T19:51:56 https://maestrodatabase.com/blog/ceding-to-one-side-on-health-bill-trump-risks-alienating-another 2017-04-05T11:23:29 https://maestrodatabase.com/blog/regeneron-and-sanofi-offer-praluent-alirocumab-at-a-new-reduced-u-dot-s-list-price 2019-02-11T19:46:23 https://maestrodatabase.com/blog/insurers-again-blame-prostheses-list-for-high-premium-costs 2017-04-05T20:55:59 https://maestrodatabase.com/blog/clementia-granted-rare-paediatric-disease-designation-by-fda-for-palovarotene-for-fibrodysplasia-ossificans-progressiva 2019-02-11T20:06:10 https://maestrodatabase.com/blog/voxelotor-for-the-treatment-of-patients-with-haemolytic-anaemia-caused-by-sickle-cell-disease 2024-06-12T06:00:34 https://maestrodatabase.com/blog/republicans-try-to-revive-health-care-effort-as-leaders-seek-to-temper-expectations 2017-04-05T21:07:27 https://maestrodatabase.com/blog/smc---february-2019-decisions 2019-02-11T20:00:42 https://maestrodatabase.com/blog/differences-in-treatment-effect-size-between-overall-survival-and-progression-free-survival-in-immunotherapy-trials-a-meta-epidemiologic-study-of-trials-with-results-posted-at-clinicaltrials-dot-gov 2017-04-05T21:15:58 https://maestrodatabase.com/blog/one-and-done-for-new-drugs-could-cut-patent-thickets-and-boost-generic-competition 2019-02-11T20:20:05 https://maestrodatabase.com/blog/the-art-of-repeal----republicans-health-care-reform-muddle 2017-04-05T21:53:52 https://maestrodatabase.com/blog/anti-viral-covid-19-treatment-now-available-in-the-netherlands-for-1-250-euros 2022-12-04T10:58:42 https://maestrodatabase.com/blog/apellis-pharmaceuticals-apl-2-receives-fast-track-designation-from-the-fda-for-the-treatment-of-patients-with-paroxysmal-nocturnal-haemoglobinuria 2019-02-11T20:24:45 https://maestrodatabase.com/blog/medicare-patients-face-surging-costs-for-some-life-saving-drugs 2019-02-11T20:13:00 https://maestrodatabase.com/blog/statistical-approaches-to-establishing-bioequivalence 2022-12-04T07:02:36 https://maestrodatabase.com/blog/pembrolizumab-in-combination-with-trastuzumab-and-chemotherapy-for-the-first-line-treatment-of-patients-with-locally-advanced-unresectable-or-metastatic-her2-positive-gastric-or-gastro-oesophageal-junction-adenocarcinoma-final-guidance 2024-06-12T07:04:12 https://maestrodatabase.com/blog/anti-viral-drug-should-not-be-first-choice-in-treating-covid-19 2022-12-04T03:22:13 https://maestrodatabase.com/blog/ema-validates-application-for-arpraziquantel-to-treat-schistosomiasis-in-pre-school-aged-children 2022-12-04T03:15:36 https://maestrodatabase.com/blog/fda-alerts-health-care-professionals-and-oncology-clinical-investigators-about-an-efficacy-issue-identified-in-clinical-trials-for-some-patients-taking-keytruda-pembrolizumab-or-tecentriq-atezolizumab-as-monotherapy-to-treat-urothelial-cancer-with-low-expression-of-pd-l1 2018-06-22T23:34:43 https://maestrodatabase.com/blog/nice-backs-ocrevus-but-primary-progressive-group-kept-waiting 2018-06-22T23:41:15 https://maestrodatabase.com/blog/fda-announces-program-to-enhance-early-communications-with-biological-product-developers 2018-06-22T23:53:52 https://maestrodatabase.com/blog/bob-katter-wants-keytruda-added-to-pbs 2018-06-22T23:47:10 https://maestrodatabase.com/blog/sanofis-dupixent-approved-for-routine-nhs-use 2018-06-22T23:50:46 https://maestrodatabase.com/blog/bluerock-therapeutics-receives-fda-fast-track-designation-for-opct-001-for-the-treatment-of-primary-photoreceptor-diseases 2025-02-27T23:35:49 https://maestrodatabase.com/blog/fda-and-european-medicines-agency-collaborate-on-drug-quality-and-manufacturing-data-to-improve-patient-access-to-medically-necessary-medications 2019-08-02T06:07:41 https://maestrodatabase.com/blog/toppling-the-ethical-balance----health-care-refusal-and-the-trump-administration 2019-08-02T06:04:09 https://maestrodatabase.com/blog/why-competition-wont-bring-down-drug-prices 2018-06-23T00:00:44 https://maestrodatabase.com/blog/depression-in-adults-campaigners-and-doctors-demand-full-revision-of-nice-guidance 2018-06-23T00:04:46 https://maestrodatabase.com/blog/pharmac-seeking-feedback-on-funding-trikafta 2022-12-04T19:32:52 https://maestrodatabase.com/blog/voyager-therapeutics-announces-fda-regenerative-medicine-advanced-therapy-designation-granted-for-vy-aadc-for-the-treatment-of-parkinsons-disease 2018-06-23T00:23:18 https://maestrodatabase.com/blog/htx-011-for-post-operative-pain-management-receives-breakthrough-therapy-designation-from-fda 2018-06-23T00:15:09 https://maestrodatabase.com/blog/medical-device-price-savings-for-millions-of-australians-from-today 2020-02-02T20:43:10 https://maestrodatabase.com/blog/pfizer-and-biontech-submit-application-to-us-fda-for-emergency-use-authorisation-of-omicron-ba-dot-4-slash-ba-dot-5-adapted-bivalent-covid-19-vaccine-in-children-under-5-years 2022-12-06T20:05:10 https://maestrodatabase.com/blog/mylan-and-biocon-launch-first-trastuzumab-biosimilar-ogivri-in-australia 2019-08-02T06:20:12 https://maestrodatabase.com/blog/molnupiravir-effective-covid-19-anti-viral-acting-cmo-michael-kidd 2022-12-06T20:09:58 https://maestrodatabase.com/blog/icer-identifies-most-significant-2021-us-drug-price-hikes-unsupported-by-new-clinical-evidence 2022-12-06T19:56:23 https://maestrodatabase.com/blog/health-insurers-walk-delicate-line-against-democrats-health-proposals 2019-08-02T07:57:53 https://maestrodatabase.com/blog/emergent-biosolutions-announces-us-fda-acceptance-and-priority-review-of-supplemental-new-drug-application-for-over-the-counter-narcan-naloxone-hydrochloride-nasal-spray 2022-12-06T11:35:50 https://maestrodatabase.com/blog/reinforced-eu-slash-us-collaboration-on-medicines 2018-06-23T00:33:52 https://maestrodatabase.com/blog/trudeau-pledges-steady-drug-supply-in-canada-amid-concerns-over-trump-policy 2019-08-02T07:55:18 https://maestrodatabase.com/blog/syndax-announces-us-fda-breakthrough-therapy-designation-granted-for-revumenib-for-the-treatment-of-adult-and-paediatric-patients-with-relapsed-or-refractory-kmt2a-rearranged-acute-leukaemia 2022-12-06T11:40:04 https://maestrodatabase.com/blog/istesso-announces-fda-fast-track-and-orphan-drug-designation-for-mbs2320 2022-12-06T20:33:26 https://maestrodatabase.com/blog/ideaya-biosciences-receives-fast-track-designation-for-darovasertib-combination-therapy-with-crizotinib-for-the-treatment-of-metastatic-uveal-melanoma 2022-12-06T20:28:13 https://maestrodatabase.com/blog/ionis-announces-european-medicines-agency-accepts-marketing-authorisation-application-of-tofersen-to-treat-rare-genetic-form-of-als 2022-12-06T20:22:03 https://maestrodatabase.com/blog/towards-a-better-health-care-system-how-everyone-benefits-through-collaboration 2018-06-24T07:42:32 https://maestrodatabase.com/blog/fda-accepts-bla-for-tlx250-cdx-zircaix-for-kidney-cancer-imaging-grants-priority-review 2025-02-27T23:59:27 https://maestrodatabase.com/blog/swissmedic-approves-quviviq-daridorexant---a-first-in-class-treatment-for-chronic-insomnia-disorder-to-improve-both-nighttime-symptoms-and-daytime-functioning 2022-12-06T20:17:12 https://maestrodatabase.com/blog/nocdurna-desmopressin-acetate-now-approved-by-u-dot-s-fda-as-first-sublingual-tablet-to-treat-nocturia-due-to-nocturnal-polyuria 2018-06-23T02:26:49 https://maestrodatabase.com/blog/select-committee-wont-recommend-inquiry-into-pharmac 2019-08-02T08:42:35 https://maestrodatabase.com/blog/public-consultation---standardised-redactions-of-public-summary-documents 2019-08-02T08:38:17 https://maestrodatabase.com/blog/germanys-use-of-reference-pricing-for-biologics-lessons-for-the-us 2022-12-06T20:54:15 https://maestrodatabase.com/blog/nucala-receives-eu-approval-for-self-administration-by-patients-with-severe-eosinophilic-asthma 2019-08-02T08:34:18 https://maestrodatabase.com/blog/pharmac-and-a-very-curious-case-of-media-management 2022-12-06T20:43:29 https://maestrodatabase.com/blog/data-sharing-and-the-growth-of-medical-knowledge 2022-12-06T20:40:52 https://maestrodatabase.com/blog/us-fda-grants-priority-review-to-sobis-supplemental-biologics-licence-application-for-gamifant-emapalumab-lzsg 2025-02-28T01:19:32 https://maestrodatabase.com/blog/pbs-arrangements-for-tocilizumab-shortage 2021-08-13T07:18:09 https://maestrodatabase.com/blog/abbvie-receives-u-dot-s-fda-priority-review-for-investigational-oral-treatment-elagolix-for-the-management-of-endometriosis-with-associated-pain 2017-10-28T05:19:13 https://maestrodatabase.com/blog/in-search-of-a-common-currency-a-comparison-of-seven-eq-5d-5l-value-sets 2017-10-28T05:26:18 https://maestrodatabase.com/blog/government-of-canada-signs-pharmacare-agreement-with-manitoba-to-improve-affordable-access-to-medications 2025-02-28T01:57:57 https://maestrodatabase.com/blog/when-a-health-insurer-also-wants-to-be-a-hospice-company 2018-06-24T08:28:27 https://maestrodatabase.com/blog/making-vaccines-available-to-other-countries-before-offering-domestic-booster-vaccinations 2021-08-13T10:20:21 https://maestrodatabase.com/blog/tracking-the-cost-of-gene-therapy 2017-10-28T06:01:31 https://maestrodatabase.com/blog/gc-pharma-announces-greengene-f-approval-in-china-for-the-treatment-of-haemophilia-a 2021-08-13T07:27:05 https://maestrodatabase.com/blog/fda-accepts-sbla-and-grants-priority-review-for-bavencio-avelumab-plus-inlyta-axitinib-for-the-treatment-of-advanced-renal-cell-carcinoma 2019-02-11T23:53:18 https://maestrodatabase.com/blog/2020-a-strong-year-for-new-drug-therapy-approvals---despite-many-covid-19-challenges 2021-01-10T11:04:22 https://maestrodatabase.com/blog/the-accelerated-approval-program-for-cancer-drugs----finding-the-right-balance 2023-09-10T04:21:40 https://maestrodatabase.com/blog/european-commission-expands-mercks-ervebo-ebola-zaire-vaccine-live-indication-to-include-children-1-year-of-age-and-older 2023-09-10T04:16:52 https://maestrodatabase.com/blog/australia-close-to-gaining-access-to-oxfords-promising-covid-19-vaccine 2020-08-16T09:07:01 https://maestrodatabase.com/blog/agenda-for-june-27-tc-meeting 2018-06-24T09:08:59 https://maestrodatabase.com/blog/ausbiotech-says-r-and-d-tax-incentive-critical-to-2030-innovation-strategy 2017-04-06T03:35:05 https://maestrodatabase.com/blog/with-brexit-underway-eu-drug-agency-prepares-to-leave-london 2017-04-06T05:13:42 https://maestrodatabase.com/blog/ema-validates-seattle-genetics-marketing-authorisation-application-for-tucatinib-for-patients-with-locally-advanced-or-metastatic-her2-positive-breast-cancer 2020-02-02T22:44:30 https://maestrodatabase.com/blog/vistagen-receives-fda-fast-track-designation-for-development-of-ph10-to-treat-major-depressive-disorder 2022-12-06T23:07:39 https://maestrodatabase.com/blog/industry-urges-eu-to-scrap-national-hta-bodies 2018-06-24T21:49:41 https://maestrodatabase.com/blog/pharmac-strategy-provides-opportunity-for-improving-pacific-health 2017-04-06T06:13:32 https://maestrodatabase.com/blog/a-drug-costs-272-000-dollars-a-year-not-so-fast-says-new-york-state 2018-06-24T21:54:07 https://maestrodatabase.com/blog/drug-makers-push-back-against-governments-generic-price-cut-plan 2025-12-28T10:00:43 https://maestrodatabase.com/blog/national-medicines-policy-2-dot-0-a-vision-for-the-future 2020-02-02T23:47:41 https://maestrodatabase.com/blog/arrevus-receives-fda-qualified-infectious-disease-product-designation-for-the-treatment-of-cystic-fibrosis-pulmonary-exacerbations 2020-02-03T00:00:16 https://maestrodatabase.com/blog/tga-provisionally-approves-pfizers-covid-19-vaccine-comirnaty-for-use-as-a-booster-for-individual-aged-12-15-years-old 2022-04-08T09:20:24 https://maestrodatabase.com/blog/tga-approved-yuflyma 2022-04-08T09:30:45 https://maestrodatabase.com/blog/bayer-application-for-nifurtimox-to-treat-paediatric-patients-with-chagas-disease-submitted-for-approval-in-us 2020-02-02T23:54:45 https://maestrodatabase.com/blog/sqz-biotechnologies-receives-fda-fast-track-designation-for-its-eapc-therapeutic-candidate-for-treatment-of-hpv16-positive-tumours 2022-12-06T23:49:45 https://maestrodatabase.com/blog/abbvie-receives-positive-chmp-opinion-for-venclyxto-as-a-chemotherapy-free-combination-regimen-for-patients-with-previously-untreated-chronic-lymphocytic-leukaemia 2020-02-03T00:43:19 https://maestrodatabase.com/blog/launch-of-the-medicine-status-website 2020-02-03T00:24:06 https://maestrodatabase.com/blog/ocuphire-pharma-announces-submission-of-new-drug-application-to-fda-for-nyxol-eye-drops-for-reversal-of-mydriasis 2022-12-07T06:18:55 https://maestrodatabase.com/blog/alnylam-receives-positive-chmp-opinion-for-givlaari-givosiran-for-the-treatment-of-acute-hepatic-porphyria-in-adults-and-adolescents 2020-02-03T01:55:10 https://maestrodatabase.com/blog/differences-in-evidentiary-requirements-between-european-medicines-agency-and-european-health-technology-assessment-of-oncology-drugs--can-alignment-be-enhanced 2022-12-07T06:14:29 https://maestrodatabase.com/blog/sage-therapeutics-and-biogen-complete-rolling-submission-of-new-drug-application-for-zuranolone-in-the-treatment-of-major-depressive-disorder-and-post-partum-depression 2022-12-07T05:39:52 https://maestrodatabase.com/blog/immunitybio-receives-fda-rmat-designation-for-anktiva-and-car-nk-for-the-reversal-of-lymphopaenia-in-patients-receiving-standard-of-care-chemotherapy-slash-radiotherapy-and-in-treatment-of-multiply-relapsed-locally-advanced-or-metastatic-pancreatic-cancer 2025-02-28T05:28:51 https://maestrodatabase.com/blog/piqray-is-approved-and-now-available-in-canada-as-the-first-and-only-treatment-specifically-for-patients-with-a-pik3ca-mutation-in-hr-positive-her2-negative-advanced-breast-cancer 2020-08-16T21:40:40 https://maestrodatabase.com/blog/bayer-receives-positive-chmp-opinion-for-darolutamide-as-a-new-treatment-for-men-with-non-metastatic-castration-resistant-prostate-cancer 2020-02-03T02:01:12 https://maestrodatabase.com/blog/direct-or-indirect-comparison-reliance-on-innovative-drug-data-key-to-engaging-data-protection 2020-08-16T21:14:56 https://maestrodatabase.com/blog/etf-concludes-that-bivalent-original-slash-omicron-ba-dot-4-5-mrna-vaccines-may-be-used-for-primary-vaccination 2022-12-07T10:23:01 https://maestrodatabase.com/blog/addressing-the-challenges-of-implementing-a-health-technology-assessment-policy-framework-in-south-africa 2020-08-16T21:21:04 https://maestrodatabase.com/blog/farxiga-approved-in-the-us-for-the-treatment-of-paediatric-type-2-diabetes-mellitus 2024-06-12T23:28:14 https://maestrodatabase.com/blog/2020-april-price-disclosure-cycle---indicative-prices 2020-02-03T04:37:12 https://maestrodatabase.com/blog/rare-diseases-expensive-drugs---health-canada-showdown-coming 2018-06-25T01:51:12 https://maestrodatabase.com/blog/esperion-announces-positive-chmp-opinion-for-the-marketing-authorisation-application-for-bempedoic-acid-for-the-treatment-of-hypercholesterolaemia-and-mixed-dyslipidaemia 2020-02-03T05:15:19 https://maestrodatabase.com/blog/congress-should-fix-fdas-accelerated-approval-program-for-the-next-30-years 2021-08-13T22:19:42 https://maestrodatabase.com/blog/eisai-statement-on-the-centers-for-medicare-and-medicaid-services-national-coverage-determination-with-coverage-with-evidence-development-for-monoclonal-antibodies-directed-against-amyloid-for-the-treatment-of-alzheimers-disease 2022-04-08T21:22:45 https://maestrodatabase.com/blog/emergent-biosolutions-receives-positive-chmp-opinion-for-vaxchora-anticipates-near-term-approval-by-european-medicines-agency 2020-02-03T04:46:15 https://maestrodatabase.com/blog/fda-approves-odactra-for-the-treatment-of-house-dust-mite-allergy-in-young-children 2025-02-28T05:37:57 https://maestrodatabase.com/blog/mans-friends-start-nz-billboard-campaign-to-raise-funds-for-his-cancer-treatment 2020-02-03T04:41:48 https://maestrodatabase.com/blog/fda-approves-belzutifan-for-cancers-associated-with-von-hippel-lindau-disease 2021-08-13T22:22:36 https://maestrodatabase.com/blog/fda-approves-selpercatinib-for-ret-fusion-positive-thyroid-cancer 2024-06-13T00:15:04 https://maestrodatabase.com/blog/crohns-disease-and-colitis-sufferers-plead-with-pharmac-to-fund-new-drug 2021-01-10T23:28:59 https://maestrodatabase.com/blog/pfizer-receives-positive-chmp-opinion-for-oncology-biosimilar-ruxience-rituximab 2020-02-03T05:21:13 https://maestrodatabase.com/blog/fda-allows-marketing-of-first-direct-to-consumer-tests-that-provide-genetic-risk-information-for-certain-conditions 2017-04-06T20:44:39 https://maestrodatabase.com/blog/u-dot-s-fda-approves-addition-of-overall-survival-and-other-secondary-outcome-data-to-nubeqa-darolutamide-prescribing-information 2021-01-10T23:22:44 https://maestrodatabase.com/blog/optimising-safety-information-for-medicines-in-europe-throughout-product-lifecycle 2017-04-06T20:38:52 https://maestrodatabase.com/blog/regulatory-review-of-new-therapeutic-agents----fda-versus-ema-2011-2015 2017-04-06T20:48:23 https://maestrodatabase.com/blog/tukysa-tucatinib-reimbursed-in-british-columbia-for-the-treatment-of-patients-with-advanced-or-metastatic-her2-positive-breast-cancer 2022-12-07T20:01:51 https://maestrodatabase.com/blog/migraine-foundation-submits-application-to-pharmac-to-fund-emgality 2022-12-07T19:57:43 https://maestrodatabase.com/blog/f-dot-d-a-nominee-deflects-criticism-about-ties-to-drug-makers-at-hearing 2017-04-06T20:53:36 https://maestrodatabase.com/blog/regeneron-announces-evinacumab-has-received-fda-breakthrough-therapy-designation-for-homozygous-familial-hypercholesterolaemia 2017-04-06T20:57:30 https://maestrodatabase.com/blog/blame-game-over-high-drug-prices-gets-worse-with-lobbys-new-ad 2017-04-06T21:12:15 https://maestrodatabase.com/blog/pharmaceutical-innovativeness-is-highly-variable-as-cms-will-soon-find-out-when-it-does-comparative-effectiveness-assessments 2023-09-11T01:30:21 https://maestrodatabase.com/blog/csiro-says-red-tape-holding-back-australias-medical-technology-pharmaceutical-industries 2017-04-06T21:32:35 https://maestrodatabase.com/blog/pharma-warns-new-nice-rules-will-delay-access-to-medicines 2017-04-06T21:23:05 https://maestrodatabase.com/blog/updated-eligibility-for-covid-19-oral-treatment 2022-12-07T20:35:36 https://maestrodatabase.com/blog/cadth-symposium-promotes-the-use-of-evidence-in-health-care 2017-04-06T21:35:53 https://maestrodatabase.com/blog/novavax-nuvaxovid-covid-19-vaccine-approved-in-canada-for-use-as-a-primary-series-in-adolescents 2022-12-07T20:29:22 https://maestrodatabase.com/blog/moleculin-granted-fda-fast-track-designation-of-wp1122-for-the-treatment-of-glioblastoma-multiforme 2022-12-07T20:21:08 https://maestrodatabase.com/blog/pharmac-funds-more-medicines-for-new-zealanders 2022-12-07T20:06:50 https://maestrodatabase.com/blog/us-fda-accepts-for-priority-review-the-biologics-license-application-for-pfizers-respiratory-syncytial-virus-vaccine-candidate-for-the-prevention-of-rsv-disease-in-older-adults 2022-12-07T20:09:59 https://maestrodatabase.com/blog/health-canada-issues-notice-of-compliance-with-conditions-for-idhifa-the-first-oral-targeted-therapy-for-adult-patients-with-relapsed-or-refractory-acute-myeloid-leukaemia-and-an-idh2-mutation 2019-02-12T02:01:23 https://maestrodatabase.com/blog/seattle-genetics-achieves-30-dollars-million-milestone-payment-for-european-commission-approval-of-adcetris-brentuximab-vedotin-in-frontline-hodgkin-lymphom 2019-02-12T01:56:06 https://maestrodatabase.com/blog/breast-cancer-patients-die-while-waiting-for-medicines 2019-02-12T02:23:06 https://maestrodatabase.com/blog/us-backs-delay-to-decision-on-covid-patent-waiver-extension 2022-12-07T20:51:45 https://maestrodatabase.com/blog/us-fda-approves-agios-aqvesme-mitapivat-for-the-treatment-of-anaemia-in-adults-with-alfa-or-beta-thalassaemia 2025-12-29T20:01:13 https://maestrodatabase.com/blog/adtralza-tralokinumab-pre-filled-pen-now-available-in-canada 2024-06-13T01:38:53 https://maestrodatabase.com/blog/unicycive-therapeutics-announces-resubmission-of-new-drug-application-for-oxylanthanum-carbonate 2025-12-30T08:45:41 https://maestrodatabase.com/blog/baricitinib-for-the-treatment-of-patients-with-juvenile-idiopathic-arthritis 2024-06-13T02:05:17 https://maestrodatabase.com/blog/fda-accepts-for-review-inovios-bla-for-ino-3107-for-the-treatment-of-adults-with-recurrent-respiratory-papillomatosis 2025-12-30T09:24:51 https://maestrodatabase.com/blog/nice-recommends-koselugo-for-the-treatment-of-neurofibromatosis-type-1 2022-04-08T22:55:25 https://maestrodatabase.com/blog/fda-takes-steps-to-provide-clarity-on-developing-new-drug-products-in-the-age-of-individualised-medicine 2021-01-11T02:04:46 https://maestrodatabase.com/blog/grudge-against-health-premiums-grows-accc 2018-06-25T07:50:59 https://maestrodatabase.com/blog/praxis-precision-medicines-announces-the-fda-has-granted-breakthrough-therapy-designation-for-ulixacaltamide-hydrochloride-in-essential-tremor 2025-12-29T23:12:00 https://maestrodatabase.com/blog/doh-publishes-revised-agenda-for-march-2021-pbac-meeting 2021-01-11T00:45:40 https://maestrodatabase.com/blog/health-care-access-australians-top-concern 2018-06-25T12:14:45 https://maestrodatabase.com/blog/healthengine-patients-exposure-when-on-line-is-out-of-line 2018-06-25T12:16:51 https://maestrodatabase.com/blog/prometic-completes-the-filing-of-its-plasminogen-biologics-license-application-with-the-u-dot-s-fda 2017-04-06T23:15:51 https://maestrodatabase.com/blog/evaluating-new-zealanders-values-for-drug-coverage-decision-making-trade-offs-between-treatments-for-rare-and-common-conditions 2021-01-11T03:35:41 https://maestrodatabase.com/blog/medicare-allows-more-benefits-for-chronically-ill-aiming-to-improve-care-for-millions 2018-06-25T12:07:12 https://maestrodatabase.com/blog/fda-approves-first-drug-comprised-of-an-active-ingredient-derived-from-marijuana-to-treat-rare-severe-forms-of-epilepsy 2018-06-25T21:10:51 https://maestrodatabase.com/blog/pbs-push-for-stage-three-melanoma-drug 2018-06-25T21:28:58 https://maestrodatabase.com/blog/statement-by-fda-commissioner-on-the-importance-of-conducting-proper-research-to-prove-safe-and-effective-medical-uses-for-the-active-chemicals-in-marijuana-and-its-components 2018-06-25T21:13:55 https://maestrodatabase.com/blog/imbruvica-ibrutinib-supplemental-new-drug-application-accepted-for-review-by-u-dot-s-fda-with-potential-to-broaden-treatment-use-as-a-combination-treatment-option-with-rituximab-in-waldenstroems-macroglobulinemia-a-rare-form-of-blood-cancer 2018-06-25T21:19:02 https://maestrodatabase.com/blog/as-the-drug-industry-eyes-the-burgeoning-biosimilar-market-its-united-front-is-starting-to-crack 2018-06-25T21:55:48 https://maestrodatabase.com/blog/pbac-recommendation-for-nirmatrelvir-and-ritonavir-paxlovid---march-2022 2022-04-09T01:15:53 https://maestrodatabase.com/blog/comparing-new-medicine-availability-across-europe 2024-06-13T03:48:46 https://maestrodatabase.com/blog/accc-tells-private-health-funds-be-more-honest-with-your-customers 2018-06-25T21:49:18 https://maestrodatabase.com/blog/innovent-receives-fast-track-designation-from-the-us-fda-for-ibi343-topo1i-anti-cldn18-dot-2-adc-as-monotherapy-for-advanced-pancreatic-cancer 2024-06-13T05:40:18 https://maestrodatabase.com/blog/life-saving-drugs-program---medicines-reviews-recommendations 2022-04-09T02:16:26 https://maestrodatabase.com/blog/ultragenyx-completes-rolling-submission-of-biologics-license-application-to-us-fda-for-dtx401-aav-gene-therapy-for-glycogen-storage-disease-type-ia 2025-12-31T07:46:57 https://maestrodatabase.com/blog/historic-new-drug-application-for-the-use-of-scenesse-in-rare-metabolic-disorder-epp 2018-06-26T06:11:19 https://maestrodatabase.com/blog/cogent-biosciences-announces-submission-of-new-drug-application-for-bezuclastinib-in-non-advanced-systemic-mastocytosis 2025-12-31T07:54:46 https://maestrodatabase.com/blog/european-commission-grants-marketing-authorisation-for-gileads-biktarvy-bictegravir-emtricitabine-tenofovir-alafenamide-for-the-treatment-of-hiv-1-infection 2018-06-26T05:59:07 https://maestrodatabase.com/blog/fda-grants-breakthrough-therapy-designation-for-biomarins-valoctocogene-roxaparvovec-formerly-bmn-270-an-investigational-gene-therapy-for-hemophilia-a 2017-10-28T23:37:13 https://maestrodatabase.com/blog/surgery-figures-a-sign-of-private-health-insurance-ills 2018-06-26T06:28:27 https://maestrodatabase.com/blog/gsk-announces-ema-accepted-marketing-authorisation-application-for-belantamab-mafodotin-for-the-treatment-of-relapsed-or-refractory-multiple-myeloma 2020-02-03T11:10:09 https://maestrodatabase.com/blog/la-jolla-pharmaceutical-company-announces-european-medicines-agency-validation-of-marketing-authorisation-application-for-giapreza-angiotensin-ii 2018-06-26T06:21:00 https://maestrodatabase.com/blog/joint-statement-from-cms-administrator-chiquita-brooks-lasure-and-fda-commissioner-robert-m-califf-on-ensuring-access-to-safe-and-effective-treatments 2022-04-09T02:06:49 https://maestrodatabase.com/blog/fda-accepts-supplemental-biologics-license-application-for-mercks-keytruda-pembrolizumab-as-adjuvant-therapy-in-advanced-melanoma 2018-06-26T06:43:15 https://maestrodatabase.com/blog/house-dust-mite-allergen-for-the-treatment-of-patients-with-allergic-rhinitis-and-allergic-asthma-caused-by-house-dust-mites-review-of-ta834 2024-06-13T06:21:36 https://maestrodatabase.com/blog/fda-and-ftc-announce-new-efforts-to-further-deter-anti-competitive-business-practices-support-competitive-market-for-biological-products-to-help-americans 2020-02-03T20:02:13 https://maestrodatabase.com/blog/acts-productivity-perspective-on-pharmac-medication-and-treatments-will-hurt-minorities 2023-09-11T08:28:09 https://maestrodatabase.com/blog/verona-pharma-announces-the-us-fda-has-accepted-the-new-drug-application-filing-for-ensifentrine-for-the-maintenance-treatment-of-copd 2023-09-11T08:53:12 https://maestrodatabase.com/blog/stemline-therapeutics-announces-completion-of-rolling-bla-submission-for-elzonris-tagraxofusp-sl-401-for-the-treatment-of-bpdcn 2018-06-26T06:33:49 https://maestrodatabase.com/blog/rinvoq-nice-approval-could-benefit-54-000-people 2020-02-03T19:55:57 https://maestrodatabase.com/blog/pbs-expenditure-and-prescriptions-report-2024-25 2025-12-31T00:09:16 https://maestrodatabase.com/blog/achaogen-submits-plazomicin-new-drug-application-to-the-u-dot-s-fda-for-treatment-of-complicated-urinary-tract-infections-and-bloodstream-infections 2017-10-28T23:51:57 https://maestrodatabase.com/blog/vanda-pharmaceuticals-announces-fda-approval-of-nereus-tradipitant-for-the-prevention-of-vomiting-induced-by-motion-a-historic-scientific-milestone-in-the-prevention-of-motion-sickness 2025-12-31T01:06:59 https://maestrodatabase.com/blog/others-to-follow-enbrel-biosimilar-launch-in-australia-merck-says 2017-04-07T03:56:19 https://maestrodatabase.com/blog/roches-xofluza-approved-by-the-european-commission-for-the-treatment-of-influenza-the-first-new-influenza-antiviral-for-patients-in-almost-20-years 2021-01-11T19:40:51 https://maestrodatabase.com/blog/yale-experts-discuss-impact-of-medicare-price-negotiation-legislation 2023-09-11T10:28:18 https://maestrodatabase.com/blog/upadacitinib-abrocitinib-and-tralokinumab-for-atopic-dermatitis 2022-04-09T03:28:41 https://maestrodatabase.com/blog/us-fda-accepts-supplemental-new-drug-application-for-jardiance-empagliflozin-for-adults-with-heart-failure-with-reduced-ejection-fraction 2021-01-11T19:47:16 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-january-2026 2025-12-31T22:25:19 https://maestrodatabase.com/blog/an-alternative-measure-of-health-for-value-assessment-the-equal-value-life-year 2023-09-11T09:33:22 https://maestrodatabase.com/blog/axsome-therapeutics-announces-fda-acceptance-and-priority-review-of-supplemental-new-drug-application-for-axs-05-for-the-treatment-of-alzheimers-disease-agitation 2026-01-01T01:09:36 https://maestrodatabase.com/blog/outlook-therapeutics-provides-regulatory-update-on-us-fda-review-of-ons-5010-slash-lytenava-bevacizumab-vikg-for-the-treatment-of-wet-amd-december-2025 2026-01-01T02:20:24 https://maestrodatabase.com/blog/myriad-genetics-receives-first-reimbursement-decision-for-mychoice-diagnostic-system-in-japan-enabling-women-with-ovarian-cancer-to-benefit-from-treatment-with-zejula 2021-01-11T20:13:17 https://maestrodatabase.com/blog/united-therapeutics-announces-u-dot-s-fda-filing-acceptance-of-supplemental-new-drug-application-for-tyvaso-for-pulmonary-hypertension-associated-with-interstitial-lung-disease 2020-08-17T10:39:31 https://maestrodatabase.com/blog/most-australians-will-get-the-astrazeneca-coronavirus-vaccine-but-priority-groups-will-receive-the-pfizer-drug-whats-the-difference 2021-01-11T20:22:06 https://maestrodatabase.com/blog/csl-in-talks-with-astrazeneca-to-produce-covid-19-vaccine-in-melbourne 2020-08-17T08:10:29 https://maestrodatabase.com/blog/smc---september-2023-decisions 2023-09-11T10:47:01 https://maestrodatabase.com/blog/smc-to-support-innovative-new-medicines-pathway 2021-01-11T19:52:54 https://maestrodatabase.com/blog/nice-publishes-guidance-on-astellas-xospata 2020-08-17T08:14:10 https://maestrodatabase.com/blog/organogenesis-renu-receives-fda-regenerative-medicine-advanced-therapy-designation-for-osteoarthritis-of-the-knee 2021-01-11T19:57:47 https://maestrodatabase.com/blog/democrats-have-their-best-shot-yet-at-letting-medicare-negotiate-drug-prices----but-its-still-not-a-done-deal 2021-01-11T20:04:37 https://maestrodatabase.com/blog/msac-guidelines-review 2020-08-17T09:07:40 https://maestrodatabase.com/blog/ema-publishes-agenda-for-11-14-september-2023-chmp-meeting 2023-09-11T10:39:22 https://maestrodatabase.com/blog/celebrating-25-years-of-pharmac 2018-06-26T21:48:28 https://maestrodatabase.com/blog/heron-therapeutics-granted-fda-fast-track-designation-for-htx-011-to-reduce-post-operative-pain-and-the-need-for-opioid-analgesics-for-72-hours 2017-10-29T00:20:55 https://maestrodatabase.com/blog/janssen-and-others-have-appealed-nices-decision-to-reject-abiraterone-acetate-for-patients-with-for-high-risk-hormone-sensitive-metastatic-prostate-cancer 2020-08-17T12:20:14 https://maestrodatabase.com/blog/osteoporosis-after-menopause-fewer-vertebral-fractures-with-teriparatide-than-with-risedronate 2022-12-08T19:49:48 https://maestrodatabase.com/blog/generic-drugs-should-be-cheap-but-insurers-are-charging-thousands-of-dollars-for-them 2023-09-11T21:06:39 https://maestrodatabase.com/blog/just-how-much-is-a-medical-miracle-worth 2017-04-07T13:33:41 https://maestrodatabase.com/blog/health-cap-to-leave-insurers-on-the-brink 2018-06-26T21:44:34 https://maestrodatabase.com/blog/fda-takes-action-on-updated-mrna-covid-19-vaccines-to-better-protect-against-currently-circulating-variants 2023-09-11T20:47:57 https://maestrodatabase.com/blog/pbs-listing-of-paxlovid-nirmatrelvir-and-ritonavir 2022-04-09T03:47:09 https://maestrodatabase.com/blog/more-insights-from-the-agenda-for-november-2023-pbac-meeting 2023-09-11T20:56:39 https://maestrodatabase.com/blog/g1-therapeutics-announces-acceptance-and-priority-review-of-nda-for-trilaciclib-for-patients-with-small-cell-lung-cancer 2020-08-17T20:38:37 https://maestrodatabase.com/blog/fda-approves-first-therapy-for-rare-joint-tumour 2019-08-03T02:18:11 https://maestrodatabase.com/blog/gop-house-leaders-say-health-bill-tweak-shows-progress-but-larger-divisions-remain 2017-04-07T13:39:55 https://maestrodatabase.com/blog/astrazeneca-seals-deal-with-ec-for-coronavirus-vaccine-supply 2020-08-17T10:54:51 https://maestrodatabase.com/blog/insights-from-the-january-2021-issue-of-the-schedule-of-pharmaceutical-benefits 2021-01-11T20:34:03 https://maestrodatabase.com/blog/fda-grants-priority-review-to-genentechs-baloxavir-marboxil-for-the-treatment-of-influenza 2018-06-26T21:55:02 https://maestrodatabase.com/blog/how-pharmaceutical-companies-game-the-system-to-keep-drugs-expensive 2017-04-07T13:42:26 https://maestrodatabase.com/blog/biolinerx-announces-fda-approval-of-aphexda-motixafortide-in-combination-with-filgrastim-to-mobilise-haematopoietic-stem-cells-for-collection-and-subsequent-autologous-transplantation-in-patients-with-multiple-myeloma 2023-09-11T11:26:43 https://maestrodatabase.com/blog/new-uses-for-old-drugs 2018-06-26T21:59:41 https://maestrodatabase.com/blog/iqwig-updates-its-general-methods 2022-12-08T20:27:22 https://maestrodatabase.com/blog/the-cost-of-drugs-for-rare-diseases-is-threatening-the-u-dot-s-health-care-system 2017-04-07T13:55:36 https://maestrodatabase.com/blog/new-zealand-health-system-universalism-struggles-with-persisting-inequities 2019-08-03T02:36:28 https://maestrodatabase.com/blog/myovant-sciences-announces-fda-acceptance-of-new-drug-application-for-once-daily-relugolix-combination-tablet-for-uterine-fibroids 2020-08-17T20:50:42 https://maestrodatabase.com/blog/speedier-drug-approvals-hit-slowdown-as-fda-faces-scrutiny 2022-12-08T20:34:30 https://maestrodatabase.com/blog/drugs-and-manners-of-administration-that-meet-the-f2-slash-multi-brand-criteria-30-month-clock-for-originator-removal-calculation-for-the-2017-october-cycle 2017-04-07T13:49:28 https://maestrodatabase.com/blog/fda-approves-two-hepatitis-c-drugs-for-paediatric-patients 2017-04-07T21:54:36 https://maestrodatabase.com/blog/abbvies-maviret-glecaprevir-slash-pibrentasvir-approved-by-european-commission-to-shorten-treatment-duration-to-eight-weeks-for-treatment-naive-patients-with-chronic-hepatitis-c-and-compensated-cirrhosis 2019-08-03T02:29:14 https://maestrodatabase.com/blog/nice-recommends-livtencity-maribavir-for-the-treatment-of-adults-with-post-transplant-cytomegalovirus-refractory-with-or-without-resistance-to-prior-therapies 2022-12-08T20:22:27 https://maestrodatabase.com/blog/atara-biotherapeutics-receives-rare-paediatric-disease-designation-from-fda-for-ata230-for-treatment-of-congenital-cytomegalovirus-infection 2017-10-29T00:36:36 https://maestrodatabase.com/blog/acute-myeloid-leukaemia-developing-drugs-and-biological-products-for-treatment 2020-08-17T20:56:53 https://maestrodatabase.com/blog/visiox-pharma-announces-fda-acceptance-of-new-drug-application-for-glaucoma 2022-12-08T19:54:29 https://maestrodatabase.com/blog/corcept-receives-complete-response-letter-for-relacorilant-as-a-treatment-for-patients-with-hypercortisolism 2026-01-01T09:49:00 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-reviews-final-report-on-treatments-for-rheumatoid-arthritis-finds-evidence-inadequate-to-distinguish-overall-benefits-between-newer-agents-and-prices-too-high-in-relationship-to-the-clinical-value-provided-to-patients 2017-04-07T21:57:57 https://maestrodatabase.com/blog/hansa-biopharma-announces-positive-reimbursement-decision-in-italy-for-idefirix-imlifidase-as-desensitization-treatment-for-highly-sensitized-patients-in-kidney-transplantation 2022-12-08T20:01:31 https://maestrodatabase.com/blog/merck-receives-complete-response-letter-from-the-u-dot-s-fda-for-tecos-study-with-sitagliptin 2017-04-07T22:04:28 https://maestrodatabase.com/blog/halifax-man-devastated-after-insurer-reverses-decision-to-cover-25-000-dollars-cystic-fibrosis-drug 2021-08-14T02:59:05 https://maestrodatabase.com/blog/ptc-announces-the-acceptance-of-the-european-marketing-authorisation-application-for-evrysdi-risdiplam-for-the-treatment-of-spinal-muscular-atrophy 2020-08-17T21:34:41 https://maestrodatabase.com/blog/genomic-diagnostic-tests-face-persistent-pricing-and-reimbursement-challenges 2021-08-14T03:11:01 https://maestrodatabase.com/blog/cancer-patient-forced-to-crowd-fund-for-life-saving-drug-treatment 2019-08-03T03:07:33 https://maestrodatabase.com/blog/cancer-drugs-petition-rejected 2019-08-03T03:04:46 https://maestrodatabase.com/blog/creating-a-coronavirus-vaccine-is-only-the-first-step-itll-take-years-to-manufacture-and-distribute 2020-08-17T21:53:33 https://maestrodatabase.com/blog/castration-resistant-prostate-cancer-with-a-high-risk-of-metastasis-enzalutamide-has-an-additional-benefit 2020-08-17T21:01:22 https://maestrodatabase.com/blog/fda-authorises-updated-bivalent-covid-19-vaccines-for-children-down-to-6-months-of-age 2022-12-08T20:44:19 https://maestrodatabase.com/blog/ipsen-announces-withdrawal-of-palovarotene-nda-confirming-intention-to-resubmit-following-additional-data-analyses 2021-08-14T02:12:35 https://maestrodatabase.com/blog/clinical-trials-of-coronavirus-drugs-are-taking-longer-than-expected 2020-08-17T21:18:33 https://maestrodatabase.com/blog/takedas-qdenga-dengue-tetravalent-vaccine-live-attenuated-approved-for-use-in-european-union 2022-12-08T20:38:45 https://maestrodatabase.com/blog/irish-pharmacists-lobby-for-biosimilar-substitution 2020-08-17T21:30:42 https://maestrodatabase.com/blog/janssen-submits-biologics-license-application-to-us-fda-for-talquetamab-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma 2022-12-10T01:55:22 https://maestrodatabase.com/blog/novartis-oral-fabhalta-iptacopan-receives-positive-chmp-opinion-for-the-treatment-of-adults-living-with-c3-glomerulopathy 2025-03-01T01:32:42 https://maestrodatabase.com/blog/sesen-bio-receives-complete-response-letter-from-fda-for-vicineum-oportuzumab-monatox-qqrs 2021-08-14T03:18:50 https://maestrodatabase.com/blog/linvoseltamab-recommended-for-eu-approval-by-the-chmp-to-treat-relapsed-slash-refractory-multiple-myeloma 2025-03-01T01:20:00 https://maestrodatabase.com/blog/aquestive-therapeutics-receives-fda-acceptance-of-new-drug-application-for-libervant-diazepam-buccal-film-in-paediatric-patients-and-assignment-of-pdufa-date 2023-09-11T23:15:13 https://maestrodatabase.com/blog/yescarta-rejected-among-other-smc-decisions 2019-02-12T10:15:45 https://maestrodatabase.com/blog/sobi-receives-approval-from-health-canada-for-empaveli-pegcetacoplan-for-the-treatment-of-certain-patients-with-paroxysmal-nocturnal-haemoglobinuria 2022-12-10T02:14:27 https://maestrodatabase.com/blog/exicure-granted-two-fast-track-designations-for-cavrotolimod-ast-008-from-the-u-dot-s-food-and-drug-administration 2021-01-11T23:11:51 https://maestrodatabase.com/blog/lillys-jaypirca-pirtobrutinib-recommended-by-chmp-for-approval-in-the-european-union-for-adults-with-relapsed-or-refractory-chronic-lymphocytic-leukaemia-previously-treated-with-a-btk-inhibitor 2025-03-01T01:57:17 https://maestrodatabase.com/blog/enhertu-recommended-for-approval-in-the-eu-by-chmp-for-patients-with-her2-low-or-her2-ultra-low-metastatic-breast-cancer-following-at-least-one-endocrine-therapy 2025-03-01T01:46:16 https://maestrodatabase.com/blog/fda-accepts-biogen-biologics-license-application-for-biib800-a-biosimilar-candidate-referencing-actemra-tocilizumab 2022-12-10T02:02:52 https://maestrodatabase.com/blog/valneva-receives-emas-positive-chmp-opinion-for-adolescent-label-extension-for-chikungunya-vaccine-ixchiq 2025-03-01T02:31:12 https://maestrodatabase.com/blog/innocrin-pharmaceuticals-granted-fast-track-designation-by-fda-for-seviteronel-treatment-of-women-with-triple-negative-breast-cancer-and-women-or-men-with-estrogen-receptor-positive-breast-cancer 2017-04-07T23:19:47 https://maestrodatabase.com/blog/bimzelx-bimekizumab-negotiations-with-pcpa-concluded-successfully-following-positive-cda-and-inesss-recommendations-for-adults-with-active-psoriatic-arthritis-and-adults-with-active-ankylosing-spondylitis 2025-03-01T02:24:06 https://maestrodatabase.com/blog/abbvie-receives-positive-chmp-opinion-for-upadacitinib-rinvoq-for-the-treatment-of-adults-with-giant-cell-arteritis 2025-03-01T02:13:42 https://maestrodatabase.com/blog/efruxifermin-granted-fda-breakthrough-therapy-designation-for-nash 2022-12-10T02:28:20 https://maestrodatabase.com/blog/receipt-of-complete-response-letter-from-us-fda-for-nd0612 2024-06-13T11:48:09 https://maestrodatabase.com/blog/pfizer-and-biontech-receive-us-fda-fast-track-designation-for-single-dose-mrna-based-vaccine-candidate-against-covid-19-and-influenza 2022-12-10T02:21:15 https://maestrodatabase.com/blog/health-canada-authorises-the-pfizer-biontech-omicron-ba-dot-4-slash-ba-dot-5-bivalent-adapted-covid-19-booster-for-children-5-to-11-years-of-age 2022-12-10T02:49:31 https://maestrodatabase.com/blog/vbi-vaccines-announces-health-canada-approval-for-prehevbrio-for-the-prevention-of-hepatitis-b-in-adults 2022-12-10T02:43:43 https://maestrodatabase.com/blog/outlook-therapeutics-resubmits-biologics-license-application-for-ons-5010-as-a-treatment-for-wet-amd-to-the-us-fda 2025-03-01T23:03:27 https://maestrodatabase.com/blog/cystic-fibrosis-scandal-fury-over-us-firms-refusal-to-set-price-for-life-saving-drugs 2019-02-12T19:35:46 https://maestrodatabase.com/blog/teva-and-medincell-announce-fda-acceptance-of-supplemental-new-drug-application-for-uzedy-risperidone-extended-release-injectable-suspension-as-a-treatment-for-patients-with-bipolar-i-disorder 2025-03-02T03:36:27 https://maestrodatabase.com/blog/nice-expands-draft-recommendation-for-lokelma 2019-08-03T05:04:12 https://maestrodatabase.com/blog/atagi-statement-on-use-of-booster-doses-in-adolescents-aged-12-15-years 2022-04-09T05:29:04 https://maestrodatabase.com/blog/statement-from-fda-commissioner-on-ongoing-efforts-to-stop-the-spread-of-illicit-opioids-further-secure-the-u-dot-s-drug-supply-chain-and-forcefully-confront-opioid-epidemic 2019-02-12T19:53:52 https://maestrodatabase.com/blog/catalyst-pharma-sees-net-price-of-drug-once-free-topping-300-000-dollars 2019-02-12T19:48:23 https://maestrodatabase.com/blog/fda-grants-approval-to-atezolizumab-for-alveolar-soft-part-sarcoma 2022-12-10T02:58:26 https://maestrodatabase.com/blog/decision-to-widen-access-to-valganciclovir-for-transplant-patients 2021-01-12T00:39:58 https://maestrodatabase.com/blog/mresvia-rsv-vaccine-approved-to-protect-patients-aged-60-and-over 2025-03-02T04:14:10 https://maestrodatabase.com/blog/we-stand-to-lose-billions-in-blockbuster-drug-patent-challenge 2025-03-02T04:06:28 https://maestrodatabase.com/blog/krystal-biotech-receives-positive-chmp-opinion-for-vyjuvek-for-the-treatment-of-dystrophic-epidermolysis-bullosa 2025-03-02T03:45:53 https://maestrodatabase.com/blog/zemdri-plazomicin-approved-by-fda-for-the-treatment-of-adults-with-complicated-urinary-tract-infections 2018-06-27T01:11:07 https://maestrodatabase.com/blog/aerie-pharmaceuticals-receives-european-commission-approval-for-roclanda-netarsudil-and-latanoprost-ophthalmic-solution-0-dot-02-percent-slash-0-dot-005-percent 2021-01-12T01:12:06 https://maestrodatabase.com/blog/obseva-provides-update-on-yselty-linzagolix-clinical-development-program 2021-01-12T02:02:41 https://maestrodatabase.com/blog/pre-approval-promises-to-voluntarily-withdraw-fda-approved-drugs 2022-12-10T23:45:26 https://maestrodatabase.com/blog/youre-cured-till-youre-not-should-disease-free-survival-be-used-as-a-regulatory-or-clinical-endpoint-for-adjuvant-therapy-of-cancer 2022-12-10T23:41:25 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-repotrectinib-for-adult-and-paediatric-patients-with-ntrk-gene-fusion-positive-solid-tumours 2024-06-13T21:04:02 https://maestrodatabase.com/blog/from-1-february-2021-pre-covid-19-special-authority-criteria-will-be-reinstated 2021-01-12T03:50:22 https://maestrodatabase.com/blog/fda-approves-adbry-tralokinumab-ldrm-auto-injector-for-the-treatment-of-adults-with-moderate-to-severe-atopic-dermatitis 2024-06-13T21:43:22 https://maestrodatabase.com/blog/health-canada-approves-bavencio-for-the-maintenance-treatment-of-patients-with-advanced-bladder-cancer 2021-01-12T06:17:47 https://maestrodatabase.com/blog/savara-resubmits-the-biologics-license-application-to-the-us-fda-for-molbreevi-for-the-potential-treatment-of-auto-immune-pulmonary-alveolar-proteinosis 2026-01-02T00:09:23 https://maestrodatabase.com/blog/anavex-life-sciences-announces-fast-track-designation-granted-by-u-dot-s-fda-for-anavex-2-73-blarcamesine-clinical-development-program-for-the-treatment-of-rett-syndrome 2020-02-04T00:23:30 https://maestrodatabase.com/blog/copayment-incentive-increased-medication-use-and-reduced-spending-among-indigenous-australians-after-2010 2020-02-04T00:36:06 https://maestrodatabase.com/blog/acrux-receives-fda-approval-for-its-generic-testosterone-topical-solution 2021-01-12T04:35:48 https://maestrodatabase.com/blog/neurotech-pharmaceuticals-granted-fast-track-designation-from-the-us-fda-for-the-treatment-of-macular-telangiectasia-type-2 2019-02-13T01:06:22 https://maestrodatabase.com/blog/prac-recommends-further-restrictions-for-multiple-sclerosis-medicine-zinbryta-due-to-risk-of-serious-liver-damage 2017-10-29T20:35:04 https://maestrodatabase.com/blog/resverlogix-receives-us-fda-breakthrough-therapy-designation-for-apabetalone 2020-02-04T00:31:34 https://maestrodatabase.com/blog/the-fda-struggle-to-withdraw-makena-problems-with-the-accelerated-approval-process 2022-12-11T01:20:31 https://maestrodatabase.com/blog/employers-shoulder-plenty-of-drug-costs-but-havent-lobbied-much-to-lower-them----until-now 2020-02-04T00:43:14 https://maestrodatabase.com/blog/refocusing-medication-prior-authorisation-on-its-intended-purpose 2020-02-04T00:39:15 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-january-2026 2026-01-02T00:57:23 https://maestrodatabase.com/blog/mylan-launches-wixela-inhub-fluticasone-propionate-and-salmeterol-inhalation-powder-usp-the-first-generic-of-advair-diskus-fluticasone-propionate-and-salmeterol-inhalation-powder-at-a-list-price-70-percent-less-than-the-brand 2019-02-13T08:42:38 https://maestrodatabase.com/blog/genmab-announces-u-dot-s-fda-approval-of-darzalex-daratumumab-split-dosing-regimen 2019-02-13T08:16:46 https://maestrodatabase.com/blog/european-medicines-agency-has-accepted-for-review-a-marketing-authorisation-application-for-voraxaze 2020-08-18T05:44:44 https://maestrodatabase.com/blog/lynparza-olaparib-granted-breakthrough-therapy-designation-by-us-fda-for-treatment-of-brca1-slash-2-or-atm-gene-mutated-metastatic-castration-resistant-prostate-cancer 2019-02-13T09:37:27 https://maestrodatabase.com/blog/trumps-free-market-approach-to-drug-pricing-will-help-lower-costs 2019-02-13T19:24:44 https://maestrodatabase.com/blog/industry-lauds-fda-rwe-framework-calls-for-tweaks 2019-02-13T19:26:52 https://maestrodatabase.com/blog/pharmac-to-review-its-practices-following-criticism-of-breast-cancer-drug-funding 2019-02-13T19:18:17 https://maestrodatabase.com/blog/rybelsus-oral-semaglutide-recommended-for-approval-for-the-treatment-of-adults-with-type-2-diabetes-by-the-european-regulatory-authorities 2020-02-04T01:17:06 https://maestrodatabase.com/blog/sandoz-restrained-from-selling-mabthera-biosimilar-in-australia 2018-06-27T07:35:35 https://maestrodatabase.com/blog/china-pushes-forward-reforms-to-expand-access-to-anti-cancer-drugs 2019-02-13T20:02:11 https://maestrodatabase.com/blog/statement-from-fda-commissioner-on-new-programs-to-promote-the-adoption-of-innovations-in-drug-manufacturing-that-can-improve-quality-and-lower-drug-costs 2019-02-13T19:59:47 https://maestrodatabase.com/blog/seqirus-announces-u-dot-s-fda-approval-of-its-first-ever-adjuvanted-cell-based-pandemic-influenza-a-h5n1-vaccine 2020-02-04T01:12:39 https://maestrodatabase.com/blog/clinical-disease-activity-index-cdai-first-choice-when-assessing-treatment-effects 2022-12-11T02:13:12 https://maestrodatabase.com/blog/sky-high-deductibles-broke-the-u-dot-s-health-insurance-system 2018-06-27T13:16:49 https://maestrodatabase.com/blog/defying-predictions-obamacare-insurers-see-boom-times-ahead 2018-06-27T13:21:48 https://maestrodatabase.com/blog/prices-soar-for-antibiotics-as-desperate-parents-search-for-strep-a-medicine 2022-12-11T02:04:59 https://maestrodatabase.com/blog/fda-accepts-for-review-supplemental-new-drug-application-for-recarbrio-imipenem-cilastatin-and-relebactam-for-the-treatment-of-adults-with-hospital-acquired-and-ventilator-associated-bacterial-pneumonia 2020-02-04T04:13:48 https://maestrodatabase.com/blog/miracle-medicines-a-cancer-specialist-sends-a-message-to-pharmac 2022-12-11T01:49:02 https://maestrodatabase.com/blog/limit-drug-prices-trumps-health-secretary-calls-the-idea-superficially-appealing 2018-06-27T07:44:51 https://maestrodatabase.com/blog/highlights-from-the-24-27-february-2025-chmp-meeting 2025-03-02T09:54:32 https://maestrodatabase.com/blog/gottlieb-calls-on-payers-to-share-data-to-aid-drug-innovation 2018-06-27T13:41:51 https://maestrodatabase.com/blog/improving-access-to-new-treatments-in-rare-diseases 2018-06-27T13:26:16 https://maestrodatabase.com/blog/puma-biotechnology-announces-results-of-chmp-re-examination-of-maa-for-neratinib-for-extended-adjuvant-treatment-of-her2-positive-early-stage-breast-cancer 2018-06-27T13:33:46 https://maestrodatabase.com/blog/medicaid-must-pay-for-drugs-approved-through-fdas-accelerated-pathway-agency-tells-states 2018-06-27T21:32:55 https://maestrodatabase.com/blog/health-canada-offers-hta-aligned-reviews-for-drugs-and-biologics 2018-06-27T13:46:19 https://maestrodatabase.com/blog/aafp-joins-campaign-to-push-back-against-rising-drug-prices 2017-04-09T04:30:05 https://maestrodatabase.com/blog/array-biopharma-announces-fda-approval-of-braftovi-encorafenib-in-combination-with-mektovi-binimetinib 2018-06-27T21:27:12 https://maestrodatabase.com/blog/icer-to-evaluate-whether-price-increases-on-prescription-drugs-are-unsupported-by-new-clinical-evidence 2018-06-27T21:44:38 https://maestrodatabase.com/blog/therapeuticsmd-announces-submission-of-new-drug-application-prior-approval-efficacy-supplement-to-the-u-dot-s-fda-for-lower-dose-of-bijuva 2020-02-04T04:29:19 https://maestrodatabase.com/blog/u-dot-s-fda-grants-priority-review-for-pfizers-new-drug-application-for-glasdegib-in-patients-with-previously-untreated-acute-myeloid-leukaemia 2018-06-27T21:36:21 https://maestrodatabase.com/blog/new-from-cadth-procedural-guidelines-and-a-streamlined-therapeutic-review-framework 2018-06-27T21:56:11 https://maestrodatabase.com/blog/cms-approves-state-proposal-to-advance-specific-medicaid-value-based-arrangements-with-drug-makers 2018-06-27T21:48:01 https://maestrodatabase.com/blog/metastasis-free-survival----a-new-end-point-in-prostate-cancer-trials 2018-06-27T21:51:23 https://maestrodatabase.com/blog/authorisations-of-human-medicinal-products-with-a-new-active-substance-and-additional-indications-2024 2025-03-02T10:01:10 https://maestrodatabase.com/blog/pharmac-invites-entire-staff-to-top-secret-drug-ranking-meetings 2021-08-15T20:54:18 https://maestrodatabase.com/blog/coronavirus-covid-19-update-fda-authorises-additional-vaccine-dose-for-certain-immunocompromised-individuals 2021-08-15T09:10:47 https://maestrodatabase.com/blog/ema-receives-application-for-conditional-marketing-authorisation-of-covid-19-vaccine-astrazeneca 2021-01-12T10:03:01 https://maestrodatabase.com/blog/australia-secures-one-million-pfizer-doses-from-poland-with-more-than-half-destined-for-sydney 2021-08-15T21:03:36 https://maestrodatabase.com/blog/janssens-ulcerative-colitis-treatment-to-receive-reimbursement 2021-01-12T11:41:36 https://maestrodatabase.com/blog/vaccine-is-not-good-enough-to-stop-the-virus 2021-01-12T19:48:48 https://maestrodatabase.com/blog/astra-blitz-scott-morrison-says-get-the-covid-19-vaccine-now 2021-07-22T21:02:14 https://maestrodatabase.com/blog/fda-approves-treatment-for-paediatric-patients-with-type-2-diabetes-mellitus 2021-07-22T21:08:31 https://maestrodatabase.com/blog/a-citizens-pathway-gone-astray----delaying-competition-from-generic-drugs 2017-03-03T02:11:36 https://maestrodatabase.com/blog/alnylam-receives-european-medicines-agency-prime-designation-for-accelerated-assessment-of-givosiran-an-investigational-rnai-therapeutic-for-the-treatment-of-acute-hepatic-porphyrias 2017-03-02T23:27:43 https://maestrodatabase.com/blog/icer-publishes-research-protocol-for-assessing-price-increases-of-prescription-drugs-in-california 2022-03-16T20:42:29 https://maestrodatabase.com/blog/trump-vows-to-slash-restraints-on-drug-development-for-fda 2017-03-03T00:18:14 https://maestrodatabase.com/blog/hhs-announces-15-additional-drugs-selected-for-medicare-drug-price-negotiations-in-continued-effort-to-lower-prescription-drug-costs-for-seniors 2025-01-17T22:08:29 https://maestrodatabase.com/blog/rinvoq-upadacitinib-receives-fda-approval-for-the-treatment-of-adults-with-moderately-to-severely-active-ulcerative-colitis 2022-03-16T21:58:36 https://maestrodatabase.com/blog/covid-19-vaccines---are-we-there-yet 2021-02-02T03:26:59 https://maestrodatabase.com/blog/how-to-slash-half-a-billion-dollars-a-year-from-australias-drugs-bill 2017-03-03T22:06:11 https://maestrodatabase.com/blog/dupixent-dupilumab-injection-receives-positive-recommendation-from-cadth-and-inesss-for-the-treatment-of-severe-asthma 2021-07-22T21:29:00 https://maestrodatabase.com/blog/no-new-patients-should-start-treatment-with-lartruvo-after-study-shows-cancer-medicine-does-not-prolong-life 2019-01-23T19:23:28 https://maestrodatabase.com/blog/ema-relocation-updates 2019-01-23T19:26:13 https://maestrodatabase.com/blog/european-medicines-agency-validates-santheras-marketing-authorisation-application-for-vamorolone-in-duchenne-muscular-dystrophy 2022-11-01T02:14:02 https://maestrodatabase.com/blog/novartis-aims-to-beat-rivals-to-novel-10-dollars-billion-cancer-treatment-market 2021-07-22T21:48:17 https://maestrodatabase.com/blog/it-is-time-to-reconsider-the-3-percent-discount-rate 2024-05-16T00:54:27 https://maestrodatabase.com/blog/vertexs-cf-drug-gets-label-extension-as-pricing-row-continues-vertexs-cf-drug-gets-label-extension-as-pricing-row-continues 2019-01-23T19:44:01 https://maestrodatabase.com/blog/tga-set-to-greenlight-pfizer-jab-for-children-aged-between-12-and-16-year-old 2021-07-22T21:13:10 https://maestrodatabase.com/blog/biogen-sees-heavy-patient-interest-in-new-alzheimers-drug 2021-07-22T21:24:51 https://maestrodatabase.com/blog/more-community-pharmacies-and-additional-gps-to-deliver-covid-19-vaccines 2021-07-22T21:18:24 https://maestrodatabase.com/blog/citizens-ask---scientists-answer-the-iqwig-sets-four-new-topics-for-hta-reports 2019-01-23T19:29:49 https://maestrodatabase.com/blog/icer-launches-international-collaborative-to-develop-new-methods-to-guide-value-based-pricing-of-potential-cures 2019-01-23T19:53:59 https://maestrodatabase.com/blog/eisai-and-merck-provide-update-on-supplemental-new-drug-application-for-lenvatinib-in-first-line-unresectable-hepatocellular-carcinoma 2018-05-26T02:44:22 https://maestrodatabase.com/blog/fda-approves-first-treatment-for-frequent-urination-at-night-due-to-overproduction-of-urine 2017-03-03T23:03:23 https://maestrodatabase.com/blog/physicians-perspectives-on-fda-approval-standards-and-off-label-drug-marketing 2019-01-23T19:48:16 https://maestrodatabase.com/blog/the-scandal-of-generic-drug-pricing-drug-regulation-policies-need-review 2017-03-03T23:08:32 https://maestrodatabase.com/blog/trump-calls-the-fda-slow-and-burdensome-but-its-faster-than-ever 2017-03-03T23:18:35 https://maestrodatabase.com/blog/the-strange-world-of-canadian-drug-pricing 2019-01-23T20:10:22 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-publishes-white-paper-on-assessment-and-payment-methods-for-gene-therapies 2017-03-03T23:12:15 https://maestrodatabase.com/blog/trudeau-spreads-the-big-pharmacare-myth-that-scores-of-canadians-cant-afford-medicine 2019-01-23T20:14:50 https://maestrodatabase.com/blog/house-leaders-forge-ahead-with-health-bills-hoping-to-bulldoze-internal-strife 2017-03-03T23:16:31 https://maestrodatabase.com/blog/discrete-choice-experiments-in-health-economics-past-present-and-future 2019-01-23T20:07:02 https://maestrodatabase.com/blog/the-risks-and-benefits-of-expedited-drug-reviews 2018-05-26T03:02:10 https://maestrodatabase.com/blog/president-donald-j-trump-is-taking-action-to-lower-drug-costs-and-ensure-that-americans-have-access-to-life-saving-medications 2020-07-26T11:38:53 https://maestrodatabase.com/blog/flu-vaccine-stocks-to-be-boosted-after-early-rush-saps-supplies-across-australia 2018-05-26T03:05:10 https://maestrodatabase.com/blog/trump-plan-to-force-drug-makers-to-advertise-prices-might-work-but-not-if-pharma-gets-its-way 2019-01-23T20:18:07 https://maestrodatabase.com/blog/indivior-announces-regulatory-submission-to-australias-therapeutic-goods-administration-for-sublocade-buprenorphine-extended-release-injection-for-the-treatment-of-opioid-dependence 2018-05-26T02:53:27 https://maestrodatabase.com/blog/gsk-receives-positive-chmp-opinion-recommending-approval-of-belantamab-mafodotin-for-the-treatment-of-relapsed-and-refractory-multiple-myeloma 2020-07-26T11:24:37 https://maestrodatabase.com/blog/als-patients-losing-time-and-hope-as-they-wait-for-insurers-to-cover-a-pricey-new-drug 2018-05-26T03:07:38 https://maestrodatabase.com/blog/mother-of-teen-with-cystic-fibrosis-pleads-for-pharmac-to-fund-new-medication 2020-07-26T11:29:05 https://maestrodatabase.com/blog/international-collaboration-provides-new-guidance-on-the-use-of-surrogate-outcomes-in-cost-effectiveness-analysis 2025-01-17T23:23:16 https://maestrodatabase.com/blog/selinexor-in-combination-with-bortezomib-and-dexamethasone-for-the-treatment-of-patients-with-relapsed-slash-refractory-multiple-myeloma-final-guidance 2024-05-16T01:32:06 https://maestrodatabase.com/blog/coronavirus-vaccine-access-could-come-back-to-old-alliances-as-world-powers-ramp-up-search-for-covid-19-cure 2020-07-26T21:12:45 https://maestrodatabase.com/blog/viatris-and-mapi-pharma-announce-fda-acceptance-of-new-drug-application-filing-for-glatiramer-acetate-depot-for-the-treatment-of-relapsing-forms-of-multiple-sclerosis 2023-08-07T11:12:37 https://maestrodatabase.com/blog/debating-drug-prices-in-the-shadow-of-coronavirus-access-versus-innovation-can-both-sides-win 2020-07-26T21:15:19 https://maestrodatabase.com/blog/i-need-something-to-move-forward-says-edmonton-mom-waiting-for-approval-for-sons-life-saving-treatment 2020-07-26T21:19:07 https://maestrodatabase.com/blog/salvat-laboratories-announces-submission-of-new-drug-application-to-the-us-fda-for-clobetasol-nanoemulsion-for-treating-inflammation-and-pain-after-ocular-surgery 2022-11-01T03:56:59 https://maestrodatabase.com/blog/gp-leaders-advise-practices-not-to-prescribe-cholesterol-lowering-drug-inclisiran 2023-08-07T08:20:17 https://maestrodatabase.com/blog/fda-approves-zurzuvae-zuranolone-the-first-and-only-oral-treatment-approved-for-women-with-postpartum-depression-and-issues-a-complete-response-letter-for-major-depressive-disorder 2023-08-07T08:24:17 https://maestrodatabase.com/blog/pharmac-widening-access-to-rituximab-and-zoledronic-acid 2022-03-17T02:32:13 https://maestrodatabase.com/blog/janssen-submits-new-drug-application-to-u-dot-s-fda-for-apalutamide-arn-509-to-treat-men-with-non-metastatic-castration-resistant-prostate-cancer 2017-10-12T01:43:03 https://maestrodatabase.com/blog/agenda-for-the-8-march-2017-tc-meeting 2017-03-04T08:22:23 https://maestrodatabase.com/blog/states-urge-hospitals-to-bill-insurers 2017-03-04T21:24:31 https://maestrodatabase.com/blog/public-summary-documents---pbac-november-2016-meeting 2017-03-04T22:45:20 https://maestrodatabase.com/blog/gao-drug-makers-want-more-clarity-on-antibiotic-incentives 2017-03-04T23:15:30 https://maestrodatabase.com/blog/smc---august-2023-decisions 2023-08-07T20:59:18 https://maestrodatabase.com/blog/acerus-files-a-new-drug-submission-for-gynoflor-in-canada 2017-03-05T00:49:11 https://maestrodatabase.com/blog/qiagen-receives-fda-approval-for-companion-diagnostic-to-blueprint-medicines-ayvakit-avapritinib-in-gastro-intestinal-stromal-tumours 2023-08-07T20:53:46 https://maestrodatabase.com/blog/huidagene-therapeutics-receives-fda-rare-paediatric-disease-designation-for-hg004-to-treat-inherited-blindness 2023-08-07T20:45:02 https://maestrodatabase.com/blog/alberta-will-cover-pricey-drug-believed-to-extend-and-enhance-lives-of-als-patients 2023-08-07T21:25:31 https://maestrodatabase.com/blog/scottish-medicines-consortium-accepts-vazkepa-icosapent-ethyl-to-help-reduce-cardiovascular-risk-for-patients-in-scotland 2023-08-07T21:14:27 https://maestrodatabase.com/blog/fda-harnesses-technology-and-collaboration-to-support-rare-disease-product-development 2020-01-19T19:16:43 https://maestrodatabase.com/blog/acceptability-of-using-real-world-data-to-estimate-relative-treatment-effects-in-health-technology-assessments-barriers-and-future-steps 2024-05-16T02:30:31 https://maestrodatabase.com/blog/closing-the-cycle-of-innovation-in-health-care-in-europe 2020-01-19T19:24:44 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-17-march-2022 2022-03-17T04:19:37 https://maestrodatabase.com/blog/china-drives-down-drug-prices-with-bulk-buy-bidding 2020-01-19T19:20:15 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-november-2022 2022-11-01T05:44:36 https://maestrodatabase.com/blog/first-immunotherapy-for-patients-with-a-potentially-life-threatening-type-of-non-melanoma-skin-cancer-now-available-on-the-pbs 2022-11-01T06:02:31 https://maestrodatabase.com/blog/dyne-therapeutics-receives-fda-fast-track-designation-for-dyne-251-for-the-treatment-of-duchenne-muscular-dystrophy 2022-11-01T06:48:18 https://maestrodatabase.com/blog/modernising-clinical-trials-for-patients-with-cancer 2019-01-23T23:10:55 https://maestrodatabase.com/blog/health-canada-approves-otsuka-and-lundbecks-abilify-asimtufii-aripiprazole-the-first-and-only-once-every-two-months-long-acting-injectable-treatment-for-schizophrenia-and-for-maintenance-monotherapy-of-bipolar-i-disorder-in-adults 2025-01-18T01:27:30 https://maestrodatabase.com/blog/toward-an-effective-innovation-agenda 2019-01-24T00:04:23 https://maestrodatabase.com/blog/tisagenlecleucel-for-the-treatment-of-patients-with-relapsed-or-refractory-b-cell-acute-lymphoblastic-leukaemia 2024-05-16T03:07:56 https://maestrodatabase.com/blog/australians-paying-four-times-above-international-prices-for-drugs 2017-03-05T20:18:45 https://maestrodatabase.com/blog/could-trump-and-hill-democrats-make-a-deal-to-curb-medicare-drug-prices 2019-01-24T00:12:17 https://maestrodatabase.com/blog/vaxzevria-receives-full-marketing-authorisation-in-the-eu-for-the-prevention-of-covid-19 2022-11-01T07:14:37 https://maestrodatabase.com/blog/the-who-says-cancer-drug-prices-are-impairing-access-to-treatment 2019-01-24T00:18:13 https://maestrodatabase.com/blog/response-to-the-grattan-institute-report-on-medicine-prices 2017-03-06T03:35:59 https://maestrodatabase.com/blog/drug-pricing-report-shows-scope-for-more-savings 2017-03-06T04:52:07 https://maestrodatabase.com/blog/chronic-obstructive-pulmonary-disorder-review---stakeholder-forum 2017-03-06T03:30:42 https://maestrodatabase.com/blog/aquestive-therapeutics-receives-fda-fast-track-designation-for-aqst-109-for-emergency-treatment-of-allergic-reactions-including-anaphylaxis 2022-03-17T19:42:14 https://maestrodatabase.com/blog/verzenio-abemaciclib-receives-positive-reimbursement-recommendation-from-cadth-for-early-breast-cancer 2022-11-01T19:54:28 https://maestrodatabase.com/blog/single-payer-health-care-in-california-heres-what-it-would-take 2018-05-27T01:44:17 https://maestrodatabase.com/blog/macrogenics-announces-fda-approval-of-margenza-for-patients-with-pretreated-metastatic-her2-positive-breast-cancer 2020-12-17T11:12:37 https://maestrodatabase.com/blog/celltrion-receives-health-canada-approval-for-eydenzelt-a-biosimilar-referencing-eylea-aflibercept-2-mg 2025-11-28T02:12:34 https://maestrodatabase.com/blog/vigil-neuroscience-receives-fda-fast-track-designation-for-vgl101-for-the-treatment-of-patients-with-alsp 2022-11-01T19:46:02 https://maestrodatabase.com/blog/u-dot-s-fda-approves-foundationone-cdx-as-a-companion-diagnostic-for-egfr-therapeutics-targeting-exon-19-deletions-or-exon-21-substitutions-in-non-small-cell-lung-cancer 2022-03-17T19:55:04 https://maestrodatabase.com/blog/its-outrageous-doctors-slam-practice-of-inflating-patient-fees 2018-05-27T00:15:26 https://maestrodatabase.com/blog/japan-to-lower-drug-prices-to-reduce-medical-costs 2020-12-17T11:18:46 https://maestrodatabase.com/blog/pharmac-seeks-feedback-on-the-funding-of-paediatric-cancer-medicines 2022-11-01T19:49:41 https://maestrodatabase.com/blog/nice-issues-decision-on-mylotarg-besponsa-for-leukaemia 2018-05-27T21:30:23 https://maestrodatabase.com/blog/icer-publishes-evidence-report-on-novel-agents-to-prevent-chemotherapy-induced-neutropenia-and-other-myelosuppressive-effects 2022-03-17T19:32:27 https://maestrodatabase.com/blog/pbs-expenditure-and-prescriptions-report-2019-20 2020-12-17T10:57:05 https://maestrodatabase.com/blog/congress-fda-need-to-change-biosimilar-rules-to-lower-drug-prices 2018-05-27T02:06:56 https://maestrodatabase.com/blog/is-innovation-causing-accessibility-timing-issues-for-private-drug-plans 2020-01-19T20:51:16 https://maestrodatabase.com/blog/amgen-submits-sotorasib-new-drug-application-to-u-dot-s-fda-for-advanced-or-metastatic-non-small-cell-lung-cancer-with-kras-g12c-mutation 2020-12-17T11:04:19 https://maestrodatabase.com/blog/evusheld-approved-to-prevent-covid-19-in-people-whose-immune-response-is-poor 2022-03-17T19:38:41 https://maestrodatabase.com/blog/medical-bills-how-out-of-pocket-costs-can-get-out-of-control 2018-05-27T21:18:36 https://maestrodatabase.com/blog/gbt-provides-regulatory-and-pipeline-updates-in-sickle-cell-disease 2021-07-23T07:22:32 https://maestrodatabase.com/blog/agreement-reached-on-funding-reforms-for-medical-devices 2022-03-17T20:19:21 https://maestrodatabase.com/blog/arrowhead-pharmaceuticals-announces-acceptance-of-new-drug-application-by-us-fda-of-plozasiran-for-the-treatment-of-familial-chylomicronaemia-syndrome 2025-01-18T03:34:46 https://maestrodatabase.com/blog/nice-publishes-draft-guidance-on-the-use-of-etelcalcetide-for-secondary-hyperparathyroidism 2017-03-06T10:41:46 https://maestrodatabase.com/blog/new-drug-to-treat-chronic-lung-disease-has-price-slashed 2018-05-27T21:41:51 https://maestrodatabase.com/blog/health-canada-authorises-modernas-covid-19-vaccine-in-children-6-11-years 2022-03-17T20:38:15 https://maestrodatabase.com/blog/patients-medical-payments-can-vary-up-to-400-percent-among-specialists-report-finds 2017-03-06T10:51:03 https://maestrodatabase.com/blog/tga-provisional-approval-of-pfizer-biontech-covid-19-vaccine-to-include-12-15-year-age-group 2021-07-23T07:29:29 https://maestrodatabase.com/blog/panel-scrutinises-quick-fda-drug-approvals 2022-03-17T20:27:09 https://maestrodatabase.com/blog/icers-final-report-on-disease-modifying-therapies-for-multiple-sclerosis-finds-most-drugs-are-over-priced-in-relation-to-benefits-for-patients-highlights-need-for-stakeholder-collaboration-to-address-system-issues 2017-03-06T20:23:23 https://maestrodatabase.com/blog/republicans-fine-tune-plan-to-dismantle-obamacare 2017-03-06T20:29:57 https://maestrodatabase.com/blog/keytruda-reimbursement-provides-global-standard-care-for-korean-lung-cancer-patients 2022-03-17T20:02:08 https://maestrodatabase.com/blog/cadth-publishes-initial-recommendations-for-three-medicines-for-non-small-cell-lung-cancer 2017-03-06T10:56:10 https://maestrodatabase.com/blog/merck-and-pfizer-announce-u-dot-s-fda-and-ema-filing-acceptances-of-three-marketing-applications-for-ertugliflozin-containing-medicines-for-adults-with-type-2-diabetes 2017-03-06T20:15:51 https://maestrodatabase.com/blog/patience-gone-koch-backed-groups-will-pressure-g-dot-o-p-on-health-repeal 2017-03-06T20:40:39 https://maestrodatabase.com/blog/reforms-to-deliver-lower-prices-for-medical-devices-and-lower-private-health-insurance-premiums 2022-03-17T20:16:17 https://maestrodatabase.com/blog/easier-access-to-hiv-medicines-from-next-year 2025-11-28T04:09:17 https://maestrodatabase.com/blog/repeal-of-health-law-faces-a-new-hurdle-older-americans 2017-03-06T20:43:01 https://maestrodatabase.com/blog/association-between-us-drug-price-and-measures-of-efficacy-for-oncology-drugs-approved-by-the-us-fda-from-2015-to-2020 2022-11-01T20:02:10 https://maestrodatabase.com/blog/gilead-executive-says-pharmacy-benefit-managers-keep-prices-high 2017-03-06T20:33:05 https://maestrodatabase.com/blog/backing-life-saving-local-cancer-drug-development 2022-03-17T20:07:01 https://maestrodatabase.com/blog/women-make-plea-ahead-of-decision-on-breast-cancer-drug-kadcyla 2017-03-06T20:37:48 https://maestrodatabase.com/blog/utilisation-of-real-world-evidence-in-regulatory-approvals-for-multiple-myeloma-therapies 2025-11-28T04:31:01 https://maestrodatabase.com/blog/kites-tecartus-kte-x19-granted-conditional-marketing-authorisation-for-the-treatment-of-relapsed-or-refractory-mantle-cell-lymphoma-in-europe 2020-12-17T19:50:57 https://maestrodatabase.com/blog/pharmac-proposes-funding-for-rare-disorder-treatment 2025-11-28T03:04:50 https://maestrodatabase.com/blog/icer-publishes-final-evidence-report-and-policy-recommendations-on-new-therapies-for-bladder-cancer 2020-12-17T19:59:34 https://maestrodatabase.com/blog/illuccix-receives-european-approval 2025-01-18T03:42:50 https://maestrodatabase.com/blog/update-on-assessment-of-marketing-authorisation-application-for-modernas-mrna-1273-covid-19-vaccine 2020-12-17T19:46:44 https://maestrodatabase.com/blog/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-for-keytruda-pembrolizumab-plus-chemotherapy-as-first-line-treatment-for-locally-advanced-unresectable-or-metastatic-oesophageal-and-gastro-esophageal-junction-cancer 2020-12-17T20:25:41 https://maestrodatabase.com/blog/fda-updates-list-of-off-patent-off-exclusivity-drugs-without-an-approved-generic 2020-12-17T20:37:30 https://maestrodatabase.com/blog/hospitals-discover-a-surprise-in-their-vaccine-deliveries-extra-doses 2020-12-17T20:44:04 https://maestrodatabase.com/blog/fda-approves-gsks-benlysta-as-the-first-medicine-for-adult-patients-with-active-lupus-nephritis-in-the-us 2020-12-17T20:05:45 https://maestrodatabase.com/blog/fda-grants-rmat-designation-for-cook-myosites-investigational-autologous-muscle-derived-cells-for-urinary-sphincter-repair 2020-12-17T20:11:08 https://maestrodatabase.com/blog/forget-a-christmas-miracle---pharmac-consults-on-making-the-ultimate-sacrifice 2022-11-02T02:33:31 https://maestrodatabase.com/blog/who-warns-countries-in-asia-pacific-may-not-get-vaccine-until-mid-to-late-2021 2020-12-17T20:49:01 https://maestrodatabase.com/blog/most-expensive-medicines-in-australia-revealed 2020-12-17T20:51:44 https://maestrodatabase.com/blog/department-tweaks-the-agenda-for-the-nov-2022-pbac-meeting-yet-again 2022-11-02T02:22:34 https://maestrodatabase.com/blog/negotiations-for-an-eighth-community-pharmacy-agreement 2023-08-08T05:42:49 https://maestrodatabase.com/blog/henlius-novel-anti-pd-1-mab-hansizhuang-serplulimab-receives-nmpa-approval-for-the-treatment-of-sqnsclc 2022-11-02T02:42:13 https://maestrodatabase.com/blog/australian-cancer-patients-to-get-improved-access-to-clinical-trials 2022-03-18T00:30:20 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-posts-draft-scoping-document-on-treatments-for-ovarian-cancer 2017-03-07T06:05:12 https://maestrodatabase.com/blog/time-for-public-listing-of-specialist-fees 2017-03-07T19:59:00 https://maestrodatabase.com/blog/aprocitentan-approved-to-treat-adults-with-hypertension-whose-blood-pressure-cannot-be-controlled-by-other-medications 2025-01-19T00:42:14 https://maestrodatabase.com/blog/2017-seasonal-influenza-vaccines 2017-03-07T20:01:21 https://maestrodatabase.com/blog/japan-joins-trump-in-drug-price-war-crimping-pharma-profits 2017-03-07T06:15:55 https://maestrodatabase.com/blog/defining-the-non-inferiority-margin-and-analysing-non-inferiority-an-overview 2017-03-07T06:20:33 https://maestrodatabase.com/blog/actelion-is-granted-marketing-authorisation-by-the-european-commission-for-ledaga-chlormethine-gel-for-the-treatment-of-mf-ctcl 2017-03-07T20:19:39 https://maestrodatabase.com/blog/personalised-medicines---focus-on-patients-and-healthcare-professionals 2017-03-07T20:05:59 https://maestrodatabase.com/blog/new-reimbursement-approved-by-the-japanese-ministry-of-health-labor-and-welfare-for-the-accuray-cyberknife-system-to-treat-trigeminal-neuralgia-a-condition-often-causing-severe-facial-pain 2022-11-02T02:57:52 https://maestrodatabase.com/blog/house-republicans-release-long-awaited-plan-to-replace-obamacare 2017-03-07T20:14:25 https://maestrodatabase.com/blog/pbac-publishes-final-two-outcomes-from-the-november-2016-meeting 2017-03-07T20:39:00 https://maestrodatabase.com/blog/what-aspects-of-an-economic-evaluation-are-commercially-sensitive 2017-03-07T21:01:02 https://maestrodatabase.com/blog/us-fda-approves-foundationone-cdx-as-a-companion-diagnostic-for-ojemda-tovorafenib-to-treat-the-most-common-form-of-childhood-brain-tumour-in-paediatric-patients 2025-01-19T00:25:48 https://maestrodatabase.com/blog/trump-sends-pharma-stocks-down-with-new-tweet-on-drug-prices 2017-03-07T20:28:29 https://maestrodatabase.com/blog/ontario-cancer-patient-in-limbo-over-chemotherapy-drug-shortage 2017-03-07T20:32:41 https://maestrodatabase.com/blog/dont-believe-drug-companies-340b-is-a-program-worth-saving 2023-08-08T20:44:02 https://maestrodatabase.com/blog/ardelyx-collaboration-partner-kyowa-kirin-announces-submission-of-new-drug-application-for-tenapanor-for-hyperphosphataemia-in-japan 2022-11-02T03:10:49 https://maestrodatabase.com/blog/health-technology-assessment-criteria-as-drivers-of-coverage-with-managed-entry-agreements-a-case-study-of-cancer-medicines-in-four-countries 2023-08-08T10:56:29 https://maestrodatabase.com/blog/ukhsa-unveils-vdec-in-step-change-for-uks-growing-vaccine-capabilities 2023-08-08T20:35:54 https://maestrodatabase.com/blog/ozempic-among-the-next-drugs-up-for-medicare-price-negotiations 2025-01-19T00:45:38 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-for-mesoblasts-cell-therapy-in-children-with-acute-graft-versus-host-disease 2017-03-07T23:09:38 https://maestrodatabase.com/blog/tga-hopes-to-approve-moderna-covid-19-vaccine-by-early-august 2021-07-23T11:34:11 https://maestrodatabase.com/blog/how-industrial-policy-could-accelerate-innovation-in-the-life-sciences 2023-08-08T21:09:10 https://maestrodatabase.com/blog/major-us-health-systems-expect-to-offer-alzheimers-drug-leqembi-in-a-few-months 2023-08-08T20:59:36 https://maestrodatabase.com/blog/when-memory-fades-misinformation-about-alzheimers-disease-and-aduhelm-must-be-limited 2021-07-23T11:42:57 https://maestrodatabase.com/blog/most-clinical-trials-failed-to-meet-u-dot-s-transparency-requirements-for-recently-approved-drugs 2021-07-23T12:03:10 https://maestrodatabase.com/blog/gsks-respiratory-syncytial-virus-older-adult-vaccine-candidate-granted-priority-review-by-us-fda 2022-11-02T14:56:35 https://maestrodatabase.com/blog/public-summary-documents---november-2021-pbac-meeting-first-time-rejections-and-deferrals 2022-03-18T05:21:57 https://maestrodatabase.com/blog/donald-trumps-fda-plans-could-affect-drug-regulation-in-australia-leading-medic-warns 2017-03-08T19:47:09 https://maestrodatabase.com/blog/us-fda-approves-vemlidy-tenofovir-alafenamide-for-treatment-of-chronic-hepatitis-b-virus-infection-in-paediatric-patients 2022-11-02T14:46:33 https://maestrodatabase.com/blog/moves-to-end-veto-on-health-insurance-premiums 2017-03-08T19:52:17 https://maestrodatabase.com/blog/income-separates-the-winners-and-losers-in-republicans-health-care-plans 2017-03-08T20:07:43 https://maestrodatabase.com/blog/high-u-dot-s-drug-prices-cannot-be-explained-by-r-and-d-spending-alone 2017-03-08T20:10:04 https://maestrodatabase.com/blog/icer-publishes-evidence-report-on-gene-therapies-for-haemophilia-a-and-b 2022-11-02T14:42:23 https://maestrodatabase.com/blog/greg-hunt-to-rule-on-corrupting-prostheses-regime 2017-03-08T19:55:40 https://maestrodatabase.com/blog/g-dot-o-p-health-bill-faces-revolt-from-conservative-forces 2017-03-08T20:04:25 https://maestrodatabase.com/blog/germany-to-scrap-plan-to-lower-prices-of-new-drugs-lawmakers 2017-03-08T20:26:20 https://maestrodatabase.com/blog/lower-1-000-dollars-pill-price-wed-love-it-says-express-scripts 2017-03-08T20:16:35 https://maestrodatabase.com/blog/fda-approves-use-of-0-dot-5-ml-dose-of-fluzone-quadrivalent-influenza-vaccine-in-children-as-young-as-6-months-of-age 2019-01-24T06:38:25 https://maestrodatabase.com/blog/fda-accepts-supplemental-new-drug-application-for-vraylar-cariprazine 2017-03-08T20:21:50 https://maestrodatabase.com/blog/no-wonder-the-republicans-hid-the-health-bill 2017-03-08T20:55:44 https://maestrodatabase.com/blog/insurers-drug-companies-testify-against-drug-pricing-bill 2017-03-08T20:38:33 https://maestrodatabase.com/blog/janssen-submits-application-to-u-dot-s-fda-seeking-approval-of-new-darzalex-daratumumab-subcutaneous-formulation 2019-07-13T07:21:14 https://maestrodatabase.com/blog/genmab-announces-initiation-of-u-dot-s-fda-regulatory-submission-for-label-expansion-of-daratumumab-in-combination-with-lenalidomide-and-dexamethasone-in-front-line-multiple-myeloma 2019-01-24T09:08:59 https://maestrodatabase.com/blog/government-considers-new-pbs-fund-to-slash-wait-times-for-treatments 2025-11-29T05:53:40 https://maestrodatabase.com/blog/esperoct-is-now-approved-in-canada-for-the-treatment-of-haemophilia-a-in-both-children-and-adults 2019-07-13T07:15:05 https://maestrodatabase.com/blog/ptc-therapeutics-announces-fda-acknowledgment-of-new-drug-application-filing-for-translarna-for-the-treatment-of-nonsense-mutation-duchenne-muscular-dystrophy 2017-03-09T02:11:46 https://maestrodatabase.com/blog/eton-pharmaceuticals-provides-update-on-em-100-program 2019-07-13T07:35:21 https://maestrodatabase.com/blog/fda-approves-amgens-riabni-rituximab-arrx-a-biosimilar-to-rituxan-rituximab 2020-12-17T23:38:30 https://maestrodatabase.com/blog/protecting-pharmac-and-cancer-treatment 2019-07-13T07:29:48 https://maestrodatabase.com/blog/marinus-pharmaceuticals-announces-fda-approval-of-ztalmy-ganaxolone-for-cdkl5-deficiency-disorder 2022-03-18T20:22:51 https://maestrodatabase.com/blog/early-benefit-assessment-reveals-weaknesses-in-the-development-of-new-drugs 2019-07-13T07:27:39 https://maestrodatabase.com/blog/polypid-announces-receipt-of-qualified-infectious-disease-product-designation-from-fda-for-d-plex-in-post-cardiac-surgery-sternal-infection 2017-03-09T02:33:43 https://maestrodatabase.com/blog/decibel-therapeutics-announces-db-020-has-been-granted-fast-track-designation-by-the-u-dot-s-fda 2020-12-17T23:20:21 https://maestrodatabase.com/blog/long-wait-for-cancer-drug-approvals-causing-great-anguish-among-patients-doctors 2025-01-19T01:24:20 https://maestrodatabase.com/blog/community-voices-important-to-pharmac 2018-05-28T03:42:31 https://maestrodatabase.com/blog/novartis-investigational-oral-therapy-iptacopan-lnp023-receives-fda-breakthrough-therapy-designation-for-pnh-and-rare-paediatric-disease-designation-for-c3g 2020-12-17T23:27:33 https://maestrodatabase.com/blog/new-eu-rules-for-health-technology-assessments-become-effective 2025-01-19T01:21:09 https://maestrodatabase.com/blog/grassley-deal-to-lower-drug-prices-moving-forward-very-soon 2019-07-13T07:57:43 https://maestrodatabase.com/blog/sharing-health-care-data-with-digital-giants 2020-01-20T01:24:12 https://maestrodatabase.com/blog/new-science-strategy-prepares-regulatory-scientists-for-the-future 2020-01-20T01:05:51 https://maestrodatabase.com/blog/fda-approves-oral-mek-inhibitor-cobimetinib-for-histiocytic-neoplasms-research-led-by-memorial-sloan-kettering-cancer-center 2022-11-02T15:52:32 https://maestrodatabase.com/blog/submission-to-senate-inquiry-seeks-support-for-tga-bill 2017-03-09T19:49:08 https://maestrodatabase.com/blog/the-secret-slug-that-will-make-the-200-dollars-annual-increase-in-health-fund-premiums-cost-more 2017-03-09T19:59:11 https://maestrodatabase.com/blog/as-childhood-asthma-worsens-insurers-restrict-access-to-an-essential-medication 2024-05-16T21:20:10 https://maestrodatabase.com/blog/update-to-the-statutory-scheme-to-control-the-costs-of-branded-health-service-medicines 2022-03-18T21:13:13 https://maestrodatabase.com/blog/industry-group-versus-california-newcomer-in-medical-technology-price-row 2017-03-09T20:09:52 https://maestrodatabase.com/blog/medical-device-industry-supports-evidenced-based-reform-not-alternative-facts 2017-03-09T19:52:18 https://maestrodatabase.com/blog/amending-obamacare-could-break-parts-of-the-health-insurance-market 2017-03-09T20:27:35 https://maestrodatabase.com/blog/accc-loses-appeal-against-pfizer-over-lipitor-sales 2018-05-28T05:52:04 https://maestrodatabase.com/blog/uk-children-with-cancer-could-miss-out-on-drug-trials-after-brexit-doctors-warn 2017-03-09T20:35:14 https://maestrodatabase.com/blog/despite-discounts-for-hepatitis-c-drugs-coverage-denials-continue-to-rise 2017-03-09T20:20:41 https://maestrodatabase.com/blog/trump-meets-with-democrats-at-white-house-on-drug-prices 2017-03-09T20:23:52 https://maestrodatabase.com/blog/proposal-to-list-a-range-of-orthopaedic-implants-and-associated-products-supplied-by-lmt-surgical-pty-ltd 2017-03-09T20:49:31 https://maestrodatabase.com/blog/american-medical-association-opposes-republican-health-plan 2017-03-09T20:38:13 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-tarlatamab-dlle-for-extensive-stage-small-cell-lung-cancer 2024-05-16T21:12:00 https://maestrodatabase.com/blog/health-groups-denounce-g-dot-o-p-bill-as-its-backers-scramble 2017-03-09T20:43:42 https://maestrodatabase.com/blog/moderna-submits-amendment-to-the-emergency-use-authorisation-for-an-additional-booster-dose-of-its-covid-19-vaccine-in-the-u-dot-s 2022-03-18T21:00:22 https://maestrodatabase.com/blog/axogen-initiates-rolling-submission-of-biologics-license-application-to-us-fda-for-avance-nerve-graft 2024-05-16T12:21:22 https://maestrodatabase.com/blog/health-fund-premiums-to-be-reined-in-under-sweeping-turnbull-government-changes 2017-10-12T10:37:05 https://maestrodatabase.com/blog/advocates-say-pharmac-too-slow-on-drugs-to-help-treat-covid-19 2022-03-18T22:05:44 https://maestrodatabase.com/blog/medicines-have-prices-slashed-from-june 2018-05-28T09:09:38 https://maestrodatabase.com/blog/first-fda-approval-agnostic-of-cancer-site----when-a-biomarker-defines-the-indication 2017-10-12T10:31:38 https://maestrodatabase.com/blog/foiled-in-congress-trump-moves-on-his-own-to-undermine-obamacare 2017-10-12T10:40:57 https://maestrodatabase.com/blog/australians-must-understand-and-question-surgical-fees-for-better-health-outcomes 2018-05-28T21:18:07 https://maestrodatabase.com/blog/new-treatment-option-for-people-with-gastro-intestinal-cancer 2017-10-12T10:46:41 https://maestrodatabase.com/blog/boots-faces-probe-over-nhs-drug-prices 2018-05-28T21:22:43 https://maestrodatabase.com/blog/product-information 2017-10-12T10:43:30 https://maestrodatabase.com/blog/health-insurer-hcf-looks-to-start-ups-innovation-to-help-retain-members 2018-05-28T21:04:08 https://maestrodatabase.com/blog/statement-from-health-canada-on-the-publication-of-a-white-paper-on-public-release-of-clinical-information-in-drug-submissions-and-medical-device-applications 2017-03-10T06:20:50 https://maestrodatabase.com/blog/ebe-efpia-and-ifpma-have-today-launched-a-position-paper-entitled-considerations-for-physicians-on-switching-decisions-regarding-biosimilars 2017-03-10T06:25:27 https://maestrodatabase.com/blog/fda-grants-priority-review-for-potential-new-indication-for-lillys-verzenio-abemaciclib-as-initial-treatment-of-advanced-breast-cancer 2017-10-12T10:51:19 https://maestrodatabase.com/blog/out-of-pocket-costs-causing-australians-to-leave-private-health-insurance 2018-05-28T21:06:19 https://maestrodatabase.com/blog/few-people-actually-benefit-from-breakthrough-cancer-immunotherapy 2017-03-09T23:24:11 https://maestrodatabase.com/blog/delegation-from-taiwan-visits-iqwig 2024-05-16T21:30:46 https://maestrodatabase.com/blog/ema-starts-review-of-dexamethasone-for-treating-adults-with-covid-19-requiring-respiratory-support 2020-07-27T07:55:23 https://maestrodatabase.com/blog/why-trumps-plan-will-not-cut-drug-prices 2018-05-28T21:41:15 https://maestrodatabase.com/blog/junshi-biosciences-announces-toripalimabs-approval-in-australia 2025-01-19T20:49:43 https://maestrodatabase.com/blog/nicox-resubmits-ac-170-zerviate-nda-to-the-u-dot-s-fda 2017-03-10T06:45:16 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-sndas-for-pifeltro-doravirine-and-delstrigo-doravirine-slash-lamivudine-slash-tenofovir-disoproxil-fumarate 2019-01-24T10:47:31 https://maestrodatabase.com/blog/beigene-receives-european-commission-approval-for-brukinsa-zanubrutinib-for-the-treatment-of-adults-with-marginal-zone-lymphoma 2022-11-03T13:38:27 https://maestrodatabase.com/blog/cancer-killing-car-t-cell-immunotherapy-to-become-more-accessible-to-patients 2018-05-28T21:30:01 https://maestrodatabase.com/blog/kyowa-kirin-receives-positive-chmp-opinion-for-the-expanded-use-of-crysvita-burosumab-to-include-older-adolescents-and-adults-for-the-treatment-of-x-linked-hypophosphataemia 2020-07-27T07:58:22 https://maestrodatabase.com/blog/pfizers-elranatamab-granted-fda-breakthrough-therapy-designation-for-relapsed-or-refractory-multiple-myeloma 2022-11-03T13:18:19 https://maestrodatabase.com/blog/sandoz-canada-receives-authorisation-from-health-canada-to-launch-new-biosimilar-hyrimoz-adalimumab 2020-12-18T01:56:03 https://maestrodatabase.com/blog/paying-twice-a-push-for-affordable-prices-for-taxpayer-funded-drugs 2018-05-28T21:35:53 https://maestrodatabase.com/blog/psoriasis-drugs-ilumya-and-tremfya-to-be-available-under-pbs-from-february-1 2019-01-24T19:13:26 https://maestrodatabase.com/blog/biosimilar-insulin-glargine-on-the-pbs---information-for-health-professionals-and-patients 2020-07-27T07:49:27 https://maestrodatabase.com/blog/trumps-drug-price-panic 2020-07-27T07:51:44 https://maestrodatabase.com/blog/big-pharma-spends-record-millions-on-lobbying-amid-pressure-to-lower-drug-prices 2019-01-24T10:57:06 https://maestrodatabase.com/blog/keryx-biopharmaceuticals-announces-u-dot-s-fda-filing-acceptance-of-supplemental-new-drug-application-for-auryxia-ferric-citrate-tablets 2017-03-10T07:12:43 https://maestrodatabase.com/blog/health-insurers-billion-dollar-remedy 2017-10-12T19:50:24 https://maestrodatabase.com/blog/missing-out-on-cancer-drugs 2017-10-12T19:45:45 https://maestrodatabase.com/blog/phrma-blasts-trumps-plan-to-tie-u-dot-s-drug-prices-to-other-countries----but-some-of-its-criticisms-dont-hold-up 2019-01-24T19:30:28 https://maestrodatabase.com/blog/greg-hunt-wants-state-help-on-affordable-health 2017-03-10T22:21:46 https://maestrodatabase.com/blog/bms-announces-voluntary-withdrawal-of-u-dot-s-application-for-opdivo-plus-low-dose-yervoy-for-treatment-of-first-line-lung-cancer-in-patients-with-tumor-mutational-burden-10-mutations-slash-megabase-following-discussions-with-the-u-dot-s-fda 2019-01-24T19:24:22 https://maestrodatabase.com/blog/regeneron-ceo-on-drug-prices-a-few-bad-actors-are-not-the-problem 2017-03-10T22:24:08 https://maestrodatabase.com/blog/u-dot-s-fda-approves-lyrica-cr-pregabalin-extended-release-tablets 2017-10-12T19:59:42 https://maestrodatabase.com/blog/confirmed-prices---2017-april-cycle-of-price-disclosure 2017-03-10T08:01:23 https://maestrodatabase.com/blog/health-care-the-measure-of-a-robust-system 2017-10-12T19:53:39 https://maestrodatabase.com/blog/patients-with-rare-cancers-fight-for-more-research-funding-support 2017-03-10T22:19:05 https://maestrodatabase.com/blog/john-kasich-end-the-partisan-warfare-on-health-care 2017-03-10T22:34:38 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-to-evaluate-cystic-fibrosis-treatments-in-upcoming-report 2017-10-12T20:16:59 https://maestrodatabase.com/blog/fda-statement-from-commissioner-announcing-efforts-to-improve-the-quality-of-the-information-used-to-assess-the-effectiveness-of-rems-programs-in-supporting-the-safe-use-of-medications 2019-01-24T19:36:20 https://maestrodatabase.com/blog/governor-baker-has-plan-to-rein-in-soaring-drug-costs-in-state-medicaid-program 2019-01-24T19:39:43 https://maestrodatabase.com/blog/after-halting-start-trump-plunges-into-effort-to-repeal-health-law 2017-03-10T22:26:32 https://maestrodatabase.com/blog/r-and-d-costs-for-pharmaceutical-companies-do-not-explain-elevated-us-drug-prices 2017-03-10T22:30:11 https://maestrodatabase.com/blog/human-medicines-in-2024 2025-01-19T21:04:56 https://maestrodatabase.com/blog/trump-signs-order-to-undermine-obamacare-insurance-rules 2017-10-12T20:25:08 https://maestrodatabase.com/blog/ottawas-push-for-lower-drug-costs-may-hurt-patients-stunt-innovation 2019-01-24T19:32:38 https://maestrodatabase.com/blog/how-amazon-becoming-a-pharmacy-could-lower-the-price-of-drugs-according-to-morgan-stanley 2017-10-12T20:30:07 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-releases-revised-report-on-targeted-immune-modulators-for-treatment-of-rheumatoid-arthritis 2017-03-11T00:28:15 https://maestrodatabase.com/blog/grassley-to-hold-drug-pricing-hearing 2019-01-24T20:00:49 https://maestrodatabase.com/blog/cms-delivers-savings-for-seniors-on-15-major-drugs-for-cancer-and-chronic-disease 2025-11-29T22:59:24 https://maestrodatabase.com/blog/trump-picks-scott-gottlieb-to-serve-as-fda-commissioner 2017-03-11T01:21:50 https://maestrodatabase.com/blog/looking-to-2020-democrats-take-on-prescription-drug-prices 2019-01-24T20:07:48 https://maestrodatabase.com/blog/imfinzi-recommended-for-approval-in-the-eu-by-chmp-for-extensive-stage-small-cell-lung-cancer 2020-07-27T08:12:54 https://maestrodatabase.com/blog/fda-clears-first-7t-magnetic-resonance-imaging-device 2017-10-12T20:33:10 https://maestrodatabase.com/blog/radius-health-receives-notification-of-pdufa-extension-for-abaloparatide 2017-03-11T01:24:32 https://maestrodatabase.com/blog/nuvalent-receives-us-fda-breakthrough-therapy-designation-for-nvl-655 2024-05-16T23:28:09 https://maestrodatabase.com/blog/heron-therapeutics-announces-approval-of-zynrelef-by-health-canada-for-the-management-of-post-operative-pain 2022-03-19T02:03:07 https://maestrodatabase.com/blog/rhythm-pharmaceuticals-announces-setmelanotide-granted-breakthrough-therapy-designation-for-hypothalamic-obesity-by-the-us-fda 2022-11-03T14:18:31 https://maestrodatabase.com/blog/calquence-recommended-for-approval-in-the-eu-by-chmp-for-chronic-lymphocytic-leukaemia 2020-07-27T08:17:18 https://maestrodatabase.com/blog/battle-over-hips-and-the-hip-pocket-as-prostheses-costs-fight-heats-up 2017-03-12T20:14:25 https://maestrodatabase.com/blog/medical-devices-savings-missed 2022-03-19T04:35:39 https://maestrodatabase.com/blog/the-tragedy-of-aviana 2017-03-12T05:26:21 https://maestrodatabase.com/blog/the-g-dot-o-p-dot-s-high-risk-strategy-for-health-law-repeal 2017-03-12T20:09:47 https://maestrodatabase.com/blog/senate-showdown-on-60-day-dispensing 2023-08-09T20:47:25 https://maestrodatabase.com/blog/insurers-cant-avoid-covering-weight-loss-drugs-forever 2023-08-09T20:38:54 https://maestrodatabase.com/blog/health-canada-approves-saladaxs-5-fluorouracil-chemotherapy-therapeutic-drug-monitoring-test 2024-05-17T00:57:23 https://maestrodatabase.com/blog/seeking-expressions-of-interest---health-technology-assessment-advisory-committees 2023-08-09T07:02:19 https://maestrodatabase.com/blog/acelrx-pharmaceuticals-receives-complete-response-letter-from-the-fda-for-dsuvia-nda 2017-10-12T21:38:18 https://maestrodatabase.com/blog/covid-19-a-second-booster-reserved-for-those-most-at-risk 2022-03-19T05:11:23 https://maestrodatabase.com/blog/advocate-gutted-as-pharmac-reviews-blanket-funding-of-child-cancer-medicines 2022-11-03T19:42:37 https://maestrodatabase.com/blog/gilead-and-galapagos-announce-positive-european-chmp-opinion-for-jyseleca-filgotinib-for-the-treatment-of-adults-with-moderate-to-severe-rheumatoid-arthritis 2020-07-27T11:34:56 https://maestrodatabase.com/blog/public-health-experts-welcome-malcolm-turnbulls-tough-vaccines-push 2017-03-13T04:08:20 https://maestrodatabase.com/blog/four-years-of-early-benefit-assessment-of-new-drugs-in-germany-a-qualitative-study-on-methodological-requirements-for-quality-of-life-data 2017-03-12T22:04:59 https://maestrodatabase.com/blog/health-canada-authorises-second-bivalent-covid-19-booster-targeting-the-omicron-ba-dot-4-slash-5-variants 2022-11-03T19:37:57 https://maestrodatabase.com/blog/rare-diseases-patients-need-more-than-miracles-and-trumpcare 2017-03-13T01:41:09 https://maestrodatabase.com/blog/new-us-cancer-drug-prices-rise-53-percent-in-five-years 2022-11-03T14:52:05 https://maestrodatabase.com/blog/fda-approves-pralsetinib-for-non-small-cell-lung-cancer-with-ret-gene-fusions 2023-08-09T21:02:16 https://maestrodatabase.com/blog/why-cancelling-your-private-health-insurance-could-have-unintended-consequences 2020-01-20T03:58:02 https://maestrodatabase.com/blog/advanced-cervical-cancer-pembrolizumab-prolongs-life 2022-11-03T19:26:20 https://maestrodatabase.com/blog/new-fee-website-shows-nsw-pays-up-to-40-times-more-in-out-of-pocket-costs 2020-01-20T03:44:05 https://maestrodatabase.com/blog/sobi-will-file-for-a-re-examination-of-emapalumab-in-europe-following-negative-opinion-by-chmp 2020-07-27T11:27:51 https://maestrodatabase.com/blog/final-reconciliation-of-savings-from-side-agreements-for-the-full-year-2021 2022-03-19T05:01:41 https://maestrodatabase.com/blog/public-pharma-is-the-best-solution-to-the-on-going-problem-of-drug-shortages 2023-08-09T20:49:54 https://maestrodatabase.com/blog/insmed-receives-positive-chmp-opinion-for-arikayce-liposomal-590-mg-nebuliser-dispersion-for-the-treatment-of-ntm-lung-infections-caused-by-mac-in-non-cf-patients-with-limited-treatment-options 2020-07-27T12:07:12 https://maestrodatabase.com/blog/efanesoctocog-alfa-for-the-treatment-and-prevention-of-bleeding-episodes-in-patients-with-haemophilia-a 2024-05-17T02:44:47 https://maestrodatabase.com/blog/chemists-to-lose-dollar-discount-option-as-government-bows-to-pharmacy-guild-pressure 2024-05-17T02:28:11 https://maestrodatabase.com/blog/report-on-the-collection-of-under-co-payment-data-2019-20 2020-12-18T04:49:05 https://maestrodatabase.com/blog/scpharmaceuticals-announces-fda-acceptance-of-furoscix-new-drug-application-resubmission 2020-07-27T21:02:51 https://maestrodatabase.com/blog/protection-against-rsv-for-mums-and-bubs-with-free-vaccine-available-from-3-february 2025-01-19T22:25:46 https://maestrodatabase.com/blog/g-dot-o-p-desire-to-keep-party-feuds-private-breaks-down-over-health-care 2017-03-13T09:32:07 https://maestrodatabase.com/blog/checkmate-pharmaceuticals-granted-fda-fast-track-designation-for-cmp-001-combined-with-pd-1-blockade-in-the-treatment-of-certain-types-of-metastatic-or-unresectable-melanoma 2020-07-27T11:44:41 https://maestrodatabase.com/blog/novartis-kisqali-ribociclib-lee011-receives-fda-approval-as-first-line-treatment-for-hr-plus-slash-her2--metastatic-breast-cancer-in-combination-with-any-aromatase-inhibitor 2017-03-13T20:00:59 https://maestrodatabase.com/blog/galera-receives-complete-response-letter-from-us-fda-for-avasopasem-manganese 2023-08-09T21:37:54 https://maestrodatabase.com/blog/how-republicans-want-to-change-medicaid 2017-03-13T20:16:15 https://maestrodatabase.com/blog/enhancing-transparency-at-the-us-fda-moving-beyond-the-21st-century-cures-act 2017-03-13T20:19:01 https://maestrodatabase.com/blog/eton-pharmaceuticals-submits-new-drug-application-to-the-fda-for-orphan-drug-dehydrated-alcohol-injection 2020-07-27T11:50:38 https://maestrodatabase.com/blog/review-of-the-drug-trials-snapshots-program-of-the-us-fda-women-in-cardiovascular-drug-trials 2017-03-13T20:10:37 https://maestrodatabase.com/blog/eu-talks-with-pfizer-sanofi-j-and-j-on-covid-vaccines-hit-snags 2020-07-27T21:32:01 https://maestrodatabase.com/blog/smc---march-2017-decisions 2017-03-13T20:26:22 https://maestrodatabase.com/blog/tga-approves-zeposia-for-patients-with-multiple-sclerosis 2020-07-27T21:34:33 https://maestrodatabase.com/blog/korea-launches-sweeping-drug-pricing-reform-to-curb-generic-dominance 2025-11-30T07:22:28 https://maestrodatabase.com/blog/skyrocketing-drug-prices-key-question-in-trump-health-care-reform 2017-03-13T20:29:13 https://maestrodatabase.com/blog/pilot-run-of-herbal-medicine-reimbursement-starts-in-october 2020-07-27T21:14:07 https://maestrodatabase.com/blog/cadth-posts-final-recommendation-for-aimovig 2020-07-27T21:20:09 https://maestrodatabase.com/blog/show-drugs-work-before-selling-them 2017-03-14T02:57:12 https://maestrodatabase.com/blog/u-dot-s-food-and-drug-administration-approves-first-lag-3-blocking-antibody-combination-opdualag-nivolumab-and-relatlimab-rmbw-as-treatment-for-patients-with-unresectable-or-metastatic-melanoma 2022-03-20T02:40:26 https://maestrodatabase.com/blog/24-million-would-lose-health-insurance-coverage-by-2026-under-gops-obamacare-replacement-new-estimate-says 2017-03-14T08:37:46 https://maestrodatabase.com/blog/future-hta-cooperation-in-europe 2017-03-14T08:40:15 https://maestrodatabase.com/blog/mylan-announces-global-settlement-and-license-agreements-with-genentech-and-roche-on-herceptin 2017-03-14T05:09:57 https://maestrodatabase.com/blog/senate-inquiry-to-probe-the-complexity-of-prostheses-pricing 2017-03-14T06:10:13 https://maestrodatabase.com/blog/medibank-private-highhanded-cynical-in-misleading-consumers-accc 2017-03-14T20:05:27 https://maestrodatabase.com/blog/release-of-documents-on-two-medicines-temporarily-halted 2017-03-14T20:08:48 https://maestrodatabase.com/blog/push-to-cut-costs-of-medical-devices 2017-03-14T19:57:57 https://maestrodatabase.com/blog/corrupt-system-drives-australian-health-costs 2017-03-14T20:01:01 https://maestrodatabase.com/blog/logistic-regression-diagnostics-understanding-how-well-a-model-predicts-outcomes 2017-03-14T20:29:49 https://maestrodatabase.com/blog/how-republicans-want-to-change-the-health-insurance-market 2017-03-14T20:35:02 https://maestrodatabase.com/blog/nice-publishes-appraisal-consultation-document-for-nivolumab-opdivo 2017-03-14T20:12:42 https://maestrodatabase.com/blog/novartis-wins-u-dot-s-approval-for-breast-cancer-drug-to-compete-with-pfizers-ibrance 2017-03-14T20:23:10 https://maestrodatabase.com/blog/trumpcare-vs-obamacare-apocalypse-foretold 2017-03-14T20:48:02 https://maestrodatabase.com/blog/trading-health-care-for-the-poor-for-tax-cuts-for-the-rich 2017-03-14T20:50:25 https://maestrodatabase.com/blog/dalvance-dalbavancin-receives-fda-approval-to-treat-acute-bacterial-skin-and-skin-structure-infections-in-paediatric-patients 2021-07-24T04:14:23 https://maestrodatabase.com/blog/greater-sydney-residents-vaccine-shopping-70-km-from-postcode 2021-07-24T03:57:25 https://maestrodatabase.com/blog/first-biosimilar-monoclonal-antibody-in-oncology-granted-eu-approval-implications-for-the-u-dot-s-market 2017-03-15T02:27:45 https://maestrodatabase.com/blog/access-to-medicines-working-group 2017-03-15T10:33:17 https://maestrodatabase.com/blog/covid-19-vaccine-spikevax-approved-for-children-aged-12-to-17-in-eu 2021-07-24T04:19:48 https://maestrodatabase.com/blog/health-canada-aims-to-release-secret-drug-records 2017-03-15T02:17:45 https://maestrodatabase.com/blog/can-a-statistical-method-speed-drug-approvals 2017-03-15T02:25:00 https://maestrodatabase.com/blog/merck-provides-update-on-supplemental-biologics-license-application-for-keytruda-pembrolizumab-in-previously-treated-advanced-microsatellite-instability-high-cancer 2017-03-15T10:53:54 https://maestrodatabase.com/blog/blueprint-medicines-submits-supplemental-new-drug-application-to-fda-for-ayvakit-avapritinib-for-the-treatment-of-advanced-systemic-mastocytosis 2020-12-18T07:43:44 https://maestrodatabase.com/blog/fda-approves-mercks-keytruda-pembrolizumab-for-adult-and-paediatric-patients-with-classical-hodgkin-lymphoma-refractory-to-treatment-or-who-have-relapsed-after-three-or-more-prior-lines-of-therapy 2017-03-15T10:58:54 https://maestrodatabase.com/blog/compliance-with-legal-requirement-to-report-clinical-trial-results-on-clinicaltrials-dot-gov-a-cohort-study 2020-01-20T07:23:27 https://maestrodatabase.com/blog/health-canada-approves-alhemo-concizumab-injection-for-the-treatment-of-patients-living-with-haemophilia-a-with-fviii-inhibitors 2023-08-10T01:43:46 https://maestrodatabase.com/blog/more-options-for-pregnant-women-and-65-plus-to-get-funded-influenza-vaccines 2017-03-15T10:37:54 https://maestrodatabase.com/blog/sanofi-displeased-with-nice-decision-on-rare-disease-drug 2017-03-15T10:45:38 https://maestrodatabase.com/blog/fees-and-charges-proposal-2020-21 2020-01-20T05:58:23 https://maestrodatabase.com/blog/new-cadth-guidelines-for-the-economic-evaluation-of-health-technologies 2017-03-15T20:06:48 https://maestrodatabase.com/blog/sanofis-dupilumab-joins-uks-early-access-scheme 2017-03-15T20:19:20 https://maestrodatabase.com/blog/ipsen-announces-health-canada-approval-of-dysport-therapeutic-abobotulinumtoxina-for-the-treatment-of-patients-with-cervical-dystonia-and-adult-upper-limb-spasticity 2017-03-15T11:12:59 https://maestrodatabase.com/blog/medibank-skips-health-insurance-grilling 2017-03-15T20:02:02 https://maestrodatabase.com/blog/us-cancer-patients-skipping-medicines-or-delaying-treatment-due-to-high-drug-prices 2017-03-15T20:52:14 https://maestrodatabase.com/blog/hlb-shares-plummet-following-fda-rejection-of-liver-cancer-drug-approval 2024-05-17T23:24:54 https://maestrodatabase.com/blog/novartis-announces-eu-approval-of-mayzent-siponimod-for-adult-patients-with-secondary-progressive-multiple-sclerosis-with-active-disease 2020-01-20T19:44:17 https://maestrodatabase.com/blog/g-dot-o-p-senators-suggest-changes-for-health-care-bill-offered-by-house 2017-03-15T20:28:33 https://maestrodatabase.com/blog/nice-publishes-draft-guidance-on-the-use-of-adalimumab-and-dexamethasone-for-uveitis 2017-03-15T20:41:39 https://maestrodatabase.com/blog/nhs-to-introduce-ps20-milion-cap-on-new-drugs 2017-03-16T10:51:13 https://maestrodatabase.com/blog/nhs-fast-tracks-new-gamechanging-drug-for-lung-cancer 2022-03-20T03:17:05 https://maestrodatabase.com/blog/australia-known-as-treasure-island-by-health-giants 2017-03-16T11:05:22 https://maestrodatabase.com/blog/lynparza-regulatory-submission-granted-priority-review-in-the-us-for-hrr-mutated-metastatic-castration-resistant-prostate-cancer 2020-01-20T10:37:07 https://maestrodatabase.com/blog/new-uk-drug-cost-rules-leave-companies-fuming 2017-03-16T10:40:04 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac---november-2020 2020-12-18T07:25:10 https://maestrodatabase.com/blog/marathons-89-000-dollars-drug-scrutinised-for-unusual-approval 2017-03-16T10:45:53 https://maestrodatabase.com/blog/ten-recommendations-to-unlock-the-potential-of-big-data-for-public-health-in-the-eu 2020-01-20T10:28:05 https://maestrodatabase.com/blog/house-obamacare-repeal-bill-faces-first-big-test-thursday 2017-03-16T20:12:18 https://maestrodatabase.com/blog/novo-nordisk-files-for-eu-regulatory-approval-of-once-weekly-semaglutide-2-dot-4-mg-for-weight-management 2020-12-18T10:11:40 https://maestrodatabase.com/blog/how-a-controversial-us-drug-policy-could-be-harming-cancer-patients-worldwide 2023-08-10T02:49:36 https://maestrodatabase.com/blog/gsk-announces-us-regulatory-submission-seeking-expanded-indication-for-fluarix-quadrivalent-influenza-vaccine-for-infants-6-months-and-older 2017-03-16T20:26:20 https://maestrodatabase.com/blog/nine-submissions-done-and-two-due-by-month-end-dot-dot-dot 2017-03-16T11:14:06 https://maestrodatabase.com/blog/nice-gets-go-ahead-to-fast-track-more-drug-approvals 2017-03-16T20:07:45 https://maestrodatabase.com/blog/fda-delays-decision-on-intercepts-nash-drug-by-three-months 2020-01-20T20:00:56 https://maestrodatabase.com/blog/abbvie-expands-immunology-portfolio-in-canada-as-health-canada-approves-skyrizi-risankizumab-for-the-treatment-of-adults-with-active-psoriatic-arthritis 2022-03-20T03:52:55 https://maestrodatabase.com/blog/cardiome-receives-notice-of-compliance-from-health-canada-for-its-brinavess-nds 2017-03-16T20:36:09 https://maestrodatabase.com/blog/call-for-feedback-new-drugs-for-type-2-diabetes-second-line-therapy-a-therapeutic-review-update 2017-03-16T20:44:18 https://maestrodatabase.com/blog/patients-still-struggle-to-balance-high-costs-of-ms-treatment-despite-generic 2020-01-20T19:54:35 https://maestrodatabase.com/blog/sunovion-submits-supplemental-new-drug-application-to-fda-for-use-of-aptiom-eslicarbazepine-acetate-for-the-treatment-of-partial-onset-seizures-in-children-4-years-of-age-and-older 2017-03-16T20:30:36 https://maestrodatabase.com/blog/after-20-years-of-using-economic-evaluation-should-nice-be-considered-a-methods-innovator 2020-01-20T20:18:16 https://maestrodatabase.com/blog/ema-publishes-updated-list-of-applications-for-new-human-medicines-under-evaluation-by-the-chmp 2017-03-16T20:52:35 https://maestrodatabase.com/blog/talkin-about-a-resolution-issues-in-the-push-for-greater-transparency-of-medicine-prices 2020-01-20T20:15:19 https://maestrodatabase.com/blog/the-institute-for-clinical-and-economic-review-appoints-new-members-to-each-of-its-three-independent-evidence-appraisal-councils 2017-03-16T22:42:13 https://maestrodatabase.com/blog/pharmacs-rare-disorders-advisory-committee-makes-new-recommendations-for-funding 2023-08-10T02:14:28 https://maestrodatabase.com/blog/novaremed-receives-fast-track-designation-from-the-fda-for-nrd135s-dot-e1-for-the-treatment-of-painful-diabetic-peripheral-neuropathy 2020-12-18T12:00:20 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-december-2025 2025-11-30T23:23:29 https://maestrodatabase.com/blog/medicines-for-hepatitis-c-remain-in-the-high-cost-protection-after-tlvs-reconsideration 2020-12-18T20:20:21 https://maestrodatabase.com/blog/fda-approves-first-oral-hormone-therapy-for-treating-advanced-prostate-cancer 2020-12-18T20:11:28 https://maestrodatabase.com/blog/handoks-aml-treatment-vyxeos-receives-insurance-coverage-in-korea 2025-01-20T01:50:12 https://maestrodatabase.com/blog/doctors-say-pharmac-too-slow-to-act-over-hormone-replacement-therapy-patch-shortage 2024-05-19T21:22:31 https://maestrodatabase.com/blog/fda-withdraws-accelerated-approval-to-infigratinib-for-metastatic-cholangiocarcinoma 2024-05-18T23:41:02 https://maestrodatabase.com/blog/australians-benefit-from-freeze-to-maximum-cost-of-pbs-medicines 2025-01-20T03:30:33 https://maestrodatabase.com/blog/ucb-announces-the-approval-of-cimzia-certolizumab-pegol-for-moderate-to-severe-plaque-psoriasis-representing-an-important-new-option-for-patients-in-the-u-dot-s 2018-05-29T05:10:08 https://maestrodatabase.com/blog/cure-prospects-for-out-of-pocket-pain 2018-05-29T04:53:03 https://maestrodatabase.com/blog/medicines-for-the-treatment-of-psoriasis-listed-on-the-pbs 2019-01-25T00:08:59 https://maestrodatabase.com/blog/ab-science-provides-update-on-eu-marketing-authorisation-application-for-masitinib-in-the-treatment-of-amyotrophic-lateral-sclerosis 2018-05-29T10:15:38 https://maestrodatabase.com/blog/expedited-pathways-for-prescription-medicines 2017-03-17T02:58:26 https://maestrodatabase.com/blog/dr-reddys-laboratories-received-approval-of-xeglyze-abametapir-0-dot-74-percent-lotion-in-the-u-dot-s 2020-07-28T00:07:07 https://maestrodatabase.com/blog/pfizers-xalkori-crizotinib-receives-fda-breakthrough-therapy-designation-in-two-new-indications 2018-05-29T20:59:44 https://maestrodatabase.com/blog/ema-publishes-agenda-for-28-31-may-chmp-meeting 2018-05-29T10:28:22 https://maestrodatabase.com/blog/trump-to-sign-right-to-try-bill-next-week 2018-05-29T20:56:17 https://maestrodatabase.com/blog/fda-accepts-larotrectinib-new-drug-application-and-grants-priority-review 2018-05-29T21:08:54 https://maestrodatabase.com/blog/major-reforms-to-make-private-health-insurance-simpler-and-more-affordable 2017-10-13T02:02:43 https://maestrodatabase.com/blog/construction-of-new-ema-building-in-amsterdam-on-track 2018-05-29T21:19:10 https://maestrodatabase.com/blog/nice-publishes-draft-guidance-on-the-use-of-daratumumab-darzalex-on-the-nhs 2017-03-17T03:54:35 https://maestrodatabase.com/blog/acorda-announces-ema-validation-of-the-maa-submission-for-inbrija-levodopa-inhalation-powder 2018-05-29T21:31:23 https://maestrodatabase.com/blog/orkambi-hunt-pbs-comments-raise-cautious-hope 2018-05-29T21:26:15 https://maestrodatabase.com/blog/saving-sarah-cop-starting-cancer-treatment-next-month-after-$80k-in-donations 2018-05-29T21:45:00 https://maestrodatabase.com/blog/clovis-oncology-announces-european-commission-authorisation-of-rubraca-rucaparib-for-women-with-recurrent-ovarian-cancer 2018-05-29T21:39:03 https://maestrodatabase.com/blog/my-health-record-enshrines-choice 2019-01-25T03:06:38 https://maestrodatabase.com/blog/shire-receives-european-approval-for-label-extension-of-cinryze-to-prevent-and-treat-hereditary-angioedema-hae-attacks-in-paediatric-patients-with-hae 2017-03-17T05:02:53 https://maestrodatabase.com/blog/using-the-e-value-to-assess-the-potential-effect-of-unmeasured-confounding-in-observational-studies 2019-01-25T03:12:29 https://maestrodatabase.com/blog/nice-recommends-longer-lasting-battery-technology-for-implantable-heart-rhythm-devices 2017-03-17T11:59:52 https://maestrodatabase.com/blog/complaints-against-surgeons-triple-amid-backlash-against-health-cover-con 2018-05-29T21:52:32 https://maestrodatabase.com/blog/cystic-fibrosis-advocates-push-for-affordable-access-to-orkambi-only-drug-available-in-australia 2017-03-17T12:07:40 https://maestrodatabase.com/blog/fda-approves-first-adjuvant-therapy-for-most-common-type-of-lung-cancer 2020-12-18T22:58:54 https://maestrodatabase.com/blog/new-covid-19-vaccine-and-booster-shots-for-this-fall-to-be-available-by-end-of-september 2023-08-10T20:53:41 https://maestrodatabase.com/blog/changes-to-nices-cost-effectiveness-thresholds-confirmed 2025-12-01T21:16:01 https://maestrodatabase.com/blog/us-fda-accepts-astellas-snda-for-cresemba-isavuconazonium-sulphate-in-children 2023-08-10T20:48:21 https://maestrodatabase.com/blog/lilly-lowers-the-price-of-zepbound-tirzepatide-single-dose-vials 2025-12-01T21:22:30 https://maestrodatabase.com/blog/vanda-pharmaceuticals-provides-regulatory-update-on-tradipitant-for-motion-sickness 2025-12-01T21:27:53 https://maestrodatabase.com/blog/bio-statement-on-new-list-of-medicines-targeted-for-government-price-setting 2025-01-20T06:50:49 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-talquetamab-tgvs-for-relapsed-or-refractory-multiple-myeloma 2023-08-10T20:37:29 https://maestrodatabase.com/blog/cullinan-therapeutics-receives-fda-fast-track-designation-for-cln-049-a-novel-flt3xcd3-t-cell-engager-in-relapsed-slash-refractory-acute-myeloid-leukemia 2025-12-01T23:10:00 https://maestrodatabase.com/blog/priority-review-granted-to-beigenes-new-drug-application-of-pamiparib-in-ovarian-cancer-in-china 2020-07-28T07:55:17 https://maestrodatabase.com/blog/codagenix-receives-fda-fast-track-designation-for-live-attenuated-intranasal-rsv-vaccine-candidate-codavax-rsv 2022-11-04T07:03:39 https://maestrodatabase.com/blog/pharma-execs-decline-trump-offer-for-meeting-on-drug-prices 2020-07-28T08:06:00 https://maestrodatabase.com/blog/european-commission-grants-marketing-authorisation-for-worlds-first-subcutaneous-formulation-of-infliximab-remsima-sc-for-an-additional-five-indications-including-for-use-in-inflammatory-bowel-disease-and-ankylosing-spondylitis 2020-07-28T07:37:41 https://maestrodatabase.com/blog/medicine-costs-to-halve-after-labor-wins-60-day-dispensing-vote 2023-08-10T20:59:18 https://maestrodatabase.com/blog/decision-to-fund-dexamethasone-implants-ozurdex 2017-10-13T03:43:47 https://maestrodatabase.com/blog/lumos-pharma-announces-sale-of-priority-review-voucher 2020-07-28T07:47:59 https://maestrodatabase.com/blog/european-commission-expands-jemperli-dostarlimab-plus-chemotherapy-approval-to-all-adult-patients-with-primary-advanced-or-recurrent-endometrial-cancer 2025-01-20T20:20:47 https://maestrodatabase.com/blog/patient-and-citizen-participation-at-the-organisational-level-in-health-technology-assessment-an-exploratory-study-in-five-jurisdictions 2023-08-10T21:05:33 https://maestrodatabase.com/blog/hunt-puts-best-foot-forward-on-health-but-well-need-to-monitor-developments 2017-10-13T03:58:51 https://maestrodatabase.com/blog/at-last-good-news-on-health-insurance 2017-10-13T03:52:22 https://maestrodatabase.com/blog/2020-october-price-disclosure-cycle---indicative-prices 2020-07-28T08:33:10 https://maestrodatabase.com/blog/additional-public-summary-documents-from-the-november-2016-pbac-meeting 2017-03-18T09:56:06 https://maestrodatabase.com/blog/apellis-announces-plans-to-submit-24-month-phase-3-data-to-the-fda-for-pegcetacoplan-nda-for-geographic-atrophy 2022-11-04T07:14:23 https://maestrodatabase.com/blog/astrazeneca-receives-complete-response-letter-from-us-fda-for-zs-9-sodium-zirconium-cyclosilicate-for-hyperkalaemia 2017-03-18T10:31:25 https://maestrodatabase.com/blog/amgen-to-refund-cholesterol-drug-if-patients-suffer-heart-attack 2017-03-18T10:06:40 https://maestrodatabase.com/blog/car-t-drugs-worth-up-to-$649k-in-childhood-leukaemia-says-u-dot-k-report 2017-03-18T10:22:19 https://maestrodatabase.com/blog/health-canada-expands-tresiba-insulin-degludec-injection-label-with-efficacy-and-safety-for-use-in-pregnant-women-with-diabetes 2022-11-04T07:08:50 https://maestrodatabase.com/blog/beyfortus-approved-in-the-eu-for-the-prevention-of-rsv-lower-respiratory-tract-disease-in-infants 2022-11-04T07:57:01 https://maestrodatabase.com/blog/changes-announced-to-rebif-listing-on-pbs 2022-11-04T07:51:11 https://maestrodatabase.com/blog/iveric-bio-announces-submission-of-first-part-of-nda-for-rolling-review-of-avacincaptad-pegol-for-the-treatment-of-geographic-atrophy 2022-11-04T07:22:13 https://maestrodatabase.com/blog/sound-pharmaceuticals-receives-fda-breakthrough-therapy-designation-for-spi-1005-to-treat-menieres-disease 2025-12-01T23:52:17 https://maestrodatabase.com/blog/chemocentryx-announces-withdrawal-of-phase-ii-based-conditional-marketing-authorisation-application-for-anca-associated-vasculitis-in-europe 2019-01-25T04:59:05 https://maestrodatabase.com/blog/momenta-pharmaceuticals-announces-fda-rare-paediatric-disease-designation-for-nipocalimab-in-hdfn 2020-07-28T12:10:32 https://maestrodatabase.com/blog/drug-pricing-insanity-pay-5-dollars-50-cents-or-pay-1-900-dollars-your-choice 2020-07-28T12:28:45 https://maestrodatabase.com/blog/novartis-receives-complete-response-letter-from-u-dot-s-fda-for-inclisiran 2020-12-18T23:49:42 https://maestrodatabase.com/blog/clovis-oncology-announces-european-commission-authorisation-of-rubraca-rucaparib-tablets-as-maintenance-treatment-for-women-with-relapsed-ovarian-cancer 2019-01-25T06:08:00 https://maestrodatabase.com/blog/global-cooperation-and-early-access--clinical-outcomes-matter 2024-05-20T07:39:53 https://maestrodatabase.com/blog/overall-survival-benefits-of-cancer-drugs-initially-approved-by-the-us-fda-on-the-basis-of-immature-survival-data-a-retrospective-analysis 2024-05-20T07:31:23 https://maestrodatabase.com/blog/black-diamond-therapeutics-granted-fast-track-designation-by-the-fda-for-bdtx-189-for-the-treatment-of-adult-patients-with-a-solid-tumour-harbouring-an-allosteric-her2-mutation-or-an-egfr-or-her2-exon-20-insertion-mutation 2020-07-28T12:05:17 https://maestrodatabase.com/blog/hemoshear-therapeutics-receives-fda-fast-track-and-rare-paediatric-disease-designations-for-hst5040-to-treat-methylmalonic-acidaemia-and-propionic-acidaemia 2020-07-28T21:03:15 https://maestrodatabase.com/blog/hundreds-of-patients-to-have-access-to-head-and-neck-cancer-drug-after-new-deal-says-nice 2017-10-13T09:15:13 https://maestrodatabase.com/blog/ionis-receives-us-fda-breakthrough-therapy-designation-for-olezarsen-for-severe-hypertriglyceridaemia 2025-12-02T00:06:25 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-december-2025 2025-12-02T00:22:02 https://maestrodatabase.com/blog/pharmac-report-should-rich-people-get-subsidised-medicine 2020-07-28T21:09:34 https://maestrodatabase.com/blog/u-dot-s-insulin-costs-per-patient-nearly-doubled-from-2012-to-2016-study 2019-01-25T20:18:22 https://maestrodatabase.com/blog/merck-granted-fast-track-designation-by-the-us-fda-for-mk-2214-for-the-treatment-of-alzheimers-disease 2025-12-02T00:39:34 https://maestrodatabase.com/blog/janssen-receives-chmp-positive-opinion-for-expanded-use-of-imbruvica-ibrutinib-in-combination-with-rituximab-for-previously-untreated-patients-with-chronic-lymphocytic-leukaemia 2020-07-28T12:37:01 https://maestrodatabase.com/blog/avita-medical-announces-fda-breakthrough-device-designations-for-the-recell-system 2022-11-04T08:43:57 https://maestrodatabase.com/blog/in-praise-of-studies-that-use-more-than-one-generic-preference-based-measure 2019-07-14T21:06:50 https://maestrodatabase.com/blog/cadth-publishes-final-recommendation-for-a-new-combination-product-for-hiv-infection 2020-07-28T21:33:09 https://maestrodatabase.com/blog/fda-approves-first-interchangeable-biosimilars-to-eylea-to-treat-macular-degeneration-and-other-eye-conditions 2024-05-20T21:22:32 https://maestrodatabase.com/blog/we-have-a-health-care-crisis-democrats-take-aim-after-trump-abandons-drug-prices-plan 2019-07-14T21:01:33 https://maestrodatabase.com/blog/how-the-fda-uses-science-to-speed-medical-device-innovation 2019-07-14T20:57:55 https://maestrodatabase.com/blog/mulhollands-maori-health-inquiry-submission-to-focus-firmly-on-drug-funding-problems 2019-07-14T20:52:21 https://maestrodatabase.com/blog/health-canada-and-the-fda-collaborate-on-generic-drug-information-sharing-initiative 2025-12-02T02:03:14 https://maestrodatabase.com/blog/u-dot-s-fda-grants-priority-review-to-astellas-new-drug-application-for-gilteritinib-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-acute-myeloid-leukaemia 2018-05-30T02:26:25 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-to-produce-new-evidence-update-including-updated-value-based-price-benchmarks-for-pcsk9-inhibitors-to-treat-high-cholesterol 2017-03-18T21:42:51 https://maestrodatabase.com/blog/pfizer-ceo-says-trumps-executive-orders-overhauling-u-dot-s-drug-pricing-will-upend-the-industry 2020-07-28T21:18:13 https://maestrodatabase.com/blog/australias-pbs-faces-heat-from-trumps-new-drug-pricing-deal 2025-12-02T02:23:10 https://maestrodatabase.com/blog/samsung-bioepis-announces-launch-of-denosumab-biosimilars-obodence-and-xbryk-in-europe 2025-12-02T02:26:40 https://maestrodatabase.com/blog/trump-and-g-dot-o-p-work-to-win-repeal-of-obamas-health-act 2017-03-18T21:51:58 https://maestrodatabase.com/blog/health-canada-grants-marketing-authorisation-with-conditions-for-gileads-veklury-remdesivir-for-the-treatment-of-coronavirus-disease-2019-covid-19 2020-07-28T21:27:50 https://maestrodatabase.com/blog/bev-takes-14-pills-a-day-shes-far-from-alone 2019-07-14T21:20:54 https://maestrodatabase.com/blog/solid-biosciences-receives-fda-rare-paediatric-disease-designation-for-sgt-212-dual-route-of-administration-gene-therapy-for-friedreichs-ataxia 2025-12-02T03:05:18 https://maestrodatabase.com/blog/patent-portfolios-protecting-10-top-selling-prescription-drugs 2024-05-20T22:07:26 https://maestrodatabase.com/blog/california-plans-to-push-single-payer-health-care-using-waivers 2017-03-18T21:55:16 https://maestrodatabase.com/blog/guide-to-recent-biosimilar-activity-by-fda-and-in-the-supreme-court 2017-03-18T22:00:45 https://maestrodatabase.com/blog/highlights-from-the-chmp-9-12-october-2017-meeting 2017-10-13T11:05:39 https://maestrodatabase.com/blog/ema-validates-type-ii-variation-application-for-padcev-enfortumab-vedotin-with-keytruda-pembrolizumab-for-certain-patients-with-muscle-invasive-bladder-cancer 2025-12-02T01:38:20 https://maestrodatabase.com/blog/procare-supports-pharmacs-proposal-to-widen-access-to-the-flu-vaccine 2022-03-20T20:06:05 https://maestrodatabase.com/blog/critics-say-australias-private-health-insurance-system-is-broken-heres-what-they-say-we-can-do-to-fix-it 2022-03-20T20:03:52 https://maestrodatabase.com/blog/update-on-us-regulatory-review-of-roxadustat-in-anaemia-of-chronic-kidney-disease 2021-08-11T20:30:01 https://maestrodatabase.com/blog/incyte-provides-regulatory-update-on-retifanlimab-for-the-treatment-of-certain-patients-with-squamous-cell-carcinoma-of-the-anal-canal 2021-07-24T07:36:29 https://maestrodatabase.com/blog/gsks-jemperli-now-standard-in-endometrial-cancer-as-reimbursement-expands-to-first-line-therapy 2025-12-02T04:48:09 https://maestrodatabase.com/blog/fda-takes-additional-action-in-fight-against-covid-19-by-issuing-emergency-use-authorisation-for-second-covid-19-vaccine 2020-12-19T01:14:49 https://maestrodatabase.com/blog/medincells-partner-teva-today-announced-refiling-for-approval-of-mdc-irm-and-confirmed-planned-launch-in-the-us-in-h1-2023 2022-11-04T09:12:23 https://maestrodatabase.com/blog/a-holy-cow-moment-the-fda-approved-a-record-number-of-generics 2017-10-13T20:04:52 https://maestrodatabase.com/blog/braeburn-resubmits-opioid-use-disorder-drug-cam2038-for-fda-consideration 2018-05-30T03:10:44 https://maestrodatabase.com/blog/donald-trumps-health-care-orders-will-hurt-middle-class-self-employed-americans 2017-10-13T20:00:18 https://maestrodatabase.com/blog/immunotherapy-qarziba-to-be-reimbursed-for-high-risk-neuroblastoma-patients-starting-next-month 2025-01-21T00:15:44 https://maestrodatabase.com/blog/trioxbio-announces-fast-track-designation-granted-by-u-dot-s-fda-to-raviten-for-the-treatment-of-intradialytic-hypotension 2018-05-30T03:20:49 https://maestrodatabase.com/blog/mums-fear-as-promising-cancer-drug-out-of-reach 2022-03-21T02:19:05 https://maestrodatabase.com/blog/formycon-receives-eu-approval-for-fyb203-aflibercept-a-biosimilar-to-eylea-under-the-brand-names-ahzantive-and-baiama 2025-01-21T04:56:41 https://maestrodatabase.com/blog/drug-shortage-crisis-demands-intervention-ama-warns-as-patients-struggle-to-secure-medicines 2025-01-21T04:49:49 https://maestrodatabase.com/blog/biomed-valley-discoveries-ulixertinib-bvd-523-a-first-in-class-erk-inhibitor-cancer-therapy-receives-fast-track-designation-and-launches-phase-ii-trial-in-collaboration-with-cmed-and-strata-oncology 2020-07-29T06:51:16 https://maestrodatabase.com/blog/aprinoia-therapeutics-announces-fast-track-designation-granted-by-us-fda-to-apn-1607-florzolotau-for-the-diagnosis-of-progressive-supranuclear-palsy 2024-05-20T23:33:40 https://maestrodatabase.com/blog/albertan-with-rare-blood-cancer-calls-on-health-canada-to-approve-life-saving-drug 2025-01-21T04:34:16 https://maestrodatabase.com/blog/nabriva-receives-european-approval-for-xenleta-lefamulin-for-treatment-of-community-acquired-pneumonia 2020-07-29T06:55:41 https://maestrodatabase.com/blog/takedas-fruzaqla-fruquintinib-receives-health-canada-market-authorisation-for-metastatic-colorectal-cancer 2025-01-21T04:27:13 https://maestrodatabase.com/blog/kyowa-kirin-provides-update-on-application-for-marketing-authorisation-of-istradefylline-in-europe-for-the-treatment-of-off-episodes-in-people-living-with-parkinsons 2021-07-24T10:30:11 https://maestrodatabase.com/blog/doh-publishes-revised-agenda-for-this-months-pbac-meeting 2022-03-21T04:06:28 https://maestrodatabase.com/blog/health-canada-authorises-vabysmo-faricimab-injection-pre-filled-syringe-for-three-leading-causes-of-vision-loss 2025-01-21T04:11:19 https://maestrodatabase.com/blog/are-big-clinical-trials-relevant-researchers-disagree 2018-05-30T04:56:19 https://maestrodatabase.com/blog/a-proposed-lottery-system-to-allocate-scarce-covid-19-medications-promoting-fairness-and-generating-knowledge 2020-07-29T06:43:36 https://maestrodatabase.com/blog/tga-approves-new-medicine-for-basal-cell-carcinoma 2020-07-29T07:26:19 https://maestrodatabase.com/blog/electronic-prescriptions-to-revolutionise-health-care 2020-07-29T07:38:07 https://maestrodatabase.com/blog/protara-therapeutics-receives-rare-paediatric-disease-designation-for-tara-002-for-the-treatment-of-lymphatic-malformations 2020-07-29T07:02:55 https://maestrodatabase.com/blog/will-erbituxs-reimbursement-be-expanded-to-first-line-treatment-of-colorectal-cancer 2024-05-20T23:50:03 https://maestrodatabase.com/blog/anti-pd-l1-tagitanlimab-approved-for-marketing-by-the-national-medical-products-administration 2025-01-21T05:14:57 https://maestrodatabase.com/blog/chmp-recommends-eu-approval-of-roches-alecensa-alectinib-as-a-first-line-treatment-for-people-with-alk-positive-nsclc 2017-10-13T21:14:29 https://maestrodatabase.com/blog/sanofi-and-gsk-agree-with-the-uk-government-to-supply-up-to-60-million-doses-of-covid-19-vaccine 2020-07-29T07:10:35 https://maestrodatabase.com/blog/paracetamol-supply-issue 2020-07-29T07:17:31 https://maestrodatabase.com/blog/ptc-sticks-its-face-in-a-drug-pricing-wasps-nest 2017-03-19T20:24:10 https://maestrodatabase.com/blog/fda-approves-roches-new-ventana-her2-dual-ish-test-as-companion-diagnostic-to-identify-breast-cancer-patients-eligible-for-targeted-therapy 2020-07-29T20:52:12 https://maestrodatabase.com/blog/fda-finalises-umbrella-trial-guidance-for-cell-and-gene-therapies 2022-11-05T13:31:27 https://maestrodatabase.com/blog/alzheimers-promising-blood-test-for-early-stage-of-disease 2020-07-29T21:02:40 https://maestrodatabase.com/blog/bristol-myers-squibb-and-bluebird-bio-announce-submission-of-biologics-license-application-to-fda-for-idecabtagene-vicleucel-ide-cel-bb2121-for-adults-with-relapsed-and-refractory-multiple-myeloma 2020-07-29T21:07:25 https://maestrodatabase.com/blog/jazz-pharmaceuticals-receives-eu-marketing-authorisation-for-sunosi-solriamfetol-for-excessive-daytime-sleepiness-in-adults-with-narcolepsy-or-obstructive-sleep-apnea 2020-01-21T01:28:00 https://maestrodatabase.com/blog/eq-5d-and-the-euroqol-group-past-present-and-future 2017-03-19T22:44:44 https://maestrodatabase.com/blog/trump-administration-continues-to-keep-out-of-pocket-drug-costs-low-for-seniors 2020-07-29T21:39:12 https://maestrodatabase.com/blog/gripes-about-obamacare-aside-health-insurers-are-in-a-profit-spiral 2017-03-20T07:28:12 https://maestrodatabase.com/blog/teva-announces-new-drug-application-filing-in-japan-for-ajovy-fremanezumab-injection 2020-07-29T21:55:42 https://maestrodatabase.com/blog/atagi-update-following-weekly-covid-19-meeting-16-march-2022 2022-03-21T09:35:30 https://maestrodatabase.com/blog/hcf-launches-tool-that-calculates-procedural-costs-names-doctors-who-charge-extra 2017-03-20T07:36:51 https://maestrodatabase.com/blog/chemotherapy-compounding-payment-scheme---extension-to-the-non-mandatory-claiming-period 2017-03-20T00:28:22 https://maestrodatabase.com/blog/the-fake-freedom-of-american-health-care 2017-03-20T07:25:28 https://maestrodatabase.com/blog/european-commission-approves-darzalex-daratumumab-in-combination-with-bortezomib-thalidomide-and-dexamethasone-for-patients-with-newly-diagnosed-multiple-myeloma-who-are-transplant-eligible 2020-01-21T02:03:14 https://maestrodatabase.com/blog/ema-publishes-draft-agenda-for-march-chmp-meeting 2017-03-20T20:09:44 https://maestrodatabase.com/blog/two-million-to-quit-or-downgrade-private-health-insurance-cover-research-suggests 2017-03-20T20:03:26 https://maestrodatabase.com/blog/modernas-mysterious-coronavirus-vaccine-delivery-system 2020-07-29T21:13:18 https://maestrodatabase.com/blog/doctors-call-for-medicare-authority-as-government-looks-to-lift-rebate 2017-03-20T20:06:06 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-to-review-certain-non-pharmacologic-interventions-for-chronic-low-back-and-neck-pain-in-upcoming-review 2017-03-20T20:40:12 https://maestrodatabase.com/blog/moderna-pitches-virus-vaccine-at-about-$50-$60-per-course 2020-07-29T21:16:40 https://maestrodatabase.com/blog/theres-a-middle-ground-in-amgens-drug-price-battle 2017-03-20T20:44:30 https://maestrodatabase.com/blog/novartis-receives-piqray-approval-in-europe---the-first-and-only-targeted-medicine-for-hr-plus-slash-her2--advanced-breast-cancer-with-a-pik3ca-mutation 2020-07-29T21:25:56 https://maestrodatabase.com/blog/karyopharm-announces-fda-approval-of-xpovio-selinexor-as-a-treatment-for-patients-with-multiple-myeloma-after-at-least-one-prior-therapy 2020-12-19T02:37:54 https://maestrodatabase.com/blog/four-former-fda-commissioners-denounce-drug-importation-citing-dangers-to-consumers 2017-03-20T20:22:41 https://maestrodatabase.com/blog/array-biopharma-provides-update-on-fda-submission-for-binimetinib 2017-03-20T20:54:58 https://maestrodatabase.com/blog/eli-lilly-wants-you-to-know-that-its-price-hikes-dont-work 2017-03-20T20:47:46 https://maestrodatabase.com/blog/a-better-balance-between-accelerated-access-and-high-priced-new-drugs-a-new-conditional-approval-option 2017-03-20T20:50:59 https://maestrodatabase.com/blog/takedas-exkivity-mobocertinib-granted-conditional-marketing-authorisation-in-great-britain 2022-03-21T10:25:28 https://maestrodatabase.com/blog/nice-recommends-elosulfase-alfa-for-routine-nhs-use-for-patients-with-rare-life-limiting-metabolic-disorder 2022-03-21T19:22:20 https://maestrodatabase.com/blog/ema-publishes-agenda-for-21-24-march-chmp-meeting 2022-03-21T09:55:33 https://maestrodatabase.com/blog/genomics-australia-to-guide-the-future-of-genomic-health-and-medicine-over-the-coming-decade 2022-03-21T10:08:43 https://maestrodatabase.com/blog/cadth-releases-its-annual-list-of-health-technology-trends-to-watch 2022-03-21T19:41:25 https://maestrodatabase.com/blog/janssen-seeks-expanded-use-of-imbruvica-ibrutinib-in-combination-with-rituximab-for-patients-with-previously-untreated-chronic-lymphocytic-leukaemia 2020-01-21T02:37:37 https://maestrodatabase.com/blog/new-australian-agency-to-accelerate-genomic-research-and-drive-innovation-in-health-care 2022-03-21T19:45:48 https://maestrodatabase.com/blog/mannkind-announces-us-fda-accepts-for-review-its-supplemental-new-drug-application-of-furoscix-readyflow-auto-injector-for-the-treatment-of-oedema-in-adults-with-chronic-heart-failure-or-chronic-kidney-disease 2025-12-02T07:46:54 https://maestrodatabase.com/blog/provention-bio-announces-fda-acceptance-of-the-biologics-license-application-resubmission-for-teplizumab-for-the-delay-of-clinical-type-1-diabetes-in-at-risk-individuals 2022-03-21T19:26:51 https://maestrodatabase.com/blog/korea-eases-path-to-breakthrough-drugs-with-flexible-icer-rules 2025-12-02T08:55:56 https://maestrodatabase.com/blog/european-commission-approves-lazcluze-lazertinib-in-combination-with-rybrevant-amivantamab-for-the-first-line-treatment-of-patients-with-egfr-mutated-advanced-non-small-cell-lung-cancer 2025-01-21T20:36:09 https://maestrodatabase.com/blog/patient-advocacy-organisations-and-fda-drug-approval-lessons-from-aduhelm 2021-07-25T01:34:35 https://maestrodatabase.com/blog/ema-chmp-adopts-positive-opinion-recommending-authorisation-for-the-use-of-the-moderna-covid-19-vaccine-in-adolescents-12-17-years-of-age-in-the-european-union 2021-07-25T11:36:39 https://maestrodatabase.com/blog/fda-approves-pembrolizumab-for-advanced-endometrial-carcinoma 2022-03-21T20:28:24 https://maestrodatabase.com/blog/health-gap-fees-up-to-10-times-higher-in-northern-sydney-than-elsewhere-in-nsw 2020-01-21T02:53:19 https://maestrodatabase.com/blog/government-to-introduce-oral-covid-19-medicine-lagevrio-for-100-000-patients-this-week-interior-minister 2022-03-21T20:06:37 https://maestrodatabase.com/blog/atagi-statement-response-to-nsw-covid-19-outbreak-24-july-2021 2021-07-25T01:27:20 https://maestrodatabase.com/blog/highlights-from-the-19-22-july-chmp-meeting 2021-07-25T01:23:32 https://maestrodatabase.com/blog/chinas-nmpa-grants-greater-access-to-rheumatology-biosimilars 2022-03-21T20:00:01 https://maestrodatabase.com/blog/mum-says-miracle-drug-saved-ill-baby-kaan-hunters-life 2020-01-21T19:55:14 https://maestrodatabase.com/blog/european-commission-approves-roches-polivy-for-people-with-previously-treated-aggressive-lymphoma 2020-01-21T12:35:22 https://maestrodatabase.com/blog/achieving-cost-savings-with-biosimilars-will-require-new-strategies-authors-say 2020-01-21T20:21:25 https://maestrodatabase.com/blog/the-biosimilar-solution-to-expensive-cancer-care 2020-01-21T20:18:48 https://maestrodatabase.com/blog/pharma-says-price-regulation-will-take-life-saving-drugs-away-from-us-but-heres-the-truth 2020-01-21T20:05:56 https://maestrodatabase.com/blog/baxdrostat-new-drug-application-accepted-under-fda-priority-review-in-the-us-for-patients-with-hard-to-control-hypertension 2025-12-02T20:24:24 https://maestrodatabase.com/blog/will-the-fda-give-the-go-ahead-to-a-prescription-video-game-the-wait-goes-on-as-new-data-come-in 2020-01-21T20:01:14 https://maestrodatabase.com/blog/humacyte-receives-fda-regenerative-medicine-advanced-therapy-expedited-review-designation-for-humacyl-in-vascular-access-for-haemodialysis 2017-03-21T02:33:20 https://maestrodatabase.com/blog/house-republicans-unveil-changes-to-their-health-care-bill 2017-03-21T11:16:03 https://maestrodatabase.com/blog/spravato-esketamine-approved-in-the-us-as-the-first-and-only-monotherapy-for-adults-with-treatment-resistant-depression 2025-01-21T21:25:21 https://maestrodatabase.com/blog/fda-grants-breakthrough-therapy-designation-to-mercks-novel-hif-2a-inhibitor-mk-6482-for-treatment-of-certain-patients-with-von-hippel-lindau-disease-associated-renal-cell-carcinoma 2020-07-29T23:59:54 https://maestrodatabase.com/blog/provisional-approval-pathway-for-prescription-medicines 2017-09-01T21:23:58 https://maestrodatabase.com/blog/us-fda-grants-priority-review-of-belantamab-mafodotin-for-patients-with-relapsed-or-refractory-multiple-myeloma 2020-01-21T20:29:32 https://maestrodatabase.com/blog/chmp-issues-a-positive-opinion-on-janssens-zytiga-to-include-earlier-stage-prostate-cancer-patients 2017-10-13T23:14:34 https://maestrodatabase.com/blog/fda-approves-first-treatment-for-thyroid-eye-disease 2020-01-21T20:41:33 https://maestrodatabase.com/blog/fda-approves-drug-to-treat-parkinsons-disease 2017-03-21T20:02:08 https://maestrodatabase.com/blog/old-drug-new-tricks-existing-medicines-show-promise-in-fighting-cancer 2020-01-21T20:38:46 https://maestrodatabase.com/blog/tga-seeks-feedback-on-support-needs-for-smes 2017-03-21T20:06:53 https://maestrodatabase.com/blog/ridgeback-biotherapeutics-announces-priority-review-of-biologics-license-application-for-ansuvimab-ebola-treatment 2020-07-29T23:50:37 https://maestrodatabase.com/blog/genprex-receives-u-dot-s-fda-fast-track-designation-for-gene-therapy-that-targets-lung-cancer 2020-01-21T20:34:02 https://maestrodatabase.com/blog/arrowhead-pharmaceuticals-receives-fda-breakthrough-therapy-designation-for-plozasiran-in-severe-hypertriglyceridaemia 2025-12-03T00:17:19 https://maestrodatabase.com/blog/donald-trump-just-sent-drug-stocks-tumbling--again 2017-03-21T20:22:02 https://maestrodatabase.com/blog/drug-device-industries-get-one-year-delay-on-off-label-rule 2017-03-21T20:13:49 https://maestrodatabase.com/blog/fda-expedites-review-of-novartis-drug-promacta-for-first-line-severe-aplastic-anaemia 2018-05-30T07:38:53 https://maestrodatabase.com/blog/sanofi-cvs-others-accused-of-insulin-price-fixing 2017-03-21T20:25:17 https://maestrodatabase.com/blog/agenda-for-22-march-2017-tc-meeting 2017-03-21T20:38:33 https://maestrodatabase.com/blog/fda-nears-decision-authorising-covid-19-treatment-with-convalescent-plasma 2020-07-30T00:06:16 https://maestrodatabase.com/blog/nice-strengthens-engagement-with-lse-health 2017-03-21T20:35:39 https://maestrodatabase.com/blog/nice-has-made-six-times-more-lung-cancer-treatment-recommendations-over-the-past-ten-years-than-in-the-previous-decade 2025-01-21T21:46:14 https://maestrodatabase.com/blog/launch-of-new-canadian-guidelines-for-the-economic-evaluation-of-health-technologies 2017-03-21T20:46:49 https://maestrodatabase.com/blog/moderna-receives-health-canada-authorisation-for-second-omicron-targeting-bivalent-booster 2022-11-06T07:08:44 https://maestrodatabase.com/blog/pharmac-proposes-widening-access-to-a-brain-cancer-treatment-to-help-reduce-the-impact-of-a-discontinuation 2023-08-11T06:11:28 https://maestrodatabase.com/blog/vital-directions-for-health-and-health-care-priorities-from-a-national-academy-of-medicine-initiative 2017-03-22T04:29:01 https://maestrodatabase.com/blog/independent-review-into-medicare-compliance 2022-11-06T09:39:32 https://maestrodatabase.com/blog/health-canada-approves-brivlera-brivaracetam-to-treat-partial-onset-seizures-in-paediatric-epilepsy-patients 2020-07-30T01:41:46 https://maestrodatabase.com/blog/dyne-therapeutics-receives-fda-fast-track-designation-for-dyne-101-for-the-treatment-of-myotonic-dystrophy-type-1 2025-01-21T23:39:38 https://maestrodatabase.com/blog/consumer-involvement-in-their-own-healthcare---key-to-a-sustainable-national-health-system 2017-03-22T03:35:24 https://maestrodatabase.com/blog/asfotase-alfa-for-the-treatment-of-certain-patients-with-paediatric-onset-hypophosphatasia 2023-03-02T20:17:47 https://maestrodatabase.com/blog/sangamo-therapeutics-receives-us-fda-fast-track-designation-for-st-503-for-the-treatment-of-small-fibre-neuropathy 2025-12-03T00:24:55 https://maestrodatabase.com/blog/henlius-and-accord-healthcare-receive-ema-approval-for-zercepac-trastuzumab-biosimilar 2020-07-30T01:47:02 https://maestrodatabase.com/blog/bulevirtide-acetate-for-the-treatment-of-patients-with-chronic-hepatitis-d 2022-11-06T09:31:12 https://maestrodatabase.com/blog/wugen-announces-rmat-and-prime-designations-for-wu-cart-007-to-accelerate-regulatory-reviews 2024-05-21T08:19:12 https://maestrodatabase.com/blog/solid-biosciences-receives-fda-fast-track-designation-for-sgt-212-dual-route-of-administration-gene-therapy-for-friedreichs-ataxia 2025-01-21T23:25:26 https://maestrodatabase.com/blog/trump-warns-house-republicans-repeal-health-law-or-lose-your-seats 2017-03-22T04:34:17 https://maestrodatabase.com/blog/federal-trade-commission-actions-on-prescription-drugs-2000-2022 2024-05-21T06:01:31 https://maestrodatabase.com/blog/ionis-receives-us-fda-breakthrough-therapy-designation-for-zilganersen-for-alexander-disease 2025-12-03T00:57:04 https://maestrodatabase.com/blog/pathological-complete-response-in-neo-adjuvant-treatment-of-high-risk-early-stage-breast-cancer-use-as-an-endpoint-to-support-accelerated-approval 2020-07-30T01:57:15 https://maestrodatabase.com/blog/life-molecular-imaging-secures-fda-fast-track-designation-for-18f-florbetaben-in-diagnosing-cardiac-al-and-attr-amyloidosis 2025-01-21T23:17:17 https://maestrodatabase.com/blog/woman-who-has-to-pay-$115k-for-unfunded-cancer-drug-asks-what-price-is-a-life 2022-11-06T07:48:52 https://maestrodatabase.com/blog/duke-experts-caution-against-loosening-fda-regulations 2017-03-22T06:22:22 https://maestrodatabase.com/blog/fda-approves-niraparib-and-abiraterone-acetate-plus-prednisone-for-brca-mutated-metastatic-castration-resistant-prostate-cancer 2023-08-11T21:30:19 https://maestrodatabase.com/blog/kiwis-with-rare-disorders-want-faster-progress-on-life-or-death-health-strategy 2022-11-06T07:46:17 https://maestrodatabase.com/blog/us-fda-designates-pycs-lead-as-a-fast-track-development-program 2023-08-11T21:24:44 https://maestrodatabase.com/blog/teva-and-alvotech-announce-simlandi-adalimumab-ryvk-injection-now-available-in-the-us 2024-05-21T05:20:07 https://maestrodatabase.com/blog/as-part-of-efforts-to-combat-opioid-crisis-fda-launches-innovation-challenge-to-spur-development-of-medical-devices---including-digital-health-and-diagnostics---that-target-pain-addiction-and-diversion 2018-05-30T20:52:28 https://maestrodatabase.com/blog/nacuity-pharmaceuticals-granted-us-fda-fast-track-designation-for-npi-001-n-acetylcysteine-amide-tablets-for-the-treatment-of-retinitis-pigmentosa 2025-01-22T00:02:37 https://maestrodatabase.com/blog/hlbs-us-subsidiary-scores-fda-fast-track-designation-for-merkel-cell-cancer-vaccine 2022-11-06T10:23:05 https://maestrodatabase.com/blog/statement-from-fda-commissioner-on-the-signing-of-the-right-to-try-act 2018-05-30T20:54:45 https://maestrodatabase.com/blog/prescription-medicines-applications-under-evaluation-march-2022 2022-03-22T01:48:29 https://maestrodatabase.com/blog/report-on-the-current-status-of-the-use-of-real-world-data-and-real-world-evidence-in-drug-development-and-regulation 2019-07-15T05:13:37 https://maestrodatabase.com/blog/accelerated-approval-of-medicines-fit-for-purpose 2018-05-30T21:03:14 https://maestrodatabase.com/blog/bristol-myers-squibb-announces-updated-action-date-by-the-us-fda-for-subcutaneous-nivolumab-nivolumab-and-hyaluronidase 2024-05-21T11:03:53 https://maestrodatabase.com/blog/fda-approves-new-treatment-for-moderately-to-severely-active-ulcerative-colitis 2018-05-30T20:57:22 https://maestrodatabase.com/blog/trump-says-drug-companies-to-announce-massive-price-cuts-soon 2018-05-30T21:22:56 https://maestrodatabase.com/blog/nice-terminates-four-single-technology-assessments 2017-03-22T10:43:24 https://maestrodatabase.com/blog/proposal-to-fund-an-additional-brand-of-budesonide-with-eformoterol 2020-07-30T04:45:12 https://maestrodatabase.com/blog/a-republican-health-care-bill-in-search-of-a-problem 2017-03-22T10:35:27 https://maestrodatabase.com/blog/pharmaceutical-benefits-scheme-restrictions-on-anti-epileptic-drug-prescribing-promote-unsafe-and-outdated-practice 2019-07-15T05:23:47 https://maestrodatabase.com/blog/watch-trump-sign-right-to-try-allowing-gravely-ill-patients-to-bypass-fda-for-experimental-treatment 2018-05-30T21:26:32 https://maestrodatabase.com/blog/academies-call-on-health-minsters-to-resolve-health-data-issues 2019-07-15T05:20:00 https://maestrodatabase.com/blog/celltrion-completes-resubmission-for-biosimilar-candidate-to-fda-for-review 2018-05-30T21:13:37 https://maestrodatabase.com/blog/australia-is-racing-to-make-mrna-covid-vaccines-here----but-can-we-do-it-without-big-pharma 2021-07-25T21:34:25 https://maestrodatabase.com/blog/nice-rejects-nhs-funding-for-kyowa-kirins-poteligeo 2020-07-30T20:54:43 https://maestrodatabase.com/blog/older-americans-want-elected-leaders-to-lower-rx-prices 2017-03-22T11:02:02 https://maestrodatabase.com/blog/medicinal-cannabis-mp-pushes-to-make-medicinal-cannabis-cheaper-through-pbs-listing 2017-03-22T11:17:49 https://maestrodatabase.com/blog/bluejay-therapeutics-receives-us-fda-breakthrough-therapy-designation-for-brelovitug-bjt-778-for-the-treatment-of-chronic-hepatitis-delta 2025-01-22T00:10:04 https://maestrodatabase.com/blog/exelixis-announces-u-dot-s-fda-accepts-supplemental-new-drug-application-for-cabometyx-cabozantinib-in-previously-treated-advanced-hepatocellular-carcinoma 2018-05-30T21:29:08 https://maestrodatabase.com/blog/merck-announces-two-us-regulatory-milestones-for-keytruda-pembrolizumab-in-triple-negative-breast-cancer 2020-07-30T21:20:11 https://maestrodatabase.com/blog/trumps-promise-to-rein-in-drug-prices-could-open-dam-to-importation-laws 2017-03-22T11:32:47 https://maestrodatabase.com/blog/post-menopausal-women-with-a-family-history-of-breast-cancer-should-be-offered-anastrozole-says-nice-in-updated-guidance 2017-03-22T19:54:55 https://maestrodatabase.com/blog/aia-launches-insurance-to-pay-huge-costs-of-immunotherapy-cancer-drugs 2017-03-22T11:42:00 https://maestrodatabase.com/blog/fda-approves-genentechs-tecentriq-plus-cotellic-and-zelboraf-for-people-with-advanced-melanoma 2020-07-30T21:26:00 https://maestrodatabase.com/blog/therapeuticsmd-announces-fda-approval-of-tx-004hr-imvexxy-oestradiol-vaginal-inserts-the-lowest-dose-vaginal-oestrogen-product-approved-for-the-treatment-of-moderate-to-severe-dyspareunia-due-to-menopause 2018-05-30T21:37:02 https://maestrodatabase.com/blog/call-for-experts-in-anonymisation-of-clinical-data 2017-03-23T10:56:34 https://maestrodatabase.com/blog/pharmac-removes-dispensing-restrictions---now-distributing-three-months-supply 2020-07-30T21:00:39 https://maestrodatabase.com/blog/covid-19-demand-leads-to-australian-shortages-of-rheumatoid-arthritis-drug 2021-07-25T21:43:15 https://maestrodatabase.com/blog/lockdown-in-melbourne-prevents-invercargill-woman-from-receiving-cancer-treatment 2020-07-30T21:03:55 https://maestrodatabase.com/blog/multiplicity-considerations-in-clinical-trials 2018-05-30T21:48:19 https://maestrodatabase.com/blog/first-anniversary-of-prime---experience-so-far 2017-03-22T20:01:03 https://maestrodatabase.com/blog/eton-pharmaceuticals-submits-new-drug-application-to-the-fda-for-zonisamide-oral-suspension-et-104 2020-07-30T21:16:12 https://maestrodatabase.com/blog/replimune-announces-biologics-license-application-acceptance-and-priority-review-for-rp1-for-the-treatment-of-advanced-melanoma 2025-01-22T00:31:50 https://maestrodatabase.com/blog/imago-biosciences-granted-access-by-european-medicines-agency-to-prime-scheme-for-img-7289-bomedemstat-in-myelofibrosis 2020-07-30T21:45:48 https://maestrodatabase.com/blog/the-role-of-imperfect-surrogate-endpoint-information-in-drug-approval-and-reimbursement-decisions 2017-03-22T20:10:23 https://maestrodatabase.com/blog/takeda-announces-u-dot-s-fda-breakthrough-therapy-designation-granted-for-pevonedistat-for-the-treatment-of-patients-with-higher-risk-myelodysplastic-syndromes 2020-07-30T21:28:59 https://maestrodatabase.com/blog/gop-bills-medicaid-cuts-draw-fire-ahead-of-house-floor-vote 2017-03-22T20:28:25 https://maestrodatabase.com/blog/british-columbia-lists-epclusa-on-public-drug-plan-to-treat-all-six-genotypes-of-chronic-hepatitis-c-infection 2017-03-23T09:50:12 https://maestrodatabase.com/blog/marinus-pharmaceuticals-receives-rare-paediatric-disease-designation-from-fda-for-ganaxolone-for-the-treatment-of-cdkl5-deficiency-disorder 2020-07-30T21:33:15 https://maestrodatabase.com/blog/bernie-sanders-thinks-this-$89-000-slash-year-drug-should-be-$1-000-slash-year 2017-03-23T09:54:48 https://maestrodatabase.com/blog/this-is-not-a-test-rmat-designation-goes-live 2017-03-23T10:00:43 https://maestrodatabase.com/blog/shire-receives-fda-fast-track-designation-for-recombinant-adamts13-shp655-for-treatment-of-hereditary-thrombotic-thrombocytopenic-purpura 2017-03-23T10:04:34 https://maestrodatabase.com/blog/travere-therapeutics-submits-new-drug-application-for-sparsentan-for-the-treatment-of-iga-nephropathy 2022-03-22T03:42:41 https://maestrodatabase.com/blog/transposon-receives-us-fda-fast-track-designation-for-tpn-101-for-progressive-supranuclear-palsy 2024-05-21T23:28:27 https://maestrodatabase.com/blog/abiraterone-acetate-with-niraparib-tosylate-monohydrate-and-prednisone-for-untreated-hormone-relapsed-metastatic-prostate-cancer 2025-01-22T01:32:28 https://maestrodatabase.com/blog/house-republicans-deeply-divided-face-painful-choice-on-health-vote 2017-03-23T10:23:47 https://maestrodatabase.com/blog/jacobio-pharma-announces-breakthrough-therapy-designation-from-china-cde-for-kras-g12c-inhibitor-glecirasib-for-the-treatment-of-pancreatic-cancer 2023-08-12T04:03:46 https://maestrodatabase.com/blog/public-summary-document-for-keytruda-pembrolizumab 2017-03-23T10:28:51 https://maestrodatabase.com/blog/the-mirage-of-reform----republicans-struggle-to-dismantle-obamacare 2017-03-23T10:52:27 https://maestrodatabase.com/blog/ractigen-therapeutics-secures-fda-fast-track-designation-for-rag-01-a-first-in-class-sarna-therapy 2024-05-21T23:41:38 https://maestrodatabase.com/blog/use-of-big-data-to-improve-human-and-animal-health 2017-03-23T19:53:18 https://maestrodatabase.com/blog/fda-approves-first-treatment-for-rare-form-of-skin-cancer 2017-03-23T19:56:57 https://maestrodatabase.com/blog/kye-pharmaceuticals-files-accrufer-new-drug-submission-in-canada-for-the-treatment-of-iron-deficiency 2022-03-22T04:43:43 https://maestrodatabase.com/blog/fda-grants-breakthrough-therapy-designation-to-roches-inavolisib-for-advanced-hormone-receptor-positive-her2-negative-breast-cancer-with-a-pik3ca-mutation 2024-05-22T00:42:56 https://maestrodatabase.com/blog/update-on-us-regulatory-decision-for-farxiga-in-type-1-diabetes 2019-07-15T07:32:27 https://maestrodatabase.com/blog/an-fda-program-incentivising-rare-disease-drugs-will-be-investigated-for-abuses 2017-03-23T20:12:09 https://maestrodatabase.com/blog/durect-corporation-receives-fda-breakthrough-therapy-designation-for-larsucosterol-in-alcohol-associated-hepatitis 2024-05-22T00:24:33 https://maestrodatabase.com/blog/house-vote-to-repeal-affordable-care-act-is-postponed-despite-trumps-effort 2017-03-23T20:32:07 https://maestrodatabase.com/blog/cadth-recommends-reimbursement-of-stelara-for-new-indication 2017-03-23T20:17:08 https://maestrodatabase.com/blog/as-rivals-stand-silent-one-health-insurer-protests-g-dot-o-p-plan 2017-03-23T20:34:01 https://maestrodatabase.com/blog/hope-of-b-dot-c-coverage-for-life-saving-cystic-fibrosis-drug-dashed 2017-03-24T01:05:55 https://maestrodatabase.com/blog/lundbeck-and-otsukas-brexpiprazole-for-adult-patients-with-schizophrenia-accepted-for-review-by-ema 2017-03-24T01:10:04 https://maestrodatabase.com/blog/anzupgo-delgocitinib-cream-now-available-in-canada-for-adult-patients-living-with-moderate-to-severe-chronic-hand-eczema 2025-12-03T02:57:15 https://maestrodatabase.com/blog/ascentage-pharmas-mdm2-p53-inhibitor-alrizomadlin-apg-115-granted-rare-paediatric-disease-designation-by-the-us-fda-for-the-treatment-of-neuroblastoma 2022-03-22T05:20:17 https://maestrodatabase.com/blog/new-hope-for-rare-cancer-patients-as-first-immunotherapy-treatment-subsidised 2025-12-03T03:31:13 https://maestrodatabase.com/blog/pharmac-widens-access-to-pneumococcal-vaccine 2022-11-07T20:02:09 https://maestrodatabase.com/blog/global-regulatory-workshop-on-covid-19-therapeutics-number-2-agreement-on-acceptable-outcomes-for-clinical-trials 2020-07-31T12:28:24 https://maestrodatabase.com/blog/rhythm-pharmaceuticals-announces-european-commission-authorisation-of-imcivree-setmelanotide-for-the-treatment-of-obesity-and-control-of-hunger-associated-with-pomc-pcsk1-and-lepr-deficiency 2021-07-26T07:19:50 https://maestrodatabase.com/blog/global-regulatory-workshop-on-covid-19-real-world-evidence-and-observational-studies 2020-07-31T12:30:53 https://maestrodatabase.com/blog/ultomiris-recommended-for-approval-in-the-eu-by-chmp-for-children-and-adolescents-with-paroxysmal-nocturnal-haemoglobinuria 2021-07-26T06:11:24 https://maestrodatabase.com/blog/european-commission-approves-amgevita-biosimilar-adalimumab-for-the-treatment-of-certain-inflammatory-diseases 2017-03-24T06:51:05 https://maestrodatabase.com/blog/bristol-myers-squibb-statement-on-opdivo-nivolumab-monotherapy-post-sorafenib-hepatocellular-carcinoma-u-dot-s-indication 2021-07-26T06:41:33 https://maestrodatabase.com/blog/non-opioid-treatment-alternatives-for-pain-face-clinical-development-and-reimbursement-challenges 2022-11-07T20:25:45 https://maestrodatabase.com/blog/protecting-australians-from-unsafe-compounding-of-replica-weight-loss-products 2024-05-22T02:56:21 https://maestrodatabase.com/blog/new-pmprb-guidelines-proposed-for-assessing-prices-of-patented-medicines-sold-in-canada 2022-11-07T20:37:31 https://maestrodatabase.com/blog/the-national-advisory-committee-on-immunization-recommends-beyfortus-to-protect-all-infants-against-rsv 2024-05-22T02:47:42 https://maestrodatabase.com/blog/mhra-updates-biosimilar-guidance-to-allow-interchangeability-between-products 2022-11-07T20:21:46 https://maestrodatabase.com/blog/pfizer-and-biontech-to-provide-u-dot-s-government-with-an-additional-200-million-doses-of-covid-19-vaccine-to-help-meet-continued-need-for-vaccine-supply-in-the-u-dot-s 2021-07-26T07:28:12 https://maestrodatabase.com/blog/sanofi-and-gsk-selected-for-operation-warp-speed-to-supply-united-states-government-with-100-million-doses-of-covid-19-vaccine 2020-07-31T12:33:53 https://maestrodatabase.com/blog/43-dollars-9-cents-million-to-boost-fight-against-hiv-infection 2024-05-22T02:44:39 https://maestrodatabase.com/blog/sensorion-announces-us-fda-grants-rare-paediatric-disease-designation-to-otof-gt-for-the-treatment-of-otoferlin-gene-mediated-hearing-loss 2022-11-07T20:16:04 https://maestrodatabase.com/blog/new-nice-criteria-for-drug-access 2017-05-07T05:28:15 https://maestrodatabase.com/blog/the-australian-government-is-committed-to-ensuring-the-safety-of-those-at-risk-of-monkeypox-and-has-been-working-closely-with-states-territories-and-key-stakeholders-to-ensure-a-coordinated-national-response 2022-11-07T20:07:48 https://maestrodatabase.com/blog/australia-in-talks-with-us-over-trump-demands-to-pay-more-for-medicine 2025-12-03T03:47:11 https://maestrodatabase.com/blog/nice-recommends-bavencio-avelumab-in-combination-with-axitinib-for-first-line-treatment-of-adult-patients-with-advanced-renal-cell-carcinoma 2020-07-31T12:38:47 https://maestrodatabase.com/blog/nice-plays-key-role-in-european-project-to-help-give-better-care-to-patients-with-blood-cancers 2017-03-24T20:16:50 https://maestrodatabase.com/blog/china-to-soften-generic-drug-buying-program 2019-07-15T12:12:08 https://maestrodatabase.com/blog/aadi-bioscience-announces-fda-acceptance-and-priority-review-for-the-new-drug-application-of-fyarro-for-the-treatment-of-advanced-malignant-pecoma 2021-07-26T12:03:57 https://maestrodatabase.com/blog/bill-shock-couple-faces-7000-dollars-health-insurance-price-rise 2017-03-24T20:13:25 https://maestrodatabase.com/blog/nice-recommends-skyrizi-forxiga 2019-07-15T12:06:08 https://maestrodatabase.com/blog/iterum-therapeutics-receives-complete-response-letter-from-u-dot-s-fda-for-oral-sulopenem 2021-07-26T12:10:16 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-crisaborole-and-dupilumab-for-atopic-dermatitis 2017-03-24T20:20:02 https://maestrodatabase.com/blog/cost-effective-but-unaffordable-an-emerging-challenge-for-health-systems 2017-03-24T20:30:52 https://maestrodatabase.com/blog/are-prescription-drug-prices-going-down 2019-07-15T12:24:54 https://maestrodatabase.com/blog/vabysmo-faricimab-receives-positive-cadth-recommendation-for-the-treatment-of-diabetic-macular-oedema-in-adults 2022-11-07T20:52:55 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-positive-chmp-opinion-recommending-opdivo-nivolumab-for-the-treatment-of-squamous-cell-cancer-of-the-head-and-neck-in-adults-progressing-on-or-after-platinum-based-therapy 2017-03-24T20:41:10 https://maestrodatabase.com/blog/sirolimus-for-the-treatment-of-patients-with-facial-angiofibroma-caused-by-tuberous-sclerosis-complex 2024-05-22T03:04:37 https://maestrodatabase.com/blog/us-supreme-court-to-hear-amgen-bid-to-revive-cholesterol-drug-patents 2022-11-07T20:41:07 https://maestrodatabase.com/blog/how-republicans-new-health-plan-would-affect-american-incomes 2017-03-24T20:36:52 https://maestrodatabase.com/blog/can-we-use-existing-guidance-to-support-the-development-of-robust-real-world-evidence-for-health-technology-assessment-slash-payer-decision-making 2022-11-07T20:48:22 https://maestrodatabase.com/blog/shingrix-approved-in-the-us-for-prevention-of-shingles-in-immunocompromised-adults 2021-07-26T21:12:35 https://maestrodatabase.com/blog/teva-announces-fda-approval-of-airduo-digihaler-fluticasone-propionate-113-mcg-and-salmeterol-14-mcg-inhalation-powder 2019-07-15T20:57:10 https://maestrodatabase.com/blog/tagrisso-granted-breakthrough-therapy-designation-in-the-us-for-the-adjuvant-treatment-of-patients-with-stage-ib-iiia-egfr-mutated-lung-cancer 2020-07-31T13:00:32 https://maestrodatabase.com/blog/atara-biotherapeutics-submits-tabalecleucel-tab-cel-biologics-license-application-for-treatment-of-epstein-barr-virus-positive-post-transplant-lymphoproliferative-disease-with-us-fda 2024-05-22T03:51:31 https://maestrodatabase.com/blog/private-health-care-facing-death-spiral-if-young-healthy-users-abandon-insurance-report-says 2019-07-15T20:51:50 https://maestrodatabase.com/blog/brexit-no-guarantee-of-medicines-if-no-eu-deal-agreed 2019-07-15T12:42:59 https://maestrodatabase.com/blog/beigene-announces-approval-in-canada-of-brukinsa-zanubrutinib-for-the-treatment-of-patients-with-mantle-cell-lymphoma 2021-07-26T21:24:44 https://maestrodatabase.com/blog/fda-grants-breakthrough-therapy-designation-for-rituxan-rituximab-in-pemphigus-vulgaris 2017-03-24T20:54:59 https://maestrodatabase.com/blog/biden-health-care-plan-would-curb-drug-prices-raise-taxes-on-rich 2019-07-15T12:30:08 https://maestrodatabase.com/blog/sanofi-and-gsk-in-advanced-discussions-with-european-union-to-supply-up-to-300-million-doses-of-covid-19-vaccine 2020-07-31T22:15:10 https://maestrodatabase.com/blog/sarclisa-approved-in-the-eu-as-the-first-anti-cd38-therapy-in-combination-with-standard-of-care-vrd-to-treat-transplant-ineligible-newly-diagnosed-multiple-myeloma 2025-01-22T19:58:52 https://maestrodatabase.com/blog/tga-international-engagement-strategy-2021-2025 2021-07-26T21:20:22 https://maestrodatabase.com/blog/owp-pharmaceuticals-announces-fda-filing-acceptance-for-new-drug-application-of-subvenite-lamotrigine-oral-suspension 2024-05-22T03:45:30 https://maestrodatabase.com/blog/drug-pricing-will-make-or-break-democrats-health-care-agenda 2021-07-26T12:31:15 https://maestrodatabase.com/blog/biomarin-announces-incremental-progress-on-biologics-license-application-review-for-valoctocogene-roxaparvovec-aav-gene-therapy-for-adults-with-severe-haemophilia-a-program 2022-11-08T05:38:34 https://maestrodatabase.com/blog/implementation-of-coverage-with-evidence-development-drug-approval-strategies-found-lacking 2019-07-15T21:07:12 https://maestrodatabase.com/blog/u-dot-s-food-and-drug-administration-approves-stelara-ustekinumab-for-treatment-of-paediatric-patients-with-moderate-to-severe-plaque-psoriasis 2020-07-31T12:49:52 https://maestrodatabase.com/blog/the-fda-disagrees-with-its-own-expert-panels-how-often 2019-07-15T21:02:40 https://maestrodatabase.com/blog/full-fda-approval-is-needed-to-overcome-vaccine-hesitancy 2021-07-26T21:07:20 https://maestrodatabase.com/blog/nice-and-partners-announce-this-years-theme-for-world-evidence-based-healthcare-day 2021-07-26T12:37:09 https://maestrodatabase.com/blog/on-prescription-drug-prices-will-trump-turn-words-into-action 2019-07-15T21:21:11 https://maestrodatabase.com/blog/using-updated-pubmed-new-features-and-functions-to-enhance-literature-searches 2021-07-26T21:45:34 https://maestrodatabase.com/blog/there-is-no-single-best-policy-for-drug-prices 2019-07-15T21:17:13 https://maestrodatabase.com/blog/fda-approves-bayers-gadavist-gadobutrol-injection-as-the-first-and-only-contrast-agent-for-use-in-cardiac-magnetic-resonance-imaging-in-adult-patients-with-known-or-suspected-coronary-artery-disease 2019-07-15T21:11:27 https://maestrodatabase.com/blog/weighing-the-benefits-and-risks-of-proliferating-observational-treatment-assessments-observational-cacophony-randomised-harmony 2020-07-31T22:18:40 https://maestrodatabase.com/blog/fda-asks-pfizer-moderna-to-test-their-vaccines-in-more-children-to-help-rule-out-safety-issues 2021-07-26T21:33:57 https://maestrodatabase.com/blog/evren-technologies-receives-fda-breakthrough-device-designation-for-the-phoenix 2021-07-26T21:39:37 https://maestrodatabase.com/blog/medicare-expands-coverage-for-bracanalysis-cdx-in-prostate-cancer 2020-07-31T22:24:14 https://maestrodatabase.com/blog/to-avoid-tariffs-uk-agrees-to-trumps-demand-to-pay-more-for-drugs 2025-12-03T09:10:08 https://maestrodatabase.com/blog/valeo-pharma-secures-additional-public-reimbursement-for-redesca-enerzair-breezhaler-and-atectura-breezhaler 2022-03-22T19:41:08 https://maestrodatabase.com/blog/doctors-break-rules-for-prescribing-safe-sex-drug-as-pharmac-considers-change 2022-03-22T10:52:30 https://maestrodatabase.com/blog/sandoz-receives-european-commission-approval-for-wyost-and-jubbonti-the-first-and-only-biosimilars-of-denosumab-in-europe 2024-05-22T05:01:37 https://maestrodatabase.com/blog/high-us-drug-prices-have-global-implications 2022-03-22T19:46:42 https://maestrodatabase.com/blog/ema-responds-to-bmj-article-questioning-benefits-of-recent-cancer-drug-approvals 2017-10-14T03:52:56 https://maestrodatabase.com/blog/hope-for-quadriplegics-as-miracle-treatment-gets-green-light-from-regulator 2022-03-22T10:49:09 https://maestrodatabase.com/blog/nearly-one-third-of-new-drugs-are-no-better-than-older-drugs-and-some-are-worse 2017-10-14T04:16:28 https://maestrodatabase.com/blog/paying-for-prescription-drugs-around-the-world-why-is-the-u-dot-s-an-outlier 2017-10-14T04:04:33 https://maestrodatabase.com/blog/pharmacy-benefit-managers-are-the-wrong-target-in-bidens-quest-to-reduce-drug-prices 2022-03-22T19:49:39 https://maestrodatabase.com/blog/prescription-medicines-new-or-extended-uses-or-new-combinations-of-registered-medicines-february-2022 2022-03-22T20:01:40 https://maestrodatabase.com/blog/u-dot-s-senate-to-vote-this-spring-on-lowering-insulin-prices---senator-schumer 2022-03-22T20:34:33 https://maestrodatabase.com/blog/omeros-corporation-receives-decision-from-fda-on-formal-dispute-resolution-request-for-narsoplimab 2022-11-08T20:44:35 https://maestrodatabase.com/blog/nice-final-draft-guidance-adds-further-treatment-option-for-triple-negative-breast-cancer 2022-11-08T14:56:10 https://maestrodatabase.com/blog/janssen-korea-to-cease-supply-of-anti-fungal-drug-sporanox 2024-05-22T10:02:55 https://maestrodatabase.com/blog/supporting-innovative-medicines-funding-in-scotland 2020-01-22T06:26:05 https://maestrodatabase.com/blog/parents-demanding-pharmac-funding-boost-unleash-on-politicians-at-parliament-steps 2020-01-22T05:57:00 https://maestrodatabase.com/blog/fda-grants-traditional-approval-to-pirtobrutinib-for-chronic-lymphocytic-leukaemia-and-small-lymphocytic-lymphoma 2025-12-03T19:56:59 https://maestrodatabase.com/blog/amazon-just-filed-a-bunch-of-international-trademarks-for-amazon-pharmacy 2020-01-22T05:54:23 https://maestrodatabase.com/blog/guard-therapeutics-granted-fda-fast-track-designation-for-rmc-035 2022-11-08T21:26:12 https://maestrodatabase.com/blog/libtayo-cemiplimab-rwlc-in-combination-with-chemotherapy-approved-by-the-fda-as-first-line-treatment-for-advanced-non-small-cell-lung-cancer 2022-11-08T21:45:42 https://maestrodatabase.com/blog/new-covid-19-variant-leads-to-increase-in-cases 2022-11-08T21:07:48 https://maestrodatabase.com/blog/blue-earth-therapeutics-awarded-uk-mhra-innovation-passport-for-investigational-177lu-rhpsma-10-dot-1-for-treatment-of-metastatic-castrate-resistant-prostate-cancer 2022-11-08T21:11:33 https://maestrodatabase.com/blog/roche-granted-fda-breakthrough-device-designation-for-blood-test-measuring-lp-a---a-key-marker-for-hereditary-cardiovascular-risk 2024-05-22T23:32:27 https://maestrodatabase.com/blog/immunomic-therapeutics-receives-fda-fast-track-designation-for-iti-3000-a-pdna-vaccine-in-development-for-the-treatment-of-merkel-cell-carcinoma 2022-11-08T20:51:18 https://maestrodatabase.com/blog/ema-to-start-the-review-of-the-marketing-authorisation-applications-for-encorafenib-and-binimetinib-for-the-treatment-of-braf-mutant-advanced-melanoma 2017-10-14T20:38:05 https://maestrodatabase.com/blog/after-falling-under-obama-americas-uninsured-rate-looks-to-be-rising 2019-01-26T22:06:12 https://maestrodatabase.com/blog/sage-therapeutics-announces-fda-acceptance-of-nda-filing-and-grant-of-priority-review-for-brexanolone-iv-in-the-treatment-of-post-partum-depression 2018-05-31T05:47:14 https://maestrodatabase.com/blog/nice-rejects-janssens-stelara-on-cost-efficiency-grounds 2020-01-22T11:18:55 https://maestrodatabase.com/blog/dusc-utilisation-analysis-public-release-documents-june-2025 2025-12-03T21:00:25 https://maestrodatabase.com/blog/fda-accepts-evoke-pharmas-nda-resubmission-for-gimoti 2020-01-22T11:23:30 https://maestrodatabase.com/blog/u-dot-s-fda-designates-for-priority-review-eisais-supplemental-new-drug-application-for-anti-epiletic-drug-fycompa-as-treatment-for-paediatric-patients-with-epilepsy 2018-05-31T05:59:53 https://maestrodatabase.com/blog/medexus-announces-fda-approval-of-grapafex-treosulphan-for-injection 2025-01-23T01:44:17 https://maestrodatabase.com/blog/janssen-announces-u-dot-s-fda-approval-of-stelara-ustekinumab-for-the-treatment-of-adolescents-with-moderate-to-severe-plaque-psoriasis 2017-10-14T21:09:10 https://maestrodatabase.com/blog/decision-to-remove-restrictions-from-and-award-a-tender-to-candesartan-cilexetil 2018-05-31T06:08:03 https://maestrodatabase.com/blog/nhs-patients-denied-new-lung-cancer-drug-after-another-nice-deadlock 2020-01-22T19:10:27 https://maestrodatabase.com/blog/prometic-announces-fda-acceptance-of-its-biologics-license-application-for-plasminogen-ryplazim 2017-10-14T21:30:53 https://maestrodatabase.com/blog/health-canada-releases-what-we-heard-report-from-the-public-engagement-on-the-national-strategy-for-drugs-for-rare-diseases 2021-07-27T06:57:31 https://maestrodatabase.com/blog/eu-group-calls-for-targeted-actions-to-mitigate-impact-of-brexit 2020-01-22T11:41:11 https://maestrodatabase.com/blog/fda-approves-keytruda-pembrolizumab-for-treatment-of-patients-with-high-risk-early-stage-triple-negative-breast-cancer-in-combination-with-chemotherapy-as-neo-adjuvant-treatment-then-continued-as-single-agent-as-adjuvant-treatment-after-surgery 2021-07-27T10:46:21 https://maestrodatabase.com/blog/the-fda-continues-to-struggle-with-the-implications-of-approving-sareptas-drugs 2020-01-22T19:25:54 https://maestrodatabase.com/blog/competition-not-capping-increases-is-the-cure-for-high-drug-prices 2020-01-22T19:20:38 https://maestrodatabase.com/blog/study-high-concordance-in-breakthrough-therapy-prime-decisions 2022-11-09T06:11:55 https://maestrodatabase.com/blog/supreme-court-refuses-to-fast-track-a-challenge-to-the-affordable-care-act 2020-01-22T19:18:31 https://maestrodatabase.com/blog/mitsubishi-tanabe-pharma-canada-announces-canadian-authorisation-of-radicava-edarvarone-oral-suspension-for-the-treatment-of-patients-with-als 2022-11-09T06:04:28 https://maestrodatabase.com/blog/merck-strengthens-gonal-f-portfolio-with-approval-for-150-iu-pen-in-the-european-union 2020-01-22T19:14:26 https://maestrodatabase.com/blog/medicago-philip-morris-and-health-canada-a-predictable-and-avoidable-fiasco 2022-03-23T03:38:31 https://maestrodatabase.com/blog/supernus-announces-fda-acceptance-for-review-of-new-drug-application-for-spn-812-for-the-treatment-of-adhd 2020-01-22T19:36:09 https://maestrodatabase.com/blog/3-dollars-3-cents-million-to-support-australians-living-with-a-rare-disease 2021-07-27T20:56:59 https://maestrodatabase.com/blog/court-of-justice-upholds-emas-approach-to-transparency 2020-01-22T19:31:32 https://maestrodatabase.com/blog/sol-gel-technologies-announces-fda-approval-of-twyneo 2021-07-27T20:51:53 https://maestrodatabase.com/blog/j-and-j-and-pfizer-quietly-resolve-remicade-biosimilar-lawsuit 2021-07-27T21:22:54 https://maestrodatabase.com/blog/hospital-costs-not-drug-prices-are-the-real-us-health-care-scandal 2021-07-27T21:02:17 https://maestrodatabase.com/blog/reimbursement-for-repatha-to-expand-treatment-options-for-ascvd-patients 2020-01-22T20:12:01 https://maestrodatabase.com/blog/day-one-receives-fda-rare-paediatric-disease-designation-for-day101-for-the-treatment-of-paediatric-low-grade-glioma 2021-07-27T12:18:21 https://maestrodatabase.com/blog/roche-wins-approval-for-cancer-drug-kadcyla-in-fast-growing-china-market 2020-01-22T20:07:45 https://maestrodatabase.com/blog/how-biogen-found-a-believer-at-the-fda-a-hard-nosed-regulator-was-won-over-on-controversial-alzheimers-drug 2021-07-27T20:48:22 https://maestrodatabase.com/blog/instrumental-variables-and-heterogeneous-treatment-effects 2022-03-23T03:03:41 https://maestrodatabase.com/blog/morneau-says-ottawa-will-need-to-work-with-provinces-on-issues-like-universal-pharmacare 2020-01-22T20:03:57 https://maestrodatabase.com/blog/australians-with-cancer-infants-with-epilepsy-to-benefit-from-pbs-listings 2020-08-01T09:39:06 https://maestrodatabase.com/blog/fda-approves-monjuvi-tafasitamab-cxix-in-combination-with-lenalidomide-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma 2020-08-01T10:06:08 https://maestrodatabase.com/blog/morphosys-and-incyte-announce-swissmedic-temporary-approval-of-minjuvi-tafasitamab-in-combination-with-lenalidomide-for-the-treatment-of-adults-with-r-slash-r-dlbcl 2022-03-23T04:57:26 https://maestrodatabase.com/blog/orphazyme-announces-withdrawal-of-european-marketing-authorisation-application-for-arimoclomol-for-the-treatment-of-niemann-pick-disease-type-c 2022-03-23T07:21:51 https://maestrodatabase.com/blog/stemcyte-has-submitted-its-application-for-a-biologics-license-for-its-allogeneic-umbilical-cord-haematopoietic-progenitor-cell-product-hpc-cord-blood-to-the-us-fda 2022-03-23T05:29:54 https://maestrodatabase.com/blog/the-biggest-pbms-are-handling-more-and-more-of-the-countrys-drug-price-negotiations 2022-03-23T09:25:16 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-august-2020 2020-08-01T10:27:10 https://maestrodatabase.com/blog/fda-approves-symproic-naldemedine-once-daily-tablets-c-ii-for-the-treatment-of-opioid-induced-constipation-in-adults-with-chronic-non-cancer-pain 2017-03-25T07:51:42 https://maestrodatabase.com/blog/pharmacs-role-in-the-response-to-covid-19 2022-03-23T05:15:50 https://maestrodatabase.com/blog/acerus-receives-notice-of-deficiency-withdrawal-letter-from-health-canada-regarding-gynoflor-application 2019-01-26T23:31:00 https://maestrodatabase.com/blog/european-medicines-agencys-chmp-recommends-approval-of-mercks-keytruda-pembrolizumab-for-the-treatment-of-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma 2017-03-25T08:01:50 https://maestrodatabase.com/blog/incannex-granted-fda-fast-track-designation-for-ihl-42x-in-obstructive-sleep-apnea 2025-12-04T03:56:08 https://maestrodatabase.com/blog/south-korea-approves-second-covid-19-pill-lagevrio 2022-03-23T20:13:35 https://maestrodatabase.com/blog/aleta-biotherapeutics-receives-innovation-passport-designation-for-biologic-car-t-cell-therapy-engager-aleta-001 2022-11-10T06:34:42 https://maestrodatabase.com/blog/acceptability-of-manufacturer-proposed-utility-values-for-nice-cancer-medicine-appraisals-analysis-of-manufacturers-information-sources 2022-03-23T20:04:27 https://maestrodatabase.com/blog/almirall-and-sun-pharma-announce-regulatory-filing-of-tildrakizumab-in-europe 2017-03-25T08:09:00 https://maestrodatabase.com/blog/moderna-has-initiated-a-submission-to-the-fda-for-emergency-use-authorization-of-mrna-1273-in-children-6-to-under-12-years-of-age 2022-03-23T19:48:48 https://maestrodatabase.com/blog/government-opts-for-additional-consultation-on-national-medicines-policy-review 2022-03-23T19:45:02 https://maestrodatabase.com/blog/fda-approves-new-indication-for-drug-containing-an-active-ingredient-derived-from-cannabis-to-treat-seizures-in-rare-genetic-disease 2020-08-01T22:00:45 https://maestrodatabase.com/blog/pfizer-announces-availability-of-abrysvo-in-canada-for-immunisation-of-pregnant-individuals-and-adults-60-plus 2024-05-23T02:18:58 https://maestrodatabase.com/blog/novartis-pluvicto-approved-by-fda-as-first-targeted-radioligand-therapy-for-treatment-of-progressive-psma-positive-metastatic-castration-resistant-prostate-cancer 2022-03-23T20:33:36 https://maestrodatabase.com/blog/symbiomix-therapeutics-announces-fdas-acceptance-of-new-drug-application-for-solosec-with-priority-review-status 2017-03-25T22:04:52 https://maestrodatabase.com/blog/health-funds-plot-to-dump-cover-for-breast-cancer-from-most-policies 2018-05-31T21:01:32 https://maestrodatabase.com/blog/health-canada-approves-cosentyx-a-biologic-therapy-for-the-treatment-of-adults-with-moderate-to-severe-hidradenitis-suppurativa 2024-05-23T02:00:41 https://maestrodatabase.com/blog/scilex-announces-that-the-us-fda-has-acknowledged-the-submission-of-our-supplemental-new-drug-application-for-elyxyb-in-acute-pain-indication 2025-01-23T03:37:29 https://maestrodatabase.com/blog/statement-from-fda-commissioner-on-new-policies-to-reduce-the-ability-of-brand-drug-makers-to-use-rems-programs-as-a-way-to-block-timely-generic-drug-entry-helping-promote-competition-and-access 2018-05-31T21:07:09 https://maestrodatabase.com/blog/pfizers-xalkori-makes-it-onto-cancer-drugs-fund 2018-05-31T11:32:51 https://maestrodatabase.com/blog/trump-says-drug-companies-to-unveil-price-cuts-in-two-weeks 2018-05-31T21:22:50 https://maestrodatabase.com/blog/health-insurance-reform-passes-lower-house 2018-05-31T21:30:54 https://maestrodatabase.com/blog/high-risk-early-breast-cancer-patients-in-quebec-left-behind-by-recent-inesss-recommendation 2025-12-04T04:55:09 https://maestrodatabase.com/blog/nhs-cancer-nurse-who-crowdfunded-her-own-cancer-drug-treatment-thanks-donors-for-extending-her-life 2018-05-31T21:16:13 https://maestrodatabase.com/blog/cartesian-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-designation-for-descartes-08-for-the-treatment-of-myasthenia-gravis 2024-05-23T02:41:04 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-june-2018 2018-05-31T21:33:17 https://maestrodatabase.com/blog/pmprb-report-examines-availability-and-pricing-of-new-medicines 2024-05-23T02:31:34 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-june-2018-update 2018-05-31T21:38:16 https://maestrodatabase.com/blog/msac-cant-find-a-place-for-carvykti 2022-11-10T11:41:54 https://maestrodatabase.com/blog/rfp---supply-of-rituximab 2019-07-16T02:08:59 https://maestrodatabase.com/blog/decision-to-fund-vedolizumab-for-inflammatory-bowel-disease-and-brentuximab-for-rare-lymphomas 2022-11-10T11:53:34 https://maestrodatabase.com/blog/irish-cystic-fibrosis-family-face-eu12-400-bill-after-deportation-victory-in-australia 2019-07-16T02:04:51 https://maestrodatabase.com/blog/cota-announces-extended-collaboration-with-fda-to-advance-the-use-of-real-world-data-in-cancer-research 2024-05-23T03:03:26 https://maestrodatabase.com/blog/private-health-insurance-industry-must-pass-on-savings 2017-10-15T04:49:29 https://maestrodatabase.com/blog/vadadustat-for-the-treatment-of-adults-with-symptomatic-anaemia-on-dialysis-for-chronic-kidney-disease 2025-01-23T09:56:52 https://maestrodatabase.com/blog/icer-finds-price-of-erenumab-aligns-with-clinical-benefit-in-patients-for-whom-other-therapies-have-failed-to-prevent-migraines 2018-05-31T23:20:54 https://maestrodatabase.com/blog/advancing-access-to-cell-and-gene-therapies-in-medicaid 2024-05-23T03:25:53 https://maestrodatabase.com/blog/medical-device-industry-signs-historic-agreement-to-reduce-health-funds-premiums 2017-10-15T04:51:52 https://maestrodatabase.com/blog/pharmac-commits-to-being-more-transparent 2021-07-28T01:29:58 https://maestrodatabase.com/blog/mhra-extends-cosentyx-licence-for-paediatric-arthritis 2022-11-10T12:36:30 https://maestrodatabase.com/blog/lyndra-therapeutics-investigational-oral-weekly-opioid-use-disorder-treatment-lyn-014-granted-fast-track-designation-by-fda 2021-07-28T00:06:20 https://maestrodatabase.com/blog/pre-filled-syringe-presentation-of-byooviz-samsung-bioepis-biosimilar-to-lucentis-ranibizumab-gains-european-approval 2025-12-04T07:25:15 https://maestrodatabase.com/blog/agenda-for-the-november-2021-pbac-meeting 2021-07-28T04:45:30 https://maestrodatabase.com/blog/biolinerx-announces-us-fda-acceptance-of-new-drug-application-for-aphexda-motixafortide-in-stem-cell-mobilisation 2022-11-10T13:13:21 https://maestrodatabase.com/blog/advisory-panel-to-develop-a-framework-for-a-pan-canadian-prescription-drug-list 2021-07-28T02:22:09 https://maestrodatabase.com/blog/rare-cancer-drug-added-to-pbs 2017-03-26T05:36:19 https://maestrodatabase.com/blog/setmelanotide-acetate-for-the-treatment-of-patients-with-obesity-and-hyperphagia-in-bardet-biedl-syndrome-final-guidance 2024-05-23T03:39:14 https://maestrodatabase.com/blog/fda-and-ema-accept-applications-for-higher-dose-regimen-of-nusinersen-in-spinal-muscular-atrophy 2025-01-23T21:17:57 https://maestrodatabase.com/blog/jazz-pharmaceuticals-submits-new-drug-application-for-jzp-258-for-cataplexy-and-excessive-daytime-sleepiness-associated-with-narcolepsy 2020-01-23T02:27:26 https://maestrodatabase.com/blog/decision-to-fund-long-acting-paliperidone-for-people-with-schizophrenia-and-ibrutinib-for-people-with-chronic-lymphocytic-leukaemia 2022-11-10T14:24:46 https://maestrodatabase.com/blog/historical-archive-of-the-schedule-of-pharmaceutical-benefits-1951-2002 2024-05-23T06:45:33 https://maestrodatabase.com/blog/fda-accepts-file-and-accelerates-review-of-novartis-sickle-cell-disease-medicine-crizanlizumab 2019-07-16T05:54:41 https://maestrodatabase.com/blog/eu-hta-maintaining-the-achievements-of-amnog 2025-01-23T22:27:51 https://maestrodatabase.com/blog/federal-government-announce-1100-medicines-to-have-prices-cut-including-rosuvastatin 2017-03-26T21:10:43 https://maestrodatabase.com/blog/stealth-biotherapeutics-announces-pdufa-action-date-extension-for-elamipretide-to-treat-patients-with-barth-syndrome 2025-01-23T23:10:01 https://maestrodatabase.com/blog/mood-disorders-society-of-canada-urges-action-on-improving-canadians-access-to-life-saving-medications 2017-03-26T21:42:39 https://maestrodatabase.com/blog/jiangsu-to-reapply-for-us-approval-of-rivoceranib-combo-therapy-asap 2024-05-23T21:15:36 https://maestrodatabase.com/blog/icer-announces-new-annual-launch-price-and-access-report-for-2025 2025-01-23T23:06:58 https://maestrodatabase.com/blog/theriva-biologics-announces-fast-track-designation-granted-by-the-us-fda-for-vcn-01-for-the-treatment-of-metastatic-pancreatic-cancer 2024-05-23T21:01:16 https://maestrodatabase.com/blog/tanvex-submits-new-drug-submission-for-tx01-to-health-canada 2019-01-27T00:46:37 https://maestrodatabase.com/blog/an-innovation-surcharge-to-fund-the-repurposing-of-generic-drugs 2022-12-07T04:59:30 https://maestrodatabase.com/blog/more-states-to-expand-medicaid-now-that-obamacare-remains-law 2017-03-26T22:49:08 https://maestrodatabase.com/blog/fda-approves-tremelimumab-in-combination-with-durvalumab-and-platinum-based-chemotherapy-for-metastatic-non-small-cell-lung-cancer 2022-11-15T01:52:39 https://maestrodatabase.com/blog/seagen-announces-us-fda-approval-of-new-indication-for-adcetris-brentuximab-vedotin-for-children-with-previously-untreated-high-risk-hodgkins-lymphoma 2022-11-10T21:38:50 https://maestrodatabase.com/blog/first-he-blamed-them-now-president-trump-wants-democrats-support-for-health-care-reform 2017-03-26T22:52:48 https://maestrodatabase.com/blog/sick-of-high-drug-prices-insurers-join-hospitals-to-make-their-own-generic-medications 2020-01-23T10:52:39 https://maestrodatabase.com/blog/brainstorm-cell-therapeutics-receives-refusal-to-file-letter-from-fda-for-its-new-biologics-license-application-for-nurown-for-the-treatment-of-als 2022-11-10T21:33:39 https://maestrodatabase.com/blog/caladrius-biosciences-receives-advanced-therapy-medicinal-product-classification-for-clbs12-its-cd34-plus-cell-therapy-for-critical-limb-ischaemia 2019-07-16T06:18:43 https://maestrodatabase.com/blog/update-of-the-frequently-asked-questions-for-the-pbs-botulinum-toxin-program 2020-01-23T04:33:35 https://maestrodatabase.com/blog/new-regulation-limiting-generic-drugs-will-change-industrial-paradigm 2021-07-28T10:34:38 https://maestrodatabase.com/blog/federal-court-of-australia-dismisses-preliminary-discovery-application-regarding-biosimilar-suspected-of-infringing-manufacturing-process-patents 2017-03-26T23:04:47 https://maestrodatabase.com/blog/gilead-and-novartis-seek-to-expand-what-fda-considers-as-real-world-data-and-real-world-evidence 2019-07-16T06:14:58 https://maestrodatabase.com/blog/fda-says-its-working-as-quickly-as-possible-to-review-for-full-approval-of-vaccines 2021-07-28T10:15:37 https://maestrodatabase.com/blog/want-to-know-how-contentious-drug-pricing-is-in-washington-check-the-receipts 2020-01-23T19:56:36 https://maestrodatabase.com/blog/baudax-bio-announces-pdufa-date-for-intravenous-meloxicam 2020-01-23T11:01:48 https://maestrodatabase.com/blog/public-summary-documents-first-time-decisions-not-to-recommend-and-deferrals---july-2022-pbac-meeting 2022-11-11T06:00:42 https://maestrodatabase.com/blog/hunt-denies-helping-liberal-donor-push-for-regulators-review 2020-01-23T10:56:52 https://maestrodatabase.com/blog/health-canada-approves-camzyos-mavacamten-for-the-treatment-of-adults-with-symptomatic-obstructive-hypertrophic-cardiomyopathy 2022-11-11T05:56:46 https://maestrodatabase.com/blog/dicerna-receives-breakthrough-therapy-designation-for-dcr-phxc-for-treatment-of-primary-hyperoxaluria-type-1 2019-07-16T06:25:26 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-august-2020 2020-08-02T01:33:44 https://maestrodatabase.com/blog/woman-denied-cancer-drug-on-nhs-which-could-extend-her-life-because-of-where-she-lives 2020-01-23T20:20:14 https://maestrodatabase.com/blog/pharmac-protest-ride-from-dunedin-ends-with-conflict-in-parliament 2020-01-23T20:16:23 https://maestrodatabase.com/blog/sanders-will-absolutely-work-with-trump-to-lower-prescription-drug-costs 2017-03-27T19:58:18 https://maestrodatabase.com/blog/the-intricacies-of-rising-drug-prices-in-the-us 2020-01-23T20:01:25 https://maestrodatabase.com/blog/lung-cancer-drug-subsidy-will-make-big-difference-for-patients 2020-12-20T19:42:05 https://maestrodatabase.com/blog/re-thinking-the-different-perspectives-that-can-be-used-when-eliciting-preferences-in-health 2017-03-27T02:08:26 https://maestrodatabase.com/blog/olaparib-for-adjuvant-treatment-of-patients-with-high-risk-her2-negative-brca-positive-early-breast-cancer-after-chemotherapy 2022-11-10T21:54:59 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-24-march-2022 2022-03-24T04:25:12 https://maestrodatabase.com/blog/cadth-recommends-tevas-cinqair 2017-03-27T20:08:40 https://maestrodatabase.com/blog/fda-approves-lisocabtagene-maraleucel-for-relapsed-or-refractory-marginal-zone-lymphoma 2025-12-04T22:35:40 https://maestrodatabase.com/blog/fewer-australians-are-taking-up-health-insurance-each-year-new-data-shows 2017-03-27T20:23:36 https://maestrodatabase.com/blog/health-technology-assessment-around-the-world-broadening-the-understanding-of-cross-country-differences 2020-01-23T20:28:22 https://maestrodatabase.com/blog/pfizer-chief-says-government-efforts-to-contain-drug-prices-will-backfire 2017-03-27T20:25:59 https://maestrodatabase.com/blog/more-than-obamacare-repeal-small-businesses-want-congress-to-rein-in-costs 2017-03-27T20:34:01 https://maestrodatabase.com/blog/implementation-of-the-patented-medicine-prices-review-boards-proposed-guidelines-will-harm-canadian-patients 2022-11-11T06:04:11 https://maestrodatabase.com/blog/gop-retreat-on-healthcare-rekindles-fire-in-democrats 2017-03-27T20:30:45 https://maestrodatabase.com/blog/akari-therapeutics-granted-fda-rare-paediatric-disease-designation-of-nomacopan-for-the-treatment-of-paediatric-hsct-tma 2022-11-11T06:08:11 https://maestrodatabase.com/blog/cadth-launches-consultation-on-real-world-evidence-reporting-guidance 2022-11-11T06:51:00 https://maestrodatabase.com/blog/sanofi-and-gsks-next-generation-covid-19-booster-vaccine-vidprevtyn-beta-approved-by-the-european-commission 2022-11-11T14:22:32 https://maestrodatabase.com/blog/fda-approves-isopsa---cleveland-diagnostics-novel-blood-based-prostate-cancer-test 2025-12-04T21:56:47 https://maestrodatabase.com/blog/new-budget-test-puts-uk-on-front-line-in-global-drug-price-fight 2017-03-27T20:43:46 https://maestrodatabase.com/blog/fda-approves-maintenance-treatment-for-recurrent-epithelial-ovarian-fallopian-tube-or-primary-peritoneal-cancers 2017-03-28T02:49:00 https://maestrodatabase.com/blog/should-we-pay-more-to-treat-rare-diseases 2017-03-27T20:47:15 https://maestrodatabase.com/blog/chmp-issues-opinion-related-to-review-of-medicines-within-the-janus-kinase-inhibitor-class 2022-11-11T14:53:36 https://maestrodatabase.com/blog/hope-medicines-hmi-115-received-us-fda-fast-track-designation-accelerating-global-development 2025-12-04T23:34:16 https://maestrodatabase.com/blog/swiss-to-start-pfizer-covid-19-vaccine-jabs-after-watchdogs-ok 2020-12-20T21:52:54 https://maestrodatabase.com/blog/public-summary-documents---september-2022-pbac-meeting 2023-01-13T05:16:10 https://maestrodatabase.com/blog/post-market-review-of-the-use-of-biologics-in-the-treatment-of-severe-chronic-plaque-psoriasis---public-consultation-process 2017-06-09T06:00:12 https://maestrodatabase.com/blog/fda-grants-priority-review-for-eagle-pharmaceuticals-ryanodex-nda-for-the-treatment-of-exertional-heat-stroke 2017-03-28T06:57:57 https://maestrodatabase.com/blog/dupixent-dupilumab-recommended-for-eu-approval-by-the-chmp-for-the-treatment-of-prurigo-nodularis 2022-11-11T14:44:47 https://maestrodatabase.com/blog/surging-drug-prices-poised-to-become-hot-button-issue-in-2020-race 2019-01-27T01:30:34 https://maestrodatabase.com/blog/antengenes-xpovio-moves-close-to-getting-insurance-benefits 2024-05-23T23:31:18 https://maestrodatabase.com/blog/cannabidiol-for-the-treatment-of-patients-with-seizures-caused-by-tuberous-sclerosis-complex 2022-11-11T14:28:22 https://maestrodatabase.com/blog/lilly-announces-complete-response-letter-for-sintilimab-in-combination-with-pemetrexed-and-platinum-chemotherapy-for-the-first-line-treatment-of-people-with-non-squamous-non-small-cell-lung-cancer 2022-03-24T11:59:10 https://maestrodatabase.com/blog/xeljanz-tofacitinib-citrate-receives-marketing-authorisation-in-the-european-union-for-the-treatment-of-moderate-to-severe-active-rheumatoid-arthritis 2017-03-28T07:07:50 https://maestrodatabase.com/blog/eqrx-no-longer-seeks-to-disrupt-prices-in-non-small-cell-lung-cancer-space 2022-11-11T15:21:33 https://maestrodatabase.com/blog/aia-nz-shakes-up-nzs-insurance-market-with-bolt-on-cancer-product 2017-03-28T07:17:12 https://maestrodatabase.com/blog/australias-tga-approves-registration-of-csls-andembry-garadacimab-for-the-prevention-of-recurrent-hereditary-angioedema-attacks 2025-01-24T05:21:29 https://maestrodatabase.com/blog/nice-says-pancreatic-cancer-drug-is-not-cost-effective-for-routine-nhs-use 2017-03-28T11:14:36 https://maestrodatabase.com/blog/tga-approves-new-medicine-for-patients-with-multiple-sclerosis 2022-03-24T08:04:19 https://maestrodatabase.com/blog/amneal-announces-us-fda-filing-acceptance-of-new-drug-application-for-ipx203-for-the-treatment-of-parkinsons-disease 2022-11-11T15:07:15 https://maestrodatabase.com/blog/emerging-technology-which-aims-to-improve-muscle-movement-is-nices-100th-medtech-innovation-briefing 2017-03-28T11:12:22 https://maestrodatabase.com/blog/meeting-highlights-from-the-7-10-november-2022-chmp-meeting 2022-11-11T14:59:53 https://maestrodatabase.com/blog/in-health-bills-defeat-medicaid-comes-of-age 2017-03-28T11:28:43 https://maestrodatabase.com/blog/moderna-finalises-strategic-partnership-with-australian-government 2022-03-24T11:49:26 https://maestrodatabase.com/blog/pushing-obamacare-over-the-cliff 2017-03-28T11:19:36 https://maestrodatabase.com/blog/new-data-on-drug-approvals-and-reimbursement-recommendations-in-canada 2025-12-05T00:28:05 https://maestrodatabase.com/blog/mycovia-pharmaceuticals-announces-u-dot-s-fda-acceptance-and-priority-review-of-new-drug-application-for-oteseconazole-for-the-treatment-of-recurrent-vulvovaginal-candidiasis 2021-07-28T20:57:22 https://maestrodatabase.com/blog/most-canadians-get-timely-medical-treatment-report 2017-03-28T11:32:54 https://maestrodatabase.com/blog/hikma-launches-generic-advair-diskus-following-fda-approval 2020-12-20T22:24:03 https://maestrodatabase.com/blog/u-dot-s-fda-approves-streamlined-process-for-initiating-hiv-therapy-with-cabenuva-cabotegravir-and-rilpivirine-the-first-and-only-complete-long-acting-injectable-hiv-treatment 2022-03-24T19:52:26 https://maestrodatabase.com/blog/u-dot-s-fda-grants-breakthrough-therapy-designation-to-takedas-investigational-compound-tak-994-an-oral-orexin-agonist-in-clinical-development-for-narcolepsy-type-1 2021-07-28T21:02:18 https://maestrodatabase.com/blog/nivolumab-with-ipilimumab-for-untreated-advanced-renal-cell-carcinoma 2022-03-24T20:01:54 https://maestrodatabase.com/blog/fda-approves-new-eczema-drug-dupixent 2017-03-28T19:57:21 https://maestrodatabase.com/blog/fresenius-kabi-announces-fda-approval-of-smoflipid-lipid-injectable-emulsion-for-paediatric-patients-requiring-parenteral-nutrition 2022-03-24T19:57:12 https://maestrodatabase.com/blog/severe-eczema-drug-is-approved-by-fda-price-tag-is-37-000-dollars-a-year 2017-03-28T20:13:16 https://maestrodatabase.com/blog/fda-to-lower-number-of-trials-required-for-approval-of-drugs-other-medical-products 2025-12-05T01:50:26 https://maestrodatabase.com/blog/tesaro-wont-reveal-price-of-ovarian-cancer-drug-but-itll-likely-be-near-14-000-dollars-a-month 2017-03-28T20:19:19 https://maestrodatabase.com/blog/pfizer-and-biontech-receive-positive-chmp-opinion-for-omicron-ba-dot-4-slash-ba-dot-5-adapted-bivalent-covid-19-vaccine-booster-for-children-5-through-11-years-of-age-in-european-union 2022-11-11T15:43:33 https://maestrodatabase.com/blog/apic-bio-receives-fda-fast-track-designation-for-apb-102-for-the-treatment-of-patients-with-sod1-als 2021-07-28T12:42:42 https://maestrodatabase.com/blog/pfizer-granted-fda-breakthrough-therapy-designation-for-respiratory-syncytial-virus-vaccine-candidate-for-the-prevention-of-rsv-in-older-adults 2022-03-24T19:46:28 https://maestrodatabase.com/blog/roche-withdraws-submission-for-avastin 2017-03-28T20:31:28 https://maestrodatabase.com/blog/despite-competition-u-dot-s-cancer-drug-prices-rose-even-as-they-fell-in-germany-and-switzerland 2022-03-24T20:24:23 https://maestrodatabase.com/blog/controversy-and-progress-in-alzheimers-disease----fda-approval-of-aducanumab 2021-07-28T21:35:41 https://maestrodatabase.com/blog/revisiting-fda-approval-of-aducanumab 2021-07-28T21:32:19 https://maestrodatabase.com/blog/systematic-reviews-of-economic-evaluations-how-extensive-are-their-searches 2017-03-28T20:36:49 https://maestrodatabase.com/blog/priorities-for-nice-in-health-and-social-care 2022-03-24T20:27:16 https://maestrodatabase.com/blog/lecanemab-in-early-alzheimers-disease-previously-unpublished-data-show-no-additional-benefit 2025-12-05T00:03:41 https://maestrodatabase.com/blog/rick-scott-phrma-hasnt-provided-a-single-answer-on-lower-drug-prices 2019-07-16T12:00:20 https://maestrodatabase.com/blog/pharmac-releases-drug-wish-list-to-be-more-transparent-but-advocates-say-it-gives-false-hope 2021-07-28T21:09:27 https://maestrodatabase.com/blog/evusheld-long-acting-antibody-combination-recommended-for-approval-in-the-eu-for-the-pre-exposure-prophylaxis-of-covid-19 2022-03-24T20:12:53 https://maestrodatabase.com/blog/celltrion-announces-us-fda-approval-of-300-mg-strength-of-omyclo-omalizumab-igec-the-first-and-only-fda-approved-interchangeable-biosimilar-to-xolair 2025-12-05T00:11:01 https://maestrodatabase.com/blog/german-federal-joint-committee-g-ba-confirms-additional-benefit-of-anti-cancer-agent-kisplyx-lenvatinib-mesylate-in-treatment-of-advanced-renal-cell-carcinoma 2017-03-29T04:56:46 https://maestrodatabase.com/blog/abbotts-freestyle-libre-is-first-and-only-cgm-system-to-gain-expanded-reimbursement-in-japan-to-include-all-people-with-diabetes-who-use-insulin 2022-03-24T20:20:00 https://maestrodatabase.com/blog/cheaper-multiple-sclerosis-and-rare-cancer-medicines-now-on-pbs 2025-12-05T00:20:20 https://maestrodatabase.com/blog/national-health-amendment-pharmaceutical-benefits-act-2017 2017-03-29T03:24:38 https://maestrodatabase.com/blog/fda-approves-first-interchangeable-biosimilar-insulin-product-for-treatment-of-diabetes 2021-07-28T21:28:23 https://maestrodatabase.com/blog/astrazeneca-shares-progress-on-lynparza-olaparib-tablets-in-the-us 2017-03-29T05:08:48 https://maestrodatabase.com/blog/advocates-frustrated-over-pace-of-drug-price-reform 2019-07-16T13:09:38 https://maestrodatabase.com/blog/kamala-harris-wants-the-federal-government-to-set-the-price-of-some-drugs-to-lower-costs 2019-07-16T21:14:23 https://maestrodatabase.com/blog/why-isnt-insulin-a-complex-generic-pa-representative-asks-the-fda 2019-07-16T21:10:05 https://maestrodatabase.com/blog/pressured-by-patients-fda-reviews-als-drug-with-modest-data 2022-03-24T20:42:07 https://maestrodatabase.com/blog/seattle-genetics-and-astellas-announce-submission-of-biologics-license-application-to-fda-for-enfortumab-vedotin-for-patients-with-locally-advanced-or-metastatic-urothelial-cancer 2019-07-16T21:04:55 https://maestrodatabase.com/blog/price-increases-of-protected-class-drugs-in-medicare-part-d-relative-to-inflation-2012-2017 2019-07-16T21:26:47 https://maestrodatabase.com/blog/agenda-for-the-december-2025-pbac-meeting 2025-12-05T05:41:02 https://maestrodatabase.com/blog/national-regulator-denied-offer-to-give-canadian-physicians-training-on-abortion-pill 2019-07-16T21:22:16 https://maestrodatabase.com/blog/cempra-withdraws-solithromycin-marketing-authorisation-application-in-europe 2017-03-29T05:25:16 https://maestrodatabase.com/blog/drop-in-us-drug-approvals-but-no-similar-trend-in-the-eu 2017-03-29T05:32:59 https://maestrodatabase.com/blog/ask-whether-a-drug-works-before-worrying-about-what-it-costs 2019-07-16T21:18:39 https://maestrodatabase.com/blog/closure-of-the-post-market-review-of-the-use-of-biologics-in-the-treatment-of-severe-chronic-plaque-psoriasis 2020-12-21T00:17:57 https://maestrodatabase.com/blog/new-fast-acting-mealtime-insulin-fiasp-now-approved-and-available-in-canada-for-the-treatment-of-diabetes 2017-03-29T05:45:32 https://maestrodatabase.com/blog/nhs-england-to-issue-new-guidance-on-low-value-prescription-items 2017-03-29T06:49:41 https://maestrodatabase.com/blog/how-pharma-under-attack-from-all-sides-keeps-winning-in-washington 2019-07-16T21:37:04 https://maestrodatabase.com/blog/superannuation-raids-to-pay-for-fat-surgery 2019-07-16T21:29:53 https://maestrodatabase.com/blog/nsw-pharmacists-to-prescribe-the-pill-antibiotics-in-health-shake-up 2022-11-12T21:01:12 https://maestrodatabase.com/blog/fda-approves-roches-ocrevus-ocrelizumab-for-relapsing-and-primary-progressive-forms-of-multiple-sclerosis 2017-03-29T07:11:45 https://maestrodatabase.com/blog/charities-unite-to-oppose-nice-rare-disease-rules 2017-03-29T07:25:23 https://maestrodatabase.com/blog/curis-announces-fda-fast-track-designation-for-fimepinostat-cudc-907-development-in-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma 2018-06-01T06:53:03 https://maestrodatabase.com/blog/european-commission-approves-livtencity-maribavir-for-the-treatment-of-adults-with-post-transplant-cytomegalovirus-infection-and-slash-or-disease-that-are-refractory-with-or-without-resistance-to-one-or-more-prior-therapies 2022-11-12T20:48:24 https://maestrodatabase.com/blog/nektar-therapeutics-announces-submission-of-a-new-drug-application-to-the-u-dot-s-fda-for-nktr-181-a-first-in-class-investigational-opioid-to-treat-chronic-low-back-pain-in-adult-patients-new-to-opioid-therapy 2018-06-01T07:02:42 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac---april-2018 2018-06-01T07:12:25 https://maestrodatabase.com/blog/bausch-health-announces-additional-public-drug-plan-listings-for-uceris-budesonide-aerosol-foam-to-treat-mild-to-moderate-distal-ulcerative-colitis-in-adults 2024-05-24T02:55:47 https://maestrodatabase.com/blog/cancer-groups-want-to-stop-classifying-disease-by-the-body-part-it-grows-in 2017-10-16T02:16:18 https://maestrodatabase.com/blog/nice-terminates-another-appraisal-for-a-roche-medicine 2021-10-06T05:10:20 https://maestrodatabase.com/blog/$30m-damages-for-infringement-of-bayers-australian-yasmin-patent---a-small-jurisdiction-with-big-benefits 2017-03-29T19:56:35 https://maestrodatabase.com/blog/repeal-of-affordable-care-act-is-back-on-agenda-republicans-say 2017-03-29T08:39:45 https://maestrodatabase.com/blog/newly-approved-treatment-could-save-a-young-child-in-edmonton-with-a-rare-disease-it-costs-2-dot-8-million-dollars-per-dose 2020-12-21T01:16:40 https://maestrodatabase.com/blog/social-value-and-individual-choice-the-value-of-a-choice-based-decision-making-process-in-a-collectively-funded-health-system 2017-10-16T02:40:16 https://maestrodatabase.com/blog/the-eu-price-list-for-covid-19-vaccines-was-leaked-will-canada-release-its-prices 2020-12-21T01:20:34 https://maestrodatabase.com/blog/novartis-announces-first-car-t-cell-therapy-bla-for-paediatric-and-young-adult-patients-with-r-slash-r-b-cell-all-granted-fda-priority-review 2017-03-29T20:02:35 https://maestrodatabase.com/blog/camurus-receives-ema-acceptance-of-maa-filing-for-octreotide-sc-depot-cam2029-for-the-treatment-of-acromegaly 2024-05-24T03:44:05 https://maestrodatabase.com/blog/regenerons-new-drug-price-could-disappoint-everyone-heres-why-thats-a-good-thing 2017-03-29T20:16:19 https://maestrodatabase.com/blog/fda-clears-new-robotically-assisted-surgical-device-for-adult-patients 2017-10-16T02:44:24 https://maestrodatabase.com/blog/new-analysis-shows-using-icers-value-assessments-would-limit-access-to-life-saving-medicines-in-medicare-part-b 2018-06-01T07:30:58 https://maestrodatabase.com/blog/x4-pharmaceuticals-announces-ema-validation-of-marketing-authorisation-application-for-mavorixafor---licenced-to-norgine-for-commercialisation-in-europe 2025-01-25T05:59:17 https://maestrodatabase.com/blog/mylan-comments-on-generic-advair-diskus-abbreviated-new-drug-application 2017-03-29T20:22:46 https://maestrodatabase.com/blog/idelvion-newly-approved-3-500-iu-vial-to-provide-convenience-to-patients-using-larger-volumes 2018-06-01T07:35:49 https://maestrodatabase.com/blog/clarity-receives-us-fda-fast-track-designation-for-cu-64-sar-bispsma-in-biochemical-recurrence-of-prostate-cancer 2025-01-24T23:20:31 https://maestrodatabase.com/blog/leaked-trips-proposal-misguided-about-improving-global-covid-19-vaccination-rates 2022-03-24T23:23:19 https://maestrodatabase.com/blog/u-dot-s-fda-approves-supplemental-new-drug-application-for-takedas-iclusig-ponatinib-for-adult-patients-with-resistant-or-intolerant-chronic-phase-cml 2020-12-21T01:25:17 https://maestrodatabase.com/blog/trumps-nominee-to-lead-the-fda-got-paid-millions-by-the-health-care-industry 2017-03-29T21:11:34 https://maestrodatabase.com/blog/scott-gottlieb-and-the-credibility-of-u-dot-s-therapeutics 2017-03-30T00:51:07 https://maestrodatabase.com/blog/trump-is-slashing-fda-rules-why-isnt-big-pharma-excited 2017-03-30T01:03:36 https://maestrodatabase.com/blog/an-fda-commissioner-for-the-21st-century 2017-03-30T00:54:27 https://maestrodatabase.com/blog/health-canada-approves-expanded-indication-for-soliqua 2020-12-21T02:21:17 https://maestrodatabase.com/blog/garadacimab-andembry-approved-to-prevent-angioedema-attacks 2025-01-25T20:56:44 https://maestrodatabase.com/blog/eu-rapid-drug-approval-plan-worries-some-national-hta-agencies 2017-03-30T01:06:27 https://maestrodatabase.com/blog/updates-from-the-health-technology-assessment-policy-and-methods-review-reference-committee-august-2023 2023-08-14T02:59:20 https://maestrodatabase.com/blog/fda-officials-priority-review-drugs-have-higher-likelihood-of-getting-boxed-warning-after-approval 2017-03-30T02:43:33 https://maestrodatabase.com/blog/pharmac-to-fund-new-diabetes-medicines-with-amended-special-authority-criteria 2020-12-21T02:26:31 https://maestrodatabase.com/blog/fda-grants-priority-review-for-amgens-blincyto-blinatumomab-supplemental-biologics-license-application 2017-03-30T02:47:24 https://maestrodatabase.com/blog/expanded-pbs-access-to-breakthrough-medicine-for-lung-cancer 2020-12-21T02:05:57 https://maestrodatabase.com/blog/trump-fda-nominee-wants-lower-drug-costs-with-more-generics 2017-03-30T03:55:56 https://maestrodatabase.com/blog/enhertu-approved-in-the-us-as-first-her2-directed-therapy-for-patients-with-her2-low-or-her2-ultralow-metastatic-breast-cancer-following-disease-progression-after-one-or-more-endocrine-therapies 2025-01-28T00:21:13 https://maestrodatabase.com/blog/fda-grants-priority-review-to-mercks-application-for-welireg-belzutifan-for-the-treatment-of-patients-with-advanced-pheochromocytoma-and-paraganglioma 2025-01-27T21:34:45 https://maestrodatabase.com/blog/democratic-lawmakers-push-far-reaching-bills-to-lower-drug-prices 2017-03-30T12:31:53 https://maestrodatabase.com/blog/u-dot-s-fda-approves-addition-of-moderate-to-severe-fingernail-psoriasis-data-to-abbvies-humira-adalimumab-prescribing-information 2017-03-30T11:58:50 https://maestrodatabase.com/blog/gsk-and-vir-biotechnology-announce-joint-procurement-agreement-with-european-commission-for-covid-19-treatment-sotrovimab 2021-07-29T01:24:08 https://maestrodatabase.com/blog/new-resource-understanding-canadas-drug-approval-and-reimbursement-pathway 2025-12-06T21:29:35 https://maestrodatabase.com/blog/fda-approves-leqembi-lecanemab-irmb-iv-maintenance-dosing-for-the-treatment-of-early-alzheimers-disease 2025-01-27T07:03:29 https://maestrodatabase.com/blog/fda-helping-small-businesses-get-big-results 2017-03-30T20:04:06 https://maestrodatabase.com/blog/perc-publishes-final-outcome-for-amgens-kyprolis 2017-03-30T20:21:44 https://maestrodatabase.com/blog/kiwis-going-into-debt-to-pay-for-drugs-other-countries-fund 2020-12-21T04:09:07 https://maestrodatabase.com/blog/drugs-for-rare-diseases---ontario-agreement 2025-01-28T05:56:57 https://maestrodatabase.com/blog/apellis-receives-approval-of-syfovre-pegcetacoplan-in-australia-for-geographic-atrophy 2025-01-28T05:42:56 https://maestrodatabase.com/blog/gsks-shingrix-new-pre-filled-syringe-presentation-accepted-for-review-by-ema 2025-01-28T05:40:28 https://maestrodatabase.com/blog/where-the-fda-is-going-under-trump 2017-10-16T04:38:41 https://maestrodatabase.com/blog/five-ways-to-stop-rising-drug-prices-now 2017-03-30T20:38:54 https://maestrodatabase.com/blog/the-hidden-cost-keeping-your-health-insurance-premiums-high 2017-03-30T20:32:18 https://maestrodatabase.com/blog/perc-publishes-final-recommendation-for-sanofi-genzymes-caprelsa 2017-03-30T20:45:24 https://maestrodatabase.com/blog/oyster-point-pharma-submits-new-drug-application-to-the-u-dot-s-fda-for-oc-01-varenicline-nasal-spray-for-the-treatment-of-signs-and-symptoms-of-dry-eye-disease 2020-12-21T04:03:29 https://maestrodatabase.com/blog/immunitybio-announces-ema-acceptance-of-marketing-authorisation-application-for-anktiva-for-the-treatment-of-patients-with-bcg-unresponsive-non-muscle-invasive-bladder-cancer-carcinoma-in-situ 2025-01-28T04:12:07 https://maestrodatabase.com/blog/fda-authorizes-baricitinib-alone-as-treatment-for-covid-19 2021-07-29T02:17:55 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-29-july-2021 2021-07-29T02:27:08 https://maestrodatabase.com/blog/vanda-pharmaceuticals-accepts-fda-opportunity-for-a-hearing-on-new-drug-application-for-tradipitant-in-gastroparesis 2025-01-28T09:56:12 https://maestrodatabase.com/blog/proposal-to-list-5-aminolevulinic-acid-hydrochloride-gliolan-in-the-hospital-medicines-list 2017-03-31T02:51:01 https://maestrodatabase.com/blog/nice-and-nhs-england-announce-plan-to-enable-innovative-tech-to-be-adopted-quicker 2024-05-24T07:56:53 https://maestrodatabase.com/blog/tarlatamab-for-previously-treated-patients-with-advanced-small-cell-lung-cancer 2025-01-28T06:05:26 https://maestrodatabase.com/blog/gsk-announces-first-approval-of-shingrix-in-canada 2017-10-16T05:13:14 https://maestrodatabase.com/blog/cadth-calls-for-nominations 2018-03-20T05:34:33 https://maestrodatabase.com/blog/lost-beneath-headlines-of-five-figure-drug-costs----pharmaceutical-price-growth-is-weakening 2017-10-16T05:10:03 https://maestrodatabase.com/blog/access-for-aotearoa---campaigning-for-access-to-modern-medications-for-kiwis-with-cystic-fibrosis 2020-08-02T20:57:42 https://maestrodatabase.com/blog/updated-procedures-and-guidelines-for-company-submissions-to-ace 2022-03-25T01:27:41 https://maestrodatabase.com/blog/maestro-daily-and-mailchimp 2020-08-02T21:17:48 https://maestrodatabase.com/blog/logicbio-therapeutics-receives-rare-paediatric-disease-designation-for-lb-001-for-the-treatment-of-methylmalonic-acidaemia 2019-07-17T06:44:01 https://maestrodatabase.com/blog/spesolimab-for-the-treatment-of-patients-with-generalised-pustular-psoriasis-flares 2025-01-28T21:58:08 https://maestrodatabase.com/blog/harnessing-expertise-to-improve-patient-access-to-innovative-health-technologies 2025-01-28T21:55:00 https://maestrodatabase.com/blog/knight-therapeutics-announces-health-canada-has-approved-nerlynx-for-early-stage-breast-cancer 2019-07-17T01:48:20 https://maestrodatabase.com/blog/january-2025-decisions 2025-01-28T21:50:00 https://maestrodatabase.com/blog/sobi-receives-us-fda-fast-track-designation-for-emapalumab-lzsg-being-investigated-in-macrophage-activation-syndrome 2024-05-25T01:10:52 https://maestrodatabase.com/blog/ema-restricts-use-of-keytruda-and-tecentriq-in-bladder-cancer 2018-06-01T23:59:46 https://maestrodatabase.com/blog/outcome-statement---september-2022-dusc-meeting 2022-11-03T12:47:31 https://maestrodatabase.com/blog/fda-approves-expanded-indication-for-qudexy-xr-topiramate-extended-release-capsules-to-include-prophylaxis-of-migraine-headache-in-adults-and-adolescents 2017-03-31T05:06:46 https://maestrodatabase.com/blog/ema-validates-henlius-and-organon-filings-for-prolia-and-xgeva-denosumab-biosimilar-candidate-hlx14 2024-05-25T02:04:46 https://maestrodatabase.com/blog/sandoz-receives-positive-chmp-opinion-for-proposed-biosimilar-adalimumab 2018-06-02T00:12:52 https://maestrodatabase.com/blog/beacon-therapeutics-granted-fda-regenerative-medicine-advanced-therapy-designation-for-laru-zova-agtc-501 2025-01-28T23:39:55 https://maestrodatabase.com/blog/novartis-receives-positive-chmp-opinion-for-aimovig-erenumab-for-the-prevention-of-migraine 2018-06-02T00:03:45 https://maestrodatabase.com/blog/ucb-announces-us-fda-acceptance-of-new-drug-application-and-ema-maa-validation-for-zilucoplan-for-the-treatment-of-generalized-myasthenia-gravis-in-adult-patients 2022-11-14T07:07:22 https://maestrodatabase.com/blog/celltrion-receives-european-commission-approval-of-omlyclo-ct-p39-the-first-and-only-omalizumab-biosimilar-approved-in-europe 2024-05-25T01:40:47 https://maestrodatabase.com/blog/fda-approves-olumiant-baricitinib-2-mg-tablets-for-the-treatment-of-adults-with-moderately-to-severely-active-rheumatoid-arthritis 2018-06-02T00:16:47 https://maestrodatabase.com/blog/verastem-oncology-announces-the-initiation-of-a-rolling-submission-of-nda-to-fda-seeking-accelerated-approval-of-avutometinib-and-defactinib-combination-for-the-treatment-of-adult-patients-with-recurrent-kras-mutant-low-grade-serous-ovarian-cancer 2024-05-25T01:31:05 https://maestrodatabase.com/blog/moving-forward-on-pharmacare-for-canadians 2024-05-25T01:21:02 https://maestrodatabase.com/blog/saol-therapeutics-announces-fda-acceptance-of-new-drug-application-for-sl1009-for-treatment-of-pyruvate-dehydrogenase-complex-deficiency 2025-01-28T23:32:00 https://maestrodatabase.com/blog/pbs-website-updates-for-stage-2-pbs-process-improvements 2020-12-21T05:46:15 https://maestrodatabase.com/blog/depemokimab-accepted-for-review-by-the-ema-for-use-in-asthma-with-type-2-inflammation-and-crswnp 2025-01-29T00:06:26 https://maestrodatabase.com/blog/expanded-pbs-listing-for-lung-disease-medication 2022-03-25T05:26:55 https://maestrodatabase.com/blog/atagi-statement-on-recommendations-on-a-winter-booster-dose-of-covid-19-vaccine 2022-03-25T05:19:51 https://maestrodatabase.com/blog/roches-skin-cancer-drug-erivedge-pulled-from-cdf 2017-10-16T09:41:36 https://maestrodatabase.com/blog/fda-advisory-committee-panel-strongly-recommends-approval-of-shield-blood-test-for-colorectal-cancer-screening-as-a-primary-non-invasive-screening-option 2024-05-25T02:24:38 https://maestrodatabase.com/blog/beckman-coulter-receives-fda-breakthrough-device-designation-for-alzheimers-disease-blood-test 2025-01-28T23:55:02 https://maestrodatabase.com/blog/swissmedic-approves-buvidal-for-the-treatment-of-opioid-dependence 2020-12-21T06:16:35 https://maestrodatabase.com/blog/health-canada-approves-keytruda-pembrolizumab-as-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma 2020-01-24T02:04:28 https://maestrodatabase.com/blog/biosimilar-awareness-initiative---april-2017-update 2017-03-31T20:41:08 https://maestrodatabase.com/blog/breast-cancer-patients-to-have-further-nice-approved-drug-combination-option-on-cancer-drugs-fund 2020-01-16T09:25:15 https://maestrodatabase.com/blog/fda-approves-ozempic-semaglutide-as-the-only-glp-1-ra-to-reduce-the-risk-of-worsening-kidney-disease-and-cardiovascular-death-in-adults-with-type-2-diabetes-and-chronic-kidney-disease 2025-01-29T01:23:31 https://maestrodatabase.com/blog/fda-approves-omisirge-as-first-approved-cell-therapy-to-treat-severe-aplastic-anaemia 2025-12-07T01:36:00 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-mirvetuximab-soravtansine-gynx-for-folate-receptor-alfa-positive-platinum-resistant-epithelial-ovarian-fallopian-tube-or-peritoneal-cancer 2022-11-15T01:57:53 https://maestrodatabase.com/blog/government-supporting-australians-living-with-type-1-diabetes 2022-11-15T01:48:13 https://maestrodatabase.com/blog/perc-publishes-initial-recommendation-for-roches-gazyva 2017-03-31T21:37:39 https://maestrodatabase.com/blog/imfinzi-plus-chemotherapy-recommended-for-approval-in-the-eu-by-chmp-as-first-immunotherapy-regimen-for-advanced-biliary-tract-cancer 2022-11-15T01:41:35 https://maestrodatabase.com/blog/kamala-harris-introduces-plan-to-lower-prescription-drug-prices 2019-07-17T09:38:48 https://maestrodatabase.com/blog/ready-for-rescue---new-nasally-administered-glucagon-for-severe-hypoglycaemia-available-in-canada 2020-01-24T02:47:01 https://maestrodatabase.com/blog/hls-therapeutics-files-new-drug-submission-for-perseris-in-canada 2020-01-24T02:43:19 https://maestrodatabase.com/blog/covid-19-vaccine-safety-report-3-november-2022 2022-11-15T02:26:08 https://maestrodatabase.com/blog/tagrisso-osimertinib-receives-us-fda-full-approval 2017-03-31T22:55:31 https://maestrodatabase.com/blog/enhertu-recommended-for-approval-in-the-eu-by-chmp-for-patients-with-previously-treated-her2-positive-advanced-gastric-cancer 2022-11-15T02:32:22 https://maestrodatabase.com/blog/pharmac-seeking-views-on-new-cystic-fibrosis-medicine 2020-01-24T04:02:38 https://maestrodatabase.com/blog/novo-nordisk-resubmits-new-drug-application-for-fast-acting-insulin-aspart-in-the-us 2017-03-31T23:00:38 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-therapies-for-sickle-cell-disease 2020-01-24T02:50:07 https://maestrodatabase.com/blog/cancer-drug-study-data-was-falsified-says-astrazeneca 2017-10-16T10:49:39 https://maestrodatabase.com/blog/new-gene-therapy-to-treat-adult-patients-with-multiple-myeloma 2022-03-25T20:06:12 https://maestrodatabase.com/blog/junshi-biosciences-announces-submission-of-a-marketing-authorisation-application-to-the-european-medicines-agency-for-toripalimab 2022-11-15T03:08:59 https://maestrodatabase.com/blog/what-would-single-payer-healthcare-look-like-in-california-lawmakers-release-new-details 2017-04-01T01:08:51 https://maestrodatabase.com/blog/characteristics-and-strength-of-evidence-of-covid-19-studies-registered-on-clinicaltrials-dot-gov 2020-08-03T02:05:26 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-april-2017 2017-04-01T02:22:08 https://maestrodatabase.com/blog/exelixis-announces-u-dot-s-fda-grants-priority-review-for-cabometyx-cabozantinib-as-a-treatment-for-previously-untreated-advanced-renal-cell-carcinoma 2017-10-16T19:57:51 https://maestrodatabase.com/blog/we-must-fight-them-trump-goes-after-conservatives-of-freedom-caucus 2017-04-01T01:11:38 https://maestrodatabase.com/blog/emas-business-continuity-plan-for-brexit-published 2017-10-16T19:51:36 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-allergans-new-drug-application-for-bimatoprost-sustained-release-in-patients-with-open-angle-glaucoma-or-ocular-hypertension 2019-07-17T12:43:03 https://maestrodatabase.com/blog/von-hippel-lindau-disease-drug-welireg-listed-on-pbs-slashing-cost-by-11-000-dollars-a-month-for-patients 2025-01-29T03:22:42 https://maestrodatabase.com/blog/fda-approves-mercks-recarbrio-imipenem-cilastatin-and-relebactam-for-the-treatment-of-adults-with-complicated-urinary-tract-and-complicated-intra-abdominal-bacterial-infections-where-limited-or-no-alternative-treatment-options-are-available 2019-07-17T12:26:59 https://maestrodatabase.com/blog/the-cost-of-developing-drugs-is-insane-that-paper-that-says-otherwise-is-insanely-bad 2017-10-16T20:08:49 https://maestrodatabase.com/blog/fda-approves-first-treatment-option-specifically-for-patients-with-epithelioid-sarcoma-a-rare-soft-tissue-cancer 2020-01-24T04:44:54 https://maestrodatabase.com/blog/early-payouts-for-health-care-super-silly-treasury-told 2019-07-17T20:47:30 https://maestrodatabase.com/blog/health-insurance-still-expensive-despite-reforms-analysts 2017-10-16T20:14:53 https://maestrodatabase.com/blog/valneva-announces-pdufa-date-extension-for-chikungunya-virus-vaccine-candidate 2023-08-14T07:00:45 https://maestrodatabase.com/blog/trump-to-order-drive-for-improved-flu-vaccine 2019-07-17T13:17:40 https://maestrodatabase.com/blog/fda-accepts-application-for-genentechs-faricimab-for-the-treatment-of-wet-age-related-macular-degeneration-and-diabetic-macular-oedema 2021-07-29T10:47:58 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-bristol-myers-squibbs-application-for-opdivo-nivolumab-in-patients-with-resected-high-risk-advanced-melanoma-and-grants-priority-review 2017-10-16T20:24:15 https://maestrodatabase.com/blog/trump-administration-weighs-rollback-of-policy-that-supporters-say-helped-lower-drug-prices 2017-10-16T20:20:56 https://maestrodatabase.com/blog/durect-announces-that-the-fda-agreed-to-file-the-full-response-to-the-posimir-complete-response-letter-as-a-complete-class-2-resubmission 2019-07-17T20:56:02 https://maestrodatabase.com/blog/alvotech-and-teva-announce-filing-acceptance-of-us-biologics-license-applications-for-avt05-a-proposed-biosimilar-to-simponi-and-simponi-aria-golimumab 2025-01-29T11:16:19 https://maestrodatabase.com/blog/perth-boy-battles-cystic-fibrosis-with-a-life-extending-drug-frustratingly-out-of-reach 2019-07-17T20:50:49 https://maestrodatabase.com/blog/cancer-patients-advocates-gobsmacked-pharmac-declining-funding-application-for-life-changing-drug 2021-07-29T10:40:28 https://maestrodatabase.com/blog/part-d-beneficiaries-may-pay-more-for-some-generics-biosimilars-than-brand-name-drugs 2019-07-17T21:23:09 https://maestrodatabase.com/blog/ema-publishes-agenda-for-27-30-january-2025-chmp-meeting 2025-01-29T22:15:47 https://maestrodatabase.com/blog/majority-of-patients-not-asked-for-consent-before-being-switched-to-a-biosimilar-survey-finds 2019-07-17T21:20:01 https://maestrodatabase.com/blog/arrowhead-pharmaceuticals-receives-breakthrough-therapy-designation-from-u-dot-s-fda-for-aro-aat-for-the-treatment-of-alfa-1-anti-trypsin-deficiency-associated-liver-disease 2021-07-29T11:36:46 https://maestrodatabase.com/blog/on-drug-prices-trump-must-resist-left-wing-approaches-that-would-lead-to-disaster 2019-07-17T21:10:20 https://maestrodatabase.com/blog/advanz-and-private-equity-groups-fined-for-1-000-per-cent-drug-price-hike 2021-07-29T11:29:10 https://maestrodatabase.com/blog/car-shopping-handbags-and-wealthy-uncles-the-quest-to-explain-high-drug-prices 2019-07-17T21:05:38 https://maestrodatabase.com/blog/what-mark-cuban-gets-wrong-about-prescription-drugs 2023-08-14T07:11:22 https://maestrodatabase.com/blog/issues-challenges-and-opportunities-for-economic-evaluations-of-orphan-drugs-in-rare-diseases-an-umbrella-review 2024-05-25T22:13:53 https://maestrodatabase.com/blog/hhs-secretary-azar-statement-on-court-victory-for-president-trumps-drug-pricing-agenda 2020-08-03T05:28:56 https://maestrodatabase.com/blog/key-eu-medicines-regulator-closes-london-office-with-loss-of-900-jobs 2019-01-27T11:03:06 https://maestrodatabase.com/blog/fda-approves-expanded-botox-onabotulinumtoxina-label-to-include-eight-new-muscles-to-treat-adults-with-upper-limb-spasticity 2021-07-29T21:07:06 https://maestrodatabase.com/blog/congress-presses-the-fda-to-move-faster-on-als-drugs 2021-07-29T21:22:20 https://maestrodatabase.com/blog/fda-says-its-working-as-fast-as-possible-to-fully-approve-vaccines-as-urgency-rises-amid-covid-19-surge 2021-07-29T21:11:40 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-elranatamab-bcmm-for-multiple-myeloma 2023-08-14T21:06:07 https://maestrodatabase.com/blog/us-fda-approves-first-therapeutic-indication-for-revances-daxxify-daxibotulinumtoxina-lanm-for-injection-for-the-treatment-of-cervical-dystonia 2023-08-14T21:00:54 https://maestrodatabase.com/blog/in-the-case-of-a-devastating-disease-the-fda-weighs-an-experimental-drugs-muddled-data-and-a-desperate-need 2023-08-14T20:56:55 https://maestrodatabase.com/blog/after-years-of-campaigning-pharmac-agrees-to-fund-wonder-drug-to-treat-kids-with-cystic-fibrosis 2020-01-24T06:47:05 https://maestrodatabase.com/blog/novartis-cosentyx-receives-eu-approval-for-first-line-systemic-treatment-in-paediatric-psoriasis 2020-08-03T05:24:43 https://maestrodatabase.com/blog/biofourmis-earns-fdas-first-ever-breakthrough-device-designation-for-a-novel-digital-therapeutic-for-heart-failure 2021-07-29T11:46:48 https://maestrodatabase.com/blog/ema-recommends-first-covid-19-vaccine-for-authorisation-in-the-eu 2020-12-21T19:47:09 https://maestrodatabase.com/blog/private-health-insurance-families-hit-with-127-dollar-a-year-premium-lift 2020-12-21T19:52:18 https://maestrodatabase.com/blog/insurers-wont-cover-new-alzheimers-treatment-for-some-customers 2023-08-14T21:28:09 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-april-2017 2017-04-01T03:02:06 https://maestrodatabase.com/blog/how-advocates-pushed-big-pharma-to-cut-tuberculosis-drug-prices 2023-08-14T21:20:20 https://maestrodatabase.com/blog/novartis-receives-positive-chmp-opinion-for-jakavi-to-treat-acute-and-chronic-graft-versus-host-disease 2022-03-25T20:58:59 https://maestrodatabase.com/blog/ardelyx-receives-complete-response-letter-from-u-dot-s-fda-for-new-drug-application-for-tenapanor-for-the-control-of-serum-phosphorus-in-adult-patients-with-ckd-on-dialysis 2021-07-29T21:24:49 https://maestrodatabase.com/blog/european-commission-approves-aimmunes-palforzia-as-first-ever-treatment-for-peanut-allergy-in-the-eu 2020-12-21T11:18:35 https://maestrodatabase.com/blog/imara-announces-imr-687-granted-fast-track-designation-and-rare-paediatric-disease-designation-for-treatment-of-beta-thalassaemia 2020-08-03T06:30:28 https://maestrodatabase.com/blog/siga-announces-marketing-authorisation-filing-for-oral-tecovirimat-with-the-european-medicines-agency-for-multiple-indications 2020-08-03T06:35:16 https://maestrodatabase.com/blog/scholar-rock-submits-biologics-license-application-to-the-us-fda-for-apitegromab-as-a-treatment-for-patients-with-spinal-muscular-atrophy 2025-01-29T23:35:24 https://maestrodatabase.com/blog/merck-receives-positive-eu-chmp-opinion-for-keytruda-pembrolizumab-plus-chemotherapy-with-or-without-bevacizumab-as-treatment-for-patients-with-persistent-recurrent-or-metastatic-cervical-cancer-whose-tumours-express-pd-l1-cps-1 2022-03-25T21:09:26 https://maestrodatabase.com/blog/lynparza-in-combination-with-abiraterone-recommended-for-approval-in-the-eu-by-chmp-as-first-line-treatment-for-patients-with-metastatic-castration-resistant-prostate-cancer 2022-11-15T04:29:31 https://maestrodatabase.com/blog/santheras-duchenne-muscular-dystrophy-drug-agamree-accepted-by-smc 2025-01-29T23:47:19 https://maestrodatabase.com/blog/fda-grants-vicores-buloxibutid-fast-track-designation-for-idiopathic-pulmonary-fibrosis 2025-01-29T23:41:19 https://maestrodatabase.com/blog/sonoran-biosciences-announces-qualified-infectious-disease-product-designation-granted-by-fda-for-sbg003-for-surgical-site-infections-in-abdominal-surgery 2020-08-03T21:04:43 https://maestrodatabase.com/blog/incytes-first-in-class-mutcalr-targeted-monoclonal-antibody-inca033989-granted-breakthrough-therapy-designation-by-us-fda 2025-12-08T00:11:31 https://maestrodatabase.com/blog/trikafta-manufacturer-to-fast-track-application-to-have-miracle-cystic-fibrosis-drug-funded-in-new-zealand 2020-08-04T21:34:49 https://maestrodatabase.com/blog/janssen-announces-u-dot-s-fda-approval-of-spravato-esketamine-nasal-spray-to-treat-depressive-symptoms-in-adults-with-major-depressive-disorder-with-acute-suicidal-ideation-or-behaviour 2020-08-03T21:25:27 https://maestrodatabase.com/blog/ispor-announces-virtual-ispor-asia-pacific-2020 2020-08-03T21:35:33 https://maestrodatabase.com/blog/medicare-part-d-plans-rarely-cover-brand-name-drugs-when-generics-are-available 2020-08-03T21:38:09 https://maestrodatabase.com/blog/house-votes-to-repeal-obamacare-tax-once-seen-as-key-to-health-law 2019-07-18T12:23:10 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-for-bcx9930-in-pnh 2020-08-03T21:09:59 https://maestrodatabase.com/blog/chmp-recommends-eu-approval-of-roches-polivy-combination-for-people-with-previously-untreated-diffuse-large-b-cell-lymphoma 2022-03-25T21:37:53 https://maestrodatabase.com/blog/ema-publishes-agenda-for-8-11-december-2025-chmp-meeting 2025-12-08T19:47:47 https://maestrodatabase.com/blog/lifemax-receives-rare-paediatric-disease-designation-for-lm-030-for-the-treatment-of-netherton-syndrome 2019-07-18T12:16:40 https://maestrodatabase.com/blog/polypid-granted-fast-track-designation-from-fda-for-d-plex-for-prevention-of-surgical-site-infections-in-abdominal-surgery 2020-08-03T21:14:47 https://maestrodatabase.com/blog/atagi-update-on-boosters-following-covid-19-meeting-on-11-november-2022 2022-11-15T07:45:47 https://maestrodatabase.com/blog/fda-accepts-and-grants-priority-review-of-vandas-applications-for-hetlioz-tasimelteon-in-the-treatment-of-smith-magenis-syndrome 2020-08-03T21:20:42 https://maestrodatabase.com/blog/fda-approves-medicines360s-liletta-levonorgestrel-releasing-intrauterine-system-52-mg-to-prevent-pregnancy-for-up-to-eight-years 2022-11-15T07:51:38 https://maestrodatabase.com/blog/horizon-therapeutics-announces-u-dot-s-fda-acceptance-of-its-new-drug-application-to-make-procysbi-cysteamine-bitartrate-available-as-oral-granules-in-packets 2019-07-18T21:22:01 https://maestrodatabase.com/blog/japan-and-pfizer-reach-covid-19-vaccine-deal-to-treat-60-million-people 2020-08-03T21:52:53 https://maestrodatabase.com/blog/two-cancer-immunotherapy-makers-face-different-situations-in-reimbursement-talks 2019-07-18T12:32:19 https://maestrodatabase.com/blog/private-health-insurance-worthy-of-support 2019-07-18T12:28:28 https://maestrodatabase.com/blog/toddler-died-of-only-meningococcal-strain-not-on-vaccine-program 2019-07-18T21:45:42 https://maestrodatabase.com/blog/slow-start-for-infliximab-biosimilars 2020-08-03T21:43:14 https://maestrodatabase.com/blog/health-insurance-rebate-still-a-pain-in-the-budget 2019-07-18T21:38:52 https://maestrodatabase.com/blog/house-passes-bill-that-reauthorises-the-fdas-paediatric-priority-voucher-pathway 2025-12-08T01:28:06 https://maestrodatabase.com/blog/novartis-receives-positive-chmp-opinion-for-kymriah-car-t-cell-therapy-for-adult-patients-with-relapsed-or-refractory-follicular-lymphoma-in-europe 2022-03-25T21:46:22 https://maestrodatabase.com/blog/canada-warns-u-dot-s-against-drug-import-plans-citing-shortage-concerns 2019-07-18T21:27:26 https://maestrodatabase.com/blog/depemokimab-applications-accepted-for-review-in-china-and-japan-for-asthma-with-type-2-inflammation-and-crswnp 2025-01-30T01:22:18 https://maestrodatabase.com/blog/rozlytrek-roches-first-tumour-agnostic-therapy-approved-in-europe-for-people-with-ntrk-fusion-positive-solid-tumours-and-for-people-with-ros1-positive-advanced-non-small-cell-lung-cancer 2020-08-03T21:48:41 https://maestrodatabase.com/blog/agenda-for-5-april-2017-tc-meeting 2017-04-01T22:50:03 https://maestrodatabase.com/blog/amgen-statement-on-complete-response-letter-from-the-u-dot-s-fda-for-abp-980-a-biosimilar-candidate-to-herceptin-trastuzumab 2018-06-02T04:53:52 https://maestrodatabase.com/blog/cms-statement-on-lowering-the-cost-of-prescription-drugs 2025-01-30T07:17:47 https://maestrodatabase.com/blog/evaluation-of-ethical-analyses-in-seven-reports-from-the-european-network-for-health-technology-assessment 2019-07-18T21:55:00 https://maestrodatabase.com/blog/ironwood-pharmaceuticals-initiates-apraglutide-nda-submission 2025-01-30T07:08:08 https://maestrodatabase.com/blog/lundbeck-and-otsukas-rxulti-brexpiprazole-receives-positive-opinion-in-eu-from-chmp-for-the-treatment-of-schizophrenia-in-adults 2018-06-02T04:42:40 https://maestrodatabase.com/blog/personalised-treatments-may-be-threatened-by-drug-cost-containment-proposals 2019-07-18T21:52:26 https://maestrodatabase.com/blog/vertex-announces-fda-approvals-of-trikafta-elexacaftor-slash-tezacaftor-slash-ivacaftor-and-ivacaftor-symdeko-tezacaftor-slash-ivacaftor-and-ivacaftor-and-kalydeco-ivacaftor-for-use-in-people-with-cystic-fibrosis-with-certain-rare-mutations 2020-12-21T21:35:17 https://maestrodatabase.com/blog/atagi-recommendations-on-use-of-the-pfizer-bivalent-original-slash-omicron-ba-dot-1-covid-19-vaccine 2022-11-15T11:33:59 https://maestrodatabase.com/blog/sesen-bio-submits-completed-biologics-license-application-to-the-fda-for-vicineum-and-has-requested-priority-review 2020-12-21T22:10:58 https://maestrodatabase.com/blog/akari-therapeutics-announces-fda-fast-track-designation-for-coversin 2017-04-01T23:18:58 https://maestrodatabase.com/blog/janssen-initiates-rolling-submission-of-a-biologics-license-application-to-u-dot-s-fda-for-bcma-car-t-therapy-ciltacabtagene-autoleucel-cilta-cel-for-the-treatment-of-relapsed-and-slash-or-refractory-multiple-myeloma 2020-12-21T22:37:12 https://maestrodatabase.com/blog/perkinelmer-announces-its-eonis-scid-sma-kit-is-first-to-receive-marketing-authorisation-by-us-fda-for-sma-screening-in-newborns 2022-11-15T11:40:37 https://maestrodatabase.com/blog/expansion-of-access-to-menb-vaccine-urgently-needed 2022-11-15T15:53:09 https://maestrodatabase.com/blog/this-is-how-access-to-older-antibiotics-can-be-strengthened 2022-11-15T15:48:29 https://maestrodatabase.com/blog/the-fda-grants-io-biotech-breakthrough-therapy-designation-for-io102-and-io103-in-combination-with-anti-pd-1-in-unresectable-slash-metastatic-melanoma 2020-12-21T23:12:16 https://maestrodatabase.com/blog/aura-biosciences-announces-initiation-of-phase-1b-clinical-trial-and-receipt-of-fda-fast-track-designation-for-au-011-for-the-treatment-of-primary-ocular-melanoma 2017-04-01T23:55:45 https://maestrodatabase.com/blog/price-disclosure-2021-april-cycle-outcomes-summary 2020-12-21T22:51:45 https://maestrodatabase.com/blog/drugmakers-show-restraint-on-price-increases-in-new-trump-era 2025-01-30T07:55:03 https://maestrodatabase.com/blog/atagi-recommendations-on-use-of-the-pfizer-covid-19-vaccine-for-children-aged-6-months-to-4-years 2022-11-15T11:45:43 https://maestrodatabase.com/blog/agios-provides-update-on-us-snda-for-mitapivat-in-thalassaemia 2025-12-08T23:46:57 https://maestrodatabase.com/blog/merck-receives-positive-eu-chmp-opinion-for-keytruda-pembrolizumab-for-patients-with-microsatellite-instability-high-or-mismatch-repair-deficient-tumours-in-five-different-types-of-cancer 2022-03-25T22:27:21 https://maestrodatabase.com/blog/announcement-of-the-national-medicines-policy-review-committee-and-terms-of-reference 2021-07-30T01:06:41 https://maestrodatabase.com/blog/tga-grants-provisional-determination-to-pfizers-covid-19-bivalent-comirnaty-bivalent-omicron-ba-dot-4-slash-ba-dot-5-booster-dose-vaccine 2022-11-16T06:55:02 https://maestrodatabase.com/blog/ipsen-receives-positive-chmp-opinion-for-cabometyx-in-radioactive-iodine-refractory-differentiated-thyroid-cancer 2022-03-25T22:17:50 https://maestrodatabase.com/blog/ruxolitinib-phosphate-for-the-treatment-of-patients-with-acute-graft-versus-host-disease-that-is-refractory-to-the-use-of-corticosteroids 2022-11-16T06:37:31 https://maestrodatabase.com/blog/pbs-safe-government-vows-after-us-uk-medicines-deal-to-increase-spending-revealed 2025-12-09T02:59:59 https://maestrodatabase.com/blog/kite-completes-submission-of-u-dot-s-biologics-license-application-for-axicabtagene-ciloleucel-as-the-first-car-t-therapy-for-the-treatment-of-patients-with-aggressive-non-hodgkin-lymphoma 2017-04-02T00:22:18 https://maestrodatabase.com/blog/innovative-pharmaceutical-pricing-agreements-in-five-european-markets-a-survey-of-stakeholder-attitudes-and-experience 2018-06-02T06:35:28 https://maestrodatabase.com/blog/ruxolitinib-phosphate-for-the-treatment-of-patients-with-chronic-graft-versus-host-disease-that-is-refractory-to-the-use-of-corticosteroids 2022-11-17T04:32:17 https://maestrodatabase.com/blog/akcea-and-ionis-receive-positive-eu-chmp-opinion-for-tegsedi 2018-06-02T06:42:46 https://maestrodatabase.com/blog/targeted-treatment-for-rare-form-of-aggressive-lung-cancer-gets-nice-approval 2022-11-17T04:23:16 https://maestrodatabase.com/blog/canadian-migraine-sufferers-have-a-new-treatment-option---health-canada-approves-ubrelvy-ubrogepant 2022-11-17T04:27:10 https://maestrodatabase.com/blog/saskatchewan-adds-capvaxive-to-publicly-funded-adult-immunisation-program 2025-12-09T02:09:15 https://maestrodatabase.com/blog/ibrance-palbociclib-receives-fda-regular-approval-and-expanded-indication-for-first-line-hr-plus-her2--metastatic-breast-cancer 2017-04-02T01:09:43 https://maestrodatabase.com/blog/new-covid-19-vaccines-for-eligible-australians 2022-11-17T04:17:57 https://maestrodatabase.com/blog/amarin-announces-vazkepa-icosapent-ethyl-approved-by-the-tga-in-australia 2022-11-17T08:17:39 https://maestrodatabase.com/blog/a-tussle-over-medicines-pricing-is-looming-in-britain 2022-11-17T08:06:34 https://maestrodatabase.com/blog/nice-recommends-3-treatments-for-covid-19-in-draft-guidance 2022-11-17T08:10:19 https://maestrodatabase.com/blog/napp-announces-acceptance-of-their-rezafungin-marketing-authorisation-application-for-the-treatment-of-invasive-candidiasis-to-the-uk-medicines-and-healthcare-products-regulatory-agency 2022-11-17T08:03:02 https://maestrodatabase.com/blog/new-treatments-for-people-with-chronic-migraine-and-soft-tissue-sarcoma-added-to-the-pbs 2023-08-15T02:13:01 https://maestrodatabase.com/blog/jazz-pharmaceuticals-announces-initiation-of-biologics-license-application-submission-for-jzp-458-for-the-treatment-of-acute-lymphoblastic-leukaemia-or-lymphoblastic-lymphoma 2020-12-22T00:25:42 https://maestrodatabase.com/blog/obamacare-can-survive-trump 2017-04-02T22:16:34 https://maestrodatabase.com/blog/payers-experiences-with-confidential-pharmaceutical-price-discounts-a-survey-of-public-and-statutory-health-systems-in-north-america-europe-and-australasia 2017-04-02T22:11:51 https://maestrodatabase.com/blog/300-cancer-patients-given-a-chance-to-live-thanks-to-immunotherapy-drugs 2017-04-02T23:12:27 https://maestrodatabase.com/blog/the-nominee-to-run-americas-drug-regulator-is-a-sound-choice 2017-04-02T22:19:17 https://maestrodatabase.com/blog/were-nhs-chiefs-right-to-deny-miracle-life-giving-pancreatic-cancer-drug-as-nice-reviews-abraxane-the-mail-reveals-there-were-concerns-the-study-results-were-inappropriately-rosy-three-years-ago 2017-04-02T23:29:57 https://maestrodatabase.com/blog/fda-approves-treatment-for-ebola-virus 2020-12-22T00:38:52 https://maestrodatabase.com/blog/novartis-drug-combination-of-tafinlar-and-mekinist-receives-eu-approval-for-braf-v600-positive-advanced-non-small-cell-lung-cancer 2017-04-03T05:25:38 https://maestrodatabase.com/blog/fda-grants-breakthrough-therapy-designation-to-investigational-drug-adrabetadex-for-individuals-with-infantile-onset-niemann-pick-disease-type-c 2025-12-10T01:17:55 https://maestrodatabase.com/blog/erytech-granted-u-dot-s-fda-fast-track-designation-for-eryaspase-in-hypersensitive-all 2021-07-30T06:43:45 https://maestrodatabase.com/blog/biogen-receives-health-canada-authorisation-for-zurzuvae-zuranolone-the-first-and-only-treatment-indicated-for-adults-with-postpartum-depression-in-canada 2025-12-10T01:39:50 https://maestrodatabase.com/blog/cipaglucosidase-alfa-and-miglustat-for-the-treatment-of-patients-with-late-onset-pompe-disease 2023-08-15T06:38:18 https://maestrodatabase.com/blog/gsk-announces-fda-approval-for-nucala-mepolizumab-for-use-in-adults-with-chronic-rhinosinusitis-with-nasal-polyps 2021-07-30T07:08:42 https://maestrodatabase.com/blog/fda-approves-prosthetic-implant-for-above-the-knee-amputations 2020-12-22T01:32:42 https://maestrodatabase.com/blog/shionogis-novel-antibiotic-fetcroja-cefiderocol-has-been-selected-by-uks-nice-slash-nhse-and-i-as-part-of-an-antimicrobial-subscription-style-reimbursement-model 2020-12-22T11:17:19 https://maestrodatabase.com/blog/the-cost-of-cancer-new-drugs-show-success-at-a-steep-price 2017-04-03T06:51:38 https://maestrodatabase.com/blog/vertex-announces-fda-approval-of-journavx-suzetrigine-a-first-in-class-treatment-for-adults-with-moderate-to-severe-acute-pain 2025-01-30T23:40:18 https://maestrodatabase.com/blog/shared-decision-making-is-an-integral-part-of-healthcare-says-nice 2020-12-22T19:06:02 https://maestrodatabase.com/blog/2021-october-price-disclosure-cycle---indicative-prices 2021-07-30T07:45:07 https://maestrodatabase.com/blog/fda-approves-paediatric-indication-for-xeomin-incobotulintoxina-for-the-treatment-of-chronic-sialorrhoea 2020-12-22T01:16:01 https://maestrodatabase.com/blog/viiv-healthcare-announces-the-marketing-authorisation-of-the-first-complete-long-acting-injectable-hiv-treatment-in-europe 2020-12-22T19:27:35 https://maestrodatabase.com/blog/senti-bio-receives-fda-regenerative-medicine-advanced-therapy-designation-for-senti-202-in-the-treatment-of-adults-with-relapsed-or-refractory-acute-myeloid-leukaemia 2025-12-10T01:51:53 https://maestrodatabase.com/blog/amgen-submits-sotorasib-marketing-authorisation-application-to-the-european-medicines-agency 2020-12-22T19:39:50 https://maestrodatabase.com/blog/ema-organises-a-second-public-meeting-about-the-new-covid-19-vaccines 2020-12-22T19:08:22 https://maestrodatabase.com/blog/stan-zemaneks-widow-marcella-calls-for-more-funding-into-rare-cancers 2017-04-03T13:50:15 https://maestrodatabase.com/blog/ocular-therapeutix-announces-submission-to-the-fda-of-a-supplemental-new-drug-application-for-dextenza-dexamethasone-ophthalmic-insert-for-the-treatment-of-ocular-itching-associated-with-allergic-conjunctivitis 2020-12-22T19:11:50 https://maestrodatabase.com/blog/how-a-$37-000-a-year-medicine-sets-a-good-model-for-drug-pricing 2017-04-03T21:08:26 https://maestrodatabase.com/blog/trump-claims-he-will-rally-on-health-care 2017-04-03T20:58:32 https://maestrodatabase.com/blog/fda-approves-kineret-anakinra-for-the-treatment-of-deficiency-of-il-1-receptor-antagonist 2020-12-22T19:18:28 https://maestrodatabase.com/blog/when-65-000-dollars-a-year-for-a-drug-is-applauded 2017-04-03T21:11:03 https://maestrodatabase.com/blog/first-approval-in-commissioners-national-priority-voucher-pilot-program-strengthens-domestic-antibiotic-manufacturing-capacity 2025-12-10T02:54:31 https://maestrodatabase.com/blog/cms-finalises-2018-payment-and-policy-updates-for-medicare-health-and-drug-plans-and-releases-a-request-for-information 2017-04-03T21:19:49 https://maestrodatabase.com/blog/trumps-dispute-with-azar-gives-new-life-to-drug-pricing-plan 2020-01-25T02:38:43 https://maestrodatabase.com/blog/fda-chief-outlines-new-ways-to-speed-cancer-drug-approvals 2018-06-03T02:18:08 https://maestrodatabase.com/blog/bipolar-disorder-patients-suffer-terrible-side-effects-after-pharmac-drug-brand-switch 2020-01-25T02:35:15 https://maestrodatabase.com/blog/pharmac-considering-a-new-way-of-contracting-for-medicines 2020-08-04T03:57:34 https://maestrodatabase.com/blog/fda-approves-first-gene-therapy-treatment-for-wiskott-aldrich-syndrome 2025-12-10T03:08:17 https://maestrodatabase.com/blog/axsome-therapeutics-announces-fda-approval-of-symbravo-meloxicam-and-rizatriptan-for-the-acute-treatment-of-migraine-with-or-without-aura-in-adults 2025-01-31T01:48:50 https://maestrodatabase.com/blog/registry-data---of-sufficient-quality---are-suitable-for-the-extended-benefit-assessment-of-drugs 2020-01-25T02:47:39 https://maestrodatabase.com/blog/icer-posts-draft-scoping-document-for-the-assessment-of-treatments-for-haemophilia-a 2020-01-25T03:33:20 https://maestrodatabase.com/blog/rystiggo-rozanolixizumab-for-generalised-myasthenia-gravis-receives-eu-approval-for-two-new-administration-methods 2025-01-31T08:30:50 https://maestrodatabase.com/blog/lactiga-receives-fda-rare-paediatric-disease-designation-for-groundbreaking-mucosal-immunoglobulin-therapy-for-common-variable-immunodeficiency-disease 2023-08-15T08:03:13 https://maestrodatabase.com/blog/vertex-announces-casgevy-reimbursement-agreement-for-the-treatment-of-sickle-cell-disease-in-england 2025-01-31T08:22:02 https://maestrodatabase.com/blog/thousands-of-people-with-a-severe-dust-mite-allergy-are-set-to-benefit-from-life-changing-treatment 2025-01-31T01:56:18 https://maestrodatabase.com/blog/bristol-myers-squibb-announces-new-prescription-drug-user-fee-act-goal-date-for-reblozyl-luspatercept-aamt-supplemental-biologics-license-application 2022-03-25T23:53:34 https://maestrodatabase.com/blog/jazz-pharmaceuticals-completes-rolling-submission-of-new-drug-application-for-vyxeos-cpx-351-an-investigational-treatment-for-acute-myeloid-leukaemia 2017-04-04T01:09:40 https://maestrodatabase.com/blog/teva-announces-fda-approval-of-austedo-deutetrabenazine-tablets-for-the-treatment-of-chorea-associated-with-huntingtons-disease 2017-04-04T02:38:27 https://maestrodatabase.com/blog/highlights-from-the-chmp-21-24-march-2022-meeting 2022-03-25T23:50:06 https://maestrodatabase.com/blog/outcomes-from-the-december-2024-pbac-meeting 2025-01-31T08:34:50 https://maestrodatabase.com/blog/delcath-systems-announces-fda-approval-of-hepzato-kit-for-the-treatment-of-adult-patients-with-unresectable-hepatic-dominant-metastatic-uveal-melanoma 2023-08-15T09:10:41 https://maestrodatabase.com/blog/cognition-therapeutics-receives-fast-track-designation-from-u-dot-s-fda-for-first-in-class-alzheimers-candidate-ct1812 2017-10-17T04:20:54 https://maestrodatabase.com/blog/ema-publishes-agenda-for-27-30-may-2024-chmp-meeting 2024-05-27T22:24:29 https://maestrodatabase.com/blog/was-it-really-a-smart-move-for-the-fda-to-approve-a-smart-pill-for-treating-schizophrenia 2019-07-19T13:39:04 https://maestrodatabase.com/blog/meningococcal-b-vaccine-must-be-urgently-added-to-the-national-immunisation-program 2019-07-19T13:34:07 https://maestrodatabase.com/blog/pbac-public-summary-documents-first-time-rejections-and-deferrals---march-2019-meeting 2019-07-22T09:03:13 https://maestrodatabase.com/blog/us-fda-approves-foundationone-cdx-as-a-companion-diagnostic-for-janssens-akeega-niraparib-and-abiraterone-acetate-dual-action-tablet-for-patients-with-brca-positive-metastatic-castration-resistant-prostate-cancer 2023-08-15T09:55:19 https://maestrodatabase.com/blog/highlights-from-the-27-30-january-2025-chmp-meeting 2025-01-31T11:10:57 https://maestrodatabase.com/blog/patient-registries-may-prove-valuable-in-regulatory-decisions-ema-study-finds 2019-07-19T13:43:07 https://maestrodatabase.com/blog/fda-approves-first-drug-that-can-delay-onset-of-type-1-diabetes 2022-11-18T13:21:21 https://maestrodatabase.com/blog/health-canada-gives-kiss-of-death-to-planned-policy-for-rare-disease-drugs 2017-10-17T04:44:31 https://maestrodatabase.com/blog/doj-blasts-industry-attempt-to-delay-medicare-drug-price-negotiations 2023-08-15T21:25:40 https://maestrodatabase.com/blog/ab2-bios-tadekinig-alfa-therapy-receives-breakthrough-therapy-designation-from-the-us-fda-for-the-treatment-of-monogenic-interleukin-18-associated-auto-inflammatory-conditions-with-ongoing-systemic-inflammation 2017-04-04T07:33:26 https://maestrodatabase.com/blog/pbac-public-summary-document-november-2022 2022-11-18T13:17:01 https://maestrodatabase.com/blog/from-drug-shortages-to-high-prices-us-systems-shortcomings-have-deep-roots 2023-08-15T21:14:45 https://maestrodatabase.com/blog/swissmedic-updates-requirements-concerning-the-fast-track-authorisation-procedure 2017-10-17T04:54:30 https://maestrodatabase.com/blog/venatorx-pharmaceuticals-announces-fda-acceptance-and-priority-review-of-new-drug-application-for-cefepime-taniborbactam-to-treat-complicated-urinary-tract-infections-including-pyelonephritis-in-adults 2023-08-15T20:52:28 https://maestrodatabase.com/blog/trumps-new-talk-on-u-dot-s-drug-prices-sends-biotech-index-down 2017-10-17T05:20:34 https://maestrodatabase.com/blog/pharmac-indicates-interest-to-fund-more-oestradiol-treatments-to-relieve-supply-issue 2023-08-15T10:03:18 https://maestrodatabase.com/blog/we-took-a-shot-and-it-worked-immunotherapy-delivering-results-for-cancer-sufferers 2017-10-17T07:27:53 https://maestrodatabase.com/blog/dbv-technologies-receives-complete-response-letter-from-fda-for-viaskin-peanut-bla-in-children-ages-4-11-years 2020-08-04T09:11:48 https://maestrodatabase.com/blog/fda-approves-a-new-dosing-regimen-for-asparaginase-erwinia-chrysanthemi-recombinant 2022-11-19T00:00:09 https://maestrodatabase.com/blog/anika-announces-regulatory-approval-for-monovisc-in-australia-for-the-treatment-of-pain-associated-with-osteoarthritis-of-all-synovial-joints 2017-10-17T05:24:11 https://maestrodatabase.com/blog/diabetic-accuses-pharmac-of-faulty-analysis-of-glucose-monitors 2022-11-18T23:44:46 https://maestrodatabase.com/blog/us-fda-accepts-supplemental-biologics-license-application-for-imfinzi-in-locally-advanced-unresectable-non-small-cell-lung-cancer 2017-10-17T19:39:40 https://maestrodatabase.com/blog/calliditas-partner-everest-medicines-new-drug-application-for-nefecon-is-accepted-by-the-china-nmpa 2022-11-18T23:50:13 https://maestrodatabase.com/blog/evaluation-of-evidence-of-statistical-support-and-corroboration-of-sub-group-claims-in-randomised-clinical-trials 2017-04-04T07:57:30 https://maestrodatabase.com/blog/medicines-industry-calls-for-discount-rate-reduction-now 2022-11-18T13:28:31 https://maestrodatabase.com/blog/chemists-accused-of-putting-profits-ahead-of-patient-safety-in-codeine-prescription-row 2017-10-17T19:48:57 https://maestrodatabase.com/blog/generic-drug-user-fees-reauthorisation-a-victory-for-public-health 2017-10-17T19:57:50 https://maestrodatabase.com/blog/emas-procedural-handling-of-safety-review-was-complete-and-independent 2017-10-17T19:53:26 https://maestrodatabase.com/blog/uk-increases-covid-19-vaccine-manufacturing-capacity 2020-08-04T10:33:23 https://maestrodatabase.com/blog/no-deal-brexit-could-cost-nhs-ps500m-a-year 2017-10-17T20:16:58 https://maestrodatabase.com/blog/trump-declares-obamacare-dead-urges-democratic-help-for-short-term-fix 2017-10-17T20:06:26 https://maestrodatabase.com/blog/our-divided-dysfunctional-government-should-at-least-be-able-to-lower-drug-prices 2019-01-28T03:05:04 https://maestrodatabase.com/blog/tesaros-ovarian-cancer-drug-zejula-added-to-cancer-drugs-fund 2018-06-03T06:40:40 https://maestrodatabase.com/blog/biosight-granted-u-dot-s-fda-fast-track-designation-for-bst-236-for-the-treatment-of-acute-myeloid-leukaemia 2020-08-04T21:00:44 https://maestrodatabase.com/blog/innovative-medicines-canada-responds-to-the-revised-draft-pmprb-guidelines-consultation 2020-08-04T21:41:08 https://maestrodatabase.com/blog/apellis-announces-fda-acceptance-of-nda-amendment-and-new-pdufa-date-of-26-february-2023-for-pegcetacoplan-for-geographic-atrophy 2022-11-19T01:17:50 https://maestrodatabase.com/blog/goldman-sachs-predicts-fda-will-approve-coronavirus-vaccine-this-year 2020-08-04T20:54:12 https://maestrodatabase.com/blog/servier-announces-fda-filing-acceptance-and-priority-review-for-tibsovo-ivosidenib-tablets-in-the-treatment-of-idh1-mutated-relapsed-or-refractory-myelodysplastic-syndromes 2023-08-16T00:02:12 https://maestrodatabase.com/blog/pacira-biosciences-announces-fda-acceptance-of-snda-for-exparel-use-in-paediatric-patients 2020-08-04T20:57:04 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-positive-chmp-opinion-for-car-t-cell-therapy-breyanzi-for-relapsed-or-refractory-follicular-lymphoma 2025-01-31T21:09:51 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-positive-chmp-opinion-for-opdivo-nivolumab-plus-yervoy-ipilimumab-as-a-first-line-treatment-option-for-adult-patients-with-unresectable-or-advanced-hepatocellular-carcinoma 2025-01-31T21:29:43 https://maestrodatabase.com/blog/janssen-announces-health-canada-approval-of-darzalex-sc-a-new-subcutaneous-formulation-for-the-treatment-of-patients-with-multiple-myeloma 2020-08-04T21:55:10 https://maestrodatabase.com/blog/european-commission-approves-enjaymo-sutimlimab-for-treatment-of-haemolytic-anaemia-in-adult-patients-with-cold-agglutinin-disease 2022-11-19T01:39:54 https://maestrodatabase.com/blog/fda-allows-drugs-without-proven-clinical-benefit-to-languish-for-years-on-accelerated-pathway 2021-07-31T02:39:17 https://maestrodatabase.com/blog/frustrated-cystic-fibrosis-patient-speaks-out-after-drug-coverage-denial 2021-07-31T02:12:04 https://maestrodatabase.com/blog/tricvalve-transcatheter-bicaval-valves-system-granted-designation-as-breakthrough-device-by-the-u-dot-s-fda 2020-12-23T00:13:32 https://maestrodatabase.com/blog/janssen-announces-health-canada-approval-of-darzalex-combination-regimen-for-newly-diagnosed-transplant-eligible-patients-with-multiple-myeloma 2020-12-23T01:18:00 https://maestrodatabase.com/blog/iveric-bio-announces-fda-has-granted-breakthrough-therapy-designation-for-avacincaptad-pegol-for-geographic-atrophy 2022-11-19T05:31:26 https://maestrodatabase.com/blog/the-impact-of-proposed-price-regulations-on-new-patented-medicine-launches-in-canada-a-retrospective-cohort-study 2024-05-28T01:25:20 https://maestrodatabase.com/blog/iovance-biotherapeutics-provides-update-on-biologics-license-application-submission-for-lifileucel-in-advanced-melanoma 2022-11-19T05:25:08 https://maestrodatabase.com/blog/increased-manufacturing-capacity-and-supply-for-spikevax 2021-07-31T01:54:24 https://maestrodatabase.com/blog/telix-submits-nda-for-new-prostate-cancer-imaging-agent 2024-05-28T01:10:38 https://maestrodatabase.com/blog/health-canada-approves-alks-ragwitek-sublingual-allergy-immunotherapy-tablets-for-paediatric-patients-with-ragweed-allergy 2020-12-23T01:31:36 https://maestrodatabase.com/blog/occlutechs-atrial-flow-regulator-receives-u-dot-s-fda-breakthrough-device-designation 2020-12-23T02:15:44 https://maestrodatabase.com/blog/beigene-receives-european-commission-approval-for-brukinsa-zanubrutinib-for-the-treatment-of-adults-with-chronic-lymphocytic-leukaemia 2022-11-19T05:58:01 https://maestrodatabase.com/blog/senators-reach-deal-to-continue-obamacare-health-insurance-subsidy-payments 2017-10-18T06:43:12 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-therapies-for-iga-nephropathy 2025-12-11T19:44:55 https://maestrodatabase.com/blog/janssen-seeks-ema-approval-for-novel-subcutaneous-formulation-of-darzalex-daratumumab 2019-07-20T01:14:48 https://maestrodatabase.com/blog/trumps-reports-of-obamacares-death-are-greatly-exaggerated 2017-10-18T07:20:15 https://maestrodatabase.com/blog/landmark-pbs-listing-for-australians-with-cystic-fibrosis 2022-03-26T23:04:23 https://maestrodatabase.com/blog/agenda-for-the-march-2021-pbac-meeting 2021-02-15T01:43:54 https://maestrodatabase.com/blog/blueprint-medicines-announces-european-medicines-agency-validation-of-marketing-authorisation-application-for-avapritinib-for-the-treatment-of-pdgfra-d842v-mutant-gist-and-fourth-line-gist 2019-07-20T01:44:01 https://maestrodatabase.com/blog/the-european-commission-approves-zogenixs-fintempa-fenfluramine-oral-solution-for-the-treatment-of-seizures-in-dravet-syndrome 2020-12-23T09:43:53 https://maestrodatabase.com/blog/eu-starts-evaluating-samsung-bioepis-sales-application-for-avastin-biosimilar 2019-07-20T01:40:03 https://maestrodatabase.com/blog/us-fda-grants-priority-review-to-bristol-myers-squibbs-application-for-opdivo-nivolumab-plus-chemotherapy-combination-for-classical-hodgkins-lymphoma 2025-12-11T19:38:19 https://maestrodatabase.com/blog/fda-approves-bracco-diagnostics-prohance-gadoteridol-injection-279-dot-3-mg-slash-ml-for-paediatric-patients-younger-than-two-years 2020-12-23T19:43:58 https://maestrodatabase.com/blog/biosimilar-drugs-a-boon-to-be-applauded-as-they-provide-equivalent-treatment-at---sometimes---half-the-price 2019-07-20T02:10:36 https://maestrodatabase.com/blog/pfizer-to-supply-us-with-additional-100-million-vaccine-doses 2020-12-23T19:37:41 https://maestrodatabase.com/blog/fda-approves-otezla-apremilast-for-the-treatment-of-oral-ulcers-associated-with-behcets-disease 2019-07-20T02:05:42 https://maestrodatabase.com/blog/sarclisa-accepted-for-fda-priority-review-for-the-treatment-of-transplant-ineligible-newly-diagnosed-multiple-myeloma 2024-05-28T04:40:57 https://maestrodatabase.com/blog/amgen-and-allergans-mvasi-bevacizumab-awwb-and-kanjinti-trastuzumab-anns-now-available-in-the-united-states 2019-07-20T02:13:16 https://maestrodatabase.com/blog/biohavens-nurtec-riluzole-505-b-2-application-for-amyotrophic-lateral-sclerosis-affected-by-issues-related-to-apotex-plant-complete-response-letter-received-from-fda 2019-07-20T02:33:59 https://maestrodatabase.com/blog/novavaxs-covid-19-booster-has-been-approved-for-adults-health-canada-says 2022-11-19T07:03:19 https://maestrodatabase.com/blog/ignyta-receives-european-medicines-agency-prime-designation-for-entrectinib-in-ntrk-fusion-positive-solid-tumours 2017-10-18T10:51:12 https://maestrodatabase.com/blog/pear-therapeutics-announces-fda-submission-for-somryst-a-prescription-digital-therapeutic-for-the-treatment-of-adults-with-chronic-insomnia-and-depression 2019-07-20T03:29:38 https://maestrodatabase.com/blog/ema-takes-note-of-the-european-ombudsmans-decision-on-pre-submission-activities 2019-07-20T02:44:59 https://maestrodatabase.com/blog/kymera-therapeutics-announces-us-fda-fast-track-designation-for-kt-621-a-first-in-class-oral-stat6-degrader-for-the-treatment-of-atopic-dermatitis 2025-12-11T23:23:20 https://maestrodatabase.com/blog/ted-cruz-bill-would-speed-fda-approval-of-drugs-okd-in-other-countries 2019-07-20T03:35:39 https://maestrodatabase.com/blog/icer-publishes-evidence-report-on-medication-for-smoking-cessation 2025-12-11T23:55:45 https://maestrodatabase.com/blog/merry-christmas-to-all-maestro-daily-readers 2022-12-22T22:07:13 https://maestrodatabase.com/blog/datopotamab-deruxtecan-recommended-for-approval-in-the-eu-by-chmp-for-patients-with-previously-treated-metastatic-hr-positive-her2-negative-breast-cancer 2025-01-31T23:45:04 https://maestrodatabase.com/blog/peptilogics-receives-qualified-infectious-disease-product-designation-from-fda-for-lead-compound-plg0206-as-a-treatment-for-prosthetic-joint-infection 2018-06-04T00:50:28 https://maestrodatabase.com/blog/trump-plan-to-lower-drug-prices-could-increase-costs-for-some-patients 2018-06-04T00:39:24 https://maestrodatabase.com/blog/tris-pharma-announces-fda-acceptance-of-nda-for-once-nightly-low-sodium-oxybate-product-for-narcolepsy-and-idiopathic-hypersomnia 2025-12-11T21:14:22 https://maestrodatabase.com/blog/radius-health-receives-fda-fast-track-designation-for-elacestrant-rad1901 2017-10-18T19:49:33 https://maestrodatabase.com/blog/us-fda-accepts-regulatory-submission-for-lynparza-in-metastatic-breast-cancer-and-grants-priority-review 2017-10-18T19:59:39 https://maestrodatabase.com/blog/economic-evaluation-of-personalised-medicine-a-call-for-real-world-data 2017-10-18T19:53:02 https://maestrodatabase.com/blog/regulator-oks-eisai-koreas-leqembi-for-early-alzheimers-disease-treatment 2024-05-28T09:18:50 https://maestrodatabase.com/blog/fresenius-announces-fda-acceptance-for-review-of-denosumab-biosimilar-application 2024-05-28T05:34:00 https://maestrodatabase.com/blog/why-do-we-need-drug-rebates-anyway-a-top-law-maker-wants-to-know 2017-10-18T20:20:52 https://maestrodatabase.com/blog/cancer-drug-prices-rising-far-faster-than-inflation 2017-10-18T20:37:20 https://maestrodatabase.com/blog/cvs-to-cover-migraine-drugs-from-teva-lilly-excludes-amgen 2019-01-28T06:34:55 https://maestrodatabase.com/blog/drug-supply-players-point-a-finger-everywhere-but-themselves 2017-10-18T20:23:02 https://maestrodatabase.com/blog/congress-isnt-acting-to-curb-drug-prices-so-states-are-stepping-up-heres-how 2017-10-18T20:54:45 https://maestrodatabase.com/blog/vasomune-therapeutics-receives-us-fda-fast-track-designation-for-novel-investigational-medicine-av-001 2024-05-28T20:59:37 https://maestrodatabase.com/blog/david-seymours-special-envoy-in-medicines-is-dumping-his-drug-company-investments 2024-05-28T10:08:48 https://maestrodatabase.com/blog/fda-wants-to-shorten-new-drug-monopolies-to-cut-costs 2018-06-04T01:17:45 https://maestrodatabase.com/blog/lords-continue-to-call-for-clarity-on-no-deal-brexit-medicines-access 2019-01-28T19:18:20 https://maestrodatabase.com/blog/abbvie-announces-u-dot-s-fda-approval-of-imbruvica-ibrutinib-plus-obinutuzumab-gazyva---first-chemotherapy-free-anti-cd20-combination-regimen-approved-for-chronic-lymphocytic-leukaemia-slash-small-lymphocytic-lymphoma-in-previously-untreated-patients 2019-01-28T19:12:08 https://maestrodatabase.com/blog/inflation-reduction-act-drug-pricing-provisions-arent-at-all-like-price-controls-in-europe 2022-11-19T09:47:20 https://maestrodatabase.com/blog/pharmac-reconsiders-oestradiol-patch-options-following-community-feedback 2025-02-01T01:33:45 https://maestrodatabase.com/blog/fda-chief-expects-agency-to-play-role-in-overseeing-requests-for-unproven-drugs 2018-06-04T01:19:48 https://maestrodatabase.com/blog/cystic-fibrosis-patients-lobby-vertex-to-drop-drug-prices 2019-01-28T19:23:55 https://maestrodatabase.com/blog/ptc-therapeutics-announces-health-canada-approval-of-sephience-sepiapterin-for-the-treatment-of-children-and-adults-living-with-phenylketonuria 2025-12-12T01:31:02 https://maestrodatabase.com/blog/covid-19-vaccine-safety-report-17-november-2022 2022-11-19T09:32:52 https://maestrodatabase.com/blog/in-a-rare-move-fda-threatens-to-fine-a-company-for-failing-to-report-clinical-trial-results 2023-08-16T20:53:29 https://maestrodatabase.com/blog/landmark-uk-us-pharmaceuticals-deal-to-safeguard-medicines-access-and-drive-vital-investment-for-uk-patients-and-businesses 2025-12-12T02:03:46 https://maestrodatabase.com/blog/us-fda-approves-ipsens-sohonos-palovarotene-capsules-the-first-and-only-treatment-for-people-with-fibrodysplasia-ossificans-progressiva 2023-08-16T20:45:31 https://maestrodatabase.com/blog/fda-approves-uplinza-for-adults-with-generalised-myasthenia-gravis 2025-12-12T02:05:38 https://maestrodatabase.com/blog/vera-therapeutics-receives-us-fda-breakthrough-therapy-designation-for-atacicept-in-immunoglobulin-a-nephropathy 2024-05-28T23:22:52 https://maestrodatabase.com/blog/boehringer-ingelheims-jardiance-gets-expanded-coverage-for-hfpef-patients 2025-02-01T02:01:00 https://maestrodatabase.com/blog/amazon-pharmacy-automates-discounts-to-help-insulin-patients-get-pledged-prices 2023-08-16T12:23:05 https://maestrodatabase.com/blog/pharmac-calls-for-applications-from-the-suppliers-of-vaccines-that-protect-against-covid-19 2023-08-16T08:10:58 https://maestrodatabase.com/blog/refined-interpretation-of-the-mutual-recognition-agreement-between-canada-and-switzerland 2025-02-01T03:13:17 https://maestrodatabase.com/blog/the-collateral-damage-of-adhd-drug-shortages 2023-08-16T21:24:24 https://maestrodatabase.com/blog/cerecor-receives-rare-paediatric-disease-designation-for-cerc-006-in-lymphatic-malformations 2020-08-05T03:08:39 https://maestrodatabase.com/blog/pharmac-publishes-agenda-for-this-weeks-ptac-meeting 2023-08-16T20:56:26 https://maestrodatabase.com/blog/leo-pharma-announces-us-fda-fast-track-designation-for-delgocitinib-cream-for-the-treatment-of-adults-with-moderate-to-severe-chronic-hand-eczema 2020-08-05T03:12:14 https://maestrodatabase.com/blog/strengthening-the-aca-for-the-long-term 2017-11-30T00:32:42 https://maestrodatabase.com/blog/fda-approves-novel-non-opioid-treatment-for-moderate-to-severe-acute-pain 2025-02-01T03:16:12 https://maestrodatabase.com/blog/using-medicare-prices----toward-equity-and-affordability-in-the-aca-marketplace 2017-10-18T22:34:54 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-august-2021 2021-07-31T21:50:02 https://maestrodatabase.com/blog/making-pharmaceutical-companies-report-what-matters-about-innovation 2021-07-31T21:37:18 https://maestrodatabase.com/blog/fda-approves-the-first-interchangeable-biosimilar-insulin-will-it-really-lower-the-cost 2021-07-31T22:04:56 https://maestrodatabase.com/blog/new-migraine-spinal-muscular-atrophy-drugs-on-pbs-ease-financial-pain 2021-07-31T21:54:52 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-august-2021 2021-07-31T21:31:04 https://maestrodatabase.com/blog/groundbreaking-one-off-gene-therapy-approved-for-severe-sickle-cell-disease 2025-02-01T05:12:03 https://maestrodatabase.com/blog/pharmac-welcomes-myeloma-nz-as-first-patient-advocacy-group-to-present-to-ptac 2022-11-20T20:14:53 https://maestrodatabase.com/blog/bupa-and-healthscope-end-battle-over-hospital-payments-meaning-no-gap-fees-for-stays 2025-02-01T05:09:17 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-february-2025 2025-02-01T04:22:13 https://maestrodatabase.com/blog/pharmac-calls-for-applications-for-medicines-for-rare-disorders 2023-11-13T04:13:55 https://maestrodatabase.com/blog/fda-authorises-regen-cov-monoclonal-antibody-therapy-for-post-exposure-prophylaxis-for-covid-19 2021-07-31T22:09:29 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-february-2025 2025-02-01T04:06:33 https://maestrodatabase.com/blog/high-quality-evidence-for-the-treatment-of-very-rare-diseases-iqwig-is-involved-in-the-eu-project-realised 2025-02-01T08:31:23 https://maestrodatabase.com/blog/the-use-of-real-world-data-for-estimating-relative-treatment-effects-in-nice-health-technology-assessment-submissions-a-review 2025-02-01T05:24:44 https://maestrodatabase.com/blog/proposal-for-changes-to-funded-haemophilia-treatments 2019-01-29T04:24:00 https://maestrodatabase.com/blog/big-pharma-should-accept-cap-on-drug-price-increases 2019-01-29T04:34:13 https://maestrodatabase.com/blog/australian-medical-association-warns-hospital-funding-crisis-jeopardises-patient-safety 2019-01-29T04:38:27 https://maestrodatabase.com/blog/dabrafenib-mesylate-in-combination-with-trametinib-dimethyl-sulphoxide-for-the-treatment-of-children-and-adolescents-with-braf-v600e-mutation-positive-glioma 2024-05-29T05:16:25 https://maestrodatabase.com/blog/reviral-announces-fda-fast-track-designation-granted-to-sisunatovir-for-the-treatment-of-serious-respiratory-syncytial-virus-infection 2020-08-05T06:35:32 https://maestrodatabase.com/blog/update-from-the-pbac-december-2025 2025-12-18T04:54:59 https://maestrodatabase.com/blog/fda-approves-first-interchangeable-biosimilar-for-two-rare-diseases 2024-05-29T04:55:06 https://maestrodatabase.com/blog/trastuzumab-deruxtecan-for-the-treatment-of-patients-with-advanced-her2-mutation-positive-non-small-cell-lung-cancer-after-platinum-based-chemotherapy 2024-05-29T04:28:41 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-selpercatinib-for-paediatric-patients-two-years-and-older-with-ret-altered-metastatic-thyroid-cancer-or-solid-tumours 2024-05-29T21:01:40 https://maestrodatabase.com/blog/myr-pharmaceuticals-receives-conditional-marketing-authorisation-by-the-european-commission-for-hepcludex 2020-08-05T06:40:22 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-european-commission-approval-for-opdivo-nivolumab-in-combination-with-cisplatin-and-gemcitabine-for-the-first-line-treatment-of-adult-patients-with-unresectable-or-metastatic-urothelial-carcinoma 2024-05-29T12:01:15 https://maestrodatabase.com/blog/krpia-urges-incoming-assembly-to-recognise-new-drugs-value 2024-05-29T08:36:31 https://maestrodatabase.com/blog/zanubrutinib-in-combination-with-obinutuzumab-for-the-treatment-of-patients-with-relapsed-or-refractory-b-cell-follicular-lymphoma-after-two-or-more-treatments 2024-05-29T05:48:01 https://maestrodatabase.com/blog/pickering-ont-mother-living-with-cystic-fibrosis-approved-for-miracle-drug-im-in-shock 2020-01-26T04:44:48 https://maestrodatabase.com/blog/federal-budget-vision-must-extend-beyond-election-day-to-secure-better-long-term-health-for-all-australians 2022-03-28T03:47:44 https://maestrodatabase.com/blog/getting-the-price-right-lessons-for-medicare-price-negotiation-from-peer-countries 2022-11-21T00:28:20 https://maestrodatabase.com/blog/sumitovant-biopharma-announces-urovant-sciences-receives-u-dot-s-fda-approval-of-gemtesa-vibegron-75-mg-tablets-for-the-treatment-of-patients-with-overactive-bladder 2020-12-26T10:19:07 https://maestrodatabase.com/blog/fda-grants-priority-review-to-mercks-application-for-keytruda-pembrolizumab-plus-chemotherapy-as-first-line-treatment-of-patients-with-unresectable-advanced-or-metastatic-malignant-pleural-mesothelioma 2024-05-29T23:36:15 https://maestrodatabase.com/blog/us-fda-approves-celltrions-avtozma-tocilizumab-anoh-a-biosimilar-to-actemra 2025-02-02T01:46:47 https://maestrodatabase.com/blog/cell-and-gene-therapies---improving-access-and-outcomes-for-medicare-and-medicaid-beneficiaries 2025-02-02T01:18:57 https://maestrodatabase.com/blog/family-says-choice-is-life-in-australia-or-death-waiting-for-pharmac 2021-08-01T21:01:04 https://maestrodatabase.com/blog/2022-seasonal-influenza-vaccines 2022-03-28T05:42:46 https://maestrodatabase.com/blog/fda-under-pressure-to-grant-full-approval-to-covid-19-vaccines 2021-08-01T21:22:35 https://maestrodatabase.com/blog/muscular-atrophy-cholesterol-and-migraine-medications-added-to-pbs 2021-08-01T21:08:20 https://maestrodatabase.com/blog/life-saving-lung-cancer-drug-added-to-pbs-slashing-price-from-10-000-dollars-a-month-to-30-dollars-per-script 2025-02-02T02:39:34 https://maestrodatabase.com/blog/fda-approves-niraparib-and-abiraterone-acetate-plus-prednisone-for-brca2-mutated-metastatic-castration-sensitive-prostate-cancer 2025-12-12T22:34:00 https://maestrodatabase.com/blog/cheaper-medicine-for-lung-cancer-patients 2025-02-02T02:33:45 https://maestrodatabase.com/blog/japans-ministry-of-health-labour-and-welfare-accepts-bristol-myers-squibbs-application-for-breyanzi-lisocabtagene-maraleucel-as-a-second-line-therapy-for-relapsed-or-refractory-large-b-cell-lymphoma 2022-03-28T05:38:09 https://maestrodatabase.com/blog/axsome-therapeutics-receives-fda-breakthrough-therapy-designation-for-axs-12-for-the-treatment-of-narcolepsy 2020-08-05T20:52:25 https://maestrodatabase.com/blog/heartbreaking-parents-of-sick-11-month-old-want-greater-meningitis-awareness 2022-11-21T04:58:53 https://maestrodatabase.com/blog/state-attorneys-general-use-federal-law-to-lower-cost-increase-supply-of-covid-19-drug-remdesivir 2020-08-05T20:59:28 https://maestrodatabase.com/blog/public-consultation-draft-2025-26-cost-recovery-implementation-statement-for-listing-medicines-on-the-pbs-and-designated-vaccines-on-the-nip 2025-02-02T07:51:11 https://maestrodatabase.com/blog/johnson-and-johnson-reaches-deal-with-u-dot-s-for-100-million-doses-of-coronavirus-vaccine-at-more-than-1-dollars-billion 2020-08-05T21:06:14 https://maestrodatabase.com/blog/canada-approves-the-moderna-vaccine-paving-the-way-for-inoculations-in-its-vast-far-north 2020-12-26T21:14:56 https://maestrodatabase.com/blog/nice-publishes-draft-guidance-on-the-use-of-a-topical-gel-by-patients-with-a-rare-cancer 2020-08-05T21:39:34 https://maestrodatabase.com/blog/health-canada-grants-marketing-authorisation-for-kalydeco-ivacaftor-for-patients-with-cystic-fibrosis-between-the-ages-of-4-months-and-18-years-with-the-r117h-mutation-in-the-cftr-gene 2022-03-28T06:39:43 https://maestrodatabase.com/blog/big-pharma-may-have-to-reveal-government-deals-in-whos-draft-pandemic-rules 2022-11-21T06:09:41 https://maestrodatabase.com/blog/anavex-life-sciences-receives-tga-special-access-scheme-approval-for-anavex-2-73-blarcamesine-for-alzheimers-disease-patients 2020-08-05T21:56:39 https://maestrodatabase.com/blog/moderna-is-pricing-coronavirus-vaccine-at-32-dollars-to-37-dollars-per-dose-for-some-customers 2020-08-05T21:11:56 https://maestrodatabase.com/blog/atagi-update-following-weekly-covid-19-meeting-23-march-2022 2022-03-28T06:07:09 https://maestrodatabase.com/blog/roche-announces-fda-authorisation-for-the-first-epstein-barr-virus-quantitative-test-on-the-cobas-6800-slash-8800-systems-to-improve-care-for-transplant-patients 2020-08-05T21:27:59 https://maestrodatabase.com/blog/fda-grants-priority-review-to-roches-inavolisib-for-advanced-hormone-receptor-positive-her2-negative-breast-cancer-with-a-pik3ca-mutation 2024-05-30T00:44:37 https://maestrodatabase.com/blog/a-drug-that-treats-cystic-fibrosis-has-been-listed-on-the-pharmaceutical-benefits-scheme 2019-07-21T13:53:12 https://maestrodatabase.com/blog/fda-cancer-chief-wants-quicker-ways-to-pull-failed-drugs 2022-11-21T05:16:37 https://maestrodatabase.com/blog/canada-inks-deals-with-pfizer-moderna-for-coronavirus-vaccine-candidates 2020-08-05T21:33:52 https://maestrodatabase.com/blog/evusheld-long-acting-antibody-combination-approved-in-the-eu-for-pre-exposure-prophylaxis-of-covid-19-in-a-broad-population 2022-03-28T06:22:59 https://maestrodatabase.com/blog/why-do-americans-pay-so-much-for-prescription-drugs 2019-07-21T10:07:59 https://maestrodatabase.com/blog/atidarsagene-autotemcel-for-treating-metachromatic-leukodystrophy 2022-03-28T10:13:38 https://maestrodatabase.com/blog/novadip-biosciences-receives-rare-paediatric-disease-priority-review-and-orphan-disease-designation 2020-12-26T22:18:40 https://maestrodatabase.com/blog/health-canada-grants-market-authorisation-for-kalydeco-ivacaftor-in-children-ages-12-to-<24-months-with-certain-mutations-in-the-cftr-gene 2019-01-29T06:02:05 https://maestrodatabase.com/blog/xenpozyme-olipudase-alfa-approved-in-japan-first-and-only-approved-therapy-indicated-to-treat-acid-sphingomyelinase-deficiency 2022-03-28T09:56:04 https://maestrodatabase.com/blog/blueprint-medicines-ayvakyt-avapritinib-receives-european-commission-approval-for-the-treatment-of-adults-with-advanced-systemic-mastocytosis 2022-03-28T10:24:00 https://maestrodatabase.com/blog/quebec-becomes-first-province-in-canada-to-list-new-subcutaneous-opdivo-on-public-drug-plan-for-solid-tumour-indications 2025-12-13T07:37:02 https://maestrodatabase.com/blog/biocryst-announces-fda-approval-of-orladeyo-berotralstat-oral-pellets-first-and-only-oral-prophylactic-treatment-for-patients-with-hae-aged-2-to-<12-years 2025-12-13T07:43:09 https://maestrodatabase.com/blog/adjustment-for-baseline-characteristics-in-randomised-clinical-trials 2022-11-21T07:46:18 https://maestrodatabase.com/blog/are-patient-satisfaction-instruments-harming-both-patients-and-physicians 2022-11-21T07:34:37 https://maestrodatabase.com/blog/fda-approves-two-oral-therapies-to-treat-gonorrhea 2025-12-13T07:53:52 https://maestrodatabase.com/blog/china-approves-takeda-cancer-drug 2022-03-28T09:51:15 https://maestrodatabase.com/blog/bristol-myers-squibb-warns-us-price-reforms-will-dent-drug-development 2022-11-21T07:43:42 https://maestrodatabase.com/blog/cormedix-announces-fda-acceptance-of-resubmission-of-new-drug-application-for-defencath 2023-06-21T22:04:51 https://maestrodatabase.com/blog/new-quality-innovation-expert-group-supports-medicine-innovation 2022-11-21T20:12:25 https://maestrodatabase.com/blog/fda-updates-sotrovimab-emergency-use-authorisation 2022-04-05T20:23:41 https://maestrodatabase.com/blog/us-fda-accepts-for-priority-review-the-biologics-license-application-for-epcoritamab-duobody-cd3xcd20-for-the-treatment-of-relapsed-slash-refractory-large-b-cell-lymphoma 2022-11-21T20:14:44 https://maestrodatabase.com/blog/moderna-applies-to-swissmedic-for-authorisation-of-a-second-bivalent-covid-19-vaccine 2022-11-21T20:09:37 https://maestrodatabase.com/blog/icer-publishes-evidence-report-on-treatments-for-covid-19 2022-03-28T19:55:39 https://maestrodatabase.com/blog/u-dot-s-fda-approves-fintempla-fenfluramine-oral-solution-for-treatment-of-seizures-associated-with-lennox-gastaut-syndrome 2022-03-28T19:50:02 https://maestrodatabase.com/blog/nucala-mepolizumab-receives-positive-chmp-opinion-for-treatment-of-chronic-obstructive-pulmonary-disease 2025-12-13T08:23:48 https://maestrodatabase.com/blog/kiwi-myeloma-cancer-sufferers-dont-have-access-to-daratumumab-a-drug-available-in-australia 2022-11-21T20:42:25 https://maestrodatabase.com/blog/depemokimab-receives-positive-chmp-opinion-for-severe-asthma-with-type-2-inflammation-and-chronic-rhinosinusitis-with-nasal-polyps 2025-12-13T08:30:43 https://maestrodatabase.com/blog/dupixent-dupilumab-injection-now-approved-in-canada-for-the-treatment-of-severe-asthma-in-children-aged-six-to-11-years-with-type-2-inflammation 2022-03-28T20:23:15 https://maestrodatabase.com/blog/medicare-2-dot-0---a-vision-for-the-future-of-americas-health-insurance-plan 2022-11-21T20:29:34 https://maestrodatabase.com/blog/te-pati-maori-demand-accountability-from-pharmac-ce-for-lie-about-live-saving-trikafta-drug-cost 2022-03-28T20:13:37 https://maestrodatabase.com/blog/tlv-subsidises-anti-viral-treatment-of-covid-19-to-risk-groups 2022-11-21T20:33:01 https://maestrodatabase.com/blog/tlv-subsidises-drugs-against-cystic-fibrosis 2022-11-21T20:23:50 https://maestrodatabase.com/blog/fda-use-of-proxies-to-expedite-drug-approvals-not-supported-by-evidence-analysis-finds 2024-05-30T01:28:37 https://maestrodatabase.com/blog/upmc-health-plan-announces-innovative-value-based-agreement-with-astrazeneca 2019-01-29T06:32:55 https://maestrodatabase.com/blog/janssen-announces-european-commission-approval-of-erleada-apalutamide-for-non-metastatic-castration-resistant-prostate-cancer-patients-who-are-at-high-risk-of-developing-metastatic-disease 2019-01-29T06:28:14 https://maestrodatabase.com/blog/cytokinetics-announces-positive-chmp-opinion-of-myqorzo-aficamten-for-the-treatment-of-obstructive-hypertrophic-cardiomyopathy 2025-12-13T08:02:04 https://maestrodatabase.com/blog/gsks-rsv-vaccine-arexvy-receives-positive-chmp-opinion-for-all-adults-18-years-and-older 2025-12-13T08:07:43 https://maestrodatabase.com/blog/vyluma-announces-marketing-authorisation-application-validation-for-the-european-union 2024-05-30T02:12:40 https://maestrodatabase.com/blog/its-not-minutes-to-midnight-private-health-insurers-are-financially-robust-says-former-regulator 2019-07-21T22:43:28 https://maestrodatabase.com/blog/reducing-the-cost-of-medicines-through-new-pbs-listings 2021-08-02T02:16:54 https://maestrodatabase.com/blog/the-china-center-for-drug-evaluation-national-medical-products-administration-has-recommended-breakthrough-therapy-designation-for-ciltacabtagene-autoleucel-an-investigational-bcma-car-t-cell-therapy 2020-08-06T01:03:22 https://maestrodatabase.com/blog/sharing-of-clinical-trial-data-and-results-reporting-practices-among-large-pharmaceutical-companies-cross-sectional-descriptive-study-and-pilot-of-a-tool-to-improve-company-practices 2019-07-21T22:49:25 https://maestrodatabase.com/blog/fda-approves-car-t-cell-therapy-to-treat-adults-with-certain-types-of-large-b-cell-lymphoma 2017-10-19T04:45:37 https://maestrodatabase.com/blog/2019-october-price-disclosure-cycle---indicative-prices 2019-07-22T08:40:47 https://maestrodatabase.com/blog/novartis-key-multiple-sclerosis-product-gilenya-approved-in-china 2019-07-22T08:34:10 https://maestrodatabase.com/blog/decision-to-decline-inactive-medicines-funding-applications 2020-03-20T03:02:04 https://maestrodatabase.com/blog/lessons-from-the-latest-aca-battle 2017-10-19T04:57:25 https://maestrodatabase.com/blog/uptravi-selexipag-receives-fda-approval-for-intravenous-use-in-adult-patients-with-pulmonary-arterial-hypertension 2021-08-02T02:30:49 https://maestrodatabase.com/blog/nice-announces-details-of-health-technology-evaluation-methods-review 2019-07-22T12:46:01 https://maestrodatabase.com/blog/national-medicines-policy-review-will-be-significant-for-all-australians 2021-08-02T02:24:43 https://maestrodatabase.com/blog/abbvie-announces-european-commission-approval-of-aquipta-atogepant-for-the-preventive-treatment-of-migraine-in-adults 2023-08-17T07:29:34 https://maestrodatabase.com/blog/australias-national-medicines-policy-is-outdated-and-in-need-of-review 2019-07-22T09:13:11 https://maestrodatabase.com/blog/government-subsidises-medicine-to-combat-high-cholesterol-in-high-risk-australians 2021-08-02T02:40:27 https://maestrodatabase.com/blog/infants-with-cystic-fibrosis-to-breathe-easier-with-new-pbs-listing 2019-07-22T08:56:41 https://maestrodatabase.com/blog/vertex-submits-new-drug-application-to-the-u-dot-s-fda-for-triple-combination-regimen-of-vx-445-elexacaftor-tezacaftor-and-ivacaftor-in-cystic-fibrosis 2019-07-22T12:57:34 https://maestrodatabase.com/blog/government-to-invest-ps16-million-in-life-saving-medical-advances 2019-07-22T12:48:35 https://maestrodatabase.com/blog/fda-approves-first-generics-of-lyrica 2019-07-22T21:24:01 https://maestrodatabase.com/blog/nice-numbers-at-20 2019-07-22T13:15:36 https://maestrodatabase.com/blog/should-national-pharmacare-apply-a-value-based-insurance-design 2019-07-22T13:07:18 https://maestrodatabase.com/blog/phrma-scrambles-to-fight-potential-drug-pricing-reforms-in-budget-deal 2019-07-22T13:03:06 https://maestrodatabase.com/blog/verrica-pharmaceuticals-announces-resubmission-of-new-drug-application-for-vp-102-for-the-treatment-of-molluscum-contagiosum 2023-01-24T19:13:42 https://maestrodatabase.com/blog/i-owe-it-everything-cancer-drug-approval-win-for-rare-cancers 2019-07-22T21:29:27 https://maestrodatabase.com/blog/affimed-receives-fast-track-designation-for-combination-therapy-of-afm24-with-atezolizumab-for-egfr-wild-type-non-small-cell-lung-cancer 2024-05-30T04:26:17 https://maestrodatabase.com/blog/pandemic-delays-fda-decision-on-biocons-bevacizumab-application 2020-12-27T02:43:34 https://maestrodatabase.com/blog/more-efficacious-dose-of-wegovy-recommended-by-the-ema-can-help-people-with-obesity-achieve-an-average-of-20-dot-7-percent-weight-loss 2025-12-13T21:27:54 https://maestrodatabase.com/blog/dr-reddys-laboratories-global-response-aid-and-appili-therapeutics-announce-the-filing-of-an-application-for-reeqonus-favipiravir-tablets-for-the-treatment-of-covid-19-under-health-canadas-interim-order 2020-12-27T03:47:00 https://maestrodatabase.com/blog/roche-receives-fda-approval-for-the-first-companion-diagnostic-to-identify-patients-with-her2-ultralow-metastatic-breast-cancer-eligible-for-enhertu 2025-02-03T05:13:47 https://maestrodatabase.com/blog/fda-approves-another-amazing-and-costly-cancer-killing-gene-therapy 2017-10-19T06:56:31 https://maestrodatabase.com/blog/us-fda-accepts-biologics-license-application-for-hlx11-biosimilar-candidate-of-perjeta-pertuzumab 2025-02-03T05:10:14 https://maestrodatabase.com/blog/seqirus-receives-health-canada-approval-for-expanded-age-indication-of-its-cell-based-quadrivalent-influenza-vaccine-for-people-as-young-as-six-months 2022-03-29T01:24:30 https://maestrodatabase.com/blog/teva-announces-submission-of-biologics-license-application-for-fremanezumab-to-the-u-dot-s-fda 2017-10-19T07:06:09 https://maestrodatabase.com/blog/proposal-to-fund-a-new-oral-contraceptive-pill 2025-02-03T01:30:44 https://maestrodatabase.com/blog/fda-acceptance-for-the-filing-of-new-drug-application 2020-12-27T04:45:17 https://maestrodatabase.com/blog/same-cancer-worse-results-and-twice-the-cost-in-the-us 2018-06-04T05:14:36 https://maestrodatabase.com/blog/odronextamab-receives-ema-filing-acceptance-for-treatment-of-relapsed-slash-refractory-follicular-lymphoma-and-diffuse-large-b-cell-lymphoma 2023-08-17T20:46:29 https://maestrodatabase.com/blog/apotex-builds-momentum-in-canadas-biosimilar-market-after-worlds-first-approval 2018-06-04T05:06:55 https://maestrodatabase.com/blog/imfinzi-recommended-for-approval-in-the-eu-by-chmp-as-first-and-only-immunotherapy-for-limited-stage-small-cell-lung-cancer 2025-02-03T07:54:18 https://maestrodatabase.com/blog/keytruda-backed-for-basket-of-new-cancers-via-nhs 2023-08-17T20:42:32 https://maestrodatabase.com/blog/amicus-therapeutics-announces-approval-and-launch-of-new-pompe-disease-therapy-in-the-united-kingdom 2023-08-17T21:38:45 https://maestrodatabase.com/blog/pbac-weight-loss-drug-decision-imminent 2025-12-13T22:17:17 https://maestrodatabase.com/blog/data-privacy-in-the-age-of-big-data 2017-10-19T19:55:17 https://maestrodatabase.com/blog/european-commission-adopts-rules-for-joint-clinical-assessments 2024-05-30T06:13:12 https://maestrodatabase.com/blog/aflibercept-8-mg-recommended-for-eu-approval-for-third-retinal-indication 2025-12-13T23:11:18 https://maestrodatabase.com/blog/health-insurer-anthem-takes-pharmacy-business-in-house-taps-cvs-to-help 2017-10-19T20:04:42 https://maestrodatabase.com/blog/do-france-germany-and-italy-agree-on-the-added-therapeutic-value-of-medicines 2023-08-17T21:03:21 https://maestrodatabase.com/blog/open-letter-to-health-ministers-on-codeine-upscheduling 2017-10-19T20:00:08 https://maestrodatabase.com/blog/trump-appears-to-back-further-away-from-bipartisan-health-care-push 2017-10-19T20:14:04 https://maestrodatabase.com/blog/atagi-statement-regarding-vaccination-of-adolescents-aged-12-15-years 2021-08-02T04:58:22 https://maestrodatabase.com/blog/breast-cancer-brca-study-sent-to-canada-because-u-dot-s-thinks-women-cant-handle-genetic-test-results 2017-10-19T20:29:18 https://maestrodatabase.com/blog/saphnelo-anifrolumab-approved-in-the-us-for-moderate-to-severe-systemic-lupus-erythematosus 2021-08-02T06:26:19 https://maestrodatabase.com/blog/neurocrine-biosciences-announces-regulatory-approval-of-dysval-valbenazine-for-the-treatment-of-tardive-dyskinesia-in-japan 2022-03-29T09:55:30 https://maestrodatabase.com/blog/record-investment-in-the-future-of-australias-health-system 2022-03-29T09:59:35 https://maestrodatabase.com/blog/european-medicines-agency-commences-review-of-novel-gene-therapy-candidate-etranacogene-dezaparvovec-for-people-with-haemophilia-b 2022-03-29T09:39:39 https://maestrodatabase.com/blog/ondexxya-approved-in-japan-for-reversal-of-acute-major-bleeds-in-patients-on-factor-xa-inhibitors 2022-03-29T09:48:20 https://maestrodatabase.com/blog/santhera-and-reveragen-start-rolling-nda-submission-to-the-fda-for-vamorolone-for-the-treatment-of-duchenne-muscular-dystrophy 2022-03-29T11:06:44 https://maestrodatabase.com/blog/european-medicines-agency-accepts-iveric-bios-marketing-authorisation-application-for-avacincaptad-pegol-for-geographic-atrophy 2023-08-17T23:45:24 https://maestrodatabase.com/blog/novo-nordisk-receives-fda-approval-of-higher-dose-ozempic-2-mg-providing-increased-glycemic-control-for-adults-with-type-2-diabetes 2022-03-29T11:23:59 https://maestrodatabase.com/blog/tarlige-tablets-approved-in-japan-for-treatment-of-patients-with-neuropathic-pain 2022-03-29T10:24:27 https://maestrodatabase.com/blog/budget-2022-23---no-big-bang-announcements-in-health 2022-03-29T10:10:17 https://maestrodatabase.com/blog/consequences-of-us-fda-approval-decisions-in-high-income-countries 2022-03-29T11:00:35 https://maestrodatabase.com/blog/two-more-eu-member-states-benefit-from-eu-us-mutual-recognition-agreement-for-inspections 2018-06-04T07:39:08 https://maestrodatabase.com/blog/nice-recommends-sobis-doptelet-to-treat-thrombocytopenia 2022-11-22T10:03:34 https://maestrodatabase.com/blog/durvalumab-with-tremelimumab-for-the-first-line-treatment-of-patients-with-advanced-or-unresectable-hepatocellular-carcinoma 2025-02-04T01:37:54 https://maestrodatabase.com/blog/prices-keep-rising-for-drugs-treating-painful-sex-in-women 2018-06-04T08:22:59 https://maestrodatabase.com/blog/six-month-countdown-to-go-live-for-the-clinical-trials-information-system 2021-08-02T10:08:23 https://maestrodatabase.com/blog/european-medicines-agency-validates-bristol-myers-squibbs-application-for-opdivo-nivolumab-with-chemotherapy-as-neo-adjuvant-treatment-for-resectable-non-small-cell-lung-cancer 2022-03-29T20:05:05 https://maestrodatabase.com/blog/insurer-denies-access-to-drugs-granted-accelerated-approval-by-fda 2025-02-04T01:07:35 https://maestrodatabase.com/blog/gadopiclenol-marketing-authorisation-dossier-submissions-accepted-for-review-by-ema-and-fda 2022-03-29T19:59:42 https://maestrodatabase.com/blog/government-fails-to-adequately-address-medicine-affordability-for-working-australians 2022-03-29T19:47:54 https://maestrodatabase.com/blog/palatin-technologies-announces-fda-acceptance-for-review-of-bremelanotide-nda 2018-06-04T11:36:27 https://maestrodatabase.com/blog/carfilzomib-in-combination-with-daratumumab-and-dexamethasone-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma 2022-11-22T08:01:53 https://maestrodatabase.com/blog/us-fda-approves-bristol-myers-squibbs-breyanzi-as-a-new-car-t-cell-therapy-for-relapsed-or-refractory-mantle-cell-lymphoma 2024-05-30T20:56:23 https://maestrodatabase.com/blog/federal-budget-2022-more-funding-for-breast-cancer-drug-trodelvy 2022-03-29T19:55:52 https://maestrodatabase.com/blog/clovis-oncology-submits-application-to-ema-to-expand-use-of-rubraca-rucaparib-to-include-maintenance-treatment-for-women-with-recurrent-ovarian-cancer 2018-06-04T11:14:06 https://maestrodatabase.com/blog/budget-2024-health-no-funding-for-promised-cancer-drugs-disappoints-breast-cancer-patient---extension-to-screening-welcomed 2024-05-30T20:51:08 https://maestrodatabase.com/blog/lipocine-announces-its-partner-received-fda-approval-of-tlando 2022-03-29T19:50:13 https://maestrodatabase.com/blog/tisagenlecleucel-for-the-treatment-of-patients-with-follicular-lymphoma-after-two-or-more-therapies 2022-11-22T07:53:57 https://maestrodatabase.com/blog/europes-drug-agency-warns-of-bigger-staff-losses-in-brexit-move 2018-06-04T11:51:17 https://maestrodatabase.com/blog/gsk-provides-an-update-on-blenrep-belantamab-mafodotin-blmf-us-marketing-authorisation 2022-11-22T19:29:00 https://maestrodatabase.com/blog/alkermes-receives-fda-fast-track-designation-for-nemvaleukin-alfa-for-the-treatment-of-mucosal-melanoma 2021-08-02T11:27:17 https://maestrodatabase.com/blog/rule-out-chemotherapy-for-early-breast-cancer---but-first-take-a-5-000-dollars-test 2018-06-04T12:11:02 https://maestrodatabase.com/blog/working-towards-harmonised-access-to-clinical-trial-data-across-european-drug-regulatory-agencies 2021-08-02T11:19:22 https://maestrodatabase.com/blog/fda-authorises-second-booster-dose-of-two-covid-19-vaccines-for-older-and-immunocompromised-individuals 2022-03-29T20:15:56 https://maestrodatabase.com/blog/libtayo-cemiplimab-approved-by-the-european-commission-as-the-first-immunotherapy-in-second-line-recurrent-or-metastatic-cervical-cancer-irrespective-of-pd-l1-expression-level-or-tumour-histology 2022-11-22T19:23:06 https://maestrodatabase.com/blog/milestone-receives-fda-approval-of-cardamyst-etripamil-as-first-and-only-self-administered-nasal-spray-for-adults-with-paroxysmal-supraventricular-tachycardia 2025-12-14T01:13:17 https://maestrodatabase.com/blog/statement-from-fda-commissioner-on-proposed-modernisation-of-fdas-drug-review-office 2018-06-04T21:04:05 https://maestrodatabase.com/blog/junshi-biosciences-announces-approval-of-supplemental-application-for-additional-indications-of-adalimumab-injection 2022-11-22T19:17:46 https://maestrodatabase.com/blog/english-translation-of-iqwigs-updated-general-methods-now-available 2018-06-04T21:10:55 https://maestrodatabase.com/blog/benlysta-now-approved-in-canada-in-addition-to-standard-therapy-for-treatment-of-active-lupus-nephritis-in-adult-patients 2021-08-02T10:25:47 https://maestrodatabase.com/blog/fda-approves-first-biosimilar-to-neulasta-to-help-reduce-the-risk-of-infection-during-cancer-treatment 2018-06-04T20:59:08 https://maestrodatabase.com/blog/cimzia-is-the-first-and-only-biologic-approved-in-europe-with-the-option-for-a-reduced-maintenance-dose-for-patients-across-the-full-axial-spondyloarthritis-spectrum 2020-08-06T08:39:33 https://maestrodatabase.com/blog/argenx-announces-us-fda-acceptance-of-biologics-license-application-for-subcutaneous-efgartigimod-in-generalised-myasthenia-gravis-with-priority-review 2022-11-22T10:18:37 https://maestrodatabase.com/blog/gsk-receives-authorization-under-health-canadas-interim-order-for-sotrovimab-for-injection-to-treat-covid-19-in-high-risk-adults-and-adolescents 2021-08-02T10:36:38 https://maestrodatabase.com/blog/nurix-therapeutics-awarded-innovation-passport-for-entry-into-innovative-licensing-and-access-pathway-in-the-united-kingdom-for-nx-1607 2022-03-29T20:10:33 https://maestrodatabase.com/blog/health-experts-to-fda-make-your-vaccine-deliberations-public 2020-08-06T20:52:47 https://maestrodatabase.com/blog/fondazione-telethon-submits-eu-marketing-authorisation-application-for-etuvetidigene-autotemcel-gene-therapy-for-the-treatment-of-wiskott-aldrich-syndrome 2025-02-04T04:34:31 https://maestrodatabase.com/blog/private-patients-in-public-beds-pushing-up-costs-hunt 2018-06-04T21:25:21 https://maestrodatabase.com/blog/principles-for-deliberative-processes-in-health-technology-assessment 2020-08-06T21:00:13 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-european-commission-approval-for-opdivo-nivolumab-as-adjuvant-treatment-for-oesophageal-or-gastro-oesophageal-junction-cancer-patients-with-residual-pathologic-disease-following-chemoradiotherapy 2021-08-02T11:43:25 https://maestrodatabase.com/blog/ucb-submits-response-to-fda-complete-response-letter-for-bimekizumab 2022-11-22T19:41:10 https://maestrodatabase.com/blog/comparison-of-clinical-evidence-submitted-to-the-fda-and-ema-for-cell-and-gene-therapies 2025-02-04T04:31:20 https://maestrodatabase.com/blog/ucbs-bimekizumab-issued-nice-recommendation-for-severe-plaque-psoriasis 2021-08-02T11:53:38 https://maestrodatabase.com/blog/fda-approves-gsks-blenrep-belantamab-mafodotin-blmf-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma 2020-08-06T11:00:43 https://maestrodatabase.com/blog/darolutamide-in-prostate-cancer-indication-of-considerable-added-benefit 2020-08-06T21:26:08 https://maestrodatabase.com/blog/mark-cuban-has-taken-on-pharmacy-benefit-managers-and-forever-disrupted-healthcare-in-america 2022-11-22T20:06:28 https://maestrodatabase.com/blog/chmp-recommends-subcutaneous-rybrevant-amivantamab-for-the-treatment-of-patients-with-advanced-egfr-mutated-non-small-cell-lung-cancer 2025-02-04T06:41:59 https://maestrodatabase.com/blog/nice-supports-use-of-new-medicine-for-patients-with-malignant-disease 2020-08-06T21:30:36 https://maestrodatabase.com/blog/gamida-cell-provides-regulatory-update-on-omidubicel 2022-11-22T20:09:29 https://maestrodatabase.com/blog/icer-publishes-evidence-report-on-treatment-for-chronic-obstructive-pulmonary-disease 2024-05-30T22:38:01 https://maestrodatabase.com/blog/the-world-is-spending-nowhere-near-enough-on-a-coronavirus-vaccine 2020-08-06T21:04:46 https://maestrodatabase.com/blog/trump-signs-executive-order-requiring-government-to-buy-essential-drugs-from-u-dot-s-companies 2020-08-06T21:09:12 https://maestrodatabase.com/blog/highlights-from-the-8-11-december-2025-chmp-meeting 2025-12-14T01:31:08 https://maestrodatabase.com/blog/italy-becomes-first-country-to-require-pharma-to-disclose-public-funding-for-r-and-d-costs 2020-08-06T21:13:36 https://maestrodatabase.com/blog/improving-our-assessments-of-drugs-with-companion-diagnostic-tests 2024-05-30T22:04:09 https://maestrodatabase.com/blog/fda-reinforces-need-for-applicants-to-submit-thorough-and-timely-safety-information-for-combination-medical-products 2019-07-23T02:38:13 https://maestrodatabase.com/blog/novartis-psoriatic-arthritis-drug-to-get-expanded-reimbursement 2021-08-02T21:11:23 https://maestrodatabase.com/blog/nice-scientific-advice-launches-collaborative-programme-with-life-sciences-industry-body 2019-01-29T11:07:17 https://maestrodatabase.com/blog/intelgenx-receives-fda-pdufa-date-for-rizafilm 2022-11-22T20:15:58 https://maestrodatabase.com/blog/smart-pill-schizophrenia-drug-unlikely-to-move-payers 2019-07-23T02:48:45 https://maestrodatabase.com/blog/baxter-announces-u-dot-s-fda-approval-of-myxredlin-the-first-and-only-ready-to-use-insulin-for-iv-infusion 2019-07-23T02:43:31 https://maestrodatabase.com/blog/novartis-urges-government-to-minimise-disruption-in-no-deal-brexit 2019-01-29T11:11:17 https://maestrodatabase.com/blog/pfizer-moderna-raise-prices-of-covid-19-coronavirus-vaccines-for-european-union 2021-08-02T21:01:14 https://maestrodatabase.com/blog/european-medicines-agency-is-advised-to-take-steps-to-avoid-bias-concerns-over-approvals 2019-07-23T02:41:10 https://maestrodatabase.com/blog/nice-approves-first-treatment-in-pilot-of-new-approach-to-cost-comparison-fast-track-appraisals 2021-08-02T12:47:22 https://maestrodatabase.com/blog/ibrance-tough-pill-to-swallow-for-two-rotorua-women-fighting-for-lives 2019-01-29T19:30:22 https://maestrodatabase.com/blog/restore-health-insurance-rebate 2019-01-29T19:34:16 https://maestrodatabase.com/blog/drug-middlemen-got-big-markup-in-new-york-pharmacists-say 2019-01-29T19:45:52 https://maestrodatabase.com/blog/alex-azar-why-drug-prices-keep-going-up----and-why-they-need-to-come-down 2019-01-30T20:38:55 https://maestrodatabase.com/blog/americas-love-affair-with-cheap-drugs-has-a-hidden-cost 2019-01-29T19:41:23 https://maestrodatabase.com/blog/ema-publishes-agenda-for-28-31-january-chmp-meeting 2019-01-29T20:01:32 https://maestrodatabase.com/blog/identifying-the-need-for-good-practices-in-health-technology-assessment-summary-of-the-ispor-hta-council-working-group-report-on-good-practices-in-hta 2019-01-29T20:10:30 https://maestrodatabase.com/blog/pfizer-launches-chinas-first-pay-for-performance-model-for-cancer 2019-01-29T19:49:43 https://maestrodatabase.com/blog/health-affairs-study-misses-the-mark-on-medicine-costs 2019-01-29T19:56:58 https://maestrodatabase.com/blog/fdas-pazdur-challenges-attack-on-accelerated-approval-program 2021-08-02T22:34:08 https://maestrodatabase.com/blog/payers-need-access-to-pre-approval-drug-information 2017-10-19T23:15:28 https://maestrodatabase.com/blog/cystic-fibrosis-patients-may-take-state-to-court-over-medicine-funding 2017-10-19T23:35:29 https://maestrodatabase.com/blog/estimating-overall-survival-in-people-receiving-pbs-listed-cancer-medicines-in-australian-clinical-practice 2023-08-18T03:56:00 https://maestrodatabase.com/blog/nh-theraguix-receives-fda-fast-track-designation-for-aguix-its-novel-radio-enhancer-in-the-treatment-of-malignant-gliomas-and-provides-an-update-on-its-developments-and-prospects 2024-05-31T01:42:16 https://maestrodatabase.com/blog/medexus-and-ontarios-provincial-health-services-successfully-complete-agreements-for-public-reimbursement-of-trecondyv-treosulfan-for-injection-in-ontario-canada 2025-02-05T04:40:40 https://maestrodatabase.com/blog/annual-report-highlights-progress-in-science-medicines-and-health-in-2023 2024-05-31T01:35:25 https://maestrodatabase.com/blog/gilead-submits-marketing-authorisation-applications-to-ema-for-twice-yearly-lenacapavir-for-hiv-prevention 2025-02-05T04:32:41 https://maestrodatabase.com/blog/fda-approves-roches-susvimo-as-the-first-and-only-continuous-delivery-treatment-for-the-leading-cause-of-diabetes-related-blindness 2025-02-05T04:29:24 https://maestrodatabase.com/blog/comanche-biopharma-awarded-innovation-passport-designation-by-the-uk-innovative-licensing-and-access-pathway-steering-group-for-cbp-4888-an-investigational-sirna-drug-candidate-for-the-treatment-of-sflt1-mediated-preterm-pre-eclampsia 2025-02-04T23:21:25 https://maestrodatabase.com/blog/lynparza-approved-in-japan-for-the-treatment-of-advanced-ovarian-prostate-and-pancreatic-cancers 2020-12-28T09:22:48 https://maestrodatabase.com/blog/a-conservative-group-paints-trumps-drug-pricing-experiment-as-socialist-dot-is-it 2019-07-23T04:20:31 https://maestrodatabase.com/blog/cystic-fibrosis-early-access-granted-to-the-kaftrio-slash-kalydeco-combination 2022-03-30T01:34:01 https://maestrodatabase.com/blog/fda-approves-first-gene-therapy-to-treat-adults-with-haemophilia-b 2022-11-23T02:44:06 https://maestrodatabase.com/blog/drug-maker-group-boosts-lobbying-as-push-to-lower-prices-stalls 2019-07-23T06:06:33 https://maestrodatabase.com/blog/informed-financial-consent-guide---launched 2019-07-23T06:03:04 https://maestrodatabase.com/blog/pembrolizumab-for-adjuvant-treatment-of-patients-with-resected-non-small-cell-lung-cancer-final-guidance 2025-02-05T04:57:12 https://maestrodatabase.com/blog/elacestrant-dihydrochloride-for-the-treatment-of-patients-with-advanced-oestrogen-receptor-positive-her2-negative-breast-cancer-with-an-esr1-mutation-after-endocrine-treatment-final-guidance 2025-02-05T04:50:01 https://maestrodatabase.com/blog/mum-needs-100-000-dollars-to-treat-baby-son-with-infantile-hypophosphatasia 2019-07-23T05:59:48 https://maestrodatabase.com/blog/viiv-healthcare-announces-fda-approval-of-an-expanded-indication-for-dovato-dolutegravir-slash-lamivudine-a-complete-two-drug-regimen-for-virologically-suppressed-adults-with-hiv-1 2020-08-07T00:32:18 https://maestrodatabase.com/blog/ucb-announces-approval-of-cimzia-in-china 2019-07-23T06:16:39 https://maestrodatabase.com/blog/catalyst-pharmaceuticals-firdapse-amifampridine-phosphate-receives-marketing-approval-in-canada-for-patients-with-lems 2020-08-07T01:18:15 https://maestrodatabase.com/blog/pbs-listings-bring-greater-hope-in-fight-against-multiple-myeloma-and-severe-psoriasis 2020-12-28T10:21:09 https://maestrodatabase.com/blog/imfinzi-durvalumab-us-label-updated-with-overall-survival-data-in-unresectable-stage-iii-non-small-cell-lung-cancer 2019-07-23T06:12:08 https://maestrodatabase.com/blog/shoot-bambi-nib-boss-pushes-to-abolish-medicare 2019-07-23T06:41:57 https://maestrodatabase.com/blog/the-commercial-differential-for-hospital-prices-responses-from-states-and-employers 2019-07-23T06:31:45 https://maestrodatabase.com/blog/chi-med-initiates-rolling-submission-of-nda-to-u-dot-s-fda-for-surufatinib-for-the-treatment-of-advanced-neuroendocrine-tumours 2020-12-28T20:26:03 https://maestrodatabase.com/blog/ema-publishes-agenda-for-22-25-july-chmp-meeting 2019-07-23T08:55:15 https://maestrodatabase.com/blog/us-fda-grants-rare-paediatric-disease-designation-to-paxalisib-for-dipg 2020-08-07T02:25:31 https://maestrodatabase.com/blog/merck-and-eisai-receive-third-breakthrough-therapy-designation-from-fda-for-keytruda-pembrolizumab-plus-lenvima-lenvatinib-combination-treatment 2019-07-23T21:30:24 https://maestrodatabase.com/blog/imbruvica-ibrutinib-u-dot-s-prescribing-information-updated-to-include-long-term-data-for-waldenstroems-macroglobulinemia 2020-12-28T10:32:40 https://maestrodatabase.com/blog/izchiq-vaccine-approved-to-protect-adults-against-chikungunya 2025-02-05T20:10:56 https://maestrodatabase.com/blog/u-dot-s-district-court-orders-fda-to-reconsider-application-for-final-approval-of-brixadi-buprenorphine-extended-release-injection-for-the-treatment-of-opioid-use-disorder 2019-07-23T14:24:37 https://maestrodatabase.com/blog/life-saving-cystic-fibrosis-miracle-drug-stuck-in-limbo 2020-12-28T20:21:24 https://maestrodatabase.com/blog/update-on-regulatory-review-of-lecanemab-for-early-alzheimers-disease-in-the-european-union-july-2024 2025-02-05T20:05:09 https://maestrodatabase.com/blog/pelosi-aide-major-bill-to-lower-drug-prices-coming-in-september 2019-07-23T13:41:43 https://maestrodatabase.com/blog/pacylex-granted-fda-fast-track-designation-for-pclx-001-for-the-treatment-of-relapsed-or-refractory-acute-myeloid-leukaemia 2022-11-23T03:32:39 https://maestrodatabase.com/blog/government-hopes-to-hook-voters-with-cheaper-drugs 2022-03-30T02:34:18 https://maestrodatabase.com/blog/lupin-submits-marketing-authorisation-application-for-etanercept-biosimilar-in-europe 2018-06-05T01:43:14 https://maestrodatabase.com/blog/drug-trials-a-ticking-time-bomb-ex-tga-agent 2022-03-30T02:25:37 https://maestrodatabase.com/blog/astellas-submits-new-drug-application-for-conditional-approval-of-avacincaptad-pegol-for-geographic-atrophy-in-japan 2025-02-05T21:55:57 https://maestrodatabase.com/blog/agenda-for-the-march-2023-pbac-meeting 2022-11-23T03:55:07 https://maestrodatabase.com/blog/blueprint-medicines-submits-supplemental-new-drug-application-to-fda-for-ayvakit-avapritinib-for-the-treatment-of-indolent-systemic-mastocytosis 2022-11-23T05:14:49 https://maestrodatabase.com/blog/adicet-bio-receives-fda-fast-track-designation-for-adi-001-for-the-treatment-of-refractory-systemic-lupus-erythematosus-with-extra-renal-involvement 2025-02-05T23:19:00 https://maestrodatabase.com/blog/trump-ally-meadows-says-president-wants-to-work-with-house-democrats-to-lower-drug-prices 2019-01-30T02:34:02 https://maestrodatabase.com/blog/abbvie-announces-european-commission-approval-of-skyrizi-risankizumab-for-the-treatment-of-moderate-to-severe-active-crohns-disease 2022-11-23T07:34:46 https://maestrodatabase.com/blog/takedas-biologics-license-application-for-dengue-vaccine-candidate-tak-003-granted-priority-review-by-us-fda 2022-11-23T05:56:34 https://maestrodatabase.com/blog/serplulimab-approved-in-the-eu-for-first-line-treatment-of-extensive-stage-small-cell-lung-cancer 2025-02-06T04:00:09 https://maestrodatabase.com/blog/bayer-files-for-approval-of-finerenone-in-heart-failure-in-the-eu 2025-02-06T03:56:24 https://maestrodatabase.com/blog/insulin-probe-looms-as-congress-opens-hearings-on-spiking-drug-prices 2019-01-30T07:05:41 https://maestrodatabase.com/blog/duchesnay-receives-approval-of-supplemental-new-drug-application-to-add-moderate-to-severe-vaginal-dryness-a-symptom-of-vulvar-and-vaginal-atrophy-due-to-menopause-to-the-indication-of-osphena-ospemifene 2019-01-30T07:13:47 https://maestrodatabase.com/blog/palisade-bio-is-granted-fast-track-designation-from-the-us-fda-for-lb1148-for-accelerated-return-of-bowel-function-following-gi-surgery 2022-11-23T05:37:26 https://maestrodatabase.com/blog/darwin-eu-welcomes-first-data-partners 2022-11-23T19:44:21 https://maestrodatabase.com/blog/y-mabs-announces-completion-of-submission-of-omburtamab-biologics-license-application-to-fda 2020-08-07T03:35:08 https://maestrodatabase.com/blog/amicus-therapeutics-announces-european-commission-approval-of-galafold-migalastat-for-adolescents-with-fabry-disease 2021-08-03T02:22:06 https://maestrodatabase.com/blog/axicabtagene-ciloleucel-for-the-treatment-of-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-after-one-systemic-treatment 2022-11-23T19:47:18 https://maestrodatabase.com/blog/biomarin-announces-advancements-in-fda-review-of-roctavian-valoctocogene-roxaparvovec-for-adults-with-severe-haemophilia-a 2022-11-23T19:37:49 https://maestrodatabase.com/blog/fda-plans-to-release-ai-drug-development-guidance-this-year 2024-05-31T05:46:34 https://maestrodatabase.com/blog/national-medicines-policy-review-committee-and-terms-of-reference 2021-08-03T02:17:07 https://maestrodatabase.com/blog/dying-father-speaks-out-about-failing-health-system 2019-01-30T20:19:42 https://maestrodatabase.com/blog/csl-lands-world-first-gene-therapy-with-5-dollars-3-cents-million-haemophilia-treatment 2022-11-23T19:33:35 https://maestrodatabase.com/blog/cancer-patient-relying-on-family-and-friends-to-help-pay-4-500-dollars-every-three-weeks-for-medication 2019-01-30T20:22:39 https://maestrodatabase.com/blog/statement-from-fda-commissioner-on-the-agencys-efforts-to-enhance-the-utility-of-the-orange-book-to-foster-drug-competition 2019-01-30T20:09:33 https://maestrodatabase.com/blog/msac-secretariat-publishes-agenda-for-march-2023-msac-meeting 2022-11-23T09:16:44 https://maestrodatabase.com/blog/farewell-london-hallo-amsterdam-ema-lowers-flag-on-24-years-in-uk 2019-01-30T20:34:48 https://maestrodatabase.com/blog/merck-receives-breakthrough-therapy-designation-from-fda-for-v114-the-companys-investigational-15-valent-conjugate-vaccine-for-the-prevention-of-invasive-pneumococcal-disease-in-infants-children-and-adolescents 2019-01-30T20:30:26 https://maestrodatabase.com/blog/immunogen-submits-biologics-license-application-to-the-us-food-and-drug-administration-for-mirvetuximab-soravtansine-in-ovarian-cancer 2022-03-30T05:28:14 https://maestrodatabase.com/blog/icer-to-assess-gene-therapies-for-sickle-cell-disease 2022-11-23T20:03:20 https://maestrodatabase.com/blog/rezvoglar-becomes-second-interchangeable-insulin-biosimilar 2022-11-23T20:14:30 https://maestrodatabase.com/blog/on-both-ends-of-capitol-both-parties-warn-big-pharma-on-drug-prices 2019-01-30T20:53:36 https://maestrodatabase.com/blog/drug-prices-are-forecast-to-grow-slowly-over-the-next-five-years-but-some-will-still-feel-pain 2019-01-30T20:40:30 https://maestrodatabase.com/blog/house-democratic-leaders-probe-3-major-drug-makers-on-insulin-prices 2019-01-30T20:42:57 https://maestrodatabase.com/blog/forxiga-approved-in-china-to-reduce-the-risk-of-cardiovascular-death-and-hospitalisation-in-adult-patients-with-symptomatic-chronic-heart-failure 2023-08-18T06:57:25 https://maestrodatabase.com/blog/innocare-announces-approval-of-hibruka-orelabrutinib-for-the-treatment-of-mantle-cell-lymphoma-in-singapore 2022-11-23T19:55:51 https://maestrodatabase.com/blog/statement-from-fda-commissioner-on-2019-efforts-to-advance-the-development-of-complex-generics-to-improve-patient-access-to-medicines 2019-01-30T21:36:16 https://maestrodatabase.com/blog/fda-drafts-new-guidance-on-formal-meetings-between-fda-biosimilar-sponsors 2018-06-05T02:52:51 https://maestrodatabase.com/blog/cms-proposes-medicare-advantage-and-part-d-payment-and-policy-updates-to-maximise-competition-and-coverage 2019-01-30T21:40:41 https://maestrodatabase.com/blog/hansa-biopharma-announces-reimbursement-in-the-netherlands-of-idefirix-imlifidase-as-desensitisation-treatment-for-highly-sensitised-kidney-transplant-patients 2021-08-03T02:45:47 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-june-2024 2024-05-31T10:43:42 https://maestrodatabase.com/blog/fda-approves-pfizers-biosimilar-ruxience-rituximab-pvvr-for-certain-cancers-and-auto-immune-conditions 2019-07-24T23:50:36 https://maestrodatabase.com/blog/fda-approves-first-generic-advair-diskus 2019-01-30T20:57:00 https://maestrodatabase.com/blog/celltrion-healthcare-announces-acceptance-and-priority-review-by-health-canada-of-new-drug-submission-for-its-monoclonal-antibody-treatment-for-covid-19-regdanvimab-ct-p59 2021-08-03T03:21:52 https://maestrodatabase.com/blog/time-for-big-picture-health-focus-doctors 2019-07-24T08:24:55 https://maestrodatabase.com/blog/mercks-biosimilar-to-abbvies-humira-wins-fda-approval 2019-07-24T08:14:29 https://maestrodatabase.com/blog/mustang-bio-receives-european-medicines-agency-prime-designation-for-mb-107-to-treat-x-linked-severe-combined-immunodeficiency-in-newly-diagnosed-infants 2021-08-03T02:39:19 https://maestrodatabase.com/blog/supernus-announces-fda-approval-of-onapgo-apomorphine-hydrochloride-for-parkinsons-disease 2025-02-06T20:06:15 https://maestrodatabase.com/blog/the-drug-price-problem-wont-heal-itself 2019-07-23T23:23:41 https://maestrodatabase.com/blog/enanta-pharmaceuticals-receives-fda-fast-track-designation-for-edp-235-its-oral-3cl-protease-inhibitor-specifically-designed-for-the-treatment-and-prevention-of-covid-19 2022-03-30T08:33:27 https://maestrodatabase.com/blog/evoke-announces-fda-submission-of-new-drug-application-for-gimoti 2018-06-05T03:14:46 https://maestrodatabase.com/blog/tagraxofusp-for-treating-blastic-plasmacytoid-dendritic-cell-neoplasm 2022-03-30T07:05:22 https://maestrodatabase.com/blog/ema-starts-rolling-review-of-covid-19-vaccine-hipra-phh-1v 2022-03-30T08:43:08 https://maestrodatabase.com/blog/fda-approves-treosulfan-with-fludarabine-as-a-preparative-regimen-for-allohsct-in-adult-and-paediatric-patients-with-aml-or-mds 2025-02-06T20:58:40 https://maestrodatabase.com/blog/msac-publishes-agenda-for-july-2022-meeting 2022-03-30T05:39:31 https://maestrodatabase.com/blog/u-dot-s-senators-grassley-wyden-announce-bipartisan-proposal-to-lower-drug-prices 2019-07-24T08:38:02 https://maestrodatabase.com/blog/acrivon-therapeutics-announces-fda-has-granted-breakthrough-device-designation-for-acr-368-oncosignature-assay-for-endometrial-cancer 2025-02-06T22:21:09 https://maestrodatabase.com/blog/novartis-receives-ec-approval-for-new-xolair-indication-to-treat-severe-chronic-rhinosinusitis-with-nasal-polyps 2020-08-07T07:57:53 https://maestrodatabase.com/blog/mabion-completes-marketing-authorisation-application-for-flagship-drug-mabioncd20-to-the-ema 2018-06-05T05:47:37 https://maestrodatabase.com/blog/gsk-files-for-licensure-of-mmr-vaccine-in-the-us 2021-08-03T05:30:19 https://maestrodatabase.com/blog/fda-approves-oral-treatment-for-spinal-muscular-atrophy 2020-08-07T21:50:47 https://maestrodatabase.com/blog/gsk-meets-south-australian-politicians-to-push-meningococcal-vaccine-program 2018-06-05T05:43:14 https://maestrodatabase.com/blog/alnylam-launches-onpattro-patisiran-for-the-treatment-of-polyneuropathy-in-hattr-amyloidosis-the-first-ever-rnai-therapeutic-approved-in-canada 2019-07-24T08:59:07 https://maestrodatabase.com/blog/fda-expands-lillys-alimta-pemetrexed-label-to-include-combination-with-keytruda-pembrolizumab-and-carboplatin-as-first-line-treatment-for-metastatic-non-squamous-non-small-cell-lung-cancer-irrespective-of-pd-l1-expression 2018-06-05T13:21:18 https://maestrodatabase.com/blog/dont-want-a-vaccine-be-prepared-to-pay-more-for-insurance 2021-08-03T09:29:54 https://maestrodatabase.com/blog/bracco-imaging-receives-fda-fast-track-designation-for-br55-ultrasound-molecular-imaging-agent-for-the-detection-of-active-bowel-inflammation-in-crohns-disease 2025-02-06T23:04:16 https://maestrodatabase.com/blog/nice-rules-against-first-line-use-of-ipsens-cabometyx 2018-06-05T13:17:43 https://maestrodatabase.com/blog/marinus-pharmaceuticals-submits-new-drug-application-to-fda-for-ganaxolone-for-the-treatment-of-seizures-associated-with-cdkl5-deficiency-disorder 2021-08-03T11:24:58 https://maestrodatabase.com/blog/nice-draft-guidance-recommends-novel-treatment-for-debilitating-inherited-skin-condition 2023-08-18T13:41:28 https://maestrodatabase.com/blog/unwavering-regulatory-safeguards-for-covid-19-vaccines 2020-08-07T21:59:42 https://maestrodatabase.com/blog/us-fda-grants-priority-review-to-roches-tecentriq-as-adjuvant-treatment-for-certain-people-with-early-non-small-cell-lung-cancer 2021-08-03T09:16:33 https://maestrodatabase.com/blog/fda-approves-first-liquid-biopsy-next-generation-sequencing-companion-diagnostic-test 2020-08-07T22:02:10 https://maestrodatabase.com/blog/urgent-appeal-for-migraine-sufferers-to-access-new-treatment 2018-06-05T13:42:23 https://maestrodatabase.com/blog/doh-publishes-revised-agenda-for-nov-2021-pbac-meeting 2021-08-03T07:18:09 https://maestrodatabase.com/blog/fda-accepts-biogens-aducanumab-biologics-license-application-for-alzheimers-disease-with-priority-review 2020-08-07T22:08:04 https://maestrodatabase.com/blog/the-fda-finally-gets-moving-on-pfizer 2021-08-03T09:20:48 https://maestrodatabase.com/blog/fda-grants-priority-review-to-roches-hemlibra-for-people-with-haemophilia-a-without-factor-viii-inhibitors 2018-06-05T13:28:45 https://maestrodatabase.com/blog/postmarket-studies-required-by-the-us-fda-for-new-drugs-and-biologics-approved-between-2009-and-2012-cross-sectional-analysis 2018-06-05T21:05:50 https://maestrodatabase.com/blog/embracing-competition-to-empower-biosimilars 2018-06-05T21:15:44 https://maestrodatabase.com/blog/fda-approves-first-generic-of-drug-used-to-treat-severe-hypoglycaemia 2020-12-29T00:52:30 https://maestrodatabase.com/blog/medibank-slams-labors-fee-cap-we-risk-ambulances-queues 2018-06-05T21:39:24 https://maestrodatabase.com/blog/rheumatoid-arthritis-drug-rinvoq-gets-insurance-benefit 2020-08-07T22:19:45 https://maestrodatabase.com/blog/where-do-the-ontario-political-parties-stand-on-prescription-drug-coverage 2018-06-05T21:22:56 https://maestrodatabase.com/blog/gradalis-secures-fda-regenerative-medicine-advanced-therapy-designation-for-vigil-gemogenovatucel-t-an-investigational-personalised-immunotherapy-for-advanced-ovarian-cancer 2025-02-06T23:13:16 https://maestrodatabase.com/blog/fda-proposes-process-modernisation-to-support-new-drug-development 2018-06-05T21:28:52 https://maestrodatabase.com/blog/pbs-legislative-amendments---1-june-2018 2018-06-06T01:56:02 https://maestrodatabase.com/blog/drug-prices-are-falling--but-not-necessarily-in-a-way-that-helps-patients 2018-06-05T21:49:28 https://maestrodatabase.com/blog/cara-therapeutics-submits-new-drug-application-to-u-dot-s-fda-for-korsuva-injection-in-haemodialysis-patients-with-moderate-to-severe-pruritus 2020-12-29T01:21:00 https://maestrodatabase.com/blog/astrazeneca-ceo-on-immunotherapy-drug-prices 2018-06-05T21:51:47 https://maestrodatabase.com/blog/senate-hearings-on-drug-prices-many-questions-few-useful-answers 2019-07-24T12:46:47 https://maestrodatabase.com/blog/bristol-myers-squibb-statement-on-istodax-romidepsin-relapsed-slash-refractory-peripheral-t-cell-lymphoma-u-dot-s-indication 2021-08-03T20:54:26 https://maestrodatabase.com/blog/fda-grants-priority-review-for-full-approval-of-tarpeyo-for-the-treatment-of-iga-nephropathy 2023-08-18T23:30:36 https://maestrodatabase.com/blog/fda-grants-priority-review-to-insmeds-brensocatib-for-treatment-of-bronchiectasis 2025-02-07T01:12:18 https://maestrodatabase.com/blog/complete-response-letter-received-from-fda-for-treosulfan 2021-08-03T13:22:49 https://maestrodatabase.com/blog/cancer-delays-slammed---health-minister-david-clark-silent-on-independent-agency 2019-07-24T21:04:30 https://maestrodatabase.com/blog/u-dot-s-dependence-on-china-for-medicine-is-a-major-problem 2019-07-24T13:01:35 https://maestrodatabase.com/blog/lorbrena-lorlatinib-supplementary-new-drug-application-in-previously-untreated-alk-positive-lung-cancer-accepted-for-priority-review-by-u-dot-s-fda 2020-12-29T01:28:41 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-additive-cardiovascular-disease-therapies 2019-07-24T12:56:09 https://maestrodatabase.com/blog/fda-approves-new-berinert-c1-esterase-inhibitor-human-intravenous-administration-kit-for-increased-patient-convenience 2021-08-03T13:35:04 https://maestrodatabase.com/blog/enough-talk--its-time-to-act-on-drug-prices 2019-07-24T21:27:47 https://maestrodatabase.com/blog/azar-calling-gop-senators-to-back-grassley-drug-price-plan 2019-07-24T21:15:16 https://maestrodatabase.com/blog/fda-seeks-input-on-biomarker-endpoint-glossary 2019-07-24T21:11:41 https://maestrodatabase.com/blog/private-health-insurance-leaves-plenty-of-people-unhappy-so-how-can-it-be-fixed 2019-07-24T21:08:08 https://maestrodatabase.com/blog/moderna-receives-fda-fast-track-designation-for-respiratory-syncytial-virus-vaccine-mrna-1345 2021-08-03T21:08:02 https://maestrodatabase.com/blog/fda-approves-first-treatment-for-severe-hypoglycaemia-that-can-be-administered-without-an-injection 2019-07-24T21:41:06 https://maestrodatabase.com/blog/patients-backed-by-dark-money-group-get-ready-to-debate-duchenne-drug-prices-it-will-not-be-boring 2019-07-24T21:30:00 https://maestrodatabase.com/blog/viiv-healthcare-announces-us-fda-approval-of-cabenuva-cabotegravir-rilpivirine-for-virologically-suppressed-adolescents-living-with-hiv-who-are-12-years-of-age-or-older-and-weigh-at-least-35-kg 2022-03-30T10:04:52 https://maestrodatabase.com/blog/janssen-submits-european-marketing-authorisation-application-for-amivantamab-for-the-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations 2020-12-29T03:13:18 https://maestrodatabase.com/blog/us-fda-approves-daybue-stix-trofinetide-for-oral-solution-a-new-powder-formulation-for-rett-syndrome 2025-12-15T02:38:29 https://maestrodatabase.com/blog/outcome-in-relation-to-discussion-of-covid-19-oral-treatments---november-2022-pbac-meeting 2022-11-24T05:21:08 https://maestrodatabase.com/blog/quebec-becomes-the-first-province-to-reimburse-minjuvi-tafasitamab-in-combination-with-lenalidomide-for-patients-with-diffuse-large-b-cell-lymphoma 2023-08-19T01:03:19 https://maestrodatabase.com/blog/bio-thera-solutions-announces-regulatory-filing-acceptance-for-bat2506-a-proposed-biosimilar-to-simponi-in-the-european-union 2025-02-08T02:15:39 https://maestrodatabase.com/blog/enhertu-approved-in-japan-for-patients-with-previously-treated-her2-positive-metastatic-breast-cancer 2022-11-24T06:03:50 https://maestrodatabase.com/blog/european-medicines-agency-validates-bristol-myers-squibbs-application-for-zeposia-ozanimod-for-the-treatment-of-ulcerative-colitis 2020-12-29T03:32:49 https://maestrodatabase.com/blog/luspatercept-for-the-treatment-of-patients-with-anaemia-caused-by-myelodysplastic-syndrome 2022-11-24T04:51:32 https://maestrodatabase.com/blog/us-fda-approves-emblaveo-aztreonam-and-avibactam-for-the-treatment-of-adults-with-complicated-intra-abdominal-infections-with-limited-or-no-treatment-options 2025-02-07T23:55:28 https://maestrodatabase.com/blog/luspatercept-for-the-treatment-of-patients-with-anaemia-caused-by-beta-thalassaemia 2022-11-24T03:28:06 https://maestrodatabase.com/blog/korea-to-add-canada-australia-to-drug-pricing-reference-country-list 2022-11-24T03:16:26 https://maestrodatabase.com/blog/fda-approves-new-opioid-for-intravenous-use-in-hospitals-other-controlled-clinical-settings 2020-08-08T01:00:04 https://maestrodatabase.com/blog/new-life-extending-treatment-for-rare-forms-of-advanced-gastro-oesophageal-cancer-recommended-by-nice 2022-11-24T09:24:35 https://maestrodatabase.com/blog/highlights-from-the-27-30-may-2024-chmp-meeting 2024-05-31T22:11:05 https://maestrodatabase.com/blog/akebia-therapeutics-receives-complete-response-letter-from-the-fda-for-vadadustat-for-the-treatment-of-anaemia-due-to-chronic-kidney-disease-in-adult-patients 2022-03-30T19:48:58 https://maestrodatabase.com/blog/camurus-announces-that-braeburn-resubmits-nda-for-brixadi-in-the-us 2022-11-24T09:17:10 https://maestrodatabase.com/blog/pfizers-oral-covid-19-treatment-arrives-in-new-zealand 2022-03-30T20:28:48 https://maestrodatabase.com/blog/veopoz-pozelimab-bbfg-receives-fda-approval-as-the-first-treatment-for-children-and-adults-with-chaple-disease 2023-08-19T02:15:49 https://maestrodatabase.com/blog/fda-officials-aim-to-stop-misuse-of-the-term-digital-biomarker 2022-03-30T20:22:10 https://maestrodatabase.com/blog/y-mabs-announces-sale-of-priority-review-voucher 2020-12-29T03:55:22 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-for-priority-review-taiho-oncologys-new-drug-application-for-futibatinib-for-cholangiocarcinoma 2022-03-30T19:57:59 https://maestrodatabase.com/blog/gps-cant-prescribe-adhd-medication-some-say-thats-a-problem 2022-11-24T19:15:22 https://maestrodatabase.com/blog/vertex-announces-new-drug-submission-for-investigational-triple-combination-medicine-for-the-treatment-of-cystic-fibrosis-has-been-accepted-for-priority-review-by-health-canada 2020-12-29T04:42:10 https://maestrodatabase.com/blog/roche-government-miss-deadline-for-tecentriq-reimbursement-talks 2022-03-30T20:08:03 https://maestrodatabase.com/blog/nice-no-for-opdivo-in-urothelial-carcinoma 2017-10-20T09:48:22 https://maestrodatabase.com/blog/xenon-provides-key-regulatory-updates-on-xen007-and-xen1101 2019-01-31T00:26:12 https://maestrodatabase.com/blog/national-prep-service-would-be-cost-effective-research-finds 2017-10-20T09:53:56 https://maestrodatabase.com/blog/mhra-chief-floats-faster-reviews-closer-ties-to-nice 2017-10-20T09:57:05 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-february-2019-update 2019-01-31T00:51:52 https://maestrodatabase.com/blog/moderna-receives-us-fda-approval-for-rsv-vaccine-mresvia 2024-05-31T23:14:44 https://maestrodatabase.com/blog/aeglea-biotherapeutics-receives-fda-breakthrough-therapy-designation-for-pegzilarginase-for-treatment-of-arginase-1-deficiency 2019-07-24T23:45:43 https://maestrodatabase.com/blog/innate-pharma-receives-fda-fast-track-designation-for-iph4102-in-relapsed-or-refractory-sezary-syndrome 2019-01-31T01:42:56 https://maestrodatabase.com/blog/application-process-changes-for-access-to-section-100---highly-specialised-drugs-medicines 2019-07-25T00:07:05 https://maestrodatabase.com/blog/albanese-labor-government-strengthening-medicare-with-over-500-dollars-million-for-womens-health 2025-02-09T20:02:37 https://maestrodatabase.com/blog/a-review-of-patient-reported-outcomes-labelling-for-oncology-drugs-approved-by-the-fda-and-the-ema-2012-2016 2019-01-31T06:55:16 https://maestrodatabase.com/blog/public-consultation-on-key-principles-for-the-electronic-product-information-of-eu-medicines 2019-01-31T13:50:36 https://maestrodatabase.com/blog/stemline-therapeutics-announces-validation-of-marketing-authorisation-application-by-the-european-medicines-agency 2019-01-31T07:04:45 https://maestrodatabase.com/blog/fda-expands-lillys-alimta-pemetrexed-label-with-combination-of-keytruda-pembrolizumab-and-platinum-chemotherapy-for-the-first-line-treatment-of-metastatic-non-squamous-non-small-cell-lung-cancer 2019-01-31T19:35:10 https://maestrodatabase.com/blog/the-pharmacist-is-out-supermarkets-close-pharmacy-counters 2020-01-27T06:48:40 https://maestrodatabase.com/blog/2022-april-cycle---brand-price-reductions-and-savings-to-patients 2022-03-31T03:50:44 https://maestrodatabase.com/blog/relief-as-government-funded-hep-c-drugs-become-available 2019-01-31T19:45:37 https://maestrodatabase.com/blog/decision-to-open-access-to-atomoxetine-and-change-funded-brand 2019-01-31T19:41:04 https://maestrodatabase.com/blog/pharmac-secures-advance-purchase-agreement-for-a-pre-exposure-covid-19-treatment 2022-03-31T03:54:25 https://maestrodatabase.com/blog/net-drug-prices-are-falling-even-as-list-prices-increase 2019-01-31T20:11:08 https://maestrodatabase.com/blog/were-giving-up-too-soon-advanced-breast-cancer-expert-calls-for-attitude-change-in-nz 2019-01-31T19:59:22 https://maestrodatabase.com/blog/vertex-an-extreme-outlier-in-pricing-and-behaviour-says-nhs-england 2019-01-31T20:26:19 https://maestrodatabase.com/blog/ema-accepts-leo-pharmas-marketing-authorisation-application-for-delgocitinib-cream-in-chronic-hand-eczema 2023-08-19T05:08:50 https://maestrodatabase.com/blog/ceos-hide-as-pressure-on-drug-prices-grows 2019-01-31T20:13:57 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-february-2019-update 2019-01-31T20:17:11 https://maestrodatabase.com/blog/boston-startup-signs-up-millions-for-lower-prescription-drug-costs 2019-08-13T08:47:42 https://maestrodatabase.com/blog/nice-rejects-janssens-zytiga-for-early-aggressive-prostate-cancer 2018-06-06T10:30:35 https://maestrodatabase.com/blog/new-action-plan-to-foster-development-of-advanced-therapies 2017-10-20T23:23:50 https://maestrodatabase.com/blog/life-extending-lung-cancer-drug-will-be-more-widely-available-on-the-nhs-after-nice-review 2018-06-06T10:02:50 https://maestrodatabase.com/blog/method-paper-iqwig-puts-draft-version-6-dot-1-up-for-discussion 2021-08-24T05:44:45 https://maestrodatabase.com/blog/scottish-medicines-consortium-accepts-buvidal-for-treatment-of-opioid-dependence 2019-08-13T09:27:45 https://maestrodatabase.com/blog/optimising-the-data-available-via-health-canadas-clinical-information-portal 2021-08-24T05:37:47 https://maestrodatabase.com/blog/junshi-biosciences-and-coherus-share-update-on-the-fda-review-of-the-biologics-license-application-for-toripalimab-as-treatment-for-recurrent-or-metastatic-nasopharyngeal-carcinoma 2022-12-26T01:50:42 https://maestrodatabase.com/blog/cyltezo-adalimumab-biosimilar-from-boehringer-ingelheim-approved-in-europe-for-the-treatment-of-multiple-chronic-inflammatory-diseases 2017-11-14T19:45:30 https://maestrodatabase.com/blog/nice-to-play-key-role-in-uk-drug-fast-track-scheme 2017-11-14T19:57:20 https://maestrodatabase.com/blog/mereo-receives-ema-prime-designation-for-bps-804 2017-11-14T19:49:01 https://maestrodatabase.com/blog/xalkori-approved-by-health-canada-for-the-treatment-of-patients-with-ros1-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer 2017-11-14T20:00:50 https://maestrodatabase.com/blog/the-utility-in-composite-outcome-measures 2017-11-14T20:24:39 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-releases-draft-evidence-report-on-voretigene-neparvovec-gene-therapy-for-blindness 2017-11-14T21:20:36 https://maestrodatabase.com/blog/cost-of-medicines-a-key-election-issue 2022-04-23T05:41:23 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-july-2024 2024-06-30T21:28:59 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac---march-2022 2022-04-23T05:38:36 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-july-2024 2024-06-30T21:20:38 https://maestrodatabase.com/blog/gsk-receives-european-marketing-authorisation-for-self-injectable-formulation-of-benlysta-for-the-treatment-of-systemic-lupus-erythematosus 2017-11-14T22:01:03 https://maestrodatabase.com/blog/quanterix-granted-breakthrough-device-designation-from-u-dot-s-fda-for-nfl-test-for-multiple-sclerosis 2022-04-23T05:51:22 https://maestrodatabase.com/blog/treatment-effects-in-multi-centre-randomised-clinical-trials 2019-03-02T00:29:04 https://maestrodatabase.com/blog/fda-approves-eylea-aflibercept-injection-pre-filled-syringe 2019-08-13T20:51:45 https://maestrodatabase.com/blog/roches-vabysmo-gets-chmp-recommendation-for-third-indication-retinal-vein-occlusion 2024-06-30T22:42:46 https://maestrodatabase.com/blog/windtree-announces-fda-fast-track-designation-for-istaroxime 2019-08-13T21:07:11 https://maestrodatabase.com/blog/pfizer-receives-positive-chmp-opinion-for-lorviqua-lorlatinib-for-certain-adult-patients-with-previously-treated-alk-positive-advanced-non-small-cell-lung-cancer 2019-03-02T00:49:42 https://maestrodatabase.com/blog/memo-to-the-novartis-ceo-when-in-doubt-give-the-fda-a-heads-up 2019-08-13T21:02:41 https://maestrodatabase.com/blog/ottawas-move-to-cut-drug-prices-may-lead-to-fewer-new-launches-less-r-and-d 2019-08-13T21:19:43 https://maestrodatabase.com/blog/why-americas-biggest-charities-are-owned-by-pharmaceutical-companies 2019-08-13T21:17:21 https://maestrodatabase.com/blog/proposed-new-drug-regulations-will-hurt-all-canadians----and-ottawa-has-been-warned 2019-08-13T21:14:31 https://maestrodatabase.com/blog/canadian-drug-price-regulator-may-be-flexible-on-rare-diseases 2019-08-13T21:12:08 https://maestrodatabase.com/blog/fda-approves-daratumumab-and-hyaluronidase-fihj-with-bortezomib-lenalidomide-and-dexamethasone-for-newly-diagnosed-multiple-myeloma 2026-01-27T21:11:04 https://maestrodatabase.com/blog/trumps-canada-drug-import-plan-cant-happen-without-big-pharma 2019-08-13T21:36:43 https://maestrodatabase.com/blog/dna-data-shared-in-ways-patients-may-find-surprising 2019-08-13T21:30:22 https://maestrodatabase.com/blog/boom-in-scripts-to-fight-depression 2022-12-26T04:36:33 https://maestrodatabase.com/blog/fda-takes-new-steps-to-improve-drug-supply-chain-integrity-and-patient-safety-by-announcing-its-intention-to-begin-deactivating-outdated-drug-listing-records-in-its-database 2019-08-13T21:27:12 https://maestrodatabase.com/blog/bioarctics-partner-eisai-initiates-bla-submission-of-data-for-lecanemab-in-china 2022-12-26T04:30:27 https://maestrodatabase.com/blog/gsks-application-to-expand-use-of-nucala-mepolizumab-for-the-treatment-of-copd-accepted-for-review-by-the-european-medicines-agency 2025-03-25T01:50:49 https://maestrodatabase.com/blog/libevitug-approved-in-china-as-first-in-class-treatment-for-hepatitis-d 2026-01-27T20:35:20 https://maestrodatabase.com/blog/odronextamab-bla-for-treatment-of-relapsed-slash-refractory-follicular-lymphoma-and-diffuse-large-b-cell-lymphoma-accepted-for-fda-priority-review 2023-09-29T21:16:54 https://maestrodatabase.com/blog/european-commission-approves-rinvoq-upadacitinib-as-first-jak-inhibitor-in-the-european-union-for-the-treatment-of-both-adults-and-adolescents-with-moderate-to-severe-atopic-dermatitis 2021-08-24T20:39:08 https://maestrodatabase.com/blog/leqembi-lecanemab-for-the-treatment-of-alzheimers-disease-launched-in-china 2024-07-01T02:41:26 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-february-2021 2021-01-31T20:29:04 https://maestrodatabase.com/blog/fabre-kramer-pharmaceuticals-announces-fda-approval-of-exxua-the-first-and-only-oral-selective-5ht1a-receptor-agonist-for-the-treatment-of-major-depressive-disorder-in-adults 2023-09-29T20:58:27 https://maestrodatabase.com/blog/clovis-oncology-announces-availability-of-and-reimbursement-for-rubraca-rucaparib-tablets-for-women-with-relapsed-ovarian-cancer-in-switzerland 2021-08-24T10:34:55 https://maestrodatabase.com/blog/fda-launches-pilot-program-to-help-further-accelerate-development-of-rare-disease-therapies 2023-09-29T20:55:01 https://maestrodatabase.com/blog/ucb-announces-european-commission-approval-of-bimzelx-bimekizumab-for-the-treatment-of-adults-with-moderate-to-severe-plaque-psoriasis 2021-08-24T11:08:32 https://maestrodatabase.com/blog/fda-drug-makers-propose-new-pilots-aimed-at-speeding-rare-disease-drugs-as-part-of-user-fee-update 2021-08-24T10:39:14 https://maestrodatabase.com/blog/icer-uses-observational-real-world-evidence-to-update-2018-assessment-on-therapies-for-hereditary-angioedema-finds-therapies-far-less-cost-effective-than-earlier-estimates 2021-08-24T21:00:33 https://maestrodatabase.com/blog/esperion-announces-fda-approval-of-nexletol-bempedoic-acid-tablet-an-oral-once-daily-non-statin-ldl-cholesterol-lowering-medicine 2020-02-23T00:44:11 https://maestrodatabase.com/blog/ema-publishes-agenda-for-26-29-january-2026-chmp-meeting 2026-01-27T21:26:39 https://maestrodatabase.com/blog/humanetics-corporations-bio-300-receives-fast-track-designation-from-fda 2021-08-24T21:11:00 https://maestrodatabase.com/blog/sungen-biomedicals-world-first-new-drug-sgc001-monoclonal-antibody-receives-fda-fast-track-approval 2025-03-25T05:28:03 https://maestrodatabase.com/blog/fda-approves-expanded-peripheral-artery-disease-indication-for-xarelto-rivaroxaban-plus-aspirin-to-include-patients-after-lower-extremity-revascularisation-due-to-symptomatic-peripheral-artery-disease 2021-08-24T20:44:06 https://maestrodatabase.com/blog/increase-in-vaccine-manufacturing-capacity-for-covid-19-vaccines-from-biontech-slash-pfizer-and-moderna 2021-08-24T20:51:27 https://maestrodatabase.com/blog/rare-disease-day-2020-fda-continues-important-work-on-treatments-for-rare-diseases 2020-02-23T00:49:56 https://maestrodatabase.com/blog/sarah-fitt-appointed-as-pharmac-chief-executive 2017-11-15T00:05:59 https://maestrodatabase.com/blog/fda-approves-lundbecks-vyepti-eptinezumab-jjmr---the-first-and-only-intravenous-preventive-treatment-for-migraine 2020-02-23T02:34:12 https://maestrodatabase.com/blog/proposal-to-widen-funded-access-to-pulmonary-arterial-hypertension-treatments 2017-11-15T00:09:17 https://maestrodatabase.com/blog/immunocore-announces-that-u-dot-s-food-and-drug-administration-and-european-medicines-agency-accept-biologics-license-application-and-marketing-authorisation-application-for-tebentafusp-in-metastatic-uveal-melanoma 2021-08-24T21:22:20 https://maestrodatabase.com/blog/beigene-announces-acceptance-of-a-supplemental-biologics-license-application-in-china-for-tislelizumab-in-nasopharyngeal-cancer 2021-08-24T21:37:58 https://maestrodatabase.com/blog/government-of-canada-signs-bilateral-agreement-with-quebec-for-drugs-for-rare-diseases 2025-03-25T05:59:18 https://maestrodatabase.com/blog/geron-announces-ema-validation-of-marketing-authorisation-application-for-imetelstat-for-the-treatment-of-lower-risk-mds 2023-09-30T04:13:11 https://maestrodatabase.com/blog/stalled-initiatives-to-cut-drug-prices-frustrate-trump 2020-02-23T03:02:44 https://maestrodatabase.com/blog/health-canada-and-cadth-launch-new-initiative-to-provide-early-parallel-scientific-advice 2019-03-02T02:03:04 https://maestrodatabase.com/blog/medison-pharma-announces-public-formulary-listing-of-qinlock-ripretinib-in-canadian-provinces-ontario-and-quebec-for-advanced-gastro-intestinal-stromal-tumour-treatment 2023-09-30T05:43:27 https://maestrodatabase.com/blog/fasenra-benralizumab-receives-us-fda-approval-for-severe-eosinophilic-asthma 2017-11-15T01:15:22 https://maestrodatabase.com/blog/faslodex-fulvestrant-receives-eu-approval-for-the-treatment-of-hormone-receptor-positive-advanced-breast-cancer-in-combination-with-palbociclib 2017-11-15T01:23:17 https://maestrodatabase.com/blog/abbvie-receives-chmp-positive-opinion-for-risankizumab-skyrizi-for-the-treatment-of-moderate-to-severe-plaque-psoriasis 2019-03-02T02:19:08 https://maestrodatabase.com/blog/kyowa-hakko-kirin-announces-marketing-authorisation-application-for-mogamulizumab-validated-by-european-medicines-agency 2017-11-15T01:44:10 https://maestrodatabase.com/blog/fda-grants-approval-for-eylea-biosimilar-fyb203-slash-azhantive-aflibercept-mrbb 2024-07-01T05:10:26 https://maestrodatabase.com/blog/fda-approves-biosimilar-pyzchiva-ustekinumab-ttwe-to-be-commercialised-by-sandoz-in-us 2024-07-01T05:04:17 https://maestrodatabase.com/blog/faslodex-receives-us-fda-approval-for-the-treatment-of-advanced-breast-cancer-in-combination-with-abemaciclib 2017-11-15T11:03:51 https://maestrodatabase.com/blog/doh-publishes-revised-agenda-for-july-2024-pbac-meeting-1-july-2024 2024-07-01T05:59:54 https://maestrodatabase.com/blog/3-actions-congress-can-take-to-reduce-drug-prices 2020-02-23T20:26:17 https://maestrodatabase.com/blog/chmp-recommends-zynquista-sotagliflozin-for-the-treatment-of-adults-with-type-1-diabetes 2019-03-02T02:32:10 https://maestrodatabase.com/blog/ema-to-work-with-stakeholders-to-improve-the-product-information-for-eu-medicines 2017-11-15T11:10:36 https://maestrodatabase.com/blog/medicines-australias-position-on-potential-european-union-restrictions-and-vaccines-supply 2021-01-31T22:19:34 https://maestrodatabase.com/blog/fda-unveils-a-streamlined-path-for-the-authorisation-of-tumour-profiling-tests-alongside-its-latest-product-action 2017-11-15T19:05:02 https://maestrodatabase.com/blog/fda-opens-doors-for-more-treatments-for-rare-diseases-through-the-new-start-pilot-program 2024-07-01T05:48:51 https://maestrodatabase.com/blog/real-world-evidence-submissions-to-the-center-for-biologics-evaluation-and-research 2024-07-01T05:32:55 https://maestrodatabase.com/blog/janet-woodcock-wants-you-to-know-the-fda-is-not-picking-speed-over-safety-in-drug-approvals 2017-11-15T19:01:08 https://maestrodatabase.com/blog/first-digital-pill-approved-to-worries-about-biomedical-big-brother 2017-11-15T19:11:37 https://maestrodatabase.com/blog/fda-grants-marketing-authorisation-of-the-first-device-for-use-in-helping-to-reduce-the-symptoms-of-opioid-withdrawal 2017-11-15T19:08:37 https://maestrodatabase.com/blog/fda-grants-priority-review-for-biologics-license-application-and-ema-accepts-marketing-authorisation-application-for-apitegromab-as-a-treatment-for-spinal-muscular-atrophy 2025-03-26T00:57:16 https://maestrodatabase.com/blog/fda-approves-treatment-for-rare-genetic-enzyme-disorder 2017-11-15T19:15:19 https://maestrodatabase.com/blog/sipavibart-ema-regulatory-submission-accepted-under-accelerated-assessment-for-covid-19-prevention 2024-07-01T06:22:46 https://maestrodatabase.com/blog/blujepa-gepotidacin-approved-by-us-fda-for-treatment-of-uncomplicated-urinary-tract-infections-in-female-adults-and-paediatric-patients-12-years-of-age-and-older 2025-03-26T00:52:24 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-february-2021 2021-01-31T22:29:30 https://maestrodatabase.com/blog/drug-farm-announces-fda-fast-track-designation-for-first-in-class-alpk1-inhibitor-df-003-for-the-treatment-of-rosah-syndrome 2026-01-27T23:10:08 https://maestrodatabase.com/blog/innovent-announces-ibi3003-gprc5d-slash-bcma-slash-cd3-trispecific-antibody-receives-fast-track-designation-from-the-us-fda-for-relapsed-or-refractory-multiple-myeloma 2026-01-27T23:14:32 https://maestrodatabase.com/blog/lynparza-and-imfinzi-combination-recommended-for-approval-in-the-eu-by-chmp-for-patients-with-mismatch-repair-proficient-advanced-or-recurrent-endometrial-cancer 2024-07-01T06:07:08 https://maestrodatabase.com/blog/willoughby-mum-continues-push-for-breakthrough-treatment-for-muscle-wasting-disease 2017-11-15T19:24:03 https://maestrodatabase.com/blog/tolebrutinib-regulatory-submission-accepted-for-priority-review-in-the-us-for-patients-with-multiple-sclerosis 2025-03-26T00:46:18 https://maestrodatabase.com/blog/novel-drug-approvals-for-2025 2026-01-28T02:17:15 https://maestrodatabase.com/blog/trumps-hhs-secretary-nominee-boosted-drug-prices-while-at-eli-lilly 2017-11-15T20:01:23 https://maestrodatabase.com/blog/theratechnologies-receives-fda-approval-for-egrifta-wr-tesamorelin-f8-to-treat-excess-visceral-abdominal-fat-in-adults-with-hiv-and-lipodystrophy 2025-03-26T07:56:54 https://maestrodatabase.com/blog/revised-procedure-for-the-cadth-common-drug-review-resubmissions 2017-11-15T20:17:20 https://maestrodatabase.com/blog/otsuka-announces-fda-acceptance-and-priority-review-of-new-drug-application-for-centanafadine-for-the-treatment-of-adhd-in-children-adolescents-and-adults 2026-01-28T02:42:48 https://maestrodatabase.com/blog/new-hope-for-people-with-breathing-condition-copd-as-nice-approves-innovative-treatment 2026-01-28T00:23:52 https://maestrodatabase.com/blog/stealth-biotherapeutics-submits-elamipretide-new-drug-application-to-fda-for-treatment-of-barth-syndrome 2021-08-25T00:11:52 https://maestrodatabase.com/blog/mhra-takes-over-chair-of-international-access-consortium-for-2026 2026-01-28T00:42:11 https://maestrodatabase.com/blog/the-european-commission-extended-the-marketing-authorisation-for-vueway-gadopiclenol-in-the-european-union-for-use-in-paediatric-patients-under-2-years-of-age 2026-01-28T01:31:44 https://maestrodatabase.com/blog/evaluation-of-the-impact-of-patient-input-in-health-technology-assessments-at-nice 2021-01-31T23:06:27 https://maestrodatabase.com/blog/amarin-receives-positive-chmp-opinion-for-icosapent-ethyl-for-cardiovascular-risk-reduction 2021-01-31T23:11:33 https://maestrodatabase.com/blog/savara-completes-submission-of-the-biologics-license-application-to-the-us-fda-for-molbreevi-as-a-treatment-for-auto-immune-pulmonary-alveolar-proteinosis 2025-03-27T02:46:12 https://maestrodatabase.com/blog/medexus-pharmaceuticals-announces-resubmission-of-treosulfan-nda 2022-04-23T11:24:43 https://maestrodatabase.com/blog/fda-approves-cabozantinib-for-adults-and-paediatric-patients-12-years-of-age-and-older-with-pnet-and-epnet 2025-03-27T02:39:24 https://maestrodatabase.com/blog/chmp-recommends-eu-approval-of-roches-piasky-for-people-with-pnh-a-rare-life-threatening-blood-condition 2024-07-01T12:02:41 https://maestrodatabase.com/blog/canada-is-settling-for-half-measures-on-drug-price-regulations 2022-04-23T11:45:50 https://maestrodatabase.com/blog/soleno-therapeutics-announces-us-fda-approval-of-vykat-xr-to-treat-hyperphagia-in-prader-willi-syndrome 2025-03-27T03:04:01 https://maestrodatabase.com/blog/eu-export-restrictions-on-covid-19-vaccines-may-jeopardise-global-supply 2021-02-01T02:01:51 https://maestrodatabase.com/blog/neurocrine-biosciences-announces-us-fda-accepts-new-drug-applications-and-grants-priority-review-for-crinecerfont-for-paediatric-and-adult-patients-with-cah 2024-07-01T21:44:18 https://maestrodatabase.com/blog/updated-information-about-pharmacs-priority-lists 2024-10-08T04:23:08 https://maestrodatabase.com/blog/when-is-a-medicine-currently-under-review-by-the-tga-not-under-evaluation 2021-02-01T02:15:41 https://maestrodatabase.com/blog/novavax-submits-vaccine-for-approval-as-ottawa-seeks-eu-reassurances-on-export-rules 2021-02-01T01:39:59 https://maestrodatabase.com/blog/determinants-of-managed-entry-agreements-in-the-context-of-health-technology-assessment-a-comparative-analysis-of-oncology-therapies-in-four-countries 2021-02-01T01:55:35 https://maestrodatabase.com/blog/european-commission-approves-mercks-capvaxive-pneumococcal-21-valent-conjugate-vaccine-for-prevention-of-invasive-pneumococcal-disease-and-pneumococcal-pneumonia-in-adults 2025-03-27T05:26:57 https://maestrodatabase.com/blog/american-pharmaceutical-boss-does-not-support-tariffs-on-australian-medicines 2025-03-27T05:22:33 https://maestrodatabase.com/blog/new-and-expanded-cheaper-medicines 2025-03-27T04:57:12 https://maestrodatabase.com/blog/highlights-from-the-19-22-april-2022-chmp-meeting 2022-04-23T21:47:44 https://maestrodatabase.com/blog/janssen-announces-health-canada-approval-of-tremfya-guselkumab-for-the-treatment-of-adult-moderate-to-severe-plaque-psoriasis 2017-11-16T01:11:06 https://maestrodatabase.com/blog/chmp-recommends-eu-conditional-approval-of-roches-potential-first-in-class-bispecific-antibody-mosunetuzumab-for-people-with-relapsed-or-refractory-follicular-lymphoma 2022-04-23T21:51:42 https://maestrodatabase.com/blog/chlamydia-vaccine-candidate-granted-fast-track-designation-by-the-us-fda 2025-03-27T05:48:49 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-october-2023 2023-09-30T23:25:11 https://maestrodatabase.com/blog/viiv-healthcare-announces-reimbursement-for-apretude-for-hiv-1-pre-exposure-prophylaxis-under-the-non-insured-health-benefits-nihb-program 2025-03-27T05:44:21 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-october-2023 2023-09-30T23:05:38 https://maestrodatabase.com/blog/fda-grants-first-marketing-authorisation-for-a-dna-test-to-assess-predisposition-for-dozens-of-cancer-types 2023-09-30T23:17:18 https://maestrodatabase.com/blog/spain-says-barcelona-back-in-the-race-to-host-eu-drugs-agency 2017-11-16T02:08:43 https://maestrodatabase.com/blog/fda-approves-biogens-tofidence-tocilizumab-bavi-a-biosimilar-referencing-actemra 2023-10-01T01:13:25 https://maestrodatabase.com/blog/akcea-and-ionis-announce-acceptance-of-marketing-applications-in-us-eu-and-canada-for-volanesorsen-for-the-treatment-of-fcs 2017-11-16T02:17:31 https://maestrodatabase.com/blog/ema-publishes-agenda-for-24-27-march-2025-chmp-meeting 2025-03-27T07:04:22 https://maestrodatabase.com/blog/icer-publishes-evidence-report-on-treatment-for-retinitis-pigmentosa 2025-03-27T06:56:43 https://maestrodatabase.com/blog/chmp-recommends-approval-of-dupixent-dupilumab-for-asthma-indication 2019-03-02T20:51:25 https://maestrodatabase.com/blog/lynparza-receives-positive-eu-chmp-opinion-for-use-in-germline-brca-mutated-her2-negative-advanced-breast-cancer 2019-03-02T20:59:35 https://maestrodatabase.com/blog/richter-announces-submission-to-ema-for-biosimilar-tocilizumab-in-multiple-indications 2025-03-28T04:32:09 https://maestrodatabase.com/blog/takedas-hyqvia-receives-expanded-market-authorisation-as-maintenance-therapy-for-chronic-inflammatory-demyelinating-polyneuropathy 2025-03-28T02:11:52 https://maestrodatabase.com/blog/biogens-litifilimab-receives-fda-breakthrough-therapy-designation-for-cutaneous-lupus-erythematosus-a-disease-with-no-targeted-treatment-options 2026-01-28T23:42:24 https://maestrodatabase.com/blog/immix-biopharma-receives-us-fda-breakthrough-therapy-designation-for-nxc-201 2026-01-28T23:47:04 https://maestrodatabase.com/blog/neurim-pharmaceuticals-receives-european-marketing-authorisation-for-paediatric-prolonged-release-melatonin-slenyto-for-the-treatment-of-insomnia-in-children-with-adhd 2025-03-28T02:02:27 https://maestrodatabase.com/blog/elevar-therapeutics-submits-new-drug-application-to-fda-for-lirafugratinib-as-second-line-treatment-option-for-cholangiocarcinoma 2026-01-29T01:55:18 https://maestrodatabase.com/blog/antengene-announces-xpovio-selinexor-national-health-insurance-service-approval-for-reimbursement-in-south-korea 2024-07-01T23:29:05 https://maestrodatabase.com/blog/health-canada-grants-marketing-authorisation-for-minjuvi-tafasitamab-in-combination-with-lenalidomide-for-the-treatment-of-adults-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma 2021-08-25T03:17:01 https://maestrodatabase.com/blog/fresenius-receives-fda-approval-for-their-denosumab-biosimilars-and-secures-global-settlement-agreement 2025-03-28T01:56:04 https://maestrodatabase.com/blog/crinetics-pharmaceuticals-announces-ema-validation-of-marketing-authorisation-application-and-orphan-drug-designation-for-paltusotine-in-acromegaly 2025-03-28T04:48:22 https://maestrodatabase.com/blog/cipher-pharmaceuticals-announces-health-canadas-acceptance-for-review-of-new-drug-submission-for-natroba-spinosad 2026-01-29T02:47:39 https://maestrodatabase.com/blog/harm-reduction-therapeutics-new-drug-application-for-rivive-over-the-counter-naloxone-nasal-spray-accepted-and-granted-priority-review-by-fda 2022-12-27T03:33:20 https://maestrodatabase.com/blog/fda-label-updates-reflect-bayers-commitment-to-womens-healthcare 2021-08-25T20:34:46 https://maestrodatabase.com/blog/avastin-biosimilar-may-bring-insurance-benefits-for-tecentriq 2021-08-25T10:41:07 https://maestrodatabase.com/blog/dong-a-st-receives-health-canada-approval-for-stelara-biosimilar-imuldosa 2026-01-29T05:17:41 https://maestrodatabase.com/blog/ema-starts-rolling-review-of-regn-cov2-antibody-combination-casirivimab-slash-imdevimab 2021-02-01T19:42:55 https://maestrodatabase.com/blog/new-hiv-drug-gets-cheaper-with-subsidies 2019-03-02T23:05:55 https://maestrodatabase.com/blog/fda-accelerates-review-of-novartis-stamp-inhibitor-asciminib-abl001-for-patients-with-chronic-myeloid-leukaemia 2021-08-25T20:45:47 https://maestrodatabase.com/blog/nice-publishes-appraisal-guidance-on-new-medicine-for-patients-with-biliary-tract-cancer 2021-08-25T20:52:39 https://maestrodatabase.com/blog/adamas-announces-fda-approval-for-second-indication-for-gocovri-as-an-adjunctive-treatment-to-levodopa-slash-carbidopa-in-parkinsons-disease-patients-experiencing-off-episodes 2021-02-01T20:01:35 https://maestrodatabase.com/blog/novartis-receives-positive-chmp-opinion-for-tabrecta-for-patients-with-metex14-advanced-non-small-cell-lung-cancer 2022-04-24T01:34:34 https://maestrodatabase.com/blog/hansa-biopharma-announces-european-medicines-agency-accepts-marketing-authorisation-application-for-idefirix-imlifidase 2019-03-02T23:09:39 https://maestrodatabase.com/blog/ono-and-takeda-receive-an-approval-for-opdivo-nivolumab-and-cabometyx-cabozantinib-combination-therapy-in-japan-for-treatment-of-unresectable-or-metastatic-renal-cell-carcinoma 2021-08-25T21:09:32 https://maestrodatabase.com/blog/patient-advocate-slams-cancer-agency-report-over-wall-of-silence-on-pharmac-funding 2021-02-01T20:06:11 https://maestrodatabase.com/blog/icer-to-assess-novel-agents-to-prevent-chemotherapy-induced-neutropenia 2021-08-25T21:02:48 https://maestrodatabase.com/blog/csl-to-deliver-one-million-australian-manufactured-covid-19-vaccines-a-week-from-the-end-of-march 2021-02-01T19:48:24 https://maestrodatabase.com/blog/incyte-announces-positive-chmp-opinion-for-pemigatinib-for-the-treatment-of-adults-with-previously-treated-unresectable-locally-advanced-or-metastatic-cholangiocarcinoma-with-a-fibroblast-growth-factor-receptor-2-fusion-or-rearrangement 2021-02-01T19:51:28 https://maestrodatabase.com/blog/biogen-announces-fda-approval-of-plegridy-peginterferon-beta-1a-intramuscular-administration-for-multiple-sclerosis 2021-02-01T19:57:18 https://maestrodatabase.com/blog/new-fda-guidance-explains-that-plan-b-is-not-an-abortion-pill 2022-12-27T07:49:56 https://maestrodatabase.com/blog/chmp-recommends-eu-approval-of-roches-tecentriq-as-adjuvant-treatment-for-a-subset-of-people-with-early-stage-non-small-cell-lung-cancer 2022-04-24T01:50:31 https://maestrodatabase.com/blog/fda-issues-complete-response-letter-for-etripamil-for-psvt 2025-03-30T00:45:07 https://maestrodatabase.com/blog/fda-approves-durvalumab-for-muscle-invasive-bladder-cancer 2025-03-29T03:23:09 https://maestrodatabase.com/blog/acer-therapeutics-and-relief-therapeutics-announce-us-fda-approval-of-olpruva-for-patients-with-urea-cycle-disorders 2022-12-27T19:59:52 https://maestrodatabase.com/blog/fda-approves-novel-treatment-for-haemophilia-a-or-b-with-or-without-factor-inhibitors 2025-03-29T03:19:40 https://maestrodatabase.com/blog/merck-receives-positive-eu-chmp-opinion-for-expanded-approval-of-keytruda-pembrolizumab-in-certain-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma 2021-02-01T20:09:59 https://maestrodatabase.com/blog/ascendis-pharma-announces-u-dot-s-fda-approval-of-skytrofa-lonapegsomatropin-tcgd-the-first-once-weekly-treatment-for-paediatric-growth-hormone-deficiency 2021-08-25T21:15:48 https://maestrodatabase.com/blog/chmp-adopts-positive-opinion-for-filsuvez-for-the-treatment-of-dystrophic-and-junctional-eb 2022-04-24T01:42:18 https://maestrodatabase.com/blog/eu-nations-have-received-18-dot-5-million-covid-19-vaccines 2021-02-01T20:25:58 https://maestrodatabase.com/blog/noden-pharma-announces-fda-approval-of-tekturna-aliskiren-oral-pellets-for-the-treatment-of-hypertension-in-adults-and-children-6-years-of-age-and-older 2017-11-16T07:29:13 https://maestrodatabase.com/blog/nzaf-welcomes-pharmacs-milestone-proposal-to-fund-pre-exposure-prophylaxis 2017-11-16T08:00:02 https://maestrodatabase.com/blog/trelegy-ellipta-once-daily-single-inhaler-triple-therapy-gains-marketing-authorisation-in-europe-for-the-treatment-of-copd 2017-11-16T11:44:18 https://maestrodatabase.com/blog/vertex-pharma-gets-approval-for-cystic-fibrosis-drug-for-infants-in-canada 2021-08-25T21:48:19 https://maestrodatabase.com/blog/dont-meddle-with-medicare-to-save-a-budget 2021-08-25T21:34:53 https://maestrodatabase.com/blog/breast-cancer-patients-to-have-routine-access-to-two-life-extending-drugs-after-new-deal-say-nice-in-draft-guidance 2017-11-16T11:32:31 https://maestrodatabase.com/blog/statement-from-fda-commissioner-on-fdas-comprehensive-new-policy-approach-to-facilitating-the-development-of-innovative-regenerative-medicine-products-to-improve-human-health 2017-11-16T19:53:37 https://maestrodatabase.com/blog/fda-announces-comprehensive-regenerative-medicine-policy-framework 2017-11-16T19:50:37 https://maestrodatabase.com/blog/ema-validates-henlius-and-organon-filing-for-perjeta-pertuzumab-biosimilar-candidate-hlx11 2025-03-30T07:59:17 https://maestrodatabase.com/blog/fda-approves-new-treatment-to-prevent-bleeding-in-certain-patients-with-haemophilia-a 2017-11-16T19:58:03 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-positive-chmp-opinion-for-peri-operative-regimen-of-neo-adjuvant-opdivo-nivolumab-and-chemotherapy-followed-by-surgery-and-adjuvant-opdivo-for-resectable-non-small-cell-lung-cancer-in-patients-with-tumour-cell-pd-l1-expression-1-percent 2025-03-30T07:53:11 https://maestrodatabase.com/blog/world-first-as-mhra-approves-trofolastat-for-diagnostic-imaging-of-prostate-cancer-in-men 2025-03-30T00:59:57 https://maestrodatabase.com/blog/uwe-reinhardt-80-dies-a-listened-to-voice-on-health-care-policy 2017-11-16T20:17:40 https://maestrodatabase.com/blog/springworks-therapeutics-completes-submission-of-new-drug-application-to-the-fda-for-nirogacestat-for-the-treatment-of-adults-with-desmoid-tumours 2022-12-27T23:03:13 https://maestrodatabase.com/blog/fda-approves-genentechs-gazyva-for-previously-untreated-advanced-follicular-lymphoma 2017-11-16T20:29:03 https://maestrodatabase.com/blog/british-columbia-and-prince-edward-island-become-the-first-provinces-to-add-erelzi-etanercept-to-public-drug-plans-for-the-treatment-of-multiple-inflammatory-diseases 2017-11-16T20:38:55 https://maestrodatabase.com/blog/syncromune-granted-fda-fast-track-designation-for-sync-t-sv-102-for-the-treatment-of-metastatic-castrate-resistant-prostate-cancer 2024-07-02T02:03:51 https://maestrodatabase.com/blog/new-and-expanded-pbs-listings-for-breast-cancer-leukaemia-and-lupus-treatments 2024-07-02T02:33:27 https://maestrodatabase.com/blog/fda-expands-approval-of-sutent-to-reduce-the-risk-of-kidney-cancer-returning 2017-11-16T20:54:20 https://maestrodatabase.com/blog/industry-fees-are-applicable-to-all-cdr-resubmissions 2017-11-16T20:51:57 https://maestrodatabase.com/blog/tenpoint-therapeutics-announces-fda-approval-of-yuvezzi-the-first-and-only-combination-eye-drop-approved-to-treat-presbyopia 2026-01-29T20:31:32 https://maestrodatabase.com/blog/summit-therapeutics-announces-us-fda-acceptance-of-biologics-license-application-seeking-approval-for-ivonescimab-in-combination-with-chemotherapy-in-treatment-of-patients-with-egfrm-nsclc-post-tki-therapy 2026-01-29T20:48:43 https://maestrodatabase.com/blog/cms-announces-selection-of-drugs-for-third-cycle-of-medicare-drug-price-negotiation-program-including-first-ever-part-b-drugs 2026-01-29T21:49:07 https://maestrodatabase.com/blog/cms-proposes-policies-to-lower-the-cost-of-prescription-drugs-and-combat-the-opioid-crisis 2017-11-16T22:01:59 https://maestrodatabase.com/blog/health-canada-approves-tecentriq-atezolizumab-first-new-treatment-in-20-years-for-aggressive-form-of-lung-cancer 2019-08-14T06:50:09 https://maestrodatabase.com/blog/janssen-announces-european-commission-approval-of-imbruvica-ibrutinib-for-expanded-use-in-two-indications 2019-08-14T07:05:23 https://maestrodatabase.com/blog/ibt-is-granted-breakthrough-therapy-designation-for-its-drug-candidate 2025-03-30T21:48:15 https://maestrodatabase.com/blog/eoflow-submits-application-to-the-us-fda-for-its-wearable-insulin-pump-eopatch 2022-12-28T09:34:08 https://maestrodatabase.com/blog/calquence-granted-us-breakthrough-therapy-designation-for-chronic-lymphocytic-leukaemia 2019-08-14T12:19:40 https://maestrodatabase.com/blog/imfinzi-plus-imjudo-approved-in-japan-for-advanced-liver-and-non-small-cell-lung-cancers-and-imfinzi-approved-for-unresectable-biliary-tract-and-liver-cancers 2022-12-28T09:31:04 https://maestrodatabase.com/blog/vyne-therapeutics-announces-fda-approval-of-amzeeq-minocycline-label-ppdate 2021-02-01T23:56:22 https://maestrodatabase.com/blog/calquence-approved-in-japan-for-adults-with-treatment-naive-chronic-lymphocytic-leukaemia 2022-12-28T09:27:03 https://maestrodatabase.com/blog/icer-to-assess-evidence-on-supervised-injection-facilities-and-digital-apps-for-opioid-use-disorder 2020-02-24T04:23:07 https://maestrodatabase.com/blog/this-drug-will-save-childrens-lives-it-costs-2-dollars-million 2019-08-14T12:33:15 https://maestrodatabase.com/blog/novartis-violated-fdas-sacred-principle-in-god-we-trust-all-others-must-bring-data 2019-08-14T12:28:23 https://maestrodatabase.com/blog/japan-ministry-of-health-labor-and-welfare-approves-opdivo-nivolumab-for-the-treatment-of-patients-with-unresectable-advanced-or-recurrent-oesophageal-cancer 2020-02-24T04:19:48 https://maestrodatabase.com/blog/costing-methods-applied-to-cancer 2019-08-14T12:44:48 https://maestrodatabase.com/blog/discount-chemists-the-new-uber-former-accc-chief-backs-pharmacy-deregulation 2019-08-14T20:51:40 https://maestrodatabase.com/blog/fda-approves-new-drug-for-treatment-resistant-forms-of-tuberculosis-that-affects-the-lungs 2019-08-14T20:43:55 https://maestrodatabase.com/blog/pierre-fabre-laboratories-announce-granting-of-european-marketing-authorisation-for-obgemsa-vibegron-in-overactive-bladder 2024-07-02T06:08:08 https://maestrodatabase.com/blog/valneva-receives-marketing-authorisation-in-europe-for-the-worlds-first-chikungunya-vaccine-ixchiq 2024-07-02T06:03:37 https://maestrodatabase.com/blog/akari-therapeutics-receives-fda-fast-track-designation-for-nomacopan-for-paediatric-haematopoietic-stem-cell-transplant-related-thrombotic-microangiopathy 2019-08-14T21:00:59 https://maestrodatabase.com/blog/u-dot-s-law-makers-push-mylan-teva-over-drug-pricing-probe 2019-08-14T21:13:57 https://maestrodatabase.com/blog/drug-company-aspen-may-pay-nhs-ps8-million-after-investigation-alleges-illegal-deal-to-hike-drug-price 2019-08-14T21:10:58 https://maestrodatabase.com/blog/fda-grants-breakthrough-therapy-designation-for-trilaciclib-based-on-myelopreservation-data-in-small-cell-lung-cancer-patients 2019-08-14T21:05:24 https://maestrodatabase.com/blog/idorsias-jeraygo-aprocitentan-approved-in-europe-as-first-and-only-era-for-the-treatment-of-resistant-hypertension 2024-07-02T06:28:03 https://maestrodatabase.com/blog/states-eager-to-lower-drug-prices-regroup-after-courts-strike-down-maryland-price-gouging-law 2019-03-03T09:57:57 https://maestrodatabase.com/blog/canadians-benefitting-from-substantially-lower-generic-drug-prices 2019-08-14T21:33:44 https://maestrodatabase.com/blog/biogen-responds-to-cadths-updated-recommendation-regarding-coverage-for-spinraza 2019-03-03T09:47:12 https://maestrodatabase.com/blog/pssst-dot-dot-dot-want-to-buy-some-insulin-or-other-lifesaving-medicine-go-to-canada 2019-08-14T21:24:51 https://maestrodatabase.com/blog/the-window-for-congress-to-do-something-on-drug-prices-wont-be-open-forever 2019-08-14T21:19:43 https://maestrodatabase.com/blog/standardisation-of-practice-on-publication-of-indications-in-swiss-public-assessment-report 2024-07-02T10:22:03 https://maestrodatabase.com/blog/transformative-hiv-prep-shot-slowly-overcomes-cost-hurdles 2026-01-29T23:35:22 https://maestrodatabase.com/blog/pharmac-seeks-feedback-on-a-biosimilar-brand-of-adalimumab-being-considered-for-funding 2021-08-26T04:39:18 https://maestrodatabase.com/blog/celltrion-healthcare-receives-health-canada-marketing-authorization-for-worlds-first-subcutaneous-formulation-of-infliximab-remsima-sc-for-the-treatment-of-people-with-rheumatoid-arthritis 2021-02-02T02:10:13 https://maestrodatabase.com/blog/syapse-announces-research-collaboration-with-the-fda-focused-on-the-regulatory-use-of-real-world-evidence 2019-08-14T21:42:34 https://maestrodatabase.com/blog/longboard-pharmaceuticals-receives-breakthrough-therapy-designation-for-bexicaserin 2024-07-02T08:38:47 https://maestrodatabase.com/blog/qtx-2101-awarded-fda-fast-track-designation-for-the-treatment-of-acute-promyelocytic-leukaemia 2026-01-29T23:40:58 https://maestrodatabase.com/blog/springworks-therapeutics-completes-submission-of-new-drug-application-to-the-fda-for-mirdametinib-for-the-treatment-of-children-and-adults-with-nf1-pn 2024-07-02T07:09:15 https://maestrodatabase.com/blog/fda-approves-treatment-for-adults-with-alzheimers-disease 2024-07-02T21:13:31 https://maestrodatabase.com/blog/pfizer-and-biontech-initiate-rolling-submission-of-supplemental-biologics-license-application-to-u-dot-s-fda-for-booster-dose-of-comirnaty-in-individuals-16-and-older 2021-08-26T05:18:48 https://maestrodatabase.com/blog/icer-publishes-evidence-report-on-treatment-for-anaemia-in-myelodysplastic-syndrome 2024-07-02T12:30:30 https://maestrodatabase.com/blog/no-one-knows-the-true-cost-of-medicines-and-blaming-other-countries-wont-help 2019-03-03T19:58:07 https://maestrodatabase.com/blog/fda-breakthrough-therapy-designation-reduced-late-stage-drug-development-time 2024-07-02T10:30:12 https://maestrodatabase.com/blog/altos-biologics-files-for-approval-of-aflibercept-biosimilar 2024-07-02T10:25:19 https://maestrodatabase.com/blog/bristol-myers-squibb-application-for-zeposia-ozanimod-for-the-treatment-of-ulcerative-colitis-accepted-for-filing-with-priority-review-by-u-dot-s-fda 2021-02-02T02:33:44 https://maestrodatabase.com/blog/multiple-myeloma-treatments-available-to-more-people 2024-07-02T21:22:46 https://maestrodatabase.com/blog/canadians-wait-too-long-for-access-to-innovative-drugs-cautions-the-mei 2026-01-30T02:07:53 https://maestrodatabase.com/blog/mirum-pharmaceuticals-announces-completion-of-rolling-nda-submission-for-maralixibat-in-alagille-syndrome 2021-02-02T02:44:57 https://maestrodatabase.com/blog/novartis-announces-fda-and-ema-filing-acceptance-of-ofatumumab-a-novel-b-cell-therapy-for-patients-with-relapsing-forms-of-multiple-sclerosis 2020-02-24T07:12:32 https://maestrodatabase.com/blog/government-of-canada-announces-the-new-chairperson-of-the-patented-medicine-prices-review-board 2026-01-30T01:52:26 https://maestrodatabase.com/blog/celltrion-secures-canadian-approval-for-omlyclo-300-mg-pfs-and-auto-injector-formulations 2026-01-30T01:56:19 https://maestrodatabase.com/blog/pharmac-proposing-to-fund-two-brands-of-oestradiol-patches 2025-03-31T00:28:35 https://maestrodatabase.com/blog/fda-expands-pluvictos-metastatic-castration-resistant-prostate-cancer-indication 2025-03-31T01:16:52 https://maestrodatabase.com/blog/is-it-time-to-stop-using-statistical-significance 2021-02-02T03:29:57 https://maestrodatabase.com/blog/otsuka-files-biologics-license-application-for-sibeprenlimab-in-the-treatment-of-immunoglobulin-a-nephropathy 2025-03-31T01:29:21 https://maestrodatabase.com/blog/lillys-statement-about-the-chmp-opinion-issued-for-donanemab 2025-03-31T01:21:21 https://maestrodatabase.com/blog/icer-publishes-special-report-on-eliquis-and-xarelto-submitted-to-cms-as-part-of-public-comment-process-on-medicare-drug-price-negotiations 2023-10-02T20:16:42 https://maestrodatabase.com/blog/us-fda-accepts-for-review-the-biologics-license-application-for-pfizers-investigational-pentavalent-meningococcal-vaccine-candidate-menabcwy-in-adolescents 2022-12-29T07:10:17 https://maestrodatabase.com/blog/chiesi-group-receives-the-european-marketing-authorization-for-the-extrafine-triple-combination-therapy-for-the-treatment-of-moderate-to-severe-asthma 2021-02-02T04:37:51 https://maestrodatabase.com/blog/apellis-announces-us-fda-approval-of-the-empaveli-injector-a-device-to-streamline-self-administration 2023-10-02T21:07:42 https://maestrodatabase.com/blog/investigation-reveals-no-specific-risk-of-covid-19-vaccinations-in-elderly-patients 2021-02-02T04:44:09 https://maestrodatabase.com/blog/tg-therapeutics-announces-fda-approval-of-briumvi-ublituximab-xiiy 2022-12-29T06:52:13 https://maestrodatabase.com/blog/fda-launches-new-purple-book-searchable-database-to-help-patients-and-prescribers-identify-fda-approved-biologic-and-biosimilar-treatment-options 2020-02-24T19:49:29 https://maestrodatabase.com/blog/real-world-evidence---from-safety-to-a-potential-tool-for-advancing-innovative-ways-to-develop-new-medical-therapies 2020-02-24T19:46:28 https://maestrodatabase.com/blog/drug-pricing-review-group-signs-deal-with-aetion-for-patient-data 2020-02-24T20:06:49 https://maestrodatabase.com/blog/icer-and-aetion-partner-to-develop-real-world-evidence-for-value-assessment-of-treatments 2020-02-24T19:56:31 https://maestrodatabase.com/blog/explaining-health-state-utility-assessment 2020-03-17T20:45:05 https://maestrodatabase.com/blog/alnylam-initiates-rolling-submission-of-new-drug-application-to-u-dot-s-fda-for-patisiran-for-the-treatment-of-hereditary-attr-amyloidosis 2017-11-17T03:11:40 https://maestrodatabase.com/blog/takeda-announces-u-dot-s-fda-grants-priority-review-for-supplemental-new-drug-application-for-alunbrig-brigatinib-as-a-first-line-treatment-for-alk-plus-metastatic-non-small-cell-lung-cancer 2020-02-24T20:16:33 https://maestrodatabase.com/blog/celgene-and-bluebird-bio-announce-bb2121-anti-bcma-car-t-cell-therapy-has-been-granted-breakthrough-therapy-designation-from-fda-and-prime-eligibility-from-ema-for-relapsed-and-refractory-multiple-myeloma 2017-11-17T03:24:15 https://maestrodatabase.com/blog/teva-announces-fda-approval-of-armonair-digihaler-fluticasone-propionate-inhalation-powder 2020-02-24T20:11:50 https://maestrodatabase.com/blog/highlights-from-the-26-29-january-2026-chmp-meeting 2026-01-30T21:54:54 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac---december-2025-intracycle-meeting 2026-01-30T22:05:40 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-gsks-application-for-zejula-niraparib-for-first-line-maintenance-treatment-for-women-with-platinum-responsive-advanced-ovarian-cancer 2020-02-24T20:23:47 https://maestrodatabase.com/blog/this-year-drug-makers-cut-prices-for-several-widely-used-drugs 2026-01-31T00:25:13 https://maestrodatabase.com/blog/seqirus-receives-fda-approval-for-fluad-quadrivalent-influenza-vaccine-adjuvanted-for-adults-65-years-and-older 2020-02-24T20:35:17 https://maestrodatabase.com/blog/forxiga-approved-in-japan-for-the-treatment-of-chronic-kidney-disease-in-patients-with-and-without-type-2-diabetes 2021-08-26T06:37:16 https://maestrodatabase.com/blog/cellmax-life-earns-fda-breakthrough-device-designation-for-colon-cancer-and-pre-cancerous-adenomas-screening-blood-test 2021-08-26T06:41:32 https://maestrodatabase.com/blog/kygevvi-doxecitine-and-doxribtimine-recommended-for-approval-in-the-european-union-as-treatment-for-thymidine-kinase-2-deficiency 2026-01-31T00:30:51 https://maestrodatabase.com/blog/contrafect-announces-u-dot-s-fda-grants-breakthrough-therapy-designation-to-exebacase-for-the-treatment-of-methicillin-resistant-staphylococcus-aureus-mrsa-bacteraemia-including-right-sided-endocarditis 2020-02-24T20:29:49 https://maestrodatabase.com/blog/us-fda-issues-complete-response-letter-for-lebrikizumab-based-on-inspection-findings-at-third-party-manufacturer 2023-10-02T22:49:33 https://maestrodatabase.com/blog/albertas-switch-to-biosimilar-drugs-may-pose-legal-challenges-for-doctors 2020-02-24T20:55:39 https://maestrodatabase.com/blog/digital-therapeutics-leaders-focus-on-reimbursement 2020-02-24T20:48:47 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-26-august-2021 2021-08-26T06:29:47 https://maestrodatabase.com/blog/pharmacists-patients-are-stuck-in-the-middle-of-a-profit-before-all-else-pharmacy-racket 2020-02-24T20:44:33 https://maestrodatabase.com/blog/servier-announces-fda-approval-of-tibsovo-ivosidenib-tablets-in-idh-mutated-cholangiocarcinoma 2021-08-26T08:33:50 https://maestrodatabase.com/blog/avenge-bio-receives-fda-fast-track-designation-for-avb-001-a-novel-cell-therapy-leveraging-the-lococyte-immunotherapy-platform 2023-10-02T23:12:58 https://maestrodatabase.com/blog/rocket-pharmaceuticals-announces-fda-acceptance-of-biologics-license-application-with-priority-review-for-rp-l201-marnetegragene-autotemcel-for-the-treatment-of-severe-leukocyte-adhesion-deficiency-i 2023-10-03T00:11:15 https://maestrodatabase.com/blog/icer-to-assess-treatments-for-covid-19 2021-08-26T21:06:03 https://maestrodatabase.com/blog/government-eases-criteria-for-haemophilia-a-drug-reimbursement 2021-08-26T21:19:16 https://maestrodatabase.com/blog/heres-how-pharmacies-set-drug-prices-and-what-consumers-can-do-to-save-money 2021-08-26T21:16:48 https://maestrodatabase.com/blog/ironwood-pharmaceuticals-announces-fda-approval-of-revised-linzess-linaclotide-label 2021-08-26T20:55:41 https://maestrodatabase.com/blog/sesen-bio-pulls-e-dot-u-application-for-fda-rejected-cancer-drug 2021-08-26T20:52:39 https://maestrodatabase.com/blog/congressional-report-us-fda-broke-own-protocols-in-approving-biogen-alzheimers-drug 2022-12-29T22:14:36 https://maestrodatabase.com/blog/moderna-completes-submission-of-biologics-license-application-to-the-us-fda-for-its-covid-19-vaccine 2021-08-26T20:59:13 https://maestrodatabase.com/blog/biden-administration-likely-to-approve-covid-19-boosters-at-six-months 2021-08-26T21:45:51 https://maestrodatabase.com/blog/precision-medicine-helping-to-change-the-prognosis-of-a-rare-subtype-of-bowel-cancer 2021-02-02T07:01:40 https://maestrodatabase.com/blog/innovative-health-sciences-receives-fda-clearance-for-insignis-subcutaneous-needle-sets 2021-08-26T21:33:40 https://maestrodatabase.com/blog/cvs-juggles-biosimilar-options-on-its-formulary 2021-08-26T21:49:12 https://maestrodatabase.com/blog/abbvie-receives-a-positive-reimbursement-recommendation-from-the-canadian-agencies-for-drugs-and-technology-in-health-cadth-pan-canadian-oncology-drug-review-expert-review-committee-perc-for-venclexta-venetoclax-in-combination-with-azacitidine-for-acute-myeloid-leukaemia-patients 2021-08-26T21:23:29 https://maestrodatabase.com/blog/novavax-submits-application-to-health-canada-for-updated-protein-based-2024-2025-formula-covid-19-vaccine 2024-07-03T02:21:51 https://maestrodatabase.com/blog/cancer-patients-gain-new-hope-as-keytruda-treatment-recommended-for-subsidy-under-pbs 2026-01-31T21:31:36 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-february-2026 2026-01-31T21:57:40 https://maestrodatabase.com/blog/99mtc-maraciclatide-granted-fda-fast-track-designation-for-the-diagnosis-of-superficial-peritoneal-endometriosis 2024-07-03T02:50:03 https://maestrodatabase.com/blog/janssen-announces-car-t-therapy-ciltacabtagene-autoleucel-cilta-cel-accepted-for-accelerated-assessment-in-europe-for-the-treatment-of-patients-with-heavily-pretreated-multiple-myeloma 2021-02-02T07:12:29 https://maestrodatabase.com/blog/sobi-initiates-rolling-biologics-license-application-to-fda-for-sel-212-for-the-potential-treatment-of-chronic-refractory-gout 2024-07-03T04:43:17 https://maestrodatabase.com/blog/the-rare-paediatric-disease-voucher-program-creates-new-treatments-i-have-new-data-to-prove-it 2024-07-03T03:23:18 https://maestrodatabase.com/blog/fda-approves-polareans-xenoview-xenon-xe-129-hyperpolarised-for-use-with-mri-for-the-evaluation-of-lung-ventilation 2022-12-29T23:48:20 https://maestrodatabase.com/blog/dupixent-dupilumab-approved-in-the-european-union-as-the-first-ever-targeted-therapy-for-patients-with-copd 2024-07-03T05:35:10 https://maestrodatabase.com/blog/formycon-and-fresenius-kabi-announce-ema-acceptance-of-the-marketing-authorisation-application-for-fyb202-an-ustekinumab-biosimilar-candidate 2023-10-03T01:43:41 https://maestrodatabase.com/blog/kye-pharmaceuticals-announces-the-availability-of-quillivant-er-chewable-tablets-for-the-treatment-of-children-with-adhd 2024-07-03T06:16:15 https://maestrodatabase.com/blog/government-launches-scheme-to-deliver-five-breakthrough-technologies-a-year 2017-11-17T19:49:56 https://maestrodatabase.com/blog/bayer-receives-approval-in-the-uk-for-xarelto-rivaroxaban-to-treat-children-with-venous-thromboembolism-and-to-prevent-recurrence 2021-02-02T19:48:44 https://maestrodatabase.com/blog/cheaper-prescriptions-and-suncare-as-aussie-pharmacy-chain-hits-nz 2017-11-17T19:45:06 https://maestrodatabase.com/blog/novo-nordisk-receives-positive-opinion-from-the-european-regulatory-authorities-for-once-weekly-sogroya-somapacitan-for-the-treatment-of-adult-growth-hormone-deficiency 2021-02-02T19:54:17 https://maestrodatabase.com/blog/vbi-vaccines-announces-u-dot-s-fda-acceptance-of-bla-filing-for-vbis-3-antigen-prophylactic-hepatitis-b-vaccine 2021-02-02T20:09:05 https://maestrodatabase.com/blog/biden-freeze-hits-two-trump-drug-price-rules 2021-02-02T20:14:10 https://maestrodatabase.com/blog/cystic-fibrosis-sufferer-bella-powell-hits-out-at-drug-company-for-stalling-pharmac-funding 2021-02-02T20:05:19 https://maestrodatabase.com/blog/takeda-provides-update-on-exkivity-mobocertinib 2023-10-03T01:54:25 https://maestrodatabase.com/blog/swissmedic-grants-conditional-marketing-authorisation-for-novavax-covid-19-vaccine 2022-04-25T03:23:25 https://maestrodatabase.com/blog/if-2021-is-to-be-the-year-of-u-dot-s-drug-price-controls-how-should-biopharma-companies-respond 2021-02-02T20:16:21 https://maestrodatabase.com/blog/pharmac-reject-request-to-fund-womens-hygiene-products 2017-04-19T00:50:04 https://maestrodatabase.com/blog/osimertinib-mesylate-for-the-adjuvant-treatment-of-patients-with-egfr-mutation-positive-non-small-cell-lung-cancer-after-complete-tumour-resection 2024-07-03T06:39:17 https://maestrodatabase.com/blog/approval-of-newest-alzheimers-drug-will-accelerate-new-era-of-treatment 2024-07-03T07:18:13 https://maestrodatabase.com/blog/european-chmp-adopts-positive-opinion-on-ondexxya-andexanet-alfa-portola-pharmaceuticals-factor-xa-inhibitor-reversal-agent 2019-03-04T06:30:52 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-february-2026 2026-02-01T01:34:33 https://maestrodatabase.com/blog/ultragenyx-resubmits-biologics-license-application-for-ux111-aav-gene-therapy-to-treat-sanfilippo-syndrome-type-a-mps-iiia-to-us-fda 2026-02-01T01:44:48 https://maestrodatabase.com/blog/health-canada-approves-tecentriq-atezolizumab-for-patients-with-locally-advanced-and-metastatic-bladder-cancer 2017-04-19T01:22:23 https://maestrodatabase.com/blog/biomarin-receives-positive-chmp-opinion-in-europe-for-palynziq-pegvaliase-injection-for-treatment-of-patients-with-phenylketonuria-aged-16-and-older 2019-03-04T06:35:09 https://maestrodatabase.com/blog/novo-nordisk-files-for-a-label-update-for-fiasp-to-the-ema-and-the-fda-seeking-approval-for-use-in-children-and-adolescents 2019-03-04T07:14:43 https://maestrodatabase.com/blog/egalet-announces-u-dot-s-fda-acceptance-of-file-for-prior-approval-supplement-for-oxaydo-oxycodone-hydrochloride-tablets-10-mg-and-15-mg-dosage-strengths 2017-04-19T01:37:14 https://maestrodatabase.com/blog/chinas-national-medical-products-administration-approves-xtandi-enzalutamide-in-metastatic-hormone-sensitive-prostate-cancer 2024-07-03T10:08:27 https://maestrodatabase.com/blog/fda-approves-first-generic-of-proair-hfa 2020-02-25T06:41:10 https://maestrodatabase.com/blog/biocryst-announces-acceptance-of-regulatory-applications-for-orladeyo-berotralstat-by-health-canada-and-swissmedic 2021-08-27T01:47:11 https://maestrodatabase.com/blog/akcea-and-ionis-receive-positive-eu-chmp-opinion-for-waylivra-volanesorsen 2019-03-04T07:09:32 https://maestrodatabase.com/blog/heron-therapeutics-announces-filing-of-an-efficacy-supplement-for-zynrelef-and-provision-in-newly-passed-congressional-bill-anticipated-to-provide-separate-reimbursement-outside-of-the-packaged-surgical-payment-for-zynrelef 2022-12-30T03:48:22 https://maestrodatabase.com/blog/johnson-and-johnson-receives-approval-from-us-fda-and-european-commission-for-sirturo-bedaquiline 2024-07-03T09:59:43 https://maestrodatabase.com/blog/csl-behrings-haemophilia-b-drug-idelvion-gets-insurance-coverage 2024-07-03T09:47:36 https://maestrodatabase.com/blog/cluster-randomised-trials 2019-03-04T07:25:56 https://maestrodatabase.com/blog/inozyme-pharma-announces-fda-fast-track-designation-for-inz-701-in-abcc6-deficiency 2024-07-03T07:30:49 https://maestrodatabase.com/blog/regulatory-information---adjusted-fees-for-applications-to-ema-from-1-april-2019 2019-03-04T10:00:28 https://maestrodatabase.com/blog/nice-publishes-second-appraisal-consultation-document-for-cabozantinib-maleate 2017-04-19T10:25:50 https://maestrodatabase.com/blog/sanofis-rezurock-recommended-for-eu-approval-by-the-chmp-to-treat-chronic-graft-vs-host-disease 2026-02-01T01:25:30 https://maestrodatabase.com/blog/improving-access-to-cancer-treatments-the-role-of-biosimilars 2017-04-19T10:22:43 https://maestrodatabase.com/blog/senators-tell-fda-to-speed-up-approvals-of-generic-insulin 2019-03-04T07:20:54 https://maestrodatabase.com/blog/towards-a-single-development-programme-for-new-antibiotics-in-eu-japan-and-us 2017-11-17T20:54:27 https://maestrodatabase.com/blog/vertex-chief-jeffrey-leiden-to-weigh-in-on-orkambi-inquiry 2019-03-04T19:51:09 https://maestrodatabase.com/blog/tremelimumab-accepted-under-priority-review-in-the-us-for-patients-with-unresectable-liver-cancer-in-combination-with-imfinzi 2022-04-25T06:29:47 https://maestrodatabase.com/blog/how-to-avoid-a-disastrous-gene-therapy-price-battle 2017-11-17T21:00:48 https://maestrodatabase.com/blog/drug-companies-and-doctors-battle-over-the-future-of-faecal-transplants 2019-03-04T10:07:14 https://maestrodatabase.com/blog/has-clarifies-the-framework-of-the-bet-on-early-access-to-medicines 2024-07-03T21:27:00 https://maestrodatabase.com/blog/lilly-to-introduce-lower-priced-insulin 2019-03-04T19:47:25 https://maestrodatabase.com/blog/gadopiclenol-as-an-mri-contrast-agent-first-benefit-assessment-of-a-diagnostic-agent 2024-07-03T21:24:26 https://maestrodatabase.com/blog/pharmacists-call-for-medicare-rebates-for-medical-consultations-at-the-chemist 2019-08-15T20:37:16 https://maestrodatabase.com/blog/health-insurers-make-case-for-subsidies-but-get-little-assurance-from-administration 2017-04-19T21:01:18 https://maestrodatabase.com/blog/prescription-drug-pricing-hearing-is-the-senate-probing-in-the-wrong-place 2019-03-04T20:06:19 https://maestrodatabase.com/blog/panel-backs-provincial-funding-for-expensive-drug-to-treat-rare-disease-but-only-for-children 2019-03-04T20:08:43 https://maestrodatabase.com/blog/government-to-set-up-express-freight-service-for-medicinal-products-in-event-of-no-deal-brexit 2019-08-15T11:22:16 https://maestrodatabase.com/blog/argenx-announces-validation-of-european-marketing-authorisation-application-for-efgartigimod-in-generalised-myasthenia-gravis 2021-08-27T01:54:11 https://maestrodatabase.com/blog/cancer-patients-want-new-zealand-funded-treatment 2017-04-19T21:09:08 https://maestrodatabase.com/blog/intellipharmaceutics-announces-resubmission-of-new-drug-application-to-the-u-dot-s-fda-for-its-oxycodone-er 2019-03-04T20:00:09 https://maestrodatabase.com/blog/president-biden-novo-nordisk-eli-lilly-must-stop-ripping-off-americans-with-high-drug-prices 2024-07-03T10:27:36 https://maestrodatabase.com/blog/formulary-coverage-of-brand-name-adalimumab-and-biosimilars-across-medicare-part-d-plans 2024-07-03T10:16:47 https://maestrodatabase.com/blog/private-health-insurance-attacked-for-lack-of-value-and-transparency-by-experts 2017-04-19T21:06:28 https://maestrodatabase.com/blog/european-medicines-agency-adopts-positive-opinion-for-mercks-keytruda-pembrolizumab-for-six-week-dosing-schedule-across-all-current-monotherapy-indications 2019-03-04T20:22:58 https://maestrodatabase.com/blog/harmony-biosciences-announces-fda-approval-of-wakix-pitolisant-a-first-in-class-medication-for-the-treatment-of-excessive-daytime-sleepiness-in-adult-patients-with-narcolepsy 2019-08-15T20:54:50 https://maestrodatabase.com/blog/a-better-way-to-fund-medicines 2019-08-15T20:47:02 https://maestrodatabase.com/blog/nice-nod-for-novartis-cosentyx-in-psoriatic-arthritis 2017-04-19T21:24:06 https://maestrodatabase.com/blog/the-financial-cost-of-a-cancer-diagnosis-leaves-many-patients-in-poverty 2019-08-15T20:44:29 https://maestrodatabase.com/blog/in-the-debate-over-rising-drug-prices-both-drug-makers-and-pbms-claim-innocence 2017-04-19T21:16:59 https://maestrodatabase.com/blog/nine-new-parliamentary-petitions-launched-for-vital-medicine 2019-08-15T20:40:11 https://maestrodatabase.com/blog/first-covid-19-vaccine-approved-for-nz-how-did-we-get-here-and-what-comes-next 2021-02-03T02:19:44 https://maestrodatabase.com/blog/the-fdas-breakthrough-program-for-medical-devices-keeps-gaining-steam 2022-12-30T04:56:34 https://maestrodatabase.com/blog/eli-lilly-rolling-out-half-price-insulin-diabetics-say-its-not-enough 2019-03-04T20:14:27 https://maestrodatabase.com/blog/adlon-therapeutics-announces-fda-approval-for-adhansia-xr-methylphenidate-hydrochloride-extended-release-capsules-cii-for-the-treatment-of-adhd 2019-03-04T20:31:18 https://maestrodatabase.com/blog/swissmedic-approves-moderna-coronavirus-vaccine-spikevax-xbb-dot-1-5 2023-10-03T04:36:03 https://maestrodatabase.com/blog/icer-issues-final-report-and-policy-recommendations-regarding-treatments-for-duchenne-muscular-dystrophy 2019-08-15T21:10:10 https://maestrodatabase.com/blog/fda-approves-third-oncology-drug-that-targets-a-key-genetic-driver-of-cancer-rather-than-a-specific-type-of-tumour 2019-08-15T20:59:39 https://maestrodatabase.com/blog/us-judge-refuses-to-block-medicare-from-negotiating-drug-prices 2023-10-03T04:27:01 https://maestrodatabase.com/blog/the-lengths-americans-go-to-for-cheap-medicine 2019-08-15T21:20:08 https://maestrodatabase.com/blog/us-politicians-round-on-generics-firms-for-blocking-drug-pricing-probe 2019-08-15T21:17:37 https://maestrodatabase.com/blog/reevaluating-eligibility-criteria----balancing-patient-protection-and-participation-in-oncology-trials 2017-04-19T21:46:34 https://maestrodatabase.com/blog/trump-health-official-controversial-drug-pricing-move-is-top-priority 2019-08-15T21:15:29 https://maestrodatabase.com/blog/cheaper-medicines-to-help-men-fight-prostate-cancer 2026-02-01T22:15:50 https://maestrodatabase.com/blog/mediwound-announces-fda-approval-of-nexobrid-for-the-treatment-of-severe-thermal-burns-in-adults 2022-12-30T05:17:39 https://maestrodatabase.com/blog/cerecor-announces-fast-track-designation-for-cerc-803-for-the-treatment-of-leukocyte-adhesion-deficiency-type-ii 2021-02-03T02:43:00 https://maestrodatabase.com/blog/fda-approves-genentechs-rozlytrek-entrectinib-for-people-with-ros1-positive-metastatic-non-small-cell-lung-cancer-and-ntrk-gene-fusion-positive-solid-tumours 2019-08-15T21:27:05 https://maestrodatabase.com/blog/growing-numbers-of-priority-and-competitive-andas-under-review-as-approvals-trickle-in 2019-08-15T21:51:29 https://maestrodatabase.com/blog/unitedhealthcare-will-prefer-amgens-anti-cancer-biosimilars-beginning-in-october 2019-08-15T21:44:51 https://maestrodatabase.com/blog/icers-value-framework-and-patient-feedback-q-and-a-with-steve-pearson 2019-08-15T21:37:26 https://maestrodatabase.com/blog/calquence-plus-chemoimmunotherapy-recommended-for-approval-in-the-eu-by-chmp-as-first-and-only-btk-inhibitor-for-first-line-mantle-cell-lymphoma 2025-03-31T06:53:24 https://maestrodatabase.com/blog/imfinzi-approved-in-the-us-as-first-and-only-peri-operative-immunotherapy-for-patients-with-muscle-invasive-bladder-cancer 2025-03-31T06:49:27 https://maestrodatabase.com/blog/sol-gel-technologies-and-galderma-announce-fda-approval-of-epsolay 2022-04-25T20:34:20 https://maestrodatabase.com/blog/is-it-best-to-remove-insurance-benefits-from-drugs-prescribed-in-bribery 2022-04-25T21:02:01 https://maestrodatabase.com/blog/fda-grants-regenerative-medicine-advanced-therapy-designation-to-autolus-car-t-cell-therapy-obe-cel-for-the-treatment-of-adult-b-all 2022-04-25T20:48:43 https://maestrodatabase.com/blog/fda-approves-first-covid-19-treatment-for-young-children 2022-04-25T20:56:11 https://maestrodatabase.com/blog/statement-by-cms-administrator-chiquita-brooks-lasure-on-manufacturers-of-selected-drugs-who-have-indicated-they-intend-to-participate-in-the-medicare-drug-price-negotiation-program 2023-10-03T20:20:55 https://maestrodatabase.com/blog/fda-approves-once-weekly-wegovy-injection-for-the-treatment-of-obesity-in-teens-aged-12-years-and-older 2022-12-30T20:13:19 https://maestrodatabase.com/blog/chinook-receives-rare-paediatric-disease-designation-from-u-dot-s-fda-for-chk-336-for-treatment-of-primary-hyperoxaluria 2021-02-03T07:35:47 https://maestrodatabase.com/blog/us-fda-grants-approval-for-technegas 2023-10-03T20:15:15 https://maestrodatabase.com/blog/loncastuximab-tesirine-for-the-treatment-of-adults-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-and-high-grade-b-cell-lymphoma-after-2-or-more-systemic-treatments 2023-10-03T10:39:36 https://maestrodatabase.com/blog/ideaya-biosciences-receives-us-fda-breakthrough-therapy-designation-for-darovasertib-monotherapy-in-neo-adjuvant-uveal-melanoma 2025-03-31T23:07:40 https://maestrodatabase.com/blog/pharming-group-receives-complete-response-letter-from-us-fda-for-snda-for-joenja-leniolisib-in-children-aged-4-to-11-years-with-apds 2026-02-02T05:30:24 https://maestrodatabase.com/blog/geistlich-pharma-granted-fda-breakthrough-device-designation-for-chondro-gide-articular-cartilage-cover 2021-02-03T08:29:52 https://maestrodatabase.com/blog/cost-recovery-implementation-statement-2020-2021 2021-02-03T08:01:04 https://maestrodatabase.com/blog/adalimumab-adbm-boehringer-ingelheims-interchangeable-biosimilar-to-humira-now-available-at-low-wholesale-acquisition-cost 2023-10-03T20:36:05 https://maestrodatabase.com/blog/fda-approves-rivfloza-for-children-9-years-old-and-adults-living-with-primary-hyperoxaluria-type-1-a-rare-genetic-condition 2023-10-03T20:29:42 https://maestrodatabase.com/blog/new-toolbox-available-for-emas-prime-designees 2021-02-03T08:58:53 https://maestrodatabase.com/blog/eagle-pharmaceuticals-receives-additional-fda-questions-regarding-vasopressin-court-date-set-for-7-july-2021-in-vasopressin-trial 2021-02-03T09:06:34 https://maestrodatabase.com/blog/imfinzi-perioperative-raegimen-recommended-for-approval-in-the-eu-by-chmp-for-patients-with-early-gastric-and-gastro-oesophageal-cancers 2026-02-02T07:21:35 https://maestrodatabase.com/blog/health-canada-authorises-rybrevant-amivantamab-in-combination-with-carboplatin-and-pemetrexed-as-the-only-targeted-first-line-treatment-approved-for-patients-with-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations 2024-07-04T04:11:40 https://maestrodatabase.com/blog/obseva-announces-confirmation-of-positive-chmp-opinion-for-linzagolix-an-oral-gnrh-antagonist-for-the-treatment-of-uterine-fibroids 2022-04-26T01:19:52 https://maestrodatabase.com/blog/samsung-bioepis-to-launch-eylea-biosimilar-opuviz-in-europe 2026-02-02T05:54:48 https://maestrodatabase.com/blog/ema-publishes-agenda-for-24-27-february-chmp-meeting 2020-02-25T09:30:51 https://maestrodatabase.com/blog/chiesi-global-rare-diseases-and-protalix-biotherapeutics-receive-positive-chmp-opinion-for-an-additional-dosing-regimen-of-2-mg-slash-kg-body-weight-every-four-weeks-for-elfabrio-pegunigalsidase-alfa-in-the-eu 2026-02-02T06:24:32 https://maestrodatabase.com/blog/call-for-access-to-improve-quality-of-life-for-thyroid-cancer-survivors 2026-02-02T06:33:15 https://maestrodatabase.com/blog/aquestive-therapeutics-announces-fda-issuance-of-complete-response-letter-for-anaphylm 2026-02-02T21:37:27 https://maestrodatabase.com/blog/patients-gain-early-access-to-pfizers-atopic-dermatitis-drug 2021-02-03T19:47:07 https://maestrodatabase.com/blog/nice-green-light-for-gsks-nucala 2021-02-03T19:49:26 https://maestrodatabase.com/blog/durect-corporation-announces-u-dot-s-fda-approval-of-posimir-for-post-surgical-pain-reduction-for-up-to-72-hours-following-arthroscopic-subacromial-decompression 2021-02-03T19:53:30 https://maestrodatabase.com/blog/swissmedic-has-accepted-the-new-oral-edarvarone-formulation-for-the-treatment-of-als 2022-04-26T02:06:36 https://maestrodatabase.com/blog/nice-no-for-janssens-darzalex-combo 2021-08-27T21:17:37 https://maestrodatabase.com/blog/parkinsons-disease-drug-equifina-gets-insurance-benefits 2021-02-03T19:44:08 https://maestrodatabase.com/blog/full-life-technologies-granted-fda-fast-track-designation-for-225ac-fl-020-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer 2024-07-04T05:46:43 https://maestrodatabase.com/blog/everyone-wants-to-help-but-still-the-red-tape-prevents-dylan-barker-getting-medicine 2020-02-25T10:00:56 https://maestrodatabase.com/blog/bavarian-nordic-receives-us-fda-approval-of-freeze-dried-smallpox-and-mpox-vaccine 2025-04-01T01:20:41 https://maestrodatabase.com/blog/asana-biosciences-gusacitinib-granted-fda-fast-track-designation-for-moderate-to-severe-chronic-hand-eczema 2021-02-03T20:06:24 https://maestrodatabase.com/blog/oxford-biotherapeutics-announces-partner-boehringer-ingelheim-received-us-fda-fast-track-designation-for-bi-764532-for-the-treatment-of-extensive-stage-small-cell-lung-cancer-and-extrapulmonary-neuroendocrine-cancers 2023-10-03T23:50:46 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-tepotinib-for-metastatic-non-small-cell-lung-cancer 2021-02-03T20:11:51 https://maestrodatabase.com/blog/biocryst-announces-fda-approval-of-supplemental-new-drug-application-for-rapivab-expanding-patient-population-to-include-children-six-months-and-older 2021-02-03T20:00:14 https://maestrodatabase.com/blog/biden-administrations-methodical-approach-to-drug-price-reform 2021-02-03T20:31:28 https://maestrodatabase.com/blog/icer-issues-final-report-and-policy-recommendations-on-acute-treatments-for-migraine 2020-02-25T19:48:44 https://maestrodatabase.com/blog/donanemab-in-early-alzheimers-disease-important-questions-remain-unanswered 2026-02-02T21:49:34 https://maestrodatabase.com/blog/fda-accepts-genentechs-biologics-license-application-for-fixed-dose-subcutaneous-combination-of-perjeta-and-herceptin-for-her2-positive-breast-cancer 2020-02-25T11:19:11 https://maestrodatabase.com/blog/hutchmed-announces-nda-acceptance-in-china-for-tazemetostat-for-the-treatment-of-relapsed-or-refractory-follicular-lymphoma-with-priority-review-status 2024-07-04T06:23:36 https://maestrodatabase.com/blog/what-states-are-doing-to-combat-rising-prescription-drug-prices 2020-02-25T11:15:41 https://maestrodatabase.com/blog/cystic-fibrosis-survivor-calls-for-life-saving-drug-trikafta-to-be-funded-as-pharmac-dangles-hope 2021-02-03T20:20:58 https://maestrodatabase.com/blog/datroway-granted-priority-review-in-the-us-as-first-line-treatment-for-patients-with-metastatic-triple-negative-breast-cancer-who-are-not-candidates-for-immunotherapy 2026-02-03T09:14:27 https://maestrodatabase.com/blog/va-could-lead-way-for-nation-on-lower-drug-pricing 2020-02-25T20:00:49 https://maestrodatabase.com/blog/update-on-us-regulatory-review-of-saphnelo-subcutaneous-administration-in-systemic-lupus-erythematosus 2026-02-03T09:25:59 https://maestrodatabase.com/blog/fundapen-initiative-extended-to-all-kiwis-in-need-of-life-saving-epipen-auto-injectors 2020-02-25T20:37:22 https://maestrodatabase.com/blog/senate-republican-gets-on-board-with-government-drug-price-negotiations 2020-02-25T20:33:14 https://maestrodatabase.com/blog/perrigo-and-catalent-announce-fda-approval-of-perrigos-ab-rated-generic-version-of-proair-hfa 2020-02-25T20:20:29 https://maestrodatabase.com/blog/tivdak-tisotumab-vedotin-approved-by-european-commission-for-previously-treated-recurrent-or-metastatic-cervical-cancer 2025-04-01T01:31:12 https://maestrodatabase.com/blog/lysogene-receives-fda-fast-track-designation-for-lys-saf302-gene-therapy-in-mps-iiia 2020-02-25T20:10:06 https://maestrodatabase.com/blog/galderma-announces-us-fda-acceptance-of-relabotulinumtoxina-biologics-license-application-resubmission 2026-02-03T09:41:26 https://maestrodatabase.com/blog/moonlake-announces-fda-fast-track-designation-for-sonelokimab-palmoplantar-pustulosis 2026-02-02T23:11:55 https://maestrodatabase.com/blog/tlv-has-decided-on-a-policy-for-patient-participation 2020-02-25T20:49:15 https://maestrodatabase.com/blog/us-patent-office-wont-review-two-novo-nordisk-patents-for-wegovy-ozempic 2023-10-04T00:20:27 https://maestrodatabase.com/blog/therapeutic-goods-administration-approves-afstyla---csl-behrings-novel-recombinant-haemophilia-a-treatment 2017-04-20T12:33:46 https://maestrodatabase.com/blog/how-to-stop-drug-price-gouging 2017-04-20T12:43:13 https://maestrodatabase.com/blog/cadth-recommends-kevzara 2017-04-20T20:41:20 https://maestrodatabase.com/blog/ipsen-in-talks-with-nice-over-cabometyx-rejection 2017-04-20T20:53:36 https://maestrodatabase.com/blog/exelixis-announces-us-fda-accepted-the-new-drug-application-for-zanzalintinib-in-combination-with-an-immune-checkpoint-inhibitor-for-patients-with-metastatic-colorectal-cancer 2026-02-03T09:48:20 https://maestrodatabase.com/blog/acadia-pharmaceuticals-provides-update-on-regulatory-submission-for-trofinetide-for-the-treatment-of-rett-syndrome-in-the-european-union 2026-02-03T09:54:49 https://maestrodatabase.com/blog/health-canada-grants-authorization-for-bayers-hyrnuo-sevabertinib-for-previously-treated-patients-with-locally-advanced-or-metastatic-her2-mutant-non-small-cell-lung-cancer 2026-02-03T10:02:00 https://maestrodatabase.com/blog/pence-very-confident-congress-will-repeal-obamacare 2017-04-20T21:05:17 https://maestrodatabase.com/blog/tesaro-undercuts-parp-rivals-with-$118k-price-tag-on-zejula--or-did-it 2017-04-20T21:01:08 https://maestrodatabase.com/blog/recordati-rare-diseases-canada-announces-health-canada-approval-of-cystadrops-cysteamine-ophthalmic-solution-for-cystinosis-patients 2019-03-05T06:06:00 https://maestrodatabase.com/blog/propping-up-private-health-insurance-is-like-putting-lipstick-on-a-pig 2017-04-20T21:19:28 https://maestrodatabase.com/blog/france-backs-lille-as-best-choice-to-host-eu-drug-agency-after-brexit 2017-04-20T21:13:49 https://maestrodatabase.com/blog/full-federal-court-confirms-an-application-to-list-medicine-on-the-pbs-prior-to-patent-expiry-is-a-non-infringing-act 2017-04-20T21:22:53 https://maestrodatabase.com/blog/dangerous-path-medicare-seriously-threatened-by-private-health-insurance 2017-04-20T21:29:29 https://maestrodatabase.com/blog/no-prostheses-list-healing-between-insurers-and-suppliers 2017-04-20T21:26:50 https://maestrodatabase.com/blog/methodological-problems-in-the-method-used-by-iqwig-within-early-benefit-assessment-of-new-pharmaceuticals-in-germany 2019-03-05T08:19:36 https://maestrodatabase.com/blog/donald-trump-threatens-to-sabotage-obamacare 2017-04-20T21:40:10 https://maestrodatabase.com/blog/zilucoplan-sodium-for-the-treatment-of-patients-with-generalised-antibody-positive-myasthenia-gravis 2024-07-04T09:52:18 https://maestrodatabase.com/blog/meet-the-lawyer-trying-to-pry-drug-pricing-secrets-out-of-big-pharma 2017-04-20T21:32:54 https://maestrodatabase.com/blog/teenagers-meningococcal-death-prompts-coroner-to-urge-free-b-strain-vaccine 2019-03-05T10:39:56 https://maestrodatabase.com/blog/ema-starts-review-of-tavneos-a-medicine-for-rare-auto-immune-diseases-gpa-and-mpa 2026-02-03T21:58:27 https://maestrodatabase.com/blog/fda-authorises-updated-novavax-covid-19-vaccine-formulated-to-better-protect-against-currently-circulating-variants 2023-10-04T00:50:34 https://maestrodatabase.com/blog/future-unrelated-medical-costs-need-to-be-considered-in-cost-effectiveness-analysis 2019-03-05T08:15:48 https://maestrodatabase.com/blog/fda-approves-first-of-its-kind-stroke-rehabilitation-system 2021-08-27T23:58:38 https://maestrodatabase.com/blog/jaypirca-pirtobrutinib-the-first-and-only-non-covalent-reversible-btk-inhibitor-now-available-in-canada-for-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-and-chronic-lymphocytic-leukaemia 2026-02-03T20:56:58 https://maestrodatabase.com/blog/fda-grants-rolling-review-for-cytodyns-planned-bla-for-investigational-hiv-therapy-leronlimab-pro-140 2019-03-05T11:05:52 https://maestrodatabase.com/blog/st-vincents-splits-with-insurer-nib-amid-private-hospitals-crisis 2024-07-04T21:24:03 https://maestrodatabase.com/blog/lisocabtagene-maraleucel-for-the-treatment-of-patients-with-relapsed-or-refractory-aggressive-b-cell-non-hodgkin-lymphoma 2024-07-04T21:19:03 https://maestrodatabase.com/blog/checkpoint-therapeutics-announces-biologics-license-application-resubmission-for-cosibelimab 2024-07-04T12:14:02 https://maestrodatabase.com/blog/moving-upstream-in-anti-cancer-drug-development 2019-03-05T11:29:13 https://maestrodatabase.com/blog/mhra-authorises-ucbs-bimzelx-via-post-brexit-licensing-pathway 2021-08-28T00:39:22 https://maestrodatabase.com/blog/us-fda-approves-expanded-farxiga-and-xigduo-xr-labels-for-use-in-patients-with-type-2-diabetes-and-moderate-renal-impairment 2019-03-05T11:18:05 https://maestrodatabase.com/blog/genentech-provides-update-on-tecentriq-u-dot-s-indication-for-pd-l1-positive-metastatic-triple-negative-breast-cancer 2021-08-28T00:43:02 https://maestrodatabase.com/blog/fda-is-working-to-bridge-gaps-and-meet-needs-for-rare-disease-product-development 2019-03-05T19:51:31 https://maestrodatabase.com/blog/house-democrats-to-begin-considering-drug-pricing-legislation-next-week 2019-03-05T19:54:33 https://maestrodatabase.com/blog/insights-from-the-march-2022-pbac-meeting-part-1 2022-04-26T08:03:20 https://maestrodatabase.com/blog/stock-price-effects-of-breakthrough-therapy-designation 2019-03-05T11:32:56 https://maestrodatabase.com/blog/can-netflix-show-americans-how-to-cut-the-cost-of-drugs 2019-03-05T20:30:00 https://maestrodatabase.com/blog/lilly-receives-fda-priority-review-designation-for-emgality-galcanezumab-gnlm-injection-for-the-preventive-treatment-of-episodic-cluster-headache-in-adults 2019-03-05T19:58:11 https://maestrodatabase.com/blog/gyre-therapeutics-announces-chinas-nmpa-approval-of-avatrombopag-maleate-tablets-for-the-treatment-of-cld-associated-thrombocytopenia 2024-07-04T21:27:38 https://maestrodatabase.com/blog/determining-the-comparative-value-of-pharmaceutical-risk-sharing-policies-in-non-small-cell-lung-cancer-using-real-world-data 2019-03-05T20:46:44 https://maestrodatabase.com/blog/how-to-fix-a-problem-like-orkambi-solutions-suggested-ahead-of-showdown 2019-03-05T20:40:05 https://maestrodatabase.com/blog/nhs-englands-medicines-chief-stop-salami-slicing-and-get-faster-market-access 2019-03-05T20:44:01 https://maestrodatabase.com/blog/health-economic-assessment-of-leqvio-in-the-treatment-of-high-ldl-cholesterol-and-mixed-lipid-disorders 2022-04-26T20:35:38 https://maestrodatabase.com/blog/pharming-receives-promising-innovative-medicine-designation-for-leniolisib-from-uk-mhra 2022-04-26T10:49:58 https://maestrodatabase.com/blog/evaluating-canadians-values-for-drug-coverage-decision-making 2019-03-05T20:51:23 https://maestrodatabase.com/blog/european-commission-approves-biomarins-voxzogo-vosoritide-for-the-treatment-of-children-with-achondroplasia-from-age-2-until-growth-plates-close 2021-08-28T01:26:13 https://maestrodatabase.com/blog/rsv-vaccination-protecting-older-people-from-serious-complications 2024-07-04T22:32:05 https://maestrodatabase.com/blog/vbl-therapeutics-receives-fda-fast-track-designation-for-ofra-vec-for-the-treatment-of-platinum-resistant-ovarian-cancer 2022-04-26T20:54:30 https://maestrodatabase.com/blog/has-decides-in-favour-of-reimbursement-of-paxlovid 2022-04-26T20:40:31 https://maestrodatabase.com/blog/treadwell-therapeutics-announces-fast-track-designation-granted-by-the-fda-to-cfi-400945-for-the-treatment-of-acute-myeloid-leukaemia 2022-04-26T20:49:46 https://maestrodatabase.com/blog/prothena-receives-fda-fast-track-designation-for-prx012-a-next-generation-anti-amyloid-beta-antibody-under-investigation-for-the-treatment-of-alzheimers-disease 2022-04-26T21:14:44 https://maestrodatabase.com/blog/amarin-partner-hls-therapeutics-completes-reimbursement-negotiations-with-pan-canadian-pharmaceutical-alliance-for-vascepa-icosapent-ethyl 2022-04-26T21:25:06 https://maestrodatabase.com/blog/intra-cellular-therapies-announces-fda-approval-of-new-dosage-strengths-for-caplyta-lumateperone-for-specific-patient-populations 2022-04-26T21:00:15 https://maestrodatabase.com/blog/abbvie-receives-fda-approval-of-rinvoq-upadacitinib-an-oral-jak-inhibitor-for-the-treatment-of-moderate-to-severe-rheumatoid-arthritis 2019-08-16T20:43:04 https://maestrodatabase.com/blog/just-one-in-five-new-cancer-treatments-available-to-irish-patients 2022-04-26T21:29:06 https://maestrodatabase.com/blog/european-medicines-agency-validates-marketing-application-for-filgotinib-for-the-treatment-of-rheumatoid-arthritis 2019-08-16T21:00:05 https://maestrodatabase.com/blog/pbs-brings-hope-to-cancer-patients 2022-04-26T21:37:36 https://maestrodatabase.com/blog/quebec-first-province-to-publicly-reimburse-jemperli-dostarlimab-for-injection-plus-chemotherapy-via-ramq-for-the-treatment-of-all-adult-patients-with-primary-advanced-or-first-recurrent-endometrial-cancer 2026-02-04T01:34:21 https://maestrodatabase.com/blog/ema-slash-fda-analysis-shows-high-degree-of-alignment-in-marketing-application-decisions-between-eu-and-us 2019-08-16T20:54:03 https://maestrodatabase.com/blog/with-35-dollars-million-in-funding-waltz-health-aims-to-lower-drug-prices-working-with---not-against---the-system 2022-04-26T21:31:58 https://maestrodatabase.com/blog/enhertu-granted-breakthrough-therapy-designation-in-the-us-for-patients-with-her2-low-metastatic-breast-cancer 2022-04-27T07:31:37 https://maestrodatabase.com/blog/relay-therapeutics-announces-zovegalisib-granted-breakthrough-therapy-designation-by-us-fda-for-pik3ca-mutant-hr-plus-slash-her2--advanced-breast-cancer 2026-02-03T23:32:28 https://maestrodatabase.com/blog/fda-approves-new-nasal-spray-medication-for-treatment-resistant-depression-available-only-at-a-certified-doctors-office-or-clinic 2019-03-06T01:14:31 https://maestrodatabase.com/blog/proposal-for-various-medicines-in-the-neurology-immunology-and-nephrology-therapeutic-areas 2017-04-21T05:59:14 https://maestrodatabase.com/blog/fda-approves-treatment-for-patients-with-rare-bone-marrow-disorder 2019-08-16T21:41:21 https://maestrodatabase.com/blog/ema-starts-rolling-review-of-novavaxs-covid-19-vaccine-nvx-cov2373 2021-02-04T01:39:55 https://maestrodatabase.com/blog/what-will-pmprb-drug-pricing-changes-mean-for-plan-sponsors 2019-08-16T21:36:16 https://maestrodatabase.com/blog/brexits-disruptive-impact-on-u-dot-k-and-european-prescription-drug-market 2019-08-16T21:19:41 https://maestrodatabase.com/blog/swiss-medical-regulator-rejects-oxford-slash-astrazeneca-covid-19-vaccine 2021-02-04T02:42:33 https://maestrodatabase.com/blog/fda-grants-rare-paediatric-disease-designation-to-odiparcil-for-the-treatment-of-mps-vi 2019-03-06T02:36:16 https://maestrodatabase.com/blog/u-dot-s-fda-grants-priority-review-for-fedratinib-new-drug-application-in-myelofibrosis 2019-03-06T02:23:16 https://maestrodatabase.com/blog/vanda-pharmaceuticals-announces-the-submission-of-an-nda-to-the-fda-for-bysanti-for-the-treatments-of-acute-bipolar-i-disorder-and-schizophrenia 2025-04-01T03:44:26 https://maestrodatabase.com/blog/fda-chief-tough-on-e-cigs-steps-down-in-surprise-resignation 2019-03-06T02:48:40 https://maestrodatabase.com/blog/samsung-bioepis-gains-approval-to-sell-bigger-size-ontruzant-in-europe 2019-03-06T02:51:40 https://maestrodatabase.com/blog/australia-secures-10-million-extra-doses-of-pfizer-covid-19-vaccine 2021-02-04T02:37:28 https://maestrodatabase.com/blog/outcomes-and-impacts-of-10-year-hta-implementation-in-taiwan 2019-03-06T04:51:25 https://maestrodatabase.com/blog/brexit---implications-for-therapeutic-goods-in-australia 2020-02-25T06:34:51 https://maestrodatabase.com/blog/rezurock-now-reimbursed-in-ontario-and-british-columbia-for-people-living-with-chronic-graft-versus-host-disease 2026-02-04T02:11:43 https://maestrodatabase.com/blog/pegunigalsidase-alfa-for-the-treatment-of-patients-with-fabry-disease 2023-10-04T19:41:46 https://maestrodatabase.com/blog/pfizer-and-biontech-submit-application-for-u-dot-s-emergency-use-authorisation-for-a-covid-19-vaccine-booster-dose-in-children-5-through-11-years-of-age 2022-04-27T10:32:10 https://maestrodatabase.com/blog/determining-the-right-offer-price-in-medicare-drug-negotiations 2023-10-04T11:01:37 https://maestrodatabase.com/blog/editas-medicine-receives-fda-rare-paediatric-disease-designation-for-edit-301-for-the-treatment-of-beta-thalassaemia 2022-04-27T10:36:21 https://maestrodatabase.com/blog/abbvie-submits-regulatory-applications-to-fda-and-ema-for-upadacitinib-rinvoq-in-adults-and-adolescents-with-vitiligo 2026-02-04T06:06:33 https://maestrodatabase.com/blog/galderma-announces-progress-with-relabotulinumtoxina-regulatory-submissions 2023-10-04T20:10:56 https://maestrodatabase.com/blog/no-fault-covid-19-indemnity-scheme 2021-08-28T04:30:23 https://maestrodatabase.com/blog/os-therapies-initiates-us-fda-bla-filing-for-ost-her2-in-the-prevention-or-delay-of-recurrent-fully-resected-pulmonary-metastatic-osteosarcoma 2026-02-04T03:56:12 https://maestrodatabase.com/blog/arthritis-patients-suffer-after-medication-diverted-due-to-covid-19 2022-04-27T10:51:27 https://maestrodatabase.com/blog/atagi-recommendations-on-the-use-of-covid-19-vaccines-in-all-young-adolescents-in-australia 2021-08-28T04:26:05 https://maestrodatabase.com/blog/european-medicines-agency-grants-prime-designation-to-biocrysts-alk-2-inhibitor-bcx9250-for-treatment-of-fibrodysplasia-ossificans-progressiva 2022-04-27T20:21:13 https://maestrodatabase.com/blog/incyte-and-morphosys-announce-the-european-commission-approval-of-minjuvi-tafasitamab-in-combination-with-lenalidomide-for-the-treatment-of-adults-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma 2021-08-28T04:36:11 https://maestrodatabase.com/blog/pharmac-welcomes-analysis-into-cancer-medicines-in-aotearoa 2022-04-27T20:16:09 https://maestrodatabase.com/blog/phrmas-steve-ubl-cbo-report-makes-clear-patients-face-future-with-less-hope-under-congress-drug-pricing-plan 2021-08-28T04:13:07 https://maestrodatabase.com/blog/oncoc4-announces-fast-track-designation-granted-by-the-u-dot-s-fda-for-onc-392-monotherapy-in-pd-l-1-resistant-nsclc 2022-04-27T10:43:31 https://maestrodatabase.com/blog/t2-biosystems-announces-submission-for-fda-breakthrough-device-designation-for-t2biothreat-panel 2022-04-27T20:38:42 https://maestrodatabase.com/blog/venetoclax-with-low-dose-cytarabine-for-untreated-acute-myeloid-leukaemia 2022-04-27T20:42:45 https://maestrodatabase.com/blog/decision-to-fund-ivacaftor-kalydeco-for-people-with-cystic-fibrosis-with-the-g551d-mutation 2020-02-26T02:46:26 https://maestrodatabase.com/blog/pfizer-and-biohavens-vydura-rimegapant-granted-first-ever-marketing-authorisation-by-european-commission-for-both-acute-treatment-of-migraine-and-prophylaxis-of-episodic-migraine 2022-04-27T20:30:41 https://maestrodatabase.com/blog/insights-from-the-march-2022-pbac-meeting-part-2 2022-04-27T21:22:57 https://maestrodatabase.com/blog/sqz-biotechnologies-receives-fda-fast-track-designation-for-its-lead-cell-therapy-candidate-for-the-treatment-of-hpv16-positive-tumours 2022-04-28T01:34:33 https://maestrodatabase.com/blog/janssen-receives-health-canada-approval-of-balversa-erdafitinib-the-first-fgfr-kinase-inhibitor-for-the-treatment-of-patients-with-locally-advanced-or-metastatic-urothelial-carcinoma-with-certain-fgfr-genetic-alterations 2020-02-26T08:13:38 https://maestrodatabase.com/blog/tagrisso-with-the-addition-of-chemotherapy-approved-in-the-eu-as-new-first-line-treatment-for-patients-with-egfr-mutated-advanced-lung-cancer 2024-07-05T06:20:20 https://maestrodatabase.com/blog/health-canada-approves-vraylar-cariprazine-for-the-treatment-of-bipolar-l-disorder-and-schizophrenia-in-adults 2022-04-27T20:53:41 https://maestrodatabase.com/blog/dutch-minister-plans-to-implement-new-reimbursement-system-for-high-cost-medicine 2024-07-05T03:14:19 https://maestrodatabase.com/blog/icer-publishes-final-evidence-report-on-treatment-for-acute-pain 2025-04-01T04:26:38 https://maestrodatabase.com/blog/bimekizumab-for-the-treatment-of-patients-with-active-psoriatic-arthritis 2023-10-04T20:32:36 https://maestrodatabase.com/blog/pharmac-opens-first-consultation-for-cancer-medicines-after-funding-boost 2024-07-05T03:07:18 https://maestrodatabase.com/blog/tucatinib-for-adults-with-her2-positive-advanced-breast-cancer 2022-04-27T20:58:16 https://maestrodatabase.com/blog/pembrolizumab-in-combination-with-carboplatin-and-paclitaxel-for-the-treatment-of-patients-with-advanced-or-recurrent-endometrial-cancer 2025-04-01T04:56:28 https://maestrodatabase.com/blog/vertex-announces-availability-of-cystic-fibrosis-medicine-kalydeco-ivacaftor-in-new-zealand 2020-02-26T10:47:48 https://maestrodatabase.com/blog/baqsimi-nasal-glucagon-rescue-treatment-for-severe-hypoglycaemia-now-covered-in-british-colombia-alberta-and-saskatchewan 2022-04-28T01:46:33 https://maestrodatabase.com/blog/fda-grants-btx-1801-new-qualified-infectious-disease-product-designation-status 2022-04-28T01:55:14 https://maestrodatabase.com/blog/independent-review-of-the-reforms-to-the-therapeutic-goods-advertising-framework-to-commence 2020-02-26T10:33:42 https://maestrodatabase.com/blog/nemolizumab-for-the-treatment-of-patients-with-moderate-to-severe-atopic-dermatitis 2025-04-01T04:48:17 https://maestrodatabase.com/blog/nice-evidence-request-for-blincyto-for-acute-lymphoblastic-leukaemia 2019-03-06T19:37:28 https://maestrodatabase.com/blog/why-prescription-drug-costs-are-big-issue-for-south-carolina-voters 2020-02-26T19:02:52 https://maestrodatabase.com/blog/polivy-struck-by-nice-no 2020-02-26T18:58:06 https://maestrodatabase.com/blog/european-medicines-agency-grants-marinus-pharmaceuticals-accelerated-assessment-of-ganaxolone-for-treatment-of-cdkl5-deficiency-disorder 2021-08-28T22:10:31 https://maestrodatabase.com/blog/prescription-drug-prices-can-vary-by-thousands-of-dollars-depending-on-where-you-buy-them 2019-03-06T10:07:08 https://maestrodatabase.com/blog/nocira-becomes-first-company-ever-to-announce-breakthrough-device-designation-by-the-fda-for-acute-treatment-of-migraine 2022-04-28T01:38:34 https://maestrodatabase.com/blog/canada-should-create-new-drug-agency-and-list-of-medications-available-to-everyone-council-says 2019-03-06T19:57:37 https://maestrodatabase.com/blog/uk-nice-to-announce-decision-on-vertexs-therapy-trikafta-in-december 2020-02-26T19:17:25 https://maestrodatabase.com/blog/donald-trump-just-lost-his-most-popular-bureaucrat 2019-03-06T20:00:10 https://maestrodatabase.com/blog/eurneffy-1-mg-adrenaline-nasal-spray-recommended-for-approval-in-the-eu-for-emergency-treatment-of-type-1-allergic-reactions-including-anaphylaxis-in-children-weighing-15-kg-to-<30-kg 2026-02-04T10:32:11 https://maestrodatabase.com/blog/forxiga-approved-in-china-for-heart-failure 2021-02-04T07:07:03 https://maestrodatabase.com/blog/firm-in-nhs-row-over-cystic-fibrosis-drug-paid-almost-no-uk-tax 2019-03-06T19:46:01 https://maestrodatabase.com/blog/patient-advocacy-groups-in-canada-with-ties-to-pharma-are-big-boosters-for-government-coverage 2019-03-06T19:50:11 https://maestrodatabase.com/blog/puma-biotechnology-receives-u-dot-s-fda-approval-of-supplemental-new-drug-application-for-neratinib-to-treat-her2-positive-metastatic-breast-cancer 2020-02-26T19:11:18 https://maestrodatabase.com/blog/n-dot-s-father-says-drug-pricing-chess-game-cost-his-daughter-her-life 2020-02-26T19:26:48 https://maestrodatabase.com/blog/ultomiris-approved-in-the-us-for-adults-with-generalised-myasthenia-gravis 2022-04-28T11:25:19 https://maestrodatabase.com/blog/china-moves-to-expand-cancer-medicine-access 2019-03-06T20:28:11 https://maestrodatabase.com/blog/translate-bio-receives-fda-fast-track-designation-for-mrt5005-for-the-treatment-of-cystic-fibrosis 2020-02-26T19:22:43 https://maestrodatabase.com/blog/two-maryland-bills-are-the-states-latest-attempt-to-rein-in-drug-prices 2019-03-06T20:07:20 https://maestrodatabase.com/blog/access-criteria-for-antiviral-treatments-widened-as-molnupiravir-arrives-in-new-zealand 2022-04-28T11:30:46 https://maestrodatabase.com/blog/in-uk-and-ireland-sma-patients-demand-reimbursement-for-spinraza 2019-03-06T20:13:00 https://maestrodatabase.com/blog/csl-behring-announces-first-two-patients-treated-with-hemgenix-etranacogene-dezaparvovec-gene-therapy-for-haemophilia-b-in-europe 2024-07-05T06:51:08 https://maestrodatabase.com/blog/fda-approves-mycovia-pharmaceuticals-vivjoa-oteseconazole-the-first-and-only-fda-approved-medication-for-recurrent-vulvovaginal-candidiasis 2022-04-28T21:06:33 https://maestrodatabase.com/blog/astellas-xospata-gilteritinib-receives-conditional-approval-by-chinas-national-medical-products-administration-for-relapsed-or-refractory-acute-myeloid-leukaemia-with-a-flt3-mutation 2021-02-04T07:40:05 https://maestrodatabase.com/blog/cancer-agency-report-duplicates-pharmac-role 2022-04-28T11:49:11 https://maestrodatabase.com/blog/market-for-new-medicines-in-canada-has-not-slowed-over-last-two-years-despite-focus-on-covid-19-treatments 2022-04-28T21:17:30 https://maestrodatabase.com/blog/aruvant-announces-the-ema-granted-prime-designation-to-aru-1801-for-the-treatment-of-sickle-cell-disease 2021-02-04T07:44:05 https://maestrodatabase.com/blog/fda-launches-new-interactive-pdf-based-template-to-promote-greater-efficiency-and-consistency-in-preparation-and-review-of-510-k-medical-device-applications 2020-02-26T19:30:04 https://maestrodatabase.com/blog/tga-grants-provisional-determination-for-the-moderna-bivalent-covid-19-vaccine-spikevax-bivalent-zero-slash-omicron 2022-04-28T11:42:18 https://maestrodatabase.com/blog/repurposing-of-prescription-medicines 2021-02-04T07:53:13 https://maestrodatabase.com/blog/coronavirus-mix-and-match-vaccine-trial-amid-shortage-fears 2021-02-04T07:58:15 https://maestrodatabase.com/blog/janssen-submits-marketing-authorisation-application-to-ema-seeking-approval-of-niraparib-and-abiraterone-acetate-dual-action-tablet-plus-prednisone-for-the-treatment-of-patients-with-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer 2022-04-28T21:49:24 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-28-april-2022 2022-04-28T21:20:01 https://maestrodatabase.com/blog/singapore-approves-modernas-covid-19-vaccine-side-effects-of-jab-similar-to-pfizers 2021-02-04T07:49:51 https://maestrodatabase.com/blog/public-summary-documents---march-2024-pbac-meeting-round-1 2024-07-05T07:45:02 https://maestrodatabase.com/blog/insights-from-the-march-2022-pbac-meeting-part-3 2022-04-28T21:26:25 https://maestrodatabase.com/blog/an-online-pharmacy-pledged-to-make-prescriptions-easier-it-sent-the-wrong-drugs-instead 2024-07-05T07:40:52 https://maestrodatabase.com/blog/cms-seeks-recommendations-that-allow-americans-to-purchase-health-insurance-across-state-lines 2019-03-06T23:02:27 https://maestrodatabase.com/blog/prescription-drugs--list-price-net-price-and-the-rebate-caught-in-the-middle 2019-03-06T22:58:32 https://maestrodatabase.com/blog/bayer-receives-approval-for-nubeqa-in-china-for-the-treatment-of-men-with-non-metastatic-castration-resistant-prostate-cancer 2021-02-04T11:23:28 https://maestrodatabase.com/blog/thousands-of-lung-cancer-patients-to-benefit-from-life-extending-treatment 2021-02-04T11:46:19 https://maestrodatabase.com/blog/cumberland-pharmaceuticals-receives-fda-fast-track-designation-for-its-ifetroban-duchenne-muscular-dystrophy-program 2026-02-04T23:30:43 https://maestrodatabase.com/blog/patients-will-be-pushed-to-use-generic-drugs-as-medicine-prices-fall-in-the-upcoming-federal-budget 2017-04-21T23:07:32 https://maestrodatabase.com/blog/nices-processes-of-technology-evaluation---presenting-a-case-for-change 2021-02-04T19:50:30 https://maestrodatabase.com/blog/vedanta-biosciences-announces-first-patient-dosed-in-phase-2-clinical-trial-of-ve202-for-the-treatment-of-ulcerative-colitis-and-receives-fast-track-designation 2023-10-05T10:45:20 https://maestrodatabase.com/blog/theratechnologies-lead-peptide-drug-conjugate-th1902-receives-fda-fast-track-designation-for-the-treatment-of-sortilin-expressing-cancers 2021-02-04T19:54:36 https://maestrodatabase.com/blog/innovent-and-lilly-jointly-announce-the-approval-of-tyvyt-sintilimab-by-china-nmpa-in-combination-with-pemetrexed-and-platinum-chemotherapy-as-first-line-therapy-for-non-squamous-non-small-cell-lung-cancer 2021-02-04T11:27:10 https://maestrodatabase.com/blog/ema-covid-19-assessments-open-to-non-eu-regulators 2021-02-04T11:35:33 https://maestrodatabase.com/blog/ema-reviewing-data-on-monoclonal-antibody-use-for-covid-19 2021-02-04T20:05:11 https://maestrodatabase.com/blog/biden-harris-administration-moves-forward-with-medicare-drug-price-negotiations-to-lower-prescription-drug-costs-for-people-with-medicare 2023-10-05T19:41:54 https://maestrodatabase.com/blog/first-national-action-plan-for-rare-diseases 2020-02-27T01:55:23 https://maestrodatabase.com/blog/oncolytics-biotech-receives-fda-fast-track-designation-for-pelareorep-in-second-line-kras-mutant-mss-metastatic-colorectal-cancer 2026-02-05T00:42:32 https://maestrodatabase.com/blog/cystic-fibrosis-is-the-reason-for-denial-of-irish-mans-re-entry-visa-by-australian-government-family-says 2020-02-27T02:53:31 https://maestrodatabase.com/blog/life-changing-calls-for-eczema-drug-to-be-pbs-listed-to-help-with-mental-health 2020-02-27T02:48:34 https://maestrodatabase.com/blog/building-a-stronger-medicare-with-mymedicare-now-open-to-patients 2023-10-05T20:16:42 https://maestrodatabase.com/blog/new-drug-added-to-pbs-to-help-treat-australias-deadliest-cancer 2020-02-27T02:44:23 https://maestrodatabase.com/blog/leads-biolabs-gprc5d-slash-cd3-bispecific-t-cell-engager-lbl-034-earns-fda-fast-track-designation--accelerating-launch-of-potential-best-in-class-therapy-for-relapsed-slash-refractory-multiple-myeloma 2026-02-05T00:04:05 https://maestrodatabase.com/blog/new-payment-models-are-needed-to-finance-new-advanced-treatments 2023-10-05T20:13:28 https://maestrodatabase.com/blog/agomab-receives-fda-fast-track-designation-for-agmb-129-in-fibrostenosing-crohns-disease 2023-10-05T20:00:29 https://maestrodatabase.com/blog/calliditas-announces-filing-with-uk-mhra-for-kinpeygo-in-iga-nephropathy 2023-10-05T20:44:42 https://maestrodatabase.com/blog/european-commission-approves-pfizers-rsv-vaccine-abrysvo-to-help-protect-adults-aged-18-59-against-rsv-lower-respiratory-tract-disease 2025-04-01T21:34:15 https://maestrodatabase.com/blog/orphan-drug-for-multiple-myeloma-g-ba-must-formally-certify-legally-assumed-additional-benefit 2023-10-05T20:33:24 https://maestrodatabase.com/blog/japan-to-step-up-price-cuts-for-off-patent-drugs 2017-11-18T23:23:48 https://maestrodatabase.com/blog/pharmac-proposes-wider-access-to-a-treatment-for-people-with-a-rare-blood-cancer 2026-02-05T01:07:13 https://maestrodatabase.com/blog/drug-companies-are-warming-up-to-the-idea-of-an-amazon-pharmacy 2017-11-18T23:44:26 https://maestrodatabase.com/blog/u-dot-s-fda-extends-review-for-tlando-advisory-committee-meeting-date-of-10-january-2018-remains-unchanged 2017-11-18T23:31:41 https://maestrodatabase.com/blog/as-sarepta-awaits-approval-of-new-duchenne-drug-big-questions-hang-over-therapy-already-on-market 2019-08-17T01:43:03 https://maestrodatabase.com/blog/breakthrough-pbs-listings-to-benefit-thousands-of-australians 2021-08-29T01:20:44 https://maestrodatabase.com/blog/korea-to-exclude-australia-from-new-drug-pricing-reference-country-list 2023-01-02T09:02:40 https://maestrodatabase.com/blog/china-cde-slash-nmpa-recommends-priority-review-for-nefecon-for-the-treatment-of-primary-iga-nephropathy 2023-01-02T10:00:51 https://maestrodatabase.com/blog/eu-relocation-looms-for-medicine-and-banking-bodies 2017-11-19T01:43:47 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-positive-chmp-opinion-recommending-approval-of-opdivo-nivolumab-for-the-treatment-of-patients-with-previously-treated-locally-advanced-or-metastatic-urothelial-carcinoma-a-type-of-bladder-cancer 2017-04-22T01:20:30 https://maestrodatabase.com/blog/biogens-spinraza-nusinersen-receives-positive-chmp-opinion-for-the-treatment-of-spinal-muscular-atrophy 2017-04-22T01:28:05 https://maestrodatabase.com/blog/zogenix-announces-fda-extension-of-review-period-for-fintepla-in-dravet-syndrome 2020-02-27T20:10:24 https://maestrodatabase.com/blog/fda-begins-adding-suffixes-to-newly-approved-biologics-names 2017-11-19T01:46:30 https://maestrodatabase.com/blog/fluoxetine-depression-pill-shortage-pharmac-playing-with-peoples-lives-pharmacist-warns 2020-02-27T20:07:12 https://maestrodatabase.com/blog/fda-grants-actinogen-rare-paediatric-disease-designation-in-fragile-x-syndrome 2021-02-05T01:51:00 https://maestrodatabase.com/blog/nice-recommends-new-chemotherapy-free-treatment-for-lymphoma 2020-02-27T10:56:42 https://maestrodatabase.com/blog/biomarin-receives-positive-chmp-opinion-in-europe-for-brineura-cerliponase-alfa-for-first-treatment-of-cln2-disease-a-form-of-batten-disease-and-ultra-rare-and-fatal-brain-disorder-in-children 2017-04-22T01:33:41 https://maestrodatabase.com/blog/ultragenyx-and-kyowa-kirin-announce-fda-acceptance-and-priority-review-designation-of-supplemental-biologics-license-application-for-crysvita-burosumab-for-tumour-induced-osteomalacia 2020-02-27T20:18:13 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-to-review-drugs-for-tardive-dyskinesia-in-upcoming-report 2017-04-22T01:40:01 https://maestrodatabase.com/blog/sandoz-proposed-biosimilars-rituximab-and-etanercept-recommended-for-approval-in-europe 2017-04-22T01:46:56 https://maestrodatabase.com/blog/highlights-from-the-24-27-march-2025-chmp-meeting 2025-04-01T22:36:36 https://maestrodatabase.com/blog/valeants-patient-access-and-pricing-committee-announces-pricing-for-siliq-brodalumab-as-the-lowest-priced-injectable-biologic-for-moderate-to-severe-plaque-psoriasis 2017-04-22T01:56:51 https://maestrodatabase.com/blog/fda-approves-samsung-bioepis-copy-of-j-and-js-remicade-company 2017-04-22T02:06:28 https://maestrodatabase.com/blog/one-in-10-people-not-filling-prescriptions-because-of-cost 2020-02-27T20:29:41 https://maestrodatabase.com/blog/moderna-files-for-authorisation-of-its-covid-19-vaccine-in-young-children-six-months-to-under-six-years-of-age 2022-04-29T05:53:10 https://maestrodatabase.com/blog/prioritise-lung-cancer-treatments-patients-tell-mps 2019-03-07T12:06:04 https://maestrodatabase.com/blog/timber-pharmaceuticals-announces-fast-track-designation-granted-by-fda-for-tmb-001-in-severe-subtypes-of-congenital-ichthyosis 2022-04-29T07:02:28 https://maestrodatabase.com/blog/statement-from-fda-commissioner-on-fdas-steps-on-naming-of-biological-medicines-to-balance-competition-and-safety-for-patients-receiving-these-products 2019-03-07T19:54:53 https://maestrodatabase.com/blog/drug-price-fix-seen-in-supply-of-generics-rebates-senator-says 2019-03-07T12:10:03 https://maestrodatabase.com/blog/one-gop-senator-is-urging-the-drug-industry-to-make-good-on-lowering-prices 2019-03-07T12:14:26 https://maestrodatabase.com/blog/grin-therapeutics-receives-prime-designation-from-ema-for-radiprodil-in-the-treatment-of-grin-related-neurodevelopmental-disorder 2025-04-01T23:49:28 https://maestrodatabase.com/blog/fda-accepts-genentechs-supplemental-new-drug-application-for-xofluza-baloxavir-marboxil-for-the-treatment-of-influenza-in-people-at-high-risk-of-complications 2019-03-07T20:12:16 https://maestrodatabase.com/blog/many-local-governments-shrug-off-fda-warning-about-canadian-drug-imports 2019-03-07T20:02:46 https://maestrodatabase.com/blog/gottlieb-drug-rebates-not-benefiting-sicker-patients 2019-03-07T20:06:20 https://maestrodatabase.com/blog/forget-about-an-international-pricing-index-for-drugs-cost-effectiveness-is-a-better-bargain 2019-03-07T20:25:37 https://maestrodatabase.com/blog/genentech-submits-supplemental-new-drug-application-to-fda-for-venclexta-plus-gazyva-for-previously-untreated-chronic-lymphocytic-leukaemia-with-co-existing-medical-conditions 2019-03-07T20:19:14 https://maestrodatabase.com/blog/u-dot-s-food-and-drug-administration-approves-camzyos-mavacamten-for-the-treatment-of-adults-with-symptomatic-new-york-heart-association-class-ii-iii-obstructive-hypertrophic-cardiomyopathy-to-improve-functional-capacity-and-symptoms 2022-04-29T07:52:06 https://maestrodatabase.com/blog/the-100-000-dollars-dark-money-mystery-group-behind-a-pharma-bashing-facebook-campaign 2019-03-07T20:28:11 https://maestrodatabase.com/blog/what-if-you-knew-alzheimers-was-coming-for-you 2017-11-19T10:01:19 https://maestrodatabase.com/blog/agenda-update-for-the-may-2022-pbac-intracycle-meeting 2022-04-29T08:14:20 https://maestrodatabase.com/blog/mark-cubans-cost-plus-drug-company-continues-to-revolutionise-generic-drug-pricing 2023-01-02T21:22:57 https://maestrodatabase.com/blog/health-insurance-pressure-can-only-crimp-margins 2017-11-19T19:37:06 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-umbralisib-for-marginal-zone-lymphoma-and-follicular-lymphoma 2021-02-06T21:43:04 https://maestrodatabase.com/blog/beigene-announces-acceptance-of-twelfth-regulatory-submission-in-china-for-pd-1-inhibitor-tislelizumab 2023-01-02T21:05:34 https://maestrodatabase.com/blog/more-than-150-0000-dollars-spent-on-mysterious-election-2017-project-by-drug-lobby-group 2017-11-19T19:31:58 https://maestrodatabase.com/blog/cheaper-medicines-from-today 2023-01-02T20:55:22 https://maestrodatabase.com/blog/johnson-and-johnson-announces-submission-of-application-to-the-u-dot-s-fda-for-emergency-use-authorisation-of-its-investigational-single-shot-janssen-covid-19-vaccine-candidate 2021-02-06T22:01:30 https://maestrodatabase.com/blog/fda-approves-lisocabtagene-maraleucel-for-relapsed-or-refractory-large-b-cell-lymphoma 2021-02-06T21:53:25 https://maestrodatabase.com/blog/ibsa-usa-announces-fda-approval-of-vybrique-the-first-and-only-oral-film-to-treat-men-with-erectile-dysfunction 2026-02-06T06:45:33 https://maestrodatabase.com/blog/fda-blasts-keytruda-data-for-new-breast-cancer-indication-as-questionable-immature-and-unreliable 2021-02-06T22:18:37 https://maestrodatabase.com/blog/moderna-covid-19-vaccine-gets-health-canada-approval-for-kids-12-plus 2021-08-29T21:00:51 https://maestrodatabase.com/blog/with-fda-accelerated-approval-of-alzheimers-drug-lecanemab-likely-6-january-discussion-turns-to-price-and-reimbursement 2023-01-02T21:48:36 https://maestrodatabase.com/blog/merck-announces-health-canada-approval-of-enflonsia-for-the-prevention-of-rsv-in-newborns-and-infants 2026-02-06T07:10:24 https://maestrodatabase.com/blog/teva-canada-announces-approval-of-expanded-indication-of-ajovy-fremanezumab-solution-for-subcutaneous-injection-the-first-anti-cgrp-preventive-treatment-for-paediatric-episodic-migraine 2026-02-06T07:13:40 https://maestrodatabase.com/blog/fda-announces-advisory-committee-meeting-to-discuss-janssen-biotechs-covid-19-vaccine-candidate 2021-02-06T22:07:28 https://maestrodatabase.com/blog/covid-19-vaccine-claims-scheme 2021-08-29T20:51:38 https://maestrodatabase.com/blog/a-new-weight-loss-drug-could-become-the-best-selling-drug-of-all-time-who-can-afford-it 2023-01-02T21:40:06 https://maestrodatabase.com/blog/fda-authorises-marketing-of-novel-device-to-reduce-snoring-and-mild-obstructive-sleep-apnea-in-patients-18-years-and-older 2021-02-06T22:12:45 https://maestrodatabase.com/blog/fennec-pharmaceuticals-announces-fda-acceptance-for-filing-of-new-drug-application-resubmission-for-pedmark 2022-04-29T12:14:54 https://maestrodatabase.com/blog/doctors-push-for-weight-loss-drugs-to-be-added-to-the-pbs 2025-04-02T02:09:24 https://maestrodatabase.com/blog/apellis-announces-fda-acceptance-and-priority-review-of-the-supplemental-new-drug-application-for-empaveli-pegcetacoplan-for-c3g-and-primary-ic-mpgn 2025-04-02T03:14:00 https://maestrodatabase.com/blog/next-phase-in-effective-cost-control-in-health-care 2019-03-08T00:02:11 https://maestrodatabase.com/blog/novavax-announces-start-of-rolling-review-by-multiple-regulatory-authorities-for-covid-19-vaccine-authorisation 2021-02-07T03:34:43 https://maestrodatabase.com/blog/agenda-for-the-july-2025-pbac-meeting 2025-04-02T03:19:46 https://maestrodatabase.com/blog/sanofi-launches-new-cholesterol-lowering-injection-in-korea-with-health-insurance-coverage 2025-04-02T05:34:10 https://maestrodatabase.com/blog/nucala-mepolizumab-approved-by-the-european-commission-for-the-treatment-of-chronic-obstructive-pulmonary-disease 2026-02-06T11:06:45 https://maestrodatabase.com/blog/continued-support-for-australias-community-pharmacies 2019-03-08T02:48:36 https://maestrodatabase.com/blog/coherus-announces-resubmission-of-biologics-license-application-supplement-for-udenyca-onbody 2023-10-06T22:15:54 https://maestrodatabase.com/blog/fda-accepts-supplemental-biologics-license-applications-for-botox-onabotulinumtoxina-for-paediatric-patients-with-upper-and-lower-limb-spasticity 2019-03-08T02:41:53 https://maestrodatabase.com/blog/decision-to-make-changes-to-funded-haemophilia-treatments 2019-03-08T02:52:06 https://maestrodatabase.com/blog/fda-grants-interchangeable-designation-to-pfizers-biosimilar-abrilada 2023-10-06T22:35:04 https://maestrodatabase.com/blog/fda-grants-priority-review-for-hympavzi-marstacimab-sbla-for-the-treatment-of-two-haemophilia-a-or-b-patient-populations-with-significant-medical-need 2026-02-06T20:54:47 https://maestrodatabase.com/blog/amylyx-pharmaceuticals-provides-update-on-acces-compassionnel-for-amx0035-in-france 2023-10-06T22:29:02 https://maestrodatabase.com/blog/hinova-pharmaceuticals-receives-fda-fast-track-designation-for-hp518-for-treatment-of-androgen-receptor-triple-negative-breast-cancer 2024-07-05T23:43:19 https://maestrodatabase.com/blog/when-can-intermediate-outcomes-be-used-as-surrogate-outcomes 2020-02-28T03:22:09 https://maestrodatabase.com/blog/rinvoq-upadacitinib-approved-by-u-dot-s-fda-as-an-oral-treatment-for-adults-with-active-ankylosing-spondylitis 2022-04-29T21:52:31 https://maestrodatabase.com/blog/timaru-mother-with-terminal-bowel-cancer-calling-on-government-to-fund-cetuximab 2021-02-07T20:01:03 https://maestrodatabase.com/blog/fears-alp-to-axe-$6bn-health-insurance-rebate 2017-04-22T07:38:30 https://maestrodatabase.com/blog/the-balloon-the-box-and-health-care 2017-04-22T07:41:37 https://maestrodatabase.com/blog/alberta-promises-to-offer-universal-access-to-the-abortion-pill 2017-04-22T07:44:35 https://maestrodatabase.com/blog/janssen-submits-application-to-the-european-medicines-agency-for-rybrevant-amivantamab-in-combination-with-chemotherapy-for-the-first-line-treatment-of-adult-patients-with-advanced-non-small-cell-lung-cancer-with-activating-egfr-exon-20-insertion-mutations 2023-10-07T01:27:27 https://maestrodatabase.com/blog/patient-and-public-involvement-in-health-technology-assessment-update-of-a-systematic-review-of-international-experiences 2021-02-07T20:28:01 https://maestrodatabase.com/blog/marketing-authorisation-for-glybera-to-expire-on-25-october-2017 2017-04-23T02:18:05 https://maestrodatabase.com/blog/australians-to-have-proof-of-their-coronavirus-vaccination-on-their-smartphone 2021-02-07T20:44:32 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac---march-2017 2017-04-22T07:53:56 https://maestrodatabase.com/blog/entrogen-receives-fda-approval-for-crcdx-ras-mutation-detection-kit-as-companion-diagnostic-for-vectibix 2023-10-07T02:03:49 https://maestrodatabase.com/blog/new-melanoma-drug-gets-medsafe-registration-for-lung-cancer 2017-04-23T20:53:43 https://maestrodatabase.com/blog/white-house-debuts-drug-buying-site-trumprx-with-roughly-40-medications 2026-02-06T21:33:45 https://maestrodatabase.com/blog/nices-discounting-review-clear-thinking-on-rational-revision-meets-obstacle-of-industrial-interests 2021-02-07T20:04:57 https://maestrodatabase.com/blog/modifying-nices-approach-to-equity-weighting 2021-02-07T20:08:13 https://maestrodatabase.com/blog/health-canada-authorises-dayvigo-lemborexant 2021-02-07T20:21:51 https://maestrodatabase.com/blog/rystiggo-now-approved-for-adults-with-generalised-myasthenia-gravis-in-canada 2025-04-02T06:08:25 https://maestrodatabase.com/blog/tessa-therapeutics-announces-u-dot-s-fda-regenerative-medicine-advanced-therapy-designation-granted-to-its-cd30-car-t-cell-therapy-for-the-treatment-of-relapsed-or-refractory-cd30-positive-classical-hodgkin-lymphoma 2020-02-28T03:55:17 https://maestrodatabase.com/blog/direct-acting-anti-virals-for-hepatitis-c---outcome-statement 2019-03-08T06:47:23 https://maestrodatabase.com/blog/european-medicines-agency-validates-application-for-bavencio-avelumab-plus-inlyta-axitinib-for-the-treatment-of-advanced-renal-cell-carcinoma 2019-03-08T08:15:02 https://maestrodatabase.com/blog/high-price-of-cystic-fibrosis-drug-not-political-firms-boss-tells-mps 2019-03-08T06:28:25 https://maestrodatabase.com/blog/efanesoctocog-alfa-for-the-treatment-and-prevention-of-bleeding-episodes-in-patients-with-haemophilia-a-final-guidance 2025-04-02T06:53:32 https://maestrodatabase.com/blog/summary-of-consultation-to-widen-access-to-cancer-medicines-and-treatments-to-prevent-fungal-infections 2024-07-06T01:49:53 https://maestrodatabase.com/blog/judge-rules-against-boehringer-ingelheim-in-pharmas-latest-legal-loss-on-medicare-negotiation 2024-07-06T01:41:12 https://maestrodatabase.com/blog/submission-of-nidlegy-marketing-authorisation-application-validated-by-ema 2024-07-06T00:56:53 https://maestrodatabase.com/blog/valnevas-chikungunya-vaccine-ixchiq-now-authorised-in-eu-for-adolescents-aged-12-and-above 2025-04-02T07:57:46 https://maestrodatabase.com/blog/zatolmilast-an-investigational-treatment-for-fragile-x-syndrome-receives-rare-paediatric-disease-designation-from-the-us-fda 2023-10-07T02:42:18 https://maestrodatabase.com/blog/supernus-announces-fda-approval-of-qelbree-for-the-treatment-of-attention-deficit-hyperactivity-disorder-in-adults 2022-04-30T08:34:21 https://maestrodatabase.com/blog/scott-morrison-pledges-to-cut-10-dollars-from-pharmaceutical-benefit-scheme-scripts 2022-04-30T08:30:06 https://maestrodatabase.com/blog/cancer-drug-shortage-eases-slightly-but-its-still-living-from-paycheck-to-paycheck 2023-10-07T03:22:02 https://maestrodatabase.com/blog/fda-approves-arcutis-zoryve-roflumilast-0-dot-3-percent-cream-for-treatment-of-psoriasis-in-children-ages-6-to-11 2023-10-07T03:25:01 https://maestrodatabase.com/blog/managed-entry-agreements-for-oncology-drugs-lessons-from-the-european-experience-to-inform-the-future 2017-04-24T00:49:15 https://maestrodatabase.com/blog/tga-one-of-only-five-non-european-regulators-invited-to-participate-on-european-committees-on-covid-19-vaccines-and-therapeutics 2021-02-08T07:36:12 https://maestrodatabase.com/blog/more-contraceptive-choice-for-australian-women 2020-02-28T06:14:40 https://maestrodatabase.com/blog/sydnexis-announces-positive-chmp-opinion-in-europe-for-syd-101-for-slowing-the-progression-of-paediatric-myopia 2025-04-02T22:51:53 https://maestrodatabase.com/blog/fda-grants-breakthrough-device-designation-for-roches-elecsys-growth-differentiation-factor-15-assay-to-help-identify-patients-suitable-for-innovative-treatment-addressing-unintentional-weight-loss-in-cancer-patients 2021-02-08T11:58:59 https://maestrodatabase.com/blog/kisqali-receives-positive-draft-recommendation-from-canadas-drug-agency-for-all-eligible-early-breast-cancer-patients-at-high-risk-of-recurrence 2026-02-07T05:26:33 https://maestrodatabase.com/blog/international-regulators-working-together-to-enhance-collaboration-on-covid-19-observational-research 2021-02-08T19:40:37 https://maestrodatabase.com/blog/pendopharm-announces-the-approval-of-yorvipath-palopegteriparatide-injection-for-the-treatment-of-chronic-hypoparathyroidism-in-adults 2026-02-07T06:03:10 https://maestrodatabase.com/blog/puzzle-medical-devices-receives-u-dot-s-fda-breakthrough-device-designation-for-its-revolutionary-minimally-invasive-transcatheter-heart-pump 2021-02-08T11:53:31 https://maestrodatabase.com/blog/biogens-investigational-tau-targeting-therapy-biib080-receives-fda-fast-track-designation-for-the-treatment-of-alzheimers-disease 2025-04-02T23:43:46 https://maestrodatabase.com/blog/biohavens-nurtec-odt-rimegapant-receives-fda-approval-for-the-acute-treatment-of-migraine-in-adults 2020-02-28T06:28:06 https://maestrodatabase.com/blog/covid-19-vaccine-certificates-to-be-available-online-within-days-of-immunisation 2021-02-08T20:02:33 https://maestrodatabase.com/blog/s-africa-suspends-covid-19-vaccination-over-astrazeneca-study-as-who-deliberates-on-usage 2021-02-08T20:48:48 https://maestrodatabase.com/blog/acacia-pharma-announces-us-approval-of-barhemsys-amisulpride-for-the-treatment-and-prevention-of-ponv 2020-02-28T06:38:38 https://maestrodatabase.com/blog/ellodi-pharmaceuticals-announces-fast-track-designation-granted-by-the-fda-to-apt-1011-for-the-treatment-of-eosinophilic-osophagitis 2021-02-08T19:51:10 https://maestrodatabase.com/blog/moderna-files-to-expand-conditional-marketing-authorisation-for-its-covid-19-vaccine-to-include-children-six-months-to-under-six-years-in-the-european-union 2022-05-01T00:54:30 https://maestrodatabase.com/blog/sanofi-receives-fda-approval-of-thymoglobulin-for-the-prevention-of-acute-kidney-transplant-rejection 2017-04-24T23:37:32 https://maestrodatabase.com/blog/incyte-announces-positive-chmp-opinion-for-zynyz-retifanlimab-for-first-line-treatment-of-advanced-squamous-cell-carcinoma-of-the-anal-canal 2026-02-07T05:21:30 https://maestrodatabase.com/blog/open-letter-from-the-pharmaceutical-industry-heads-of-research-and-efpia-on-the-relocation-of-the-european-medicines-agency 2017-04-24T23:34:37 https://maestrodatabase.com/blog/smc---february-2021-decisions 2021-02-08T19:57:23 https://maestrodatabase.com/blog/denali-therapeutics-announces-initiation-of-bla-filing-for-accelerated-approval-of-tividenofusp-alfa-for-the-treatment-of-hunter-syndrome 2025-04-02T23:58:55 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-may-2022 2022-05-01T01:28:26 https://maestrodatabase.com/blog/fda-grants-genentechs-tecentriq-in-combination-with-abraxane-accelerated-approval-for-people-with-pd-l1-positive-metastatic-triple-negative-breast-cancer 2019-03-08T21:22:29 https://maestrodatabase.com/blog/nuvo-pharmaceuticals-announces-health-canada-approves-suvexx-for-the-acute-treatment-of-migraine 2020-02-28T06:44:19 https://maestrodatabase.com/blog/moderna-submits-covid-19-vaccine-for-kids-5-and-under-to-health-canada-for-review 2022-05-01T01:45:20 https://maestrodatabase.com/blog/gsk-koreas-long-acting-hiv-injection-therapy-gains-insurance-benefit 2025-04-03T00:16:40 https://maestrodatabase.com/blog/fda-to-undertake-priority-review-of-dupixent-dupilumab-for-adults-with-inadequately-controlled-severe-chronic-rhinosinusitis-with-nasal-polyps 2019-03-08T22:04:45 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-january-2023 2023-01-03T01:49:29 https://maestrodatabase.com/blog/changes-to-the-pbs-to-make-medicines-more-affordable 2023-01-03T02:03:21 https://maestrodatabase.com/blog/public-summary-documents---may-2021-pbac-meeting 2021-08-30T05:57:27 https://maestrodatabase.com/blog/new-pharmaceutical-benefits-scheme-listings-to-save-patients-millions 2022-05-01T03:27:37 https://maestrodatabase.com/blog/hansa-biopharma-announces-positive-reimbursement-decision-for-idefirix-imlifidase-in-the-czech-republic 2023-01-03T06:28:13 https://maestrodatabase.com/blog/four-decades-of-orphan-drugs-and-priorities-for-the-future 2024-07-06T12:28:54 https://maestrodatabase.com/blog/legend-biotech-announces-acceptance-of-its-new-drug-application-for-ciltacabtagene-autoleucel-in-china 2023-01-03T03:07:41 https://maestrodatabase.com/blog/fda-approves-novartis-cosentyx-as-first-intravenous-formulation-interleukin-17a-antagonist-for-rheumatic-diseases 2023-10-08T01:01:23 https://maestrodatabase.com/blog/campaigners-call-for-nhs-access-to-orkambi-as-mp-inquiry-gets-underway 2019-03-08T23:25:15 https://maestrodatabase.com/blog/yescarta-now-approved-in-japan-for-initial-treatment-of-relapsed-slash-refractory-large-b-cell-lymphoma 2023-01-03T02:25:56 https://maestrodatabase.com/blog/libtayo-cemiplimab-approved-in-japan-for-advanced-or-recurrent-cervical-cancer 2023-01-03T02:17:14 https://maestrodatabase.com/blog/shingles-vaccine-now-free-for-nearly-5-million-australians 2023-10-08T01:21:48 https://maestrodatabase.com/blog/averoa-receives-positive-opinion-from-the-ema-for-xoancyl-an-oral-therapy-for-chronic-kidney-disease 2025-04-03T01:16:14 https://maestrodatabase.com/blog/marginal-effects--quantifying-the-effect-of-changes-in-risk-factors-in-logistic-regression-models 2019-03-09T02:32:51 https://maestrodatabase.com/blog/us-fda-grants-breakthrough-designation-for-blood-test-to-help-diagnose-inaccessible-brain-tumours 2023-01-03T06:31:47 https://maestrodatabase.com/blog/americans-look-to-canada-for-lower-drug-prices-but-are-they-getting-the-full-picture 2023-10-08T01:34:18 https://maestrodatabase.com/blog/shiratronics-receives-fda-breakthrough-device-designation-for-chronic-migraine-neurostimulation 2021-02-09T00:04:25 https://maestrodatabase.com/blog/fda-approves-new-drug-that-could-take-a-slice-out-of-johnson-and-johnsons-best-seller 2017-04-25T12:40:28 https://maestrodatabase.com/blog/novartis-receives-fda-breakthrough-therapy-designations-for-investigational-stamp-inhibitor-asciminib-abl001-in-chronic-myeloid-leukaemia 2021-02-09T00:12:22 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-may-2022 2022-05-01T06:03:49 https://maestrodatabase.com/blog/nice-during-the-pre-election-period 2019-11-13T10:43:58 https://maestrodatabase.com/blog/teen-thriving-on-pharmac-funded-medicine 2021-02-09T00:17:45 https://maestrodatabase.com/blog/iqwig-in-dialogue-2017-programme-is-now-online 2017-04-25T20:59:41 https://maestrodatabase.com/blog/european-immunisation-week-statement-of-guido-rasi-the-executive-director-of-the-european-medicines-agency 2017-04-25T20:56:10 https://maestrodatabase.com/blog/review-of-the-national-medicines-policy---call-for-submissions 2021-08-30T06:48:11 https://maestrodatabase.com/blog/fda-takes-action-against-fraudulent-cancer-products 2017-04-25T21:06:25 https://maestrodatabase.com/blog/foamix-announces-fda-acceptance-of-new-drug-application-for-fmx101-minocycline-foam-for-the-treatment-of-moderate-to-severe-acne 2019-03-09T06:05:49 https://maestrodatabase.com/blog/cadth-symposium-examines-tough-questions-about-assessing-value-in-health-care 2017-04-25T21:03:11 https://maestrodatabase.com/blog/express-scripts-says-likely-to-lose-top-client-anthem 2017-04-25T21:16:26 https://maestrodatabase.com/blog/white-house-says-vote-on-healthcare-plan-may-not-come-for-weeks 2017-04-25T21:09:37 https://maestrodatabase.com/blog/u-dot-s-fda-grants-breakthrough-device-designation-to-vascular-perfusion-solutions-for-its-visionary-vp-dot-s-encore-cardiac-transport-device 2021-02-09T06:48:30 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-european-commission-approval-for-inrebic-fedratinib-for-adult-patients-with-newly-diagnosed-and-previously-treated-myelofibrosis 2021-02-09T06:54:17 https://maestrodatabase.com/blog/pertuzumab-and-pertuzumab-with-trastuzumab-in-breast-cancer-now-a-minor-additional-clinical-benefit 2023-01-03T09:39:20 https://maestrodatabase.com/blog/tagrisso-receives-full-approval-in-the-eu 2017-04-25T21:24:58 https://maestrodatabase.com/blog/biologic-medicines-the-biggest-driver-of-rising-drug-prices 2019-03-09T10:47:27 https://maestrodatabase.com/blog/pfizer-vaccine-bound-for-australia-wont-be-blocked 2021-02-09T00:24:25 https://maestrodatabase.com/blog/ema-publishes-withdrawal-assessment-report-for-zioxtenzo 2017-04-25T21:37:43 https://maestrodatabase.com/blog/viiv-healthcare-receives-marketing-authorisation-for-rukobia-fostemsavir-a-first-in-class-attachment-inhibitor-in-combination-with-other-antiretrovirals-for-the-treatment-of-adults-with-multidrug-resistant-hiv 2021-02-09T06:45:11 https://maestrodatabase.com/blog/sun-pharma-announces-us-fda-filing-acceptance-of-new-drug-application-for-deuruxolitinib 2023-10-08T03:31:54 https://maestrodatabase.com/blog/how-a-christmas-miracle-became-a-nightmare-for-heart-failure-patients 2017-04-25T21:46:38 https://maestrodatabase.com/blog/sanofi-and-regeneron-announce-fda-approval-of-a-new-once-monthly-dosing-option-for-praluent-alirocumab-injection 2017-04-25T21:55:17 https://maestrodatabase.com/blog/dutch-join-backlash-at-expensive-drugs-by-making-their-own 2019-03-09T10:52:16 https://maestrodatabase.com/blog/novartis-receives-fda-accelerated-approval-for-vanrafia-atrasentan-the-first-and-only-selective-endothelin-a-receptor-antagonist-for-proteinuria-reduction-in-primary-iga-nephropathy 2025-04-03T03:13:37 https://maestrodatabase.com/blog/bayer-submits-european-marketing-authorisation-application-for-darolutamide 2019-03-10T01:23:46 https://maestrodatabase.com/blog/spravato-esketamine-nasal-spray-authorised-in-europe-for-the-rapid-reduction-of-depressive-symptoms-in-a-psychiatric-emergency-for-patients-with-major-depressive-disorder 2021-02-09T07:04:40 https://maestrodatabase.com/blog/family-of-sick-toddler-launches-petition-urging-pharmac-to-fund-life-extending-drug-spinraza 2019-03-10T00:48:36 https://maestrodatabase.com/blog/real-world-evidence-to-support-health-technology-assessment-and-payer-decision-making-is-it-now-or-never 2025-04-03T03:18:40 https://maestrodatabase.com/blog/epizyme-announces-tazemetostat-fast-track-designation-for-follicular-lymphoma-and-plenary-session-on-phase-2-nhl-data-at-icml 2017-04-25T23:06:30 https://maestrodatabase.com/blog/covid-19-oral-treatment-listed-on-pbs-from-1-may-2022 2022-05-01T10:47:07 https://maestrodatabase.com/blog/fda-approves-genentechs-vabysmo-pre-filled-syringe-for-three-leading-causes-of-vision-loss 2024-07-07T02:33:38 https://maestrodatabase.com/blog/agenda-for-the-july-2017-pbac-meeting 2017-04-26T08:54:10 https://maestrodatabase.com/blog/novartis-drug-tasigna-nilotinib-secures-eu-approval-for-first-and-second-line-treatment-of-ph-plus-cml-cp-in-children 2017-11-20T06:37:36 https://maestrodatabase.com/blog/ema-publishes-withdrawal-assessment-report-for-graspa 2017-04-26T09:16:18 https://maestrodatabase.com/blog/nice-backs-nhs-use-of-lillys-taltz-for-plaque-psoriasis 2017-04-26T12:15:55 https://maestrodatabase.com/blog/samsung-bioepis-receives-regulatory-approval-for-europes-first-trastuzumab-biosimilar-ontruzant 2017-11-20T06:57:24 https://maestrodatabase.com/blog/lung-cancer-patients-call-for-funded-keytruda 2017-04-26T20:48:48 https://maestrodatabase.com/blog/biocon-biologics-receives-complete-response-letter-from-us-fda-for-biosimilar-insulin-aspart 2023-10-08T10:26:08 https://maestrodatabase.com/blog/belumosudil-mesylate-for-the-treatment-of-patients-with-chronic-graft-versus-host-disease-after-two-or-more-lines-of-systemic-therapy 2023-10-08T09:17:21 https://maestrodatabase.com/blog/changes-to-pharmaceutical-extension-of-term-application-procedures-the-latest-front-in-the-battle-for-savings-in-australias-health-care-budget 2017-04-26T20:52:09 https://maestrodatabase.com/blog/ema-to-relocate-to-amsterdam-the-netherlands 2017-11-20T19:49:42 https://maestrodatabase.com/blog/a-decade-of-health-innovation-the-impact-of-new-medicines-on-patient-health-and-the-implications-for-nices-size-of-benefit-multiplier 2023-10-08T07:51:24 https://maestrodatabase.com/blog/push-to-speed-up-access-to-treatment-for-cancer-patients 2017-11-20T20:00:11 https://maestrodatabase.com/blog/tesaro-announces-approval-of-varuby-oral-rolapitant-tablets-by-european-commission 2017-04-26T21:02:30 https://maestrodatabase.com/blog/tga-business-plan-2017-18 2017-11-20T19:51:56 https://maestrodatabase.com/blog/paris-and-amsterdam-win-brexit-races-for-london-based-eu-agencies 2017-11-20T20:08:59 https://maestrodatabase.com/blog/clinical-studies-you-can-see-better-with-the-second-arm 2023-10-08T04:25:43 https://maestrodatabase.com/blog/explainer-how-is-the-price-of-medicine-decided-in-australia 2017-11-20T20:04:12 https://maestrodatabase.com/blog/use-of-health-care-databases-to-support-supplemental-indications-of-approved-medications 2017-11-20T20:16:16 https://maestrodatabase.com/blog/orexigen-therapeutics-announces-new-drug-submission-for-contrave-in-canada 2017-04-26T21:10:21 https://maestrodatabase.com/blog/bureaucracy-and-duplication-the-reality-of-the-pprs 2017-11-20T20:12:30 https://maestrodatabase.com/blog/house-freedom-caucus-leaders-back-new-health-care-plan 2017-04-26T21:18:10 https://maestrodatabase.com/blog/fda-approves-label-update-for-kites-yescarta-for-relapsed-slash-refractory-primary-central-nervous-system-lymphoma 2026-02-08T04:13:23 https://maestrodatabase.com/blog/2018-medicare-parts-a-and-b-premiums-and-deductibles-announced 2017-11-20T20:20:45 https://maestrodatabase.com/blog/bayers-stivarga-wins-nice-approval-for-gist 2017-11-20T20:40:52 https://maestrodatabase.com/blog/lilly-gives-no-time-frame-on-arthritis-drug-delay-shares-fall 2017-04-26T21:21:21 https://maestrodatabase.com/blog/intra-cellular-therapies-receives-fda-fast-track-designation-for-lumateperone-for-the-treatment-of-schizophrenia 2017-11-20T20:31:31 https://maestrodatabase.com/blog/out-of-pocket-costs-review-needed-more-than-ever 2017-11-20T20:51:11 https://maestrodatabase.com/blog/more-senior-australians-to-get-cheaper-health-care-and-medication-under-$70m-coalition-election-pitch 2022-05-01T21:19:24 https://maestrodatabase.com/blog/highlights-from-the-24-27-february-2020-chmp-meeting 2020-02-29T02:50:44 https://maestrodatabase.com/blog/u-dot-s-drug-prices-but-not-out-of-pocket-costs-are-the-worlds-highest 2019-03-11T01:10:25 https://maestrodatabase.com/blog/health-insurers-battle-public-hospitals-over-$1billion-a-year-cash-grab 2019-03-11T01:00:27 https://maestrodatabase.com/blog/health-funds-warn-they-will-be-on-life-support-without-premium-relief 2019-03-11T01:06:04 https://maestrodatabase.com/blog/trudeau-government-signals-it-will-soon-announce-pharmacare-plan 2019-03-11T04:46:30 https://maestrodatabase.com/blog/cost-of-some-life-saving-drugs-to-be-slashed 2022-05-01T21:23:42 https://maestrodatabase.com/blog/tb-medicine-pretomanid-enters-regulatory-review-process-in-the-united-states 2019-03-11T04:38:49 https://maestrodatabase.com/blog/biogen-offers-free-alzheimers-drug-as-medicare-payment-uncertainty-remains 2021-08-30T20:48:32 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-positive-chmp-opinion-for-the-subcutaneous-formulation-of-opdivo-nivolumab-across-multiple-solid-tumour-indications 2025-04-04T00:48:51 https://maestrodatabase.com/blog/evrysdi-risdiplam-receives-cadth-reimbursement-recommendation-for-some-patients-with-spinal-muscular-atrophy 2021-08-30T20:53:22 https://maestrodatabase.com/blog/nice-provisionally-approves-almiralls-ilumetri-tildrakizumab-as-a-cost-effective-option-for-adults-with-moderate-to-severe-plaque-psoriasis 2019-03-11T05:46:32 https://maestrodatabase.com/blog/uplinza-inebulizumab-cdon-is-now-the-first-and-only-fda-approved-treatment-for-igg4-related-disease 2025-04-04T00:14:56 https://maestrodatabase.com/blog/roche-to-withdraw-2-parkinsons-drugs-from-korean-market 2021-08-30T21:16:37 https://maestrodatabase.com/blog/health-canada-approves-myinfla-colchicine-0-dot-5-mg-extended-release-tablets-a-new-repurposed-treatment-for-cardiovascular-disease 2021-08-30T21:20:55 https://maestrodatabase.com/blog/cancer-patient-david-downs-working-to-bring-treatment-that-helped-him-to-nz 2019-08-18T03:38:50 https://maestrodatabase.com/blog/imbruvica-ibrutinib-combination-regimen-to-treat-waldenstroems-macroglobulinemia-approved-through-health-canada-priority-review 2019-03-11T06:06:05 https://maestrodatabase.com/blog/fda-orphan-drug-approval-octapharmas-octagam-10-percent-receives-7-years-of-market-exclusivity-for-adult-dermatomyositis 2021-08-30T20:58:52 https://maestrodatabase.com/blog/janssen-koreas-zytiga-secures-expanded-reimbursement-for-first-line-prostate-cancer-treatment 2025-04-04T01:19:48 https://maestrodatabase.com/blog/how-a-post-brexit-trade-deal-with-the-us-could-make-life-saving-drugs-unaffordable-for-the-nhs 2019-03-11T11:07:26 https://maestrodatabase.com/blog/cystic-fibrosis-breakthrough-vital-drug-could-be-made-available-as-early-as-next-month 2019-03-11T11:00:34 https://maestrodatabase.com/blog/ucb-announces-briviact-brivaracetam-now-fda-approved-to-treat-partial-onset-seizures-in-paediatric-patients-one-month-of-age-and-older 2021-08-30T21:44:23 https://maestrodatabase.com/blog/uniqure-receives-european-medicines-agency-priority-medicines-prime-designation-for-amt-060-in-haemophilia-b 2017-04-27T00:22:40 https://maestrodatabase.com/blog/novartis-ceo-says-fda-process-could-have-been-handled-better 2019-08-18T03:58:50 https://maestrodatabase.com/blog/vulnerable-and-shocked-patients-targeted-by-hospital-revenue-push 2019-03-11T11:29:08 https://maestrodatabase.com/blog/zimmer-biomet-and-canary-medical-announce-fda-de-novo-classification-grant-and-authorisation-to-market-the-worlds-first-and-only-smart-knee-implant 2021-08-30T21:50:03 https://maestrodatabase.com/blog/nice-nod-for-almiralls-ilumetri-ucbs-cimzia 2019-03-11T11:24:59 https://maestrodatabase.com/blog/australia-is-ending-its-zero-covid-strategy 2021-08-30T21:28:14 https://maestrodatabase.com/blog/fda-grants-breakthrough-device-designation-for-impedimeds-sozo-digital-health-platform-for-renal-failure 2021-08-30T21:38:12 https://maestrodatabase.com/blog/allergan-announces-fda-acceptance-of-new-drug-application-for-ubrogepant-for-the-acute-treatment-of-migraine 2019-03-11T19:23:32 https://maestrodatabase.com/blog/ema-and-fda-historically-agree-on-just-about-every-new-drug-approval-but-is-that-slowly-changing 2019-08-18T04:05:38 https://maestrodatabase.com/blog/celgene-submits-application-to-ema-for-ozanimod-for-the-treatment-of-relapsing-remitting-multiple-sclerosis 2019-03-11T19:37:10 https://maestrodatabase.com/blog/gsk-filing-accepted-by-european-medicines-agency-for-trelegy-ellipta-use-in-adult-patients-with-asthma 2020-02-29T04:51:59 https://maestrodatabase.com/blog/eisai-and-imbrium-therapeutics-announce-u-dot-s-fda-filing-acceptance-of-new-drug-application-for-lemborexant-for-the-treatment-of-insomnia 2019-03-11T19:31:53 https://maestrodatabase.com/blog/fda-approves-first-generic-of-daraprim 2020-02-29T04:48:35 https://maestrodatabase.com/blog/smc---march-2019-decisions 2019-03-11T19:45:03 https://maestrodatabase.com/blog/ema-now-operating-from-amsterdam 2019-03-11T19:42:49 https://maestrodatabase.com/blog/aldeyra-therapeutics-receives-complete-response-letter-from-the-us-fda-for-the-reproxalap-new-drug-application-for-the-treatment-of-signs-and-symptoms-of-dry-eye-disease 2025-04-04T04:17:47 https://maestrodatabase.com/blog/helsinn-submits-a-new-formulation-of-akynzeo-to-the-ema 2025-04-04T03:54:57 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-march-2020 2020-02-29T21:00:06 https://maestrodatabase.com/blog/european-medicines-agency-validates-application-for-extension-of-indication-for-vozogo-vosoritide-for-injection-to-treat-children-with-achondroplasia-under-the-age-of-2 2023-01-04T03:52:23 https://maestrodatabase.com/blog/enhertu-approved-in-the-eu-as-first-her2-directed-therapy-for-patients-with-hr-positive-her2-low-or-her2-ultralow-metastatic-breast-cancer-following-at-least-one-endocrine-therapy 2025-04-04T06:45:30 https://maestrodatabase.com/blog/samsung-bioepis-announces-health-canada-approval-of-citrate-free-high-concentration-of-humira-biosimilar-adalimumab-sb5 2023-01-04T03:44:49 https://maestrodatabase.com/blog/burning-rock-received-fda-breakthrough-device-designation-for-its-overc-multi-cancer-detection-blood-test 2023-01-04T03:35:23 https://maestrodatabase.com/blog/fda-approves-dupixent-dupilumab-for-moderate-to-severe-atopic-dermatitis-in-adolescents 2019-03-12T06:43:11 https://maestrodatabase.com/blog/u-dot-s-fda-approves-pfizers-oncology-biosimilar-trazimera-trastuzumab-qyyp-a-biosimilar-to-herceptin 2019-03-12T06:49:28 https://maestrodatabase.com/blog/multiple-sclerosis-hardly-any-evidence-for-good-patient-care 2023-10-09T02:07:39 https://maestrodatabase.com/blog/fda-allows-first-use-of-a-novel-cancer-drug 2019-03-12T04:40:47 https://maestrodatabase.com/blog/european-medicines-agency-validates-marketing-authorisation-application-for-trodelvy-sacituzumab-govitecan-hziy-for-pre-treated-hr-plus-slash-her2--metastatic-breast-cancer 2023-01-04T04:02:17 https://maestrodatabase.com/blog/imfinzi-based-peri-operative-regimen-approved-in-the-eu-for-resectable-non-small-cell-lung-cancer 2025-04-04T07:40:49 https://maestrodatabase.com/blog/smc-says-no-to-novartis-kymriah-for-adults-with-lymphoma 2019-03-12T08:42:06 https://maestrodatabase.com/blog/kiadis-pharma-announces-filing-of-marketing-authorisation-with-the-european-medicines-agency-for-atir101-in-blood-cancers 2017-04-27T01:44:57 https://maestrodatabase.com/blog/international-pricing-index-outsourcing-negotiations-will-continue-the-us-drug-cost-crisis 2019-03-12T08:33:46 https://maestrodatabase.com/blog/melanoma-medicine-added-to-the-pharmaceutical-benefits-scheme 2020-02-29T21:43:25 https://maestrodatabase.com/blog/janssen-submits-marketing-authorisation-application-to-the-european-medicines-agency-seeking-approval-of-talquetamab-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma 2023-01-04T04:24:12 https://maestrodatabase.com/blog/overview-of-cost-effectiveness-analysis 2019-03-12T08:51:30 https://maestrodatabase.com/blog/nice-u-turn-backs-use-of-darzalex-combo-for-myeloma-relapse 2019-03-12T11:29:09 https://maestrodatabase.com/blog/agenda-for-the-march-2026-pbac-meeting-9-february-2026 2026-02-09T20:53:12 https://maestrodatabase.com/blog/orasis-pharmaceuticals-submits-new-drug-application-for-investigational-novel-eye-drop-candidate-csf-1-for-the-treatment-of-presbyopia 2023-01-04T04:51:46 https://maestrodatabase.com/blog/new-government-must-be-more-ambitious-in-securing-a-world-class-nhs-says-uk-pharmaceutical-industry 2017-04-27T09:05:32 https://maestrodatabase.com/blog/the-evolving-nature-of-health-technology-assessment-a-critical-appraisal-of-nices-new-methods-manual 2023-10-09T02:44:24 https://maestrodatabase.com/blog/using-the-budget-to-improve-patient-experience 2017-04-27T09:11:58 https://maestrodatabase.com/blog/the-multi-billion-dollar-subsidy-for-private-health-insurance-isnt-worth-it 2017-04-27T09:27:02 https://maestrodatabase.com/blog/private-patients-pay-729-dollars-million-more-for-medical-implants 2017-04-27T09:19:51 https://maestrodatabase.com/blog/updated-agenda-for-the-march-2023-pbac-meeting 2023-01-04T06:08:03 https://maestrodatabase.com/blog/negotiating-drug-prices-should-state-agencies-band-together 2017-04-27T09:30:25 https://maestrodatabase.com/blog/cancer-care-drug-costs-concern-group 2017-04-27T09:34:08 https://maestrodatabase.com/blog/using-health-technology-assessment-to-assess-the-value-of-new-medicines-results-of-a-systematic-review-and-expert-consultation-across-eight-european-countries 2018-01-23T20:19:56 https://maestrodatabase.com/blog/sanofis-rilzabrutinib-designated-breakthrough-therapy-in-the-us-and-orphan-drug-in-japan-for-the-treatment-of-warm-autoimmune-haemolytic-anaemia 2026-02-09T22:02:09 https://maestrodatabase.com/blog/xpovio-selinexor-approved-for-new-indication-in-dlbcl-in-china-bringing-a-new-treatment-option-to-patients-in-the-country 2024-07-08T06:04:00 https://maestrodatabase.com/blog/americans-are-skipping-medically-necessary-prescriptions-because-of-the-cost 2020-02-29T23:26:45 https://maestrodatabase.com/blog/smc-issues-positive-decision-for-treatment-with-abbvies-rinvoq-upadacitinib-in-severe-active-rheumatoid-arthritis 2021-02-09T20:09:52 https://maestrodatabase.com/blog/scottish-approval-of-a-new-treatment-for-people-with-chronic-obstructive-pulmonary-disease---formoterol-fumarate-dihydrate-slash-glycopyrronium-bromide-slash-budesonide 2021-02-09T20:15:52 https://maestrodatabase.com/blog/woodcock-vs-sharfstein-a-head-to-head-comparison-of-bidens-top-choices-for-fda-commissioner 2021-02-09T19:54:42 https://maestrodatabase.com/blog/supernus-resubmits-new-drug-application-for-spn-812-for-the-treatment-of-adhd-in-paediatric-patients 2021-02-09T19:58:03 https://maestrodatabase.com/blog/enhertu-type-ii-variation-application-validated-by-ema-for-the-treatment-of-her2-mutant-metastatic-non-small-cell-lung-cancer 2023-01-04T07:10:41 https://maestrodatabase.com/blog/the-biden-administration-needs-to-look-beyond-icer-for-evaluating-drug-therapies 2021-02-09T20:02:45 https://maestrodatabase.com/blog/roche-drug-approval-offers-a-glimpse-at-the-future-of-cancer-treatment 2019-08-18T06:14:20 https://maestrodatabase.com/blog/who-profits-most-from-americas-baffling-health-care-system 2023-10-09T03:56:32 https://maestrodatabase.com/blog/scotland-approves-ms-drug-that-was-rejected-in-england-and-wales 2021-02-09T20:05:23 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-publishes-white-paper-on-alternative-models-for-pharmaceutical-rebates 2019-03-12T19:23:09 https://maestrodatabase.com/blog/fda-grants-breakthrough-therapy-designation-for-debiopharms-novel-chemo-radio-sensititiser-debio-1143-for-front-line-treatment-of-head-and-neck-cancer 2020-02-29T23:51:04 https://maestrodatabase.com/blog/scottish-medicines-consortium-accepts-prostap-sr-dcs-and-prostap-3-dcs-leuprorelin-acetate-to-treat-early-and-advanced-breast-cancer 2021-02-09T20:24:03 https://maestrodatabase.com/blog/why-the-italian-health-minister-is-pushing-for-global-transparency-on-drug-pricing 2019-03-12T19:36:53 https://maestrodatabase.com/blog/aarp-launches-stop-rx-greed-campaign-targeting-high-prescription-drug-prices 2019-03-12T19:39:27 https://maestrodatabase.com/blog/collaboration-between-the-fda-and-industry-is-essential-to-foster-innovation-in-alzheimers-treatments 2021-02-09T20:40:00 https://maestrodatabase.com/blog/roche-cancer-treatment-priced-at-17-050-dollars-a-month-lower-than-rival-vitrakvi 2019-08-18T06:25:57 https://maestrodatabase.com/blog/post-market-review-workplan-may-2024 2024-07-08T06:32:20 https://maestrodatabase.com/blog/womens-cancer-fight-reaches-parliament-and-health-select-committee 2019-03-12T19:30:52 https://maestrodatabase.com/blog/cancer-institutes-sharpless-tapped-as-acting-chief-of-fda 2019-03-12T20:18:15 https://maestrodatabase.com/blog/besremi-retries-for-insurance-coverage-promising-a-potential-operational-cure 2024-07-08T10:55:40 https://maestrodatabase.com/blog/optimism-on-orkambi-in-england-as-talks-to-resume 2019-03-12T20:22:30 https://maestrodatabase.com/blog/icer-releases-evidence-report-on-therapies-for-iga-nephropathy 2026-02-09T22:47:26 https://maestrodatabase.com/blog/will-washington-finally-do-something-about-high-drug-prices 2019-03-12T19:41:40 https://maestrodatabase.com/blog/prescription-drug-prices-arent-rising----theyre-falling-for-the-first-time-in-47-years 2019-03-12T19:43:35 https://maestrodatabase.com/blog/options-for-cms-drug-price-negotiations 2023-01-04T21:26:52 https://maestrodatabase.com/blog/smc---february-2026-decisions 2026-02-09T22:54:22 https://maestrodatabase.com/blog/clinigen-and-onxeo-initiate-managed-access-programme-for-belinostat-in-europe-for-patients-with-peripheral-t-cell-lymphoma 2017-04-27T11:37:23 https://maestrodatabase.com/blog/krystal-biotech-announces-rmat-designation-granted-by-fda-to-kb707-for-the-treatment-of-advanced-or-metastatic-non-small-cell-lung-cancer 2026-02-09T23:12:45 https://maestrodatabase.com/blog/vertex-receives-approval-for-symdeko-tezacaftor-slash-ivacaftor-and-ivacaftor-in-australia-to-treat-the-underlying-cause-of-cystic-fibrosis-in-people-aged-12-and-older-with-certain-cftr-gene-mutations 2019-03-12T20:33:20 https://maestrodatabase.com/blog/nice-recommends-amgens-blincyto-blinatumomab-for-adults-with-relapsed-or-refractory-philadelphia-chromosome-negative-b-precursor-acute-lymphoblastic-leukaemia 2017-04-27T21:21:56 https://maestrodatabase.com/blog/foquest-receives-approval-for-expanded-indication-for-children-and-adolescents-with-adhd 2019-03-13T01:40:15 https://maestrodatabase.com/blog/fda-expands-approved-use-of-stivarga-to-treat-liver-cancer 2017-04-27T21:28:51 https://maestrodatabase.com/blog/fda-approves-libtayo-cemiplimab-rwlc-as-first-immunotherapy-indicated-for-patients-with-advanced-basal-cell-carcinoma 2021-02-09T23:55:02 https://maestrodatabase.com/blog/fda-approves-a-new-generic-valsartan 2019-03-12T22:42:04 https://maestrodatabase.com/blog/drug-makers-to-raise-prices-on-at-least-350-drugs-in-us-in-january 2023-01-04T22:36:54 https://maestrodatabase.com/blog/regenxbio-announces-regulatory-update-on-rgx-121-bla-for-mps-ii 2026-02-10T01:09:26 https://maestrodatabase.com/blog/fda-intends-to-take-action-against-non-fda-approved-glp-1-drugs 2026-02-10T01:16:51 https://maestrodatabase.com/blog/fda-approves-first-treatment-for-a-form-of-batten-disease 2017-04-27T21:37:27 https://maestrodatabase.com/blog/u-dot-s-top-court-grapples-over-making-copycat-biologics-available-sooner 2017-04-27T21:43:33 https://maestrodatabase.com/blog/house-freedom-caucus-backs-amended-gop-health-care-bill 2017-04-27T21:41:41 https://maestrodatabase.com/blog/painkillers-and-hrt-therapies-among-drugs-not-being-subsidised-under-pbs 2026-02-10T03:45:16 https://maestrodatabase.com/blog/aerie-pharmaceuticals-announces-u-dot-s-fda-approval-of-rocklatan-netarsudil-and-latanoprost-ophthalmic-solution-0-dot-02-percent-slash-0-dot-005-percent-for-the-reduction-of-intra-ocular-pressure-in-patients-with-open-angle-glaucoma-or-ocular-hypertension 2019-03-13T02:03:22 https://maestrodatabase.com/blog/axsome-therapeutics-receives-fda-complete-response-letter-for-new-drug-application-for-axs-07-for-the-acute-treatment-of-migraine 2022-05-02T12:01:11 https://maestrodatabase.com/blog/women-with-advanced-breast-cancer-ask-health-select-committee-for-pharmac-review 2019-03-13T02:57:39 https://maestrodatabase.com/blog/junshi-biosciences-and-coherus-receive-complete-response-letter-from-u-dot-s-fda-for-toripalimab-bla 2022-05-02T12:06:58 https://maestrodatabase.com/blog/advicenne-announces-submission-of-european-marketing-authorisation-application-for-adv7103-as-treatment-for-distal-renal-tubular-acidosis 2019-03-13T02:29:19 https://maestrodatabase.com/blog/janssen-submits-application-to-u-dot-s-fda-seeking-approval-of-darzalex-daratumumab-combination-therapy-for-patients-with-newly-diagnosed-multiple-myeloma-who-are-transplant-ineligible 2019-03-13T03:59:27 https://maestrodatabase.com/blog/mum-and-son-hold-their-breath-for-cystic-fibrosis-drug-trikafta-ahead-of-budget 2022-05-02T11:44:14 https://maestrodatabase.com/blog/ravulizumab-for-the-treatment-of-adults-with-generalised-myasthenia-gravis 2023-10-09T04:56:37 https://maestrodatabase.com/blog/pharmac-funding-should-be-doubled---breast-cancer-advocate 2019-03-13T03:46:52 https://maestrodatabase.com/blog/would-drug-makers-lower-their-insulin-prices-if-congress-asks-nicely 2022-05-02T11:57:35 https://maestrodatabase.com/blog/u-dot-s-fda-declines-to-approve-two-more-china-tested-drugs 2022-05-02T11:55:53 https://maestrodatabase.com/blog/fda-grants-breakthrough-therapy-designation-and-orphan-drug-designation-to-pellepharm-for-topical-patidegib-in-gorlin-syndrome 2017-11-21T03:24:33 https://maestrodatabase.com/blog/myovant-sciences-announces-european-commission-approval-for-orgovyx-relugolix-for-the-treatment-of-advanced-hormone-sensitive-prostate-cancer 2022-05-02T20:50:41 https://maestrodatabase.com/blog/spinex-receives-fda-breakthrough-device-designation-for-scip 2022-05-02T20:57:35 https://maestrodatabase.com/blog/unitedhealth-expands-drug-rebate-program-to-consumers 2019-03-13T07:01:34 https://maestrodatabase.com/blog/the-rights-left-turn-on-drug-prices 2019-08-18T21:00:28 https://maestrodatabase.com/blog/sage-therapeutics-and-biogen-initiate-rolling-submission-of-new-drug-application-to-us-fda-for-zuranolone-for-the-potential-treatment-of-major-depressive-disorder 2022-05-02T12:14:44 https://maestrodatabase.com/blog/senate-panel-asks-cvs-and-four-other-pharmacy-middlemen-to-testify-about-drug-prices 2019-03-13T07:04:18 https://maestrodatabase.com/blog/pfizers-next-generation-alk-slash-ros1-inhibitor-lorlatinib-granted-breakthrough-therapy-designation-from-fda-for-alk-positive-metastatic-non-small-cell-lung-cancer 2017-04-27T23:14:33 https://maestrodatabase.com/blog/lack-of-transparency-hampers-cancer-drug-debate 2019-08-18T20:53:14 https://maestrodatabase.com/blog/us-fda-accepts-new-drug-application-and-grants-priority-review-for-takedas-oveporexton-tak-861-as-a-potential-first-in-class-therapy-for-narcolepsy-type-1 2026-02-10T20:03:46 https://maestrodatabase.com/blog/bavarian-nordic-announces-fda-delay-in-the-review-of-the-biologics-license-application-for-mva-bn-smallpox-vaccine 2019-03-13T05:34:08 https://maestrodatabase.com/blog/orphalan-announces-fda-approval-of-cuvrior-for-the-treatment-of-adult-patients-with-stable-wilsons-disease-who-are-de-coppered-and-tolerant-to-penicillamine 2022-05-02T12:20:04 https://maestrodatabase.com/blog/has-clarifies-the-framework-for-use-of-xevudy 2022-05-02T21:11:14 https://maestrodatabase.com/blog/sedana-medical-receives-fda-fast-track-designation-in-the-us 2023-01-05T00:30:10 https://maestrodatabase.com/blog/prices-of-tecentriq-avastin-go-down-due-to-broader-insurance-benefits 2022-05-02T21:22:24 https://maestrodatabase.com/blog/bring-in-pharmacare-now-health-experts-ask-federal-leaders 2019-08-18T21:09:32 https://maestrodatabase.com/blog/great-britain-faces-food-fuel-and-medicine-shortages-in-no-deal-brexit-official-leaked-papers-say 2019-08-18T21:06:24 https://maestrodatabase.com/blog/most-people-wont-get-a-$10-$12-medicine-price-cut-after-election 2022-05-02T21:18:11 https://maestrodatabase.com/blog/tesaro-announces-european-commission-approval-of-zejula-for-women-with-recurrent-ovarian-cancer 2017-11-21T10:59:52 https://maestrodatabase.com/blog/gilead-sciences-hepatitis-b-drug-vemlidy-gets-expanded-insurance-benefit 2022-05-02T21:01:26 https://maestrodatabase.com/blog/decision-to-list-5-aminolevulinic-acid-hydrochloride-gliolan-on-the-hospital-medicines-list 2017-04-29T09:13:09 https://maestrodatabase.com/blog/zubsolv-receives-authorisation-for-treatment-of-opioid-dependence-in-europe 2017-11-21T10:54:21 https://maestrodatabase.com/blog/tlv-submits-proposals-for-increased-access-to-new-gene-therapies 2022-05-02T21:09:10 https://maestrodatabase.com/blog/cancer-drugs-fund-condemned-as-expensive-and-ineffective 2017-04-29T09:20:46 https://maestrodatabase.com/blog/european-commission-extends-license-for-janssens-zytiga-plus-prednisone-slash-prednisolone-to-include-earlier-stage-prostate-cancer-patients 2017-11-21T11:19:37 https://maestrodatabase.com/blog/what-is-the-hta-review-and-why-is-it-important-for-australias-health-system 2022-05-02T21:04:18 https://maestrodatabase.com/blog/ema-and-heads-of-national-competent-authorities-discuss-consequences-of-brexit 2017-04-29T09:17:55 https://maestrodatabase.com/blog/roche-sues-pfizer-to-block-biosimilar-of-cancer-drug-herceptin 2017-11-21T11:52:28 https://maestrodatabase.com/blog/european-commission-approves-bristol-myers-squibbs-opdivo-nivolumab-for-squamous-cell-cancer-of-the-head-and-neck-in-adults-progressing-on-or-after-platinum-based-therapy 2017-04-29T09:24:06 https://maestrodatabase.com/blog/fda-approves-pembrolizumab-with-paclitaxel-for-platinum-resistant-epithelial-ovarian-fallopian-tube-or-primary-peritoneal-carcinoma 2026-02-10T20:56:11 https://maestrodatabase.com/blog/mum-fights-to-get-drug-on-pbs 2017-11-21T19:41:22 https://maestrodatabase.com/blog/novartis-receives-fda-approval-for-rydapt-in-newly-diagnosed-flt3-mutated-acute-myeloid-leukaemia-and-three-types-of-systemic-mastocytosis 2017-04-29T09:30:51 https://maestrodatabase.com/blog/janssen-seeks-expanded-use-of-darzalex-daratumumab-from-ema-in-newly-diagnosed-multiple-myeloma 2017-11-21T19:49:47 https://maestrodatabase.com/blog/fda-approves-radius-healths-tymlos-abaloparatide-a-bone-building-agent-for-the-treatment-of-postmenopausal-women-with-osteoporosis-at-high-risk-for-fracture 2017-04-29T15:22:24 https://maestrodatabase.com/blog/janssen-submits-application-to-u-dot-s-fda-to-expand-indication-for-darzalex-daratumumab-combination-therapy-for-patients-with-newly-diagnosed-multiple-myeloma-who-are-transplant-ineligible 2017-11-21T19:53:32 https://maestrodatabase.com/blog/vaxxinity-receives-fda-fast-track-designation-for-ub-311-for-treatment-of-alzheimers-disease 2022-05-02T21:38:15 https://maestrodatabase.com/blog/a-review-of-international-coverage-and-pricing-strategies-for-personalised-medicine-and-orphan-drugs 2017-11-21T20:06:49 https://maestrodatabase.com/blog/government-strengthens-support-for-melanoma-patients-with-breakthrough-treatment-expanded-on-pbs 2020-03-01T01:08:24 https://maestrodatabase.com/blog/fda-approves-first-two-drug-regimen-for-certain-patients-with-hiv 2017-11-21T19:59:14 https://maestrodatabase.com/blog/fighting-cancer-one-patient-at-a-time 2017-11-21T20:11:54 https://maestrodatabase.com/blog/terminal-breast-cancer-patients-push-for-pharmac-inquiry-and-the-funding-of-life-preserving-drugs 2019-03-13T09:10:48 https://maestrodatabase.com/blog/takeda-announces-fda-accelerated-approval-of-alunbrig-brigatinib 2017-04-29T15:38:04 https://maestrodatabase.com/blog/statement-from-fda-commissioner-on-steps-to-promote-development-of-generic-versions-of-opioids-formulated-to-deter-abuse 2017-11-21T20:25:16 https://maestrodatabase.com/blog/is-the-nhs-being-taken-for-a-ride-on-drug-prices-we-need-to-know 2017-11-21T20:16:45 https://maestrodatabase.com/blog/united-kingdoms-withdrawal-from-the-european-union 2017-11-21T20:38:43 https://maestrodatabase.com/blog/new-powerful-cancer-website-for-doctors 2017-11-21T20:34:13 https://maestrodatabase.com/blog/myriad-genetics-and-clovis-oncology-sign-agreement-for-use-of-fda-approved-bracanalysis-cdx-test-to-identify-patients-with-germline-brca-mutations-for-rubraca-rucaparib-treatment 2017-04-29T15:54:12 https://maestrodatabase.com/blog/the-wider-role-of-regulatory-scientists 2017-04-29T16:03:03 https://maestrodatabase.com/blog/accelerating-development-of-scientific-evidence-for-medical-products-within-the-existing-us-regulatory-framework 2017-04-29T16:11:19 https://maestrodatabase.com/blog/checkpoint-therapeutics-submits-biologics-license-application-to-fda-for-cosibelimab-as-a-treatment-for-patients-with-metastatic-or-locally-advanced-cutaneous-squamous-cell-carcinoma 2023-01-05T03:19:30 https://maestrodatabase.com/blog/ema-preparing-guidance-to-tackle-covid-19-variants 2021-02-10T19:51:15 https://maestrodatabase.com/blog/clarification-on-sputnik-v-vaccine-in-the-eu-approval-process 2021-02-10T19:55:22 https://maestrodatabase.com/blog/due-to-aducanumabs-new-pdufa-date-icer-extends-timeline-for-alzheimers-disease-assessment 2021-02-10T19:58:10 https://maestrodatabase.com/blog/alnylam-announces-receipt-of-complete-response-letter-from-us-fda-for-supplemental-new-drug-application-for-patisiran-for-the-treatment-of-the-cardiomyopathy-of-attr-amyloidosis 2023-10-09T19:30:51 https://maestrodatabase.com/blog/ligands-partner-gloria-biosciences-receives-approval-in-china-for-zimberelimab-for-the-treatment-of-recurrent-or-refractory-classical-hodgkins-lymphoma 2021-08-31T09:24:30 https://maestrodatabase.com/blog/budget-reconciliation-may-be-the-only-hope-for-lower-drug-prices 2021-02-10T20:13:48 https://maestrodatabase.com/blog/new-drugs-entering-canada-at-steady-rate-over-past-5-years---canada-still-among-top-10-oecd-countries-in-terms-of-access-to-new-drugs 2021-02-10T20:24:56 https://maestrodatabase.com/blog/mesoblast-resubmits-biologics-license-application-with-us-fda-for-approval-of-ryoncil-in-children-with-steroid-refractory-acute-graft-versus-host-disease 2024-07-09T10:38:59 https://maestrodatabase.com/blog/it-will-be-six-years-before-the-world-is-vaccinated-against-covid-19-experts 2021-02-10T20:32:27 https://maestrodatabase.com/blog/tlv-believes-that-the-requirements-for-evidence-in-new-eu-legislation-must-be-strengthened 2023-10-09T19:56:01 https://maestrodatabase.com/blog/botox-onabotulinumtoxina-receives-fda-approval-for-paediatric-detrusor-overactivity-associated-with-a-neurologic-condition 2021-02-10T20:03:05 https://maestrodatabase.com/blog/ema-expected-to-approve-johnson-and-johnson-vaccine-by-march 2021-02-10T20:07:43 https://maestrodatabase.com/blog/smc---october-2023-decisions 2023-10-09T19:44:00 https://maestrodatabase.com/blog/drug-maker-will-slash-prices-on-cancer-medicines-to-end-price-gouging-probe-in-europe 2021-02-10T20:11:39 https://maestrodatabase.com/blog/fund-pharmac-properly-health-advocates-countrywide-journey-to-discuss-medicine-funding 2023-10-09T19:47:05 https://maestrodatabase.com/blog/fda-medical-adviser-congress-is-owned-by-pharma 2019-03-13T19:54:07 https://maestrodatabase.com/blog/small-town-pharmacies-suffer-in-federal-government-reclassification-funding-and-fear-for-covid-vaccine-rollout 2021-02-10T20:46:10 https://maestrodatabase.com/blog/rx-drug-costs-list-prices-versus-net-prices-and-the-importance-of-staying-within-the-data 2019-03-13T19:57:24 https://maestrodatabase.com/blog/medtech-firms-health-funds-clash-over-pricing-shake-up 2021-02-10T22:13:18 https://maestrodatabase.com/blog/fda-approves-updated-indication-for-mercks-keytruda-pembrolizumab-for-treatment-of-certain-patients-with-urothelial-carcinoma-bladder-cancer 2021-08-31T20:38:18 https://maestrodatabase.com/blog/pharma-urges-politicians-to-stop-no-deal-brexit-in-todays-vote 2019-03-13T20:06:46 https://maestrodatabase.com/blog/covid-who-backs-oxford-vaccine-even-if-variants-present 2021-02-10T20:36:20 https://maestrodatabase.com/blog/cancer-patient-denied-life-prolonging-drug-as-she-lives-half-a-mile-outside-england 2019-03-13T20:15:02 https://maestrodatabase.com/blog/fgfr4-inhibitor-irpagratinib-granted-fda-fast-track-designation-for-hcc-patients 2026-02-10T23:11:13 https://maestrodatabase.com/blog/anti-vaxxers-letter-drop-households-as-australia-prepares-for-covid-19-vaccine-rollout 2021-02-10T20:40:07 https://maestrodatabase.com/blog/ani-pharmaceuticals-announces-fda-acceptance-of-purified-cortrophin-gel-supplemental-new-drug-application-for-multiple-indications-including-multiple-sclerosis-rheumatoid-arthritis-and-nephrotic-syndrome 2021-08-31T11:20:57 https://maestrodatabase.com/blog/european-union-admits-errors-in-coronavirus-vaccine-rollout-deeply-regrets-decision-on-export-curbs 2021-02-10T20:42:05 https://maestrodatabase.com/blog/drug-price-watchdog-icer-dives-into-trump-fueled-pharma-rebate-debate 2019-03-13T20:01:23 https://maestrodatabase.com/blog/real-world-outcomes-associated-with-new-cancer-medicines-approved-by-the-fda-and-ema-a-retrospective-cohort-study 2021-08-31T21:09:37 https://maestrodatabase.com/blog/canadians-wait-on-average-more-than-65-weeks-longer-for-access-to-new-medicines-than-europeans-and-90-weeks-more-than-americans 2026-02-11T02:44:39 https://maestrodatabase.com/blog/nda-submission-for-vivagel-bv-in-the-us 2017-11-21T23:06:46 https://maestrodatabase.com/blog/price-relief-as-epilepsy-drug-pbs-listed 2021-08-31T21:37:35 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-september-2021-update 2021-08-31T21:21:46 https://maestrodatabase.com/blog/teva-and-medincell-announce-fda-acceptance-of-new-drug-application-for-tv-46000-slash-mdc-irm-as-a-treatment-for-patients-with-schizophrenia 2021-08-31T20:49:10 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-september-2021-update 2021-08-31T20:53:11 https://maestrodatabase.com/blog/health-insurers-call-for-prostheses-tender 2020-03-01T19:57:45 https://maestrodatabase.com/blog/nirsevimab-us-regulatory-submission-accepted-for-the-prevention-of-rsv-lower-respiratory-tract-disease-in-infants-and-children-up-to-age-24-months 2023-01-05T08:02:37 https://maestrodatabase.com/blog/insurers-pocketed-50-dollars-billion-from-medicare-for-diseases-no-doctor-treated 2024-07-09T11:12:37 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-march-2020-update 2020-03-01T20:04:34 https://maestrodatabase.com/blog/limaca-medical-receives-fda-breakthrough-device-designation 2022-05-03T04:13:42 https://maestrodatabase.com/blog/trump-administration-rejects-expanding-medicare-medicaid-coverage-of-obesity-drugs 2025-04-05T06:03:57 https://maestrodatabase.com/blog/genmab-announces-european-marketing-authorisation-for-darzalex-daratumumab-for-relapsed-or-refractory-multiple-myeloma 2017-04-30T07:09:05 https://maestrodatabase.com/blog/vbi-vaccines-announces-european-commission-marketing-authorisation-for-prehevbri-a-3-antigen-adult-hepatitis-b-vaccine 2022-05-03T04:56:08 https://maestrodatabase.com/blog/foundationone-liquid-cdx-receives-fda-approval-as-a-companion-diagnostic-for-rozlytrek-entrectinib 2023-01-05T09:28:21 https://maestrodatabase.com/blog/cystic-fibrosis-advocate-asks-p-dot-e-i-to-fast-track-coverage-of-new-mind-blowing-drug 2021-02-11T08:39:55 https://maestrodatabase.com/blog/chemotherapy-compounder-id-mandatory-within-pbs-claims-from-1-december-2017 2017-11-22T00:06:51 https://maestrodatabase.com/blog/onconano-medicines-pegsitacianine-granted-breakthrough-therapy-designation-for-real-time-surgical-imaging-by-the-fda 2023-01-05T09:20:53 https://maestrodatabase.com/blog/moderna-receives-refusal-to-file-letter-from-the-us-fda-for-its-investigational-seasonal-influenza-vaccine-mrna-1010 2026-02-11T10:39:23 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-regulatory-submission-and-grants-priority-review-for-us-worldmeds-lofexidine 2017-11-22T00:38:33 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-report-finds-evidence-limited-on-treatments-for-tardive-dyskinesia-discounts-of-up-to-90-percent-needed-to-align-cost-of-drugs-with-benefit-to-patient 2017-11-22T00:41:53 https://maestrodatabase.com/blog/cmss-decision-to-restrict-coverage-of-aduhelm-very-unlikely-to-impact-other-accelerated-approvals-in-other-classes 2022-05-03T06:14:05 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-may-2017-update 2017-04-30T07:41:19 https://maestrodatabase.com/blog/fdas-generic-drug-program-in-2020-helped-ensure-availability-of-high-quality-affordable-drugs-amid-covid-19 2021-02-11T19:48:41 https://maestrodatabase.com/blog/fda-approves-first-in-class-evkeeza-evinacumab-dgnb-for-patients-with-ultra-rare-inherited-form-of-high-cholesterol 2021-02-11T19:51:14 https://maestrodatabase.com/blog/pharmac-confirms-changes-to-simplify-biologic-medicine-funding-criteria 2026-02-11T21:44:52 https://maestrodatabase.com/blog/brainq-gets-fda-breakthrough-status-for-its-device-for-reducing-disability-following-stroke 2021-02-11T20:08:06 https://maestrodatabase.com/blog/braincool-receives-fda-breakthrough-device-designation-for-cooral-system-for-prevention-of-oral-mucositis 2021-02-11T20:11:50 https://maestrodatabase.com/blog/mendelian-randomisation 2017-11-22T01:59:22 https://maestrodatabase.com/blog/are-you-scared-of-dying-dad-the-constant-uncertainty-of-immunotherapy 2017-11-22T11:48:14 https://maestrodatabase.com/blog/cerus-endovascular-receives-fda-breakthrough-device-designation-for-its-contour-neurovascular-system 2021-02-11T19:57:36 https://maestrodatabase.com/blog/seagen-and-genmab-submit-tisotumab-vedotin-biologics-license-application-to-the-u-dot-s-fda-for-patients-with-recurrent-or-metastatic-cervical-cancer 2021-02-11T20:03:17 https://maestrodatabase.com/blog/health-canada-approves-victoza-as-the-first-and-only-glp-1-receptor-agonist-to-reduce-the-risk-of-cardiovascular-death-in-patients-with-type-2-diabetes-and-established-cardiovascular-disease 2017-11-22T06:26:33 https://maestrodatabase.com/blog/an-institutional-ethnographic-analysis-of-public-and-patient-engagement-activities-at-a-national-health-technology-assessment-agency 2021-02-11T20:31:42 https://maestrodatabase.com/blog/new-zealand-cancer-patients-renew-call-for-more-funded-medicines-as-report-reveals-682-million-dollar-hole 2017-11-22T11:52:03 https://maestrodatabase.com/blog/covid-19-vaccine-shipment-could-arrive-in-australia-as-early-as-next-week 2021-02-11T20:48:10 https://maestrodatabase.com/blog/how-well-will-vaccines-work 2021-02-11T20:54:46 https://maestrodatabase.com/blog/fda-approves-first-implanted-lens-that-can-be-adjusted-after-cataract-surgery-to-improve-vision-without-eyeglasses-in-some-patients 2017-11-22T20:17:10 https://maestrodatabase.com/blog/a-key-medicine-agency-has-left-britain-this-is-the-start-of-a-brexodus 2017-11-22T12:35:07 https://maestrodatabase.com/blog/csl-confident-it-can-make-vaccine-to-cover-variants-if-needed 2021-02-11T20:17:46 https://maestrodatabase.com/blog/government-health-adviser-rejects-calls-for-mandatory-covid-19-vaccine 2021-02-11T20:20:03 https://maestrodatabase.com/blog/a-third-of-people-are-worried-about-the-covid-19-vaccine 2021-02-11T20:23:34 https://maestrodatabase.com/blog/world-first-agreement-between-novartis-and-the-nhs-enables-broad-and-rapid-access-to-first-in-class-cholesterol-lowering-medicine-leqvio-inclisiran 2021-09-01T00:37:50 https://maestrodatabase.com/blog/agenda-for-3-may-2017-tc-meeting 2017-04-30T09:50:40 https://maestrodatabase.com/blog/hutchmed-receives-complete-response-letter-from-the-u-dot-s-fda-for-surufatinib-for-the-treatment-of-advanced-neuroendocrine-tumours 2022-05-03T10:45:38 https://maestrodatabase.com/blog/pharmac-widens-access-to-funded-treatments-for-multiple-sclerosis 2021-02-12T21:35:22 https://maestrodatabase.com/blog/re-evaluating-eligibility-criteria-for-oncology-clinical-trials-analysis-of-investigational-new-drug-applications-in-2015 2017-11-22T20:52:58 https://maestrodatabase.com/blog/ema-starts-rolling-review-of-curevacs-covid-19-vaccine-cvncov 2021-02-12T21:38:01 https://maestrodatabase.com/blog/unwanted-advice-frequency-characteristics-and-outcomes-of-negative-advisory-committee-votes-for-fda-approved-drugs 2022-05-03T11:05:33 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-therapies-for-multiple-myeloma 2021-02-12T21:43:45 https://maestrodatabase.com/blog/broadening-eligibility-criteria-to-make-clinical-trials-more-representative-american-society-of-clinical-oncology-and-friends-of-cancer-research-joint-research-statement 2017-11-22T20:45:23 https://maestrodatabase.com/blog/fda-grants-purdue-pharmas-nalmefene-hydrochloride-injection-fast-track-designation-for-the-emergency-treatment-of-known-or-suspected-opioid-overdose 2019-03-14T05:40:39 https://maestrodatabase.com/blog/vaccine-rollout-to-support-people-from-all-backgrounds-in-australia 2021-02-14T07:00:41 https://maestrodatabase.com/blog/u-dot-s-fda-approves-panzyga-for-the-treatment-of-adults-with-chronic-inflammatory-demyelinating-polyneuropathy 2021-02-14T07:03:02 https://maestrodatabase.com/blog/belite-bio-receives-fda-fast-track-designation-for-lbs-008 2022-05-03T12:00:36 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-may-2017 2017-04-30T19:14:21 https://maestrodatabase.com/blog/rescindo-therapeutics-rsc-57-receives-fda-orphan-drug-designation-and-rare-paediatric-disease-designation-for-kabuki-syndrome 2021-02-12T21:58:16 https://maestrodatabase.com/blog/first-australian-vaccines-to-arrive-later-this-week 2021-02-14T06:58:41 https://maestrodatabase.com/blog/reform-of-the-orphan-drug-program---transition-arrangements 2017-05-01T06:57:19 https://maestrodatabase.com/blog/first-million-dollar-medicine-listed-on-the-pbs 2022-05-03T21:47:47 https://maestrodatabase.com/blog/update-on-us-fda-bla-for-novavaxs-covid-19-vaccine 2025-04-06T23:45:50 https://maestrodatabase.com/blog/cystic-fibrosis-miracle-drug-among-turnbull-governments-310-dollars-million-pbs-listing 2017-05-01T07:01:01 https://maestrodatabase.com/blog/boehringer-ingelheim-canada-announces-reimbursement-for-ofev-nintedanib-in-seven-public-drug-plans-for-the-treatment-of-progressive-fibrosing-interstitial-lung-diseases 2022-05-03T21:14:22 https://maestrodatabase.com/blog/making-310-dollars-million-of-new-vital-drugs-available-for-australian-patients 2017-05-01T07:05:21 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-supplemental-new-drug-application-and-grants-priority-review-for-darolutamide-in-combination-with-docetaxel-for-metastatic-hormone-sensitive-prostate-cancer 2022-05-03T12:16:42 https://maestrodatabase.com/blog/nice-u-turn-recommends-some-access-to-takedas-adcetris 2017-05-01T07:15:21 https://maestrodatabase.com/blog/the-fda-just-approved-one-of-the-most-expensive-drugs-in-the-world 2017-05-01T07:31:16 https://maestrodatabase.com/blog/cancer-pill-costs-soar-as-drug-companies-retain-pricing-power 2017-05-01T07:28:03 https://maestrodatabase.com/blog/basic-bronze-proposal-to-cut-health-insurance-premiums 2017-05-01T07:41:05 https://maestrodatabase.com/blog/takeda-receives-positive-chmp-opinion-for-subcutaneous-formulation-of-vedolizumab-for-use-as-maintenance-therapy-in-adults-with-moderately-to-severely-active-ulcerative-colitis-or-crohns-disease 2020-03-02T00:27:02 https://maestrodatabase.com/blog/does-nice-influence-the-adoption-and-uptake-of-generics-in-the-uk 2021-02-14T20:00:04 https://maestrodatabase.com/blog/fda-approves-drug-to-reduce-bone-marrow-suppression-caused-by-chemotherapy 2021-02-14T20:06:35 https://maestrodatabase.com/blog/the-promise-and-challenges-of-car-t-gene-therapy 2017-11-22T22:40:14 https://maestrodatabase.com/blog/assessment-of-fda-and-ema-approved-systemic-oncology-therapies-and-clinically-meaningful-improvements-in-quality-of-life 2021-02-14T20:32:01 https://maestrodatabase.com/blog/sick-australians-risk-being-locked-out-of-lifesaving-medicines-by-outdated-pbs 2026-02-12T02:29:31 https://maestrodatabase.com/blog/skin-cancer-drug-recommended-for-routine-nhs-use 2021-02-14T20:39:19 https://maestrodatabase.com/blog/lifesaving-drugs-blocked-by-australias-broken-approvals-process 2026-02-12T02:44:31 https://maestrodatabase.com/blog/rule-of-two-for-faster-access-to-medicines 2025-04-07T00:03:10 https://maestrodatabase.com/blog/mallinckrodt-provides-regulatory-update-on-stratagraft 2021-02-14T20:12:16 https://maestrodatabase.com/blog/agenda-for-the-march-2026-pbac-meeting-12-february-2026 2026-02-12T03:43:21 https://maestrodatabase.com/blog/biomarin-receives-health-canada-notice-of-compliance-with-conditions-for-voxzogo-for-achondroplasia 2026-02-12T03:50:02 https://maestrodatabase.com/blog/manitoba-is-canadas-first-province-to-nab-home-grown-vaccine 2021-02-14T20:19:45 https://maestrodatabase.com/blog/there-will-be-enough-vaccines-for-all--if-rich-countries-share 2021-02-14T20:27:56 https://maestrodatabase.com/blog/price-therapeutic-value-impact-international-submission-times-for-new-drugs 2026-02-12T03:55:59 https://maestrodatabase.com/blog/its-outrageous-costly-cancer-drugs-thrown-out-because-of-one-size-fits-all-packaging 2020-03-02T02:24:28 https://maestrodatabase.com/blog/challenges-in-ensuring-global-access-to-covid-19-vaccines-production-affordability-allocation-and-deployment 2021-02-14T20:44:46 https://maestrodatabase.com/blog/budget-2017-doctors-reject-changes-on-generic-drugs-which-could-save-almost-2-dollars-billion 2017-05-01T15:40:13 https://maestrodatabase.com/blog/rfp---supply-of-infliximab 2019-08-19T04:24:20 https://maestrodatabase.com/blog/calls-to-sack-pharmac-boss-after-sick-sneering-remarks 2023-10-10T19:50:24 https://maestrodatabase.com/blog/will-medicare-part-b-premiums-go-up-again-in-2024 2023-10-10T19:55:16 https://maestrodatabase.com/blog/european-commission-approves-seagens-tukysa-tucatinib-for-the-treatment-of-patients-with-locally-advanced-or-metastatic-her2-positive-breast-cancer 2021-02-14T22:18:34 https://maestrodatabase.com/blog/patient-access-to-medicines-for-rare-health-conditions-at-sustainable-costs-can-be-strengthened 2023-10-10T19:46:00 https://maestrodatabase.com/blog/majorities-of-democrats-republicans-and-independents-support-actions-to-lower-drug-costs-including-allowing-americans-to-buy-drugs-from-canada 2017-05-01T17:51:55 https://maestrodatabase.com/blog/abbvies-aquipta-atogepant-is-now-available-in-scotland-for-the-prevention-of-migraines-in-adults 2023-10-10T07:28:23 https://maestrodatabase.com/blog/us-fda-approves-foundationone-cdx-as-a-companion-diagnostic-for-lillys-retevmo-selpercatinib-for-certain-patients-with-solid-tumours 2023-10-10T08:50:59 https://maestrodatabase.com/blog/obstacles-to-the-adoption-of-biosimilars-for-chronic-diseases 2017-05-01T20:50:58 https://maestrodatabase.com/blog/astrazenecas-imfinzi-durvalumab-receives-us-fda-accelerated-approval-for-previously-treated-patients-with-advanced-bladder-cancer 2017-05-02T04:53:04 https://maestrodatabase.com/blog/cancer-fund-failure-highlights-the-dilemma-of-drug-pricing 2017-05-01T21:24:29 https://maestrodatabase.com/blog/pharma-group-warns-drug-price-cuts-threaten-industry-investment 2026-02-12T07:15:46 https://maestrodatabase.com/blog/pear-therapeutics-and-spero-health-to-expand-access-to-prescription-digital-therapeutics-for-people-in-recovery-across-multiple-locations-and-states 2023-01-06T00:53:19 https://maestrodatabase.com/blog/pharmac-seeking-feedback-on-plans-to-modernise-the-pharmaceutical-schedule 2026-02-12T07:20:58 https://maestrodatabase.com/blog/immpact-bio-granted-fda-fast-track-designation-for-impt-514-for-the-treatment-of-both-active-refractory-lupus-nephritis-and-systemic-lupus-erythematosus 2023-10-10T20:41:00 https://maestrodatabase.com/blog/datroway-supplemental-new-drug-application-submitted-in-japan-for-patients-with-metastatic-triple-negative-breast-cancer-who-are-not-candidates-for-immunotherapy 2026-02-12T07:24:54 https://maestrodatabase.com/blog/sanofi-genzyme-announces-approval-of-cerdelga-eliglustat-tartrate-by-health-canada-for-rare-genetic-condition 2017-05-02T05:43:25 https://maestrodatabase.com/blog/survey-shows-biotech-industry-buoyant-but-fearing-imminent-policy-change 2017-05-02T05:09:35 https://maestrodatabase.com/blog/lynparza-olaparib-accepted-for-use-in-scotland-as-adjuvant-treatment-for-patients-with-germline-brca-mutated-her2-negative-high-risk-early-breast-cancer 2023-10-10T20:24:56 https://maestrodatabase.com/blog/why-proper-understanding-of-confidence-intervals-and-statistical-significance-is-important 2021-02-14T23:24:08 https://maestrodatabase.com/blog/pharmacy-middlemen-appear-to-be-inflating-drug-prices-ftc-says 2024-07-09T21:35:25 https://maestrodatabase.com/blog/biosimilars-is-interchangeability-the-proof-of-the-pudding 2021-02-14T23:26:16 https://maestrodatabase.com/blog/a-new-gene-therapy-transformative-cystic-fibrosis-medicines-and-an-obesity-jab-included-in-guidance-recommended-during-pre-election-period 2024-07-09T21:32:07 https://maestrodatabase.com/blog/xeris-pharmaceuticals-receives-european-commission-approval-of-ogluo-glucagon-injection-for-the-treatment-of-severe-hypoglycaemia-in-adults-adolescents-and-children-aged-2-years-and-over-with-diabetes-mellitus 2021-02-15T00:35:27 https://maestrodatabase.com/blog/sunesis-pharmaceuticals-announces-withdrawal-of-european-marketing-authorisation-application-for-vosaroxin-as-a-treatment-for-relapsed-slash-refractory-aml 2017-05-02T05:48:36 https://maestrodatabase.com/blog/adicet-bio-receives-fda-fast-track-designation-for-adi-270-in-metastatic-slash-advanced-clear-cell-renal-cell-carcinoma 2024-07-09T21:26:29 https://maestrodatabase.com/blog/how-eli-lillys-new-generic-insulin-could-impact-prices-across-the-market 2019-03-14T11:03:58 https://maestrodatabase.com/blog/horizon-pharma-announces-fda-approval-to-expand-the-age-range-for-ravicti-glycerol-phenylbutyrate-oral-liquid-to-people-with-urea-cycle-disorders-two-months-of-age-and-older 2017-05-02T08:12:15 https://maestrodatabase.com/blog/house-democrats-investigate-trump-backed-short-term-health-plans 2019-03-14T19:43:04 https://maestrodatabase.com/blog/msd-plans-2017-launch-of-renflexis-infliximab-in-australia 2017-05-02T08:19:23 https://maestrodatabase.com/blog/uk-breast-cancer-patients-win-early-access-to-tecentriq-slash-nab-paclitaxel 2019-03-14T19:48:05 https://maestrodatabase.com/blog/cms-updates-drug-dashboards-with-prescription-drug-pricing-and-spending-data 2019-03-14T19:33:53 https://maestrodatabase.com/blog/atlantic-healthcare-initiates-fda-rolling-submission-of-its-new-drug-application-for-alicaforsen-in-the-treatment-of-pouchitis 2017-05-02T08:25:22 https://maestrodatabase.com/blog/fda-refusing-to-review-moderna-mrna-flu-shot-application 2026-02-12T20:14:32 https://maestrodatabase.com/blog/statement-by-fda-commissioner-on-new-strategies-to-modernise-clinical-trials-to-advance-precision-medicine-patient-protections-and-more-efficient-product-development 2019-03-14T19:38:19 https://maestrodatabase.com/blog/european-commission-approves-mercks-keytruda-pembrolizumab-in-combination-with-chemotherapy-for-first-line-treatment-of-adults-with-metastatic-squamous-non-small-cell-lung-cancer 2019-03-14T19:54:47 https://maestrodatabase.com/blog/its-time-to-fast-track-innovation-in-medical-devices-for-children 2021-02-15T00:43:20 https://maestrodatabase.com/blog/amendments-to-the-process-for-reviewing-and-remaking-positive-pbac-listing-recommendations-that-have-not-been-accepted-by-applicants 2021-02-15T00:55:00 https://maestrodatabase.com/blog/european-commission-approves-roches-hemlibra-for-people-with-severe-haemophilia-a-without-factor-viii-inhibitors 2019-03-14T19:51:26 https://maestrodatabase.com/blog/an-eu-wide-approach-to-hta-an-irrelevant-development-or-an-opportunity-not-to-be-missed 2019-03-14T20:15:34 https://maestrodatabase.com/blog/japan-approves-pfizers-covid-19-vaccine 2021-02-15T02:03:55 https://maestrodatabase.com/blog/bluebird-bios-beta-thalassaemia-gene-therapy-rejected-by-nice 2021-02-15T02:08:42 https://maestrodatabase.com/blog/pliant-therapeutics-receives-fda-fast-track-designation-for-pln-74809-for-the-treatment-of-idiopathic-pulmonary-fibrosis 2022-05-04T03:30:36 https://maestrodatabase.com/blog/japans-mhlw-presents-drug-pricing-changes 2017-11-23T02:49:06 https://maestrodatabase.com/blog/erbitux-approved-for-first-line-use-in-china-in-patients-with-recurrent-and-slash-or-metastatic-squamous-cell-carcinoma-of-the-head-and-neck 2020-03-02T08:48:35 https://maestrodatabase.com/blog/treating-hepatitis-c-in-new-zealand 2017-11-23T01:32:29 https://maestrodatabase.com/blog/polaryx-therapeutics-receives-both-rare-paediatric-disease-and-orphan-drug-designations-for-the-treatment-of-krabbe-disease-with-plx-300 2021-02-15T02:18:29 https://maestrodatabase.com/blog/the-liberals-plan-for-pharmacare-were-still-waiting 2019-03-14T20:39:03 https://maestrodatabase.com/blog/budget-2017-peak-gp-body-supports-governments-generic-drug-scheme-but-medical-community-split 2017-05-02T21:04:00 https://maestrodatabase.com/blog/graphite-bio-announces-u-dot-s-fda-fast-track-designation-granted-to-gph101-for-the-treatment-of-sickle-cell-disease 2022-05-04T03:20:56 https://maestrodatabase.com/blog/white-house-seeks-quick-vote-on-healthcare-overhaul-but-hurdles-remain 2017-05-02T13:22:33 https://maestrodatabase.com/blog/one-in-four-cancer-patients-wait-two-months-for-treatment-as-nhs-performance-hits-record-low 2019-03-14T20:43:34 https://maestrodatabase.com/blog/alberta-expands-coverage-for-cystic-fibrosis-drug 2020-03-02T09:01:39 https://maestrodatabase.com/blog/addressing-bias-and-conflict-of-interest-among-biomedical-researchers 2017-05-02T21:10:43 https://maestrodatabase.com/blog/patient-advocates-applaud-cancer-drug-parity-act-filed-in-both-the-u-dot-s-house-and-senate 2019-03-14T20:24:01 https://maestrodatabase.com/blog/fennec-pharmaceuticals-receives-ema-validation-for-marketing-authorisation-application-for-sodium-thiosulphate 2020-03-02T08:56:27 https://maestrodatabase.com/blog/pay-for-plasma-collection-coming-to-alberta-by-end-of-the-year 2021-02-15T01:56:30 https://maestrodatabase.com/blog/new-multimillion-dollar-campaign-against-high-drug-prices-launches-with-a-spoof-drug-ad 2017-05-02T21:17:17 https://maestrodatabase.com/blog/disclosing-the-conflicts-of-interest-of-us-food-and-drug-administration-advisory-committee-members 2017-05-02T21:13:51 https://maestrodatabase.com/blog/icer-publishes-final-evidence-report-on-medication-for-smoking-cessation 2026-02-12T22:02:31 https://maestrodatabase.com/blog/stop-stripping-pharmac-of-its-money---campaigners-message-to-government 2017-05-02T21:24:17 https://maestrodatabase.com/blog/fda-approves-arcutis-zorvye-roflumilast-cream-0-dot-15-percent-for-the-treatment-of-atopic-dermatitis-in-adults-and-children-down-to-6-years-of-age 2024-07-09T22:39:12 https://maestrodatabase.com/blog/japans-national-insurance-to-cover-novartis-gene-therapy-zolgensma 2020-03-02T09:09:52 https://maestrodatabase.com/blog/drug-prices-by-committee-one-way-biden-could-lower-costs 2021-02-15T02:57:10 https://maestrodatabase.com/blog/international-harmonisation-of-ingredient-names---pbs-changes 2017-05-03T05:37:46 https://maestrodatabase.com/blog/first-australian-covid-19-vaccines-from-pfizer-have-arrived-in-australia 2021-02-15T03:01:20 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-regulatory-submission-for-tanezumab-a-potential-first-in-class-treatment-for-patients-with-chronic-pain-due-to-moderate-to-severe-osteoarthritis 2020-03-02T19:58:06 https://maestrodatabase.com/blog/altor-bioscience-corporation-announces-fda-fast-track-designation-for-lead-candidate-alt-803-in-patients-with-non-muscle-invasive-bladder-cancer 2017-05-03T05:41:28 https://maestrodatabase.com/blog/coronavirus-covid-19-pharmacs-response 2020-03-02T09:29:27 https://maestrodatabase.com/blog/changes-to-dispensing-frequency-rules-and-stat-medicines-list 2020-03-02T09:27:49 https://maestrodatabase.com/blog/post-market-review-of-medicines-for-smoking-cessation---stakeholder-forum-outcome 2021-02-15T03:59:20 https://maestrodatabase.com/blog/european-commission-approves-cabometyx-as-a-second-line-treatment-for-people-living-with-radioactive-iodine-refractory-differentiated-thyroid-cancer 2022-05-04T10:40:40 https://maestrodatabase.com/blog/over-6-000-people-will-benefit-from-pharmac-funding-proposal-if-approved 2024-07-10T01:29:13 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-releases-draft-evidence-report-on-siponimod-for-treating-secondary-progressive-multiple-sclerosis 2019-03-14T21:24:21 https://maestrodatabase.com/blog/fda-approves-new-therapy-for-patients-with-previously-treated-multiple-myeloma 2020-03-02T20:07:51 https://maestrodatabase.com/blog/azafaros-receives-fast-track-designation-for-lead-asset-az-3102 2023-01-06T01:53:57 https://maestrodatabase.com/blog/obsidian-therapeutics-announces-fda-fast-track-designation-for-obx-115-for-the-treatment-of-advanced-melanoma 2024-07-10T01:02:16 https://maestrodatabase.com/blog/99mtc-maraciclatide-granted-fda-fast-track-designation-for-the-visualisation-of-inflammation-in-interstitial-lung-disease 2026-02-12T23:19:16 https://maestrodatabase.com/blog/extension-to-feedback-for-public-consultation---standardised-redactions-of-pbac-public-summary-documents 2019-08-19T06:00:56 https://maestrodatabase.com/blog/athenexs-partner-almirall-announces-ema-acceptance-for-filing-of-marketing-authorisation-application-for-tirbanibulin-ointment-in-actinic-keratosis 2020-03-02T20:25:37 https://maestrodatabase.com/blog/coronavirus-triggers-national-medical-stockpile-as-covid-19-threat-intensifies 2020-03-02T20:23:33 https://maestrodatabase.com/blog/pharmacs-handling-of-funding-request-for-sanitary-products-labelled-devious-and-underhanded 2020-03-02T20:20:02 https://maestrodatabase.com/blog/ema-organisational-changes-come-into-effect 2020-03-02T20:14:18 https://maestrodatabase.com/blog/biodelivery-sciences-announces-the-approval-of-bunavail-for-induction-of-buprenorphine-treatment-for-opioid-dependence 2017-05-03T06:04:19 https://maestrodatabase.com/blog/fda-approves-labelling-changes-to-menopausal-hormone-therapy-products 2026-02-12T22:41:46 https://maestrodatabase.com/blog/boehringer-ingelheim-receives-positive-chmp-opinion-for-nintedanib-for-the-treatment-of-systemic-sclerosis-associated-interstitial-lung-disease 2020-03-02T20:31:02 https://maestrodatabase.com/blog/case-dismissed 2019-08-19T06:05:11 https://maestrodatabase.com/blog/seastar-medical-granted-fda-breakthrough-device-designation-for-a-novel-immunomodulatory-therapy-for-acute-kidney-injury-patients 2022-05-04T11:32:18 https://maestrodatabase.com/blog/u-dot-k-sets-red-lines-on-drug-prices-food-in-u-dot-s-trade-talks 2020-03-02T20:37:27 https://maestrodatabase.com/blog/imfinzi-plus-chemotherapy-granted-priority-review-in-the-us-for-patients-with-locally-advanced-or-metastatic-biliary-tract-cancer-based-on-topaz-1-phase-iii-trial 2022-05-04T11:06:33 https://maestrodatabase.com/blog/bicycle-therapeutics-announces-fda-fast-track-designation-granted-to-bt8009-for-the-treatment-of-adult-patients-with-previously-treated-locally-advanced-or-metastatic-urothelial-cancer 2023-01-06T02:15:17 https://maestrodatabase.com/blog/microtransponder-receives-fda-approval-for-breakthrough-device-benefiting-stroke-survivors 2021-09-01T02:45:56 https://maestrodatabase.com/blog/lisocabtagene-maraleucel-for-the-treatment-of-adults-with-relapsed-or-refractory-aggressive-b-cell-non-hodgkins-lymphoma 2024-07-10T04:24:24 https://maestrodatabase.com/blog/republicans-still-dont-know-whether-they-have-enough-votes-to-pass-obamacare-repeal 2017-05-03T14:49:25 https://maestrodatabase.com/blog/patient-financial-assistance-programs-a-path-to-affordability-or-a-barrier-to-accessible-cancer-care 2017-05-03T14:54:34 https://maestrodatabase.com/blog/jazz-pharmaceuticals-announces-health-canada-approval-of-sunosi-solriamfetol-for-excessive-daytime-sleepiness-associated-with-narcolepsy-or-obstructive-sleep-apnea 2021-09-01T02:33:46 https://maestrodatabase.com/blog/cosmo-announces-submission-of-winlevi-to-the-ema 2023-10-11T01:19:16 https://maestrodatabase.com/blog/law-finally-passed-to-ban-medicine-price-hiking-by-greedy-drug-firms 2017-05-03T15:11:45 https://maestrodatabase.com/blog/mirvie-receives-fda-breakthrough-device-designation-for-first-test-designed-to-indicate-risk-of-preeclampsia-months-before-symptoms-occur 2022-05-04T11:56:31 https://maestrodatabase.com/blog/patients-who-rely-on-obamacare-protections-are-worried 2017-05-03T15:51:54 https://maestrodatabase.com/blog/x-therma-receives-fda-breakthrough-device-designation-for-xt-vivo-preservation-solution-and-timeseal-organ-transport-device 2022-05-04T12:15:19 https://maestrodatabase.com/blog/joe-biden-on-his-new-cancer-initiative-drug-prices-and-donald-trump 2017-05-03T15:43:47 https://maestrodatabase.com/blog/astrazeneca-covid-19-vaccine-authorised-for-emergency-use-by-the-world-health-organization 2021-02-15T20:11:23 https://maestrodatabase.com/blog/roche-receives-fda-approval-for-complementary-pd-l1-sp263-biomarker-test-in-urothelial-carcinoma 2017-05-03T16:06:43 https://maestrodatabase.com/blog/amylyx-pharmaceuticals-announces-health-canada-accepts-for-review-the-new-drug-submission-for-amx0035-for-the-treatment-of-als 2021-09-01T03:05:55 https://maestrodatabase.com/blog/nice-rejects-lillys-verzenios-for-advanced-breast-cancer 2021-02-15T20:08:21 https://maestrodatabase.com/blog/mirum-pharmaceuticals-livmarli-approved-in-the-european-union-for-patients-with-progressive-familial-intrahepatic-cholestasis 2024-07-10T06:01:46 https://maestrodatabase.com/blog/ucb-announces-rozanolixizumab-bla-for-the-treatment-of-generalised-myasthenia-gravis-filed-with-us-fda-and-designated-for-priority-review 2023-01-06T06:24:17 https://maestrodatabase.com/blog/aum-biosciences-receives-us-fda-rare-paediatric-disease-designation-for-aum302-for-treatment-of-neuroblastoma 2023-01-06T04:16:18 https://maestrodatabase.com/blog/aptose-receives-fast-track-designation-for-hm43239-in-relapsed-slash-refractory-aml-patients-and-flt3-mutation 2022-05-04T21:13:04 https://maestrodatabase.com/blog/one-billion-dollar-bid-to-go-it-alone-with-covid-19-vaccine-hub 2021-02-15T21:43:52 https://maestrodatabase.com/blog/novartis-kymriah-receives-ec-approval-as-first-car-t-cell-therapy-for-adults-with-relapsed-or-refractory-follicular-lymphoma 2022-05-04T21:17:45 https://maestrodatabase.com/blog/infexs-novel-amr-drug-candidate-met-x-receives-fda-qidp-designation 2023-01-06T06:36:28 https://maestrodatabase.com/blog/phathom-pharmaceuticals-announces-fda-approval-of-voquenza-triple-pak-vonoprazan-amoxicillin-clarithromycin-and-voquenza-dual-pak-vonoprazan-amoxicillin-for-the-treatment-of-h-pylori-infection-in-adults 2022-05-04T12:31:43 https://maestrodatabase.com/blog/updates-to-the-hta-policy-and-methods-review 2024-07-10T07:06:47 https://maestrodatabase.com/blog/people-with-multiple-sclerosis-unable-to-access-life-changing-treatment-in-nz 2022-05-04T21:42:05 https://maestrodatabase.com/blog/methods-paper-new-version-6-dot-1-becomes-effective---english-translation-now-available 2022-05-04T21:37:26 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-for-alzheimers-disease-treatment 2023-01-06T20:31:07 https://maestrodatabase.com/blog/unitedhealthcare-restricts-coverage-of-aduhelm-following-medicare 2022-05-04T21:46:37 https://maestrodatabase.com/blog/the-price-of-a-life-stark-choice-facing-kiwis-needing-unfunded-medicines 2021-02-15T21:49:37 https://maestrodatabase.com/blog/fda-permits-marketing-for-new-test-to-improve-diagnosis-of-alzheimers-disease 2022-05-04T21:25:16 https://maestrodatabase.com/blog/new-handbook-on-health-economic-assessments-of-medical-devices 2022-08-22T21:24:10 https://maestrodatabase.com/blog/labor-drug-policy-always-part-of-the-plan 2022-05-04T21:33:54 https://maestrodatabase.com/blog/amgen-and-harvard-pilgrim-agree-to-first-cardiovascular-outcomes-based-refund-contract-for-repatha-evolocumab 2017-05-03T21:10:18 https://maestrodatabase.com/blog/nice-recommends-ebglyss-lebrikizumab-for-use-in-moderate-to-severe-atopic-dermatitis-in-the-nhs-england-in-eligible-adolescents-and-adults 2024-07-10T21:11:28 https://maestrodatabase.com/blog/karyopharm-announces-fda-extension-of-review-period-for-selinexor-new-drug-application 2019-03-15T00:58:43 https://maestrodatabase.com/blog/productivity-adjusted-life-years-a-new-metric-for-quantifying-disease-burden 2021-02-15T22:36:58 https://maestrodatabase.com/blog/insurer-relents-will-cover-costly-muscular-atrophy-drug-for-all-patients 2017-05-03T21:16:51 https://maestrodatabase.com/blog/pfizer-announces-u-dot-s-fda-filing-acceptance-of-supplemental-new-drug-application-for-xeljanz-tofacitinib-citrate-for-the-treatment-of-adult-patients-with-active-psoriatic-arthritis 2017-05-03T21:21:13 https://maestrodatabase.com/blog/ptc-therapeutics-provides-regulatory-update-on-translarna 2026-02-13T10:36:32 https://maestrodatabase.com/blog/nice-recommends-janssens-first-of-its-kind-crohns-drug-stelara 2017-05-03T21:29:21 https://maestrodatabase.com/blog/the-failure-of-solanezumab----how-the-fda-saved-taxpayers-billions 2017-05-04T05:38:27 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-treatments-for-osteoporosis-including-abaloparatide-and-romosozumab 2017-05-04T05:29:38 https://maestrodatabase.com/blog/agilent-receives-fda-approval-for-pd-l1-ihc-22c3-pharmdx-in-epithelial-ovarian-fallopian-tube-or-primary-peritoneal-carcinoma 2026-02-13T10:16:24 https://maestrodatabase.com/blog/bimekizumab-for-the-treatment-of-patients-with-axial-spondyloarthritis 2023-10-11T02:44:52 https://maestrodatabase.com/blog/outlook-therapeutics-announces-uk-mhra-marketing-authorisation-of-lytenava-bevacizumab-gamma-for-the-treatment-of-wet-amd 2024-07-10T23:01:33 https://maestrodatabase.com/blog/health-canada-begins-release-of-clinical-data-on-drugs-and-devices 2019-03-15T01:48:06 https://maestrodatabase.com/blog/eton-pharmaceuticals-submits-new-drug-application-for-ds-200 2019-03-15T01:09:43 https://maestrodatabase.com/blog/your-money-or-your-life---the-high-cost-of-cancer-drugs-under-medicare-part-d 2022-05-05T00:29:55 https://maestrodatabase.com/blog/prostheses-reforms-to-deliver-better-value-for-private-health-insurance 2017-05-04T06:13:34 https://maestrodatabase.com/blog/mhra-approves-rinvoq-upadacitinib-as-first-jak-inhibitor-in-gb-for-the-treatment-of-both-adults-and-adolescents-with-moderate-to-severe-atopic-dermatitis 2021-09-01T09:16:24 https://maestrodatabase.com/blog/another-small-victory-for-australian-government-in-its-pursuit-of-damages-for-pbs-over-payments-during-interlocutory-injunction-period 2017-05-04T19:41:46 https://maestrodatabase.com/blog/metoprolol-shortage-ends-but-pharmacists-remain-concerned 2017-05-04T19:36:34 https://maestrodatabase.com/blog/private-health-insurance-premiums-set-to-get-cheaper-across-australia 2017-05-04T19:47:08 https://maestrodatabase.com/blog/aplidin-will-be-re-evaluated-by-the-ema-the-european-commission-revokes-the-decision-that-initially-denied-pharmamars-marketing-authorisation-for-multiple-myeloma-due-to-a-conflict-of-interest 2024-07-10T23:33:15 https://maestrodatabase.com/blog/nice-approves-ground-breaking-cholesterol-lowering-drug-inclisiran 2021-09-01T07:37:00 https://maestrodatabase.com/blog/real-world-evidence---where-are-we-now 2022-05-05T02:56:48 https://maestrodatabase.com/blog/who-to-begin-pilot-pre-qualification-of-biosimilars-for-cancer-treatment 2017-05-04T19:59:02 https://maestrodatabase.com/blog/novo-nordisk-receives-complete-response-letter-in-the-us-for-once-weekly-basal-insulin-icodec 2024-07-11T12:51:06 https://maestrodatabase.com/blog/european-commission-approves-amgens-uplinza-for-generalised-myasthenia-gravis 2026-02-13T19:46:19 https://maestrodatabase.com/blog/tga-approves-new-formulation-of-glatiramer-acetate 2021-02-15T23:47:12 https://maestrodatabase.com/blog/high-income-earners-could-be-in-medicare-firing-line 2017-05-04T19:50:11 https://maestrodatabase.com/blog/nib-boss-lambasts-ideological-health-insurance-rules 2019-08-19T09:52:31 https://maestrodatabase.com/blog/louisiana-proposes-tapping-a-century-old-patent-law-to-cut-hepatitis-c-drug-prices 2017-05-04T20:01:37 https://maestrodatabase.com/blog/the-us-regulatory-system-and-covid-19-vaccines-the-importance-of-a-strong-and-capable-fda 2021-02-16T00:45:17 https://maestrodatabase.com/blog/roches-erivedge-no-longer-funded-by-the-nhs 2017-11-23T19:48:09 https://maestrodatabase.com/blog/tga-provisionally-approves-astrazenecas-covid-19-vaccine 2021-02-16T02:07:22 https://maestrodatabase.com/blog/statement-from-centers-for-medicare-and-medicaid-services-administrator-seema-verma 2017-05-04T20:04:44 https://maestrodatabase.com/blog/pharma-company-lawsuit-forces-dutch-health-agency-to-reassess-cancer-drug 2024-07-10T23:53:22 https://maestrodatabase.com/blog/gsk-submits-landmark-impact-data-to-us-regulatory-authority-to-support-expanded-label-for-trelegy-ellipta 2017-11-23T19:53:18 https://maestrodatabase.com/blog/targovax-receives-fast-track-designation-for-oncos-102 2021-02-15T23:17:38 https://maestrodatabase.com/blog/cancer-treatments-account-for-9-dot-3-percent-of-total-drug-claims-in-2020 2021-09-01T09:25:08 https://maestrodatabase.com/blog/pfizer-to-give-out-breast-cancer-drug-free-while-awaiting-nhs-decision 2017-05-04T20:13:53 https://maestrodatabase.com/blog/tga-approves-new-medicine-for-patients-with-rare-forms-of-non-hodgkins-lymphoma 2021-02-15T23:25:56 https://maestrodatabase.com/blog/uk-publishes-paper-on-brexit-and-medicines-regulation 2017-11-23T20:04:32 https://maestrodatabase.com/blog/health-canada-approves-ipsens-cabometyx-cabozantinib-for-patients-with-previously-treated-radioactive-iodine-refractory-or-ineligible-differentiated-thyroid-cancer 2022-05-05T02:37:06 https://maestrodatabase.com/blog/fda-and-nih-release-final-template-for-clinical-trial-protocols 2017-05-04T20:09:38 https://maestrodatabase.com/blog/ema-forges-closer-ties-with-hta-umbrella-group 2017-11-23T20:01:07 https://maestrodatabase.com/blog/cancer-drugs-are-getting-better-and-dearer 2017-05-04T20:18:25 https://maestrodatabase.com/blog/fda-accepts-morphosys-biologics-license-application-and-grants-priority-review-for-tafasitamab-and-lenalidomide-for-the-treatment-of-relapsed-slash-refractory-dlbcl 2020-03-02T23:30:17 https://maestrodatabase.com/blog/us-new-drug-price-exceeds-200-000-dollars-median-in-2022 2023-01-06T21:47:41 https://maestrodatabase.com/blog/medicines-in-new-zealand-are-overlooked-and-underfunded 2017-05-04T20:27:22 https://maestrodatabase.com/blog/fda-approves-drug-for-schizophrenia-to-be-administered-at-a-six-month-interval 2021-09-01T20:49:14 https://maestrodatabase.com/blog/how-drugmakers-face-global-push-back-on-high-prices 2017-05-04T20:24:14 https://maestrodatabase.com/blog/u-dot-s-fda-grants-breakthrough-device-designation-for-innovative-endosound-vision-ultrasound-system 2021-09-01T20:42:34 https://maestrodatabase.com/blog/the-gop-just-voted-to-undo-obamacare-without-knowing-how-many-people-would-lose-health-insurance 2017-05-04T20:33:53 https://maestrodatabase.com/blog/pharmac-needs-to-work-for-patients-not-itself 2023-10-11T04:12:55 https://maestrodatabase.com/blog/ftc-to-sue-drug-managers-over-insulin-prices 2024-07-11T21:40:06 https://maestrodatabase.com/blog/canada-wide-program-aims-to-get-young-cancer-patients-faster-access-to-new-therapies 2017-11-23T20:31:51 https://maestrodatabase.com/blog/celltrion-healthcare-receives-european-commission-approval-for-the-first-high-concentration-low-volume-and-citrate-free-biosimilar-adalimumab-yuflyma-ct-p17 2021-02-16T03:29:45 https://maestrodatabase.com/blog/australian-children-with-neuroblastoma-given-free-access-to-500-000-dollar-cancer-drug-dfmo 2024-07-11T12:55:01 https://maestrodatabase.com/blog/intelivation-technologies-received-fda-approval-for-the-golden-isles-pedicle-screw-system 2021-09-01T21:11:24 https://maestrodatabase.com/blog/kempharm-submits-kp415-nda-to-the-fda-for-the-treatment-of-adhd 2020-03-03T00:10:09 https://maestrodatabase.com/blog/alkermes-new-drug-application-for-investigational-product-designed-for-initiation-onto-aristada-accepted-for-filing-by-u-dot-s-fda 2017-11-23T21:36:19 https://maestrodatabase.com/blog/in2bones-receives-fda-clearance-for-pre-surgery-orthoplanify-patient-specific-planning-software-and-3d-printed-cutting-guides-for-quantum-total-ankle-system 2021-09-01T21:14:06 https://maestrodatabase.com/blog/fda-requires-warnings-about-increased-risk-of-serious-heart-related-events-cancer-blood-clots-and-death-for-jak-inhibitors-that-treat-certain-chronic-inflammatory-conditions 2021-09-01T20:57:37 https://maestrodatabase.com/blog/vaxcytes-vax-24-granted-fda-breakthrough-therapy-designation-for-the-prevention-of-invasive-pneumococcal-disease-in-adults 2023-01-06T21:50:28 https://maestrodatabase.com/blog/fda-approves-new-antibiotic-to-treat-community-acquired-bacterial-pneumonia 2019-08-19T20:53:18 https://maestrodatabase.com/blog/disc-medicine-receives-complete-response-letter-from-fda-for-bitopertin-for-the-treatment-of-epp 2026-02-13T23:15:23 https://maestrodatabase.com/blog/government-cancer-plan-strong-leadership-early-access-to-medicines 2019-08-19T20:47:40 https://maestrodatabase.com/blog/bluebird-bio-sells-second-priority-review-voucher-for-95-dollars-million 2023-01-06T22:39:09 https://maestrodatabase.com/blog/sangamo-therapeutics-announces-special-regulatory-designations-from-the-fda-for-three-clinical-programs 2017-05-05T08:07:23 https://maestrodatabase.com/blog/stada-and-bio-thera-receive-european-marketing-authorization-for-gotenfia-a-biosimilar-to-simponi 2026-02-14T01:15:41 https://maestrodatabase.com/blog/quebec-becomes-first-province-to-list-lonsurf-trifluridine-slash-tipiracil-for-public-reimbursement-for-adult-patients-with-metastatic-colorectal-cancer 2019-08-19T21:29:45 https://maestrodatabase.com/blog/influenza-or-the-covid-vaccines-pfizer-or-astrazeneca----which-jab-should-australians-get-first 2021-02-16T07:32:16 https://maestrodatabase.com/blog/fda-approves-zanubrutinib-for-waldenstroems-macroglobulinaemia 2021-09-01T21:53:53 https://maestrodatabase.com/blog/despite-their-pledges-democrats-havent-yet-lowered-drug-prices-heres-how-theyre-explaining-themselves 2019-08-19T21:02:38 https://maestrodatabase.com/blog/when-will-the-mainstream-media-attacks-end 2019-08-19T21:43:23 https://maestrodatabase.com/blog/us-fda-accepts-for-priority-review-the-supplemental-biologics-license-application-for-pfizers-20-valent-pneumococcal-conjugate-vaccine-in-infants-and-children 2023-01-07T00:15:01 https://maestrodatabase.com/blog/engaging-specialist-oncologists-in-the-assessment-of-oncology-drugs-in-canada 2017-05-05T09:54:50 https://maestrodatabase.com/blog/abbvie-prices-new-rheumatoid-arthritis-drug-at-59-000-dollars-a-year 2019-08-19T21:37:57 https://maestrodatabase.com/blog/nice-rejects-orexigens-weight-loss-pill 2017-05-06T20:25:15 https://maestrodatabase.com/blog/new-guide-on-biosimilar-medicines-for-health-care-professionals 2017-05-06T20:20:49 https://maestrodatabase.com/blog/cancer-drugs-fund-of-minimal-benefit 2017-06-07T13:18:30 https://maestrodatabase.com/blog/ema-receives-application-for-conditional-marketing-authorisation-of-covid-19-vaccine-janssen 2021-02-16T19:47:51 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-5-may-2022 2022-05-05T05:46:58 https://maestrodatabase.com/blog/astrazeneca-daiichi-sankyos-enhertu-scores-approval-in-the-uk 2021-02-16T19:51:12 https://maestrodatabase.com/blog/fda-grants-priority-review-to-genentechs-bispecific-antibody-glofitamab-for-people-with-relapsed-or-refractory-large-b-cell-lymphoma 2023-01-07T00:33:39 https://maestrodatabase.com/blog/fda-approves-drug-to-treat-als 2017-05-06T20:36:16 https://maestrodatabase.com/blog/european-commission-approves-keytruda-pembrolizumab-for-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma-who-failed-autologous-stem-cell-transplant-and-brentuximab-vedotin-or-who-are-transplant-ineligible-and-have-failed-brentuximab-vedotin 2017-05-07T05:04:38 https://maestrodatabase.com/blog/after-a-controversial-alzheimers-drug-review-fdas-woodcock-rejects-proposal-to-firewall-agency-and-drug-companies 2021-02-16T20:04:21 https://maestrodatabase.com/blog/forge-biologics-receives-fda-fast-track-orphan-drug-and-rare-paediatric-disease-designations-for-fbx-101-gene-therapy-for-patients-with-krabbe-disease 2021-02-16T20:24:20 https://maestrodatabase.com/blog/enhertu-approved-in-the-us-for-patients-with-her2-positive-metastatic-breast-cancer-treated-with-a-prior-anti-her2-based-regimen 2022-05-05T06:19:19 https://maestrodatabase.com/blog/post-approval-studies-of-drugs-initially-approved-by-the-fda-on-the-basis-of-limited-evidence-systematic-review 2017-05-07T05:17:56 https://maestrodatabase.com/blog/measure-on-pre-existing-conditions-energises-opposition-to-health-bill 2017-05-07T05:15:20 https://maestrodatabase.com/blog/conditional-approval-of-medicines-by-the-ema 2017-05-07T05:21:06 https://maestrodatabase.com/blog/novartis-entresto-granted-expanded-indication-in-chronic-heart-failure-by-fda 2021-02-16T19:54:23 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-reviews-draft-evidence-report-on-abuse-deterrent-opioids-evaluates-clinical-and-economic-evidence-on-nine-formulations 2017-05-07T05:42:14 https://maestrodatabase.com/blog/sesen-bio-announces-fda-acceptance-and-priority-review-of-its-biologics-license-application-for-vicineum 2021-02-16T19:59:12 https://maestrodatabase.com/blog/redistribution-and-redesign-in-health-care-an-ebbing-tide-in-england-versus-growing-concerns-in-the-united-states 2017-05-07T05:31:23 https://maestrodatabase.com/blog/updates-to-the-hta-policy-and-methods-review-reference-committee-october-2023 2023-10-11T07:33:46 https://maestrodatabase.com/blog/alks-hdm-slit-tablet-acarizax-approved-in-canada 2017-05-07T06:01:56 https://maestrodatabase.com/blog/novavax-requests-expanded-authorisation-of-nuvaxovid-covid-19-vaccine-to-adolescents-aged-12-through-17-years-in-great-britain 2022-05-05T08:29:58 https://maestrodatabase.com/blog/updates-to-the-hta-policy-and-methods-review-reference-committee-11-october-2023 2023-10-11T06:42:45 https://maestrodatabase.com/blog/role-of-economic-evaluations-on-pricing-of-medicines-reimbursed-by-the-italian-national-health-service 2023-01-07T00:50:30 https://maestrodatabase.com/blog/aadi-bioscience-announces-unique-permanent-j-code-issued-for-fyarro-from-centers-for-medicare-and-medicaid-services 2022-05-05T08:06:51 https://maestrodatabase.com/blog/fdas-use-of-adcomms-prior-to-drug-approval-decreased-over-the-last-decade 2022-05-05T07:53:37 https://maestrodatabase.com/blog/vanda-pharmaceuticals-fda-update-for-hetlioz-in-the-treatment-of-jet-lag-disorder 2019-08-20T01:10:06 https://maestrodatabase.com/blog/novan-submits-new-drug-application-to-the-us-fda-for-berdazimer-sb206-10-dot-3-percent-topical-gel-for-the-treatment-of-molluscum-contagiosum 2023-01-07T07:16:55 https://maestrodatabase.com/blog/coherus-and-junshi-biosciences-announce-completion-of-rolling-bla-submission-to-u-dot-s-fda-for-toripalimab-for-the-treatment-of-nasopharyngeal-carcinoma 2021-09-01T23:12:54 https://maestrodatabase.com/blog/fda-commissioner-califf-says-business-of-health-is-booming-in-u-dot-s-but-patients-outcomes-arent-improving 2022-05-05T10:21:03 https://maestrodatabase.com/blog/meiragtx-announces-priority-medicines-prime-and-advanced-therapy-medicinal-product-designations-granted-by-the-ema-to-aav-rpgr-gene-therapy-for-the-treatment-of-x-linked-retinitis-pigmentosa 2020-03-03T01:12:29 https://maestrodatabase.com/blog/insights-from-the-march-2022-pbac-meeting-part-4 2022-05-05T10:30:46 https://maestrodatabase.com/blog/eisais-approach-to-us-pricing-for-leqembi-lecanemab-a-treatment-for-early-alzheimers-disease-sets-forth-out-concept-of-societal-value-of-medicine-in-relation-to-price-of-medicine 2023-01-07T07:04:22 https://maestrodatabase.com/blog/european-commission-approves-subcutaneous-rybrevant-amivantamab-for-the-treatment-of-patients-with-advanced-egfr-mutated-non-small-cell-lung-cancer 2025-04-07T23:05:57 https://maestrodatabase.com/blog/selumetinib-for-treating-symptomatic-and-inoperable-plexiform-neurofibromas-associated-with-type-1-neurofibromatosis-in-children-aged-3-and-over 2022-05-05T09:56:54 https://maestrodatabase.com/blog/cablivi-caplacizumab-approved-by-health-canada-for-adults-living-with-acquired-thrombotic-thrombocytopenic-purpura 2020-03-03T02:04:36 https://maestrodatabase.com/blog/novartis-receives-european-commission-approval-for-jakavi-to-be-the-first-post-steroid-treatment-for-acute-and-chronic-graft-versus-host-disease 2022-05-05T10:06:52 https://maestrodatabase.com/blog/ema-publishes-agenda-for-9-12-october-2023-chmp-meeting 2023-10-11T19:33:40 https://maestrodatabase.com/blog/sarepta-therapeutics-receives-complete-response-letter-from-the-us-fda-for-golodirsen-new-drug-application 2019-08-20T01:15:28 https://maestrodatabase.com/blog/funding-for-insomnia-drug-praised-by-parents-as-pharmac-gets-$60m-boost 2017-05-07T20:41:49 https://maestrodatabase.com/blog/agenda-for-22-november-tc-meeting 2017-11-24T00:01:02 https://maestrodatabase.com/blog/moderna-receives-fda-fast-track-designation-for-zika-vaccine-mrna-1893 2019-08-20T02:21:33 https://maestrodatabase.com/blog/many-new-zealanders-to-benefit-from-latest-pharmac-funding-proposals 2017-05-08T06:57:40 https://maestrodatabase.com/blog/icer-to-assess-gene-therapies-for-haemophilia-a-and-b 2022-05-05T21:53:33 https://maestrodatabase.com/blog/proposal-for-various-oncology-medicines 2017-05-08T06:59:56 https://maestrodatabase.com/blog/hiv-treatment-proposal-welcomed-by-new-zealand-aids-foundation 2017-05-08T07:08:12 https://maestrodatabase.com/blog/medicare-may-plan-to-negotiate-drug-prices-but-some-states-are-taking-their-own-steps-to-lower-costs 2023-10-11T19:54:27 https://maestrodatabase.com/blog/proposal-on-various-anti-infective-medicines 2017-05-08T07:05:07 https://maestrodatabase.com/blog/icers-favourable-assessment-of-bluebird-bios-gene-therapy-zynteglo-may-have-important-pricing-and-reimbursement-implications 2022-05-05T21:35:43 https://maestrodatabase.com/blog/rare-disorders-nz-appalled-by-attitude-within-pharmac-calls-for-chairs-removal 2023-10-11T19:44:34 https://maestrodatabase.com/blog/southern-cross-launches-cover-for-cancer-drugs-not-funded-by-pharmac 2017-05-08T07:16:39 https://maestrodatabase.com/blog/fda-establishes-new-advisory-committee-on-digital-health-technologies 2023-10-11T19:49:53 https://maestrodatabase.com/blog/hereditary-amyloidosis-community-hopes-positive-funding-recommendations-for-new-treatments-lead-to-swift-access-for-patients 2020-03-03T02:34:41 https://maestrodatabase.com/blog/pbac-public-summary-documents---november-2018-meeting-rejections-and-deferrals 2019-03-15T07:17:58 https://maestrodatabase.com/blog/cheaper-medicines-for-people-living-with-cystic-fibrosis 2026-02-16T02:19:37 https://maestrodatabase.com/blog/jazz-pharmaceuticals-completes-submission-of-supplemental-new-drug-application-for-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-for-idiopathic-hypersomnia 2021-02-16T23:03:25 https://maestrodatabase.com/blog/extended-release-drugs-could-be-costing-u-dot-s-health-care-system-billions 2020-03-03T02:41:31 https://maestrodatabase.com/blog/sanders-defends-trumps-praise-of-australian-health-care-system 2017-05-08T08:31:59 https://maestrodatabase.com/blog/will-medicare-price-negotiation-delay-cancer-drug-launches 2023-10-11T22:28:35 https://maestrodatabase.com/blog/cheaper-medicines-for-chronic-kidney-disease-and-psoriasis 2026-02-16T05:20:42 https://maestrodatabase.com/blog/neffy-adrenaline-nasal-spray-now-approved-to-treat-anaphylaxis-in-australia 2026-02-16T20:15:20 https://maestrodatabase.com/blog/eisai-submits-supplemental-biologics-license-application-to-fda-for-traditional-approval-of-leqembi-lecanemab-irmb-for-the-treatment-of-alzheimers-disease 2023-01-07T22:04:20 https://maestrodatabase.com/blog/medicines-australia-statement-on-tgas-provisional-approval-of-astrazenecas-covid-19-vaccine 2021-02-16T23:42:31 https://maestrodatabase.com/blog/allogene-granted-three-us-fda-fast-track-designations-for-allo-329-a-next-generation-dual-targeted-cd19-slash-cd70-allogeneic-car-t-for-the-treatment-of-lupus-myositis-and-scleroderma 2025-04-08T00:33:35 https://maestrodatabase.com/blog/fda-approves-encorafenib-with-binimetinib-for-metastatic-non-small-cell-lung-cancer-with-a-braf-v600e-mutation 2023-10-11T22:45:00 https://maestrodatabase.com/blog/reflections-on-a-record-year-for-novel-device-innovation-despite-covid-19-challenges 2021-02-17T00:18:10 https://maestrodatabase.com/blog/askbio-receives-fda-fast-track-and-mhra-innovation-passport-designations-for-ab-1005-investigational-gdnf-gene-therapy-for-parkinsons-disease 2024-07-12T05:14:52 https://maestrodatabase.com/blog/health-canada-approves-reblozyl-luspatercept-new-class-of-treatment-for-adult-patients-living-with-myelodysplastic-syndromes 2021-02-17T01:48:54 https://maestrodatabase.com/blog/sandoz-canada-completes-its-fifth-biosimilar-launch-with-new-biosimilar-hyrimoz-adalimumab 2021-02-17T02:13:25 https://maestrodatabase.com/blog/otsuka-and-lundbeck-announce-fda-acceptance-and-priority-review-of-snda-for-brexpiprazole-for-the-treatment-of-agitation-associated-with-alzheimers-dementia 2023-01-08T20:14:38 https://maestrodatabase.com/blog/tlv-is-tasked-with-reducing-costs-for-medicines 2021-02-17T01:18:09 https://maestrodatabase.com/blog/medicines-australias-statement-on-the-arrival-of-the-pfizer-vaccine 2021-02-17T06:45:12 https://maestrodatabase.com/blog/spectrum-pharmaceuticals-provides-bla-filing-update-for-rolontis-eflapegrastim 2019-03-15T23:57:46 https://maestrodatabase.com/blog/immortal-time-bias-in-observational-studies 2021-02-17T07:27:50 https://maestrodatabase.com/blog/fda-grants-sotorasib-priority-review-designation-for-the-treatment-of-patients-with-kras-g12c-mutated-locally-advanced-or-metastatic-non-small-cell-lung-cancer 2021-02-17T02:18:19 https://maestrodatabase.com/blog/fda-approves-first-in-the-world-first-of-its-kind-implant-for-the-treatment-of-rare-bone-disease-as-a-humanitarian-use-device 2021-02-17T19:57:44 https://maestrodatabase.com/blog/beigene-announces-u-dot-s-fda-acceptance-of-supplemental-new-drug-application-for-brukinsa-zanubrutinib-in-waldenstroems-macroglobulinaemia 2021-02-17T20:06:28 https://maestrodatabase.com/blog/life-sciences-leaders-unite-to-condemn-radical-plans-to-rewrite-medicines-scheme 2023-10-12T03:57:07 https://maestrodatabase.com/blog/european-commission-approves-tremfya-guselkumab-for-the-treatment-of-moderate-to-severe-plaque-psoriasis-in-the-european-union 2017-11-24T01:14:24 https://maestrodatabase.com/blog/verrica-pharmaceuticals-announces-fda-filing-acceptance-of-resubmitted-new-drug-application-for-vp-102-for-the-treatment-of-molluscum-contagiosum 2021-02-17T20:10:46 https://maestrodatabase.com/blog/covid-19-vaccine-approval-process-does-it-take-too-long 2021-02-17T07:41:11 https://maestrodatabase.com/blog/bluebird-bio-baffled-after-nice-rejects-beta-thalassaemia-gene-therapy 2021-02-17T09:21:43 https://maestrodatabase.com/blog/european-commission-approves-roches-mabthera-rituximab-for-a-rare-auto-immune-disease 2019-03-16T02:36:17 https://maestrodatabase.com/blog/supplier-of-expensive-cystic-fibrosis-medication-yet-to-apply-for-pharmac-approval 2021-02-17T19:54:05 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-publishes-revised-protocol-for-assessing-unsupported-price-increases-for-prescription-drugs 2019-03-16T00:53:06 https://maestrodatabase.com/blog/fda-accepts-new-drug-application-for-vx-445-elexacaftor-tezacaftor-and-ivacaftor-combination-treatment 2019-08-20T12:42:48 https://maestrodatabase.com/blog/pda-slash-fda-biosimilars-conference---26-27-june-2017 2017-05-08T10:34:04 https://maestrodatabase.com/blog/south-rampart-pharma-receives-us-fda-fast-track-designation-for-srp-001-for-acute-pain 2023-10-12T11:57:20 https://maestrodatabase.com/blog/congress-moves-toward-reforming-fda-accelerated-approvals-but-with-pharma-friendly-concessions 2022-05-06T12:09:16 https://maestrodatabase.com/blog/a-republican-principle-is-shed-in-the-fight-on-health-care 2017-05-08T10:17:46 https://maestrodatabase.com/blog/a-drug-maker-replaces-an-old-treatment-and-boosts-the-price-by-1-300-percent 2019-08-20T11:59:13 https://maestrodatabase.com/blog/lupin-responds-to-nice-appraisal-consultation-document-on-namuscla-mexiletine-to-treat-symptomatic-myotonia-in-adults-with-non-dystrophic-myotonic-disorders 2021-02-17T20:23:36 https://maestrodatabase.com/blog/incorporating-real-option-value-in-valuing-innovation-a-way-forward 2024-07-12T06:53:05 https://maestrodatabase.com/blog/obama-missed-opportunity-to-address-drug-costs-in-obamacare 2019-03-16T02:46:36 https://maestrodatabase.com/blog/patient-reported-outcome-assessment-must-be-inclusive-and-equitable 2022-05-06T12:03:49 https://maestrodatabase.com/blog/alvotech-provides-update-on-status-of-us-biologics-license-application-for-avt04 2023-10-12T11:39:14 https://maestrodatabase.com/blog/updated-agenda-for-the-july-2022-pbac-meeting 2022-05-06T08:14:43 https://maestrodatabase.com/blog/life-saving-cancer-treatments-could-help-41-000-aussies-but-they-arent-funded 2019-08-20T21:05:13 https://maestrodatabase.com/blog/a-check-up-on-canadas-health-care-system 2017-11-24T10:34:01 https://maestrodatabase.com/blog/private-health-insurance-woes-escalate-as-premiums-out-of-pocket-costs-rise 2019-08-20T21:01:15 https://maestrodatabase.com/blog/women-with-advanced-breast-cancer-ask-the-pm-to-intervene 2019-03-16T02:48:55 https://maestrodatabase.com/blog/eiger-announces-fda-breakthrough-therapy-designation-for-peginterferon-lambda-for-treatment-of-hepatitis-delta-virus-infection 2019-08-20T12:51:29 https://maestrodatabase.com/blog/law-makers-want-to-lower-drug-prices-their-plan-would-end-up-harming-patients 2019-08-20T21:18:44 https://maestrodatabase.com/blog/the-first-als-drug-in-22-years-is-approved----and-it-costs-4-times-what-it-does-in-japan 2017-05-08T18:25:27 https://maestrodatabase.com/blog/brand-name-drug-prices-rising-at-slower-pace-lower-amounts 2019-08-20T21:15:57 https://maestrodatabase.com/blog/smc---may-2017-decisions 2017-05-08T13:57:05 https://maestrodatabase.com/blog/involving-patients-in-discussions-on-benefits-and-risks-of-medicines 2017-05-08T18:32:27 https://maestrodatabase.com/blog/european-commission-approves-expanded-label-for-kaftrio-in-combination-with-ivacaftor-for-people-with-cystic-fibrosis 2025-04-08T02:03:16 https://maestrodatabase.com/blog/ousted-novartis-scientist-categorically-denies-wrongdoing-in-data-manipulation-scandal 2019-08-20T21:10:55 https://maestrodatabase.com/blog/nices-track-record-in-cancer-drugs-the-impact-of-the-cdf-and-interim-funding 2019-08-20T21:45:55 https://maestrodatabase.com/blog/updated-agenda-for-the-november-2021-pbac-meeting 2021-09-02T04:50:42 https://maestrodatabase.com/blog/china-adds-148-drugs-to-key-insurance-list 2019-08-20T21:42:00 https://maestrodatabase.com/blog/as-some-republicans-rush-to-defend-house-health-bill-senate-gop-warily-pauses 2017-05-08T18:37:52 https://maestrodatabase.com/blog/moderna-announces-submission-of-initial-data-to-us-fda-for-its-covid-19-vaccine-booster 2021-09-02T05:10:30 https://maestrodatabase.com/blog/teva-launches-generic-version-of-epipen-for-young-children 2019-08-20T21:31:58 https://maestrodatabase.com/blog/ptc-therapeutics-dmd-drug-emflaza-to-cost-35-000-dollars-a-year-and-launch-within-the-coming-weeks 2017-05-08T21:41:55 https://maestrodatabase.com/blog/mallinckrodt-initiates-rolling-submission-of-new-drug-application-to-the-u-dot-s-fda-for-terlipressin-for-the-treatment-of-patients-with-hepatorenal-syndrome-type-1 2020-03-03T05:57:56 https://maestrodatabase.com/blog/mimivax-granted-fast-track-designation-from-fda-for-survaxm-for-newly-diagnosed-glioblastoma 2023-10-12T19:45:03 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-2-september-2021 2021-09-02T04:36:41 https://maestrodatabase.com/blog/novartis-delayed-reveal-of-bad-data-for-2-dollars-1-cents-million-gene-therapy-now-patients-and-pharma-suffer 2019-08-20T21:53:42 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-posts-draft-scoping-document-on-treatments-for-tardive-dyskinesia-including-recently-approved-ingrezza 2017-05-08T21:30:12 https://maestrodatabase.com/blog/teva-announces-fda-filing-acceptance-for-ajovy-fremanezumab-in-paediatric-episodic-migraine-prevention 2025-04-08T03:19:27 https://maestrodatabase.com/blog/patient-voice-prompts-new-medicines-funding 2017-05-09T05:56:38 https://maestrodatabase.com/blog/health-economic-assessment-of-the-gene-therapy-hemgenix-in-severe-and-moderate-haemophilia-b 2023-10-12T20:45:01 https://maestrodatabase.com/blog/statement-from-fda-commissioner-and-director-of-the-center-for-devices-and-radiological-health-on-efforts-to-evaluate-materials-in-medical-devices-to-address-potential-safety-questions 2019-03-17T00:48:01 https://maestrodatabase.com/blog/toward-a-strategy-to-involve-patients-in-health-technology-assessment-in-spain 2019-03-17T01:09:07 https://maestrodatabase.com/blog/jamp-pharma-group-receives-health-canada-approval-for-jamp-sitagliptin-a-new-generic-alternative-for-the-treatment-of-type-2-diabetes 2023-01-08T23:54:23 https://maestrodatabase.com/blog/have-you-got-insurance-the-us-style-question-finding-its-way-to-australian-hospitals 2019-03-17T00:54:01 https://maestrodatabase.com/blog/on-the-use-of-list-prices-in-drug-pricing-research 2019-03-17T00:57:27 https://maestrodatabase.com/blog/axsome-therapeutics-receives-fda-fast-track-designation-for-axs-05-for-alzheimers-disease-agitation 2017-05-09T06:34:38 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-to-xylocor-therapeutics-lead-candidate-xc001 2017-05-09T06:40:10 https://maestrodatabase.com/blog/new-iron-treatment-funded-for-people-who-have-experienced-serious-reactions 2026-02-17T07:07:06 https://maestrodatabase.com/blog/strategic-agreement-between-the-innovative-pharmaceutical-industry-and-government-delivers-certainty-for-industry-savings-to-taxpayers-and-benefits-to-patients 2017-05-09T17:43:28 https://maestrodatabase.com/blog/novartis-receives-fda-approval-for-first-of-its-kind-kisqali-femara-co-pack-for-initial-treatment-of-hr-plus-slash-her2--advanced-or-metastatic-breast-cancer 2017-05-09T06:49:59 https://maestrodatabase.com/blog/fda-limits-use-of-janssen-covid-19-vaccine-to-certain-individuals 2022-05-07T01:55:15 https://maestrodatabase.com/blog/axonics-receives-fda-approval-for-third-generation-implantable-neurostimulator 2021-02-17T22:59:15 https://maestrodatabase.com/blog/budget-2017-pbs-shake-up-to-cut-cost-of-drugs 2017-05-09T17:51:41 https://maestrodatabase.com/blog/budget-recognises-the-vital-role-of-community-pharmacy 2017-05-09T17:46:51 https://maestrodatabase.com/blog/cancer-sufferer-pushes-for-life-changing-drug-palbociclib-to-be-subsidised-in-australia 2017-05-09T17:56:07 https://maestrodatabase.com/blog/mcconnell-obamacare-replacement-bill-will-not-be-quick 2017-05-09T18:07:48 https://maestrodatabase.com/blog/federal-budget-2017-medicare-rebates-to-increase-as-part-of-10-dollars-billion-healthcare 2017-05-09T18:03:14 https://maestrodatabase.com/blog/therapeuticsmd-receives-complete-response-letter-from-fda-for-tx-004hr-new-drug-application 2017-05-09T18:10:11 https://maestrodatabase.com/blog/sanofi-pricing-principles-for-the-u-dot-s 2017-05-09T18:19:49 https://maestrodatabase.com/blog/ecdc-and-ema-highlight-considerations-for-additional-and-booster-doses-of-covid-19-vaccines 2021-09-02T09:56:13 https://maestrodatabase.com/blog/express-scripts-to-offer-cheaper-drugs-for-uninsured-customers 2017-05-09T18:17:05 https://maestrodatabase.com/blog/cipher-pharmaceuticals-receives-health-canada-approval-of-ozanex-ozenoxacin-1-percent-cream 2017-05-09T18:46:53 https://maestrodatabase.com/blog/new-safety-risks-detected-in-one-third-of-fda-approved-drugs 2017-05-10T05:29:31 https://maestrodatabase.com/blog/pan-canadian-oncology-drug-review-recommendation-supports-the-use-of-tagrisso-osimertinib-as-the-standard-of-care-for-t790m-mutated-non-small-cell-lung-cancer 2017-05-09T18:51:44 https://maestrodatabase.com/blog/senate-confirms-trumps-pick-for-fda 2017-05-10T05:35:22 https://maestrodatabase.com/blog/mtpconnect-welcomes-2017-budget-investment-in-mtp-research-translation-and-commercialisation 2017-05-10T05:31:59 https://maestrodatabase.com/blog/cancer-drug-pricing-the-truth-and-the-rhetoric 2017-05-10T05:40:18 https://maestrodatabase.com/blog/push-to-cut-cancer-drug-cost 2017-05-10T05:43:56 https://maestrodatabase.com/blog/fda-to-hold-advisory-committee-meeting-to-discuss-pfizer-biontechs-application-for-covid-19-booster 2021-09-02T20:47:54 https://maestrodatabase.com/blog/fda-approves-rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-as-the-only-egfr-targeted-therapy-that-can-be-administered-once-a-month 2026-02-17T20:08:11 https://maestrodatabase.com/blog/fda-grants-bavencio-avelumab-approval-for-a-common-type-of-advanced-bladder-cancer 2017-05-10T05:49:59 https://maestrodatabase.com/blog/nhs-to-reimburse-hemlibra 2019-08-21T10:39:35 https://maestrodatabase.com/blog/exdensur-depemokimab-approved-by-the-european-commission-for-severe-asthma-with-type-2-inflammation-and-chronic-rhinosinusitis-with-nasal-polyps 2026-02-17T20:17:45 https://maestrodatabase.com/blog/provincial-drug-plans-including-ontario-and-bc-make-entyvio-vedolizumab-available-to-treat-inflammatory-bowel-disease 2017-05-10T06:01:14 https://maestrodatabase.com/blog/car-t-therapy-kymriah-fails-to-get-insurance-benefits 2021-09-02T11:43:24 https://maestrodatabase.com/blog/novartis-heart-failure-treatment-entresto-sacubitril-slash-valsartan-now-available-to-patients-in-ontario-through-the-public-provincial-drug-plan 2017-05-10T06:05:43 https://maestrodatabase.com/blog/fda-reaches-milestone-in-competitive-generic-therapy-drug-approvals 2021-09-02T21:14:04 https://maestrodatabase.com/blog/scottish-medicines-consortium-approves-santheras-raxone-idebenone-for-restricted-use-in-patients-with-lhon-within-nhs-scotland 2017-05-10T06:11:57 https://maestrodatabase.com/blog/pfizers-acromegaly-treatment-receives-reimbursement 2021-09-02T21:06:33 https://maestrodatabase.com/blog/hepatitis-c-drug-could-avert-liver-transplants---doctors 2017-05-10T06:18:56 https://maestrodatabase.com/blog/house-committees-demand-fda-records-on-alzheimers-drug-approval 2021-09-02T21:22:50 https://maestrodatabase.com/blog/vueway-gadopiclenol-receives-positive-chmp-opinion 2023-10-13T01:32:41 https://maestrodatabase.com/blog/us-fda-accepts-bristol-myers-squibbs-new-drug-application-for-iberdomide-in-patients-with-relapsed-or-refractory-multiple-myeloma 2026-02-17T19:56:36 https://maestrodatabase.com/blog/cassiopea-announces-fda-submission-of-new-drug-application-for-clascoterone-1-percent-cream-the-first-new-mechanism-of-action-for-acne-in-nearly-40-years 2019-08-21T11:28:36 https://maestrodatabase.com/blog/natco-pharma-canada-announces-the-launch-of-nat-lenalidomide-capsules-the-first-generic-alternative-to-revlimid 2021-09-02T20:57:26 https://maestrodatabase.com/blog/the-european-commission-approves-more-effective-dose-of-injectable-wegovy-for-adults-with-obesity-clinical-study-showed-people-lost-about-21-percent-of-their-body-weight-on-average 2026-02-17T20:01:45 https://maestrodatabase.com/blog/political-preoccupation-with-prescription-drug-costs-may-distract-from-larger-problem-of-hospital-costs 2021-09-02T21:02:37 https://maestrodatabase.com/blog/fda-on-novartis-data-manipulation-controversy-we-happened-to-be-lucky 2019-08-21T12:26:07 https://maestrodatabase.com/blog/get-it-done-we-need-it-trumps-coronavirus-message-to-big-pharma 2020-03-03T07:36:20 https://maestrodatabase.com/blog/ptac-continues-to-find-new-ways-to-reject-funding-applications-part-1 2019-08-21T11:55:17 https://maestrodatabase.com/blog/nices-fast-track-catapults-skyrizi-into-market 2019-08-21T11:42:27 https://maestrodatabase.com/blog/cerecor-receives-fast-track-designation-from-fda-for-cerc-802-for-the-treatment-of-mannose-phosphate-isomerase-deficiency 2019-08-21T13:04:42 https://maestrodatabase.com/blog/a-collaborative-pilot-on-current-awareness-alerts-for-disinvestment-and-horizon-scanning 2021-09-02T21:28:37 https://maestrodatabase.com/blog/cadth-publishes-initial-perc-recommendation-for-roches-alectinib-hydrochloride 2018-07-08T21:29:06 https://maestrodatabase.com/blog/chinese-stealing-health-and-medical-research-data-report 2019-08-21T12:59:43 https://maestrodatabase.com/blog/what-1-april-2019-private-health-insurance-changes-mean-for-you 2019-03-17T19:59:36 https://maestrodatabase.com/blog/heres-what-can-go-wrong-when-you-shop-in-mexico-and-canada-for-cheap-drugs 2019-08-21T12:49:49 https://maestrodatabase.com/blog/ultragenyx-announces-approval-of-dojolvi-ux007-slash-triheptanoin-in-canada-for-the-treatment-of-long-chain-fatty-acid-oxidation-disorders-in-adults-and-children 2021-02-18T01:17:01 https://maestrodatabase.com/blog/prescription-drug-prices-are-out-of-control 2019-03-17T20:05:52 https://maestrodatabase.com/blog/sebela-pharmaceuticals-announces-fda-approval-of-pizensy-for-oral-solution-for-the-treatment-of-chronic-idiopathic-constipation-in-adults 2020-03-03T07:49:10 https://maestrodatabase.com/blog/patients-in-the-netherlands-wait-1-dot-5-years-for-access-to-new-medicines 2021-09-02T21:34:17 https://maestrodatabase.com/blog/act-cancer-patients-have-been-slugged-with-an-unfair-fee-until-now 2018-07-08T21:17:05 https://maestrodatabase.com/blog/meningococcal-b-survivors-push-government-for-free-vaccine 2019-08-21T21:04:28 https://maestrodatabase.com/blog/remove-rugs-from-aged-care-to-reduce-health-insurance-costs-report-says 2019-08-26T21:46:55 https://maestrodatabase.com/blog/icer-proposes-updates-to-2020-value-assessment-framework-methods-and-procedures 2019-08-21T20:53:25 https://maestrodatabase.com/blog/acrotech-biopharma-announces-fda-approval-of-adquey-difamilast-1-percent-ointment-for-the-treatment-of-mild-to-moderate-atopic-dermatitis 2026-02-17T20:58:31 https://maestrodatabase.com/blog/appealing-court-ruling-trump-administration-renews-fight-to-require-drug-prices-in-tv-ads 2019-08-21T21:13:23 https://maestrodatabase.com/blog/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of-adults-with-giant-cell-arteritis 2025-04-08T06:13:13 https://maestrodatabase.com/blog/former-fda-commissioners-seek-to-expand-use-of-rwe-in-regulatory-payment-decisions 2019-08-21T21:10:00 https://maestrodatabase.com/blog/supreme-court-to-hear-obamacare-appeal 2020-03-03T09:06:53 https://maestrodatabase.com/blog/strategic-collaboration-announced-by-nice-and-health-technology-wales 2020-03-03T11:08:33 https://maestrodatabase.com/blog/beigene-announces-u-dot-s-fda-acceptance-and-grant-of-priority-review-for-its-new-drug-application-of-zanubrutinib-in-patients-with-relapsed-slash-refractory-mantle-cell-lymphoma 2019-08-21T21:49:17 https://maestrodatabase.com/blog/show-me-the-money 2019-08-21T21:19:48 https://maestrodatabase.com/blog/empirical-evidence-supports-critics-of-patented-medicine-prices-review-board-regulations 2019-08-21T21:15:50 https://maestrodatabase.com/blog/the-coronavirus-could-help-pharma-reset-its-reputation-in-washington 2020-03-03T19:58:20 https://maestrodatabase.com/blog/notification-of-dates-for-entecavir-brand-switch 2018-07-08T23:15:56 https://maestrodatabase.com/blog/fda-grants-breakthrough-therapy-designation-for-genentechs-esbriet-pirfenidone-in-unclassifiable-interstitial-lung-disease 2020-03-03T11:19:13 https://maestrodatabase.com/blog/rising-prices-of-targeted-oral-anti-cancer-medications-and-associated-financial-burden-on-medicare-beneficiaries 2017-08-02T12:08:55 https://maestrodatabase.com/blog/2024-medicare-parts-a-and-b-premiums-and-deductibles 2023-10-13T03:31:08 https://maestrodatabase.com/blog/fda-grants-rare-paediatric-disease-designation-to-stealth-biotherapeutics-for-elamipretide-for-the-treatment-of-barth-syndrome 2020-03-03T20:09:29 https://maestrodatabase.com/blog/no-free-kicks-from-government-for-health-care-industry-says-primary-health-boss 2017-11-25T02:33:26 https://maestrodatabase.com/blog/progress-on-science-medicines-and-health 2017-05-10T09:32:49 https://maestrodatabase.com/blog/icer-to-postpone-assessment-of-gene-therapy-for-beta-thalassemia 2020-03-03T20:01:04 https://maestrodatabase.com/blog/eu-ombudsman-confirms-emas-correct-handling-of-declared-interests 2017-11-25T02:24:37 https://maestrodatabase.com/blog/reflections-on-the-nice-decision-to-reject-patient-production-losses 2017-11-25T02:37:43 https://maestrodatabase.com/blog/ayala-pharmaceuticals-granted-u-dot-s-fda-fast-track-designation-for-al101-for-the-treatment-of-recurrent-or-metastatic-adenoid-cystic-carcinoma 2020-03-03T20:16:26 https://maestrodatabase.com/blog/u-dot-s-fda-grants-xtandi-enzalutamide-application-priority-review-for-the-treatment-of-men-with-metastatic-hormone-sensitive-prostate-cancer 2019-08-22T02:08:55 https://maestrodatabase.com/blog/datroway-approved-in-the-eu-for-patients-with-previously-treated-metastatic-hr-positive-her2-negative-breast-cancer 2025-04-08T06:33:55 https://maestrodatabase.com/blog/health-canada-approves-keytruda-sc-a-subcutaneous-formulation-of-pembrolizumab-across-multiple-cancer-indications 2026-02-18T01:52:49 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-to-9mw2821-for-the-treatment-of-patients-with-locally-advanced-or-metastatic-nectin-4-positive-tnbc 2024-07-13T00:36:54 https://maestrodatabase.com/blog/biosimilar-drug-poses-new-test-for-medicare-price-negotiations 2026-02-18T02:57:03 https://maestrodatabase.com/blog/deciphera-pharmaceuticals-announces-us-fda-acceptance-for-filing-of-new-drug-application-for-tirabrutinib-in-patients-with-relapsed-or-refractory-pcnsl 2026-02-18T05:21:15 https://maestrodatabase.com/blog/myovant-and-pfizer-provide-update-on-supplemental-new-drug-application-for-myfembree-for-the-management-of-moderate-to-severe-pain-associated-with-endometriosis 2022-05-08T02:20:50 https://maestrodatabase.com/blog/mundipharma-announces-the-licence-extension-submission-for-invokana-canagliflozin-and-vokanamet-canagliflozin-and-metformin-to-the-european-medicines-agency 2019-08-22T02:39:51 https://maestrodatabase.com/blog/supporting-innovation-in-medicaid-policy---interventions-to-increase-adoption-of-rcts 2022-05-08T01:55:06 https://maestrodatabase.com/blog/nice-recommends-first-ever-disease-modifying-treatment-for-arg1-deficiency 2026-02-18T01:06:36 https://maestrodatabase.com/blog/abbvie-submits-regulatory-applications-to-fda-and-ema-for-upadacitinib-rinvoq-in-giant-cell-arteritis 2024-07-13T01:01:11 https://maestrodatabase.com/blog/cytokinetics-announces-european-commission-approval-of-myqorzo-aficamten-for-the-treatment-of-adults-with-symptomatic-obstructive-hypertrophic-cardiomyopathy 2026-02-18T01:12:51 https://maestrodatabase.com/blog/nhs-rolls-out-life-saving-arthritis-drug-to-treat-covid 2022-05-08T12:03:25 https://maestrodatabase.com/blog/telix-submits-european-marketing-authorisation-application-for-tlx101-px-for-brain-cancer-imaging 2026-02-18T01:19:21 https://maestrodatabase.com/blog/pharmac-proposes-funding-new-treatments-that-could-transform-early-care-for-people-with-chronic-lymphocytic-leukaemia-a-type-of-blood-cancer 2026-02-18T01:24:52 https://maestrodatabase.com/blog/astellas-and-seagen-announce-submission-of-two-supplemental-biologics-license-applications-to-the-u-dot-s-fda-for-padcev-enfortumab-vedotin-ejfv-in-locally-advanced-or-metastatic-urothelial-cancer 2021-02-18T19:43:22 https://maestrodatabase.com/blog/states-still-cant-import-drugs-from-canada-now-many-are-seeking-to-import-canadian-prices 2021-02-18T19:50:16 https://maestrodatabase.com/blog/outcomes-of-the-september-2023-pbac-intracycle-meeting 2023-10-13T05:58:25 https://maestrodatabase.com/blog/novartis-gets-fda-fast-track-designation-for-lna043-in-knee-osteoarthritis 2021-09-02T23:35:57 https://maestrodatabase.com/blog/pfizer-and-biontech-to-supply-the-european-union-with-200-million-additional-doses-of-cominarty 2021-02-18T09:58:10 https://maestrodatabase.com/blog/fate-of-a-lifesaving-drug-in-colorado-is-in-the-hands-of-a-state-board-that-parents-say-is-ignoring-their-pleas-for-help 2023-10-13T04:27:45 https://maestrodatabase.com/blog/wearable-technology-promises-to-revolutionise-health-care 2022-05-08T21:26:21 https://maestrodatabase.com/blog/johnson-and-johnson-has-only-a-few-million-covid-19-vaccine-doses-in-stock-as-likely-launch-nears 2021-02-18T20:07:39 https://maestrodatabase.com/blog/santhera-and-reveragen-announce-fda-acceptance-of-new-drug-application-for-vamorolone-in-duchenne-muscular-dystrophy 2023-01-09T18:58:22 https://maestrodatabase.com/blog/fresenius-kabi-canada-launches-idacio-adalimumab-injection-a-biosimilar-to-humira-adalimumab-for-the-treatment-of-multiple-chronic-inflammatory-conditions 2021-02-18T20:16:05 https://maestrodatabase.com/blog/coherus-bla-filing-for-adalimumab-biosimilar-candidate-accepted-by-fda-for-review 2021-02-18T20:20:46 https://maestrodatabase.com/blog/the-one-two-punch-to-knock-out-high-drug-prices 2021-02-18T19:54:42 https://maestrodatabase.com/blog/astellas-receives-positive-chmp-opinion-for-veoza-fezolinetant 2023-10-13T12:31:28 https://maestrodatabase.com/blog/hls-therapeutics-provides-update-on-private-and-public-payer-reimbursement-for-vascepa 2021-02-18T19:57:32 https://maestrodatabase.com/blog/time-to-throw-in-the-towel-on-biosimilars 2019-08-22T05:19:33 https://maestrodatabase.com/blog/initial-towns-suburbs-and-hubs-for-covid-19-vaccine 2021-02-18T20:03:03 https://maestrodatabase.com/blog/us-fda-approves-pfizers-velspity-for-adults-with-moderately-to-severely-active-ulcerative-colitis 2023-10-13T20:17:16 https://maestrodatabase.com/blog/harmony-biosciences-receives-us-fda-approval-for-wakix-pitolisant-for-the-treatment-of-cataplexy-in-paediatric-narcolepsy 2026-02-18T19:48:21 https://maestrodatabase.com/blog/a-sixth-of-australias-vaccine-supply-at-risk-due-to-syringe-shortage 2021-02-18T20:37:12 https://maestrodatabase.com/blog/health-canada-approves-tagrisso-with-the-addition-of-chemotherapy-for-patients-with-egfr-mutated-advanced-lung-cancer 2024-07-13T02:03:34 https://maestrodatabase.com/blog/tga-grants-provisional-approval-to-gilead-sciences-to-extend-the-use-of-the-covid-19-treatment-veklury-remdesivir 2022-05-09T06:52:59 https://maestrodatabase.com/blog/new-treatment-option-for-heavily-pre-treated-multiple-myeloma-patients 2023-10-13T20:14:06 https://maestrodatabase.com/blog/how-to-avoid-giving-the-right-answers-to-the-wrong-questions-the-need-for-integrated-assessments-of-complex-health-technologies 2017-11-25T21:35:07 https://maestrodatabase.com/blog/abpi-position-on-us-trade-deal-and-medicines-pricing 2019-08-22T05:50:14 https://maestrodatabase.com/blog/viatris-launches-hulio-adalimumab-biosimilar-in-canada 2021-02-18T20:26:50 https://maestrodatabase.com/blog/health-economic-assessment-of-blenrep-in-the-treatment-of-multiple-myeloma 2022-05-09T21:19:35 https://maestrodatabase.com/blog/smc---may-2022-decisions 2022-05-09T21:12:54 https://maestrodatabase.com/blog/the-center-for-medicare-and-medicaid-innovation---toward-value-based-care 2022-05-09T21:22:50 https://maestrodatabase.com/blog/additive-orthopaedics-announces-fda-approval-of-patient-specific-talus-spacer-first-approved-in-the-u-dot-s 2021-02-18T20:45:43 https://maestrodatabase.com/blog/product-information-update-for-covid-19-treatment-xevudy-sotrovimab 2022-05-09T10:54:56 https://maestrodatabase.com/blog/sandoz-receives-us-fda-approval-to-expand-enzeevu-aflibercept-abzv-label-for-multiple-retinal-indications 2026-02-18T06:49:30 https://maestrodatabase.com/blog/choices-that-fail-health-and-wellbeing 2022-05-09T07:34:57 https://maestrodatabase.com/blog/krystal-biotech-announces-fdas-3-month-extension-of-bla-pdufa-date-and-regulatory-update-for-b-vec-to-treat-patients-with-dystrophic-epidermolysis-bullosa 2023-01-09T19:17:56 https://maestrodatabase.com/blog/next-health-minister-must-restart-the-national-medicines-policy-review 2022-05-09T21:03:39 https://maestrodatabase.com/blog/kura-oncology-and-kyowa-kirin-announce-submission-of-new-drug-application-for-ziftomenib-to-fda 2025-04-08T23:23:18 https://maestrodatabase.com/blog/fda-approves-nivolumab-with-ipilimumab-for-unresectable-or-metastatic-msi-h-or-dmmr-colorectal-cancer 2025-04-09T00:38:18 https://maestrodatabase.com/blog/fda-approves-mercks-keytruda-pembrolizumab-as-first-line-combination-therapy-with-pemetrexed-and-carboplatin-for-patients-with-metastatic-non-squamous-non-small-cell-lung-cancer-irrespective-of-pd-l1-expression 2017-05-11T03:58:02 https://maestrodatabase.com/blog/health-economic-assessment-of-abecma-in-the-treatment-of-multiple-myeloma 2022-05-09T21:35:29 https://maestrodatabase.com/blog/moderna-receives-european-commission-marketing-authorisation-for-covid-19-vaccine-mnexspike 2026-02-18T20:46:28 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-posts-briefing-paper-on-assessing-the-value-of-drugs-for-rare-conditions 2017-05-11T04:08:24 https://maestrodatabase.com/blog/opticyte-earns-fda-breakthrough-device-designation-for-the-first-cell-o2-patient-monitor-for-organ-failure 2023-01-09T20:06:19 https://maestrodatabase.com/blog/efficient-trial-design----fda-approval-of-valbenazine-for-tardive-dyskinesia 2017-05-11T04:18:17 https://maestrodatabase.com/blog/us-fda-issues-a-crl-for-the-biologics-license-application-for-insulin-r 2023-01-09T20:10:58 https://maestrodatabase.com/blog/the-fda-has-approved-a-crazy-number-of-new-and-groundbreaking-drugs-this-year 2017-05-11T04:28:33 https://maestrodatabase.com/blog/european-commission-approves-the-only-immunotherapy-for-high-risk-neuroblastoma-bringing-hope-to-thousands-of-children-affected-by-a-rare-and-devastating-form-of-cancer 2017-05-11T05:30:07 https://maestrodatabase.com/blog/european-commission-grants-approval-for-mercks-new-pergoveris-pen-for-fertility-treatment 2017-05-11T05:41:49 https://maestrodatabase.com/blog/ema-launches-second-communication-perception-survey 2017-05-11T13:24:28 https://maestrodatabase.com/blog/nice-publishes-second-appraisal-consultation-document-for-venetoclax 2017-05-11T13:28:30 https://maestrodatabase.com/blog/billions-saved-because-fda-didnt-rush-approval-of-alzheimers-drug 2017-05-11T13:43:37 https://maestrodatabase.com/blog/cbo-will-finally-score-house-obamacare-bill-early-in-week-of-may-22 2017-05-11T13:40:47 https://maestrodatabase.com/blog/mylan-disagrees-with-fda-over-generic-advair-delay 2017-05-11T13:47:06 https://maestrodatabase.com/blog/aetna-is-the-latest-health-insurer-to-quit-obamacare-markets 2017-05-11T13:52:33 https://maestrodatabase.com/blog/moderna-announces-the-us-fda-will-initiate-the-review-of-its-investigational-seasonal-influenza-vaccine-submission 2026-02-18T20:54:29 https://maestrodatabase.com/blog/icer-identifies-most-significant-2019-us-drug-price-hikes----even-after-rebates----that-were-not-supported-by-new-clinical-evidence 2021-01-12T19:51:07 https://maestrodatabase.com/blog/uk-patients-get-early-access-to-abbvies-hepatitis-regimen 2017-05-11T21:51:04 https://maestrodatabase.com/blog/gsk-escapes-advair-hit-for-now-as-second-generic-bid-fails 2017-05-11T21:56:33 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-for-priority-review-the-biologics-license-application-for-v114-mercks-investigational-15-valent-pneumococcal-conjugate-vaccine-for-use-in-adults-18-years-of-age-and-older 2021-01-12T20:10:48 https://maestrodatabase.com/blog/urgent-review-needed-into-private-health-insurance-system-apra 2020-02-04T06:23:16 https://maestrodatabase.com/blog/dbv-technologies-provides-update-on-regulatory-status-of-viaskin-peanut-for-the-treatment-of-peanut-allergic-children-4-to-11-years-of-age 2019-02-14T02:24:26 https://maestrodatabase.com/blog/chinas-first-trastuzumab-biosimilar-approved-by-nmpa 2020-08-18T10:52:40 https://maestrodatabase.com/blog/u-dot-s-fda-grants-priority-review-to-new-drug-application-for-finerenone-to-treat-patients-with-chronic-kidney-disease-and-type-2-diabetes-mellitus 2021-01-12T19:56:44 https://maestrodatabase.com/blog/novartis-receives-fda-approval-for-egaten-for-the-treatment-of-fascioliasis-a-neglected-tropical-disease 2019-02-14T01:46:39 https://maestrodatabase.com/blog/gw-pharmaceuticals-and-greenwich-biosciences-submit-supplemental-new-drug-application-to-u-dot-s-fda-for-epidiolex-cannabidiol-for-the-treatment-of-tuberous-sclerosis-complex 2020-02-04T04:56:29 https://maestrodatabase.com/blog/imfinzi-granted-fda-priority-review-for-less-frequent-fixed-dose-use 2020-08-18T10:56:17 https://maestrodatabase.com/blog/middlemen-sue-to-block-a-signature-trump-drug-pricing-proposal 2021-01-12T20:18:58 https://maestrodatabase.com/blog/start-rwe-structured-template-for-planning-and-reporting-on-the-implementation-of-real-world-evidence-studies 2021-01-12T20:35:39 https://maestrodatabase.com/blog/further-insights-from-the-agenda-for-the-2021-slash-1-pbac-meeting 2021-01-12T20:38:58 https://maestrodatabase.com/blog/reference-committee-for-the-health-technology-assessment-policy-and-methods-review 2022-10-27T02:21:28 https://maestrodatabase.com/blog/rationing-of-health-care-in-the-united-states-an-inevitable-consequence-of-increasing-health-care-costs 2019-02-14T03:06:41 https://maestrodatabase.com/blog/new-year-relief-with-cheaper-medicines-1800medicare-and-more-mental-health-support 2026-01-02T03:30:37 https://maestrodatabase.com/blog/harmony-biosciences-announces-file-acceptance-of-its-new-drug-application-for-pitolisant 2019-02-14T03:58:01 https://maestrodatabase.com/blog/universal-medicine-access-through-lump-sum-remuneration----australias-approach-to-hepatitis-c 2019-02-14T05:22:55 https://maestrodatabase.com/blog/fda-approves-blinatumomab-as-consolidation-for-cd19-positive-philadelphia-chromosome-negative-b-cell-precursor-acute-lymphoblastic-leukaemia 2024-06-14T22:43:08 https://maestrodatabase.com/blog/eisai-submits-application-in-europe-seeking-approval-for-fycompa-as-treatment-for-paediatric-patients-with-epilepsy 2019-02-14T04:07:46 https://maestrodatabase.com/blog/health-technology-assessment-review-reference-committee-will-drive-reform-to-support-australian-patients 2022-04-10T09:41:04 https://maestrodatabase.com/blog/germany-agrees-on-new-pharmaceutical-bill 2019-02-14T06:11:50 https://maestrodatabase.com/blog/sensing-an-advantage-democrats-dare-trump-to-talk-drug-prices-during-state-of-the-union 2020-02-04T10:21:42 https://maestrodatabase.com/blog/eu-flags-are-up-in-emas-new-building-in-amsterdam 2020-02-04T08:22:47 https://maestrodatabase.com/blog/oia-responses-exploring-ways-to-publish-them 2019-02-14T05:27:30 https://maestrodatabase.com/blog/fda-approves-durvalumab-with-chemotherapy-for-mismatch-repair-deficient-primary-advanced-or-recurrent-endometrial-cancer 2024-06-14T22:16:52 https://maestrodatabase.com/blog/the-inflation-reduction-act-will-lead-to-fewer-new-medicines 2023-09-12T06:36:02 https://maestrodatabase.com/blog/new-weight-loss-pill-launched-in-australia 2019-02-14T19:45:04 https://maestrodatabase.com/blog/motif-bio-receives-complete-response-letter-from-the-fda 2019-02-14T20:01:01 https://maestrodatabase.com/blog/the-blame-game-on-drug-prices-is-getting-dangerous 2017-04-09T20:57:28 https://maestrodatabase.com/blog/med-techs-propose-new-prostheses-price-model 2017-04-09T20:54:07 https://maestrodatabase.com/blog/questions-over-nhmrc-cancer-funding-model-as-top-killers-low-on-list 2017-04-09T21:03:47 https://maestrodatabase.com/blog/nice-provides-first-scientific-advice-on-patient-preference-study-design 2019-02-14T19:52:05 https://maestrodatabase.com/blog/interferon-kaletra-to-get-insurance-benefit-for-new-coronavirus-treatment 2020-02-04T20:11:50 https://maestrodatabase.com/blog/broader-types-of-data-to-be-used-in-development-of-nice-guidance 2020-02-04T20:04:04 https://maestrodatabase.com/blog/quebec-appeals-court-orders-province-to-restore-full-coverage-of-rheumatoid-arthritis-drug-remicade 2019-02-14T20:13:39 https://maestrodatabase.com/blog/lives-will-continue-to-be-lost-to-meningococcal-disease-as-pharmac-funding-for-vaccines-does-not-go-far-enough 2022-12-11T20:49:49 https://maestrodatabase.com/blog/determining-value-in-health-technology-assessment-stay-the-course-or-tack-away 2019-02-14T20:09:11 https://maestrodatabase.com/blog/appeal-panel-rules-that-nice-needs-to-request-evidence-for-erenumab-effectiveness-in-subgroup-of-people-with-chronic-migraine 2020-02-04T20:00:11 https://maestrodatabase.com/blog/how-to-reduce-prescription-drug-prices-first-do-no-harm 2019-02-14T20:22:13 https://maestrodatabase.com/blog/cystic-fibrosis-breakthrough-hope-for-british-sufferers-as-life-saving-drug-talks-resume 2019-02-14T20:32:48 https://maestrodatabase.com/blog/national-dna-screening-could-save-lives-for-people-with-high-risk-hereditary-disease-gene-variants 2022-12-11T20:47:27 https://maestrodatabase.com/blog/push-for-medicare-buy-in-picks-up-with-50-and-over-bill 2019-02-14T20:19:09 https://maestrodatabase.com/blog/amphastar-receives-fda-approval-for-ganirelix-acetate-injection 2022-04-10T21:08:33 https://maestrodatabase.com/blog/health-canada-approves-lundbecks-vyepti-eptinezumab---the-first-and-only-intravenous-preventive-treatment-for-migraine 2021-01-13T01:19:15 https://maestrodatabase.com/blog/sunovion-announces-health-canada-approval-of-aptiom-eslicarbazepine-acetate-as-monotherapy-to-treat-partial-onset-seizures-in-adults-with-epilepsy 2018-06-28T01:47:18 https://maestrodatabase.com/blog/precedents-are-important-aduhelm-coverage-restrictions-could-shape-the-future-of-accelerated-approval 2022-04-10T20:51:54 https://maestrodatabase.com/blog/cms-made-the-wrong-decision-on-aduhelm-but-there-might-be-a-silver-lining 2022-04-10T20:46:23 https://maestrodatabase.com/blog/avobis-bio-receives-fda-fast-track-designation-for-avb-114-implantable-cell-therapy-for-crohns-perianal-fistulas 2025-03-03T00:16:43 https://maestrodatabase.com/blog/faster-patient-access-to-new-medicines-must-be-a-priority-for-next-government 2022-04-10T20:49:50 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-march-2025 2025-03-03T00:55:34 https://maestrodatabase.com/blog/amyloid-cardiomyopathy-drug-vyndamax-to-get-health-insurance-from-march 2025-03-03T02:34:31 https://maestrodatabase.com/blog/melbourne-to-pioneer-free-treatment-to-save-sickest-cancer-kids 2019-08-04T05:20:11 https://maestrodatabase.com/blog/vertex-receives-chmp-positive-opinion-for-expanded-label-for-kaftrio-in-combination-with-ivacaftor-for-people-with-cystic-fibrosis-to-include-rare-mutations 2025-03-03T02:26:22 https://maestrodatabase.com/blog/a-life-is-more-important-than-money-grieving-parents-plea-for-funded-vaccination 2019-08-04T05:12:44 https://maestrodatabase.com/blog/cushings-disease-drug-added-to-pbs 2025-03-03T02:17:22 https://maestrodatabase.com/blog/jazz-pharmaceuticals-announces-fda-acceptance-of-supplemental-new-drug-application-for-xyrem-sodium-oxybate-to-treat-cataplexy-and-excessive-daytime-sleepiness-in-paediatric-narcolepsy-patients 2018-06-28T03:14:41 https://maestrodatabase.com/blog/pharmac-ce-resigns 2025-03-03T01:58:33 https://maestrodatabase.com/blog/imfinzi-based-perioperative-regimen-recommended-for-approval-in-the-eu-by-chmp-for-resectable-non-small-cell-lung-cancer 2025-03-03T07:04:46 https://maestrodatabase.com/blog/canadas-drug-agency-publishes-new-guidance-for-rare-disease-registries-in-canada 2025-03-03T05:47:10 https://maestrodatabase.com/blog/supporting-the-development-of-drugs-for-rare-diseases---the-importance-of-regulatory-transparency 2025-03-03T02:53:23 https://maestrodatabase.com/blog/pharmacist-substitution-of-pbs-medicines-without-a-prescription-during-shortages-serious-scarcity-substitution-instrument---8-february-2022 2022-02-08T01:29:38 https://maestrodatabase.com/blog/affimed-receives-fda-fast-track-designation-for-afm13-in-combination-with-allonk-for-the-treatment-of-patients-with-relapsed-or-refractory-hodgkin-lymphoma 2023-09-12T20:38:12 https://maestrodatabase.com/blog/morphosys-and-incyte-announce-acceptance-by-health-canada-of-the-new-drug-submission-for-tafasitamab 2021-01-13T02:26:40 https://maestrodatabase.com/blog/chronocort-marketing-authorisation-application-submitted-to-the-uk-mhra 2021-01-13T05:18:11 https://maestrodatabase.com/blog/regeneron-announces-u-dot-s-government-agreement-to-purchase-additional-covid-19-antibody-cocktail-doses 2021-01-13T05:23:00 https://maestrodatabase.com/blog/nice-issues-two-recommendations-for-ucbs-inflammatory-disease-drug 2023-09-12T21:09:02 https://maestrodatabase.com/blog/whether-the-tga-should-publish-that-a-prescription-medicine-is-under-evaluation 2019-02-15T01:45:51 https://maestrodatabase.com/blog/fda-authorises-first-interoperable-insulin-pump-intended-to-allow-patients-to-customise-treatment-through-their-individual-diabetes-management-devices 2019-02-15T01:42:29 https://maestrodatabase.com/blog/mhras-new-international-recognition-procedure-how-does-it-shape-up 2023-09-12T21:01:21 https://maestrodatabase.com/blog/health-canada-approves-onureg-azacitidine-tablets-first-maintenance-therapy-for-patients-in-remission-from-acute-myeloid-leukaemia 2021-01-13T04:36:15 https://maestrodatabase.com/blog/taking-a-proportionate-approach-to-technology-appraisals 2023-09-12T21:05:14 https://maestrodatabase.com/blog/eu-america-and-china-will-all-get-new-medicines-ahead-of-britain-after-brexit-drug-company-boss-warns 2019-02-15T02:34:27 https://maestrodatabase.com/blog/swissmedic-authorises-covid-19-vaccine-moderna-for-use-in-switzerland 2021-01-13T06:17:07 https://maestrodatabase.com/blog/government-races-to-secure-more-vaccines-but-stares-down-astrazeneca-critics 2021-01-13T09:24:29 https://maestrodatabase.com/blog/drug-makers-pledge-speedier-european-market-launches-to-avert-stricter-regulation 2022-04-11T02:09:32 https://maestrodatabase.com/blog/familys-desperate-plea-as-lifesaving-cancer-drug-delayed-by-pbs-bureaucracy 2026-01-03T03:50:22 https://maestrodatabase.com/blog/sarepta-announces-fda-acceptance-of-golodirsen-srp-4053-new-drug-application-for-patients-with-duchenne-muscular-dystrophy-amenable-to-skipping-exon-53 2019-02-15T02:40:46 https://maestrodatabase.com/blog/new-covid-19-oral-treatment-on-pbs 2022-04-11T01:13:45 https://maestrodatabase.com/blog/ema-publishes-agenda-for-the-12-15-december-chmp-meeting 2022-12-13T20:39:47 https://maestrodatabase.com/blog/morphosys-receives-us-fda-fast-track-designation-for-tulmimetostat-in-endometrial-cancer 2023-09-12T23:31:02 https://maestrodatabase.com/blog/leading-biosciences-announces-fda-fast-track-designation-granted-to-lb1148-for-the-treatment-of-post-operative-gastro-intestinal-dysfunction-associated-with-paediatric-cardiovascular-surgery 2021-01-13T19:51:35 https://maestrodatabase.com/blog/pharmajet-partner-immunomic-therapeutics-receives-fda-fast-track-designation-for-pdna-vaccine-for-skin-cancer 2022-12-13T20:31:50 https://maestrodatabase.com/blog/greater-support-for-kidney-disease-patients-following-key-new-medicines-listing-on-pbs 2020-02-05T01:20:45 https://maestrodatabase.com/blog/innovent-announces-nmpa-acceptance-of-a-supplemental-new-drug-application-for-tyvyt-sintilimab-injection-in-combination-with-byvasda-bevacizumab-injection-as-first-line-therapy-in-hepatocellular-carcinoma 2021-01-13T10:28:11 https://maestrodatabase.com/blog/pharmac-petition-fear-tamariki-with-cancer-wont-have-access-to-lifesaving-medicines 2022-12-13T20:26:47 https://maestrodatabase.com/blog/qut-mtpconnect-and-industry-partnership-will-help-to-ensure-australia-stays-globally-competitive 2017-04-10T11:52:37 https://maestrodatabase.com/blog/reporting-irregularities-that-may-affect-medicines 2017-04-10T11:47:18 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-adagrasib-for-kras-g12c-mutated-nsclc 2022-12-13T20:22:17 https://maestrodatabase.com/blog/incorporating-added-therapeutic-benefit-and-domestic-reference-pricing-into-medicare-payment-for-expensive-part-b-drugs 2023-09-12T22:48:54 https://maestrodatabase.com/blog/d-day-for-women-battling-to-get-breast-cancer-drug-kadcyla 2017-04-10T12:00:56 https://maestrodatabase.com/blog/bass-battled-u-dot-s-drug-patents-and-prices-but-lost-to-cabal 2017-04-10T11:57:24 https://maestrodatabase.com/blog/cadth-publishes-initial-recommendation-for-nivolumab-for-nsclc 2021-01-13T20:15:41 https://maestrodatabase.com/blog/insights-from-the-outcomes-from-the-november-2020-pbac-meeting 2021-01-13T20:27:43 https://maestrodatabase.com/blog/target-trial-emulation-a-framework-for-causal-inference-from-observational-data 2022-12-13T21:28:35 https://maestrodatabase.com/blog/rdd-pharma-receives-fast-track-designation-from-fda-for-rdd-0315-for-treatment-of-faecal-incontinence-in-spinal-cord-injury-patients 2019-02-15T03:08:50 https://maestrodatabase.com/blog/galera-submits-new-drug-application-for-avasopasem-for-severe-oral-mucositis 2022-12-13T21:10:54 https://maestrodatabase.com/blog/womans-brain-tumour-shrunk-by-keytruda 2017-04-10T20:41:57 https://maestrodatabase.com/blog/a-look-at-whether-your-insurer-will-pay-for-what-the-government-wont-if-you-get-cancer 2017-04-10T20:34:53 https://maestrodatabase.com/blog/cognito-therapeutics-receives-fda-breakthrough-device-designation-for-next-generation-digital-therapeutic-in-alzheimers-disease 2021-01-13T19:57:46 https://maestrodatabase.com/blog/no-death-spiral-insurers-may-soon-profit-from-obamacare-plans-analysis-finds 2017-04-10T20:51:47 https://maestrodatabase.com/blog/push-for-australia-to-develop-a-world-leading-coronavirus-vaccine 2021-01-13T20:05:08 https://maestrodatabase.com/blog/8-700-more-pacific-peoples-need-treatment-to-prevent-gout-each-year-to-achieve-equity 2022-04-11T02:36:56 https://maestrodatabase.com/blog/enhertu-supplemental-new-drug-application-submitted-in-japan-for-patients-with-her2-mutant-metastatic-non-small-cell-lung-cancer 2022-12-13T20:56:00 https://maestrodatabase.com/blog/acelrx-receives-european-commission-approval-for-dzuveo 2018-06-28T05:10:37 https://maestrodatabase.com/blog/cadth-publishes-initial-pcodr-recommendation-for-entrectinib 2021-01-13T20:09:19 https://maestrodatabase.com/blog/cancer-drug-kadcyla-approved-for-use-by-nhs-scotland 2017-04-10T21:00:29 https://maestrodatabase.com/blog/how-patent-trolls-sparked-a-failed-assault-on-high-drug-prices 2017-04-10T20:55:11 https://maestrodatabase.com/blog/smc---april-2017-decisions 2017-04-10T21:05:58 https://maestrodatabase.com/blog/nice-backs-roches-alecensa 2018-06-28T10:12:54 https://maestrodatabase.com/blog/what-happened-to-trumps-drug-price-promises 2018-06-28T10:22:19 https://maestrodatabase.com/blog/medicines-australia-welcomes-shortages-legislation 2018-06-28T08:57:45 https://maestrodatabase.com/blog/alzheimers-drug-makers-seek-accelerated-fda-review-despite-u-dot-s-coverage-decision 2022-04-11T04:39:06 https://maestrodatabase.com/blog/call-for-funding-applications-for-medicines-for-rare-disorders 2019-04-17T06:48:19 https://maestrodatabase.com/blog/high-cost-specialty-drugs-continue-to-dominate-the-new-drug-landscape 2018-06-28T12:40:56 https://maestrodatabase.com/blog/fda-approves-genentechs-tnkase-in-acute-ischaemic-stroke-in-adults 2025-03-03T22:40:18 https://maestrodatabase.com/blog/the-problem-with-high-drug-prices-isnt-foreign-freeloading-its-the-patent-system 2018-06-28T10:31:52 https://maestrodatabase.com/blog/the-biopharmaceutical-industry-provides-75-percent-of-the-fdas-drug-review-budget-is-this-a-problem 2018-06-28T21:32:15 https://maestrodatabase.com/blog/sticker-shock-the-real-cost-of-americas-10-most-expensive-drugs 2018-06-28T21:35:28 https://maestrodatabase.com/blog/statement-from-fda-commissioner-on-agencys-continued-efforts-relating-to-compounded-drugs-for-patients-who-cannot-use-an-fda-approved-drug 2018-06-28T21:21:19 https://maestrodatabase.com/blog/not-at-a-crisis-point-yet-doctors-defend-going-private-to-give-birth 2018-06-28T21:29:49 https://maestrodatabase.com/blog/media-statement---flu-vaccines 2017-10-30T09:42:08 https://maestrodatabase.com/blog/merck-provides-update-on-european-application-for-keytruda-pembrolizumab-in-combination-with-pemetrexed-and-carboplatin-for-first-line-treatment-of-non-squamous-non-small-cell-lung-cancer 2017-10-30T09:50:29 https://maestrodatabase.com/blog/update-on-biosimilars 2018-06-28T21:38:44 https://maestrodatabase.com/blog/pharma-execs-argue-new-canadian-regulations-for-setting-drug-prices-will-hurt-the-country 2020-02-05T02:47:01 https://maestrodatabase.com/blog/experts-slam-utterly-false-claims-australians-given-budget-flu-vaccine 2017-10-30T09:45:24 https://maestrodatabase.com/blog/alexion-submits-application-for-approval-of-alxn1210-as-a-treatment-for-patients-with-paroxysmal-nocturnal-haemoglobinuria-in-the-european-union 2018-06-28T21:51:35 https://maestrodatabase.com/blog/predictive-validation-and-the-re-analysis-of-cost-effectiveness-do-we-dare-to-tread 2017-10-30T10:24:28 https://maestrodatabase.com/blog/european-medicines-agency-validates-type-ii-variation-for-astellas-xtandi-enzalutamide-for-treatment-of-non-metastatic-hormone-sensitive-prostate-cancer-with-high-risk-biochemical-recurrence 2023-09-13T02:30:11 https://maestrodatabase.com/blog/blue-cross-blue-shield-of-michigan-dropping-coverage-of-weight-loss-drugs 2024-06-15T03:32:00 https://maestrodatabase.com/blog/novavax-submits-application-to-us-fda-for-updated-protein-based-2024-2025-formula-covid-19-vaccine 2024-06-15T03:22:57 https://maestrodatabase.com/blog/tga-decides-not-to-register-lecanemab-in-australia 2025-03-03T22:48:28 https://maestrodatabase.com/blog/chemists-beware-amazons-attack-on-pharmacies-has-just-begun 2018-06-28T22:14:40 https://maestrodatabase.com/blog/medicines-matter---pre-election-focus-on-health-and-better-access-to-new-medicines 2019-02-15T05:23:51 https://maestrodatabase.com/blog/european-medicines-agency-validates-bristol-myers-squibbs-type-ii-variation-application-for-opdivo-nivolumab-for-treatment-of-patients-with-resected-high-risk-advanced-melanoma 2017-10-30T11:11:11 https://maestrodatabase.com/blog/role-of-big-data-for-evaluation-and-supervision-of-medicines-in-the-eu 2019-02-15T13:19:37 https://maestrodatabase.com/blog/latigo-biotherapeutics-granted-fda-fast-track-designation-for-ltg-001-potential-best-in-class-nav1-dot-8-inhibitor-for-the-non-opioid-treatment-of-acute-pain 2025-03-03T23:12:25 https://maestrodatabase.com/blog/cms-proposes-coverage-with-evidence-development-for-chimeric-antigen-receptor-car-t-cell-therapy 2019-02-15T20:43:12 https://maestrodatabase.com/blog/xeljanz-tofacitinib-citrate-receives-marketing-authorisation-in-the-european-union-for-active-psoriatic-arthritis 2018-06-28T23:12:39 https://maestrodatabase.com/blog/nice-draft-guidance-recommends-pertuzumab-for-new-breast-cancer-indication-after-improved-price-offer-from-company 2019-02-15T20:33:39 https://maestrodatabase.com/blog/the-innovation-health-care-really-needs-help-people-manage-their-own-health 2017-10-30T19:56:29 https://maestrodatabase.com/blog/fda-advances-new-efforts-to-promote-development-of-safe-and-effective-regenerative-medicine-products 2019-02-15T21:08:59 https://maestrodatabase.com/blog/patient-centred-care-is-missing-in-action-in-australia 2017-10-30T20:03:58 https://maestrodatabase.com/blog/bernie-sanders-lauds-canadian-health-care-system-in-toronto-speech 2017-10-30T20:00:02 https://maestrodatabase.com/blog/italy-proposes-the-who-set-international-standards-for-drug-pricing-transparency 2019-02-15T21:20:26 https://maestrodatabase.com/blog/statement-from-fda-commissioner-on-new-policy-to-improve-access-and-foster-price-competition-for-drugs-that-face-inadequate-generic-competition 2019-02-15T21:04:42 https://maestrodatabase.com/blog/formycon-announces-file-acceptance-for-fyb203-a-biosimilar-candidate-to-eylea-aflibercept-by-the-us-fda 2023-09-13T03:48:59 https://maestrodatabase.com/blog/bayer-receives-fda-approval-for-xarelto-10-mg-once-daily-for-the-extended-treatment-of-venous-thromboembolism 2017-10-30T20:19:20 https://maestrodatabase.com/blog/a-new-team-aims-to-slash-drug-development-time----with-help-from-the-feds 2017-10-30T20:33:33 https://maestrodatabase.com/blog/icer-publishes-final-new-evidence-update-for-alirocumab-a-pcsk9-inhibitor-for-treating-high-cholesterol 2019-02-15T21:26:38 https://maestrodatabase.com/blog/mesoblast-submits-completed-biologics-license-application-for-ryoncil-to-us-fda 2020-02-05T04:01:35 https://maestrodatabase.com/blog/depemokimab-applications-accepted-for-review-by-the-us-fda-for-asthma-with-type-2-inflammation-and-for-chronic-rhinosinusitis-with-nasal-polyps 2025-03-04T00:15:43 https://maestrodatabase.com/blog/hugel-says-fdas-complete-response-letter-will-not-affect-letybo-approval 2022-04-11T11:27:55 https://maestrodatabase.com/blog/pfizers-alk-targeted-therapy-lorviqua-passes-reimbursement-review 2022-04-11T11:49:02 https://maestrodatabase.com/blog/artificial-intelligence-in-medicine-regulation 2021-08-16T10:13:58 https://maestrodatabase.com/blog/inxmeds-in10018-receives-u-dot-s-fda-fast-track-designation-for-the-treatment-of-platinum-resistant-ovarian-cancer 2021-08-16T07:21:28 https://maestrodatabase.com/blog/government-of-canada-negotiates-additional-agreement-with-moderna-for-vaccine-supply-beyond-2021 2021-08-16T10:23:38 https://maestrodatabase.com/blog/uk-patients-granted-early-access-for-radioligand-therapy-in-advanced-prostate-cancer 2022-04-11T11:54:39 https://maestrodatabase.com/blog/spectrum-pharmaceuticals-announces-fda-acceptance-of-bla-resubmission-for-eflapegrastim 2022-04-11T11:33:10 https://maestrodatabase.com/blog/orchard-therapeutics-announces-reimbursement-agreement-making-libmeldy-available-for-all-eligible-mld-patients-in-italy 2022-04-11T11:39:45 https://maestrodatabase.com/blog/u-dot-s-fda-approves-ticovac-pfizers-tick-borne-encephalitis-vaccine 2021-08-16T07:12:00 https://maestrodatabase.com/blog/ema-starts-evaluating-use-of-roactemra-in-hospitalised-adults-with-severe-covid-19 2021-08-16T20:53:33 https://maestrodatabase.com/blog/smc---april-2022-decisions 2022-04-11T20:25:29 https://maestrodatabase.com/blog/pharmac-to-fund-the-epipen-for-severe-allergies 2022-12-14T21:05:53 https://maestrodatabase.com/blog/health-canada-approves-gardasil-9-human-papillomavirus-9-valent-vaccine-recombinant-for-the-prevention-of-oropharyngeal-and-other-head-and-neck-cancers 2022-04-11T20:39:11 https://maestrodatabase.com/blog/treatment-options-for-people-with-glioma-a-type-of-brain-cancer 2023-09-13T05:37:20 https://maestrodatabase.com/blog/a-review-of-patient-reported-outcome-labelling-of-fda-approved-new-drugs-2016-2020-counts-categories-and-comprehensibility 2022-04-11T20:32:02 https://maestrodatabase.com/blog/lanadelumab-in-hereditary-angioedema-added-benefit-not-proven 2021-08-16T20:58:49 https://maestrodatabase.com/blog/the-future-of-drug-pricing-transparency 2021-02-14T20:24:39 https://maestrodatabase.com/blog/poxel-announces-pxl770-awarded-fda-fast-track-designation-for-x-linked-adrenoleukodystrophy 2022-04-11T20:10:18 https://maestrodatabase.com/blog/amneal-launches-generic-abiraterone-acetate-500-mg-tablets-following-anda-approval-by-fda 2021-01-14T02:48:40 https://maestrodatabase.com/blog/pfizer-and-biontech-announce-submission-of-initial-data-to-u-dot-s-fda-to-support-booster-dose-of-covid-19-vaccine 2021-08-16T20:47:42 https://maestrodatabase.com/blog/eton-pharmaceuticals-announces-fda-approval-of-cysteine-hydrochloride-injection 2022-04-11T20:17:50 https://maestrodatabase.com/blog/fda-approves-lyumjev-insulin-lispro-aabc-injection-100-units-slash-ml-for-use-in-insulin-pumps 2021-08-16T11:12:42 https://maestrodatabase.com/blog/the-eq-hwb-overview-of-the-development-of-a-measure-of-health-and-wellbeing-and-key-results 2022-04-11T20:54:39 https://maestrodatabase.com/blog/edgewise-receives-u-dot-s-fda-fast-track-designation-for-edg-5506-for-the-treatment-of-individuals-with-becker-muscular-dystrophy 2021-08-16T21:15:38 https://maestrodatabase.com/blog/hira-sets-up-system-to-manage-super-expensive-drugs 2022-12-14T21:42:33 https://maestrodatabase.com/blog/spinal-muscular-atrophy-second-and-third-active-ingredients-undergo-benefit-assessment 2021-08-16T21:20:27 https://maestrodatabase.com/blog/carrick-therapeutics-receives-fda-fast-track-designations-for-two-samuraciclib-combinations-for-the-treatment-of-hr-plus-her2--advanced-breast-cancer-and-locally-advanced-or-metastatic-triple-negative-breast-cancer 2021-08-16T21:03:37 https://maestrodatabase.com/blog/agilent-resolution-ctdx-first-receives-fda-approval-as-a-liquid-biopsy-companion-diagnostic-test-for-advanced-non-small-cell-lung-cancer 2022-12-14T21:37:07 https://maestrodatabase.com/blog/more-than-5-200-people-could-benefit-after-nice-broadens-recommendation-on-chronic-lung-disease-treatment 2022-12-14T21:11:41 https://maestrodatabase.com/blog/ema-publishes-agenda-for-16-19-august-chmp-meeting 2022-08-16T21:09:40 https://maestrodatabase.com/blog/drug-pricing-with-evidence-development 2022-04-11T20:49:50 https://maestrodatabase.com/blog/icer-posts-draft-scoping-document-on-cognitive-and-mind-body-interventions-to-treat-chronic-low-back-and-neck-pain 2017-04-11T01:08:03 https://maestrodatabase.com/blog/icer-publishes-special-report-on-copd-therapies-as-part-of-cms-public-comment-process-on-medicare-drug-price-negotiations 2025-03-04T04:10:30 https://maestrodatabase.com/blog/merck-canada-initiates-rolling-submission-to-health-canada-for-molnupiravir-an-investigational-oral-therapeutic-agent-for-the-treatment-of-covid-19 2021-08-16T21:33:43 https://maestrodatabase.com/blog/pharmac-must-explain-funding-decisions 2021-08-16T21:28:30 https://maestrodatabase.com/blog/fda-files-corcepts-new-drug-application-for-relacorilant-as-treatment-for-patients-with-hypercortisolism 2025-03-04T03:31:55 https://maestrodatabase.com/blog/abbotts-amplatzer-amulet-device-approved-by-fda-to-treat-people-with-atrial-fibrillation-at-risk-of-stroke 2021-08-16T21:41:08 https://maestrodatabase.com/blog/qalsody-tofersen-injection-receives-conditional-marketing-authorisation-from-health-canada-as-the-first-als-treatment-targeting-a-genetic-cause 2025-03-04T03:23:53 https://maestrodatabase.com/blog/cymabay-therapeutics-announces-seladelpar-granted-breakthrough-therapy-designation-by-the-fda-for-the-treatment-of-primary-biliary-cholangitis 2019-02-15T23:16:52 https://maestrodatabase.com/blog/cms-unleashes-innovation-to-ensure-our-nations-seniors-have-access-to-the-latest-advancements 2021-01-14T03:48:26 https://maestrodatabase.com/blog/health-canada-approves-imbruvica-ibrutinib-plus-rituximab-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia 2021-01-14T06:12:53 https://maestrodatabase.com/blog/extremely-rare-disease-drug-ceprotin-clears-major-hurdle-to-reimbursement 2024-06-15T05:25:38 https://maestrodatabase.com/blog/novartis-ligelizumab-qge031-receives-fda-breakthrough-therapy-designation-for-patients-with-chronic-spontaneous-urticaria 2021-01-14T19:31:54 https://maestrodatabase.com/blog/health-canada-approves-symdeko-tezacaftor-slash-ivacaftor-and-ivacaftor-to-treat-the-underlying-cause-of-cystic-fibrosis-in-people-ages-12-and-older-with-certain-mutations-in-the-cftr-gene 2018-06-29T02:37:35 https://maestrodatabase.com/blog/amneals-bla-submissions-for-two-denosumab-biosimilars-accepted-for-review-by-us-fda 2025-03-04T09:20:54 https://maestrodatabase.com/blog/workshop-on-evaluating-rwe-from-observational-studies-in-regulatory-decision-making 2021-01-14T07:22:45 https://maestrodatabase.com/blog/fda-releases-artificial-intelligence-slash-machine-learning-action-plan 2021-01-14T07:33:16 https://maestrodatabase.com/blog/viiv-healthcare-receives-eu-marketing-authorisation-for-the-first-ever-dispersible-tablet-formulation-of-dolutegravir-tivicay-a-treatment-for-children-living-with-hiv-in-europe 2021-01-14T10:34:26 https://maestrodatabase.com/blog/roche-koreas-multiple-sclerosis-drug-scores-reimbursement 2025-03-04T09:10:00 https://maestrodatabase.com/blog/pursuing-herd-immunity-australias-two-stage-strategy-to-protect-community 2021-01-14T19:49:56 https://maestrodatabase.com/blog/pfizer-boosts-its-covid-19-vaccine-output-by-2-billion-doses 2021-01-14T19:52:06 https://maestrodatabase.com/blog/first-bladder-cancer-patient-dosed-with-commercially-available-intravesical-gene-therapy-adstiladrin-nadofaragene-firadenovec-vncg 2023-09-13T08:00:16 https://maestrodatabase.com/blog/oxford-vaccine-chief-says-australia-cant-afford-to-delay-the-jabs-rollout 2021-01-14T19:55:48 https://maestrodatabase.com/blog/fda-veteran-woodcock-being-considered-to-lead-agency-under-biden 2021-01-14T19:37:21 https://maestrodatabase.com/blog/ema-to-support-development-of-vaccines-and-treatments-for-novel-coronavirus 2020-02-05T06:22:19 https://maestrodatabase.com/blog/innovation-pharmaceuticals-brilacidin-for-the-treatment-of-covid-19-receives-fda-fast-track-designation 2021-01-14T19:41:13 https://maestrodatabase.com/blog/fda-proposes-changes-to-key-approval-pathway-for-medical-devices-five-years-after-promising 2023-09-13T09:00:29 https://maestrodatabase.com/blog/johnson-and-johnson-could-apply-for-ema-approval-in-february 2021-01-14T20:00:07 https://maestrodatabase.com/blog/covid-19-nz-vaccine-timeline-remains-the-same-in-light-of-new-variant-strains 2021-01-14T20:05:46 https://maestrodatabase.com/blog/the-era-of-bipartisan-work-on-lowering-drug-prices-might-be-over 2021-01-14T20:08:14 https://maestrodatabase.com/blog/madrigal-pharmaceuticals-announces-nda-acceptance-and-priority-review-of-the-new-drug-application-for-resmetirom-for-the-treatment-of-nash-with-liver-fibrosis 2023-09-13T20:14:23 https://maestrodatabase.com/blog/paladin-labs-announced-favourable-cadth-recommendation-for-xcopri-cenobamate-tablets 2023-09-13T11:20:58 https://maestrodatabase.com/blog/here-we-go-again---version-4 2023-09-14T09:55:38 https://maestrodatabase.com/blog/fda-takes-significant-step-in-coronavirus-response-efforts-issues-emergency-use-authorisation-for-the-first-2019-novel-coronavirus-diagnostic 2020-02-05T11:09:46 https://maestrodatabase.com/blog/democrats-interrupted-trumps-state-of-the-union-to-chant-about-their-drug-pricing-bill 2020-02-05T11:04:47 https://maestrodatabase.com/blog/recursion-is-granted-fast-track-designation-for-rec-4881-for-the-potential-treatment-of-familial-adenomatous-polyposis 2022-04-12T01:09:14 https://maestrodatabase.com/blog/health-canada-authorises-moderna-covid-19-vaccine-targeting-the-omicron-xbb-dot-1-5-sub-variant 2023-09-13T20:34:56 https://maestrodatabase.com/blog/takeda-announces-fda-acceptance-of-bla-for-subcutaneous-administration-of-entyvio-vedolizumab-for-maintenance-therapy-in-moderately-to-severely-active-crohns-disease 2023-09-13T20:28:42 https://maestrodatabase.com/blog/instant-prescription-providers-prompt-warnings-from-gps-and-pharmacists 2020-02-05T11:19:27 https://maestrodatabase.com/blog/inhibrx-granted-fast-track-designation-for-inbrx-109-for-the-treatment-of-unresectable-or-metastatic-conventional-chondrosarcoma-patients 2021-01-14T23:02:43 https://maestrodatabase.com/blog/merck-receives-approval-for-belsomra-suvorexant-c-iv-label-update-to-include-findings-from-study-of-insomnia-in-patients-with-mild-to-moderate-alzheimers-disease 2020-02-05T11:13:19 https://maestrodatabase.com/blog/merck-cant-sue-over-drug-pricing-plan-hhs-tells-court 2023-09-13T20:22:46 https://maestrodatabase.com/blog/first-treatment-for-acute-migraine-to-be-recommended-by-nice-set-to-benefit-thousands 2023-09-14T10:26:48 https://maestrodatabase.com/blog/people-at-risk-of-hiv-in-scotland-to-be-given-prep-drug-on-nhs 2017-04-11T07:46:12 https://maestrodatabase.com/blog/gamechanging-cancer-drug-rejected-for-use-on-nhs 2017-04-11T11:54:59 https://maestrodatabase.com/blog/nice-says-head-and-neck-cancer-drug-is-not-cost-effective 2017-04-11T11:49:59 https://maestrodatabase.com/blog/why-drugs-like-these-for-orphan-diseases-are-a-booming-business-with-colossal-costs-for-patients 2017-04-11T12:00:46 https://maestrodatabase.com/blog/wpd-pharmaceuticals-annamycin-drug-received-fda-approval-of-fast-track-designation 2020-02-05T19:44:10 https://maestrodatabase.com/blog/elrexfio-elranatamab-bcmm-now-available-from-onco360 2023-09-14T10:16:29 https://maestrodatabase.com/blog/nice-plans-to-widen-the-net-for-data-it-uses-in-guidance 2020-02-05T11:51:28 https://maestrodatabase.com/blog/rules-to-delay-pancreatic-cancer-treatment-warns-oncosil 2017-04-11T20:44:43 https://maestrodatabase.com/blog/children-parents-protest-pharmac-funding-review-at-parliament 2022-12-15T03:58:07 https://maestrodatabase.com/blog/federal-budget-2017-budget-razor-gang-to-consider-medicine-scheme-shake-up 2017-04-11T20:47:51 https://maestrodatabase.com/blog/five-pillars-for-societal-perspective 2020-02-05T19:57:00 https://maestrodatabase.com/blog/scotland-gets-life-extending-crucial-cancer-drug-that-is-too-expensive-for-england 2017-04-11T21:13:33 https://maestrodatabase.com/blog/its-time-to-fix-the-fda-by-breaking-it-up 2022-04-12T02:26:52 https://maestrodatabase.com/blog/trump-administration-to-pay-health-law-subsidies-disputed-by-house 2017-04-11T21:09:16 https://maestrodatabase.com/blog/prescription-medicines-applications-under-evaluation 2022-08-24T21:05:39 https://maestrodatabase.com/blog/achieving-universal-coverage-without-turning-to-a-single-payer-lessons-from-3-other-countries 2017-04-11T21:18:59 https://maestrodatabase.com/blog/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-for-keytruda-pembrolizumab-in-combination-with-inlyta-axitinib-as-first-line-treatment-for-advanced-renal-cell-carcinoma 2019-02-16T02:10:14 https://maestrodatabase.com/blog/orsini-pharmaceutical-services-now-providing-fda-approved-vyondys-53-golodirsen-injection-for-duchenne-muscular-dystrophy 2020-02-05T20:18:57 https://maestrodatabase.com/blog/policies-for-use-of-real-world-data-in-health-technology-assessment-a-comparative-study-of-six-hta-agencies 2017-04-11T21:28:22 https://maestrodatabase.com/blog/icer-publishes-evidence-report-on-gene-therapy-for-metachromatic-leukodystrophy 2023-09-14T20:51:06 https://maestrodatabase.com/blog/final-terms-of-reference-and-public-consultation-to-the-post-market-review-of-opiate-dependence-treatment-program-medicines 2021-08-17T02:28:53 https://maestrodatabase.com/blog/trump-says-tax-reform-will-be-better-if-obamacare-repeal-passed-first 2017-04-11T21:46:39 https://maestrodatabase.com/blog/alector-announces-fda-fast-track-designation-granted-to-al101-for-the-treatment-of-patients-with-frontotemporal-dementia 2020-02-05T23:22:50 https://maestrodatabase.com/blog/mayzent-is-granted-temporary-subsidy 2020-02-05T20:25:04 https://maestrodatabase.com/blog/pharmac-to-fund-new-cardiovascular-medicine-with-amended-special-authority-criteria 2021-08-17T02:25:02 https://maestrodatabase.com/blog/funding-of-pharmaceutical-innovation-during-and-after-the-covid-19-pandemic 2021-01-15T04:49:36 https://maestrodatabase.com/blog/capricor-therapeutics-announces-fda-acceptance-and-priority-review-of-its-biologics-license-application-for-deramiocel-to-treat-duchenne-muscular-dystrophy 2025-03-05T02:50:13 https://maestrodatabase.com/blog/celltrion-receives-us-fda-approval-for-stoboclo-denosumab-bmwo-and-osenvelt-denosumab-bmwo-biosimilars-referencing-prolia-and-xgeva 2025-03-05T02:27:06 https://maestrodatabase.com/blog/spikevax-ema-recommends-approval-of-adapted-covid-19-vaccine-targeting-omicron-xbb-dot-1-5 2023-09-14T21:00:22 https://maestrodatabase.com/blog/fda-approves-new-and-updated-indications-for-temozolomide-under-project-renewal 2023-09-14T20:56:43 https://maestrodatabase.com/blog/dupixent-dupilumab-approved-by-european-commission-as-the-first-and-only-targeted-medicine-indicated-for-prurigo-nodularis 2022-12-15T06:20:54 https://maestrodatabase.com/blog/trifluridine-with-tipiracil-hydrochloride-for-the-treatment-of-patients-with-metastatic-gastric-cancer-or-gastro-oesophageal-junction-adenocarcinoma-after-two-or-more-treatments 2022-12-15T10:10:13 https://maestrodatabase.com/blog/fda-approves-first-drug-to-treat-tardive-dyskinesia 2017-04-11T22:43:12 https://maestrodatabase.com/blog/pembrolizumab-for-the-neo-adjuvant-and-adjuvant-treatment-of-patients-with-early-or-locally-advanced-triple-negative-breast-cancer 2022-12-15T10:04:07 https://maestrodatabase.com/blog/update-on-us-regulatory-priority-review-of-lynparza-in-combination-with-abiraterone-in-metastatic-castration-resistant-prostate-cancer 2022-12-15T07:07:26 https://maestrodatabase.com/blog/tga-approves-new-medicine-for-patients-with-sle 2022-04-12T02:46:18 https://maestrodatabase.com/blog/cabozantinib-maleate-for-patients-with-previously-treated-advanced-hepatocellular-carcinoma 2022-12-15T06:43:40 https://maestrodatabase.com/blog/obesity-management-needs-medications-on-pbs-racgp 2025-03-05T03:06:44 https://maestrodatabase.com/blog/alunbrig-recommended-by-nice-for-non-small-cell-lung-cancer 2019-02-16T05:50:03 https://maestrodatabase.com/blog/china-national-medical-products-administration-approves-tislelizumab-in-combination-with-chemotherapy-in-first-line-advanced-squamous-non-small-cell-lung-cancer 2021-01-15T07:23:52 https://maestrodatabase.com/blog/thea-pharma-announces-fda-approval-of-iyuzeh-for-the-reduction-of-elevated-intra-ocular-pressure-in-patients-with-open-angle-glaucoma-or-ocular-hypertension 2022-12-15T21:10:16 https://maestrodatabase.com/blog/esketamine-hydrochloride-for-patients-with-treatment-resistant-depression 2022-12-15T20:43:36 https://maestrodatabase.com/blog/fda-approves-updated-drug-labelling-including-new-indications-and-dosing-regimens-for-capecitabine-tablets-under-project-renewal 2022-12-15T20:38:55 https://maestrodatabase.com/blog/innocrin-pharmaceuticals-granted-fast-track-designation-by-fda-for-vt-464-treatment-of-patients-with-metastatic-castrate-resistant-prostate-cancer 2019-02-16T21:30:24 https://maestrodatabase.com/blog/imfinzi-approved-in-the-eu-for-less-frequent-fixed-dose-use-in-unresectable-non-small-cell-lung-cancer 2021-01-15T07:12:28 https://maestrodatabase.com/blog/pfizers-xalkori-crizotinib-approved-by-fda-for-alk-positive-anaplastic-large-cell-lymphoma-in-children-and-young-adults 2021-01-15T07:16:22 https://maestrodatabase.com/blog/pharmac-consulting-on-two-new-medicines-for-lung-cancer 2022-12-15T20:28:43 https://maestrodatabase.com/blog/skyrizi-risankizumab-now-available-for-moderately-to-severely-active-ulcerative-colitis-expanding-abbvies-portfolio-across-inflammatory-bowel-disease 2025-03-05T03:27:28 https://maestrodatabase.com/blog/phase-iii-trial-of-darolutamide-in-patients-with-non-metastatic-castration-resistant-prostate-cancer-meets-primary-endpoint 2019-02-16T21:45:08 https://maestrodatabase.com/blog/avatrombopag-maleate-for-the-treatment-of-patients-with-primary-chronic-immune-thrombocytopenia 2022-12-15T21:41:05 https://maestrodatabase.com/blog/first-new-alzheimers-drugs-in-20-years-to-bring-hope-for-early-stage-patients 2024-06-16T21:17:43 https://maestrodatabase.com/blog/fresenius-kabi-receives-us-fda-approval-for-biosimilar-idacio-adalimumab 2022-12-15T21:29:41 https://maestrodatabase.com/blog/proposed-changes-to-medicare-advantage-and-part-d-will-provide-better-coverage-more-access-and-improved-transparency-for-medicare-beneficiaries 2020-02-06T01:46:38 https://maestrodatabase.com/blog/fixing-price-instability-can-improve-access-to-affordable-prescription-drugs 2022-12-15T21:38:36 https://maestrodatabase.com/blog/tokai-pharmaceuticals-galeterone-receives-fast-track-designation-from-the-fda-for-the-treatment-of-advanced-prostate-cancer 2019-02-16T21:54:22 https://maestrodatabase.com/blog/oncogenex-announces-fast-track-designation-granted-for-custirsen-in-combination-with-cabazitaxel-slash-prednisone-as-second-line-chemotherapy-in-phase-3-affinity-trial-of-men-with-metastatic-castrate-resistant-prostate-cancer 2019-02-16T21:59:47 https://maestrodatabase.com/blog/nice-backs-gsks-zejula-in-advanced-ovarian-cancer 2021-01-15T12:12:10 https://maestrodatabase.com/blog/oncopeptides-pepaxto-receives-a-permanent-j-code-clarifying-reimbursement-processes-in-hospital-outpatient-and-physician-office-settings-of-care 2021-08-17T06:02:45 https://maestrodatabase.com/blog/information-act-shows-racism-in-pharmacs-decision-making 2021-08-17T05:56:14 https://maestrodatabase.com/blog/a-closer-look-at-pete-buttigiegs-aggressive-wonky-plan-to-lower-drug-prices 2020-02-06T02:16:45 https://maestrodatabase.com/blog/helius-medical-technologies-announces-fda-breakthrough-device-designation-for-the-treatment-of-dynamic-gait-and-balance-deficits-following-a-stroke 2021-08-17T20:39:49 https://maestrodatabase.com/blog/tevimbra-approved-in-us-for-first-line-treatment-of-advanced-oesophageal-squamous-cell-carcinoma-in-combination-with-chemotherapy 2025-03-05T06:02:19 https://maestrodatabase.com/blog/gc-biopharmas-livmarli-listed-for-national-health-insurance-coverage-for-alagille-syndrome 2026-01-04T21:18:41 https://maestrodatabase.com/blog/bayer-koreas-eylea-pre-filled-syringe-8-mg-to-receive-health-insurance-coverage 2026-01-04T21:24:19 https://maestrodatabase.com/blog/ema-validates-bristol-myers-squibbs-applications-for-opdivo-nivolumab-and-yervoy-ipilimumab-and-opdivo-and-chemotherapy-as-first-line-treatments-for-unresectable-advanced-recurrent-or-metastatic-oesophageal-squamous-cell-carcinoma 2021-08-17T21:09:00 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-of-jemperli-dostarlimab-gxly-for-dmmr-recurrent-or-advanced-solid-tumours 2021-08-17T20:48:33 https://maestrodatabase.com/blog/major-pharmaceuticals-january-drug-price-hikes-were-smallest-in-at-least-6-years 2020-02-06T08:59:57 https://maestrodatabase.com/blog/icer-publishes-final-evidence-report-and-policy-recommendations-on-therapies-for-atopic-dermatitis 2021-08-17T20:57:23 https://maestrodatabase.com/blog/agios-announces-fda-acceptance-and-priority-review-of-new-drug-application-for-mitapivat-for-treatment-of-adults-with-pyruvate-kinase-deficiency 2021-08-17T20:53:20 https://maestrodatabase.com/blog/tempus-submits-pma-application-to-the-fda-for-its-xt-onco-assay 2021-08-17T21:37:29 https://maestrodatabase.com/blog/will-government-further-expand-reimbursement-for-rare-leukaemia-drugs 2021-08-17T21:14:14 https://maestrodatabase.com/blog/pharma-companies-are-seeking-a-new-treatment----for-the-backlash-against-high-drug-prices 2017-04-12T20:50:48 https://maestrodatabase.com/blog/why-arent-cancer-drugs-available-throughout-uk 2017-04-12T10:01:47 https://maestrodatabase.com/blog/novartis-secures-new-approval-in-china-for-cosentyx-secukinumab-in-paediatric-psoriasis 2021-08-17T21:28:35 https://maestrodatabase.com/blog/soligenix-announces-submission-of-new-drug-application-to-the-fda-for-hybryte-in-the-treatment-of-cutaneous-t-cell-lymphoma 2022-12-16T03:52:01 https://maestrodatabase.com/blog/this-is-how-obamacare-might-actually-explode 2017-04-12T20:57:13 https://maestrodatabase.com/blog/maryland-general-assembly-passes-bill-aimed-at-drug-price-gouging 2017-04-12T21:01:08 https://maestrodatabase.com/blog/pharmacy-benefit-management-companies-do-they-create-value-in-the-us-health-care-system 2017-04-12T21:08:44 https://maestrodatabase.com/blog/call-to-reduce-scary-gene-therapy-costs 2020-02-06T23:11:24 https://maestrodatabase.com/blog/nice-publishes-draft-guidance-on-the-use-of-holoclar-ex-vivo-expanded-autologous-human-corneal-epithelial-cells-containing-stem-cells 2017-04-12T21:15:24 https://maestrodatabase.com/blog/why-drug-appraisal-methods-need-to-take-into-account-treatments-for-rare-diseases 2017-04-12T21:33:59 https://maestrodatabase.com/blog/has-publishes-transparency-commission-opinion-for-keytruda 2017-04-12T21:45:51 https://maestrodatabase.com/blog/patented-medicine-prices-review-board-will-hear-closing-arguments-in-the-matter-of-the-price-of-soliris 2017-04-12T21:39:44 https://maestrodatabase.com/blog/fda-accepts-supplemental-biologics-license-application-for-roches-gazyva-slash-gazyvaro-for-the-treatment-of-lupus-nephritis 2025-03-05T20:46:26 https://maestrodatabase.com/blog/us-fda-updates-pdufa-action-date-for-lifileucel-for-the-treatment-of-advanced-melanoma 2023-09-15T02:45:02 https://maestrodatabase.com/blog/cancer-treatment-campaigner-urges-government-to-double-pharmacs-funding 2019-08-04T22:57:25 https://maestrodatabase.com/blog/abbvies-skyrizi-now-publicly-reimbursed-in-ontario-alberta-saskatchewan-and-quebec-for-the-treatment-of-moderate-to-severe-plaque-psoriasis 2020-02-07T01:18:23 https://maestrodatabase.com/blog/smc---december-2025-decisions 2026-01-05T04:12:30 https://maestrodatabase.com/blog/company-led-submission-pilot-for-early-evaluation-of-non-cancer-drugs 2023-09-15T02:10:53 https://maestrodatabase.com/blog/sanofis-tzield-accepted-for-priority-review-in-the-us-for-young-children-with-stage-2-type-1-diabetes 2026-01-05T10:17:52 https://maestrodatabase.com/blog/blueprint-medicines-announces-pdufa-date-extension-for-new-drug-application-of-avapritinib-for-the-treatment-of-adults-with-fourth-line-gastro-intestinal-stromal-tumour 2020-02-07T03:40:46 https://maestrodatabase.com/blog/governments-refuse-to-fund-meningococcal-b-vaccine 2019-08-04T23:35:51 https://maestrodatabase.com/blog/revance-announces-u-dot-s-fda-acceptance-of-biologics-license-application-for-daxi-to-treat-glabellar-frown-lines 2020-02-07T03:47:51 https://maestrodatabase.com/blog/vas-narasimhan-of-novartis-we-are-not-at-all-prepared-for-a-pandemic 2019-08-04T23:53:35 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-to-padeliporfin-impact-for-steba-biotech 2021-01-15T22:21:45 https://maestrodatabase.com/blog/regulation-of-software-based-medical-devices 2021-01-15T22:12:19 https://maestrodatabase.com/blog/takeda-and-protagonist-announce-submission-of-new-drug-application-for-rusfertide-for-treatment-of-polycythemia-vera 2026-01-05T19:49:10 https://maestrodatabase.com/blog/sparsentan-for-the-treatment-of-patients-with-primary-iga-nephropathy 2025-03-05T23:30:19 https://maestrodatabase.com/blog/proposal-to-widen-access-to-zoledronic-acid-for-early-breast-cancer 2017-10-31T19:08:36 https://maestrodatabase.com/blog/cemiplimab-in-combination-with-platinum-based-chemotherapy-for-the-treatment-of-patients-with-advanced-non-small-cell-lung-cancer 2025-03-06T04:24:04 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-november-2017 2017-10-31T19:14:39 https://maestrodatabase.com/blog/day-one-announces-updated-firefly-1-data-for-tovorafenib-and-completion-of-rolling-nda-submission-to-fda-for-relapsed-or-progressive-pediatric-low-grade-glioma 2023-09-15T05:10:48 https://maestrodatabase.com/blog/fund-for-next-generation-medicines-investigated 2017-10-31T19:21:18 https://maestrodatabase.com/blog/clinuvel-reaches-agreement-on-german-scenesse-pricing-through-amnog-arbitration-board 2017-04-13T07:19:39 https://maestrodatabase.com/blog/private-health-insurers-under-pressure-to-limit-premium-rises-and-be-more-transparent 2017-10-31T19:31:34 https://maestrodatabase.com/blog/idebenone-for-the-treatment-of-patients-12-years-of-age-and-older-with-visual-impairment-in-lebers-hereditary-optic-neuropathy-updated-draft-guidance 2025-03-06T00:03:26 https://maestrodatabase.com/blog/australians-buying-useless-health-insurance-ama-head-says 2017-10-31T19:37:50 https://maestrodatabase.com/blog/health-system-cant-work-without-insurers 2017-10-31T19:34:15 https://maestrodatabase.com/blog/eu-fda-mutual-recognition-of-inspections-of-medicines-manufacturers-enters-operational-phase 2017-10-31T19:43:28 https://maestrodatabase.com/blog/health-funds-poised-to-cheat-members-of-1-dot-5-billion-dollars-in-savings-says-device-manufacturers 2017-10-31T19:40:18 https://maestrodatabase.com/blog/myovant-sciences-and-pfizer-provide-update-on-supplemental-new-drug-application-for-myfembree-for-the-management-of-moderate-to-severe-pain-associated-with-endometriosis 2022-04-12T20:34:38 https://maestrodatabase.com/blog/fda-approves-new-treatment-for-adults-with-mantle-cell-lymphoma 2017-10-31T19:49:05 https://maestrodatabase.com/blog/another-uninformative-update-from-the-health-technology-assessment-policy-and-methods-review-reference-committee 2023-09-15T06:02:29 https://maestrodatabase.com/blog/fda-grants-direct-biologics-regenerative-medicine-advanced-therapy-designation-for-the-use-of-exoflo-in-covid-19-related-ards 2022-04-12T20:14:37 https://maestrodatabase.com/blog/aeglea-biotherapeutics-submits-bla-to-fda-for-pegzilarginase-for-the-treatment-of-arginase-1-deficiency 2022-04-12T20:23:22 https://maestrodatabase.com/blog/prospective-measures-to-combat-rising-drug-prices-in-germany 2022-04-12T20:53:17 https://maestrodatabase.com/blog/nice-reaches-important-milestone-in-the-uks-efforts-to-tackle-antimicrobial-resistance 2022-04-12T20:44:20 https://maestrodatabase.com/blog/agenda-for-19-april-2017-tc-meeting 2017-04-13T23:46:54 https://maestrodatabase.com/blog/jardiance-empagliflozin-becomes-the-first-and-only-approved-treatment-in-canada-for-adults-with-chronic-heart-failure-regardless-of-ejection-fraction 2022-04-12T21:01:23 https://maestrodatabase.com/blog/thousands-of-patients-to-access-medicare-subsidies-for-life-saving-treatments 2017-10-31T20:01:14 https://maestrodatabase.com/blog/ema-and-the-eunethta-21-consortium-set-priorities-for-their-collaboration 2022-04-12T20:56:34 https://maestrodatabase.com/blog/fda-takes-unprecedented-step-toward-more-efficient-global-pharmaceutical-manufacturing-inspections 2017-10-31T19:58:18 https://maestrodatabase.com/blog/janssen-announces-imbruvica-ibrutinib-as-the-first-approved-treatment-for-chronic-graft-versus-host-disease-granted-by-health-canada-priority-review 2017-10-31T20:09:32 https://maestrodatabase.com/blog/drug-firms-warn-ottawa-against-crippling-price-cuts 2017-10-31T20:04:45 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-announces-new-13-dot-9-million-dollar-grant-from-the-laura-and-john-arnold-foundation 2017-10-31T20:17:32 https://maestrodatabase.com/blog/us-fda-grants-fast-track-designation-for-paradigms-phase-3-osteoarthritis-program 2022-04-12T21:09:56 https://maestrodatabase.com/blog/novartis-submits-application-to-fda-for-kymriah-tisagenlecleucel-in-adult-patients-with-r-slash-r-dlbcl-seeking-second-indication-for-first-ever-fda-approved-car-t-therapy 2017-10-31T20:21:51 https://maestrodatabase.com/blog/beigene-and-eusa-pharma-announce-china-nmpa-approval-of-qarziba-dinutuximab-beta-for-patients-with-high-risk-neuroblastoma 2021-08-18T01:21:14 https://maestrodatabase.com/blog/relmada-announces-fda-fast-track-designation-for-d-methadone-for-adjunctive-treatment-of-major-depressive-disorder 2017-04-14T00:02:05 https://maestrodatabase.com/blog/moderna-covid-19-vaccine-approved-by-mhra-in-12-17-year-olds 2021-08-18T01:27:44 https://maestrodatabase.com/blog/health-canada-has-approved-zeposia-ozanimod-an-oral-treatment-for-adults-with-moderately-to-severely-active-ulcerative-colitis 2022-04-12T21:05:26 https://maestrodatabase.com/blog/pharmaceutical-companies-should-pay-for-raiding-natures-medicine-cabinet 2021-08-18T01:18:33 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-november-2017-update 2017-10-31T20:47:27 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-darzalex-faspro-for-newly-diagnosed-light-chain-amyloidosis 2021-01-16T00:28:50 https://maestrodatabase.com/blog/fda-approves-fam-trastuzumab-deruxtecan-nxki-for-her2-positive-gastric-adenocarcinomas 2021-01-16T00:19:45 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac---november-2022 2022-12-16T09:04:18 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-july-2018-update 2018-06-30T11:53:51 https://maestrodatabase.com/blog/nices-approach-to-measuring-value 2021-01-16T03:04:46 https://maestrodatabase.com/blog/fda-approves-pembrolizumab-with-chemotherapy-for-primary-advanced-or-recurrent-endometrial-carcinoma 2024-06-17T22:44:40 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-july-2018-update 2018-06-30T12:19:03 https://maestrodatabase.com/blog/price-of-breast-cancer-drug-ribociclib-cut-after-being-placed-on-pharmaceutical-benefits-scheme 2018-06-30T12:09:53 https://maestrodatabase.com/blog/herd-immunity-muddies-the-waters 2021-01-16T03:20:53 https://maestrodatabase.com/blog/strengthening-patient-outcome-evidence-in-health-technology-assessment-a-coproduction-approach 2021-01-16T03:13:51 https://maestrodatabase.com/blog/bavarian-nordic-completes-bla-submission-to-us-fda-for-its-chikungunya-vaccine-candidate 2024-06-17T23:09:48 https://maestrodatabase.com/blog/pharma-giant-aspen-accused-of-withholding-drugs-to-force-up-prices 2017-04-14T08:05:18 https://maestrodatabase.com/blog/trump-dangles-obamacare-payments-to-force-democrats-to-the-table 2017-04-14T01:33:58 https://maestrodatabase.com/blog/government-parks-scheme-to-contain-costs-of-medicare-safety-net-while-doctors-continue-to-raise-fees 2017-04-14T08:10:01 https://maestrodatabase.com/blog/csl-receives-positive-chmp-opinion-for-etranacogene-dezaparvovec---gene-therapy-for-adults-with-haemophilia-b 2022-12-16T09:46:52 https://maestrodatabase.com/blog/fast-start-for-fda-drug-approvals-in-2017 2017-04-14T08:12:46 https://maestrodatabase.com/blog/u-dot-s-fda-issues-complete-response-letter-for-baricitinib 2017-04-14T21:38:17 https://maestrodatabase.com/blog/dizal-announces-china-cde-acceptance-of-new-drug-application-for-golidocitinib-for-relapsed-or-refractory-ptcl 2023-09-15T08:09:48 https://maestrodatabase.com/blog/is-drug-pricing-at-an-inflection-point 2017-04-14T21:56:23 https://maestrodatabase.com/blog/defiant-generic-drug-maker-continues-to-raise-prices 2017-04-14T22:05:20 https://maestrodatabase.com/blog/ema-recommends-non-renewal-of-authorisation-of-multiple-myeloma-medicine-blenrep 2023-09-15T13:00:38 https://maestrodatabase.com/blog/moderna-announces-global-regulatory-submissions-for-its-investigational-seasonal-influenza-vaccine 2026-01-06T03:50:13 https://maestrodatabase.com/blog/pbac-public-summary-documents-rejections-slash-deferrals-slash-other-matters---september-2020-intracycle-meeting 2021-01-16T22:17:43 https://maestrodatabase.com/blog/abiraterone-acetate-for-treating-newly-diagnosed-high-risk-hormone-sensitive-metastatic-prostate-cancer 2021-08-18T05:56:58 https://maestrodatabase.com/blog/us-fda-approves-capvaxive-pneumococcal-21-valent-conjugate-vaccine-for-prevention-of-invasive-pneumococcal-disease-and-pneumococcal-pneumonia-in-adults 2024-06-18T03:06:20 https://maestrodatabase.com/blog/maplight-therapeutics-receives-fast-track-designation-for-ml-007c-ma-for-alzheimers-disease-psychosis 2026-01-05T23:07:03 https://maestrodatabase.com/blog/amoydx-pan-lung-cancer-pcr-panel-receives-mhlw-approval-as-companion-diagnostic-for-tepmetko-tepotinib 2021-08-18T06:05:01 https://maestrodatabase.com/blog/patients-push-for-transplant-medications-to-be-free-in-australia 2019-08-05T05:02:24 https://maestrodatabase.com/blog/protara-therapeutics-receives-both-fda-breakthrough-therapy-and-fast-track-designations-for-tara-002-in-paediatric-patients-with-lymphatic-malformations 2026-01-05T23:15:56 https://maestrodatabase.com/blog/covid-19-vaccines-additional-doses-codes-and-payment 2021-08-18T05:26:03 https://maestrodatabase.com/blog/altimmune-receives-fda-breakthrough-therapy-designation-for-pemvidutide-in-mash 2026-01-05T23:50:34 https://maestrodatabase.com/blog/awiqli---worlds-first-once-weekly-basal-insulin---now-available-in-canada 2024-06-18T02:29:12 https://maestrodatabase.com/blog/talks-to-recover-reimbursement-for-dementia-treatment-aid-almost-complete 2021-08-18T20:42:50 https://maestrodatabase.com/blog/sutro-biopharma-announces-stro-002-fda-fast-track-designation-for-patients-with-advanced-ovarian-cancer 2021-08-18T20:34:13 https://maestrodatabase.com/blog/us-fda-approves-jardiance-empagliflozin-to-treat-adults-living-with-heart-failure-with-reduced-ejection-fraction 2021-08-18T20:49:38 https://maestrodatabase.com/blog/billionaire-mark-cuban-wants-to-lower-drug-prices-with-generics-startup 2021-01-17T20:03:07 https://maestrodatabase.com/blog/joint-statement-from-hhs-public-health-and-medical-experts-on-covid-19-booster-shots 2021-08-18T20:30:17 https://maestrodatabase.com/blog/nice-recommends-new-treatment-option-for-highly-active-multiple-sclerosis 2026-01-06T05:36:42 https://maestrodatabase.com/blog/dacomitinib-in-advanced-lung-cancer-variety-of-disadvantages-lifts-survival-advantage 2019-08-05T08:18:54 https://maestrodatabase.com/blog/update-on-actemra-tocilizumab-supply-in-the-u-dot-s 2021-08-18T08:32:00 https://maestrodatabase.com/blog/decision-on-spinal-muscular-atrophy-treatment-spinraza-deferred 2019-02-18T01:13:14 https://maestrodatabase.com/blog/fda-issues-draft-guidance-regarding-clinical-trial-design-for-newborns 2019-08-05T08:39:02 https://maestrodatabase.com/blog/white-house-weighs-september-rollout-of-health-plan 2019-08-05T08:30:33 https://maestrodatabase.com/blog/fda-grants-breakthrough-device-designation-to-impella-ecp-the-worlds-smallest-heart-pump 2021-08-18T21:01:21 https://maestrodatabase.com/blog/arrowhead-pharmaceuticals-announces-health-canada-approval-of-redemplo-plozasiran-to-reduce-triglycerides-in-adults-with-familial-chylomicronaemia-syndrome 2026-01-06T03:54:46 https://maestrodatabase.com/blog/novartis-receives-positive-chmp-opinion-for-kymriah-for-treating-two-aggressive-blood-cancers-marking-important-medical-advance-for-patients-in-europe 2018-06-30T13:48:59 https://maestrodatabase.com/blog/eli-lilly-confirms-probe-by-new-yorks-attorney-general-over-insulin-prices 2019-08-05T08:27:25 https://maestrodatabase.com/blog/ms-drug-hull-couples-treatment-denied-by-cruel-postcode-lottery 2021-08-18T21:16:24 https://maestrodatabase.com/blog/who-calls-on-roche-to-ensure-fair-access-to-covid-19-drug-amid-shortage 2021-08-18T21:12:30 https://maestrodatabase.com/blog/idorsias-jeraygo-aprocitentan-approved-in-canada-for-the-treatment-of-resistant-hypertension 2026-01-06T04:29:34 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-mavacamten-for-hypertrophic-cardiomyopathy 2021-08-18T20:54:48 https://maestrodatabase.com/blog/forxiga-label-updated-in-the-eu-in-type-2-diabetes-mellitus 2019-08-05T11:40:04 https://maestrodatabase.com/blog/vaccinating-our-kids-shouldnt-be-this-hard 2019-08-05T09:26:42 https://maestrodatabase.com/blog/subcutaneous-amivantamab-biologics-license-application-submitted-to-us-fda-for-patients-with-egfr-mutated-non-small-cell-lung-cancer 2024-06-18T03:35:58 https://maestrodatabase.com/blog/abbvie-submits-new-drug-application-to-us-fda-for-investigational-elagolix-for-management-of-heavy-menstrual-bleeding-associated-with-uterine-fibroids-in-women 2019-08-05T12:42:25 https://maestrodatabase.com/blog/nice-publishes-final-guidance-on-the-use-of-a-topical-gel-for-patients-with-a-rare-cancer 2021-08-18T21:22:40 https://maestrodatabase.com/blog/how-much-will-americans-sacrifice-for-good-health-care 2019-02-18T02:55:27 https://maestrodatabase.com/blog/medicines-for-rare-disorders 2019-02-18T03:12:40 https://maestrodatabase.com/blog/hospital-drug-prices-are-up-to-7-times-greater-than-medicare-pricing 2019-02-18T02:17:09 https://maestrodatabase.com/blog/alnylam-announces-u-dot-s-fda-granted-priority-review-of-the-givosiran-new-drug-application-for-the-treatment-of-acute-hepatic-porphyria 2019-08-05T21:02:56 https://maestrodatabase.com/blog/high-stakes-as-trump-democrats-open-drug-price-talks 2019-02-18T02:19:52 https://maestrodatabase.com/blog/bayer-receives-breakthrough-therapy-designation-in-the-us-and-china-for-sevabertinib-as-a-first-line-treatment-for-patients-with-her2-mutant-non-small-cell-lung-cancer 2026-01-06T20:01:25 https://maestrodatabase.com/blog/foamix-submits-new-drug-application-to-u-dot-s-fda-for-fmx103-for-the-treatment-of-moderate-to-severe-papulopustular-rosacea 2019-08-05T21:13:41 https://maestrodatabase.com/blog/bausch-health-provides-update-for-duobrii-filing 2019-02-18T06:37:30 https://maestrodatabase.com/blog/ucb-receives-chmp-positive-opinion-of-zilucoplan-for-the-treatment-of-adults-with-generalized-myasthenia-gravis-in-europe 2023-09-15T21:45:58 https://maestrodatabase.com/blog/2020-election-creates-perfect-storm-for-drug-price-reform-by-year-end 2019-08-05T21:25:24 https://maestrodatabase.com/blog/novo-nordisk-lilly-sanofi-must-face-insulin-drug-pricing-suit 2019-02-18T19:57:49 https://maestrodatabase.com/blog/a-smarter-way-to-curb-drug-prices-through-imports 2019-08-05T21:23:17 https://maestrodatabase.com/blog/china-increases-drug-price-control-measures 2019-08-05T21:19:34 https://maestrodatabase.com/blog/us-fda-rare-paediatric-disease-designation-granted-to-rc220-bisantrene-for-the-treatment-of-paediatric-aml 2024-06-18T05:17:29 https://maestrodatabase.com/blog/brexit-will-britons-living-in-the-eu-still-get-health-care 2019-02-18T20:37:22 https://maestrodatabase.com/blog/dupixent-dupilumab-recommended-for-eu-approval-by-the-chmp-for-the-treatment-of-eosinophilic-oesophagitis 2022-12-16T23:04:34 https://maestrodatabase.com/blog/pharmac-improves-access-to-breast-cancer-treatments 2024-06-18T06:26:54 https://maestrodatabase.com/blog/amag-submits-supplemental-new-drug-application-to-fda-for-makena-hydroxyprogesterone-caproate-injection-auto-injector-for-subcutaneous-use 2017-04-17T20:52:22 https://maestrodatabase.com/blog/expanding-cadths-drug-review-processes-to-include-radiopharmaceuticals 2017-04-17T21:05:00 https://maestrodatabase.com/blog/alixorexton-granted-breakthrough-therapy-designation-by-us-fda-for-the-treatment-of-narcolepsy-type-1 2026-01-06T23:33:43 https://maestrodatabase.com/blog/patients-resort-to-paying-consultants-to-help-navigate-canadas-byzantine-health-care-system 2017-04-17T21:11:10 https://maestrodatabase.com/blog/oculis-announces-us-fda-breakthrough-therapy-designation-granted-to-privosegtor-for-treatment-of-optic-neuritis 2026-01-06T23:49:54 https://maestrodatabase.com/blog/abbvie-submits-supplemental-new-drug-application-to-us-fda-to-support-new-indication-of-linzess-linaclotide-for-functional-constipation-in-children-and-adolescents-6-to-17-years-of-age 2022-12-17T00:12:14 https://maestrodatabase.com/blog/cms-issues-final-rule-to-increase-choices-and-encourage-stability-in-health-insurance-market-for-2018 2017-04-17T21:23:50 https://maestrodatabase.com/blog/grifols-biotest-receives-fda-approval-for-innovative-yimmugo-immunoglobulin-to-treat-primary-immunodeficiencies 2024-06-18T07:17:07 https://maestrodatabase.com/blog/neurotechs-encelto-revakinagene-taroretcel-lwey-approved-by-the-fda-for-the-treatment-of-macular-telangiectasia-type-2 2025-03-07T01:16:46 https://maestrodatabase.com/blog/enzyvant-receives-fda-breakthrough-therapy-designation-and-regenerative-medicine-advanced-therapy-designation-for-investigational-therapy-rvt-802 2017-04-17T23:34:24 https://maestrodatabase.com/blog/as-medical-costs-mount-japan-to-weigh-cost-effectiveness-in-setting-drug-prices 2019-02-19T02:05:50 https://maestrodatabase.com/blog/johnson-and-johnson-submits-application-to-the-ema-for-tecvayli-teclistamab-in-combination-with-darzalex-daratumumab-subcutaneous-formulation-for-patients-with-relapsed-slash-refractory-multiple-myeloma 2026-01-07T01:13:56 https://maestrodatabase.com/blog/milestone-pharmaceuticals-announces-acceptance-of-marketing-authorisation-application-for-etripamil-nasal-spray-in-psvt-by-the-ema 2026-01-07T01:27:17 https://maestrodatabase.com/blog/maviret-receives-health-canada-approval-for-the-treatment-of-acute-hepatitis-c-virus 2026-01-07T01:42:37 https://maestrodatabase.com/blog/fda-approves-genentechs-lucentis-ranibizumab-injection-for-diabetic-retinopathy-the-leading-cause-of-blindness-among-working-age-adults-in-the-united-states 2017-04-18T00:03:31 https://maestrodatabase.com/blog/submissions-received-and-tga-response-orphan-drug-program 2017-04-18T01:13:21 https://maestrodatabase.com/blog/enhertu-recommended-for-approval-in-the-eu-by-chmp-for-patients-with-her2-mutant-advanced-non-small-cell-lung-cancer 2023-09-15T23:47:21 https://maestrodatabase.com/blog/koreas-next-homegrown-drug-could-be-a-first-local-car-t-as-payer-keeps-widening-access 2026-01-07T00:23:55 https://maestrodatabase.com/blog/janssen-receives-health-canada-approval-of-darzalex-daratumumab-by-priority-review-for-patients-with-multiple-myeloma-who-have-had-at-least-one-prior-therapy 2017-04-18T01:07:21 https://maestrodatabase.com/blog/european-chmp-adopts-positive-opinion-for-yescarta-axicabtagene-ciloleucel-for-the-treatment-of-relapsed-or-refractory-dlbcl-and-pmbcl-after-two-or-more-lines-of-systemic-therapy 2018-07-01T00:57:21 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-positive-chmp-opinion-recommending-approval-of-opdivo-nivolumab-for-the-adjuvant-treatment-of-adult-patients-with-melanoma 2018-07-01T00:52:04 https://maestrodatabase.com/blog/public-summary-documents---march-2018-pbac-meeting 2018-07-13T05:49:32 https://maestrodatabase.com/blog/vertex-receives-chmp-positive-opinion-for-kaftrio-ivacaftor-slash-tezacaftor-slash-elexacaftor-in-combination-with-ivacaftor-for-children-with-cystic-fibrosis-ages-2-through-5 2023-09-16T00:09:06 https://maestrodatabase.com/blog/fda-allows-off-label-health-care-economic-discussions-is-there-more-to-come 2018-07-01T01:04:13 https://maestrodatabase.com/blog/ferring-receives-health-canada-approval-for-rebyota-faecal-microbiota-live 2025-03-07T03:36:19 https://maestrodatabase.com/blog/biosplice-announces-the-submission-of-its-new-drug-application-to-the-fda-for-lorecivivint-to-treat-knee-osteoarthritis 2026-01-07T03:42:01 https://maestrodatabase.com/blog/a-drug-that-elongates-life-in-breast-cancer-patients-listed-on-pbs-today---but-only-for-some 2018-07-01T02:10:53 https://maestrodatabase.com/blog/peak-bodies-unite-against-threat-to-commercialisation-of-australian-medical-research 2017-04-18T03:09:26 https://maestrodatabase.com/blog/scpharmaceuticals-announces-fda-approval-of-supplemental-new-drug-application-expanding-the-furoscix-indication-to-include-the-treatment-of-oedema-in-patients-with-chronic-kidney-disease 2025-03-07T03:32:51 https://maestrodatabase.com/blog/fda-chief-on-amazons-health-care-move-disruptive-competition-is-a-good-thing 2018-07-01T02:15:07 https://maestrodatabase.com/blog/novartis-car-t-cell-therapy-ctl019-receives-fda-breakthrough-therapy-designation-for-treatment-of-adult-patients-with-r-slash-r-dlbcl 2017-04-18T08:20:17 https://maestrodatabase.com/blog/sorry-republicans-but-most-people-support-single-payer-health-care 2017-04-18T07:56:29 https://maestrodatabase.com/blog/china-to-establish-collaboration-network-for-rare-disease-diagnosis-treatment 2019-02-19T07:50:31 https://maestrodatabase.com/blog/dont-blame-drug-companies-for-high-prices 2019-02-19T08:18:54 https://maestrodatabase.com/blog/miravo-healthcare-announces-receipt-of-health-canada-notice-of-compliance-for-the-paediatric-use-of-blexten 2021-08-19T00:54:59 https://maestrodatabase.com/blog/abbvie-announces-new-drug-application-accepted-for-priority-review-by-u-dot-s-fda-for-upadacitinib-for-treatment-of-moderate-to-severe-rheumatoid-arthritis 2019-02-19T19:23:34 https://maestrodatabase.com/blog/fda-grants-roches-tecentriq-atezolizumab-accelerated-approval-as-initial-treatment-for-certain-people-with-advanced-bladder-cancer 2017-04-18T20:40:33 https://maestrodatabase.com/blog/new-early-breast-cancer-drug-to-be-made-available-in-singapore-via-special-access-program 2019-02-19T08:25:22 https://maestrodatabase.com/blog/merck-receives-positive-eu-chmp-opinion-for-keytruda-pembrolizumab-as-adjuvant-treatment-for-adults-with-non-small-cell-lung-cancer-at-high-risk-of-recurrence-following-complete-resection-and-platinum-based-chemotherapy 2023-09-16T00:48:27 https://maestrodatabase.com/blog/second-consultation-launched-on-nhs-funding-for-alzheimers-treatments 2025-03-07T03:55:13 https://maestrodatabase.com/blog/tga-reduces-timeframe-for-publishing-adverse-event-reports 2021-08-19T00:48:22 https://maestrodatabase.com/blog/amivantamab-in-combination-with-pemetrexed-disodium-heptahydrate-and-carboplatin-for-the-treatment-of-patients-with-advanced-egfr-exon-20-insertion-mutation-positive-non-small-cell-lung-cancer 2025-03-07T04:22:20 https://maestrodatabase.com/blog/big-opportunities-in-big-data-but-ema-and-industry-just-getting-started 2019-02-19T19:59:56 https://maestrodatabase.com/blog/obamacares-insurers-struggle-for-stability-amid-trump-threats 2017-04-18T20:49:53 https://maestrodatabase.com/blog/pfenex-announces-fda-acceptance-of-nda-for-pf708 2019-02-19T20:04:36 https://maestrodatabase.com/blog/us-fda-approves-skyrizi-risankizumab-rzaa-for-ulcerative-colitis-expanding-abbvies-portfolio-across-inflammatory-bowel-disease 2024-06-19T01:20:33 https://maestrodatabase.com/blog/fda-grants-priority-review-to-roches-personalised-medicine-entrectinib 2019-02-19T19:33:24 https://maestrodatabase.com/blog/how-nz-is-preparing-for-the-biggest-vaccine-roll-out-in-history 2021-01-18T02:03:47 https://maestrodatabase.com/blog/my-health-record-reflects-new-consensus-says-ceo-tim-kelsey 2019-02-19T19:57:28 https://maestrodatabase.com/blog/norwegian-investigation-of-covid-19-vaccination-risks-for-elderly-very-frail-patients 2021-01-18T02:31:59 https://maestrodatabase.com/blog/drug-prices-are-killing-diabetics-walmart-insulin-isnt-the-solution 2019-02-19T20:12:35 https://maestrodatabase.com/blog/take-the-mystery-out-of-drug-pricing 2017-04-18T21:09:49 https://maestrodatabase.com/blog/nice-rejects-ocrelizumab-ocrevus-for-primary-progressive-ms-in-england-and-wales 2018-07-01T04:55:34 https://maestrodatabase.com/blog/why-replacing-the-aca-has-republicans-in-a-tizzy 2017-04-18T21:04:12 https://maestrodatabase.com/blog/icer-issues-correction-to-final-evidence-report-on-new-therapies-for-bladder-cancer 2021-01-18T02:43:32 https://maestrodatabase.com/blog/tga-approves-lumakras 2022-04-13T03:46:12 https://maestrodatabase.com/blog/daratumumab-monotherapy-for-treating-relapsed-and-refractory-multiple-myeloma 2022-04-13T04:48:01 https://maestrodatabase.com/blog/private-health-insurance-a-hard-sell-to-medicare-generation 2018-07-01T21:50:43 https://maestrodatabase.com/blog/highest-risk-covid-19-patients-receive-brilliant-new-antivirals-at-home 2022-04-13T04:43:45 https://maestrodatabase.com/blog/fda-sped-progress-for-most-of-2020s-novel-drugs 2021-01-18T03:29:15 https://maestrodatabase.com/blog/changes-to-medicare-advantage-and-part-d-will-provide-better-coverage-more-access-and-improved-transparency-for-medicare-beneficiaries 2021-01-18T03:33:50 https://maestrodatabase.com/blog/ema-recommends-non-renewal-of-authorisation-of-duchenne-muscular-dystrophy-medicine-translarna 2023-09-16T02:00:31 https://maestrodatabase.com/blog/fda-grants-priority-review-to-roches-polatuzumab-vedotin-in-previously-treated-aggressive-lymphoma 2019-02-20T08:28:50 https://maestrodatabase.com/blog/pfizer-receives-european-approval-for-zirabev-bevacizumab-a-biosimilar-to-avastin 2019-02-20T08:39:24 https://maestrodatabase.com/blog/fda-approves-mercks-keytruda-pembrolizumab-for-the-adjuvant-treatment-of-patients-with-melanoma-with-involvement-of-lymph-node-s-following-complete-resection 2019-02-20T08:34:12 https://maestrodatabase.com/blog/novo-nordisk-receives-us-fda-approval-of-esperoct-turoctocog-alfa-pegol-n8-gp 2019-02-20T08:49:13 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-19-august-2021 2021-08-19T02:53:45 https://maestrodatabase.com/blog/gilead-receives-approval-in-canada-for-yescarta-axicabtagene-ciloleucel-car-t-therapy-for-adults-with-relapsed-or-refractory-large-b-cell-lymphoma-after-two-or-more-lines-of-systemic-therapy 2019-02-20T08:44:26 https://maestrodatabase.com/blog/beigene-announces-acceptance-by-swissmedic-of-marketing-authorisation-application-for-brukinsa-zanubrutinib-in-waldenstroems-macroglobulinaemia 2021-08-19T02:58:34 https://maestrodatabase.com/blog/u-dot-s-top-court-rejects-maryland-bid-to-revive-drug-price-gouging-law 2019-02-20T11:27:29 https://maestrodatabase.com/blog/nice-terminates-appraisal-of-combination-regimen-for-patients-with-advanced-platinum-sensitive-ovarian-cancer 2019-02-20T11:33:02 https://maestrodatabase.com/blog/new-drug-landscape-dominated-by-high-cost-medicines 2019-02-20T08:54:18 https://maestrodatabase.com/blog/governments-health-reforms-mean-health-fund-members-lose-benefits 2019-02-20T19:54:08 https://maestrodatabase.com/blog/my-health-record-opt-out-doubles-to-2-dot-5-million-people 2019-02-20T19:57:34 https://maestrodatabase.com/blog/updates-for-patients-and-communities 2019-02-20T19:45:10 https://maestrodatabase.com/blog/hhs-regulations-with-enduring-impact-on-pricing-and-reimbursement-of-medical-services-and-technologies 2021-01-18T04:51:45 https://maestrodatabase.com/blog/agios-announces-fda-acceptance-of-supplemental-new-drug-application-for-tibsovo-ivosidenib-for-the-treatment-of-patients-with-newly-diagnosed-acute-myeloid-leukaemia-with-an-idh1-mutation-not-eligible-for-standard-therapy 2019-02-20T20:09:04 https://maestrodatabase.com/blog/smc---january-2021-decisions 2021-01-18T19:54:07 https://maestrodatabase.com/blog/double-vaccine-rollout-in-plan-to-defeat-covid-19 2021-01-18T20:02:03 https://maestrodatabase.com/blog/brexit-doesnt-mean-eu-agency-can-break-canary-wharf-lease 2019-02-20T20:00:16 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-gene-therapy-for-beta-thalassaemia 2022-04-13T20:13:35 https://maestrodatabase.com/blog/norway-finds-no-direct-link-between-elderly-deaths-and-vaccine 2021-01-18T20:04:57 https://maestrodatabase.com/blog/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-for-keytruda-pembrolizumab-monotherapy-for-third-line-treatment-of-patients-with-advanced-small-cell-lung-cancer 2019-02-20T20:04:22 https://maestrodatabase.com/blog/drug-pricing-fight-centers-on-insulin 2019-02-20T20:15:06 https://maestrodatabase.com/blog/diverging-from-fda-health-canada-announces-suffix-free-biologic-and-biosimilar-naming-convention 2019-02-20T20:18:39 https://maestrodatabase.com/blog/vera-therapeutics-announces-us-fda-granted-priority-review-to-biologics-license-application-for-atacicept-for-treatment-of-adults-with-iga-nephropathy 2026-01-08T00:09:03 https://maestrodatabase.com/blog/pear-therapeutics-receives-safer-technologies-program-designation-from-fda-for-product-candidate-to-treat-acute-and-chronic-pain 2022-04-13T20:37:33 https://maestrodatabase.com/blog/fda-takes-important-steps-to-increase-racial-and-ethnic-diversity-in-clinical-trials 2022-04-13T20:41:39 https://maestrodatabase.com/blog/briacell-receives-fda-fast-track-approval-for-targeted-breast-cancer-immunotherapy 2022-04-13T20:23:49 https://maestrodatabase.com/blog/quizartinib-recommended-for-approval-in-eu-by-chmp-for-patients-with-newly-diagnosed-flt3-itd-positive-aml 2023-09-16T03:06:15 https://maestrodatabase.com/blog/insights-from-the-tgas-publication-of-submissions-for-prescription-medicines-currently-under-evaluation 2021-01-18T20:24:52 https://maestrodatabase.com/blog/european-commission-approves-padcev-enfortumab-vedotin-for-locally-advanced-or-metastatic-urothelial-cancer 2022-04-13T20:30:55 https://maestrodatabase.com/blog/fda-approves-new-2-gram-presentation-of-fibryga-enhancing-convenience-and-precision-in-treating-acquired-fibrinogen-deficiency 2026-01-08T01:13:56 https://maestrodatabase.com/blog/nice-backs-biogens-vumerity-for-multiple-sclerosis 2022-04-13T21:00:10 https://maestrodatabase.com/blog/insulin-isnt-affordable-for-many-americans-that-may-be-a-human-rights-abuse-report-says 2022-04-13T21:09:38 https://maestrodatabase.com/blog/paxlovid-inaccessible-to-many-patients-in-canada-heres-why-that-needs-to-change 2022-04-13T21:06:26 https://maestrodatabase.com/blog/tafamidis-meglumine-for-the-treatment-of-patients-with-transthyretin-amyloidosis-with-cardiomyopathy-final-guidance 2024-06-19T06:36:34 https://maestrodatabase.com/blog/committee-releases-report-uncovering-significant-conflicts-of-interest-at-mckinsey-related-to-work-for-fda-and-opioid-manufacturers 2022-04-13T20:49:23 https://maestrodatabase.com/blog/ocular-therapeutix-announces-nda-resubmission-of-dextenza 2018-07-02T00:32:13 https://maestrodatabase.com/blog/why-the-drug-pricing-debate-is-focused-on-insulin 2022-04-13T20:53:38 https://maestrodatabase.com/blog/how-ai-is-revolutionising-drug-development 2024-06-19T07:54:22 https://maestrodatabase.com/blog/europes-new-hta-system-spurs-more-debate-concern 2022-04-13T21:28:46 https://maestrodatabase.com/blog/amneal-achieves-second-u-dot-s-biosimilars-approval-with-alymsys-bevacizumab-maly 2022-04-13T21:12:59 https://maestrodatabase.com/blog/irish-cancer-patients-wait-four-months-longer-for-access-to-new-drugs-than-rest-of-europe 2022-04-13T21:22:41 https://maestrodatabase.com/blog/public-summary-documents---november-2024-pbac-meeting 2025-03-07T07:03:40 https://maestrodatabase.com/blog/cheaper-medicines-for-childrens-inflammatory-diseases-rare-liver-disease-and-multiple-sclerosis 2026-01-08T05:15:27 https://maestrodatabase.com/blog/vanda-pharmaceuticals-announces-receipt-of-fda-decision-letter-on-hetlioz-supplemental-new-drug-application-for-jet-lag-disorder 2026-01-08T19:48:57 https://maestrodatabase.com/blog/tga-approves-name-change-of-covid-19-vaccine-astrazeneca-to-vaxzevria 2021-08-19T06:30:59 https://maestrodatabase.com/blog/national-cancer-drug-promise-pharmac-minister-wont-guarantee-those-13-drugs-will-be-funded 2024-06-19T08:52:39 https://maestrodatabase.com/blog/roche-receives-fda-approval-for-first-companion-diagnostic-to-identify-dmmr-solid-tumour-patients-eligible-for-anti-pd-1-immunotherapy 2021-08-19T20:45:43 https://maestrodatabase.com/blog/is-nudging-biologic-patients-towards-biosimilars-a-good-choice-for-plan-sponsors 2018-07-02T01:47:22 https://maestrodatabase.com/blog/senhwas-silmitasertib-receives-us-fda-fast-track-designation-for-the-treatment-of-recurrent-sonic-hedgehog-driven-medulloblastoma 2021-08-19T20:52:31 https://maestrodatabase.com/blog/lazertinib-approved-for-use-in-combination-with-amivantamab-for-the-treatment-of-adults-with-non-small-cell-lung-cancer 2025-03-07T22:54:15 https://maestrodatabase.com/blog/nice-recommends-first-treatment-for-rare-blood-disorder 2021-08-19T20:41:08 https://maestrodatabase.com/blog/contradicting-who-us-advises-adults-to-receive-covid-19-boosters 2021-08-19T21:24:19 https://maestrodatabase.com/blog/mtaa-calls-for-national-audit-office-to-inspect-private-health-insurance-books 2017-11-01T19:20:23 https://maestrodatabase.com/blog/nice-back-roches-tecentriq-for-cdf 2017-11-01T19:30:43 https://maestrodatabase.com/blog/nices-health-technology-assessment-methods-and-processes-to-be-evaluated 2021-08-19T21:29:54 https://maestrodatabase.com/blog/booster-shots-make-a-mockery-of-vaccine-equity-the-whos-africa-director-says 2021-08-19T21:26:26 https://maestrodatabase.com/blog/drug-giants-threaten-nhs-with-legal-action-over-cheaper-drug-that-could-save-84-million-pounds-a-year 2017-11-01T19:27:17 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-posts-draft-scoping-document-to-guide-review-of-tezacaftor-and-lumacaftor-for-cystic-fibrosis 2017-11-01T19:39:16 https://maestrodatabase.com/blog/endopredict-for-breast-cancer---the-company-chose-not-to-participate-with-data 2021-08-19T20:59:23 https://maestrodatabase.com/blog/citius-pharmaceuticals-receives-fast-track-designation-by-fda-for-mino-lok-investigational-trial 2017-11-01T19:53:44 https://maestrodatabase.com/blog/ema-validates-gileads-marketing-authorisation-application-for-lenacapavir-an-investigational-long-acting-capsid-inhibitor-for-the-treatment-of-hiv-1-in-people-with-limited-therapy-options 2021-08-19T21:06:04 https://maestrodatabase.com/blog/european-commission-grants-sobi-marketing-authorisation-for-altuvoct-for-treatment-of-haemophilia-a 2024-06-19T22:33:59 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-european-commission-approval-for-opdivo-nivolumab-plus-yervoy-ipilimumab-for-the-first-line-treatment-of-adult-patients-with-unresectable-or-advanced-hepatocellular-carcinoma 2025-03-07T23:16:50 https://maestrodatabase.com/blog/revolution-medicines-announces-fda-breakthrough-therapy-designation-for-zoldonrasib 2026-01-09T00:53:38 https://maestrodatabase.com/blog/geron-announces-fast-track-designation-granted-to-imetelstat-for-lower-risk-myelodysplastic-syndromes 2017-11-01T20:08:40 https://maestrodatabase.com/blog/argenx-announces-positive-chmp-opinion-for-subcutaneous-efgartigimod-for-generalised-myasthenia-gravis 2023-09-16T04:06:04 https://maestrodatabase.com/blog/vectory-therapeutics-receives-fda-fast-track-designation-for-vtx-002-a-first-in-class-vectorised-antibody-targeting-underlying-disease-biology-in-als 2026-01-09T01:00:09 https://maestrodatabase.com/blog/bayer-announces-bay94-9027-biologics-license-application-accepted-by-u-dot-s-food-and-drug-administration 2017-11-01T20:25:29 https://maestrodatabase.com/blog/cadth-welcomes-transfer-of-drug-safety-and-effectiveness-network 2021-08-19T21:37:44 https://maestrodatabase.com/blog/gw-pharmaceuticals-and-its-u-dot-s-subsidiary-greenwich-biosciences-completes-rolling-new-drug-application-submission-to-u-dot-s-food-and-drug-administration-for-epidiolex-cannabidiol-in-the-treatment-of-lennox-gastaut-syndrome-and-dravet-syndrome 2017-11-01T20:36:08 https://maestrodatabase.com/blog/annexon-submits-tanruprubart-marketing-authorisation-application-to-the-ema-for-guillain-barre-syndrome 2026-01-09T01:23:27 https://maestrodatabase.com/blog/nabriva-therapeutics-announces-acceptance-of-new-drug-applications-by-the-fda-for-intravenous-and-oral-lefamulin-to-treat-community-acquired-bacterial-pneumonia-in-adults 2019-02-21T05:25:39 https://maestrodatabase.com/blog/wockhardt-files-marketing-authorisation-application-for-wck-5222-with-ema 2026-01-09T01:37:11 https://maestrodatabase.com/blog/trump-talks-tough-but-little-action-seen-on-drug-prices 2017-11-01T20:48:07 https://maestrodatabase.com/blog/u-dot-s-states-allege-broad-generic-drug-price-fixing-collusion 2017-11-01T20:41:53 https://maestrodatabase.com/blog/complement-therapeutics-announces-fda-fast-track-designation-for-ctx001-for-the-treatment-of-geographic-atrophy-secondary-to-amd 2026-01-09T00:33:45 https://maestrodatabase.com/blog/alessa-therapeutics-announces-fda-fast-track-designation-for-enolen-a-first-of-its-kind-treatment-for-localised-prostate-cancer 2026-01-09T00:38:57 https://maestrodatabase.com/blog/provention-bio-announces-breakthrough-therapy-designation-for-teplizumab-for-the-prevention-or-delay-of-clinical-type-1-diabetes-in-at-risk-individuals 2019-08-06T07:02:59 https://maestrodatabase.com/blog/858-therapeutics-announces-fda-fast-track-designation-for-parg-inhibitor-etx-19477-for-the-treatment-of-patients-with-brca-mutated-platinum-resistant-ovarian-cancer 2026-01-09T00:45:38 https://maestrodatabase.com/blog/fdas-final-breakthrough-devices-guidance-now-includes-technologies-that-address-health-disparities 2023-09-16T04:43:58 https://maestrodatabase.com/blog/acadia-pharmaceuticals-announces-fda-approval-of-new-dosing-formulation-and-strength-for-nuplazid-pimavanserin 2018-07-02T03:18:13 https://maestrodatabase.com/blog/dermira-receives-fda-approval-for-qbrexza-glycopyrronium-cloth-to-treat-primary-axillary-hyperhidrosis 2018-07-02T03:24:43 https://maestrodatabase.com/blog/chmp-recommends-approval-of-cablivi-caplacizumab 2018-07-02T03:31:49 https://maestrodatabase.com/blog/fdas-accelerated-approval-guidance-gets-pushback-from-industry 2025-03-08T01:50:51 https://maestrodatabase.com/blog/ultragenyx-announces-positive-chmp-opinion-for-mepsevii-vestronidase-alfa-for-the-treatment-of-mucopolysaccharidosis-vii 2018-07-02T03:40:39 https://maestrodatabase.com/blog/us-fda-approves-vraylar-cariprazine-as-an-adjunctive-treatment-for-major-depressive-disorder 2022-12-18T00:24:50 https://maestrodatabase.com/blog/gsks-shingrix-recombinant-zoster-vaccine-pre-filled-syringe-presentation-approved-by-the-european-commission 2026-01-09T04:29:50 https://maestrodatabase.com/blog/acarizax-approved-in-canada-for-treatment-of-young-children 2025-03-08T01:38:54 https://maestrodatabase.com/blog/agenda-for-the-march-2026-pbac-meeting-9-january-2026 2026-01-09T05:37:01 https://maestrodatabase.com/blog/valeant-is-back-to-its-old-drug-pricing-ways 2018-07-02T05:12:26 https://maestrodatabase.com/blog/amazons-pillpack-deal-gives-it-access-to-sensitive-health-data 2018-07-02T05:08:34 https://maestrodatabase.com/blog/another-multi-product-proposal-from-novartis-this-time-involving-ten-pharmaceuticals 2018-07-02T07:41:37 https://maestrodatabase.com/blog/a-closer-look-at-bernie-sanders-plans-to-upend-pharma-and-lower-drug-prices 2020-02-09T11:38:38 https://maestrodatabase.com/blog/alimera-announces-iluvien-regulatory-approval-in-australia-for-the-treatment-of-diabetic-macular-oedema 2019-08-06T07:38:05 https://maestrodatabase.com/blog/how-this-gene-therapy-drug-earned-its-2-dollars-1-cents-million-price-tag 2020-02-09T11:34:55 https://maestrodatabase.com/blog/proposals-for-funding-in-the-immunosuppressant-cardiovascular-and-anti-nausea-therapeutic-areas 2019-08-06T07:30:47 https://maestrodatabase.com/blog/biosimilars-and-interchangeable-biosimilars-licensure-for-fewer-than-all-conditions-of-use-for-which-the-reference-product-has-been-licensed-guidance-for-industry 2020-02-09T12:22:55 https://maestrodatabase.com/blog/this-immunotherapy-drug-helped-me-beat-cancer---instead-of-$229k-it-now-costs-31-dollars 2025-03-08T03:23:11 https://maestrodatabase.com/blog/aurion-biotech-receives-breakthrough-therapy-designation-and-regenerative-medicine-advanced-therapy-designation-for-its-drug-candidate-aurn001 2024-06-20T01:23:32 https://maestrodatabase.com/blog/anatomy-of-a-97-000-percent-drug-price-hike-one-familys-fight-to-save-their-son 2018-07-02T12:05:53 https://maestrodatabase.com/blog/n-dot-s-senior-blasts-province-over-blood-thinner-coverage-under-pharmacare 2020-02-09T11:55:18 https://maestrodatabase.com/blog/chmp-recommends-expansion-of-eu-label-for-hemlibra-to-include-people-with-moderate-haemophilia-a 2022-12-18T00:30:32 https://maestrodatabase.com/blog/jeff-bezos-just-did-president-trump-a-big-favour-on-drug-pricing 2018-07-02T12:08:55 https://maestrodatabase.com/blog/extreme-regulations-to-lower-drug-prices-mean-canada-will-get-fewer-new-drugs 2020-02-09T11:51:40 https://maestrodatabase.com/blog/vertex-announces-uk-mhra-approval-of-alyftrek-deutivacaftor-slash-tezacaftor-slash-vanzacaftor-a-once-daily-next-in-class-cftr-modulator-for-the-treatment-of-cystic-fibrosis 2025-03-08T02:12:52 https://maestrodatabase.com/blog/ardelyx-provides-update-on-fda-appeal-for-xphozah-tenapanor-for-the-control-of-serum-phosphorus-in-adult-patients-with-chronic-kidney-disease-on-dialysis 2022-12-18T01:17:13 https://maestrodatabase.com/blog/amicus-therapeutics-receives-positive-chmp-opinion-for-pombiliti-cipaglucosidase-alfa-for-late-onset-pompe-disease 2022-12-18T00:53:48 https://maestrodatabase.com/blog/ojjaara-momelotinib-approved-in-the-us-as-the-first-and-only-treatment-indicated-for-myelofibrosis-patients-with-anaemia 2023-09-17T01:12:32 https://maestrodatabase.com/blog/finerenone-receives-positive-chmp-opinion-for-eu-label-extension-for-broad-range-of-patients-with-chronic-kidney-disease-and-type-2-diabetes 2022-12-18T00:41:47 https://maestrodatabase.com/blog/pfizer-hikes-cost-of-viagra-and-100-other-drugs-report-says 2018-07-02T21:01:22 https://maestrodatabase.com/blog/fda-approves-aristada-initio-for-the-initiation-of-aristada-for-schizophrenia 2018-07-02T21:04:14 https://maestrodatabase.com/blog/public-summary-documents---december-2021-pbac-meeting-first-time-decisions-not-to-recommend-deferrals-and-other-matters 2022-04-14T05:14:32 https://maestrodatabase.com/blog/haemophilia-a-and-sialorrhoea-contemporary-comparative-therapies-not-implemented-so-added-benefit-not-proven 2018-07-02T21:30:40 https://maestrodatabase.com/blog/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-for-keytruda-pembrolizumab-in-combination-with-chemotherapy-as-first-line-treatment-for-metastatic-squamous-non-small-cell-lung-cancer 2018-07-02T21:17:45 https://maestrodatabase.com/blog/fortress-biotech-announces-cyprium-therapeutics-cutx-101-copper-histidinate-granted-fda-fast-track-designation-for-treatment-of-classic-menkes-disease 2018-07-02T21:25:44 https://maestrodatabase.com/blog/fda-approves-first-gene-therapy-for-the-treatment-of-high-risk-non-muscle-invasive-bladder-cancer 2022-12-18T01:48:37 https://maestrodatabase.com/blog/pharmaceutical-benefits-scheme-process-improvements-webinar-information-forum 2019-02-21T08:25:58 https://maestrodatabase.com/blog/abbvies-humira-adalimumab-approved-by-health-canada-to-treat-paediatric-patients-with-chronic-non-infectious-anterior-uveitis 2019-02-21T10:59:15 https://maestrodatabase.com/blog/highlights-from-the-11-14-september-2023-chmp-meeting 2023-09-17T21:47:55 https://maestrodatabase.com/blog/a-better-path-to-universal-health-care 2019-02-21T11:05:49 https://maestrodatabase.com/blog/japan-approves-two-gene-treatments-in-bid-to-catch-up 2019-02-21T11:08:56 https://maestrodatabase.com/blog/us-fda-designates-alexis-bios-realskin-as-regenerative-medicine-advanced-therapy 2022-12-18T02:23:43 https://maestrodatabase.com/blog/expanded-reimbursement-for-rinvoq-enhances-atopic-dermatitis-treatment-options 2025-03-09T03:52:28 https://maestrodatabase.com/blog/apellis-submits-marketing-authorisation-application-to-the-ema-for-pegcetacoplan-for-geographic-atrophy 2022-12-18T02:41:39 https://maestrodatabase.com/blog/modis-therapeutics-announces-that-mt1621-receives-breakthrough-therapy-designation-from-fda-for-the-treatment-of-tk2-deficiency 2019-02-21T11:14:54 https://maestrodatabase.com/blog/cerecor-receives-fast-track-designation-from-fda-for-cerc-801-for-the-treatment-of-pgm1-deficiency 2019-02-21T11:32:05 https://maestrodatabase.com/blog/aquestive-therapeutics-announces-regulatory-development-for-anaphylm-dibutepinephrine-sublingual-film 2026-01-11T21:33:06 https://maestrodatabase.com/blog/alpelisib-for-patients-with-advanced-hormone-receptor-positive-her2-negative-pik3ca-mutated-breast-cancer 2022-04-14T06:14:27 https://maestrodatabase.com/blog/neurelis-announces-that-intravail-licensee-ars-pharmaceuticals-intranasal-epinephrine-program-given-fast-track-designation 2019-02-21T11:23:03 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-14-april-2022 2022-04-14T05:49:28 https://maestrodatabase.com/blog/catalyst-pharmaceuticals-defends-375-000-dollars-drug-price-after-bernie-sanders-rebuke 2019-02-21T19:57:03 https://maestrodatabase.com/blog/stimulant-meds-for-adhd-now-fastest-growing-drug-on-pbs 2026-01-11T20:32:39 https://maestrodatabase.com/blog/camurus-announces-fda-acceptance-of-nda-resubmission-for-oclaiz-for-the-treatment-of-acromegaly 2026-01-11T20:37:13 https://maestrodatabase.com/blog/canada-finds-insufficient-evidence-that-janssen-blocked-biosimilar-competition 2019-02-21T20:05:51 https://maestrodatabase.com/blog/tessa-therapeutics-receives-prime-designation-from-european-medicines-agency-for-cd30-car-t-therapy 2021-01-19T06:21:13 https://maestrodatabase.com/blog/novo-nordisk-to-sell-obesity-drug-wegovy-direct-to-patients-at-lower-price 2025-03-09T04:12:41 https://maestrodatabase.com/blog/indivior-launches-generic-version-of-its-suboxone-opioid-drug 2019-02-21T20:03:31 https://maestrodatabase.com/blog/linking-cancer-drug-prices-to-treatment-success-could-speed-up-approvals-but-what-do-patients-consider-success 2019-02-21T20:20:56 https://maestrodatabase.com/blog/new-form-of-fast-acting-insulin-added-to-the-pbs 2023-09-18T02:20:35 https://maestrodatabase.com/blog/how-big-pharma-donations-may-influence-public-drug-coverage 2019-02-21T20:09:02 https://maestrodatabase.com/blog/canadian-shelves-would-run-dry-if-u-dot-s-imports-drugs 2019-02-21T20:13:22 https://maestrodatabase.com/blog/dupixent-dupilumab-approved-by-european-commission-for-adolescents-with-moderate-to-severe-atopic-dermatitis 2019-08-06T10:37:15 https://maestrodatabase.com/blog/kalvista-submits-new-drug-application-to-fda-for-sebetralstat-as-first-oral-on-demand-treatment-for-hereditary-angioedema 2024-06-20T03:11:33 https://maestrodatabase.com/blog/the-fighter-the-saint-and-the-odd-man-out-the-executives-who-will-defend-pharma-before-congress 2019-02-21T20:24:29 https://maestrodatabase.com/blog/high-pharma-margins-squeeze-health-care-systems 2019-02-21T20:32:43 https://maestrodatabase.com/blog/nhs-patients-to-benefit-from-first-full-access-deal-in-europe-for-new-car-t-therapy-recommended-by-nice 2021-02-25T20:18:09 https://maestrodatabase.com/blog/the-european-medicines-agencys-eu-conditional-marketing-authorisations-for-covid-19-vaccines 2021-01-19T08:14:36 https://maestrodatabase.com/blog/metacrine-announces-fda-fast-track-designation-for-met642-as-a-treatment-of-nash 2021-01-19T19:47:27 https://maestrodatabase.com/blog/occlutechs-atrial-flow-regulator-receives-u-dot-s-fda-breakthrough-device-designation-for-heart-failure 2021-01-19T19:51:13 https://maestrodatabase.com/blog/icer-publishes-2022-research-protocol-for-assessing-unsupported-price-increases-on-prescription-drugs 2022-04-14T22:16:50 https://maestrodatabase.com/blog/on-target-laboratories-announces-expanded-indication-of-cytalux-pafolacianine-injection-for-detection-of-lung-cancer-during-surgery 2022-12-18T04:04:17 https://maestrodatabase.com/blog/global-regulators-highlight-key-role-of-health-care-professionals-in-fostering-confidence-in-covid-19-vaccines 2021-01-19T20:00:35 https://maestrodatabase.com/blog/regulators-ok-yuhans-leclaza-as-31st-novel-drug 2021-01-19T08:40:46 https://maestrodatabase.com/blog/statement-on-data-accuracy-issues-with-recently-approved-gene-therapy 2019-08-06T21:05:25 https://maestrodatabase.com/blog/bracco-diagnostics-receives-u-dot-s-fda-approval-for-varibar-thin-liquid-barium-sulphate-for-oral-suspension 2019-08-06T11:24:44 https://maestrodatabase.com/blog/u-dot-s-fda-extends-review-of-biologics-license-application-for-regen-cov-casivirimab-and-imdemivab-for-treatment-and-prophylaxis-of-covid-19 2022-04-14T22:07:56 https://maestrodatabase.com/blog/insights-from-the-outcomes-from-the-2020-slash-3-pbac-meeting 2021-01-19T09:28:39 https://maestrodatabase.com/blog/taysha-gene-therapies-receives-rare-paediatric-disease-and-orphan-drug-designations-for-tsha-105-for-the-treatment-of-epilepsy-caused-by-slc13a5-deficiency 2021-01-19T20:17:23 https://maestrodatabase.com/blog/rockwell-medical-announces-acceptance-by-fda-of-new-drug-application-for-i-dot-v-triferic 2019-08-06T21:23:35 https://maestrodatabase.com/blog/medicines-nz-hopes-country-can-roll-out-covid-19-vaccines-early 2021-01-19T20:23:38 https://maestrodatabase.com/blog/golidocitinib-approved-in-china-as-first-in-class-jak1-only-inhibitor-for-the-treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma 2024-06-20T05:44:38 https://maestrodatabase.com/blog/knight-therapeutics-and-pan-canadian-pharmaceutical-alliance-reach-agreement-for-probuphine-for-opioid-dependence 2019-08-06T21:16:35 https://maestrodatabase.com/blog/additional-insights-from-the-tgas-publication-of-applications-for-prescription-medicines-under-evaluation 2021-01-19T20:26:03 https://maestrodatabase.com/blog/mark-cuban-is-going-to-help-big-pharmas-image 2021-01-19T20:04:57 https://maestrodatabase.com/blog/over-700-people-a-year-could-benefit-from-a-new-potentially-life-extending-lung-cancer-drug-which-targets-a-specific-genetic-mutation 2022-04-14T22:28:59 https://maestrodatabase.com/blog/icer-seeks-public-comment-on-proposed-methods-adaptations-for-assessments-of-potential-cures-and-other-transformative-therapies 2019-08-06T21:39:04 https://maestrodatabase.com/blog/cancer-doctors-are-calling-for-a-permanent-fix-to-drug-shortages-in-canada 2019-08-06T21:34:10 https://maestrodatabase.com/blog/biologics-license-application-for-narsoplimab-in-hsct-tma-accepted-for-priority-review-by-u-dot-s-fda 2021-01-19T20:09:59 https://maestrodatabase.com/blog/boris-pledges-a-ps1-dot-8-billion-cash-injection-for-the-nhs 2019-08-06T21:29:42 https://maestrodatabase.com/blog/merck-announces-us-fda-has-granted-breakthrough-therapy-designation-for-v116-the-companys-investigational-21-valent-pneumococcal-conjugate-vaccine-for-the-prevention-of-invasive-pneumococcal-disease-and-pneumococcal-pneumonia-in-adults 2022-04-14T22:33:32 https://maestrodatabase.com/blog/the-problem-of-limited-supply-agreements-for-medicare-price-negotiation 2023-09-18T03:42:34 https://maestrodatabase.com/blog/quality-adjusted-life-years-quality-adjusted-life-year-like-measures-or-neither-the-debate-continues 2024-06-20T07:27:59 https://maestrodatabase.com/blog/novartis-hid-manipulated-data-while-seeking-approval-for-2-dollars-1-cents-million-treatment 2019-08-06T21:54:17 https://maestrodatabase.com/blog/health-ministry-to-reimburse-novartis-revolade-treating-severe-aplastic-anaemia 2019-08-06T21:46:59 https://maestrodatabase.com/blog/what-good-are-whizzy-new-drugs-if-the-world-cant-afford-them 2024-06-20T07:19:57 https://maestrodatabase.com/blog/a-watchdog-group-sets-aside-emotions-to-assess-drugs-value-patients-say-their-lives-are-more-than-a-number 2019-08-06T21:44:30 https://maestrodatabase.com/blog/covid-19-coronavirus-ashley-bloomfield---vaccine-approval-just-a-couple-of-weeks-away 2021-01-19T20:41:34 https://maestrodatabase.com/blog/u-dot-s-fda-grants-priority-review-for-kites-kte-x19-biologics-license-application-in-relapsed-or-refractory-mantle-cell-lymphoma 2020-02-11T01:04:04 https://maestrodatabase.com/blog/health-professionals-warn-australia-is-struggling-to-deal-with-post-covid-19-medication-shortage 2021-01-19T20:44:27 https://maestrodatabase.com/blog/truqap-plus-faslodex-approved-in-the-eu-for-patients-with-advanced-oestrogen-receptor-positive-breast-cancer 2024-06-20T06:27:16 https://maestrodatabase.com/blog/new-labelling-for-antibiotics-in-australia 2021-01-19T20:50:40 https://maestrodatabase.com/blog/health-minister-committed-to-listing-weight-loss-drugs-on-pbs 2026-01-11T23:39:52 https://maestrodatabase.com/blog/nanobiotix-announces-fast-track-designation-granted-by-u-dot-s-fda-for-investigation-of-first-in-class-nbtxr3-in-head-and-neck-cancer 2020-02-11T00:53:43 https://maestrodatabase.com/blog/pharmac-funds-treatment-for-rare-disorders 2026-01-12T03:04:33 https://maestrodatabase.com/blog/us-fda-approves-celltrions-omlyclo-omalizumab-igec-as-the-first-and-only-biosimilar-with-interchangeability-designation-referencing-xolair 2025-03-10T01:37:56 https://maestrodatabase.com/blog/fda-approval-of-sofdra---the-first-new-drug-for-primary-axillary-hyperhidrosis 2024-06-20T21:12:45 https://maestrodatabase.com/blog/too-much-politics-clouding-cancer-drugs-process-decision---pharmac-minister 2024-06-20T21:09:29 https://maestrodatabase.com/blog/the-value-of-the-quality-adjusted-life-years 2024-06-20T07:49:09 https://maestrodatabase.com/blog/janssen-announces-submission-to-u-dot-s-fda-for-new-darzalex-daratumumab--based-combination-regimen-for-patients-with-relapsed-slash-refractory-multiple-myeloma 2020-02-11T03:59:34 https://maestrodatabase.com/blog/quality-use-of-medicines-who-owns-it-now 2024-06-20T07:39:46 https://maestrodatabase.com/blog/cellerant-therapeutics-announces-fda-grants-regenerative-medicine-advanced-therapy-designation-for-romyelocel-l-to-prevent-infections-during-neutropenia 2018-07-03T01:53:44 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-to-visterras-vis410-for-treatment-of-hospitalised-patients-with-influenza-a 2017-11-02T02:51:41 https://maestrodatabase.com/blog/fda-grants-rare-paediatric-disease-designation-to-arqules-miransertib-arq-092-for-the-treatment-of-proteus-syndrome 2017-11-02T03:03:31 https://maestrodatabase.com/blog/fda-expands-approval-of-gene-therapy-for-patients-with-duchenne-muscular-systrophy 2024-06-20T22:28:25 https://maestrodatabase.com/blog/aquestive-therapeutics-announces-u-dot-s-fda-filing-acceptance-of-new-drug-application-for-libervant-diazepam-buccal-film 2020-02-11T04:16:02 https://maestrodatabase.com/blog/novartis-stands-behind-zolgensma-onasemnogene-abeparvovec-xioi-for-the-treatment-of-children-less-than-2-years-of-age-with-spinal-muscular-atrophy 2019-08-06T23:08:59 https://maestrodatabase.com/blog/covid-19-vaccine-contract-summary 2023-09-18T04:35:08 https://maestrodatabase.com/blog/trumps-2021-budget-request-seeks-modest-funding-increase-for-fda 2020-02-11T05:04:34 https://maestrodatabase.com/blog/evusheld-receives-health-canada-approval-for-pre-exposure-prophylaxis-prevention-of-covid-19-in-immune-compromised-individuals 2022-04-15T01:13:17 https://maestrodatabase.com/blog/astellas-receives-european-commission-approval-for-first-in-class-evrenzo-roxadustat-for-adult-patients-with-symptomatic-anaemia-of-chronic-kidney-disease 2021-08-20T04:43:32 https://maestrodatabase.com/blog/tga-provisionally-approves-glaxosmithklines-covid-19-treatment-sotrovimab-xevudy 2021-08-20T04:48:29 https://maestrodatabase.com/blog/pediapharm-receives-health-canada-approval-for-cuvposa 2017-11-02T04:28:46 https://maestrodatabase.com/blog/trump-eyes-drug-price-cuts-after-his-health-care-record-is-attacked 2020-02-11T05:17:59 https://maestrodatabase.com/blog/tg-therapeutics-announces-voluntary-withdrawal-of-the-bla-slash-snda-for-u2-to-treat-patients-with-cll-and-sll 2022-04-15T21:17:21 https://maestrodatabase.com/blog/paying-tax-on-unfunded-cancer-medication-outrageous-says-nelson-patient 2020-02-11T05:15:12 https://maestrodatabase.com/blog/final-nice-nod-for-sanofis-kevzara 2017-11-02T14:10:30 https://maestrodatabase.com/blog/in-re-election-bid-a-gop-law-maker-campaigns-on-pelosis-drug-pricing-bill 2020-02-11T13:17:21 https://maestrodatabase.com/blog/challenges-in-measuring-the-affordability-of-us-health-care 2017-11-03T09:04:21 https://maestrodatabase.com/blog/in-their-words-warren-buttigieg-klobuchar-and-other-democrats-explain-exactly-how-theyd-lower-drug-prices 2020-02-11T10:30:22 https://maestrodatabase.com/blog/insulin-or-death-new-hampshire-voters-gripped-by-skyrocketing-drug-prices 2020-02-11T10:27:56 https://maestrodatabase.com/blog/nhs-patients-to-get-faster-access-to-breakthrough-medicines 2017-11-03T09:17:28 https://maestrodatabase.com/blog/sandoz-receives-positive-chmp-opinion-for-breast-and-gastric-cancer-biosimilar-trastuzumab 2023-09-18T05:35:13 https://maestrodatabase.com/blog/what-level-of-health-spending-is-affordable 2017-11-03T09:11:35 https://maestrodatabase.com/blog/trevena-resubmits-new-drug-application-for-oliceridine 2020-02-11T10:20:12 https://maestrodatabase.com/blog/icr-responds-to-government-report-produced-following-accelerated-access-review 2017-11-03T09:21:03 https://maestrodatabase.com/blog/novartis-announces-met-inhibitor-capmatinib-inc280-the-first-potential-treatment-for-metex14-mutated-advanced-non-small-cell-lung-cancer-granted-priority-fda-review 2020-02-11T13:19:15 https://maestrodatabase.com/blog/gsks-investigational-bcma-antibody-drug-conjugate-receives-breakthrough-therapy-designation-from-us-fda-for-relapsed-and-refractory-multiple-myeloma 2017-11-03T09:25:29 https://maestrodatabase.com/blog/eagle-pharmaceuticals-receives-final-fda-approval-for-pemfexy-pemetrexed-for-injection 2020-02-11T13:33:21 https://maestrodatabase.com/blog/smc---february-2020-decisions 2020-02-11T13:28:21 https://maestrodatabase.com/blog/valneva-covid-19-vaccine-approved-by-mhra 2022-04-15T21:57:58 https://maestrodatabase.com/blog/smc-approves-first-two-ultra-orphan-pathway-meds 2020-02-11T14:09:38 https://maestrodatabase.com/blog/many-in-u-dot-s-worry-about-affording-health-care-in-retirement 2020-02-11T14:08:02 https://maestrodatabase.com/blog/choosing-a-time-horizon-in-cost-and-cost-effectiveness-analyses 2019-02-22T07:46:52 https://maestrodatabase.com/blog/nice-says-drug-to-treat-batten-disease-cannot-be-recommended-for-nhs-use-because-company-is-unable-to-address-concerns-about-long-term-effectiveness 2019-02-22T09:15:05 https://maestrodatabase.com/blog/acting-fda-chief-janet-woodcock-ruled-out-as-biden-nominee 2021-08-20T06:47:08 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac---july-2021 2021-08-20T06:08:00 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-european-commission-approval-for-abecma-idecabtagene-vicleucel-the-first-anti-bcma-car-t-cell-therapy-for-relapsed-and-refractory-multiple-myeloma 2021-08-20T08:22:34 https://maestrodatabase.com/blog/auspar-content-january-2018-registration-timelines 2017-11-03T09:58:17 https://maestrodatabase.com/blog/statement-from-fda-commissioner-and-director-of-fdas-center-for-drug-evaluation-and-research-on-the-fdas-continuing-efforts-to-maintain-its-strong-oversight-of-generic-drug-quality-issues-domestically-and-abroad 2019-02-22T23:47:03 https://maestrodatabase.com/blog/ionis-announces-submission-of-marketing-authorisation-application-for-inotersen-to-the-european-medicines-agency 2017-11-04T06:19:08 https://maestrodatabase.com/blog/icer-to-publish-upcoming-assessment-on-additive-cardiovascular-disease-therapies 2019-02-22T23:50:01 https://maestrodatabase.com/blog/biosimilar-trastuzumab-on-the-pbs---information-for-health-professionals-and-patients 2019-12-02T06:28:29 https://maestrodatabase.com/blog/icers-assessment-finds-spinraza-and-zolgensma-provide-substantial-health-benefits-for-people-with-spinal-muscular-atrophy 2019-02-22T23:53:19 https://maestrodatabase.com/blog/nice-draft-guidance-extends-recommendation-for-sapropterin-to-pregnant-women-and-people-aged-up-to-22-years-with-rare-inherited-metabolic-condition-phenylketonuria 2021-08-20T08:43:21 https://maestrodatabase.com/blog/u-dot-s-senates-mcconnell-cites-hurdles-to-agreement-on-lowering-drug-prices 2020-02-11T23:29:09 https://maestrodatabase.com/blog/cancer-drug-advocate-holds-back-tears-pleading-for-pharmac-funding-boost 2019-08-07T02:42:39 https://maestrodatabase.com/blog/uk-authorises-regeneron-antibody-cocktail-to-prevent-and-treat-acute-covid-19-infection 2021-08-20T11:25:25 https://maestrodatabase.com/blog/fennec-pharmaceuticals-completes-rolling-submission-of-new-drug-application-to-u-dot-s-fda-for-pedmark-and-also-submits-marketing-authorisation-application-to-ema 2020-02-11T23:20:11 https://maestrodatabase.com/blog/ascendis-pharma-receives-positive-chmp-opinion-for-transcon-pth-palopegteriparatide-for-adults-with-chronic-hypoparathyroidism 2023-09-18T11:31:00 https://maestrodatabase.com/blog/fda-accepts-new-drug-application-for-pimicotinib-for-the-treatment-of-tenosynovial-giant-cell-tumoir 2026-01-12T22:38:50 https://maestrodatabase.com/blog/australian-made-cancer-drug-gets-billion-dollar-us-fda-approval 2023-09-18T21:27:30 https://maestrodatabase.com/blog/orexo-submits-new-drug-application-to-fda-for-ox124-a-high-dose-rescue-medication-for-opioid-overdose 2023-09-18T21:21:25 https://maestrodatabase.com/blog/fda-approves-first-treatment-for-children-with-menkes-disease 2026-01-12T22:32:03 https://maestrodatabase.com/blog/biomarin-receives-positive-chmp-opinion-in-europe-to-expand-use-of-voxzogo-vosoritide-to-treat-children-aged-4-months-and-older-with-achondroplasia 2023-09-18T11:40:02 https://maestrodatabase.com/blog/encoded-therapeutics-announces-us-fda-breakthrough-therapy-designation-granted-to-etx101-for-the-treatment-of-dravet-syndrome 2026-01-12T23:33:13 https://maestrodatabase.com/blog/sanofis-teizeild-approved-in-the-eu-for-patients-with-stage-2-type-1-diabetes 2026-01-12T23:48:58 https://maestrodatabase.com/blog/deloitte-survey-finds-biopharma-companies-are-accelerating-adoption-of-real-world-evidence 2018-07-03T06:42:30 https://maestrodatabase.com/blog/galderma-announces-the-authorisation-of-nemluvio-nemolizumab-for-atopic-dermatitis-and-prurigo-nodularis-in-canada 2026-01-13T02:01:14 https://maestrodatabase.com/blog/kymera-therapeutics-receives-us-fda-fast-track-designation-for-kt-333-a-first-in-class-investigational-stat3-degrader-for-the-treatment-of-relapsed-slash-refractory-cutaneous-t-cell-lymphoma-and-relapsed-slash-refractory-peripheral-t-cell-lymphoma 2023-09-18T23:12:54 https://maestrodatabase.com/blog/sebela-pharmaceuticals-announces-submission-of-new-drug-application-to-fda-for-tegoprazan-for-the-treatment-of-gastro-oesophageal-reflux-disease 2026-01-13T03:52:05 https://maestrodatabase.com/blog/life-changing-new-drug-available-for-elderly-australians-with-devastating-eye-condition 2025-03-10T06:47:40 https://maestrodatabase.com/blog/health-canada-approves-rybelsus-semaglutide-tablets-to-reduce-the-risk-of-major-adverse-cardiovascular-events-in-adults-with-type-2-diabetes 2026-01-13T03:56:41 https://maestrodatabase.com/blog/new-hope-for-families-affected-by-spinal-muscular-atrophy-with-tga-approving-drug 2017-11-05T06:41:27 https://maestrodatabase.com/blog/fda-approves-nivolumab-for-adjuvant-treatment-of-urothelial-carcinoma 2021-08-20T21:48:05 https://maestrodatabase.com/blog/summit-therapeutics-announces-submission-of-biologics-license-application-to-us-fda-seeking-approval-for-ivonescimab-in-combination-with-chemotherapy-in-second-line-or-later-treatment-of-patients-with-egfrm-nsclc 2026-01-13T04:00:16 https://maestrodatabase.com/blog/bausch-and-lomb-and-nicox-announce-fda-approval-of-vyzulta-latanoprostene-bunod-ophthalmic-solution-0-dot-024-percent 2017-11-05T06:49:03 https://maestrodatabase.com/blog/proposal-for-funding-of-oncology-multiple-sclerosis-and-respiratory-treatments 2019-08-07T09:10:52 https://maestrodatabase.com/blog/covid-19-vaccines-and-equity-some-kiwis-may-get-more-effective-jabs-than-other 2021-01-20T10:32:06 https://maestrodatabase.com/blog/nice-recommends-additional-treatment-option-for-people-with-early-breast-cancer 2019-08-07T09:03:25 https://maestrodatabase.com/blog/is-novavax-the-dark-horse-of-australias-covid-19-vaccines 2021-01-20T10:34:30 https://maestrodatabase.com/blog/click-therapeutics-receives-fda-breakthrough-device-designation-for-prescription-digital-therapeutic-to-treat-episodic-migraine 2022-12-18T10:52:04 https://maestrodatabase.com/blog/ontario-doctors-urge-domestic-drug-manufacturing-over-fears-of-pandemic-shortage 2021-01-20T10:51:49 https://maestrodatabase.com/blog/dhb-backs-pharmac-in-making-hard-calls 2019-08-07T09:21:31 https://maestrodatabase.com/blog/nice-says-tookad-too-expensive-for-prostate-cancer 2018-07-03T12:33:57 https://maestrodatabase.com/blog/amryts-myalepta-scores-nice-backing-for-rare-lipid-disorder 2021-01-20T10:13:41 https://maestrodatabase.com/blog/eu-green-light-for-cimzia-to-treat-psoriasis 2018-07-03T12:42:12 https://maestrodatabase.com/blog/2021-april-price-disclosure-cycle---indicative-prices 2021-01-20T10:17:18 https://maestrodatabase.com/blog/abbvie-and-trump-administration-reach-agreement-to-improve-access-and-affordability-for-americans 2026-01-13T00:47:13 https://maestrodatabase.com/blog/pharmac-considers-funding-breast-cancer-drug-kadcyla-advocates-have-been-fighting-for 2019-08-07T09:16:56 https://maestrodatabase.com/blog/astrazeneca-covid-19-vaccine-claims-not-evidence-based 2021-01-20T10:20:17 https://maestrodatabase.com/blog/enhertu-approved-in-the-eu-for-the-treatment-of-her2-positive-metastatic-breast-cancer 2021-01-20T10:25:47 https://maestrodatabase.com/blog/aarp-united-healthcare-and-cvs-keep-prescription-drug-prices-higher-for-seniors 2020-02-12T01:00:49 https://maestrodatabase.com/blog/eq-5d-y-3l-value-sets-valuation-methods-and-conceptual-questions 2022-12-18T10:49:06 https://maestrodatabase.com/blog/centers-for-medicare-and-medicaid-services-releases-reports-on-the-performance-of-the-exchanges-and-individual-health-insurance-market 2018-07-03T12:53:12 https://maestrodatabase.com/blog/ama-call-for-mass-upscaling-of-home-made-drug-manufacture 2021-01-20T20:06:04 https://maestrodatabase.com/blog/pair-of-democrat-senators-probe-drug-pricing-middlemen-distributors-over-high-costs 2018-07-03T13:15:51 https://maestrodatabase.com/blog/scottish-health-technologies-group-enhancing-patient-engagement 2021-01-20T20:07:57 https://maestrodatabase.com/blog/conservatives-buck-trump-over-worries-of-socialist-drug-pricing 2019-08-07T10:25:39 https://maestrodatabase.com/blog/finally-some-answers-on-the-effects-of-medicaid-expansion 2018-07-03T12:49:17 https://maestrodatabase.com/blog/how-trumps-plan-to-import-canadian-drugs-would-work 2019-08-07T09:31:09 https://maestrodatabase.com/blog/u-dot-s-food-and-drug-administration-accepts-for-priority-review-application-for-opdivo-nivolumab-as-adjuvant-therapy-for-patients-with-resected-oesophageal-or-gastro-oesophageal-junction-cancer 2021-01-20T20:11:52 https://maestrodatabase.com/blog/why-july-is-a-risky-month-for-drug-price-backlash 2018-07-03T13:37:05 https://maestrodatabase.com/blog/scotland-backs-roches-rozlytrek-for-ros1-lung-cancer 2021-01-20T19:48:43 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-announces-departure-of-dan-ollendorf-launches-search-for-new-chief-scientific-officer 2018-07-03T20:56:53 https://maestrodatabase.com/blog/health-canada-has-approved-taltz-ixekizumab-for-the-treatment-of-active-ankylosing-spondylitis-radiographic-axial-spondyloarthritis 2020-02-12T01:11:33 https://maestrodatabase.com/blog/pbac-rejects-first-submission-supported-by-real-world-evidence 2018-07-03T13:19:47 https://maestrodatabase.com/blog/u-dot-s-fda-approves-vericiguat-for-patients-with-symptomatic-chronic-heart-failure 2021-01-20T19:53:31 https://maestrodatabase.com/blog/the-representation-of-public-values-in-health-technology-assessment-to-inform-funding-decisions-the-case-of-australias-national-funding-bodies 2021-01-20T20:01:36 https://maestrodatabase.com/blog/creates-act-will-bring-lower-priced-prescription-drugs-to-market-for-hardworking-americans 2018-07-03T21:18:17 https://maestrodatabase.com/blog/tga-grants-additional-provisional-determination-for-a-covid-19-vaccine 2021-01-20T20:38:27 https://maestrodatabase.com/blog/european-medicines-agency-validates-bristol-myers-squibbs-application-for-subcutaneous-nivolumab 2024-06-21T12:55:42 https://maestrodatabase.com/blog/trump-administration-strikes-policy-that-supporters-say-helped-lower-drug-prices 2017-11-05T07:15:35 https://maestrodatabase.com/blog/cvs-health-ceo-surprised-by-azars-comments-on-drug-prices 2018-07-03T21:21:44 https://maestrodatabase.com/blog/secret-pacemaker-payments-boosting-private-hospital-coffers-but-costing-the-health-system 2018-07-03T21:08:25 https://maestrodatabase.com/blog/ebglyss-lebrikizumab-receives-positive-chmp-opinion-for-moderate-to-severe-atopic-dermatitis 2023-09-19T01:41:49 https://maestrodatabase.com/blog/seeking-to-hire-new-talent-fda-hints-it-wants-flexibility-to-pay-more-staff-higher-salaries 2018-07-03T21:13:27 https://maestrodatabase.com/blog/progenics-pharmaceuticals-completes-submission-of-nda-for-azedra-iobenguane-i-131-in-pheochromocytoma-and-paraganglioma 2017-11-05T07:19:18 https://maestrodatabase.com/blog/outcomes-from-the-may-2024-pbac-intracycle-meeting 2024-06-21T06:05:21 https://maestrodatabase.com/blog/patient-involvement-in-relative-effectiveness-assessments-in-the-european-network-for-health-technology-assessment 2021-01-20T20:17:21 https://maestrodatabase.com/blog/trevena-announces-submission-of-new-drug-application-to-u-dot-s-fda-for-olinvo-oliceridine-injection 2017-11-05T07:34:38 https://maestrodatabase.com/blog/this-tweet-captures-the-state-of-health-care-in-america-today 2018-07-03T21:26:20 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-for-priority-review-application-for-opdivo-nivolumab-combined-with-chemotherapy-as-first-line-treatment-in-metastatic-gastric-cancer-gastro-oesophageal-junction-cancer-and-oesophageal-adenocarcinoma 2021-01-20T20:21:27 https://maestrodatabase.com/blog/icers-final-report-on-cgrp-inhibitors-for-migraine-prevention-explores-specific-coverage-policy-options-in-light-of-responsible-manufacturer-pricing 2018-07-03T21:30:00 https://maestrodatabase.com/blog/10-dollars-million-for-adhd-medicine-on-the-pbs 2019-02-23T04:45:33 https://maestrodatabase.com/blog/the-responses-to-the-cancer-drugs-scandal-must-fully-involve-patients--an-essay-by-tessa-richards 2017-11-05T07:55:30 https://maestrodatabase.com/blog/nhs-patients-should-have-a-choice-of-drug-for-wet-age-related-macular-degeneration-despite-pressure-from-pharma 2017-11-05T07:53:06 https://maestrodatabase.com/blog/cellectar-biosciences-receives-european-medicines-agency-priority-medicines-prime-designation-for-iopofosine-for-waldenstroms-macroglobulinaemia 2023-09-19T02:05:28 https://maestrodatabase.com/blog/fda-grants-priority-review-and-accepts-sbla-of-soliris-eculizumab-as-a-treatment-for-patients-with-neuromyelitis-optica-spectrum-disorder 2019-02-23T05:05:26 https://maestrodatabase.com/blog/quebec-new-brunswick-newfoundland-nova-scotia-and-manitoba-join-alberta-saskatchewan-in-adding-knights-probuphine-to-their-provincial-drug-plans-in-the-fight-against-the-opioid-crisis 2020-02-12T02:10:38 https://maestrodatabase.com/blog/alder-biopharmaceuticals-submits-biologics-license-application-to-the-u-dot-s-fda-for-eptinezumab 2019-02-23T05:12:20 https://maestrodatabase.com/blog/astex-pharmaceuticals-announces-u-dot-s-fda-acceptance-for-review-of-an-nda-for-the-combination-oral-hypomethylating-agent-cedazuridine-and-decitabine-astx727-or-oral-c-dec-for-the-treatment-of-mds-and-cmml 2020-02-12T02:05:59 https://maestrodatabase.com/blog/blueprint-medicines-announces-fda-acceptance-of-new-drug-application-for-avapritinib-for-the-treatment-of-pdgfra-exon-18-mutant-gist-and-fourth-line-gist 2019-08-07T12:39:22 https://maestrodatabase.com/blog/hhss-multi-pronged-approach-to-lower-drug-prices-will-it-work 2019-02-23T05:50:08 https://maestrodatabase.com/blog/argenx-announces-fda-acceptance-of-supplemental-biologics-license-application-with-priority-review-for-vyvgart-in-achr-ab-seronegative-gmg 2026-01-14T04:46:53 https://maestrodatabase.com/blog/johnson-and-johnson-submits-application-to-us-fda-seeking-approval-of-tremfya-guselkumab-for-the-treatment-of-moderately-to-severely-active-crohns-disease 2024-06-21T13:49:54 https://maestrodatabase.com/blog/new-insulin-medicine-proposed-for-people-with-diabetes 2025-03-10T22:53:31 https://maestrodatabase.com/blog/affordable-eczema-drug-dupixent-still-out-of-reach-for-children 2026-01-14T05:07:22 https://maestrodatabase.com/blog/fda-confirms-a-pdufa-goal-date-of-30-august-2026-for-the-sbla-submission-of-ropeginterferon-alfa-2b-njft-in-essential-thrombocythemia 2026-01-14T05:11:15 https://maestrodatabase.com/blog/wainzua-eplontersen-approved-in-the-eu-for-the-treatment-of-hereditary-transthyretin-mediated-amyloidosis-in-adults-with-stage-1-or-stage-2-polyneuropathy 2025-03-10T22:41:55 https://maestrodatabase.com/blog/henlius-fifth-us-filing-product-bevacizumab-biosimilar-hlx04-receives-fda-bla-acceptance 2026-01-14T05:21:44 https://maestrodatabase.com/blog/chmp-recommends-eu-marketing-authorisation-for-veyvondi-vonicog-alfa-recombinant-von-willebrand-factor-for-adults-with-von-willebrand-disease 2018-07-04T03:39:26 https://maestrodatabase.com/blog/health-canada-approves-actemra-tocilizumab-for-canadians-living-with-giant-cell-arteritis 2017-11-05T10:09:05 https://maestrodatabase.com/blog/obamacare-vs-the-saboteurs 2017-11-05T10:05:05 https://maestrodatabase.com/blog/amags-female-libido-injectable-therapy-to-sell-at-899-dollars 2019-08-07T13:13:30 https://maestrodatabase.com/blog/us-fda-grants-ipsens-ipn60340-ict01-breakthrough-therapy-designation-in-first-line-unfit-acute-myeloid-leukaemia 2026-01-14T00:19:07 https://maestrodatabase.com/blog/fda-approves-xeomin-incobotulinumtoxina-for-adult-patients-with-sialorrhoea 2018-07-04T04:34:38 https://maestrodatabase.com/blog/pbac-to-adopt-a-revised-approach-to-considering-brand-equivalence-slash-substitution-for-biosimilar-medicines 2018-07-04T05:52:37 https://maestrodatabase.com/blog/smc---march-2025-decisions 2025-03-10T23:26:33 https://maestrodatabase.com/blog/ortho-dermatologics-announces-u-dot-s-fda-filing-acceptance-for-idp-123-treatment-for-acne-vulgaris-in-lotion-form 2019-08-07T21:09:13 https://maestrodatabase.com/blog/obamacare-is-proving-hard-to-kill 2018-07-04T11:39:33 https://maestrodatabase.com/blog/fda-should-take-additional-steps-to-address-factors-that-may-affect-approval-rates-in-the-first-review-cycle 2019-08-07T21:05:54 https://maestrodatabase.com/blog/bimzelz-bimekizumab-injection-approved-in-canada-for-treatment-of-moderate-to-severe-hidradenitis-suppurativa 2026-01-14T02:08:11 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-adagrasib-with-cetuximab-for-kras-g12c-mutated-colorectal-cancer 2024-06-21T21:03:43 https://maestrodatabase.com/blog/amazon-could-start-selling-discounted-meds-to-cash-payers-as-soon-as-the-pillpack-deal-closes 2018-07-04T20:32:52 https://maestrodatabase.com/blog/why-using-your-health-cover-in-a-public-hospital-is-adding-100-dollars-to-your-health-fund-premiums 2019-08-07T21:18:18 https://maestrodatabase.com/blog/trump-administration-makes-car-t-cell-cancer-therapy-available-to-medicare-beneficiaries-nationwide 2019-08-07T21:14:08 https://maestrodatabase.com/blog/two-of-three-us-pharma-companies-receive-independence-day-treat-from-nice 2018-07-04T21:03:23 https://maestrodatabase.com/blog/nations-first-free-meningococcal-b-vaccination-program-to-be-funded-in-south-australia 2018-07-04T12:07:25 https://maestrodatabase.com/blog/orchard-therapeutics-announces-acceptance-of-biologics-license-application-for-otl-200-in-mld-and-receives-priority-review 2023-09-19T05:23:44 https://maestrodatabase.com/blog/gravy-train-of-private-health-to-run-off-rails 2018-07-04T20:27:08 https://maestrodatabase.com/blog/travere-therapeutics-announces-fda-extends-review-of-snda-for-filspari-sparsentan-in-fsgs 2026-01-14T19:39:31 https://maestrodatabase.com/blog/new-osteoporosis-treatment-set-to-provide-another-option-for-patients 2018-07-04T23:41:51 https://maestrodatabase.com/blog/icer-issues-statement-regarding-manufacturers-manipulation-of-data-from-animal-testing-of-zolgensma 2019-08-07T21:20:53 https://maestrodatabase.com/blog/private-health-sector-on-life-support-as-patients-care-delayed 2024-06-21T21:37:11 https://maestrodatabase.com/blog/fibrogen-announces-u-dot-s-fda-acceptance-of-new-drug-application-for-roxadustat-for-the-treatment-of-anaemia-of-chronic-kidney-disease 2020-02-12T06:13:16 https://maestrodatabase.com/blog/decision-for-funding-in-the-blood-alimentary-and-immunosuppressant-therapy-areas 2020-02-12T06:18:28 https://maestrodatabase.com/blog/cystic-fibrosis-patients-advocates-urge-ontario-government-to-provide-miracle-drug-funding 2021-08-21T00:05:09 https://maestrodatabase.com/blog/health-canada-approves-erleada-apalutamide-tablets-the-first-treatment-for-men-with-non-metastatic-castration-resistant-prostate-cancer 2018-07-05T02:17:00 https://maestrodatabase.com/blog/international-work-sharing-pilot---apalutamide-erlyand 2018-07-05T02:10:17 https://maestrodatabase.com/blog/sandoz-confirms-european-commission-approval-of-ondibta-insulin-glargine-strengthening-overall-biosimilars-leadership-and-position-in-diabetes 2026-01-14T20:33:37 https://maestrodatabase.com/blog/fda-widens-scope-of-navigator---information-tool-for-expanded-access 2017-11-05T11:39:56 https://maestrodatabase.com/blog/takedas-hyqvia-approved-as-replacement-therapy-for-primary-humoral-immunodeficiency-and-secondary-humoral-immunodeficiency-in-paediatric-patients-2-years-of-age-and-older 2024-06-22T02:05:48 https://maestrodatabase.com/blog/health-canada-authorises-lazcluze-lazertinib-in-combination-with-rybrevant-amivantamab-as-a-first-line-chemotherapy-free-treatment-for-patients-with-egfr-mutated-advanced-lung-cancer 2025-03-11T05:14:08 https://maestrodatabase.com/blog/takeda-receives-approval-from-european-commission-for-fruzaqla-in-previously-treated-metastatic-colorectal-cancer 2024-06-22T01:59:25 https://maestrodatabase.com/blog/with-a-new-president-and-a-new-congress-its-time-for-medicare-drug-price-negotiation 2021-01-21T04:26:47 https://maestrodatabase.com/blog/when-will-sma-oral-drug-evrysdi-get-insurance-benefits 2022-04-16T20:16:37 https://maestrodatabase.com/blog/tga-approves-registration-of-lenacapavir-for-pre-exposure-prophylaxis-for-hiv-yeytuo 2026-01-14T21:39:44 https://maestrodatabase.com/blog/altuviiio-supplemental-biologics-license-application-based-on-positive-final-results-from-phase-3-xtend-kids-study-accepted-by-fda 2023-09-19T12:10:32 https://maestrodatabase.com/blog/nice-enables-access-to-first-treatment-that-targets-the-underlying-pathophysiology-of-rare-disease-x-linked-hypophosphataemia-in-adults 2024-06-22T02:20:48 https://maestrodatabase.com/blog/fda-accepts-for-priority-review-mercks-supplemental-new-drug-application-for-welireg-belzutifan-in-certain-previously-treated-patients-with-advanced-renal-cell-carcinoma 2023-09-19T11:44:19 https://maestrodatabase.com/blog/new-report-indicates-covid-19-vaccines-saved-australias-economy 2022-12-19T02:16:06 https://maestrodatabase.com/blog/when-biotechs-get-breakthrough-therapy-status-mr-market-yawns 2019-02-23T23:42:12 https://maestrodatabase.com/blog/aussies-to-access-subsidised-cancer-drug 2019-02-23T23:37:02 https://maestrodatabase.com/blog/fda-approves-first-treatment-for-certain-patients-with-erdheim-chester-disease-a-rare-blood-cancer 2017-11-06T16:51:48 https://maestrodatabase.com/blog/ema-publishes-agenda-for-6-9-november-chmp-meeting 2017-11-06T16:28:25 https://maestrodatabase.com/blog/mhra-approves-modernas-adapted-covid-19-vaccine-spikevax-that-targets-omicron-xbb-dot-1-5 2023-09-19T07:54:31 https://maestrodatabase.com/blog/shionogi-receives-european-union-marketing-authorisation-for-lusutrombopag-for-the-treatment-of-severe-thrombocytopenia-in-adults-with-chronic-liver-disease-undergoing-invasive-procedures 2019-02-24T00:07:26 https://maestrodatabase.com/blog/doptelet-avatrombopag-approved-in-the-eu-for-treatment-of-itp 2021-01-21T06:24:33 https://maestrodatabase.com/blog/timely-consistent-transparent-assessment-of-market-access-evidence-implementing-tools-based-on-the-hta-core-model-in-a-pharmaceutical-company 2019-02-23T23:45:26 https://maestrodatabase.com/blog/novartis-reaches-another-regulatory-milestone-for-ctl019-tisagenlecleucel-with-submission-of-its-maa-to-ema-for-children-young-adults-with-r-slash-r-b-cell-all-and-adult-patients-with-r-slash-r-dlbcl 2017-11-06T17:25:45 https://maestrodatabase.com/blog/theratechnologies-submits-novel-single-vial-formulation-of-egrifta-tesamorelin-for-injection-for-fda-approval 2018-07-05T03:33:53 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-final-report-recommends-enhanced-coverage-of-certain-non-drug-management-options-for-chronic-low-back-pain 2017-11-06T18:29:28 https://maestrodatabase.com/blog/health-canada-approves-otsuka-and-lundbecks-abilify-maintena-aripiprazole-once-monthly-as-treatment-for-bipolar-i-disorder-in-adults 2017-11-06T19:35:10 https://maestrodatabase.com/blog/shionogi-receives-european-union-marketing-authorisation-for-rizmoic-naldemedine-for-the-treatment-of-opioid-induced-constipation-in-adults-previously-treated-with-a-laxative 2019-02-24T00:11:50 https://maestrodatabase.com/blog/allergy-advocate-group-absolutely-delighted-after-pharmac-announces-full-funding-for-epipen-auto-injectors 2022-12-19T02:39:49 https://maestrodatabase.com/blog/fda-approves-genentechs-alecensa-alectinib-as-first-line-treatment-for-people-with-specific-type-of-lung-cancer 2017-11-06T19:41:30 https://maestrodatabase.com/blog/how-iqwig-assesses---version-7-dot-0-of-the-method-paper-comes-into-force 2023-09-19T20:45:44 https://maestrodatabase.com/blog/pbs-drug-price-reforms-come-up-840-million-dollars-short 2017-11-07T06:40:25 https://maestrodatabase.com/blog/fda-clears-common-blood-cell-count-test-that-offers-faster-results-for-patients-and-providers 2017-11-07T06:48:34 https://maestrodatabase.com/blog/impel-neuropharma-announces-u-dot-s-fda-acceptance-of-new-drug-application-for-inp104-for-the-acute-treatment-of-migraine 2021-01-21T06:56:04 https://maestrodatabase.com/blog/bayer-submits-application-for-marketing-approval-of-rivaroxaban-for-patients-with-coronary-or-peripheral-artery-disease-to-european-medicines-agency 2017-11-07T06:55:21 https://maestrodatabase.com/blog/the-future-of-health-care-in-australia 2017-11-19T21:45:00 https://maestrodatabase.com/blog/ucbs-vimpat-lacosamide-now-approved-by-fda-to-treat-partial-onset-seizures-in-paediatric-epilepsy-patients 2017-11-07T07:05:06 https://maestrodatabase.com/blog/ucb-provides-update-on-us-regulatory-review-of-bimekizumab 2023-09-19T21:09:49 https://maestrodatabase.com/blog/sanofis-rsv-treatment-nirsevimab-awarded-pim-status 2021-01-21T07:39:22 https://maestrodatabase.com/blog/statement-from-fda-commissioner-scott-gottlieb-m-dot-d-on-implementation-of-agencys-streamlined-development-and-review-pathway-for-consumer-tests-that-evaluate-genetic-health-risks 2017-11-07T07:02:50 https://maestrodatabase.com/blog/health-canada-approves-imfinzi-durvalumab-for-previously-treated-patients-with-advanced-bladder-cancer 2017-11-07T07:16:56 https://maestrodatabase.com/blog/access-to-covid-19-anti-viral-treatments-widened-for-more-people-at-risk 2023-09-20T06:55:01 https://maestrodatabase.com/blog/tyenne-fresenius-kabis-tocilizumab-biosimilar-receives-european-commission-approval 2023-09-20T07:36:50 https://maestrodatabase.com/blog/otsuka-and-astex-announce-that-the-european-commission-has-approved-inaqovi-oral-decitabine-and-cedazuridine-for-the-treatment-of-adults-with-newly-diagnosed-acute-myeloid-leukaemia 2023-09-20T06:45:08 https://maestrodatabase.com/blog/withdrawal-from-the-drug-benefits-on-1-march-2020 2020-02-12T13:36:13 https://maestrodatabase.com/blog/international-hta-collaboration-expands 2023-09-20T06:24:48 https://maestrodatabase.com/blog/vertex-announces-extended-long-term-reimbursement-agreement-with-nhs-england-for-access-to-cystic-fibrosis-medicines-kaftrio-symkevi-and-orkambi 2024-06-22T04:40:49 https://maestrodatabase.com/blog/australias-biotech-innovations-heading-offshore-prompting-calls-for-greater-funding-to-bring-them-to-market 2020-02-12T13:31:23 https://maestrodatabase.com/blog/who-goes-first-government-leaders-and-prioritisation-of-sars-cov-2-vaccine 2021-01-21T08:13:53 https://maestrodatabase.com/blog/researchers-wanted-to-study-the-publics-views-of-health-related-quality-of-life 2020-02-12T13:26:40 https://maestrodatabase.com/blog/european-commission-approves-pfizers-litfulo-for-adolescents-and-adults-with-severe-alopecia-areata 2023-09-20T05:46:49 https://maestrodatabase.com/blog/nice-refuses-keytruda-inlyta-cancer-combo 2020-02-12T13:23:41 https://maestrodatabase.com/blog/fda-issues-complete-response-letter-for-neffy-epinephrine-nasal-spray-new-drug-application-with-request-for-additional-study 2023-09-20T09:58:41 https://maestrodatabase.com/blog/chmp-adopts-positive-opinion-to-extend-the-use-of-veklury-remdesivir-to-treat-covid-19-in-people-with-hepatic-impairment 2023-09-20T08:13:23 https://maestrodatabase.com/blog/leukaemia-advanced-kidney-cancer-bladder-cancer-and-liver-cancer-drugs-added-to-pbs 2019-02-24T02:04:42 https://maestrodatabase.com/blog/icer-methods-could-be-illegal-in-us-claims-us-think-tank 2020-02-12T13:40:28 https://maestrodatabase.com/blog/american-als-patients-contend-with-us$158k-price-tag-on-new-drug 2022-12-19T06:26:48 https://maestrodatabase.com/blog/paladin-labs-announces-approval-of-envarsus-pa-tacrolimus-prolonged-release-tablets-in-canada 2019-02-24T06:23:58 https://maestrodatabase.com/blog/pharmac-funds-new-oral-contraceptive-pill 2025-03-11T22:19:33 https://maestrodatabase.com/blog/icer-to-assess-treatment-for-non-cystic-fibrosis-bronchiectasis 2025-03-11T22:11:43 https://maestrodatabase.com/blog/pembrolizumab-for-previously-treated-endometrial-biliary-colorectal-gastric-or-small-intestine-cancer-with-high-microsatellite-instability-or-mismatch-repair-deficiency 2023-09-20T11:09:28 https://maestrodatabase.com/blog/ema-gets-ready-for-relocation-decision 2017-11-07T19:23:42 https://maestrodatabase.com/blog/gsk-submits-us-regulatory-application-for-mepolizumab-in-eosinophilic-chronic-obstructive-pulmonary-disease 2017-11-08T06:26:01 https://maestrodatabase.com/blog/takeda-announces-fda-acceptance-of-nda-resubmission-of-tak-721-budesonide-oral-suspension-for-the-short-term-treatment-of-eosinophilic-oesophagitis 2023-09-20T22:02:41 https://maestrodatabase.com/blog/imfinzi-plus-imjudo-recommended-for-approval-in-the-eu-by-chmp-for-the-treatment-of-advanced-liver-and-lung-cancers 2022-12-19T07:28:01 https://maestrodatabase.com/blog/fintepla-fenfluramine-oral-solution-recommended-for-approval-in-the-eu-for-adjunctive-treatment-of-seizures-associated-with-lennox-gastaut-syndrome 2022-12-19T07:23:15 https://maestrodatabase.com/blog/alvotech-provides-us-regulatory-update-on-avt02-a-high-concentration-interchangeable-biosimilar-candidate-to-humira-adalimumab 2023-09-21T11:39:06 https://maestrodatabase.com/blog/human-medicines-highlights-of-2020 2021-01-21T10:49:08 https://maestrodatabase.com/blog/company-statement-on-resubmission-of-biosimilar-trastuzumab-and-pegfilgrastim-dossiers-with-ema 2017-11-08T06:43:10 https://maestrodatabase.com/blog/forxiga-recommended-for-approval-in-the-eu-by-chmp-for-symptomatic-chronic-heart-failure 2022-12-19T07:48:09 https://maestrodatabase.com/blog/enhertu-approved-in-the-eu-for-patients-with-previously-treated-her2-positive-advanced-gastric-cancer 2022-12-19T07:34:07 https://maestrodatabase.com/blog/takeda-receives-positive-chmp-opinion-for-adcetris-brentuximab-vedotin-for-the-treatment-of-adult-patients-with-previously-untreated-cd30-plus-stage-iii-hodgkin-lymphoma-in-combination-with-avd 2023-09-21T11:25:15 https://maestrodatabase.com/blog/u-dot-s-fda-approves-auryxia-ferric-citrate-tablets-as-a-treatment-for-people-with-iron-deficiency-anaemia-and-chronic-kidney-disease-not-on-dialysis 2017-11-08T06:48:44 https://maestrodatabase.com/blog/enhertu-recommended-for-approval-in-the-eu-by-chmp-for-patients-with-her2-low-metastatic-breast-cancer 2022-12-19T07:44:31 https://maestrodatabase.com/blog/ontario-pioneers-access-to-treatment-for-severe-alopecia-areata-with-lillys-olumiant 2026-01-15T02:27:53 https://maestrodatabase.com/blog/disc-medicine-receives-fda-fast-track-designation-for-mwtx-003-for-the-treatment-of-polycythemia-vera 2023-09-21T07:04:39 https://maestrodatabase.com/blog/fda-grants-priority-review-to-mercks-application-for-keytruda-pembrolizumab-plus-concurrent-chemoradiotherapy-as-treatment-for-patients-with-newly-diagnosed-high-risk-locally-advanced-cervical-cancer 2023-09-21T07:36:30 https://maestrodatabase.com/blog/fda-grants-priority-review-to-genentechs-esbriet-pirfenidone-for-unclassifiable-interstitial-lung-disease 2021-01-21T10:56:46 https://maestrodatabase.com/blog/pbs-cost-recovery-implementation-statement-2018-2019 2018-07-05T05:56:05 https://maestrodatabase.com/blog/proposal-to-list-methylnaltrexone-bromide 2017-11-08T07:12:55 https://maestrodatabase.com/blog/collegium-receives-fda-approval-for-snda-for-xtampza-er 2017-11-08T06:59:19 https://maestrodatabase.com/blog/statement-from-fda-commissioner-scott-gottlieb-on-new-steps-to-improve-fda-review-of-shared-risk-evaluation-and-mitigation-strategies-to-improve-generic-drug-access 2017-11-08T20:10:09 https://maestrodatabase.com/blog/nice-publishes-final-guidance-backing-jyseleca-for-rheumatoid-arthritis 2021-01-21T10:52:23 https://maestrodatabase.com/blog/paediatric-exclusivity-and-regulatory-authority 2017-11-08T20:15:22 https://maestrodatabase.com/blog/european-commission-approves-menarini-groups-orserdu-elacestrant-for-the-treatment-of-patients-with-er-plus-her2--locally-advanced-or-metastatic-breast-cancer-with-an-activating-esr1-mutation 2023-09-21T11:52:44 https://maestrodatabase.com/blog/supply-and-insurance-issues-snarl-fall-covid-19-vaccine-campaign-for-some 2023-09-21T21:07:03 https://maestrodatabase.com/blog/decision-to-fund-zoster-vaccine 2017-11-09T07:16:21 https://maestrodatabase.com/blog/mind-the-gap-revisited 2017-11-09T07:24:01 https://maestrodatabase.com/blog/biocon-biologics-receives-european-commission-approval-for-yesafili-biosimilar-aflibercept 2023-09-21T20:57:09 https://maestrodatabase.com/blog/pbs-prescription-medicines-more-affordable-for-australians 2026-01-15T19:19:11 https://maestrodatabase.com/blog/nice-turns-down-bayers-stivarga-for-liver-cancer 2017-11-09T07:30:07 https://maestrodatabase.com/blog/deciphera-pharmaceuticals-announces-u-dot-s-fda-acceptance-of-new-drug-application-and-priority-review-for-ripretinib-in-patients-with-advanced-gastro-intestinal-stromal-tumour 2020-02-13T00:17:59 https://maestrodatabase.com/blog/merck-receives-fda-approval-of-prevymis-letermovir-for-prevention-of-cytomegalovirus-infection-and-disease-in-adult-allogeneic-stem-cell-transplant-patients 2017-11-09T13:24:59 https://maestrodatabase.com/blog/fda-is-making-it-easier-to-meet-required-extra-safety-measures-for-certain-fda-approved-drugs 2017-11-09T13:21:55 https://maestrodatabase.com/blog/nda-accepted-for-filing-by-the-fda-for-antisense-oligonucleotide-viltolarsen 2020-02-13T01:15:52 https://maestrodatabase.com/blog/the-magic-of-randomisation-versus-the-myth-of-real-world-evidence 2020-02-13T00:25:09 https://maestrodatabase.com/blog/italy-ponders-suing-pfizer-for-delays-in-coronavirus-vaccine 2021-01-21T20:12:25 https://maestrodatabase.com/blog/neurotech-pharmaceuticals-receives-priority-review-of-biologics-license-application-for-nt-501-revakinagene-taroretcel-as-a-treatment-for-macular-telangiectasia-type-2 2024-06-23T05:32:27 https://maestrodatabase.com/blog/medicares-historic-prescription-drug-price-negotiations 2023-09-21T21:54:58 https://maestrodatabase.com/blog/beigene-announces-positive-regulatory-updates-in-europe-and-the-us-after-recently-regaining-global-rights-for-tevimbra 2023-09-21T21:31:15 https://maestrodatabase.com/blog/industry-pooling-helps-maintain-affordability-of-high-cost-drugs-despite-significant-inflationary-pressures 2021-01-21T19:39:18 https://maestrodatabase.com/blog/mobilising-australias-covid-19-vaccine-workforce 2021-01-21T19:50:30 https://maestrodatabase.com/blog/biden-appoints-veteran-woodcock-as-interim-fda-commissioner 2021-01-21T20:05:38 https://maestrodatabase.com/blog/dbv-technologies-submits-biologics-license-application-to-u-dot-s-fda-for-viaskin-peanut-for-the-treatment-of-peanut-allergy 2019-08-08T01:55:32 https://maestrodatabase.com/blog/the-marathon-of-covid-19-vaccination 2021-01-21T20:39:41 https://maestrodatabase.com/blog/eagle-pharmaceuticals-receives-fda-approval-for-additional-indication-for-pemfexy-in-combination-with-pembrolizumab-and-platinum-chemotherapy 2022-12-19T21:08:34 https://maestrodatabase.com/blog/facilitating-decentralised-clinical-trials-in-the-eu 2022-12-19T20:51:01 https://maestrodatabase.com/blog/draft-guidance-document-on-the-collection-and-analysis-of-disaggregated-data-in-clinical-trials-transparency 2022-12-19T20:55:20 https://maestrodatabase.com/blog/china-nmpa-approves-tislelizumab-for-patients-with-second-line-oesophageal-squamous-cell-carcinoma 2022-04-18T05:56:58 https://maestrodatabase.com/blog/molecular-partners-strategic-partner-allergan-announced-today-that-ema-has-validated-the-marketing-authorisation-application-for-abicipar 2019-08-08T02:17:10 https://maestrodatabase.com/blog/pharmac-funds-more-treatments-for-people-with-inflammatory-bowel-disease 2022-12-19T20:41:13 https://maestrodatabase.com/blog/cancer-care-advocate-malcolm-mulholland-cancer-society-welcome-pharmac-announcement 2019-08-08T02:01:03 https://maestrodatabase.com/blog/risks-to-the-340b-drug-pricing-program-related-to-manufacturer-restrictions-on-drug-availability 2022-04-18T20:41:04 https://maestrodatabase.com/blog/ex-pharma-exec-azar-is-top-choice-to-run-u-dot-s-health-agency 2017-11-09T14:15:58 https://maestrodatabase.com/blog/89bio-announces-us-fda-has-granted-breakthrough-therapy-designation-for-pegozafermin-in-non-alcoholic-steatohepatitis 2023-09-22T00:20:04 https://maestrodatabase.com/blog/the-opaque-industry-secretly-inflating-prices-for-prescription-drugs 2024-06-23T06:35:49 https://maestrodatabase.com/blog/top-fda-official-peter-marks-overruled-staff-review-team-to-approve-sarepta-gene-therapy 2024-06-23T06:29:58 https://maestrodatabase.com/blog/updates-to-the-health-technology-assessment-policy-and-methods-review-reference-committee---22-september-2023 2023-09-21T23:54:54 https://maestrodatabase.com/blog/securing-the-future-of-australias-world-class-healthcare-system 2022-04-18T20:26:14 https://maestrodatabase.com/blog/drug-pricing-reform-in-the-inflation-reduction-act-what-are-the-implications-part-1 2022-12-19T21:54:45 https://maestrodatabase.com/blog/msds-anti-viral-prevymis-fails-to-win-nice-backing 2018-07-05T10:38:07 https://maestrodatabase.com/blog/the-inflation-reduction-act-and-access-to-high-cost-cardiovascular-therapies 2023-09-21T23:32:41 https://maestrodatabase.com/blog/switzerland-approves-its-first-protein-based-covid-vaccine 2022-04-18T20:37:44 https://maestrodatabase.com/blog/fdas-breakthrough-device-program-meant-to-benefit-patients-is-delivering-the-biggest-gains-for-companies 2022-04-18T20:34:58 https://maestrodatabase.com/blog/us-health-insurance-coverage-and-financing 2022-12-19T21:50:45 https://maestrodatabase.com/blog/drug-makers-defy-trumps-call-to-drop-prices 2018-07-05T20:58:33 https://maestrodatabase.com/blog/clovis-oncology-receives-ema-validation-for-its-application-for-a-new-indication-for-rubraca-rucaparib-as-maintenance-treatment-for-women-with-recurrent-ovarian-cancer 2018-07-05T21:11:57 https://maestrodatabase.com/blog/european-commission-approves-expanded-indication-for-sprycel-dasatinib-to-include-treatment-of-children-with-philadelphia-chromosome-positive-chronic-myeloid-leukaemia-in-chronic-phase 2018-07-05T11:05:55 https://maestrodatabase.com/blog/b-dot-c-charity-fights-feds-for-access-to-life-saving-medicine 2018-07-05T21:24:37 https://maestrodatabase.com/blog/survey-shows-public-support-for-nhs-tax-rise 2018-07-05T21:19:43 https://maestrodatabase.com/blog/a-risky-drug-approval-lesson 2018-07-05T21:37:19 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-for-priority-review-bristol-myers-squibbs-biologics-license-application-for-lisocabtagene-maraleucel-liso-cel-for-adult-patients-with-relapsed-or-refractory-large-b-cell-lymphoma 2020-02-13T14:26:05 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac---december-2019-intracycle-meeting 2020-02-13T11:12:02 https://maestrodatabase.com/blog/vertex-calls-nhs-england-outrageous-as-orkambi-talks-stall-again 2018-07-05T21:55:15 https://maestrodatabase.com/blog/the-health-202-gag-clauses-mean-you-might-be-paying-more-for-prescription-drugs-than-you-need-to 2018-07-05T21:33:33 https://maestrodatabase.com/blog/the-grass-is-the-same-colour-part-ii-prescription-drug-woes-on-both-sides-of-the-us-canada-border 2020-02-13T14:35:10 https://maestrodatabase.com/blog/nice-brings-on-board-sigma-to-boost-med-tech-uptake 2017-11-09T16:44:30 https://maestrodatabase.com/blog/drug-prices-are-suppressed-overseas-white-house-study-finds 2020-02-13T14:31:48 https://maestrodatabase.com/blog/diurnal-groups-new-drug-application-accepted-by-the-us-fda 2020-02-13T14:55:29 https://maestrodatabase.com/blog/fda-grants-soligenix-fast-track-designation-for-rivax-in-the-prevention-of-ricin-poisoning 2020-02-13T14:49:43 https://maestrodatabase.com/blog/pmprb-report-shows-increased-plan-costs-promising-pharmaceutical-innovation-expert 2023-09-22T01:03:05 https://maestrodatabase.com/blog/lexicon-pharmaceuticals-resubmits-sotagliflozin-nda-for-type-1-diabetes 2024-06-23T12:17:05 https://maestrodatabase.com/blog/how-protected-classes-in-medicare-part-d-influence-u-dot-s-drug-sales-utilisation-and-price 2020-02-13T15:06:12 https://maestrodatabase.com/blog/health-canada-approves-keytruda-pembrolizumab-for-the-treatment-of-adult-patients-with-high-risk-early-stage-triple-negative-breast-cancer-in-combination-with-chemotherapy-as-neo-adjuvant-treatment-and-then-continued-as-monotherapy-as-adjuvant-treatment-after-surgery 2022-04-19T01:44:02 https://maestrodatabase.com/blog/prescription-medicines-applications-under-evaluation-april-2022 2022-04-19T01:48:23 https://maestrodatabase.com/blog/natalizumab-for-the-treatment-of-patients-with-highly-active-relapsing-remitting-multiple-sclerosis-after-disease-modifying-therapy 2025-03-12T01:54:42 https://maestrodatabase.com/blog/expanded-pbs-listings-for-lung-cancer-and-a-chronic-skin-disease 2024-06-24T06:52:23 https://maestrodatabase.com/blog/hutchmed-initiates-rolling-submission-of-nda-to-us-fda-for-fruquintinib-for-the-treatment-of-refractory-colorectal-cancer 2022-12-20T00:19:54 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-to-assess-erenumab-for-migraine-prevention-guselkumab-and-tildrakizumab-for-plaque-psoriasis 2017-11-10T07:27:29 https://maestrodatabase.com/blog/qiagen-receives-fda-approval-for-companion-diagnostic-to-mirati-therapeutics-krazati-in-non-small-cell-lung-cancer 2022-12-20T00:51:31 https://maestrodatabase.com/blog/zolbetuximab-in-combination-with-chemotherapy-for-the-first-line-treatment-of-adults-with-claudin-18-dot-2-positive-her2-negative-unresectable-advanced-gastric-or-gastro-oesophageal-junction-adenocarcinoma-final-guidance 2025-03-12T02:38:32 https://maestrodatabase.com/blog/seattle-genetics-announces-fda-approval-of-adcetris-brentuximab-vedotin-for-primary-cutaneous-anaplastic-large-cell-lymphoma-and-cd30-expressing-mycosis-fungoides 2017-11-10T07:41:50 https://maestrodatabase.com/blog/drug-makers-face-senate-over-drug-pricing 2019-02-25T02:11:06 https://maestrodatabase.com/blog/argenx-announces-fda-approval-of-vyvgart-hytrulo-for-chronic-inflammatory-demyelinating-polyneuropathy 2024-06-24T07:25:35 https://maestrodatabase.com/blog/dynavax-announces-fda-approval-of-heplisav-b-for-prevention-of-hepatitis-b-in-adults 2017-11-10T07:52:52 https://maestrodatabase.com/blog/atezolizumab-for-the-first-line-treatment-of-adults-with-advanced-or-recurrent-non-small-cell-lung-cancer-when-platinum-doublet-chemotherapy-is-unsuitable 2025-03-12T02:47:33 https://maestrodatabase.com/blog/new-lung-cancer-treatment-option-approved-by-nice 2019-08-08T11:45:11 https://maestrodatabase.com/blog/decision-for-funding-in-the-immunosuppressant-oncology-vasodilator-and-smoking-cessation-therapeutic-areas 2019-08-08T11:39:29 https://maestrodatabase.com/blog/man-27-dies-after-he-and-fiancee-switch-to-over-the-counter-insulin-to-save-money 2019-08-08T12:17:59 https://maestrodatabase.com/blog/radicava-edaravone-oral-suspension-receives-positive-recommendation-from-inesss-for-the-treatment-of-patients-with-als 2022-12-20T01:21:09 https://maestrodatabase.com/blog/highly-protected-species-calls-for-government-to-stop-propping-up-pharmacies 2019-08-08T12:04:46 https://maestrodatabase.com/blog/its-criminal-that-it-took-so-long-for-pharmac-to-fund-cancer-drug-kadcyla-campaigner-says 2019-08-08T11:54:31 https://maestrodatabase.com/blog/fda-requests-the-withdrawal-of-the-weight-loss-drug-belviq-belviq-xr-lorcaserin-from-the-market 2020-02-14T00:32:00 https://maestrodatabase.com/blog/fda-approves-first-extended-release-injectable-drug-regimen-for-adults-living-with-hiv 2021-01-21T22:47:09 https://maestrodatabase.com/blog/nice-draft-guidance-and-nhs-england-review-highlight-need-for-more-research-on-cannabis-based-medicinal-products 2019-08-08T11:49:48 https://maestrodatabase.com/blog/atara-biotherapeutics-ebvallo-tabelecleucel-receives-european-commission-approval-as-first-ever-therapy-for-adults-and-children-with-ebv-plus-ptld 2022-12-20T01:07:10 https://maestrodatabase.com/blog/under-representation-of-elderly-in-clinical-trials-an-analysis-of-the-initial-approval-documents-in-the-fda-database 2019-02-25T05:17:28 https://maestrodatabase.com/blog/heron-therapeutics-announces-u-dot-s-fda-approval-of-cinvanti-aprepitant-injectable-emulsion-for-the-prevention-of-acute-and-delayed-chemotherapy-induced-nausea-and-vomiting 2017-11-10T08:52:28 https://maestrodatabase.com/blog/nice-recommends-mavenclad-cladribine-tablets-for-highly-active-multiple-sclerosis 2017-11-10T09:02:11 https://maestrodatabase.com/blog/pharmac-cancer-model-must-be-reworked-specialists-warn 2019-08-08T21:08:00 https://maestrodatabase.com/blog/labour-has-finally-woken-up-on-pharmac-cancer-drug-funding 2019-08-08T21:05:11 https://maestrodatabase.com/blog/agenda-for-9-november-tc-meeting 2017-11-10T09:07:49 https://maestrodatabase.com/blog/health-canada-approves-otsuka-and-lundbecks-rexulti-brexpiprazole-as-adjunctive-treatment-of-major-depressive-disorder 2019-02-25T06:39:19 https://maestrodatabase.com/blog/accrufer-ferric-maltol-is-now-available-in-canada-as-a-prescription-oral-treatment-for-iron-deficiency-anaemia 2025-03-12T04:05:35 https://maestrodatabase.com/blog/trump-to-unveil-drug-price-index-in-september-health-are-speech 2019-08-08T21:19:19 https://maestrodatabase.com/blog/health-care-and-insurance-industries-mobilise-to-kill-medicare-for-all 2019-02-25T07:49:52 https://maestrodatabase.com/blog/its-time-for-pharmaceutical-companies-to-have-their-tobacco-moment 2019-02-25T10:04:37 https://maestrodatabase.com/blog/insurers-snooping-in-our-health-records 2019-08-08T21:15:09 https://maestrodatabase.com/blog/report-offers-blueprint-to-sustain-australias-health-care-system 2019-08-08T21:11:39 https://maestrodatabase.com/blog/pbm-practices-drive-up-costs-for-rx-drugs 2019-02-25T07:46:40 https://maestrodatabase.com/blog/getting-away-with-murder-in-drug-pricing 2019-02-25T10:26:01 https://maestrodatabase.com/blog/internal-fda-emails-reveal-how-price-sanderss-pressure-played-a-role-in-competitors-approval-catalyst-claims 2020-02-14T01:09:05 https://maestrodatabase.com/blog/ezharmia-launched-in-japan-as-first-dual-ezh1-and-ezh2-inhibitor-therapy-for-patients-with-adult-t-cell-leukaemia-lymphoma 2022-12-20T01:55:03 https://maestrodatabase.com/blog/the-economics-of-biologic-drugs 2019-08-08T21:27:55 https://maestrodatabase.com/blog/canada-ponders-a-federal-programme-for-pharmaceuticals 2020-02-14T00:56:12 https://maestrodatabase.com/blog/roche-has-a-5-dollars-billion-chance-to-lead-on-drug-prices 2019-02-25T10:14:07 https://maestrodatabase.com/blog/astrazeneca-ceo-on-drug-prices-the-system-has-to-change 2019-08-08T21:22:18 https://maestrodatabase.com/blog/fda-issues-guidance-on-modernising-statistical-methods-for-clinical-trials 2026-01-16T00:10:46 https://maestrodatabase.com/blog/inside-a-clinic-as-alzheimers-patients-and-families-gamble-on-controversial-and-costly-new-drugs 2026-01-16T01:05:15 https://maestrodatabase.com/blog/fda-approves-taiho-oncologys-lonsulf-trifluridine-slash-tipiracil-for-adult-patients-with-previously-treated-advanced-gastric-or-gastro-esophageal-junction-gej-adenocarcinoma 2019-02-25T20:15:44 https://maestrodatabase.com/blog/argenx-announces-vyvgart-efgartigimod-alfa-authorised-for-sale-by-health-canada-for-generalised-myasthenia-gravis 2023-09-23T07:10:08 https://maestrodatabase.com/blog/geron-announces-european-commission-approval-of-rytelo-imetelstat-a-first-in-class-telomerase-inhibitor-for-the-treatment-of-adults-with-transfusion-dependent-anaemia-due-to-lower-risk-mds 2025-03-12T21:46:22 https://maestrodatabase.com/blog/abbvies-skyrizi-now-listed-on-the-nova-scotia-formulary-for-the-treatment-of-moderate-to-severe-plaque-psoriasis 2020-02-14T01:53:31 https://maestrodatabase.com/blog/prescriptions-to-rise-to-ps9-from-april 2019-02-25T20:03:41 https://maestrodatabase.com/blog/fda-reports-lack-of-interest-high-rejection-rate-for-its-star-program 2026-01-16T05:06:30 https://maestrodatabase.com/blog/european-commission-authorises-viiv-healthcares-apretude-cabotegravir-long-acting-and-tablets-for-hiv-prevention 2023-09-23T06:48:46 https://maestrodatabase.com/blog/celltrions-infliximab-the-first-monoclonal-antibody-biosimilar-is-now-remdantry-in-canada 2025-03-12T21:08:31 https://maestrodatabase.com/blog/human-medicines-in-2025 2026-01-17T00:30:15 https://maestrodatabase.com/blog/regulatory-challenges-is-a-surrogate-endpoint-instead-of-overall-survival-enough-for-regulatory-approval-of-neo-adjuvant-cancer-treatment-the-swissmedic-perspective 2023-09-22T05:04:21 https://maestrodatabase.com/blog/novartis-ianalumab-receives-fda-breakthrough-therapy-designation-for-sjoegrens-disease 2026-01-17T00:34:18 https://maestrodatabase.com/blog/quality-of-life-an-important-element-of-treatment-value 2017-11-10T09:37:06 https://maestrodatabase.com/blog/alkermes-and-biogen-announce-u-dot-s-fda-acceptance-of-diroximel-fumarate-new-drug-application-for-multiple-sclerosis 2019-02-25T20:21:55 https://maestrodatabase.com/blog/fda-accepts-otsukas-resubmission-to-support-a-regulatory-review-of-tolvaptan-in-the-treatment-of-adpkd 2017-11-10T09:42:48 https://maestrodatabase.com/blog/santhera-receives-swissmedic-approval-of-agamree-vamorolone-for-the-treatment-of-duchenne-muscular-dystrophy 2026-01-16T02:14:59 https://maestrodatabase.com/blog/refreshed-national-medicines-policy 2022-12-20T07:06:18 https://maestrodatabase.com/blog/drug-prices-arent-falling-despite-more-generics-report-finds 2019-02-25T20:34:26 https://maestrodatabase.com/blog/agenda-for-july-11-tc-meeting 2018-07-06T03:24:45 https://maestrodatabase.com/blog/guiding-principles-of-good-ai-practice-in-drug-development 2026-01-16T02:38:38 https://maestrodatabase.com/blog/u-dot-s-fda-grants-breakthrough-therapy-designation-to-amicus-at-gaa-in-late-onset-pompe-disease 2019-02-25T20:28:54 https://maestrodatabase.com/blog/albireo-submits-bylvay-alagille-syndrome-regulatory-filings-to-fda-and-ema 2022-12-20T06:57:03 https://maestrodatabase.com/blog/family-fight-for-cancer-treatment-in-usa-because-drugs-not-available-in-uk 2019-02-25T20:44:58 https://maestrodatabase.com/blog/hearings-on-sky-high-drug-prices-show-how-little-has-changed-in-60-years 2019-02-25T20:37:15 https://maestrodatabase.com/blog/how-pharma-lost-its-edge-in-washington 2019-02-25T20:39:45 https://maestrodatabase.com/blog/jazz-pharmaceuticals-receives-european-commission-approval-for-enrylaze-a-recombinant-erwinia-asparaginase-or-crisantaspase-for-the-treatment-of-acute-lymphoblastic-leukaemia-and-lymphoblastic-lymphoma 2023-09-23T08:34:17 https://maestrodatabase.com/blog/sydnexis-announces-fda-acceptance-of-new-drug-application-and-pdufa-date-for-syd-101-for-the-treatment-of-progression-of-paediatric-myopia 2025-03-12T22:44:49 https://maestrodatabase.com/blog/f2g-announces-fda-filing-acceptance-of-new-drug-application-for-olorofim-for-the-treatment-of-invasive-fungal-infections 2022-12-20T07:12:10 https://maestrodatabase.com/blog/just-released-national-medicines-policy-sets-high-ambitions-for-better-health-outcomes-for-all-australians 2022-12-20T07:52:44 https://maestrodatabase.com/blog/fondazione-telethon-receives-european-marketing-authorisation-for-waskyra-etuvetidigene-autotemcel-a-gene-therapy-for-the-treatment-of-wiskott-aldrich-syndrome 2026-01-17T01:32:41 https://maestrodatabase.com/blog/us-fda-delays-two-drug-reviews-in-new-voucher-program-after-safety-efficacy-concerns 2026-01-17T01:37:03 https://maestrodatabase.com/blog/drug-pricing-reform-in-the-inflation-reduction-act-what-are-the-implications-part-2 2022-12-20T07:40:02 https://maestrodatabase.com/blog/some-drugmakers-quietly-concerned-about-legal-risk-with-speedy-fda-review-program 2026-01-17T02:23:27 https://maestrodatabase.com/blog/atsena-therapeutics-granted-us-fda-fast-track-designation-for-atsn-201-gene-therapy-to-treat-x-linked-retinoschisis 2025-03-12T23:05:06 https://maestrodatabase.com/blog/decision-to-widen-access-and-change-the-funded-enzyme-replacement-therapy-for-gaucher-disease 2018-07-06T04:27:03 https://maestrodatabase.com/blog/seattle-genetics-announces-fda-filing-acceptance-for-priority-review-of-tucatinib-new-drug-application-for-patients-with-locally-advanced-or-metastatic-her2-positive-breast-cancer 2020-02-14T03:35:55 https://maestrodatabase.com/blog/funding-boost-means-more-medicines-for-more-new-zealanders 2024-06-24T21:05:32 https://maestrodatabase.com/blog/nice-recommends-jyseleca-filgotinib-on-nhs-in-landmark-decision-for-rheumatoid-arthritis 2021-01-22T03:45:39 https://maestrodatabase.com/blog/update-from-the-pbac-june-2024 2024-06-25T06:31:38 https://maestrodatabase.com/blog/meta-analyses-with-very-few-studies-different-beta-binomial-models-in-comparison 2022-12-20T20:04:52 https://maestrodatabase.com/blog/covid-19-vaccine-safety-report-15-december-2022 2022-12-20T20:06:58 https://maestrodatabase.com/blog/sellas-announces-us-fda-rare-paediatric-disease-designation-granted-to-sls009-for-the-treatment-of-paediatric-acute-lymphoblastic-leukaemia 2024-06-25T06:23:07 https://maestrodatabase.com/blog/nice-recommends-enhertu-for-more-people-with-advanced-breast-cancer 2022-12-20T19:58:15 https://maestrodatabase.com/blog/astellas-seagen-and-merck-announce-fda-acceptance-of-supplemental-biologics-license-applications-for-padcev-enfortumab-vedotin-ejfv-with-keytruda-pembrolizumab-for-the-first-line-treatment-of-certain-patients-with-locally-advanced-or-metastatic-urothelial-cancer 2022-12-20T19:46:55 https://maestrodatabase.com/blog/will-trodelvy-get-innovative-new-drug-status-backed-by-100-000-petitions 2024-06-25T06:18:13 https://maestrodatabase.com/blog/us-fda-approves-jardiance-for-the-treatment-of-adults-with-chronic-kidney-disease 2023-09-24T00:52:48 https://maestrodatabase.com/blog/takeda-announces-approval-of-livtencity-maribavir-in-japan-for-post-transplant-cytomegalovirus-cmv-infection-slash-disease-that-is-refractory-to-existing-anti-cmv-therapies 2024-06-25T00:48:17 https://maestrodatabase.com/blog/micurx-receives-fda-qualified-infectious-disease-product-and-fast-track-designation-for-contezolid-and-contezolid-acefosamil 2023-09-24T00:24:13 https://maestrodatabase.com/blog/biontech-and-dualitybio-receive-fda-fast-track-designation-for-antibody-drug-conjugate-candidate-bnt324-slash-db-1311-in-prostate-cancer 2024-06-25T06:56:50 https://maestrodatabase.com/blog/yescarta-approved-in-japan-for-treatment-of-patients-with-relapsed-slash-refractory-large-b-cell-lymphomas 2021-01-22T07:47:50 https://maestrodatabase.com/blog/competition-consolidation-and-evolution-in-the-pharmacy-market 2021-08-21T06:24:52 https://maestrodatabase.com/blog/nice-recommends-lillys-mirikizumab-omvoh-for-the-treatment-of-eligible-adults-with-moderately-to-severely-active-ulcerative-colitis 2023-09-24T02:31:01 https://maestrodatabase.com/blog/menarini-receives-european-commission-approval-of-elzonris-tagraxofusp-for-the-treatment-of-blastic-plasmacytoid-dendritic-cell-neoplasm 2021-01-22T07:56:37 https://maestrodatabase.com/blog/tagrisso-with-the-addition-of-chemotherapy-approved-in-japan-as-new-first-line-treatment-for-patients-with-egfr-mutated-advanced-lung-cancer 2024-06-25T06:52:05 https://maestrodatabase.com/blog/a-national-medicines-policy-fit-for-the-future 2022-12-20T20:22:23 https://maestrodatabase.com/blog/jemperli-dostarlimab-plus-chemotherapy-application-accepted-for-review-by-the-ema-to-expand-use-to-all-patients-with-primary-advanced-or-recurrent-endometrial-cancer 2024-06-25T06:46:54 https://maestrodatabase.com/blog/incyte-announces-acceptance-and-priority-review-of-bla-for-retifanlimab-as-a-potential-treatment-for-patients-with-squamous-cell-carcinoma-of-the-anal-canal 2021-01-22T07:07:09 https://maestrodatabase.com/blog/novavax-submits-application-to-ema-for-updated-protein-based-2024-2025-formula-covid-19-vaccine 2024-06-25T06:42:17 https://maestrodatabase.com/blog/icer-provides-update-on-value-based-pricing-of-paxlovid-as-an-outpatient-treatment-for-covid-19 2022-12-20T20:13:57 https://maestrodatabase.com/blog/valneva-announces-health-canada-approval-of-the-worlds-first-chikungunya-vaccine-ixchiq 2024-06-25T06:37:10 https://maestrodatabase.com/blog/ezharmia-approved-in-japan-as-first-dual-ezh1-and-ezh2-inhibitor-therapy-for-patients-with-peripheral-t-cell-lymphoma 2024-06-25T07:38:00 https://maestrodatabase.com/blog/oncoinvent-receives-fda-fast-track-designation-for-radspherin-as-treatment-for-peritoneal-carcinomatosis-from-ovarian-cancer 2024-06-25T07:03:28 https://maestrodatabase.com/blog/fda-takes-steps-to-encourage-more-informative-labelling-on-prescription-drug-and-biological-products-indications-and-usage 2018-07-07T00:33:19 https://maestrodatabase.com/blog/icer-publishes-evidence-report-on-therapies-for-high-cholesterol 2021-01-22T21:30:35 https://maestrodatabase.com/blog/what-does-a-drug-cost-it-depends-on-where-you-live 2018-07-07T00:49:41 https://maestrodatabase.com/blog/drug-makers-try-evasion-tougher-negotiations-to-fight-new-u-dot-s-insurer-tactic 2018-07-07T00:44:24 https://maestrodatabase.com/blog/u-dot-s-fda-expands-approval-of-sprycel-dasatinib-to-include-treatment-of-children-with-philadelphia-chromosome-positive-chronic-myeloid-leukemia-in-chronic-phase 2017-11-10T11:52:54 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-therapies-for-lupus-nephritis 2021-01-22T21:01:33 https://maestrodatabase.com/blog/building-trust-between-physicians-hospitals-and-payers-a-renewed-opportunity-for-transforming-us-health-care 2019-02-26T06:45:09 https://maestrodatabase.com/blog/ema-publishes-agenda-for-june-24-27-2024-chmp-meeting 2024-06-25T10:40:28 https://maestrodatabase.com/blog/themis-bioscience-receives-fda-fast-track-designation-for-chikungunya-vaccine-candidate 2019-02-26T06:47:41 https://maestrodatabase.com/blog/fda-approves-nivolumab-plus-cabozantinib-for-advanced-renal-cell-carcinoma 2021-01-22T21:19:30 https://maestrodatabase.com/blog/darzalex-clears-hira-hurdle-for-al-amyloidosis-reimbursement-in-korea 2026-01-18T21:21:29 https://maestrodatabase.com/blog/highlights-from-the-chmp-6-9-november-2017-meeting 2017-11-10T13:05:42 https://maestrodatabase.com/blog/bausch-plus-lomb-announces-fda-approval-of-lotemax-sm-loteprednol-etabonate-ophthalmic-gel-0-dot-38-percent-for-the-treatment-of-post-operative-inflammation-and-pain-following-ocular-surgery 2019-02-26T06:51:44 https://maestrodatabase.com/blog/enhertu-granted-priority-review-in-the-u-dot-s-for-patients-with-previously-treated-her2-mutant-metastatic-non-small-cell-lung-cancer 2022-04-19T06:09:30 https://maestrodatabase.com/blog/eylea-8-mg-approved-in-the-eu-for-third-retinal-indication 2026-01-19T20:07:39 https://maestrodatabase.com/blog/sobi-receives-european-commission-approval-for-aspaveli-pegcetacoplan-for-the-treatment-of-c3g-and-primary-ic-mpgn 2026-01-19T20:16:37 https://maestrodatabase.com/blog/dispensing-disruption-are-pharmacies-ready-for-digital-rivals 2018-07-07T02:31:48 https://maestrodatabase.com/blog/doh-publishes-revised-agenda-for-july-2024-pbac-meeting-21-june-2024 2024-06-25T12:13:21 https://maestrodatabase.com/blog/epizyme-announces-fda-acceptance-of-new-drug-application-for-filing-with-priority-review-for-tazverik-tazemetostat-for-the-treatment-of-follicular-lymphoma 2020-02-14T14:30:32 https://maestrodatabase.com/blog/organon-announces-us-fda-approval-of-supplemental-new-drug-application-extending-duration-of-use-of-nexplanon-etonogestrel-implant-68-mg-radiopaque 2026-01-19T04:53:59 https://maestrodatabase.com/blog/smc---january-2026-decisions 2026-01-19T19:49:23 https://maestrodatabase.com/blog/enhertu-plus-pertuzumab-type-ii-variation-application-validated-in-the-eu-as-first-line-treatment-of-patients-with-her2-positive-metastatic-breast-vancer 2026-01-19T19:53:55 https://maestrodatabase.com/blog/procedural-update-on-submission-of-type-i-variations-to-ema-in-march-april-and-may-2019 2019-02-26T19:54:47 https://maestrodatabase.com/blog/roches-ocrevus-subcutaneous-administration-approved-by-european-commission-as-first-and-only-twice-a-year-injection-for-relapsing-and-primary-progressive-multiple-sclerosis 2024-06-25T21:40:17 https://maestrodatabase.com/blog/the-fdas-oncology-center-of-excellence----quantifying-the-patient-experience 2019-02-26T19:58:59 https://maestrodatabase.com/blog/pharmac-on-notice-as-cancer-patient-advocates-welcome-incredible-medicines-spend 2024-06-25T21:35:39 https://maestrodatabase.com/blog/abbvie-provides-us-regulatory-update-on-abbv-951-foscarbidopa-slash-foslevodopa 2024-06-25T12:23:39 https://maestrodatabase.com/blog/are-low-priced-drugs-becoming-an-endangered-species 2019-02-26T12:04:51 https://maestrodatabase.com/blog/wacky-drug-price-system-keeps-costs-high-for-patients-paying-for-prescriptions-fda-chief-says 2019-02-26T20:17:16 https://maestrodatabase.com/blog/details-of-doug-ford-governments-health-care-overhaul-including-new-super-agency-coming-tuesday 2019-02-26T20:04:25 https://maestrodatabase.com/blog/a-small-drug-maker-settles-charges-for-paying-others-to-submit-its-fda-applications 2019-02-26T20:13:05 https://maestrodatabase.com/blog/pharma-executives-offer-senate-ideas-to-lower-drug-costs---except-actually-cutting-prices 2019-02-26T20:27:47 https://maestrodatabase.com/blog/drug-industry-defence-for-high-prices-blame-insurance-companies 2019-02-26T20:31:40 https://maestrodatabase.com/blog/spero-therapeutics-receives-qidp-designation-from-the-u-dot-s-fda-for-the-development-of-spr720 2019-02-26T20:20:46 https://maestrodatabase.com/blog/benralizumab-receives-positive-eu-chmp-opinion-for-severe-uncontrolled-eosinophilic-asthma 2017-11-10T17:05:39 https://maestrodatabase.com/blog/fda-approves-three-drugs-for-non-prescription-use-through-rx-to-otc-switch-process 2020-02-14T23:41:44 https://maestrodatabase.com/blog/first-daily-pill-for-endometriosis-approved-for-nhs-use 2025-03-13T20:24:53 https://maestrodatabase.com/blog/former-novartis-executive-wins-1-dollars-5-cents-million-after-claiming-she-was-fired-for-complaining-about-a-study 2019-02-26T20:35:42 https://maestrodatabase.com/blog/lenvatinib-and-pembrolizumab-in-endometrial-cancer-patients-live-significantly-longer 2022-04-19T11:49:18 https://maestrodatabase.com/blog/how-will-brexit-affect-health-services-in-the-uk-an-updated-evaluation 2019-02-26T20:39:48 https://maestrodatabase.com/blog/adicet-bio-receives-fda-fast-track-designation-for-lead-candidate-adi-001 2022-04-19T11:32:47 https://maestrodatabase.com/blog/they-cant-get-their-medicines-so-theyre-moving-to-scotland 2019-02-26T20:46:28 https://maestrodatabase.com/blog/china-national-medical-products-administration-grants-approval-of-roches-tecentriq-in-combination-with-chemotherapy-as-first-line-treatment-of-people-with-extensive-stage-small-cell-lung-cancer 2020-02-15T02:51:26 https://maestrodatabase.com/blog/lung-cancer-second-treatment-alunbrig-likely-to-get-insurance-coverage 2019-02-26T20:42:19 https://maestrodatabase.com/blog/us-food-and-drug-administration-accepts-new-drug-application-for-daprodustat 2022-04-19T11:27:17 https://maestrodatabase.com/blog/fda-approves-agile-therapeutics-twirla-levonorgestrel-and-ethinyl-estradiol-transdermal-system---a-new-weekly-contraceptive-patch-delivering-a-30-mcg-daily-dose-of-oestrogen-and-120-mcg-daily-dose-of-progestin 2020-02-15T02:45:08 https://maestrodatabase.com/blog/early-access-to-supposedly-innovative-medicines-for-a-more-informed-bet 2026-01-19T21:03:11 https://maestrodatabase.com/blog/new-iron-treatment-proposed-for-people-who-have-experienced-low-phosphate-levels 2026-01-20T00:33:58 https://maestrodatabase.com/blog/lillys-sofetabart-mipitecan-receives-us-fdas-breakthrough-therapy-designation-for-the-treatment-of-certain-patients-with-platinum-resistant-ovarian-cancer 2026-01-20T19:52:33 https://maestrodatabase.com/blog/novavax-announces-approval-of-nuvaxovid-covid-19-vaccine-for-primary-and-booster-immunisation-in-japan 2022-04-19T20:50:04 https://maestrodatabase.com/blog/fda-grants-regenerative-medicine-advanced-therapy-designation-to-iregenes-nouvneu001-making-it-the-worlds-first-ipsc-therapy-with-both-ftd-and-rmat-recognitions 2026-01-20T20:01:52 https://maestrodatabase.com/blog/supply-related-data-in-manufacturer-dossiers-things-are-not-going-smoothly-yet 2022-04-19T21:09:35 https://maestrodatabase.com/blog/seikagaku-announces-receipt-of-a-complete-response-letter-concerning-the-biologics-license-application-in-the-us-for-si-6603-condoliase 2025-03-13T21:16:33 https://maestrodatabase.com/blog/ihealthscreen-announces-tga-approval-for-ipredict-automated-ai-system-for-early-diagnosis-of-diabetic-retinopathy-age-related-macular-degeneration-and-glaucoma-suspect 2022-04-19T21:19:56 https://maestrodatabase.com/blog/roches-ocrevus-ocrelizumab-gains-positive-chmp-opinion-for-relapsing-forms-of-multiple-sclerosis-and-primary-progressive-multiple-sclerosis 2017-11-10T17:48:25 https://maestrodatabase.com/blog/new-and-removed-exchange-groups 2020-02-16T11:33:24 https://maestrodatabase.com/blog/aytu-biopharma-announces-fast-track-designation-granted-to-ar101-for-the-treatment-of-vascular-ehlers-danlos-syndrome 2022-04-19T20:59:50 https://maestrodatabase.com/blog/the-americans-forced-into-bankruptcy-to-pay-for-prescriptions 2020-02-16T10:04:20 https://maestrodatabase.com/blog/prioritising-reference-products-over-biosimilars-led-to-millions-of-missed-savings-for-part-d 2022-04-19T21:38:09 https://maestrodatabase.com/blog/rwe-cost-and-time-savings-entice-sponsors-as-pitfalls-linger 2020-02-16T11:45:08 https://maestrodatabase.com/blog/medicares-decision-not-to-fund-aduhelm-changes-landscape-for-us-pharma-industry 2022-04-19T21:45:54 https://maestrodatabase.com/blog/whos-profiting-from-your-outrageous-medical-bills 2020-02-16T11:40:19 https://maestrodatabase.com/blog/innovative-cellular-therapeutics-receives-fda-fast-track-designation-for-gcc19cart-its-lead-solid-tumour-candidate-in-the-treatment-of-patients-with-relapsed-or-refractory-metastatic-colorectal-cancer 2022-04-19T21:32:51 https://maestrodatabase.com/blog/after-a-new-version-of-a-decades-old-drug-gets-orphan-status-the-price-suddenly-skyrockets 2020-02-16T15:06:11 https://maestrodatabase.com/blog/life-changing-batten-disease-drug-gives-hope-to-children-affected-by-fatal-illness 2018-07-08T03:03:35 https://maestrodatabase.com/blog/new-rules-for-weight-loss-wonder-drug-after-regulator-clamp-down 2023-09-24T21:17:35 https://maestrodatabase.com/blog/regenerons-ceo-has-been-outspoken-about-drug-price-hikes-but-one-of-his-companys-drugs-just-got-more-expensive 2018-07-08T05:36:50 https://maestrodatabase.com/blog/first-licensed-treatment-for-ultra-rare-immune-disorder-recommended 2025-03-13T22:09:25 https://maestrodatabase.com/blog/amazon-is-already-undercutting-prices-on-over-the-counter-pills 2018-07-08T03:10:36 https://maestrodatabase.com/blog/health-canada-authorizes-lillys-ebglyss-lebrikizumab-for-the-treatment-of-moderate-to-severe-atopic-dermatitis-in-adults-and-adolescents-12-years-and-older 2024-06-26T06:25:45 https://maestrodatabase.com/blog/fda-approves-aurinia-pharmaceuticals-lupkynis-voclosporin-for-adult-patients-with-active-lupus-nephritis 2021-01-23T04:54:51 https://maestrodatabase.com/blog/tagrisso-with-the-addition-of-chemotherapy-approved-in-china-as-first-line-treatment-for-patients-with-egfr-mutated-advanced-lung-cancer 2024-06-26T07:14:02 https://maestrodatabase.com/blog/otsuka-and-lundbeck-announce-fda-acceptance-of-snda-filing-for-brexpiprazole-in-combination-with-sertraline-for-the-treatment-of-adults-with-post-traumatic-stress-disorder 2024-06-26T07:07:36 https://maestrodatabase.com/blog/excellthera-announces-emas-acceptance-under-accelerated-assessment-of-market-authorisation-application-for-um171-cell-therapy-for-patients-with-haematological-malignancies-who-lack-a-readily-available-suitable-donor 2024-06-26T06:47:21 https://maestrodatabase.com/blog/ucbs-epilepsy-drug-briviant-brivaracetam-approved-in-japan-for-treatment-of-focal-onset-seizures 2024-06-26T06:39:12 https://maestrodatabase.com/blog/pharmamar-and-jazz-pharmaceuticals-announce-fda-acceptance-and-priority-review-of-new-drug-application-for-lurbinectedin-in-relapsed-small-cell-lung-cancer 2020-02-18T02:35:01 https://maestrodatabase.com/blog/government-of-canada-announces-changes-to-lower-drug-prices-and-lay-the-foundation-for-national-pharmacare 2019-08-10T08:00:08 https://maestrodatabase.com/blog/presidential-candidates-arent-talking-about-drug-shortages-they-should-be 2019-08-10T07:55:50 https://maestrodatabase.com/blog/nice-terminates-appraisal-of-nivolumab 2022-04-20T05:08:11 https://maestrodatabase.com/blog/ouro-medicines-receives-us-fda-fast-track-designation-for-gamgertamig-in-immune-thrombocytopenia-and-auto-immune-haemolytic-anaemia 2026-01-20T23:06:06 https://maestrodatabase.com/blog/kala-pharmaceuticals-receives-fda-complete-response-letter-for-kpi-121-0-dot-25-percent-nda-and-plans-to-respond-with-data-from-stride-3-trial 2019-08-10T10:34:48 https://maestrodatabase.com/blog/novartis-receives-ec-approval-for-beovu-a-next-generation-anti-vegf-treatment-for-wet-amd-a-leading-cause-of-blindness-worldwide 2020-02-18T03:01:07 https://maestrodatabase.com/blog/icer-to-assess-treatments-for-sickle-cell-disease 2019-08-10T10:30:55 https://maestrodatabase.com/blog/randomised-clinical-trials-of-artificial-intelligence 2020-02-18T02:58:11 https://maestrodatabase.com/blog/celcuity-announces-fda-acceptance-of-new-drug-application-for-gedatolisib-in-hr-plus-slash-her2--slash-pik3ca-wild-type-advanced-breast-cancer 2026-01-20T23:14:03 https://maestrodatabase.com/blog/aequus-announces-health-canada-notice-of-compliance-for-zimed-preservative-free-bimatoprost-0-dot-03-percent 2022-12-21T05:35:00 https://maestrodatabase.com/blog/lyrica-a-drug-linked-to-depression-and-anxiety-now-the-top-pain-medication-on-the-pbs 2020-02-18T02:54:01 https://maestrodatabase.com/blog/vifor-pharma-acquires-priority-review-voucher 2020-02-18T02:51:38 https://maestrodatabase.com/blog/big-data-big-tech-and-protecting-patient-privacy 2019-08-10T10:26:02 https://maestrodatabase.com/blog/ontario-expanding-safe-use-of-biosimilars 2022-12-21T05:53:51 https://maestrodatabase.com/blog/bioxcel-therapeutics-submits-supplemental-new-drug-application-to-us-fda-for-igalmi-label-expansion-in-the-at-home-setting 2026-01-21T03:48:24 https://maestrodatabase.com/blog/family-remains-hopeful-after-request-for-life-saving-drug-is-denied 2020-02-18T03:08:22 https://maestrodatabase.com/blog/pbs-cost-recovery-information-forum---webinar-recording-and-resources-available 2020-02-18T03:05:07 https://maestrodatabase.com/blog/truqap-faces-double-barrier-in-korea-as-ngs-and-drug-reimbursement-lag 2026-01-21T00:44:49 https://maestrodatabase.com/blog/lbl-024-opamtistomig-pd-l1-slash-4-1bb-bispecific-antibody-granted-fast-track-designation-by-the-us-fda 2026-01-21T01:03:12 https://maestrodatabase.com/blog/iovance-biotherapeutics-was-granted-fast-track-designation-for-ln-145-for-cervical-cancer 2019-02-27T04:35:59 https://maestrodatabase.com/blog/brain-cancer-survivor-who-finished-year-12-hoping-medication-can-get-pbs-listing 2026-01-21T02:13:41 https://maestrodatabase.com/blog/private-health-cover-numbers-still-dwindling-apra-reports 2020-02-18T06:42:11 https://maestrodatabase.com/blog/ani-pharmaceuticals-announces-fda-approval-of-new-purified-cortrophin-gel-pre-filled-syringe 2025-03-14T01:27:07 https://maestrodatabase.com/blog/fda-accepts-biocrysts-nda-for-oral-once-daily-berotralstat-bcx7353-to-prevent-hae-attacks 2020-02-18T20:05:46 https://maestrodatabase.com/blog/iveric-bio-announces-completion-of-rolling-nda-submission-to-fda-for-avacincaptad-pegol-for-the-treatment-of-geographic-atrophy 2022-12-21T07:19:13 https://maestrodatabase.com/blog/fda-calls-states-bluffs-on-drug-importation 2020-02-18T20:03:17 https://maestrodatabase.com/blog/calls-to-change-private-health-after-funds-lose-47-000-younger-members 2020-02-18T20:00:34 https://maestrodatabase.com/blog/biocryst-announces-approval-of-orladeyo-berotralstat-in-japan-for-the-prophylactic-treatment-of-hereditary-angioedema 2021-01-24T03:56:24 https://maestrodatabase.com/blog/heron-announces-fda-approval-of-supplemental-new-drug-application-to-expand-cinvanti-label-for-iv-push 2019-02-27T04:43:05 https://maestrodatabase.com/blog/australia-on-track-for-coronavirus-vaccines-despite-global-shortages 2021-01-24T19:51:44 https://maestrodatabase.com/blog/horizon-therapeutics-announces-u-dot-s-fda-approval-of-new-dosage-form-for-procysbi-cysteamine-bitartrate-delayed-release-oral-granules 2020-02-18T20:23:35 https://maestrodatabase.com/blog/golidocitinib-granted-priority-review-by-china-nmpa-for-the-treatment-of-relapsed-slash-refractory-peripheral-t-cell-lymphoma 2023-09-25T10:49:58 https://maestrodatabase.com/blog/alx-oncologys-alx148-receives-two-fast-track-designations-from-fda-for-the-treatment-of-patients-with-head-and-neck-squamous-cell-carcinoma-and-patients-with-gastric-or-gastro-esophageal-junction-adenocarcinoma 2020-02-18T20:14:35 https://maestrodatabase.com/blog/canadas-drug-makers-rattle-their-sabers-over-a-government-plan-to-control-medicine-spending 2021-01-24T19:56:39 https://maestrodatabase.com/blog/dawnzera-donidalorsen-granted-european-union-marketing-authorisation-for-the-prevention-of-hereditary-angioedema 2026-01-21T20:00:26 https://maestrodatabase.com/blog/lynparza-in-combination-with-abiraterone-approved-in-the-eu-as-first-line-treatment-for-patients-with-metastatic-castration-resistant-prostate-cancer 2022-12-21T07:43:54 https://maestrodatabase.com/blog/the-stakes-for-choosing-the-right-fda-commissioner-couldnt-be-higher 2021-01-24T19:59:05 https://maestrodatabase.com/blog/once-weekly-altuviiio-approved-in-japan-as-a-new-class-of-factor-viii-therapy-for-haemophilia-a 2023-09-25T07:13:12 https://maestrodatabase.com/blog/ceadm-applauds-cadths-decision-to-recommend-an-innovative-depression-medication-for-publicly-funded-drug-plans-in-canada 2020-02-18T20:37:05 https://maestrodatabase.com/blog/pbs-expenditure-and-prescriptions-report-2021-22 2022-12-21T07:31:38 https://maestrodatabase.com/blog/celgene-corporation-announces-key-regulatory-update-for-revlimid-in-lymphoma 2019-02-27T06:42:57 https://maestrodatabase.com/blog/population-based-payments-may-help-ensure-access-to-life-saving-antibiotics-for-medicare-beneficiaries 2020-02-18T20:29:15 https://maestrodatabase.com/blog/imfinzi-plus-chemotherapy-approved-in-the-eu-as-first-immunotherapy-regimen-for-patients-with-advanced-biliary-tract-cancer 2022-12-21T07:26:30 https://maestrodatabase.com/blog/calls-to-expand-vaccine-portfolio-after-government-fails-to-secure-moderna-vaccine 2021-01-24T19:47:27 https://maestrodatabase.com/blog/ema-publishes-agenda-for-25-28-february-2019-chmp-meeting 2019-02-27T07:04:25 https://maestrodatabase.com/blog/theratechnologies-submits-tesamorelin-f8-formulation-sbla-for-fda-review 2023-09-25T12:33:11 https://maestrodatabase.com/blog/car-t-cell-therapy-breyanzi-approved-as-relapsed-or-refractory-large-b-cell-lymphoma-second-line-therapy-in-japan 2022-12-21T08:12:16 https://maestrodatabase.com/blog/tofidence-tocilizumab-a-biosimilar-referencing-roactemra-approved-in-the-european-union 2024-06-26T22:50:25 https://maestrodatabase.com/blog/fda-granted-cmg901-fast-track-designation-for-unresectable-or-metastatic-gastric-and-gastro-oesophageal-junction-cancer-which-have-relapsed-and-slash-or-are-refractory-to-approved-therapies 2022-04-20T06:49:20 https://maestrodatabase.com/blog/house-democrats-reveal-plan-for-medicare-for-all 2019-02-27T06:55:33 https://maestrodatabase.com/blog/fda-grants-fast-track-to-edesa-biotechs-ards-drug-candidate 2022-12-21T08:07:36 https://maestrodatabase.com/blog/tga-to-give-australians-confidence-to-get-the-covid-19-jab 2021-01-24T20:02:07 https://maestrodatabase.com/blog/creating-a-patient-and-community-advisory-committee-at-the-canadian-agency-for-drugs-and-technologies-in-health 2021-01-24T20:04:54 https://maestrodatabase.com/blog/abbvie-announces-european-commission-approval-of-tepkinly-epcoritamab-for-adults-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma 2023-09-25T12:11:18 https://maestrodatabase.com/blog/harmony-biosciences-receives-us-fda-approval-for-wakix-pitolisant-in-paediatric-patients-with-narcolepsy 2024-06-26T22:13:27 https://maestrodatabase.com/blog/paying-clinical-trial-participants-legal-risks-and-mitigation-strategies 2020-02-18T22:45:52 https://maestrodatabase.com/blog/patritumab-deruxtecan-bla-submission-receives-complete-response-letter-from-fda-due-to-inspection-findings-at-third-party-manufacturer 2024-06-27T10:44:34 https://maestrodatabase.com/blog/ucb-announces-approval-of-rystiggo-rozanolixizumab-and-zilbryso-zilucoplan-for-the-treatment-of-adult-patients-with-generalised-myasthenia-gravis-in-japan 2023-09-25T20:27:49 https://maestrodatabase.com/blog/dusc-utilisation-analysis-public-release-documents-october-2024 2025-03-14T05:52:31 https://maestrodatabase.com/blog/medical-device-application-processing-times 2020-02-19T04:44:42 https://maestrodatabase.com/blog/carisma-therapeutics-granted-fda-fast-track-designation-for-ct-0525-for-the-treatment-of-her2-overexpressing-solid-tumours 2024-06-27T11:20:07 https://maestrodatabase.com/blog/radius-healths-tymlos-abaloparatide-receives-us-fda-approval-as-a-treatment-to-increase-bone-density-in-men-with-osteoporosis-at-high-risk-for-fracture 2022-12-21T19:46:42 https://maestrodatabase.com/blog/hhs-announces-cost-savings-for-64-prescription-drugs-thanks-to-the-medicare-rebate-program-established-by-the-biden-harris-administrations-lower-cost-prescription-drug-law 2024-06-27T11:11:29 https://maestrodatabase.com/blog/bavarian-nordic-submits-marketing-authorisation-application-for-its-chikungunya-vaccine-candidate-to-ema 2024-06-27T11:04:07 https://maestrodatabase.com/blog/ionis-announces-olezarsen-fcs-new-drug-application-accepted-for-priority-review 2024-06-27T10:55:40 https://maestrodatabase.com/blog/european-commission-approves-vyndaqel-the-first-treatment-in-the-eu-for-transthyretin-amyloid-cardiomyopathy-attr-cm 2020-02-19T06:24:49 https://maestrodatabase.com/blog/icer-finalises-2023-updates-to-value-assessment-framework 2023-09-25T20:32:39 https://maestrodatabase.com/blog/idorsia-submits-a-new-drug-application-to-the-us-fda-for-aprocitentan-for-the-treatment-of-patients-with-difficult-to-control-hypertension 2022-12-21T20:15:48 https://maestrodatabase.com/blog/expanding-our-scientific-advice-services-for-the-life-sciences-sector-in-canada 2024-06-27T21:44:56 https://maestrodatabase.com/blog/economic-analysis-falls-short-when-it-comes-to-medicines-value 2019-02-27T11:36:03 https://maestrodatabase.com/blog/verona-pharma-announces-us-fda-approval-of-ohtuvayre-ensifentrine 2024-06-27T21:34:36 https://maestrodatabase.com/blog/icer-publishes-final-evidence-report-on-treatment-for-post-traumatic-stress-disorder 2024-06-27T21:24:48 https://maestrodatabase.com/blog/tga-provisionally-approves-pfizer-covid-19-vaccine 2021-01-24T22:21:56 https://maestrodatabase.com/blog/european-commission-approves-eladynos-abaloparatide-for-the-treatment-of-osteoporosis-in-post-menopausal-women-at-increased-risk-of-fracture 2022-12-21T19:56:07 https://maestrodatabase.com/blog/pharma-industry-swamped-with-no-deal-brexit-info-says-bia 2019-02-27T11:41:01 https://maestrodatabase.com/blog/vir-biotechnology-receives-fda-fast-track-designation-for-tobevibart-and-elebsiran-for-the-treatment-of-chronic-hepatitis-delta-infection 2024-06-27T11:26:38 https://maestrodatabase.com/blog/icer-publishes-evidence-report-on-treatments-for-multiple-sclerosis 2022-12-21T19:52:24 https://maestrodatabase.com/blog/leqembi-intravenous-infusion-lecanemab-approved-for-the-treatment-of-alzheimers-disease-in-japan 2023-09-25T20:55:43 https://maestrodatabase.com/blog/fda-approves-genentechs-actemra-for-the-treatment-of-covid-19-in-hospitalised-adults 2022-12-21T20:44:52 https://maestrodatabase.com/blog/fda-issues-complete-response-letter-for-udencya-onbody-biologics-license-application-solely-due-to-an-on-going-review-of-inspection-findings-at-a-third-party-filler 2023-09-25T21:16:17 https://maestrodatabase.com/blog/bayer-completes-rolling-submission-for-darolutamide-in-u-dot-s 2019-02-27T19:57:04 https://maestrodatabase.com/blog/sanofi-pasteur-covid-19-vaccine-authorised-by-mhra 2022-12-21T20:36:09 https://maestrodatabase.com/blog/classifying-ageing-as-a-disease-could-speed-fda-drug-approvals 2022-12-21T20:20:15 https://maestrodatabase.com/blog/pfizer-announces-fda-and-ema-acceptance-of-etrasimod-regulatory-submissions-for-ulcerative-colitis 2022-12-21T20:28:37 https://maestrodatabase.com/blog/health-insurance-reforms-to-bring-more-clarity-to-coverage 2019-02-27T20:07:51 https://maestrodatabase.com/blog/senator-big-pharma-is-morally-repugnant 2019-02-27T20:15:38 https://maestrodatabase.com/blog/depriving-sick-babies-of-right-to-life---nzord-boss-blasts-pharmac-decision-to-defer-spinraza 2019-02-27T20:00:59 https://maestrodatabase.com/blog/koreas-30th-novel-drug-k-cab-to-get-insurance-benefit-from-march 2019-02-27T20:28:27 https://maestrodatabase.com/blog/china-approves-first-biosimilar-of-foreign-drug-breaking-roche-monopoly 2019-02-27T20:31:31 https://maestrodatabase.com/blog/teva-and-medincell-receive-complete-response-letter-for-tv-46000-slash-mdc-irm 2022-04-20T09:10:21 https://maestrodatabase.com/blog/while-some-patients-pay-for-biologic-drugs-prison-inmates-get-them-for-free 2019-02-27T20:20:05 https://maestrodatabase.com/blog/nice-terminates-yet-another-appraisal 2020-10-07T20:00:43 https://maestrodatabase.com/blog/new-drug-application-resubmission-update 2022-04-20T20:38:05 https://maestrodatabase.com/blog/making-number-medicinesmatter-for-all-australians 2022-04-20T20:44:49 https://maestrodatabase.com/blog/u-dot-s-senators-relay-personal-experiences-as-they-chastise-pharma-execs-for-high-drug-prices 2019-02-27T20:35:59 https://maestrodatabase.com/blog/final-report-for-the-post-market-review-of-medicines-for-smoking-cessation-and-review-outcomes 2022-12-22T04:09:04 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-treatment-for-pulmonary-arterial-hypertension 2023-09-25T21:45:43 https://maestrodatabase.com/blog/fda-grants-regenerative-medicine-advanced-therapy-designation-to-allovirs-posoleucel-for-prevention-of-multiple-life-threatening-infections-from-six-viruses-in-allogeneic-haematopoietic-cell-transplant-patients 2022-04-20T20:30:53 https://maestrodatabase.com/blog/zynlonta-loncastuximab-tesirine-approved-in-the-eu-for-the-treatment-of-relapsed-or-refractory-diffuse-large-b-cell-lymphoma 2022-12-22T03:56:42 https://maestrodatabase.com/blog/fda-grants-toripalimab-fast-track-designation-for-mucosal-melanoma 2021-01-25T07:05:28 https://maestrodatabase.com/blog/european-commission-approves-bavencio-avelumab-for-first-line-maintenance-treatment-of-locally-advanced-or-metastatic-urothelial-carcinoma 2021-01-25T07:10:44 https://maestrodatabase.com/blog/health-canada-grants-marketing-authorisation-for-trikafta-elexacaftor-slash-tezacaftor-slash-ivacaftor-and-ivacaftor-in-children-with-cystic-fibrosis-ages-6-through-11-years-with-at-least-one-f508del-mutation 2022-04-20T21:48:15 https://maestrodatabase.com/blog/otsuka-announces-health-canada-approval-of-tavneos-avacopan-for-anca-associated-vasculitis 2022-04-20T20:59:23 https://maestrodatabase.com/blog/pharmac-decision-to-fund-more-cancer-drugs-massive-relief-to-kiwi-mum-paying-6-500-dollars-per-month-to-survive 2019-08-11T01:15:12 https://maestrodatabase.com/blog/extrapolation-of-drug-indications-from-study-populations-by-fda-is-common 2022-04-20T20:51:01 https://maestrodatabase.com/blog/accelerated-approval---an-unexpected-pathway-to-value-based-pricing 2021-08-22T02:03:22 https://maestrodatabase.com/blog/push-for-24-hour-convenience-stores-to-sell-prescription-medicines 2019-08-11T01:18:07 https://maestrodatabase.com/blog/tga-approves-new-covid-19-treatment-for-use-in-australia 2021-08-22T01:22:07 https://maestrodatabase.com/blog/tga-provisionally-approves-pfizer-slash-biontech-covid-19-vaccine-for-use-in-australia 2021-01-25T07:19:32 https://maestrodatabase.com/blog/calquence-approved-in-japan-for-the-treatment-of-relapsed-or-refractory-chronic-lymphocytic-leukaemia 2021-01-25T07:23:48 https://maestrodatabase.com/blog/ani-pharmaceuticals-announces-fda-approval-for-expansion-of-iluvien-label 2025-03-17T05:15:15 https://maestrodatabase.com/blog/aldeyra-therapeutics-submits-new-drug-application-to-the-us-fda-for-adx-2191-for-the-treatment-of-primary-vitreoretinal-lymphoma 2022-12-22T04:39:59 https://maestrodatabase.com/blog/imfinzi-approved-in-the-eu-as-first-and-only-immunotherapy-for-limited-stage-small-cell-lung-cancer 2025-03-17T07:32:06 https://maestrodatabase.com/blog/us-fda-grants-to-wugens-wu-cart-007-breakthrough-therapy-designation-for-treatment-of-relapsed-or-refractory-t-cell-acute-lymphoblastic-leukaemia-slash-t-cell-lymphoblastic-lymphoma 2026-01-21T23:14:29 https://maestrodatabase.com/blog/scynexis-receives-fda-qualified-infectious-disease-product-and-fast-track-designations-for-scy-247 2026-01-21T23:20:31 https://maestrodatabase.com/blog/iecure-receives-fda-regenerative-medicine-advanced-therapy-designation-for-ecur-506-for-neonatal-onset-ornithine-transcarbamylase-deficiency 2026-01-21T23:35:19 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-epcoritamab-bysp-for-relapsed-or-refractory-follicular-lymphoma 2024-06-28T01:14:02 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-approval-from-the-european-commission-to-expand-use-of-car-t-cell-therapy-breyanzi-for-relapsed-or-refractory-follicular-lymphoma 2025-03-17T05:34:27 https://maestrodatabase.com/blog/ema-publishes-agenda-for-25-29-january-chmp-meeting 2021-01-25T21:14:41 https://maestrodatabase.com/blog/european-commission-approves-abbvies-rinvoq-upadacitinib-for-the-treatment-of-psoriatic-arthritis-and-ankylosing-spondylitis 2021-01-25T21:20:32 https://maestrodatabase.com/blog/ultragenyx-launches-evkeeza-evinacumab-for-injection-in-canada-for-the-treatment-of-homozygous-familial-hypercholesterolaemia 2023-09-26T08:12:31 https://maestrodatabase.com/blog/patient-experience-data-and-bias----what-ratings-dont-tell-us 2019-02-27T23:57:26 https://maestrodatabase.com/blog/details-of-canadas-biggest-drug-pricing-overhaul-in-decades 2019-08-11T01:59:39 https://maestrodatabase.com/blog/mirati-announces-adagrasib-krazati-receives-breakthrough-therapy-designation-from-fda-for-patients-with-advanced-kras-mutated-colorectal-cancer 2022-12-22T05:34:33 https://maestrodatabase.com/blog/sandoz-receives-european-commission-approval-for-tyruko-natalizumab-first-and-only-biosimilar-for-multiple-sclerosis-in-europe 2023-09-26T08:04:05 https://maestrodatabase.com/blog/dupixent-dupilimab-sbla-for-treatment-of-eosinophilic-oesophagitis-in-children-aged-1-to-11-accepted-for-fda-priority-review 2023-09-26T07:53:48 https://maestrodatabase.com/blog/coronavirus-pfizer-jab-cleared-for-first-rollout-with-more-planned 2021-01-25T20:58:36 https://maestrodatabase.com/blog/albireo-announces-u-dot-s-fda-acceptance-of-new-drug-application-for-odevixibat 2021-01-26T01:45:45 https://maestrodatabase.com/blog/government-delivering-even-more-choice-for-womens-contraception-endometriosis-and-ivf-journeys 2025-03-17T08:58:07 https://maestrodatabase.com/blog/intrabio-receives-european-commission-approval-of-aqneursa-for-the-treatment-of-niemann-pick-type-c-disease 2026-01-22T03:35:12 https://maestrodatabase.com/blog/fda-approves-theranicas-nerivio-for-acute-treatment-of-migraine-in-adolescents 2021-01-26T02:27:06 https://maestrodatabase.com/blog/symbicort-turbuhaler-approved-in-china-as-an-anti-inflammatory-reliever-in-mild-asthma 2021-01-26T07:33:57 https://maestrodatabase.com/blog/astrazeneca-is-finding-it-hard-to-keep-its-covid-19-vaccine-promises 2021-01-25T22:09:53 https://maestrodatabase.com/blog/iterum-therapeutics-announces-u-dot-s-fda-filing-acceptance-of-new-drug-application-for-oral-sulopenem 2021-01-26T01:40:14 https://maestrodatabase.com/blog/takeda-announces-approval-of-cuvitru-subcutaneous-immunoglobulin-in-japan-for-patients-with-agammaglobulinaemia-or-hypogammaglobulinaemia 2023-09-26T09:58:43 https://maestrodatabase.com/blog/house-panel-passes-bills-to-expand-medicare-obesity-drug-coverage-cancer-screening 2024-06-28T02:18:21 https://maestrodatabase.com/blog/pharmac-proposes-to-fund-life-changing-treatments-for-people-with-cystic-fibrosis 2026-01-22T04:34:37 https://maestrodatabase.com/blog/nice-publishes-second-appraisal-consultation-document-for-zytiga 2021-01-26T20:05:55 https://maestrodatabase.com/blog/thousands-living-with-lupus-offered-hope-from-twice-yearly-infusion 2026-01-22T10:43:39 https://maestrodatabase.com/blog/vertex-announces-u-dot-s-fda-acceptance-of-supplemental-new-drug-application-for-trikafta-elexacaftor-slash-tezacaftor-slash-ivacaftor-and-ivacaftor-in-children-with-cystic-fibrosis-ages-6-through-11-with-certain-mutations 2021-01-26T19:50:43 https://maestrodatabase.com/blog/recordati-rare-diseases-carbaglu-carglumic-acid-receives-u-dot-s-fda-approval-for-a-new-indication-to-treat-acute-hyperammonaemia-associated-with-propionic-acidemia-and-methylmalonic-acidemia 2021-01-26T19:56:04 https://maestrodatabase.com/blog/understanding-the-role-of-comparative-clinical-studies-in-the-development-of-oncology-biosimilars 2020-02-19T08:32:11 https://maestrodatabase.com/blog/new-hope-for-lung-cancer-patients-with-ground-breaking-treatment-option-to-be-listed-on-the-pbs 2020-02-19T19:41:08 https://maestrodatabase.com/blog/meiragtx-announces-aav-cnga3-granted-fast-track-designation-by-u-dot-s-fda-for-treatment-of-achromatopsia 2021-01-26T20:17:53 https://maestrodatabase.com/blog/merck-receives-complete-response-letter-from-the-us-fda-for-supplemental-biologics-license-applications-for-keytruda-pembrolizumab-six-week-dosing-schedule 2020-02-19T09:07:38 https://maestrodatabase.com/blog/frustration-as-life-saving-epipens-sit-in-warehouses-pharmacists-out-of-stock 2020-02-19T20:01:20 https://maestrodatabase.com/blog/updates-to-the-hta-policy-and-methods-review-reference-committee---26-september-2023 2023-09-26T11:40:38 https://maestrodatabase.com/blog/trio-of-prescription-cost-bills-pass-off-senate-floor 2020-02-19T19:56:19 https://maestrodatabase.com/blog/maine-moves-closer-to-importation-of-medicine-from-canada 2020-02-19T19:54:34 https://maestrodatabase.com/blog/fda-grants-priority-review-to-genentechs-tecentriq-monotherapy-as-first-line-treatment-of-certain-people-with-advanced-non-small-cell-lung-cancer 2020-02-19T20:16:44 https://maestrodatabase.com/blog/seattle-genetics-and-astellas-receive-fda-breakthrough-therapy-designation-for-padcev-enfortumab-vedotin-ejfv-in-combination-with-pembrolizumab-in-first-line-advanced-bladder-cancer 2020-02-19T20:08:06 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-karyopharms-supplemental-new-drug-application-for-xpovio-selinexor-as-a-treatment-for-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma 2020-02-19T20:22:58 https://maestrodatabase.com/blog/new-institute-launched-to-ensure-the-u-dot-s-health-care-system-is-ready-for-gene-therapies 2020-02-19T20:32:48 https://maestrodatabase.com/blog/cara-therapeutics-announces-approval-of-korsuva-iv-injection-syringe-in-japan-for-the-treatment-of-pruritus-in-haemodialysis-patients 2023-09-26T20:55:08 https://maestrodatabase.com/blog/kiwi-women-fighting-for-early-ovarian-cancer-diagnosis-and-access-to-drugs 2019-02-28T01:05:17 https://maestrodatabase.com/blog/nice-draft-guidance-recognises-potential-of-new-targeted-treatment-for-type-of-advanced-breast-cancer 2023-09-26T20:43:38 https://maestrodatabase.com/blog/how-the-drug-lobby-lost-its-mojo-in-washington 2020-02-19T20:29:32 https://maestrodatabase.com/blog/medicare-advantage-and-medicare-prescription-drug-programs-to-remain-stable-in-2024 2023-09-26T20:49:46 https://maestrodatabase.com/blog/white-house-to-house-democrats-drug-price-plan-is-a-winning-issue 2021-08-22T20:25:09 https://maestrodatabase.com/blog/biontech-receives-fda-fast-track-designation-for-mrna-cancer-immunotherapy-candidate-bnt113-in-hpv16-plus-head-and-neck-cancer 2026-01-22T21:23:29 https://maestrodatabase.com/blog/fda-touts-generic-drug-research-in-2019 2020-02-19T20:48:16 https://maestrodatabase.com/blog/scott-morrison-says-australia-will-not-be-a-hostage-to-global-vaccine-shortages 2021-01-26T23:10:32 https://maestrodatabase.com/blog/the-evolution-of-real-world-studies 2019-08-11T13:09:06 https://maestrodatabase.com/blog/hansa-biopharma-granted-added-benefit-asmr-3-by-french-transparency-commission-for-idefirix-imlifidase-as-desensitisation-treatment-for-highly-sensitised-kidney-transplant-patients 2022-04-21T04:33:01 https://maestrodatabase.com/blog/watchdog-declines-to-back-nhs-cannabis-treatment-for-epilepsy 2019-08-11T21:17:41 https://maestrodatabase.com/blog/pharmacs-flatlining-funding-by-stealth 2019-08-11T13:13:38 https://maestrodatabase.com/blog/us-fda-extends-review-of-pfizers-new-drug-application-for-paxlovid 2022-12-22T09:38:34 https://maestrodatabase.com/blog/us-patients-struggle-to-obtain-eli-lillys-half-price-insulin 2019-08-11T21:35:05 https://maestrodatabase.com/blog/patient-groups-push-back-against-gileads-pricey-hiv-prevention-treatment 2019-08-11T21:30:34 https://maestrodatabase.com/blog/drug-policy-experts-accuse-industry-and-patient-groups-of-fearmongering-with-concerns-about-new-drug-pricing-rule 2019-08-11T21:27:04 https://maestrodatabase.com/blog/pedra-technology-receives-fda-breakthrough-device-designation-for-its-pedra-xauron-real-time-tissue-perfusion-system 2021-01-27T00:00:47 https://maestrodatabase.com/blog/the-fdas-digital-health-chief-on-how-to-regulate-futuristic-ai-products 2019-08-11T21:52:12 https://maestrodatabase.com/blog/if-we-get-rid-of-private-health-insurance-what-happens-next 2019-08-11T21:43:41 https://maestrodatabase.com/blog/ontario-family-forced-to-fight-for-life-saving-drug-highlights-need-for-national-rare-disease-strategy 2022-04-21T04:37:57 https://maestrodatabase.com/blog/alleviant-medical-receives-breakthrough-device-designation-from-fda-for-transcatheter-technology 2021-01-27T00:17:17 https://maestrodatabase.com/blog/abeona-therapeutics-submits-biologics-license-application-to-us-fda-seeking-priority-review-and-approval-of-eb-101-for-the-treatment-of-patients-with-recessive-dystrophic-epidermolysis-bullosa 2023-09-26T23:47:05 https://maestrodatabase.com/blog/skyclarys-omaveloxolone-approval-by-health-canada-ushers-in-a-new-era-for-friedreichs-ataxia-treatment-in-canada 2025-03-18T04:29:09 https://maestrodatabase.com/blog/ideaya-receives-fast-track-designation-for-potential-first-in-class-parg-inhibitor-ide161-for-treatment-of-pretreated-platinum-resistant-advanced-or-metastatic-ovarian-cancer-patients-having-tumours-with-brca1-slash-2-mutations 2023-09-27T00:56:15 https://maestrodatabase.com/blog/mythic-therapeutics-receives-fda-fast-track-designation-for-mytx-011-for-patients-with-non-small-cell-lung-cancer-with-cmet-over-expression 2023-09-27T00:20:09 https://maestrodatabase.com/blog/icer-publishes-final-evidence-report-on-gene-therapies-for-haemophilia-a-and-b 2022-12-22T19:43:19 https://maestrodatabase.com/blog/cellphire-therapeutics-clph-511-fast-track-designation-granted 2025-03-18T05:43:54 https://maestrodatabase.com/blog/will-canadians-get-to-choose-which-covid-19-vaccine-they-get 2021-01-27T03:45:45 https://maestrodatabase.com/blog/nice-recommends-a-weekly-injection-for-treating-growth-failure-in-children 2022-12-22T19:52:53 https://maestrodatabase.com/blog/heron-therapeutics-announces-fda-extension-of-review-period-for-nda-for-htx-011-for-the-management-of-post-operative-pain 2020-02-20T01:38:13 https://maestrodatabase.com/blog/fda-approves-new-hiv-drug-for-adults-with-limited-treatment-options 2022-12-22T20:04:38 https://maestrodatabase.com/blog/european-commission-approves-keytruda-pembrolizumab-as-first-line-treatment-in-adult-patients-with-metastatic-microsatellite-instability-high-or-mismatch-repair-deficient-colorectal-cancer 2021-01-27T10:30:15 https://maestrodatabase.com/blog/covid-19-vaccine-safety-report-22-december-2022 2022-12-22T20:51:13 https://maestrodatabase.com/blog/serving-public-health-paramount-in-a-successful-2019-for-fdas-generic-drug-program 2020-02-20T01:45:17 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-treatments-for-alzheimers-disease 2022-12-22T20:33:08 https://maestrodatabase.com/blog/government-rejects-claim-overseas-production-issues-threaten-access-to-vaccines 2021-01-27T19:44:50 https://maestrodatabase.com/blog/australias-covid-19-vaccine-information-campaign-begins 2021-01-27T19:48:28 https://maestrodatabase.com/blog/zorvye-cream-0-dot-15-percent-approved-by-health-canada-for-the-treatment-of-mild-to-moderate-atopic-dermatitis-in-adults-and-children-as-young-as-six-years-of-age 2025-03-18T08:17:29 https://maestrodatabase.com/blog/expanded-medicines-for-breast-cancer-and-leukaemia-on-the-pbs 2023-09-27T02:13:06 https://maestrodatabase.com/blog/pfizers-ixifi-will-be-available-in-canada-as-of-1-april-2025 2025-03-18T08:12:59 https://maestrodatabase.com/blog/nice-recommends-revlimid-for-newly-diagnosed-multiple-myeloma-patients 2021-01-27T10:25:18 https://maestrodatabase.com/blog/abm-therapeutics-abm-1310-granted-fast-track-designation-by-the-fda-following-orphan-drug-designation 2023-09-27T01:43:17 https://maestrodatabase.com/blog/nice-publishes-final-guidance-on-new-use-for-lonsurf 2021-01-27T20:10:56 https://maestrodatabase.com/blog/e-dot-u-and-u-dot-k-fighting-over-scarce-vaccines 2021-01-27T20:20:40 https://maestrodatabase.com/blog/on-the-role-of-cost-effectiveness-thresholds-in-health-care-priority-setting 2021-01-27T20:49:50 https://maestrodatabase.com/blog/abbvie-receives-positive-chmp-opinion-for-epcoritamab-tepkinly-for-the-treatment-of-adults-with-relapsed-slash-refractory-follicular-lymphoma 2024-06-28T07:08:37 https://maestrodatabase.com/blog/coronavirus-eu-threat-to-australias-vaccine-program 2021-01-27T19:51:14 https://maestrodatabase.com/blog/european-medicines-agency-accepts-gbts-marketing-authorisation-application-for-oxbryta-voxelotor-for-the-treatment-of-haemolytic-anemia-in-sickle-cell-disease 2021-01-27T19:56:04 https://maestrodatabase.com/blog/update-on-us-regulatory-status-of-avt02-alvotechs-proposed-high-concentration-interchangeable-biosimilar-to-humira 2022-12-22T21:10:40 https://maestrodatabase.com/blog/eu-demands-uk-made-astrazeneca-vaccine-doses 2021-01-27T20:07:52 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-24-april-2022 2022-04-21T07:34:07 https://maestrodatabase.com/blog/pfizer-and-biontech-receive-positive-chmp-opinion-for-omicron-jn-dot-1-adapted-covid-19-vaccine-in-the-european-union 2024-06-28T07:24:00 https://maestrodatabase.com/blog/nipocalimab-the-first-and-only-investigational-treatment-to-be-granted-us-fda-breakthrough-therapy-designation-for-the-treatment-of-adults-with-moderate-to-severe-sjoegrens-disease-has-now-received-fast-track-designation 2025-03-19T04:29:32 https://maestrodatabase.com/blog/fda-accepts-submission-to-add-ph-ild-to-yutrepia-label 2023-09-27T04:01:40 https://maestrodatabase.com/blog/us-fda-grants-priority-review-for-new-indication-of-finerenone-for-patients-with-common-form-of-heart-failure 2025-03-19T04:20:20 https://maestrodatabase.com/blog/what-role-does-equity-play-in-australias-health-technology-assessment-processes-a-review-of-the-pbac-recommendations-regarding-vaccines 2026-01-23T03:32:19 https://maestrodatabase.com/blog/agenda-for-november-2023-pbac-meeting---25-september-2023-update 2023-09-27T09:35:22 https://maestrodatabase.com/blog/scienture-announces-the-us-fda-approval-of-its-nda-for-scn-102-to-be-launched-as-arbli-losartan-potassium-10-mg-slash-ml-oral-suspension 2025-03-19T05:04:32 https://maestrodatabase.com/blog/guardant-health-receives-fda-approval-for-guardant360-cdx-as-companion-diagnostic-for-braftovi-encorafenib-combination-in-patients-with-braf-v600e-mutant-metastatic-colorectal-cancer 2026-01-23T01:37:58 https://maestrodatabase.com/blog/the-past-present-and-possible-future-of-public-opinion-on-the-aca 2020-02-20T11:42:37 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-therapies-for-cystic-fibrosis 2020-02-20T19:53:45 https://maestrodatabase.com/blog/fda-announces-collaborative-review-of-scientific-evidence-to-support-associations-between-genetic-information-and-specific-medications 2020-02-20T19:49:23 https://maestrodatabase.com/blog/fda-works-to-ensure-smooth-regulatory-transition-of-insulin-and-other-biological-products 2020-02-20T19:46:05 https://maestrodatabase.com/blog/canadian-regulator-considers-changes-to-new-drug-pricing-plan 2020-02-20T20:06:49 https://maestrodatabase.com/blog/enhertu-approved-in-china-as-the-first-and-only-her2-directed-adc-for-the-second-line-treatment-of-patients-with-her2-positive-metastatic-gastric-cancer 2026-01-23T03:45:10 https://maestrodatabase.com/blog/japanese-regulator-oks-celltrions-humira-biosimilar 2023-09-27T10:05:12 https://maestrodatabase.com/blog/outcomes-from-the-november-2019-ptac-meeting 2020-02-20T20:33:11 https://maestrodatabase.com/blog/fda-names-genes-that-may-interact-with-specific-drugs-offering-clarity-to-genetic-testing-industry 2020-02-20T20:22:56 https://maestrodatabase.com/blog/outlook-therapeutics-announces-validation-of-marketing-authorisation-application-by-the-european-medicines-agency-for-ons-5010-as-a-treatment-for-wet-amd 2022-12-23T04:28:27 https://maestrodatabase.com/blog/alberta-announces-funding-for-pricey-gene-therapy-drug-zolgensma 2021-01-28T02:01:37 https://maestrodatabase.com/blog/2024-25-cost-recovery-implementation-statement-for-listing-medicines-on-the-pbs-and-designated-vaccines-on-the-nip 2024-06-28T10:37:26 https://maestrodatabase.com/blog/icer-to-assess-treatments-for-bladder-cancer 2020-02-20T22:14:50 https://maestrodatabase.com/blog/revance-receives-fda-acceptance-of-bla-resubmission-for-daxibotulinumtoxina-for-injection-for-glabellar-lines 2022-04-21T20:24:41 https://maestrodatabase.com/blog/zambon-receives-u-dot-s-fda-breakthrough-therapy-designation-for-cms-i-neb-in-patients-with-non-cystic-fibrosis-bronchiectasis 2022-04-21T20:19:46 https://maestrodatabase.com/blog/linzagolix-choline-in-endometriosis-comparative-data-are-lacking 2025-03-19T08:08:30 https://maestrodatabase.com/blog/abbvies-crohns-disease-drug-given-green-light-by-mhra 2022-04-21T20:57:53 https://maestrodatabase.com/blog/travere-therapeutics-submits-snda-to-fda-for-approval-of-filspari-sparsentan-for-the-treatment-of-focal-segmental-glomerulosclerosis 2025-03-20T03:55:14 https://maestrodatabase.com/blog/icer-to-assess-treatments-for-multiple-sclerosis 2022-04-21T21:01:17 https://maestrodatabase.com/blog/alvotech-and-dr-reddys-announce-fda-acceptance-of-biologic-license-application-for-avt03-a-proposed-biosimilar-to-prolia-and-xgeva 2025-03-20T03:49:32 https://maestrodatabase.com/blog/odronextamab-recommended-for-eu-approval-by-the-chmp-to-treat-relapsed-slash-refractory-follicular-lymphoma-and-diffuse-large-b-cell-lymphoma 2024-06-28T11:39:14 https://maestrodatabase.com/blog/global-pharma-gives-up-reimbursement-in-korea-and-this-is-a-serious-concern 2025-03-20T03:43:41 https://maestrodatabase.com/blog/astellas-announces-reimbursement-for-xospata-gilteritinib-in-most-provinces-for-patients-with-relapsed-or-refractory-acute-myeloid-leukaemia-with-a-flt3-mutation 2022-04-21T20:37:08 https://maestrodatabase.com/blog/are-high-cost-prescription-drugs-the-price-of-innovation-disclose-the-costs-of-clinical-trials 2022-04-21T20:44:49 https://maestrodatabase.com/blog/forma-therapeutics-announces-ft-4202-granted-fast-track-designation-and-rare-paediatric-disease-designation-for-treatment-of-sickle-cell-disease 2020-02-20T23:10:20 https://maestrodatabase.com/blog/bridge-to-life-receives-breakthrough-device-designation-from-the-fda 2022-04-21T21:15:57 https://maestrodatabase.com/blog/fda-approves-pembrolizumab-for-her2-positive-gastric-or-gastro-oesophageal-junction-adenocarcinoma-expressing-pd-l1 2025-03-20T04:46:03 https://maestrodatabase.com/blog/fdas-new-real-world-evidence-program-offers-early-agency-feedback 2022-12-23T10:59:58 https://maestrodatabase.com/blog/azercabtagene-zapreleucel-granted-fda-fast-track-designation-in-blood-cancer-dlbcl 2025-03-20T04:29:58 https://maestrodatabase.com/blog/european-collaboration-on-health-technology-assessment-looking-backward-and-forward 2022-04-21T21:34:10 https://maestrodatabase.com/blog/health-canada-approves-keytruda-for-the-treatment-of-adult-patients-with-primary-advanced-or-recurrent-endometrial-carcinoma-in-combination-with-carboplatin-and-paclitaxel-and-then-continued-as-monotherapy 2025-03-20T04:24:15 https://maestrodatabase.com/blog/pbs-medication-to-cost-no-more-than-25-dollars-under-labor-re-election-pitch 2025-03-20T04:19:40 https://maestrodatabase.com/blog/ucb-announces-fda-acceptance-of-bla-resubmission-for-bimekizumab 2022-12-23T06:58:31 https://maestrodatabase.com/blog/australia-defends-pbs-as-us-companies-urge-trump-to-impose-reciprocal-tariffs 2025-03-20T04:16:36 https://maestrodatabase.com/blog/will-the-shadow-of-aduhelm-cloud-fdas-decision-making-on-an-als-therapy 2022-04-21T21:12:10 https://maestrodatabase.com/blog/big-pharmas-plea-to-trump-to-punish-australia-for-cheaper-medicines 2025-03-20T04:11:52 https://maestrodatabase.com/blog/what-counts-as-a-breakthrough-8-insights-on-the-fdas-approach-to-medical-devices 2022-04-21T21:06:25 https://maestrodatabase.com/blog/atagi-update-following-weekly-covid-19-meeting-18-august-2021 2021-08-23T03:18:44 https://maestrodatabase.com/blog/dulaglutide-receives-medsafe-approval 2021-08-23T03:11:26 https://maestrodatabase.com/blog/clarification-of-comirnaty-dosage-interval 2021-01-28T19:49:37 https://maestrodatabase.com/blog/after-16-reviews-we-know-how-to-fix-health-care-experts-say 2019-02-28T04:26:00 https://maestrodatabase.com/blog/advocacy-groups-urge-biden-administration-not-to-tap-woodcock-as-fda-commissioner 2021-01-28T19:55:16 https://maestrodatabase.com/blog/bio-thera-solutions-announces-fda-accepts-biologics-license-application-for-bat1706-a-proposed-biosimilar-to-avastin 2021-01-28T19:57:15 https://maestrodatabase.com/blog/tga-to-rule-on-psychedelic-drug-access-for-mental-health-problems 2021-01-28T09:48:54 https://maestrodatabase.com/blog/astrazeneca-pfizer-hope-to-meet-vaccine-supply-dates-despite-fluid-europe-situation 2021-01-28T20:16:23 https://maestrodatabase.com/blog/germany-moves-to-exclude-seniors-from-astrazenecas-covid-19-vaccine 2021-01-28T20:23:43 https://maestrodatabase.com/blog/public-summary-documents---pbac-july-2017-meeting 2017-11-12T11:09:29 https://maestrodatabase.com/blog/m6p-therapeutics-receives-six-rare-paediatric-disease-designations-from-the-u-dot-s-fda-for-companys-deep-pipeline-of-programs-for-lysosomal-storage-disorders 2021-01-28T20:01:28 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-march-2019-update 2019-02-28T05:25:34 https://maestrodatabase.com/blog/prescription-drug-rices-in-the-u-dot-s-are-2-dot-56-times-higher-than-other-nations---brand-named-drugs-3-dot-44-times-higher 2021-01-28T20:09:39 https://maestrodatabase.com/blog/nhs-england-roche-come-to-agreement-on-perjeta 2017-11-12T20:55:30 https://maestrodatabase.com/blog/minimal-residual-disease-and-complete-response-in-multiple-myeloma-use-as-outcomes-to-support-accelerated-approval 2026-01-23T21:33:25 https://maestrodatabase.com/blog/fda-expands-indication-for-soliqua-100-slash-33 2019-02-28T09:36:00 https://maestrodatabase.com/blog/evaluation-of-patient-and-public-involvement-initiatives-in-health-technology-assessment-a-survey-of-international-agencies 2017-11-12T20:33:11 https://maestrodatabase.com/blog/janssen-announces-u-dot-s-fda-approval-of-novel-tremfya-guselkumab-one-press-patient-controlled-injector-for-adults-with-moderate-to-severe-plaque-psoriasis 2019-02-28T09:32:40 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-march-2019-update 2019-02-28T10:41:55 https://maestrodatabase.com/blog/baudax-bio-announces-fda-approval-of-anjeso-for-the-management-of-moderate-to-severe-pain 2020-02-21T01:31:45 https://maestrodatabase.com/blog/biomarins-biologics-license-application-for-valoctocogene-roxaparvovec-accepted-for-priority-review-by-fda-with-review-action-date-of-21-august-2020 2020-02-21T02:09:31 https://maestrodatabase.com/blog/icer-publishes-evidence-report-on-roxadustat-for-treating-anaemia-in-chronic-kidney-disease 2021-01-28T22:43:30 https://maestrodatabase.com/blog/icer-appoints-daniel-ollendorf-as-chief-scientific-officer-and-director-of-hta-methods-and-engagement 2023-09-27T22:15:35 https://maestrodatabase.com/blog/role-of-registries-in-medicare-coverage-of-new-alzheimer-disease-drugs 2023-09-27T22:18:31 https://maestrodatabase.com/blog/first-guidance-on-new-rules-for-certain-medical-devices 2019-02-28T19:56:30 https://maestrodatabase.com/blog/repurposing-off-patent-drugs-offers-big-hopes-of-new-treatments 2019-02-28T20:00:19 https://maestrodatabase.com/blog/address-health-care-costs-not-just-insurance-says-medibank 2019-02-28T19:53:20 https://maestrodatabase.com/blog/novartis-faces-shareholder-criticism-over-drug-prices-at-agm 2019-02-28T20:15:15 https://maestrodatabase.com/blog/drug-industry-ceos-say-the-problem-isnt-high-prices-its-how-misunderstood-they-are 2019-02-28T20:18:09 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-mosunetuzumab-axgb-for-relapsed-or-refractory-follicular-lymphoma 2022-12-23T22:26:47 https://maestrodatabase.com/blog/drug-prices-arent-a-big-problem-but-ottawas-trying-to-control-the-market-anyway 2019-02-28T20:03:56 https://maestrodatabase.com/blog/rebates-and-drug-costs-what-the-new-proposal-would-mean 2019-02-28T20:10:40 https://maestrodatabase.com/blog/u-dot-s-senator-sanders-urges-fda-to-allow-older-versions-of-375-000-dollars-drug 2019-02-28T20:27:35 https://maestrodatabase.com/blog/ocuphire-pharma-and-viatris-announce-fda-approval-of-ryzumvi-phentolamine-ophthalmic-solution-0-dot-75-percent-eye-drops-for-the-treatment-of-pharmacologically-induced-mydriasis-produced-by-adrenergic-agonists-e-dot-g-phenylephrine-or-parasympatholytic-e-dot-g-tropicamide-agents 2023-09-27T22:39:52 https://maestrodatabase.com/blog/fda-approves-herceptin-hylecta-for-subcutaneous-injection-in-certain-her2-positive-breast-cancers 2019-02-28T20:21:06 https://maestrodatabase.com/blog/botanix-pharmaceuticals-suffers-setback-in-fda-approval-for-sofpironium-bromide-gel-to-treat-hyperhidrosis 2023-09-28T01:37:43 https://maestrodatabase.com/blog/astrazeneca-vaccine-warnings-based-on-maths-not-safety 2021-01-29T01:04:21 https://maestrodatabase.com/blog/new-zealands-access-to-funded-medicines-well-behind-the-rest-of-the-world 2019-08-12T06:28:53 https://maestrodatabase.com/blog/where-medical-statistics-meets-artificial-intelligence 2023-09-28T02:00:31 https://maestrodatabase.com/blog/fda-approves-bosutinib-for-paediatric-patients-with-chronic-myelogenous-leukaemia 2023-09-28T03:43:59 https://maestrodatabase.com/blog/avadel-pharmaceuticals-receives-new-pdufa-date-for-av001-of-15-december-2019 2019-08-12T06:37:04 https://maestrodatabase.com/blog/janssen-announces-u-dot-s-fda-accelerated-approval-for-sirturo-bedaquiline-as-part-of-combination-therapy-to-treat-adolescents-with-pulmonary-multidrug-resistant-tuberculosis 2019-08-12T07:00:14 https://maestrodatabase.com/blog/us-fda-approves-subcutaneous-administration-of-takedas-entyvio-vedolizumab-for-maintenance-therapy-in-moderately-to-severely-active-ulcerative-colitis 2023-09-28T02:53:15 https://maestrodatabase.com/blog/china-national-medical-products-administration-approves-biktarvy-bictegravir-emtricitabine-and-tenofovir-alafenamide-for-treatment-of-hiv-1-infection 2019-08-12T07:19:28 https://maestrodatabase.com/blog/health-economics-methods-advisory-group-selects-first-area-for-study-assessing-treatment-benefits-appropriate-to-consider-in-hta-decision-making 2025-03-20T08:04:41 https://maestrodatabase.com/blog/alpha-cognition-announces-submission-of-new-drug-application-to-the-fda-for-alpha-1062-for-mild-to-moderate-alzheimers-disease 2023-09-28T04:12:08 https://maestrodatabase.com/blog/valneva-completes-bla-submission-to-us-fda-for-its-single-shot-chikungunya-vaccine-candidate 2022-12-24T04:20:38 https://maestrodatabase.com/blog/first-covid-19-vaccine-safety-update-published 2021-01-29T08:29:41 https://maestrodatabase.com/blog/drug-maker-will-make-21-dollars-billion-from-treating-cystic-fibrosis 2019-08-12T20:49:01 https://maestrodatabase.com/blog/is-rate-of-return-pricing-a-useful-approach-when-value-based-pricing-is-not-appropriate 2019-08-12T20:43:48 https://maestrodatabase.com/blog/dare-bioscience-receives-qidp-designation-from-the-fda-for-dare-bv1-for-the-treatment-of-bacterial-vaginosis 2019-08-12T12:32:32 https://maestrodatabase.com/blog/biogen-and-eisai-announce-fdas-3-month-extension-of-review-period-for-the-biologics-license-application-for-aducanumab 2021-01-29T20:25:37 https://maestrodatabase.com/blog/regulator-oks-pfizers-vizimpro-as-first-line-treatment-of-mutated-lung-cancer 2020-02-21T08:32:59 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac---december-2020-intracycle-meeting 2021-01-29T05:28:02 https://maestrodatabase.com/blog/smc---august-2019-decisions 2019-08-12T21:01:52 https://maestrodatabase.com/blog/aarp-unveils-giant-calculator-tallying-high-prescription-drug-prices 2019-08-12T20:58:49 https://maestrodatabase.com/blog/canadians-are-hopping-mad-about-trumps-drug-importation-plan-some-of-them-are-trying-to-stop-it 2019-08-12T20:54:50 https://maestrodatabase.com/blog/ema-recommends-covid-19-vaccine-astrazeneca-for-authorisation-in-the-eu 2021-01-29T20:33:15 https://maestrodatabase.com/blog/democratic-senators-urge-fda-to-take-action-against-drug-company-that-hid-faulty-data 2019-08-12T21:11:55 https://maestrodatabase.com/blog/not-acceptable-disappointment-as-cystic-fibrosis-drug-not-approved-in-scotland 2019-08-12T21:08:39 https://maestrodatabase.com/blog/cystic-fibrosis-drugs-rejected-for-use-by-nhs-in-scotland 2019-08-12T21:05:48 https://maestrodatabase.com/blog/federal-changes-to-drug-prices-win-praise-from-patient-advocates-but-spark-industry-warnings 2019-08-12T21:22:11 https://maestrodatabase.com/blog/democratic-hopefuls-take-aim-at-insurer-and-pharma-profits 2019-08-12T21:17:53 https://maestrodatabase.com/blog/advanced-ovarian-cancer-drug-gets-initial-no-for-nhs-in-england 2019-08-15T21:22:55 https://maestrodatabase.com/blog/secretome-therapeutics-granted-fda-fast-track-designation-for-stm-01-a-neonatal-cardiac-progenitor-cell-therapy-for-hfpef 2025-03-21T05:00:53 https://maestrodatabase.com/blog/fortress-biotech-announces-cellvations-ceva101-granted-fda-regenerative-medicine-advanced-therapy-designation-for-the-treatment-of-traumatic-brain-injury 2017-11-13T01:30:47 https://maestrodatabase.com/blog/tga-grants-provisional-determination-to-roche-combination-covid-19-treatment-casirivimab-and-imdevimab-ronapreve 2021-08-23T06:12:00 https://maestrodatabase.com/blog/tga-grants-provisional-determination-to-celltrion-healthcares-anti-viral-covid-19-treatment-regdanvimab 2021-08-23T06:19:06 https://maestrodatabase.com/blog/medibank-disappointed-that-the-accc-is-appealing-federal-court-decision-says-ceo-craig-drummond 2017-11-13T07:28:40 https://maestrodatabase.com/blog/us-fda-approves-tremfya-guselkumab-the-first-and-only-il-23-inhibitor-offering-both-subcutaneous-and-intravenous-induction-options-for-adult-patients-with-moderately-to-severely-active-crohns-disease 2025-03-21T07:10:59 https://maestrodatabase.com/blog/highlights-from-25-29-january-2021-chmp-meeting 2021-01-29T21:22:14 https://maestrodatabase.com/blog/why-us-drug-giants-are-so-angry-about-australias-pbs 2025-03-21T05:46:49 https://maestrodatabase.com/blog/novartis-receives-positive-chmp-opinion-for-kesimpta-ofatumumab-a-self-administered-treatment-for-adult-patients-with-relapsing-multiple-sclerosis 2021-01-29T21:25:25 https://maestrodatabase.com/blog/novartis-receives-third-fda-approval-for-oral-fabhalta-iptacopan---the-first-and-only-treatment-approved-in-c3-glomerulopathy 2025-03-21T07:33:07 https://maestrodatabase.com/blog/hikma-announces-health-canada-approval-of-kloxxado-naloxone-hydrochloride-nasal-spray-8-mg 2025-03-21T07:23:55 https://maestrodatabase.com/blog/xeljanz-tofacitinib-citrate-receives-marketing-authorisation-in-the-european-union-for-the-treatment-of-active-polyarticular-juvenile-idiopathic-arthritis-and-juvenile-psoriatic-arthritis 2021-08-23T10:04:29 https://maestrodatabase.com/blog/alnylam-announces-fda-approval-of-amvuttra-vutrisiran-the-first-rnai-therapeutic-to-reduce-cardiovascular-death-hospitalisations-and-urgent-heart-failure-visits-in-adults-with-attr-amyloidosis-with-cardiomyopathy 2025-03-21T07:16:15 https://maestrodatabase.com/blog/eu-bans-coronavirus-vaccine-exports-to-australia 2021-01-29T21:57:23 https://maestrodatabase.com/blog/strengthening-medicare-cheaper-medicines-to-get-even-cheaper 2025-03-21T07:54:46 https://maestrodatabase.com/blog/patient-organisations-welcome-approval-of-six-life-extending-cancer-treatments-through-ontarios-fast-program-urge-national-expansion 2026-01-26T02:23:48 https://maestrodatabase.com/blog/astrazenecas-tagrisso-and-calquence-among-first-oncology-treatments-granted-accelerated-access-through-ontarios-fast-program 2026-01-26T01:56:19 https://maestrodatabase.com/blog/u-dot-s-food-and-drug-administration-accepts-for-priority-review-bristol-myers-squibbs-application-for-orencia-abatacept-for-the-prevention-of-acute-graft-versus-host-disease 2021-08-23T20:50:53 https://maestrodatabase.com/blog/estimands-estimators-and-estimates 2021-08-23T20:46:56 https://maestrodatabase.com/blog/sunovion-announces-fda-acceptance-for-review-of-new-drug-application-for-dasotraline-for-the-treatment-of-adhd 2017-11-13T09:24:56 https://maestrodatabase.com/blog/public-summary-documents-first-time-rejections-and-deferrals---november-2024-pbac-meeting 2025-03-21T08:27:41 https://maestrodatabase.com/blog/nearly-half-of-recent-eu-approvals-based-on-a-single-pivotal-study 2017-11-13T09:19:45 https://maestrodatabase.com/blog/neurocrine-biosciences-announces-us-fda-accepts-supplemental-new-drug-application-for-valbenazine-as-a-treatment-for-chorea-associated-with-huntington-disease 2022-12-24T07:35:48 https://maestrodatabase.com/blog/fda-approves-first-covid-19-vaccine 2021-08-23T20:34:30 https://maestrodatabase.com/blog/fda-launches-new-resource-to-provide-easily-accessible-more-accurate-historical-drug-approval-data 2020-02-22T00:56:36 https://maestrodatabase.com/blog/axsome-therapeutics-provides-update-on-the-new-drug-application-for-axs-05-for-the-treatment-of-major-depressive-disorder 2021-08-23T12:05:07 https://maestrodatabase.com/blog/health-ministers-condemn-novartis-lottery-for-zolgensma-the-worlds-most-expensive-drug 2020-02-22T01:21:10 https://maestrodatabase.com/blog/heartbreaking-death-of-cystic-fibrosis-patient-shines-light-on-drug-access-issues 2020-02-22T01:17:22 https://maestrodatabase.com/blog/fda-authorises-marketing-of-the-first-genetic-test-to-aid-in-the-diagnosis-of-fragile-x-syndrome 2020-02-22T01:07:22 https://maestrodatabase.com/blog/cara-therapeutics-and-vifor-pharma-announce-u-dot-s-fda-approval-of-korsuva-difelikefalin-injection-for-the-treatment-of-moderate-to-severe-pruritus-in-hemodialysis-patients 2021-08-23T21:17:48 https://maestrodatabase.com/blog/europe-has-its-first-lucentis-biosimilar-samsung-bioepis-byooviz 2021-08-23T21:03:05 https://maestrodatabase.com/blog/pfizer-biontech-covid-19-vaccine-comirnaty-receives-full-u-dot-s-fda-approval-for-individuals-16-years-and-older 2021-08-23T21:24:14 https://maestrodatabase.com/blog/ema-and-eunethta-finalise-joint-work-plan-for-2017-2020 2017-11-13T16:57:51 https://maestrodatabase.com/blog/trump-health-agency-challenges-consensus-on-reducing-costs 2017-11-13T10:45:53 https://maestrodatabase.com/blog/uk-deal-over-inclisiran 2020-02-22T01:33:42 https://maestrodatabase.com/blog/ipsen-receives-complete-response-letter-for-palovarotene-an-investigational-treatment-for-fibrodysplasia-ossificans-progressiva 2022-12-24T08:02:08 https://maestrodatabase.com/blog/smc---november-2017-decisions 2017-11-13T17:43:31 https://maestrodatabase.com/blog/nice-no-for-short-bowel-syndrome-drug-revestive 2017-11-13T18:11:43 https://maestrodatabase.com/blog/trump-chooses-alex-azar-for-health-and-human-services-secretary 2017-11-13T17:54:56 https://maestrodatabase.com/blog/ema-grants-alnylam-accelerated-assessment-of-patisiran-for-patients-with-hereditary-attr-amyloidosis 2017-11-13T18:18:13 https://maestrodatabase.com/blog/adaptimmune-announces-initiation-of-biologics-license-application-submission-for-afami-cel-its-first-generation-engineered-tcr-t-cell-therapy-targeting-mage-a4-for-the-treatment-of-synovial-sarcoma 2022-12-24T07:52:26 https://maestrodatabase.com/blog/thousands-could-benefit-from-new-take-at-home-treatment-for-advanced-prostate-cancer 2026-01-26T19:43:35 https://maestrodatabase.com/blog/akebia-therapeutics-resubmits-new-drug-application-to-the-fda-for-vadadustat 2023-09-28T20:48:21 https://maestrodatabase.com/blog/patient-access-to-cost-effective-treatments-increased-with-launch-of-new-biosimilar-in-canada 2019-03-01T04:33:16 https://maestrodatabase.com/blog/allergan-receives-fda-approval-for-use-of-vraylar-cariprazine-in-the-maintenance-treatment-of-schizophrenia 2017-11-13T18:39:16 https://maestrodatabase.com/blog/intercept-resubmits-new-drug-application-to-us-fda-for-obeticholic-acid-in-patients-with-liver-fibrosis-due-to-nash 2022-12-24T09:37:05 https://maestrodatabase.com/blog/akebia-announces-approval-of-vafseo-vadadustat-in-australia 2023-09-28T20:42:57 https://maestrodatabase.com/blog/astellas-announces-acceptance-of-xospata-gilteritinib-for-regulatory-review-by-the-european-medicines-agency 2019-03-01T04:27:55 https://maestrodatabase.com/blog/theravance-biopharma-and-mylan-submit-new-drug-application-to-fda-for-revefenacin-td-4208-in-adults-with-chronic-obstructive-pulmonary-disease 2017-11-13T18:46:06 https://maestrodatabase.com/blog/celltrion-usa-announces-submission-of-the-biologics-license-application-of-novel-subcutaneous-formulation-of-ct-p13-to-us-fda 2022-12-24T08:14:40 https://maestrodatabase.com/blog/sarepta-gets-a-belated-but-helpful-boost-from-anthem-for-its-pricey-drug 2017-11-13T18:55:39 https://maestrodatabase.com/blog/merck-astrazeneca-bristol-myers-squibb-to-participate-in-medicare-drug-price-negotiations 2023-09-28T20:36:32 https://maestrodatabase.com/blog/gsks-rsv-vaccine-arexvy-receives-european-approval-for-expanded-use-in-all-adults-18-years-and-older 2026-01-26T20:51:06 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-announces-final-modified-framework-for-assessing-value-of-treatments-for-ultra-rare-diseases 2017-11-13T19:24:20 https://maestrodatabase.com/blog/esperion-announces-submissions-of-two-ndas-and-official-completion-of-two-maa-validations-for-both-bempedoic-acid-and-the-bempedoic-acid-slash-ezetimibe-combination-tablet 2019-03-01T05:04:56 https://maestrodatabase.com/blog/phase-1-drug-candidate-glr2007-developed-by-gan-and-lee-has-been-granted-fast-track-designation-by-the-u-dot-s-fda 2021-01-30T06:44:35 https://maestrodatabase.com/blog/the-use-of-historical-controls-in-clinical-trials 2023-09-28T20:52:59 https://maestrodatabase.com/blog/mirum-submits-new-drug-application-to-fda-for-chenodiol-for-the-treatment-of-ctx 2024-06-29T07:40:03 https://maestrodatabase.com/blog/pharmacies-to-offer-covid-19-vaccine-shots 2021-01-30T21:54:58 https://maestrodatabase.com/blog/high-costs-of-fda-approval-for-formerly-unapproved-marketed-drugs 2017-11-13T20:35:48 https://maestrodatabase.com/blog/iovance-biotherapeutics-submits-marketing-authorisation-application-to-european-medicines-agency-for-lifileucel-in-advanced-melanoma 2024-06-29T07:29:32 https://maestrodatabase.com/blog/novos-ozempic-to-gain-insurance-coverage-for-diabetes-in-korea-from-february-under-new-criteria 2026-01-27T00:43:21 https://maestrodatabase.com/blog/rocket-pharmaceuticals-provides-regulatory-update-on-kresladi-marnetegragene-autotemcel 2024-06-29T07:51:17 https://maestrodatabase.com/blog/amicus-therapeutics-announces-fda-approval-and-launch-of-new-treatment-for-pompe-disease 2023-09-28T23:22:24 https://maestrodatabase.com/blog/soleno-therapeutics-announces-submission-of-new-drug-application-to-the-us-fda-for-diazoxide-choline-extended-release-tablets-for-the-treatment-of-prader-willi-syndrome 2024-06-29T07:44:40 https://maestrodatabase.com/blog/vaccine-distribution--equity-left-behind 2021-01-30T22:13:16 https://maestrodatabase.com/blog/fda-approves-new-prostate-cancer-imaging-agent-gozellix 2025-03-23T02:10:36 https://maestrodatabase.com/blog/nice-recommends-csl-behrings-haemophilia-b-gene-therapy-hemgenix 2024-06-29T10:56:38 https://maestrodatabase.com/blog/cogent-biosciences-announces-breakthrough-therapy-designation-for-bezuclastinib-in-combination-with-sunitinib-for-patients-with-gastro-intestinal-stromal-tumours 2026-01-26T23:40:41 https://maestrodatabase.com/blog/tga-approves-first-new-medicine-for-2021 2021-01-30T22:03:00 https://maestrodatabase.com/blog/pbac-public-summary-documents---november-2018-meeting 2019-03-01T06:04:53 https://maestrodatabase.com/blog/fda-accepts-leqembi-iqlik-lecanemab-irmb-supplemental-biologics-license-application-as-a-subcutaneous-starting-dose-for-the-treatment-of-early-alzheimers-disease-under-priority-peview 2026-01-27T03:32:59 https://maestrodatabase.com/blog/appili-therapeutics-announces-us-fda-approval-of-likmez-ati-1501-metronidazole-oral-suspension 2023-09-29T00:01:24 https://maestrodatabase.com/blog/health-canada-authorises-gazyva-obinutuzumab-for-adults-with-active-lupus-nephritis 2026-01-27T03:41:28 https://maestrodatabase.com/blog/limited-access-to-lifesaving-cystic-fibrosis-drug-trikafta-under-pharmaceutical-benefits-scheme 2021-08-24T02:10:02 https://maestrodatabase.com/blog/eisai-submits-marketing-authorisation-variation-to-ema-for-intravenous-maintenance-dosing-every-four-weeks-with-leqembi-lecanemab 2026-01-27T04:09:40 https://maestrodatabase.com/blog/mannkind-announces-fda-approval-of-updated-afrezza-label-providing-starting-dose-guidance-when-switching-from-multiple-daily-injections-or-insulin-pump-mealtime-therapy 2026-01-27T03:04:18 https://maestrodatabase.com/blog/merck-receives-priority-review-from-fda-for-new-biologics-license-application-for-sotatercept-an-activin-signaling-inhibitor-to-treat-adults-with-pulmonary-arterial-hypertension 2023-09-29T02:24:13 https://maestrodatabase.com/blog/pfizer-and-biontech-receive-health-canada-authorisation-for-xbb-dot-1-5-adapted-monovalent-covid-19-vaccine 2023-09-29T03:01:52 https://maestrodatabase.com/blog/new-pbs-listing-brings-greater-hope-for-australians-with-pulmonary-arterial-hypertension 2021-01-31T00:16:07 https://maestrodatabase.com/blog/the-patients-to-benefit-from-new-cancer-funding 2019-08-13T07:05:11 https://maestrodatabase.com/blog/cstone-submits-application-to-the-ema-for-new-indication-of-sugemalimab-in-stage-iii-non-small-cell-lung-cancer 2025-03-24T01:37:06 https://maestrodatabase.com/blog/greater-access-to-life-changing-medicine-for-australians-with-adhd 2021-01-31T00:05:27 https://maestrodatabase.com/blog/fda-approves-pill-with-sensor-that-digitally-tracks-if-patients-have-ingested-their-medication 2017-11-14T01:12:23 https://maestrodatabase.com/blog/karuna-therapeutics-submits-new-drug-application-to-us-fda-for-karxt-for-the-treatment-of-schizophrenia 2023-09-29T04:43:55 https://maestrodatabase.com/blog/the-supreme-court-ruling-in-sandoz-v-amgen 2017-11-14T01:15:21 https://maestrodatabase.com/blog/tubulis-receives-fda-fast-track-designation-for-antibody-drug-conjugate-candidate-tub-040-in-platinum-resistant-ovarian-cancer 2024-06-29T23:13:30 https://maestrodatabase.com/blog/theratechnologies-announces-decision-by-the-fda-to-extend-the-ibalizumab-review-period-to-3-april-2018 2017-11-14T03:51:20 https://maestrodatabase.com/blog/emd-serono-receives-fda-approval-for-new-gonal-f-rff-redi-ject-pen 2017-11-14T03:42:16 https://maestrodatabase.com/blog/abdera-therapeutics-announces-fda-fast-track-designation-for-abd-147-a-next-generation-precision-radiopharmaceutical-therapy-for-the-treatment-of-patients-with-extensive-stage-small-cell-lung-cancer 2024-06-29T23:06:06 https://maestrodatabase.com/blog/proposal-to-fund-hiv-pre-exposure-prophylaxis-prep 2017-11-14T05:07:32 https://maestrodatabase.com/blog/stada-and-calliditas-announce-the-filing-for-full-marketing-authorisation-of-kinpeygo-in-the-eu 2023-09-29T04:18:22 https://maestrodatabase.com/blog/proposal-to-widen-access-to-various-anti-infectives 2017-11-14T05:11:39 https://maestrodatabase.com/blog/steffan-crausaz-stepping-down-as-pharmac-chief-executive 2017-11-14T05:20:48 https://maestrodatabase.com/blog/fda-grants-breakthrough-device-designation-for-renal-failure 2021-08-24T04:23:53 https://maestrodatabase.com/blog/highlights-from-the-24-27-june-2024-chmp-meeting 2024-06-29T23:19:10 https://maestrodatabase.com/blog/affinia-therapeutics-granted-fda-fast-track-designation-for-aftx-201-as-a-treatment-for-people-living-with-bag3-associated-dilated-cardiomyopathy 2026-03-04T23:42:20 https://maestrodatabase.com/blog/trulicity-dulaglutide-is-the-first-and-only-type-2-diabetes-medicine-approved-to-reduce-cardiovascular-events-in-adults-with-and-without-established-cardiovascular-disease 2020-02-22T22:56:04 https://maestrodatabase.com/blog/nice-recommends-offering-app-based-treatment-for-people-with-insomnia-instead-of-sleeping-pills 2022-05-23T06:43:28 https://maestrodatabase.com/blog/government-announces-cancer-control-agency-and-60-dollars-million-pharmac-funding-boost 2019-09-01T03:32:34 https://maestrodatabase.com/blog/pharmac-reveals-new-cancer-drugs-on-the-way-contraception-more-available 2019-09-01T03:30:05 https://maestrodatabase.com/blog/emas-refusal-to-authorise-herceptin-biosimilar-unfair 2022-05-23T06:53:34 https://maestrodatabase.com/blog/public-summary-documents---july-2023-pbac-meeting 2023-10-27T05:58:45 https://maestrodatabase.com/blog/atagi-update-following-weekly-covid-19-meeting-18-may-2022 2022-05-23T10:42:43 https://maestrodatabase.com/blog/no-jab-no-pay-threat-prompts-an-extra-174-000-children-to-be-vaccinated-in-one-year 2019-09-01T03:39:01 https://maestrodatabase.com/blog/draft-cadth-recommendation-for-spinraza-nusinersen-sodium-fails-adults-in-need-of-treatment-for-spinal-muscular-atrophy 2022-05-23T20:13:39 https://maestrodatabase.com/blog/icer-publishes-protocol-for-annual-assessment-of-drug-coverage-policies-that-present-barriers-to-fair-access 2024-06-05T21:09:38 https://maestrodatabase.com/blog/us-fda-accepts-for-review-biohavens-new-drug-application-filing-of-intranasal-zavegepant-for-the-acute-treatment-of-migraine 2022-05-23T20:05:48 https://maestrodatabase.com/blog/pharmac-board-endorse-action-plan-to-enhance-organisational-culture 2023-10-27T06:22:54 https://maestrodatabase.com/blog/the-4-biggest-questions-about-the-fdas-forthcoming-changes-to-accelerated-approvals 2023-01-25T19:57:12 https://maestrodatabase.com/blog/covid-19-anti-viral-access-criteria-assessment-tool 2022-05-24T04:56:05 https://maestrodatabase.com/blog/medicines-australia-ready-to-work-with-new-government-on-medicines-reform-and-life-sciences 2022-05-24T05:02:34 https://maestrodatabase.com/blog/new-proposal-aims-to-reduce-complications-following-a-stem-cell-transplant 2026-03-05T01:13:10 https://maestrodatabase.com/blog/pricing-of-medicines-in-switzerland-|-three-yearly-price-review-what-are-the-most-important-changes-for-2023 2023-01-25T21:07:14 https://maestrodatabase.com/blog/immunitybio-submits-biologics-license-application-for-n-803-plus-bcg-for-patients-with-bcg-unresponsive-non-muscle-invasive-bladder-cancer-carcinoma-in-situ 2022-05-24T06:32:38 https://maestrodatabase.com/blog/uk-to-introduce-first-of-its-kind-framework-to-make-it-easier-to-manufacture-innovative-medicines-at-the-point-of-care 2023-01-25T21:02:41 https://maestrodatabase.com/blog/immunogen-announces-acceptance-of-biologics-license-application-for-mirvetuximab-soravtansine-in-ovarian-cancer-by-us-food-and-drug-administration-with-priority-review 2022-05-24T05:18:10 https://maestrodatabase.com/blog/nice-approves-new-migraine-drug-for-nhs-use-in-england-and-wales 2023-01-25T20:08:54 https://maestrodatabase.com/blog/nymox-receives-rtf-letter-from-fda 2022-05-24T05:11:25 https://maestrodatabase.com/blog/us-fda-approves-alks-odactra-house-dust-mite-allergen-extract-tablet-for-sublingual-use-as-immunotherapy-for-adolescents 2023-01-25T20:01:07 https://maestrodatabase.com/blog/more-than-400-people-set-to-benefit-after-nice-approves-ground-breaking-car-t-therapy-to-treat-aggressive-form-of-blood-cancer 2023-01-26T08:27:10 https://maestrodatabase.com/blog/evolus-receives-regulatory-approval-for-nuceiva-in-australia 2023-01-26T10:32:26 https://maestrodatabase.com/blog/enhertu-approved-in-the-eu-as-the-first-her2-directed-therapy-for-patients-with-her2-low-metastatic-breast-cancer 2023-01-26T08:19:55 https://maestrodatabase.com/blog/bill-shorten-commits-to-53-million-dollar-plan-to-make-hiv-history-in-australia 2017-12-10T19:44:46 https://maestrodatabase.com/blog/rare-cancer-treatment-a-success-for-jie-eccles 2017-12-10T19:41:03 https://maestrodatabase.com/blog/a-method-of-use-to-prevent-generic-and-biosimilar-market-entry 2023-01-26T08:15:25 https://maestrodatabase.com/blog/prescription-drugs-may-cost-more-with-insurance-than-without-it 2017-12-10T19:55:20 https://maestrodatabase.com/blog/update-on-us-fda-emergency-use-authorisation-of-evusheld 2023-01-26T19:21:28 https://maestrodatabase.com/blog/epipen-outrage-drug-maker-mylan-may-have-gouged-us-taxpayers-by-1-dollars-7-cents-billion 2017-06-01T11:24:27 https://maestrodatabase.com/blog/avacopan-for-treating-severe-active-granulomatosis-with-polyangiitis-or-microscopic-polyangiitis 2022-05-24T10:38:24 https://maestrodatabase.com/blog/laws-introduced-to-guarantee-medicare 2017-06-01T11:19:41 https://maestrodatabase.com/blog/miracle-drug-keeping-eva-mcgauleys-cancer-at-bay 2017-12-10T19:48:26 https://maestrodatabase.com/blog/new-atopic-dermatitis-drugs-for-young-patients-to-get-expanded-coverage 2023-01-26T19:28:04 https://maestrodatabase.com/blog/britain-backs-first-line-use-of-mercks-keytruda-under-cancer-fund 2017-06-01T20:58:16 https://maestrodatabase.com/blog/draft-methods-version-7-dot-0-iqwig-is-extending-the-comment-period 2023-01-26T19:17:46 https://maestrodatabase.com/blog/patent-reform-and-lower-drug-prices-should-be-bipartisan-priorities 2023-01-26T19:06:19 https://maestrodatabase.com/blog/discgenics-announces-fda-regenerative-medicine-advanced-therapy-designation-granted-to-idct-for-degenerative-disc-disease 2023-01-26T19:08:58 https://maestrodatabase.com/blog/secukinumab-and-ixekizumab-in-psoriasis-significant-additional-benefit-for-certain-patients 2017-06-01T21:06:02 https://maestrodatabase.com/blog/fda-approves-dermavants-vtama-tapinarof-1-percent-cream-for-the-treatment-of-plaque-psoriasis-in-adults-first-topical-novel-chemical-entity-launched-for-psoriasis-in-the-u-dot-s-in-25-years 2022-05-24T10:20:21 https://maestrodatabase.com/blog/more-new-cancer-drugs-mean-higher-costs-but-also-longer-lives 2017-06-01T21:29:04 https://maestrodatabase.com/blog/accc-more-aggressive-towards-private-health-insurers 2017-06-01T21:23:57 https://maestrodatabase.com/blog/priovant-announces-fda-acceptance-and-priority-review-of-new-drug-application-for-brepocitinib-in-dermatomyositis 2026-03-05T02:58:17 https://maestrodatabase.com/blog/fda-approves-genentechs-vabysmo-for-the-treatment-of-retinal-vein-occlusion 2023-10-27T11:38:32 https://maestrodatabase.com/blog/fda-grants-breakthrough-device-designation-to-anumanas-ecg-pulmonary-hypertension-early-detection-ai-algorithm 2022-05-24T20:36:51 https://maestrodatabase.com/blog/neuronascent-receives-fda-rare-paediatric-drug-designation-for-nni-351-treatment-for-fragile-x-syndrome 2022-05-24T10:44:53 https://maestrodatabase.com/blog/fda-accepts-csl-behrings-biologics-license-application-for-etranacogene-dezaparvovec-for-priority-review 2022-05-24T20:30:22 https://maestrodatabase.com/blog/organon-canada-announces-availability-of-a-high-concentration-citrate-free-formulation-of-hadlima-a-biosimilar-to-humira 2023-10-27T11:31:31 https://maestrodatabase.com/blog/budget-2022-pharmac-funding-boost-a-glimpse-of-hope-for-cystic-fibrosis-sufferer 2022-05-24T20:26:28 https://maestrodatabase.com/blog/hls-therapeutics-obtains-public-reimbursement-for-vascepa-in-quebec 2022-05-24T21:01:17 https://maestrodatabase.com/blog/terminal-cancer-patient-wants-complete-overhaul-of-pharmac 2023-10-27T20:59:33 https://maestrodatabase.com/blog/nice-doesnt-recommend-ibrutinib-for-those-with-waldenstroms-macroglobulinaemia 2022-05-24T21:09:58 https://maestrodatabase.com/blog/gw-pharmaceuticals-submits-type-ii-variation-application-to-the-ema-to-expand-the-use-of-epidyolex-cannabidiol-oral-solution-for-the-treatment-of-seizures-associated-with-tuberous-sclerosis-complex 2020-03-14T01:38:14 https://maestrodatabase.com/blog/drugs-are-outrageously-expensive--canada-found-a-way-to-fight-back 2023-10-27T20:43:12 https://maestrodatabase.com/blog/united-therapeutics-announces-fda-approval-of-tyvaso-dpi 2022-05-24T20:43:09 https://maestrodatabase.com/blog/thousands-of-people-in-england-could-benefit-after-nice-recommends-treatment-option-for-two-forms-of-sight-loss 2022-05-24T20:55:30 https://maestrodatabase.com/blog/ema-guidance-supports-development-of-new-antibiotics 2022-05-24T20:50:51 https://maestrodatabase.com/blog/exelixis-announces-u-dot-s-fda-approval-of-cabometyx-cabozantinib-for-patients-with-previously-treated-radioactive-iodine-refractory-differentiated-thyroid-cancer 2021-09-18T02:58:04 https://maestrodatabase.com/blog/big-pharma-groups-rejoin-battle-with-governments-on-drug-prices 2023-01-26T20:46:53 https://maestrodatabase.com/blog/pharmac-boss-apologises-over-stories-of-patients-self-funding-treatments 2023-10-27T21:59:37 https://maestrodatabase.com/blog/how-health-care-costs-stopped-rising 2023-10-27T21:20:38 https://maestrodatabase.com/blog/fda-approves-pembrolizumab-as-adjuvant-treatment-for-non-small-cell-lung-cancer 2023-01-26T22:52:40 https://maestrodatabase.com/blog/review-of-discount-rate-in-the-pbac-guidelines 2022-05-25T03:34:43 https://maestrodatabase.com/blog/why-test-for-proportional-hazards 2020-03-14T02:18:58 https://maestrodatabase.com/blog/expanded-atagi-recommendations-on-winter-covid-19-booster-doses-for-people-at-increased-risk-of-severe-covid-19 2022-05-25T04:19:14 https://maestrodatabase.com/blog/blue-lake-biotechnology-announces-fda-fast-track-designation-for-blb-201-intranasal-rsv-vaccine 2022-05-24T23:37:37 https://maestrodatabase.com/blog/verrica-receives-complete-response-letter-from-the-fda-for-its-nda-for-vp-102 2022-05-25T01:29:20 https://maestrodatabase.com/blog/kiwis-with-cystic-fibrosis-feel-forced-to-move-overseas-for-affordable-treatment 2022-05-25T00:05:30 https://maestrodatabase.com/blog/servier-announces-fda-approval-of-tibsovo-ivosidenib-tablets-in-combination-with-azacitidine-for-patients-with-newly-diagnosed-idh1-mutated-acute-myeloid-leukaemia 2022-05-25T20:56:41 https://maestrodatabase.com/blog/fda-advisory-committee-votes-unanimously-in-favour-of-comirnaty-booster-for-emergency-use-in-people-65-and-older-and-certain-high-risk-population 2021-09-18T05:12:07 https://maestrodatabase.com/blog/new-injectable-immunotherapy-treatment-for-rare-form-of-triple-negative-breast-cancer-recommended-by-nice 2022-05-25T13:27:57 https://maestrodatabase.com/blog/syros-receives-fast-track-designation-from-the-fda-for-tamibarotene-for-the-treatment-of-higher-risk-myelodysplastic-syndrome 2023-01-26T23:16:13 https://maestrodatabase.com/blog/bausch-plus-lomb-receives-health-canada-approval-of-lumify-redness-reliever-eye-drops 2022-05-25T05:00:30 https://maestrodatabase.com/blog/remake-of-national-health-supply-of-pharmaceutical-benefits---under-co-payment-data-and-claims-for-payment-rules-2022 2022-05-25T05:22:59 https://maestrodatabase.com/blog/health-economic-assessment-of-trodelvy-in-advanced-triple-negative-breast-cancer 2022-05-25T21:20:05 https://maestrodatabase.com/blog/elevation-oncology-announces-fda-fast-track-designation-granted-to-seribantumab-for-the-tumour-agnostic-treatment-of-solid-tumours-harbouring-nrg1-gene-fusions 2022-05-25T21:03:48 https://maestrodatabase.com/blog/intensive-work-ongoing-to-give-35-children-with-cystic-fibrosis-access-to-life-changing-drug 2022-05-25T21:12:23 https://maestrodatabase.com/blog/chmp-recommends-approval-of-oczyesa-for-treatment-of-acromegaly-in-the-eu 2025-04-26T06:18:32 https://maestrodatabase.com/blog/immunogen-announces-european-medicines-agency-acceptance-of-marketing-authorisation-application-for-mirvetuximab-soravtansine-in-platinum-resistant-ovarian-cancer 2023-10-28T01:27:11 https://maestrodatabase.com/blog/medicare-spending-on-drugs-with-accelerated-approval 2022-05-25T21:38:31 https://maestrodatabase.com/blog/pdufa-action-date-for-hansa-biopharmas-imlifidase-bla-set-for-19-december-2026 2026-03-05T21:18:25 https://maestrodatabase.com/blog/astellas-receives-positive-chmp-opinion-for-zolbetuximab-in-combination-with-chemotherapy-for-treatment-of-advanced-gastric-and-gastro-oesophageal-junction-cancer 2024-07-27T04:03:40 https://maestrodatabase.com/blog/phathom-pharmaceuticals-announces-fda-acceptance-for-filing-of-vonoprazan-nda-for-the-treatment-of-erosive-oesophagitis 2022-05-25T21:44:35 https://maestrodatabase.com/blog/noveome-biotherapeutics-receives-rare-paediatric-disease-designation-and-orphan-drug-designation-for-the-treatment-of-necrotising-enterocolitis-in-neonates 2022-05-25T21:27:02 https://maestrodatabase.com/blog/astellas-receives-positive-chmp-opinion-for-padcev-enfortumab-vedotin-in-combination-with-keytruda-pembrolizumab-for-first-line-treatment-of-advanced-bladder-cancer 2024-07-27T03:38:33 https://maestrodatabase.com/blog/target-trial-emulation-for-transparent-and-robust-estimation-of-treatment-effects-for-health-technology-assessment-using-real-world-data-opportunities-and-challenges 2022-05-25T21:32:55 https://maestrodatabase.com/blog/marketing-authorisation-application-for-lecanemab-as-treatment-for-early-alzheimers-disease-accepted-by-ema 2023-01-27T01:38:28 https://maestrodatabase.com/blog/dying-father-pleads-for-cancer-drug-subsidy-to-keep-being-a-dad 2026-03-05T04:26:30 https://maestrodatabase.com/blog/new-multi-indication-pbs-listing-for-two-immunotherapy-treatments-from-march-2026 2026-03-05T22:45:18 https://maestrodatabase.com/blog/incyte-announces-health-canada-conditional-approval-of-pemazyre-pemigatinib-as-first-targeted-treatment-for-adults-with-previously-treated-unresectable-locally-advanced-or-metastatic-cholangiocarcinoma 2021-09-18T05:29:54 https://maestrodatabase.com/blog/fda-approves-teclistamab-in-combination-with-daratumumab-hyaluronidase-fihj-for-relapsed-or-refractory-multiple-myeloma 2026-03-05T22:49:44 https://maestrodatabase.com/blog/push-for-blood-cancer-breakthrough 2019-09-01T21:08:00 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-september-2019 2019-09-01T21:02:19 https://maestrodatabase.com/blog/the-role-and-value-of-real-world-evidence-in-health-technology-decision-making-in-france-germany-italy-spain-and-the-uk-insights-on-external-control-arms 2025-04-27T01:00:34 https://maestrodatabase.com/blog/thumbs-up-from-foundation-for-cancer-announcements 2019-09-01T20:49:13 https://maestrodatabase.com/blog/abbvie-submits-biologics-license-application-to-us-fda-for-trenibotulinumtoxine-trenibote-for-the-treatment-of-glabellar-lines 2025-04-27T00:53:51 https://maestrodatabase.com/blog/icer-posts-draft-scoping-document-for-the-assessment-of-treatments-for-sickle-cell-disease 2019-09-01T21:23:26 https://maestrodatabase.com/blog/hemab-therapeutics-receives-fda-breakthrough-therapy-designation-for-sutacimig-in-glanzmann-thrombasthenia 2026-03-05T21:45:24 https://maestrodatabase.com/blog/acoramidis-approved-to-treat-wild-type-or-variant-transthyretin-amyloidosis-in-adults-with-cardiomyopathy 2025-04-27T00:50:51 https://maestrodatabase.com/blog/nhs-leaders-warn-of-no-deal-brexit-flu-vaccine-delays 2019-09-01T21:16:42 https://maestrodatabase.com/blog/tremfya-guselkumab-receives-european-commission-approval-for-adults-with-moderately-to-severely-active-ulcerative-colitis-strengthening-johnson-and-johnsons-leadership-in-inflammatory-bowel-disease 2025-04-27T00:44:40 https://maestrodatabase.com/blog/60-dollars-million-for-new-cancer-drugs-is-piddly 2019-09-01T21:12:13 https://maestrodatabase.com/blog/outrageously-expensive-new-drug-approval-will-cost-ontario-family-100k-per-year 2019-09-01T21:29:57 https://maestrodatabase.com/blog/hls-therapeutics-announces-nilemdo-bempedoic-acid-is-now-available-in-canada-for-the-reduction-of-ldl-cholesterol-in-patients-at-risk-of-cardiovascular-disease 2026-03-06T02:51:59 https://maestrodatabase.com/blog/vertex-announces-fda-acceptance-of-new-drug-application-for-vanzacaftor-slash-tezacaftor-slash-deutivacaftor-a-next-in-class-triple-combination-treatment-for-cystic-fibrosis 2024-07-27T04:53:37 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-september-2019-update 2019-09-01T21:35:36 https://maestrodatabase.com/blog/msac-publishes-agenda-for-april-2023-pasc-meeting 2023-01-27T03:49:29 https://maestrodatabase.com/blog/roches-columvi-takedas-fruzaqla-pass-first-review-for-korea-insurance-coverage 2026-03-06T01:19:47 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac---december-2022-intracycle-meeting 2023-01-27T05:24:21 https://maestrodatabase.com/blog/risankizumab-for-the-treatment-of-patients-with-previously-treated-moderate-to-severe-active-crohns-disease 2023-01-27T04:33:24 https://maestrodatabase.com/blog/public-summary-documents-first-time-decisions-not-to-recommend-and-deferrals---december-2024-pbac-meeting 2025-04-27T01:38:22 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac---march-2025 2025-04-27T01:31:52 https://maestrodatabase.com/blog/mhra-approves-first-uk-treatment-for-friedreichs-ataxia-omaveloxolone 2025-04-27T01:28:43 https://maestrodatabase.com/blog/insulin-costs-may-be-capped-in-a-medicare-program 2020-03-14T05:41:46 https://maestrodatabase.com/blog/dupixent-dupilumab-recommended-for-expanded-eu-approval-by-the-chmp-to-treat-children-as-young-as-six-months-old-with-severe-atopic-dermatitis 2023-01-27T06:23:30 https://maestrodatabase.com/blog/tga-approves-new-medicine-for-patients-with-cushings-syndrome 2022-05-26T03:22:03 https://maestrodatabase.com/blog/valeo-pharma-announces-filing-of-a-new-drug-submission-with-health-canada-for-sabizabulin-for-the-treatment-of-hospitalised-covid-19-patients 2023-01-27T06:27:34 https://maestrodatabase.com/blog/romosozumab-for-treating-severe-osteoporosis 2022-05-26T04:58:34 https://maestrodatabase.com/blog/australian-rollout-to-include-4-500-gp-clinics-as-it-moves-to-phase-1b 2021-03-07T04:33:00 https://maestrodatabase.com/blog/prescription-medicines-applications-under-evaluation-may-2022 2022-05-26T05:55:43 https://maestrodatabase.com/blog/coherus-and-junshi-biosciences-announce-fda-pproval-of-loqtorzi-toripalimab-tpzi-in-all-lines-of-treatment-for-recurrent-or-metastatic-nasopharyngeal-carcinoma 2023-10-29T19:54:57 https://maestrodatabase.com/blog/rhizen-pharmaceuticals-s-dot-a-receives-fda-fast-track-designation-for-rp6530-tenalisib-a-highly-selective-dual-pi3k-delta-slash-gamma-inhibitor-for-the-treatment-of-patients-with-relapsed-slash-refractory-peripheral-t-cell-lymphoma 2017-12-11T00:21:48 https://maestrodatabase.com/blog/100-000-patients-eligible-for-heart-drug-under-pbs 2023-10-29T19:51:51 https://maestrodatabase.com/blog/roche-announces-fda-approval-of-companion-diagnostic-to-identify-alk-positive-non-small-cell-lung-cancer-patients 2017-06-02T01:41:23 https://maestrodatabase.com/blog/spinraza-nusinersen-approved-in-the-european-union-as-first-treatment-for-spinal-muscular-atrophy 2017-06-02T01:31:40 https://maestrodatabase.com/blog/ipsen-receives-chmp-positive-opinions-for-iqirvo-elafibranor-in-primary-biliary-cholangitis-and-kayfanda-odevixibat-in-alagille-syndrome-two-rare-cholestatic-liver-diseases 2024-07-27T06:47:38 https://maestrodatabase.com/blog/single-payer-healthcare-is-popular-with-californians----unless-it-raises-their-taxes 2017-06-02T01:47:29 https://maestrodatabase.com/blog/transparency-commission-revises-asmr-for-imbruvica 2017-06-02T02:17:24 https://maestrodatabase.com/blog/roches-polivy-combination-approved-by-european-commission-for-people-with-previously-untreated-diffuse-large-b-cell-lymphoma 2022-05-26T07:39:34 https://maestrodatabase.com/blog/agenda-for-the-march-2026-pbac-meeting-4-march-2026 2026-03-06T06:02:16 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-pirtobrutinib-for-relapsed-or-refractory-mantle-cell-lymphoma 2023-01-27T20:00:56 https://maestrodatabase.com/blog/agenda-for-13-december-tc-meeting 2017-12-11T01:25:48 https://maestrodatabase.com/blog/canada-authorises-one-shot-covid-19-vaccine-from-johnson-and-johnson 2021-03-07T04:40:14 https://maestrodatabase.com/blog/botox-placed-on-pbs-to-help-stroke-victims 2019-09-02T02:07:50 https://maestrodatabase.com/blog/public-summary-documents---november-2025-pbac-meeting 2026-03-06T06:30:21 https://maestrodatabase.com/blog/dupilumab-for-the-treatment-of-patients-with-moderate-to-severe-chronic-obstructive-pulmonary-disease 2025-04-27T22:45:16 https://maestrodatabase.com/blog/update-on-regulatory-review-of-lecanemab-for-early-alzheimers-disease-in-the-european-union-january-2025 2025-02-01T01:29:22 https://maestrodatabase.com/blog/highlights-from-the-chmp-23-26-january-2023-meeting 2023-01-27T20:50:05 https://maestrodatabase.com/blog/new-position-statement-aims-to-guide-the-use-of-ai-methods-in-health-technology-assessment 2025-04-28T00:04:09 https://maestrodatabase.com/blog/a-month-in-trumprx-falls-short-of-presidents-grand-promises 2026-03-06T23:12:32 https://maestrodatabase.com/blog/ketamine-nasal-spray-to-become-cheaper-for-australians-with-treatment-resistant-depression 2025-04-27T23:36:57 https://maestrodatabase.com/blog/fda-approves-elacestrant-for-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast-cancer 2023-01-27T21:29:41 https://maestrodatabase.com/blog/egetis-announces-ema-validation-of-marketing-authorisation-application-for-emcitate-for-the-treatment-of-mct8-deficiency 2023-10-30T02:09:44 https://maestrodatabase.com/blog/desperate-families-waiting-to-learn-if-miracle-drug-covered 2017-12-11T03:09:20 https://maestrodatabase.com/blog/expressions-of-interest-to-join-the-pharmaceutical-benefits-remuneration-tribunal 2023-10-30T02:02:44 https://maestrodatabase.com/blog/call-for-feedback-medicine-for-the-management-of-rheumatoid-arthritis 2017-12-11T04:31:00 https://maestrodatabase.com/blog/reforming-pharmacy-benefit-managers---a-review-of-bipartisan-legislation 2023-10-30T01:50:59 https://maestrodatabase.com/blog/drug-makers-continue-to-owe-fda-numerous-clinical-trials 2017-12-11T03:13:41 https://maestrodatabase.com/blog/nhs-advises-gps-not-to-prescribe-low-value-drugs 2017-12-11T04:37:58 https://maestrodatabase.com/blog/new-treatment-against-duchenne-muscular-dystrophy 2025-04-28T00:57:26 https://maestrodatabase.com/blog/pharmac-does-a-great-job-but-its-losing-the-pr-battle-hands-down 2021-03-07T20:12:50 https://maestrodatabase.com/blog/cancer-society-says-pharmac-review-doesnt-go-far-enough 2021-03-07T20:16:02 https://maestrodatabase.com/blog/bristol-myers-squibb-announces-positive-chmp-opinion-for-once-daily-sotyktu-deucravacitinib-as-a-treatment-for-adults-with-moderate-to-severe-plaque-psoriasis 2023-01-27T22:19:36 https://maestrodatabase.com/blog/first-treatment-against-severe-thyroid-eye-disease 2025-04-28T00:49:27 https://maestrodatabase.com/blog/we-cant-do-much-with-50-doses-gps-concerned-about-supply-capability-of-covid-19-vaccine 2021-03-07T20:18:43 https://maestrodatabase.com/blog/primary-dyslipidaemia-drug-praluent-gets-insurance-benefit 2021-03-07T20:22:00 https://maestrodatabase.com/blog/trumps-drive-to-get-europe-to-pay-more-for-drugs-creates-uncertainty-for-countries-patients 2026-03-07T00:51:08 https://maestrodatabase.com/blog/lantheus-announces-fda-approval-of-pylarify-truvu-piflufolastat-f-18-injection 2026-03-07T01:20:36 https://maestrodatabase.com/blog/where-is-the-corrigenda 2021-03-07T20:07:27 https://maestrodatabase.com/blog/us-fda-approves-leqselvi-deuruxolitinib-an-oral-jak-inhibitor-for-the-treatment-of-severe-alopecia-areata 2024-07-27T08:24:55 https://maestrodatabase.com/blog/leo-pharma-receives-positive-chmp-opinion-of-anzupgo-delgocitinib-cream-for-the-treatment-of-adults-with-moderate-to-severe-chronic-hand-eczema 2024-07-27T08:10:57 https://maestrodatabase.com/blog/chmp-recommends-bayers-darolutamide-for-the-treatment-of-metastatic-hormone-sensitive-prostate-cancer 2023-01-27T22:26:51 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-26-may-2022 2022-05-26T09:08:50 https://maestrodatabase.com/blog/european-commission-approves-keytruda-pembrolizumab-plus-chemotherapy-as-neo-adjuvant-treatment-then-continued-as-adjuvant-monotherapy-after-surgery-for-locally-advanced-or-early-stage-triple-negative-breast-cancer-at-high-risk-of-recurrence 2022-05-26T10:23:02 https://maestrodatabase.com/blog/celltrion-usa-announces-distribution-and-incorporation-of-yuflyma-adalimumab-aaty-a-humira-biosimilar-to-carepartners-specialty-pharmacy-cost-savings-programs 2023-10-30T04:23:06 https://maestrodatabase.com/blog/updated-agenda-for-november-2023-pbac-meeting-30-october-2023 2023-10-30T04:09:17 https://maestrodatabase.com/blog/genentech-provides-update-on-supplemental-biologics-licence-application-for-tecentriq-in-first-line-metastatic-non-squamous-non-small-cell-lung-cancer 2019-09-02T05:01:18 https://maestrodatabase.com/blog/galcanezumab-is-the-first-of-three-investigational-non-opioid-treatments-in-lillys-pain-portfolio 2017-12-11T11:50:30 https://maestrodatabase.com/blog/otago-academic-to-head-new-national-cancer-strategy 2019-09-02T04:57:17 https://maestrodatabase.com/blog/australians-paying-more-for-their-medication-after-prescription-changes-knocked-back 2019-09-02T04:53:34 https://maestrodatabase.com/blog/reata-pharmaceuticals-announces-fda-filing-acceptance-and-priority-review-designation-for-the-nda-for-omaveloxolone-for-the-treatment-of-patients-with-friedreichs-ataxia 2022-05-26T20:55:09 https://maestrodatabase.com/blog/ipsen-receives-chmp-negative-opinion-for-palovarotene-as-a-treatment-for-fibrodysplasia-ossificans-progressiva-in-eu 2023-01-28T01:10:57 https://maestrodatabase.com/blog/expanded-access-to-chronic-heart-failure-treatment-on-the-pbs 2023-10-30T04:55:56 https://maestrodatabase.com/blog/updates-to-the-hta-review-research-and-analysis-papers-collection-draft-hta-expert-paper-published-30-october-2023 2023-10-30T05:04:08 https://maestrodatabase.com/blog/us-fda-approves-bristol-myers-squibbs-sotyktu-deucravacitinib-for-the-treatment-of-adults-with-active-psoriatic-arthritis 2026-03-07T03:12:22 https://maestrodatabase.com/blog/rfp---supply-of-a-cdk4-slash-cdk6-inhibitor-for-the-treatment-of-hr-positive-her2-negative-locally-advanced-or-metastatic-breast-cancer 2019-09-02T11:50:28 https://maestrodatabase.com/blog/fda-official-offers-insights-on-agencys-criteria-for-real-world-data-in-regulatory-submissions 2026-03-07T03:53:32 https://maestrodatabase.com/blog/china-expands-drug-bulk-buy-program-puts-pressure-on-pharma-firms 2019-09-02T11:47:55 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-positive-chmp-opinion-for-reblozyl-luspatercept-for-adult-patients-with-anaemia-associated-non-transfusion-dependent-beta-thalassaemia 2023-01-28T00:33:34 https://maestrodatabase.com/blog/come-to-grips-fighting-lymphoma-from-home 2025-04-28T02:49:31 https://maestrodatabase.com/blog/pfizer-granted-fda-fast-track-designation-for-ervogastat-slash-clesacostat-combination-for-the-treatment-of-non-alcoholic-steatohepatitis 2022-05-26T20:50:57 https://maestrodatabase.com/blog/nhs-saves-more-than-ps700-million-on-medicines-costs 2019-09-02T11:40:48 https://maestrodatabase.com/blog/european-commission-approves-brineura-cerliponase-alfa-the-first-treatment-for-cln2-disease-a-form-of-batten-disease-and-ultra-rare-brain-disorder-in-children 2017-06-02T12:42:46 https://maestrodatabase.com/blog/janssens-psoriatic-arthritis-drug-tremfya-gets-insurance-coverage 2022-05-26T21:15:13 https://maestrodatabase.com/blog/nice-u-turn-backs-combo-for-kidney-cancer 2017-12-11T12:32:53 https://maestrodatabase.com/blog/nice-recommends-libtayo-cemiplimab-for-routine-nhs-commissioning-as-the-first-and-only-systemic-treatment-for-advanced-cscc-in-england 2022-05-26T21:05:01 https://maestrodatabase.com/blog/impossible-to-shop-around-patients-struggling-to-get-information-about-costs-from-surgeons 2017-12-11T12:45:47 https://maestrodatabase.com/blog/kiwi-women-plead-for-pharmac-funding-of-a-newly-approved-breakthrough-treatment-for-ovarian-cancer 2022-05-26T21:09:59 https://maestrodatabase.com/blog/smc---december-2017-decisions 2017-12-11T19:41:21 https://maestrodatabase.com/blog/pharmac---year-in-review-2017 2017-12-11T12:53:24 https://maestrodatabase.com/blog/new-breast-cancer-drug-approved-for-use-in-scotland 2017-12-11T19:48:20 https://maestrodatabase.com/blog/european-medicines-agency-validates-bristol-myers-squibbs-application-for-opdivo-nivolumab-in-combination-with-cisplatin-based-chemotherapy-for-the-first-line-treatment-of-adult-patients-with-unresectable-or-metastatic-urothelial-carcinoma 2023-10-30T19:41:43 https://maestrodatabase.com/blog/perrigo-announces-u-dot-s-fda-approval-for-omeprazole-magnesium-delayed-release-mini-capsules 2022-05-26T21:27:30 https://maestrodatabase.com/blog/fresh-hope-over-discontinued-painkiller-but-patients-fear-replacement-doses-are-useless 2023-10-30T08:15:41 https://maestrodatabase.com/blog/fda-approves-admelog-the-first-short-acting-follow-on-insulin-product-to-treat-diabetes 2017-12-11T19:54:14 https://maestrodatabase.com/blog/revolutionary-wearable-ultrasound-device-gains-fda-approval 2022-05-26T21:22:21 https://maestrodatabase.com/blog/from-scientific-discovery-to-covered-treatments-understanding-the-payer-perspective-as-a-keystone-to-achieving-high-value-care 2022-05-26T21:40:07 https://maestrodatabase.com/blog/biovie-receives-fda-fast-track-designation-for-biv201-for-the-treatment-of-refractory-ascites-due-to-advanced-liver-cirrhosis 2017-12-11T20:01:23 https://maestrodatabase.com/blog/incyte-announces-the-european-commission-approval-of-zynyz-retifanlimab-for-the-first-line-treatment-of-advanced-squamous-cell-carcinoma-of-the-anal-canal 2026-03-08T10:07:55 https://maestrodatabase.com/blog/let-states-lower-drug-prices 2017-12-11T20:07:16 https://maestrodatabase.com/blog/bluebird-bio-enters-into-advance-agreement-to-sell-priority-review-voucher-if-granted-for-103-dollars-million 2023-10-30T19:55:33 https://maestrodatabase.com/blog/arrivent-receives-fda-breakthrough-therapy-designation-for-furmonertinib-for-first-line-treatment-of-advanced-or-metastatic-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations 2023-10-30T19:49:02 https://maestrodatabase.com/blog/icer-posts-draft-scoping-documents-on-bladder-cancer-and-digital-apps-for-opioid-use-disorder 2020-03-15T10:41:15 https://maestrodatabase.com/blog/brexit-means-coronavirus-vaccine-will-be-slower-to-reach-the-uk 2020-03-15T10:37:40 https://maestrodatabase.com/blog/ottawa-should-allow-all-drugs-approved-in-the-eu-and-us-to-be-marketed-in-canada 2026-03-08T02:20:43 https://maestrodatabase.com/blog/how-australias-health-care-system-works-and-how-it-compares-with-the-united-states 2019-09-02T21:09:14 https://maestrodatabase.com/blog/cancer-agency-a-vessel-for-progress 2019-09-02T20:58:42 https://maestrodatabase.com/blog/cancer-sufferers-to-benefit-from-pharmac-funding-boost---jacinda-ardern 2019-09-02T20:54:28 https://maestrodatabase.com/blog/covid-19-treatments-to-enter-the-market-with-a-hefty-price-tag 2023-10-30T20:15:27 https://maestrodatabase.com/blog/icer-publishes-final-evidence-report-on-gene-therapy-for-metachromatic-leukodystrophy 2023-10-30T20:20:03 https://maestrodatabase.com/blog/aarp-fights-high-drug-prices-on-behalf-of-members 2019-09-02T12:53:50 https://maestrodatabase.com/blog/burning-issues-in-health-technology-assessment-and-policy-making-whats-keeping-senior-health-technology-assessment-users-and-producers-up-at-night 2020-03-15T20:02:37 https://maestrodatabase.com/blog/alvotech-welcomes-positive-chmp-opinion-for-avt02-a-proposed-biosimilar-to-humira 2021-09-18T23:48:14 https://maestrodatabase.com/blog/la-jolla-pharmaceutical-receives-european-commission-approval-for-giapreza-angiotensin-ii 2019-09-02T21:26:53 https://maestrodatabase.com/blog/roche-receives-positive-chmp-opinion-for-gavreto-pralsetinib-for-the-treatment-of-adults-with-ret-fusion-positive-advanced-non-small-cell-lung-cancer 2021-09-18T23:59:10 https://maestrodatabase.com/blog/government-cancer-plan-not-sufficient-warn-advocates 2019-09-02T21:24:15 https://maestrodatabase.com/blog/dutch-experience-demonstrates-effective-benchmarking-of-biosimilar-use-in-health-systems 2019-09-02T21:18:35 https://maestrodatabase.com/blog/mending-the-broken-social-contract-for-pharmaceutical-pricing-and-innovation 2020-03-15T20:19:30 https://maestrodatabase.com/blog/biosimilars-forums-public-letter-in-response-to-anti-biosimilars-op-ed 2019-09-02T21:32:47 https://maestrodatabase.com/blog/for-second-time-fda-rejects-intarcias-diabetes-implant 2020-03-15T20:07:27 https://maestrodatabase.com/blog/fda-finalises-guidance-for-industry-on-applications-for-drugs-with-inadequate-generic-competition 2020-03-15T20:25:15 https://maestrodatabase.com/blog/merck-receives-positive-eu-chmp-opinion-for-keytruda-pembrolizumab-in-combination-with-chemotherapy-for-certain-patients-with-locally-recurrent-unresectable-or-metastatic-triple-negative-breast-cancer-whose-tumours-express-pd-l1-cps-10 2021-09-19T00:12:52 https://maestrodatabase.com/blog/beigene-receives-positive-chmp-opinion-for-brukinsa-zanubrutinib-for-the-treatment-of-adults-with-waldenstroems-macroglobulinaemia 2021-09-19T00:04:51 https://maestrodatabase.com/blog/switzerland-restricts-reimbursement-of-orphan-drugs 2023-10-30T22:05:56 https://maestrodatabase.com/blog/vertex-receives-chmp-positive-opinion-for-alyftrek-a-new-once-daily-cftr-modulator-for-the-treatment-of-cystic-fibrosis 2025-04-28T11:03:26 https://maestrodatabase.com/blog/jazz-pharmaceuticals-receives-chmp-positive-opinion-for-zanidatamab-for-the-treatment-of-advanced-her2-positive-biliary-tract-cancer 2025-04-28T07:27:59 https://maestrodatabase.com/blog/sellas-life-sciences-receives-fast-track-designation-from-fda-for-sls009-for-treatment-of-relapsed-slash-refractory-peripheral-t-cell-lymphomas 2023-10-30T23:10:10 https://maestrodatabase.com/blog/lynozyfic-linvoseltamab-approved-in-the-european-union-for-the-treatment-of-relapsed-slash-refractory-multiple-myeloma 2025-04-28T11:14:56 https://maestrodatabase.com/blog/jacinda-ardern-responds-to-heartfelt-plea-from-pharmac-funding-advocate-malcolm-mulholland 2021-03-08T01:29:05 https://maestrodatabase.com/blog/more-startling-revelations-from-the-public-summary-document-for-upadacitinib-monohydrate-rinvoq 2021-03-08T01:49:08 https://maestrodatabase.com/blog/end-of-temporary-funding-of-palivizumab-for-preventing-rsv 2023-10-31T06:18:57 https://maestrodatabase.com/blog/telix-provides-regulatory-update-on-tlx101-cdx 2025-04-28T23:18:50 https://maestrodatabase.com/blog/day-one-announces-fda-acceptance-of-nda-and-priority-review-for-tovorafenib-in-relapsed-or-progressive-paediatric-low-grade-glioma 2023-10-31T06:49:21 https://maestrodatabase.com/blog/nice-backs-opdivo-for-classical-hodgkin-lymphoma 2017-06-02T23:47:54 https://maestrodatabase.com/blog/european-commission-approves-bristol-myers-squibbs-opdivo-nivolumab-for-previously-treated-locally-advanced-unresectable-or-metastatic-urothelial-carcinoma-in-adults-after-failure-of-prior-platinum-containing-therapy 2017-06-02T23:40:01 https://maestrodatabase.com/blog/express-scripts-sues-maker-of-overdose-drug-intensifying-feud 2017-06-02T23:58:23 https://maestrodatabase.com/blog/pbs-listing-expanded-to-include-treatment-resistant-high-frequency-episodic-migraine 2023-10-31T06:57:21 https://maestrodatabase.com/blog/pfizer-announces-acceptance-of-regulatory-submissions-by-u-dot-s-fda-and-ema-for-sutent-sunitinib-for-adjuvant-treatment-of-adult-patients-at-high-risk-of-recurrent-renal-cell-carcinoma-after-surgery 2017-06-03T00:26:27 https://maestrodatabase.com/blog/is-the-department-of-health-guilty-of-abusing-its-monopsonistic-power 2021-03-08T05:38:54 https://maestrodatabase.com/blog/health-canada-approves-iqirvo-as-a-first-in-class-dual-peroxisome-proliferator-activated-receptor-treatment-for-primary-biliary-cholangitis 2025-04-29T03:14:35 https://maestrodatabase.com/blog/department-of-health-publishes-public-summary-document-for-medicine-without-a-published-outcome 2021-03-08T06:25:51 https://maestrodatabase.com/blog/more-health-plans-are-eyeing-deals-for-drugs-based-on-patient-outcomes 2017-06-03T01:08:09 https://maestrodatabase.com/blog/cessation-therapeutics-receives-fda-fast-track-designation-for-csx-1004-for-prevention-of-fentanyl-and-fentanyl-analogue-overdose 2023-10-31T19:31:05 https://maestrodatabase.com/blog/cara-therapeutics-and-vifor-pharma-announce-u-dot-s-fda-acceptance-and-priority-review-of-nda-for-korsuva-injection-in-haemodialysis-patients-with-moderate-to-severe-pruritus 2021-03-08T10:12:45 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-november-2023 2023-10-31T19:26:22 https://maestrodatabase.com/blog/eton-pharmaceuticals-announces-submission-of-nda-for-et-600-desmopressin-oral-solution 2025-04-29T03:32:15 https://maestrodatabase.com/blog/phathom-pharmaceuticals-announces-fda-approval-of-reformulated-vonoprazan-tablets-for-voquenza-triple-pak-vonoprazan-amoxicillin-clarithromycin-and-voquenza-dual-pak-vonoprazan-amoxicillin-for-the-treatment-of-h-pylori-infection-in-adults 2023-10-31T09:19:39 https://maestrodatabase.com/blog/tga-cautions-against-over-buying-medicines 2020-03-16T00:04:48 https://maestrodatabase.com/blog/nice-approves-life-changing-gene-therapy-for-treating-spinal-muscular-atrophy 2021-03-08T10:04:17 https://maestrodatabase.com/blog/reliance-on-china-for-medicines-an-emergency 2020-03-16T00:02:21 https://maestrodatabase.com/blog/ema-recommends-approval-of-adapted-nuvaxovid-covid-19-vaccine-targeting-omicron-xbb-dot-1-5 2023-10-31T20:18:18 https://maestrodatabase.com/blog/biomarin-announces-fda-regenerative-medicine-advanced-therapy-designation-granted-to-valoctocogene-roxaparvovec-investigational-gene-therapy-for-haemophilia-a 2021-03-08T20:10:35 https://maestrodatabase.com/blog/viatris-and-kindeva-drug-delivery-announce-fda-tentative-approval-of-the-first-abbreviated-new-drug-application-generic-version-of-symbicort-budesonide-slash-formoterol-fumarate-dihydrate-inhalation-aerosol 2021-03-08T20:16:43 https://maestrodatabase.com/blog/australia-a-world-leader-in-genetic-screening-as-medicare-to-provide-free-testing 2023-10-31T20:14:38 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-november-2023 2023-10-31T19:42:57 https://maestrodatabase.com/blog/genentech-provides-update-on-tecentriq-u-dot-s-indication-in-prior-platinum-treated-metastatic-bladder-cancer 2021-03-08T20:03:36 https://maestrodatabase.com/blog/nice-launches-first-modular-update-to-its-methods-and-processes 2023-10-31T19:37:16 https://maestrodatabase.com/blog/democratic-law-makers-call-for-insurance-plans-to-fully-cover-over-the-counter-birth-control-pill 2023-10-31T20:29:45 https://maestrodatabase.com/blog/us-fda-awards-both-rare-paediatric-disease-and-orphan-drug-designations-to-hg204-a-crispr-rna-editing-therapy-for-the-treatment-of-mecp2-duplication-syndrome 2023-10-31T20:21:19 https://maestrodatabase.com/blog/gsk-receives-chmp-positive-opinions-recommending-approval-of-nucala-mepolizumab-in-three-additional-eosinophil-driven-diseases 2021-09-19T20:36:18 https://maestrodatabase.com/blog/highlights-from-the-chmp-13-16-september-2021-meeting 2021-09-19T20:43:54 https://maestrodatabase.com/blog/should-regulatory-authorities-approve-drugs-based-on-surrogate-outcomes 2021-09-19T20:41:23 https://maestrodatabase.com/blog/enhertu-granted-priority-review-in-the-us-as-post-neoadjuvant-treatment-for-patients-with-her2-positive-early-breast-cancer 2026-03-09T06:51:29 https://maestrodatabase.com/blog/pacific-pharmacists-want-inclusion-on-pharmac-review 2021-03-08T20:20:52 https://maestrodatabase.com/blog/fda-accepts-supplemental-biologics-license-application-assigns-priority-review-to-mercks-keytruda-pembrolizumab-for-treatment-of-relapsed-or-refractory-primary-mediastinal-large-b-cell-lymphoma 2017-12-12T00:06:17 https://maestrodatabase.com/blog/basic-health-insurance-to-cover-test-that-can-predict-return-of-breast-cancer 2023-10-31T22:34:08 https://maestrodatabase.com/blog/ipsen-voluntarily-withdraws-tazverik-tazemetostat-in-follicular-lymphoma-and-epithelioid-sarcoma 2026-03-09T20:33:47 https://maestrodatabase.com/blog/fda-approves-novartis-cosentyx-as-the-first-new-biologic-treatment-option-for-hidradenitis-suppurativa-patients-in-nearly-a-decade 2023-10-31T22:25:46 https://maestrodatabase.com/blog/manufacturers-perceptions-of-the-decision-making-process-for-new-drug-reimbursement-in-south-korea 2021-09-19T20:49:22 https://maestrodatabase.com/blog/icer-to-assess-treatment-for-parkinsons-disease 2026-03-09T21:02:59 https://maestrodatabase.com/blog/mayne-pharma-announces-pbs-listing-of-kapanol-for-chronic-breathlessness 2019-09-03T07:55:03 https://maestrodatabase.com/blog/worlds-most-expensive-drug-given-the-green-light-in-scotland 2021-03-08T20:33:53 https://maestrodatabase.com/blog/fda-grants-breakthrough-device-designation-for-emilys-care-nourish-test-system 2022-05-27T07:50:32 https://maestrodatabase.com/blog/life-changing-medicine-for-children-with-cystic-fibrosis 2024-07-29T04:21:17 https://maestrodatabase.com/blog/the-tga-launches-new-tool-to-help-sponsors-find-information-on-registering-prescription-medicines 2019-09-03T07:48:41 https://maestrodatabase.com/blog/hi-bio-announces-felzartamab-granted-breakthrough-therapy-designation-by-us-food-and-drug-administration-for-primary-membranous-nephropathy 2023-10-31T23:31:01 https://maestrodatabase.com/blog/some-positives-but-also-unanswered-questions-in-governments-cancer-announcement 2019-09-03T07:45:45 https://maestrodatabase.com/blog/fda-approves-interchangeable-biosimilar-for-multiple-inflammatory-diseases 2023-10-31T23:24:34 https://maestrodatabase.com/blog/bad-diagnosis-health-care-system-muddled-lacking-leadership-major-report-finds 2019-09-03T03:48:21 https://maestrodatabase.com/blog/italys-block-on-astrazeneca-covid-19-vaccines-prompts-warning-against-vaccine-protectionism-from-australian-government 2021-03-08T20:37:52 https://maestrodatabase.com/blog/as-congress-considers-lowering-drug-costs-pharma-ceos-target-key-senators-with-campaign-cash 2019-09-03T11:30:44 https://maestrodatabase.com/blog/health-canada-approves-keytruda-pembrolizumab-as-first-line-treatment-for-adults-with-metastatic-microsatellite-instability-high-or-mismatch-repair-deficient-colorectal-cancer 2021-03-08T20:25:28 https://maestrodatabase.com/blog/added-therapeutic-benefit-and-drug-licensing 2019-09-03T11:10:51 https://maestrodatabase.com/blog/smc---march-2021-decisions 2021-03-08T20:30:29 https://maestrodatabase.com/blog/free-prescriptions-blocked-by-the-pharmacy-guild-of-australia 2019-09-03T20:50:05 https://maestrodatabase.com/blog/cancer-action-10-year-plan-should-only-be-a-start 2019-09-03T20:47:06 https://maestrodatabase.com/blog/northland-cancer-workers-patients-welcome-new-agency-and-drug-funding 2019-09-03T20:44:04 https://maestrodatabase.com/blog/the-fda-and-sarepta-a-window-into-the-real-world-of-drug-regulation 2019-09-03T11:37:21 https://maestrodatabase.com/blog/2020-seasonal-influenza-vaccines 2020-03-16T02:45:30 https://maestrodatabase.com/blog/price-rises-above-inflation-already-standard-for-drugs 2019-09-03T21:05:27 https://maestrodatabase.com/blog/women-report-worse-side-effects-after-a-covid-19-vaccine 2021-03-08T20:40:39 https://maestrodatabase.com/blog/320-dollars-a-night-to-stay-in-a-public-hospital-after-two-funds-slash-rebate 2019-09-03T21:00:56 https://maestrodatabase.com/blog/u-dot-s-fda-grants-fast-track-designation-to-three-passage-bio-gene-therapy-candidates-targeting-rare-cns-disorders 2021-03-08T20:56:18 https://maestrodatabase.com/blog/accc-sues-medibank-for-incorrectly-rejecting-health-insurance-claims 2019-09-03T20:56:36 https://maestrodatabase.com/blog/how-a-drug-company-made-114-dollars-billion-by-gaming-the-us-patent-system 2023-01-29T08:10:23 https://maestrodatabase.com/blog/more-than-half-pay-top-dollar-for-health-insurance 2019-09-03T20:54:07 https://maestrodatabase.com/blog/mylan-and-biocon-get-a-second-complete-response-letter-for-insulin-glargine-follow-on 2019-09-03T21:17:27 https://maestrodatabase.com/blog/luye-pharma-announces-us-fda-approval-of-erzofri-paliperidone-palmitate-extended-release-injectable-suspension-for-treating-schizophrenia-and-schizoaffective-disorder 2024-07-29T05:15:46 https://maestrodatabase.com/blog/fda-takes-further-steps-to-streamline-biosimilar-development-and-make-medicines-more-affordable 2026-03-09T21:17:12 https://maestrodatabase.com/blog/janssen-announces-u-dot-s-fda-breakthrough-therapy-designation-for-investigational-prophylactic-vaccine-for-the-prevention-of-respiratory-syncytial-virus-in-older-adults 2019-09-03T21:09:04 https://maestrodatabase.com/blog/medicare-bulk-billing-rates-at-all-time-high 2021-09-20T02:58:14 https://maestrodatabase.com/blog/eu-panel-rejects-pfizers-tanezumab-for-osteoarthritis-pain 2021-09-20T03:02:51 https://maestrodatabase.com/blog/decision-to-widen-access-to-various-anti-infectives 2017-12-12T01:24:39 https://maestrodatabase.com/blog/carvykti-ciltacabtagene-autoleucel-granted-conditional-approval-by-the-european-commission-for-the-treatment-of-patients-with-relapsed-and-refractory-multiple-myeloma 2022-05-27T10:10:52 https://maestrodatabase.com/blog/precision-biosciences-receives-fda-fast-track-sesignation-for-pbgene-dmd 2026-03-09T23:43:21 https://maestrodatabase.com/blog/biden-has-confidence-in-the-fda-and-its-commissioner-white-house-says 2022-05-27T10:03:05 https://maestrodatabase.com/blog/fixed-duration-calquence-based-regimens-recommended-for-approval-in-the-eu-by-chmp-for-first-line-chronic-lymphocytic-leukaemia 2025-04-29T07:28:02 https://maestrodatabase.com/blog/hiv-drug-prep-to-be-available-across-england 2020-03-16T05:43:08 https://maestrodatabase.com/blog/lilly-receives-fda-breakthrough-therapy-designation-for-baricitinib-for-the-treatment-of-alopecia-areata 2020-03-16T20:10:40 https://maestrodatabase.com/blog/covid-19-medicine-vaccine-supply-disruptions-likely---pharmac 2020-03-16T05:54:25 https://maestrodatabase.com/blog/regulatory-and-health-technology-assessment-advice-on-post-licensing-and-post-launch-evidence-generation-is-a-foundation-for-lifecycle-data-collection-for-medicines 2020-03-16T20:27:16 https://maestrodatabase.com/blog/inotrem-announces-fast-track-designation-granted-by-u-dot-s-fda-to-nangibotide-development-program-for-the-treatment-of-septic-shock 2019-09-04T06:44:32 https://maestrodatabase.com/blog/nice-hits-keytruda-with-no-for-urothelial-cancer 2020-03-16T20:18:54 https://maestrodatabase.com/blog/recommendation-made-by-the-pbac---april-2017 2017-06-03T05:22:13 https://maestrodatabase.com/blog/mps-back-nebhrajani-as-nices-new-chair-after-vetting-meeting 2020-03-16T20:16:21 https://maestrodatabase.com/blog/key-senate-committee-proposes-a-council-to-ensure-fda-better-coordinates-on-accelerated-approvals 2022-05-27T21:36:47 https://maestrodatabase.com/blog/genetx-and-ultragenyx-announce-orphan-drug-designation-and-rare-paediatric-disease-designation-for-gtx-102 2019-09-04T10:47:17 https://maestrodatabase.com/blog/a-systematic-review-of-economic-evaluations-of-advanced-therapy-medicinal-products 2020-03-16T20:41:09 https://maestrodatabase.com/blog/nice-recommends-novel-gene-therapy-treatment-for-rare-inherited-eye-disorder 2019-09-04T10:41:33 https://maestrodatabase.com/blog/medicare-bulk-billing-at-record-level 2019-09-04T07:53:31 https://maestrodatabase.com/blog/chinese-official-warns-against-u-dot-s-effort-to-limit-foreign-medicine-supplies 2020-03-16T20:31:28 https://maestrodatabase.com/blog/vertex-announces-letter-of-intent-with-pan-canadian-pharmaceutical-alliance-for-public-reimbursement-of-cftr-modulators-extended-to-include-trikafta-elexacaftor-slash-tezacaftor-slash-ivacaftor-and-ivacaftor 2021-09-20T06:48:36 https://maestrodatabase.com/blog/former-agency-heads-health-groups-push-for-fdas-sharpless-to-be-permanent-commissioner 2019-09-09T21:20:21 https://maestrodatabase.com/blog/chiesi-global-rare-diseases-and-protalix-biotherapeutics-announce-european-commission-approval-of-additional-dosing-regimen-of-every-four-weeks-for-elfabrio-pegunigalsidase-alfa 2026-03-10T02:32:13 https://maestrodatabase.com/blog/how-moves-towards-universal-health-coverage-could-encourage-poor-quality-drugs-an-essay-by-elizabeth-pisani 2019-09-04T11:29:57 https://maestrodatabase.com/blog/forty-seven-granted-fast-track-designation-for-magrolimab-for-the-treatment-of-myelodysplastic-syndrome-and-acute-myeloid-leukaemia 2019-09-04T10:54:36 https://maestrodatabase.com/blog/drug-industry-group-sues-to-stop-california-drug-price-law 2017-12-12T03:02:09 https://maestrodatabase.com/blog/siga-technologies-announces-fda-submission-of-its-new-drug-application-for-oral-tpoxx-tecovirimat-to-treat-smallpox 2017-12-12T02:29:50 https://maestrodatabase.com/blog/tlv-has-decided-to-reconsider-subsidy-restrictions-for-several-drugs 2020-03-16T20:46:45 https://maestrodatabase.com/blog/capital-rx-to-inject-transparency-in-prescription-drug-prices 2019-09-04T21:08:44 https://maestrodatabase.com/blog/pharmacy-face-off-chemist-warehouses-push-to-provide-free-prescription-medicine 2019-09-04T21:04:19 https://maestrodatabase.com/blog/medicare-premium-increase-from-alzheimers-drug-to-be-lowered-next-year 2022-05-27T22:12:10 https://maestrodatabase.com/blog/regeneron-announces-fda-acceptance-of-sbla-filing-for-12-week-dosing-of-eylea-aflibercept-injection-for-patients-with-wet-amd 2017-12-12T03:05:20 https://maestrodatabase.com/blog/four-cancers-10-years-thames-man-launches-petition-for-life-saving-drug 2019-09-04T20:55:27 https://maestrodatabase.com/blog/health-canada-updates-its-biosimilar-fact-sheet 2019-09-04T21:26:55 https://maestrodatabase.com/blog/releasing-the-potential-of-real-world-evidence 2019-09-04T21:22:49 https://maestrodatabase.com/blog/nhs-funds-eye-gene-therapy-after-novartis-cuts-ps613-000-price 2019-09-04T21:18:07 https://maestrodatabase.com/blog/ndp-promises-to-restore-special-drugs-program 2019-09-04T21:35:03 https://maestrodatabase.com/blog/manitoba-liberals-promise-to-opt-into-national-pharmacare-program 2019-09-04T21:31:57 https://maestrodatabase.com/blog/koselugo-approved-in-canada-for-plexiform-neurofibromas-in-adults-with-neurofibromatosis-type-1 2026-03-10T02:49:11 https://maestrodatabase.com/blog/u-dot-s-food-and-drug-administration-accepts-for-priority-review-bristol-myers-squibbs-application-for-lag-3-blocking-antibody-relatlimab-and-nivolumab-fixed-dose-combination-as-treatment-for-patients-with-unresectable-or-metastatic-melanoma 2021-09-20T20:21:08 https://maestrodatabase.com/blog/cabozantinib-maleate-for-previously-treated-adults-with-advanced-differentiated-thyroid-cancer-that-is-unsuitable-for-or-refractory-to-radioactive-iodine 2023-11-01T07:28:14 https://maestrodatabase.com/blog/immunitybio-announces-resubmission-of-supplemental-bla-to-the-fda-for-anktiva-plus-bcg-in-bcg-unresponsive-nmibc-with-papillary-disease-following-agency-review-of-additional-data 2026-03-10T03:53:11 https://maestrodatabase.com/blog/shortcomings-in-the-us-pharmaceutical-supply-chain-potential-risks-associated-with-international-manufacturing-and-trade-related-tariffs 2020-03-16T22:14:04 https://maestrodatabase.com/blog/magenta-therapeutics-announces-fda-regenerative-medicine-advanced-therapy-designation-granted-to-mgta-456-for-the-treatment-of-inherited-metabolic-disorders 2019-09-04T23:44:10 https://maestrodatabase.com/blog/sangamo-therapeutics-advances-rolling-submission-of-bla-to-us-fda-for-st-920-in-fabry-disease 2026-03-10T03:58:21 https://maestrodatabase.com/blog/bayers-rivaroxaban-submitted-to-u-dot-s-fda-for-approval-in-patients-with-coronary-and-slash-or-peripheral-artery-disease 2017-12-12T03:39:00 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-to-assess-treatments-for-obesity-management 2025-04-29T12:14:33 https://maestrodatabase.com/blog/rinvoq-upadacitinib-receives-us-fda-approval-for-giant-cell-arteritis 2025-04-29T11:38:31 https://maestrodatabase.com/blog/its-the-law-not-the-code---mas-director-of-ethics-and-compliance---deborah-monk 2017-12-12T04:27:48 https://maestrodatabase.com/blog/proposals-to-redesign-medicare-part-d----easing-the-burden-of-rising-drug-prices 2019-09-04T21:45:10 https://maestrodatabase.com/blog/abbvie-submits-regulatory-application-to-fda-for-risankizumab-rzaa-skyrizi-for-the-treatment-of-patients-16-years-and-older-with-moderate-to-severe-crohns-disease 2021-09-20T20:16:52 https://maestrodatabase.com/blog/empagliflozin-for-the-treatment-of-adults-with-chronic-heart-failure-with-preserved-or-mildly-reduced-ejection-fraction 2023-11-01T07:41:54 https://maestrodatabase.com/blog/paratek-pharmaceuticals-announces-the-submission-of-the-pre-emergency-use-authorisation-application-to-the-fda-for-nuzyra-omadacycline 2020-03-16T22:21:14 https://maestrodatabase.com/blog/marinus-pharmaceuticals-announces-fda-acceptance-for-filing-and-priority-review-of-new-drug-application-for-ganaxolone-in-cdkl5-deficiency-disorder 2021-09-20T20:41:53 https://maestrodatabase.com/blog/innorna-announces-fda-rare-paediatric-disease-designation-granted-to-in013-for-treatment-of-wilson-disease 2025-04-29T21:59:27 https://maestrodatabase.com/blog/fda-clears-first-technology-to-distinguish-between-bacterial-and-viral-infections-using-the-bodys-immune-response---the-memed-bv-test-and-memed-key-platform 2021-09-20T20:29:23 https://maestrodatabase.com/blog/fda-approves-first-biosimilar-to-treat-macular-degeneration-disease-and-other-eye-conditions 2021-09-20T20:35:02 https://maestrodatabase.com/blog/cstone-announces-european-commission-approval-of-sugemalimab-cejemly-as-first-line-treatment-for-non-small-cell-lung-cancer 2024-07-29T22:04:10 https://maestrodatabase.com/blog/epcoritamab-for-the-treatment-of-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-after-2-or-more-systemic-treatments 2023-11-01T09:45:41 https://maestrodatabase.com/blog/health-canada-authorizes-vabysmo-faricimab-injection-for-the-treatment-of-macular-oedema-secondary-to-retinal-vein-occlusion 2024-07-30T02:16:30 https://maestrodatabase.com/blog/melinta-therapeutics-announces-two-key-milestones-expanding-reimbursement-and-access-for-kimyrsa-oritavancin 2021-09-20T20:57:01 https://maestrodatabase.com/blog/aveo-oncology-announces-ficlatuzumab-granted-fast-track-designation-by-the-u-dot-s-fda-for-the-treatment-of-relapsed-or-recurrent-head-and-neck-squamous-cell-carcinoma 2021-09-20T21:07:32 https://maestrodatabase.com/blog/covid-19-vaccine-safety-report-27-january-2023 2023-01-29T21:35:42 https://maestrodatabase.com/blog/pfizer-receives-positive-chmp-opinion-for-conversion-of-paxlovid-conditional-marketing-authorisation-to-full-marketing-authorisation-in-the-european-union 2023-01-29T21:38:06 https://maestrodatabase.com/blog/148-dollars-million-in-new-medicare-rebates-for-genetic-testing 2023-11-01T09:40:25 https://maestrodatabase.com/blog/syndax-announces-pdufa-action-date-extension-for-revumenib-nda-for-relapsed-or-refractory-kmt2ar-acute-leukaemia 2024-07-30T01:00:04 https://maestrodatabase.com/blog/sesen-bio-submits-marketing-authorisation-application-to-the-european-medicines-agency-for-vicineum 2021-03-09T01:23:50 https://maestrodatabase.com/blog/x4-pharmaceuticals-announces-fda-acceptance-with-priority-review-of-us-nda-for-mavorixafor-in-whim-syndrome 2023-11-01T19:43:49 https://maestrodatabase.com/blog/nice-disappointed-companies-unwilling-to-offer-fair-price-to-make-enhertu-available-for-advanced-breast-cancer 2024-07-30T02:52:56 https://maestrodatabase.com/blog/icer-to-assess-treatment-for-acute-pain 2024-07-30T02:49:04 https://maestrodatabase.com/blog/tricida-announces-submission-of-new-drug-application-for-veverimer-for-the-treatment-of-metabolic-acidosis-in-patients-with-chronic-kidney-disease 2019-09-05T01:05:48 https://maestrodatabase.com/blog/alvotech-provides-update-on-fda-action-regarding-avt02-proposed-high-concentration-biosimilar-to-humira-adalimumab 2021-09-20T21:24:51 https://maestrodatabase.com/blog/hls-announces-reimbursement-for-vascepa-under-albertas-provincial-drug-plan 2024-07-30T02:34:21 https://maestrodatabase.com/blog/verrica-pharmaceuticals-receives-complete-response-letter-from-the-fda-identifying-deficiencies-at-a-facility-of-a-contract-manufacturer-for-its-new-drug-application-for-vp-102-for-the-treatment-of-molluscum-contagiosum 2021-09-20T21:17:23 https://maestrodatabase.com/blog/fda-approves-first-drug-for-eosinophilic-granulomatosis-with-polyangiitis-a-rare-disease-formerly-known-as-the-churg-strauss-syndrome 2017-12-12T19:53:42 https://maestrodatabase.com/blog/icer-to-assess-mdma-assisted-therapy-for-post-traumatic-stress-disorder 2023-11-01T19:24:04 https://maestrodatabase.com/blog/british-medical-journal-holds-up-new-zealand-pm-jacinda-ardern-as-example-of-voice-against-free-markets 2017-12-12T20:04:35 https://maestrodatabase.com/blog/novartis-scemblix-granted-fda-priority-review-for-the-treatment-of-adults-with-newly-diagnosed-cml 2024-07-30T02:22:18 https://maestrodatabase.com/blog/fda-approves-pembrolizumab-with-chemotherapy-for-biliary-tract-cancer 2023-11-01T19:28:21 https://maestrodatabase.com/blog/cancer-patients-in-new-zealand-waiting-months-for-treatment-as-hospitals-struggle-to-cope 2017-12-12T20:00:31 https://maestrodatabase.com/blog/european-commission-approves-expanded-use-of-janssens-stelara-ustekinumab-for-the-treatment-of-moderately-to-severely-active-ulcerative-colitis-in-the-european-union 2019-09-05T01:12:31 https://maestrodatabase.com/blog/mhra-authorises-litfulo-as-a-treatment-for-severe-alopecia-areata-in-adults-and-adolescents-12-years-and-older 2023-11-01T20:13:04 https://maestrodatabase.com/blog/final-nhs-no-for-obesity-pill-mysimba 2017-12-12T20:21:29 https://maestrodatabase.com/blog/government-must-place-a-higher-value-on-vaccines-and-medicines-that-deliver-long-term-benefits 2023-01-29T22:19:17 https://maestrodatabase.com/blog/submissions-for-health-insurance-premiums-increased-knocked-back 2017-12-12T20:14:41 https://maestrodatabase.com/blog/dupixent-dupilumab-approved-by-european-commission-as-the-first-and-only-targeted-medicine-indicated-for-eosinophilic-oesophagitis 2023-01-30T06:10:35 https://maestrodatabase.com/blog/abbott-receives-fda-approval-for-minimally-invasive-portico-with-flexnav-tavr-system-to-treat-patients-with-aortic-valve-disease 2021-09-20T21:53:03 https://maestrodatabase.com/blog/cstone-announces-nmpa-approval-of-sugemalimab-for-patients-with-relapsed-or-refractory-extranodal-nk-slash-t-cell-lymphoma-the-first-anti-pd-1-slash-pd-l1-mab-approved-for-this-indication 2023-11-01T20:07:10 https://maestrodatabase.com/blog/indivior-announces-nda-acceptance-of-rbp-7000-risperidone-monthly-depot 2017-12-12T20:27:32 https://maestrodatabase.com/blog/seagen-and-genmab-announce-fda-accelerated-approval-for-tivdak-tisotumab-vedotin-tftv-in-previously-treated-recurrent-or-metastatic-cervical-cancer 2021-09-20T21:35:45 https://maestrodatabase.com/blog/landmark-listing-of-first-three-countries-as-who-listed-regulatory-authorities 2023-11-01T19:51:25 https://maestrodatabase.com/blog/ema-publishes-agenda-for-11-14-december-chmp-meeting 2017-12-12T20:41:51 https://maestrodatabase.com/blog/medicare-drug-price-negotiation----why-now-and-how 2019-09-05T02:20:04 https://maestrodatabase.com/blog/bringing-early-feasibility-studies-for-medical-devices-back-to-the-united-states 2017-12-12T20:49:18 https://maestrodatabase.com/blog/32-dollars-million-available-to-support-vital-translational-health 2019-09-05T02:16:59 https://maestrodatabase.com/blog/sandoz-receives-positive-chmp-opinion-for-citrate-free-high-concentration-formulation-of-adalimumab-biosimilar 2023-01-30T06:57:28 https://maestrodatabase.com/blog/lecanemab-receives-priority-review-status-in-japan 2023-01-30T06:48:42 https://maestrodatabase.com/blog/medicare-bulk-billing-strengthened-as-largest-investment-in-40-years-takes-effect 2023-11-01T20:25:34 https://maestrodatabase.com/blog/incyclix-bio-granted-us-fda-fast-track-designation-for-inx-315-to-treat-ccne1-amplified-platinum-resistant-slash-refractory-ovarian-cancer 2025-04-29T23:11:51 https://maestrodatabase.com/blog/fda-approves-novartis-kymriah-car-t-cell-therapy-for-adult-patients-with-relapsed-or-refractory-follicular-lymphoma 2022-05-28T00:04:04 https://maestrodatabase.com/blog/argenx-receives-notification-of-pdufa-date-extension-for-sc-efgartigimod 2023-01-30T07:34:05 https://maestrodatabase.com/blog/aurinia-pharmaceuticals-initiates-rolling-submission-of-a-new-drug-application-to-the-u-dot-s-food-and-drug-administration-for-voclosporin-in-the-treatment-of-lupus-nephritis 2020-03-16T23:19:00 https://maestrodatabase.com/blog/bioinvent-receives-fda-fast-track-designation-for-bi-1808-for-the-treatment-of-cutaneous-t-cell-lymphoma 2025-04-29T23:49:43 https://maestrodatabase.com/blog/affyimmune-receives-fda-regenerative-medicine-advanced-therapy-designation-for-aic100-in-recurrent-anaplastic-thyroid-cancer 2024-07-30T07:12:05 https://maestrodatabase.com/blog/u-dot-s-fda-declines-to-approve-eton-pharmas-anti-seizure-drug 2022-05-28T02:40:49 https://maestrodatabase.com/blog/altrubios-neihulizumab-granted-fast-track-designation-by-the-fda-for-steroid-refractory-acute-graft-versus-host-disease 2021-03-09T04:29:38 https://maestrodatabase.com/blog/amneal-achieves-third-u-dot-s-biosimilar-approval-with-fylnetra-pegfilgrastim-pbbk 2022-05-28T03:05:06 https://maestrodatabase.com/blog/where-is-the-pharmac-review 2022-05-28T02:53:56 https://maestrodatabase.com/blog/u-dot-s-food-and-drug-administration-approves-two-opdivo-nivolumab-based-regimens-as-first-line-treatments-for-unresectable-advanced-or-metastatic-oesophageal-squamous-cell-carcinoma 2022-05-28T02:29:42 https://maestrodatabase.com/blog/roche-granted-fda-breakthrough-device-designation-for-first-ai-driven-companion-diagnostic-for-non-small-cell-lung-cancer 2025-04-30T00:29:51 https://maestrodatabase.com/blog/achieving-patient-centeredness-in-medicares-new-drug-price-negotiation-program 2023-01-30T07:56:19 https://maestrodatabase.com/blog/vertex-announces-fda-acceptance-of-new-drug-application-for-suzetrigine-for-the-treatment-of-moderate-to-severe-acute-pain 2024-07-30T21:32:44 https://maestrodatabase.com/blog/european-commission-approves-roches-vabysmo-for-treatment-of-retinal-vein-occlusion 2024-07-30T21:26:55 https://maestrodatabase.com/blog/alpha-cognitions-oral-therapy-zunveyl-receives-fda-approval-to-treat-alzheimers-disease 2024-07-30T11:58:41 https://maestrodatabase.com/blog/pfizer-hikes-u-dot-s-prices-of-91-drugs-by-average-20-percent-in-2017 2017-06-04T00:05:06 https://maestrodatabase.com/blog/life-sciences-industry-calls-for-better-funding-for-medicine-and-technology-regulator 2023-01-30T19:45:13 https://maestrodatabase.com/blog/moderna-granted-fda-breakthrough-therapy-designation-for-mrna-1345-an-investigational-respiratory-syncytial-virus-vaccine-candidate 2023-01-30T19:52:14 https://maestrodatabase.com/blog/fda-accepts-telix-nda-for-new-prostate-cancer-imaging-agent 2024-07-30T21:53:12 https://maestrodatabase.com/blog/merck-receives-accelerated-approval-of-keytruda-pembrolizumab-the-first-fda-approved-anti-pd-1-therapy 2017-06-04T01:11:40 https://maestrodatabase.com/blog/us-fda-approves-zevaskyn-prademagene-zamikeracel-the-first-and-only-cell-based-gene-therapy-for-patients-with-recessive-dystrophic-epidermolysis-bullosa 2025-04-30T00:51:09 https://maestrodatabase.com/blog/viiv-healthcare-submits-regulatory-applications-for-the-first-hiv-maintenance-regimen-comprising-only-two-medicines 2017-06-04T01:18:14 https://maestrodatabase.com/blog/smc---april-2025-decisions 2025-04-30T01:23:42 https://maestrodatabase.com/blog/rhythm-pharmaceuticals-completes-submission-of-supplemental-new-drug-application-to-u-dot-s-food-and-drug-administration-for-imcivree-setmelanotide-for-the-treatment-of-obesity-and-control-of-hunger-in-bardet-biedl-and-alstroem-syndromes 2021-09-21T05:12:55 https://maestrodatabase.com/blog/junshi-biosciences-announces-approval-for-marketing-of-vv116-in-china 2023-01-30T20:07:03 https://maestrodatabase.com/blog/nanoscope-therapeutics-receives-fast-track-designation-by-the-fda-for-mco-010-for-the-treatment-of-stargardt-disease 2023-01-30T19:59:06 https://maestrodatabase.com/blog/amazons-bold-5-dollars-prescription-drug-program-is-the-future-of-pharmacy 2023-01-30T20:39:24 https://maestrodatabase.com/blog/us-law-makers-call-on-biden-administration-to-lower-the-price-of-enzalutamide 2023-01-30T20:24:01 https://maestrodatabase.com/blog/why-drug-makers-have-raised-prices-on-nearly-1-000-drugs-so-far-this-year 2023-01-30T20:27:21 https://maestrodatabase.com/blog/alpha-biopharma-submits-new-drug-application-for-zorifertinib-a-next-generation-egfr-tki-to-treat-egfr-mutated-nsclc-patients-with-cns-metastases 2023-01-30T20:14:39 https://maestrodatabase.com/blog/pharmac-funding-boost-gives-hope-to-many-too-late-for-some 2019-09-05T08:20:50 https://maestrodatabase.com/blog/request-for-proposals---supply-of-adalimumab 2021-03-09T06:03:52 https://maestrodatabase.com/blog/fda-approves-daratumumab-and-hyaluronidase-fihj-with-bortezomib-lenalidomide-and-dexamethasone-for-multiple-myeloma 2024-07-30T22:36:51 https://maestrodatabase.com/blog/agenda-for-7-june-2017-tc-meeting 2017-06-04T03:01:39 https://maestrodatabase.com/blog/ema-approves-bio-thera-solutions-bat1706-avzivi-bevacizumab-a-biosimilar-referencing-avastin 2024-07-31T11:05:16 https://maestrodatabase.com/blog/fda-approves-first-treatment-for-patients-with-cerebral-folate-transport-deficiency 2026-03-10T22:23:48 https://maestrodatabase.com/blog/ptc-therapeutics-announces-sepiapterin-nda-submission-to-fda 2024-07-31T10:57:16 https://maestrodatabase.com/blog/measuring-value-and-benefit--a-matter-of-perspective 2017-06-04T07:15:51 https://maestrodatabase.com/blog/nhs-patients-gain-access-to-covid-19-treatment-ronapreve 2021-09-21T08:43:50 https://maestrodatabase.com/blog/national-immunisation-program---changes-to-shingles-vaccination-from-today 2023-11-02T01:38:09 https://maestrodatabase.com/blog/european-commission-approves-mercks-keytruda-pembrolizumab-in-combination-with-inlyta-axitinib-as-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma 2019-09-05T11:33:06 https://maestrodatabase.com/blog/canberra-girl-with-cystic-fibrosis-lobbies-the-federal-government-to-give-all-access-to-the-drug-orkambi 2017-06-04T11:19:26 https://maestrodatabase.com/blog/rationales-of-delay-and-difference-in-regulatory-review-by-japan-the-usa-and-europe-among-new-drugs-first-approved-in-japan 2021-03-09T06:32:13 https://maestrodatabase.com/blog/nice-rejects-azs-lynparza-for-metastatic-prostate-cancer 2021-03-09T10:34:47 https://maestrodatabase.com/blog/abbisko-therapeutics-announces-that-us-fda-has-granted-breakthrough-therapy-designation-for-its-csf-1r-inhibitor-pimicotinib-absk021 2023-01-30T23:37:09 https://maestrodatabase.com/blog/roche-receives-fda-approval-for-ventana-alk-d5f3-cdx-assay-to-identify-lung-cancer-patients-eligible-for-targeted-treatment-with-lorbrena-lorlatinib 2021-03-09T10:47:28 https://maestrodatabase.com/blog/redxs-rxc008-granted-us-fda-fast-track-designation-for-fibrostenotic-crohns-disease 2026-03-10T23:33:30 https://maestrodatabase.com/blog/cutting-edge-cancer-treatment-research-heading-offshore-as-local-patients-miss-out 2026-03-10T23:37:10 https://maestrodatabase.com/blog/pfizer-covid-vaccine-states-agree-to-secrecy-over-unused-jabs 2021-03-09T20:22:32 https://maestrodatabase.com/blog/americans-increasingly-turn-to-pharmacists-for-help-finding-affordable-drugs-new-study-shows 2021-03-09T20:35:17 https://maestrodatabase.com/blog/sun-pharma-announces-drizalma-sprinkle-duloxetine-delayed-release-capsules-is-now-covered-by-most-medicare-part-d-plans 2021-03-09T20:39:17 https://maestrodatabase.com/blog/acadia-pharmaceuticals-provides-regulatory-update-on-supplemental-new-drug-application-for-pimavanserin-for-the-treatment-of-hallucinations-and-delusions-associated-with-dementia-related-psychosis 2021-03-09T19:58:39 https://maestrodatabase.com/blog/a-bipartisan-effort-states-pass-record-number-of-laws-to-reel-in-drug-prices 2019-09-05T12:04:13 https://maestrodatabase.com/blog/hhs-secretary-becerras-statement-on-the-fdas-approval-of-wezlana 2023-11-02T02:46:18 https://maestrodatabase.com/blog/alnylam-completes-submission-of-new-drug-application-to-u-dot-s-fda-for-patisiran-for-the-treatment-of-hereditary-attr-amyloidosis 2017-12-13T00:22:55 https://maestrodatabase.com/blog/update-on-revised-process-for-biosimilars 2017-12-13T00:19:20 https://maestrodatabase.com/blog/pandemic-forces-fda-to-sharply-curtail-drug-company-inspections 2021-03-09T20:15:01 https://maestrodatabase.com/blog/medicare-drug-price-negotiation-in-the-united-states-implications-and-unanswered-questions 2023-01-31T04:12:56 https://maestrodatabase.com/blog/teva-and-celltrion-healthcare-announce-u-dot-s-availability-of-herzuma-trastuzumab-pkrb-for-injection 2020-03-17T04:39:10 https://maestrodatabase.com/blog/u-dot-s-judge-approves-cvs-purchase-of-insurer-aetna 2019-09-05T21:01:27 https://maestrodatabase.com/blog/texas-doctor-stephen-m-hahn-is-a-top-contender-to-head-fda 2019-09-05T20:59:08 https://maestrodatabase.com/blog/bidens-silence-on-an-fda-nominee-underscores-how-tough-it-is-to-fill-that-job 2021-03-09T20:45:56 https://maestrodatabase.com/blog/health-canada-approves-ultomiris-for-adults-with-neuromyelitis-optica-spectrum-disorder 2023-11-02T04:10:44 https://maestrodatabase.com/blog/fda-notes-continued-growth-of-orbis-collaborative-review-program-adds-ema-as-observer 2023-11-02T03:49:24 https://maestrodatabase.com/blog/international-price-comparison-of-medicines-2022 2023-01-31T11:20:06 https://maestrodatabase.com/blog/fda-provides-transparency-and-clarity-on-the-humanitarian-device-exemption-pathway-helping-bring-more-life-saving-medical-devices-to-patients-in-need 2019-09-05T21:26:22 https://maestrodatabase.com/blog/is-the-fda-out-to-get-this-2-dollars-9-cents-billion-diabetes-drug-class 2019-09-05T21:21:15 https://maestrodatabase.com/blog/call-for-enhertu-to-be-registered-on-pharmaceutical-benefits-scheme 2023-01-31T11:24:36 https://maestrodatabase.com/blog/achieve-life-sciences-announces-fda-grants-breakthrough-therapy-designation-to-cytisinicline-for-the-treatment-of-e-cigarette-or-vaping-nicotine-dependence 2024-08-01T00:38:23 https://maestrodatabase.com/blog/association-between-pre-approval-confirmatory-trial-initiation-and-conversion-to-traditional-approval-or-withdrawal-in-the-fda-accelerated-approval-pathway 2023-01-31T06:08:41 https://maestrodatabase.com/blog/gbt-announces-u-dot-s-fda-acceptance-of-new-drug-application-and-priority-review-for-voxelotor-for-the-treatment-of-sickle-cell-disease 2019-09-05T21:04:31 https://maestrodatabase.com/blog/immuneering-granted-fda-fast-track-designation-for-imm-1-104-in-first-line-pancreatic-cancer 2024-08-01T00:12:59 https://maestrodatabase.com/blog/erlotinib-new-exchange-groups 2020-03-17T05:40:17 https://maestrodatabase.com/blog/distribution-markups-and-taxes-for-prescription-pharmaceuticals-do-we-see-the-complete-picture-of-the-pharmaceutical-price 2023-01-31T05:47:13 https://maestrodatabase.com/blog/tagrisso-approved-in-china-as-a-first-line-treatment-for-egfr-mutated-non-small-cell-lung-cancer 2019-09-05T21:32:08 https://maestrodatabase.com/blog/what-is-the-value-of-market-wide-health-care-price-transparency 2019-09-05T21:29:32 https://maestrodatabase.com/blog/options-for-a-reformed-prostheses-list-pre-listing-assessment-framework-and-governance-structure 2023-01-31T05:06:27 https://maestrodatabase.com/blog/fda-may-not-always-require-post-approval-trials-to-be-enrolled-before-accelerated-approvals 2023-01-31T05:10:33 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-february-2023 2023-01-31T19:58:49 https://maestrodatabase.com/blog/fda-approves-lexette-for-adolescent-plaque-psoriasis 2021-09-21T20:19:22 https://maestrodatabase.com/blog/a-watershed-year-for-biosimilars----if-regulators-and-policy-makers-step-up 2023-01-31T20:08:20 https://maestrodatabase.com/blog/fda-authorises-software-that-can-help-identify-prostate-cancer 2021-09-21T20:22:31 https://maestrodatabase.com/blog/life-changing-cancer-treatment-jab-added-to-pbs 2024-08-01T02:22:10 https://maestrodatabase.com/blog/ionis-receives-fda-fast-track-designation-for-olezarsen-in-patients-with-familial-chylomicronaemia-syndrome 2023-01-31T19:54:34 https://maestrodatabase.com/blog/ridiculous-to-force-women-to-visit-gp-for-a-repeat-pill-prescription-pharmacists-say 2019-09-05T21:36:34 https://maestrodatabase.com/blog/reneo-pharmaceuticals-receives-fast-track-designation-from-the-fda-for-mavodelpar-ren001-in-a-genotype-of-long-chain-fatty-acid-oxidation-disorder 2023-01-31T19:39:55 https://maestrodatabase.com/blog/prestige-biopharmas-herceptin-biosimilar-tuznue-receives-positive-chmp-opinion-from-the-ema 2024-08-01T02:02:19 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-february-2023 2023-01-31T19:45:28 https://maestrodatabase.com/blog/amjevita-adalimumab-atto-first-biosimilar-to-humira-now-available-in-the-united-states 2023-01-31T11:44:03 https://maestrodatabase.com/blog/msac-publishes-agenda-for-november-2024-msac-meeting 2024-08-01T01:45:58 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-august-2024 2024-08-01T00:48:33 https://maestrodatabase.com/blog/new-parkinsons-disease-treatment-added-to-pbs 2023-02-01T02:16:57 https://maestrodatabase.com/blog/ivosidenib-for-the-treatment-of-patients-with-advanced-idh1-mutation-positive-cholangiocarcinoma-after-at-least-one-line-of-treatment 2023-11-02T08:53:22 https://maestrodatabase.com/blog/u-dot-s-food-and-drug-administration-reasoning-in-approval-decisions-when-efficacy-evidence-is-borderline-2013-2018 2021-09-21T20:52:39 https://maestrodatabase.com/blog/seqirus-announces-u-dot-s-fda-approval-of-expanded-age-indication-of-its-cell-based-quadrivalent-influenza-vaccine-for-people-two-years-of-age-and-older 2021-03-09T23:14:10 https://maestrodatabase.com/blog/incyte-announces-u-dot-s-fda-approval-of-opzelura-ruxolitinib-cream-a-topical-jak-inhibitor-for-the-treatment-of-atopic-dermatitis 2021-09-21T20:59:49 https://maestrodatabase.com/blog/use-of-clinical-trials-information-system-becomes-mandatory-for-new-clinical-trial-applications-in-the-eu 2023-02-01T02:14:05 https://maestrodatabase.com/blog/phathom-pharmaceuticals-announces-fda-approval-of-voquenza-vonoprazan-tablets-for-the-treatment-of-erosive-gerd-and-relief-of-heartburn-associated-with-erosive-gerd-in-adults 2023-11-02T07:49:56 https://maestrodatabase.com/blog/lilly-announces-procurement-agreement-with-european-commission-to-supply-bamlanivimab-and-etesevimab-together-for-the-treatment-of-confirmed-covid-19 2021-09-21T20:37:46 https://maestrodatabase.com/blog/us-health-care-from-a-global-perspective-2022-accelerating-spending-worsening-outcomes 2023-01-31T20:24:14 https://maestrodatabase.com/blog/eu-hta-regulation-methodical-preparations-for-implementation-start-with-iqwig-and-g-ba 2021-09-21T20:30:33 https://maestrodatabase.com/blog/chmp-recommends-rybrevant-amivantamab-in-combination-with-chemotherapy-for-the-treatment-of-adult-patients-with-advanced-egfr-mutated-non-small-cell-lung-cancer-after-failure-of-prior-therapy 2024-08-01T02:50:34 https://maestrodatabase.com/blog/covid-19-delta-outbreak-major-pharmac-review-report-delayed-by-lockdown 2021-09-21T20:42:28 https://maestrodatabase.com/blog/omeros-corporation-announces-fda-approval-of-omidria-for-use-in-paediatric-patients 2017-12-13T01:07:09 https://maestrodatabase.com/blog/jazz-pharmaceuticals-receives-nice-recommendation-for-the-reimbursement-of-epidyolex-cannabidiol-for-the-treatment-of-seizures-associated-with-tuberous-sclerosis-complex-in-england 2023-01-31T20:18:12 https://maestrodatabase.com/blog/new-concentrated-insulin-approved-and-available-for-canadian-patients 2017-12-13T01:17:20 https://maestrodatabase.com/blog/rhythm-pharmaceuticals-receives-positive-cadth-reimbursement-recommendation-for-imcivree-setmelanotide 2023-11-02T19:16:12 https://maestrodatabase.com/blog/australia-eyes-pfizers-covid-19-vaccines-for-kids-aged-5-to-11 2021-09-21T21:27:30 https://maestrodatabase.com/blog/the-fda-and-modernas-cosy-relationship-how-lax-rules-enable-a-revolving-door-culture 2023-11-02T11:14:55 https://maestrodatabase.com/blog/edmonton-woman-begs-alberta-to-cover-life-changing-$250k-cystic-fibrosis-drug 2017-12-13T01:21:17 https://maestrodatabase.com/blog/rocket-pharmaceuticals-receives-fda-regenerative-medicine-advanced-therapy-designation-for-rp-l201-gene-therapy-for-leukocyte-adhesion-deficiency-i 2021-03-09T23:20:59 https://maestrodatabase.com/blog/inventiva-announces-fda-decision-that-fast-track-designation-granted-to-lanifibranor-in-nash-encompasses-the-treatment-of-nash-with-compensated-cirrhosis 2021-09-21T21:04:34 https://maestrodatabase.com/blog/launch-of-the-australian-cancer-plan 2023-11-02T10:56:44 https://maestrodatabase.com/blog/stage-2-pbs-process-improvements---resubmission-pathways-webinar 2021-03-09T23:48:15 https://maestrodatabase.com/blog/bluebird-bio-submits-biologics-license-application-to-fda-for-betibeglogene-autotemcel-beti-cel-gene-therapy-for-patients-with-b-thalassaemia-who-require-regular-red-blood-cell-transfusions 2021-09-21T21:18:43 https://maestrodatabase.com/blog/bionets-recombinant-pertussis-vaccine-submitted-to-ema 2024-08-01T05:40:51 https://maestrodatabase.com/blog/changes-applying-to-evaluation-of-new-substances-for-listed-medicines 2023-02-01T02:32:49 https://maestrodatabase.com/blog/nectero-medical-granted-breakthrough-therapy-designation-for-the-nectero-east-system-to-treat-infrarenal-aaa 2023-11-02T09:00:41 https://maestrodatabase.com/blog/upadacitinib-monohydrate-for-the-treatment-of-patients-with-active-non-radiographic-axial-spondyloarthritis 2023-02-01T10:59:58 https://maestrodatabase.com/blog/first-targeted-treatment-made-available-for-hundreds-of-blood-cancer-patients-on-the-nhs 2024-08-01T07:16:48 https://maestrodatabase.com/blog/somatrogon-for-treating-growth-disturbance-in-people-3-years-and-over 2023-02-01T19:53:19 https://maestrodatabase.com/blog/tecvayli-teclistamab-monotherapy-application-submitted-to-the-ema-for-relapsed-slash-refractory-multiple-myeloma-after-at-least-one-prior-therapy 2026-03-11T05:52:01 https://maestrodatabase.com/blog/mesoblast-resubmits-biologic-license-application-to-fda-for-remestemcel-l-in-children-with-steroid-refractory-acute-graft-versus-host-disease 2023-02-01T19:48:36 https://maestrodatabase.com/blog/artiva-biotherapeutics-receives-fda-fast-track-designation-for-ab-101 2023-02-01T11:28:39 https://maestrodatabase.com/blog/trastuzumab-deruxtecan-for-treating-her2-positive-unresectable-or-metastatic-breast-cancer-after-one-or-more-anti-her2-treatments 2023-02-01T12:04:35 https://maestrodatabase.com/blog/making-a-new-vaccine-is-not-a-race-it-is-a-lottery 2020-03-17T10:50:44 https://maestrodatabase.com/blog/insurers-cover-fewer-drugs-leaving-some-patients-struggling-to-get-needed-treatments 2020-03-17T20:16:06 https://maestrodatabase.com/blog/nice-publishes-its-first-medtech-briefing-on-artificial-intelligence-software 2020-03-17T19:57:25 https://maestrodatabase.com/blog/supernus-announces-spn-830-apomorphine-infusion-device-nda-accepted-for-review-by-fda 2023-11-02T20:28:37 https://maestrodatabase.com/blog/simceres-covid-19-pill-goes-on-sale-in-china-at-less-than-half-the-price-of-pfizers-paxlovid 2023-02-01T20:28:21 https://maestrodatabase.com/blog/generic-identity-gets-lost-when-companies-juggle-both-generic-and-brand-drugs 2020-03-17T20:26:59 https://maestrodatabase.com/blog/nintedanib-esylate-for-the-treatment-of-adults-with-idiopathic-pulmonary-fibrosis-when-forced-vital-capacity-is-above-80-percent-predicted 2023-02-01T20:10:00 https://maestrodatabase.com/blog/fda-provides-more-regulatory-relief-during-outbreak-continues-to-help-expedite-availability-of-diagnostics 2020-03-17T20:20:23 https://maestrodatabase.com/blog/abpi-response-to-new-mhra-fees-announced-for-1-april-2023 2023-02-01T20:07:06 https://maestrodatabase.com/blog/lenz-therapeutics-announces-submission-of-marketing-authorisation-application-to-the-ema-for-vizz-for-the-treatment-of-presbyopia 2026-03-11T05:32:34 https://maestrodatabase.com/blog/when-can-fda-refuse-to-file-ndas-and-blas-new-draft-guidance-explains 2017-12-13T03:08:18 https://maestrodatabase.com/blog/mass-shipment-of-testing-kits-arrives-as-government-pleads-for-supplies 2020-03-17T20:30:32 https://maestrodatabase.com/blog/johnson-and-johnson-receives-fda-approval-for-imaavy-nipocalimab-aahu-a-new-fcrn-blocker-offering-long-lasting-disease-control-in-the-broadest-population-of-people-living-with-generalized-myasthenia-gravis 2025-04-30T21:23:02 https://maestrodatabase.com/blog/flag-therapeutics-receives-rare-paediatric-disease-designation-for-flag-003-for-the-treatment-of-children-with-diffuse-intrinsic-pontine-glioma 2023-02-01T20:41:42 https://maestrodatabase.com/blog/mark-cuban-cost-plus-drug-company-and-oncopower-team-up-to-bring-medication-adherence-and-cost-savings-to-cancer-patients 2023-02-01T20:37:30 https://maestrodatabase.com/blog/introducing-a-new-way-of-prioritising-our-guidance-topics 2024-08-01T11:10:50 https://maestrodatabase.com/blog/pharmac-closes-inactive-medicine-applications-for-greater-clarity 2024-08-01T11:06:12 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-august-2024 2024-08-01T10:57:35 https://maestrodatabase.com/blog/pharmac-to-fund-life-changing-treatments-for-children-with-cystic-fibrosis 2026-03-11T06:32:13 https://maestrodatabase.com/blog/accelerated-approval-unfulfilled-promises-for-fdas-expedited-review-program 2022-05-29T02:35:21 https://maestrodatabase.com/blog/corvus-pharmaceuticals-granted-fda-fast-track-designation-for-soquelitinib-for-treatment-of-patients-with-relapsed-or-refractory-peripheral-t-cell-lymphoma 2024-08-01T23:14:05 https://maestrodatabase.com/blog/fda-approves-first-oral-treatment-for-anaemia-caused-by-chronic-kidney-disease-for-adults-on-dialysis 2023-02-02T00:17:09 https://maestrodatabase.com/blog/sanbio-obtains-marketing-approval-for-akuugo-suspension-for-intracranial-implantation-vandefitemcel-as-a-therapeutic-agent-for-improving-chronic-motor-paralysis-from-traumatic-brain-injury 2024-08-01T22:57:15 https://maestrodatabase.com/blog/guardant-healths-fda-approved-shield-blood-test-now-commercially-available-in-us-as-a-primary-screening-option-for-colorectal-cancer 2024-08-01T23:51:30 https://maestrodatabase.com/blog/q32-bio-announces-fda-fast-track-designation-granted-to-bempikibart-adx-914-for-the-treatment-of-alopecia-areata 2025-04-30T23:28:37 https://maestrodatabase.com/blog/200-women-dead-100-more-may-follow-in-wait-for-cancer-drug-decision 2019-09-06T22:29:29 https://maestrodatabase.com/blog/professor-john-skerritt-retirement 2023-02-02T06:55:28 https://maestrodatabase.com/blog/cigna-rolls-out-new-plan-to-fully-cover-multi-million-dollar-gene-therapies 2019-09-06T05:58:21 https://maestrodatabase.com/blog/nordimet-methotrexate-self-injection-pen-now-available-in-canada-for-treatment-of-rheumatoid-arthritis-and-psoriasis-slash-psoriatic-arthritis 2024-08-02T01:39:17 https://maestrodatabase.com/blog/perverse-incentives---hiv-prevention-and-the-340b-drug-pricing-program 2022-05-29T08:14:51 https://maestrodatabase.com/blog/eunethta-relative-effectiveness-assessments-efforts-to-increase-usability-transparency-and-inclusiveness 2022-05-29T08:32:28 https://maestrodatabase.com/blog/capricor-therapeutics-announces-establishment-of-new-pdufa-date-for-deramiocel-bla 2026-03-11T20:12:42 https://maestrodatabase.com/blog/health-canada-approves-celltrions-steqeyma-a-biosimilar-to-stelara-ustekinumab-for-the-treatment-of-multiple-chronic-inflammatory-conditions 2024-08-02T01:33:04 https://maestrodatabase.com/blog/fda-expands-endometrial-cancer-indication-for-dostarlimab-gxly-with-chemotherapy 2024-08-01T23:57:40 https://maestrodatabase.com/blog/2-000-000-000-dollars-profit-shows-private-health-insurance-reform-needed-to-tackle-cost-of-living-crisis 2022-05-29T21:17:02 https://maestrodatabase.com/blog/atagi-update-following-weekly-covid-19-meeting-25-may-2022 2022-05-29T21:13:05 https://maestrodatabase.com/blog/application-accompanying-data-collection-in-the-case-of-market-access-for-several-active-substances-in-a-class-iqwig-presents-a-concept 2022-05-29T21:09:00 https://maestrodatabase.com/blog/tga-approves-zolgensma 2021-03-10T03:29:06 https://maestrodatabase.com/blog/calliditas-receives-conditional-marketing-authorisation-from-uk-mhra-for-kinpeygo-in-iga-nephropathy 2023-02-02T10:42:06 https://maestrodatabase.com/blog/mallinckrodt-completes-rolling-submission-of-new-drug-application-to-the-u-dot-s-fda-for-terlipressin-for-the-treatment-of-patients-with-hepatorenal-syndrome-type-1 2020-03-17T23:03:54 https://maestrodatabase.com/blog/developers-of-russian-sputnik-v-vaccine-doubt-eu-regulators-neutrality-want-apology 2021-03-10T03:24:34 https://maestrodatabase.com/blog/iron-infusions-in-the-community 2017-09-11T07:37:57 https://maestrodatabase.com/blog/obama-unwittingly-handed-trump-a-weapon-to-cripple-the-health-law 2017-06-05T03:32:42 https://maestrodatabase.com/blog/the-single-payer-party-democrats-shift-left-on-health-care 2017-06-05T03:29:56 https://maestrodatabase.com/blog/the-specialists-stranglehold-on-medicine 2017-06-05T03:41:29 https://maestrodatabase.com/blog/adverum-biotechnologies-announces-fda-regenerative-medicine-advanced-therapy-designation-granted-for-ixo-vec-for-the-treatment-of-wet-amd 2024-08-02T03:01:19 https://maestrodatabase.com/blog/the-doctor-is-in-co-pay-$40-000 2017-06-05T03:37:54 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-uvision360-submission-for-novel-luminelle-dtx-system-biopsy-sheath 2021-03-10T05:08:44 https://maestrodatabase.com/blog/european-medicines-agency-validates-pierre-fabre-laboratories-marketing-authorisation-application-for-combination-braftovi-encorafenib-and-mektovi-binimetinib-for-patients-with-braf-v600-mutant-advanced-non-small-cell-lung-cancer 2023-11-03T01:11:57 https://maestrodatabase.com/blog/enhertu-launched-as-gastric-cancer-tertiary-treatment-in-korea-insurance-benefits-loading 2023-02-02T19:51:53 https://maestrodatabase.com/blog/portola-pharmaceuticals-provides-update-on-european-marketing-authorisation-application-for-betrixaban 2017-12-13T20:19:26 https://maestrodatabase.com/blog/medexus-secures-public-reimbursement-for-cuvposa-in-quebec 2023-02-02T19:45:01 https://maestrodatabase.com/blog/fda-launches-new-tool-for-sharing-information-that-allows-doctors-to-better-manage-antibiotic-use-improve-patient-care 2017-12-13T20:09:06 https://maestrodatabase.com/blog/australias-therapeutic-goods-administration-approves-feraccru-to-treat-iron-deficiency-with-or-without-anaemia-in-adults 2021-03-10T06:11:11 https://maestrodatabase.com/blog/advanced-breast-cancer-now-a-significant-added-benefit-for-trastuzumab-deruxtecan 2023-02-02T19:35:23 https://maestrodatabase.com/blog/tezspire-approved-for-self-administration-in-the-us-with-a-new-pre-filled-pen 2023-02-02T19:39:12 https://maestrodatabase.com/blog/enough-sickness-to-share-gp-load-among-pharmacists-nurses 2023-02-02T11:05:11 https://maestrodatabase.com/blog/thousands-of-australians-waiting-for-gamechanger-cystic-fibrosis-drug 2021-09-22T04:12:58 https://maestrodatabase.com/blog/novartis-investigational-lung-cancer-therapy-capmatinib-inc280-granted-fda-breakthrough-therapy-designation-for-patients-with-met-mutated-advanced-non-small-cell-lung-cancer 2019-09-06T23:30:05 https://maestrodatabase.com/blog/pbac-updates-public-summary-document-for-medicine-without-a-published-outcome 2021-03-10T20:21:03 https://maestrodatabase.com/blog/moving-in-the-wrong-direction----health-care-under-the-ahca 2017-06-05T06:48:28 https://maestrodatabase.com/blog/a-prescription-drug-affordability-board-would-lower-prescription-costs 2023-02-02T20:04:28 https://maestrodatabase.com/blog/aveo-oncology-announces-u-dot-s-fda-approval-of-fotivda-tivozanib-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-advanced-renal-cell-carcinoma 2021-03-10T20:30:35 https://maestrodatabase.com/blog/the-first-hundred-days-for-health-care 2017-06-05T06:44:31 https://maestrodatabase.com/blog/fda-accepts-the-new-drug-application-for-review-of-idorsias-daridorexant-for-the-treatment-of-adult-patients-with-insomnia 2021-03-10T10:45:33 https://maestrodatabase.com/blog/prospects-for-health-care-reform-in-the-u-dot-s-senate 2017-06-28T21:57:12 https://maestrodatabase.com/blog/pharmac-saving-money-at-the-expense-of-kiwis-health 2021-03-10T20:04:01 https://maestrodatabase.com/blog/drug-prices-increase-5-dot-6-percent-as-government-ramps-up-pressure-to-lower-costs 2023-02-02T19:58:43 https://maestrodatabase.com/blog/vertex-announces-fda-fast-track-designation-and-initiation-of-a-phase-1-slash-2-clinical-trial-for-vx-880-a-novel-investigational-cell-therapy-for-the-treatment-of-type-1-diabetes 2021-03-10T20:10:13 https://maestrodatabase.com/blog/astrazeneca-korea-reapplies-for-lynparza-reimbursement-in-prostate-cancer 2025-05-01T05:05:41 https://maestrodatabase.com/blog/outcry-over-epipen-prices-hasnt-made-them-lower 2017-06-05T11:06:42 https://maestrodatabase.com/blog/nice-finally-publishes-final-guidance-for-aimovig 2021-03-10T20:43:14 https://maestrodatabase.com/blog/nice-publishes-updated-guidance-on-the-use-of-pembrolizumab-keytruda-for-patients-with-untreated-metastatic-non-squamous-non-small-cell-lung-cancer 2021-03-10T20:51:28 https://maestrodatabase.com/blog/ridgeback-biotherapeutics-announces-receipt-of-breakthrough-therapy-designation-from-fda-for-mab114 2019-09-07T00:16:32 https://maestrodatabase.com/blog/mounjaro-tirzepatide-the-first-and-only-single-molecule-gip-and-glp-1-receptor-agonist-for-the-treatment-of-adults-with-type-2-diabetes-is-now-available-in-canada 2023-11-03T02:00:23 https://maestrodatabase.com/blog/fda-expands-use-of-sapien-3-artificial-heart-valve-for-high-risk-patients 2017-06-05T20:40:43 https://maestrodatabase.com/blog/top-medicines-panel-benefits-from-second-consumer-representative 2017-06-05T12:34:41 https://maestrodatabase.com/blog/amgen-submits-regulatory-applications-for-repatha-evolocumab-cardiovascular-outcomes-data-in-us-and-europe 2017-06-05T20:45:32 https://maestrodatabase.com/blog/marius-pharmaceuticals-submits-kyzatrex-testosterone-undecanoate-capsules-for-approval-to-health-canada 2024-08-02T22:39:13 https://maestrodatabase.com/blog/up-to-1-000-women-a-year-could-benefit-from-new-at-home-treatment-for-endometriosis 2025-05-01T22:29:39 https://maestrodatabase.com/blog/deadline-approaching 2017-06-05T20:53:34 https://maestrodatabase.com/blog/mhra-authorises-cancer-treatment-variation-with-an-administration-time-of-3-5-minutes 2025-05-01T22:20:15 https://maestrodatabase.com/blog/cadth-publishes-final-outcome-for-gazyva-for-new-indication 2017-06-05T21:08:04 https://maestrodatabase.com/blog/primas-trial-backs-safety-of-metastatic-breast-cancer-drug 2017-06-05T21:23:55 https://maestrodatabase.com/blog/fda-approves-first-treatment-for-patients-with-rare-type-of-lung-disease 2019-09-07T01:23:31 https://maestrodatabase.com/blog/medicines-australia-welcomes-governments-covid-19-package 2020-03-18T03:51:37 https://maestrodatabase.com/blog/massachusetts-proposed-medicaid-reforms----cheaper-drugs-and-better-coverage 2017-12-13T22:47:28 https://maestrodatabase.com/blog/fda-grants-okyo-pharma-fast-track-designation-to-urcosimod-for-neuropathic-corneal-pain 2025-05-01T23:30:49 https://maestrodatabase.com/blog/quoin-pharmaceuticals-announces-fda-grants-fast-track-designation-for-qrx003-for-the-treatment-of-netherton-syndrome 2026-03-12T01:01:10 https://maestrodatabase.com/blog/fda-approves-first-gene-therapy-to-treat-adults-with-metastatic-synovial-sarcoma 2024-08-02T23:38:21 https://maestrodatabase.com/blog/health-ministry-cautious-on-timing-of-generic-drug-price-cuts-reaffirms-no-exception-principle 2026-03-12T01:05:32 https://maestrodatabase.com/blog/500-000-eligible-to-benefit-from-new-non-hormonal-treatment-for-hot-flushes-caused-by-menopause 2026-03-12T02:42:06 https://maestrodatabase.com/blog/nice-sets-out-further-details-on-menopause-guideline-update 2022-05-30T06:06:30 https://maestrodatabase.com/blog/tga-approves-leqvio 2021-09-22T09:02:58 https://maestrodatabase.com/blog/fda-approves-ruxolitinib-for-chronic-graft-versus-host-disease 2021-09-22T20:27:21 https://maestrodatabase.com/blog/dbv-technologies-provides-update-on-viaskin-peanut-bla-for-children-ages-4-11-years 2020-03-18T07:44:00 https://maestrodatabase.com/blog/nice-terminates-yet-another-appraisal-of-daratumumab 2022-02-09T04:08:49 https://maestrodatabase.com/blog/nice-terminates-yet-another-appraisal-of-a-medicine-for-multiple-myeloma 2021-09-22T20:54:09 https://maestrodatabase.com/blog/takeda-says-drug-makers-could-cut-prices-in-face-of-global-crises 2022-05-30T21:08:26 https://maestrodatabase.com/blog/first-regulatory-workshop-on-covid-19-facilitates-global-collaboration-on-vaccine-development 2020-03-18T20:02:31 https://maestrodatabase.com/blog/2022-biosimilar-awareness-week-30-may---3-june 2022-05-30T21:05:14 https://maestrodatabase.com/blog/ema-gives-advice-on-the-use-of-non-steroidal-anti-inflammatories-for-covid-19 2020-03-18T20:00:39 https://maestrodatabase.com/blog/pharmaceuticals-and-medical-devices-agencys-horizon-scanning-and-the-science-board-co-operation-toward-extracellular-vesicle-based-products 2021-09-22T21:02:15 https://maestrodatabase.com/blog/icer-indefinitely-postpones-public-meetings-for-sickle-cell-disease-and-cystic-fibrosis-expands-other-assessment-timelines-up-to-three-months 2020-03-18T20:20:35 https://maestrodatabase.com/blog/pfizer-ceo-rallies-staff-to-fight-democrats-drug-price-negotiation 2021-09-22T20:42:08 https://maestrodatabase.com/blog/hundreds-of-scientists-scramble-to-find-a-coronavirus-treatment 2020-03-18T20:16:34 https://maestrodatabase.com/blog/jubilant-radiopharma-announces-eckert-and-zieglers-galliapharm-approved-for-use-with-netspot-in-canada 2021-09-22T20:48:02 https://maestrodatabase.com/blog/coronavirus-covid-19-update-fda-issues-guidance-for-conducting-clinical-trials 2020-03-18T20:12:56 https://maestrodatabase.com/blog/illuccix-reimbursement-milestone-and-launch-updates-pass-through-status-granted-in-the-u-dot-s 2022-05-30T10:59:25 https://maestrodatabase.com/blog/arthex-biotech-granted-fda-fast-track-designation-for-atx-01-for-the-treatment-of-myotonic-dystrophy-type-1 2026-03-12T02:28:33 https://maestrodatabase.com/blog/professor-gillian-leng-cbe-appointed-as-new-nice-chief-executive 2020-03-18T20:04:56 https://maestrodatabase.com/blog/fda-approves-additional-indication-for-fibryga-for-fibrinogen-supplementation-in-bleeding-patients-with-acquired-fibrinogen-deficiency-potentially-ushering-in-a-new-standard-of-care 2024-08-03T06:23:14 https://maestrodatabase.com/blog/pfizers-alk-lung-cancer-drug-lorviqua-lands-first-line-reimbursement-in-korea 2025-05-02T00:54:26 https://maestrodatabase.com/blog/viiv-healthcare-commits-to-grant-voluntary-licence-for-patents-relating-to-cabotegravir-long-acting-for-prep-to-medicines-patent-pool 2022-05-30T21:30:49 https://maestrodatabase.com/blog/covid-19-an-update-from-dr-brian-orourke-cadth-president-and-ceo 2020-03-18T20:39:28 https://maestrodatabase.com/blog/health-insurance-faces-handbrake-under-labor-ubs 2022-05-30T21:49:10 https://maestrodatabase.com/blog/genmab-announces-u-dot-s-fda-approval-of-arzerra-ofatumumab-as-extended-treatment-for-recurrent-or-progressive-cll 2017-06-05T23:59:16 https://maestrodatabase.com/blog/access-to-cancer-medicines-deemed-essential-by-oncologists-in-82-countries-an-international-cross-sectional-survey 2021-09-22T21:24:39 https://maestrodatabase.com/blog/why-wont-the-fda-let-doctors-prescribe-fluvoxamine-for-covid 2022-05-30T21:27:05 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-bristol-myers-squibbs-application-for-opdivo-nivolumab-plus-yervoy-ipilimumab-in-intermediate-and-poor-risk-patients-with-advanced-renal-cell-carcinoma-and-grants-priority-review 2017-12-14T00:46:32 https://maestrodatabase.com/blog/bayer-submits-new-drug-application-to-us-fda-for-elinzanetant-for-the-treatment-of-moderate-to-severe-vasomotor-symptoms-associated-with-menopause 2024-08-03T06:29:30 https://maestrodatabase.com/blog/ec-approves-ryeqo-for-the-symptomatic-treatment-of-endometriosis 2023-11-03T10:40:52 https://maestrodatabase.com/blog/biohavens-verdiperstat-receives-fast-track-designation-for-the-treatment-of-multiple-system-atrophy 2020-03-18T23:17:24 https://maestrodatabase.com/blog/coronavirus-covid-19-update-fda-focuses-on-safety-of-regulated-products-while-scaling-back-domestic-inspections 2020-03-18T23:28:26 https://maestrodatabase.com/blog/panic-buying-sparks-national-shortages-of-childrens-medication 2020-03-18T23:25:49 https://maestrodatabase.com/blog/bayer-receives-fda-approval-of-mybetaapp-and-betaconnect-navigator 2017-06-06T01:16:06 https://maestrodatabase.com/blog/endo-announces-submission-of-biologics-license-application-to-fda-for-collagenase-clostridium-histolyticum-in-patients-with-cellulite 2019-09-07T04:15:49 https://maestrodatabase.com/blog/swissmedic-authorises-dengue-fever-vaccine 2024-08-03T10:56:23 https://maestrodatabase.com/blog/new-formulation-of-oncaspar-pegaspargase-receives-marketing-authorisation-in-europe-for-patients-with-acute-lymphoblastic-leukaemia 2017-12-14T01:40:18 https://maestrodatabase.com/blog/drugs-in-rare-paediatric-disease-priority-review-voucher-program-have-similar-revenue-to-brand-drugs 2024-08-03T10:53:36 https://maestrodatabase.com/blog/fda-approves-new-pfizer-biosimilar 2017-12-14T01:26:57 https://maestrodatabase.com/blog/up-to-3-000-women-to-benefit-from-pharmac-decision 2017-12-14T20:00:50 https://maestrodatabase.com/blog/cytokinetics-announces-new-pdufa-date-for-aficamten-in-obstructive-hypertrophic-cardiomyopathy 2025-05-02T04:20:42 https://maestrodatabase.com/blog/nice-changes-its-mind-on-imbruvica-for-mantle-cell-lymphoma 2017-12-14T20:12:50 https://maestrodatabase.com/blog/doh-publishes-revised-agenda-for-the-may-2025-pbac-meeting 2025-05-02T06:40:41 https://maestrodatabase.com/blog/bumper-crop-of-new-drugs-fails-to-lift-big-pharma-r-and-d-returns 2017-12-14T20:38:49 https://maestrodatabase.com/blog/report-on-the-collection-of-under-co-payment-data-2016-17 2017-12-14T20:19:42 https://maestrodatabase.com/blog/japan-to-cut-price-of-infamously-expensive-cancer-drug-again 2017-12-14T20:46:58 https://maestrodatabase.com/blog/novo-nordisk-latest-drugmaker-to-face-setback-in-ira-litigation 2024-08-03T11:06:41 https://maestrodatabase.com/blog/months-after-approval-breakthrough-cancer-drug-given-to-just-five-patients 2017-12-14T20:41:42 https://maestrodatabase.com/blog/a-bipartisan-approach-on-drug-prices-is-emerging 2017-12-14T20:52:25 https://maestrodatabase.com/blog/satsuma-pharmaceuticals-announces-us-fda-approval-for-atzumi-dihydroergotamine-nasal-powder-for-the-acute-treatment-of-migraine 2025-05-02T04:37:35 https://maestrodatabase.com/blog/transitional-arrangements-for-general-schedule-deletions-and-replacements---1-june-2017-pbs-schedule 2017-06-06T02:29:22 https://maestrodatabase.com/blog/wegovy-a-weight-loss-drug-similar-to-ozempic-will-be-sold-in-australia-from-august-5 2024-08-03T11:02:21 https://maestrodatabase.com/blog/icer-publishes-third-annual-assessment-of-barriers-to-fair-access-within-us-commercial-insurance-prescription-drug-coverage 2023-11-03T20:51:24 https://maestrodatabase.com/blog/new-steps-to-facilitate-beneficial-medical-device-innovation 2017-12-14T20:57:34 https://maestrodatabase.com/blog/experts-tell-congress-how-to-cut-drug-prices-we-give-you-some-odds 2017-12-14T20:54:37 https://maestrodatabase.com/blog/enhanced-msac-application-now-available-for-march-2023-deadline 2023-02-03T08:10:33 https://maestrodatabase.com/blog/bristol-myers-squibbs-opdivo-nivolumab-plus-yervoy-ipilimumab-regimen-receives-expanded-fda-approval-in-unresectable-or-metastatic-melanoma-across-braf-status 2017-06-06T03:14:10 https://maestrodatabase.com/blog/improved-access-to-pbs-medicines-for-pulmonary-arterial-hypertension 2023-02-03T08:12:53 https://maestrodatabase.com/blog/strengthening-medicare-for-the-future 2023-02-03T08:06:43 https://maestrodatabase.com/blog/vimkunya-vaccine-approved-to-prevent-disease-caused-by-the-chikungunya-virus-in-people-12-years-of-age-and-older 2025-05-03T01:54:16 https://maestrodatabase.com/blog/biocryst-announces-rapivab-paediatric-snda-acceptance 2017-06-06T05:13:52 https://maestrodatabase.com/blog/no-need-to-stockpile-medicines-says-ma-chief 2020-03-19T02:42:25 https://maestrodatabase.com/blog/mhra-approves-rinvoq-upadacitinib-monohydrate-as-first-oral-advanced-therapy-to-treat-adults-with-moderately-to-severely-active-crohns-disease 2023-02-03T19:54:02 https://maestrodatabase.com/blog/xbrance-provides-update-on-ranibizumab-biosimilar-candidate-fda-filing 2022-05-31T03:14:39 https://maestrodatabase.com/blog/medication-for-opioid-addiction-is-getting-easier-to-access 2023-02-03T19:46:42 https://maestrodatabase.com/blog/zai-lab-announces-nda-for-sulbactam-durlobactam-granted-priority-review-by-chinas-nmpa 2023-02-03T11:00:58 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-treatment-for-narcolepsy 2026-03-12T22:42:06 https://maestrodatabase.com/blog/fda-accepts-dupixent-dupilumab-for-priority-review-in-adults-with-prurigo-nodularis 2022-05-31T05:24:10 https://maestrodatabase.com/blog/novartis-drug-tasigna-receives-eu-approval-for-inclusion-of-treatment-free-remission-data-in-product-label 2017-06-06T05:43:54 https://maestrodatabase.com/blog/america-is-a-world-leader-in-health-inequality 2017-06-06T13:06:43 https://maestrodatabase.com/blog/janssen-submits-ponesimod-new-drug-application-to-the-u-dot-s-fda-for-treatment-of-adults-with-relapsing-multiple-sclerosis 2020-03-19T03:33:21 https://maestrodatabase.com/blog/the-value-of-using-registries-to-evaluate-randomised-clinical-trial-study-populations 2017-06-06T12:58:29 https://maestrodatabase.com/blog/ma-welcomes-the-governments-actions-to-ensure-continued-access-to-medicines 2020-03-19T03:31:45 https://maestrodatabase.com/blog/proposal-to-list-a-range-of-orthopaedic-implants-and-associated-products-supplied-by-johnson-and-johnson 2017-06-06T21:03:40 https://maestrodatabase.com/blog/fda-has-accepted-a-bla-for-bentracimab-the-first-and-only-ticagrelor-reversal-agent-for-filing-and-priority-review 2024-08-03T13:04:05 https://maestrodatabase.com/blog/obamacare-didnt-destroy-insurance-markets-but-it-also-didnt-fix-them 2017-06-06T13:17:04 https://maestrodatabase.com/blog/research-backs-case-for-health-insurance-discount-for-young 2017-06-06T21:10:31 https://maestrodatabase.com/blog/nice-backs-allergans-ozurdex-abbvies-humira-for-uveitis 2017-06-06T21:15:30 https://maestrodatabase.com/blog/senate-panel-to-hold-hearing-on-drug-prices 2017-06-06T21:32:13 https://maestrodatabase.com/blog/drug-prices-become-target-for-fda-as-chief-expands-purview 2017-06-06T21:24:12 https://maestrodatabase.com/blog/workshop-addressing-unmet-needs-of-children-with-pulmonary-arterial-hypertension 2017-06-06T21:39:25 https://maestrodatabase.com/blog/ama-will-vote-on-requiring-drug-makers-to-disclose-prices-in-consumer-ads 2017-06-06T21:35:31 https://maestrodatabase.com/blog/fda-approves-sacituzumab-govitecan-hziy-for-hr-positive-breast-cancer 2023-02-03T20:25:14 https://maestrodatabase.com/blog/doubt-over-australian-covid-vaccine-rollout-completion-date 2021-03-11T06:05:32 https://maestrodatabase.com/blog/pfizer-receives-fda-fast-track-designation-for-tafimidis-for-transthyretin-cardiomyopathy 2017-06-07T01:34:33 https://maestrodatabase.com/blog/kadmon-announces-u-dot-s-fda-has-extended-the-review-period-for-belumosudil-in-chronic-graft-versus-host-disease 2021-03-11T06:08:52 https://maestrodatabase.com/blog/fda-grants-breakthrough-device-designation-for-inivatas-radar-assay 2021-03-11T06:24:18 https://maestrodatabase.com/blog/medicares-new-device-coverage-pathway----breakthrough-or-breakdown 2021-03-11T06:36:16 https://maestrodatabase.com/blog/ema-starts-rolling-review-of-eli-lilly-antibodies-bamlanivimab-and-etesemivab-for-covid-19 2021-03-11T11:43:43 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-to-spectrum-pharmaceuticals-poziotinib 2021-03-11T12:13:17 https://maestrodatabase.com/blog/ema-recommends-covid-19-vaccine-janssen-for-authorisation-in-the-eu 2021-03-11T20:09:24 https://maestrodatabase.com/blog/who-updates-essential-medicines-list-with-new-advice-on-use-of-antibiotics-and-adds-medicines-for-hepatitis-c-hiv-tuberculosis-and-cancer 2017-06-07T03:01:08 https://maestrodatabase.com/blog/fda-accepts-filing-application-for-oral-semaglutide-25-mg-which-if-approved-would-be-the-first-oral-glp-1-treatment-for-obesity 2025-05-03T03:32:14 https://maestrodatabase.com/blog/lonsurf-trifluridine-slash-tipiracil-receives-marketing-authorisation-in-europe-for-patients-with-previously-treated-metastatic-gastric-cancer 2019-09-07T10:11:32 https://maestrodatabase.com/blog/its-time-for-congress-to-go-all-in-on-drug-pricing-reform 2019-09-07T07:27:27 https://maestrodatabase.com/blog/refixia-nonacog-beta-pegol-n9-gp-approved-in-the-eu 2017-06-07T05:11:11 https://maestrodatabase.com/blog/astellas-submits-new-drug-application-for-enfortumab-vedotin-in-japan 2021-03-11T11:36:59 https://maestrodatabase.com/blog/fda-approves-two-month-aristada-for-treatment-of-schizophrenia 2017-06-07T05:16:24 https://maestrodatabase.com/blog/berlin-heals-receives-breakthrough-device-designation-from-fda-for-its-c-mic-heart-failure-device-and-initiates-early-feasibility-study-in-the-united-states 2021-03-11T20:16:51 https://maestrodatabase.com/blog/dose-of-reality-on-vaccination-target 2021-03-11T20:25:29 https://maestrodatabase.com/blog/european-commission-approves-roches-tecentriq-in-combination-with-chemotherapy-for-the-initial-treatment-of-people-with-extensive-stage-small-cell-lung-cancer 2019-09-07T10:24:25 https://maestrodatabase.com/blog/mhra-authorises-lillys-ret-inhibitor-retsevmo 2021-03-11T20:27:51 https://maestrodatabase.com/blog/denali-therapeutics-announces-fast-track-designation-granted-by-the-u-dot-s-fda-to-etv-ids-dnl310-for-the-treatment-of-patients-with-hunter-syndrome 2021-03-11T20:12:53 https://maestrodatabase.com/blog/updates-to-the-hta-policy-and-methods-review-reference-committee-3-november-2023 2023-11-04T01:11:06 https://maestrodatabase.com/blog/revolutionary-option-for-medical-device-sterilisation-approved-by-fda 2021-03-11T20:51:05 https://maestrodatabase.com/blog/the-broader-societal-impacts-of-covid-19-and-the-growing-importance-of-capturing-these-in-health-economic-analyses 2021-03-11T20:55:49 https://maestrodatabase.com/blog/achievements-and-challenges-of-the-sakigake-designation-system-in-japan 2021-03-11T20:37:24 https://maestrodatabase.com/blog/covid-19-vaccine-astrazeneca-prac-investigating-cases-of-thromboembolic-events---vaccines-benefits-currently-still-outweigh-risks 2021-03-11T20:43:34 https://maestrodatabase.com/blog/european-commission-approves-roches-new-tecentriq-based-combination-therapy-as-an-initial-treatment-for-most-common-form-of-advanced-lung-cancer 2019-09-07T10:43:51 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-23-september-2021 2021-09-23T04:47:35 https://maestrodatabase.com/blog/limits-on-dispensing-and-sales-of-prescription-and-over-the-counter-medicines 2020-03-19T06:33:59 https://maestrodatabase.com/blog/limits-on-dispensing-and-sales-of-medicines 2020-03-19T06:28:07 https://maestrodatabase.com/blog/insurers-pitch-new-ways-to-pay-for-million-dollar-therapies 2019-09-07T11:10:42 https://maestrodatabase.com/blog/gsks-rsv-vaccine-arexvy-approved-in-us-for-expanded-age-indication-in-adults-aged-18-49-years-at-increased-risk 2026-03-13T20:24:53 https://maestrodatabase.com/blog/sandoz-announces-new-global-act4biosimilars-initiative-to-improve-patient-access-and-increase-adoption-by-at-least-30-percent-in-30-plus-countries-by-2030 2022-05-31T07:58:03 https://maestrodatabase.com/blog/novartis-cosentyx-receives-fda-approval-for-paediatric-patients-aged-12-plus-with-moderate-to-severe-hidradenitis-suppurativa 2026-03-13T20:30:43 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-obeticholic-acid-for-non-alcoholic-steatohepatitis 2020-03-19T19:52:02 https://maestrodatabase.com/blog/insulin-prices-and-pharmacy-benefit-manager-rebates-pin-the-tail-on-the-patient 2020-03-19T10:10:39 https://maestrodatabase.com/blog/medicare-may-test-policy-of-paying-less-for-accelerated-approval-drugs 2023-02-03T21:51:27 https://maestrodatabase.com/blog/novartis-receives-approval-from-japanese-ministry-of-health-labour-and-welfare-for-zolgensma-the-only-gene-therapy-for-patients-with-spinal-muscular-atrophy 2020-03-19T10:01:15 https://maestrodatabase.com/blog/call-to-pool-research-resources-into-large-multi-centre-multi-arm-clinical-trials-to-generate-sound-evidence-on-covid-19-treatments 2020-03-19T20:03:03 https://maestrodatabase.com/blog/coronavirus-covid-19-update-fda-continues-to-facilitate-development-of-treatments 2020-03-19T19:59:30 https://maestrodatabase.com/blog/hormone-replacement-therapy-patch-shortages-are-having-a-big-impact-on-the-women-who-need-them 2023-11-04T02:14:38 https://maestrodatabase.com/blog/fda-approves-new-treatment-for-paediatric-patients-with-any-strain-of-hepatitis-c 2020-03-19T19:56:02 https://maestrodatabase.com/blog/fda-approves-label-extension-for-evrysdi-for-infants-with-spinal-muscular-atrophy-under-2-months-old 2022-05-31T08:31:15 https://maestrodatabase.com/blog/getting-value-right-the-case-for-indirect-benefits 2020-03-19T20:18:17 https://maestrodatabase.com/blog/mhra-approves-deuruxolitinib-leqselvi-to-treat-severe-alopecia-areata-in-adults 2026-03-13T10:12:04 https://maestrodatabase.com/blog/low-prices-wont-keep-new-medicines-out-of-canada 2020-03-19T20:11:42 https://maestrodatabase.com/blog/us-fda-approves-takedas-takhyzro-lanadelumab-flyo-to-prevent-hereditary-angioedema-attacks-in-children-2-years-of-age-and-older 2023-02-04T03:55:36 https://maestrodatabase.com/blog/how-to-tell-if-biden-drove-a-hard-bargain-in-medicare-drug-price-negotiations 2024-08-04T05:03:25 https://maestrodatabase.com/blog/tg-therapeutics-announces-fda-extension-of-bla-pdufa-date-for-ublituximab-to-treat-patients-with-rms 2022-05-31T20:46:16 https://maestrodatabase.com/blog/european-commission-approves-label-expansion-of-roches-hemlibra-to-include-people-with-moderate-haemophilia-a-in-the-eu 2023-02-04T03:50:12 https://maestrodatabase.com/blog/agenda-for-the-november-2024-pbac-meeting-version-1 2024-08-04T04:59:56 https://maestrodatabase.com/blog/us-fda-accepts-new-drug-application-filed-by-avillion-for-astrazenecas-pt027-for-the-as-needed-treatment-or-prevention-of-symptoms-in-asthma-patients 2022-05-31T10:08:24 https://maestrodatabase.com/blog/medicare-is-urged-to-consider-amgen-patent-manoeuvres-when-negotiating-the-price-for-a-drug 2023-11-04T03:08:28 https://maestrodatabase.com/blog/first-time-limited-reimbursement-recommendation-supports-earlier-patient-access-to-a-promising-cancer-treatment 2024-08-04T06:40:42 https://maestrodatabase.com/blog/priothera-receives-fast-track-designation-for-mocravimod-in-combination-with-allogeneic-haematopoietic-stem-cell-transplant-for-post-remission-therapy-of-acute-myeloid-leukaemia-patients 2022-05-31T21:11:49 https://maestrodatabase.com/blog/special-fda-designations-for-drug-development-orphan-fast-track-accelerated-approval-priority-review-and-breakthrough-therapy 2024-08-04T06:25:16 https://maestrodatabase.com/blog/timber-pharmaceuticals-receives-fda-breakthrough-therapy-designation-for-tmb-001-for-the-treatment-of-congenital-ichthyosis 2022-05-31T20:52:23 https://maestrodatabase.com/blog/how-can-health-technology-assessment-be-improved-to-optimise-access-to-medicines-results-from-a-delphi-study-in-europe 2024-08-04T05:49:43 https://maestrodatabase.com/blog/genomic-medicines-can-cost-3-dollars-million-a-dose-how-to-make-them-affordable 2024-08-04T05:44:20 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-june-2022 2022-05-31T20:57:27 https://maestrodatabase.com/blog/anthem-to-leave-ohios-obamacare-insurance-market-in-2018 2017-06-07T13:15:05 https://maestrodatabase.com/blog/actuaries-push-for-insurers-to-pay-cancer-patients-upfront 2017-06-07T21:22:44 https://maestrodatabase.com/blog/argenx-announces-the-uk-mhra-has-granted-early-access-to-efgartigimod-for-generalised-myasthenia-gravis 2022-05-31T21:50:03 https://maestrodatabase.com/blog/converging-on-the-value-of-value-frameworks 2017-06-07T13:23:06 https://maestrodatabase.com/blog/alarming-variations-in-treatment-signal-need-for-reforms 2017-06-07T21:27:05 https://maestrodatabase.com/blog/senate-gop-aiming-to-conclude-divisive-health-care-push----one-way-or-the-other 2017-06-07T21:43:17 https://maestrodatabase.com/blog/handok-paves-the-way-for-a-smooth-introduction-of-its-new-cancer-drug 2023-11-04T04:07:37 https://maestrodatabase.com/blog/new-uk-law-to-control-generic-drug-prices---implications-for-pharma 2017-06-07T21:39:50 https://maestrodatabase.com/blog/fda-to-fast-track-clinical-trials-for-coronavirus-therapies 2020-03-19T23:16:00 https://maestrodatabase.com/blog/y-mabs-announces-fda-acceptance-of-biologics-license-application-for-omblastys-omburtamab-for-the-treatment-of-neuroblastoma-for-priority-review 2022-05-31T21:16:47 https://maestrodatabase.com/blog/coronavirus-donald-trump-announces-two-drugs-will-be-made-available-to-treat-illness 2020-03-19T23:10:48 https://maestrodatabase.com/blog/swiss-drug-prices-still-soar-above-european-levels 2022-05-31T21:31:39 https://maestrodatabase.com/blog/targeting-unconscionable-prescription-drug-prices----marylands-anti-price-gouging-law 2017-07-12T21:49:47 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-june-2022 2022-05-31T21:23:38 https://maestrodatabase.com/blog/groundbreaking-therapy-for-terminal-cancers-finally-publicly-funded 2024-08-04T07:29:12 https://maestrodatabase.com/blog/calithera-biosciences-announces-fda-fast-track-designation-granted-to-cb-839-for-treatment-of-patients-with-renal-cell-carcinoma 2017-06-07T23:31:48 https://maestrodatabase.com/blog/key-senate-panel-to-consider-pbm-drug-pricing-reform-package 2023-11-04T06:03:58 https://maestrodatabase.com/blog/government-lists-life-changing-epilepsy-drug-fenfluramine-on-pbs 2025-05-04T21:46:57 https://maestrodatabase.com/blog/health-canada-accepts-semaglutide-2-dot-4-mg-a-glp-1-receptor-agonist-treatment-for-mash-as-a-supplemental-new-drug-submission-under-the-priority-review-policy 2025-05-04T01:19:25 https://maestrodatabase.com/blog/high-priced-medicine-could-be-our-best-chance-to-lower-drug-prices 2023-02-04T22:19:51 https://maestrodatabase.com/blog/complexity-in-the-us-health-care-system-is-the-enemy-of-access-and-affordability 2023-11-04T06:42:24 https://maestrodatabase.com/blog/mateon-therapeutics-receives-fda-fast-track-designation-for-oxi4503-in-patients-with-acute-myeloid-leukaemia 2017-06-08T00:15:06 https://maestrodatabase.com/blog/fda-authorises-booster-dose-of-pfizer-biontech-covid-19-vaccine-for-certain-populations 2021-09-23T07:41:21 https://maestrodatabase.com/blog/innovent-announces-nmpa-acceptance-of-a-supplemental-new-drug-application-for-sintilimab-in-combination-with-chemotherapy-as-first-line-therapy-for-oesophageal-squamous-cell-carcinoma 2021-09-23T12:03:39 https://maestrodatabase.com/blog/amicus-therapeutics-submits-new-drug-application-to-u-dot-s-fda-for-migalastat-for-treatment-of-fabry-disease 2017-12-15T02:50:38 https://maestrodatabase.com/blog/nices-new-methods-reflect-societys-values 2023-02-04T23:30:20 https://maestrodatabase.com/blog/significant-step-forward-proposed-for-bowel-cancer 2024-08-05T00:05:05 https://maestrodatabase.com/blog/a-middle-ground-for-accelerated-drug-approval--lessons-from-aducanumab 2021-09-23T20:48:55 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-to-assess-elagolix-for-management-of-endometriosis 2017-12-15T02:57:58 https://maestrodatabase.com/blog/the-end-of-cancer-how-cell-therapy-breakthroughs-have-us-on-the-edge-of-a-cure 2026-03-15T00:18:16 https://maestrodatabase.com/blog/astrazeneca-chadox1-s-covid-19-vaccine 2021-04-16T20:58:27 https://maestrodatabase.com/blog/canada-should-negotiate-a-fairer-share-of-drug-r-and-d-costs 2021-09-23T20:42:40 https://maestrodatabase.com/blog/atagi-statement-about-the-need-for-additional-doses-of-covid-19-vaccines 2021-09-23T20:37:10 https://maestrodatabase.com/blog/smoothing-medicare-part-d-out-of-pocket-costs-under-the-inflation-reduction-act 2023-02-05T06:31:56 https://maestrodatabase.com/blog/strong-demand-for-health-insurance-as-deadline-looms 2017-12-15T04:41:05 https://maestrodatabase.com/blog/pbac-public-summary-documents---november-2019-meeting-first-time-rejections-and-deferrals 2020-03-20T07:06:54 https://maestrodatabase.com/blog/revised-pbs-listings-for-antibiotic-use-from-1-april-2020 2020-03-20T06:59:29 https://maestrodatabase.com/blog/us-fda-issues-complete-response-letter-for-empagliflozin-2-dot-5-mg-as-adjunct-to-insulin-for-adults-with-type-1-diabetes 2020-03-20T21:07:07 https://maestrodatabase.com/blog/coronavirus-vindicates-capitalism 2020-03-20T07:11:22 https://maestrodatabase.com/blog/astrazenecas-imfinzi-plus-chemotherapy-approved-by-mhra-for-biliary-tract-cancer 2023-02-05T08:01:51 https://maestrodatabase.com/blog/bristol-myers-squibb-announces-us-fda-approval-for-opdivo-nivolumab-as-a-single-agent-for-the-treatment-of-patients-with-previously-untreated-braf-wild-type-advanced-melanoma 2017-06-08T03:50:07 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-approval-from-the-us-fda-for-the-opdivo-nivolumab-plus-yervoy-ipilimumab-regimen-in-braf-v600-wild-type-unresectable-or-metastatic-melanoma 2017-06-08T04:04:47 https://maestrodatabase.com/blog/government-response-to-independent-pharmac-review 2022-06-01T04:30:07 https://maestrodatabase.com/blog/elexacaftor-with-tezacaftor-and-ivacaftor-tezacaftor-with-ivacaftor-and-lumacaftor-with-ivacaftor-for-the-treatment-of-patients-with-cystic-fibrosis 2023-11-04T21:34:03 https://maestrodatabase.com/blog/fda-grants-efanesoctocog-alfa-breakthrough-therapy-designation-for-haemophilia-a 2022-06-01T05:15:13 https://maestrodatabase.com/blog/biosimilar-drugs-offer-promise-for-drug-price-savings-but-risks-remain 2017-06-08T04:54:48 https://maestrodatabase.com/blog/major-flaws-in-us-drugs-with-accelerated-approval-research-suggests 2017-06-08T07:19:31 https://maestrodatabase.com/blog/msac-secretariat-publishes-revised-agenda-for-november-2023-msac-meeting 2023-11-04T22:05:14 https://maestrodatabase.com/blog/telix-resubmits-nda-to-us-fda-for-tlx101-px-pixclara-brain-cancer-imaging-candidate 2026-03-16T00:52:56 https://maestrodatabase.com/blog/novartis-commits-to-donate-up-to-130-million-doses-of-hydroxychloroquine-to-support-the-global-covid-19-pandemic-response 2020-03-20T21:51:38 https://maestrodatabase.com/blog/amazons-rxpass-doesnt-yet-really-compete-with-mark-cubans-cost-plus-drug-company 2023-02-05T20:00:50 https://maestrodatabase.com/blog/release-of-the-strengthening-medicare-taskforce-report 2023-02-05T19:54:13 https://maestrodatabase.com/blog/how-should-the-fda-evaluate-psychedelic-medicine 2023-11-04T22:38:01 https://maestrodatabase.com/blog/generating-comparative-evidence-on-new-drugs-and-devices-before-approval 2020-03-20T23:19:55 https://maestrodatabase.com/blog/ucb-announces-european-commission-approval-for-320-mg-device-presentations-of-bimzelx-bimekizumab 2024-08-05T05:35:07 https://maestrodatabase.com/blog/bristol-myers-squibb-announces-availability-of-new-orencia-abatacept-subcutaneous-administration-option-for-patients-2-years-of-age-and-older-with-moderately-to-severely-active-polyarticular-juvenile-idiopathic-arthritis 2017-06-08T12:11:13 https://maestrodatabase.com/blog/rezolute-receives-breakthrough-therapy-designation-from-fda-for-ersodetug-in-the-treatment-of-hypoglycaemia-due-to-tumour-hyperinsulinism 2025-05-06T05:43:04 https://maestrodatabase.com/blog/ichnos-glenmark-innovation-receives-us-fda-fast-track-designation-for-isb-2001-for-relapsed-slash-refractory-multiple-myeloma 2025-05-06T05:35:13 https://maestrodatabase.com/blog/filgotinib-maleate-for-patients-with-moderate-to-severe-active-ulcerative-colitis 2022-06-01T07:52:40 https://maestrodatabase.com/blog/senate-health-bill-may-alienate-g-dot-o-p-conservatives 2017-06-08T12:34:53 https://maestrodatabase.com/blog/alterity-therapeutics-granted-us-fda-fast-track-designation-for-ath434-to-treat-multiple-system-atrophy 2025-05-06T05:30:07 https://maestrodatabase.com/blog/icer-to-assess-treatments-for-cystic-fibrosis 2019-09-08T07:25:00 https://maestrodatabase.com/blog/icer-to-assess-treatments-for-ulcerative-colitis 2019-09-08T06:05:53 https://maestrodatabase.com/blog/teva-and-alvotech-announce-fda-approval-of-interchangeability-for-selarsdi-ustekinumab-aekn-with-stelara-ustekinumab 2025-05-06T05:20:16 https://maestrodatabase.com/blog/generating-comparative-evidence-on-new-drugs-and-devices-after-approval 2020-03-21T00:03:01 https://maestrodatabase.com/blog/imfinzi-approved-in-the-eu-as-first-and-only-peri-operative-immunotherapy-for-patients-with-early-gastric-and-gastro-oesophageal-cancers 2026-03-16T08:39:43 https://maestrodatabase.com/blog/fda-submission-to-expand-minimum-age-for-xenoview 2024-08-05T22:10:19 https://maestrodatabase.com/blog/kiwi-toddler-fights-spinal-muscular-atrophy-in-australia-after-pharmac-stall-access-to-life-saving-drug 2019-09-08T07:40:06 https://maestrodatabase.com/blog/trudeaus-drug-price-overhaul-is-set-to-cost-drug-makers-billions 2019-09-08T07:31:17 https://maestrodatabase.com/blog/health-canada-has-granted-approval-for-tzield-the-first-and-only-disease-modifying-therapy-in-auto-immune-type-1-diabetes-in-canada 2025-05-06T06:09:26 https://maestrodatabase.com/blog/ascentage-pharmas-mdm2-p53-inhibitor-alrizomadlin-apg-115-granted-fast-track-designation-by-the-us-fda-for-the-treatment-of-relapsed-slash-refractory-unresectable-or-metastatic-melanoma 2021-09-24T01:27:50 https://maestrodatabase.com/blog/calquence-plus-chemoimmunotherapy-approved-in-the-eu-as-first-and-only-btk-inhibitor-for-first-line-mantle-cell-lymphoma 2025-05-06T06:05:47 https://maestrodatabase.com/blog/ema-appoints-chief-medical-officer 2022-06-01T10:01:31 https://maestrodatabase.com/blog/novartis-announces-fda-approval-of-beovu-for-the-treatment-of-diabetic-macular-oedema 2022-06-01T20:44:28 https://maestrodatabase.com/blog/changes-to-hpv-vaccine-dose-schedule-for-young-australians 2023-02-06T06:21:17 https://maestrodatabase.com/blog/italfarmaco-announces-us-fda-grants-fast-track-designation-to-givinostat-in-treatment-of-polycythemia-vera 2025-05-06T23:03:21 https://maestrodatabase.com/blog/ema-proposes-new-paper-on-proof-of-concept-studies-for-paediatric-oncology-drugs 2026-03-16T05:01:12 https://maestrodatabase.com/blog/nice-recommends-potentially-life-changing-treatment-for-people-with-short-bowel-syndrome 2022-06-01T09:56:40 https://maestrodatabase.com/blog/who-labels-prep-an-essential-medicine 2017-06-08T21:15:34 https://maestrodatabase.com/blog/fda-requests-removal-of-opana-er-for-risks-related-to-abuse 2017-06-08T21:36:48 https://maestrodatabase.com/blog/public-health-needs-private-patients-to-help-keep-specialists 2017-06-08T21:32:54 https://maestrodatabase.com/blog/icer-to-assess-treatment-for-vasomotor-symptoms-associated-with-menopause 2022-06-01T21:06:48 https://maestrodatabase.com/blog/health-minister-urges-pharmac-to-focus-on-equity-and-collaboration 2022-06-01T21:09:57 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-reviews-final-report-on-treatments-for-atopic-dermatitis-provides-policy-recommendations-to-support-appropriate-patient-access-to-dupilumab 2017-06-08T21:42:21 https://maestrodatabase.com/blog/attralus-receives-breakthrough-therapy-designation-for-its-pan-amyloid-diagnostic-pet-imaging-candidate-124i-evuzamitide-at-01-for-cardiac-amyloidosis 2024-08-06T00:31:40 https://maestrodatabase.com/blog/novartiss-next-challenge-pricing-breakthrough-cancer-treatment 2017-06-08T21:50:35 https://maestrodatabase.com/blog/apellis-announces-submission-of-new-drug-application-to-the-fda-for-pegcetacoplan-for-geographic-atrophy 2022-06-01T20:54:03 https://maestrodatabase.com/blog/fda-accepts-resubmission-of-bla-for-narsoplimab-for-haematopoietic-stem-cell-transplant-associated-thrombotic-microangiopathy-and-assigns-late-september-pdufa-date 2025-05-06T23:15:16 https://maestrodatabase.com/blog/fda-approval-of-lymphoma-medicine-ukoniq-umbralisib-is-withdrawn-due-to-safety-concerns 2022-06-01T21:03:43 https://maestrodatabase.com/blog/sandoz-biologics-license-application-for-proposed-biosimilar-denosumab-accepted-by-us-fda 2023-02-06T06:28:36 https://maestrodatabase.com/blog/teva-to-donate-potential-covid-19-treatment-hydroxychloroquine-sulphate-tablets-to-us-hospitals-nationwide 2020-03-21T06:47:34 https://maestrodatabase.com/blog/cancer-drug-prices-are-so-high-that-doctors-will-test-cutting-doses 2017-06-08T21:56:27 https://maestrodatabase.com/blog/callous-pharmac-has-left-too-many-people-in-the-waiting-room-of-death 2022-06-01T21:25:53 https://maestrodatabase.com/blog/barriers-in-place-access-to-asthma-medication-key-to-reducing-deaths 2019-09-08T20:16:25 https://maestrodatabase.com/blog/vbi-vaccines-announces-uk-mhra-marketing-authorisation-for-prehevbri-a-3-antigen-adult-hepatitis-b-vaccine 2022-06-01T21:29:28 https://maestrodatabase.com/blog/nice-recommends-ucbs-fintepla-for-dravet-syndrome 2022-06-01T21:13:14 https://maestrodatabase.com/blog/summary-of-us-fda-chimeric-antigen-receptor-t-cell-biologics-license-application-approvals-from-a-statistical-perspective 2022-06-01T21:22:12 https://maestrodatabase.com/blog/cancer-rare-disorder-advocates-call-for-more-radical-change-after-damning-pharmac-review 2022-06-01T21:17:44 https://maestrodatabase.com/blog/health-canada-authorises-vabysmo-faricimab-injection-for-the-treatment-of-neovascular-wet-age-related-macular-degeneration-and-diabetic-macular-oedema 2022-06-01T21:37:05 https://maestrodatabase.com/blog/icer-publishes-evidence-report-on-therapies-for-lupus-nephritis 2021-03-13T05:59:16 https://maestrodatabase.com/blog/burtomab-receives-breakthrough-therapy-designation-for-advanced-form-of-paediatric-cancer 2017-06-08T23:31:48 https://maestrodatabase.com/blog/immunitybio-requests-an-urgent-meeting-with-fda-to-address-the-change-in-the-agencys-unambiguous-guidance-on-jan-2025-to-submit-a-sbla-for-nmibc-bcg-unresponsive-papillary-disease-following-an-inconsistent-refusal-to-file-letter-on-2-may-2025 2025-05-07T01:14:49 https://maestrodatabase.com/blog/omaveloxolone-for-the-treatment-of-patients-with-friedreichs-ataxia 2025-05-07T00:56:33 https://maestrodatabase.com/blog/covid-19-vaccines---safety-and-effectiveness-in-older-adults 2021-03-13T05:56:24 https://maestrodatabase.com/blog/marius-pharmaceuticals-receives-pdufa-date-for-kyzatrex-nda-for-treatment-of-hypogonadism 2021-03-13T06:57:44 https://maestrodatabase.com/blog/aeolus-announces-fda-fast-track-designation-granted-to-aeol-10150-for-treatment-of-patients-with-lung-acute-radiation-syndrome-following-a-radiologial-or-nuclear-event 2017-06-09T00:39:44 https://maestrodatabase.com/blog/maralixibat-chloride-for-the-treatment-of-patients-with-cholestatic-pruritus-associated-with-alagille-syndrome 2024-08-06T06:36:28 https://maestrodatabase.com/blog/cogent-biosciences-announces-fda-acceptance-of-new-drug-application-for-bezuclastinib-in-patients-with-non-advanced-systemic-mastocytosis 2026-03-16T23:40:29 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-accelerated-approval-of-opdivo-nivolumab-from-the-us-fda 2017-06-09T01:09:53 https://maestrodatabase.com/blog/pear-therapeutics-announces-additional-coverage-decisions-and-formulary-adoption-of-its-prescription-digital-therapeutics 2021-09-24T03:46:56 https://maestrodatabase.com/blog/statement-from-fda-commissioner-on-new-fda-efforts-to-support-more-efficient-development-of-targeted-therapies 2017-12-15T23:31:41 https://maestrodatabase.com/blog/argo-biopharma-receives-fda-fast-track-designation-for-bw-20805-an-investigational-sirna-therapy-for-the-treatment-of-hae 2026-03-17T02:01:30 https://maestrodatabase.com/blog/u-dot-s-pharma-that-makes-potential-coronavirus-drug-touted-by-donald-trump-doubled-price-to-19-dollars-88-cents-a-pill 2020-03-21T22:45:54 https://maestrodatabase.com/blog/pfizer-announces-fda-approval-of-xeljanz-tofacitinib-and-xeljanz-xr-for-the-treatment-of-active-psoriatic-arthritis 2017-12-15T23:37:12 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac---november-2017 2017-12-15T23:47:43 https://maestrodatabase.com/blog/nice-publishes-first-rapid-covid-19-guidelines 2020-03-21T23:09:28 https://maestrodatabase.com/blog/fda-targets-insulin-for-increased-competition-to-lower-prices 2017-12-15T23:54:36 https://maestrodatabase.com/blog/potential-coronavirus-treatment-touted-by-trump-already-in-shortage-pharmacists-say 2020-03-21T23:00:34 https://maestrodatabase.com/blog/an-open-source-consensus-based-approach-to-value-assessment 2017-12-15T23:51:45 https://maestrodatabase.com/blog/janssen-announces-health-canada-approval-of-cabenuva-the-first-long-acting-regimen-for-the-treatment-of-hiv 2020-03-21T22:53:00 https://maestrodatabase.com/blog/new-drug-on-pbs-offers-hope-for-women-with-aggressive-breast-cancer 2023-11-06T02:39:13 https://maestrodatabase.com/blog/expanded-reimbursement-for-spinraza-improves-patient-access 2023-11-06T01:18:29 https://maestrodatabase.com/blog/adcentrx-therapeutics-granted-fast-track-designation-for-adrx-0706-nectin-4-antibody-drug-conjugate-for-the-treatment-of-advanced-cervical-cancer 2025-05-07T23:21:29 https://maestrodatabase.com/blog/viridian-therapeutics-receives-fda-breakthrough-therapy-designation-for-veligrotug-for-the-treatment-of-thyroid-eye-disease 2025-05-07T23:16:55 https://maestrodatabase.com/blog/fda-grants-amg-510-fast-track-designation-for-previously-treated-metastatic-nsclc-with-kras-g12c-mutation 2019-09-09T02:57:59 https://maestrodatabase.com/blog/clinical-trials-to-combat-reproductive-cancers 2019-09-09T02:54:12 https://maestrodatabase.com/blog/genomic-testing-cutting-edge-cancer-care-denied-to-thousands 2021-03-14T03:24:50 https://maestrodatabase.com/blog/eagle-pharmaceuticals-announces-submission-of-new-drug-application-to-us-fda-for-landiolol-a-beta-1-adrenergic-blocker 2022-06-02T03:15:47 https://maestrodatabase.com/blog/covid-19-vaccinations-are-free----but-theyre-taking-a-toll-on-local-pharmacies-bottom-lines 2021-03-14T04:06:52 https://maestrodatabase.com/blog/pharmac-review-misses-political-elephant-in-the-room 2021-03-14T04:10:01 https://maestrodatabase.com/blog/discounting-in-economic-evaluation-of-health-care-interventions-what-about-the-risk-term 2021-03-14T04:27:37 https://maestrodatabase.com/blog/pharma-giants-get-their-pennies-pinched-on-drug-pricing 2021-03-14T03:58:40 https://maestrodatabase.com/blog/reining-in-drug-patents-isnt-a-silver-bullet-against-high-drug-prices 2021-03-14T04:01:23 https://maestrodatabase.com/blog/choosing-the-right-director-for-the-u-dot-s-patent-and-trademark-office-can-help-lower-drug-prices 2021-03-14T04:04:26 https://maestrodatabase.com/blog/annual-private-health-insurance-premium-rise 2023-02-06T19:35:25 https://maestrodatabase.com/blog/over-1-dollars-1-cents-billion-to-extend-australias-covid-19-health-response 2021-03-14T20:35:58 https://maestrodatabase.com/blog/pharma-industry-urges-halt-to-further-rises-in-record-revenue-clawbacks 2023-02-06T19:41:26 https://maestrodatabase.com/blog/all-australians-aged-over-50-to-be-given-covid-19-vaccine-from-june-in-new-rollout-plan 2021-03-14T20:46:05 https://maestrodatabase.com/blog/savvy-vaccine-brokers-help-americans-secure-hot-commodity-jabs 2021-03-14T20:48:39 https://maestrodatabase.com/blog/european-commission-approves-tremfya-guselkumab-the-first-dual-acting-il-23-inhibitor-offering-both-subcutaneous-and-intravenous-induction-options-for-adult-patients-with-moderately-to-severely-active-crohns-disease 2025-05-08T01:18:14 https://maestrodatabase.com/blog/pbac-advice-on-equitable-access-to-glp-1-obesity-treatments 2026-03-17T05:17:06 https://maestrodatabase.com/blog/lilly-novo-nordisk-seek-insurance-coverage-in-korea-for-diabetes-drugs-mounjaro-and-ozempic 2025-05-08T01:13:29 https://maestrodatabase.com/blog/fda-approves-vorasidenib-for-grade-2-astrocytoma-or-oligodendroglioma-with-a-susceptible-idh1-or-idh2-mutation 2024-08-06T22:00:12 https://maestrodatabase.com/blog/patient-group-urges-quick-reimbursement-of-besremi-for-polycythemia-vera 2025-05-08T01:08:32 https://maestrodatabase.com/blog/value-based-drug-pricing-makes-sense-but-is-difficult-to-pull-off 2017-06-09T05:55:11 https://maestrodatabase.com/blog/sage-therapeutics-and-biogen-announce-fda-accepts-filing-of-new-drug-application-and-grants-priority-review-of-zuranolone-in-the-treatment-of-major-depressive-disorder-and-post-partum-depression 2023-02-06T20:05:11 https://maestrodatabase.com/blog/sun-pharma-announces-us-fda-acceptance-of-supplemental-biologics-license-application-for-ilumya-tildrakizumab-asmn-for-the-treatment-of-adults-with-active-psoriatic-arthritis 2026-03-17T04:02:20 https://maestrodatabase.com/blog/endogena-therapeutics-receives-us-fda-fast-track-designation-for-ea-2353-for-the-treatment-of-retinitis-pigmentosa 2023-02-06T19:59:56 https://maestrodatabase.com/blog/its-challenging-health-authorities-fret-over-vaccine-supply 2021-03-14T20:50:29 https://maestrodatabase.com/blog/chinas-2022-nrdl-readout 2023-02-06T19:55:29 https://maestrodatabase.com/blog/doctors-unlawfully-denied-drug-to-girl-with-spinal-muscular-atrophy-appeal-court-rules 2021-03-14T20:56:49 https://maestrodatabase.com/blog/public-funding-of-approved-lung-cancer-treatments-needed-now 2017-06-09T07:15:48 https://maestrodatabase.com/blog/actions-to-support-the-development-of-medicines-for-children 2023-02-06T19:43:41 https://maestrodatabase.com/blog/tlv-proposes-a-new-process-for-health-economic-assessments-that-are-made-in-a-short-time-and-under-special-circumstances 2023-02-06T19:51:18 https://maestrodatabase.com/blog/mhra-authorises-krazati-as-a-treatment-for-non-small-cell-lung-cancer-in-adults 2023-11-06T07:51:50 https://maestrodatabase.com/blog/fda-reiterates-the-importance-of-vaccines-such-as-the-measles-mumps-and-rubella-mmr-vaccine 2019-09-09T04:58:30 https://maestrodatabase.com/blog/international-collaboration 2023-02-06T20:39:48 https://maestrodatabase.com/blog/respiri-becomes-first-australian-company-to-receive-us-reimbursements 2023-02-06T20:28:19 https://maestrodatabase.com/blog/achieving-appropriate-model-transparency-challenges-and-potential-solutions-for-making-value-based-decisions-in-the-united-states 2019-09-09T05:01:53 https://maestrodatabase.com/blog/medical-technology-strategy 2023-02-06T20:19:37 https://maestrodatabase.com/blog/pbs-listing-for-australians-with-hereditary-transthyretin-mediated-amyloidosis-with-polyneuropathy 2024-08-06T22:52:07 https://maestrodatabase.com/blog/novo-nordisk-launching-additional-us-insulin-affordability-offerings-in-january-2020 2019-09-09T05:32:33 https://maestrodatabase.com/blog/meta-pharmaceuticals-announces-fda-grants-rare-paediatric-disease-designation-to-meta-001-ph-for-the-treatment-of-primary-hyperoxaluria 2024-08-07T02:51:08 https://maestrodatabase.com/blog/new-treatment-for-women-battling-aggressive-breast-cancer 2023-11-06T19:36:40 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-the-combination-of-avutometinib-and-defactinib-for-kras-mutated-recurrent-low-grade-serous-ovarian-cancer 2025-05-08T21:41:07 https://maestrodatabase.com/blog/atagi-update-following-weekly-covid-19-meeting-22-september-2021 2021-09-24T08:42:41 https://maestrodatabase.com/blog/eu-drugs-regulator-to-decide-on-pfizer-vaccine-booster-in-early-october 2021-09-24T06:23:07 https://maestrodatabase.com/blog/abaloparatide-for-the-treatment-of-women-with-osteoporosis-after-menopause 2024-08-07T03:07:03 https://maestrodatabase.com/blog/brentuximab-vedotin-in-combination-with-chemotherapy-for-the-treatment-of-patients-with-stage-3-or-4-cd30-positive-hodgkin-lymphoma 2025-05-08T08:33:06 https://maestrodatabase.com/blog/mhra-approves-teprotumumab-as-the-first-uk-treatment-for-adults-with-moderate-to-severe-thyroid-eye-disease 2025-05-08T08:23:30 https://maestrodatabase.com/blog/aviadobio-announces-fda-ind-clearance-and-fast-track-designation-for-avb-101-for-the-treatment-of-frontotemporal-dementia-with-progranulin-mutations 2023-11-06T19:44:06 https://maestrodatabase.com/blog/fda-approves-the-first-drug-with-an-indication-for-treatment-of-smallpox 2018-07-13T21:29:32 https://maestrodatabase.com/blog/medibank-boss-warns-of-big-challenges-for-health-system-but-australia-well-placed 2020-03-22T20:09:47 https://maestrodatabase.com/blog/royal-childrens-hospital-takes-action-to-give-sick-boy-wonder-drug-access 2018-07-13T21:42:00 https://maestrodatabase.com/blog/tga-calls-on-drug-company-to-improve-warnings-over-childrens-asthma-drug-after-suicide 2018-07-13T21:46:25 https://maestrodatabase.com/blog/george-medicines-files-new-drug-application-with-fda-for-novel-low-dose-triple-combination-for-treatment-of-hypertension-following-successful-international-phase-3-development-program 2024-08-07T04:34:57 https://maestrodatabase.com/blog/amgen-and-ucb-resubmit-biologics-license-application-for-evenity-romosozumab-to-the-us-fda 2018-07-13T21:52:10 https://maestrodatabase.com/blog/inside-drug-makers-strategy-to-boost-cancer-medicines-with-lazarus-effect 2019-09-09T20:49:03 https://maestrodatabase.com/blog/health-canada-ordered-to-release-confidential-drug-company-data-on-hpv-vaccines 2018-07-13T22:12:20 https://maestrodatabase.com/blog/state-prescription-drug-affordability-boards-could-end-up-limiting-access-to-the-life-saving-cystic-fibrosis-medication-trikafta 2023-11-06T21:01:47 https://maestrodatabase.com/blog/u-dot-s-ended-value-based-pricing-plan-for-cancer-drug-because-of-doubts-it-would-work 2018-07-13T22:16:01 https://maestrodatabase.com/blog/fda-budget-matters-investing-in-advanced-domestic-manufacturing 2018-07-13T21:58:32 https://maestrodatabase.com/blog/approval-of-updated-storage-conditions-for-the-pfizer-covid-19-vaccine 2021-03-14T23:27:33 https://maestrodatabase.com/blog/durvalumab-in-combination-with-chemotherapy-before-surgery-neo-adjuvant-then-alone-after-surgery-adjuvant-for-the-treatment-of-adults-with-resectable-non-small-cell-lung-cancer 2024-08-07T04:55:16 https://maestrodatabase.com/blog/ema-publishes-agenda-for-6-9-november-2023-chmp-meeting 2023-11-06T20:47:12 https://maestrodatabase.com/blog/will-the-uk-run-out-of-insulin-and-other-vital-medicines-in-a-no-deal-brexit 2019-09-09T21:05:40 https://maestrodatabase.com/blog/health-canada-oks-pfizer-covid-19-booster-shot-for-teens-ages-16-and-17 2022-06-02T08:27:45 https://maestrodatabase.com/blog/pharmac-funds-and-widens-access-to-melanoma-medicines 2025-05-08T23:47:25 https://maestrodatabase.com/blog/getting-it-right-epha-recommendations-on-how-to-improve-the-european-commission-proposal-on-health-technology-assessment 2018-07-13T22:30:14 https://maestrodatabase.com/blog/smc---september-2019-decisions 2019-09-09T21:00:05 https://maestrodatabase.com/blog/fast-track-designation-granted-to-mtx110-development-for-the-treatment-of-recurrent-glioblastoma 2022-06-02T09:15:17 https://maestrodatabase.com/blog/new-u-dot-s-trade-deal-may-bring-higher-drug-prices-to-u-dot-k 2018-07-13T22:23:14 https://maestrodatabase.com/blog/whos-missing-from-breast-cancer-trials-men-says-the-fda 2019-09-09T20:54:16 https://maestrodatabase.com/blog/fda-developing-guidance-on-real-world-data-quality-issues-officials-say 2019-09-09T21:16:56 https://maestrodatabase.com/blog/u-dot-s-fda-approves-xtandi-enzalutamide-for-the-treatment-of-men-with-non-metastatic-castration-resistant-prostate-cancer 2018-07-15T04:25:46 https://maestrodatabase.com/blog/allergan-and-molecular-partners-announce-acceptance-of-u-dot-s-fda-biologics-license-application-and-validation-of-ema-marketing-authorisation-for-abicipar-pegol-in-patients-with-neovascular-wet-age-related-macular-degeneration 2019-09-09T21:11:15 https://maestrodatabase.com/blog/reeling-from-scandal-novartis-vows-to-voluntarily-release-info-on-manipulated-data-in-the-future 2019-09-09T21:40:42 https://maestrodatabase.com/blog/bernie-sanders-went-to-canada-and-a-dream-of-medicare-for-all-flourished 2019-09-09T21:33:51 https://maestrodatabase.com/blog/subscription-model-for-antibiotic-development 2019-09-09T21:30:28 https://maestrodatabase.com/blog/accutar-biotechnology-announces-fast-track-designation-granted-by-fda-to-ac0176-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer 2022-06-02T09:52:09 https://maestrodatabase.com/blog/as-value-assessment-frameworks-evolve-are-they-finally-ready-for-prime-time 2019-09-09T21:26:34 https://maestrodatabase.com/blog/life-saving-drug-subsidies-for-thousands-of-patients-battling-rare-cancers 2018-07-15T04:42:08 https://maestrodatabase.com/blog/polaryx-therapeutics-receives-fda-fast-track-designation-for-plx-200-for-late-infantile-neuronal-ceroid-lipofuscinosis 2026-03-17T23:31:24 https://maestrodatabase.com/blog/aeglea-biotherapeutics-receives-refusal-to-file-letter-from-fda-for-pegzilarginase-for-the-treatment-of-arginase-1-deficiency 2022-06-02T20:52:16 https://maestrodatabase.com/blog/takeda-announces-mhra-approval-for-dengue-virus-vaccine-candidate-qdenga 2023-02-07T09:38:16 https://maestrodatabase.com/blog/myovant-sciences-and-pfizer-announce-fda-acceptance-of-supplemental-new-drug-application-for-myfembree 2022-06-02T11:48:32 https://maestrodatabase.com/blog/forxiga-approved-in-the-eu-for-the-treatment-of-symptomatic-chronic-heart-failure 2023-02-07T09:25:29 https://maestrodatabase.com/blog/icer-publishes-evidence-report-on-gene-therapy-for-beta-thalassaemia 2022-06-02T11:56:43 https://maestrodatabase.com/blog/rocket-pharmaceuticals-receives-fda-regenerative-medicine-advanced-therapy-designation-for-rp-a501-gene-therapy-for-danon-disease 2023-02-07T19:48:31 https://maestrodatabase.com/blog/biogen-and-samsung-bioepis-byooviz-ranibizumab-nuna-launches-in-the-united-states 2022-06-02T21:16:08 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-2-june-2022 2022-06-02T21:24:17 https://maestrodatabase.com/blog/aldeyra-therapeutics-announces-fda-acceptance-of-new-drug-application-for-reproxalap-for-the-treatment-of-dry-eye-disease 2023-02-07T19:43:09 https://maestrodatabase.com/blog/hope-for-change-after-pharmac-independent-review 2022-06-02T21:21:56 https://maestrodatabase.com/blog/itulatek-approved-for-treatment-of-children-and-adolescents-in-canada 2025-05-09T01:27:31 https://maestrodatabase.com/blog/pds-biotechnology-granted-fda-fast-track-designation-for-lead-candidate-pds0101 2022-06-02T20:59:17 https://maestrodatabase.com/blog/post-menopausal-osteoporosis-advantages-of-teriparatide-over-risedronate-sodium 2022-06-02T21:09:58 https://maestrodatabase.com/blog/tlv-reconsiders-subsidy-of-the-il-17-and-il-23-inhibitors 2022-06-02T21:05:51 https://maestrodatabase.com/blog/14-000-women-at-risk-of-fractures-after-the-menopause-to-benefit-from-bone-disease-drug 2024-08-07T11:41:33 https://maestrodatabase.com/blog/pfizer-asks-fda-to-authorise-covid-19-vaccine-for-youngest-kids 2022-06-02T21:40:51 https://maestrodatabase.com/blog/payback-and-health-technology-assessment-in-italy-a-new-governance-for-medical-devices 2023-02-07T20:23:23 https://maestrodatabase.com/blog/possible-resurrection-of-build-back-better-from-the-dead-drug-price-measures-could-be-key-component 2022-06-02T21:37:06 https://maestrodatabase.com/blog/miracle-cystic-fibrosis-drug-kept-out-of-reach-in-developing-countries 2023-02-07T20:17:05 https://maestrodatabase.com/blog/patients-to-get-new-medicines-up-to-six-months-sooner 2026-03-18T02:59:47 https://maestrodatabase.com/blog/the-medicine-is-a-miracle-but-only-if-you-can-afford-it 2023-02-07T20:04:20 https://maestrodatabase.com/blog/the-eu-butts-heads-with-big-pharma-to-make-medicines-cheaper 2023-02-07T20:09:07 https://maestrodatabase.com/blog/valeo-pharma-obtains-public-reimbursement-for-onstryv-in-quebec 2023-02-07T19:58:48 https://maestrodatabase.com/blog/thousands-sign-petition-demanding-35-kids-with-cystic-fibrosis-be-given-life-saving-drug-kaftrio 2022-06-02T21:31:41 https://maestrodatabase.com/blog/osimertinib-mesylate-in-combination-with-pemetrexed-disodium-heptahydrate-and-platinum-based-chemotherapy-for-patients-with-advanced-egfr-mutation-positive-non-small-cell-lung-cancer-final-guidance 2025-05-09T02:48:52 https://maestrodatabase.com/blog/nice-launches-refreshed-support-service-for-life-sciences-industry 2023-11-07T00:25:46 https://maestrodatabase.com/blog/calliditas-announces-submission-of-new-drug-application-to-u-dot-s-fda-for-nefecon-in-patients-with-primary-iga-nephropathy 2021-03-15T10:55:02 https://maestrodatabase.com/blog/health-canada-approves-doptelet-avatrombopag-for-two-indications-in-thrombocytopenia 2023-11-07T01:28:20 https://maestrodatabase.com/blog/doh-publishes-revised-agenda-for-the-july-2025-pbac-meeting 2025-05-09T10:07:53 https://maestrodatabase.com/blog/pfizer-and-opko-announce-extension-of-u-dot-s-fda-review-of-biologics-license-application-of-somatrogon-for-paediatric-growth-hormone-deficiency 2021-09-25T01:16:29 https://maestrodatabase.com/blog/bioxcel-therapeutics-receives-fda-breakthrough-therapy-designation-for-bxcl501-for-the-acute-treatment-of-agitation-associated-with-dementia 2021-03-15T11:07:47 https://maestrodatabase.com/blog/ontario-providing-access-to-life-changing-treatment-for-cystic-fibrosis-patients 2021-09-25T03:04:00 https://maestrodatabase.com/blog/when-generic-versions-of-weight-loss-drugs-arrive-public-plans-should-cover-them-experts-say 2026-03-18T03:58:23 https://maestrodatabase.com/blog/vertexs-supplement-to-a-new-drug-submission-for-kalydeco-ivacaftor-for-patients-with-cystic-fibrosis-between-the-ages-of-4-months-and-18-years-with-the-r117h-mutation-in-the-cftr-gene-accepted-for-priority-review-by-health-canada 2021-09-25T03:30:19 https://maestrodatabase.com/blog/adagrasib-for-previously-treated-patients-with-advanced-kras-g12c-mutation-positive-non-small-cell-lung-cancer 2025-05-09T10:17:08 https://maestrodatabase.com/blog/melinta-therapeutics-announces-fda-approval-of-kimyrsa-ortivancin-for-the-treatment-of-adult-patients-with-acute-bacterial-skin-and-skin-structure-infections 2021-03-15T20:06:42 https://maestrodatabase.com/blog/patients-upset-over-repeated-failures-to-reimburse-blood-cancer-drugs 2023-11-07T03:35:00 https://maestrodatabase.com/blog/the-drugs-at-the-heart-of-our-pricing-crisis 2021-03-15T20:18:12 https://maestrodatabase.com/blog/health-economic-assessment-of-zolgensma-in-spinal-muscular-atrophy 2021-03-15T20:22:41 https://maestrodatabase.com/blog/fda-approves-first-generic-of-drug-for-prevention-of-hiv-and-to-treat-hiv-1 2017-06-10T05:01:43 https://maestrodatabase.com/blog/millions-of-vaccinations-are-set-to-be-ready-by-the-end-of-may 2021-03-15T19:51:53 https://maestrodatabase.com/blog/emas-safety-committee-continues-investigation-of-covid-19-vaccine-astrazeneca-and-thromboembolic-events 2021-03-15T19:54:12 https://maestrodatabase.com/blog/japan-government-scraps-proposals-for-drug-price-cuts-in-policy-guidelines 2017-06-10T05:09:16 https://maestrodatabase.com/blog/trumps-fda-stirs-a-generic-drug-storm 2017-06-10T05:06:24 https://maestrodatabase.com/blog/pharmaessentia-provides-u-dot-s-regulatory-update-on-ropeginterferon-alfa-2b-njft-for-the-treatment-of-polycythemia-vera 2021-03-15T20:00:27 https://maestrodatabase.com/blog/nice-rejects-zurampic-for-hyperuricaemia-in-gout-patients 2017-06-10T05:29:48 https://maestrodatabase.com/blog/facebook-to-label-all-posts-about-coronavirus-vaccines 2021-03-15T20:40:38 https://maestrodatabase.com/blog/carisma-therapeutics-announces-u-dot-s-fda-grants-fast-track-designation-to-ct-0508-for-the-treatment-of-patients-with-solid-tumours 2021-09-25T08:08:34 https://maestrodatabase.com/blog/icer-to-assess-treatments-for-myasthenia-gravis 2021-03-15T20:46:07 https://maestrodatabase.com/blog/aurinia-announces-positive-cost-effectiveness-assessment-of-lupkynis-voclosporin-in-latest-icer-draft-evidence-report 2021-03-15T20:55:16 https://maestrodatabase.com/blog/msac-publishes-agenda-for-upcoming-pasc-meeting 2021-09-25T08:28:40 https://maestrodatabase.com/blog/fda-approves-repatha-evolocumab-in-paediatric-patients-age-10-and-older-with-heterozygous-familial-hypercholesterolaemia 2021-09-25T05:46:17 https://maestrodatabase.com/blog/novartis-receives-fda-accelerated-approval-for-fabhalta-iptacopan-the-first-and-only-complement-inhibitor-for-the-reduction-of-proteinuria-in-primary-iga-nephropathy 2024-08-07T23:39:07 https://maestrodatabase.com/blog/pharmac-work-in-funding-medicines-for-rare-disorders-progressing 2018-07-16T03:30:54 https://maestrodatabase.com/blog/multiple-countries-pause-astrazeneca-vaccine-use 2021-03-15T20:29:39 https://maestrodatabase.com/blog/doctors-too-keen-to-operate-say-experts 2021-09-25T05:42:17 https://maestrodatabase.com/blog/biden-harris-administration-increases-medicare-payment-for-life-saving-covid-19-vaccine 2021-03-15T20:33:12 https://maestrodatabase.com/blog/fast-tracking-research-into-treatments-for-covid-19 2020-03-23T02:19:12 https://maestrodatabase.com/blog/confirmation-of-technigas-us-fda-timetable 2021-03-15T20:35:07 https://maestrodatabase.com/blog/determinants-of-orphan-drug-prices-in-germany 2020-03-23T02:35:59 https://maestrodatabase.com/blog/250-dollars-million-investment-in-life-changing-cancer-medicines 2018-07-16T03:33:51 https://maestrodatabase.com/blog/nice-backs-azs-asthma-biologic-fasenra 2018-07-16T12:39:49 https://maestrodatabase.com/blog/germany-belgium-and-france-among-those-hit-hardest-as-commissions-pharma-legislation-proposals-risk-europe-losing-a-third-of-its-share-of-global-r-and-d-by-2040 2023-11-07T19:42:34 https://maestrodatabase.com/blog/my-health-record-opens-new-era-for-health-care 2018-07-16T03:54:27 https://maestrodatabase.com/blog/vertex-announces-casgevy-reimbursement-agreement-for-the-treatment-of-transfusion-dependent-beta-thalassemia-in-england 2024-08-08T03:07:34 https://maestrodatabase.com/blog/fda-approval-of-icotyde-icotrokinra-ushers-in-new-era-for-first-line-systemic-treatment-of-plaque-psoriasis-with-a-targeted-oral-peptide 2026-03-18T19:58:11 https://maestrodatabase.com/blog/trump-fails-at-lowering-drug-prices-as-costs-keep-going-up 2018-07-16T12:56:51 https://maestrodatabase.com/blog/lawmaker-asks-pfizer-to-make-recent-rollback-on-drug-prices-permanent 2018-07-16T12:59:29 https://maestrodatabase.com/blog/2018-october-price-disclosure-cycle---indicative-prices 2018-07-16T12:46:18 https://maestrodatabase.com/blog/medicare-finalises-reimbursement-rule-for-breakthrough-medical-devices 2024-08-08T01:01:06 https://maestrodatabase.com/blog/my-health-record-opt-out-period-begins-but-privacy-concerns-remain 2018-07-16T12:51:00 https://maestrodatabase.com/blog/neurogene-announces-rmat-designation-for-ngn-401-investigational-gene-therapy-for-rett-syndrome 2024-08-08T00:57:01 https://maestrodatabase.com/blog/phrma-responds-to-trump-blueprint-with-its-own-drug-pricing-proposal-reduce-payments-to-pbms 2018-07-16T21:52:32 https://maestrodatabase.com/blog/u-dot-s-fda-extends-review-timeline-for-invokana-canagliflozin-supplemental-new-drug-application 2018-07-16T21:56:12 https://maestrodatabase.com/blog/emas-proactive-publication-of-clinical-data-a-success 2018-07-16T21:48:26 https://maestrodatabase.com/blog/atagi-2023-booster-advice 2023-02-08T01:00:19 https://maestrodatabase.com/blog/health-minister-greg-hunt-defends-my-health-record-amid-opt-out-faults 2018-07-16T22:02:11 https://maestrodatabase.com/blog/aldeyra-therapeutics-receives-complete-response-letter-from-the-us-food-and-drug-administration-for-the-reproxalap-new-drug-application-for-the-treatment-of-signs-and-symptoms-of-dry-eye-disease 2026-03-18T09:46:54 https://maestrodatabase.com/blog/fda-issues-a-complete-response-letter-regarding-the-nda-for-idebenone-for-leber-hereditary-optic-neuropathy-in-the-united-states 2026-03-18T11:13:15 https://maestrodatabase.com/blog/meiragtx-granted-fda-regenerative-medicine-advanced-therapy-designation-for-aav-gad-for-the-treatment-of-parkinsons-disease 2025-05-10T00:02:26 https://maestrodatabase.com/blog/update-on-finalisation-of-mcit-rule-to-provide-national-medicare-coverage-for-fda-breakthrough-devices-and-diagnostics 2021-03-15T23:44:06 https://maestrodatabase.com/blog/gamida-cell-completes-rolling-biologics-license-application-submission-to-the-fda-for-omidubicel 2022-06-03T02:17:19 https://maestrodatabase.com/blog/final-reconciliation-of-savings-from-side-agreements-full-year-2019 2020-03-23T06:01:20 https://maestrodatabase.com/blog/hansoh-pharmas-ameile-almonertinib-receives-marketing-authorisation-in-china-for-second-line-treatment-for-patients-with-egfr-t790-mutation-non-small-cell-lung-cancer 2020-03-23T08:07:28 https://maestrodatabase.com/blog/coronavirus-covid-19-update-fda-provides-update-on-patient-access-to-certain-rems-drugs-during-covid-19-public-health-emergency 2020-03-23T20:17:53 https://maestrodatabase.com/blog/scientists-identify-69-drugs-to-test-against-the-coronavirus 2020-03-23T20:13:47 https://maestrodatabase.com/blog/insulin-gains-new-pathway-to-increased-competition 2020-03-23T20:09:22 https://maestrodatabase.com/blog/coronavirus-patients-in-limbo-as-gilead-suspends-emergency-drug-access 2020-03-23T20:04:10 https://maestrodatabase.com/blog/fda-and-ema-collaborate-to-facilitate-sars-cov-2-vaccine-development 2020-03-23T20:26:03 https://maestrodatabase.com/blog/malaria-and-arthritis-drugs-touted-as-potential-coronavirus-cure-triggering-pharmacy-rush 2020-03-23T20:23:34 https://maestrodatabase.com/blog/trump-promised-the-worlds-lowest-drug-prices-we-checked-the-numbers 2026-03-18T22:26:26 https://maestrodatabase.com/blog/eiger-biopharmaceuticals-completes-submission-of-new-drug-application-to-fda-for-lonafarnib-for-treatment-of-progeria-and-progeroid-laminopathies 2020-03-23T20:40:30 https://maestrodatabase.com/blog/fda-finalises-guidance-on-real-time-review-of-oncology-drugs 2023-11-08T00:01:28 https://maestrodatabase.com/blog/ema-grants-prime-designation-to-tolerogenixxs-mic-lx-therapy-for-donor-specific-immune-tolerance-in-kidney-transplantation 2026-03-18T22:32:12 https://maestrodatabase.com/blog/intra-cellular-prices-schizophrenia-drug-at-1-320-dollars-per-month 2020-03-23T20:31:43 https://maestrodatabase.com/blog/mitsubishi-tanabe-pharma-canada-announces-that-companys-oral-treatment-formulation-for-amyotrophic-lateral-sclerosis-has-been-added-to-the-provincial-drug-plans-in-prince-edward-island-newfoundland-and-labrador 2023-11-08T01:49:04 https://maestrodatabase.com/blog/rush-to-raise-funds-for-large-covid-19-drug-trial-in-australian-hospitals 2020-03-23T21:20:07 https://maestrodatabase.com/blog/nivolumab-in-combination-with-fluoropyrimidine--and-platinum-based-chemotherapy-for-patients-with-untreated-unresectable-advanced-recurrent-or-metastatic-oesophageal-squamous-cell-carcinoma 2023-02-08T10:37:42 https://maestrodatabase.com/blog/bayer-submits-aflibercept-8-mg-for-regulatory-approval-in-two-major-retinal-eye-diseases-in-the-eu 2023-02-08T07:16:23 https://maestrodatabase.com/blog/covid-19-and-processing-times 2020-03-23T20:52:06 https://maestrodatabase.com/blog/atagi-recommendations-on-use-of-the-pfizer-bivalent-original-slash-omicron-ba-dot-4-slash-5-covid-19-vaccine 2023-02-08T07:20:30 https://maestrodatabase.com/blog/fintepla-fenfluramine-oral-solution-approved-in-the-eu-for-adjunctive-treatment-of-seizures-associated-with-lennox-gastaut-syndrome 2023-02-08T07:10:46 https://maestrodatabase.com/blog/pelosi-drug-pricing-plan-would-let-government-negotiate-most-costly-medicines 2019-09-10T05:55:24 https://maestrodatabase.com/blog/speeding-up-access-to-new-medicines-in-scotland-abbreviated-process 2023-02-08T19:59:00 https://maestrodatabase.com/blog/appili-therapeutics-announces-that-fda-accepts-the-ati-1501-nda 2023-02-08T19:46:53 https://maestrodatabase.com/blog/santhera-concludes-agreement-with-french-authorities-on-raxone-reimbursement-and-plans-to-submit-a-request-for-an-early-access-program-for-vamorolone 2023-02-08T11:02:32 https://maestrodatabase.com/blog/tonix-pharmaceuticals-receives-fast-track-designation-from-the-u-dot-s-fda-for-tnx-102-sl-for-treatment-of-agitation-in-alzheimers-disease 2018-07-16T23:11:23 https://maestrodatabase.com/blog/the-fda-either-will-find-its-voice-or-get-its-comeuppance-under-commissioner-gottlieb 2017-06-11T01:26:21 https://maestrodatabase.com/blog/stakeholders-want-more-clarity-on-fdas-statistical-approach-to-assessing-bioequivalence 2023-02-08T10:43:16 https://maestrodatabase.com/blog/pharmac-proposing-to-fully-fund-testosterone-gel-for-all-who-need-it 2023-11-08T04:15:43 https://maestrodatabase.com/blog/cvs-health-responds-to-request-for-information-on-trump-administrations-blueprint-to-lower-drug-prices 2018-07-17T12:17:59 https://maestrodatabase.com/blog/subsequent-entry-products-for-non-biological-complex-drugs 2017-06-11T01:38:10 https://maestrodatabase.com/blog/novartis-ceo-narasimhan-suggests-possible-legislative-action-to-reverse-inflation-reduction-acts-impact-on-drug-prices-what-can-and-cant-be-done 2023-02-08T20:51:50 https://maestrodatabase.com/blog/sanofis-venglustat-earns-breakthrough-therapy-designation-in-the-us-for-type-3-gaucher-disease 2026-03-18T23:14:16 https://maestrodatabase.com/blog/abbvie-announces-humira-adalimumab-patent-license-with-mylan 2018-07-17T12:21:42 https://maestrodatabase.com/blog/medical-reviews-prescribe-economies-in-health-care 2017-06-11T01:32:33 https://maestrodatabase.com/blog/janssen-submits-phase-3-study-data-to-the-european-medicines-agency-and-us-food-and-drug-administration-for-sirturo-bedaquiline 2023-11-08T04:10:02 https://maestrodatabase.com/blog/pharmacy-guild-plan-to-halve-pbs-general-patient-charge-for-prescription-medicine-prices 2021-09-26T00:14:01 https://maestrodatabase.com/blog/fluoguide-receives-fda-fast-track-designation-for-fg001-in-high-grade-glioma 2026-03-18T23:21:56 https://maestrodatabase.com/blog/congress-ready-to-forbid-drug-price-gag-clauses-against-pharmacies 2018-07-17T21:41:32 https://maestrodatabase.com/blog/all-adults-now-eligible-for-a-2023-covid-19-booster-dose 2023-02-08T20:09:00 https://maestrodatabase.com/blog/proqr-receives-fast-track-designation-from-fda-for-qr-1123-for-autosomal-dominant-retinitis-pigmentosa 2019-09-10T06:11:09 https://maestrodatabase.com/blog/my-health-record-confusion-as-some-australians-shocked-they-already-have-one 2018-07-17T21:44:17 https://maestrodatabase.com/blog/fda-grants-fast-track-status-to-amplyx-pharmaceuticals-for-iv-and-oral-formulations-of-fosmanogepix-apx001-for-seven-different-indications 2019-09-10T06:05:54 https://maestrodatabase.com/blog/regorafenib-monohydrate-for-patients-with-previously-treated-metastatic-colorectal-cancer 2023-02-08T20:02:52 https://maestrodatabase.com/blog/statement-from-fda-commissioner-on-new-efforts-to-empower-consumers-by-advancing-access-to-nonprescription-drugs 2018-07-17T21:38:45 https://maestrodatabase.com/blog/federal-government-to-announce-50-dollars-million-custom-cancer-drug-trial 2018-07-17T21:55:07 https://maestrodatabase.com/blog/u-dot-k-health-officials-make-a-counteroffer-to-vertex-for-its-pricey-cystic-fibrosis-drugs 2018-07-17T21:47:22 https://maestrodatabase.com/blog/johnson-and-johnson-ceo-defends-drug-prices-calls-for-changes-in-how-medical-costs-are-covered 2018-07-17T21:50:21 https://maestrodatabase.com/blog/opko-partner-vifor-fresenius-receives-marketing-approval-for-rayaldee-in-canada 2018-07-17T22:40:21 https://maestrodatabase.com/blog/the-wrong-cancer-pharmaceutical-benefits-scheme-failing-rare-cancer-sufferers 2017-06-11T10:29:07 https://maestrodatabase.com/blog/private-health-insurance-rankings-to-give-consumers-more-information-about-coverage-and-benchmarks 2018-07-17T21:59:16 https://maestrodatabase.com/blog/mhra-authorises-enzyme-inhibitor-anastrozole-to-prevent-breast-cancer-in-post-menopausal-women 2023-11-08T05:45:00 https://maestrodatabase.com/blog/takeda-receives-european-commission-approval-for-adzynma-recombinant-adamts13-as-the-first-and-only-recombinant-adamts13-replacement-therapy-for-congenital-thrombotic-thrombocytopenic-purpura 2024-08-08T06:13:52 https://maestrodatabase.com/blog/the-secret-slugs-doubling-your-health-fund-premium 2017-06-11T21:40:29 https://maestrodatabase.com/blog/coolhealth-enters-us-market-with-targetcool-a-breakthrough-fda-class-ii-medical-device-offering-unprecedented-precise-rapid-cooling-for-pain-management-and-bruise-minimisation 2023-02-09T05:28:55 https://maestrodatabase.com/blog/myriad-genetics-receives-fda-approval-of-the-mychoice-cdx-test-as-the-companion-diagnostic-for-zejula-niraparib-for-patients-with-ovarian-cancer 2026-03-19T01:19:02 https://maestrodatabase.com/blog/pharmac-publishes-agenda-for-november-2023-ptac-meeting 2023-11-08T05:32:14 https://maestrodatabase.com/blog/astrazeneca-to-supply-the-us-with-up-to-half-a-million-additional-doses-of-the-potential-covid-19-antibody-treatment-azd7442 2021-03-16T08:01:45 https://maestrodatabase.com/blog/zydus-receives-us-fda-approval-for-zituvimet-to-treat-adult-patients-with-type-2-diabetes-mellitus 2023-11-08T05:25:06 https://maestrodatabase.com/blog/eylea-aflibercept-injection-approved-as-the-first-pharmacological-treatment-for-preterm-infants-with-retinopathy-of-prematurity-by-the-fda 2023-02-09T04:49:03 https://maestrodatabase.com/blog/fda-approves-new-medication-for-chronic-weight-management 2023-11-08T19:42:44 https://maestrodatabase.com/blog/biogen-sage-therapeutics-post-partum-depression-pill-priced-at-15-900-dollars 2023-11-08T19:33:58 https://maestrodatabase.com/blog/proposal-for-various-medicines-in-the-neurology-immunology-and-nephrology-therapeutic-areas-approved 2017-06-12T02:37:14 https://maestrodatabase.com/blog/remix-therapeutics-granted-fda-fast-track-designation-for-rem-422-for-the-treatment-of-recurrent-metastatic-or-unresectable-adenoid-cystic-carcinoma 2026-03-19T22:02:03 https://maestrodatabase.com/blog/gilead-sciences-korea-seeks-reimbursement-for-trodelvy 2023-11-08T06:35:45 https://maestrodatabase.com/blog/changes-to-the-national-immunisation-schedule---meningococcal-c-conjugate-vaccine 2017-06-12T02:41:18 https://maestrodatabase.com/blog/are-breakthrough-drugs-as-safe-as-other-fda-approved-medicines 2018-07-17T23:08:10 https://maestrodatabase.com/blog/lynavoy-linerixibat-approved-by-the-us-fda-for-cholestatic-pruritus-in-patients-with-primary-biliary-cholangitis 2026-03-19T22:12:29 https://maestrodatabase.com/blog/first-electronic-product-information-published-for-selected-human-medicines 2023-11-08T20:13:37 https://maestrodatabase.com/blog/samsung-bioepis-and-organon-announce-fda-acceptance-of-supplemental-biologics-license-application-for-interchangeability-designation-for-hadlima-adalimumab-bwwd-a-biosimilar-to-humira 2023-11-08T20:00:11 https://maestrodatabase.com/blog/fda-approves-fourth-product-under-national-priority-voucher-program-higher-dose-semaglutide 2026-03-19T22:31:30 https://maestrodatabase.com/blog/iaso-bio-and-innovent-jointly-announce-the-nmpa-acceptance-of-the-new-drug-application-for-equecabtagene-autoleucel-for-the-treatment-of-relapsed-and-slash-or-refractory-multiple-myeloma 2022-06-03T06:59:08 https://maestrodatabase.com/blog/janssen-announces-u-dot-s-fda-approval-of-symtuza-the-first-and-only-complete-darunavir-based-single-tablet-regimen-for-the-treatment-of-hiv-1-infection 2018-07-18T01:42:53 https://maestrodatabase.com/blog/highlights-from-december-2017-chmp-meeting 2017-12-17T00:59:55 https://maestrodatabase.com/blog/ema-publishes-agenda-for-23-26-march-chmp-meeting 2020-03-23T23:58:39 https://maestrodatabase.com/blog/worlds-first-gene-editing-therapy-for-blood-disorder-to-be-available-to-hundreds-of-patients-in-england 2024-08-08T21:48:59 https://maestrodatabase.com/blog/50-dollars-million-to-provide-life-saving-support-to-cancer-patients 2018-07-18T01:34:03 https://maestrodatabase.com/blog/horizon-therapeutics-announces-the-fda-has-granted-priority-review-of-the-teprotumumab-biologics-license-application-for-the-treatment-of-active-thyroid-eye-disease 2019-09-10T07:28:09 https://maestrodatabase.com/blog/eu-and-japan-reinforce-their-collaboration-on-inspections-of-medicine-manufacturers 2018-07-18T21:52:35 https://maestrodatabase.com/blog/vertex-mulls-over-nhs-englands-offer-for-cf-drugs 2018-07-18T21:54:39 https://maestrodatabase.com/blog/pharmac-seeks-feedback-on-updates-to-covid-19-antiviral-medicines 2025-05-11T23:27:20 https://maestrodatabase.com/blog/biopharmaceutical-industry-takes-bold-new-policy-position-on-how-payments-should-work-in-us-supply-chain 2018-07-18T05:36:06 https://maestrodatabase.com/blog/novartis-kisqali-now-first-and-only-cdk4-slash-6-inhibitor-indicated-in-us-as-first-line-therapy-specifically-for-pre-menopausal-women-and-as-initial-therapy-with-fulvestrant-in-postmenopausal-women 2018-07-18T21:48:46 https://maestrodatabase.com/blog/availability-of-sanofis-nexviadyme-avalglucosidase-alfa-provides-nhs-with-new-treatment-for-pompe-disease 2023-02-09T09:06:05 https://maestrodatabase.com/blog/fda-grants-regenerative-medicine-advanced-therapy-designation-for-rexlemestrocel-l-in-chronic-low-back-oain 2023-02-09T08:50:56 https://maestrodatabase.com/blog/karyopharm-initiates-rolling-submission-of-new-drug-application-to-u-dot-s-fda-for-selinexor-as-a-treatment-for-patients-with-penta-refractory-multiple-myeloma 2018-07-18T21:58:25 https://maestrodatabase.com/blog/quebec-becomes-first-province-to-cover-brukinsa-zanubrutinib-for-the-treatment-of-waldenstroems-macroglobulinemia 2023-02-09T06:51:36 https://maestrodatabase.com/blog/investigation-of-covid-19-vaccine-astrazeneca-and-thromboembolic-events-continues 2021-03-16T19:49:14 https://maestrodatabase.com/blog/erdafitinib-for-the-treatment-of-patients-with-unresectable-or-metastatic-urothelial-cancer-with-an-fgfr3-alteration-after-a-pd-1-or-pd-l1-inhibitor 2025-05-12T09:59:53 https://maestrodatabase.com/blog/helsinn-announces-european-approval-of-the-iv-formulation-of-akynzeo-fosnetupitant-with-palonosetron 2020-03-24T01:33:31 https://maestrodatabase.com/blog/box-office-hit-moves-china-to-act-on-cancer-drugs 2018-07-18T22:21:34 https://maestrodatabase.com/blog/merck-receives-priority-review-from-fda-for-new-drug-application-for-hif-2a-inhibitor-belzutifan-mk-6482 2021-03-16T19:52:56 https://maestrodatabase.com/blog/edaravone-for-amyotrophic-lateral-sclerosis-barriers-to-access-and-lifeboat-ethics 2020-03-24T01:28:54 https://maestrodatabase.com/blog/breast-cancer-patients-can-access-new-interest-free-payment-plan-for-genomic-test-that-may-help-them-avoid-chemotherapy 2021-03-16T19:57:09 https://maestrodatabase.com/blog/trixeo-aerosphere-approved-in-the-uk-as-first-inhaled-respiratory-medicine-using-next-generation-propellant-with-near-zero-global-warming-potential 2025-05-12T06:43:07 https://maestrodatabase.com/blog/remarks-from-fda-commissioner-as-prepared-for-delivery-at-the-brookings-institution-on-the-release-of-the-fdas-biosimilars-action-plan 2018-07-18T22:23:48 https://maestrodatabase.com/blog/greg-hunts-medical-deals-come-back-to-bite-him 2019-09-10T20:57:00 https://maestrodatabase.com/blog/canada-releases-final-amendments-to-patented-medicines-pricing-regulations 2019-09-10T20:45:38 https://maestrodatabase.com/blog/icers-blasted-pharma-pricing-for-years-but-now-drug-makers-are-rolling-up-their-sleeves-to-cooperate 2019-09-10T12:44:55 https://maestrodatabase.com/blog/trump-says-he-will-sign-executive-order-on-drug-price-caps 2025-05-12T04:57:50 https://maestrodatabase.com/blog/doctors-complain-of-gag-over-astrazeneca-vaccine 2021-03-16T10:52:13 https://maestrodatabase.com/blog/xeris-pharmaceuticals-receives-u-dot-s-fda-approval-for-gvoke-glucagon-the-first-ready-to-use-stable-liquid-glucagon-for-severe-hypoglycaemia 2019-09-10T21:12:10 https://maestrodatabase.com/blog/once-again-the-viability-of-the-u-dot-s-biosimilar-market-is-thrown-into-question 2021-03-16T20:14:23 https://maestrodatabase.com/blog/dapagliflozin-propanediol-monohydrate-for-the-treatment-of-patients-with-chronic-heart-failure-with-preserved-or-mildly-reduced-ejection-fraction 2023-02-09T11:42:50 https://maestrodatabase.com/blog/atagi-statement-in-response-to-european-decisions-about-the-astrazeneca-vaccine 2021-03-16T20:24:41 https://maestrodatabase.com/blog/why-do-post-marketing-drug-studies-required-by-the-fda-take-so-long 2019-09-10T21:08:11 https://maestrodatabase.com/blog/frontrunner-to-lead-fda-dogged-by-controversies-has-developed-knack-for-confronting-them 2019-09-10T21:03:56 https://maestrodatabase.com/blog/empagliflozin-for-the-treatment-of-patients-with-chronic-heart-failure-with-preserved-or-mildly-reduced-ejection-fraction 2023-02-09T11:36:23 https://maestrodatabase.com/blog/more-americans-went-without-health-insurance-last-year-its-the-first-increase-in-almost-a-decade 2019-09-10T20:59:23 https://maestrodatabase.com/blog/health-canada-approves-perjeta-for-use-pre-surgery-in-patients-with-aggressive-early-breast-cancer 2021-03-16T20:32:53 https://maestrodatabase.com/blog/drug-prices-get-washingtons-attention-ahead-of-2020-election 2019-09-10T21:31:25 https://maestrodatabase.com/blog/for-drug-companies-there-are-real-costs-to-unpopularity 2019-09-10T21:29:17 https://maestrodatabase.com/blog/drug-prices-keep-rising-amid-political-pressure-but-not-as-fast 2019-09-10T21:26:56 https://maestrodatabase.com/blog/nice-recommends-genetic-test-to-prevent-newborn-babies-going-deaf 2023-02-09T10:01:43 https://maestrodatabase.com/blog/eu-regulators-team-up-with-u-dot-s-and-uk-on-pharmaceutical-mergers 2021-03-16T20:04:04 https://maestrodatabase.com/blog/the-pharmac-compromise 2021-03-16T20:08:12 https://maestrodatabase.com/blog/drug-formulary-managers-use-of-step-therapy-can-lead-to-sub-optimal-outcomes 2019-09-10T21:48:22 https://maestrodatabase.com/blog/digital-mental-health-tech-for-children-and-young-people-recommended-by-nice-in-first-rapid-healthtech-guidance 2023-02-09T20:09:46 https://maestrodatabase.com/blog/fda-accepts-biologics-license-application-for-filing-and-grants-priority-review-for-sacituzumab-govitecan-for-the-treatment-of-metastatic-triple-negative-breast-cancer 2018-07-19T02:40:26 https://maestrodatabase.com/blog/bidens-sotu-targets-drug-companies-but-misses-opportunity-to-challenge-health-insurers-and-pharmacy-benefit-managers 2023-02-09T20:00:56 https://maestrodatabase.com/blog/fda-grants-breakthrough-therapy-designation-for-genentechs-tecentriq-in-combination-with-avastin-as-first-line-treatment-for-advanced-or-metastatic-hepatocellular-carcinoma 2018-07-18T23:12:07 https://maestrodatabase.com/blog/erosion-of-physician-and-patient-treatment-choice-continues---alliance-for-safe-biologic-medicines-raises-concerns-for-patients-as-british-columbia-expands-biologics-forced-switching-policy 2019-09-10T21:43:53 https://maestrodatabase.com/blog/covid-19-vaccine-safety-report-09-february-2023 2023-02-09T20:04:32 https://maestrodatabase.com/blog/biden-to-push-for-insulin-cost-caps-but-unlikely-to-secure-congressional-approval 2023-02-09T19:49:10 https://maestrodatabase.com/blog/astrazeneca-vaccine-fears-may-be-more-deadly-than-any-side-effect 2021-03-16T20:55:05 https://maestrodatabase.com/blog/lorlatinib-for-the-first-line-treatment-of-patients-with-alk-positive-advanced-non-small-cell-lung-cancer 2023-02-09T11:50:16 https://maestrodatabase.com/blog/statement-by-fda-commissioner-on-the-formation-of-a-new-work-group-to-develop-focused-drug-importation-policy-options-to-address-access-challenges-related-to-certain-sole-source-medicines-with-limited-patient-availability-but-no-blocking-patents-or-exclusivities 2018-07-19T23:16:28 https://maestrodatabase.com/blog/fda-grants-regular-approval-to-dostarlimab-gxly-for-dmmr-endometrial-cancer 2023-02-09T20:49:48 https://maestrodatabase.com/blog/lillys-once-weekly-trulicity-dulaglutide-label-updated-to-include-data-showing-benefits-for-adults-with-type-2-diabetes-and-chronic-kidney-disease 2018-07-19T23:36:41 https://maestrodatabase.com/blog/ema-confirms-acceptance-of-application-for-avt04-a-proposed-biosimilar-to-stelara-ustekinumab 2023-02-09T20:32:27 https://maestrodatabase.com/blog/nexus-pharmaceuticals-receives-fda-approval-for-tirofiban-hydrochloride-injection 2023-02-09T20:17:51 https://maestrodatabase.com/blog/dentists-banned-from-prescribing-potential-covid-19-drug-to-self-family 2020-03-24T03:31:36 https://maestrodatabase.com/blog/ocular-therapeutix-announces-fda-acceptance-of-nda-resubmission-for-dextenza 2018-07-19T23:56:27 https://maestrodatabase.com/blog/drug-makers-game-the-patent-system-and-reap-billions-fda-says 2018-07-19T23:46:50 https://maestrodatabase.com/blog/covid-19-hydroxychloroquine 2020-03-24T03:27:12 https://maestrodatabase.com/blog/new-zealand-to-expand-pharmac-to-the-pacific 2018-07-19T23:51:19 https://maestrodatabase.com/blog/biosimilar-pegfilgrastim-on-the-pbs---information-for-health-professionals-and-patients 2020-09-10T23:54:59 https://maestrodatabase.com/blog/the-drug-helping-coronavirus-patients 2020-03-24T05:58:37 https://maestrodatabase.com/blog/an-update-on-the-2020-annual-meeting-in-beijing-china 2020-03-24T04:41:11 https://maestrodatabase.com/blog/public-summary-documents-first-time-decisions-not-to-recommend-and-deferrals---november-2025-pbac-meeting 2026-03-20T05:36:24 https://maestrodatabase.com/blog/regulators-in-eu-japan-and-us-take-steps-to-facilitate-development-of-new-antibiotics 2017-06-12T11:07:05 https://maestrodatabase.com/blog/nice-refuses-to-expand-use-of-roches-ipf-drug-esbriet 2017-06-12T11:10:24 https://maestrodatabase.com/blog/novartis-joins-pfizer-in-holding-line-on-drug-prices-in-u-dot-s 2018-07-20T01:59:33 https://maestrodatabase.com/blog/u-dot-s-fda-approves-supplemental-new-drug-application-for-expanded-indication-of-eucrisa-crisaborole-2-percent-ointment-in-children-as-young-as-3-months-of-age-with-mild-to-moderate-atopic-dermatitis 2020-03-24T19:59:23 https://maestrodatabase.com/blog/smc---june-2017-decisions 2017-06-12T20:56:54 https://maestrodatabase.com/blog/coherus-biosciences-receives-complete-response-letter-from-fda-for-its-biologics-license-application-for-chs-1701-pegfilgrastim-biosimilar-candidate 2017-06-12T21:01:24 https://maestrodatabase.com/blog/updates-to-the-hta-policy-and-methods-review-reference-committee-9-november-2023 2023-11-09T00:58:15 https://maestrodatabase.com/blog/high-costs-lack-of-affordability-most-common-factors-that-lead-consumers-to-cancel-health-insurance-coverage 2017-06-12T21:10:09 https://maestrodatabase.com/blog/us-fda-grants-fast-track-designation-to-renova-therapeutics-rt-100-ac6-gene-transfer-for-the-treatment-of-heart-failure 2017-12-17T02:21:16 https://maestrodatabase.com/blog/dont-let-opt-out-debate-shroud-potential-benefits-of-my-health-record 2018-07-20T02:50:26 https://maestrodatabase.com/blog/updates-from-lilly-about-insulin-supply-and-affordability 2020-03-24T20:12:54 https://maestrodatabase.com/blog/malcolm-turnbull-defends-insurers-access-to-health-records 2018-07-20T02:53:39 https://maestrodatabase.com/blog/regenxbio-announces-fda-acceptance-and-priority-review-of-the-bla-for-rgx-121-for-mps-ii 2025-05-13T23:30:56 https://maestrodatabase.com/blog/for-the-first-time-45-counties-could-have-no-insurer-in-the-obamacare-marketplaces 2017-06-12T21:18:29 https://maestrodatabase.com/blog/trump-thanks-novartis-pfizer-for-not-raising-drug-prices 2018-07-20T02:05:28 https://maestrodatabase.com/blog/samsung-bioepis-announces-fda-approval-of-420-mg-multi-dose-vial-of-ontruzant-trastuzumab-dttb 2020-03-24T20:06:34 https://maestrodatabase.com/blog/smc---may-2025-decisions 2025-05-13T06:29:51 https://maestrodatabase.com/blog/supreme-court-speeds-copycat-biologic-drugs-to-market 2017-06-12T21:14:46 https://maestrodatabase.com/blog/trumps-drug-plan-picks-up-momentum-as-merck-lowers-some-prices 2018-07-20T02:07:42 https://maestrodatabase.com/blog/proposal-to-fund-a-pangenotypic-hepatitis-c-treatment---glecaprevir-and-pibrentasvir-maviret 2018-07-20T06:04:01 https://maestrodatabase.com/blog/two-new-kidney-cancer-drugs-approved-for-nhs-scotland 2017-06-12T21:22:45 https://maestrodatabase.com/blog/amylyx-pharmaceuticals-receives-notification-of-pdufa-date-extension-for-amx0035-for-the-treatment-of-als 2022-06-04T01:41:28 https://maestrodatabase.com/blog/quebec-based-pharmaceutical-company-donates-1-million-doses-of-malaria-drug-for-covid-19-patients-across-canada 2020-03-24T20:27:51 https://maestrodatabase.com/blog/global-regulators-map-out-data-requirements-for-phase-1-covid-19-vaccine-trials 2020-03-24T20:21:42 https://maestrodatabase.com/blog/nhs-scotland-reject-extremely-effective-breast-cancer-drug-for-third-time-despite-drug-being-offered-to-english-patients 2017-06-12T21:25:35 https://maestrodatabase.com/blog/coronavirus-drug-to-be-trialled-on-frontline-health-workers 2020-03-24T20:18:08 https://maestrodatabase.com/blog/dusc-utilisation-analysis-public-release-documents-october-2025 2026-03-20T11:28:14 https://maestrodatabase.com/blog/on-new-recommendation-for-treatment-of-covid-19-patients-who-calls-for-equitable-access-to-casirivimab-and-imdevimab-for-covid-19 2021-09-26T21:26:47 https://maestrodatabase.com/blog/drug-prices-this-time-is-different 2017-06-12T21:39:50 https://maestrodatabase.com/blog/meningococcal-b-vaccine-to-be-added-to-immunisation-scheme-if-experts-recommend-it 2018-07-20T06:29:17 https://maestrodatabase.com/blog/fda-fast-tracks-therapy-for-radiation-induced-dry-mouth 2025-05-14T01:02:46 https://maestrodatabase.com/blog/canada-pays-more-for-prescription-drugs-for-common-conditions-than-other-wealthy-countries-cmaj-study 2017-06-12T21:31:20 https://maestrodatabase.com/blog/nice-backs-radionuclide-therapy-for-some-neuroendocrine-tumours 2018-07-20T11:35:51 https://maestrodatabase.com/blog/sanofi-withdraws-tga-submission-for-kevzara 2018-07-20T06:08:16 https://maestrodatabase.com/blog/olaratumab-recommended-for-nhs-use-in-england 2017-06-12T21:52:51 https://maestrodatabase.com/blog/as-trump-touts-an-unproven-coronavirus-treatment-supplies-evaporate-for-patients-who-need-those-drugs 2020-03-24T20:40:40 https://maestrodatabase.com/blog/senate-set-to-hear-pitch-on-three-ideas-to-bring-down-drug-prices 2017-06-12T21:42:24 https://maestrodatabase.com/blog/trumps-drug-price-push-butts-into-two-megadeals 2018-07-20T11:52:49 https://maestrodatabase.com/blog/manitoba-family-calling-for-province-to-cover-life-changing-drug 2021-09-26T21:07:47 https://maestrodatabase.com/blog/australia-secures-supply-of-drug-that-treats-arthritis-and-covid 2021-09-26T21:17:52 https://maestrodatabase.com/blog/fda-tweaks-biosimilar-application-review-program 2021-09-26T21:13:35 https://maestrodatabase.com/blog/orkambi-drugs-maker-says-nhs-undervalues-patient-lives 2018-07-20T11:47:24 https://maestrodatabase.com/blog/wtx101-granted-fast-track-designation-by-the-u-dot-s-fda-for-the-treatment-of-wilson-disease 2017-12-17T02:42:40 https://maestrodatabase.com/blog/fda-approves-first-targeted-treatment-for-patients-with-relapsed-or-refractory-acute-myeloid-leukeamia-who-have-a-certain-genetic-mutation 2018-07-20T22:42:24 https://maestrodatabase.com/blog/fda-approves-new-indications-for-zomacton-somatropin-as-ferring-plans-launch-of-needle-free-delivery-system 2018-07-20T12:13:40 https://maestrodatabase.com/blog/merck-is-lowering-drug-prices-theres-a-catch 2018-07-20T13:29:12 https://maestrodatabase.com/blog/mhra-approves-first-uk-treatment-for-congenital-thrombotic-thrombocytopenic-purpura 2025-05-14T02:04:41 https://maestrodatabase.com/blog/lilly-canada-announces-availability-of-mounjaro-kwikpen-tirzepatide-in-all-doses-advancing-care-for-adults-living-with-type-2-diabetes 2025-05-14T01:28:06 https://maestrodatabase.com/blog/ema-starts-review-of-ixchiq-live-attenuated-chikungunya-vaccine 2025-05-14T01:24:39 https://maestrodatabase.com/blog/fda-provides-scientific-and-regulatory-clarity-for-generic-drug-developers-through-the-issuance-of-43-new-or-revised-product-specific-guidance-documents-including-hard-to-copy-complex-generics-and-abuse-deterrent-formulations-of-opioids 2018-07-20T22:57:40 https://maestrodatabase.com/blog/pharmac-asked-to-reconsider-funding-rsv-drug-for-at-risk-babies 2023-11-09T02:02:09 https://maestrodatabase.com/blog/fda-approves-nivolumab-with-chemotherapy-for-previously-untreated-hodgkin-lymphoma 2026-03-20T20:46:04 https://maestrodatabase.com/blog/u-dot-s-fda-approves-pfizers-biosimilar-nivestym-filgrastim-aafi 2018-07-20T23:15:18 https://maestrodatabase.com/blog/statement-from-fda-commissioner-on-agencys-efforts-to-encourage-the-development-of-and-broaden-access-to-generic-versions-of-opioid-analgesics-that-are-formulated-to-deter-abuse 2018-07-20T23:00:33 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-inotersen-and-patisiran-for-hereditary-transthyretin-amyloidosis 2018-07-20T23:06:14 https://maestrodatabase.com/blog/sellas-receives-fast-track-designation-from-fda-for-galinpepimut-s-for-the-treatment-of-patients-with-multiple-myeloma 2018-07-20T23:24:27 https://maestrodatabase.com/blog/fdas-califf-wants-to-get-the-public-as-excited-about-life-expectancy-as-cures 2023-11-09T03:01:48 https://maestrodatabase.com/blog/pharmacs-drug-switch 2021-03-17T03:37:40 https://maestrodatabase.com/blog/paddy-gower-has-issues-blind-solo-mum-desperate-for-pharmac-to-fund-life-changing-medicine-so-she-can-see-her-kids 2023-11-09T02:29:17 https://maestrodatabase.com/blog/takeda-receives-us-fda-approval-of-fruzaqla-fruquintinib-for-previously-treated-metastatic-colorectal-cancer 2023-11-09T02:39:58 https://maestrodatabase.com/blog/bristol-myers-squibb-transforms-the-classical-hodgkin-lymphoma-treatment-paradigm-with-expanded-us-and-ema-approvals-for-opdivo-nivolumab 2026-03-20T22:16:09 https://maestrodatabase.com/blog/rhythm-pharmaceuticals-announces-fda-approval-of-imcivree-setmelanotide-for-patients-with-acquired-hypothalamic-obesity 2026-03-20T21:08:06 https://maestrodatabase.com/blog/fda-approves-belzutifan-for-pheochromocytoma-or-paraganglioma 2025-05-14T23:16:22 https://maestrodatabase.com/blog/new-restrictions-on-prescribing-hydroxychloroquine-for-covid-19 2020-03-24T22:45:42 https://maestrodatabase.com/blog/nhs-spending-watchdog-to-review-evidence-on-alzheimers-treatments 2026-03-20T21:20:01 https://maestrodatabase.com/blog/national-health-expenditure-projections-2019-28-expected-rebound-in-prices-drives-rising-spending-growth 2020-03-24T22:42:02 https://maestrodatabase.com/blog/outrageous-prices-of-orphan-drugs-a-call-for-collaboration 2018-07-22T12:14:38 https://maestrodatabase.com/blog/the-man-who-should-be-four-years-dead 2018-07-23T08:36:36 https://maestrodatabase.com/blog/us-fda-approves-krintafel-tafenoquine-for-the-radical-cure-of-p-vivax-malaria 2018-07-22T09:21:49 https://maestrodatabase.com/blog/we-desperately-need-this-data-nib-boss-wants-members-digital-health-records 2018-07-23T08:59:54 https://maestrodatabase.com/blog/tasmanian-pharmacies-facing-deluge-of-demand-for-meningococcal-vaccines 2018-07-23T08:53:26 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-telisotuzumab-vedotin-tllv-for-non-small-cell-lung-cancer-with-high-c-met-protein-overexpression 2025-05-14T23:46:09 https://maestrodatabase.com/blog/aerie-pharmaceuticals-announces-early-notification-of-fda-acceptance-of-nda-submission-for-roclatan-netarsudil-slash-latanoprost-ophthalmic-solution 2018-07-23T13:20:28 https://maestrodatabase.com/blog/eleven-states-now-letting-uninsured-sign-up-for-obamacare 2020-03-24T23:04:12 https://maestrodatabase.com/blog/political-influence-a-serious-problem-for-fda-under-trump-former-commissioner-says 2026-03-20T23:37:44 https://maestrodatabase.com/blog/beigene-announces-plan-to-pursue-accelerated-approval-in-the-u-dot-s-of-btk-inhibitor-zanubrutinib-in-waldenstroem-macroglobulinaemia 2018-07-23T13:10:30 https://maestrodatabase.com/blog/hhs-considers-removing-j-and-js-stelara-from-medicare-drug-price-negotiations 2023-11-09T04:14:23 https://maestrodatabase.com/blog/deal-agreed-for-continued-access-to-life-changing-treatment-for-rare-inherited-disease 2025-05-15T00:35:51 https://maestrodatabase.com/blog/hhs-releases-initial-guidance-for-medicare-prescription-drug-inflation-rebate-program 2023-02-10T03:27:00 https://maestrodatabase.com/blog/health-inequalities---an-update-to-nices-methods-for-health-technology-evaluation 2025-05-15T00:32:59 https://maestrodatabase.com/blog/prevail-therapeutics-receives-u-dot-s-fda-fast-track-designation-for-pr006-to-slow-the-progression-of-frontotemporal-dementia-with-a-grn-mutation 2020-03-24T23:36:37 https://maestrodatabase.com/blog/proposed-pmprb-changes-could-limit-canadas-access-to-new-drugs 2018-07-23T21:21:54 https://maestrodatabase.com/blog/rhythm-pharmaceuticals-receives-european-medicines-agency-prime-designation-for-setmelanotide-in-rare-genetic-disorders-of-obesity 2018-07-23T21:15:09 https://maestrodatabase.com/blog/will-trumps-plans-bring-down-drug-prices 2018-07-23T21:35:05 https://maestrodatabase.com/blog/roche-hiked-cancer-drug-prices-before-pledge-to-keep-them-flat 2018-07-23T21:25:43 https://maestrodatabase.com/blog/precision-medicine-success-hinges-on-diagnostics-clinical-utility 2018-07-23T21:30:24 https://maestrodatabase.com/blog/allergan-receives-fda-fast-track-designation-for-agn-241751-for-the-treatment-of-major-depressive-disorder 2018-07-23T21:51:10 https://maestrodatabase.com/blog/covid-19-sacubitril-with-valsartan-entresto 2020-03-24T23:54:17 https://maestrodatabase.com/blog/biocryst-announces-fda-acceptance-of-nda-for-orladeyo-berotralstat-oral-granules-in-patients-with-hereditary-angioedema-aged-2-to-11-years 2025-05-15T03:33:50 https://maestrodatabase.com/blog/lowering-drug-prices-is-a-political-move-that-makes-both-trump-and-drug-companies-look-good-says-analyst 2018-07-23T21:37:50 https://maestrodatabase.com/blog/pricing-pledges-from-drug-makers-include-plenty-of-fine-print 2018-07-23T21:40:06 https://maestrodatabase.com/blog/tasmania-to-expand-meningococcal-vaccination-program 2018-07-24T11:55:54 https://maestrodatabase.com/blog/toward-greater-transparency-at-the-fda---now-is-the-time-to-act 2026-03-21T10:34:48 https://maestrodatabase.com/blog/how-the-trump-administration-is-browbeating-big-pharma-on-drug-prices 2018-07-24T12:14:39 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-elects-three-new-members-to-governance-board 2018-07-23T21:55:16 https://maestrodatabase.com/blog/rfp---supply-of-recombinant-factor-viii-recombinant-factor-ix-and-bypassing-agents-for-the-treatment-of-haemophilia 2018-07-24T11:49:33 https://maestrodatabase.com/blog/nobel-prize-winner-says-virus-curve-will-flatten-in-couple-of-weeks 2020-03-25T00:07:05 https://maestrodatabase.com/blog/us-fda-accepts-for-priority-review-bristol-myers-squibbs-application-for-breyanzi-lisocabtagene-maraleucel-for-relapsed-or-refractory-chronic-lymphocytic-leukaemia-or-small-lymphocytic-lymphoma 2023-11-09T19:30:15 https://maestrodatabase.com/blog/debunking-the-myths-about-a-canadian-pharmacare-program 2018-07-24T12:18:29 https://maestrodatabase.com/blog/vanflyta-approved-in-the-eu-as-the-first-flt3-inhibitor-specifically-for-patients-with-newly-diagnosed-flt3-itd-positive-aml 2023-11-09T07:01:46 https://maestrodatabase.com/blog/citius-pharmaceuticals-receives-fda-approval-for-lymphir-denileukin-diftitox-cxdl-immunotherapy-for-the-treatment-of-adults-with-relapsed-or-refractory-cutaneous-t-cell-lymphoma 2024-08-09T05:27:58 https://maestrodatabase.com/blog/mhra-authorises-diabetes-drug-mounjaro-tirzepatide-for-weight-management-and-weight-loss 2023-11-09T19:24:55 https://maestrodatabase.com/blog/abbvie-receives-u-dot-s-fda-approval-of-orilissa-elagolix-for-the-management-of-moderate-to-severe-pain-associated-with-endometriosis 2018-07-24T12:34:17 https://maestrodatabase.com/blog/same-drug-two-prices-why-the-higher-price-prevails 2023-11-09T06:34:47 https://maestrodatabase.com/blog/millions-to-opt-out-of-my-health-record-as-backlash-builds 2018-07-24T21:12:23 https://maestrodatabase.com/blog/cystic-fibrosis-patients-launch-class-action-suit-over-access-to-costly-drug 2018-07-24T21:29:02 https://maestrodatabase.com/blog/assessing-the-value-of-innovative-devices-and-diagnostics-the-importance-of-clear-and-relevant-claims-of-benefit 2018-07-24T12:45:54 https://maestrodatabase.com/blog/fda-extends-pdufa-date-of-biohavens-troriluzole-nda-for-rare-disease-spinocerebellar-ataxia 2025-05-15T03:38:44 https://maestrodatabase.com/blog/health-canada-approves-increlex-first-and-only-recombinant-human-insulin-like-growth-factor-1-therapy-in-canada-for-the-treatment-of-severe-growth-failure-associated-with-ultra-rare-condition-in-children-and-adolescents 2021-03-17T05:09:43 https://maestrodatabase.com/blog/enzalutamide-for-the-treatment-of-patients-with-non-metastatic-prostate-cancer-after-radical-prostatectomy-or-radiotherapy 2024-08-09T04:21:29 https://maestrodatabase.com/blog/my-health-record-program-will-save-lives-theres-no-debate 2018-07-24T13:01:32 https://maestrodatabase.com/blog/eli-lilly-opposes-using-imports-to-tackle-high-drug-prices 2018-07-24T21:38:26 https://maestrodatabase.com/blog/democrats-take-aim-at-high-drug-prices-with-bill-allowing-medicare-to-negotiate 2018-07-24T21:41:36 https://maestrodatabase.com/blog/prescribing-biosimilars 2018-07-24T21:34:26 https://maestrodatabase.com/blog/fda-amends-pembrolizumabs-gastric-cancer-indication 2023-11-09T19:45:41 https://maestrodatabase.com/blog/majority-think-trumps-drug-plan-wont-lower-prices-they-pay 2018-07-24T21:49:55 https://maestrodatabase.com/blog/casi-pharmaceuticals-announces-market-approval-of-cnct19-by-china-nmpa 2023-11-09T19:37:02 https://maestrodatabase.com/blog/apellis-pharmaceuticals-apl-2-receives-fast-track-designation-from-fda-for-the-treatment-of-patients-with-geographic-atrophy 2018-07-24T21:53:09 https://maestrodatabase.com/blog/the-health-202-this-mothers-tweet-about-drug-prices-went-viral-trumps-plans-are-unlikely-to-help-her 2018-07-24T21:43:51 https://maestrodatabase.com/blog/abbvie-prices-new-endometriosis-drug-at-10-000-dollars-a-year 2018-07-24T21:46:46 https://maestrodatabase.com/blog/pharmac-to-get-one-time-66-dollars-million-boost 2023-02-10T06:07:55 https://maestrodatabase.com/blog/what-next-for-pharmac-boss-after-sick-sneering-remarks-about-rachel-smalley 2023-11-09T20:15:41 https://maestrodatabase.com/blog/a-new-alzheimers-drug-gave-patients-hope-millions-cant-get-it 2023-02-10T19:57:44 https://maestrodatabase.com/blog/unitedhealth-unit-to-add-eight-insulin-products-to-its-reimbursement-list 2023-11-09T20:07:46 https://maestrodatabase.com/blog/getting-ready-for-emas-website-relaunch-on-5-december-2023 2023-11-09T20:13:23 https://maestrodatabase.com/blog/modified-release-paracetamol-containing-products-to-be-suspended-from-eu-market 2017-12-17T08:56:42 https://maestrodatabase.com/blog/updates-from-the-health-technology-assessment-policy-and-methods-review-reference-committee-february-2023 2023-02-10T06:34:03 https://maestrodatabase.com/blog/fda-approves-first-treatment-for-patients-with-rare-inherited-blood-clotting-disorder 2023-11-09T19:52:26 https://maestrodatabase.com/blog/novel-cancer-drug-gets-stymied-by-medicare-rigid-billing-system 2017-12-17T10:18:58 https://maestrodatabase.com/blog/pharmac-indicates-interest-in-funding-cancer-treatment-bevacizumab 2024-08-09T06:46:26 https://maestrodatabase.com/blog/looming-tipping-point-for-japan-pharma 2017-12-17T20:55:25 https://maestrodatabase.com/blog/fda-approves-first-nalmefene-hydrochloride-auto-injector-to-reverse-opioid-overdose 2024-08-09T06:38:50 https://maestrodatabase.com/blog/canadas-drug-agency-taking-steps-to-expand-access-to-real-world-evidence 2024-08-09T06:30:31 https://maestrodatabase.com/blog/biomarin-announces-updated-strategy-for-roctavian-to-focus-on-us-germany-and-italy 2024-08-09T21:28:23 https://maestrodatabase.com/blog/coronavirus-drugs-vaccine-are-many-months-away-health-experts-say 2020-03-25T04:50:17 https://maestrodatabase.com/blog/covid-19-and-angiotensin-converting-enzyme-inhibitors-and-angiotensin-receptor-blockers-what-is-the-evidence 2020-03-25T04:40:19 https://maestrodatabase.com/blog/treating-covid-19--off-label-drug-use-compassionate-use-and-randomised-clinical-trials-during-pandemics 2020-03-25T04:34:52 https://maestrodatabase.com/blog/enhertu-approved-in-japan-for-treatment-of-patients-with-her2-positive-unresectable-or-metastatic-breast-cancer 2020-03-25T09:00:39 https://maestrodatabase.com/blog/fda-approves-first-nasal-spray-for-treatment-of-anaphylaxis 2024-08-09T21:57:52 https://maestrodatabase.com/blog/novo-nordisk-upset-as-dutch-agency-advises-against-insurance-cover-for-wegovy 2024-08-09T21:53:29 https://maestrodatabase.com/blog/mythbusting-pharmac 2021-03-17T07:52:36 https://maestrodatabase.com/blog/tepmetko-tepotinib-approved-in-japan-for-advanced-nsclc-with-metex14-skipping-alterations 2020-03-25T09:05:34 https://maestrodatabase.com/blog/leveraging-real-world-evidence-in-regulatory-submissions-of-medical-devices 2021-03-17T10:41:04 https://maestrodatabase.com/blog/states-say-some-doctors-stockpile-trial-coronavirus-drugs-for-themselves 2020-03-25T20:02:17 https://maestrodatabase.com/blog/fda-announces-funding-opportunity-to-explore-the-use-of-real-world-data-to-generate-real-world-evidence-in-regulatory-decision-making 2020-03-25T19:57:24 https://maestrodatabase.com/blog/chf-supports-healthy-people-healthy-systems 2017-12-18T03:35:41 https://maestrodatabase.com/blog/not-so-anonymous-medicare-data-can-be-used-to-identify-individual-patients-researchers-say 2017-12-18T03:29:52 https://maestrodatabase.com/blog/fda-sets-pdufa-date-for-xspray-pharmas-re-submitted-application-for-dasynoc 2025-05-15T23:07:54 https://maestrodatabase.com/blog/ama-president-tony-bartone-vows-to-safeguard-patient-privacy-in-my-health 2018-07-25T09:26:45 https://maestrodatabase.com/blog/decision-relating-to-various-oncology-medicines 2017-06-13T03:40:14 https://maestrodatabase.com/blog/oracle-providing-white-house-with-software-to-study-unproven-coronavirus-drugs 2020-03-25T20:18:49 https://maestrodatabase.com/blog/india-bans-export-of-drug-being-tested-for-coronavirus-treatment 2020-03-25T20:04:29 https://maestrodatabase.com/blog/fda-grants-regenerative-medicine-advanced-therapy-designation-for-brainchild-bios-b7-h3-car-t-cell-therapy-for-incurable-paediatric-brain-tumours 2025-05-16T00:07:45 https://maestrodatabase.com/blog/icer-analyses-are-flawed-undervalue-life-saving-medicines-and-are-biased-toward-price-controls-finds-new-pri-brief 2021-03-17T20:08:03 https://maestrodatabase.com/blog/false-and-reckless-health-minister-slams-anti-vaccination-documentary-maker 2018-07-25T21:05:16 https://maestrodatabase.com/blog/zytiga-to-get-insurance-benefit-for-primary-therapy-in-metastatic-hormone-sensitive-prostate-cancer 2021-03-17T20:12:56 https://maestrodatabase.com/blog/fda-approves-retifanlimab-dlwr-with-carboplatin-and-paclitaxel-and-as-a-single-agent-for-squamous-cell-carcinoma-of-the-anal-canal 2025-05-16T00:00:45 https://maestrodatabase.com/blog/sydney-uni-software-helps-hospitals-cut-medicine-bill 2018-07-25T09:41:11 https://maestrodatabase.com/blog/a-new-cure-cheap-for-hepatitis-c-is-being-ignored-by-thousands 2018-07-25T20:58:45 https://maestrodatabase.com/blog/scientist-invented-a-new-pathway-to-approve-biosimilars-and-the-fda-is-listening 2018-07-25T21:23:06 https://maestrodatabase.com/blog/fda-publishes-list-of-surrogate-outcomes-used-in-drug-approvals 2018-07-25T21:26:40 https://maestrodatabase.com/blog/meningococcal-scare-has-hobart-chemists-swamped-by-requests-for-vaccine 2018-07-25T21:08:34 https://maestrodatabase.com/blog/sparta-biomedical-receives-fda-breakthrough-device-designation-for-sbm-01-biomimetic-implant 2021-03-17T20:00:07 https://maestrodatabase.com/blog/senate-committee-advances-bill-to-eliminate-gag-clauses-limiting-disclosures-on-drug-prices 2018-07-25T21:37:42 https://maestrodatabase.com/blog/dont-call-yet-gps-inundated-by-demands-for-covid-19-vaccine-bookings 2021-03-17T20:27:30 https://maestrodatabase.com/blog/europes-vaccine-suspension-may-be-driven-as-much-by-politics-as-science 2021-03-17T20:36:55 https://maestrodatabase.com/blog/icer-publishes-final-evidence-report-on-treatment-for-retinitis-pigmentosa 2025-05-16T00:29:40 https://maestrodatabase.com/blog/doctors-hold-the-key-to-lower-drug-prices 2018-07-25T21:32:09 https://maestrodatabase.com/blog/this-pharmacist-had-vaccine-doses-to-spare-so-he-hit-the-road 2021-03-17T20:46:34 https://maestrodatabase.com/blog/cms-empowers-patients-and-ensures-site-neutral-payment-in-proposed-rule 2018-07-25T21:49:54 https://maestrodatabase.com/blog/abbvie-announces-extension-of-review-for-supplemental-new-drug-application-of-upadacitinib-for-the-treatment-of-adults-with-active-psoriatic-arthritis 2021-03-17T20:17:01 https://maestrodatabase.com/blog/kaerus-biosciences-lead-candidate-ker-0193-granted-orphan-drug-designation-and-rare-paediatric-drug-designation-by-us-fda-for-treatment-of-fragile-x-syndrome 2025-05-16T00:16:19 https://maestrodatabase.com/blog/we-are-in-the-crisis-of-the-century-europe-threatens-to-seize-astrazeneca-factories 2021-03-17T20:22:48 https://maestrodatabase.com/blog/aafp-calls-for-wide-ranging-approach-to-lowering-drug-prices 2018-07-25T21:44:18 https://maestrodatabase.com/blog/general-practices-join-the-covid-19-vaccination-program 2021-03-17T20:24:38 https://maestrodatabase.com/blog/phathom-pharmaceuticals-provides-regulatory-updates 2023-02-10T21:47:44 https://maestrodatabase.com/blog/amneal-receives-us-fda-approval-for-brekiya-dihydroergotamine-mesylate-injection-for-the-acute-treatment-of-migraine-and-cluster-headaches-in-adults 2025-05-16T01:47:21 https://maestrodatabase.com/blog/health-canada-approves-new-indication-for-lung-cancer-treatment-option-alunbrig 2021-03-17T20:50:05 https://maestrodatabase.com/blog/u-dot-s-plans-to-use-real-world-and-trial-data-to-determine-when-vaccines-need-to-be-updated 2021-03-17T20:55:49 https://maestrodatabase.com/blog/decision-for-funding-in-the-immunosuppressant-cardiovascular-and-anti-nausea-therapeutic-areas 2019-09-11T05:54:32 https://maestrodatabase.com/blog/sagimet-biosciences-receives-fast-track-designation-from-u-dot-s-fda-for-fasn-inhibitor-tvb-2640-in-nash 2021-03-17T23:04:50 https://maestrodatabase.com/blog/lykos-therapeutics-announces-complete-response-letter-for-midomafetamine-capsules-for-ptsd 2024-08-09T23:15:28 https://maestrodatabase.com/blog/european-commission-approves-expanded-indication-for-mercks-keytruda-pembrolizumab-in-adult-and-paediatric-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma 2021-03-17T22:54:35 https://maestrodatabase.com/blog/proposal-to-list-a-range-of-interventional-cardiology-products-supplied-by-edwards-lifesciences 2017-06-13T05:11:15 https://maestrodatabase.com/blog/fda-permits-marketing-of-first-sars-cov-2-diagnostic-test-using-traditional-premarket-review-process 2021-03-17T23:47:18 https://maestrodatabase.com/blog/praluent-alirocumab-now-approved-in-european-union-to-reduce-the-risk-of-cardiovascular-events-in-patients-with-established-cardiovascular-disease 2019-03-18T05:29:37 https://maestrodatabase.com/blog/japans-mhlw-approves-padcev-enfortumab-vedotin-for-advanced-urothelial-cancer 2021-09-27T08:09:44 https://maestrodatabase.com/blog/investment-in-innovative-medicines-needed-to-safeguard-australias-long-term-prosperity 2021-03-18T00:06:39 https://maestrodatabase.com/blog/fda-approves-pfizers-supplemental-new-drug-application-for-cibinqo-abrocitinib 2023-02-10T22:32:20 https://maestrodatabase.com/blog/intrabio-announces-submission-of-supplemental-new-drug-application-for-levacetylleucine-for-ataxia-telangiectasia 2026-03-22T03:39:52 https://maestrodatabase.com/blog/the-republican-war-on-obamacare----what-has-it-achieved 2018-07-25T23:45:53 https://maestrodatabase.com/blog/outside-political-groups-not-always-what-they-appear 2019-03-18T11:25:39 https://maestrodatabase.com/blog/state-of-the-union-highlights-americas-awkward-conversation-on-financing-the-development-of-new-medicines 2023-02-11T00:24:44 https://maestrodatabase.com/blog/merck-announces-fda-breakthrough-therapy-designation-for-investigational-therapy-tepotinib-in-patients-with-metastatic-nsclc-with-metex14-skipping-alterations 2019-09-11T06:35:45 https://maestrodatabase.com/blog/nice-celebrates-its-20th-anniversary 2019-03-18T11:10:02 https://maestrodatabase.com/blog/cma-drops-anti-competitive-case-against-msd 2019-03-18T11:12:41 https://maestrodatabase.com/blog/new-early-breast-cancer-drug-to-reduce-risk-of-recurrence-or-death-approved-for-australian-women 2019-03-18T19:53:28 https://maestrodatabase.com/blog/canada-oks-celltrions-biosimilar 2019-09-11T07:10:13 https://maestrodatabase.com/blog/pharmac-places-temporary-dispensing-limits-on-all-funded-community-medicines 2020-03-26T00:15:21 https://maestrodatabase.com/blog/u-dot-s-food-and-drug-administration-accepts-bristol-myers-squibbs-applications-for-opdivo-nivolumab-plus-yervoy-ipilimumab-and-opdivo-plus-chemotherapy-for-unresectable-advanced-recurrent-or-metastatic-oesophageal-squamous-cell-carcinoma 2021-09-27T20:52:45 https://maestrodatabase.com/blog/three-new-drugs-added-to-pbs-to-ease-cost-pain 2019-03-18T19:59:33 https://maestrodatabase.com/blog/preserving-clinical-trial-integrity-during-the-coronavirus-pandemic 2020-03-26T00:12:31 https://maestrodatabase.com/blog/astrazeneca-chadox1-s-covid-19 2021-03-18T06:36:35 https://maestrodatabase.com/blog/cytodyn-reaches-historical-milestone-submits-first-of-three-sections-of-bla-to-fda-for-leronlimab-pro-140-as-a-combination-therapy-for-hiv 2019-03-18T11:32:51 https://maestrodatabase.com/blog/will-price-of-avastin-staple-in-anti-cancer-therapy-go-down 2021-09-27T21:00:39 https://maestrodatabase.com/blog/allergan-announces-fda-approval-of-avycaz-ceftazidime-and-avibactam-for-paediatric-patients 2019-03-18T20:12:36 https://maestrodatabase.com/blog/the-use-of-validated-and-non-validated-surrogate-endpoints-in-two-ema-expedited-approval-pathways-a-cross-sectional-study-of-products-authorised-2011-2018 2019-09-11T07:19:30 https://maestrodatabase.com/blog/the-impact-of-pharmaceutical-rebates-on-patients-drug-expenditures 2019-03-18T20:07:03 https://maestrodatabase.com/blog/cms-will-pay-for-covid-19-booster-shots-eligible-consumers-can-receive-at-no-cost 2021-09-27T20:49:09 https://maestrodatabase.com/blog/the-policy-initiatives-scott-gottlieb-championed-at-the-fda-will-remain-after-he-departs 2019-03-18T20:10:22 https://maestrodatabase.com/blog/ema-evaluating-data-on-booster-dose-of-covid-19-vaccine-spikevax 2021-09-27T20:37:17 https://maestrodatabase.com/blog/medicines-only-work-if-patients-can-afford-them-solutions-for-the-high-drug-prices-era 2019-03-18T20:24:54 https://maestrodatabase.com/blog/canadian-cancer-patients-have-new-affordable-treatment-option 2021-09-27T21:36:59 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-bla-filing-of-aimmune-therapeutics-ar101-for-peanut-allergy 2019-03-18T20:19:00 https://maestrodatabase.com/blog/two-new-treatment-options-for-incurable-blood-cancer-assessed 2024-08-10T01:52:40 https://maestrodatabase.com/blog/chile-takes-several-unorthodox-steps-to-push-back-on-drug-prices-angering-pharma 2019-03-18T20:31:05 https://maestrodatabase.com/blog/drug-utilisation-subcommittee-utilisation-analysis-public-release-documents 2021-03-18T06:40:21 https://maestrodatabase.com/blog/could-discount-pbs-prices-become-a-thing-of-the-past 2021-09-27T21:06:51 https://maestrodatabase.com/blog/reimbursement-for-orphan-drug-spinraza-imminent 2019-03-18T20:35:18 https://maestrodatabase.com/blog/ohio-accuses-unitedhealths-optumrx-of-drug-overcharges-in-lawsuit 2019-03-18T20:28:12 https://maestrodatabase.com/blog/access-to-and-affordability-of-cancer-medicines-time-to-focus-on-the-last-mile 2021-09-27T21:17:05 https://maestrodatabase.com/blog/biosimilar-and-interchangeable-inseparable-scientific-concepts 2019-09-11T09:28:58 https://maestrodatabase.com/blog/melissas-battle-hurts 2017-12-18T11:08:52 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-positive-chmp-opinion-recommending-approval-of-yervoy-ipilimumab-for-the-treatment-of-paediatric-patients-12-years-and-older-with-unresectable-or-metastatic-melanoma 2017-12-18T19:32:59 https://maestrodatabase.com/blog/looking-north-can-a-single-payer-health-system-work-in-the-u-dot-s 2017-12-18T19:50:59 https://maestrodatabase.com/blog/gilead-marks-fifth-approval-for-trodelvy-in-metastatic-triple-negative-breast-cancer-under-project-orbis-initiative-with-health-canada-authorisation 2021-09-27T21:39:56 https://maestrodatabase.com/blog/humana-in-talks-to-buy-kindred-healthcare-with-equity-firms 2017-12-18T19:48:52 https://maestrodatabase.com/blog/public-summary-documents---november-2019-pbac-meeting-supplement 2020-03-26T04:03:17 https://maestrodatabase.com/blog/the-doctors-betraying-their-oath-to-do-no-harm 2021-09-27T21:52:53 https://maestrodatabase.com/blog/sanofi-and-alnylam-submit-marketing-authorisation-application-to-the-european-medicines-agency-for-patisiran-for-the-treatment-of-hereditary-attr-amyloidosis 2017-12-18T19:56:03 https://maestrodatabase.com/blog/covid-19-private-health-funds-dump-april-1-premium-rises-suspend-policies 2020-03-26T06:55:32 https://maestrodatabase.com/blog/amneal-receives-us-fda-approval-for-ipx203-for-treatment-of-parkinsons-disease-to-be-launched-as-crexont-carbidopa-and-levodopa-extended-release-capsules 2024-08-10T04:16:20 https://maestrodatabase.com/blog/us-fda-accepts-regulatory-submission-for-tagrisso-in-first-line-egfr-mutated-non-small-cell-lung-cancer 2017-12-18T20:03:58 https://maestrodatabase.com/blog/novartis-and-life-sciences-companies-commit-expertise-and-assets-to-the-fight-against-covid-19-pandemic-alongside-bill-and-melinda-gates-foundation 2020-03-26T06:47:54 https://maestrodatabase.com/blog/covid-19-will-it-result-in-a-total-lockdown-of-new-pbs-listings 2020-03-26T05:00:54 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-diabetes-therapies 2019-09-11T11:19:05 https://maestrodatabase.com/blog/covid-19-frontline-virus-fighters-to-trial-tb-vaccine 2020-03-26T19:58:22 https://maestrodatabase.com/blog/fda-accepts-biologics-license-application-for-fremanezumab-with-priority-review-for-prevention-of-migraine-and-grants-fast-track-designation-for-cluster-headache-development-program 2017-12-18T20:14:22 https://maestrodatabase.com/blog/u-dot-s-fda-approves-bristol-myers-squibbs-zeposia-ozanimod-a-new-oral-treatment-for-relapsing-forms-of-multiple-sclerosis 2020-03-26T10:40:43 https://maestrodatabase.com/blog/health-canada-approves-adtralza-tralokinumab-for-the-treatment-of-adolescents-aged-12-to-17-with-moderate-to-severe-atopic-dermatitis 2023-02-11T01:19:58 https://maestrodatabase.com/blog/crowdsourcing-to-fight-covid-19 2020-03-26T20:09:44 https://maestrodatabase.com/blog/pbs-continued-dispensing-arrangements 2021-03-18T08:16:17 https://maestrodatabase.com/blog/time-for-big-pharma-to-step-up-before-the-drug-price-debate-rises-again 2017-12-18T20:25:14 https://maestrodatabase.com/blog/fda-continues-to-support-transparency-and-collaboration-in-drug-approval-process-as-the-clinical-data-summary-pilot-concludes 2020-03-26T20:03:16 https://maestrodatabase.com/blog/covid-19-existing-drugs-may-be-key-to-vaccine 2020-03-26T20:00:52 https://maestrodatabase.com/blog/orphan-technologies-receives-rare-paediatric-disease-designation-from-fda-for-ot-58-to-treat-cystathionine-b-synthase-deficiency-homocystinuria 2020-03-26T20:22:15 https://maestrodatabase.com/blog/uber-for-pharmacies-launches 2020-03-26T20:19:11 https://maestrodatabase.com/blog/anti-depressant-medicine-brand-switch-theyve-been-used-as-guinea-pigs 2019-09-11T20:48:15 https://maestrodatabase.com/blog/government-injects-ps130-million-into-cancer-and-debilitating-illnesses 2019-09-11T20:45:30 https://maestrodatabase.com/blog/jazz-pharmaceuticals-announces-fda-acceptance-of-new-drug-application-for-jzp-258-for-cataplexy-and-excessive-daytime-sleepiness-associated-with-narcolepsy 2020-03-26T20:47:16 https://maestrodatabase.com/blog/gilead-declines-rare-disease-status-for-experimental-coronavirus-drug 2020-03-26T20:43:35 https://maestrodatabase.com/blog/united-therapeutics-announces-fda-acceptance-of-trevyent-new-drug-application-for-review 2019-09-11T12:11:47 https://maestrodatabase.com/blog/how-to-correct-this-big-medicare-mistake 2019-09-11T21:13:46 https://maestrodatabase.com/blog/germany-may-have-the-answer-for-reducing-drug-prices 2019-09-11T21:00:31 https://maestrodatabase.com/blog/digital-health-predictions-uncertainty-will-trigger-innovation-in-2023 2023-02-11T01:50:30 https://maestrodatabase.com/blog/puma-biotechnology-announces-u-dot-s-fda-acceptance-of-supplemental-new-drug-application-for-neratinib-to-treat-her2-positive-metastatic-breast-cancer 2019-09-11T20:55:28 https://maestrodatabase.com/blog/price-negotiations-begin-for-breast-cancer-combo-drugs 2020-03-26T20:55:52 https://maestrodatabase.com/blog/immunotherapy-a-groundbreaking-new-cancer-treatment-but-prohibitively-expensive 2019-09-11T21:26:25 https://maestrodatabase.com/blog/public-summary-documents---july-2023-pbac-meeting-round-2 2023-11-10T07:31:17 https://maestrodatabase.com/blog/bms-receives-european-commission-approval-for-peri-operative-regimen-of-neo-adjuvant-opdivo-nivolumab-and-chemotherapy-followed-by-adjuvant-opdivo-for-resectable-high-risk-non-small-cell-lung-cancer-with-pd-l1-expression-1-percent 2025-05-16T11:20:23 https://maestrodatabase.com/blog/we-need-to-make-biosimilars-easier-to-get 2019-09-11T21:21:24 https://maestrodatabase.com/blog/children-with-rare-inherited-condition-to-benefit-from-drug-through-managed-access-agreement 2019-09-11T21:17:02 https://maestrodatabase.com/blog/republicans-back-lawsuit-to-overturn-fda-approval-of-abortion-pill-and-pull-the-medication-from-us-market 2023-02-11T05:23:54 https://maestrodatabase.com/blog/chemotherapy-free-treatment-option-to-be-offered-to-patients-with-englands-most-common-leukaemia 2021-04-21T07:30:59 https://maestrodatabase.com/blog/uk-approval-for-daiichi-sankyos-cholesterol-lowering-treatments 2021-03-18T10:07:58 https://maestrodatabase.com/blog/fda-approves-first-vaccine-to-prevent-disease-caused-by-chikungunya-virus 2023-11-10T07:22:24 https://maestrodatabase.com/blog/nice-publishes-its-600th-technology-appraisal-guidance 2019-09-11T21:34:12 https://maestrodatabase.com/blog/celularity-announces-fast-track-designation-by-the-fda-for-its-natural-killer-cell-therapy-cynk-001-in-the-treatment-of-recurrent-glioblastoma-multiforme 2021-03-18T20:08:38 https://maestrodatabase.com/blog/mhra-joins-global-regulatory-partners-in-celebrating-ten-years-of-international-medicines-regulatory-cooperation 2023-11-10T07:55:48 https://maestrodatabase.com/blog/covid-19-vaccine-astrazeneca-benefits-still-outweigh-the-risks-despite-possible-link-to-rare-blood-clots-with-low-blood-platelets 2021-03-18T20:03:35 https://maestrodatabase.com/blog/kiniksa-announces-fda-approval-of-arcalyst-rilonacept-for-recurrent-pericarditis 2021-03-18T20:39:08 https://maestrodatabase.com/blog/amazon-to-expand-health-care-service-across-us 2021-03-18T20:45:56 https://maestrodatabase.com/blog/stimdia-medical-receives-fda-breakthrough-device-designation-for-the-pdstim-system-designed-to-facilitate-weaning-patients-from-mechanical-ventilation 2021-03-18T20:14:31 https://maestrodatabase.com/blog/generic-and-biosimilar-prescription-medicines-2016 2017-06-13T09:19:21 https://maestrodatabase.com/blog/novartis-kisqali-ribociclib-product-monograph-in-canada-now-includes-monaleesa-3-data-demonstrating-statistically-significant-improvement-in-overall-survival-in-postmenopausal-women-with-hr-plus-slash-her2--advanced-breast-cancer 2021-03-18T20:27:22 https://maestrodatabase.com/blog/youre-probably-going-to-need-medicaid 2017-06-13T09:34:46 https://maestrodatabase.com/blog/nice-publishes-appraisal-consultation-document-for-inotuzumab-ozogamicin 2017-06-13T09:24:59 https://maestrodatabase.com/blog/amgens-myeloma-treatment-kyprolis-gains-nice-approval 2017-06-13T20:59:59 https://maestrodatabase.com/blog/nice-to-work-with-partners-on-developing-new-ways-to-measure-quality-of-life-across-health-and-social-care 2017-06-13T20:55:13 https://maestrodatabase.com/blog/statement-from-fda-commissioner-scott-gottlieb-m-dot-d---fda-is-taking-new-steps-to-help-assess-opioid-drugs-with-abuse-deterrent-properties 2017-06-13T21:10:04 https://maestrodatabase.com/blog/patients-at-risk-as-hospitals-report-shortages-of-1500-life-saving-medicines 2017-06-13T21:18:42 https://maestrodatabase.com/blog/integrating-companion-diagnostics-into-cdr-and-pcodr-reviews 2017-06-13T21:25:18 https://maestrodatabase.com/blog/european-medicines-agency-grants-atara-biotherapeutics-accelerated-assessment-of-tab-cel-for-the-treatment-of-epstein-barr-virus-positive-post-transplant-lymphoproliferative-disease 2021-09-28T05:13:32 https://maestrodatabase.com/blog/government-negotiation-of-prescription-drug-prices-isnt-a-panacea-for-lower-costs 2017-06-13T21:21:21 https://maestrodatabase.com/blog/the-halfhearted-opposition-to-the-g-dot-o-p-dot-s-health-care-misery 2017-06-13T21:33:39 https://maestrodatabase.com/blog/in-drug-price-hearing-congress-tries-to-answer-some-basic-questions 2017-06-13T21:29:19 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-reviews-new-evidence-update-on-pcks9-inhibitors-highlights-lack-of-mortality-benefit-with-evolocumab 2017-06-13T21:43:57 https://maestrodatabase.com/blog/cannabis-rules-loosened-after-senate-gangs-up-on-government 2017-06-13T21:37:50 https://maestrodatabase.com/blog/new-treatment-option-now-available-in-canada-for-newly-diagnosed-patients-with-advanced-lung-cancer 2019-03-19T05:08:02 https://maestrodatabase.com/blog/eisai-initiates-rolling-submission-to-the-u-dot-s-fda-for-biologics-license-application-of-lecanemab-ban2401-for-early-alzheimers-disease-under-the-accelerated-approval-pathway 2021-09-28T05:32:28 https://maestrodatabase.com/blog/vfmcrp-announces-approval-for-tavneos-avacopan-for-the-treatment-of-anca-associated-vasculitis-in-japan 2021-09-28T05:18:12 https://maestrodatabase.com/blog/stada-and-alvotech-receive-positive-chmp-opinion-for-europes-first-ustekinumab-biosimilar-to-stelara 2023-11-10T20:21:38 https://maestrodatabase.com/blog/fully-human-anti-tnf-alfa-monoclonal-antibody-humira-obtains-additional-approval-for-high-dose-regimen-of-ulcerative-colitis-in-adult-patients-and-for-new-regimen-in-paediatric-patients 2021-09-28T05:24:20 https://maestrodatabase.com/blog/data-on-astrazeneca-vaccine-insufficient-for-swiss-approval 2021-03-19T04:21:54 https://maestrodatabase.com/blog/critical-technologies-for-australia---agriculture-and-health-sectors 2021-03-19T05:08:56 https://maestrodatabase.com/blog/boehringer-ingelheim-announces-fda-and-ema-regulatory-submission-for-nintedanib-in-systemic-sclerosis-associated-ild 2019-03-19T05:32:14 https://maestrodatabase.com/blog/nice-rejects-keytruda-for-advanced-bladder-cancer-in-final-guidance 2021-03-19T05:20:00 https://maestrodatabase.com/blog/biohaven-secures-priority-review-voucher-to-expedite-regulatory-review-of-rimegepant-zydis-odt-new-drug-application 2019-03-19T06:11:26 https://maestrodatabase.com/blog/mirati-therapeutics-receives-positive-opinion-from-chmp-for-krazati-adagrasib-as-a-targeted-treatment-option-for-patients-with-advanced-non-small-cell-lung-cancer-with-a-kras-g12c-mutation-following-a-re-examination-procedure 2023-11-10T21:03:00 https://maestrodatabase.com/blog/intrabio-fast-track-designation-for-gm2-gangliosidosis 2020-03-27T01:37:55 https://maestrodatabase.com/blog/seqirus-announces-health-canada-approval-of-expanded-age-indication-of-its-cell-based-quadrivalent-influenza-vaccine-for-people-two-years-of-age-and-older 2021-03-19T06:07:59 https://maestrodatabase.com/blog/fda-grants-priority-review-to-viiv-healthcares-new-drug-application-for-cabotegravir-long-acting-for-prevention-of-hiv 2021-09-28T20:43:33 https://maestrodatabase.com/blog/fda-accepts-libtayo-cemiplimab-rwlc-for-priority-review-for-advanced-cervical-cancer 2021-09-28T20:24:01 https://maestrodatabase.com/blog/gw-pharmaceuticals-announces-the-sale-of-priority-review-voucher-for-105-dollars-million 2019-03-19T06:05:57 https://maestrodatabase.com/blog/ucb-receives-chmp-positive-opinion-for-rozanolixizumab-for-treatment-of-adults-with-generalised-myasthenia-gravis-in-europe 2023-11-10T20:55:13 https://maestrodatabase.com/blog/washington-must-change-the-system-that-encourages-high-drug-prices 2019-03-19T06:32:10 https://maestrodatabase.com/blog/saphnelo-approved-in-japan-for-systemic-lupus-erythematosus 2021-09-28T10:28:54 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-appoints-new-members-to-each-of-its-three-independent-evidence-appraisal-councils 2019-03-19T06:18:39 https://maestrodatabase.com/blog/lilly-again-reduces-list-price-of-insulin-lispro-injection-as-latest-change-to-affordability-options 2021-09-28T10:45:32 https://maestrodatabase.com/blog/fda-implements-new-policies-to-advance-the-development-of-drugs-to-treat-or-prevent-hiv-including-in-paediatric-patients-as-part-of-efforts-to-end-hiv-infection 2019-03-19T19:22:58 https://maestrodatabase.com/blog/people-share-their-stories-the-human-cost-of-high-prescription-drug-prices 2021-09-28T21:06:49 https://maestrodatabase.com/blog/the-fdas-pazdur-on-accelerated-approval-single-arm-studies-and-his-own-future 2022-06-05T07:44:30 https://maestrodatabase.com/blog/valuing-sf-6dv2-in-australia-using-an-international-protocol 2021-09-28T21:04:03 https://maestrodatabase.com/blog/blueprint-medicines-ayvakyt-avapritinib-receives-positive-chmp-opinion-as-the-first-and-only-therapy-for-indolent-systemic-mastocytosis 2023-11-10T21:18:49 https://maestrodatabase.com/blog/cystic-fibrosis-patients-call-on-premier-ford-to-provide-immediate-access-to-life-saving-treatments 2021-03-19T21:01:48 https://maestrodatabase.com/blog/medicare-for-all-is-divisive-in-the-democratic-party 2019-03-19T10:57:24 https://maestrodatabase.com/blog/values-principles-strategies-and-frameworks-underlying-patient-and-public-involvement-in-health-technology-assessment-and-guideline-development-a-scoping-review 2022-06-05T20:57:10 https://maestrodatabase.com/blog/think-drugs-are-expensive-in-the-u-dot-s-just-try-china 2019-03-19T11:11:04 https://maestrodatabase.com/blog/lipocine-announces-fda-affirmation-of-class-1-nda-resubmission-for-tlando 2021-09-28T21:12:08 https://maestrodatabase.com/blog/private-health-insurance-costs-the-biggest-household-spending-concern-survey-finds 2019-03-19T19:40:08 https://maestrodatabase.com/blog/ema-publishes-agenda-for-23-26-march-2026-chmp-meeting 2026-03-23T20:51:39 https://maestrodatabase.com/blog/big-business-lobbies-bitterly-divided-over-drug-pricing-reform 2021-09-28T21:01:44 https://maestrodatabase.com/blog/fda-approves-genentechs-tecentriq-in-combination-with-chemotherapy-for-the-initial-treatment-of-adults-with-extensive-stage-small-cell-lung-cancer 2019-03-19T19:28:52 https://maestrodatabase.com/blog/a-review-of-utility-measurement-methods-used-in-pharmacoeconomic-submissions-to-hira-in-south-korea-methodological-consistency-and-areas-for-improvement 2021-09-28T20:52:41 https://maestrodatabase.com/blog/biosimilars-forum-and-medicines-for-europe-call-for-changes-to-the-us-biosimilars-market 2019-03-19T19:51:52 https://maestrodatabase.com/blog/onpattro-patisiran-now-reimbursed-in-canada-for-the-treatment-of-hereditary-transthyretin-mediated-amyloidosis 2021-09-28T21:37:08 https://maestrodatabase.com/blog/nice-wants-to-stop-saying-no---but-needs-pharmas-co-operation 2019-03-19T19:54:32 https://maestrodatabase.com/blog/enhertu-approved-in-japan-as-first-tumour-agnostic-her2-directed-medicine-for-previously-treated-patients-with-her2-positive-metastatic-solid-tumours 2026-03-23T09:51:28 https://maestrodatabase.com/blog/a-drug-pricing-mystery-whos-behind-all-the-outrage-over-rebates 2019-03-19T19:45:21 https://maestrodatabase.com/blog/enhertu-now-available-in-japan-as-first-antibody-drug-conjugate-for-the-second-line-treatment-of-patients-with-her2-positive-metastatic-gastric-cancer 2026-03-23T09:58:59 https://maestrodatabase.com/blog/fewer-people-are-strategising-with-prescription-drug-choices-to-control-their-health-care-costs 2019-03-19T19:47:06 https://maestrodatabase.com/blog/too-fast-or-too-slow-is-the-fda-moving-at-the-right-speed 2021-03-19T21:31:09 https://maestrodatabase.com/blog/is-single-payer-the-answer-for-the-us-health-care-system 2017-12-18T23:53:51 https://maestrodatabase.com/blog/ovarian-cancer-patients-to-have-nice-approved-drug-combination-option-on-cancer-drugs-fund 2021-03-19T21:11:58 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-bristol-myers-squibbs-application-for-mavacamten-in-symptomatic-obstructive-hypertrophic-cardiomyopathy 2021-03-19T21:17:09 https://maestrodatabase.com/blog/tga-grants-provisional-determination-to-roche-covid-19-treatment-tocilizumab-actemra 2021-09-28T21:17:42 https://maestrodatabase.com/blog/janssen-announces-u-dot-s-fda-approval-of-ponvory-ponesimod-an-oral-treatment-for-adults-with-relapsing-multiple-sclerosis-proven-superior-to-aubagio-teriflunomide-in-reducing-annual-relapses-and-brain-lesions 2021-03-19T21:24:18 https://maestrodatabase.com/blog/satellos-receives-rare-paediatric-disease-designation-from-the-us-fda-for-sat-3247-for-the-treatment-of-duchenne-muscular-dystrophy 2024-08-11T05:20:05 https://maestrodatabase.com/blog/canada-as-single-payer-exemplar-for-universal-health-care-in-the-united-states-a-borderline-option 2017-12-18T23:56:00 https://maestrodatabase.com/blog/pfizer-and-bionntech-submit-initial-data-to-u-dot-s-fda-from-pivotal-trial-of-covid-19-vaccine-in-children-5-to-<12-years-of-age 2021-09-28T21:26:38 https://maestrodatabase.com/blog/fda-approves-first-treatment-for-post-partum-depression 2019-03-19T22:18:42 https://maestrodatabase.com/blog/ama-calls-for-two-months-of-medicines-to-be-dispensed-from-a-single-script 2023-02-12T03:44:35 https://maestrodatabase.com/blog/senate-narrowly-confirms-becerra-as-health-secretary 2021-03-19T21:54:14 https://maestrodatabase.com/blog/change-to-monthly-dispensing 2020-03-27T04:32:01 https://maestrodatabase.com/blog/stealth-biotherapeutics-granted-fast-track-designation-for-elamipretide-for-the-treatment-of-lebers-hereditary-optic-neuropathy 2017-12-19T00:12:47 https://maestrodatabase.com/blog/arvelle-announces-european-medicines-agency-acceptance-of-the-marketing-authorisation-application-for-cenobamate 2020-03-27T11:17:46 https://maestrodatabase.com/blog/mhra-approves-vaccine-to-protect-against-pneumococcal-infections-such-as-pneumonia-and-meningitis 2025-05-17T09:13:15 https://maestrodatabase.com/blog/sanofi-receives-positive-chmp-opinion-for-sarclisa-isatuximab-for-the-treatment-of-relapsed-and-refractory-multiple-myeloma 2020-03-27T11:29:35 https://maestrodatabase.com/blog/merck-receives-positive-eu-chmp-opinion-for-keytruda-pembrolizumab-plus-gemcitabine-and-cisplatin-as-first-line-treatment-for-locally-advanced-unresectable-or-metastatic-biliary-tract-cancer 2023-11-10T22:00:45 https://maestrodatabase.com/blog/novartis-multiple-sclerosis-therapy-fingolimod-granted-fda-breakthrough-therapy-designation-for-paediatric-multiple-sclerosis 2017-12-19T01:26:28 https://maestrodatabase.com/blog/merck-receives-positive-eu-chmp-opinion-for-keytruda-pembrolizumab-plus-chemotherapy-as-first-line-treatment-for-her2-negative-advanced-gastric-or-gastro-oesophageal-junction-adenocarcinoma-expressing-pd-l1-cps-1 2023-10-13T21:39:32 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-for-celyads-ischemic-heart-failure-therapy-c-cure 2017-05-12T01:02:00 https://maestrodatabase.com/blog/gilead-files-challenge-to-government-patents-for-hiv-prevention-pill 2019-08-22T20:47:52 https://maestrodatabase.com/blog/fiasp-approved-in-europe-for-the-management-of-diabetes-in-adolescents-and-children-aged-one-year-and-above 2019-08-22T11:02:11 https://maestrodatabase.com/blog/sir-andrew-dillon-to-stand-down-as-nice-chief-executive 2019-08-22T10:56:28 https://maestrodatabase.com/blog/bayer-files-for-approval-of-aflibercept-8-mg-for-treatment-of-retinal-vein-occlusion-in-eu 2025-04-09T01:42:08 https://maestrodatabase.com/blog/roxadustat-approved-in-china-for-the-treatment-of-anaemia-in-non-dialysis-dependent-patients-with-chronic-kidney-disease 2019-08-22T21:03:43 https://maestrodatabase.com/blog/astrazeneca-agrees-to-buy-us-fda-priority-review-voucher-from-sobi 2019-08-22T21:00:17 https://maestrodatabase.com/blog/breast-cancer-patients-in-northland-poised-for-publicly-funded-medicines 2019-08-22T20:53:08 https://maestrodatabase.com/blog/ema-publishes-agenda-for-19-22-august-chmp-meeting 2019-08-22T21:26:31 https://maestrodatabase.com/blog/updated-procedure-and-submission-guidelines-for-the-cadth-common-drug-review 2019-08-22T21:15:39 https://maestrodatabase.com/blog/china-vows-to-maintain-stable-drug-prices 2019-08-24T06:10:10 https://maestrodatabase.com/blog/ptac-continues-to-find-new-ways-to-reject-new-medicines-part-2 2019-08-22T21:36:56 https://maestrodatabase.com/blog/chemist-warehouse-continues-store-expansion-set-to-open-one-of-its-largest-stores-yet 2019-08-22T21:34:12 https://maestrodatabase.com/blog/rhythm-receives-expanded-fda-breakthrough-therapy-designation-for-setmelanotide-for-rare-genetic-disorders-of-obesity 2017-05-12T01:54:40 https://maestrodatabase.com/blog/is-the-public-health-system-so-good-you-dont-actually-need-private-insurance 2017-11-26T19:57:55 https://maestrodatabase.com/blog/novartis-receives-health-canada-approval-for-mayzent-siponimod-to-treat-secondary-progressive-multiple-sclerosis-with-active-disease 2020-03-04T02:09:15 https://maestrodatabase.com/blog/eisai-completes-rolling-submission-to-the-u-dot-s-fda-for-biologics-license-application-of-lecanemab-for-early-alzheimers-disease-under-the-accelerated-approval-pathway 2022-05-10T02:27:33 https://maestrodatabase.com/blog/beigene-receives-positive-chmp-opinion-for-brukinsa-zanubrutinib-in-relapsed-or-refractory-follicular-lymphoma 2023-10-13T22:28:12 https://maestrodatabase.com/blog/high-risk-covid-19-patients-can-now-get-two-antiviral-prescription-drugs----but-some-are-still-missing-out 2022-05-10T03:18:11 https://maestrodatabase.com/blog/syn-004-ribaxamase-receives-breakthrough-therapy-designation-from-u-dot-s-fda-for-prevention-of-clostridium-difficile-infection 2017-05-12T02:09:25 https://maestrodatabase.com/blog/alnylam-announces-approval-of-givlaari-givosiran-in-the-european-union-for-the-treatment-of-acute-hepatic-porphyria-in-adults-and-adolescents 2020-03-04T02:14:18 https://maestrodatabase.com/blog/qulipta-now-approved-by-health-canada-for-the-preventive-treatment-of-episodic-migraine-in-adults 2023-01-10T01:48:17 https://maestrodatabase.com/blog/fertility-drug-rekovelle-gets-reimbursable-in-combo-with-hmg 2022-05-10T12:28:37 https://maestrodatabase.com/blog/moderna-considers-price-of-$110-$130-for-covid-19-vaccine 2023-01-10T02:29:18 https://maestrodatabase.com/blog/merck-invited-to-submit-a-cdf-proposal-for-merkel-cell-cancer-drug 2017-11-27T10:11:42 https://maestrodatabase.com/blog/novos-ozempic-wins-reimbursement-in-korea-but-strict-criteria-limit-early-access 2026-02-18T22:45:42 https://maestrodatabase.com/blog/turning-point-therapeutics-granted-breakthrough-therapy-designation-for-repotrectinib-treatment-in-patients-with-one-prior-ros1-tyrosine-kinase-inhibitor-and-no-prior-chemotherapy 2022-05-10T21:13:44 https://maestrodatabase.com/blog/kidney-disease-drug-recommended-by-nice-may-do-more-harm-than-good 2017-11-27T10:30:37 https://maestrodatabase.com/blog/new-alzheimers-drug-wont-be-covered-by-dutch-health-insurance 2026-02-18T22:49:02 https://maestrodatabase.com/blog/we-dont-need-to-change-how-we-subsidise-breakthrough-cancer-treatments 2017-11-27T10:18:10 https://maestrodatabase.com/blog/proteon-therapeutics-receives-fda-breakthrough-therapy-designation-for-vonapanitase 2017-05-12T02:45:14 https://maestrodatabase.com/blog/revised-process-for-filing-cdr-submissions-and-resubmissions 2017-11-27T20:08:56 https://maestrodatabase.com/blog/first-treatment-option-indicated-for-ckd-in-scotland-for-20-years 2022-05-10T11:46:54 https://maestrodatabase.com/blog/he-raised-drug-prices-at-eli-lilly-can-he-lower-them-for-the-u-dot-s 2017-11-27T10:39:59 https://maestrodatabase.com/blog/commonwealth-to-cut-funding-for-botched-operations 2017-11-27T20:30:27 https://maestrodatabase.com/blog/icer-publishes-final-evidence-report-and-policy-recommendations-on-outpatient-treatments-for-covid-19 2022-05-10T12:11:36 https://maestrodatabase.com/blog/nice-no-for-halaven-in-new-indication 2017-11-27T20:15:26 https://maestrodatabase.com/blog/hira-unveils-detailed-reimbursement-criteria-for-olumiant-rinvoq 2022-05-10T11:53:56 https://maestrodatabase.com/blog/exit-aduhelm-enter-lecanemab-biogen-and-eisai-have-another-go 2022-05-10T21:37:47 https://maestrodatabase.com/blog/as-health-care-changes-insurers-hospitals-and-drugstores-team-up 2017-11-27T20:35:49 https://maestrodatabase.com/blog/efanesoctocog-alfa-granted-fda-fast-track-designation-for-treatment-of-haemophilia-a 2021-02-19T03:13:44 https://maestrodatabase.com/blog/democrats-drug-pricing-plan-is-the-wrong-prescription-for-inflation 2022-05-10T21:33:35 https://maestrodatabase.com/blog/calls-for-health-minister-to-release-final-report-from-pharmac-review 2022-05-10T21:45:12 https://maestrodatabase.com/blog/where-is-astrazenecas-vaccine-health-canada-says-not-yet-ready-to-greenlight 2021-02-19T03:17:22 https://maestrodatabase.com/blog/fda-approves-treatment-for-covid-19-in-certain-hospitalised-adults 2022-05-10T21:19:44 https://maestrodatabase.com/blog/trumps-latest-affordable-care-act-move-adds-to-insurers-uncertainty 2018-07-09T04:39:34 https://maestrodatabase.com/blog/who-wants-transparency-market-revamp-for-fairer-drug-pricing 2017-05-12T09:17:08 https://maestrodatabase.com/blog/fda-launches-new-accelerating-rare-disease-cures-arc-program 2022-05-10T21:24:00 https://maestrodatabase.com/blog/immunitybio-receives-authorisation-from-the-european-commission-for-anktiva-with-bcg-for-non-muscle-invasive-bladder-cancer-carcinoma-in-situ-expanding-global-access-to-33-countries 2026-02-19T03:45:13 https://maestrodatabase.com/blog/vericel-receives-fda-regenerative-medicine-advanced-therapy-designation-for-ixmyelocel-t-for-the-treatment-of-advanced-heart-failure-due-to-ischaemic-dilated-cardiomyopathy 2017-05-12T09:49:53 https://maestrodatabase.com/blog/clinical-decision-support-software 2021-02-19T05:10:44 https://maestrodatabase.com/blog/statement-by-fda-commissioner-on-balancing-access-to-appropriate-treatment-for-patients-with-chronic-and-end-of-life-pain-with-need-to-take-steps-to-stem-misuse-and-abuse-of-opioids 2018-07-09T21:00:00 https://maestrodatabase.com/blog/rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-receives-us-fda-breakthrough-therapy-designation-for-patients-with-advanced-head-and-neck-cancer 2026-02-18T23:20:16 https://maestrodatabase.com/blog/pah-patients-in-england-denied-access-to-actelions-uptravi-on-nhs 2018-07-09T08:34:33 https://maestrodatabase.com/blog/estimated-research-and-development-investment-needed-to-bring-a-new-medicine-to-market-2009-2018 2020-03-04T03:22:33 https://maestrodatabase.com/blog/vertex-nhs-england-no-closer-to-orkambi-settlement 2018-07-09T09:30:03 https://maestrodatabase.com/blog/four-types-of-bias-in-medical-ai-are-running-under-the-fdas-radar 2023-01-10T03:09:20 https://maestrodatabase.com/blog/nhs-england-says-yes-to-roches-hemlibra 2018-07-09T21:15:11 https://maestrodatabase.com/blog/smc---july-2018-decisions 2018-07-09T21:03:41 https://maestrodatabase.com/blog/catalyst-pharmaceuticals-announces-health-canadas-acceptance-of-agamree-new-drug-submission-with-priority-review 2025-04-09T03:09:07 https://maestrodatabase.com/blog/how-millennials-choices-are-reshaping-private-health-insurance-for-everyone 2018-07-09T21:11:36 https://maestrodatabase.com/blog/enzyvant-announces-initiation-of-rvt-802-rolling-bla-submission-for-the-treatment-of-complete-digeorge-anomaly 2018-07-09T21:28:31 https://maestrodatabase.com/blog/pharmacy-benefit-managers-and-the-federal-trade-commission-a-relationship-gone-sour 2023-01-10T04:38:43 https://maestrodatabase.com/blog/tenpoint-therapeutics-submits-new-drug-application-to-us-fda-for-brimichol-pf-for-the-treatment-of-presbyopia 2025-04-09T03:36:30 https://maestrodatabase.com/blog/amylyx-pharmaceuticals-receives-negative-chmp-opinion-on-its-marketing-authorisation-application-for-amx0035-for-the-treatment-of-als-in-the-european-union-following-re-examination-process 2023-10-14T05:29:07 https://maestrodatabase.com/blog/smc-rejects-ocrelizumab-ocrevus-for-relapsing-remitting-ms-in-scotland 2018-07-09T21:20:36 https://maestrodatabase.com/blog/government-quit-test-of-pricey-cancer-treatment-amid-concerns-over-industry-role 2018-07-09T21:24:11 https://maestrodatabase.com/blog/us-fda-approves-opdivo-nivolumab-as-adjuvant-treatment-for-eligible-patients-with-completely-resected-stage-iib-or-stage-iic-melanoma 2023-10-14T05:24:57 https://maestrodatabase.com/blog/trump-attacks-pfizer-over-drug-cost-in-latest-dig-at-pharma 2018-07-09T21:38:04 https://maestrodatabase.com/blog/hhs-secretary-recent-drug-price-increases-creating-a-tipping-point 2018-07-09T21:41:06 https://maestrodatabase.com/blog/oncolytics-biotech-announces-fda-fast-track-designation-for-reolysin-in-metastatic-breast-cancer 2017-05-12T10:20:46 https://maestrodatabase.com/blog/only-immuno-oncology-combination-therapy-approved-by-health-canada-as-first-line-treatment-for-advanced-or-metastatic-renal-cell-carcinoma 2018-07-09T21:34:01 https://maestrodatabase.com/blog/cadth-publishes-final-cdec-recommendation-for-dupilumab 2018-07-09T21:53:27 https://maestrodatabase.com/blog/fda-acceptance-for-filing-of-new-drug-application-for-trientine-tetrahydrochloride-for-the-treatment-of-wilsons-disease 2021-09-03T06:21:38 https://maestrodatabase.com/blog/simponi-golimumab-receives-european-commission-approval-for-early-dose-optimisation-treatment-in-patients-with-ulcerative-colitis 2018-07-09T21:48:50 https://maestrodatabase.com/blog/us-supreme-court-rebuffs-pfizer-plan-to-help-patients-pay-for-heart-medication 2023-01-10T04:54:05 https://maestrodatabase.com/blog/xspray-pharma-re-submits-its-fda-application 2025-04-09T03:45:45 https://maestrodatabase.com/blog/ultomiris-approved-in-the-eu-for-children-and-adolescents-with-paroxysmal-nocturnal-haemoglobinuria 2021-09-03T06:26:21 https://maestrodatabase.com/blog/remake-of-the-national-health-pharmaceuticals-and-vaccines---cost-recovery-regulations-2009 2022-05-11T04:09:45 https://maestrodatabase.com/blog/clintons-life-could-be-cut-short-unless-he-pays-thousands-for-pbs-listed-medication 2026-02-19T06:39:15 https://maestrodatabase.com/blog/fda-authorises-use-of-new-device-to-treat-oesophageal-birth-defect-in-babies 2017-05-13T03:28:33 https://maestrodatabase.com/blog/innorna-announces-us-fda-rare-paediatric-disease-designation-granted-to-in016-for-the-treatment-of-progressive-familial-intrahepatic-cholestasis 2024-07-13T23:54:37 https://maestrodatabase.com/blog/enhertu-type-ii-variation-application-validated-in-the-eu-as-post-neoadjuvant-treatment-for-patients-with-her2-positive-early-breast-cancer 2026-02-19T07:35:54 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-releases-revised-evidence-report-on-dupilumab-and-crisaborole-for-treatment-of-atopic-dermatitis 2017-05-13T03:58:32 https://maestrodatabase.com/blog/fresenius-announces-ema-validation-of-marketing-authorisation-application-for-denosumab-biosimilar-candidates 2024-07-14T00:12:38 https://maestrodatabase.com/blog/pfizer-and-biontech-submit-covid-19-vaccine-stability-data-at-standard-freezer-temperature-to-the-u-dot-s-fda 2021-02-20T21:41:27 https://maestrodatabase.com/blog/patients-beg-for-pricey-drugs-on-facebook-black-market 2017-05-13T04:09:22 https://maestrodatabase.com/blog/changes-in-list-prices-net-prices-and-discounts-for-branded-drugs-in-the-us-2007-2018 2020-03-04T05:39:51 https://maestrodatabase.com/blog/confusion-over-russias-eu-vaccine-approval-bid-could-be-result-of-misdirected-application 2021-02-20T21:22:33 https://maestrodatabase.com/blog/immunocores-tebentafusp-granted-breakthrough-therapy-designation-for-unresectable-or-metastatic-uveal-melanoma-from-fda 2021-02-20T21:24:51 https://maestrodatabase.com/blog/junshi-biosciences-announces-acceptance-by-the-nmpa-of-supplemental-new-drug-application-for-toripalimab-combined-with-chemotherapy-for-the-first-line-treatment-of-nasopharyngeal-carcinoma 2021-02-20T22:03:04 https://maestrodatabase.com/blog/who-will-be-the-next-fda-chief 2021-02-20T22:10:21 https://maestrodatabase.com/blog/heart-failure-med-jardiance-scores-mhra-approval 2021-09-03T09:45:09 https://maestrodatabase.com/blog/incyte-announces-acceptance-and-priority-review-of-nda-for-ruxolitinib-cream-for-atopic-dermatitis 2021-02-20T21:49:12 https://maestrodatabase.com/blog/amicus-therapeutics-receives-notification-of-pdufa-date-extensions-for-at-gaa 2022-05-11T06:44:57 https://maestrodatabase.com/blog/dynavax-announces-european-commission-marketing-authorization-for-heplisav-b-a-two-dose-adult-hepatitis-b-adjuvanted-vaccine 2021-02-20T21:54:10 https://maestrodatabase.com/blog/acute-myeloid-leukaemia-drug-xospata-nears-getting-insurance-benefits 2021-09-03T23:49:19 https://maestrodatabase.com/blog/impel-neuropharma-announces-u-dot-s-fda-approval-of-trudhesa-dihydroergotamine-mesylate-nasal-spray-for-the-acute-treatment-of-migraine 2021-09-03T23:54:00 https://maestrodatabase.com/blog/government-of-canada-announces-new-appointment-to-the-patented-medicine-prices-review-board 2024-10-18T04:28:50 https://maestrodatabase.com/blog/catalyst-pharmaceuticals-announces-fda-acceptance-of-the-supplemental-new-drug-application-for-firdapse 2023-10-14T21:02:51 https://maestrodatabase.com/blog/intellia-therapeutics-receives-priority-medicines-prime-designation-from-the-ema-for-ntla-2002-an-investigational-in-vivo-crispr-genome-editing-treatment-for-hereditary-angioedema 2023-10-14T20:54:00 https://maestrodatabase.com/blog/garetosmab-biologics-license-application-accepted-for-fda-priority-review-for-the-treatment-of-fibrodysplasia-ossificans-progressiva 2026-02-19T21:15:40 https://maestrodatabase.com/blog/epilepsy-drug-deaths-coronial-inquiry-into-medication-linked-deaths-resumes 2021-02-21T20:01:38 https://maestrodatabase.com/blog/atagi-update-following-weekly-covid-19-meeting-4-may-2022 2022-05-11T21:14:11 https://maestrodatabase.com/blog/democrats-plan-crackdown-on-rising-drug-costs 2021-02-21T20:09:41 https://maestrodatabase.com/blog/von-der-leyen-admits-to-covid-19-vaccine-failures 2021-02-21T20:21:34 https://maestrodatabase.com/blog/the-price-of-success--how-to-evaluate-covid-19-vaccines-when-theyre-available-outside-of-clinical-trials 2021-02-21T20:24:37 https://maestrodatabase.com/blog/avelumab-for-maintenance-treatment-of-locally-advanced-or-metastatic-urothelial-cancer-after-platinum-based-chemotherapy 2022-05-11T21:47:29 https://maestrodatabase.com/blog/democrats-want-to-let-medicare-negotiate-drug-prices-has-pharma-found-a-way-to-lessen-the-blow-already 2021-09-04T00:05:17 https://maestrodatabase.com/blog/first-covid-19-vaccinations-in-australia 2021-02-21T19:58:58 https://maestrodatabase.com/blog/nice-recommends-novartis-cosentyx-for-children-with-severe-psoriasis 2021-09-04T00:07:23 https://maestrodatabase.com/blog/clovis-oncology-announces-availability-and-reimbursement-for-rubraca-rucaparib-tablets-for-women-with-relapsed-ovarian-cancer-in-spain 2020-03-04T06:39:27 https://maestrodatabase.com/blog/outlook-therapeutics-announces-acceptance-of-biologics-license-application-by-us-fda-for-ons-5010-as-a-treatment-for-wet-amd 2025-04-09T09:47:04 https://maestrodatabase.com/blog/ontario-makes-commitment-to-funding-cf-drugs-after-approval-process-completed 2021-02-21T20:27:40 https://maestrodatabase.com/blog/ferring-receives-swiss-approval-for-rekovelle-the-first-personalised-fertility-treatment-using-an-approved-dosing-algorithm 2017-11-28T10:32:03 https://maestrodatabase.com/blog/comparing-safety-information-of-biosimilars-with-their-originators-a-cross-sectional-analysis-of-european-risk-management-plans 2017-11-28T10:27:35 https://maestrodatabase.com/blog/pilatus-biosciences-receives-fda-fast-track-designation-for-metabolic-checkpoint-inhibitor-plt012-in-hepatocellular-carcinoma 2026-02-19T23:05:58 https://maestrodatabase.com/blog/sobi-receives-approval-from-health-canada-for-orfadin-oral-suspension-for-the-treatment-of-ht-1 2017-11-28T10:35:51 https://maestrodatabase.com/blog/european-medicines-agency-validates-bristol-myers-squibbs-type-ii-variation-application-for-opdivo-nivolumab-plus-yervoy-ipilimumab-in-intermediate-and-poor-risk-patients-with-advanced-renal-cell-carcinoma 2017-11-28T20:09:57 https://maestrodatabase.com/blog/guidance-to-help-pharma-companies-prepare-for-brexit 2017-11-28T10:41:30 https://maestrodatabase.com/blog/fda-issues-guidance-that-could-make-it-easier-for-epipen-rivals-to-come-to-market 2017-11-28T20:28:28 https://maestrodatabase.com/blog/expanding-access-and-reducing-prices-for-drugs-to-prevent-hiv-should-government-enforce-its-patent-rights-against-the-pharmaceutical-industry 2020-03-04T09:51:18 https://maestrodatabase.com/blog/the-european-medicines-agency-accepts-regulatory-submission-for-tagrisso-in-first-line-egfr-mutated-non-small-cell-lung-cancer 2017-11-28T20:14:50 https://maestrodatabase.com/blog/drug-shortages-in-the-united-states-are-some-prices-too-low 2020-03-04T09:18:08 https://maestrodatabase.com/blog/kyowa-hakko-kirin-announces-fda-acceptance-for-filing-and-priority-review-designation-of-mogamulizumabs-biologics-license-application 2017-11-28T20:31:58 https://maestrodatabase.com/blog/anti-flu-pill-can-fight-illness-as-soon-as-symptoms-show 2020-03-04T09:09:56 https://maestrodatabase.com/blog/stop-panic-buying-medicines-pharmacists-warn 2020-03-04T10:23:23 https://maestrodatabase.com/blog/pharmas-paradox-cure-a-deadly-childhood-disease-and-then-get-attacked-on-price 2017-11-28T20:38:20 https://maestrodatabase.com/blog/worlds-main-supplier-of-generic-drugs-could-run-out-of-ingredients 2020-03-04T10:20:40 https://maestrodatabase.com/blog/stealth-biotherapeutics-granted-fast-track-designation-for-the-treatment-of-barth-syndrome 2017-11-28T20:43:32 https://maestrodatabase.com/blog/ema-accepts-titan-pharmaceuticals-marketing-authorisation-application-for-probuphine 2017-11-28T20:50:09 https://maestrodatabase.com/blog/aeterna-zentaris-marketing-authorization-application-for-macrilen-macimorelin-for-evaluation-of-adult-growth-hormone-deficiency-accepted-by-european-medicines-agency 2017-11-28T20:54:59 https://maestrodatabase.com/blog/dova-pharmaceuticals-announces-fda-acceptance-of-the-avatrombopag-new-drug-application-with-priority-review 2017-11-28T20:59:44 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-12-may-2022 2022-05-12T08:27:34 https://maestrodatabase.com/blog/the-health-care-bills-insults-to-women 2017-05-13T08:23:53 https://maestrodatabase.com/blog/when-a-drug-study-abruptly-ends-volunteers-are-left-to-cope 2020-03-04T19:51:53 https://maestrodatabase.com/blog/agenda-for-17-may-2017-tc-meeting 2017-05-14T02:10:33 https://maestrodatabase.com/blog/zosano-pharma-announces-fda-acceptance-of-505-b-2-new-drug-application-for-qtrypta-for-the-acute-treatment-of-migraine 2020-03-04T20:05:01 https://maestrodatabase.com/blog/restrictions-to-new-zealands-supply-of-drugs-likely-as-coronavirus-fears-grow 2020-03-04T20:01:18 https://maestrodatabase.com/blog/revised-procedure-for-the-sponsor-review-of-initial-cadth-pcodr-reports 2020-03-04T19:55:44 https://maestrodatabase.com/blog/joe-bidens-health-care-plan-would-spend-750-dollars-billion-more-on-obamacare-and-cap-drug-price-inflation 2020-03-04T20:13:46 https://maestrodatabase.com/blog/endotheia-announces-fda-breakthrough-device-designation-for-technology-to-improve-endoscopic-surgery 2023-01-11T03:36:08 https://maestrodatabase.com/blog/medicines-australia-welcomes-day-1-of-australias-vaccination-rollout 2021-02-22T02:05:00 https://maestrodatabase.com/blog/sanofi-fighting-back-in-insulin-price-debate-says-its-net-prices-fell-11-percent 2020-03-04T20:17:51 https://maestrodatabase.com/blog/micronoma-receives-fda-breakthrough-device-designation-for-oncobiotalung-a-novel-liquid-biopsy-assay-for-lung-carcinoma-detection 2023-01-11T04:12:36 https://maestrodatabase.com/blog/prescription-drug-policy-2022-and-2023-the-year-in-review-and-the-year-ahead 2023-01-11T06:31:16 https://maestrodatabase.com/blog/health-canada-approves-gazyva-for-previously-untreated-advanced-follicular-lymphoma 2018-07-10T01:46:30 https://maestrodatabase.com/blog/cder-director-calls-for-simplifying-clinical-trials-to-boost-diversity 2023-01-11T06:26:58 https://maestrodatabase.com/blog/medibank-joins-nexus-hospitals-joint-replacement-surgery-trial-guaranteeing-zero-out-of-pocket-costs 2019-08-23T06:55:30 https://maestrodatabase.com/blog/lupin-and-exeltis-announce-reimbursement-approval-of-namuscla-in-spain-for-the-symptomatic-treatment-of-myotonia-in-adults-with-non-dystrophic-myotonic-disorders 2023-01-11T06:50:59 https://maestrodatabase.com/blog/emerald-health-pharmaceuticals-receives-fast-track-designation-from-us-fda-for-ehp-101-in-the-treatment-of-systemic-sclerosis 2020-03-04T23:11:20 https://maestrodatabase.com/blog/covid-19-vaccine-spikevax-elasomeran 2021-09-04T08:59:33 https://maestrodatabase.com/blog/social-spending-to-improve-population-health----does-the-united-states-spend-as-wisely-as-other-countries 2020-03-04T23:17:58 https://maestrodatabase.com/blog/voluntary-withdrawal-of-imfinzi-indication-in-advanced-bladder-cancer-in-the-us 2021-02-22T07:06:48 https://maestrodatabase.com/blog/one-pivotal-trial-the-new-default-option-for-fda-approval----ending-the-two-trial-dogma 2026-02-20T06:41:28 https://maestrodatabase.com/blog/us-fda-approves-combination-treatment-of-venclexta-venetoclax-and-acalabrutinib-for-previously-untreated-patients-with-chronic-lymphocytic-leukaemia 2026-02-20T07:45:38 https://maestrodatabase.com/blog/pharmac-proposal-to-increase-access-to-five-medicines-for-cancer-and-other-health-conditions 2024-07-15T02:24:53 https://maestrodatabase.com/blog/wysa-receives-fda-breakthrough-device-designation-for-ai-led-mental-health-conversational-agent 2022-05-12T20:43:04 https://maestrodatabase.com/blog/pharmac-confirms-new-breast-cancer-medicine-to-be-funded 2020-03-04T23:24:45 https://maestrodatabase.com/blog/nivolumab-in-combination-with-platinum-and-fluoropyrimidine-based-chemotherapy-for-the-first-line-treatment-of-patients-with-advanced-her2-negative-gastric-gastro-oesophageal-junction-or-oesophageal-adenocarcinoma 2023-01-11T08:36:53 https://maestrodatabase.com/blog/international-work-sharing-initiative---baloxavir-marboxil-xofluza 2020-03-04T23:32:11 https://maestrodatabase.com/blog/fda-approves-oral-formulation-of-treatment-for-amyotrophic-lateral-sclerosis 2022-05-12T21:11:42 https://maestrodatabase.com/blog/fda-grants-breakthrough-device-designation-to-remedee-labs-for-its-groundbreaking-endorphin-stimulation-solution-for-the-management-of-fibromyalgia 2022-05-12T20:47:18 https://maestrodatabase.com/blog/moderna-completes-fda-submission-for-use-of-covid-shot-in-adolescents-kids 2022-05-12T21:04:56 https://maestrodatabase.com/blog/after-a-5-year-fight-to-lower-drug-prices-ottawas-pledge-quietly-falls-apart 2022-05-12T20:51:50 https://maestrodatabase.com/blog/union-therapeutics-receives-fda-fast-track-designation-for-oral-orismilast-for-the-treatment-of-moderate-to-severe-hidradenitis-suppurativa 2023-01-11T19:16:02 https://maestrodatabase.com/blog/calquence-plus-venetoclax-approved-in-the-us-as-first-all-oral-fixed-duration-combination-for-patients-with-chronic-lymphocytic-leukaemia-in-the-1st-line-setting 2026-02-20T07:57:03 https://maestrodatabase.com/blog/gsks-shingles-vaccine-shingrix-gains-uk-license 2021-09-04T22:03:24 https://maestrodatabase.com/blog/chemist-giants-are-testing-the-rules 2021-02-22T19:49:56 https://maestrodatabase.com/blog/federal-investigators-find-medicare-advantage-plans-too-often-deny-delay-needed-care 2022-05-12T21:32:14 https://maestrodatabase.com/blog/atagi-update-following-weekly-covid-19-meeting-11-may-2022 2022-05-12T21:18:11 https://maestrodatabase.com/blog/cadth-expands-scientific-advice-program-to-include-advice-on-real-world-evidence 2022-05-12T21:39:12 https://maestrodatabase.com/blog/basket-trials-review-of-current-practice-and-innovations-for-future-trials 2022-05-12T21:35:20 https://maestrodatabase.com/blog/fda-outlines-fast-path-for-shots-against-new-virus-variants 2021-02-22T20:08:47 https://maestrodatabase.com/blog/celsion-corporation-receives-fda-fast-track-designation-for-gen-1-in-advanced-ovarian-cancer 2021-02-22T20:11:17 https://maestrodatabase.com/blog/janssen-submits-european-marketing-authorisation-application-for-ponesimod-for-treatment-of-adults-with-relapsing-multiple-sclerosis 2020-03-05T02:06:58 https://maestrodatabase.com/blog/supernus-receives-fda-notice-assigning-early-april-2021-pdufa-date-for-spn-812-nda 2021-02-22T20:15:35 https://maestrodatabase.com/blog/fda-approves-libtayo-cemiplimab-rwlc-monotherapy-for-patients-with-first-line-advanced-non-small-cell-lung-cancer-with-pd-l1-expression-of-50-percent 2021-02-22T19:54:26 https://maestrodatabase.com/blog/savara-announces-the-us-fda-filed-the-molbreevi-biologics-license-application-in-auto-immune-pulmonary-alveolar-proteinosis 2026-02-20T23:59:25 https://maestrodatabase.com/blog/maker-of-epilepsy-drug-warned-over-quality-control 2021-02-22T20:02:26 https://maestrodatabase.com/blog/germans-turn-backs-on-astrazeneca-vaccine 2021-02-22T20:06:05 https://maestrodatabase.com/blog/piccolo-medical-receives-u-dot-s-fda-clearance-of-its-smartpicc-system-for-the-positioning-of-peripherally-inserted-central-catheters 2021-02-22T20:37:01 https://maestrodatabase.com/blog/clinical-relevance-of-patient-reported-outcomes-new-threshold-proves-to-be-practical 2021-02-22T20:40:46 https://maestrodatabase.com/blog/icer-releases-obesity-medications-white-paper-examining-strategies-to-ensure-affordable-access 2025-04-10T00:54:25 https://maestrodatabase.com/blog/proposal-leaves-surgeons-bound-by-private-health 2021-02-22T20:46:29 https://maestrodatabase.com/blog/intra-cellular-therapies-applies-for-fda-approval-of-caplyta-lumateperone-for-the-treatment-of-bipolar-depression 2021-02-22T20:19:43 https://maestrodatabase.com/blog/treadwell-therapeutics-announces-fast-track-designation-granted-by-the-fda-to-cfi-402257-for-the-treatment-of-er-plus-slash-her2--breast-cancer 2023-01-11T19:48:01 https://maestrodatabase.com/blog/ema-plots-earlier-engagement-with-patient-groups 2021-02-22T20:25:26 https://maestrodatabase.com/blog/ema-publishes-agenda-for-22-25-february-chmp-meeting 2021-02-22T20:30:53 https://maestrodatabase.com/blog/tga-removes-age-limit-for-bbibp-corv-sinopharm-covid-19-vaccine-recognition-for-international-travel-to-australia 2022-05-13T06:01:40 https://maestrodatabase.com/blog/mhra-approves-zanidatamab-ziihera-for-the-treatment-of-biliary-tract-cancer 2026-02-21T00:38:23 https://maestrodatabase.com/blog/fda-approves-acalabrutinib-with-venetoclax-for-chronic-lymphocytic-leukaemia-or-small-lymphocytic-lymphoma 2026-02-21T00:10:33 https://maestrodatabase.com/blog/first-and-only-rescue-medication-approved-in-the-us-for-as-needed-use-to-reduce-risk-of-asthma-exacerbations 2023-01-11T20:24:10 https://maestrodatabase.com/blog/onco360-selected-as-a-limited-distribution-specialty-pharmacy-partner-for-rytelo-imetelstat 2024-07-15T05:26:49 https://maestrodatabase.com/blog/vanda-pharmaceuticals-announces-fda-approval-of-bysanti-milsaperidone-for-the-treatment-of-bipolar-i-disorder-and-schizophrenia---a-new-chemical-entity-opening-new-horizons-in-psychiatric-innovation 2026-02-21T03:29:31 https://maestrodatabase.com/blog/switzerland-could-sell-or-give-away-astrazeneca-doses-if-regulator-dithers 2021-02-22T22:39:44 https://maestrodatabase.com/blog/fda-accepts-new-drug-application-for-roches-giredestrant-in-esr1-mutated-er-positive-advanced-breast-cancer 2026-02-21T01:06:19 https://maestrodatabase.com/blog/clinical-benefit-reimbursement-outcomes-and-prices-of-fda-approved-cancer-drugs-reviewed-through-project-orbis-in-the-usa-canada-england-and-scotland-a-retrospective-comparative-analysis 2024-07-15T22:35:09 https://maestrodatabase.com/blog/tga-commences-evaluation-of-moderna-covid-19-vaccine-spikevax-for-children-aged-6-months-to-5-years-old 2022-05-13T21:50:56 https://maestrodatabase.com/blog/canadas-public-drug-plans-shouldnt-cover-new-alzheimers-drug-agency-says 2026-02-21T03:47:34 https://maestrodatabase.com/blog/us-fda-accepts-tevas-new-drug-application-for-olanzapine-extended-release-injectable-suspension-tev--749-for-the-once-monthly-treatment-of-schizophrenia-in-adults 2026-02-21T03:53:34 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-to-aclaris-therapeutics-investigational-jak-inhibitor-for-the-treatment-of-alopecia-areata 2018-07-10T05:22:39 https://maestrodatabase.com/blog/aumorlertinib-mesylate-tablets-approved-in-the-eu-as-monotherapy 2026-02-21T04:02:13 https://maestrodatabase.com/blog/why-the-meningococcal-b-vaccine-must-be-put-on-the-pbs 2017-05-14T12:53:07 https://maestrodatabase.com/blog/women-with-moderate-to-severe-fibroids-set-to-be-offered-new-one-a-day-treatment-following-final-draft-guidance-from-nice 2022-05-13T22:00:34 https://maestrodatabase.com/blog/do-children-get-priority-in-australias-drug-funding-decisions 2026-02-21T04:07:03 https://maestrodatabase.com/blog/specialty-drug-coverage-varies-across-commercial-health-plans-in-the-us 2018-07-10T06:08:39 https://maestrodatabase.com/blog/medicines-australia-welcomes-priority-review-pathway-programme-milestone 2018-07-10T07:59:56 https://maestrodatabase.com/blog/nhs-patients-missing-out-on-new-medicines-that-could-extend-lives 2022-05-13T22:35:45 https://maestrodatabase.com/blog/insurers-scramble-after-trump-suspends-billions-in-obamacare-payments 2018-07-10T21:06:03 https://maestrodatabase.com/blog/fda-budget-matters-a-cross-cutting-data-enterprise-for-real-world-evidence 2018-07-10T21:09:49 https://maestrodatabase.com/blog/over-reliance-in-cardiovascular-treatment---a-supply-risk-that-needs-to-change 2017-11-29T03:12:58 https://maestrodatabase.com/blog/ema-identifies-gaps-in-industry-preparedness-for-brexit 2018-07-10T20:53:05 https://maestrodatabase.com/blog/moderna-announces-submission-of-data-to-european-medicines-agency-for-its-covid-19-vaccine-booster 2021-09-05T05:10:22 https://maestrodatabase.com/blog/sanofi-denounces-cadth-negative-recommendation-on-dupixent 2018-07-10T21:22:55 https://maestrodatabase.com/blog/president-trump-attacks-symptom-not-disease-in-prescription-drug-price-attack 2018-07-10T21:13:40 https://maestrodatabase.com/blog/a-new-messaging-tactic-on-the-left-drug-prices-rise-as-pharma-prospers-from-tax-law 2018-07-10T21:16:33 https://maestrodatabase.com/blog/life-saving-news-for-gold-coast-family-after-little-beau-allowed-to-take-drug-orkambi-to-slow-cystic-fibrosis-diagnosis 2019-08-23T22:30:30 https://maestrodatabase.com/blog/brett-kavanaugh-trumps-pick-for-court-has-left-trail-of-opinions-on-health-care-and-pharma-issues 2018-07-10T21:46:16 https://maestrodatabase.com/blog/nice-to-work-with-company-on-addressing-issues-in-appraisals-of-cannabidiol-for-treating-difficult-to-control-epilepsies 2019-08-23T22:25:17 https://maestrodatabase.com/blog/pharmac-to-fund-medicines-for-blood-cancers-inflammatory-bowel-disease-eczema-and-arthritis 2025-04-10T01:56:54 https://maestrodatabase.com/blog/time-to-entry-for-new-cancer-medicines-from-european-union-wide-marketing-authorisation-to-patient-access-in-belgium-estonia-scotland-and-sweden 2018-07-10T21:31:46 https://maestrodatabase.com/blog/recommendations-made-by-the-pbac---july-2019 2019-08-23T22:56:24 https://maestrodatabase.com/blog/will-the-fda-change-how-it-vets-drugs-following-the-alzheimers-debacle 2022-05-13T23:00:59 https://maestrodatabase.com/blog/astrazeneca-vaccine-review-is-in-the-final-stages-health-canada-says 2021-02-23T01:17:25 https://maestrodatabase.com/blog/fda-focuses-on-novartis-delay-in-reporting-drug-test-data-manipulation 2019-08-23T22:52:25 https://maestrodatabase.com/blog/australias-deadliest-cancer-has-a-new-treatment 2019-08-23T22:46:28 https://maestrodatabase.com/blog/polarityte-announces-fda-regenerative-medicine-advanced-therapy-designation-granted-to-skinte 2022-05-13T23:13:10 https://maestrodatabase.com/blog/lorlatinib-for-the-treatment-of-patients-with-advanced-alk-positive-non-small-cell-lung-cancer-review-of-ta909 2025-04-10T02:23:15 https://maestrodatabase.com/blog/new-pfizer-covid-vaccine-doses-hit-australia-as-anthony-albanese-lines-up-for-jab 2021-02-23T00:35:12 https://maestrodatabase.com/blog/doh-updates-agenda-for-march-2021-pbac-meeting 2021-02-23T00:39:15 https://maestrodatabase.com/blog/fda-approves-novel-dual-targeted-treatment-for-type-2-diabetes 2022-05-13T23:28:26 https://maestrodatabase.com/blog/could-fda-use-off-label-data-for-drug-approvals-its-possible-agency-official-says 2018-07-11T01:42:13 https://maestrodatabase.com/blog/eu-delays-approval-of-novavaxs-revised-covid-vaccine 2023-10-16T03:26:38 https://maestrodatabase.com/blog/biomarin-sells-second-priority-review-voucher-for-125-million-dollars 2017-11-29T07:46:03 https://maestrodatabase.com/blog/pfizer-to-roll-back-drug-price-hikes-after-trump-tweets 2018-07-11T01:59:54 https://maestrodatabase.com/blog/multiple-sclerosis-sufferer-natalie-adams-lives-in-fear 2017-11-29T20:08:38 https://maestrodatabase.com/blog/senate-inquiry-adds-pressure-to-medical-device-industry 2017-05-14T21:39:02 https://maestrodatabase.com/blog/the-man-behind-value-based-pricing-saw-pharma-distorting-his-message----and-walked-away 2022-05-13T23:36:41 https://maestrodatabase.com/blog/auckland-mum-is-having-to-self-fund-drugs-to-extend-her-life 2017-11-29T20:05:29 https://maestrodatabase.com/blog/cheaper-medicines-for-cervical-cancer-urotherial-cancer-and-spinal-muscular-atrophy 2023-10-16T03:33:43 https://maestrodatabase.com/blog/why-you-could-have-to-pay-1-dollars-more-for-medicine 2017-05-14T21:42:00 https://maestrodatabase.com/blog/is-the-fda-withholding-data-about-a-controversial-drug-to-protect-its-manufacturer 2017-11-29T20:17:20 https://maestrodatabase.com/blog/trump-health-nominee-set-to-be-grilled-about-ties-to-drug-industry 2017-11-29T20:32:01 https://maestrodatabase.com/blog/u-dot-s-fda-grants-fast-track-designation-for-idera-pharmaceuticals-imo-2125-in-combination-with-ipilimumab-for-treatment-of-pd-1-refractory-metastatic-melanoma 2017-11-29T20:23:37 https://maestrodatabase.com/blog/medical-devices---tragedy-and-triumph 2017-11-29T20:43:39 https://maestrodatabase.com/blog/life-extending-breast-cancer-drug-ibrance-to-be-fully-funded-from-april 2020-03-05T05:16:54 https://maestrodatabase.com/blog/america-desperately-needs-a-much-better-fda 2021-09-05T20:57:53 https://maestrodatabase.com/blog/gsk-submits-us-regulatory-application-for-single-dose-tafenoquine-for-plasmodium-vivax-malaria 2017-11-29T20:35:42 https://maestrodatabase.com/blog/trump-backs-bipartisan-fixes-to-obamacare-markets 2017-11-29T20:45:59 https://maestrodatabase.com/blog/cstone-announces-chinas-nmpa-has-accepted-its-new-drug-application-for-sugemalimab-in-the-treatment-of-stage-iii-nsclc 2021-09-05T21:06:04 https://maestrodatabase.com/blog/pharming-submits-supplemental-biologics-license-application-to-fda-for-ruconest-for-prophylaxis-of-hereditary-angioedema-attacks 2017-11-29T20:52:31 https://maestrodatabase.com/blog/bridgebio-pharma-sells-rare-pediatric-disease-priority-review-voucher-for-110-dollars-million 2022-05-14T00:12:19 https://maestrodatabase.com/blog/the-u-dot-s-has-a-problem-with-prescription-drug-prices-canada-shouldnt-try-to-fix-it 2020-03-05T05:21:10 https://maestrodatabase.com/blog/eisai-submits-marketing-authorisation-application-for-lecanemab-as-treatment-for-early-alzheimers-disease-in-europe 2023-01-12T02:28:36 https://maestrodatabase.com/blog/pfizers-paxlovid-not-included-in-chinas-national-insurance 2023-01-12T02:24:11 https://maestrodatabase.com/blog/mundipharma-and-cidara-therapeutics-receive-positive-chmp-opinion-for-rezafungin-for-the-treatment-of-invasive-candidiasis-in-adults 2023-10-16T05:04:05 https://maestrodatabase.com/blog/apparently-the-tga-thinks-it-can-approve-a-first-generic-of-a-given-medicine-on-more-than-one-occasion 2021-02-23T03:45:11 https://maestrodatabase.com/blog/santhera-receives-positive-chmp-opinion-recommending-approval-of-agamree-vamorolone-for-the-treatment-of-duchenne-muscular-dystrophy 2023-10-16T04:55:59 https://maestrodatabase.com/blog/drug-makers-cancel-price-hikes-after-california-law-takes-effect 2018-07-11T05:08:40 https://maestrodatabase.com/blog/tagrisso-plus-chemotherapy-granted-priority-review-in-the-us-for-patients-with-egfr-mutated-advanced-lung-cancer 2023-10-16T06:28:56 https://maestrodatabase.com/blog/editas-medicine-granted-fda-regenerative-medicine-advanced-therapy-designation-for-edit-301-for-the-treatment-of-severe-sickle-cell-disease 2023-10-16T19:53:02 https://maestrodatabase.com/blog/sumitomo-pharma-announces-that-dsp-5336-has-received-fda-fast-track-designation-for-the-treatment-of-relapsed-or-refractory-acute-myeloid-leukaemia 2024-07-16T05:08:00 https://maestrodatabase.com/blog/doug-ford-wants-canada-to-approve-drugs-faster-is-that-possible 2024-07-16T05:00:40 https://maestrodatabase.com/blog/eton-pharmaceuticals-announces-fda-acceptance-of-nda-response-for-dehydrated-alcohol-injection 2023-01-12T19:01:01 https://maestrodatabase.com/blog/health-canada-grants-marketing-authorisation-for-trikafta-elexacaftor-slash-tezacaftor-slash-ivacaftor-and-ivacaftor-for-people-with-cystic-fibrosis-aged-2-years-and-older-with-certain-rare-mutations 2024-07-16T04:48:08 https://maestrodatabase.com/blog/intellia-therapeutics-awarded-innovation-passport-in-the-united-kingdom-for-ntla-2002-an-investigational-genome-editing-treatment-for-hereditary-angioedema 2023-01-12T18:53:35 https://maestrodatabase.com/blog/epilepsy-drug-deaths-medsafe-told-pharmac-it-was-not-desirable-to-switch-brands 2021-02-23T20:10:34 https://maestrodatabase.com/blog/standardised-redactions-to-public-summary-documents---nominations-open-for-participation-in-the-final-trial-and-implementation-from-july-2020 2020-03-05T07:28:06 https://maestrodatabase.com/blog/fda-to-allow-pfizer-biontech-vaccine-to-be-stored-at-higher-temperatures 2021-02-23T20:15:01 https://maestrodatabase.com/blog/hundreds-of-people-in-england-to-benefit-from-take-at-home-tablet-bladder-cancer-treatment 2025-04-10T20:55:25 https://maestrodatabase.com/blog/smc---july-2024-decisions 2024-07-16T05:35:27 https://maestrodatabase.com/blog/fda-approves-endoclot-hemostat-to-manage-gi-bleeding 2021-02-23T20:19:14 https://maestrodatabase.com/blog/mhra-approves-seagens-oral-her2-drug-tukysa 2021-02-23T07:09:16 https://maestrodatabase.com/blog/ausperbio-receives-breakthrough-therapy-designation-for-ahb-137-in-chronic-hepatitis-b-treatment 2024-07-16T05:28:18 https://maestrodatabase.com/blog/amgen-submits-supplemental-new-drug-application-for-otezla-apremilast-for-adults-with-mild-to-moderate-plaque-psoriasis 2021-02-23T19:54:40 https://maestrodatabase.com/blog/arrivo-announces-fda-fast-track-designation-for-rabi-767-for-patients-with-acute-pancreatitis-predicted-to-progress-to-severe-disease 2024-07-16T05:17:38 https://maestrodatabase.com/blog/fda-approves-neo-adjuvant-slash-adjuvant-pembrolizumab-for-resectable-non-small-cell-lung-cancer 2023-10-16T22:54:33 https://maestrodatabase.com/blog/companies-file-suit-in-canada-challenging-new-rules-to-lower-drug-prices 2019-08-24T05:42:42 https://maestrodatabase.com/blog/elranatamab-for-the-treatment-of-patients-with-relapsed-and-refractory-multiple-myeloma-after-three-or-more-treatments 2024-07-16T06:06:09 https://maestrodatabase.com/blog/the-bcma-car-t-co-developed-by-innovent-and-iaso-was-granted-breakthrough-therapy-designation-by-the-nmpa-for-the-treatment-of-relapsed-slash-refractory-multiple-myeloma 2021-02-23T20:23:32 https://maestrodatabase.com/blog/life-changing-drugs-almost-nobody-can-afford 2019-08-24T06:33:31 https://maestrodatabase.com/blog/trump-has-made-a-priority-of-trying-to-lower-drug-prices-but-many-of-his-most-ardent-supporters-dont-know-it 2019-08-24T06:14:25 https://maestrodatabase.com/blog/tga-bans-pfizer-astrazeneca-brand-mentions-in-covid-19-vaccine-advertising 2021-02-23T20:29:14 https://maestrodatabase.com/blog/ottawa-heightens-scrutiny-on-opioid-manufacturers-marketing 2018-07-11T12:30:05 https://maestrodatabase.com/blog/supply-of-100-uk-medicines-to-be-disrupted-warns-ema 2018-07-11T12:40:05 https://maestrodatabase.com/blog/bristol-myers-squibbs-opdivo-nivolumab-and-low-dose-yervoy-ipilimumab-is-the-first-immuno-oncology-combination-approved-for-msi-h-slash-dmmr-mcrc-patients-who-progressed-following-treatment-with-a-fluoropyrimidine-oxaliplatin-and-irinotecan 2018-07-11T12:22:05 https://maestrodatabase.com/blog/statement-from-fda-commissioner-on-agencys-efforts-to-advance-development-of-gene-therapies 2018-07-11T21:02:07 https://maestrodatabase.com/blog/defining-innovation-with-respect-to-new-medicines-a-systematic-review-from-a-payer-perspective 2018-07-11T13:11:18 https://maestrodatabase.com/blog/challenges-and-methodologies-in-using-progression-free-survival-as-a-surrogate-for-overall-survival-in-oncology 2018-07-11T13:16:20 https://maestrodatabase.com/blog/amsterdam-looks-to-lure-more-companies-from-london-after-ema-move 2018-07-11T21:12:45 https://maestrodatabase.com/blog/cannabis-medication-for-kids-with-epilepsy-can-cost-up-to-$100k 2018-07-11T21:06:57 https://maestrodatabase.com/blog/trump-told-pfizer-ceo-price-hikes-hurt-his-drug-plan-source-says 2018-07-11T21:33:13 https://maestrodatabase.com/blog/trevena-announces-fda-has-set-pdufa-date-of-7-august-2020-for-oliceridine 2020-03-05T19:54:29 https://maestrodatabase.com/blog/fda-accepts-biologics-license-application-for-subcutaneous-formulation-of-herceptin 2018-07-11T21:17:33 https://maestrodatabase.com/blog/fda-track-pdufa-performance 2020-03-05T19:51:50 https://maestrodatabase.com/blog/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-for-keytruda-pembrolizumab-for-the-treatment-of-patients-with-advanced-hepatocellular-carcinoma 2018-07-11T21:26:58 https://maestrodatabase.com/blog/dying-to-survive-china-shows-the-way-on-drug-prices 2018-07-11T21:51:27 https://maestrodatabase.com/blog/why-putting-drug-prices-in-ads-is-a-bad-idea 2018-07-11T21:35:54 https://maestrodatabase.com/blog/allergan-receives-fda-approval-for-durysta-bimatoprost-implant-the-first-and-only-intracameral-biodegradable-sustained-release-implant-to-lower-intra-ocular-pressure-in-open-angle-glaucoma-or-ocular-hypertension-patients 2020-03-05T20:12:53 https://maestrodatabase.com/blog/nice-pushes-doptelet-for-pre-surgery-liver-disease-treatment 2020-03-05T20:06:36 https://maestrodatabase.com/blog/pfizer-wins-korea-nod-for-paediatric-arthritis-use-of-oral-jak-inhibitor-xeljanz 2025-04-10T23:00:41 https://maestrodatabase.com/blog/urovant-sciences-announces-u-dot-s-fda-acceptance-of-new-drug-application-for-vibegron-for-the-treatment-of-overactive-bladder 2020-03-05T20:36:01 https://maestrodatabase.com/blog/new-zealands-tocilizumab-supply-to-be-paused 2021-09-06T01:46:01 https://maestrodatabase.com/blog/how-would-single-payer-health-care-in-the-us-impact-pharma-a-pricing-perspective 2020-03-05T20:25:38 https://maestrodatabase.com/blog/online-pharmacy-ro-is-testing-a-program-that-sends-you-generic-prescriptions-for-5-dollars-per-month-without-insurance 2020-03-05T20:20:40 https://maestrodatabase.com/blog/gene-and-cell-therapies-continue-growth-in-patients-financing-and-costs 2020-03-05T20:53:08 https://maestrodatabase.com/blog/fda-approves-ferrings-clenpiq-sodium-picosulfate-magnesium-oxide-and-anhydrous-citric-acid-oral-solution-for-colonoscopy-prep 2017-11-30T03:40:03 https://maestrodatabase.com/blog/merck-receives-fda-approval-for-isentress-raltegravir-in-combination-with-other-antiretroviral-agents-for-the-treatment-of-hiv-1-infection-in-newborns-weighing-at-least-2-kg 2017-11-30T03:18:14 https://maestrodatabase.com/blog/new-treatment-option-for-schizophrenia-reagila-listed-on-pbs 2021-09-06T02:36:03 https://maestrodatabase.com/blog/adamis-pharmaceuticals-submits-prior-approval-supplement-to-fda-for-the-paediatric-version-of-symjepi 2017-11-30T03:44:34 https://maestrodatabase.com/blog/arcturus-therapeutics-receives-us-fda-fast-track-designation-for-the-starr-mrna-vaccine-candidate-arct-2304-for-pandemic-influenza-a-virus-h5n1 2025-04-10T23:30:46 https://maestrodatabase.com/blog/trastuzumab-deruxtecan-approved-to-treat-adults-with-her2-positive-cancer-that-has-spread-or-cannot-be-removed-by-surgery 2025-04-10T23:51:27 https://maestrodatabase.com/blog/icer-publishes-final-evidence-report-on-treatment-for-chronic-obstructive-pulmonary-disease 2024-07-16T12:14:44 https://maestrodatabase.com/blog/four-million-pfizer-doses-arrive-to-super-charge-vaccine-roll-out 2021-09-06T02:46:04 https://maestrodatabase.com/blog/gsk-receives-positive-chmp-opinion-recommending-approval-of-jemperli-dostarlimab-plus-chemotherapy-as-a-new-frontline-treatment-for-dmmr-slash-msi-h-primary-advanced-or-recurrent-endometrial-cancer 2023-10-17T01:14:52 https://maestrodatabase.com/blog/13-000-people-to-benefit-from-new-insulin-medicine 2025-04-11T00:26:42 https://maestrodatabase.com/blog/statement-on-moderna-covid-19-vaccine 2021-09-06T03:37:08 https://maestrodatabase.com/blog/which-biosimilar-medicines-are-available-in-australia 2017-11-30T11:13:37 https://maestrodatabase.com/blog/health-nominee-grilled-on-commitment-to-lower-drug-prices 2017-11-30T11:48:22 https://maestrodatabase.com/blog/health-economic-assessment-of-sarclisa-in-multiple-myeloma 2021-09-06T20:34:31 https://maestrodatabase.com/blog/democrats-plans-to-introduce-prescription-drug-pricing-reform-face-formidable-obstacles 2021-09-06T20:31:18 https://maestrodatabase.com/blog/reducing-the-waste-in-the-massive-health-care-system 2017-11-30T20:06:26 https://maestrodatabase.com/blog/leap-forward-for-patients-accessing-medicines 2021-09-06T20:38:38 https://maestrodatabase.com/blog/prioritise-investment-in-the-pbs-to-improve-access-to-all-cancer-medicines 2017-11-30T11:58:36 https://maestrodatabase.com/blog/advancing-medicinal-nicotine-replacement-therapies-as-new-drugs---a-new-step-in-fdas-comprehensive-approach-to-tobacco-and-nicotine 2017-11-30T20:17:33 https://maestrodatabase.com/blog/how-exactly-would-single-payer-health-care-work 2017-11-30T20:11:34 https://maestrodatabase.com/blog/congress-concerned-by-apparent-anomalies-around-fdas-approval-of-aduhelm 2021-09-06T20:26:17 https://maestrodatabase.com/blog/u-dot-s-government-should-negotiate-drug-prices-adviser-group-says 2017-11-30T20:21:37 https://maestrodatabase.com/blog/medcura-receives-breakthrough-device-designation-for-its-lifegel-absorbable-surgical-hemostat 2023-01-12T23:43:32 https://maestrodatabase.com/blog/incoming-novartis-ceo-on-475-000-dollar-cancer-therapy-no-question-that-the-list-price-raises-eyebrows 2017-11-30T20:26:40 https://maestrodatabase.com/blog/hundreds-of-patients-to-get-life-extending-lung-cancer-drug-on-the-nhs 2022-05-14T03:35:17 https://maestrodatabase.com/blog/jw-therapeutics-announces-nmpa-approval-of-relmacabtagene-autoleucel-injection-in-china 2021-09-06T21:20:31 https://maestrodatabase.com/blog/biocon-biologics-announces-us-fda-approval-for-jobevne-biosimilar-bevacizumab 2025-04-11T01:19:57 https://maestrodatabase.com/blog/new-report-reveals-need-for-a-gender-based-approach-to-health-funding-for-women-to-have-full-economic-empowerment 2017-11-30T20:33:21 https://maestrodatabase.com/blog/uk-mhra-grants-gensight-biologics-lumevoq-ophthalmic-gene-therapy-promising-innovative-medicine-designation 2021-09-06T20:57:42 https://maestrodatabase.com/blog/sandoz-confirms-european-commission-approval-for-ranluspec-ranibizumab 2026-02-23T19:45:12 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-december-2017 2017-11-30T20:41:06 https://maestrodatabase.com/blog/opioid-addiction-meds-to-be-free-under-pbs 2019-08-25T01:03:36 https://maestrodatabase.com/blog/ema-evaluating-data-on-booster-dose-of-covid-19-vaccine-comirnaty 2021-09-06T20:42:38 https://maestrodatabase.com/blog/health-canada-accepts-snds-filing-and-grants-priority-review-of-oral-edarvarone-formulation-for-the-treatment-of-als 2022-05-14T03:12:29 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-december-2017-update 2017-11-30T20:53:12 https://maestrodatabase.com/blog/hansa-biopharma-announces-temporary-marketing-authorisation-in-switzerland-for-idefirix-imlifidase-in-kidney-transplantation 2022-05-14T03:27:58 https://maestrodatabase.com/blog/health-canada-approves-imfinzi-durvalumab-as-the-first-and-only-immunotherapy-regimen-for-adult-patients-with-limited-stage-small-cell-lung-cancer 2025-04-11T01:44:59 https://maestrodatabase.com/blog/zepbound-tirzepatide-the-most-prescribed-weight-management-medication-in-2025-now-available-in-multi-dose-kwikpen 2026-02-23T20:43:32 https://maestrodatabase.com/blog/glofitamab-for-the-treatment-of-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-after-2-or-more-systemic-treatments 2023-10-17T02:31:35 https://maestrodatabase.com/blog/health-canada-approves-dupixent-dupilumab-as-the-first-biologic-for-the-treatment-of-moderate-to-severe-atopic-dermatitis-in-children-aged-6-to-11-years 2021-02-24T01:20:51 https://maestrodatabase.com/blog/ema-publishes-agenda-for-23-26-february-2026-chmp-meeting 2026-02-23T20:09:29 https://maestrodatabase.com/blog/inovise-receives-breakthrough-device-designation-for-novel-non-invasive-system-to-remotely-monitor-risk-of-decompensation-in-heart-failure-patients 2021-02-24T01:02:56 https://maestrodatabase.com/blog/argenx-announces-fda-approval-of-vyvgart-hytrulo-pre-filled-syringe-for-self-injection-in-generalised-myasthenia-gravis-and-chronic-inflammatory-demyelinating-polyneuropathy 2025-04-11T01:49:40 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-for-priority-review-pfizers-application-for-ticovac-tick-borne-encephalitis-vaccine 2021-02-24T01:14:30 https://maestrodatabase.com/blog/antengene-announces-new-drug-application-for-atg-010-selinexor-granted-priority-review-by-chinas-nmpa 2021-02-24T02:16:09 https://maestrodatabase.com/blog/us-fda-grants-full-approval-of-vitrakvi-larotrectinib-for-adult-and-paediatric-patients-with-ntrk-gene-fusion-positive-solid-tumours 2025-04-11T02:11:48 https://maestrodatabase.com/blog/akcea-and-ionis-announce-approval-of-tegsedi-inotersen-in-the-european-union 2018-07-12T01:08:19 https://maestrodatabase.com/blog/enhertu-approved-by-health-canada-as-the-first-her2-directed-therapy-for-patients-with-her2-low-metastatic-breast-cancer 2023-01-13T01:40:58 https://maestrodatabase.com/blog/advaxis-provides-update-on-maa-filing 2018-07-12T01:14:38 https://maestrodatabase.com/blog/proposal-to-list-bendamustine-hydrochloride 2017-05-15T05:48:56 https://maestrodatabase.com/blog/pharmac-knew-of-epilepsy-drug-change-risks-within-some-patients-but-went-ahead-with-switch 2021-02-24T09:10:52 https://maestrodatabase.com/blog/new-strategic-agreements-with-the-medicines-industry 2021-09-07T02:06:07 https://maestrodatabase.com/blog/as-cms-asks-for-the-publics-feedback-on-implementing-the-inflation-reduction-act-unresolved-issues-related-to-drug-price-negotiations-remain 2023-01-13T01:55:31 https://maestrodatabase.com/blog/landmark-new-medicines-agreements-to-bring-significant-benefits-for-australian-patients 2021-09-07T02:08:58 https://maestrodatabase.com/blog/viiv-healthcare-submits-supplemental-new-drug-application-to-us-fda-for-expanded-use-of-cabenuva-cabotegravir-rilpivirine-as-an-hiv-treatment-for-use-every-2-months 2021-02-24T20:12:23 https://maestrodatabase.com/blog/the-biden-harris-administration-releases-final-part-two-guidance-to-help-people-with-medicare-prescription-drug-coverage-manage-prescription-drug-costs 2024-07-17T00:12:07 https://maestrodatabase.com/blog/anti-cancer-drugs-ninlaro-lutathera-to-get-insurance-benefits-from-march 2021-02-24T20:19:18 https://maestrodatabase.com/blog/takedas-drug-for-acute-hereditary-angioedema-seizure-to-get-larger-benefits 2021-02-24T20:22:48 https://maestrodatabase.com/blog/ema-starts-rolling-review-of-celltrion-antibody-regdanvimab-for-covid-19 2021-02-24T19:59:59 https://maestrodatabase.com/blog/time-for-fda-to-release-complete-responses-letters-debate-reignites 2019-08-25T02:54:30 https://maestrodatabase.com/blog/locate-bios-chondro3-granted-fda-breakthrough-device-designation 2021-02-24T20:05:18 https://maestrodatabase.com/blog/covid-treatment-molnupiravir-to-hit-chinese-market-on-friday 2023-01-13T03:12:27 https://maestrodatabase.com/blog/tga-reviewing-covid-19-tests-to-rule-out-issues-diagnosing-variants 2021-02-24T20:37:51 https://maestrodatabase.com/blog/bladder-cancer-drug-shortage-resolved-with-health-canada-approval 2021-02-24T20:41:16 https://maestrodatabase.com/blog/mediposts-pneumostem-gets-fdas-fast-track-designation 2019-08-25T03:02:55 https://maestrodatabase.com/blog/pharmac-knew-of-epilepsy-drug-change-risks---inquest 2021-02-24T20:45:42 https://maestrodatabase.com/blog/nice-terminates-appraisal-of-novartis-medicine 2021-02-24T20:26:44 https://maestrodatabase.com/blog/tecartus-recommended-by-nice 2021-02-24T20:32:54 https://maestrodatabase.com/blog/cannabis-oil-too-expensive-to-prescribe-to-epileptic-children-on-nhs-advisory-body-finds 2019-08-25T03:31:14 https://maestrodatabase.com/blog/biden-to-sign-order-seeking-homegrown-fixes-for-shortfalls-of-foreign-made-items 2021-02-24T20:56:06 https://maestrodatabase.com/blog/tessera-therapeutics-receives-us-fda-fast-track-and-orphan-drug-designations-for-its-lead-in-vivo-gene-editing-program-tsra-196-for-the-treatment-of-adults-with-aatd 2026-02-23T23:53:02 https://maestrodatabase.com/blog/fda-approves-nivolumab-with-ipilimumab-for-unresectable-or-metastatic-hepatocellular-carcinoma 2025-04-11T21:57:01 https://maestrodatabase.com/blog/beren-therapeutics-announces-fda-acceptance-of-its-new-drug-application-for-adrabetadex-in-infantile-onset-niemann-pick-disease-type-c 2026-02-23T23:20:40 https://maestrodatabase.com/blog/csl-behring-announces-positive-reimbursement-decision-in-canada-for-hemgenix-etranacogene-dezaparvovec-the-first-gene-therapy-for-haemophilia-b 2024-07-17T04:12:36 https://maestrodatabase.com/blog/daiichi-sankyo-submits-application-for-marketing-approval-of-mrna-covid-19-vaccine-ds-5670-in-japan 2023-01-13T04:18:43 https://maestrodatabase.com/blog/health-canada-authorizes-alecensaro-alectinib-as-the-first-and-only-adjuvant-treatment-for-people-with-alk-positive-early-stage-lung-cancer 2024-07-17T01:50:39 https://maestrodatabase.com/blog/us-fda-grants-reunion-neurosciences-luvesilocin-re104-breakthrough-therapy-designation-status 2026-02-23T23:42:06 https://maestrodatabase.com/blog/ocrelizumab-approved-as-an-injection-to-treat-multiple-sclerosis-in-adults 2024-07-17T08:27:01 https://maestrodatabase.com/blog/covid-19-vaccine-safety-report-12-january-2023 2023-01-13T05:28:40 https://maestrodatabase.com/blog/fda-approves-first-once-monthly-buprenorphine-injection-a-medication-assisted-treatment-option-for-opioid-use-disorder 2017-12-01T00:44:34 https://maestrodatabase.com/blog/armata-pharmaceuticals-receives-fda-qualified-infectious-disease-product-designation-for-ap-sa02 2026-02-24T00:16:15 https://maestrodatabase.com/blog/tezspire-approved-for-self-administration-in-the-eu-in-a-new-pre-filled-pen 2023-01-13T07:05:40 https://maestrodatabase.com/blog/fda-announces-approval-cms-proposes-coverage-of-first-breakthrough-designated-test-to-detect-extensive-number-of-cancer-biomarkers 2017-12-01T01:00:50 https://maestrodatabase.com/blog/a-test-could-have-saved-alison-from-chemotherapy 2023-10-17T06:17:02 https://maestrodatabase.com/blog/new-cervical-cancer-test-is-great-news-for-australian-women 2017-12-01T00:51:18 https://maestrodatabase.com/blog/europes-top-biotech-expects-delays-from-drugs-watchdogs-hq-move 2017-12-01T01:10:21 https://maestrodatabase.com/blog/fda-aims-to-expand-early-approval-program-for-promising-drugs 2017-12-01T01:05:58 https://maestrodatabase.com/blog/diakonos-oncology-awarded-fda-fast-track-designation-for-innovative-dendritic-cell-vaccine-for-glioblastoma 2023-10-17T19:33:26 https://maestrodatabase.com/blog/brensocatib-licensed-as-the-first-medicine-specifically-designed-to-treat-non-cystic-fibrosis-bronchiectasis-in-patients-12-years-and-older 2026-02-24T10:01:41 https://maestrodatabase.com/blog/price-predicts-obamacare-repeal-passes-senate-by-august 2017-05-15T13:12:42 https://maestrodatabase.com/blog/dupixent-dupilumab-approved-in-the-us-as-the-first-and-only-medicine-for-allergic-fungal-rhinosinusitis 2026-02-24T20:11:26 https://maestrodatabase.com/blog/fda-grants-traditional-approval-to-encorafenib-for-metastatic-colorectal-cancer-with-a-braf-v600e-mutation 2026-02-24T20:25:21 https://maestrodatabase.com/blog/us-fda-has-granted-accelerated-approval-of-loargys-pegzilarginase-nbln-for-the-treatment-of-hyperargininemia-in-patients-2-years-and-older-with-arginase-1-deficiency 2026-02-24T20:37:04 https://maestrodatabase.com/blog/artios-receives-us-fda-fast-track-designation-for-dna-polymerase-theta-inhibitor-art6043-for-treatment-of-gbrca-mutated-her2-negative-breast-cancer 2026-02-24T00:54:33 https://maestrodatabase.com/blog/who-technical-advisory-group-on-pricing-policies-for-medicines 2023-10-17T19:55:29 https://maestrodatabase.com/blog/first-treatment-to-be-recommended-by-nice-at-the-same-time-it-is-approved-for-advanced-lymphoma-in-the-uk 2023-10-17T19:45:26 https://maestrodatabase.com/blog/fda-launches-framework-for-accelerating-development-of-individualised-therapies-for-ultra-rare-diseases 2026-02-24T01:58:49 https://maestrodatabase.com/blog/northsea-therapeutics-receives-fda-rare-paediatric-disease-designation-for-sefa-6179-for-the-treatment-of-intestinal-failure-associated-liver-disease 2023-10-17T19:38:50 https://maestrodatabase.com/blog/pharmac-proposes-to-widen-access-to-two-medicines-for-people-with-melanoma 2026-02-24T02:06:15 https://maestrodatabase.com/blog/ultragenyx-announces-us-fda-acceptance-and-priority-review-of-the-biologics-license-application-for-dtx401-aav-gene-therapy-for-glycogen-storage-disease-type-ia 2026-02-24T02:52:51 https://maestrodatabase.com/blog/ucb-announces-us-fda-approval-of-zilbrysq-zilucoplan-for-the-treatment-of-adults-with-generalised-myasthenia-gravis 2023-10-17T22:14:34 https://maestrodatabase.com/blog/novo-nordisk-announces-significant-reduction-in-us-list-price-for-wegovy-ozempic-and-rybelsus-semaglutide-medicines-building-on-continued-efforts-to-expand-access 2026-02-24T20:45:11 https://maestrodatabase.com/blog/publication-and-reporting-of-the-results-of-post-market-studies-for-drugs-required-by-the-us-fda-009-to-2013 2017-05-15T21:15:51 https://maestrodatabase.com/blog/european-commission-opens-formal-investigation-into-aspen-pharmas-pricing-practices-for-cancer-medicines 2017-05-15T21:08:28 https://maestrodatabase.com/blog/hta-programme-response-to-the-challenges-of-dealing-with-orphan-medicinal-products-process-evaluation-in-selected-european-countries 2017-05-15T21:26:34 https://maestrodatabase.com/blog/financing-and-distribution-of-pharmaceuticals-in-the-united-states 2017-05-15T21:21:30 https://maestrodatabase.com/blog/first-treatment-for-vitiligo-recommended-by-nice-for-nhs-use-bringing-hope-to-over-80-000-people 2026-02-24T20:58:18 https://maestrodatabase.com/blog/verve-therapeutics-receives-us-fda-fast-track-designation-for-verve-102-an-in-vivo-base-editing-medicine-targeting-pcsk9 2025-04-11T23:04:55 https://maestrodatabase.com/blog/ema-publishes-draft-agenda-for-may-chmp-meeting 2017-05-15T21:43:40 https://maestrodatabase.com/blog/the-trump-administration-could-bring-down-drug-prices-but-it-would-take-guts 2017-05-15T21:36:08 https://maestrodatabase.com/blog/tc-publishes-opinion-on-pfizers-ibrance 2017-05-15T21:53:28 https://maestrodatabase.com/blog/kura-oncology-receives-fda-breakthrough-therapy-designation-for-tipifarnib-in-head-and-neck-squamous-cell-carcinoma 2021-02-25T00:39:49 https://maestrodatabase.com/blog/recent-patent-reform-bills-and-their-implications-for-prescription-drugs 2023-01-13T21:38:44 https://maestrodatabase.com/blog/top-democrats-demands-more-details-on-pricing-deal-between-pfizer-and-trump 2018-07-12T06:54:28 https://maestrodatabase.com/blog/abbvie-announces-submission-of-supplemental-new-drug-application-to-us-fda-for-venetoclax-in-newly-diagnosed-acute-myeloid-leukaemia-patients-ineligible-for-intensive-chemotherapy 2018-07-12T06:58:57 https://maestrodatabase.com/blog/the-nations-first-drug-affordability-board-is-set-up-in-maryland-but-it-has-no-money 2019-08-25T20:49:38 https://maestrodatabase.com/blog/australia-could-be-world-leader-with-its-digital-medical-data-banks 2019-08-25T20:44:07 https://maestrodatabase.com/blog/new-zealands-medicines-waiting-list-international-disgrace-for-patient-equity 2018-07-12T07:12:08 https://maestrodatabase.com/blog/dascena-announces-fda-breakthrough-device-designation-granted-to-machine-learning-diagnostic-method 2021-02-25T00:45:38 https://maestrodatabase.com/blog/are-health-apps-good-for-your-health-have-your-say 2018-07-12T07:24:28 https://maestrodatabase.com/blog/humira-adalimumab-receives-fda-approval-to-treat-paediatric-patients-living-with-moderately-to-severely-active-ulcerative-colitis 2021-02-25T02:23:41 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-anti-androgen-therapies-for-non-metastatic-castration-resistant-prostate-cancer 2018-07-12T21:03:59 https://maestrodatabase.com/blog/cancer-drug-for-children-recommended-after-becoming-cost-effective-for-nhs-patients 2018-07-12T07:27:16 https://maestrodatabase.com/blog/takedas-exkivity-mobocertinib-receives-approval-from-the-nmpa-of-china-becoming-the-first-and-only-therapy-available-for-patients-with-egfr-exon20-insertion-positive-nsclc 2023-01-13T23:05:56 https://maestrodatabase.com/blog/opdivo-plus-yervoy-first-combination-immunotherapy-for-advanced-renal-cell-carcinoma-kidney-cancer-receives-tga-approval 2018-07-12T11:34:31 https://maestrodatabase.com/blog/multiple-sclerosis-treatments 2021-02-25T02:52:34 https://maestrodatabase.com/blog/to-lower-drug-costs-define-cost-to-mean-net-cost-after-rebates 2021-09-07T10:54:31 https://maestrodatabase.com/blog/nice-says-no-to-darzalex 2018-07-12T21:19:22 https://maestrodatabase.com/blog/law-makers-again-urge-the-biden-administration-to-use-federal-law-to-widen-access-to-a-cancer-drug 2023-01-13T22:27:01 https://maestrodatabase.com/blog/after-feuding-with-drug-middlemen-startup-fields-a-competitor 2018-07-12T21:22:18 https://maestrodatabase.com/blog/launch-of-new-masters-degree-in-evaluation-of-health-care-interventions-and-outcomes 2018-07-12T21:16:08 https://maestrodatabase.com/blog/tga-approves-new-cancer-medicine 2021-09-07T21:11:21 https://maestrodatabase.com/blog/two-boys-one-horrific-disease-different-wonder-drug-funding 2018-07-12T21:30:54 https://maestrodatabase.com/blog/singapores-health-care-system-key-features-challenges-and-shifts 2021-09-07T21:04:44 https://maestrodatabase.com/blog/pharmac-places-temporary-dispensing-limits-on-paracetamol 2020-03-06T04:32:51 https://maestrodatabase.com/blog/statement-by-fda-commissioner-on-the-formation-of-a-new-drug-shortages-task-force-and-fdas-efforts-to-advance-long-term-solutions-to-prevent-shortages 2018-07-12T21:25:47 https://maestrodatabase.com/blog/pharmaceutical-companies-ignore-donald-trump-and-raise-drug-prices 2018-07-12T21:28:01 https://maestrodatabase.com/blog/abbvies-skyrizi-for-the-treatment-of-moderate-to-severe-plaque-psoriasis-now-publicly-reimbursed-across-canada 2021-02-25T03:00:48 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-for-priority-review-supplemental-new-drug-application-for-oxbryta-voxelotor-for-the-treatment-of-sickle-cell-disease-in-children-ages-4-to-11 2021-09-07T20:49:40 https://maestrodatabase.com/blog/reimbursement-uncertain-for-piqray-targeting-pik3ca-mutation-in-breast-cancer 2021-09-07T20:36:42 https://maestrodatabase.com/blog/the-drug-pricing-playbook-how-pharma-companies-keep-costs-high 2018-07-12T21:35:38 https://maestrodatabase.com/blog/longeveron-announces-us-fda-grants-fast-track-designation-for-lomecel-b-for-the-treatment-of-mild-alzheimers-disease 2024-07-17T23:46:24 https://maestrodatabase.com/blog/teleflex-announces-submission-of-biologics-license-application-for-its-investigational-freeze-dried-plasma 2021-02-25T03:22:49 https://maestrodatabase.com/blog/joint-statement-supply-allocations-of-intravenous-tocilizumab-actemra-during-serious-shortage 2021-10-07T06:56:50 https://maestrodatabase.com/blog/wegovy-and-mounjaro-for-weight-loss-not-funded 2026-02-24T22:56:50 https://maestrodatabase.com/blog/veru-submits-new-drug-application-for-proprietary-tadfin-for-benign-prostatic-hyperplasia 2021-02-25T03:48:43 https://maestrodatabase.com/blog/three-steps-can-help-companies-speed-fda-approval-of-new-drugs 2021-02-25T03:56:24 https://maestrodatabase.com/blog/the-common-medicines-hit-with-shortages-as-covid-supply-issues-worsen 2021-02-25T04:02:48 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-treatments-for-transthyretin-amyloid-cardiomyopathy 2024-07-17T23:55:16 https://maestrodatabase.com/blog/roche-announces-the-european-commission-approval-of-xofluza-for-the-treatment-and-prevention-of-influenza-in-children-aged-one-year-and-above 2023-01-14T01:29:19 https://maestrodatabase.com/blog/johnson-and-johnson-seeks-fda-approval-of-imavvy-nipocalimab-aahu-as-the-first-ever-fda-approved-treatment-for-warm-autoimmune-hemolytic-anemia 2026-02-25T00:50:42 https://maestrodatabase.com/blog/sellas-announces-us-fda-rare-paediatric-disease-designation-granted-to-sls009-for-the-treatment-of-paediatric-acute-myeloid-leukaemia 2024-07-18T00:12:52 https://maestrodatabase.com/blog/continuing-to-make-new-medicines-affordable-for-australians 2017-12-01T04:12:53 https://maestrodatabase.com/blog/merck-receives-positive-eu-chmp-opinion-for-prevymis-for-prevention-of-cmv-disease-in-high-risk-adult-kidney-transplant-recipients-and-extended-200-day-dosing-in-adult-hsct-recipients-at-risk-for-late-cmv-infection-and-disease 2023-10-18T01:21:42 https://maestrodatabase.com/blog/diakonos-oncology-receives-fda-fast-track-designation-for-pancreatic-cancer-dendritic-cell-vaccine 2024-07-18T00:32:40 https://maestrodatabase.com/blog/public-summary-documents---december-2024-pbac-meeting 2025-04-12T01:49:14 https://maestrodatabase.com/blog/rimegepant-sulphate-for-the-treatment-of-patients-with-acute-migraine 2023-10-18T02:17:03 https://maestrodatabase.com/blog/flobio-receives-fdas-breakthrough-device-designation-for-bleeding-risk-diagnostic-test 2023-10-18T02:01:33 https://maestrodatabase.com/blog/abbvies-rinvoq-upadacitinib-receives-health-canada-approval-as-the-first-and-only-oral-therapy-for-the-treatment-of-adults-with-moderately-to-severely-active-crohns-disease 2023-10-18T01:41:35 https://maestrodatabase.com/blog/larimar-therapeutics-announces-fda-breakthrough-therapy-designation-for-nomlabofusp-in-fa-and-reiterates-planned-bla-submission-in-june-2026 2026-02-25T04:51:08 https://maestrodatabase.com/blog/adapting-covid-19-vaccines-to-sars-cov-2-variants-guidance-for-vaccine-manufacturers 2021-02-25T19:49:42 https://maestrodatabase.com/blog/zilbrysq-zilucoplan-injection-now-approved-for-adults-with-generalised-myasthenia-gravis-in-canada 2024-07-18T02:32:42 https://maestrodatabase.com/blog/nice-draft-guidance-recommends-sapropterin-for-children-with-rare-inherited-metabolic-condition-phenylketonuria 2021-02-25T19:52:12 https://maestrodatabase.com/blog/international-cooperation-to-align-approaches-for-regulation-of-covid-19-vaccines-and-medicines 2021-02-25T19:46:55 https://maestrodatabase.com/blog/allergan-submits-new-drug-application-for-investigational-agn-190584-for-the-treatment-of-presbyopia 2021-02-25T20:12:26 https://maestrodatabase.com/blog/rucaparib-camsylate-for-maintenance-treatment-of-advanced-ovarian-fallopian-tube-and-peritoneal-cancer-after-response-to-first-line-platinum-based-chemotherapy 2024-07-18T03:16:17 https://maestrodatabase.com/blog/mirum-pharmaceuticals-announces-new-pdufa-date-for-livmarli-for-the-treatment-of-cholestatic-pruritus-in-progressive-familial-intrahepatic-cholestasis 2023-10-18T04:26:09 https://maestrodatabase.com/blog/aktis-oncology-receives-us-fda-fast-track-designation-for-aky-1189-a-nectin-4-miniprotein-radioconjugate 2026-02-25T05:48:51 https://maestrodatabase.com/blog/teclistamab-for-the-treatment-of-patients-with-relapsed-and-refractory-multiple-myeloma-after-three-or-more-treatments-review-of-previous-guidance 2024-07-18T03:09:55 https://maestrodatabase.com/blog/exelixis-announces-breakthrough-therapy-designation-granted-to-cabozantinib-for-the-treatment-of-patients-with-previously-treated-radioactive-iodine-refractory-differentiated-thyroid-cancer 2021-02-25T20:03:24 https://maestrodatabase.com/blog/soliris-approved-in-china-for-the-treatment-of-adults-with-neuromyelitis-optica-spectrum-disorder 2023-10-18T06:08:09 https://maestrodatabase.com/blog/bimzelx-approved-by-the-us-fda-for-the-treatment-of-adults-with-moderate-to-severe-plaque-psoriasis 2023-10-18T05:54:09 https://maestrodatabase.com/blog/nice-draft-guidance-recommends-apalutamide-for-treating-prostate-cancer 2021-09-08T09:44:03 https://maestrodatabase.com/blog/mhra-approves-imlunestrant-tosylate-inluryo---a-new-treatment-for-breast-cancer 2026-02-25T09:31:23 https://maestrodatabase.com/blog/health-canada-approves-tagrisso-osimertinib-as-first-line-treatment-for-egfr-mutated-non-small-cell-lung-cancer 2018-07-13T01:51:27 https://maestrodatabase.com/blog/fda-approves-xphozah-tenapanor-a-first-in-class-phosphate-absorption-inhibitor 2023-10-18T10:28:07 https://maestrodatabase.com/blog/congress-is-ready-to-dig-into-drug-prices 2021-09-08T11:59:32 https://maestrodatabase.com/blog/msac-publishes-agenda-for-feb-2024-esc-meeting 2023-10-18T06:32:21 https://maestrodatabase.com/blog/siren-biotechnology-receives-fda-fast-track-designation-for-srn-101-for-the-treatment-of-recurrent-high-grade-glioma 2026-02-25T06:24:15 https://maestrodatabase.com/blog/hyloris-announces-us-fda-approval-of-maxigesic-iv 2023-10-18T20:06:32 https://maestrodatabase.com/blog/intelivation-technologies-received-fda-approval-for-the-advantage-c-peek-cervical-interbody-fusion-device 2021-09-08T20:56:57 https://maestrodatabase.com/blog/ultragenyx-canada-announces-health-canada-approval-of-a-second-indication-for-crysvita-burosumab-injection-for-the-treatment-of-tumour-induced-osteomalacia-in-adults 2021-09-08T21:07:46 https://maestrodatabase.com/blog/health-economic-assessment-of-beyfortus-for-the-prevention-of-lower-respiratory-tract-disease-caused-by-respiratory-syncytial-virus 2023-10-18T20:03:17 https://maestrodatabase.com/blog/abbvies-epkinly-epcoritamab-receives-health-canada-authorisation-with-conditions-as-the-first-and-only-subcutaneous-bi-specific-antibody-to-treat-adult-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma 2023-10-18T10:40:22 https://maestrodatabase.com/blog/hibercell-receives-fast-track-designation-from-fda-for-first-in-human-studies-of-perk-inhibitor-perki-hc-5404-fu 2021-09-08T20:40:31 https://maestrodatabase.com/blog/health-canada-grants-market-authorisation-for-trikafta-elexacaftor-slash-tezacaftor-slash-ivacaftor-and-ivacaftor-in-children-with-cystic-fibrosis-ages-2-to-5-years-with-at-least-one-f508del-mutation 2023-10-18T10:35:46 https://maestrodatabase.com/blog/phathom-pharmaceuticals-submits-two-ndas-to-u-dot-s-fda-for-vonoprazan-based-treatment-regimens-for-the-treatment-of-h-pylori-infection 2021-09-08T20:52:29 https://maestrodatabase.com/blog/fda-grants-madorra-breakthrough-device-designation-status-for-treatment-of-moderate-to-severe-vulvovaginal-atrophy 2021-09-08T20:47:27 https://maestrodatabase.com/blog/transparent-and-complete-reporting-of-surrogate-endpoints-in-trials-the-spirit-surrogate-and-consort-surrogate-extensions 2024-07-18T09:22:12 https://maestrodatabase.com/blog/privately-insured-patients-get-vip-treatment-in-public-hospitals 2019-08-26T06:02:05 https://maestrodatabase.com/blog/nivolumab-scores-a-rare-no-from-nice 2021-09-08T21:18:54 https://maestrodatabase.com/blog/dont-give-up-on-biosimilars--congress-can-give-them-a-boost 2019-08-26T06:14:02 https://maestrodatabase.com/blog/digital-health-devices-must-prove-a-benefit-to-get-reimbursement 2022-05-15T10:03:13 https://maestrodatabase.com/blog/the-6-dollars-million-drug-claim 2019-08-26T06:04:40 https://maestrodatabase.com/blog/retrotope-granted-rare-paediatric-disease-designation-from-fda-for-lead-development-candidate-rt001-in-two-life-threatening-neurodegenerative-indications 2021-02-26T01:09:24 https://maestrodatabase.com/blog/gilead-receives-approval-in-canada-for-biktarvy-bictegravir-emtricitabine-tenofovir-alafenamide-for-the-treatment-of-hiv-1-infection 2018-07-13T02:13:56 https://maestrodatabase.com/blog/pharmac-publishes-agenda-for-may-2022-ptac-meeting 2022-05-15T23:32:13 https://maestrodatabase.com/blog/bc-doctor-calls-on-the-province-to-cover-obesity-medications 2024-07-18T10:17:58 https://maestrodatabase.com/blog/doctors-raise-the-stakes-in-turf-war-with-pharmacists 2019-08-26T20:49:26 https://maestrodatabase.com/blog/withdrawals-from-pharmaceutical-benefits-on-1-october-2021 2021-09-08T21:27:38 https://maestrodatabase.com/blog/drug-price-reforms-need-not-affect-research-on-rare-diseases---or-the-canadians-who-have-them 2019-08-26T20:46:26 https://maestrodatabase.com/blog/lilly-receives-u-dot-s-fda-approval-for-taltz-ixekizumab-for-the-treatment-of-active-ankylosing-spondylitis-radiographic-axial-spondyloarthritis 2019-08-26T11:19:12 https://maestrodatabase.com/blog/junshi-biosciences-announces-the-acceptance-of-the-supplemental-new-drug-application-for-toripalimab-combined-with-bevacizumab-for-the-first-line-treatment-of-advanced-hepatocellular-carcinoma 2024-07-18T09:25:55 https://maestrodatabase.com/blog/fda-encourages-inclusion-of-male-patients-in-breast-cancer-clinical-trials 2019-08-26T21:02:01 https://maestrodatabase.com/blog/empirical-spine-initiates-pma-submission-process-for-fda-approval-of-limiflex-for-degenerative-spondylolisthesis 2021-02-26T04:20:13 https://maestrodatabase.com/blog/medexus-announces-expanded-availability-of-gleolan-in-canada 2021-02-26T04:24:35 https://maestrodatabase.com/blog/biocryst-receives-positive-chmp-opinion-for-orladeyo-berotralstat-an-oral-once-daily-therapy-to-prevent-attacks-in-patients-with-hereditary-angioedema 2021-02-26T04:30:07 https://maestrodatabase.com/blog/biohavens-trigriluzole-receives-fast-track-designation-from-u-dot-s-fda 2017-05-16T01:10:50 https://maestrodatabase.com/blog/pbs-support-for-end-of-life-care-and-opioid-dependency 2019-08-26T20:54:51 https://maestrodatabase.com/blog/fda-approves-us-worldmeds-myobloc-rimabotulinumtoxinb-injection-for-chronic-sialorrhea 2019-08-26T21:14:23 https://maestrodatabase.com/blog/developing-real-world-data-and-evidence-to-support-regulatory-decision-making 2019-08-26T21:08:14 https://maestrodatabase.com/blog/china-loosens-curbs-on-small-unapproved-drug-imports 2019-08-26T21:31:22 https://maestrodatabase.com/blog/pharmac-widens-access-to-medicine-for-rsv 2022-05-16T00:04:29 https://maestrodatabase.com/blog/more-competition-will-improve-drug-affordability 2019-08-26T21:27:26 https://maestrodatabase.com/blog/china-revises-law-to-ensure-drug-safety 2019-08-26T21:23:01 https://maestrodatabase.com/blog/conservative-group-launches-ad-campaign-against-democratic-drug-pricing-plan 2019-08-26T21:20:40 https://maestrodatabase.com/blog/aust-stent-costs-five-times-higher-than-nz 2019-08-26T21:59:04 https://maestrodatabase.com/blog/imara-receives-rare-paediatric-disease-designation-from-fda-for-lead-product-candidate-imr-687-for-sickle-cell-disease 2017-05-16T02:06:43 https://maestrodatabase.com/blog/ignyta-granted-breakthrough-therapy-designation-for-entrectinib-by-u-dot-s-food-and-drug-administration 2017-05-16T02:50:29 https://maestrodatabase.com/blog/thousands-of-people-a-year-could-benefit-from-new-twice-a-day-tablet-for-advanced-breast-cancer 2025-04-14T00:35:56 https://maestrodatabase.com/blog/emgality-galcanezumab-now-approved-for-use-in-canada-for-the-treatment-of-episodic-cluster-headache 2021-02-26T06:32:35 https://maestrodatabase.com/blog/fda-authorises-marketing-of-novel-device-to-help-protect-athletes-brains-during-head-impacts 2021-02-26T20:33:58 https://maestrodatabase.com/blog/travere-therapeutics-announces-fda-acceptance-and-priority-review-of-new-drug-application-for-sparsentan-for-the-treatment-of-iga-nephropathy 2022-05-16T11:17:49 https://maestrodatabase.com/blog/medical-technology-industry-welcomes-balanced-prostheses-list-report 2017-05-16T08:24:42 https://maestrodatabase.com/blog/scpharmaceuticals-announces-fda-acceptance-of-furoscix-new-drug-application 2022-05-16T11:09:11 https://maestrodatabase.com/blog/senate-inquiry-releases-prostheses-list-pricing-report 2017-05-16T08:31:47 https://maestrodatabase.com/blog/therapeutic-development-a-key-focus-of-the-roadmap 2017-05-16T08:27:37 https://maestrodatabase.com/blog/thousands-of-breast-cancer-patients-to-have-routine-access-to-nice-approved-drug-combination 2021-02-26T20:28:54 https://maestrodatabase.com/blog/why-some-cant-wait-for-a-repeal-of-obamacare 2017-05-16T09:14:09 https://maestrodatabase.com/blog/spravato-approved-for-reimbursement-in-ireland-for-adults-with-treatment-resistant-major-depressive-disorder 2022-05-16T20:32:35 https://maestrodatabase.com/blog/insulin-producers-face-fresh-lawsuit-in-us-over-pricing 2022-05-16T20:36:27 https://maestrodatabase.com/blog/lillys-taltz-ixekizumab-receives-u-dot-s-fda-approval-for-the-treatment-of-active-psoriatic-arthritis 2017-12-02T01:52:03 https://maestrodatabase.com/blog/fda-approves-first-biosimilar-for-the-treatment-of-certain-breast-and-stomach-cancers 2017-12-02T02:02:55 https://maestrodatabase.com/blog/roche-receives-positive-chmp-opinion-for-evrysdi-the-first-and-only-at-home-spinal-muscular-atrophy-treatment-with-proven-efficacy-in-adults-children-and-infants-two-months-and-older 2021-02-26T20:46:17 https://maestrodatabase.com/blog/amazon-is-in-exploratory-talks-with-generic-drug-makers 2017-12-02T01:58:24 https://maestrodatabase.com/blog/pfizer-and-biontech-provide-update-on-covid-19-vaccine-supply-agreement-with-european-commission 2022-05-16T11:26:19 https://maestrodatabase.com/blog/aerie-pharmaceuticals-announces-fda-acceptance-of-nda-submission-for-rhopressa-netarsudil-ophthalmic-solution-0-dot-02-percent 2017-05-16T13:44:59 https://maestrodatabase.com/blog/fda-rejects-anti-depressant-seen-as-possible-covid-19-treatment 2022-05-16T20:49:27 https://maestrodatabase.com/blog/fda-grants-seastar-medicals-selective-cytopheretic-device-breakthrough-device-designation-for-hepatorenal-syndrome 2023-10-19T01:05:52 https://maestrodatabase.com/blog/pembrolizumab-in-non-small-cell-lung-cancer-a-hint-of-considerable-added-benefit 2017-05-16T20:56:12 https://maestrodatabase.com/blog/tofacitinib-citrate-for-the-treatment-of-patients-with-active-ankylosing-spondylitis 2023-10-19T00:48:01 https://maestrodatabase.com/blog/hospital-waiting-list-queue-jumpers-outrage 2017-05-16T20:51:10 https://maestrodatabase.com/blog/new-guidance-for-patient-group-partners-taking-part-in-smc-committee-meetings 2017-05-16T21:02:04 https://maestrodatabase.com/blog/girl-loses-high-court-battle-over-nice-review-of-biomarins-phenylketonuria-drug 2020-03-06T22:03:18 https://maestrodatabase.com/blog/tepmetko-is-granted-a-temporary-subsidy 2022-05-16T20:42:12 https://maestrodatabase.com/blog/public-summary-documents---november-2019-pbac-meeting 2020-03-25T04:53:11 https://maestrodatabase.com/blog/dr-gottliebs-first-remarks-to-fda-staff 2017-05-16T21:14:07 https://maestrodatabase.com/blog/more-than-400-people-could-benefit-from-life-extending-advanced-lung-cancer-treatment-after-it-was-recommended-for-routine-use-on-the-nhs 2022-05-16T20:45:50 https://maestrodatabase.com/blog/reducing-preventable-harm-from-medications-too-big-for-fda-to-do-alone 2017-05-16T21:06:29 https://maestrodatabase.com/blog/canada-must-and-can-take-control-of-drug-prices 2017-05-16T21:25:38 https://maestrodatabase.com/blog/accelerated-access-to-new-drugs-and-technologies 2017-12-02T02:20:21 https://maestrodatabase.com/blog/gastric-cancer-drug-liporaxel-nears-getting-insurance-benefit 2020-03-06T22:11:25 https://maestrodatabase.com/blog/ema-publishes-agenda-for-16-19-may-2022-chmp-meeting 2022-05-16T21:14:35 https://maestrodatabase.com/blog/health-minister-launches-high-drug-price-consultations 2017-05-16T21:22:06 https://maestrodatabase.com/blog/public-summary-documents---august-2017-pbac-meeting 2017-12-02T02:25:49 https://maestrodatabase.com/blog/nice-chair-nominee-nebhrajani-to-face-mp-scrutiny-next-week 2020-03-06T22:06:52 https://maestrodatabase.com/blog/european-commission-approves-roches-columvi-as-the-first-bispecific-antibody-for-diffuse-large-b-cell-lymphoma-after-initial-therapy 2025-04-14T22:06:17 https://maestrodatabase.com/blog/biosimilar-uptake-drivers 2019-02-05T01:05:16 https://maestrodatabase.com/blog/korea-clears-permit-for-samsung-bioepis-lucentis-biosimilar-after-us 2022-05-16T21:21:28 https://maestrodatabase.com/blog/fda-approves-amgens-repatha-evolocumab-to-prevent-heart-attack-and-stroke 2017-12-02T02:40:47 https://maestrodatabase.com/blog/japan-pharma-lobbies-say-pricing-scheme-leading-to-renewed-drug-lag 2022-05-16T21:00:13 https://maestrodatabase.com/blog/aarp-peoples-hearing-will-highlight-rx-struggles 2022-05-16T20:57:26 https://maestrodatabase.com/blog/sun-pharma-announces-us-fda-approval-for-generic-mesalamine-extended-release-capsules 2022-05-16T21:08:02 https://maestrodatabase.com/blog/sangamo-receives-fast-track-designation-from-the-fda-for-sb-525-investigational-haemophilia-a-gene-therapy 2017-05-17T09:46:04 https://maestrodatabase.com/blog/pfizer-settles-two-lawsuits-starts-another-over-etanercept-biosimilar-in-australia 2022-05-16T21:24:35 https://maestrodatabase.com/blog/msd-australia-endorses-new-medicines-strategic-agreement 2021-09-09T03:22:17 https://maestrodatabase.com/blog/orexo-shares-new-information-on-ox124-a-high-dose-naloxone-rescue-medication-in-development-for-opioid-overdose 2024-07-19T02:53:43 https://maestrodatabase.com/blog/viberzi-now-approved-in-canada-for-patients-with-irritable-bowel-syndrome-with-diarrhoea 2017-05-17T10:07:45 https://maestrodatabase.com/blog/albireo-sells-priority-review-voucher-for-105-dollars-million 2021-09-09T03:41:27 https://maestrodatabase.com/blog/consumers-to-have-more-say-on-medicine-access-issues 2021-09-09T03:38:13 https://maestrodatabase.com/blog/european-commission-approves-adcetris-brentuximab-vedotin-for-the-treatment-of-adult-patients-with-previously-untreated-cd30-positive-stage-iii-hodgkin-lymphoma-in-combination-with-avd 2023-10-19T01:52:12 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-9-september-2021 2021-09-09T04:06:08 https://maestrodatabase.com/blog/atara-biotherapeutics-announces-us-fda-acceptance-and-priority-review-of-the-biologics-license-application-for-tabelecleucel-for-the-treatment-of-epstein-barr-virus-positive-post-transplant-lymphoproliferative-disease 2024-07-19T03:24:46 https://maestrodatabase.com/blog/phrma-statement-on-efforts-to-support-real-world-evidence 2018-07-13T06:05:37 https://maestrodatabase.com/blog/synox-therapeutics-receives-fast-track-designation-from-us-fda-for-emactuzumab-for-tenosynovial-giant-cell-tumours 2025-04-14T23:08:21 https://maestrodatabase.com/blog/pharmac-proposes-to-widen-access-to-urinary-tract-infections-treatment-and-fund-a-new-epilepsy-treatment 2024-07-19T03:54:54 https://maestrodatabase.com/blog/bavarian-nordic-receives-ema-filing-acceptance-and-validation-of-the-maa-for-its-chikungunya-vaccine 2024-07-19T03:44:24 https://maestrodatabase.com/blog/diamyd-medical-receives-second-us-fda-fast-track-designation-for-diamyd---for-the-prevention-of-type-1-diabetes 2024-07-19T03:34:10 https://maestrodatabase.com/blog/outcome-statement---june-2024-dusc-meeting 2024-07-19T04:16:12 https://maestrodatabase.com/blog/albireo-receives-uk-mhra-approval-of-bylvay-odevixibat 2021-09-09T06:04:50 https://maestrodatabase.com/blog/people-are-getting-angry-health-funds-accused-of-obscene-profits 2017-05-17T20:57:49 https://maestrodatabase.com/blog/poor-funding-for-research-treatment-means-lower-survival-rates-for-rare-cancers 2017-05-17T20:53:31 https://maestrodatabase.com/blog/fda-expands-approved-use-of-kalydeco-to-treat-additional-mutations-of-cystic-fibrosis 2017-05-17T21:07:29 https://maestrodatabase.com/blog/coalition-calls-on-cadth-to-balance-scales-and-fix-system 2017-05-17T21:24:59 https://maestrodatabase.com/blog/bipartisan-health-care-talks-pick-up-steam-in-senate 2017-05-17T21:11:36 https://maestrodatabase.com/blog/discount-rate-adjustment-for-the-health-of-future-generations 2022-05-17T05:43:54 https://maestrodatabase.com/blog/centers-for-medicare-and-medicaid-services-offers-new-health-coverage-enrolment-option-for-small-business 2017-05-17T21:40:12 https://maestrodatabase.com/blog/brexits-potential-health-benefits 2017-05-17T21:30:53 https://maestrodatabase.com/blog/how-patients-are-changing-clinical-trials 2017-05-17T21:49:11 https://maestrodatabase.com/blog/european-commission-approves-keytruda-pembrolizumab-as-adjuvant-treatment-for-adults-with-non-small-cell-lung-cancer-at-high-risk-of-recurrence-following-complete-resection-and-platinum-based-chemotherapy 2023-10-19T04:45:20 https://maestrodatabase.com/blog/orasis-pharmaceuticals-announces-fda-approval-of-qlosi-pilocarpine-hydrochloride-ophthalmic-solution-0-dot-4-percent-for-the-treatment-of-presbyopia 2023-10-19T04:38:51 https://maestrodatabase.com/blog/novavax-receives-full-marketing-authorisation-for-prototype-covid-19-vaccine-nuvaxovid-in-united-kingdom 2023-10-19T03:07:14 https://maestrodatabase.com/blog/fda-approves-new-treatment-for-adults-with-cushings-disease 2020-03-07T03:20:45 https://maestrodatabase.com/blog/health-canada-approves-nduvra-tapinarof-1-percent-cream-for-the-topical-treatment-of-plaque-psoriasis-in-adults 2025-04-15T02:19:48 https://maestrodatabase.com/blog/health-canada-approves-opdivo-nivolumab-for-the-treatment-of-squamous-cell-carcinoma-of-the-head-and-neck 2017-05-18T01:24:21 https://maestrodatabase.com/blog/fda-approves-drug-for-adult-and-paediatric-patients-aged-6-and-older-with-allergic-fungal-rhinosinusitis 2026-02-26T02:42:16 https://maestrodatabase.com/blog/mercks-keytruda-pembrolizumab-approved-in-china-in-combination-with-chemotherapy-for-first-line-treatment-of-patients-with-locally-advanced-unresectable-or-metastatic-oesophageal-or-gastro-oesophageal-junction-carcinoma 2021-09-09T11:16:54 https://maestrodatabase.com/blog/controversy-over-using-quality-adjusted-life-years-in-cost-effectiveness-analyses-a-systematic-literature-review 2021-09-09T06:59:09 https://maestrodatabase.com/blog/health-funds-reject-claims-hospitals-hit-by-prostheses-reforms 2021-09-09T11:37:57 https://maestrodatabase.com/blog/glycomimetics-gmi-1271-receives-fda-breakthrough-therapy-designation-for-adult-relapsed-slash-refractory-acute-myeloid-leukaemia 2017-05-18T01:41:37 https://maestrodatabase.com/blog/daridorexant-hydrochloride-for-the-treatment-of-patients-with-long-term-insomnia 2023-10-19T04:54:54 https://maestrodatabase.com/blog/myovant-sciences-and-pfizer-announce-fda-acceptance-of-supplemental-new-drug-application-for-myfembree-for-the-management-of-moderate-to-severe-pain-associated-with-endometriosis 2021-09-09T20:58:30 https://maestrodatabase.com/blog/european-medicines-agency-accepts-marketing-authorisation-applications-for-mylan-and-biocons-proposed-biosimilars-trastuzumab-and-pegfilgrastim 2017-12-02T22:33:55 https://maestrodatabase.com/blog/bayer-receives-fda-priority-review-for-investigational-anti-cancer-compound-copanlisib 2017-05-18T02:04:41 https://maestrodatabase.com/blog/nice-recommends-treatment-for-people-with-juvenile-idiopathic-arthritis 2021-09-09T20:42:42 https://maestrodatabase.com/blog/fda-grants-jardiance-breakthrough-therapy-designation-for-heart-failure-with-preserved-ejection-fraction 2021-09-09T20:48:25 https://maestrodatabase.com/blog/tabelecleucel-for-the-treatment-of-patients-with-a-post-transplant-lymphoproliferative-disorder-caused-by-the-epstein-barr-virus 2023-10-19T05:51:28 https://maestrodatabase.com/blog/novo-nordisk-announces-fda-approval-of-label-update-for-rybelsus-semaglutide-allowing-use-as-a-first-line-option-for-adults-with-type-2-diabetes 2023-01-15T01:14:09 https://maestrodatabase.com/blog/senate-considers-pegging-medicare-drug-prices-to-deeply-discounted-veterans-affairs-rates 2021-09-09T21:16:36 https://maestrodatabase.com/blog/dusc-utilisation-analysis-public-release-documents-june-2024 2024-07-19T05:54:39 https://maestrodatabase.com/blog/professor-gillian-leng-to-retire-from-nice 2021-09-09T21:08:35 https://maestrodatabase.com/blog/eloxx-pharmaceuticals-announces-fast-track-designation-for-elx-02-for-the-treatment-of-cystic-fibrosis-patients-with-nonsense-mutations 2021-09-09T21:04:15 https://maestrodatabase.com/blog/biden-administration-unveils-plan-to-cut-prescription-drug-prices 2021-09-09T21:13:32 https://maestrodatabase.com/blog/insurance-benefits-for-pfizers-heart-drug-vyndamax-uncertain 2021-09-09T21:10:42 https://maestrodatabase.com/blog/arog-pharmaceuticals-receives-fda-fast-track-designation-for-crenolanib-in-relapsed-or-refractory-flt3-positive-aml 2017-12-02T23:08:18 https://maestrodatabase.com/blog/health-economic-assessment-of-spinraza-for-type-5q-spinal-muscular-atrophy 2023-10-19T11:21:47 https://maestrodatabase.com/blog/valneva-receives-notice-of-european-commissions-intent-to-terminate-covid-19-vaccine-purchase-agreement 2022-05-17T08:04:42 https://maestrodatabase.com/blog/brainstorm-cell-therapeutics-to-meet-with-us-fda-to-discuss-development-plan-for-nurown-as-a-treatment-of-als 2023-10-19T08:17:48 https://maestrodatabase.com/blog/goodrx-to-offer-sanofis-insulin-injection-for-only-35-dollars 2023-10-20T19:36:23 https://maestrodatabase.com/blog/vanda-pharmaceuticals-announces-fda-acceptance-of-biologics-license-application-filing-for-imsidolimab-for-the-treatment-of-generalised-pustular-psoriasis 2026-02-26T04:14:56 https://maestrodatabase.com/blog/public-summary-documents-first-time-decisions-not-to-recommend-and-deferrals---march-2024-pbac-meeting 2024-07-19T06:25:04 https://maestrodatabase.com/blog/access-to-new-medicines-in-new-zealand---2017-in-review 2017-12-03T01:12:31 https://maestrodatabase.com/blog/coronavirus-government-considers-stockpiling-drugs-as-infections-climb 2020-03-07T22:42:56 https://maestrodatabase.com/blog/mhra-marketing-authorisation-granted-for-eli-lillys-verzenios-as-early-breast-cancer-treatment 2022-05-17T12:41:34 https://maestrodatabase.com/blog/vor33-granted-u-dot-s-fda-fast-track-designation-for-aml 2021-09-10T00:42:54 https://maestrodatabase.com/blog/sumitomo-pharma-and-pfizer-in-canada-receive-health-canada-approval-for-myfembree 2023-10-20T20:11:47 https://maestrodatabase.com/blog/armagens-agt-181-granted-fast-track-designation-for-the-treatment-of-hurler-syndrome 2017-12-03T01:35:34 https://maestrodatabase.com/blog/european-commission-approves-empliciti-elotuzumab-plus-pomalidomide-and-low-dose-dexamethasone-for-the-treatment-of-patients-with-relapsed-and-refractory-multiple-myeloma 2019-08-27T20:45:10 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-to-anpd001-autologous-investigational-cell-therapy-for-the-treatment-of-parkinsons-disease 2023-10-20T20:06:19 https://maestrodatabase.com/blog/an-fda-report-reveals-the-agency-believed-novartis-data-problems-were-resolved-months-ago 2019-08-27T13:52:21 https://maestrodatabase.com/blog/fda-grants-fast-track-designation-for-farxiga-in-chronic-kidney-disease 2019-08-27T13:47:16 https://maestrodatabase.com/blog/viela-bio-announces-u-dot-s-fda-accepts-for-review-inebilizumab-biologics-license-application-for-neuromyelitis-optica-spectrum-disorder 2019-08-27T21:01:17 https://maestrodatabase.com/blog/is-it-time-to-nationalise-the-pharmaceutical-industry 2020-03-07T23:38:13 https://maestrodatabase.com/blog/finerenone-for-treating-chronic-kidney-disease-in-people-with-type-2-diabetes 2022-05-17T20:47:38 https://maestrodatabase.com/blog/let-pharmacists-take-the-load-off-gps 2019-08-27T20:55:51 https://maestrodatabase.com/blog/ottawa-unveils-new-draft-regulations-for-drug-pricing 2017-12-03T02:05:08 https://maestrodatabase.com/blog/governor-hochul-announces-new-watchdog-bureau-to-tackle-prescription-drug-costs 2022-05-17T20:52:10 https://maestrodatabase.com/blog/fda-grants-breakthrough-device-designation-to-the-novottf-200t-system-for-advanced-liver-cancer 2021-09-10T02:04:40 https://maestrodatabase.com/blog/clinical-equivalence-and-non-inferiority-within-health-technology-assessment 2026-02-26T06:45:37 https://maestrodatabase.com/blog/fda-approves-new-add-on-drug-to-treat-off-episodes-in-adults-with-parkinsons-disease 2019-08-27T21:16:56 https://maestrodatabase.com/blog/the-drugs-that-give-her-life-cost-more-than-half-the-familys-income 2022-05-17T20:36:29 https://maestrodatabase.com/blog/delivering-promising-new-medicines-without-sacrificing-safety-and-efficacy 2019-08-27T21:12:08 https://maestrodatabase.com/blog/fda-authorises-first-covid-19-test-available-without-a-prescription-that-also-detects-influenza-and-rsv 2022-05-17T12:49:00 https://maestrodatabase.com/blog/akorn-receives-fda-approval-for-azelastine-hydrochloride-0-dot-15-percent-nasal-spray 2019-08-27T21:05:34 https://maestrodatabase.com/blog/fda-approves-first-treatment-for-molybdenum-cofactor-deficiency-type-a 2021-02-27T23:52:44 https://maestrodatabase.com/blog/international-regulators-and-who-support-health-care-professionals-to-enhance-public-confidence-in-covid-19-vaccines 2022-05-17T20:41:28 https://maestrodatabase.com/blog/federal-health-minister-vows-to-bring-down-unacceptably-high-drug-costs 2017-05-18T06:12:10 https://maestrodatabase.com/blog/familys-joy-at-access-to-drug-for-son 2019-08-27T21:26:32 https://maestrodatabase.com/blog/fda-expands-eligibility-for-pfizer-biontech-covid-19-vaccine-booster-dose-to-children-5-through-11-years 2022-05-17T21:17:24 https://maestrodatabase.com/blog/dental-ai-start-up-wins-second-fda-clearance-to-detect-top-oral-diseases 2022-05-17T21:11:47 https://maestrodatabase.com/blog/low-income-patients-report-better-care-and-health-after-aca-passage-study-finds 2017-05-18T21:07:18 https://maestrodatabase.com/blog/reining-in-the-spending-on-drugs-what-massachusetts-can-learn-from-other-states 2019-08-27T21:23:47 https://maestrodatabase.com/blog/double-whammy-leaves-private-and-public-patients-short 2017-05-18T20:57:20 https://maestrodatabase.com/blog/free-care-at-public-hospitals-is-coming-to-an-end-as-state-and-territory-governments-charge 2017-05-18T21:25:28 https://maestrodatabase.com/blog/congress-should-be-promoting-not-discouraging-the-development-of-biosimilars 2019-08-27T21:35:51 https://maestrodatabase.com/blog/fda-issues-emergency-use-authorisation-for-third-covid-19-vaccine 2021-02-27T23:59:36 https://maestrodatabase.com/blog/clinical-trial-participants-should-have-a-say-in-new-drug-pricing 2017-05-18T21:13:47 https://maestrodatabase.com/blog/we-need-a-more-rational-biosimilars-policy 2019-08-27T21:33:25 https://maestrodatabase.com/blog/ontario-british-columbia-nova-scotia-new-brunswick-and-newfoundland-join-a-growing-list-of-provinces-providing-public-drug-plan-reimbursement-for-teva-canadas-ajovy-fremanezumab-for-the-preventive-treatment-of-migraine-in-adults 2022-05-17T20:57:02 https://maestrodatabase.com/blog/johnson-and-johnson-bms-fight-us-drug-price-plan-at-third-circuit 2024-07-19T07:59:20 https://maestrodatabase.com/blog/more-than-40-000-people-could-benefit-after-nice-recommends-new-take-at-home-pill-for-advanced-prostate-cancer 2024-07-19T07:42:58 https://maestrodatabase.com/blog/fda-approves-mercks-keytruda-pembrolizumab-for-certain-patients-with-locally-advanced-or-metastatic-urothelial-carcinoma-a-type-of-bladder-cancer 2017-05-18T21:42:35 https://maestrodatabase.com/blog/a-new-health-technology-assessment-system-for-devices-the-first-five-years 2017-05-18T21:31:17 https://maestrodatabase.com/blog/health-economic-assessment-of-xevudy-for-the-treatment-of-covid-19 2022-05-17T21:08:45 https://maestrodatabase.com/blog/pharmacists-demand-audit-over-gliatilins-insurance-benefit 2019-08-27T21:29:56 https://maestrodatabase.com/blog/pfizer-to-price-covid-drug-paxlovid-at-1-390-dollars-per-course 2023-10-20T20:29:53 https://maestrodatabase.com/blog/china-eases-rules-on-cheap-drug-imports-to-fight-chronic-diseases 2019-08-27T21:43:37 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-zongertinib-for-unresectable-or-metastatic-non-squamous-non-small-cell-lung-cancer 2026-02-26T20:55:47 https://maestrodatabase.com/blog/incorporating-affordability-concerns-within-cost-effectiveness-analysis-for-health-technology-assessment 2019-08-27T21:39:13 https://maestrodatabase.com/blog/understanding-evergreening-making-minor-modifications-of-existing-medications-to-extend-protections 2022-05-17T21:50:00 https://maestrodatabase.com/blog/mhra-approves-faricimab-through-international-work-sharing-initiative 2022-05-17T21:37:05 https://maestrodatabase.com/blog/ethical-considerations-for-the-inclusion-of-patient-reported-outcomes-in-clinical-research 2022-05-17T21:24:51 https://maestrodatabase.com/blog/united-kingdom-mhra-grants-marketing-authorisation-for-fyb201-formycons-biosimilar-for-lucentis 2022-05-17T21:42:11 https://maestrodatabase.com/blog/discgenics-receives-fda-fast-track-designation-for-disc-degeneration-cell-therapy 2019-08-27T21:49:35 https://maestrodatabase.com/blog/sage-therapeutics-receives-fast-track-designation-for-sage-217-for-the-treatment-of-major-depressive-disorder 2017-05-19T02:34:10 https://maestrodatabase.com/blog/pharmacs-year-in-review-leaves-much-to-be-desired 2023-01-15T20:02:09 https://maestrodatabase.com/blog/lexicon-pharmaceuticals-receives-20-december-2024-pdufa-goal-date-for-sotagliflozin-type-1-diabetes-nda-resubmission 2024-07-19T08:55:15 https://maestrodatabase.com/blog/spark-therapeutics-completes-rolling-biologics-license-application-submission-to-fda-for-investigational-gene-therapy-voretigene-neparvovec 2017-05-19T02:42:59 https://maestrodatabase.com/blog/regeneron-and-sanofi-provide-update-on-dupixent-dupilumab-sbla-for-chronic-spontaneous-urticaria 2023-10-20T21:19:46 https://maestrodatabase.com/blog/post-market-review-of-ezetimibe---notice-of-public-consultation 2017-05-19T03:04:21 https://maestrodatabase.com/blog/phathom-pharmaceuticals-announces-fda-approval-of-voquenza-vonoprazan-tablets-for-the-relief-of-heartburn-associated-with-non-erosive-gerd-in-adults 2024-07-19T09:17:46 https://maestrodatabase.com/blog/us-to-announce-list-of-drugs-for-pricing-negotiations-1-september 2023-01-15T20:13:03 https://maestrodatabase.com/blog/price-controls-imposed-by-shortsighted-politicians-keep-new-life-saving-drugs-out 2020-03-08T01:48:00 https://maestrodatabase.com/blog/acacia-pharmaceuticals-and-neuren-pharmaceuticals-announce-rare-paediatric-disease-designation-for-trofinetide-for-the-treatment-of-rett-syndrome 2020-03-08T01:30:54 https://maestrodatabase.com/blog/gsk-receives-chmp-positive-opinion-recommending-approval-of-dostarlimab-for-women-with-recurrent-or-advanced-endometrial-cancer 2021-02-28T00:20:11 https://maestrodatabase.com/blog/decibel-therapeutics-receives-orphan-drug-and-rare-paediatric-disease-designations-for-db-oto-for-the-treatment-of-otoferlin-related-congenital-hearing-loss 2021-09-10T02:55:33 https://maestrodatabase.com/blog/precision-biosciences-receives-us-fda-fast-track-designation-for-pbgene-hbv-a-first-in-class-gene-editing-therapy-designed-to-eliminate-the-root-cause-of-chronic-hepatitis-b 2025-04-15T23:10:08 https://maestrodatabase.com/blog/ethical-and-legal-considerations-in-social-media-research-for-health-technology-assessment-conclusions-from-a-scoping-review 2023-10-20T23:22:53 https://maestrodatabase.com/blog/fda-expands-paediatric-indication-for-entrectinib-and-approves-new-pellet-formulation 2023-10-20T23:29:19 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-treatment-for-secondary-progressive-multiple-sclerosis 2025-04-15T23:27:48 https://maestrodatabase.com/blog/regulatory-and-clinical-consequences-of-negative-confirmatory-trials-of-accelerated-approval-cancer-drugs-retrospective-observational-study 2021-09-10T03:08:57 https://maestrodatabase.com/blog/us-fda-grants-interchangeable-designation-to-yuflyma-adalimumab-aaty-celltrions-biosimilar-to-humira-adalimumab 2025-04-16T00:50:01 https://maestrodatabase.com/blog/fda-approves-penbraya-the-first-and-only-vaccine-for-the-prevention-of-the-five-most-common-serogroups-causing-meningococcal-disease-in-adolescents 2023-10-21T01:40:29 https://maestrodatabase.com/blog/bristol-myers-squibb-receives-ema-validation-of-application-for-opdivo-nivolumab-plus-yervoy-ipilimumab-for-first-line-treatment-of-unresectable-or-advanced-hepatocellular-carcinoma 2024-07-19T11:18:35 https://maestrodatabase.com/blog/pbac-public-summary-documents-first-time-decisions-not-to-recommend-deferrals-and-other-matters---may-2021-meeting 2021-09-10T06:23:31 https://maestrodatabase.com/blog/leqembi-lecanemab-is-the-first-medicine-that-slows-progression-of-early-alzheimers-disease-to-be-authorised-in-the-european-union 2025-04-16T01:53:22 https://maestrodatabase.com/blog/co-dot-don-decisive-step-towards-european-expansion 2017-05-20T00:40:56 https://maestrodatabase.com/blog/uk-approval-for-pfizers-jak-inhibitor-cibinqo 2021-09-10T21:02:52 https://maestrodatabase.com/blog/eli-lilly-issues-warning-for-australia-as-trump-signals-pharma-tariffs 2025-04-16T02:09:35 https://maestrodatabase.com/blog/scilex-announces-approval-of-a-new-drug-submission-from-the-health-canada-for-elyxybs-acute-treatment-of-migraine-with-or-without-aura-in-canada 2025-04-16T02:01:25 https://maestrodatabase.com/blog/brodalumab-a-novel-biologic-for-people-with-moderate-to-severe-psoriasis-receives-positive-opinion-from-european-chmp 2017-05-20T00:51:04 https://maestrodatabase.com/blog/chmp-recommends-veltassa-for-the-treatment-of-hyperkalaemia-in-the-eu 2017-05-20T01:03:26 https://maestrodatabase.com/blog/states-get-involved-in-lawsuit-to-shield-obamacare-saying-trump-cant-be-trusted 2017-05-20T01:13:05 https://maestrodatabase.com/blog/five-years-on-biosimilars-need-support-from-all-health-care-players 2020-03-08T20:26:53 https://maestrodatabase.com/blog/brukinsa-receives-positive-recommendation-from-nice-in-the-uk-for-adult-patients-with-chronic-lymphocytic-leukaemia 2023-10-21T02:44:06 https://maestrodatabase.com/blog/how-did-vertex-win-an-fda-approval-without-running-a-clinical-trial 2017-05-20T01:15:11 https://maestrodatabase.com/blog/britain-without-the-ema 2017-05-20T01:31:43 https://maestrodatabase.com/blog/no-pharmac-help-for-crohns-sufferer 2017-05-20T01:25:30 https://maestrodatabase.com/blog/olezarsen-snda-accepted-by-the-fda-for-priority-review-for-the-treatment-of-severe-hypertriglyceridaemia 2026-02-26T23:29:25 https://maestrodatabase.com/blog/ema-accepts-marketing-application-for-somatrogon-to-treat-paediatric-patients-with-growth-hormone-deficiency 2021-02-28T20:27:33 https://maestrodatabase.com/blog/exactech-announces-fda-breakthrough-device-designation-for-jointmedicas-polymotion-hip-resurfacing-system 2022-05-18T03:50:45 https://maestrodatabase.com/blog/icer-publishes-evidence-report-on-treatments-for-myasthenia-gravis 2021-09-10T21:59:20 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-march-2021 2021-02-28T20:31:44 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-march-2021 2021-02-28T20:08:46 https://maestrodatabase.com/blog/eczema-medicine-dupixent-added-to-pharmaceutical-benefits-scheme 2021-02-28T20:20:25 https://maestrodatabase.com/blog/venostent-technology-receives-breakthrough-device-designation-by-fda 2022-05-18T03:27:24 https://maestrodatabase.com/blog/the-first-doses-of-the-oxford-astrazeneca-covid-vaccine-have-arrived-what-happens-next 2021-02-28T20:24:28 https://maestrodatabase.com/blog/mhra-approves-amgens-lumykras-under-project-orbis 2021-09-10T22:51:41 https://maestrodatabase.com/blog/fda-approves-luye-pharmas-rykindo-for-the-treatment-of-schizophrenia-and-bipolar-1-disorder 2023-01-16T01:23:22 https://maestrodatabase.com/blog/neurogene-announces-fda-breakthrough-therapy-designation-for-ngn-401-gene-therapy-for-rett-syndrome 2026-02-27T00:24:34 https://maestrodatabase.com/blog/fate-therapeutics-receives-regenerative-medicine-advanced-therapy-designation-from-fda-for-ft819-to-treat-moderate-to-severe-systemic-lupus-erythematosus 2025-04-16T03:18:39 https://maestrodatabase.com/blog/estimated-savings-from-international-reference-pricing-for-prescription-drugs 2021-09-11T00:13:06 https://maestrodatabase.com/blog/ema-accepts-decipheras-marketing-authorisation-application-for-vimseltinib-for-treatment-of-patients-with-tenosynovial-giant-cell-tumour 2024-07-20T01:22:25 https://maestrodatabase.com/blog/blenrep-belantamab-mafodotin-combinations-in-multiple-myeloma-application-accepted-for-review-by-the-ema 2024-07-20T01:18:59 https://maestrodatabase.com/blog/novartis-receives-positive-chmp-opinion-for-first-line-use-of-zykadia-in-alk-positive-advanced-non-small-cell-lung-cancer 2017-05-20T09:11:32 https://maestrodatabase.com/blog/angiotensin-ii-acetate-for-the-treatment-of-patients-with-vasosuppressor-resistant-hypotension-caused-by-septic-or-distributive-shock 2023-01-16T08:07:25 https://maestrodatabase.com/blog/rezolute-receives-priority-medicines-prime-eligibility-from-ema-for-enhanced-regulatory-support-of-rz358-in-congenital-hyperinsulinism 2023-10-21T05:34:51 https://maestrodatabase.com/blog/the-game-changing-plan-to-cut-barriers-to-medical-abortion 2023-01-16T19:22:17 https://maestrodatabase.com/blog/smc---january-2023-decisions 2023-01-16T19:16:57 https://maestrodatabase.com/blog/merck-receives-chmp-positive-opinion-recommending-approval-of-isentress-raltegravir-600-mg-in-the-european-union 2017-05-20T10:28:35 https://maestrodatabase.com/blog/representativeness-of-participants-eligible-to-be-enrolled-in-clinical-trials-of-aducanumab-for-alzheimer-disease-compared-with-medicare-beneficiaries-with-alzheimer-disease-and-mild-cognitive-impairment 2021-09-11T01:55:25 https://maestrodatabase.com/blog/medicare-begins-to-rein-in-drug-costs-for-older-americans 2023-01-16T08:14:58 https://maestrodatabase.com/blog/a-new-us-law-aims-to-reduce-drug-prices-but-first-it-might-raise-them 2023-01-16T19:43:56 https://maestrodatabase.com/blog/china-nmpa-approved-penpulimab-for-first-line-treatment-of-locally-advanced-or-metastatic-quamous-nsclc 2023-01-16T19:36:01 https://maestrodatabase.com/blog/abbvie-and-eli-lilly-two-of-the-worlds-largest-pharmaceutical-companies-have-sent-a-warning-signal-to-the-uk-government-by-leaving-the-voluntary-medicines-pricing-agreement-in-protest-over-increasingly-punitive-revenue-clawbacks 2023-01-16T19:28:10 https://maestrodatabase.com/blog/european-medicines-agency-validates-application-for-bristol-myers-squibbs-sprycel-dasatinib-in-children-with-chronic-myelogenous-leukaemia 2017-05-20T14:12:42 https://maestrodatabase.com/blog/janssen-files-suit-in-u-dot-s-to-block-sale-of-samsung-bioepis-remicade-copy 2017-05-20T14:18:29 https://maestrodatabase.com/blog/cancer-patient-stares-down-the-cost-of-buying-time 2022-05-18T09:30:21 https://maestrodatabase.com/blog/rising-insulin-prices-have-diabetics-crying-foul 2017-05-20T23:04:25 https://maestrodatabase.com/blog/fda-ema-officials-discuss-impediments-to-cell-and-gene-therapies 2022-05-18T08:58:09 https://maestrodatabase.com/blog/sanofi-receives-chmp-recommendation-for-approval-of-insulin-lispro-biosimilar 2017-05-20T23:11:42 https://maestrodatabase.com/blog/mercks-tepmetko-wins-reimbursement-in-korea-after-3-dot-5-years-expanding-access-for-lung-cancer-patients-with-rare-met-mutation 2025-04-16T22:29:55 https://maestrodatabase.com/blog/ides-selected-for-ema-priority-medicines-prime-scheme 2017-05-20T23:38:00 https://maestrodatabase.com/blog/patient-voice-aotearoa-calls-for-pharmac-reform 2019-08-28T06:15:23 https://maestrodatabase.com/blog/alnylam-announces-health-canada-authorisation-of-oxlumo-lumasiran-the-first-and-only-treatment-for-primary-hyperoxaluria-type-1-to-lower-urinary-oxalate-levels-in-paediatric-and-adult-patients 2022-05-18T21:08:17 https://maestrodatabase.com/blog/highlights-from-the-chmp-15-18-may-2017-meeting 2017-05-20T23:44:35 https://maestrodatabase.com/blog/fda-grants-fast-track-status-to-prescients-ptx-100-advancing-commercialisation-pathway 2025-04-16T23:11:09 https://maestrodatabase.com/blog/cms-unveils-more-user-friendly-medicare-website 2022-05-18T21:16:01 https://maestrodatabase.com/blog/tlv-reconsiders-subsidy-of-cgrp-inhibitors 2022-05-18T20:40:18 https://maestrodatabase.com/blog/toward-incorporating-health-related-quality-of-life-as-co-primary-endpoints-in-clinical-trials-time-to-achieve-clinical-important-differences-and-quality-of-life-profiles 2022-05-18T20:58:43 https://maestrodatabase.com/blog/budget-2022-two-year-old-girl-and-mum-travel-to-wellington-in-hopes-of-getting-funding-for-devastating-spinal-illness 2022-05-18T20:48:06 https://maestrodatabase.com/blog/meningococcal-w-death-prompts-vaccination-update-plea 2017-12-04T08:59:20 https://maestrodatabase.com/blog/dutch-minister-warns-big-pharma-to-come-clean-on-drugs-prices 2019-08-28T09:43:49 https://maestrodatabase.com/blog/mhra-statement-on-booster-doses-of-pfizer-and-astrazeneca-covid-19-vaccines 2021-09-11T07:55:15 https://maestrodatabase.com/blog/therapeuticsmd-announces-resubmission-of-new-drug-application-for-tx-004hr 2017-12-04T08:45:46 https://maestrodatabase.com/blog/agenda-for-the-november-2019-pbac-meeting 2019-08-28T09:33:58 https://maestrodatabase.com/blog/prescription-drug-costs-should-be-fair---not-cheap 2017-12-04T19:48:06 https://maestrodatabase.com/blog/australian-public-assessment-reports-for-prescription-medicines 2019-08-28T09:55:58 https://maestrodatabase.com/blog/alnylam-chief-makes-pricing-pledges-before-drug-is-even-approved 2017-12-04T19:55:16 https://maestrodatabase.com/blog/brand-name-drug-sales-soar-in-canada-while-r-and-d-sags 2017-12-04T19:50:28 https://maestrodatabase.com/blog/finding-health-care-prices-online--how-difficult-is-it-to-be-an-informed-health-care-consumer 2017-12-04T20:08:09 https://maestrodatabase.com/blog/statement-by-fda-commissioner-on-fda-ushering-in-new-era-of-3d-printing-of-medical-products-provides-guidance-to-manufacturers-of-medical-devices 2017-12-04T20:04:59 https://maestrodatabase.com/blog/european-commission-approves-soliris-eculizumab-for-the-treatment-of-adults-with-neuromyelitis-optica-spectrum-disorder 2019-08-28T09:46:17 https://maestrodatabase.com/blog/encouraging-new-uses-for-old-drugs 2017-12-04T20:12:12 https://maestrodatabase.com/blog/free-flu-jabs-for-kids-on-nip-move-is-welcomed-by-state-health-minister-steven-miles 2019-08-28T20:36:33 https://maestrodatabase.com/blog/is-it-time-for-the-fda-to-consider-a-differentiated-approval-system 2017-12-04T20:22:01 https://maestrodatabase.com/blog/fda-warns-testing-companies-dont-tell-patients-how-their-dna-influences-response-to-specific-drugs 2019-08-28T10:54:12 https://maestrodatabase.com/blog/cvs-health-to-acquire-aetna-for-69-dollars-billion-in-years-largest-acquisition 2017-12-04T20:16:51 https://maestrodatabase.com/blog/access-to-new-indications-in-new-zealand---2017-in-review 2017-12-04T20:38:29 https://maestrodatabase.com/blog/who-could-replace-sir-andrew-dillon-at-nice 2019-08-28T21:15:35 https://maestrodatabase.com/blog/batten-disease-treatment-parents-can-take-fight-to-high-court 2019-08-28T21:04:45 https://maestrodatabase.com/blog/brexit-may-mean-british-patients-have-to-wait-longer-for-life-saving-drugs-with-the-nhs-forced-to-shell-out-more-for-them-pharmaceutical-bosses-warn 2017-12-04T20:25:54 https://maestrodatabase.com/blog/dutch-health-minister-threatens-to-name-and-shame-pharma-over-prices 2019-08-28T21:01:14 https://maestrodatabase.com/blog/academics-and-researchers-raise-concerns-with-fdas-plan-for-integrated-reviews 2019-08-28T20:47:35 https://maestrodatabase.com/blog/reformatting-product-information-frequently-asked-questions 2020-03-09T05:57:04 https://maestrodatabase.com/blog/fda-urges-inclusion-of-men-in-breast-cancer-clinical-trials 2019-08-28T21:26:40 https://maestrodatabase.com/blog/placebos-and-blinding-in-randomised-controlled-cancer-clinical-trials-for-drug-and-biological-products-guidance-for-industry 2019-08-28T21:23:19 https://maestrodatabase.com/blog/an-international-perspective-on-the-paradoxes-of-us-health-care 2019-08-28T21:19:48 https://maestrodatabase.com/blog/xspray-pharma-resubmits-its-fda-application-for-dasynoc 2026-02-27T10:03:39 https://maestrodatabase.com/blog/celltrion-applies-for-european-approval-of-humira-biosimilar 2020-03-09T06:06:17 https://maestrodatabase.com/blog/enhertu-supplemental-new-drug-application-submitted-in-japan-as-adjuvant-therapy-for-patients-with-her2-positive-early-breast-cancer 2026-02-27T10:11:03 https://maestrodatabase.com/blog/promoting-paediatric-drug-research-and-labelling----outcomes-of-legislation 2019-08-28T21:56:02 https://maestrodatabase.com/blog/reports-of-epilepsy-drug-harm-increase-30-fold-since-pharmac-switches-brands 2020-03-09T05:59:52 https://maestrodatabase.com/blog/china-nmpa-approves-bio-thera-solutions-bat1806-a-biosimilar-to-actemra-tocilizumab 2023-01-17T02:38:43 https://maestrodatabase.com/blog/celltrion-gets-nod-from-canadian-regulator-for-sales-of-avastin-biosimilar 2023-01-17T03:44:59 https://maestrodatabase.com/blog/nhs-lung-cancer-patients-in-england-get-early-access-to-breakthrough-cancer-drug 2021-09-12T01:35:18 https://maestrodatabase.com/blog/expanding-access-to-life-changing-medicines-for-thousands-of-australians 2021-03-01T03:00:22 https://maestrodatabase.com/blog/neuren-receives-rare-paediatric-disease-designation-from-fda 2024-07-20T23:31:47 https://maestrodatabase.com/blog/neurelis-announces-fda-approval-for-immediate-use-seizure-medication-valtoco-diazepam-nasal-spray-in-age-2-to-5 2025-04-17T01:10:44 https://maestrodatabase.com/blog/proposal-to-fully-fund-mercilon-28-for-oral-contraception 2021-03-01T04:07:19 https://maestrodatabase.com/blog/novartis-receives-positive-chmp-opinion-for-remibrutinib-in-chronic-spontaneous-urticaria 2026-02-27T20:49:38 https://maestrodatabase.com/blog/health-canada-approves-astrazenecas-covid-19-vaccine 2021-03-01T03:55:41 https://maestrodatabase.com/blog/johnson-and-johnson-covid-19-vaccine-authorised-by-u-dot-s-fda-for-emergency-use---first-single-shot-vaccine-in-fight-against-global-pandemic 2021-03-01T04:01:16 https://maestrodatabase.com/blog/should-insurance-cover-wegovy-ozempic-and-other-new-weight-loss-drugs 2023-10-22T05:09:47 https://maestrodatabase.com/blog/bayer-shifts-pharma-focus-away-from-innovation-unfriendly-europe 2023-01-17T09:29:12 https://maestrodatabase.com/blog/us-food-and-drug-administration-approves-biomarins-voxzogo-vosoritide-for-children-under-5-years-with-achondroplasia 2023-10-22T01:11:02 https://maestrodatabase.com/blog/biden-administrations-prescription-drug-pricing-plan-promotes-incremental-change-not-overhaul-of-system 2021-09-12T20:52:32 https://maestrodatabase.com/blog/we-need-a-public-option-for-pharmaceuticals 2023-10-22T05:22:47 https://maestrodatabase.com/blog/pharmac-will-use-biggest-budget-increase-ever-to-fund-more-medicines-for-more-new-zealanders 2022-05-19T02:42:13 https://maestrodatabase.com/blog/dupixent-dupilumab-recommended-for-eu-approval-to-treat-chronic-spontaneous-urticaria-in-young-children-with-ongoing-symptoms-despite-treatment 2026-02-27T21:46:10 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-biologics-license-application-for-mylan-and-biocons-proposed-biosimilar-bevacizumab-for-review 2020-03-09T11:22:18 https://maestrodatabase.com/blog/regulating-medicines-in-a-globalised-world-with-increased-recognition-and-reliance-among-regulators 2020-03-09T11:13:45 https://maestrodatabase.com/blog/athenex-announces-fda-acceptance-for-filing-of-u-dot-s-nda-for-tirbanibulin-ointment-in-actinic-keratosis 2020-03-09T11:27:47 https://maestrodatabase.com/blog/eylea-hd-aflibercept-injection-8-mg-sbla-accepted-for-fda-priority-review-for-both-the-treatment-of-macular-oedema-following-retinal-vein-occlusion-and-for-monthly-dosing-in-approved-indications 2025-04-17T22:26:17 https://maestrodatabase.com/blog/smc---march-2020-decisions 2020-03-09T20:01:54 https://maestrodatabase.com/blog/fda-approves-first-treatment-for-group-of-progressive-interstitial-lung-diseases 2020-03-09T19:54:42 https://maestrodatabase.com/blog/covid-19-and-ispor-conferences 2020-07-22T21:16:20 https://maestrodatabase.com/blog/nice-rejects-nhs-funding-sanofi-slash-regenerons-dupixent-in-asthma 2020-03-09T20:18:21 https://maestrodatabase.com/blog/hhs-finalises-historic-rules-to-provide-patients-more-control-of-their-health-data 2020-03-09T20:08:05 https://maestrodatabase.com/blog/fda-proposes-broad-approach-for-conducting-safety-trials-for-type-2-diabetes-medications 2020-03-09T20:45:32 https://maestrodatabase.com/blog/phrma-federal-biosimilar-payment-policies-are-having-a-positive-effect 2020-03-09T20:37:14 https://maestrodatabase.com/blog/health-canada-expands-jemperli-dostarlimab-for-injection-plus-chemotherapy-approval-to-all-adult-patients-with-primary-advanced-or-first-recurrent-endometrial-cancer-as-the-first-and-only-immuno-oncology-based-treatment-to-show-an-overall-survival-benefit-for-these-patients 2025-04-18T02:09:05 https://maestrodatabase.com/blog/european-commission-grants-abbvie-marketing-authorisation-shortening-maviret-glecaprevir-slash-pibrentasvir-treatment-duration-to-eight-weeks-for-treatment-naive-chronic-hcv-patients-with-genotype-3-and-compensated-cirrhosis 2020-03-09T20:27:23 https://maestrodatabase.com/blog/ema-accepts-pfizers-marketing-authorisation-application-for-its-investigational-20-valent-pneumococcal-conjugate-vaccine-for-adults-18-years-of-age-or-older 2021-03-01T05:35:45 https://maestrodatabase.com/blog/fda-allows-more-flexible-storage-transportation-conditions-for-pfizer-biontech-covid-19-vaccine 2021-03-01T06:24:18 https://maestrodatabase.com/blog/uniqure-announces-fda-breakthrough-therapy-designation-granted-to-amt-130-for-the-treatment-of-huntingtons-disease 2025-04-17T23:54:35 https://maestrodatabase.com/blog/health-economic-assessment-of-kadcyla-in-the-treatment-of-her2-positive-early-breast-cancer 2020-03-09T20:48:42 https://maestrodatabase.com/blog/lillys-olumiant-baricitinib-recommended-by-chmp-for-approval-of-expanded-use-in-the-european-union-for-adolescents-with-severe-alopecia-areata 2026-02-27T23:44:35 https://maestrodatabase.com/blog/multiple-funding-proposals-being-considered-by-pharmac 2022-05-19T05:53:24 https://maestrodatabase.com/blog/draft-nice-guidance-recommends-innovative-technology-used-to-establish-whether-breast-cancer-has-spread 2022-05-19T04:18:25 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-19-may-2022 2022-05-19T05:19:51 https://maestrodatabase.com/blog/opus-genetics-announces-fda-acceptance-of-supplemental-new-drug-application-for-phentolamine-ophthalmic-solution-0-dot-75-percent-for-the-treatment-of-presbyopia 2026-02-28T00:34:03 https://maestrodatabase.com/blog/fda-approves-once-weekly-yuwivel-navepegritide-for-children-with-achondroplasia-aged-2-years-and-older 2026-02-28T01:50:56 https://maestrodatabase.com/blog/regeneron-provides-update-on-eylea-hd-aflibercept-injection-8-mg-supplemental-biologics-license-application 2025-04-18T22:51:18 https://maestrodatabase.com/blog/dupixent-dupilumab-approved-in-the-us-as-the-first-new-targeted-therapy-in-over-a-decade-for-chronic-spontaneous-urticaria 2025-04-18T22:42:41 https://maestrodatabase.com/blog/fda-approves-novo-nordisks-sogroya-as-the-first-and-only-once-weekly-long-acting-growth-hormone-for-three-additional-paediatric-indications 2026-02-28T02:05:23 https://maestrodatabase.com/blog/canadas-drug-agency-announces-new-5-year-strategic-plan 2025-04-18T02:27:25 https://maestrodatabase.com/blog/icer-publishes-second-annual-assessment-of-barriers-to-fair-access-within-us-commercial-insurance-prescription-drug-coverage 2023-01-17T19:16:20 https://maestrodatabase.com/blog/stada-and-xbrane-receive-approval-for-ximluci 2023-01-17T19:21:19 https://maestrodatabase.com/blog/incyte-announces-the-validation-by-the-european-medicines-agency-of-its-marketing-authorisation-application-for-retifanlimab-as-a-treatment-for-patients-with-squamous-cell-anal-carcinoma 2021-03-01T07:10:43 https://maestrodatabase.com/blog/ema-accepts-filing-of-marketing-authorisation-application-for-valnevas-inactivated-covid-19-vaccine-candidate 2022-05-19T10:54:34 https://maestrodatabase.com/blog/innovative-medicines-canada-proposes-framework-for-innovative-agreements-for-drug-reimbursement 2023-01-17T19:40:07 https://maestrodatabase.com/blog/end-of-covid-19-emergency-response 2023-10-22T23:30:34 https://maestrodatabase.com/blog/switzerlands-bitter-sweet-news-for-alzheimers-patients 2026-02-28T02:32:31 https://maestrodatabase.com/blog/orphagen-pharmaceuticals-receives-rare-paediatric-disease-designation-from-fda-for-or-449-for-the-treatment-of-paediatric-adrenocortical-carcinoma 2023-01-17T19:34:26 https://maestrodatabase.com/blog/budget-2022-pharmac-boost-leaves-patients-cold-it-wont-be-enough 2022-05-19T11:20:03 https://maestrodatabase.com/blog/pendopharm-announces-the-commercialisation-of-buccolam-in-canada 2026-02-28T03:23:35 https://maestrodatabase.com/blog/photocure-partner-asieris-announces-that-ema-has-accepted-marketing-authorisation-application-for-cevira-in-europe 2026-02-28T04:04:51 https://maestrodatabase.com/blog/california-sues-largest-us-insulin-manufacturers-and-pbms-for-overpricing 2023-01-17T20:45:26 https://maestrodatabase.com/blog/vutrisiran-in-hereditary-transthyretin-amyloidosis-hint-of-minor-added-benefit 2023-01-17T20:10:11 https://maestrodatabase.com/blog/1-november-2023-changes-to-the-pbs-listings-of-medicines-for-children-and-adolescents-with-chronic-plaque-psoriasis 2023-10-23T00:05:48 https://maestrodatabase.com/blog/siga-receives-approval-from-the-fda-for-intravenous-formulation-of-tpoxx-tecovirimat 2022-05-19T11:41:26 https://maestrodatabase.com/blog/ontario-becomes-the-first-province-to-publicly-reimburse-the-first-targeted-oral-therapy-for-adults-with-grade-2-idh-mutant-glioma 2026-02-28T02:23:43 https://maestrodatabase.com/blog/agenda-for-6-december-tc-meeting 2017-12-05T01:34:54 https://maestrodatabase.com/blog/amgen-submits-biologics-license-application-to-the-fda-for-erenumab 2017-05-21T10:56:05 https://maestrodatabase.com/blog/nusinersen-in-spinal-muscular-atrophy-indication-of-considerable-added-benefit-in-children-with-an-early-onset-of-the-disease 2021-03-01T19:52:35 https://maestrodatabase.com/blog/major-parties-committed-to-major-medicines-policy-reform-and-reviews---whoever-wins-on-saturday 2022-05-19T20:56:27 https://maestrodatabase.com/blog/asieris-announces-ema-accepts-marketing-authorisation-application-for-apl-1702 2026-02-28T04:28:10 https://maestrodatabase.com/blog/product-familiarisation-programs 2017-12-05T01:43:22 https://maestrodatabase.com/blog/zydus-receives-us-fda-approval-for-zituvio-to-treat-adult-patients-with-type-2-diabetes-mellitus 2023-10-23T00:36:33 https://maestrodatabase.com/blog/review-asks-how-government-can-get-the-new-drugs-it-wants-funded 2021-03-01T19:57:46 https://maestrodatabase.com/blog/plea-to-make-new-depression-spray-affordable 2022-05-19T21:00:25 https://maestrodatabase.com/blog/fda-grants-accelerated-approval-to-melphalan-flufenamide-for-relapsed-or-refractory-multiple-myeloma 2021-03-01T19:39:38 https://maestrodatabase.com/blog/g-ba-certifies-active-ingredients-against-breast-and-oesophageal-cancer-as-having-a-high-additional-benefit 2022-05-19T20:38:49 https://maestrodatabase.com/blog/highlights-from-the-23-26-february-2026-chmp-meeting 2026-02-28T04:56:07 https://maestrodatabase.com/blog/institute-for-clinical-and-economic-review-posts-draft-scoping-documents-for-two-reviews-cgrp-inhibitors-for-migraine-and-update-to-prior-review-of-plaque-psoriasis-treatments 2017-12-05T01:46:42 https://maestrodatabase.com/blog/bms-sprycel-reimbursement-criteria-to-be-broadened-for-paediatric-philadelphia-chromosome-positive-all 2022-05-19T20:48:09 https://maestrodatabase.com/blog/fda-authorises-first-robotically-assisted-surgical-device-for-performing-transvaginal-hysterectomy 2021-03-01T19:44:01 https://maestrodatabase.com/blog/budget-2022-critically-ill-patients-bitterly-disappointed-by-pharmac-funding 2022-05-19T20:44:34 https://maestrodatabase.com/blog/dapagliflozin-in-chronic-heart-failure-hint-of-added-benefit 2021-03-01T19:48:37 https://maestrodatabase.com/blog/1-november-2023-changes-to-the-pbs-listings-of-medicines-for-severe-active-rheumatoid-arthritis 2023-10-23T01:37:51 https://maestrodatabase.com/blog/1-october-2021-price-disclosure-confirmed-prices 2021-09-13T01:40:51 https://maestrodatabase.com/blog/modernising-the-prostheses-list-committee-process 2023-01-18T01:34:38 https://maestrodatabase.com/blog/cormedix-receives-complete-response-letter-from-fda-for-defencath-catheter-lock-solution 2021-03-01T20:18:10 https://maestrodatabase.com/blog/fda-approves-cabtreo-clindamycin-phosphate-adapalene-and-benzoyl-peroxide-topical-gel-for-the-treatment-of-acne-vulgaris-in-patients-twelve-years-of-age-and-older 2023-10-23T01:07:22 https://maestrodatabase.com/blog/lfb-announces-that-the-ema-has-accepted-for-filing-the-marketing-authorisation-application-for-eptacog-beta-activated-a-recombinant-coagulation-factor-viia 2021-03-01T20:00:41 https://maestrodatabase.com/blog/rare-disease-day-2021-fda-shows-sustained-support-of-rare-disease-product-development-during-the-public-health-emergency 2021-03-01T20:08:58 https://maestrodatabase.com/blog/medicines-australia-puts-spotlight-on-reform-priority-for-the-next-government 2022-05-19T21:14:42 https://maestrodatabase.com/blog/alphaeon-submits-biologics-license-application-for-dwp-450-neuromodulator-bla-submitted-within-three-years-of-first-patient-enrolment 2017-05-21T13:09:57 https://maestrodatabase.com/blog/neurometrix-reports-that-quell-wearable-neuromodulation-device-has-received-fda-de-novo-authorisation-as-first-non-pharmacological-treatment-for-fibromyalgia 2022-05-19T21:30:59 https://maestrodatabase.com/blog/athenex-receives-fda-complete-response-letter-for-oral-paclitaxel-plus-encequidar-for-the-treatment-of-metastatic-breast-cancer 2021-03-01T20:11:33 https://maestrodatabase.com/blog/health-canada-approves-fast-acting-mealtime-insulin-fiasp-for-children-with-diabetes 2020-03-10T01:25:17 https://maestrodatabase.com/blog/ultomiris-approved-in-canada-for-adults-with-generalied-myasthenia-gravis 2023-01-18T02:19:42 https://maestrodatabase.com/blog/trodelvy-approved-following-heroic-efforts-of-breast-cancer-sufferer-alison-day 2021-09-13T02:02:42 https://maestrodatabase.com/blog/maribavir-for-the-treatment-of-patients-with-a-refractory-cytomegalovirus-infection-after-transplant 2023-01-18T02:26:15 https://maestrodatabase.com/blog/voxelotor-for-the-treatment-of-patients-with-sickle-cell-disease 2023-01-18T04:41:22 https://maestrodatabase.com/blog/avadel-pharmaceuticals-announces-fda-acceptance-of-new-drug-application-for-ft218-in-adults-with-narcolepsy-for-the-treatment-of-excessive-daytime-sleepiness-and-cataplexy 2021-03-01T21:31:12 https://maestrodatabase.com/blog/updates-to-the-hta-policy-and-methods-review-reference-committee-23-october-2023 2023-10-23T02:54:42 https://maestrodatabase.com/blog/beigene-announces-u-dot-s-fda-acceptance-of-biologics-license-application-for-tislelizumab-in-oesophageal-squamous-cell-carcinoma 2021-09-13T05:58:03 https://maestrodatabase.com/blog/celltrion-usa-announces-us-fda-approval-of-zymfentra-infliximab-dyyb-the-first-and-only-subcutaneous-infliximab-for-the-treatment-of-people-with-inflammatory-bowel-disease 2023-10-23T04:19:22 https://maestrodatabase.com/blog/mosunetuzumab-for-the-treatment-of-patients-with-relapsed-or-refractory-follicular-lymphoma 2023-06-02T00:00:29 https://maestrodatabase.com/blog/emd-serono-receives-health-canada-notice-of-compliance-for-mavenclad-cladribine-tablets-for-patients-living-with-relapsing-remitting-multiple-sclerosis 2017-12-05T03:00:41 https://maestrodatabase.com/blog/life-changing-gene-therapy-for-babies-with-spinal-muscular-atrophy 2023-10-23T02:29:54 https://maestrodatabase.com/blog/medunik-canada-obtains-new-notice-of-compliance-from-health-canada-for-ruzurgi-amifampridine-following-a-favourable-canadian-federal-court-of-appeal-ruling 2023-01-18T02:53:16 https://maestrodatabase.com/blog/health-canada-approves-dupixent-the-first-targeted-treatment-for-adults-with-moderate-to-severe-atopic-dermatitis 2017-12-05T03:07:01 https://maestrodatabase.com/blog/forge-biologics-receives-prime-designation-from-the-ema-for-novel-gene-therapy-fbx-101-for-the-treatment-of-patients-with-krabbe-disease 2023-01-18T03:28:26 https://maestrodatabase.com/blog/ema-publishes-agenda-for-13-16-september-chmp-meeting 2021-09-13T20:52:35 https://maestrodatabase.com/blog/joint-statement-of-support-for-an-australian-patent-box 2021-09-13T20:49:35 https://maestrodatabase.com/blog/uk-terminates-valneva-covid-19-vaccine-supply-agreement 2021-09-13T20:58:43 https://maestrodatabase.com/blog/us-fda-accepts-mercks-gefapixant-new-drug-application-for-review 2021-03-01T21:37:57 https://maestrodatabase.com/blog/medicare-benefits-schedule-continuous-review-to-improve-patient-care 2021-09-13T09:18:45 https://maestrodatabase.com/blog/major-purchasers-predict-expensive-new-therapies-will-keep-driving-drug-price-hikes 2023-01-18T19:30:18 https://maestrodatabase.com/blog/myovant-sciences-submits-marketing-authorisation-application-to-the-ema-for-relugolix-combination-tablet-for-the-treatment-of-women-with-uterine-fibroids 2020-03-10T02:08:04 https://maestrodatabase.com/blog/reimagining-pharmaceutical-market-exclusivities-should-the-duration-of-guaranteed-monopoly-periods-be-value-based 2021-09-13T21:37:03 https://maestrodatabase.com/blog/enhertu-approved-in-the-eu-as-the-first-her2-directed-therapy-for-patients-with-her2-mutant-advanced-non-small-cell-lung-cancer 2023-10-23T06:08:29 https://maestrodatabase.com/blog/pharmac-seeking-feedback-on-funding-a-second-spinal-muscular-atrophy-treatment 2023-01-18T19:33:23 https://maestrodatabase.com/blog/paratek-pharmaceuticals-announces-inclusion-of-nuzyra-omadacycline-in-chinas-national-reimbursement-drug-list-nrdl 2023-01-18T19:25:50 https://maestrodatabase.com/blog/smc---september-2021-decisions 2021-09-13T21:01:43 https://maestrodatabase.com/blog/tlv-is-commissioned-to-secure-access-to-antibiotics 2021-09-13T21:15:34 https://maestrodatabase.com/blog/vascular-graft-solutions-wins-fda-approval-to-market-the-viola-clampless-proximal-anastomosis-system-for-cabg 2021-03-01T22:58:50 https://maestrodatabase.com/blog/plx-pharma-receives-fda-approval-of-sndas-for-both-vazalore-325-mg-and-81-mg 2021-03-01T23:05:00 https://maestrodatabase.com/blog/beigene-announces-expansion-of-coverage-on-chinas-national-reimbursement-drug-list 2023-01-18T19:57:21 https://maestrodatabase.com/blog/emalex-biosciences-receives-fda-fast-track-designation-for-ecopipam-for-the-treatment-of-patients-with-tourette-syndrome 2019-08-29T03:17:17 https://maestrodatabase.com/blog/agios-submits-supplemental-new-drug-application-to-fda-for-tibsovo-ivosidenib-for-patients-with-previously-treated-idh1-mutant-cholangiocarcinoma 2021-03-01T23:10:20 https://maestrodatabase.com/blog/avidity-biosciences-granted-fda-fast-track-designation-for-aoc-1020-for-the-treatment-of-facioscapulohumeral-muscular-dystrophy 2023-01-18T19:42:40 https://maestrodatabase.com/blog/we-cant-let-drug-companies-get-out-of-negotiating-prices 2023-10-23T19:55:39 https://maestrodatabase.com/blog/fda-grants-priority-review-for-nalmefene-pre-filled-syringe-for-the-treatment-of-known-or-suspected-opioid-overdose 2023-01-18T19:48:34 https://maestrodatabase.com/blog/fdas-breakthrough-program-faster-drug-oks-without-sacrificing-safety 2023-01-18T19:38:53 https://maestrodatabase.com/blog/ozempic-and-wegovy-dont-cost-what-you-think-they-do 2023-10-23T19:51:53 https://maestrodatabase.com/blog/mhra-authorises-bispecific-antibody-therapy-tepkinly-as-a-treatment-for-diffuse-large-b-cell-lymphoma-in-adults 2023-10-23T19:41:09 https://maestrodatabase.com/blog/apollo-endosurgery-receives-fda-breakthrough-device-designation-for-the-orbera-intragastric-balloon-for-treatment-of-patients-with-nash 2021-03-02T00:02:43 https://maestrodatabase.com/blog/decision-to-fund-betamethasone-dipropionate-with-calcipotriol-enstilar-foam-spray-for-psoriasis 2020-03-10T03:37:18 https://maestrodatabase.com/blog/vetex-medical-receives-fda-clearance-for-revene-thrombectomy-catheter 2021-03-01T23:23:05 https://maestrodatabase.com/blog/zai-lab-announces-inclusion-of-qinlock-ripretinib-and-nuzyra-omadacycline-in-chinas-national-reimbursement-drug-list 2023-01-18T20:13:21 https://maestrodatabase.com/blog/health-canada-approves-rydapt-midostaurin-first-targeted-therapy-for-common-form-of-acute-myeloid-leukaemia 2017-12-05T11:07:49 https://maestrodatabase.com/blog/hutchmed-announces-agreement-with-nhsa-for-inclusion-of-orpathys-in-the-national-reimbursement-drug-list-in-china 2023-01-18T20:04:36 https://maestrodatabase.com/blog/elective-surgery-surge-for-private-patients-in-public-hospitals 2017-12-05T19:40:51 https://maestrodatabase.com/blog/pharma-exec-says-industry-must-get-fair-about-pricing-new-drugs 2017-05-22T10:41:20 https://maestrodatabase.com/blog/adelaide-mum-makes-plea-for-cystic-fibrosis-drug-to-be-added-to-pbs 2017-12-05T19:43:58 https://maestrodatabase.com/blog/green-light-given-for-new-eudravigilance-system-for-collection-and-monitoring-of-suspected-adverse-reactions 2017-05-22T20:56:23 https://maestrodatabase.com/blog/how-giving-private-patients-priority-in-public-hospitals-is-pushing-up-health-fund-premiums 2017-12-05T19:52:52 https://maestrodatabase.com/blog/the-webster-family-spent-their-life-savings-to-save-their-son-matthew-after-rare-cancer-diagnosis 2017-12-05T19:49:02 https://maestrodatabase.com/blog/novartis-and-roche-get-nice-rejections 2017-12-05T19:59:06 https://maestrodatabase.com/blog/ema-should-remain-in-london-post-brexit-to-soften-transition-uk-lawmakers-hear 2017-12-05T19:55:37 https://maestrodatabase.com/blog/fda-approves-first-drug-to-specifically-treat-giant-cell-arteritis 2017-05-22T21:02:15 https://maestrodatabase.com/blog/canadas-regulator-of-patented-drug-prices-is-rigging-data-and-risking-our-health 2017-12-05T20:04:57 https://maestrodatabase.com/blog/democrats-accuse-white-house-of-causing-aca-tremors-then-shifting-blame 2017-05-22T21:13:33 https://maestrodatabase.com/blog/cvs-and-aetna-say-merger-will-improve-your-health-care-can-they-deliver 2017-12-05T20:13:46 https://maestrodatabase.com/blog/a-vital-drug-runs-low-though-its-base-ingredient-is-in-many-kitchens 2017-05-22T21:28:27 https://maestrodatabase.com/blog/this-company-is-about-to-flood-the-u-dot-s-with-cheap-hiv-drugs 2017-12-05T20:09:22 https://maestrodatabase.com/blog/drugs-approved-with-limited-data-arent-always-well-tested-later 2017-05-22T21:16:14 https://maestrodatabase.com/blog/us-fda-approves-biomarins-palynziq-pegvaliase-pqpz-for-adolescents-12-years-of-age-and-older-with-phenylketonuria 2026-03-01T01:39:56 https://maestrodatabase.com/blog/melbourne-man-tests-positive-to-hiv-while-taking-preventative-drug 2017-05-22T21:41:39 https://maestrodatabase.com/blog/hta-for-pharmaceuticals-in-europe-will-the-mountain-deliver-a-mouse 2020-03-10T06:19:30 https://maestrodatabase.com/blog/nice-updates-type-2-guidelines-to-reflect-new-advice-on-drug-treatments 2017-05-22T21:45:30 https://maestrodatabase.com/blog/another-voice-patients-have-a-right-to-the-treatments-ordered-by-doctors 2017-05-22T21:56:32 https://maestrodatabase.com/blog/proposal-to-amend-listing-in-the-national-immunisation-schedule---meningococcal-c-conjugate-vaccine 2017-05-23T02:54:21 https://maestrodatabase.com/blog/post-market-review-of-ezetimibe---revised-draft-report 2017-05-23T06:06:30 https://maestrodatabase.com/blog/sanofi-and-regeneron-announce-fda-approval-of-kevzara-sarilumab-for-the-treatment-of-moderately-to-severely-active-rheumatoid-arthritis-in-adult-patients 2017-05-23T06:14:29 https://maestrodatabase.com/blog/fujifilm-kyowa-kirin-biologics-announces-marketing-authorisation-application-for-fkb327-accepted-for-review-by-european-medicines-agency 2017-05-23T06:21:40 https://maestrodatabase.com/blog/changes-to-the-national-immunisation-schedule 2017-05-23T07:41:40 https://maestrodatabase.com/blog/new-fda-pathway-to-accelerate-development-of-cell-therapies 2017-05-23T07:35:18 https://maestrodatabase.com/blog/hiv-drug-prep-praised-for-helping-prevent-other-sexually-transmitted-diseases 2017-05-23T11:03:23 https://maestrodatabase.com/blog/the-fdas-expedited-programs-and-clinical-development-times-for-novel-therapeutics-2012-2016 2017-12-05T22:26:16 https://maestrodatabase.com/blog/health-canada-accepts-nirsevimab-regulatory-submission-for-infant-rsv 2023-01-19T04:17:42 https://maestrodatabase.com/blog/medicines-new-zealand-supportive-of-governments-pharmac-review-assuming-it-is-not-a-box-ticking-exercise 2021-03-02T02:55:07 https://maestrodatabase.com/blog/diabetes-scanning-technology-replaces-pricking 2017-05-23T11:10:49 https://maestrodatabase.com/blog/fda-approves-first-cancer-treatment-for-any-solid-tumour-with-a-specific-genetic-feature 2017-05-23T20:14:11 https://maestrodatabase.com/blog/trump-seeks-delay-of-ruling-on-health-law-subsidies-prolonging-uncertainty 2017-05-23T11:17:34 https://maestrodatabase.com/blog/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-for-keytruda-pembrolizumab-for-treatment-of-recurrent-or-advanced-gastric-or-gastro-oesophageal-junction-adenocarcinoma 2017-05-23T20:17:54 https://maestrodatabase.com/blog/seladelpar-granted-revised-breakthrough-therapy-designation-for-the-treatment-of-primary-biliary-cholangitis-including-pruritus-in-patients-without-cirrhosis-or-with-compensated-cirrhosis 2023-10-23T23:14:19 https://maestrodatabase.com/blog/abbott-receives-fda-approval-for-navitor-a-next-generation-tavi-system-designed-to-treat-aortic-stenosis 2023-01-19T19:11:45 https://maestrodatabase.com/blog/nervgen-pharma-receives-fast-track-designation-for-nvg-291-for-the-treatment-of-individuals-with-spinal-cord-injury 2023-10-23T23:03:57 https://maestrodatabase.com/blog/neuroendocrine-cancer-sufferers-take-on-pharmac 2017-05-23T20:33:36 https://maestrodatabase.com/blog/mirum-pharmaceuticals-submits-european-marketing-authorisation-application-for-maralixibat-in-alagille-syndrome-supported-by-new-positive-results-from-natural-history-study-comparison 2021-09-14T01:31:58 https://maestrodatabase.com/blog/japan-to-bring-forward-target-for-increased-generic-drug-use 2017-05-23T20:25:20 https://maestrodatabase.com/blog/a-court-decision-on-skinny-labeling-another-challenge-for-less-expensive-drugs 2021-09-14T00:27:42 https://maestrodatabase.com/blog/fda-grants-rare-paediatric-disease-status-to-gc-pharmas-san-filippo-syndrome-therapy 2023-01-19T05:22:18 https://maestrodatabase.com/blog/trump-budget-contains-little-on-drug-prices-despite-tough-talk 2017-05-23T20:37:16 https://maestrodatabase.com/blog/us-pharma-giant-merck-and-co-accused-of-blocking-cheaper-arthritis-drugs-for-the-nhs 2017-05-23T20:41:04 https://maestrodatabase.com/blog/a-message-from-the-minister 2017-05-24T08:07:58 https://maestrodatabase.com/blog/g20-agrees-to-tackle-antibiotic-resistance-issues 2017-05-24T08:05:12 https://maestrodatabase.com/blog/multiple-sclerosis-patients-in-us-left-without-essential-patient-support-program-will-now-receive-equivalent-backing-from-cycle-pharmaceuticals-following-fdas-approval-of-tascenso-odt-fingolimod 2023-01-19T19:38:45 https://maestrodatabase.com/blog/zensun-announces-the-investigation-of-neucardin-for-chronic-heart-failure-receives-fast-track-designation-from-the-us-fda 2019-08-29T05:05:15 https://maestrodatabase.com/blog/mirati-therapeutics-submits-marketing-authorisation-application-to-the-european-medicines-agency-for-investigational-adagrasib-as-a-treatment-for-previously-treated-krasg12c-mutated-non-small-cell-lung-cancer 2022-05-20T04:33:40 https://maestrodatabase.com/blog/evaxion-receives-fda-fast-track-designation-for-personalised-cancer-immunotherapy 2023-01-19T19:33:20 https://maestrodatabase.com/blog/synlogic-receives-rare-paediatric-disease-designation-from-fda-for-synb1934-for-phenylketonuria 2023-01-19T19:27:27 https://maestrodatabase.com/blog/plazomicin-granted-fda-breakthrough-therapy-designation 2017-05-24T09:31:09 https://maestrodatabase.com/blog/addressing-the-potential-impact-of-novel-coronavirus-disease-covid-19-on-medicines-supply-in-the-eu 2020-03-10T09:49:42 https://maestrodatabase.com/blog/ultragenyx-announces-recombinant-human-beta-glucuronidase-biologics-license-application-and-marketing-authorisation-application-filed-and-accepted-for-review-fda-grants-priority-review-status 2017-05-24T09:38:56 https://maestrodatabase.com/blog/fda-accepts-intercepts-new-drug-application-for-oca-for-the-treatment-of-pre-cirrhotic-liver-fibrosis-due-to-nash 2023-01-19T19:19:25 https://maestrodatabase.com/blog/alnylam-submits-marketing-authorisation-application-to-the-european-medicines-agency-for-investigational-vutrisiran-for-the-treatment-of-hereditary-attr-amyloidosis-with-polyneuropathy 2021-09-14T01:38:48 https://maestrodatabase.com/blog/the-battle-over-european-drug-pricing 2023-01-19T20:02:16 https://maestrodatabase.com/blog/eton-pharmaceuticals-announces-us-fda-approval-for-desmoda-desmopressin-acetate-oral-solution 2026-03-01T10:27:37 https://maestrodatabase.com/blog/drugs-added-to-reimbursement-list 2023-01-19T19:56:32 https://maestrodatabase.com/blog/evaluating-alternative-payment-models-in-oncology 2017-05-24T11:23:21 https://maestrodatabase.com/blog/nobody-can-afford-this-family-left-helpless-after-health-canada-approves-official-version-of-prescription-eye-drops 2019-08-29T05:27:01 https://maestrodatabase.com/blog/european-commission-grants-marketing-authorisation-for-zebinix-eslicarbazepine-acetate-as-once-daily-monotherapy-in-adults-with-newly-diagnosed-partial-onset-epilepsy 2017-05-24T10:59:24 https://maestrodatabase.com/blog/innovent-announces-inclusion-in-the-china-national-reimbursement-drug-list-of-tyvyt-in-two-new-indications-olverembatinib-for-the-first-listing-byvadsa-halpryza-and-sulinno-in-multiple-new-indications 2023-01-19T19:50:25 https://maestrodatabase.com/blog/u-dot-s-food-and-drug-administration-accepts-for-priority-review-bristol-myers-squibbs-application-for-opdivo-nivolumab-in-previously-treated-hepatocellular-carcinoma 2017-05-24T20:51:29 https://maestrodatabase.com/blog/is-the-affordable-care-act-imploding 2017-05-24T11:26:41 https://maestrodatabase.com/blog/nice-recommends-all-oral-triplet-regimen-for-patients-living-with-relapsed-or-refractory-multiple-myeloma 2023-01-19T19:46:35 https://maestrodatabase.com/blog/4dmt-receives-ema-priority-medicines-prime-designation-for-4d-150-clinical-stage-genetic-medicine-for-treatment-of-wet-amd 2023-10-24T04:48:22 https://maestrodatabase.com/blog/scottish-medicines-consortium-recommends-mercks-tepmetko 2023-01-19T20:40:06 https://maestrodatabase.com/blog/sigma-launches-suit-to-enforce-supply-deal-as-share-price-tanks 2017-05-24T21:05:55 https://maestrodatabase.com/blog/nice-backs-alnylams-amvuttra-for-rare-form-of-amyloidosis 2023-01-19T20:25:00 https://maestrodatabase.com/blog/sumitomo-pharma-announces-authorisation-in-canada-of-orogvyx-relugolix-for-the-treatment-of-men-with-advanced-prostate-cancer 2023-10-24T04:40:15 https://maestrodatabase.com/blog/estimated-23-million-would-lose-health-insurance-under-republican-bill-cbo 2017-05-24T21:02:24 https://maestrodatabase.com/blog/seagen-announces-fda-accelerated-approval-of-tukysa-tucatinib-in-combination-with-trastuzumab-for-people-with-previously-treated-ras-wild-type-her2-positive-metastatic-colorectal-cancer 2023-01-19T20:30:35 https://maestrodatabase.com/blog/radicava-edarvarone-oral-suspension-receives-positive-recommendation-from-cadth-for-the-treatment-of-patients-with-als 2023-01-19T20:13:42 https://maestrodatabase.com/blog/400-dollars-billion-price-tag-for-california-single-payer-bill 2017-05-24T21:18:09 https://maestrodatabase.com/blog/nice-nod-for-psoriatic-arthritis-drugs-cimzia-and-cosentyx 2017-05-24T21:10:31 https://maestrodatabase.com/blog/nice-recommends-reimbursement-for-translarna 2023-01-19T20:06:28 https://maestrodatabase.com/blog/ipsen-updates-on-eu-marketing-authorisation-application-for-odevixibat-in-alagille-syndrome 2023-10-24T04:32:40 https://maestrodatabase.com/blog/trumps-quiet-on-drug-pricing-but-his-fda-isnt 2017-05-24T21:22:34 https://maestrodatabase.com/blog/accelerated-approval-and-expensive-drugs----a-challenging-combination 2017-05-24T21:49:49 https://maestrodatabase.com/blog/nice-terminates-appraisal-of-afatinib-dimaleate 2017-05-24T21:44:16 https://maestrodatabase.com/blog/viatris-and-biocon-biologics-launch-abevmy-bevacizumab-their-third-oncology-siosimilar-in-canada 2022-05-20T05:56:59 https://maestrodatabase.com/blog/white-house-principles-for-reducing-drug-costs 2020-03-10T19:54:50 https://maestrodatabase.com/blog/new-brand-name-hiv-prevention-pill-not-worth-the-added-cost 2020-03-10T20:05:04 https://maestrodatabase.com/blog/ozempic-semaglutide-approved-in-the-us 2017-12-06T07:42:39 https://maestrodatabase.com/blog/coronavirus-disease-2019-covid-19-update-foreign-inspections 2020-03-10T20:01:52 https://maestrodatabase.com/blog/ema-publishes-agenda-for-22-25-april-2025-chmp-meeting 2025-04-22T21:45:47 https://maestrodatabase.com/blog/consultation-on-the-revised-pbs-post-market-review-framework---publication-of-responses 2023-01-20T00:39:00 https://maestrodatabase.com/blog/inappropriate-use-of-progression-free-survival-in-cancer-drug-approvals 2020-03-10T20:49:24 https://maestrodatabase.com/blog/us-food-and-drug-administration-accepts-for-review-astrazenecas-supplemental-biologics-license-application-for-self-administration-of-flumist-quadrivalent 2023-10-24T06:06:08 https://maestrodatabase.com/blog/fda-grants-genentechs-avastin-full-approval-for-most-aggressive-form-of-brain-cancer 2017-12-06T07:46:14 https://maestrodatabase.com/blog/clovis-announces-priority-review-designation-for-rucaparib-supplemental-new-drug-application 2017-12-06T07:51:10 https://maestrodatabase.com/blog/gc-pharma-submits-biologics-license-application-to-us-fda-for-immune-globulin-gc5107 2021-03-02T04:20:32 https://maestrodatabase.com/blog/direct-supply-risks 2017-12-06T07:57:09 https://maestrodatabase.com/blog/global-companies-expand-the-reach-of-their-cancer-drugs-in-china 2020-03-10T20:52:30 https://maestrodatabase.com/blog/immunitybio-announces-biological-license-application-resubmission-for-n-803-in-bcg-unresponsive-non-muscle-invasive-bladder-cancer-carcinoma-in-situ 2023-10-24T10:35:05 https://maestrodatabase.com/blog/new-pbs-listing-for-immunotherapy-cancer-drugs-opdivo-and-yervoy-to-be-slashed 2026-03-01T21:12:11 https://maestrodatabase.com/blog/fda-approves-ivosidenib-for-myelodysplastic-syndromes 2023-10-24T20:02:22 https://maestrodatabase.com/blog/international-harmonisation-of-ingredient-names---update-on-pbs-changes 2017-12-06T08:18:31 https://maestrodatabase.com/blog/insulin-is-increasingly-affordable-in-the-us-what-about-the-rest-of-the-world 2023-10-24T19:48:34 https://maestrodatabase.com/blog/lumasiran-for-treating-primary-hyperoxaluria-type-1 2022-05-20T11:20:01 https://maestrodatabase.com/blog/limiting-the-impact-on-kiwis-as-api-leaves-the-nz-market 2021-09-14T03:25:31 https://maestrodatabase.com/blog/bristol-myers-squibb-announces-us-fda-breakthrough-therapy-designation-for-investigational-lpa1-antagonist-for-progressive-pulmonary-fibrosis 2023-10-24T19:37:50 https://maestrodatabase.com/blog/ema-takes-further-steps-to-address-critical-shortages-of-medicines-in-the-eu 2023-10-24T19:46:07 https://maestrodatabase.com/blog/milestone-pharmaceuticals-announces-submission-of-new-drug-application-to-the-us-fda-for-etripamil 2023-10-24T19:30:01 https://maestrodatabase.com/blog/ema-chmp-recommends-eu-approval-of-henlius-pertuzumab-biosimilar-hlx11 2026-03-01T21:45:56 https://maestrodatabase.com/blog/mtaa-supports-call-for-future-of-private-health-summit 2021-09-14T05:59:46 https://maestrodatabase.com/blog/chmp-recommends-approval-of-lilly-and-incytes-olumiant-baricitinib-as-the-first-and-only-centrally-authorised-treatment-for-adults-with-severe-alopecia-areata 2022-05-20T13:00:34 https://maestrodatabase.com/blog/immatics-receives-fda-regenerative-medicine-advanced-therapy-designation-for-actengine-ima203-tcr-t-monotherapy 2023-10-24T20:34:10 https://maestrodatabase.com/blog/abiraterone-thousands-of-men-miss-out-on-life-extending-prostate-cancer-drug 2023-10-24T20:30:17 https://maestrodatabase.com/blog/branded-price-variation-in-the-united-states-drug-market-2010-to-2019 2021-09-14T03:34:30 https://maestrodatabase.com/blog/highlights-from-the-16-19-may-2022-chmp-meeting 2022-05-20T12:47:57 https://maestrodatabase.com/blog/access-consortium-alignment-with-icmra-consensus-on-immunobridging-for-authorising-new-covid-19-vaccines 2021-09-14T03:30:06 https://maestrodatabase.com/blog/biden-drug-pricing-plan-seeks-to-balance-access-and-innovation 2021-09-14T04:25:23 https://maestrodatabase.com/blog/abbvie-submits-new-drug-application-to-u-dot-s-fda-for-investigational-abbv-951-foscarbidopa-slash-foslevodopa-for-the-treatment-of-advanced-parkinsons-disease 2022-05-20T12:52:58 https://maestrodatabase.com/blog/new-therapy-to-treat-advanced-small-cell-lung-cancer-approved-for-australian-patients 2021-09-14T20:27:02 https://maestrodatabase.com/blog/axsome-therapeutics-announces-fda-acceptance-of-new-drug-application-for-axs-07-for-the-acute-treatment-of-migraine 2021-09-14T20:31:34 https://maestrodatabase.com/blog/fda-grants-breakthrough-therapy-designation-for-brainchild-bios-b7-h3-car-t-cell-therapy-for-incurable-paediatric-brain-tumours 2025-04-22T23:17:25 https://maestrodatabase.com/blog/nyxoah-announces-u-dot-s-fda-breakthrough-device-designation-granted-for-the-genio-system-for-obstructive-sleep-apnea-and-complete-concentric-collapse 2021-09-14T10:48:33 https://maestrodatabase.com/blog/fda-approves-mercks-keytruda-pembrolizumab-for-adult-and-pediatric-patients-with-unresectable-or-metastatic-microsatellite-instability-high-or-mismatch-repair-deficient-cancer 2017-05-25T05:53:11 https://maestrodatabase.com/blog/trodelvy-approved-by-the-tga 2021-09-14T21:01:18 https://maestrodatabase.com/blog/fda-accepts-new-drug-application-for-buprenorphine-sublingual-spray-from-insys-therapeutics 2017-12-06T20:08:10 https://maestrodatabase.com/blog/ema-study-reveals-need-for-rwe-framework-submission-structure 2021-09-14T20:54:26 https://maestrodatabase.com/blog/growth-of-private-care-in-public-hospitals-raises-equity-questions 2017-12-06T20:22:18 https://maestrodatabase.com/blog/what-the-cvs-aetna-deal-means-for-the-future-of-health-care 2017-12-06T20:18:11 https://maestrodatabase.com/blog/academics-and-consumer-groups-protest-fda-plan-to-summarise-review-documents 2019-08-29T21:01:46 https://maestrodatabase.com/blog/isa-pharmaceuticals-receives-fast-track-designation-for-lead-product-isa101b 2021-09-14T20:44:44 https://maestrodatabase.com/blog/prescription-2020-democratic-candidates-and-drug-pricing 2019-08-29T20:54:29 https://maestrodatabase.com/blog/moderate-house-democrats-threaten-drug-pricing-bill-in-house-panel 2021-09-14T20:49:25 https://maestrodatabase.com/blog/fda-approves-first-treatment-for-eosinophilic-esophagitis-a-chronic-immune-disorder 2022-05-20T20:40:30 https://maestrodatabase.com/blog/are-reasonable-restraints-on-drug-price-increases-doomed-by-pharma-lobbying 2019-08-29T11:07:17 https://maestrodatabase.com/blog/ema-offers-edits-on-fda-draft-guidance-on-biosimilars 2019-08-29T21:18:46 https://maestrodatabase.com/blog/drug-prices-and-value-of-oncology-drugs-in-italy 2021-09-14T21:12:02 https://maestrodatabase.com/blog/full-green-light-for-biogens-ms-drug-fampyra 2017-05-25T07:27:30 https://maestrodatabase.com/blog/prep-school-a-field-manual-for-the-battle-over-hiv-prevention-drug-pricing 2019-08-29T21:12:22 https://maestrodatabase.com/blog/european-commission-approves-roches-tecentriq-in-combination-with-abraxane-for-people-with-pd-l1-positive-metastatic-triple-negative-breast-cancer 2019-08-29T21:04:21 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-march-2026 2026-03-02T01:20:40 https://maestrodatabase.com/blog/assessing-the-health-effects-of-a-no-deal-brexit 2019-08-29T21:55:09 https://maestrodatabase.com/blog/u-dot-s-prices-for-multiple-sclerosis-drugs-are-on-the-rise 2019-08-29T21:38:37 https://maestrodatabase.com/blog/u-dot-s-fda-approves-mylan-generic-of-lilly-lung-cancer-drug-alimta 2019-08-29T21:21:38 https://maestrodatabase.com/blog/updates-to-the-hta-review-research-and-analysis-papers-collection-draft-hta-expert-papers-published 2024-01-04T02:31:15 https://maestrodatabase.com/blog/why-10-000-aussies-a-year-being-forced-to-fund-their-own-cancer-treatment 2024-07-22T01:02:31 https://maestrodatabase.com/blog/updates-from-the-health-technology-assessment-policy-and-methods-review-reference-committee 2023-06-30T01:48:51 https://maestrodatabase.com/blog/patients-in-the-fight-for-our-lives-call-on-parliament-to-stop-the-pmprb 2020-03-11T02:54:58 https://maestrodatabase.com/blog/fda-approves-zanubrutinib-for-chronic-lymphocytic-leukaemia-or-small-lymphocytic-lymphoma 2023-01-20T06:55:09 https://maestrodatabase.com/blog/republicans-get-ready-for-the-trumpcare-headlines 2017-05-25T11:27:08 https://maestrodatabase.com/blog/new-medicines-funding-for-breast-cancer-still-elusive 2017-05-25T11:42:12 https://maestrodatabase.com/blog/us-fda-issues-complete-response-letter-for-accelerated-approval-of-donanemab 2023-01-20T06:37:27 https://maestrodatabase.com/blog/dare-bioscience-receives-fda-fast-track-designation-for-dare-bv1-for-the-treatment-of-bacterial-vaginosis 2020-03-11T03:45:26 https://maestrodatabase.com/blog/drug-pricing-battle-moves-to-ohio-as-duelling-ads-begin-over-a-ballot-measure 2017-05-25T11:35:45 https://maestrodatabase.com/blog/uks-voluntary-scheme-for-branded-medicines-pricing-and-access-vpas-faces-a-potential-crisis 2023-01-20T07:58:27 https://maestrodatabase.com/blog/boehringer-ingelheim-and-goodrx-announce-exclusive-patient-affordability-initiative-for-adalimumab-adbm-injection-boehringers-biosimilar-to-humira 2024-07-22T07:24:26 https://maestrodatabase.com/blog/more-cheaper-medicines-to-help-australians-fight-complex-and-chronic-illness 2026-03-02T02:25:00 https://maestrodatabase.com/blog/health-canada-approves-lumakras-sotorasib-the-first-and-only-targeted-treatment-for-patients-with-kras-g12c-mutated-locally-advanced-or-metastatic-non--small-cell-lung-cancer 2021-09-15T02:09:16 https://maestrodatabase.com/blog/european-commission-approves-use-of-ameluz-for-the-treatment-of-actinic-keratosis-on-extremities-and-trunk-slash-neck 2020-03-11T04:23:36 https://maestrodatabase.com/blog/medicines-australia-and-ausbiotech-say-covid-19-vaccine-patent-waiver-will-not-speed-up-global-vaccination 2021-09-15T02:02:43 https://maestrodatabase.com/blog/fda-chief-proposes-rules-changes-to-fight-high-drug-prices 2017-05-25T21:18:54 https://maestrodatabase.com/blog/cadth-recommends-reimbursement-of-gileads-odefsey 2017-05-25T21:07:51 https://maestrodatabase.com/blog/annexon-receives-prime-designation-from-the-ema-for-anx007-for-the-treatment-of-geographic-atrophy 2023-10-25T01:15:38 https://maestrodatabase.com/blog/strength-in-clinical-trials-set-to-grow-with-funding-boost 2017-05-25T21:25:27 https://maestrodatabase.com/blog/medical-research-reforms-to-improve-our-future-health 2017-05-25T21:46:21 https://maestrodatabase.com/blog/transparency-commission-publishes-its-review-of-keytrudas-smr-and-asmr 2017-05-25T21:37:06 https://maestrodatabase.com/blog/earlier-access-to-new-drugs-could-solve-canadas-affordability-crisis 2017-05-25T21:51:16 https://maestrodatabase.com/blog/health-canada-approves-keytruda-plus-pemetrexed-and-platinum-chemotherapy-as-first-line-treatment-for-adult-patients-with-unresectable-advanced-or-metastatic-malignant-pleural-mesothelioma 2025-04-23T01:42:39 https://maestrodatabase.com/blog/world-first-cheaper-immunotherapy-treatment-listing-for-patients-with-advanced-or-rare-cancers 2026-03-02T03:03:44 https://maestrodatabase.com/blog/regeneron-announces-new-u-dot-s-government-agreement-to-purchase-additional-doses-of-regen-cov-casirivimab-and-imdemivab-antibody-cocktail 2021-09-15T04:27:16 https://maestrodatabase.com/blog/final-report-on-the-australian-government-response-to-the-recommendations-of-the-senate-community-affairs-references-committee-report 2021-09-15T03:41:20 https://maestrodatabase.com/blog/pdufa-goal-date-extension-for-nefecon-nda-in-the-u-dot-s 2021-09-15T03:16:41 https://maestrodatabase.com/blog/government-announces-review-into-pharmac 2021-03-02T07:09:48 https://maestrodatabase.com/blog/daratumumab-in-combination-with-lenalidomide-and-dexamethasone-for-untreated-patients-with-multiple-myeloma-who-are-ineligible-for-stem-cell-transplantation 2023-10-25T01:49:23 https://maestrodatabase.com/blog/opiant-pharmaceuticals-announces-fda-acceptance-and-priority-review-of-nda-for-opnt003-nasal-nalmefene-for-opioid-overdose 2023-01-20T19:56:48 https://maestrodatabase.com/blog/orphelia-pharma-files-eu-marketing-authorisation-application-for-kizfizo 2023-10-25T01:39:06 https://maestrodatabase.com/blog/pharmac-commits-to-equity-target-by-2025 2017-12-07T02:56:47 https://maestrodatabase.com/blog/investing-5-dollars-9-cents-million-to-tackle-antimicrobial-resistance 2017-05-26T02:48:03 https://maestrodatabase.com/blog/speed-safety-and-industry-funding---from-pdufa-i-to-pdufa-vi 2017-12-07T02:50:36 https://maestrodatabase.com/blog/cms-launches-groundbreaking-model-to-lower-out-of-pocket-expenses-for-insulin 2020-03-11T20:00:41 https://maestrodatabase.com/blog/fda-accepts-viatris-supplemental-new-drug-application-for-mr-141-phentolamine-ophthalmic-solution-0-dot-75-percent-for-the-treatment-of-presbyopia 2026-03-02T04:32:13 https://maestrodatabase.com/blog/calcimedica-receives-fast-track-designation-for-cm4620-a-novel-crac-channel-inhibitor-to-treat-acute-pancreatitis 2017-05-26T03:10:26 https://maestrodatabase.com/blog/u-dot-s-fda-approves-opdivo-nivolumab-plus-yervoy-ipilimumab-for-patients-with-hepatocellular-carcinoma-previously-treated-with-sorafenib 2020-03-11T19:55:02 https://maestrodatabase.com/blog/bowel-cancer-patient-heartbroken-she-needs-unfunded-drug-keytruda-to-survive 2020-03-11T20:24:14 https://maestrodatabase.com/blog/novartis-cosentyx-secukinumab-receives-positive-chmp-opinion-for-expanded-use-in-childhood-arthritic-conditions 2022-05-20T22:11:27 https://maestrodatabase.com/blog/decision-to-widen-funded-access-to-lenalidomide-for-multiple-myeloma 2020-03-11T20:19:15 https://maestrodatabase.com/blog/covid-19-ema-meetings-with-delegates-and-experts-will-be-held-virtually-until-end-april-2020 2020-03-11T20:16:46 https://maestrodatabase.com/blog/lilly-to-participate-in-new-model-designed-to-make-insulins-more-affordable-for-seniors-in-medicare-part-d 2020-03-11T20:03:33 https://maestrodatabase.com/blog/mirikizumab-for-the-treatment-of-patients-with-moderate-to-severe-active-ulcerative-colitis 2023-10-25T03:51:35 https://maestrodatabase.com/blog/obseva-announces-submission-of-new-drug-application-to-u-dot-s-fda-for-linzagolix-for-the-treatment-of-uterine-fibroids 2021-09-15T08:56:53 https://maestrodatabase.com/blog/sunovion-receives-fda-approval-for-lonhala-magnair-inhalation-solution-to-treat-copd 2017-12-07T04:27:49 https://maestrodatabase.com/blog/aduhelm-backlash-threatens-to-reverse-progress-in-fdas-reviews-of-rare-and-ultra-rare-disease-drugs 2021-09-15T09:01:30 https://maestrodatabase.com/blog/janssen-announces-u-dot-s-fda-breakthrough-therapy-designation-granted-for-jnj-6372-for-the-treatment-of-non-small-cell-lung-cancer 2020-03-11T20:30:47 https://maestrodatabase.com/blog/marstacimab-approved-to-treat-patients-aged-12-years-and-above-weighing-at-least-35-kg-with-haemophilia-a-or-b 2025-04-23T21:21:31 https://maestrodatabase.com/blog/health-canada-grants-approval-for-ocaliva-obeticholic-acid-for-the-treatment-of-patients-with-primary-biliary-cholangitis 2017-05-26T03:48:09 https://maestrodatabase.com/blog/us-fda-accepts-supplemental-new-drug-application-for-jardiance-for-adults-with-chronic-kidney-disease 2023-01-20T21:12:29 https://maestrodatabase.com/blog/ema-and-health-canada-publish-clinical-data-used-to-support-their-authorisations-of-the-moderna-covid-19-vaccine 2021-03-02T19:52:26 https://maestrodatabase.com/blog/venetoclax-in-acute-myeloid-leukaemia-indication-of-a-considerable-added-benefit 2021-09-15T20:37:39 https://maestrodatabase.com/blog/fda-advances-data-it-modernisation-efforts-with-new-office-of-digital-transformation 2021-09-15T20:48:23 https://maestrodatabase.com/blog/nhs-prescription-charges-set-to-rise-in-england 2021-03-02T19:59:10 https://maestrodatabase.com/blog/drug-prices-measure-blocked-in-house-committee-as-democrats-splinter 2021-09-15T20:42:28 https://maestrodatabase.com/blog/takeda-and-protagonist-announce-us-fda-accepts-new-drug-application-and-grants-priority-review-for-rusfertide-as-a-potential-first-in-class-therapy-for-polycythemia-vera 2026-03-02T07:43:42 https://maestrodatabase.com/blog/nice-backs-opdivo-for-head-and-neck-cancer 2021-09-15T20:23:24 https://maestrodatabase.com/blog/u-dot-s-fda-grants-brukinsa-zanubrutinib-accelerated-approval-in-relapsed-or-refractory-marginal-zone-lymphoma 2021-09-15T20:30:11 https://maestrodatabase.com/blog/baricitinib-for-the-treatment-of-patients-with-severe-alopecia-areata-update 2023-10-25T05:17:58 https://maestrodatabase.com/blog/what-could-bidens-possible-bid-for-a-national-health-technology-assessment-entity-look-like 2021-03-02T20:19:29 https://maestrodatabase.com/blog/anuncia-receives-fda-breakthrough-device-designation-for-reflow-system-mini 2021-03-02T21:26:11 https://maestrodatabase.com/blog/merck-provides-update-on-keytruda-pembrolizumab-indication-in-metastatic-small-cell-lung-cancer-in-the-us 2021-03-02T20:05:09 https://maestrodatabase.com/blog/lilly-to-supply-388-000-doses-of-etesevimab-to-u-dot-s-government-for-treatment-of-covid-19 2021-09-15T20:59:49 https://maestrodatabase.com/blog/fda-ema-launch-complex-generic-hybrid-product-advice-pilot 2021-09-15T21:15:39 https://maestrodatabase.com/blog/icer-publishes-final-evidence-report-and-policy-recommendations-on-new-therapies-for-high-cholesterol 2021-03-02T20:11:49 https://maestrodatabase.com/blog/eyenovia-announces-fda-acceptance-of-the-mydcombi-new-drug-application 2021-03-02T20:15:30 https://maestrodatabase.com/blog/fda-approves-samsung-bioepis-epysqli-eculizumab-aagh-as-a-biosimilar-to-soliris-eculizumab 2024-07-23T08:36:18 https://maestrodatabase.com/blog/akebia-receives-fda-acceptance-of-resubmission-to-nda-of-vadadustat-for-the-treatment-of-anaemia-due-to-chronic-kidney-disease 2023-10-25T19:49:26 https://maestrodatabase.com/blog/drug-industry-pushes-fda-to-solve-growing-inspection-backlog 2021-03-02T21:30:24 https://maestrodatabase.com/blog/johnson-and-johnson-seeks-us-fda-approval-of-spravato-esketamine-as-the-first-and-only-monotherapy-for-adults-with-treatment-resistant-depression 2024-07-23T08:11:34 https://maestrodatabase.com/blog/cook-medical-receives-fda-breakthrough-device-designation-for-zenith-fenestrated-plus-endovascular-graft 2021-03-02T21:49:47 https://maestrodatabase.com/blog/at-550-dollars-slash-month-new-menopause-hot-flash-drug-may-be-out-of-reach-for-many-women 2023-10-25T19:44:46 https://maestrodatabase.com/blog/hepatera-eligibility-to-prime-scheme-granted-to-myrcludex-b-by-the-european-medicines-agency 2017-05-26T05:30:40 https://maestrodatabase.com/blog/alk-secures-pricing-and-reimbursement-for-acarizax-in-france 2017-12-07T06:57:21 https://maestrodatabase.com/blog/eu-regulator-accepts-usvs-application-for-biosimilar-pegfilgrastim 2017-12-07T07:06:23 https://maestrodatabase.com/blog/the-drugs-we-couldnt-get-enough-of-more-than-200-cases-of-shortages-over-six-years 2017-12-07T10:53:52 https://maestrodatabase.com/blog/biosimilar-awareness-initiative---literature-review 2018-09-03T10:07:50 https://maestrodatabase.com/blog/pulmocides-lead-drug-candidate-opelconazole-pc945-granted-orphan-drug-fast-track-and-qualified-infectious-disease-product-designations-by-us-fda 2021-09-15T23:04:54 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-march-2026 2026-03-02T23:27:23 https://maestrodatabase.com/blog/conservatism-and-the-cancer-drugs-fund 2017-05-26T14:13:12 https://maestrodatabase.com/blog/relivion-wearable-brain-neuromodulation-technology-cleared-by-fda-for-the-treatment-of-migraine 2021-03-03T06:53:24 https://maestrodatabase.com/blog/consumers-voice-drives-digital-health 2017-12-07T19:55:09 https://maestrodatabase.com/blog/health-canada-approves-brukinsa-zanubrutinib-for-the-treatment-of-waldenstroems-macroglobulinaemia 2021-03-03T07:37:12 https://maestrodatabase.com/blog/novartis-receives-fda-approval-for-expanded-use-of-zykadia-in-first-line-alk-positive-metastatic-non-small-cell-lung-cancer 2017-05-26T23:02:29 https://maestrodatabase.com/blog/nice-launches-prima-to-health-check-economic-models 2017-12-07T19:50:46 https://maestrodatabase.com/blog/out-of-pocket-health-spending-in-2016-increased-at-the-fastest-rate-in-a-decade 2017-12-07T20:05:42 https://maestrodatabase.com/blog/the-prospect-of-amazons-entry-is-a-spur-to-a-massive-deal-in-health-care 2017-12-07T19:58:43 https://maestrodatabase.com/blog/fda-required-studies-of-approved-drugs-make-a-big-difference-for-public-health 2017-12-07T20:14:53 https://maestrodatabase.com/blog/fda-seeks-to-speed-approvals-of-generic-drug-device-combos 2017-12-07T20:08:51 https://maestrodatabase.com/blog/other-countries-control-drug-prices-the-us-could-too 2017-12-07T20:23:09 https://maestrodatabase.com/blog/how-to-reduce-medical-drug-prices-at-a-stroke 2017-12-07T20:20:25 https://maestrodatabase.com/blog/how-a-powerful-lobby-group-is-pushing-up-pbs-medicine-prices 2019-08-30T03:55:26 https://maestrodatabase.com/blog/roches-tecentriq-available-via-cdf 2017-12-07T20:30:46 https://maestrodatabase.com/blog/pharmac-funds-new-medicine-mepolizumab-for-severe-asthma 2020-03-12T02:58:12 https://maestrodatabase.com/blog/nice-backs-nhs-use-of-lillys-olumiant-in-eczema 2021-03-03T10:28:41 https://maestrodatabase.com/blog/medpacto-receives-us-fda-fast-track-designation-for-vactosertib-for-the-treatment-of-metastatic-osteosarcoma 2023-01-21T01:00:16 https://maestrodatabase.com/blog/oyster-point-pharma-announces-fda-acceptance-for-filing-new-drug-application-for-oc-01-varenicline-nasal-spray-for-the-treatment-of-signs-and-symptoms-of-dry-eye-disease 2021-03-03T10:51:26 https://maestrodatabase.com/blog/pharmac-ripe-for-reassessment 2021-03-03T19:56:12 https://maestrodatabase.com/blog/csl-warns-astrazeneca-booster-shots-not-available-until-end-of-year 2021-03-03T10:31:49 https://maestrodatabase.com/blog/sarclisa-approved-in-canada-for-patients-with-newly-diagnosed-multiple-myeloma 2025-04-24T01:28:53 https://maestrodatabase.com/blog/fda-grants-de-novo-to-ml-based-real-time-indicator-of-patient-deterioration 2021-03-03T10:35:55 https://maestrodatabase.com/blog/kempharm-announces-fda-approval-of-azstarys-serdexmethylphenidate-and-dexmethylphenidate-capsules-for-oral-use-cii-a-new-once-daily-treatment-for-adhd 2021-03-03T10:40:55 https://maestrodatabase.com/blog/paying-for-prescription-drugs-in-the-new-administration 2021-03-03T20:09:44 https://maestrodatabase.com/blog/on-target-laboratories-announces-u-dot-s-fda-acceptance-and-priority-review-of-new-drug-application-for-pafolacianine-sodium-injection-for-identification-of-ovarian-cancer-during-surgery 2021-03-03T20:15:58 https://maestrodatabase.com/blog/cancer-patient-told-palliative-care-only-option-after-being-rejected-pharmac-funding 2021-03-03T19:59:17 https://maestrodatabase.com/blog/oblato-announces-fast-track-designation-of-okn-007-for-diffuse-intrinsic-pontine-glioma-from-the-fda 2021-03-03T20:05:11 https://maestrodatabase.com/blog/pharmac-funds-new-treatment-for-rheumatoid-arthritis-to-support-people-impacted-by-tocilizumab-stock-shortage 2021-09-16T02:23:53 https://maestrodatabase.com/blog/fda-accepts-mesoblasts-biologics-license-application-for-ryoncil-in-children-with-steroid-refractory-acute-graft-versus-host-disease 2024-07-24T06:30:47 https://maestrodatabase.com/blog/sage-therapeutics-receives-fast-track-designation-for-sage-718-for-the-treatment-of-huntingtons-disease 2021-09-16T02:50:59 https://maestrodatabase.com/blog/pharmac-funds-tocilizumab-to-treat-cases-of-covid-19 2021-09-16T02:30:21 https://maestrodatabase.com/blog/nz-government-review-of-pharmac-bound-to-come-up-short 2021-03-03T20:22:08 https://maestrodatabase.com/blog/takedas-exkivity-mobocertinib-approved-by-u-dot-s-fda-as-the-first-oral-therapy-specifically-designed-for-patients-with-egfr-exon-20-insertion-positive-nsclc 2021-09-16T01:55:50 https://maestrodatabase.com/blog/latest-update-on-us-fda-bla-for-novavaxs-covid-19-vaccine 2025-04-24T04:59:07 https://maestrodatabase.com/blog/strongbridge-biopharma-announces-submission-of-new-drug-application-for-recorlev-levoketoconazole-for-the-treatment-of-endogenous-cushings-syndrome-to-the-u-dot-s-fda 2021-03-03T21:17:00 https://maestrodatabase.com/blog/therapeutic-goods-administration-prepare-to-fast-track-coronavirus-vaccines-and-treatment 2020-03-12T03:56:40 https://maestrodatabase.com/blog/fixing-the-reimbursement-and-coverage-divide-between-breakthrough-drugs-and-medical-devices 2024-07-24T06:47:15 https://maestrodatabase.com/blog/karyopharm-and-menarini-group-receive-positive-chmp-opinion-for-nexpovio-selinexor-for-the-treatment-of-patients-with-refractory-multiple-myeloma 2022-05-21T00:06:17 https://maestrodatabase.com/blog/covid-19-vaccine-weekly-safety-report-16-september-2021 2021-09-16T05:18:43 https://maestrodatabase.com/blog/stop-blaming-biogen-for-putting-profit-at-the-expense-of-patients-blame-the-systems-that-enabled-it 2023-01-21T03:02:49 https://maestrodatabase.com/blog/dr-steve-pearson-outlines-the-importance-of-thresholds-on-determining-value 2017-05-27T07:51:22 https://maestrodatabase.com/blog/senate-mulls-health-law-rewrite-pushing-obamacare-repeal-to-2020 2017-05-27T08:01:31 https://maestrodatabase.com/blog/us-drug-prices-are-so-high-that-canada-wants-other-countries-as-reference-points 2017-05-27T07:55:24 https://maestrodatabase.com/blog/abbvies-epkinly-receives-first-ever-time-limited-reimbursement-recommendation-by-canadas-drug-agency 2024-07-24T08:15:13 https://maestrodatabase.com/blog/drug-approvals-bounce-back-as-r-and-d-labs-churn-out-new-winners 2017-05-27T08:04:08 https://maestrodatabase.com/blog/unitedhealth-and-merck-strike-a-deal-to-explore-linking-payments-to-drug-performance 2017-05-27T08:07:42 https://maestrodatabase.com/blog/this-gene-therapy-may-not-work-so-why-did-the-fda-fully-approve-it 2024-07-24T06:59:26 https://maestrodatabase.com/blog/mcconnell-may-have-been-right-it-may-be-too-hard-to-replace-obamacare 2017-05-27T08:21:40 https://maestrodatabase.com/blog/piramal-imaging-and-isologic-innovative-radiopharmaceuticals-announce-commercial-approval-of-neuraceq-by-health-canada 2017-05-27T09:12:11 https://maestrodatabase.com/blog/valneva-submits-chikungunya-vaccine-marketing-application-to-ema-and-announces-chmp-accelerated-assessment 2023-10-26T00:01:22 https://maestrodatabase.com/blog/for-only-the-second-time-a-big-drug-maker-offers-a-warranty-on-a-medicine 2023-01-21T03:19:00 https://maestrodatabase.com/blog/chmp-recommends-approval-of-xenpozyme-olipudase-alfa-the-first-and-only-treatment-for-asmd 2022-05-21T00:20:37 https://maestrodatabase.com/blog/ema-starts-rolling-review-of-the-sputnik-v-covid-19-vaccine 2021-03-04T10:49:25 https://maestrodatabase.com/blog/ivf-options-for-older-women-curtailed-as-government-views-medicare-costs 2017-05-27T23:09:10 https://maestrodatabase.com/blog/nice-rejects-rare-blood-cancer-treatment-poteligeo-in-final-appraisal 2021-03-04T10:52:01 https://maestrodatabase.com/blog/jeff-shuren-medical-devices-head-at-fda-to-leave-the-agency 2024-07-24T08:29:18 https://maestrodatabase.com/blog/sunovion-receives-complete-response-letter-from-fda-for-sun-101-slash-eflow-glycopyrrolate-new-drug-application-for-chronic-obstructive-pulmonary-disease 2017-05-28T03:15:43 https://maestrodatabase.com/blog/bioatla-granted-fda-fast-track-designation-for-ozuriftamab-vedotin-cab-ror2-adc-for-treatment-of-patients-with-recurrent-or-metastatic-squamous-cell-carcinoma-of-the-head-and-neck 2024-07-24T08:25:10 https://maestrodatabase.com/blog/expanded-reimbursement-for-roche-koreas-evrysdi-broadens-access-for-sma-patients 2026-03-03T02:09:36 https://maestrodatabase.com/blog/assessing-and-extending-californias-insulin-manufacturing-initiative 2023-01-21T19:28:53 https://maestrodatabase.com/blog/voydeya-approved-in-canada-as-add-on-therapy-to-ravulizumab-or-eculizumab-for-adults-with-the-rare-disease-pnh-who-have-residual-haemolytic-anaemia-due-to-extravascular-haemolysis 2024-07-24T08:21:08 https://maestrodatabase.com/blog/health-canada-approves-ozempic-semaglutide-injection-to-reduce-the-risk-of-major-adverse-cardiovascular-events-in-adults-with-type-2-diabetes 2026-03-03T02:25:44 https://maestrodatabase.com/blog/remegen-announces-two-indications-for-anti-her2-antibody-drug-conjugate-disitamab-vedotin-included-in-chinas-national-reimbursement-drug-list-for-2023 2023-01-21T20:24:37 https://maestrodatabase.com/blog/keytruda-pembrolizumab-plus-lenvima-lenvatinib-is-available-for-the-first-line-treatment-of-adult-patients-with-advanced-or-metastatic-renal-cell-carcinoma 2023-10-26T01:15:26 https://maestrodatabase.com/blog/medalliance-receives-fourth-fda-breakthrough-device-designation-for-sirolimus-drug-eluting-balloon-in-treatment-of-de-novo-coronary-lesions 2021-03-04T11:09:26 https://maestrodatabase.com/blog/fda-accepts-dupixent-dupilumab-for-review-in-children-with-moderate-to-severe-asthma 2021-03-04T11:13:30 https://maestrodatabase.com/blog/novartis-warns-us-plan-to-curb-drug-prices-could-hit-key-research 2023-01-21T20:21:22 https://maestrodatabase.com/blog/fda-releases-a-new-plan-to-bring-its-data-skills-up-to-speed 2021-03-04T11:26:49 https://maestrodatabase.com/blog/the-pharmac-non-review 2021-03-04T10:56:34 https://maestrodatabase.com/blog/chinas-first-and-only-approved-third-generation-bcr-abl-inhibitor-olverembatinib-included-into-the-2022-national-reimbursement-drug-list 2023-01-21T20:12:02 https://maestrodatabase.com/blog/pharmac-swapping-epilepsy-drugs-cannot-be-discounted-as-a-cause-of-deaths----neurologist 2021-03-04T10:59:53 https://maestrodatabase.com/blog/u-dot-s-fda-expands-approval-of-pfizers-lorbrena-as-first-line-treatment-for-alk-positive-metastatic-lung-cancer 2021-03-04T11:03:52 https://maestrodatabase.com/blog/kite-receives-u-dot-s-food-and-drug-administration-priority-review-for-axicabtagene-ciloleucel 2017-05-28T05:20:44 https://maestrodatabase.com/blog/martin-shkreli-accused-of-drug-monopoly-scheme-by-insurer 2021-03-04T20:08:21 https://maestrodatabase.com/blog/ofev-nintedanib-receives-positive-recommendation-from-cadth-and-inesss-for-the-treatment-of-progressive-fibrosing-interstitial-lung-diseases 2021-03-04T20:13:02 https://maestrodatabase.com/blog/sources-of-innovation-in-gene-therapies---approaches-to-achieving-affordable-prices 2023-01-21T20:46:24 https://maestrodatabase.com/blog/create-a-u-dot-s-institute-of-health-technology-assessment-to-preserve-innovation-and-control-costs 2021-03-04T20:18:07 https://maestrodatabase.com/blog/fda-approves-accu-joint-hemi-implant-a-hemi-arthroplasty-metatarsal-head-or-phalangeal-base-implant-for-the-metatarsophalangeal-joint 2021-03-04T19:57:40 https://maestrodatabase.com/blog/italy-eu-refuse-astrazeneca-request-to-ship-250-000-doses-of-vaccine-to-australia 2021-03-04T20:03:03 https://maestrodatabase.com/blog/astrazeneca-ceo-pascal-soriot-says-vaccine-is-100-per-cent-effective 2021-03-04T20:22:41 https://maestrodatabase.com/blog/modified-covid-19-vaccines-for-variants-to-be-fast-tracked-says-mhra-and-other-regulators 2021-03-04T20:34:54 https://maestrodatabase.com/blog/alnylam-receives-positive-recommendation-from-canadas-drug-agency-for-the-public-reimbursement-of-amvuttra-vutrisiran-injection-the-first-and-only-rnai-therapeutic-for-the-treatment-of-cardiomyopathy-in-adult-patients-with-attr-amyloidosis 2026-03-03T02:50:47 https://maestrodatabase.com/blog/u-dot-s-fda-accepts-for-review-supplemental-new-drug-application-for-aptiom-eslicarbazepine-acetate-for-the-treatment-of-partial-onset-seizures-in-children-4-to-17-years-of-age 2017-05-28T22:41:32 https://maestrodatabase.com/blog/springworks-therapeutics-receives-breakthrough-therapy-designation-for-nirogacestat-for-the-treatment-of-adult-patients-with-progressive-unresectable-recurrent-or-refractory-desmoid-tumours 2019-08-30T06:43:52 https://maestrodatabase.com/blog/sunovion-announces-fda-filing-acceptance-of-new-drug-application-for-sun-101-slash-eflow-for-the-treatment-of-patients-with-chronic-obstructive-pulmonary-disease 2017-05-28T22:55:44 https://maestrodatabase.com/blog/acorda-resubmits-new-drug-application-for-inbrija-cvt-301-levodopa-inhalation-powder 2017-12-08T03:29:25 https://maestrodatabase.com/blog/were-not-selling-fruit-and-veg-here-why-pharmacists-doctors-and-retailers-are-fighting-over-your-medicines 2019-08-30T07:00:20 https://maestrodatabase.com/blog/harmonisation-of-authority-required-streamlined-listings-across-public-and-private-hospital-pbs-items-for-the-section-100---highly-specialised-drugs-program 2019-10-25T05:29:31 https://maestrodatabase.com/blog/russia-approves-spinraza-to-treat-all-sma-patients 2019-08-30T06:48:42 https://maestrodatabase.com/blog/post-market-review-of-the-use-of-biologics-in-the-treatment-of-severe-chronic-plaque-psoriasis---stakeholder-forum-outcome 2017-12-08T03:41:50 https://maestrodatabase.com/blog/consumer-outcome-statement-for-the-post-market-review-of-pah-medicines 2017-12-08T03:51:17 https://maestrodatabase.com/blog/concentric-analgesics-receives-fda-fast-track-designation-for-ca-008-for-post-surgical-pain 2017-12-08T04:02:38 https://maestrodatabase.com/blog/junshi-biosciences-and-coherus-biosciences-announce-initiation-of-rolling-submission-of-bla-for-toripalimab-to-the-u-dot-s-fda-for-the-treatment-of-nasopharyngeal-carcinoma 2021-03-04T23:09:31 https://maestrodatabase.com/blog/xpovio-receives-reimbursement-approval-in-south-korea-for-a-second-multiple-myeloma-indication 2026-03-03T10:19:15 https://maestrodatabase.com/blog/bio-thera-solutions-announces-regulatory-filing-acceptance-for-bat2206-a-proposed-biosimilar-to-stelara-in-the-us-and-eu 2024-07-25T05:40:59 https://maestrodatabase.com/blog/nivolumab-in-skin-cancer-additional-benefit-upgraded-on-the-basis-of-an-indirect-comparison 2021-09-16T20:37:01 https://maestrodatabase.com/blog/abbvie-announces-new-formulary-listings-for-skyrizi-in-the-treatment-of-moderate-to-severe-plaque-psoriasis 2020-03-12T07:37:30 https://maestrodatabase.com/blog/abbvie-submits-regulatory-applications-to-fda-and-ema-for-upadacitinib-rinvoq-for-the-treatment-of-adults-with-moderately-to-severely-active-ulcerative-colitis 2021-09-16T20:45:17 https://maestrodatabase.com/blog/radiomedix-and-curium-announce-copper-cu-64-dotatate-injection-was-granted-priority-review-by-the-u-dot-s-fda 2020-03-12T07:31:50 https://maestrodatabase.com/blog/consynance-therapeutics-receives-fda-rare-paediatric-disease-designation-for-csti-500-in-prader-willi-syndrome 2024-07-25T00:14:40 https://maestrodatabase.com/blog/u-dot-s-government-aims-at-high-insulin-prices-with-plan-for-35-dollars-copay-in-medicare 2020-03-12T19:57:17 https://maestrodatabase.com/blog/us-fda-grants-fast-track-designation-to-jardiance-for-the-treatment-of-chronic-kidney-disease 2020-03-12T19:53:43 https://maestrodatabase.com/blog/blueprint-medicines-announces-ema-validation-of-type-ii-variation-marketing-authorisation-application-for-ayvakyt-avapritinib-for-the-treatment-of-advanced-systemic-mastocytosis 2021-03-04T23:30:12 https://maestrodatabase.com/blog/tiziana-life-sciences-granted-fda-fast-track-designation 2024-07-24T23:31:24 https://maestrodatabase.com/blog/around-10-000-people-could-benefit-from-new-migraine-drug-as-nice-says-its-cost-effective 2020-03-12T11:30:13 https://maestrodatabase.com/blog/biocrysts-hae-med-orladeyo-wins-nice-nod 2021-09-16T20:31:14 https://maestrodatabase.com/blog/remarks-from-fda-commissioner-as-prepared-for-oral-testimony-before-the-u-dot-s-senate-committee-on-health-education-labor-and-pensions-hearing-implementation-of-the-21st-century-cures-act-progress-and-the-path-forward-for-medical-innovation 2017-12-08T04:32:46 https://maestrodatabase.com/blog/raising-the-bar-for-using-surrogate-outcomes-in-drug-regulation-and-health-technology-assessment 2021-09-16T21:24:35 https://maestrodatabase.com/blog/new-clot-busting-drug-recommended-by-nice-set-to-save-nhs-millions-of-pounds 2024-07-25T06:31:11 https://maestrodatabase.com/blog/statement-from-fda-commissioner-on-advancing-new-digital-health-policies-to-encourage-innovation-bring-efficiency-and-modernisation-to-regulation 2017-12-08T04:29:26 https://maestrodatabase.com/blog/abbvie-receives-european-commission-approval-of-venclyxto-combination-regimen-for-patients-with-previously-untreated-chronic-lymphocytic-leukaemia 2020-03-12T20:06:58 https://maestrodatabase.com/blog/aptinyx-granted-fast-track-designation-initiates-phase-1-for-second-clinical-candidate-nyx-783-in-post-traumatic-stress-disorder 2017-12-08T04:43:20 https://maestrodatabase.com/blog/new-trade-barriers-could-hamper-the-supply-of-masks-and-medicines 2020-03-12T20:01:35 https://maestrodatabase.com/blog/moderna-announces-health-canada-approves-its-covid-19-vaccine 2021-09-16T21:33:34 https://maestrodatabase.com/blog/trumpcares-cruelty-reaffirmed 2017-05-29T00:34:27 https://maestrodatabase.com/blog/atagi-update-following-weekly-covid-19-meeting---15-september-2021 2021-09-16T21:28:06 https://maestrodatabase.com/blog/kye-pharmaceuticals-secures-exclusive-license-supply-and-commercialisation-agreement-with-catalyst-pharmaceuticals-for-agamree-a-novel-treatment-for-duchenne-muscular-dystrophy-in-canada 2024-07-25T05:59:17 https://maestrodatabase.com/blog/switzerlands-drug-approval-process-lags-behind-europe 2024-07-25T05:53:13 https://maestrodatabase.com/blog/with-remdesivir-the-federal-joint-committee-assesses-the-additional-benefit-of-an-anti-viral-covid-19-drug-for-the-first-time 2021-09-16T20:53:27 https://maestrodatabase.com/blog/tga-adopts-access-consortium-guidance-for-fast-tracking-authorisations-of-modified-covid-19-vaccines-for-variant 2021-03-05T01:03:28 https://maestrodatabase.com/blog/acacia-pharma-announces-brief-extension-of-fda-review-period-for-nda-for-byfavo-an-ultra-short-acting-and-reversible-anesthetic-for-procedural-sedation 2020-03-12T20:17:39 https://maestrodatabase.com/blog/draft-report-for-the-post-market-review-of-copd-medicines 2017-05-29T01:34:27 https://maestrodatabase.com/blog/emergency-use-authorisation-for-lillys-bamlanivimab-and-etesevimab-administered-together-expanded-to-include-post-exposure-prophylaxis-for-covid-19 2021-09-16T21:01:47 https://maestrodatabase.com/blog/massive-shortages-rural-australian-pharmacies-low-on-essential-medications-amid-coronavirus 2020-03-12T20:14:36 https://maestrodatabase.com/blog/drug-makers-see-disaster-in-medicare-negotiating-prices-dont-listen-to-them 2021-09-16T20:58:38 https://maestrodatabase.com/blog/health-canada-grants-full-approval-to-jemperli-for-the-treatment-of-patients-with-recurrent-or-advanced-dmmr-slash-msi-h-endometrial-cancer 2024-07-25T05:45:02 https://maestrodatabase.com/blog/designing-clinical-trials-that-accept-new-arms-an-example-in-metastatic-breast-cancer 2017-05-29T03:11:27 https://maestrodatabase.com/blog/decision-to-fund-methylnaltrexone-in-palliative-care 2017-12-08T05:01:29 https://maestrodatabase.com/blog/merck-receives-approval-updated-registration-for-mavenclad-cladribine-tablets-in-australia 2017-12-08T07:18:50 https://maestrodatabase.com/blog/cf-canada-pleads-with-ottawa-to-pave-way-for-access-to-life-saving-drugs 2020-03-12T20:36:09 https://maestrodatabase.com/blog/law-makers-pressure-big-pharma-on-drug-supply-chains-amid-coronavirus-outbreak 2020-03-12T20:26:52 https://maestrodatabase.com/blog/drug-middlemen-push-patients-to-pricier-medicines-house-probe-finds 2024-07-25T10:38:02 https://maestrodatabase.com/blog/new-deal-will-give-people-with-kidney-cancer-another-treatment-option 2017-12-08T11:25:38 https://maestrodatabase.com/blog/hhs-secretary-alex-azar-expresses-hope-in-biosimilar-uptake-notes-positive-momentum 2020-03-12T20:55:03 https://maestrodatabase.com/blog/coronavirus-spurs-u-dot-s-efforts-to-end-chinas-chokehold-on-drugs 2020-03-12T20:52:01 https://maestrodatabase.com/blog/defining-the-role-of-the-public-in-health-technology-assessment-hta-and-hta-informed-decision-making-processes 2020-03-12T20:40:06 https://maestrodatabase.com/blog/we-all-have-pre-existing-conditions 2017-05-29T10:57:28 https://maestrodatabase.com/blog/shock-surgical-costs-around-new-zealand 2017-05-29T20:52:05 https://maestrodatabase.com/blog/cadth-publishes-final-recommendations-for-two-servier-medicines 2017-05-29T21:08:19 https://maestrodatabase.com/blog/leaked-documents-reveal-secret-plan-for-radical-hospital-overhaul 2017-05-29T20:56:36 https://maestrodatabase.com/blog/uks-nice-recommends-novartis-afinitor-to-treat-neuroendocrine-tumours 2017-05-29T21:23:01 https://maestrodatabase.com/blog/high-priced-drugs-raise-costs-for-seniors-in-medicare-part-d 2017-05-29T22:02:38 https://maestrodatabase.com/blog/health-minister-greg-hunt-shoots-down-departments-secret-hospital-plan 2017-05-29T21:36:18 https://maestrodatabase.com/blog/pbac-public-summary-documents---november-2020-meeting 2021-03-05T06:19:25 https://maestrodatabase.com/blog/new-legislation-to-support-medicine-substitutions 2021-03-05T06:28:21 https://maestrodatabase.com/blog/icer-publishes-special-report-on-treatment-for-ulcerative-colitis-and-crohns-disease-as-part-of-cms-public-comment-process-on-medicare-drug-price-negotiations 2026-03-03T21:11:33 https://maestrodatabase.com/blog/idorsia-submits-european-marketing-authorisation-application-for-daridorexant-for-the-treatment-of-adult-patients-with-insomnia 2021-03-05T07:59:02 https://maestrodatabase.com/blog/viiv-healthcare-receives-approval-from-chinas-national-medical-products-administration-for-vocabria-cabotegravir-used-in-combination-with-rekambys-rilpivirine-the-first-and-only-complete-long-acting-hiv-1-injectable-treatment 2023-10-26T06:36:00 https://maestrodatabase.com/blog/ptc-therapeutics-receives-positive-chmp-opinion-for-upstaza-for-the-treatment-of-aadc-deficiency 2022-05-21T08:24:29 https://maestrodatabase.com/blog/first-nice-recommended-treatment-for-parkinsons-set-to-benefit-hundreds 2023-10-26T10:37:32 https://maestrodatabase.com/blog/bridgebio-pharma-receives-fda-fast-track-designation-for-investigational-therapy-for-the-treatment-of-limb-girdle-muscular-dystrophy-type-2i-lgmd2i 2021-09-17T00:51:14 https://maestrodatabase.com/blog/olipudase-alfa-for-the-treatment-of-patients-with-acid-sphingomyelinase-deficiency-niemann-pick-disease-type-b-and-ab 2023-10-26T19:34:06 https://maestrodatabase.com/blog/fda-approves-azacitidine-for-newly-diagnosed-juvenile-myelomonocytic-leukaemia 2022-05-21T08:14:20 https://maestrodatabase.com/blog/athersys-announces-fast-track-designation-by-fda-for-stroke-program-and-other-progress 2017-05-29T23:32:50 https://maestrodatabase.com/blog/people-dying-of-covid-while-life-saving-drugs-go-unused-doctors-say 2022-05-21T08:06:25 https://maestrodatabase.com/blog/icer-releases-draft-evidence-report-on-therapies-for-severe-asthma 2021-09-17T00:43:19 https://maestrodatabase.com/blog/arcutis-submits-supplemental-new-drug-application-for-zorvye-roflumilast-foam-to-the-fda-for-the-treatment-of-scalp-and-body-psoriasis-in-adults-and-adolescents-ages-12-and-over 2024-07-26T00:10:09 https://maestrodatabase.com/blog/us-fda-grants-paige-breakthrough-device-designation-for-cancer-detection-in-breast-lymph-nodes 2023-10-26T19:40:17 https://maestrodatabase.com/blog/fda-accepts-immunitybios-bla-resubmission-as-complete-and-sets-new-pdufa-date 2023-10-26T19:44:34 https://maestrodatabase.com/blog/jcyte-receives-regenerative-medicine-advanced-therapy-designation 2017-05-30T01:15:28 https://maestrodatabase.com/blog/paying-for-it-how-health-care-costs-and-medical-debt-are-making-americans-sicker-and-poorer 2023-10-26T19:56:13 https://maestrodatabase.com/blog/pfizer-biontech-covid-19-vaccine-comirnaty-receives-full-health-canada-approval-for-individuals-12-years-and-older 2021-09-17T02:10:35 https://maestrodatabase.com/blog/accc-takes-health-fund-nib-to-court-over-concealing-changes-to-its-medigap-scheme 2017-05-30T01:59:56 https://maestrodatabase.com/blog/pharmaceuticals-campaigner-moving-to-australia-after-drug-she-desperately-needs-for-spinal-muscular-atrophy-is-only-funded-for-under-18s 2023-01-22T19:32:39 https://maestrodatabase.com/blog/heart-failure-drug-entresto-will-be-available-on-pharmaceutical-benefits-scheme 2017-05-30T04:14:31 https://maestrodatabase.com/blog/apogenix-granted-prime-designation-by-european-medicines-agency-for-asunercept-to-treat-glioblastoma 2017-05-30T06:47:33 https://maestrodatabase.com/blog/nice-to-launch-new-evidence-tool-for-medtech-product-developers 2017-05-30T12:16:27 https://maestrodatabase.com/blog/drug-lobbyists-battle-cry-over-prices-blame-the-others 2017-05-30T12:11:14 https://maestrodatabase.com/blog/a-look-at-major-drug-pricing-proposals 2017-05-30T12:31:42 https://maestrodatabase.com/blog/rebates-fail-to-cushion-us-drug-costs 2017-05-30T12:29:10 https://maestrodatabase.com/blog/final-terms-of-reference-and-public-consultation-to-the-post-market-review-of-medicines-for-smoking-cessation 2020-03-13T01:00:53 https://maestrodatabase.com/blog/national-mp-urges-pharmac-to-consider-gold-standard-neuroendocrine-cancer-treatment 2017-05-30T12:38:03 https://maestrodatabase.com/blog/fda-approves-first-generic-strattera-for-the-treatment-of-adhd 2017-05-30T21:08:36 https://maestrodatabase.com/blog/political-roundup-is-the-government-spending-enough-on-health 2017-05-30T12:40:54 https://maestrodatabase.com/blog/medicare-patients-dont-share-in-drug-discounts-given-insurers-and-pbms 2017-05-30T21:20:35 https://maestrodatabase.com/blog/55-000-dollars-spent-but-hospital-funding-reform-will-never-be-policy 2017-05-30T21:18:04 https://maestrodatabase.com/blog/european-commission-approves-pfizers-durveqtix-fidanacogene-elaparvovec-a-one-time-gene-therapy-for-adults-with-haemophilia-b 2024-07-26T01:22:27 https://maestrodatabase.com/blog/harvard-pilgrim-signs-outcomes-based-contracts-with-astrazeneca-for-brilinta-and-bydureon 2017-05-30T21:36:38 https://maestrodatabase.com/blog/mcconnell-faces-a-challenge-passing-health-care-in-senate 2017-05-30T21:31:45 https://maestrodatabase.com/blog/us-fda-approves-biomarins-brineura-cerliponase-alfa-for-children-under-3-years-with-cln2-disease 2024-07-26T01:16:39 https://maestrodatabase.com/blog/novo-nordisk-submits-application-in-the-us-for-including-data-from-the-devote-trial-in-the-tresiba-label 2017-05-30T22:43:53 https://maestrodatabase.com/blog/dualitybio-announces-db-1303-granted-fast-track-designation-by-the-us-fda-for-the-treatment-of-advanced-recurrent-or-metastatic-endometrial-carcinoma-with-her2-overexpression 2023-01-22T21:35:56 https://maestrodatabase.com/blog/renalguard-therapy-receives-fda-breakthrough-device-designation-for-prevention-of-cardiac-surgery-associated-aki 2023-01-23T02:09:43 https://maestrodatabase.com/blog/mums-push-for-cystic-fibrosis-treatment-to-be-subsidised-for-children-under-12 2023-01-23T02:02:14 https://maestrodatabase.com/blog/icer-releases-evidence-report-on-treatments-for-sickle-cell-disease 2020-03-13T01:59:29 https://maestrodatabase.com/blog/bonesupport-receives-market-authorisation-for-cerement-g-in-the-us 2022-05-21T21:58:28 https://maestrodatabase.com/blog/amo-pharma-announces-fda-fast-track-designation-for-amo-02-for-treatment-of-congenital-myotonic-dystrophy 2017-05-30T23:27:03 https://maestrodatabase.com/blog/fda-approves-lillys-omvoh-mirikizumab-mrkz-a-first-in-class-treatment-for-adults-with-moderately-to-severely-active-ulcerative-colitis 2023-10-26T22:27:10 https://maestrodatabase.com/blog/tga-grants-provisional-approval-to-pfizers-covid-19-bivalent-comirnaty-original-slash-omicron-ba-dot-4-5-covid-19-vaccine-booster-dose-vaccine 2023-01-23T02:44:16 https://maestrodatabase.com/blog/chinas-drug-pricing-policy-impedes-biotech-profits 2023-01-23T02:32:40 https://maestrodatabase.com/blog/tga-commences-evaluation-of-moderna-covid-19-vaccine-spikevax-for-potential-transition-to-full-registration 2023-01-23T02:36:05 https://maestrodatabase.com/blog/european-commission-approves-pfizers-trumenba-to-help-prevent-meningococcal-group-b-disease-in-adolescents-and-adults 2017-05-31T01:19:03 https://maestrodatabase.com/blog/mhra-approves-glp-1-receptor-agonist-semaglutide-to-reduce-risk-of-serious-heart-problems-in-obese-or-overweight-adults 2024-07-26T01:45:56 https://maestrodatabase.com/blog/merck-receives-fda-approval-of-isentress-hd-raltegravir-a-new-once-daily-option-in-combination-with-other-anti-retroviral-agents-for-the-treatment-of-hiv-1-infection-in-appropriate-patients 2017-05-31T01:25:31 https://maestrodatabase.com/blog/icer-publishes-final-evidence-report-and-policy-recommendations-on-roxadustat 2021-03-05T23:40:12 https://maestrodatabase.com/blog/johnson-and-johnson-therapy-nipocalimab-granted-us-fda-fast-track-designation-in-systemic-lupus-erythematosus 2026-03-03T23:47:17 https://maestrodatabase.com/blog/brukinsa-zanubrutinib-receives-marketing-authorisation-for-chronic-lymphocytic-leukaemia-and-marginal-zone-lymphoma-in-great-britain-by-mhra 2023-01-23T07:35:11 https://maestrodatabase.com/blog/indivior-submits-new-drug-application-to-u-dot-s-fda-for-rbp-6000-buprenorphine-monthly-depot 2017-05-31T03:12:23 https://maestrodatabase.com/blog/kineret-approved-in-canada-for-the-treatment-of-neonatal-onset-multisystem-inflammatory-disease-nomid 2017-05-31T03:33:04 https://maestrodatabase.com/blog/oncternal-therapeutics-announces-fda-granted-fast-track-designation-for-onct-534-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer 2023-10-26T23:47:06 https://maestrodatabase.com/blog/blueprint-medicines-announces-fda-acceptance-of-supplemental-new-drug-application-for-ayvakit-avapritinib-for-the-treatment-of-indolent-systemic-mastocytosis 2023-01-23T19:14:43 https://maestrodatabase.com/blog/the-ema-validated-regulatory-application-for-arpraziquantel-a-potential-treatment-for-schistosomiasis-in-pre-school-aged-children 2023-01-23T09:03:33 https://maestrodatabase.com/blog/sandoz-proposed-biosimilars-adalimumab-and-infliximab-accepted-for-regulatory-review-by-the-european-medicines-agency 2017-05-31T05:11:59 https://maestrodatabase.com/blog/south-australia-slashes-pathology-medical-science-jobs 2017-05-31T07:49:04 https://maestrodatabase.com/blog/ema-publishes-agenda-for-22-25-july-2024-chmp-meeting 2024-07-26T02:39:26 https://maestrodatabase.com/blog/new-action-plan-to-support-smes-as-drivers-of-pharmaceutical-innovation 2017-05-31T20:59:25 https://maestrodatabase.com/blog/altimmune-granted-fast-track-designation-by-fda-for-pemvidutide-for-the-treatment-of-non-alcoholic-steatohepatitis 2023-10-27T00:37:57 https://maestrodatabase.com/blog/fda-approves-penpulimab-kcqx-for-non-keratinizing-nasopharyngeal-carcinoma 2025-04-25T21:37:04 https://maestrodatabase.com/blog/cadrenal-therapeutics-granted-fda-fast-track-designation-for-tecarfarin-for-prevention-of-systemic-thromboembolism-of-cardiac-origin-in-patients-with-end-stage-renal-disease-and-atrial-fibrillation 2023-01-23T19:31:37 https://maestrodatabase.com/blog/regulatory-guidance-for-industry-to-prepare-for-the-uks-withdrawal-from-the-eu 2017-05-31T20:56:45 https://maestrodatabase.com/blog/schedule-of-pharmaceutical-benefits---1-june-2017 2017-05-31T21:14:50 https://maestrodatabase.com/blog/ac-immunes-aci-35-dot-030-now-jnj-2056-granted-fda-fast-track-designation-for-alzheimers-aisease 2024-07-26T03:08:47 https://maestrodatabase.com/blog/theracosbio-announces-fda-approval-of-brenzavvy-bexagliflozin-for-the-treatment-of-adults-with-type-2-diabetes 2023-01-23T19:24:20 https://maestrodatabase.com/blog/nsw-kidney-patient-in-desperate-plea-to-drug-authority 2017-05-31T21:24:43 https://maestrodatabase.com/blog/agenus-receives-fast-track-designation-for-balstilimab-and-zalifrelimab-in-advanced-cervical-cancer 2020-03-13T04:18:16 https://maestrodatabase.com/blog/new-zealand-pharmaceutical-schedule---1-june-2017 2017-05-31T21:29:59 https://maestrodatabase.com/blog/drug-makers-brace-for-trumps-proposals-to-tackle-u-dot-s-prices 2017-05-31T21:45:45 https://maestrodatabase.com/blog/how-a-supreme-court-ruling-on-printer-cartridges-could-have-a-big-impact-on-drug-prices 2017-05-31T21:38:20 https://maestrodatabase.com/blog/tonix-pharmaceuticals-granted-fast-track-designation-by-fda-for-tonmya-for-fibromyalgia 2024-07-26T04:08:46 https://maestrodatabase.com/blog/fda-approves-first-generic-of-flovent-hfa-for-treatment-of-asthma 2026-03-04T02:23:11 https://maestrodatabase.com/blog/multiple-myeloma-drug-subsidised-after-treatment-costs-ballooned 2025-04-25T21:44:37 https://maestrodatabase.com/blog/icer-publishes-final-evidence-report-on-fezolinetant-for-vasomotor-symptoms-associated-with-menopause 2023-01-23T19:38:57 https://maestrodatabase.com/blog/keytruda-made-available-on-the-nhs-for-certain-oesophageal-cancer-patients 2021-09-17T11:31:45 https://maestrodatabase.com/blog/pharmas-strategy-to-exploit-a-depression-era-antitrust-law-would-raise-drug-costs-for-consumers 2023-01-23T20:00:25 https://maestrodatabase.com/blog/calls-to-allow-private-health-insurance-to-cover-fee-gaps 2023-01-23T20:06:30 https://maestrodatabase.com/blog/tga-response-to-coronavirus-covid-19 2020-03-13T05:06:32 https://maestrodatabase.com/blog/ema-publishes-agenda-for-23-26-january-2023-chmp-meeting 2023-01-23T19:54:26 https://maestrodatabase.com/blog/nice-nods-for-abbvie-in-hepatitis-c-and-novartis-in-lung-cancer 2017-12-09T21:44:16 https://maestrodatabase.com/blog/fda-grants-breakthrough-therapy-designation-for-alnylams-givosiran-for-the-prophylaxis-of-attacks-in-patients-with-acute-hepatic-porphyria 2017-05-31T23:27:54 https://maestrodatabase.com/blog/engaging-with-patients-on-health-policy-changes-an-urgent-issue 2017-12-09T21:41:07 https://maestrodatabase.com/blog/new-drug-its-made-a-huge-difference-asthma-sufferer-says 2020-03-13T05:11:34 https://maestrodatabase.com/blog/mirums-livmarli-now-approved-for-pfic-in-patients-12-months-and-older 2024-07-26T04:44:33 https://maestrodatabase.com/blog/despite-court-ruling-fda-will-continue-with-its-approach-to-approving-orphan-drug-exclusivity 2023-01-23T20:15:51 https://maestrodatabase.com/blog/splisense-granted-ema-early-prime-designation-for-spl84-in-cystic-fibrosis 2026-03-04T03:31:40 https://maestrodatabase.com/blog/proqr-receives-fast-track-designation-from-the-fda-for-qr-110-for-lebers-congenital-amaurosis-type-10 2017-05-31T23:57:24 https://maestrodatabase.com/blog/legislation-expands-access-to-breakthrough-alzheimers-treatment 2023-10-27T02:13:05 https://maestrodatabase.com/blog/conditional-power-how-likely-is-trial-success 2023-01-23T21:48:12 https://maestrodatabase.com/blog/catalyst-pharmaceuticals-reports-fda-approval-of-agamree-vamorolone-for-duchenne-muscular-dystrophy-granted-to-santhera-pharmaceuticals 2023-10-27T02:01:11 https://maestrodatabase.com/blog/health-canada-authorises-csls-hemgenix-etranacogene-dezaparvovec-as-first-gene-therapy-for-haemophilia-b 2023-10-27T01:43:47 https://maestrodatabase.com/blog/sandoz-launches-biosimilar-pyzchiva-ustekinumab-across-europe-to-treat-chronic-inflammatory-diseases 2024-07-26T05:24:22 https://maestrodatabase.com/blog/private-insurance-can-contribute-to-a-healthier-system 2023-01-24T04:09:54 https://maestrodatabase.com/blog/abbvie-announces-european-commission-approval-of-skyrizi-risankizumab-for-the-treatment-of-adults-with-moderately-to-severely-active-ulcerative-colitis 2024-07-26T06:07:43 https://maestrodatabase.com/blog/j-and-j-korea-receives-reimbursement-for-balversa-in-urothelial-carcinoma 2026-03-04T09:25:15 https://maestrodatabase.com/blog/jazz-pharmaceuticals-announces-fda-acceptance-of-nda-for-vyxeos-cpx-351-an-investigational-treatment-for-acute-myeloid-leukaemia-with-priority-review-status 2017-06-01T02:15:34 https://maestrodatabase.com/blog/boryung-adds-xpovio-to-blood-cancer-portfolio-under-antengene-license-deal 2026-03-04T09:33:47 https://maestrodatabase.com/blog/reform-medicare-to-sustain-system 2023-01-24T19:43:22 https://maestrodatabase.com/blog/has-updates-its-recommendations-for-the-proper-use-of-osteoporosis-drugs 2023-01-24T19:51:55 https://maestrodatabase.com/blog/checkpoint-therapeutics-announces-fda-acceptance-of-bla-resubmission-of-cosibelimab-for-the-treatment-of-advanced-cutaneous-squamous-cell-carcinoma 2024-07-26T12:19:55 https://maestrodatabase.com/blog/sequential-multiple-assignment-randomised-trial-designs 2023-01-24T19:37:56 https://maestrodatabase.com/blog/fabre-kramer-pharmaceuticals-announces-fda-acceptance-of-nda-resubmission-as-complete-response-and-assignment-of-pdufa-regulatory-action-date 2023-01-24T19:22:54 https://maestrodatabase.com/blog/nicox-receives-fda-approval-of-zerviate-cetirizine-ophthalmic-solution-0-dot-24-percent 2017-06-01T02:46:04 https://maestrodatabase.com/blog/novo-nordisk-receives-us-fda-approval-of-rebinyn-nonacog-beta-pegol-n9-gp 2017-06-01T03:05:09 https://maestrodatabase.com/blog/u-dot-s-fda-approves-yescarta-for-relapsed-or-refractory-follicular-lymphoma-after-two-or-more-lines-of-systemic-therapy 2021-03-06T04:10:12 https://maestrodatabase.com/blog/the-fdas-power-to-approve-drugs-faces-sweeping-challenge-in-lawsuit-seeking-to-pull-abortion-pill-from-us-market 2023-01-24T20:38:09 https://maestrodatabase.com/blog/genentechs-actemra-becomes-the-first-biologic-therapy-approved-by-the-fda-for-slowing-the-rate-of-decline-in-pulmonary-function-in-adults-with-systemic-sclerosis-associated-interstitial-lung-disease-a-rare-debilitating-condition 2021-03-06T04:01:40 https://maestrodatabase.com/blog/swissmedic-touts-2016-performance-42-new-approvals 2017-06-01T03:29:12 https://maestrodatabase.com/blog/introducing-rxpass-from-amazon-pharmacy-a-5-dollars-prescription-subscription-that-helps-prime-members-who-take-multiple-medications-save-time-and-money 2023-01-24T20:44:59 https://maestrodatabase.com/blog/new-appointments-to-the-pbac 2017-06-01T04:21:16 https://maestrodatabase.com/blog/health-policy-trials 2017-06-01T04:17:22 https://maestrodatabase.com/blog/its-scary-the-thought-of-not-having-access-new-anti-depressant-considered-for-pbs 2022-05-22T09:09:32 https://maestrodatabase.com/blog/nice-backs-new-drug-for-gaucher-disease 2017-06-01T06:40:15 https://maestrodatabase.com/blog/patients-deserve-immediate-access-to-fda-approved-innovations----not-bureaucratic-restrictions 2022-05-22T09:14:16